{"meta":{"query_hash":"295742b6fa46","filters":{"topic":"CAR-T cell therapy research"},"cohort_total":2024,"direct_labels_cover":5,"predictions_cover":2024,"exported":2024,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/295742b6fa46","api":"https://metacan.xera.ac/api/v1/cohort?topic=CAR-T+cell+therapy+research"},"results":[{"id":"W131397720","doi":"10.3833/pdr.v2011i5.1473","title":"Mundipharma Gains Commercialisation Rights to Allos Therapeutics’ Folotyn® Outside of North America","year":2011,"lang":"en","type":"article","venue":"PharmaDeals Review","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Business","score_opus":0.2517164448078097,"score_gpt":0.43659777920550064,"score_spread":0.18488133439769094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W131397720","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.46606842,0.3126324,0.002458244,0.025703566,0.001352227,0.026133008,0.00037799313,0.0007798936,0.16449423],"genre_scores_gemma":[0.71312714,0.24095081,0.0018998804,0.041142974,0.00037821836,0.0003931728,0.00016090537,0.00011313144,0.0018337463],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99759823,0.00034126357,0.0007184636,0.00033719538,0.00057482615,0.00042999533],"domain_scores_gemma":[0.9984167,0.000113861766,0.0002280344,0.0006128134,0.00028241225,0.00034614815],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00052239053,0.00025928387,0.0008631024,0.00016420969,0.00007643428,0.0000072225644,0.000332618,0.00004142466,0.010020165],"category_scores_gemma":[0.000047816924,0.00020523388,0.00028647514,0.00061892776,0.00012390866,0.000095241674,0.00008293985,0.0002889283,0.00057381],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00093346264,0.0012977044,0.017226927,0.0063941623,0.001077192,0.00009434475,0.003928805,0.0000015434417,0.04361036,0.00013720799,0.023139808,0.9021585],"study_design_scores_gemma":[0.0014000043,0.00052117265,0.015515103,0.0016524439,0.000731422,0.000032856624,0.000015513348,0.0000321049,0.023963671,0.00007923141,0.95574725,0.00030924342],"about_ca_topic_score_codex":0.00045927477,"about_ca_topic_score_gemma":0.000047164613,"teacher_disagreement_score":0.9326074,"about_ca_system_score_codex":0.00009734927,"about_ca_system_score_gemma":0.000092646515,"threshold_uncertainty_score":0.99088484},"labels":[],"label_agreement":null},{"id":"W1460819011","doi":"10.4049/jimmunol.194.supp.206.37","title":"Deep profiling of single T cell receptor repertoire and phenotype with targeted RNA-seq (TECH2P.927)","year":2015,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"T-cell receptor; Biology; CD8; T cell; Gene; Deep sequencing; FOXP3; Amplicon; Molecular biology; Genetics; Computational biology; Polymerase chain reaction; Antigen; Genome; Immune system","score_opus":0.027794646758186606,"score_gpt":0.2699135668608347,"score_spread":0.24211892010264807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1460819011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873982,0.008600931,0.0003062784,0.0014959001,0.00016276084,0.00022015667,8.7769536e-7,0.000011082203,0.0018038301],"genre_scores_gemma":[0.9942618,0.0006255329,0.0034037034,0.0000869479,0.00013574971,0.0000015210046,0.0000020721088,0.0000320698,0.0014506207],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99872047,0.00023667113,0.0003931891,0.00009294199,0.00031648038,0.00024022147],"domain_scores_gemma":[0.9984279,0.0001700834,0.000366944,0.00030649753,0.0006333092,0.00009522881],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010346797,0.0001199543,0.00041436907,0.00015580723,0.000048729118,0.0000071120035,0.00020035647,0.00010692795,0.0002877934],"category_scores_gemma":[0.00025064006,0.000061273626,0.000052558706,0.00021312197,0.00037087078,0.00006875904,0.00006820027,0.0005375183,0.0000072631024],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007373255,0.0001651699,0.00065100676,0.000029966155,0.0002298615,0.000027374252,0.0014816283,0.000021271608,0.98067087,0.00001562985,0.00017451274,0.009159478],"study_design_scores_gemma":[0.004562804,0.007954162,0.000543755,0.00012224822,0.0001430182,0.0013030842,0.0031199274,0.00009138934,0.97825426,0.00016706764,0.0036359043,0.00010235608],"about_ca_topic_score_codex":0.000052131625,"about_ca_topic_score_gemma":0.000005963602,"teacher_disagreement_score":0.009057122,"about_ca_system_score_codex":0.00010850399,"about_ca_system_score_gemma":0.00027537605,"threshold_uncertainty_score":0.31511357},"labels":[],"label_agreement":null},{"id":"W1484293858","doi":"","title":"Antibody Examination Practice at the Canadian Patent Office: Immune to Change?","year":2013,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Scrutiny; Interpretation (philosophy); Jurisprudence; Law; Political science; Law and economics; Medicine; Engineering ethics; Sociology; Engineering; Computer science","score_opus":0.03390859746517152,"score_gpt":0.32529781374666394,"score_spread":0.29138921628149245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1484293858","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8760638,0.007458021,0.00021376804,0.09778378,0.0003348316,0.0020046711,0.0000027566375,0.000030624014,0.016107721],"genre_scores_gemma":[0.95980537,0.003956205,0.000026740085,0.0019404873,0.0006172001,0.00006087922,0.00003190188,0.00003942753,0.033521794],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99641615,0.0002503514,0.00024400909,0.00019120764,0.0006529713,0.0022452828],"domain_scores_gemma":[0.99855286,0.00011836006,0.00010523737,0.00033321476,0.0005108688,0.0003794369],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.003443377,0.0001437675,0.00017410661,0.00025164898,0.0005105857,0.00011712073,0.00023135754,0.00008792358,0.0030221401],"category_scores_gemma":[0.0003414126,0.00009769119,0.000092717644,0.00037530976,0.000048047634,0.0002509125,0.00005331444,0.0018709474,0.0011263768],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005990593,0.0002564857,0.0031952006,0.000022461858,0.0007483523,0.000090850466,0.0032163705,0.000009810761,0.26714313,0.0035309792,0.0025230274,0.7186643],"study_design_scores_gemma":[0.00455451,0.00463024,0.28152207,0.00015547163,0.00030738325,0.013409535,0.012097652,0.00036181204,0.005241071,0.0023070397,0.67475533,0.00065791444],"about_ca_topic_score_codex":0.12942445,"about_ca_topic_score_gemma":0.2913622,"teacher_disagreement_score":0.7180064,"about_ca_system_score_codex":0.0057831495,"about_ca_system_score_gemma":0.0030773429,"threshold_uncertainty_score":0.9996514},"labels":[],"label_agreement":null},{"id":"W1503366801","doi":"10.4049/jimmunol.188.supp.124.3","title":"A specialized tube to make enrichment of specific cell subsets faster and easier (124.3)","year":2012,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stemcell Technologies","funders":"","keywords":"Centrifugation; Differential centrifugation; Peripheral blood mononuclear cell; CD19; Pipette; Cell; Chromatography; Chemistry; Molecular biology; Biology; In vitro; Biochemistry","score_opus":0.031912582575127545,"score_gpt":0.302126773513856,"score_spread":0.27021419093872845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1503366801","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9821692,0.010215109,0.00009165883,0.001903287,0.00045729624,0.0002795876,0.0000020698847,0.000003519769,0.0048782793],"genre_scores_gemma":[0.99093604,0.0028949212,0.00038080328,0.00025823998,0.00050687,0.0000018974499,6.856735e-7,0.000021736007,0.0049987757],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99850553,0.00027150346,0.00046085502,0.000072399576,0.00032551773,0.00036418674],"domain_scores_gemma":[0.99893874,0.00020323375,0.00020578393,0.0003224844,0.00018876133,0.00014099813],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012522102,0.00012202181,0.0004435631,0.00023390955,0.000037369948,0.000007360523,0.00020219987,0.000081245256,0.003037392],"category_scores_gemma":[0.00004795025,0.00007462855,0.000083189654,0.00017695368,0.00018029207,0.000048776074,0.00011408113,0.0004012227,0.0000657677],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047441684,0.00025323578,0.005169255,0.000019239924,0.00021634638,0.000020017518,0.0031166384,6.5660527e-7,0.96576065,0.000056510773,0.001681203,0.018962055],"study_design_scores_gemma":[0.008783496,0.004024282,0.26602185,0.00013009955,0.00023813991,0.0038551763,0.0031350278,0.000002026323,0.37293863,0.00013819826,0.34052384,0.00020924218],"about_ca_topic_score_codex":0.000017519313,"about_ca_topic_score_gemma":0.0000027208273,"teacher_disagreement_score":0.592822,"about_ca_system_score_codex":0.00008869487,"about_ca_system_score_gemma":0.00006495464,"threshold_uncertainty_score":0.99787396},"labels":[],"label_agreement":null},{"id":"W1504284254","doi":"10.4049/jimmunol.188.supp.46.4","title":"Inducible B effector cells (iBECs) for cancer immunotherapy (46.4)","year":2012,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"CD80; Medicine; CD86; Cancer research; Immunology; Cytotoxic T cell; Immunotherapy; Adoptive cell transfer; T cell; Biology; CD40; Immune system; In vitro","score_opus":0.038275709970793104,"score_gpt":0.35256542540662417,"score_spread":0.31428971543583106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1504284254","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96494734,0.029654695,0.00027944142,0.0025528972,0.0016146658,0.00054560346,0.000005271031,0.000018759389,0.0003813012],"genre_scores_gemma":[0.98258835,0.009172408,0.00046402848,0.0008698927,0.001564668,0.000035301644,0.000001825158,0.00009302146,0.005210518],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99847454,0.00027616112,0.0004028656,0.00007524401,0.00024614355,0.000525069],"domain_scores_gemma":[0.9982956,0.00065964623,0.00028617372,0.00038773438,0.00027888245,0.000091985894],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019726907,0.00014937166,0.00045887224,0.00018531684,0.00008580938,0.000010245053,0.00033341488,0.00014245216,0.002135585],"category_scores_gemma":[0.00007915454,0.000087520515,0.00022755288,0.00017843141,0.00018897044,0.00011610532,0.000043204513,0.0006317862,0.00004023017],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048444015,0.00018443857,0.0012285414,0.000025046298,0.0008071176,0.0000030695703,0.0011871032,0.0000046338905,0.94740784,0.000034446886,0.0030861124,0.04118723],"study_design_scores_gemma":[0.0047786213,0.0020194775,0.0125137335,0.00007762041,0.00016282294,0.0006997645,0.00032536435,0.000007763327,0.7157121,0.00008856167,0.26350257,0.00011166159],"about_ca_topic_score_codex":0.00012516868,"about_ca_topic_score_gemma":0.0000064724964,"teacher_disagreement_score":0.26041645,"about_ca_system_score_codex":0.00021679424,"about_ca_system_score_gemma":0.00022055977,"threshold_uncertainty_score":0.9987766},"labels":[],"label_agreement":null},{"id":"W153967471","doi":"10.4049/jimmunol.186.supp.46.4","title":"Inflammatory cytokines determine the susceptibility of human CD8 T cells to Fas-mediated activation-induced cell death through modulation of FasL and c-FLIP expression (46.4)","year":2011,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University","funders":"","keywords":"CD8; T cell; Programmed cell death; Cytotoxic T cell; Fas ligand; TCIRG1; Cell biology; Apoptosis; Biology; Molecular biology; Immunology; Chemistry; Immune system; Interleukin 21; In vitro; Biochemistry","score_opus":0.05902705006003339,"score_gpt":0.3086606830461397,"score_spread":0.2496336329861063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W153967471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986054,0.00015890313,0.00015071325,0.00018879362,0.00009642019,0.0004307396,0.000002372721,0.000006661753,0.0003599992],"genre_scores_gemma":[0.99921256,0.00019264645,0.000313274,0.00004887135,0.000079357334,0.000003401219,0.0000021681021,0.00001898496,0.00012872046],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99822766,0.00042878647,0.0006991702,0.000115327915,0.00031776394,0.00021128451],"domain_scores_gemma":[0.99785155,0.0004487811,0.00065862684,0.00049715996,0.0004917496,0.00005212108],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011315433,0.00014292377,0.00041918972,0.00015985122,0.00009003541,0.0000042263805,0.00030056367,0.00013352961,0.00041432923],"category_scores_gemma":[0.00018011215,0.000078802186,0.00009180451,0.0001723698,0.00023897683,0.0001346861,0.00012598907,0.0004161392,0.0000020822158],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021376242,0.00014691192,0.008079388,0.00004223604,0.00009434422,0.000003290866,0.006936973,0.000011537361,0.9811353,0.000011976854,0.000024622097,0.0013757691],"study_design_scores_gemma":[0.0012781911,0.0014980115,0.20437218,0.00008901683,0.000046289573,0.000036056026,0.0008830278,0.0000292852,0.79147804,0.00019430788,0.000043351472,0.00005226334],"about_ca_topic_score_codex":0.00020341927,"about_ca_topic_score_gemma":0.000024804294,"teacher_disagreement_score":0.1962928,"about_ca_system_score_codex":0.00007205468,"about_ca_system_score_gemma":0.00010607368,"threshold_uncertainty_score":0.45366147},"labels":[],"label_agreement":null},{"id":"W1543052164","doi":"10.1038/mt.2015.119","title":"T Cells Engineered With Chimeric Antigen Receptors Targeting NKG2D Ligands Display Lethal Toxicity in Mice","year":2015,"lang":"en","type":"article","venue":"Molecular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster University Medical Centre","funders":"Canadian Institutes of Health Research","keywords":"NKG2D; Chimeric antigen receptor; Immunotherapy; Receptor; Adoptive cell transfer; Cancer research; Antigen; Biology; T cell; Cytotoxic T cell; Immunology; Cell biology; Molecular biology; In vitro; Immune system; Biochemistry","score_opus":0.017646758895214415,"score_gpt":0.27537780957187835,"score_spread":0.2577310506766639,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1543052164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99410975,0.001741238,0.0010011329,0.00049122836,0.00016168227,0.00068035163,0.0000032101207,0.000078937665,0.0017324714],"genre_scores_gemma":[0.9958989,0.00031693687,0.001800909,0.00038266022,0.0001403773,0.00003770605,0.00004150874,0.000099428406,0.0012815698],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99797004,0.00012139285,0.00027662358,0.00042695767,0.0006488895,0.0005560671],"domain_scores_gemma":[0.9990732,0.000046934383,0.000063099316,0.0003821143,0.00012302514,0.0003116237],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00063981995,0.00028370688,0.0004269271,0.00021986244,0.000039144994,0.00003617922,0.00020807896,0.00013904458,0.00039441205],"category_scores_gemma":[0.000043725846,0.00022629344,0.00010859481,0.0007065831,0.000088265384,0.000069529255,0.000035708323,0.00043975533,0.000059285518],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012350802,0.00023785117,0.0042494163,0.000016177557,0.00012420324,0.00028334223,0.0014167464,0.00027820113,0.9871802,0.000006404649,0.00036938174,0.0046030288],"study_design_scores_gemma":[0.004307806,0.0008347226,0.0011387315,0.0000608346,0.000010068333,0.000041802225,0.00022719105,0.00057092425,0.98097336,0.000015108163,0.011539307,0.00028016244],"about_ca_topic_score_codex":0.00018033234,"about_ca_topic_score_gemma":0.0000112679745,"teacher_disagreement_score":0.011169926,"about_ca_system_score_codex":0.00015520239,"about_ca_system_score_gemma":0.00018064692,"threshold_uncertainty_score":0.92279786},"labels":[],"label_agreement":null},{"id":"W1543857745","doi":"10.3389/fimmu.2015.00247","title":"Adoptive T Cell Therapy Targeting CD1 and MR1","year":2015,"lang":"en","type":"review","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; National Institutes of Health; University of Toronto; Canadian Institutes of Health Research; Government of Ontario","keywords":"T cell; CD1; Adoptive cell transfer; Antigen; Immunotherapy; Immunology; Effector; Human leukocyte antigen; Biology; Cancer research; Cell biology; Medicine; Antigen-presenting cell; Immune system","score_opus":0.04836614119864218,"score_gpt":0.34278296991815316,"score_spread":0.29441682871951097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1543857745","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009869781,0.9906601,0.000070387316,0.000051655144,0.0013938957,0.0015383803,0.000015482106,0.00004798471,0.0061234324],"genre_scores_gemma":[0.000003702518,0.9856356,0.0032893503,0.000054652282,0.0002327928,0.00015466641,0.00019536326,0.00011759924,0.010316287],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972519,0.00056314474,0.00061912916,0.00062971876,0.0002576985,0.0006783732],"domain_scores_gemma":[0.9988199,0.00011593737,0.00023679454,0.0005707357,0.00012988172,0.00012673711],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00084924424,0.0004834925,0.0026963695,0.00079800934,0.00005191883,0.000022097565,0.00032388585,0.0008611763,0.00050495815],"category_scores_gemma":[0.000088581364,0.00039407346,0.00027169174,0.000504637,0.00044215602,0.00005237948,0.00018877434,0.0016435502,0.00005198593],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027228784,0.00010146063,0.00014358317,0.0014055729,0.0004432647,0.00012559014,0.00036723356,6.536784e-8,0.000057498903,0.000008007672,0.019479146,0.9775963],"study_design_scores_gemma":[0.0019651088,0.00054342835,0.000015063391,0.0012283513,0.00013155947,0.000110270696,0.00039782666,0.0000053194162,0.000020254378,0.000091229274,0.9951865,0.00030509694],"about_ca_topic_score_codex":0.000052740797,"about_ca_topic_score_gemma":0.0000014087659,"teacher_disagreement_score":0.97729117,"about_ca_system_score_codex":0.0005749467,"about_ca_system_score_gemma":0.0007308909,"threshold_uncertainty_score":0.9998511},"labels":[],"label_agreement":null},{"id":"W1547750496","doi":"10.1038/leu.2015.155","title":"Antileukemia multifunctionality of CD4+ T cells genetically engineered by HLA class I-restricted and WT1-specific T-cell receptor gene transfer","year":2015,"lang":"en","type":"article","venue":"Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"University of Warwick; Uehara Memorial Foundation; Fujita Health University; Takeda Science Foundation","keywords":"Cytotoxic T cell; CD8; Biology; Interleukin 21; Adoptive cell transfer; Leukemia; T-cell receptor; T cell; Natural killer T cell; Interleukin 3; Immunotherapy; Cancer research; Interleukin 12; Streptamer; ZAP70; Immunology; Molecular biology; Antigen; Immune system; Genetics","score_opus":0.02644519815614984,"score_gpt":0.25639002476318545,"score_spread":0.2299448266070356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1547750496","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99199724,0.0016498895,0.0018857031,0.00017399486,0.0002968061,0.0007102079,0.00015642522,0.00009348026,0.0030362739],"genre_scores_gemma":[0.98551774,0.0010905617,0.0027762598,0.00015489946,0.00030656336,0.00003393638,0.00024625368,0.000085398424,0.0097884005],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974009,0.00013921148,0.00055553776,0.0005673342,0.0008337036,0.00050334935],"domain_scores_gemma":[0.99812615,0.00021102944,0.00005250647,0.00057976233,0.00040709745,0.00062345894],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00037150382,0.00031324156,0.0005594492,0.00017064439,0.000046811925,0.000030346895,0.00018748073,0.00034736062,0.0012846887],"category_scores_gemma":[0.00006505975,0.00029111104,0.00014242016,0.00047084398,0.00025910753,0.00006419694,0.000051984545,0.0005387234,0.00008805425],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011655971,0.00016890612,0.00083920435,0.00010850473,0.00008126498,0.000018301518,0.0002345218,0.000100998026,0.953159,0.0000224969,0.04001507,0.0040861373],"study_design_scores_gemma":[0.0076455325,0.0005733698,0.0037379363,0.000035488098,0.00006342822,0.000026185693,0.00006882234,0.0022310622,0.8660703,0.000019706013,0.1192418,0.0002864082],"about_ca_topic_score_codex":0.00018156323,"about_ca_topic_score_gemma":0.0000037435743,"teacher_disagreement_score":0.08708873,"about_ca_system_score_codex":0.0008080205,"about_ca_system_score_gemma":0.0008571912,"threshold_uncertainty_score":0.9999541},"labels":[],"label_agreement":null},{"id":"W1556179571","doi":"10.1080/2162402x.2015.1008354","title":"T cell receptor-therapy in HBV-related hepatocellularcarcinoma","year":2015,"lang":"en","type":"article","venue":"OncoImmunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":46,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Wellcome Trust","keywords":"T-cell receptor; Chimeric antigen receptor; Adoptive cell transfer; Medicine; Antigen; Immunology; Hepatitis B virus; T cell; Receptor; Cell therapy; Hepatitis B; Cancer research; Virology; Cell; Virus; Immune system; Biology; Internal medicine","score_opus":0.05337410790290423,"score_gpt":0.30603250749086675,"score_spread":0.25265839958796255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1556179571","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9340681,0.007418521,0.000006030007,0.0015163433,0.00040744865,0.0006454285,0.0000021896815,0.000104575505,0.055831406],"genre_scores_gemma":[0.9605528,0.0010990975,0.0002580195,0.0002900656,0.00008662848,0.00006314611,0.000060559698,0.00006382135,0.037525866],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979258,0.00029317808,0.00042904873,0.0004139415,0.00032406964,0.0006139188],"domain_scores_gemma":[0.9987847,0.00009489284,0.00007914228,0.0006774038,0.00017257011,0.00019125202],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0006939629,0.00022120918,0.0005253332,0.00040094933,0.000034651035,0.000013387108,0.00025395153,0.00038894502,0.006198713],"category_scores_gemma":[0.00008852966,0.00020545357,0.00011809725,0.000598741,0.00024267998,0.00006579756,0.000097663054,0.00078433583,0.0015429812],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002732539,0.00081177964,0.14542793,0.000020215955,0.00010122258,0.00045150428,0.002139681,0.000004269587,0.7926689,0.00021709783,0.005142124,0.05028277],"study_design_scores_gemma":[0.04198354,0.0087474175,0.05807793,0.000102574704,0.00003118841,0.0006586135,0.0017654487,0.00056330254,0.17710131,0.0014024888,0.7088002,0.00076600135],"about_ca_topic_score_codex":0.0006333554,"about_ca_topic_score_gemma":0.0000236069,"teacher_disagreement_score":0.70365804,"about_ca_system_score_codex":0.00048255431,"about_ca_system_score_gemma":0.0005099124,"threshold_uncertainty_score":0.99923444},"labels":[],"label_agreement":null},{"id":"W1556899888","doi":"10.1111/j.1600-065x.2011.01065.x","title":"The TNF receptor super family in immune regulation","year":2011,"lang":"en","type":"article","venue":"Immunological Reviews","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Immune system; Immunology; Tumor necrosis factor receptor; Biology; Receptor; Tumor necrosis factor alpha; Genetics","score_opus":0.14590713457191773,"score_gpt":0.3516593720056134,"score_spread":0.2057522374336957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1556899888","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.35429156,0.5651243,0.000051032606,0.0018904713,0.0004115488,0.00293474,0.0000016192458,0.00009806065,0.07519668],"genre_scores_gemma":[0.21398938,0.74770683,0.0018517203,0.00071568287,0.00017981276,0.0005653596,0.000033380005,0.00004830326,0.034909513],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980935,0.00044860662,0.00061110087,0.00025233597,0.00022201226,0.00037246247],"domain_scores_gemma":[0.9989234,0.00018172387,0.00008306685,0.00068620883,0.000070894166,0.000054684544],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0018072781,0.00015426888,0.00046656624,0.000059855247,0.00009405656,0.000018716035,0.00027473105,0.00015043444,0.007381564],"category_scores_gemma":[0.0009315663,0.00007815148,0.00020723409,0.00037070905,0.00023559408,0.000062736035,0.00010068876,0.00050406763,0.0014356817],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039155345,0.00009869738,0.00041688108,0.00001459339,0.000015898262,0.000005262719,0.00013713581,1.5456251e-8,0.2772041,0.0007082384,0.00042231887,0.7205853],"study_design_scores_gemma":[0.0005815491,0.00034375855,0.14221053,0.00014097795,0.00000933336,0.000011461208,0.00007497327,0.0000056945123,0.004180775,0.00048983266,0.85186076,0.000090347676],"about_ca_topic_score_codex":0.00009149094,"about_ca_topic_score_gemma":0.0000064468986,"teacher_disagreement_score":0.85143846,"about_ca_system_score_codex":0.00012422762,"about_ca_system_score_gemma":0.000037707923,"threshold_uncertainty_score":0.99934185},"labels":[],"label_agreement":null},{"id":"W1558461865","doi":"10.4049/jimmunol.188.supp.124.9","title":"A simple and rapid method for the isolation of untouched human memory CD8 T cells (124.9)","year":2012,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stemcell Technologies","funders":"","keywords":"CD8; Cytotoxic T cell; Immunomagnetic separation; Antigen; Biology; Cell biology; Antibody; Immunology; Molecular biology; Chemistry; In vitro; Biochemistry","score_opus":0.04958857896967336,"score_gpt":0.37592114523412995,"score_spread":0.3263325662644566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1558461865","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96933687,0.013889196,0.013402028,0.0019964124,0.00026651955,0.0005431196,0.0000030629474,0.0000055938117,0.00055717485],"genre_scores_gemma":[0.99560153,0.0011949991,0.001835968,0.0001758952,0.00033345743,0.000004240925,0.0000012554433,0.00001893882,0.00083371764],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998784,0.00040603377,0.00036738798,0.000047577247,0.00016167891,0.00023334526],"domain_scores_gemma":[0.99761784,0.0015252143,0.00032702307,0.00026721688,0.00022020526,0.00004248862],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034039677,0.00008373508,0.00031327878,0.000112298374,0.00011190554,0.0000049788596,0.00018408321,0.00008035554,0.00070717646],"category_scores_gemma":[0.00015299651,0.00004256714,0.0000930106,0.00009951336,0.00020366149,0.00006711317,0.000054445693,0.00035194564,0.0000019865602],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015403829,0.000067302746,0.0001708548,0.000021916398,0.00041898576,6.0129776e-7,0.0021972635,0.0000067002284,0.9731492,0.00011255766,0.0005187256,0.021795535],"study_design_scores_gemma":[0.0053208554,0.0035463234,0.018147111,0.00004203616,0.00062727503,0.0008838736,0.004002537,0.000476314,0.9455757,0.0010809898,0.020193446,0.0001035447],"about_ca_topic_score_codex":0.00006234945,"about_ca_topic_score_gemma":0.000005006619,"teacher_disagreement_score":0.027573481,"about_ca_system_score_codex":0.000041492865,"about_ca_system_score_gemma":0.00005637337,"threshold_uncertainty_score":0.7743086},"labels":[],"label_agreement":null},{"id":"W1558649589","doi":"10.4049/jimmunol.1403145","title":"Quantitative TCR:pMHC Dissociation Rate Assessment by NTAmers Reveals Antimelanoma T Cell Repertoires Enriched for High Functional Competence","year":2015,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research","keywords":"Avidity; T-cell receptor; CD8; T cell; Cytotoxic T cell; Peptide; Biology; Immune system; Antigen; Molecular biology; Chemistry; Cell biology; Immunology; Biochemistry; In vitro","score_opus":0.04405224908136289,"score_gpt":0.34109835500132574,"score_spread":0.29704610591996283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1558649589","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984586,0.0026123547,0.004899551,0.00633493,0.0005455235,0.00040257504,0.000016029338,0.000011462909,0.00059158937],"genre_scores_gemma":[0.9915472,0.0008101535,0.0018270342,0.0003275413,0.00014364546,0.000010501188,0.00003657933,0.000022840939,0.0052744537],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99801964,0.00068550825,0.0005113126,0.00012190411,0.0003823626,0.0002792674],"domain_scores_gemma":[0.996897,0.0012987988,0.00061482715,0.00021583529,0.00088736427,0.00008616907],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027341526,0.00013508649,0.00043914074,0.00013057134,0.00013194013,0.000017163771,0.00020957271,0.000098511,0.0003090943],"category_scores_gemma":[0.00047162254,0.00008761235,0.000121472935,0.00017562594,0.00022071491,0.0001190453,0.00004501364,0.0004566448,0.000014678403],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005537109,0.00020721795,0.0021556702,0.000013489536,0.0004922677,0.000010166728,0.0006372133,0.00003783962,0.9748635,0.0005484531,0.014359169,0.0011378728],"study_design_scores_gemma":[0.049299166,0.047948334,0.5644484,0.00038219188,0.0016665586,0.001848317,0.02545016,0.0021857694,0.26423693,0.015613938,0.025901536,0.0010186925],"about_ca_topic_score_codex":0.000089045265,"about_ca_topic_score_gemma":0.0000042497627,"teacher_disagreement_score":0.7106266,"about_ca_system_score_codex":0.00038977587,"about_ca_system_score_gemma":0.00041947069,"threshold_uncertainty_score":0.3572728},"labels":[],"label_agreement":null},{"id":"W1566703402","doi":"10.1212/wnl.84.14_supplement.p7.201","title":"Baseline Demographics and Disease Characteristics from OPERA I and II, Two Phase III Trials Evaluating Ocrelizumab in Patients with Relapsing Multiple Sclerosis (P7.201)","year":2015,"lang":"en","type":"article","venue":"Neurology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Neurological Institute and Hospital; University of British Columbia","funders":"","keywords":"Ocrelizumab; Medicine; Demographics; Multiple sclerosis; Relapsing remitting; Clinical trial; Internal medicine; Family medicine; Demography; Psychiatry","score_opus":0.11844849721392953,"score_gpt":0.3645933301292611,"score_spread":0.24614483291533157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1566703402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968073,0.0004647214,0.00009930335,0.0012216135,0.0001989477,0.0010465457,0.000106944164,0.000033816577,0.000020835687],"genre_scores_gemma":[0.9972671,0.00021323063,0.00054715323,0.001415045,0.00018457642,0.000039773535,0.00024032732,0.00004748655,0.000045298788],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972045,0.00089016237,0.0005593414,0.00053845503,0.00044264508,0.00036490383],"domain_scores_gemma":[0.9975885,0.0010125244,0.00017111802,0.0003580916,0.00026977804,0.0005999538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017554048,0.00022077526,0.0007151931,0.0002502951,0.00009846056,0.000033719738,0.00007799185,0.000113633345,0.00014484124],"category_scores_gemma":[0.0047178324,0.00017930068,0.000042974934,0.0002259677,0.00022581119,0.00009613933,0.00014874862,0.00049084774,0.0000018534053],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07671257,0.00075963995,0.8593637,0.000019282912,0.00007352267,0.00009978387,0.00048811504,0.00001236186,0.0112909665,0.0000037885793,0.0001190734,0.05105724],"study_design_scores_gemma":[0.1909815,0.014587718,0.7250685,0.00020821602,0.0004502466,0.000019337822,0.000030363186,0.06664372,0.00011945441,0.00013953404,0.0013528216,0.00039859512],"about_ca_topic_score_codex":0.00026483464,"about_ca_topic_score_gemma":0.000079511214,"teacher_disagreement_score":0.13429517,"about_ca_system_score_codex":0.000034695957,"about_ca_system_score_gemma":0.00024159628,"threshold_uncertainty_score":0.73116696},"labels":[],"label_agreement":null},{"id":"W1574902133","doi":"10.1038/nri1257","title":"T-cell development made simple","year":2004,"lang":"en","type":"review","venue":"Nature reviews. Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":315,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Women's College Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Lymphopoiesis; Cell biology; Thymocyte; Extracellular matrix; Function (biology); Biology; Stem cell; Cellular differentiation; Receptor; Chemistry; T cell; Haematopoiesis; Immunology; Biochemistry; Gene; Immune system","score_opus":0.05349645198295755,"score_gpt":0.3988182439844727,"score_spread":0.34532179200151514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1574902133","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000019215993,0.9867931,0.000014562136,0.0001041355,0.0006650032,0.0046148445,0.000014659852,0.00012078882,0.007671002],"genre_scores_gemma":[7.1454826e-7,0.9701222,0.0015930787,0.00036702768,0.0003959416,0.0006435478,0.0010269412,0.00021036754,0.025640173],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99486333,0.00066565105,0.0017707326,0.0010757749,0.00053363823,0.001090861],"domain_scores_gemma":[0.9969083,0.00024453693,0.00068450544,0.0017491188,0.00018591224,0.0002276204],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.0011814102,0.0010590045,0.0060049053,0.00066082,0.00013890707,0.000033227825,0.00088203093,0.0033809007,0.0066361334],"category_scores_gemma":[0.00037463882,0.0007502059,0.0015221824,0.001061692,0.00020623604,0.00004758103,0.0003892873,0.006787135,0.004656053],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029399676,0.00018861657,7.9677795e-7,0.058305684,0.0005046154,0.00014718533,0.00003777243,1.1161251e-8,0.000112778,0.00008912229,0.005105504,0.9354785],"study_design_scores_gemma":[0.0008897245,0.00019679815,0.0000036849974,0.02661093,0.0006859532,0.0010944095,0.0000041591124,2.7449243e-8,0.000102295904,0.000030677704,0.96981317,0.00056816684],"about_ca_topic_score_codex":0.000010603154,"about_ca_topic_score_gemma":0.0000038280937,"teacher_disagreement_score":0.9647077,"about_ca_system_score_codex":0.0016883143,"about_ca_system_score_gemma":0.0030390245,"threshold_uncertainty_score":0.9994949},"labels":[],"label_agreement":null},{"id":"W1585793952","doi":"10.1111/j.1365-2567.2011.03550.x","title":"Reversal of functional defects in highly differentiated young and old CD8 T cells by PDL blockade","year":2011,"lang":"en","type":"article","venue":"Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Biotechnology and Biological Sciences Research Council; Directorate for Biological Sciences","keywords":"Blockade; CD8; Biology; Chemistry; Immunology; Medicine; Internal medicine; Receptor; Immune system","score_opus":0.02305902225775291,"score_gpt":0.24560267586284384,"score_spread":0.22254365360509093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1585793952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962423,0.0011523952,0.000020691938,0.0000765229,0.00022415398,0.00021017964,0.00000814317,0.000022619863,0.0020430356],"genre_scores_gemma":[0.993001,0.00024510414,0.000035933066,0.000043381424,0.000027397413,0.000012655682,0.000026339943,0.00001766479,0.0065905186],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990893,0.00009151665,0.00021186633,0.0002098089,0.00013185627,0.0002656664],"domain_scores_gemma":[0.9995451,0.00007305212,0.00005316427,0.0002246438,0.000058308622,0.000045714063],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001189565,0.00010920754,0.00027822456,0.00018491139,0.000020631007,0.000002926873,0.00007255382,0.00017091326,0.0020255884],"category_scores_gemma":[0.000031345324,0.00009956493,0.00004583123,0.00015342732,0.00021665552,0.000030335646,0.00007023731,0.00029915338,0.000016705972],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011707828,0.0002170327,0.040291175,0.000025343,0.00011867607,0.000025221774,0.00039762227,1.0194313e-7,0.9562976,0.00008466048,0.0004888521,0.00088295527],"study_design_scores_gemma":[0.004255925,0.0008172035,0.36594573,0.000047278387,0.00004014904,0.0000816141,0.00009724368,0.000017971166,0.62754834,0.000095649724,0.00094504276,0.00010787312],"about_ca_topic_score_codex":0.00079230283,"about_ca_topic_score_gemma":0.00006363817,"teacher_disagreement_score":0.32874927,"about_ca_system_score_codex":0.00005222813,"about_ca_system_score_gemma":0.000037445814,"threshold_uncertainty_score":0.9988867},"labels":[],"label_agreement":null},{"id":"W1587247252","doi":"10.1038/nri1259","title":"Translational research in immunology: Japanese perspectives","year":2004,"lang":"en","type":"review","venue":"Nature reviews. Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; RIKEN; Canadian Institutes of Health Research","keywords":"Translational research; Immunology; Clinical immunology; Tumor immunology; Biology; Computational biology; Medicine; Immune system; Pathology; Immunotherapy","score_opus":0.1123179514854199,"score_gpt":0.477389463997891,"score_spread":0.3650715125124711,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1587247252","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000018502536,0.9839529,0.0000013270837,0.0011596822,0.00053107576,0.0061525856,0.000035229274,0.00008492636,0.0080638025],"genre_scores_gemma":[0.000033399996,0.9917752,0.00030776518,0.000063984175,0.0005533506,0.001095746,0.00050587027,0.00019904111,0.005465604],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9900649,0.003912051,0.0018422308,0.0016242608,0.00096669345,0.0015898439],"domain_scores_gemma":[0.9956305,0.0012550758,0.00039569067,0.0019593209,0.00059437304,0.00016506323],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.0047381655,0.0009916098,0.00605888,0.0030799813,0.00019078174,0.000044986475,0.0011973664,0.004826388,0.004763639],"category_scores_gemma":[0.0011392665,0.00075654057,0.0017087944,0.0038436074,0.001362734,0.00012765992,0.0002926192,0.01817944,0.0015770022],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025818584,0.00051207736,0.000003858671,0.021653807,0.00090874743,0.00036474166,0.0009951133,7.802731e-8,0.00013620206,0.0031231416,0.00031718073,0.9717269],"study_design_scores_gemma":[0.0015984457,0.00045774007,0.00006723495,0.040094215,0.00027242317,0.0020137392,0.00026190284,2.337493e-7,0.0000034913835,0.0003922076,0.9543474,0.00049098994],"about_ca_topic_score_codex":0.00012961555,"about_ca_topic_score_gemma":0.00005419304,"teacher_disagreement_score":0.9712359,"about_ca_system_score_codex":0.0022969581,"about_ca_system_score_gemma":0.003130223,"threshold_uncertainty_score":0.99948853},"labels":[],"label_agreement":null},{"id":"W1592754702","doi":"10.4049/jimmunol.1401717","title":"Specific Roles of Each TCR Hemichain in Generating Functional Chain-Centric TCR","year":2015,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute","keywords":"Avidity; T-cell receptor; Biology; Major histocompatibility complex; T cell; clone (Java method); Gene rearrangement; Gene; Repertoire; Antigen; Molecular biology; Cell biology; Immunology; Genetics; Immune system","score_opus":0.05067838008250416,"score_gpt":0.29385822090145947,"score_spread":0.2431798408189553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1592754702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9779055,0.018513542,0.0004829413,0.0016313493,0.0003640048,0.00013736723,0.0000010613506,0.0000049123623,0.0009593349],"genre_scores_gemma":[0.9959462,0.0015377074,0.00039883668,0.000121130695,0.0005583036,0.000001643707,0.0000029570626,0.00001955822,0.0014136379],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982564,0.00038819664,0.00058523,0.00008360964,0.00041342378,0.00027313153],"domain_scores_gemma":[0.9987732,0.00021906564,0.00030904805,0.00024579675,0.00038256915,0.00007028973],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023172263,0.00010709669,0.00039213715,0.00038902325,0.000034087476,0.000005969429,0.00022572222,0.00009913886,0.00064562744],"category_scores_gemma":[0.00025034862,0.00007049044,0.000096288946,0.00034437436,0.0001862859,0.00004820513,0.00007419319,0.00072985,0.000016226435],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029858137,0.00018852371,0.003212154,0.000009175652,0.00017199967,0.000059069145,0.0015416895,0.00038098296,0.96949595,0.00009805199,0.0015504084,0.020306177],"study_design_scores_gemma":[0.046858374,0.010267001,0.067214206,0.00073370046,0.00031222054,0.025027307,0.025251558,0.005435972,0.73899525,0.0021384652,0.077043734,0.00072217954],"about_ca_topic_score_codex":0.000029867859,"about_ca_topic_score_gemma":0.00000963215,"teacher_disagreement_score":0.23050067,"about_ca_system_score_codex":0.00022626919,"about_ca_system_score_gemma":0.0003128126,"threshold_uncertainty_score":0.7069168},"labels":[],"label_agreement":null},{"id":"W1595298938","doi":"10.1111/cei.12465","title":"Generation of β cell-specific human cytotoxic T cells by lentiviral transduction and their survival in immunodeficient human leucocyte antigen-transgenic mice","year":2014,"lang":"en","type":"article","venue":"Clinical & Experimental Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Allergy and Infectious Diseases; Leona M. and Harry B. Helmsley Charitable Trust; Canadian Institutes of Health Research; University of Massachusetts Medical School; National Cancer Institute; National Institutes of Health; National Institute on Drug Abuse; Canadian Diabetes Association","keywords":"Cytotoxic T cell; Biology; Antigen; Immunology; T cell; CD8; Major histocompatibility complex; Antigen-presenting cell; T-cell receptor; Cell biology; Immune system; In vitro","score_opus":0.09438824903010129,"score_gpt":0.38201046209632167,"score_spread":0.2876222130662204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1595298938","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903705,0.0072370097,0.00018075635,0.00006865959,0.0007374363,0.0006635224,0.000012553652,0.000036673253,0.0006928734],"genre_scores_gemma":[0.9973124,0.001543205,0.000066773275,0.000051737698,0.00021239978,0.00003768861,0.0001518451,0.000052683677,0.00057126244],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99672395,0.00075718266,0.0011427741,0.0006749679,0.00023086168,0.00047028804],"domain_scores_gemma":[0.99899,0.0001543961,0.00018177503,0.00052087667,0.00006394211,0.00008900807],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010750939,0.0003008977,0.00081537286,0.00019281448,0.00016228699,0.0000252639,0.0002196236,0.00035450893,0.0008215406],"category_scores_gemma":[0.0000096302465,0.00028071794,0.00027840395,0.00019007508,0.00093601394,0.00010182984,0.00007926289,0.00063438143,0.000021649934],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000621148,0.0019241689,0.0013904561,0.00001969471,0.000085451604,0.000002111423,0.0010113507,0.0000018342241,0.99287564,0.00013070376,0.00012970775,0.0018077337],"study_design_scores_gemma":[0.005865261,0.0030032122,0.007886242,0.000031475964,0.000013962985,0.000009622953,0.00089719944,0.000067087174,0.97924423,0.000016202297,0.0027412348,0.0002242851],"about_ca_topic_score_codex":0.00015936905,"about_ca_topic_score_gemma":0.00002010989,"teacher_disagreement_score":0.013631425,"about_ca_system_score_codex":0.00013769412,"about_ca_system_score_gemma":0.00003636448,"threshold_uncertainty_score":0.9999645},"labels":[],"label_agreement":null},{"id":"W1600048668","doi":"10.4049/jimmunol.171.7.3407","title":"Death Decoy Receptor TR6/DcR3 Inhibits T Cell Chemotaxis In Vitro and In Vivo","year":2003,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Hôpital Notre-Dame; Université de Montréal","funders":"Canadian Institutes of Health Research; Heart And Stroke Foundation Of Quebec; Roche Organ Transplant Research Foundation; Kidney Foundation of Canada; Heart and Stroke Foundation of Canada","keywords":"Chemotaxis; In vivo; In vitro; Decoy; Cell biology; Receptor; Chemistry; Biology; Biochemistry; Genetics","score_opus":0.01840289684404731,"score_gpt":0.2821109137389473,"score_spread":0.2637080168949,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1600048668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895507,0.005426571,0.000009420934,0.0011769002,0.00012635197,0.00018638297,9.912756e-7,0.0000034342704,0.0035192566],"genre_scores_gemma":[0.99267876,0.0044169,0.0003602056,0.00019563684,0.000048591613,0.0000021858618,3.8198135e-7,0.000019371933,0.0022779691],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99854094,0.00041639764,0.0004440289,0.000097084114,0.00017956212,0.00032198362],"domain_scores_gemma":[0.9991826,0.00029882666,0.00015434537,0.00020913374,0.000092928116,0.000062212384],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015532288,0.000117958516,0.000402828,0.00032948586,0.000029779061,0.0000073231436,0.00014655212,0.00012748684,0.001300783],"category_scores_gemma":[0.00026252583,0.00007937097,0.000058854108,0.00027229215,0.00013331613,0.000059556867,0.00004207789,0.0008420869,0.00001388061],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036243487,0.00016769726,0.0029419584,0.000013736491,0.00004471911,0.000056065033,0.0008808951,0.0000023082646,0.98793256,0.000012883066,0.00017745601,0.004145357],"study_design_scores_gemma":[0.005370189,0.00071685354,0.0060617146,0.00006854695,0.000019489004,0.0014823755,0.0006387852,0.000009293784,0.9744689,0.00019418426,0.010892664,0.00007701898],"about_ca_topic_score_codex":0.00006238366,"about_ca_topic_score_gemma":0.00002044089,"teacher_disagreement_score":0.013463691,"about_ca_system_score_codex":0.0001816627,"about_ca_system_score_gemma":0.000174127,"threshold_uncertainty_score":0.99961215},"labels":[],"label_agreement":null},{"id":"W1755519748","doi":"10.1093/cid/civ615","title":"T-Cell Therapy: Options for Infectious Diseases: Table 1.","year":2015,"lang":"en","type":"review","venue":"Clinical Infectious Diseases","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Medical Research Council; UBS Optimus Foundation; European and Developing Countries Clinical Trials Partnership; European Commission","keywords":"Medicine; Table (database); Infectious disease (medical specialty); Intensive care medicine; Virology; Internal medicine; Disease; Data mining","score_opus":0.16972029812464032,"score_gpt":0.4852632705340213,"score_spread":0.315542972409381,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1755519748","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012390206,0.9805887,0.00012718068,0.000056221837,0.0018672214,0.007766691,0.0017734265,0.00089037773,0.006806292],"genre_scores_gemma":[0.000101072554,0.9735419,0.00001870302,0.00052452483,0.0042582266,0.0035844552,0.0022585643,0.0004095849,0.015302967],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9935028,0.0009595879,0.0020807434,0.0015420096,0.00080815906,0.0011067017],"domain_scores_gemma":[0.9905205,0.0036359683,0.00075595145,0.0018650644,0.0010226286,0.0021999087],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0011259535,0.001072242,0.004929357,0.0005702255,0.00035947966,0.00024384154,0.0004974588,0.0010250643,0.0029455242],"category_scores_gemma":[0.0026423752,0.00085090124,0.0041714576,0.0011520705,0.0006438338,0.00018127212,0.00025873404,0.0013751118,0.00082956266],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021218434,0.0064242147,0.004819937,0.011866652,0.001476229,0.000064531385,0.000009645072,0.000004163022,6.3534884e-7,0.00009474763,0.090418145,0.8846089],"study_design_scores_gemma":[0.00622482,0.0030688902,0.00017224575,0.0025068393,0.005465459,0.00005351193,0.000010444896,0.000022985947,3.056493e-7,0.0009997085,0.9806608,0.00081401574],"about_ca_topic_score_codex":0.000041136558,"about_ca_topic_score_gemma":0.000010972747,"teacher_disagreement_score":0.89024264,"about_ca_system_score_codex":0.00074656215,"about_ca_system_score_gemma":0.0049589477,"threshold_uncertainty_score":0.9999484},"labels":[],"label_agreement":null},{"id":"W1774891022","doi":"10.1080/19420862.2016.1227665","title":"Antibody Engineering &amp; Therapeutics 2016: The Antibody Society's annual meeting, December 11–15, 2016, San Diego, CA","year":2016,"lang":"en","type":"article","venue":"mAbs","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Viventia Bio (Canada); Simon Fraser University","funders":"National Institute of Neurological Disorders and Stroke","keywords":"Bispecific antibody; Daratumumab; Antibody; Medicine; Session (web analytics); Immunology; Computer science; Monoclonal antibody; World Wide Web","score_opus":0.02193367853374353,"score_gpt":0.32755611131672957,"score_spread":0.30562243278298606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1774891022","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9642639,0.0048751733,0.006000638,0.00865627,0.0009941784,0.0014078831,0.00013543387,0.00043866702,0.01322784],"genre_scores_gemma":[0.8202749,0.0037227615,0.0016177701,0.0022222262,0.002420424,0.00006826315,0.00020494386,0.00031993553,0.16914876],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974677,0.000099688674,0.0003740683,0.00046381252,0.0007453866,0.00084933924],"domain_scores_gemma":[0.99800885,0.00045137835,0.000094210765,0.0009621047,0.00026535246,0.00021811151],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008883706,0.00034493537,0.0004010303,0.00009508188,0.00019890018,0.000063647036,0.00037484092,0.00021316137,0.007981573],"category_scores_gemma":[0.000117332864,0.00019008607,0.0003336821,0.00030344987,0.0002302754,0.00013495622,0.00019803767,0.00039911567,0.000766855],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013190418,0.00011780943,0.014428326,0.000064865395,0.00032989436,0.000020937,0.0012054367,0.000008747338,0.8908487,0.0000579001,0.0848322,0.007953256],"study_design_scores_gemma":[0.0019280548,0.00016641928,0.01346128,0.00034504893,0.00011139296,0.000081206264,0.00027673476,0.00031699598,0.01198075,0.00004675721,0.97093827,0.00034708294],"about_ca_topic_score_codex":0.00020210238,"about_ca_topic_score_gemma":0.00015668983,"teacher_disagreement_score":0.8861061,"about_ca_system_score_codex":0.00014727695,"about_ca_system_score_gemma":0.00019618124,"threshold_uncertainty_score":0.9929253},"labels":[],"label_agreement":null},{"id":"W1848034928","doi":"10.1182/blood-2014-11-612903","title":"Eradication of B-ALL using chimeric antigen receptor–expressing T cells targeting the TSLPR oncoprotein","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":130,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"National Center for Research Resources; National Cancer Institute","keywords":"Chimeric antigen receptor; Antigen; Receptor; Adoptive cell transfer; Genetically engineered; Molecular biology; Cell biology; Chemistry; Biology; Virology; Immunology; T cell; Immune system; Gene; Biochemistry","score_opus":0.0622499523900424,"score_gpt":0.3304704845190863,"score_spread":0.2682205321290439,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1848034928","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99352986,0.0017810484,0.00026974926,0.00033598434,0.000120710996,0.0005580291,0.0000031233994,0.00003810403,0.0033634154],"genre_scores_gemma":[0.9861238,0.00010800403,0.012373703,0.00010465554,0.00048957486,0.000012073204,0.000018132176,0.00004373521,0.0007263309],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985569,0.00014947691,0.00028583602,0.00020996043,0.00052290293,0.00027491842],"domain_scores_gemma":[0.9990642,0.0000642934,0.00016522635,0.00039726513,0.00016954832,0.00013944416],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008468543,0.00011708695,0.00023109767,0.000087840504,0.00007542905,0.000024911367,0.00017048519,0.000075835735,0.00039284828],"category_scores_gemma":[0.00015037421,0.000085618536,0.000078109384,0.00030541344,0.00011675173,0.000070184185,0.00006502399,0.00024197082,0.000030824227],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008264243,0.00022488882,0.0024223358,0.000037304635,0.000085257874,0.0000044793615,0.0012258056,0.00003048749,0.99082685,0.0000051505226,0.00048383826,0.004570951],"study_design_scores_gemma":[0.0019006289,0.00016950027,0.0003811417,0.00011566665,0.00007767933,0.00001983846,0.0003122764,0.00087128434,0.9828095,0.000038583927,0.013206174,0.00009773842],"about_ca_topic_score_codex":0.00028349675,"about_ca_topic_score_gemma":0.0000020038085,"teacher_disagreement_score":0.012722335,"about_ca_system_score_codex":0.00005985359,"about_ca_system_score_gemma":0.00024204089,"threshold_uncertainty_score":0.4301413},"labels":[],"label_agreement":null},{"id":"W1848220679","doi":"10.1186/1471-2407-3-21","title":"Therapeutic limitations in tumor-specific CD8+ memory T cell engraftment","year":2003,"lang":"en","type":"article","venue":"BMC Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Institute of Allergy and Infectious Diseases; U.S. Department of Defense","keywords":"CTL*; Adoptive cell transfer; Cytotoxic T cell; CD8; Immunotherapy; Immunology; Cancer research; Ex vivo; Medicine; T cell; Cell therapy; In vivo; Biology; Immune system; In vitro; Stem cell; Cell biology","score_opus":0.13128983042894174,"score_gpt":0.34173204699587895,"score_spread":0.2104422165669372,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1848220679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7313542,0.023102026,0.00018998855,0.0007549886,0.0005610449,0.0016104678,0.000010685053,0.00008260861,0.24233401],"genre_scores_gemma":[0.93930435,0.001976704,0.00052981294,0.00064891623,0.0001586979,0.00037921336,0.0000059638824,0.000045793517,0.05695057],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99865764,0.00012253215,0.00021779793,0.00028519987,0.00035816742,0.00035867226],"domain_scores_gemma":[0.99922967,0.00016969038,0.000037297672,0.00036469247,0.00007552001,0.00012314453],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00028214254,0.00013841508,0.00021458647,0.00017637065,0.00004770401,0.000020622025,0.00008182699,0.000049908234,0.008703247],"category_scores_gemma":[0.000025259591,0.00012430987,0.00009518449,0.00039287974,0.00006345965,0.000040657033,0.000013322314,0.00025509193,0.00017170658],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001276581,0.0019766071,0.078546084,0.00045402435,0.00016473015,0.00021504384,0.0054388177,0.00096180465,0.76780117,0.0029270523,0.014558643,0.12567943],"study_design_scores_gemma":[0.005734873,0.00027279562,0.055802956,0.00009961266,0.000038336042,0.000027236621,0.001520585,0.00015922812,0.1332283,0.00048682638,0.8023138,0.00031546358],"about_ca_topic_score_codex":0.000112514834,"about_ca_topic_score_gemma":0.0007333162,"teacher_disagreement_score":0.78775513,"about_ca_system_score_codex":0.00049065996,"about_ca_system_score_gemma":0.00043868975,"threshold_uncertainty_score":0.99220294},"labels":[],"label_agreement":null},{"id":"W1877911682","doi":"10.1038/nm.3910","title":"NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma","year":2015,"lang":"en","type":"article","venue":"Nature Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":848,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Carleton University","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute","keywords":"Cytotoxic T cell; Antigen; Medicine; Multiple myeloma; Immunology; T-cell receptor; Chimeric antigen receptor; Cancer research; Bone marrow; T cell; Immune system; Biology; In vitro","score_opus":0.0176906565937794,"score_gpt":0.2984853652944252,"score_spread":0.2807947087006458,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1877911682","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90626377,0.06310382,0.00025706348,0.008097109,0.0042623635,0.0028820531,0.000014512351,0.00038097712,0.014738327],"genre_scores_gemma":[0.9818885,0.0049861427,0.0006582647,0.0011119065,0.0037024936,0.000063736814,0.00020761043,0.00017606177,0.007205292],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99450964,0.00026972083,0.0008058513,0.0009535852,0.0021987052,0.001262485],"domain_scores_gemma":[0.99626565,0.00062530825,0.00015246744,0.0012141136,0.0006732654,0.0010691995],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002089701,0.00063957286,0.0014164315,0.0013614796,0.00007483766,0.000034497432,0.00051659666,0.0008069148,0.0016297983],"category_scores_gemma":[0.00086264784,0.000491093,0.00017082258,0.0023348052,0.00043770406,0.00014891957,0.00013111507,0.0029447582,0.00024937422],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028656237,0.00048186717,0.00490857,0.00047737994,0.00015661177,0.0076430202,0.0021727015,0.000019236395,0.80561477,0.0012322933,0.15438798,0.020039959],"study_design_scores_gemma":[0.031015629,0.0028261596,0.046290442,0.0012701482,0.000065016815,0.00038628653,0.0015703674,0.00043108984,0.20131926,0.0005635001,0.7134046,0.0008574751],"about_ca_topic_score_codex":0.000044153112,"about_ca_topic_score_gemma":0.000025897754,"teacher_disagreement_score":0.6042955,"about_ca_system_score_codex":0.0007013414,"about_ca_system_score_gemma":0.00036814908,"threshold_uncertainty_score":0.9997541},"labels":[],"label_agreement":null},{"id":"W192314534","doi":"10.4049/jimmunol.186.supp.46.9","title":"A rapid method for the isolation of untouched naive CD8 T cells from peripheral blood mononuclear cells (46.9)","year":2011,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stemcell Technologies","funders":"","keywords":"CD8; Cytotoxic T cell; Peripheral blood mononuclear cell; Flow cytometry; Molecular biology; T cell; Biology; Antigen; Antigen-presenting cell; Chemistry; Immunology; Immune system; In vitro; Biochemistry","score_opus":0.0440716771957844,"score_gpt":0.3086865900586058,"score_spread":0.2646149128628214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W192314534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96616733,0.0071720164,0.02279544,0.0012296643,0.0006095472,0.00080112147,0.000017153014,0.000012587604,0.0011951199],"genre_scores_gemma":[0.9575622,0.0051593785,0.03443452,0.00039657406,0.00050775544,0.000010771162,0.0000030189747,0.00007267742,0.0018531153],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981648,0.00059988414,0.0005874742,0.000113093425,0.00024749586,0.00028728307],"domain_scores_gemma":[0.99715835,0.0013146857,0.0005615028,0.00048076772,0.00043184462,0.000052864998],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017399446,0.00015182095,0.0005011733,0.0001238922,0.00010502836,0.000008661069,0.0004975864,0.00015543979,0.004019561],"category_scores_gemma":[0.000107279455,0.00008223205,0.00029685526,0.00015231072,0.00027750578,0.00007183745,0.000077330165,0.00061667664,0.000011602041],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008634491,0.00020797276,0.000037433092,0.000012018795,0.0015903685,0.00000797113,0.009333388,0.000023193732,0.9630382,0.000044166158,0.00035375502,0.016717052],"study_design_scores_gemma":[0.0051039746,0.004028703,0.002314087,0.000050597504,0.0008986949,0.00023000344,0.0037935143,0.0012212504,0.9769561,0.0009362604,0.004368114,0.00009865782],"about_ca_topic_score_codex":0.00051398017,"about_ca_topic_score_gemma":0.000011187313,"teacher_disagreement_score":0.016618393,"about_ca_system_score_codex":0.000059879436,"about_ca_system_score_gemma":0.000156924,"threshold_uncertainty_score":0.9968909},"labels":[],"label_agreement":null},{"id":"W1963522404","doi":"10.1182/blood-2011-10-384388","title":"B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1445,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Institutes of Health","keywords":"CD19; Medicine; Chimeric antigen receptor; Cytokine; Cytokine release syndrome; Adoptive cell transfer; Immunology; Cell therapy; T cell; Ex vivo; Antigen; Cancer research; In vivo; Cell; Immune system; Biology","score_opus":0.05428349638532947,"score_gpt":0.3184524654414508,"score_spread":0.2641689690561213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1963522404","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973534,0.00015119476,0.000022225684,0.000031040287,0.00007785418,0.000991026,0.000023316075,0.000023965007,0.0013260115],"genre_scores_gemma":[0.9979069,0.00086590525,0.00087389,0.000019153593,0.000055415563,0.000013273108,0.00001769719,0.000032907854,0.00021480522],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99786305,0.00027667085,0.0008085643,0.00034609818,0.00040732752,0.00029828405],"domain_scores_gemma":[0.9988495,0.00019132782,0.00028922618,0.00035297163,0.00014346495,0.00017349726],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000983645,0.0001687097,0.0007398141,0.0001682093,0.000026617976,0.0000037827924,0.00011981694,0.00021364393,0.00045632807],"category_scores_gemma":[0.0001687316,0.00013644292,0.00015251333,0.00044660823,0.00017728301,0.000044704273,0.000035844805,0.00032026425,0.000003148085],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010457441,0.0061210277,0.15947329,0.0000796713,0.00014173341,0.000028064243,0.00052722933,2.1283742e-7,0.8225816,0.0000037700295,0.00002590406,0.000560056],"study_design_scores_gemma":[0.07727594,0.0034224687,0.18115906,0.00025451602,0.0001467954,0.000007841009,0.000065461034,0.000010292756,0.7374966,0.0000071854165,0.00003373436,0.00012010952],"about_ca_topic_score_codex":0.00051696086,"about_ca_topic_score_gemma":0.00007298506,"teacher_disagreement_score":0.08508501,"about_ca_system_score_codex":0.000016495298,"about_ca_system_score_gemma":0.00021899235,"threshold_uncertainty_score":0.5563981},"labels":[],"label_agreement":null},{"id":"W1963617813","doi":"10.5015/utmj.v87i3.1265","title":"An Interview with Dr. Tak W. Mak","year":2010,"lang":"en","type":"article","venue":"University of Toronto Medical Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Library science; Carcinogenesis; Biology; Political science; Genetics; Cancer","score_opus":0.019287347984752172,"score_gpt":0.29556488616097604,"score_spread":0.27627753817622386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1963617813","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9030935,0.0005653457,0.0035094782,0.010669577,0.00041359395,0.00024243281,0.000004858595,0.000049411115,0.08145176],"genre_scores_gemma":[0.9734396,0.0019520288,0.00560157,0.0008563096,0.0009908938,1.0714742e-7,0.000009744293,0.000031910287,0.017117862],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984291,0.00010056735,0.00012795607,0.00013560202,0.0009823472,0.00022441782],"domain_scores_gemma":[0.99846023,0.00004289166,0.00007786389,0.0002541123,0.00023170763,0.00093317166],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007931343,0.00008918918,0.00025550008,0.00004155281,0.00009939095,0.000012531295,0.00038406957,0.00013901289,0.13668491],"category_scores_gemma":[0.00006854327,0.000070259965,0.00010472657,0.000037997528,0.00033752286,0.00020888181,0.000055338456,0.00084338966,0.000015950825],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019442197,0.00078242226,0.0070003155,0.00009007061,0.00034259862,0.0028986272,0.002252037,3.2750896e-7,0.048089836,0.00021029213,0.014494068,0.9218952],"study_design_scores_gemma":[0.008655259,0.0038920336,0.06249076,0.0005880724,0.00021651528,0.0059267515,0.0050918255,0.00047131136,0.0010443556,0.000061475985,0.91129917,0.00026246285],"about_ca_topic_score_codex":0.0013113912,"about_ca_topic_score_gemma":0.008216399,"teacher_disagreement_score":0.9216327,"about_ca_system_score_codex":0.00014502431,"about_ca_system_score_gemma":0.0004791405,"threshold_uncertainty_score":0.8641043},"labels":[],"label_agreement":null},{"id":"W1965468259","doi":"10.1016/j.clim.2009.03.323","title":"F.60. CD4+CD25+Foxp3+ T Cells are Cytotoxic for Human Neurons","year":2009,"lang":"en","type":"article","venue":"Clinical Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Cytotoxic T cell; FOXP3; IL-2 receptor; Cell biology; Chemistry; Immunology; Cancer research; Biology; In vitro; Immune system; Biochemistry","score_opus":0.12531112768824668,"score_gpt":0.45328004616357775,"score_spread":0.32796891847533105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965468259","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865436,0.0005488706,0.00015011219,0.006907634,0.0008259679,0.001195368,0.000018464012,0.00016969147,0.003640304],"genre_scores_gemma":[0.9643037,0.00051274727,0.00041335067,0.004964021,0.00090240024,0.000065181426,0.00006687201,0.00005930764,0.028712457],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973748,0.00026641236,0.0008470475,0.00060812075,0.00019082776,0.00071283424],"domain_scores_gemma":[0.99741584,0.0010091838,0.00018289113,0.0009808971,0.00019729794,0.00021390874],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007475674,0.00022956882,0.00082387956,0.0001478094,0.00016166082,0.00002235794,0.0003767881,0.0005099301,0.0016259354],"category_scores_gemma":[0.0007896924,0.0002062512,0.0005002333,0.00019781987,0.000550715,0.00004482592,0.00009931538,0.0010520375,0.0005366054],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015897132,0.0013364836,0.002857115,0.000025859168,0.00026141998,0.00019031778,0.000052070456,0.0000011870484,0.9363605,0.00078209874,0.01008156,0.046461716],"study_design_scores_gemma":[0.018326534,0.023621479,0.38868514,0.00014935242,0.00034949003,0.00021209315,0.0001912112,0.00011949871,0.089252725,0.009081338,0.46929988,0.00071125274],"about_ca_topic_score_codex":0.000011942339,"about_ca_topic_score_gemma":0.000015841317,"teacher_disagreement_score":0.8471077,"about_ca_system_score_codex":0.00007242246,"about_ca_system_score_gemma":0.00012353023,"threshold_uncertainty_score":0.9992867},"labels":[],"label_agreement":null},{"id":"W1968020819","doi":"10.1016/j.pcl.2014.10.001","title":"Hematopoietic Cell Transplantation and Cellular Therapeutics in the Treatment of Childhood Malignancies","year":2014,"lang":"en","type":"review","venue":"Pediatric Clinics of North America","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Children's Hospital","funders":"National Cancer Institute","keywords":"Medicine; Immunotherapy; Chimeric antigen receptor; Hematopoietic cell; Transplantation; Malignancy; Immunology; Hematopoietic stem cell transplantation; Cancer; Leukemia; Oncology; Haematopoiesis; Immune system; Cancer research; Stem cell; Internal medicine","score_opus":0.044349233649137905,"score_gpt":0.346508210763165,"score_spread":0.3021589771140271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968020819","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.031974964,0.96603096,0.000040587212,0.00003124956,0.00006287974,0.0015559806,0.000097747106,0.000009857947,0.00019578276],"genre_scores_gemma":[0.0035129609,0.99551994,0.00017459478,0.000048995968,0.00025763075,0.000081802515,0.00024161811,0.00005070504,0.00011173302],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972844,0.00032052404,0.0012417545,0.0003645616,0.0005023996,0.00028632698],"domain_scores_gemma":[0.9967165,0.0017208292,0.0007833858,0.0006130516,0.00008507906,0.00008114524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036777998,0.00036829486,0.0021276807,0.00033773147,0.000029932664,0.000008887255,0.0002407138,0.00017742501,0.000055702552],"category_scores_gemma":[0.000026458085,0.00023198818,0.00058714446,0.00077815674,0.00017472426,0.0000173696,0.000015656364,0.0003138852,0.000008822031],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000053425912,0.0012710297,0.009417699,0.018206116,0.000115874165,0.000027184933,0.0018168164,0.0000016032319,8.532251e-7,0.0000013968618,0.000011578374,0.9690764],"study_design_scores_gemma":[0.0022830488,0.0045372876,0.0039358903,0.0008923878,0.0074209105,0.000057446498,0.00013471422,0.000010911336,0.000010230257,0.000019157624,0.9803192,0.00037884153],"about_ca_topic_score_codex":0.000046386172,"about_ca_topic_score_gemma":0.000013385474,"teacher_disagreement_score":0.9803076,"about_ca_system_score_codex":0.000041018608,"about_ca_system_score_gemma":0.00036748324,"threshold_uncertainty_score":0.9460203},"labels":[],"label_agreement":null},{"id":"W1968504589","doi":"10.1371/journal.pone.0041074","title":"Stimulation of Wnt/ß-Catenin Pathway in Human CD8+ T Lymphocytes from Blood and Lung Tumors Leads to a Shared Young/Memory Phenotype","year":2012,"lang":"en","type":"article","venue":"PLoS ONE","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame; Centre Hospitalier de l’Université de Montréal","funders":"Institute of Cancer Research; Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; Multiple Sclerosis Society; Multiple Sclerosis Society of Canada","keywords":"Wnt signaling pathway; Cytotoxic T cell; Biology; CD8; Stem cell; T cell; Cell biology; Adoptive cell transfer; Cancer research; Immunology; Molecular biology; Signal transduction; Antigen; Immune system; Biochemistry; In vitro","score_opus":0.05546506743339357,"score_gpt":0.28910696466842933,"score_spread":0.23364189723503576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968504589","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99683684,0.0011606931,0.000004144278,0.000089331705,0.00002043007,0.0007340767,0.00002610738,0.00004143307,0.001086962],"genre_scores_gemma":[0.9973162,0.00001945581,0.00076334976,0.000060848306,0.00022758599,0.000045937577,0.000100197365,0.000044031116,0.0014223862],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985182,0.00006906856,0.00031184757,0.0002473928,0.0005060089,0.00034743242],"domain_scores_gemma":[0.9992413,0.00011008827,0.000066538334,0.00025470054,0.00011397138,0.00021339503],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00030786736,0.00014702875,0.00042416493,0.00023866259,0.000037960388,0.000015731075,0.00009255413,0.00008823244,0.0016238928],"category_scores_gemma":[0.00016063718,0.00014464797,0.000037458198,0.00027021015,0.00005599733,0.00012648036,0.000081677324,0.00015955746,0.000032857537],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035554354,0.001140371,0.26825264,0.00011410279,0.00011960169,0.000009314979,0.0023803215,0.000004209322,0.72709286,0.000013315319,0.00001579325,0.0005018958],"study_design_scores_gemma":[0.0031484463,0.0003070178,0.2763252,0.00044051922,0.00012433644,0.0000025781371,0.00011206484,0.00041057725,0.71895164,0.00004064339,0.0000031460036,0.00013380163],"about_ca_topic_score_codex":0.00076451874,"about_ca_topic_score_gemma":0.00012116758,"teacher_disagreement_score":0.008141219,"about_ca_system_score_codex":0.00014181323,"about_ca_system_score_gemma":0.00007496773,"threshold_uncertainty_score":0.99928874},"labels":[],"label_agreement":null},{"id":"W1968805055","doi":"10.1038/cgt.2008.96","title":"Retrovirally transduced murine T lymphocytes expressing FasL mediate effective killing of prostate cancer cells","year":2008,"lang":"en","type":"article","venue":"Cancer Gene Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto","funders":"National Institutes of Health; Prostate Cancer Foundation","keywords":"LNCaP; Fas ligand; Cancer research; Cytotoxic T cell; Prostate cancer; Transduction (biophysics); Biology; Cancer cell; Apoptosis; Immunology; Cancer; In vitro; Programmed cell death","score_opus":0.030397075779760866,"score_gpt":0.3157771978177423,"score_spread":0.2853801220379814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1968805055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9628545,0.034253377,0.00008247334,0.00025938524,0.00042739458,0.0015913475,0.000070965965,0.00009406333,0.00036648544],"genre_scores_gemma":[0.8808792,0.11468596,0.0003720807,0.00039910155,0.000664725,0.00055311236,0.000018210985,0.00012144997,0.0023061375],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975007,0.0001573646,0.00046528009,0.00055554433,0.00069210574,0.0006289907],"domain_scores_gemma":[0.99855334,0.00014436111,0.00019533349,0.00051571295,0.00034982077,0.00024142751],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00031145036,0.00036021546,0.00076001266,0.00021292249,0.0001483408,0.00001571162,0.00022948989,0.00014153385,0.002001042],"category_scores_gemma":[0.0000120729555,0.00030046544,0.0002515288,0.00048357976,0.00032980624,0.00012674423,0.00002818026,0.0003054412,0.000007801892],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040307436,0.00011892833,0.006684507,0.00013287434,0.00033443057,0.00006101392,0.0055523547,0.00036302904,0.8436088,7.351968e-7,0.00013399177,0.13897859],"study_design_scores_gemma":[0.008072446,0.0007570587,0.006473167,0.000278522,0.000046359255,0.000022710734,0.00008011127,0.00029175775,0.9799591,0.000020105717,0.0037111118,0.0002875594],"about_ca_topic_score_codex":0.0009919147,"about_ca_topic_score_gemma":0.000033860604,"teacher_disagreement_score":0.13869102,"about_ca_system_score_codex":0.00055750157,"about_ca_system_score_gemma":0.00085207605,"threshold_uncertainty_score":0.99994475},"labels":[],"label_agreement":null},{"id":"W1969405636","doi":"10.1007/s10549-009-0559-y","title":"Density of tumour stroma is correlated to outcome after adoptive transfer of CD4+ and CD8+ T cells in a murine mammary carcinoma model","year":2009,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Victoria; BC Cancer Agency","funders":"Canadian Institutes of Health Research","keywords":"Adoptive cell transfer; CD8; Stroma; Pathology; Cytotoxic T cell; Infiltration (HVAC); Ovalbumin; Lymph node; Immunotherapy; Stromal cell; Cancer research; T cell; Breast cancer; Biology; Medicine; Immunology; Cancer; Immune system; Immunohistochemistry; Internal medicine; In vitro","score_opus":0.04772655796454484,"score_gpt":0.34449636715946963,"score_spread":0.2967698091949248,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1969405636","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99547243,0.0007303549,0.000032368658,0.0020530943,0.000008958898,0.0011514063,0.0003043399,0.000007633039,0.00023940032],"genre_scores_gemma":[0.99719197,0.00065314944,0.00017182183,0.00007193715,0.000020976879,0.000108957865,0.0000071677514,0.000017246171,0.0017567986],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99817324,0.00008041677,0.00030468838,0.0004054091,0.0005550503,0.00048120975],"domain_scores_gemma":[0.9989583,0.000054686796,0.00001930253,0.0002932705,0.00029159442,0.0003828625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023898564,0.00019309425,0.000516971,0.00040138524,0.000033527696,0.000012875204,0.000073060706,0.000082902276,0.0002415791],"category_scores_gemma":[0.0000049349746,0.00014933667,0.00007352482,0.0003801733,0.00014732682,0.00006130863,0.000055202734,0.00023177895,0.0000022234362],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029466787,0.002196038,0.57599044,0.00027350808,0.00026524172,0.00087712205,0.004111624,0.000047324374,0.33005768,0.000068985806,0.00007344502,0.05657182],"study_design_scores_gemma":[0.0062083276,0.003455913,0.90992254,0.0001523625,0.000044165627,0.0000879097,0.00013871408,0.0012072952,0.07857025,0.00008295962,0.000015291056,0.00011428941],"about_ca_topic_score_codex":0.0045677563,"about_ca_topic_score_gemma":0.00067491224,"teacher_disagreement_score":0.3339321,"about_ca_system_score_codex":0.00038909397,"about_ca_system_score_gemma":0.0002942937,"threshold_uncertainty_score":0.69051117},"labels":[],"label_agreement":null},{"id":"W1972406166","doi":"10.4161/onci.27156","title":"An allogeneic NK cell line engineered to express chimeric antigen receptors","year":2013,"lang":"en","type":"article","venue":"OncoImmunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Labex Immuno-Oncology; Institut National Du Cancer; Ligue Contre le Cancer; Agence Nationale de la Recherche","keywords":"Cytotoxic T cell; Chimeric antigen receptor; Antigen; Interleukin 21; NK-92; Biology; Antibody; Antibody-dependent cell-mediated cytotoxicity; Adoptive cell transfer; Immunology; Natural killer T cell; Immunotherapy; Cancer research; T cell; Monoclonal antibody; Immune system; CD8; In vitro","score_opus":0.019229888736515183,"score_gpt":0.29912613956505857,"score_spread":0.2798962508285434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972406166","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902543,0.0014437936,0.00034080783,0.0014877439,0.000501277,0.0009762394,0.000004683691,0.00018225868,0.004808906],"genre_scores_gemma":[0.96759254,0.00092753005,0.004300886,0.0010406718,0.00039377136,0.00021773537,0.000107982705,0.00010429723,0.025314609],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981476,0.00014635644,0.0003209213,0.00046470008,0.00024050864,0.0006799087],"domain_scores_gemma":[0.99846256,0.00007787259,0.000053956875,0.00096049934,0.00015772217,0.00028737372],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00020172998,0.0002465083,0.00048689847,0.00032340435,0.000069574155,0.000026916396,0.00039244955,0.00025459132,0.018964006],"category_scores_gemma":[0.00005814652,0.00022265481,0.00010518918,0.00042291151,0.00011547064,0.00009854436,0.0001154558,0.00041178227,0.0023307533],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019812396,0.00030821958,0.001612153,0.000020953283,0.000088550805,0.000019055371,0.0005558314,0.000034936988,0.94113696,0.000008708781,0.003298184,0.05271833],"study_design_scores_gemma":[0.0027199571,0.0044209664,0.04387355,0.000042566633,0.000036346202,0.00010592069,0.00043256115,0.0002761055,0.6132514,0.00003724426,0.33434367,0.00045971043],"about_ca_topic_score_codex":0.0007395365,"about_ca_topic_score_gemma":0.000011594039,"teacher_disagreement_score":0.3310455,"about_ca_system_score_codex":0.00013001445,"about_ca_system_score_gemma":0.00012502073,"threshold_uncertainty_score":0.99844605},"labels":[],"label_agreement":null},{"id":"W1976188450","doi":"10.1016/s0041-1345(00)02125-4","title":"Generation of partial agonist ligands of the T-cell receptor by engineering of antibodies against CD3","year":2001,"lang":"en","type":"article","venue":"Transplantation Proceedings","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Agonist; Antibody; Receptor; Partial agonist; CD3; Chemistry; Immunology; Biology; Medicine; Cell biology; Biochemistry; Antigen; CD8","score_opus":0.027627751245534706,"score_gpt":0.27203847230993816,"score_spread":0.24441072106440345,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1976188450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974543,0.000114729286,0.00015748385,0.00016353039,0.000060697104,0.0002859626,0.000034567765,0.000016676233,0.0017120929],"genre_scores_gemma":[0.99725443,0.0017070234,0.00020132867,0.000022209679,0.00007252646,0.000009265815,0.000058896447,0.000016776447,0.0006575644],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990508,0.0000044526278,0.00034318096,0.00012408629,0.00034727764,0.00013018775],"domain_scores_gemma":[0.9995017,0.000023123703,0.00013586819,0.00007047649,0.0002299492,0.00003890275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000185658,0.00009421728,0.00020867206,0.00008076356,0.000031967804,0.0000070121064,0.00008241745,0.00006470037,0.00011508157],"category_scores_gemma":[0.000018226889,0.00007434921,0.000081820326,0.00026458723,0.00007637659,0.00008170791,0.00000543095,0.000099784695,0.0000011363035],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030941732,0.00008723129,0.014278234,0.000787838,0.000031870575,4.869802e-7,0.0020825858,0.000048664268,0.9814723,0.00006183108,0.00030379373,0.00053572835],"study_design_scores_gemma":[0.0011085178,0.0001440671,0.0027684188,0.0001645007,0.000061323604,0.00000790436,0.00012462815,0.0013204562,0.99360716,0.0000020213083,0.0006303427,0.000060639555],"about_ca_topic_score_codex":0.000024004643,"about_ca_topic_score_gemma":0.0000013733032,"teacher_disagreement_score":0.012134861,"about_ca_system_score_codex":0.000019713454,"about_ca_system_score_gemma":0.000042051583,"threshold_uncertainty_score":0.3031873},"labels":[],"label_agreement":null},{"id":"W1979479636","doi":"10.1007/s00262-015-1662-z","title":"The safety of allogeneic innate lymphocyte therapy for glioma patients with prior cranial irradiation","year":2015,"lang":"en","type":"article","venue":"Cancer Immunology Immunotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Toronto","funders":"Elsa U. Pardee Foundation","keywords":"Radiation therapy; Cytotoxic T cell; Glioma; Immunotherapy; Temozolomide; Medicine; Cell therapy; Cancer research; CD8; Immune system; Parenchyma; Immunology; Cell; Pathology; Biology; Internal medicine; In vitro","score_opus":0.025060749338043902,"score_gpt":0.30951494330881996,"score_spread":0.28445419397077604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979479636","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96211123,0.032583334,0.00019268336,0.0014773742,0.00071371807,0.0026280219,0.00005642633,0.000060418075,0.0001767997],"genre_scores_gemma":[0.9491724,0.042747237,0.0006374653,0.0010859919,0.0003592204,0.001537599,0.00017053414,0.00025161353,0.004037932],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978841,0.00018741097,0.0005424312,0.00036641932,0.00044428292,0.0005753487],"domain_scores_gemma":[0.9975162,0.00026203855,0.0003228293,0.0007932396,0.0010201989,0.00008549705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006379073,0.00029892393,0.0005462327,0.00017361526,0.0002632458,0.00003203118,0.0004189317,0.00022294479,0.0003341505],"category_scores_gemma":[0.000062790845,0.00017232448,0.00017610415,0.00040396288,0.000595025,0.000119309545,0.000032900836,0.00022742571,0.000011074282],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10649996,0.00032230644,0.017515212,0.000016489907,0.0018808703,0.0000027228339,0.0012205282,0.000018899404,0.20756763,0.0000869336,0.00031540138,0.66455305],"study_design_scores_gemma":[0.093361646,0.008025368,0.30636218,0.000098298,0.00007944142,0.00003341746,0.00022748059,0.00007361876,0.096785486,0.00029442937,0.4941941,0.00046452656],"about_ca_topic_score_codex":0.00024452113,"about_ca_topic_score_gemma":0.00003543842,"teacher_disagreement_score":0.6640885,"about_ca_system_score_codex":0.0007005363,"about_ca_system_score_gemma":0.0012165587,"threshold_uncertainty_score":0.7027188},"labels":[],"label_agreement":null},{"id":"W1979942820","doi":"10.1002/ijc.10325","title":"Adenosine acts through an A<sub>3</sub> receptor to prevent the induction of murine anti‐CD3‐activated killer T cells","year":2002,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Faculty of Medicine, Dalhousie University; Killam Trusts; Dalhousie University; Natural Sciences and Engineering Research Council of Canada; Dalhousie Medical Research Foundation","keywords":"Adenosine; Cytotoxic T cell; Biology; Adenosine A2B receptor; Adenosine receptor; Adenosine deaminase; Adenosine A3 receptor; T cell; Molecular biology; Receptor; Endocrinology; Biochemistry; Immunology; Immune system; Agonist; In vitro","score_opus":0.041876414396230126,"score_gpt":0.3541307143807335,"score_spread":0.3122542999845034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979942820","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836216,0.0006939266,0.00007512702,0.012623751,0.002157433,0.00026306018,0.000017985698,0.000008177777,0.0005389185],"genre_scores_gemma":[0.9922351,0.003553393,0.00019102785,0.00061494973,0.001851007,0.0000101624355,0.0000061601577,0.00002833662,0.0015098266],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979591,0.000085135616,0.0004790823,0.00014527196,0.0011557618,0.0001756889],"domain_scores_gemma":[0.9980721,0.00006539563,0.00035142936,0.00018224069,0.0011942085,0.00013465132],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00028895208,0.00012622162,0.0002575682,0.00019890911,0.00003233177,0.000027942713,0.00032189614,0.00006827253,0.0058590863],"category_scores_gemma":[0.00008227357,0.00008544549,0.00013977414,0.00024755453,0.00006858463,0.000336954,0.000050419418,0.00039197173,0.00002354047],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00080019794,0.0005079183,0.00033708813,0.000011867737,0.00053566054,0.000022479355,0.00089155784,0.0004379485,0.93759435,0.000021636546,0.012446913,0.04639237],"study_design_scores_gemma":[0.0012686842,0.0004713914,0.0036780436,0.00026169623,0.000046601082,0.0001024469,0.000089932655,0.000044622968,0.87179464,0.000035771685,0.12213216,0.0000740031],"about_ca_topic_score_codex":0.00007516869,"about_ca_topic_score_gemma":0.00002049226,"teacher_disagreement_score":0.10968525,"about_ca_system_score_codex":0.0003922967,"about_ca_system_score_gemma":0.00012232842,"threshold_uncertainty_score":0.9950497},"labels":[],"label_agreement":null},{"id":"W1981955743","doi":"10.1158/1538-7445.am2013-3972","title":"Abstract 3972: Carpet bombing with CARs: Influence of dose, timing, lymphodepletion and costimulatory domain on efficacy of mRNA engineered anti-CD19 Chimeric Antigen Receptor T cells in preclinical xenograft models.","year":2013,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Chimeric antigen receptor; CD28; Electroporation; Cancer research; Ex vivo; Transduction (biophysics); Genetic enhancement; CD19; Viral vector; T cell; Antigen; Medicine; Immunology; Biology; In vivo; Immune system; Gene; Recombinant DNA","score_opus":0.07944169261502196,"score_gpt":0.39057946450735204,"score_spread":0.31113777189233005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1981955743","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99652606,0.0009145767,0.00001014289,0.00015996322,0.000040710132,0.0018916781,0.000034969216,0.000024761663,0.00039715573],"genre_scores_gemma":[0.99687904,0.0022447107,0.00040573798,0.000026065276,0.000073063144,0.00013131127,0.000017329103,0.00006727456,0.00015546911],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9965522,0.00024861874,0.00060839264,0.00058154046,0.0013114858,0.00069771055],"domain_scores_gemma":[0.9974772,0.00083696534,0.00013579239,0.00063711125,0.0006005011,0.0003124532],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015783298,0.00023443348,0.0006692668,0.0006675523,0.000063120606,0.000032278425,0.00027754763,0.00020165542,0.0005330408],"category_scores_gemma":[0.00019277149,0.00019843857,0.00008395993,0.0009142254,0.00061806093,0.00019573799,0.0001123189,0.00083618454,0.000018188139],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017287371,0.00041167432,0.018611545,0.00039473656,0.00011546831,0.000016462503,0.0011854157,0.018218625,0.949854,0.000011992898,0.000223441,0.009227878],"study_design_scores_gemma":[0.011314939,0.0020317389,0.6269922,0.002663447,0.00002666739,0.000009353072,0.00034947883,0.0040359013,0.35162857,0.00006786329,0.00051933515,0.0003604778],"about_ca_topic_score_codex":0.0057443217,"about_ca_topic_score_gemma":0.00006292364,"teacher_disagreement_score":0.6083807,"about_ca_system_score_codex":0.00035922814,"about_ca_system_score_gemma":0.00068657007,"threshold_uncertainty_score":0.8683734},"labels":[],"label_agreement":null},{"id":"W1983098174","doi":"10.1038/sj.cgt.7700595","title":"Intramuscular gene transfer of soluble B7.1/IgG1 fusion cDNA induces potent antitumor immunity as an adjuvant for DNA vaccination","year":2003,"lang":"en","type":"article","venue":"Cancer Gene Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Cancer Institute; Natural Sciences and Engineering Research Council of Canada","keywords":"DNA vaccination; Electroporation; Immune system; Adjuvant; Fusion protein; Antigen; CTL*; Molecular biology; Biology; Cytotoxic T cell; Carcinoembryonic antigen; Antibody; Adoptive cell transfer; Genetic enhancement; Immunoglobulin G; Fusion gene; Recombinant DNA; Immunology; T cell; Gene; Cancer; In vitro; CD8; Biochemistry; Immunization","score_opus":0.050493848064465066,"score_gpt":0.34780160852314007,"score_spread":0.297307760458675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1983098174","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98654264,0.008644435,0.0016142501,0.00040998423,0.00048031705,0.0018424804,0.000032863314,0.00005313226,0.00037987845],"genre_scores_gemma":[0.9817142,0.015885342,0.00059187354,0.00040487398,0.00025724364,0.00022992137,0.00012048886,0.00008807341,0.00070799777],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979761,0.00020921847,0.0004158322,0.00042126264,0.0005124902,0.00046507313],"domain_scores_gemma":[0.99853873,0.00004318513,0.00007837141,0.00066190015,0.00047056397,0.00020726676],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00082244223,0.00026640212,0.0005305592,0.00020829464,0.00017709982,0.00002784268,0.00023454038,0.00016924934,0.0036392857],"category_scores_gemma":[0.000029340248,0.00022868208,0.0002357147,0.00034954253,0.00006724972,0.00015389145,0.000015316613,0.00025239433,0.0000053878107],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017578372,0.00045291526,0.0003683608,0.00007449732,0.00019747933,0.0000062985737,0.0009181684,0.0000417195,0.8221012,0.00010372951,0.000077335855,0.17390046],"study_design_scores_gemma":[0.006655918,0.0021251652,0.009919671,0.000047266487,0.000062210645,0.000029646151,0.00020801777,0.00015888018,0.96969086,0.00039403344,0.010469456,0.00023885584],"about_ca_topic_score_codex":0.00049725536,"about_ca_topic_score_gemma":0.00007051938,"teacher_disagreement_score":0.1736616,"about_ca_system_score_codex":0.00024003806,"about_ca_system_score_gemma":0.00043963044,"threshold_uncertainty_score":0.99727154},"labels":[],"label_agreement":null},{"id":"W1984150894","doi":"10.1371/journal.pone.0016700","title":"Anti-Leukemia Activity of In Vitro-Expanded Human Gamma Delta T Cells in a Xenogeneic Ph+ Leukemia Model","year":2011,"lang":"en","type":"article","venue":"PLoS ONE","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University Health Network; Princess Margaret Cancer Centre","funders":"University of Toronto","keywords":"Bone marrow; Clonogenic assay; Cytotoxic T cell; Leukemia; Spleen; In vitro; Immunology; Molecular biology; Biology; Chemistry; Cancer research","score_opus":0.11613691442097497,"score_gpt":0.30059894980939245,"score_spread":0.1844620353884175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984150894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934526,0.000080803664,0.00003979756,0.000029492432,0.000010950457,0.00082621054,0.000025412583,0.00004158388,0.005493159],"genre_scores_gemma":[0.99631226,0.00015173142,0.0011574193,0.000052632837,0.000054021697,0.00006551,0.000018532797,0.00006196283,0.0021259128],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977596,0.00012013218,0.00043634875,0.00044452868,0.0006773955,0.00056201377],"domain_scores_gemma":[0.99882513,0.00006392872,0.000115603565,0.0006950147,0.00012055856,0.00017977729],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049514126,0.0002316258,0.000825901,0.0005053502,0.000032110147,0.000008238769,0.00025754512,0.00021966151,0.000695635],"category_scores_gemma":[0.000053628715,0.0002326914,0.00011103382,0.0004925545,0.00013968273,0.00011773735,0.00012764592,0.00062229467,0.000029041465],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015982287,0.002332273,0.010573495,0.00032220662,0.00013633302,0.000091703296,0.0013447423,0.00006223317,0.98185146,0.000010992244,0.000022360502,0.0016539706],"study_design_scores_gemma":[0.0038516945,0.00026994655,0.018865604,0.00027055974,0.00006121074,0.0000034872419,0.000045683373,0.020820897,0.9554443,0.00017327558,0.0000030751735,0.0001902968],"about_ca_topic_score_codex":0.0022151624,"about_ca_topic_score_gemma":0.00042395666,"teacher_disagreement_score":0.026407192,"about_ca_system_score_codex":0.0010355002,"about_ca_system_score_gemma":0.0005573254,"threshold_uncertainty_score":0.948888},"labels":[],"label_agreement":null},{"id":"W1984454936","doi":"10.4161/onci.1.2.18231","title":"Anti-leukemia activity of human gamma delta T cells","year":2012,"lang":"en","type":"article","venue":"OncoImmunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Robarts Clinical Trials; University of Toronto; Western University","funders":"","keywords":"Leukemia; Chronic lymphocytic leukemia; Cancer research; Adoptive cell transfer; Medicine; Immunology; T cell; Immune system","score_opus":0.040782841344297514,"score_gpt":0.3459616183447385,"score_spread":0.305178777000441,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1984454936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97364604,0.00073190965,0.000027732185,0.00016523368,0.0002799604,0.0002579389,0.0000063371576,0.00004679775,0.024838071],"genre_scores_gemma":[0.99001634,0.0001871799,0.00013502927,0.000067145906,0.00019247936,0.000013069412,0.000013953824,0.000032820277,0.009341995],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986719,0.0001420346,0.00022560456,0.00018904076,0.0002218876,0.0005495208],"domain_scores_gemma":[0.9989552,0.00011430894,0.000104616054,0.0006228285,0.00009827424,0.00010479808],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00041160965,0.00014459982,0.0005053406,0.00017494176,0.00006207512,0.0000042723464,0.00017546098,0.00023770983,0.004876762],"category_scores_gemma":[0.000043174765,0.00013175062,0.0001278641,0.00020495088,0.00032386306,0.000089548426,0.00013076644,0.00044612866,0.00019512585],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002425633,0.0003161167,0.016559305,0.000047809364,0.00013682613,0.000012795913,0.00034673847,3.7524723e-7,0.9518203,0.00024272787,0.00064750545,0.029626919],"study_design_scores_gemma":[0.0015176068,0.000616768,0.16543971,0.000026011947,0.00004315063,0.00007938955,0.00008195684,0.000007508131,0.80476505,0.000028780569,0.02728456,0.00010950679],"about_ca_topic_score_codex":0.00051576487,"about_ca_topic_score_gemma":0.000017358478,"teacher_disagreement_score":0.1488804,"about_ca_system_score_codex":0.00029015998,"about_ca_system_score_gemma":0.00017846338,"threshold_uncertainty_score":0.9960329},"labels":[],"label_agreement":null},{"id":"W1988486780","doi":"10.1038/cgt.2011.18","title":"Adjuvant effect of HER-2/neu-specific adenoviral vector stimulating CD8+ T and natural killer cell responses on anti-HER-2/neu antibody therapy for well-established breast tumors in HER-2/neu transgenic mice","year":2011,"lang":"en","type":"article","venue":"Cancer Gene Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; Saskatchewan Cancer Agency","funders":"","keywords":"Cytotoxic T cell; Immunology; CTL*; Immunotherapy; CD8; HER2/neu; Cancer research; Antibody; Immune system; Antigen; Adjuvant; Biology; Medicine; Cancer; Breast cancer; Internal medicine","score_opus":0.03215954182566027,"score_gpt":0.3251027456786804,"score_spread":0.29294320385302014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1988486780","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96695024,0.027110452,0.00003410466,0.0003364462,0.000993202,0.0040532,0.00013612348,0.00011922534,0.00026701225],"genre_scores_gemma":[0.9834605,0.012720017,0.0002321584,0.00040128434,0.0006907381,0.00033942517,0.00008293936,0.0003029122,0.0017700618],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9948064,0.0007478004,0.0010029844,0.001314389,0.0008580281,0.001270371],"domain_scores_gemma":[0.99710244,0.00092968147,0.00033716625,0.00099764,0.00027794065,0.00035511577],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013251457,0.00090959924,0.0016900568,0.0006831273,0.00020087481,0.0000767948,0.000557054,0.00034426805,0.0018630653],"category_scores_gemma":[0.00003476853,0.0007251887,0.00050383876,0.0009195492,0.000427259,0.00026563974,0.000052637217,0.00091045484,0.000011911077],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.061959695,0.0006213972,0.03645707,0.00027124898,0.00028532647,0.000060143848,0.0027608254,0.000075397824,0.85102326,0.000008261055,0.00019890178,0.046278488],"study_design_scores_gemma":[0.028348468,0.008936861,0.24025302,0.00051850174,0.00006404683,0.00008531945,0.00022069617,0.00040774298,0.7173641,0.000024887146,0.0029528532,0.0008235402],"about_ca_topic_score_codex":0.0007867441,"about_ca_topic_score_gemma":0.00008451167,"teacher_disagreement_score":0.20379594,"about_ca_system_score_codex":0.00033895395,"about_ca_system_score_gemma":0.00040008425,"threshold_uncertainty_score":0.99951994},"labels":[],"label_agreement":null},{"id":"W1989273697","doi":"10.1172/jci32103","title":"Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Investigation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":835,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute of Allergy and Infectious Diseases; Canadian Institutes of Health Research; School of Medicine, Stanford University; National Heart, Lung, and Blood Institute; School of Medicine, Oregon Health and Science University; National Cancer Institute; National Institutes of Health; National Center for Research Resources; Cancer Research Institute","keywords":"Adoptive cell transfer; Cytotoxic T cell; Biology; CD8; Effector; Immunology; T cell; Immunotherapy; Antigen; Cell biology; Immune system; In vitro; Genetics","score_opus":0.07917265780015434,"score_gpt":0.3354791466112934,"score_spread":0.25630648881113904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1989273697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969844,0.0005033549,0.00009851745,0.0005403641,0.00066301733,0.0005425514,0.000019112082,0.000011952197,0.0006367349],"genre_scores_gemma":[0.9943975,0.0011090956,0.0030932701,0.00033935052,0.0005977594,0.0000040605532,0.000019290668,0.000036222104,0.0004034417],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9955803,0.00072510535,0.002087693,0.00029081877,0.0009518571,0.0003641894],"domain_scores_gemma":[0.9961279,0.0019464025,0.00055531727,0.00027611168,0.0005034066,0.00059086876],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017258461,0.00022711344,0.0011266329,0.00025603242,0.000044067845,0.000018561544,0.0002303376,0.00030305627,0.000809481],"category_scores_gemma":[0.0006313491,0.00018567832,0.00075380737,0.00023938558,0.0006549574,0.00029621008,0.000030650153,0.0010846966,0.000016662578],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00207448,0.0007062325,0.04299587,0.00019108572,0.00017970176,0.00018297408,0.0026780325,0.00065917015,0.9481181,0.0000012434574,0.00067076954,0.0015423642],"study_design_scores_gemma":[0.0060269753,0.0017284831,0.15562727,0.0003859039,0.00021220345,0.000027511946,0.00061812147,0.00076470966,0.83428115,0.000045132474,0.00013368396,0.0001488735],"about_ca_topic_score_codex":0.00016047127,"about_ca_topic_score_gemma":0.000017770795,"teacher_disagreement_score":0.11383694,"about_ca_system_score_codex":0.00017483241,"about_ca_system_score_gemma":0.0008389903,"threshold_uncertainty_score":0.88632494},"labels":[],"label_agreement":null},{"id":"W1995172908","doi":"10.1097/01.tp.0000332697.73980.0c","title":"ADOPTIVE TRANSFER OF CD4+CD25+ REGULATORY CELLS COMBINED WITH LOW-DOSE SIROLIMUS PRESERVES SUPPRESSIVE FUNCTION OF REGULATORY T CELLS AND DELAYED ACUTE REJECTION OF RENAL ALLOGRAFTS IN CYNOMOLGUS MONKEYS","year":2008,"lang":"en","type":"article","venue":"Transplantation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Notre-Dame","funders":"","keywords":"Sirolimus; Adoptive cell transfer; IL-2 receptor; Function (biology); Regulatory T cell; Medicine; Immunology; FOXP3; Cell biology; Internal medicine; Biology; Immune system; T cell","score_opus":0.011629538001184764,"score_gpt":0.23509310440200626,"score_spread":0.2234635664008215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995172908","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973157,0.00015671206,0.0009164018,0.000023987717,0.000056969668,0.0011287503,0.0001324061,0.00002580845,0.00024328772],"genre_scores_gemma":[0.9977905,0.0012702044,0.0002725804,0.000013016558,0.000023059709,0.000036917274,0.00016917984,0.00003945885,0.00038505488],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99793625,0.00020353937,0.0006289075,0.00035606697,0.0006247085,0.00025052007],"domain_scores_gemma":[0.99894506,0.00016562911,0.0001777783,0.00030987838,0.00029508138,0.00010657537],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023471982,0.0002317523,0.0005671692,0.0004276361,0.000044154185,0.000003497866,0.00008331426,0.00020673989,0.000116211275],"category_scores_gemma":[0.00000418464,0.00020894592,0.000113257745,0.00040223007,0.0004115426,0.00022773983,0.000006986037,0.00025304378,6.3944304e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05347566,0.00044479952,0.004216403,0.0009401505,0.00040440308,0.00010144687,0.0055166604,0.0016443332,0.93268865,0.000022069817,0.000024319825,0.0005211229],"study_design_scores_gemma":[0.009158929,0.0035296164,0.22676787,0.00037339344,0.00040620173,0.00006466607,0.00016027261,0.00048329838,0.75888854,0.000025156287,0.0000054899606,0.00013657202],"about_ca_topic_score_codex":0.00037196127,"about_ca_topic_score_gemma":0.00020021909,"teacher_disagreement_score":0.22255147,"about_ca_system_score_codex":0.00005908698,"about_ca_system_score_gemma":0.00015109938,"threshold_uncertainty_score":0.8520567},"labels":[],"label_agreement":null},{"id":"W1995574992","doi":"10.1016/s0008-8749(02)00508-7","title":"Synergistic effect of adoptive T-cell therapy and intratumoral interferon γ-inducible protein-10 transgene expression in treatment of established tumors","year":2002,"lang":"en","type":"article","venue":"Cellular Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan","funders":"","keywords":"Adoptive cell transfer; Biology; Cancer research; Cytotoxic T cell; Immunotherapy; Cell therapy; CD8; T cell; IL-2 receptor; Perforin; Interleukin 21; Genetic enhancement; Immunology; Cell; Immune system; In vitro","score_opus":0.027188119436949737,"score_gpt":0.2616038370125026,"score_spread":0.23441571757555288,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1995574992","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98604375,0.011201048,0.000023620538,0.00006108069,0.00006200974,0.001519346,0.000005462567,0.000019814393,0.0010638963],"genre_scores_gemma":[0.9955562,0.0010467181,0.00010934584,0.0000036204708,0.000028810577,0.00014011901,0.000027147922,0.000040732008,0.0030473184],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99813867,0.00043530492,0.00046094315,0.00039824581,0.00018724224,0.00037962192],"domain_scores_gemma":[0.99907833,0.00013979939,0.00013805779,0.0005057586,0.00006441113,0.00007361167],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00025671136,0.00027569872,0.0008512386,0.0003705727,0.000028330263,0.000007717857,0.00013463086,0.00020014614,0.002373833],"category_scores_gemma":[0.000030020163,0.00020838402,0.00012360697,0.00030384894,0.00036979662,0.000057774643,0.000033536428,0.00024607463,0.000009130643],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057846704,0.000990552,0.00083001814,0.00016439862,0.00009469585,0.00014140546,0.0014042906,0.0000034324632,0.9714053,0.000007773716,0.000010226244,0.019163182],"study_design_scores_gemma":[0.009298092,0.019534828,0.00061766955,0.00020464566,0.000032497574,0.000018835757,0.00012899912,0.00014152624,0.96958727,0.000013794611,0.00028868386,0.00013314112],"about_ca_topic_score_codex":0.00014324293,"about_ca_topic_score_gemma":0.0000050455765,"teacher_disagreement_score":0.01903004,"about_ca_system_score_codex":0.00013936723,"about_ca_system_score_gemma":0.00004883366,"threshold_uncertainty_score":0.99853814},"labels":[],"label_agreement":null},{"id":"W1998048839","doi":"10.4161/21624011.2014.958951","title":"Unleashing antitumor T-cell activation without ensuing autoimmunity: the case for A20-deletion in adoptive CD8<sup>+</sup>T-cell therapy","year":2014,"lang":"en","type":"article","venue":"OncoImmunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Nautical Research Society","funders":"","keywords":"Autoimmunity; Cytotoxic T cell; Adoptive cell transfer; Immune system; CD8; Immunology; T cell; Inflammation; Cancer research; Immunotherapy; Immunity; Immune checkpoint; Biology; Medicine; In vitro; Biochemistry","score_opus":0.03481339900123783,"score_gpt":0.3126402239680923,"score_spread":0.2778268249668545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998048839","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867139,0.00061300554,0.0027538363,0.0018222032,0.00014580648,0.0017569977,0.000005446185,0.00011129306,0.0060775173],"genre_scores_gemma":[0.99394715,0.0004398004,0.0009538763,0.00067363353,0.00022032345,0.00025471277,0.00007018322,0.000091496346,0.0033487973],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99733686,0.00074297946,0.0004945144,0.00047992019,0.00025442353,0.0006913082],"domain_scores_gemma":[0.9974782,0.0011141433,0.00022548795,0.0008415685,0.00027408762,0.00006650184],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018764785,0.00031874847,0.0005861981,0.00038856192,0.00037908804,0.0000608128,0.00031254793,0.00031530732,0.00031019392],"category_scores_gemma":[0.00035758023,0.00024845728,0.00017247467,0.0004637239,0.0003319263,0.00019062618,0.00010740773,0.0011074999,0.00004924282],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032189996,0.00074505527,0.0029622212,0.000121125835,0.00012260649,0.00013158687,0.0071977335,0.00048705412,0.84712446,0.0005880867,0.00016787752,0.13713318],"study_design_scores_gemma":[0.058656704,0.011041819,0.018679153,0.00079036236,0.00025200768,0.0038524326,0.03276428,0.10542565,0.55991083,0.00213858,0.20468578,0.0018024361],"about_ca_topic_score_codex":0.0012862238,"about_ca_topic_score_gemma":0.000065818356,"teacher_disagreement_score":0.28721368,"about_ca_system_score_codex":0.0004145517,"about_ca_system_score_gemma":0.00024868015,"threshold_uncertainty_score":0.9999968},"labels":[],"label_agreement":null},{"id":"W1998487002","doi":"10.1016/j.tips.2010.05.003","title":"Fighting cancers from within: augmenting tumor immunity with cytokine therapy","year":2010,"lang":"en","type":"review","venue":"Trends in Pharmacological Sciences","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Immune system; Adjuvant; Immunology; Cytokine; Immunity; Medicine; Immunotherapy; Vaccination; Enthusiasm; Psychology","score_opus":0.1874054981151227,"score_gpt":0.46626342224757616,"score_spread":0.27885792413245347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1998487002","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.045382734,0.9335292,0.0000011390287,0.00018240041,0.00049931504,0.0008520568,0.00004963787,0.00012602498,0.019377496],"genre_scores_gemma":[0.0039091823,0.9920926,0.001001778,0.00034595793,0.0006262111,0.00028965902,0.00007668934,0.000041224823,0.0016166994],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99587125,0.00050846837,0.0007555168,0.00096904335,0.0010493624,0.00084637775],"domain_scores_gemma":[0.99802226,0.00083156873,0.0004704533,0.00031502146,0.00006378707,0.00029689158],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0021087164,0.0005586574,0.0018123114,0.0005607494,0.00037306506,0.00012799414,0.0010119512,0.0002774471,0.022080807],"category_scores_gemma":[0.000088072426,0.00029403513,0.0003141614,0.0027749573,0.001242826,0.00013943421,0.0002195513,0.0027040178,0.00002472282],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018390593,0.00019529644,0.00038131184,0.00018820788,0.00013892453,0.00027045558,0.000112100504,0.000007167911,0.002212195,0.000009306264,0.000110961846,0.9961902],"study_design_scores_gemma":[0.002451019,0.0013576827,0.00039895103,0.003397123,0.00039889853,0.000121731,0.000101981415,0.00022986114,0.0010040484,0.000040197658,0.9898529,0.0006455734],"about_ca_topic_score_codex":0.000989167,"about_ca_topic_score_gemma":0.0002516824,"teacher_disagreement_score":0.9955446,"about_ca_system_score_codex":0.00048800104,"about_ca_system_score_gemma":0.0008359921,"threshold_uncertainty_score":0.9999512},"labels":[],"label_agreement":null},{"id":"W1999935620","doi":"10.1016/j.leukres.2009.12.008","title":"A diphtheria toxin interleukin-3 fusion protein synergizes with tyrosine kinase inhibitors in killing leukemic progenitors from BCR/ABL positive acute leukemia","year":2010,"lang":"en","type":"article","venue":"Leukemia Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"National Cancer Institute; Terry Fox Research Institute","keywords":"Dasatinib; Diphtheria toxin; Tyrosine kinase; Imatinib; Cancer research; Leukemia; Imatinib mesylate; Fusion protein; Progenitor cell; Biology; Immunology; Stem cell; Signal transduction; Microbiology; Cell biology; Toxin; Myeloid leukemia; Recombinant DNA; Biochemistry","score_opus":0.020862546613417465,"score_gpt":0.3207704883987825,"score_spread":0.29990794178536506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1999935620","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99043316,0.00033779765,0.000033115062,0.001208469,0.00031457547,0.00449097,0.000076657714,0.00021435862,0.0028909072],"genre_scores_gemma":[0.98562455,0.00016526136,0.0021945862,0.00012722198,0.0013096005,0.0010639023,0.00025508046,0.0002927141,0.008967062],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9913921,0.0007800583,0.0009678916,0.001700505,0.002974073,0.0021853733],"domain_scores_gemma":[0.9955774,0.00073701737,0.00014872287,0.0016225851,0.0010061122,0.0009081546],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0027033677,0.0007549716,0.0010619198,0.0015308384,0.00043632073,0.00033181586,0.0009344258,0.000801754,0.0025087364],"category_scores_gemma":[0.00058080524,0.0006077928,0.0002649809,0.0027161883,0.0011450517,0.0004702461,0.0007188766,0.006050057,0.00028134658],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009034159,0.00029741754,0.0062978524,0.00012968037,0.00026780984,0.0022861925,0.0017069255,0.000021697233,0.95870894,0.00011593304,0.0007698201,0.020363543],"study_design_scores_gemma":[0.00942201,0.0022889357,0.007035581,0.0019517126,0.000075610806,0.00023309948,0.0011759128,0.002523261,0.9690562,0.0003400977,0.005138893,0.0007586993],"about_ca_topic_score_codex":0.014711343,"about_ca_topic_score_gemma":0.0030998976,"teacher_disagreement_score":0.019604843,"about_ca_system_score_codex":0.0077296044,"about_ca_system_score_gemma":0.0052355235,"threshold_uncertainty_score":0.99963737},"labels":[],"label_agreement":null},{"id":"W2004715375","doi":"10.1371/journal.pone.0028232","title":"B7-H4 Treatment of T Cells Inhibits ERK, JNK, p38, and AKT Activation","year":2012,"lang":"en","type":"article","venue":"PLoS ONE","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Canadian Institutes of Health Research; Michael Smith Health Research BC","keywords":"Protein kinase B; p38 mitogen-activated protein kinases; MAPK/ERK pathway; Cell biology; Chemistry; PI3K/AKT/mTOR pathway; Cancer research; Kinase; Signal transduction; Biology","score_opus":0.10702791174885241,"score_gpt":0.304363100164806,"score_spread":0.1973351884159536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004715375","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99422014,0.00047666882,0.0000059005124,0.00041215259,0.000017381415,0.0005279998,0.0000055991663,0.000021376653,0.004312798],"genre_scores_gemma":[0.98968154,0.0004283956,0.0004927697,0.000051607694,0.0002326995,0.000028950415,0.000015862419,0.000020692236,0.009047458],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99915457,0.00003406485,0.00013667434,0.00012210949,0.00033590762,0.0002166876],"domain_scores_gemma":[0.99944293,0.00008631884,0.00004441901,0.0002100503,0.00007544615,0.00014083085],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00011055923,0.000092623384,0.0002441853,0.000097463686,0.000024152097,0.0000057033067,0.000023767885,0.000062368206,0.0009727874],"category_scores_gemma":[0.000027895661,0.000075624645,0.000035237783,0.00012137101,0.000048396494,0.00008023829,0.000017609775,0.00006840248,0.00004675182],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030488757,0.0030680303,0.023806732,0.00013442959,0.0002033082,0.000001231167,0.0009998017,9.926413e-8,0.961938,0.00001830362,0.00006314012,0.009462018],"study_design_scores_gemma":[0.0017938304,0.00085792615,0.009794376,0.00009645947,0.000110245004,0.0000021486026,0.000064612505,0.000028805378,0.9859095,0.000013077526,0.001268211,0.000060806524],"about_ca_topic_score_codex":0.00007091064,"about_ca_topic_score_gemma":0.000004229517,"teacher_disagreement_score":0.023971481,"about_ca_system_score_codex":0.00010604639,"about_ca_system_score_gemma":0.0000284484,"threshold_uncertainty_score":0.99994045},"labels":[],"label_agreement":null},{"id":"W2004772469","doi":"10.1073/pnas.1221609110","title":"T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy","year":2013,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":243,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"National Institute of General Medical Sciences; National Cancer Institute","keywords":"Avidity; T-cell receptor; Autoimmunity; CD8; Immunotherapy; Biology; T cell; Immunology; Antigen; Receptor; Immune system; Cytotoxic T cell; Cell biology; Adoptive cell transfer; In vitro; Cancer research; Biochemistry","score_opus":0.04937329098992603,"score_gpt":0.3259618820631226,"score_spread":0.27658859107319655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2004772469","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99004865,0.00071229733,6.969007e-8,0.0053690616,0.000010283153,0.00043079653,0.000006225803,0.000009274962,0.0034133524],"genre_scores_gemma":[0.9969051,0.00058294076,0.0010631044,0.00023739785,0.000023144072,0.000016922693,1.2059023e-7,0.00000593721,0.0011653649],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9984425,0.000036227353,0.00029941447,0.00022700372,0.00081238785,0.00018250279],"domain_scores_gemma":[0.99903196,0.0004090289,0.00020799918,0.000016029831,0.00028121588,0.000053760625],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032166631,0.00010547666,0.0002260999,0.00026786773,0.00015671019,0.000037277514,0.00033791957,0.00008979397,0.00020662445],"category_scores_gemma":[0.0006784491,0.00007109276,0.000043538166,0.00066544965,0.0013175374,0.0003555588,0.00015337949,0.00032768256,0.0000026961707],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033022554,0.00012637019,0.056625385,0.00009706688,0.0000050284452,9.553935e-9,0.0003210995,7.8045036e-7,0.9410678,0.0003109459,0.0004567167,0.0006585707],"study_design_scores_gemma":[0.0007946948,0.00015936635,0.55666703,0.000073625866,0.0000034579678,0.00000958266,0.00025110098,0.00016324951,0.43810225,0.003343594,0.00036890912,0.00006313664],"about_ca_topic_score_codex":0.00011082625,"about_ca_topic_score_gemma":1.6757178e-7,"teacher_disagreement_score":0.50296557,"about_ca_system_score_codex":0.000044141747,"about_ca_system_score_gemma":0.000082195016,"threshold_uncertainty_score":0.48545215},"labels":[],"label_agreement":null},{"id":"W2005406905","doi":"10.1371/journal.pone.0032420","title":"Embryonic Stem Cell-Derived Factors Inhibit T Effector Activation and Induce T Regulatory Cells by Suppressing PKC-θ Activation","year":2012,"lang":"en","type":"article","venue":"PLoS ONE","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"King Saud bin Abdulaziz University for Health Science; Canadian Blood Services; Canadian Institutes of Health Research; Government of Ontario; University of Ottawa","keywords":"Cell biology; Protein kinase C; T cell; Embryonic stem cell; IL-2 receptor; Signal transduction; Biology; Transcription factor; FOXP3; Chemistry; Immune system; Immunology; Biochemistry","score_opus":0.05209488130475428,"score_gpt":0.2657956606357296,"score_spread":0.21370077933097534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005406905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978423,0.00024972274,0.0000436101,0.00021653951,0.000053067502,0.0009528146,0.000010082622,0.000103630286,0.000528199],"genre_scores_gemma":[0.99496543,0.00005243032,0.00013136803,0.00009196313,0.00025035522,0.000038911763,0.00009439491,0.00007245513,0.0043026744],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99809486,0.0001716538,0.00022329866,0.00031851043,0.0007177531,0.00047392305],"domain_scores_gemma":[0.99876845,0.0003248161,0.0001407089,0.00036261132,0.00011097376,0.00029242635],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032301497,0.00023219732,0.00037173872,0.0001725745,0.00013716417,0.00005234894,0.00007340074,0.00022591837,0.000477946],"category_scores_gemma":[0.000051145296,0.00021427163,0.00005379632,0.000223601,0.000081768565,0.0005091898,0.000066558605,0.00045901755,0.0000340355],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023523545,0.0009615234,0.012964861,0.0004164112,0.0001396156,5.3439237e-7,0.0012558716,3.952614e-7,0.98140323,0.0000014780982,0.0004394118,0.002181402],"study_design_scores_gemma":[0.0013600364,0.00019980363,0.032597836,0.00035374778,0.00009133451,9.76107e-7,0.00026958084,0.00006191849,0.96453893,0.0000019535266,0.00032955568,0.00019431993],"about_ca_topic_score_codex":0.000026965656,"about_ca_topic_score_gemma":5.5419787e-7,"teacher_disagreement_score":0.019632977,"about_ca_system_score_codex":0.00030813078,"about_ca_system_score_gemma":0.000068632755,"threshold_uncertainty_score":0.87377435},"labels":[],"label_agreement":null},{"id":"W2006202814","doi":"10.1002/eji.200636726","title":"JNK2 negatively regulates CD8<sup>+</sup> T cell effector function and anti‐tumor immune response","year":2007,"lang":"en","type":"article","venue":"European Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Allergy and Infectious Diseases","keywords":"Biology; Cytotoxic T cell; CD8; Immune system; Effector; Cell biology; Granzyme B; T cell; Immunology; In vitro; Biochemistry","score_opus":0.014185191460929473,"score_gpt":0.2609474413674198,"score_spread":0.24676224990649034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2006202814","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902153,0.005416133,0.00048497316,0.0006946267,0.00030594761,0.00024377619,0.000002341372,0.000031925752,0.00260499],"genre_scores_gemma":[0.994055,0.00033743304,0.00048775962,0.00019571616,0.00035187323,5.5305776e-7,0.000003289485,0.00007640398,0.004491987],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.996353,0.001821495,0.00078944524,0.00023659137,0.0003173886,0.00048211578],"domain_scores_gemma":[0.9978636,0.0007961263,0.00042753533,0.00035742228,0.00037341294,0.00018192756],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0061314614,0.00023367713,0.0005558534,0.00060550164,0.00012962939,0.0000356762,0.00022090308,0.000064325715,0.0008550298],"category_scores_gemma":[0.0006612056,0.00018710882,0.00019173409,0.00031346266,0.00039159882,0.0001398854,0.00012210048,0.00094968337,0.00016245652],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032709077,0.00016636465,0.0015240143,0.000034780587,0.00029043088,0.002050525,0.00066440884,0.000010520607,0.94300014,0.000010643639,0.00040282295,0.019136248],"study_design_scores_gemma":[0.009722223,0.009279218,0.70102847,0.00022669473,0.0001339885,0.0054812785,0.0008617731,0.00003055541,0.23545758,0.000022383845,0.037537087,0.0002187319],"about_ca_topic_score_codex":0.0000062851364,"about_ca_topic_score_gemma":2.4577176e-7,"teacher_disagreement_score":0.7075426,"about_ca_system_score_codex":0.00012271147,"about_ca_system_score_gemma":0.000121409845,"threshold_uncertainty_score":0.9361977},"labels":[],"label_agreement":null},{"id":"W2007861438","doi":"10.1016/j.celrep.2013.06.016","title":"A Hybrid Mechanism of Action for BCL6 in B Cells Defined by Formation of Functionally Distinct Complexes at Enhancers and Promoters","year":2013,"lang":"en","type":"article","venue":"Cell Reports","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":196,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"National Cancer Institute","keywords":"Corepressor; Enhancer; Repressor; Promoter; Germinal center; Biology; BCL6; Epigenetics; Cell biology; Psychological repression; Chromatin; Death-associated protein 6; Genetics; Transcription factor; B cell; Gene; Nuclear protein; Gene expression","score_opus":0.023551413400595068,"score_gpt":0.2725848694703221,"score_spread":0.24903345606972704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2007861438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99391216,0.000076485325,0.003500378,0.00007481746,0.00010162682,0.0013069832,0.000009347703,0.00001591319,0.0010022812],"genre_scores_gemma":[0.9959445,0.000045099732,0.00056020473,0.000016084321,0.000017741932,0.00011030056,0.00009788589,0.000019615545,0.003188581],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989186,0.000021494001,0.00044789346,0.00019256602,0.00026186206,0.00015758154],"domain_scores_gemma":[0.9992031,0.00008484981,0.00030188248,0.0001817171,0.0001615203,0.000066968874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028869146,0.000095264295,0.0002479215,0.00010960649,0.000028020402,0.000006761105,0.000023476256,0.000045275945,0.00055169803],"category_scores_gemma":[0.00004040316,0.00008620713,0.000062340696,0.000069730086,0.00005403161,0.00010466738,0.000026503323,0.0000635697,0.0000026137557],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022512574,0.000119765515,0.0007306513,0.0005425414,0.000013353453,0.000006789562,0.00013367737,0.0000025894674,0.9927987,0.0000066671064,0.0019394741,0.0034806835],"study_design_scores_gemma":[0.0008491273,0.000399866,0.0016672775,0.000057153047,0.000023090646,0.0000898587,0.00007037374,0.0009397947,0.99390864,0.0006491876,0.0012763477,0.00006928358],"about_ca_topic_score_codex":0.0002853574,"about_ca_topic_score_gemma":0.00004245237,"teacher_disagreement_score":0.0034114,"about_ca_system_score_codex":0.00014058861,"about_ca_system_score_gemma":0.00006472521,"threshold_uncertainty_score":0.60407066},"labels":[],"label_agreement":null},{"id":"W2008355700","doi":"10.1089/hum.2010.126","title":"T-Cell Receptor Gene Therapy in Human Melanoma-Bearing Immune-Deficient Mice: Human but not Mouse T Cells Recapitulate Outcome of Clinical Studies","year":2011,"lang":"en","type":"article","venue":"Human Gene Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Erasmus+; Institute of Genetics; Erasmus Medisch Centrum; European Commission","keywords":"Genetic enhancement; Immune system; Immunology; Melanoma; Biology; Receptor; Cancer research; Cell therapy; Gene; Cell; Medicine; Genetics","score_opus":0.25570744165459464,"score_gpt":0.42328980427734475,"score_spread":0.16758236262275011,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2008355700","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9561322,0.040145114,0.0000051122993,0.00003185567,0.00031966937,0.0019531308,0.000017937562,0.00015371382,0.0012413205],"genre_scores_gemma":[0.9172092,0.07140375,0.00082780106,0.00022659915,0.000371811,0.00014117917,0.0000479404,0.00025055476,0.009521173],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99314344,0.00078354916,0.0029458003,0.001147681,0.00092174904,0.0010577921],"domain_scores_gemma":[0.99651265,0.0002132715,0.00078093086,0.0018239422,0.00036160822,0.0003075958],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0034432434,0.0007445009,0.0024467444,0.00073379104,0.00038418328,0.000042266412,0.0008930182,0.0004200962,0.0035957047],"category_scores_gemma":[0.000028713966,0.0006294231,0.0009140099,0.00045935932,0.000673407,0.0001195329,0.0002545903,0.0010778304,0.00012548245],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015506676,0.00239278,0.012653842,0.00016143433,0.00064766966,0.00006669606,0.006415384,0.0000059130643,0.9671038,0.00007900611,0.00007170997,0.008851124],"study_design_scores_gemma":[0.011233315,0.0041489126,0.013628296,0.00012764632,0.00005748423,0.00001343303,0.00068153295,0.000005135101,0.96675694,0.00010759027,0.002624118,0.0006156155],"about_ca_topic_score_codex":0.0008045198,"about_ca_topic_score_gemma":0.000058041955,"teacher_disagreement_score":0.038922958,"about_ca_system_score_codex":0.0002632051,"about_ca_system_score_gemma":0.0001139769,"threshold_uncertainty_score":0.9996157},"labels":[],"label_agreement":null},{"id":"W2010214177","doi":"10.1371/journal.pone.0094817","title":"Development of Genetically Flexible Mouse Models of Sarcoma Using RCAS-TVA Mediated Gene Delivery","year":2014,"lang":"en","type":"article","venue":"PLoS ONE","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"","keywords":"Sarcoma; Mesenchymal stem cell; Biology; Progenitor cell; Cancer research; Oncogene; Population; Cell cycle; Cell; Immunology; Medicine; Pathology; Stem cell; Cell biology; Genetics","score_opus":0.1370266237838407,"score_gpt":0.29660518469194,"score_spread":0.15957856090809933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010214177","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99524426,0.00024549518,0.0027280562,0.000058891703,0.000010696385,0.0004021026,0.000008752607,0.000039430088,0.0012622862],"genre_scores_gemma":[0.85418063,0.00014140122,0.14455307,0.000076132106,0.00006116615,0.000011391413,0.000027666612,0.000046705805,0.000901853],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99790657,0.00007382037,0.0005233847,0.00023906858,0.00092930254,0.00032784784],"domain_scores_gemma":[0.99869233,0.00012692435,0.0001092997,0.00043134874,0.0004474487,0.00019264636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045320726,0.00014268504,0.00052323035,0.0002214007,0.000035757665,0.0000055741807,0.0001609451,0.0001090237,0.00073828414],"category_scores_gemma":[0.000112935515,0.00013603218,0.000065268374,0.00024658252,0.00011642244,0.00004424098,0.000118795084,0.00015658372,0.00002143884],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045661454,0.0014341082,0.00079188857,0.00032065783,0.0004271968,0.0000042927804,0.0005270656,0.00013146408,0.9923658,0.000043463555,0.000008104875,0.0034893847],"study_design_scores_gemma":[0.0015058701,0.00025540945,0.00058221555,0.0001802625,0.00010820765,0.00000387049,0.000028279263,0.047020607,0.95005685,0.00007610953,0.00006601956,0.00011630392],"about_ca_topic_score_codex":0.000046949695,"about_ca_topic_score_gemma":0.00001039676,"teacher_disagreement_score":0.14182502,"about_ca_system_score_codex":0.00010614332,"about_ca_system_score_gemma":0.00033277535,"threshold_uncertainty_score":0.80836934},"labels":[],"label_agreement":null},{"id":"W2010618607","doi":"10.1016/j.stem.2008.09.001","title":"The Systematic Production of Cells for Cell Therapies","year":2008,"lang":"en","type":"review","venue":"Cell stem cell","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":302,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Heart and Stroke Foundation; University Health Network; University of Toronto","funders":"Natural Sciences and Engineering Research Council of Canada; Canada Research Chairs; John Simon Guggenheim Memorial Foundation","keywords":"Expediting; Bioprocess; Biomanufacturing; Biology; Biotechnology; Biochemical engineering; Cell therapy; Stem cell; Risk analysis (engineering); Engineering; Cell biology; Systems engineering; Medicine","score_opus":0.06763248157530957,"score_gpt":0.33158083660507354,"score_spread":0.263948355029764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010618607","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008166937,0.9745192,0.00003223454,0.000029250403,0.0014124939,0.01410986,0.00003165222,0.000073649404,0.009709977],"genre_scores_gemma":[0.00008339284,0.76635015,0.00010709635,0.000010151248,0.00048012298,0.0010523007,0.000047648828,0.00021137061,0.23165774],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9949965,0.0006472961,0.0017670728,0.0008469259,0.00096188637,0.00078034186],"domain_scores_gemma":[0.9942951,0.0016797314,0.0013389481,0.0020012741,0.00047491968,0.00020999974],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012958806,0.00079590885,0.0035109767,0.00031067603,0.0003341938,0.000063709114,0.0007405905,0.0005202251,0.00015947297],"category_scores_gemma":[0.000027236494,0.0004704199,0.001734431,0.00059287966,0.0002878871,0.00005378857,0.00011324041,0.0007055904,0.000260155],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011268641,0.00047287508,6.2214957e-7,0.84949726,0.00030745025,0.000015048006,0.00070813874,0.0000013987977,0.0051115463,0.0000059370586,0.011333006,0.13243401],"study_design_scores_gemma":[0.00076012494,0.0005294415,9.68428e-8,0.025356518,0.0013038723,0.00007726531,0.0004753018,0.000009000837,0.02980146,0.0000055937176,0.941287,0.0003943501],"about_ca_topic_score_codex":0.000012271893,"about_ca_topic_score_gemma":0.0000027087904,"teacher_disagreement_score":0.929954,"about_ca_system_score_codex":0.00034507163,"about_ca_system_score_gemma":0.00075875426,"threshold_uncertainty_score":0.99977475},"labels":[],"label_agreement":null},{"id":"W2011291539","doi":"10.1016/j.tmrv.2007.05.007","title":"Cellular Therapies: A Canadian Blood Services Research and Development Symposium","year":2007,"lang":"en","type":"article","venue":"Transfusion Medicine Reviews","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine","score_opus":0.07950197469516655,"score_gpt":0.37290959930709583,"score_spread":0.29340762461192926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2011291539","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81810105,0.13680422,0.00031409174,0.008002179,0.00021065309,0.004260836,0.0000026175005,0.00007532633,0.03222905],"genre_scores_gemma":[0.08530248,0.8912709,0.0019980837,0.0029348675,0.001288055,0.00018270235,0.000112962545,0.00013466463,0.016775314],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964079,0.00023249273,0.0007979481,0.00055406877,0.0010776093,0.00092997804],"domain_scores_gemma":[0.9976411,0.00022988798,0.00005385597,0.00057985634,0.00031123727,0.0011841054],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.008587369,0.0002879543,0.0007861261,0.00083371974,0.00036532144,0.000020707372,0.00023790162,0.00017701663,0.0061956597],"category_scores_gemma":[0.000035988785,0.00019407994,0.00006903307,0.00089112244,0.00033191833,0.00005798913,0.00003116214,0.0007370676,0.00013979003],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000277263,0.00019435125,0.011993263,0.0020402865,0.00012587331,0.0003653787,0.018617082,2.7298304e-8,0.66352487,0.00008093336,0.00077619636,0.30200452],"study_design_scores_gemma":[0.0025907573,0.00093560625,0.003210477,0.0021089825,0.000080826154,0.00016492498,0.002111721,0.0000040725968,0.025386034,0.000024657735,0.96318275,0.00019918518],"about_ca_topic_score_codex":0.060799595,"about_ca_topic_score_gemma":0.14616366,"teacher_disagreement_score":0.9624066,"about_ca_system_score_codex":0.00018655576,"about_ca_system_score_gemma":0.00043041116,"threshold_uncertainty_score":0.9947128},"labels":[],"label_agreement":null},{"id":"W2013046654","doi":"10.1016/j.cellimm.2012.01.004","title":"The activation, by antigen, of naïve TCR transgenic CD4 T cells cultured at physiological, rather than artificially high, frequencies more accurately reflects the in vivo activation of normal numbers of naïve CD4+ T cells","year":2012,"lang":"en","type":"article","venue":"Cellular Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Biology; T-cell receptor; Molecular biology; Cell biology; In vivo; T cell; Population; CD80; CD40; In vitro; Immunology; Cytotoxic T cell; Immune system; Biochemistry; Genetics","score_opus":0.04038695446152873,"score_gpt":0.3019408328044642,"score_spread":0.2615538783429355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2013046654","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995809,0.00133514,0.00009733313,0.00071385456,0.00023622537,0.0010545197,0.00003380506,0.000022745071,0.0006973589],"genre_scores_gemma":[0.9963612,0.0011041579,0.00008202206,0.00007720735,0.0000776403,0.000051588846,0.000077928715,0.000044211483,0.0021240222],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99707973,0.000595628,0.0008258861,0.00033632276,0.00048541068,0.00067704095],"domain_scores_gemma":[0.9977699,0.00044661647,0.0005902612,0.00079347135,0.00033302247,0.0000667306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007528065,0.0003180682,0.0006832601,0.00013724966,0.00018631727,0.000012315833,0.0005158094,0.0004299386,0.000846021],"category_scores_gemma":[0.00012411582,0.00019537556,0.00025586947,0.00066321215,0.0012295627,0.00018270257,0.00010309368,0.00055378414,0.000014935668],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015323961,0.00043346413,0.0004969979,0.00006825868,0.0003523101,0.0000016526836,0.005766877,0.0000463677,0.989935,0.00021881575,0.00069873,0.00044917653],"study_design_scores_gemma":[0.0011930135,0.0004742994,0.0050656223,0.00005751576,0.000046016303,0.000003974959,0.0022266496,0.00001990398,0.98693734,0.00010145109,0.003703035,0.00017118685],"about_ca_topic_score_codex":0.00055210036,"about_ca_topic_score_gemma":0.000056364024,"teacher_disagreement_score":0.0045686243,"about_ca_system_score_codex":0.00018683531,"about_ca_system_score_gemma":0.0001993681,"threshold_uncertainty_score":0.92633367},"labels":[],"label_agreement":null},{"id":"W2014381944","doi":"10.1017/s0317167100002055","title":"Human Autologous In Vitro Models of Glioma Immunogene Therapy Using B7-2, GM-CSF, and IL12","year":2002,"lang":"en","type":"article","venue":"Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; University of Alberta","funders":"Fondation pour la Recherche Médicale; University of Alberta; Congress of Neurological Surgeons","keywords":"Interleukin 12; Peripheral blood mononuclear cell; Cytotoxic T cell; Glioma; Immunology; CD8; Cancer research; Biology; Granulocyte macrophage colony-stimulating factor; Immunotherapy; Molecular biology; Immune system; Cytokine; In vitro","score_opus":0.10671148152665887,"score_gpt":0.3251389034829766,"score_spread":0.2184274219563177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014381944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989741,0.005623899,0.00000853309,0.001925408,0.00024336082,0.00023867661,0.0000072316707,0.000010038899,0.002201832],"genre_scores_gemma":[0.9962991,0.001094925,0.0013340699,0.001079676,0.00013472947,0.0000017120584,1.4619202e-7,0.000015342635,0.00004033327],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99525607,0.0008765621,0.0010672668,0.00051211147,0.00093371485,0.0013542944],"domain_scores_gemma":[0.9969025,0.00032372418,0.00062753336,0.00019557342,0.00044963567,0.0015010157],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0038106027,0.00032100859,0.00080059643,0.001877256,0.0012669177,0.0003121225,0.0012228452,0.0002294055,0.0005926646],"category_scores_gemma":[0.0006344859,0.00022125253,0.00023178245,0.0017984299,0.007477254,0.0008166823,0.00007248015,0.0013065531,6.760877e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001245567,0.00038099277,0.6585853,0.000045814904,0.00010909301,0.037375517,0.0029051881,0.010113023,0.23036107,0.0007932367,0.00022496113,0.057860192],"study_design_scores_gemma":[0.005950823,0.23865269,0.30043188,0.0003037175,0.000141288,0.29013574,0.0011657333,0.10112633,0.02424566,0.034814794,0.0016103365,0.0014210157],"about_ca_topic_score_codex":0.004797166,"about_ca_topic_score_gemma":0.014345307,"teacher_disagreement_score":0.35815346,"about_ca_system_score_codex":0.00027253668,"about_ca_system_score_gemma":0.0012597019,"threshold_uncertainty_score":0.9952238},"labels":[],"label_agreement":null},{"id":"W2014711973","doi":"10.1038/sj.cgt.7700685","title":"Carcinoembryonic antigen-immunoglobulin Fc fusion protein (CEA-Fc) for identification and activation of anti-CEA immunoglobulin-T-cell receptor-modified T cells, representative of a new class of Ig fusion proteins","year":2004,"lang":"en","type":"article","venue":"Cancer Gene Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Carcinoembryonic antigen; Fusion protein; Antibody; Molecular biology; Fc receptor; Chemistry; Antigen; Monoclonal antibody; Fragment crystallizable region; Chimeric antigen receptor; Immunoglobulin G; Receptor; T cell; Immune system; Biology; Recombinant DNA; Immunology; Biochemistry; Cancer","score_opus":0.043963003631289674,"score_gpt":0.3274272862154109,"score_spread":0.2834642825841212,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2014711973","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98316693,0.005636324,0.0035023782,0.00057094084,0.00017328621,0.0066836528,0.00014357618,0.000035097284,0.00008778158],"genre_scores_gemma":[0.98213637,0.01316774,0.0022001353,0.00003429564,0.00015393805,0.00031326283,0.0001953527,0.00008389418,0.0017149984],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99706405,0.00016415725,0.0010152194,0.00064620504,0.00071525085,0.0003951093],"domain_scores_gemma":[0.9971073,0.00007449961,0.0009451232,0.0008809948,0.0008521048,0.00013994676],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006656023,0.00033728342,0.00082035037,0.00029991614,0.000117767566,0.000020549334,0.00029226634,0.00025497607,0.0003946086],"category_scores_gemma":[0.000053427044,0.0003107593,0.0002460269,0.0006950698,0.0002693805,0.00017337714,0.00008159094,0.00026542594,0.0000033031197],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012026362,0.000639793,0.0007179864,0.0005936934,0.00021601653,8.8667963e-7,0.0034928333,0.00050296244,0.9638987,0.000021808686,0.00021098535,0.017677974],"study_design_scores_gemma":[0.012117394,0.0023881197,0.0081251925,0.0005337271,0.000045922337,0.0000029872247,0.0006973917,0.00016890981,0.97472805,0.00021294462,0.000741113,0.00023825919],"about_ca_topic_score_codex":0.0035743695,"about_ca_topic_score_gemma":0.00003721614,"teacher_disagreement_score":0.017439714,"about_ca_system_score_codex":0.0002760433,"about_ca_system_score_gemma":0.0011276895,"threshold_uncertainty_score":0.99993443},"labels":[],"label_agreement":null},{"id":"W2015663429","doi":"10.1038/mt.2013.255","title":"Immunotherapy-induced CD8+ T Cells Instigate Immune Suppression in the Tumor","year":2013,"lang":"en","type":"article","venue":"Molecular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster University Medical Centre","funders":"Canadian Institutes of Health Research; Terry Fox Foundation; McMaster University","keywords":"Immune system; Immunogenicity; Immunosuppression; Immunotherapy; CD8; Immunology; Melanoma; Cancer immunotherapy; Cytotoxic T cell; Adoptive cell transfer; T cell; Vaccination; Acquired immune system; Cancer research; Biology; Medicine; In vitro","score_opus":0.021438038717656427,"score_gpt":0.291111750775051,"score_spread":0.2696737120573946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2015663429","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869381,0.0024304425,0.00006334394,0.003580849,0.00018026153,0.0023168614,0.0000018273994,0.00006831107,0.0044199885],"genre_scores_gemma":[0.9919285,0.00071474956,0.00021954921,0.004981277,0.00009078878,0.00037151514,0.000019534034,0.000097235556,0.001576829],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99727005,0.00046008278,0.00044426348,0.00042118956,0.0007720085,0.0006324367],"domain_scores_gemma":[0.9983472,0.000101937774,0.00009266398,0.0012118563,0.00012289913,0.00012342082],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000698708,0.00032343558,0.0004339038,0.00023364142,0.00011151261,0.00011992687,0.0005717825,0.00013709527,0.0053313817],"category_scores_gemma":[0.000023837632,0.00020768662,0.0002676188,0.0005807655,0.00011938737,0.00012267599,0.00005351019,0.00068912975,0.00046256103],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004077191,0.0003199617,0.0002729065,0.000013588463,0.00008146281,0.00020553046,0.0011760273,0.000005585436,0.94703233,0.000042269374,0.00032860614,0.05011403],"study_design_scores_gemma":[0.0049171117,0.0006196655,0.010762637,0.00007714912,0.0000071188406,0.000072293515,0.00027792284,0.00016875022,0.95820177,0.00044152007,0.024208317,0.00024575714],"about_ca_topic_score_codex":0.00073808123,"about_ca_topic_score_gemma":0.0000048219686,"teacher_disagreement_score":0.04986827,"about_ca_system_score_codex":0.000094537056,"about_ca_system_score_gemma":0.00012066054,"threshold_uncertainty_score":0.9955779},"labels":[],"label_agreement":null},{"id":"W2020138546","doi":"10.1038/cmi.2012.37","title":"A novel T cell-based vaccine capable of stimulating long-term functional CTL memory against B16 melanoma via CD40L signaling","year":2012,"lang":"en","type":"article","venue":"Cellular and Molecular Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; University of Saskatchewan; Saskatchewan Cancer Agency","funders":"Canadian Institutes of Health Research; Saskatchewan Health Research Foundation","keywords":"CTL*; Melanoma; CD40; Term (time); Immunology; Medicine; Cancer research; Biology; Virology; Immune system; Cytotoxic T cell; Genetics; CD8","score_opus":0.018455802643470517,"score_gpt":0.25652043286581316,"score_spread":0.23806463022234264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020138546","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91893965,0.011625022,0.06712402,0.00010586316,0.00022047084,0.000450034,0.0000047614917,0.000039995586,0.0014902065],"genre_scores_gemma":[0.997334,0.000046204306,0.001126764,0.00027710016,0.0001275643,0.000025564386,0.0002005814,0.00006660356,0.0007956111],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99815524,0.0001231975,0.000428958,0.0003492055,0.00031410923,0.0006293209],"domain_scores_gemma":[0.99888206,0.00012997353,0.00014643307,0.00047730975,0.00018224864,0.00018196524],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00045243037,0.00026983072,0.00051851943,0.0002859466,0.00011295642,0.000012661254,0.000121546655,0.0002466958,0.0010910016],"category_scores_gemma":[0.00005349336,0.0002618028,0.00019480512,0.00022062357,0.00014578165,0.00006709898,0.00011208081,0.00040882936,0.000020199246],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006346764,0.00045065276,0.012586306,0.00018887289,0.00029475798,0.00009730474,0.0001545925,0.00041355312,0.9819091,0.00004145925,0.000011229865,0.0032174888],"study_design_scores_gemma":[0.0054101846,0.0005013428,0.007755848,0.000077671175,0.00016637388,0.00010032215,0.00006300631,0.001325281,0.9841119,0.000009786886,0.00024175127,0.00023652131],"about_ca_topic_score_codex":0.00005935622,"about_ca_topic_score_gemma":0.0000019389504,"teacher_disagreement_score":0.078394376,"about_ca_system_score_codex":0.00008296521,"about_ca_system_score_gemma":0.00013647637,"threshold_uncertainty_score":0.99998343},"labels":[],"label_agreement":null},{"id":"W2022364340","doi":"10.4161/2162402x.2014.990803","title":"miR-23a blockade enhances adoptive T cell transfer therapy by preserving immune-competence in the tumor microenvironment","year":2015,"lang":"en","type":"article","venue":"OncoImmunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Immunosuppression; Tumor microenvironment; Adoptive cell transfer; Blockade; Medicine; CD8; Cytotoxic T cell; Immune system; T cell; Immunology; Cancer research; Tumor-infiltrating lymphocytes; Biology; Internal medicine; Receptor","score_opus":0.028752533743026068,"score_gpt":0.28106612261061253,"score_spread":0.2523135888675865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022364340","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9649888,0.022552421,0.0000440793,0.0026190968,0.00014867651,0.0009952107,0.000011441342,0.000034551354,0.008605704],"genre_scores_gemma":[0.99012125,0.0028213488,0.00021238443,0.0008262793,0.00008099109,0.00022270952,0.000037679427,0.000046017212,0.0056313486],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99750715,0.00050935167,0.00041726808,0.00044770862,0.00045572364,0.00066278543],"domain_scores_gemma":[0.9988028,0.00022355132,0.00005918497,0.00077612343,0.000050685336,0.000087691784],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008002925,0.00027625103,0.00048676218,0.00012506392,0.000081761704,0.000028290715,0.00072331756,0.00014959536,0.0017691571],"category_scores_gemma":[0.000027453185,0.00019468534,0.00012911318,0.00027360144,0.00043702414,0.00009270578,0.000096917014,0.00078544667,0.00014511695],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013175604,0.0007076594,0.0016950296,0.000015774902,0.000073600444,0.0000943091,0.0067822407,0.0000048938127,0.98506135,0.000010999453,0.0009595964,0.0032769833],"study_design_scores_gemma":[0.0065034754,0.0021690421,0.017613862,0.00005786355,0.000026173051,0.00018427805,0.0050281235,0.000040590752,0.7525325,0.00008425111,0.21548451,0.00027536752],"about_ca_topic_score_codex":0.0010114746,"about_ca_topic_score_gemma":0.00006701023,"teacher_disagreement_score":0.2325289,"about_ca_system_score_codex":0.00025147782,"about_ca_system_score_gemma":0.00019074895,"threshold_uncertainty_score":0.99914336},"labels":[],"label_agreement":null},{"id":"W2022374489","doi":"10.1002/pbc.24437","title":"Children's Oncology Group's 2013 blueprint for research: Stem cell transplantation","year":2012,"lang":"en","type":"review","venue":"Pediatric Blood & Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"National Cancer Institute; Children’s Oncology Group; National Institutes of Health; Children's Hospital of Philadelphia; American Cancer Society","keywords":"Medicine; Oncology; Hematopoietic stem cell transplantation; Stem cell; Transplantation; Internal medicine","score_opus":0.1817762848082525,"score_gpt":0.44492386670492745,"score_spread":0.263147581896675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2022374489","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006835536,0.9891764,0.000039707527,0.0001741555,0.0008071604,0.0070140096,0.0006292037,0.00009259931,0.0013832286],"genre_scores_gemma":[0.000108435226,0.97455853,0.00027580783,0.0000478088,0.01348536,0.0047075236,0.0007182796,0.0002444279,0.005853836],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9947344,0.00068064494,0.00095780025,0.0009922562,0.0011319121,0.0015029825],"domain_scores_gemma":[0.996472,0.0012756045,0.00039584874,0.0008085099,0.00041980325,0.0006282538],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0024745439,0.0006003288,0.002169176,0.001020955,0.00019932416,0.00004726478,0.00053144485,0.0009568648,0.0021959774],"category_scores_gemma":[0.000020016547,0.0004970669,0.0008908201,0.0011268322,0.00013245887,0.0000998769,0.000118214,0.0020446102,0.00029902946],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023172436,0.0007312108,0.00049830636,0.05351925,0.000490053,0.000032138825,0.00026111284,4.9349075e-7,0.00001777142,0.000022898788,0.004030979,0.9401641],"study_design_scores_gemma":[0.0027275572,0.0008583825,0.0001654368,0.0010759253,0.011431173,0.00018076692,0.000019147878,0.0000011230597,0.000025495407,0.000011287811,0.9830518,0.0004519246],"about_ca_topic_score_codex":0.0006992054,"about_ca_topic_score_gemma":0.00014806984,"teacher_disagreement_score":0.9790208,"about_ca_system_score_codex":0.00071187643,"about_ca_system_score_gemma":0.002176042,"threshold_uncertainty_score":0.9997481},"labels":[],"label_agreement":null},{"id":"W2023548208","doi":"10.1016/s0092-8674(00)00140-9","title":"Mannose 6-Phosphate/Insulin-like Growth Factor II Receptor Is a Death Receptor for Granzyme B during Cytotoxic T Cell–Induced Apoptosis","year":2000,"lang":"en","type":"article","venue":"Cell","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":388,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Alberta","funders":"","keywords":"Cytotoxic T cell; Granzyme B; Biology; Granzyme; Perforin; Cell biology; Granzyme A; Apoptosis; Molecular biology; Cancer research; Biochemistry; In vitro","score_opus":0.028643670292111612,"score_gpt":0.2806585660275285,"score_spread":0.25201489573541686,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2023548208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9866781,0.0007736487,0.000019113279,0.0008072375,0.00055545545,0.0026719049,0.00021531557,0.00028056066,0.007998664],"genre_scores_gemma":[0.80122685,0.0018686369,0.001233536,0.00070915255,0.00070055097,0.00037474476,0.00016135152,0.00023235433,0.19349283],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9959808,0.00010893912,0.0006809911,0.0011065226,0.0008058324,0.0013168895],"domain_scores_gemma":[0.99767333,0.00018267237,0.000150278,0.0009628334,0.00029458743,0.0007363002],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0003372671,0.0006131391,0.000822934,0.00029616526,0.00051422056,0.00008778509,0.00048192358,0.00043589255,0.055477735],"category_scores_gemma":[0.000050372106,0.00057779765,0.00056560175,0.00058656815,0.000090287824,0.00019311518,0.00012145935,0.00066040154,0.0018493541],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002802121,0.000857675,0.00044788184,0.0006050567,0.000107810985,0.000012120371,0.0019990646,9.9641e-7,0.97568876,0.000004568626,0.012362087,0.0051118676],"study_design_scores_gemma":[0.0072275116,0.0012736272,0.00057415996,0.000105052764,0.00007963503,0.000008946807,0.00012421701,0.000052879248,0.8750815,0.000030244255,0.11490175,0.0005404838],"about_ca_topic_score_codex":0.00016468037,"about_ca_topic_score_gemma":0.0000038730977,"teacher_disagreement_score":0.18549417,"about_ca_system_score_codex":0.00048789624,"about_ca_system_score_gemma":0.0002209977,"threshold_uncertainty_score":0.99966735},"labels":[],"label_agreement":null},{"id":"W2024119342","doi":"10.1158/1535-7163.targ-11-c225","title":"Abstract C225: Differential regulation of simultaneous antitumor and alloreactive CD8+ T cell responses in the same host by rapamycin.","year":2011,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Epitope; Immunogenicity; Vaccinia; Biology; CD8; T cell; Cytotoxic T cell; Immune system; Cancer; Adjuvant; Virus; Antigen; Immunology; Cancer research; Virology; In vitro; Recombinant DNA; Genetics; Gene","score_opus":0.03717051993193556,"score_gpt":0.30991346684701493,"score_spread":0.2727429469150794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2024119342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950419,0.0025227505,0.00019258517,0.0003130975,0.00005480974,0.0006392532,0.00004106286,0.000015676518,0.0011788777],"genre_scores_gemma":[0.99752605,0.0011622176,0.000102023165,0.0005665537,0.000034951907,0.000029904046,0.000016780981,0.000041366267,0.00052013196],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985653,0.00016376108,0.00026761816,0.00027183397,0.00045557608,0.00027591988],"domain_scores_gemma":[0.99910927,0.00020905749,0.00011897127,0.00038742088,0.00011486435,0.00006041737],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000233774,0.0001909333,0.00028874082,0.0001251127,0.000042210744,0.000018993904,0.000162019,0.00011554651,0.0005219866],"category_scores_gemma":[0.000018361572,0.0001423142,0.000084756706,0.00021178763,0.0002217886,0.000041850457,0.000030669155,0.0003118475,0.000002353262],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028509016,0.00032067156,0.0024923522,0.00006475568,0.000121068064,0.00008486626,0.0034301537,0.000005419309,0.9796812,0.000028638233,0.000018421928,0.010901531],"study_design_scores_gemma":[0.0022246852,0.0004817332,0.06291502,0.000070591625,0.00014074081,0.000022320159,0.0005694895,0.00045301617,0.9307709,0.0001373354,0.0020341338,0.00018007965],"about_ca_topic_score_codex":0.00064416666,"about_ca_topic_score_gemma":0.00006204781,"teacher_disagreement_score":0.06042267,"about_ca_system_score_codex":0.00007738357,"about_ca_system_score_gemma":0.00010362449,"threshold_uncertainty_score":0.58034045},"labels":[],"label_agreement":null},{"id":"W2028133066","doi":"10.1158/2159-8290.cd-13-0064","title":"Hit Parade for Adoptive Cell Transfer Therapy: The Best T Cells for Superior Clinical Responses","year":2013,"lang":"en","type":"letter","venue":"Cancer Discovery","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Adoptive cell transfer; Parade; Cell therapy; Cancer; Cancer therapy; Medicine; Cell; Computational biology; Computer science; Biology; T cell; Immunology; Internal medicine; Political science; Genetics; Immune system","score_opus":0.11753330179108,"score_gpt":0.3915685188405148,"score_spread":0.2740352170494348,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2028133066","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16145258,0.019214157,0.0014272921,0.78155524,0.0048274156,0.022278193,0.007661842,0.00011369931,0.0014695963],"genre_scores_gemma":[0.0054462557,0.020401068,0.00021615728,0.51443493,0.025214437,0.011658899,0.00084139255,0.0005499141,0.42123696],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959733,0.00036129617,0.0008199641,0.0010697953,0.00068590586,0.0010897588],"domain_scores_gemma":[0.99463534,0.0035588897,0.00012881424,0.0011777703,0.000331075,0.00016811368],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00073032454,0.00066856755,0.0012926477,0.00015535632,0.0002181992,0.00025230425,0.0006605277,0.001161267,0.002755529],"category_scores_gemma":[0.00006937127,0.00042328765,0.0015413332,0.00017411954,0.00069026265,0.00021147593,0.00005129965,0.0021959401,0.00007073507],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00954832,0.00022389196,0.0002804143,0.0006436859,0.000763643,0.000042676715,0.00041002425,0.0000032925373,0.019082677,0.000008356045,0.957087,0.0119060315],"study_design_scores_gemma":[0.0054801493,0.002054913,0.0001587126,0.00024925917,0.00048642282,0.000007686627,0.00023102612,0.000026793008,0.0281079,0.00007454657,0.9626121,0.000510511],"about_ca_topic_score_codex":0.00022697792,"about_ca_topic_score_gemma":0.000026668078,"teacher_disagreement_score":0.41976738,"about_ca_system_score_codex":0.0003622729,"about_ca_system_score_gemma":0.0017985943,"threshold_uncertainty_score":0.9998219},"labels":[],"label_agreement":null},{"id":"W2033172239","doi":"10.1038/leu.2011.99","title":"Anti-leukemia effect of ex vivo expanded DNT cells from AML patients: a potential novel autologous T-cell adoptive immunotherapy","year":2011,"lang":"en","type":"article","venue":"Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; Toronto General Hospital","funders":"National Institutes of Health; Government of Ontario; Ontario Institute for Cancer Research","keywords":"Ex vivo; Medicine; Granzyme; Immunotherapy; Perforin; CD8; Immunology; Myeloid leukemia; Leukemia; Granzyme B; Cancer research; CD34; Adoptive cell transfer; Peripheral blood mononuclear cell; Granzyme A; T cell; In vivo; Stem cell; Biology; Immune system; In vitro","score_opus":0.014339668091707055,"score_gpt":0.2535317871441942,"score_spread":0.23919211905248716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2033172239","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891921,0.00027107526,0.00061808235,0.000007924288,0.0005735138,0.0014061104,0.00013454726,0.00013255102,0.007664053],"genre_scores_gemma":[0.99469495,0.00022989007,0.0016782837,0.0001699849,0.00021369776,0.000058423724,0.00010021449,0.0001275334,0.002727021],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9968245,0.00021544196,0.00068066723,0.0007094644,0.00083575805,0.000734177],"domain_scores_gemma":[0.9978541,0.00025382396,0.00032134648,0.00103222,0.00027347662,0.00026503185],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000360816,0.00050481025,0.0011092438,0.00026758722,0.00008686374,0.000024977973,0.00045911528,0.00043703796,0.005489744],"category_scores_gemma":[0.000038195274,0.00041713376,0.00045445838,0.00035172317,0.0003178688,0.0001318864,0.00015091313,0.00068336655,0.0001858274],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057728374,0.00047213354,0.009579931,0.00012755011,0.0003774314,0.00007168972,0.002751344,0.000022270267,0.96847576,0.0000038571957,0.0008026408,0.011542557],"study_design_scores_gemma":[0.018765932,0.0032400806,0.05972113,0.00015884588,0.00018047835,0.0000152559705,0.00015194912,0.0005946944,0.9158785,0.000020052574,0.00088914623,0.00038395546],"about_ca_topic_score_codex":0.0055298503,"about_ca_topic_score_gemma":0.000024959709,"teacher_disagreement_score":0.05259728,"about_ca_system_score_codex":0.0012879071,"about_ca_system_score_gemma":0.0006006829,"threshold_uncertainty_score":0.99982804},"labels":[],"label_agreement":null},{"id":"W2033380259","doi":"10.1002/path.1777","title":"PU.1 protein expression has a positive linear association with protein expression of germinal centre B cell genes including <i>BCL‐6, CD10, CD20</i> and <i>CD22</i> : identification of PU.1 putative binding sites in the <i>BCL‐6</i> promotor","year":2005,"lang":"en","type":"article","venue":"The Journal of Pathology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"BCL6; Germinal center; B cell; CD22; Molecular biology; Biology; Population; Follicular lymphoma; PAX5; Transcription factor; Cell; Gene; Diffuse large B-cell lymphoma; B-cell lymphoma; Lymphoma; Antibody; Genetics; Immunology; Medicine","score_opus":0.02743003368574839,"score_gpt":0.3033733703464049,"score_spread":0.2759433366606565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2033380259","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99400276,0.00084458606,0.00037940487,0.0027856205,0.000026851178,0.0018111138,0.000027492577,0.000007428473,0.00011472107],"genre_scores_gemma":[0.99633455,0.00015972902,0.0024547854,0.00006533928,0.00019750216,0.000037950485,0.000011335007,0.00003122624,0.00070760836],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9960912,0.0015100149,0.00093722495,0.00022937146,0.00089257327,0.00033962066],"domain_scores_gemma":[0.99671113,0.00048456193,0.0018335164,0.00027166636,0.00061873964,0.00008038567],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041856533,0.00021886636,0.00055185956,0.00032579224,0.00017500954,0.000027105249,0.00028479434,0.00018764225,0.00003799267],"category_scores_gemma":[0.00033046876,0.00012325952,0.00010056937,0.00040797284,0.0002689488,0.0002903673,0.000112179994,0.0007388971,0.0000023425239],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024303433,0.00047649027,0.005061543,0.00016295446,0.000033976186,0.00009788186,0.016826116,0.000044806333,0.97251254,0.0000049061764,0.000048873466,0.0022995796],"study_design_scores_gemma":[0.0025611233,0.0012870552,0.0023706902,0.0008567098,0.0001151015,0.00043620638,0.003463113,0.0001525089,0.988411,0.000079648555,0.00015493992,0.00011191714],"about_ca_topic_score_codex":0.000014744594,"about_ca_topic_score_gemma":0.00001789213,"teacher_disagreement_score":0.015898455,"about_ca_system_score_codex":0.0002101766,"about_ca_system_score_gemma":0.00020457031,"threshold_uncertainty_score":0.50263774},"labels":[],"label_agreement":null},{"id":"W2036481615","doi":"10.1371/journal.pone.0013940","title":"Expansion and Characterization of Human Melanoma Tumor-Infiltrating Lymphocytes (TILs)","year":2010,"lang":"en","type":"article","venue":"PLoS ONE","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; Ontario Institute for Cancer Research","funders":"Canadian Breast Cancer Research Alliance; Government of Ontario; Ontario Institute for Cancer Research; Campbell Institute","keywords":"Tumor-infiltrating lymphocytes; Melanoma; Cancer research; Medicine; Biology; Pathology; Immunology; Immunotherapy; Immune system","score_opus":0.04171770144823088,"score_gpt":0.28033857371009296,"score_spread":0.23862087226186207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2036481615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99767137,0.000022008942,0.0000030806978,0.000121739096,0.00001835681,0.00030143454,0.000005142031,0.00003604713,0.0018208385],"genre_scores_gemma":[0.9979994,0.000030603256,0.00043332062,0.000062304985,0.00017438523,0.000014592422,0.000050114908,0.00002186984,0.0012133708],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99916875,0.000023077657,0.00019031034,0.00015540284,0.00031957988,0.00014285007],"domain_scores_gemma":[0.99944794,0.000044822355,0.00007251912,0.00022563244,0.0001228429,0.00008624286],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00017318009,0.000080824975,0.00023073397,0.00009543576,0.00005564914,0.00001520333,0.00004925164,0.000053885913,0.0013486963],"category_scores_gemma":[0.00008675695,0.00007397971,0.00002461852,0.00009980287,0.00007512571,0.00007219061,0.00003234442,0.00016272764,0.000009232068],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000796659,0.00034929812,0.044026576,0.0001786899,0.00004739147,0.0000068404584,0.00030224028,5.4012776e-9,0.95217174,0.00005706166,0.0000020755704,0.0027784123],"study_design_scores_gemma":[0.0008309696,0.00032005474,0.09838885,0.00017782323,0.00003938821,0.000013804113,0.000036660967,0.00025928958,0.899823,0.000021795919,0.000028053606,0.000060313774],"about_ca_topic_score_codex":0.000037864305,"about_ca_topic_score_gemma":0.000012070329,"teacher_disagreement_score":0.054362275,"about_ca_system_score_codex":0.000019997125,"about_ca_system_score_gemma":0.000048058475,"threshold_uncertainty_score":0.99956423},"labels":[],"label_agreement":null},{"id":"W2037319473","doi":"10.1111/imr.12129","title":"Human cell‐based artificial antigen‐presenting cells for cancer immunotherapy","year":2013,"lang":"en","type":"review","venue":"Immunological Reviews","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":126,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute","keywords":"Adoptive cell transfer; Cell therapy; Immunotherapy; T cell; Immunology; Cancer; Antigen; Cancer immunotherapy; Cancer research; Chimeric antigen receptor; Adoptive immunotherapy; Cell; Biology; Medicine; Immune system; Internal medicine","score_opus":0.288011356370987,"score_gpt":0.47790319856529384,"score_spread":0.18989184219430683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037319473","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004110917,0.98329407,0.00013631301,0.000089495734,0.0005494268,0.01420187,0.000057031728,0.00022333488,0.0014073517],"genre_scores_gemma":[0.000002541371,0.97639567,0.0012213676,0.00026563022,0.00086114835,0.007124274,0.00023799433,0.00030032426,0.013591025],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.993564,0.0009563874,0.0024353322,0.0012050495,0.0005518283,0.0012873821],"domain_scores_gemma":[0.99608094,0.000609875,0.0011442952,0.0016589826,0.00027904008,0.00022687289],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0017092249,0.0010987316,0.0060167434,0.00035985775,0.0003007646,0.00018829596,0.0009836297,0.0010605343,0.013091239],"category_scores_gemma":[0.00025118544,0.00069784716,0.0035743841,0.0006914444,0.00034870268,0.00007699226,0.00018422146,0.0016529113,0.0009878571],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004300992,0.00036548762,0.0000012713458,0.015935268,0.00025610332,0.000015317164,0.0000146697885,1.8449587e-7,0.034245078,0.000031673047,0.0017167812,0.9473752],"study_design_scores_gemma":[0.00072357303,0.00045822447,0.0000034615662,0.010099355,0.0005177582,0.000010787575,0.0000057259535,0.000007393734,0.001846633,0.000048417533,0.9856125,0.0006661789],"about_ca_topic_score_codex":0.000097549906,"about_ca_topic_score_gemma":0.0000044787184,"teacher_disagreement_score":0.9838957,"about_ca_system_score_codex":0.00044928328,"about_ca_system_score_gemma":0.00049968984,"threshold_uncertainty_score":0.99979},"labels":[],"label_agreement":null},{"id":"W2037604674","doi":"10.1016/s1098-3015(10)70902-5","title":"PSS7 THE COST-EFFECTIVENESS OF RANIBIZUMAB COMPARED TO PDT-VAND BSC FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION IN CANADA","year":2008,"lang":"en","type":"article","venue":"Value in Health","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Macular degeneration; Ranibizumab; Medicine; Ophthalmology; Oncology; Internal medicine; Optometry; Chemotherapy","score_opus":0.11774405482990875,"score_gpt":0.3684899964738832,"score_spread":0.25074594164397446,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037604674","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907678,0.0018627355,0.00013745399,0.0011689183,0.00010637769,0.005878605,0.000029680195,0.0000037764269,0.00004469774],"genre_scores_gemma":[0.9983635,0.0009340107,0.00008918122,0.00008826808,0.000024233115,0.00033860354,0.000029725632,0.00001542986,0.00011707965],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9983282,0.0005370235,0.00041441087,0.00016432018,0.00030588286,0.00025017103],"domain_scores_gemma":[0.9985165,0.00093121274,0.0000811288,0.00030852048,0.000084208994,0.00007845872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009082951,0.00009890077,0.00040550777,0.000094872354,0.00007333047,0.0000022582938,0.00008749132,0.000033225806,0.000035100144],"category_scores_gemma":[0.00006296938,0.000059166643,0.00005683436,0.0003931153,0.00005577943,0.000011564809,0.00000830704,0.00009323201,5.301795e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018798731,0.0022618526,0.22248444,0.002057026,0.0005020991,0.00016836499,0.022951579,0.54141915,0.10814286,0.00079174543,0.0010109695,0.0794112],"study_design_scores_gemma":[0.037350778,0.005376308,0.6878572,0.0010028357,0.0000788347,0.000106343025,0.0013940714,0.10813898,0.14440538,0.0002147972,0.013778467,0.0002959966],"about_ca_topic_score_codex":0.8777398,"about_ca_topic_score_gemma":0.57010126,"teacher_disagreement_score":0.46537277,"about_ca_system_score_codex":0.0019665533,"about_ca_system_score_gemma":0.0021077038,"threshold_uncertainty_score":0.5142469},"labels":[],"label_agreement":null},{"id":"W2037616844","doi":"10.1016/j.blre.2014.08.002","title":"Harnessing the power of alloreactivity without triggering graft-versus-host disease: how non-engrafting alloreactive cellular therapy might change the landscape of acute myeloid leukemia treatment","year":2014,"lang":"en","type":"review","venue":"Blood Reviews","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Università di Bologna","keywords":"Immunology; Context (archaeology); Medicine; Myeloid leukemia; Adjuvant; Graft-versus-host disease; Immune system; Blockade; Myeloid; Disease; Transplantation; Leukemia; Cell therapy; Cell; Biology; Internal medicine; Receptor","score_opus":0.08429626560051727,"score_gpt":0.35123953303396205,"score_spread":0.26694326743344476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2037616844","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0035342479,0.985084,0.000017279057,0.00029835105,0.00033386625,0.0097576585,0.00010334165,0.000041371968,0.0008298634],"genre_scores_gemma":[0.0037315723,0.9918892,0.000076751705,0.0000554181,0.00085252174,0.0018164082,0.00021935455,0.00022461593,0.0011341607],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.994181,0.0016371191,0.0013574929,0.0009874984,0.0010438507,0.00079303596],"domain_scores_gemma":[0.99348706,0.0011186635,0.002253339,0.002569888,0.00024288072,0.0003281772],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0028091394,0.0012425787,0.005702698,0.00030180367,0.0002763641,0.0000964504,0.0009158161,0.0003710033,0.0002927043],"category_scores_gemma":[0.00022247412,0.0005543422,0.0030913209,0.0009005026,0.00042726763,0.00017771512,0.00021718761,0.0011021342,0.000022043258],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000720727,0.0005344147,0.00009228735,0.010325573,0.005232844,0.000058186917,0.0015428371,6.663487e-8,0.0034050583,0.0000067783258,0.00012892621,0.9779523],"study_design_scores_gemma":[0.0035509518,0.0009363762,0.00011855224,0.017878925,0.010986746,0.000048174097,0.00009245753,0.000015902639,0.001723841,0.0000010547195,0.9641473,0.00049967173],"about_ca_topic_score_codex":0.0001279892,"about_ca_topic_score_gemma":0.000017468503,"teacher_disagreement_score":0.97745264,"about_ca_system_score_codex":0.00038646438,"about_ca_system_score_gemma":0.0008143495,"threshold_uncertainty_score":0.99969083},"labels":[],"label_agreement":null},{"id":"W2044365745","doi":"10.1038/nm1134","title":"Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells","year":2004,"lang":"en","type":"article","venue":"Nature Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":293,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research","funders":"National Cancer Institute; National Institutes of Health","keywords":"BCL6; Corepressor; Cancer research; Biology; Psychological repression; Repressor; Lymphoma; Cell biology; B cell; Transcription factor; Gene; Germinal center; Genetics; Immunology; Gene expression; Antibody","score_opus":0.019227616320513556,"score_gpt":0.2900272092528044,"score_spread":0.27079959293229083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2044365745","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96535397,0.013105374,0.00084929535,0.0073054666,0.0006632726,0.0008988594,0.000014533425,0.00006972485,0.01173949],"genre_scores_gemma":[0.98601323,0.0023766654,0.0015158257,0.001946386,0.0005491299,0.000024020921,0.000044637098,0.000047423724,0.0074826847],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99755746,0.00007558472,0.00046389856,0.00057762687,0.0008432212,0.0004821781],"domain_scores_gemma":[0.9988727,0.0001711425,0.00007112177,0.0004098611,0.00014574161,0.0003294266],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007701476,0.00029639073,0.00060101075,0.00046005796,0.000051840012,0.000013912655,0.00020714388,0.00043102654,0.0024420393],"category_scores_gemma":[0.00009024229,0.00023038083,0.00009315616,0.00055710156,0.0002606805,0.00007587927,0.00004206261,0.0010915834,0.000057899648],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007524528,0.00031504864,0.00022855689,0.00013710873,0.000027930928,0.00037300878,0.0008760204,0.0000017436003,0.9871638,0.0017543507,0.0012535286,0.007116463],"study_design_scores_gemma":[0.061643053,0.0044315434,0.04204903,0.002817878,0.00016852094,0.0012997634,0.0014024387,0.00003917922,0.8093811,0.019303842,0.056683257,0.0007803411],"about_ca_topic_score_codex":0.00008886264,"about_ca_topic_score_gemma":0.00004135057,"teacher_disagreement_score":0.17778264,"about_ca_system_score_codex":0.0004254571,"about_ca_system_score_gemma":0.00018302642,"threshold_uncertainty_score":0.9984699},"labels":[],"label_agreement":null},{"id":"W2045257451","doi":"10.1016/j.jim.2014.03.012","title":"Adapting in vitro embryonic stem cell differentiation to the study of locus control regions","year":2014,"lang":"en","type":"article","venue":"Journal of Immunological Methods","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"National Institute on Minority Health and Health Disparities; Canadian Institutes of Health Research; National Institutes of Health; New York State Stem Cell Science; National Institute of General Medical Sciences; Canada Research Chairs","keywords":"Biology; Transgene; Chromatin; Embryonic stem cell; Gene; Locus control region; Cellular differentiation; Reporter gene; Genetics; Gene expression; Regulation of gene expression; Locus (genetics); Computational biology; Cell biology; Enhancer","score_opus":0.06945535665012202,"score_gpt":0.3900136198179751,"score_spread":0.3205582631678531,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2045257451","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93527657,0.00084625365,0.061141454,0.0017232995,0.00016638503,0.000577955,4.860217e-7,0.000006945694,0.00026066977],"genre_scores_gemma":[0.9892135,0.00006343151,0.0100842565,0.00011912251,0.000116943265,0.0000125133765,1.8864351e-7,0.0000122359725,0.00037779045],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9952755,0.0031992337,0.00071055203,0.00014047882,0.0004220446,0.00025221347],"domain_scores_gemma":[0.9967439,0.002122864,0.00043190384,0.00034078147,0.00027637032,0.0000841344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0055688806,0.00012349158,0.0006644822,0.00025006547,0.00005587743,0.00001841667,0.00031107143,0.000100373036,0.000089670124],"category_scores_gemma":[0.000978688,0.00006538428,0.00018476235,0.00039041362,0.000052964846,0.000042011176,0.00007935063,0.0008477632,0.0000029128032],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024208704,0.00085226254,0.0008393434,0.000011048452,0.00011009719,0.000012224315,0.00065955066,0.00011697239,0.78566384,0.00002361706,0.000012817706,0.20927738],"study_design_scores_gemma":[0.03303707,0.035454787,0.38944924,0.00041153398,0.0006357866,0.00031011016,0.01858112,0.004574275,0.50880665,0.0007967187,0.007498461,0.00044421986],"about_ca_topic_score_codex":0.00002052603,"about_ca_topic_score_gemma":0.0000036232022,"teacher_disagreement_score":0.3886099,"about_ca_system_score_codex":0.00012567059,"about_ca_system_score_gemma":0.000050354007,"threshold_uncertainty_score":0.36831564},"labels":[],"label_agreement":null},{"id":"W2052914628","doi":"10.1182/blood-2006-04-013813","title":"Expression of interleukin-3 receptor subunits on defined subpopulations of acute myeloid leukemia blasts predicts the cytotoxicity of diphtheria toxin interleukin-3 fusion protein against malignant progenitors that engraft in immunodeficient mice","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute; BC Cancer Agency","funders":"","keywords":"Myeloid leukemia; Biology; Molecular biology; Progenitor cell; CD38; Diphtheria toxin; Leukemia; Haematopoiesis; Cancer research; Interleukin 15; CD34; Interleukin; Immunology; Stem cell; Cytokine; Cell biology; Microbiology; Toxin","score_opus":0.017335440033182554,"score_gpt":0.25592899077339853,"score_spread":0.238593550740216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2052914628","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959932,0.00023323859,0.000038110942,0.00009030766,0.00010689467,0.0027685713,0.00013764793,0.000040987266,0.00059105165],"genre_scores_gemma":[0.9984803,0.00008270445,0.00040842599,0.000018044764,0.00007160251,0.0002026523,0.00013808944,0.000064246946,0.0005339113],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99668616,0.00038221106,0.0010413686,0.00045107774,0.0009797419,0.00045941447],"domain_scores_gemma":[0.99799657,0.00019108139,0.0005809368,0.0008274828,0.00031582793,0.000088127505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007752715,0.00034590845,0.0006808784,0.00046184068,0.00007817239,0.000016271139,0.0004481215,0.00023317196,0.00017311092],"category_scores_gemma":[0.00014350793,0.0002423708,0.00026273748,0.00075864367,0.00033078075,0.000089501875,0.0002337751,0.00046996368,0.0000053134318],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023949998,0.0019703363,0.015925782,0.00023991877,0.0001219164,0.000017065235,0.001291752,0.00009613228,0.9768234,0.000049220755,0.00005106178,0.0010184308],"study_design_scores_gemma":[0.004657941,0.0012592337,0.028728241,0.0022308077,0.0001071292,0.00002331737,0.00034811828,0.00013177854,0.96222717,0.000031300275,0.00007616388,0.00017881165],"about_ca_topic_score_codex":0.0005757251,"about_ca_topic_score_gemma":0.0001408508,"teacher_disagreement_score":0.014596227,"about_ca_system_score_codex":0.00028917374,"about_ca_system_score_gemma":0.0003166965,"threshold_uncertainty_score":0.98835945},"labels":[],"label_agreement":null},{"id":"W2053967595","doi":"10.1084/jem.20091918","title":"Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts","year":2010,"lang":"en","type":"article","venue":"The Journal of Experimental Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":887,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Howard Hughes Medical Institute; University College London; Swim Across America; Memorial Sloan-Kettering Cancer Center; Cancer Research Institute","keywords":"Cytotoxic T cell; Adoptive cell transfer; Cancer research; Biology; CD8; Melanoma; Interleukin 21; Immunology; Antigen; In vitro; Biochemistry","score_opus":0.01306096873143876,"score_gpt":0.30389109359166705,"score_spread":0.2908301248602283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2053967595","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993064,0.0019924538,0.00008654485,0.002664246,0.00052067207,0.00060745963,0.00000484016,0.000015610507,0.0010442028],"genre_scores_gemma":[0.9973286,0.0002450846,0.00018525329,0.0009208108,0.00066918763,0.000021389336,0.0000024178366,0.000056342422,0.00057091354],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975953,0.00023818968,0.00053065637,0.00024349478,0.00093098223,0.00046138468],"domain_scores_gemma":[0.9983098,0.00035188996,0.00017029933,0.00041170866,0.00023947557,0.00051684724],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001786586,0.00031728612,0.00071597367,0.00028250716,0.00014675166,0.000026349875,0.00030947174,0.000112523696,0.0045047356],"category_scores_gemma":[0.00014250011,0.00018221367,0.00010831269,0.00036269982,0.0006334383,0.00031292703,0.00010324717,0.0010823073,0.000017811419],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006193503,0.0004079499,0.0016388609,0.00002737192,0.00020994313,0.00035375057,0.008896226,6.8730536e-8,0.97959024,0.0000136409035,0.00035030473,0.0023181194],"study_design_scores_gemma":[0.008437872,0.0021673914,0.025555918,0.00020333739,0.00016945532,0.0029036112,0.0027151422,0.000024444622,0.95392805,0.000033432603,0.0036767074,0.00018461407],"about_ca_topic_score_codex":0.00016498126,"about_ca_topic_score_gemma":0.00004179596,"teacher_disagreement_score":0.025662187,"about_ca_system_score_codex":0.00024519913,"about_ca_system_score_gemma":0.00030298473,"threshold_uncertainty_score":0.9964053},"labels":[],"label_agreement":null},{"id":"W2054635400","doi":"10.1007/s10555-014-9542-0","title":"Immunotherapy of melanoma: Present options and future promises","year":2015,"lang":"en","type":"review","venue":"Cancer and Metastasis Reviews","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Vancouver Coastal Health Research Institute; University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Ipilimumab; Medicine; Melanoma; Immunotherapy; Clinical trial; Oncology; Immune system; Immunology; Nivolumab; Adjuvant; Monoclonal antibody; CTLA-4; Internal medicine; T cell; Antibody; Cancer research","score_opus":0.1540316203694242,"score_gpt":0.444403877725553,"score_spread":0.2903722573561288,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2054635400","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000008511865,0.99360406,0.0000034083962,0.00020682612,0.00018608602,0.004184258,0.00020727115,0.000013848946,0.0015857174],"genre_scores_gemma":[1.026495e-7,0.99091417,0.0005565076,0.000044939094,0.00087731384,0.0012334868,0.00008815113,0.00006583229,0.0062194727],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99764544,0.0003827617,0.00088173785,0.00048000462,0.00033014567,0.00027988947],"domain_scores_gemma":[0.9984008,0.00006672932,0.00041162944,0.00065916224,0.00017695455,0.00028469382],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001116324,0.000453577,0.0039474284,0.00021196704,0.000050941257,0.00002913839,0.00015480173,0.0001926721,0.0016431722],"category_scores_gemma":[0.000034261044,0.00027589922,0.00057511596,0.00039054823,0.00018509335,0.000058232596,0.00008675097,0.00040040823,0.000009822494],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000041969157,0.000056770758,0.0000046519867,0.03619205,0.00061584945,0.0000045024703,0.00009512424,7.251456e-9,0.000021778997,0.000039490136,0.0062671346,0.9566607],"study_design_scores_gemma":[0.0007703143,0.00019030207,0.000007279286,0.007721077,0.002312146,0.000102843165,0.00002316042,2.8982183e-7,0.0000110914925,0.000011160309,0.9886349,0.0002154495],"about_ca_topic_score_codex":0.000048530746,"about_ca_topic_score_gemma":0.0000073846886,"teacher_disagreement_score":0.98236775,"about_ca_system_score_codex":0.00012646502,"about_ca_system_score_gemma":0.0005928643,"threshold_uncertainty_score":0.9999693},"labels":[],"label_agreement":null},{"id":"W2056056608","doi":"10.1038/cgt.2009.80","title":"Human neural stem cells transduced with IFN-β and cytosine deaminase genes intensify bystander effect in experimental glioma","year":2009,"lang":"en","type":"article","venue":"Cancer Gene Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of British Columbia Hospital","funders":"National Science Council","keywords":"Cytosine deaminase; Bystander effect; Glioma; Cancer research; Suicide gene; Prodrug; Neural stem cell; Genetic enhancement; Biology; Stem cell; Pharmacology; Gene; Immunology; Cell biology; Biochemistry","score_opus":0.03365276231240223,"score_gpt":0.33831107962555396,"score_spread":0.30465831731315174,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2056056608","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9759154,0.02217421,0.000013783585,0.0005163223,0.000078240875,0.0011400249,0.000006419355,0.000058757203,0.00009689497],"genre_scores_gemma":[0.99717957,0.0009529798,0.000037458638,0.0008257157,0.0002107686,0.00011019167,0.000007382787,0.000059721675,0.0006162169],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99834925,0.00012893339,0.00024242724,0.0004710285,0.00035033244,0.0004580385],"domain_scores_gemma":[0.99929136,0.000032087773,0.00004734699,0.0003492812,0.00007484538,0.00020508895],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020413908,0.0003232108,0.0005249974,0.00020688112,0.00008198487,0.0000390461,0.0001138231,0.00009896761,0.00047085522],"category_scores_gemma":[7.0159354e-7,0.00023725767,0.0000799792,0.00033306787,0.00011964768,0.0000782454,0.000011457934,0.00024149175,0.0000018972679],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005107298,0.00017364461,0.0017862781,0.000024893863,0.00007851857,0.00028975695,0.0011645649,0.000017675398,0.9041223,0.0000030363387,0.000070526985,0.08716152],"study_design_scores_gemma":[0.011805947,0.006059996,0.010735781,0.00007958213,0.000021505584,0.00011211977,0.00023943787,0.00014113772,0.9702135,0.0000045163256,0.00033372603,0.00025277273],"about_ca_topic_score_codex":0.00016407193,"about_ca_topic_score_gemma":0.000059118738,"teacher_disagreement_score":0.08690875,"about_ca_system_score_codex":0.00023560385,"about_ca_system_score_gemma":0.000076636206,"threshold_uncertainty_score":0.96750873},"labels":[],"label_agreement":null},{"id":"W2056397238","doi":"10.1186/2051-1426-2-s3-p17","title":"Tri-functional T cell receptor antigen coupler (Tri-TAC): a novel method to direct T cells against tumors","year":2014,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Chimeric antigen receptor; Modular design; Antigen; Receptor; T cell; Cell biology; Cancer research; Biology; Immunology; Computer science; Chemistry; Immune system; Genetics","score_opus":0.034115129421557464,"score_gpt":0.360206308257852,"score_spread":0.3260911788362945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2056397238","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7824463,0.009160543,0.18409541,0.0056853,0.0052565997,0.003931692,0.00033024882,0.00011946249,0.008974407],"genre_scores_gemma":[0.32305685,0.02952564,0.25156945,0.022847105,0.015666535,0.0012820225,0.00014897913,0.001421791,0.35448164],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970043,0.00013784552,0.00083277986,0.00038893643,0.0010015123,0.000634633],"domain_scores_gemma":[0.99749,0.00048670938,0.00043628732,0.00042649236,0.00081695535,0.00034358457],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002317004,0.0003342258,0.00088935153,0.00046535174,0.00023493895,0.00006982345,0.00031806255,0.00016316246,0.0064526163],"category_scores_gemma":[0.000082371786,0.00027281124,0.0006678148,0.00047641006,0.00008348015,0.0001273796,0.00003015436,0.00054546434,0.00003000768],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070211613,0.00032093353,0.00056180515,0.00007673389,0.00045196296,0.0000016492413,0.00034627115,0.00078867766,0.8701937,0.0000119160795,0.020690387,0.099534765],"study_design_scores_gemma":[0.006448164,0.0009987215,0.0013397725,0.00016764343,0.00003536367,0.000022049899,0.000051132218,0.00052167854,0.4689899,0.000023155582,0.52119917,0.00020324583],"about_ca_topic_score_codex":0.00013594932,"about_ca_topic_score_gemma":0.000012335201,"teacher_disagreement_score":0.5005088,"about_ca_system_score_codex":0.0004759136,"about_ca_system_score_gemma":0.00064025586,"threshold_uncertainty_score":0.9999724},"labels":[],"label_agreement":null},{"id":"W2056809624","doi":"10.1182/blood-2014-10-609271","title":"Thymic expression of a T-cell receptor targeting a tumor-associated antigen coexpressed in the thymus induces T-ALL","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"National Cancer Institute; National Institutes of Health","keywords":"T-cell receptor; Thymocyte; Biology; Cancer research; Receptor; Transgene; Signal transduction; Immunology; Survivin; Antigen; T cell; Cell biology; Molecular biology; Cancer; Gene; Genetics; CD8; Immune system","score_opus":0.04458352362943507,"score_gpt":0.3033461817699167,"score_spread":0.2587626581404816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2056809624","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912375,0.001619263,0.0000015477085,0.0002431961,0.00006828893,0.00065970316,0.000011723886,0.00004031293,0.0061184242],"genre_scores_gemma":[0.99852157,0.00017112448,0.00040538874,0.00019201548,0.00012318342,0.00004302729,0.000046519795,0.000033404896,0.00046375644],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99784094,0.0003914138,0.00036672078,0.00026424264,0.0007482341,0.00038845447],"domain_scores_gemma":[0.99890333,0.00023910498,0.00017318068,0.00037977588,0.00017378197,0.00013081092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015288357,0.00015930794,0.00035623138,0.00014686916,0.000037221278,0.000023656938,0.00031900077,0.00011771147,0.00031921105],"category_scores_gemma":[0.00062030856,0.000107788874,0.00009063286,0.00042111185,0.00007049772,0.000068025394,0.000091026086,0.0004202075,0.000028751727],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025294034,0.0015380345,0.01103369,0.00004569674,0.000034696837,0.000049318143,0.0054608416,0.0000017502344,0.979107,0.0000034094096,0.0023427086,0.00012987832],"study_design_scores_gemma":[0.0076989625,0.0005431081,0.0028289668,0.00024344059,0.000040984458,0.000010674281,0.0026168628,0.000026401878,0.98325,0.000087355475,0.0025187067,0.00013454069],"about_ca_topic_score_codex":0.00024372665,"about_ca_topic_score_gemma":0.000011746769,"teacher_disagreement_score":0.008204723,"about_ca_system_score_codex":0.00005153596,"about_ca_system_score_gemma":0.00022771324,"threshold_uncertainty_score":0.43955028},"labels":[],"label_agreement":null},{"id":"W2057283586","doi":"10.1093/emboj/cdf588","title":"Inducible gene deletion reveals different roles for B‐Raf and Raf‐1 in B‐cell antigen receptor signalling","year":2002,"lang":"en","type":"article","venue":"The EMBO Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Leibniz-Gemeinschaft; Deutsche Forschungsgemeinschaft","keywords":"Biology; Signalling; Gene; B cell; B-cell receptor; Antigen; Genetics; Receptor; Molecular biology; Cell biology; Cancer research; Antibody","score_opus":0.06014735966484382,"score_gpt":0.3056308840700656,"score_spread":0.24548352440522178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057283586","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99106807,0.004414837,0.0005353389,0.0027757422,0.000109655986,0.00051570864,0.0000034730601,0.0000123425925,0.00056482456],"genre_scores_gemma":[0.98772395,0.0059072967,0.00057078135,0.0002155735,0.00077493134,0.000018297866,0.0000043089044,0.000033496442,0.0047513754],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985973,0.00016598633,0.00033673245,0.00017883573,0.00034789165,0.00037321638],"domain_scores_gemma":[0.9992529,0.00019174142,0.00010913414,0.00017912737,0.00010314787,0.00016393443],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012044965,0.00013794981,0.0002858896,0.00017488914,0.00018905684,0.00007296318,0.00014063428,0.00007470988,0.00198534],"category_scores_gemma":[0.000076421005,0.000088532295,0.00009637531,0.00014057042,0.000052029485,0.00006581739,0.000037095404,0.0005442457,0.00001723965],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040764097,0.00015446302,0.0055487473,0.00004058852,0.000051029292,0.000016692584,0.0013366033,0.00003997909,0.963701,0.000009392374,0.002720613,0.025973253],"study_design_scores_gemma":[0.016193967,0.0022986364,0.030119399,0.0009469466,0.00018778819,0.0014110107,0.0016723828,0.014303876,0.9064982,0.004108973,0.02158662,0.0006722137],"about_ca_topic_score_codex":0.000008299849,"about_ca_topic_score_gemma":0.00000897591,"teacher_disagreement_score":0.057202812,"about_ca_system_score_codex":0.00011459855,"about_ca_system_score_gemma":0.000028223807,"threshold_uncertainty_score":0.998927},"labels":[],"label_agreement":null},{"id":"W2057893105","doi":"10.1182/blood-2010-03-272336","title":"CD8+ T-cell expansion and maintenance after recombinant adenovirus immunization rely upon cooperation between hematopoietic and nonhematopoietic antigen-presenting cells","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Christie (Canada); McMaster University","funders":"Canadian Institutes of Health Research","keywords":"Antigen; Biology; Immunology; Antigen presentation; Antigen-presenting cell; Cytotoxic T cell; Population; Haematopoiesis; CD8; T cell; Hematopoietic stem cell; Stem cell; Cell biology; Immune system; Medicine","score_opus":0.012551380640342715,"score_gpt":0.2585916342091094,"score_spread":0.2460402535687667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057893105","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99695206,0.00076977554,0.00014827239,0.00027489045,0.00016645102,0.0007608487,0.0000047940193,0.000061969404,0.00086095114],"genre_scores_gemma":[0.99529076,0.0011960949,0.0010650661,0.00005710642,0.00014394871,0.00003620488,0.000029454362,0.00006261504,0.0021187342],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99833274,0.000086730615,0.00038467505,0.0004573872,0.000335902,0.00040256683],"domain_scores_gemma":[0.99886465,0.00014512276,0.00010064732,0.0005006987,0.0001875884,0.00020128243],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048973423,0.00022503635,0.000368318,0.00016043882,0.00019376657,0.00010971793,0.000101067446,0.00020719765,0.00028365158],"category_scores_gemma":[0.0001113449,0.00019946214,0.000052269548,0.0002520553,0.00011955264,0.00015986655,0.00015330913,0.00050005555,0.00003833366],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009771817,0.00025998554,0.06351164,0.00028958046,0.00003107791,0.000065699045,0.00088753237,3.4797287e-7,0.93347025,0.00003355805,0.00005275296,0.0012998295],"study_design_scores_gemma":[0.0054035983,0.00034513118,0.051187877,0.0003217091,0.00016959163,0.00032722316,0.00017679123,0.00024869273,0.939966,0.00016250934,0.0013507168,0.0003401604],"about_ca_topic_score_codex":0.00005761944,"about_ca_topic_score_gemma":0.000039395516,"teacher_disagreement_score":0.012323766,"about_ca_system_score_codex":0.00001634304,"about_ca_system_score_gemma":0.00006938942,"threshold_uncertainty_score":0.81338304},"labels":[],"label_agreement":null},{"id":"W2060346254","doi":"10.1038/sj.cgt.7700213","title":"T-cell killing of heterogenous tumor or viral targets with bispecific chimeric immune receptors","year":2000,"lang":"en","type":"article","venue":"Cancer Gene Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Institutes of Health","keywords":"Epitope; Cytolysis; Biology; T cell; Immune system; Antibody; Chimeric antigen receptor; Antigen; Molecular biology; Virology; Cytotoxic T cell; Immunology; In vitro","score_opus":0.02669625071036997,"score_gpt":0.29264648787782516,"score_spread":0.2659502371674552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060346254","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9630482,0.034087155,0.00003251718,0.00014154313,0.00020538298,0.00081885455,0.00001866369,0.00007171255,0.0015759246],"genre_scores_gemma":[0.92356527,0.051927377,0.0010090161,0.0004705194,0.0005385702,0.00016579115,0.00003365071,0.00016830454,0.022121498],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998058,0.00007957767,0.00039023897,0.00042738128,0.0004931604,0.00055160414],"domain_scores_gemma":[0.9989056,0.0000378512,0.00012130615,0.00062068587,0.00013046266,0.00018410562],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00018909073,0.00029753617,0.00060131686,0.00014955204,0.000099303244,0.000018050368,0.00023929485,0.00007080875,0.04301131],"category_scores_gemma":[0.0000020806037,0.0002034602,0.00016451329,0.00053441897,0.0002070185,0.000061041355,0.0000142093795,0.0002738192,0.00006221938],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010371865,0.00029684216,0.0010181989,0.00004457625,0.00023028099,0.000055011817,0.00095707265,0.00016022363,0.7966553,5.4015374e-7,0.00024226007,0.18996783],"study_design_scores_gemma":[0.0049046823,0.002776929,0.0010444593,0.00007846596,0.000029082641,0.00007114498,0.00009375453,0.000080050915,0.8925706,0.0000063078924,0.09808339,0.0002611079],"about_ca_topic_score_codex":0.00036848392,"about_ca_topic_score_gemma":0.000015820046,"teacher_disagreement_score":0.18970671,"about_ca_system_score_codex":0.00019430721,"about_ca_system_score_gemma":0.00037551913,"threshold_uncertainty_score":0.9578635},"labels":[],"label_agreement":null},{"id":"W2062752944","doi":"10.1016/j.molonc.2014.05.002","title":"From biomarker development towards implementation of multidimensional biomarker panels in a clinical setting","year":2014,"lang":"en","type":"editorial","venue":"Molecular Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"","keywords":"Biomarker; PTEN; Oncology; Immunohistochemistry; Medicine; Internal medicine; Computational biology; Bioinformatics; Biology; Genetics","score_opus":0.04979045729444718,"score_gpt":0.4495815692546231,"score_spread":0.3997911119601759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2062752944","genre_codex":"empirical","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6050075,0.00045708162,0.0013041054,0.0011275713,0.38879058,0.0020248925,0.00019788746,0.000054353663,0.0010359946],"genre_scores_gemma":[0.18395463,0.0006500214,0.095327556,0.0019056817,0.68655854,0.0011613399,0.02667542,0.0008299461,0.002936881],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99416226,0.0012395844,0.0018331237,0.00087379076,0.0013167125,0.000574547],"domain_scores_gemma":[0.9964048,0.0017581239,0.00057546137,0.00053970015,0.0004991511,0.0002227568],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0036071648,0.0003878787,0.0013986387,0.0005031066,0.00003570364,0.000010203192,0.00024329887,0.0016726166,0.002368657],"category_scores_gemma":[0.0013067825,0.0003711094,0.00033457557,0.00027564674,0.00021475562,0.000024671006,0.00034820547,0.0010827974,0.00005306656],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015855703,0.00047100667,0.0017582106,0.00014899478,0.00086602644,0.00073047244,0.00053532457,6.7615207e-7,0.18958808,0.0000021538492,0.28711104,0.51720244],"study_design_scores_gemma":[0.008927819,0.00076309114,0.032036997,0.00023366133,0.0001615462,0.000010402123,0.00018227413,0.00011876144,0.018626189,0.000029663679,0.9385926,0.00031695593],"about_ca_topic_score_codex":0.0015923947,"about_ca_topic_score_gemma":0.00031902862,"teacher_disagreement_score":0.65148157,"about_ca_system_score_codex":0.0008784188,"about_ca_system_score_gemma":0.0053845746,"threshold_uncertainty_score":0.99987406},"labels":[],"label_agreement":null},{"id":"W2063178906","doi":"10.1089/hum.2004.15.945","title":"Combined Immunotherapy and Antiangiogenic Therapy of Cancer with Microencapsulated Cells","year":2004,"lang":"en","type":"article","venue":"Human Gene Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Angiostatin; Immunotherapy; Medicine; Cancer research; Angiogenesis; Cancer immunotherapy; Genetic enhancement; Melanoma; Pharmacology; Immunology; Immune system; Biology","score_opus":0.026762385993778042,"score_gpt":0.30824109233987224,"score_spread":0.2814787063460942,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063178906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9770061,0.020852922,0.000026449,0.0004347782,0.00005906926,0.0011951528,0.0000148516265,0.000085116626,0.00032559017],"genre_scores_gemma":[0.9538014,0.043369263,0.0004965719,0.0006235449,0.00011658598,0.000059820803,0.000028440041,0.00012437186,0.0013799965],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981682,0.00007251014,0.00038297806,0.00044765044,0.0004508281,0.00047787852],"domain_scores_gemma":[0.9987657,0.000026234668,0.00015778061,0.0006669717,0.00022560709,0.00015772424],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00022534783,0.00034954006,0.0006140121,0.00025753918,0.00014950754,0.00003323437,0.00021421404,0.00013379805,0.002459209],"category_scores_gemma":[0.0000010490751,0.00026119628,0.00017603919,0.00042791557,0.00039589798,0.00006616101,0.000021810596,0.00023334229,0.000008726437],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048131933,0.0005070002,0.004862235,0.000022025419,0.0009188231,0.00004079265,0.00147558,0.000024732592,0.9698698,0.00005344525,0.00006715253,0.017345216],"study_design_scores_gemma":[0.023930702,0.0037129472,0.036691587,0.000092778995,0.000020583186,0.000046804747,0.000055573517,0.0000043433856,0.93214446,0.0002653898,0.0027609183,0.0002738791],"about_ca_topic_score_codex":0.00090038637,"about_ca_topic_score_gemma":0.00005374989,"teacher_disagreement_score":0.03772531,"about_ca_system_score_codex":0.000102827624,"about_ca_system_score_gemma":0.00022414973,"threshold_uncertainty_score":0.999984},"labels":[],"label_agreement":null},{"id":"W2063847092","doi":"10.5582/ddt.2011.v5.3.107","title":"Prospects of cancer biotherapy","year":2011,"lang":"en","type":"article","venue":"Drug Discoveries & Therapeutics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Phenomenome Discoveries (Canada)","funders":"","keywords":"Radiation therapy; Medicine; Immune system; Cancer research; Cancer; Targeted therapy; Cancer cell; Immunotherapy; Cancer treatment; Genetic enhancement; Chemotherapy; Immunology; Oncology; Internal medicine; Biology; Gene","score_opus":0.05589061693243864,"score_gpt":0.33978204868637296,"score_spread":0.28389143175393433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2063847092","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96716964,0.006396386,0.000064431435,0.0008589138,0.0002706636,0.0007431259,0.000051050545,0.00008206128,0.024363741],"genre_scores_gemma":[0.97262806,0.0073636277,0.00055245456,0.0011097603,0.00017508608,0.00006648771,0.000009902998,0.00008847736,0.018006124],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985541,0.000045661545,0.00030001666,0.00027316532,0.00044802178,0.00037901872],"domain_scores_gemma":[0.9990255,0.00003713163,0.00011489878,0.0005713116,0.00014903082,0.000102122234],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00015460803,0.00021619978,0.00039572775,0.000113652364,0.000057489542,0.000018447883,0.00020400723,0.00008316004,0.0072762687],"category_scores_gemma":[0.0000042741,0.00016945507,0.00016930565,0.00033962078,0.00043250242,0.00014494952,0.000047776917,0.00021576344,0.000019953744],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00521178,0.0013381422,0.21077089,0.00035839478,0.001828928,0.000039539947,0.030122185,0.0000032877026,0.6603063,0.0075860587,0.00047735544,0.08195716],"study_design_scores_gemma":[0.0023013833,0.0006081941,0.029150585,0.000112916015,0.0002395906,0.00001280893,0.0012565899,0.000049893675,0.79131895,0.001168223,0.17346646,0.00031442745],"about_ca_topic_score_codex":0.00062910834,"about_ca_topic_score_gemma":0.00017269036,"teacher_disagreement_score":0.1816203,"about_ca_system_score_codex":0.000094599374,"about_ca_system_score_gemma":0.00024912387,"threshold_uncertainty_score":0.99363124},"labels":[],"label_agreement":null},{"id":"W2064357373","doi":"10.12816/0003140","title":"Immunotherapy for B-Cell Neoplasms Using T-Cells Expressing Chimeric Antigen Receptors : From Antigen Choice to Clinical Implementation","year":2012,"lang":"en","type":"article","venue":"Sultan Qaboos University medical journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; University of Saskatchewan; McGill University Health Centre; Royal Victoria Regional Health Centre","funders":"","keywords":"Chimeric antigen receptor; Antigen; CD19; Immunotherapy; Immunology; Medicine; Immune system; B cell; Cancer research; Antibody","score_opus":0.06092115815099508,"score_gpt":0.39461125777776707,"score_spread":0.333690099626772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2064357373","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.980139,0.0004356974,0.015695548,0.00081408274,0.0017071572,0.0007306318,0.000043000364,0.000044257642,0.0003906116],"genre_scores_gemma":[0.94452983,0.0047796937,0.037464764,0.0020215784,0.00800597,0.0000023602522,0.00013992938,0.0001510485,0.0029048147],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964925,0.0004331179,0.0006196113,0.00036527668,0.0011987868,0.00089068344],"domain_scores_gemma":[0.99665475,0.00073529413,0.00028482257,0.00030047525,0.00031416377,0.0017105036],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018358391,0.00025559802,0.0005539644,0.00040093943,0.0005154159,0.00006952093,0.00043851836,0.00028400746,0.010323781],"category_scores_gemma":[0.0002605925,0.0002454713,0.0003623372,0.00058156066,0.00018015734,0.0004020521,0.00012286285,0.00089369086,0.000058046255],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003382017,0.0009004063,0.1993479,0.000030044774,0.0005913213,0.00011704895,0.003610428,0.0000064489864,0.5764345,0.0000048801035,0.00936623,0.20620877],"study_design_scores_gemma":[0.024002325,0.0013606412,0.054269888,0.00038960404,0.00026655145,0.00016525466,0.008634638,0.0006746697,0.09029744,0.00001772437,0.819221,0.0007002675],"about_ca_topic_score_codex":0.00038853203,"about_ca_topic_score_gemma":0.000025823654,"teacher_disagreement_score":0.80985475,"about_ca_system_score_codex":0.0004414033,"about_ca_system_score_gemma":0.0008453221,"threshold_uncertainty_score":0.99999976},"labels":[],"label_agreement":null},{"id":"W2068343048","doi":"10.1182/blood-2013-11-536433","title":"Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":617,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Concordance; Lymphoma; Diffuse large B-cell lymphoma; Gene expression profiling; Germinal center; Pathology; Cancer research; Medicine; Computational biology; Biology; Molecular biology; B cell; Gene expression; Gene; Immunology; Internal medicine; Antibody; Genetics","score_opus":0.025362049045606384,"score_gpt":0.3065655540313091,"score_spread":0.2812035049857027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068343048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99711525,0.00046919225,0.00070790655,0.000008383644,0.00007669683,0.00037457954,0.0000081165235,0.000028805702,0.0012110625],"genre_scores_gemma":[0.9890652,0.000056652596,0.010116849,0.000026200212,0.00011958447,0.000012488142,0.000016486276,0.00005033995,0.0005362013],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99811375,0.00013771575,0.0005536761,0.00029017834,0.00044432105,0.00046038465],"domain_scores_gemma":[0.99883837,0.0001816282,0.00022467076,0.0005211393,0.00009338899,0.00014083229],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055097404,0.00019285113,0.000558424,0.00027180515,0.000042084732,0.0000106718835,0.00018647479,0.00016571776,0.00018000072],"category_scores_gemma":[0.00008235472,0.00017430392,0.00009902279,0.0002734518,0.00005626727,0.000080129816,0.00011511203,0.0001409885,0.000010044118],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025011614,0.003947221,0.035582077,0.0003124327,0.000017072365,0.00003751345,0.0009667765,0.0000125170955,0.9558092,0.0000075949415,0.000009089887,0.0030484023],"study_design_scores_gemma":[0.023478674,0.00044098852,0.00235774,0.00022035956,0.00007435823,0.000022827095,0.00011450331,0.0026086671,0.97002035,0.000017326945,0.0004886932,0.00015553788],"about_ca_topic_score_codex":0.000048558526,"about_ca_topic_score_gemma":0.000014801995,"teacher_disagreement_score":0.033224337,"about_ca_system_score_codex":0.000037054007,"about_ca_system_score_gemma":0.00013040102,"threshold_uncertainty_score":0.71079075},"labels":[],"label_agreement":null},{"id":"W2068574639","doi":"10.1002/ijc.20043","title":"Synergistic effect of lymphotactin and interferon γ‐inducible protein‐10 transgene expression in T‐cell localization and adoptive T‐cell therapy of tumors","year":2004,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; Saskatchewan Cancer Agency","funders":"University of Saskatchewan","keywords":"CD8; Adoptive cell transfer; Cytotoxic T cell; CXCR3; Biology; T cell; Granzyme B; Molecular biology; Transgene; Immunology; Cancer research; Chemokine; In vitro; Antigen; Immune system; Chemokine receptor; Biochemistry","score_opus":0.015375306465241453,"score_gpt":0.3273272014006939,"score_spread":0.31195189493545245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2068574639","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99504644,0.0032675348,0.0008273905,0.00014969734,0.00009601666,0.0003071024,0.0000068699223,0.000002246582,0.0002966822],"genre_scores_gemma":[0.99771714,0.0018137279,0.00012274916,0.000023375262,0.00009617,0.000011548085,0.0000025063023,0.00001698453,0.00019579222],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99872875,0.00007806291,0.0004374364,0.00012895976,0.00052371516,0.000103102655],"domain_scores_gemma":[0.9990727,0.00007574537,0.0003186675,0.00007434265,0.00038699422,0.00007158235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003424943,0.000113817674,0.0003214092,0.0003209257,0.00001056562,0.000010681783,0.00010849571,0.00006146588,0.00042236768],"category_scores_gemma":[0.0000350676,0.0000854517,0.00006586156,0.00011677793,0.00009613981,0.000111210655,0.000020271553,0.00016143837,3.003405e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009187596,0.00019302563,0.005471832,0.00012547354,0.00008098084,0.00004190168,0.0007992188,0.00095438707,0.9728802,0.0000057752522,0.000009768293,0.010249834],"study_design_scores_gemma":[0.0092223445,0.002027491,0.003237129,0.0013525838,0.000020004027,0.00003176705,0.00008356027,0.00014093507,0.9835778,0.00007234298,0.00017184111,0.00006219798],"about_ca_topic_score_codex":0.00021640987,"about_ca_topic_score_gemma":0.000020325302,"teacher_disagreement_score":0.010697597,"about_ca_system_score_codex":0.00022526701,"about_ca_system_score_gemma":0.00021648998,"threshold_uncertainty_score":0.462463},"labels":[],"label_agreement":null},{"id":"W2070037020","doi":"10.1186/2051-1426-2-s3-p5","title":"A clinical grade cell-based artificial APT, aAPC/mOKT3, for unbiased expansion of CD3+ T lymphocytes","year":2014,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Adoptive cell transfer; CD3; Medicine; Tumor-infiltrating lymphocytes; T cell; Cancer research; Cancer; Immunology; Internal medicine; Immunotherapy; CD8; Immune system","score_opus":0.07337979631303736,"score_gpt":0.4284327000562539,"score_spread":0.3550529037432165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070037020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96418655,0.00483163,0.026013477,0.0016008872,0.0014270433,0.0016797207,0.00007393802,0.000026377837,0.00016038388],"genre_scores_gemma":[0.9826509,0.0031116523,0.008097893,0.0012398933,0.0019981372,0.00021170867,0.00002477784,0.00015882346,0.002506209],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970933,0.00017445054,0.0013385277,0.0002794811,0.00065753545,0.0004567115],"domain_scores_gemma":[0.99664176,0.0011868965,0.00077018084,0.0004424414,0.00077605975,0.00018269464],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002285467,0.00024000947,0.000948745,0.0002783183,0.00014770724,0.000027912132,0.00027885404,0.00022563573,0.0009820474],"category_scores_gemma":[0.00022507316,0.00019211274,0.0010813038,0.00021039828,0.000255563,0.00007444768,0.00001233524,0.00032411414,0.0000016427166],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021866726,0.0005473862,0.0020265705,0.00029431682,0.00031583646,0.0000013673724,0.00017923617,0.00023878513,0.7469788,0.000042783304,0.002146795,0.22536135],"study_design_scores_gemma":[0.024790328,0.005938296,0.0022646878,0.0004962933,0.00017430776,0.000014556442,0.00010153513,0.006266706,0.8186038,0.0010015089,0.1401007,0.00024728215],"about_ca_topic_score_codex":0.000112626825,"about_ca_topic_score_gemma":0.000025924897,"teacher_disagreement_score":0.22511406,"about_ca_system_score_codex":0.00023170936,"about_ca_system_score_gemma":0.0011439882,"threshold_uncertainty_score":0.9999312},"labels":[],"label_agreement":null},{"id":"W2070049862","doi":"10.1371/journal.pbio.0060156","title":"Micromanagement of Lymphomas","year":2008,"lang":"en","type":"article","venue":"PLoS Biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Biology; breakpoint cluster region; B-cell receptor; Antigen; B cell; Cell biology; B-1 cell; Naive B cell; Immune system; Clonal deletion; Receptor; Antibody; Molecular biology; Antigen-presenting cell; T cell; Immunology; T-cell receptor; Genetics","score_opus":0.05988049581368391,"score_gpt":0.31350806457063857,"score_spread":0.25362756875695464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070049862","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96234363,0.00035724504,0.000015488204,0.00049931696,0.00004167255,0.00020249424,0.0000034644306,0.00002395572,0.036512725],"genre_scores_gemma":[0.9889056,0.00041547223,0.00047815472,0.0002755876,0.00007886547,0.000011610952,0.000017299148,0.000009922976,0.009807507],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99944645,0.000036068803,0.0001303431,0.00013840354,0.00007936505,0.0001693508],"domain_scores_gemma":[0.9995969,0.000042802094,0.000027466227,0.00023447319,0.00005073585,0.00004762778],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0000678353,0.000057250414,0.0001973304,0.000093272225,0.000020910558,5.7818784e-7,0.00007659308,0.000059102502,0.003405038],"category_scores_gemma":[0.000035026715,0.000045358895,0.000054080137,0.000100646146,0.00018324051,0.0000071913228,0.000054605174,0.000056470544,0.00011179331],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017260226,0.00022479662,0.04908596,0.000037199155,0.00014132255,0.00004504461,0.00014824192,7.60793e-8,0.9438053,0.00038464024,0.0014063779,0.0045484826],"study_design_scores_gemma":[0.0034472907,0.0015609438,0.070984006,0.000034790573,0.000057519355,0.00025630914,0.00005175138,0.0000635062,0.7570349,0.0005163986,0.16585155,0.00014102148],"about_ca_topic_score_codex":0.0000483421,"about_ca_topic_score_gemma":0.0000024761746,"teacher_disagreement_score":0.18677035,"about_ca_system_score_codex":0.000036569236,"about_ca_system_score_gemma":0.000045509907,"threshold_uncertainty_score":0.99750596},"labels":[],"label_agreement":null},{"id":"W2070396091","doi":"10.1016/j.jval.2014.03.416","title":"Evolving Treatment Patterns in Metastatic Melanoma in Canada","year":2014,"lang":"en","type":"article","venue":"Value in Health","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Vemurafenib; Trametinib; Dacarbazine; Internal medicine; Metastatic melanoma; Ipilimumab; Oncology; Salvage therapy; Melanoma; Lomustine; Temozolomide; Targeted therapy; Cancer; Chemotherapy; Vincristine; Immunotherapy","score_opus":0.06466749246790013,"score_gpt":0.34066119184665805,"score_spread":0.27599369937875795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2070396091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99518764,0.0005380607,0.000015199568,0.0028666721,0.00009119711,0.00068342686,0.0000070957085,0.0000071056493,0.0006036177],"genre_scores_gemma":[0.9984754,0.00030073355,0.00021508169,0.0005365525,0.000041588195,0.000054825014,0.000011527601,0.000020585221,0.00034373382],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998052,0.0004608478,0.00042608735,0.00023788607,0.00031525682,0.0005079481],"domain_scores_gemma":[0.99910605,0.00037165763,0.000049696842,0.00027572605,0.000015762585,0.00018111688],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00091066724,0.00011504634,0.00041214834,0.0002845509,0.000016712733,0.0000063388047,0.00006854928,0.000022743649,0.00052143517],"category_scores_gemma":[0.000108262655,0.00009995074,0.00002593558,0.00030833157,0.000010081622,0.000026270212,0.000016820373,0.00021575931,0.00000765281],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000079641366,0.0001560187,0.95481277,0.0002857868,0.000011575058,0.00018983646,0.001148299,0.0011679546,0.00016563726,0.000043785047,0.00006550121,0.041873176],"study_design_scores_gemma":[0.004911445,0.00096970843,0.9296562,0.00064680725,0.0000047209205,0.000031582877,0.0006984485,0.05937283,0.00030037656,0.00013806614,0.0031340457,0.0001357413],"about_ca_topic_score_codex":0.9965118,"about_ca_topic_score_gemma":0.98933923,"teacher_disagreement_score":0.058204878,"about_ca_system_score_codex":0.005886759,"about_ca_system_score_gemma":0.002967911,"threshold_uncertainty_score":0.99792945},"labels":[],"label_agreement":null},{"id":"W2071392212","doi":"10.1097/01.tp.0000330554.83483.f5","title":"ALLOREACTIVE REGULATORY T CELLS CAN CONTROL THE EARLY STAGE OF REJECTION BY THE DIRECT PATHWAY.","year":2008,"lang":"en","type":"article","venue":"Transplantation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Armand Frappier Museum","funders":"","keywords":"Cell biology; Control (management); Immunology; Biology; Computer science","score_opus":0.017526829876886373,"score_gpt":0.25370052755431133,"score_spread":0.23617369767742497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071392212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99293244,0.00011494228,0.00029595537,0.00046804146,0.00007445543,0.0007518016,0.0001777565,0.00003187609,0.005152703],"genre_scores_gemma":[0.99030834,0.00058969,0.000008457808,0.00015732691,0.000059899117,0.000038335715,0.000051228457,0.000018682722,0.008768006],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989044,0.00018118904,0.0001823749,0.00014787017,0.0004265667,0.00015761686],"domain_scores_gemma":[0.99928117,0.00026171622,0.00007837158,0.00024191034,0.00009316344,0.00004370017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033984298,0.00009666144,0.00015973528,0.00004579476,0.00013362846,0.0000064403575,0.00008125371,0.000059029368,0.00020299645],"category_scores_gemma":[0.000007838869,0.00005670624,0.00008301524,0.00014820418,0.00018430801,0.000053813215,0.000001946186,0.00020599528,0.000006538459],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018658254,0.0000642233,0.0030455077,0.000054151853,0.000111290974,0.000020775044,0.006915907,0.000038361675,0.98537517,0.0000412155,0.0003082514,0.00215932],"study_design_scores_gemma":[0.002849259,0.00039840594,0.13324724,0.00003355384,0.00010035153,0.0000632201,0.0003247997,0.00013893968,0.8595778,0.000011555937,0.0031724111,0.000082480256],"about_ca_topic_score_codex":0.002053401,"about_ca_topic_score_gemma":0.00020310203,"teacher_disagreement_score":0.13020173,"about_ca_system_score_codex":0.00006196538,"about_ca_system_score_gemma":0.00009279448,"threshold_uncertainty_score":0.3104142},"labels":[],"label_agreement":null},{"id":"W2071754795","doi":"10.4161/onci.26770","title":"TCR/CD3 activation and co-stimulation combined in one T cell retargeting system improve anti-tumor immunity","year":2013,"lang":"en","type":"article","venue":"OncoImmunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Retargeting; T cell; T-cell receptor; Cancer research; Antigen; CD3; Bispecific antibody; Immunity; Co-stimulation; Cell; Chimeric antigen receptor; Medicine; Stimulation; Antibody; Immunology; Immune system; CD28; CD8; Biology; Computer science; Monoclonal antibody; Internal medicine","score_opus":0.023860766809999833,"score_gpt":0.2860688319584116,"score_spread":0.2622080651484118,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2071754795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99076766,0.00025384614,0.00008906206,0.00047999984,0.00011093191,0.001209744,0.000002286991,0.00009069082,0.006995792],"genre_scores_gemma":[0.99802434,0.00005945354,0.00031722494,0.00008341161,0.000054690572,0.00007662476,0.00008105123,0.000034676286,0.0012685138],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99843,0.00028978457,0.00040408643,0.0002915514,0.00019884633,0.0003857378],"domain_scores_gemma":[0.99888825,0.00028489745,0.00016692365,0.0004165346,0.00018080206,0.00006259157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000563177,0.00016637027,0.00047542033,0.0002822023,0.00011017974,0.000031174724,0.00010740659,0.00019869943,0.00064985483],"category_scores_gemma":[0.00015060412,0.00016469293,0.000045192413,0.0002509974,0.00013822953,0.00018184174,0.00008473029,0.0006069714,0.00012226198],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004181992,0.00022094318,0.028084848,0.00020661703,0.00004280087,0.000009446971,0.0004254834,0.000006567857,0.9624259,0.000081594495,0.000030736406,0.0080468925],"study_design_scores_gemma":[0.007872058,0.0013621016,0.7036634,0.00024088156,0.000030989184,0.000043978765,0.0016513573,0.006917732,0.2773582,0.00008635218,0.0005302672,0.00024268313],"about_ca_topic_score_codex":0.0021970554,"about_ca_topic_score_gemma":0.000011690557,"teacher_disagreement_score":0.68506765,"about_ca_system_score_codex":0.00038641092,"about_ca_system_score_gemma":0.00010587547,"threshold_uncertainty_score":0.71154547},"labels":[],"label_agreement":null},{"id":"W2076379671","doi":"10.1371/journal.pone.0030229","title":"Ex Vivo Expansion of Human CD8+ T Cells Using Autologous CD4+ T Cell Help","year":2012,"lang":"en","type":"article","venue":"PLoS ONE","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto","funders":"National Cancer Institute; American Society of Hematology; National Institutes of Health; Cancer Research Institute","keywords":"T cell; CD8; Cytotoxic T cell; Biology; Cell biology; IL-2 receptor; FOXP3; Antigen-presenting cell; Interleukin 21; Immune system; Immunology; In vitro; Biochemistry","score_opus":0.10944666410691732,"score_gpt":0.323557040482938,"score_spread":0.21411037637602065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2076379671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98832774,0.00059102196,0.000023629285,0.00006210329,0.00006981277,0.0005162225,0.000006753848,0.00006256514,0.010340176],"genre_scores_gemma":[0.9842581,0.00008086729,0.0023351011,0.000082458166,0.00039715975,0.000007637727,0.000009302581,0.00005503923,0.012774342],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99817413,0.00008812939,0.00030118867,0.00021344153,0.00070792786,0.0005151875],"domain_scores_gemma":[0.9989004,0.000079101315,0.00010105205,0.00052433915,0.00014950994,0.0002455938],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00036460054,0.000156377,0.00046348583,0.00018095718,0.000070775415,0.000008665119,0.00012533204,0.00014365753,0.005703579],"category_scores_gemma":[0.00003054306,0.00014537087,0.00009832561,0.00020684286,0.00010928875,0.00008943588,0.00009433226,0.00027948758,0.00014415318],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012220255,0.0021658067,0.005444866,0.0004395041,0.00009894669,0.000014281291,0.00080198824,0.0000013436891,0.99032885,0.000010793344,0.00023624758,0.0003351627],"study_design_scores_gemma":[0.0010354563,0.00043741876,0.0011403272,0.00023179816,0.00017777475,0.000007966312,0.00015948359,0.00027168868,0.99611217,0.000016222135,0.00027784283,0.0001318325],"about_ca_topic_score_codex":0.00014147643,"about_ca_topic_score_gemma":0.0000032824844,"teacher_disagreement_score":0.0057833316,"about_ca_system_score_codex":0.00012141406,"about_ca_system_score_gemma":0.000072674426,"threshold_uncertainty_score":0.99520534},"labels":[],"label_agreement":null},{"id":"W2077416999","doi":"10.1002/cyto.b.20115","title":"Flow cytometric assessment of autologous γδ T cells in patients with acute myeloid leukemia: Potential effector cells for immunotherapy?","year":2006,"lang":"en","type":"article","venue":"Cytometry Part B Clinical Cytometry","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"University Health Network","keywords":"Medicine; Immunophenotyping; Immunology; Immunotherapy; Bone marrow; Myeloid; T cell; Flow cytometry; Myeloid leukemia; Minimal residual disease; Immune system; Population; Leukemia","score_opus":0.020395248722752318,"score_gpt":0.3542690597803617,"score_spread":0.3338738110576094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077416999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9838019,0.0003227967,0.008740568,0.0000815038,0.0013914957,0.0039280904,0.0006501869,0.00017268906,0.0009107399],"genre_scores_gemma":[0.9803625,0.0003286028,0.014809367,0.0002814634,0.00082468917,0.00024209594,0.00053736137,0.00023824547,0.0023756877],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99124,0.0005978713,0.0028030437,0.0015353808,0.0022301208,0.0015935679],"domain_scores_gemma":[0.9928034,0.0032946328,0.0008687635,0.0016149898,0.0008783123,0.00053988467],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0036440715,0.00083187217,0.0027786063,0.004256343,0.00016273932,0.00009655086,0.0007903443,0.0010245165,0.0014751097],"category_scores_gemma":[0.00041926515,0.0006917482,0.0011004355,0.008413262,0.000699624,0.00024809476,0.00025956842,0.0017689482,0.00010331612],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011980253,0.006610023,0.7983334,0.00068700017,0.0016628518,0.00029191573,0.000020185043,0.0005184233,0.14160898,0.0000117256495,0.0038632248,0.03441203],"study_design_scores_gemma":[0.032930244,0.010162041,0.89837617,0.00023117896,0.00049622863,0.000025549896,0.000020687936,0.0028968558,0.048915375,0.000027156668,0.005094012,0.0008244939],"about_ca_topic_score_codex":0.00008139219,"about_ca_topic_score_gemma":0.000008091873,"teacher_disagreement_score":0.1000428,"about_ca_system_score_codex":0.0012164569,"about_ca_system_score_gemma":0.0010252062,"threshold_uncertainty_score":0.9995534},"labels":[],"label_agreement":null},{"id":"W2077633929","doi":"10.1097/cji.0b013e318243f213","title":"Cytotoxic T-lymphocyte Immunotherapy for Ovarian Cancer","year":2012,"lang":"en","type":"article","venue":"Journal of Immunotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"National Cancer Institute","keywords":"Ovarian cancer; Cytotoxic T cell; Immunotherapy; Medicine; Cancer immunotherapy; Immunology; Lymphocyte; Cancer; Cancer research; Immune system; Internal medicine; Biology","score_opus":0.03650980964972917,"score_gpt":0.3572020405419712,"score_spread":0.320692230892242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2077633929","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8895075,0.09518518,0.0056442535,0.0037539403,0.0025554982,0.0015683138,0.00002628658,0.0000558521,0.0017031918],"genre_scores_gemma":[0.87455446,0.07098187,0.014011152,0.0066163526,0.0082976455,0.00023216537,0.000012712829,0.00045485934,0.0248388],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974337,0.000114904135,0.00084256363,0.00016237109,0.00069408125,0.00075236754],"domain_scores_gemma":[0.9979409,0.00022652453,0.0005202669,0.00048716753,0.0005455307,0.0002796023],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001638997,0.0002915753,0.0007607908,0.00040073888,0.00014001934,0.00005832296,0.00034719097,0.00018865385,0.0069776066],"category_scores_gemma":[0.000054143904,0.00022286203,0.00070990133,0.00033833706,0.00011105963,0.00037563493,0.000017510887,0.00045076493,0.000023573819],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008910521,0.00042374356,0.0043891235,0.000036403013,0.0010123887,0.00001021262,0.0010887285,0.0000054347074,0.74057484,0.00008922252,0.0020528752,0.24140653],"study_design_scores_gemma":[0.023431906,0.0020187586,0.02197187,0.0003019636,0.00008734102,0.0010441612,0.00020992305,0.0000458213,0.2309029,0.00020095454,0.7194452,0.00033917604],"about_ca_topic_score_codex":0.000073788455,"about_ca_topic_score_gemma":0.0000028063262,"teacher_disagreement_score":0.7173924,"about_ca_system_score_codex":0.0007508512,"about_ca_system_score_gemma":0.0006520085,"threshold_uncertainty_score":0.99393016},"labels":[],"label_agreement":null},{"id":"W2078469038","doi":"10.1371/journal.pone.0056820","title":"Co-Introduced Functional CCR2 Potentiates In Vivo Anti-Lung Cancer Functionality Mediated by T Cells Double Gene-Modified to Express WT1-Specific T-Cell Receptor","year":2013,"lang":"en","type":"article","venue":"PLoS ONE","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"Ministry of Education, Culture, Sports, Science and Technology","keywords":"Cancer research; In vivo; Lung cancer; CCR2; Biology; Receptor; Cell biology; Chemistry; Medicine; Chemokine receptor; Chemokine; Biochemistry; Genetics; Pathology","score_opus":0.05567032743398227,"score_gpt":0.2829390526640674,"score_spread":0.22726872523008512,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078469038","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991473,0.0010873646,0.00011640802,0.00232489,0.00037968683,0.0023342345,0.00024298739,0.0001362544,0.0019051783],"genre_scores_gemma":[0.95476776,0.0009885537,0.00053826754,0.0006143664,0.0011621483,0.0011851689,0.00064175506,0.00011691573,0.039985076],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99622756,0.0001413709,0.00056161615,0.00087861234,0.0014342567,0.0007566035],"domain_scores_gemma":[0.99794453,0.00020273303,0.00011252508,0.00065170164,0.0006026386,0.0004858445],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00045344487,0.00033894525,0.0006489336,0.00032502357,0.00012940535,0.00009302484,0.00023014838,0.0002204977,0.07297054],"category_scores_gemma":[0.000043651686,0.00032731236,0.000120926605,0.00063224195,0.000097087446,0.00019360853,0.00007206712,0.0005418781,0.0010994442],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014637725,0.0024685045,0.011380174,0.0001572359,0.00028916766,0.000004689118,0.0001517976,0.0001043161,0.8449848,0.0000032175135,0.13890001,0.00009226667],"study_design_scores_gemma":[0.0055172746,0.00016616499,0.0059127393,0.00011274162,0.000068917325,0.0000013678776,0.000061403436,0.0007021319,0.9823138,0.0000069781136,0.0048030675,0.0003334263],"about_ca_topic_score_codex":0.001336751,"about_ca_topic_score_gemma":0.00003591002,"teacher_disagreement_score":0.13732894,"about_ca_system_score_codex":0.00055108004,"about_ca_system_score_gemma":0.00020290287,"threshold_uncertainty_score":0.99991786},"labels":[],"label_agreement":null},{"id":"W2078523816","doi":"10.1016/j.ymthe.2005.09.018","title":"Recombinant Adenovirus Vaccines Can Successfully Elicit CD8+ T Cell Immunity under Conditions of Extreme Leukopenia","year":2005,"lang":"en","type":"article","venue":"Molecular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Canadian Institutes of Health Research; Cancer Research Society","keywords":"Antigen; Cytotoxic T cell; Immunology; Biology; Bone marrow; CD8; Immune system; Immunity; Immunization; Radioresistance; Virology; Leukopenia; Cell culture; In vitro","score_opus":0.040569501405109946,"score_gpt":0.31546352850991566,"score_spread":0.2748940271048057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2078523816","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860748,0.002980776,0.00031764506,0.0035675324,0.000104491504,0.00083111605,0.000022080676,0.00007111644,0.006030451],"genre_scores_gemma":[0.9869946,0.0015243394,0.00036843828,0.0016129753,0.000095930496,0.000058556074,0.00009586295,0.00009012769,0.009159129],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99792755,0.00022593739,0.00046155616,0.0003540116,0.0005495009,0.00048146077],"domain_scores_gemma":[0.99831295,0.00008457064,0.00014166857,0.0009458628,0.00030755615,0.00020736261],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003515755,0.00028489105,0.00050575304,0.00027844604,0.00013085626,0.000035790403,0.0003731186,0.00015731939,0.00829508],"category_scores_gemma":[0.0000225752,0.00025289616,0.00026408557,0.0004775591,0.00012188482,0.00008148878,0.000067460074,0.0004326294,0.00009599552],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000544004,0.0007040379,0.0015630814,0.00003362858,0.0001971116,0.000058892623,0.0002960613,0.00008134872,0.9813212,0.00028400813,0.0006036298,0.014312957],"study_design_scores_gemma":[0.0060300734,0.0007688529,0.010475579,0.00005882458,0.00005465938,0.00006377102,0.00018047681,0.000102278595,0.9470994,0.0006031644,0.03426381,0.0002990958],"about_ca_topic_score_codex":0.0010144304,"about_ca_topic_score_gemma":0.000204456,"teacher_disagreement_score":0.03422182,"about_ca_system_score_codex":0.00018707226,"about_ca_system_score_gemma":0.00028713897,"threshold_uncertainty_score":0.9999923},"labels":[],"label_agreement":null},{"id":"W2079589100","doi":"10.1016/j.critrevonc.2009.08.005","title":"Treatment for metastatic malignant melanoma: Old drugs and new strategies","year":2009,"lang":"en","type":"review","venue":"Critical Reviews in Oncology/Hematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":121,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; Directorate for Biological Sciences","keywords":"Medicine; Dacarbazine; Melanoma; Metastatic melanoma; Immunotherapy; Clinical trial; Oncology; Chemotherapy; First line; Refractory (planetary science); Cancer; Internal medicine; Cancer research","score_opus":0.2065223788696071,"score_gpt":0.5077436865363419,"score_spread":0.3012213076667348,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079589100","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000044869766,0.9841579,0.00029632088,0.00283585,0.00027188179,0.007293915,0.000031662614,0.000047182082,0.0050607664],"genre_scores_gemma":[0.0000058854184,0.98492956,0.0076865335,0.0005449544,0.0002647508,0.002278531,0.00013012832,0.00009562528,0.004064003],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99367136,0.0013505723,0.0023039877,0.0012145459,0.0002456964,0.0012138634],"domain_scores_gemma":[0.9916978,0.0063453726,0.00030988193,0.0008691831,0.00011982726,0.00065796723],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014039814,0.00094256684,0.010305129,0.0005316427,0.00008205358,0.000051132418,0.00032877046,0.000940182,0.0009891624],"category_scores_gemma":[0.002576615,0.0006295028,0.0010857088,0.0004330041,0.0006468871,0.00008316277,0.000109334156,0.00086124276,0.00018076389],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011643591,0.00057482865,0.0000021395026,0.026195848,0.00020137643,0.00091802306,0.00010757585,8.797837e-9,0.00000287248,0.09290206,0.0023214018,0.8766574],"study_design_scores_gemma":[0.0024835332,0.004129028,7.893671e-7,0.017285371,0.0027044232,0.006316675,0.000114725044,0.000006565182,0.0000046674427,0.009013466,0.95751715,0.00042358818],"about_ca_topic_score_codex":0.000040025603,"about_ca_topic_score_gemma":0.00006321073,"teacher_disagreement_score":0.9551958,"about_ca_system_score_codex":0.0010137906,"about_ca_system_score_gemma":0.0028716412,"threshold_uncertainty_score":0.99992406},"labels":[],"label_agreement":null},{"id":"W2079809618","doi":"10.1038/mt.2011.298","title":"Cell Fate Control Gene Therapy Based on Engineered Variants of Human Deoxycytidine Kinase","year":2012,"lang":"en","type":"article","venue":"Molecular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Suicide gene; Deoxycytidine kinase; Thymidine kinase; Biology; Genetic enhancement; Cell biology; Cancer research; Gene; Genetics; Deoxycytidine; Cancer","score_opus":0.024715979408354426,"score_gpt":0.2928219588182776,"score_spread":0.2681059794099232,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2079809618","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9842358,0.004078084,0.0062154057,0.00041799503,0.00013736854,0.0013222893,0.000023941077,0.00008945688,0.0034796249],"genre_scores_gemma":[0.9953393,0.0004951551,0.00047193197,0.0021104098,0.00023282268,0.000089863126,0.000066594584,0.00014068381,0.001053259],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99751854,0.00026718655,0.00039144215,0.00035360584,0.0007612738,0.0007079772],"domain_scores_gemma":[0.9982461,0.00010378285,0.000119497054,0.0010041374,0.00017611313,0.00035041213],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00067417405,0.00036915456,0.0005953382,0.00032549875,0.00007312102,0.000019454754,0.00025097173,0.00018389792,0.0033478793],"category_scores_gemma":[0.000024451358,0.00030816323,0.00033745918,0.00039961052,0.00008983818,0.000055158187,0.0000152312205,0.0003343801,0.000054823093],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002641828,0.0015245627,0.0021597967,0.000025618543,0.00022853898,0.0001168345,0.00016305751,0.00017496796,0.983998,0.000089056164,0.00013071216,0.00874702],"study_design_scores_gemma":[0.018683892,0.0022814882,0.00856682,0.000036065598,0.00003160658,0.000012680526,0.00001293403,0.0010711749,0.96216625,0.00003702127,0.0068233926,0.00027669777],"about_ca_topic_score_codex":0.000056199784,"about_ca_topic_score_gemma":4.0935518e-7,"teacher_disagreement_score":0.021831779,"about_ca_system_score_codex":0.00009942169,"about_ca_system_score_gemma":0.000089016314,"threshold_uncertainty_score":0.99993706},"labels":[],"label_agreement":null},{"id":"W2080601632","doi":"10.1371/journal.pone.0068916","title":"Quantifying Biomass Changes of Single CD8+ T Cells during Antigen Specific Cytotoxicity","year":2013,"lang":"en","type":"article","venue":"PLoS ONE","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Center for AIDS Research, University of California Los Angeles; Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California Los Angeles; Natural Sciences and Engineering Research Council of Canada; National Institutes of Health; National Cancer Institute; Center for AIDS Research, University of Washington; Howard Hughes Medical Institute","keywords":"Cytotoxic T cell; Mass cytometry; Single-cell analysis; Flow cytometry; CD8; Population; Cytotoxicity; Cell biology; T cell; Cell; Intracellular; Antigen-presenting cell; Chemistry; Biology; Antigen; Molecular biology; Immunology; Immune system; In vitro; Phenotype; Biochemistry; Medicine","score_opus":0.16671218482417297,"score_gpt":0.2961743190881353,"score_spread":0.12946213426396233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2080601632","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954202,0.0006003216,0.00000873378,0.0005526663,0.000040096493,0.0008879706,0.0000090737285,0.00008141529,0.0023995],"genre_scores_gemma":[0.9944211,0.00077346363,0.001338024,0.000032070315,0.00029333818,0.000031846233,0.000008961233,0.00005072632,0.0030504342],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99828696,0.00005359343,0.0002558849,0.00030085127,0.00067277264,0.0004299438],"domain_scores_gemma":[0.9989384,0.00008220884,0.000094493225,0.0004988796,0.00021759133,0.00016846844],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001934745,0.00015551984,0.0004485409,0.00025408648,0.000067426474,0.000032604574,0.00015388388,0.00010023464,0.005907608],"category_scores_gemma":[0.000041153,0.00014525412,0.00008007889,0.0003418562,0.0001190715,0.00008233063,0.00009620659,0.00018706384,0.0003721367],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010662212,0.0015813797,0.01557804,0.00056971255,0.00021387564,0.00002072454,0.00032955364,1.5546402e-7,0.9810087,0.000003961972,0.00009281125,0.0004944669],"study_design_scores_gemma":[0.00081365,0.00031136343,0.02988829,0.00036878028,0.000024047336,0.0000048032953,0.00012725852,0.000056246095,0.96807516,0.000009462311,0.00018862195,0.00013233151],"about_ca_topic_score_codex":0.0001704706,"about_ca_topic_score_gemma":0.000028147939,"teacher_disagreement_score":0.014310251,"about_ca_system_score_codex":0.000101674304,"about_ca_system_score_gemma":0.000026744501,"threshold_uncertainty_score":0.99500114},"labels":[],"label_agreement":null},{"id":"W2081113588","doi":"10.1016/j.biomaterials.2014.07.029","title":"siRNA therapy in cutaneous T-cell lymphoma cells using polymeric carriers","year":2014,"lang":"en","type":"article","venue":"Biomaterials","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency; University of Alberta","funders":"Natural Sciences and Engineering Research Council of Canada; Alberta Innovates; Alberta Innovates - Health Solutions; Alberta Cancer Foundation","keywords":"Small interfering RNA; Jurkat cells; Gene silencing; RNA interference; Cancer research; Cell; Lipofectamine; Cell growth; Chemistry; Cell biology; Molecular biology; Biology; Transfection; Cell culture; T cell; Biochemistry; Immunology; RNA; Immune system","score_opus":0.029160782149316902,"score_gpt":0.2984648197056167,"score_spread":0.26930403755629984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081113588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957025,0.00034255226,0.000018348386,0.00008666112,0.000823583,0.0005727683,0.000015346031,0.00008619573,0.0023520505],"genre_scores_gemma":[0.99686354,0.00022258502,0.00037948327,0.0003393578,0.00042834601,0.00001631098,0.000013873794,0.00007662414,0.0016598614],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998025,0.00025289677,0.00041446733,0.00037713005,0.00037336734,0.0005571279],"domain_scores_gemma":[0.99904406,0.00008458912,0.00010805745,0.00050559494,0.000048982918,0.00020869264],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00044155028,0.00024159103,0.00053036853,0.00027705065,0.0000610335,0.0000743521,0.00017796337,0.00016941072,0.002705145],"category_scores_gemma":[0.000031759624,0.00020776503,0.00010587993,0.00032520076,0.00012348291,0.0000514017,0.000050536128,0.00001856376,0.00011616802],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007516903,0.00017632815,0.00057302165,0.00005680926,0.000028350438,0.00013682748,0.0002628654,0.0000025452077,0.97954345,0.0000040941763,0.00012122436,0.01834278],"study_design_scores_gemma":[0.0034544026,0.00046442394,0.0004617399,0.000046962537,0.000014160003,0.00020586926,0.00006704743,0.0002079758,0.982847,0.000023175295,0.011995159,0.0002121254],"about_ca_topic_score_codex":0.0011561278,"about_ca_topic_score_gemma":0.0000070166993,"teacher_disagreement_score":0.018130654,"about_ca_system_score_codex":0.00020587031,"about_ca_system_score_gemma":0.00016211496,"threshold_uncertainty_score":0.9982065},"labels":[],"label_agreement":null},{"id":"W2081783238","doi":"10.1126/scisignal.2004113","title":"BIM, PUMA, and the Achilles’ Heel of Oncogene Addiction","year":2013,"lang":"en","type":"review","venue":"Science Signaling","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Oncogene; Epigenetics; Phenotype; Biology; Cancer research; Addiction; Puma; Cancer; CRISPR; Medicine; Neuroscience; Genetics; Apoptosis; Gene; Cell cycle","score_opus":0.07743560108723829,"score_gpt":0.38838772421854184,"score_spread":0.31095212313130355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2081783238","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005654847,0.9948918,0.000050472852,0.00008221701,0.00016970777,0.0013823726,0.0000074044424,0.000018981547,0.0028315384],"genre_scores_gemma":[0.0006268929,0.99727726,0.0002766336,0.00003797408,0.00025150162,0.00007418094,0.000007929609,0.0000254016,0.001422206],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975709,0.0001660707,0.00047149006,0.00044047055,0.0009891312,0.00036195273],"domain_scores_gemma":[0.998443,0.0003924515,0.00026080068,0.00050084945,0.00023669864,0.0001661885],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0033629076,0.00021195578,0.0010299787,0.00041435295,0.00020770977,0.00007874831,0.00042442785,0.00012121842,0.0012336076],"category_scores_gemma":[0.0003357401,0.0001124902,0.0002642129,0.0012270507,0.002003109,0.00010684438,0.00018034842,0.0004712988,0.00004130499],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001911279,0.000015744461,0.0000020658872,0.0013521567,0.00005628911,0.0000022536897,0.000119370314,0.0000010015884,0.0057011195,0.00021004962,0.000035868612,0.992485],"study_design_scores_gemma":[0.0010576154,0.00019052894,0.0000046247746,0.009787855,0.0005908948,0.00019664978,0.00013897452,0.000256289,0.0017348987,0.00013563025,0.98568606,0.00021998907],"about_ca_topic_score_codex":0.00010272099,"about_ca_topic_score_gemma":0.0000014170354,"teacher_disagreement_score":0.992265,"about_ca_system_score_codex":0.000134998,"about_ca_system_score_gemma":0.00095900486,"threshold_uncertainty_score":0.9996794},"labels":[],"label_agreement":null},{"id":"W2083962744","doi":"10.1002/eji.200636938","title":"Non‐myeloablative mixed chimerism approaches and tolerance, a split decision","year":2007,"lang":"en","type":"article","venue":"European Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research; National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases; Alberta Heritage Foundation for Medical Research; Fondation pour la Recherche Médicale","keywords":"Chimera (genetics); Immune tolerance; Clonal deletion; Biology; Immunology; Bone marrow; Antigen; CD8; Haematopoiesis; Transplantation Chimera; Mixed lymphocyte reaction; Immune system; T cell; Stem cell; Hematopoietic cell; Cell biology; Genetics; Gene","score_opus":0.0361690223443372,"score_gpt":0.2871695163606968,"score_spread":0.2510004940163596,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083962744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9636555,0.0032947164,0.00451056,0.0003398991,0.0003023738,0.00015100697,6.4590927e-7,0.000009866104,0.027735468],"genre_scores_gemma":[0.9897004,0.00061888277,0.007161601,0.00012373926,0.00037069267,3.622762e-7,0.0000014107897,0.000040438797,0.0019824915],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9984682,0.00022549382,0.0005641627,0.00016876556,0.0002554084,0.00031796863],"domain_scores_gemma":[0.9989836,0.0002079684,0.00025357018,0.0002344812,0.00017607826,0.00014425493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024297119,0.00014537643,0.00040890655,0.00035133562,0.0000705977,0.00001914187,0.00018101781,0.0000503988,0.0003667115],"category_scores_gemma":[0.00016689826,0.00011098414,0.00011736726,0.00021227717,0.0002810057,0.00008425709,0.00010101053,0.0006969782,0.000052815434],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054794145,0.0001496837,0.0028689033,0.00001445767,0.0003558911,0.0017131607,0.0015890476,0.000004403416,0.25297177,0.000076357705,0.00044373405,0.73433316],"study_design_scores_gemma":[0.0077739903,0.0037818816,0.8884302,0.00026173785,0.00007409069,0.0071038227,0.001205648,0.000063741296,0.02300007,0.00012123715,0.06799058,0.00019303456],"about_ca_topic_score_codex":0.0000023894656,"about_ca_topic_score_gemma":0.0000011194572,"teacher_disagreement_score":0.8855613,"about_ca_system_score_codex":0.00005285741,"about_ca_system_score_gemma":0.000060541122,"threshold_uncertainty_score":0.45258018},"labels":[],"label_agreement":null},{"id":"W2086451783","doi":"10.1186/s12967-015-0495-z","title":"Defining novel parameters for the optimal priming and expansion of minor histocompatibility antigen-specific T cells in culture","year":2015,"lang":"en","type":"article","venue":"Journal of Translational Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Canadian Institutes of Health Research; Fonds de Recherche du Québec - Santé; Genome Canada","keywords":"Priming (agriculture); Immunology; Antigen; CD8; Population; Biology; Minor histocompatibility antigen; T cell; Antigen-presenting cell; Major histocompatibility complex; Immune system; Medicine","score_opus":0.11521047356614113,"score_gpt":0.35692543894881884,"score_spread":0.24171496538267773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2086451783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96576047,0.010514821,0.018359574,0.004328419,0.00022490328,0.0006694619,0.000010218272,0.0000030277315,0.00012913444],"genre_scores_gemma":[0.9579865,0.00046012172,0.041173305,0.00009647716,0.00020209828,0.000005556132,0.000007739782,0.000012931589,0.000055298384],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99834114,0.000043382002,0.0006501633,0.00012595451,0.00069505925,0.00014428353],"domain_scores_gemma":[0.9983178,0.0007490497,0.00023704993,0.000120633515,0.0004346342,0.00014084231],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001752245,0.00010783446,0.00041630317,0.0001899288,0.000033989316,0.000004796166,0.000095242576,0.00006552059,0.000060016697],"category_scores_gemma":[0.00018650459,0.00006261536,0.00009286981,0.00017085404,0.00022286842,0.00008298042,0.0000072317,0.0002987849,2.0054873e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009049733,0.00037915388,0.025631461,0.0002712657,0.00020620778,0.000024433439,0.019710911,0.004461891,0.873926,0.00033697736,0.0017804063,0.06422157],"study_design_scores_gemma":[0.11794732,0.0180494,0.52016884,0.006572721,0.00080656365,0.0020057866,0.019600682,0.054591507,0.13692282,0.0020875249,0.120371,0.00087582826],"about_ca_topic_score_codex":0.000027096045,"about_ca_topic_score_gemma":0.000006884387,"teacher_disagreement_score":0.73700315,"about_ca_system_score_codex":0.000071912655,"about_ca_system_score_gemma":0.0002037861,"threshold_uncertainty_score":0.25533804},"labels":[],"label_agreement":null},{"id":"W2087289616","doi":"10.1586/erv.11.88","title":"Optimizing vaccine-induced CD8<sup>+</sup>T-cell immunity: focus on recombinant adenovirus vectors","year":2011,"lang":"en","type":"review","venue":"Expert Review of Vaccines","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster University Medical Centre","funders":"","keywords":"CD8; Virology; Cytotoxic T cell; Biology; Immunology; Population; T cell; Memory T cell; Viral vector; Adenoviridae; Antigen; Transgene; Genetic enhancement; Recombinant DNA; Immune system; Medicine; In vitro; Genetics; Gene","score_opus":0.08485817954589985,"score_gpt":0.38656943356336637,"score_spread":0.3017112540174665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2087289616","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006484148,0.98371965,0.0000050132403,0.00036010792,0.0007370996,0.0054804785,0.000019453242,0.00016809742,0.009445271],"genre_scores_gemma":[0.000020709305,0.99176925,0.000596197,0.0005470094,0.0010806117,0.000801241,0.00020469147,0.00048197343,0.0044982918],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99216026,0.0012470395,0.0030815084,0.001356155,0.0009912183,0.0011638367],"domain_scores_gemma":[0.99298203,0.0007935848,0.0014392129,0.0036135842,0.00060139166,0.0005702062],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0018489572,0.0017307788,0.008806333,0.001076011,0.0001867187,0.000045695306,0.001499971,0.000796829,0.011111236],"category_scores_gemma":[0.0008130416,0.0012040703,0.003018732,0.0016418864,0.00004148063,0.00015958703,0.00051414873,0.002174143,0.0006823777],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016610445,0.0007622652,0.0000032188248,0.14026606,0.00058869645,0.000103655744,0.0003043847,1.00965856e-7,0.0002045176,0.000026208327,0.013742815,0.84383196],"study_design_scores_gemma":[0.0012910591,0.0013793589,0.0000017411228,0.24462475,0.0011188234,0.00026283364,0.000045330962,0.0000040992254,0.00091642333,0.0000079939455,0.74956214,0.0007854764],"about_ca_topic_score_codex":0.0004947581,"about_ca_topic_score_gemma":0.0000066707753,"teacher_disagreement_score":0.8430465,"about_ca_system_score_codex":0.00057091354,"about_ca_system_score_gemma":0.0009892766,"threshold_uncertainty_score":0.99954385},"labels":[],"label_agreement":null},{"id":"W2087846338","doi":"10.1038/scibx.2011.183","title":"EMMPRIN's new clothes","year":2011,"lang":"en","type":"article","venue":"Science-Business eXchange","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Matrix metalloproteinase; Regulator; Master regulator; Neuroscience; Medicine; Computational biology; Psychology; Biology; Internal medicine; Gene; Genetics; Transcription factor","score_opus":0.1358298003475303,"score_gpt":0.3316468873210078,"score_spread":0.19581708697347747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2087846338","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.67205703,0.001136964,0.0006280699,0.0027757527,0.001284533,0.0009831989,0.0000044608346,0.00030257035,0.32082742],"genre_scores_gemma":[0.826533,0.0007776417,0.004412677,0.0013497613,0.0017281087,0.00005953422,0.0000066363395,0.00008604355,0.16504656],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9976863,0.000020141151,0.00017829293,0.00049652514,0.00093722367,0.00068150973],"domain_scores_gemma":[0.99837244,0.000023448618,0.000052463565,0.0006812504,0.0004176907,0.00045271573],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00071367127,0.00017073777,0.00025184333,0.00050801184,0.00018539435,0.00006082741,0.00050166756,0.00007122294,0.020562181],"category_scores_gemma":[0.00019606027,0.00013407982,0.0000663606,0.002541051,0.0008367395,0.00034772602,0.00021516667,0.00016488106,0.0005104174],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005897194,0.0004386601,0.024088534,0.00022456422,0.000039315244,0.00021906768,0.009078534,4.6741053e-7,0.36759648,0.001602856,0.0069553475,0.58916646],"study_design_scores_gemma":[0.0024606385,0.00039639018,0.5989595,0.00017061083,0.000045942696,0.0002306479,0.00045808946,0.000086854765,0.097513445,0.0016310405,0.297576,0.00047080492],"about_ca_topic_score_codex":0.0010052412,"about_ca_topic_score_gemma":0.00006557361,"teacher_disagreement_score":0.58869565,"about_ca_system_score_codex":0.0001353031,"about_ca_system_score_gemma":0.00083989516,"threshold_uncertainty_score":0.98033315},"labels":[],"label_agreement":null},{"id":"W2089572944","doi":"10.1586/14737167.2015.1017563","title":"Cost–effectiveness of therapies for melanoma","year":2015,"lang":"en","type":"review","venue":"Expert Review of Pharmacoeconomics & Outcomes Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Dalhousie University; BC Cancer Agency; Canadian Centre for Applied Research in Cancer Control","funders":"","keywords":"Dabrafenib; Medicine; Vemurafenib; Ipilimumab; Trametinib; Melanoma; Intensive care medicine; Cost effectiveness; Oncology; Disease; Internal medicine; Metastatic melanoma; Immunotherapy; Cancer; Cancer research","score_opus":0.22221636620857801,"score_gpt":0.6187242438974649,"score_spread":0.39650787768888696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2089572944","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000020965268,0.97870225,0.000025563464,0.0003163433,0.0004554397,0.017488435,0.000391063,0.000029110091,0.00257086],"genre_scores_gemma":[0.000003699,0.990376,0.00074336963,0.00025021186,0.0004104714,0.0046865903,0.00043979683,0.00026259036,0.0028272765],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99169785,0.0027937524,0.0023508703,0.0009552962,0.0011754921,0.0010267698],"domain_scores_gemma":[0.9885966,0.006486693,0.00076791167,0.0016328346,0.0019898736,0.0005260923],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.017923655,0.00078772113,0.008699667,0.0010692922,0.00008882918,0.000033787837,0.0013699132,0.00039375387,0.0032673867],"category_scores_gemma":[0.0010888441,0.0005753846,0.0028156345,0.0007373355,0.00058376143,0.00013682834,0.0004995929,0.0012521407,0.00011984832],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028244493,0.00025460473,0.000024287772,0.3218532,0.0017124413,0.000007463561,0.00008615035,7.679272e-8,0.00018998992,0.00011855806,0.010277043,0.66519374],"study_design_scores_gemma":[0.002188152,0.000530821,0.0000049124264,0.08694532,0.0005078811,0.00004202672,0.000042876673,0.000009882554,0.00052242074,0.000052055333,0.9087814,0.00037222754],"about_ca_topic_score_codex":0.00010640543,"about_ca_topic_score_gemma":0.0000021918972,"teacher_disagreement_score":0.8985044,"about_ca_system_score_codex":0.001397229,"about_ca_system_score_gemma":0.0033697993,"threshold_uncertainty_score":0.99966973},"labels":[],"label_agreement":null},{"id":"W2090444045","doi":"10.1002/eji.200737443","title":"The T cell antigen receptor: “The Hunting of the Snark”","year":2007,"lang":"en","type":"review","venue":"European Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"T-cell receptor; Biology; Major histocompatibility complex; T cell; Gene; Genetics; Immune system","score_opus":0.06913682266927274,"score_gpt":0.3529011281434265,"score_spread":0.28376430547415377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090444045","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006916201,0.9619861,0.000010054542,0.0005058904,0.0015043499,0.00047377043,0.0000030404512,0.0000065552595,0.034818612],"genre_scores_gemma":[0.00016468998,0.9861953,0.000072189796,0.00008568524,0.0008995063,0.000001062191,0.0000022441427,0.000107191176,0.012472114],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9934625,0.003687107,0.0016318107,0.00017864697,0.00055003713,0.0004898675],"domain_scores_gemma":[0.99519217,0.0011531737,0.0021136831,0.0010551023,0.00041988224,0.00006599574],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.007894427,0.00030436701,0.0012558606,0.00021633899,0.00029371862,0.0000373391,0.001899395,0.00012317095,0.0007878177],"category_scores_gemma":[0.0006034186,0.00012200371,0.0012202312,0.00051261345,0.0007863636,0.000030353885,0.00042886223,0.0029243866,0.00017912789],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013982403,0.000053390886,0.00002440636,0.00055430847,0.00074024574,0.00010497273,0.0001836359,1.7148491e-7,0.0023078467,0.000027530305,0.0031935598,0.9926701],"study_design_scores_gemma":[0.0005364144,0.00049734575,0.0002059251,0.0036506413,0.000315864,0.0018193639,0.00019279437,1.6827536e-7,0.00038082237,0.0000028580469,0.9922989,0.00009890943],"about_ca_topic_score_codex":0.000005378159,"about_ca_topic_score_gemma":0.0000013131449,"teacher_disagreement_score":0.9925712,"about_ca_system_score_codex":0.00013090942,"about_ca_system_score_gemma":0.0005352092,"threshold_uncertainty_score":0.9993759},"labels":[],"label_agreement":null},{"id":"W2090651585","doi":"10.1158/0008-5472.can-11-3589","title":"The Mixed Lineage Leukemia (MLL) Fusion–Associated Gene <i>AF4</i> Promotes CD133 Transcription","year":2012,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Canadian Institutes of Health Research; Natural Sciences and Engineering Research Council of Canada; Canadian Institute for Advanced Research","keywords":"Fusion gene; Gene; Leukemia; Biology; Genetics; Lineage (genetic); Transcription factor; Cancer research; Computational biology","score_opus":0.10541274828704732,"score_gpt":0.40275766184470135,"score_spread":0.297344913557654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2090651585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97893155,0.008586926,0.0000148218205,0.004388838,0.0005686671,0.0016889515,0.000040669744,0.00011595295,0.0056636026],"genre_scores_gemma":[0.9258929,0.004718208,0.000038398754,0.00017369694,0.0014935967,0.0005725756,0.000071348964,0.00009217608,0.06694714],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9949014,0.0005932989,0.00037951025,0.00041056797,0.0020375543,0.0016776212],"domain_scores_gemma":[0.99723506,0.0005241439,0.00006126611,0.0007545977,0.0008490287,0.0005759167],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0054458375,0.00022010977,0.00033959476,0.00023272973,0.0008096838,0.00012600476,0.00044299738,0.0002518456,0.0024025897],"category_scores_gemma":[0.0006906357,0.00015092077,0.00018893646,0.0011988041,0.00043043756,0.00017464002,0.00014706657,0.0015723242,0.00025235926],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00083867443,0.00019682308,0.0028981774,0.000076718134,0.00015069304,0.000024750798,0.0008883073,0.0000018012364,0.9233236,0.000083140425,0.022448804,0.049068548],"study_design_scores_gemma":[0.002660062,0.0004439443,0.01788158,0.00016502618,0.000047485715,0.000025443065,0.00050661294,0.00019462615,0.7105027,0.00010462351,0.26724175,0.00022616117],"about_ca_topic_score_codex":0.0013609626,"about_ca_topic_score_gemma":0.00060794735,"teacher_disagreement_score":0.24479292,"about_ca_system_score_codex":0.0019751727,"about_ca_system_score_gemma":0.0010424991,"threshold_uncertainty_score":0.99850935},"labels":[],"label_agreement":null},{"id":"W2093933397","doi":"10.1038/sj.onc.1208334","title":"Deregulated expression of RasGRP1 initiates thymic lymphomagenesis independently of T-cell receptors","year":2004,"lang":"en","type":"article","venue":"Oncogene","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stemcell Technologies; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Biology; T-cell receptor; Transgene; Thymocyte; Clonal deletion; Negative selection; Cancer research; Genetics; Lymphoma; T cell; Immunology; Gene; Immune system","score_opus":0.023364628346616397,"score_gpt":0.2923473955752778,"score_spread":0.2689827672286614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2093933397","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98887837,0.0012287959,0.000106702886,0.000076488934,0.00010452271,0.0003762987,0.000012864218,0.00003881353,0.0091771325],"genre_scores_gemma":[0.99461246,0.0006633181,0.0015618604,0.00004775342,0.000064395506,0.000013235666,0.000045999594,0.00005140346,0.0029395956],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99828607,0.00007862567,0.00044656204,0.0002752098,0.00062970043,0.0002838228],"domain_scores_gemma":[0.9988701,0.000071850525,0.00018577291,0.00047740748,0.00023650366,0.00015842007],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00028836334,0.00017425598,0.00045060078,0.0002589052,0.000036787562,0.0000056759513,0.00018389292,0.00018824222,0.0028680682],"category_scores_gemma":[0.00005743137,0.00015136515,0.00017332117,0.00043696057,0.00013603103,0.000061517676,0.00009097475,0.00012855501,0.000039897146],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00066977803,0.00053421233,0.0030891167,0.00019387878,0.000059199756,0.000028701123,0.0003779896,0.000043164186,0.98352736,0.000007925229,0.00014568372,0.011322995],"study_design_scores_gemma":[0.0053358637,0.00050472905,0.0030285271,0.00025563187,0.00005994898,0.0000323887,0.00023041712,0.000007706039,0.9897209,0.00012288574,0.0005773395,0.00012366212],"about_ca_topic_score_codex":0.00023889489,"about_ca_topic_score_gemma":0.0000133885815,"teacher_disagreement_score":0.011199333,"about_ca_system_score_codex":0.00017135212,"about_ca_system_score_gemma":0.0004515667,"threshold_uncertainty_score":0.9980434},"labels":[],"label_agreement":null},{"id":"W2097018577","doi":"10.1186/1479-5876-9-63","title":"Value of large scale expansion of tumor infiltrating lymphocytes in a compartmentalised gas-permeable bag: interests for adoptive immunotherapy","year":2011,"lang":"en","type":"article","venue":"Journal of Translational Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"CD8; Melanoma; Cancer research; Adoptive cell transfer; Immunotherapy; Adoptive immunotherapy; Cytotoxic T cell; Cancer immunotherapy; T cell; Medicine; Tumor-infiltrating lymphocytes; Immunology; Biology; In vitro; Immune system; Biochemistry","score_opus":0.056013678362032485,"score_gpt":0.3482293450844783,"score_spread":0.2922156667224458,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097018577","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99437183,0.0016599189,0.0018476973,0.0005628395,0.00012613206,0.0005944056,0.000035345896,0.0000042347156,0.00079759536],"genre_scores_gemma":[0.987408,0.00015000395,0.012026982,0.0001506491,0.00016501345,0.000010371915,0.000020564377,0.000023684954,0.000044753724],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99768656,0.00010033825,0.0011669787,0.00012751963,0.0006996832,0.00021892699],"domain_scores_gemma":[0.9982908,0.00043000476,0.0005067979,0.00014101456,0.00052272825,0.00010869],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012892378,0.00014820354,0.0007439348,0.00045998523,0.0000282084,0.0000020890889,0.00014227275,0.00005794428,0.0010588041],"category_scores_gemma":[0.00011595777,0.00010991939,0.00019883379,0.0002762654,0.00019331585,0.00014424772,0.0000074610953,0.00020557389,3.8278606e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016057879,0.0009587568,0.056187354,0.0003947237,0.00030468195,0.000032421358,0.013791886,0.0001303682,0.9070079,0.0005168891,0.00013408392,0.0044831107],"study_design_scores_gemma":[0.06263977,0.010202791,0.20863341,0.0064145247,0.0002414394,0.0005256023,0.005936695,0.01188964,0.6906029,0.002065568,0.00060248096,0.0002451641],"about_ca_topic_score_codex":0.000075333184,"about_ca_topic_score_gemma":0.000028816032,"teacher_disagreement_score":0.21640493,"about_ca_system_score_codex":0.00010021229,"about_ca_system_score_gemma":0.00034763297,"threshold_uncertainty_score":0.9998544},"labels":[],"label_agreement":null},{"id":"W2097514222","doi":"10.1002/emmm.201100165","title":"PD‐L1 co‐stimulation contributes to ligand‐induced T cell receptor down‐modulation on CD8+ T cells","year":2011,"lang":"en","type":"article","venue":"EMBO Molecular Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":271,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Medical Research Council; Versus Arthritis; University College London","keywords":"T-cell receptor; CD28; Cell biology; Cytotoxic T cell; CD8; T cell; Signal transduction; Biology; Ubiquitin ligase; Molecular biology; Chemistry; Immune system; Immunology; In vitro; Ubiquitin; Biochemistry","score_opus":0.03756454992700576,"score_gpt":0.3166916339564182,"score_spread":0.27912708402941244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2097514222","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94740015,0.00021318738,0.0062399106,0.002970825,0.0006138461,0.0020153106,0.000011013312,0.00014976451,0.04038599],"genre_scores_gemma":[0.99027056,0.00004507962,0.0008030241,0.0037334377,0.0004571814,0.00006675363,0.00022571275,0.00009216343,0.004306063],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99697137,0.00017679807,0.000578394,0.0006494181,0.0010431045,0.0005809432],"domain_scores_gemma":[0.9979199,0.00016767313,0.00013957614,0.00084311364,0.00041248757,0.00051723723],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00082502555,0.00036965086,0.0006641803,0.0005826563,0.0001070451,0.000017466908,0.0002144436,0.00025686045,0.0049463394],"category_scores_gemma":[0.0003802939,0.000307344,0.00014294355,0.00070413767,0.0001108979,0.000062367464,0.000050736646,0.00046510046,0.0008645997],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016155863,0.00027546068,0.0006799399,0.000067900924,0.00009688962,0.00008552195,0.0010810471,0.00007199947,0.98373353,0.00020277123,0.006400852,0.00568849],"study_design_scores_gemma":[0.0056295064,0.0031393466,0.011726492,0.00033133477,0.000118843,0.000008646915,0.00013641441,0.00060646434,0.95842654,0.00020829758,0.019394655,0.00027345915],"about_ca_topic_score_codex":0.00021689954,"about_ca_topic_score_gemma":0.0000045522647,"teacher_disagreement_score":0.042870436,"about_ca_system_score_codex":0.0002698732,"about_ca_system_score_gemma":0.000120284356,"threshold_uncertainty_score":0.9999379},"labels":[],"label_agreement":null},{"id":"W2101928501","doi":"10.4049/jimmunol.0902181","title":"Bim-Mediated Apoptosis Is Not Necessary for Thymic Negative Selection to Ubiquitous Self-Antigens","year":2009,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research; Fondation pour la Recherche Médicale","keywords":"Negative selection; Repertoire; Biology; Selection (genetic algorithm); Clonal deletion; Thymocyte; Nerve growth factor IB; Apoptosis; CD8; Self Tolerance; Mechanism (biology); Central tolerance; Cell biology; Immunology; T cell; Antigen; T-cell receptor; Immune tolerance; Genetics; Immune system; Transcription factor; Computer science; Gene","score_opus":0.022841009114509307,"score_gpt":0.3170039209102526,"score_spread":0.2941629117957433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2101928501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97284305,0.00050039066,0.00063589297,0.024627725,0.00031429084,0.0006209619,0.0000065271915,0.000035257963,0.0004158781],"genre_scores_gemma":[0.9908207,0.001716321,0.001570354,0.004375225,0.00039948965,0.0000075975254,0.0000028580753,0.000029047807,0.001078399],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984438,0.00022616169,0.0004699996,0.0001321913,0.00030613368,0.00042173528],"domain_scores_gemma":[0.998147,0.00057699473,0.0002745277,0.0002433966,0.0006534097,0.0001046872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00093047373,0.00016179738,0.00045990574,0.0003841115,0.00015491906,0.000016351893,0.0003081682,0.00015537029,0.0004888698],"category_scores_gemma":[0.00032521188,0.000106476116,0.00018840979,0.00051931693,0.00007419443,0.00008690321,0.000034576187,0.000621986,0.000052856165],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007055921,0.00019988426,0.00011518546,0.000010432406,0.00068086485,0.0000043075383,0.002849041,0.000015292793,0.96533924,0.000025404264,0.005082668,0.018621778],"study_design_scores_gemma":[0.004005904,0.010570474,0.016482214,0.00007223575,0.00029514122,0.0008307482,0.0009973958,0.00017776355,0.9522888,0.0006011936,0.013522866,0.00015525367],"about_ca_topic_score_codex":0.00005116915,"about_ca_topic_score_gemma":0.0000071413665,"teacher_disagreement_score":0.0202525,"about_ca_system_score_codex":0.00023946313,"about_ca_system_score_gemma":0.0002724679,"threshold_uncertainty_score":0.53527814},"labels":[],"label_agreement":null},{"id":"W2108334708","doi":"10.3389/fimmu.2013.00221","title":"Beyond the Antigen Receptor: Editing the Genome of T-Cells for Cancer Adoptive Cellular Therapies","year":2013,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Chimeric antigen receptor; Adoptive cell transfer; Antigen; Immunology; Genome editing; Receptor; Biology; Perspective (graphical); Genome; T cell; Computational biology; Medicine; Genetics; Immune system; Computer science; Gene","score_opus":0.015015016267789023,"score_gpt":0.26508284523526454,"score_spread":0.25006782896747554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2108334708","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9297377,0.050758097,0.002161836,0.00875851,0.0033347723,0.0031412,0.00004320872,0.000028781846,0.0020359193],"genre_scores_gemma":[0.9533171,0.016627882,0.008598513,0.001252027,0.0013652381,0.0017734868,0.00006343506,0.00013254052,0.016869783],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99860764,0.00019029097,0.0003219937,0.00023298703,0.00018229158,0.00046482045],"domain_scores_gemma":[0.99889296,0.0002354621,0.00014414612,0.0004901002,0.00020935139,0.000027948548],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005475463,0.00015635276,0.00039773487,0.00014227764,0.0001301808,0.000016216762,0.00041644162,0.00015362936,0.0016399372],"category_scores_gemma":[0.000061019102,0.00009131622,0.00013804884,0.00024759842,0.0007525703,0.000059924438,0.00008703465,0.00041518797,0.000017340379],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034609094,0.00006722041,0.005888569,0.000031594358,0.00065061223,0.0000012677954,0.005943219,0.000013422838,0.92219424,0.00013445964,0.018067112,0.046662174],"study_design_scores_gemma":[0.004000224,0.000988363,0.018319407,0.000088430206,0.00009505477,0.000008611268,0.03295596,0.00054262276,0.37984085,0.003830211,0.55900526,0.00032497404],"about_ca_topic_score_codex":0.00052663416,"about_ca_topic_score_gemma":0.000022263002,"teacher_disagreement_score":0.5423534,"about_ca_system_score_codex":0.00014667734,"about_ca_system_score_gemma":0.00012524417,"threshold_uncertainty_score":0.9992727},"labels":[],"label_agreement":null},{"id":"W2114219301","doi":"10.4049/jimmunol.1300521","title":"Complete TCR-α Gene Locus Control Region Activity in T Cells Derived In Vitro from Embryonic Stem Cells","year":2013,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"National Center for Research Resources; National Institute of General Medical Sciences; National Institute on Minority Health and Health Disparities; Canadian Institutes of Health Research","keywords":"Biology; T-cell receptor; Transgene; Embryonic stem cell; Gene; Locus control region; Locus (genetics); Reporter gene; Stem cell; T cell; Cellular differentiation; Genetics; Molecular biology; Gene expression; Cell biology; Promoter; Immune system","score_opus":0.028440671084610052,"score_gpt":0.264324315485082,"score_spread":0.23588364440047196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114219301","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928833,0.0024290776,0.00038146006,0.0032715984,0.00030710074,0.00059530186,0.0000053382037,0.000008163184,0.0001186471],"genre_scores_gemma":[0.9971941,0.0017441163,0.00008124474,0.0002753379,0.00012954055,0.000008344718,0.000001471853,0.000029001865,0.0005368517],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997407,0.0011299719,0.000542757,0.00015394083,0.00028293196,0.00048339574],"domain_scores_gemma":[0.9980788,0.00083553157,0.00038320443,0.00044625578,0.00017087584,0.00008531358],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008093107,0.00018645306,0.00079215114,0.00032852354,0.000042591004,0.000018837525,0.00041837868,0.0001832089,0.0004768184],"category_scores_gemma":[0.000027575792,0.00012689759,0.00014513369,0.0002302007,0.00026193983,0.00012002731,0.00008305857,0.001310847,0.00011135119],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070934896,0.00020448783,0.00021527898,0.000008408604,0.00023504952,0.0003339834,0.00053913315,0.00006559371,0.97159386,0.0000010487349,0.00012232362,0.01958734],"study_design_scores_gemma":[0.009927722,0.00076411857,0.023182746,0.00007689768,0.000058892576,0.00041258527,0.00039616245,0.00046273365,0.9637651,0.00015572255,0.00067694724,0.00012038586],"about_ca_topic_score_codex":0.0016029456,"about_ca_topic_score_gemma":0.000098913326,"teacher_disagreement_score":0.022967467,"about_ca_system_score_codex":0.0003926646,"about_ca_system_score_gemma":0.00018203826,"threshold_uncertainty_score":0.5695051},"labels":[],"label_agreement":null},{"id":"W2114643167","doi":"10.4049/jimmunol.1200979","title":"Comparative and Functional Evaluation of In Vitro Generated to Ex Vivo CD8 T Cells","year":2012,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"Canadian Institutes of Health Research","keywords":"Cytotoxic T cell; CD8; Biology; Cell biology; Ex vivo; In vitro; Haematopoiesis; Immune system; Immunology; Stem cell; Biochemistry","score_opus":0.10106963564029958,"score_gpt":0.3725239955399382,"score_spread":0.2714543598996386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2114643167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994515,0.0038086993,0.0000860042,0.0005805541,0.00021758513,0.00021494347,0.0000014585675,0.0000013348707,0.0005744004],"genre_scores_gemma":[0.9990561,0.00016664,0.00013935333,0.000090244714,0.00013009904,0.0000020704965,0.0000012430228,0.0000053903655,0.00040888693],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986501,0.00053727324,0.0002872532,0.00004080677,0.00032930606,0.0001553136],"domain_scores_gemma":[0.9990237,0.00019754058,0.0001417826,0.00010936655,0.00047966096,0.00004797984],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00258783,0.00006105689,0.00026937333,0.00021080833,0.000021974909,0.0000024806038,0.000059600836,0.000048699207,0.001283532],"category_scores_gemma":[0.00007181957,0.000038892296,0.00003184743,0.00018074186,0.000105261715,0.000057348538,0.000031370146,0.0002668687,0.000012139221],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042029466,0.000120497796,0.0004697715,0.0000034013783,0.0001600435,9.655414e-7,0.0022587306,0.00018045685,0.9891183,0.000008229505,0.00044451785,0.0030321726],"study_design_scores_gemma":[0.0024925,0.00057929906,0.059572183,0.000020351448,0.00009289293,0.0003040337,0.0009756024,0.0003738292,0.9345714,0.000043647848,0.00093867833,0.00003557874],"about_ca_topic_score_codex":0.000029930323,"about_ca_topic_score_gemma":0.000005471263,"teacher_disagreement_score":0.059102412,"about_ca_system_score_codex":0.00011821944,"about_ca_system_score_gemma":0.0001397965,"threshold_uncertainty_score":0.99962944},"labels":[],"label_agreement":null},{"id":"W2115339711","doi":"10.1126/scitranslmed.3002207","title":"Establishment of Antitumor Memory in Humans Using in Vitro–Educated CD8 <sup>+</sup> T Cells","year":2011,"lang":"en","type":"article","venue":"Science Translational Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":105,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute","keywords":"In vitro; Cytotoxic T cell; Cancer research; Chemistry; CD8; Biology; Cell biology; Molecular biology; Immunology; Biochemistry; Antigen","score_opus":0.08711942904721322,"score_gpt":0.3547967759323328,"score_spread":0.26767734688511957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2115339711","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891217,0.00024330584,0.00012774984,0.0009482902,0.00014703744,0.000629215,0.0000068168124,0.000014776379,0.008761141],"genre_scores_gemma":[0.9967365,0.000032926877,0.0026653842,0.00014825916,0.00009802687,0.000010698662,0.000013385394,0.000015222596,0.00027954046],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970442,0.000067762085,0.0005974925,0.00043574706,0.0013766278,0.00047814735],"domain_scores_gemma":[0.99905884,0.00011820748,0.00007842219,0.00030952992,0.00023305748,0.00020196554],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0022329884,0.00015852357,0.00041849702,0.0013677984,0.00006362401,0.0000065205836,0.00029479477,0.00004886967,0.003718137],"category_scores_gemma":[0.00012009736,0.00013108748,0.000047809976,0.002395122,0.0015200964,0.00028189618,0.000022020748,0.00031069768,0.0000069972725],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047518665,0.00033610748,0.016942663,0.00007805459,0.0000077417835,0.000044974186,0.011348843,0.00047202336,0.96732473,0.00012842267,0.000013659603,0.0028275654],"study_design_scores_gemma":[0.008544197,0.000622038,0.18092401,0.0009952016,0.00005527131,0.000050815383,0.004895059,0.026652584,0.77573097,0.0010109316,0.00019679236,0.00032210897],"about_ca_topic_score_codex":0.0018356959,"about_ca_topic_score_gemma":0.00007004181,"teacher_disagreement_score":0.19159377,"about_ca_system_score_codex":0.00018545626,"about_ca_system_score_gemma":0.0009837341,"threshold_uncertainty_score":0.9971926},"labels":[],"label_agreement":null},{"id":"W2119966117","doi":"10.1126/scitranslmed.3000885","title":"Of Mice and Men: How an Oncogene Transgresses the Limits and Predisposes to T Cell Acute Lymphoblastic Leukemia","year":2010,"lang":"en","type":"article","venue":"Science Translational Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer","funders":"Canadian Institutes of Health Research","keywords":"Lymphoblastic Leukemia; Medicine; Leukemia; Cancer research; Oncogene; Immunology; Internal medicine; Cancer; Cell cycle","score_opus":0.02828802231561585,"score_gpt":0.3272745458485826,"score_spread":0.2989865235329668,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2119966117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9683603,0.00040983479,0.00035301797,0.028358143,0.0001262231,0.0005408041,0.000023034321,0.000016722664,0.0018119062],"genre_scores_gemma":[0.9974392,0.00016488486,0.0012790344,0.0003195453,0.00020733212,0.000014404675,0.0000079627125,0.000012666306,0.0005549385],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99807847,0.000032169024,0.00019979899,0.00037381932,0.0010406151,0.0002751427],"domain_scores_gemma":[0.9986509,0.00039501826,0.000044109638,0.00025450846,0.0002634291,0.00039202254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009375467,0.00014216153,0.00024755567,0.00023260694,0.00018433391,0.000025204805,0.00024036497,0.000046330537,0.0002640993],"category_scores_gemma":[0.00014434033,0.00008525674,0.000023381013,0.00066986156,0.0021953462,0.00021282077,0.0000151487275,0.00019988784,0.0000010061406],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032626017,0.000037328013,0.0018232696,0.0000546648,0.000016268848,0.0000055286305,0.0027795746,0.000010134395,0.9769271,0.00032083836,0.000054073997,0.01764498],"study_design_scores_gemma":[0.0069109406,0.0034668806,0.24917348,0.0002553369,0.0003771226,0.00047357086,0.0015099563,0.0066789156,0.725297,0.000772617,0.0047640614,0.00032013678],"about_ca_topic_score_codex":0.00005198485,"about_ca_topic_score_gemma":0.00010769216,"teacher_disagreement_score":0.2516301,"about_ca_system_score_codex":0.000023692954,"about_ca_system_score_gemma":0.000553255,"threshold_uncertainty_score":0.8088845},"labels":[],"label_agreement":null},{"id":"W2120261661","doi":"10.1158/0008-5472.can-11-1659","title":"B Effector Cells Activated by a Chimeric Protein Consisting of IL-2 and the Ectodomain of TGF-β Receptor II Induce Potent Antitumor Immunity","year":2012,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Canadian Institutes of Health Research","keywords":"Ectodomain; Antigen; Medicine; Cancer research; Immunology; CD8; Cytotoxic T cell; Tumor antigen; Molecular biology; Immune system; Biology; Receptor; Immunotherapy; In vitro; Internal medicine","score_opus":0.05778358443386004,"score_gpt":0.37915640540113293,"score_spread":0.3213728209672729,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120261661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916444,0.0040272716,0.0000045966895,0.0007474777,0.0000723726,0.002627947,0.00008051042,0.000017001363,0.0007784298],"genre_scores_gemma":[0.99660933,0.000517021,0.000097311786,0.000027634811,0.00013690231,0.00032108522,0.000012486023,0.000042144482,0.0022360673],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9962751,0.0013961456,0.0003491892,0.00024877556,0.0010179447,0.0007127929],"domain_scores_gemma":[0.9975842,0.0009711934,0.00014339236,0.00056859816,0.00048401472,0.00024857672],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004771297,0.00016530095,0.00054941647,0.00022286047,0.00027494805,0.000016682985,0.0002644722,0.00010653667,0.0013448459],"category_scores_gemma":[0.00096749223,0.00011065443,0.000093791685,0.0008371251,0.001489993,0.00008353039,0.0003604204,0.0010803571,0.000010178684],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035853232,0.0002927434,0.0012365885,0.00050694443,0.00019859687,0.0000018054684,0.0011347533,3.1819187e-7,0.9830912,0.000046270532,0.0017578849,0.008147593],"study_design_scores_gemma":[0.003705949,0.0006503266,0.00209002,0.00039634237,0.000026972759,0.0000070417536,0.0003946535,0.0000137947445,0.9886096,0.00001349385,0.0039943294,0.00009748405],"about_ca_topic_score_codex":0.0044367807,"about_ca_topic_score_gemma":0.000010730831,"teacher_disagreement_score":0.008050109,"about_ca_system_score_codex":0.00021236292,"about_ca_system_score_gemma":0.00043508632,"threshold_uncertainty_score":0.99956805},"labels":[],"label_agreement":null},{"id":"W2120672212","doi":"10.1158/0008-5472.can-06-4309","title":"Regression of Experimental Medulloblastoma following Transfer of HER2-Specific T Cells","year":2007,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":190,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"","keywords":"Medulloblastoma; Cancer research; Adoptive cell transfer; Medicine; Immunology; T cell; Biology; Immune system","score_opus":0.09518931613407072,"score_gpt":0.44727331356468614,"score_spread":0.3520839974306154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2120672212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98442644,0.0063094525,0.00008890052,0.00018541339,0.00022169009,0.00073216646,0.00000899922,0.000019672198,0.008007275],"genre_scores_gemma":[0.99361455,0.0009585546,0.00015717659,0.000017051048,0.00021198619,0.000045365698,0.000004573578,0.000054695432,0.0049360306],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99627745,0.0001638344,0.00044668114,0.000370559,0.0020364781,0.0007049713],"domain_scores_gemma":[0.99845356,0.00031256126,0.000030832736,0.00053835276,0.00037305953,0.0002916304],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0024061755,0.00015533595,0.0004544108,0.0005200905,0.00008320828,0.000010158752,0.00028004745,0.00014745402,0.0067856032],"category_scores_gemma":[0.00003403849,0.0001222793,0.0002627422,0.0008910582,0.0004282762,0.000065663604,0.00008753051,0.00058913464,0.000022422995],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003068786,0.00033126582,0.0013561422,0.00013296354,0.00008591781,0.00010851913,0.0015456905,0.0000015786081,0.97537345,0.00008527943,0.0017733772,0.016137019],"study_design_scores_gemma":[0.0021753027,0.00081167516,0.0014221012,0.0005311123,0.0000066681837,0.000006621642,0.0017306797,0.000005843836,0.9729601,0.000013243839,0.020244583,0.000092072914],"about_ca_topic_score_codex":0.000413237,"about_ca_topic_score_gemma":0.000041574585,"teacher_disagreement_score":0.018471207,"about_ca_system_score_codex":0.00040049848,"about_ca_system_score_gemma":0.00030786401,"threshold_uncertainty_score":0.9941223},"labels":[],"label_agreement":null},{"id":"W2122826668","doi":"10.1186/1479-0556-2-15","title":"Effects of recombinant adenovirus-mediated expression of IL-2 and IL-12 in human B lymphoma cells on co-cultured PBMC.","year":2004,"lang":"en","type":"article","venue":"Genetic Vaccines and Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Hector Stiftung; McMaster University","keywords":"Lymphoma; Cytokine; Cancer research; Peripheral blood mononuclear cell; Cytotoxic T cell; Immune system; Molecular biology; Medicine; Cell culture; Cytotoxicity; Immunology; Biology; In vitro","score_opus":0.013691741329263039,"score_gpt":0.28165763387356885,"score_spread":0.2679658925443058,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2122826668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937947,0.0050311335,0.0000052212317,0.00011898474,0.00008288513,0.00082426204,0.0000065417225,0.000011913241,0.00012437807],"genre_scores_gemma":[0.9861469,0.013125136,0.00014119402,0.00009389221,0.000055493754,0.000022558124,0.000009830032,0.00003129578,0.00037365058],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987903,0.00008071999,0.00033509074,0.00029639294,0.0002511248,0.00024636442],"domain_scores_gemma":[0.9993496,0.00010856413,0.00010956912,0.00025449833,0.000059484402,0.00011826803],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015314065,0.0001989372,0.0004718271,0.00019514223,0.000043004682,0.000009666967,0.00008645545,0.00013730522,0.00014596086],"category_scores_gemma":[0.000017016304,0.00014181483,0.000063054285,0.00017169598,0.00006117064,0.000023291741,0.00002697159,0.000098846904,0.00000250137],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014267853,0.00050053134,0.008200291,0.00021042331,0.000038635302,0.000027532027,0.0010188175,0.0000075370945,0.9593204,0.000008599433,0.00006899642,0.02917141],"study_design_scores_gemma":[0.01560351,0.0023420725,0.2074318,0.00030791722,0.000012214539,0.000013125399,0.00006651893,0.000007774985,0.7729394,0.00022421217,0.0009406817,0.00011076265],"about_ca_topic_score_codex":0.00013099881,"about_ca_topic_score_gemma":0.000016198548,"teacher_disagreement_score":0.1992315,"about_ca_system_score_codex":0.00003194283,"about_ca_system_score_gemma":0.000044996374,"threshold_uncertainty_score":0.57830405},"labels":[],"label_agreement":null},{"id":"W2123380826","doi":"10.25011/cim.v33i6.14584","title":"Discovery research to clinical trial: A ten year journey","year":2010,"lang":"en","type":"article","venue":"Clinical and investigative medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Vancouver Hospital and Health Sciences Centre; University of British Columbia","funders":"Michael Smith Health Research BC; Canadian Institutes of Health Research; Terry Fox Foundation; Cancer Research Society","keywords":"Medicine; Clinical trial; Internal medicine","score_opus":0.5668532213575824,"score_gpt":0.55408223613295,"score_spread":0.01277098522463238,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2123380826","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8718472,0.000107383035,0.000022386674,0.114086874,0.0018347614,0.0014952009,0.0000058860965,0.000049637918,0.01055066],"genre_scores_gemma":[0.9255988,0.0007271283,0.0016511932,0.009209664,0.014049687,0.000096625314,0.000026436901,0.000071642455,0.048568834],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945657,0.0011441419,0.0015608318,0.000893671,0.001188086,0.0006475279],"domain_scores_gemma":[0.9930379,0.0030984408,0.00013843618,0.0008678948,0.0006818437,0.0021755183],"candidate_categories":["metaresearch","sts","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.016436653,0.00024935784,0.0011783083,0.00031893334,0.00018035546,0.000056174253,0.00033771305,0.0004020837,0.0019693207],"category_scores_gemma":[0.047953833,0.00015569836,0.00021970426,0.0008163652,0.020045929,0.00017534324,0.00035699032,0.0043361923,0.0002915724],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04359916,0.0016145238,0.5522221,0.00013832886,0.00046424984,0.00027847194,0.0014097698,6.749609e-8,0.04682986,0.016314564,0.2503168,0.08681212],"study_design_scores_gemma":[0.09388999,0.028727919,0.44817662,0.0006995538,0.00015041188,0.000061657236,0.0011051968,0.00004814152,0.001259836,0.03635432,0.38914558,0.0003807701],"about_ca_topic_score_codex":0.00013478938,"about_ca_topic_score_gemma":0.000079597434,"teacher_disagreement_score":0.1388288,"about_ca_system_score_codex":0.000027863856,"about_ca_system_score_gemma":0.000584945,"threshold_uncertainty_score":0.99894303},"labels":[],"label_agreement":null},{"id":"W2124668663","doi":"10.1158/2326-6066.cir-14-0222","title":"Optimization of T-cell Reactivity by Exploiting TCR Chain Centricity for the Purpose of Safe and Effective Antitumor TCR Gene Therapy","year":2015,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"National Cancer Institute; Hospital for Sick Children","keywords":"T-cell receptor; Chemistry; Major histocompatibility complex; Antigen; T cell; Biology; Epitope; Molecular biology; Cell biology; Immunology; Immune system","score_opus":0.09014275203993506,"score_gpt":0.39063135939160626,"score_spread":0.3004886073516712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2124668663","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9664224,0.026023516,0.0018606196,0.0011463672,0.00012746731,0.0035472868,0.000073399715,0.000017081991,0.00078189076],"genre_scores_gemma":[0.979821,0.01728469,0.0003505971,0.000041618965,0.00011614285,0.0007400248,0.000028522216,0.000043683704,0.001573692],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99781275,0.000444907,0.00029592897,0.00036294706,0.0005378801,0.0005455602],"domain_scores_gemma":[0.9962127,0.001740442,0.00015007347,0.000483709,0.0013055095,0.00010753506],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033215487,0.00015031354,0.00047417753,0.00025793863,0.00016227501,0.00001521266,0.00025599808,0.00016300101,0.00017471319],"category_scores_gemma":[0.0008051074,0.00011015847,0.000081765895,0.0006089345,0.00096870563,0.000094053066,0.000166036,0.00058462465,0.0000013815464],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067223697,0.00032072476,0.0040463884,0.000117273026,0.00024132285,0.000003910422,0.0008488532,0.00010263369,0.89841616,0.000026061027,0.00081311306,0.088341214],"study_design_scores_gemma":[0.006595019,0.0019607327,0.0034501164,0.00006463564,0.000026473383,0.0000158259,0.0009422225,0.0021639431,0.9795614,0.00006289005,0.0050548045,0.000101923455],"about_ca_topic_score_codex":0.0010170238,"about_ca_topic_score_gemma":0.000012157037,"teacher_disagreement_score":0.08823929,"about_ca_system_score_codex":0.0003011691,"about_ca_system_score_gemma":0.000517497,"threshold_uncertainty_score":0.4492132},"labels":[],"label_agreement":null},{"id":"W2130024935","doi":"10.4161/onci.23621","title":"Lessons learned from a highly-active CD22-specific chimeric antigen receptor","year":2013,"lang":"en","type":"article","venue":"OncoImmunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"","keywords":"CD22; Chimeric antigen receptor; Epitope; Antigen; Bispecific antibody; Receptor; Antibody; Immunology; Computational biology; Cancer research; Medicine; Immunotherapy; Biology; Monoclonal antibody; Internal medicine; Immune system","score_opus":0.07570445915132859,"score_gpt":0.34021376943611,"score_spread":0.2645093102847814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130024935","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95011336,0.003029833,0.000060161317,0.017706066,0.00064165716,0.00079978304,0.000033065535,0.00018908705,0.027426977],"genre_scores_gemma":[0.9395764,0.011949884,0.0020254282,0.0006733328,0.00068734935,0.00030273138,0.00037497297,0.00013937803,0.044270534],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978806,0.00023773138,0.00032349356,0.0006039998,0.00029155938,0.00066263275],"domain_scores_gemma":[0.99837637,0.00025535666,0.00011388836,0.00090513314,0.00019315637,0.00015608434],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00014229605,0.000261017,0.0006329252,0.00023177815,0.00013693584,0.00004066458,0.00032665516,0.00031927926,0.06862086],"category_scores_gemma":[0.00008388387,0.00023347214,0.00016948339,0.00041042204,0.00041136472,0.00013572704,0.00017083657,0.00076978194,0.010004231],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005264676,0.00019588784,0.00069523987,0.0000037929121,0.00028032454,0.000020136433,0.00063192745,2.3237746e-7,0.6595682,0.00016079453,0.0060649,0.3318521],"study_design_scores_gemma":[0.003156278,0.0008753847,0.13641529,0.000045468038,0.000026354965,0.0000440548,0.0010936243,0.000022918552,0.07344133,0.00085274887,0.7837338,0.00029278666],"about_ca_topic_score_codex":0.002648021,"about_ca_topic_score_gemma":0.000022133627,"teacher_disagreement_score":0.7776689,"about_ca_system_score_codex":0.00029415928,"about_ca_system_score_gemma":0.00020120834,"threshold_uncertainty_score":0.9907666},"labels":[],"label_agreement":null},{"id":"W2132636334","doi":"10.4049/jimmunol.192.supp.65.9","title":"Translational control of memory CD8 T cell differentiation (LYM4P.752)","year":2014,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Biology; CD8; Cytotoxic T cell; Cell biology; T cell; Transcriptome; Gene expression; Translation (biology); Memory T cell; Cellular differentiation; Antigen; Messenger RNA; Immunology; Gene; Immune system; Genetics; In vitro","score_opus":0.013980575158538388,"score_gpt":0.26965158199532585,"score_spread":0.25567100683678745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2132636334","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9828894,0.0019209263,0.008989761,0.0029182234,0.00024850384,0.00015700216,0.0000021940434,0.0000048986253,0.0028690682],"genre_scores_gemma":[0.9983963,0.000281299,0.00006900721,0.00013599255,0.00021160221,9.614453e-7,0.0000022779332,0.000012130016,0.00089044153],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99865645,0.00040834784,0.00042743824,0.00005062352,0.00030390677,0.00015321553],"domain_scores_gemma":[0.99862343,0.00053175935,0.00031680692,0.00020007974,0.00029145586,0.000036449972],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010520425,0.000079043886,0.00033323746,0.00015372182,0.00004030238,0.0000032720236,0.00018375566,0.00008201998,0.0016373467],"category_scores_gemma":[0.000090255446,0.00004863099,0.0001432161,0.000084998224,0.00016423542,0.00004302174,0.000012219829,0.00038593786,0.000012823436],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027502917,0.00013996776,0.0014364595,0.000020464257,0.00026460525,0.0000021244805,0.00064809434,0.000061616985,0.9790242,0.00018176057,0.00008153253,0.0153889125],"study_design_scores_gemma":[0.029967342,0.0055829394,0.27452412,0.00014579014,0.00084539165,0.0012438816,0.0006860458,0.0027204123,0.67388695,0.003909438,0.006276765,0.00021091395],"about_ca_topic_score_codex":0.00001377289,"about_ca_topic_score_gemma":0.0000024830988,"teacher_disagreement_score":0.30513722,"about_ca_system_score_codex":0.000029425884,"about_ca_system_score_gemma":0.000095394804,"threshold_uncertainty_score":0.99927527},"labels":[],"label_agreement":null},{"id":"W2135832041","doi":"10.7150/jca.6572","title":"Optimizing the Immune System to Achieve Control of the Metastatic Malignant Lesion","year":2013,"lang":"en","type":"article","venue":"Journal of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Precision BioLogic (Canada)","funders":"","keywords":"Immune system; Immunotherapy; Malignancy; Medicine; Lesion; Cancer immunotherapy; Immunology; Cancer research; Computer science; Pathology","score_opus":0.030698494210376372,"score_gpt":0.3332146775319073,"score_spread":0.30251618332153096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2135832041","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9543575,0.01513017,0.0017340627,0.025548454,0.00071414496,0.0013876186,0.000006628992,0.0000062255563,0.0011151669],"genre_scores_gemma":[0.99716496,0.00022045501,0.00028983358,0.00038540078,0.0002216524,0.000025200789,6.5368475e-8,0.000016605534,0.0016758189],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984681,0.00017457918,0.00047152652,0.00006419914,0.00064132526,0.00018028528],"domain_scores_gemma":[0.9986609,0.00015964927,0.00034555444,0.0002700439,0.0004685778,0.00009526439],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087612093,0.00008463324,0.00037114145,0.00007281876,0.000059541817,0.00002287923,0.000252971,0.00002413653,0.00078608806],"category_scores_gemma":[0.00006630603,0.000034753277,0.00022690948,0.00018417063,0.00005240521,0.00006067065,0.000039364557,0.00028895366,0.000009388763],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012259667,0.000055556073,0.0009383664,0.0001583004,0.00057165395,0.000019779754,0.0010510256,0.0023194142,0.96566325,0.00013307438,0.0010408527,0.026822744],"study_design_scores_gemma":[0.022561437,0.0051273117,0.081145875,0.011893805,0.0024697527,0.0019022267,0.0137798395,0.012724976,0.8085133,0.00016087694,0.039208833,0.00051177427],"about_ca_topic_score_codex":0.00028424474,"about_ca_topic_score_gemma":0.000012505175,"teacher_disagreement_score":0.15714997,"about_ca_system_score_codex":0.00020775424,"about_ca_system_score_gemma":0.00023560367,"threshold_uncertainty_score":0.86071134},"labels":[],"label_agreement":null},{"id":"W2136875369","doi":"10.1111/j.1600-6143.2012.04286.x","title":"Cord Blood T Cells Retain Early Differentiation Phenotype Suitable for Immunotherapy After TCR Gene Transfer to Confer EBV Specificity","year":2012,"lang":"en","type":"article","venue":"American Journal of Transplantation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Institute for Health and Care Research; Cancer Research UK; NHS Blood and Transplant","keywords":"Immunology; Antigen; T-cell receptor; Adoptive cell transfer; Immunotherapy; Immune system; Transplantation; Cytotoxic T cell; Biology; Medicine; T cell; Cancer research; In vitro; Internal medicine","score_opus":0.019279022799342356,"score_gpt":0.2850536739189206,"score_spread":0.26577465111957826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2136875369","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9034357,0.00020992631,0.095013015,0.00031585447,0.00021450828,0.00059477554,0.000065774315,0.000012586917,0.00013784059],"genre_scores_gemma":[0.9937485,0.0007443719,0.0041000308,0.00036780754,0.0004881445,0.000029923107,0.000035769768,0.00005193239,0.00043353238],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982725,0.00013707117,0.00051236973,0.00015724811,0.0004938701,0.00042696553],"domain_scores_gemma":[0.9989594,0.00015947779,0.00010228468,0.00017133515,0.0003368566,0.00027059752],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058036327,0.00018284842,0.00045671564,0.00025280527,0.000056954137,0.000038226157,0.000113488924,0.00006057107,0.00090279925],"category_scores_gemma":[0.000008670852,0.00015641835,0.00023251424,0.00025280006,0.00008301097,0.00023616842,0.0000024955407,0.00025110607,0.000014383326],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021686027,0.00029178456,0.013612241,0.00006942232,0.0003502666,0.000016723512,0.004388753,0.00001318984,0.9282844,0.000030508398,0.000035943518,0.031220717],"study_design_scores_gemma":[0.005473542,0.0055827633,0.25104067,0.00011544746,0.0006201515,0.00017544725,0.00030601022,0.000025569661,0.7344318,0.00002717411,0.0019475174,0.00025391826],"about_ca_topic_score_codex":0.000084212435,"about_ca_topic_score_gemma":0.000011324016,"teacher_disagreement_score":0.23742844,"about_ca_system_score_codex":0.000085649874,"about_ca_system_score_gemma":0.000085868385,"threshold_uncertainty_score":0.9885019},"labels":[],"label_agreement":null},{"id":"W2138051343","doi":"10.1002/stem.2115","title":"In Vitro T-Cell Generation From Adult, Embryonic, and Induced Pluripotent Stem Cells: Many Roads to One Destination","year":2015,"lang":"en","type":"review","venue":"Stem Cells","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institutes of Health","keywords":"Biology; Induced pluripotent stem cell; Embryonic stem cell; Cell biology; Stem cell; Progenitor cell; Haematopoiesis; Cellular differentiation; In vitro; Immunology; Genetics","score_opus":0.1004801585316933,"score_gpt":0.33762347317055624,"score_spread":0.23714331463886296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2138051343","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.025894776,0.9655437,0.00012220726,0.00019952633,0.000944766,0.0056787967,0.0001592242,0.000077564364,0.0013794485],"genre_scores_gemma":[0.0010686689,0.9686568,0.0008441692,0.00019541744,0.0012139825,0.00041420193,0.00033166452,0.00022240427,0.027052715],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99544305,0.00063324854,0.0010460658,0.0011355404,0.0011039074,0.00063819473],"domain_scores_gemma":[0.9975127,0.0001883179,0.00038250606,0.0009143636,0.0004141751,0.00058795547],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00095584977,0.0006761483,0.0021933757,0.00065834814,0.00006450488,0.00012840168,0.00031196044,0.00067536114,0.00023658226],"category_scores_gemma":[0.000011869268,0.00062045094,0.0002648327,0.00064884295,0.00004031521,0.00013036984,0.00022134154,0.00092054665,0.00056563475],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014190626,0.00022168606,0.000001352833,0.0037508644,0.000097820586,0.00009261798,0.00028408633,0.000003614061,0.30455956,0.0000069816415,0.0017846619,0.68905485],"study_design_scores_gemma":[0.002929904,0.0006254585,0.0000029567384,0.0054088132,0.00069194345,0.000031123272,0.00016826545,0.0004278473,0.19614735,0.000010695091,0.7927447,0.0008109275],"about_ca_topic_score_codex":0.00044073575,"about_ca_topic_score_gemma":0.000078565776,"teacher_disagreement_score":0.7909601,"about_ca_system_score_codex":0.0013055118,"about_ca_system_score_gemma":0.00075437815,"threshold_uncertainty_score":0.99962467},"labels":[],"label_agreement":null},{"id":"W2140080463","doi":"10.1021/bi900674m","title":"Steady-State and Stopped-Flow Kinetic Studies of Three <i>Escherichia coli</i> NfsB Mutants with Enhanced Activity for the Prodrug CB1954","year":2009,"lang":"en","type":"article","venue":"Biochemistry","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Biotechnology and Biological Sciences Research Council","keywords":"Mutant; Enzyme kinetics; Prodrug; Escherichia coli; Enzyme; Chemistry; Biology; Biochemistry; Active site; Gene","score_opus":0.031236943259429304,"score_gpt":0.31376420359354235,"score_spread":0.282527260334113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140080463","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99488604,0.0019289416,0.00035231767,0.0010747266,0.000028246845,0.0010082313,0.000031115465,0.0000244625,0.0006659013],"genre_scores_gemma":[0.99362046,0.0004142108,0.0006941629,0.00012764276,0.0001031383,0.00007780887,0.0000041710036,0.000021412367,0.004937008],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988683,0.000016969274,0.0001703057,0.00032201642,0.00032631034,0.0002961156],"domain_scores_gemma":[0.99892914,0.00020126461,0.00010271198,0.0004420334,0.00023070276,0.00009417343],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024137017,0.00019230547,0.00035986418,0.000020162948,0.00008523849,0.000015100631,0.0001243132,0.000066101486,0.000039443003],"category_scores_gemma":[0.00013247532,0.00012096771,0.00005901347,0.00017288854,0.00030812723,0.000028954953,0.000039389004,0.00019855051,0.000001039785],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022768273,0.00015461851,0.00029918592,0.00040904857,0.00020716427,0.0000055928654,0.00041859437,0.0000049909877,0.95872515,0.000001139878,0.00022417332,0.03727353],"study_design_scores_gemma":[0.0022437368,0.00072493043,0.006010186,0.00017205757,0.000104254395,0.000013638599,0.00025989875,0.00033680364,0.98962146,0.00005791569,0.0003174816,0.00013765476],"about_ca_topic_score_codex":0.0000094982115,"about_ca_topic_score_gemma":0.000015368369,"teacher_disagreement_score":0.037135873,"about_ca_system_score_codex":0.000060490045,"about_ca_system_score_gemma":0.00015056627,"threshold_uncertainty_score":0.49329197},"labels":[],"label_agreement":null},{"id":"W2140619977","doi":"10.4049/jimmunol.1202970","title":"Loss of T Cell Progenitor Checkpoint Control Underlies Leukemia Initiation in <i>Rag1</i>-Deficient Nonobese Diabetic Mice","year":2013,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; National Institutes of Health; University of Toronto; University of Cambridge; California Institute of Technology","keywords":"Biology; Nod; Transcriptome; NOD mice; Progenitor cell; Genetics; Cell biology; Cancer research; Gene; Stem cell; Gene expression","score_opus":0.0148439948634221,"score_gpt":0.2643098244594854,"score_spread":0.2494658295960633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2140619977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936058,0.003044176,0.00012874913,0.0017402741,0.00018776958,0.00055620394,0.0000017851203,0.00000537887,0.0007298695],"genre_scores_gemma":[0.9984804,0.0007684528,0.0001003047,0.00016593766,0.00009715181,0.000012918686,0.0000012935375,0.000019593324,0.00035394423],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981594,0.00039236908,0.0007264656,0.00008589408,0.00031211684,0.00032375028],"domain_scores_gemma":[0.9982785,0.00044485411,0.00045560667,0.00026918753,0.00049638195,0.000055473316],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011390649,0.00012701504,0.00046517694,0.0002793883,0.000035692345,0.000010449334,0.00027300394,0.000114761686,0.00077360816],"category_scores_gemma":[0.0001773888,0.000081897655,0.00012777116,0.00022729745,0.00031076348,0.00009409206,0.00005364565,0.0006417655,0.000056537083],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012549721,0.00025884598,0.003331748,0.00005803361,0.00014688968,0.000019404277,0.0013974066,0.00009283611,0.9913867,0.000019429677,0.00007055962,0.0019631486],"study_design_scores_gemma":[0.013220028,0.0035756107,0.09205808,0.00022989098,0.00020469385,0.00090671063,0.0034222137,0.00058212446,0.8843875,0.00066745444,0.0005768025,0.00016890901],"about_ca_topic_score_codex":0.00019014196,"about_ca_topic_score_gemma":0.000012308448,"teacher_disagreement_score":0.10699924,"about_ca_system_score_codex":0.0003719115,"about_ca_system_score_gemma":0.0004076852,"threshold_uncertainty_score":0.8470467},"labels":[],"label_agreement":null},{"id":"W2141410122","doi":"10.1158/1078-0432.ccr-07-0674","title":"Genetically Targeted T Cells Eradicate Systemic Acute Lymphoblastic Leukemia Xenografts","year":2007,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":466,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Chimeric antigen receptor; Immunology; Adoptive cell transfer; Cancer research; T cell; Homing (biology); Medicine; Ex vivo; Systemic administration; CD28; Immunotherapy; Leukemia; In vivo; Biology; Immune system","score_opus":0.1267420617162681,"score_gpt":0.4841363589671988,"score_spread":0.35739429725093075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2141410122","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9845899,0.003192235,0.00061326387,0.0012963796,0.0011216128,0.0019455784,0.00004053016,0.00017842489,0.0070220926],"genre_scores_gemma":[0.9621128,0.007220078,0.0006776449,0.00080833497,0.0031510056,0.00019392875,0.0000310269,0.00016025218,0.025644962],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9911961,0.00085245975,0.0015730847,0.0012163129,0.002904716,0.0022573425],"domain_scores_gemma":[0.99191207,0.003335268,0.00013733798,0.0013864196,0.0013385512,0.0018903356],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.011821756,0.0003477754,0.0009728475,0.0006329559,0.00029357916,0.000107040665,0.00084886904,0.00061849743,0.0076338993],"category_scores_gemma":[0.0011018348,0.0002931771,0.00046737038,0.0017706598,0.0016430091,0.00007517867,0.0004421939,0.0027389629,0.0016570598],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011012082,0.00062461843,0.024777928,0.000497378,0.0010198234,0.0021378682,0.00020985788,0.000032490825,0.81425464,0.00013653877,0.03509162,0.11020517],"study_design_scores_gemma":[0.031811245,0.011679098,0.19602393,0.002382375,0.00082670164,0.00091180525,0.00052733393,0.0044867448,0.37728387,0.0007110121,0.37135908,0.0019968005],"about_ca_topic_score_codex":0.00041974866,"about_ca_topic_score_gemma":0.00010916058,"teacher_disagreement_score":0.43697074,"about_ca_system_score_codex":0.0020586383,"about_ca_system_score_gemma":0.0035370728,"threshold_uncertainty_score":0.999952},"labels":[],"label_agreement":null},{"id":"W2144004068","doi":"10.1182/blood.v98.10.2887","title":"Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein","year":2001,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":250,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"John and Lucille Van Geest Foundation; North West Cancer Research; Trent University; Nottingham Trent University","keywords":"Myeloid leukemia; K562 cells; Biology; Human leukocyte antigen; Cytotoxic T cell; Fusion protein; Leukemia; Cancer research; Immunology; Antigen; In vitro; Genetics; Recombinant DNA","score_opus":0.048150746881359716,"score_gpt":0.2904851457881751,"score_spread":0.24233439890681535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2144004068","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9841119,0.010012547,0.000011506254,0.0011600666,0.00010929283,0.0020325077,0.000016491224,0.00016442098,0.0023812356],"genre_scores_gemma":[0.97830325,0.0039016241,0.00011117398,0.00018951479,0.0003625946,0.00018943292,0.000038967748,0.000067449975,0.016835986],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9969906,0.00047081927,0.00034719918,0.0005360827,0.0010021984,0.0006530622],"domain_scores_gemma":[0.99762493,0.00080645084,0.00019894583,0.0010167487,0.00017510062,0.00017784591],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00079416577,0.00029341676,0.0004454251,0.00007574853,0.00024915847,0.00009680122,0.0005111148,0.00018660384,0.0030087554],"category_scores_gemma":[0.00056436256,0.00020263196,0.0002755968,0.0004278129,0.00016026701,0.0001365461,0.00026185735,0.0005227816,0.00026540426],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055099605,0.00051606674,0.020321934,0.000019740006,0.000407145,0.00013171321,0.00057739153,0.0000035980613,0.97231126,5.9062666e-7,0.00081083237,0.0043487437],"study_design_scores_gemma":[0.0037471657,0.00038590544,0.07805884,0.00081061694,0.000299613,0.000033599215,0.00018008178,0.000084831976,0.91209644,0.000049165843,0.0040191747,0.0002345693],"about_ca_topic_score_codex":0.0038943705,"about_ca_topic_score_gemma":0.00027177038,"teacher_disagreement_score":0.060214814,"about_ca_system_score_codex":0.00025608315,"about_ca_system_score_gemma":0.00031051878,"threshold_uncertainty_score":0.99790263},"labels":[],"label_agreement":null},{"id":"W2145284843","doi":"10.1158/0008-5472.can-14-3283","title":"Genetic Regulation of Fate Decisions in Therapeutic T Cells to Enhance Tumor Protection and Memory Formation","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Cancer Research UK","keywords":"Biology; Cancer research","score_opus":0.15296459169601045,"score_gpt":0.4465292280537598,"score_spread":0.2935646363577493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2145284843","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941078,0.0007580106,0.0016480841,0.00082201423,0.00005486025,0.0018902831,0.0000031680904,0.000012543607,0.0007032627],"genre_scores_gemma":[0.996886,0.000216249,0.00030124112,0.000041779178,0.00008639628,0.00041108695,0.000001539316,0.000019856569,0.0020358285],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980994,0.00024020177,0.00025556827,0.00023862922,0.0008551437,0.0003110646],"domain_scores_gemma":[0.99875706,0.000109581604,0.000038324855,0.00030095328,0.00058765855,0.00020639965],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015149416,0.000077399665,0.00017703901,0.00058348116,0.000049267976,0.000022209824,0.000096147254,0.000054668744,0.00018015564],"category_scores_gemma":[0.00021447275,0.00006853264,0.000022899905,0.000932438,0.00010219264,0.000109223765,0.00007116415,0.00030587107,0.000031583008],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008895826,0.000040270428,0.00043443963,0.00006272942,0.0000069895054,0.00000384417,0.0011073863,0.00028547217,0.8679772,0.000011013289,0.00016577495,0.12901528],"study_design_scores_gemma":[0.0010230913,0.0006703397,0.03338205,0.0002804179,0.000005622236,0.000013558298,0.00057981996,0.0016114914,0.9593772,0.0013551544,0.0016203742,0.00008086868],"about_ca_topic_score_codex":0.000996281,"about_ca_topic_score_gemma":0.00041757931,"teacher_disagreement_score":0.12893441,"about_ca_system_score_codex":0.0005888966,"about_ca_system_score_gemma":0.00037033376,"threshold_uncertainty_score":0.27946797},"labels":[],"label_agreement":null},{"id":"W2149734942","doi":"10.1007/s11248-006-9030-6","title":"Ubiquitous expression of mRFP-1 in vivo by site-directed transgenesis","year":2006,"lang":"en","type":"article","venue":"Transgenic Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; McGill University","funders":"Canadian Institutes of Health Research; Canada Research Chairs; McGill University","keywords":"Biology; Transgene; Green fluorescent protein; Transgenesis; Cell biology; Molecular biology; Genetically modified mouse; Genetics; Gene; Embryo; Reproductive technology","score_opus":0.05248255087783065,"score_gpt":0.3722276798583937,"score_spread":0.31974512898056306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2149734942","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.979461,0.0017844816,0.000120398676,0.00061775104,0.000036224577,0.0013315325,0.00007728675,0.000107739186,0.01646359],"genre_scores_gemma":[0.97099537,0.0007978976,0.00028219048,0.000018746576,0.00013296196,0.0001376406,0.000057787307,0.00008449502,0.027492931],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99481475,0.00066838454,0.00068764755,0.0006240012,0.0021117674,0.0010934331],"domain_scores_gemma":[0.997997,0.00057106896,0.000040540217,0.0007411983,0.00039735812,0.00025286476],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002130409,0.00024075262,0.00061312056,0.00088131736,0.00010029699,0.000025724692,0.0003809032,0.0002992406,0.009589071],"category_scores_gemma":[0.00007056744,0.00021589712,0.000247195,0.0019603583,0.00038962867,0.00009653444,0.000035733377,0.00087871915,0.00005556697],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022498572,0.0008334068,0.006743055,0.00032769024,0.000026768645,0.00005782719,0.0005574213,0.000018241211,0.97496223,0.000024378138,0.010689259,0.0035098582],"study_design_scores_gemma":[0.0040567685,0.00056707923,0.0075808363,0.0001918673,0.00001741006,0.000013131251,0.00012250167,0.0001789734,0.9714345,0.0001410812,0.015515914,0.00017999196],"about_ca_topic_score_codex":0.0036623706,"about_ca_topic_score_gemma":0.0007051654,"teacher_disagreement_score":0.011029338,"about_ca_system_score_codex":0.00022732823,"about_ca_system_score_gemma":0.00034097873,"threshold_uncertainty_score":0.9913163},"labels":[],"label_agreement":null},{"id":"W2150305853","doi":"10.4049/jimmunol.1203240","title":"Control of In Vivo Collateral Damage Generated by T Cell Immunity","year":2013,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Bystander effect; T cell; CD8; Immune system; Biology; In vivo; Immunology; Cell biology","score_opus":0.013009218876555964,"score_gpt":0.2702400980035213,"score_spread":0.2572308791269653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2150305853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994355,0.0023071223,0.00004238106,0.0014182201,0.00012011888,0.0003071612,0.0000051516017,0.0000038098085,0.0014410083],"genre_scores_gemma":[0.99616545,0.00072312687,0.000042530955,0.00021147872,0.000044065913,0.0000029597634,0.0000013858688,0.000015597348,0.002793402],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99827325,0.00066215225,0.00055088126,0.00005347434,0.00019702943,0.0002632334],"domain_scores_gemma":[0.99868196,0.0002824512,0.0002977186,0.00030839842,0.00037962123,0.000049848884],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009815545,0.000104532686,0.0004703605,0.0001895549,0.00003621026,0.000008123627,0.00032030974,0.00011154595,0.005424652],"category_scores_gemma":[0.00006162858,0.000064684195,0.000085935964,0.00022695688,0.00025176685,0.00007388763,0.00004996677,0.00070786144,0.00002298533],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018421087,0.00021713645,0.0028595964,0.000011164775,0.00018502455,0.000018160741,0.00045201552,0.00002406983,0.9908382,0.0000040390914,0.0025444368,0.0010040392],"study_design_scores_gemma":[0.011790236,0.0025818094,0.02732542,0.000057314635,0.00007764682,0.0005045395,0.0007115964,0.00045094689,0.952273,0.00010813298,0.004021561,0.00009781128],"about_ca_topic_score_codex":0.0010013505,"about_ca_topic_score_gemma":0.000013346715,"teacher_disagreement_score":0.038565222,"about_ca_system_score_codex":0.000093446724,"about_ca_system_score_gemma":0.00015099025,"threshold_uncertainty_score":0.99548453},"labels":[],"label_agreement":null},{"id":"W2154006657","doi":"10.1634/theoncologist.10-9-760","title":"Nimotuzumab: Evidence of Clinical Benefit Without Rash","year":2005,"lang":"en","type":"letter","venue":"The Oncologist","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Rash; Nimotuzumab; Dermatology; Pharmacology; Oncology; Intensive care medicine; Internal medicine; Cancer; Epidermal growth factor receptor","score_opus":0.23652912594375666,"score_gpt":0.4906644354273119,"score_spread":0.2541353094835552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154006657","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.024244474,0.0025950808,0.000016353275,0.9332659,0.0008557102,0.0016853908,0.000026667205,0.00011471098,0.03719566],"genre_scores_gemma":[0.02609547,0.0051509864,0.00094680843,0.61606956,0.026464086,0.00012030656,0.000083135055,0.00016309187,0.3249066],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99571157,0.0005378022,0.0012336024,0.00062964275,0.0012518585,0.00063552783],"domain_scores_gemma":[0.993413,0.0035672504,0.0006314551,0.0018823413,0.00037555877,0.00013042033],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0034634396,0.00037796484,0.0016303386,0.00013421208,0.000091121,0.000030688927,0.0010956991,0.0013810855,0.0076520178],"category_scores_gemma":[0.0016626972,0.0002284113,0.000670132,0.00026603646,0.0017624139,0.00005177561,0.0003375774,0.005065183,0.00050963147],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011771302,0.00014497955,0.008969498,0.00029503714,0.00029114244,0.0003598841,0.000062608,0.0000036111583,0.0006354377,0.00001419549,0.9238102,0.06423627],"study_design_scores_gemma":[0.0014414742,0.0017004982,0.009269919,0.00077952497,0.00036235055,0.00014959804,0.000021320993,0.000049583603,0.00025417414,0.00011390519,0.98563087,0.00022677502],"about_ca_topic_score_codex":0.00037349653,"about_ca_topic_score_gemma":0.00018288873,"teacher_disagreement_score":0.31719643,"about_ca_system_score_codex":0.0004398674,"about_ca_system_score_gemma":0.0010297264,"threshold_uncertainty_score":0.9999153},"labels":[],"label_agreement":null},{"id":"W2155493718","doi":"10.4049/jimmunol.1102757","title":"Substrate Rigidity Regulates Human T Cell Activation and Proliferation","year":2012,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":323,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Common Fund; National Institutes of Health; National Eye Institute; York University; University of Pennsylvania","keywords":"CD28; Ex vivo; T cell; Materials science; Cytotoxic T cell; CD8; Cell biology; Cell growth; T-cell receptor; Priming (agriculture); Cell adhesion; Biophysics; Chemistry; Cell; In vitro; Biology; Immunology; Immune system; Biochemistry","score_opus":0.03637093820036858,"score_gpt":0.31530961644803185,"score_spread":0.2789386782476633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155493718","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964826,0.001112235,0.000049270227,0.0011451578,0.00008891134,0.00013822899,2.0627742e-7,0.000005510011,0.0009778744],"genre_scores_gemma":[0.99800247,0.0003793994,0.000054202766,0.000060646857,0.00029123764,0.0000010290269,0.0000017436329,0.000008745662,0.0012005097],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992433,0.00019451487,0.00021877205,0.000036110203,0.00013885865,0.00016844914],"domain_scores_gemma":[0.9993891,0.00010086767,0.00018516653,0.00013491059,0.00014592381,0.000044042823],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010066107,0.00006315002,0.00015487426,0.0000882634,0.00010007278,0.0000095346595,0.000068840054,0.000068759335,0.00032197678],"category_scores_gemma":[0.000041054784,0.000038008675,0.000033153206,0.00006942673,0.00012525161,0.00016463632,0.000020942578,0.00035530617,0.0000065542604],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006349433,0.0000892322,0.009435545,0.000011071133,0.00006870634,0.0000012060277,0.00084090413,0.0000015602797,0.9869331,0.00011802772,0.00015630657,0.001709372],"study_design_scores_gemma":[0.0010070555,0.0005781193,0.25551167,0.000018722109,0.00004424794,0.0005205588,0.00022011824,0.000007977848,0.7405515,0.00038598472,0.0011194979,0.000034578097],"about_ca_topic_score_codex":0.000015409514,"about_ca_topic_score_gemma":0.0000017314569,"teacher_disagreement_score":0.24638166,"about_ca_system_score_codex":0.000054003205,"about_ca_system_score_gemma":0.000042945216,"threshold_uncertainty_score":0.35254198},"labels":[],"label_agreement":null},{"id":"W2157049259","doi":"10.3747/co.21.1661","title":"Anticancer activity of combination targeted therapy using cetuximab plus vemurafenib for refractory BRAFV600E-mutant metastatic colorectal carcinoma","year":2013,"lang":"en","type":"article","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Cetuximab; Medicine; Vemurafenib; KRAS; Colorectal cancer; Trametinib; Cancer research; Dabrafenib; Targeted therapy; Oncology; Epidermal growth factor receptor; Kinase; Internal medicine; Refractory (planetary science); EGFR inhibitors; Cancer; Melanoma; MAPK/ERK pathway; Metastatic melanoma; Biology","score_opus":0.1687028635476653,"score_gpt":0.43949911364329836,"score_spread":0.270796250095633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157049259","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932778,0.0013276559,0.00087108446,0.0004075068,0.000926669,0.0028813789,0.000038478065,0.0000388278,0.00023063518],"genre_scores_gemma":[0.99842966,0.00029004525,0.00056655233,0.000049557155,0.0001639402,0.00028288228,0.00006024382,0.000045147503,0.00011199093],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980385,0.00029520932,0.0004086462,0.00037426496,0.00039444753,0.0004889869],"domain_scores_gemma":[0.99800605,0.0005965131,0.0002919897,0.00029357438,0.0006471954,0.00016467774],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00045317668,0.0002229815,0.000804799,0.00025635233,0.00008870414,0.000014917311,0.00013844908,0.00013477587,0.0014384834],"category_scores_gemma":[0.00020649101,0.00019070879,0.00019969587,0.00030644005,0.00029173883,0.00016281052,0.000054279713,0.00038282108,0.000012376304],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024979226,0.0018506428,0.0063372757,0.00021389514,0.00017350509,0.000006767829,0.0007805626,0.0000045239876,0.8002275,0.00005651037,0.00029674912,0.1875541],"study_design_scores_gemma":[0.047802474,0.0155328605,0.1913507,0.00016983126,0.00042239658,0.00013145404,0.0006895169,0.08642077,0.6188834,0.0007037441,0.037215337,0.0006775235],"about_ca_topic_score_codex":0.00020361146,"about_ca_topic_score_gemma":0.000020269155,"teacher_disagreement_score":0.1868766,"about_ca_system_score_codex":0.00092352356,"about_ca_system_score_gemma":0.0009909407,"threshold_uncertainty_score":0.99947435},"labels":[],"label_agreement":null},{"id":"W2157193492","doi":"10.1586/14760584.2013.843456","title":"Mobilizing and evaluating anticancer T cells: pitfalls and solutions","year":2013,"lang":"en","type":"review","venue":"Expert Review of Vaccines","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Clinical trial; Immunotherapy; Medicine; Cancer immunotherapy; Cancer; Immunology; Immune system; Pathology; Internal medicine","score_opus":0.16076705040350686,"score_gpt":0.48535803052621684,"score_spread":0.32459098012271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157193492","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000034645418,0.9953993,0.000006095545,0.00027550088,0.0001479104,0.003424074,0.000008781118,0.000024530844,0.0006791364],"genre_scores_gemma":[0.0000011408113,0.99531585,0.0019371992,0.00027646453,0.00045421132,0.00053414435,0.000022022065,0.000080246995,0.0013787337],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99719554,0.0003303143,0.0010607513,0.0005645307,0.0004484643,0.0004003914],"domain_scores_gemma":[0.9978667,0.0005203494,0.00040037712,0.000690886,0.00031049832,0.00021120477],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012405638,0.00046224057,0.003166904,0.00019488062,0.00009307646,0.00003062247,0.000172248,0.00017878591,0.003118776],"category_scores_gemma":[0.0005209128,0.00030743264,0.00041384812,0.0003662327,0.000095489886,0.000071234426,0.00025693048,0.00037994256,0.000030360148],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000003118492,0.000035848087,0.0000031050467,0.19818857,0.00014807722,0.0000026684102,0.000047154106,5.40188e-9,0.00093532784,0.000014499074,0.003760513,0.7968611],"study_design_scores_gemma":[0.00025787944,0.0001640908,0.0000041598123,0.22740895,0.00062919396,0.00013023934,0.000023493576,0.000016727774,0.000029996378,0.0000050055696,0.77111846,0.00021182175],"about_ca_topic_score_codex":0.00008693597,"about_ca_topic_score_gemma":0.0000025702511,"teacher_disagreement_score":0.7966493,"about_ca_system_score_codex":0.000085716434,"about_ca_system_score_gemma":0.0003095932,"threshold_uncertainty_score":0.9999378},"labels":[],"label_agreement":null},{"id":"W2157706519","doi":"10.1007/s00280-011-1798-2","title":"Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children’s Oncology Group study","year":2011,"lang":"en","type":"article","venue":"Cancer Chemotherapy and Pharmacology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Center for Research Resources; National Cancer Institute; Frank A. Campini Foundation","keywords":"Sunitinib; Medicine; Pharmacokinetics; Neutropenia; Dosing; Tolerability; Refractory (planetary science); Internal medicine; Tyrosine-kinase inhibitor; Pharmacology; Gastroenterology; Urology; Adverse effect; Toxicity; Cancer","score_opus":0.03107978894315848,"score_gpt":0.350450297542223,"score_spread":0.3193705085990645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2157706519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99620086,0.0005114493,0.0000026308387,0.00009649183,0.000079718964,0.0024611147,0.00001867966,0.000020127274,0.00060891005],"genre_scores_gemma":[0.997824,0.0009969444,0.000072960815,0.0005095789,0.00016672564,0.00031402984,0.00001778359,0.000032186745,0.000065796696],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99854225,0.00020253804,0.00038450447,0.00038570925,0.00017529541,0.000309705],"domain_scores_gemma":[0.9993093,0.00009943557,0.0001730504,0.00013218407,0.00014506814,0.00014094342],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00031275264,0.00019603419,0.0005280018,0.00022455376,0.000041699805,0.0000037136952,0.00007572848,0.00010299977,0.005098005],"category_scores_gemma":[0.000007060626,0.00016029531,0.000030618914,0.0002651364,0.00016267964,0.00010513071,0.000035851408,0.00034742648,6.8471417e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009530779,0.0032509593,0.90415597,0.00016176332,0.00016396733,0.000010519489,0.005556425,7.2532583e-7,0.02608564,0.0000016056781,0.000066095214,0.051015567],"study_design_scores_gemma":[0.021836136,0.0060115843,0.95549184,0.00001788513,0.00015189538,0.000008128804,0.00014712372,0.000050386887,0.01589533,0.000015892054,0.00022027275,0.0001535061],"about_ca_topic_score_codex":0.00023578544,"about_ca_topic_score_gemma":0.00006525161,"teacher_disagreement_score":0.051335905,"about_ca_system_score_codex":0.00013704314,"about_ca_system_score_gemma":0.00015965205,"threshold_uncertainty_score":0.99581146},"labels":[],"label_agreement":null},{"id":"W2159926306","doi":"10.1007/s00262-009-0788-2","title":"Performance of serum-supplemented and serum-free media in IFNγ Elispot Assays for human T cells","year":2009,"lang":"en","type":"article","venue":"Cancer Immunology Immunotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sanofi (Canada)","funders":"Leids Universitair Medisch Centrum; Universiteit Leiden; Wallace H. Coulter Foundation; Cancer Research Institute; Bill and Melinda Gates Foundation","keywords":"ELISPOT; Peripheral blood mononuclear cell; Immunology; Medicine; Antigen; Chemistry; In vitro","score_opus":0.0256241263572497,"score_gpt":0.3322961344563678,"score_spread":0.3066720080991181,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2159926306","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98417085,0.011408747,0.000020284375,0.0020441029,0.00028023717,0.0012978947,0.00017476009,0.000050995917,0.0005521334],"genre_scores_gemma":[0.9788659,0.01769004,0.0005317406,0.00079470087,0.00011698135,0.00020090851,0.000044979446,0.00006377766,0.0016909417],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99785054,0.00009950682,0.00065464777,0.0004355196,0.00027309003,0.00068667944],"domain_scores_gemma":[0.99847007,0.00016836677,0.00019197297,0.0008821779,0.00022102441,0.00006637759],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00060404796,0.00031213378,0.00075025664,0.00042077393,0.000118542506,0.000015607722,0.00044785166,0.00028359934,0.0033885972],"category_scores_gemma":[0.000033642602,0.00029630418,0.00013571294,0.0003867827,0.0003668768,0.00012912373,0.0000580238,0.0004835971,0.0000039698593],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027914005,0.0001983437,0.016836297,0.00007358189,0.00026668,0.0000054925695,0.001306164,0.000004964604,0.8138339,0.0001584383,0.00035007336,0.1641747],"study_design_scores_gemma":[0.022338104,0.0033930112,0.39222053,0.00027631354,0.00004612362,0.00002912707,0.0003206617,0.00018218077,0.56414616,0.00050691556,0.01618866,0.0003521782],"about_ca_topic_score_codex":0.00017658564,"about_ca_topic_score_gemma":0.00015912188,"teacher_disagreement_score":0.37538424,"about_ca_system_score_codex":0.00026830798,"about_ca_system_score_gemma":0.00021174208,"threshold_uncertainty_score":0.9999489},"labels":[],"label_agreement":null},{"id":"W2161751938","doi":"10.1158/0008-5472.can-05-0436","title":"Targeted Elimination of Prostate Cancer by Genetically Directed Human T Lymphocytes","year":2005,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Antigen; Chimeric antigen receptor; Cancer research; In vivo; Prostate cancer; Cancer; Glutamate carboxypeptidase II; Adoptive cell transfer; Immunology; T cell; Prostate; Biology; Medicine; Immune system; Internal medicine","score_opus":0.05288526224692186,"score_gpt":0.4252216114787874,"score_spread":0.37233634923186554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2161751938","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9800742,0.010942259,0.000004387203,0.0041378816,0.00004818512,0.0011388568,0.000093066934,0.0000799649,0.0034811553],"genre_scores_gemma":[0.95156443,0.0061426503,0.00018718845,0.00011528373,0.00039188605,0.00065664196,0.00008157237,0.000068035355,0.040792294],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99667037,0.00023869498,0.00036135773,0.00043960894,0.0015332672,0.0007566966],"domain_scores_gemma":[0.9975996,0.0001495791,0.000059774953,0.0004355965,0.0014603671,0.00029508476],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009295838,0.0001568522,0.000329856,0.0003682481,0.00015984497,0.000034660414,0.00025496478,0.00012929233,0.01414193],"category_scores_gemma":[0.00017997676,0.00014018417,0.00007938414,0.0009486527,0.00046826288,0.00008217887,0.00011010025,0.00047071555,0.000042721254],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071820617,0.00018461618,0.005530967,0.00015711777,0.00009192626,0.0000063904135,0.00043216906,0.00002188229,0.85644275,0.000042007254,0.021658743,0.114713214],"study_design_scores_gemma":[0.0025119986,0.0004325329,0.018340725,0.00017084404,0.000021508724,0.0000030324504,0.00006645699,0.0005580608,0.89964986,0.00004180929,0.07806366,0.00013951157],"about_ca_topic_score_codex":0.002656107,"about_ca_topic_score_gemma":0.00050973543,"teacher_disagreement_score":0.1145737,"about_ca_system_score_codex":0.0012460662,"about_ca_system_score_gemma":0.00096163276,"threshold_uncertainty_score":0.9867593},"labels":[],"label_agreement":null},{"id":"W2163158239","doi":"10.1084/jem.20060998","title":"Synergy between the pre–T cell receptor and Notch: cementing the αβ lineage choice","year":2006,"lang":"en","type":"review","venue":"The Journal of Experimental Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Progenitor cell; Notch signaling pathway; T-cell receptor; Lineage (genetic); Cell biology; Biology; T cell; Progenitor; Haematopoiesis; Receptor; Signal transduction; Stem cell; Immunology; Genetics; Gene; Immune system","score_opus":0.09096115410738888,"score_gpt":0.4148267785781319,"score_spread":0.323865624470743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163158239","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0032346172,0.98904884,0.000012691877,0.0020868964,0.0005680526,0.0014072349,0.000010787326,0.000013880436,0.0036169973],"genre_scores_gemma":[0.004528851,0.978012,0.000044645956,0.00037899718,0.00910931,0.000032287677,0.00003870089,0.00011785494,0.0077373516],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99517566,0.00097279507,0.0015971487,0.00026326254,0.0014717687,0.00051933574],"domain_scores_gemma":[0.9941642,0.003240477,0.001390501,0.0007930233,0.00016557775,0.00024619035],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003882027,0.00056391826,0.0020135096,0.00021525848,0.00038596496,0.0000453894,0.0009838293,0.0002045759,0.0013439447],"category_scores_gemma":[0.00024843705,0.0002027963,0.00044888692,0.00047145633,0.0007500627,0.00007726248,0.00031577476,0.0020470442,0.000017003971],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00077800156,0.0007091457,0.0001855358,0.0069186045,0.0033545396,0.00014064235,0.007274757,0.0000022502584,0.059057128,0.000030936037,0.10409679,0.81745166],"study_design_scores_gemma":[0.0018378051,0.0015365455,0.00002661675,0.008362106,0.0022651865,0.0006216276,0.0011636977,0.0000049327105,0.006197169,0.0000030050353,0.97779477,0.00018651846],"about_ca_topic_score_codex":0.00023992875,"about_ca_topic_score_gemma":0.0000047683725,"teacher_disagreement_score":0.873698,"about_ca_system_score_codex":0.00028431686,"about_ca_system_score_gemma":0.00023143593,"threshold_uncertainty_score":0.99956894},"labels":[],"label_agreement":null},{"id":"W2163766654","doi":"10.5966/sctm.2014-0294","title":"Concise Review: Process Development Considerations for Cell Therapy","year":2015,"lang":"en","type":"review","venue":"Stem Cells Translational Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":147,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"International Society for Cellular Therapy","funders":"","keywords":"Commercialization; Process (computing); Risk analysis (engineering); Clinical trial; New product development; Computer science; Identification (biology); Cell therapy; Product (mathematics); Resource (disambiguation); Medicine; Business; Stem cell","score_opus":0.229728009574061,"score_gpt":0.43651379201537255,"score_spread":0.20678578244131154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163766654","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000015676793,0.9797397,0.00027451548,0.0017191649,0.00043513134,0.011191747,0.00015039186,0.00008759218,0.0064001563],"genre_scores_gemma":[0.0000051510615,0.98079604,0.0012258937,0.0012044777,0.0009281586,0.0019490892,0.0013189221,0.00016902255,0.012403223],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9948734,0.00022080445,0.0018514219,0.0008140919,0.0016996865,0.0005406118],"domain_scores_gemma":[0.995546,0.0014316919,0.00047398766,0.0005705594,0.0014271544,0.0005506287],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019893062,0.00075685757,0.0034320785,0.00039555738,0.00017418862,0.000018265811,0.00023390101,0.00038632064,0.005500474],"category_scores_gemma":[0.000060385577,0.00052648166,0.0005124415,0.00053917913,0.00024294986,0.00007302811,0.000013514804,0.0006384404,0.00012913364],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012439395,0.00020882099,0.0000013268487,0.112292096,0.00038565116,0.000031673007,0.00055149436,9.894185e-7,0.00006314604,0.000042607433,0.04020761,0.8460902],"study_design_scores_gemma":[0.0040207924,0.00046785624,4.034542e-7,0.046617687,0.0010787522,0.00012924078,0.000034419554,0.000008228759,0.00020010267,0.0001486793,0.94686306,0.00043076076],"about_ca_topic_score_codex":0.0000032486123,"about_ca_topic_score_gemma":0.0000034824425,"teacher_disagreement_score":0.9066555,"about_ca_system_score_codex":0.00023601092,"about_ca_system_score_gemma":0.005876828,"threshold_uncertainty_score":0.9997589},"labels":[],"label_agreement":null},{"id":"W2166891849","doi":"10.1084/jem.20010032","title":"Tumor Growth Enhances Cross-Presentation Leading to Limited T Cell Activation without Tolerance","year":2002,"lang":"en","type":"article","venue":"The Journal of Experimental Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":128,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research","keywords":"Immunotherapy; T cell; Cancer research; Antigen; Tumor antigen; Biology; Avidity; Immunology; Antigen presentation; Cross-presentation; Immune system","score_opus":0.052986425692390954,"score_gpt":0.38244690927748526,"score_spread":0.3294604835850943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2166891849","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98540527,0.0019245624,0.00033477752,0.0040497645,0.00033529752,0.0004420052,5.3013514e-7,0.00001692392,0.0074908882],"genre_scores_gemma":[0.9917301,0.00019753369,0.0002991553,0.0015344279,0.00123465,0.000009224597,0.0000017133989,0.000030387147,0.0049628],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99795747,0.00013110405,0.0005364468,0.00014127222,0.00096426945,0.00026945776],"domain_scores_gemma":[0.9987068,0.00022904531,0.00030066687,0.00022179694,0.0003015289,0.00024012517],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006661853,0.00017019072,0.00039680366,0.0002483052,0.00013225315,0.000023049788,0.00024134856,0.000037731446,0.0036368975],"category_scores_gemma":[0.00023948983,0.0001026542,0.00007451637,0.00041749806,0.00021136334,0.0002536253,0.00003884738,0.00036919757,0.00005356648],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017314035,0.00020932288,0.0019771003,0.000025855885,0.000039131413,0.000024659972,0.0073103276,0.000021761338,0.9840568,0.0000073549586,0.0035172086,0.0010791318],"study_design_scores_gemma":[0.0035442729,0.0029091043,0.0031137313,0.00041104792,0.000040683764,0.00031573378,0.0031047298,0.00035779728,0.9849694,0.000015037875,0.0011232527,0.000095228716],"about_ca_topic_score_codex":0.0000514688,"about_ca_topic_score_gemma":0.0000010810073,"teacher_disagreement_score":0.0063248575,"about_ca_system_score_codex":0.00021551992,"about_ca_system_score_gemma":0.000025551808,"threshold_uncertainty_score":0.9972739},"labels":[],"label_agreement":null},{"id":"W2170981225","doi":"10.1038/nbt1395","title":"Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors","year":2008,"lang":"en","type":"article","venue":"Nature Biotechnology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":120,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"National Institute of General Medical Sciences; National Cancer Institute; National Heart, Lung, and Blood Institute","keywords":"Immunotherapy; Major histocompatibility complex; Biology; Immunology; T cell; Cancer research; Antigen; Immune system","score_opus":0.017552820196238515,"score_gpt":0.3226385269139143,"score_spread":0.3050857067176758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2170981225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98430294,0.009227685,0.000101834776,0.003973036,0.00043267405,0.00068510673,0.000022711372,0.00042251742,0.00083152065],"genre_scores_gemma":[0.9879452,0.0016124445,0.0030783762,0.0018856778,0.00022550691,0.000024070789,0.000016117794,0.000105805215,0.0051068254],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976562,0.00006947478,0.00027525803,0.00064465177,0.00045196628,0.00090241304],"domain_scores_gemma":[0.9984824,0.000059985265,0.00011075976,0.0010004336,0.00014230028,0.00020410914],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0003061239,0.00032050937,0.00052545563,0.00035785913,0.00030991147,0.000013931842,0.00047377538,0.0020554082,0.0011721458],"category_scores_gemma":[0.00019712806,0.00028479434,0.00022122929,0.0008670239,0.0008521214,0.000056604407,0.00014594615,0.002656402,0.00006302956],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006259491,0.00009873459,0.0037327413,0.000031760184,0.00012222504,0.0005018845,0.00029383253,0.000004834048,0.98449916,0.00006917257,0.0018059377,0.00821379],"study_design_scores_gemma":[0.00249266,0.0004808231,0.0011912675,0.000025205707,0.00001813148,0.0018976773,0.00022934108,0.00014650346,0.7463037,0.000056063578,0.24689849,0.00026018635],"about_ca_topic_score_codex":0.000057190144,"about_ca_topic_score_gemma":0.000014048984,"teacher_disagreement_score":0.24509254,"about_ca_system_score_codex":0.00032074703,"about_ca_system_score_gemma":0.00037851374,"threshold_uncertainty_score":0.9999604},"labels":[],"label_agreement":null},{"id":"W2179030446","doi":"10.18632/oncotarget.6175","title":"Therapeutic potential of CAR-T cell-derived exosomes: a cell-free modality for targeted cancer therapy","year":2015,"lang":"en","type":"review","venue":"Oncotarget","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":154,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia","funders":"Natural Science Foundation of Guangxi Province; VGH and UBC Hospital Foundation","keywords":"Medicine; Microvesicles; Cancer research; Targeted therapy; Cancer; Cancer therapy; Cell; microRNA; Internal medicine; Biology","score_opus":0.106303381061443,"score_gpt":0.401792904577189,"score_spread":0.29548952351574603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2179030446","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010096576,0.9874386,0.0001683991,0.00025827807,0.0008410934,0.006734018,0.001491173,0.000118253425,0.0019405334],"genre_scores_gemma":[0.00027054583,0.9790652,0.0009374414,0.000192857,0.0011794624,0.0016189453,0.0010117821,0.0003810241,0.015342763],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9944119,0.0005533055,0.001394563,0.001118582,0.0014260309,0.0010956407],"domain_scores_gemma":[0.99511373,0.00029828065,0.00086763705,0.002174137,0.0009910574,0.0005551606],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012050599,0.0010611535,0.004537508,0.00044102533,0.00011829947,0.000048909544,0.0011405566,0.00095316384,0.0037337397],"category_scores_gemma":[0.00006759678,0.0008026372,0.0020406207,0.00070668414,0.0002900817,0.000096104115,0.00021811867,0.0010105286,0.000041651034],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026816702,0.0021794941,0.000078080055,0.050385322,0.0029256283,0.00008617156,0.000791353,0.000016279893,0.052933156,0.000022772632,0.031326078,0.856574],"study_design_scores_gemma":[0.007251351,0.0011380188,0.000018892015,0.0018481662,0.0014844534,0.000022459257,0.00008242168,0.00006133196,0.0031150354,0.0003187715,0.9839383,0.00072080403],"about_ca_topic_score_codex":0.00054705364,"about_ca_topic_score_gemma":0.000021022202,"teacher_disagreement_score":0.9526122,"about_ca_system_score_codex":0.0008550037,"about_ca_system_score_gemma":0.004259811,"threshold_uncertainty_score":0.99944246},"labels":[],"label_agreement":null},{"id":"W2179389093","doi":"10.1093/annonc/mdv382","title":"Targeting the undruggable: immunotherapy meets personalized oncology in the genomic era","year":2015,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; Simon Fraser University; Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency; University of British Columbia","funders":"National Cancer Institute; European Research Council; National Institutes of Health; Genome British Columbia; Canadian Cancer Society; Ludwig Institute for Cancer Research; Canadian Institutes of Health Research; Genome Canada; Ovarian Cancer Research Fund; U.S. Department of Defense","keywords":"Immunotherapy; Medicine; Personalized medicine; Cancer immunotherapy; Precision medicine; Clinical trial; Cancer; Computational biology; Genomic sequencing; Bioinformatics; Internal medicine; Gene; Genome; Biology; Genetics; Pathology","score_opus":0.24542338659995216,"score_gpt":0.5002399680797417,"score_spread":0.25481658147978953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2179389093","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020823469,0.9467931,0.0000017836753,0.010334096,0.0004050157,0.0028106691,0.000031493586,0.0000208551,0.039394747],"genre_scores_gemma":[0.00003918216,0.9900567,0.00012012578,0.0027465948,0.00073096174,0.00046309162,0.00013120423,0.00010410408,0.005608051],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9924991,0.0040125917,0.0014344467,0.0005354759,0.00066017674,0.0008581975],"domain_scores_gemma":[0.9943478,0.0031683352,0.0009011864,0.0009885727,0.00046083378,0.00013327465],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.009742085,0.00050332193,0.0035988197,0.0004096992,0.000116107374,0.000020080588,0.0012707677,0.0008949257,0.0032426014],"category_scores_gemma":[0.00046659412,0.00026719825,0.00082439097,0.00081419444,0.0008119091,0.00004391147,0.00019434682,0.0021173595,0.00013870254],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00058685016,0.00048963405,0.0000056792805,0.0014777975,0.0006808134,0.0001661081,0.0024243975,0.0000016011018,0.00022299487,0.00028119466,0.050750274,0.94291264],"study_design_scores_gemma":[0.0019965807,0.0028300495,0.000009983539,0.00084601395,0.0002706421,0.00049648626,0.0007235553,0.000008293344,0.0000044287394,0.0001647236,0.99243116,0.00021806093],"about_ca_topic_score_codex":0.00031826165,"about_ca_topic_score_gemma":0.00006822311,"teacher_disagreement_score":0.9426946,"about_ca_system_score_codex":0.00067428563,"about_ca_system_score_gemma":0.006009441,"threshold_uncertainty_score":0.999978},"labels":[],"label_agreement":null},{"id":"W2184558141","doi":"10.1158/1078-0432.ccr-15-2023","title":"Toward Personalized Lymphoma Immunotherapy: Identification of Common Driver Mutations Recognized by Patient CD8+ T Cells","year":2015,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia; University of Victoria; Simon Fraser University; BC Cancer Agency","funders":"Canadian Institutes of Health Research; Canada's Michael Smith Genome Sciences Centre","keywords":"Follicular lymphoma; Lymphoma; CD8; Biology; Immunogenicity; Immunology; Immunotherapy; Cancer research; Antigen; Immune system","score_opus":0.26599864206247,"score_gpt":0.5073295551678475,"score_spread":0.24133091310537752,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2184558141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98945546,0.002751344,0.00007248653,0.0031330057,0.00044074535,0.0015558515,0.0001419191,0.000048721296,0.002400469],"genre_scores_gemma":[0.9814984,0.0031337827,0.00016474497,0.00029786973,0.00023404222,0.00035539368,0.00014395872,0.00007043883,0.014101379],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99402523,0.0014541937,0.0012516162,0.00058971083,0.0020972383,0.0005819949],"domain_scores_gemma":[0.9949307,0.001356075,0.00024446577,0.0007791598,0.0021357615,0.00055385253],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0053971102,0.00017827968,0.00067235576,0.00027213077,0.00012181656,0.00005893295,0.00039920164,0.00025589904,0.003970368],"category_scores_gemma":[0.0009910936,0.00015758013,0.00031121427,0.00087825925,0.0012401945,0.000111287845,0.00012244319,0.0006958544,0.00025053305],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010216233,0.0025141968,0.0097872075,0.00015492832,0.00045595696,0.00003679154,0.0039571994,0.0000061508968,0.55952865,0.000051934225,0.076960444,0.33633032],"study_design_scores_gemma":[0.03837684,0.0055546653,0.016524354,0.00039550348,0.00015906627,0.000023774604,0.005058626,0.001326704,0.5099326,0.0019603122,0.42005497,0.0006326025],"about_ca_topic_score_codex":0.0016871104,"about_ca_topic_score_gemma":0.00004686025,"teacher_disagreement_score":0.34309453,"about_ca_system_score_codex":0.00063507917,"about_ca_system_score_gemma":0.0014407892,"threshold_uncertainty_score":0.99694014},"labels":[],"label_agreement":null},{"id":"W2185958617","doi":"10.7150/thno.12040","title":"A Two-Step Pretargeted Nanotherapy for CD20 Crosslinking May Achieve Superior Anti-Lymphoma Efficacy to Rituximab","year":2015,"lang":"en","type":"article","venue":"Theranostics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institutes of Health; National Institute of General Medical Sciences; McGill University; University of Utah","keywords":"Pretargeting; CD20; Rituximab; Lymphoma; Medicine; Cancer research; B-cell lymphoma; Radioimmunotherapy; Monoclonal antibody; Pharmacology; Antibody; Immunology","score_opus":0.05752494232739792,"score_gpt":0.36146813677482886,"score_spread":0.30394319444743095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2185958617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9789282,0.0014664675,0.010980845,0.0027379114,0.0006348388,0.003588639,0.00007554773,0.0006727044,0.0009148215],"genre_scores_gemma":[0.9710477,0.00015524203,0.019472271,0.0028924407,0.0011059428,0.00016042608,0.000078904195,0.00049215014,0.0045948946],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970045,0.00014550479,0.0005180193,0.00059531187,0.00080689,0.00092974206],"domain_scores_gemma":[0.9971555,0.0006661453,0.000085919004,0.000874662,0.00059987785,0.00061793363],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00086645916,0.00041799605,0.0008126452,0.00023411738,0.00013268,0.00014632208,0.00039671687,0.00021629468,0.00026486765],"category_scores_gemma":[0.000745256,0.00036569856,0.00026605415,0.00049503567,0.00018088448,0.00008969346,0.00008782906,0.00024692927,0.00013113538],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016368821,0.0018152092,0.0037468732,0.00016117131,0.0005821231,0.0001420379,0.006859705,0.00019369279,0.7825862,0.00055044104,0.0026857688,0.18430796],"study_design_scores_gemma":[0.10300943,0.0074468935,0.005928273,0.0004986978,0.00034606556,0.0003086508,0.00069212244,0.0074203764,0.20456038,0.0006399774,0.66775256,0.0013965562],"about_ca_topic_score_codex":0.00010565522,"about_ca_topic_score_gemma":0.000023227663,"teacher_disagreement_score":0.6650668,"about_ca_system_score_codex":0.00030363418,"about_ca_system_score_gemma":0.00054332934,"threshold_uncertainty_score":0.9998795},"labels":[],"label_agreement":null},{"id":"W2200809230","doi":"10.3892/ol.2015.4069","title":"Real-world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma","year":2015,"lang":"en","type":"article","venue":"Oncology Letters","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Medical Research Council; Canadian Institutes of Health Research; National Health and Medical Research Council; Hunter Cancer Research Alliance","keywords":"Ipilimumab; Medicine; Metastatic melanoma; Melanoma; Toxicity; Molecular medicine; Oncology; Oncogene; Cancer; Internal medicine; Cell cycle; Cancer research; Immunotherapy","score_opus":0.10931781929838652,"score_gpt":0.4357684455983323,"score_spread":0.32645062629994576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2200809230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9764609,0.00006301463,0.000013807384,0.008764358,0.000118064716,0.0007598915,0.0000026357652,0.00001730903,0.013800027],"genre_scores_gemma":[0.9921121,0.00051865476,0.0031842291,0.0011986209,0.000078930505,0.000051197756,0.000013450693,0.000021125947,0.0028217067],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9984399,0.00034333687,0.00043730062,0.0002921245,0.00021916113,0.00026814087],"domain_scores_gemma":[0.9989933,0.0003947413,0.00008451107,0.00030330606,0.000027444663,0.00019671531],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009213815,0.00012808305,0.00058323727,0.00020303958,0.000013984651,0.0000040859004,0.00007845897,0.000056481505,0.00018454151],"category_scores_gemma":[0.000029681878,0.0001029857,0.00008896859,0.00020776902,0.00027100384,0.00002395739,0.000069145746,0.0001785944,0.000020887637],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011052725,0.008780586,0.45643088,0.00023775984,0.0025334442,0.0067242263,0.0017890361,0.000031819876,0.025313921,0.0005516127,0.008771404,0.47778258],"study_design_scores_gemma":[0.0627716,0.012250721,0.85645115,0.00014648832,0.00080494466,0.00012687218,0.00082089717,0.0003256418,0.0037447894,0.00010354848,0.062148273,0.00030504397],"about_ca_topic_score_codex":0.00049578655,"about_ca_topic_score_gemma":0.0007969908,"teacher_disagreement_score":0.47747752,"about_ca_system_score_codex":0.00067812,"about_ca_system_score_gemma":0.00013337893,"threshold_uncertainty_score":0.4199635},"labels":[],"label_agreement":null},{"id":"W2202293179","doi":"10.1016/j.exphem.2015.06.026","title":"From stem cells to T cells, in vitro applications and in vivo implications","year":2015,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Biology; Progenitor cell; Stem cell; Haematopoiesis; Cell biology; CD34; Stromal cell; Lineage markers; Bone marrow; Immunology; In vitro; Molecular biology; Cancer research; Genetics","score_opus":0.04236395684393758,"score_gpt":0.3629172667746409,"score_spread":0.32055330993070336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2202293179","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913943,0.0025370135,0.00013604779,0.0011850202,0.00007004578,0.0012695405,0.000039445546,0.000035308443,0.0033333183],"genre_scores_gemma":[0.996275,0.00001528471,0.0015237218,0.00033776197,0.000051866005,0.0007856699,0.000015134333,0.000022316897,0.0009732379],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989514,0.000054875913,0.00025322003,0.00035154333,0.000121995254,0.0002669699],"domain_scores_gemma":[0.9992491,0.000082351115,0.00002709771,0.00035046035,0.000025735495,0.00026524242],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010061948,0.00011584989,0.00030502505,0.00019878184,0.000022305381,0.000010081062,0.000108359534,0.00009592994,0.00034531628],"category_scores_gemma":[0.0000029108587,0.00011934778,0.000025365605,0.00026657918,0.0000766303,0.000035650854,0.00011372566,0.00014256516,0.0001396628],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031928436,0.0003750042,0.0017312273,0.000008256609,0.00000809687,0.00001929763,0.0017814682,0.0000014079051,0.9929036,0.00065288926,0.0014106934,0.0007888112],"study_design_scores_gemma":[0.0014975503,0.00008852229,0.00021273311,0.000011315809,0.000002855843,0.000052068786,0.0028648265,0.000049955735,0.9805091,0.00014572807,0.014470727,0.00009459825],"about_ca_topic_score_codex":0.00048589785,"about_ca_topic_score_gemma":0.00007285945,"teacher_disagreement_score":0.013060034,"about_ca_system_score_codex":0.00022390309,"about_ca_system_score_gemma":0.00007074947,"threshold_uncertainty_score":0.48668614},"labels":[],"label_agreement":null},{"id":"W2208384071","doi":"10.1158/1078-0432.ccr-15-2361","title":"Eradication of Large Solid Tumors by Gene Therapy with a T-Cell Receptor Targeting a Single Cancer-Specific Point Mutation","year":2015,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; University of Chicago; Connaught Fund; Universitätsspital Zürich; Universität Zürich; Berlin Institute of Health; University of Toronto","keywords":"T-cell receptor; Biology; Cancer research; Cancer; Antigen; Targeted therapy; Adoptive cell transfer; Cancer cell; Avidity; T cell; Molecular biology; Immunology; Immune system; Genetics","score_opus":0.22862007228663447,"score_gpt":0.49842278518530214,"score_spread":0.26980271289866764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2208384071","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9806494,0.011268161,0.00029226753,0.0045196647,0.00018954411,0.0015465282,0.00009527584,0.00005477127,0.0013843947],"genre_scores_gemma":[0.9842748,0.008502679,0.0009959897,0.00028339305,0.0009968585,0.00050504756,0.00017426093,0.000105236635,0.0041617528],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.994563,0.00089529995,0.00093188137,0.0007250662,0.0020312567,0.0008534966],"domain_scores_gemma":[0.99567425,0.00068733667,0.00026755553,0.0006200592,0.00206969,0.0006810808],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0067569367,0.0002099586,0.0006482357,0.00025528355,0.00013912778,0.00005167314,0.000343198,0.00020379985,0.0035306471],"category_scores_gemma":[0.00055967714,0.00016460074,0.00014741062,0.0010940869,0.0006107275,0.00013451638,0.00010092526,0.0012099695,0.000068550406],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0101919025,0.0020993333,0.014376259,0.00011906174,0.0001360388,0.000032226384,0.0012979436,0.00002940786,0.8432313,0.000015581954,0.08823569,0.04023521],"study_design_scores_gemma":[0.016140727,0.008721692,0.002164106,0.00038712771,0.000024913254,0.000011561479,0.0016090473,0.00066678255,0.7697942,0.00013356647,0.1999818,0.0003644733],"about_ca_topic_score_codex":0.0011415726,"about_ca_topic_score_gemma":0.00009570317,"teacher_disagreement_score":0.1117461,"about_ca_system_score_codex":0.0008048518,"about_ca_system_score_gemma":0.0018608447,"threshold_uncertainty_score":0.99738026},"labels":[],"label_agreement":null},{"id":"W2211214375","doi":"10.1200/jco.2014.32.18_suppl.lba9000","title":"Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":130,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Cohort; Ipilimumab; Gastroenterology; Cancer; Immunotherapy","score_opus":0.06520723822404939,"score_gpt":0.4496459923851462,"score_spread":0.3844387541610968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2211214375","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99174863,0.0001006752,0.000041632862,0.0035057203,0.000368192,0.0003350598,0.0000027549718,0.0000029521802,0.0038943528],"genre_scores_gemma":[0.99750984,0.00043327868,0.00065108255,0.00069821626,0.00041581912,0.0000010513176,0.000002138836,0.000018429388,0.00027014344],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99617636,0.0008931564,0.0018305146,0.00019716751,0.0006366635,0.00026614626],"domain_scores_gemma":[0.9946498,0.0032388621,0.0011251979,0.00028757262,0.00042288948,0.00027566223],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042777155,0.00013601054,0.0014420429,0.00014189156,0.000036368023,0.0000063583593,0.00025711066,0.0002939214,0.0002818805],"category_scores_gemma":[0.0030645144,0.000072930794,0.0002371335,0.00022674704,0.000524759,0.00006618251,0.000113665534,0.0012779676,0.000004675183],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014248909,0.0019523678,0.8535339,0.000030066009,0.00019219934,0.00006454307,0.00010268153,0.000014732821,0.0017227608,0.000073415846,0.00025653918,0.12780784],"study_design_scores_gemma":[0.024825325,0.0149651505,0.9255873,0.00018215852,0.000101930316,0.00013435124,0.000029759924,0.000120252014,0.00022674388,0.00007886152,0.033678908,0.00006928737],"about_ca_topic_score_codex":0.00003019323,"about_ca_topic_score_gemma":0.00004712237,"teacher_disagreement_score":0.12773855,"about_ca_system_score_codex":0.00009246082,"about_ca_system_score_gemma":0.0007629121,"threshold_uncertainty_score":0.5552204},"labels":[],"label_agreement":null},{"id":"W2221239533","doi":"10.1186/s40425-015-0099-4","title":"Designed ankyrin repeat proteins are effective targeting elements for chimeric antigen receptors","year":2015,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster University Medical Centre","funders":"Terry Fox Foundation; Government of Ontario","keywords":"Chimeric antigen receptor; Antigen; Cytotoxic T cell; Degranulation; Ankyrin repeat; Tumor antigen; Antibody; Biology; Cancer research; Immunology; Cell biology; Receptor; Immunotherapy; Immune system; In vitro; Gene; Genetics","score_opus":0.04065385021059447,"score_gpt":0.38164280807278034,"score_spread":0.34098895786218586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2221239533","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96111035,0.018914787,0.0091988575,0.0012058034,0.0015965841,0.0076261545,0.00005098226,0.00004468945,0.00025176583],"genre_scores_gemma":[0.77362645,0.02433199,0.11978056,0.0023622413,0.009364468,0.009163243,0.00014093594,0.0011237556,0.060106374],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99787754,0.00012819922,0.0006361029,0.00025822537,0.0005894487,0.0005105146],"domain_scores_gemma":[0.9977533,0.00015346768,0.0006384373,0.0002466671,0.0010072837,0.00020081739],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018776647,0.00023220337,0.00061505847,0.00022888435,0.00019783805,0.000042584838,0.0002066288,0.000109838445,0.0007702549],"category_scores_gemma":[0.00028488005,0.00018511094,0.00040609,0.00025881536,0.000083138635,0.00014949104,0.000017841867,0.00028518782,0.0000021892777],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016317137,0.000207993,0.015485236,0.00014936627,0.0011169256,0.00000387996,0.0011422004,0.0000373054,0.7221398,0.000003823704,0.009799078,0.2335973],"study_design_scores_gemma":[0.020599548,0.006276421,0.0060597225,0.0006185612,0.00010131953,0.000043378473,0.00082051405,0.00021451122,0.554008,0.00038413674,0.41053686,0.0003369975],"about_ca_topic_score_codex":0.00009797011,"about_ca_topic_score_gemma":0.00001189453,"teacher_disagreement_score":0.4007378,"about_ca_system_score_codex":0.0006037886,"about_ca_system_score_gemma":0.00045832276,"threshold_uncertainty_score":0.843375},"labels":[],"label_agreement":null},{"id":"W2230036583","doi":"10.4049/jimmunol.194.supp.143.6","title":"Retroviral transfer for a chimeric antigen receptor to generate regulatory T-like cells for the suppression of undesired immune responses. (VAC7P.1036)","year":2015,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"FOXP3; Adoptive cell transfer; Immune system; Immunology; Chimeric antigen receptor; Biology; Antigen; Autoimmunity; Antigen-presenting cell; Cell biology; T cell","score_opus":0.05798689285139266,"score_gpt":0.3217708482802225,"score_spread":0.2637839554288298,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2230036583","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9799823,0.007822336,0.004189485,0.0053678956,0.0011835826,0.0013669159,0.000028752078,0.000011081276,0.0000476304],"genre_scores_gemma":[0.9873187,0.0014405,0.0015755187,0.0003412471,0.00040017295,0.00003296662,0.0000067786027,0.00006835372,0.008815785],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99771094,0.0005880027,0.0007391647,0.0001432028,0.00040186604,0.0004168426],"domain_scores_gemma":[0.9972443,0.0010054121,0.0002486963,0.00065008854,0.0007358544,0.00011564468],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003911729,0.00018393574,0.00063307374,0.00024215947,0.0001421322,0.000012493797,0.00059290027,0.00016002616,0.0002058938],"category_scores_gemma":[0.00037387194,0.00009906011,0.00033191958,0.0002738054,0.00032590886,0.000067472625,0.0000670966,0.0004121012,0.000008161996],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.056783635,0.00010695435,0.00003947669,0.00002544936,0.0005550539,0.0000027740552,0.0016488866,0.00006327883,0.9237824,0.00003118498,0.008269438,0.008691443],"study_design_scores_gemma":[0.0065775365,0.007333606,0.0036316381,0.00010513957,0.00023670259,0.00022216815,0.0010743248,0.00012667953,0.924498,0.00013556158,0.05593499,0.00012362753],"about_ca_topic_score_codex":0.000039011044,"about_ca_topic_score_gemma":0.0000029033936,"teacher_disagreement_score":0.0502061,"about_ca_system_score_codex":0.00015805334,"about_ca_system_score_gemma":0.00058374787,"threshold_uncertainty_score":0.4039554},"labels":[],"label_agreement":null},{"id":"W2232969484","doi":"10.1182/blood.v124.21.1624.1624","title":"Cell-of-Origin Assignment in Diffuse Large B-Cell Lymphoma Determined By Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Has Prognostic Significance Independent of IPI and MYC/BCL2 Immunohistochemistry","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Spinal Cord Injury BC; BC Cancer Agency","funders":"","keywords":"Diffuse large B-cell lymphoma; Tissue microarray; Immunohistochemistry; Concordance; Lymphoma; Pathology; Gene expression profiling; Biology; Germinal center; Cancer research; Medicine; Gene expression; Gene; B cell; Bioinformatics; Immunology; Antibody; Genetics","score_opus":0.013016549360451162,"score_gpt":0.2711677360484875,"score_spread":0.2581511866880363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2232969484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996151,0.001781938,0.00043627122,0.000034042052,0.000040306688,0.0010817789,0.000028108312,0.000020854712,0.00042573374],"genre_scores_gemma":[0.99737066,0.00014201897,0.0011904569,0.000021088397,0.000045032404,0.00018711822,0.000058854566,0.00004428,0.0009404925],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99759656,0.00014736617,0.0006968245,0.00045432107,0.0006005948,0.0005043119],"domain_scores_gemma":[0.99869525,0.00023957071,0.000263917,0.00055305293,0.00007013173,0.00017807278],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00060638913,0.00027013128,0.0006129415,0.00016709036,0.000038571023,0.000018001985,0.00022619436,0.00022435699,0.00010285655],"category_scores_gemma":[0.00008693787,0.00025416634,0.000067041576,0.00021799191,0.0001235804,0.00006499668,0.00013343536,0.0002325642,0.000003616001],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006285856,0.010065679,0.02627151,0.0005801733,0.000019827823,0.000055888744,0.0006786074,0.000003188006,0.9604757,0.0000013230942,0.00007967456,0.0011398764],"study_design_scores_gemma":[0.04062291,0.00060917326,0.0040988475,0.0002858591,0.000053023814,0.000017761613,0.00010273778,0.00035356177,0.9533181,0.000014467239,0.00030733435,0.0002162162],"about_ca_topic_score_codex":0.000100911166,"about_ca_topic_score_gemma":0.000007702253,"teacher_disagreement_score":0.039994325,"about_ca_system_score_codex":0.00011984216,"about_ca_system_score_gemma":0.000187531,"threshold_uncertainty_score":0.99999106},"labels":[],"label_agreement":null},{"id":"W2264439609","doi":"10.4049/jimmunol.188.supp.111.45","title":"Cellular and molecular profiling of CD8 T cell differentiation with respect to positive and negative selection in vitro reveals a role for Notch signaling (111.45)","year":2012,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Sunnybrook Hospital; University of Toronto","funders":"","keywords":"Cell biology; Biology; Notch signaling pathway; CD8; Stromal cell; Progenitor cell; Cellular differentiation; Cytotoxic T cell; Haematopoiesis; T cell; Negative selection; Stem cell; Immunology; Signal transduction; Cancer research; Antigen; Immune system; In vitro; Genetics","score_opus":0.01238562688592718,"score_gpt":0.27571373303465935,"score_spread":0.26332810614873214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2264439609","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99172866,0.002298804,0.004975535,0.0003388321,0.000020917163,0.0005879465,0.0000023175378,0.0000023531827,0.000044625227],"genre_scores_gemma":[0.99706954,0.00009589076,0.0026636317,0.000044181343,0.000054232823,0.000007630191,0.0000015182267,0.00001598298,0.00004737871],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989811,0.00029852276,0.00027711075,0.00007757187,0.00015047094,0.00021522281],"domain_scores_gemma":[0.99902225,0.00036136553,0.0002293066,0.00006974196,0.00026574862,0.000051565396],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010016488,0.000091334085,0.0003087071,0.00023901118,0.0000447137,0.000006583888,0.00005358482,0.00006325129,0.000012459979],"category_scores_gemma":[0.000109984634,0.0000599205,0.000034274643,0.00018136472,0.000069045,0.00007365917,0.000028581002,0.00029130332,2.3587766e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012964541,0.000086229746,0.0020779625,0.00003632438,0.0001556507,0.0000030865654,0.0037202674,0.000022147988,0.97954977,0.000021037655,0.0000011626315,0.0013618215],"study_design_scores_gemma":[0.0021664072,0.0024214226,0.008850766,0.000107159016,0.000116175754,0.0001647024,0.0015017742,0.00014858898,0.9842631,0.00020057437,0.0000054871257,0.000053815013],"about_ca_topic_score_codex":0.000047329417,"about_ca_topic_score_gemma":0.000003281745,"teacher_disagreement_score":0.010798134,"about_ca_system_score_codex":0.0000856883,"about_ca_system_score_gemma":0.000050443323,"threshold_uncertainty_score":0.24434872},"labels":[],"label_agreement":null},{"id":"W2281961904","doi":"10.1188/16.onf.131-132","title":"Innovation, Creation, Inspiration","year":2016,"lang":"en","type":"editorial","venue":"Oncology nursing forum","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Medicine","score_opus":0.02492412686004447,"score_gpt":0.4035082028614964,"score_spread":0.37858407600145194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2281961904","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00023041402,0.0002695117,0.0010389615,0.019719766,0.8238635,0.00081121305,0.000056756504,0.0001709067,0.15383898],"genre_scores_gemma":[0.00032274844,0.00021828809,0.000473312,0.00046790313,0.85156053,0.000111340865,0.0019566708,0.00011824436,0.14477094],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972423,0.00014834077,0.0006294827,0.000526348,0.00087647495,0.0005770652],"domain_scores_gemma":[0.9965545,0.00063131173,0.00035703322,0.00054772064,0.0017985718,0.00011089531],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00073178834,0.00029245563,0.00064777216,0.00077967084,0.00020822806,0.00003752,0.0001866998,0.0019609705,0.0025011457],"category_scores_gemma":[0.0013732424,0.0002459045,0.000110087916,0.0006679968,0.00042699365,0.00012663439,0.000035234658,0.0010437694,0.0002955333],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006058958,0.00021993177,0.00008719027,0.0000355172,0.000078048244,0.000017971812,0.00017623368,1.5045187e-7,0.0072092847,0.0008261239,0.75873953,0.2320041],"study_design_scores_gemma":[0.0027775671,0.0017196684,0.000077834105,0.0007466476,0.00011559063,0.000024219162,0.0000775169,0.000008855674,0.0011310285,0.002206595,0.990895,0.00021949872],"about_ca_topic_score_codex":0.00002474876,"about_ca_topic_score_gemma":0.000026589987,"teacher_disagreement_score":0.23215544,"about_ca_system_score_codex":0.0038201758,"about_ca_system_score_gemma":0.003777654,"threshold_uncertainty_score":0.99999934},"labels":[],"label_agreement":null},{"id":"W2289192290","doi":"10.1096/fasebj.22.2_supplement.516","title":"Interleukin‐12 immunotherapy in a murine model of leukemia","year":2008,"lang":"en","type":"article","venue":"The FASEB Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Ontario Institute for Cancer Research","funders":"","keywords":"CTL*; Cytotoxic T cell; CD8; Immunotherapy; Immunology; Cancer research; Systemic administration; T cell; Population; Medicine; Interleukin 2; Antigen; In vivo; Biology; Immune system; In vitro","score_opus":0.05248198627890809,"score_gpt":0.3080619103356193,"score_spread":0.2555799240567112,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2289192290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926094,0.00055639044,0.0004618753,0.0005915318,0.0000649125,0.00019200833,0.0000025738207,0.000010672975,0.005510639],"genre_scores_gemma":[0.98758006,0.001825491,0.00041242162,0.00028057053,0.00017257869,0.000004949412,0.000001405518,0.000028145256,0.0096943965],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986369,0.00009971667,0.00039019788,0.00010412058,0.00047256603,0.00029652563],"domain_scores_gemma":[0.99927217,0.00007609731,0.000109660556,0.00034290148,0.000096839816,0.000102314996],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00073369156,0.0001189979,0.00029981774,0.00022196832,0.00008609131,0.000010282282,0.00027117244,0.000057005123,0.0017498606],"category_scores_gemma":[0.00003810353,0.000074736374,0.0001688365,0.00018695832,0.00020698908,0.000069034875,0.000043086005,0.00081383355,0.000016585682],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018183662,0.00011544873,0.0056094634,0.000012967199,0.000092838985,0.00018713552,0.0028855696,0.0011654667,0.9785851,0.00003318969,0.0005850848,0.0089093195],"study_design_scores_gemma":[0.017473567,0.0015676898,0.022030933,0.0004802715,0.000048674978,0.012658728,0.0008953019,0.056312285,0.88425833,0.0017881002,0.0021497828,0.0003363105],"about_ca_topic_score_codex":0.00010315964,"about_ca_topic_score_gemma":0.00002061453,"teacher_disagreement_score":0.094326794,"about_ca_system_score_codex":0.0003548527,"about_ca_system_score_gemma":0.0005084379,"threshold_uncertainty_score":0.9991627},"labels":[],"label_agreement":null},{"id":"W2300532045","doi":"10.4049/jimmunol.190.supp.177.7","title":"Novel immunotherapy for AML using DNT cells (P4348)","year":2013,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Ontario Power Generation","funders":"","keywords":"Myeloid leukemia; Leukemia; Bone marrow; Cancer research; CD8; CD33; CD34; Immunology; Ex vivo; Immunotherapy; In vivo; Myeloid; Stem cell; Medicine; Biology; Immune system; Cell biology","score_opus":0.048363747561261855,"score_gpt":0.3332003433325073,"score_spread":0.2848365957712454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2300532045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98150533,0.00402014,0.009394399,0.0033452285,0.0006278093,0.0006979873,0.0000028243717,0.000010890023,0.00039535871],"genre_scores_gemma":[0.97234046,0.0038088858,0.012195246,0.0017571625,0.0010305115,0.000020555024,0.0000024617877,0.00012362633,0.008721081],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986498,0.00012256051,0.00051023095,0.00008649442,0.00023980788,0.00039112623],"domain_scores_gemma":[0.99822235,0.00043397027,0.00033238519,0.00039123447,0.00055864075,0.000061389415],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009882811,0.00014337566,0.00043163582,0.00019533647,0.000116172734,0.000022655759,0.00037663034,0.00012304165,0.002671194],"category_scores_gemma":[0.000072924035,0.00008566386,0.00023054515,0.0001504412,0.00024522137,0.000106211715,0.000050495943,0.00053808076,0.00004707701],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017575348,0.00015324124,0.000041398314,0.000012010172,0.00054729957,0.0000040075984,0.0005366804,0.00003076678,0.97376144,0.00003925315,0.00081747014,0.022298919],"study_design_scores_gemma":[0.013864694,0.0049730153,0.0061012595,0.00016466244,0.00024680552,0.0063040783,0.0016515724,0.0012150167,0.8972542,0.0011685605,0.06678305,0.0002730284],"about_ca_topic_score_codex":0.00020683203,"about_ca_topic_score_gemma":0.000002419695,"teacher_disagreement_score":0.076507166,"about_ca_system_score_codex":0.0001637872,"about_ca_system_score_gemma":0.00021863704,"threshold_uncertainty_score":0.9982405},"labels":[],"label_agreement":null},{"id":"W2301752124","doi":"10.1093/annonc/mdu344.44","title":"A Phase Ii Study (Nct01883323) Evaluating the Infusion of Autologous Tumor-Infiltrating Lymphocytes (Til) and Low-Dose Interleukin-2 (Il-2) Therapy Following Non-Myeloablative Lymphodepletion Using Cyclophosphamide and Fludarabine in Patients with Metastatic Melanoma","year":2014,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Fludarabine; Cyclophosphamide; Oncology; Chemotherapy; Internal medicine","score_opus":0.06449802489123993,"score_gpt":0.40676060335234526,"score_spread":0.3422625784611053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2301752124","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972465,0.00036583527,0.00007038861,0.00016379262,0.00005986044,0.0018963168,0.000006457581,0.000013838376,0.00017702964],"genre_scores_gemma":[0.9982692,0.00007537452,0.0012528442,0.00025918003,0.000026642816,0.000054209326,0.000011191614,0.00003614983,0.000015231824],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9970069,0.0008066287,0.0008516824,0.00041913954,0.00052585837,0.0003898038],"domain_scores_gemma":[0.99745494,0.0011467431,0.00058106444,0.0003282092,0.00038967773,0.00009935986],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029565394,0.00027759932,0.0009879282,0.00031474166,0.00017326813,0.000016238775,0.00013384724,0.00007686449,0.000036878493],"category_scores_gemma":[0.0007189473,0.0001863769,0.0000859957,0.00044205075,0.0003133678,0.0001519397,0.0001589326,0.00021758261,3.332159e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015773714,0.003881945,0.26441103,0.0001226447,0.0004912256,0.000054642667,0.014687162,0.00016432603,0.16186836,0.0000089474925,0.000003861658,0.53853214],"study_design_scores_gemma":[0.1175284,0.28418782,0.47616175,0.0012285837,0.00039560883,0.00015591233,0.006849101,0.07514193,0.03742568,0.00030313228,0.00008494892,0.00053713314],"about_ca_topic_score_codex":0.0006467542,"about_ca_topic_score_gemma":0.000094583986,"teacher_disagreement_score":0.53799504,"about_ca_system_score_codex":0.00014021613,"about_ca_system_score_gemma":0.00038784553,"threshold_uncertainty_score":0.76002294},"labels":[],"label_agreement":null},{"id":"W2303852857","doi":"10.1172/jci82771","title":"Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Investigation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":476,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Child and Family Research Institute","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; University of British Columbia; Canadian Blood Services","keywords":"Chimeric antigen receptor; Immunology; Antigen; Immunotherapy; Human leukocyte antigen; Transplantation; Immune system; Cell therapy; Adoptive cell transfer; Major histocompatibility complex; Biology; Graft-versus-host disease; T cell; Medicine; Stem cell; Cell biology","score_opus":0.10537970307624715,"score_gpt":0.3739260898684617,"score_spread":0.26854638679221454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2303852857","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99284744,0.00037518085,0.0006197025,0.0048840526,0.00057371537,0.00026293486,0.0000027216552,0.000024715737,0.00040951863],"genre_scores_gemma":[0.967007,0.00438352,0.016164895,0.0013525645,0.003529114,0.000004751862,0.000008869924,0.00008024821,0.0074690436],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99676836,0.00039504576,0.0014354476,0.00025713033,0.0008796581,0.0002643848],"domain_scores_gemma":[0.99688405,0.0004530374,0.0008857495,0.0003622926,0.0008102794,0.0006046167],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0025313965,0.00016595436,0.0006377936,0.00020058262,0.000056392946,0.000030126574,0.00017223583,0.00019725402,0.0021230686],"category_scores_gemma":[0.00040802642,0.00009104595,0.00025407836,0.00038903893,0.00053264207,0.00023751611,0.000023419145,0.0004963729,0.00013775653],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014395284,0.00013994663,0.054305777,0.000013597953,0.00020322535,0.000049414957,0.000071014256,0.0000052159567,0.88236237,0.000040634743,0.01680805,0.044561204],"study_design_scores_gemma":[0.007075466,0.003472198,0.22855806,0.0007244016,0.00007985451,0.00020006375,0.000044065302,0.00006134022,0.5624907,0.00027753258,0.19676977,0.00024655854],"about_ca_topic_score_codex":0.0000032412113,"about_ca_topic_score_gemma":0.0000014860672,"teacher_disagreement_score":0.3198717,"about_ca_system_score_codex":0.00009273122,"about_ca_system_score_gemma":0.0006991338,"threshold_uncertainty_score":0.99878913},"labels":[],"label_agreement":null},{"id":"W2304098313","doi":"10.3324/haematol.2015.132712","title":"Expression of a dominant T-cell receptor can reduce toxicity and enhance tumor protection of allogeneic T-cell therapy","year":2016,"lang":"en","type":"article","venue":"Haematologica","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Medical Research Council; University College London Hospitals NHS Foundation Trust; National Institute for Health and Care Research; Cancer Research UK","keywords":"Adoptive cell transfer; Immunology; Receptor; Biology; Cell therapy; T cell; Chimeric antigen receptor; Antigen; Graft-versus-host disease; Endogeny; Cancer research; Receptor expression; Immune system; Stem cell; Cell biology; Endocrinology","score_opus":0.03489163423556973,"score_gpt":0.29882062272251286,"score_spread":0.26392898848694313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2304098313","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958638,0.0008869236,0.00018617933,0.00062311697,0.00005184554,0.0011579687,0.000011779078,0.000027007352,0.0011914072],"genre_scores_gemma":[0.9949921,0.0014084087,0.00095023663,0.000041993477,0.000032158336,0.0001237939,0.0000016901544,0.00002010885,0.0024295244],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984865,0.0001810239,0.0003800155,0.0003668806,0.0003164472,0.0002690857],"domain_scores_gemma":[0.99891186,0.00013189836,0.000266589,0.00041176332,0.0001613646,0.00011652378],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00038210815,0.00016861946,0.00054895354,0.00009994259,0.000048998336,0.0000041781864,0.0001282692,0.00012696562,0.00114754],"category_scores_gemma":[0.00012820293,0.00009289338,0.00008354828,0.00015051693,0.0002675607,0.000036519363,0.00006596371,0.00013127204,0.0000117997115],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002198636,0.00051857525,0.0010099738,0.00025577217,0.000011713776,0.000017599525,0.00022496902,8.333073e-8,0.98479915,0.000009497691,0.00026922888,0.010684833],"study_design_scores_gemma":[0.0022412122,0.0016773028,0.00065098447,0.0003265037,0.000009158845,0.00008517919,0.00008357231,0.0000021312615,0.99339855,0.00010403284,0.0013118669,0.000109531895],"about_ca_topic_score_codex":0.00005224184,"about_ca_topic_score_gemma":0.000005015976,"teacher_disagreement_score":0.010575301,"about_ca_system_score_codex":0.0000440725,"about_ca_system_score_gemma":0.00009667871,"threshold_uncertainty_score":0.9997656},"labels":[],"label_agreement":null},{"id":"W2313438481","doi":"10.2741/200","title":"Thymus-bound: the many features of T cell progenitors","year":2011,"lang":"en","type":"review","venue":"Frontiers in Bioscience-Scholar","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Lymphopoiesis; Progenitor cell; Haematopoiesis; Bone marrow; Progenitor; Lineage (genetic); Biology; Stem cell; Cell biology; Immunology; Transplantation; T cell; Cancer research; Medicine; Immune system; Genetics; Internal medicine; Gene","score_opus":0.046047318286260415,"score_gpt":0.3354656723612491,"score_spread":0.28941835407498867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2313438481","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00036034407,0.9835886,0.000035711357,0.000046311747,0.002417834,0.0026669097,0.00004111709,0.00003858966,0.010804582],"genre_scores_gemma":[0.000027654236,0.9814793,0.0047679394,0.00008288637,0.00031772788,0.00016286112,0.000024371358,0.00008456691,0.013052696],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.995684,0.00052615127,0.0008500756,0.0009050704,0.0011664222,0.0008682563],"domain_scores_gemma":[0.997728,0.00008903832,0.00044273952,0.0013087873,0.0001604556,0.0002709955],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.003175545,0.0005732312,0.0019105185,0.0009598511,0.00030274154,0.0001225588,0.001717347,0.0005986586,0.00042418277],"category_scores_gemma":[0.00036679168,0.00034163977,0.0007994592,0.002236637,0.0011342652,0.00021643088,0.00031255715,0.0030145112,0.000042814376],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000059448856,0.00022368124,0.00025099976,0.004377002,0.00009621543,0.00004046751,0.00047316382,3.501147e-8,0.00028983786,0.00003319761,0.006340446,0.9878155],"study_design_scores_gemma":[0.00042102896,0.00026474317,0.00017531133,0.0026810283,0.00031570072,0.0000716702,0.0003057693,0.0000032304285,0.0007264617,0.00007245842,0.9946412,0.00032141648],"about_ca_topic_score_codex":0.00007635657,"about_ca_topic_score_gemma":0.000004817021,"teacher_disagreement_score":0.98830074,"about_ca_system_score_codex":0.00042487646,"about_ca_system_score_gemma":0.0012071365,"threshold_uncertainty_score":0.99990356},"labels":[],"label_agreement":null},{"id":"W2314878272","doi":"10.1042/bst20150254","title":"Homing to solid cancers: a vascular checkpoint in adoptive cell therapy using CAR T-cells","year":2016,"lang":"en","type":"review","venue":"Biochemical Society Transactions","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Medical Research Council; Wellcome Trust","keywords":"Extravasation; Homing (biology); CD8; Adoptive cell transfer; Cytotoxic T cell; Medicine; Cancer research; Angiogenesis; T cell; Immunology; Pericyte; Infiltration (HVAC); Blood vessel; Pathology; Antigen; Biology; Immune system; Endothelial stem cell; Internal medicine","score_opus":0.06953278686535672,"score_gpt":0.372831998871406,"score_spread":0.30329921200604926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2314878272","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001190155,0.98683965,0.008526213,0.000104686704,0.00022038285,0.0026874177,0.00016833928,0.00007978705,0.00018337522],"genre_scores_gemma":[0.00015027141,0.99421936,0.0032361886,0.0001614272,0.00043689835,0.00036996105,0.000041698386,0.00016910245,0.0012150693],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967855,0.000121816025,0.0007396928,0.00090824784,0.0005976474,0.0008470565],"domain_scores_gemma":[0.99839115,0.00016746995,0.00013481465,0.00066083984,0.00014555122,0.0005001614],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000390436,0.00062480854,0.0018643131,0.00016918026,0.0001287926,0.00003846589,0.00029628954,0.0008754255,0.0019941197],"category_scores_gemma":[0.000010023684,0.0004886306,0.002833799,0.00097534835,0.00018921342,0.000058062997,0.00002509971,0.0012260403,0.00007037432],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009179416,0.00045069188,6.327636e-7,0.0049223052,0.0011608802,0.000016697504,0.0013072478,0.00001641194,0.5732246,3.706006e-7,0.0007002267,0.41810814],"study_design_scores_gemma":[0.0017969649,0.00015277242,4.3170402e-7,0.008916018,0.00056459307,0.000024665083,0.00027323508,0.000071166825,0.08201991,0.0000022249837,0.9055392,0.0006388046],"about_ca_topic_score_codex":0.0003412219,"about_ca_topic_score_gemma":0.000007279881,"teacher_disagreement_score":0.904839,"about_ca_system_score_codex":0.0035639105,"about_ca_system_score_gemma":0.0015334213,"threshold_uncertainty_score":0.9997565},"labels":[],"label_agreement":null},{"id":"W2315367769","doi":"10.1042/bst20150251","title":"SHP-1: the next checkpoint target for cancer immunotherapy?","year":2016,"lang":"en","type":"review","venue":"Biochemical Society Transactions","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Medical Research Council; Wellcome Trust","keywords":"Protein tyrosine phosphatase; Immunotherapy; Cancer immunotherapy; Cytotoxic T cell; Cancer research; Immune system; Regulator; Antigen; Proto-oncogene tyrosine-protein kinase Src; Biology; Immune checkpoint; T cell; Fusion protein; Cell biology; Phosphorylation; Immunology; Biochemistry; In vitro; Recombinant DNA","score_opus":0.0845359419127644,"score_gpt":0.38984653570998384,"score_spread":0.3053105937972195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2315367769","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000003478196,0.97882426,0.01400629,0.0032108407,0.0003334132,0.0027974714,0.0004817185,0.00017089378,0.00017164594],"genre_scores_gemma":[0.000004102763,0.97729087,0.0013068224,0.00033916975,0.0010257495,0.0030828803,0.00010936135,0.00022409188,0.016616931],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976905,0.000065692926,0.00059594616,0.00058359373,0.00042803402,0.0006362309],"domain_scores_gemma":[0.9982173,0.0005299728,0.00014801724,0.0007232912,0.00016877944,0.00021267855],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003764441,0.0004905772,0.0012821854,0.000038033268,0.00025283935,0.000055250865,0.00039002328,0.0007497759,0.0076460596],"category_scores_gemma":[0.00002158914,0.00026735268,0.0043298383,0.00038405333,0.00040158944,0.000049930957,0.000013370553,0.00093926437,0.000045574685],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006639825,0.00016277427,1.1781668e-7,0.0048667197,0.0018586273,4.990034e-7,0.00013575738,1.0032341e-7,0.015867963,0.000008108027,0.013422698,0.96361023],"study_design_scores_gemma":[0.00091466075,0.0000904145,2.8035436e-7,0.0033076603,0.0007845904,0.000029329743,0.000043258093,0.000014858157,0.002914069,0.00004061154,0.9915453,0.00031493776],"about_ca_topic_score_codex":0.000053469405,"about_ca_topic_score_gemma":0.0000019338165,"teacher_disagreement_score":0.97812265,"about_ca_system_score_codex":0.00081780413,"about_ca_system_score_gemma":0.00097457797,"threshold_uncertainty_score":0.9999779},"labels":[],"label_agreement":null},{"id":"W2323183075","doi":"10.1038/srep23821","title":"CD4+ and CD8+ TCRβ repertoires possess different potentials to generate extraordinarily high-avidity T cells","year":2016,"lang":"en","type":"article","venue":"Scientific Reports","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; Ontario Institute for Cancer Research","funders":"Japan Society for the Promotion of Science; Canadian Institutes of Health Research; National Cancer Institute; Universiteit Leiden; National Institutes of Health; Natural Sciences and Engineering Research Council of Canada; Princess Margaret Cancer Foundation","keywords":"Avidity; T-cell receptor; Cytotoxic T cell; CD8; Biology; Cell biology; Immunology; T cell; Antigen; Immune system; Genetics; In vitro","score_opus":0.028772189044475507,"score_gpt":0.29616678453415485,"score_spread":0.26739459548967937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2323183075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98778135,0.00024356956,0.00046911396,0.0027087417,0.007180041,0.00095659436,0.00000920093,0.00015864613,0.0004927523],"genre_scores_gemma":[0.88988477,0.00007115798,0.00035328855,0.000118261814,0.00033603417,0.0000496501,0.000014129291,0.000055543554,0.10911719],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99575496,0.00013373475,0.0006948678,0.0014730397,0.0012258459,0.0007175626],"domain_scores_gemma":[0.9968562,0.00009773615,0.00019990014,0.0017291702,0.00041022344,0.0007067535],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018390376,0.00029163412,0.0005268279,0.00035526158,0.00038381695,0.00038589715,0.00016735718,0.00012922776,0.0028685788],"category_scores_gemma":[0.00027349105,0.00017957321,0.00015766177,0.00042635784,0.0004620514,0.00017050847,0.00027409283,0.00015264892,0.00010177115],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001276522,0.00015409461,0.005860061,0.000043924727,0.00004897123,0.0017695902,0.00014046534,0.000002130733,0.9335738,0.000024404888,0.025661467,0.03259343],"study_design_scores_gemma":[0.0006420552,0.00023751413,0.019785602,0.00017852313,0.00004904434,0.0008221208,0.0000437001,0.000013069785,0.9262129,0.0016535805,0.050062273,0.00029960848],"about_ca_topic_score_codex":0.00026452894,"about_ca_topic_score_gemma":0.00007611486,"teacher_disagreement_score":0.108624436,"about_ca_system_score_codex":0.00018138315,"about_ca_system_score_gemma":0.00021995851,"threshold_uncertainty_score":0.99804294},"labels":[],"label_agreement":null},{"id":"W2327586678","doi":"10.1158/1538-7445.am2015-4701","title":"Abstract 4701: NY-ESO T cells administered post ASCT for MM exhibit extended functionality without exhaustion in a natural pattern of effector and memory programming","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Computer Research Institute of Montréal","funders":"","keywords":"Medicine; CD28; Immunology; Antigen; Immunotherapy; Immune system; Multiple myeloma; Oncology; Cancer; Internal medicine; Leukapheresis; T cell; Stem cell; CD34; Biology","score_opus":0.11997577695296056,"score_gpt":0.43846624403139967,"score_spread":0.3184904670784391,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2327586678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99386984,0.0018786398,0.000031551957,0.0006648443,0.00022731267,0.0029439616,0.000068848414,0.00002868791,0.00028629243],"genre_scores_gemma":[0.9955804,0.000061336475,0.00014862313,0.000053069463,0.00035837188,0.0007282892,0.000078184574,0.00004890015,0.002942838],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99693614,0.00024217916,0.00038558643,0.00053323025,0.0012338453,0.0006689917],"domain_scores_gemma":[0.99756265,0.000477115,0.00008449683,0.00040062884,0.001105727,0.0003693996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003389169,0.00018575846,0.00043881842,0.0003970415,0.000075834265,0.00005797374,0.00015960778,0.00015114756,0.0004832565],"category_scores_gemma":[0.00045666323,0.00015940881,0.00010052298,0.00040725447,0.00034073458,0.00013354483,0.00011378421,0.0007774771,0.000012073499],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009808698,0.00036316636,0.017907241,0.001701575,0.0000996762,0.000042510103,0.0009646885,0.000004458774,0.72528034,0.00000268966,0.0008037301,0.24302125],"study_design_scores_gemma":[0.026070813,0.0062103895,0.46208873,0.0019230215,0.00008983618,0.000076829834,0.0038867465,0.0011140285,0.48472154,0.00011137841,0.013065984,0.0006406977],"about_ca_topic_score_codex":0.0027840612,"about_ca_topic_score_gemma":0.0011381499,"teacher_disagreement_score":0.4441815,"about_ca_system_score_codex":0.00062235136,"about_ca_system_score_gemma":0.00088386255,"threshold_uncertainty_score":0.6500503},"labels":[],"label_agreement":null},{"id":"W2328382622","doi":"10.1038/sj.leu.2402079","title":"Suppressed apoptosis of pre-B cells in bone marrow of pre-leukemic p190bcr/abl transgenic mice","year":2001,"lang":"en","type":"article","venue":"Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Cancer Institute; Medical Research Council Canada","keywords":"Apoptosis; Bone marrow; Biology; Genetically modified mouse; Leukemia; Carcinogenesis; B cell; Cancer research; Flow cytometry; Transgene; Molecular biology; Immunology; Antibody; Cancer; Biochemistry; Genetics","score_opus":0.017765350528368383,"score_gpt":0.28255142525930055,"score_spread":0.2647860747309322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2328382622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908434,0.00072857074,0.00008790696,0.00020176874,0.00014369347,0.001031787,0.00003810659,0.00004646165,0.006878288],"genre_scores_gemma":[0.9799575,0.0011636757,0.0005499352,0.00010848558,0.00013704668,0.00006139873,0.00003646021,0.000073887626,0.01791159],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971326,0.00016539189,0.0008456808,0.00047585805,0.0007460191,0.00063443324],"domain_scores_gemma":[0.99832743,0.0002817005,0.00018397109,0.0008353013,0.00016236515,0.00020922611],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005743314,0.00028459175,0.00084791286,0.00042443105,0.00002629728,0.000009904247,0.00036160322,0.00030457403,0.0034838424],"category_scores_gemma":[0.000076105935,0.00027801073,0.00028957604,0.0008679378,0.00022126258,0.00011604021,0.000064266256,0.00058068486,0.000028677701],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041336655,0.00026495822,0.0056925174,0.00067181926,0.00011428044,0.000020517096,0.0016523395,0.00026125944,0.98027277,0.000012619712,0.0016594994,0.005243738],"study_design_scores_gemma":[0.0064092083,0.00053213147,0.020257711,0.00034619076,0.000107649335,0.000035113153,0.00015159263,0.000928076,0.9654398,0.00007235793,0.005493264,0.00022693536],"about_ca_topic_score_codex":0.00199305,"about_ca_topic_score_gemma":0.0001715888,"teacher_disagreement_score":0.014833015,"about_ca_system_score_codex":0.00077817595,"about_ca_system_score_gemma":0.0006920308,"threshold_uncertainty_score":0.9999672},"labels":[],"label_agreement":null},{"id":"W2333997296","doi":"10.1038/nbt.3525","title":"Quality cell therapy manufacturing by design","year":2016,"lang":"en","type":"article","venue":"Nature Biotechnology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":311,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"World Wildlife Fund Canada; University of Toronto","funders":"Health Canada; Natural Sciences and Engineering Research Council of Canada; Canada Research Chairs; Government of Canada; University of Pennsylvania","keywords":"Biopharmaceutical; Quality by Design; Quality (philosophy); Manufacturing process; New product development; Risk analysis (engineering); Good manufacturing practice; Computer science; Product (mathematics); Biochemical engineering; Process (computing); Population; Process development; Manufacturing engineering; Engineering; Medicine; Business; Biotechnology; Operations management; Biology","score_opus":0.028718145894029157,"score_gpt":0.33436713477928703,"score_spread":0.3056489888852579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2333997296","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9097158,0.01009421,0.010241415,0.061154485,0.00043834458,0.0013537189,0.000033262793,0.0010475566,0.0059212395],"genre_scores_gemma":[0.9775464,0.0030876182,0.001926183,0.001149936,0.00013043672,0.000027492335,0.000006429158,0.000047385798,0.016078096],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983773,0.000113813716,0.00021505961,0.00048002144,0.00033084486,0.0004829288],"domain_scores_gemma":[0.99874806,0.0002456818,0.00006961703,0.0007803924,0.000054302025,0.000101940466],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005059892,0.0001983577,0.0003261697,0.00022359102,0.00005888125,0.000009339037,0.00030955905,0.0019464543,0.0022323367],"category_scores_gemma":[0.000119808494,0.00011912698,0.00010334909,0.00018056248,0.00024337263,0.00004025677,0.00007626353,0.0011914413,0.00016363549],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044140458,0.00008629121,0.00017221004,0.000010318026,0.000033954217,0.000018782846,0.00000986827,2.760462e-8,0.7503033,0.00018578643,0.010310488,0.23842752],"study_design_scores_gemma":[0.0017115098,0.00030188693,0.0005046682,0.0000116801375,0.0000034341547,0.000025855652,0.000010624986,7.7921806e-7,0.67852795,0.0004754443,0.31831932,0.00010686287],"about_ca_topic_score_codex":0.000016393755,"about_ca_topic_score_gemma":0.000002095363,"teacher_disagreement_score":0.30800885,"about_ca_system_score_codex":0.0001659808,"about_ca_system_score_gemma":0.00006973793,"threshold_uncertainty_score":0.99934924},"labels":[],"label_agreement":null},{"id":"W2338745842","doi":"10.1158/2326-6074.cricimteatiaacr15-a084","title":"Abstract A084: Identification of mutation-reactive T cells in patients with gastrointestinal cancers","year":2016,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"clone (Java method); Cancer research; Cancer; CD8; Biology; Somatic cell; Mutation; Germline mutation; Cancer cell; Cell culture; Metastasis; Human leukocyte antigen; Exome sequencing; T cell; Molecular biology; Antigen; Immunology; Gene; Genetics; Immune system","score_opus":0.041750560219818406,"score_gpt":0.37331365738303157,"score_spread":0.3315630971632132,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2338745842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973551,0.00019013773,0.000043267468,0.0006009891,0.00007271342,0.00084091374,0.000049483246,0.000014815695,0.0008325837],"genre_scores_gemma":[0.9971339,0.00013966885,0.00005418339,0.000010653034,0.000041561536,0.00022418241,0.00001663964,0.000030246434,0.0023489695],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99778324,0.00016820495,0.00037724592,0.00038700993,0.0007073265,0.00057698326],"domain_scores_gemma":[0.9975998,0.00045354897,0.00013440927,0.00044886424,0.0012782329,0.000085174484],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008243655,0.00012610614,0.0002799024,0.00058696885,0.00006072006,0.000010855788,0.00022555146,0.00008263727,0.0020720526],"category_scores_gemma":[0.00024344418,0.0000869017,0.000042921452,0.00063808705,0.0009077557,0.0001457809,0.00005893997,0.00054000225,0.0000691179],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044995626,0.00018026218,0.2631061,0.000038715305,0.00008460956,0.000023038114,0.00020749934,0.0000073674496,0.6992096,0.000016922504,0.000120352415,0.032506015],"study_design_scores_gemma":[0.0036643343,0.0007894297,0.74341536,0.00036460604,0.000006996453,0.0000077043505,0.00020219854,0.0000052025703,0.25128445,0.000039469527,0.00015199475,0.00006827391],"about_ca_topic_score_codex":0.0020518864,"about_ca_topic_score_gemma":0.00029743326,"teacher_disagreement_score":0.48030925,"about_ca_system_score_codex":0.001471268,"about_ca_system_score_gemma":0.0011631518,"threshold_uncertainty_score":0.9988402},"labels":[],"label_agreement":null},{"id":"W2339374946","doi":"10.1038/mtm.2016.22","title":"Biodistribution studies: understanding international expectations","year":2016,"lang":"en","type":"article","venue":"Molecular Therapy — Methods & Clinical Development","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Canada","funders":"","keywords":"Session (web analytics); Agency (philosophy); Biodistribution; Scopus; Regulatory agency; Medicine; Political science; Presentation (obstetrics); Food and drug administration; Library science; Medical education; Pharmacology; MEDLINE; Business; Public administration; Biotechnology; Computer science; Law; Sociology; Social science","score_opus":0.41642445970119,"score_gpt":0.569495207973406,"score_spread":0.153070748272216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2339374946","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11106802,0.001429483,0.8741986,0.009629253,0.0010495639,0.0006859971,0.0000072102494,0.00013012096,0.0018017108],"genre_scores_gemma":[0.26079667,0.006456131,0.72344154,0.0025431649,0.0004025307,0.00030787406,0.000089477144,0.000097523254,0.005865099],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9966691,0.00082369056,0.0009146853,0.00056626665,0.00063821976,0.00038802705],"domain_scores_gemma":[0.9974341,0.0014078267,0.00015690934,0.0004153253,0.0003409514,0.00024492407],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0033561501,0.00023052437,0.00048129685,0.00018995788,0.00014125164,0.00003314649,0.00023242057,0.00016278916,0.0015820033],"category_scores_gemma":[0.0016451403,0.00015230515,0.00027998735,0.0003076218,0.00027284687,0.000068506975,0.000113286325,0.00024838743,0.00013619981],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006776712,0.00032120655,0.002738425,0.000010258789,0.001548397,0.000064991626,0.0006310993,3.183311e-7,0.2519869,0.0017150709,0.00043244433,0.73987323],"study_design_scores_gemma":[0.012369912,0.00086684106,0.011382206,0.0004157718,0.00007903638,0.000055004068,0.002647909,0.000045060675,0.498047,0.013954952,0.45942482,0.00071148423],"about_ca_topic_score_codex":0.000001427464,"about_ca_topic_score_gemma":0.0000012209518,"teacher_disagreement_score":0.73916173,"about_ca_system_score_codex":0.0010392364,"about_ca_system_score_gemma":0.00036517528,"threshold_uncertainty_score":0.9993307},"labels":[],"label_agreement":null},{"id":"W2343859107","doi":"10.1016/j.jim.2016.04.010","title":"A global look into human T cell subsets before and after cryopreservation using multiparametric flow cytometry and two-dimensional visualization analysis","year":2016,"lang":"en","type":"article","venue":"Journal of Immunological Methods","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Héma-Québec","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Cryopreservation; Flow cytometry; Immunophenotyping; Biology; Peripheral blood mononuclear cell; Cytotoxic T cell; Immunology; Cytometry; Andrology; Molecular biology; Cell biology; In vitro; Medicine; Genetics","score_opus":0.04975519665246256,"score_gpt":0.44132915878342843,"score_spread":0.39157396213096585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2343859107","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9181167,0.0026793228,0.078764774,0.00017424997,0.00005625141,0.00016794326,0.0000037145783,0.000011575781,0.000025501475],"genre_scores_gemma":[0.73580617,0.00013838598,0.2637577,0.00008807792,0.000084659325,0.0000028651027,0.0000026175912,0.000010447745,0.000109061795],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9974882,0.00083292584,0.0006272466,0.00026432824,0.00052959035,0.00025773147],"domain_scores_gemma":[0.99816036,0.00057072775,0.00033423753,0.00020836055,0.00054262456,0.00018368],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024664989,0.00018271632,0.0006475256,0.00092552707,0.0001028497,0.00005238634,0.00010822834,0.00020738252,0.0006092169],"category_scores_gemma":[0.001325617,0.000104920735,0.00021072947,0.0018537747,0.0002439236,0.000240842,0.00016408662,0.00024989457,0.0000010959334],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011253968,0.00026266757,0.3389441,0.00003086673,0.00062887324,0.00006380542,0.00007499682,0.000052036765,0.5615545,0.000013556149,0.0000050214576,0.097244196],"study_design_scores_gemma":[0.00435401,0.0016810395,0.96008176,0.0001420797,0.000967262,0.0002487525,0.00005794879,0.00993587,0.020446735,0.0018036145,0.00010102216,0.00017988514],"about_ca_topic_score_codex":0.000041709536,"about_ca_topic_score_gemma":0.00000809947,"teacher_disagreement_score":0.6211377,"about_ca_system_score_codex":0.0003051391,"about_ca_system_score_gemma":0.000059236576,"threshold_uncertainty_score":0.6670498},"labels":[],"label_agreement":null},{"id":"W2345568581","doi":"10.1186/s12916-016-0623-5","title":"Cancer immunotherapy: the beginning of the end of cancer?","year":2016,"lang":"en","type":"review","venue":"BMC Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1192,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Oncolytic virus; Medicine; Immunotherapy; Cancer immunotherapy; Cancer; Adoptive cell transfer; Immune system; Immune checkpoint; Monoclonal antibody; Immunology; Cytotoxic T cell; Cancer research; Antibody; T cell; Biology; Internal medicine","score_opus":0.1089515662707683,"score_gpt":0.4438961115139246,"score_spread":0.3349445452431563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2345568581","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000095920856,0.9918358,0.000017368468,0.0021948318,0.0008560384,0.0019548421,0.000060205108,0.000025666144,0.002959363],"genre_scores_gemma":[0.0000953279,0.9793103,0.000016654309,0.00022524888,0.0016866615,0.00034221885,0.000008064556,0.00013887923,0.018176666],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965782,0.0003962917,0.0010506513,0.00037364403,0.0011990012,0.00040220606],"domain_scores_gemma":[0.99577564,0.0012747481,0.0009212157,0.0016542126,0.00027539223,0.000098793964],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013591204,0.00041504548,0.002521362,0.00020384832,0.00006412641,0.0000034378666,0.0008740386,0.00023835506,0.011332994],"category_scores_gemma":[0.0003256736,0.00014535846,0.00066785427,0.0007530347,0.0015189642,0.000019542053,0.00014690637,0.0006821399,0.000006044244],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011106716,0.000028282975,0.0005134141,0.013145115,0.0007506499,0.0000024620365,0.00032725715,2.2144762e-7,0.00144283,0.00009455609,0.0031413645,0.98044276],"study_design_scores_gemma":[0.0013760029,0.00016025754,0.00028515182,0.0861817,0.00092621974,0.0000290976,0.0000638801,0.0000016556054,0.00020371476,0.00002111685,0.9106293,0.0001219591],"about_ca_topic_score_codex":0.0023163168,"about_ca_topic_score_gemma":0.00025588897,"teacher_disagreement_score":0.9803208,"about_ca_system_score_codex":0.00031549163,"about_ca_system_score_gemma":0.002340377,"threshold_uncertainty_score":0.9895708},"labels":[],"label_agreement":null},{"id":"W2396404964","doi":"10.1186/s13048-016-0236-9","title":"Adoptive immunotherapy against ovarian cancer","year":2016,"lang":"en","type":"review","venue":"Journal of Ovarian Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Università degli Studi di Torino; Associazione Italiana per la Ricerca sul Cancro; Ministero della Salute; University Health Network","keywords":"Medicine; Immunotherapy; Debulking; Ovarian cancer; Tumor-infiltrating lymphocytes; Oncology; Adoptive cell transfer; Immunology; Cell therapy; Minimal residual disease; Disease; Cancer; Internal medicine; Immune system; T cell; Cell","score_opus":0.1929220044923839,"score_gpt":0.4955053859190608,"score_spread":0.3025833814266769,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2396404964","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000022541042,0.9794425,0.000090949965,0.0016155158,0.00076617004,0.0018618099,0.0000856062,0.000021825614,0.016093086],"genre_scores_gemma":[0.00001021296,0.9539118,0.00057984097,0.000118418335,0.0047216616,0.000121318386,0.000014480368,0.00028140604,0.04024091],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98955697,0.0022188178,0.0020334008,0.0006365513,0.004038397,0.0015158899],"domain_scores_gemma":[0.99202394,0.0017361216,0.0010331635,0.0013086731,0.0029848712,0.0009131992],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.009853118,0.0006616556,0.003736879,0.0030872575,0.00027688168,0.0002281235,0.001484379,0.0009045157,0.017832393],"category_scores_gemma":[0.0008143601,0.000401721,0.001936527,0.0020136961,0.0005756866,0.00024271,0.0002975108,0.0059159235,0.00044211114],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012149394,0.0002921371,0.000014462157,0.004368167,0.0029046289,0.0019741873,0.00016529107,1.78223e-7,0.00084759056,0.00020528924,0.012012958,0.9760002],"study_design_scores_gemma":[0.0032260926,0.0010691762,0.000046900128,0.0443619,0.00024394057,0.0012967654,0.000060697617,0.0000013156854,0.000044381075,0.00013881993,0.9491658,0.00034418114],"about_ca_topic_score_codex":0.000092296024,"about_ca_topic_score_gemma":0.0000069987186,"teacher_disagreement_score":0.975656,"about_ca_system_score_codex":0.0028226075,"about_ca_system_score_gemma":0.0106896935,"threshold_uncertainty_score":0.9998435},"labels":[],"label_agreement":null},{"id":"W2397071140","doi":"10.1158/2326-6074.cricimteatiaacr15-a176","title":"Abstract A176: Efficacy and safety of allogeneic double negative T cell as anti-AML therapy and its underlying mechanism","year":2016,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Institute of Cancer Research; University of Toronto","funders":"","keywords":"Medicine; Myeloid leukemia; Chemotherapy; Leukemia; CD8; Minimal residual disease; Stem cell; Immunotherapy; Oncology; Immunology; Transplantation; Cytotoxic T cell; Cancer research; Internal medicine; Immune system; In vitro; Biology","score_opus":0.16024945242818145,"score_gpt":0.42543022106325934,"score_spread":0.2651807686350779,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2397071140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9721044,0.020603847,0.000007680372,0.0026534284,0.000099823184,0.0013292925,0.000018232342,0.000031296615,0.0031520461],"genre_scores_gemma":[0.9179397,0.0762483,0.000029153349,0.000051895116,0.00006460758,0.00010915805,0.0000033267615,0.000050623195,0.005503179],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973913,0.00027725866,0.00035025997,0.00059535,0.0005637075,0.0008221482],"domain_scores_gemma":[0.99751216,0.0011212188,0.0000926068,0.00048955355,0.0005897707,0.00019466561],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013755779,0.00022236301,0.0005347157,0.000407421,0.00024503647,0.00002571636,0.000273974,0.00029876846,0.004648509],"category_scores_gemma":[0.0001421737,0.00015436232,0.000065639506,0.00037094095,0.00094251335,0.00012640005,0.00026186238,0.0007235779,0.000071116054],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006290541,0.00014190223,0.0017723246,0.0000916935,0.0003626324,0.000038048252,0.0006456516,5.06863e-7,0.9329979,0.0010450472,0.000047378468,0.056566373],"study_design_scores_gemma":[0.015797412,0.0014528062,0.09530194,0.00026379141,0.00001713721,0.000056317356,0.00041257378,0.000006446073,0.8828792,0.0011077912,0.0025251408,0.0001794538],"about_ca_topic_score_codex":0.0005612191,"about_ca_topic_score_gemma":0.000024830102,"teacher_disagreement_score":0.09352961,"about_ca_system_score_codex":0.00022740869,"about_ca_system_score_gemma":0.00064951414,"threshold_uncertainty_score":0.99626136},"labels":[],"label_agreement":null},{"id":"W2398298261","doi":"10.1182/blood-2015-08-664250","title":"Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":115,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"","keywords":"CD19; Immunology; Leukemia; Medicine; Cancer research; Biology; Antigen","score_opus":0.031122916195809064,"score_gpt":0.2884574029197534,"score_spread":0.2573344867239443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2398298261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931175,0.0003965478,0.00009669863,0.0024415401,0.00056499295,0.0011043927,0.000054154905,0.00009213482,0.0021320211],"genre_scores_gemma":[0.9906903,0.00010275271,0.00023796334,0.00050774787,0.0011884597,0.00006612181,0.000015034922,0.00007477648,0.007116874],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971758,0.00020726943,0.00027029475,0.0005276691,0.0010913474,0.00072763267],"domain_scores_gemma":[0.9979788,0.00008644889,0.000078822515,0.0009090271,0.00025117042,0.00069573143],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007925529,0.0002932919,0.0004446889,0.00015795098,0.00010391856,0.00005345938,0.0003986944,0.00016647964,0.0007601765],"category_scores_gemma":[0.00014091656,0.00020810959,0.0002159588,0.00023258192,0.00014359529,0.0000649062,0.00027991168,0.0005573553,0.00038000464],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060233823,0.0006221032,0.001600418,0.00003175984,0.0002678672,0.00078184286,0.00032857063,0.00006661882,0.9894677,0.0000036705653,0.0021109085,0.004116194],"study_design_scores_gemma":[0.0070602493,0.00087397295,0.023254795,0.00002387993,0.0003384589,0.00027394955,0.00019059223,0.00023773867,0.96020544,0.000025847085,0.0072211055,0.00029397805],"about_ca_topic_score_codex":0.0006660067,"about_ca_topic_score_gemma":0.000055965156,"teacher_disagreement_score":0.029262276,"about_ca_system_score_codex":0.00018639337,"about_ca_system_score_gemma":0.0004936171,"threshold_uncertainty_score":0.8486463},"labels":[],"label_agreement":null},{"id":"W2413352928","doi":"10.1016/j.exphem.2016.06.002","title":"Overexpression of LMO2 causes aberrant human T-Cell development in vivo by three potentially distinct cellular mechanisms","year":2016,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Stichting Kinderen Kankervrij","keywords":"Progenitor cell; Biology; Haematopoiesis; CD8; Cell biology; T cell; Stem cell; CD34; Cancer research; Immunology; Molecular biology; Immune system","score_opus":0.02300132305908279,"score_gpt":0.3063083605959264,"score_spread":0.2833070375368436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2413352928","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99254507,0.0016499369,0.0014604963,0.00009893658,0.00011383324,0.0006079729,0.000011822104,0.00004095826,0.0034709964],"genre_scores_gemma":[0.9944348,0.000008224282,0.0011515098,0.00003920504,0.000021895765,0.000090014095,0.000019822279,0.000046946203,0.004187634],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99799573,0.00008208326,0.00055475073,0.00044005038,0.00045766003,0.00046973475],"domain_scores_gemma":[0.9992129,0.00006782899,0.00013353923,0.00038463538,0.000043478096,0.00015757297],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001848009,0.00024485635,0.00055987504,0.00016010956,0.00007428526,0.000006150976,0.00019994583,0.00017614348,0.010214567],"category_scores_gemma":[0.0000129343925,0.00017434305,0.00009522864,0.00010221534,0.00018094585,0.00005841328,0.00020302573,0.00013205192,0.00005138302],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00041751214,0.0010481525,0.002220445,0.0000832661,0.0000363924,0.00012509608,0.000391025,5.9390306e-8,0.99172586,0.0027138938,0.0008952489,0.00034307444],"study_design_scores_gemma":[0.0038564652,0.00047271705,0.0002143612,0.000296115,0.000007313432,0.000079525336,0.00019819828,0.000004311579,0.99269015,0.0002637907,0.001725172,0.00019185522],"about_ca_topic_score_codex":0.00014215798,"about_ca_topic_score_gemma":0.000058271864,"teacher_disagreement_score":0.010163184,"about_ca_system_score_codex":0.00021696543,"about_ca_system_score_gemma":0.00010077371,"threshold_uncertainty_score":0.99069023},"labels":[],"label_agreement":null},{"id":"W2416659570","doi":"10.1038/mto.2015.14","title":"Chimeric antigen receptor–engineered T cells as oncolytic virus carriers","year":2015,"lang":"en","type":"article","venue":"Molecular Therapy — Oncolytics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster University Medical Centre","funders":"","keywords":"Oncolytic virus; Chimeric antigen receptor; Adoptive cell transfer; Virus; Immune system; Antigen; Cancer research; Antibody; Immunology; Receptor; Biology; Immunotherapy; Virology; T cell","score_opus":0.035945221340119994,"score_gpt":0.3239435815978033,"score_spread":0.2879983602576833,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2416659570","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9718275,0.003859696,0.001428251,0.001025307,0.0009406494,0.00202627,0.000027839973,0.0003198254,0.018544646],"genre_scores_gemma":[0.95075554,0.004485335,0.005495506,0.0054790997,0.0009332865,0.0001742706,0.00016077815,0.000538556,0.031977605],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99613225,0.00021379947,0.0005525968,0.00066331733,0.0014989367,0.0009390952],"domain_scores_gemma":[0.99694407,0.0000905372,0.00014315457,0.0012275871,0.00043900934,0.0011556306],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0007241262,0.0005275937,0.0008027705,0.0003502809,0.00010344715,0.000101747995,0.00046583242,0.0003557764,0.0027640134],"category_scores_gemma":[0.00016210675,0.00050102436,0.00038158675,0.0010444215,0.00023036807,0.00009852896,0.0000961583,0.00069815613,0.0011878733],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000882598,0.0004280802,0.00023490559,0.00002991113,0.00049622287,0.0005312213,0.0011907878,0.00033632832,0.962043,0.00007633386,0.005524746,0.028225904],"study_design_scores_gemma":[0.00501947,0.0018199303,0.000070570604,0.000048144226,0.00005705622,0.00009332135,0.00036294688,0.0008488349,0.62851584,0.00012575535,0.36261034,0.000427776],"about_ca_topic_score_codex":0.00041689817,"about_ca_topic_score_gemma":0.000008710991,"teacher_disagreement_score":0.3570856,"about_ca_system_score_codex":0.00093411416,"about_ca_system_score_gemma":0.0014273454,"threshold_uncertainty_score":0.9997441},"labels":[],"label_agreement":null},{"id":"W2485297274","doi":"10.1158/1538-7445.am2016-846","title":"Abstract 846: Improving T-cell receptor clonotyping of T-cell lymphomas using hybrid-Capture and next-generation sequencing","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University Health Network; Calgary Laboratory Services","funders":"","keywords":"T-cell receptor; Biology; Sanger sequencing; T cell; Molecular biology; DNA sequencing; Gene rearrangement; Computational biology; Genetics; Gene","score_opus":0.1702651020974911,"score_gpt":0.37797427230038,"score_spread":0.2077091702028889,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2485297274","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928238,0.0034845783,0.00022265584,0.00054429664,0.00016960445,0.0007400897,0.000033494474,0.000032517986,0.0019489952],"genre_scores_gemma":[0.99223715,0.001641193,0.00079464965,0.00006462491,0.0007622065,0.000050824645,0.000011045344,0.000078254765,0.0043600425],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99710727,0.00016268849,0.00039941815,0.00058880367,0.0009645908,0.00077721],"domain_scores_gemma":[0.9980743,0.00030909837,0.00012094003,0.0005103059,0.00065919553,0.00032618042],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001738792,0.00020163324,0.00035886664,0.0004281122,0.00022557439,0.0000869542,0.00020033373,0.00015364587,0.002444728],"category_scores_gemma":[0.00022349013,0.00015346853,0.00009298107,0.00040412042,0.0003301872,0.00029974952,0.00016074686,0.000493919,0.000026798723],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034788743,0.00004625761,0.0010374786,0.00051246036,0.000027702397,0.00002552683,0.00039581282,0.000008494758,0.9486371,0.000010939721,0.0004839158,0.04846641],"study_design_scores_gemma":[0.0020929466,0.00016045728,0.00024526002,0.00043435907,0.000018561244,0.000022497123,0.0003407623,0.001267085,0.9926419,0.000020507277,0.0025818776,0.00017373207],"about_ca_topic_score_codex":0.00339863,"about_ca_topic_score_gemma":0.00007168616,"teacher_disagreement_score":0.048292678,"about_ca_system_score_codex":0.0016212001,"about_ca_system_score_gemma":0.0016820247,"threshold_uncertainty_score":0.99846715},"labels":[],"label_agreement":null},{"id":"W2485508368","doi":"10.1186/s12967-016-0791-2","title":"Melanoma and immunotherapy bridge 2015","year":2016,"lang":"en","type":"article","venue":"Journal of Translational Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Sunnybrook Health Science Centre; University Health Network; Royal Victoria Hospital; Princess Margaret Cancer Centre; Health Sciences Centre","funders":"Hungarian Scientific Research Fund; Harry J. Lloyd Charitable Trust; Melanoma Research Alliance; GlaxoSmithKline","keywords":"Melanoma; Ipilimumab; Immunotherapy; Immune checkpoint; Tumor microenvironment; Cancer research; Medicine; Cancer immunotherapy; Cancer; PI3K/AKT/mTOR pathway; Blockade; Immune system; Immunology; Internal medicine; Biology; Receptor; Signal transduction","score_opus":0.041907919345375626,"score_gpt":0.35480410493217523,"score_spread":0.3128961855867996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2485508368","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.72866935,0.015699925,0.0071625323,0.2426652,0.00045942835,0.00033143378,0.000011647673,0.000017368888,0.0049831024],"genre_scores_gemma":[0.99103796,0.0026964226,0.0008498945,0.00064681517,0.0013451341,0.0000015265088,0.0000024570375,0.000022641643,0.0033971623],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99846715,0.00005156761,0.0004700651,0.00010095184,0.00075549254,0.00015476039],"domain_scores_gemma":[0.9988484,0.0003692031,0.00013975159,0.00011929475,0.00032073076,0.00020266991],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00079533434,0.00010675213,0.00035975038,0.00025551356,0.00003184641,0.000004588665,0.00007898622,0.00005999957,0.005440474],"category_scores_gemma":[0.00009943558,0.000054954882,0.0000893961,0.00012241994,0.00022149037,0.00012180921,0.0000043670575,0.00018342228,0.000008625023],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028233987,0.000085606494,0.029912064,0.00003232193,0.00030311727,0.00012255216,0.00049045164,4.9235354e-7,0.64684683,0.00042811738,0.006343299,0.31261176],"study_design_scores_gemma":[0.022332264,0.0033124909,0.74338835,0.00092588185,0.0001271528,0.0041336347,0.000043235308,0.000022956187,0.004664739,0.0034069861,0.2174995,0.00014279825],"about_ca_topic_score_codex":0.0000093787185,"about_ca_topic_score_gemma":0.000002408019,"teacher_disagreement_score":0.7134763,"about_ca_system_score_codex":0.00004113758,"about_ca_system_score_gemma":0.00014789184,"threshold_uncertainty_score":0.9954687},"labels":[],"label_agreement":null},{"id":"W2486023327","doi":"10.1002/stem.2465","title":"Efficient Regeneration of Human Vα24+ Invariant Natural Killer T Cells and Their Anti-Tumor Activity In Vivo","year":2016,"lang":"en","type":"article","venue":"Stem Cells","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Health Sciences Centre Foundation","keywords":"Biology; Reprogramming; Induced pluripotent stem cell; Cytotoxic T cell; Cancer immunotherapy; Immunotherapy; Natural killer T cell; Cell biology; Cancer research; In vivo; Immunology; Immune system; In vitro; Cell; T cell; Embryonic stem cell; Biochemistry","score_opus":0.021652407618799805,"score_gpt":0.2746484096368931,"score_spread":0.25299600201809325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2486023327","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972958,0.00017607778,0.00006597875,0.00025957945,0.00034986847,0.0006350995,0.00001298067,0.000019271105,0.0011853763],"genre_scores_gemma":[0.98764175,0.000054096767,0.000028319042,0.000043673193,0.00009199715,0.000011192721,0.0000011087997,0.000024915664,0.012102961],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99867046,0.00015482242,0.0002603527,0.00033140197,0.00028796025,0.00029500428],"domain_scores_gemma":[0.9991822,0.0001521364,0.00010010826,0.00037446024,0.00008844236,0.00010261328],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053046906,0.00016581405,0.00037174998,0.00018443404,0.000049115733,0.000015371334,0.000090013076,0.00007615718,0.0005759469],"category_scores_gemma":[0.000007940665,0.00009990468,0.00007142644,0.00018503769,0.00012940449,0.000042184976,0.00007750501,0.00016748138,0.000014706882],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017518608,0.00016677892,0.00059785874,0.00009206875,0.000024637327,0.000021673552,0.0004494863,0.000015623284,0.9929197,0.00005089155,0.00039014284,0.005095957],"study_design_scores_gemma":[0.0019222419,0.00023797569,0.0023051356,0.00017731632,0.000008750277,0.000009865019,0.000103695114,0.000871706,0.99327147,0.000010857752,0.00096227654,0.000118708835],"about_ca_topic_score_codex":0.00010761906,"about_ca_topic_score_gemma":0.00006384138,"teacher_disagreement_score":0.010917584,"about_ca_system_score_codex":0.00012041778,"about_ca_system_score_gemma":0.00007429091,"threshold_uncertainty_score":0.63062143},"labels":[],"label_agreement":null},{"id":"W2488182312","doi":"10.1038/icb.2016.45","title":"Purity of transferred CD8<sup>+</sup> T cells is crucial for safety and efficacy of combinatorial tumor immunotherapy in the absence of SHP‐1","year":2016,"lang":"en","type":"article","venue":"Immunology and Cell Biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Medical Research Council; Cardiff University; Wellcome Trust; Wellcome","keywords":"Adoptive cell transfer; Cytotoxic T cell; CD8; Cancer research; Immunology; Immunotherapy; Biology; T cell; Cell biology; Immune system; Biochemistry; In vitro","score_opus":0.014596609812870911,"score_gpt":0.28392477736033767,"score_spread":0.26932816754746675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2488182312","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951513,0.002782607,0.00009681323,0.00051367976,0.00015151076,0.0007927242,0.00009590309,0.000005299764,0.00041020737],"genre_scores_gemma":[0.9955832,0.004063713,0.00005493267,0.00007868026,0.000042138872,0.000020718864,0.0000072626913,0.000011463138,0.00013789712],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998552,0.0003071323,0.0005162736,0.00026226084,0.000080346676,0.0002819407],"domain_scores_gemma":[0.9981786,0.0012462336,0.00012453075,0.0003261457,0.00009869492,0.000025792948],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006367734,0.00014800577,0.00063937186,0.00012684341,0.0000417952,0.000001669867,0.0002158273,0.00026363437,0.00027489226],"category_scores_gemma":[0.00006196709,0.00008939141,0.00011284662,0.00011672752,0.0014200892,0.000024958734,0.000037719652,0.00019491464,9.4373763e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012727372,0.0003709496,0.003699356,0.000084469626,0.00012388111,0.000002251823,0.0018956708,2.5102415e-7,0.9550005,0.0015460597,0.000015228635,0.024533996],"study_design_scores_gemma":[0.022921747,0.004916725,0.020791914,0.00007850151,0.000037297603,0.00002646562,0.00038148134,0.000018919072,0.93945384,0.003085007,0.008150621,0.00013746637],"about_ca_topic_score_codex":0.00015683628,"about_ca_topic_score_gemma":0.0000058140613,"teacher_disagreement_score":0.02439653,"about_ca_system_score_codex":0.000016389065,"about_ca_system_score_gemma":0.000100832265,"threshold_uncertainty_score":0.52323776},"labels":[],"label_agreement":null},{"id":"W2489660615","doi":"10.1182/blood.v126.23.3252.3252","title":"Proxe: A Public Repository of Xenografts to Facilitate Studies of Biology and Expedite Preclinical Drug Development in Leukemia and Lymphoma","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Lymphoma; Context (archaeology); Cancer research; Biology; Immunophenotyping; Transplantation; Leukemia; Computational biology; Medicine; Immunology; Flow cytometry; Internal medicine","score_opus":0.14710807587399818,"score_gpt":0.3776092034881212,"score_spread":0.23050112761412303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2489660615","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99347204,0.005205724,0.0000017545034,0.00028168378,0.000058730897,0.00046508652,0.0000026014213,0.000010977679,0.0005014012],"genre_scores_gemma":[0.9972112,0.00021181177,0.0012054878,0.000028510573,0.000051484833,0.000067745335,0.0000028119637,0.0000084100375,0.0012125202],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99883616,0.00011634157,0.0004243887,0.00024233492,0.00019123123,0.00018951728],"domain_scores_gemma":[0.999149,0.0002023694,0.00006386351,0.00018268071,0.00022328527,0.0001787704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00085992017,0.000093848634,0.0004043339,0.0001801097,0.000017147517,0.000004633116,0.000059659305,0.00006281285,0.0000038864255],"category_scores_gemma":[0.0006119595,0.00007467203,0.00002095368,0.00016338013,0.00025969392,0.00003306832,0.00017515245,0.00006965682,9.280506e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010499422,0.0009001716,0.7950009,0.0005745866,0.0005107577,0.000055364348,0.040452123,2.9519816e-7,0.10549796,0.000028429566,0.00066134305,0.055268146],"study_design_scores_gemma":[0.03985304,0.004982834,0.5167046,0.0008132893,0.00015570411,0.000284184,0.009224445,0.000025110812,0.37973532,0.00034406467,0.047379717,0.0004976609],"about_ca_topic_score_codex":0.00007946495,"about_ca_topic_score_gemma":0.00007498313,"teacher_disagreement_score":0.27829626,"about_ca_system_score_codex":0.00007188382,"about_ca_system_score_gemma":0.00048707853,"threshold_uncertainty_score":0.30450374},"labels":[],"label_agreement":null},{"id":"W2503724939","doi":"10.1158/1538-7445.am2016-2300","title":"Abstract 2300: Human CD133-specific chimeric antigen receptor (CAR) modified T cells target patient-derived glioblastoma brain tumors","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McMaster University","funders":"","keywords":"Chimeric antigen receptor; Cancer research; Antigen; Immunoglobulin light chain; Flow cytometry; CD28; Single-chain variable fragment; Biology; CD8; Monoclonal antibody; Antibody; T cell; Immunology; Immune system","score_opus":0.06752122905625818,"score_gpt":0.3716309087200256,"score_spread":0.3041096796637674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2503724939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987341,0.0010561829,0.000031211734,0.004352222,0.0003583645,0.0019311121,0.00015955635,0.00017101156,0.0045993514],"genre_scores_gemma":[0.9828219,0.0013701265,0.00012862358,0.0001833437,0.0010306237,0.0004654693,0.000038805214,0.0002053765,0.01375576],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99324435,0.00048134162,0.00067884667,0.0011667449,0.002475381,0.001953312],"domain_scores_gemma":[0.9961975,0.00055455544,0.00014552279,0.0013377841,0.00084979675,0.0009147977],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0014872977,0.0004303375,0.00069954916,0.00087717717,0.0005043219,0.0001277633,0.0007180665,0.00025928603,0.047370005],"category_scores_gemma":[0.00019388147,0.00031935427,0.00028219752,0.0012886728,0.0009474653,0.00023325175,0.00032979366,0.0011847871,0.0015885994],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019205378,0.00025966333,0.00072563294,0.00010354175,0.00012848196,0.00015425887,0.00066498684,0.0000063002685,0.893455,0.000051405335,0.06663667,0.035893477],"study_design_scores_gemma":[0.0027929791,0.0012838272,0.0065249624,0.00040799164,0.0000048932375,0.00001171551,0.00035000604,0.000007815833,0.86872256,0.0001555473,0.119373925,0.00036377716],"about_ca_topic_score_codex":0.00081438135,"about_ca_topic_score_gemma":0.00007695466,"teacher_disagreement_score":0.05273726,"about_ca_system_score_codex":0.0012122021,"about_ca_system_score_gemma":0.0007657516,"threshold_uncertainty_score":0.99992585},"labels":[],"label_agreement":null},{"id":"W2506102763","doi":"10.1158/1538-7445.am2016-1481","title":"Abstract 1481: Preclinical validation of a novel CD133/CD3 bispecific T-cell engager (BiTE) antibody to target patient-derived glioblastoma cells","year":2016,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McMaster University","funders":"","keywords":"Antigen; Cancer research; Flow cytometry; Antibody; CD3; Monoclonal antibody; Population; Peripheral blood mononuclear cell; Immunophenotyping; Medicine; Cancer; Immunology; Biology; Internal medicine; In vitro; CD8","score_opus":0.11999431366524654,"score_gpt":0.43986873323908154,"score_spread":0.319874419573835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2506102763","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99192435,0.00034823344,0.00044554335,0.0016998494,0.00031461677,0.0020038784,0.00019333321,0.000059084883,0.0030111198],"genre_scores_gemma":[0.9914595,0.0007063936,0.00066566304,0.0000938173,0.000506076,0.00024434883,0.000024116385,0.0001102532,0.0061898693],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.994613,0.00039527487,0.00077379245,0.0008772758,0.0022256086,0.0011150608],"domain_scores_gemma":[0.99491954,0.0017031295,0.00014728766,0.0010799274,0.0014449779,0.0007051682],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0025973707,0.00026512495,0.00058005156,0.00077349925,0.00016194671,0.00005895204,0.0004786429,0.00025768077,0.013376728],"category_scores_gemma":[0.00090799335,0.00020013678,0.00023104693,0.0011308878,0.0004390719,0.00017702911,0.00030999456,0.0009755026,0.00052392355],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038084888,0.00096589915,0.0014533433,0.00023432382,0.000081310776,0.000057834342,0.00067582494,0.00002290179,0.9648573,0.00001204171,0.004884676,0.022946075],"study_design_scores_gemma":[0.003634847,0.0017509033,0.004116579,0.00045831376,0.000013220215,0.0000072466128,0.00017075118,0.000017202336,0.9449412,0.000023014542,0.04465321,0.00021346439],"about_ca_topic_score_codex":0.00029712834,"about_ca_topic_score_gemma":0.000029057384,"teacher_disagreement_score":0.039768536,"about_ca_system_score_codex":0.00056054734,"about_ca_system_score_gemma":0.000910837,"threshold_uncertainty_score":0.98752517},"labels":[],"label_agreement":null},{"id":"W2507694805","doi":"10.1182/blood.v118.21.2470.2470","title":"Effects of LMO2 on Human T-Cell Development Are Modulated by Notch Signaling","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; University of Toronto","funders":"","keywords":"Biology; Cancer research; Myeloid; Haematopoiesis; Leukemia; Myeloid leukemia; Progenitor cell; Severe combined immunodeficiency; Stem cell; Immunology; Hematopoietic stem cell; Genetic enhancement; Cell biology; Gene; Genetics","score_opus":0.03933927042758498,"score_gpt":0.2833253290993687,"score_spread":0.24398605867178372,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2507694805","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99074835,0.00023991866,0.000015769356,0.000011861492,0.000030394722,0.00045833277,0.0000015713873,0.000043828753,0.008449982],"genre_scores_gemma":[0.9950774,0.000008740317,0.00040909022,0.000066563276,0.00003929974,0.000023707864,0.000014231379,0.000035009358,0.004325997],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998895,0.000045122746,0.00021349991,0.0002226667,0.00037008696,0.0002536637],"domain_scores_gemma":[0.999423,0.000061951796,0.00007529209,0.0002351215,0.00008412054,0.00012047144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017183778,0.00013194198,0.00025850814,0.000103851446,0.000050243438,0.0000048014153,0.000109368775,0.00009003747,0.0008850147],"category_scores_gemma":[0.000025897609,0.000115685514,0.00005960374,0.0001407886,0.00003418228,0.000015880805,0.000035409234,0.00017991062,0.000057655612],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001329201,0.0020264545,0.0037170614,0.00032317493,0.00012853689,0.00007798626,0.0008316594,6.415263e-7,0.9915064,0.000004359075,0.00020362633,0.0010471557],"study_design_scores_gemma":[0.0043501677,0.00057149003,0.011669277,0.00022709639,0.00006658005,0.0000041504536,0.00002853881,0.0000052283,0.98252106,0.000017198428,0.0004295263,0.000109682434],"about_ca_topic_score_codex":0.000050179857,"about_ca_topic_score_gemma":0.0000026796126,"teacher_disagreement_score":0.008985359,"about_ca_system_score_codex":0.000033060944,"about_ca_system_score_gemma":0.00005111742,"threshold_uncertainty_score":0.96902907},"labels":[],"label_agreement":null},{"id":"W2507731619","doi":"10.1182/blood.v118.21.87.87","title":"Gene Risk Scores Based on Expression of 6 Genes Quanitated by Nuclease Protection Assay in Formalin Fixed Paraffin-Embedded Tissue (FFPET) Specimens From CHOP and RCHOP Treated Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Predict Outcome: An ECOG and SWOG Study","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Diffuse large B-cell lymphoma; CHOP; Rituximab; Oncology; Internal medicine; Proportional hazards model; International Prognostic Index; Medicine; Pathology; Biology; Immunohistochemistry; Lymphoma; Immunology","score_opus":0.020916844062654837,"score_gpt":0.255847837616466,"score_spread":0.23493099355381117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2507731619","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959505,0.00016552622,0.000035468354,0.0000054263305,0.000024261048,0.0032506362,0.00043296066,0.000078160396,0.000057048444],"genre_scores_gemma":[0.99876964,0.000057696976,0.0005557462,0.000021069725,0.00003257956,0.00012998791,0.00027090474,0.00007952419,0.00008284661],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99733394,0.0005482404,0.00051937834,0.0006245419,0.0005728285,0.0004010694],"domain_scores_gemma":[0.998597,0.00011546188,0.00026366854,0.00057715795,0.0001432858,0.00030342236],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00045030733,0.0003515208,0.0005652104,0.00031424998,0.00011126623,0.000031180396,0.00011920876,0.00016431903,0.00020544008],"category_scores_gemma":[0.0000977929,0.0002663206,0.00004005495,0.00028031296,0.00008509339,0.00016858187,0.00006420531,0.00022695916,0.000004194873],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009062744,0.044588536,0.7751779,0.00006340616,0.0001014015,0.0000649505,0.002056731,0.0000017928012,0.16561726,1.2062962e-7,0.000013130702,0.0032520574],"study_design_scores_gemma":[0.09085759,0.0066532237,0.55029804,0.00009832845,0.00021637113,0.0000018181283,0.00029643596,0.00120331,0.35015544,0.0000032492435,0.000013750743,0.00020245003],"about_ca_topic_score_codex":0.0019846247,"about_ca_topic_score_gemma":0.0005099132,"teacher_disagreement_score":0.22487983,"about_ca_system_score_codex":0.000058777347,"about_ca_system_score_gemma":0.000050491424,"threshold_uncertainty_score":0.9999789},"labels":[],"label_agreement":null},{"id":"W2508398069","doi":"10.1007/978-1-4939-3801-8_11","title":"Viral Engineering of Chimeric Antigen Receptor Expression on Murine and Human T Lymphocytes","year":2016,"lang":"en","type":"article","venue":"Methods in molecular biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster University Medical Centre","funders":"","keywords":"Chimeric antigen receptor; Adoptive cell transfer; Receptor; Antigen; Virology; Biology; Immunology; Cancer research; Molecular biology; Immunotherapy; Immune system; T cell; Genetics","score_opus":0.02493786642087454,"score_gpt":0.4078942568493336,"score_spread":0.3829563904284591,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2508398069","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90359765,0.0006389849,0.09491248,0.00010973255,0.000070818794,0.0002075447,0.000002654277,0.000019936197,0.00044020818],"genre_scores_gemma":[0.39427176,0.00044133398,0.6045372,0.000104526145,0.000082168306,0.000035438876,0.000008911583,0.00004519194,0.0004735174],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99883544,0.00038955122,0.00020936837,0.0002624507,0.00007863595,0.00022456307],"domain_scores_gemma":[0.999374,0.00022046543,0.000044314187,0.0002743817,0.000025582247,0.000061288076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006713562,0.0001183257,0.00032210778,0.00024219025,0.000014130203,0.0000019301638,0.00008440748,0.00012309827,0.00032922887],"category_scores_gemma":[0.00032568874,0.000078241756,0.000053231895,0.00012597897,0.000117889715,0.000010874069,0.000087697845,0.00010296186,0.000002666536],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015776185,0.000041971394,0.005266518,0.000025410576,0.000023252584,0.00001041111,0.000035855668,0.0000015609982,0.9280871,0.0003694494,0.0000053569925,0.06597536],"study_design_scores_gemma":[0.001418444,0.0006794874,0.004679218,0.00012877896,0.000004585436,0.000010490694,0.0000043500722,0.000027660799,0.9892594,0.00032750305,0.0033758034,0.000084238614],"about_ca_topic_score_codex":0.000027868362,"about_ca_topic_score_gemma":3.4836893e-7,"teacher_disagreement_score":0.50962466,"about_ca_system_score_codex":0.00005280148,"about_ca_system_score_gemma":0.000021077612,"threshold_uncertainty_score":0.3604825},"labels":[],"label_agreement":null},{"id":"W2508616096","doi":"10.1172/jci86437","title":"BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Investigation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":215,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Structural Genomics Consortium; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; European Federation of Pharmaceutical Industries and Associations; University of Toronto; Ministero dello Sviluppo Economico; Genome Canada; Fundação de Amparo à Pesquisa do Estado de São Paulo; Ontario Ministry of Economic Development and Innovation; Novartis Pharma; Ontario Genomics Institute; Wellcome Trust; Pfizer; Princess Margaret Cancer Foundation; National Institutes of Health; Ontario Genomics","keywords":"Adoptive immunotherapy; Immunotherapy; Bromodomain; Persistence (discontinuity); Adoptive cell transfer; Function (biology); Cancer research; Immunology; Biology; T cell; Computational biology; Immune system; Cell biology; Epigenetics; Genetics","score_opus":0.12780423115335657,"score_gpt":0.3737692853268149,"score_spread":0.24596505417345835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2508616096","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99110186,0.00043662972,0.004297529,0.0032110324,0.00016606586,0.00019307631,0.0000015875955,0.000007116275,0.00058510795],"genre_scores_gemma":[0.9943363,0.0022985574,0.0018614732,0.00049843924,0.0003468935,0.0000038092658,0.0000018896937,0.000013302017,0.0006393323],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99792564,0.00034456473,0.0009802633,0.00017270955,0.00043151123,0.00014532618],"domain_scores_gemma":[0.99820596,0.00068127445,0.0005006778,0.00012001722,0.00030427272,0.00018779999],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026726592,0.000098508244,0.00038664378,0.00018655177,0.000032139542,0.000019398809,0.000050224786,0.00015723138,0.00015699575],"category_scores_gemma":[0.00041941353,0.00006421496,0.00014639563,0.00017405442,0.00031371063,0.0005238177,0.000015110242,0.000373927,0.0000058395335],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031802016,0.00020850934,0.031414088,0.00004201181,0.000057867608,0.000024566281,0.000532445,0.00002699497,0.8835962,0.00020046646,0.0002197649,0.0804969],"study_design_scores_gemma":[0.03136184,0.013968758,0.44802213,0.0034092169,0.00020173647,0.00026738716,0.0011939212,0.0036417386,0.38361287,0.11145806,0.0023691864,0.0004931661],"about_ca_topic_score_codex":0.000009631982,"about_ca_topic_score_gemma":0.000007826032,"teacher_disagreement_score":0.4999833,"about_ca_system_score_codex":0.00009735835,"about_ca_system_score_gemma":0.00022593164,"threshold_uncertainty_score":0.261861},"labels":[],"label_agreement":null},{"id":"W2512229218","doi":"10.1093/intimm/dxq203","title":"Column-free methods for the fast and versatile isolation of highly purified, functional and expandable human regulatory T cell populations (LL3-3)","year":2010,"lang":"en","type":"article","venue":"International Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stemcell Technologies","funders":"","keywords":"Population; Interleukin-7 receptor; Chemistry; IL-2 receptor; Immunology; Cell biology; Molecular biology; Biology; T cell; Medicine; Immune system","score_opus":0.04206263198002131,"score_gpt":0.3701477093093158,"score_spread":0.3280850773292945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2512229218","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9733186,0.0006923035,0.01741136,0.0030936943,0.0011169392,0.00063043804,0.000047150636,0.000027605636,0.0036619415],"genre_scores_gemma":[0.97269744,0.000051016803,0.0147542665,0.00008232388,0.00021210233,0.00008884403,0.00010218132,0.00001862148,0.011993218],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99923503,0.00005231861,0.00023771566,0.00018722292,0.00015836036,0.0001293733],"domain_scores_gemma":[0.9988112,0.00045016417,0.00010554104,0.00029380346,0.00030641208,0.000032878324],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004436865,0.000086563196,0.00015461883,0.0001546071,0.00015790215,0.000023400187,0.0001416641,0.00012231588,0.0011940555],"category_scores_gemma":[0.00019650867,0.00007272636,0.000054678465,0.00006366397,0.00031504806,0.00009230895,0.00010934216,0.00024414304,0.0000020541147],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042773946,0.00007041862,0.00550515,0.000013565668,0.00016134397,3.9798812e-7,0.00020361067,0.0000085371985,0.96231514,0.014551651,0.0008769255,0.015865503],"study_design_scores_gemma":[0.009058965,0.00084060064,0.7086446,0.00003161462,0.00018326925,0.00017837917,0.0005953438,0.009257289,0.15425245,0.019349443,0.09736173,0.00024627562],"about_ca_topic_score_codex":0.00021770099,"about_ca_topic_score_gemma":0.00012310542,"teacher_disagreement_score":0.80806273,"about_ca_system_score_codex":0.00003868132,"about_ca_system_score_gemma":0.000057517613,"threshold_uncertainty_score":0.99971896},"labels":[],"label_agreement":null},{"id":"W2513504681","doi":"10.1158/2326-6066.cir-16-0179","title":"Zeroing in on Tumor-Reactive TILs","year":2016,"lang":"en","type":"letter","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Adoptive cell transfer; Cancer immunotherapy; Cancer; Immunotherapy; Cancer research; Adoptive immunotherapy; Tumor cells; Medicine; Immunology; T cell; Immune system; Internal medicine","score_opus":0.11938313846503769,"score_gpt":0.4404190876862732,"score_spread":0.3210359492212355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2513504681","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06681279,0.0057134703,0.0000017219321,0.8585442,0.0009120904,0.0023903633,0.00009575296,0.00009805314,0.06543161],"genre_scores_gemma":[0.018870467,0.008032167,0.000028824812,0.4017226,0.017541712,0.004207599,0.0002788427,0.0006910044,0.5486268],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9925965,0.0013521087,0.00052616856,0.0012899003,0.0016852199,0.0025500671],"domain_scores_gemma":[0.99514556,0.002187454,0.000118875985,0.0016578634,0.0007559775,0.00013426835],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.0020906292,0.00048544956,0.0011231216,0.0025479593,0.00017395701,0.000052777974,0.0009046586,0.0014518446,0.015100274],"category_scores_gemma":[0.0006311296,0.00037926654,0.00023865409,0.0009995439,0.0014814112,0.00008973372,0.00043746672,0.014619197,0.0021475295],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028282036,0.000087543725,0.001284342,0.00022197825,0.00052868866,0.0061522895,0.00025445397,2.1650021e-7,0.17417865,0.000034770987,0.76223874,0.052190136],"study_design_scores_gemma":[0.0030196982,0.001096122,0.0024270394,0.0018465022,0.00001839335,0.00017994618,0.000083619445,0.0000025940499,0.02393514,0.0003546028,0.96669954,0.00033678729],"about_ca_topic_score_codex":0.001392184,"about_ca_topic_score_gemma":0.00008459295,"teacher_disagreement_score":0.4831952,"about_ca_system_score_codex":0.0040946687,"about_ca_system_score_gemma":0.0023918783,"threshold_uncertainty_score":0.99986595},"labels":[],"label_agreement":null},{"id":"W2514206384","doi":"10.1158/2159-8290.cd-16-0789","title":"Activating TCR Signaling to Thwart T-ALL","year":2016,"lang":"en","type":"letter","venue":"Cancer Discovery","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"Canadian Institutes of Health Research; Leukemia and Lymphoma Society","keywords":"T-cell receptor; CD3; T cell; Biology; Apoptosis; Cell biology; Negative selection; Cancer research; Programmed cell death; Leukemia; Immunology; Cancer; CD8; Immune system; Gene; Genetics","score_opus":0.05794416019105975,"score_gpt":0.35355197102179325,"score_spread":0.2956078108307335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2514206384","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011920075,0.001543951,0.00065189356,0.95586777,0.0015268369,0.0016848285,0.00023172025,0.0001331415,0.026439805],"genre_scores_gemma":[0.0023908725,0.0004441819,0.000104710365,0.7038923,0.027033024,0.00049178675,0.00013269296,0.00021700014,0.26529345],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967474,0.00012316398,0.00040359795,0.00078760175,0.0010048406,0.0009334034],"domain_scores_gemma":[0.9981884,0.0005094096,0.00015672758,0.00081307004,0.00014951923,0.00018289039],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00036056648,0.00044047032,0.00094382523,0.0002997322,0.00006930991,0.00014948522,0.00033640524,0.0005356902,0.0068616304],"category_scores_gemma":[0.00014111525,0.0003128282,0.00041982942,0.00023189448,0.00016136547,0.00023715926,0.00018814144,0.0017517607,0.00025987864],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012528042,0.000011313247,0.00013502492,0.0004672709,0.00049874705,0.00033437094,0.0002429187,0.000005864276,0.10348713,0.0000145212325,0.8706155,0.02293457],"study_design_scores_gemma":[0.0029639371,0.0001002728,0.000022275473,0.0021057583,0.00010656747,0.000017593273,0.000024838635,0.0000041427097,0.026214745,0.00012877185,0.96791315,0.00039792468],"about_ca_topic_score_codex":0.0003460699,"about_ca_topic_score_gemma":0.000010642284,"teacher_disagreement_score":0.25197548,"about_ca_system_score_codex":0.0010776246,"about_ca_system_score_gemma":0.0007795686,"threshold_uncertainty_score":0.9999324},"labels":[],"label_agreement":null},{"id":"W2514926023","doi":"10.1097/cji.0000000000000134","title":"Engineering Hematopoietic Cells for Cancer Immunotherapy: Strategies to Address Safety and Toxicity Concerns","year":2016,"lang":"en","type":"review","venue":"Journal of Immunotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Blood Services; University of Toronto","funders":"","keywords":"Chimeric antigen receptor; Immunotherapy; Suicide gene; Cancer immunotherapy; Immune system; Cancer; Antigen; Cancer cell; Medicine; Cancer research; Haematopoiesis; Immunology; Genetic enhancement; Biology; Stem cell; Internal medicine; Gene","score_opus":0.04820959936286296,"score_gpt":0.38546702949439904,"score_spread":0.3372574301315361,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2514926023","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018950409,0.992594,0.0035206906,0.0003821006,0.0007802067,0.0022279683,0.00013678666,0.000043902226,0.00012482016],"genre_scores_gemma":[0.00002871885,0.9946616,0.00090402126,0.00021198932,0.0012017034,0.00013093078,0.000004363943,0.00033057368,0.0025260837],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966617,0.00014038033,0.0015683959,0.0003810257,0.0006222118,0.0006262479],"domain_scores_gemma":[0.99701595,0.00077719707,0.0008632419,0.00057368184,0.00047859843,0.0002913523],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011582997,0.0006638647,0.003288384,0.00057220715,0.00008341415,0.00015997083,0.000513647,0.00039896453,0.0016831886],"category_scores_gemma":[0.00004717987,0.00043561737,0.00111795,0.00031090385,0.00010995983,0.00019282578,0.000049814495,0.00074885535,0.000009292122],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019014593,0.000092829636,0.0000013699419,0.0056739766,0.0023608485,0.000034167704,0.00052711344,0.000009874073,0.063187405,0.000062940824,0.0006635776,0.9254844],"study_design_scores_gemma":[0.0034091715,0.0010374831,0.000005511713,0.028342444,0.0002485414,0.00041579723,0.00006269016,0.0000036685246,0.0027007193,0.000023682353,0.96331877,0.0004315353],"about_ca_topic_score_codex":0.000023636541,"about_ca_topic_score_gemma":0.0000034981053,"teacher_disagreement_score":0.9626552,"about_ca_system_score_codex":0.0006916647,"about_ca_system_score_gemma":0.0013645387,"threshold_uncertainty_score":0.99980956},"labels":[],"label_agreement":null},{"id":"W2517307419","doi":"10.1016/j.exphem.2016.06.221","title":"Stroma-free, serum-free differentiation and expansion of hematopoietic progenitors to the T cell lineage","year":2016,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stemcell Technologies","funders":"","keywords":"Progenitor cell; CD34; Biology; Haematopoiesis; Stromal cell; Molecular biology; Cell biology; T cell; CD8; CD38; CD3; Stem cell; Immunology; Antigen; Cancer research; Immune system","score_opus":0.016806643182092774,"score_gpt":0.3026090281807192,"score_spread":0.2858023849986264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2517307419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940971,0.0021293378,0.00014737714,0.0018600799,0.00018198178,0.0008500441,0.00001643138,0.000038172817,0.0006794647],"genre_scores_gemma":[0.9974451,0.000028906228,0.0005233113,0.000105807594,0.00009703173,0.00010466032,0.0000050035887,0.000031559623,0.0016586363],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986586,0.0000949603,0.00031274877,0.00030434027,0.0003339927,0.00029538624],"domain_scores_gemma":[0.99876803,0.0001327741,0.000079524456,0.00080564927,0.000056330093,0.00015770253],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00013661284,0.00016576644,0.00035504717,0.000109606284,0.000067141205,0.000008888813,0.00026403542,0.00010605355,0.0012511995],"category_scores_gemma":[0.00006441788,0.00009392534,0.00008103189,0.00012570756,0.0001690604,0.00005083681,0.0003728718,0.000096682656,0.000039254137],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004013379,0.0002725966,0.009329454,0.000093110364,0.000032500982,0.00001904014,0.0012624402,6.460531e-8,0.98393273,0.0018019106,0.0020072155,0.00084762153],"study_design_scores_gemma":[0.0028595077,0.0007812349,0.0024216375,0.000083961124,0.000017735692,0.0002291944,0.0008988589,0.000013981274,0.99189186,0.000088357185,0.00061564613,0.00009802864],"about_ca_topic_score_codex":0.000018779192,"about_ca_topic_score_gemma":0.000008154774,"teacher_disagreement_score":0.007959149,"about_ca_system_score_codex":0.000060409686,"about_ca_system_score_gemma":0.000040336843,"threshold_uncertainty_score":0.9996618},"labels":[],"label_agreement":null},{"id":"W2524917460","doi":"10.1016/j.cell.2016.08.032","title":"Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells","year":2016,"lang":"en","type":"article","venue":"Cell","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":243,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Center for Research Resources; National Cancer Institute","keywords":"Biology; Suppressor; Lymphoma; Cancer research; Cell biology; Immunology; Genetics; Gene","score_opus":0.018274862974997697,"score_gpt":0.26503782767556433,"score_spread":0.24676296470056663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2524917460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99520695,0.00023824167,0.000015988313,0.00062512956,0.00008218512,0.00036336586,0.000021313452,0.000008923525,0.0034378849],"genre_scores_gemma":[0.9848615,0.000067362824,0.000015229776,0.000081281716,0.000041099047,0.000012639421,0.0000026443424,0.000016482336,0.014901784],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99917716,0.000079979385,0.00017035897,0.00015061088,0.00024341223,0.00017846555],"domain_scores_gemma":[0.99937034,0.00011173328,0.000052380426,0.00034690127,0.000052383926,0.00006628602],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020030394,0.00008205888,0.0001623918,0.000051834144,0.000021886066,0.000007298283,0.00010412272,0.0000552356,0.0002610639],"category_scores_gemma":[0.00003312249,0.000046410623,0.000038346017,0.00012013916,0.00014357457,0.000042400156,0.000053616965,0.00006049164,0.000013286779],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024551357,0.00009253151,0.0030679207,0.000057731177,0.000004908611,0.000008544459,0.00032642757,0.0000011237875,0.9914771,0.000010597794,0.0031922434,0.0015153998],"study_design_scores_gemma":[0.0028595799,0.00009933513,0.007997036,0.0000601907,0.000008924209,0.0000063671787,0.000063970154,0.000068360234,0.9813941,0.0000747057,0.0073094964,0.000057920817],"about_ca_topic_score_codex":0.00013760783,"about_ca_topic_score_gemma":0.000029786801,"teacher_disagreement_score":0.0114639,"about_ca_system_score_codex":0.000085799446,"about_ca_system_score_gemma":0.000077869634,"threshold_uncertainty_score":0.28584665},"labels":[],"label_agreement":null},{"id":"W2531414011","doi":"10.1182/blood.v110.11.579.579","title":"Targeted ‘Off-the-Shelf’ Tumor Immunotherapy Using Allogeneic T-Cell Precursors.","year":2007,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Adoptive cell transfer; Cytotoxic T cell; Immunology; Cancer research; T cell; Major histocompatibility complex; Biology; Antigen; Immunotherapy; Chimeric antigen receptor; Transplantation; Stem cell; Immune system; Medicine; Cell biology; In vitro; Internal medicine","score_opus":0.024396877895186513,"score_gpt":0.3006860082770211,"score_spread":0.27628913038183456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2531414011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98067653,0.00865449,0.00022452266,0.00021575038,0.00019133305,0.00088741217,0.0000063707894,0.000106977845,0.009036639],"genre_scores_gemma":[0.986996,0.00040193496,0.0025226988,0.0009707625,0.00067487685,0.00002239903,0.000021186406,0.00012474894,0.008265426],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99789536,0.000089824185,0.00036554053,0.00035341625,0.00058186776,0.00071398023],"domain_scores_gemma":[0.9986852,0.00016800743,0.00009669961,0.0007154146,0.00014186365,0.00019282018],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010593694,0.00023343597,0.0003227739,0.00017488867,0.00016770157,0.000038208327,0.00028474463,0.00011142011,0.002194257],"category_scores_gemma":[0.000056048302,0.00017531712,0.00021045278,0.00046331369,0.0001473234,0.00005207391,0.00005854121,0.0004102325,0.00009174683],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005108351,0.00079918996,0.008283166,0.000034862795,0.0002071324,0.00018378557,0.00037110253,0.0000042126308,0.97944754,0.000013725001,0.00019233633,0.009952119],"study_design_scores_gemma":[0.0073570106,0.0005477917,0.009264285,0.00004188386,0.00015131084,0.00041232994,0.00014901241,0.00010832725,0.93220246,0.00007296521,0.04943282,0.0002597863],"about_ca_topic_score_codex":0.000114823255,"about_ca_topic_score_gemma":0.000020790694,"teacher_disagreement_score":0.049240485,"about_ca_system_score_codex":0.000090574256,"about_ca_system_score_gemma":0.00020439528,"threshold_uncertainty_score":0.99871784},"labels":[],"label_agreement":null},{"id":"W2531711809","doi":"10.1182/blood.v120.21.3625.3625","title":"SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On Leukemia Blasts and Cancer Stem Cells, Is Active As a Single Agent in Patients with Advanced AML","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Internal medicine; Oncology; Leukemia; Stem cell; Cancer; Immunology; Biology","score_opus":0.018398359243683517,"score_gpt":0.27549451968944527,"score_spread":0.2570961604457618,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2531711809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955248,0.00085949356,0.0000016440423,0.0006254826,0.00016236688,0.0021816264,0.00004561664,0.000051961597,0.0005469818],"genre_scores_gemma":[0.995853,0.00032266,0.000078385216,0.00068091846,0.00017032638,0.00034808574,0.000013747591,0.00006179192,0.0024710577],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99815637,0.00014843681,0.00020276339,0.00038031864,0.0005808611,0.0005312393],"domain_scores_gemma":[0.9989908,0.000103276674,0.000080752325,0.00041110555,0.00013605555,0.0002780126],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013901335,0.0002480762,0.00031282502,0.00014452926,0.00006215453,0.000027276787,0.00013767924,0.0000794185,0.00084418274],"category_scores_gemma":[0.000018843271,0.00015315802,0.00004953001,0.00038365333,0.00008192022,0.00009307894,0.00007343994,0.00032199264,0.000042283744],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023251692,0.00572256,0.08266065,0.00007346374,0.00088972726,0.000015735057,0.026584998,0.00003278135,0.49601784,0.000003440759,0.0035568029,0.3611903],"study_design_scores_gemma":[0.012881663,0.004173236,0.13924631,0.00032044243,0.000050111143,0.0000025121237,0.0004893889,0.000016993547,0.7969677,0.0000015724087,0.045597818,0.00025226132],"about_ca_topic_score_codex":0.00031643859,"about_ca_topic_score_gemma":0.00008790648,"teacher_disagreement_score":0.36093804,"about_ca_system_score_codex":0.00051814324,"about_ca_system_score_gemma":0.00013491523,"threshold_uncertainty_score":0.9243209},"labels":[],"label_agreement":null},{"id":"W2534178318","doi":"10.1016/j.it.2016.09.008","title":"T Cell Genesis: In Vitro Veritas Est ?","year":2016,"lang":"en","type":"review","venue":"Trends in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"National Institute of Allergy and Infectious Diseases","keywords":"Immunotherapy; Cancer immunotherapy; Immune system; Immunology; Chimeric antigen receptor; Haematopoiesis; Biology; Progenitor cell; Induced pluripotent stem cell; Antigen; Cell therapy; Stem cell; Cancer research; Antigen-presenting cell; T cell; Cell biology; Embryonic stem cell","score_opus":0.06661487666658868,"score_gpt":0.3849451041923543,"score_spread":0.3183302275257656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2534178318","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015565704,0.966774,8.932884e-7,0.000107201115,0.00041905427,0.00038948155,0.000036905174,0.000047416193,0.032069426],"genre_scores_gemma":[0.00009226828,0.9673603,0.00008735664,0.000029256034,0.0001586681,0.00029374444,0.00022281903,0.00011628264,0.031639285],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99693817,0.0004922849,0.00084776717,0.0006560981,0.00022435252,0.00084134],"domain_scores_gemma":[0.99829435,0.0003367134,0.00017468362,0.0010825527,0.00003459743,0.00007707648],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0004446866,0.00048170556,0.0025726967,0.0023494463,0.000021737,0.000010421914,0.00049025146,0.000876996,0.008363379],"category_scores_gemma":[0.0000563741,0.00036067876,0.00045678328,0.0010922609,0.00024819936,0.000037190777,0.00022519316,0.0011795074,0.0010035015],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030501286,0.00022930461,0.0000107969645,0.0017025444,0.00015870055,0.00048778846,0.000059980346,1.577915e-8,0.0023930739,0.000025690775,0.0004394459,0.99418765],"study_design_scores_gemma":[0.0021456624,0.0002431224,0.00007515456,0.0036998817,0.00012671258,0.0002577881,0.00001894786,4.5695407e-7,0.0002563365,0.000020644404,0.99285984,0.00029543153],"about_ca_topic_score_codex":0.00024339587,"about_ca_topic_score_gemma":0.00004491082,"teacher_disagreement_score":0.9938922,"about_ca_system_score_codex":0.0007821555,"about_ca_system_score_gemma":0.00043197727,"threshold_uncertainty_score":0.99988455},"labels":[],"label_agreement":null},{"id":"W2536114475","doi":"10.3791/54697","title":"Generating &lt;em&gt;De Novo&lt;/em&gt; Antigen-specific Human T Cell Receptors by Retroviral Transduction of Centric Hemichain","year":2016,"lang":"en","type":"article","venue":"Journal of Visualized Experiments","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Princess Margaret Cancer Foundation; Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; National Cancer Institute; National Institutes of Health; Ontario Institute for Cancer Research","keywords":"T-cell receptor; Antigen; Biology; Transduction (biophysics); Cell biology; T cell; Chimeric antigen receptor; Cloning (programming); Computational biology; Molecular biology; Immunology; Immune system; Computer science; Biochemistry","score_opus":0.0315232736830054,"score_gpt":0.3764037305717227,"score_spread":0.3448804568887173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2536114475","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99087816,0.0056251795,0.0016636789,0.00014576668,0.0007082964,0.0004094135,0.000012142796,0.000028966933,0.00052839465],"genre_scores_gemma":[0.98657614,0.004005203,0.0027647514,0.00009785883,0.001099993,0.000010002928,0.00001936051,0.00010979003,0.005316881],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99565834,0.00040557593,0.0013835968,0.00037235487,0.0015089705,0.0006711744],"domain_scores_gemma":[0.99790996,0.00008768838,0.00082081696,0.0003838576,0.00037097532,0.0004267174],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013643616,0.00034428303,0.0008401128,0.00055719225,0.00015775528,0.00005420328,0.00032460564,0.0002351549,0.004837936],"category_scores_gemma":[0.000074697055,0.00026148898,0.00043986522,0.0004619066,0.00013194839,0.00026776007,0.00004633497,0.00039204847,0.000020327267],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017398592,0.00092199136,0.0011811823,0.00004266517,0.00019928713,0.000058442147,0.0025258337,0.0000025079096,0.97280383,0.00001716086,0.012642879,0.0078643495],"study_design_scores_gemma":[0.010384156,0.0016769083,0.00016547076,0.00029194666,0.000034903715,0.00015017723,0.00072117255,0.000030228972,0.9469688,0.000014823929,0.03932165,0.00023978911],"about_ca_topic_score_codex":0.000010276503,"about_ca_topic_score_gemma":0.0000012153894,"teacher_disagreement_score":0.026678773,"about_ca_system_score_codex":0.00075997843,"about_ca_system_score_gemma":0.00018390584,"threshold_uncertainty_score":0.9999837},"labels":[],"label_agreement":null},{"id":"W2536860185","doi":"10.1182/blood.v114.22.620.620","title":"Accurate Classification of Diffuse Large B Cell Lymphoma Into Germinal Center and Activated B Cell Subtypes Using a Nuclease Protection Assay On Formalin Fixed Paraffin Embedded Tissue: A Study From the Lymphoma and Leukemia Molecular Profiling Project.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"BCL6; Diffuse large B-cell lymphoma; Germinal center; Tissue microarray; Gene expression profiling; Cancer research; Biology; Lymphoma; Molecular biology; B cell; Immunohistochemistry; Computational biology; Gene expression; Gene; Antibody; Genetics; Immunology","score_opus":0.03007597998786294,"score_gpt":0.30898896765822115,"score_spread":0.2789129876703582,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2536860185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961659,0.00015153762,0.00020135754,0.00008763145,0.000022383156,0.0031905577,0.000020936968,0.00005220118,0.00010751769],"genre_scores_gemma":[0.99899864,0.000027970245,0.00060822064,0.00007474751,0.000064378866,0.00007703861,0.00003939889,0.000039582224,0.000070016904],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980324,0.0003755065,0.00036365562,0.0004672191,0.00043527334,0.00032594442],"domain_scores_gemma":[0.9990024,0.000094067196,0.00023121653,0.0004318632,0.00013488438,0.00010555409],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047849855,0.00025382405,0.00033656202,0.00015354066,0.00017132291,0.000076995355,0.00011584494,0.00014690206,0.0000147219125],"category_scores_gemma":[0.00009057367,0.00019009337,0.00005437872,0.0003265513,0.00005946744,0.00013626553,0.00006083082,0.00017781496,0.000002277265],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002507764,0.0072980477,0.0033892614,0.00010028834,0.00008052103,0.00006812192,0.0029669954,0.0000021358455,0.97249895,0.0000055356004,0.0000051983984,0.011077167],"study_design_scores_gemma":[0.029112728,0.0017334237,0.04511937,0.00012688272,0.0002484361,0.000038341062,0.0017102743,0.008219956,0.9134117,0.000026454874,0.0000511095,0.00020134395],"about_ca_topic_score_codex":0.00040156208,"about_ca_topic_score_gemma":0.000030008216,"teacher_disagreement_score":0.059087284,"about_ca_system_score_codex":0.00015743927,"about_ca_system_score_gemma":0.0002363968,"threshold_uncertainty_score":0.77517825},"labels":[],"label_agreement":null},{"id":"W2538054564","doi":"10.1017/cjn.2016.367","title":"PS2 - 172 Preclinical Validation of a Novel CD33/CD3 Bispecific T-Cell Engager (BiTE) Antibody to Target Patient-Derived Glioblastoma Cells","year":2016,"lang":"en","type":"article","venue":"Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency; McMaster University","funders":"","keywords":"CD3; Cancer research; Antigen; Cytotoxic T cell; Medicine; Antibody; Cytotoxicity; T cell; Immunotherapy; Immunology; In vitro; Biology; CD8; Immune system","score_opus":0.06129883404073664,"score_gpt":0.3289810666139488,"score_spread":0.26768223257321216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2538054564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905159,0.00033680888,0.0003228409,0.0057242983,0.0009482226,0.00044721167,0.000042071817,0.000019960677,0.0016426708],"genre_scores_gemma":[0.9928415,0.00028958672,0.004374264,0.0020051906,0.00033401302,0.0000042076895,4.53053e-7,0.000024373661,0.00012643762],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9931422,0.001237737,0.0015444022,0.00079360657,0.0016168425,0.0016652436],"domain_scores_gemma":[0.99262863,0.0015582825,0.0010116079,0.00031599271,0.0010831419,0.0034023244],"candidate_categories":["sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005636259,0.0004127974,0.00085795403,0.0017126616,0.0012273587,0.00034861514,0.0017811565,0.00028019378,0.0015977294],"category_scores_gemma":[0.0037514563,0.00024183314,0.0004419884,0.001986503,0.0054288465,0.00079063344,0.00013109962,0.0012916342,0.000012758901],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013506104,0.00033586076,0.26470968,0.000024690602,0.000041169515,0.0051236604,0.0008432802,0.0013751796,0.715283,0.000117202544,0.001089575,0.009706112],"study_design_scores_gemma":[0.0040355464,0.41042832,0.083059855,0.00042575836,0.00014879328,0.034516726,0.0006219114,0.00082621677,0.43766502,0.0027616948,0.02436446,0.0011457175],"about_ca_topic_score_codex":0.0005287087,"about_ca_topic_score_gemma":0.0044411304,"teacher_disagreement_score":0.41009244,"about_ca_system_score_codex":0.00032614643,"about_ca_system_score_gemma":0.004072198,"threshold_uncertainty_score":0.99931496},"labels":[],"label_agreement":null},{"id":"W2539531174","doi":"10.1016/j.jtho.2016.09.008","title":"ORAL01.03: CheckMate 012: Safety and Efficacy of First-Line Nivolumab and Ipilimumab in Advanced NSCLC","year":2016,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital; Princess Margaret Cancer Centre; University of Toronto; McMaster University; Juravinski Cancer Centre","funders":"","keywords":"Nivolumab; Ipilimumab; Medicine; Internal medicine; Adverse effect; Oncology; Discontinuation; Clinical trial; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Immunotherapy; Cancer","score_opus":0.027884889969543695,"score_gpt":0.41439323166111675,"score_spread":0.38650834169157305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2539531174","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98759264,0.0019857776,0.00012732705,0.008086385,0.00017961777,0.00030830887,0.0000060363486,0.000007747373,0.0017061542],"genre_scores_gemma":[0.9897314,0.0061651682,0.0015309503,0.00010150496,0.00019297839,0.0000025205102,9.516737e-7,0.000025737188,0.0022488046],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9981191,0.00021755556,0.0008279185,0.000202603,0.00031265093,0.00032016385],"domain_scores_gemma":[0.9980001,0.00080045784,0.00046236027,0.0002278444,0.00027423952,0.00023502193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014464845,0.00015564496,0.0009004789,0.00037634556,0.00003816622,0.000006433583,0.00013195496,0.00019065395,0.00055047544],"category_scores_gemma":[0.0006094051,0.00010095897,0.00010045245,0.00023483983,0.0002965205,0.00015191313,0.000102626414,0.00041431648,0.0000057601474],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033117868,0.0004605737,0.010538361,0.00015319834,0.00010974069,0.00030974764,0.0003783386,0.000006364424,0.12936978,0.000015620457,0.00012736162,0.82541305],"study_design_scores_gemma":[0.09355594,0.033790816,0.5080074,0.0043339087,0.00061604375,0.008782637,0.0010084645,0.00041368962,0.08208799,0.0014552174,0.26522136,0.00072649156],"about_ca_topic_score_codex":0.000015628166,"about_ca_topic_score_gemma":0.00010871148,"teacher_disagreement_score":0.8246865,"about_ca_system_score_codex":0.00034448196,"about_ca_system_score_gemma":0.0002746604,"threshold_uncertainty_score":0.602732},"labels":[],"label_agreement":null},{"id":"W2543488039","doi":"10.1200/jco.2015.33.15_suppl.e14019","title":"ZW38, a bispecific CD3 x CD19 azymetric antibody to deplete human leukemic B cells by the “controlled” activation of T cells.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"CD19; Antibody; Blinatumomab; Antigen; T cell; Cancer research; Cytokine; Immune system; CD3; B cell; Cytotoxic T cell; Immunology; Molecular biology; Medicine; Biology; In vitro; CD8; Biochemistry","score_opus":0.2066256439881135,"score_gpt":0.5094023533349838,"score_spread":0.30277670934687034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2543488039","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98402894,0.000438928,0.0005330484,0.0063513075,0.0012171009,0.00079035974,0.0000051896204,0.000010246273,0.006624868],"genre_scores_gemma":[0.989466,0.0005188214,0.0005988616,0.0019917262,0.001698397,0.000007288147,0.0000042403876,0.000038377697,0.005676257],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9940528,0.0011647806,0.0029720915,0.00026641125,0.0011386607,0.00040520445],"domain_scores_gemma":[0.9907475,0.0049682707,0.0018739399,0.00047857186,0.001216945,0.0007147762],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010261479,0.00019646916,0.0021320812,0.0005523365,0.000063316904,0.000021595422,0.0005232233,0.0004380334,0.00062152126],"category_scores_gemma":[0.004213495,0.000117799515,0.0007558114,0.00082347146,0.00029149724,0.000107019165,0.00011103083,0.0016362682,0.00007401484],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01568578,0.0015053359,0.004159195,0.000022750924,0.0004755669,0.00009272942,0.00021727404,0.00006825182,0.83942944,0.000029595514,0.09716125,0.041152857],"study_design_scores_gemma":[0.07088437,0.05111451,0.01934249,0.00018168041,0.0006118133,0.00024068548,0.00072296493,0.00034106494,0.12943467,0.00037158522,0.72644037,0.00031381045],"about_ca_topic_score_codex":0.000097779,"about_ca_topic_score_gemma":0.000015340423,"teacher_disagreement_score":0.70999473,"about_ca_system_score_codex":0.00052342395,"about_ca_system_score_gemma":0.0020414633,"threshold_uncertainty_score":0.71088624},"labels":[],"label_agreement":null},{"id":"W2545245164","doi":"10.1186/s13073-016-0369-x","title":"Approaches to modernize the combination drug development paradigm","year":2016,"lang":"en","type":"review","venue":"Genome Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":101,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"Government of Ontario","keywords":"Precision medicine; Paradigm shift; Exploit; Drug development; Informatics; Medicine; Regulatory science; Transformative learning; Computer science; Drug discovery; Flexibility (engineering); Risk analysis (engineering); Computational biology; Data science; Bioinformatics; Drug; Biology; Psychology; Engineering; Pharmacology","score_opus":0.2797227624177357,"score_gpt":0.36757413963859303,"score_spread":0.08785137722085734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2545245164","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000015746142,0.9723279,0.00065062527,0.010842491,0.00029870626,0.004130296,0.0000096281765,0.00007820963,0.011646421],"genre_scores_gemma":[0.00003998818,0.9245333,0.00016921986,0.00045344525,0.0012161031,0.0007829063,0.0002656964,0.00012737265,0.07241197],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962487,0.00028502027,0.00091465,0.0006957503,0.001210224,0.0006456244],"domain_scores_gemma":[0.9976291,0.00046108768,0.00023619615,0.0011433852,0.00008533706,0.00044489466],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0020584846,0.00057417137,0.0021120661,0.00051700656,0.00017905151,0.000021548085,0.00064392,0.00020456889,0.003671679],"category_scores_gemma":[0.00017391198,0.00026366234,0.0002481487,0.0006313994,0.00025210352,0.000030618092,0.00022292932,0.0006471327,0.0013042266],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003990092,0.00007229934,0.0000017121574,0.004880152,0.00037314877,0.000026980835,0.0015238554,2.0256539e-7,0.000016929564,0.00041533652,0.0025972922,0.99005216],"study_design_scores_gemma":[0.0010423943,0.00018490275,0.000035943332,0.00935142,0.00038207154,0.00013840114,0.000058415295,0.0000032530586,0.0000050328554,0.0001566062,0.98835886,0.00028269205],"about_ca_topic_score_codex":0.000016343638,"about_ca_topic_score_gemma":0.00000654355,"teacher_disagreement_score":0.9897695,"about_ca_system_score_codex":0.0008398559,"about_ca_system_score_gemma":0.00082137913,"threshold_uncertainty_score":0.9999816},"labels":[],"label_agreement":null},{"id":"W2548887552","doi":"10.1158/2326-6066.imm2016-b079","title":"Abstract B079: The efficacy of CD133 BiTEs and CAR-T cells in preclinical model of recurrent glioblastoma","year":2016,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McMaster University","funders":"","keywords":"Antigen; Flow cytometry; Antibody; Population; Peripheral blood mononuclear cell; Immunophenotyping; Monoclonal antibody; Cancer research; Immunology; Medicine; Chimeric antigen receptor; Immunotherapy; Biology; In vitro; Immune system","score_opus":0.13215498967667308,"score_gpt":0.44975309362495114,"score_spread":0.31759810394827803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2548887552","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891287,0.006153531,0.0000046988134,0.0032245582,0.00010289659,0.0008001957,0.000041753072,0.000010524619,0.00053311535],"genre_scores_gemma":[0.9873916,0.009911913,0.00003055258,0.000017131835,0.00007117219,0.00011703746,0.0000012629287,0.000027164613,0.0024321584],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974328,0.0003794099,0.00057939655,0.00040169698,0.00059488916,0.00061178603],"domain_scores_gemma":[0.99541104,0.00314714,0.00010584415,0.00073752634,0.0004998687,0.00009860821],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0023806603,0.00014083933,0.0005167309,0.00043739632,0.000055570654,0.0000073002398,0.0004097726,0.00023236235,0.0009780697],"category_scores_gemma":[0.0008779431,0.000072738076,0.00010893023,0.0005051202,0.002277499,0.000052822386,0.00032044694,0.00093416683,0.00001688068],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0074285828,0.00029928028,0.009309967,0.00011701834,0.00014218673,0.0000075384137,0.00050595764,0.000011047401,0.8744703,0.00006995669,0.00041360085,0.10722456],"study_design_scores_gemma":[0.007009929,0.0026076136,0.13079275,0.00087323535,0.00002540383,0.000012897452,0.00027234288,0.00044789416,0.85529894,0.00042946354,0.0020866846,0.00014283122],"about_ca_topic_score_codex":0.00025266342,"about_ca_topic_score_gemma":0.00018695115,"teacher_disagreement_score":0.12148278,"about_ca_system_score_codex":0.00018959967,"about_ca_system_score_gemma":0.00073788984,"threshold_uncertainty_score":0.99993515},"labels":[],"label_agreement":null},{"id":"W2551364694","doi":"10.1182/blood.v112.11.574.574","title":"Gamma Delta T Cells (GDTCs) to Eliminate Minimal Residual Disease (MRD) in Chronic Myeloid Leukemia (CML) : A Pre-Clinical Model","year":2008,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Minimal residual disease; Peripheral blood mononuclear cell; Medicine; Flow cytometry; clone (Java method); Molecular biology; Immunology; Concanavalin A; Immunophenotyping; Leukemia; Chemistry; Biology; In vitro","score_opus":0.049167904948384175,"score_gpt":0.3399301732050876,"score_spread":0.2907622682567034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2551364694","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99441564,0.0008893395,0.000059892747,0.0008082784,0.00008249455,0.0012418575,0.000056089328,0.000097251745,0.0023491567],"genre_scores_gemma":[0.97561914,0.0009185176,0.0012774186,0.00055852643,0.0008084494,0.00015340585,0.000045942492,0.00009952899,0.020519055],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9963397,0.0001924601,0.0007840084,0.00085247046,0.00088139717,0.0009499844],"domain_scores_gemma":[0.9974589,0.0002479151,0.00008081604,0.0009898506,0.00013981058,0.0010827392],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00072003924,0.00033179496,0.00062521355,0.00030698424,0.00009573772,0.000024643541,0.0003925,0.00023209608,0.0008976621],"category_scores_gemma":[0.00033603612,0.00031898,0.00024895289,0.0004578443,0.00023362803,0.00009671114,0.00027788064,0.00078168634,0.00030717836],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028302338,0.008381257,0.07830309,0.0010525443,0.00075148226,0.014165503,0.004576206,0.0077069034,0.7833649,0.00010274124,0.03782023,0.03547281],"study_design_scores_gemma":[0.075484045,0.010320764,0.583478,0.0012773053,0.001146191,0.00059433293,0.00018608253,0.08818628,0.21722494,0.00042044668,0.019201258,0.0024803968],"about_ca_topic_score_codex":0.00018915025,"about_ca_topic_score_gemma":0.00022737046,"teacher_disagreement_score":0.56613994,"about_ca_system_score_codex":0.0005380967,"about_ca_system_score_gemma":0.0032931042,"threshold_uncertainty_score":0.9999262},"labels":[],"label_agreement":null},{"id":"W2551609581","doi":"10.1097/mph.0000000000000703","title":"Nivolumab in the Treatment of Refractory Pediatric Hodgkin Lymphoma","year":2016,"lang":"en","type":"article","venue":"Journal of Pediatric Hematology/Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Child and Family Research Institute; University of British Columbia; BC Children's Hospital; BC Cancer Agency","funders":"Bristol-Myers Squibb","keywords":"Medicine; Nivolumab; Renal cell carcinoma; Oncology; Lymphoma; Adverse effect; Internal medicine; Cancer; Refractory (planetary science); Progressive disease; Disease; Immunotherapy","score_opus":0.03797851027425286,"score_gpt":0.357507728957379,"score_spread":0.3195292186831261,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2551609581","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98342687,0.008371986,0.000059264232,0.0046973904,0.000566051,0.00045629288,0.0000059381427,0.000011036184,0.0024051948],"genre_scores_gemma":[0.9617376,0.034045815,0.0005370144,0.00017808544,0.0025502178,0.000026491754,0.0000012863484,0.000033546607,0.00088998594],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963047,0.0008243372,0.0014186437,0.00025800258,0.0006311846,0.0005631608],"domain_scores_gemma":[0.9950309,0.0028469476,0.0010539361,0.00046413788,0.00038210716,0.00022198378],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017067203,0.00024793454,0.001303292,0.0011569215,0.00004589097,0.0000060431453,0.00041178297,0.00046696607,0.0009745965],"category_scores_gemma":[0.0005507702,0.00012627794,0.00042218433,0.0007982427,0.00020060525,0.000107749445,0.000038539867,0.0003076944,0.000060781247],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005931238,0.011489876,0.65634686,0.00023007664,0.00037506834,0.008296492,0.004393671,0.0000013921665,0.0081991535,0.00028655652,0.020934394,0.28351521],"study_design_scores_gemma":[0.08240716,0.09159574,0.23941202,0.00008719358,0.0026460935,0.03517789,0.0027985738,0.000014933825,0.0052740723,0.0016234592,0.5382417,0.0007211702],"about_ca_topic_score_codex":0.000037652662,"about_ca_topic_score_gemma":0.00003575497,"teacher_disagreement_score":0.5173073,"about_ca_system_score_codex":0.0011771417,"about_ca_system_score_gemma":0.0020996272,"threshold_uncertainty_score":0.99993867},"labels":[],"label_agreement":null},{"id":"W2552600182","doi":"10.1182/blood.v116.21.3298.3298","title":"Phase I Trial Results for SL-401, a Novel Cancer Stem Cell (CSC) Targeting Agent, Demonstrate Clinical Efficacy at Tolerable Doses In Patients with Heavily Pre-Treated AML, Poor Risk Elderly AML, and High Risk MDS","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Internal medicine; Regimen; Stem cell; Oncology; Myeloid leukemia; Myelodysplastic syndromes; Phases of clinical research; Gastroenterology; Clinical trial; Pharmacology; Bone marrow; Biology","score_opus":0.031739725853460424,"score_gpt":0.33958333020650794,"score_spread":0.30784360435304753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2552600182","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934494,0.0002245986,0.000020997635,0.00009022586,0.00032381873,0.0045164814,0.0011203268,0.00008280843,0.00017133441],"genre_scores_gemma":[0.9957295,0.00038466687,0.0012065024,0.000045307224,0.00052453723,0.00022502443,0.00021537022,0.000087600674,0.0015814761],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99643064,0.00022253869,0.0010782381,0.0009368483,0.0005545809,0.00077713083],"domain_scores_gemma":[0.9971897,0.0009737064,0.0005374247,0.0005438691,0.00029737508,0.0004579319],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014325514,0.0003946229,0.00084437215,0.00017061555,0.00025528652,0.00008343179,0.00018794251,0.0003419131,0.000120351724],"category_scores_gemma":[0.000421179,0.000302521,0.00017402972,0.00035412525,0.00024011053,0.00012355672,0.00008700849,0.0010273618,0.000006572961],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40342182,0.02079027,0.48046887,0.0001513181,0.0005991542,0.000046893387,0.00042234908,0.00001960422,0.046726383,0.0000014354964,0.0008773009,0.04647462],"study_design_scores_gemma":[0.7689316,0.022156658,0.1472555,0.00021529279,0.00096807774,0.0000060255716,0.000049538383,0.00054409297,0.05721245,0.000005691508,0.002168206,0.0004868466],"about_ca_topic_score_codex":0.0027604108,"about_ca_topic_score_gemma":0.0016200487,"teacher_disagreement_score":0.3655098,"about_ca_system_score_codex":0.00007985654,"about_ca_system_score_gemma":0.00031036112,"threshold_uncertainty_score":0.9999427},"labels":[],"label_agreement":null},{"id":"W2554791934","doi":"10.1182/blood.v106.11.3323.3323","title":"Functional and Molecular Analysis of Maturation of Thymocytes in Bcl10 or Malt1 Deficient Mice.","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Biology; T-cell receptor; BCL10; Cell biology; CD8; T cell; Cytotoxic T cell; Negative selection; Transgene; Molecular biology; Immune system; Cancer research; Immunology; Lymphoma; In vitro; Genetics; Gene","score_opus":0.019880569465848454,"score_gpt":0.28697990934894885,"score_spread":0.2670993398831004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2554791934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99778384,0.00088863744,0.000076007906,0.00025212244,0.000007258114,0.00013602598,0.000006543882,0.0000046105715,0.00084497867],"genre_scores_gemma":[0.99854475,0.000092782684,0.0007373025,0.000055759152,0.000020466048,0.0000057813177,0.000024705712,0.00000561068,0.0005128405],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99931663,0.000025683821,0.00019109716,0.00011756391,0.00025816265,0.0000908497],"domain_scores_gemma":[0.99966425,0.000051901814,0.00004452469,0.00012727652,0.00007855292,0.00003352367],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00016868346,0.000051561034,0.00020147067,0.00034920388,0.000008011625,0.0000036594931,0.000026750316,0.000040303225,0.0011136403],"category_scores_gemma":[0.000042525022,0.000040524545,0.000060798084,0.0005716408,0.00003941752,0.000023911634,0.000016948103,0.00006489127,0.000002070227],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000665184,0.0005608515,0.022113867,0.000053618718,0.0004506915,0.000010617267,0.00016340938,0.00028315868,0.97258073,0.00012159909,0.00002254357,0.0029737153],"study_design_scores_gemma":[0.0033666005,0.00031422474,0.29195997,0.000036302536,0.0009041948,0.000023788463,0.00013474825,0.002827244,0.70009613,0.000017069926,0.00025469065,0.00006503311],"about_ca_topic_score_codex":0.000044343215,"about_ca_topic_score_gemma":0.00010940849,"teacher_disagreement_score":0.2724846,"about_ca_system_score_codex":0.000017930286,"about_ca_system_score_gemma":0.000047485722,"threshold_uncertainty_score":0.9997995},"labels":[],"label_agreement":null},{"id":"W2556774727","doi":"10.1101/085910","title":"Harnessing the lymphocyte meta-phenotype to optimize adoptive cell therapy","year":2016,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Tumor-infiltrating lymphocytes; Melanoma; Adoptive cell transfer; Ex vivo; CD8; Immunotherapy; Immunology; Cancer research; T cell; Phenotype; Medicine; Biology; Immune system; In vivo","score_opus":0.044921024017284754,"score_gpt":0.27885834531680154,"score_spread":0.23393732129951678,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2556774727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91644186,0.036729,0.012428253,0.012139883,0.004774771,0.013008288,0.0007358912,0.0018821895,0.0018598833],"genre_scores_gemma":[0.97830254,0.002730243,0.010809785,0.0031222466,0.0020669408,0.0013909565,7.793192e-7,0.0005975936,0.0009788951],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9945078,0.0004916376,0.0007816576,0.0016909881,0.0012868124,0.0012411409],"domain_scores_gemma":[0.99366933,0.00034190997,0.00044625122,0.0034598354,0.0013142127,0.00076843123],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017646416,0.0010831269,0.0016214079,0.0004784867,0.0003609758,0.00040359783,0.0012246944,0.0007120187,0.0030870114],"category_scores_gemma":[0.000228779,0.0006831502,0.00080182735,0.0008856133,0.0003355554,0.00014746856,0.0009607263,0.0013368153,0.0005527146],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013026005,0.00028554225,0.0003633577,0.00020440745,0.002662458,0.00015222916,0.00007344309,0.00008798971,0.99307287,0.00012907993,0.0015649038,0.00010111753],"study_design_scores_gemma":[0.0038548391,0.0003476272,0.009069424,0.00047125493,0.0015244001,1.196258e-7,0.000012773676,0.00018269553,0.8609007,0.000006641157,0.1223459,0.0012836194],"about_ca_topic_score_codex":0.000100482146,"about_ca_topic_score_gemma":0.0000014008228,"teacher_disagreement_score":0.13217217,"about_ca_system_score_codex":0.001111297,"about_ca_system_score_gemma":0.0023666776,"threshold_uncertainty_score":0.99956197},"labels":[],"label_agreement":null},{"id":"W2557043878","doi":"10.1093/intimm/dxq141","title":"CTL-based immunotherapy (PP-109)","year":2010,"lang":"en","type":"article","venue":"International Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; University Health Network","funders":"","keywords":"CTL*; Immunotherapy; Virology; Immunology; Medicine; Computational biology; Biology; Immune system; CD8","score_opus":0.019425011160685346,"score_gpt":0.34029186535423345,"score_spread":0.3208668541935481,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2557043878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93057215,0.00042364933,0.0003849885,0.010872513,0.0029884272,0.00030567675,0.00001362587,0.00013837706,0.054300614],"genre_scores_gemma":[0.9713467,0.00017984779,0.0013513407,0.0019130756,0.0005050575,0.00006092965,0.000101810576,0.0000446221,0.024496647],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.998862,0.00003973136,0.00024438903,0.0002504493,0.0003275751,0.0002758469],"domain_scores_gemma":[0.9990176,0.00015049784,0.00006345611,0.00045767616,0.00025606327,0.000054686978],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00022581732,0.0001365405,0.00020106781,0.0002238279,0.000051477306,0.000030268346,0.00037890655,0.00018824013,0.0383908],"category_scores_gemma":[0.0001250212,0.00012440453,0.00014456596,0.00011976397,0.0002602969,0.000063361236,0.000054984925,0.00071471534,0.0006362708],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010040926,0.00022769129,0.005300543,0.0000030000476,0.00031203707,0.00005110449,0.000055471937,0.0000019405243,0.93549794,0.002792818,0.0010731203,0.053680245],"study_design_scores_gemma":[0.004188857,0.00036961611,0.041198395,0.000016181793,0.000010509106,0.00032063888,0.000026518888,0.00054997305,0.16207317,0.0006606551,0.790431,0.0001544832],"about_ca_topic_score_codex":0.00017423632,"about_ca_topic_score_gemma":0.000036752834,"teacher_disagreement_score":0.7893579,"about_ca_system_score_codex":0.00009627757,"about_ca_system_score_gemma":0.00018177625,"threshold_uncertainty_score":0.96248823},"labels":[],"label_agreement":null},{"id":"W2557455968","doi":"10.1182/blood.v118.21.3235.3235","title":"Development of a Novel Method for in Vitro Analysis of CD8 Thymocyte Selection and Maturation,","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Université de Montréal","funders":"","keywords":"CD8; Stromal cell; Biology; Thymocyte; Cell biology; T cell; T-cell receptor; Major histocompatibility complex; Immunology; Molecular biology; Cancer research; Immune system","score_opus":0.05900095867821804,"score_gpt":0.3447154979956255,"score_spread":0.2857145393174075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2557455968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9675544,0.00006536883,0.03163923,0.000016381226,0.0000069242033,0.0003025786,0.0000052695677,0.0000054554475,0.0004044195],"genre_scores_gemma":[0.62911403,0.000008028402,0.37065196,0.000009230707,0.000008462483,0.000027269256,0.000013341081,0.000005776001,0.000161911],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99943745,0.000017590652,0.00022182216,0.00011145001,0.00012438485,0.000087294444],"domain_scores_gemma":[0.9996481,0.000051867286,0.000060242885,0.000081177765,0.0001305536,0.000028090411],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042779598,0.000047893587,0.0002360541,0.00034532475,0.0000126886725,0.0000017960324,0.000026273268,0.000040141967,0.000086392705],"category_scores_gemma":[0.00004815894,0.0000416255,0.000046527257,0.0005407981,0.000012105075,0.000021431697,0.000011873955,0.00004407021,1.2199506e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008593373,0.00046909193,0.0029770134,0.0000707387,0.00074074016,3.0037927e-7,0.0021757332,0.0000012107744,0.9833578,0.000030666757,0.0000015562747,0.009315823],"study_design_scores_gemma":[0.0025658372,0.00009138939,0.05446777,0.000012386375,0.00048757426,0.0000051887946,0.000103389655,0.0020364858,0.9400807,0.000014683821,0.00009882198,0.000035782938],"about_ca_topic_score_codex":0.00009159543,"about_ca_topic_score_gemma":0.00019574915,"teacher_disagreement_score":0.3390127,"about_ca_system_score_codex":0.000017789727,"about_ca_system_score_gemma":0.00008349081,"threshold_uncertainty_score":0.16974387},"labels":[],"label_agreement":null},{"id":"W2559957079","doi":"10.1038/mtm.2016.74","title":"Preclinical validation: LV/IL-12 transduction of patient leukemia cells for immunotherapy of AML","year":2016,"lang":"en","type":"article","venue":"Molecular Therapy — Methods & Clinical Development","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Rehabilitation Institute; University of Toronto; University Health Network","funders":"","keywords":"Myeloid leukemia; Cancer research; Haematopoiesis; Transduction (biophysics); Leukemia; Biology; Immunotherapy; Myeloid; Stem cell; Immunology; Medicine; Immune system; Cell biology","score_opus":0.11771135276962931,"score_gpt":0.464357905794052,"score_spread":0.3466465530244227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559957079","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6468112,0.00061485276,0.34881607,0.0007689635,0.0006312622,0.002079272,0.00001641328,0.000045327262,0.00021667873],"genre_scores_gemma":[0.18542443,0.0038615626,0.8072833,0.00077370706,0.00019824081,0.00041160788,0.000037665715,0.00015477615,0.0018547417],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9935303,0.0016350048,0.0027223956,0.0007759255,0.0008389754,0.00049740146],"domain_scores_gemma":[0.9950715,0.0024662768,0.0006370507,0.00094273867,0.0006189862,0.00026350567],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.006764178,0.00036977493,0.0012537583,0.00020879615,0.0000654229,0.000012368375,0.00034579664,0.00043288473,0.001649672],"category_scores_gemma":[0.0006070305,0.00025709905,0.0009110285,0.0002931612,0.00040599206,0.00006755624,0.000054820182,0.0003259511,0.0000123199525],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003877096,0.00046342154,0.0006220667,0.00005151036,0.00054909236,0.0000027389858,0.000337683,0.0000041506523,0.49361566,0.000046433055,0.000049048394,0.5003811],"study_design_scores_gemma":[0.008215323,0.002785893,0.004454786,0.00018717333,0.00005463302,0.000006191928,0.000038533588,0.000018301474,0.86400205,0.00081590295,0.119157545,0.00026366775],"about_ca_topic_score_codex":0.000008209208,"about_ca_topic_score_gemma":7.894006e-7,"teacher_disagreement_score":0.5001174,"about_ca_system_score_codex":0.00025575748,"about_ca_system_score_gemma":0.001002482,"threshold_uncertainty_score":0.99998814},"labels":[],"label_agreement":null},{"id":"W2559960264","doi":"10.1182/blood.v124.21.3717.3717","title":"Epitope Spreading Is Required for Long-Term Protection Against Acute Lymphoblastic Leukemia","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia; Child and Family Research Institute","funders":"","keywords":"Immune system; Antigen; Immunology; Biology; Chimeric antigen receptor; Leukemia; Epitope; Immunotherapy; Cancer research; T cell; Immune tolerance","score_opus":0.029530755368999295,"score_gpt":0.29937104822267463,"score_spread":0.26984029285367533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2559960264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98868763,0.00009167871,0.005472274,0.00035949177,0.00019779251,0.0016007363,0.000009495419,0.00013253398,0.0034483422],"genre_scores_gemma":[0.9891553,0.000093386756,0.00051197544,0.00037584454,0.0009179491,0.00029568217,0.000035690406,0.00007053425,0.008543669],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985919,0.000046900488,0.00024201129,0.00037387223,0.0003183619,0.00042697284],"domain_scores_gemma":[0.9990663,0.00010267794,0.000073811134,0.00044894483,0.00013282317,0.00017545142],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034562516,0.00017146683,0.00031216032,0.00014536051,0.00012330305,0.00004598467,0.00012866282,0.00014230775,0.00025195672],"category_scores_gemma":[0.00019932489,0.00015547113,0.00015559749,0.00018908888,0.00005898848,0.000085805485,0.00004710503,0.00015418245,0.000106398715],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050969917,0.00018021674,0.0036963134,0.00025736165,0.000309611,0.000028440285,0.00018736042,0.000002329786,0.90665734,0.000024541429,0.0003447385,0.08780203],"study_design_scores_gemma":[0.014732478,0.0017547782,0.010845682,0.0004370582,0.00053582736,0.00022127478,0.000014149003,0.0027956762,0.9630473,0.00018265675,0.0051047434,0.0003283712],"about_ca_topic_score_codex":0.000020134745,"about_ca_topic_score_gemma":0.000010643305,"teacher_disagreement_score":0.08747366,"about_ca_system_score_codex":0.00024076179,"about_ca_system_score_gemma":0.00016667954,"threshold_uncertainty_score":0.63399285},"labels":[],"label_agreement":null},{"id":"W2562371662","doi":"10.1182/blood.v104.11.2538.2538","title":"Autologous Gamma-Delta T (GD-T) Cells in Acute Myeloid Leukemia (AML): Potential Immune Effector Cells for Minimal Disease?.","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Immune system; Immunology; Myeloid; T cell; Medicine; Population; Cancer research; Flow cytometry","score_opus":0.00960392900285659,"score_gpt":0.2671208666193089,"score_spread":0.2575169376164523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2562371662","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945633,0.00096613646,0.00026916774,0.0005641793,0.000448893,0.0023675382,0.00025280373,0.00014547758,0.00042253218],"genre_scores_gemma":[0.99192125,0.00027173862,0.0018432525,0.0001867191,0.0005627555,0.00028815455,0.00021358825,0.0001235692,0.004588985],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99705476,0.00009689538,0.0005561888,0.0006890696,0.0006007626,0.0010023107],"domain_scores_gemma":[0.99837065,0.00016919628,0.00011135809,0.0007477051,0.00012315484,0.0004779246],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00042343192,0.00038677375,0.0007096837,0.00030865966,0.000107236716,0.000056304754,0.0003615841,0.00024932384,0.00061072625],"category_scores_gemma":[0.000073185634,0.00036094198,0.0004625088,0.0003704208,0.00018258527,0.000096566415,0.0001414914,0.0004854473,0.00021966097],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036052298,0.0011110093,0.00059944653,0.00030348887,0.0003806129,0.0016181713,0.00017844891,0.00015174157,0.98890495,0.000024242338,0.00038760656,0.0027350697],"study_design_scores_gemma":[0.029848576,0.0016666895,0.019555455,0.00020258977,0.0008305906,0.00013357896,0.00003640638,0.00027599282,0.9435554,0.00016625087,0.003268694,0.00045976695],"about_ca_topic_score_codex":0.00023384987,"about_ca_topic_score_gemma":0.000028179467,"teacher_disagreement_score":0.045349523,"about_ca_system_score_codex":0.00042393713,"about_ca_system_score_gemma":0.0009163458,"threshold_uncertainty_score":0.99988425},"labels":[],"label_agreement":null},{"id":"W2563072979","doi":"10.1016/s1525-0016(16)33457-8","title":"649. Developing FGFR4 Chimeric Antigen Receptor CAR T Cell Therapy Against Rhabdomyosarcoma","year":2016,"lang":"en","type":"article","venue":"Molecular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Fibroblast growth factor receptor 4; Immunohistochemistry; Molecular biology; Cancer research; Biology; Fusion protein; Antibody; Receptor; Fibroblast growth factor receptor; Recombinant DNA; Immunology; Fibroblast growth factor; Gene","score_opus":0.026978972563908698,"score_gpt":0.29250451104614145,"score_spread":0.26552553848223276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2563072979","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9755724,0.008364363,0.003976962,0.004195774,0.00030503224,0.0013722074,0.000012033472,0.0002461135,0.0059550903],"genre_scores_gemma":[0.9396218,0.035907403,0.005072795,0.007263597,0.00050591724,0.00018736249,0.00006331286,0.0003543657,0.011023431],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.996572,0.00031949874,0.00047560528,0.0007861461,0.00088867656,0.0009580624],"domain_scores_gemma":[0.998018,0.00012047786,0.00014071798,0.0011270464,0.00025196953,0.00034175665],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005097876,0.00050836086,0.0006357825,0.00032601444,0.00017812,0.00006198081,0.0004894232,0.00024298836,0.0033131486],"category_scores_gemma":[0.00003694654,0.00034488257,0.00040386853,0.0006646606,0.00022216907,0.00011562659,0.000076709504,0.00033275882,0.00064498285],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000674859,0.0001566445,0.002389092,0.000012974969,0.0002155434,0.00011921511,0.00023874518,6.7866046e-7,0.7024934,0.00004989136,0.00057848287,0.29307047],"study_design_scores_gemma":[0.0052864486,0.0004947323,0.002448465,0.000086015614,0.000005606027,0.000022396422,0.000041215393,0.0000068579543,0.6802543,0.00008886665,0.31089213,0.00037296698],"about_ca_topic_score_codex":0.000047978883,"about_ca_topic_score_gemma":0.0000017317551,"teacher_disagreement_score":0.31031367,"about_ca_system_score_codex":0.00027888612,"about_ca_system_score_gemma":0.00041927575,"threshold_uncertainty_score":0.99990034},"labels":[],"label_agreement":null},{"id":"W2564086249","doi":"10.1158/1538-7445.am2015-ct226","title":"Abstract CT226: A pilot study of adoptive cell therapy with in vitro educated MART1 T cells in combination with ipilimumab for the treatment of metastatic melanoma","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Leukapheresis; Ipilimumab; CD80; Immunotherapy; Immunology; Priming (agriculture); CD8; Cell therapy; Antigen-presenting cell; T cell; Antigen; Cytotoxic T cell; Internal medicine; Oncology; Immune system; CD40; In vitro; Cell; Stem cell; Biology","score_opus":0.17990204074965363,"score_gpt":0.4271268304117442,"score_spread":0.24722478966209058,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2564086249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991084,0.001436171,0.000004992894,0.00034009464,0.000027645208,0.006747843,0.000028584072,0.0000058803907,0.00032482238],"genre_scores_gemma":[0.99616635,0.00059517956,0.00009732973,0.000008338514,0.00002268748,0.0020321398,0.000016450718,0.000044173445,0.0010173414],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99756294,0.00031136104,0.0003257916,0.00032582693,0.0010319282,0.00044213783],"domain_scores_gemma":[0.99766946,0.000769907,0.000102321705,0.00045864916,0.0008752934,0.00012435195],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013681138,0.00017017312,0.00048751172,0.0005098297,0.00004420886,0.000016472828,0.00019318143,0.000027447857,0.00018252373],"category_scores_gemma":[0.000021948208,0.0000939431,0.00003336176,0.0010679411,0.0002453873,0.000060427126,0.000018744642,0.00028305582,0.0000020575421],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18286918,0.039492495,0.015481436,0.00027151886,0.00061796565,0.000082142935,0.03178826,0.00043397833,0.69588053,0.000005893675,0.00019083678,0.03288575],"study_design_scores_gemma":[0.06488135,0.1372959,0.040710468,0.00014797744,0.000060142298,0.000003466945,0.03158998,0.00026951882,0.724399,0.000041802858,0.00044998917,0.00015043205],"about_ca_topic_score_codex":0.013154478,"about_ca_topic_score_gemma":0.0041476726,"teacher_disagreement_score":0.11798783,"about_ca_system_score_codex":0.000878306,"about_ca_system_score_gemma":0.0014544863,"threshold_uncertainty_score":0.993417},"labels":[],"label_agreement":null},{"id":"W2564655741","doi":"10.1016/s1525-0016(16)33216-6","title":"407. A Novel Rabbit Antibody-Derived, Anti-CD123 LV/CAR Construct for AML Immunotherapy","year":2016,"lang":"en","type":"article","venue":"Molecular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Interleukin-3 receptor; Chimeric antigen receptor; Myelopoiesis; Cancer research; Immunotherapy; Haematopoiesis; Immunology; Immunotoxin; Antibody; Myeloid leukemia; Biology; Antigen; Cytotoxic T cell; Progenitor cell; Cancer immunotherapy; Monoclonal antibody; Stem cell; Immune system; Cell biology; In vitro","score_opus":0.026582898935742005,"score_gpt":0.327772995134769,"score_spread":0.301190096199027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2564655741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9169128,0.0029593615,0.07220608,0.0036138594,0.00031880935,0.0024653217,0.00009467413,0.00020869248,0.00122039],"genre_scores_gemma":[0.97711307,0.0053806882,0.0063125556,0.0039356262,0.00042529343,0.00029579326,0.00009645365,0.0003523549,0.0060881423],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9968919,0.00012350135,0.00051748357,0.00078902673,0.0007245727,0.0009534747],"domain_scores_gemma":[0.9977166,0.00022837227,0.00015690779,0.0012305201,0.0003912739,0.00027631738],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00056490937,0.0005008692,0.00080902636,0.00030808715,0.00017150925,0.00007596525,0.0004413027,0.0002793857,0.0027901696],"category_scores_gemma":[0.00007832807,0.00035007807,0.0006367237,0.00038254686,0.00045598965,0.00011914151,0.00005377879,0.00025799513,0.00012628762],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002274524,0.00033982567,0.0015272598,0.000031717642,0.0006859596,0.00007710844,0.00017120161,0.0000010930687,0.8749012,0.00054349453,0.00024034016,0.11920631],"study_design_scores_gemma":[0.020965476,0.0011687868,0.0029010414,0.000142723,0.00003178203,0.00020656556,0.00005057281,0.00004269327,0.83080894,0.00047678733,0.1427527,0.00045195664],"about_ca_topic_score_codex":0.000054863125,"about_ca_topic_score_gemma":0.0000026379764,"teacher_disagreement_score":0.14251237,"about_ca_system_score_codex":0.00016461691,"about_ca_system_score_gemma":0.00030496708,"threshold_uncertainty_score":0.9998951},"labels":[],"label_agreement":null},{"id":"W2565750033","doi":"10.1007/978-3-319-48066-4_15","title":"Promising Immunotherapeutic Approaches in Clinical Trials","year":2016,"lang":"en","type":"book-chapter","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Monoclonal antibody; Nivolumab; Ipilimumab; Clinical trial; Immunotherapy; Cancer; Pembrolizumab; Chimeric antigen receptor; Antibody; Immunology; Melanoma; Cancer immunotherapy; Antigen; Oncology; Cancer research; Internal medicine","score_opus":0.49952443829530163,"score_gpt":0.47340625695037064,"score_spread":0.02611818134493099,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2565750033","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00027587495,0.002386288,0.000112514484,0.0017178748,0.0002526974,0.0024405075,0.000007858433,0.00008071714,0.9927257],"genre_scores_gemma":[0.0016873027,0.001983317,0.00035421975,0.00041988317,0.0012205543,0.000038705097,0.000017894723,0.00016586824,0.99411225],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99599403,0.00039708006,0.0019386016,0.0006599906,0.00060362654,0.0004066435],"domain_scores_gemma":[0.9965522,0.0019500661,0.00033998513,0.0008990904,0.00007839564,0.0001802409],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.010393838,0.00039022768,0.0020642392,0.00039997863,0.000027073236,0.00003571423,0.00021687071,0.00092616567,0.037357643],"category_scores_gemma":[0.00050108327,0.00024173531,0.00085011974,0.00003749391,0.00028657945,0.000040551964,0.00008912348,0.0011540772,0.00068059703],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002702829,0.00013661248,0.00023379971,0.00014319179,0.0007876741,0.000086245396,0.00006741868,3.6437328e-8,0.0040048333,0.027490886,0.00063338014,0.9637131],"study_design_scores_gemma":[0.013299884,0.0010338455,0.00047316766,0.0022030722,0.00034006458,0.00009914724,0.000028797554,0.000045812292,0.000992384,0.021552255,0.9592053,0.00072622637],"about_ca_topic_score_codex":0.00001031462,"about_ca_topic_score_gemma":0.000014121211,"teacher_disagreement_score":0.9629869,"about_ca_system_score_codex":0.00025106728,"about_ca_system_score_gemma":0.00052011263,"threshold_uncertainty_score":0.985768},"labels":[],"label_agreement":null},{"id":"W2567305346","doi":"10.7490/f1000research.1097361.1","title":"A clinical grade cell-based artificial APC, aAPC/mOKT3, for unbiased expansion of CD3+ lymphocytes","year":2014,"lang":"en","type":"article","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"CD80; Biology; T cell; Molecular biology; Cancer research; Immunology; CD40; Cytotoxic T cell; In vitro; Immune system; Biochemistry","score_opus":0.09470279552810677,"score_gpt":0.39928785896147495,"score_spread":0.30458506343336816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2567305346","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96657884,0.000073717376,0.024948616,0.0013272219,0.00031757384,0.0014388039,0.000014613895,0.0001244984,0.005176088],"genre_scores_gemma":[0.98730594,0.00002519049,0.0060906624,0.0010507476,0.0005929678,0.00006918659,0.00006895431,0.000056999015,0.004739347],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975826,0.000213089,0.0007689494,0.0004441879,0.0005564241,0.00043475273],"domain_scores_gemma":[0.996845,0.0017896659,0.00013965955,0.00066119037,0.0002691991,0.00029529454],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016363242,0.00019517759,0.0006289268,0.00018563465,0.000065420805,0.000017497468,0.00017563156,0.00023426182,0.0019848258],"category_scores_gemma":[0.0006666844,0.00015482078,0.00045075302,0.00024180593,0.00022628545,0.00003483053,0.000037148515,0.00019790242,0.000061022027],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058096508,0.0014444229,0.0071441163,0.0004403812,0.000076144366,0.000008963333,0.000102200145,0.00006149382,0.885752,0.00051544624,0.006898445,0.09174672],"study_design_scores_gemma":[0.010309539,0.0029556253,0.0021982582,0.000096224976,0.00010335151,0.0000041468643,0.00011636284,0.036593795,0.9211005,0.0004938337,0.02580508,0.00022329266],"about_ca_topic_score_codex":0.00013844522,"about_ca_topic_score_gemma":0.00004186335,"teacher_disagreement_score":0.091523424,"about_ca_system_score_codex":0.00008591423,"about_ca_system_score_gemma":0.0004911204,"threshold_uncertainty_score":0.9989275},"labels":[],"label_agreement":null},{"id":"W2568716921","doi":"10.1182/blood.v120.21.3016.3016","title":"Discovering Optimal Targets for Adoptive T-Cell Immunotherapy of Leukemia.","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer","funders":"","keywords":"Antigen; Immunology; Adoptive cell transfer; Immunotherapy; CD8; Transplantation; CTL*; Leukemia; Cancer research; Cancer immunotherapy; Minor histocompatibility antigen; Biology; T cell; Major histocompatibility complex; Immune system; Medicine; Internal medicine","score_opus":0.022728131410619568,"score_gpt":0.2976592045055155,"score_spread":0.2749310730948959,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2568716921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864898,0.0033721314,0.0011653492,0.000043504304,0.00010406532,0.000686549,0.0000246347,0.000027624033,0.008086373],"genre_scores_gemma":[0.98671,0.00020488809,0.0072750687,0.000054685745,0.00036576597,0.00006404109,0.000025362522,0.000050053055,0.005250115],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989891,0.000020983849,0.00019512376,0.000145183,0.00023879725,0.0004107817],"domain_scores_gemma":[0.9993666,0.000089067486,0.00006433794,0.00028316327,0.00008229709,0.000114561306],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027519453,0.00012426345,0.00028564376,0.00007585691,0.000038203154,0.000007637368,0.00009921895,0.000074446216,0.00072781614],"category_scores_gemma":[0.000025788739,0.00010688135,0.00016525896,0.0001037204,0.00006293354,0.00010187668,0.000035729176,0.00013837263,0.000013653016],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00081926543,0.00088524376,0.008226359,0.00012425907,0.00021817921,0.00000323193,0.0012726295,0.000016523718,0.9847905,0.00009699278,0.00024020813,0.0033065993],"study_design_scores_gemma":[0.008445979,0.00078198744,0.004762812,0.000038654405,0.00009056343,0.000021979613,0.0002705382,0.000073668736,0.9690249,0.000014986983,0.01633813,0.00013582998],"about_ca_topic_score_codex":0.000037981397,"about_ca_topic_score_gemma":8.910862e-7,"teacher_disagreement_score":0.016097924,"about_ca_system_score_codex":0.000074345786,"about_ca_system_score_gemma":0.00012517154,"threshold_uncertainty_score":0.79690766},"labels":[],"label_agreement":null},{"id":"W2570331680","doi":"10.1182/blood.v124.21.2490.2490","title":"Selective Depletion of Recipient-Alloreactive T-Cells While Retaining Viral-Specific and Memory T-Cells Enables Safe and Efficacious Haplo-Identical HSCT","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Immunology; Antigen; Cancer immunotherapy; Cancer research; Immunotherapy; Medicine; Biology; Immune system","score_opus":0.016833925913653618,"score_gpt":0.25102648556191937,"score_spread":0.23419255964826574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2570331680","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862652,0.00065696513,0.00020529787,0.00011999952,0.000083214116,0.0006789369,0.000008889169,0.000050008315,0.011931534],"genre_scores_gemma":[0.99674064,0.00089255656,0.00083160435,0.000057988604,0.00018742122,0.00002412677,0.00001419451,0.00005259915,0.0011988448],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979336,0.00022408563,0.0003832924,0.00054418435,0.00050086743,0.00041396765],"domain_scores_gemma":[0.9985191,0.0005236899,0.00013232118,0.00036100295,0.00022340433,0.00024048798],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008351278,0.00022963037,0.0005356853,0.00022650289,0.000109503584,0.00004238144,0.00009316888,0.00017668282,0.00019706445],"category_scores_gemma":[0.00017726765,0.00021117598,0.00008805389,0.00022929886,0.00031799896,0.00009622447,0.00009970699,0.00040284492,0.000020722893],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00078624807,0.00057113357,0.0038602245,0.0001169303,0.00021003989,0.000024769526,0.001266779,0.0000027172207,0.9778645,0.00015896652,0.000323874,0.014813789],"study_design_scores_gemma":[0.007575357,0.0016088908,0.012404271,0.00020308935,0.00021077236,0.000110060704,0.00041818747,0.00024108101,0.973055,0.00027098006,0.0036469637,0.00025533614],"about_ca_topic_score_codex":0.00006941807,"about_ca_topic_score_gemma":0.000018057874,"teacher_disagreement_score":0.014558453,"about_ca_system_score_codex":0.000061901235,"about_ca_system_score_gemma":0.000060119375,"threshold_uncertainty_score":0.8611507},"labels":[],"label_agreement":null},{"id":"W2573216598","doi":"10.1007/s40265-017-0690-8","title":"Chimeric Antigen Receptor (CAR) T Cells: Lessons Learned from Targeting of CD19 in B-Cell Malignancies","year":2017,"lang":"en","type":"review","venue":"Drugs","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":146,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute","keywords":"Chimeric antigen receptor; Medicine; Immunotherapy; CD19; Cell therapy; Immunology; Lymphoma; Chronic lymphocytic leukemia; B cell; Cancer research; Clinical trial; T cell; Leukemia; Antigen; Oncology; Stem cell; Internal medicine; Immune system; Biology; Antibody","score_opus":0.15225248355467466,"score_gpt":0.40610138065618046,"score_spread":0.2538488971015058,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2573216598","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0034595453,0.98672205,0.0000022186332,0.00014788233,0.0004270382,0.0012362095,0.00025979598,0.000045080025,0.0077001695],"genre_scores_gemma":[0.00020649642,0.97885334,0.0005249958,0.000023127563,0.00047480894,0.00007750855,0.0006649536,0.00016066179,0.019014077],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965591,0.0003903142,0.0009581715,0.00077299273,0.0006716276,0.00064781297],"domain_scores_gemma":[0.9971857,0.00042104776,0.00077945896,0.0012974517,0.0001246585,0.00019170372],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010181979,0.00052698085,0.003053017,0.00045538033,0.00009751887,0.000050983454,0.0007332276,0.0004896784,0.003206335],"category_scores_gemma":[0.00021359161,0.00044785265,0.00078935025,0.00039740693,0.00022553676,0.00006897914,0.00027345488,0.0010566968,0.00051208714],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000050141687,0.00022022809,0.00008634125,0.010319764,0.0002150022,0.000049022827,0.0009780335,3.2691966e-7,0.040690243,0.0000047048716,0.003221155,0.94416505],"study_design_scores_gemma":[0.00082332874,0.00006937983,0.0000179171,0.011887444,0.00023368374,0.000002452245,0.00027952937,0.0000050366853,0.006152862,0.000014023147,0.98015636,0.00035796317],"about_ca_topic_score_codex":0.0015868768,"about_ca_topic_score_gemma":0.000018624909,"teacher_disagreement_score":0.9769352,"about_ca_system_score_codex":0.0002184319,"about_ca_system_score_gemma":0.00085198076,"threshold_uncertainty_score":0.99979734},"labels":[],"label_agreement":null},{"id":"W2573460873","doi":"10.1136/jnnp-2016-315106.143","title":"OCRELIZUMAB IN PRIMARY PROGRESSIVE MS: THE ORATORIO STUDY","year":2016,"lang":"en","type":"article","venue":"Journal of Neurology Neurosurgery & Psychiatry","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; NeuroRx Research (Canada)","funders":"","keywords":"Placebo; Medicine; Ocrelizumab; Clinical endpoint; Adverse effect; Internal medicine; Clinical trial; Surgery; Pathology; Rituximab","score_opus":0.019005072194279514,"score_gpt":0.3005907274350342,"score_spread":0.2815856552407547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2573460873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9446906,0.0009934129,0.000004311418,0.04908935,0.0038847816,0.0006791919,0.0000024688125,0.0000235527,0.0006323568],"genre_scores_gemma":[0.98942244,0.00034464942,0.000026035901,0.008171647,0.0014570802,0.000024403083,3.8099625e-7,0.00006879351,0.00048458407],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960744,0.0009957979,0.0011257527,0.0003941487,0.00084004697,0.0005698806],"domain_scores_gemma":[0.9972429,0.00092244305,0.00065054436,0.0006796977,0.0002762797,0.00022809868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014224378,0.00027278412,0.00074677373,0.00057182123,0.00009639331,0.00003198262,0.00043753718,0.00015445,0.00061598513],"category_scores_gemma":[0.0004113258,0.0001402377,0.0003352504,0.0006519106,0.00028465132,0.0001809943,0.00011427097,0.0014163342,0.00002831046],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00889566,0.0019754618,0.9429891,0.00002513009,0.00012760055,0.0041489317,0.0001273655,0.0000026048915,0.02000687,0.000015651256,0.0147221,0.006963492],"study_design_scores_gemma":[0.005670511,0.0068870056,0.9541241,0.00009442117,0.00007959151,0.0076525356,0.000059502727,0.0000024583808,0.00016855451,0.00023217889,0.024883516,0.00014562217],"about_ca_topic_score_codex":0.0000036503634,"about_ca_topic_score_gemma":0.0000095335845,"teacher_disagreement_score":0.044731855,"about_ca_system_score_codex":0.000066487155,"about_ca_system_score_gemma":0.00094456965,"threshold_uncertainty_score":0.67446053},"labels":[],"label_agreement":null},{"id":"W2575232561","doi":"10.1126/scitranslmed.aag2196","title":"Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma","year":2017,"lang":"en","type":"article","venue":"Science Translational Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":330,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bausch Health (Canada)","funders":"Ben and Catherine Ivy Foundation; National Cancer Institute; National Institute of Neurological Disorders and Stroke; Wellcome; Royal Society; Wellcome Trust","keywords":"Glioma; Cytotoxic T cell; Cancer research; Immunotherapy; Reporter gene; Medicine; Genetic enhancement; Gene; Pet imaging; Pathology; Immunology; Biology; Gene expression; Positron emission tomography; Immune system; Nuclear medicine; In vitro; Genetics","score_opus":0.04301497310250961,"score_gpt":0.3738410366915573,"score_spread":0.3308260635890477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2575232561","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.971753,0.0018666699,0.00038157156,0.010095224,0.0004075129,0.0005189025,0.0000058316814,0.000017153629,0.014954116],"genre_scores_gemma":[0.99790704,0.00012118706,0.0012511229,0.00010935127,0.00016724507,0.000011896808,0.000013469235,0.0000134745615,0.00040520608],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99736136,0.000028465338,0.0005123962,0.00037624655,0.0013832643,0.00033824902],"domain_scores_gemma":[0.9985925,0.0000710883,0.0002041391,0.00066698116,0.00031974752,0.00014555482],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020403052,0.00012772938,0.0003181894,0.000550899,0.00019693693,0.000019577568,0.00040250694,0.000028045575,0.0021662596],"category_scores_gemma":[0.00020364593,0.000098216005,0.000062592815,0.00050497137,0.001803026,0.0002634636,0.000022250786,0.00018673575,0.0000047213766],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033398345,0.00009858997,0.060706794,0.000029048642,0.000006798373,0.00007257379,0.0008523425,0.0000054594784,0.89797485,0.000068353904,0.000043015807,0.039808203],"study_design_scores_gemma":[0.0054925433,0.00031385006,0.7129175,0.0002699021,0.000016155538,0.0001303317,0.000109456596,0.0023357577,0.2758324,0.0011084087,0.0013352381,0.00013844758],"about_ca_topic_score_codex":0.0002235411,"about_ca_topic_score_gemma":0.000023658476,"teacher_disagreement_score":0.6522107,"about_ca_system_score_codex":0.0000707811,"about_ca_system_score_gemma":0.00046886943,"threshold_uncertainty_score":0.9987459},"labels":[],"label_agreement":null},{"id":"W2578427280","doi":"10.1182/blood.v126.23.1355.1355","title":"Efficacy and Safety of Allogeneic Double Negative T Cell As a Cellular Therapy for AML and Its Underlying Mechanism","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Chemotherapy; Myeloid leukemia; Leukemia; CD8; Minimal residual disease; Medicine; Immunology; Hematopoietic stem cell transplantation; Chemotherapy regimen; Transplantation; Haematopoiesis; Stem cell; Cancer research; Oncology; Internal medicine; Immune system; Biology","score_opus":0.08970118677423887,"score_gpt":0.3391773637705651,"score_spread":0.24947617699632624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2578427280","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915924,0.0037544302,0.00018603451,0.00023438263,0.000034861507,0.001674413,0.000008400223,0.00002430727,0.0024907645],"genre_scores_gemma":[0.9958401,0.00084198575,0.00080156256,0.000079326244,0.00006325182,0.000045568653,0.000009992519,0.00003672133,0.0022815233],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989821,0.00004628067,0.00018886168,0.00027292583,0.00026202408,0.00024784755],"domain_scores_gemma":[0.99915814,0.00018045622,0.00006594414,0.00019718209,0.00017386994,0.00022438426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042249207,0.00014174532,0.0003076792,0.0000833486,0.000056865367,0.000016515052,0.000071220216,0.000099279976,0.00012640955],"category_scores_gemma":[0.000046114455,0.00011891185,0.000051551106,0.00010624641,0.00005660215,0.000043953245,0.000049010963,0.0001176619,0.0000058742603],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003907137,0.0004725737,0.00019970103,0.00010723791,0.00019345996,0.000014760868,0.0016961667,0.0000013438743,0.9900457,0.0010138957,0.000018715287,0.002329264],"study_design_scores_gemma":[0.045548987,0.0024770007,0.00028575468,0.000043957632,0.00010812258,0.0000308091,0.0003636903,0.00009350969,0.9476754,0.002223527,0.0010254981,0.00012371838],"about_ca_topic_score_codex":0.00004664573,"about_ca_topic_score_gemma":0.0000040269338,"teacher_disagreement_score":0.04237032,"about_ca_system_score_codex":0.000020640282,"about_ca_system_score_gemma":0.0001524692,"threshold_uncertainty_score":0.48490846},"labels":[],"label_agreement":null},{"id":"W2579077000","doi":"10.1182/blood.v114.22.3580.3580","title":"PD-L1 Immuno-Gene Therapy Under Cell Fate Control: Persistence of Cellular Delivery Vehicle and Transgene Expression.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Ontario Institute for Cancer Research","funders":"","keywords":"Biology; Jurkat cells; Genetic enhancement; CD19; Gene delivery; T cell; Cell biology; Transgene; Viral vector; Transfection; Cell therapy; Ex vivo; Molecular biology; Flow cytometry; Immune system; In vivo; Gene; Stem cell; Immunology; Genetics; Recombinant DNA","score_opus":0.02661883014036972,"score_gpt":0.2510072339640696,"score_spread":0.22438840382369987,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2579077000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9800045,0.017313434,0.00020465345,0.00045062034,0.000029398521,0.00047242825,0.000013366582,0.000036998623,0.0014745829],"genre_scores_gemma":[0.99380916,0.0036477472,0.00037139657,0.00041067015,0.00007720761,0.000009130826,0.000009488064,0.000027570399,0.0016376297],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985778,0.00009366108,0.0002719768,0.00031303882,0.0004089404,0.00033460557],"domain_scores_gemma":[0.999125,0.000077381155,0.000066690016,0.00043414213,0.00013395703,0.00016280734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024341625,0.00018287743,0.00038030616,0.000097711396,0.00007866547,0.000017597353,0.00015074444,0.00012020223,0.0005699286],"category_scores_gemma":[0.0000070312485,0.00013722638,0.00016293884,0.00015666946,0.00012221053,0.000065768654,0.00001552069,0.00020861221,0.000008392687],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011625001,0.0008807711,0.00081926107,0.00003441427,0.0001026585,0.000037160877,0.00041913823,0.000011509844,0.9912014,0.000004385469,0.000024343166,0.0053024786],"study_design_scores_gemma":[0.013643253,0.0012090638,0.011546348,0.000054490265,0.00010318471,0.00002463708,0.000173523,0.000080687176,0.9725204,0.000067435845,0.00043148792,0.00014546922],"about_ca_topic_score_codex":0.00002975131,"about_ca_topic_score_gemma":8.9322674e-7,"teacher_disagreement_score":0.018680958,"about_ca_system_score_codex":0.000018262237,"about_ca_system_score_gemma":0.00007838496,"threshold_uncertainty_score":0.62403184},"labels":[],"label_agreement":null},{"id":"W2581462115","doi":"10.1172/jci.insight.89580","title":"Transient stimulation expands superior antitumor T cells for adoptive therapy","year":2017,"lang":"en","type":"article","venue":"JCI Insight","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Japan Society for the Promotion of Science; National Institutes of Health; University of Toronto; National Cancer Institute; Princess Margaret Cancer Foundation","keywords":"CD28; Adoptive cell transfer; Cell therapy; CD8; Immunotherapy; Cytotoxic T cell; T cell; Immunology; Cancer research; Stimulation; Medicine; Chimeric antigen receptor; Antigen; Biology; Cell biology; Immune system; In vitro; Stem cell; Internal medicine","score_opus":0.07534149144604835,"score_gpt":0.3615606458141226,"score_spread":0.28621915436807427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2581462115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9775912,0.00044075242,0.00096693885,0.0007975318,0.00044657054,0.0017916847,0.000027166427,0.000058033915,0.017880099],"genre_scores_gemma":[0.98797446,0.0006669233,0.0006734956,0.00024985662,0.00047708693,0.00011166695,0.00003279287,0.000047075784,0.009766659],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987999,0.000026940914,0.00020770045,0.00031100403,0.00034162911,0.00031277715],"domain_scores_gemma":[0.9988146,0.00008572152,0.00007172567,0.0006636666,0.00021899685,0.00014530479],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00019591727,0.0001648326,0.0003099738,0.00010826465,0.00033476859,0.00010827214,0.00018055105,0.00010336646,0.0014460111],"category_scores_gemma":[0.00003764269,0.00012921626,0.00018287812,0.000058468344,0.00013157733,0.00018342515,0.000016899452,0.00015856152,0.00004267165],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025831745,0.00036505394,0.0021392049,0.00006530011,0.000110274304,0.00004286111,0.0033338983,0.00001793094,0.93907577,0.00016539833,0.0013980711,0.050703082],"study_design_scores_gemma":[0.00972475,0.0019536016,0.030158205,0.00008861364,0.000044689343,0.000012477362,0.00013175188,0.001878327,0.6151514,0.00011420278,0.34048104,0.00026093057],"about_ca_topic_score_codex":0.000036664605,"about_ca_topic_score_gemma":0.0000117809395,"teacher_disagreement_score":0.339083,"about_ca_system_score_codex":0.000073241106,"about_ca_system_score_gemma":0.00011167857,"threshold_uncertainty_score":0.9994668},"labels":[],"label_agreement":null},{"id":"W2581473011","doi":"10.1182/blood.v114.22.3032.3032","title":"Superior Cytotoxicity of Clonal Versus Polyclonal Gamma Delta T Cells against Philadelphia Chromosome Positive and B-CLL Derived Leukemic Cells.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Biology; Immunology; Flow cytometry; Molecular biology; Cancer research","score_opus":0.019217311547471562,"score_gpt":0.2717472288953481,"score_spread":0.2525299173478765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2581473011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954489,0.0008684597,0.000009555953,0.00064831885,0.00011941196,0.0006473716,0.00017929217,0.00005739444,0.0020212992],"genre_scores_gemma":[0.99764967,0.0005574162,0.00044654813,0.0005750528,0.00036794785,0.000011208322,0.000078973964,0.000043527165,0.00026967024],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99773556,0.000081249986,0.00041853514,0.00051743654,0.0006607776,0.0005864225],"domain_scores_gemma":[0.9987772,0.00016993204,0.00010499794,0.00040844918,0.00018275598,0.00035662614],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00021141049,0.00032023963,0.0005920023,0.00020477701,0.00010041229,0.000030197361,0.00020302116,0.00022029971,0.00060485053],"category_scores_gemma":[0.000034674667,0.00031034107,0.00020595186,0.00029682796,0.0003195055,0.000102787744,0.0000905485,0.00045691684,0.000024255962],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028010728,0.00088257843,0.00063044124,0.00005742466,0.00025018334,0.00027492252,0.00035558848,0.0000037904342,0.992743,0.000018413142,0.00013411556,0.0018484683],"study_design_scores_gemma":[0.014307762,0.0021622947,0.024650974,0.00010835448,0.00019542867,0.00013239413,0.000072611016,0.000098751225,0.95770985,0.000022188198,0.0002669972,0.00027241293],"about_ca_topic_score_codex":0.00007984522,"about_ca_topic_score_gemma":0.000015562966,"teacher_disagreement_score":0.03503317,"about_ca_system_score_codex":0.00013606445,"about_ca_system_score_gemma":0.00035185448,"threshold_uncertainty_score":0.99993485},"labels":[],"label_agreement":null},{"id":"W2583075130","doi":"10.1016/j.molmed.2016.12.004","title":"Cell-Based Therapeutics: Making a Faustian Pact with Biology","year":2017,"lang":"en","type":"article","venue":"Trends in Molecular Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Simon Fraser University; Canada's Michael Smith Genome Sciences Centre","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research","keywords":"Context (archaeology); Synthetic biology; Biology; Computational biology; Repurposing; Systems biology; Neuroscience; Computer science","score_opus":0.05970813121522932,"score_gpt":0.40620568239687505,"score_spread":0.3464975511816457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2583075130","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.67144835,0.0041544447,0.013478352,0.042190447,0.00041869795,0.0010242575,0.0000124691915,0.0002145947,0.2670584],"genre_scores_gemma":[0.9935504,0.00004518814,0.0013570698,0.0022364957,0.00017502112,0.000031542335,0.00004526052,0.000064606196,0.0024944008],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99813807,0.00011523475,0.00028211396,0.00045913996,0.00045679783,0.0005486136],"domain_scores_gemma":[0.99818826,0.00007255474,0.00015135077,0.0013429782,0.00008502724,0.00015981322],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004943245,0.0002738692,0.0005496364,0.0005943333,0.00012534735,0.000023725479,0.00036805304,0.00015849604,0.00317796],"category_scores_gemma":[0.00007191182,0.00018509943,0.00008511558,0.0002906096,0.0006693399,0.00003385401,0.00005296075,0.00053681375,0.000014416656],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017382228,0.0002999185,0.065267414,0.00011271892,0.00020337157,0.0027399475,0.00062114175,0.000031371485,0.71226895,0.00019092187,0.00029266108,0.21623336],"study_design_scores_gemma":[0.095717415,0.022225495,0.46158898,0.0042244405,0.001498334,0.0006561177,0.0012270701,0.009368953,0.2510098,0.0010763819,0.14925335,0.0021536665],"about_ca_topic_score_codex":0.00031144355,"about_ca_topic_score_gemma":0.00009143314,"teacher_disagreement_score":0.4612592,"about_ca_system_score_codex":0.000117920674,"about_ca_system_score_gemma":0.00011290478,"threshold_uncertainty_score":0.9977333},"labels":[],"label_agreement":null},{"id":"W2583613336","doi":"10.18632/oncotarget.15088","title":"Turn to TCRs when CARs fail","year":2017,"lang":"en","type":"letter","venue":"Oncotarget","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Medicine; Computational biology; Neuroscience; Biology","score_opus":0.04420339295434641,"score_gpt":0.3412371811177224,"score_spread":0.297033788163376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2583613336","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0066879857,0.00052788865,0.000016335867,0.866995,0.0013625303,0.0011814224,0.00015370281,0.0001301618,0.12294497],"genre_scores_gemma":[0.00025540046,0.00007597212,0.0007461736,0.44849902,0.011578761,0.000092178256,0.00055840856,0.00018326454,0.53801084],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.996392,0.00010973996,0.00035166417,0.00081195874,0.001343671,0.000990931],"domain_scores_gemma":[0.9968585,0.00012713912,0.00015383412,0.0022248842,0.000249251,0.00038644258],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00041910875,0.0004898729,0.000987212,0.0003704182,0.00015850196,0.00016371738,0.0008307918,0.0010413927,0.019370764],"category_scores_gemma":[0.0002540678,0.0004299084,0.00040890486,0.00009861465,0.00014646628,0.00007527667,0.00026126465,0.0031918776,0.003692881],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012116648,0.000024280253,0.0015297261,0.00017869088,0.00022344985,0.0035231642,0.0005430964,3.4100327e-7,0.0036630456,0.00000173717,0.9867138,0.0034774982],"study_design_scores_gemma":[0.0009378031,0.00038329634,0.00073506683,0.00025565672,0.000099984456,0.00013868949,0.000019941202,0.0000048040706,0.00054821,0.00014596626,0.99634844,0.00038212736],"about_ca_topic_score_codex":0.00083577377,"about_ca_topic_score_gemma":0.000063510415,"teacher_disagreement_score":0.41849598,"about_ca_system_score_codex":0.00052307197,"about_ca_system_score_gemma":0.00055957003,"threshold_uncertainty_score":0.9998153},"labels":[],"label_agreement":null},{"id":"W2584913109","doi":"10.1172/jci89455","title":"Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Investigation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":321,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"Peter MacCallum Cancer Centre","keywords":"Chimeric antigen receptor; Cancer research; Adenosine; T cell; CD8; Antigen; Adenosine A2A receptor; Immunology; Receptor; Chemistry; Medicine; Adenosine receptor; Biology; Pharmacology; Immune system; Internal medicine","score_opus":0.11478170529418573,"score_gpt":0.4295939475704932,"score_spread":0.31481224227630744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2584913109","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9736769,0.0007489386,0.00008357565,0.02216284,0.0015789095,0.00033708217,0.0000020243483,0.0000151038585,0.0013945819],"genre_scores_gemma":[0.9790823,0.003754917,0.0053841327,0.0010059308,0.0064157466,0.0000039059682,0.000012540987,0.000038968858,0.0043015913],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99665457,0.000465768,0.0015564621,0.00022402083,0.0008261105,0.0002730491],"domain_scores_gemma":[0.9951717,0.0011788377,0.0021359387,0.0005335212,0.0005753466,0.00040461746],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005168532,0.0001598,0.00060897594,0.00008647118,0.0004101944,0.00016192258,0.0005647771,0.00018416537,0.0017924565],"category_scores_gemma":[0.009536851,0.00009791174,0.00036965997,0.00014450015,0.00072908995,0.0003339617,0.000084831874,0.0012142959,0.00016847851],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011196471,0.0003588737,0.11746644,0.000059113765,0.00019830247,0.000016026575,0.0004901883,0.000018554409,0.78416723,0.000025778394,0.04830845,0.047771413],"study_design_scores_gemma":[0.006603254,0.0029808453,0.34838885,0.00074175536,0.00021399483,0.000046801713,0.00029418853,0.0006097345,0.3909094,0.0005105523,0.24837977,0.00032086734],"about_ca_topic_score_codex":0.000019900906,"about_ca_topic_score_gemma":0.0000012640672,"teacher_disagreement_score":0.39325783,"about_ca_system_score_codex":0.00004984423,"about_ca_system_score_gemma":0.00045616232,"threshold_uncertainty_score":0.99912006},"labels":[],"label_agreement":null},{"id":"W2586528038","doi":"10.1016/s0923-7534(21)00568-8","title":"410P Ipilimumab efficacy and safety profile in metastatic melanoma in Saskatchewan","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan","funders":"","keywords":"Ipilimumab; Medicine; Internal medicine; Melanoma; Adverse effect; Oncology; Metastatic melanoma; Retrospective cohort study; Confidence interval; Surgery; Immunotherapy; Cancer; Cancer research","score_opus":0.08230944959589033,"score_gpt":0.40613393726275415,"score_spread":0.32382448766686384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2586528038","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97654665,0.00045403023,0.000008374836,0.013259042,0.00003807121,0.0006193606,0.000012339248,0.000010710293,0.009051429],"genre_scores_gemma":[0.9949755,0.00062423944,0.00046800368,0.00042885437,0.0000366237,0.000035815578,0.0000054896996,0.000017252694,0.0034082027],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9985326,0.00025708985,0.00041600238,0.00025063343,0.00018032448,0.00036333568],"domain_scores_gemma":[0.99860024,0.0007980261,0.00007907337,0.00031979752,0.00008841091,0.000114443574],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010200822,0.000110841,0.0005579055,0.0002971559,0.000012226732,0.0000023822595,0.00012138927,0.000104729326,0.00196995],"category_scores_gemma":[0.00044297279,0.00007644503,0.000047625505,0.0002476129,0.0002163412,0.000053839925,0.000095787975,0.00017774188,0.00003215124],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059002535,0.0009037752,0.022693869,0.00010089722,0.000088954985,0.0002938234,0.0017820997,7.4751733e-7,0.14216585,0.00012081193,0.0013063648,0.82464254],"study_design_scores_gemma":[0.048351698,0.018113568,0.71001136,0.00064345193,0.00005756128,0.00027385628,0.0027644937,0.00007159901,0.09431571,0.002457305,0.12253301,0.00040639596],"about_ca_topic_score_codex":0.00030909042,"about_ca_topic_score_gemma":0.0016396382,"teacher_disagreement_score":0.82423615,"about_ca_system_score_codex":0.00008648447,"about_ca_system_score_gemma":0.0004269467,"threshold_uncertainty_score":0.9989424},"labels":[],"label_agreement":null},{"id":"W2587000238","doi":"10.1093/neuonc/now212.409","title":"IMST-53. THE EFFICACY OF CD133 BiTEs AND CAR-T CELLS IN PRECLINICAL MODEL OF RECURRENT GLIOBLASTOMA","year":2016,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McMaster University","funders":"","keywords":"Chimeric antigen receptor; Antigen; Cytotoxic T cell; Monoclonal antibody; Cancer research; Antibody; T cell; Glioma; Biology; Immunology; Immune system; In vitro","score_opus":0.05883081224816337,"score_gpt":0.37817687441619924,"score_spread":0.31934606216803585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587000238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936982,0.00019193927,0.000020146574,0.004019256,0.0001950905,0.00067632506,0.000020257074,0.000013282929,0.0011655147],"genre_scores_gemma":[0.9980602,0.0009919793,0.00013736157,0.00024814784,0.00010733927,0.000028375607,8.467324e-7,0.000024003708,0.00040169907],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981063,0.00038283085,0.0005732127,0.00033682198,0.0002926382,0.0003081684],"domain_scores_gemma":[0.9948985,0.0042137215,0.00016967993,0.0004637807,0.00012819315,0.00012611627],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069831643,0.00013731912,0.00058159354,0.00017772634,0.000019060428,0.000002804023,0.00020021768,0.00018776135,0.00030643446],"category_scores_gemma":[0.00089909707,0.000070785834,0.000116937525,0.0002133418,0.00058203266,0.000029941359,0.00017984357,0.00037409854,0.000013731824],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041123754,0.00049527746,0.0038129692,0.000048545728,0.00002580724,0.000022098488,0.00045803897,0.000014889376,0.8779774,0.0000644376,0.00069650187,0.112271674],"study_design_scores_gemma":[0.013244255,0.015160346,0.008723427,0.00018943145,0.0001028658,0.00009997991,0.000114082744,0.0037054608,0.9296714,0.00044420536,0.028367281,0.00017725561],"about_ca_topic_score_codex":0.00001620771,"about_ca_topic_score_gemma":0.00007154377,"teacher_disagreement_score":0.112094425,"about_ca_system_score_codex":0.000083383,"about_ca_system_score_gemma":0.00029613407,"threshold_uncertainty_score":0.33552426},"labels":[],"label_agreement":null},{"id":"W2587952432","doi":"10.1182/blood.v106.11.63.63","title":"Adoptive Transfer of In Vitro Generated T Cell Precursors Enhances Donor T Cell Reconstitution and Graft-Versus-Tumor Activity in Allogeneic Hematopoietic Stem Cell Transplantation Recipients.","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Stem cell; Biology; Haematopoiesis; Bone marrow; T cell; Transplantation; Immunology; CD8; Stromal cell; Lymphopoiesis; Adoptive cell transfer; Cancer research; Molecular biology; Cell biology; Antigen; Internal medicine; Immune system; Medicine","score_opus":0.021396971761077764,"score_gpt":0.2620470736761161,"score_spread":0.24065010191503836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2587952432","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99554074,0.0009270002,0.00012179757,0.000057556088,0.00007847421,0.0009779639,0.00004471356,0.00002256932,0.002229169],"genre_scores_gemma":[0.99748075,0.0015555738,0.00043755007,0.00001803665,0.00004385518,0.00007460731,0.000035568788,0.000024160863,0.00032988898],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982893,0.00021311434,0.00040254992,0.00043631284,0.00030395074,0.00035475538],"domain_scores_gemma":[0.99942,0.0001284386,0.00007261954,0.0001900101,0.00006944366,0.00011950853],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038654634,0.00021999142,0.00043227707,0.0003274567,0.00003487972,0.000013111752,0.00009032551,0.00014328047,0.0001384062],"category_scores_gemma":[0.0000045985066,0.00021562408,0.00008163206,0.00043024938,0.00013371043,0.00017647586,0.000010432098,0.00030923876,0.0000073390215],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004771491,0.0018167385,0.004767855,0.00046500601,0.000028886925,0.000048943657,0.0029082722,0.00007993065,0.9807922,0.0000032099447,0.0000024255207,0.0043150065],"study_design_scores_gemma":[0.0134177385,0.0005233282,0.0054274136,0.00011748628,0.0001407544,0.000021197804,0.00027816487,0.00015475934,0.9796748,0.0000028009754,0.000056375815,0.00018513977],"about_ca_topic_score_codex":0.0001459901,"about_ca_topic_score_gemma":0.0005378691,"teacher_disagreement_score":0.008646247,"about_ca_system_score_codex":0.00011604819,"about_ca_system_score_gemma":0.00017526331,"threshold_uncertainty_score":0.8792895},"labels":[],"label_agreement":null},{"id":"W2592318296","doi":"10.1080/2162402x.2017.1299303","title":"Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma","year":2017,"lang":"en","type":"review","venue":"OncoImmunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Institut National Du Cancer","keywords":"Immune system; Medicine; Melanoma; Immune checkpoint; Adjuvant; Immunotherapy; Blockade; Immunology; Cancer research; Internal medicine; Receptor","score_opus":0.09316718438393705,"score_gpt":0.39413803994122476,"score_spread":0.3009708555572877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2592318296","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009614294,0.9832396,0.000005682472,0.00042908324,0.0003508463,0.0053362357,0.00023112868,0.00004722079,0.0007458963],"genre_scores_gemma":[0.0012439577,0.9903524,0.00053572154,0.000006560516,0.000105037616,0.0013589773,0.00020187542,0.00011793433,0.0060775345],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99662507,0.00038085892,0.0014447642,0.00068426295,0.00024987085,0.00061515864],"domain_scores_gemma":[0.9970293,0.00080566976,0.0006531621,0.0012158585,0.00018769439,0.00010831847],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012083821,0.0004847424,0.0032618397,0.0012321714,0.00011023639,0.000026966762,0.00046943474,0.0008568232,0.00022057547],"category_scores_gemma":[0.0013061304,0.00041905456,0.00059876667,0.0003354124,0.00047263812,0.000044490913,0.00032724923,0.0006384695,0.000018777459],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003800987,0.0002562347,0.0001970956,0.008207562,0.0013167144,0.00013482316,0.00020956015,3.1901873e-8,0.03012276,0.00000774761,0.000029285824,0.9557172],"study_design_scores_gemma":[0.002313922,0.004167934,0.0022397672,0.012195738,0.00078249985,0.0024428244,0.00008482823,0.0000058778573,0.0017043476,0.000019558836,0.9737584,0.00028428854],"about_ca_topic_score_codex":0.00042964437,"about_ca_topic_score_gemma":0.00003551473,"teacher_disagreement_score":0.97372913,"about_ca_system_score_codex":0.00046149534,"about_ca_system_score_gemma":0.00083014445,"threshold_uncertainty_score":0.99982613},"labels":[],"label_agreement":null},{"id":"W2594407313","doi":"10.1158/2326-6074.tumimm16-pr09","title":"Abstract PR09: A novel chimeric antigen receptor containing JAK-STAT signaling domains mediates superior antitumor effects","year":2017,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Chimeric antigen receptor; Cancer research; CD19; Cytokine; CD28; STAT5; T cell; T-cell receptor; JAK-STAT signaling pathway; Cytokine receptor; Signal transduction; Immunology; Biology; Medicine; Tyrosine kinase; Cell biology; Antigen; Immune system","score_opus":0.08268631610408858,"score_gpt":0.4196002134770678,"score_spread":0.33691389737297917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594407313","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9822592,0.009577832,0.00002393453,0.0024655925,0.0008572078,0.0017844898,0.00004757858,0.000112096866,0.00287203],"genre_scores_gemma":[0.988214,0.006160513,0.00037131712,0.00011741418,0.0008595166,0.00058577076,0.000053063763,0.00013651172,0.0035018933],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99518883,0.00030840983,0.0005103927,0.0009238739,0.0011319913,0.0019364747],"domain_scores_gemma":[0.9957231,0.0012487418,0.00020018248,0.0016176415,0.00082365813,0.0003866496],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0026911946,0.0003873707,0.0009411599,0.00063785224,0.0016336449,0.00031073755,0.0011894173,0.00038176455,0.00583867],"category_scores_gemma":[0.0022404005,0.00034469357,0.00022297673,0.00044265683,0.0024149206,0.00033642584,0.0006129514,0.0022604417,0.00042738896],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027502119,0.00022752293,0.06103952,0.00026922786,0.0007247382,0.00031513016,0.0010541041,0.0000020976872,0.9105674,0.00006856083,0.0004629064,0.02251855],"study_design_scores_gemma":[0.008689327,0.0018423595,0.37700698,0.0010017299,0.000050950366,0.00011853015,0.0011549594,0.00007158225,0.58360624,0.000056253262,0.025908079,0.00049303024],"about_ca_topic_score_codex":0.0025195747,"about_ca_topic_score_gemma":0.0001264511,"teacher_disagreement_score":0.3269612,"about_ca_system_score_codex":0.00065402046,"about_ca_system_score_gemma":0.001597994,"threshold_uncertainty_score":0.9999005},"labels":[],"label_agreement":null},{"id":"W2594697025","doi":"10.1158/2326-6074.tumimm16-a74","title":"Abstract A74: CAR-T cells harboring camelid single domain antibody as targeting agent to CEACAM6 antigen in pancreatic cancer","year":2017,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada; Helix Biopharma (Canada)","funders":"","keywords":"Antigen; Antibody; Cancer research; Cytotoxic T cell; Biology; CD28; Chimeric antigen receptor; T cell; Pancreatic cancer; Molecular biology; Immunology; Cancer; Immune system; In vitro; CD8; Biochemistry","score_opus":0.0871099523506898,"score_gpt":0.44197770087871424,"score_spread":0.35486774852802444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594697025","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9727054,0.009814563,0.0000066668827,0.004255661,0.0008124303,0.0018165241,0.000035545185,0.000061984356,0.010491218],"genre_scores_gemma":[0.9803113,0.009920112,0.00018919108,0.0001809128,0.000699361,0.0006651366,0.000024068559,0.00013017857,0.007879744],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9944466,0.00041208553,0.0006500999,0.0010702916,0.0011724579,0.0022485154],"domain_scores_gemma":[0.9965926,0.00037079075,0.00017754221,0.0017504671,0.00066619896,0.00044241562],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002955316,0.00038684503,0.00089826924,0.0008967265,0.0008889546,0.00026028664,0.001224664,0.00038751328,0.007778044],"category_scores_gemma":[0.0007689151,0.00037400395,0.00016945023,0.000624599,0.00087702234,0.0002393386,0.0008130729,0.0021857682,0.0005309794],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013526869,0.00022059423,0.10739887,0.00016584517,0.00028759264,0.00073479913,0.0016108529,0.000025608013,0.8720008,0.000025251285,0.0010920732,0.01508499],"study_design_scores_gemma":[0.0029777386,0.00063145976,0.4143162,0.0010210495,0.000024143523,0.000024512186,0.0014532887,0.000026503374,0.5222064,0.00009070039,0.05679513,0.0004328045],"about_ca_topic_score_codex":0.038520765,"about_ca_topic_score_gemma":0.0014971272,"teacher_disagreement_score":0.3497944,"about_ca_system_score_codex":0.0021824662,"about_ca_system_score_gemma":0.0014596179,"threshold_uncertainty_score":0.9998712},"labels":[],"label_agreement":null},{"id":"W2594993143","doi":"10.1182/blood.v120.21.1909.1909","title":"Irradiated NK-92 Targets AML Leukemic Stem Cells in Vivo and Gene-Modified CD16+NK-92 Mediates Antibody Dependent Cell Mediated Cytotoxicity (ADCC) Against CD123+ Cells","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Antibody-dependent cell-mediated cytotoxicity; Cancer research; Leukemia; Stem cell; CD38; CD34; Cytotoxic T cell; Biology; Immunology; Antibody; Monoclonal antibody; In vitro; Cell biology","score_opus":0.020130242991296392,"score_gpt":0.27302105172603636,"score_spread":0.25289080873473996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2594993143","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98678327,0.006048175,0.000021629457,0.00010112132,0.00055273494,0.0021354994,0.00030425037,0.00025209336,0.0038012343],"genre_scores_gemma":[0.98844826,0.006949139,0.00022609967,0.00045659524,0.00061099755,0.00010321286,0.00023538384,0.00020358106,0.0027667154],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99384594,0.0005225439,0.0011181951,0.0010805812,0.0013818422,0.0020508799],"domain_scores_gemma":[0.99646896,0.00063748675,0.000336625,0.000994576,0.00021322444,0.001349129],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015710669,0.00082003867,0.0012909694,0.0007674757,0.00018460811,0.000099514335,0.00052250765,0.0006982788,0.0008802586],"category_scores_gemma":[0.0000862473,0.0007676188,0.00024574203,0.0008680162,0.00028564598,0.00033543725,0.00032179386,0.0011859965,0.00031255058],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046416346,0.002754369,0.032775823,0.00045505754,0.000247265,0.0004029309,0.0015195126,0.000041581883,0.96047604,0.000005345091,0.00055754656,0.00030038244],"study_design_scores_gemma":[0.01442692,0.0004822605,0.010324372,0.00014705656,0.00023153679,0.00006873172,0.00032699728,0.0008423055,0.971427,0.000013802916,0.00095529045,0.0007536996],"about_ca_topic_score_codex":0.000509302,"about_ca_topic_score_gemma":0.00014579782,"teacher_disagreement_score":0.022451451,"about_ca_system_score_codex":0.00044024695,"about_ca_system_score_gemma":0.00045579878,"threshold_uncertainty_score":0.9994775},"labels":[],"label_agreement":null},{"id":"W2596837612","doi":"10.1182/blood.v128.22.221.221","title":"Analysis of a Global Registration Trial of the Efficacy and Safety of CTL019 in Pediatric and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hospital for Sick Children; University of Toronto; Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Medicine; Clinical endpoint; Clinical trial; Internal medicine; Cytokine release syndrome; Adverse effect; Salvage therapy; Oncology; Chimeric antigen receptor; Chemotherapy; Immunotherapy; Cancer","score_opus":0.009385437605929787,"score_gpt":0.2620527594645376,"score_spread":0.2526673218586078,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2596837612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9986573,0.00022792513,0.000017324017,0.000060284052,0.000023436201,0.00052214885,0.000040615676,0.000004541671,0.00044641146],"genre_scores_gemma":[0.99883294,0.0009362623,0.000038571194,0.0000037726074,0.000042901007,0.0000058026076,0.0000045072297,0.0000072321727,0.00012799664],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998806,0.00009133231,0.00037844924,0.0002007851,0.00039468723,0.00012876611],"domain_scores_gemma":[0.99903417,0.00023974018,0.00024750075,0.000320382,0.000102548576,0.000055643868],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003113002,0.00009601407,0.00039740908,0.00013641248,0.000013071594,0.0000031267505,0.0000767195,0.000082376726,0.000026601496],"category_scores_gemma":[0.0002263258,0.00005251746,0.00007266801,0.0007690954,0.00015847624,0.00004363099,0.000037162717,0.00006765366,1.537205e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11846914,0.00084734097,0.8278735,0.00019829907,0.0016149766,0.0000158244,0.0005161626,0.000007043569,0.045176335,0.000048303464,0.000010035339,0.00522303],"study_design_scores_gemma":[0.12192516,0.001796846,0.8708949,0.00014203643,0.0032149667,0.000018698282,0.000037479753,0.000044794135,0.0018518569,0.000007432431,0.000005713655,0.000060120332],"about_ca_topic_score_codex":0.0002586355,"about_ca_topic_score_gemma":0.0005035395,"teacher_disagreement_score":0.043324478,"about_ca_system_score_codex":0.00009564953,"about_ca_system_score_gemma":0.0003175771,"threshold_uncertainty_score":0.21415998},"labels":[],"label_agreement":null},{"id":"W2597783812","doi":"10.1158/1078-0432.ccr-15-2440","title":"Molecular Pathways: Evaluating the Potential for B7-H4 as an Immunoregulatory Target","year":2017,"lang":"en","type":"review","venue":"Clinical Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Blockade; Medicine; Cancer research; Fusion protein; Cytokine; Chimeric antigen receptor; T cell; Cancer; Antibody; Immunology; Immunotherapy; Antigen; Receptor; Biology; Immune system; Internal medicine; Gene","score_opus":0.6778716969775834,"score_gpt":0.676147262922812,"score_spread":0.0017244340547714065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597783812","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002227662,0.9852117,0.000027467338,0.0005843633,0.001027023,0.008738006,0.00017014654,0.0000625878,0.0019510933],"genre_scores_gemma":[0.0002258419,0.9782235,0.00026348673,0.0002035635,0.004921459,0.0043219766,0.00032170152,0.00032927177,0.011189171],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9862432,0.004900676,0.0018984271,0.0017000156,0.0035511055,0.0017065669],"domain_scores_gemma":[0.9883167,0.0036857317,0.0005993628,0.004470748,0.002089537,0.0008379147],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.032838363,0.0006147731,0.0030755703,0.00039610855,0.0011684266,0.00041979717,0.0027632376,0.0011854733,0.0042759376],"category_scores_gemma":[0.008146278,0.0003942833,0.002530152,0.00047537917,0.00214401,0.00012935264,0.00096367486,0.0056129596,0.00027403858],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013349771,0.00029610292,0.0000111970085,0.006483961,0.0009071432,0.00015750868,0.00003883609,0.0000026743414,0.00023505033,0.00021298375,0.0020201071,0.9882994],"study_design_scores_gemma":[0.0021314253,0.0041925213,0.000053988002,0.0065739723,0.0007187736,0.0000622117,0.00005527186,0.00041777367,0.000036917023,0.0016678998,0.9836831,0.0004061336],"about_ca_topic_score_codex":0.00050974265,"about_ca_topic_score_gemma":0.000028338856,"teacher_disagreement_score":0.98789334,"about_ca_system_score_codex":0.000748864,"about_ca_system_score_gemma":0.010986206,"threshold_uncertainty_score":0.9998509},"labels":[],"label_agreement":null},{"id":"W2597968140","doi":"10.1182/blood.v128.22.5193.5193","title":"In Vitro Comparison of ADCC and CAR Sensitivity of Adult HER-2+ B-ALL Using the NK-92 Human Cell Line Transduced with a Human CD16 (ADCC) or an Anti-HER2 Chimeric Antigen Receptor (CAR)","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Antibody-dependent cell-mediated cytotoxicity; Cytotoxic T cell; Medicine; Chimeric antigen receptor; CD20; Immunology; Antigen; Antibody; Cancer research; Monoclonal antibody; In vitro; Biology; Immunotherapy; Immune system","score_opus":0.04747231502687925,"score_gpt":0.34110462667759395,"score_spread":0.2936323116507147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2597968140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99838525,0.00021082337,0.00006167494,0.00020248641,0.000027287264,0.00087605976,0.00005555895,0.000027889644,0.00015296259],"genre_scores_gemma":[0.99867684,0.00010616775,0.0006705305,0.00006270816,0.00014743076,0.000008497855,0.000020974398,0.0000666156,0.0002402102],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997668,0.00044080208,0.0005170597,0.0004431367,0.0004999264,0.0004310465],"domain_scores_gemma":[0.9985988,0.00017496123,0.00022900307,0.0005917741,0.00023964606,0.00016578277],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059971295,0.00027389798,0.0008782091,0.00019269797,0.00009667358,0.000014230857,0.00015013132,0.0001365092,0.00023696014],"category_scores_gemma":[0.000030412632,0.00015487005,0.00009828091,0.00037685857,0.0003995246,0.0001164426,0.00004584454,0.0003002539,0.0000013972801],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013337564,0.0018783842,0.03988317,0.00025390342,0.00017858636,0.000043608954,0.002774239,0.0000029046305,0.9523143,0.000004160392,0.0000105090785,0.0013224541],"study_design_scores_gemma":[0.009324865,0.0020569542,0.016027283,0.0003523159,0.00020845002,0.00004950232,0.00073753175,0.00017404841,0.9707726,0.0000041424237,0.00008454417,0.0002077472],"about_ca_topic_score_codex":0.002649848,"about_ca_topic_score_gemma":0.0013421307,"teacher_disagreement_score":0.023855887,"about_ca_system_score_codex":0.0000413158,"about_ca_system_score_gemma":0.00013652683,"threshold_uncertainty_score":0.6315417},"labels":[],"label_agreement":null},{"id":"W2602369513","doi":"10.1200/jco.2016.71.3024","title":"Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":561,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Seagen (Canada)","funders":"","keywords":"Medicine; Fludarabine; Lymphoma; Chemotherapy; Chimeric antigen receptor; Follicular lymphoma; Cyclophosphamide; Mantle cell lymphoma; Gastroenterology; Internal medicine; Immunology; T cell; Immune system","score_opus":0.1467258729733652,"score_gpt":0.46062969264205533,"score_spread":0.31390381966869013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2602369513","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9774203,0.00015849365,0.000028003853,0.017568449,0.0018994715,0.00030768165,0.000046535482,0.000023835739,0.0025472497],"genre_scores_gemma":[0.98000216,0.0010181416,0.00047060326,0.00150767,0.0013525342,0.0000029843345,0.000008816227,0.000064962805,0.015572144],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99503607,0.00092954485,0.0021948968,0.00038985262,0.0008748884,0.0005747576],"domain_scores_gemma":[0.9903299,0.0024218706,0.0044634994,0.000758375,0.0010991453,0.00092716765],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004436018,0.00028341232,0.0025276183,0.0001782927,0.00029034493,0.00005981677,0.00077739835,0.0007566557,0.0047093015],"category_scores_gemma":[0.0077354005,0.00018460705,0.000488243,0.00018273068,0.0008413096,0.00021951002,0.00017360112,0.0014863805,0.000075017546],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061185085,0.004685826,0.3497611,0.000042307154,0.0028795947,0.0021330852,0.000313883,0.0000048596694,0.32234818,0.000007738519,0.19964679,0.11205815],"study_design_scores_gemma":[0.017621929,0.012086934,0.7664518,0.00063462113,0.0002656098,0.00015108121,0.00018070824,0.000025720736,0.0108589865,0.000043328433,0.1914572,0.00022210227],"about_ca_topic_score_codex":0.00009041276,"about_ca_topic_score_gemma":0.00007514347,"teacher_disagreement_score":0.41669068,"about_ca_system_score_codex":0.00047230112,"about_ca_system_score_gemma":0.002154152,"threshold_uncertainty_score":0.9962005},"labels":[],"label_agreement":null},{"id":"W2603085196","doi":"10.1158/0008-5472.can-16-3247","title":"Development of a T-cell Receptor Mimic Antibody against Wild-Type p53 for Cancer Immunotherapy","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Biotechnology and Biological Sciences Research Council; Medical Research Council; Directorate for Biological Sciences; Medical Research Council Canada; University of Oxford; National Institute for Health and Care Research; Cancer Research UK; Pancreatic Cancer UK","keywords":"Epitope; Cancer immunotherapy; Cancer; Immunotherapy; Cancer research; Monoclonal antibody; Antibody; Antigen; T cell; T-cell receptor; Cancer cell; Biology; Immune system; Context (archaeology); Immunology","score_opus":0.13443582584041167,"score_gpt":0.4802923012255702,"score_spread":0.3458564753851585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2603085196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888831,0.0038804954,0.00004943371,0.0016850405,0.00045859642,0.002087076,0.000047088226,0.000044419503,0.0028647901],"genre_scores_gemma":[0.9094595,0.024964243,0.005553625,0.000280133,0.0010847627,0.0016099551,0.00010362546,0.00030557188,0.056638606],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9967291,0.00010467662,0.00044058458,0.00055298524,0.0012059999,0.0009666489],"domain_scores_gemma":[0.99664164,0.00017776969,0.0001694618,0.0012367805,0.001507023,0.00026735573],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018895086,0.00022149296,0.00053300505,0.000345499,0.00061251107,0.00010203838,0.0008278824,0.00017519885,0.0028201144],"category_scores_gemma":[0.0002158207,0.00019342042,0.00015531093,0.00032711707,0.000521518,0.000119515025,0.00020782143,0.0006164765,0.000046953555],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031750822,0.00020627884,0.003922232,0.00046586076,0.00022616265,0.0000055580085,0.0011391959,0.0000022217432,0.864158,0.0000150957285,0.005289755,0.12139461],"study_design_scores_gemma":[0.0029399851,0.0002616232,0.0028188333,0.0003520814,0.000008791551,7.9839396e-7,0.00016753707,0.00003721569,0.6036591,0.00001548059,0.38959208,0.0001464407],"about_ca_topic_score_codex":0.001012652,"about_ca_topic_score_gemma":0.00034951177,"teacher_disagreement_score":0.38430235,"about_ca_system_score_codex":0.00084612734,"about_ca_system_score_gemma":0.0035899442,"threshold_uncertainty_score":0.99809146},"labels":[],"label_agreement":null},{"id":"W2604684472","doi":"10.1182/blood.v128.22.1852.1852","title":"Biomarkers of Cytokine Release Syndrome and Neurotoxicity after CD19 CAR-T Cells and Mitigation of Toxicity By Cell Dose","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Cytokine release syndrome; Medicine; CD8; Toxicity; CD19; Immunology; T cell; Internal medicine; Gastroenterology; Chimeric antigen receptor; Antigen; Immune system","score_opus":0.008121120329729692,"score_gpt":0.23716369371763285,"score_spread":0.22904257338790315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604684472","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99828905,0.0003718568,0.000014085718,0.00020776007,0.000021327272,0.0005729093,0.0001964658,0.0000149020725,0.00031163997],"genre_scores_gemma":[0.99852014,0.00037038498,0.00015304342,0.000055598935,0.000017920001,0.00001956962,0.000005346906,0.00002293287,0.00083505694],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99885494,0.000086029526,0.00027359964,0.00027837735,0.00030175224,0.00020529426],"domain_scores_gemma":[0.9991729,0.00014398986,0.00009944294,0.00030321482,0.0000857818,0.00019465505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022013288,0.00013660366,0.00031362308,0.0001108862,0.000018784911,0.000006045583,0.000057117064,0.000097170436,0.0003366875],"category_scores_gemma":[0.000053388816,0.00010025448,0.000059776787,0.00014410743,0.00027472913,0.00006650973,0.00006563634,0.0000864219,0.0000029022399],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00061239686,0.0004627284,0.02775605,0.0003252593,0.00007122384,0.000063731306,0.00007125659,2.1817506e-8,0.96932447,0.00000123909,0.00013791877,0.0011736804],"study_design_scores_gemma":[0.005142758,0.0008311335,0.05824124,0.0001268447,0.00010585934,0.000080369005,0.000014543757,0.000007184192,0.93513966,0.000023177852,0.00019372754,0.00009348952],"about_ca_topic_score_codex":0.000072744566,"about_ca_topic_score_gemma":0.000006528388,"teacher_disagreement_score":0.034184825,"about_ca_system_score_codex":0.00001637791,"about_ca_system_score_gemma":0.000043241922,"threshold_uncertainty_score":0.4088259},"labels":[],"label_agreement":null},{"id":"W2604892075","doi":"10.1182/blood.v128.22.1841.1841","title":"ZW38, a Novel Azymetric Bispecific CD19-Directed CD3 T Cell Engager Antibody Drug Conjugate with Controlled T Cell Activation and Improved B Cell Cytotoxicity","year":2016,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Blinatumomab; CD19; Antibody; T cell; Antibody-drug conjugate; Cancer research; B cell; Immunology; Medicine; Molecular biology; Chemistry; Biology; Immune system; Monoclonal antibody","score_opus":0.013718849653266661,"score_gpt":0.2543328361908271,"score_spread":0.24061398653756041,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604892075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98421776,0.00042300846,0.00081169803,0.00034165938,0.00007120589,0.0026818174,0.00005122676,0.00026003222,0.011141576],"genre_scores_gemma":[0.9722502,0.00040813355,0.00090904685,0.00015041932,0.0002416933,0.000109441986,0.000034939778,0.00011518861,0.025780905],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970114,0.00024146013,0.0005076061,0.0008157802,0.0006779793,0.00074572314],"domain_scores_gemma":[0.99716586,0.0010139443,0.0002982607,0.00070439937,0.0004206328,0.00039691475],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00085051643,0.0004539001,0.0009009193,0.00062561355,0.00020614527,0.00009267971,0.00019296075,0.00021027247,0.0008188308],"category_scores_gemma":[0.00020034846,0.00028614237,0.00016763841,0.00095072074,0.00019703903,0.00020064604,0.0000907866,0.00056036207,0.000059485985],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004599571,0.0024905268,0.005082613,0.0001771295,0.00017074894,0.00003915681,0.0002510343,4.2065113e-7,0.98654777,0.0000047227745,0.00018507571,0.00045125524],"study_design_scores_gemma":[0.08751049,0.0010388575,0.0072292145,0.00010971349,0.00026392078,0.0000272954,0.00009845177,0.00022950301,0.90200514,0.0000063198186,0.0011082405,0.0003728338],"about_ca_topic_score_codex":0.00015380334,"about_ca_topic_score_gemma":0.000017319171,"teacher_disagreement_score":0.08454259,"about_ca_system_score_codex":0.00011243364,"about_ca_system_score_gemma":0.000288098,"threshold_uncertainty_score":0.99995905},"labels":[],"label_agreement":null},{"id":"W2605822943","doi":"10.1200/jco.2012.30.15_suppl.tps8604","title":"OPTiM: A randomized phase III trial to evaluate the efficacy and safety of talimogene laherparepvec (T-VEC) compared with subcutaneously (sc) administered GM-CSF for the treatment (tx) of unresectable stage IIIb, IIIc, and IV melanoma.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Oncolytic virus; Clinical endpoint; Internal medicine; Melanoma; Stage (stratigraphy); Randomized controlled trial; Clinical trial; Phases of clinical research; Oncology; Immune system; Gastroenterology; Urology; Surgery; Immunology; Cancer; Cancer research","score_opus":0.1822183919849854,"score_gpt":0.5002039924997621,"score_spread":0.3179856005147767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605822943","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863306,0.002362588,0.00041446707,0.004296118,0.00041688915,0.0054202927,0.000042722808,0.0000053347276,0.0007109621],"genre_scores_gemma":[0.99366736,0.002087719,0.001407969,0.000303709,0.00080449175,0.00010026992,0.0000062217446,0.00003367814,0.0015885741],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99395764,0.0017996888,0.0028867538,0.000251586,0.0006586848,0.0004456454],"domain_scores_gemma":[0.96966183,0.027041439,0.0015970459,0.00046697535,0.0006754185,0.00055730063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.013536276,0.0002615068,0.003459422,0.00012822158,0.00011817126,0.000018148494,0.00025798078,0.00022592758,0.00055606867],"category_scores_gemma":[0.003649509,0.00011436174,0.0005907044,0.00018188353,0.00090842304,0.000069993774,0.00008189336,0.00046111495,0.0000010839221],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.942212,0.0047200182,0.00047591073,0.000038943384,0.0032672011,0.000068801506,0.0014608192,0.000044645647,0.003020132,0.00004795876,0.0002546085,0.044389002],"study_design_scores_gemma":[0.86327136,0.097803354,0.000862246,0.00009125245,0.0026139037,0.00040275647,0.000545073,0.00069133664,0.0013356094,0.000018929124,0.03224922,0.00011498928],"about_ca_topic_score_codex":0.00009601117,"about_ca_topic_score_gemma":0.00012999165,"teacher_disagreement_score":0.09308334,"about_ca_system_score_codex":0.00014590754,"about_ca_system_score_gemma":0.0012585219,"threshold_uncertainty_score":0.6088562},"labels":[],"label_agreement":null},{"id":"W2608951168","doi":"10.1182/blood.v120.21.2560.2560","title":"A Highly Selective Anti-ROR1 Monoclonal Antibody Inhibits Human Acute Myeloid Leukemia CD34+ Cell Survival and Self-Renewal.","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; BC Cancer Agency","funders":"","keywords":"Biology; Myeloid leukemia; Leukemia; Cancer research; Stem cell; CD34; Acute leukemia; Stromal cell; Bone marrow; Population; Myeloid; Immunology; Molecular biology; Medicine; Cell biology","score_opus":0.01692193652536604,"score_gpt":0.29997526656942486,"score_spread":0.2830533300440588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2608951168","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97114515,0.0010619105,0.00000843507,0.00011822318,0.00016093379,0.0006472257,0.000027082397,0.00019593493,0.026635092],"genre_scores_gemma":[0.9922611,0.00057657715,0.0005756921,0.00009944542,0.00093244144,0.000028812929,0.00010183301,0.000091838796,0.0053322604],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99738324,0.00015464479,0.00033444155,0.0005098165,0.0006805358,0.0009373511],"domain_scores_gemma":[0.9986218,0.00011535492,0.00010256292,0.0004261731,0.00020098816,0.0005330812],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000567397,0.00035446582,0.0005788225,0.0002484786,0.00022432307,0.00005698153,0.00016128458,0.00023785367,0.0003223361],"category_scores_gemma":[0.000026212554,0.0003249278,0.00014117497,0.0004520718,0.00012962638,0.00020510201,0.00018065148,0.0005704532,0.00009092118],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012770339,0.0013484461,0.12951347,0.000098785444,0.0005999683,0.00008115152,0.0010063675,2.9533908e-7,0.86645454,0.00010538337,0.0003498038,0.00031405478],"study_design_scores_gemma":[0.009534398,0.000925401,0.14048904,0.000060111113,0.0007169416,0.00036099018,0.00012554978,0.000017423257,0.84351933,0.000068815076,0.0037350266,0.0004469489],"about_ca_topic_score_codex":0.00024908522,"about_ca_topic_score_gemma":0.000026289285,"teacher_disagreement_score":0.022935217,"about_ca_system_score_codex":0.00017997446,"about_ca_system_score_gemma":0.00031051465,"threshold_uncertainty_score":0.99992025},"labels":[],"label_agreement":null},{"id":"W2609196580","doi":"10.1080/2162402x.2017.1321184","title":"Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma","year":2017,"lang":"en","type":"article","venue":"OncoImmunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Canada's Michael Smith Genome Sciences Centre; University of Victoria; Simon Fraser University; BC Cancer Agency","funders":"Canadian Institutes of Health Research","keywords":"Lymphoma; CD8; Human leukocyte antigen; Immunology; Cytotoxic T cell; Antigen; Immune system; T cell; Biology; Cancer research; Medicine; Genetics","score_opus":0.0506683785153188,"score_gpt":0.34524345492769154,"score_spread":0.29457507641237274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2609196580","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97652775,0.000895318,0.000004414858,0.0058746105,0.00013229635,0.00047129186,0.000001732897,0.000013636964,0.016078927],"genre_scores_gemma":[0.99224347,0.0002501878,0.00009411201,0.00022138198,0.000046832847,0.00007526976,0.0000072522457,0.00001608964,0.00704541],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9989834,0.000110106426,0.00022179532,0.00026439325,0.000118202486,0.00030212558],"domain_scores_gemma":[0.9990473,0.00010064428,0.00006393395,0.0006986794,0.00004359605,0.000045854325],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035692248,0.00010375964,0.00024108881,0.00025187794,0.00026405475,0.000035664547,0.0002526854,0.00010651195,0.00030913315],"category_scores_gemma":[0.00015910588,0.000081394464,0.000035280445,0.00013230888,0.00028609575,0.000052822088,0.00021799914,0.0002645814,0.00004990251],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024609838,0.00034805946,0.11804991,0.0000403393,0.00004027676,0.00028716197,0.0129029555,0.0000027948024,0.42384395,0.00031868523,0.0003891409,0.44353062],"study_design_scores_gemma":[0.0028854134,0.00030693383,0.9454557,0.00011886779,0.0000058081,0.00006181629,0.0014755246,0.000052389896,0.0021128478,0.00028157528,0.047144078,0.00009909545],"about_ca_topic_score_codex":0.0011673213,"about_ca_topic_score_gemma":0.001606629,"teacher_disagreement_score":0.82740575,"about_ca_system_score_codex":0.00023647888,"about_ca_system_score_gemma":0.000097011165,"threshold_uncertainty_score":0.3384791},"labels":[],"label_agreement":null},{"id":"W2609629414","doi":"10.1111/trf.14094","title":"Optimizing autologous nonmobilized mononuclear cell collections for cellular therapy in pediatric patients with high‐risk leukemia","year":2017,"lang":"en","type":"article","venue":"Transfusion","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"Hospital for Sick Children","keywords":"Peripheral blood mononuclear cell; Medicine; Apheresis; Immunotherapy; Cell; Internal medicine; Cancer; Biology","score_opus":0.016491352304269874,"score_gpt":0.26347789029391083,"score_spread":0.24698653798964096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2609629414","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993246,0.000122176,0.0013791964,0.000118079304,0.00016158535,0.0028676598,0.00002274702,0.0000730403,0.002009511],"genre_scores_gemma":[0.9903612,0.00264958,0.0032692016,0.00003089503,0.00013595408,0.0001829363,0.000034856475,0.00008322221,0.0032521642],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99843025,0.00007551461,0.0002728132,0.00044748434,0.000348274,0.00042568782],"domain_scores_gemma":[0.99879634,0.00012871585,0.00011824426,0.00065379904,0.00016104252,0.0001418521],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003145447,0.00021541111,0.00039359348,0.00030082208,0.0007610959,0.00007512142,0.00021377686,0.00018352502,0.0005604343],"category_scores_gemma":[0.000034112465,0.00017224287,0.00013787308,0.0002768813,0.00008420451,0.00011985932,0.000021956861,0.0004073278,0.000010117089],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05877858,0.00485924,0.5300215,0.000697742,0.00026006505,0.00013561209,0.007451655,0.0041193464,0.2672482,0.000020083357,0.0014620052,0.124945976],"study_design_scores_gemma":[0.15718693,0.01796492,0.59303993,0.000194278,0.0005577547,0.00000884098,0.00034621384,0.0101946145,0.21141313,0.00024063334,0.0075680166,0.0012847491],"about_ca_topic_score_codex":0.0013233674,"about_ca_topic_score_gemma":0.0002987573,"teacher_disagreement_score":0.12366123,"about_ca_system_score_codex":0.00027461717,"about_ca_system_score_gemma":0.00023253333,"threshold_uncertainty_score":0.7023861},"labels":[],"label_agreement":null},{"id":"W2610080631","doi":"10.1016/j.ymthe.2017.04.010","title":"Perspectives on Manufacturing of High-Quality Cell Therapies","year":2017,"lang":"en","type":"article","venue":"Molecular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quality (philosophy); Business; Biotechnology; Biology","score_opus":0.04017176802711962,"score_gpt":0.35569623676941486,"score_spread":0.3155244687422952,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2610080631","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97451806,0.0015133884,0.00017894368,0.0016170494,0.00007494274,0.0004641493,0.000006340639,0.000040999385,0.021586154],"genre_scores_gemma":[0.993823,0.0012485504,0.00043662312,0.00029138546,0.00009376507,0.00002009467,0.0000045480288,0.000052063995,0.00403],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984371,0.00013327187,0.00021511927,0.00036595817,0.0005619724,0.00028654726],"domain_scores_gemma":[0.99809545,0.000061290935,0.0001684011,0.0014670561,0.00010888253,0.000098932054],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004005633,0.00020064913,0.000395732,0.00011571868,0.00017892073,0.000059757607,0.00035843885,0.00009919378,0.0017060315],"category_scores_gemma":[0.000037558955,0.0001599328,0.00023886826,0.000035948982,0.00025984526,0.000055790617,0.000050514598,0.00026858947,0.00003873148],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014755635,0.00042024656,0.0007824255,0.000037854345,0.00023028276,0.00006325454,0.0019472355,0.0000055345176,0.93890005,0.0015973835,0.00003081511,0.054509323],"study_design_scores_gemma":[0.0031560068,0.0007017042,0.056387402,0.0000342166,0.000009925766,0.000004238857,0.0006016781,0.0000023907787,0.9340486,0.00119669,0.003709376,0.00014777356],"about_ca_topic_score_codex":0.00033235416,"about_ca_topic_score_gemma":0.0000036609863,"teacher_disagreement_score":0.055604976,"about_ca_system_score_codex":0.000068881476,"about_ca_system_score_gemma":0.000050668215,"threshold_uncertainty_score":0.99920654},"labels":[],"label_agreement":null},{"id":"W2611322156","doi":"10.15173/m.v1i26.948","title":"Chimeric Antigen Receptors: The Future of Cancer Immunotherapy","year":2014,"lang":"en","type":"article","venue":"The Meducator","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Chimeric antigen receptor; Immunotherapy; Cancer immunotherapy; Cancer; Receptor; Immunology; Medicine; Antigen; Immune system; Internal medicine","score_opus":0.015394156067549106,"score_gpt":0.33340639458003285,"score_spread":0.3180122385124837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2611322156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95555794,0.013632314,0.000009126949,0.026436891,0.0013971814,0.000550819,0.0000026182386,0.00004531723,0.002367784],"genre_scores_gemma":[0.96724015,0.008401829,0.00012677045,0.0026251015,0.0045343153,0.00013562666,0.0000054242523,0.00010064109,0.016830115],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99879473,0.00020060573,0.00018984842,0.00015858401,0.0003838527,0.00027239783],"domain_scores_gemma":[0.998739,0.00017420069,0.00008902307,0.00083165,0.000090595495,0.00007552389],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00073786406,0.00013048585,0.0002547193,0.000052258692,0.00009721325,0.000013311382,0.00040227926,0.000055962697,0.00707578],"category_scores_gemma":[0.00003647009,0.000059897793,0.00013629344,0.00035586953,0.0002677748,0.000022103657,0.000035260164,0.00030400456,0.00005449452],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047991375,0.00019492026,0.021086367,0.000051444127,0.0004116346,4.6702385e-7,0.0081318375,0.0000013665098,0.41554707,0.0004374446,0.030695792,0.52296174],"study_design_scores_gemma":[0.0006118325,0.00014126308,0.0443339,0.000039807364,0.00003246207,0.000010162447,0.0013552817,0.000015518764,0.053279698,0.00014037466,0.8999561,0.00008358571],"about_ca_topic_score_codex":0.00046012757,"about_ca_topic_score_gemma":0.000037164926,"teacher_disagreement_score":0.8692603,"about_ca_system_score_codex":0.000056870682,"about_ca_system_score_gemma":0.00025861332,"threshold_uncertainty_score":0.9938319},"labels":[],"label_agreement":null},{"id":"W2612204637","doi":"10.1080/21645515.2017.1314874","title":"A new therapeutic potential for cancers: One CAR with 2 different engines!","year":2017,"lang":"en","type":"letter","venue":"Human Vaccines & Immunotherapeutics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Ontario Institute for Cancer Research","funders":"","keywords":"Chimeric antigen receptor; Antigen; Immune system; NK-92; Immunotherapy; Cancer immunotherapy; MHC class I; Cytotoxic T cell; Biology; Immunology; Antigen-presenting cell; Cancer research; Major histocompatibility complex; T cell; In vitro","score_opus":0.054112037923925736,"score_gpt":0.32526531025099725,"score_spread":0.27115327232707154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2612204637","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.046415772,0.07202596,0.02116733,0.81809497,0.0060407524,0.027595714,0.00073095126,0.001961522,0.0059670424],"genre_scores_gemma":[0.04616869,0.004749323,0.0019410931,0.384831,0.05178954,0.0016274207,0.0036525044,0.0029807477,0.5022597],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9949963,0.00012346057,0.0008308262,0.0012056505,0.0012685589,0.0015752077],"domain_scores_gemma":[0.99518806,0.00019345425,0.0006313076,0.0031322148,0.0006194033,0.00023554938],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.0002377359,0.0013355702,0.002016055,0.0005476717,0.00067567924,0.00045948272,0.0012714654,0.0013024337,0.0047841496],"category_scores_gemma":[0.00001330424,0.0010517124,0.00083790795,0.00017034316,0.00017646776,0.0001393195,0.00010337825,0.002851547,0.000036312977],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011295366,0.0007632477,0.0011062885,0.004332974,0.023307955,0.001073328,0.0016321283,0.00003760956,0.21647392,0.00019792042,0.59205925,0.14772],"study_design_scores_gemma":[0.013335733,0.0029874572,0.0021567643,0.000978779,0.0027391515,0.00029047328,0.00003536651,0.00011716915,0.0037464413,0.00050515495,0.9717808,0.0013267564],"about_ca_topic_score_codex":0.00078884943,"about_ca_topic_score_gemma":0.00025246412,"teacher_disagreement_score":0.49629262,"about_ca_system_score_codex":0.0009281425,"about_ca_system_score_gemma":0.0011274542,"threshold_uncertainty_score":0.9999941},"labels":[],"label_agreement":null},{"id":"W2612845307","doi":"","title":"CORD BLOOD-DERIVED MESENCHYMAL STROMAL CELLS DOWN-MODULATE CD4+ T-CELL ACTIVATION BY INDUCING IL-10 PRODUCING TH1 CELLS","year":2013,"lang":"en","type":"article","venue":"2013 CIS Annual Meeting: Regulation & Dysregulation of Immunity April 25 - 28, 2013","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Mesenchymal stem cell; Stromal cell; Cell biology; Cord blood; Cell; Chemistry; Immunology; Biology; Molecular biology; Cancer research; Biochemistry","score_opus":0.01685769129565926,"score_gpt":0.257580438712427,"score_spread":0.24072274741676772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2612845307","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98945343,0.00021292678,0.00078409136,0.0019898517,0.00044325626,0.0033890465,0.00010940372,0.0002826179,0.0033353865],"genre_scores_gemma":[0.9639889,0.00015392285,0.005388106,0.00010895698,0.00044854791,0.00013667904,0.0009844044,0.00020004011,0.02859043],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99255335,0.0009331129,0.0020396574,0.0012220832,0.0020753795,0.0011764409],"domain_scores_gemma":[0.9921539,0.0005934684,0.0017177917,0.001965815,0.0030462032,0.0005228169],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0021245326,0.0008788599,0.0012229971,0.0008856599,0.00067494495,0.00026702776,0.0006438417,0.0007508041,0.010235355],"category_scores_gemma":[0.0003542211,0.00088683196,0.00041725807,0.0011946392,0.0004946203,0.0019414246,0.0003951931,0.0010548973,0.0004411113],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006445408,0.0008020798,0.00065302936,0.0002878375,0.00022797949,0.0000014924116,0.0024271382,0.0045678406,0.9533697,0.000032980304,0.026682401,0.010302997],"study_design_scores_gemma":[0.00413352,0.0012780889,0.061173856,0.00049897603,0.00022119128,0.000016697948,0.0014774357,0.015322119,0.90600276,0.00019458227,0.008791767,0.00088902155],"about_ca_topic_score_codex":0.006235204,"about_ca_topic_score_gemma":0.000043395277,"teacher_disagreement_score":0.060520828,"about_ca_system_score_codex":0.00037614498,"about_ca_system_score_gemma":0.00032116735,"threshold_uncertainty_score":0.99935824},"labels":[],"label_agreement":null},{"id":"W2621545768","doi":"10.1002/hon.2439_20","title":"Analysis of preclinical and clinical samples after treatment with a <scp>CD37</scp> targeting antibody drug conjugate (<scp>AGS67E</scp>) support a high level of <scp>CD37</scp> expression in <scp>NHL</scp>","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Foundation; BC Cancer Agency","funders":"","keywords":"Antibody; Flow cytometry; Antibody-drug conjugate; Medicine; Cancer research; Monoclonal antibody; Molecular biology; Immunology; Biology","score_opus":0.12475944141595334,"score_gpt":0.42955576042117627,"score_spread":0.3047963190052229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2621545768","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912381,0.0015212921,0.0003190175,0.00045071286,0.00027478134,0.002271376,0.00033704162,0.00013344697,0.0034542056],"genre_scores_gemma":[0.98353815,0.0039044858,0.006915087,0.00044514838,0.00031010248,0.00042947815,0.00039281987,0.00013155321,0.003933166],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98775095,0.0021675008,0.0039979587,0.0024840243,0.0014832458,0.0021163076],"domain_scores_gemma":[0.9635084,0.029735139,0.00252657,0.0021785728,0.000779566,0.0012717166],"candidate_categories":["metaresearch","metaepi_narrow","sts","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.004824197,0.0011828517,0.006799644,0.001045165,0.00036744404,0.00012268922,0.0010320378,0.001921386,0.00033433287],"category_scores_gemma":[0.019691987,0.0008224194,0.0013884598,0.0010198518,0.0033964082,0.00032635522,0.0011474601,0.0017849517,0.00006007312],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00063814636,0.0065764133,0.95005196,0.00046169607,0.0032159456,0.0024868718,0.0024423779,0.000022086655,0.027840052,0.00015612529,0.0031967016,0.0029116238],"study_design_scores_gemma":[0.019320065,0.014133758,0.884212,0.0006898261,0.004039995,0.00049581216,0.004784102,0.0010128167,0.036946703,0.00045058393,0.03374658,0.00016773187],"about_ca_topic_score_codex":0.00063733035,"about_ca_topic_score_gemma":0.00095706526,"teacher_disagreement_score":0.06583993,"about_ca_system_score_codex":0.00036410993,"about_ca_system_score_gemma":0.0010091288,"threshold_uncertainty_score":0.99942267},"labels":[],"label_agreement":null},{"id":"W2624207812","doi":"10.1002/hon.2438_72","title":"PHASE I/II CLINICAL TRIAL OF AN ACTIVATED WHOLE TUMOR CELL VACCINE FOLLOWED BY TRANSFER OF IMMUNE T CELLS IN PATIENTS WITH MANTLE CELL LYMPHOMA","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Leukapheresis; Mantle cell lymphoma; Autologous stem-cell transplantation; Internal medicine; Vaccination; Rash; Minimal residual disease; Adverse effect; Peripheral blood mononuclear cell; Oncology; Gastroenterology; Immunology; Lymphoma; CD34; Bone marrow; Stem cell","score_opus":0.043524360428083414,"score_gpt":0.38495610131224156,"score_spread":0.3414317408841582,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2624207812","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99464494,0.00005054115,0.000017616638,0.00026726897,0.00019316834,0.0019098677,0.000048355538,0.0000243704,0.0028438538],"genre_scores_gemma":[0.9985562,0.00003636137,0.0003524089,0.00008801849,0.00004375112,0.00005373742,0.000082180784,0.00003612828,0.0007512427],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.996612,0.0004899463,0.0013820746,0.00055031234,0.00044872504,0.00051690475],"domain_scores_gemma":[0.99764025,0.0004714473,0.00047194026,0.00092982384,0.00020560849,0.00028091905],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009364089,0.00027681715,0.0019686958,0.00013474388,0.00010045139,0.0000090636995,0.00049146224,0.0004884821,0.0011695251],"category_scores_gemma":[0.00018416908,0.00019046327,0.00027490317,0.00016156975,0.00040980938,0.00010432892,0.00013598826,0.00044227904,0.00001527692],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29730025,0.08091693,0.008981935,0.00014507803,0.00007647132,0.0003242724,0.0001085993,5.2764756e-7,0.6048338,0.000008800189,0.00047262828,0.0068307123],"study_design_scores_gemma":[0.39424312,0.07639873,0.0073948274,0.00004377659,0.00008520785,0.000011812357,0.000052041694,0.000037840273,0.5185124,0.000012809569,0.003049517,0.00015790328],"about_ca_topic_score_codex":0.00008299757,"about_ca_topic_score_gemma":0.000021104786,"teacher_disagreement_score":0.09694286,"about_ca_system_score_codex":0.00009904312,"about_ca_system_score_gemma":0.00029508932,"threshold_uncertainty_score":0.9997435},"labels":[],"label_agreement":null},{"id":"W2626261656","doi":"10.1080/14656566.2017.1340938","title":"Novel therapy for childhood acute lymphoblastic leukemia","year":2017,"lang":"en","type":"review","venue":"Expert Opinion on Pharmacotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Medicine; Clinical trial; Intensive care medicine; Disease; Minimal residual disease; Oncology; Risk stratification; Lymphoblastic Leukemia; Expert opinion; Internal medicine; Leukemia","score_opus":0.17184688914497115,"score_gpt":0.48562954739914893,"score_spread":0.3137826582541778,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2626261656","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000033655335,0.984981,0.0004614745,0.0004797272,0.0034059868,0.007968266,0.00037302577,0.00027494825,0.0020522105],"genre_scores_gemma":[0.0000012644957,0.9746264,0.0007409585,0.0031172845,0.006554798,0.003341942,0.0007708848,0.00067599764,0.010170474],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951146,0.00017772138,0.001064735,0.0014872211,0.0010400043,0.0011157036],"domain_scores_gemma":[0.995912,0.00062391855,0.0007216477,0.0019321864,0.00022165048,0.00058860844],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0005993195,0.0013812516,0.0034493918,0.0007066356,0.00050265365,0.00021928748,0.0012317409,0.00074300537,0.004429816],"category_scores_gemma":[0.00006047216,0.0010300193,0.0023543346,0.0002870339,0.0002234224,0.00015152752,0.000074458534,0.0009665324,0.000276819],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016046425,0.00090520777,2.8104867e-7,0.0010827385,0.0029553485,0.000016745174,0.00025431573,4.087932e-7,0.0039722547,0.00006186347,0.0302221,0.9589241],"study_design_scores_gemma":[0.015396504,0.0017943823,0.0000029384926,0.0074429014,0.00010728869,0.00032679382,0.000006741064,0.000049810027,0.0014281197,0.000014451793,0.97249454,0.0009355074],"about_ca_topic_score_codex":0.000029426092,"about_ca_topic_score_gemma":3.4706554e-7,"teacher_disagreement_score":0.95798856,"about_ca_system_score_codex":0.0013127311,"about_ca_system_score_gemma":0.0025165624,"threshold_uncertainty_score":0.9998938},"labels":[],"label_agreement":null},{"id":"W2666106632","doi":"10.1016/j.trsl.2017.06.009","title":"Antigen-specific regulatory T cells: are police CARs the answer?","year":2017,"lang":"en","type":"review","venue":"Translational research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research","keywords":"Immunology; Immune system; Autoimmunity; Antigen; Chimeric antigen receptor; Cell therapy; Polyclonal antibodies; Major histocompatibility complex; Biology; T-cell receptor; T cell; Medicine; Stem cell; Cell biology","score_opus":0.4782631353955542,"score_gpt":0.5226650620180232,"score_spread":0.044401926622469,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2666106632","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007961462,0.9687755,0.000009339074,0.0012214257,0.00026093257,0.0031523206,0.00020850262,0.000055182703,0.026237166],"genre_scores_gemma":[0.0001602931,0.9677853,0.000075358315,0.000033627948,0.00204367,0.00026312534,0.00025846582,0.00019065126,0.029189536],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99131215,0.001255285,0.00079008,0.0009698438,0.004458089,0.0012145699],"domain_scores_gemma":[0.9936161,0.002124227,0.00023153081,0.0026011833,0.0009649166,0.00046203102],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00513244,0.00052725885,0.0016464901,0.00094977644,0.0011394414,0.00028414762,0.0015844122,0.0006580612,0.005404843],"category_scores_gemma":[0.00009985584,0.00035481414,0.0010663476,0.0009214544,0.0014137983,0.00012548607,0.00014416598,0.0035978202,0.0013700806],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013240332,0.00012035086,0.000040612507,0.003430574,0.00038192671,0.00008675972,0.0003402795,0.0000010786234,0.00016859885,0.00062562164,0.014623093,0.9800487],"study_design_scores_gemma":[0.0005436118,0.00008672373,0.0009477458,0.005090983,0.000062377716,0.00010676302,0.000071775146,0.000008532174,0.000035000052,0.00011607422,0.9926604,0.0002700069],"about_ca_topic_score_codex":0.00035617792,"about_ca_topic_score_gemma":0.00014728497,"teacher_disagreement_score":0.9797787,"about_ca_system_score_codex":0.00040771137,"about_ca_system_score_gemma":0.0029091695,"threshold_uncertainty_score":0.9998904},"labels":[],"label_agreement":null},{"id":"W2727251202","doi":"10.1002/eji.201646732","title":"Curtailed T‐cell activation curbs effector differentiation and generates CD8<sup>+</sup> T cells with a naturally‐occurring memory stem cell phenotype","year":2017,"lang":"en","type":"article","venue":"European Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Ministero della Salute; Fondazione Italiana per la Ricerca sul Cancro; European Research Council; Fondazione Cariplo; European Commission; Wellcome Trust","keywords":"Biology; Effector; Phenotype; Cytotoxic T cell; Cell biology; Cell; CD8; T cell; Genetics; Gene; Antigen; In vitro; Immune system","score_opus":0.015503367576592549,"score_gpt":0.24834962890308623,"score_spread":0.2328462613264937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2727251202","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994912,0.0015036258,0.000291379,0.00021818548,0.00026222735,0.0003064533,0.0000025735844,0.000020496911,0.0024830168],"genre_scores_gemma":[0.99647224,0.00039383592,0.00039702913,0.000080427366,0.00040620373,0.0000018600763,0.000006745618,0.000067812514,0.0021738266],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979928,0.00067949336,0.00043454333,0.00025027007,0.00031398842,0.00032892017],"domain_scores_gemma":[0.9981287,0.00016218716,0.00072565523,0.00048510742,0.00036877597,0.00012954045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007375598,0.00024176463,0.00045595382,0.00024885827,0.00027767348,0.00014427725,0.00034915225,0.000069935966,0.0002828509],"category_scores_gemma":[0.000059516453,0.00017487846,0.0001014036,0.00007261253,0.00018415018,0.00029152088,0.00013944108,0.0008456697,0.00004889746],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022806025,0.00013925729,0.003411042,0.000108629356,0.00023805909,0.0002054029,0.0011553753,0.00010001042,0.9689108,0.000003011281,0.00018050829,0.023267297],"study_design_scores_gemma":[0.011974605,0.0039753085,0.08388045,0.00045046504,0.0002199605,0.00030924473,0.00062394893,0.0010299755,0.8945555,0.000005127436,0.0026412497,0.00033418546],"about_ca_topic_score_codex":0.000011355147,"about_ca_topic_score_gemma":0.0000012226126,"teacher_disagreement_score":0.08046941,"about_ca_system_score_codex":0.00010132511,"about_ca_system_score_gemma":0.00009626765,"threshold_uncertainty_score":0.71313363},"labels":[],"label_agreement":null},{"id":"W2731890350","doi":"","title":"c-Myb Dependent Smooth Muscle Cell Differentiation from Mouse Embryonic Stem Cells","year":2011,"lang":"en","type":"dissertation","venue":"Library and Archives Canada (Government of Canada)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Embryonic stem cell; Stem cell; Cell biology; MYB; Biology; Cellular differentiation; Myocyte; Genetics; Transcription factor; Gene","score_opus":0.00646697671264232,"score_gpt":0.171243234624626,"score_spread":0.1647762579119837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2731890350","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.78990865,0.00080434984,0.000009263565,0.0001807368,0.0005073676,0.00053811475,0.0006243335,0.000017936623,0.20740925],"genre_scores_gemma":[0.6580598,0.00089782325,0.00010650208,0.00026734252,0.00011171178,0.000022057706,0.0004335547,0.00008204779,0.3400192],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9957163,0.00009993166,0.0004368726,0.00051806285,0.0027890138,0.00043983437],"domain_scores_gemma":[0.99853325,0.00018974498,0.00033476192,0.0004770342,0.000002385475,0.0004628233],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0000140367965,0.00039434203,0.00057749863,0.00006917673,0.00013264315,0.000033963184,0.0002875961,0.00012848049,0.001324687],"category_scores_gemma":[0.0000010443832,0.00038356707,0.00009351689,0.00007480567,0.000039378516,0.00017794437,0.00008890273,0.0004699372,3.783036e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025029562,0.00019452951,0.002838535,0.00088702905,0.00025675222,0.0001474617,0.0003844928,0.000005071656,0.9604365,0.0006516095,0.0010439865,0.030651042],"study_design_scores_gemma":[0.0011405678,0.00019480762,0.046245106,0.00021685536,0.00015534584,0.0000010012947,0.003694097,0.00021164375,0.93691206,0.00016986988,0.010676766,0.00038186426],"about_ca_topic_score_codex":0.016055906,"about_ca_topic_score_gemma":0.12041979,"teacher_disagreement_score":0.13260996,"about_ca_system_score_codex":0.000035168036,"about_ca_system_score_gemma":0.0029223338,"threshold_uncertainty_score":0.9998616},"labels":[],"label_agreement":null},{"id":"W2734515449","doi":"10.1016/j.ymthe.2017.07.004","title":"Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy","year":2017,"lang":"en","type":"article","venue":"Molecular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":280,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Research and Development; Graduate Women – New South Wales; Northwest University; Department of Health and Social Care; NIH Clinical Center; National Cancer Institute; National Institutes of Health; U.S. Department of Health and Human Services; Government of Canada; Geoffrey Beene Cancer Research Center; National Institute for Health and Care Research; National Cancer Research Institute","keywords":"Chimeric antigen receptor; CD19; Lymphoma; Medicine; Antigen; Receptor; Immunology; B cell; Cell; Cancer research; Biology; T cell; Antibody; Internal medicine; Immune system","score_opus":0.02657168721673962,"score_gpt":0.30328610520036575,"score_spread":0.2767144179836261,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2734515449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896389,0.0041381367,0.0010481214,0.00078216405,0.00022532935,0.0012692919,0.00005892547,0.000072344024,0.002766743],"genre_scores_gemma":[0.9841714,0.009282957,0.00066195923,0.00079976977,0.00016675444,0.000073537354,0.00012314039,0.00014596127,0.0045745256],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971335,0.00024629326,0.0005291575,0.0006147669,0.00081200997,0.0006642688],"domain_scores_gemma":[0.99689204,0.000053440453,0.00038501454,0.0021009522,0.0002626045,0.0003059627],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004459816,0.0004123437,0.0006724916,0.00021705336,0.0003661113,0.000119920274,0.00059515866,0.00023464556,0.003303402],"category_scores_gemma":[0.00003686666,0.00034319487,0.00043387388,0.00021861553,0.00023800216,0.00014755595,0.00011181967,0.0002593802,0.00015106678],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016825008,0.0030159198,0.018561058,0.000050667033,0.000155317,0.00013771093,0.00061382167,8.5336694e-7,0.9609182,0.000008482669,0.00036443697,0.014491064],"study_design_scores_gemma":[0.01835688,0.00068943226,0.09450651,0.00007687023,0.000020623695,0.000014898656,0.000047228565,0.00014723837,0.8258918,0.00003034974,0.059881832,0.0003363382],"about_ca_topic_score_codex":0.00010499767,"about_ca_topic_score_gemma":0.000003879043,"teacher_disagreement_score":0.13502637,"about_ca_system_score_codex":0.000082871324,"about_ca_system_score_gemma":0.00019116448,"threshold_uncertainty_score":0.999902},"labels":[],"label_agreement":null},{"id":"W2735819532","doi":"10.4049/immunohorizons.1700022","title":"Transfection of FcγRIIIa (CD16) Alone Can Be Sufficient To Enable Human αβTCR T Lymphocytes To Mediate Antibody-Dependent Cellular Cytotoxicity","year":2017,"lang":"en","type":"article","venue":"ImmunoHorizons","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Institut National de la Santé et de la Recherche Médicale","keywords":"Antibody-dependent cell-mediated cytotoxicity; CD16; Transfection; Fc receptor; Jurkat cells; Cell biology; Molecular biology; Biology; Immunology; CD3; Chemistry; Antibody; Immune system; Monoclonal antibody; T cell; Cell culture; CD8","score_opus":0.0320016045442368,"score_gpt":0.34345838496717995,"score_spread":0.31145678042294317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2735819532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901312,0.00021043811,0.0005087617,0.0015730059,0.0007607612,0.001808968,0.00012354017,0.00010262737,0.0047806967],"genre_scores_gemma":[0.9920502,0.00011479139,0.00012787324,0.00017438245,0.0003563612,0.00010864158,0.000077299635,0.000084788604,0.0069056717],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9966771,0.00012484766,0.0005987851,0.00064485974,0.0010783004,0.00087611214],"domain_scores_gemma":[0.99708015,0.0000808258,0.000153989,0.0018005912,0.00036192368,0.0005225037],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001107428,0.00035008072,0.0007587718,0.00043685813,0.0007549279,0.00012877036,0.00067968527,0.00019146861,0.0013812674],"category_scores_gemma":[0.00023701493,0.00033831995,0.00027679335,0.00032651657,0.0002240738,0.00011582927,0.0002555009,0.00036592103,0.000106020154],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006446447,0.0005709659,0.0037239313,0.000100309,0.00020809854,0.00008763636,0.0018585802,0.000036305053,0.99094445,0.00019195095,0.00035071914,0.0012823952],"study_design_scores_gemma":[0.0028936376,0.00261637,0.016357394,0.00017211765,0.00011395979,0.000028255032,0.00031488275,0.000039291,0.97210044,0.000046844532,0.0049952734,0.00032155635],"about_ca_topic_score_codex":0.010911067,"about_ca_topic_score_gemma":0.0015852232,"teacher_disagreement_score":0.018844046,"about_ca_system_score_codex":0.0006635303,"about_ca_system_score_gemma":0.0003486644,"threshold_uncertainty_score":0.9999069},"labels":[],"label_agreement":null},{"id":"W2740810776","doi":"10.1158/1538-7445.am2017-3770","title":"Abstract 3770: CAR-T cell harboring a camelid single domain antibody as a targeting agent to kill tumors expressing VEGFR2","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Helix Biopharma (Canada)","funders":"","keywords":"Antibody; Angiogenesis; Cancer research; Kinase insert domain receptor; Vascular endothelial growth factor; Biology; Antigen; Molecular biology; Immunology; Vascular endothelial growth factor A; VEGF receptors","score_opus":0.09703834215230762,"score_gpt":0.44731707181678015,"score_spread":0.35027872966447254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2740810776","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96045434,0.0015495644,0.000031597836,0.0023583653,0.0003555848,0.0014547686,0.000022956072,0.00009024206,0.033682555],"genre_scores_gemma":[0.9844723,0.00032262603,0.0005917285,0.00018998995,0.0014860231,0.0003178039,0.00001673346,0.00016507157,0.012437721],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9939084,0.00023504399,0.0005057487,0.0010363456,0.0023508447,0.001963585],"domain_scores_gemma":[0.99575907,0.00027102948,0.00016258047,0.0017214104,0.0007553835,0.0013305143],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0031065133,0.00035076498,0.00060435757,0.0005889474,0.0015526469,0.00079722144,0.001042911,0.000179894,0.0052544414],"category_scores_gemma":[0.0013586862,0.0003325126,0.00020865438,0.0004382318,0.00044637808,0.00030658976,0.0008292411,0.0016013532,0.0004928886],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00077158003,0.0001729794,0.006717017,0.0004019393,0.00005748014,0.0011906308,0.0023910801,0.000034798893,0.9762496,0.000014488602,0.003189103,0.008809343],"study_design_scores_gemma":[0.00224994,0.0005639209,0.01370211,0.0016251928,0.000017752704,0.000027059212,0.0019986443,0.000040273415,0.8832486,0.00009352164,0.09599403,0.0004389183],"about_ca_topic_score_codex":0.008718015,"about_ca_topic_score_gemma":0.00014188256,"teacher_disagreement_score":0.093000926,"about_ca_system_score_codex":0.0015092024,"about_ca_system_score_gemma":0.001349414,"threshold_uncertainty_score":0.9999127},"labels":[],"label_agreement":null},{"id":"W2741674151","doi":"10.1158/1538-7445.am2017-3758","title":"Abstract 3758: The efficacy of CD133 BiTEs and CAR-T cells in preclinical model of glioblastoma","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McMaster University","funders":"","keywords":"Antigen; Population; Flow cytometry; Antibody; Peripheral blood mononuclear cell; Immunophenotyping; Cancer research; Monoclonal antibody; Immunology; Chimeric antigen receptor; Medicine; CD3; Biology; Immunotherapy; CD8; In vitro; Immune system","score_opus":0.19397652111056424,"score_gpt":0.4941647106937867,"score_spread":0.30018818958322246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2741674151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936969,0.00090487656,0.0000016290209,0.0015083043,0.000045588233,0.0007955973,0.000033404263,0.000006049047,0.0030076231],"genre_scores_gemma":[0.9954449,0.0019111012,0.000037436574,0.000017906728,0.00013393913,0.00006302622,9.955135e-7,0.000027392882,0.0023632788],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976932,0.00013608045,0.00040009824,0.00032924625,0.000978736,0.00046263414],"domain_scores_gemma":[0.9969025,0.0012978627,0.00011631814,0.001104808,0.00041119877,0.00016726018],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027080723,0.00011038296,0.000408522,0.00024376715,0.00013999346,0.00004119938,0.0005593926,0.00013141337,0.00063118106],"category_scores_gemma":[0.0010252378,0.000075340526,0.00009803046,0.00020456225,0.0014530881,0.00007437633,0.00033809218,0.00090584275,0.00000812055],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030397333,0.00024520015,0.020813549,0.00035137203,0.00006304229,0.000016679704,0.0007446402,0.00020862813,0.95212877,0.000069669426,0.0007256742,0.021593064],"study_design_scores_gemma":[0.004427833,0.00073608174,0.21550031,0.0006016187,0.000020022537,0.000003749901,0.00022840186,0.0046459935,0.77238953,0.00035675807,0.00097193185,0.000117764415],"about_ca_topic_score_codex":0.0018450614,"about_ca_topic_score_gemma":0.0005961178,"teacher_disagreement_score":0.19468677,"about_ca_system_score_codex":0.00010110221,"about_ca_system_score_gemma":0.00064811524,"threshold_uncertainty_score":0.691099},"labels":[],"label_agreement":null},{"id":"W2745610517","doi":"10.1016/j.ccell.2017.07.012","title":"A Viro-Immunotherapy Triple Play for the Treatment of Glioblastoma","year":2017,"lang":"en","type":"letter","venue":"Cancer Cell","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Terry Fox Foundation","keywords":"Oncolytic virus; Immunotherapy; Glioblastoma; Cancer immunotherapy; Cancer research; Cancer; Computational biology; Medicine; Biology; Tumor cells; Internal medicine","score_opus":0.041652691385909615,"score_gpt":0.3458401190213027,"score_spread":0.3041874276353931,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2745610517","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015680373,0.20399994,0.0002517574,0.7235518,0.006344319,0.018097073,0.0023403745,0.00015905322,0.029575286],"genre_scores_gemma":[0.0012004275,0.0612731,0.00011851557,0.13561727,0.014620143,0.0039465344,0.00021139115,0.00035935402,0.7826533],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982601,0.000046813904,0.00031175287,0.000427389,0.0004565206,0.00049744244],"domain_scores_gemma":[0.9974509,0.00039592627,0.00030196804,0.0015767582,0.00021478483,0.000059698836],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00013567318,0.00037088234,0.0007908026,0.00008599313,0.0001688196,0.000041040767,0.00046130063,0.00048585807,0.0066797314],"category_scores_gemma":[0.00001218407,0.00022630677,0.00064489513,0.000060823008,0.00024207009,0.000030559317,0.000019574583,0.00046051445,0.00002342446],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024351247,0.00018686084,0.000026275638,0.00033768232,0.00078014075,0.00007928154,0.00088128884,0.0000016500022,0.030766534,6.484826e-7,0.8795281,0.08497638],"study_design_scores_gemma":[0.0061608083,0.0030011663,0.000038262933,0.00011038179,0.00027206584,0.000011015503,0.000032650278,0.000043017728,0.0705636,0.000012945272,0.91957074,0.00018333824],"about_ca_topic_score_codex":0.0011849264,"about_ca_topic_score_gemma":0.00017791559,"teacher_disagreement_score":0.753078,"about_ca_system_score_codex":0.00074642216,"about_ca_system_score_gemma":0.0005203995,"threshold_uncertainty_score":0.9942283},"labels":[],"label_agreement":null},{"id":"W2745636200","doi":"10.1200/jco.2017.35.15_suppl.10523","title":"Patient-reported quality of life (QOL) following CTL019 in pediatric and young adult patients (pts) with relapsed/refractory (r/r) b-cell acute lymphoblastic leukemia (B-ALL).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Medicine; Adverse effect; Quality of life (healthcare); Internal medicine; Interim analysis; Transplantation; Clinical trial; Refractory (planetary science); Surgery; Oncology","score_opus":0.07681099857292675,"score_gpt":0.42978525930950356,"score_spread":0.3529742607365768,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2745636200","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952247,0.00023705223,0.000016828388,0.00039387855,0.0011741482,0.00040347417,0.0000044589437,0.0000070870265,0.002538386],"genre_scores_gemma":[0.99650466,0.001659281,0.0006134919,0.00041234875,0.0004261357,0.0000050296444,0.000004464328,0.000036756952,0.00033780828],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9933963,0.0007310451,0.0039720275,0.0003636485,0.0011186632,0.00041831104],"domain_scores_gemma":[0.98949003,0.0025825873,0.0056087077,0.0006068923,0.0010150505,0.00069674244],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004003853,0.000234543,0.0021943767,0.00029460818,0.00008489673,0.000024781222,0.00031505007,0.0005546341,0.00009645911],"category_scores_gemma":[0.014028044,0.00016834341,0.0004957563,0.00014882398,0.00027751992,0.00028861884,0.0001724296,0.001502996,0.0000052181254],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017062513,0.002510357,0.954718,0.000110416826,0.00058890897,0.0009357615,0.00028842603,0.000004609555,0.00076691824,0.0000046200985,0.00036480962,0.022644663],"study_design_scores_gemma":[0.045507364,0.017863583,0.934828,0.0001247743,0.0006505891,0.000069606336,0.00012312767,0.000055754193,0.000064182386,0.000041640506,0.0005123139,0.00015908279],"about_ca_topic_score_codex":0.0004169099,"about_ca_topic_score_gemma":0.00027950027,"teacher_disagreement_score":0.028444849,"about_ca_system_score_codex":0.000545733,"about_ca_system_score_gemma":0.0038825697,"threshold_uncertainty_score":0.99427724},"labels":[],"label_agreement":null},{"id":"W2746101152","doi":"10.1016/s0140-6736(17)31816-0","title":"KEYNOTE-006: a success in melanoma, but a long way to go","year":2017,"lang":"en","type":"letter","venue":"The Lancet","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences North","funders":"","keywords":"Ipilimumab; Medicine; Nivolumab; Melanoma; Dacarbazine; Internal medicine; Oncology; Discontinuation; Adverse effect; Trametinib; Cancer; Immunotherapy; Cancer research","score_opus":0.06118385273849644,"score_gpt":0.35217894887002316,"score_spread":0.29099509613152674,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2746101152","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09606544,0.0005616401,0.000013573714,0.84676224,0.00043718313,0.0013241568,0.000102787744,0.00007485938,0.054658152],"genre_scores_gemma":[0.033404026,0.00029715284,0.00010396458,0.5809349,0.03179398,0.00029623532,0.0002548414,0.00018607447,0.3527288],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.997122,0.00022055194,0.0003064805,0.00053699926,0.00082009286,0.0009939005],"domain_scores_gemma":[0.99651575,0.00029977242,0.00012875098,0.0028479872,0.000089497444,0.00011826829],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0009593106,0.0003558114,0.001257478,0.0002500066,0.00011227795,0.0001672066,0.0016273013,0.00054168416,0.0029386997],"category_scores_gemma":[0.00025386648,0.00023261805,0.00017422957,0.00018548426,0.00017092607,0.000052115935,0.00032615388,0.0032653736,0.0015238156],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007913529,0.00002611767,0.007670882,0.00032864916,0.00012102885,0.0035747148,0.00035717207,0.0000010623623,0.0011772913,0.000005556039,0.9779647,0.0079815],"study_design_scores_gemma":[0.0024110423,0.00017503739,0.028034296,0.0005738316,0.000051570463,0.00017154404,0.00000863578,0.000016361204,0.0006705279,0.00011800354,0.96748996,0.00027920157],"about_ca_topic_score_codex":0.0014836363,"about_ca_topic_score_gemma":0.0007279156,"teacher_disagreement_score":0.29807067,"about_ca_system_score_codex":0.00025995675,"about_ca_system_score_gemma":0.00015318832,"threshold_uncertainty_score":0.99925363},"labels":[],"label_agreement":null},{"id":"W2747143180","doi":"10.13034/jsst.v10i1.116","title":"Revolutionizing Cancer Therapeutics: Molecular Pathways and Techniques in Cancer Immunotherapy","year":2017,"lang":"en","type":"article","venue":"Journal of Student Science and Technology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Immunotherapy; Cancer immunotherapy; Cancer; Medicine; Cancer cell; Cancer treatment; Cancer research; Immunology; Internal medicine","score_opus":0.049124493848262805,"score_gpt":0.40551647146991365,"score_spread":0.35639197762165087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2747143180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9756789,0.013051063,0.000028499775,0.010707013,0.00007394913,0.00019028921,5.085585e-7,0.000019111749,0.0002506403],"genre_scores_gemma":[0.9650435,0.034073606,0.0005138216,0.0002504587,0.000041214134,0.000016665335,1.664983e-8,0.000009911986,0.000050800056],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99886924,0.000011862368,0.00022835824,0.00016829185,0.00048165588,0.00024056954],"domain_scores_gemma":[0.9990541,0.000012296011,0.00021213756,0.0002587987,0.00040821175,0.000054455722],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009833693,0.0000840886,0.00024891808,0.0006201633,0.00021931698,0.00008198095,0.00040283467,0.00008750437,0.000026730599],"category_scores_gemma":[0.00004990182,0.00006246219,0.00002337738,0.0003101402,0.0012422699,0.00020245745,0.00015374839,0.00036905077,1.4508713e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000033652806,0.000039992286,0.21963173,0.000006556058,0.000023631288,0.000050382074,0.00016504445,1.11861866e-7,0.5973615,0.0003280891,0.0000048445563,0.1823545],"study_design_scores_gemma":[0.0027266452,0.0013652389,0.47285816,0.0007056845,0.000049817416,0.0005093467,0.0012336484,0.00005676095,0.50545216,0.004157648,0.010678652,0.00020620186],"about_ca_topic_score_codex":0.00010772793,"about_ca_topic_score_gemma":0.000044219185,"teacher_disagreement_score":0.25322646,"about_ca_system_score_codex":0.00022291641,"about_ca_system_score_gemma":0.0003557741,"threshold_uncertainty_score":0.45771953},"labels":[],"label_agreement":null},{"id":"W2748186599","doi":"10.3389/fmed.2017.00134","title":"More Haste, Less Speed: Could Public–Private Partnerships Advance Cellular Immunotherapies?","year":2017,"lang":"en","type":"review","venue":"Frontiers in Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Genome Canada; Université de Montréal; Hôpital Maisonneuve-Rosemont; Simon Fraser University","funders":"Alberta Innovates; Genome Alberta; Stem Cell Network; Génome Québec; Genome Canada","keywords":"Commercialization; Business; Private sector; Public relations; Cancer immunotherapy; Public sector; Marketing; Cancer; Immunotherapy; Political science; Economics; Medicine; Economic growth","score_opus":0.22687117474745241,"score_gpt":0.42279938533500394,"score_spread":0.19592821058755153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2748186599","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000023385004,0.97934437,0.001061709,0.0037077088,0.003455592,0.0031269332,0.000036936726,0.00013283028,0.009110556],"genre_scores_gemma":[0.000016284135,0.9435063,0.001515224,0.0004368195,0.0023016352,0.00020141708,0.00063907984,0.00035572544,0.051027503],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99276894,0.0005355629,0.0017884912,0.0013997352,0.0019406313,0.0015666151],"domain_scores_gemma":[0.99405557,0.00025920104,0.0010728021,0.0036480515,0.00027773014,0.00068667],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003011336,0.0012600155,0.007280814,0.0016660335,0.0002639462,0.0001054927,0.0019027813,0.0010996254,0.0020491637],"category_scores_gemma":[0.0011317434,0.00094848656,0.0007600109,0.00097544736,0.0019761785,0.0002627367,0.0002831302,0.0034583975,0.000081926555],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025650777,0.00016391657,0.00049213873,0.014169309,0.0009741828,0.00096911314,0.00033212648,2.8238247e-7,0.00005355484,0.000103300314,0.045465916,0.93701965],"study_design_scores_gemma":[0.0040248535,0.00038976752,0.000021853744,0.032708887,0.00074781716,0.00015091385,0.0006380135,0.00005006129,0.000011197008,0.00013427885,0.9604134,0.00070897985],"about_ca_topic_score_codex":0.00006685956,"about_ca_topic_score_gemma":0.000014281429,"teacher_disagreement_score":0.93631065,"about_ca_system_score_codex":0.0011057351,"about_ca_system_score_gemma":0.000907185,"threshold_uncertainty_score":0.99929655},"labels":[],"label_agreement":null},{"id":"W2748227909","doi":"10.1016/j.exphem.2017.06.301","title":"Generation of a new, human growth factor-dependent, de novo model of AML from c-MYC-transduced normal human CD34+ hematopoietic cells","year":2017,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Haematopoiesis; CD34; Myeloid leukemia; Biology; Bone marrow; Leukemia; Cancer research; Myeloid; CD33; Progenitor cell; Stromal cell; Cord blood; Immunology; Stem cell; Molecular biology; Cell biology","score_opus":0.1093038196477219,"score_gpt":0.38482649031607685,"score_spread":0.27552267066835495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2748227909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948722,0.000519608,0.0006238602,0.0001010582,0.00012907438,0.0005003999,0.00004218471,0.00003390379,0.003177701],"genre_scores_gemma":[0.9964675,0.000013897669,0.0011546784,0.000054828277,0.0001567435,0.000031201187,0.00006741776,0.000054361117,0.0019994143],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99803114,0.00007082982,0.0005983587,0.00042000157,0.00044375286,0.00043590006],"domain_scores_gemma":[0.9984845,0.000032737324,0.0003029456,0.00084840844,0.0000944792,0.00023691484],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00012511414,0.00026129637,0.00076673983,0.00015193806,0.00023047802,0.000026019512,0.0004243344,0.00025375548,0.0034881001],"category_scores_gemma":[0.00001564566,0.0002630771,0.00021348822,0.000042796088,0.00034484718,0.00014777832,0.00015053035,0.00024895312,0.000017491231],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002504109,0.0005591973,0.0077341637,0.00008701735,0.00012729426,0.000046994293,0.004133958,0.00000699032,0.9816036,0.0052099586,0.00019535725,0.00004501969],"study_design_scores_gemma":[0.003956473,0.00047995793,0.0006855785,0.0000570443,0.000037957292,0.00010436433,0.00037512477,0.0007078451,0.99291664,0.0004824322,0.0000086550945,0.00018794274],"about_ca_topic_score_codex":0.001604015,"about_ca_topic_score_gemma":0.00017177065,"teacher_disagreement_score":0.011312987,"about_ca_system_score_codex":0.00012989211,"about_ca_system_score_gemma":0.00016218176,"threshold_uncertainty_score":0.9999821},"labels":[],"label_agreement":null},{"id":"W2749189538","doi":"10.1016/j.jss.2006.12.420","title":"P236","year":2007,"lang":"en","type":"article","venue":"Journal of Surgical Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"CD8; NOD mice; Biology; T-cell receptor; Downregulation and upregulation; Transgene; Molecular biology; Insulitis; Genetically modified mouse; Nod; Cancer research; Laser capture microdissection; Islet; T cell; Antigen; Immunology; Immune system; Gene expression; Endocrinology; Gene; Autoimmunity; Diabetes mellitus","score_opus":0.17742359097034613,"score_gpt":0.507812912080879,"score_spread":0.3303893211105329,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2749189538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8529114,0.0010806834,0.00008016723,0.0061066854,0.00013848644,0.00019371022,5.9913697e-7,0.000009123757,0.13947913],"genre_scores_gemma":[0.96535087,0.0015361705,0.0004242556,0.000061693805,0.0016870372,0.0000010557054,7.4910184e-7,0.000026608037,0.030911548],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99509853,0.00021580009,0.00056422217,0.00014034146,0.0032278143,0.00075327524],"domain_scores_gemma":[0.99521834,0.0018849099,0.00007681498,0.00025766305,0.0017323184,0.0008299406],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.016581453,0.000086584136,0.00035680627,0.0008294324,0.00009145822,0.00004255307,0.00026343155,0.00013474522,0.010565021],"category_scores_gemma":[0.00087486545,0.00005904024,0.00026254402,0.0009539982,0.00029639632,0.00009420506,0.00009896264,0.0020711133,0.00019651215],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022896409,0.0014878087,0.029418148,0.00015155465,0.0003436742,0.05031781,0.00036071226,0.000003020845,0.3358907,0.0015402088,0.074821115,0.48276883],"study_design_scores_gemma":[0.0040420834,0.002176649,0.017113805,0.00014090569,0.000011927279,0.0051902183,0.00032458614,0.000017529957,0.029229343,0.0005695212,0.9411035,0.00007991432],"about_ca_topic_score_codex":0.000020521165,"about_ca_topic_score_gemma":0.0000029223593,"teacher_disagreement_score":0.8662824,"about_ca_system_score_codex":0.0003036233,"about_ca_system_score_gemma":0.00046189915,"threshold_uncertainty_score":0.99033946},"labels":[],"label_agreement":null},{"id":"W2750629076","doi":"10.1016/j.exphem.2017.09.002","title":"Lenalidomide modulates gene expression in human ABC-DLBCL cells by regulating IKAROS interaction with an intronic control region of SPIB","year":2017,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children’s Health Research Institute; Western University","funders":"Canadian Institutes of Health Research; Leukemia and Lymphoma Society of Canada","keywords":"Lenalidomide; Transcription factor; Cancer research; Downregulation and upregulation; Diffuse large B-cell lymphoma; Cereblon; Biology; IRF4; Ubiquitin ligase; Molecular biology; Lymphoma; Genetics; Gene; Ubiquitin; Multiple myeloma; Immunology","score_opus":0.027510226992156314,"score_gpt":0.35983815069253416,"score_spread":0.33232792370037784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2750629076","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99735653,0.00085011456,0.0001307658,0.00014997969,0.00007823487,0.00065153517,0.0000024923045,0.000028815713,0.00075155636],"genre_scores_gemma":[0.9982394,0.000015854788,0.00057634496,0.00004175365,0.000077672594,0.00007630704,0.00003312106,0.0000439225,0.00089564687],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998423,0.00014388435,0.00042112247,0.0004135551,0.0002442984,0.00035414673],"domain_scores_gemma":[0.99879485,0.00005171985,0.0003000814,0.0006821803,0.000052594783,0.000118579665],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001883266,0.00020299896,0.0005857294,0.00011898596,0.00018410009,0.000028851557,0.0002060222,0.00015231594,0.00075296784],"category_scores_gemma":[0.000016727947,0.00017106609,0.000069590336,0.000042877833,0.00031499652,0.00026671996,0.00006683349,0.00026035542,0.0000071644517],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032114876,0.0006931106,0.006323595,0.00004859109,0.000037993443,0.00008870497,0.0006598401,0.000020489293,0.9877924,0.00020069355,0.00016049125,0.0007626225],"study_design_scores_gemma":[0.009807794,0.0013323138,0.00048459752,0.00026953238,0.000011681311,0.0004341006,0.0007215151,0.0013347784,0.98532414,0.000046024626,0.00008757755,0.0001459258],"about_ca_topic_score_codex":0.00044127065,"about_ca_topic_score_gemma":0.000039832565,"teacher_disagreement_score":0.006596307,"about_ca_system_score_codex":0.00020130182,"about_ca_system_score_gemma":0.00003141077,"threshold_uncertainty_score":0.824447},"labels":[],"label_agreement":null},{"id":"W2751257824","doi":"10.2217/rme-2017-0031","title":"Opportunities and Challenges for the Cellular Immunotherapy Sector: A Global Landscape of Clinical Trials","year":2017,"lang":"en","type":"article","venue":"Regenerative Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; Université de Montréal; Hôpital Maisonneuve-Rosemont; University of Alberta; Genome Canada","funders":"Genome Alberta; Alberta Innovates - Health Solutions; University of Alberta; Stem Cell Network; Génome Québec; Canadian Institutes of Health Research; Genome Canada","keywords":"Clinical trial; Identification (biology); Business; Translational research; Immunotherapy; Medicine; Cancer; Biology","score_opus":0.5894884327791456,"score_gpt":0.5097814868901752,"score_spread":0.07970694588897043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2751257824","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.39599758,0.3757064,0.002429823,0.19732204,0.0017300963,0.004581194,0.00016386199,0.000057088142,0.022011915],"genre_scores_gemma":[0.79127336,0.19284259,0.00033991985,0.00050562655,0.004736209,0.00015592993,0.000034309334,0.00004128767,0.010070792],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975789,0.00059371715,0.0008504808,0.00030393785,0.00043607716,0.00023687769],"domain_scores_gemma":[0.995728,0.002332148,0.00054766994,0.0008702267,0.00035389958,0.00016806286],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.009092333,0.00019859108,0.0013319037,0.00005201416,0.00028079978,0.0000233295,0.00025589147,0.0001359494,0.0009974545],"category_scores_gemma":[0.00336917,0.00010066502,0.00023693933,0.00003646246,0.0011921712,0.000051087012,0.000060309987,0.0001877365,0.0000010413057],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005994755,0.00021960544,0.006607455,0.00041844844,0.0021090913,0.000045918445,0.0022043954,8.3223586e-7,0.096101075,0.016270284,0.008949528,0.8610786],"study_design_scores_gemma":[0.045580555,0.011038459,0.05536261,0.00095068134,0.0010190952,0.00010514378,0.009358893,0.0024422267,0.04533819,0.001794361,0.8265358,0.00047396758],"about_ca_topic_score_codex":0.000086583685,"about_ca_topic_score_gemma":0.00005903169,"teacher_disagreement_score":0.86060464,"about_ca_system_score_codex":0.000023152556,"about_ca_system_score_gemma":0.00020725046,"threshold_uncertainty_score":0.9999158},"labels":[],"label_agreement":null},{"id":"W2753212558","doi":"10.1016/j.clml.2017.07.213","title":"Global Pivotal Phase 2 Trial of the CD19-Targeted Therapy CTL019 In Adult Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)—An Interim Analysis","year":2017,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Université de Montréal; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Interim; Diffuse large B-cell lymphoma; Oncology; Interim analysis; Internal medicine; Clinical trial; Chimeric antigen receptor; Refractory (planetary science); Phases of clinical research; Medicine; Follicular lymphoma; Lymphoma; Biology; Cancer; Immunotherapy","score_opus":0.039864800314428975,"score_gpt":0.37971674502119257,"score_spread":0.3398519447067636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2753212558","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947119,0.00007797535,0.000023287515,0.00018203133,0.0008238042,0.002266343,0.0002927193,0.00008878961,0.0015331517],"genre_scores_gemma":[0.9963458,0.00026777378,0.00017968376,0.0006295253,0.00049769494,0.00010459749,0.00023576015,0.00011200215,0.0016271343],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9924976,0.0011159466,0.0022475661,0.0013688605,0.0016744577,0.0010955661],"domain_scores_gemma":[0.99213445,0.00071802293,0.0014765732,0.004201594,0.00074065663,0.0007286792],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016775236,0.00070569577,0.002103385,0.00031735795,0.00040354938,0.00015915374,0.0018188426,0.00077674934,0.0007784231],"category_scores_gemma":[0.0023512393,0.00043119278,0.0012702176,0.0012311949,0.0011547522,0.00042599236,0.0004911724,0.000519423,0.00003523867],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34601772,0.040766343,0.32044542,0.00004670031,0.0012019842,0.00022411032,0.00026929213,0.0000012564503,0.00084607885,0.000022073724,0.0002698182,0.2898892],"study_design_scores_gemma":[0.39208654,0.008221565,0.5962593,0.00010993209,0.00038448308,0.00000753916,0.000086714004,0.0006543852,0.00056522945,0.00001677976,0.001280243,0.00032730584],"about_ca_topic_score_codex":0.0010807123,"about_ca_topic_score_gemma":0.0013920875,"teacher_disagreement_score":0.2895619,"about_ca_system_score_codex":0.0018568857,"about_ca_system_score_gemma":0.0026585662,"threshold_uncertainty_score":0.999814},"labels":[],"label_agreement":null},{"id":"W2753890414","doi":"10.1158/1078-0432.ccr-16-3065","title":"Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity","year":2017,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":181,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Clinical trial; Medicine; Surrogate endpoint; Oncology; Clinical endpoint; Milestone; Clinical study design; Drug development; Cancer; Internal medicine; Phases of clinical research; Biomarker; Pharmacology; Drug","score_opus":0.511372098794355,"score_gpt":0.6422053277657701,"score_spread":0.13083322897141514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2753890414","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9030439,0.0003373207,0.000015991107,0.013554793,0.002110073,0.0021429393,0.000017473176,0.00008835318,0.078689106],"genre_scores_gemma":[0.9633348,0.00400308,0.00020907295,0.0004073657,0.0063394825,0.00045569614,0.0000063196026,0.00009796595,0.025146196],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9919903,0.0016980945,0.0014168121,0.0012474027,0.0021408382,0.0015065483],"domain_scores_gemma":[0.9883782,0.0058701737,0.00044737625,0.0031118153,0.001189172,0.0010032252],"candidate_categories":["metaresearch","sts","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.025028601,0.0002862738,0.0013394756,0.0002575161,0.0010941455,0.0003064385,0.0016216218,0.00080046174,0.013606792],"category_scores_gemma":[0.02363364,0.0002415108,0.0007229679,0.00024254191,0.0028686011,0.0002665557,0.0015210538,0.0051580397,0.00055244594],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3001928,0.0019131192,0.0232401,0.00012161291,0.0004962969,0.00056078524,0.0002267145,6.9220334e-7,0.03344724,0.00009192,0.009246812,0.6304619],"study_design_scores_gemma":[0.22179502,0.020158924,0.15382552,0.0006340812,0.00016876322,0.00005544645,0.00035037845,0.00024791388,0.012170314,0.0014114528,0.58843094,0.0007512478],"about_ca_topic_score_codex":0.0024703627,"about_ca_topic_score_gemma":0.000727298,"teacher_disagreement_score":0.6297107,"about_ca_system_score_codex":0.00094006315,"about_ca_system_score_gemma":0.0036602442,"threshold_uncertainty_score":0.999845},"labels":[],"label_agreement":null},{"id":"W2754249088","doi":"10.4049/jimmunol.196.supp.55.16","title":"Defining the role of Tim-3 in T cells","year":2016,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"École Nationale d'Administration Publique","funders":"","keywords":"Cytotoxic T cell; T cell; Immune system; Effector; Cell biology; Biology; Stimulation; IL-2 receptor; Ectopic expression; Immunology; T-cell receptor; In vitro; Neuroscience; Cell culture; Genetics","score_opus":0.013075516426153205,"score_gpt":0.2875619280963081,"score_spread":0.27448641167015486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2754249088","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9815607,0.009920802,0.000025426618,0.004180873,0.00011684972,0.0000871771,8.155431e-7,0.0000022249594,0.0041051116],"genre_scores_gemma":[0.9962964,0.0021965033,0.000047525235,0.00008842433,0.000054750733,7.4173613e-7,6.569863e-8,0.000009651728,0.0013059584],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99900174,0.00027810637,0.00032648383,0.000038060032,0.00017552312,0.00018006528],"domain_scores_gemma":[0.9986318,0.00077315705,0.00019981273,0.00025734876,0.00011801547,0.000019916548],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001403596,0.000056694196,0.00022968148,0.00012202341,0.000024407564,0.0000020363848,0.00029300747,0.000054442,0.0011083188],"category_scores_gemma":[0.00015241673,0.000021230442,0.00007517373,0.00012684707,0.00025792688,0.000030458243,0.0000625062,0.00035360813,0.000043914137],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011976421,0.000042949232,0.0018865336,0.0000023341997,0.00010844441,0.000010280427,0.0007146595,0.0000025920046,0.92482126,0.00041744404,0.00011878914,0.07067706],"study_design_scores_gemma":[0.0029836807,0.0013587123,0.023219796,0.00019393968,0.000055680077,0.0011311834,0.0016388306,0.000011816592,0.9433671,0.0023679682,0.023620594,0.00005065762],"about_ca_topic_score_codex":0.000048327267,"about_ca_topic_score_gemma":0.000008947917,"teacher_disagreement_score":0.0706264,"about_ca_system_score_codex":0.000055938694,"about_ca_system_score_gemma":0.00012385803,"threshold_uncertainty_score":0.9998048},"labels":[],"label_agreement":null},{"id":"W2754671817","doi":"10.1016/j.jcyt.2017.06.009","title":"A roadmap for cost-of-goods planning to guide economic production of cell therapy products","year":2017,"lang":"en","type":"review","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Engineering and Physical Sciences Research Council; Natural Sciences and Engineering Research Council of Canada","keywords":"Procurement; Cog; Product (mathematics); Process (computing); Production (economics); Business; Transformative learning; Risk analysis (engineering); Computer science; Economics; Marketing","score_opus":0.24824589398353608,"score_gpt":0.47717196651248867,"score_spread":0.22892607252895258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2754671817","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0005543101,0.982715,0.0001056705,0.00028799276,0.0010641089,0.012936448,0.00009036435,0.000051192466,0.002194887],"genre_scores_gemma":[0.000027096557,0.9599697,0.0024343901,0.000058055153,0.0017835171,0.001293365,0.00013192989,0.00026424887,0.0340377],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967608,0.0001509329,0.0012023282,0.00097652344,0.00036292934,0.00054650655],"domain_scores_gemma":[0.9960868,0.00019116607,0.0010870761,0.0021134468,0.00032991465,0.0001916194],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014109145,0.0005876238,0.0030490572,0.0006288488,0.000110254085,0.000039467966,0.0006675776,0.0003725098,0.00039174504],"category_scores_gemma":[0.00018985284,0.00047757782,0.0007767989,0.00022180518,0.0001717282,0.00008882135,0.000050584382,0.00036755734,0.000035900048],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00092784356,0.00022509048,0.00002100203,0.012364391,0.00055483595,0.0000038825247,0.00046557013,0.000007661371,0.014091023,0.000013229833,0.009162865,0.9621626],"study_design_scores_gemma":[0.0016881103,0.0014178033,0.00001096648,0.0062053595,0.00017410149,0.00003775077,0.000021312204,0.0000036665683,0.03315092,0.000015743639,0.9569141,0.00036011965],"about_ca_topic_score_codex":0.00005584278,"about_ca_topic_score_gemma":0.000003884316,"teacher_disagreement_score":0.9618025,"about_ca_system_score_codex":0.00045754996,"about_ca_system_score_gemma":0.0019292636,"threshold_uncertainty_score":0.9997676},"labels":[],"label_agreement":null},{"id":"W2755752847","doi":"10.1038/leu.2017.290","title":"Generation of a multi-antigen-directed immune response for durable control of acute lymphoblastic leukemia","year":2017,"lang":"en","type":"letter","venue":"Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Children's Hospital","funders":"Canadian Institutes of Health Research","keywords":"Lymphoblastic Leukemia; Immune system; Immunology; Antigen; Medicine; Acute lymphocytic leukemia; Leukemia; Asparaginase","score_opus":0.04461783480646685,"score_gpt":0.32009800181135867,"score_spread":0.2754801670048918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2755752847","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8907792,0.0039886134,0.011355341,0.07346505,0.0026675367,0.012572596,0.0036622426,0.00045866298,0.0010507666],"genre_scores_gemma":[0.52372414,0.0018410217,0.010225,0.06774988,0.011075523,0.0020370514,0.006814872,0.0012343823,0.37529814],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99611974,0.00039431974,0.0011261338,0.0007095974,0.0008850774,0.0007651281],"domain_scores_gemma":[0.9948763,0.0010036755,0.0010522855,0.0018838167,0.0010564607,0.00012745545],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0011491603,0.00054743723,0.0018425101,0.00055564457,0.00017651854,0.000048659393,0.0006042191,0.0013764554,0.00065381435],"category_scores_gemma":[0.0012160006,0.00050156924,0.00074192125,0.000200198,0.00037588493,0.00009892542,0.00008296084,0.0011463834,0.00003051918],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009761985,0.000043911226,0.000090527894,0.00068597693,0.0014811538,0.0003123519,0.00014068444,0.000042514654,0.77586806,0.000001515855,0.21040855,0.0011627766],"study_design_scores_gemma":[0.038867455,0.0022284344,0.0054253982,0.0014252667,0.0020951573,0.00033202328,0.000016608361,0.07165547,0.5026444,0.000019274154,0.37438193,0.00090854696],"about_ca_topic_score_codex":0.0007586054,"about_ca_topic_score_gemma":0.000017348,"teacher_disagreement_score":0.37424737,"about_ca_system_score_codex":0.0026111112,"about_ca_system_score_gemma":0.0048695416,"threshold_uncertainty_score":0.99991995},"labels":[],"label_agreement":null},{"id":"W2756071038","doi":"10.1182/blood-2017-06-793141","title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1112,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; National Heart, Lung, and Blood Institute; Juno Therapeutics; National Institutes of Health","keywords":"Chimeric antigen receptor; Cytokine release syndrome; CD19; Immunology; Receptor; Antigen; Medicine; Cell therapy; Cytokine; Immunotherapy; Cancer research; Biology; Cell; Immune system; Internal medicine; Biochemistry","score_opus":0.021497684031937653,"score_gpt":0.2764908282456986,"score_spread":0.25499314421376096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2756071038","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98904794,0.0020507283,0.0000043547557,0.00038489376,0.00008760545,0.00058848545,0.00004123591,0.000031533167,0.007763242],"genre_scores_gemma":[0.9920476,0.0036403525,0.0005804933,0.00008704815,0.00009106987,0.000024517549,0.000019167908,0.000055875276,0.003453855],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99859977,0.00005942796,0.00026423822,0.0003518452,0.00038862092,0.00033610844],"domain_scores_gemma":[0.99844927,0.000052546267,0.00015715077,0.0010127325,0.00010541947,0.0002228968],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001916821,0.00020983511,0.00041626787,0.00013694826,0.000093419185,0.000043593787,0.00023138007,0.00013742525,0.0017946182],"category_scores_gemma":[0.00006143269,0.00017790058,0.000116417454,0.00011495026,0.0002948671,0.000071247865,0.000107906235,0.0001899708,0.00002726802],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015982423,0.0010537856,0.06346476,0.00015215957,0.000394395,0.00022883447,0.00018524588,2.8738796e-7,0.92337555,0.0000026121816,0.0003969585,0.009147156],"study_design_scores_gemma":[0.017506862,0.0023228629,0.5160027,0.00020008507,0.00016803057,0.00049829466,0.00007238649,0.00002431619,0.45657474,0.000046599853,0.006198857,0.00038427857],"about_ca_topic_score_codex":0.00013976631,"about_ca_topic_score_gemma":0.0000050147455,"teacher_disagreement_score":0.4668008,"about_ca_system_score_codex":0.000012472466,"about_ca_system_score_gemma":0.000057931848,"threshold_uncertainty_score":0.99911785},"labels":[],"label_agreement":null},{"id":"W2757868227","doi":"10.2741/4605","title":"Immune ligands for cytotoxic T Lymphocytes CTLS in cancer stem cells CSCS","year":2017,"lang":"en","type":"article","venue":"Frontiers in bioscience","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sault Area Hospital","funders":"","keywords":"Cytotoxic T cell; Immune system; Cancer stem cell; Cancer; Cancer research; Cancer cell; Stem cell; Immunology; Immunotherapy; Biology; Medicine; Cell biology; In vitro; Internal medicine; Genetics","score_opus":0.038385817761890324,"score_gpt":0.33806210878583753,"score_spread":0.2996762910239472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2757868227","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921582,0.0021986435,0.0005946766,0.001139582,0.0019515594,0.0011040504,0.000025403186,0.000023891595,0.0008039949],"genre_scores_gemma":[0.98185974,0.0016745464,0.00229599,0.00018573912,0.00012023681,0.00018814353,0.0000015655114,0.000024026886,0.013650034],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99821,0.000016239259,0.00028793467,0.00047009476,0.00040200163,0.00061370217],"domain_scores_gemma":[0.99888736,0.000046337034,0.00011712908,0.0007449749,0.00006909871,0.00013511853],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00084767136,0.00015540747,0.0003866925,0.00032387962,0.00021247879,0.00010902814,0.0007272449,0.00011748248,0.00007612174],"category_scores_gemma":[0.00010093497,0.00013654563,0.00008695503,0.00032992242,0.0006567908,0.00022366912,0.0001322143,0.00017442348,0.0000061501673],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037000203,0.00010492772,0.12025666,0.0000808764,0.000010069303,0.00002818043,0.0004504986,0.000014418835,0.8272074,0.000017545683,0.0019598037,0.049499616],"study_design_scores_gemma":[0.003326636,0.00024065182,0.063692495,0.0002729912,0.000008325926,0.0000049747823,0.00035990746,0.0057964493,0.9182579,0.00013673889,0.0077022067,0.00020075045],"about_ca_topic_score_codex":0.0005026346,"about_ca_topic_score_gemma":0.000115471514,"teacher_disagreement_score":0.091050476,"about_ca_system_score_codex":0.00070339977,"about_ca_system_score_gemma":0.00047228506,"threshold_uncertainty_score":0.5568169},"labels":[],"label_agreement":null},{"id":"W2760319029","doi":"10.1016/j.cjca.2017.07.056","title":"RNA-SEQ DATA ANALYSIS IDENTIFIES STEM CELL TRANSCRIPTOMIC SIGNATURES UNDERPINNING THE THERAPEUTIC EFFECTIVENESS OF PATIENT CELLS IN THE IMPACT-CABG TRIAL","year":2017,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Transcriptome; Ejection fraction; Bioinformatics; Stem cell; Stem-cell therapy; Clinical trial; Gene expression; Heart failure; Oncology; Computational biology; Internal medicine; Gene; Biology; Genetics; Transplantation","score_opus":0.05987179097038111,"score_gpt":0.3432953018408447,"score_spread":0.28342351087046364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2760319029","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992779,0.0034275982,0.00042587135,0.0004964997,0.00063433073,0.0006815914,0.00007547694,0.0000016110301,0.0014780189],"genre_scores_gemma":[0.99932075,0.00016017126,0.0000039744223,0.000068527304,0.00035507928,0.0000068443205,0.000011785284,0.000017866709,0.000054989265],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99658173,0.0019000922,0.00051911053,0.00022349854,0.0003582562,0.00041729564],"domain_scores_gemma":[0.996796,0.0009237341,0.0004134921,0.0014420066,0.00020913429,0.0002156424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004217491,0.0001763513,0.0009381212,0.0005657724,0.00023600565,0.00010994804,0.0014847524,0.00016371207,0.000066114764],"category_scores_gemma":[0.000105782456,0.00009533599,0.00061400904,0.00029788355,0.0005020178,0.00012781323,0.00003914222,0.0008122182,0.0000014262046],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.072017536,0.00014995596,0.09480229,0.00050869066,0.02849419,0.0026745552,0.01669945,0.061537307,0.6567658,0.00020310265,0.0057475353,0.06039959],"study_design_scores_gemma":[0.081466734,0.008667689,0.7979337,0.000592378,0.010477994,0.00076651963,0.013825372,0.0013046603,0.0659533,0.0018737556,0.016211336,0.00092658977],"about_ca_topic_score_codex":0.0071556265,"about_ca_topic_score_gemma":0.0051326714,"teacher_disagreement_score":0.7031314,"about_ca_system_score_codex":0.00024864214,"about_ca_system_score_gemma":0.0014526725,"threshold_uncertainty_score":0.9994558},"labels":[],"label_agreement":null},{"id":"W2762831145","doi":"10.1016/j.omtm.2017.10.003","title":"Targeted Cell-to-Cell Delivery of Protein Payloads via the Granzyme-Perforin Pathway","year":2017,"lang":"en","type":"article","venue":"Molecular Therapy — Methods & Clinical Development","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; University of British Columbia; Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency","funders":"BC Cancer Foundation; Genome British Columbia","keywords":"Granzyme; Granzyme B; Perforin; Cell biology; Cytotoxic T cell; Biology; Granzyme A; Chemistry; Biochemistry","score_opus":0.08815676302751622,"score_gpt":0.431487083930083,"score_spread":0.34333032090256677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762831145","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92943996,0.0017929189,0.059683714,0.001795481,0.00044770393,0.0034050508,0.0000049866144,0.0000667983,0.0033634081],"genre_scores_gemma":[0.52477664,0.00054896466,0.4633629,0.0021055227,0.00019159794,0.00048220702,0.000021576241,0.00015230704,0.008358265],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99341583,0.002095404,0.0015759032,0.0009349735,0.0011676359,0.0008102438],"domain_scores_gemma":[0.995204,0.0006802417,0.0005399097,0.0025076864,0.0005109694,0.00055721996],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.010150529,0.0005013737,0.0011264754,0.00017445054,0.0004916334,0.000097422126,0.0013308944,0.00037220473,0.0012237113],"category_scores_gemma":[0.0006524487,0.00033715216,0.0006310201,0.00030449312,0.0004470426,0.00006526058,0.00045748006,0.0010286154,0.00014020335],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001180215,0.0005597222,0.0012507811,0.000049381633,0.00021306757,0.00006664013,0.0003592717,0.0000027144165,0.5751164,0.000015717338,0.000056253055,0.42112982],"study_design_scores_gemma":[0.0039988724,0.0010463445,0.016298495,0.00008661002,0.000033898694,0.000006737662,0.000047775015,0.0000873453,0.85092485,0.00029871956,0.12680963,0.00036072047],"about_ca_topic_score_codex":0.000099946905,"about_ca_topic_score_gemma":0.0000060485427,"teacher_disagreement_score":0.4207691,"about_ca_system_score_codex":0.00013017084,"about_ca_system_score_gemma":0.0008667831,"threshold_uncertainty_score":0.99990803},"labels":[],"label_agreement":null},{"id":"W2763124655","doi":"10.4049/jimmunol.196.supp.140.34","title":"The increase in thymopoiesis following T cell progenitor therapy is dependent upon the input population and continued interaction between developing T cells and the thymic microenvironment.","year":2016,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; Sunnybrook Health Science Centre","funders":"","keywords":"Thymocyte; Biology; Lymphopoiesis; Progenitor cell; Haematopoiesis; Population; T cell; Cell biology; Immunology; Recombination-activating gene; Stem cell; Andrology; Internal medicine; Immune system; Biochemistry; Medicine","score_opus":0.01583986409306786,"score_gpt":0.2770231082955858,"score_spread":0.26118324420251793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763124655","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97589964,0.00875335,0.000068326095,0.014431074,0.00019834316,0.00061317405,0.0000015542267,0.0000041253074,0.000030415587],"genre_scores_gemma":[0.9807862,0.018358482,0.000033359778,0.0002524626,0.00014262929,0.0000109452685,6.5479867e-7,0.000019628053,0.00039562507],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977542,0.0011032538,0.000494088,0.00011684492,0.00026343612,0.00026813208],"domain_scores_gemma":[0.9972109,0.002046718,0.00036869312,0.00028919269,0.000050395814,0.000034098863],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029199573,0.00014872692,0.00031254368,0.00009817449,0.00031228035,0.00004873058,0.0002824271,0.00008410797,0.000039704297],"category_scores_gemma":[0.00011595878,0.000051109266,0.00009958872,0.00009869188,0.0002933061,0.000120294026,0.00012973911,0.0004893624,0.0000044594863],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005722457,0.000034814,0.034638796,0.000007291802,0.0005258965,0.000010097332,0.003514248,7.644427e-7,0.85994315,0.000013403828,0.000054017444,0.09553506],"study_design_scores_gemma":[0.020984516,0.00092258636,0.45041135,0.00037802168,0.00038682765,0.0007812824,0.0058842115,0.000032418742,0.5084941,0.0012311876,0.010246054,0.00024744595],"about_ca_topic_score_codex":0.00032819674,"about_ca_topic_score_gemma":0.00005707234,"teacher_disagreement_score":0.41577256,"about_ca_system_score_codex":0.00018950288,"about_ca_system_score_gemma":0.00005974475,"threshold_uncertainty_score":0.24018395},"labels":[],"label_agreement":null},{"id":"W2763751953","doi":"10.1158/2159-8290.cd-17-0698","title":"Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells","year":2017,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1364,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; National Heart, Lung, and Blood Institute; Juno Therapeutics","keywords":"Neurotoxicity; Medicine; Cytokine release syndrome; Immunology; Bone marrow; Blood–brain barrier; Pericyte; Endothelium; Chimeric antigen receptor; Cancer research; Immunotherapy; Endothelial stem cell; Internal medicine; Central nervous system; Immune system; Toxicity; Biology","score_opus":0.017069140314072143,"score_gpt":0.30439871479742864,"score_spread":0.2873295744833565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2763751953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968907,0.0001953699,0.00011916851,0.00084322924,0.000124087,0.00096430804,0.00009117692,0.000016470502,0.00075547973],"genre_scores_gemma":[0.9914401,0.0007502206,0.00003823792,0.000628761,0.0003103473,0.00036886972,0.000008831924,0.000048479196,0.0064061335],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987343,0.00006827261,0.00016689632,0.0003995792,0.000323186,0.00030778596],"domain_scores_gemma":[0.9991278,0.000071664115,0.0001096098,0.0005379993,0.000056007386,0.00009693399],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016909333,0.00019797424,0.00028266304,0.00010679528,0.00012662512,0.00018335402,0.00011799117,0.00009117803,0.00043269293],"category_scores_gemma":[0.00003544825,0.00015610876,0.00006110157,0.000075140604,0.0002712747,0.00068272674,0.000054906308,0.00031982106,0.0000030983995],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057017,0.000098234894,0.10935333,0.00005715216,0.00008337406,0.000058330224,0.0007839753,0.000013010918,0.8776358,0.000016899443,0.00003672804,0.006161468],"study_design_scores_gemma":[0.0057758456,0.0004905535,0.46914983,0.0003029887,0.000036079055,0.000013284869,0.00013917757,0.000051378116,0.52181596,0.000051868155,0.0019490413,0.00022397439],"about_ca_topic_score_codex":0.0010873256,"about_ca_topic_score_gemma":0.00048098873,"teacher_disagreement_score":0.3597965,"about_ca_system_score_codex":0.00018056604,"about_ca_system_score_gemma":0.00021330491,"threshold_uncertainty_score":0.63659304},"labels":[],"label_agreement":null},{"id":"W2765591174","doi":"10.3389/fimmu.2017.01460","title":"Engineered Tolerance: Tailoring Development, Function, and Antigen-Specificity of Regulatory T Cells","year":2017,"lang":"en","type":"review","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research","keywords":"Chimeric antigen receptor; FOXP3; Immune system; Adoptive cell transfer; Immunology; Autoimmunity; Antigen; Cell therapy; Transplantation; T cell; Biology; Regulatory T cell; Immune tolerance; Stem cell; Cancer research; Medicine; Cell biology; IL-2 receptor","score_opus":0.05643181468725787,"score_gpt":0.313203595503149,"score_spread":0.25677178081589114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765591174","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014070059,0.9935856,0.00055577065,0.000007802453,0.002626339,0.0008774401,0.000008736509,0.000030702733,0.000900635],"genre_scores_gemma":[0.00015602015,0.9916072,0.0025118564,0.000005540642,0.00015214786,0.000074634474,0.00004587964,0.000068976085,0.0053777643],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978341,0.00014457728,0.00081558205,0.0005165479,0.00022600565,0.0004631884],"domain_scores_gemma":[0.9984515,0.00006087366,0.00038161158,0.00092800264,0.00010590212,0.00007213868],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005584058,0.00037727112,0.0024618593,0.0008221309,0.000094917465,0.000016814742,0.0003382222,0.0006432876,0.00023707694],"category_scores_gemma":[0.00006624475,0.00035706177,0.00020535164,0.0002293642,0.00036093,0.00006482711,0.00016219771,0.00088903005,0.000013175314],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020226455,0.00006622298,0.00071437453,0.005185831,0.0007448922,0.000026180554,0.00013110288,3.82826e-7,0.00076686346,0.00003563353,0.001611693,0.9905146],"study_design_scores_gemma":[0.0009425333,0.000106252875,0.0031393736,0.004227415,0.00010799736,0.00004019965,0.00005353021,0.0000030855365,0.00042833708,0.000023662808,0.99067426,0.0002533439],"about_ca_topic_score_codex":0.0000138996,"about_ca_topic_score_gemma":0.0000023234957,"teacher_disagreement_score":0.9902612,"about_ca_system_score_codex":0.00033979255,"about_ca_system_score_gemma":0.0006059159,"threshold_uncertainty_score":0.9998881},"labels":[],"label_agreement":null},{"id":"W2766125827","doi":"10.1136/jclinpath-2017-204761","title":"T cell clonality assessment: past, present and future","year":2017,"lang":"en","type":"review","venue":"Journal of Clinical Pathology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of Calgary","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Pfizer Canada; Terry Fox Research Institute; Terry Fox Foundation; Canada Foundation for Innovation; Ontario Institute for Cancer Research; Pfizer; Princess Margaret Cancer Foundation; University of Calgary; Multiple Myeloma Research Foundation","keywords":"Computational biology; Biology; Bioinformatics; Cell; T cell; Function (biology); Immunology; Genetics; Immune system","score_opus":0.33858689799350855,"score_gpt":0.5972838326131215,"score_spread":0.2586969346196129,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766125827","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022916227,0.9839504,0.000016162647,0.0033024913,0.0020037773,0.0005649675,0.000021966758,0.000007029271,0.00990406],"genre_scores_gemma":[0.0000115700095,0.96450514,0.0011330391,0.00018720327,0.029227115,0.000007784951,0.000014814594,0.000052081683,0.0048612524],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9933237,0.0020557505,0.003086641,0.00044376828,0.0007018891,0.000388263],"domain_scores_gemma":[0.9927496,0.0019290567,0.003342079,0.00092072506,0.00044193503,0.0006166416],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00802401,0.00036388484,0.005467158,0.00022224255,0.00008919024,0.000051597675,0.00053437834,0.0012473484,0.0010487454],"category_scores_gemma":[0.0003956547,0.00022887184,0.0019527591,0.000079127596,0.00054589915,0.00007287648,0.00027775258,0.00465944,0.000025993795],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020509881,0.00047133022,0.0009544326,0.0051058605,0.00033281517,0.004142959,0.000009999491,1.0921169e-8,0.0000017638762,0.000020209252,0.011469672,0.97728586],"study_design_scores_gemma":[0.0020457734,0.001839438,0.0050367024,0.001955169,0.0014248857,0.0061595147,0.000008715605,8.639807e-7,2.157905e-7,0.00017297726,0.98119557,0.00016015882],"about_ca_topic_score_codex":0.0000015137218,"about_ca_topic_score_gemma":4.1707324e-7,"teacher_disagreement_score":0.9771257,"about_ca_system_score_codex":0.00008094387,"about_ca_system_score_gemma":0.0015636788,"threshold_uncertainty_score":0.99986446},"labels":[],"label_agreement":null},{"id":"W2766414528","doi":"10.3389/fimmu.2017.01418","title":"Reproducibility and Reuse of Adaptive Immune Receptor Repertoire Data","year":2017,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":114,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Simon Fraser University","funders":"National Institute of General Medical Sciences; Canadian Institutes of Health Research; National Institutes of Health; Agence Nationale de la Recherche; Genentech; Illumina; National Institute of Allergy and Infectious Diseases; Amgen","keywords":"Computer science; Acquired immune system; Data sharing; Protocol (science); Reuse; USable; Data science; Computational biology; Immune system; Medicine; Immunology; Biology; World Wide Web","score_opus":0.0581464792657464,"score_gpt":0.33131980892766344,"score_spread":0.27317332966191704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766414528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9749983,0.015511837,0.00013078409,0.0041944943,0.0012811301,0.0006824214,0.000049685535,0.00002814369,0.00312319],"genre_scores_gemma":[0.95657384,0.0064406134,0.025820546,0.000050382623,0.0001365215,0.000029040988,0.00010525207,0.0000448364,0.010798979],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99780166,0.00019036849,0.00041767556,0.0011259549,0.00015968089,0.0003046848],"domain_scores_gemma":[0.98583156,0.00006526729,0.00021516495,0.013723601,0.00011778091,0.000046604408],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002274707,0.00013471874,0.0006239165,0.00016823149,0.00012842959,0.000014539807,0.0011722029,0.00019709917,0.00030579304],"category_scores_gemma":[0.007051238,0.00012403243,0.000047564878,0.00009038888,0.0013414597,0.00019179845,0.0015929714,0.0004731438,0.0000052528053],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009013082,0.0004002445,0.28226545,0.000100912854,0.0006324575,0.00006827791,0.0014044947,2.566497e-7,0.37143558,0.00010347393,0.02045646,0.3141193],"study_design_scores_gemma":[0.00765218,0.0017389404,0.8114184,0.00034113557,0.000093099115,0.00012455863,0.0021584302,0.0004868016,0.07592223,0.0021328116,0.09755582,0.0003755627],"about_ca_topic_score_codex":0.00095290947,"about_ca_topic_score_gemma":0.00003369462,"teacher_disagreement_score":0.529153,"about_ca_system_score_codex":0.00011582571,"about_ca_system_score_gemma":0.00015762368,"threshold_uncertainty_score":0.84414995},"labels":[],"label_agreement":null},{"id":"W2766745670","doi":"10.1182/blood-2017-07-793760","title":"Infectious complications of CD19-targeted chimeric antigen receptor–modified T-cell immunotherapy","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":566,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; Juno Therapeutics; National Institutes of Health; National Institute of Allergy and Infectious Diseases; Washington State University","keywords":"Chimeric antigen receptor; Immunotherapy; Medicine; CD19; Antigen; Immunology; Virology; Cancer research; Immune system","score_opus":0.030049117923058317,"score_gpt":0.31668949529388235,"score_spread":0.28664037737082404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766745670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8989978,0.000643845,0.00010497075,0.0003704591,0.000113904476,0.0006050103,0.000017907962,0.00007313865,0.09907297],"genre_scores_gemma":[0.99392563,0.0010095392,0.0005428556,0.000094385025,0.00012769761,0.00004350717,0.000041707597,0.00004458531,0.00417012],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988654,0.000052152758,0.00026993916,0.00025269188,0.0002884934,0.00027130972],"domain_scores_gemma":[0.99809396,0.000056552257,0.00021552539,0.0013358966,0.0001890324,0.00010904599],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00020749624,0.00014440369,0.0003347387,0.00013095088,0.00027908027,0.000038680817,0.0003289296,0.00009741773,0.002044236],"category_scores_gemma":[0.000069951275,0.00013482066,0.00015172218,0.00014018573,0.00020856751,0.000064238986,0.00005869888,0.00022119621,0.0001243641],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010499973,0.0011971319,0.06875755,0.00003732231,0.00021083513,0.0000030389654,0.00018903209,0.0000012402381,0.9228965,0.00006472454,0.0004913266,0.0060463236],"study_design_scores_gemma":[0.008861482,0.0005970226,0.34265468,0.00005028644,0.00006727065,0.000032802738,0.000034727997,0.00004283021,0.63451207,0.0001459162,0.012805718,0.00019519725],"about_ca_topic_score_codex":0.0003987299,"about_ca_topic_score_gemma":0.000010941493,"teacher_disagreement_score":0.2883844,"about_ca_system_score_codex":0.00001791631,"about_ca_system_score_gemma":0.0001258281,"threshold_uncertainty_score":0.99886805},"labels":[],"label_agreement":null},{"id":"W2767090199","doi":"10.1158/1078-0432.ccr-17-2228","title":"Allogeneic Human Double Negative T Cells as a Novel Immunotherapy for Acute Myeloid Leukemia and Its Underlying Mechanisms","year":2017,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":106,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Amgen (Canada); Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; National Institutes of Health; Canadian Cancer Society; Leukemia and Lymphoma Society","keywords":"Myeloid leukemia; Immunotherapy; Leukemia; Medicine; Immunology; Myeloid; Cancer research; Biology; Immune system","score_opus":0.42368212276545314,"score_gpt":0.5829602507286331,"score_spread":0.15927812796317997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767090199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854968,0.00097007275,0.00039523438,0.004196801,0.00040940332,0.0038730218,0.000070807844,0.00005771279,0.0045301514],"genre_scores_gemma":[0.9313386,0.006981146,0.0011040671,0.00068148295,0.00078052125,0.0011091036,0.00001782866,0.0001532751,0.057833996],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9958571,0.00020512514,0.00065636414,0.000993298,0.0011657745,0.0011223123],"domain_scores_gemma":[0.99567616,0.001320245,0.00020213045,0.0012246015,0.0009881785,0.00058869884],"candidate_categories":["sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0050267004,0.00027736,0.00078104745,0.00022346056,0.001554144,0.00036013924,0.0008682583,0.00040760767,0.0020405005],"category_scores_gemma":[0.00049077417,0.000238284,0.0003109917,0.00019101093,0.00089353893,0.00020440391,0.00049839047,0.001563965,0.000076719596],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007945402,0.00020021237,0.00038127098,0.00011358202,0.00079407246,0.000041625743,0.00026362418,0.000001899547,0.96222275,0.0030835203,0.0008121982,0.024139851],"study_design_scores_gemma":[0.051257584,0.008751714,0.015125735,0.0005375049,0.00022598924,0.000046645288,0.00047780116,0.0009342236,0.86964417,0.01902127,0.033212405,0.0007649453],"about_ca_topic_score_codex":0.0020555966,"about_ca_topic_score_gemma":0.00046652337,"teacher_disagreement_score":0.09257856,"about_ca_system_score_codex":0.0006588538,"about_ca_system_score_gemma":0.0016217539,"threshold_uncertainty_score":0.9997457},"labels":[],"label_agreement":null},{"id":"W2767484600","doi":"10.1093/neuonc/nox168.913","title":"RTHP-31. A 40-YEAR MULTI-INSTITUTIONAL REVIEW OF INTRACRANIAL GERM CELL TUMORS IN ADOLESCENTS AND YOUNG ADULT","year":2017,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Princess Margaret Cancer Centre; BC Children's Hospital; BC Cancer Agency","funders":"","keywords":"Medicine; Chemotherapy; Germ cell tumors; Germinoma; Radiation therapy; Internal medicine; Cancer; Surgery; Pediatrics","score_opus":0.03156829688521367,"score_gpt":0.3459923063730421,"score_spread":0.31442400948782845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767484600","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98717993,0.0017471132,0.000013214376,0.001955859,0.00047733763,0.0011039405,0.00001623709,0.000020556654,0.0074857934],"genre_scores_gemma":[0.9844678,0.013016047,0.00040930804,0.0015627836,0.00023500193,0.00003898366,0.000008656913,0.000024703715,0.0002367146],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99833626,0.00016813993,0.00045019787,0.00036597432,0.00033803875,0.00034137614],"domain_scores_gemma":[0.99880767,0.000078195204,0.00023669741,0.000492455,0.00020760806,0.00017736624],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047279245,0.0001725781,0.0006355344,0.00013905716,0.00010624516,0.00001368157,0.0002508602,0.00015816213,0.0002764591],"category_scores_gemma":[0.0011564934,0.00014926157,0.00009840208,0.00009318222,0.00047581282,0.00008321785,0.00017865654,0.0006150271,0.000043393033],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021015424,0.0012852292,0.32071042,0.0057641314,0.000026360027,0.001871731,0.00030354966,8.6267335e-7,0.60206693,0.00009180559,0.0010133052,0.06476408],"study_design_scores_gemma":[0.03504753,0.0036313185,0.8613476,0.011179305,0.00018593605,0.00242075,0.00014421837,0.0010802214,0.026437627,0.000049906772,0.057914365,0.00056119927],"about_ca_topic_score_codex":0.00028783779,"about_ca_topic_score_gemma":0.00030062252,"teacher_disagreement_score":0.57562935,"about_ca_system_score_codex":0.00018187643,"about_ca_system_score_gemma":0.0005873705,"threshold_uncertainty_score":0.608671},"labels":[],"label_agreement":null},{"id":"W2767574526","doi":"10.1182/blood-2017-05-787598","title":"CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":225,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Cancer Research UK; Wellcome Trust","keywords":"T-cell receptor; Transgene; Biology; Cancer research; CRISPR; Immunology; Molecular biology; Cell biology; T cell; Genetics; Gene; Immune system","score_opus":0.034131408438636324,"score_gpt":0.3280309917116137,"score_spread":0.2938995832729774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767574526","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880668,0.0006269022,0.000020227286,0.0014264601,0.00024977393,0.00062306743,0.000028951627,0.00006892493,0.008888913],"genre_scores_gemma":[0.97999686,0.0012025544,0.0003702002,0.0003189794,0.00050077593,0.00006308226,0.000025898724,0.000054007072,0.01746766],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998353,0.000045059314,0.00025091367,0.00039719982,0.0004805426,0.00047330986],"domain_scores_gemma":[0.9983956,0.000052634325,0.00006119891,0.0011185528,0.00012296496,0.00024901383],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003226734,0.00018192058,0.00033880267,0.0000776208,0.00025255748,0.00011175925,0.0002768127,0.00010826214,0.009827715],"category_scores_gemma":[0.00008622041,0.0001542194,0.00014348247,0.00007310042,0.00017204351,0.00007762168,0.000058147853,0.00024502093,0.00031727628],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003695012,0.0004898018,0.028478742,0.00007124432,0.00025511725,0.00008610694,0.00024782558,5.1086386e-7,0.9672153,0.000009023142,0.001130881,0.0016459415],"study_design_scores_gemma":[0.007912339,0.0005595975,0.019925667,0.000052628824,0.00020741037,0.000027544247,0.000046322628,0.00008739036,0.9398169,0.000011140204,0.031167101,0.0001859721],"about_ca_topic_score_codex":0.00016235327,"about_ca_topic_score_gemma":0.00006991782,"teacher_disagreement_score":0.03003622,"about_ca_system_score_codex":0.00003396643,"about_ca_system_score_gemma":0.00019303503,"threshold_uncertainty_score":0.9910774},"labels":[],"label_agreement":null},{"id":"W2767639660","doi":"10.1093/neuonc/nox168.182","title":"CMET-35. PRELIMINARY SCREENING OF A NOVEL EpCAM BISPECIFIC T-CELL ENGAGER (BiTE) ANTIBODY TO TARGET A BMIC POPULATION IN HUMAN BRAIN METASTASES","year":2017,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McMaster University","funders":"","keywords":"Epithelial cell adhesion molecule; Antigen; Population; Monoclonal antibody; Cancer research; Flow cytometry; Antibody; Cancer stem cell; Cancer; Metastasis; Biology; Immunology; Medicine; Genetics","score_opus":0.08009285261940259,"score_gpt":0.40502036812942266,"score_spread":0.3249275155100201,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2767639660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898485,0.00015394737,0.0007919404,0.0024804315,0.00023196437,0.0013772744,0.000043323904,0.000045525983,0.005027119],"genre_scores_gemma":[0.99135804,0.000029945886,0.006327184,0.00081844046,0.0002573788,0.00006351063,0.00015728718,0.00007621234,0.0009120024],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99716026,0.0005485174,0.0006356926,0.00062797137,0.00045911837,0.000568461],"domain_scores_gemma":[0.99739164,0.00088760024,0.0003432139,0.0010140557,0.00012844578,0.00023506618],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014389493,0.00026051872,0.0008159246,0.0007683147,0.00025595326,0.000039027207,0.0004279771,0.00022275766,0.00085455517],"category_scores_gemma":[0.00119602,0.00025857138,0.00017100666,0.00029182626,0.00018854321,0.00015871342,0.000329733,0.00079370633,0.00002105055],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001665664,0.0010153909,0.024512269,0.0000935228,0.000037342335,0.00054598897,0.000557223,0.00012491451,0.95765704,0.00008768559,0.0015566119,0.012146371],"study_design_scores_gemma":[0.016329682,0.013466892,0.5119588,0.00027157078,0.00015276605,0.000517011,0.00050106755,0.002151671,0.33600366,0.00009157443,0.117979005,0.00057630864],"about_ca_topic_score_codex":0.000985208,"about_ca_topic_score_gemma":0.00019692494,"teacher_disagreement_score":0.6216534,"about_ca_system_score_codex":0.00019214893,"about_ca_system_score_gemma":0.0001691499,"threshold_uncertainty_score":0.99998665},"labels":[],"label_agreement":null},{"id":"W2768137129","doi":"10.1111/imm.12870","title":"Immune correlates of clinical outcome in melanoma","year":2017,"lang":"en","type":"review","venue":"Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences North","funders":"","keywords":"Immunotherapy; Blockade; Melanoma; Immune system; Immunology; Immune checkpoint; Medicine; Antibody; Cancer research; Internal medicine","score_opus":0.2773866442031829,"score_gpt":0.5278624877814799,"score_spread":0.25047584357829705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2768137129","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001112274,0.9880815,7.5922196e-7,0.000070546506,0.001390423,0.0010071724,0.0000140133525,0.000024065037,0.008299212],"genre_scores_gemma":[0.00037394813,0.9812091,0.000042565633,0.0000103284565,0.00018157551,0.00006752707,0.00009090186,0.00007183993,0.017952228],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99565345,0.0006201011,0.0025919173,0.00045843326,0.00021196697,0.00046412746],"domain_scores_gemma":[0.99582237,0.0011343771,0.0010289386,0.0018435895,0.00010458429,0.0000661508],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0018306593,0.0003502707,0.005923106,0.00051533355,0.000035008383,0.000009585446,0.00076032843,0.0013701121,0.0026135347],"category_scores_gemma":[0.0016575317,0.00026750084,0.0012446333,0.00017333162,0.0007196797,0.000031835894,0.00036835903,0.0023058553,0.00057399],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021083214,0.00021185153,0.0099664545,0.0034519308,0.00083468715,0.00026480664,0.000021873475,9.150167e-9,0.000018745155,0.000103801576,0.00003699236,0.984878],"study_design_scores_gemma":[0.0017988507,0.00066915655,0.012130342,0.005651398,0.00037880486,0.00040598374,0.000008930711,0.0000010429058,0.0000040859563,0.00003107939,0.97873676,0.00018357762],"about_ca_topic_score_codex":0.00021624901,"about_ca_topic_score_gemma":0.000016296157,"teacher_disagreement_score":0.9846944,"about_ca_system_score_codex":0.00012313417,"about_ca_system_score_gemma":0.00071805716,"threshold_uncertainty_score":0.9999959},"labels":[],"label_agreement":null},{"id":"W2768576952","doi":"10.1158/0008-5472.can-16-1911","title":"TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer","year":2017,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":156,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control; BC Cancer Agency; University of British Columbia","funders":"National Institute of Allergy and Infectious Diseases; National Institute of General Medical Sciences; National Institutes of Health; National Cancer Institute; National Heart, Lung, and Blood Institute; American Association for Cancer Research","keywords":"Triple-negative breast cancer; Triple negative; Cancer; Breast cancer; Medicine; Cancer research; Internal medicine","score_opus":0.14082927648636506,"score_gpt":0.4641538463131926,"score_spread":0.32332456982682756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2768576952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96328115,0.0074305767,0.000028382034,0.011090313,0.0010911907,0.0069611906,0.0010591458,0.00010776369,0.008950284],"genre_scores_gemma":[0.88678557,0.02628738,0.00014555121,0.00035176103,0.002945665,0.0045686862,0.000035222583,0.00021106674,0.07866909],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9948926,0.00028502336,0.00038997483,0.0010051081,0.0017960966,0.0016311782],"domain_scores_gemma":[0.99481565,0.0004352296,0.0001542888,0.0017908846,0.0021322314,0.0006717437],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001966191,0.00035708855,0.0006949723,0.0004623504,0.0013797721,0.000378819,0.0010729308,0.00027101618,0.031630263],"category_scores_gemma":[0.0002630711,0.0002923628,0.00031800653,0.0005023631,0.0011073448,0.00026046648,0.00023474325,0.00125229,0.0002497669],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010696272,0.00022252345,0.0024877407,0.00014818991,0.00029204687,0.00007689295,0.0011288659,0.000004274082,0.8047775,0.00012223597,0.09844898,0.08159447],"study_design_scores_gemma":[0.012693544,0.0010318765,0.02222161,0.0003602678,0.000024867837,0.00003194436,0.0009318937,0.00012585019,0.6421467,0.0006451297,0.319359,0.00042728533],"about_ca_topic_score_codex":0.010855762,"about_ca_topic_score_gemma":0.0006631694,"teacher_disagreement_score":0.22091001,"about_ca_system_score_codex":0.0012902103,"about_ca_system_score_gemma":0.0022052648,"threshold_uncertainty_score":0.99995285},"labels":[],"label_agreement":null},{"id":"W2769557540","doi":"10.4049/jimmunol.190.supp.132.49","title":"Utilizing dual-specific CD4+ T cells in combination with oncolytic virotherapy for treatment of cancer (P2118)","year":2013,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Oncolytic virus; Adoptive cell transfer; Chimeric antigen receptor; Cancer research; CD8; Cytotoxic T cell; T cell; Immunology; Cell therapy; Medicine; Immune system; Biology; Tumor cells; Stem cell; Cell biology; In vitro","score_opus":0.040831989705213706,"score_gpt":0.3340263686037616,"score_spread":0.29319437889854794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2769557540","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897064,0.0063545355,0.00011999275,0.0024773378,0.00013235919,0.0009467501,0.0000018754675,0.0000035043442,0.0002572394],"genre_scores_gemma":[0.9842497,0.013800391,0.00027011626,0.000059712725,0.00008027456,0.00005061296,0.0000010320708,0.000024313811,0.0014638205],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990105,0.00013780397,0.00038710807,0.00007173256,0.00018076705,0.00021206905],"domain_scores_gemma":[0.9988573,0.00034637735,0.00027816746,0.00020393131,0.00028230392,0.000031878102],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00036009998,0.00010571862,0.000416872,0.00021867726,0.00003437078,0.000006703778,0.0001044887,0.000064883025,0.0010126856],"category_scores_gemma":[0.000008705118,0.0000576903,0.000082018225,0.00016495431,0.00016730177,0.000060710918,0.000008535682,0.00014049646,0.000005721695],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046270434,0.0005473386,0.001084246,0.0000150753685,0.00034603942,0.000008991019,0.0017547141,0.000035855777,0.894563,0.00006437125,0.00014182534,0.096811496],"study_design_scores_gemma":[0.033271775,0.028358903,0.05805248,0.00033262727,0.00016491172,0.00044800833,0.0034005947,0.00032069604,0.8491244,0.0006211463,0.025741765,0.00016271937],"about_ca_topic_score_codex":0.00045754388,"about_ca_topic_score_gemma":0.000074558135,"teacher_disagreement_score":0.09664878,"about_ca_system_score_codex":0.0004093074,"about_ca_system_score_gemma":0.00017722772,"threshold_uncertainty_score":0.9999005},"labels":[],"label_agreement":null},{"id":"W2773872797","doi":"10.1038/nchembio.2529","title":"Human antibody-based chemically induced dimerizers for cell therapeutic applications","year":2017,"lang":"en","type":"article","venue":"Nature Chemical Biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":73,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of General Medical Sciences; Damon Runyon Cancer Research Foundation; University of California, San Francisco; University of Toronto; Howard Hughes Medical Institute; National Cancer Institute; National Institutes of Health; National Science Foundation","keywords":"Small molecule; Antibody; Epitope; Computational biology; Cell; Chemistry; Cell biology; Phage display; Chemical biology; Cell signaling; Signal transduction; Biology; Biochemistry; Immunology","score_opus":0.03464166878283531,"score_gpt":0.4088710815662788,"score_spread":0.3742294127834435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2773872797","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98045015,0.0005311997,0.00051551603,0.006033151,0.00013825356,0.001860001,0.000049835886,0.00012385857,0.010298039],"genre_scores_gemma":[0.99481624,0.000012438836,0.0011803722,0.0018427679,0.0005080882,0.0003100384,0.00053189957,0.00004180068,0.000756367],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986383,0.000022506429,0.0002240513,0.00051717664,0.00014505495,0.00045296137],"domain_scores_gemma":[0.9983358,0.00017995585,0.00013314899,0.0009657337,0.00019493485,0.00019047255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018622798,0.00020662564,0.00039311158,0.00006938687,0.00022985203,0.000029805915,0.0005626461,0.0010869481,0.00040513792],"category_scores_gemma":[0.00015611736,0.00016749716,0.00022341002,0.00008047529,0.00039424055,0.000023092225,0.00008199493,0.0010802085,0.000022025044],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029048725,0.00021671924,0.0015036855,0.00007495431,0.000058149624,0.00000140591,0.000009438619,1.6598381e-8,0.9886639,0.0005628756,0.00029946605,0.008318916],"study_design_scores_gemma":[0.0023602375,0.00022910078,0.00072398275,0.000013346596,0.000053712083,0.0000045193124,0.0000037757468,0.000027153781,0.9345844,0.0014263166,0.060403015,0.00017043696],"about_ca_topic_score_codex":0.000009228359,"about_ca_topic_score_gemma":7.5878006e-7,"teacher_disagreement_score":0.06010355,"about_ca_system_score_codex":0.00008275426,"about_ca_system_score_gemma":0.00012667452,"threshold_uncertainty_score":0.83835393},"labels":[],"label_agreement":null},{"id":"W2777439917","doi":"10.1136/bmjopen-2017-019321","title":"Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in patients with haematological and solid malignancies: protocol for a systematic review and meta-analysis","year":2017,"lang":"en","type":"review","venue":"BMJ Open","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; Health Canada; Ottawa Hospital; University of Winnipeg; Canada's Michael Smith Genome Sciences Centre; University of Ottawa","funders":"Ottawa Hospital Anesthesia Alternate Funds Association","keywords":"Medicine; Chimeric antigen receptor; Meta-analysis; Protocol (science); Immunology; Systematic review; Antigen; Oncology; Immunotherapy; MEDLINE; Bioinformatics; Intensive care medicine; Internal medicine; Alternative medicine; Pathology; Immune system","score_opus":0.31165593145801906,"score_gpt":0.5167738930980517,"score_spread":0.2051179616400326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2777439917","genre_codex":"protocol","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000017934688,0.49663618,0.0000033709134,0.00004666161,0.0000020438818,0.5030985,0.000070469825,0.0000046004884,0.00012020911],"genre_scores_gemma":[0.000003041054,0.56813616,0.00041129816,0.000060379436,0.0000062465515,0.43036485,0.0000622142,0.000041993677,0.00091384014],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99587667,0.00087232713,0.0016334644,0.0007771418,0.00050282426,0.00033756153],"domain_scores_gemma":[0.9960425,0.0005049856,0.0016792883,0.0013356196,0.00025689922,0.00018072799],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003078568,0.0005707914,0.01368443,0.0002729798,0.00010238414,0.0001269685,0.00054611627,0.00022285763,0.00051422924],"category_scores_gemma":[0.0004299556,0.0002833992,0.00069701584,0.00044798525,0.00022587998,0.00010310477,0.0003680512,0.0002455388,0.00000279145],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013367546,0.0003415794,0.00027164505,0.95212674,0.036674026,0.000008172299,0.000067618676,2.5929797e-8,9.930167e-7,0.000003643223,0.00011662763,0.009052185],"study_design_scores_gemma":[0.018534508,0.0047987755,0.0006812,0.42176837,0.40794832,0.000097810334,0.000027497383,0.000005111943,0.000008671136,0.0000062796466,0.14499226,0.0011311959],"about_ca_topic_score_codex":0.000038108043,"about_ca_topic_score_gemma":0.000011492893,"teacher_disagreement_score":0.5303584,"about_ca_system_score_codex":0.00004516511,"about_ca_system_score_gemma":0.00033373668,"threshold_uncertainty_score":0.9999618},"labels":[],"label_agreement":null},{"id":"W2785134906","doi":"10.1182/blood.v130.suppl_1.5215.5215","title":"Patient-Reported Quality of Life (QoL) Following CTL019 Infusion in Adult Patients (pts) with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL)","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont; McMaster University; Juravinski Hospital","funders":"","keywords":"Diffuse large B-cell lymphoma; Medicine; Quality of life (healthcare); Refractory (planetary science); Lymphoma; Chemotherapy regimen; Internal medicine; Oncology; Chemotherapy; Biology; Nursing","score_opus":0.02112061102851404,"score_gpt":0.29239476268406583,"score_spread":0.2712741516555518,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2785134906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935728,0.00013251569,0.000004424822,0.000063515574,0.00018294793,0.0010214254,0.000027327023,0.00005159568,0.0049434747],"genre_scores_gemma":[0.9985322,0.00008674393,0.00013750514,0.00015540633,0.000060684633,0.000044938013,0.000078584606,0.00007140582,0.00083253434],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964497,0.00020086393,0.0009239186,0.0005457804,0.0012915942,0.0005881545],"domain_scores_gemma":[0.9966897,0.0001596267,0.00076069764,0.0016416227,0.00040699603,0.00034139492],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006401984,0.0002991845,0.0007554194,0.00023592226,0.00020470643,0.000043161417,0.00029928537,0.00023812738,0.00013854163],"category_scores_gemma":[0.0015649326,0.00024584914,0.00024054165,0.00020659633,0.00009525384,0.00024608336,0.00025650644,0.00033525628,0.000020553638],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00209519,0.03459217,0.924667,0.0002265854,0.00022081203,0.0001786964,0.0011740254,1.8442782e-7,0.03161117,0.000012811289,0.00007304356,0.0051482855],"study_design_scores_gemma":[0.16130899,0.0017496259,0.81979316,0.00042122265,0.00015276388,0.0000050208546,0.0002889522,0.000022554319,0.015265648,0.000015396736,0.00066127523,0.00031537403],"about_ca_topic_score_codex":0.0015493401,"about_ca_topic_score_gemma":0.0004611597,"teacher_disagreement_score":0.1592138,"about_ca_system_score_codex":0.00013022381,"about_ca_system_score_gemma":0.00037415154,"threshold_uncertainty_score":0.9999994},"labels":[],"label_agreement":null},{"id":"W2785907460","doi":"10.1182/blood.v130.suppl_1.5211.5211","title":"Clinical Pharmacology of CTL019 in Patients with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL)","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Hospital","funders":"","keywords":"Oncology; Biology; Internal medicine; Proportional hazards model; Diffuse large B-cell lymphoma; Medicine; Pharmacology; Lymphoma","score_opus":0.024839222204071004,"score_gpt":0.34428355097916125,"score_spread":0.3194443287750902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2785907460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915831,0.00013502546,0.00000144843,0.00011018463,0.00030911167,0.0005910455,0.000022078375,0.000020832806,0.0072271787],"genre_scores_gemma":[0.9963604,0.00017653253,0.0001139026,0.00019117875,0.0002490918,0.000018897104,0.000020549705,0.00004265386,0.0028267961],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982254,0.00014574634,0.00043598257,0.0003494213,0.00042384933,0.00041958925],"domain_scores_gemma":[0.99840254,0.00017585517,0.00025430857,0.0008155301,0.00015095422,0.00020083073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005419591,0.00015827011,0.0005081967,0.00013110621,0.00007694232,0.000012785615,0.00032590824,0.0001902263,0.0007684747],"category_scores_gemma":[0.00014967383,0.00012577181,0.000116783965,0.000078571094,0.00023943055,0.00008796062,0.00016140053,0.00034383775,0.000055916964],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024935408,0.057529278,0.9271463,0.00008064919,0.00014979465,0.00013006097,0.00010686,3.9933724e-8,0.0065651042,0.000004476145,0.0006037563,0.005190126],"study_design_scores_gemma":[0.18412736,0.0020104984,0.79990774,0.000055752804,0.00013162353,0.000003708934,0.000014470931,0.000007195452,0.007471121,0.000004531102,0.006153928,0.0001120814],"about_ca_topic_score_codex":0.00005286726,"about_ca_topic_score_gemma":0.000033581506,"teacher_disagreement_score":0.18163382,"about_ca_system_score_codex":0.00004500808,"about_ca_system_score_gemma":0.00021437967,"threshold_uncertainty_score":0.84142596},"labels":[],"label_agreement":null},{"id":"W2787301955","doi":"10.1056/nejmoa1709866","title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","year":2018,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5641,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Centre Hospitalier Universitaire Sainte-Justine; Université de Montréal","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; Novartis Pharmaceuticals Corporation","keywords":"Lymphoblastic Leukemia; Medicine; Leukemia; Immunology","score_opus":0.008970916473494756,"score_gpt":0.2580174046244769,"score_spread":0.24904648815098215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2787301955","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99268687,0.0015887849,0.00015869824,0.00107545,0.00016318419,0.00022671233,9.671351e-7,0.000008426132,0.004090901],"genre_scores_gemma":[0.99148506,0.0008854503,0.00037860373,0.00029073068,0.004197399,8.530593e-7,0.000003623548,0.000028427692,0.0027298783],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984068,0.000069611044,0.00041557444,0.00017641818,0.0006447802,0.00028677337],"domain_scores_gemma":[0.9988749,0.00012290436,0.00016607904,0.00017868921,0.00022053532,0.00043688007],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00074850227,0.00016445966,0.00047834127,0.0003559602,0.000036167265,0.000010291581,0.00011436649,0.00007123092,0.0010374081],"category_scores_gemma":[0.00017722775,0.00009854275,0.000031158295,0.00029643925,0.00029129465,0.00007583806,0.000024466879,0.0004217398,0.0000081406115],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019946463,0.00018692798,0.503536,0.00010657767,0.00024723218,0.0011040369,0.006881388,0.000007506688,0.070017904,0.000014710242,0.007882032,0.39006922],"study_design_scores_gemma":[0.31687737,0.01970884,0.6209462,0.0024585165,0.000288554,0.025753465,0.0004982126,0.00029523022,0.006135383,0.00013356176,0.0066509764,0.0002536392],"about_ca_topic_score_codex":0.00065020646,"about_ca_topic_score_gemma":0.0002833824,"teacher_disagreement_score":0.3898156,"about_ca_system_score_codex":0.00017203199,"about_ca_system_score_gemma":0.00044338734,"threshold_uncertainty_score":0.9998758},"labels":[],"label_agreement":null},{"id":"W2787578932","doi":"10.1038/nm.4478","title":"A novel chimeric antigen receptor containing a JAK–STAT signaling domain mediates superior antitumor effects","year":2018,"lang":"en","type":"article","venue":"Nature Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":600,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute","keywords":"Chimeric antigen receptor; T-cell receptor; CD28; Cell biology; Signal transduction; T cell; Biology; STAT5; Cytokine; Cancer research; Antigen; Immunology; Immune system","score_opus":0.013873236535743582,"score_gpt":0.3217982719610501,"score_spread":0.3079250354253065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2787578932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9793535,0.0071309516,0.000683718,0.0052504246,0.0017466053,0.0014250637,0.000014389353,0.00023870017,0.004156649],"genre_scores_gemma":[0.9817162,0.00036081375,0.0054668193,0.0037911134,0.006612626,0.00005941275,0.0001392969,0.00013311286,0.0017205791],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9961869,0.00015188512,0.00055237935,0.00075759005,0.0013985554,0.000952694],"domain_scores_gemma":[0.9972726,0.000827609,0.00015826256,0.0006406945,0.0005175822,0.0005832337],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001516007,0.0004792845,0.0011206522,0.0005532246,0.00025340242,0.00003145836,0.00033892546,0.0004939444,0.006188303],"category_scores_gemma":[0.0019112065,0.0003431754,0.00016588472,0.0012153382,0.0009260674,0.00011948229,0.0001094124,0.0017035704,0.00017821978],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016812278,0.0001479689,0.006410505,0.00025566877,0.0002683389,0.0002327049,0.0031993694,1.5717154e-7,0.97526747,0.00012369321,0.003323264,0.009089656],"study_design_scores_gemma":[0.025271999,0.0119742,0.020650014,0.0038620376,0.0003448451,0.00094390876,0.0028970113,0.00025902982,0.7406715,0.00018249472,0.19201204,0.0009308965],"about_ca_topic_score_codex":0.00014867247,"about_ca_topic_score_gemma":0.000029205743,"teacher_disagreement_score":0.23459592,"about_ca_system_score_codex":0.00020986541,"about_ca_system_score_gemma":0.00029730817,"threshold_uncertainty_score":0.999902},"labels":[],"label_agreement":null},{"id":"W2788965461","doi":"10.1097/cji.0000000000000216","title":"Characterization of Postinfusion Phenotypic Differences in Fresh Versus Cryopreserved TCR Engineered Adoptive Cell Therapy Products","year":2018,"lang":"en","type":"article","venue":"Journal of Immunotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"David Geffen School of Medicine, University of California, Los Angeles; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Allergy and Infectious Diseases; National Institutes of Health; National Cancer Institute; National Heart, Lung, and Blood Institute; UCLA AIDS Institute; Center for AIDS Research, University of Washington; Jonsson Comprehensive Cancer Center; Parker Institute for Cancer Immunotherapy","keywords":"Flow cytometry; Ex vivo; T cell; Immunology; T-cell receptor; Transgene; Cell therapy; Cell; Genetically modified mouse; Medicine; Biology; Cancer research; In vivo; Immune system; Biochemistry","score_opus":0.03856796019210099,"score_gpt":0.28483959101902384,"score_spread":0.24627163082692285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2788965461","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961296,0.0016466933,0.0001267235,0.00054364017,0.0006174862,0.0005290099,0.0000065461777,0.000012687285,0.0003876335],"genre_scores_gemma":[0.9928911,0.004961737,0.0006655428,0.000091782305,0.0006382172,0.000005478075,0.000013074088,0.000045067605,0.000688054],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979553,0.00017010228,0.0007429503,0.00018815271,0.000650665,0.00029278328],"domain_scores_gemma":[0.9978325,0.00013275964,0.00053438684,0.00036902798,0.0010512623,0.000080071586],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006403898,0.00021063798,0.00059278414,0.0004955434,0.000045594967,0.00002674761,0.00030554953,0.00012975837,0.002251774],"category_scores_gemma":[0.000108902466,0.00015821797,0.00014930069,0.00061668636,0.00015315431,0.00021737331,0.000025993122,0.00040965775,0.000006857358],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023333026,0.00058579864,0.008955608,0.000032764427,0.00016615051,0.000013318103,0.002490983,0.0000012726354,0.9451183,0.000005840983,0.00005567709,0.019241225],"study_design_scores_gemma":[0.01183887,0.005568121,0.27095917,0.00022631677,0.000013853601,0.000017793172,0.0001828958,0.00006044985,0.7092326,0.000021598067,0.0017509455,0.00012735052],"about_ca_topic_score_codex":0.000047377118,"about_ca_topic_score_gemma":0.000008737004,"teacher_disagreement_score":0.26200357,"about_ca_system_score_codex":0.0001247285,"about_ca_system_score_gemma":0.0002930719,"threshold_uncertainty_score":0.9986603},"labels":[],"label_agreement":null},{"id":"W2792513622","doi":"10.1016/j.ymthe.2018.03.011","title":"Tumor-Resident Dendritic Cells and Macrophages Modulate the Accumulation of TCR-Engineered T Cells in Melanoma","year":2018,"lang":"en","type":"article","venue":"Molecular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Centers for Disease Control and Prevention; Medical Research Council; Bloodwise","keywords":"T-cell receptor; Tumor microenvironment; CD11c; Cancer research; T cell; Biology; Melanoma; Immunotherapy; Immunology; Antigen-presenting cell; Cancer immunotherapy; Chimeric antigen receptor; Cell biology; Immune system; Phenotype; Gene","score_opus":0.029995863977328407,"score_gpt":0.3176004062087195,"score_spread":0.2876045422313911,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2792513622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99621814,0.0017285412,0.0005009707,0.000371795,0.0000995952,0.00075617136,0.0000058227133,0.000022331318,0.0002966281],"genre_scores_gemma":[0.9980106,0.0004109215,0.0002531984,0.00035132834,0.000079938574,0.000022413431,0.000004999211,0.00004687613,0.0008197661],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99857026,0.00016312451,0.00028753935,0.00027585108,0.00039958692,0.0003036351],"domain_scores_gemma":[0.99915266,0.00008773932,0.000059829174,0.0004945792,0.0001201784,0.000084990184],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038168428,0.00017433194,0.00028462202,0.00018306937,0.000046659752,0.000030892857,0.00015896578,0.00007218768,0.0006030031],"category_scores_gemma":[0.000018420633,0.00012957929,0.00008673075,0.00030108364,0.0001941661,0.000042652155,0.000043900603,0.00019098139,0.000025350364],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036019768,0.00006748367,0.00056325516,0.000032538286,0.00007354141,0.0001289052,0.00069850223,0.0001335515,0.9905285,0.00005233057,0.000045597495,0.0073155933],"study_design_scores_gemma":[0.0022335025,0.0005569919,0.018365039,0.000053323616,0.000016723674,0.000028130691,0.00007059532,0.0033399044,0.9740171,0.00029793032,0.00090351026,0.000117255775],"about_ca_topic_score_codex":0.00019314105,"about_ca_topic_score_gemma":0.00001853878,"teacher_disagreement_score":0.017801784,"about_ca_system_score_codex":0.00005141275,"about_ca_system_score_gemma":0.00004729744,"threshold_uncertainty_score":0.6602461},"labels":[],"label_agreement":null},{"id":"W2794671395","doi":"10.1111/ajt.14747","title":"Engineering therapeutic T cells to suppress alloimmune responses using TCRs, CARs, or BARs","year":2018,"lang":"en","type":"review","venue":"American Journal of Transplantation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"National Heart, Lung, and Blood Institute; Horizon 2020 Framework Programme; National Institutes of Health; Canadian Institutes of Health Research; European Commission; BC Children's Hospital","keywords":"Allorecognition; Chimeric antigen receptor; Immunology; Cytotoxic T cell; T cell; Effector; Antigen; Immune system; Transplantation; Cell therapy; Receptor; Biology; Medicine; Cell biology; Stem cell; Genetics","score_opus":0.07733087107896719,"score_gpt":0.39568142814846646,"score_spread":0.3183505570694993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2794671395","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01103928,0.9805146,0.0064021684,0.00008073069,0.00068218156,0.0010920962,0.00011802542,0.000032696997,0.000038262944],"genre_scores_gemma":[0.00066982413,0.9924048,0.005581073,0.00008932462,0.00048088765,0.000010336711,0.000030648174,0.00012954787,0.00060353964],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99723464,0.00038179287,0.0010098225,0.00027088067,0.0006972859,0.00040559273],"domain_scores_gemma":[0.9978789,0.00065802777,0.0005796348,0.0003317742,0.00026174466,0.0002899047],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00079027354,0.00039283608,0.0018550818,0.00093555945,0.00005408641,0.000052149437,0.0003396822,0.00012150195,0.00046927115],"category_scores_gemma":[0.0000438814,0.00028528293,0.00056560856,0.0007929451,0.00013045296,0.00010945466,0.000013563808,0.0006363555,0.00002188293],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039712335,0.00008201767,0.000007959464,0.00623221,0.0013246449,0.0008476769,0.0012804017,0.00012703794,0.025107177,0.0000011463367,0.00008072444,0.9609378],"study_design_scores_gemma":[0.0012407282,0.0036912085,0.000082138264,0.029578654,0.0050909533,0.009714653,0.00021103692,0.000072303745,0.0031152545,6.802954e-7,0.94669235,0.0005100516],"about_ca_topic_score_codex":0.0000743355,"about_ca_topic_score_gemma":0.0000036454767,"teacher_disagreement_score":0.9604277,"about_ca_system_score_codex":0.00032403326,"about_ca_system_score_gemma":0.0008306996,"threshold_uncertainty_score":0.99995995},"labels":[],"label_agreement":null},{"id":"W2799371896","doi":"10.1016/j.jcyt.2018.02.010","title":"T cells engineered with T-cell antigen coupler (TAC) receptors display robust efficacy against solid and liquid tumor xenografts in the absence of any toxicity","year":2018,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Chimeric antigen receptor; T-cell receptor; Antigen; Receptor; Cell biology; T cell; Major histocompatibility complex; Chemistry; Immunology; Cancer research; Biology; Molecular biology; Immune system; Biochemistry","score_opus":0.019141914678027904,"score_gpt":0.2796416926210811,"score_spread":0.2604997779430532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2799371896","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967522,0.000441391,0.00018690937,0.00025863192,0.00011064401,0.0010538877,0.000012027982,0.000037908612,0.0011463839],"genre_scores_gemma":[0.99651635,0.0013026556,0.0005763855,0.0005800845,0.00028937124,0.000027282887,0.000010153628,0.000065175016,0.0006325354],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981276,0.00011498275,0.00033895572,0.0004034129,0.0005175212,0.0004975244],"domain_scores_gemma":[0.99873495,0.0002245049,0.000109831184,0.00061761827,0.00015640949,0.0001567137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006343871,0.00027179957,0.00046319977,0.00018949351,0.000087031694,0.000034590736,0.00028989112,0.00010023877,0.0006067617],"category_scores_gemma":[0.000025794729,0.00017447135,0.000078336016,0.0005968681,0.0005531281,0.00007673917,0.000030288902,0.00032806772,0.000018126388],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002507447,0.0005232891,0.007707253,0.00007292978,0.00006594917,0.000035501536,0.00362467,0.00009957155,0.9836277,0.000009062414,0.00053542195,0.0011912158],"study_design_scores_gemma":[0.0057743154,0.004205735,0.027897457,0.00026209123,0.000015284553,0.00003509577,0.0005218086,0.0015591263,0.9513646,0.0000032503735,0.008041513,0.00031976384],"about_ca_topic_score_codex":0.000058837344,"about_ca_topic_score_gemma":0.00007959088,"teacher_disagreement_score":0.03226313,"about_ca_system_score_codex":0.000060005317,"about_ca_system_score_gemma":0.00012783665,"threshold_uncertainty_score":0.7114735},"labels":[],"label_agreement":null},{"id":"W2799722841","doi":"10.1016/j.beha.2018.04.002","title":"Pre-clinical development of chimeric antigen receptor T-cell immunotherapy: Implications of design for efficacy and safety","year":2018,"lang":"en","type":"review","venue":"Best Practice & Research Clinical Haematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"King's College London; Medical Research Council; British Lung Foundation; National Institute for Health and Care Research; Medical Research Council Canada; King's Health Partners; Cancer Research UK","keywords":"Chimeric antigen receptor; Medicine; Clinical trial; Immunotherapy; Cell therapy; Adoptive cell transfer; Population; Immunology; Oncology; T cell; Internal medicine; Cell; Immune system; Biology","score_opus":0.4215104802943227,"score_gpt":0.6003140329752126,"score_spread":0.17880355268088988,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2799722841","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015597405,0.97754157,0.0041479613,0.0011000513,0.0004023191,0.013317655,0.00008556465,0.00004108511,0.0018040698],"genre_scores_gemma":[0.00004287281,0.92261565,0.073580615,0.000059907965,0.00038837764,0.000697056,0.00016689816,0.00017509972,0.0022735514],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9804934,0.0095207365,0.0061631836,0.0015595665,0.0011142766,0.001148835],"domain_scores_gemma":[0.90440464,0.087649584,0.0023310236,0.0020786126,0.0028913587,0.000644783],"candidate_categories":["metaresearch","metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.03571013,0.00057740905,0.005943115,0.00069824216,0.0003071613,0.000037915885,0.0011404578,0.0016564366,0.0010239669],"category_scores_gemma":[0.036356077,0.00046461975,0.0010002527,0.0011874583,0.004304477,0.00014960345,0.00070108724,0.0029964687,0.00029011522],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008483083,0.0074070757,0.00020559989,0.012960526,0.002226725,0.000018899449,0.00023053211,5.4400388e-8,0.00012404016,0.00015156469,0.005858186,0.96233374],"study_design_scores_gemma":[0.0042230394,0.007980084,0.00021020179,0.0044336068,0.00075372355,0.00032476638,0.000089390494,0.000007925408,0.00008970468,0.000061073224,0.98149484,0.00033164825],"about_ca_topic_score_codex":0.000034505083,"about_ca_topic_score_gemma":0.0000070713027,"teacher_disagreement_score":0.97563666,"about_ca_system_score_codex":0.00017410191,"about_ca_system_score_gemma":0.008946668,"threshold_uncertainty_score":0.99988925},"labels":[],"label_agreement":null},{"id":"W2800862488","doi":"10.1016/j.ebiom.2018.04.020","title":"Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy","year":2018,"lang":"en","type":"review","venue":"EBioMedicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":150,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"Canadian Institutes of Health Research; Terry Fox Research Institute; Ontario Institute for Cancer Research","keywords":"Oncolytic virus; Immunotherapy; Tumor microenvironment; Medicine; Viral therapy; Cancer research; Immunology; Coronavirus disease 2019 (COVID-19); Tumor cells; Pathology; Immune system","score_opus":0.08349230093765672,"score_gpt":0.39991262404596356,"score_spread":0.3164203231083068,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2800862488","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013038095,0.9933943,0.000010192275,0.0005794461,0.00033554598,0.0029970063,0.000012335664,0.000034127617,0.0013332315],"genre_scores_gemma":[0.00004763612,0.9921283,0.00028710565,0.0010101241,0.002386121,0.00015455099,0.00010560598,0.00015631277,0.0037242451],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960441,0.00041193518,0.0011050688,0.00066850585,0.001003865,0.00076651445],"domain_scores_gemma":[0.99772245,0.0004321684,0.00037725558,0.0012700534,0.0000402029,0.00015788327],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002006893,0.00061343523,0.0022801538,0.0005481725,0.00013332698,0.000038256447,0.00061163085,0.0002584711,0.0030856659],"category_scores_gemma":[0.00009748486,0.0003455131,0.0005151979,0.0011960514,0.00051130634,0.00003785028,0.00012245882,0.0011382931,0.0002564207],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010573435,0.00033061087,0.0000185386,0.008312095,0.00032806248,0.0009541533,0.0009363159,6.1519714e-8,0.0015007108,0.0000027447638,0.0026769198,0.9848341],"study_design_scores_gemma":[0.0016866551,0.0007604241,0.000025193804,0.030052407,0.000490996,0.0016608079,0.00018319298,0.000050069713,0.000018332163,0.000006018995,0.96479017,0.00027573862],"about_ca_topic_score_codex":0.00016701678,"about_ca_topic_score_gemma":0.000007167864,"teacher_disagreement_score":0.9845583,"about_ca_system_score_codex":0.0012140487,"about_ca_system_score_gemma":0.00055973267,"threshold_uncertainty_score":0.9998997},"labels":[],"label_agreement":null},{"id":"W2801354368","doi":"10.1111/bjh.15232","title":"A tale of two antibodies: obinutuzumab <i>versus</i> rituximab","year":2018,"lang":"en","type":"review","venue":"British Journal of Haematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":195,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia; BC Cancer Agency","funders":"Centers for Disease Control and Prevention","keywords":"Obinutuzumab; Rituximab; Medicine; CD20; Clinical trial; Immunology; Oncology; Context (archaeology); Dosing; Lymphoma; Internal medicine; Biology","score_opus":0.06548623625567729,"score_gpt":0.39946261266057015,"score_spread":0.33397637640489286,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2801354368","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0017224326,0.9919973,0.000033985816,0.000041574625,0.0012336584,0.0006567418,0.00007848397,0.000017702787,0.004218129],"genre_scores_gemma":[0.00009794803,0.9963118,0.0010618458,0.000047110712,0.0008397003,0.000011587095,0.00003766678,0.00011350961,0.0014788447],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99542505,0.0005419766,0.0022267466,0.0003887295,0.0007939721,0.0006235484],"domain_scores_gemma":[0.9956473,0.0006492973,0.0018456717,0.00052520516,0.0010207955,0.00031171815],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011379508,0.00041730527,0.006536482,0.00063502253,0.00007962186,0.000044648543,0.0006663426,0.0005341556,0.0034700262],"category_scores_gemma":[0.00070402585,0.0004026787,0.001762258,0.00047967202,0.00089065253,0.000116489566,0.00019783684,0.0014988545,0.00012644114],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007113132,0.0005348206,0.000007220005,0.030338656,0.0024716763,0.08166056,0.000079983656,9.1928705e-8,0.000028233973,0.00010529557,0.042593595,0.8414686],"study_design_scores_gemma":[0.004850871,0.0008275688,5.202619e-7,0.02596785,0.0011199246,0.39171532,0.000029561963,9.2285023e-7,0.000032922246,0.000055205983,0.5752349,0.00016444316],"about_ca_topic_score_codex":0.00012567101,"about_ca_topic_score_gemma":0.00007163855,"teacher_disagreement_score":0.8413041,"about_ca_system_score_codex":0.00038394373,"about_ca_system_score_gemma":0.0025950456,"threshold_uncertainty_score":0.9998425},"labels":[],"label_agreement":null},{"id":"W2802158658","doi":"10.1038/s41591-018-0031-9","title":"CAR T cells for childhood diffuse midline gliomas","year":2018,"lang":"en","type":"letter","venue":"Nature Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children","funders":"","keywords":"Chimeric antigen receptor; Glioma; Mutant; Antigen; Cancer research; Medicine; Receptor; Pathology; Biology; Immunology; Immune system; Immunotherapy; Internal medicine; Genetics; Gene","score_opus":0.016336221712926296,"score_gpt":0.3207687209710808,"score_spread":0.30443249925815447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802158658","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007559948,0.009863579,0.00008167898,0.9629795,0.00561905,0.0044594044,0.00034153732,0.0003066023,0.008788717],"genre_scores_gemma":[0.0013991086,0.0006023504,0.00074906397,0.73483247,0.123786345,0.00020608143,0.0042735436,0.00043299003,0.13371806],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9941864,0.00013571074,0.0008095413,0.0013119247,0.0022469377,0.0013095045],"domain_scores_gemma":[0.9954847,0.00085049355,0.0003145118,0.0018790488,0.0010403488,0.00043087662],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0008642285,0.00095352053,0.0019980448,0.0010642624,0.00015695154,0.000027700331,0.00073469273,0.0048288004,0.0084033515],"category_scores_gemma":[0.0010070796,0.00066492206,0.000564725,0.0007870994,0.00073234225,0.000048153397,0.00013336824,0.009410269,0.00017721512],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049675076,0.00018784031,0.000020073043,0.0010427941,0.00055770716,0.0011827517,0.00033599706,3.477266e-8,0.05838805,0.000007217596,0.9353865,0.0023943058],"study_design_scores_gemma":[0.011691174,0.0027487762,0.00014780015,0.0012413656,0.00089551095,0.00041167915,0.000030645457,0.000020645963,0.0207103,0.00017461022,0.96139765,0.0005298731],"about_ca_topic_score_codex":0.000050518225,"about_ca_topic_score_gemma":0.000015648802,"teacher_disagreement_score":0.22814703,"about_ca_system_score_codex":0.0003683,"about_ca_system_score_gemma":0.00042666827,"threshold_uncertainty_score":0.9995802},"labels":[],"label_agreement":null},{"id":"W2802233748","doi":"10.1016/j.jcyt.2018.02.012","title":"BCMA-specific TAC receptor-engineered T cells for multiple myeloma","year":2018,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Chimeric antigen receptor; Receptor; Antigen; Cell biology; Cancer research; T cell; Biology; Immunology; Molecular biology; Immune system; Biochemistry","score_opus":0.04063145682494303,"score_gpt":0.30919427135994704,"score_spread":0.268562814535004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802233748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96585155,0.0019269838,0.01406504,0.0025354342,0.002038907,0.0038938061,0.00012901875,0.00057034456,0.008988893],"genre_scores_gemma":[0.8578776,0.002076268,0.021900207,0.0020539963,0.0075666117,0.000487287,0.000145897,0.00043041894,0.107461676],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981954,0.000047175494,0.00029944867,0.00047511712,0.0003758781,0.00060694164],"domain_scores_gemma":[0.99837995,0.0002613345,0.000057908714,0.00073083857,0.00032029953,0.00024967012],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0003682982,0.00025592878,0.000401933,0.00019691236,0.00014845976,0.000049803173,0.00023069429,0.00018540403,0.01390307],"category_scores_gemma":[0.000044556724,0.00022740474,0.00023118481,0.00033757166,0.00022042224,0.00006922066,0.000020964553,0.00021529337,0.0008054469],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018531765,0.00014106177,0.00026489602,0.00003244622,0.00010428568,0.000004310784,0.00053161907,0.0000014260183,0.8595345,0.000105733656,0.06861139,0.06881517],"study_design_scores_gemma":[0.0033889422,0.00082711055,0.00052462274,0.000026644737,0.000005673431,0.000006994955,0.000048614987,0.000304632,0.4552283,0.000050548228,0.539441,0.00014696321],"about_ca_topic_score_codex":0.0000129312975,"about_ca_topic_score_gemma":0.000008064697,"teacher_disagreement_score":0.47082958,"about_ca_system_score_codex":0.00017060457,"about_ca_system_score_gemma":0.00009647474,"threshold_uncertainty_score":0.9999725},"labels":[],"label_agreement":null},{"id":"W2802513889","doi":"10.1038/s41568-018-0009-4","title":"Oncolytic viruses as engineering platforms for combination immunotherapy","year":2018,"lang":"en","type":"review","venue":"Nature reviews. Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":416,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; University of Ottawa; BC Cancer Agency; Ottawa Hospital; University of British Columbia; Ontario Institute for Cancer Research","funders":"","keywords":"Oncolytic virus; Cytotoxic T cell; Immunotherapy; Immune checkpoint; Immune system; Cancer immunotherapy; Antigen; Melanoma; Cancer; Cancer research; Immunology; Priming (agriculture); T cell; Medicine; Biology; Internal medicine; In vitro","score_opus":0.08964551249103939,"score_gpt":0.46388039306834317,"score_spread":0.3742348805773038,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802513889","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000052488517,0.9882796,0.000059076778,0.00006151491,0.0014038302,0.008901496,0.000074278905,0.000101428595,0.0011135301],"genre_scores_gemma":[6.789702e-7,0.98281306,0.000472468,0.000835134,0.0022206993,0.003859752,0.00022211576,0.00026927414,0.00930681],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996956,0.00005647156,0.0010440726,0.0007138652,0.0006256032,0.00060400204],"domain_scores_gemma":[0.9975475,0.00043419315,0.0005335725,0.0009355841,0.0003545114,0.00019461659],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011520829,0.0007478745,0.003551291,0.000419825,0.00009370843,0.00006310808,0.0004493635,0.0013843455,0.003017918],"category_scores_gemma":[0.00058761274,0.00050489313,0.0015897219,0.00080962887,0.000068745,0.00011879837,0.00005674804,0.0019297127,0.0002873461],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008631118,0.000065560955,0.0000011876426,0.053310584,0.0005140808,0.0000051971992,0.000030034334,9.8268245e-8,0.000045792407,0.00023180884,0.012524839,0.9331845],"study_design_scores_gemma":[0.001118943,0.0003934676,0.0000014638568,0.05750165,0.0008835904,0.000075838536,0.0000014999952,0.000012696075,0.000055946704,0.000043300814,0.9394582,0.00045339958],"about_ca_topic_score_codex":0.000027941562,"about_ca_topic_score_gemma":0.000014396598,"teacher_disagreement_score":0.9327311,"about_ca_system_score_codex":0.0017192252,"about_ca_system_score_gemma":0.0011294208,"threshold_uncertainty_score":0.9999121},"labels":[],"label_agreement":null},{"id":"W2802710454","doi":"10.1016/j.omtm.2018.04.007","title":"An Integrated Approach toward the Biomanufacturing of Engineered Cell Therapy Products in a Stirred-Suspension Bioreactor","year":2018,"lang":"en","type":"article","venue":"Molecular Therapy — Methods & Clinical Development","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Canadian Institutes of Health Research; Alberta Innovates - Health Solutions","keywords":"Biomanufacturing; Bioreactor; Microcarrier; Cell therapy; Cell culture; Process development; Bioprocess; Biochemical engineering; Stem cell; Biotechnology; Biology; Process engineering; Cell biology; Engineering","score_opus":0.15738111655114348,"score_gpt":0.44549887193408755,"score_spread":0.28811775538294404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802710454","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9413224,0.0013253457,0.05339997,0.0008242077,0.00035108073,0.0022713009,0.0000028498898,0.00009176591,0.00041107353],"genre_scores_gemma":[0.58266103,0.00066568854,0.41555873,0.00047304842,0.0001472808,0.00010069443,0.000054743592,0.00009148651,0.0002473122],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9937274,0.0023321619,0.0014550101,0.0010126443,0.0008032517,0.00066956074],"domain_scores_gemma":[0.99701697,0.00055872597,0.00027299055,0.0013316143,0.0005278344,0.0002918597],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.007881289,0.00049131835,0.0009967859,0.00037759557,0.000080009646,0.00004926885,0.00066875055,0.00035447718,0.00040463512],"category_scores_gemma":[0.00047665864,0.00030517025,0.00025833168,0.0011052544,0.00049062807,0.00007521133,0.0001153783,0.0008408189,0.000017307868],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018590859,0.0012002381,0.00065052026,0.00003866932,0.00018836747,0.000029046105,0.0021617403,0.0000041709186,0.5800655,0.0000049220357,0.000025419302,0.41377234],"study_design_scores_gemma":[0.0043197083,0.0015540937,0.023660783,0.00007291152,0.00001741526,0.000021094624,0.00032644556,0.0005243076,0.93244386,0.00007266372,0.036650244,0.00033650143],"about_ca_topic_score_codex":0.00008170126,"about_ca_topic_score_gemma":0.0000025100358,"teacher_disagreement_score":0.41343585,"about_ca_system_score_codex":0.00016522525,"about_ca_system_score_gemma":0.00076555146,"threshold_uncertainty_score":0.99994004},"labels":[],"label_agreement":null},{"id":"W2802900288","doi":"10.1016/j.jcyt.2018.02.304","title":"A new immunotherapy approach against acute lymphoblastic leukemia by transducing hematopoietic stem cells with a car under regulation of cell specific promoter","year":2018,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Chimeric antigen receptor; Haematopoiesis; Cytotoxic T cell; Cancer research; Stem cell; Transgene; Biology; Immunotherapy; Leukemia; Hematopoietic stem cell; Genetic enhancement; Immunology; Cell biology; In vitro; Immune system; Gene; Genetics","score_opus":0.017139491358313403,"score_gpt":0.24890907844705087,"score_spread":0.23176958708873746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2802900288","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.898533,0.0012672378,0.094717935,0.00016382022,0.000103892,0.0017213707,0.000017465825,0.00011914305,0.0033561406],"genre_scores_gemma":[0.96653897,0.000951692,0.008203204,0.00041988632,0.00040456076,0.000056390865,0.00004006388,0.0002698174,0.02311544],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972333,0.00012559557,0.0005458732,0.0007003557,0.00079121266,0.0006036715],"domain_scores_gemma":[0.998263,0.000072216426,0.00021046745,0.000984362,0.0002152037,0.0002547302],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00030552526,0.00044091252,0.00072901516,0.00024750963,0.0001155343,0.00006155527,0.00028562182,0.0002331677,0.0016699883],"category_scores_gemma":[5.9176136e-7,0.00034754054,0.00021116583,0.00064779853,0.0003390542,0.00013267911,0.000014859014,0.00027159066,0.00004800881],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033555666,0.00025433765,0.000068957306,0.00013984255,0.00037640813,0.000008685756,0.0054174447,0.00007541953,0.97389704,0.000029975314,0.00256302,0.013813301],"study_design_scores_gemma":[0.010366254,0.0020730968,0.00027858937,0.00022239835,0.00006720105,0.000085479856,0.00044477475,0.0010120313,0.97865194,0.00006294901,0.006344596,0.00039071697],"about_ca_topic_score_codex":0.000052271283,"about_ca_topic_score_gemma":0.0000031378727,"teacher_disagreement_score":0.086514734,"about_ca_system_score_codex":0.0005778141,"about_ca_system_score_gemma":0.00061408506,"threshold_uncertainty_score":0.99989766},"labels":[],"label_agreement":null},{"id":"W2805523469","doi":"10.1158/2159-8290.cd-17-1319","title":"Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia","year":2018,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":924,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; Emerald Foundation; Parker Institute for Cancer Immunotherapy; Alberta Emerald Foundation; Memorial Sloan-Kettering Cancer Center; American Society of Clinical Oncology; Juno Therapeutics; Leukemia and Lymphoma Society; American Society of Hematology","keywords":"Lymphoblastic Leukemia; Neurotoxicity; Medicine; Leukemia; Cell; Cancer research; Oncology; Immunology; Biology; Internal medicine; Toxicity; Genetics","score_opus":0.026596257846077314,"score_gpt":0.3056077702695786,"score_spread":0.27901151242350125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2805523469","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99823135,0.00022431466,0.000018492961,0.000023404125,0.00009849584,0.00079436967,0.000059887865,0.00001918468,0.00053048617],"genre_scores_gemma":[0.99780697,0.0008901278,0.000018317936,0.00024306131,0.00008064821,0.000041185594,0.000029185794,0.00003397683,0.00085654604],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984147,0.00014763586,0.00033357023,0.00043205297,0.00033376244,0.00033830586],"domain_scores_gemma":[0.99898195,0.00027339582,0.00015587972,0.00027343532,0.00018226095,0.00013305784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002206867,0.00020607855,0.0005290411,0.00008192606,0.000038818085,0.000020624342,0.00011504117,0.00016850473,0.00018050216],"category_scores_gemma":[0.000050168954,0.00012449226,0.00006323906,0.00031869055,0.0008998015,0.00011248844,0.00005529641,0.00031732305,0.0000030723365],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008759233,0.0005998213,0.9795348,0.00002138474,0.00014550914,0.000020895455,0.000119843775,0.0000091373395,0.00917459,0.0000018045589,0.00009245255,0.0015205455],"study_design_scores_gemma":[0.016249483,0.008924246,0.9650727,0.000199686,0.000060363513,0.0000017951428,0.00002986605,0.0001356484,0.0090804305,0.000009789634,0.00007082629,0.0001651789],"about_ca_topic_score_codex":0.00014132891,"about_ca_topic_score_gemma":0.000078439305,"teacher_disagreement_score":0.014462098,"about_ca_system_score_codex":0.00022843675,"about_ca_system_score_gemma":0.00051771314,"threshold_uncertainty_score":0.5076647},"labels":[],"label_agreement":null},{"id":"W2807637103","doi":"10.1200/jco.2018.77.8084","title":"T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":791,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"NIH Clinical Center; National Cancer Institute; National Institutes of Health; Kite Pharma; AstraZeneca; Celgene; Gilead Sciences","keywords":"Medicine; Chimeric antigen receptor; Multiple myeloma; Minimal residual disease; Cytokine release syndrome; Antigen; Cyclophosphamide; Bone marrow; Fludarabine; Immunology; Regimen; Cancer research; Internal medicine; T cell; Oncology; Chemotherapy; Immune system","score_opus":0.1424856689320132,"score_gpt":0.4582241318970513,"score_spread":0.3157384629650381,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2807637103","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918557,0.00013942679,0.0008930776,0.0031064535,0.0013538455,0.00072096026,0.000014524817,0.000023013074,0.0018930326],"genre_scores_gemma":[0.95644647,0.0013754534,0.03792319,0.0009845967,0.0021189665,0.0000070850338,0.000010535873,0.000057801084,0.0010758784],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9940622,0.0010968038,0.002996368,0.00045296625,0.00088327535,0.0005083808],"domain_scores_gemma":[0.9932472,0.0018139287,0.0014725267,0.0005508784,0.0016835239,0.0012319179],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0035211917,0.00024896435,0.0017251442,0.00034952004,0.00010824026,0.000023353341,0.0005121107,0.00070035993,0.001717882],"category_scores_gemma":[0.0033178062,0.00019150459,0.00051772734,0.0004888546,0.0004915545,0.00016256902,0.00014762588,0.0010807888,0.00008814525],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010209597,0.0024649638,0.023291279,0.000033177068,0.00025447842,0.000113860304,0.0004073669,0.000031351723,0.90770674,0.0000047329186,0.007632538,0.047849916],"study_design_scores_gemma":[0.009864193,0.03322637,0.24798158,0.0002179764,0.00024887288,0.00011670187,0.00025177427,0.0016355846,0.64362633,0.000041044557,0.062487647,0.00030194598],"about_ca_topic_score_codex":0.00004364363,"about_ca_topic_score_gemma":0.00001965836,"teacher_disagreement_score":0.26408044,"about_ca_system_score_codex":0.0001162619,"about_ca_system_score_gemma":0.0014348021,"threshold_uncertainty_score":0.9991947},"labels":[],"label_agreement":null},{"id":"W2809223047","doi":"10.1016/bs.ircmb.2018.05.010","title":"T Lymphocyte–Based Cancer Immunotherapeutics","year":2018,"lang":"en","type":"review","venue":"International review of cell and molecular biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Western University","funders":"","keywords":"Oncolytic virus; Chimeric antigen receptor; Biology; Immunotherapy; Cancer immunotherapy; Immune system; Immune checkpoint; Cancer; Cancer research; Antigen; Immunology","score_opus":0.044694708807888735,"score_gpt":0.43338938753530215,"score_spread":0.3886946787274134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2809223047","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000008071388,0.9913253,0.00025170212,0.00021957277,0.00026386202,0.00075908453,0.000084132196,0.000009917622,0.007078343],"genre_scores_gemma":[0.000004375156,0.9950468,0.0004662552,0.002222184,0.00014321788,0.00013007865,0.000359981,0.000044754765,0.001582378],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984017,0.00018356586,0.00062565017,0.00035802176,0.000239071,0.00019200379],"domain_scores_gemma":[0.998767,0.00010764553,0.0003575712,0.00036148855,0.00032797077,0.00007828564],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000331992,0.0002802675,0.0013955194,0.00018528152,0.000015552938,0.0000068137815,0.0002974303,0.00024246382,0.002981271],"category_scores_gemma":[0.000066002016,0.00020025295,0.00058048655,0.00014176487,0.00023914421,0.000009108503,0.00009574228,0.00020495677,0.000032986034],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000030869363,0.000062707884,0.0000030080446,0.068300955,0.00047740713,0.000016053851,0.0000024804676,9.078173e-9,0.0029017713,0.00019461704,0.00018629576,0.92782384],"study_design_scores_gemma":[0.00045813966,0.00018622194,4.1794357e-7,0.05810971,0.00061325746,0.000052548097,3.614935e-7,0.000005734997,0.0011488256,0.000034744906,0.9392457,0.00014432875],"about_ca_topic_score_codex":0.0000219806,"about_ca_topic_score_gemma":7.535034e-7,"teacher_disagreement_score":0.93905944,"about_ca_system_score_codex":0.00014488479,"about_ca_system_score_gemma":0.00073855784,"threshold_uncertainty_score":0.9979301},"labels":[],"label_agreement":null},{"id":"W2809614382","doi":"10.1007/s12032-018-1167-7","title":"Generalizability of clinical trials of advanced melanoma in the real-world, population-based setting","year":2018,"lang":"en","type":"article","venue":"Medical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada); Occupational Cancer Research Centre; University of Calgary","funders":"Mach-Gaensslen Foundation of Canada","keywords":"Medicine; Ipilimumab; Clinical trial; Cohort; Internal medicine; Population; Vemurafenib; Cancer; Oncology; Metastatic melanoma; Immunotherapy","score_opus":0.17206039468019826,"score_gpt":0.5487670947428749,"score_spread":0.3767067000626766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2809614382","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98010856,0.0000503593,0.000100689715,0.011187514,0.00035266601,0.0007335498,0.000007155844,0.000012318776,0.0074472125],"genre_scores_gemma":[0.9954058,0.000048222148,0.0017259318,0.0017065124,0.0008039318,0.000035825855,0.00003875607,0.000011610158,0.00022341489],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9907364,0.0055056927,0.002350296,0.00027303363,0.000868065,0.00026647345],"domain_scores_gemma":[0.98478335,0.013659166,0.0005800326,0.0005421466,0.00023674876,0.00019853987],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.037257656,0.000099069155,0.001334279,0.00015799681,0.000026452353,0.0000016294354,0.0002655617,0.00030692274,0.0074903145],"category_scores_gemma":[0.030847602,0.00006013461,0.00026313454,0.00045313194,0.0007165701,0.000016465654,0.00004882552,0.0004975089,0.0000067254496],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026363884,0.0008178188,0.64308506,0.00008286903,0.000045430526,0.00003910683,0.00023720143,0.000004348785,0.0032585168,0.00032556718,0.00077222195,0.34869546],"study_design_scores_gemma":[0.011419598,0.004336309,0.93572927,0.00013152072,0.0000760917,0.000010050664,0.00015553429,0.0034261253,0.0027023118,0.0006066957,0.041316226,0.00009028163],"about_ca_topic_score_codex":0.0014998101,"about_ca_topic_score_gemma":0.0032013545,"teacher_disagreement_score":0.34860516,"about_ca_system_score_codex":0.00012574092,"about_ca_system_score_gemma":0.0012733022,"threshold_uncertainty_score":0.99341697},"labels":[],"label_agreement":null},{"id":"W2809695328","doi":"10.1158/1078-0432.ccr-18-1552","title":"Two Weeks' Notice from Allogeneic Sources","year":2018,"lang":"en","type":"letter","venue":"Clinical Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"T-cell receptor; Human leukocyte antigen; Medicine; Notice; Cancer; Immunology; T cell; Antigen; Biology; Internal medicine; Immune system; Political science","score_opus":0.34897601776317844,"score_gpt":0.565567767512028,"score_spread":0.21659174974884954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2809695328","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.10821459,0.0070385197,0.000010217373,0.8507562,0.0027568392,0.0025367932,0.0006699199,0.00020450374,0.027812421],"genre_scores_gemma":[0.0021520657,0.00735483,0.00042761478,0.5479647,0.15365145,0.0006354092,0.0010803546,0.00048472267,0.28624886],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9859701,0.0030672175,0.0014674328,0.0022453258,0.004936511,0.0023134039],"domain_scores_gemma":[0.9848171,0.009165163,0.00023877432,0.0028389853,0.0021096973,0.00083031534],"candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.007600634,0.0005956691,0.0017840972,0.0006370624,0.00034442253,0.00024965854,0.001825929,0.002510994,0.0974199],"category_scores_gemma":[0.003120634,0.0004941483,0.00090825965,0.0009903456,0.0033912668,0.00007971909,0.0011331976,0.018241711,0.0059945034],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017896538,0.00020538825,0.012106249,0.00025727702,0.00088936667,0.0017204212,0.000080489706,4.3991193e-7,0.0018144008,0.0000028073584,0.9579489,0.023184579],"study_design_scores_gemma":[0.0035349377,0.0014878658,0.0035562988,0.0006107467,0.00020978773,0.000016270005,0.00004178567,0.000037016984,0.0010394143,0.00045284248,0.9885457,0.0004673263],"about_ca_topic_score_codex":0.0090472875,"about_ca_topic_score_gemma":0.0008698774,"teacher_disagreement_score":0.3027915,"about_ca_system_score_codex":0.00080200797,"about_ca_system_score_gemma":0.003255842,"threshold_uncertainty_score":0.99975103},"labels":[],"label_agreement":null},{"id":"W2810960090","doi":"10.1093/annonc/mdy225","title":"Early-drug development in the era of immuno-oncology: are we ready to face the challenges?","year":2018,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Drug development; Dosing; Clinical trial; Drug; Face (sociological concept); Intensive care medicine; Immunotherapy; Competition (biology); Toxicity; Maximum tolerated dose; Pharmacology; Oncology; Medical physics; Risk analysis (engineering); Immune system; Internal medicine; Immunology","score_opus":0.3627134592304156,"score_gpt":0.5024936264408392,"score_spread":0.13978016721042358,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2810960090","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015454429,0.9456171,0.0000011015605,0.033155564,0.00025200535,0.0028704645,0.000021907683,0.0000125459865,0.016523909],"genre_scores_gemma":[0.00035983676,0.9955168,0.00014174517,0.0011092273,0.0003073696,0.000528421,0.000024022112,0.000056827612,0.0019557702],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9950028,0.0018536962,0.0013472834,0.000504016,0.0006410725,0.0006511201],"domain_scores_gemma":[0.99509317,0.0021470082,0.0008689823,0.0012280832,0.000536955,0.00012580882],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0054841605,0.0004137149,0.0029501736,0.00034436426,0.0000722688,0.000008241315,0.0012873724,0.0006428993,0.00046714325],"category_scores_gemma":[0.00041094024,0.00022276671,0.00041025132,0.00059372606,0.00048305807,0.00003062006,0.00038958524,0.0013841105,0.00017548793],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029189832,0.00057916535,0.000007726943,0.003560559,0.00051213574,0.00009225288,0.01058355,1.5793086e-7,0.000017472148,0.000130054,0.019783894,0.9644411],"study_design_scores_gemma":[0.0005963583,0.002959679,0.00032394638,0.005899585,0.00014907907,0.00013644158,0.0016178663,1.7191753e-7,0.00008430783,0.000046870806,0.9880095,0.00017619498],"about_ca_topic_score_codex":0.00013950524,"about_ca_topic_score_gemma":0.00058870745,"teacher_disagreement_score":0.9682256,"about_ca_system_score_codex":0.00031192237,"about_ca_system_score_gemma":0.0026749007,"threshold_uncertainty_score":0.9084163},"labels":[],"label_agreement":null},{"id":"W2811326314","doi":"10.1097/ccm.0000000000003258","title":"Management of the Critically Ill Adult Chimeric Antigen Receptor-T Cell Therapy Patient: A Critical Care Perspective","year":2018,"lang":"en","type":"review","venue":"Critical Care Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mount Sinai Hospital; Toronto General Hospital","funders":"National Cancer Institute","keywords":"Medicine; Critically ill; Perspective (graphical); Chimeric antigen receptor; Intensive care medicine; Critical illness; Cell therapy; Immunology; Immunotherapy; Immune system; Cell","score_opus":0.04671614563417579,"score_gpt":0.40520449036306533,"score_spread":0.3584883447288895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2811326314","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009775185,0.92759615,0.00004641366,0.003997235,0.0015598286,0.003423948,0.00023825391,0.00010195119,0.062938474],"genre_scores_gemma":[0.0059383544,0.9878489,0.00079082407,0.002004302,0.001834201,0.00037944724,0.00019662891,0.00028644124,0.000720922],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99199414,0.0009357186,0.0015570399,0.0015506371,0.002621153,0.0013412863],"domain_scores_gemma":[0.9852099,0.0014682341,0.00016239211,0.0021857242,0.010117449,0.00085634366],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00040141013,0.0011084435,0.0034267781,0.00041703417,0.0003205254,0.000041310184,0.0010232913,0.00072214974,0.007336437],"category_scores_gemma":[0.0042947084,0.00066755136,0.0013973298,0.001375792,0.0051628863,0.000072724775,0.0005063878,0.0018437528,0.00017053566],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004333074,0.0006979286,0.00003601218,0.121346295,0.0006120259,0.0005685051,0.008272208,1.7044686e-8,0.000100064084,0.010351055,0.0048416033,0.852741],"study_design_scores_gemma":[0.0019849376,0.0049910764,0.000033842876,0.042944215,0.0028121823,0.00016816298,0.056668624,0.0000014325165,0.00027810465,0.0002197433,0.889177,0.0007206746],"about_ca_topic_score_codex":0.00012050903,"about_ca_topic_score_gemma":0.000004609426,"teacher_disagreement_score":0.8843354,"about_ca_system_score_codex":0.00103239,"about_ca_system_score_gemma":0.00070880953,"threshold_uncertainty_score":0.9995776},"labels":[],"label_agreement":null},{"id":"W2883138099","doi":"10.1097/01.tp.0000542905.98105.1f","title":"Humanization and Pre-Clinical Validation of an Anti-HLA-A*02","year":2018,"lang":"en","type":"article","venue":"Transplantation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Drug Research and Development; BC Children's Hospital; University of British Columbia","funders":"","keywords":"Immunogenicity; Polyclonal antibodies; Human leukocyte antigen; Antigen; Immunology; Humanized mouse; Chimeric antigen receptor; Antibody; Biology; Immunotherapy; Computational biology; Immune system","score_opus":0.06023133680711768,"score_gpt":0.4084449172840989,"score_spread":0.3482135804769812,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2883138099","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99461085,0.000016403172,0.0034001353,0.00006625071,0.00007218225,0.0003172363,0.000007778766,0.000033312514,0.0014758833],"genre_scores_gemma":[0.9980067,0.00032304844,0.0007530887,0.000046087956,0.00021365765,0.0000037712687,0.00029359097,0.00001383572,0.00034623672],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9991751,0.00009388789,0.0002578297,0.00016696422,0.0002159859,0.000090236324],"domain_scores_gemma":[0.999516,0.000056902576,0.000057883677,0.00013741641,0.00016929964,0.00006250528],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038540302,0.00006117701,0.00014349408,0.00008394182,0.000043616197,0.000014274664,0.00003422959,0.00007704685,0.0007760216],"category_scores_gemma":[0.000021122652,0.00005741727,0.000025123194,0.00012590286,0.00012641605,0.00018729334,0.000002831255,0.00007350865,0.000012798011],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023374835,0.00037203892,0.14114448,0.0004803576,0.000087126864,0.000011986506,0.0059729135,0.000011569054,0.8017093,0.00038862255,0.000053256357,0.047430877],"study_design_scores_gemma":[0.002340802,0.001354771,0.6330733,0.00006476469,0.00012031814,0.000040724844,0.00006274415,0.0010572189,0.36154947,0.00013052965,0.00013524102,0.00007017579],"about_ca_topic_score_codex":0.000049755043,"about_ca_topic_score_gemma":0.000027289252,"teacher_disagreement_score":0.49192876,"about_ca_system_score_codex":0.000010417468,"about_ca_system_score_gemma":0.000032967193,"threshold_uncertainty_score":0.8496893},"labels":[],"label_agreement":null},{"id":"W2884280196","doi":"10.1016/j.celrep.2018.06.040","title":"HDACi Delivery Reprograms Tumor-Infiltrating Myeloid Cells to Eliminate Antigen-Loss Variants","year":2018,"lang":"en","type":"article","venue":"Cell Reports","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster University Medical Centre","funders":"Canadian Institutes of Health Research; Canadian Cancer Society; Ontario Institute for Cancer Research","keywords":"Myeloid; Tumor microenvironment; Cancer research; Cytotoxic T cell; Antigen; Immune system; Biology; CD8; Oncolytic virus; Immunology; In vitro","score_opus":0.023877029503952322,"score_gpt":0.29881351260138017,"score_spread":0.27493648309742785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2884280196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9440877,0.00017723138,0.0001820833,0.00021783763,0.0009379714,0.0011943355,0.000002777869,0.00031532202,0.05288475],"genre_scores_gemma":[0.9714983,0.00008088378,0.0034529336,0.000822443,0.0010369234,0.000052602347,0.00001711106,0.00013800774,0.022900812],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99601394,0.00008874808,0.00086897024,0.0011013348,0.00093825464,0.0009887514],"domain_scores_gemma":[0.99662507,0.00008908536,0.00030549,0.0016595208,0.00063173566,0.0006891251],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014191358,0.0003496529,0.0005478923,0.00024466074,0.00024965842,0.00012126151,0.00019575914,0.00015632344,0.0032749188],"category_scores_gemma":[0.0002576495,0.00032986992,0.00021479241,0.00069436384,0.0002363643,0.0001296406,0.0002123904,0.00041835182,0.0007530389],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026892193,0.00026752954,0.017614782,0.00010838642,0.000057677345,0.013217193,0.0007287138,0.0000042104903,0.9312293,0.000003565555,0.0036849973,0.032814745],"study_design_scores_gemma":[0.00062554,0.0011249043,0.012296144,0.00018116253,0.000053085376,0.0030645193,0.00023820838,0.00012201906,0.8956419,0.000057383844,0.08618948,0.000405615],"about_ca_topic_score_codex":0.0004436931,"about_ca_topic_score_gemma":0.0000371401,"teacher_disagreement_score":0.08250448,"about_ca_system_score_codex":0.00016911693,"about_ca_system_score_gemma":0.00038408738,"threshold_uncertainty_score":0.99991536},"labels":[],"label_agreement":null},{"id":"W2885193471","doi":"10.1158/1538-7445.am2018-ct110","title":"Abstract CT110: Clinical pharmacology of tisagenlecleucel (CTL019) in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL)","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Hospital","funders":"","keywords":"Cmax; Medicine; Diffuse large B-cell lymphoma; Internal medicine; Pharmacokinetics; Cytokine release syndrome; CD19; Oncology; Logistic regression; Lymphoma; Immunotherapy; Immunology; Gastroenterology; Pharmacology; Cancer; Peripheral blood","score_opus":0.08152018180211967,"score_gpt":0.4497604693759716,"score_spread":0.3682402875738519,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2885193471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898593,0.0005271569,0.0000030120812,0.00032081266,0.00048604698,0.0013852728,0.000064041466,0.00003371295,0.0073206904],"genre_scores_gemma":[0.9914572,0.0009469558,0.000052760864,0.0002689742,0.00094254245,0.0001486388,0.000032690572,0.00010051504,0.0060497024],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949938,0.0005550206,0.0007411398,0.0007502526,0.0016631066,0.0012966583],"domain_scores_gemma":[0.9966214,0.00069058064,0.00015257561,0.0007816509,0.0012344926,0.00051935914],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002752496,0.0002463508,0.0006650346,0.00063785695,0.00013393574,0.000022101298,0.000504298,0.00032691527,0.011140714],"category_scores_gemma":[0.00022564841,0.0002017599,0.00013791745,0.0010376471,0.0012197522,0.00013841956,0.00027755057,0.001283153,0.00032489115],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02644935,0.034359165,0.6965763,0.0005177759,0.00030589986,0.00025864714,0.000846915,6.776166e-7,0.15542337,0.00001541834,0.032759823,0.052486658],"study_design_scores_gemma":[0.080131546,0.004604172,0.8165335,0.0002295005,0.00003468425,0.0000027191986,0.0001301969,0.00003228559,0.044249095,0.000014823768,0.053797875,0.000239605],"about_ca_topic_score_codex":0.00080126035,"about_ca_topic_score_gemma":0.00039797818,"teacher_disagreement_score":0.11995721,"about_ca_system_score_codex":0.0007096326,"about_ca_system_score_gemma":0.0015117849,"threshold_uncertainty_score":0.98976326},"labels":[],"label_agreement":null},{"id":"W2885524635","doi":"10.1158/1538-7445.am2018-3563","title":"Abstract 3563: Impact of the affinity of chimeric antigen receptor on immune activation profiles of T cells","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nexen (Canada)","funders":"","keywords":"Chimeric antigen receptor; Epitope; Antigen; Chemistry; Human leukocyte antigen; Antibody; Molecular biology; Immune system; T cell; Cell biology; Biology; Immunology","score_opus":0.10411668772737546,"score_gpt":0.4527555669926724,"score_spread":0.3486388792652969,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2885524635","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935272,0.00016752604,0.0000011694908,0.0002729519,0.0000979404,0.0010382242,0.00006604913,0.000007699934,0.004821247],"genre_scores_gemma":[0.9975522,0.0004967172,0.00003153055,0.000006871061,0.00023570533,0.00003889499,0.000007561374,0.000030187986,0.001600315],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975657,0.0002273447,0.00036228745,0.00022778344,0.001229535,0.0003873586],"domain_scores_gemma":[0.99748695,0.00033575334,0.00019869984,0.0007582128,0.0011270144,0.0000933479],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013852206,0.000117522315,0.00036011715,0.00028799757,0.00008473909,0.0000073342517,0.00037363355,0.00010230374,0.010238091],"category_scores_gemma":[0.00035550687,0.000073963165,0.00021871539,0.0010932687,0.0009053916,0.00005802913,0.00011992644,0.000542142,0.000029259627],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025787873,0.00030327056,0.012179792,0.00023633067,0.00015989559,3.598709e-7,0.00055679004,0.000009719948,0.97116846,0.000012937534,0.0020338418,0.010759842],"study_design_scores_gemma":[0.00052837137,0.0010088205,0.30956376,0.00032614573,0.0000043674486,3.0498506e-7,0.00009120609,0.0000079558,0.6880157,0.000016552784,0.00039795114,0.000038881833],"about_ca_topic_score_codex":0.0045370357,"about_ca_topic_score_gemma":0.000023237182,"teacher_disagreement_score":0.29738396,"about_ca_system_score_codex":0.0003128351,"about_ca_system_score_gemma":0.0011629598,"threshold_uncertainty_score":0.9906667},"labels":[],"label_agreement":null},{"id":"W2885654872","doi":"10.1158/1538-7445.am2018-1763","title":"Abstract 1763: BiTEs vs CAR-Ts: Preclinical targeting of CD133+ brain tumor initiating cells using immunotherapy-based treatment strategies","year":2018,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McMaster University","funders":"","keywords":"Chimeric antigen receptor; Antigen; Immunotherapy; Cytotoxic T cell; Cancer research; Brain tumor; Antibody; Monoclonal antibody; Glioma; T cell; Tumor antigen; Immunology; Biology; Medicine; Immune system; Pathology; In vitro","score_opus":0.18447562576547308,"score_gpt":0.49285059538041026,"score_spread":0.30837496961493716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2885654872","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99358416,0.001987946,0.00004801242,0.00081921346,0.00018492925,0.0012842537,0.00007124328,0.00006539293,0.001954879],"genre_scores_gemma":[0.9957745,0.0003438847,0.0014660073,0.00020696173,0.0012127513,0.00016002382,0.000026093432,0.000116749514,0.0006930089],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9954345,0.000525791,0.00083094335,0.0006646445,0.001402085,0.0011420043],"domain_scores_gemma":[0.99545413,0.0020793553,0.00021526488,0.0007247893,0.001231607,0.00029487716],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0025983981,0.00030924418,0.0007177492,0.00053352397,0.00035039056,0.00014322854,0.00036121035,0.00017643893,0.007552085],"category_scores_gemma":[0.00051502197,0.0002574694,0.0002713675,0.0009007794,0.0011367938,0.00018572898,0.0001002146,0.00081167254,0.000047730195],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029132778,0.00037632757,0.0053804824,0.0003538287,0.00023125515,0.000074634176,0.0018797757,0.00014883063,0.97529155,0.000012742085,0.00039509975,0.012942206],"study_design_scores_gemma":[0.0041596116,0.0030862691,0.0042868447,0.00077095133,0.00002856838,0.0000073415613,0.0026307337,0.0017826669,0.9763525,0.00009000166,0.0065466347,0.00025786084],"about_ca_topic_score_codex":0.0074918675,"about_ca_topic_score_gemma":0.00035136842,"teacher_disagreement_score":0.012684345,"about_ca_system_score_codex":0.0012411138,"about_ca_system_score_gemma":0.005060204,"threshold_uncertainty_score":0.9999878},"labels":[],"label_agreement":null},{"id":"W2886321703","doi":"10.1038/s41467-018-05395-y","title":"The chimeric TAC receptor co-opts the T cell receptor yielding robust anti-tumor activity without toxicity","year":2018,"lang":"en","type":"article","venue":"Nature Communications","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":123,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; McMaster University","funders":"Terry Fox Foundation","keywords":"Chimeric antigen receptor; Cytotoxic T cell; CD28; Cancer research; Cytokine release syndrome; Cytokine; Antigen; CD8; Cytotoxicity; T-cell receptor; Immunotherapy; T cell; In vitro; Chemistry; Biology; Immunology; Immune system; Biochemistry","score_opus":0.04732461507935709,"score_gpt":0.3628452382667252,"score_spread":0.3155206231873681,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2886321703","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86076593,0.005748697,0.00018353156,0.054310724,0.0008609019,0.0022250481,0.00007293009,0.00027157753,0.07556063],"genre_scores_gemma":[0.9864973,0.0024794966,0.0023027437,0.0011473193,0.00056244445,0.000111984125,0.000047214715,0.00005461229,0.006796924],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99775946,0.0006425649,0.00026766627,0.00031609542,0.00054830353,0.00046592645],"domain_scores_gemma":[0.9935968,0.0015052968,0.00019694325,0.004103969,0.00043299832,0.00016399717],"candidate_categories":["sts","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013154481,0.0002285013,0.00029698733,0.00008716489,0.0021473295,0.00013062524,0.001917546,0.00026760064,0.001197745],"category_scores_gemma":[0.00074715336,0.00013686897,0.00016838807,0.00075787393,0.001130874,0.00012277429,0.00051261234,0.0029672657,0.00028794457],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031278556,0.00047323827,0.0071316073,0.000020525385,0.00014861624,6.757393e-7,0.0008077991,0.0000021685416,0.8979693,0.0005072655,0.08080196,0.0118240835],"study_design_scores_gemma":[0.00065659324,0.0002206819,0.011771197,0.000060666654,0.000058777685,0.000019416111,0.00042398725,0.0007804225,0.17940953,0.000020485,0.8063712,0.00020700427],"about_ca_topic_score_codex":0.000076462966,"about_ca_topic_score_gemma":0.00033693796,"teacher_disagreement_score":0.7255693,"about_ca_system_score_codex":0.00020430378,"about_ca_system_score_gemma":0.00026744357,"threshold_uncertainty_score":0.99971527},"labels":[],"label_agreement":null},{"id":"W2886489059","doi":"10.1111/cei.13145","title":"Infusion of<i>ex-vivo</i>expanded human TCR-αβ+ double-negative regulatory T cells delays onset of xenogeneic graft-<i>versus</i>-host disease","year":2018,"lang":"en","type":"article","venue":"Clinical & Experimental Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Ex vivo; In vivo; Immunology; T cell; Immune system; T-cell receptor; Humanized mouse; Regulatory T cell; Graft-versus-host disease; Biology; Medicine; Cancer research; Stem cell; Cell biology; IL-2 receptor","score_opus":0.07825711958929048,"score_gpt":0.42539361532358083,"score_spread":0.34713649573429034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2886489059","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99240875,0.0016718314,0.0000062120694,0.00017148038,0.0011463376,0.0010515599,0.00006155294,0.00007033909,0.0034119536],"genre_scores_gemma":[0.99630296,0.00031167924,0.00025762463,0.00030474542,0.00035413823,0.000061186736,0.000075098185,0.00007727891,0.0022553005],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9959718,0.00051166664,0.0015390724,0.0007770919,0.00056018715,0.0006401576],"domain_scores_gemma":[0.99659204,0.0006905983,0.0005027331,0.0013889078,0.00040299498,0.00042274312],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007355755,0.00039297505,0.0011608584,0.0002532914,0.00018145786,0.000012063268,0.0005038974,0.00044197793,0.0077027804],"category_scores_gemma":[0.00018772304,0.00035990574,0.00060628663,0.00036722154,0.0046127015,0.000112399415,0.00062828814,0.00060789805,0.00018069438],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035699695,0.0025017979,0.0042101108,0.000040864532,0.0006241885,0.000054038468,0.0007954454,3.84449e-7,0.9538927,0.00030272038,0.0012816496,0.00059640204],"study_design_scores_gemma":[0.018330282,0.009287831,0.020939315,0.00013793942,0.00015107123,0.000016098573,0.00085514045,0.000013046717,0.9473456,0.00009520668,0.002540899,0.00028754477],"about_ca_topic_score_codex":0.00026999455,"about_ca_topic_score_gemma":0.000028278082,"teacher_disagreement_score":0.017369414,"about_ca_system_score_codex":0.0002051078,"about_ca_system_score_gemma":0.00035575614,"threshold_uncertainty_score":0.9998853},"labels":[],"label_agreement":null},{"id":"W2887634491","doi":"10.1097/mot.0000000000000566","title":"Taking regulatory T-cell therapy one step further","year":2018,"lang":"en","type":"review","venue":"Current Opinion in Organ Transplantation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Chimeric antigen receptor; Cell therapy; Alloimmunity; Immunology; Homing (biology); Autoimmunity; Genetic enhancement; Antigen; In vivo; Ex vivo; Adoptive cell transfer; T cell; Biology; Medicine; Cancer research; Stem cell; Immune system; Cell biology; Gene; Biotechnology","score_opus":0.17448715471353066,"score_gpt":0.422205049717559,"score_spread":0.24771789500402835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887634491","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022660302,0.99306816,0.0003486394,0.000036296657,0.002950106,0.0023429298,0.000075034426,0.00010012131,0.0008521294],"genre_scores_gemma":[0.00009289256,0.9951469,0.00013826165,0.000012878932,0.0017711278,0.00016015748,0.0021161758,0.00017658625,0.00038506094],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966477,0.00039655252,0.00092847197,0.0007280118,0.0007692268,0.0005300179],"domain_scores_gemma":[0.99847645,0.0001753542,0.00043922258,0.0006096859,0.00013239778,0.0001668657],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006806008,0.00052300794,0.001290268,0.0007368467,0.00007449072,0.000048665464,0.00027973173,0.00042610636,0.00430348],"category_scores_gemma":[0.000015329479,0.0004647609,0.00039219065,0.0007452125,0.00012819802,0.000106436986,0.000019259069,0.0009044036,0.0003427701],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021973062,0.00040895474,0.0001583747,0.056533046,0.00009497572,0.000005158445,0.00070994545,1.640294e-7,0.00012569722,0.000024823148,0.00044675503,0.9412724],"study_design_scores_gemma":[0.0029205193,0.00028765,0.00054796954,0.046366345,0.00023464266,0.0000718376,0.000027940961,0.000007333474,0.00015470671,0.000011251731,0.9488992,0.00047060507],"about_ca_topic_score_codex":0.000014947148,"about_ca_topic_score_gemma":0.0000048709003,"teacher_disagreement_score":0.9484525,"about_ca_system_score_codex":0.00036563893,"about_ca_system_score_gemma":0.00053543306,"threshold_uncertainty_score":0.9997804},"labels":[],"label_agreement":null},{"id":"W2887911630","doi":"10.1093/intimm/dxy051","title":"Producing proT cells to promote immunotherapies","year":2018,"lang":"en","type":"review","venue":"International Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"Canadian Institutes of Health Research; Canada First Research Excellence Fund; Ontario Institute for Regenerative Medicine; Krembil Foundation; University of Toronto","keywords":"Immunotherapy; Chimeric antigen receptor; Cancer immunotherapy; Induced pluripotent stem cell; Immune system; T cell; Cell therapy; Immunology; Progenitor cell; Antigen-presenting cell; Antigen; Biology; Major histocompatibility complex; Cancer research; Stem cell; Cell biology; Embryonic stem cell","score_opus":0.06643699078101255,"score_gpt":0.4047386559700356,"score_spread":0.33830166518902305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887911630","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021164697,0.9869849,0.000037372633,0.0007673926,0.0024259512,0.0038737825,0.000042674612,0.00012362006,0.005532669],"genre_scores_gemma":[0.000006405917,0.91546065,0.0011180355,0.00018172071,0.0013620122,0.00088426,0.00015714196,0.0001393853,0.08069039],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99726087,0.00016643312,0.0007669279,0.0008037695,0.0004972511,0.00050472317],"domain_scores_gemma":[0.9980386,0.000108003725,0.00026288175,0.00095935847,0.00054153905,0.000089635956],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0005368826,0.00045552882,0.0013641119,0.00082043244,0.000071481234,0.0000739518,0.00087247894,0.0004082808,0.008676265],"category_scores_gemma":[0.00023550898,0.00036767568,0.0004915063,0.0003632858,0.00022062386,0.00006910071,0.00039393455,0.0008099149,0.0037989253],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002468005,0.00018845341,0.0000016866322,0.0015416516,0.0024752223,0.00006212611,0.0005210134,7.578119e-8,0.0105946185,0.00005455481,0.0024255684,0.98188823],"study_design_scores_gemma":[0.0004600058,0.0006455399,0.000011990706,0.006777979,0.00014317784,0.0005960778,0.000011143796,0.0000014852877,0.0021982298,0.00004127665,0.98882526,0.00028783886],"about_ca_topic_score_codex":0.00009222813,"about_ca_topic_score_gemma":0.0000071058403,"teacher_disagreement_score":0.9863997,"about_ca_system_score_codex":0.0006599765,"about_ca_system_score_gemma":0.00057288026,"threshold_uncertainty_score":0.9998775},"labels":[],"label_agreement":null},{"id":"W2889810537","doi":"10.1093/annonc/mdy398","title":"Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies","year":2018,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Queen's University","funders":"European Society for Medical Oncology; National Institute for Health and Care Research; Cancer Research UK","keywords":"Medicine; Clinical trial; Task force; Immunotherapy; Medical physics; Drug development; Inefficiency; Intensive care medicine; Risk analysis (engineering); Cancer; Internal medicine; Pharmacology; Drug","score_opus":0.83767867545436,"score_gpt":0.6555024798137091,"score_spread":0.1821761956406509,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889810537","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0023180877,0.986723,0.0026133447,0.0043940293,0.00035595256,0.003381697,0.00015700852,0.0000040255104,0.000052830354],"genre_scores_gemma":[0.00020396615,0.9791299,0.01906727,0.00043514016,0.0000799599,0.000736266,0.000042900097,0.000029422885,0.00027518882],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9947923,0.0027288373,0.0017948649,0.00027532977,0.00021567766,0.00019298136],"domain_scores_gemma":[0.95578104,0.03977637,0.0018112151,0.00044420856,0.0021622714,0.000024917199],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00761838,0.00023140904,0.002519956,0.00018435845,0.000098450546,0.0000026536977,0.000356987,0.00027827884,0.00016631273],"category_scores_gemma":[0.0015006438,0.0001196487,0.00028750516,0.00039335297,0.0016112424,0.0000230913,0.00010510087,0.0003429079,6.030009e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011425643,0.00042568936,0.000034929075,0.0008571375,0.009379283,2.1533349e-7,0.0076880264,3.5751938e-7,0.00040647548,0.0005319779,0.0038960879,0.97563726],"study_design_scores_gemma":[0.0023954818,0.009130055,0.00043964456,0.003428681,0.00047969297,0.0000022975007,0.0018326576,0.000002360215,0.0020919316,0.0020503236,0.9780237,0.00012317579],"about_ca_topic_score_codex":0.00009653183,"about_ca_topic_score_gemma":0.000052422438,"teacher_disagreement_score":0.97551405,"about_ca_system_score_codex":0.00006439383,"about_ca_system_score_gemma":0.0016318192,"threshold_uncertainty_score":0.593669},"labels":[],"label_agreement":null},{"id":"W2890616344","doi":"10.1038/s41586-018-0499-y","title":"A homing system targets therapeutic T cells to brain cancer","year":2018,"lang":"en","type":"article","venue":"Nature","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":39,"is_retracted":true,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of British Columbia","funders":"National Institute of Allergy and Infectious Diseases; National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institutes of Health","keywords":"ALCAM; Homing (biology); Cytotoxic T cell; Extravasation; Cancer cell; Immune system; Cancer research; Cell adhesion molecule; Cell adhesion; Immunotherapy; Cancer immunotherapy; Cell biology; Chemistry; Cancer; Immunology; Cell; Biology; Medicine; In vitro; Internal medicine; Biochemistry","score_opus":0.017823140015528424,"score_gpt":0.3489033750336359,"score_spread":0.33108023501810746,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890616344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8836392,0.017321242,0.0003592768,0.039780084,0.0043656044,0.002938502,0.00006018738,0.00048360464,0.05105231],"genre_scores_gemma":[0.9515703,0.00002435147,0.00030461675,0.010635755,0.0017405815,0.00004442328,0.0000038014807,0.000046068784,0.035630137],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986882,0.000053492913,0.00012442944,0.00029688558,0.0004576208,0.00037936817],"domain_scores_gemma":[0.9990942,0.00007623491,0.000027800043,0.00037547262,0.00022557206,0.00020072493],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003007907,0.000136355,0.00023453239,0.00013354619,0.00008200708,0.000026901811,0.00015853475,0.000626266,0.0024478077],"category_scores_gemma":[0.000039520004,0.00010550882,0.000078381585,0.00037768867,0.000047487574,0.000030243382,0.000047971975,0.0013275509,0.00030230195],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043418794,0.00003136319,0.0005426649,0.00014161038,0.000104117295,0.000047032125,0.00096267986,0.0000011481466,0.90465355,0.00015510904,0.060621336,0.03230517],"study_design_scores_gemma":[0.0010069098,0.00033939484,0.0024498818,0.00027414985,0.000032823235,0.00003422362,0.00023594391,0.00024306268,0.3078442,0.000015786205,0.68736804,0.00015560033],"about_ca_topic_score_codex":0.0000819985,"about_ca_topic_score_gemma":0.00008457342,"teacher_disagreement_score":0.6267467,"about_ca_system_score_codex":0.00029189244,"about_ca_system_score_gemma":0.0001415704,"threshold_uncertainty_score":0.9984641},"labels":[],"label_agreement":null},{"id":"W2890672884","doi":"10.1200/jco.2018.36.15_suppl.tps9600","title":"A randomized phase III study of duration of anti-PD-1 therapy in metastatic melanoma (STOP-GAP): Canadian Clinical Trials Group study (CCTG) ME.13.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saskatchewan Cancer Agency; Ottawa Hospital; CancerCare Manitoba; Health Sciences Centre; Sunnybrook Health Science Centre; Juravinski Cancer Centre; University of Saskatchewan; Cancer Care Ontario; Queen's University; McMaster University; Horizon Health Network; London Health Sciences Centre; Princess Margaret Cancer Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Clinical endpoint; Adverse effect; Internal medicine; Clinical trial; Quality of life (healthcare); Population; Randomized controlled trial; Oncology; Melanoma; Phases of clinical research; Surgery","score_opus":0.4135943830261517,"score_gpt":0.6025961119743353,"score_spread":0.18900172894818357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890672884","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908162,0.00028385612,0.00008139072,0.0016763929,0.0014414066,0.005007891,0.000007751404,0.000005731908,0.00067943323],"genre_scores_gemma":[0.99641633,0.0010858853,0.00044074553,0.00045343718,0.0013553634,0.00004075859,0.0000041229805,0.000035247205,0.0001680868],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9568275,0.026359808,0.014822139,0.00041671228,0.0011250443,0.00044879434],"domain_scores_gemma":[0.9609269,0.029073255,0.0069691134,0.0006069848,0.0015776065,0.0008461367],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.1369045,0.00028017137,0.009901096,0.0009769445,0.00005676456,0.000014909962,0.00046696293,0.00042889506,0.002096061],"category_scores_gemma":[0.043184906,0.00018169342,0.0014476358,0.0006318744,0.0008796519,0.00014919422,0.000050317103,0.0016172768,0.00000813477],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7258633,0.04916473,0.0925053,0.000022727452,0.0053163664,0.0010410809,0.003384139,0.0000032175985,0.003164916,0.000027811351,0.0005511156,0.11895532],"study_design_scores_gemma":[0.75700635,0.16248056,0.07291431,0.00007209872,0.00128714,0.00008107408,0.00421162,0.00027757246,0.00018352507,0.00018627624,0.0011714671,0.00012801522],"about_ca_topic_score_codex":0.014626968,"about_ca_topic_score_gemma":0.0714086,"teacher_disagreement_score":0.118827306,"about_ca_system_score_codex":0.00022094577,"about_ca_system_score_gemma":0.004463251,"threshold_uncertainty_score":0.99881613},"labels":[],"label_agreement":null},{"id":"W2891114267","doi":"10.4155/bio-2018-0203","title":"Flow Cytometry in Cell-Based Pharmacokinetics or Cellular Kinetics in Adoptive Cell Therapy","year":2018,"lang":"en","type":"editorial","venue":"Bioanalysis","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Flow cytometry; Kinetics; Cell therapy; Pharmacokinetics; Cell; Chemistry; Medicine; Pharmacology; Immunology; Biochemistry; Physics","score_opus":0.026463677672429887,"score_gpt":0.33265494908000975,"score_spread":0.30619127140757985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891114267","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06863398,0.047324996,0.0020576273,0.0009779257,0.85026485,0.00848316,0.0022269436,0.00049958896,0.019530943],"genre_scores_gemma":[0.09013635,0.023116626,0.0063618636,0.00044653384,0.815028,0.00033171583,0.005117139,0.00076330354,0.058698453],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9928505,0.000539458,0.0012773471,0.0014147967,0.002771036,0.0011469057],"domain_scores_gemma":[0.9955557,0.0011893474,0.0004288282,0.0015270202,0.0008757786,0.00042334193],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0012973191,0.00094589987,0.002020649,0.003959956,0.000055871373,0.00010458798,0.0008484508,0.0017009353,0.014187954],"category_scores_gemma":[0.00036747384,0.0007920372,0.00077132427,0.0053855744,0.00036046808,0.000052203097,0.000157599,0.0023180787,0.00020728471],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010625472,0.0054854327,0.00250941,0.0011254721,0.0011735138,0.002626577,0.00064586906,0.00083829963,0.16796824,9.400282e-8,0.7908936,0.01610798],"study_design_scores_gemma":[0.011734923,0.0016563676,0.000099237805,0.00020081899,0.00074963004,8.286282e-7,0.00012975447,0.010684745,0.1188333,0.0000027865033,0.855098,0.0008096177],"about_ca_topic_score_codex":0.0004847794,"about_ca_topic_score_gemma":0.00031777716,"teacher_disagreement_score":0.06420434,"about_ca_system_score_codex":0.001284597,"about_ca_system_score_gemma":0.0013700544,"threshold_uncertainty_score":0.9999836},"labels":[],"label_agreement":null},{"id":"W2891568037","doi":"10.1200/jco.2017.35.15_suppl.10524","title":"A phase I/II study of atezolizumab in pediatric and young adult patients with refractory/relapsed solid tumors (iMATRIX-Atezolizumab).","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Atezolizumab; Medicine; Ependymoma; Refractory (planetary science); Internal medicine; Sarcoma; Gastroenterology; Oncology; Cancer; Surgery; Pathology; Nivolumab; Immunotherapy","score_opus":0.07854338184453231,"score_gpt":0.4758854040754624,"score_spread":0.3973420222309301,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2891568037","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99666303,0.00012436147,0.0000025669103,0.0005761951,0.00054308824,0.0007734698,0.0000051036377,0.0000062901086,0.0013058821],"genre_scores_gemma":[0.99775845,0.00085005554,0.00020358124,0.00009813987,0.0006660997,0.000007944263,0.0000021424,0.00003595532,0.0003776633],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9947899,0.00056458847,0.0029633513,0.00033212028,0.00094074034,0.00040927524],"domain_scores_gemma":[0.993124,0.00089961913,0.0036035492,0.0005832686,0.0012763109,0.00051322806],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028296437,0.00022736694,0.0022833415,0.00044554623,0.00014858092,0.000024991643,0.00042674615,0.00034239027,0.00018901794],"category_scores_gemma":[0.0053611295,0.00015437671,0.00023661253,0.00017951854,0.0003686391,0.0002631665,0.00021158718,0.0017403956,0.0000044496637],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047191627,0.030246234,0.8425703,0.000066563276,0.0002715158,0.0013693097,0.0008336008,0.000002261749,0.00013088518,0.0000044514873,0.0002737453,0.077039495],"study_design_scores_gemma":[0.11780428,0.18226214,0.6983367,0.00009706019,0.0003246899,0.00012580647,0.00036071727,0.00006584344,0.000025506675,0.000034499597,0.00044455242,0.00011820056],"about_ca_topic_score_codex":0.00026922772,"about_ca_topic_score_gemma":0.00060122524,"teacher_disagreement_score":0.15201591,"about_ca_system_score_codex":0.0002092682,"about_ca_system_score_gemma":0.0014107183,"threshold_uncertainty_score":0.7561249},"labels":[],"label_agreement":null},{"id":"W2892229061","doi":"10.1200/jco.2017.35.15_suppl.e21004","title":"Generalizability of clinical trials in metastatic melanoma.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada); University of British Columbia","funders":"","keywords":"Medicine; Ipilimumab; Clinical trial; Internal medicine; Population; Vemurafenib; Cancer; Cohort; Oncology; Melanoma; Metastatic melanoma; Immunotherapy","score_opus":0.6925201321336265,"score_gpt":0.6835808158821697,"score_spread":0.00893931625145683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892229061","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9778595,0.00036799084,0.000107598935,0.011744023,0.0021221275,0.00043778218,0.0000054004977,0.0000033466997,0.0073522152],"genre_scores_gemma":[0.9866888,0.0019399675,0.0069029084,0.00093232625,0.0021956945,0.000004244964,0.0000013266332,0.000019596348,0.0013151583],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.97424954,0.011413026,0.012960004,0.0002915282,0.00076218654,0.00032370258],"domain_scores_gemma":[0.9454775,0.039949115,0.011562429,0.0011690303,0.0010481664,0.0007937476],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.1735477,0.00014610976,0.0067372792,0.00019444275,0.0000432931,0.000016989909,0.0006001253,0.00052170845,0.0026622915],"category_scores_gemma":[0.25850177,0.00009482343,0.0021685176,0.00009072712,0.0009693655,0.00013502344,0.00015399266,0.0020528617,0.00001884176],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016100885,0.0034336739,0.54722786,0.000060306218,0.00072434347,0.0008175017,0.000045231547,0.000005158607,0.0013623997,0.00012465133,0.0028239184,0.42727408],"study_design_scores_gemma":[0.028205799,0.016402354,0.8611443,0.00010659679,0.0004978968,0.00018852369,0.000058150443,0.0002545104,0.00044232103,0.0023717005,0.09023451,0.00009332591],"about_ca_topic_score_codex":0.0001329965,"about_ca_topic_score_gemma":0.00017722856,"teacher_disagreement_score":0.42718074,"about_ca_system_score_codex":0.000111418696,"about_ca_system_score_gemma":0.0037703891,"threshold_uncertainty_score":0.9982494},"labels":[],"label_agreement":null},{"id":"W2892293944","doi":"10.1200/jco.2018.36.15_suppl.3056","title":"Initial safety assessment of MAGE-A10<sup>c796</sup>TCR T-cells in two clinical trials.","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; T-cell receptor; Clinical trial; Cancer research; Oncology; Internal medicine; T cell; Immunology; Immune system","score_opus":0.3952715896467518,"score_gpt":0.6543995209197939,"score_spread":0.2591279312730421,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892293944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94292855,0.00016990895,0.0009142434,0.008599244,0.0037540046,0.0008753873,0.00002114209,0.000014840042,0.042722657],"genre_scores_gemma":[0.97190076,0.0020715368,0.00953853,0.0031898837,0.011605019,0.0000059615586,0.00000588102,0.000051051484,0.0016313902],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9738367,0.010814581,0.01292299,0.00047271207,0.0013337503,0.0006192764],"domain_scores_gemma":[0.96057546,0.031327862,0.0047214753,0.00068172434,0.0016322848,0.0010611733],"candidate_categories":["metaresearch","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.09385996,0.0002792867,0.0057576452,0.0004823428,0.000048498798,0.000017843642,0.0005817597,0.0009081968,0.009557629],"category_scores_gemma":[0.028914476,0.00020208706,0.0019693598,0.0004652893,0.0015412866,0.00015330991,0.00024351681,0.004357689,0.00009728172],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054651264,0.010308318,0.15067944,0.000083037834,0.0013727364,0.0022456157,0.00022277185,0.00007067919,0.0056734052,0.00035636174,0.016980128,0.7573562],"study_design_scores_gemma":[0.113721475,0.08623229,0.29574803,0.0005136931,0.0009894496,0.0006574937,0.00048345397,0.0047884146,0.0016057505,0.0013774083,0.49347523,0.00040734178],"about_ca_topic_score_codex":0.00006827153,"about_ca_topic_score_gemma":0.000121921665,"teacher_disagreement_score":0.7569489,"about_ca_system_score_codex":0.0004042691,"about_ca_system_score_gemma":0.00696723,"threshold_uncertainty_score":0.99866235},"labels":[],"label_agreement":null},{"id":"W2892758519","doi":"10.1038/s41591-018-0146-z","title":"Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia","year":2018,"lang":"en","type":"article","venue":"Nature Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":567,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"CD19; Chimeric antigen receptor; Loss of heterozygosity; Biology; Antigen; Cancer research; Mutation; Immunology; Gene; Genetics; T cell; Allele; Immune system","score_opus":0.011473866223421164,"score_gpt":0.3115330090825917,"score_spread":0.3000591428591705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2892758519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99006444,0.003905974,0.0008968255,0.0008631236,0.00048297262,0.00070648437,0.000017886547,0.000028148723,0.0030341293],"genre_scores_gemma":[0.99374884,0.002015161,0.0017546723,0.0007346844,0.00063944416,0.000011769843,0.000025815161,0.000051273506,0.0010183282],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975026,0.00009474924,0.00057069433,0.00037274472,0.0010378871,0.00042130373],"domain_scores_gemma":[0.99836826,0.00015818758,0.00017271559,0.00063677126,0.0004918511,0.00017220333],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006145802,0.0002459981,0.00085345964,0.00052598224,0.000026569714,0.0000020908446,0.0003007014,0.00044635718,0.0036748236],"category_scores_gemma":[0.0001899909,0.0001731906,0.00010688528,0.0009445762,0.00065442076,0.000031698717,0.000056008364,0.00062362495,0.000012374355],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001739644,0.000120267614,0.012589629,0.00011132696,0.0003007381,0.00018841944,0.001242759,0.0000028137306,0.9760619,0.00032218953,0.0009989311,0.006321376],"study_design_scores_gemma":[0.011387997,0.0049318844,0.13153878,0.0006618403,0.000091675756,0.00020199633,0.00018214295,0.0005327331,0.84273595,0.0025386512,0.004994619,0.00020173681],"about_ca_topic_score_codex":0.0002912637,"about_ca_topic_score_gemma":0.000035692705,"teacher_disagreement_score":0.13332596,"about_ca_system_score_codex":0.00023215119,"about_ca_system_score_gemma":0.00048225012,"threshold_uncertainty_score":0.99723595},"labels":[],"label_agreement":null},{"id":"W2894424410","doi":"10.1080/2162402x.2018.1502905","title":"Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study","year":2018,"lang":"en","type":"article","venue":"OncoImmunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":124,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Anticancer Fund; Kræftens Bekæmpelse","keywords":"Medicine; Tumor-infiltrating lymphocytes; Tolerability; Ovarian cancer; Melanoma; Oncology; Immunotherapy; Internal medicine; Cancer; Immune system; Aldesleukin; Progressive disease; T cell; Chemotherapy; Immunology; Cancer research; Adverse effect","score_opus":0.03149604510729136,"score_gpt":0.3048349407159007,"score_spread":0.27333889560860936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2894424410","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99321073,0.000385306,0.000019572231,0.0001131247,0.00007949088,0.0019989985,0.000008233061,0.00005639232,0.0041281683],"genre_scores_gemma":[0.99743074,0.0000531562,0.0009436783,0.0002910082,0.00007228512,0.00028301132,0.000017235347,0.000070071364,0.00083883625],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997876,0.000297829,0.00032524753,0.00049320725,0.00041874114,0.0005889721],"domain_scores_gemma":[0.9987028,0.00013927754,0.00016408577,0.00054432894,0.00036805982,0.00008141391],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003150902,0.00029210717,0.0006146109,0.00028717224,0.000120048346,0.000026296138,0.00021023527,0.00003674148,0.0018254424],"category_scores_gemma":[0.000023675482,0.00019757287,0.000027660284,0.00067063776,0.00042660194,0.00010362197,0.000056239758,0.00037496965,0.000041456504],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03694336,0.00616166,0.9097241,0.000024812705,0.00070418726,0.00021110791,0.0055641215,0.000008229799,0.020777963,0.000017798204,0.000032700438,0.019829951],"study_design_scores_gemma":[0.04453985,0.116145015,0.82796574,0.000116827665,0.00008196664,0.000038539667,0.0032503873,0.000038122,0.006723002,0.000011724343,0.0007883446,0.00030049053],"about_ca_topic_score_codex":0.0045200307,"about_ca_topic_score_gemma":0.0021313347,"teacher_disagreement_score":0.109983355,"about_ca_system_score_codex":0.0004922738,"about_ca_system_score_gemma":0.0007664163,"threshold_uncertainty_score":0.99908704},"labels":[],"label_agreement":null},{"id":"W2894501339","doi":"10.4049/jimmunol.198.supp.198.9","title":"Characterisation of gene-modified CD3-enhanced CD4+ T cells for cancer immunotherapy","year":2017,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"T-cell receptor; CD3; CD8; Cytotoxic T cell; Antigen; Biology; Adoptive cell transfer; Cancer research; T cell; Molecular biology; Immunotherapy; Immunology; Immune system; In vitro; Biochemistry","score_opus":0.04585417149622763,"score_gpt":0.3626579439399351,"score_spread":0.3168037724437075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2894501339","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917234,0.0024450158,0.0016746668,0.0026100194,0.000773823,0.00043596746,0.000008987063,0.000007550797,0.00032056042],"genre_scores_gemma":[0.9884965,0.008504355,0.0002739858,0.00014804496,0.000365345,0.000014646868,0.0000019207002,0.000037687427,0.0021575177],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988181,0.00012599076,0.0005061995,0.0000835414,0.0002209156,0.0002452806],"domain_scores_gemma":[0.99751925,0.00020257948,0.0010510405,0.0006292237,0.0005626286,0.00003527984],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010272856,0.000118096235,0.00048305854,0.00012566969,0.00015510149,0.00001804239,0.0005393716,0.000117705174,0.00043258513],"category_scores_gemma":[0.00010677268,0.00007567245,0.00020179943,0.000043212258,0.00031177,0.00011237073,0.000035438487,0.00033667378,0.0000036737572],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008227025,0.000084317144,0.00012271067,0.000022318018,0.0005826288,0.0000024652456,0.0011142016,0.0000109943485,0.9245943,0.00002180363,0.0001012227,0.065116],"study_design_scores_gemma":[0.0044477475,0.0012759828,0.029824218,0.000077790835,0.00008878084,0.00009877309,0.00016993225,0.00004364155,0.95906377,0.0001857746,0.004655739,0.00006786555],"about_ca_topic_score_codex":0.00014500934,"about_ca_topic_score_gemma":0.000011520746,"teacher_disagreement_score":0.06504814,"about_ca_system_score_codex":0.000105982974,"about_ca_system_score_gemma":0.000241179,"threshold_uncertainty_score":0.4736504},"labels":[],"label_agreement":null},{"id":"W2895872316","doi":"10.1093/annonc/mdy281.157","title":"Phase I studies assessing the safety and clinical activity of multiple doses of a NKG2D-based CAR-T therapy, CYAD-01, in metastatic colorectal cancer","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; European Regional Development Fund; Engineering and Physical Sciences Research Council; Agència de Gestió d'Ajuts Universitaris i de Recerca; Canadian Institutes of Health Research; Knut och Alice Wallenbergs Stiftelse; Koning Boudewijnstichting; Cancer Research Foundation in Northern Sweden; Generalitat de Catalunya; Umeå Universitet; Vetenskapsrådet; Fondation contre le Cancer; Cancerfonden; McGill University","keywords":"Medicine; Chimeric antigen receptor; NKG2D; FOLFOX; Colorectal cancer; Oncology; Internal medicine; Clinical trial; Context (archaeology); Tumor microenvironment; Bevacizumab; Immunotherapy; Cancer; Chemotherapy; Oxaliplatin; Cytotoxic T cell","score_opus":0.335728840455008,"score_gpt":0.5838037167005191,"score_spread":0.2480748762455111,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2895872316","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935714,0.0022770294,0.000022762244,0.0030393768,0.00011246256,0.000613624,0.00003712291,0.0000060759703,0.00032015145],"genre_scores_gemma":[0.99437225,0.0048953365,0.0002274798,0.0003389711,0.00008630239,0.00002815774,0.0000023242544,0.0000141585,0.00003501972],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977375,0.0008876074,0.00062805373,0.00022959009,0.00026404756,0.00025319326],"domain_scores_gemma":[0.99412376,0.0046284464,0.00039427803,0.0002318884,0.00055519573,0.000066452056],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025557827,0.00013112887,0.0010296467,0.00013993523,0.000048058322,0.000003307859,0.000118534306,0.00010132955,0.00018650484],"category_scores_gemma":[0.0012563538,0.00008457244,0.00014814397,0.00029654853,0.0019604168,0.00005978351,0.00007065877,0.0002648133,3.9619817e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015455915,0.0039903237,0.109805,0.00016284118,0.0010036579,0.000022385106,0.0018042129,0.0000068613153,0.41973713,0.000008792039,0.00021059132,0.4477923],"study_design_scores_gemma":[0.027678214,0.029441101,0.27376315,0.00027350785,0.00018738717,0.000014064703,0.0023368855,0.0023283262,0.65744853,0.000090013025,0.0062821163,0.00015672712],"about_ca_topic_score_codex":0.0012396506,"about_ca_topic_score_gemma":0.0026279066,"teacher_disagreement_score":0.44763556,"about_ca_system_score_codex":0.000052894065,"about_ca_system_score_gemma":0.0007919082,"threshold_uncertainty_score":0.7223237},"labels":[],"label_agreement":null},{"id":"W2896410911","doi":"10.1093/annonc/mdy288.113","title":"Study of TBI-1301 (NY-ESO-1 specific TCR gene transduced autologous T lymphocytes) in patients with solid tumors","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cancer research; T-cell receptor; Cytotoxic T cell; Immunology; Epitope; Viral vector; Antigen; Cancer immunotherapy; Genetic enhancement; T cell; Immunotherapy; Immune system; Biology; Gene; In vitro","score_opus":0.0837797317816706,"score_gpt":0.3920301412292962,"score_spread":0.3082504094476256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2896410911","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932715,0.00013742346,0.0000043103273,0.0003927158,0.00012215212,0.0012065792,0.0000120686755,0.000022460037,0.004830743],"genre_scores_gemma":[0.9988892,0.0000956295,0.00017552705,0.00027493315,0.00012629437,0.000033582564,0.00001644619,0.000038509163,0.0003498815],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99755883,0.00027927826,0.0007073803,0.00040531784,0.0005242588,0.0005249085],"domain_scores_gemma":[0.99818355,0.00018128351,0.00024885868,0.0005442812,0.0006899263,0.00015213],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00063683884,0.00020296907,0.0010119566,0.00042712546,0.000037759197,0.000003790026,0.00025241196,0.00016721468,0.0010459754],"category_scores_gemma":[0.00007422367,0.00016459273,0.00008410921,0.0005484042,0.00045726198,0.000053439326,0.000057755722,0.00022708494,0.000027366952],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0357207,0.02508784,0.62511873,0.00015550946,0.00081849546,0.0007674985,0.016054396,0.000035490695,0.08464807,0.000033780187,0.002762161,0.2087973],"study_design_scores_gemma":[0.019957637,0.08545036,0.78665894,0.00007751701,0.000044513148,0.00004152019,0.0010981237,0.000024743056,0.10292849,0.00003552289,0.0034927095,0.00018990085],"about_ca_topic_score_codex":0.00026003455,"about_ca_topic_score_gemma":0.00034031586,"teacher_disagreement_score":0.2086074,"about_ca_system_score_codex":0.00014327058,"about_ca_system_score_gemma":0.00050494383,"threshold_uncertainty_score":0.9998672},"labels":[],"label_agreement":null},{"id":"W2896839095","doi":"10.1002/jcp.27519","title":"Predictive and therapeutic biomarkers in chimeric antigen receptor T‐cell therapy: A clinical perspective","year":2018,"lang":"en","type":"review","venue":"Journal of Cellular Physiology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Institute for Medical Research Development; Tehran University of Medical Sciences and Health Services","keywords":"Chimeric antigen receptor; Medicine; Immunotherapy; Biomarker; Clinical trial; Cell therapy; Adverse effect; Cancer; Immunology; Oncology; Cell; Pharmacology; Internal medicine; Biology","score_opus":0.08719668679768336,"score_gpt":0.4173001961641955,"score_spread":0.3301035093665121,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2896839095","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014593798,0.98260695,0.000020024914,0.00009195676,0.0006371875,0.0012079482,0.000011855601,0.000011562671,0.0008187131],"genre_scores_gemma":[0.0016415422,0.995653,0.00015976759,0.00011082098,0.0018977815,0.00001892719,0.000017572482,0.00010966652,0.0003909359],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9948247,0.0019952592,0.001597044,0.00062708976,0.00043251968,0.0005233562],"domain_scores_gemma":[0.996601,0.0007745794,0.0013355504,0.00049814576,0.0004890121,0.00030169784],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018960704,0.00053670007,0.0036554637,0.00079537544,0.000055274257,0.000020201576,0.00040197768,0.00074192707,0.0010930005],"category_scores_gemma":[0.0001535054,0.00036174475,0.0012715076,0.00061665365,0.00085817365,0.000059615646,0.00011358858,0.0018910171,0.000051575804],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064870403,0.002020004,0.00030600076,0.0033440578,0.009248243,0.00032412983,0.0011595929,2.647231e-7,0.053851373,0.000020131329,0.001407867,0.9218313],"study_design_scores_gemma":[0.0042150854,0.0089112595,0.00093386235,0.0037300754,0.00077464944,0.00045464843,0.00041665445,0.000020829188,0.000361459,0.0003107544,0.9794506,0.00042014336],"about_ca_topic_score_codex":0.000021555843,"about_ca_topic_score_gemma":0.0000011225364,"teacher_disagreement_score":0.9780427,"about_ca_system_score_codex":0.00035850218,"about_ca_system_score_gemma":0.0014214052,"threshold_uncertainty_score":0.9998835},"labels":[],"label_agreement":null},{"id":"W2897377013","doi":"10.3389/fimmu.2018.02380","title":"CAR T Cell Therapy for Neuroblastoma","year":2018,"lang":"en","type":"review","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":156,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Hyundai Hope On Wheels; Sarcoma Alliance for Research through Collaboration; American Association for Cancer Research; Children's Health Research Institute; Stand Up To Cancer; Entertainment Industry Foundation","keywords":"Chimeric antigen receptor; Neuroblastoma; Medicine; Cell therapy; Immunotherapy; Clinical trial; Monoclonal antibody; Targeted therapy; Oncology; T cell; Immunology; Cell; Internal medicine; Antibody; Immune system; Cancer; Biology; Cell culture","score_opus":0.04147406529802984,"score_gpt":0.34212395765616954,"score_spread":0.3006498923581397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897377013","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006365836,0.99001765,0.00038158352,0.000063276064,0.0036104773,0.0035156093,0.000038337465,0.00006535549,0.0022440474],"genre_scores_gemma":[0.0000011189491,0.9723067,0.0025880698,0.00012144159,0.0005495243,0.0007604975,0.00017082982,0.00019332113,0.023308469],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971925,0.00035399274,0.00069288694,0.0007417248,0.00019480666,0.00082408095],"domain_scores_gemma":[0.99828696,0.00021878169,0.00023477108,0.0010481278,0.0001244083,0.00008696214],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00043071577,0.00051215553,0.0026563383,0.00094213965,0.00006486218,0.000018818218,0.0005768507,0.0009320249,0.000623512],"category_scores_gemma":[0.00009316656,0.00042781144,0.0007888134,0.00050041423,0.0004483427,0.000034157947,0.00011305996,0.0009998636,0.0001123891],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006537373,0.00016425265,0.000017015762,0.0034856359,0.000490319,0.000047994374,0.00008313488,3.4176313e-8,0.00013540439,0.000007743723,0.05391037,0.94100434],"study_design_scores_gemma":[0.0024906306,0.0018704077,0.000008922466,0.0014769579,0.00017413081,0.00011940299,0.000034867597,0.00000660492,0.00011235194,0.0000755764,0.9933296,0.00030055293],"about_ca_topic_score_codex":0.000019395318,"about_ca_topic_score_gemma":0.0000031129491,"teacher_disagreement_score":0.9407038,"about_ca_system_score_codex":0.00043656785,"about_ca_system_score_gemma":0.00072705094,"threshold_uncertainty_score":0.9998174},"labels":[],"label_agreement":null},{"id":"W2897385169","doi":"10.2147/ott.s184898","title":"Novel EXO-T vaccine using polyclonal CD4&lt;sup&gt;+&lt;/sup&gt; T cells armed with HER2-specific exosomes for HER2-positive breast cancer","year":2018,"lang":"en","type":"review","venue":"OncoTargets and Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan","funders":"","keywords":"Microvesicles; Polyclonal antibodies; Breast cancer; Medicine; Trastuzumab; Cancer research; Virology; Cancer; Immunology; Antibody; Chemistry; Internal medicine; microRNA; Biochemistry","score_opus":0.05716456505432307,"score_gpt":0.35005826712262816,"score_spread":0.2928937020683051,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2897385169","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0044548507,0.9861975,0.000353317,0.0004991621,0.0005533508,0.005276636,0.0018828326,0.00010488161,0.0006774706],"genre_scores_gemma":[0.00014689114,0.9826492,0.003121238,0.00040158402,0.004258353,0.0005717891,0.00048776125,0.00055064686,0.007812528],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99426425,0.00023282669,0.0011013084,0.0017611579,0.0011174792,0.001522997],"domain_scores_gemma":[0.9963477,0.0004983228,0.0006279718,0.0010411723,0.00075052486,0.0007342869],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0007549826,0.0015328744,0.0038080565,0.00056116044,0.00047941817,0.00022664173,0.000501229,0.00074211846,0.0046196333],"category_scores_gemma":[0.000010424733,0.0010452477,0.00092680665,0.0007481132,0.00043685385,0.00020301725,0.00012935801,0.00090081326,0.00003281578],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005901874,0.0012774601,0.00010937517,0.004655324,0.0036754417,0.00014781546,0.00067755335,0.000004040305,0.014386445,0.00008562876,0.005281485,0.96379757],"study_design_scores_gemma":[0.0078043235,0.0019454749,0.00021033322,0.009913965,0.0006663888,0.001173885,0.000052121923,0.00011929749,0.0005384133,0.000024572251,0.97634965,0.0012015607],"about_ca_topic_score_codex":0.00029902803,"about_ca_topic_score_gemma":0.00011456223,"teacher_disagreement_score":0.9710682,"about_ca_system_score_codex":0.0007555957,"about_ca_system_score_gemma":0.0013474089,"threshold_uncertainty_score":0.999742},"labels":[],"label_agreement":null},{"id":"W2898156792","doi":"10.1093/annonc/mdy424.048","title":"Safety and anti-tumor effects of MAGE-A10c796 TCR T-cells in two clinical trials","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Neutropenia; Fludarabine; Gastroenterology; Leukopenia; Context (archaeology); Cyclophosphamide; Oncology; Surgery; Chemotherapy","score_opus":0.21175907972974456,"score_gpt":0.5512415840560463,"score_spread":0.3394825043263017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898156792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862202,0.0007527589,0.000028564937,0.0022140539,0.00040823768,0.0009134592,0.00001116062,0.0000108230615,0.009440761],"genre_scores_gemma":[0.9931902,0.003445909,0.0003348878,0.0014655895,0.0005003656,0.000010032607,0.0000041424173,0.000021168282,0.0010276837],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9960141,0.0017832745,0.0012999167,0.0003073036,0.0002453023,0.00035006856],"domain_scores_gemma":[0.99338025,0.0053614792,0.0003952292,0.00036812056,0.00031144006,0.00018347282],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009606749,0.00013344771,0.0017533072,0.00023926533,0.000019830257,0.0000033225956,0.00013707225,0.00016896162,0.00088955887],"category_scores_gemma":[0.003810319,0.000108373984,0.0002091992,0.0002491667,0.00085368735,0.000038002807,0.00011501255,0.00033137383,0.00003257162],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008511046,0.0013221544,0.028445393,0.00034520717,0.00024404335,0.00028838284,0.00030054167,5.6568933e-7,0.5970695,0.00016202015,0.0063977423,0.3569134],"study_design_scores_gemma":[0.025759613,0.02252982,0.1421336,0.00033595948,0.0001380695,0.00008440654,0.00009085563,0.000126011,0.6165146,0.0004788042,0.19161038,0.00019789225],"about_ca_topic_score_codex":0.00017850578,"about_ca_topic_score_gemma":0.00010051427,"teacher_disagreement_score":0.35671547,"about_ca_system_score_codex":0.000023409102,"about_ca_system_score_gemma":0.00034030998,"threshold_uncertainty_score":0.97400457},"labels":[],"label_agreement":null},{"id":"W2898361810","doi":"10.1093/annonc/mdy288.029","title":"Initial safety assessment of MAGE-A4 SPEAR T-cells","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Context (archaeology); Internal medicine; Radioimmunotherapy; Oncology; Gastroenterology; Adverse effect; Immunology; Antibody","score_opus":0.1546058658359326,"score_gpt":0.5108487402034521,"score_spread":0.35624287436751945,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2898361810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5746314,0.00007838182,0.00015295148,0.0041877455,0.00030619622,0.00036947615,0.00002462939,0.00001561084,0.4202336],"genre_scores_gemma":[0.9906221,0.0004331273,0.0016609946,0.0013148896,0.00056402193,0.000005899961,0.000013107788,0.00002071301,0.0053651403],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985265,0.00018406968,0.0004335118,0.00019475508,0.0003536112,0.0003075151],"domain_scores_gemma":[0.9985135,0.00023535846,0.00016073129,0.00037024598,0.0005908216,0.0001293208],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009686276,0.00010100647,0.00052008213,0.00016209293,0.000028169548,0.0000025840477,0.00015381059,0.00015761233,0.01286668],"category_scores_gemma":[0.000088568915,0.000089661735,0.00013587218,0.00018557395,0.00056804484,0.000035257304,0.000102554026,0.0002221749,0.000084391744],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022615164,0.0011700522,0.0030255634,0.00012712202,0.0002818735,0.000116743104,0.00045490693,0.0000018907306,0.76124245,0.0008143793,0.025564877,0.20493864],"study_design_scores_gemma":[0.0030214437,0.016797362,0.027468342,0.000055780332,0.000044448363,0.00004760544,0.00016172434,0.00011300887,0.46750686,0.00034502023,0.48433504,0.00010335007],"about_ca_topic_score_codex":0.00012107299,"about_ca_topic_score_gemma":0.000038949005,"teacher_disagreement_score":0.45877016,"about_ca_system_score_codex":0.000053780856,"about_ca_system_score_gemma":0.0006177337,"threshold_uncertainty_score":0.9880357},"labels":[],"label_agreement":null},{"id":"W2899452213","doi":"10.1158/1557-3125.advbc17-a25","title":"Abstract A25: TEM8 specific CAR T cells induce regression of patient-derived xenograft and metastatic models of triple-negative breast cancer","year":2018,"lang":"en","type":"article","venue":"Molecular Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Triple-negative breast cancer; Cancer research; Cancer; Metastasis; Breast cancer; Flow cytometry; Chimeric antigen receptor; In vivo; Biology; Immunology; Medicine; Immunotherapy; Internal medicine","score_opus":0.08494532212698017,"score_gpt":0.3960223410974566,"score_spread":0.31107701897047646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2899452213","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99244124,0.0038480663,0.000079138816,0.000516536,0.000120673634,0.0015896169,0.00026318198,0.000016536662,0.001125004],"genre_scores_gemma":[0.99547946,0.0031283274,0.0004782877,0.000044225413,0.00010660204,0.00019505761,0.000011456317,0.00008052142,0.00047605438],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99558496,0.00043684198,0.0005671326,0.0006340973,0.0020282927,0.0007486496],"domain_scores_gemma":[0.99664456,0.00019403509,0.00020921517,0.0007318678,0.0018527164,0.00036760463],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009577002,0.00027988013,0.0007017155,0.00064041,0.0001342415,0.000032097567,0.0002885392,0.00014030369,0.0027686933],"category_scores_gemma":[0.00007459035,0.00021969741,0.00016101963,0.0011317872,0.0012975233,0.00014324154,0.00024772517,0.00075368467,0.000008922963],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025984873,0.00023545422,0.00033858765,0.00043589793,0.00030911094,0.00009502945,0.0023911244,0.000034662804,0.9604824,0.000033559507,0.00087836734,0.03216731],"study_design_scores_gemma":[0.0026032536,0.0007787754,0.0025804036,0.00088406715,0.000048799768,0.000018054112,0.0010090321,0.000320247,0.99065703,0.00034732465,0.0005719138,0.0001811128],"about_ca_topic_score_codex":0.006788097,"about_ca_topic_score_gemma":0.00021471297,"teacher_disagreement_score":0.031986196,"about_ca_system_score_codex":0.00033442635,"about_ca_system_score_gemma":0.0007917238,"threshold_uncertainty_score":0.9998258},"labels":[],"label_agreement":null},{"id":"W2900183696","doi":"10.1182/blood-2018-99-119086","title":"Efficacy and Safety of a Single Dose of Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Following T-Cell-Depleted Haploidentical HSCT: A Pooled Analysis of Two Phase II Studies","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Juravinski Hospital; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Hematopoietic stem cell transplantation; Graft-versus-host disease; Stem cell; Internal medicine; Immune system; Transplantation; Immunology; T cell; Leukemia; Gastroenterology; Biology","score_opus":0.03347189124600687,"score_gpt":0.3430399669022948,"score_spread":0.30956807565628797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900183696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99674195,0.0015793119,0.00006787298,0.000038869868,0.000042926607,0.000792866,0.00007943997,0.00002467815,0.00063207914],"genre_scores_gemma":[0.99849474,0.00015639904,0.0010466381,0.000020131974,0.000051522362,0.000014601018,0.00002984304,0.00004099094,0.00014511724],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997155,0.00018457853,0.0010750564,0.00044907333,0.0007718847,0.00036440435],"domain_scores_gemma":[0.99685335,0.0009886223,0.0005114571,0.0006153226,0.0008631749,0.00016805253],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006969405,0.0002764758,0.0017379944,0.0007579739,0.000076447424,0.0000070120855,0.00019013797,0.000113898335,0.0001518738],"category_scores_gemma":[0.0007327868,0.00023679032,0.00053795555,0.0016019979,0.0007817216,0.000077630975,0.00022561957,0.00013244242,0.0000011373362],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0062383544,0.008200185,0.0043026283,0.00028874233,0.01808113,0.00002734229,0.0045040934,0.0000040838568,0.9563367,0.00002194952,0.000012385295,0.0019824381],"study_design_scores_gemma":[0.051735643,0.0055968906,0.0036596765,0.00031053036,0.014331642,0.0000062950407,0.0008711207,0.00057458825,0.9226973,0.00003052425,0.000019617879,0.00016618113],"about_ca_topic_score_codex":0.00032769566,"about_ca_topic_score_gemma":0.00009714665,"teacher_disagreement_score":0.045497287,"about_ca_system_score_codex":0.00007972276,"about_ca_system_score_gemma":0.00019083437,"threshold_uncertainty_score":0.96560293},"labels":[],"label_agreement":null},{"id":"W2900391822","doi":"10.2147/dddt.s138765","title":"CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia","year":2018,"lang":"en","type":"review","venue":"Drug Design Development and Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":111,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Cytokine release syndrome; Chimeric antigen receptor; Context (archaeology); Medicine; Oncology; Internal medicine; Immunotherapy; Cancer; Biology","score_opus":0.06862769789823206,"score_gpt":0.32885039219268575,"score_spread":0.26022269429445366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900391822","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0031538457,0.9888503,0.0007121105,0.000042152864,0.0003639463,0.0061812876,0.000026960144,0.00014450992,0.00052489655],"genre_scores_gemma":[0.00005340739,0.95747125,0.0057746423,0.00027475163,0.0004611357,0.0011352854,0.00028235654,0.0003310518,0.034216136],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99564517,0.0004053067,0.0010360274,0.0013053,0.0006625649,0.0009456179],"domain_scores_gemma":[0.9970195,0.0011185677,0.00042174288,0.0007186223,0.00024788346,0.0004736546],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015268752,0.0011346034,0.0024821854,0.0005840969,0.0004059251,0.0001763473,0.00038868334,0.0006532726,0.0005205207],"category_scores_gemma":[0.000035103407,0.0008487454,0.00042491956,0.0004291489,0.00031778397,0.00012293232,0.00009775831,0.0005800917,0.000075945405],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013439057,0.00018148721,0.000007812578,0.0025054319,0.0016376538,0.000049893955,0.0013874675,2.9685317e-8,0.0010898972,0.0000051175493,0.006612908,0.9851784],"study_design_scores_gemma":[0.0084151905,0.0010801473,0.000017838189,0.002647165,0.00035063436,0.00013982334,0.000040801442,0.00001282244,0.00394208,0.00006454978,0.9823734,0.0009155481],"about_ca_topic_score_codex":0.000012217167,"about_ca_topic_score_gemma":0.0000020047094,"teacher_disagreement_score":0.9842628,"about_ca_system_score_codex":0.0007452839,"about_ca_system_score_gemma":0.0033439388,"threshold_uncertainty_score":0.9993963},"labels":[],"label_agreement":null},{"id":"W2900662379","doi":"10.1182/blood-2018-99-112572","title":"Checkpoint Inhibitors Augment CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Relapsed B-Cell Acute Lymphoblastic Leukemia","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":155,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital","funders":"","keywords":"Cytokine release syndrome; Medicine; Chimeric antigen receptor; CD19; T cell; Internal medicine; Immunology; B cell; Blinatumomab; Pembrolizumab; Oncology; Immunotherapy; Antigen; Immune system; Cancer; Antibody","score_opus":0.013840445879683815,"score_gpt":0.26218224226146203,"score_spread":0.24834179638177822,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900662379","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98342204,0.00093408243,0.000008052916,0.00019841989,0.0005128229,0.0013431429,0.000016041498,0.00028974106,0.013275656],"genre_scores_gemma":[0.9824382,0.0016667378,0.001130305,0.00032673808,0.0009934189,0.00012072875,0.00007389964,0.00015990758,0.013090074],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99660677,0.0002074631,0.00068780687,0.00078147027,0.000801508,0.00091501285],"domain_scores_gemma":[0.9982536,0.00011737595,0.00018339693,0.00084302085,0.00022175242,0.0003808749],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00053730723,0.0004459744,0.00067764515,0.00045375485,0.00012662442,0.000047918693,0.00031595572,0.00029028766,0.004308338],"category_scores_gemma":[0.00006238907,0.00039174972,0.00025549278,0.0011720402,0.0002534586,0.00007037296,0.00012225585,0.00050194055,0.0008400789],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012255606,0.0018466482,0.0075185946,0.000054359974,0.00023154332,0.00011142543,0.0010772876,0.0000017993167,0.9815207,0.000001178422,0.0027458076,0.0036651006],"study_design_scores_gemma":[0.02253923,0.0029318272,0.010045999,0.00014740956,0.00010233221,0.00004476732,0.0001204737,0.00019266029,0.9531388,0.000015529005,0.010319346,0.00040161159],"about_ca_topic_score_codex":0.00053586886,"about_ca_topic_score_gemma":0.000046370817,"teacher_disagreement_score":0.02838188,"about_ca_system_score_codex":0.000606096,"about_ca_system_score_gemma":0.00076707057,"threshold_uncertainty_score":0.9999379},"labels":[],"label_agreement":null},{"id":"W2900733038","doi":"10.1182/blood-2018-99-118344","title":"Mosunetuzumab, a Full-Length Bispecific CD20/CD3 Antibody, Displays Clinical Activity in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NHL): Interim Safety and Efficacy Results from a Phase 1 Study","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Medicine; Tolerability; Mantle cell lymphoma; Internal medicine; Follicular lymphoma; CD20; Lymphoma; Gastroenterology; Rituximab; Refractory (planetary science); Adverse effect; Biology","score_opus":0.04516121939774342,"score_gpt":0.3896615740049443,"score_spread":0.34450035460720085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900733038","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922761,0.0002534038,0.00006508209,0.00019554682,0.00044725885,0.0021568697,0.00027664364,0.0001124051,0.004216691],"genre_scores_gemma":[0.9962737,0.00063384307,0.0003036033,0.00007840587,0.0011518796,0.000032748354,0.0001493735,0.00011303908,0.0012634154],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99466276,0.00081062835,0.0013400373,0.0015495789,0.00081435085,0.00082266564],"domain_scores_gemma":[0.99558336,0.0016597278,0.00033867283,0.001658267,0.00018312187,0.0005768627],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0023148265,0.00053373695,0.0012514025,0.0003839487,0.00018354531,0.00009246671,0.00042899884,0.00040756154,0.00069998816],"category_scores_gemma":[0.0007282702,0.00047419002,0.0002488129,0.00064918987,0.00063097634,0.00016563045,0.00045616683,0.0009881973,0.00017501182],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1382599,0.106252044,0.04595418,0.00008220778,0.0008151402,0.0019667118,0.0068077235,6.6473234e-7,0.5339423,0.0000026714722,0.0007901817,0.16512628],"study_design_scores_gemma":[0.3506332,0.03810691,0.57257086,0.00049007405,0.00053266995,0.0001112714,0.0012491171,0.0014337564,0.018804766,0.000014876898,0.015173379,0.0008790983],"about_ca_topic_score_codex":0.0011669255,"about_ca_topic_score_gemma":0.000639182,"teacher_disagreement_score":0.5266167,"about_ca_system_score_codex":0.00021420841,"about_ca_system_score_gemma":0.00041030513,"threshold_uncertainty_score":0.999771},"labels":[],"label_agreement":null},{"id":"W2900935567","doi":"10.1007/978-1-4939-8885-3_2","title":"An Economical, Quantitative, and Robust Protocol for High-Throughput T Cell Receptor Sequencing from Tumor or Blood","year":2018,"lang":"en","type":"article","venue":"Methods in molecular biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Rosetrees Trust; National Institute for Health and Care Research; Cancer Research UK; Francis Crick Institute","keywords":"Biology; Complementary DNA; T-cell receptor; Computational biology; Receptor; DNA sequencing; Immune system; DNA; T cell; Gene; Immunology; Genetics","score_opus":0.12476649692176618,"score_gpt":0.48898686531799096,"score_spread":0.3642203683962248,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900935567","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.41542757,0.000055564105,0.53090876,0.00023750043,0.00012762676,0.05273102,0.000049393824,0.000050034065,0.00041253568],"genre_scores_gemma":[0.00080586853,0.0000069397947,0.95831823,0.00053980696,0.00019899895,0.03982682,0.00003923915,0.000056666497,0.00020743177],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970966,0.0012595075,0.00041439536,0.00072592555,0.000064202,0.00043937884],"domain_scores_gemma":[0.9983806,0.0007437891,0.00011417487,0.00048539683,0.0001266465,0.00014938551],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015441097,0.00021843026,0.00055944896,0.00017062559,0.00006598734,0.000025551064,0.00019057663,0.00021756665,0.001846358],"category_scores_gemma":[0.0006225268,0.00017387538,0.00006493996,0.00016955787,0.00048199235,0.000045565183,0.00009160788,0.00026620502,0.000008843256],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002168697,0.00016115388,0.00068602315,0.0000771811,0.00006992018,0.00002552494,0.00024886796,0.000005184803,0.9893166,0.00090867135,0.00004788239,0.006284313],"study_design_scores_gemma":[0.0056187594,0.0061079655,0.00009157811,0.000048517268,0.000037900645,0.000018046054,0.0001484519,0.0017329162,0.9695404,0.005673498,0.01076237,0.00021956986],"about_ca_topic_score_codex":0.00031489748,"about_ca_topic_score_gemma":0.000073650466,"teacher_disagreement_score":0.42740947,"about_ca_system_score_codex":0.000111470545,"about_ca_system_score_gemma":0.0002465344,"threshold_uncertainty_score":0.9990661},"labels":[],"label_agreement":null},{"id":"W2901026782","doi":"10.1182/blood-2018-99-111061","title":"Comparison of Efficacy and Toxicity of CD19-Specific Chimeric Antigen Receptor T-Cells Alone or in Combination with Ibrutinib for Relapsed and/or Refractory CLL","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Ibrutinib; Medicine; Fludarabine; Internal medicine; Leukapheresis; Neutropenia; Chronic lymphocytic leukemia; Cyclophosphamide; Immunology; Leukemia; Gastroenterology; Toxicity; Chemotherapy; Stem cell; Biology","score_opus":0.05115529306873292,"score_gpt":0.34419640482197367,"score_spread":0.29304111175324077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901026782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99776083,0.00039401455,0.00006245708,0.00012258612,0.000045379642,0.0011977375,0.00001586835,0.00001644407,0.00038469455],"genre_scores_gemma":[0.99568534,0.00048463914,0.00297792,0.000021153804,0.00007063548,0.000017324212,0.000021920516,0.000027769902,0.0006932695],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987566,0.00008219176,0.0003953551,0.00026834046,0.00029171084,0.00020581801],"domain_scores_gemma":[0.9988802,0.00039620916,0.00019288935,0.00026240593,0.00017966972,0.000088628505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045045943,0.00012968354,0.000543562,0.00017668938,0.000039794446,0.0000068509207,0.00007909621,0.00010061207,0.00030917762],"category_scores_gemma":[0.00011423314,0.00009228001,0.00002813564,0.00033047478,0.0002819174,0.00004993808,0.00003454831,0.00014668536,0.000002296868],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01245091,0.0033097495,0.039523486,0.00022642789,0.000094623974,0.0000025383865,0.0012296999,1.7666575e-7,0.93533474,0.000017651446,0.00043324498,0.0073767463],"study_design_scores_gemma":[0.026727235,0.013905569,0.083087765,0.00027576138,0.00006076856,0.000011047416,0.0002424609,0.0000797761,0.8725393,0.000011981917,0.0029281615,0.00013020805],"about_ca_topic_score_codex":0.000029797446,"about_ca_topic_score_gemma":0.00004486473,"teacher_disagreement_score":0.06279548,"about_ca_system_score_codex":0.000021571863,"about_ca_system_score_gemma":0.000094894465,"threshold_uncertainty_score":0.37630695},"labels":[],"label_agreement":null},{"id":"W2901228410","doi":"10.1182/blood-2018-99-110561","title":"Multivariable Modeling of Disease and Treatment Characteristics of Adults with B-ALL in MRD-Negative CR after CD19 CAR-T Cells Identifies Factors Impacting Disease-Free Survival","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Minimal residual disease; Bone marrow; Internal medicine; Fludarabine; Chimeric antigen receptor; Leukemia; Immunotherapy; Oncology; Immunology; Chemotherapy; Cancer; Cyclophosphamide","score_opus":0.030691553626037777,"score_gpt":0.2904626950089509,"score_spread":0.25977114138291313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901228410","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99861354,0.000102769525,0.00003585965,0.00003107408,0.000050640123,0.0006873174,0.00037964422,0.000015635382,0.00008353981],"genre_scores_gemma":[0.99916184,0.00010693294,0.00027883588,0.000008014379,0.00010375797,0.000032952386,0.000033836575,0.000039175764,0.0002346299],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99853265,0.00008054073,0.00034526305,0.0003259783,0.0003993014,0.00031625543],"domain_scores_gemma":[0.9986183,0.00020605598,0.0001279517,0.0004730378,0.0002472949,0.00032736428],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015588947,0.00022028429,0.00046889187,0.00015666641,0.000032998993,0.00001953622,0.00009124637,0.00005072601,0.00015863024],"category_scores_gemma":[0.00023327624,0.0001615172,0.00007748858,0.00015406148,0.00018281485,0.00010338817,0.00008278904,0.000109601126,0.0000011354498],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017254753,0.0024027966,0.8012493,0.0007551608,0.0007571062,0.00017010662,0.012694889,0.00003750719,0.16428442,0.000004517392,0.0000033912634,0.0003860161],"study_design_scores_gemma":[0.021688925,0.0024095357,0.7585842,0.0017446169,0.0012467119,0.0000033633494,0.00300182,0.010721781,0.2000631,0.00009697385,0.000008051268,0.0004309358],"about_ca_topic_score_codex":0.002055971,"about_ca_topic_score_gemma":0.00039424349,"teacher_disagreement_score":0.04266514,"about_ca_system_score_codex":0.00007372645,"about_ca_system_score_gemma":0.00018513932,"threshold_uncertainty_score":0.658648},"labels":[],"label_agreement":null},{"id":"W2901850955","doi":"10.1038/s41591-018-0266-5","title":"Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers","year":2018,"lang":"en","type":"article","venue":"Nature Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":579,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"Horizon 2020 Framework Programme; BC Cancer Foundation; Krebsliga Beider Basel","keywords":"T-cell receptor; CD8; Immune system; Tumor-infiltrating lymphocytes; Cancer research; Cytotoxic T cell; Infiltration (HVAC); Repertoire; T cell; Biology; Pathology; Immunology; Medicine; In vitro","score_opus":0.011790611396794251,"score_gpt":0.3190317624480587,"score_spread":0.3072411510512644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2901850955","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97395146,0.00090326945,0.000003841423,0.0037559485,0.00037745855,0.00046615812,0.0000039245374,0.000019024277,0.020518936],"genre_scores_gemma":[0.9937781,0.000042354808,0.0000673184,0.0013743108,0.0008661462,0.000010932187,0.000005718353,0.000021343412,0.003833785],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985125,0.00009380475,0.00025635058,0.00029879663,0.00055295776,0.0002855884],"domain_scores_gemma":[0.9989509,0.00010970606,0.000095598494,0.00053171196,0.00019807012,0.00011401279],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00081024045,0.00014588772,0.0004313963,0.00014570328,0.000079713565,0.000004296861,0.00015839108,0.00018344657,0.0011267952],"category_scores_gemma":[0.00067913457,0.00008488406,0.000034174078,0.000691019,0.0009000367,0.000047795478,0.000072917144,0.0012609535,9.420823e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00058952265,0.00008563989,0.02050743,0.00019857984,0.00003515713,0.00005662297,0.00082265335,3.3926688e-7,0.9665691,0.00048801245,0.004858501,0.005788419],"study_design_scores_gemma":[0.009596151,0.0028222196,0.21991763,0.0035568862,0.00012689667,0.0004390162,0.0007141692,0.0002873403,0.7170351,0.0013814797,0.04383531,0.0002877859],"about_ca_topic_score_codex":0.001680473,"about_ca_topic_score_gemma":0.00089312735,"teacher_disagreement_score":0.24953401,"about_ca_system_score_codex":0.00024718244,"about_ca_system_score_gemma":0.00027555836,"threshold_uncertainty_score":0.9997863},"labels":[],"label_agreement":null},{"id":"W2902954276","doi":"10.1182/blood-2018-99-119740","title":"Modeling Targeted Lymphodepletion with Radiolabeled CD45 Antibody As a Promising Preparative Regimen Prior to Adoptive Cell Therapy or CAR-T","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Immune system; Medicine; Adoptive cell transfer; Immunology; Cytokine release syndrome; T cell; Bone marrow; Cancer research; Myeloid; Haematopoiesis; Cell therapy; Tumor microenvironment; Transplantation; Stem cell; Chimeric antigen receptor; Internal medicine; Biology","score_opus":0.029191515712546977,"score_gpt":0.3330513123574293,"score_spread":0.30385979664488233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2902954276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879253,0.00037322752,0.0024735027,0.00022915317,0.000050052142,0.0031980115,0.000007742217,0.00017069317,0.0055723162],"genre_scores_gemma":[0.98204255,0.00016331514,0.008771597,0.00036787393,0.00048430514,0.00013119206,0.00004809843,0.00011294954,0.007878146],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99750835,0.00017836857,0.00032471164,0.00071484025,0.0006667142,0.00060699956],"domain_scores_gemma":[0.9982085,0.000065489214,0.000096712036,0.0006254925,0.0006827931,0.00032101694],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043672652,0.00033002978,0.0005322722,0.00022803829,0.0002217202,0.00007037791,0.00018799704,0.00014726982,0.00082050863],"category_scores_gemma":[0.00008385455,0.00022989535,0.000087881024,0.0006880798,0.00011674648,0.000143562,0.000058289614,0.00023169706,0.00010372685],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021093931,0.0008888435,0.00072359137,0.00004042161,0.00043840506,0.00011802477,0.010007528,0.00011131646,0.9645647,0.000008979686,0.0000842447,0.0019200204],"study_design_scores_gemma":[0.026870722,0.015411591,0.00039344613,0.00037558342,0.0002408516,0.0003509694,0.0011801233,0.01825072,0.9344029,0.000028651357,0.0019408826,0.00055354956],"about_ca_topic_score_codex":0.00032197125,"about_ca_topic_score_gemma":0.000047844787,"teacher_disagreement_score":0.030161785,"about_ca_system_score_codex":0.00019695549,"about_ca_system_score_gemma":0.00083253987,"threshold_uncertainty_score":0.937486},"labels":[],"label_agreement":null},{"id":"W2903062212","doi":"10.1056/nejmoa1804980","title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","year":2018,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4044,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Hospital; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Cytokine release syndrome; Neutropenia; Internal medicine; Hematopoietic stem cell transplantation; Diffuse large B-cell lymphoma; Lymphoma; Refractory (planetary science); Transplantation; Gastroenterology; Febrile neutropenia; Rituximab; Clinical endpoint; Oncology; Phases of clinical research; Salvage therapy; Immunology; Immunotherapy; Chimeric antigen receptor; Chemotherapy; Clinical trial; Cancer","score_opus":0.026080307824309687,"score_gpt":0.31679131502515506,"score_spread":0.29071100720084536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2903062212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9785358,0.0011343692,0.00018176284,0.0061293324,0.0008561048,0.00025306985,0.0000025198267,0.000020255358,0.012886796],"genre_scores_gemma":[0.9560993,0.0019952625,0.00042941447,0.0021147795,0.009333962,0.0000017921509,0.0000057874986,0.000053232587,0.029966522],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971784,0.00020520872,0.00083899463,0.00022112305,0.0010601943,0.0004961312],"domain_scores_gemma":[0.99770194,0.0004188839,0.00031383237,0.00038569648,0.000529125,0.0006505487],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017223372,0.00022327877,0.00073845976,0.0005726768,0.000056449244,0.000011279362,0.0002495496,0.00015966807,0.006417438],"category_scores_gemma":[0.0013254345,0.00013386263,0.00010305533,0.0005094261,0.00020932916,0.000118395175,0.00004330706,0.00062612654,0.000063336774],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036082342,0.0044623637,0.01219038,0.00019118816,0.00021492186,0.00664496,0.008884333,4.0701644e-7,0.2546434,0.000059655922,0.08809042,0.5885356],"study_design_scores_gemma":[0.48545104,0.0130687505,0.012230601,0.001114607,0.00014812758,0.0029103225,0.0007313819,0.00012642557,0.0077919206,0.00015239973,0.4760789,0.00019551939],"about_ca_topic_score_codex":0.00019202958,"about_ca_topic_score_gemma":0.0003956351,"teacher_disagreement_score":0.5883401,"about_ca_system_score_codex":0.00024423117,"about_ca_system_score_gemma":0.0006421408,"threshold_uncertainty_score":0.9944908},"labels":[],"label_agreement":null},{"id":"W2903610511","doi":"10.1016/j.ymthe.2018.12.003","title":"The Bumpy Road to CAR Activation","year":2018,"lang":"en","type":"article","venue":"Molecular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Chimeric antigen receptor; Immunotherapy; Scopus; CD28; T cell; Cancer immunotherapy; Cancer research; Biology; T-cell receptor; Cell biology; Immunology; Immune system; Biochemistry; MEDLINE","score_opus":0.0272269844559087,"score_gpt":0.3419275600672362,"score_spread":0.31470057561132747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2903610511","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97840863,0.00033555183,0.00199134,0.007837512,0.00013389433,0.00078058534,8.109726e-7,0.0000632413,0.010448405],"genre_scores_gemma":[0.98132616,0.00020384039,0.0002804371,0.0054514683,0.00043567756,0.0000753013,0.000006677399,0.000053092983,0.01216733],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99878186,0.00008885596,0.00013155259,0.00023196367,0.00044823004,0.00031754415],"domain_scores_gemma":[0.99895835,0.000037787806,0.000025870011,0.00062501896,0.00021357987,0.00013941234],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00031782818,0.00012106758,0.00013213884,0.00007429376,0.00018380035,0.000052341627,0.00018238479,0.00006427573,0.0009796798],"category_scores_gemma":[0.000060633247,0.00008008633,0.000092675764,0.0003339238,0.000109154396,0.000028324615,0.000030968222,0.00015135386,0.00034132012],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006158532,0.00003188685,0.00010258521,0.0000014021939,0.00006508937,0.00000914879,0.00030146257,8.06845e-7,0.7418517,0.00014255049,0.0011271326,0.2557504],"study_design_scores_gemma":[0.000759414,0.0006273851,0.0024899037,0.000012098368,0.0000033958272,0.000007963071,0.0000458233,0.000040623974,0.62820816,0.00014933507,0.36758667,0.00006920928],"about_ca_topic_score_codex":0.00009218904,"about_ca_topic_score_gemma":0.000007702098,"teacher_disagreement_score":0.36645955,"about_ca_system_score_codex":0.00008844748,"about_ca_system_score_gemma":0.00007440804,"threshold_uncertainty_score":0.99993354},"labels":[],"label_agreement":null},{"id":"W2903752946","doi":"10.3390/vaccines7010001","title":"The Modified Vaccination Technique","year":2018,"lang":"en","type":"article","venue":"Vaccines","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Immune system; Antigen; Immunization; Vaccination; Immunology; Antibody; Virology; Medicine","score_opus":0.03333662805329284,"score_gpt":0.34464637864826364,"score_spread":0.3113097505949708,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2903752946","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7219878,0.0010525294,0.007418201,0.022085605,0.0008402439,0.003460562,0.000003914482,0.00060802605,0.24254315],"genre_scores_gemma":[0.9606328,0.00017670776,0.0002481534,0.00020311262,0.0008682828,0.00011484421,0.0000041618605,0.000023616354,0.037728302],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99925196,0.000038618797,0.00013846932,0.00015293372,0.00020592991,0.00021205764],"domain_scores_gemma":[0.9991213,0.000105821746,0.00003121794,0.00040022467,0.000281131,0.00006030722],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00040448733,0.00008272156,0.00010640068,0.000083707586,0.00019182857,0.00003274055,0.00013307971,0.00006236454,0.0018021155],"category_scores_gemma":[0.0001634036,0.000049159662,0.000050966228,0.00032205041,0.000021928152,0.00004458278,0.000044812597,0.00012804638,0.00013745246],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013243061,0.00010832409,0.003299648,0.00004276135,0.000084120955,0.000011973756,0.00022752429,7.77399e-7,0.5908703,0.0037068503,0.032062802,0.36826062],"study_design_scores_gemma":[0.0019198551,0.0008744397,0.08549213,0.00004027219,0.000034789748,0.00013286072,0.000099546596,0.0013930106,0.57147497,0.0035961955,0.33476046,0.00018145752],"about_ca_topic_score_codex":0.000036232555,"about_ca_topic_score_gemma":0.000045822293,"teacher_disagreement_score":0.36807916,"about_ca_system_score_codex":0.000048663864,"about_ca_system_score_gemma":0.000049195187,"threshold_uncertainty_score":0.9991104},"labels":[],"label_agreement":null},{"id":"W2904192212","doi":"10.1182/blood-2018-99-115252","title":"Sustained Disease Control for Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: An Updated Analysis of Juliet, a Global Pivotal Phase 2 Trial of Tisagenlecleucel","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Hospital; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Diffuse large B-cell lymphoma; Medicine; Refractory (planetary science); Lymphoma; Oncology; Phases of clinical research; Clinical trial; Internal medicine; Disease; Biology","score_opus":0.010535377818389088,"score_gpt":0.30110402064912417,"score_spread":0.2905686428307351,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2904192212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937567,0.00003626727,0.00040914153,0.000041160052,0.00006289211,0.0026279078,0.0027286084,0.00004761117,0.00028971935],"genre_scores_gemma":[0.9970337,0.000007038049,0.00021161046,0.00014951389,0.00018362244,0.00009411026,0.0014198341,0.00004744846,0.00085309404],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974159,0.00017807743,0.00061811565,0.00048675155,0.0007817946,0.00051937706],"domain_scores_gemma":[0.99643606,0.00011909005,0.0003628263,0.0008318983,0.0017414874,0.0005086348],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030793052,0.0002666963,0.00089650106,0.0002836883,0.00008173487,0.000016432652,0.00021450827,0.00013278911,0.00062007573],"category_scores_gemma":[0.00043570367,0.0001936304,0.0003455377,0.0011292784,0.00022835616,0.000115140516,0.000050054427,0.00008158444,0.0000030850492],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8097761,0.15327662,0.018254446,0.00016606222,0.004489796,0.000077118515,0.0002690115,5.3643527e-7,0.010938403,0.000030716375,0.0005371974,0.0021839358],"study_design_scores_gemma":[0.94112563,0.030092595,0.011542578,0.000032331245,0.01054061,0.0000011957133,0.00015687298,0.001925835,0.0038729492,0.000012584134,0.00045483056,0.00024195806],"about_ca_topic_score_codex":0.000074142095,"about_ca_topic_score_gemma":0.0001548632,"teacher_disagreement_score":0.1313495,"about_ca_system_score_codex":0.000114993665,"about_ca_system_score_gemma":0.00064505375,"threshold_uncertainty_score":0.78960186},"labels":[],"label_agreement":null},{"id":"W2904522373","doi":"10.1182/bloodadvances.2017014639","title":"CapTCR-seq: hybrid capture for T-cell receptor repertoire profiling","year":2018,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; Calgary Laboratory Services; University of Calgary; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; Terry Fox Foundation; Ontario Ministry of Research and Innovation; Canada Research Chairs; Princess Margaret Cancer Foundation","keywords":"T-cell receptor; Biology; Sanger sequencing; Polymerase chain reaction; Molecular biology; Locus (genetics); Gene; DNA sequencing; genomic DNA; Population; Gene rearrangement; Genetics; T cell","score_opus":0.019576549644762124,"score_gpt":0.3100120321077201,"score_spread":0.290435482462958,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2904522373","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9404412,0.014852545,0.0005802906,0.0020363054,0.001070233,0.0027686378,0.00011008915,0.00031624496,0.037824485],"genre_scores_gemma":[0.81299025,0.0013161957,0.039006267,0.0011630488,0.0048129493,0.00043234424,0.00019386473,0.00017743348,0.13990764],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99832016,0.000033895627,0.00026373184,0.00050120783,0.00037151523,0.0005095075],"domain_scores_gemma":[0.9987728,0.00013285324,0.000087069435,0.00047010134,0.00034705567,0.00019010855],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00027238327,0.00020567779,0.00033633734,0.000091650334,0.0001872613,0.00002896397,0.00017611752,0.00008069843,0.0013058909],"category_scores_gemma":[0.00023100717,0.00016659821,0.00014591552,0.00018193736,0.0002113005,0.00014743968,0.00004482109,0.00022335084,0.00009714461],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00087588764,0.00039005306,0.0040644165,0.0003931677,0.000089500834,0.000034148543,0.0003087285,0.0000015061406,0.957289,0.000084125575,0.005115105,0.0313544],"study_design_scores_gemma":[0.0021435097,0.0007032222,0.000028575687,0.00007312107,0.000060533624,0.000057377758,0.00027004041,0.000059656915,0.6498666,0.00017180941,0.34641176,0.00015379566],"about_ca_topic_score_codex":0.000020878708,"about_ca_topic_score_gemma":0.000022040289,"teacher_disagreement_score":0.34129664,"about_ca_system_score_codex":0.00004834454,"about_ca_system_score_gemma":0.00016573537,"threshold_uncertainty_score":0.999607},"labels":[],"label_agreement":null},{"id":"W2905241205","doi":"10.1182/blood-2018-99-112599","title":"Updated Analysis of the Efficacy and Safety of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed/Refractory (r/r) Acute Lymphoblastic Leukemia","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Sunnybrook Health Science Centre; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Medicine; Clinical endpoint; Internal medicine; Blinatumomab; Peripheral blood mononuclear cell; Oncology; Phases of clinical research; Cytokine release syndrome; Chimeric antigen receptor; Gastroenterology; Clinical trial; Leukemia; Immunotherapy; Lymphoblastic Leukemia; Biology; Cancer","score_opus":0.006299406194958854,"score_gpt":0.23970613893982043,"score_spread":0.23340673274486157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905241205","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9988079,0.00014187905,0.000004921285,0.00001630252,0.000026143674,0.0003733425,0.000032308624,0.000008242428,0.0005889798],"genre_scores_gemma":[0.99923664,0.00032713835,0.00006683567,0.000024883358,0.00003432651,0.00000405099,0.000024818426,0.000018006122,0.00026331117],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988055,0.00007581659,0.00030377373,0.00024176865,0.0003839302,0.00018918332],"domain_scores_gemma":[0.9990482,0.00011085369,0.00014541061,0.00036006217,0.00025297722,0.00008250547],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015574676,0.00012247145,0.00038714925,0.00033590003,0.00003972479,0.0000058381274,0.000097208234,0.00008195384,0.00013550081],"category_scores_gemma":[0.00010706677,0.00007951811,0.000049943847,0.0013402757,0.00023561499,0.000041870306,0.000081272156,0.00013899298,0.0000012624913],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001690709,0.0005011445,0.9865667,0.000051307885,0.0009788601,0.000005931772,0.00062608,0.0000030792776,0.008513245,0.0000040787904,0.000027494156,0.0010313434],"study_design_scores_gemma":[0.014086542,0.00083225715,0.97860396,0.0000461816,0.0032298497,0.000005159485,0.00002622258,0.00017612608,0.0029001168,0.0000024827746,0.000013620668,0.000077493605],"about_ca_topic_score_codex":0.00018899544,"about_ca_topic_score_gemma":0.00025342937,"teacher_disagreement_score":0.012395833,"about_ca_system_score_codex":0.000059218437,"about_ca_system_score_gemma":0.00015390992,"threshold_uncertainty_score":0.32426545},"labels":[],"label_agreement":null},{"id":"W2905385734","doi":"10.1007/978-1-4939-8958-4_4","title":"Monoclonal Antibodies for the Treatment of Melanoma: Present and Future Strategies","year":2018,"lang":"en","type":"review","venue":"Methods in molecular biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Quest University Canada; University of British Columbia","funders":"","keywords":"Ipilimumab; Nivolumab; Monoclonal antibody; Pembrolizumab; Medicine; Melanoma; Antibody; Adverse effect; Immunotherapy; TIGIT; Immunology; Monoclonal; Oncology; Immune system; Internal medicine; Cancer research","score_opus":0.1160249317433525,"score_gpt":0.5236938188093235,"score_spread":0.40766888706597104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905385734","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000040744897,0.96855253,0.028298471,0.00022769645,0.00022225358,0.0022460658,0.000047290825,0.000008057514,0.00035688467],"genre_scores_gemma":[1.9348956e-7,0.8040353,0.19451258,0.000010962646,0.0006240241,0.00037909308,0.000060199898,0.000031344207,0.00034631594],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99755496,0.0011854357,0.00044560852,0.00042593203,0.00008598671,0.00030209104],"domain_scores_gemma":[0.9979159,0.0012650791,0.00015933941,0.00052746607,0.000084045256,0.00004814518],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000932192,0.00031976277,0.001654691,0.00020393208,0.00003774098,0.000011893894,0.00017528128,0.00042560083,0.00010175626],"category_scores_gemma":[0.000056089608,0.00016565232,0.00045411,0.00016778837,0.00055117905,0.000007803137,0.00006527281,0.00018321743,7.573992e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010924149,0.00010294405,0.00001315277,0.002744962,0.0008194027,0.000016760263,0.00014550034,1.03931896e-7,0.0022629988,0.0009988856,0.00003405489,0.992752],"study_design_scores_gemma":[0.000631251,0.0019880827,0.0000119168135,0.00034497227,0.00063134276,0.00007581426,0.00009049881,0.000017947155,0.0013395468,0.0013305257,0.99341327,0.00012480334],"about_ca_topic_score_codex":0.00004714926,"about_ca_topic_score_gemma":0.0000060124157,"teacher_disagreement_score":0.99337924,"about_ca_system_score_codex":0.00007720322,"about_ca_system_score_gemma":0.00026669845,"threshold_uncertainty_score":0.6755105},"labels":[],"label_agreement":null},{"id":"W2905496875","doi":"10.1016/j.biotechadv.2018.12.002","title":"Standardizing CAR-T therapy: Getting it scaled up","year":2018,"lang":"en","type":"review","venue":"Biotechnology Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Health Canada; Jiangnan University; National Natural Science Foundation of China; Six Talent Peaks Project in Jiangsu Province; Natural Science Foundation of Jiangsu Province; Government of Jiangsu Province; University of Pennsylvania; Gilead Sciences","keywords":"CAR T-cell therapy; Production (economics); Cancer therapy; Monoclonal antibody; Key (lock); Computer science; Medicine; Business; Cancer; Immunotherapy; Antibody; Immunology; Internal medicine; Chimeric antigen receptor; Economics","score_opus":0.0709283191270123,"score_gpt":0.4124309006885732,"score_spread":0.3415025815615609,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905496875","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000037486647,0.9919172,0.00015563951,0.0009165134,0.00085339573,0.0017625688,0.000049942006,0.000635829,0.0036714214],"genre_scores_gemma":[0.0000066602415,0.9898939,0.0016360017,0.00016401135,0.0008490614,0.00021136885,0.00006370694,0.00016380985,0.007011457],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963576,0.00019733957,0.0008371684,0.0011002126,0.0005771101,0.00093055086],"domain_scores_gemma":[0.99742955,0.0004007853,0.0004525379,0.0013724038,0.00019495098,0.00014975895],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00085580035,0.00070244825,0.002749561,0.0008186138,0.00026077253,0.00004049738,0.00072762166,0.0019695638,0.0015392418],"category_scores_gemma":[0.0005495807,0.00052517356,0.0007179735,0.0010193448,0.0011309177,0.000111476766,0.0002872514,0.0018194318,0.00029660694],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009832527,0.000038689806,0.0000067551887,0.004151343,0.0004279798,0.00008634969,0.000031484306,2.7019153e-8,0.0003938702,0.00008281552,0.0013864548,0.9932959],"study_design_scores_gemma":[0.0008457293,0.00053857936,3.1510635e-7,0.0087624965,0.0002662442,0.0004162041,0.00009910167,0.0000014678559,0.0023050627,0.00011354887,0.98618144,0.00046982232],"about_ca_topic_score_codex":0.000009488281,"about_ca_topic_score_gemma":0.000013792435,"teacher_disagreement_score":0.9928261,"about_ca_system_score_codex":0.00042097823,"about_ca_system_score_gemma":0.0005571383,"threshold_uncertainty_score":0.99972},"labels":[],"label_agreement":null},{"id":"W2905623501","doi":"10.1016/j.jval.2018.09.154","title":"PCN72 - BUDGET IMPACT ANALYSIS OF TISAGENLECLEUCEL FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN ENGLAND","year":2018,"lang":"en","type":"article","venue":"Value in Health","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Novartis (Canada)","funders":"","keywords":"Medicine; Cytokine release syndrome; Diffuse large B-cell lymphoma; Gemcitabine; Rituximab; Hematopoietic stem cell transplantation; Oncology; Salvage therapy; Internal medicine; Lymphoma; Immunotherapy; Transplantation; Chemotherapy; Cancer; Chimeric antigen receptor","score_opus":0.03206869418140544,"score_gpt":0.34377035954052426,"score_spread":0.3117016653591188,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905623501","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99743354,0.000360654,0.00003213408,0.00014092022,0.000045263132,0.0016894741,0.00022695909,0.0000079882375,0.00006309242],"genre_scores_gemma":[0.9977934,0.0011753836,0.0002088197,0.000094836774,0.000055328204,0.00006914193,0.000084849424,0.00003125481,0.00048702836],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99806124,0.00024631477,0.0005657069,0.00027059088,0.00041397166,0.00044217665],"domain_scores_gemma":[0.99795693,0.000823323,0.00025778578,0.00058245746,0.00023569172,0.00014378167],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005918409,0.00016588237,0.00069190585,0.0005346867,0.00004921497,0.0000049081527,0.00011205435,0.00008195074,0.00018148252],"category_scores_gemma":[0.0001332281,0.00008724827,0.00015807812,0.0011471504,0.000098195145,0.000033625838,0.000014085311,0.000077898796,0.0000016988091],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024265267,0.024054084,0.89654845,0.00043772798,0.001016454,0.0000111657955,0.017125774,0.00011150039,0.0010612481,0.000009209342,0.00010835167,0.035250764],"study_design_scores_gemma":[0.09134347,0.032029554,0.85236156,0.00021570084,0.0003524511,0.000001368645,0.00037472666,0.016662924,0.0024274064,0.000010694277,0.0040737214,0.0001463951],"about_ca_topic_score_codex":0.012720774,"about_ca_topic_score_gemma":0.00490684,"teacher_disagreement_score":0.0670782,"about_ca_system_score_codex":0.0007809467,"about_ca_system_score_gemma":0.0006116747,"threshold_uncertainty_score":0.9938536},"labels":[],"label_agreement":null},{"id":"W2905662036","doi":"10.1016/j.jval.2018.09.253","title":"PCN170 - COST-EFFECTIVENESS OF TISAGENLECLEUCEL IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: A CANADIAN SOCIETAL PERSPECTIVE","year":2018,"lang":"en","type":"article","venue":"Value in Health","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Novartis (Canada)","funders":"","keywords":"Medicine; Salvage therapy; Oncology; Refractory (planetary science); Young adult; Pediatrics; Chemotherapy; Internal medicine","score_opus":0.024353770187356884,"score_gpt":0.31183947846377785,"score_spread":0.28748570827642095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2905662036","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959541,0.00034085242,0.00001151626,0.000111096284,0.00013792035,0.0022184947,0.00005534304,0.00001558753,0.0011550707],"genre_scores_gemma":[0.9981113,0.0009877337,0.00017523857,0.00014472948,0.00010120319,0.00007745593,0.000020372805,0.000051697963,0.0003302556],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975113,0.00049547816,0.0003823698,0.00048343992,0.00046319718,0.00066421565],"domain_scores_gemma":[0.9982753,0.00040742898,0.0001442711,0.0002894063,0.00042850088,0.00045511543],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008679984,0.00020882596,0.0005077674,0.0005851349,0.00009208016,0.000011597152,0.00010721904,0.00017082904,0.000095357325],"category_scores_gemma":[0.00025090636,0.0001720946,0.000042660176,0.00095276075,0.00021637502,0.000095618154,0.000036256246,0.000469744,0.00000976037],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.010269214,0.00082428986,0.97100013,0.0021354551,0.00009215682,0.00025306127,0.011737985,0.00006438167,0.0010235069,0.000078412304,0.0002167419,0.0023046746],"study_design_scores_gemma":[0.01935048,0.007219544,0.96960247,0.0005723894,0.000059203627,0.00004448662,0.0010317242,0.0014300627,0.00034481368,0.000052254716,0.00005526942,0.00023732877],"about_ca_topic_score_codex":0.39269707,"about_ca_topic_score_gemma":0.10184767,"teacher_disagreement_score":0.2908494,"about_ca_system_score_codex":0.0064334353,"about_ca_system_score_gemma":0.0063744998,"threshold_uncertainty_score":0.99925846},"labels":[],"label_agreement":null},{"id":"W2906002519","doi":"10.1016/j.jval.2018.09.260","title":"PCN177 - COST-EFFECTIVENESS OF TISAGENLECLEUCEL FOR ADULTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA : A CANADIAN SOCIETAL PERSPECTIVE","year":2018,"lang":"en","type":"article","venue":"Value in Health","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Novartis (Canada)","funders":"","keywords":"Medicine; Oncology; Salvage therapy; Refractory (planetary science); Quality-adjusted life year; Internal medicine; Cost effectiveness; Chemotherapy; Biology","score_opus":0.05165991619322524,"score_gpt":0.3583497100789593,"score_spread":0.3066897938857341,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2906002519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911834,0.0005685168,0.00015405337,0.00063328526,0.0001583156,0.005071604,0.00021816378,0.00003639216,0.0019762937],"genre_scores_gemma":[0.99655044,0.00018862926,0.0006217659,0.0003993248,0.00018845958,0.00029887067,0.000040742165,0.00008263255,0.0016291366],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9973063,0.00047483965,0.00036573212,0.0005202338,0.0004202594,0.0009126238],"domain_scores_gemma":[0.99755937,0.00072089094,0.00014973081,0.00047641227,0.0005043928,0.0005891878],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017033687,0.00021994609,0.00058382907,0.0003438164,0.00017291211,0.0000114676,0.00015828456,0.00017128339,0.00026115432],"category_scores_gemma":[0.00029908994,0.00017550967,0.000112010086,0.00058568234,0.00022740902,0.00007330203,0.000028422648,0.00025381977,0.000016035621],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3680882,0.058241047,0.06634948,0.03698099,0.001910038,0.0013232366,0.2699591,0.00010020661,0.08165658,0.0075807143,0.01123187,0.09657857],"study_design_scores_gemma":[0.47273576,0.10360597,0.19562292,0.011640069,0.00025411576,0.00044738228,0.05388362,0.025556633,0.04327698,0.0010330362,0.08979118,0.0021523198],"about_ca_topic_score_codex":0.27913168,"about_ca_topic_score_gemma":0.10906063,"teacher_disagreement_score":0.21607548,"about_ca_system_score_codex":0.0035741364,"about_ca_system_score_gemma":0.0062136687,"threshold_uncertainty_score":0.99942017},"labels":[],"label_agreement":null},{"id":"W2906423725","doi":"10.1016/j.jval.2018.09.150","title":"PCN68 - BUDGET IMPACT ANALYSIS OF TISAGENLECLEUCEL FOR THE TREATMENT OF PAEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA IN ENGLAND","year":2018,"lang":"en","type":"article","venue":"Value in Health","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Novartis (Canada)","funders":"","keywords":"Blinatumomab; Medicine; Fludarabine; Population; Leukapheresis; Pediatrics; Internal medicine; Chemotherapy; CD19; Cyclophosphamide; Stem cell","score_opus":0.022785619237043562,"score_gpt":0.32269402317777024,"score_spread":0.29990840394072665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2906423725","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973244,0.0008525275,0.000038155886,0.000075395204,0.000054743225,0.0014703096,0.00014037745,0.0000065358695,0.00003757256],"genre_scores_gemma":[0.9956931,0.003509902,0.00027662766,0.000038616286,0.0000637291,0.000055664917,0.000051734627,0.000026761543,0.00028384928],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99827033,0.00018969688,0.0005337743,0.00027996002,0.00035995973,0.00036627718],"domain_scores_gemma":[0.9980555,0.00094899745,0.00025593655,0.00038781887,0.00020743976,0.00014429817],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005146708,0.00016858571,0.00065395003,0.00064501545,0.00004755147,0.000006294968,0.00008238994,0.00008207571,0.00007725227],"category_scores_gemma":[0.000121560726,0.00009112968,0.000108163455,0.0013242809,0.00012353974,0.000038324266,0.000014695937,0.00009746036,7.747315e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012422695,0.0015101817,0.9593661,0.00031961093,0.0008284427,0.000009124947,0.007013498,0.00030203367,0.0008084503,0.0000024629344,0.000046440564,0.017370986],"study_design_scores_gemma":[0.025830962,0.027595129,0.92174214,0.00013122584,0.0008183977,0.000004177488,0.0001874954,0.022528855,0.00078404375,0.000010169364,0.00024180587,0.00012560008],"about_ca_topic_score_codex":0.013145008,"about_ca_topic_score_gemma":0.0029006153,"teacher_disagreement_score":0.037623934,"about_ca_system_score_codex":0.0007663934,"about_ca_system_score_gemma":0.0006826245,"threshold_uncertainty_score":0.99342656},"labels":[],"label_agreement":null},{"id":"W2906996236","doi":"10.1182/blood-2018-99-116745","title":"Efficacy and Toxicity of JCAR014 in Combination with Durvalumab for the Treatment of Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Durvalumab; Medicine; Fludarabine; Cyclophosphamide; Internal medicine; Tolerability; Combination therapy; Refractory (planetary science); Immunotherapy; Oncology; Gastroenterology; Immunology; Pharmacology; Chemotherapy; Adverse effect; Cancer; Nivolumab; Biology","score_opus":0.01234072366315731,"score_gpt":0.26925204596260044,"score_spread":0.25691132229944313,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2906996236","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974875,0.00023950962,0.000032861604,0.00003896357,0.000020255498,0.0017485095,0.000018861132,0.000006140679,0.00040742],"genre_scores_gemma":[0.9991757,0.00013108851,0.00028061777,0.000012888433,0.000033217573,0.00007242233,0.000019964498,0.000022785733,0.00025129205],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9991082,0.000045451747,0.00018684875,0.00019111365,0.00030548108,0.00016288132],"domain_scores_gemma":[0.9988657,0.0003076008,0.00020568885,0.00029324956,0.00027741102,0.00005030158],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001274621,0.00012200889,0.00027994314,0.000094434305,0.00004274291,0.000005220557,0.000062884465,0.000056752535,0.0000374944],"category_scores_gemma":[0.000038442435,0.00006772049,0.00003440973,0.00016663212,0.00025271837,0.000033713844,0.0000133624835,0.000039478324,7.579654e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043167666,0.058967322,0.6630809,0.0004451727,0.0009987527,0.000030060948,0.009940213,0.0000054408924,0.0853777,0.000028635044,0.000076112105,0.13788205],"study_design_scores_gemma":[0.107334696,0.03961367,0.5694038,0.000200284,0.00025308543,0.000004477629,0.00012755145,0.00009511239,0.2826183,0.000011131813,0.00024667816,0.000091209215],"about_ca_topic_score_codex":0.00008644802,"about_ca_topic_score_gemma":0.00007130193,"teacher_disagreement_score":0.1972406,"about_ca_system_score_codex":0.00006585694,"about_ca_system_score_gemma":0.00010858938,"threshold_uncertainty_score":0.27615613},"labels":[],"label_agreement":null},{"id":"W2907052423","doi":"10.1182/blood-2018-99-111528","title":"Immunotherapy with T-Cells Engineered with a Chimeric Antigen Receptor Bearing a Human CD19-Binding Single Chain Variable Fragment for Relapsed or Refractory Acute Lymphoblastic Leukemia and B-Cell Non-Hodgkin Lymphoma","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Fludarabine; Medicine; Cyclophosphamide; Bone marrow; Immunology; CD8; Leukemia; Antigen; Chimeric antigen receptor; Immunotherapy; Lymphoma; Cancer research; Internal medicine; Immune system; Chemotherapy","score_opus":0.012418857225724647,"score_gpt":0.24743296599175882,"score_spread":0.23501410876603418,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907052423","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928588,0.00021247166,0.0031162868,0.000029318611,0.000117137686,0.0019412244,0.000030440764,0.00014337832,0.0015509265],"genre_scores_gemma":[0.9496792,0.00016189183,0.03347859,0.00012958057,0.0005304532,0.00030031145,0.00007672526,0.0002999143,0.01534335],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99737716,0.000059382208,0.0004093565,0.00074996636,0.0005421262,0.0008619824],"domain_scores_gemma":[0.9984244,0.00020645976,0.00020278805,0.0006764738,0.00020096946,0.00028888698],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00046308595,0.0004744596,0.00069158146,0.00033384893,0.0003691507,0.000114996066,0.0002302208,0.00020788371,0.00060782616],"category_scores_gemma":[0.000023572866,0.00035084196,0.00008332429,0.00059806503,0.0002382924,0.00014174641,0.00006926716,0.0002104494,0.000021924989],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006232619,0.0012315346,0.0005996522,0.00022358725,0.0009562001,0.00005452689,0.0012294976,0.000007977297,0.9872093,0.0000065268405,0.00015022716,0.0020983485],"study_design_scores_gemma":[0.050856978,0.0220791,0.0007823139,0.00075264124,0.00047102224,0.0002593478,0.0002878608,0.0007290192,0.9169617,0.000006175043,0.006153681,0.0006601518],"about_ca_topic_score_codex":0.0001474904,"about_ca_topic_score_gemma":0.00002230113,"teacher_disagreement_score":0.0702476,"about_ca_system_score_codex":0.00050744053,"about_ca_system_score_gemma":0.00064729946,"threshold_uncertainty_score":0.9998944},"labels":[],"label_agreement":null},{"id":"W2907079093","doi":"10.1182/blood-2018-99-110429","title":"Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Spinal Cord Injury BC; University Health Network","funders":"","keywords":"CHOP; Medicine; Alemtuzumab; Internal medicine; Clinical endpoint; Interim analysis; Peripheral T-cell lymphoma; Lymphoma; Randomized controlled trial; Surgery; Oncology; Transplantation; Immunology; Immune system; T cell","score_opus":0.011782559397960343,"score_gpt":0.2600723246321082,"score_spread":0.24828976523414786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907079093","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942707,0.00030948702,0.00010703082,0.000037000606,0.000023387724,0.004775634,0.00013124858,0.00005164424,0.0002939006],"genre_scores_gemma":[0.996654,0.00009876806,0.00009075546,0.00007144484,0.00003934748,0.00022713881,0.00012812376,0.00007837837,0.0026120648],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99685115,0.00046324145,0.00076778873,0.0006251952,0.0007715803,0.00052104215],"domain_scores_gemma":[0.9982238,0.0001874609,0.00044317712,0.0006558515,0.00029670203,0.00019303845],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044679188,0.00048993714,0.0022979567,0.0003093322,0.00010015319,0.000041147003,0.00022058956,0.00018627144,0.0005184474],"category_scores_gemma":[0.0000066995544,0.00023258747,0.00018148376,0.0009682578,0.0007730526,0.000085678184,0.00001852674,0.00022115592,0.0000014059927],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9338173,0.0057292692,0.03230419,0.00020566629,0.0035182121,0.000076831086,0.004066386,0.0000053125664,0.019837381,3.1058187e-7,0.000014040513,0.00042509308],"study_design_scores_gemma":[0.92360973,0.00883324,0.0009551554,0.00041409963,0.0062868507,0.00017854777,0.00035232512,0.0016344779,0.057402764,2.0775256e-7,0.000014758259,0.00031786368],"about_ca_topic_score_codex":0.0004761184,"about_ca_topic_score_gemma":0.00031434651,"teacher_disagreement_score":0.03756538,"about_ca_system_score_codex":0.00012604207,"about_ca_system_score_gemma":0.00046464454,"threshold_uncertainty_score":0.94846416},"labels":[],"label_agreement":null},{"id":"W2907883664","doi":"10.1182/blood-2018-99-117333","title":"Obinutuzumab Plus Gemcitabine, Dexamethasone and Cisplatin (O-GDP) As Salvage Chemotherapy Prior to Autologous Stem Cell Transplant in Aggressive B Cell Lymphoma","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University Health Network; University of Toronto; BC Cancer Agency; Simon Fraser University; Princess Margaret Cancer Centre","funders":"","keywords":"Obinutuzumab; Medicine; Rituximab; Internal medicine; Oncology; Salvage therapy; Follicular lymphoma; Gemcitabine; Chemotherapy regimen; Autologous stem-cell transplantation; Regimen; Aggressive lymphoma; Lymphoma; Chemotherapy; Surgery","score_opus":0.01397642299068248,"score_gpt":0.27317063032083616,"score_spread":0.2591942073301537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2907883664","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98482174,0.0015758708,0.00009064739,0.00040847136,0.00011663041,0.0015980562,0.000036865033,0.00010957692,0.011242128],"genre_scores_gemma":[0.9862913,0.0005238869,0.0021022866,0.00083926873,0.00027274757,0.00010178166,0.00001576133,0.00011190299,0.009741055],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99716014,0.00015160782,0.00048604066,0.00078449765,0.00058422575,0.000833467],"domain_scores_gemma":[0.9983144,0.0002735478,0.00016020522,0.0006618062,0.00013319762,0.00045686506],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00045345887,0.00040558062,0.0007463313,0.00038583975,0.00011163518,0.000055819386,0.00027612527,0.00029481578,0.0009782028],"category_scores_gemma":[0.000034692912,0.00036606746,0.00011601174,0.00057698693,0.00021955499,0.00007503258,0.00007761782,0.00031002486,0.0002278498],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006154206,0.0017896907,0.006553131,0.0005187105,0.0002018527,0.0029860034,0.017137896,0.0000057420707,0.8269645,0.00003396581,0.00064970925,0.13700461],"study_design_scores_gemma":[0.05326263,0.0048516397,0.030376062,0.00049498543,0.00020895322,0.0011366749,0.0005956533,0.00041736962,0.9021754,0.000058166363,0.005728878,0.00069356646],"about_ca_topic_score_codex":0.00048324172,"about_ca_topic_score_gemma":0.00021305917,"teacher_disagreement_score":0.13631105,"about_ca_system_score_codex":0.0003534723,"about_ca_system_score_gemma":0.0006239462,"threshold_uncertainty_score":0.99993503},"labels":[],"label_agreement":null},{"id":"W2908110248","doi":"10.1016/j.imbio.2018.12.003","title":"Enhancing the pro-inflammatory anti-cancer T cell response via biomanufactured, secretome-based, immunotherapeutics","year":2018,"lang":"en","type":"article","venue":"Immunobiology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Blood Services; University of British Columbia","funders":"Canadian Institutes of Health Research; Health Canada; Canadian Blood Services","keywords":"CD8; Peripheral blood mononuclear cell; Biology; Cancer research; Cancer; HeLa; Cell growth; T cell; Immunology; Cancer cell; Cytotoxic T cell; Melanoma; Cell; In vitro; Immune system; Biochemistry","score_opus":0.021087395476401625,"score_gpt":0.3203290674038167,"score_spread":0.2992416719274151,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908110248","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899188,0.005036535,0.00047691647,0.001716166,0.00076040026,0.0010194108,0.000019838406,0.00014438225,0.00090754445],"genre_scores_gemma":[0.99002475,0.00047955196,0.00017825459,0.0023626082,0.0005692433,0.00013868327,0.000033145592,0.00009160605,0.0061221626],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972818,0.0006747885,0.00050648814,0.0004711539,0.00027384603,0.0007919053],"domain_scores_gemma":[0.9976361,0.000557019,0.0001814982,0.0012223198,0.0003065631,0.000096498465],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015249074,0.0003358799,0.00046163885,0.00016378633,0.0003347798,0.000037632097,0.0004932836,0.00036539036,0.00915386],"category_scores_gemma":[0.0000623473,0.00022306135,0.00021559106,0.0002720691,0.0011089838,0.00006482559,0.00012964118,0.0005355227,0.0004935484],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008021231,0.00010484007,0.0015149959,0.000059743736,0.00018207457,0.000019205241,0.00078534894,0.0000017904224,0.9823583,0.000005235804,0.00018451594,0.0067627286],"study_design_scores_gemma":[0.0026934934,0.0010635505,0.0073620537,0.00004853381,0.00005468132,0.00007351686,0.00022172417,0.00007692883,0.86412776,0.000022259248,0.12402957,0.00022595606],"about_ca_topic_score_codex":0.00022834261,"about_ca_topic_score_gemma":0.00008342541,"teacher_disagreement_score":0.123845056,"about_ca_system_score_codex":0.0003489613,"about_ca_system_score_gemma":0.0006059313,"threshold_uncertainty_score":0.9917519},"labels":[],"label_agreement":null},{"id":"W2908201785","doi":"10.1182/blood-2018-99-115123","title":"Age Subgroup Analysis of Health-Related Quality of Life of Blinatumomab Versus Standard-of-Care Chemotherapy in Patients with Relapsed or Refractory Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label, Phase 3 Study (TOWER)","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Blinatumomab; Medicine; Internal medicine; Minimal residual disease; Chemotherapy; Gastroenterology; Oncology; Leukemia; Immunology; Surgery; Lymphoblastic Leukemia","score_opus":0.04176677496032077,"score_gpt":0.36662445671732125,"score_spread":0.32485768175700047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908201785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99285185,0.0005624799,0.000010594595,0.0000397546,0.00006081984,0.0058671115,0.00035398264,0.000016001995,0.00023743101],"genre_scores_gemma":[0.9990737,0.00017083572,0.00032703456,0.000019885878,0.000013611289,0.00011472676,0.00014229323,0.00006207222,0.00007587812],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.993246,0.0016176542,0.0026708667,0.00065246044,0.0013623754,0.0004505986],"domain_scores_gemma":[0.99421346,0.0014966342,0.002024231,0.00096056564,0.0011093903,0.00019570506],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0029659353,0.00038768092,0.0045246715,0.0012642738,0.000041645853,0.0000112842245,0.00049630884,0.00020955043,0.00058917736],"category_scores_gemma":[0.0011595932,0.0002933005,0.00023477525,0.0038271223,0.00075611845,0.00015725032,0.00014066676,0.0004007079,8.350173e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91686237,0.026980082,0.020830674,0.0006127625,0.008341796,0.00003440769,0.017464953,0.000012290575,0.008104029,0.0000039502715,0.000011700619,0.00074098987],"study_design_scores_gemma":[0.890752,0.06238331,0.024199205,0.0005903901,0.002147817,4.4177693e-7,0.0020033326,0.00013464419,0.01753373,0.000007927434,0.0000030454578,0.00024411206],"about_ca_topic_score_codex":0.0020527728,"about_ca_topic_score_gemma":0.0017452844,"teacher_disagreement_score":0.03540323,"about_ca_system_score_codex":0.0007582626,"about_ca_system_score_gemma":0.0026205361,"threshold_uncertainty_score":0.9999519},"labels":[],"label_agreement":null},{"id":"W2908342487","doi":"10.1182/blood-2018-99-118569","title":"T Cells Engineered with a Novel Chimeric Receptor Demonstrate Durable In Vivo Efficacy Against Disseminated Multiple Myeloma","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Chimeric antigen receptor; Multiple myeloma; Cancer research; Immunotherapy; In vivo; T cell; Medicine; Cytokine; Immunology; Biology; Immune system","score_opus":0.013051482795145466,"score_gpt":0.2546756408468227,"score_spread":0.24162415805167725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908342487","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922513,0.000081832484,0.00005387198,0.00012703807,0.00008139811,0.0008675959,0.000036593916,0.000126654,0.0063737407],"genre_scores_gemma":[0.99145246,0.00008153047,0.0026575103,0.000052322142,0.00021212662,0.000075483804,0.00003120842,0.00007819413,0.0053591845],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99828494,0.00003867399,0.0002894264,0.00042685826,0.00036384523,0.000596238],"domain_scores_gemma":[0.9989196,0.00015779545,0.00006267121,0.00046721418,0.00014167499,0.00025100991],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00022258711,0.00025296822,0.00038484955,0.00023795279,0.00006866242,0.000031508724,0.00017021272,0.0001265809,0.001524358],"category_scores_gemma":[0.000116086834,0.00020628245,0.000069810616,0.0009414737,0.00018160597,0.000069541034,0.00003979219,0.0003353936,0.000110446024],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00080472615,0.001695167,0.008843188,0.000052332212,0.00014244353,0.00004930212,0.00041328548,0.00000937935,0.9841236,0.000002091311,0.00028506268,0.0035794566],"study_design_scores_gemma":[0.012765415,0.0009177863,0.01375037,0.00029867757,0.000050207585,0.000044045773,0.00013234532,0.00073376426,0.967846,6.706239e-7,0.0032086899,0.00025205777],"about_ca_topic_score_codex":0.00007174608,"about_ca_topic_score_gemma":0.000099541976,"teacher_disagreement_score":0.016277594,"about_ca_system_score_codex":0.00006021027,"about_ca_system_score_gemma":0.0001507285,"threshold_uncertainty_score":0.9993884},"labels":[],"label_agreement":null},{"id":"W2908403203","doi":"10.1182/blood-2018-99-115593","title":"High Vs. Low-Intensity Bridging Chemotherapy in Children with Acute Lymphoblastic Leukemia Awaiting Chimeric Antigen Receptor T-Cell Therapy: A Population-Based Study from Ontario, Canada","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Children's Hospital of Eastern Ontario; London Health Sciences Centre; McMaster University; McMaster Children's Hospital; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Medicine; Chimeric antigen receptor; Population; Chemotherapy regimen; Neutropenia; Regimen; Contraindication; Internal medicine; Pediatrics; Cytokine release syndrome; Chemotherapy; Immunotherapy; Cancer; Pathology","score_opus":0.007779938623790587,"score_gpt":0.22598578685935888,"score_spread":0.2182058482355683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908403203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978842,0.000049757302,0.000027987846,0.00014883859,0.00011730822,0.0015562965,0.000030666062,0.000080830425,0.000104130086],"genre_scores_gemma":[0.99717593,0.0000145770455,0.000599062,0.0009411119,0.0004884416,0.000039984436,0.00024645397,0.000102585676,0.00039184818],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973874,0.000101843296,0.00041215634,0.0007030615,0.0007761922,0.00061935413],"domain_scores_gemma":[0.9986916,0.00008701913,0.00017095546,0.00063533586,0.00019680106,0.00021828886],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002309,0.00037715732,0.0006762126,0.000185905,0.00018379028,0.000056812925,0.00024336945,0.00009439986,0.002120573],"category_scores_gemma":[0.0000214921,0.00032363355,0.0000754968,0.0005300355,0.00006671064,0.000069654896,0.000039114842,0.00039145566,0.000014496487],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022238637,0.0009769298,0.9628885,0.0000059329323,0.00074159226,0.00008415282,0.00064439647,0.000029512428,0.03089357,1.5685849e-7,0.00011445743,0.001396976],"study_design_scores_gemma":[0.02090288,0.0012766068,0.9238458,0.00011584145,0.00011867403,0.000024132061,0.0000799785,0.00028944266,0.052971292,0.000002298951,0.000043271226,0.0003297529],"about_ca_topic_score_codex":0.98266923,"about_ca_topic_score_gemma":0.89998835,"teacher_disagreement_score":0.08268088,"about_ca_system_score_codex":0.0014723411,"about_ca_system_score_gemma":0.003215038,"threshold_uncertainty_score":0.99992156},"labels":[],"label_agreement":null},{"id":"W2908417681","doi":"10.1182/blood-2018-99-115126","title":"Factors Impacting Progression-Free Survival after CD19-Specific CAR-T Cell Therapy for Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Fludarabine; Internal medicine; Cyclophosphamide; Oncology; Non-Hodgkin's lymphoma; Lymphoma; Aggressive lymphoma; Immunology; Chemotherapy; Gastroenterology; Rituximab","score_opus":0.03312583949626026,"score_gpt":0.3160237853105035,"score_spread":0.28289794581424327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908417681","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853195,0.00367266,0.00007533956,0.00015367517,0.00091720367,0.0023704823,0.00010634037,0.00017241726,0.0072123725],"genre_scores_gemma":[0.9888477,0.0008027164,0.0011831996,0.00014308645,0.002401545,0.000349222,0.00007697476,0.00026027326,0.005935337],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9959425,0.00018538175,0.00058451167,0.0009304124,0.001135574,0.0012216701],"domain_scores_gemma":[0.9961245,0.0007204759,0.00044468217,0.001573337,0.0005776972,0.00055930804],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007236074,0.0006156293,0.00077141944,0.00032307373,0.0003278207,0.00010014016,0.000584863,0.00042900763,0.002465098],"category_scores_gemma":[0.0002152019,0.0004593686,0.00050610123,0.0004277744,0.00030570728,0.00020289874,0.00020742405,0.00044922638,0.00010310499],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0087577095,0.006651881,0.09624094,0.00031360865,0.00049811456,0.00030930561,0.0053964606,2.443236e-7,0.8163115,0.0000048313354,0.0051548807,0.06036056],"study_design_scores_gemma":[0.04051676,0.006978761,0.053967297,0.00037752677,0.00016758198,0.000043833188,0.0009994276,0.00002111741,0.84489733,0.00010409449,0.051146038,0.0007802172],"about_ca_topic_score_codex":0.0000601589,"about_ca_topic_score_gemma":0.000022390252,"teacher_disagreement_score":0.05958034,"about_ca_system_score_codex":0.00021380544,"about_ca_system_score_gemma":0.0004532954,"threshold_uncertainty_score":0.9997858},"labels":[],"label_agreement":null},{"id":"W2908444719","doi":"10.1111/trf.15121","title":"Leukoreduction system chambers are a reliable cellular source for the manufacturing of T‐cell therapeutics","year":2018,"lang":"en","type":"article","venue":"Transfusion","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Université de Montréal; Héma-Québec; Hôpital Maisonneuve-Rosemont","funders":"Canadian Donation and Transplantation Research Program","keywords":"Leukoreduction; Peripheral blood mononuclear cell; Leukapheresis; Immunology; T cell; Medicine; Immune system; Cytotoxic T cell; Transplantation; Immunotherapy; Biology; CD34; Blood transfusion; Stem cell; In vitro; Internal medicine","score_opus":0.03251321626058433,"score_gpt":0.27810157513417905,"score_spread":0.2455883588735947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908444719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97890186,0.00043157907,0.016349759,0.0005603954,0.00032763308,0.0013515988,0.0000047782946,0.000075569806,0.0019968173],"genre_scores_gemma":[0.9917614,0.00030573813,0.0004040303,0.00006683954,0.00038532508,0.00004036921,0.0000065527024,0.000046935933,0.006982843],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99891126,0.000033393735,0.0002262563,0.00022307108,0.00034700855,0.0002589878],"domain_scores_gemma":[0.9992406,0.000089302725,0.00007222166,0.00041277695,0.00012656474,0.000058528218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040395345,0.00012946913,0.00022237044,0.000064967724,0.00025019445,0.000016476006,0.00011242405,0.00010678354,0.0002994408],"category_scores_gemma":[0.000003173738,0.00008684134,0.00015640675,0.00012481581,0.0001703071,0.000034813296,0.000012797064,0.00017170834,0.000014022593],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013183614,0.000081642545,0.00017211825,0.000644009,0.000071216826,0.0000018987066,0.0024465467,0.00006082208,0.98237264,0.000013615852,0.00014344118,0.012673667],"study_design_scores_gemma":[0.0016059726,0.00052279566,0.0002842052,0.00018529728,0.00015597264,0.000020503145,0.0028607768,0.005773062,0.94338435,0.000008737158,0.04511473,0.00008362457],"about_ca_topic_score_codex":0.00026949323,"about_ca_topic_score_gemma":0.000023506032,"teacher_disagreement_score":0.04497129,"about_ca_system_score_codex":0.00010248942,"about_ca_system_score_gemma":0.00005536692,"threshold_uncertainty_score":0.35412872},"labels":[],"label_agreement":null},{"id":"W2908870872","doi":"10.1016/j.bulcan.2018.12.001","title":"Prise en charge pratique du syndrome de relargage des cytokines (CRS) post-CAR-T cells chez l’adulte et l’enfant : recommandation de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC)","year":2019,"lang":"fr","type":"review","venue":"Bulletin du Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Sanofi Pasteur; Gilead Sciences; Meso Scale Diagnostics; Sanofi; Astellas Pharma; Astellas Pharma US; Pfizer","keywords":"Medicine","score_opus":0.017368712495199064,"score_gpt":0.3293118334841755,"score_spread":0.3119431209889764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2908870872","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.19750743,0.7704178,0.0021326842,0.011005018,0.002023108,0.0069498946,0.0011528771,0.0003656939,0.008445499],"genre_scores_gemma":[0.020369163,0.9348146,0.003204047,0.0037031418,0.0027783525,0.002196357,0.0006180922,0.0007299483,0.031586308],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98310757,0.009706651,0.0016303493,0.0015675882,0.0010821053,0.0029057385],"domain_scores_gemma":[0.9910054,0.004650149,0.001074226,0.0014613545,0.00066554296,0.0011433214],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.014328401,0.0016240021,0.0030799871,0.00048987987,0.0005315284,0.00032678482,0.001248052,0.0024814764,0.050514724],"category_scores_gemma":[0.0019129928,0.0015652135,0.0011904389,0.0008570346,0.0006638449,0.00017627714,0.0005246703,0.0044826544,0.0013646962],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0032532737,0.003633081,0.018729895,0.10699019,0.0053192335,0.0069750994,0.055595577,0.0009770276,0.27914837,0.0008853162,0.11475739,0.40373555],"study_design_scores_gemma":[0.0049923067,0.00074840826,0.004161227,0.021417791,0.0012243913,0.0027176652,0.0004663889,0.00081587164,0.009929598,0.00007429781,0.9519913,0.0014607077],"about_ca_topic_score_codex":0.00940934,"about_ca_topic_score_gemma":0.00049661094,"teacher_disagreement_score":0.83723396,"about_ca_system_score_codex":0.009010804,"about_ca_system_score_gemma":0.013355486,"threshold_uncertainty_score":0.9996507},"labels":[],"label_agreement":null},{"id":"W2910040477","doi":"10.1038/s41408-018-0168-2","title":"Humanized anti-CD123 antibody facilitates NK cell antibody-dependent cell-mediated cytotoxicity (ADCC) of Hodgkin lymphoma targets via ARF6/PLD-1","year":2019,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Antibody-dependent cell-mediated cytotoxicity; Cytotoxicity; Cancer research; Antibody; Monoclonal antibody; Cell culture; Chemistry; Biology; Immunology; In vitro","score_opus":0.015420752743249182,"score_gpt":0.30757546229849314,"score_spread":0.292154709555244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2910040477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852248,0.008848909,0.00022324173,0.00023393461,0.0008309888,0.0011947674,0.00019446634,0.00008557443,0.0031633268],"genre_scores_gemma":[0.9838683,0.008619896,0.00033449195,0.00023818965,0.0006556879,0.000021045253,0.000112095855,0.00013310435,0.006017176],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9944257,0.00037620842,0.0012393666,0.00074492896,0.0019583043,0.0012554671],"domain_scores_gemma":[0.9966828,0.00026070196,0.0007179352,0.0008221128,0.0008227704,0.00069367024],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00136514,0.0005991487,0.0014426707,0.00060351874,0.00024472954,0.00011270428,0.0006580554,0.00034507082,0.014728283],"category_scores_gemma":[0.000085178086,0.0005181312,0.00057475345,0.0006274333,0.00023352052,0.00028922598,0.00019903707,0.0010479752,0.00032641483],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010545262,0.0016315221,0.108735986,0.0006403799,0.0005384283,0.0004398767,0.0007480285,0.00004469523,0.8845309,0.000002282208,0.00049611315,0.0011372792],"study_design_scores_gemma":[0.022638975,0.0016903968,0.055517755,0.00041358895,0.00036987665,0.00058778026,0.0004574669,0.00037143956,0.91444826,0.00005230041,0.0028766966,0.00057547796],"about_ca_topic_score_codex":0.0007059641,"about_ca_topic_score_gemma":0.000036218808,"teacher_disagreement_score":0.05321823,"about_ca_system_score_codex":0.0003632189,"about_ca_system_score_gemma":0.0010796767,"threshold_uncertainty_score":0.999727},"labels":[],"label_agreement":null},{"id":"W2910164268","doi":"10.1158/1078-0432.ccr-18-0432","title":"CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors","year":2019,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":672,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; National Institutes of Health; Deutsche Krebshilfe","keywords":"Cancer; Antigen; Medicine; Cancer research; Solid tumor; Pathology; Immunology; Internal medicine","score_opus":0.14806278979406062,"score_gpt":0.49720794026348103,"score_spread":0.3491451504694204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2910164268","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98533994,0.003253832,0.000011214311,0.005847967,0.0007036951,0.0028150387,0.00008756288,0.00011041553,0.0018303266],"genre_scores_gemma":[0.9643725,0.023320084,0.0001365617,0.0008407559,0.0028754768,0.00029052596,0.00001821236,0.00015300633,0.007992871],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9897418,0.0021695541,0.0016056048,0.0019224073,0.0024334837,0.0021271661],"domain_scores_gemma":[0.99078,0.005341197,0.000333242,0.0011309152,0.00097449234,0.0014401298],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0120682465,0.000493136,0.0016050391,0.0004776772,0.00036345836,0.00018081201,0.0006691451,0.00059570256,0.0033313602],"category_scores_gemma":[0.0026596524,0.00042389758,0.0005544425,0.001371895,0.0011931608,0.0002350091,0.00082770333,0.004511038,0.00035074525],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004396376,0.00085009594,0.6721124,0.0007020161,0.00024655715,0.00032217364,0.00018414264,0.00004701467,0.19367912,0.00000780114,0.01127073,0.11618153],"study_design_scores_gemma":[0.018024659,0.006515795,0.8512455,0.0014247593,0.00021923435,0.0000481983,0.0009443463,0.0068663,0.07905229,0.0002894633,0.033522423,0.0018469803],"about_ca_topic_score_codex":0.0011319362,"about_ca_topic_score_gemma":0.0002001922,"teacher_disagreement_score":0.17913312,"about_ca_system_score_codex":0.00051293004,"about_ca_system_score_gemma":0.0030548908,"threshold_uncertainty_score":0.9998213},"labels":[],"label_agreement":null},{"id":"W2910406726","doi":"10.1182/blood-2018-99-113516","title":"Somatic PRAME Deletions Are Associated with Decreased Immunogenicity, Apoptosis Resistance and Poor Outcomes in Diffuse Large B-Cell Lymphoma","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Spinal Cord Injury BC","funders":"","keywords":"Diffuse large B-cell lymphoma; Lymphoma; Oncology; Population; Internal medicine; Biology; Immunology; Cancer research; Medicine","score_opus":0.013721261010528483,"score_gpt":0.26497802880941534,"score_spread":0.25125676779888684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2910406726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996366,0.0004050432,0.000015440224,0.00068707066,0.000019740519,0.0006448495,0.000048876187,0.00008058059,0.0017323954],"genre_scores_gemma":[0.99410313,0.00006474696,0.00039642092,0.00031110182,0.000037515605,0.0000786286,0.00003146765,0.00004886627,0.0049281204],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983284,0.00013937471,0.0002798291,0.0003237712,0.00044123366,0.00048737862],"domain_scores_gemma":[0.99881566,0.00026421726,0.000125649,0.00043228577,0.00018042803,0.00018178114],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033798546,0.0002008985,0.0004544968,0.00018148492,0.00013930004,0.000047746034,0.00013275011,0.00012667393,0.00016491197],"category_scores_gemma":[0.0004622083,0.00016163234,0.0000738559,0.00044037783,0.00015703509,0.00006527662,0.00007199464,0.00014782543,0.000024429883],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008566976,0.02665782,0.8813909,0.00017868938,0.00064965704,0.00010536197,0.0007426161,3.3587135e-8,0.088935964,0.0000344857,0.00022562132,0.00022212337],"study_design_scores_gemma":[0.09879981,0.00072696724,0.81433904,0.0006366775,0.0004542323,0.000029172505,0.00044553392,0.00007385941,0.08346109,0.00012311476,0.00053991,0.0003705719],"about_ca_topic_score_codex":0.00013208283,"about_ca_topic_score_gemma":0.0022227813,"teacher_disagreement_score":0.09794311,"about_ca_system_score_codex":0.00012321508,"about_ca_system_score_gemma":0.00015067187,"threshold_uncertainty_score":0.6591176},"labels":[],"label_agreement":null},{"id":"W2910482049","doi":"10.1080/13696998.2019.1569446","title":"Cohort versus patient level simulation for the economic evaluation of single versus combination immuno-oncology therapies in metastatic melanoma","year":2019,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Augmentium Pharma Consulting (Canada)","funders":"","keywords":"Medicine; Metastatic melanoma; Cohort; Oncology; Internal medicine; Melanoma; Overall survival; Cancer","score_opus":0.14165245733668508,"score_gpt":0.4049893729289035,"score_spread":0.26333691559221845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2910482049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936266,0.0005711721,0.00023697052,0.0021610886,0.0018151444,0.0010775989,0.0000075243884,0.0000021110536,0.00050177734],"genre_scores_gemma":[0.9990137,0.00049739884,0.00021409635,0.00006672275,0.00012925916,0.000021273285,0.000013924983,0.000016748776,0.00002687423],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9980988,0.0002054552,0.0008943394,0.00012131106,0.0005207738,0.0001593276],"domain_scores_gemma":[0.9953254,0.003435483,0.00064304477,0.00019239393,0.0003203632,0.00008330319],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0055915685,0.00009822755,0.00046350356,0.0001991524,0.000025573727,0.00001482938,0.0001866755,0.00012342414,0.0018235083],"category_scores_gemma":[0.00095310225,0.00007334269,0.00017249111,0.000053466236,0.00009444278,0.00013153917,0.000031177864,0.0002386387,0.0000081638555],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.039132535,0.0008508342,0.0046649226,0.00008334165,0.002282773,0.000004961229,0.0022957257,0.12766252,0.002649857,0.0011141009,0.00020113932,0.8190573],"study_design_scores_gemma":[0.08436578,0.01079635,0.0139626255,0.00009909633,0.0006022279,0.000035601704,0.0029183396,0.8733308,0.0017062307,0.00090314564,0.011129142,0.00015068888],"about_ca_topic_score_codex":0.00005110351,"about_ca_topic_score_gemma":0.00014601304,"teacher_disagreement_score":0.8189066,"about_ca_system_score_codex":0.0019161474,"about_ca_system_score_gemma":0.0014648425,"threshold_uncertainty_score":0.99908894},"labels":[],"label_agreement":null},{"id":"W2910585122","doi":"10.1111/imcb.12231","title":"<i>In vitro</i>‐generated <scp>MART</scp>‐1‐specific <scp>CD</scp>8 T cells display a broader T‐cell receptor repertoire than <i>ex vivo</i> naïve and tumor‐infiltrating lymphocytes","year":2019,"lang":"en","type":"article","venue":"Immunology and Cell Biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; Sunnybrook Hospital; Sunnybrook Health Science Centre","funders":"Krembil Foundation; Canadian Institutes of Health Research; Terry Fox Foundation","keywords":"T-cell receptor; Biology; Antigen; Repertoire; Cytotoxic T cell; Cell biology; CD8; Ex vivo; In vitro; Major histocompatibility complex; Molecular biology; Antigen-presenting cell; Immunology; T cell; Immune system; Genetics","score_opus":0.008317179847681978,"score_gpt":0.23267884798335517,"score_spread":0.22436166813567318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2910585122","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95648587,0.026312113,0.000007916699,0.00020979447,0.00093538495,0.0009965897,0.00006505863,0.000104346625,0.0148829585],"genre_scores_gemma":[0.94933224,0.008520386,0.00038581414,0.0011662683,0.00028780068,0.00008961605,0.00020168358,0.00010604909,0.039910153],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99556667,0.0006860278,0.00078855676,0.0013498946,0.00020528867,0.0014035393],"domain_scores_gemma":[0.99673355,0.0017058813,0.00029728928,0.0008377974,0.0001675878,0.00025787656],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006840759,0.00065364124,0.0011967979,0.00039911387,0.00024464735,0.00006523049,0.00035186464,0.0009167728,0.00065544766],"category_scores_gemma":[0.00014865756,0.0005703279,0.00017968025,0.0005297759,0.0009467886,0.00016391018,0.00030055322,0.0010979469,0.00041597092],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004127499,0.0002898495,0.011387053,0.00013307515,0.00015135335,0.00012266646,0.0014455299,0.0000037940918,0.9809899,0.000054064392,0.0033284328,0.0016815412],"study_design_scores_gemma":[0.0051035616,0.00110189,0.0012100734,0.000055733635,0.00004138256,0.00026879786,0.0014161747,0.00015095303,0.8222592,0.00006222821,0.16818519,0.00014485003],"about_ca_topic_score_codex":0.0002824789,"about_ca_topic_score_gemma":0.000026783639,"teacher_disagreement_score":0.16485676,"about_ca_system_score_codex":0.00017236985,"about_ca_system_score_gemma":0.00026437716,"threshold_uncertainty_score":0.9996748},"labels":[],"label_agreement":null},{"id":"W2910852524","doi":"10.1158/1078-0432.ccr-18-2291","title":"Developing Allogeneic Double-Negative T Cells as a Novel Off-the-Shelf Adoptive Cellular Therapy for Cancer","year":2019,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; Canadian Cancer Society","keywords":"Adoptive cell transfer; Cancer; Medicine; Cancer therapy; Cell therapy; Cancer research; Immunology; Biology; Immune system; T cell; Internal medicine; Stem cell; Cell biology","score_opus":0.36519421318107037,"score_gpt":0.542524949221723,"score_spread":0.17733073604065264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2910852524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9644063,0.0059941164,0.00033253036,0.015283828,0.0011261635,0.009059391,0.00010704806,0.00007063107,0.0036199768],"genre_scores_gemma":[0.8187601,0.041050468,0.0023216256,0.00611473,0.004399923,0.0074647595,0.000062738654,0.0003887909,0.119436875],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99375004,0.0005338191,0.00094071357,0.0012732494,0.001940065,0.0015620947],"domain_scores_gemma":[0.990608,0.0051478394,0.00018512602,0.0011593734,0.0023765117,0.00052318786],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0067208875,0.0003785853,0.00094018976,0.00028050062,0.0003913191,0.00012540272,0.0009594478,0.0004419573,0.0076122913],"category_scores_gemma":[0.0005428852,0.0002631546,0.0005598579,0.0011749506,0.0010239171,0.00012370135,0.00038888725,0.0021953383,0.00048323654],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04804274,0.0011120002,0.018140547,0.0005095295,0.002018608,0.000049622897,0.0019083981,0.00010769222,0.7129293,0.0021653045,0.008500462,0.20451578],"study_design_scores_gemma":[0.02193878,0.003314281,0.0048551112,0.00043088107,0.00006234949,0.0000066085718,0.00083528925,0.00053002726,0.43608773,0.0009029275,0.5305254,0.0005106109],"about_ca_topic_score_codex":0.0028174631,"about_ca_topic_score_gemma":0.0004880824,"teacher_disagreement_score":0.5220249,"about_ca_system_score_codex":0.0010721728,"about_ca_system_score_gemma":0.005262537,"threshold_uncertainty_score":0.99998206},"labels":[],"label_agreement":null},{"id":"W2911247197","doi":"10.1158/2326-6074.cricimteatiaacr18-b052","title":"Abstract B052: Immunotherapy for melanoma by adenovirus-mediated full-length antibody, nivolumab","year":2019,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Nivolumab; Melanoma; Immunotherapy; Medicine; Antibody; Cancer research; Cancer immunotherapy; Cancer; Immunology; Immune system; Monoclonal antibody; Virology; Oncology; Internal medicine","score_opus":0.04798463207347491,"score_gpt":0.4053823627487281,"score_spread":0.35739773067525316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911247197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9531035,0.031718124,0.000026547317,0.003696251,0.00068141817,0.0034986015,0.00023861772,0.0001525231,0.0068844575],"genre_scores_gemma":[0.9140294,0.016644895,0.00010870832,0.0004193524,0.00048659125,0.0011277574,0.00067097624,0.00024982938,0.06626244],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9950257,0.00027221369,0.0006130541,0.0010028679,0.0011083876,0.0019777834],"domain_scores_gemma":[0.99594283,0.0011411913,0.0001311659,0.0014411408,0.0010941396,0.00024954515],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.002115522,0.0003949231,0.0008840999,0.0007275343,0.00033215532,0.00009018454,0.0009093726,0.00066210737,0.031548027],"category_scores_gemma":[0.0002583077,0.00036395,0.00029646172,0.0009667872,0.00092827243,0.00019357004,0.00022218905,0.0021063057,0.0018164413],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010582299,0.00034990808,0.011874746,0.0001818604,0.0010027318,0.000031092248,0.0002935614,0.0000010001002,0.9111278,0.000070222675,0.020895932,0.04358883],"study_design_scores_gemma":[0.019730669,0.005475961,0.059158165,0.00027917235,0.000038101232,0.000114686096,0.000820543,0.00019451289,0.19196105,0.0001876471,0.7213732,0.0006663046],"about_ca_topic_score_codex":0.0010789317,"about_ca_topic_score_gemma":0.000066976376,"teacher_disagreement_score":0.71916676,"about_ca_system_score_codex":0.00092833565,"about_ca_system_score_gemma":0.0013669012,"threshold_uncertainty_score":0.99988127},"labels":[],"label_agreement":null},{"id":"W2911426225","doi":"10.1038/s42003-019-0296-7","title":"On-demand serum-free media formulations for human hematopoietic cell expansion using a high dimensional search algorithm","year":2019,"lang":"en","type":"article","venue":"Communications Biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Haematopoiesis; Process (computing); Set (abstract data type); Mathematical optimization; Reagent; Substitution (logic); Computer science; Free space; Algorithm; Mathematics; Chemistry; Stem cell; Biology; Physics","score_opus":0.08002752794135846,"score_gpt":0.38401909444580423,"score_spread":0.30399156650444575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911426225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888864,0.0005506423,0.0044911313,0.0023284976,0.00013688477,0.00166875,0.00016142914,0.000070922695,0.0017053135],"genre_scores_gemma":[0.9593804,0.00008685407,0.03777274,0.00026955598,0.000075554075,0.00010252875,0.00088257674,0.000042369316,0.0013874172],"study_design_codex":"bench_or_experimental","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.9985422,0.00022507254,0.00034365582,0.00031263247,0.00020066851,0.000375759],"domain_scores_gemma":[0.995192,0.0014040989,0.00007459593,0.0028731506,0.00031934094,0.0001368276],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00052066735,0.0001627367,0.00034745157,0.00029572993,0.0004261774,0.000015952884,0.00071523193,0.00020618574,0.0012630842],"category_scores_gemma":[0.00010882042,0.0001439108,0.00013247972,0.0002691307,0.00027765636,0.000050219427,0.00059185666,0.0004021547,0.00010362991],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030777967,0.0014229058,0.007819515,0.00017876965,0.000195508,0.0000027863296,0.0015917306,0.00024235352,0.8963314,0.07117298,0.0011059835,0.019628242],"study_design_scores_gemma":[0.04351446,0.00769077,0.03811429,0.0009800969,0.00059721555,0.0003580639,0.0012890346,0.37394807,0.12445273,0.38054973,0.02630763,0.0021978861],"about_ca_topic_score_codex":0.000092268005,"about_ca_topic_score_gemma":0.00003519959,"teacher_disagreement_score":0.7718787,"about_ca_system_score_codex":0.00014941268,"about_ca_system_score_gemma":0.0001842176,"threshold_uncertainty_score":0.9996499},"labels":[],"label_agreement":null},{"id":"W2911451382","doi":"10.1016/j.tmrv.2019.01.005","title":"Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis","year":2019,"lang":"en","type":"review","venue":"Transfusion Medicine Reviews","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":190,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; Institute for Clinical Evaluative Sciences; Vancouver Coastal Health Research Institute; Vancouver Coastal Health; Simon Fraser University; BC Cancer Agency; Ottawa Hospital; University of Manitoba; University of British Columbia; University of Ottawa","funders":"","keywords":"Medicine; Chimeric antigen receptor; Cytokine release syndrome; Internal medicine; Oncology; Cancer; Meta-analysis; Clinical trial; Immunotherapy","score_opus":0.3217246896835683,"score_gpt":0.4496143182220625,"score_spread":0.12788962853849417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911451382","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000656926,0.975582,0.000007286759,0.0005339933,0.000056479974,0.023342833,0.00009334036,0.000020682819,0.00029768926],"genre_scores_gemma":[0.000001116028,0.9946948,0.00008741296,0.00056404923,0.000077469624,0.001943653,0.00014456033,0.000116557225,0.0023703387],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9909833,0.002303001,0.004041995,0.0011859293,0.0009876649,0.00049812],"domain_scores_gemma":[0.99557334,0.00067759026,0.0015270666,0.0016472223,0.00021144029,0.00036331156],"candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0055987155,0.0011179647,0.033727754,0.0012696243,0.00005056565,0.0000120022305,0.0004075938,0.00039146392,0.009668803],"category_scores_gemma":[0.0002303301,0.00058188476,0.0031963028,0.0036473772,0.00024341272,0.000064419124,0.000059346487,0.0009847073,0.00003347897],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019547753,0.00009248441,0.000031982432,0.7622396,0.02186438,0.0000032915991,0.0001659052,1.1196789e-7,0.00003442205,0.0000016854418,0.00019681022,0.21534981],"study_design_scores_gemma":[0.00082205306,0.0004733002,0.000009751912,0.22860382,0.5179577,0.000037695925,0.000014067356,0.0000014918145,0.0000041343965,5.2434166e-7,0.25176084,0.00031460045],"about_ca_topic_score_codex":0.00204775,"about_ca_topic_score_gemma":0.00021574843,"teacher_disagreement_score":0.53363574,"about_ca_system_score_codex":0.00011604726,"about_ca_system_score_gemma":0.0002591103,"threshold_uncertainty_score":0.99966323},"labels":[],"label_agreement":null},{"id":"W2911474691","doi":"10.1080/13696998.2019.1582059","title":"CAR T-cells: costs, comparisons, and commentary","year":2019,"lang":"en","type":"letter","venue":"Journal of Medical Economics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; Health Sciences Centre; Queen's University","funders":"","keywords":"Medicine; Intensive care medicine; Actuarial science; Economics","score_opus":0.033320510649939156,"score_gpt":0.3124527859559872,"score_spread":0.279132275306048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911474691","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.034283083,0.0024096677,0.000026477355,0.9598537,0.0018227998,0.00030848067,0.000040295323,0.000007417092,0.0012480925],"genre_scores_gemma":[0.000368138,0.021546422,0.00036158977,0.96285194,0.012173616,0.000002190502,0.000094647075,0.000085159765,0.0025162902],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99724644,0.00015803339,0.001041985,0.00025264753,0.0008959353,0.00040494918],"domain_scores_gemma":[0.9975965,0.00084041554,0.000584201,0.00038722463,0.00011737286,0.00047430434],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016888024,0.00028055013,0.0013957483,0.0003049131,0.000036845162,0.00006112549,0.0005084986,0.0011326243,0.0048897467],"category_scores_gemma":[0.0001317802,0.00023358918,0.0003330384,0.000045931494,0.0002770686,0.00007235541,0.00018315329,0.006178195,0.000065797765],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022606572,0.00007603866,0.00084604236,0.00026124922,0.0006127893,0.001194671,0.00004086013,0.0000012911127,0.00007538485,0.000004460906,0.98490846,0.011752657],"study_design_scores_gemma":[0.0037343903,0.00060334126,0.00005676069,0.0005286482,0.00020446119,0.0021824662,0.000103014216,0.0005472615,0.00010992504,0.000016712478,0.9917281,0.00018486967],"about_ca_topic_score_codex":0.000088782646,"about_ca_topic_score_gemma":0.000012687916,"teacher_disagreement_score":0.033914942,"about_ca_system_score_codex":0.00071931054,"about_ca_system_score_gemma":0.00090427726,"threshold_uncertainty_score":0.9961146},"labels":[],"label_agreement":null},{"id":"W2911503195","doi":"10.1016/j.bbmt.2018.12.464","title":"A New Specific Promoter Allow Hematopoietic Stem Cell Immunotherapy Approach Against Acute Lymphoblastic Leukemia Using Chimeric Antigen Receptor","year":2019,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; Université de Montréal","funders":"","keywords":"Chimeric antigen receptor; Jurkat cells; Biology; Cytotoxic T cell; Haematopoiesis; Interleukin 21; Molecular biology; Stem cell; Transfection; T cell; Nucleofection; Cancer research; Cell biology; Cell culture; Immunology; In vitro; Immune system","score_opus":0.015719189403738665,"score_gpt":0.24827979397620228,"score_spread":0.2325606045724636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911503195","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99346995,0.0018166618,0.0027250051,0.00003628129,0.00013378612,0.000837282,0.000027801589,0.00003371708,0.00091950194],"genre_scores_gemma":[0.9846577,0.008217953,0.0055497927,0.000056871202,0.00008425418,0.000009447122,0.00022217365,0.000038458256,0.0011633551],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998748,0.000095765216,0.00032641258,0.0003802016,0.00015718953,0.00029240028],"domain_scores_gemma":[0.99945384,0.000051912164,0.00011752849,0.00022821336,0.000044627173,0.00010389289],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017003957,0.00020862719,0.00044503357,0.00016429342,0.0000463927,0.000013021699,0.000099640856,0.00019504172,0.00034715293],"category_scores_gemma":[5.6378104e-7,0.00017723373,0.00010713468,0.00017252342,0.00010101619,0.000064660424,0.000009398651,0.00014353302,0.00001626043],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012621523,0.00011501772,0.0072021387,0.0004591907,0.00030250303,0.000009433621,0.0014621296,0.000008357326,0.9797913,0.000020128367,0.000017043083,0.00935063],"study_design_scores_gemma":[0.012772084,0.0016202537,0.0049240263,0.0002933118,0.0003924795,0.00048018372,0.000251592,0.00054763333,0.97728056,0.000035484412,0.0010048941,0.0003975146],"about_ca_topic_score_codex":0.000043041266,"about_ca_topic_score_gemma":8.81462e-7,"teacher_disagreement_score":0.011509933,"about_ca_system_score_codex":0.000040006787,"about_ca_system_score_gemma":0.00020410091,"threshold_uncertainty_score":0.7227382},"labels":[],"label_agreement":null},{"id":"W2911504656","doi":"10.1182/blood-2018-11-883710","title":"Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":401,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Juno Therapeutics; National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; Celgene","keywords":"Medicine; CAR T-cell therapy; CD19; Internal medicine; Oncology; Immunology; T cell; Chimeric antigen receptor; Antibody; Immune system","score_opus":0.019104211371907664,"score_gpt":0.2534960935338183,"score_spread":0.23439188216191065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911504656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906471,0.00014000987,5.7320165e-7,0.00008227414,0.00007805332,0.00150884,0.000041861233,0.00006189974,0.0074394112],"genre_scores_gemma":[0.98889863,0.000101168735,0.000036866226,0.0003618391,0.000040936262,0.00006700472,0.000087557164,0.0000976159,0.010308348],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975819,0.00019167448,0.000320771,0.00050578144,0.0007262894,0.0006735965],"domain_scores_gemma":[0.99859905,0.0002791431,0.00013920404,0.00047444287,0.00030601496,0.00020215426],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00023251583,0.0003357751,0.0005268477,0.000215439,0.000040622323,0.000040253744,0.0001868838,0.00020224915,0.0015080712],"category_scores_gemma":[0.000099804274,0.0002443121,0.00013031582,0.0004160965,0.00005756458,0.00014126301,0.000053099793,0.00058544055,0.00010520268],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007567676,0.002938472,0.9012592,0.00005928744,0.00021800377,0.0000341282,0.0029234546,0.0000037733523,0.0915934,7.397785e-7,0.000069907175,0.00014287527],"study_design_scores_gemma":[0.036937933,0.0026103177,0.75714254,0.0003034808,0.00009678229,0.000001131355,0.00053016597,0.000028666946,0.20142162,0.000008724396,0.00049108686,0.00042754316],"about_ca_topic_score_codex":0.00035545925,"about_ca_topic_score_gemma":0.00028364567,"teacher_disagreement_score":0.14411664,"about_ca_system_score_codex":0.00019700419,"about_ca_system_score_gemma":0.00013920169,"threshold_uncertainty_score":0.99940467},"labels":[],"label_agreement":null},{"id":"W2911843886","doi":"10.1016/j.bbmt.2018.12.783","title":"Lymphodepletion with CD45 Radioimmunotherapy as a Targeted Conditioning Regimen Prior to Adoptive Cell Therapy or CAR-T","year":2019,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Medicine; Radioimmunotherapy; Conditioning; Regimen; Conditioning regimen; Oncology; Internal medicine; Immunology; Cyclophosphamide; Chemotherapy; Monoclonal antibody","score_opus":0.012069016687963181,"score_gpt":0.2685406101849105,"score_spread":0.2564715934969473,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911843886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962808,0.0008148734,0.00028366633,0.0002860606,0.000052804087,0.00119498,0.000042933134,0.00003696568,0.0010069179],"genre_scores_gemma":[0.9931948,0.0027649982,0.0014348592,0.00037001816,0.000040239556,0.000055129618,0.00033179647,0.000026648244,0.0017814625],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990266,0.00010420913,0.00020660956,0.00030259602,0.00014539702,0.00021461389],"domain_scores_gemma":[0.99944997,0.00010392842,0.00008786642,0.00016498947,0.0001119564,0.0000813141],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00018996908,0.00015771671,0.00032573126,0.00016977322,0.000057611564,0.000009152015,0.000055421744,0.00013663704,0.0009877601],"category_scores_gemma":[0.0000038810554,0.0001129397,0.000047846854,0.00017267719,0.00010207727,0.0000616063,0.000003685334,0.000101626305,0.000012193437],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016233426,0.00013707807,0.012974063,0.00012302428,0.00024248844,0.000019728443,0.0026039404,0.000007147356,0.9626707,0.00007465893,0.00001562244,0.0048981654],"study_design_scores_gemma":[0.021749655,0.011212951,0.025269745,0.000204467,0.00020632774,0.00032625342,0.0005627125,0.000027294407,0.9381394,0.00004565492,0.0019983386,0.0002572501],"about_ca_topic_score_codex":0.00019308839,"about_ca_topic_score_gemma":0.000020063086,"teacher_disagreement_score":0.024531305,"about_ca_system_score_codex":0.00002185817,"about_ca_system_score_gemma":0.00015600094,"threshold_uncertainty_score":0.9999255},"labels":[],"label_agreement":null},{"id":"W2911882091","doi":"10.1007/s00262-019-02307-x","title":"Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2","year":2019,"lang":"en","type":"article","venue":"Cancer Immunology Immunotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":141,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"Canadian Institutes of Health Research; Princess Margaret Cancer Foundation","keywords":"Medicine; Melanoma; Clinical endpoint; Response Evaluation Criteria in Solid Tumors; Aldesleukin; Population; Adverse effect; Chemotherapy; Interleukin 2; Immune system; Internal medicine; Oncology; Immunotherapy; Gastroenterology; Phases of clinical research; Clinical trial; Immunology; Cancer research","score_opus":0.03161818977587048,"score_gpt":0.3569993678410537,"score_spread":0.3253811780651832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911882091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867945,0.0066822227,0.00007584942,0.0001339698,0.000426055,0.0055548027,0.00006691745,0.000058219153,0.00020747165],"genre_scores_gemma":[0.99319386,0.0029607709,0.0015603924,0.0004514671,0.00008244266,0.00067665323,0.0000774631,0.00013066141,0.0008662666],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99718046,0.00028777285,0.0008990982,0.0006806095,0.0003380927,0.000613948],"domain_scores_gemma":[0.9972658,0.00070116844,0.0006508058,0.00076932914,0.00051913934,0.00009375253],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00056267827,0.00046076335,0.0013857973,0.00023786051,0.00014700629,0.000027083914,0.00030141222,0.00017672632,0.00094282435],"category_scores_gemma":[0.000037991744,0.00031571143,0.00022574353,0.00028839355,0.0008663993,0.00015499437,0.000053443022,0.00046240937,0.0000050321537],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6345927,0.004996504,0.018088397,0.00010382498,0.0028236003,0.000015082641,0.0015838603,0.0000039223623,0.10815866,0.00002124045,0.00003359243,0.22957857],"study_design_scores_gemma":[0.7199928,0.19530635,0.013387587,0.00029555632,0.00017213274,0.00005084219,0.00059672166,0.00013051009,0.065950975,0.000028712573,0.0036085097,0.00047928694],"about_ca_topic_score_codex":0.00012745087,"about_ca_topic_score_gemma":0.000010662604,"teacher_disagreement_score":0.22909929,"about_ca_system_score_codex":0.00022434987,"about_ca_system_score_gemma":0.000983078,"threshold_uncertainty_score":0.99997044},"labels":[],"label_agreement":null},{"id":"W2912271788","doi":"","title":"Randomized comparison of two doses of the anti-programmed death-1 monoclonal antibody MK-3475 for ipilimumab (IPI)-refractory and IPI-naive melanoma","year":2014,"lang":"en","type":"article","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Ipilimumab; Medicine; Refractory (planetary science); Monoclonal antibody; Melanoma; Oncology; Internal medicine; Monoclonal; Antibody; Immunology; Immunotherapy; Cancer research; Cancer; Biology","score_opus":0.047287008811841814,"score_gpt":0.3897588026719732,"score_spread":0.3424717938601314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912271788","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98896617,0.00079700677,0.0019155836,0.00044027917,0.00016624609,0.002803829,0.000018910434,0.000038787082,0.0048532104],"genre_scores_gemma":[0.9954866,0.00013843432,0.0021968456,0.000088352506,0.00015666394,0.00008066746,0.000038147205,0.00004079499,0.0017734683],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974911,0.0003895347,0.0007406533,0.00035989642,0.0006107774,0.00040802566],"domain_scores_gemma":[0.9964621,0.0020882513,0.00031991076,0.0005855222,0.0003840292,0.00016020353],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015420333,0.00025340694,0.0015316205,0.0001562624,0.00009295804,0.000022383068,0.00025075482,0.00012948205,0.0004952017],"category_scores_gemma":[0.00055334746,0.00015085141,0.00045091167,0.00019445491,0.0006162628,0.00006478363,0.00012779346,0.00026214635,0.0000028119273],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11884312,0.0012592021,0.21436001,0.00064957957,0.0011764246,0.0000021160918,0.0014279546,0.000011587865,0.62231326,0.0040343357,0.0005668719,0.035355523],"study_design_scores_gemma":[0.5313998,0.0019823178,0.038382407,0.00027791757,0.0008147681,0.00003025302,0.00073910685,0.017912928,0.4004535,0.0011290839,0.0064980476,0.00037985243],"about_ca_topic_score_codex":0.0004756665,"about_ca_topic_score_gemma":0.000050349325,"teacher_disagreement_score":0.41255668,"about_ca_system_score_codex":0.000039623563,"about_ca_system_score_gemma":0.00014432419,"threshold_uncertainty_score":0.6151542},"labels":[],"label_agreement":null},{"id":"W2912829588","doi":"10.1158/2326-6074.cricimteatiaacr18-b035","title":"Abstract B035: Enhancing antitumoral activity of cell-based immunotherapies by modulating the JAK-STAT axis","year":2019,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Priming (agriculture); Chimeric antigen receptor; Adoptive cell transfer; CD40; Immunology; Antigen; Cytotoxic T cell; T cell; Cancer research; Medicine; Immunotherapy; Interleukin 21; Antigen-presenting cell; Immune system; Biology; In vitro","score_opus":0.050236515303171025,"score_gpt":0.3845353745239244,"score_spread":0.33429885922075336,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2912829588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9842134,0.008834584,0.000050512863,0.001681725,0.00032371064,0.0012330064,0.000035820176,0.000046188386,0.003581047],"genre_scores_gemma":[0.9875983,0.0011631115,0.00006353182,0.00008875965,0.00009192187,0.00015764823,0.000017969796,0.00007526847,0.01074346],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9964019,0.0005153278,0.0004263584,0.0005457795,0.001021171,0.0010894738],"domain_scores_gemma":[0.9969263,0.0009484051,0.00016593015,0.0012141117,0.0006564268,0.0000888298],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002412892,0.0002520959,0.0006076673,0.00035868393,0.0003057468,0.00005085108,0.0006245154,0.00024449066,0.008882258],"category_scores_gemma":[0.00016506428,0.00018900222,0.0001987929,0.0008107036,0.0011327843,0.00014820241,0.00021521545,0.001900826,0.00014549146],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022791352,0.00023485874,0.01612243,0.000287865,0.0002529182,0.00001143902,0.0006374714,0.000044678498,0.96136224,0.000014271325,0.00060355046,0.018149145],"study_design_scores_gemma":[0.0026753198,0.0006914618,0.055705786,0.00021740807,0.000013735567,0.000007823774,0.0007477297,0.0004958865,0.9337241,0.000034977922,0.0055140425,0.0001717147],"about_ca_topic_score_codex":0.0040185614,"about_ca_topic_score_gemma":0.00010364626,"teacher_disagreement_score":0.039583355,"about_ca_system_score_codex":0.0004892188,"about_ca_system_score_gemma":0.0010608616,"threshold_uncertainty_score":0.99202377},"labels":[],"label_agreement":null},{"id":"W2913199767","doi":"10.1182/blood-2018-99-119045","title":"T Cells Engineered with T Cell Antigen Coupler (TAC) Receptors for Haematological Malignancies","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trillium Therapeutics (Canada); McMaster University","funders":"","keywords":"Chimeric antigen receptor; Cytotoxic T cell; Antigen; Cancer research; T-cell receptor; Immunology; Biology; T cell; Cytokine; CD19; Antigen-presenting cell; Molecular biology; Immune system; In vitro; Biochemistry","score_opus":0.025981840969429938,"score_gpt":0.2740505944299949,"score_spread":0.24806875346056498,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913199767","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99215114,0.00025954115,0.000512072,0.00024040852,0.00015735728,0.0009640529,0.000015076377,0.000116978146,0.0055833845],"genre_scores_gemma":[0.97786605,0.00010548687,0.007216993,0.00015476684,0.00043059184,0.000088554916,0.000025829271,0.00005676325,0.014054957],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99865395,0.000022713726,0.00019084928,0.00032634477,0.00032991768,0.0004762358],"domain_scores_gemma":[0.9990395,0.00011747579,0.00004429591,0.00036707488,0.00025011683,0.0001815476],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00021642755,0.00018118188,0.00035704504,0.0000890373,0.00008331068,0.000025318113,0.00013949079,0.0001369973,0.002698679],"category_scores_gemma":[0.00004097654,0.00012670194,0.000097471086,0.00021238743,0.0002027925,0.000036738693,0.000035126846,0.00014020204,0.00016142725],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005746612,0.00073348125,0.012949446,0.0001807962,0.00015379074,0.00005979863,0.0003220723,0.0000013772773,0.97801673,0.00007106216,0.006529969,0.0004068244],"study_design_scores_gemma":[0.004779085,0.0021742273,0.0017237054,0.00006137382,0.000095902964,0.00009646508,0.00009141072,0.00009143379,0.94266534,0.000021882273,0.048016567,0.00018258799],"about_ca_topic_score_codex":0.000011747583,"about_ca_topic_score_gemma":0.000009236171,"teacher_disagreement_score":0.0414866,"about_ca_system_score_codex":0.00002114667,"about_ca_system_score_gemma":0.00010232071,"threshold_uncertainty_score":0.998213},"labels":[],"label_agreement":null},{"id":"W2913763056","doi":"10.1007/s11899-019-0498-6","title":"Industry’s Giant Leap Into Cellular Therapy: Catalyzing Chimeric Antigen Receptor T Cell (CAR-T) Immunotherapy","year":2019,"lang":"en","type":"review","venue":"Current Hematologic Malignancy Reports","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"NIH Clinical Center; Novartis Pharmaceuticals Corporation; University of Pennsylvania","keywords":"Chimeric antigen receptor; Medicine; Immunotherapy; Hematology; Cytokine release syndrome; Internal medicine; Clinical trial; Oncology; Cancer","score_opus":0.09754620024724776,"score_gpt":0.37582670228071946,"score_spread":0.2782805020334717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913763056","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0029150108,0.9828251,0.00005240909,0.00007509598,0.004060277,0.0073730373,0.000025551672,0.00055528653,0.0021182387],"genre_scores_gemma":[0.00036987505,0.9890337,0.00028189234,0.00006786306,0.0007002603,0.00079842383,0.0010565985,0.00058078853,0.0071106106],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9896409,0.000681273,0.0035561188,0.0027094746,0.0016316683,0.0017805614],"domain_scores_gemma":[0.99172366,0.00027032476,0.002986685,0.0040081562,0.0003949351,0.0006162602],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.0016129664,0.0020239362,0.0070192544,0.00094453734,0.0003071552,0.00018110177,0.00091393554,0.0030473268,0.008560743],"category_scores_gemma":[0.0001672154,0.0015186542,0.0025618032,0.001626505,0.00036500185,0.00018733714,0.0004268435,0.005482815,0.0011689189],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008501563,0.0010284887,0.0015063789,0.040724058,0.00079289044,0.0028139704,0.00029364743,3.0113674e-7,0.0042185015,0.000027648448,0.0045793126,0.9439298],"study_design_scores_gemma":[0.00092287443,0.0003717445,0.000017167351,0.023653032,0.00047197903,0.003932106,0.000041087085,0.0000030170156,0.0034841003,0.00006927982,0.96558404,0.0014495952],"about_ca_topic_score_codex":0.00013214012,"about_ca_topic_score_gemma":0.0000020195,"teacher_disagreement_score":0.96100473,"about_ca_system_score_codex":0.0007562988,"about_ca_system_score_gemma":0.0025921122,"threshold_uncertainty_score":0.9996088},"labels":[],"label_agreement":null},{"id":"W2913828923","doi":"10.1172/jci.insight.123672","title":"Systematic testing and specificity mapping of alloantigen-specific chimeric antigen receptors in regulatory T cells","year":2019,"lang":"en","type":"article","venue":"JCI Insight","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":97,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia Hospital; University of British Columbia; Centre for Drug Research and Development; BC Children's Hospital","funders":"Canadian Institutes of Health Research","keywords":"Chimeric antigen receptor; Receptor; Computational biology; Antigen; Cell biology; Biology; Immunology; Chemistry; Genetics; Immunotherapy; Immune system","score_opus":0.04166199188990639,"score_gpt":0.2625196182458322,"score_spread":0.22085762635592582,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2913828923","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9771189,0.0033307231,0.000015513002,0.00003588741,0.00031415917,0.0014729247,0.0000016117887,0.000042399046,0.01766788],"genre_scores_gemma":[0.9939072,0.00092054636,0.0014088167,0.000042083655,0.00012022185,0.000014447568,0.0000040593222,0.000049867016,0.0035327217],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997821,0.0001674556,0.00069675036,0.00042192792,0.0005303235,0.0003625707],"domain_scores_gemma":[0.99851066,0.0004064082,0.00021602097,0.000609016,0.00013002892,0.00012784927],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007556182,0.00020807637,0.000806667,0.0004761795,0.00004012216,0.000025100513,0.00014567982,0.00012669947,0.0011027569],"category_scores_gemma":[0.00010163106,0.00017955923,0.00008877861,0.0008626615,0.00011593714,0.00009570269,0.00008843983,0.00031651327,0.00012129842],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007492666,0.0001266142,0.079927914,0.0059867557,0.00006755701,0.000031267213,0.0016878662,0.000008775956,0.9101195,0.00005075776,0.00013482594,0.0017832875],"study_design_scores_gemma":[0.0048305695,0.0009334029,0.4471285,0.021753626,0.00005480502,0.00015768428,0.0032338556,0.001751995,0.49692678,0.000104820196,0.02218231,0.00094164634],"about_ca_topic_score_codex":0.00006853749,"about_ca_topic_score_gemma":0.000005162642,"teacher_disagreement_score":0.41319266,"about_ca_system_score_codex":0.0001356379,"about_ca_system_score_gemma":0.000083309096,"threshold_uncertainty_score":0.9998104},"labels":[],"label_agreement":null},{"id":"W2914888321","doi":"10.3389/fimmu.2019.00111","title":"Is There a Positive Side to T Cell Exhaustion?","year":2019,"lang":"en","type":"review","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences North","funders":"","keywords":"Immunosurveillance; Receptor; Autoimmunity; Immunology; Biology; Cell; Cell biology; Senescence; Immunotherapy; Immune system","score_opus":0.03726496116236359,"score_gpt":0.3517307754025052,"score_spread":0.3144658142401416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2914888321","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004811261,0.96897745,0.0002320573,0.00031832702,0.0018400821,0.002821125,0.00006598933,0.000040670464,0.02565621],"genre_scores_gemma":[0.000008715672,0.90988773,0.0014331351,0.00033188798,0.00016131473,0.00023561904,0.00014574348,0.00012423357,0.08767163],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972194,0.00037206456,0.0006240746,0.00076121395,0.00028293335,0.00074031495],"domain_scores_gemma":[0.9983278,0.00015879385,0.00017802393,0.001091837,0.00012440032,0.00011913567],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00032554328,0.0004945302,0.0027096611,0.0011304389,0.00004131047,0.000023392671,0.00050551345,0.0009194563,0.0022368752],"category_scores_gemma":[0.00007139646,0.00042689036,0.00055611145,0.0007712394,0.00016070502,0.00004357972,0.00025508364,0.0015199621,0.00163405],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003084481,0.00014956202,0.00013668371,0.0044049527,0.00077290996,0.00019775557,0.00039122585,3.080902e-7,0.00008198489,0.000019202549,0.0343909,0.9591461],"study_design_scores_gemma":[0.001011479,0.0006344803,0.00013601533,0.005516371,0.00042833114,0.00012951005,0.00025754998,0.0000020198156,0.00006429829,0.000046695495,0.9914283,0.0003449291],"about_ca_topic_score_codex":0.000118334276,"about_ca_topic_score_gemma":0.000004598946,"teacher_disagreement_score":0.95880115,"about_ca_system_score_codex":0.0010554341,"about_ca_system_score_gemma":0.00075234234,"threshold_uncertainty_score":0.99981827},"labels":[],"label_agreement":null},{"id":"W2915025135","doi":"10.1038/s41551-019-0359-6","title":"Cancer immunotherapies repurposed for use in autoimmunity","year":2019,"lang":"en","type":"article","venue":"Nature Biomedical Engineering","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"","keywords":"Cancer; Autoimmunity; Medicine; Immunotherapy; Immunology; Cancer immunotherapy; Immune system; Internal medicine","score_opus":0.014626808452377293,"score_gpt":0.30752249056818587,"score_spread":0.2928956821158086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2915025135","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916337,0.0045495536,0.00040445506,0.0010770018,0.0009216161,0.0011034465,0.00002484528,0.00015831924,0.0001270634],"genre_scores_gemma":[0.9895003,0.00033881306,0.0034870976,0.00048539467,0.00033259837,0.00015357464,0.00007273425,0.000080438156,0.0055490676],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987349,0.000015702357,0.00022878409,0.0002412283,0.00039157996,0.00038782798],"domain_scores_gemma":[0.99912703,0.0002904495,0.000025583828,0.0003608657,0.000074050986,0.00012202026],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00038529251,0.00015416398,0.00032799254,0.00031688347,0.000018643306,0.00002252768,0.000146341,0.00046528448,0.0013051445],"category_scores_gemma":[0.00030415287,0.00013011704,0.00011333954,0.0004637248,0.000046199508,0.00008098536,0.00004010517,0.0011290478,0.000009825003],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00074998516,0.00017206954,0.005698974,0.00044348722,0.0001873547,0.000030137997,0.00026372442,0.00010178456,0.95506257,0.00022441435,0.0007093514,0.036356162],"study_design_scores_gemma":[0.00798688,0.00046321176,0.08101255,0.00074425415,0.000026876218,0.000033145316,0.000052436313,0.040702134,0.015405926,0.000022801982,0.85317093,0.00037883187],"about_ca_topic_score_codex":0.0001447662,"about_ca_topic_score_gemma":0.000009745562,"teacher_disagreement_score":0.9396566,"about_ca_system_score_codex":0.00025471556,"about_ca_system_score_gemma":0.00012969624,"threshold_uncertainty_score":0.9996078},"labels":[],"label_agreement":null},{"id":"W2915478666","doi":"10.1182/blood-2018-99-113642","title":"CAR-Modified Th1/Tc1-Polarized T-Rapa Cells Dissociate Inflammatory Cytokine Secretion from Anti-Tumor Cytotoxicity","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Immunology; Cytokine release syndrome; Chimeric antigen receptor; Cytokine; Interleukin 21; Interleukin 12; Cancer research; Biology; Medicine; Immunotherapy; Cytotoxic T cell; T cell; Immune system; In vitro","score_opus":0.018173105808239463,"score_gpt":0.2748453735791264,"score_spread":0.256672267770887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2915478666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98903954,0.0001578592,0.00021935056,0.00030087493,0.0002644475,0.0009859293,0.00014203237,0.00025246115,0.008637482],"genre_scores_gemma":[0.99501294,0.00007784964,0.00027194008,0.0005676092,0.001704767,0.00004717287,0.00015227642,0.00009345721,0.0020719978],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971502,0.00024283449,0.00052117754,0.00062349037,0.0007605707,0.0007017179],"domain_scores_gemma":[0.9979526,0.0001726524,0.00020229732,0.0008636645,0.00043501635,0.00037379374],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006584117,0.00034291876,0.0006887329,0.00019787066,0.00022316407,0.00008149798,0.00026713207,0.00025567558,0.0025028812],"category_scores_gemma":[0.000215684,0.00031372614,0.00027264954,0.00037995985,0.00031651565,0.00014905068,0.00015360264,0.0005691675,0.00040410456],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006248773,0.0006054501,0.015080086,0.000059397382,0.00035754702,0.00017200503,0.0005284268,4.0017218e-7,0.9819693,0.000047182897,0.0003962694,0.0001590755],"study_design_scores_gemma":[0.010394503,0.00052388845,0.054239746,0.00011961208,0.00029351225,0.000028318758,0.00009064864,0.00031707413,0.9299818,0.00037716844,0.0032870984,0.0003465843],"about_ca_topic_score_codex":0.0005397885,"about_ca_topic_score_gemma":0.000095267875,"teacher_disagreement_score":0.051987436,"about_ca_system_score_codex":0.00014767265,"about_ca_system_score_gemma":0.00024407572,"threshold_uncertainty_score":0.99993145},"labels":[],"label_agreement":null},{"id":"W2915844515","doi":"10.1038/s41586-019-0967-z","title":"Retraction Note: A homing system targets therapeutic T cells to brain cancer","year":2019,"lang":"en","type":"retraction","venue":"Nature","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":true,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of British Columbia","funders":"","keywords":"Homing (biology); Brain cancer; Neuroscience; Cognitive science; Biology; Psychology; Cancer; Ecology; Genetics","score_opus":0.019744595819964437,"score_gpt":0.3627102256696908,"score_spread":0.34296562984972634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2915844515","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012854679,0.3556165,0.0012679698,0.061815195,0.25800726,0.029684413,0.0021135572,0.0023422493,0.27629817],"genre_scores_gemma":[0.074526146,0.007523339,0.00032875035,0.0069176825,0.017026689,0.00027622178,0.0007000996,0.0004965493,0.8922045],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99633646,0.00017430242,0.00037956887,0.00083344773,0.0016506453,0.00062555744],"domain_scores_gemma":[0.9978248,0.00034441322,0.00025219395,0.00082091545,0.0004909644,0.00026670733],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0007739357,0.0004818319,0.00090586155,0.00065202225,0.0001088424,0.00008592369,0.00025347783,0.010210656,0.0029645672],"category_scores_gemma":[0.00012379726,0.0004166689,0.00036132126,0.00067318685,0.000025277439,0.00010640136,0.00005419,0.016714172,0.00067779486],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010703519,0.00007336281,0.000043508917,0.003541959,0.0003751013,0.00010247098,0.0002601933,0.000018128012,0.34668827,0.0000128386155,0.50568277,0.14213103],"study_design_scores_gemma":[0.0008707892,0.00026816898,0.00045204844,0.0023027246,0.00023006709,0.00011407101,0.000090898946,0.00026949798,0.020293348,0.0000020842067,0.97472817,0.00037813897],"about_ca_topic_score_codex":0.00034893266,"about_ca_topic_score_gemma":0.00009608177,"teacher_disagreement_score":0.61590636,"about_ca_system_score_codex":0.0032538166,"about_ca_system_score_gemma":0.0008756486,"threshold_uncertainty_score":0.9998285},"labels":[{"model":"gemma","categories":["research_integrity"],"domain":null,"study_design":"not_applicable","genre":"other","about_ca_system":false,"about_ca_topic":false,"confidence":"high"},{"model":"gpt","categories":["research_integrity"],"domain":null,"study_design":"not_applicable","genre":"editorial","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W2917009888","doi":"10.1016/j.blre.2019.02.001","title":"Cellular immunotherapy for acute myeloid leukemia: How specific should it be?","year":2019,"lang":"en","type":"review","venue":"Blood Reviews","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto Rehabilitation Institute; University of Toronto; University Health Network","funders":"Canadian Cancer Society Research Institute; Leukemia and Lymphoma Society","keywords":"Chimeric antigen receptor; Medicine; Myeloid leukemia; Immunotherapy; Cytokine release syndrome; Immunology; Leukemia; Immune system; Hematopoietic stem cell transplantation; Antigen; Myeloid; Cell therapy; Cancer; T cell; Lymphoma; Cancer research; Stem cell; Transplantation; Internal medicine; Biology","score_opus":0.21423503775867625,"score_gpt":0.4130453928163727,"score_spread":0.19881035505769645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2917009888","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000019354009,0.97329754,0.000156029,0.0008613135,0.0008773795,0.019988276,0.00020831394,0.000099820645,0.00450942],"genre_scores_gemma":[3.5247982e-8,0.8368868,0.0015632479,0.0008152715,0.002044725,0.0022209808,0.0010930403,0.00046247922,0.15491343],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9938072,0.0006178122,0.0018597308,0.0015442738,0.0009596341,0.0012113347],"domain_scores_gemma":[0.994443,0.0004798871,0.0010148216,0.0034462356,0.00023902136,0.00037704283],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0025103614,0.0014374874,0.009068763,0.0005054077,0.00015067475,0.00018984663,0.0011666516,0.0012258142,0.0059075113],"category_scores_gemma":[0.00013567168,0.0009910343,0.0051402324,0.00086975074,0.00016224729,0.00011279281,0.00017984539,0.00195904,0.0013448248],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000071892115,0.0001663011,4.325181e-7,0.052204136,0.0021677588,0.000078261415,0.000054083368,1.6161371e-8,0.0020136354,0.000033920427,0.08740131,0.85580826],"study_design_scores_gemma":[0.0025664181,0.00070269115,1.1265979e-7,0.024557192,0.0079651335,0.00039610494,0.0000103112525,0.0000011341475,0.0002575597,0.0000055159767,0.9626816,0.00085623097],"about_ca_topic_score_codex":0.0000067318656,"about_ca_topic_score_gemma":0.0000021233993,"teacher_disagreement_score":0.87528026,"about_ca_system_score_codex":0.0006658225,"about_ca_system_score_gemma":0.0012763633,"threshold_uncertainty_score":0.9998375},"labels":[],"label_agreement":null},{"id":"W2917035693","doi":"10.1001/jamanetworkopen.2019.0035","title":"Long-term Survival and Cost-effectiveness Associated With Axicabtagene Ciloleucel vs Chemotherapy for Treatment of B-Cell Lymphoma","year":2019,"lang":"en","type":"article","venue":"JAMA Network Open","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":92,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Spark Therapeutics; Genentech; Regeneron Pharmaceuticals; AstraZeneca; Laura and John Arnold Foundation; Kaiser Permanente; GlaxoSmithKline; Blue Shield of California Foundation; Sanofi; National Pharmaceutical Council; Mallinckrodt Pharmaceuticals; Alnylam Pharmaceuticals; California Health Care Foundation","keywords":"Medicine; Oncology; Lymphoma; Survival analysis; Internal medicine; Cost effectiveness; Quality-adjusted life year; Cohort","score_opus":0.04220927045853014,"score_gpt":0.3345751585168903,"score_spread":0.29236588805836017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2917035693","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860716,0.0004638788,0.00012885292,0.00025968577,0.00011185625,0.007487858,0.00003067257,0.000024548788,0.0054210746],"genre_scores_gemma":[0.98311514,0.00062808645,0.0002097092,0.00013442728,0.00022631974,0.00046802673,0.00017206371,0.0000853351,0.014960917],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99829507,0.00023840838,0.00024100862,0.00044624318,0.0003120212,0.00046725644],"domain_scores_gemma":[0.99817896,0.0008134208,0.00015850956,0.00047508685,0.00020436507,0.00016967449],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009299371,0.00025417557,0.000876319,0.000051885258,0.00007168294,0.00008913251,0.00022225069,0.00016597244,0.0005670891],"category_scores_gemma":[0.000019981435,0.00018860181,0.00011329977,0.00026840053,0.00008556002,0.00010350886,0.000081214916,0.00005793138,0.0000094483885],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041799992,0.0023155543,0.78679943,0.0002544653,0.0012977177,0.00004058759,0.00028608827,0.00006820643,0.028093064,0.000041604028,0.00024879887,0.13875449],"study_design_scores_gemma":[0.06696442,0.007581338,0.890977,0.00046625832,0.00014355806,0.000013738279,0.00003837215,0.0004911969,0.029583165,0.000023819635,0.0034697554,0.0002473755],"about_ca_topic_score_codex":0.00014018027,"about_ca_topic_score_gemma":0.00008395132,"teacher_disagreement_score":0.13850711,"about_ca_system_score_codex":0.00035246165,"about_ca_system_score_gemma":0.00021504077,"threshold_uncertainty_score":0.7690959},"labels":[],"label_agreement":null},{"id":"W2917127842","doi":"10.1182/blood-2018-11-887067","title":"The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":336,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; National Institutes of Health; Juno Therapeutics; University of British Columbia; Celgene; Fred Hutchinson Cancer Research Center","keywords":"Medicine; Fludarabine; Cyclophosphamide; Cytokine release syndrome; Cytokine; Immunology; Internal medicine; Immunotherapy; Gastroenterology; Chemotherapy; Immune system; Chimeric antigen receptor","score_opus":0.005690642519163778,"score_gpt":0.24280284708367725,"score_spread":0.23711220456451346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2917127842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967811,0.000058469373,0.0000032086439,0.00023312759,0.00004230042,0.0020346763,0.000018857352,0.000038060825,0.0007901627],"genre_scores_gemma":[0.9957189,0.00002624792,0.00012093075,0.00018802713,0.00004302089,0.00007432757,0.000026394198,0.000071962226,0.0037301749],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978201,0.00023475986,0.00022752023,0.00040854316,0.00073832815,0.00057079864],"domain_scores_gemma":[0.99830544,0.00029169075,0.00013115963,0.0007491138,0.00025476614,0.00026780556],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004886565,0.00024457605,0.000342609,0.00023591229,0.00007879343,0.00005331181,0.00018125234,0.00010362029,0.0001573183],"category_scores_gemma":[0.00010579409,0.0001385636,0.000052284482,0.0006733315,0.0000722301,0.000069103335,0.000053494154,0.00013021305,0.00019007479],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.064367734,0.0010963104,0.6300261,0.00003592719,0.000213895,0.00026290203,0.0010854842,0.00003388877,0.2993216,0.0000010182277,0.0001768568,0.0033782905],"study_design_scores_gemma":[0.034545843,0.0067520654,0.80110174,0.00044269627,0.00007954845,0.000040743216,0.00016708371,0.00002824833,0.15561318,0.0000014169875,0.0010063688,0.00022102616],"about_ca_topic_score_codex":0.00038218385,"about_ca_topic_score_gemma":0.00014396815,"teacher_disagreement_score":0.17107569,"about_ca_system_score_codex":0.00031119672,"about_ca_system_score_gemma":0.00040144788,"threshold_uncertainty_score":0.56504595},"labels":[],"label_agreement":null},{"id":"W2921590257","doi":"10.1016/j.jcyt.2019.02.003","title":"Advancing cellular therapies towards standard of care: a focus on testing of cellular therapy products","year":2019,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"International Society for Cellular Therapy","funders":"","keywords":"Chimeric antigen receptor; Cell therapy; Genetic enhancement; Medicine; Cell; Intensive care medicine; Business; Immunology; Gene; Immunotherapy; Biology; Immune system; Genetics","score_opus":0.025992854661869104,"score_gpt":0.2952986005582571,"score_spread":0.26930574589638795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921590257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97790533,0.011647318,0.00023964605,0.0008137592,0.00022543299,0.002064359,0.000029144509,0.00009644557,0.006978578],"genre_scores_gemma":[0.9930226,0.0012225943,0.0033726394,0.00018320436,0.00027975018,0.00003923354,0.000013837299,0.00015557572,0.0017105505],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99688554,0.00017125087,0.0006083932,0.00060769275,0.0011416594,0.00058547163],"domain_scores_gemma":[0.9972371,0.0002475355,0.00030348718,0.0012020017,0.00087318465,0.00013673406],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00073640654,0.00038591598,0.0010612743,0.0003497378,0.00006218115,0.000020438683,0.00031655698,0.00016691774,0.0018363486],"category_scores_gemma":[0.00012353409,0.0003082101,0.00025935413,0.0008090819,0.00020378076,0.0000940772,0.00003606749,0.00038892071,0.000024440247],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004784908,0.00022163484,0.0072858897,0.00038142176,0.00022737274,0.00001779245,0.0035851728,0.00002630038,0.8213674,0.00016791323,0.000065100205,0.16186911],"study_design_scores_gemma":[0.005520609,0.009308165,0.001209985,0.00040470608,0.0000208092,0.0000075509583,0.0008509564,0.000039240298,0.9629358,0.0002915143,0.019142976,0.0002676813],"about_ca_topic_score_codex":0.00013067508,"about_ca_topic_score_gemma":0.0000045915845,"teacher_disagreement_score":0.16160144,"about_ca_system_score_codex":0.00021729596,"about_ca_system_score_gemma":0.0005993465,"threshold_uncertainty_score":0.999937},"labels":[],"label_agreement":null},{"id":"W2921870084","doi":"10.1016/j.stem.2019.02.013","title":"Close Quarters Can Be a Good Fit for Stem Cells to Become T Cells","year":2019,"lang":"en","type":"letter","venue":"Cell stem cell","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Biology; Mesoderm; Stem cell; Induced pluripotent stem cell; Cell biology; Haematopoiesis; Stromal cell; Mesenchymal stem cell; Organoid; Embryonic stem cell; Cell; Immunology; Genetics; Cancer research; Gene","score_opus":0.04010783111700474,"score_gpt":0.28767264997784114,"score_spread":0.2475648188608364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2921870084","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16891487,0.0033154378,0.00039714013,0.63515043,0.017215498,0.048448574,0.0075378306,0.0011493174,0.117870905],"genre_scores_gemma":[0.0040554805,0.00015882173,0.00034145813,0.27103826,0.0043929145,0.0005991797,0.0005623367,0.0007200912,0.7181314],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99143314,0.00034593913,0.0013303238,0.0023493047,0.001906335,0.0026349365],"domain_scores_gemma":[0.9936618,0.0013197133,0.00053911936,0.0031764307,0.00048296145,0.00081994734],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.00087360624,0.0014859851,0.0024936018,0.00090369844,0.0001987449,0.00025950273,0.0013942386,0.0020920367,0.003358914],"category_scores_gemma":[0.0000037892305,0.0014381135,0.0013616419,0.00060505193,0.00013957493,0.00008838291,0.00033233158,0.0033024296,0.0033412587],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040186857,0.00025011506,0.00002308199,0.005525825,0.00018856899,0.0006504068,0.001232398,0.00001998543,0.20401055,0.0000012952733,0.7853894,0.0023064683],"study_design_scores_gemma":[0.0033703092,0.0019210741,0.0000020296527,0.0002575908,0.00034118892,0.000022796123,0.00040567864,0.00006312614,0.2921923,0.000003964793,0.70041436,0.0010055518],"about_ca_topic_score_codex":0.00030363948,"about_ca_topic_score_gemma":0.00005529559,"teacher_disagreement_score":0.60026056,"about_ca_system_score_codex":0.0012536776,"about_ca_system_score_gemma":0.0008962809,"threshold_uncertainty_score":0.99978894},"labels":[],"label_agreement":null},{"id":"W2922063178","doi":"10.1093/annonc/mdx440.048","title":"Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: A randomized, double-blind, phase 3 trial (CheckMate 238)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Ipilimumab; Internal medicine; Nivolumab; Hazard ratio; Clinical endpoint; Population; Melanoma; Stage (stratigraphy); Randomized controlled trial; Oncology; Gastroenterology; Surgery; Cancer; Confidence interval; Immunotherapy","score_opus":0.24749111930518156,"score_gpt":0.4682165581798732,"score_spread":0.22072543887469162,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2922063178","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97615623,0.00095967745,0.00005952505,0.0020767138,0.0006641991,0.00407658,0.00006476367,0.00003442243,0.015907856],"genre_scores_gemma":[0.9922304,0.0021062766,0.00015132122,0.00015165895,0.0005201404,0.00046144487,0.00005106957,0.000061654115,0.004266014],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9965833,0.000549999,0.0009558971,0.00052507926,0.0007635982,0.0006221411],"domain_scores_gemma":[0.9958874,0.0006776999,0.000998863,0.0013199946,0.00087959034,0.00023647452],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0026360503,0.00033470412,0.002155326,0.0003864138,0.0001894645,0.000038719358,0.00044348277,0.0003347402,0.0030186994],"category_scores_gemma":[0.00024102733,0.00024816883,0.0005132493,0.00017487512,0.0013090369,0.00021149246,0.00013490775,0.00051389384,0.000022843695],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.94137436,0.002209171,0.00007684908,0.00009893459,0.0014757211,0.00021296972,0.0007434034,0.000004148963,0.024194818,0.00010242531,0.0005192081,0.028988011],"study_design_scores_gemma":[0.8966685,0.052732915,0.0001232652,0.00009121375,0.00018123651,0.000030674077,0.0001795616,0.00016936573,0.02719334,0.00005528351,0.022372527,0.00020211353],"about_ca_topic_score_codex":0.001532107,"about_ca_topic_score_gemma":0.00087685476,"teacher_disagreement_score":0.050523743,"about_ca_system_score_codex":0.00011477593,"about_ca_system_score_gemma":0.0007102843,"threshold_uncertainty_score":0.9999971},"labels":[],"label_agreement":null},{"id":"W2923979336","doi":"10.1111/cei.13297","title":"Methods to manufacture regulatory T cells for cell therapy","year":2019,"lang":"en","type":"review","venue":"Clinical & Experimental Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"Networks of Centres of Excellence of Canada; Canadian Institutes of Health Research; BC Children’s Hospital Foundation; Canadian Donation and Transplantation Research Program","keywords":"Clinical trial; Cell therapy; Medicine; Genome editing; Disease; Genetic enhancement; Regulatory T cell; Immunology; T cell; Cell; Immune system; Computational biology; Genome; Biology; Gene; Internal medicine; Genetics","score_opus":0.26687176563560006,"score_gpt":0.5797990509666617,"score_spread":0.3129272853310617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2923979336","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00041713018,0.98728156,0.00015554337,0.0001145116,0.003796274,0.005667241,0.00004050823,0.00010436107,0.0024228853],"genre_scores_gemma":[0.0000110127885,0.9323611,0.011521856,0.0014212397,0.00090942153,0.0010493805,0.00022833743,0.00029335145,0.05220425],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9938478,0.001503082,0.0019009422,0.0014812823,0.00031394296,0.0009529843],"domain_scores_gemma":[0.994072,0.0028069892,0.0004695837,0.0021430808,0.00012050447,0.00038780732],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0017609997,0.00085603574,0.0050073466,0.0003366204,0.00009670436,0.00003836365,0.00087610394,0.0020042236,0.0060718264],"category_scores_gemma":[0.00012529935,0.0006536432,0.0028548858,0.0002506928,0.00047084046,0.000044318087,0.00047298882,0.0017534998,0.0015268063],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012449119,0.0011776375,0.0000012420348,0.0017097614,0.0010255366,0.00001895188,0.0000952325,7.1804145e-8,0.046659943,0.000026865924,0.007204101,0.9408358],"study_design_scores_gemma":[0.0031769585,0.0055863904,0.0000064847422,0.0009665,0.0003220782,0.00005230757,0.00008716662,9.0322106e-7,0.08018428,0.0000118625485,0.9090865,0.00051855296],"about_ca_topic_score_codex":0.000009396592,"about_ca_topic_score_gemma":2.0788346e-7,"teacher_disagreement_score":0.9403172,"about_ca_system_score_codex":0.00046440912,"about_ca_system_score_gemma":0.0006572418,"threshold_uncertainty_score":0.99959147},"labels":[],"label_agreement":null},{"id":"W2924424204","doi":"10.1126/scitranslmed.aar5012","title":"Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy","year":2019,"lang":"en","type":"article","venue":"Science Translational Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":213,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"H2020 European Research Council; Instituto de Salud Carlos III; Fonds de Recherche du Québec - Santé; Fundación Fero; Ministerio de Economía y Competitividad; Worldwide Cancer Research; Fundación BBVA","keywords":"Proof of concept; Cell; Medicine; Chemistry; Cancer research; Computer science; Biochemistry","score_opus":0.04406228012434552,"score_gpt":0.337331160789339,"score_spread":0.29326888066499346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2924424204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97992784,0.00039412733,0.0009080842,0.005125601,0.00025516876,0.0018721934,0.000016606313,0.000029735518,0.01147064],"genre_scores_gemma":[0.99654007,0.000019114748,0.0014206644,0.00038121073,0.0002750626,0.00002191402,0.00001721048,0.000020137286,0.0013046396],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9965658,0.000064277374,0.00037877852,0.00057307474,0.001989056,0.00042897448],"domain_scores_gemma":[0.99833703,0.0003003825,0.00011092666,0.00044829247,0.00051087496,0.00029250327],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012075739,0.00018688706,0.0004811041,0.00034854907,0.00010912653,0.000017560595,0.0003490186,0.0000558925,0.0071207373],"category_scores_gemma":[0.00013347788,0.00013408475,0.0000627037,0.0014998538,0.0008056763,0.00029842835,0.00002819835,0.00029255834,0.00003273696],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037089433,0.00015322847,0.018670648,0.0000395028,0.000018350978,0.0000035880018,0.0019041911,0.00015046507,0.9131175,0.0000947793,0.000047452337,0.065429375],"study_design_scores_gemma":[0.0039915424,0.0014330404,0.11585029,0.00028359695,0.000016496897,0.000007633383,0.00021060088,0.0013017348,0.87508065,0.00030609514,0.0013578347,0.00016046461],"about_ca_topic_score_codex":0.00037010218,"about_ca_topic_score_gemma":0.000010938805,"teacher_disagreement_score":0.097179644,"about_ca_system_score_codex":0.000072497125,"about_ca_system_score_gemma":0.0008880731,"threshold_uncertainty_score":0.9937869},"labels":[],"label_agreement":null},{"id":"W2926447864","doi":"10.1097/hs9.0000000000000185","title":"CAR‐T Cell Therapy in Diffuse Large B Cell Lymphoma: Hype and Hope","year":2019,"lang":"en","type":"review","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Sanofi Genzyme; Therakos; Celgene; Mallinckrodt Pharmaceuticals; Gilead Sciences; Sanofi; AOP Orphan; GlaxoSmithKline; Amgen","keywords":"Medicine; Chimeric antigen receptor; Cytokine release syndrome; Lymphoma; Hematopoietic stem cell transplantation; Cell therapy; Clinical trial; Oncology; Transplantation; Immunotherapy; Adverse effect; Blinatumomab; Immunology; Internal medicine; Stem cell; CD19; Antigen; Immune system; Biology","score_opus":0.05290399143292113,"score_gpt":0.3387629218292847,"score_spread":0.28585893039636356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2926447864","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0035693434,0.9563654,0.0000016113712,0.000031314834,0.00021047094,0.002761345,0.000051564497,0.00006391559,0.036945023],"genre_scores_gemma":[0.00025602605,0.902877,0.000075574106,0.0001595306,0.00029333032,0.00015312292,0.00013273601,0.00024830134,0.09580443],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966037,0.00029146307,0.00068005413,0.0009294572,0.0006045221,0.0008907802],"domain_scores_gemma":[0.9977859,0.0003353217,0.00022216169,0.0012477601,0.00008548494,0.00032332842],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00048521403,0.00073868094,0.0027852408,0.00021967014,0.00005583873,0.00006497814,0.0003341393,0.00076035666,0.0044196974],"category_scores_gemma":[0.00002753116,0.0005622981,0.0005514665,0.00059585104,0.000086488035,0.00006733076,0.00021158856,0.0007973171,0.00079722906],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001364988,0.002843291,0.00017726839,0.03250128,0.00010859561,0.00038860567,0.00022047642,2.7476702e-8,0.00014366534,0.000016154214,0.003465016,0.95999914],"study_design_scores_gemma":[0.014862964,0.0003916089,0.000025576439,0.0043094587,0.00021898824,0.00011898431,0.00009912381,0.0000063374223,0.00010155037,0.0000073882634,0.9793566,0.0005014124],"about_ca_topic_score_codex":0.00012671588,"about_ca_topic_score_gemma":0.000050147322,"teacher_disagreement_score":0.9758916,"about_ca_system_score_codex":0.0003497485,"about_ca_system_score_gemma":0.00081952516,"threshold_uncertainty_score":0.99998075},"labels":[],"label_agreement":null},{"id":"W2928326859","doi":"10.1158/2326-6066.cir-18-0013","title":"Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment","year":2019,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"National Institutes of Health; Oncolytics Biotech; National Cancer Institute; National Institute for Health and Care Research; Cancer Research UK","keywords":"Phenotype; Immunotherapy; Cancer research; Cell culture; Cell; Biology; Immunology; Medicine; Cancer; Genetics; Gene","score_opus":0.0742356342109851,"score_gpt":0.36868867120983173,"score_spread":0.2944530369988466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2928326859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93924093,0.046728782,0.000005189068,0.0023516826,0.00040755924,0.0028630411,0.00008109289,0.000118601856,0.008203099],"genre_scores_gemma":[0.93425435,0.02286146,0.00023756346,0.00015086547,0.00044167828,0.0007968325,0.00012715453,0.00015201248,0.040978055],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9955298,0.00051243923,0.000388662,0.0010943258,0.0009515389,0.0015232557],"domain_scores_gemma":[0.9967718,0.00082509365,0.00010948977,0.0014618853,0.00054002233,0.0002917104],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0006451968,0.00045903272,0.0008581168,0.00034973546,0.00028596213,0.00009024985,0.0006326946,0.00032073498,0.046413124],"category_scores_gemma":[0.000047233236,0.00035663068,0.00026452602,0.0005670205,0.0007362441,0.00017058612,0.0002594203,0.0011219621,0.0016634546],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008330393,0.0016035811,0.050203145,0.00009704343,0.0006633862,0.0001912535,0.0022538512,0.000010885389,0.9068409,0.000011446959,0.00082763657,0.028966468],"study_design_scores_gemma":[0.016387617,0.009216626,0.025009817,0.00014573235,0.000056343055,0.000028309583,0.0013440336,0.00046311706,0.8580321,0.0001621319,0.08869642,0.000457722],"about_ca_topic_score_codex":0.007389186,"about_ca_topic_score_gemma":0.00046861882,"teacher_disagreement_score":0.08786878,"about_ca_system_score_codex":0.0013423448,"about_ca_system_score_gemma":0.0013021397,"threshold_uncertainty_score":0.99988854},"labels":[],"label_agreement":null},{"id":"W2936379593","doi":"10.1016/j.joca.2019.02.011","title":"Safe cell and gene therapy combination: are we there yet in arthritis?","year":2019,"lang":"en","type":"article","venue":"Osteoarthritis and Cartilage","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute","funders":"","keywords":"Arthritis; Induced pluripotent stem cell; Medicine; Genetic enhancement; Disease; Computational biology; Bioinformatics; Cell; Cancer research; Gene; Immunology; Biology; Internal medicine; Genetics; Embryonic stem cell","score_opus":0.015076649275773466,"score_gpt":0.2535215225541983,"score_spread":0.23844487327842484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2936379593","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9054588,0.076125465,5.331522e-7,0.0012971647,0.000112172995,0.0007527454,0.000023082224,0.000027414277,0.016202644],"genre_scores_gemma":[0.92727405,0.06402207,0.00004228718,0.00035703758,0.00006230545,0.000042376854,0.000019856832,0.000036409387,0.008143624],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99861056,0.000091946524,0.00024572093,0.00039342974,0.00031278768,0.0003455707],"domain_scores_gemma":[0.99931777,0.000069641006,0.000056473484,0.00031947123,0.00006595298,0.00017069656],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00026722773,0.00018856153,0.00040209747,0.00012224335,0.00006354928,0.000058820046,0.0000626759,0.00013490982,0.0028305673],"category_scores_gemma":[0.00000884805,0.00017911196,0.000060931405,0.00017905013,0.000112425994,0.00012117423,0.00005618724,0.00025822668,0.00006536792],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036549533,0.00015953861,0.076430954,0.00008739051,0.000004663555,0.00032955877,0.00067836547,4.82262e-7,0.60586977,0.00010637594,0.0004951427,0.31547228],"study_design_scores_gemma":[0.05634097,0.0063927514,0.097776,0.0019384145,0.000022177703,0.00081262883,0.0032997858,0.00004578707,0.5722393,0.0015826081,0.25855887,0.0009907564],"about_ca_topic_score_codex":0.000017862361,"about_ca_topic_score_gemma":0.00016930852,"teacher_disagreement_score":0.31448153,"about_ca_system_score_codex":0.000029910603,"about_ca_system_score_gemma":0.000042316085,"threshold_uncertainty_score":0.99808097},"labels":[],"label_agreement":null},{"id":"W2936424103","doi":"10.1007/978-3-030-11769-6_26","title":"Novel Therapies in Paediatric NHL","year":2019,"lang":"en","type":"book-chapter","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Chimeric antigen receptor; Immunotherapy; Refractory (planetary science); Disease; Oncology; Clinical trial; Intensive care medicine; Internal medicine; Cancer","score_opus":0.04353536456719345,"score_gpt":0.2996625126831642,"score_spread":0.2561271481159707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2936424103","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00042726725,0.003237715,0.00003462632,0.0008753827,0.00021804674,0.0009434145,0.000014338207,0.00006433108,0.99418485],"genre_scores_gemma":[0.0015450834,0.0029260525,0.00028914626,0.0006768333,0.0006015463,0.000009740429,0.00004918058,0.00012338988,0.993779],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99831945,0.00000914063,0.00031626565,0.00041469716,0.0006134429,0.00032702085],"domain_scores_gemma":[0.9989134,0.00017225202,0.00006663991,0.0006360915,0.000101591526,0.00010999472],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00029679207,0.00030541726,0.00061156537,0.0006208998,0.000014481999,0.000019913501,0.00016928522,0.00046163838,0.06457049],"category_scores_gemma":[0.000019419094,0.00023841784,0.00023372873,0.000071748436,0.00007333602,0.00003203454,0.00009526405,0.0008712597,0.0019535993],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002902135,0.0007675875,0.007472022,0.0017421236,0.0019425028,0.0006970416,0.0017455549,0.000007283888,0.09128382,0.29239076,0.0598933,0.5391559],"study_design_scores_gemma":[0.002785848,0.0003476943,0.0010765377,0.0001605933,0.00005130787,0.000056205066,0.000035835805,0.000028653143,0.0001695893,0.001408692,0.99352676,0.00035228307],"about_ca_topic_score_codex":0.00010559529,"about_ca_topic_score_gemma":0.00011038255,"teacher_disagreement_score":0.93363345,"about_ca_system_score_codex":0.00019918228,"about_ca_system_score_gemma":0.00036293312,"threshold_uncertainty_score":0.9988235},"labels":[],"label_agreement":null},{"id":"W2936882789","doi":"10.1186/s13046-019-1126-y","title":"Targeting late-stage non-small cell lung cancer with a combination of DNT cellular therapy and PD-1 checkpoint blockade","year":2019,"lang":"en","type":"article","venue":"Journal of Experimental & Clinical Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research; University of Toronto; Toronto General Hospital; University Health Network","funders":"National Cancer Institute; Canadian Institutes of Health Research; University Health Network; People's Government of Jilin Province; Canadian Cancer Society; National Natural Science Foundation of China","keywords":"Blockade; Immune checkpoint; Stage (stratigraphy); Medicine; Cancer research; PD-L1; Oncology; Apoptosis; Lung cancer; Pharmacology; Cancer; Internal medicine; Chemistry; Biology; Receptor; Immunotherapy; Biochemistry","score_opus":0.10535085609553471,"score_gpt":0.4687386574166479,"score_spread":0.36338780132111315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2936882789","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9782947,0.018540183,0.000015186151,0.00075894373,0.00023108456,0.0012688217,0.000008593771,0.0000068736426,0.0008756382],"genre_scores_gemma":[0.98618567,0.008483325,0.00033226694,0.00010597995,0.00043813468,0.000054986267,0.0000036012943,0.00006582495,0.004330219],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99568135,0.0004404066,0.0011606759,0.00040677885,0.0017329869,0.0005778146],"domain_scores_gemma":[0.99716204,0.00055140967,0.00051436457,0.00033635364,0.0009817028,0.00045414115],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0042092684,0.00022399085,0.0008414517,0.0003205322,0.00009545218,0.000054460146,0.00031341665,0.0001873666,0.004677907],"category_scores_gemma":[0.00007439263,0.00015928614,0.0002520216,0.0003748496,0.00038959336,0.00014836816,0.00017328412,0.0017133333,0.0000069588855],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0077798874,0.0011690917,0.1513018,0.00022201633,0.00025452374,0.00008874637,0.0011699166,0.00008388054,0.8363022,0.0000053092376,0.00021018018,0.0014124515],"study_design_scores_gemma":[0.014824379,0.007815974,0.015636863,0.00063063635,0.000035938476,0.000010597096,0.0018511743,0.0023679712,0.9542984,0.000006461293,0.002333432,0.00018820573],"about_ca_topic_score_codex":0.0010714752,"about_ca_topic_score_gemma":0.000020366853,"teacher_disagreement_score":0.13566494,"about_ca_system_score_codex":0.00054175255,"about_ca_system_score_gemma":0.0010237569,"threshold_uncertainty_score":0.996232},"labels":[],"label_agreement":null},{"id":"W2936913202","doi":"10.1182/bloodadvances.2018030577","title":"Targeting CD47 in Sézary syndrome with SIRPαFc","year":2019,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":98,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trillium Therapeutics (Canada)","funders":"National Cancer Institute","keywords":"CD47; Phagocytosis; Lymphoma; Decoy; Medicine; Cutaneous T-cell lymphoma; Cancer research; Immunology; Receptor; Internal medicine; Mycosis fungoides","score_opus":0.009672638446286328,"score_gpt":0.2801466938646356,"score_spread":0.27047405541834924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2936913202","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97946966,0.004311919,0.000006870401,0.0002746273,0.00007405648,0.0005062772,0.0000021551089,0.000051731,0.015302721],"genre_scores_gemma":[0.9867179,0.00041718574,0.0013865505,0.00015057872,0.00007747352,0.000026535457,0.000011656305,0.00003207212,0.011180069],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988027,0.000032614433,0.00016797875,0.00029042942,0.00036062367,0.00034562504],"domain_scores_gemma":[0.99947023,0.000098152515,0.000042812608,0.00025910634,0.000042529737,0.00008717263],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00020822725,0.00012499733,0.00028836066,0.00012570171,0.000024743416,0.0000134426145,0.00010609021,0.000044927358,0.00180013],"category_scores_gemma":[0.000036614558,0.00009355202,0.000036483576,0.00030521705,0.000052391893,0.0001772902,0.00003641786,0.00025715958,0.00015791487],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00079639076,0.0005137779,0.78475875,0.0004666513,0.0001256777,0.0024893223,0.00033039873,0.000275651,0.19705325,0.00008257122,0.00007007222,0.013037514],"study_design_scores_gemma":[0.04285132,0.0129272835,0.41775775,0.0036339585,0.0002955827,0.007354936,0.0043182,0.0008918782,0.11599791,0.0010437898,0.39086,0.0020673804],"about_ca_topic_score_codex":0.00002800582,"about_ca_topic_score_gemma":0.000022962562,"teacher_disagreement_score":0.39078993,"about_ca_system_score_codex":0.00002942664,"about_ca_system_score_gemma":0.00007496431,"threshold_uncertainty_score":0.99911237},"labels":[],"label_agreement":null},{"id":"W2939487002","doi":"10.1080/14712598.2019.1608179","title":"Facing the future: challenges and opportunities in adoptive T cell therapy in cancer","year":2019,"lang":"en","type":"review","venue":"Expert Opinion on Biological Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Immunotherapy; Tumor microenvironment; Chimeric antigen receptor; T cell; Cancer immunotherapy; Context (archaeology); Medicine; Adoptive cell transfer; Cell therapy; Cancer; Cancer research; Immune system; Immunology; Cell; Biology; Internal medicine","score_opus":0.5050365452917507,"score_gpt":0.4602758091893972,"score_spread":0.04476073610235348,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2939487002","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004813971,0.990005,3.666456e-7,0.003879794,0.0006738211,0.0028466587,0.000019859826,0.00004312105,0.0020499506],"genre_scores_gemma":[0.00012332914,0.9950368,0.000012038927,0.002180108,0.0011642943,0.000975449,0.00008906631,0.00006982402,0.0003491333],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99649537,0.0011013434,0.0006078427,0.0008456102,0.0003745619,0.0005752785],"domain_scores_gemma":[0.9982822,0.00072071777,0.00019853386,0.0005989368,0.000066259076,0.00013335816],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00083915837,0.000673645,0.0019925463,0.00035568886,0.000064686974,0.000035245113,0.0003889443,0.0008045979,0.0013845998],"category_scores_gemma":[0.000016980934,0.00032024694,0.0003727879,0.00024239218,0.00025763284,0.00004692079,0.000087346176,0.001306445,0.000020170211],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006179204,0.00029367468,0.000015989157,0.00018037911,0.000087781555,0.000020063817,0.0013117451,2.1628557e-7,0.00006969391,0.0002553955,0.00022244648,0.9969247],"study_design_scores_gemma":[0.0019092647,0.0019897467,0.00020736546,0.0027096332,9.062545e-7,0.000017044898,0.0012900867,0.000002641045,0.00003101696,0.000039825325,0.99142617,0.00037629332],"about_ca_topic_score_codex":0.000059313214,"about_ca_topic_score_gemma":0.000009077406,"teacher_disagreement_score":0.9965484,"about_ca_system_score_codex":0.00026393106,"about_ca_system_score_gemma":0.00025329358,"threshold_uncertainty_score":0.99992496},"labels":[],"label_agreement":null},{"id":"W2942462405","doi":"10.1093/neuonc/noz036.126","title":"IMMU-05. COMBINATIONAL CAR T-CELL AND EPIGENETIC MODIFIER THERAPY TO TARGET POSTERIOR FOSSA TUMORS","year":2019,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medulloblastoma; Medicine; Oncology; Internal medicine; Ependymoma; Cancer research; Gastroenterology; Surgery","score_opus":0.02445736219046114,"score_gpt":0.31455335705601534,"score_spread":0.2900959948655542,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2942462405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9771778,0.0004583807,0.000013850197,0.00688201,0.0005286495,0.0014992907,0.000014572875,0.000043426775,0.013382027],"genre_scores_gemma":[0.984466,0.00021210586,0.00036412064,0.0082137985,0.00016588619,0.00008960045,0.000025635596,0.00006479542,0.006398029],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980744,0.00023593564,0.00030194258,0.0005103583,0.00039930482,0.00047802704],"domain_scores_gemma":[0.9985471,0.00041128322,0.00006970524,0.00042238308,0.00017262613,0.0003769284],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003143308,0.00021116657,0.00049456826,0.0002294068,0.000065178014,0.000024081286,0.00018395852,0.00017242796,0.004449735],"category_scores_gemma":[0.0000814566,0.00019147339,0.00009180514,0.00020608043,0.00011930407,0.000045401608,0.00013484464,0.00040376547,0.00037994154],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00089355535,0.00029805375,0.006370114,0.000029354294,0.000030190506,0.00025928894,0.0005782441,0.000021574184,0.9623919,0.00005406823,0.001584224,0.027489416],"study_design_scores_gemma":[0.014080702,0.015698384,0.051813487,0.000024888483,0.000029682542,0.0013402819,0.00025335155,0.0007048985,0.2668497,0.0003525288,0.64844084,0.0004112784],"about_ca_topic_score_codex":0.000042490385,"about_ca_topic_score_gemma":0.000003959637,"teacher_disagreement_score":0.6955422,"about_ca_system_score_codex":0.00017870526,"about_ca_system_score_gemma":0.0004547174,"threshold_uncertainty_score":0.9964603},"labels":[],"label_agreement":null},{"id":"W2943387000","doi":"10.1101/625285","title":"Efficient and robust NK-Cell transduction with Baboon Envelope pseudotyped lentivector: a major tool for immunotherapy","year":2019,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec; Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"National Cancer Institute; Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; Fondation ARC pour la Recherche sur le Cancer; Institut National de la Santé et de la Recherche Médicale","keywords":"Biology; Vesicular stomatitis virus; Transduction (biophysics); Baboon; CD19; Virology; Measles virus; Cell culture; Molecular biology; Antigen; Immunology; Virus; Genetics","score_opus":0.017089277477769473,"score_gpt":0.2381834091941415,"score_spread":0.22109413171637202,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943387000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9795427,0.0025045797,0.010687541,0.00030713534,0.0007732003,0.005676135,0.00019552754,0.00027593027,0.000037268426],"genre_scores_gemma":[0.98356515,0.0009434601,0.01316346,0.00016506351,0.00057475234,0.00076662545,0.0000024162503,0.00036594103,0.00045310272],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99636877,0.00013902134,0.0005614253,0.0014365675,0.00070711196,0.0007870846],"domain_scores_gemma":[0.99707806,0.00013185365,0.00030793875,0.0014333159,0.00078720617,0.00026164416],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009150951,0.0007425366,0.0009976178,0.00046687963,0.00018336378,0.0002036807,0.00031308472,0.0005951853,0.00051704765],"category_scores_gemma":[0.00005212111,0.00067293143,0.00025151027,0.00043715286,0.00021124847,0.00007029486,0.00012711885,0.0009911716,0.000043006967],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033649171,0.0004896052,0.0035040579,0.0020726724,0.0005401288,0.00002597635,0.00006271725,0.00051050057,0.98919505,0.000051182287,0.00015172166,0.000031476076],"study_design_scores_gemma":[0.014396957,0.0015940709,0.06810075,0.001412535,0.0006152733,5.290183e-7,0.000022252809,0.0041167336,0.89302117,8.756439e-7,0.015066912,0.0016519553],"about_ca_topic_score_codex":0.000056814722,"about_ca_topic_score_gemma":0.0000027382107,"teacher_disagreement_score":0.09617389,"about_ca_system_score_codex":0.0005149597,"about_ca_system_score_gemma":0.0010717645,"threshold_uncertainty_score":0.9995722},"labels":[],"label_agreement":null},{"id":"W2947005140","doi":"10.1200/jco.2019.37.15_suppl.e14220","title":"MDNA109: Effect of an interleukin-2 superkine on CD8 T-cell properties in the tumor microenvironment.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pharma Medica Research (Canada); Université de Montréal","funders":"","keywords":"IL-2 receptor; Cytotoxic T cell; Cancer research; CD8; Interleukin 2; Cytokine; Immunotherapy; Tumor microenvironment; Medicine; T cell; In vivo; Immune system; Immunology; Molecular biology; Biology; In vitro; Biochemistry","score_opus":0.0849344890506948,"score_gpt":0.4362207527314609,"score_spread":0.3512862636807661,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947005140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909386,0.00022986597,9.0293565e-7,0.0028148578,0.0004444087,0.0005672785,0.0000010214883,0.0000027114659,0.0050003766],"genre_scores_gemma":[0.9958007,0.00023918318,0.000117302356,0.0019200847,0.000509611,0.0000053278372,0.0000012033651,0.000020847932,0.0013857741],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99549395,0.0018530892,0.0016385876,0.00018802399,0.0005717583,0.00025462027],"domain_scores_gemma":[0.9959546,0.0027762298,0.00063339947,0.00039089657,0.00007841348,0.00016648861],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00779793,0.00014477452,0.0013652198,0.00016734851,0.000013565036,0.000007660464,0.00040815995,0.00019084734,0.0012653456],"category_scores_gemma":[0.0010014072,0.000070903705,0.00041957383,0.00010958639,0.0002819042,0.000073370684,0.000058653535,0.001588927,0.00008125099],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05256158,0.0072917473,0.19809401,0.00025507066,0.00022187908,0.0010709658,0.0007078281,0.000044023225,0.6299804,0.000009873305,0.0010416002,0.10872105],"study_design_scores_gemma":[0.04390281,0.38051337,0.25680417,0.0006877083,0.0003106825,0.0014208797,0.00092045096,0.00027785296,0.13601623,0.000054640226,0.17884992,0.00024127148],"about_ca_topic_score_codex":0.000023025033,"about_ca_topic_score_gemma":0.000018359657,"teacher_disagreement_score":0.49396414,"about_ca_system_score_codex":0.00015721214,"about_ca_system_score_gemma":0.00035190454,"threshold_uncertainty_score":0.9996476},"labels":[],"label_agreement":null},{"id":"W2947087421","doi":"10.1200/jco.2019.37.15_suppl.2537","title":"Effect of minimal lymphodepletion prior to ACT with TBI-1301, NY-ESO-1 specific gene-engineered TCR-T cells, on clinical responses and CRS.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Fludarabine; Immunology; Cyclophosphamide; Adoptive cell transfer; Cytokine release syndrome; Internal medicine; T cell; Immune system; Chemotherapy; Chimeric antigen receptor","score_opus":0.09368089686190016,"score_gpt":0.47088243630873095,"score_spread":0.37720153944683077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947087421","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99377096,0.00033231464,0.000051937695,0.0025709572,0.0011888875,0.0008589033,0.0000071830095,0.000013557976,0.0012053108],"genre_scores_gemma":[0.9900032,0.0014771229,0.0037158355,0.0008983666,0.0016058245,0.000005613916,0.0000025425134,0.00005579962,0.002235694],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9929581,0.0024422018,0.0028412484,0.00045198147,0.0008928934,0.000413533],"domain_scores_gemma":[0.9774435,0.019600537,0.0011903758,0.00050205924,0.000480907,0.00078262354],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014595335,0.00026770445,0.0026188218,0.0003699135,0.000032636566,0.000017145494,0.00027162768,0.0006287878,0.00075609726],"category_scores_gemma":[0.004788677,0.00017099452,0.00060157216,0.0002663097,0.00031850385,0.00007653858,0.00008999495,0.001458908,0.000100344885],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38725182,0.002390506,0.17533763,0.00017745429,0.0007703345,0.0010101732,0.00013229804,0.000052305746,0.12304532,0.000015194423,0.005678646,0.30413833],"study_design_scores_gemma":[0.032656964,0.3279675,0.481502,0.00039223992,0.00035120055,0.0007755192,0.000056076242,0.000118603304,0.028601715,0.000008754611,0.12733117,0.00023826025],"about_ca_topic_score_codex":0.0000074406116,"about_ca_topic_score_gemma":0.0000061084797,"teacher_disagreement_score":0.35459486,"about_ca_system_score_codex":0.00023997792,"about_ca_system_score_gemma":0.0013319758,"threshold_uncertainty_score":0.82787347},"labels":[],"label_agreement":null},{"id":"W2947759305","doi":"10.1200/jco.2019.37.15_suppl.9504","title":"United States Intergroup E1609: A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon-α2b for resected high-risk melanoma.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Internal medicine; Clinical endpoint; Discontinuation; Ipilimumab; Adverse effect; Placebo; Adjuvant; Hazard ratio; Randomized controlled trial; Intention-to-treat analysis; Oncology; Gastroenterology; Surgery; Cancer; Confidence interval; Immunotherapy; Pathology","score_opus":0.1243248276908649,"score_gpt":0.49600989343293717,"score_spread":0.3716850657420723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947759305","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909097,0.00019384809,0.00024013319,0.0013490749,0.0033425915,0.0036604146,0.00004552241,0.000028315993,0.0002304124],"genre_scores_gemma":[0.99159074,0.0011915658,0.0012075296,0.00028311793,0.00097602134,0.0000713998,0.000072006085,0.00007702867,0.004530603],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9885586,0.0036541205,0.0057349214,0.00050559593,0.00094537786,0.00060136913],"domain_scores_gemma":[0.95972496,0.032745287,0.003908312,0.00072421686,0.0022539455,0.00064325565],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.013028889,0.00038215576,0.006072917,0.0008625466,0.00006169707,0.000023837034,0.00064190465,0.00055394496,0.0072599812],"category_scores_gemma":[0.017288236,0.00023595938,0.0011136543,0.0006014834,0.0005131989,0.00015828334,0.00025221403,0.0021367846,0.000042427357],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9213307,0.014099493,0.0007656218,0.000091081405,0.0054227235,0.00045009673,0.0010882571,0.000039894745,0.0028463388,0.00002331105,0.003107153,0.05073534],"study_design_scores_gemma":[0.71991444,0.25951698,0.0008889875,0.00018963397,0.001652406,0.00006346353,0.0024352514,0.002190805,0.00053292763,0.00014823847,0.012290572,0.00017627004],"about_ca_topic_score_codex":0.0006872066,"about_ca_topic_score_gemma":0.00064406445,"teacher_disagreement_score":0.24541749,"about_ca_system_score_codex":0.0004218579,"about_ca_system_score_gemma":0.0016348154,"threshold_uncertainty_score":0.9936475},"labels":[],"label_agreement":null},{"id":"W2949444368","doi":"10.1097/01.hs9.0000561592.51072.9b","title":"S828 A RANDOMIZED, DOUBLE BLIND PHASE 2 STUDY OF 3 DIFFERENT DOSES OF PRM‐151 IN PATIENTS WITH MYELOFIBROSIS WHO WERE PREVIOUSLY TREATED WITH OR INELIGIBLE FOR RUXOLITINIB","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myelofibrosis; Medicine; Ruxolitinib; Essential thrombocythemia; Internal medicine; Randomization; Bone marrow; Polycythemia vera; Gastroenterology; Randomized controlled trial; Anemia","score_opus":0.031235462883460782,"score_gpt":0.3296657506900283,"score_spread":0.2984302878065675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949444368","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98188585,0.0001348473,0.000012124741,0.000029009962,0.000019247751,0.016455403,0.000033372857,0.000029175097,0.00140094],"genre_scores_gemma":[0.98883843,0.000041200667,0.00016588645,0.000013555251,0.000028399247,0.00089735,0.00008452416,0.00008081189,0.009849867],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.997447,0.00013486133,0.0007398194,0.00047809753,0.00073595723,0.0004642553],"domain_scores_gemma":[0.99800646,0.00037448332,0.0003316171,0.0006615399,0.0004655835,0.00016030484],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00032623994,0.00034802422,0.0018759411,0.00018304716,0.000029380792,0.000018238443,0.00016204463,0.00010937077,0.0021442124],"category_scores_gemma":[0.00005312975,0.00018875452,0.00014890893,0.000515019,0.0001296993,0.000098377095,0.000053953525,0.0001900488,0.0000043678638],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.69073164,0.0072963284,0.2959671,0.00126226,0.0004859821,0.000006857167,0.0015579554,0.000010965511,0.0011711885,0.00001568151,0.00008123071,0.001412789],"study_design_scores_gemma":[0.93853724,0.026462601,0.008935053,0.0018013589,0.00040308328,0.000003967467,0.0018775786,0.00011347451,0.021509368,0.0000088704855,0.000097068754,0.00025031142],"about_ca_topic_score_codex":0.00046183597,"about_ca_topic_score_gemma":0.00042347505,"teacher_disagreement_score":0.28703204,"about_ca_system_score_codex":0.00009242212,"about_ca_system_score_gemma":0.00019288994,"threshold_uncertainty_score":0.998768},"labels":[],"label_agreement":null},{"id":"W2949669015","doi":"10.1097/01.hs9.0000562584.48238.c8","title":"PS1073 PRELIMINARY RESULTS OF ASTX660, A NOVEL NON‐PEPTIDOMIMETIC CIAP1/2 AND XIAP ANTAGONIST, IN RELAPSED/REFRACTORY PERIPHERAL T‐CELL LYMPHOMA AND CUTANEOUS T CELL LYMPHOMA","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lymphoma; Mycosis fungoides; Internal medicine; Refractory (planetary science); Adverse effect; Peripheral T-cell lymphoma; Cutaneous T-cell lymphoma; Brentuximab vedotin; Oncology; Gastroenterology; T cell; Immunology; Hodgkin lymphoma; Immune system","score_opus":0.010926125519944384,"score_gpt":0.2491841757747903,"score_spread":0.23825805025484592,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949669015","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9547735,0.0035213185,0.00000940207,0.00015061973,0.00013791931,0.0012742354,0.00005424823,0.00004860329,0.04003015],"genre_scores_gemma":[0.94295025,0.0006622133,0.00115912,0.00014797675,0.0001180129,0.000030375133,0.000032736454,0.000117840835,0.054781478],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99677795,0.00011068261,0.00079724955,0.0009265444,0.00066446955,0.0007231284],"domain_scores_gemma":[0.99791807,0.00040427034,0.00025870636,0.0009019497,0.00015077772,0.00036622965],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00043071204,0.0004665877,0.00094731024,0.00019030795,0.000075386626,0.000046639463,0.00022016357,0.00039452408,0.0010327926],"category_scores_gemma":[0.00007979331,0.00044166262,0.00015372632,0.000399345,0.00032701693,0.00011911754,0.00024828987,0.00032303226,0.00006416282],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023766695,0.0032674135,0.0104048345,0.0019221911,0.00009066265,0.00068366725,0.0034671838,0.000036813228,0.923413,0.0000118159,0.001188073,0.03174767],"study_design_scores_gemma":[0.23333423,0.028843489,0.088538356,0.0028724498,0.00044355562,0.0075263404,0.010326814,0.018469142,0.56149715,0.00013679692,0.045404278,0.002607384],"about_ca_topic_score_codex":0.00047519436,"about_ca_topic_score_gemma":0.0000673755,"teacher_disagreement_score":0.3619158,"about_ca_system_score_codex":0.00033590192,"about_ca_system_score_gemma":0.0004550919,"threshold_uncertainty_score":0.9998804},"labels":[],"label_agreement":null},{"id":"W2949814266","doi":"10.1002/hon.118_2630","title":"CORRELATIVE ANALYSES OF CYTOKINE RELEASE SYNDROME AND NEUROLOGICAL EVENTS IN TISAGENLECLEUCEL‐TREATED RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA PATIENTS","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; McMaster University","funders":"","keywords":"Cytokine release syndrome; Medicine; Internal medicine; Refractory (planetary science); Gastroenterology; Clinical endpoint; Lymphoma; Diffuse large B-cell lymphoma; Phases of clinical research; Cytokine; Peripheral T-cell lymphoma; Clinical trial; Immunotherapy; Immunology; T cell; Immune system; Cancer; Biology","score_opus":0.03648638014391697,"score_gpt":0.33761168354361193,"score_spread":0.30112530339969495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2949814266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949792,0.00031993078,0.000009088615,0.00017543219,0.00009799022,0.0010939562,0.000023668923,0.000054589655,0.0032461702],"genre_scores_gemma":[0.99769706,0.0002615998,0.000115372175,0.0004323085,0.000010830584,0.000045855748,0.000074819414,0.000029746605,0.0013323888],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967701,0.0007265485,0.00075665285,0.000683933,0.00043341503,0.00062935223],"domain_scores_gemma":[0.9976528,0.0011834506,0.00028648955,0.00041979222,0.00014863534,0.00030880788],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00035893294,0.00031073176,0.0014263025,0.0003188635,0.000042837233,0.000003738064,0.00018336152,0.0006616547,0.002201002],"category_scores_gemma":[0.0005287587,0.00022353535,0.00017402548,0.0005175185,0.0002544988,0.000076771044,0.00026254644,0.0005756715,0.00018055651],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044807415,0.016233364,0.9585636,0.00014138802,0.00008777887,0.0020001198,0.00012804527,0.0000023681532,0.016436933,0.00010155013,0.0000900702,0.0017340278],"study_design_scores_gemma":[0.033957448,0.011849665,0.94838566,0.00007151147,0.00010091249,0.00059442304,0.00006695381,0.0007371784,0.0019192132,0.00018094225,0.0019021706,0.00023395257],"about_ca_topic_score_codex":0.000056069257,"about_ca_topic_score_gemma":0.000013870248,"teacher_disagreement_score":0.029476708,"about_ca_system_score_codex":0.00020251084,"about_ca_system_score_gemma":0.00012080874,"threshold_uncertainty_score":0.9987111},"labels":[],"label_agreement":null},{"id":"W2950210042","doi":"10.1002/hon.119_2630","title":"MANAGING CYTOKINE RELEASE SYNDROME (CRS) AND NEUROTOXICITY WITH STEP‐UP DOSING OF MOSUNETUZUMAB IN RELAPSED/REFRACTORY (R/R) B‐CELL NON‐HODGKIN LYMPHOMA (NHL)","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia; Jewish General Hospital; BC Cancer Agency","funders":"","keywords":"Medicine; Dosing; Cytokine release syndrome; Adverse effect; Gastroenterology; Chills; Internal medicine; Refractory (planetary science); Toxicity; Lymphoma; Neurotoxicity; Anesthesia; Immunotherapy; Cancer; Chimeric antigen receptor","score_opus":0.021715764776681783,"score_gpt":0.2974048794280057,"score_spread":0.2756891146513239,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950210042","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98779213,0.0003565152,0.00010267809,0.0006676169,0.0001087851,0.0014409273,0.0000045085326,0.00006319625,0.009463629],"genre_scores_gemma":[0.99652475,0.00025058177,0.000995503,0.0005046201,0.000022510194,0.000061973326,0.000009011689,0.000047621783,0.001583456],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99715203,0.00034671836,0.00066286273,0.0007160889,0.0004533451,0.0006689559],"domain_scores_gemma":[0.9979835,0.0008085261,0.00025953157,0.00056334963,0.000099182114,0.0002859196],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005556806,0.00031989967,0.0013894498,0.00034460457,0.00004989278,0.000013226493,0.00021139669,0.00044133601,0.0011343606],"category_scores_gemma":[0.00012642257,0.0002398691,0.000105801715,0.0005001218,0.00041392603,0.0000785731,0.00022653468,0.0006581138,0.00006194666],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029130308,0.005345892,0.3195799,0.003075826,0.00023452398,0.025953721,0.00087228615,0.00011957026,0.54675037,0.0009212164,0.00043456696,0.06758181],"study_design_scores_gemma":[0.13426478,0.09467867,0.5313249,0.0028453723,0.0005350563,0.056699384,0.0029306419,0.029755624,0.11103548,0.0014215476,0.031886097,0.0026224053],"about_ca_topic_score_codex":0.00015928531,"about_ca_topic_score_gemma":0.000047783797,"teacher_disagreement_score":0.4357149,"about_ca_system_score_codex":0.00038021026,"about_ca_system_score_gemma":0.00029513382,"threshold_uncertainty_score":0.99977875},"labels":[],"label_agreement":null},{"id":"W2950542774","doi":"10.1097/01.hs9.0000559388.41193.da","title":"PF294 IMPROVED OUTCOMES IN PATIENTS (PTS) WITH BCL2‐POSITIVE DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) TREATED WITH VENETOCLAX (VEN) PLUS R‐CHOP: RESULTS FROM THE PHASE 2 CAVALLI STUDY","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital de l'Enfant-Jésus; Jewish General Hospital","funders":"","keywords":"Medicine; International Prognostic Index; Internal medicine; Diffuse large B-cell lymphoma; Clinical endpoint; CHOP; Rituximab; Oncology; Lymphoma; Regimen; Gastroenterology; Randomized controlled trial","score_opus":0.01167698582169717,"score_gpt":0.27383872382028873,"score_spread":0.26216173799859155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950542774","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99083585,0.00013915182,0.0000067354426,0.00013679158,0.00008923203,0.00546938,0.00041473858,0.00009495323,0.002813183],"genre_scores_gemma":[0.9801942,0.000017669034,0.00008688611,0.0002872711,0.000088521236,0.00017890599,0.000395539,0.00013976355,0.01861121],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99635625,0.0003000169,0.00057149836,0.0009494185,0.0009999885,0.0008228254],"domain_scores_gemma":[0.9971785,0.0005050685,0.00024263043,0.0014408466,0.00035628444,0.0002766697],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00035086562,0.00054137845,0.0009234873,0.000082257735,0.00012927638,0.00007630308,0.000359596,0.00017378911,0.00082813593],"category_scores_gemma":[0.00009538018,0.00030704838,0.00012883538,0.0005575063,0.000108596374,0.00015755939,0.00014128057,0.00046524827,0.00017200045],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0661178,0.029249864,0.8825102,0.00006501922,0.0009863044,0.0005424003,0.009445323,0.00002520961,0.0045893565,0.0000030246554,0.0005566457,0.005908879],"study_design_scores_gemma":[0.47824308,0.014174705,0.49176663,0.00036443496,0.0003241776,0.000007831152,0.006578345,0.0012546696,0.0047120675,0.0000037754642,0.0019466291,0.00062367064],"about_ca_topic_score_codex":0.006310521,"about_ca_topic_score_gemma":0.00426797,"teacher_disagreement_score":0.41212526,"about_ca_system_score_codex":0.0010650214,"about_ca_system_score_gemma":0.0005140634,"threshold_uncertainty_score":0.9999382},"labels":[],"label_agreement":null},{"id":"W2950731790","doi":"10.1097/01.hs9.0000562564.17744.e5","title":"PS1067 AXICABTAGENE CILOLEUCEL (AXI‐CEL) IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA: PRELIMINARY RESULTS OF EARLIER STEROID USE","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Cytokine release syndrome; Internal medicine; Adverse effect; Refractory (planetary science); Cohort; Tocilizumab; Lymphoma; Gastroenterology; Clinical endpoint; Surgery; Oncology; Chimeric antigen receptor; Cancer; Disease; Randomized controlled trial; Immunotherapy","score_opus":0.012470315148255274,"score_gpt":0.23937852626221545,"score_spread":0.22690821111396017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2950731790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9814812,0.00047004112,0.000006701129,0.00006221369,0.00013427538,0.0013752864,0.00009962716,0.00004919868,0.016321437],"genre_scores_gemma":[0.9352751,0.00007897788,0.0004405599,0.00014701969,0.000055559158,0.000028022598,0.00015016364,0.00010513769,0.0637195],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99689627,0.00014711295,0.0006233001,0.0006562483,0.0009993162,0.00067773374],"domain_scores_gemma":[0.99778265,0.0002173458,0.00023423636,0.0012342759,0.00028167316,0.00024983496],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003928481,0.0003323796,0.00064063317,0.00015921805,0.000039851562,0.000022626902,0.0002307469,0.0002731146,0.0027627524],"category_scores_gemma":[0.000076167235,0.00027237623,0.00013608464,0.0004407562,0.00009317944,0.0002694471,0.00016908841,0.00040358046,0.00032650752],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0714377,0.014324846,0.84024423,0.001244084,0.00021765164,0.00030231604,0.0024472189,0.00003469707,0.04955077,0.000018709943,0.008093172,0.012084605],"study_design_scores_gemma":[0.09033931,0.0115288785,0.82125527,0.00079733116,0.00008189966,0.00001285542,0.00063888705,0.00012885552,0.03425743,0.000008360669,0.040389348,0.0005615514],"about_ca_topic_score_codex":0.00016872343,"about_ca_topic_score_gemma":0.000059944352,"teacher_disagreement_score":0.047398064,"about_ca_system_score_codex":0.00025111315,"about_ca_system_score_gemma":0.00026350812,"threshold_uncertainty_score":0.9999728},"labels":[],"label_agreement":null},{"id":"W2951090524","doi":"10.1097/01.hs9.0000564792.15111.43","title":"S1636 FRACTIONATED DOSING OF ARI‐0001 CELLS (A3B1:CD8:4–1BB:CD3Z CAR19) AND EARLY TOCILIZUMAB ADMINISTRATION MAY REDUCE THE INCIDENCE OF SEVERE CYTOKINE RELEASE SYNDROME IN PATIENTS WITH CD19+ MALIGNANCIES","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Apheresis Group","funders":"","keywords":"Medicine; Cytokine release syndrome; Cyclophosphamide; Fludarabine; Internal medicine; Cohort; Cytokine; CD8; Toxicity; Immunology; Dosing; Gastroenterology; Immune system; Cancer; Chemotherapy; Immunotherapy","score_opus":0.012196298858509851,"score_gpt":0.25969541848738176,"score_spread":0.24749911962887192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951090524","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967074,0.0002322458,0.0000052909945,0.00020529173,0.00006048919,0.0011652452,0.000027654873,0.000019070556,0.0015773142],"genre_scores_gemma":[0.99562633,0.000049082155,0.00025605125,0.000032846197,0.000018757833,0.000023189828,0.00002379819,0.0000348028,0.0039351354],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980628,0.00010556255,0.00044961157,0.00034700814,0.00075304386,0.0002820086],"domain_scores_gemma":[0.99859446,0.00018566618,0.0002596539,0.00050218735,0.00035738136,0.00010065221],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00027129575,0.00019996818,0.000440263,0.00008562497,0.00004861876,0.000021717777,0.00013279924,0.00014024242,0.0011275578],"category_scores_gemma":[0.00007522605,0.00014484434,0.00005937872,0.00048316558,0.00018142251,0.00021923656,0.000057205965,0.00034727977,0.000013628738],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064312085,0.00063402916,0.6388951,0.0009640692,0.00015225711,0.00012753213,0.0015509477,0.00013396845,0.3469519,0.00012976461,0.00019517151,0.0038340415],"study_design_scores_gemma":[0.005642319,0.0027766544,0.855926,0.001303053,0.00007215733,0.00018074956,0.0011480307,0.000101062986,0.1321613,0.0000519296,0.00038801873,0.00024872913],"about_ca_topic_score_codex":0.0008856234,"about_ca_topic_score_gemma":0.00014479656,"teacher_disagreement_score":0.21703088,"about_ca_system_score_codex":0.00014299393,"about_ca_system_score_gemma":0.00031451392,"threshold_uncertainty_score":0.99978554},"labels":[],"label_agreement":null},{"id":"W2951165653","doi":"10.1097/01.hs9.0000559032.62059.eb","title":"PF204 TARP AS IMMUNOTHERAPEUTIC TARGET IN AML EXPRESSED IN THE LSC COMPARTMENT","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Saint-Luc","funders":"","keywords":"CD34; CD38; Haematopoiesis; Stem cell; Biology; Cancer research; Myeloid leukemia; Leukemia; Cytotoxic T cell; Cord blood; T-cell receptor; Hematopoietic stem cell; Immunology; T cell; Immune system; Cell biology; In vitro","score_opus":0.02690869596386572,"score_gpt":0.3173762327065463,"score_spread":0.29046753674268055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951165653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93320596,0.0028322786,0.00000827498,0.002230777,0.000107818545,0.0015023533,0.0000036414795,0.000032925374,0.060075942],"genre_scores_gemma":[0.9804209,0.00015054713,0.00022910604,0.0018157373,0.000075037424,0.00013317318,0.000024443021,0.00004141999,0.01710965],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981249,0.00020033585,0.00031551416,0.00031893075,0.0005654245,0.0004748731],"domain_scores_gemma":[0.9988933,0.00019632155,0.000047589056,0.00075870764,0.000037188307,0.00006688507],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00055235403,0.00018924096,0.00038342108,0.0000756838,0.00002904799,0.00003278718,0.00028379966,0.00010187844,0.030585812],"category_scores_gemma":[0.0000201809,0.00013306529,0.00010287926,0.00038583414,0.00006251567,0.00006410043,0.000050849252,0.00048998836,0.0012504428],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003301121,0.0023866352,0.20168811,0.0004924402,0.00022937827,0.0005807037,0.012785714,0.00033329107,0.7475764,0.0015564325,0.007920988,0.021148782],"study_design_scores_gemma":[0.018415043,0.0015391406,0.09282438,0.0006808785,0.000037140366,0.0001433166,0.009291891,0.0021662554,0.06740147,0.0021123195,0.8047481,0.00064003334],"about_ca_topic_score_codex":0.00044532993,"about_ca_topic_score_gemma":0.00014214299,"teacher_disagreement_score":0.79682714,"about_ca_system_score_codex":0.00019024468,"about_ca_system_score_gemma":0.00014305428,"threshold_uncertainty_score":0.9995272},"labels":[],"label_agreement":null},{"id":"W2951473081","doi":"10.1002/hon.127_2629","title":"HIGH RATE OF DURABLE COMPLETE REMISSION IN FOLLICULAR LYMPHOMA AFTER CD19 CAR‐T CELL IMMUNOTHERAPY","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Follicular lymphoma; Chemoimmunotherapy; Fludarabine; Internal medicine; Lymphoma; Cyclophosphamide; Gastroenterology; Immunotherapy; Oncology; Rituximab; Immunology; Surgery; Chemotherapy; Cancer","score_opus":0.025236009386087662,"score_gpt":0.31089935114862133,"score_spread":0.28566334176253366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951473081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886222,0.0009476544,0.00002697024,0.0013953836,0.00016669223,0.00091965473,0.0000051295606,0.000040661882,0.007875661],"genre_scores_gemma":[0.9919688,0.00043667425,0.0011690648,0.0010598483,0.000034258188,0.00008574766,0.00001951454,0.000030899642,0.00519518],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976568,0.00045400913,0.00062888465,0.0004558406,0.0002633243,0.00054110814],"domain_scores_gemma":[0.9984639,0.0005552584,0.00015883186,0.0005498828,0.00011824542,0.00015385287],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006781083,0.00022275234,0.001232239,0.00017780568,0.000025164974,0.000006754823,0.00020261807,0.00047443752,0.013545003],"category_scores_gemma":[0.000073960975,0.00015969125,0.0002126388,0.00034527146,0.00018209635,0.000041157324,0.000106835585,0.00031527545,0.00033965803],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006236092,0.0010469196,0.03299004,0.0002265551,0.000052073072,0.0011736489,0.00016632915,0.00000964568,0.95387304,0.00070504827,0.00044051697,0.003080071],"study_design_scores_gemma":[0.038821984,0.008409007,0.15078737,0.0004194185,0.00006850138,0.0013595863,0.00042215505,0.00070079305,0.50163347,0.0032747914,0.29338396,0.0007189706],"about_ca_topic_score_codex":0.0002027899,"about_ca_topic_score_gemma":0.000013107808,"teacher_disagreement_score":0.4522396,"about_ca_system_score_codex":0.00030152616,"about_ca_system_score_gemma":0.00021219478,"threshold_uncertainty_score":0.9873567},"labels":[],"label_agreement":null},{"id":"W2951525681","doi":"10.1016/j.bulcan.2019.05.001","title":"Prise en charge pratique d’une encéphalopathie liée au traitement par cellules CAR-T chez l’adulte et l’enfant : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC)","year":2019,"lang":"fr","type":"article","venue":"Bulletin du Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Université de Montréal","funders":"","keywords":"Medicine","score_opus":0.00974675718258218,"score_gpt":0.30659144753831247,"score_spread":0.2968446903557303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2951525681","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86293066,0.023191256,0.00231529,0.073606364,0.0019808768,0.0033099507,0.0005233375,0.00021038504,0.031931866],"genre_scores_gemma":[0.85201496,0.057373375,0.0030775566,0.005673646,0.0035785842,0.0017428574,0.00022824727,0.0003458767,0.07596487],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99118495,0.0037270305,0.00095881737,0.0010120736,0.00087075913,0.0022463652],"domain_scores_gemma":[0.99531144,0.0020588108,0.00041073465,0.00096999406,0.00030800974,0.00094101153],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.008160927,0.0007984107,0.0010599849,0.00024309635,0.00043758165,0.00018104947,0.00065638806,0.000950204,0.06248308],"category_scores_gemma":[0.00050982845,0.0008248468,0.00046215838,0.00058578193,0.000510709,0.00012195983,0.00026531625,0.0022432213,0.00076715037],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0017367356,0.0028955534,0.060613282,0.0033206753,0.0013012947,0.0008908761,0.13136178,0.0020359955,0.5977033,0.0026215028,0.12533094,0.070188075],"study_design_scores_gemma":[0.0076026544,0.0006180635,0.01854707,0.001930926,0.00026701714,0.00019937477,0.002906499,0.00357771,0.089654416,0.00022293371,0.8736168,0.0008565156],"about_ca_topic_score_codex":0.021311777,"about_ca_topic_score_gemma":0.0017920665,"teacher_disagreement_score":0.7482859,"about_ca_system_score_codex":0.004921147,"about_ca_system_score_gemma":0.009018906,"threshold_uncertainty_score":0.9994202},"labels":[],"label_agreement":null},{"id":"W2952255623","doi":"10.1016/j.retram.2019.05.002","title":"An international survey on the management of patients receiving CAR T-cell therapy for haematological malignancies on behalf of the Chronic Malignancies Working Party of EBMT","year":2019,"lang":"en","type":"article","venue":"Current Research in Translational Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Menzies Centre for Australian Studies, King's College London, University of London; Universitätsklinikum Köln; Hospices Civils de Lyon; King's College London; Vanderbilt University; Moffitt Cancer Center; Knight Cancer Institute, Oregon Health and Science University; Mayo Clinic; King's University College; Centre hospitalier régional universitaire de Lille; Zhejiang University; King Faisal Specialist Hospital and Research Centre; University of Washington; Washington University in St. Louis; Oregon Health and Science University; Memorial Sloan-Kettering Cancer Center; University of Chicago; Fred Hutchinson Cancer Research Center; King’s College Hospital Charity; Vanderbilt University Medical Center","keywords":"Medicine; Intensive care medicine; Internal medicine","score_opus":0.21277346737826647,"score_gpt":0.4289146426200575,"score_spread":0.21614117524179105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952255623","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99242586,0.0010803923,0.00003304459,0.0019460521,0.0003701471,0.0026612012,0.00007887694,0.0000054760258,0.0013989389],"genre_scores_gemma":[0.99811894,0.001256749,0.00004224858,0.00002467176,0.00009422071,0.00013176864,0.00016219815,0.000019292727,0.00014990137],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99571735,0.0006002087,0.00064135937,0.0003432612,0.00232714,0.0003706857],"domain_scores_gemma":[0.99644715,0.0021218867,0.00017767008,0.0005105085,0.0006740791,0.00006871129],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004219997,0.00016399179,0.00042678358,0.0003287138,0.00006709436,0.000006800001,0.00060052535,0.000075542484,0.0006621559],"category_scores_gemma":[0.00016097157,0.00008709004,0.00012992651,0.0006405394,0.0005823692,0.000047491263,0.000047336584,0.0004851434,0.0000024005349],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045155627,0.0019096253,0.89936686,0.0010931274,0.0001710597,0.0000023708974,0.00112324,0.00030899604,0.030676678,0.008071759,0.00028166804,0.052479032],"study_design_scores_gemma":[0.005154484,0.0022533888,0.96581066,0.0036038954,0.0000137180905,6.0055476e-7,0.00020207619,0.000574428,0.019918717,0.0006631014,0.001721291,0.00008366975],"about_ca_topic_score_codex":0.000055873224,"about_ca_topic_score_gemma":0.00003537845,"teacher_disagreement_score":0.06644375,"about_ca_system_score_codex":0.00013266322,"about_ca_system_score_gemma":0.00018656666,"threshold_uncertainty_score":0.72501427},"labels":[],"label_agreement":null},{"id":"W2952294434","doi":"10.1097/01.hs9.0000561352.05716.6c","title":"PF767 PHASE 2 STUDY EVALUATING THE SAFETY AND EFFICACY OF ONE OR TWO DOSES OF DONOR LYMPHOCYTES DEPLETED OF HOST ALLOREACTIVE T‐CELLS (ATIR101) FOLLOWING T‐CELL‐DEPLETED HAPLOIDENTICAL HSCT","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Hematopoietic stem cell transplantation; Graft-versus-host disease; Immunosuppression; Immune system; T cell; Immunology; Ex vivo; CD34; Stem cell; Transplantation; Haematopoiesis; Clinical endpoint; Internal medicine; Gastroenterology; In vivo; Clinical trial; Biology","score_opus":0.05400656725039787,"score_gpt":0.3857418889832553,"score_spread":0.3317353217328574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952294434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99355096,0.0008432067,0.00004798903,0.00006893215,0.00010047033,0.0033571771,0.0000303481,0.00003432334,0.0019665814],"genre_scores_gemma":[0.9975143,0.000069273745,0.0007551824,0.000035554796,0.00006648757,0.000033141605,0.000016998983,0.00007798863,0.0014310556],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99619514,0.000448305,0.0010386492,0.0005411802,0.0013293631,0.00044734447],"domain_scores_gemma":[0.99509364,0.0029587923,0.00045072823,0.0009039987,0.0004232746,0.00016955734],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014300185,0.00033058083,0.0012279307,0.00011459885,0.00009102823,0.00002296382,0.0002966238,0.000114647184,0.0023833818],"category_scores_gemma":[0.0007866406,0.00022495075,0.00031099308,0.00063617143,0.00027995434,0.000115631214,0.00022978176,0.00033226004,0.00001510562],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01586554,0.0031297961,0.017552575,0.00047006964,0.0010558203,0.0000303826,0.0038287898,0.000020178086,0.9482834,0.000024056711,0.000018994762,0.0097204],"study_design_scores_gemma":[0.06852896,0.01294674,0.023960864,0.0008706689,0.001223924,0.000025156623,0.013344185,0.0036328218,0.87498945,0.000024406532,0.0000972741,0.00035557194],"about_ca_topic_score_codex":0.00063540315,"about_ca_topic_score_gemma":0.000085657804,"teacher_disagreement_score":0.07329397,"about_ca_system_score_codex":0.00014578378,"about_ca_system_score_gemma":0.00045556528,"threshold_uncertainty_score":0.9985286},"labels":[],"label_agreement":null},{"id":"W2952644065","doi":"10.1097/01.hs9.0000559996.44290.19","title":"PF446 EVALUATING EX VIVO EXPANSION OF FUNCTIONALLY COMPETENT MULTI-SPECIFIC T LYMPHOCYTES TO MINOR HISTOCOMPATIBILITY ANTIGEN FOR THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Minor histocompatibility antigen; Immunology; CD8; T cell; Cytotoxic T cell; Stem cell; Priming (agriculture); Antigen; Haematopoiesis; Major histocompatibility complex; Biology; Cancer research; Immune system; Medicine; In vitro; Cell biology","score_opus":0.12491271604417466,"score_gpt":0.36601823181520166,"score_spread":0.241105515771027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952644065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909687,0.0031757134,0.0009802328,0.00020274556,0.00020538362,0.004052801,0.000029860368,0.000025485484,0.00035908204],"genre_scores_gemma":[0.97750247,0.00018441188,0.0131707955,0.000051936175,0.000074436306,0.00028284817,0.000020200967,0.000028243889,0.008684652],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981492,0.000082785176,0.00051567674,0.00039094634,0.00058347173,0.00027791524],"domain_scores_gemma":[0.9978284,0.0008021671,0.00015510371,0.00065430754,0.0004614314,0.00009854352],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00041973466,0.00019500841,0.0006236655,0.000042247804,0.000068586756,0.0000076271763,0.00013601883,0.000083793006,0.006107644],"category_scores_gemma":[0.000079195044,0.00011745007,0.00030260615,0.00016587433,0.00012214534,0.000026777645,0.000042945394,0.00005053822,0.000040077422],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028054907,0.0011443441,0.0676157,0.0004019141,0.00015578429,0.0000035600744,0.0014833988,0.00027678272,0.91112244,0.00014509766,0.00061647664,0.01422901],"study_design_scores_gemma":[0.0117613,0.009480156,0.18055765,0.00046762126,0.00013131347,0.000049422837,0.0042244387,0.009862926,0.7487285,0.000060349186,0.03436312,0.0003131792],"about_ca_topic_score_codex":0.00011583643,"about_ca_topic_score_gemma":0.000052146974,"teacher_disagreement_score":0.16239393,"about_ca_system_score_codex":0.0003594439,"about_ca_system_score_gemma":0.00021516722,"threshold_uncertainty_score":0.9948009},"labels":[],"label_agreement":null},{"id":"W2952842269","doi":"10.1182/blood.2019000905","title":"High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":174,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institutes of Health","keywords":"Follicular lymphoma; Complete remission; Medicine; Immunotherapy; CD19; Lymphoma; Oncology; Internal medicine; Cancer research; Immunology; Chemotherapy; Cancer; Peripheral blood","score_opus":0.01127728596737254,"score_gpt":0.24931235077624367,"score_spread":0.23803506480887113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952842269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940518,0.0014143756,0.0000046815953,0.00021580161,0.00009671013,0.00072517124,0.000011571585,0.000026337564,0.0034535136],"genre_scores_gemma":[0.98368114,0.0004125186,0.000382668,0.00022839326,0.00006077121,0.000033856704,0.000022460888,0.000052900406,0.01512531],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99850094,0.00012687968,0.0003529866,0.00031501646,0.00033472155,0.00036943096],"domain_scores_gemma":[0.9989481,0.00008292069,0.00008213439,0.00068992923,0.00009594143,0.00010097807],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00041759587,0.00017490829,0.00048357502,0.00017678576,0.000019434481,0.000013104713,0.00015389989,0.00012857145,0.0046031387],"category_scores_gemma":[0.000014910052,0.00014762957,0.00015159216,0.00031574184,0.000044512624,0.000054226224,0.00005056973,0.00015389023,0.00015859],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013208939,0.00069606723,0.03133833,0.00016626315,0.00007551197,0.000121398734,0.0002246712,0.0000054027337,0.9647944,0.000013884248,0.00008897614,0.0011542097],"study_design_scores_gemma":[0.022402681,0.0006206496,0.08538118,0.00025554595,0.000042902302,0.000036504825,0.00006288351,0.000070965354,0.87592626,0.00010795105,0.014896304,0.00019614953],"about_ca_topic_score_codex":0.00072526623,"about_ca_topic_score_gemma":0.000011533805,"teacher_disagreement_score":0.08886811,"about_ca_system_score_codex":0.000073248135,"about_ca_system_score_gemma":0.00012768203,"threshold_uncertainty_score":0.9963068},"labels":[],"label_agreement":null},{"id":"W2953056004","doi":"10.1073/pnas.1817255116","title":"A cell topography-based mechanism for ligand discrimination by the T cell receptor","year":2019,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Biotechnology and Biological Sciences Research Council; Medical Research Council; Cancer Research UK; Wellcome Trust","keywords":"T-cell receptor; Receptor; Biology; Major histocompatibility complex; Cell biology; T cell; Phosphatase; Cell; Antigen-presenting cell; Phosphorylation; Antigen; Immunology; Immune system; Biochemistry","score_opus":0.03935295177217326,"score_gpt":0.3236934151292771,"score_spread":0.28434046335710383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953056004","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9738262,0.00011932553,0.000008615563,0.012676993,0.000033758693,0.0010536418,0.000031308224,0.0000099234885,0.01224019],"genre_scores_gemma":[0.99312675,0.00002738514,0.0010979557,0.0006798771,0.00006202889,0.0000446733,8.92547e-7,0.0000072437088,0.004953214],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980144,0.000006379838,0.00022660125,0.00022801846,0.0013525892,0.00017204817],"domain_scores_gemma":[0.99897015,0.00024091967,0.00025479455,0.000014410268,0.0004820347,0.000037663296],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00150285,0.000088212735,0.00014479477,0.00015365818,0.00015395353,0.000026336877,0.000541721,0.0000783981,0.000105947605],"category_scores_gemma":[0.00017572069,0.000047758767,0.00014194258,0.00062339014,0.0003921076,0.00015908702,0.00005105442,0.0001643707,0.0000029643363],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008491772,0.00008479867,0.0009634863,0.00019831583,0.000007273914,5.792235e-10,0.00016360733,0.00000366294,0.9828774,0.010474629,0.0049034604,0.00023848437],"study_design_scores_gemma":[0.0006987866,0.0002537656,0.00085505645,0.00006249467,0.000018650726,8.944542e-7,0.00038396462,0.0014011075,0.9802811,0.014333424,0.0016541266,0.000056635967],"about_ca_topic_score_codex":0.000006046521,"about_ca_topic_score_gemma":2.9943894e-8,"teacher_disagreement_score":0.019300487,"about_ca_system_score_codex":0.000037854817,"about_ca_system_score_gemma":0.00006230442,"threshold_uncertainty_score":0.1947546},"labels":[],"label_agreement":null},{"id":"W2953165127","doi":"10.1002/hon.11_2630","title":"REFINEMENT OF MUM1 EXPRESSION THRESHOLD FOR DOUBLE POSITIVE CD10+ MUM1+ DIFFUSE LARGE B CELL LYMPHOMA ALLOWS A BETTER CELL OF ORIGIN CLASSIFICATION FOR GCB SUBTYPE","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"Diffuse large B-cell lymphoma; Gene expression profiling; Immunohistochemistry; Germinal center; Concordance; Lymphoma; Gene expression; Biology; Pathology; Medicine; B cell; Gene; Internal medicine; Genetics; Antibody","score_opus":0.06360683452695104,"score_gpt":0.3626921888921254,"score_spread":0.29908535436517436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953165127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98441344,0.00021054503,0.0011705029,0.0015448572,0.00017422548,0.0035625864,0.00007157764,0.000035988916,0.008816298],"genre_scores_gemma":[0.9881156,0.00007290975,0.006069175,0.0006938256,0.000081414655,0.00059050554,0.00021328157,0.000038662936,0.0041246247],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99761814,0.00011477445,0.0008010561,0.0005438747,0.00036762262,0.0005545383],"domain_scores_gemma":[0.9974323,0.0010348274,0.0004626653,0.0005247865,0.00038953242,0.00015591255],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006976001,0.00023726371,0.0010825095,0.00015192623,0.000054380427,0.0000062967392,0.0002347628,0.00051325036,0.0012137529],"category_scores_gemma":[0.000073206065,0.00017156068,0.00031649997,0.00016842326,0.00014145735,0.000048336697,0.00011819234,0.00017653462,0.000038645107],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012567155,0.008465374,0.011394452,0.000940981,0.000062784384,0.000018578588,0.00030316453,0.000001168595,0.9565849,0.003267984,0.005491365,0.0009021053],"study_design_scores_gemma":[0.051648516,0.007786456,0.005133038,0.00013874784,0.00014436987,0.00003410202,0.00045730485,0.0012415595,0.8533162,0.0005024673,0.07934052,0.00025671057],"about_ca_topic_score_codex":0.000015464648,"about_ca_topic_score_gemma":0.000011195181,"teacher_disagreement_score":0.10326868,"about_ca_system_score_codex":0.00025965978,"about_ca_system_score_gemma":0.00023156348,"threshold_uncertainty_score":0.9996993},"labels":[],"label_agreement":null},{"id":"W2953176543","doi":"10.71781/26312","title":"Les chambres de leucoréduction sont une nouvelle source de cellules pour la génération de lignées de lymphocytes T en immunothérapie","year":2018,"lang":"fr","type":"dissertation","venue":"Papyrus : Institutional Repository (Université de Montréal)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Fonds de Recherche du Québec - Santé; Université de Montréal; Astellas Pharma; Mitacs","keywords":"Molecular biology; Medicine; Biology","score_opus":0.007830240858498209,"score_gpt":0.21390317420068927,"score_spread":0.20607293334219107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953176543","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93796,0.027921531,0.008413653,0.00080248376,0.00084032497,0.00069849304,0.000048932303,0.00022188942,0.023092689],"genre_scores_gemma":[0.80799264,0.0062147486,0.004403823,0.00009830773,0.0019672057,0.00008684036,0.00054464996,0.00013274794,0.17855905],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99502015,0.0009655252,0.0006394006,0.00089457474,0.0010187009,0.0014616471],"domain_scores_gemma":[0.9968438,0.0006450513,0.00052975235,0.0006048421,0.00062887935,0.0007476832],"candidate_categories":["metaepi_narrow","sts","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.001479766,0.0007483679,0.00069997954,0.0006843752,0.0060150055,0.00017079152,0.0006021944,0.001361811,0.00051388534],"category_scores_gemma":[0.0003674639,0.0009110327,0.0005812632,0.00053927436,0.0007416888,0.00038546487,0.00018022362,0.0009691876,0.00013325295],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0041809916,0.0006137388,0.019194406,0.00059762044,0.0010246815,0.0016895897,0.12700607,0.0045988387,0.7987759,0.0042564645,0.00084068545,0.037221033],"study_design_scores_gemma":[0.004937984,0.0005966413,0.08465566,0.001822088,0.0012680746,0.005950834,0.19148307,0.028502971,0.5860448,0.0006263148,0.092884146,0.0012274148],"about_ca_topic_score_codex":0.23428214,"about_ca_topic_score_gemma":0.019385928,"teacher_disagreement_score":0.2148962,"about_ca_system_score_codex":0.03481943,"about_ca_system_score_gemma":0.013338157,"threshold_uncertainty_score":0.9999346},"labels":[],"label_agreement":null},{"id":"W2953229874","doi":"10.1002/hon.95_2629","title":"IMPROVED OUTCOMES IN PATIENTS (PTS) WITH BCL2‐POSITIVE DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) TREATED WITH VENETOCLAX (VEN) PLUS R‐CHOP: RESULTS FROM THE PHASE 2 CAVALLI STUDY","year":2019,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital de l'Enfant-Jésus; Jewish General Hospital","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Internal medicine; Clinical endpoint; Diffuse large B-cell lymphoma; CHOP; Rituximab; Ven; Oncology; Gastroenterology; Venetoclax; Regimen; Lymphoma; Randomized controlled trial; Chronic lymphocytic leukemia; Leukemia","score_opus":0.022662026207577096,"score_gpt":0.32456376199109754,"score_spread":0.3019017357835204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953229874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99161637,0.000067001376,0.000011496529,0.0005433025,0.00009890963,0.005188043,0.00017379483,0.0000967611,0.0022043453],"genre_scores_gemma":[0.9960421,0.000019261268,0.00013981694,0.00081338227,0.000048349197,0.00028721403,0.00025665681,0.000058595535,0.0023346685],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99596125,0.0007715587,0.00073970197,0.000993094,0.00063578674,0.00089863397],"domain_scores_gemma":[0.9961664,0.0019826551,0.0003126234,0.00093808456,0.0003120726,0.00028818607],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00052547955,0.0004790247,0.0015965564,0.00013246662,0.00011620513,0.000032401604,0.0003902879,0.00039402462,0.0005268992],"category_scores_gemma":[0.00031050303,0.00023594401,0.00013330743,0.00046931702,0.00026607665,0.00008081422,0.00020900073,0.00063102413,0.0001488588],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.093153566,0.05865432,0.8368514,0.000030179077,0.0005931229,0.0022353104,0.0032418258,0.0000065897493,0.0017517131,0.000025510291,0.0002591807,0.003197251],"study_design_scores_gemma":[0.44500273,0.050093085,0.49615955,0.00010425742,0.00027514723,0.000070120186,0.0025756732,0.000855826,0.001582255,0.000014972679,0.0027946378,0.00047170898],"about_ca_topic_score_codex":0.001384025,"about_ca_topic_score_gemma":0.0013999891,"teacher_disagreement_score":0.35184917,"about_ca_system_score_codex":0.0013022717,"about_ca_system_score_gemma":0.0005548764,"threshold_uncertainty_score":0.96215177},"labels":[],"label_agreement":null},{"id":"W2953537665","doi":"10.1200/jco.2019.37.15_suppl.7558","title":"Preliminary results of earlier steroid use with axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Cytokine release syndrome; Adverse effect; Tocilizumab; Internal medicine; Cohort; Clinical endpoint; Transplantation; Surgery; Gastroenterology; Oncology; Chimeric antigen receptor; Cancer; Disease; Randomized controlled trial; Immunotherapy","score_opus":0.05713734364355888,"score_gpt":0.37900502988949414,"score_spread":0.32186768624593526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2953537665","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932294,0.0001804908,0.0000149772395,0.00058416056,0.00043714614,0.00071024586,0.000024584977,0.000008671421,0.004810333],"genre_scores_gemma":[0.9896913,0.00033661246,0.0014721446,0.0007390367,0.0002642623,0.0000044241465,0.000016241203,0.00006171001,0.0074142353],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9940822,0.0008376484,0.0028751248,0.00042305686,0.0012403812,0.0005415817],"domain_scores_gemma":[0.99247974,0.0030009763,0.0022859173,0.000683172,0.0010349263,0.0005152952],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004048295,0.00026669903,0.0020041722,0.0003849089,0.000026130368,0.000012720624,0.00034276166,0.0005949585,0.00049253256],"category_scores_gemma":[0.0012222618,0.00017002721,0.00033657503,0.00033927136,0.00028845674,0.0003131566,0.00013387424,0.0014883436,0.00005384078],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29692957,0.025407065,0.6404943,0.00010716412,0.0003715831,0.00083036383,0.00035303252,0.000024790324,0.0013048836,0.0000038045857,0.0017201089,0.03245335],"study_design_scores_gemma":[0.129765,0.12902473,0.6943882,0.00032202192,0.00014424801,0.00006531575,0.0001229537,0.000034822013,0.00046770027,0.0000055318965,0.045506198,0.00015324944],"about_ca_topic_score_codex":0.00004139466,"about_ca_topic_score_gemma":0.000053201577,"teacher_disagreement_score":0.16716455,"about_ca_system_score_codex":0.00033570838,"about_ca_system_score_gemma":0.0021629673,"threshold_uncertainty_score":0.69335085},"labels":[],"label_agreement":null},{"id":"W2954202342","doi":"10.1200/jco.2019.37.15_suppl.7518","title":"Managing cytokine release syndrome (CRS) and neurotoxicity with step-fractionated dosing of mosunetuzumab in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Medicine; Cytokine release syndrome; Adverse effect; Dosing; Gastroenterology; Chills; Internal medicine; Refractory (planetary science); Lymphoma; Cancer; Immunotherapy; Chimeric antigen receptor","score_opus":0.045135116611655604,"score_gpt":0.3907390396098182,"score_spread":0.3456039229981626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954202342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927292,0.0002595177,0.00007835965,0.0015205202,0.00042025122,0.0005783346,0.0000027233073,0.000010177788,0.004400936],"genre_scores_gemma":[0.9955553,0.00097200845,0.0013456232,0.0006439245,0.00018508344,0.0000039076317,0.000002203736,0.000046353154,0.0012456187],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995664,0.00065357884,0.002240214,0.00035242093,0.0007183193,0.00037146147],"domain_scores_gemma":[0.9942112,0.0028589012,0.0017273064,0.00036551012,0.00042342342,0.00041367792],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034325302,0.00021386695,0.0018297819,0.00049422646,0.00003188336,0.000012502733,0.00020968332,0.0004287735,0.00065287825],"category_scores_gemma":[0.00084764266,0.00016241481,0.00025739678,0.00041681423,0.0002888008,0.00019063949,0.00010173528,0.0016677268,0.000016699243],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10079091,0.009918978,0.3964956,0.000715451,0.0007514464,0.014117634,0.00025107837,0.0005708289,0.14046982,0.000021088961,0.00088595535,0.33501118],"study_design_scores_gemma":[0.07329665,0.065922506,0.82095945,0.00095965626,0.0003128399,0.0063147373,0.0003676218,0.0082146,0.0027812137,0.00012054059,0.020417402,0.00033278778],"about_ca_topic_score_codex":0.00015204164,"about_ca_topic_score_gemma":0.000045582303,"teacher_disagreement_score":0.42446384,"about_ca_system_score_codex":0.00039923834,"about_ca_system_score_gemma":0.0015454702,"threshold_uncertainty_score":0.7245536},"labels":[],"label_agreement":null},{"id":"W2954364011","doi":"10.1158/1538-7445.am2019-ct225","title":"Abstract CT225: A Phase Ib/IIa randomized pilot study to investigate the safety and tolerability of autologous T-cells with enhanced T-cell receptors specific to NY-ESO-1/LAGE-1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non-small cell lung cancer","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Tolerability; Internal medicine; Oncology; Chemotherapy; Immunotherapy; Lung cancer; Phases of clinical research; Cancer; Adverse effect","score_opus":0.03804803893179919,"score_gpt":0.36638646646468603,"score_spread":0.32833842753288683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954364011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9757411,0.0006507344,0.000064273845,0.0010409071,0.00014806079,0.021217428,0.000033145247,0.00003349245,0.0010708953],"genre_scores_gemma":[0.9915386,0.0010067889,0.00029293247,0.00014996418,0.000056845707,0.0025597578,0.000011755985,0.000112199625,0.004271176],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99332047,0.00133521,0.0011286244,0.0013221729,0.0016778406,0.0012156821],"domain_scores_gemma":[0.9952548,0.0018615242,0.00024769557,0.00118542,0.0008902792,0.0005602645],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0060014087,0.0004919644,0.0017877956,0.0009106558,0.00014977377,0.00008122327,0.0005906956,0.00011115787,0.001729307],"category_scores_gemma":[0.00022683559,0.00031080277,0.0000721088,0.0027480787,0.0006102985,0.00017430501,0.00025496224,0.0015391263,0.0000230811],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4655147,0.002934172,0.017191272,0.0006918018,0.00008751083,0.00006880483,0.0086349435,0.0022591103,0.49849775,0.0000026476137,0.00017230646,0.003944984],"study_design_scores_gemma":[0.49492273,0.026739068,0.048834443,0.001829687,0.00008166566,0.000007087538,0.005665857,0.0007824368,0.41989905,0.000018884695,0.0004899922,0.00072909665],"about_ca_topic_score_codex":0.010246032,"about_ca_topic_score_gemma":0.01725044,"teacher_disagreement_score":0.078598686,"about_ca_system_score_codex":0.0015278684,"about_ca_system_score_gemma":0.0019611798,"threshold_uncertainty_score":0.99993443},"labels":[],"label_agreement":null},{"id":"W2955729565","doi":"10.1161/circulationaha.118.034497","title":"Myocarditis in the Setting of Cancer Therapeutics","year":2019,"lang":"en","type":"review","venue":"Circulation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":445,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ted Rogers Centre for Heart Research; Canada Research Chairs; University of Toronto","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; Canadian Institutes of Health Research","keywords":"Medicine; Myocarditis; Clinical trial; Cancer; Incidence (geometry); Disease; Internal medicine; Intensive care medicine; Oncology; Immunology","score_opus":0.151932586011727,"score_gpt":0.439782482553563,"score_spread":0.287849896541836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955729565","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004174475,0.9953607,0.000014511199,0.00009054762,0.00013476973,0.0014161943,0.0000130095,0.0000081569015,0.002544691],"genre_scores_gemma":[0.0042805215,0.9949905,0.000009198725,0.000083973326,0.0002461405,0.000084486775,0.000113971684,0.000034830846,0.00015634586],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986958,0.00022341874,0.000356347,0.00017838708,0.0003945233,0.0001515099],"domain_scores_gemma":[0.99905473,0.00025720414,0.00018269781,0.0004192697,0.00007022305,0.00001588395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005585135,0.00013532612,0.0007597888,0.00016189435,0.00001698899,0.000011264266,0.00012309769,0.0001849021,0.00032793262],"category_scores_gemma":[0.000023857823,0.000088888446,0.00028872816,0.00045143752,0.000026489452,0.000023149367,0.000015904248,0.000371592,0.000022741711],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000035699784,0.00001595859,0.003903677,0.0081266835,0.00013260123,0.0000024357169,0.000278148,0.000010135321,0.00004028128,0.000027462129,0.000026933045,0.9874321],"study_design_scores_gemma":[0.00028772323,0.00001826586,0.016703198,0.007336893,0.00072135794,0.000026983389,0.000039333743,0.00015095029,0.0000027073354,0.000024646522,0.97458607,0.00010184618],"about_ca_topic_score_codex":0.00009678307,"about_ca_topic_score_gemma":0.000016444303,"teacher_disagreement_score":0.98733026,"about_ca_system_score_codex":0.00020270587,"about_ca_system_score_gemma":0.0003085878,"threshold_uncertainty_score":0.36247656},"labels":[],"label_agreement":null},{"id":"W2955755622","doi":"10.3747/co.26.4381","title":"Fatal Myocarditis and Rhabdomyositis in a Patient with Stage Iv Melanoma Treated with Combined Ipilimumab and Nivolumab","year":2019,"lang":"en","type":"article","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Nivolumab; Ipilimumab; Medicine; Myocarditis; Melanoma; Internal medicine; Stage (stratigraphy); Metastatic melanoma; Oncology; Dermatology; Immunotherapy; Cancer research; Cancer","score_opus":0.028679980725852698,"score_gpt":0.32285662470990045,"score_spread":0.29417664398404775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955755622","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941585,0.0009527022,0.000010785092,0.00027837727,0.00010191922,0.0013771958,0.000036455076,0.000036944853,0.003047141],"genre_scores_gemma":[0.99845743,0.00037695927,0.000094068826,0.000051129005,0.00003645484,0.0000928442,0.00008740431,0.000033830565,0.0007698496],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984592,0.00014678326,0.0002218094,0.0004602898,0.00028009852,0.0004318288],"domain_scores_gemma":[0.9991822,0.000146506,0.00007625246,0.00028128902,0.000098096265,0.00021561151],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014411136,0.00021260216,0.0005987007,0.0002151443,0.000040362153,0.000020335643,0.000057383422,0.00011034042,0.0005478595],"category_scores_gemma":[0.00001578948,0.00015775178,0.000029189934,0.00023785344,0.00026050635,0.00007542558,0.000082537226,0.00038746538,0.000018222689],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009436588,0.000729872,0.7476976,0.00023306198,0.00017365113,0.001125793,0.001281955,0.000002405906,0.0033938522,0.00006578574,0.00025282812,0.23560663],"study_design_scores_gemma":[0.08495504,0.07140845,0.7354375,0.00079072785,0.00021652738,0.003190794,0.0022539655,0.0015934012,0.002353186,0.000026575457,0.0970349,0.0007388951],"about_ca_topic_score_codex":0.00020193514,"about_ca_topic_score_gemma":0.00037046248,"teacher_disagreement_score":0.23486772,"about_ca_system_score_codex":0.00031870313,"about_ca_system_score_gemma":0.00022375442,"threshold_uncertainty_score":0.6432931},"labels":[],"label_agreement":null},{"id":"W2955853802","doi":"10.1158/1538-7445.am2019-7","title":"Abstract 7: Discovery of OICR-10268: A potent and selective BCL6 inhibitor","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"BCL6; Lymphoma; Cancer; Cancer research; Germinal center; Medicine; Internal medicine; Immunology; B cell; Antibody","score_opus":0.05675449112698437,"score_gpt":0.4118218250370835,"score_spread":0.3550673339100991,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955853802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98329216,0.0017568432,0.0000028005375,0.00096152775,0.00010951699,0.0010734433,0.000029047394,0.00001599055,0.012758657],"genre_scores_gemma":[0.97415483,0.0012004281,0.000023196011,0.00004891412,0.000303668,0.00009187597,0.000007100676,0.000039559705,0.024130413],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975186,0.00010430101,0.00022319422,0.00041832944,0.001163449,0.0005721181],"domain_scores_gemma":[0.9985069,0.00029522114,0.000041519124,0.0004245432,0.0005326125,0.0001992115],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010313983,0.000125908,0.00033896632,0.0003394229,0.00006413228,0.000049047867,0.000148826,0.00010931945,0.002094081],"category_scores_gemma":[0.00013411573,0.00010253396,0.000082362385,0.0005687984,0.0003160152,0.00016213306,0.00018087875,0.0008264016,0.000085572996],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017562624,0.00014217108,0.02749771,0.00046658627,0.00011898681,0.000029627205,0.0004489046,0.0000032592275,0.94824797,0.00009543093,0.0026732092,0.018519886],"study_design_scores_gemma":[0.0034395584,0.001287845,0.21440443,0.0005854544,0.000018422406,0.000027132766,0.00076022453,0.000041000807,0.7661012,0.00025155384,0.012894474,0.0001887204],"about_ca_topic_score_codex":0.0017249091,"about_ca_topic_score_gemma":0.00009260899,"teacher_disagreement_score":0.18690673,"about_ca_system_score_codex":0.00042992373,"about_ca_system_score_gemma":0.0008015866,"threshold_uncertainty_score":0.99881816},"labels":[],"label_agreement":null},{"id":"W2955937053","doi":"10.1158/1538-7445.am2019-1424","title":"Abstract 1424: Preclinical development of TAC01-CD19, a CD19 specific T-cell Antigen Coupler (TAC) therapy for the treatment of CD19-positive B cell malignancies","year":2019,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"CD19; Chimeric antigen receptor; T cell; Cancer research; Antigen; Medicine; Immunology; B cell; Antibody; Immune system","score_opus":0.17306072651144228,"score_gpt":0.4446102306505628,"score_spread":0.27154950413912055,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955937053","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97771245,0.013326788,0.00003858858,0.00064804766,0.00022430817,0.0057887887,0.00012694235,0.000018723127,0.00211536],"genre_scores_gemma":[0.9417369,0.035535574,0.0005008993,0.000043235654,0.00030911562,0.00089820364,0.000048544633,0.0000905446,0.020837005],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9958444,0.00017306386,0.0007824114,0.0006737158,0.0015906021,0.0009357686],"domain_scores_gemma":[0.9951721,0.002158481,0.00019896032,0.000992181,0.0012449156,0.0002333873],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020404682,0.00030892258,0.0007728006,0.00028390827,0.00019998767,0.00003389026,0.0005158839,0.00020557907,0.0055702096],"category_scores_gemma":[0.000038118782,0.00019886155,0.00035244046,0.0005341141,0.00047441802,0.00006810359,0.000091146714,0.0004523883,0.0001167781],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007128062,0.0018405805,0.01616927,0.00036918194,0.00039316693,0.0000102660615,0.0042455015,0.000023371847,0.9311309,0.000021369862,0.0017025757,0.036965784],"study_design_scores_gemma":[0.0061678686,0.0029042666,0.06374217,0.000195365,0.000018893355,0.0000019448821,0.0009847034,0.000046929017,0.79271984,0.000023432356,0.13302529,0.0001693081],"about_ca_topic_score_codex":0.000463028,"about_ca_topic_score_gemma":0.00008092799,"teacher_disagreement_score":0.13841105,"about_ca_system_score_codex":0.0007055361,"about_ca_system_score_gemma":0.0020507101,"threshold_uncertainty_score":0.99533886},"labels":[],"label_agreement":null},{"id":"W2956407203","doi":"10.1186/s40425-019-0673-2","title":"Diverse immunotherapies can effectively treat syngeneic brainstem tumors in the absence of overt toxicity","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"National Institute of General Medical Sciences; National Cancer Institute; National Institutes of Health; Cancer Research UK; Richard M. Schulze Family Foundation; Mayo Foundation for Medical Education and Research; Hyundai Hope On Wheels; Mayo Clinic","keywords":"Medicine; Immunotherapy; Toxicity; Oncolytic virus; Immunology; Immune system; Brainstem; Cancer research; Internal medicine","score_opus":0.022841207930643707,"score_gpt":0.34046279427430043,"score_spread":0.3176215863436567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2956407203","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876729,0.009096428,0.00003464726,0.0006931489,0.000319193,0.0014503687,0.00004451535,0.000008446766,0.000680323],"genre_scores_gemma":[0.99064404,0.005050235,0.00008684834,0.00052169105,0.00013948651,0.000070534516,0.000002219713,0.000050248433,0.0034346979],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99792284,0.00019115445,0.00059217063,0.00021026129,0.0006981111,0.00038549246],"domain_scores_gemma":[0.99834895,0.00046403086,0.00040371765,0.0004400752,0.00028875167,0.000054463304],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011826089,0.0002304561,0.000705486,0.0002873723,0.00009238852,0.00002807167,0.0004206426,0.00010093566,0.0014387846],"category_scores_gemma":[0.000039488797,0.00014903733,0.00046482956,0.00037623692,0.0001930211,0.00012505913,0.000020640318,0.00041909073,0.0000022173656],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006450941,0.00025099228,0.04481001,0.00021918229,0.0004733356,0.000008910583,0.00477706,0.000078407465,0.8493126,0.0000639041,0.0001997566,0.093354896],"study_design_scores_gemma":[0.02475063,0.0064588273,0.42949754,0.0019308303,0.000087446446,0.00028953727,0.005345263,0.00021624692,0.51124364,0.0005202527,0.019172044,0.00048774978],"about_ca_topic_score_codex":0.001246635,"about_ca_topic_score_gemma":0.0002530193,"teacher_disagreement_score":0.38468754,"about_ca_system_score_codex":0.00040122579,"about_ca_system_score_gemma":0.00040422642,"threshold_uncertainty_score":0.99947405},"labels":[],"label_agreement":null},{"id":"W2956632142","doi":"10.1200/jco.2019.37.15_suppl.tps7574","title":"ZUMA-12: A phase 2 multicenter study of axicabtagene ciloleucel (axi-cel) as a first-line therapy in patients (pts) with high-risk large B-cell lymphoma (LBCL).","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Internal medicine; Rituximab; Oncology; Surgery; Lymphoma","score_opus":0.06626956772329211,"score_gpt":0.43779992131585477,"score_spread":0.37153035359256265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2956632142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955854,0.00020009592,0.000017596516,0.0007133671,0.0006841616,0.0017685592,0.000016795337,0.000010482884,0.0010035307],"genre_scores_gemma":[0.9949698,0.0015781942,0.00034029176,0.0010604897,0.00047722404,0.000017093607,0.0000084309595,0.00006383398,0.0014846327],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99318147,0.0012279763,0.0032779705,0.0004676955,0.0012643896,0.00058051955],"domain_scores_gemma":[0.9931058,0.002322363,0.0024555917,0.00065138075,0.00093471754,0.00053012004],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00460251,0.00032191875,0.002558953,0.00042985915,0.000047385845,0.000013574492,0.0004478048,0.00045166127,0.002433643],"category_scores_gemma":[0.0011046675,0.00021124478,0.00048276727,0.00035669198,0.00016852237,0.00014874217,0.0001339335,0.0013780762,0.00008990548],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.108765565,0.16545409,0.6046799,0.000046321547,0.0007417425,0.0006251482,0.00094158243,0.000023596125,0.00063548016,0.0000021129772,0.0003426662,0.11774179],"study_design_scores_gemma":[0.38246784,0.23936288,0.35239485,0.00012805105,0.00021948123,0.000025755244,0.00054409186,0.0002146079,0.0006555377,0.000017806256,0.023796316,0.00017275817],"about_ca_topic_score_codex":0.00036871812,"about_ca_topic_score_gemma":0.00044475996,"teacher_disagreement_score":0.2737023,"about_ca_system_score_codex":0.0003477061,"about_ca_system_score_gemma":0.0011815467,"threshold_uncertainty_score":0.9984783},"labels":[],"label_agreement":null},{"id":"W2960897154","doi":"10.1182/blood-2018-99-115592","title":"Outcomes of T-Cell Depleted Haploidentical Peripheral Blood Stem Cell Transplantation for Adult Acute Leukemia: A Meta-Analysis","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Myeloid leukemia; Transplantation; Hematopoietic stem cell transplantation; Internal medicine; Acute leukemia; Leukemia; Meta-analysis; Stem cell; CD34; Oncology; Gastroenterology; Immunology; Biology","score_opus":0.04250206580678483,"score_gpt":0.31770761034001443,"score_spread":0.2752055445332296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2960897154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99385923,0.00026728032,0.0024630744,0.00027188487,0.00004675013,0.0009614938,0.00021077643,0.00006342301,0.001856104],"genre_scores_gemma":[0.9829239,0.00008566768,0.0038909393,0.00030529627,0.00011060333,0.00014751022,0.00011180865,0.000056359033,0.012367898],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99766856,0.000111810805,0.0006028188,0.00047404345,0.0006999685,0.0004428081],"domain_scores_gemma":[0.9980936,0.00023033877,0.00015497245,0.0005709705,0.0007495967,0.00020051064],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00035123577,0.00026904972,0.0013090435,0.00030783552,0.000084395324,0.00003317388,0.00021696927,0.00018921975,0.0015926735],"category_scores_gemma":[0.000025476631,0.00020692399,0.001719462,0.00058628933,0.00015377664,0.000080705635,0.00002583797,0.0002058433,0.000020704092],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011645857,0.0018644581,0.017647725,0.00048604803,0.17089374,0.000102741724,0.0013386012,0.0000037075251,0.8061466,0.00006905128,0.00012963155,0.00015308395],"study_design_scores_gemma":[0.009082213,0.001091645,0.0047360943,0.000004090861,0.38684514,0.00003336838,0.0001156544,0.00030737097,0.5975351,0.000025448107,0.0000560483,0.00016787056],"about_ca_topic_score_codex":0.00012044431,"about_ca_topic_score_gemma":0.00017627892,"teacher_disagreement_score":0.21595141,"about_ca_system_score_codex":0.00004431905,"about_ca_system_score_gemma":0.00016304507,"threshold_uncertainty_score":0.99932003},"labels":[],"label_agreement":null},{"id":"W2961898921","doi":"10.1158/2326-6066.cir-18-0691","title":"TGFβ Programs Central Memory Differentiation in <i>Ex Vivo</i> –Stimulated Human T Cells","year":2019,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; BC Children's Hospital; University of British Columbia; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Leukemia and Lymphoma Society of Canada","keywords":"Cytotoxic T cell; Adoptive cell transfer; Ex vivo; Biology; Immunology; T cell; CD8; Memory T cell; Cell biology; Immunotherapy; Cancer research; In vivo; Immune system; In vitro","score_opus":0.06344752022462088,"score_gpt":0.39404221541498,"score_spread":0.3305946951903591,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2961898921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.986497,0.001841166,0.0000024890373,0.000769394,0.00047173767,0.0024187742,0.000007207061,0.00008409254,0.007908147],"genre_scores_gemma":[0.94738805,0.0007336561,0.000015529506,0.000079282225,0.00017680002,0.00025273935,0.00008479306,0.00006696289,0.051202208],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99587494,0.0005845803,0.00042586683,0.0006641053,0.0008507866,0.0015997363],"domain_scores_gemma":[0.998308,0.00017787977,0.00006145733,0.00083071186,0.00043593548,0.00018601587],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010098432,0.0002272934,0.00052508333,0.00068840815,0.00013594353,0.000058058788,0.00043588603,0.00038045473,0.017938202],"category_scores_gemma":[0.00004938112,0.00021009822,0.00012525854,0.0010928033,0.0005073184,0.00011491928,0.000259459,0.0018651508,0.00054060074],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012677663,0.00043178973,0.094915256,0.00013446328,0.000183987,0.000056617617,0.0007111403,0.000025594463,0.8822546,0.000057292036,0.00070319267,0.019258311],"study_design_scores_gemma":[0.014609663,0.0026040187,0.3255374,0.00057051925,0.00004005162,0.00003485674,0.00094573473,0.0013247782,0.6289227,0.0002537322,0.024646057,0.0005104529],"about_ca_topic_score_codex":0.0024054924,"about_ca_topic_score_gemma":0.00042047235,"teacher_disagreement_score":0.25333187,"about_ca_system_score_codex":0.0011890327,"about_ca_system_score_gemma":0.000513224,"threshold_uncertainty_score":0.9829595},"labels":[],"label_agreement":null},{"id":"W2963496214","doi":"10.1182/bloodadvances.2019000151","title":"Tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion","year":2019,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Refractory (planetary science); Diffuse large B-cell lymphoma; Lymphoma; Medicine; Internal medicine; Oncology; Cancer research; Biology","score_opus":0.010419713182177843,"score_gpt":0.26191942435312415,"score_spread":0.2514997111709463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2963496214","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98148304,0.0046127476,0.0000013411786,0.00007034311,0.00026226122,0.001047014,0.000033911714,0.00007587537,0.012413441],"genre_scores_gemma":[0.9663828,0.0014248362,0.00009459586,0.00026432844,0.00008062253,0.00005678615,0.00007700148,0.00006728844,0.031551737],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974018,0.00011907813,0.00034889166,0.0005505963,0.0009524025,0.00062725827],"domain_scores_gemma":[0.99858797,0.00010725559,0.00012202379,0.00065730384,0.00013664877,0.00038877735],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002799177,0.00026415216,0.00041819434,0.00020401725,0.000095254225,0.000021172702,0.00019366037,0.00011244738,0.0015542823],"category_scores_gemma":[0.0001389987,0.00022649828,0.0001225701,0.0003156468,0.000058689235,0.000293358,0.00017104216,0.00023377639,0.0006162856],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020656055,0.0096359905,0.91780216,0.00028008205,0.000027645878,0.00008039252,0.00021768411,0.0000057441043,0.060085107,0.000008965783,0.00013074532,0.009659859],"study_design_scores_gemma":[0.09296575,0.0011422981,0.6436487,0.00047898683,0.000119381686,0.000008534332,0.00010925106,0.00021717833,0.027614526,0.00008162692,0.23304617,0.00056758715],"about_ca_topic_score_codex":0.00004978221,"about_ca_topic_score_gemma":0.000115320145,"teacher_disagreement_score":0.27415347,"about_ca_system_score_codex":0.0002422916,"about_ca_system_score_gemma":0.00016363856,"threshold_uncertainty_score":0.9993584},"labels":[],"label_agreement":null},{"id":"W2965636153","doi":"10.1016/j.jbior.2019.100638","title":"The TCR/CD3 complex in leukemogenesis and as a therapeutic target in T-cell acute lymphoblastic leukemia","year":2019,"lang":"en","type":"review","venue":"Advances in Biological Regulation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"European Regional Development Fund; Fundação para a Ciência e a Tecnologia; Programa Operacional Temático Factores de Competitividade; Institut National de la Santé et de la Recherche Médicale; Conseil National de la Recherche Scientifique; Institute of Cancer Research; Institut National Du Cancer; Ligue Contre le Cancer; Institut Curie; University of Pittsburgh","keywords":"T-cell receptor; Biology; CD3; Thymocyte; T cell; Leukemia; Antigen; Major histocompatibility complex; Immunology; T-cell leukemia; Cell biology; Cancer research; Immune system; CD8","score_opus":0.08073849367163725,"score_gpt":0.3894962577697001,"score_spread":0.3087577640980628,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965636153","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009483342,0.9868208,0.000030853436,0.000064627944,0.00010979266,0.002047971,0.000009396901,0.000022741053,0.001410455],"genre_scores_gemma":[0.014053223,0.9839698,0.00019736095,0.000082387545,0.00007587027,0.00020321592,0.00018601654,0.000035378234,0.0011967383],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99707586,0.00060713425,0.0007978595,0.00067439105,0.00031755757,0.0005271865],"domain_scores_gemma":[0.9973604,0.0018410947,0.00024007107,0.0004378005,0.00004204954,0.00007858798],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008075404,0.0004027723,0.0014293768,0.0003229331,0.00005700657,0.00003175913,0.00027593444,0.00049356295,0.00024396487],"category_scores_gemma":[0.0001929664,0.00022686766,0.00018412438,0.0008147027,0.0003203548,0.000098962766,0.00012738582,0.00050214585,0.000050377577],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037676652,0.000058840156,0.002177279,0.0012390357,0.000032562715,0.000031223994,0.000029066381,0.000083397965,0.0006127736,0.00026447742,0.0000055717524,0.995089],"study_design_scores_gemma":[0.0019089704,0.00055699295,0.010998129,0.0026131335,0.000085338645,0.000078940786,0.000032888125,0.0011430464,0.000024119252,0.0030858673,0.97911996,0.000352616],"about_ca_topic_score_codex":0.000040184328,"about_ca_topic_score_gemma":0.00007912807,"teacher_disagreement_score":0.9947364,"about_ca_system_score_codex":0.0013861144,"about_ca_system_score_gemma":0.00038271077,"threshold_uncertainty_score":0.9251395},"labels":[],"label_agreement":null},{"id":"W2967592537","doi":"10.1055/s-0039-1692977","title":"Innovative Molecular Testing Strategies for Adjunctive Investigations in Hemostasis and Thrombosis","year":2019,"lang":"en","type":"review","venue":"Seminars in Thrombosis and Hemostasis","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"National Heart, Lung, and Blood Institute","keywords":"Hemostasis; Context (archaeology); Medicine; Thrombosis; Bioinformatics; Cancer; Computational biology; Biology; Internal medicine","score_opus":0.2072553937303359,"score_gpt":0.4296916293429816,"score_spread":0.2224362356126457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2967592537","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.017186644,0.9742134,0.000034776087,0.00049198786,0.00010311905,0.0050368444,0.0004346109,0.000051124804,0.002447475],"genre_scores_gemma":[0.00092609384,0.99067044,0.006576678,0.00027257958,0.00006695717,0.0008169382,0.00037139532,0.0001713095,0.00012761434],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99612236,0.00024813722,0.0011359402,0.0012270231,0.0004718083,0.00079471455],"domain_scores_gemma":[0.9966339,0.0017254187,0.00039942318,0.0006205717,0.00040784996,0.00021287068],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010145346,0.0008210923,0.0032916586,0.0011582972,0.00014442766,0.00016999825,0.00022475093,0.0006596508,0.000114957424],"category_scores_gemma":[0.000714486,0.0007424032,0.00025193408,0.003045717,0.0005583218,0.00027216194,0.00028604234,0.0010496168,0.0000047050985],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000046405734,0.00024495675,0.0035004287,0.022910057,0.000611529,0.000021496044,0.0015465969,0.000002640803,0.000640041,0.0011782247,0.00065335265,0.96864426],"study_design_scores_gemma":[0.009670936,0.0051631224,0.007143566,0.21872668,0.0055247354,0.00026975368,0.01944576,0.00054269854,0.0016456409,0.0092454115,0.71772635,0.004895334],"about_ca_topic_score_codex":0.00028750615,"about_ca_topic_score_gemma":0.00009180121,"teacher_disagreement_score":0.96374893,"about_ca_system_score_codex":0.00052364956,"about_ca_system_score_gemma":0.0013055326,"threshold_uncertainty_score":0.9995027},"labels":[],"label_agreement":null},{"id":"W2967929847","doi":"10.1016/j.cellimm.2019.103963","title":"Conjugated CAR T cell one step beyond conventional CAR T cell for a promising cancer immunotherapy","year":2019,"lang":"en","type":"review","venue":"Cellular Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"University of Tabriz; Tehran University of Medical Sciences and Health Services; Tabriz University of Medical Sciences; Northeastern States Research Cooperative","keywords":"Chimeric antigen receptor; Immunotherapy; Immune system; Cancer immunotherapy; Cancer research; T cell; Cancer; Biology; Cell; Immunology","score_opus":0.06636408974079762,"score_gpt":0.35277819138116534,"score_spread":0.28641410164036774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2967929847","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000756672,0.9851749,0.0003564447,0.000121342746,0.0018050671,0.009179041,0.00037318649,0.00019717206,0.002036166],"genre_scores_gemma":[0.00006340639,0.9189506,0.0005391788,0.00013944342,0.00059933483,0.0015059452,0.0025854725,0.00062721426,0.07498941],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.994411,0.0006254692,0.00152819,0.0013998619,0.00060935615,0.0014261263],"domain_scores_gemma":[0.9960875,0.0005624826,0.00089636934,0.001708293,0.000537269,0.00020808817],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008094116,0.0010872977,0.004452707,0.00070046965,0.00019428605,0.000079651334,0.0008078052,0.0016642762,0.0059836283],"category_scores_gemma":[0.00003918188,0.0010228334,0.0018962938,0.0005418955,0.00051632297,0.00008307359,0.0002173293,0.0018331575,0.00047937143],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015647002,0.0011042428,0.000012854788,0.04896527,0.0053586327,0.00013414057,0.00025940704,0.0000014407246,0.44340658,0.00022765026,0.0016296268,0.49733543],"study_design_scores_gemma":[0.007962699,0.001140977,0.0000020228567,0.0039606863,0.0021784431,0.000099664365,0.00005225947,0.000032888904,0.018661603,0.000035653018,0.96502566,0.0008474343],"about_ca_topic_score_codex":0.00024083852,"about_ca_topic_score_gemma":0.0000073930664,"teacher_disagreement_score":0.963396,"about_ca_system_score_codex":0.001200507,"about_ca_system_score_gemma":0.0030754649,"threshold_uncertainty_score":0.99963176},"labels":[],"label_agreement":null},{"id":"W2969042755","doi":"10.1038/s41577-019-0200-1","title":"Engineering universal cells that evade immune detection","year":2019,"lang":"en","type":"review","venue":"Nature reviews. Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":229,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"Astellas Pharma; Universal","keywords":"Immune system; CRISPR; Biology; Transplantation; Induced pluripotent stem cell; Immunology; Computational biology; Cell biology; Cancer research; Gene; Medicine; Embryonic stem cell; Genetics","score_opus":0.04236399632393917,"score_gpt":0.34716134679134275,"score_spread":0.3047973504674036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2969042755","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000066295916,0.99108183,0.000048730373,0.000046974994,0.002951192,0.0040901955,0.00001725328,0.00014957432,0.0016076281],"genre_scores_gemma":[0.000009627544,0.9839849,0.0001693641,0.000060826107,0.0004846716,0.00015424985,0.000217456,0.00021250616,0.014706403],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99621606,0.00062841293,0.000986879,0.00090258144,0.00042292755,0.00084313995],"domain_scores_gemma":[0.99696916,0.00037560906,0.00059037213,0.0017958371,0.00013940308,0.00012963539],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.0010435324,0.0009057068,0.005199476,0.0008844484,0.000071909555,0.000033403634,0.00069533463,0.0033122243,0.0026373588],"category_scores_gemma":[0.00028490537,0.000703489,0.0019608904,0.0009944012,0.00011187044,0.000099122124,0.00028725495,0.007213225,0.002851045],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000551251,0.00004746818,3.1679843e-7,0.029366488,0.0008394554,0.00006522697,0.000017359751,2.205733e-7,0.007454887,0.000032494732,0.00034516442,0.9617758],"study_design_scores_gemma":[0.0006629848,0.00025689657,0.000005758005,0.018252365,0.0014530539,0.00094091805,0.000005565768,0.000005567852,0.0008725664,0.0000012561627,0.97704715,0.00049595],"about_ca_topic_score_codex":0.000019899982,"about_ca_topic_score_gemma":0.0000020450696,"teacher_disagreement_score":0.976702,"about_ca_system_score_codex":0.001133205,"about_ca_system_score_gemma":0.00044616614,"threshold_uncertainty_score":0.99954164},"labels":[],"label_agreement":null},{"id":"W2969682556","doi":"10.1038/s41467-018-04262-0","title":"DOT1L inhibition attenuates graft-versus-host disease by allogeneic T cells in adoptive immunotherapy models","year":2018,"lang":"en","type":"article","venue":"Nature Communications","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Structural Genomics Consortium; Ontario Institute for Cancer Research; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Japan Society for the Promotion of Science; Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; European Federation of Pharmaceutical Industries and Associations; University of Toronto; Ministero dello Sviluppo Economico; Genome Canada; Fundação de Amparo à Pesquisa do Estado de São Paulo; Ontario Ministry of Economic Development and Innovation; Novartis Pharma; Ontario Genomics Institute; Wellcome Trust; Pfizer; Princess Margaret Cancer Foundation; Canada First Research Excellence Fund; Ontario Genomics","keywords":"T cell; Adoptive cell transfer; Immunotherapy; Cancer research; Immunology; Avidity; Priming (agriculture); Cancer immunotherapy; Immune system; Medicine; Biology; Antigen","score_opus":0.03867886273269115,"score_gpt":0.34681252955423375,"score_spread":0.3081336668215426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2969682556","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88841134,0.04937634,0.00040953376,0.032520834,0.00054883264,0.0033216563,0.00059620605,0.00033526056,0.024479982],"genre_scores_gemma":[0.98690665,0.0076748305,0.0015731793,0.0012677143,0.00011620145,0.00016444086,0.0005876051,0.000056049215,0.0016533317],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983709,0.00025399812,0.00030618152,0.00032686425,0.00038858765,0.00035345808],"domain_scores_gemma":[0.9967073,0.00034557606,0.00008708443,0.0022362354,0.00042561445,0.00019819457],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003570807,0.00020945477,0.000255718,0.00025004527,0.0002466666,0.00004108414,0.0006146806,0.00030123204,0.00048338465],"category_scores_gemma":[0.00008381545,0.00019974193,0.00013020725,0.0006942097,0.000527143,0.00019186064,0.00024515184,0.0012769937,0.00010074821],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033174162,0.0013201218,0.0025190169,0.000027365699,0.00021460935,0.00001167025,0.0014374923,0.000016785307,0.9627942,0.0026737466,0.019458095,0.0062094764],"study_design_scores_gemma":[0.029324792,0.0022655006,0.03452939,0.000891489,0.00037333273,0.000026803957,0.0017902802,0.0190496,0.25729945,0.0047862916,0.6477129,0.0019501449],"about_ca_topic_score_codex":0.00013917359,"about_ca_topic_score_gemma":0.00065189105,"teacher_disagreement_score":0.70549476,"about_ca_system_score_codex":0.00030348328,"about_ca_system_score_gemma":0.0001878934,"threshold_uncertainty_score":0.814524},"labels":[],"label_agreement":null},{"id":"W2969967730","doi":"10.1101/746685","title":"Engineering “self-homing” circulating tumour cells as novel cancer theranostics","year":2019,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Western University","funders":"","keywords":"Homing (biology); Metastatic breast cancer; Medicine; Bioluminescence imaging; Circulating tumor cell; Primary tumor; Cancer research; Breast cancer; Genetic enhancement; Metastasis; CA15-3; Cancer; Oncology; Pathology; Internal medicine; Gene; Biology; Luciferase","score_opus":0.01899425600140162,"score_gpt":0.25724522877555583,"score_spread":0.23825097277415422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2969967730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898946,0.0017895756,0.0016225084,0.00025076486,0.002968323,0.0023062755,0.00019575145,0.00085819204,0.00011399452],"genre_scores_gemma":[0.98942125,0.001162734,0.005977973,0.000287381,0.0021246106,0.0002872509,6.978314e-7,0.0005299981,0.00020809856],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99561274,0.000073947405,0.00076386286,0.0014172469,0.0009770584,0.0011551218],"domain_scores_gemma":[0.99604726,0.0002728086,0.00039315995,0.0019197512,0.0007992443,0.0005677956],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007199651,0.00093588856,0.001243289,0.0005254298,0.00013176553,0.000267256,0.00060308474,0.0008680547,0.0010374489],"category_scores_gemma":[0.00032192987,0.0009826379,0.00041316124,0.0006193279,0.00007419427,0.000107592576,0.0004914124,0.0018225044,0.00034696804],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008840944,0.0002584667,0.004311127,0.0013943583,0.00066323444,0.00015094124,0.000051977975,0.0028498652,0.99006015,0.00007754139,0.000086051376,0.000007864085],"study_design_scores_gemma":[0.0024764198,0.00017714876,0.021247592,0.0017835089,0.00044712322,2.5516795e-7,0.000005986672,0.02128969,0.92790824,3.656258e-7,0.023369638,0.0012940071],"about_ca_topic_score_codex":0.0003731729,"about_ca_topic_score_gemma":0.0000022612137,"teacher_disagreement_score":0.062151898,"about_ca_system_score_codex":0.0016183414,"about_ca_system_score_gemma":0.002518966,"threshold_uncertainty_score":0.9998757},"labels":[],"label_agreement":null},{"id":"W2969992885","doi":"10.3324/haematol.2019.224204","title":"Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network","year":2019,"lang":"en","type":"article","venue":"Haematologica","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Chimeric antigen receptor; Multiple myeloma; Medicine; Cell therapy; Clinical trial; Antigen; Daratumumab; Monoclonal antibody; Immunology; Targeted therapy; Bortezomib; Cancer research; Immunotherapy; Oncology; Cancer; Internal medicine; Antibody; Cell; Biology","score_opus":0.04202163171986532,"score_gpt":0.2957468530958976,"score_spread":0.25372522137603226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2969992885","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9761751,0.0028550122,0.00012772932,0.0027051864,0.00043475095,0.003801261,0.000072000155,0.00017671248,0.013652198],"genre_scores_gemma":[0.98597,0.0011401601,0.004617668,0.0016837727,0.0005176121,0.00015195641,0.00022823446,0.000094342475,0.0055962047],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972047,0.00058865943,0.0005004529,0.00058815046,0.00040138784,0.000716626],"domain_scores_gemma":[0.9972471,0.0013591702,0.00020904136,0.0008855684,0.00013175797,0.00016738888],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0010549902,0.0003077604,0.00063207076,0.000041305924,0.0002289487,0.000056033485,0.0003823304,0.00010453002,0.005338923],"category_scores_gemma":[0.00011473225,0.00018279959,0.00025640742,0.00026309985,0.00017791163,0.000024722707,0.0001287961,0.00031059288,0.0012120493],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0075389566,0.0010199989,0.20847858,0.00015673031,0.00094249204,0.00029194538,0.002081981,0.00007443768,0.39781958,0.00019941006,0.27446985,0.10692603],"study_design_scores_gemma":[0.009588081,0.0015143217,0.09896063,0.00012540986,0.000046791592,0.00007493817,0.00079070893,0.00066635956,0.020989409,0.00024871502,0.8665464,0.00044823717],"about_ca_topic_score_codex":0.00010573251,"about_ca_topic_score_gemma":0.000016980683,"teacher_disagreement_score":0.59207654,"about_ca_system_score_codex":0.000054124554,"about_ca_system_score_gemma":0.0000907484,"threshold_uncertainty_score":0.9995656},"labels":[],"label_agreement":null},{"id":"W2970149384","doi":"10.1007/978-1-4939-9728-2_3","title":"Gene Modification and Immunological Analyses for the Development of Immunotherapy Utilizing T Cells Redirected with Antigen-Specific Receptors","year":2019,"lang":"en","type":"article","venue":"Methods in molecular biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Chimeric antigen receptor; Immunotherapy; T-cell receptor; Antigen; T cell; Transduction (biophysics); Adoptive cell transfer; Cancer immunotherapy; Receptor; Antigen-presenting cell; Immunology; Cytotoxic T cell; Biology; Cancer research; Immune system; In vitro","score_opus":0.1313057769871186,"score_gpt":0.462946372630096,"score_spread":0.33164059564297743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970149384","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.56784785,0.0061077876,0.42501628,0.00008302847,0.00006984098,0.0007499687,0.0000012542698,0.000012058734,0.00011194556],"genre_scores_gemma":[0.08320216,0.0031388847,0.9133236,0.000048346203,0.000012957489,0.00009404188,0.000023481161,0.000023389468,0.00013315007],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983821,0.00059655553,0.00034825967,0.00033453794,0.000099434415,0.00023913394],"domain_scores_gemma":[0.99877006,0.0005793707,0.00010677832,0.00039254208,0.00012527673,0.000025951105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001656798,0.00013617818,0.0003924062,0.00018024724,0.000046054793,0.0000069576176,0.0001477337,0.00015236864,0.00017866779],"category_scores_gemma":[0.00006951916,0.00008187649,0.00006298272,0.00035174718,0.00021349596,0.00001057451,0.000041911964,0.0001822227,0.0000012039791],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00079506607,0.000044114946,0.0015108787,0.000011159787,0.0001631386,7.8591904e-7,0.00034364974,0.000010370638,0.7670046,0.000072489645,0.0000013775975,0.23004237],"study_design_scores_gemma":[0.0012576741,0.00040118216,0.0065433085,0.000025380274,0.000009537977,0.0000072846933,0.00023065996,0.0003255707,0.9801015,0.00014818604,0.010855598,0.00009409882],"about_ca_topic_score_codex":0.000014074346,"about_ca_topic_score_gemma":0.0000017379888,"teacher_disagreement_score":0.4883073,"about_ca_system_score_codex":0.000054437518,"about_ca_system_score_gemma":0.00007686271,"threshold_uncertainty_score":0.33388263},"labels":[],"label_agreement":null},{"id":"W2970263617","doi":"10.1016/j.clml.2019.07.158","title":"Correlative Analyses of Cytokine Release Syndrome and Neurological Events in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients","year":2019,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; McMaster University","funders":"","keywords":"Cytokine release syndrome; Lymphoma; Medicine; Refractory (planetary science); Cytokine; Diffuse large B-cell lymphoma; Immunology; Immunotherapy; Oncology; Biology; Immune system; Chimeric antigen receptor","score_opus":0.03538236938760417,"score_gpt":0.3367846881046666,"score_spread":0.30140231871706247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970263617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959078,0.00036756383,0.000005938994,0.00006779928,0.00029601136,0.0013415017,0.00008617172,0.00009352002,0.0018337],"genre_scores_gemma":[0.9942544,0.0005570942,0.00008494193,0.00055392494,0.00007122507,0.000037407248,0.00020750418,0.00010655884,0.0041269567],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9939996,0.0009817261,0.0018670065,0.0012691908,0.0009650014,0.0009174886],"domain_scores_gemma":[0.99525636,0.0020393673,0.0005798278,0.0011293225,0.0002994391,0.0006956573],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009904589,0.0005644462,0.0017707029,0.0004551908,0.00008077365,0.000017192775,0.0004020031,0.00082024763,0.0009603084],"category_scores_gemma":[0.0012842363,0.00047475318,0.0005061055,0.0009037516,0.00042558427,0.00021660536,0.00044066642,0.00063856196,0.0003878839],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068077887,0.008816128,0.91359246,0.00014813445,0.00021171187,0.00091113744,0.00010370775,0.0000038368185,0.0068332125,0.00001508463,0.00016267446,0.06239412],"study_design_scores_gemma":[0.058554113,0.0051947474,0.930927,0.00021449017,0.0001827129,0.000112585214,0.000037486374,0.0020125932,0.001032507,0.00007178361,0.0012743808,0.00038562954],"about_ca_topic_score_codex":0.00024174342,"about_ca_topic_score_gemma":0.000018110475,"teacher_disagreement_score":0.06200849,"about_ca_system_score_codex":0.00072831823,"about_ca_system_score_gemma":0.0006317992,"threshold_uncertainty_score":0.999953},"labels":[],"label_agreement":null},{"id":"W2970435909","doi":"10.1101/749721","title":"Functional effects of chimeric antigen receptor co-receptor signaling domains in human Tregs","year":2019,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"","keywords":"Chimeric antigen receptor; CD28; Receptor; CD80; Immunology; Antigen; Biology; T-cell receptor; Signal transduction; In vitro; Cell biology; Cancer research; T cell; Immune system; Genetics; CD40; CD8; Cytotoxic T cell","score_opus":0.018686740861283517,"score_gpt":0.2689512575339827,"score_spread":0.25026451667269917,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970435909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99365884,0.0014429198,0.0002882623,0.00010614289,0.0013843684,0.002636944,0.00017385925,0.00021366215,0.00009500921],"genre_scores_gemma":[0.99630135,0.0004535211,0.0013958262,0.00010508613,0.0009937462,0.00027685997,0.000009858717,0.00026811598,0.00019563569],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99530166,0.0003685625,0.0009645341,0.0013083783,0.0011791873,0.00087769225],"domain_scores_gemma":[0.9965696,0.00032377528,0.00055830536,0.0016156526,0.00053396006,0.0003987225],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011272137,0.00074231817,0.0015027577,0.0010614181,0.00011839771,0.00007978604,0.0005088627,0.0008215089,0.0030494859],"category_scores_gemma":[0.00028772667,0.0007837221,0.0004365866,0.0009823343,0.00028222223,0.0001142605,0.0003444616,0.001685918,0.00040710438],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004028952,0.00055056484,0.055834938,0.002207038,0.00046875118,0.000045610857,0.000032980948,0.000072057155,0.93924624,0.00006424556,0.0010664741,0.000008200846],"study_design_scores_gemma":[0.0032417485,0.0003711668,0.16069478,0.0017523298,0.00010221994,3.513886e-8,0.0000070032465,0.000058460384,0.82747096,7.1785536e-7,0.0056720288,0.000628562],"about_ca_topic_score_codex":0.00015288281,"about_ca_topic_score_gemma":0.0000020574278,"teacher_disagreement_score":0.111775294,"about_ca_system_score_codex":0.0008005095,"about_ca_system_score_gemma":0.0012143054,"threshold_uncertainty_score":0.99946135},"labels":[],"label_agreement":null},{"id":"W2971382867","doi":"10.1186/s12874-019-0823-8","title":"Integrating expert opinion with clinical trial data to extrapolate long-term survival: a case study of CAR-T therapy for children and young adults with relapsed or refractory acute lymphoblastic leukemia","year":2019,"lang":"en","type":"article","venue":"BMC Medical Research Methodology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Precision Nanosystems (Canada)","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Refractory (planetary science); Lymphoblastic Leukemia; Pediatrics; Expert opinion; Young adult; Clinical trial; Term (time); Leukemia; Oncology; Intensive care medicine; Internal medicine","score_opus":0.5060217933686972,"score_gpt":0.5783941496880564,"score_spread":0.07237235631935912,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2971382867","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97657377,0.00046931126,0.011647563,0.00018546131,0.0004946779,0.0105088195,0.00004269734,0.000047126992,0.00003059312],"genre_scores_gemma":[0.95073473,0.0036752368,0.041298762,0.0001855533,0.0015395561,0.0009129354,0.000253291,0.00021324288,0.0011866892],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98068225,0.012544605,0.0012605985,0.0017052783,0.0027116202,0.0010956546],"domain_scores_gemma":[0.947708,0.04783482,0.0002528687,0.0021444706,0.0008321916,0.0012276378],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.036670323,0.00039464273,0.0017932898,0.00056411483,0.00016894494,0.000046309127,0.000993931,0.0005398434,0.0007370544],"category_scores_gemma":[0.031068854,0.00022434095,0.00011236211,0.0007876318,0.00090580113,0.00014820784,0.0007197771,0.0017492716,0.0000053079048],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6928522,0.0015872156,0.10698953,0.00022926935,0.001211967,0.0016166953,0.0041072406,7.1869147e-7,0.0031162126,0.000010443191,0.00023081561,0.1880477],"study_design_scores_gemma":[0.53942,0.29621077,0.12712882,0.002315009,0.00023588962,0.011115542,0.018991165,0.0028361522,0.00044743056,0.000010872568,0.00048500646,0.0008033215],"about_ca_topic_score_codex":0.005555432,"about_ca_topic_score_gemma":0.01118065,"teacher_disagreement_score":0.29462355,"about_ca_system_score_codex":0.00024083561,"about_ca_system_score_gemma":0.005480793,"threshold_uncertainty_score":0.99195063},"labels":[],"label_agreement":null},{"id":"W2972212812","doi":"10.1101/760355","title":"The co-stimulation of anti-CD28 and IL-2 enhances the sensitivity of ELISPOT assays for detection of neoantigen-specific T cells in PBMC","year":2019,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Science, Technology and Innovation Commission of Shenzhen Municipality; Government of Jiangxi Province; National Natural Science Foundation of China","keywords":"ELISPOT; CD28; Immunology; Peripheral blood mononuclear cell; Immune system; T cell; Medicine; Stimulation; Antigen; Cancer research; Biology; In vitro; Internal medicine; Biochemistry","score_opus":0.023848419906066655,"score_gpt":0.27234450423348716,"score_spread":0.2484960843274205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972212812","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929451,0.0010974911,0.0030008259,0.00007836234,0.00040381568,0.0022589536,0.00018276367,0.000023756033,0.000008929435],"genre_scores_gemma":[0.997078,0.002347078,0.0002916352,0.000009896637,0.00015032904,0.00005498854,4.7656255e-7,0.000056884324,0.000010718069],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976249,0.00037286943,0.0006784118,0.00048870477,0.0005197126,0.00031543165],"domain_scores_gemma":[0.9963265,0.0011729851,0.00065310474,0.00095093664,0.00083093415,0.00006551316],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033320705,0.0002769206,0.00073128863,0.00025537898,0.00008661462,0.000035706795,0.00019593722,0.00033417766,0.00001649167],"category_scores_gemma":[0.00028718714,0.00020265506,0.00017019904,0.0004049687,0.00037132847,0.000061696,0.0001429397,0.0005208965,0.0000023265384],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005192853,0.00010909445,0.009035382,0.00082675257,0.00011349129,0.0000024644883,0.0000391232,0.00027396673,0.98891556,0.000057368117,0.000016745846,0.00009079207],"study_design_scores_gemma":[0.0007598773,0.00014330853,0.1812432,0.0003337348,0.000049201368,2.456237e-8,0.000015633837,0.0033452383,0.81285906,0.0000019687195,0.001112444,0.00013632658],"about_ca_topic_score_codex":0.00011517005,"about_ca_topic_score_gemma":0.000020179908,"teacher_disagreement_score":0.17605649,"about_ca_system_score_codex":0.000115658455,"about_ca_system_score_gemma":0.0003421914,"threshold_uncertainty_score":0.8264033},"labels":[],"label_agreement":null},{"id":"W2973137482","doi":"10.1016/j.bbmt.2019.09.013","title":"Dual T Cell Depletion with Anti-Thymocyte Globulin and Post-Transplant Cyclophosphamide Results in Low Rates of Cytokine Release Syndrome in Peripheral Blood Haplo-Hematopoietic Stem Cell Transplantation","year":2019,"lang":"en","type":"letter","venue":"Biology of Blood and Marrow Transplantation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Anti-thymocyte globulin; Haematopoiesis; Hematopoietic stem cell transplantation; Stem cell; Immunology; Cytokine; Cyclophosphamide; Transplantation; Peripheral blood; Globulin; Internal medicine; Chemotherapy; Cell biology; Biology","score_opus":0.008808940330552397,"score_gpt":0.23145738300894086,"score_spread":0.22264844267838846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2973137482","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892225,0.0025161556,0.000038860813,0.0048442665,0.00008339965,0.0015520044,0.0016065103,0.000027245023,0.00010905175],"genre_scores_gemma":[0.96875674,0.02388428,0.00020055643,0.0016102267,0.000072831484,0.00004819039,0.005115932,0.00007187547,0.00023938247],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9967251,0.00036777265,0.0011258406,0.00085602136,0.00038820787,0.00053706876],"domain_scores_gemma":[0.9986226,0.0004268524,0.00041220436,0.0003051438,0.00014083988,0.0000923794],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00045933458,0.0005456096,0.001269276,0.0006491643,0.000039433315,0.000015592945,0.000127109,0.0009701264,0.00003490774],"category_scores_gemma":[0.0000051121524,0.00047822078,0.00011717269,0.0003203254,0.00034036688,0.00012472188,0.000009500038,0.0010015632,0.0000015719431],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014499658,0.0006542188,0.08837498,0.022970393,0.00026062375,0.00599644,0.0035670924,0.00007417181,0.8632304,0.0000053863573,0.000042379263,0.0003242267],"study_design_scores_gemma":[0.058634672,0.0097673815,0.22345507,0.007923031,0.0034079014,0.008165145,0.00036208052,0.00009446683,0.6866601,0.000026739988,0.00022416844,0.0012792026],"about_ca_topic_score_codex":0.0009846387,"about_ca_topic_score_gemma":0.0003957576,"teacher_disagreement_score":0.1765703,"about_ca_system_score_codex":0.000029619554,"about_ca_system_score_gemma":0.00022264122,"threshold_uncertainty_score":0.99976695},"labels":[],"label_agreement":null},{"id":"W2973520315","doi":"10.1177/2472630319846878","title":"Biomicrofluidic Systems for Hematologic Cancer Research and Clinical Applications","year":2019,"lang":"en","type":"review","venue":"SLAS TECHNOLOGY","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network; University of Toronto","funders":"Ontario Ministry of Research and Innovation; Natural Sciences and Engineering Research Council of Canada; Ontario Ministry of Research, Innovation and Science; Cancer Research Society","keywords":"Clinical trial; Drug development; Personalized medicine; Medicine; Drug; Drug discovery; Cancer; Intensive care medicine; Pharmacology; Bioinformatics; Biology; Pathology; Internal medicine","score_opus":0.3349991428916382,"score_gpt":0.5699769598246596,"score_spread":0.2349778169330214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2973520315","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006835428,0.98702157,0.000116562485,0.0007626341,0.00028281304,0.010908775,0.00011149909,0.00021952215,0.00050824886],"genre_scores_gemma":[0.000014027573,0.9768272,0.00014934507,0.000014956268,0.00034077367,0.009177435,0.000092465714,0.00010654297,0.013277276],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968519,0.00018134434,0.00091722124,0.0010147643,0.00029134934,0.0007433938],"domain_scores_gemma":[0.9964839,0.0013086116,0.0002195698,0.0013858664,0.0004625593,0.0001394885],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0016701509,0.00032362985,0.002688738,0.0015116049,0.0001362828,0.000033912962,0.0005669388,0.0021387516,0.00013996035],"category_scores_gemma":[0.0002893272,0.00024443824,0.00034042523,0.0013917306,0.0012224249,0.000016515674,0.00039260852,0.0017681734,0.000342379],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004075509,0.00014755754,0.00013797828,0.03290293,0.0005110383,0.000012117851,0.0000026890352,2.90059e-9,0.00016708963,0.0061637606,0.00902151,0.95089257],"study_design_scores_gemma":[0.0006846222,0.0006779571,7.4301744e-7,0.0040620766,0.0004494337,0.0004402007,0.000040518255,0.000003898765,0.000035408055,0.0005605376,0.9928575,0.00018709681],"about_ca_topic_score_codex":0.000042121068,"about_ca_topic_score_gemma":0.0000070653473,"teacher_disagreement_score":0.983836,"about_ca_system_score_codex":0.00035231124,"about_ca_system_score_gemma":0.0010718422,"threshold_uncertainty_score":0.99915665},"labels":[],"label_agreement":null},{"id":"W2977427874","doi":"10.1093/annonc/mdz283.003","title":"ADP-A2M4 (MAGE-A4) in patients with synovial sarcoma","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Synovial sarcoma; Sarcoma; Dermatology; Internal medicine; Oncology; Pathology","score_opus":0.053423593404045094,"score_gpt":0.38545028891373545,"score_spread":0.33202669550969033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977427874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9520495,0.00007152779,0.0000016888599,0.0020159706,0.0001080836,0.0006046864,0.0000065069207,0.000012745346,0.045129307],"genre_scores_gemma":[0.9942478,0.00004518244,0.00013425147,0.0011891451,0.000067525696,0.000012387613,0.000023147928,0.00002219629,0.004258386],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986947,0.00010927564,0.00026240502,0.00023047555,0.0003433275,0.00035979704],"domain_scores_gemma":[0.9990451,0.00016060164,0.00008854334,0.00033997092,0.0002601747,0.00010566253],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00036937025,0.00010856989,0.00046696397,0.00022447079,0.000011611164,0.0000033655804,0.0001303756,0.00014381172,0.0038020855],"category_scores_gemma":[0.000075408556,0.000085606065,0.000062794126,0.00024900073,0.00012265494,0.00005670421,0.000062734776,0.0002782755,0.00018868902],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007384265,0.0017414178,0.84508103,0.00008712616,0.00011144048,0.00008357999,0.00032890032,0.000004757801,0.0078067547,0.00011997673,0.0043213353,0.13292943],"study_design_scores_gemma":[0.010609629,0.021942342,0.8422034,0.00008389219,0.000014460893,0.000012640978,0.00007963783,0.000023670755,0.004751467,0.00009816149,0.12005071,0.00012999873],"about_ca_topic_score_codex":0.00014402944,"about_ca_topic_score_gemma":0.00008575513,"teacher_disagreement_score":0.13279943,"about_ca_system_score_codex":0.00006219477,"about_ca_system_score_gemma":0.0002722204,"threshold_uncertainty_score":0.9971086},"labels":[],"label_agreement":null},{"id":"W2977598599","doi":"10.1182/blood-2018-99-116264","title":"A Next-Generation Fc-Bearing CD3-Engaging Bispecific DART® Platform with Extended Pharmacokinetic and Expanded Pharmacologic Window: Characterization As CD123 x CD3 and CD19 x CD3 DART Molecules","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Interleukin-3 receptor; CD3; CD19; Cmax; Cytokine release syndrome; Cytokine; Chemistry; Immunology; Pharmacology; Antigen; Medicine; Cancer research; T cell; Biology; Pharmacokinetics; Immune system; CD8","score_opus":0.059474206092329174,"score_gpt":0.31518270128561837,"score_spread":0.2557084951932892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977598599","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950783,0.0005069716,0.0002548988,0.00032732665,0.00013753101,0.001218583,0.000012263188,0.00015120319,0.0023128684],"genre_scores_gemma":[0.9952323,0.0009818968,0.0006139852,0.00047937533,0.0010033627,0.00010026699,0.00018045906,0.000075642856,0.0013327084],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977681,0.000113063055,0.00035062918,0.00068204146,0.0005474618,0.00053872337],"domain_scores_gemma":[0.99897313,0.00007033249,0.0001345899,0.00030841658,0.00021049532,0.00030303004],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00047619175,0.00034199774,0.0004055126,0.00031255776,0.00040439048,0.00024252357,0.0001173878,0.00012221944,0.00092230435],"category_scores_gemma":[0.00004801422,0.00028960264,0.000048030666,0.00037099034,0.00028453305,0.00042499157,0.000109640416,0.00042222842,0.000036888665],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00089741824,0.00037803894,0.0041655055,0.000093738745,0.00022962962,0.00012219498,0.0010926044,0.0000011041884,0.96892464,0.000029006793,0.000039031394,0.024027087],"study_design_scores_gemma":[0.01391221,0.0021088587,0.025821026,0.00017749371,0.0005074735,0.00075411436,0.00035347315,0.0042705685,0.9494145,0.00004076773,0.0021919936,0.0004475088],"about_ca_topic_score_codex":0.000025793754,"about_ca_topic_score_gemma":0.00001788137,"teacher_disagreement_score":0.023579579,"about_ca_system_score_codex":0.00005723987,"about_ca_system_score_gemma":0.0001267418,"threshold_uncertainty_score":0.999991},"labels":[],"label_agreement":null},{"id":"W2977758416","doi":"10.1097/01.hs9.0000564720.36943.22","title":"S1618 TISAGENLECLEUCEL APPEARS EFFECTIVE AND SAFE IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA WITH HIGH‐RISK CYTOGENETIC ABNORMALITIES","year":2019,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Oncology; Internal medicine; Clinical endpoint; Gastroenterology; Clinical trial","score_opus":0.0034592202711760155,"score_gpt":0.20954569199890194,"score_spread":0.20608647172772593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977758416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949107,0.0009738241,0.000018912748,0.00001396952,0.00007340679,0.0015965598,0.000027826663,0.00004483771,0.0023399428],"genre_scores_gemma":[0.9937946,0.0013507863,0.0003585458,0.00006561178,0.000085118976,0.00009113956,0.000023337361,0.00009198021,0.0041388483],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99785596,0.00015608047,0.00026653617,0.0005924939,0.0005994121,0.00052951707],"domain_scores_gemma":[0.9987273,0.00030677416,0.00013291524,0.00040185134,0.00018502394,0.00024611602],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000182734,0.0003467328,0.0005160564,0.00015463398,0.00008169088,0.00004519217,0.00008827245,0.0001687402,0.0005524653],"category_scores_gemma":[0.000054013723,0.00025947826,0.000037420476,0.00038201825,0.00017436252,0.00017130736,0.000092952774,0.00044875476,0.00006281184],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030294822,0.00012978181,0.98859423,0.00050386257,0.00018783122,0.00011009368,0.0012207617,0.000030484685,0.00081686693,0.000014785717,0.00007782556,0.0052839858],"study_design_scores_gemma":[0.01196087,0.0035817975,0.98213494,0.00037858755,0.00029235595,0.000109845794,0.000491792,0.00012468168,0.0004877952,0.00002011352,0.000073601856,0.00034362436],"about_ca_topic_score_codex":0.0008857195,"about_ca_topic_score_gemma":0.00057886756,"teacher_disagreement_score":0.008931387,"about_ca_system_score_codex":0.00039438173,"about_ca_system_score_gemma":0.00024288477,"threshold_uncertainty_score":0.99998575},"labels":[],"label_agreement":null},{"id":"W2977941468","doi":"10.1093/annonc/mdz253.009","title":"Adoptive T cell therapy with TBI-1301 results in gene-engineered T cell persistence and anti-tumour responses in patients with NY-ESO-1 expressing solid tumours","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Persistence (discontinuity); Cancer research; Genetic enhancement; Immunology; Gene; Genetics; Biology","score_opus":0.058004277633815986,"score_gpt":0.3346907633724914,"score_spread":0.2766864857386754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2977941468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926837,0.00067387294,0.0000024830877,0.0006338535,0.000037563328,0.00096453284,0.000028660254,0.000015043314,0.0049602673],"genre_scores_gemma":[0.997194,0.000539685,0.00068648235,0.00026043822,0.000027568582,0.000019746987,0.000025909663,0.00004317298,0.0012030065],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977843,0.0003176377,0.00042973962,0.00050145993,0.0004132492,0.00055357756],"domain_scores_gemma":[0.99847794,0.00042265916,0.00022946611,0.00036557965,0.00035585772,0.00014848223],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074000034,0.0002452875,0.0007201149,0.00048279678,0.000031726504,0.0000143850175,0.00016693103,0.00017023149,0.000082944076],"category_scores_gemma":[0.00006624435,0.00018642227,0.000050724404,0.00042342956,0.00023048613,0.0001400431,0.00005692351,0.00044769648,0.000005784162],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06633021,0.0023501127,0.6287989,0.00013508432,0.00007112506,0.0004346372,0.006225582,0.000623736,0.29090157,0.0000016072044,0.00028579717,0.003841636],"study_design_scores_gemma":[0.021617692,0.018604059,0.68997693,0.00028821966,0.000014907772,0.000030702813,0.001717322,0.00014394736,0.26667994,0.000003885653,0.00066173304,0.00026062317],"about_ca_topic_score_codex":0.0001195421,"about_ca_topic_score_gemma":0.000034121495,"teacher_disagreement_score":0.061178062,"about_ca_system_score_codex":0.00008768683,"about_ca_system_score_gemma":0.00044062245,"threshold_uncertainty_score":0.76020795},"labels":[],"label_agreement":null},{"id":"W2978051080","doi":"10.1016/j.cll.2019.07.011","title":"Laboratory Testing in the Context of Biologics and Cellular Therapies","year":2019,"lang":"en","type":"review","venue":"Clinics in Laboratory Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Intégré Universitaire de Santé et de Services Sociaux du Saguenay–Lac-Saint-Jean; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Centre Hospitalier Universitaire de Sherbrooke; Université de Sherbrooke","funders":"","keywords":"Monoclonal antibody; Context (archaeology); Computational biology; Medicine; Biology; Immunology; Antibody","score_opus":0.2069582118324191,"score_gpt":0.4468126421681005,"score_spread":0.2398544303356814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978051080","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0065152743,0.9896211,0.0000010931639,0.0002980399,0.0004651111,0.002133213,0.000102025275,0.000024655212,0.0008394821],"genre_scores_gemma":[0.0015592965,0.9963492,0.000089451874,0.0010489451,0.00054107147,0.000069838956,0.00008274687,0.00008330992,0.00017614619],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9948278,0.0015336577,0.0018868009,0.0006622186,0.0006287747,0.00046073424],"domain_scores_gemma":[0.989662,0.0076964893,0.00074288354,0.0012110004,0.000563943,0.00012371676],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.008206258,0.00053759513,0.0035636865,0.00065941224,0.00003868072,0.000012290027,0.0005498345,0.0007560128,0.00024851228],"category_scores_gemma":[0.00505864,0.0003063504,0.00014269921,0.0026962685,0.0011968566,0.000051742387,0.0001239989,0.0022428778,0.00001834458],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000144852,0.0003606652,0.010448784,0.03172795,0.00026598366,0.00040023672,0.0027144917,1.946282e-7,0.00065777573,0.0005888395,0.0009484815,0.95174176],"study_design_scores_gemma":[0.0021774785,0.0012438926,0.0002276385,0.021910252,0.00037178723,0.000016116475,0.0027839635,0.000009194141,0.0000153911,0.000064793894,0.97090703,0.00027248194],"about_ca_topic_score_codex":0.000033104385,"about_ca_topic_score_gemma":0.000023101908,"teacher_disagreement_score":0.96995854,"about_ca_system_score_codex":0.00015688471,"about_ca_system_score_gemma":0.0015024863,"threshold_uncertainty_score":0.99993885},"labels":[],"label_agreement":null},{"id":"W2978587517","doi":"10.1038/s41467-019-12441-w","title":"Framework engineering to produce dominant T cell receptors with enhanced antigen-specific function","year":2019,"lang":"en","type":"article","venue":"Nature Communications","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Medical Research Council; Blood Cancer UK; University College London Hospitals NHS Foundation Trust; National Institute for Health and Care Research; Cancer Research UK; Wellcome Trust","keywords":"T-cell receptor; Effector; Cell biology; T cell; Antigen; Biology; Adoptive cell transfer; Function (biology); Receptor; Chemistry; Immune system; Immunology; Biochemistry","score_opus":0.017009512821761677,"score_gpt":0.29945195658022306,"score_spread":0.2824424437584614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978587517","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9359911,0.012270436,0.011933579,0.009915447,0.0012460644,0.003917793,0.000008770758,0.00031238506,0.02440439],"genre_scores_gemma":[0.96320254,0.0017107376,0.029615676,0.00029339266,0.00014474143,0.00010195361,0.00005597108,0.000052911295,0.0048220623],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988469,0.00005419829,0.00017721609,0.00031023927,0.00034116342,0.00027031114],"domain_scores_gemma":[0.99644285,0.00024829706,0.000049717615,0.0028280453,0.00029008798,0.00014101717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002715851,0.00015505303,0.00022426262,0.00020104984,0.00011359584,0.00003236678,0.000509569,0.00026172053,0.0006958814],"category_scores_gemma":[0.00009605462,0.00012872086,0.00005154353,0.00090801506,0.00004071342,0.00006988907,0.00016116981,0.0017176998,0.00035875634],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048287734,0.00021662339,0.0022849482,0.00003687593,0.00005352668,9.053474e-7,0.0006765384,0.000090283764,0.98459154,0.0015076074,0.0038486768,0.006209614],"study_design_scores_gemma":[0.0005932617,0.00045395337,0.009322416,0.0002260983,0.000014700621,0.000007237095,0.0001545754,0.00008638858,0.17135383,0.000018580238,0.81757796,0.00019100841],"about_ca_topic_score_codex":0.000005829422,"about_ca_topic_score_gemma":0.000016181792,"teacher_disagreement_score":0.8137293,"about_ca_system_score_codex":0.00014855588,"about_ca_system_score_gemma":0.000083609375,"threshold_uncertainty_score":0.7619413},"labels":[],"label_agreement":null},{"id":"W2978615859","doi":"10.1093/annonc/mdz260.112","title":"Safety, tolerability and activity of autologous T-cells with enhanced T-cell receptors specific to NY ESO 1/LAGE 1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non-small cell lung cancer: A phase Ib/IIa randomised pilot study","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Tolerability; Receptor; Cancer research; Immunology; Pharmacology; Immunotherapy; Internal medicine; Adverse effect; Immune system","score_opus":0.03664897699676808,"score_gpt":0.3661601596427191,"score_spread":0.32951118264595103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978615859","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878862,0.00019593172,0.00013960165,0.00052716467,0.00012484606,0.008789776,0.000018656354,0.000021725287,0.002296137],"genre_scores_gemma":[0.9972708,0.0007165754,0.00044649473,0.0001165288,0.000021139484,0.00036134766,0.000010387938,0.00005145443,0.0010052484],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99649364,0.00072158175,0.00088012207,0.00080968434,0.00047898162,0.0006160084],"domain_scores_gemma":[0.9971778,0.0010258555,0.000494378,0.00062853436,0.00044508086,0.00022837761],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016636736,0.0003648084,0.0019281671,0.00053292135,0.00003813681,0.000009518702,0.00023509414,0.0001577931,0.00059717364],"category_scores_gemma":[0.00007080157,0.0002847754,0.00006472147,0.0008933382,0.00022261971,0.0001340692,0.00010592174,0.0005355456,0.0000043704017],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36905953,0.014733122,0.030303884,0.00045075963,0.000083620886,0.00008256326,0.0031980164,0.00055502536,0.55417454,9.1867133e-7,0.000068258225,0.027289724],"study_design_scores_gemma":[0.27469322,0.14241956,0.05785982,0.00031269834,0.00006958451,0.0000115693365,0.0012099815,0.0005011459,0.5221818,0.0000069169214,0.00036500965,0.00036867152],"about_ca_topic_score_codex":0.0015553412,"about_ca_topic_score_gemma":0.006238485,"teacher_disagreement_score":0.12768644,"about_ca_system_score_codex":0.00039514498,"about_ca_system_score_gemma":0.00094020105,"threshold_uncertainty_score":0.9999604},"labels":[],"label_agreement":null},{"id":"W2978880457","doi":"10.1093/annonc/mdz394.065","title":"5-year survival outcomes of the CheckMate 067 phase III trial of nivolumab plus ipilimumab (NIVO+IPI) combination therapy in advanced melanoma","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ipilimumab; Medicine; Nivolumab; Oncology; Internal medicine; Immunotherapy; Cancer","score_opus":0.08452269851717625,"score_gpt":0.42905341939770825,"score_spread":0.344530720880532,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2978880457","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836113,0.0001459106,0.0000027964097,0.0021609087,0.0005625016,0.0017969401,0.000017473949,0.00001093043,0.011691239],"genre_scores_gemma":[0.9956116,0.0006236002,0.000035115776,0.00015814876,0.000043301483,0.000030710322,0.0000139563745,0.000024852076,0.0034587272],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99774325,0.00040376288,0.0007649998,0.00024064298,0.000537502,0.00030986464],"domain_scores_gemma":[0.99797916,0.0004938819,0.0004757368,0.00058826944,0.0004047792,0.00005819216],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013096689,0.0001580782,0.0011682139,0.00023863632,0.000019598074,0.000002590132,0.00031007963,0.00020494236,0.0010875409],"category_scores_gemma":[0.00021166391,0.00011464126,0.0002800408,0.00037026362,0.00023743644,0.00007461554,0.00008556482,0.00027475585,0.000009194555],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4136187,0.007728448,0.044946317,0.0002146191,0.0006308196,0.000015861482,0.0023641381,0.00005529436,0.35529083,0.0022453289,0.0002995237,0.17259009],"study_design_scores_gemma":[0.7016314,0.039338503,0.082583465,0.00010869608,0.000041419575,0.000007233672,0.00088605465,0.00032818664,0.1662637,0.0007125775,0.007895023,0.00020371367],"about_ca_topic_score_codex":0.00030676264,"about_ca_topic_score_gemma":0.00010693139,"teacher_disagreement_score":0.2880127,"about_ca_system_score_codex":0.000106407126,"about_ca_system_score_gemma":0.0005562297,"threshold_uncertainty_score":0.9998256},"labels":[],"label_agreement":null},{"id":"W2979129329","doi":"10.1093/annonc/mdz398","title":"Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis","year":2019,"lang":"en","type":"review","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":253,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Centre Hospitalier Universitaire Vaudois; Université de Lausanne; National Cancer Institute; Ludwig Institute for Cancer Research","keywords":"Medicine; Meta-analysis; Melanoma; Internal medicine; Oncology; Confidence interval; Interleukin 2; Immunotherapy; Clinical endpoint; Aldesleukin; Surgery; Gastroenterology; Clinical trial; Cancer; Cytokine; Cancer research","score_opus":0.1985229517320195,"score_gpt":0.4500510520698057,"score_spread":0.2515281003377862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979129329","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.001139459,0.9924699,0.0000014220284,0.00021106216,0.000015271473,0.005690113,0.000023419347,0.000012453365,0.0004368835],"genre_scores_gemma":[0.0009234563,0.99752563,0.00030652093,0.0003521996,0.0000070636906,0.0003840719,0.000026619802,0.00006494639,0.0004094756],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9956409,0.0012242642,0.0018400036,0.00060425384,0.00033721974,0.00035338517],"domain_scores_gemma":[0.99409497,0.0028156412,0.0018413516,0.00074090203,0.00038766308,0.00011949504],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0015641474,0.00051147357,0.016100328,0.0007156201,0.000016616721,0.000009416383,0.00023472289,0.00022147174,0.0002036088],"category_scores_gemma":[0.0004828772,0.00029340564,0.0012429458,0.0010095785,0.0002509539,0.000049640446,0.00008927034,0.00040881545,0.0000024192223],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006418717,0.00041947066,0.000015361811,0.74236274,0.113978915,0.00031583366,0.00032844036,0.0000011697108,0.000014762376,0.000017996812,0.0000152125795,0.1418882],"study_design_scores_gemma":[0.0044429135,0.01973804,0.000014714651,0.17145237,0.74687815,0.004415398,0.00029557527,0.000011021589,0.00009214677,0.000014742979,0.05198786,0.0006570449],"about_ca_topic_score_codex":0.00009437078,"about_ca_topic_score_gemma":0.000064357875,"teacher_disagreement_score":0.6328992,"about_ca_system_score_codex":0.00012794061,"about_ca_system_score_gemma":0.0007060097,"threshold_uncertainty_score":0.9999518},"labels":[],"label_agreement":null},{"id":"W2979548369","doi":"10.1016/s1470-2045(19)30493-0","title":"Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trial","year":2019,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"National Cancer Institute; Novartis","keywords":"Medicine; Refractory (planetary science); Quality of life (healthcare); Young adult; Pediatrics; Oncology; Internal medicine; Biology","score_opus":0.03486376564826552,"score_gpt":0.34536738574798603,"score_spread":0.3105036200997205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979548369","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949364,0.00027531333,0.0000071051595,0.00032551892,0.00019952594,0.0022890137,0.00005417752,0.000037170175,0.0018757824],"genre_scores_gemma":[0.9981363,0.00027362234,0.00014904515,0.0005904725,0.00020006375,0.00008341647,0.00005001191,0.000027627892,0.00048945844],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99738544,0.0005882599,0.0006992227,0.00042285403,0.00045749042,0.0004467332],"domain_scores_gemma":[0.9982268,0.00037502882,0.000436516,0.00067391136,0.00013143347,0.00015627971],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00088572694,0.00021856422,0.0010131605,0.000095141244,0.00003358359,0.000011974808,0.00015685058,0.00026384686,0.00076371414],"category_scores_gemma":[0.00030328083,0.00013147658,0.000069722104,0.00036435423,0.00021976358,0.00007167063,0.00014025088,0.00043022234,0.000016794509],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8169523,0.003942167,0.114571415,0.00013763367,0.00031728213,0.00019497989,0.0015288381,0.0000025307381,0.047454167,0.000005431292,0.00046327012,0.014429998],"study_design_scores_gemma":[0.6494795,0.06680353,0.2782211,0.0003159372,0.00034057858,0.0005649751,0.00045600565,0.00014315784,0.0017803201,0.000043587468,0.0014670446,0.00038427318],"about_ca_topic_score_codex":0.00079138106,"about_ca_topic_score_gemma":0.0006716986,"teacher_disagreement_score":0.1674728,"about_ca_system_score_codex":0.00047114855,"about_ca_system_score_gemma":0.0007665189,"threshold_uncertainty_score":0.8362134},"labels":[],"label_agreement":null},{"id":"W2979816540","doi":"10.1182/blood.v118.21.167.167","title":"B-Cell Depletion, Remissions of Malignancy, and Cytokine-Associated Toxicity in a Clinical Trial of T Cells Genetically-Engineered to Express An Anti-CD19 Chimeric Antigen Receptor","year":2011,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Chimeric antigen receptor; Adoptive cell transfer; CD19; Immunology; Fludarabine; Chronic lymphocytic leukemia; Lymphoma; Antigen; Leukemia; Cyclophosphamide; T cell; Cancer research; Internal medicine; Chemotherapy; Immune system","score_opus":0.05633769417147613,"score_gpt":0.326840488072401,"score_spread":0.2705027939009249,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979816540","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978818,0.00014560281,0.00007866452,0.000037138103,0.00010623313,0.0011317444,0.00004556373,0.000028313056,0.0005449282],"genre_scores_gemma":[0.99487567,0.0006502207,0.004008188,0.0000371703,0.00009539443,0.000022259108,0.000019282686,0.000038229005,0.0002535646],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997621,0.0003381556,0.0009143408,0.0004028565,0.0003862769,0.0003373639],"domain_scores_gemma":[0.9985728,0.00018004276,0.00017026825,0.0005075713,0.00019769403,0.00037162303],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00107172,0.00017225507,0.00072292605,0.00020876854,0.00002371343,0.0000051667403,0.00019448227,0.0002419024,0.00062815],"category_scores_gemma":[0.0005093101,0.00015804626,0.00013501261,0.0004645276,0.00011583529,0.00003607213,0.00009710539,0.00027174136,0.0000053467843],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0053077843,0.006778856,0.03818666,0.000059684055,0.00008078049,0.000014936422,0.00049543055,0.0000012350624,0.9481756,0.0000038477133,0.00015045183,0.00074470346],"study_design_scores_gemma":[0.04296332,0.003834961,0.14615212,0.00016061799,0.00008796552,0.000003975454,0.000046138546,0.000035649107,0.806405,0.000015382577,0.00014044184,0.00015441776],"about_ca_topic_score_codex":0.00016841128,"about_ca_topic_score_gemma":0.000014650764,"teacher_disagreement_score":0.14177063,"about_ca_system_score_codex":0.000017064565,"about_ca_system_score_gemma":0.00015706642,"threshold_uncertainty_score":0.6877802},"labels":[],"label_agreement":null},{"id":"W2979850125","doi":"10.1182/blood.v120.21.3729.3729","title":"Chronic Myeloid Leukemia Patients Undergoing Interferon Alpha Therapy Exhibit Normal Peripheral Blood Gamma Delta T Cells That May Be Expanded in Vitro to Generate Predominantly CD45RA-Positive Effector Memory Cells for Immunotherapy","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Immunology; Immunotherapy; NKG2D; K562 cells; Peripheral blood mononuclear cell; Medicine; Immunophenotyping; Cytotoxic T cell; Interferon gamma; Leukemia; Myeloid leukemia; Immune system; Biology; In vitro; Antigen","score_opus":0.018237107019923933,"score_gpt":0.27089205772571906,"score_spread":0.25265495070579513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979850125","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897909,0.0029644205,0.00026326478,0.00015613185,0.0007068044,0.0054525784,0.00018143652,0.0001009779,0.00038346136],"genre_scores_gemma":[0.9909161,0.0010349576,0.001365911,0.00080840115,0.0012391058,0.000944642,0.00026646457,0.00027695374,0.0031474733],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9953289,0.00042238002,0.0007262259,0.00088282564,0.0007921461,0.0018475265],"domain_scores_gemma":[0.9977061,0.00045425157,0.00022469692,0.00085172645,0.00022359457,0.00053961395],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009117302,0.00076518493,0.0010159943,0.00042505047,0.00021625475,0.00012709599,0.0004693684,0.0003632455,0.00082992826],"category_scores_gemma":[0.000033623397,0.000689668,0.00044317287,0.0003922059,0.00013996042,0.00050714484,0.00016642494,0.0005959275,0.00004642137],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0112783015,0.0019892799,0.006460584,0.00021206954,0.0007029355,0.000032979624,0.0032387755,0.00003658876,0.9529891,0.0000022875463,0.00023442078,0.022822667],"study_design_scores_gemma":[0.046308026,0.0066369297,0.0061973054,0.00028010932,0.00016962667,0.00003490032,0.00016812881,0.000085430074,0.9383326,0.000002715364,0.0011145092,0.00066969986],"about_ca_topic_score_codex":0.00024870835,"about_ca_topic_score_gemma":0.00009983241,"teacher_disagreement_score":0.035029724,"about_ca_system_score_codex":0.0011766072,"about_ca_system_score_gemma":0.0006099224,"threshold_uncertainty_score":0.99955547},"labels":[],"label_agreement":null},{"id":"W2980176712","doi":"10.1182/blood.v124.21.3841.3841","title":"TGF-Beta Signaling Favors Central Memory Phenotype Expression By Ex-Vivo Stimulated Human T Cells","year":2014,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"CD28; Ex vivo; T cell; Biology; Cell biology; Cytotoxic T cell; CD8; Homing (biology); Adoptive cell transfer; Transforming growth factor beta; IL-2 receptor; Cytokine; Immunology; Cancer research; Transforming growth factor; In vivo; Immune system; In vitro","score_opus":0.01853857482162006,"score_gpt":0.2808982350244735,"score_spread":0.2623596602028534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980176712","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848438,0.00035061163,0.00016665176,0.00009965012,0.00016540784,0.0005124556,0.000011927084,0.0001663783,0.013683138],"genre_scores_gemma":[0.9849213,0.000023816103,0.00031070865,0.00020141437,0.00049298035,0.00000903902,0.00006693139,0.00007945533,0.013894391],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977281,0.00017585269,0.0003300238,0.0004511659,0.0006352762,0.00067954516],"domain_scores_gemma":[0.99871886,0.00013580245,0.00008566337,0.00057689846,0.000100649064,0.00038215562],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00039100964,0.00024358052,0.00039271583,0.000113522976,0.00015457574,0.00004484857,0.00022911078,0.0001814051,0.0070696124],"category_scores_gemma":[0.000042323583,0.00021344308,0.00013896184,0.00019126576,0.00008881672,0.00006766111,0.00008815179,0.0004193253,0.00013484458],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001519956,0.00063684,0.001191094,0.00008327542,0.0000907472,0.000026304388,0.00041514338,0.0000732928,0.99173003,0.000011354186,0.004210202,0.0013797204],"study_design_scores_gemma":[0.005726709,0.00043735327,0.0004032924,0.00014768427,0.0001366814,0.0000071008008,0.0000639613,0.00032962253,0.9848789,0.000047599882,0.0075927526,0.00022834641],"about_ca_topic_score_codex":0.00011457161,"about_ca_topic_score_gemma":0.000004620199,"teacher_disagreement_score":0.006934768,"about_ca_system_score_codex":0.000051501745,"about_ca_system_score_gemma":0.00005818459,"threshold_uncertainty_score":0.9938381},"labels":[],"label_agreement":null},{"id":"W2980189653","doi":"10.1016/j.smim.2019.101281","title":"Advances in T-cell co-receptor biology and cancer immunotherapy","year":2019,"lang":"en","type":"editorial","venue":"Seminars in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Université de Montréal","funders":"","keywords":"Cancer immunotherapy; Immunotherapy; Cancer; Cancer research; Biology; Computational biology; Genetics","score_opus":0.008781475914867378,"score_gpt":0.34932376429446316,"score_spread":0.34054228837959577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980189653","genre_codex":"editorial","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.049461316,0.4278512,0.0000023622924,0.00029428423,0.51517844,0.0013116548,0.00022452245,0.00007157435,0.0056046336],"genre_scores_gemma":[0.0007918516,0.85306805,0.00014346391,0.00009680413,0.12460326,0.0003917395,0.0008361748,0.00022098862,0.01984766],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99682975,0.00036987656,0.00066155667,0.0009041135,0.00032544325,0.0009092655],"domain_scores_gemma":[0.9972474,0.0015774939,0.00023621472,0.0007390575,0.00013901119,0.000060812137],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0006948887,0.00050758984,0.0014839155,0.00095617166,0.000031760257,0.000017139842,0.00044893025,0.0022273592,0.002541009],"category_scores_gemma":[0.0002872865,0.0004835528,0.00012201538,0.00039713475,0.00070497266,0.000092055416,0.00016022602,0.0028346183,0.000120576435],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059033446,0.00036395455,0.013128255,0.0004711364,0.00017573018,0.000074268115,0.00091595564,0.000002130267,0.3099142,0.000018473303,0.37991694,0.28911564],"study_design_scores_gemma":[0.006498077,0.0013825932,0.00021560403,0.0007916385,0.000015776603,0.000012921373,0.00020844769,0.000004325009,0.0035315724,0.000090129346,0.98685676,0.00039216696],"about_ca_topic_score_codex":0.0011062626,"about_ca_topic_score_gemma":0.00029510658,"teacher_disagreement_score":0.60693985,"about_ca_system_score_codex":0.0008199057,"about_ca_system_score_gemma":0.00096176844,"threshold_uncertainty_score":0.99976164},"labels":[],"label_agreement":null},{"id":"W2980338073","doi":"10.1182/blood-2018-99-116879","title":"Building Capacity for Relapsed/Refractory ALL Patients Needing CAR-T Cells: How Do We Prepare?","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency; Leukemia & Lymphoma Society of Canada; Ottawa Hospital","funders":"","keywords":"Medicine; Refractory (planetary science); Internal medicine; Cohort; Retrospective cohort study; Chimeric antigen receptor; Surgery; Pediatrics; Cancer; Immunotherapy","score_opus":0.04342856139981292,"score_gpt":0.30487345148900186,"score_spread":0.2614448900891889,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980338073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99418396,0.00029539666,0.00020330478,0.00041487764,0.0005732588,0.0011623472,0.00004323191,0.00011961087,0.0030039945],"genre_scores_gemma":[0.9871675,0.00015265943,0.007492192,0.00016960253,0.001440491,0.00009661016,0.000017376191,0.00008913376,0.0033744464],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980357,0.000056184017,0.00023805856,0.00048904965,0.00055515766,0.0006257962],"domain_scores_gemma":[0.99843895,0.00020065524,0.00011112211,0.00053764624,0.00042564442,0.00028598102],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004363212,0.00022589011,0.0003415154,0.00017931058,0.00014728475,0.00007153691,0.0002139949,0.00019223282,0.00043898768],"category_scores_gemma":[0.00030818034,0.00020643442,0.00018382758,0.00019757918,0.00015005132,0.00014863895,0.000098358396,0.00027148618,0.000028973063],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005233245,0.0011503986,0.01060419,0.00027668884,0.00037233028,0.000011021247,0.002076509,3.5771865e-7,0.9535256,0.00008359864,0.0134496605,0.017926292],"study_design_scores_gemma":[0.009997417,0.0025282626,0.0010663518,0.00025553763,0.00029515236,0.000016321443,0.00016849973,0.00007471518,0.5114179,0.00026865632,0.47359005,0.00032109607],"about_ca_topic_score_codex":0.000042433832,"about_ca_topic_score_gemma":0.00001769247,"teacher_disagreement_score":0.46014038,"about_ca_system_score_codex":0.00015052035,"about_ca_system_score_gemma":0.000089028246,"threshold_uncertainty_score":0.8418151},"labels":[],"label_agreement":null},{"id":"W2980440810","doi":"10.1182/blood.v104.11.4194.4194","title":"Transgenic Blimp-1 Promoter Directs Hematopoietic Specific Gene Expression in Mice.","year":2004,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital","funders":"","keywords":"Biology; Molecular biology; Promoter; Transfection; Transgene; clone (Java method); Gene; Repressor; Gene expression; Genetics","score_opus":0.02726622442150989,"score_gpt":0.28361040690557887,"score_spread":0.256344182484069,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980440810","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936473,0.0010617928,0.00008267489,0.00058332883,0.00007134038,0.0007543117,0.000003245444,0.000071564704,0.0037244365],"genre_scores_gemma":[0.9954782,0.00043891178,0.0019547788,0.00008287132,0.00021038977,0.000056809633,0.000015012641,0.000051722185,0.001711271],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99847585,0.000048693906,0.00026397308,0.00036727055,0.0004201231,0.00042408338],"domain_scores_gemma":[0.9993279,0.000029709781,0.00002958039,0.00039846372,0.000039589824,0.00017478105],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00022369043,0.0001666462,0.00029480987,0.00020662487,0.0000360768,0.00002160826,0.0001344138,0.00012449344,0.0015787483],"category_scores_gemma":[0.000016488255,0.00014188455,0.000119221346,0.000351803,0.000053674998,0.000056779973,0.000030942603,0.00030768584,0.00022566039],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017807659,0.0013497116,0.0010695955,0.00009986676,0.000027767454,0.00030213522,0.0011995018,0.0000029075427,0.99433315,0.0000122598,0.000051535528,0.00137349],"study_design_scores_gemma":[0.009210146,0.00028943404,0.004408,0.0002715229,0.0000302442,0.00022194283,0.000040864685,0.0000012438184,0.98290664,0.00028499286,0.002190238,0.00014470186],"about_ca_topic_score_codex":0.000020233356,"about_ca_topic_score_gemma":0.00002118687,"teacher_disagreement_score":0.011426484,"about_ca_system_score_codex":0.00009421247,"about_ca_system_score_gemma":0.00010784612,"threshold_uncertainty_score":0.9993339},"labels":[],"label_agreement":null},{"id":"W2981117365","doi":"10.1182/blood-2018-99-120120","title":"Synthetic De Novo Modeling of Human T-Cell Acute Lymphoblastic Leukemia Reveals HOXB Genes Drive Expansion of Leukemia Cells-of-Origin and Established Tumor Clones","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Biology; Leukemia; Cancer research; Progenitor cell; Haematopoiesis; Context (archaeology); Transcriptome; Stem cell; Immunology; Molecular biology; Gene; Genetics; Gene expression","score_opus":0.021214119919132746,"score_gpt":0.2869788202060972,"score_spread":0.2657647002869645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981117365","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973656,0.0006881996,0.00032766454,0.000010779294,0.00006776422,0.00046675306,0.000026936328,0.000030174084,0.0010161485],"genre_scores_gemma":[0.99619395,0.0003874833,0.0025309175,0.000020412017,0.00016623535,0.000016638347,0.000009783913,0.000061647355,0.0006129353],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99789333,0.000106509404,0.0006421627,0.00041638827,0.000514944,0.00042668325],"domain_scores_gemma":[0.998297,0.0001945235,0.00025268222,0.0006236759,0.00043741133,0.00019474352],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005117815,0.00024409937,0.0007342909,0.00030531365,0.000075426,0.000013806023,0.0002232463,0.00014335147,0.00019590568],"category_scores_gemma":[0.00008334961,0.00021881364,0.00013533513,0.00030902668,0.00039725093,0.000080644146,0.00013090484,0.00016749353,0.0000049308774],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039913578,0.00023358996,0.004036376,0.0006956212,0.00015283997,0.000052740994,0.0008361593,0.00015641341,0.99288905,0.000022980768,0.000032188498,0.00049288786],"study_design_scores_gemma":[0.0051246197,0.0013000963,0.0005577148,0.0006216818,0.0005701984,0.00012599368,0.00025094888,0.008893522,0.9821751,0.00018016936,0.00001873111,0.00018121407],"about_ca_topic_score_codex":0.0005073249,"about_ca_topic_score_gemma":0.000020596508,"teacher_disagreement_score":0.010713957,"about_ca_system_score_codex":0.00020148704,"about_ca_system_score_gemma":0.00074808445,"threshold_uncertainty_score":0.89229614},"labels":[],"label_agreement":null},{"id":"W2981248828","doi":"10.2174/1389450120666191017113051","title":"Combining Radiotherapy with Immunocheckpoint Inhibitors or CAR-T in Renal Cell Carcinoma","year":2019,"lang":"en","type":"article","venue":"Current Drug Targets","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Radiation therapy; Chimeric antigen receptor; Renal cell carcinoma; Immunotherapy; Immune checkpoint; Cancer research; Immune system; Oncology; Cancer; Antigen; Cytotoxic T cell; Kidney cancer; Internal medicine; Immunology; Biology; In vitro","score_opus":0.019738252917048088,"score_gpt":0.2927848299684734,"score_spread":0.2730465770514253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981248828","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853888,0.008954888,0.000020758285,0.00036250733,0.00074218225,0.0012851054,0.0000068172235,0.00006803282,0.003170886],"genre_scores_gemma":[0.98967904,0.0004008469,0.0003576932,0.00008868408,0.00027915882,0.000063047075,0.00006332609,0.0000904979,0.008977685],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99745613,0.00013690248,0.0004462968,0.0005658539,0.000681594,0.00071318983],"domain_scores_gemma":[0.9987511,0.00011367508,0.00011861771,0.00065208593,0.00012119471,0.00024333522],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005079485,0.00033956952,0.0006076312,0.00036191213,0.00005855351,0.000039807186,0.0002282909,0.00008864967,0.0038717631],"category_scores_gemma":[0.000021217596,0.0002457035,0.00014420022,0.0005154637,0.000109761306,0.00012312438,0.00007733047,0.0008539355,0.00016620512],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006846952,0.0013393835,0.41657922,0.0007976431,0.00011481029,0.00034231445,0.009646607,0.00008852214,0.5282805,0.00003117116,0.0058682193,0.030064689],"study_design_scores_gemma":[0.04663778,0.0039027345,0.09324327,0.0018550643,0.00009888481,0.00023750322,0.0023668283,0.0027375368,0.5767463,0.00004833022,0.2704988,0.0016269854],"about_ca_topic_score_codex":0.00018298552,"about_ca_topic_score_gemma":0.000037370835,"teacher_disagreement_score":0.32333595,"about_ca_system_score_codex":0.00045967734,"about_ca_system_score_gemma":0.00045587172,"threshold_uncertainty_score":0.9999995},"labels":[],"label_agreement":null},{"id":"W2981261950","doi":"10.1182/bloodadvances.2018026575","title":"Generation and function of progenitor T cells from StemRegenin-1–expanded CD34+ human hematopoietic progenitor cells","year":2019,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"National Institute of Allergy and Infectious Diseases; National Institute of Child Health and Human Development; Canadian Institutes of Health Research; Eunice Kennedy Shriver National Institute of Child Health and Human Development; Canada First Research Excellence Fund; National Cancer Institute; National Institutes of Health; Children's Cancer Research Fund; Ontario Institute for Regenerative Medicine; Krembil Foundation; University of Toronto","keywords":"Progenitor cell; CD34; Haematopoiesis; Progenitor; Cell biology; Function (biology); Interleukin 3; Stem cell; Biology; Immunology; T cell; Antigen-presenting cell","score_opus":0.02414054077781971,"score_gpt":0.2921499308567681,"score_spread":0.2680093900789484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981261950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923287,0.004958855,0.000038951075,0.00004196897,0.0005167989,0.0015293956,0.000026833133,0.000060107333,0.0004983966],"genre_scores_gemma":[0.9924983,0.0002456993,0.001169311,0.000032854485,0.00083306077,0.00008452524,0.00006942443,0.000046862107,0.0050199754],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99824536,0.00008165435,0.00039294336,0.0004677157,0.00052931474,0.0002829946],"domain_scores_gemma":[0.9990376,0.00006856248,0.00016994294,0.00041159312,0.00016687161,0.00014540036],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00017207,0.00021587797,0.00043634456,0.00011622349,0.00008009763,0.000035411755,0.00010022431,0.00012175544,0.0009819384],"category_scores_gemma":[0.000009554458,0.00018609478,0.00010689547,0.00017288233,0.00009892149,0.00019457338,0.00004788615,0.00017314966,0.0000626866],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026426368,0.00031041936,0.015217415,0.0002858559,0.0001653629,0.000006988171,0.00025241624,0.0000065190734,0.9765545,0.00003333039,0.00008064351,0.00682226],"study_design_scores_gemma":[0.0030737927,0.0011153723,0.0012408696,0.00009160301,0.00021670737,0.000012703329,0.00025819984,0.00008016168,0.9876751,0.0000931124,0.005962226,0.00018017938],"about_ca_topic_score_codex":0.00003454328,"about_ca_topic_score_gemma":0.000024552874,"teacher_disagreement_score":0.013976545,"about_ca_system_score_codex":0.00002888369,"about_ca_system_score_gemma":0.000086599575,"threshold_uncertainty_score":0.9999313},"labels":[],"label_agreement":null},{"id":"W2981355057","doi":"10.14288/1.0383301","title":"Engineered antigen-specific regulatory T cells","year":2019,"lang":"en","type":"article","venue":"cIRcle (University of British Columbia)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Antigen; Cell biology; Computational biology; Chemistry; Biology; Immunology","score_opus":0.010564851257838587,"score_gpt":0.1899268816691796,"score_spread":0.179362030411341,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981355057","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925208,0.00031681932,0.000062627674,0.000046168858,0.00019449824,0.00047866377,0.0000459924,0.00009253812,0.0062418715],"genre_scores_gemma":[0.9772496,0.0006524554,0.00045477957,0.00003704442,0.000062659354,2.1876711e-7,0.000031967713,0.000029454402,0.021481825],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986846,0.000046577083,0.0001094698,0.00040717778,0.00044804945,0.00030415689],"domain_scores_gemma":[0.99883693,0.0000307294,0.000054021984,0.0006344579,0.00020896144,0.0002349184],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00022712302,0.000047259306,0.00033255265,0.00008059808,0.000077687306,0.000045574252,0.00025274887,0.0001400344,0.008130758],"category_scores_gemma":[0.0000044649582,0.00017665651,0.00015765912,0.00029260395,0.0001755578,0.00021032458,0.000078891,0.00021584665,0.0003083068],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010639326,0.00029627417,0.018797364,0.00012519493,0.00009310339,0.00037191456,0.00024505824,0.000012324283,0.4690217,0.0000027875326,0.008313213,0.5026147],"study_design_scores_gemma":[0.0022754504,0.0002907148,0.9737019,0.00011704009,0.000012618069,0.000091994865,0.0007884449,0.0001758251,0.0002675367,0.000021265127,0.022086123,0.00017107982],"about_ca_topic_score_codex":0.010678644,"about_ca_topic_score_gemma":0.008068375,"teacher_disagreement_score":0.95490456,"about_ca_system_score_codex":0.00011532396,"about_ca_system_score_gemma":0.000111121895,"threshold_uncertainty_score":0.99590933},"labels":[],"label_agreement":null},{"id":"W2981371759","doi":"10.1200/cci.19.00086","title":"Impact of Increasing Wait Times on Overall Mortality of Chimeric Antigen Receptor T-Cell Therapy in Large B-Cell Lymphoma: A Discrete Event Simulation Model","year":2019,"lang":"en","type":"article","venue":"JCO Clinical Cancer Informatics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; University of Guelph; University of Waterloo","funders":"","keywords":"Chimeric antigen receptor; Medicine; Lymphoma; Refractory (planetary science); Chemotherapy; Internal medicine; Oncology; Immunotherapy; Cancer; Biology","score_opus":0.06868740518263323,"score_gpt":0.4467243361099316,"score_spread":0.3780369309272984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981371759","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937232,0.00015831043,0.0002072158,0.000022637381,0.00009934947,0.0011197746,0.00013469894,0.000018702025,0.0045160884],"genre_scores_gemma":[0.9967716,0.0018181233,0.00045765363,0.00022579057,0.00007123143,0.000013747207,0.00007647261,0.000033610046,0.0005318225],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9966961,0.00016523953,0.0017773636,0.00018698422,0.0007801326,0.00039418828],"domain_scores_gemma":[0.99762565,0.00061433594,0.0007381924,0.0006353062,0.00021507478,0.00017143358],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017861945,0.00023686739,0.0008969444,0.0001788658,0.000022676011,0.000013505963,0.00020114961,0.00022568805,0.001264048],"category_scores_gemma":[0.0001600388,0.00017791444,0.000495483,0.00031553008,0.00008621507,0.00021865571,0.000081072096,0.00034517515,0.00003260943],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071148234,0.0031046658,0.8673389,0.0005723882,0.00024061152,0.0000010390279,0.0020292709,0.10109588,0.0059486995,0.00002214929,0.00018066601,0.012350936],"study_design_scores_gemma":[0.014087713,0.001999613,0.2883282,0.00024071909,0.00003170048,4.359056e-7,0.000087295455,0.69253975,0.0022067446,0.000046601326,0.00024345508,0.00018777572],"about_ca_topic_score_codex":0.0006915594,"about_ca_topic_score_gemma":0.000013597629,"teacher_disagreement_score":0.5914439,"about_ca_system_score_codex":0.00032071403,"about_ca_system_score_gemma":0.00075306837,"threshold_uncertainty_score":0.9996489},"labels":[],"label_agreement":null},{"id":"W2981595408","doi":"10.1186/s40425-019-0762-2","title":"Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":145,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Pediatric Oncology Group","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; EMD Serono; Eisai; Servier; Amgen; Pfizer; Daiichi Sankyo Europe; Eli Lilly and Company; Eurostars; GlaxoSmithKline","keywords":"Medicine; T cell; Immunology; Fludarabine; Tumor microenvironment; Progressive disease; Synovial sarcoma; Cytotoxic T cell; Immune system; Cancer research; Internal medicine; Pathology; Sarcoma; Biology; Disease; Chemotherapy","score_opus":0.018535859971319776,"score_gpt":0.3255511113769634,"score_spread":0.3070152514056436,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981595408","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98067176,0.01659469,0.0007251451,0.00012910995,0.00057535945,0.0010043986,0.000025598625,0.0000062091844,0.00026772692],"genre_scores_gemma":[0.9928043,0.0051009767,0.00019122215,0.0000760481,0.00011000175,0.000019329316,0.0000018124839,0.000053422074,0.0016428734],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99819154,0.00012192855,0.0006834003,0.00017053835,0.00049219193,0.00034043333],"domain_scores_gemma":[0.9990917,0.00020772095,0.00014567316,0.00025756445,0.00021283026,0.0000845353],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009969873,0.00018578098,0.00078877265,0.00029865053,0.00005104053,0.00001686729,0.00018084125,0.0001387396,0.00094784424],"category_scores_gemma":[0.00001172552,0.00015444572,0.00039567752,0.00022058668,0.0001338428,0.00012843039,0.00001597374,0.0005375503,0.0000018270491],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00864249,0.00017409744,0.011090083,0.00038540812,0.00059718,0.000012242215,0.0022149382,0.00010133652,0.9219583,0.000019253837,0.00003717182,0.054767482],"study_design_scores_gemma":[0.049428657,0.0073127244,0.033210192,0.0054295114,0.00024075847,0.00039614463,0.005008857,0.00090430037,0.88506025,0.00022039736,0.012217852,0.00057038164],"about_ca_topic_score_codex":0.0005365323,"about_ca_topic_score_gemma":0.00005067927,"teacher_disagreement_score":0.054197103,"about_ca_system_score_codex":0.0003106876,"about_ca_system_score_gemma":0.00036033522,"threshold_uncertainty_score":0.9999654},"labels":[],"label_agreement":null},{"id":"W2981626013","doi":"10.1182/bloodadvances.2019000593","title":"Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy","year":2019,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute","keywords":"Hematopoietic cell; CAR T-cell therapy; CD19; Medicine; Cell therapy; Hematopoietic stem cell transplantation; Genetic enhancement; Haematopoiesis; Oncology; Toxicity; Chimeric antigen receptor; Internal medicine; Immunology; Transplantation; Stem cell; T cell; Peripheral blood; Biology; Gene; Immune system","score_opus":0.006991509777375879,"score_gpt":0.24902891076368824,"score_spread":0.24203740098631238,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981626013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96430296,0.029585121,0.0000071114227,0.0001009704,0.00011530085,0.0010409979,0.00003885231,0.000030664498,0.004778053],"genre_scores_gemma":[0.98411524,0.012151736,0.00038550675,0.00014187444,0.000058671274,0.000059017042,0.00003070898,0.00004565395,0.003011606],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981361,0.0000884238,0.00044681484,0.0004208044,0.00046671982,0.00044116282],"domain_scores_gemma":[0.9991042,0.00011970159,0.00009068576,0.00048117945,0.00007857881,0.0001256715],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00022314177,0.0002351719,0.00054638745,0.00016480859,0.00001743574,0.000005862162,0.00018788934,0.00011733048,0.0031764433],"category_scores_gemma":[0.000005558919,0.00018854052,0.0001682532,0.0002796386,0.00008264815,0.00009520979,0.000020471261,0.0002610808,0.000088788],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0066325823,0.0011461711,0.2328794,0.001069709,0.000064136715,0.00014514693,0.0022410476,0.00004186276,0.7519373,0.000006822416,0.000008697965,0.0038270794],"study_design_scores_gemma":[0.016511569,0.0014685125,0.035886705,0.0005802855,0.000051708514,0.00004119122,0.00044771857,0.000025653513,0.9333782,0.00005555509,0.011233755,0.00031913762],"about_ca_topic_score_codex":0.00004814005,"about_ca_topic_score_gemma":0.00005651113,"teacher_disagreement_score":0.19699271,"about_ca_system_score_codex":0.000029380906,"about_ca_system_score_gemma":0.00010521058,"threshold_uncertainty_score":0.9977348},"labels":[],"label_agreement":null},{"id":"W2981778203","doi":"10.1002/biot.201900286","title":"Adeno‐Associated Viral Vectors for Homology‐Directed Generation of CAR‐T Cells","year":2019,"lang":"en","type":"review","venue":"Biotechnology Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Homology (biology); Computational biology; Virology; Biology; Genetics; Cell biology; Gene","score_opus":0.10365879055873038,"score_gpt":0.3755942421227358,"score_spread":0.2719354515640054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981778203","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0023311803,0.993474,0.00014654857,0.00029840058,0.0014219247,0.001957479,0.00012453017,0.00015382557,0.00009212359],"genre_scores_gemma":[0.00013276257,0.9938163,0.000690371,0.000028656545,0.0006351103,0.000059453887,0.00025090246,0.00011762622,0.004268813],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99716294,0.00030764556,0.0010731644,0.0004557008,0.00036691877,0.00063365436],"domain_scores_gemma":[0.99760187,0.00024287251,0.0010276278,0.00059123465,0.0004081595,0.00012826228],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00087722915,0.00043799804,0.0026510328,0.0013157278,0.00012512102,0.00002295506,0.00047286393,0.003178469,0.000638189],"category_scores_gemma":[0.0005268117,0.00035057124,0.0010275461,0.000607143,0.00031015757,0.00003862739,0.000099677185,0.002284025,0.00005075575],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012745381,0.00027687414,0.000015848815,0.0040922086,0.0023058762,0.00010462767,0.00003311243,8.203079e-7,0.096876465,0.00010617949,0.01094622,0.8851143],"study_design_scores_gemma":[0.0017816384,0.0017624627,0.000005789491,0.0027622324,0.0019438043,0.0016949557,0.0000141812325,0.00006484344,0.015842812,0.00004067602,0.97376317,0.00032344574],"about_ca_topic_score_codex":0.0000116593565,"about_ca_topic_score_gemma":0.000008828778,"teacher_disagreement_score":0.96281695,"about_ca_system_score_codex":0.0007221618,"about_ca_system_score_gemma":0.0012351201,"threshold_uncertainty_score":0.9998946},"labels":[],"label_agreement":null},{"id":"W2982435333","doi":"10.3390/cells8111341","title":"MLL-Rearranged Acute Leukemia with t(4;11)(q21;q23)—Current Treatment Options. Is There a Role for CAR-T Cell Therapy?","year":2019,"lang":"en","type":"review","venue":"Cells","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AXYS Technologies (Canada)","funders":"","keywords":"Leukemia; Chromosomal translocation; Myeloid leukemia; Acute leukemia; Medicine; Oncology; Cancer research; Fusion gene; Internal medicine; Immunology; Biology; Gene; Genetics","score_opus":0.08670962398240774,"score_gpt":0.3794430066666013,"score_spread":0.2927333826841936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982435333","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00058692956,0.9816056,0.000032487005,0.00008132584,0.00048304547,0.011056502,0.0007408297,0.00011615138,0.0052971253],"genre_scores_gemma":[0.00002213268,0.8866967,0.00028541367,0.0000817266,0.0007001197,0.0018500155,0.00079133315,0.00036800205,0.10920454],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99592924,0.00023893185,0.00074476295,0.0012699473,0.00077711436,0.0010400141],"domain_scores_gemma":[0.99657893,0.00036699686,0.0004201533,0.0019117369,0.0002812955,0.00044085868],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00033276642,0.0011877266,0.0032606071,0.00038507878,0.00016150523,0.00012217609,0.0005215985,0.0005907729,0.0036033145],"category_scores_gemma":[0.000004941494,0.00074246386,0.0017457546,0.0004941968,0.00014958563,0.000071451745,0.00007663879,0.00073906063,0.0009948851],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005153422,0.00056882954,0.000010297051,0.010100915,0.0019221895,0.00006284249,0.00053596706,0.0000020028988,0.0016418468,0.000007236191,0.0073677367,0.9772648],"study_design_scores_gemma":[0.0055325357,0.0023797504,0.0000031555508,0.004566479,0.00357111,0.000063521176,0.000071981805,0.000025027071,0.0034314983,0.0000073473498,0.9796445,0.0007031003],"about_ca_topic_score_codex":0.00016594082,"about_ca_topic_score_gemma":0.000025979818,"teacher_disagreement_score":0.97656167,"about_ca_system_score_codex":0.0020231472,"about_ca_system_score_gemma":0.0026983207,"threshold_uncertainty_score":0.999783},"labels":[],"label_agreement":null},{"id":"W2982903806","doi":"10.1182/blood-2019-122781","title":"An Exploratory Analysis of Brentuximab Vedotin Plus CHP (A+CHP) in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas (ECHELON-2): Impact of Consolidative Stem Cell Transplant","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Brentuximab vedotin; Medicine; Internal medicine; Univariate analysis; Transplantation; Oncology; Surgery; Multivariate analysis; Lymphoma; CD30","score_opus":0.015816124630601492,"score_gpt":0.27362272216319433,"score_spread":0.25780659753259283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982903806","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970958,0.00046439932,0.000009006033,0.000009848569,0.000016676733,0.0011546687,0.0005908953,0.0000095548385,0.00064910087],"genre_scores_gemma":[0.99916494,0.00013977729,0.00006904961,0.000008844473,0.000016178277,0.000035480243,0.00033874754,0.00003216444,0.0001947951],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979044,0.00031330032,0.0004970925,0.00033907514,0.00063752534,0.00030857394],"domain_scores_gemma":[0.99848473,0.00015441107,0.00029382156,0.00073159114,0.00022060057,0.00011486547],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026737477,0.0002704625,0.0010693815,0.00036919647,0.000018139552,0.000007519481,0.00021341561,0.00009545088,0.0005683698],"category_scores_gemma":[0.0000022428799,0.00015931923,0.00035121673,0.0007525139,0.00013674003,0.000081959035,0.000012774228,0.00010984612,0.0000025684642],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056805913,0.016005868,0.83197486,0.00017784553,0.0023939558,0.000029958645,0.028920824,0.00043192462,0.11346277,0.0000016902521,0.0000040983355,0.0009156042],"study_design_scores_gemma":[0.06505076,0.021546395,0.620285,0.0001351006,0.0036941487,0.000004478154,0.0059679397,0.0017365464,0.28126857,0.0000014476892,0.000026226415,0.00028343755],"about_ca_topic_score_codex":0.00063553907,"about_ca_topic_score_gemma":0.00021194853,"teacher_disagreement_score":0.21168993,"about_ca_system_score_codex":0.00023114916,"about_ca_system_score_gemma":0.00047617086,"threshold_uncertainty_score":0.64968497},"labels":[],"label_agreement":null},{"id":"W2983303687","doi":"10.1182/blood-2019-125792","title":"A Comparison of Two-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel) and SCHOLAR-1 in Patients with Refractory Large B Cell Lymphoma","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Refractory (planetary science); Salvage therapy; Internal medicine; Fludarabine; Oncology; Surgery; Chemotherapy; Cyclophosphamide","score_opus":0.015596657079155847,"score_gpt":0.3028233139120027,"score_spread":0.2872266568328468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2983303687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99463326,0.0002888354,4.4721386e-7,0.000027697903,0.000029099852,0.00063933193,0.000014360312,0.000013433419,0.00435353],"genre_scores_gemma":[0.9985986,0.000023017992,0.00020012762,0.00005454064,0.000012744956,0.000010946234,0.000019801895,0.000030548086,0.0010496911],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985234,0.000090338166,0.00031544376,0.00028409087,0.0004671075,0.00031960412],"domain_scores_gemma":[0.9992637,0.000076751305,0.00008777808,0.00039495574,0.000074777694,0.00010204917],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035471044,0.00014695579,0.0005402068,0.00026318053,0.000017576845,0.000012452009,0.00010213512,0.000089118876,0.00040850477],"category_scores_gemma":[0.000040347426,0.00011825794,0.000040788847,0.00025163143,0.000039724615,0.00009100468,0.00007769277,0.0002921558,0.00003476863],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006484646,0.0070647174,0.9726284,0.000121966346,0.00004436377,0.000013807273,0.0005288811,7.2177625e-7,0.018070253,0.000011911395,0.000011375653,0.0008551395],"study_design_scores_gemma":[0.055761706,0.001236609,0.9247727,0.00010632785,0.00002823065,9.3625084e-7,0.0002635194,0.000015669608,0.017268114,0.0000054398197,0.00042290674,0.000117831456],"about_ca_topic_score_codex":0.0001129231,"about_ca_topic_score_gemma":0.0001003641,"teacher_disagreement_score":0.05511324,"about_ca_system_score_codex":0.00006587822,"about_ca_system_score_gemma":0.000093094124,"threshold_uncertainty_score":0.4822419},"labels":[],"label_agreement":null},{"id":"W2983333809","doi":"10.1182/blood-2019-126670","title":"A Phase 2 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody (Ab), in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; CD20; Mantle cell lymphoma; Rituximab; Lymphoma; Tolerability; B cell; Internal medicine; Oncology; Immunology; Gastroenterology; Antibody; Adverse effect","score_opus":0.015190308065964065,"score_gpt":0.30043175066022454,"score_spread":0.2852414425942605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2983333809","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99347097,0.00017967024,0.000003204715,0.000017160772,0.00017927762,0.0033279492,0.00003606609,0.00007231983,0.0027133774],"genre_scores_gemma":[0.9980278,0.00010748898,0.00012320463,0.000042994165,0.00010961246,0.00003316479,0.00017301171,0.00014728749,0.0012354549],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99590343,0.00026640212,0.000768383,0.00095986144,0.0013541463,0.0007477982],"domain_scores_gemma":[0.99717104,0.00011489494,0.00031369552,0.0017178352,0.0003558741,0.00032664093],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006042803,0.00045421295,0.0011011647,0.00077685073,0.00006890209,0.000042399053,0.00044020682,0.00022044205,0.0008063283],"category_scores_gemma":[0.00003698662,0.00037894756,0.00013003539,0.0011047543,0.00013593427,0.00030087092,0.00013100223,0.00046026174,0.00011851847],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027134116,0.10043159,0.6990097,0.00017883797,0.0001952595,0.000249332,0.0014203697,0.0000044843423,0.19258079,0.0000018335626,0.0000618361,0.0031525155],"study_design_scores_gemma":[0.19409312,0.036657996,0.73454595,0.00031159783,0.00021276025,0.000018308574,0.0013080841,0.000066017405,0.03146498,0.0000022800161,0.00084697333,0.00047193744],"about_ca_topic_score_codex":0.0003911098,"about_ca_topic_score_gemma":0.000051883537,"teacher_disagreement_score":0.19137971,"about_ca_system_score_codex":0.000111999856,"about_ca_system_score_gemma":0.00031436083,"threshold_uncertainty_score":0.99986625},"labels":[],"label_agreement":null},{"id":"W2983410311","doi":"10.1182/blood-2019-124492","title":"Correlation of Bridging and Lymphodepleting Chemotherapy with Clinical Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagenlecleucel","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont; Hamilton Health Sciences","funders":"","keywords":"Diffuse large B-cell lymphoma; Medicine; Blinatumomab; Refractory (planetary science); Chemotherapy regimen; Lymphoma; Chemotherapy; Internal medicine; Oncology; Rituximab; Leukemia; Biology","score_opus":0.011000794699848876,"score_gpt":0.2645559058655236,"score_spread":0.2535551111656747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2983410311","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976589,0.000066984976,0.00004977087,0.000031466352,0.000018312303,0.0009626107,0.000009408031,0.00004272868,0.0011598227],"genre_scores_gemma":[0.99753165,0.000052440955,0.00043909045,0.0001343914,0.0000228553,0.0000125040515,0.000040906165,0.00008130548,0.0016848381],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981851,0.00011023926,0.0004015986,0.00042759004,0.0005213361,0.00035412514],"domain_scores_gemma":[0.9988398,0.00024276871,0.00022861389,0.0004224674,0.00013465255,0.00013169843],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036863986,0.0002326958,0.0006073992,0.00017321714,0.000036602534,0.00001681832,0.00007846959,0.00013290184,0.00010964701],"category_scores_gemma":[0.000032624073,0.00015317749,0.00005335577,0.00028166728,0.000100424615,0.00010631888,0.000029304865,0.00019678615,0.0000087099315],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050540636,0.009347885,0.9790943,0.00008790895,0.00022166286,0.000030238056,0.00030621712,0.0000030236126,0.0011779169,0.0000015047361,0.0000055431246,0.004669733],"study_design_scores_gemma":[0.15050317,0.003192894,0.8439433,0.0002347131,0.00011144577,0.000012994289,0.00007084864,0.00028910907,0.0014062817,4.945445e-7,0.00006459402,0.00017016298],"about_ca_topic_score_codex":0.00013220482,"about_ca_topic_score_gemma":0.000046715297,"teacher_disagreement_score":0.14544912,"about_ca_system_score_codex":0.000071439485,"about_ca_system_score_gemma":0.00014418545,"threshold_uncertainty_score":0.6246397},"labels":[],"label_agreement":null},{"id":"W2983477569","doi":"10.1182/blood-2019-127664","title":"Systematic Literature Review of the Clinical Evidence in Relapsed/Refractory (R/R) Large B-Cell Lymphoma","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Internal medicine; Oncology; Brentuximab vedotin; Cochrane Library; Follicular lymphoma; Systematic review; Lymphoma; Salvage therapy; Diffuse large B-cell lymphoma; MEDLINE; Randomized controlled trial; Chemotherapy; Hodgkin lymphoma","score_opus":0.03832518770159279,"score_gpt":0.35417166811200146,"score_spread":0.3158464804104087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2983477569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.61088854,0.38239825,3.5703064e-7,0.0003998617,0.0001979435,0.0020701191,0.0000050234758,0.000014464712,0.0040254346],"genre_scores_gemma":[0.8273189,0.15375517,0.000059880047,0.0018499132,0.00014467667,0.00006267902,0.0000047997714,0.000038566846,0.016765378],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9972754,0.0007255806,0.00083974923,0.00028058566,0.00062233186,0.00025635384],"domain_scores_gemma":[0.99745506,0.0008372616,0.00024048032,0.0012029555,0.0001764909,0.00008774092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030958783,0.0001361484,0.0007680789,0.000073407464,0.000016503773,0.000011128808,0.00033800481,0.00016267555,0.0005857397],"category_scores_gemma":[0.0016220805,0.000079991914,0.00033256208,0.0005753071,0.00004611969,0.000056233224,0.00012064182,0.00042877908,0.00017380879],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022639219,0.0062015182,0.11709426,0.85481805,0.00017270485,0.00015796674,0.00044681467,6.588448e-8,0.018522628,0.00008665421,0.0016676988,0.00060527446],"study_design_scores_gemma":[0.012895492,0.0006638246,0.024121843,0.95522887,0.00035815802,0.00016609328,0.000051953433,0.000018895313,0.0032641622,0.000016794384,0.0030541678,0.00015975109],"about_ca_topic_score_codex":0.0000040553437,"about_ca_topic_score_gemma":0.0000036130857,"teacher_disagreement_score":0.22864306,"about_ca_system_score_codex":0.000047850135,"about_ca_system_score_gemma":0.00026242575,"threshold_uncertainty_score":0.6413439},"labels":[],"label_agreement":null},{"id":"W2983803118","doi":"10.1182/blood-2019-128302","title":"Impact of Tisagenlecleucel Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Attributes on Clinical Outcomes in Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL)","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont; Hamilton Health Sciences","funders":"","keywords":"Chimeric antigen receptor; Diffuse large B-cell lymphoma; Medicine; Refractory (planetary science); Lymphoma; Cytokine release syndrome; Internal medicine; Oncology; Cancer research; Immunotherapy; Immunology; Biology; Cancer","score_opus":0.03243113997427867,"score_gpt":0.3346661829572612,"score_spread":0.30223504298298254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2983803118","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949114,0.0008364272,8.4313666e-7,0.000112246045,0.00018089771,0.0023686648,0.00011135964,0.00008333188,0.0013948699],"genre_scores_gemma":[0.9874618,0.002709386,0.00025726575,0.00015186402,0.00019480744,0.000047242058,0.00011305684,0.0001427334,0.008921841],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961808,0.00038847458,0.0008604352,0.00089840527,0.0008470252,0.00082491484],"domain_scores_gemma":[0.99705464,0.0006165986,0.00036573884,0.0014396247,0.00020749841,0.00031590278],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00089947175,0.00047584152,0.0012702959,0.00033904397,0.00004791197,0.00002180389,0.00037239128,0.00022613876,0.0019511477],"category_scores_gemma":[0.0002187583,0.00029240994,0.00046518398,0.00071082485,0.000131575,0.00011629824,0.00007891185,0.0005735128,0.00029318492],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015791975,0.054387517,0.7921435,0.00014219232,0.00043414306,0.00009260342,0.00043869516,6.203477e-7,0.13152227,6.806186e-7,0.0004533818,0.004592382],"study_design_scores_gemma":[0.13743486,0.018692918,0.76900697,0.0002580939,0.00006005897,0.000019482635,0.00010795891,0.000011412686,0.07234976,0.0000014086124,0.0016958266,0.0003612342],"about_ca_topic_score_codex":0.000317724,"about_ca_topic_score_gemma":0.00004275383,"teacher_disagreement_score":0.12164288,"about_ca_system_score_codex":0.00014686202,"about_ca_system_score_gemma":0.0007245301,"threshold_uncertainty_score":0.9999528},"labels":[],"label_agreement":null},{"id":"W2984531433","doi":"10.6004/jnccn.2019.0029","title":"NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019","year":2019,"lang":"en","type":"article","venue":"Journal of the National Comprehensive Cancer Network","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":189,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada); Amgen (Canada)","funders":"National Comprehensive Cancer Network","keywords":"Medicine; Follicular lymphoma; Oncology; Lymphoma; Internal medicine; Refractory (planetary science); Diffuse large B-cell lymphoma; Cancer research; Biology","score_opus":0.054509489926656274,"score_gpt":0.3547670538761647,"score_spread":0.3002575639495084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2984531433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9140428,0.044527642,0.000037784175,0.015059745,0.0066666813,0.00088236196,0.000022906444,0.000024523499,0.0187356],"genre_scores_gemma":[0.9075756,0.0060560396,0.0014980172,0.021293864,0.01144437,0.000009310492,0.00001564601,0.00008548149,0.052021667],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972865,0.00012942619,0.00055816665,0.00016896552,0.0016091412,0.00024778157],"domain_scores_gemma":[0.99395174,0.00034475257,0.00047480155,0.00020235273,0.0048952927,0.00013106063],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00026984242,0.00016573649,0.00039214888,0.00014047988,0.00011354062,0.000028668233,0.00036348304,0.00010248089,0.0025501184],"category_scores_gemma":[0.00010630822,0.000105015,0.00036342192,0.00049878174,0.00006918304,0.00012777677,0.00013281632,0.00046030988,0.000097790464],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020247614,0.000117444826,0.009851891,0.00007196103,0.00037726585,0.000014007722,0.00010757816,0.048468336,0.0774824,0.00019946492,0.8589824,0.0023024776],"study_design_scores_gemma":[0.004785005,0.0003119034,0.018146342,0.00056554197,0.000088483175,0.0001831843,0.00008624147,0.0021059166,0.0035727106,0.0010403955,0.96896297,0.0001513274],"about_ca_topic_score_codex":0.00001915061,"about_ca_topic_score_gemma":0.0000023496277,"teacher_disagreement_score":0.109980546,"about_ca_system_score_codex":0.00069657044,"about_ca_system_score_gemma":0.0008492592,"threshold_uncertainty_score":0.9983617},"labels":[],"label_agreement":null},{"id":"W2985184701","doi":"10.1182/blood-2019-129730","title":"PRAME Expression Is Correlated with Treatment Outcome and Specific Features of the Tumor Microenvironment in Classical Hodgkin Lymphoma","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia; Spinal Cord Injury BC","funders":"","keywords":"Tumor microenvironment; Mantle cell lymphoma; Diffuse large B-cell lymphoma; Cancer research; Lymphoma; Follicular lymphoma; Medicine; Oncology; Internal medicine; Cancer; Biology","score_opus":0.014522705365294505,"score_gpt":0.2547452761588659,"score_spread":0.24022257079357137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2985184701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964751,0.000686075,6.050757e-7,0.00065801805,0.000034813263,0.00085728004,0.000007769994,0.000008705676,0.0012716034],"genre_scores_gemma":[0.99062335,0.00014390057,0.00016177184,0.00010204809,0.000024566887,0.000020317633,0.00000398085,0.000022138303,0.0088979425],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9989929,0.00006251626,0.00017926027,0.00025825272,0.00031002163,0.00019702892],"domain_scores_gemma":[0.99936795,0.00006320762,0.000063180545,0.0004240619,0.000011025812,0.00007057844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000076728895,0.00013900449,0.00028837565,0.00005870134,0.000020697873,0.000009813803,0.00007560572,0.00006456685,0.00062926585],"category_scores_gemma":[0.000006191539,0.00007228277,0.000058364225,0.00011072712,0.00011232522,0.000019456531,0.000059151705,0.00012873577,0.000017578477],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007611576,0.0011432732,0.4864437,0.000028742312,0.00005360813,0.0000535402,0.00042197257,0.0000011400165,0.50787926,0.000005700648,0.00013417775,0.0030737594],"study_design_scores_gemma":[0.011245636,0.0009927694,0.685468,0.00016080837,0.000046276884,0.00015647642,0.00011797797,0.000008736012,0.2976944,0.0000036741046,0.0040343986,0.00007081051],"about_ca_topic_score_codex":0.000031289135,"about_ca_topic_score_gemma":0.000008457351,"teacher_disagreement_score":0.21018484,"about_ca_system_score_codex":0.000108817396,"about_ca_system_score_gemma":0.0000415284,"threshold_uncertainty_score":0.689002},"labels":[],"label_agreement":null},{"id":"W2985774506","doi":"10.1007/978-1-0716-0146-4_6","title":"Lentiviral Vector Production in Suspension Culture Using Serum-Free Medium for the Transduction of CAR-T Cells","year":2019,"lang":"en","type":"article","venue":"Methods in molecular biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Transduction (biophysics); Transfection; HEK 293 cells; Cell culture; Viral vector; Cell biology; Embryonic stem cell; Suspension culture; Molecular biology; Biology; Chemistry; Recombinant DNA; Gene; Genetics; Biophysics","score_opus":0.047780012112679175,"score_gpt":0.41883066683315656,"score_spread":0.3710506547204774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2985774506","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8738969,0.00075817725,0.12103703,0.0010820692,0.0011745691,0.0019560584,0.000006639782,0.000011945646,0.00007659476],"genre_scores_gemma":[0.50597435,0.00025890063,0.49184513,0.000143255,0.0003066258,0.000088321016,0.000031330183,0.00006115435,0.0012909154],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980138,0.0009005715,0.00030400633,0.00036740198,0.00013485676,0.00027937177],"domain_scores_gemma":[0.9990901,0.00017556496,0.00007756206,0.0005139391,0.00011660333,0.000026262858],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022269916,0.00013129409,0.0003723845,0.00020498055,0.00002221367,0.0000037458344,0.00016154682,0.000226822,0.00014909725],"category_scores_gemma":[0.00037742214,0.000092449605,0.0001299534,0.0003992921,0.00013224801,0.00002752866,0.000048071015,0.00033562383,0.0000011026045],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004694646,0.00006654466,0.00210349,0.00010594234,0.000040984698,0.000003373874,0.0005918266,0.00021240076,0.9861176,0.00008531694,0.000015997231,0.010187057],"study_design_scores_gemma":[0.0015623542,0.00036985375,0.0013272419,0.00005072374,0.000041059477,0.000022980334,0.00024226656,0.0011137422,0.9924599,0.0011756538,0.0015473281,0.00008688343],"about_ca_topic_score_codex":0.00014577042,"about_ca_topic_score_gemma":0.000066020315,"teacher_disagreement_score":0.3708081,"about_ca_system_score_codex":0.00011372573,"about_ca_system_score_gemma":0.000079998914,"threshold_uncertainty_score":0.37699857},"labels":[],"label_agreement":null},{"id":"W2985861192","doi":"10.1182/blood-2019-129107","title":"Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients in the Juliet Trial","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Cytokine release syndrome; Internal medicine; Diffuse large B-cell lymphoma; Univariate analysis; Refractory (planetary science); Oncology; Gastroenterology; Salvage therapy; Chemotherapy regimen; Lymphoma; Chemotherapy; Immunotherapy; Multivariate analysis; Cancer; Chimeric antigen receptor; Biology","score_opus":0.03230198785502725,"score_gpt":0.3277322746081032,"score_spread":0.295430286753076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2985861192","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99711263,0.0000673384,3.540773e-7,0.00001717874,0.00008000747,0.0017089111,0.000059498856,0.000013734744,0.00094034127],"genre_scores_gemma":[0.9991461,0.00013661088,0.000008973084,0.00008597389,0.000030983945,0.000020414956,0.00019567946,0.00003102712,0.0003442189],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973511,0.0006912601,0.00072150317,0.00034550848,0.0005620314,0.0003285846],"domain_scores_gemma":[0.9977026,0.0013152547,0.00034891808,0.00039366237,0.00014291769,0.000096667194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066879403,0.00019774382,0.00067182543,0.00018496608,0.000027958644,0.00001602601,0.00012517824,0.00020784739,0.00011143678],"category_scores_gemma":[0.00069483265,0.00012824078,0.00010685746,0.0005016153,0.000108680935,0.000053278876,0.00006019909,0.0004194796,0.000015516065],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01900001,0.06217926,0.9139766,0.00002463156,0.00023810686,0.00008111671,0.0014770334,2.5231873e-7,0.0010758798,0.0000016195834,0.000026617136,0.0019188494],"study_design_scores_gemma":[0.27289435,0.0060101687,0.71973825,0.00013607448,0.00020622577,0.0000015797654,0.00014282741,0.00006380702,0.0006121801,0.0000014629106,0.00008761042,0.000105456966],"about_ca_topic_score_codex":0.00013077311,"about_ca_topic_score_gemma":0.00009001468,"teacher_disagreement_score":0.25389436,"about_ca_system_score_codex":0.000079958474,"about_ca_system_score_gemma":0.00013689334,"threshold_uncertainty_score":0.5229507},"labels":[],"label_agreement":null},{"id":"W2986196170","doi":"10.1182/blood-2019-123742","title":"Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":182,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Spinal Cord Injury BC; University of British Columbia; Jewish General Hospital","funders":"","keywords":"Medicine; Tolerability; Internal medicine; Follicular lymphoma; Lymphoma; Gastroenterology; Rituximab; Dosing; Oncology; Immunology; Adverse effect","score_opus":0.04627110153982159,"score_gpt":0.3115243581487076,"score_spread":0.265253256608886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2986196170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939201,0.001703456,0.0000013426394,0.00069225277,0.000088304034,0.0030362422,0.00013845578,0.000038691185,0.0003811865],"genre_scores_gemma":[0.99251705,0.0025424948,0.0026326173,0.0003233291,0.000089345434,0.00038055613,0.00005412226,0.00009299454,0.001367472],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974005,0.0001940966,0.000529598,0.0007965088,0.00046605335,0.0006132277],"domain_scores_gemma":[0.9987523,0.00029266495,0.00017118559,0.00044275587,0.0001330094,0.00020806538],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002056695,0.00040771786,0.0008081928,0.00035936615,0.000120524215,0.000059549155,0.00015939945,0.00019478278,0.00043555853],"category_scores_gemma":[0.00012136357,0.0003020106,0.00010352003,0.000901652,0.000065269436,0.00019025216,0.00019691189,0.00022840936,0.000023590186],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070636272,0.0030255527,0.5305826,0.0001500349,0.00020477701,0.00007509126,0.02112888,0.0000014144364,0.41216663,3.590228e-7,0.0001460276,0.025455024],"study_design_scores_gemma":[0.030349685,0.0041544554,0.66055644,0.004099938,0.00010942418,0.000010204232,0.0050864066,0.00016145785,0.28373712,0.000014573988,0.011057426,0.00066289096],"about_ca_topic_score_codex":0.0016001489,"about_ca_topic_score_gemma":0.00080311135,"teacher_disagreement_score":0.12997384,"about_ca_system_score_codex":0.0005010746,"about_ca_system_score_gemma":0.00023953739,"threshold_uncertainty_score":0.9999432},"labels":[],"label_agreement":null},{"id":"W2986356453","doi":"10.1172/jci126199","title":"Endogenous T cells prevent tumor immune escape following adoptive T cell therapy","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Investigation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":108,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre","funders":"Canadian Institutes of Health Research; Government of Ontario; Terry Fox Research Institute; Ontario Institute for Cancer Research","keywords":"Endogeny; Oncolytic virus; Immune system; Adoptive cell transfer; Blockade; Immune checkpoint; Cancer research; Immunology; Antigen; Biology; Cytotoxic T cell; T cell; Tumor antigen; Immunotherapy; Receptor; In vitro","score_opus":0.11018993887874642,"score_gpt":0.3819456765103028,"score_spread":0.27175573763155636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2986356453","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99281484,0.001071294,0.000042185053,0.00086153415,0.0013282838,0.0007055143,0.0000014416694,0.000016455764,0.0031584566],"genre_scores_gemma":[0.9915493,0.0006261641,0.0023664613,0.0010263794,0.00086896925,0.000004212541,0.000006490025,0.000043250093,0.0035087322],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9962664,0.00048625743,0.0017912387,0.00023548248,0.0009269016,0.00029367825],"domain_scores_gemma":[0.9969683,0.0007926853,0.0010394306,0.0003593062,0.00041073564,0.00042951974],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0038193557,0.0001818615,0.00085121987,0.00016698346,0.00004835144,0.000039353643,0.00023006034,0.00016222516,0.0014539638],"category_scores_gemma":[0.00037556773,0.00013803998,0.0009022839,0.0002577023,0.00011529319,0.00022453257,0.00004047185,0.0010700879,0.00017634437],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011392225,0.0005676422,0.025220312,0.00004371724,0.00027099354,0.0001679031,0.0004191801,0.00006409829,0.9611679,0.000015401221,0.00043707652,0.010486608],"study_design_scores_gemma":[0.010853564,0.0070119705,0.04063337,0.00040584352,0.00018263247,0.0002064692,0.0003273565,0.0005131442,0.92972016,0.00086215494,0.00903398,0.00024934803],"about_ca_topic_score_codex":0.000015888309,"about_ca_topic_score_gemma":5.080711e-7,"teacher_disagreement_score":0.03144768,"about_ca_system_score_codex":0.00010965624,"about_ca_system_score_gemma":0.0007453301,"threshold_uncertainty_score":0.99945885},"labels":[],"label_agreement":null},{"id":"W2987620291","doi":"10.1182/blood-2019-124352","title":"Longitudinal Analyses of Diagnostic-Relapse Biopsies of Diffuse Large B Cell Lymphoma Reveal a Poor Risk Subset of ABC Patients Based on the Expression of a 30 Gene Panel","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"","keywords":"Diffuse large B-cell lymphoma; Lymphoma; Gene expression profiling; Germinal center; Cancer research; Oncology; Biopsy; Biology; Internal medicine; B cell; Medicine; Gene; Pathology; Gene expression; Immunology; Antibody; Genetics","score_opus":0.033768194364330206,"score_gpt":0.2893187856528634,"score_spread":0.2555505912885332,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2987620291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99786043,0.00037528755,0.000012056324,0.000024986768,0.000039573206,0.0007474392,0.00063685945,0.000008470509,0.00029489247],"genre_scores_gemma":[0.99928653,0.00020849315,0.00017317261,0.000022359667,0.000026436006,0.000020016021,0.00006116314,0.000029990133,0.00017186375],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99774814,0.0002538005,0.0005836666,0.00027097578,0.0008721724,0.0002712755],"domain_scores_gemma":[0.99651176,0.0016637567,0.00053828245,0.0008268174,0.00036868188,0.00009071257],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046738086,0.0001884939,0.00063495967,0.00022763,0.00003149395,0.0000036992662,0.00024666684,0.00011062077,0.00074496894],"category_scores_gemma":[0.0009523263,0.000119621145,0.00026477454,0.0003555016,0.00016228126,0.000030302319,0.00008335175,0.00013041419,0.000009950688],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000877765,0.009937828,0.4567441,0.00031967487,0.000109996225,0.0000064560923,0.00022224893,0.000008139067,0.53153926,0.0000017905871,0.00010197396,0.00013073276],"study_design_scores_gemma":[0.015364906,0.0013937126,0.31763595,0.00035382627,0.00030000132,9.326623e-7,0.000087294015,0.00010215485,0.66467756,0.00000596117,0.000011033604,0.00006662331],"about_ca_topic_score_codex":0.0003561454,"about_ca_topic_score_gemma":0.0000060850684,"teacher_disagreement_score":0.13910815,"about_ca_system_score_codex":0.000020895144,"about_ca_system_score_gemma":0.00011245133,"threshold_uncertainty_score":0.8156887},"labels":[],"label_agreement":null},{"id":"W2987742353","doi":"10.1182/blood-2019-129120","title":"Portia: A Phase 1b Study Evaluating Safety and Efficacy of Tisagenlecleucel and Pembrolizumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Pembrolizumab; Medicine; Internal medicine; Oncology; Salvage therapy; Fludarabine; Diffuse large B-cell lymphoma; Lymphoma; Cyclophosphamide; Immunotherapy; Chemotherapy; Cancer","score_opus":0.014852087663057753,"score_gpt":0.30483676064559595,"score_spread":0.2899846729825382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2987742353","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963641,0.0004263168,0.0000016180178,0.000011429538,0.000024590898,0.0020663452,0.000019180128,0.000020399071,0.0010660181],"genre_scores_gemma":[0.99893767,0.000055061268,0.000064812804,0.000027936809,0.000022064822,0.000015685206,0.00002424499,0.000046883517,0.00080563],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980021,0.00016019493,0.00041277712,0.00042825515,0.000651109,0.0003455424],"domain_scores_gemma":[0.9989187,0.00018626187,0.0001564658,0.00046012673,0.00011895148,0.00015950049],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005882411,0.0001949059,0.0004933773,0.00018691702,0.0000457954,0.000014777272,0.00007909507,0.000082014965,0.00021357917],"category_scores_gemma":[0.00010761336,0.00015738735,0.00003686989,0.00023222515,0.000058700578,0.00008402346,0.000110139954,0.00020333912,0.000007468752],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011790689,0.108240396,0.84121954,0.00018888284,0.00019002297,0.000071880335,0.0026138825,3.626155e-7,0.018595278,0.0000021613748,0.000005329578,0.0170816],"study_design_scores_gemma":[0.39105365,0.010725958,0.5963656,0.00009258924,0.00017725964,0.000009781086,0.00029987583,0.000089021225,0.0010140464,0.0000014559627,0.000049659477,0.00012115309],"about_ca_topic_score_codex":0.000060094517,"about_ca_topic_score_gemma":0.000024650408,"teacher_disagreement_score":0.37926295,"about_ca_system_score_codex":0.00005259227,"about_ca_system_score_gemma":0.00014317577,"threshold_uncertainty_score":0.641807},"labels":[],"label_agreement":null},{"id":"W2987812087","doi":"10.1016/j.mayocp.2019.09.006","title":"Axicabtagene Ciloleucel Chimeric Antigen Receptor T Cell Therapy in Lymphoma With Secondary Central Nervous System Involvement","year":2019,"lang":"en","type":"letter","venue":"Mayo Clinic Proceedings","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Medicine; Chimeric antigen receptor; Central nervous system; Lymphoma; Antigen; Immunology; Immunotherapy; Virology; Internal medicine; Immune system","score_opus":0.030461654889877114,"score_gpt":0.27369918975763846,"score_spread":0.24323753486776134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2987812087","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8566257,0.0029551964,0.0000052562705,0.079987526,0.0016858481,0.006844712,0.00013014731,0.0004810944,0.05128453],"genre_scores_gemma":[0.14090972,0.009482918,0.0011569257,0.5663858,0.016965823,0.0012305098,0.0019229958,0.0015386568,0.26040664],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99286443,0.000096400625,0.0014245597,0.001829224,0.0017931359,0.0019922224],"domain_scores_gemma":[0.99743706,0.00019771686,0.0007620665,0.00085287244,0.00042782014,0.00032246453],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.0011544448,0.0010982314,0.0021076864,0.0007961192,0.00012026938,0.00018763274,0.0009151899,0.0015017296,0.005344911],"category_scores_gemma":[0.000037522885,0.0008887896,0.0005056658,0.00095517363,0.00026493744,0.00019671557,0.00022920106,0.0032847244,0.0009447667],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002948133,0.0006158618,0.023505261,0.006023293,0.00067753816,0.00075002393,0.001615695,4.3996502e-7,0.0218386,0.0000024034703,0.9096165,0.03240627],"study_design_scores_gemma":[0.011447803,0.004114487,0.01231866,0.0019087652,0.00011680962,0.00017159939,0.0010147392,0.000066589375,0.008153441,0.0000050759054,0.9595566,0.0011254358],"about_ca_topic_score_codex":0.00033028505,"about_ca_topic_score_gemma":0.000005662495,"teacher_disagreement_score":0.715716,"about_ca_system_score_codex":0.0014946298,"about_ca_system_score_gemma":0.0016051196,"threshold_uncertainty_score":0.9998331},"labels":[],"label_agreement":null},{"id":"W2988075996","doi":"10.1182/blood-2019-125963","title":"Combination of DPX-Survivac, Low Dose Cyclophosphamide, and Pembrolizumab in Recurrent/Refractory DLBCL: The Spirel Study","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nova Scotia Health Authority; Queen Elizabeth II Health Sciences Centre; Sunnybrook Health Science Centre; McGill University Health Centre; Ottawa Hospital; Health Sciences Centre","funders":"","keywords":"Medicine; Internal medicine; Cyclophosphamide; Oncology; Pembrolizumab; Refractory (planetary science); Gastroenterology; Chemotherapy; Cancer; Immunotherapy","score_opus":0.0162301028643446,"score_gpt":0.29289021987244734,"score_spread":0.2766601170081027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2988075996","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921489,0.0011227797,4.195945e-7,0.0001860169,0.00014967982,0.0015895388,0.000003832379,0.000020021365,0.0047788373],"genre_scores_gemma":[0.99799716,0.0003151079,0.000008026279,0.00004294611,0.000043062646,0.000034771936,0.000008075851,0.0000255957,0.0015252486],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998544,0.00015948294,0.00030100963,0.00026829142,0.00049736706,0.0002298623],"domain_scores_gemma":[0.9990208,0.00021151059,0.00009209359,0.0004976414,0.000106143125,0.00007181243],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006622051,0.0001351899,0.0003240936,0.00014428349,0.000030714935,0.000015852534,0.00014867022,0.00007252036,0.00041781907],"category_scores_gemma":[0.00010797882,0.00009840784,0.000054241787,0.00031873552,0.000073614494,0.00006668942,0.000093435476,0.0003466276,0.000032453914],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013443258,0.011521378,0.9261753,0.00024200599,0.00016771414,0.000044467233,0.0024314616,0.0000012552487,0.030575212,0.00013244784,0.000075900345,0.027288519],"study_design_scores_gemma":[0.026968542,0.0022299152,0.96521336,0.000117850555,0.00006909659,0.00001653713,0.0006629752,0.00007691272,0.0038038401,0.00011624188,0.0006121241,0.000112580594],"about_ca_topic_score_codex":0.00026092693,"about_ca_topic_score_gemma":0.000096154676,"teacher_disagreement_score":0.03903807,"about_ca_system_score_codex":0.000042645308,"about_ca_system_score_gemma":0.00009357898,"threshold_uncertainty_score":0.45748258},"labels":[],"label_agreement":null},{"id":"W2988183880","doi":"10.1182/blood-2019-123949","title":"Dual CD20-Targeted Therapy With Concurrent CD20-TCB and Obinutuzumab Shows Highly Promising Clinical Activity and Manageable Safety in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Preliminary Results From a Phase Ib Trial","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Obinutuzumab; Medicine; CD20; Refractory (planetary science); Lymphoma; Oncology; Phases of clinical research; Rituximab; Internal medicine; Clinical trial; Cancer research; Biology","score_opus":0.03937115457596355,"score_gpt":0.3341516338312315,"score_spread":0.2947804792552679,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2988183880","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922467,0.0010882515,0.000009837224,0.00020591546,0.00038705085,0.004624959,0.00020377069,0.0000852047,0.0011483368],"genre_scores_gemma":[0.99339616,0.0013379694,0.00055048225,0.000096948854,0.0005358173,0.00008955061,0.00016439825,0.00009643888,0.0037322429],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99576664,0.00063708704,0.0009441997,0.001282282,0.0007091835,0.0006605863],"domain_scores_gemma":[0.9966484,0.0016071815,0.00036079923,0.0008771428,0.00010902871,0.00039750212],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017435937,0.0004761628,0.0011973889,0.00023449406,0.0001161902,0.000086059605,0.0001741833,0.0004202121,0.0003399439],"category_scores_gemma":[0.00025242846,0.0003507831,0.00013403925,0.00035851635,0.00027733773,0.0002272632,0.00016540142,0.00082097086,0.000014495958],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.803779,0.0106932605,0.002429284,0.0001438017,0.00044024183,0.0007318343,0.0013660201,0.0000025949569,0.10198113,0.0000017266881,0.00027445322,0.07815664],"study_design_scores_gemma":[0.88491124,0.051380727,0.028874686,0.0005232602,0.0003020825,0.0001030739,0.00025884266,0.0019582293,0.025629591,0.000011642286,0.0054463213,0.0006003303],"about_ca_topic_score_codex":0.00081233314,"about_ca_topic_score_gemma":0.00016012718,"teacher_disagreement_score":0.08113221,"about_ca_system_score_codex":0.00025625262,"about_ca_system_score_gemma":0.0010462998,"threshold_uncertainty_score":0.99989444},"labels":[],"label_agreement":null},{"id":"W2989357527","doi":"10.1182/blood-2019-122207","title":"Changes in Tumor Immune Micro-Environment in Diffuse Large B-Cell Lymphoma (DLBCL): A Comparative Study of Relapsed Versus Diagnostic DLBCL","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Diffuse large B-cell lymphoma; Tumor microenvironment; Immune system; CD8; Lymphoma; Cancer research; Medicine; Immune checkpoint; Biology; Oncology; Pathology; Immunology; Immunotherapy","score_opus":0.024342179237805326,"score_gpt":0.2834009129939009,"score_spread":0.25905873375609556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989357527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949062,0.0011082938,2.875393e-7,0.00009954349,0.00010555077,0.0025507598,0.000017872406,0.00001708793,0.0011943922],"genre_scores_gemma":[0.9982561,0.0002529341,0.000035240566,0.000033088807,0.000036281865,0.00017641572,0.000022485596,0.00003847685,0.0011490132],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99794775,0.00023184501,0.00042025527,0.00042416557,0.00048638735,0.00048962113],"domain_scores_gemma":[0.9984044,0.000700299,0.0001243558,0.00063901587,0.000027688155,0.00010423687],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042718815,0.00023204478,0.00071854086,0.00032754452,0.000022774117,0.000009886154,0.0002056801,0.00007624477,0.00056433934],"category_scores_gemma":[0.000084162006,0.00021620875,0.00007458042,0.00034298457,0.000060283277,0.000040284172,0.00018005086,0.00026198736,0.00019562602],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004016848,0.20366476,0.41223562,0.00018537238,0.00022972668,0.0006465282,0.012159338,0.0000048440834,0.36647594,0.0000062971926,0.000030682335,0.0003440438],"study_design_scores_gemma":[0.3983393,0.0064209257,0.46719307,0.00021173866,0.00013821496,0.00001451664,0.009522082,0.0000619663,0.11730426,0.000004818448,0.00052316877,0.00026593267],"about_ca_topic_score_codex":0.00037619658,"about_ca_topic_score_gemma":0.0006743228,"teacher_disagreement_score":0.39432245,"about_ca_system_score_codex":0.00018924056,"about_ca_system_score_gemma":0.000070066344,"threshold_uncertainty_score":0.88167363},"labels":[],"label_agreement":null},{"id":"W2989833047","doi":"10.1038/s41598-019-53756-4","title":"Single variable domains from the T cell receptor β chain function as mono- and bifunctional CARs and TCRs","year":2019,"lang":"en","type":"article","venue":"Scientific Reports","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovative Targeting Solutions (Canada)","funders":"","keywords":"T-cell receptor; Chimeric antigen receptor; Jurkat cells; Computational biology; Receptor; Recombinant DNA; T cell; Cell biology; Computer science; Biology; Chemistry; Immunology; Gene; Genetics; Immune system","score_opus":0.014532922560182893,"score_gpt":0.2399776815054008,"score_spread":0.2254447589452179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2989833047","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98268384,0.00060838397,0.00006914176,0.00046482403,0.004034881,0.00062224537,0.000005422597,0.000053835854,0.011457401],"genre_scores_gemma":[0.85635453,0.000026824197,0.00036061788,0.00019075502,0.00027241974,0.000021045997,0.0001012771,0.000031892923,0.14264065],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99804115,0.000064630854,0.00026084803,0.0007014051,0.000665165,0.00026680305],"domain_scores_gemma":[0.9987358,0.00015310866,0.00011655659,0.0006852432,0.00014502933,0.00016430466],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014942676,0.00012501827,0.00018204759,0.00010218905,0.00027488655,0.0002362249,0.000049658367,0.00008681561,0.005693811],"category_scores_gemma":[0.00010956803,0.000088294364,0.00004846756,0.0003588106,0.00026404273,0.00011806845,0.00008322329,0.000193864,0.00011905876],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015294603,0.00008088645,0.03925271,0.000018642198,0.000040464092,0.000030043833,0.00035849033,0.00000896643,0.93586206,0.00005133395,0.020996014,0.003147428],"study_design_scores_gemma":[0.0011448663,0.00042730963,0.013576793,0.000075874756,0.00008408083,0.00035782074,0.0008752822,0.00031659385,0.05546775,0.0058331466,0.9216373,0.00020320115],"about_ca_topic_score_codex":0.0005279882,"about_ca_topic_score_gemma":0.000027479044,"teacher_disagreement_score":0.90064126,"about_ca_system_score_codex":0.00008544211,"about_ca_system_score_gemma":0.00020641742,"threshold_uncertainty_score":0.9952151},"labels":[],"label_agreement":null},{"id":"W2990184116","doi":"10.1182/bloodadvances.2019000717","title":"Durable preservation of antiviral antibodies after CD19-directed chimeric antigen receptor T-cell immunotherapy","year":2019,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute of Allergy and Infectious Diseases; National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; National Heart, Lung, and Blood Institute","keywords":"CD19; Immunology; Antibody; Chimeric antigen receptor; Immunotherapy; Medicine; Antigen; Receptor; Immunity; Virology; Virus; Immune system; Internal medicine","score_opus":0.009515221250823522,"score_gpt":0.2747866744039755,"score_spread":0.2652714531531519,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990184116","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9743503,0.012669095,0.000011119956,0.00015161591,0.000226974,0.00086211174,0.000021475767,0.00011400637,0.0115933055],"genre_scores_gemma":[0.9586898,0.011433215,0.0030489794,0.00008937973,0.00013702051,0.00004141781,0.00005190796,0.0000543788,0.02645389],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983757,0.00008573851,0.00035081556,0.00035306803,0.00046824006,0.00036640605],"domain_scores_gemma":[0.9989928,0.0000963719,0.00016449639,0.00048634887,0.00020525887,0.00005473691],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00021001608,0.00020529747,0.00048359454,0.00017122885,0.000044061402,0.000020822885,0.0001680156,0.00008301722,0.0035770577],"category_scores_gemma":[0.00003600733,0.0001717596,0.00014166781,0.00046175954,0.00011522904,0.00046385123,0.000043445412,0.00018239378,0.0001226671],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009875654,0.00034035614,0.28284237,0.00021105372,0.000111007765,0.000004249283,0.00023627536,0.0000026941414,0.70914656,0.0000050115077,0.00011099552,0.00600188],"study_design_scores_gemma":[0.0032494552,0.00078532664,0.1744527,0.0001805241,0.000033962675,0.0000058267656,0.00012611086,0.0000645181,0.7693141,0.000047691312,0.051530905,0.00020883649],"about_ca_topic_score_codex":0.00007085573,"about_ca_topic_score_gemma":0.00000798228,"teacher_disagreement_score":0.10838966,"about_ca_system_score_codex":0.000019722158,"about_ca_system_score_gemma":0.00008415605,"threshold_uncertainty_score":0.9973338},"labels":[],"label_agreement":null},{"id":"W2991263669","doi":"10.1182/blood-2019-128344","title":"Addition of ATIR101, an Adjunctive Treatment Following T-Cell-Depleted Haploidentical HSCT, May Decrease Non-Relapse Mortality and May Improve Survival of Patients with Hematologic Malignancies, Irrespective of Prognostic Risk Factors","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Juravinski Hospital; Université de Montréal; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Internal medicine; Hematopoietic stem cell transplantation; Transplantation; Oncology; Gastroenterology; Immunology","score_opus":0.02022450016857597,"score_gpt":0.2773847017286881,"score_spread":0.25716020156011216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2991263669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965084,0.000072888106,0.00002107183,0.0000038065434,0.000081093596,0.0023351784,0.0006499945,0.00002267337,0.00030485034],"genre_scores_gemma":[0.9992295,0.000019334428,0.00020268779,0.0000024420692,0.000015910755,0.00005836108,0.00031360463,0.000038765385,0.00011943105],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978026,0.00021413268,0.00048234337,0.00048238938,0.00070867816,0.00030986665],"domain_scores_gemma":[0.9980318,0.00046087534,0.00038066122,0.0004839504,0.00039157888,0.00025113655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026085606,0.0002848656,0.0008579507,0.00015389003,0.0000402134,0.000009181071,0.000090392656,0.00013131059,0.00021435706],"category_scores_gemma":[0.00037017008,0.00019895309,0.0001923364,0.00026638896,0.0002238881,0.00012505603,0.00005249504,0.00016187076,0.000001982233],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016918044,0.0054265116,0.92622364,0.00024418975,0.000988488,0.000028768798,0.00068867236,0.000001473279,0.06454888,0.000023440321,0.0000020193443,0.00013210987],"study_design_scores_gemma":[0.013385075,0.008002453,0.797069,0.00016571707,0.0012187557,0.0000023510052,0.0006448967,0.000059689934,0.17924802,0.000049409256,0.0000015579179,0.00015302547],"about_ca_topic_score_codex":0.0014696618,"about_ca_topic_score_gemma":0.00012522315,"teacher_disagreement_score":0.12915461,"about_ca_system_score_codex":0.00009760819,"about_ca_system_score_gemma":0.00026353772,"threshold_uncertainty_score":0.81130713},"labels":[],"label_agreement":null},{"id":"W2991564346","doi":"10.1136/jnnp-2019-abn-2.169","title":"200 AFFINITY: opicinumab in a targeted population of MS patients","year":2019,"lang":"en","type":"article","venue":"Journal of Neurology Neurosurgery & Psychiatry","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; NeuroRx Research (Canada)","funders":"","keywords":"Natalizumab; Expanded Disability Status Scale; Multiple sclerosis; Medicine; Placebo; Internal medicine; Population; Clinical endpoint; Stock options; Surrogate endpoint; Physical therapy; Oncology; Clinical trial; Immunology; Pathology","score_opus":0.012793294768442452,"score_gpt":0.2765837377508704,"score_spread":0.263790442982428,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2991564346","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915739,0.00019262907,0.0000014053462,0.003121815,0.0042755674,0.00034598613,0.000004982849,0.0000110517585,0.00047263762],"genre_scores_gemma":[0.9968292,0.00010924115,0.00006280537,0.0024531826,0.00027616977,0.0000018179098,0.000008387412,0.000042905667,0.00021628093],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99722666,0.0003767168,0.0011645486,0.0002630893,0.0006038617,0.00036510217],"domain_scores_gemma":[0.9982255,0.0002731577,0.0007297821,0.0003751916,0.00024510178,0.00015123497],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00055845187,0.00018760415,0.00078415073,0.0009283154,0.000022674569,0.000008809428,0.00017898246,0.0001948468,0.000955244],"category_scores_gemma":[0.00024654745,0.00016631685,0.00031424995,0.0005616516,0.00005724939,0.00015037712,0.00004515501,0.0010458115,0.000018256718],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004778734,0.0008885375,0.9735627,0.00008320963,0.00004271752,0.000093711766,0.000039288592,0.00008319158,0.017534366,0.000017758126,0.0018959715,0.0009797787],"study_design_scores_gemma":[0.0038032343,0.0029781547,0.9904808,0.00006844803,0.000032406228,0.00034734438,0.0000068652735,0.00006462309,0.00023666,0.00023294972,0.0016540731,0.000094476876],"about_ca_topic_score_codex":0.000032180928,"about_ca_topic_score_gemma":0.000015299483,"teacher_disagreement_score":0.017297706,"about_ca_system_score_codex":0.000030515,"about_ca_system_score_gemma":0.0002380757,"threshold_uncertainty_score":0.99995804},"labels":[],"label_agreement":null},{"id":"W2991566266","doi":"10.1182/blood-2019-126081","title":"Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of British Columbia","funders":"","keywords":"Medicine; Lymphoma; Refractory (planetary science); Internal medicine; Oncology; Cancer research; Biology","score_opus":0.010129602824365593,"score_gpt":0.2240935531776961,"score_spread":0.21396395035333052,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2991566266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99135476,0.00015820698,0.0000065758336,0.00004106951,0.00006768443,0.0011641463,0.000031870208,0.000059805196,0.007115881],"genre_scores_gemma":[0.97293794,0.000040815543,0.0003043705,0.0003072595,0.00006506242,0.000035316014,0.00007967157,0.00011151299,0.026118038],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99747264,0.00009731593,0.00028095252,0.00055845926,0.0009072101,0.0006834092],"domain_scores_gemma":[0.99845046,0.00008812389,0.000101507314,0.00091772486,0.00017902115,0.00026317337],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002398206,0.0002925892,0.00044887885,0.0002475075,0.00004611295,0.000049462524,0.0001850984,0.00016520829,0.0015883923],"category_scores_gemma":[0.000019898938,0.00021310861,0.00006989207,0.0003818779,0.00006545909,0.00023589759,0.000090236936,0.000354445,0.00042170583],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003471362,0.0102639515,0.96331614,0.0001224008,0.00014589576,0.00017804024,0.00047372683,0.0000020029643,0.020460641,0.000005175897,0.00017894543,0.00138171],"study_design_scores_gemma":[0.09772444,0.005551506,0.8598717,0.00022046878,0.00011643358,0.000018036624,0.00011534946,0.000013946911,0.019929515,0.0000023603184,0.016045906,0.00039035897],"about_ca_topic_score_codex":0.000099706755,"about_ca_topic_score_gemma":0.00007136999,"teacher_disagreement_score":0.103444465,"about_ca_system_score_codex":0.00013160956,"about_ca_system_score_gemma":0.00023716142,"threshold_uncertainty_score":0.99932426},"labels":[],"label_agreement":null},{"id":"W2992423763","doi":"10.1182/blood.v108.11.773.773","title":"LMO2 and TAL1 Cooperate in a Model of Human T−Cell Leukemogenesis.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Biology; Lymphopoiesis; CD8; Population; Haematopoiesis; T cell; Cytotoxic T cell; Cancer research; Cell biology; Molecular biology; Immunology; Stem cell; Genetics; Antigen; Immune system; Medicine; In vitro","score_opus":0.02752861885774754,"score_gpt":0.2839941180286129,"score_spread":0.25646549917086536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2992423763","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9777423,0.0007277047,0.000009569599,0.000057079484,0.0000053987305,0.00023143717,0.0000056499316,0.00001381519,0.021207055],"genre_scores_gemma":[0.98649645,0.00007021236,0.00021748916,0.000042168595,0.000048257127,0.000011403486,0.000010136526,0.000019988893,0.013083881],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99926853,0.000024031706,0.00018577438,0.00016572795,0.00017331511,0.00018260027],"domain_scores_gemma":[0.99965906,0.000017481614,0.000025741867,0.00019273485,0.00005273912,0.000052231946],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001634905,0.000082654915,0.00021613551,0.0001168651,0.000021973812,0.0000073802635,0.00005094632,0.000058082456,0.00017235946],"category_scores_gemma":[0.0000067988103,0.00007508055,0.000032933967,0.00014740224,0.000065043554,0.000023456165,0.000034157667,0.000099705154,0.000005089701],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000060474147,0.0006019516,0.017819801,0.00008724781,0.000012917703,0.00003281006,0.000082313294,0.00018053451,0.9805878,0.000112147005,0.00011142012,0.00031060647],"study_design_scores_gemma":[0.010935892,0.0004147731,0.016127825,0.000058713285,0.00006928184,0.00003121402,0.000033973953,0.0056708525,0.9659684,0.00034377584,0.00019975523,0.00014558165],"about_ca_topic_score_codex":0.0004746183,"about_ca_topic_score_gemma":0.0001703672,"teacher_disagreement_score":0.014619414,"about_ca_system_score_codex":0.000019686244,"about_ca_system_score_gemma":0.00008175876,"threshold_uncertainty_score":0.3061696},"labels":[],"label_agreement":null},{"id":"W2993613817","doi":"10.1158/1535-7163.targ-19-c048","title":"Abstract C048: Novel master checkpoint Cbl-b siRNA-based adoptive cellular therapy: Superior antitumor efficacy in a syngeneic murine hepatocellular carcinoma Hepa1-6 model following APN401 monotherapy and synergistic effects with anti-PD1","year":2019,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Cancer research; In vivo; Immune system; Immunotherapy; Medicine; Hepatocellular carcinoma; Cancer; Immunology; Pharmacology; Biology; Internal medicine","score_opus":0.034315951275988264,"score_gpt":0.280333360489796,"score_spread":0.24601740921380774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2993613817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.977085,0.011516908,0.006587491,0.00048818134,0.00017862582,0.0037849515,0.00002933565,0.0001143028,0.00021522473],"genre_scores_gemma":[0.99468076,0.00064662046,0.0015343679,0.001856966,0.00009529383,0.0003057216,0.000049148148,0.0003941194,0.0004370184],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99544877,0.00016396593,0.00071212323,0.0013027317,0.0011385839,0.0012338206],"domain_scores_gemma":[0.997772,0.0001955934,0.00021484922,0.0012429337,0.0002017714,0.00037288107],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005352499,0.0009477344,0.0013912756,0.0005159363,0.00012662167,0.00014696438,0.0003927959,0.0002983845,0.00024158641],"category_scores_gemma":[0.000014480547,0.0008023823,0.0004592666,0.00073602115,0.00025414527,0.00015347105,0.000085269916,0.00088544784,0.000017817152],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028616928,0.0010021954,0.078839995,0.00053898914,0.0008621238,0.0015662013,0.0006494967,0.005773305,0.90339893,0.000021325546,0.0000011398274,0.0044845804],"study_design_scores_gemma":[0.024068126,0.0014390468,0.031815305,0.00086755183,0.00032693564,0.000033314598,0.00008644194,0.1527539,0.7870445,0.00001879999,0.000514625,0.0010313952],"about_ca_topic_score_codex":0.0004805732,"about_ca_topic_score_gemma":0.000031208514,"teacher_disagreement_score":0.1469806,"about_ca_system_score_codex":0.0004981693,"about_ca_system_score_gemma":0.0007413194,"threshold_uncertainty_score":0.9994427},"labels":[],"label_agreement":null},{"id":"W2994926825","doi":"10.1016/j.jval.2019.09.637","title":"PCN445 INDIRECT TREATMENT COMPARISON OF AXICABTAGENE CILOLEUCEL (AXI-CEL) VERSUS TISAGENLECLEUCEL (TISA-CEL) IN RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA (RR-LBCL)","year":2019,"lang":"en","type":"article","venue":"Value in Health","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Precision Nanosystems (Canada)","funders":"","keywords":"Medicine; Leukapheresis; Population; Internal medicine; Adverse effect; Oncology; Refractory (planetary science); Clinical trial; Surgery; Gastroenterology; Stem cell","score_opus":0.08268486209824036,"score_gpt":0.36535704509718864,"score_spread":0.28267218299894825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2994926825","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97767633,0.00790852,0.000007458604,0.00048468847,0.0008240075,0.0022605667,0.00006909401,0.00007796854,0.0106913755],"genre_scores_gemma":[0.99024534,0.002622732,0.00037533173,0.00020413117,0.00014412044,0.00008577411,0.00010091683,0.000117241536,0.0061044022],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9945008,0.00083894626,0.0014254912,0.00087306846,0.0010283641,0.0013333056],"domain_scores_gemma":[0.9969633,0.00083092204,0.0004403097,0.0011668818,0.000096463424,0.00050210377],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017189723,0.0004751371,0.0015947598,0.0008939256,0.00008345634,0.000019447321,0.0003365909,0.00036647182,0.0014342378],"category_scores_gemma":[0.000111302244,0.0004570594,0.00026468822,0.001034321,0.00010116559,0.00008887623,0.00011987757,0.000611363,0.0004172786],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02196246,0.046958715,0.5706157,0.0044520563,0.0004878305,0.0005401672,0.02526788,0.002178242,0.14848633,0.00034779665,0.003039151,0.17566365],"study_design_scores_gemma":[0.2644543,0.0477658,0.26238862,0.002866857,0.00018706641,0.000073488955,0.007259138,0.029641174,0.19363207,0.00020113509,0.18944228,0.002088093],"about_ca_topic_score_codex":0.010254192,"about_ca_topic_score_gemma":0.000909865,"teacher_disagreement_score":0.30822712,"about_ca_system_score_codex":0.003634623,"about_ca_system_score_gemma":0.001824152,"threshold_uncertainty_score":0.9997881},"labels":[],"label_agreement":null},{"id":"W2995869139","doi":"","title":"Gene Therapy: An Overview of Approved and Pipeline Technologies","year":2018,"lang":"en","type":"article","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Medicine; Genetic enhancement; Intensive care medicine; Health care; Business; Gene; Economic growth","score_opus":0.12727747790170948,"score_gpt":0.38835526221496025,"score_spread":0.2610777843132508,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2995869139","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.979578,0.007644383,0.00019829287,0.0018595996,0.000030995707,0.000471635,0.0000031307693,0.00022278326,0.009991178],"genre_scores_gemma":[0.9732977,0.011348412,0.004893824,0.00039832326,0.00012936119,0.000014703811,0.000007534903,0.00002504378,0.009885099],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992854,0.000022616126,0.00014939545,0.00019239186,0.00018729403,0.00016291214],"domain_scores_gemma":[0.9992832,0.000028665856,0.00002939532,0.00045124764,0.00015828313,0.000049203194],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00025286834,0.00008782825,0.00022556902,0.00010117763,0.000025139247,0.000008004443,0.00009849181,0.00008624516,0.001890898],"category_scores_gemma":[0.00004921727,0.000058760197,0.00003262601,0.00019958538,0.00034237443,0.00004349939,0.00006430358,0.00009469568,0.000010857069],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022540323,0.00009534446,0.0013174602,0.000030381663,0.00002411347,0.0000020128755,0.00009033052,1.09446825e-8,0.6357414,0.00023537542,0.00046351997,0.36177462],"study_design_scores_gemma":[0.0015880559,0.0015526201,0.002400439,0.000024940287,0.000010372852,0.000030247451,0.00036231198,0.000430281,0.9513457,0.00067222264,0.041501734,0.00008107092],"about_ca_topic_score_codex":0.00009125195,"about_ca_topic_score_gemma":0.000033031356,"teacher_disagreement_score":0.36169356,"about_ca_system_score_codex":0.000012239756,"about_ca_system_score_gemma":0.00003847691,"threshold_uncertainty_score":0.99902153},"labels":[],"label_agreement":null},{"id":"W2996166277","doi":"10.1016/j.jval.2019.09.332","title":"PCN136 ECONOMIC VIABILITY OF CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY FOR ADULTS WITH ADVANCED LEUKEMIA: EVIDENCE FROM AN EARLY ECONOMIC MODELLING","year":2019,"lang":"en","type":"article","venue":"Value in Health","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"","keywords":"Medicine; Blinatumomab; Chimeric antigen receptor; Oncology; Immunotherapy; Salvage therapy; Internal medicine; Leukemia; Chemotherapy; Cancer; Lymphoblastic Leukemia","score_opus":0.04991998451427404,"score_gpt":0.33051687973485416,"score_spread":0.2805968952205801,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2996166277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99299204,0.0020372767,0.00042841653,0.00033532106,0.00021123246,0.0038087957,0.00007975845,0.00003523203,0.00007194708],"genre_scores_gemma":[0.9850313,0.005939421,0.008391133,0.00011344465,0.00015013217,0.00009856523,0.000045181583,0.00006975302,0.00016104427],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99762166,0.00022828237,0.0006953091,0.000748927,0.00018737845,0.0005184626],"domain_scores_gemma":[0.99791235,0.0006146703,0.00030752996,0.000856982,0.00006608152,0.00024236001],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011267759,0.0002268951,0.00074747857,0.00015979477,0.000045614743,0.000015628346,0.0002554197,0.0001196462,0.00060110004],"category_scores_gemma":[0.000016139857,0.00020327693,0.00012819895,0.00010886526,0.0000793877,0.00029360317,0.000024686718,0.00031391918,0.00006089108],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029379742,0.0004384488,0.2828641,0.0013152757,0.00011860431,0.0000014308047,0.0074338126,0.5794889,0.05983536,0.00003700096,0.000041927924,0.03904544],"study_design_scores_gemma":[0.018658562,0.017587824,0.038051773,0.0021257256,0.000016825434,0.000003585822,0.0008825543,0.8710328,0.049404174,0.00038373607,0.0012173811,0.0006351117],"about_ca_topic_score_codex":0.036938194,"about_ca_topic_score_gemma":0.00020310488,"teacher_disagreement_score":0.29154387,"about_ca_system_score_codex":0.0015203176,"about_ca_system_score_gemma":0.00202012,"threshold_uncertainty_score":0.9694749},"labels":[],"label_agreement":null},{"id":"W2996286256","doi":"10.3389/fimmu.2019.02873","title":"Efficient and Robust NK-Cell Transduction With Baboon Envelope Pseudotyped Lentivector","year":2019,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":177,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"National Cancer Institute; Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; Fondation ARC pour la Recherche sur le Cancer; Warren H. and Clara Cole Foundation","keywords":"Vesicular stomatitis virus; Baboon; Biology; Transduction (biophysics); Measles virus; Virology; Cell culture; CD19; Molecular biology; Virus; Immunology; Immune system; Genetics; Endocrinology","score_opus":0.010132946156941651,"score_gpt":0.2284956239988109,"score_spread":0.21836267784186925,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2996286256","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885457,0.0028944507,0.0022211957,0.00033679116,0.00090455776,0.0007707021,0.0000022896418,0.00003617585,0.00428813],"genre_scores_gemma":[0.9735848,0.0007624236,0.0071277483,0.000066141205,0.000057325055,0.00003452255,0.000018297002,0.000044533874,0.01830423],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99881643,0.00010072336,0.00018079484,0.00036892956,0.00017187878,0.0003612515],"domain_scores_gemma":[0.9995142,0.000029596797,0.000043601678,0.00030256703,0.000059404538,0.00005063021],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00020947128,0.00015296829,0.00036316144,0.00034091307,0.00003637561,0.000010766503,0.00008939996,0.00015568183,0.0011590574],"category_scores_gemma":[0.000012023769,0.00012894825,0.000038751594,0.0002817655,0.00022185316,0.000032093267,0.000027775928,0.0004105509,0.000049441594],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011660006,0.00069884915,0.183838,0.00027690825,0.0004268541,0.00008896581,0.002904438,0.0007852457,0.76070917,0.00009345678,0.0015440121,0.03697409],"study_design_scores_gemma":[0.0592613,0.011130355,0.60791063,0.0006232541,0.00031093156,0.000875273,0.011173802,0.0136289,0.20628545,0.00015576792,0.08706433,0.0015799929],"about_ca_topic_score_codex":0.000064347085,"about_ca_topic_score_gemma":0.000010991222,"teacher_disagreement_score":0.55442375,"about_ca_system_score_codex":0.00017329855,"about_ca_system_score_gemma":0.00010121066,"threshold_uncertainty_score":0.999754},"labels":[],"label_agreement":null},{"id":"W2996520276","doi":"10.1016/j.jacc.2019.10.049","title":"Chimeric Antigen Receptor T-Cell Therapy for Cancer and Heart","year":2019,"lang":"en","type":"review","venue":"Journal of the American College of Cardiology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":113,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; McGill University Health Centre","funders":"National Cancer Institute","keywords":"Medicine; Chimeric antigen receptor; Cardiogenic shock; Internal medicine; Adverse effect; Cell therapy; Myocarditis; Cardiology; Cytokine release syndrome; Troponin; Heart failure; Population; Troponin T; Oncology; Cancer; Immunotherapy; Cell; Myocardial infarction","score_opus":0.058436975556238314,"score_gpt":0.3875977864110855,"score_spread":0.32916081085484716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2996520276","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0063614794,0.98945904,0.000013731943,0.0008202567,0.0008505034,0.0017975249,0.0002934729,0.000004039714,0.000399939],"genre_scores_gemma":[0.00028875988,0.9942223,0.00046761945,0.00025332923,0.0013011623,0.000044737753,0.0000037115512,0.0000821428,0.0033362461],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975667,0.000570017,0.0008624135,0.00026493488,0.0003786203,0.000357304],"domain_scores_gemma":[0.99649876,0.0007504837,0.0016659071,0.00055097503,0.00039271094,0.00014116509],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00089627004,0.00032935664,0.0051482935,0.00032116775,0.00005435289,0.0000056736426,0.00044851808,0.0001651898,0.00009859675],"category_scores_gemma":[0.000110803434,0.00018472559,0.001995197,0.00054474385,0.00061493664,0.00002673698,0.00009834966,0.0006633824,0.0000034667307],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017570512,0.00007691178,0.0016191044,0.004858077,0.0042061983,0.000026740112,0.00002769489,0.00000746069,0.0054915654,0.000007899945,0.0574891,0.9244322],"study_design_scores_gemma":[0.0013180609,0.0021319415,0.00036204208,0.0015207534,0.0007881553,0.0014439399,0.000050734125,0.000001214227,0.0001191765,0.0000072600715,0.9921003,0.00015642792],"about_ca_topic_score_codex":0.000016853637,"about_ca_topic_score_gemma":7.2444857e-7,"teacher_disagreement_score":0.9346112,"about_ca_system_score_codex":0.00018224797,"about_ca_system_score_gemma":0.0017453125,"threshold_uncertainty_score":0.7532891},"labels":[],"label_agreement":null},{"id":"W2996718802","doi":"10.1016/j.jval.2019.09.632","title":"PCN439 DEVELOPING A DISCRETE-EVENT SIMULATION TO STUDY THE INFLUENCE OF WAITING TIMES ON THE EFFECTIVENESS AND COST-EFFECTIVENESS OF CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY IN LARGE B-CELL LYMPHOMA","year":2019,"lang":"en","type":"article","venue":"Value in Health","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Guelph; University of Waterloo","funders":"","keywords":"Medicine; Chimeric antigen receptor; Cost-effectiveness analysis; Cost effectiveness; Oncology; Lymphoma; Internal medicine; Immunotherapy; Cancer","score_opus":0.04619662143292034,"score_gpt":0.37127889652554735,"score_spread":0.325082275092627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2996718802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98991776,0.00039633602,0.000065841734,0.00019309828,0.00005083443,0.009289921,0.0000075899957,0.000010416459,0.00006820403],"genre_scores_gemma":[0.9993306,0.00023001857,0.000042171665,0.00013300343,0.000016713477,0.00019622852,0.0000038420003,0.000032691434,0.000014739519],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99484503,0.0034317395,0.00049828074,0.0003659022,0.00047753964,0.0003814858],"domain_scores_gemma":[0.9944236,0.004771384,0.0002018192,0.0004183761,0.00011612322,0.00006869441],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0075304164,0.00018731484,0.00054126215,0.00023653731,0.00008183731,0.00001163272,0.0001863633,0.000057733483,0.000029453613],"category_scores_gemma":[0.00025970058,0.00011680933,0.000054122112,0.0008659881,0.00005117812,0.0000532055,0.000089666326,0.00021941742,0.0000058822366],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048469426,0.0017424442,0.7365907,0.0012574852,0.00006680624,0.0000032244086,0.007511181,0.09725081,0.13513765,0.00019156752,6.614515e-7,0.015400528],"study_design_scores_gemma":[0.0075945472,0.0025754126,0.9302319,0.0013583689,0.0000044643944,0.0000011354397,0.0012964626,0.01109423,0.045616012,0.000050209685,0.000055330078,0.000121896584],"about_ca_topic_score_codex":0.0031001943,"about_ca_topic_score_gemma":0.00002211394,"teacher_disagreement_score":0.19364123,"about_ca_system_score_codex":0.00035663648,"about_ca_system_score_gemma":0.0003650645,"threshold_uncertainty_score":0.4763346},"labels":[],"label_agreement":null},{"id":"W2997394796","doi":"10.1016/j.jns.2019.10.313","title":"Safety of ocrelizumab in multiple sclerosis: Updated analysis in patients with relapsing and primary progressive multiple sclerosis","year":2019,"lang":"en","type":"article","venue":"Journal of the Neurological Sciences","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Ocrelizumab; Medicine; Multiple sclerosis; Population; Clinical trial; Internal medicine; Adverse effect; Phases of clinical research; Immunology; Environmental health","score_opus":0.03989489549209315,"score_gpt":0.26384960430142973,"score_spread":0.22395470880933657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2997394796","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9983373,0.00019904693,0.0000025780068,0.0008336737,0.00005767189,0.00043161184,0.0000031104357,0.000003674481,0.00013132552],"genre_scores_gemma":[0.9992218,0.00009701956,0.00040650085,0.00023539287,0.000012028312,0.0000018201177,8.710659e-7,0.0000050166404,0.00001955613],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977247,0.00032073082,0.000514425,0.00025268292,0.0009110415,0.00027638683],"domain_scores_gemma":[0.99876624,0.00039210366,0.00042135653,0.00017508125,0.00015201351,0.0000932193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001151118,0.00011446527,0.00050794485,0.0003723605,0.00007695069,0.000030073435,0.00034399412,0.00007409034,0.00016453283],"category_scores_gemma":[0.00040982442,0.00005424234,0.00012553221,0.0019718257,0.0005434155,0.00017967299,0.00015455578,0.00048083666,6.932111e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042866017,0.00033908134,0.98010176,0.000009709839,0.00005171919,0.0000089045325,0.00009653761,0.0012027675,0.011084658,0.0000012240715,0.000006692791,0.002810315],"study_design_scores_gemma":[0.004522851,0.00273197,0.9893092,0.00019621021,0.00006122332,0.000009494385,0.00004743204,0.0024238403,0.0006034136,0.000016872425,0.000018407101,0.00005908087],"about_ca_topic_score_codex":0.00003448269,"about_ca_topic_score_gemma":0.000033084503,"teacher_disagreement_score":0.010481245,"about_ca_system_score_codex":0.000059408467,"about_ca_system_score_gemma":0.00009060919,"threshold_uncertainty_score":0.22119385},"labels":[],"label_agreement":null},{"id":"W2998937323","doi":"10.1038/s41596-019-0249-0","title":"Activation and expansion of human T cells using artificial antigen-presenting cell scaffolds","year":2020,"lang":"en","type":"article","venue":"Nature Protocols","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; U.S. Food and Drug Administration; National Institutes of Health; Government of Canada; U.S. Department of Health and Human Services","keywords":"Cell biology; Antigen-presenting cell; T cell; Antigen; Chimeric antigen receptor; Chemistry; Cell; Cell culture; Cell therapy; Ex vivo; Biology; Molecular biology; In vitro; Stem cell; Immunology; Biochemistry; Immune system","score_opus":0.07538587506011594,"score_gpt":0.40112151878599217,"score_spread":0.3257356437258762,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2998937323","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9548348,0.000022117832,0.00013957721,0.00023514604,0.000018722643,0.043433946,0.0000029292532,0.00003854292,0.0012742161],"genre_scores_gemma":[0.9957104,0.0000020606121,0.0013132474,0.00018228481,0.00037906007,0.0022774478,0.000008387181,0.000033567085,0.000093580114],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99861944,0.00006346525,0.00027785433,0.0003053981,0.00051014486,0.00022371176],"domain_scores_gemma":[0.99929106,0.000046071647,0.00013755678,0.00020979768,0.00018037473,0.00013515142],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025412117,0.00013406533,0.00028237604,0.000108593566,0.00010195908,0.000036427064,0.0000929395,0.0002954103,0.00023703283],"category_scores_gemma":[0.000058343256,0.0001215872,0.000071858216,0.00033734855,0.00006272853,0.00010486177,0.000095046795,0.0004381273,0.000003111838],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040960574,0.000083076215,0.0030746055,0.0005391128,0.000014774949,0.000008955675,0.00039398053,0.000005942581,0.99165666,0.00007532006,0.00010817875,0.0036297701],"study_design_scores_gemma":[0.0009816214,0.0003390095,0.001503966,0.0002095877,0.000011616116,0.0000027599776,0.000095050906,0.001178967,0.99359226,0.00010845942,0.0018766127,0.00010009568],"about_ca_topic_score_codex":0.000017624858,"about_ca_topic_score_gemma":8.976095e-7,"teacher_disagreement_score":0.041156497,"about_ca_system_score_codex":0.00003508909,"about_ca_system_score_gemma":0.00009393815,"threshold_uncertainty_score":0.49581823},"labels":[],"label_agreement":null},{"id":"W2999883306","doi":"10.1097/01.cot.0000653352.65501.9d","title":"Dual-Targeted Antibody Offers Positive Outcomes for Non-Hodgkin Lymphoma","year":2020,"lang":"en","type":"article","venue":"Oncology Times","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Lymphoma; Medicine; B cell; CD20; Oncology; Cancer; Antibody; Rituximab; Internal medicine; Cancer research; Immunology","score_opus":0.028664672571640435,"score_gpt":0.37234676236506004,"score_spread":0.3436820897934196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999883306","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7914766,0.000246375,0.0007879261,0.088422135,0.0005483673,0.0030955158,0.0001512049,0.00027451196,0.11499733],"genre_scores_gemma":[0.91587937,0.000093769566,0.004490892,0.014707543,0.000789307,0.00017668594,0.00046048372,0.00011908075,0.063282885],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99845773,0.00010281454,0.00028213373,0.00041647116,0.0002535901,0.00048728744],"domain_scores_gemma":[0.99846655,0.00072620314,0.000082453786,0.00023748573,0.00018141446,0.0003058866],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00025672218,0.00021424181,0.00070481736,0.00011697662,0.00009928428,0.000015106851,0.00013508953,0.00024637178,0.0039473153],"category_scores_gemma":[0.00035819862,0.00017949287,0.0002483182,0.00023252147,0.00019632875,0.00005798816,0.00008551511,0.00017556161,0.0003264887],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059694634,0.0007986497,0.041350428,0.00014588996,0.0013969193,0.00072415516,0.0028793076,0.0000042573365,0.75007004,0.0003198284,0.10744106,0.08889999],"study_design_scores_gemma":[0.02886637,0.016214518,0.2860451,0.000078070516,0.000533961,0.00021904195,0.0014071659,0.0041331695,0.16200374,0.00026177245,0.49951875,0.0007183368],"about_ca_topic_score_codex":0.000041248633,"about_ca_topic_score_gemma":0.0000056113217,"teacher_disagreement_score":0.5880663,"about_ca_system_score_codex":0.0002273605,"about_ca_system_score_gemma":0.00050796225,"threshold_uncertainty_score":0.9969632},"labels":[],"label_agreement":null},{"id":"W2999920020","doi":"10.1002/eji.201948309","title":"CD5 blockade enhances ex vivo CD8 <sup>+</sup> T cell activation and tumour cell cytotoxicity","year":2020,"lang":"en","type":"article","venue":"European Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Western University","funders":"Institute of Cancer Research; Canadian Institutes of Health Research","keywords":"CD5; Cytotoxic T cell; Biology; Ex vivo; CD8; T cell; Cancer research; T-cell receptor; In vivo; Molecular biology; Antigen; Cell biology; Immunology; Immune system; In vitro; Biochemistry","score_opus":0.022525415814308287,"score_gpt":0.2578561671743148,"score_spread":0.23533075136000653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2999920020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9784041,0.0013239024,0.0006199636,0.0033444588,0.00007351151,0.00018543903,0.0000027570636,0.000026160527,0.016019685],"genre_scores_gemma":[0.99462026,0.0013948279,0.0006069176,0.0006946768,0.0006591127,6.715085e-7,0.0000022756076,0.00005471365,0.00196652],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99777615,0.0007363352,0.0005760394,0.00024414563,0.0003244854,0.00034287144],"domain_scores_gemma":[0.9988122,0.00016195932,0.0003694262,0.0001978978,0.00022769942,0.00023079432],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00072205934,0.00020188719,0.00045606666,0.00019120036,0.000085396845,0.000037785278,0.00028785822,0.000060891245,0.0017512003],"category_scores_gemma":[0.00021142652,0.00016974314,0.00013973528,0.00022492901,0.00019295009,0.00014781365,0.00013944808,0.0009994932,0.00012987193],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015369559,0.00014363861,0.00045586363,0.000059534475,0.0001051576,0.00050005957,0.0020942243,0.000037680376,0.9905936,0.0000031011507,0.0010192196,0.0034509767],"study_design_scores_gemma":[0.0035497688,0.0030586245,0.0054968586,0.000074036856,0.000051424908,0.0004891244,0.0009271546,0.00016169151,0.9659665,0.000007983828,0.020072475,0.00014431412],"about_ca_topic_score_codex":0.000006923501,"about_ca_topic_score_gemma":2.728201e-7,"teacher_disagreement_score":0.024627045,"about_ca_system_score_codex":0.0000655004,"about_ca_system_score_gemma":0.00012822992,"threshold_uncertainty_score":0.99916136},"labels":[],"label_agreement":null},{"id":"W3001787418","doi":"10.1158/2326-6066.cir-19-0521","title":"IL6 Induces an IL22+ CD8+ T-cell Subset with Potent Antitumor Function","year":2020,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Artificial Intelligence in Medicine (Canada); Vector Institute; University of Toronto; University Health Network; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"Canadian Institutes of Health Research; Government of Canada","keywords":"CD8; Cytotoxic T cell; Biology; Chimeric antigen receptor; T-cell receptor; Cancer research; Cytokine; Immunology; Immunotherapy; T cell; Cell biology; Antigen; Immune system; Genetics","score_opus":0.13213537955766047,"score_gpt":0.39498686672623684,"score_spread":0.26285148716857637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3001787418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97948205,0.0042324173,0.000040063725,0.0094553055,0.00020709111,0.000992096,0.00002332788,0.00012297594,0.005444648],"genre_scores_gemma":[0.98856604,0.0018953483,0.00007444545,0.00077877194,0.0005899093,0.00027344745,0.0000634258,0.0000809523,0.007677685],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99639606,0.0005151325,0.00027375246,0.00076532614,0.0010043192,0.0010454275],"domain_scores_gemma":[0.9978442,0.00014450347,0.000058131387,0.00071322086,0.000822185,0.00041772312],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000878003,0.00023263,0.00045097264,0.00036435685,0.00030479216,0.00007108536,0.00045278913,0.00024368784,0.00795475],"category_scores_gemma":[0.00011810486,0.00018539953,0.00007814858,0.0012467285,0.0008957593,0.0002067145,0.00020873485,0.0019323482,0.0003576369],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009372066,0.00027416667,0.012188239,0.00012829778,0.0002802352,0.0002629784,0.0009789747,0.00001119418,0.9511977,0.000070643866,0.0044943383,0.020741198],"study_design_scores_gemma":[0.012073243,0.022316497,0.06303466,0.0002274736,0.00014044222,0.00024921566,0.0068497886,0.0003782443,0.7097733,0.00011532704,0.1841605,0.00068130513],"about_ca_topic_score_codex":0.00070701295,"about_ca_topic_score_gemma":0.00010951122,"teacher_disagreement_score":0.24142437,"about_ca_system_score_codex":0.00032712333,"about_ca_system_score_gemma":0.0011772302,"threshold_uncertainty_score":0.9929521},"labels":[],"label_agreement":null},{"id":"W3003231717","doi":"10.1016/j.omtm.2020.01.012","title":"A High-Throughput Method for Characterizing Novel Chimeric Antigen Receptors in Jurkat Cells","year":2020,"lang":"en","type":"article","venue":"Molecular Therapy — Methods & Clinical Development","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":116,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; McGill University; National Research Council Canada","funders":"National Research Council Canada","keywords":"Jurkat cells; Chimeric antigen receptor; Antigen; Monoclonal antibody; Biology; Cell biology; Electroporation; Computational biology; T cell; Molecular biology; Chemistry; Antibody; Immunology; Immune system; Genetics; Gene","score_opus":0.16504406304242386,"score_gpt":0.4849395707982245,"score_spread":0.3198955077558006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3003231717","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.257904,0.00057212374,0.7311754,0.006636089,0.0007976787,0.0026400404,0.000007967851,0.00012756289,0.00013909886],"genre_scores_gemma":[0.0022077644,0.0014747803,0.979542,0.015019857,0.00035871915,0.0003710245,0.000086714856,0.00018782704,0.00075128645],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99339664,0.0016160449,0.0019247129,0.0014072757,0.0007013069,0.00095400336],"domain_scores_gemma":[0.99648833,0.0016309846,0.0003405684,0.000658575,0.00022185167,0.0006597002],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.007838077,0.0005604122,0.0016588606,0.00023129761,0.00011705117,0.00006531484,0.00050326675,0.0004242649,0.0009689568],"category_scores_gemma":[0.0009848358,0.00050051016,0.0006068377,0.000995029,0.00013293225,0.00008418593,0.0002143855,0.000960396,0.00006821562],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014968088,0.00039167155,0.00044484,0.000052182528,0.00036750778,0.000031068208,0.0007915749,0.0000060102875,0.5484973,0.00004347845,0.000094152776,0.44778338],"study_design_scores_gemma":[0.0059072054,0.00081473327,0.0047243205,0.000076291966,0.000029629211,0.0000070200504,0.00006473861,0.00056983624,0.6030089,0.00010399207,0.38426092,0.00043237605],"about_ca_topic_score_codex":0.00003586173,"about_ca_topic_score_gemma":0.0000020419127,"teacher_disagreement_score":0.447351,"about_ca_system_score_codex":0.00021412567,"about_ca_system_score_gemma":0.00072115543,"threshold_uncertainty_score":0.99994427},"labels":[],"label_agreement":null},{"id":"W3006233208","doi":"10.1182/bloodadvances.2019000525","title":"Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL","year":2020,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":143,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Hospital","funders":"Legend Biotech; Novartis Pharmaceuticals Corporation","keywords":"Cytokine release syndrome; Immunogenicity; Immunology; Medicine; CD19; Hazard ratio; Internal medicine; Tocilizumab; Oncology; Biology; Immunotherapy; Flow cytometry; Cancer; Antibody; Confidence interval; Chimeric antigen receptor","score_opus":0.0500624111526647,"score_gpt":0.3459240145316899,"score_spread":0.29586160337902523,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006233208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99245834,0.004899353,0.000027512184,0.0009616996,0.0001271362,0.0005852105,0.000006401986,0.000037337468,0.0008969781],"genre_scores_gemma":[0.99695563,0.0013526274,0.00068516855,0.00037639827,0.00017878217,0.0000123871605,0.000017473705,0.000030283425,0.00039121724],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981771,0.0001591547,0.0005738501,0.00046160197,0.00032285185,0.00030542456],"domain_scores_gemma":[0.99907565,0.00028963588,0.00007724372,0.00024152231,0.0000469105,0.00026901055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037465343,0.00016728441,0.0004161303,0.00014532737,0.000026683594,0.00001767875,0.00012193908,0.00014814672,0.00025184776],"category_scores_gemma":[0.00072390144,0.0001555582,0.00007587279,0.00045305467,0.000093092145,0.00011965743,0.000092826594,0.00058076484,0.000029090128],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006987373,0.0005586881,0.6938382,0.000060642466,0.000029329847,0.000100579455,0.0009171981,0.000030439922,0.28854275,0.000010557067,0.000025874378,0.015187001],"study_design_scores_gemma":[0.0062471125,0.0015831625,0.9286353,0.00009639604,0.0000346689,0.0000044588046,0.00029130458,0.000106573294,0.037960067,0.00007460302,0.02476414,0.00020219559],"about_ca_topic_score_codex":0.00007939509,"about_ca_topic_score_gemma":0.00014115204,"teacher_disagreement_score":0.2505827,"about_ca_system_score_codex":0.000052161467,"about_ca_system_score_gemma":0.00006034854,"threshold_uncertainty_score":0.6343479},"labels":[],"label_agreement":null},{"id":"W3006716329","doi":"10.1002/advs.201903164","title":"Nanotechnology Promotes Genetic and Functional Modifications of Therapeutic T Cells Against Cancer","year":2020,"lang":"en","type":"review","venue":"Advanced Science","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"National Key Research and Development Program of China; China Postdoctoral Science Foundation; National Natural Science Foundation of China","keywords":"Chimeric antigen receptor; Cancer therapy; Cell therapy; Immunotherapy; Cancer immunotherapy; T cell; Cancer; Computational biology; Nanotechnology; Cell; Medicine; Immune system; Biology; Immunology; Materials science; Genetics","score_opus":0.084066710822694,"score_gpt":0.38719439308852854,"score_spread":0.30312768226583453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006716329","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00041308868,0.9971523,0.00056877034,0.00026257712,0.00013681817,0.001128668,0.000027875936,0.000043799133,0.00026606902],"genre_scores_gemma":[0.0010876944,0.9962398,0.001589847,0.000070015136,0.000046317266,0.00022139608,0.0000061391897,0.000027771328,0.0007110295],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981821,0.000036921876,0.00035443436,0.0006242184,0.00049059314,0.00031172176],"domain_scores_gemma":[0.99884725,0.00012600758,0.00019221497,0.0004846924,0.0002046542,0.00014517616],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017940156,0.00021055783,0.0007879609,0.0003174302,0.00012452516,0.0000155213,0.00030886903,0.00013073164,0.00015768778],"category_scores_gemma":[0.00009540204,0.00016358179,0.00011450163,0.0015080976,0.0013881658,0.00006909792,0.00012226577,0.00038986182,0.000015376916],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008210572,0.000027261987,0.0000029459902,0.0014405517,0.00002974865,0.000003872304,0.000028014616,0.000013925766,0.13563953,0.00009463408,0.0000041309836,0.8627072],"study_design_scores_gemma":[0.0003333461,0.00022084832,0.000050947907,0.0021978435,0.0002062379,0.000053587668,0.000022580534,0.00041595133,0.009597305,0.00016812321,0.9865081,0.00022515484],"about_ca_topic_score_codex":0.0000058651203,"about_ca_topic_score_gemma":0.0000026230623,"teacher_disagreement_score":0.98650396,"about_ca_system_score_codex":0.00017368756,"about_ca_system_score_gemma":0.0015230027,"threshold_uncertainty_score":0.6670672},"labels":[],"label_agreement":null},{"id":"W3006968198","doi":"10.1158/1078-0432.ccr-19-3136","title":"Design and Conduct of Early Clinical Studies of Immunotherapy: Recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies 2019 (MDICT)","year":2020,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"European Society for Medical Oncology; Merck; AstraZeneca","keywords":"Clinical trial; Drug development; Task force; Medicine; Immunotherapy; Task (project management); Cancer; Test (biology); Intensive care medicine; Drug; Pharmacology; Internal medicine; Political science; Management","score_opus":0.8178733737580474,"score_gpt":0.6530636985540562,"score_spread":0.16480967520399115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3006968198","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90669495,0.02454242,0.005358321,0.059163503,0.00035894095,0.0036219864,0.0002073793,0.0000123835125,0.000040122904],"genre_scores_gemma":[0.86983854,0.0938328,0.028809117,0.0035002893,0.00095007446,0.0015643823,0.000030557923,0.00010426114,0.0013699855],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99338603,0.003509334,0.0016101688,0.00046556772,0.00067768816,0.0003512105],"domain_scores_gemma":[0.9247774,0.07192757,0.00042885428,0.00051296566,0.0022518367,0.00010139926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016748182,0.0001669699,0.0010434503,0.00008741489,0.00019957214,0.000011115896,0.00051894574,0.00017331312,0.00058616156],"category_scores_gemma":[0.0058643343,0.000088981324,0.00018048396,0.00074921024,0.0027003067,0.000041457737,0.00024741393,0.0011195249,0.0000019690358],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03454178,0.00043606973,0.041985832,0.00019396866,0.007338792,0.0000010454504,0.028053636,0.000018385304,0.113695726,0.0004065689,0.021182748,0.75214547],"study_design_scores_gemma":[0.03483527,0.033726834,0.4044024,0.0023761932,0.00051534205,0.0000017071933,0.039146196,0.0007362431,0.2964731,0.00717431,0.17985645,0.0007559456],"about_ca_topic_score_codex":0.00063812616,"about_ca_topic_score_gemma":0.00014062008,"teacher_disagreement_score":0.7513895,"about_ca_system_score_codex":0.00008256897,"about_ca_system_score_gemma":0.0017812472,"threshold_uncertainty_score":0.99493927},"labels":[],"label_agreement":null},{"id":"W3007071335","doi":"10.1182/blood.v130.suppl_1.2553.2553","title":"Pharmacokinetics and Pharmacodynamics of Tocilizumab for the Management of Cytokine Release Syndrome (CRS) in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL) Treated with CAR T-Cell Therapy, CTL019","year":2017,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Pharmacodynamics; Medicine; Cytokine release syndrome; Pharmacokinetics; Tocilizumab; Internal medicine; Pharmacology; Oncology; Cancer; Immunotherapy","score_opus":0.009843819103986807,"score_gpt":0.2545859916300531,"score_spread":0.24474217252606628,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007071335","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957536,0.0010600637,0.000026754804,0.000030666706,0.000037632468,0.002435303,0.00014818471,0.000017163891,0.0004906205],"genre_scores_gemma":[0.98408157,0.014488347,0.00032602795,0.000026600808,0.000029232644,0.000117378375,0.000045974743,0.00007589934,0.0008089539],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982548,0.000046090317,0.00038221604,0.000420425,0.000522587,0.0003738817],"domain_scores_gemma":[0.9984406,0.00014007052,0.0003680044,0.0006136594,0.0002866103,0.00015106078],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017410495,0.00031115933,0.00048628563,0.00018331266,0.00011057488,0.000029539773,0.00026837664,0.00009028647,0.000024375091],"category_scores_gemma":[0.000010373035,0.0002018006,0.000063072315,0.00018396966,0.00024070553,0.000100428944,0.00010701237,0.00023198797,5.644788e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032279376,0.0064599314,0.8618483,0.004569006,0.003385681,0.0008149001,0.0010106313,0.00012984518,0.077212356,0.000016088447,0.00008189066,0.0121920165],"study_design_scores_gemma":[0.31256837,0.013042017,0.61025125,0.000533632,0.008739258,0.00019353523,0.00030422566,0.0048460024,0.048569594,0.00001219678,0.0001824583,0.0007574986],"about_ca_topic_score_codex":0.00024891685,"about_ca_topic_score_gemma":0.000031329862,"teacher_disagreement_score":0.28028896,"about_ca_system_score_codex":0.00011288206,"about_ca_system_score_gemma":0.0001287507,"threshold_uncertainty_score":0.822919},"labels":[],"label_agreement":null},{"id":"W3007405904","doi":"10.1038/s41375-020-0777-1","title":"CD28/4-1BB CD123 CAR T cells in blastic plasmacytoid dendritic cell neoplasm","year":2020,"lang":"en","type":"article","venue":"Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Agence Nationale de la Recherche","keywords":"Interleukin-3 receptor; CD28; Plasmacytoid dendritic cell; Cancer research; Biology; Effector; Immunotherapy; Immunology; T cell; Immune system; Antigen; Dendritic cell","score_opus":0.021698490980137833,"score_gpt":0.26845814996873685,"score_spread":0.24675965898859903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007405904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97404087,0.00021776554,0.000082823484,0.0010027465,0.00025310618,0.00060169364,0.000015137009,0.00013012206,0.023655752],"genre_scores_gemma":[0.984994,0.00014326024,0.0003416449,0.0019374753,0.00047838932,0.00003718387,0.00002617217,0.000091471804,0.011950399],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99755687,0.00009890845,0.00042006932,0.000572512,0.00061336317,0.00073826214],"domain_scores_gemma":[0.9985181,0.00035007158,0.000055930024,0.0004367931,0.00007278906,0.00056633126],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0001722467,0.00028821712,0.0005222853,0.00018721275,0.00005475023,0.0000440852,0.00028191373,0.00021091494,0.0026023057],"category_scores_gemma":[0.00014772992,0.00028645108,0.00015768682,0.00062769436,0.00011639185,0.00007949129,0.00013072917,0.00096784526,0.0021420766],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006432724,0.000104412975,0.011656092,0.0005258308,0.00004434933,0.0018520184,0.001746135,0.0013292822,0.9724804,0.00003626928,0.0077940943,0.0017878091],"study_design_scores_gemma":[0.0144961355,0.0013212453,0.009743106,0.00030133463,0.00014627069,0.00019855225,0.0009059808,0.03018155,0.819465,0.0001135769,0.12227915,0.00084808905],"about_ca_topic_score_codex":0.00021352067,"about_ca_topic_score_gemma":0.00013150414,"teacher_disagreement_score":0.15301543,"about_ca_system_score_codex":0.000890978,"about_ca_system_score_gemma":0.0007680799,"threshold_uncertainty_score":0.99995875},"labels":[],"label_agreement":null},{"id":"W3007507981","doi":"10.1182/bloodadvances.2019001026","title":"Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma","year":2020,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Hospital; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Kite Pharma; MorphoSys; BeiGene; Novartis Pharmaceuticals Corporation; Celgene; Gilead Sciences; Chugai Pharmaceutical; Servier; Amgen; Pfizer; Bristol-Myers Squibb","keywords":"Refractory (planetary science); Diffuse large B-cell lymphoma; Medicine; Lymphoma; Quality of life (healthcare); Term (time); Oncology; Internal medicine; Biology","score_opus":0.03035533187023569,"score_gpt":0.3139951859388295,"score_spread":0.2836398540685938,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007507981","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98729223,0.010032785,0.000018746534,0.00026299927,0.00010245727,0.00059999415,0.00003818817,0.00006450007,0.0015881142],"genre_scores_gemma":[0.997027,0.00085544377,0.00016364748,0.000936464,0.00013270631,0.0000624147,0.00003089541,0.000048514386,0.00074296247],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99730927,0.00018246705,0.000846354,0.0004993895,0.0007061872,0.00045634026],"domain_scores_gemma":[0.99850994,0.00017968174,0.00030037353,0.00050481415,0.0001237574,0.0003814403],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002741308,0.00023363212,0.0006314895,0.00012249565,0.000031095908,0.000013020346,0.00014995069,0.00012570323,0.0011081677],"category_scores_gemma":[0.00043881836,0.00021074654,0.00017742992,0.00041721683,0.00011416155,0.00015402242,0.00011952174,0.00025228408,0.000036724447],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036313215,0.009475846,0.81320673,0.0008378301,0.00013415405,0.00063793,0.0016337953,0.0000013848756,0.14959267,0.000004844291,0.00005720383,0.020786293],"study_design_scores_gemma":[0.043544043,0.0014854237,0.8658167,0.00019521097,0.00011146003,0.000016100857,0.00039532362,0.000022916596,0.08057899,0.00002260192,0.0074219247,0.0003892942],"about_ca_topic_score_codex":0.00004556755,"about_ca_topic_score_gemma":0.000112299895,"teacher_disagreement_score":0.069013685,"about_ca_system_score_codex":0.00004969201,"about_ca_system_score_gemma":0.0002163136,"threshold_uncertainty_score":0.999805},"labels":[],"label_agreement":null},{"id":"W3007691816","doi":"10.3389/fimmu.2020.00276","title":"T-Cell Immunotherapies Targeting Histocompatibility and Tumor Antigens in Hematological Malignancies","year":2020,"lang":"en","type":"review","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Fonds de Recherche du Québec - Santé","keywords":"Minor histocompatibility antigen; Antigen; Immunology; Immunotherapy; Major histocompatibility complex; Biology; Chimeric antigen receptor; Histocompatibility; Cancer immunotherapy; Cancer research; Human leukocyte antigen; Immune system","score_opus":0.034286764600403946,"score_gpt":0.3136169474172623,"score_spread":0.2793301828168584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007691816","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003908373,0.9924587,0.00007354456,0.00014908884,0.0005730179,0.0022144134,0.000016308093,0.0000662043,0.0005403711],"genre_scores_gemma":[0.0003140179,0.99439037,0.0041481457,0.0000785619,0.000058698617,0.0002674825,0.00007084489,0.000082623184,0.00058927253],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99606675,0.000786723,0.0012326,0.0009146723,0.00022841083,0.00077084854],"domain_scores_gemma":[0.9986932,0.00026909504,0.00031354022,0.0005813939,0.0000521716,0.00009054186],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007410858,0.0005744817,0.004172955,0.0007041104,0.00006408168,0.00002485997,0.000399967,0.00059249694,0.0004437864],"category_scores_gemma":[0.00032345767,0.00048376308,0.00035973877,0.0006761821,0.0007955214,0.000054332533,0.0002898213,0.0017980834,0.000025855115],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00087690656,0.00062158477,0.0168043,0.020989679,0.0005913912,0.002269033,0.0016311227,2.8698037e-7,0.0014334151,0.00008082181,0.0049184305,0.949783],"study_design_scores_gemma":[0.0015251394,0.00034857218,0.0006243575,0.0030847706,0.00009189258,0.0003114925,0.000517341,0.00001875772,0.000052606552,0.00015413137,0.99286443,0.00040651285],"about_ca_topic_score_codex":0.00011975198,"about_ca_topic_score_gemma":0.000010025861,"teacher_disagreement_score":0.987946,"about_ca_system_score_codex":0.0007138481,"about_ca_system_score_gemma":0.0005074773,"threshold_uncertainty_score":0.9997614},"labels":[],"label_agreement":null},{"id":"W3009044390","doi":"10.3389/fimmu.2020.00326","title":"Emerging Approaches for Regulation and Control of CAR T Cells: A Mini Review","year":2020,"lang":"en","type":"review","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":101,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Computational biology; Computer science; Biology","score_opus":0.05796822622788738,"score_gpt":0.3303832482385775,"score_spread":0.2724150220106901,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3009044390","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000022455401,0.991285,0.003699768,0.00038724454,0.000422908,0.00395167,0.000040367126,0.000015657894,0.00019509334],"genre_scores_gemma":[0.0000062720455,0.99495035,0.0033890146,0.00006368233,0.0000971618,0.00050482963,0.00014972406,0.00006056294,0.0007784275],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979852,0.00033518524,0.0007999525,0.000434758,0.0001405865,0.00030431518],"domain_scores_gemma":[0.9989024,0.00019976137,0.00036656746,0.00041473052,0.00006383576,0.00005270866],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00056579616,0.00028575794,0.0032806795,0.00035558993,0.0000240105,0.0000044725934,0.00018183474,0.00037694085,0.000083365405],"category_scores_gemma":[0.00025071084,0.00024801432,0.00039192612,0.00034907693,0.00023146323,0.000026997772,0.000059585596,0.00046042952,0.0000021512985],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018386138,0.00003074905,0.000012277362,0.07382394,0.00072088913,0.0000071177938,0.00008721306,1.08472626e-7,0.000115863855,0.00003314428,0.003145484,0.92183936],"study_design_scores_gemma":[0.0014289803,0.00030212448,0.000004724376,0.01996321,0.0011259996,0.000043615397,0.00007250308,0.0001280099,0.000024025481,0.000051295963,0.9766981,0.00015740572],"about_ca_topic_score_codex":0.000008035452,"about_ca_topic_score_gemma":8.627931e-7,"teacher_disagreement_score":0.97355264,"about_ca_system_score_codex":0.00017065067,"about_ca_system_score_gemma":0.00028572706,"threshold_uncertainty_score":0.9999972},"labels":[],"label_agreement":null},{"id":"W3010357077","doi":"10.1016/j.bbmt.2020.03.002","title":"Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy","year":2020,"lang":"en","type":"article","venue":"Biology of Blood and Marrow Transplantation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":274,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Transplantation; Cell therapy; Clinical trial; Intensive care medicine; Observational study; Stem cell; Internal medicine","score_opus":0.035550017240259954,"score_gpt":0.30326553556949226,"score_spread":0.2677155183292323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010357077","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9666127,0.009263562,0.01749857,0.0036354482,0.00003603456,0.0019194168,0.0009786395,0.000033954788,0.000021703585],"genre_scores_gemma":[0.9135675,0.079501785,0.0039061694,0.00079717406,0.00013195044,0.00021409492,0.0018249167,0.000030944022,0.00002550579],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99876285,0.00010653555,0.00041034442,0.00039082702,0.00011985454,0.00020960646],"domain_scores_gemma":[0.9986134,0.00084996555,0.00019683057,0.000121071695,0.00011993643,0.00009876039],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031496308,0.0002169603,0.000415382,0.000049774404,0.00017816706,0.00001993078,0.0000830849,0.00013088885,0.00002110625],"category_scores_gemma":[0.000009155152,0.00016002842,0.0001673473,0.00012720664,0.00032653427,0.00006462123,0.0000034505,0.00012105303,3.573184e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036344298,0.000095080664,0.0052362056,0.0009733322,0.0002165652,0.0000016316853,0.0069770142,0.000001371699,0.9703019,0.000056154364,0.000043553977,0.012462729],"study_design_scores_gemma":[0.01388465,0.0025717309,0.01521284,0.00008214609,0.0009882444,0.000028775066,0.0006301088,0.00028791188,0.96498483,0.0003986571,0.0007009325,0.00022915642],"about_ca_topic_score_codex":0.00014951365,"about_ca_topic_score_gemma":0.00001547556,"teacher_disagreement_score":0.07023822,"about_ca_system_score_codex":0.0000045735783,"about_ca_system_score_gemma":0.000054378404,"threshold_uncertainty_score":0.6525769},"labels":[],"label_agreement":null},{"id":"W3011481633","doi":"10.7554/elife.49900.sa2","title":"Author response: The naive T-cell receptor repertoire has an extremely broad distribution of clone sizes","year":2020,"lang":"en","type":"peer-review","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Repertoire; Biology; clone (Java method); Computational biology; Evolutionary biology; Genetics; Physics; Gene","score_opus":0.1098761402091364,"score_gpt":0.37682350319440466,"score_spread":0.2669473629852683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011481633","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0056112288,0.09276451,0.00019114192,0.88299435,0.0016331362,0.0054868795,0.002800093,0.0003070571,0.0082116015],"genre_scores_gemma":[0.00304634,0.010708259,0.00030609322,0.0030030832,0.0010759968,0.00018774292,0.0073019518,0.00014301173,0.97422755],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99385715,0.0014711741,0.0011037703,0.0010093997,0.0019605963,0.0005979388],"domain_scores_gemma":[0.9949065,0.0009815664,0.00048401143,0.0019789538,0.0011653347,0.00048363183],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0029524607,0.00060062564,0.0016435941,0.00012228981,0.00023411887,0.000072246396,0.000760775,0.00059829955,0.029112268],"category_scores_gemma":[0.0031953019,0.00038255277,0.0006840583,0.00088123046,0.0006176565,0.00008028104,0.00027188097,0.0016743083,0.0002817867],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047951336,0.00027121222,0.000010243155,0.0029399171,0.00018625091,0.000045576246,0.00024671096,1.7481246e-7,0.10697392,0.00001856109,0.8567669,0.027745415],"study_design_scores_gemma":[0.0012072397,0.0017638645,0.00012182222,0.0027489394,0.00044009928,0.000048137972,0.00021289394,0.000055620636,0.016118594,0.000014009652,0.97691023,0.0003585572],"about_ca_topic_score_codex":0.00073718955,"about_ca_topic_score_gemma":0.00006893185,"teacher_disagreement_score":0.96601593,"about_ca_system_score_codex":0.00045515806,"about_ca_system_score_gemma":0.001816416,"threshold_uncertainty_score":0.9998626},"labels":[],"label_agreement":null},{"id":"W3011596849","doi":"10.1080/0284186x.2020.1741680","title":"Potentials, challenges and future of chimeric antigen receptor T-cell therapy in non-Hodgkin lymphomas","year":2020,"lang":"en","type":"review","venue":"Acta Oncologica","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"","keywords":"Medicine; Chimeric antigen receptor; Chemoimmunotherapy; Lymphoma; Immunology; Oncology; Diffuse large B-cell lymphoma; Immunotherapy; Cell therapy; Internal medicine; Cancer research; Rituximab; Immune system; Stem cell; Biology","score_opus":0.07575368936951236,"score_gpt":0.36169467324318155,"score_spread":0.2859409838736692,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011596849","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008625486,0.9811829,2.7040534e-7,0.0015014885,0.0002598503,0.002397081,0.000025735864,0.000045110988,0.01372504],"genre_scores_gemma":[0.00046383208,0.9967561,0.00046139242,0.00014183366,0.0010930588,0.00015783704,0.00009624624,0.000094722716,0.0007349854],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969515,0.0005150853,0.00077378243,0.0007985671,0.00047624382,0.0004847732],"domain_scores_gemma":[0.9982634,0.00035364318,0.00046874722,0.00058747095,0.000082061786,0.00024467555],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00060975086,0.0005675842,0.003387696,0.00032784182,0.00004369824,0.00001732861,0.0004426417,0.0008682218,0.0026561394],"category_scores_gemma":[0.000054753342,0.00038588565,0.0004888575,0.00057633885,0.00017531996,0.00004747419,0.00020666055,0.0007951617,0.00004698071],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027319428,0.00048496693,0.000012953233,0.004931474,0.00024054275,0.00014518891,0.00036615826,6.6769923e-9,0.0024573272,0.000008821547,0.0010056576,0.9900737],"study_design_scores_gemma":[0.0018090936,0.00278938,0.0005239675,0.0016405354,0.0001394815,0.00008053831,0.00017936522,0.000001002223,0.00009945285,0.000014330379,0.99240404,0.00031883537],"about_ca_topic_score_codex":0.000025605781,"about_ca_topic_score_gemma":0.000005457624,"teacher_disagreement_score":0.99139833,"about_ca_system_score_codex":0.00024176783,"about_ca_system_score_gemma":0.00067984057,"threshold_uncertainty_score":0.99985933},"labels":[],"label_agreement":null},{"id":"W3011747051","doi":"10.3389/fimmu.2020.00361","title":"Advances in Developing CAR T-Cell Therapy for HIV Cure","year":2020,"lang":"en","type":"review","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":61,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Canadian Institutes of Health Research","keywords":"Antiretroviral therapy; Human immunodeficiency virus (HIV); Medicine; Cell therapy; Virology; Intensive care medicine; Biology; Cell; Viral load; Genetics","score_opus":0.0393279410448842,"score_gpt":0.3567973900772711,"score_spread":0.31746944903238694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3011747051","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000007019562,0.99105805,0.0019207277,0.0006602045,0.0014848519,0.003121654,0.000026447087,0.00004343835,0.0016775934],"genre_scores_gemma":[9.677321e-7,0.986553,0.0095291305,0.00016311495,0.00021757114,0.0009032226,0.0002545209,0.00012563297,0.0022528116],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99732053,0.00030877703,0.0007816185,0.00069429964,0.00018177647,0.00071298616],"domain_scores_gemma":[0.9989465,0.00022891784,0.00021625482,0.00048018087,0.000065490865,0.00006267406],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00035355342,0.00047653812,0.0029386368,0.0008474664,0.000040296098,0.0000138776895,0.0005117619,0.00072441756,0.00013844889],"category_scores_gemma":[0.00010921086,0.00041468212,0.00041251024,0.00082341244,0.00019188915,0.000075553835,0.000100789664,0.0012628222,0.000028625516],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045331297,0.00006544379,0.00015375338,0.0056063975,0.00018678686,0.000101215104,0.0001956943,2.5112885e-7,0.000027202448,0.00007548061,0.004678705,0.9884558],"study_design_scores_gemma":[0.0029570998,0.0003332222,0.0000060769057,0.0037608675,0.00006173813,0.00004230368,0.0002634153,0.000010310782,0.000038014674,0.00020023194,0.9919848,0.00034193482],"about_ca_topic_score_codex":0.000014922376,"about_ca_topic_score_gemma":0.0000128848715,"teacher_disagreement_score":0.9881138,"about_ca_system_score_codex":0.001256792,"about_ca_system_score_gemma":0.001295128,"threshold_uncertainty_score":0.9998305},"labels":[],"label_agreement":null},{"id":"W3013325302","doi":"10.1101/2020.03.23.004325","title":"Glycoengineering of NK cells with glycan ligands of CD22 and selectins for B-cell lymphoma therapy","year":2020,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Institutes of Health; Danmarks Grundforskningsfond; National Research Foundation","keywords":"CD22; Selectin; Sialyl-Lewis X; Cancer research; Chemistry; Lymphoma; Antigen; Immunology; B cell; Molecular biology; Antibody; Biology; Cell adhesion molecule","score_opus":0.017511600526523896,"score_gpt":0.23798411222752086,"score_spread":0.22047251170099696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3013325302","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940953,0.0020585782,0.0011344032,0.00016048415,0.00023342518,0.001955513,0.00018791194,0.00014916096,0.000025184812],"genre_scores_gemma":[0.99163055,0.001754752,0.00572759,0.00007744215,0.00036190287,0.00018334521,6.9230316e-7,0.0002375181,0.000026227133],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974806,0.00003849017,0.0005862177,0.0008258513,0.0005479098,0.00052093016],"domain_scores_gemma":[0.9973868,0.00015790497,0.00039722654,0.0009286035,0.0007555132,0.00037395125],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00042042547,0.00053987635,0.0011592407,0.00034975566,0.00005553045,0.00004693961,0.00032597216,0.0003913748,0.00005838774],"category_scores_gemma":[0.00007132822,0.000501977,0.00020608098,0.0006424485,0.00018061632,0.000054676006,0.00019748842,0.00045609925,0.0000016856302],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017997373,0.00039133083,0.002783438,0.0034018024,0.00048320723,0.000029260464,0.0000683945,0.000043062144,0.9908215,0.000039399383,0.000110850335,0.000028019922],"study_design_scores_gemma":[0.0061529344,0.0014546788,0.0067971894,0.00061648607,0.00016602197,9.7236914e-8,0.000010111614,0.0011875423,0.9799899,7.8695183e-7,0.0031935037,0.00043074644],"about_ca_topic_score_codex":0.00007059955,"about_ca_topic_score_gemma":0.0000016730647,"teacher_disagreement_score":0.010831596,"about_ca_system_score_codex":0.00016995436,"about_ca_system_score_gemma":0.0010871135,"threshold_uncertainty_score":0.99974316},"labels":[],"label_agreement":null},{"id":"W3013453726","doi":"10.1158/2326-6074.tumimm19-b62","title":"Abstract B62: Development of novel chimeric antigen receptor T cells for immunotherapy of hepatocellular carcinoma","year":2020,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Epitope; Monoclonal antibody; Antigen; Immunotherapy; Effector; Cancer immunotherapy; Immunohistochemistry; Cancer research; Hepatocellular carcinoma; Antibody; Adoptive cell transfer; Molecular biology; T cell; Biology; Immunology; Immune system","score_opus":0.1458943262138125,"score_gpt":0.39103270112138505,"score_spread":0.24513837490757256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3013453726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854594,0.010075123,0.0004015121,0.0012732474,0.00018545955,0.001991083,0.000084449566,0.000028594388,0.0005011682],"genre_scores_gemma":[0.9910414,0.0025434787,0.004318699,0.0000892091,0.0001779204,0.00040552928,0.000058450656,0.00009421136,0.0012710573],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9969256,0.00011757737,0.0007859907,0.00054649456,0.00076775823,0.0008566157],"domain_scores_gemma":[0.99753326,0.0003646761,0.00019700051,0.0006053393,0.0011158535,0.00018383925],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012250745,0.00024026426,0.00081207865,0.000384159,0.00015745814,0.0000115848725,0.00061283685,0.00026645118,0.0045477212],"category_scores_gemma":[0.00014626844,0.00022447358,0.0002265992,0.0009034806,0.0007889404,0.00005992011,0.00018672526,0.000768898,0.00004076722],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052346033,0.00039016665,0.015153579,0.00053982716,0.00070688763,0.0000054517477,0.0029257366,0.0000028320196,0.9293572,0.000023364331,0.00081218744,0.04484819],"study_design_scores_gemma":[0.004583401,0.0010147971,0.028734164,0.00011445402,0.0000118777025,0.0000035908058,0.00057779875,0.00020904906,0.91352195,0.0000059220724,0.051056445,0.00016655351],"about_ca_topic_score_codex":0.00036510525,"about_ca_topic_score_gemma":0.000006418824,"teacher_disagreement_score":0.050244257,"about_ca_system_score_codex":0.0002832588,"about_ca_system_score_gemma":0.0022182893,"threshold_uncertainty_score":0.99636227},"labels":[],"label_agreement":null},{"id":"W3013906244","doi":"10.3389/fonc.2020.00448","title":"CRISPR/Cas9-Mediated Foxp1 Silencing Restores Immune Surveillance in an Immunocompetent A20 Lymphoma Model","year":2020,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children","funders":"Medical Research Council; Wellcome Trust; Bloodwise; Blood Cancer UK; University of Oxford; Cancer Research UK","keywords":"Cancer research; Immune system; Biology; Diffuse large B-cell lymphoma; Lymphoma; Immunology; T cell; Major histocompatibility complex","score_opus":0.03935570422577517,"score_gpt":0.33131085790410014,"score_spread":0.291955153678325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3013906244","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857805,0.0036948486,0.0021544402,0.0041762507,0.0007293368,0.000970533,0.000016781474,0.00011229364,0.0023650315],"genre_scores_gemma":[0.98830587,0.0010612885,0.008167166,0.0014828433,0.00023075496,0.00012682978,0.0001021304,0.00007645175,0.00044667395],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99689656,0.0005178455,0.0007266191,0.00064628455,0.00041742774,0.00079524535],"domain_scores_gemma":[0.99867344,0.00021351947,0.00013318447,0.00053837034,0.00012755439,0.00031395932],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00089664775,0.00027683077,0.0010407587,0.00044617214,0.000057781264,0.000019323452,0.0004398349,0.00036421441,0.00026316463],"category_scores_gemma":[0.0004997427,0.00028232488,0.00012592056,0.00076023454,0.00024293583,0.00013847592,0.00017620552,0.0006412693,0.000028820361],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011251929,0.0012301768,0.4647765,0.00019781172,0.00016433875,0.0020998353,0.011220989,0.0043564257,0.3651635,0.000055363715,0.01242593,0.12705721],"study_design_scores_gemma":[0.0244829,0.0050786645,0.31989172,0.00016181469,0.000036575548,0.00010795411,0.0058771875,0.6000415,0.0075067584,0.00044074684,0.035519533,0.00085467665],"about_ca_topic_score_codex":0.00059430604,"about_ca_topic_score_gemma":0.0005207775,"teacher_disagreement_score":0.59568506,"about_ca_system_score_codex":0.0016665092,"about_ca_system_score_gemma":0.00091387745,"threshold_uncertainty_score":0.99996287},"labels":[],"label_agreement":null},{"id":"W3014563464","doi":"10.1038/s41375-020-0808-y","title":"H3K79me2/3 controls enhancer–promoter interactions and activation of the pan-cancer stem cell marker PROM1/CD133 in MLL-AF4 leukemia cells","year":2020,"lang":"en","type":"article","venue":"Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Medical Research Council; Canadian Institutes of Health Research; Blood Cancer UK; University of Oxford; Research Councils UK; Bloodwise; Wellcome Trust; Lady Tata Memorial Trust; Ministerio de Economía y Competitividad; Cancer Research UK; Leukaemia UK; Medical Research Foundation; National Institute for Health and Care Research; European Hematology Association","keywords":"Leukemia; Biology; Stem cell; Cancer research; Enhancer; Cancer stem cell; Cancer; Genetics; Gene; Transcription factor","score_opus":0.025357778417561753,"score_gpt":0.2960044509883657,"score_spread":0.27064667257080394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3014563464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896283,0.00022048669,0.00009377702,0.0030269441,0.0001731474,0.0014402849,0.000019450441,0.000033659,0.0053639426],"genre_scores_gemma":[0.98637414,0.00021012215,0.000074596384,0.00094380684,0.00023905224,0.00015911534,0.000006232814,0.000046335255,0.011946572],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998166,0.00016790113,0.00045250758,0.00043052263,0.00043601493,0.00034700127],"domain_scores_gemma":[0.9989114,0.00021817366,0.00018650424,0.00041063942,0.00012749436,0.00014583049],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00024023927,0.00022216522,0.00044369663,0.0000995341,0.00005998305,0.00003384801,0.00019469067,0.00014745962,0.0016819804],"category_scores_gemma":[0.000044345106,0.00016456362,0.00012913247,0.0004623024,0.00016064178,0.00017842505,0.00013002635,0.00076528545,0.000029273355],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010940795,0.000053366275,0.005785529,0.0003031099,0.00006706557,0.000008786765,0.0018202567,0.00006413992,0.9616154,0.0000086709315,0.0015677189,0.027611895],"study_design_scores_gemma":[0.004037275,0.00023292495,0.0408819,0.00037066356,0.000062590865,0.0000064785504,0.00040128356,0.0049372306,0.9259803,0.00003328861,0.022865007,0.00019103262],"about_ca_topic_score_codex":0.00056966447,"about_ca_topic_score_gemma":0.00011422735,"teacher_disagreement_score":0.035635054,"about_ca_system_score_codex":0.0012422428,"about_ca_system_score_gemma":0.00069332006,"threshold_uncertainty_score":0.9992306},"labels":[],"label_agreement":null},{"id":"W3016228284","doi":"10.1016/j.omto.2020.03.018","title":"Viral Delivery of CAR Targets to Solid Tumors Enables Effective Cell Therapy","year":2020,"lang":"en","type":"article","venue":"Molecular Therapy — Oncolytics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":77,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ottawa Hospital; University of Ottawa","funders":"National Cancer Institute; National Institutes of Health; Ben and Catherine Ivy Foundation; Canary Foundation","keywords":"Chimeric antigen receptor; Oncolytic virus; Antigen; CD19; Cancer research; Cell therapy; Melanoma; Cell; Biology; Immunotherapy; Immunology; Virology; Immune system; Tumor cells","score_opus":0.01980434138450807,"score_gpt":0.3008079975698722,"score_spread":0.2810036561853641,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016228284","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860823,0.0039858744,0.0018205215,0.0015996651,0.00012947092,0.003014921,0.000025167892,0.000109054105,0.0032329853],"genre_scores_gemma":[0.98752135,0.0014007189,0.0015384736,0.00799724,0.00028144132,0.00013289828,0.000028594259,0.00016702192,0.0009322627],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9969811,0.00026367823,0.00052266486,0.00061169284,0.00095243496,0.00066844374],"domain_scores_gemma":[0.9980392,0.00015861185,0.00015019909,0.00064727827,0.00041004622,0.0005946768],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036100525,0.0004338715,0.0009174495,0.00020928573,0.000081476814,0.00003829995,0.0004041214,0.00019938135,0.0007392948],"category_scores_gemma":[0.000076739205,0.00038681977,0.00043010525,0.0006606625,0.000153401,0.000065358334,0.000111982605,0.00048422813,0.00010379675],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041493718,0.00048565128,0.0005502473,0.000104212835,0.00034772186,0.0004529893,0.0027217928,0.00038541705,0.9508326,0.000031953936,0.0008945983,0.039043415],"study_design_scores_gemma":[0.005622331,0.0070774774,0.0005843782,0.000066463064,0.000037906393,0.000014845976,0.0002531346,0.0007585036,0.94095886,0.000078272795,0.04419796,0.0003498769],"about_ca_topic_score_codex":0.00009629735,"about_ca_topic_score_gemma":0.0000026571404,"teacher_disagreement_score":0.043303367,"about_ca_system_score_codex":0.00023632444,"about_ca_system_score_gemma":0.000401255,"threshold_uncertainty_score":0.9998584},"labels":[],"label_agreement":null},{"id":"W3016525618","doi":"10.1016/j.ymthe.2020.04.013","title":"Check and Checkmate: Battling Cancer with Multiplex Immunotherapy","year":2020,"lang":"en","type":"letter","venue":"Molecular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Oncolytic virus; Cancer; Cancer immunotherapy; Immunotherapy; Tumor microenvironment; Cancer immunology; Medicine; Immune system; Immune checkpoint; Cancer research; Immunology; Internal medicine","score_opus":0.03190717010889309,"score_gpt":0.30537625195003276,"score_spread":0.27346908184113966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016525618","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09497844,0.034690056,0.0005896268,0.8642935,0.0002552717,0.0031138612,0.00006855889,0.00036734805,0.0016433545],"genre_scores_gemma":[0.0053384644,0.021059634,0.0013286261,0.9565264,0.0025544988,0.0005332955,0.00038059521,0.0007360688,0.011542444],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964758,0.00018359309,0.00040103655,0.0010303936,0.00109394,0.0008152232],"domain_scores_gemma":[0.99839085,0.00008180575,0.00017996097,0.0009258761,0.00020744318,0.00021403967],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001641585,0.0007726467,0.0010933363,0.00024099676,0.00012781899,0.00014874991,0.00034633902,0.0006904492,0.0037205217],"category_scores_gemma":[0.000015699348,0.00060139684,0.00029191835,0.00040346765,0.00031306138,0.00005736436,0.00006279924,0.0027280329,0.000051112223],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028876245,0.0000836946,0.0005670359,0.00039352936,0.0023856258,0.005594362,0.0007922213,0.0000070260357,0.8076742,0.0000029389225,0.1045477,0.075063996],"study_design_scores_gemma":[0.006658936,0.000840468,0.00027734326,0.00030655225,0.00008005225,0.00018669105,0.00002682008,0.00015582782,0.090376385,0.00003466684,0.9003987,0.00065758044],"about_ca_topic_score_codex":0.00035108527,"about_ca_topic_score_gemma":0.000006435309,"teacher_disagreement_score":0.795851,"about_ca_system_score_codex":0.0002144639,"about_ca_system_score_gemma":0.00041301662,"threshold_uncertainty_score":0.99964374},"labels":[],"label_agreement":null},{"id":"W3016572530","doi":"10.7554/elife.53244","title":"Landscape mapping of shared antigenic epitopes and their cognate TCRs of tumor-infiltrating T lymphocytes in melanoma","year":2020,"lang":"en","type":"article","venue":"eLife","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Japan Society for the Promotion of Science; Princess Margaret Cancer Foundation; Natural Sciences and Engineering Research Council of Canada; Mitacs; Terry Fox Research Institute; Ontario Institute for Cancer Research","keywords":"Epitope; Human leukocyte antigen; Antigen; Biology; Allele; Immunotherapy; Tumor-infiltrating lymphocytes; Immunology; Cancer immunotherapy; T-cell receptor; Melanoma; T cell; Immune system; Gene; Cancer research; Genetics","score_opus":0.036163672755717906,"score_gpt":0.2761645601904363,"score_spread":0.24000088743471837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016572530","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940964,0.0032738186,0.000015913563,0.00046216152,0.00001936892,0.00025429376,0.0000197828,0.000019663676,0.0018385933],"genre_scores_gemma":[0.99882746,0.0003797828,0.00034182615,0.0002666729,0.00008174787,0.0000058319047,0.000010441362,0.000017918193,0.00006830406],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989974,0.000055509765,0.0003400379,0.00018986918,0.00022617509,0.00019104431],"domain_scores_gemma":[0.99940234,0.0001723382,0.00009731655,0.0001401643,0.00008229321,0.00010555235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027915047,0.00010791185,0.0004086043,0.00011510927,0.000018749543,0.000010385787,0.00009122725,0.000040943447,0.00052596006],"category_scores_gemma":[0.00025953646,0.00008754782,0.000060419192,0.00032122247,0.00006533561,0.000046257657,0.00006792883,0.00012248289,0.0000042808238],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002481982,0.00002949669,0.27382183,0.0003028904,0.00006259485,0.000027725799,0.0036816578,0.0000071807162,0.7142394,0.000010047128,0.00009942742,0.0074695586],"study_design_scores_gemma":[0.0047562956,0.00056389015,0.21506764,0.00070330047,0.000017279672,0.000045545,0.004111355,0.0085876435,0.7642228,0.000017480077,0.0017219977,0.00018477025],"about_ca_topic_score_codex":0.000090045054,"about_ca_topic_score_gemma":0.000012603145,"teacher_disagreement_score":0.05875418,"about_ca_system_score_codex":0.000017606462,"about_ca_system_score_gemma":0.00012549067,"threshold_uncertainty_score":0.5758894},"labels":[],"label_agreement":null},{"id":"W3016844795","doi":"10.3747/co.27.5283","title":"Chimeric Antigen Receptor T Cell Therapy Comes to Clinical Practice","year":2020,"lang":"en","type":"review","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Hospital for Sick Children","keywords":"Chimeric antigen receptor; Medicine; Immunotherapy; Cell therapy; Cancer; Leukemia; T cell; Cancer immunotherapy; Immunology; Cancer research; Immune system; Cell; Internal medicine; Biology","score_opus":0.46528233005644404,"score_gpt":0.6140640395132099,"score_spread":0.14878170945676583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016844795","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000026744807,0.9777053,0.000031075382,0.0028869726,0.0057083066,0.0039747274,0.00004433823,0.000118558404,0.009504003],"genre_scores_gemma":[6.2569853e-7,0.9894444,0.0013907376,0.001211779,0.0048054117,0.0003296602,0.00030952352,0.00015415785,0.0023537418],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9939622,0.0021230404,0.0014892364,0.0010954706,0.00063231075,0.0006977366],"domain_scores_gemma":[0.99425787,0.0029788846,0.0006491784,0.0008798691,0.0003238468,0.00091033714],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0015886965,0.00060972385,0.0043234117,0.00031846715,0.000077807155,0.000034919234,0.0006447271,0.00071502785,0.006589124],"category_scores_gemma":[0.0015310732,0.00046467563,0.0011688091,0.0009937468,0.00021080414,0.00005466749,0.00033049364,0.0028535463,0.0060543558],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039848825,0.0015643104,0.00010333147,0.0029401097,0.00043002216,0.00011894514,0.000129776,1.2399118e-8,0.000010322962,0.000007057772,0.09394855,0.9003491],"study_design_scores_gemma":[0.0016229048,0.0037224998,0.00002522847,0.0015953821,0.0005406863,0.00016384048,0.000038797032,0.0000013696747,0.0000045625266,0.0000018757967,0.99190223,0.00038063567],"about_ca_topic_score_codex":0.0000072779467,"about_ca_topic_score_gemma":0.000001061013,"teacher_disagreement_score":0.89996845,"about_ca_system_score_codex":0.0006263209,"about_ca_system_score_gemma":0.0032744878,"threshold_uncertainty_score":0.9997805},"labels":[],"label_agreement":null},{"id":"W3016877653","doi":"10.1016/j.omto.2020.04.001","title":"A Cross-Reactive Small Protein Binding Domain Provides a Model to Study Off-Tumor CAR-T Cell Toxicity","year":2020,"lang":"en","type":"article","venue":"Molecular Therapy — Oncolytics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Canadian Cancer Society","keywords":"CD28; Chimeric antigen receptor; T cell; Peripheral blood mononuclear cell; Toxicity; CD8; Cytokine release syndrome; Cytotoxic T cell; Adoptive cell transfer; Cancer research; Cytokine; T-cell receptor; Cell; Immunology; Medicine; Antigen; Pharmacology; Biology; Chemistry; Immune system; Internal medicine; In vitro; Biochemistry","score_opus":0.05817557353079079,"score_gpt":0.3426282375479575,"score_spread":0.28445266401716673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016877653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97796845,0.00024080147,0.007609008,0.0019031947,0.00003942782,0.010032872,0.00003705424,0.00020169943,0.0019674674],"genre_scores_gemma":[0.9823852,0.000015100386,0.009498784,0.004194668,0.00017887195,0.0007832469,0.000013968285,0.00021710867,0.002713016],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9960355,0.00029170472,0.0006046731,0.0010198143,0.0011720653,0.0008762525],"domain_scores_gemma":[0.9976362,0.00008085075,0.00017544081,0.00087615,0.0003791032,0.0008522675],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000742039,0.00054667966,0.00082125154,0.0002269417,0.0002050522,0.0002049459,0.0005371628,0.00017186083,0.00030095573],"category_scores_gemma":[0.00019414129,0.0005022017,0.00033506614,0.00093461573,0.0001222303,0.00009499006,0.00025609322,0.0008009642,0.00010533246],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004717802,0.002042622,0.0015547947,0.00009854156,0.0003276173,0.0012466877,0.008657261,0.0007806892,0.96950847,0.000026357382,0.000038038346,0.011001111],"study_design_scores_gemma":[0.010084533,0.008518444,0.00024933935,0.000075652046,0.00007594236,0.0000264383,0.0016154464,0.010644409,0.96345854,0.00016803118,0.0044720853,0.0006111227],"about_ca_topic_score_codex":0.00008051017,"about_ca_topic_score_gemma":0.000021751252,"teacher_disagreement_score":0.010389988,"about_ca_system_score_codex":0.0006437951,"about_ca_system_score_gemma":0.0008031083,"threshold_uncertainty_score":0.999743},"labels":[],"label_agreement":null},{"id":"W3017464623","doi":"10.1158/2326-6066.cir-18-0508","title":"Genetic Ablation of HLA Class I, Class II, and the T-cell Receptor Enables Allogeneic T Cells to Be Used for Adoptive T-cell Therapy","year":2020,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":176,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"Ontario Institute for Cancer Research","keywords":"Chimeric antigen receptor; T cell; Immunology; Immunotherapy; Adoptive cell transfer; Cytotoxic T cell; Cell therapy; Biology; T-cell receptor; Cancer research; Medicine; Immune system; Stem cell; Cell biology; In vitro","score_opus":0.09584839896265963,"score_gpt":0.3678044325559333,"score_spread":0.2719560335932737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3017464623","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95104223,0.015346204,0.00012242385,0.028000731,0.0001555111,0.004252702,0.00007756654,0.00003123181,0.00097142544],"genre_scores_gemma":[0.96788186,0.017131474,0.0006715828,0.00181845,0.00036883497,0.0013481365,0.000033939636,0.00010046077,0.01064526],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9966038,0.0007276632,0.00045441557,0.00066434767,0.00068954116,0.0008602686],"domain_scores_gemma":[0.9968395,0.0012310079,0.000114804876,0.0006190791,0.0009519979,0.00024359445],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00149508,0.00025137543,0.00064266764,0.0002839685,0.0003395435,0.000036678794,0.000527778,0.00029991995,0.0014326725],"category_scores_gemma":[0.00018380639,0.00018370825,0.0001659349,0.0008293947,0.0013091605,0.000053234868,0.0003337372,0.000825887,0.0000249346],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013200722,0.0001595916,0.0007613784,0.00015272162,0.00028602176,0.000003883579,0.0061543714,0.000084865365,0.96149856,0.00007467424,0.010323919,0.0072992966],"study_design_scores_gemma":[0.010336668,0.0032234113,0.00058330974,0.000029642879,0.000031846193,0.0000026898722,0.0014701004,0.00046807065,0.75932664,0.00006398096,0.22431125,0.00015240254],"about_ca_topic_score_codex":0.000334216,"about_ca_topic_score_gemma":0.00004419301,"teacher_disagreement_score":0.21398732,"about_ca_system_score_codex":0.0002621786,"about_ca_system_score_gemma":0.00079278136,"threshold_uncertainty_score":0.9994801},"labels":[],"label_agreement":null},{"id":"W3019060111","doi":"10.1038/s41591-020-0827-2","title":"Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma","year":2020,"lang":"en","type":"article","venue":"Nature Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":241,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health Research Institute; University of Calgary; McGill University Health Centre; BC Children's Hospital; University of Toronto; SickKids Foundation; University of British Columbia; Hospital for Sick Children","funders":"Programme Development Grants; Canadian Institutes of Health Research; National Cancer Institute; Stand Up To Cancer; National Institutes of Health","keywords":"Medulloblastoma; Ependymoma; Chimeric antigen receptor; Medicine; Cerebrospinal fluid; Cancer research; Pathology; Oncology; Immunotherapy; Internal medicine; Cancer","score_opus":0.03507500143968219,"score_gpt":0.32943180603661787,"score_spread":0.2943568045969357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3019060111","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9516321,0.007012719,0.00036490685,0.038299672,0.00017726421,0.0021154573,0.000093895316,0.000016945121,0.00028705274],"genre_scores_gemma":[0.9947485,0.00034114684,0.001257029,0.002211041,0.000578247,0.000063005056,0.000038977996,0.000029997977,0.0007320693],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984139,0.000053674878,0.00034538194,0.0002941274,0.0006566702,0.00023624382],"domain_scores_gemma":[0.99859697,0.0004057936,0.00009615002,0.0002813318,0.00032333963,0.00029643587],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002371192,0.00019349232,0.00067221385,0.000118432334,0.000040346164,0.0000026317332,0.00013814757,0.00010502159,0.00053508545],"category_scores_gemma":[0.00019758898,0.00010578676,0.00012588546,0.00034073833,0.00026569338,0.000019390896,0.000036003625,0.00017518559,0.0000036371966],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006426115,0.00020971886,0.00043019943,0.0005819341,0.00054418243,0.00008893738,0.003272941,0.000014020701,0.94405776,0.00033986097,0.01483987,0.029194465],"study_design_scores_gemma":[0.015259721,0.034301937,0.005162205,0.00042504974,0.0010327619,0.00029532713,0.0017056908,0.0014023304,0.743534,0.000099453246,0.19656217,0.0002193369],"about_ca_topic_score_codex":0.0000726786,"about_ca_topic_score_gemma":0.000026519567,"teacher_disagreement_score":0.20052373,"about_ca_system_score_codex":0.00006415215,"about_ca_system_score_gemma":0.0001468257,"threshold_uncertainty_score":0.58588105},"labels":[],"label_agreement":null},{"id":"W3019602056","doi":"10.1634/theoncologist.2020-0194","title":"Successful Treatment of Cytokine Release Syndrome with IL-6 Blockade in a Patient Transitioning from Immune-Checkpoint to MEK/BRAF Inhibition: A Case Report and Review of Literature","year":2020,"lang":"en","type":"review","venue":"The Oncologist","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Cytokine release syndrome; Blockade; Tocilizumab; Melanoma; Immunotherapy; Oncology; Immune checkpoint; Immune system; Adverse effect; Cytokine; Chimeric antigen receptor; Internal medicine; Immunology; Cancer research; Receptor; Disease","score_opus":0.038032293583396076,"score_gpt":0.3468623536365209,"score_spread":0.30883006005312486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3019602056","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.027280284,0.9650594,0.000005347837,0.002067148,0.000030681887,0.0046364367,0.00057760085,0.000023558216,0.00031953547],"genre_scores_gemma":[0.005751826,0.9921499,0.00039670934,0.0001298399,0.00007807497,0.0006369423,0.000652124,0.00005678966,0.00014780692],"study_design_codex":"case_report","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965302,0.0005324503,0.0015905921,0.0005972472,0.00048165367,0.000267907],"domain_scores_gemma":[0.99753714,0.0003976029,0.0007796274,0.0008679379,0.00020795218,0.00020976081],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00056784204,0.00047792337,0.0033853638,0.00020921727,0.000055221073,0.000021169693,0.00011673437,0.00023085972,0.00033644077],"category_scores_gemma":[0.00021928301,0.00026560389,0.00045426344,0.0011448724,0.00027254192,0.000039620874,0.00008259982,0.00056019623,0.0000036339256],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00091167126,0.0007598585,0.000010631326,0.057538573,0.00063106715,0.5150143,0.0017674464,0.0000014484013,0.00023397514,0.0000046747023,0.000044627403,0.42308173],"study_design_scores_gemma":[0.0022117244,0.009243421,0.000020903508,0.2988981,0.0025863925,0.29506516,0.00026064445,0.0000033116098,0.00043647396,0.000010620711,0.39092973,0.00033350912],"about_ca_topic_score_codex":0.0012633586,"about_ca_topic_score_gemma":0.00022990645,"teacher_disagreement_score":0.4227482,"about_ca_system_score_codex":0.0006892948,"about_ca_system_score_gemma":0.0007782516,"threshold_uncertainty_score":0.9999796},"labels":[],"label_agreement":null},{"id":"W3025149699","doi":"10.1101/2020.05.15.098335","title":"Selective B cell depletion upon intravenous infusion of replication-incompetent anti-CD19 CAR lentivirus","year":2020,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; University of British Columbia; Canada's Michael Smith Genome Sciences Centre","funders":"","keywords":"CD19; Population; B cell; Transgene; Lentivirus; Immune system; Cell; Genetic enhancement; T cell","score_opus":0.021856212706054253,"score_gpt":0.25883849812451076,"score_spread":0.2369822854184565,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3025149699","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99421644,0.0007353276,0.00096957805,0.000516162,0.0005059214,0.0024832066,0.000147448,0.00034353658,0.00008237031],"genre_scores_gemma":[0.99549437,0.0012851096,0.002006362,0.00016820616,0.0005847315,0.0002254195,0.0000043903797,0.00020818818,0.000023251867],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9955103,0.00029131107,0.0009201533,0.0016427335,0.0010158595,0.0006196751],"domain_scores_gemma":[0.99488807,0.00011565057,0.0007257872,0.0024338465,0.0014008922,0.00043574377],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008823286,0.00061058893,0.0011612873,0.0005086432,0.00013710927,0.000078921585,0.00052408996,0.0006760285,0.0002690978],"category_scores_gemma":[0.00040244823,0.0006620089,0.00035354352,0.0009871937,0.00014535808,0.00008946654,0.0006282991,0.0015647543,0.00010125396],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036651277,0.00052107923,0.012814097,0.0015977949,0.00026926116,0.000065911256,0.0000608386,0.00006178265,0.9839472,0.000086120286,0.00019294154,0.000016414726],"study_design_scores_gemma":[0.0012236323,0.00041556795,0.15243122,0.00055895594,0.00022530262,8.524587e-8,0.000005823559,0.000948494,0.8406823,0.0000027968624,0.0030326445,0.00047312904],"about_ca_topic_score_codex":0.00038055526,"about_ca_topic_score_gemma":0.0000056845306,"teacher_disagreement_score":0.14326489,"about_ca_system_score_codex":0.0008391564,"about_ca_system_score_gemma":0.0015364221,"threshold_uncertainty_score":0.9995831},"labels":[],"label_agreement":null},{"id":"W3026980848","doi":"10.1038/s41375-020-0874-1","title":"Cytokine IL-36γ improves CAR T-cell functionality and induces endogenous antitumor response","year":2020,"lang":"en","type":"article","venue":"Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; Terry Fox Foundation; U.S. Department of Health and Human Services","keywords":"Chimeric antigen receptor; Immune system; Immunology; Cytokine; Antigen; T cell; Autocrine signalling; Cancer research; Immunotherapy; Biology; Interleukin 2; Endogeny; Medicine; Receptor; Internal medicine; Endocrinology","score_opus":0.05250146682893192,"score_gpt":0.2856146705085528,"score_spread":0.2331132036796209,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3026980848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911798,0.0005789732,0.000019022124,0.0025630514,0.00009324732,0.0004327701,0.000059104346,0.000102473,0.004971538],"genre_scores_gemma":[0.99220544,0.00013678096,0.00017539764,0.0019239306,0.0005041667,0.000021096634,0.000028343251,0.00003737134,0.0049674506],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984406,0.00014264291,0.00023131524,0.00042512102,0.00042576776,0.0003345315],"domain_scores_gemma":[0.99895114,0.00022291842,0.00005543142,0.0003077754,0.000103426086,0.00035928626],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004226304,0.00017969827,0.00031812824,0.00007715243,0.00010343936,0.000039865277,0.000110910296,0.00011305366,0.0008507071],"category_scores_gemma":[0.0002878867,0.00015780452,0.000084763305,0.00027290924,0.00016158418,0.000076762735,0.00010645114,0.00044511966,0.00010134345],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050350293,0.000043006312,0.0020222776,0.00013807909,0.000052837568,0.00029232752,0.0006120582,0.000002280599,0.98595995,0.000019720917,0.0012346421,0.0045877732],"study_design_scores_gemma":[0.0049201883,0.001751361,0.04626303,0.000030938852,0.00008576619,0.00032433853,0.00042871753,0.00024431857,0.81395525,0.000057560464,0.13165163,0.00028691444],"about_ca_topic_score_codex":0.00022906189,"about_ca_topic_score_gemma":0.0000050118724,"teacher_disagreement_score":0.17200473,"about_ca_system_score_codex":0.0003224315,"about_ca_system_score_gemma":0.00068617787,"threshold_uncertainty_score":0.9314646},"labels":[],"label_agreement":null},{"id":"W3027155039","doi":"10.3390/cancers12051321","title":"Insights into the Molecular Mechanisms Behind Intralesional Immunotherapies for Advanced Melanoma","year":2020,"lang":"en","type":"review","venue":"Cancers","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Melanoma; Medicine; Immune system; Metastatic melanoma; Cancer; Disease; Immunotherapy; Skin cancer; Adverse effect; Immune surveillance; Metastasis; Immunology; Cancer research; Dermatology; Internal medicine","score_opus":0.03532092597537828,"score_gpt":0.3543734595694293,"score_spread":0.319052533594051,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3027155039","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000033295408,0.9938675,0.0011850728,0.00055452605,0.0004361121,0.0033201894,0.000027347765,0.00005377963,0.0005221716],"genre_scores_gemma":[0.00003835358,0.99332017,0.0014196233,0.00069306005,0.00038305993,0.00155388,0.00018241738,0.00016638346,0.0022430746],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99795675,0.00013208942,0.0004588731,0.00056417496,0.00051242136,0.00037567495],"domain_scores_gemma":[0.9985693,0.0002934923,0.00019709991,0.0006269258,0.00012734214,0.00018584362],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00015567004,0.0004602556,0.0014486258,0.00014226131,0.0001546761,0.00004215252,0.0005095067,0.00027496024,0.0007838465],"category_scores_gemma":[0.00008492695,0.00028800455,0.00080628705,0.00022938014,0.00018849016,0.00004499109,0.0000927967,0.00064988487,0.00004405907],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022559728,0.000009709089,1.9622094e-8,0.0042085242,0.00085305056,0.00005795002,0.00091365067,0.0000042598194,0.0032342896,0.0020566992,0.00045911246,0.98797715],"study_design_scores_gemma":[0.0009152215,0.00049462664,1.7406047e-7,0.003519769,0.0004975403,0.000024907686,0.00012867777,0.000029073573,0.0011474962,0.0013571177,0.9915986,0.0002868138],"about_ca_topic_score_codex":0.000054741544,"about_ca_topic_score_gemma":0.00003174085,"teacher_disagreement_score":0.9911395,"about_ca_system_score_codex":0.0021099828,"about_ca_system_score_gemma":0.003096081,"threshold_uncertainty_score":0.9999572},"labels":[],"label_agreement":null},{"id":"W3027248509","doi":"10.1016/j.jcyt.2020.03.252","title":"Strategies for successful monitoring of CAR T-cells by flow cytometry","year":2020,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Caprion (Canada)","funders":"","keywords":"Chimeric antigen receptor; Flow cytometry; Context (archaeology); Cell therapy; Medicine; Cytometry; Cell; T cell; Immunology; Computational biology; Chemistry; Biology; Immune system","score_opus":0.043059149088054804,"score_gpt":0.3402613225430027,"score_spread":0.29720217345494787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3027248509","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98406434,0.002106474,0.009431651,0.001351082,0.00021115752,0.0009926808,0.00009937027,0.00010731301,0.0016359293],"genre_scores_gemma":[0.99187595,0.00091937097,0.003992459,0.000466897,0.00082732533,0.00006986702,0.000023277995,0.00009669813,0.0017281434],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986824,0.000034134075,0.0002729583,0.000300366,0.00037977408,0.00033039297],"domain_scores_gemma":[0.99913454,0.00014398007,0.000070159076,0.00028422443,0.00016111477,0.00020595903],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00016600404,0.00017554236,0.0004274382,0.0000974311,0.000046683293,0.000039885756,0.00020200525,0.00011397058,0.0011295333],"category_scores_gemma":[0.000021780132,0.00015840415,0.00017877258,0.0003843128,0.00009564274,0.00010256036,0.000017763117,0.00018857916,0.000015655165],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010221178,0.000085676715,0.0066229543,0.0002400337,0.000160018,0.000006757306,0.00094217353,0.000027525588,0.9737491,0.000031179556,0.0048585446,0.012253945],"study_design_scores_gemma":[0.0033321201,0.001146899,0.00033076352,0.000047928435,0.000024294848,0.0000031146965,0.001569203,0.0007213916,0.9387884,0.00007197125,0.05380772,0.00015618015],"about_ca_topic_score_codex":0.000028834398,"about_ca_topic_score_gemma":6.921748e-7,"teacher_disagreement_score":0.048949175,"about_ca_system_score_codex":0.000058249647,"about_ca_system_score_gemma":0.00017004853,"threshold_uncertainty_score":0.9997836},"labels":[],"label_agreement":null},{"id":"W3027422757","doi":"10.1016/j.jcyt.2020.03.218","title":"Non-toxic cross-reactivity with healthy tissues supports in vivo expansion and therapeutic efficacy of T cells engineered with synthetic antigen receptors","year":2020,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Chimeric antigen receptor; Antigen; In vivo; Antibody; Monoclonal antibody; CD28; In vitro; T cell; Cancer research; Molecular biology; Chemistry; Immunology; Biology; Immune system; Biochemistry; CD8","score_opus":0.021188320311956707,"score_gpt":0.30961075462553417,"score_spread":0.28842243431357745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3027422757","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99651533,0.0007053401,0.0002186221,0.00092607486,0.000041741292,0.0012778096,0.0000080805685,0.000061573344,0.00024543583],"genre_scores_gemma":[0.99739796,0.0012227673,0.00040702723,0.0003867615,0.00008189336,0.000029224195,0.0000046982445,0.000102095306,0.00036759168],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99814236,0.00008563793,0.00032047508,0.0005269995,0.00048443608,0.0004400992],"domain_scores_gemma":[0.9989243,0.00015754435,0.00011431946,0.00042169294,0.00008739632,0.0002947268],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00025196475,0.00029685965,0.0006707784,0.00018317602,0.000050531693,0.000028948652,0.000119876844,0.00012916782,0.0012949621],"category_scores_gemma":[0.000012322689,0.00021438552,0.000060729948,0.0005288131,0.00028367375,0.00008311519,0.000018622952,0.00032870786,0.000006772998],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0095607955,0.0003939636,0.08560428,0.0002075739,0.00011269066,0.00006554159,0.0040292647,0.000072454386,0.8851474,0.0000028402542,0.000036135312,0.014767039],"study_design_scores_gemma":[0.007936832,0.005609794,0.092464395,0.00027826556,0.000024364055,0.000050544826,0.00022260149,0.00043313063,0.88882804,0.0000048492593,0.003863728,0.000283468],"about_ca_topic_score_codex":0.00012410167,"about_ca_topic_score_gemma":0.000037929876,"teacher_disagreement_score":0.014483571,"about_ca_system_score_codex":0.0000759664,"about_ca_system_score_gemma":0.00022925438,"threshold_uncertainty_score":0.999618},"labels":[],"label_agreement":null},{"id":"W3027950647","doi":"10.1016/j.jcyt.2020.03.179","title":"Effect of cryopreservation of mesenchymal stromal cells after non-viral transfection on cell viability and transgene expression","year":2020,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"","keywords":"Transfection; Cryopreservation; Mesenchymal stem cell; Transgene; Stromal cell; Viability assay; Cell biology; Biology; Molecular biology; Cell; Cell culture; Embryo; Cancer research; Gene; Genetics","score_opus":0.012644679609469084,"score_gpt":0.282261100820444,"score_spread":0.2696164212109749,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3027950647","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99673647,0.00011295965,0.0011916821,0.00025328272,0.00004914619,0.0011248385,0.000023714534,0.00002365889,0.0004842727],"genre_scores_gemma":[0.9992658,0.00009566415,0.00018497978,0.00008590373,0.00011723909,0.000046395704,0.000008657157,0.000034589848,0.00016076014],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984943,0.0002480792,0.0003101806,0.00033074254,0.00042446822,0.00019219013],"domain_scores_gemma":[0.99927646,0.00018973804,0.000060474194,0.0002642364,0.000067140514,0.00014192495],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00040747286,0.00018366425,0.0004514819,0.00008485328,0.000026026924,0.0000071931645,0.00007580047,0.00013905087,0.001124064],"category_scores_gemma":[0.000014572266,0.00014438726,0.00017291169,0.00018232445,0.00012242621,0.00008487589,0.000008864189,0.00021852886,0.0000031266513],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01938316,0.00020520168,0.009819552,0.00081659964,0.000032307486,0.000004492855,0.0012531265,0.0000367349,0.9598173,0.0000010954396,0.000039769588,0.008590666],"study_design_scores_gemma":[0.005176415,0.011323016,0.01868247,0.00007479971,0.00003286067,0.0000012288377,0.00001925791,0.00085924816,0.9634507,0.000007693825,0.0002779285,0.000094422256],"about_ca_topic_score_codex":0.00003687243,"about_ca_topic_score_gemma":0.0000017195258,"teacher_disagreement_score":0.014206746,"about_ca_system_score_codex":0.000031575022,"about_ca_system_score_gemma":0.00003818642,"threshold_uncertainty_score":0.99978906},"labels":[],"label_agreement":null},{"id":"W3028020071","doi":"10.1016/j.jval.2020.04.1540","title":"PCN34 COMPATIBILITY OF CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY STUDIES IN THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (LBCL) FOR INDIRECT TREATMENT COMPARISON (ITC) ANALYSES","year":2020,"lang":"en","type":"article","venue":"Value in Health","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Medicine; Internal medicine; Oncology; Clinical trial; Population; Refractory (planetary science); Chimeric antigen receptor; Transplantation; Salvage therapy; Immunotherapy; Cancer; Chemotherapy","score_opus":0.2432661122207745,"score_gpt":0.42804879365365917,"score_spread":0.18478268143288468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3028020071","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9800627,0.014764527,0.00000987024,0.00038320117,0.00006729622,0.00443757,0.00018102513,0.000019078929,0.00007468201],"genre_scores_gemma":[0.9876263,0.011159838,0.00055713655,0.00016427926,0.000054180036,0.0001880816,0.00016649415,0.000039326784,0.00004437272],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99650973,0.00092066446,0.000997255,0.00049832015,0.0005822601,0.0004917725],"domain_scores_gemma":[0.99763674,0.0009705777,0.000516531,0.0005458286,0.00017755004,0.00015275695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070274074,0.00032675933,0.0014934795,0.00023693831,0.00008241411,0.000006291663,0.00017074002,0.00007939842,0.00005375703],"category_scores_gemma":[0.000051811865,0.00019036572,0.00021438455,0.0008240286,0.00016321495,0.000042766595,0.000017461633,0.00011556319,0.0000024804451],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007781943,0.030905413,0.8911341,0.0008000834,0.0003920842,0.0000037453988,0.046298664,0.00027894715,0.003487664,0.000002000524,0.00015584861,0.018759543],"study_design_scores_gemma":[0.090655014,0.09656534,0.7102589,0.0003888607,0.0001455846,8.2255883e-7,0.011890094,0.0029438792,0.07339211,0.00001579842,0.013345217,0.00039837207],"about_ca_topic_score_codex":0.0046072565,"about_ca_topic_score_gemma":0.00029666146,"teacher_disagreement_score":0.18087515,"about_ca_system_score_codex":0.0010004111,"about_ca_system_score_gemma":0.0005571575,"threshold_uncertainty_score":0.77628887},"labels":[],"label_agreement":null},{"id":"W3029082024","doi":"10.1200/jco.2020.38.15_suppl.tps3160","title":"A phase Ib, open-label, dose-escalation trial of naptumomab estafenatox (Nap) in combination with durvalumab (MEDI4736) in subjects with selected advanced or metastatic solid tumors.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Durvalumab; Nap; Medicine; Immunotherapy; Antigen; Cancer research; Immune system; Immune checkpoint; Oncology; Immunology; Nivolumab; Biology","score_opus":0.1893348622942087,"score_gpt":0.5145610612842015,"score_spread":0.32522619898999283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029082024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98982805,0.000060400936,0.00023956488,0.0069533745,0.00016467298,0.002236377,0.000003598073,0.000010843273,0.0005031246],"genre_scores_gemma":[0.9935327,0.00016735033,0.005210674,0.0006685255,0.00020322873,0.00004019411,0.000014849388,0.00004255354,0.000119928445],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9932985,0.0016066012,0.003344827,0.00035915303,0.0010045258,0.00038639418],"domain_scores_gemma":[0.99260515,0.0033208816,0.0023331156,0.00021598623,0.0010601493,0.00046473937],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.004826554,0.00022786295,0.0027923512,0.00042011766,0.00002772642,0.000020851057,0.0003572533,0.00021997964,0.00030347446],"category_scores_gemma":[0.009433542,0.00014571637,0.00010264098,0.0017376282,0.00028655078,0.0003773423,0.00007573746,0.0017219994,0.0000034525938],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.85961825,0.024309333,0.0032033292,0.0001295099,0.00034700864,0.0035796387,0.00064329564,0.0001153243,0.009007793,0.000035807218,0.00011312937,0.09889761],"study_design_scores_gemma":[0.6677011,0.31093934,0.013050223,0.00046517866,0.00022139982,0.00040836827,0.00036643067,0.0041934033,0.001745012,0.00009784615,0.00065490714,0.00015676953],"about_ca_topic_score_codex":0.000055503162,"about_ca_topic_score_gemma":0.0007007968,"teacher_disagreement_score":0.28663,"about_ca_system_score_codex":0.00036046383,"about_ca_system_score_gemma":0.006954522,"threshold_uncertainty_score":0.9989104},"labels":[],"label_agreement":null},{"id":"W3029558061","doi":"10.1200/jco.2020.38.15_suppl.10518","title":"Tisagenlecleucel (Tisa) for relapsed/refractory (r/r) acute lymphoblastic leukemia (ALL): B2001X study focusing on prior exposure to blinatumomab (BLINA) and inotuzumab (INO).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Novartis","keywords":"Medicine; Refractory (planetary science); Internal medicine; Blinatumomab; Gastroenterology; Surgery; Lymphoblastic Leukemia; Leukemia","score_opus":0.15579777345609733,"score_gpt":0.46880294045502197,"score_spread":0.31300516699892467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029558061","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9783966,0.00033804434,0.0003978439,0.017372381,0.0011009413,0.0015701276,0.000011029138,0.000027786502,0.0007852502],"genre_scores_gemma":[0.9841716,0.0004887554,0.0031722726,0.008081801,0.0029047793,0.000026888718,0.0000028278223,0.000083510175,0.0010675625],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9945806,0.0006896993,0.0025545727,0.00061039464,0.00096430385,0.00060037675],"domain_scores_gemma":[0.99075735,0.0054556006,0.0011483969,0.00039020833,0.0007419924,0.001506437],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0039019035,0.00032911386,0.0022412564,0.00033545445,0.00012058791,0.000049018872,0.0003987695,0.0005889217,0.00035051754],"category_scores_gemma":[0.009441805,0.0002594747,0.00055394875,0.0003633506,0.00019695667,0.00016713238,0.00021318099,0.0019817797,0.00006322905],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11625657,0.0056313397,0.013346832,0.00016107768,0.0025175544,0.006096353,0.0022873853,0.00009601681,0.041833412,0.00003872011,0.01760921,0.7941255],"study_design_scores_gemma":[0.09369003,0.47975874,0.17828462,0.00033948672,0.0022825275,0.0014397735,0.0013169762,0.00069087883,0.001982982,0.00022603721,0.23940133,0.0005866345],"about_ca_topic_score_codex":0.000008322726,"about_ca_topic_score_gemma":0.00002182142,"teacher_disagreement_score":0.79353887,"about_ca_system_score_codex":0.001015665,"about_ca_system_score_gemma":0.0035383604,"threshold_uncertainty_score":0.99998575},"labels":[],"label_agreement":null},{"id":"W3029703953","doi":"10.1200/jco.2020.38.15_suppl.tps11569","title":"SPEARHEAD-1: A phase II trial of ADP-A2M4 SPEAR T cells in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Fludarabine; Context (archaeology); Internal medicine; Synovial sarcoma; Myxoid liposarcoma; Phases of clinical research; Sarcoma; Oncology; Clinical trial; Liposarcoma; Surgery; Cyclophosphamide; Chemotherapy; Pathology; Adverse effect","score_opus":0.12720236253995762,"score_gpt":0.47421580929525387,"score_spread":0.3470134467552962,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029703953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99218637,0.0001116735,0.000047923197,0.0033030766,0.00089962856,0.0012064194,0.000017014221,0.000010441427,0.0022174777],"genre_scores_gemma":[0.9915895,0.00032223391,0.0038161671,0.0015173256,0.0019288078,0.0000049120663,0.000006628811,0.000053998727,0.00076042174],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9934144,0.0008982844,0.0035972106,0.0003864199,0.0011978903,0.0005058048],"domain_scores_gemma":[0.9936919,0.0023740658,0.0020145644,0.00035025607,0.0006720387,0.00089716713],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0027378418,0.00026726953,0.0027157748,0.00025905817,0.0000417801,0.0000114669965,0.00042103944,0.0004316322,0.0020392684],"category_scores_gemma":[0.0022379453,0.00017640303,0.0005625216,0.0005537236,0.00041506966,0.00017521842,0.00016303897,0.0021432247,0.000028907094],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8042608,0.034616243,0.007399278,0.00010528402,0.0002848734,0.0014545892,0.00049136387,0.00002058243,0.009376648,0.0000047760636,0.0013835214,0.14060202],"study_design_scores_gemma":[0.46892688,0.45647657,0.006137608,0.00013161269,0.00022156796,0.0000337887,0.00018536784,0.000100033976,0.0020825646,0.000020327116,0.06550667,0.00017701065],"about_ca_topic_score_codex":0.000018470788,"about_ca_topic_score_gemma":0.000035641046,"teacher_disagreement_score":0.42186034,"about_ca_system_score_codex":0.00023410787,"about_ca_system_score_gemma":0.003155931,"threshold_uncertainty_score":0.998873},"labels":[],"label_agreement":null},{"id":"W3030062209","doi":"10.1200/jco.2020.38.15_suppl.tps11571","title":"Safety and activity of autologous T cells with enhanced NY-ESO-1–specific T-cell receptor (GSK3377794) in HLA-a*02<sup>+</sup> previously-treated and -untreated patients with advanced metastatic/unresectable synovial sarcoma: A master protocol study design (IGNYTE-ESO).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Princess Margaret Cancer Centre; Mount Sinai Hospital","funders":"GlaxoSmithKline","keywords":"Medicine; Synovial sarcoma; Soft tissue sarcoma; Internal medicine; Oncology; Progressive disease; Chemotherapy; Sarcoma; Immunology; Cancer research; Pathology","score_opus":0.08339887970369389,"score_gpt":0.39242614807332304,"score_spread":0.3090272683696291,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030062209","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95975643,0.00008483075,0.0008717848,0.0004497153,0.00004580243,0.038470324,0.000013212334,0.000021346923,0.00028652308],"genre_scores_gemma":[0.9906381,0.00019504552,0.0070662824,0.00016489779,0.00012096343,0.0014130421,0.0000043801456,0.00007602917,0.00032126738],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99234205,0.0028729434,0.0025182024,0.0007151258,0.0009193915,0.00063227897],"domain_scores_gemma":[0.99234545,0.0037883967,0.0018668589,0.0003714006,0.00087260175,0.0007553153],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0027219055,0.00045964474,0.003214125,0.00027758186,0.00007235141,0.00002948308,0.00025846958,0.0003214022,0.00050078734],"category_scores_gemma":[0.0009899494,0.0002941654,0.00016438137,0.0006737859,0.0005603577,0.00028521343,0.00014391742,0.0016733935,0.000005284221],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.60398674,0.024954967,0.175756,0.000664409,0.0015705595,0.0015670701,0.0031453294,0.0010246239,0.06148893,8.7384564e-7,0.00043304448,0.12540746],"study_design_scores_gemma":[0.27501658,0.52199084,0.13164486,0.00083781057,0.0011994999,0.00014638485,0.0014690615,0.0019836214,0.060287874,0.000016032516,0.004616956,0.0007904535],"about_ca_topic_score_codex":0.000038359227,"about_ca_topic_score_gemma":0.00004221103,"teacher_disagreement_score":0.4970359,"about_ca_system_score_codex":0.0002820245,"about_ca_system_score_gemma":0.0012708062,"threshold_uncertainty_score":0.99995106},"labels":[],"label_agreement":null},{"id":"W3030083314","doi":"10.1200/jco.2020.38.15_suppl.102","title":"Phase I dose escalation and expansion trial to assess the safety and efficacy of ADP-A2M4 SPEAR T cells in advanced solid tumors.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Fludarabine; Neutropenia; Leukopenia; Cyclophosphamide; Internal medicine; Febrile neutropenia; Regimen; Gastroenterology; Chemotherapy; Oncology; Surgery","score_opus":0.20372602864825018,"score_gpt":0.5361714243604768,"score_spread":0.33244539571222664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030083314","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98566437,0.00014251222,0.00018656386,0.012621177,0.0003085747,0.00068626105,0.0000025172856,0.0000033101182,0.00038472013],"genre_scores_gemma":[0.99563974,0.0009943388,0.001009994,0.0013233664,0.0009469901,0.0000018346295,0.0000010863442,0.0000129233385,0.00006972722],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9964732,0.00074911217,0.002025925,0.00018888235,0.0003880369,0.0001748545],"domain_scores_gemma":[0.99399686,0.0044653597,0.000752274,0.00014028187,0.0002067867,0.00043842103],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0042590825,0.00010074209,0.0012673907,0.00009396355,0.000025655114,0.0000081572225,0.0001174427,0.00018112533,0.0001962891],"category_scores_gemma":[0.0057002106,0.0000630215,0.00016902237,0.00021105666,0.00018375517,0.00007630578,0.00008667918,0.0009380001,0.0000031071177],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.40672505,0.0018558393,0.0013170891,0.000029955443,0.000064766646,0.00019839968,0.0005970068,0.000088384084,0.1031509,0.000011648291,0.00021237442,0.4857486],"study_design_scores_gemma":[0.61413634,0.15417492,0.15807092,0.00034196314,0.00025904505,0.00016028229,0.0007653257,0.0026229534,0.0114066405,0.00011970389,0.057739865,0.0002020134],"about_ca_topic_score_codex":0.000005905329,"about_ca_topic_score_gemma":0.000009490154,"teacher_disagreement_score":0.4855466,"about_ca_system_score_codex":0.00005873518,"about_ca_system_score_gemma":0.0006161389,"threshold_uncertainty_score":0.68240964},"labels":[],"label_agreement":null},{"id":"W3030734898","doi":"10.1200/jco.2020.38.15_suppl.3035","title":"Efficacy of SCRI-CAR19x22 T cell product in B-ALL and persistence of anti-CD22 activity.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital","funders":"","keywords":"CD19; CD22; Medicine; Flow cytometry; T cell; CD8; Immunology; Internal medicine; Molecular biology; Antigen; Biology; Immune system","score_opus":0.3304972255175948,"score_gpt":0.501662195559655,"score_spread":0.17116497004206016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3030734898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9812784,0.00074630446,0.000008275132,0.015172552,0.0001888192,0.00026294225,0.0000017056202,0.0000027613214,0.002338219],"genre_scores_gemma":[0.99631166,0.0016449698,0.0007110716,0.00067435787,0.00045764048,4.6831795e-7,3.7528235e-7,0.000013197565,0.00018627741],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99695885,0.00055090454,0.001600427,0.0002222302,0.00046067205,0.00020690891],"domain_scores_gemma":[0.9957022,0.0022714878,0.001115739,0.00018964255,0.00036601268,0.00035491947],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0030812374,0.00010512632,0.0016707708,0.00014360689,0.00000964826,0.000003135408,0.00019944542,0.00019745207,0.00029113347],"category_scores_gemma":[0.005305931,0.00008004633,0.00036118977,0.0002677697,0.00042765986,0.00007681251,0.000099684796,0.001222838,0.0000030869933],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023280444,0.0052604303,0.17826526,0.00054228253,0.00037976244,0.0006273374,0.0012634804,0.00004475888,0.53884023,0.00001336546,0.0012278861,0.25025478],"study_design_scores_gemma":[0.032564897,0.04387926,0.7898581,0.0003195035,0.00047559495,0.00032778992,0.0005842566,0.0005136559,0.060266707,0.000043533568,0.070974045,0.00019267412],"about_ca_topic_score_codex":0.000020859701,"about_ca_topic_score_gemma":0.00000701891,"teacher_disagreement_score":0.6115928,"about_ca_system_score_codex":0.000056978548,"about_ca_system_score_gemma":0.0011464428,"threshold_uncertainty_score":0.6352078},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"not_applicable","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"medium"}],"label_agreement":"split"},{"id":"W3031522008","doi":"10.1089/jpm.2020.0138","title":"Chimeric Antigen Receptor T Cell Immunotherapy: What You Need to Know #393","year":2020,"lang":"en","type":"article","venue":"Journal of Palliative Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Microsemi (Canada)","funders":"National Institute on Aging","keywords":"Chimeric antigen receptor; Immunotherapy; Medicine; Antigen; Associate editor; Oncology; Immunology; Library science; Immune system; Computer science","score_opus":0.04554858171906813,"score_gpt":0.3492327811530041,"score_spread":0.303684199433936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031522008","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.71745384,0.03217082,0.0031826652,0.24028075,0.0015360531,0.0012527609,0.0000075484118,0.000054094773,0.0040614493],"genre_scores_gemma":[0.8032903,0.1036409,0.01054618,0.046316195,0.015141342,0.000027268978,0.000042520383,0.00034142623,0.020653851],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967894,0.00019599505,0.0009235477,0.00029618578,0.0013367115,0.00045818824],"domain_scores_gemma":[0.9972073,0.00024667347,0.000512494,0.00030072598,0.00079939264,0.00093343225],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000891903,0.00031748728,0.001113239,0.00038473666,0.00007479961,0.000041267514,0.00038765612,0.0001063791,0.014067837],"category_scores_gemma":[0.0005581383,0.0002157013,0.00027040916,0.0011533363,0.00018832575,0.00023807611,0.00006027646,0.0008910797,0.00024081212],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030471608,0.00018935445,0.011540916,0.000095915086,0.0003777676,0.00017273155,0.012250045,0.000013806667,0.8901759,0.0000072341763,0.045563217,0.036566],"study_design_scores_gemma":[0.013736634,0.01404103,0.02651156,0.0016933813,0.0001713188,0.000054074157,0.012664307,0.00013224299,0.10377326,0.000035454348,0.82681865,0.00036812428],"about_ca_topic_score_codex":0.000024735102,"about_ca_topic_score_gemma":0.00000161793,"teacher_disagreement_score":0.7864026,"about_ca_system_score_codex":0.0002517611,"about_ca_system_score_gemma":0.0002922643,"threshold_uncertainty_score":0.98683345},"labels":[],"label_agreement":null},{"id":"W3031718783","doi":"10.1200/jco.2020.38.15_suppl.e22504","title":"Bianca: Phase II, single-arm, global trial to determine efficacy and safety of tisagenlecleucel in pediatric/young adult (YA) patients (Pts) with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Novartis","keywords":"Medicine; Internal medicine; Lymphoma; Refractory (planetary science); Cytokine release syndrome; Gastroenterology; Surgery; Oncology; Immunotherapy; Chimeric antigen receptor; Cancer","score_opus":0.08639205978262311,"score_gpt":0.4210383654333999,"score_spread":0.3346463056507768,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3031718783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99290967,0.00018568475,0.0001017166,0.0025034077,0.0007840768,0.0011334773,0.000022761942,0.000010857948,0.0023483746],"genre_scores_gemma":[0.9928822,0.0008064975,0.0023092146,0.0018164415,0.0019834922,0.0000070686065,0.000006599027,0.000041106454,0.00014736906],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99402994,0.0006359745,0.0034032408,0.00047223608,0.00096924166,0.00048936426],"domain_scores_gemma":[0.99373394,0.0021835028,0.001763411,0.0002908093,0.0008268673,0.0012014955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002056707,0.00029391676,0.0022221492,0.0002214523,0.0000542341,0.0000137858815,0.00032789534,0.0005261393,0.00027834493],"category_scores_gemma":[0.006015982,0.00022477319,0.00036365833,0.000680062,0.00024124225,0.00014812271,0.00020306121,0.000996351,0.000012386857],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5277516,0.02936918,0.061385464,0.00009452214,0.00016070728,0.0010757361,0.00041130942,0.000009546706,0.002415176,0.0000014552506,0.001959107,0.37536615],"study_design_scores_gemma":[0.5231495,0.36049554,0.10511056,0.00013659774,0.00039962959,0.00011307995,0.00007451819,0.00015608013,0.00036535627,0.000007668807,0.009764104,0.00022739176],"about_ca_topic_score_codex":0.00003871928,"about_ca_topic_score_gemma":0.00010540504,"teacher_disagreement_score":0.37513876,"about_ca_system_score_codex":0.0004751563,"about_ca_system_score_gemma":0.0019139309,"threshold_uncertainty_score":0.91659844},"labels":[],"label_agreement":null},{"id":"W3032561883","doi":"10.1200/jco.2020.38.15_suppl.tps8074","title":"A phase II study of MT-3724, a novel CD20-targeting engineered toxin body, to evaluate safety, pharmacodynamics, and efficacy in subjects with relapsed or refractory diffuse large B-cell lymphoma.","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston General Hospital","funders":"","keywords":"Medicine; CD20; Lymphoma; Adverse effect; Ofatumumab; Oncology; Internal medicine; Pharmacodynamics; Rituximab; Pharmacology; Cancer research; Pharmacokinetics","score_opus":0.10107067104318164,"score_gpt":0.4645030107838141,"score_spread":0.3634323397406325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3032561883","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99383503,0.00024983974,0.00032875055,0.0037582298,0.00026367736,0.0012698291,0.000015180093,0.0000169098,0.0002625784],"genre_scores_gemma":[0.99504447,0.0005579889,0.0018298662,0.0016013806,0.0005656579,0.00000992431,0.0000048571396,0.00006155174,0.00032432776],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99394166,0.0011654021,0.0030154225,0.0004482708,0.00091342995,0.000515799],"domain_scores_gemma":[0.99258924,0.004346902,0.0012169569,0.00026577557,0.0005484545,0.0010326973],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008467413,0.00028400906,0.0023021966,0.00034800897,0.00005971148,0.000011230825,0.000314239,0.0003125316,0.000304233],"category_scores_gemma":[0.008390957,0.00019615529,0.0002371174,0.00063626224,0.00012258139,0.00011585045,0.00025055945,0.0015618135,0.00000440034],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3230998,0.2802429,0.005187941,0.00021071512,0.0010749517,0.0041569113,0.006723295,0.00015753224,0.29971588,0.0000046003656,0.0007720419,0.07865344],"study_design_scores_gemma":[0.62554646,0.32296568,0.0123664355,0.00025658173,0.0007015555,0.0002164142,0.0019387692,0.014251723,0.0014331208,0.0000030881133,0.020007508,0.00031269452],"about_ca_topic_score_codex":0.000032585056,"about_ca_topic_score_gemma":0.00011293941,"teacher_disagreement_score":0.30244663,"about_ca_system_score_codex":0.00033414207,"about_ca_system_score_gemma":0.0020992823,"threshold_uncertainty_score":0.9999618},"labels":[],"label_agreement":null},{"id":"W3033356285","doi":"10.1016/s1470-2045(20)30275-8","title":"Developing anti-CD19 antibody-based combinations in lymphoma","year":2020,"lang":"en","type":"letter","venue":"The Lancet Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Blinatumomab; Antibody-drug conjugate; Medicine; Lymphoma; Refractory (planetary science); Antibody; CD19; Cancer research; Internal medicine; Oncology; Immunology; Monoclonal antibody; Biology","score_opus":0.11330106448099528,"score_gpt":0.40981677696904834,"score_spread":0.2965157124880531,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033356285","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013636792,0.00016788387,0.00018559526,0.9726844,0.00049458834,0.00093155797,0.000032306085,0.000121031866,0.011745889],"genre_scores_gemma":[0.0125614265,0.00037256145,0.0009904272,0.9767824,0.004932344,0.00012310206,0.0009626621,0.000095198164,0.0031798931],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971949,0.00070999586,0.000417534,0.00045437974,0.00046896032,0.000754257],"domain_scores_gemma":[0.9979109,0.0010336837,0.00016404415,0.00069466204,0.00013338341,0.000063298714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006564673,0.0002914146,0.0013088761,0.00030211077,0.000104681596,0.000029129622,0.0006225569,0.00068779907,0.0008688622],"category_scores_gemma":[0.0002386491,0.00021925615,0.00014882289,0.0006524679,0.00031987566,0.000025146219,0.00015122724,0.0021465952,0.0002968087],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035616488,0.0001722533,0.0024405168,0.0005532551,0.00017711041,0.0055142315,0.00031630346,0.000005945725,0.007180984,0.00046083247,0.9751101,0.007712282],"study_design_scores_gemma":[0.0069701835,0.000385109,0.0054678395,0.00018984058,0.000059475795,0.0001504383,0.000027916585,0.00035163245,0.0005052798,0.0006278304,0.98503864,0.00022582298],"about_ca_topic_score_codex":0.00013863515,"about_ca_topic_score_gemma":0.00005891745,"teacher_disagreement_score":0.0099285105,"about_ca_system_score_codex":0.0010713523,"about_ca_system_score_gemma":0.0022550288,"threshold_uncertainty_score":0.9513432},"labels":[],"label_agreement":null},{"id":"W3035321276","doi":"10.1101/2020.06.15.149021","title":"Recombinant T cell receptors specific for HLA-A*02:01-restricted neoepitopes containing KRAS codon 12 hotspot mutations","year":2020,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Burnaby Hospital; Simon Fraser University; BC Cancer Agency; Centre Hospitalier de l’Université de Montréal; University of British Columbia; Pancreas Centre (Canada); Canada's Michael Smith Genome Sciences Centre","funders":"BC Cancer Foundation; National Institutes of Health; University of Melbourne; Cancer Research Institute; American Association for Cancer Research","keywords":"T-cell receptor; KRAS; CD8; Biology; T cell; Molecular biology; CD3; Cancer research; Cytotoxic T cell; Antigen; Genetics; Gene; Mutation; Immune system","score_opus":0.04324980804223668,"score_gpt":0.2753075742134235,"score_spread":0.2320577661711868,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3035321276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97169054,0.0030866908,0.0036988817,0.0035854331,0.0068393303,0.008703986,0.000653139,0.001441732,0.0003002828],"genre_scores_gemma":[0.9817531,0.002348656,0.0112921335,0.00044135586,0.0019836214,0.0012109813,0.00002298354,0.0005733583,0.0003737736],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99408317,0.00033758776,0.0012839762,0.0019947311,0.001009974,0.0012905606],"domain_scores_gemma":[0.9945695,0.00065592525,0.00072701345,0.0018603434,0.0011799886,0.0010072314],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00092799054,0.0010259487,0.0016140244,0.00077003037,0.0003969829,0.00038035098,0.0008264122,0.00097068876,0.0011562711],"category_scores_gemma":[0.0008405933,0.0011028578,0.00061042985,0.0011785432,0.00027398695,0.00016508912,0.0005201864,0.0021148173,0.00020595705],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014137632,0.00049996655,0.00350419,0.0011118783,0.0005509291,0.00023889441,0.00010460153,0.00004230244,0.98328006,0.00033107412,0.008848035,0.000074275005],"study_design_scores_gemma":[0.0066833654,0.0016009522,0.034462083,0.0011801766,0.00067589706,2.1517407e-7,0.000080113066,0.0008700159,0.6403286,0.000017179076,0.3123073,0.0017940997],"about_ca_topic_score_codex":0.00015504395,"about_ca_topic_score_gemma":0.0000067102646,"teacher_disagreement_score":0.34295148,"about_ca_system_score_codex":0.001070914,"about_ca_system_score_gemma":0.0019372975,"threshold_uncertainty_score":0.9997568},"labels":[],"label_agreement":null},{"id":"W3035762342","doi":"10.1172/jci.insight.136012","title":"A rational mouse model to detect on-target, off-tumor CAR T cell toxicity","year":2020,"lang":"en","type":"article","venue":"JCI Insight","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; National Institutes of Health; National Cancer Institute; Breast Cancer Society of Canada; University of Pennsylvania","keywords":"Toxicity; In vivo; Potency; Cancer research; Antigen; Downregulation and upregulation; Cell; Chimeric antigen receptor; Biology; Immunology; Chemistry; Pharmacology; In vitro; T cell; Medicine; Immune system; Internal medicine; Biochemistry; Gene","score_opus":0.05259355392620244,"score_gpt":0.29972067114915346,"score_spread":0.24712711722295103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3035762342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94163585,0.00016088145,0.0032603473,0.0059575588,0.000078460645,0.0010536406,0.000061511346,0.00015212294,0.047639634],"genre_scores_gemma":[0.9573932,0.000022031205,0.0039016483,0.017206667,0.0005524005,0.00007403774,0.000026944821,0.000064796484,0.020758253],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982529,0.00005432054,0.0002426481,0.0004224416,0.0006839942,0.00034365495],"domain_scores_gemma":[0.99883,0.000080921614,0.000037181657,0.00036372835,0.00014183907,0.0005462928],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00012081242,0.00019091538,0.00030941542,0.00011960483,0.00008099079,0.00003075474,0.00017162548,0.00007814091,0.0023166714],"category_scores_gemma":[0.00016437883,0.00016511157,0.00014011872,0.00030545477,0.000036569796,0.00006413323,0.000086562206,0.00038537712,0.000634942],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001169129,0.00015993888,0.00010163347,0.000054536402,0.00003484119,0.00008584141,0.001495143,0.0031358586,0.97469276,0.0000897292,0.017673953,0.0013066455],"study_design_scores_gemma":[0.0015449087,0.0010820361,0.000077120574,0.000013824671,0.00001580639,0.000005848438,0.00003778448,0.0465705,0.85923344,0.00007766067,0.09114897,0.0001921026],"about_ca_topic_score_codex":0.000014598451,"about_ca_topic_score_gemma":0.000012408032,"teacher_disagreement_score":0.115459315,"about_ca_system_score_codex":0.00017170321,"about_ca_system_score_gemma":0.0003145246,"threshold_uncertainty_score":0.99859536},"labels":[],"label_agreement":null},{"id":"W3035910414","doi":"10.1073/pnas.1911154117","title":"A conformation-specific ON-switch for controlling CAR T cells with an orally available drug","year":2020,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bundesministerium für Digitalisierung und Wirtschaftsstandort; Universität für Bodenkultur Wien; Austrian Science Fund; École Polytechnique Fédérale de Lausanne; Florida State University; University of Alberta; Österreichische Nationalstiftung für Forschung, Technologie und Entwicklung; Christian Doppler Forschungsgesellschaft; Cancer Research Institute","keywords":"Small molecule; Molecular switch; Lipocalin; Chemistry; Drug discovery; In vitro; Drug; Function (biology); Plasma protein binding; Biophysics; Molecule; Cell biology; Biochemistry; Biology; Pharmacology","score_opus":0.08111563383848584,"score_gpt":0.3256952133817829,"score_spread":0.24457957954329707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3035910414","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9681423,0.000120851815,0.000012434642,0.015376685,0.000014808868,0.001200519,0.000031771273,0.000025394836,0.015075254],"genre_scores_gemma":[0.99450684,0.000051282805,0.002863034,0.00146598,0.00015885924,0.000027991355,5.967071e-7,0.000008216442,0.0009171838],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99783915,0.0000045718184,0.00028834335,0.00023636129,0.001447359,0.00018424042],"domain_scores_gemma":[0.99869084,0.00017729153,0.00032409537,0.000010806951,0.0006983242,0.00009864768],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011744893,0.000096373085,0.00022296654,0.00011812529,0.00017325551,0.000032175285,0.00046564845,0.000049173126,0.00018393071],"category_scores_gemma":[0.000198314,0.000057618505,0.0000688352,0.0005884545,0.00044796758,0.00038914327,0.00003416126,0.00019205798,0.000006973758],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011049289,0.0000637336,0.00085093506,0.00016650092,0.00003470517,1.37225475e-8,0.000991385,0.0002953272,0.9783066,0.01095979,0.0066302954,0.00059577223],"study_design_scores_gemma":[0.0022763857,0.0010332201,0.00088461896,0.00015513283,0.000021702403,0.0000061427727,0.0009611097,0.019731035,0.96097356,0.0019886645,0.011849267,0.00011918727],"about_ca_topic_score_codex":0.0000037618718,"about_ca_topic_score_gemma":6.153863e-8,"teacher_disagreement_score":0.026364576,"about_ca_system_score_codex":0.00004014378,"about_ca_system_score_gemma":0.000107341286,"threshold_uncertainty_score":0.23496144},"labels":[],"label_agreement":null},{"id":"W3037220537","doi":"10.1101/2020.06.27.175158","title":"Repeated stimulation or tonic-signaling chimeric antigen receptors drive regulatory T cell exhaustion","year":2020,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"Canadian Institutes of Health Research; BC Children's Hospital","keywords":"Chimeric antigen receptor; Stimulation; Immunology; Autoimmunity; Cell therapy; Regulatory T cell; Biology; Receptor; T-cell receptor; Immune system; T cell; Immunotherapy; Cell biology; Neuroscience; Stem cell; IL-2 receptor","score_opus":0.030598613288052367,"score_gpt":0.2725001237228235,"score_spread":0.24190151043477115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037220537","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921376,0.0010074481,0.001211508,0.0004091369,0.0013793296,0.0026763766,0.000070571405,0.0010307713,0.000077225326],"genre_scores_gemma":[0.9903654,0.00081366935,0.0062797153,0.0002935279,0.0014059154,0.00018457386,0.000009131954,0.0003869546,0.00026109908],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99445844,0.0003592223,0.0010896993,0.0019040959,0.0012823915,0.0009061445],"domain_scores_gemma":[0.99534994,0.00014470263,0.00072535366,0.001983689,0.0010247652,0.00077152863],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010351407,0.0008923144,0.0012324594,0.0006434612,0.00025849213,0.00021213808,0.0005333372,0.0010374468,0.0026537413],"category_scores_gemma":[0.00044927758,0.00089223555,0.0003904811,0.0014694644,0.00020340692,0.0001961181,0.00053822045,0.0019485316,0.00025496754],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010784611,0.00022944405,0.010227936,0.0008941421,0.00036957426,0.00023023131,0.00005612256,0.00062670914,0.9853719,0.000021532118,0.0008685206,0.000025438445],"study_design_scores_gemma":[0.0022753656,0.00046707978,0.08987665,0.0010818014,0.00040057136,1.3613455e-7,0.000015777101,0.0042252555,0.8912605,0.0000017032523,0.009300057,0.001095114],"about_ca_topic_score_codex":0.00008665569,"about_ca_topic_score_gemma":0.0000013036067,"teacher_disagreement_score":0.094111405,"about_ca_system_score_codex":0.0011503844,"about_ca_system_score_gemma":0.002004006,"threshold_uncertainty_score":0.9993528},"labels":[],"label_agreement":null},{"id":"W3037602706","doi":"10.1038/s41467-020-17011-z","title":"Oncolytic virus-derived type I interferon restricts CAR T cell therapy","year":2020,"lang":"en","type":"article","venue":"Nature Communications","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"National Institute of Allergy and Infectious Diseases; National Institute of Neurological Disorders and Stroke; National Institute of General Medical Sciences; National Cancer Institute; U.S. Department of Health and Human Services; National Institutes of Health; Richard M. Schulze Family Foundation; Mayo Foundation for Medical Education and Research; Oncolytics Biotech","keywords":"Chimeric antigen receptor; Oncolytic virus; Interferon; T cell; Tumor microenvironment; Cancer research; Immune system; Immunotherapy; Chemokine; Biology; Immunology","score_opus":0.0890405139596509,"score_gpt":0.3763875587926741,"score_spread":0.2873470448330232,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037602706","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.731011,0.053790636,0.000048728092,0.086203694,0.0003563524,0.0022271648,0.000038197955,0.0004964817,0.12582779],"genre_scores_gemma":[0.97889346,0.011996308,0.0014306249,0.005239621,0.00016760148,0.000032202595,0.00012517102,0.000047201574,0.0020677908],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988284,0.00018616256,0.00021998458,0.00023394686,0.00030361058,0.0002278722],"domain_scores_gemma":[0.99720937,0.00029205758,0.000065141016,0.0018937628,0.0003005282,0.00023913338],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014332395,0.0001514989,0.0002487092,0.0000964681,0.0001562987,0.00003413647,0.0009458576,0.00029240723,0.0008806304],"category_scores_gemma":[0.0002414219,0.00013464078,0.00010392649,0.0007752174,0.00014104246,0.000057814465,0.0003091965,0.001983849,0.00025667195],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00073866727,0.0003039221,0.0009416303,0.000021456963,0.00008131823,0.000009198031,0.0014308001,0.000002300935,0.9650737,0.00024118896,0.022300141,0.0088556465],"study_design_scores_gemma":[0.0019517661,0.0011436117,0.004425099,0.000038409187,0.00004404367,0.000008316914,0.0002663682,0.0006692408,0.092323765,0.00003542491,0.89890665,0.00018728054],"about_ca_topic_score_codex":0.000049207723,"about_ca_topic_score_gemma":0.00007221196,"teacher_disagreement_score":0.8766065,"about_ca_system_score_codex":0.00014201897,"about_ca_system_score_gemma":0.00027521155,"threshold_uncertainty_score":0.9642285},"labels":[],"label_agreement":null},{"id":"W3037613484","doi":"10.1080/2162402x.2020.1782574","title":"Generation of highly activated, antigen-specific tumor-infiltrating CD8 <sup>+</sup> T cells induced by a novel T cell-targeted immunotherapy","year":2020,"lang":"en","type":"article","venue":"OncoImmunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"National Cancer Institute","keywords":"Cytotoxic T cell; CD8; Cancer research; Immunotherapy; Tumor antigen; Antigen; T cell; Immunology; Medicine; Population; Biology; Immune system; In vitro","score_opus":0.05836458485133783,"score_gpt":0.29136447492183964,"score_spread":0.23299989007050181,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037613484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912618,0.0027786666,0.0007387931,0.001663307,0.00018624312,0.00091531145,0.000053241285,0.000155204,0.0022474383],"genre_scores_gemma":[0.99403614,0.0016470354,0.001876692,0.0010151855,0.00036529187,0.00004997703,0.00024400999,0.00012770205,0.0006379872],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970226,0.00024506025,0.00084276544,0.00069003296,0.0005100406,0.00068947225],"domain_scores_gemma":[0.9982762,0.00018137072,0.000356345,0.00070990645,0.00030689721,0.00016928623],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00033674994,0.00040978286,0.00089628424,0.00024035982,0.00015920293,0.00004011747,0.00039680974,0.000374741,0.0029355683],"category_scores_gemma":[0.000062565065,0.00040286832,0.00022722613,0.0008066245,0.00022336308,0.00016062465,0.000098548844,0.0009561835,0.00012704785],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013790452,0.00050131825,0.00022059919,0.000041000578,0.00027225926,0.00002704376,0.0024304152,0.00008254423,0.98370785,0.00006208291,0.0024775527,0.00879828],"study_design_scores_gemma":[0.0054312153,0.0019162432,0.00046809818,0.00003387643,0.000015530326,0.000033032557,0.00070262444,0.0015748912,0.92919576,0.000003720903,0.060322404,0.00030259666],"about_ca_topic_score_codex":0.00027812851,"about_ca_topic_score_gemma":0.0000023102964,"teacher_disagreement_score":0.05784485,"about_ca_system_score_codex":0.00021489098,"about_ca_system_score_gemma":0.00037185292,"threshold_uncertainty_score":0.99984235},"labels":[],"label_agreement":null},{"id":"W3037719485","doi":"10.1111/bjh.16961","title":"Amelioration of COVID‐19‐related cytokine storm syndrome: parallels to chimeric antigen receptor‐T cell cytokine release syndrome","year":2020,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"International Collaboration On Repair Discoveries; University of British Columbia, Okanagan Campus; University of British Columbia","funders":"Vancouver Coastal Health Research Institute","keywords":"Cytokine release syndrome; Cytokine storm; Chimeric antigen receptor; Cytokine; Coronavirus disease 2019 (COVID-19); Immunology; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Cytokine receptor; Medicine; Receptor; 2019-20 coronavirus outbreak; Virology; Immunotherapy; Immune system; Internal medicine; Infectious disease (medical specialty); Disease","score_opus":0.025521533568235832,"score_gpt":0.2938366043423085,"score_spread":0.2683150707740727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037719485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98490083,0.0036775044,0.00088362413,0.009136616,0.00024930306,0.000733129,0.000060172973,0.000048702794,0.00031012952],"genre_scores_gemma":[0.9935689,0.0026426353,0.0017755294,0.0012708975,0.000091767026,0.000010502541,0.00005274993,0.00007357542,0.0005134305],"study_design_codex":"bench_or_experimental","study_design_gemma":"case_report","domain_scores_codex":[0.9963639,0.00040784356,0.0014823988,0.00039936198,0.0008177093,0.0005288172],"domain_scores_gemma":[0.9969529,0.00017580268,0.0007872014,0.0003005973,0.0005115891,0.0012719153],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00076061126,0.00026338032,0.0016583388,0.00046600978,0.00010377618,0.00003656743,0.00039921535,0.00027764062,0.005428517],"category_scores_gemma":[0.0010436815,0.00029262106,0.00033353342,0.0011372461,0.00023183116,0.0001877336,0.00011764494,0.00090892805,0.00016750407],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061628995,0.0016315741,0.013911732,0.0018231212,0.0013311568,0.3837421,0.0026981337,0.0008344194,0.5239218,0.0000990369,0.050642367,0.013201684],"study_design_scores_gemma":[0.009994654,0.008728452,0.011234384,0.0007896531,0.00028381552,0.9015717,0.0007086725,0.00018547311,0.022366311,0.00014899192,0.043466702,0.0005212079],"about_ca_topic_score_codex":0.00020961277,"about_ca_topic_score_gemma":0.00002858631,"teacher_disagreement_score":0.5178296,"about_ca_system_score_codex":0.00018580508,"about_ca_system_score_gemma":0.0007076073,"threshold_uncertainty_score":0.9999526},"labels":[],"label_agreement":null},{"id":"W3037829129","doi":"10.1038/s41409-020-0982-6","title":"Allogeneic haematopoietic stem cell transplantation improves outcome of adults with relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia entering remission following CD19 chimeric antigen receptor T cells","year":2020,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ministry of Agriculture","funders":"","keywords":"Medicine; Haematopoiesis; Stem cell; Transplantation; Acute lymphocytic leukemia; Chimeric antigen receptor; CD19; Philadelphia chromosome; Immunology; Refractory (planetary science); Leukemia; Hematopoietic stem cell transplantation; Acute leukemia; Lymphoblastic Leukemia; Internal medicine; Antigen; Oncology; Cancer research; T cell; Chromosomal translocation; Biology; Immune system; Genetics","score_opus":0.013609995006849932,"score_gpt":0.24787438519349161,"score_spread":0.2342643901866417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037829129","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920622,0.00037017703,0.00489818,0.00032935958,0.0002118613,0.0015153467,0.0002070223,0.0001536699,0.00025214496],"genre_scores_gemma":[0.994417,0.0026906857,0.0013659375,0.00016677917,0.000110954876,0.000060963444,0.0008174529,0.00013345057,0.00023677471],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9966057,0.00018498098,0.0009500426,0.00077784824,0.00094208587,0.0005393333],"domain_scores_gemma":[0.9985976,0.00017725886,0.000375431,0.0003244019,0.00013572033,0.0003895694],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024121873,0.00050070026,0.0008561468,0.00026711493,0.00014530502,0.000037348138,0.0001996877,0.00024595868,0.00022809756],"category_scores_gemma":[0.000006272677,0.00044777218,0.0003308933,0.00056310033,0.000103068276,0.0003410625,0.00001721391,0.00040193292,0.00003532341],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012552138,0.00014884768,0.0043062093,0.0034397722,0.00031991693,0.0007205501,0.008505928,0.00019343494,0.9677443,0.0000014804964,0.000020665373,0.0020467613],"study_design_scores_gemma":[0.01045931,0.0024281759,0.012574505,0.0017118102,0.0010889394,0.00029601488,0.00065332244,0.0011157637,0.9691077,0.000001643593,0.00005328082,0.00050953054],"about_ca_topic_score_codex":0.00008839978,"about_ca_topic_score_gemma":0.000012628636,"teacher_disagreement_score":0.008268296,"about_ca_system_score_codex":0.0003130599,"about_ca_system_score_gemma":0.00027220286,"threshold_uncertainty_score":0.9997974},"labels":[],"label_agreement":null},{"id":"W3037884364","doi":"10.1016/j.jpha.2020.06.003","title":"Use of subcutaneous tocilizumab to prepare intravenous solutions for COVID-19 emergency shortage: Comparative analytical study of physicochemical quality attributes","year":2020,"lang":"en","type":"article","venue":"Journal of Pharmaceutical Analysis","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Infection and Immunity; European Regional Development Fund; Universidad de Granada; Instituto de Salud Carlos III; Ministerio de Economía y Competitividad","keywords":"Tocilizumab; Coronavirus disease 2019 (COVID-19); Pandemic; Economic shortage; Cytokine release syndrome; Medicine; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Intensive care medicine; Pharmacology; Disease; Internal medicine","score_opus":0.4388270827938437,"score_gpt":0.5219379613527586,"score_spread":0.08311087855891491,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3037884364","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97947466,0.00018620283,0.014505355,0.004484267,0.000035763962,0.0010164698,0.00024949253,0.00001336151,0.000034400207],"genre_scores_gemma":[0.9986949,0.00006786696,0.0005324659,0.00033027306,0.00020211776,0.000015917705,0.00002803332,0.000015746986,0.00011265646],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99561673,0.0004454396,0.0018345233,0.00037818664,0.0012643377,0.00046080485],"domain_scores_gemma":[0.9949417,0.0011341374,0.0004939033,0.00032581645,0.0016261826,0.0014782354],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010364228,0.00023592282,0.0018595465,0.0003918865,0.00009253554,0.000017885392,0.00031052885,0.00009447383,0.0025898004],"category_scores_gemma":[0.0023418558,0.0001936237,0.0012032198,0.0023270198,0.00018211268,0.00009627646,0.00014894072,0.00049108703,0.0000023970856],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.059961833,0.0192084,0.077165425,0.0012327543,0.046976294,0.00048665676,0.019192027,0.03184256,0.7260917,0.0003702971,0.013861425,0.0036106273],"study_design_scores_gemma":[0.03227741,0.058030877,0.027142502,0.00017587644,0.11272269,0.00047026091,0.033658147,0.5334102,0.18060255,0.0004801451,0.018980257,0.0020490882],"about_ca_topic_score_codex":0.00011285689,"about_ca_topic_score_gemma":0.00008875591,"teacher_disagreement_score":0.54548913,"about_ca_system_score_codex":0.00028608317,"about_ca_system_score_gemma":0.0003831744,"threshold_uncertainty_score":0.99832195},"labels":[],"label_agreement":null},{"id":"W3039382149","doi":"10.1016/j.cell.2020.05.049","title":"TBL1XR1 Mutations Drive Extranodal Lymphoma by Inducing a Pro-tumorigenic Memory Fate","year":2020,"lang":"en","type":"article","venue":"Cell","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":126,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency; University of Toronto","funders":"Memorial Sloan-Kettering Cancer Center; Leukemia and Lymphoma Society; National Cancer Institute; Chemotherapy Foundation","keywords":"Biology; Germinal center; BCL6; Reprogramming; Transcription factor; Phenotype; Somatic hypermutation; Cancer research; Cell fate determination; Somatic cell; Lymphoma; B cell; Cell; Cell biology; Gene; Genetics; Immunology; Antibody","score_opus":0.033491065504405976,"score_gpt":0.2937743776601731,"score_spread":0.26028331215576717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3039382149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9553954,0.00067306164,0.0002740657,0.0023077996,0.00012762268,0.0008004995,0.000021191736,0.00012528826,0.040275063],"genre_scores_gemma":[0.9723681,0.000049803017,0.00034052072,0.0010945095,0.00035312216,0.00005991169,0.000081063474,0.00006258844,0.025590342],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99843156,0.00006755659,0.0002527925,0.0004094038,0.00042677444,0.0004119061],"domain_scores_gemma":[0.9990648,0.00007859268,0.00005645746,0.0002962389,0.00010204478,0.00040186418],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00014767007,0.0001760087,0.00027226465,0.00007880477,0.000106303545,0.00003587024,0.00016313263,0.000096517324,0.0048446846],"category_scores_gemma":[0.00006384781,0.0001670369,0.00013084362,0.00039480344,0.0001007291,0.00007950138,0.000055525667,0.00026583293,0.0008493427],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019380002,0.00015938401,0.0004307602,0.00013521373,0.000049689563,0.0001696312,0.00463724,0.000010419561,0.97238195,0.000004788,0.008356498,0.013470647],"study_design_scores_gemma":[0.004954723,0.00054258155,0.0013028191,0.00004674029,0.000096396296,0.000057381843,0.0016766617,0.0015897998,0.94078255,0.000048902086,0.048612162,0.00028928267],"about_ca_topic_score_codex":0.00006618938,"about_ca_topic_score_gemma":0.0000050104322,"teacher_disagreement_score":0.040255666,"about_ca_system_score_codex":0.00014702466,"about_ca_system_score_gemma":0.00032369167,"threshold_uncertainty_score":0.9999286},"labels":[],"label_agreement":null},{"id":"W3039452644","doi":"10.7150/thno.44259","title":"Engineering Circulating Tumor Cells as Novel Cancer Theranostics","year":2020,"lang":"en","type":"article","venue":"Theranostics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Robarts Clinical Trials; Western University","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Circulating tumor cell; Metastatic breast cancer; Homing (biology); Medicine; Bioluminescence imaging; Primary tumor; Cancer research; Breast cancer; Cancer; Metastatic tumor; Genetic enhancement; Metastasis; CA15-3; Oncology; Pathology; Internal medicine; Gene; Biology; Transfection","score_opus":0.04401718092130154,"score_gpt":0.30375917950547193,"score_spread":0.2597419985841704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3039452644","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9718125,0.0014815563,0.012764498,0.0054008365,0.00076781586,0.0014301259,0.00008505922,0.0013547557,0.0049028536],"genre_scores_gemma":[0.9896121,0.00025190276,0.0025373183,0.0051143854,0.0013127814,0.000026531918,0.000013193411,0.00032568537,0.00080610486],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99818647,0.000026433278,0.0003337854,0.00036102463,0.00057639065,0.00051589723],"domain_scores_gemma":[0.9986496,0.00036788997,0.00007191449,0.00035033227,0.0001763458,0.0003839469],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00015737336,0.00027713814,0.00041728021,0.00007016521,0.000050410126,0.00004943825,0.00020642592,0.000103895945,0.001999635],"category_scores_gemma":[0.0004424047,0.0002576534,0.00013855613,0.0003824979,0.00006459847,0.00004756062,0.000069740905,0.00053914345,0.0001369605],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024920606,0.000079199985,0.00066187105,0.00017503498,0.00016929433,0.00013878132,0.0016198226,0.003385466,0.9894913,0.0002745786,0.00028026564,0.003475199],"study_design_scores_gemma":[0.0064759334,0.00083718216,0.002329295,0.00046589793,0.0003577787,0.00016402494,0.0003783358,0.13740642,0.73085904,0.00008684753,0.11972894,0.00091027736],"about_ca_topic_score_codex":0.000096201846,"about_ca_topic_score_gemma":0.0000020970388,"teacher_disagreement_score":0.2586322,"about_ca_system_score_codex":0.00012652487,"about_ca_system_score_gemma":0.00023892404,"threshold_uncertainty_score":0.99998754},"labels":[],"label_agreement":null},{"id":"W3040607731","doi":"10.1016/j.cytogfr.2020.07.003","title":"A rational relationship: Oncolytic virus vaccines as functional partners for adoptive T cell therapy","year":2020,"lang":"en","type":"review","venue":"Cytokine & Growth Factor Reviews","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre","funders":"Terry Fox Foundation; Ontario Institute for Cancer Research","keywords":"Oncolytic virus; Immune system; Tumor microenvironment; Immunology; Adoptive cell transfer; T cell; Antigen; Cancer research; Biology; Medicine","score_opus":0.2295780936670554,"score_gpt":0.4285131004444376,"score_spread":0.19893500677738218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3040607731","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000021762202,0.98249775,0.0004963419,0.00045919587,0.0004687686,0.012647884,0.000508719,0.00013514486,0.002764412],"genre_scores_gemma":[0.000021678823,0.9757945,0.00066548656,0.0006990741,0.0026154558,0.0038647882,0.0034864724,0.0002697754,0.012582794],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99448246,0.0006538878,0.0019810991,0.0012620331,0.000930627,0.0006899156],"domain_scores_gemma":[0.9954014,0.0015783554,0.0010170792,0.00082418695,0.0005577777,0.00062121305],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00076201913,0.0011669178,0.0045630755,0.00047158296,0.00026178008,0.000109405424,0.00044592354,0.00058232294,0.0093922485],"category_scores_gemma":[0.0013641177,0.00084176974,0.0027304315,0.0012280864,0.00010843305,0.00020736357,0.000104959094,0.0013946177,0.0018283572],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007431158,0.00032418902,0.00007601646,0.01935672,0.0005777396,0.000040090665,0.00014603895,2.641409e-7,0.00028660017,0.00056718086,0.044129856,0.9337522],"study_design_scores_gemma":[0.0027548464,0.0010116862,0.000090853355,0.0038791313,0.0010229922,0.000119685275,0.000009358518,0.0000061224105,0.00010680506,0.00013576643,0.9901767,0.00068608526],"about_ca_topic_score_codex":0.000015063696,"about_ca_topic_score_gemma":0.0000050717194,"teacher_disagreement_score":0.9460468,"about_ca_system_score_codex":0.0008986025,"about_ca_system_score_gemma":0.002355097,"threshold_uncertainty_score":0.9994033},"labels":[],"label_agreement":null},{"id":"W3041665519","doi":"10.1080/2162402x.2020.1792058","title":"Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccination","year":2020,"lang":"en","type":"article","venue":"OncoImmunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Cancerföreningen i Stockholm; Medicinska Forskningsrådet; Knut och Alice Wallenbergs Stiftelse; Kommunfullmäktige, Stockholms Stad; Stiftelsen för Strategisk Forskning","keywords":"Medicine; Immunotherapy; Melanoma; Cohort; T cell; Internal medicine; Adoptive cell transfer; Vaccination; Oncology; Immune system; Immunology; Surgery; Cancer research","score_opus":0.052239993790942296,"score_gpt":0.31734485816633023,"score_spread":0.26510486437538794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3041665519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937027,0.00096406596,0.00025889964,0.0025294782,0.00002916677,0.0011703054,0.000027673379,0.000093205395,0.0012245049],"genre_scores_gemma":[0.99790287,0.0002284349,0.00073960086,0.00017309077,0.000047849546,0.00005955302,0.000113326096,0.0000673132,0.00066795596],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99699455,0.00084217516,0.00076878496,0.0006152143,0.0003039819,0.00047531305],"domain_scores_gemma":[0.99838674,0.0007512922,0.00013129615,0.00033813278,0.00023071181,0.00016182811],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074059534,0.000328136,0.0011004544,0.00024991613,0.00009333746,0.00002914857,0.00014414378,0.00021524099,0.0006150406],"category_scores_gemma":[0.00017857205,0.00024382639,0.00010263699,0.0006492826,0.00034148357,0.000102268576,0.000071136325,0.00087206345,0.000016853714],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20226029,0.00064422586,0.068723515,0.00013657029,0.00053639413,0.0010344158,0.0013132006,0.000005374183,0.71896756,0.000045465407,0.000011446037,0.0063215755],"study_design_scores_gemma":[0.05886685,0.035887696,0.81057626,0.00024409944,0.00032254256,0.00023024071,0.0013462713,0.00042216043,0.090174295,0.000008657842,0.0014770805,0.00044386912],"about_ca_topic_score_codex":0.00019054278,"about_ca_topic_score_gemma":0.00028892123,"teacher_disagreement_score":0.7418527,"about_ca_system_score_codex":0.00015187835,"about_ca_system_score_gemma":0.0002836685,"threshold_uncertainty_score":0.9942952},"labels":[],"label_agreement":null},{"id":"W3041971789","doi":"10.1111/sji.12929","title":"Metabolic optimization of adoptive T cell transfer cancer immunotherapy: A historical overview","year":2020,"lang":"en","type":"article","venue":"Scandinavian Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Adoptive cell transfer; Cytotoxic T cell; Immunotherapy; Cancer immunotherapy; Cancer research; Biology; CD8; T cell; Immunology; Cell biology; Antigen; Biochemistry; In vitro; Immune system","score_opus":0.04227273855186823,"score_gpt":0.30494933091690224,"score_spread":0.262676592365034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3041971789","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6275278,0.34387392,0.013444783,0.011923403,0.001032764,0.0007853823,0.000024845294,0.000049437087,0.0013376727],"genre_scores_gemma":[0.9410133,0.05521164,0.001813397,0.000658177,0.00035355764,0.000010379766,0.000005086209,0.00008356223,0.0008508928],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982834,0.00021232785,0.0006971289,0.00016529078,0.00035797598,0.00028391785],"domain_scores_gemma":[0.9988622,0.000054169577,0.00025440985,0.0001881778,0.00047703244,0.00016398229],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00026265686,0.00017710408,0.00089637394,0.00024769726,0.00003317955,0.000007876658,0.00024480702,0.00014925028,0.0053032567],"category_scores_gemma":[0.00003517017,0.00014456654,0.00037251285,0.00045659018,0.00013847544,0.00010940864,0.000023304288,0.00060299755,0.000004847242],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011301029,0.00050351623,0.0063323174,0.00019289799,0.0015960165,0.00017032135,0.0051115365,0.001146002,0.9076472,0.00013720819,0.0008595314,0.06500242],"study_design_scores_gemma":[0.047664467,0.024236688,0.036859676,0.0011806076,0.001892962,0.0019136369,0.001989812,0.0011634628,0.61903346,0.00016610969,0.2628272,0.0010719551],"about_ca_topic_score_codex":0.000096786694,"about_ca_topic_score_gemma":0.0000017462016,"teacher_disagreement_score":0.3134855,"about_ca_system_score_codex":0.00037150734,"about_ca_system_score_gemma":0.00037423812,"threshold_uncertainty_score":0.995606},"labels":[],"label_agreement":null},{"id":"W3045194329","doi":"10.1111/bjh.16940","title":"Building Canadian capacity for CAR‐T cells in relapsed/refractory acute lymphoblastic leukaemia: a retrospective cohort study","year":2020,"lang":"en","type":"letter","venue":"British Journal of Haematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; Ottawa Hospital; University of Manitoba; Ottawa Public Health; Canada's Michael Smith Genome Sciences Centre; University of Ottawa","funders":"","keywords":"Medicine; Chimeric antigen receptor; Malignancy; Progenitor cell; Hematopoietic stem cell transplantation; Stem cell; Internal medicine; Immunology; Haematopoiesis; Oncology; Transplantation; Immunotherapy; Cancer; Biology","score_opus":0.02159558664857928,"score_gpt":0.2844037094014702,"score_spread":0.2628081227528909,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3045194329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9277073,0.0009582689,0.00013140758,0.06519049,0.0020384933,0.0031475364,0.00041124612,0.000029094934,0.00038617442],"genre_scores_gemma":[0.7867849,0.0014096351,0.003661273,0.19644403,0.008198084,0.0003965786,0.00016552626,0.0006810291,0.002258971],"study_design_codex":"not_applicable","study_design_gemma":"case_report","domain_scores_codex":[0.99501,0.00058220356,0.001460547,0.0007572188,0.001002144,0.0011878975],"domain_scores_gemma":[0.99649477,0.0008072927,0.0007767743,0.00040045736,0.00092183065,0.00059889903],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00106819,0.00048094316,0.0032155819,0.0011454509,0.00016143374,0.00009630125,0.00059718534,0.0012004195,0.0005918989],"category_scores_gemma":[0.0012484582,0.00056809734,0.00057456025,0.00047082538,0.00030935148,0.00010179768,0.00008476113,0.00658676,0.00001590432],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004257225,0.00017320615,0.016595338,0.0003166897,0.0015800493,0.48572585,0.00024681204,0.0000030132805,0.0013116924,0.0000048395013,0.4930441,0.00057266554],"study_design_scores_gemma":[0.017512,0.006712193,0.023229554,0.0026909034,0.0026963698,0.6072628,0.000314538,0.000074831056,0.00087564124,0.0007376716,0.33670267,0.0011908566],"about_ca_topic_score_codex":0.04230548,"about_ca_topic_score_gemma":0.055299588,"teacher_disagreement_score":0.15634146,"about_ca_system_score_codex":0.0040670815,"about_ca_system_score_gemma":0.0031230524,"threshold_uncertainty_score":0.99975616},"labels":[],"label_agreement":null},{"id":"W3045469676","doi":"10.1158/1538-7445.pedca19-pr05","title":"Abstract PR05: T-cell receptor (TCR)-based immunotherapy in pediatric malignancy: Addressing the challenge of early metastasis and low immunogenicity","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control; BC Cancer Agency; Ontario Institute for Cancer Research","funders":"","keywords":"T-cell receptor; Cancer research; Metastasis; Immunotherapy; Biology; Immunogenicity; CD8; T cell; Cancer; Cancer immunotherapy; Immunology; Immune system; Genetics","score_opus":0.16093607519239192,"score_gpt":0.4025395723156677,"score_spread":0.2416034971232758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3045469676","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9550092,0.0337118,0.0000058178025,0.00849451,0.000053947853,0.0013440021,0.000053768992,0.00002601256,0.0013009319],"genre_scores_gemma":[0.9806942,0.0181162,0.00007431882,0.00020323714,0.00031594315,0.00023574363,0.000008904872,0.00007484107,0.00027666165],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9963665,0.00048297032,0.00050078897,0.00055476656,0.001335053,0.0007599029],"domain_scores_gemma":[0.9979851,0.0006031589,0.000121456214,0.00061910576,0.0004233688,0.0002477619],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0022723572,0.00022462643,0.00051913026,0.00035580955,0.00016156802,0.000069715104,0.00047581198,0.00015338953,0.0041157342],"category_scores_gemma":[0.00018737228,0.00016742534,0.00015972563,0.0013902624,0.0004139777,0.00010867163,0.000144116,0.0013982136,0.0000320732],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047565848,0.0003589036,0.01715311,0.0013792639,0.000109659384,0.000049210492,0.0027206887,0.000026594642,0.9353967,0.000016267853,0.00070201285,0.037331033],"study_design_scores_gemma":[0.015813863,0.0031676306,0.10225791,0.00093791564,0.000090317575,0.0000044562453,0.0010153563,0.0005360982,0.86413586,0.00011967906,0.0112782605,0.00064262515],"about_ca_topic_score_codex":0.0015859581,"about_ca_topic_score_gemma":0.00006971249,"teacher_disagreement_score":0.08510479,"about_ca_system_score_codex":0.0002550306,"about_ca_system_score_gemma":0.0011046717,"threshold_uncertainty_score":0.99679464},"labels":[],"label_agreement":null},{"id":"W3046293265","doi":"10.1016/j.omto.2020.07.008","title":"Molecular Rules Underpinning Enhanced Affinity Binding of Human T Cell Receptors Engineered for Immunotherapy","year":2020,"lang":"en","type":"article","venue":"Molecular Therapy — Oncolytics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Biotechnology and Biological Sciences Research Council; University of Bristol; Engineering and Physical Sciences Research Council; University of Bath; Canolfan Ymchwil Canser Cymru; Cancer Research UK; Wellcome Trust","keywords":"Underpinning; Receptor; Immunotherapy; Cell biology; Chemistry; Cell; Computational biology; Biology; Biochemistry; Immunology; Immune system; Engineering","score_opus":0.04400329613346489,"score_gpt":0.32832955590108875,"score_spread":0.2843262597676239,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3046293265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9462325,0.0016475142,0.046529338,0.001106372,0.00013922184,0.0020427613,0.000030701893,0.00016000326,0.0021116128],"genre_scores_gemma":[0.9878025,0.00064787944,0.008887798,0.0013982356,0.00015836957,0.00012054576,0.00014296324,0.00024986395,0.0005918682],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997183,0.00014328661,0.000697623,0.0005768108,0.0007484647,0.00065078796],"domain_scores_gemma":[0.99824095,0.00017657394,0.00026219993,0.00066346885,0.0003362734,0.00032052322],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00045141036,0.0004479377,0.0008657421,0.000247189,0.00013620702,0.000053573058,0.00043215667,0.0002891926,0.00064796326],"category_scores_gemma":[0.00011160452,0.0004551132,0.0005762808,0.00061262737,0.00015487599,0.00006542489,0.000064107044,0.00048749326,0.000022078138],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013064216,0.0003437524,0.000053436295,0.00023900894,0.0004448477,0.000039324328,0.001428702,0.00034388664,0.9823642,0.000362581,0.00013505384,0.01293882],"study_design_scores_gemma":[0.007895226,0.0031281975,0.000030812593,0.00010616769,0.00006332211,0.000004249366,0.00030185495,0.00094472687,0.9765014,0.00022030926,0.010399442,0.00040428722],"about_ca_topic_score_codex":0.000016254966,"about_ca_topic_score_gemma":7.5469694e-7,"teacher_disagreement_score":0.04157,"about_ca_system_score_codex":0.0002356053,"about_ca_system_score_gemma":0.00028935642,"threshold_uncertainty_score":0.9997901},"labels":[],"label_agreement":null},{"id":"W3046625345","doi":"10.1016/j.jim.2020.112831","title":"The co-stimulation of anti-CD28 and IL-2 enhances the sensitivity of ELISPOT assays for detection of neoantigen-specific T cells in PBMC","year":2020,"lang":"en","type":"article","venue":"Journal of Immunological Methods","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Science, Technology and Innovation Commission of Shenzhen Municipality; National Natural Science Foundation of China","keywords":"ELISPOT; CD28; Immunology; Peripheral blood mononuclear cell; T cell; Immune system; Medicine; Cytotoxic T cell; Antigen; Immunotherapy; Stimulation; Cancer research; Biology; In vitro; Internal medicine; Biochemistry","score_opus":0.09686982993115063,"score_gpt":0.4119008292073958,"score_spread":0.31503099927624517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3046625345","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9254381,0.0025529917,0.070767865,0.0007089165,0.000105398925,0.00036349837,0.0000051920474,0.0000030099418,0.000055031793],"genre_scores_gemma":[0.97853965,0.0039918413,0.017338244,0.000024616676,0.000079966216,0.0000022535355,4.0696506e-7,0.000007806835,0.00001522123],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971346,0.0015827727,0.0007174985,0.00011228928,0.00030138955,0.00015142898],"domain_scores_gemma":[0.99318516,0.005590737,0.00062410923,0.00015091163,0.00040921866,0.000039878367],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0067712856,0.000097786164,0.0005650176,0.000089097906,0.00005813615,0.000010360637,0.000117612,0.000120214834,0.000038005794],"category_scores_gemma":[0.0019745817,0.000049328693,0.0001920562,0.00030293752,0.00037628817,0.00005745245,0.000041265423,0.0004515411,2.0810492e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002275213,0.00008299863,0.0006145157,0.00004148482,0.00007499649,0.0000034950435,0.0002580875,0.00005911234,0.78406364,0.000026010292,0.0000053268636,0.2124951],"study_design_scores_gemma":[0.0010901634,0.0018403771,0.075852,0.00006205824,0.000031653046,0.000028359213,0.00048177768,0.0019060406,0.91670585,0.00024084869,0.0017206458,0.000040210514],"about_ca_topic_score_codex":0.00000933163,"about_ca_topic_score_gemma":0.0000015726201,"teacher_disagreement_score":0.2124549,"about_ca_system_score_codex":0.000030594332,"about_ca_system_score_gemma":0.00005033429,"threshold_uncertainty_score":0.23639013},"labels":[],"label_agreement":null},{"id":"W3046948275","doi":"10.1038/s42255-020-0256-z","title":"Metabolic conditioning of CD8+ effector T cells for adoptive cell therapy","year":2020,"lang":"en","type":"article","venue":"Nature Metabolism","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":141,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital","funders":"National Institute of Allergy and Infectious Diseases; U.S. Department of Health and Human Services; National Cancer Institute; National Institutes of Health; Max-Planck-Gesellschaft; Deutsche Forschungsgemeinschaft","keywords":"Effector; Conditioning; Cytotoxic T cell; CD8; Adoptive cell transfer; Cell therapy; Immunology; Biology; Cell; T cell; Immune system; Biochemistry; Mathematics","score_opus":0.020843282511545394,"score_gpt":0.3125214294409055,"score_spread":0.2916781469293601,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3046948275","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8920398,0.088045046,0.001303163,0.0031212347,0.0013591234,0.0064204778,0.0006292559,0.00021692518,0.006864986],"genre_scores_gemma":[0.9855545,0.001312535,0.004986724,0.003976442,0.0017361884,0.00020353863,0.00016676534,0.00010543447,0.0019578584],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99800956,0.00014203177,0.00034704813,0.0004580943,0.0006159273,0.00042733483],"domain_scores_gemma":[0.998351,0.00034728774,0.00016684504,0.00036101922,0.00047263756,0.00030120503],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003842724,0.0002880909,0.0009078197,0.00017791711,0.00007575189,0.000024676343,0.00024251924,0.00041106285,0.002055948],"category_scores_gemma":[0.0001705928,0.00023099173,0.00046595014,0.00058266864,0.00011726634,0.000093719056,0.000046401015,0.0010030771,0.000046657315],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015278241,0.00014624259,0.00009328906,0.0001512693,0.0002783867,0.000008531209,0.00085351197,0.000008839982,0.97388774,0.0010142036,0.005794162,0.016235974],"study_design_scores_gemma":[0.004231296,0.00024454616,0.0018691667,0.000013017797,0.0001384768,0.0000026696932,0.000058290538,0.000089891844,0.6091331,0.000060055067,0.3840328,0.00012670623],"about_ca_topic_score_codex":0.000010742266,"about_ca_topic_score_gemma":6.3927956e-7,"teacher_disagreement_score":0.37823862,"about_ca_system_score_codex":0.000020407193,"about_ca_system_score_gemma":0.00014523113,"threshold_uncertainty_score":0.9988563},"labels":[],"label_agreement":null},{"id":"W3047019788","doi":"10.1158/1538-7445.pedca19-a13","title":"Abstract A13: Immunogenomic approaches to optimize immunotherapeutic targeting of neuroblastoma","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Chimeric antigen receptor; Antigen; Immunotherapy; Medicine; Cancer research; Cancer; Neuroblastoma; Lymphoma; Cancer immunotherapy; Immunology; T cell; Immune system; Internal medicine; Cell culture; Biology","score_opus":0.3185861517142442,"score_gpt":0.3984366831874055,"score_spread":0.07985053147316129,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047019788","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9797738,0.00346221,0.000069049434,0.010865704,0.00007338723,0.0014262685,0.000023538665,0.00006061914,0.0042454163],"genre_scores_gemma":[0.9959628,0.0006895461,0.0006707115,0.0005343428,0.000407157,0.00021168585,0.000010508783,0.00010898347,0.0014042509],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9968348,0.00019743266,0.00045353943,0.0005605626,0.0011128802,0.00084074325],"domain_scores_gemma":[0.9983474,0.00028674968,0.00006424247,0.0005480641,0.0003031759,0.00045036437],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001234034,0.00019868414,0.0004772521,0.0002964814,0.00013490878,0.000054148568,0.0005443618,0.00010683665,0.006771125],"category_scores_gemma":[0.00024300454,0.00018337258,0.00017657489,0.0010904408,0.00027584966,0.000073419396,0.00028837303,0.0010371448,0.00024335603],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037463114,0.000101757,0.00047228398,0.0003498821,0.00017618375,0.000034135835,0.0017463547,0.00064956624,0.9677105,0.00003564875,0.001423916,0.023553455],"study_design_scores_gemma":[0.0031936478,0.0016123002,0.009926693,0.0002490238,0.000031005762,0.000014056089,0.001205822,0.0009772663,0.9398367,0.000038518232,0.042590085,0.000324873],"about_ca_topic_score_codex":0.00049112574,"about_ca_topic_score_gemma":0.0000069203443,"teacher_disagreement_score":0.04116617,"about_ca_system_score_codex":0.0003171577,"about_ca_system_score_gemma":0.00066576066,"threshold_uncertainty_score":0.9941368},"labels":[],"label_agreement":null},{"id":"W3047022674","doi":"10.1158/1538-7445.pedca19-a11","title":"Abstract A11: A comprehensive and integrative omic analysis of multiply relapsed refractory pediatric pre-B cell acute lymphoblastic leukemia predicts response to CD19 CAR T-cell therapy","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Oncology; Internal medicine; KRAS; Targeted therapy; CD19; Cancer; Cancer research; Immunology; Colorectal cancer","score_opus":0.05515896922623703,"score_gpt":0.37477869149320675,"score_spread":0.3196197222669697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047022674","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902455,0.0054240786,0.000040938216,0.001226783,0.00007306532,0.0022433957,0.00034136997,0.00007887998,0.00032596817],"genre_scores_gemma":[0.9831109,0.013017495,0.0001372075,0.00049918983,0.00027648185,0.0003020273,0.00005026277,0.00010007575,0.0025063641],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99464166,0.00088356424,0.0006696745,0.001082448,0.0018013784,0.0009212466],"domain_scores_gemma":[0.9936765,0.0027123673,0.00018543315,0.00082035246,0.0015056381,0.0010997448],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011900712,0.000409469,0.0011203702,0.0016935904,0.00017156452,0.00006610209,0.0005167959,0.0002776471,0.0011329101],"category_scores_gemma":[0.00061436463,0.0003399612,0.00031950558,0.0042431024,0.0004335844,0.00013271866,0.00029612184,0.0014373848,0.000054059903],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.055194147,0.00021826038,0.0076548923,0.00033068008,0.001170432,0.00018888662,0.01061992,0.0005405868,0.9167748,8.5651163e-7,0.005653921,0.0016526323],"study_design_scores_gemma":[0.023009887,0.010826404,0.42209938,0.00027262428,0.0016060622,0.000009928044,0.0041127605,0.007524667,0.51763433,0.000010716291,0.012058854,0.0008343685],"about_ca_topic_score_codex":0.0014598094,"about_ca_topic_score_gemma":0.000079826554,"teacher_disagreement_score":0.41444448,"about_ca_system_score_codex":0.0015400869,"about_ca_system_score_gemma":0.003035907,"threshold_uncertainty_score":0.9999052},"labels":[],"label_agreement":null},{"id":"W3047046898","doi":"10.1158/1538-7445.pedca19-a09","title":"Abstract A09: Glypican-2 targeted CAR T cells designed to effectively eradicate endogenous site density solid tumors in the absence of toxicity","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Neuroblastoma; In vivo; Cancer research; Antigen; Single-chain variable fragment; In vitro; Pediatric cancer; Biology; Cell culture; Chemistry; Molecular biology; Cancer; Antibody; Immunology; Biochemistry; Monoclonal antibody","score_opus":0.10088848235893828,"score_gpt":0.3809940487510608,"score_spread":0.28010556639212253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047046898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99273187,0.0004626696,0.000053624768,0.0029765395,0.00004412887,0.002759958,0.00006364338,0.000034533237,0.0008730521],"genre_scores_gemma":[0.9981004,0.00024094968,0.000095516334,0.00083625293,0.00024632568,0.00026745314,0.0000085420015,0.000048202248,0.00015636245],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9953249,0.00076964824,0.0004351519,0.000666022,0.00177802,0.0010262753],"domain_scores_gemma":[0.99714005,0.0009930289,0.00007648665,0.0006429603,0.0005656562,0.00058184494],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0027391897,0.00022961793,0.0006142497,0.00027185574,0.00017137406,0.000046186862,0.00069446757,0.00012183096,0.0012043536],"category_scores_gemma":[0.00076409255,0.00017665193,0.00014641823,0.0019784153,0.00042803533,0.00007106023,0.00020602912,0.0013438906,0.00016469846],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003228531,0.00018758517,0.006283913,0.0003181361,0.00006506591,0.00057754456,0.006057398,0.00017198318,0.9793849,0.000010745494,0.0012065725,0.0025075988],"study_design_scores_gemma":[0.0012747139,0.001134382,0.086437166,0.0001368692,0.000009797397,0.00001650948,0.00041825537,0.00010952094,0.9096164,0.000025967156,0.00067017245,0.00015021306],"about_ca_topic_score_codex":0.00411174,"about_ca_topic_score_gemma":0.0005267641,"teacher_disagreement_score":0.08015325,"about_ca_system_score_codex":0.0005981926,"about_ca_system_score_gemma":0.0009968296,"threshold_uncertainty_score":0.99970865},"labels":[],"label_agreement":null},{"id":"W3047089095","doi":"10.1158/1538-7445.pedca19-b49","title":"Abstract B49: Modeling a pathogenic <i>SAMD9</i> mutation in human induced pluripotent stem cells","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Induced pluripotent stem cell; Cancer research; Biology; Myeloid; Stem cell; Haematopoiesis; Chromosome 7 (human); Progenitor cell; Genetics; Embryonic stem cell; Gene; Chromosome","score_opus":0.2254322174262751,"score_gpt":0.4319023045431385,"score_spread":0.2064700871168634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047089095","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99333584,0.00080232584,0.00004360998,0.0028831533,0.00006878511,0.0013575921,0.000015730106,0.00006203374,0.0014309402],"genre_scores_gemma":[0.99753183,0.00038457348,0.000030243553,0.0003535807,0.00047172356,0.00030598207,0.000017910064,0.00007760776,0.0008265587],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9962261,0.00022288381,0.00045628127,0.0006489229,0.0015815469,0.0008642643],"domain_scores_gemma":[0.9984821,0.00011399094,0.00004480643,0.00041367588,0.0004379228,0.00050748675],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012333066,0.00018637668,0.00036742486,0.0003848887,0.00015129324,0.00008018822,0.00031060062,0.00017130349,0.001971613],"category_scores_gemma":[0.000058425354,0.00018056699,0.00012263289,0.0011126007,0.00008514272,0.00012477247,0.00015852951,0.0016539524,0.0001507424],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000635143,0.000106016654,0.00042633628,0.00030455572,0.000040522846,0.00043322542,0.0016448253,0.0020503933,0.9711281,0.000017230672,0.00029152274,0.022922147],"study_design_scores_gemma":[0.005802334,0.0009941149,0.0013804418,0.00051135675,0.000023056453,0.00001595007,0.0030562067,0.02761181,0.95772743,0.00015427379,0.0023252773,0.00039772966],"about_ca_topic_score_codex":0.0018817848,"about_ca_topic_score_gemma":0.00028552717,"teacher_disagreement_score":0.025561418,"about_ca_system_score_codex":0.00083595165,"about_ca_system_score_gemma":0.00077441527,"threshold_uncertainty_score":0.9989407},"labels":[],"label_agreement":null},{"id":"W3047123472","doi":"10.1158/1538-7445.pedca19-a48","title":"Abstract A48: YB-1-based oncolytic virotherapy in combination with CDK4/6-inhibitors against Ewing sarcoma","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Oncolytic virus; Cancer research; Immune checkpoint; Immune system; Retinoblastoma; Retinoblastoma protein; Viral replication; Biology; Cell cycle; Oncolytic adenovirus; Medicine; Immunotherapy; Virology; Immunology; Cancer; Virus; Internal medicine","score_opus":0.09914652753803432,"score_gpt":0.4084362448651844,"score_spread":0.30928971732715005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047123472","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97603965,0.0005894513,0.000047739417,0.015616321,0.00005919236,0.001896655,0.00000964018,0.00008411852,0.005657248],"genre_scores_gemma":[0.9964626,0.00031461698,0.00010454173,0.0013076303,0.00041531504,0.0003799351,0.000030006298,0.000105912535,0.00087943196],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99597585,0.00025568946,0.0003604991,0.00061477994,0.0019118777,0.0008813245],"domain_scores_gemma":[0.99821687,0.00039275436,0.00005680805,0.00043716966,0.00040528507,0.00049113255],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013303264,0.00022279787,0.0004176582,0.0005475292,0.00015498858,0.00009881482,0.00030811218,0.0001466843,0.0025107393],"category_scores_gemma":[0.0001805341,0.00019171108,0.00009547941,0.0018070705,0.0003209777,0.00014794224,0.000058397494,0.0015008848,0.00010765707],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049770395,0.00048069452,0.04073488,0.00043650935,0.0000746796,0.0005268778,0.0010532627,0.00031692444,0.8639596,0.000038047656,0.0017820073,0.08561945],"study_design_scores_gemma":[0.03669285,0.005912045,0.1424008,0.0023949728,0.000026412705,0.000012282969,0.0015743094,0.008496913,0.7260236,0.00011532297,0.07550546,0.000845041],"about_ca_topic_score_codex":0.000827223,"about_ca_topic_score_gemma":0.0003574585,"teacher_disagreement_score":0.13793604,"about_ca_system_score_codex":0.0010799419,"about_ca_system_score_gemma":0.0016043107,"threshold_uncertainty_score":0.9984011},"labels":[],"label_agreement":null},{"id":"W3047156703","doi":"10.1158/1538-7445.pedca19-ia09","title":"Abstract IA09: Immunotherapeutic approaches for pediatric solid tumors","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Chimeric antigen receptor; Immunotherapy; Rhabdomyosarcoma; Neuroblastoma; Transplantation; Oncology; Immune system; Chemotherapy; Cytokine release syndrome; Immunology; Cancer research; Sarcoma; Internal medicine; Pathology; Biology; Cell culture","score_opus":0.3021584727594122,"score_gpt":0.45402061226202023,"score_spread":0.15186213950260802,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047156703","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96273,0.008286015,0.0001592721,0.017943164,0.00012918781,0.0033682312,0.000060793205,0.00014231038,0.0071810284],"genre_scores_gemma":[0.9884568,0.001671615,0.00014573512,0.0006566545,0.0024207789,0.0010553641,0.000028336768,0.00012266797,0.005442061],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.996798,0.00010318379,0.00033667558,0.00058817235,0.0011533399,0.0010206753],"domain_scores_gemma":[0.9981872,0.0004052455,0.00004973438,0.00046178797,0.00040209203,0.00049394666],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012513518,0.00019284971,0.00041753647,0.00028277855,0.00022065907,0.000088553876,0.0004209603,0.00013357807,0.005624422],"category_scores_gemma":[0.00027531607,0.00016899823,0.00020839724,0.0009899145,0.00022555109,0.00008859712,0.00011951991,0.0010259193,0.00022444518],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007214164,0.00042296518,0.008961471,0.0029733677,0.0004211496,0.000106322026,0.0030221571,0.00010446117,0.80073404,0.00036539012,0.024011841,0.15166265],"study_design_scores_gemma":[0.021503009,0.0065733283,0.07584174,0.00041439626,0.00028983736,0.00006710873,0.0040569864,0.005552669,0.43642598,0.0016333826,0.4459773,0.0016642545],"about_ca_topic_score_codex":0.0001582612,"about_ca_topic_score_gemma":0.000011001862,"teacher_disagreement_score":0.42196548,"about_ca_system_score_codex":0.00033748557,"about_ca_system_score_gemma":0.0011516298,"threshold_uncertainty_score":0.99528456},"labels":[],"label_agreement":null},{"id":"W3047209647","doi":"10.1158/1538-7445.pedca19-a08","title":"Abstract A08: Development of FGFR4-specific chimeric antibody receptor (CAR) T cell and bispecific T cell engager (BiTE) for rhabdomyosarcoma (RMS) immunotherapy","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer research; Monoclonal antibody; In vivo; Immunotherapy; In vitro; Alveolar rhabdomyosarcoma; Antibody; T cell; Medicine; Molecular biology; Biology; Immunology; Rhabdomyosarcoma; Immune system; Pathology; Biochemistry; Sarcoma","score_opus":0.11237093703901149,"score_gpt":0.3963435076616698,"score_spread":0.28397257062265835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047209647","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97526234,0.016207205,0.0003426914,0.0016281764,0.00018326608,0.0027664665,0.00008648656,0.00006742252,0.0034559376],"genre_scores_gemma":[0.9745788,0.013737001,0.004689406,0.00019682368,0.0008077708,0.00053554185,0.00014590238,0.00022365635,0.0050850976],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9954906,0.000247453,0.00074081443,0.00092971674,0.0014705992,0.0011207822],"domain_scores_gemma":[0.99714637,0.0007144695,0.000150603,0.0006544747,0.0007454678,0.0005886164],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019535727,0.00036448552,0.00074599695,0.00048232285,0.00039817183,0.00009967737,0.0005145424,0.00021298349,0.009215525],"category_scores_gemma":[0.00007991163,0.00032851342,0.0002077506,0.0011371432,0.00049944536,0.00012365481,0.00019619949,0.0013231926,0.0001388671],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003419837,0.00040793084,0.0013674693,0.0010361802,0.00012050018,0.00001752732,0.003800258,0.0000027023689,0.9213904,0.000016134194,0.008245844,0.06017519],"study_design_scores_gemma":[0.0034099484,0.00061715493,0.0043247505,0.000111690104,0.0000070145397,0.0000023750267,0.00085105526,0.000020617386,0.63612366,0.000010053082,0.35430092,0.00022075846],"about_ca_topic_score_codex":0.0001229627,"about_ca_topic_score_gemma":0.000008214091,"teacher_disagreement_score":0.34605506,"about_ca_system_score_codex":0.00038950617,"about_ca_system_score_gemma":0.0011015418,"threshold_uncertainty_score":0.9999167},"labels":[],"label_agreement":null},{"id":"W3047210705","doi":"10.1158/1538-7445.pedca19-pr04","title":"Abstract PR04: Locoregionally administered B7H3-targeting CAR T cells mediate potent antitumor effects in atypical teratoid/rhabdoid tumor","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Atypical teratoid rhabdoid tumor; Medicine; Cancer research; Immune system; Brain tumor; Immunology; Pharmacology; Pathology; Medulloblastoma","score_opus":0.07927072980989242,"score_gpt":0.39065753962015737,"score_spread":0.31138680981026495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047210705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850265,0.0018350119,0.0000142129875,0.008993185,0.00024295552,0.0024725173,0.000039040682,0.000085665815,0.0012909446],"genre_scores_gemma":[0.99487007,0.00057317864,0.00022146055,0.0013343475,0.0013337553,0.0004973734,0.000052720716,0.00011976796,0.0009973081],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9941732,0.0004465594,0.00063065597,0.0010048001,0.002234128,0.0015106288],"domain_scores_gemma":[0.99699694,0.0007118742,0.00009125356,0.00052567414,0.0005192883,0.001154993],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016615106,0.0003457956,0.00072927796,0.00042773137,0.00017487627,0.00012490846,0.000571158,0.00017391713,0.002605751],"category_scores_gemma":[0.0008425158,0.00030598082,0.00020925363,0.0011994233,0.00044070405,0.00013643003,0.00034146704,0.0022780597,0.0004795641],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004861899,0.00026972155,0.013572226,0.0013712154,0.000083093226,0.004735413,0.00087529107,0.00003506155,0.96014667,0.000028600749,0.008737765,0.0052830297],"study_design_scores_gemma":[0.007855556,0.0019484696,0.075445615,0.0011944309,0.000029795356,0.0000606043,0.0004974732,0.000913759,0.86602724,0.00008537939,0.045333013,0.000608668],"about_ca_topic_score_codex":0.0003178057,"about_ca_topic_score_gemma":0.0000851175,"teacher_disagreement_score":0.094119444,"about_ca_system_score_codex":0.00072597456,"about_ca_system_score_gemma":0.0017275214,"threshold_uncertainty_score":0.9999392},"labels":[],"label_agreement":null},{"id":"W3047276503","doi":"10.1158/1538-7445.pedca19-ia30","title":"Abstract IA30: Using single-cell, high-dimensional approaches to unravel tumor heterogeneity in pediatric cancer","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Mass cytometry; Bone marrow; Cancer; Leukemia; B cell; Oncology; Immunology; Cancer research; Internal medicine; Antibody; Biology; Phenotype","score_opus":0.4101916416728193,"score_gpt":0.4161850809966296,"score_spread":0.005993439323810301,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047276503","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98977953,0.0024117583,0.000019536656,0.0054633943,0.00014401622,0.0013879666,0.00006445495,0.000045892048,0.00068343757],"genre_scores_gemma":[0.99587715,0.00021058443,0.0004564315,0.0008344467,0.0016068773,0.000304265,0.000015613894,0.000103268896,0.0005913654],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99527115,0.00022378525,0.00043941732,0.00093796774,0.0018949073,0.0012327785],"domain_scores_gemma":[0.9979594,0.00023096542,0.00005920992,0.0004576413,0.00033384384,0.0009589462],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011272009,0.00027097456,0.0005086248,0.0005964487,0.00016771336,0.0000849629,0.0003917117,0.00013925048,0.0044354727],"category_scores_gemma":[0.00020734157,0.00025434163,0.00012315375,0.0021483912,0.00017711849,0.00011505261,0.00038273673,0.001368363,0.00014721883],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021487053,0.0004589585,0.05056583,0.00079050043,0.000053132615,0.00037510908,0.0006133015,0.0039194394,0.9324367,0.000013102566,0.002753415,0.0058718123],"study_design_scores_gemma":[0.0071332036,0.0012957703,0.15466589,0.0004136628,0.00007639503,0.00003285897,0.00035789656,0.0047895187,0.824271,0.000062297455,0.0060068583,0.0008945923],"about_ca_topic_score_codex":0.005731104,"about_ca_topic_score_gemma":0.00088723784,"teacher_disagreement_score":0.10816564,"about_ca_system_score_codex":0.0014370969,"about_ca_system_score_gemma":0.0017901246,"threshold_uncertainty_score":0.9999909},"labels":[],"label_agreement":null},{"id":"W3047410483","doi":"10.1158/1538-7445.pedca19-b67","title":"Abstract B67: EGFR as a target in pediatric solid tumors","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Epidermal growth factor receptor; Desmoplastic small-round-cell tumor; Cancer research; Immunohistochemistry; Cancer; Epitope; Tissue microarray; Monoclonal antibody; Malignancy; Medicine; Biology; Pathology; Antibody; Immunology; Internal medicine","score_opus":0.11407814438250664,"score_gpt":0.4558578506241235,"score_spread":0.34177970624161685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047410483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9515718,0.0023974653,0.0000033129318,0.013679603,0.000076580065,0.0010321337,0.000012502835,0.0000632239,0.031163383],"genre_scores_gemma":[0.9883005,0.0024572979,0.00005876785,0.0008258115,0.0015984286,0.0002854079,0.000015460024,0.00007507674,0.0063832626],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99608004,0.00016897866,0.00036178305,0.0005955006,0.0016949672,0.0010987057],"domain_scores_gemma":[0.9981866,0.00025801978,0.000037219066,0.00041070703,0.0003542608,0.0007531904],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0013640282,0.00017316708,0.0004132842,0.0005221062,0.00009689969,0.00006384728,0.00040486787,0.00013389044,0.027396334],"category_scores_gemma":[0.00078136637,0.00015960618,0.00011055197,0.0020396588,0.00017841537,0.00010561967,0.00021341733,0.001907064,0.0014347631],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005354759,0.00051754515,0.17342296,0.0017095698,0.00010700963,0.0039939047,0.0042000073,0.00013958014,0.72267693,0.000209216,0.06337759,0.024290932],"study_design_scores_gemma":[0.014657892,0.003830603,0.43669343,0.00057306886,0.000049150105,0.00009887874,0.0023623814,0.0013201528,0.26894268,0.0015707371,0.26873562,0.0011654026],"about_ca_topic_score_codex":0.001795425,"about_ca_topic_score_gemma":0.00012654973,"teacher_disagreement_score":0.45373425,"about_ca_system_score_codex":0.0006013034,"about_ca_system_score_gemma":0.001986265,"threshold_uncertainty_score":0.99934274},"labels":[],"label_agreement":null},{"id":"W3047711886","doi":"10.1158/2326-6074.tumimm18-pr15","title":"Abstract PR15: A novel NK cell-targeted therapeutic strategy against pancreatic cancer","year":2020,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Quest University Canada","funders":"","keywords":"Pancreatic cancer; Cancer research; Immunotherapy; Cytotoxic T cell; Tumor microenvironment; Immune system; Immunology; Cancer immunotherapy; CD8; Memory T cell; Medicine; Biology; Cancer; Internal medicine; In vitro","score_opus":0.14931097674022706,"score_gpt":0.4141424449200402,"score_spread":0.2648314681798132,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3047711886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9069329,0.06031284,0.000038196675,0.012899722,0.00026767887,0.0020591195,0.000104519546,0.00019955209,0.01718551],"genre_scores_gemma":[0.96588254,0.020688497,0.000056904497,0.001647479,0.00069850957,0.0010327172,0.00006254554,0.00014876673,0.00978205],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9952176,0.00032815812,0.0005588895,0.0009707073,0.0011690551,0.0017555886],"domain_scores_gemma":[0.9971473,0.00046889842,0.00011305854,0.00085221895,0.000906399,0.000512104],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00091138046,0.0003985928,0.00080358743,0.00039758455,0.0003401894,0.00009621061,0.00075082615,0.00044755242,0.019069117],"category_scores_gemma":[0.00018786658,0.00034969024,0.00022144835,0.0015466241,0.0009929511,0.00014803659,0.0002647958,0.002969687,0.00048027706],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029064878,0.0003108755,0.0051153647,0.0004398351,0.0008192092,0.00014144761,0.00095872924,0.00007401895,0.92964745,0.000049248698,0.0026878817,0.056849483],"study_design_scores_gemma":[0.017746342,0.0038798202,0.17030317,0.0007381422,0.00025305068,0.00006461898,0.0041566915,0.0028293433,0.64791346,0.00018015283,0.1506774,0.0012578109],"about_ca_topic_score_codex":0.0020450524,"about_ca_topic_score_gemma":0.00012923888,"teacher_disagreement_score":0.28173396,"about_ca_system_score_codex":0.00080471765,"about_ca_system_score_gemma":0.00294099,"threshold_uncertainty_score":0.9998955},"labels":[],"label_agreement":null},{"id":"W3048618685","doi":"10.1016/j.jid.2020.04.004","title":"The Melanoma JID Connector Collection: An Introduction","year":2020,"lang":"en","type":"letter","venue":"Journal of Investigative Dermatology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Hidradenitis Suppurativa Foundation; Bausch Health; Celgene; Pfizer","keywords":"Narrative review; Perspective (graphical); Narrative; Field (mathematics); Computer science; Medicine; Data science; Artificial intelligence; Philosophy","score_opus":0.04442278249054914,"score_gpt":0.3070852920150112,"score_spread":0.2626625095244621,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3048618685","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01775807,0.00066907966,0.00003974544,0.97891706,0.001604689,0.000424476,0.000007972375,0.000027658341,0.00055126357],"genre_scores_gemma":[0.008252309,0.00060086587,0.001150818,0.9425981,0.039107494,0.000041189203,0.00013960291,0.00016004145,0.007949591],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99628115,0.0012775222,0.00093627564,0.00032510603,0.0007543325,0.00042559658],"domain_scores_gemma":[0.9963336,0.0007290242,0.0009919286,0.00040402074,0.0012222071,0.0003191909],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00037986258,0.00032464645,0.0010369486,0.00035446996,0.00030618918,0.00007765331,0.00039355134,0.0005794918,0.0009998525],"category_scores_gemma":[0.0015589714,0.00021491373,0.00030832447,0.00050642644,0.0014302286,0.00015105645,0.00005772428,0.004906661,0.000049532715],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005006645,0.00002611834,0.00012418715,0.00010670456,0.00071039493,0.0044061765,0.0005283554,8.021995e-7,0.0397262,0.00010581134,0.9533927,0.0003718705],"study_design_scores_gemma":[0.0011289633,0.001350328,0.00020997052,0.000045718425,0.0001940677,0.033330053,0.0002558878,0.000054632757,0.08618357,0.0017151354,0.8753731,0.00015857967],"about_ca_topic_score_codex":0.000010579379,"about_ca_topic_score_gemma":0.000012464064,"teacher_disagreement_score":0.07801962,"about_ca_system_score_codex":0.00034084378,"about_ca_system_score_gemma":0.0013001177,"threshold_uncertainty_score":0.9999134},"labels":[],"label_agreement":null},{"id":"W3072963690","doi":"10.1126/scitranslmed.aaz3866","title":"Functional effects of chimeric antigen receptor co-receptor signaling domains in human regulatory T cells","year":2020,"lang":"en","type":"article","venue":"Science Translational Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":144,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Chimeric antigen receptor; Receptor; Cell biology; Co-receptor; Signal transduction; Biology; Chemistry; Immunology; Immune system; T cell; Genetics","score_opus":0.03626150120858345,"score_gpt":0.32659367669072864,"score_spread":0.2903321754821452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3072963690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98952717,0.00043129342,0.00088110054,0.006055099,0.00029991652,0.00076777395,0.000013366318,0.000042463773,0.001981825],"genre_scores_gemma":[0.99725693,0.000039986156,0.0010080214,0.0006506886,0.0006277262,0.000016822507,0.000083196384,0.000022391738,0.00029423073],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9964649,0.00008494895,0.00051643554,0.000505495,0.00203672,0.00039146657],"domain_scores_gemma":[0.9987449,0.0003330164,0.00010779733,0.00021118596,0.00021267943,0.0003904329],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011245974,0.00018367686,0.00044819576,0.0004780303,0.00015813884,0.000008111216,0.000241432,0.00006297658,0.008315498],"category_scores_gemma":[0.00018313868,0.00015395504,0.00008841634,0.0018404615,0.0016864149,0.00017618676,0.000016899736,0.00033396378,0.00006576888],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000318104,0.00009812362,0.010942134,0.00018222039,0.000024790703,0.000007238505,0.0016499374,0.00016064048,0.98329073,0.00036555587,0.00071927893,0.0022412664],"study_design_scores_gemma":[0.005510471,0.0010626811,0.1386071,0.00043435048,0.000029773715,0.0000066660696,0.0002233002,0.00060743495,0.8496981,0.00014720159,0.0034756267,0.00019726736],"about_ca_topic_score_codex":0.000036965976,"about_ca_topic_score_gemma":0.0000025896766,"teacher_disagreement_score":0.13359258,"about_ca_system_score_codex":0.00009443194,"about_ca_system_score_gemma":0.0005301319,"threshold_uncertainty_score":0.992591},"labels":[],"label_agreement":null},{"id":"W3074819526","doi":"10.1158/1538-7445.am2020-6600","title":"Abstract 6600: Rapid generation of TCR-engineered T lymphocytes by linking the single cell transcriptome to its corresponding T cell receptor in antigen specific T cells","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"MD Precision (Canada)","funders":"","keywords":"T-cell receptor; Biology; clone (Java method); Transcriptome; CD8; T cell; Cytotoxic T cell; Molecular biology; Cell biology; Population; Cell; Antigen; Immunology; In vitro; Gene expression; Gene; Immune system; Genetics","score_opus":0.1487216237679269,"score_gpt":0.3563254740094948,"score_spread":0.2076038502415679,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3074819526","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98219144,0.010615277,0.00013587846,0.0028304001,0.00030831224,0.0017109565,0.00009941316,0.00003798154,0.0020703648],"genre_scores_gemma":[0.9895003,0.0061332383,0.00016981621,0.00025564746,0.0008012304,0.00013273959,0.000061831015,0.00009595055,0.0028492364],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99622774,0.00031536873,0.0005474984,0.00061627873,0.0014235023,0.00086963514],"domain_scores_gemma":[0.99821126,0.0004196791,0.00007030097,0.00045199474,0.0004288844,0.00041790484],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017142916,0.00023916234,0.00044538316,0.0004915319,0.00014951319,0.0001115748,0.0005399792,0.00016871227,0.0060101114],"category_scores_gemma":[0.00009678512,0.00020166354,0.00013297485,0.001966845,0.00012853158,0.00012728698,0.00009419277,0.00090837164,0.00020302644],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012424388,0.00017951154,0.00015422674,0.00033616376,0.00002272183,0.000022967404,0.004438683,0.00066827063,0.95968765,0.0000028537877,0.024261156,0.008983379],"study_design_scores_gemma":[0.0016702939,0.00048590865,0.00019356982,0.0001665615,0.000004600833,9.4119747e-7,0.0006058609,0.0006189385,0.89437574,0.0000014079244,0.10171214,0.00016404816],"about_ca_topic_score_codex":0.00018211146,"about_ca_topic_score_gemma":0.000019277992,"teacher_disagreement_score":0.077450976,"about_ca_system_score_codex":0.00081185484,"about_ca_system_score_gemma":0.00054096064,"threshold_uncertainty_score":0.99489856},"labels":[],"label_agreement":null},{"id":"W3075607378","doi":"10.3389/fimmu.2020.01850","title":"Thymic Engraftment by in vitro-Derived Progenitor T Cells in Young and Aged Mice","year":2020,"lang":"en","type":"review","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; University of Toronto","funders":"Medical Research Council; Canadian Institutes of Health Research; Ontario Institute for Regenerative Medicine; National Institutes of Health; Canada First Research Excellence Fund; National Heart, Lung, and Blood Institute; Krembil Foundation; University of Toronto","keywords":"Progenitor cell; Immunology; Biology; Stem cell; Immune system; Thymic involution; Bone marrow; Haematopoiesis; T cell; Cancer research; Cytotoxic T cell; Medicine; In vitro; Cell biology","score_opus":0.01808105124600049,"score_gpt":0.2942019284216223,"score_spread":0.2761208771756218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3075607378","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0042756004,0.99067605,0.000021053114,0.00013906044,0.0013817766,0.0032277394,0.00004195756,0.000031851105,0.0002049133],"genre_scores_gemma":[0.00020746395,0.99577177,0.0015020805,0.00004570324,0.00009646715,0.00064752944,0.00025743071,0.00010269173,0.0013688856],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964748,0.0008668378,0.0008841195,0.00080010825,0.0002287411,0.0007454207],"domain_scores_gemma":[0.9991008,0.00013791703,0.00018960169,0.0004448137,0.000023757975,0.00010309928],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00046015697,0.00051250885,0.002814894,0.00095246156,0.000028113696,0.000022571974,0.00036895205,0.00076117297,0.00010904449],"category_scores_gemma":[0.000095959535,0.000484511,0.00021685562,0.00075032125,0.0002921312,0.00004668402,0.00022175796,0.0020963706,0.00002588468],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010398269,0.0002817665,0.000417618,0.0036411262,0.00056057796,0.0006436247,0.00097483746,5.820901e-8,0.09805798,8.4256175e-7,0.0030951442,0.8912866],"study_design_scores_gemma":[0.0040864265,0.00034798475,0.00013823684,0.00249321,0.00017032711,0.00013851532,0.0004522066,0.000014148031,0.0045379507,0.00001561286,0.987174,0.00043143606],"about_ca_topic_score_codex":0.00032956846,"about_ca_topic_score_gemma":0.000067519686,"teacher_disagreement_score":0.9840788,"about_ca_system_score_codex":0.0013064381,"about_ca_system_score_gemma":0.00045264183,"threshold_uncertainty_score":0.9997606},"labels":[],"label_agreement":null},{"id":"W3081207055","doi":"10.1016/s2152-2650(20)30443-2","title":"How the COG is Approaching the High-Risk Patient with ALL: Incorporation of Immunotherapy into Frontline Treatment","year":2020,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"","keywords":"Blinatumomab; Medicine; Cog; Tolerability; Oncology; Chemotherapy; Immunotherapy; Internal medicine; Clinical trial; Refractory (planetary science); Calicheamicin; Intensive care medicine; Lymphoblastic Leukemia; Leukemia; Adverse effect; Cancer; Myeloid leukemia","score_opus":0.04984465424495905,"score_gpt":0.3120130129867003,"score_spread":0.26216835874174127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3081207055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9715738,0.0010168044,0.00086994586,0.02414306,0.000115883406,0.0018451889,0.000022431954,0.00007418823,0.00033863928],"genre_scores_gemma":[0.990299,0.0012253331,0.0019560233,0.0049233027,0.00057490484,0.00018778854,0.00007820357,0.00008249995,0.0006729743],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9967055,0.0006514505,0.0008782895,0.00059711427,0.0008017912,0.00036590596],"domain_scores_gemma":[0.9967909,0.0010386392,0.00059843645,0.0010656734,0.00024197971,0.00026438502],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070531026,0.00036208436,0.00077871786,0.000046302695,0.00022513368,0.00010649171,0.00041035892,0.00021665829,0.00025817082],"category_scores_gemma":[0.00029744243,0.00016929988,0.0003759632,0.0003772955,0.00063451624,0.00012074432,0.000120391305,0.0004252103,0.00004332057],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004558993,0.00036491765,0.014058528,0.000029629491,0.0010780051,0.000039621496,0.004214064,0.00003657826,0.0052243858,0.00013182554,0.0015741504,0.9686893],"study_design_scores_gemma":[0.03075338,0.029342012,0.7024807,0.00024036781,0.0011267128,0.0001463727,0.0041392073,0.024703786,0.034452524,0.0013497833,0.17041476,0.00085042685],"about_ca_topic_score_codex":0.0015837922,"about_ca_topic_score_gemma":0.000063942454,"teacher_disagreement_score":0.9678389,"about_ca_system_score_codex":0.0006541921,"about_ca_system_score_gemma":0.0008051614,"threshold_uncertainty_score":0.69038486},"labels":[],"label_agreement":null},{"id":"W3081590106","doi":"10.1158/1538-7445.am2020-ct162","title":"Abstract CT162: The phase 1b PORTIA study: Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL)","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Pembrolizumab; Adverse effect; Cohort; Internal medicine; Neutropenia; Refractory (planetary science); Clinical trial; Oncology; Cancer; Toxicity; Immunotherapy","score_opus":0.04802705472500542,"score_gpt":0.3721562432470194,"score_spread":0.324129188522014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3081590106","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99302036,0.0012249874,0.000004120096,0.0007866097,0.000043441632,0.003063335,0.00010082666,0.00002796629,0.001728344],"genre_scores_gemma":[0.9975155,0.00070195884,0.000006802879,0.00016185711,0.00014395014,0.00012275581,0.000039352497,0.00008920353,0.0012186317],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954651,0.0003936274,0.0005811591,0.0006898255,0.00196887,0.00090143754],"domain_scores_gemma":[0.9975781,0.0005382593,0.00014071654,0.00078009424,0.00045619844,0.0005066666],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013546534,0.00026858205,0.0006090986,0.00027649727,0.00020698215,0.00004907363,0.00043878207,0.00012768226,0.0014466109],"category_scores_gemma":[0.0003119912,0.00018305075,0.00008301752,0.0010455718,0.0004235027,0.00012912098,0.00030953292,0.0010847497,0.00003233962],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25656277,0.12273,0.3442613,0.0015384933,0.0008965229,0.0012469585,0.030131727,0.000027127104,0.06279632,0.00003403267,0.004952691,0.17482206],"study_design_scores_gemma":[0.30567247,0.005787075,0.6713499,0.00017178108,0.000056448054,0.000003147897,0.001548035,0.00012954383,0.0029847727,0.0000033264548,0.012055681,0.0002378541],"about_ca_topic_score_codex":0.0010218493,"about_ca_topic_score_gemma":0.00028310576,"teacher_disagreement_score":0.3270886,"about_ca_system_score_codex":0.00063306605,"about_ca_system_score_gemma":0.0011789206,"threshold_uncertainty_score":0.9994662},"labels":[],"label_agreement":null},{"id":"W3082159235","doi":"10.1158/2326-6074.tumimm18-b60","title":"Abstract B60: Functional genomic landscape of T-cell mediated cytotoxicity","year":2020,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Biology; CTL*; Cancer immunotherapy; Immunotherapy; CRISPR; Cytotoxic T cell; Computational biology; Gene; Cancer; Genetics","score_opus":0.10345025057284551,"score_gpt":0.3694555785910577,"score_spread":0.2660053280182122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3082159235","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97307646,0.0056022303,0.000011379413,0.0047867787,0.00012715757,0.00062712864,0.00005991843,0.00005513957,0.01565379],"genre_scores_gemma":[0.99350893,0.0024182273,0.000033438886,0.00031027917,0.00038445144,0.00012150475,0.00008066943,0.00004669592,0.0030958226],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99742335,0.00021656757,0.00037938135,0.0004679372,0.00079822494,0.0007145343],"domain_scores_gemma":[0.99802846,0.0005264223,0.000075767995,0.0004403369,0.00066742965,0.00026159934],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00087514566,0.0001625846,0.0004612372,0.00032364728,0.000122063,0.00001528258,0.00035474778,0.00026893665,0.039933015],"category_scores_gemma":[0.00036220177,0.00014718615,0.00013770218,0.0008296846,0.000692728,0.000058196387,0.00024656855,0.0015645832,0.0006415206],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004118865,0.00017432345,0.02253158,0.00017742407,0.0002722804,0.000056652712,0.0003405338,0.00001198814,0.9631587,0.000026042851,0.007187906,0.001943679],"study_design_scores_gemma":[0.0057674088,0.0012451957,0.3936466,0.000057605663,0.00002764883,0.000027629565,0.00048225236,0.00028272855,0.57767004,0.000058043388,0.020535583,0.00019926917],"about_ca_topic_score_codex":0.00029805585,"about_ca_topic_score_gemma":0.000023626775,"teacher_disagreement_score":0.3854887,"about_ca_system_score_codex":0.00024607507,"about_ca_system_score_gemma":0.0013003921,"threshold_uncertainty_score":0.9609446},"labels":[],"label_agreement":null},{"id":"W3083070660","doi":"10.1158/1538-7445.am2020-ct147","title":"Abstract CT147: Phase 1 dose escalation of MSC-1, a humanized anti-LIF monoclonal antibody, in patients with advanced solid tumors","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Neutropenia; Internal medicine; Tumor microenvironment; Adverse effect; Oncology; Radioimmunotherapy; Cancer; Monoclonal antibody; Antibody; Immunology; Toxicity","score_opus":0.08106162704801605,"score_gpt":0.45675539334713555,"score_spread":0.3756937662991195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083070660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962676,0.00023828872,0.000015622054,0.00084455527,0.00003208244,0.0016992748,0.000060715123,0.000033097724,0.0008087694],"genre_scores_gemma":[0.99888426,0.00020495665,0.00013019622,0.00008561066,0.00015534874,0.000107114756,0.00015015945,0.000064330285,0.00021802842],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.996366,0.00014364898,0.0004885295,0.00054230663,0.001757289,0.00070217665],"domain_scores_gemma":[0.99814737,0.00015365762,0.00010942733,0.00038663443,0.00082698,0.00037594722],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00068718824,0.0001963804,0.0005753187,0.0004148662,0.00008688198,0.000031985324,0.00026354883,0.000096450894,0.0034660168],"category_scores_gemma":[0.0002471336,0.00016537591,0.000082427265,0.001300017,0.00032395057,0.00019770986,0.00011727389,0.00093834574,0.00003379328],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016419305,0.0010262763,0.14875111,0.00043002752,0.00008792774,0.00009633386,0.0008655145,0.00013433454,0.8071239,0.000016689532,0.00024381673,0.024804758],"study_design_scores_gemma":[0.036132555,0.0038272033,0.7899482,0.0007540844,0.000019760211,0.000002284125,0.00025619369,0.00095344003,0.16669658,0.000030086796,0.0011006185,0.0002790042],"about_ca_topic_score_codex":0.00038759547,"about_ca_topic_score_gemma":0.000053993324,"teacher_disagreement_score":0.6411971,"about_ca_system_score_codex":0.00033063683,"about_ca_system_score_gemma":0.0007785924,"threshold_uncertainty_score":0.9974449},"labels":[],"label_agreement":null},{"id":"W3083401631","doi":"10.1158/1538-7445.am2020-3233","title":"Abstract 3233: Reduced inflammatory cytokine production by CAR-modified Th1/Tc1-polarized T-Rapa cells is not sufficient to reduce monocyte-driven production of IL-6","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Cytokine; Immunology; Biology; Chimeric antigen receptor; T cell; Interleukin 12; Interleukin 21; Cancer research; Cytotoxic T cell; Immune system; In vitro","score_opus":0.10256261673285785,"score_gpt":0.3899393690030996,"score_spread":0.28737675227024173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3083401631","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95359135,0.00041826445,0.000015201423,0.04016238,0.0005880656,0.0040705386,0.00010889667,0.000121053075,0.0009242425],"genre_scores_gemma":[0.98813915,0.00078011333,0.00011613798,0.00043673927,0.0016577278,0.0005648031,0.000053196665,0.00013170006,0.008120438],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9938073,0.0003547822,0.00083250954,0.0014713204,0.0024259135,0.001108146],"domain_scores_gemma":[0.99534935,0.00011991313,0.00019582175,0.001231406,0.002276354,0.00082713016],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002024559,0.00036407844,0.0007376212,0.0006260842,0.0002587648,0.000079848425,0.00051784894,0.00024715494,0.0010994859],"category_scores_gemma":[0.0010784132,0.00034891133,0.0002124655,0.002004544,0.0004591732,0.00022179961,0.0002729085,0.0015775876,0.00015977472],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008158417,0.00031667363,0.00015232437,0.00076747034,0.0001696407,0.000021208745,0.0042620623,0.00038128797,0.89617634,0.000010161648,0.08519019,0.0043942393],"study_design_scores_gemma":[0.0017024161,0.00078602805,0.0013695862,0.0002482268,0.000039034112,0.000008645474,0.0007520408,0.00017892105,0.9557223,0.000008706761,0.038902298,0.0002818076],"about_ca_topic_score_codex":0.0009994173,"about_ca_topic_score_gemma":0.000027774477,"teacher_disagreement_score":0.059545964,"about_ca_system_score_codex":0.0011414398,"about_ca_system_score_gemma":0.0014123799,"threshold_uncertainty_score":0.9998963},"labels":[],"label_agreement":null},{"id":"W3087314845","doi":"10.1097/moh.0000000000000614","title":"Advances in chimeric antigen receptor T cells","year":2020,"lang":"en","type":"review","venue":"Current Opinion in Hematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Chimeric antigen receptor; Medicine; Lymphoma; Clinical trial; Oncology; Immunology; Internal medicine; Immunotherapy; Cancer","score_opus":0.13340152786659926,"score_gpt":0.46622023946035557,"score_spread":0.3328187115937563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087314845","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000047514877,0.9905809,0.000018872657,0.00015761764,0.0065385257,0.0019372513,0.000024610268,0.00004865764,0.00068878324],"genre_scores_gemma":[0.0000022109587,0.9983844,0.00010220347,0.000011314091,0.00058722426,0.00037162539,0.00038291936,0.00007623821,0.00008187487],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966577,0.00046425313,0.0011436485,0.0008070937,0.00032713375,0.0006001693],"domain_scores_gemma":[0.998593,0.00038139414,0.00029929818,0.00047962574,0.000042484997,0.00020424185],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00028472277,0.00047270503,0.003233888,0.0007777513,0.000022267026,0.0000116056935,0.00035942538,0.00039830944,0.00240956],"category_scores_gemma":[0.00015462906,0.00040729827,0.0003880495,0.0013047393,0.0001511705,0.00006710041,0.0001761917,0.0014672732,0.00085547793],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004735302,0.00020448823,0.00038816643,0.053450435,0.000025085448,0.000022509308,0.00007939781,1.442452e-7,0.0000050424237,0.00022997776,0.0019544088,0.94359297],"study_design_scores_gemma":[0.0006928928,0.00013255657,0.000006529777,0.027587716,0.00002404478,0.00017683615,0.00001765711,0.000011503698,0.000014423136,0.000031767926,0.9710161,0.00028799247],"about_ca_topic_score_codex":0.0000062387803,"about_ca_topic_score_gemma":0.0000025163497,"teacher_disagreement_score":0.9690617,"about_ca_system_score_codex":0.00025678548,"about_ca_system_score_gemma":0.00060667563,"threshold_uncertainty_score":0.99992245},"labels":[],"label_agreement":null},{"id":"W3088012427","doi":"10.1016/j.annonc.2020.08.1206","title":"1082MO 5-year characterization of complete responses in patients with advanced melanoma who received nivolumab plus ipilimumab (NIVO+IPI) or NIVO alone","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Ipilimumab; Nivolumab; Internal medicine; Regimen; Oncology; Cancer; Immunotherapy","score_opus":0.08697317739299981,"score_gpt":0.3589568587274751,"score_spread":0.2719836813344753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088012427","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99265176,0.000042861866,0.000024192494,0.0046711494,0.00005260025,0.0010064405,0.000110601046,0.000026072677,0.0014143392],"genre_scores_gemma":[0.9965532,0.00032914052,0.00036009905,0.0011124727,0.00006684042,0.00003052829,0.00019420944,0.000044074754,0.0013094797],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99786353,0.00035841836,0.00059481116,0.000367069,0.0004438512,0.00037229861],"domain_scores_gemma":[0.9982285,0.00029286914,0.00034937492,0.00033744963,0.0006177713,0.00017401877],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00030747193,0.00018716611,0.0009767519,0.0002635883,0.00003089221,0.000004820774,0.00019546687,0.00016837382,0.0012705316],"category_scores_gemma":[0.00041569403,0.00015573045,0.00007875808,0.00059365656,0.00023925558,0.00012665564,0.00008448691,0.00026974073,0.000018232473],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32738793,0.0013024717,0.09232768,0.00040988266,0.0003190831,0.00015292129,0.0031880843,0.000027072576,0.495423,0.00003349687,0.00062963745,0.07879876],"study_design_scores_gemma":[0.03897931,0.048407204,0.8226659,0.0003391322,0.000053006148,0.000012510274,0.00032547358,0.00030904618,0.05185803,0.000015841948,0.036750652,0.0002838334],"about_ca_topic_score_codex":0.00006732077,"about_ca_topic_score_gemma":0.00009352853,"teacher_disagreement_score":0.7303383,"about_ca_system_score_codex":0.000118281154,"about_ca_system_score_gemma":0.0005994695,"threshold_uncertainty_score":0.99964243},"labels":[],"label_agreement":null},{"id":"W3088510493","doi":"10.1016/j.annonc.2020.08.638","title":"524O Initial results of a phase I study of MK-4830, a first-in-class anti–immunoglobulin-like transcript 4 (ILT4) myeloid-specific antibody in patients (pts) with advanced solid tumours","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa; Princess Margaret Cancer Centre; University of Toronto","funders":"Merck Sharp and Dohme","keywords":"Medicine; Tolerability; Internal medicine; Neutropenia; Phases of clinical research; Pharmacokinetics; Pharmacology; Pharmacodynamics; Pembrolizumab; Oncology; Adverse effect; Clinical trial; Cancer; Immunotherapy; Chemotherapy","score_opus":0.08599711741859951,"score_gpt":0.4161967174254941,"score_spread":0.3301996000068946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3088510493","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935069,0.00033173012,0.00000992389,0.0022096804,0.00014156164,0.002071053,0.0001824599,0.000018154446,0.0015285108],"genre_scores_gemma":[0.99850357,0.0007460978,0.00010802098,0.0003532532,0.000059685673,0.000038651953,0.00009504118,0.00004714064,0.00004851363],"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9961647,0.00038630908,0.0014953889,0.0005912537,0.0007672923,0.0005950512],"domain_scores_gemma":[0.9977654,0.00030616287,0.0005266995,0.00052589714,0.0006704228,0.00020539855],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00071229466,0.0003002896,0.001661068,0.0005119642,0.000030825908,0.000004332776,0.00037499532,0.00019549306,0.00018838674],"category_scores_gemma":[0.00023492162,0.00027115623,0.00015421855,0.0011501629,0.0003679899,0.00013329742,0.00008423851,0.00056256395,0.00000535284],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.28832024,0.059528038,0.09968521,0.0007350449,0.00072803,0.0015385377,0.041239977,0.00062984106,0.4230559,0.000015845662,0.0017688103,0.082754515],"study_design_scores_gemma":[0.2654405,0.30556706,0.28131446,0.00087271805,0.00015483747,0.000028891036,0.0105537195,0.00035349937,0.106360555,0.000023741646,0.028699957,0.0006300669],"about_ca_topic_score_codex":0.00031781354,"about_ca_topic_score_gemma":0.00044969254,"teacher_disagreement_score":0.31669533,"about_ca_system_score_codex":0.00008953438,"about_ca_system_score_gemma":0.00042844814,"threshold_uncertainty_score":0.9999741},"labels":[],"label_agreement":null},{"id":"W3089028786","doi":"10.18632/aging.104058","title":"A comprehensive analysis of the fatal toxic effects associated with CD19 CAR-T cell therapy","year":2020,"lang":"en","type":"article","venue":"Aging","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Cytokine release syndrome; Clinical trial; CD19; Adverse effect; Chimeric antigen receptor; Pharmacovigilance; Incidence (geometry); CAR T-cell therapy; Cause of death; Internal medicine; Mortality rate; Immunology; Immunotherapy; Antigen; Disease; Cancer","score_opus":0.028867188077289684,"score_gpt":0.2903957712011006,"score_spread":0.26152858312381094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089028786","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969211,0.00046522295,0.000051055875,0.0010429599,0.000025159203,0.00043166624,0.000007387517,0.000036890815,0.0010185257],"genre_scores_gemma":[0.9978644,0.000042863023,0.000027251253,0.0014434425,0.00004233491,0.000008922627,0.000019935665,0.000023353645,0.00052749785],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99880695,0.00014848719,0.00013974925,0.00021806124,0.00046163634,0.00022513601],"domain_scores_gemma":[0.9990521,0.00033002262,0.00008644695,0.0002981377,0.00013433785,0.00009892362],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009769874,0.00012275796,0.000412152,0.00010111562,0.0000569087,0.000013876076,0.00014786288,0.00004283666,0.00024491423],"category_scores_gemma":[0.000051082945,0.00007511241,0.00021339743,0.0015724782,0.00008389664,0.000027320622,0.000056122946,0.00025274456,0.000004472009],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022360937,0.000080802805,0.09486399,0.00006582948,0.0023386695,0.000047452028,0.003311253,0.00018205773,0.89632446,0.0000030932015,0.00014011134,0.0024186776],"study_design_scores_gemma":[0.004767899,0.0007643812,0.37839305,0.00014120416,0.0012791691,0.0000039034394,0.00071830145,0.006728495,0.60552704,0.000004604407,0.0014763698,0.00019556133],"about_ca_topic_score_codex":0.0001386876,"about_ca_topic_score_gemma":0.00002463468,"teacher_disagreement_score":0.29079738,"about_ca_system_score_codex":0.00005808702,"about_ca_system_score_gemma":0.0000708802,"threshold_uncertainty_score":0.30629954},"labels":[],"label_agreement":null},{"id":"W3090525098","doi":"10.1136/jitc-2020-001180","title":"Regulation of tumor growth by leukocyte-specific protein 1 in T cells","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Ministry of Education, Science and Technology; National Research Foundation of Korea; National Research Foundation","keywords":"Cancer research; Immunology; Computational biology; Biology; Medicine","score_opus":0.032812834537790075,"score_gpt":0.32360810513992944,"score_spread":0.2907952706021394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3090525098","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98268056,0.011456573,0.00061815983,0.0034755466,0.00016965238,0.0012585275,0.000028506105,0.000010430712,0.00030204552],"genre_scores_gemma":[0.9890655,0.004964843,0.0014739351,0.00047420955,0.0004103234,0.0000892391,0.00000661598,0.000078675235,0.0034366052],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984567,0.00005505122,0.00061747787,0.00015493503,0.0004829435,0.00023288414],"domain_scores_gemma":[0.9990304,0.000053298438,0.0003482656,0.00014637219,0.0003289628,0.000092668604],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00040418355,0.00013017011,0.00045543362,0.00014679099,0.000035955327,0.000014719186,0.00015985109,0.00006426116,0.0027987822],"category_scores_gemma":[0.000024412939,0.00011100636,0.00021716642,0.00031011985,0.00008546861,0.00010268284,0.000009863174,0.0003047363,0.0000016816625],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008666336,0.000108789245,0.0006449843,0.0001686914,0.00011036724,0.000002976994,0.0006139434,0.000028356653,0.95654386,0.000038916176,0.005809942,0.027262837],"study_design_scores_gemma":[0.005977863,0.0010854444,0.0020129692,0.00024078296,0.00000954138,0.000008201256,0.00008050973,0.00017200995,0.88406676,0.00020761593,0.10604733,0.00009095239],"about_ca_topic_score_codex":0.000081344486,"about_ca_topic_score_gemma":0.0000053348767,"teacher_disagreement_score":0.10023739,"about_ca_system_score_codex":0.00022046853,"about_ca_system_score_gemma":0.0002523905,"threshold_uncertainty_score":0.9981128},"labels":[],"label_agreement":null},{"id":"W3091048385","doi":"10.3390/ijms21197222","title":"Modular Chimeric Antigen Receptor Systems for Universal CAR T Cell Retargeting","year":2020,"lang":"en","type":"review","venue":"International Journal of Molecular Sciences","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"Western Economic Diversification Canada","keywords":"Chimeric antigen receptor; Modular design; Antigen; Cancer immunotherapy; T cell; Immunotherapy; Computer science; Retargeting; Biology; Cell biology; Immune system; Immunology; Artificial intelligence","score_opus":0.054215576442851354,"score_gpt":0.37178662607069096,"score_spread":0.3175710496278396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3091048385","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000547408,0.99274176,0.002381316,0.0003290624,0.0018612575,0.0006736324,0.000033865843,0.000010713904,0.0014210044],"genre_scores_gemma":[0.00040558795,0.99515826,0.0024931447,0.000069034264,0.0011300873,0.000011063747,0.000024658219,0.00003887398,0.0006692689],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966403,0.00022615341,0.00082099804,0.00033498506,0.0016933562,0.00028416901],"domain_scores_gemma":[0.99757254,0.00020193605,0.0010002435,0.00013895225,0.00087196636,0.00021433138],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001255286,0.00024640452,0.0011041078,0.0005717649,0.00009301875,0.00012523984,0.0011637289,0.00013848001,0.00018437562],"category_scores_gemma":[0.00026351822,0.00018590082,0.00086383603,0.00044227034,0.00017928712,0.00012813878,0.000117853095,0.0005096184,0.00002180892],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032038352,0.00019924014,0.000072809096,0.0060507655,0.0032973601,0.002565192,0.00045135827,0.00045033495,0.043597374,0.00046071393,0.0021181281,0.94041634],"study_design_scores_gemma":[0.0005249618,0.00049594167,0.0000010321443,0.004151223,0.00024275768,0.00044405885,0.00016270495,0.0004856074,0.000366922,0.000010629018,0.99295485,0.00015932875],"about_ca_topic_score_codex":0.000018080762,"about_ca_topic_score_gemma":1.3046261e-7,"teacher_disagreement_score":0.9908367,"about_ca_system_score_codex":0.0003765115,"about_ca_system_score_gemma":0.0018248309,"threshold_uncertainty_score":0.75808156},"labels":[],"label_agreement":null},{"id":"W3091049434","doi":"10.1016/j.cellimm.2020.104220","title":"Building a CAR-Treg: Going from the basic to the luxury model","year":2020,"lang":"en","type":"review","venue":"Cellular Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"Canadian Institutes of Health Research; University of British Columbia; BC Children's Hospital; Health Research","keywords":"Chimeric antigen receptor; Biology; Context (archaeology); Immunology; Autoimmunity; Immune system; Transplantation; Cell therapy; Function (biology); T cell; Stem cell; Cell biology; Medicine","score_opus":0.0708255561848193,"score_gpt":0.3463474842095065,"score_spread":0.2755219280246872,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3091049434","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016186545,0.9873311,0.0020074658,0.005836422,0.00062794995,0.002461193,0.00007004437,0.00011004387,0.001393914],"genre_scores_gemma":[0.000067628636,0.98782253,0.0005732181,0.0010342123,0.001178043,0.000370188,0.00019509686,0.00021912373,0.008539932],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962134,0.00080491777,0.0007423349,0.0009258459,0.0004837874,0.0008297503],"domain_scores_gemma":[0.9961641,0.0011080208,0.00023340789,0.0022325055,0.000085563224,0.00017640913],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00068507454,0.00064625894,0.0021911298,0.00018004453,0.00029492239,0.00008386975,0.0016184573,0.0006004454,0.0011968812],"category_scores_gemma":[0.00038471897,0.00036034992,0.0010007017,0.0007836323,0.00028372282,0.000033395896,0.0009919825,0.0025953855,0.0015193821],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009980745,0.000036240912,0.0000014862962,0.00082184357,0.0013782745,0.00024281845,0.0006303709,0.000011107167,0.008615305,0.0004336809,0.004450725,0.98327833],"study_design_scores_gemma":[0.00041825196,0.00014160907,0.0000011256844,0.0026996506,0.0011177284,0.00014667785,0.00007693307,0.0006008344,0.00028984144,0.00013372976,0.99406016,0.00031348714],"about_ca_topic_score_codex":0.0001768765,"about_ca_topic_score_gemma":0.000021288926,"teacher_disagreement_score":0.9896094,"about_ca_system_score_codex":0.00047057393,"about_ca_system_score_gemma":0.0010118682,"threshold_uncertainty_score":0.99988484},"labels":[],"label_agreement":null},{"id":"W3091908596","doi":"10.1016/j.xpro.2020.100124","title":"Assessing the Safety of a Cell-Based Immunotherapy for Brain Cancers Using a Humanized Model of Hematopoiesis","year":2020,"lang":"en","type":"article","venue":"STAR Protocols","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto; McMaster University","funders":"Canadian Institutes of Health Research; Terry Fox Research Institute; Ontario Institute for Cancer Research","keywords":"Immunotherapy; Haematopoiesis; Medicine; Toxicity; Cancer research; Bioinformatics; Computational biology; Immunology; Stem cell; Biology; Immune system; Internal medicine","score_opus":0.14491704303306321,"score_gpt":0.4368326941525873,"score_spread":0.2919156511195241,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3091908596","genre_codex":"protocol","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.36715108,0.00010452643,0.20679735,0.0059536607,0.000023568376,0.41833556,0.0001814057,0.00009544386,0.0013574215],"genre_scores_gemma":[0.8026993,0.00000483126,0.07925739,0.002820117,0.0001830268,0.114388674,0.000023082493,0.0002081101,0.00041546635],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984322,0.00013123915,0.0004860162,0.00023084352,0.00045015087,0.0002695099],"domain_scores_gemma":[0.99870634,0.00027885716,0.00026224682,0.00040770063,0.000269996,0.00007484263],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079436833,0.00015519363,0.00051523757,0.00006452755,0.00010730096,0.000027031085,0.0002169754,0.00007052584,0.000389273],"category_scores_gemma":[0.00012263938,0.0001134008,0.00024389951,0.0002828383,0.00016772602,0.000072932846,0.00003317673,0.00017316622,4.339755e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045402115,0.00008726032,0.000103547194,0.0017009571,0.00008996617,0.0000010792859,0.0018399793,0.0021877687,0.987811,0.000058719404,0.000118418786,0.0014610781],"study_design_scores_gemma":[0.009119343,0.00069055264,0.0000417378,0.00046590302,0.000031088268,9.2271944e-7,0.00068236317,0.29148147,0.6957133,0.00017822662,0.0014744943,0.00012062243],"about_ca_topic_score_codex":0.00009187607,"about_ca_topic_score_gemma":0.000005751239,"teacher_disagreement_score":0.43554822,"about_ca_system_score_codex":0.00019380824,"about_ca_system_score_gemma":0.0013536988,"threshold_uncertainty_score":0.46243504},"labels":[],"label_agreement":null},{"id":"W3094515317","doi":"10.1002/ijc.33357","title":"Real‐world, population‐based cohort study of toxicity and resource utilization of second‐line ipilimumab for metastatic melanoma in Ontario, Canada","year":2020,"lang":"en","type":"article","venue":"International Journal of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian Agency for Drugs and Technologies in Health; Sunnybrook Health Science Centre; St. Michael's Hospital; Health Sciences Centre; Canadian Centre for Applied Research in Cancer Control; Institute for Clinical Evaluative Sciences; Queen's University; Cancer Care Ontario; University of Toronto","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Ontario Ministry of Health and Long-Term Care; Ontario Institute for Cancer Research; Cancer Care Ontario","keywords":"Ipilimumab; Medicine; Internal medicine; Population; Cohort; Odds ratio; Surgery; Cancer; Immunotherapy","score_opus":0.0578104382998427,"score_gpt":0.3695072463203986,"score_spread":0.3116968080205559,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094515317","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99793655,0.00011746037,0.00011883257,0.0010076907,0.00010339715,0.00046767737,0.000045805587,0.0000015178758,0.0002010932],"genre_scores_gemma":[0.99901676,0.0000188475,0.00020149528,0.00023827187,0.00008548766,0.000011176688,0.00002366217,0.00001121406,0.0003930819],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998369,0.000056783443,0.00062961166,0.00010995605,0.00075232843,0.00008233969],"domain_scores_gemma":[0.99864143,0.0001647641,0.0004012309,0.000069788955,0.00063937285,0.00008342605],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003210941,0.0000770397,0.00035704288,0.00021799727,0.000010790002,0.0000068303407,0.00012038866,0.000017493048,0.0015551457],"category_scores_gemma":[0.000118297525,0.00006845598,0.000051794716,0.0001504562,0.000018746205,0.000059804093,0.000019725645,0.00015440074,2.997588e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004196302,0.0002734259,0.98320466,0.00006507962,0.00053368224,0.000029607738,0.00058444706,0.0021995297,0.0058493717,0.000017937933,0.0003286293,0.0027173476],"study_design_scores_gemma":[0.007694152,0.0008688474,0.9795765,0.00012671149,0.000118368655,0.0000073406145,0.00026973526,0.0030092732,0.0059676063,0.00003591984,0.0022680461,0.00005746181],"about_ca_topic_score_codex":0.6592316,"about_ca_topic_score_gemma":0.9823197,"teacher_disagreement_score":0.32308814,"about_ca_system_score_codex":0.0007139771,"about_ca_system_score_gemma":0.0011322794,"threshold_uncertainty_score":0.9993576},"labels":[],"label_agreement":null},{"id":"W3094639681","doi":"10.1182/blood-2020-134319","title":"Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma: Analyses of High-Risk Subgroups in the KarMMa Study","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Multiple myeloma; Medicine; Internal medicine; Refractory (planetary science); Pomalidomide; Lenalidomide; Oncology; Hematologic Neoplasms; Transplantation; Biology","score_opus":0.056192869041160075,"score_gpt":0.3303340735496066,"score_spread":0.27414120450844653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094639681","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99665946,0.0012619765,0.0000038296444,0.0005871354,0.000024893432,0.001088078,0.000014104247,0.000027161173,0.00033334858],"genre_scores_gemma":[0.9990231,0.00030363488,0.00014242725,0.00023058956,0.000108140564,0.00005284266,0.000010614062,0.00003451503,0.00009414066],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975812,0.0005399736,0.00053385034,0.00043263505,0.00060108054,0.00031125627],"domain_scores_gemma":[0.9984859,0.000649729,0.00013063266,0.0005175635,0.00007703422,0.00013913252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010155574,0.00019255835,0.0005546679,0.00023922951,0.000045760633,0.00002028319,0.0002475028,0.00009848933,0.0001811041],"category_scores_gemma":[0.0007623461,0.00014009832,0.00007980078,0.00093034713,0.00010330318,0.00006002015,0.00011668594,0.00059731887,0.00001098777],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009410532,0.002818398,0.62968045,0.00007157971,0.00019350162,0.00041347434,0.0074128658,0.0000139409285,0.3553771,0.0000034822726,0.00006323954,0.0030108988],"study_design_scores_gemma":[0.02138581,0.002326088,0.9143828,0.000044895663,0.00025940334,0.000014566152,0.0042631743,0.00023210839,0.05670284,0.00003480707,0.00019934439,0.00015413885],"about_ca_topic_score_codex":0.0031855456,"about_ca_topic_score_gemma":0.0015164273,"teacher_disagreement_score":0.2986743,"about_ca_system_score_codex":0.00003418799,"about_ca_system_score_gemma":0.00008161966,"threshold_uncertainty_score":0.5713043},"labels":[],"label_agreement":null},{"id":"W3094642003","doi":"10.1182/blood-2020-136255","title":"Single-Agent Mosunetuzumab Is a Promising Safe and Efficacious Chemotherapy-Free Regimen for Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Chemotherapy regimen; Diffuse large B-cell lymphoma; Chemotherapy; Regimen; Lymphoma; Internal medicine; Surgery; Oncology","score_opus":0.015391288486337012,"score_gpt":0.2378056077934872,"score_spread":0.2224143193071502,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094642003","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924176,0.00071548193,0.00012876632,0.001793668,0.000020569354,0.003598811,0.00008749262,0.00014948327,0.0010881609],"genre_scores_gemma":[0.99315816,0.000116254,0.0018421898,0.0015064004,0.00016581679,0.00013485855,0.00011827577,0.00017249065,0.002785532],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99764806,0.0000565884,0.0003451705,0.00070010463,0.0005576496,0.00069241005],"domain_scores_gemma":[0.99840677,0.00010214254,0.00014409685,0.00066778954,0.00021386072,0.00046534068],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014448103,0.00036410856,0.0005655447,0.00008899887,0.00014390817,0.000086391825,0.00022440651,0.000156349,0.00024974154],"category_scores_gemma":[0.0000982392,0.00029232923,0.00012272433,0.0003039947,0.00008302175,0.00007143825,0.000103912724,0.00015012118,0.000013321012],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06348469,0.119867206,0.11247887,0.0060636867,0.0057888073,0.0006717917,0.0466918,0.0000031336956,0.29802394,0.000050330018,0.018104885,0.32877085],"study_design_scores_gemma":[0.6581965,0.029398853,0.008486749,0.00066891353,0.0015448963,0.00010185307,0.00031936207,0.0008462043,0.22899468,0.00008230501,0.07013742,0.0012222729],"about_ca_topic_score_codex":0.000026072585,"about_ca_topic_score_gemma":0.000010513991,"teacher_disagreement_score":0.5947118,"about_ca_system_score_codex":0.000118477146,"about_ca_system_score_gemma":0.00014795865,"threshold_uncertainty_score":0.9999529},"labels":[],"label_agreement":null},{"id":"W3094679970","doi":"10.1182/blood-2020-137650","title":"Cite-Seq Profiling of T Cells in Multiple Myeloma Patients Undergoing BCMA Targeting CAR-T or Bites Immunotherapy","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Bone marrow; T cell; Immunology; CD8; Immune system; Immunotherapy; Antigen; Peripheral blood mononuclear cell; Cell therapy; Medicine; CD19; Biology; Cell","score_opus":0.030619094088624794,"score_gpt":0.27625283518110105,"score_spread":0.24563374109247627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094679970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99759996,0.00050522364,0.00003836365,0.00019064336,0.00006522936,0.00086807896,0.000018845225,0.00005962143,0.00065401715],"genre_scores_gemma":[0.9947307,0.00022174136,0.004199731,0.0002581651,0.00015359587,0.000027112126,0.000041229527,0.00006880064,0.00029890842],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981656,0.000097181735,0.000514744,0.00034805146,0.00046491806,0.00040951316],"domain_scores_gemma":[0.9988988,0.00044040685,0.00013361189,0.00024582367,0.00014348135,0.00013784721],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026222595,0.00018835986,0.00044217007,0.00016645071,0.00005079592,0.00001934613,0.00016739358,0.00010590665,0.0006241723],"category_scores_gemma":[0.0005472267,0.00015902088,0.000119986515,0.00058756146,0.000058975194,0.00007590952,0.00007987496,0.00030986915,0.000022244249],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00074277935,0.00044201917,0.3157526,0.00027231424,0.000086440596,0.000034862995,0.0012208663,0.000021897422,0.6786628,0.0000027723715,0.000029788835,0.0027309156],"study_design_scores_gemma":[0.013656679,0.0011131325,0.014609064,0.0002155338,0.000030945914,0.0000026775583,0.0005450856,0.0008831884,0.9682386,0.000010281361,0.0005082057,0.00018661025],"about_ca_topic_score_codex":0.000080494254,"about_ca_topic_score_gemma":0.000029860725,"teacher_disagreement_score":0.30114353,"about_ca_system_score_codex":0.000051772404,"about_ca_system_score_gemma":0.00020411267,"threshold_uncertainty_score":0.6834249},"labels":[],"label_agreement":null},{"id":"W3094684455","doi":"10.1038/s42003-020-01362-w","title":"De novo necroptosis creates an inflammatory environment mediating tumor susceptibility to immune checkpoint inhibitors","year":2020,"lang":"en","type":"article","venue":"Communications Biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster University Medical Centre; University of Guelph","funders":"National Cancer Institute; Canadian Cancer Society Research Institute; McMaster University","keywords":"Oncolytic virus; Necroptosis; Cancer research; Medicine; Melanoma; Cytotoxic T cell; Immune system; Immunotherapy; Breast cancer; Cancer; Immune checkpoint; Proinflammatory cytokine; Immunology; Inflammation; Biology; Apoptosis; Programmed cell death; Internal medicine","score_opus":0.05195242251619331,"score_gpt":0.33456894772452134,"score_spread":0.28261652520832803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094684455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97928995,0.00063993235,0.00016337747,0.017876402,0.000025628213,0.0006725992,0.000018819605,0.00010730616,0.0012059573],"genre_scores_gemma":[0.98927176,0.00035770473,0.008613705,0.0011240054,0.00014137609,0.00017768632,0.00019972752,0.000031302887,0.0000827616],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99819636,0.00048608065,0.00050682225,0.00033324267,0.00011840471,0.00035910975],"domain_scores_gemma":[0.99705696,0.00030081067,0.0000989153,0.0020436388,0.00007849542,0.0004211643],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00076003367,0.00016039984,0.000327273,0.00009704138,0.00020240633,0.000020553143,0.00074722175,0.00011275042,0.0014059299],"category_scores_gemma":[0.0006905029,0.0001516119,0.00011151283,0.0002225006,0.00044208163,0.000051853985,0.00085102307,0.00047837058,0.00019295515],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012093955,0.00017057064,0.11755641,0.000022643466,0.00004354746,0.000002371714,0.0027267039,0.00000966878,0.8710225,0.00011301612,0.000021462027,0.008190148],"study_design_scores_gemma":[0.0031817397,0.0036958712,0.21656357,0.000090861155,0.00013915227,0.00007255958,0.0045819306,0.0040089814,0.6411115,0.000597966,0.1251982,0.00075763615],"about_ca_topic_score_codex":0.00016890226,"about_ca_topic_score_gemma":0.000044176944,"teacher_disagreement_score":0.229911,"about_ca_system_score_codex":0.00028610515,"about_ca_system_score_gemma":0.00016343054,"threshold_uncertainty_score":0.9995069},"labels":[],"label_agreement":null},{"id":"W3094831999","doi":"10.1182/blood-2020-141126","title":"<i>TRAF3</i> Loss Drives Alternative NF-κB Pathway Activation in Diffuse Large B-Cell Lymphoma","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute; Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Diffuse large B-cell lymphoma; Cancer research; Germinal center; Biology; Vincristine; BCL6; B cell; Lymphoma; Immunology; Cyclophosphamide; Genetics","score_opus":0.021239539836986662,"score_gpt":0.27185099652879907,"score_spread":0.2506114566918124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094831999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98953336,0.0001290064,0.0001717733,0.0014867341,0.000047432623,0.000513239,0.000021517948,0.00007557915,0.00802138],"genre_scores_gemma":[0.99647826,0.000121852376,0.00010811234,0.0013749641,0.00037336507,0.000038401526,0.000043213964,0.00004589048,0.0014159319],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984524,0.00009410313,0.00023697923,0.0003696736,0.00045521103,0.00039162353],"domain_scores_gemma":[0.9992677,0.000112513655,0.00006645594,0.00025759728,0.00007207176,0.00022369213],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015755865,0.00017322064,0.00028748706,0.00010965127,0.000040758136,0.000027017484,0.00016325027,0.00009773266,0.00041303114],"category_scores_gemma":[0.00011285788,0.00015922703,0.00009499533,0.00036860112,0.000051466533,0.00011626609,0.000087500994,0.00023625979,0.000111114685],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005855755,0.011216472,0.015393235,0.0001411386,0.00011202514,0.00038487866,0.006312502,0.0000014001942,0.95944387,0.00015960331,0.00026601055,0.0059832786],"study_design_scores_gemma":[0.04972724,0.0005038001,0.0046469043,0.000075010386,0.000032536125,0.000013712403,0.0002840298,0.0002714436,0.93325627,0.00013446191,0.010867684,0.00018691814],"about_ca_topic_score_codex":0.00006886957,"about_ca_topic_score_gemma":0.000017435003,"teacher_disagreement_score":0.049141664,"about_ca_system_score_codex":0.000070739174,"about_ca_system_score_gemma":0.0001360775,"threshold_uncertainty_score":0.649309},"labels":[],"label_agreement":null},{"id":"W3094939491","doi":"10.1182/blood-2020-139850","title":"Real World Characteristics and Outcomes of Patients with Relapsed and Refractory Diffuse Large B Cell Lymphoma; A Provincial Experience","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Refractory (planetary science); Diffuse large B-cell lymphoma; Lymphoma; Population; Salvage therapy; Oncology; Chemotherapy","score_opus":0.012937358606757236,"score_gpt":0.25605602392409893,"score_spread":0.2431186653173417,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094939491","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9985301,0.00004040575,0.00000274806,0.00009563647,0.000019175686,0.0004226025,0.00006361182,0.000026316502,0.00079942675],"genre_scores_gemma":[0.9986758,0.00007842406,0.00017745484,0.00017449267,0.000056839373,0.000016194615,0.000024083427,0.00002583009,0.00077083305],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989877,0.00003149956,0.00019728922,0.00024717403,0.00033256473,0.00020377048],"domain_scores_gemma":[0.99936944,0.000062623396,0.0000918957,0.00018653568,0.000077865225,0.00021162358],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005956817,0.00012790186,0.0003247705,0.000057982677,0.00004029253,0.000014311131,0.000058882255,0.000047168112,0.00007605438],"category_scores_gemma":[0.00008113903,0.00009562249,0.000025216235,0.00012808523,0.000111284106,0.000057619105,0.000081120575,0.00010527461,0.0000016077144],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011475795,0.0028553894,0.9750971,0.00015515981,0.00004415527,0.00003988209,0.0031937843,1.0855786e-9,0.01555082,0.00000930548,0.000018473833,0.0018883547],"study_design_scores_gemma":[0.02466184,0.0009752416,0.96741855,0.00002800579,0.00007886258,0.0000015906712,0.00013033177,0.000010136382,0.0051206946,0.0000012694159,0.0014658803,0.000107581094],"about_ca_topic_score_codex":0.00004148445,"about_ca_topic_score_gemma":0.000023803113,"teacher_disagreement_score":0.02351426,"about_ca_system_score_codex":0.000017068302,"about_ca_system_score_gemma":0.00008180185,"threshold_uncertainty_score":0.3899372},"labels":[],"label_agreement":null},{"id":"W3095264723","doi":"10.1182/blood-2020-136465","title":"A Phase I Study of Anti-ICOS Antibody MEDI-570 for Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL) and Angioimmunoblastic T-Cell Lymphoma (AITL) (NCI-9930)","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Angioimmunoblastic T-cell lymphoma; Lymphoma; Peripheral T-cell lymphoma; Germinal center; Mycosis fungoides; T cell; Neutropenia; Follicular lymphoma; Internal medicine; Antibody; Cancer research; Oncology; Immunology; Immune system; Chemotherapy; B cell","score_opus":0.023257575199438947,"score_gpt":0.3046426809321946,"score_spread":0.28138510573275566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095264723","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99174756,0.003215753,0.00013657952,0.0002108012,0.00017922526,0.002850606,0.00009463204,0.00013948427,0.0014253496],"genre_scores_gemma":[0.99685013,0.00039256885,0.00038729492,0.00027731285,0.00041889804,0.00012897493,0.00009887996,0.00016898406,0.0012769818],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99640393,0.0001831935,0.0008266102,0.00090707256,0.00090423675,0.0007749305],"domain_scores_gemma":[0.99766254,0.0003890294,0.00028405013,0.00076424703,0.00031720495,0.0005829192],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004485323,0.00052040024,0.0011411111,0.00025084877,0.00018149814,0.00006371675,0.00039047794,0.00024503973,0.00053891056],"category_scores_gemma":[0.00024245393,0.00048281022,0.00030915183,0.0005453884,0.00023454588,0.00016624201,0.0002106955,0.00023485489,0.000029415723],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040697837,0.04574563,0.0068638776,0.00092066074,0.000571595,0.0003955116,0.00515257,0.0000027639956,0.9227059,0.000005090285,0.00047515135,0.013091461],"study_design_scores_gemma":[0.5415103,0.07681115,0.016294787,0.00034532024,0.0026496798,0.00033150404,0.00764757,0.0031089182,0.33405915,0.000026707605,0.015834343,0.0013806007],"about_ca_topic_score_codex":0.00012740768,"about_ca_topic_score_gemma":0.000008645603,"teacher_disagreement_score":0.58864677,"about_ca_system_score_codex":0.00010251817,"about_ca_system_score_gemma":0.0004941057,"threshold_uncertainty_score":0.99976236},"labels":[],"label_agreement":null},{"id":"W3095376160","doi":"10.1182/blood-2020-136571","title":"Phase 1 Study of CD19 Targeted 4-1BBL Costimulatory Agonist to Enhance T Cell (Glofitamab Combination) or NK Cell Effector Function (Obinutuzumab Combination) in Relapsed/Refractory B Cell Lymphoma","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"CD137; Cancer research; T cell; CD19; Antibody-dependent cell-mediated cytotoxicity; Immunotherapy; Immunology; Antigen; Medicine; Antibody; Immune system; Monoclonal antibody","score_opus":0.01726297855213852,"score_gpt":0.29514716114275996,"score_spread":0.2778841825906214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095376160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913692,0.00039195816,0.000085919855,0.00019239055,0.0003390512,0.004193448,0.000048492784,0.0001610987,0.0032184445],"genre_scores_gemma":[0.9948895,0.00003479243,0.00011942869,0.00047961037,0.00014066632,0.00026170723,0.00017205648,0.00012641924,0.0037758425],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99581814,0.00048452147,0.000953714,0.0009230664,0.0012123112,0.00060825964],"domain_scores_gemma":[0.9973014,0.00053597364,0.00033362606,0.00078761746,0.00049083,0.00055053306],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00057930715,0.00047673407,0.00089634745,0.00048808238,0.000153466,0.000052181094,0.00037837023,0.00024571142,0.0017734333],"category_scores_gemma":[0.0002770413,0.000467585,0.00017745388,0.0015182992,0.00009293746,0.00018438138,0.00016133237,0.00053072075,0.00052218034],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010051297,0.064057045,0.0046981773,0.00094060914,0.00013811316,0.00029637644,0.002908088,0.000099736295,0.91206765,0.0000073555148,0.0016707177,0.003064847],"study_design_scores_gemma":[0.14845741,0.048010085,0.010997714,0.00012008192,0.00039633276,0.000008150493,0.0011256185,0.0011164764,0.78614414,0.000010980288,0.0030527478,0.0005602909],"about_ca_topic_score_codex":0.00015263872,"about_ca_topic_score_gemma":0.000039398008,"teacher_disagreement_score":0.13840611,"about_ca_system_score_codex":0.00065460755,"about_ca_system_score_gemma":0.0007584767,"threshold_uncertainty_score":0.9997776},"labels":[],"label_agreement":null},{"id":"W3095414066","doi":"10.1182/blood-2020-136044","title":"Glofitamab Step-up Dosing Induces High Response Rates in Patients with Hard-to-Treat Refractory or Relapsed Non-Hodgkin Lymphoma","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Dosing; Medicine; Cytokine release syndrome; Tolerability; Pharmacokinetics; Obinutuzumab; Internal medicine; Refractory (planetary science); Lymphoma; Cmax; Pharmacology; Oncology; Gastroenterology; Rituximab; Cancer; Immunotherapy; Adverse effect","score_opus":0.025872373302044626,"score_gpt":0.2845159869658392,"score_spread":0.25864361366379457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095414066","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968169,0.00008352223,0.000010210819,0.0014403883,0.000088573084,0.0011216043,0.000025560985,0.00008889031,0.0003243562],"genre_scores_gemma":[0.99506676,0.000020303829,0.001061529,0.0009341306,0.00015664626,0.00005947508,0.000040615192,0.00009604328,0.0025644936],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99740356,0.00030518812,0.00038112755,0.000609062,0.00077232555,0.00052874326],"domain_scores_gemma":[0.99838454,0.00037602615,0.00009465541,0.00051941467,0.00018571988,0.00043963164],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041870793,0.00029866383,0.000538881,0.0003023363,0.00008096874,0.000065098866,0.00022483492,0.0001705086,0.0006897589],"category_scores_gemma":[0.00059715856,0.00021842337,0.000066382185,0.0010081629,0.00007754406,0.00015360443,0.00011227236,0.00031455013,0.00014628537],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18803063,0.0029536812,0.27337873,0.00023602694,0.00031390807,0.001128032,0.003921562,0.0000033876943,0.48812458,0.0000033767324,0.0017034591,0.040202633],"study_design_scores_gemma":[0.05011726,0.00848371,0.84336185,0.00043301875,0.00014520796,0.00001665299,0.00035526988,0.000020183228,0.09422818,0.000002574621,0.0024746812,0.0003613993],"about_ca_topic_score_codex":0.00020638261,"about_ca_topic_score_gemma":0.000026729549,"teacher_disagreement_score":0.5699831,"about_ca_system_score_codex":0.00021332742,"about_ca_system_score_gemma":0.00049325865,"threshold_uncertainty_score":0.89070463},"labels":[],"label_agreement":null},{"id":"W3095419444","doi":"10.1182/blood-2020-141505","title":"Safety and Efficacy of Ex Vivo Expanded Healthy Donor-Derived Double Negative T Cells for the Treatment of AML Relapsed after Allogeneic Stem Cell Transplantation: A First in-Human Phase I/IIa Clinical Trial","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University Health Network","funders":"","keywords":"Medicine; Transplantation; Internal medicine; Clinical trial; Hematopoietic stem cell transplantation; Oncology; Donor lymphocyte infusion; Stem cell; Immunology","score_opus":0.0826160488270848,"score_gpt":0.38051433505101945,"score_spread":0.29789828622393466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095419444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99346465,0.00065586495,0.00006285703,0.00088572234,0.00007168464,0.004600133,0.00010813308,0.000013549425,0.00013741167],"genre_scores_gemma":[0.99521357,0.003762589,0.0001713736,0.00010698111,0.00023509546,0.00020809387,0.000025066149,0.000027978058,0.00024922728],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.998167,0.00016508154,0.00083209254,0.00036157345,0.00023443789,0.00023980874],"domain_scores_gemma":[0.9979993,0.0012646755,0.0001923535,0.00028003412,0.00007334515,0.00019027609],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003522959,0.0001810514,0.00068134203,0.000057487367,0.000063156556,0.000008988814,0.000097143595,0.000119696095,0.0002836339],"category_scores_gemma":[0.000011258542,0.00012529612,0.00025601836,0.00015398592,0.00017272103,0.00002450956,0.000013376962,0.00013236396,0.0000012617251],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7704435,0.009410352,0.0016023439,0.00055141246,0.00047468193,0.000054556866,0.0152362455,0.000011147336,0.19756,0.000005600551,0.000025671294,0.0046244687],"study_design_scores_gemma":[0.55971456,0.027555699,0.0019339408,0.000057451125,0.000566646,0.0000037125367,0.00031269706,0.00005730545,0.40835667,0.00000347731,0.0013334098,0.000104431405],"about_ca_topic_score_codex":0.00009569938,"about_ca_topic_score_gemma":0.00017080498,"teacher_disagreement_score":0.21079668,"about_ca_system_score_codex":0.000036979294,"about_ca_system_score_gemma":0.00015348244,"threshold_uncertainty_score":0.51094276},"labels":[],"label_agreement":null},{"id":"W3095453737","doi":"10.1182/blood-2020-137719","title":"Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (liso-cel) Vs Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel in Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Oncology; Population; Cytokine release syndrome; Cytopenia; Chimeric antigen receptor; Immunotherapy; Cancer","score_opus":0.03325975986869781,"score_gpt":0.2778990979638786,"score_spread":0.24463933809518082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095453737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9817159,0.007913346,0.00006847133,0.00079310354,0.00016244157,0.0013207202,0.00013447765,0.00021690718,0.0076745856],"genre_scores_gemma":[0.99257284,0.0014630948,0.00093338627,0.0010472777,0.00033151545,0.0000746681,0.0001523137,0.00020669715,0.0032181935],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9945715,0.00045386818,0.0013520246,0.0011998701,0.0012233574,0.001199383],"domain_scores_gemma":[0.9971226,0.00041486142,0.00045344804,0.00096181285,0.00019907378,0.00084822543],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009615526,0.0006732839,0.0018007768,0.00057279976,0.00016422235,0.00007008715,0.00055296445,0.0005725275,0.0012657392],"category_scores_gemma":[0.00021946049,0.00070997735,0.00040062726,0.0012740785,0.0002554951,0.00017462362,0.00047665992,0.0009882066,0.00014709408],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037348373,0.015311905,0.079720415,0.0017991532,0.0006393362,0.00095307105,0.007964997,0.000018282371,0.8716519,0.000068152,0.0018979586,0.01624002],"study_design_scores_gemma":[0.12796873,0.0065491577,0.16640317,0.0007635126,0.0012874202,0.0002394913,0.002972844,0.002000345,0.6594944,0.0001714083,0.03024076,0.0019087737],"about_ca_topic_score_codex":0.0004105788,"about_ca_topic_score_gemma":0.0001962252,"teacher_disagreement_score":0.2121575,"about_ca_system_score_codex":0.00018178945,"about_ca_system_score_gemma":0.00044131975,"threshold_uncertainty_score":0.99964726},"labels":[],"label_agreement":null},{"id":"W3095487872","doi":"10.1182/blood-2020-136751","title":"Clinical Effectiveness of Combination Immunotherapy DPX-Survivac, Low Dose Cyclophosphamide, and Pembrolizumab in Recurrent/Refractory DLBCL: The Spirel Study","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; London Health Sciences Centre; Western University; Nova Scotia Health Authority; Queen Elizabeth II Health Sciences Centre; Ottawa Hospital; Health Sciences Centre; McGill University Health Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Oncology; Internal medicine; Pembrolizumab; Population; Immunotherapy; Regimen; Chemotherapy regimen; Chimeric antigen receptor; Cyclophosphamide; Immunology; Cancer; Chemotherapy","score_opus":0.03329050655822488,"score_gpt":0.35096961056598397,"score_spread":0.3176791040077591,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095487872","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946545,0.0022039872,0.0000075172516,0.00030289986,0.00014641619,0.0020668467,0.000005141264,0.000032702428,0.00058000104],"genre_scores_gemma":[0.9984275,0.0011685283,0.0000133665935,0.00012244053,0.0000967457,0.0000732817,0.000009364231,0.000038592632,0.000050143157],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99727213,0.001068136,0.0005429745,0.0003951935,0.0004846212,0.00023695675],"domain_scores_gemma":[0.9980703,0.0011160463,0.0001343948,0.00042353247,0.00013183976,0.00012386545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020092973,0.00018270547,0.0005886644,0.00008414331,0.000050527047,0.000019774165,0.0002063994,0.00011477074,0.00012532447],"category_scores_gemma":[0.0004013129,0.00013436019,0.00012514912,0.0004345947,0.0001784031,0.000065681226,0.000097728516,0.0006047865,0.0000091678085],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009140652,0.0131506855,0.88358045,0.0003529753,0.00038811605,0.000076954966,0.0016891445,0.0000010508517,0.029620416,0.000051908657,0.000018237162,0.061929405],"study_design_scores_gemma":[0.04339791,0.005128074,0.94694895,0.00015445852,0.00007670677,0.0000084006915,0.00025065793,0.000081680526,0.0034538447,0.00008145926,0.00029755037,0.00012032639],"about_ca_topic_score_codex":0.00014236882,"about_ca_topic_score_gemma":0.000022141796,"teacher_disagreement_score":0.06336848,"about_ca_system_score_codex":0.00003864398,"about_ca_system_score_gemma":0.00013543318,"threshold_uncertainty_score":0.54790497},"labels":[],"label_agreement":null},{"id":"W3095670265","doi":"10.1182/blood-2020-136360","title":"Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel in the Phase 1b/2 CARTITUDE-1 Study","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Cytokine release syndrome; Medicine; Cytokine; Multiple myeloma; Refractory (planetary science); Internal medicine; Lenalidomide; Oncology; Gastroenterology; Immunology; Cancer; Immunotherapy; Biology; Chimeric antigen receptor","score_opus":0.021718242585585707,"score_gpt":0.27168531104383725,"score_spread":0.24996706845825153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095670265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99590635,0.00009364858,0.0000029551031,0.00039650954,0.000011498693,0.0030045044,0.000036571866,0.00008159958,0.0004663528],"genre_scores_gemma":[0.9989163,0.000010446705,0.000060666705,0.00033224953,0.00004702699,0.00021209547,0.00009646519,0.00007423467,0.0002504817],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99725085,0.0002810951,0.00040357784,0.0005875159,0.0009789182,0.00049803866],"domain_scores_gemma":[0.9987105,0.00014338784,0.00009628607,0.00066592114,0.0001213976,0.00026251993],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030643435,0.0003161392,0.000544038,0.00021678585,0.000066604916,0.000033926346,0.00027554925,0.00009292437,0.00023953323],"category_scores_gemma":[0.00014522762,0.00019437098,0.000055266857,0.0011751265,0.00009200322,0.000119555516,0.00005972355,0.00069951435,0.00003246884],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009445517,0.030275913,0.940001,0.00006951951,0.00027444915,0.0063661058,0.003696121,0.000023937353,0.0079282615,8.6177977e-7,0.000052565767,0.0018657398],"study_design_scores_gemma":[0.14437959,0.02234796,0.82852733,0.00012999495,0.00023756384,0.00006602278,0.0008172267,0.00014902082,0.0026290843,5.2126745e-7,0.0004479825,0.00026769846],"about_ca_topic_score_codex":0.00039709243,"about_ca_topic_score_gemma":0.0004962917,"teacher_disagreement_score":0.13493407,"about_ca_system_score_codex":0.000103143335,"about_ca_system_score_gemma":0.00017694305,"threshold_uncertainty_score":0.79262185},"labels":[],"label_agreement":null},{"id":"W3095914190","doi":"10.1182/blood-2020-139496","title":"Preclinical Characterization of Cell-Based IL12 Immunotherapy Against Murine Acute Lymphoblastic Leukemia Using Intravital Imaging","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Interleukin 12; Bone marrow; Immunotherapy; Cancer research; Ex vivo; Immune system; Immunology; Leukemia; Medicine; Tumor microenvironment; In vivo; Biology; In vitro","score_opus":0.024411600747359298,"score_gpt":0.30081970413357145,"score_spread":0.27640810338621213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3095914190","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99577403,0.00010556413,0.0026932168,0.00038335405,0.00008055379,0.00048136912,0.000035465942,0.00007098192,0.00037544197],"genre_scores_gemma":[0.9967699,0.00011215459,0.0014263025,0.0009823837,0.00035234843,0.000010336344,0.00015821657,0.00006922475,0.000119108074],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984152,0.00007792841,0.00047706725,0.0003285817,0.0003992451,0.00030201767],"domain_scores_gemma":[0.999109,0.00009982666,0.00015962358,0.00030794778,0.00013616194,0.00018740508],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017993899,0.0001868285,0.00040268496,0.00010256527,0.0000520544,0.00002669988,0.00015198365,0.00008360909,0.0005325387],"category_scores_gemma":[0.000068122004,0.00017993285,0.00016323871,0.00031150243,0.000114681825,0.00008677233,0.000050143382,0.00023912964,0.000016592221],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009607025,0.00043921804,0.008620954,0.00014597461,0.00016145401,0.00009868308,0.00023128626,0.000043534015,0.98373574,0.0000011889579,0.0000055382493,0.0055557513],"study_design_scores_gemma":[0.012049066,0.00053207466,0.014007312,0.00014188877,0.00022285806,0.000032365708,0.000022471622,0.026260933,0.94623417,0.000002522118,0.00030439277,0.00018996501],"about_ca_topic_score_codex":0.000013149138,"about_ca_topic_score_gemma":2.123048e-7,"teacher_disagreement_score":0.037501566,"about_ca_system_score_codex":0.00010780496,"about_ca_system_score_gemma":0.00051771005,"threshold_uncertainty_score":0.73374486},"labels":[],"label_agreement":null},{"id":"W3096145151","doi":"10.1182/blood-2020-133988","title":"Shared Expression of CD93 and Other Antigens By AML and Endothelial Cells Highlights a Need for Rational Combinatorial Targeting","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"","keywords":"Chimeric antigen receptor; Cancer research; Progenitor cell; Myeloid leukemia; Haematopoiesis; Leukemia; Bone marrow; CD33; Antigen; Stem cell; Myeloid; Immunology; Immunotherapy; Medicine; Biology; CD34; Immune system; Cell biology","score_opus":0.020402313932488324,"score_gpt":0.2702720288376731,"score_spread":0.24986971490518478,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096145151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99684006,0.00042952297,0.000100089026,0.00097276585,0.00010561728,0.0007484862,0.00033210806,0.000026015789,0.00044530662],"genre_scores_gemma":[0.9976072,0.00003999107,0.0012149286,0.00019379231,0.0005381241,0.000022295846,0.00004965942,0.000028790422,0.00030525122],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992004,0.000033934022,0.00017790639,0.0002101674,0.00022969974,0.00014790198],"domain_scores_gemma":[0.9995505,0.0001093885,0.000057637357,0.000076962926,0.00006976315,0.00013571426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000118560616,0.00009494265,0.0002224387,0.000032190736,0.000054708216,0.000018697923,0.000044909466,0.00007007835,0.0003104468],"category_scores_gemma":[0.00007368636,0.00007936582,0.000041473777,0.000056260982,0.000054686687,0.000038184106,0.000037770078,0.00007784399,0.0000015395258],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008150045,0.00017803312,0.001669016,0.00012053298,0.00004354839,0.0000030687363,0.0006883629,1.5569358e-7,0.99190074,0.00021434783,0.0043032668,0.00006391464],"study_design_scores_gemma":[0.011353853,0.0005066114,0.000082964114,0.000039490293,0.00004351954,0.0000031354127,0.00006487563,0.00019057312,0.9662135,0.00013105964,0.021292707,0.0000776759],"about_ca_topic_score_codex":0.000012915643,"about_ca_topic_score_gemma":5.360132e-7,"teacher_disagreement_score":0.025687214,"about_ca_system_score_codex":0.0000052925457,"about_ca_system_score_gemma":0.000045357636,"threshold_uncertainty_score":0.3399175},"labels":[],"label_agreement":null},{"id":"W3096179361","doi":"10.1016/j.yrtph.2020.104813","title":"Considerations for setting occupational exposure limits for novel pharmaceutical modalities","year":2020,"lang":"en","type":"review","venue":"Regulatory Toxicology and Pharmacology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada; Bristol-Myers Squibb","keywords":"Modalities; Risk analysis (engineering); Biosafety; Identification (biology); Medicine; Biological hazard; Hazard; Computer science; Biology; Environmental health; Pathology","score_opus":0.2235312005008402,"score_gpt":0.4734867151995026,"score_spread":0.2499555146986624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096179361","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00031371895,0.98665047,0.0006619491,0.0032511896,0.0011796516,0.006541922,0.0010667547,0.00010549083,0.00022883486],"genre_scores_gemma":[0.00060573913,0.9793153,0.0040764688,0.0049124253,0.0033097186,0.0042329044,0.0005943034,0.00014413997,0.0028090295],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99729717,0.0003331601,0.0007867778,0.0007661716,0.00018096344,0.000635732],"domain_scores_gemma":[0.9933093,0.005587965,0.0002519605,0.00018539428,0.00026663893,0.00039870577],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00069617276,0.00048282553,0.0019276586,0.00026712907,0.00037901872,0.000025879866,0.00012758089,0.00095394906,0.0026704893],"category_scores_gemma":[0.00037907055,0.00045236762,0.00054659,0.00013448135,0.0005388116,0.00005994305,0.00008262951,0.0007740742,0.000010182259],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002831999,0.0007865515,0.00004855603,0.04602095,0.004343795,0.000096801006,0.00035736014,0.00001010647,0.030551406,0.021166855,0.06881928,0.8249663],"study_design_scores_gemma":[0.0046927757,0.00092938554,0.000017218623,0.0003447285,0.0029806995,0.0008008422,0.000019257142,0.00056442467,0.0010650045,0.0003801119,0.987858,0.00034758012],"about_ca_topic_score_codex":4.2899765e-7,"about_ca_topic_score_gemma":0.0000018072744,"teacher_disagreement_score":0.9190387,"about_ca_system_score_codex":0.00021056762,"about_ca_system_score_gemma":0.0020470205,"threshold_uncertainty_score":0.9997928},"labels":[],"label_agreement":null},{"id":"W3096607082","doi":"10.1182/blood-2020-134449","title":"Interim Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) as First-Line Therapy in Patients (Pts) With High-Risk Large B Cell Lymphoma (LBCL)","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Interim; Medicine; Internal medicine; Lymphoma; Oncology; Political science","score_opus":0.025071458830441692,"score_gpt":0.29942498192249317,"score_spread":0.27435352309205147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096607082","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99764335,0.0002569014,0.000035530036,0.00010275056,0.000024800227,0.0013727278,0.00013293151,0.000034422956,0.0003965658],"genre_scores_gemma":[0.9988442,0.00038585323,0.00007613079,0.00015816474,0.000059506685,0.000060796305,0.00012607075,0.00006135812,0.00022790478],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9970645,0.0002213168,0.000758447,0.0005859553,0.0009530771,0.0004167389],"domain_scores_gemma":[0.9982237,0.00011856567,0.0003553008,0.00075471174,0.00028706127,0.00026065667],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00036045304,0.0003116537,0.0011618605,0.000587111,0.000048057285,0.000014064673,0.00032269684,0.00010791923,0.0015644329],"category_scores_gemma":[0.00008934707,0.000245821,0.00023748638,0.0019435113,0.00007791494,0.00006357303,0.00013220117,0.00023711579,0.000012479804],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019662173,0.16709569,0.7367646,0.00019610138,0.0065962095,0.00022659628,0.011822505,0.00008151833,0.040137086,0.000002848115,0.000058146445,0.017356534],"study_design_scores_gemma":[0.37704596,0.09687065,0.29408452,0.0001221626,0.0042601335,0.0000030407164,0.0021366328,0.0012793454,0.22297962,0.0000073410274,0.00070380385,0.0005068064],"about_ca_topic_score_codex":0.0014550276,"about_ca_topic_score_gemma":0.0006128338,"teacher_disagreement_score":0.4426801,"about_ca_system_score_codex":0.000064723965,"about_ca_system_score_gemma":0.0001342082,"threshold_uncertainty_score":0.9999994},"labels":[],"label_agreement":null},{"id":"W3096624409","doi":"10.1182/blood-2020-136368","title":"Health-Related Quality of Life in the Cartitude-1 Study of Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Multiple myeloma; Medicine; Pomalidomide; Quality of life (healthcare); Internal medicine; Lenalidomide; Oncology; Gerontology; Family medicine; Nursing","score_opus":0.10097725679551099,"score_gpt":0.36493475699181815,"score_spread":0.26395750019630715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096624409","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933336,0.0010666742,0.000012505894,0.0026023386,0.000039310977,0.0025442305,0.000035041736,0.000030515133,0.00033578268],"genre_scores_gemma":[0.9990007,0.00003962583,0.000119966775,0.00047784703,0.000070663446,0.000099419594,0.000018823554,0.00002783166,0.00014510626],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973019,0.0004924683,0.0010006012,0.00029578188,0.00062293286,0.00028636816],"domain_scores_gemma":[0.99820274,0.000666099,0.00029644306,0.00050760695,0.00015141355,0.00017568626],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016047487,0.00013840827,0.0007542329,0.000088238354,0.000046234425,0.0000054357592,0.00025280015,0.00009541959,0.00013840289],"category_scores_gemma":[0.0012705018,0.000104407896,0.00014388979,0.00045507777,0.00007124554,0.00003477629,0.00006114796,0.00034967464,0.0000042627034],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005035878,0.016058,0.5650678,0.0016695115,0.00083295995,0.000035475532,0.052839622,0.000058953097,0.3512843,0.0000803377,0.0010001666,0.006036954],"study_design_scores_gemma":[0.051087808,0.010394563,0.91385055,0.000102919206,0.00014555706,0.000006098786,0.0088738585,0.00039596698,0.013603798,0.000030918403,0.0013059116,0.00020207248],"about_ca_topic_score_codex":0.0017064909,"about_ca_topic_score_gemma":0.0006850871,"teacher_disagreement_score":0.3487827,"about_ca_system_score_codex":0.000035176217,"about_ca_system_score_gemma":0.00035953618,"threshold_uncertainty_score":0.42576304},"labels":[],"label_agreement":null},{"id":"W3096697285","doi":"10.1182/blood-2020-136344","title":"A Phase 2 Study of Odronextamab (REGN1979), a CD20 x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Tolerability; CD20; Lymphoma; Internal medicine; Refractory (planetary science); Oncology; Follicular lymphoma; Antibody; Phases of clinical research; Gastroenterology; Chemotherapy; Adverse effect; Immunology; Biology","score_opus":0.020780815090792402,"score_gpt":0.2958991003380819,"score_spread":0.27511828524728954,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096697285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994577,0.00024169446,0.000011925727,0.00010179223,0.000048571546,0.0021664673,0.00002437267,0.000053638065,0.002774544],"genre_scores_gemma":[0.9989157,0.00005157121,0.00013817925,0.000116116564,0.00011397733,0.00004629715,0.000065673135,0.000091578484,0.00046092132],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971412,0.00014767697,0.00056163647,0.00063440617,0.0010277986,0.00048731896],"domain_scores_gemma":[0.9984971,0.00009298517,0.00018645028,0.0006923656,0.00019711365,0.0003339815],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00023309884,0.0003102344,0.0007243312,0.00031777096,0.0000468446,0.00002133598,0.0002785939,0.0001260708,0.0006873639],"category_scores_gemma":[0.00006141112,0.00025972855,0.00010335937,0.0009902357,0.00010391294,0.000111850335,0.00012189818,0.0003605884,0.00006305688],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015398085,0.15435635,0.62307954,0.0004009921,0.00047722054,0.0010078654,0.00860001,0.000005209932,0.18165821,0.0000024922872,0.00041821864,0.014595795],"study_design_scores_gemma":[0.47764894,0.08494043,0.39183682,0.0003479812,0.00047448793,0.000017456327,0.002595062,0.00017820387,0.0386073,0.0000042481984,0.0027066178,0.00064241275],"about_ca_topic_score_codex":0.00016460233,"about_ca_topic_score_gemma":0.000035086912,"teacher_disagreement_score":0.46225086,"about_ca_system_score_codex":0.000083663195,"about_ca_system_score_gemma":0.00026023426,"threshold_uncertainty_score":0.9999855},"labels":[],"label_agreement":null},{"id":"W3096717600","doi":"10.1182/blood-2020-137233","title":"ZUMA-4: A Phase 1/2 Multicenter Study of KTE-X19 in Pediatric and Adolescent Patients With Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Medicine; Lymphoma; Mantle cell lymphoma; Internal medicine; Lymphoblastic lymphoma; Refractory (planetary science); Malignancy; Oncology; Gastroenterology; Immunology; T cell","score_opus":0.014890253295505787,"score_gpt":0.2722694317291154,"score_spread":0.2573791784336096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096717600","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975306,0.00013958736,0.000011887509,0.000045436987,0.00004860431,0.0019958662,0.000027482483,0.00003228805,0.00016825173],"genre_scores_gemma":[0.9988938,0.00019824137,0.00011597735,0.00023669924,0.00013013158,0.000053367767,0.000020363093,0.00007156967,0.00027987736],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99775356,0.00011348604,0.0004541523,0.00055406126,0.0007027011,0.000422017],"domain_scores_gemma":[0.9987958,0.00013355729,0.00017254897,0.00037910507,0.00015271454,0.00036625427],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013562113,0.0002946695,0.0005699873,0.00025752935,0.00004005909,0.000020443758,0.00017083497,0.000106085135,0.00018850922],"category_scores_gemma":[0.000080778664,0.000218153,0.00005760429,0.0006004517,0.000062947234,0.00009411926,0.00014295024,0.00025244075,0.00001898192],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024620652,0.033245485,0.9177795,0.00085458974,0.00028485892,0.0009397341,0.0045710225,0.000008021288,0.012628351,7.853565e-8,0.0004320396,0.004635661],"study_design_scores_gemma":[0.28134972,0.024914179,0.6846296,0.00019023211,0.0011236281,0.000012714441,0.0007509662,0.00058314943,0.005855359,2.7976242e-7,0.00024369161,0.00034644027],"about_ca_topic_score_codex":0.00006109688,"about_ca_topic_score_gemma":0.00003110069,"teacher_disagreement_score":0.25672907,"about_ca_system_score_codex":0.00020146144,"about_ca_system_score_gemma":0.0004462958,"threshold_uncertainty_score":0.8896021},"labels":[],"label_agreement":null},{"id":"W3096959229","doi":"10.1182/blood-2020-141168","title":"The Tumor Associated Antigen PRAME Exhibits Dualistic Functions That Are Targetable in Diffuse Large B-Cell Lymphoma","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia; Spinal Cord Injury BC","funders":"Medical Research Council","keywords":"Diffuse large B-cell lymphoma; Biology; Tumor microenvironment; Cancer research; Immune system; Antigen; Context (archaeology); Immunotherapy; Lymphoma; Immunology","score_opus":0.030470672176324858,"score_gpt":0.2646939371310036,"score_spread":0.23422326495467874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3096959229","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988763,0.0017083767,0.000017328193,0.0028110116,0.00011268805,0.00071405387,0.00009478208,0.00013049241,0.0056483205],"genre_scores_gemma":[0.98706955,0.00021440668,0.00002166013,0.0010947473,0.00019102033,0.00006357242,0.00007708168,0.00005721493,0.011210777],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979846,0.0001806616,0.00026659318,0.00035881478,0.00055616855,0.0006531771],"domain_scores_gemma":[0.99883604,0.00029193153,0.00011722325,0.00037851342,0.00011225093,0.00026403466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044635637,0.00018952819,0.00035303272,0.00007326067,0.00022783,0.0000832103,0.00019270007,0.00009679474,0.0005961549],"category_scores_gemma":[0.00080298836,0.00014234342,0.00012570378,0.0006166648,0.00006186918,0.0000689468,0.00011778786,0.00031471072,0.000255466],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001045581,0.03494074,0.7761661,0.0003121366,0.0007549866,0.0021765444,0.0026165033,0.0000058450355,0.1539282,0.00013501386,0.02701677,0.00090162025],"study_design_scores_gemma":[0.14559735,0.0014018939,0.4878078,0.0003580635,0.00059256615,0.00013480421,0.004049673,0.002258751,0.087883204,0.00016841288,0.26878792,0.00095954165],"about_ca_topic_score_codex":0.000093418435,"about_ca_topic_score_gemma":0.00022266999,"teacher_disagreement_score":0.28835824,"about_ca_system_score_codex":0.000091832924,"about_ca_system_score_gemma":0.0002039605,"threshold_uncertainty_score":0.65274775},"labels":[],"label_agreement":null},{"id":"W3097588851","doi":"10.1182/blood-2020-136730","title":"A Matching-Adjusted Indirect Comparison of Efficacy Outcomes for Idecabtagene Vicleucel (ide-cel, bb2121), a Bcma-Directed CAR T Cell Therapy Versus Conventional Care in Triple-Class-Exposed Relapsed and Refractory Multiple Myeloma","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Precision Nanosystems (Canada)","funders":"","keywords":"Medicine; Internal medicine; Population; Progression-free survival; Oncology; Immunology; Chemotherapy","score_opus":0.06832235787039867,"score_gpt":0.3291427218745771,"score_spread":0.2608203640041784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097588851","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99269426,0.0032833861,0.00001772442,0.00035685732,0.00019000334,0.002650125,0.00014612812,0.00019435523,0.00046716427],"genre_scores_gemma":[0.9973251,0.00018072367,0.0012479845,0.00016195186,0.000115930634,0.00015175805,0.00033156495,0.0001042337,0.0003807417],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9969928,0.00027416492,0.00086491543,0.00066857034,0.00068337354,0.000516166],"domain_scores_gemma":[0.99739295,0.0012270984,0.0003126217,0.00041831812,0.00031051497,0.00033848867],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00033487153,0.00039098292,0.0012397702,0.00033109632,0.000103762424,0.00003206803,0.00023942397,0.00028446218,0.00029280674],"category_scores_gemma":[0.00048907154,0.00036760105,0.00033410254,0.00059566286,0.00013204069,0.00008951724,0.00008317593,0.0005456489,0.000009206936],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023391947,0.0025815507,0.120466776,0.0005909297,0.0006686778,0.000055782144,0.011022259,0.000014350194,0.83417326,0.0000063643606,0.00027110468,0.006757012],"study_design_scores_gemma":[0.2150449,0.0061839023,0.23738015,0.00018937168,0.00037356175,0.000007809994,0.0037880384,0.0012043781,0.53095627,0.000010048328,0.004297981,0.00056358555],"about_ca_topic_score_codex":0.00016302978,"about_ca_topic_score_gemma":0.00021282467,"teacher_disagreement_score":0.30321696,"about_ca_system_score_codex":0.00013229967,"about_ca_system_score_gemma":0.0003379445,"threshold_uncertainty_score":0.9998776},"labels":[],"label_agreement":null},{"id":"W3097603276","doi":"10.1182/blood-2020-138700","title":"Autologous Stem Cell Transplantation (ASCT) for T-Cell Non Hodgkin Lymphoma (T-NHL) Patients Who Achieve Complete Remission with First-Line Treatment: A Systematic Review and Meta-Analysis","year":2020,"lang":"en","type":"review","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Oncology; Internal medicine; Autologous stem-cell transplantation; Hazard ratio; Transplantation; Meta-analysis; Chemotherapy regimen; Progression-free survival; Surgery; Chemotherapy; Confidence interval","score_opus":0.07641804720976893,"score_gpt":0.3250659612966761,"score_spread":0.24864791408690717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097603276","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006324951,0.9809986,0.00032795296,0.00013764098,0.000013336789,0.016974308,0.001146258,0.00006144044,0.00027726014],"genre_scores_gemma":[0.00016226259,0.98997617,0.0004262957,0.00012174165,0.000040072453,0.0028236757,0.002372889,0.00015645652,0.003920421],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9955326,0.00064475276,0.0015500062,0.0011122591,0.00068495446,0.00047547894],"domain_scores_gemma":[0.99646443,0.0008290607,0.0010864198,0.0009794517,0.00024441385,0.00039625086],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004968626,0.0009895611,0.011707206,0.00038363982,0.00015845914,0.00006035226,0.00027228345,0.00032193217,0.00016898103],"category_scores_gemma":[0.000030284125,0.00056523405,0.0027433382,0.0010496401,0.000054508637,0.000057265515,0.000037770096,0.00021768709,0.000024764775],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021785598,0.0010438827,0.0000051242496,0.9013417,0.07949372,0.00012929893,0.00018927486,7.594153e-7,0.0000035369073,5.875568e-7,0.0000344301,0.017539881],"study_design_scores_gemma":[0.0061168587,0.003994501,0.0000037309348,0.046206877,0.91248435,0.00016426187,0.00000809081,0.00007157295,0.00004271936,9.83799e-7,0.030437117,0.0004689266],"about_ca_topic_score_codex":0.000040877425,"about_ca_topic_score_gemma":0.00004082657,"teacher_disagreement_score":0.8551348,"about_ca_system_score_codex":0.00023688823,"about_ca_system_score_gemma":0.0003341476,"threshold_uncertainty_score":0.9996799},"labels":[],"label_agreement":null},{"id":"W3097838507","doi":"10.1182/blood-2020-141925","title":"Tonic Signaling Leads to Off-Target Activation of T Cells Engineered with Chimeric Antigen Receptors That Is Not Seen in T Cells Engineered with T Cell Antigen Coupler (TAC) Receptors","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University","funders":"","keywords":"T-cell receptor; Chimeric antigen receptor; Cell biology; T cell; Antigen; Cytotoxic T cell; Receptor; Antigen-presenting cell; Molecular biology; Biology; Chemistry; Immunology; Immune system; Biochemistry; In vitro","score_opus":0.020323630542912162,"score_gpt":0.24080840056362807,"score_spread":0.2204847700207159,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097838507","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958493,0.00022823093,0.0005995025,0.000703045,0.00010659474,0.0017046113,0.000036117694,0.00011637943,0.00065622246],"genre_scores_gemma":[0.99116164,0.00028446698,0.0066188383,0.00038434297,0.00018801619,0.000048408852,0.00008696487,0.00017787519,0.0010494482],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9968524,0.00009116616,0.0005227198,0.00075160194,0.0010345825,0.0007475505],"domain_scores_gemma":[0.9984329,0.00016508832,0.00019138143,0.0005419179,0.00021112617,0.00045760663],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00033937133,0.00049007067,0.0008829436,0.00044165307,0.00005400309,0.000036700676,0.0003250494,0.00021532406,0.0023856203],"category_scores_gemma":[0.000033806606,0.0004179301,0.00013936455,0.0016902221,0.000076269454,0.00017566266,0.000072317416,0.0005724059,0.00006445448],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013230814,0.00048170623,0.030963188,0.00028437935,0.00029544125,0.000020254061,0.00366939,0.004289852,0.9576081,6.341098e-7,0.0005110962,0.00055286917],"study_design_scores_gemma":[0.005431304,0.0021339015,0.0038170354,0.00028927068,0.00011761581,0.0000053009144,0.00041045833,0.0010302289,0.98305374,5.40554e-7,0.0032362214,0.00047439785],"about_ca_topic_score_codex":0.00012474459,"about_ca_topic_score_gemma":0.000009119254,"teacher_disagreement_score":0.027146153,"about_ca_system_score_codex":0.00011354752,"about_ca_system_score_gemma":0.00031233372,"threshold_uncertainty_score":0.99982727},"labels":[],"label_agreement":null},{"id":"W3097912792","doi":"10.1182/blood-2020-136307","title":"CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Chimeric antigen receptor; Internal medicine; Antigen; Population; Fludarabine; Immunology; Oncology; Gastroenterology; Cyclophosphamide; Immunotherapy; Chemotherapy; Cancer","score_opus":0.032698462280976295,"score_gpt":0.29832936063552745,"score_spread":0.26563089835455117,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097912792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99316293,0.0022362971,0.00000888341,0.00017976464,0.0001375905,0.0027063468,0.00003397964,0.0002391128,0.001295098],"genre_scores_gemma":[0.99698174,0.0011209471,0.00047294513,0.00016371072,0.0002596361,0.000095870186,0.00010582459,0.0001068976,0.00069240906],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99673,0.00037726614,0.00078758347,0.0007281649,0.00083942607,0.0005375297],"domain_scores_gemma":[0.99836403,0.00014569369,0.00027756393,0.0006577326,0.00022997241,0.0003250119],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00036491916,0.00038108393,0.000794951,0.00031391115,0.0000924948,0.000033891036,0.00030722783,0.00020721777,0.001413949],"category_scores_gemma":[0.00013163859,0.00035644096,0.00017082618,0.0012466504,0.00007790593,0.00011948982,0.00009658145,0.0006167015,0.000089677465],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031414647,0.026784249,0.04050491,0.00013098364,0.00020084153,0.00015427844,0.007837698,0.000012128761,0.91431123,2.0699268e-7,0.00044034168,0.006481645],"study_design_scores_gemma":[0.073134616,0.009745675,0.06187971,0.000061156876,0.00008912748,0.000008947557,0.0013087734,0.0010804407,0.84803176,9.955986e-7,0.004269604,0.0003892159],"about_ca_topic_score_codex":0.00034246073,"about_ca_topic_score_gemma":0.00007163969,"teacher_disagreement_score":0.06999315,"about_ca_system_score_codex":0.00007290005,"about_ca_system_score_gemma":0.00025701904,"threshold_uncertainty_score":0.9998888},"labels":[],"label_agreement":null},{"id":"W3099091492","doi":"10.1101/759167","title":"Quantifying the Limits of Immunotherapies in Mice and Men","year":2019,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Engineering and Physical Sciences Research Council","keywords":"Immune system; Cart; Immunotherapy; Homing (biology); Clinical trial; Dosing; Medicine; Perfusion; Immunology; Biology; Oncology; Cancer research; Internal medicine","score_opus":0.04537657949138461,"score_gpt":0.29562579236115194,"score_spread":0.2502492128697673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3099091492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9864646,0.010754932,0.000032588337,0.0008051272,0.00028702745,0.0014514183,0.00003645827,0.00007002407,0.000097786084],"genre_scores_gemma":[0.9949442,0.0038985766,0.0005770941,0.00014196504,0.00015569711,0.000095456075,1.5582825e-7,0.00011883888,0.00006803062],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99763113,0.00020838123,0.00054793427,0.0006450091,0.00050969544,0.0004578212],"domain_scores_gemma":[0.9977236,0.00028026477,0.000283653,0.0012681908,0.00033558375,0.00010875232],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013567355,0.00038124452,0.0007780557,0.0003728244,0.00006100783,0.00008617162,0.00042692776,0.0003980006,0.00016125372],"category_scores_gemma":[0.00020054549,0.0003055586,0.00013792745,0.0004577913,0.00024868437,0.00006946009,0.00036770824,0.0011253846,0.000021439939],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027779452,0.00010576009,0.05074331,0.00092287327,0.000263265,0.000022437058,0.00010714417,0.000013342179,0.94727707,0.00018214516,0.0000671586,0.000017711438],"study_design_scores_gemma":[0.0018896653,0.00014855873,0.45281377,0.0015119261,0.00010398102,7.479397e-8,0.000046572713,0.00054569,0.538053,0.0000016923017,0.0044625117,0.00042257246],"about_ca_topic_score_codex":0.00033559234,"about_ca_topic_score_gemma":0.0000101706,"teacher_disagreement_score":0.40922406,"about_ca_system_score_codex":0.00018661802,"about_ca_system_score_gemma":0.0005653712,"threshold_uncertainty_score":0.9999397},"labels":[],"label_agreement":null},{"id":"W3099890097","doi":"10.1053/j.seminhematol.2020.11.006","title":"Genetic and epigenetic modification of human primary NK cells for enhanced antitumor activity","year":2020,"lang":"en","type":"article","venue":"Seminars in Hematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute","keywords":"Epigenetics; Immunotherapy; Biology; Immune system; Chimeric antigen receptor; Cytotoxic T cell; Immunology; Gene delivery; Cancer research; Cancer immunotherapy; Genetic enhancement; Gene; Genetics","score_opus":0.040520900348912564,"score_gpt":0.33916994809733997,"score_spread":0.2986490477484274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3099890097","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99540913,0.001229632,0.0013834996,0.0005280143,0.000032923497,0.00089498627,0.000006046416,0.000015318652,0.0005004757],"genre_scores_gemma":[0.99656045,0.00057608244,0.0024145988,0.00011770372,0.000030916253,0.00007754404,0.00000870157,0.0000208671,0.00019314827],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990336,0.000061096725,0.0002562699,0.00030581738,0.00012161029,0.00022166297],"domain_scores_gemma":[0.999358,0.00018635437,0.00008805991,0.00022239164,0.00005608405,0.00008910083],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014005603,0.00010374871,0.00044900694,0.00009856315,0.000026856542,0.000003223744,0.00008514153,0.00010739852,0.00011181691],"category_scores_gemma":[0.000074415,0.000106874075,0.000047647813,0.00015463702,0.00017390493,0.000019480018,0.00004830004,0.00013353655,0.000003330577],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040139796,0.00011426757,0.0056771664,0.0010650787,0.00001689856,0.000016590997,0.000580375,0.0000052621913,0.97884554,0.00008699121,0.00010532138,0.013085086],"study_design_scores_gemma":[0.0012573428,0.0007177816,0.01649947,0.000089865964,0.000023028651,0.000037226884,0.0000646671,0.0005992728,0.9802263,0.00026721897,0.00013348943,0.00008437824],"about_ca_topic_score_codex":0.000012534961,"about_ca_topic_score_gemma":0.000006146837,"teacher_disagreement_score":0.013000707,"about_ca_system_score_codex":0.000036441143,"about_ca_system_score_gemma":0.000065719185,"threshold_uncertainty_score":0.4358198},"labels":[],"label_agreement":null},{"id":"W3099922800","doi":"10.3390/cancers12113329","title":"Current Advances and Hurdles in Chimeric Antigen Receptor Technology","year":2020,"lang":"en","type":"editorial","venue":"Cancers","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada; Institute of Infection and Immunity; University of Ottawa","funders":"","keywords":"Chimeric antigen receptor; Current (fluid); Antigen; Medicine; Computational biology; Immunology; Computer science; Biology; Immunotherapy; Engineering; Immune system","score_opus":0.01630392485573216,"score_gpt":0.3498964100311231,"score_spread":0.3335924851753909,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3099922800","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006616875,0.22558981,0.0000057450125,0.0012936024,0.76395136,0.0009386793,0.00013767825,0.00013458854,0.0013316583],"genre_scores_gemma":[0.0004947324,0.3346167,0.00020740347,0.000057324403,0.66273004,0.00019403601,0.00028289217,0.000098979974,0.0013179365],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982702,0.000036095982,0.0002502195,0.00057310663,0.00049338886,0.0003770027],"domain_scores_gemma":[0.9992378,0.0001350368,0.00009945186,0.00027799967,0.00009622878,0.00015351108],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012079029,0.00025185687,0.00064506725,0.00038980716,0.000034861627,0.000015964555,0.00019814463,0.00045425873,0.0007017831],"category_scores_gemma":[0.00044768106,0.0002371225,0.00006383298,0.00065597397,0.0003249333,0.00004489192,0.00010188889,0.0014745642,0.000034617453],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036185284,0.000009691579,0.0013405621,0.0005716613,0.00005326235,0.000024031991,0.00012941899,0.0000015461032,0.0029880025,0.0000034577897,0.7798192,0.2146973],"study_design_scores_gemma":[0.0011270136,0.00032947713,0.000054846776,0.0005133622,0.000022331305,0.0000012766728,0.00016589198,0.0000112817015,0.00060610403,0.000051536306,0.9969169,0.00019996645],"about_ca_topic_score_codex":0.00014025044,"about_ca_topic_score_gemma":0.000086240296,"teacher_disagreement_score":0.2170977,"about_ca_system_score_codex":0.0015688431,"about_ca_system_score_gemma":0.0020244375,"threshold_uncertainty_score":0.9669575},"labels":[],"label_agreement":null},{"id":"W3100358566","doi":"10.1136/jitc-2020-sitc2020.0806","title":"806 Changes in T cell clonality in AWARE-1 study, a window-of-opportunity study with atezolizumab and the oncolytic virus pelareorep in early breast cancer","year":2020,"lang":"en","type":"article","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Atezolizumab; Medicine; Oncology; Cohort; Breast cancer; Internal medicine; Clinical endpoint; Letrozole; Trastuzumab; Oncolytic virus; Cancer; Immunotherapy; Clinical trial; Pembrolizumab","score_opus":0.052522123886921686,"score_gpt":0.3335384184004536,"score_spread":0.28101629451353194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3100358566","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99009484,0.00016277975,0.0000011238546,0.0041725477,0.000015580155,0.0041467473,0.000024516463,0.000020338852,0.0013615309],"genre_scores_gemma":[0.99857193,0.0001333193,0.0000055735895,0.0004313115,0.00005205868,0.00028477726,0.0000027371082,0.000029815988,0.00048849196],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99733406,0.00063996774,0.00044142944,0.00048223275,0.00071914215,0.00038318126],"domain_scores_gemma":[0.9989038,0.00024917617,0.000096161966,0.00040091644,0.00011177542,0.00023817038],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014354519,0.00023099061,0.00075933925,0.00021822091,0.00003330887,0.000026356287,0.000204993,0.00006738393,0.0010115004],"category_scores_gemma":[0.000054250904,0.00014231763,0.000037790753,0.0010266898,0.00023968043,0.00006202257,0.00019667437,0.00068656664,0.0000029228304],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015247298,0.0022827736,0.9505548,0.000118305936,0.00008031375,0.00054829253,0.025253454,0.0000082160595,0.0011627516,0.0000071754007,0.000014327311,0.00472231],"study_design_scores_gemma":[0.026213048,0.0029817137,0.95046324,0.000087688975,0.000054884913,0.00001624547,0.019256108,0.00024695075,0.00049280224,0.000014639887,0.000021758455,0.00015089668],"about_ca_topic_score_codex":0.10113132,"about_ca_topic_score_gemma":0.21867257,"teacher_disagreement_score":0.11754125,"about_ca_system_score_codex":0.00025270018,"about_ca_system_score_gemma":0.00052545225,"threshold_uncertainty_score":0.9999017},"labels":[],"label_agreement":null},{"id":"W3100538981","doi":"10.1136/jitc-2020-sitc2020.0379","title":"379 Initial safety, efficacy, and product attributes from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating an affinity optimized TCR targeting MAGE-A4 and a CD8α co-receptor","year":2020,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"CD8; Medicine; T-cell receptor; Internal medicine; Antigen; Cancer; T cell; Gastroenterology; Oncology; Immunology; Immune system","score_opus":0.05083607555745884,"score_gpt":0.29174663320772787,"score_spread":0.24091055765026903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3100538981","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877034,0.0016497744,0.000028218177,0.00748589,0.00013399094,0.0023831762,0.00021629038,0.00014620763,0.0002530504],"genre_scores_gemma":[0.9901129,0.00066925865,0.005553754,0.0009491079,0.0018634677,0.000045926816,0.000591942,0.00011506757,0.000098588986],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9963791,0.0005882738,0.0006779556,0.0009860826,0.0007941758,0.0005744064],"domain_scores_gemma":[0.9971172,0.00058232155,0.00034490082,0.00048388258,0.00020206957,0.0012696288],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001627317,0.0005189734,0.000867628,0.000073188436,0.00048461626,0.00039574027,0.00022564101,0.00020883816,0.00015000334],"category_scores_gemma":[0.0012101245,0.0003587706,0.00009039772,0.0003097787,0.0010350824,0.0003364893,0.0001394323,0.0009105758,0.00001066612],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.105397224,0.0007482465,0.03675377,0.00034661463,0.0008368751,0.00039514346,0.008434168,0.00013589933,0.8326491,0.000035106194,0.005593158,0.008674676],"study_design_scores_gemma":[0.31723574,0.015461815,0.109670185,0.0010727455,0.0010133969,0.00046271054,0.005204679,0.002866653,0.5051961,0.00036104108,0.03841686,0.0030380897],"about_ca_topic_score_codex":0.0005842632,"about_ca_topic_score_gemma":0.000038598224,"teacher_disagreement_score":0.32745305,"about_ca_system_score_codex":0.000052177103,"about_ca_system_score_gemma":0.00066705997,"threshold_uncertainty_score":0.99988645},"labels":[],"label_agreement":null},{"id":"W3101174158","doi":"10.1016/j.jid.2020.09.020","title":"Research Techniques Made Simple: Preclinical Development of Combination Antitumor Targeted Therapies in Dermatology","year":2020,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Cutaneous Lymphoma Foundation","keywords":"Medicine; Clinical trial; Targeted therapy; Combination therapy; Prioritization; Drug; Malignancy; Drug development; In vivo; Cancer; Pharmacology; Oncology; Internal medicine; Biology; Biotechnology","score_opus":0.1451068651535191,"score_gpt":0.4251670234765556,"score_spread":0.28006015832303655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3101174158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96656656,0.0007168959,0.00032791222,0.031405777,0.000051238858,0.00050605944,0.0000025613292,0.000020324236,0.0004026613],"genre_scores_gemma":[0.9849445,0.00017817657,0.013714458,0.0010131974,0.000065383065,0.000019847525,0.000010959703,0.000026257161,0.000027213686],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9957224,0.0013537772,0.0015473991,0.00023234995,0.00071810617,0.00042592484],"domain_scores_gemma":[0.99679184,0.0009038239,0.0005432738,0.0001711664,0.0012744457,0.00031545243],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013328607,0.00017611923,0.0010105848,0.0007959804,0.000070833914,0.000012089517,0.0003319379,0.00026135246,0.00034348524],"category_scores_gemma":[0.002272639,0.00014679898,0.00011808715,0.00092472835,0.0013642448,0.0001552955,0.00013249286,0.0014537824,0.0000113534525],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010583653,0.00040290266,0.056922514,0.00034715328,0.00024855245,0.00093454384,0.007763236,0.0000011766866,0.92427474,0.0009684189,0.0031110877,0.0039673117],"study_design_scores_gemma":[0.0021904388,0.00069141126,0.06153027,0.00016623527,0.000016227874,0.0015901087,0.0015278523,0.00013839306,0.92122155,0.0031052225,0.0077152285,0.00010703699],"about_ca_topic_score_codex":0.000009756242,"about_ca_topic_score_gemma":0.000014057358,"teacher_disagreement_score":0.030392578,"about_ca_system_score_codex":0.00014276458,"about_ca_system_score_gemma":0.0014094918,"threshold_uncertainty_score":0.6316042},"labels":[],"label_agreement":null},{"id":"W3102155626","doi":"10.3389/fimmu.2020.599253","title":"Strategies to Enhance the Efficacy of T-Cell Therapy for Central Nervous System Tumors","year":2020,"lang":"en","type":"review","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Terry Fox Research Institute","keywords":"Central nervous system; Medicine; Neuroscience; Biology","score_opus":0.027567218939237494,"score_gpt":0.3396758244206966,"score_spread":0.31210860548145913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3102155626","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000254633,0.9890769,0.0019475695,0.00022985136,0.0015396377,0.005716908,0.00004485881,0.0000525925,0.0011370628],"genre_scores_gemma":[0.0003981966,0.99545157,0.0015134615,0.000053715874,0.000283093,0.00068614655,0.000071101174,0.00011191846,0.0014307931],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99704856,0.00045717234,0.0009159381,0.00057099084,0.0002515907,0.00075577147],"domain_scores_gemma":[0.99818474,0.00042817317,0.00033614185,0.00085495587,0.00009743343,0.00009858338],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00040409013,0.00045097058,0.002851113,0.00036331895,0.00005827716,0.000027324775,0.0008600682,0.00040155917,0.000070159615],"category_scores_gemma":[0.00010164033,0.0003014019,0.0006600861,0.0006850553,0.00028797047,0.000031777545,0.00011386642,0.00087043515,0.000018026183],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013847714,0.00013458359,0.000007596981,0.00870755,0.0007239438,0.00005228529,0.0007384033,0.000003740153,0.0007535675,0.00017851338,0.004187452,0.9831276],"study_design_scores_gemma":[0.0012310079,0.0011954283,0.000041771036,0.0038029575,0.00018605265,0.000057701556,0.0017614574,0.000014455477,0.0005533891,0.00001699223,0.9909053,0.00023352803],"about_ca_topic_score_codex":0.000069484355,"about_ca_topic_score_gemma":0.000004269841,"teacher_disagreement_score":0.9867178,"about_ca_system_score_codex":0.00051799475,"about_ca_system_score_gemma":0.0012930015,"threshold_uncertainty_score":0.9999438},"labels":[],"label_agreement":null},{"id":"W3103755750","doi":"10.1101/109785","title":"A cell-topography based mechanism for ligand discrimination by the T-cell receptor","year":2017,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"University of California, San Francisco; Medical Research Council; Royal Society; Directorate for Biological Sciences; University of Oxford; Cancer Research UK; Wellcome Trust","keywords":"T-cell receptor; Major histocompatibility complex; Receptor; Cell biology; Biology; Phosphatase; T cell; Cell; Agonist; Phosphorylation; Antigen; Immunology; Immune system; Biochemistry","score_opus":0.023857386497256914,"score_gpt":0.2668557185427346,"score_spread":0.2429983320454777,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3103755750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9603321,0.0031798412,0.01502081,0.006295222,0.0029119004,0.009675139,0.0016280588,0.0006112306,0.00034570417],"genre_scores_gemma":[0.99138147,0.0006027449,0.0040747914,0.0006140023,0.0008315462,0.0015997895,0.0000075551116,0.0002929515,0.00059517473],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99639493,0.00016622033,0.0005387573,0.0012097065,0.00088688714,0.0008035044],"domain_scores_gemma":[0.9948977,0.00023414928,0.0005864778,0.0027407585,0.0011373073,0.0004036074],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013658095,0.0006803249,0.0007600869,0.0003772589,0.00056088355,0.00046366727,0.0009978575,0.0007414868,0.00025067123],"category_scores_gemma":[0.00032429848,0.0005597331,0.0005563494,0.00029392613,0.00025704797,0.00010835922,0.00032163024,0.0011594993,0.000049410526],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030955684,0.0004177265,0.0003870454,0.0013091468,0.00013557749,0.00001045186,0.000020590982,0.0000017489367,0.98389786,0.0002771733,0.013222443,0.000010647529],"study_design_scores_gemma":[0.0026224826,0.0002997908,0.00076975836,0.00042495597,0.00035133256,1.2954815e-8,0.000009647689,0.00080170715,0.9618557,0.000015986367,0.032250356,0.0005982491],"about_ca_topic_score_codex":0.000101404155,"about_ca_topic_score_gemma":0.0000027975832,"teacher_disagreement_score":0.03104935,"about_ca_system_score_codex":0.0003217365,"about_ca_system_score_gemma":0.0009677015,"threshold_uncertainty_score":0.9996854},"labels":[],"label_agreement":null},{"id":"W3103926827","doi":"10.1136/jitc-2020-sitc2020.0155","title":"155 iPSC-derived NK cells mediate robust anti-tumor activity against glioblastoma","year":2020,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cytotoxic T cell; Cancer research; Immunotherapy; Adoptive cell transfer; NK-92; Cytotoxicity; Perforin; Biology; Immunology; Interleukin 21; Immune system; CD8; T cell; In vitro","score_opus":0.03077527250515736,"score_gpt":0.25573247412130745,"score_spread":0.2249572016161501,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3103926827","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9904399,0.00032668028,0.00003463042,0.005609647,0.000330044,0.0007528602,0.00003716172,0.00026618943,0.002202919],"genre_scores_gemma":[0.9949847,0.00048410866,0.0004733313,0.0025227757,0.00073677476,0.000024276093,0.000027444114,0.000114587405,0.0006320299],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99684066,0.00015028559,0.0004771126,0.0008232445,0.00091901596,0.00078965793],"domain_scores_gemma":[0.99656725,0.000105171515,0.00020327432,0.0005435189,0.00016828549,0.002412495],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00047895883,0.00047065062,0.0007854898,0.000156024,0.00020384754,0.00014689949,0.00024160216,0.00024546485,0.00024391076],"category_scores_gemma":[0.00056214555,0.0004368229,0.00022418927,0.00044659275,0.00061829755,0.00028856902,0.00015553743,0.0008181664,0.00015842257],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003834572,0.0001271896,0.0025944328,0.0004542587,0.00014207952,0.0012931027,0.0005437895,0.00022632687,0.9877215,0.000012983098,0.00406427,0.0024366206],"study_design_scores_gemma":[0.0026852973,0.00058949227,0.031133218,0.00023606732,0.00012556122,0.00024762747,0.00020747747,0.0029173822,0.9470398,0.000036886933,0.014239373,0.00054186117],"about_ca_topic_score_codex":0.00006286561,"about_ca_topic_score_gemma":0.000020609641,"teacher_disagreement_score":0.04068173,"about_ca_system_score_codex":0.00011696312,"about_ca_system_score_gemma":0.00061004,"threshold_uncertainty_score":0.9998084},"labels":[],"label_agreement":null},{"id":"W3103985965","doi":"10.1172/jci.insight.141293","title":"A soluble activator that favors the ex vivo expansion of CD8+CD27+ T cells","year":2020,"lang":"en","type":"article","venue":"JCI Insight","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Hospital","funders":"Canadian Institutes of Health Research","keywords":"CD28; Ex vivo; Cytotoxic T cell; T cell; CD8; Chemistry; Population; Cell biology; Molecular biology; Biology; Immunology; In vitro; Immune system; Biochemistry; Medicine","score_opus":0.06198926715532612,"score_gpt":0.3009758882724902,"score_spread":0.2389866211171641,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3103985965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94738525,0.000585218,0.00013240668,0.007268192,0.00037638843,0.00097539555,0.000010236605,0.0000925783,0.04317435],"genre_scores_gemma":[0.9851003,0.00031840935,0.00013091514,0.0020010618,0.00036477728,0.000019388797,0.0000069402236,0.00004936712,0.012008802],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99834126,0.000097997654,0.00023451888,0.00030128047,0.00070782745,0.00031713094],"domain_scores_gemma":[0.99885374,0.0001883258,0.0000908118,0.0005338311,0.000099756806,0.0002335106],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00018314655,0.00017042762,0.0003549407,0.00007123307,0.00007950304,0.000024418765,0.00025055543,0.00011744163,0.006329093],"category_scores_gemma":[0.00007353528,0.00010656212,0.00017643713,0.0003895394,0.00013819333,0.000102918704,0.0001454144,0.0003973513,0.0001675422],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055385486,0.00009766964,0.00045215673,0.000101994694,0.000074100615,0.000030379257,0.0047605,0.0000042850334,0.964922,0.00004880077,0.02567552,0.0032787346],"study_design_scores_gemma":[0.0008779193,0.00034105885,0.00024414912,0.000042943433,0.000025641635,0.00000482792,0.00060328795,0.00023468804,0.7061753,0.000019613944,0.2913477,0.00008286941],"about_ca_topic_score_codex":0.00012468867,"about_ca_topic_score_gemma":0.0000084147205,"teacher_disagreement_score":0.26567218,"about_ca_system_score_codex":0.00006320017,"about_ca_system_score_gemma":0.00019757618,"threshold_uncertainty_score":0.99457926},"labels":[],"label_agreement":null},{"id":"W3105835028","doi":"10.1158/2326-6066.cir-20-0138","title":"A Bispecific Antibody Antagonizes Prosurvival CD40 Signaling and Promotes Vγ9Vδ2 T cell–Mediated Antitumor Responses in Human B-cell Malignancies","year":2020,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Academisch Medisch Centrum; Vrije Universiteit Amsterdam","keywords":"CD40; Cancer research; T cell; Chronic lymphocytic leukemia; B cell; Jurkat cells; Antibody; Cytotoxic T cell; Immunology; Biology; Leukemia; Medicine; In vitro; Immune system","score_opus":0.10189720866426633,"score_gpt":0.402953893935271,"score_spread":0.30105668527100465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3105835028","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97236305,0.019294068,0.000005751669,0.0049034986,0.0001051958,0.0018321334,0.00005634126,0.000118530435,0.0013214154],"genre_scores_gemma":[0.98803824,0.0055987802,0.00010059433,0.00016311028,0.0002650724,0.00024462718,0.00007690056,0.00010160645,0.005411079],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9948837,0.0011359215,0.0006118023,0.0010234073,0.0008969602,0.0014481718],"domain_scores_gemma":[0.99759096,0.00083577266,0.00010322282,0.00056458876,0.0005855698,0.00031986964],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0021111255,0.00035207288,0.00082251086,0.00089740194,0.00040400308,0.00013606172,0.0004968894,0.00031824523,0.001886904],"category_scores_gemma":[0.00064390677,0.00032266098,0.00010192059,0.0018651907,0.0016725519,0.00016762046,0.0004932503,0.001988902,0.00008731317],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041070133,0.00031267828,0.12702295,0.0005251216,0.00008228426,0.0007363533,0.0020496072,0.0000013735936,0.86411333,0.000044189503,0.00031083476,0.0006942814],"study_design_scores_gemma":[0.0064622583,0.0028718421,0.04306762,0.0003506706,0.000023594528,0.000061521765,0.002535766,0.00017797886,0.9366136,0.00005936584,0.007399215,0.000376521],"about_ca_topic_score_codex":0.0007382396,"about_ca_topic_score_gemma":0.00006776034,"teacher_disagreement_score":0.08395533,"about_ca_system_score_codex":0.00028909493,"about_ca_system_score_gemma":0.0013584542,"threshold_uncertainty_score":0.9999226},"labels":[],"label_agreement":null},{"id":"W3106718898","doi":"10.1101/2020.12.03.410043","title":"CRISPR-mediated deletion of the Protein tyrosine phosphatase, non-receptor type 22 (PTPN22) improves human T cell function for adoptive T cell therapy","year":2020,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Cancer Research UK; Wellcome Trust","keywords":"T cell; Adoptive cell transfer; T-cell receptor; Cancer research; Biology; PTPN22; Cancer immunotherapy; Protein tyrosine phosphatase; Immunotherapy; Immunology; Cell biology; Molecular biology; Immune system; Signal transduction; Biochemistry","score_opus":0.02312781428940109,"score_gpt":0.2578207005970101,"score_spread":0.23469288630760904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3106718898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836793,0.0026065016,0.0010514832,0.0005532601,0.0012872241,0.009548396,0.00096810836,0.0002651477,0.000040588453],"genre_scores_gemma":[0.9949717,0.00041674834,0.0017576433,0.0003726367,0.00091815426,0.0010164556,0.000032045136,0.00030202663,0.00021260668],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9962513,0.00019425312,0.0008222731,0.0011961156,0.00085387204,0.0006822302],"domain_scores_gemma":[0.9953555,0.00009887358,0.000819077,0.0015681768,0.0018056075,0.000352775],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00072037766,0.00073081505,0.0009600617,0.00025656112,0.0002416378,0.000102926555,0.00064579374,0.0007394874,0.00069640006],"category_scores_gemma":[0.0002062219,0.000605503,0.0004424846,0.0009993402,0.00025414443,0.00011375769,0.000382372,0.0013346798,0.000064273656],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024013447,0.0006267098,0.00084989297,0.001424371,0.00025095735,0.000004833133,0.000032853273,0.0000080557365,0.9908127,0.000048592367,0.003522703,0.00001697598],"study_design_scores_gemma":[0.0037773019,0.0015807503,0.01574671,0.0003787212,0.00020303007,7.961011e-9,0.000012882279,0.0002841443,0.95585793,0.0000028296947,0.021619936,0.00053576473],"about_ca_topic_score_codex":0.00015040784,"about_ca_topic_score_gemma":0.0000026746359,"teacher_disagreement_score":0.03495479,"about_ca_system_score_codex":0.00043700045,"about_ca_system_score_gemma":0.0012733254,"threshold_uncertainty_score":0.99963963},"labels":[],"label_agreement":null},{"id":"W3107015789","doi":"10.1016/j.cellimm.2020.104253","title":"Novel T regulatory cells come of age: The curious incident of a mouse in Tennessee, delayed thymectomy and chimeric receptors!","year":2020,"lang":"en","type":"article","venue":"Cellular Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Heart, Lung, and Blood Institute","keywords":"Thymectomy; Biology; Receptor; Cell biology; Immunology; Neuroscience; Genetics; Myasthenia gravis","score_opus":0.0188192193285635,"score_gpt":0.2558864227575448,"score_spread":0.2370672034289813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3107015789","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991474,0.0063513415,0.00012978363,0.0010102579,0.00011714454,0.0006289243,0.000007715563,0.000020582329,0.0002602501],"genre_scores_gemma":[0.99767685,0.00081966596,0.00017682223,0.00021159207,0.000040093855,0.000021581376,0.000021098653,0.000037391757,0.0009949285],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99845886,0.00018343274,0.0005017902,0.00029426094,0.00025054085,0.00031110487],"domain_scores_gemma":[0.99894243,0.00017519134,0.00019193096,0.000524856,0.00008608853,0.00007947654],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003545498,0.00017734389,0.00060595595,0.0001760737,0.00003437929,0.0000057993893,0.00027960617,0.0001740753,0.0005500317],"category_scores_gemma":[0.00009644594,0.0001368506,0.00010453599,0.0004965823,0.00067165564,0.00003506454,0.00023816573,0.0005068537,0.000014537104],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009230869,0.00021275032,0.0017405183,0.00011346687,0.00020285364,0.00005219579,0.00208959,0.000008420854,0.9929787,0.00012169662,0.00008075841,0.0014759515],"study_design_scores_gemma":[0.0037874146,0.0009750658,0.010019036,0.000040542996,0.000059523754,0.000057720335,0.00064287614,0.00025133963,0.97938627,0.00003443815,0.0046023857,0.00014339022],"about_ca_topic_score_codex":0.0003957446,"about_ca_topic_score_gemma":0.000023311635,"teacher_disagreement_score":0.013592444,"about_ca_system_score_codex":0.000057826262,"about_ca_system_score_gemma":0.00012568352,"threshold_uncertainty_score":0.60224617},"labels":[],"label_agreement":null},{"id":"W3107336455","doi":"10.1101/2020.12.03.410316","title":"Augmented expansion of Treg cells from healthy and autoimmune subjects via adult progenitor cell co-culture","year":2020,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"","keywords":"FOXP3; Cell therapy; Immunology; Progenitor cell; Adoptive cell transfer; Biology; Transplantation; Autoimmunity; Regulatory T cell; T cell; Immune system; Cancer research; Cell biology; Stem cell; Medicine; IL-2 receptor; Internal medicine","score_opus":0.01656281229336875,"score_gpt":0.2598523381040351,"score_spread":0.24328952581066632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3107336455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99001306,0.0045750826,0.00021567704,0.000615897,0.0007160749,0.0028310248,0.000647234,0.00035875585,0.000027181433],"genre_scores_gemma":[0.99222094,0.0022489408,0.0038505376,0.00045214494,0.0006984511,0.00021884228,0.000009753657,0.00024110169,0.000059312304],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99557143,0.0002995673,0.0009350967,0.0014458271,0.001026466,0.0007215914],"domain_scores_gemma":[0.99603575,0.00010541383,0.00062580325,0.001518645,0.00096493075,0.00074947125],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00038917398,0.0007785107,0.0014472088,0.00030481222,0.00014465807,0.00009648023,0.00045157864,0.0009404187,0.00037036874],"category_scores_gemma":[0.0001294291,0.0007562116,0.00029046214,0.0006005819,0.00025180104,0.000092509945,0.00048084554,0.001650313,0.000063729894],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001518865,0.00040928053,0.0031856354,0.0022489557,0.00033704558,0.00015914364,0.00015289815,0.0000018492229,0.99110603,0.000006974011,0.0008469997,0.000026311514],"study_design_scores_gemma":[0.003643024,0.0007127471,0.02560851,0.000837636,0.00027205434,5.2628494e-8,0.000022053007,0.0004347199,0.96380043,0.0000012753792,0.0040795626,0.0005879377],"about_ca_topic_score_codex":0.00047339645,"about_ca_topic_score_gemma":0.0000046871546,"teacher_disagreement_score":0.027305616,"about_ca_system_score_codex":0.00042410643,"about_ca_system_score_gemma":0.001327732,"threshold_uncertainty_score":0.9994889},"labels":[],"label_agreement":null},{"id":"W3107906372","doi":"10.1016/j.drudis.2020.11.028","title":"Bioengineered tissue models for the development of dynamic immuno-associated tumor models and high-throughput immunotherapy cytotoxicity assays","year":2020,"lang":"en","type":"review","venue":"Drug Discovery Today","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; BC Cancer Foundation","keywords":"Immunotherapy; Cancer immunotherapy; Immune system; Chimeric antigen receptor; Cancer; Cancer research; Tumor microenvironment; Immune checkpoint; Cancer cell; Immunology; Biology","score_opus":0.04302134812861547,"score_gpt":0.3330761081072176,"score_spread":0.29005475997860214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3107906372","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000619676,0.9642145,0.027460037,0.00030234345,0.0002632679,0.005839548,0.0010083136,0.0000975491,0.00019475116],"genre_scores_gemma":[0.006880045,0.98421174,0.0017946172,0.00009367137,0.00010823864,0.0009975166,0.0010079583,0.00029556762,0.0046106176],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958066,0.000264763,0.0014605128,0.0008728981,0.000862217,0.00073303364],"domain_scores_gemma":[0.9969632,0.0010805303,0.00060807477,0.0009810982,0.0002038942,0.00016321082],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011962547,0.0008804424,0.0032293685,0.0002529959,0.00023577135,0.00013625588,0.00068667246,0.00033364096,0.00011807296],"category_scores_gemma":[0.00008973851,0.0005947127,0.00070371054,0.0006132839,0.00022847168,0.0003520083,0.00029436682,0.00083478884,0.000009219345],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000664386,0.0005451668,9.2877536e-7,0.013325814,0.005523879,0.00003095679,0.002644938,0.0004383091,0.003438554,0.00084176956,0.0006049945,0.9719403],"study_design_scores_gemma":[0.009383452,0.00094161,0.00003968994,0.022815851,0.0033237583,0.000121221055,0.00059579004,0.070190474,0.0031313233,0.0030386534,0.8836018,0.0028164105],"about_ca_topic_score_codex":0.0001526023,"about_ca_topic_score_gemma":0.000050253955,"teacher_disagreement_score":0.9691239,"about_ca_system_score_codex":0.0009229983,"about_ca_system_score_gemma":0.0016805636,"threshold_uncertainty_score":0.9996504},"labels":[],"label_agreement":null},{"id":"W3107960404","doi":"10.1097/cmr.0000000000000708","title":"Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218)","year":2020,"lang":"en","type":"article","venue":"Melanoma Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; London Health Sciences Centre","funders":"National Center for Advancing Translational Sciences; National Cancer Institute","keywords":"Ipilimumab; Nivolumab; Medicine; Discontinuation; Expanded access; Internal medicine; Melanoma; Adverse effect; Oncology; Gastroenterology; Immunotherapy; Cancer; Cancer research","score_opus":0.04357598447339473,"score_gpt":0.35743983192359097,"score_spread":0.31386384745019624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3107960404","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937678,0.000096741875,0.00000997157,0.0010884614,0.0000222519,0.0035978518,0.00013499531,0.00007723223,0.0012046734],"genre_scores_gemma":[0.99812514,0.0001578362,0.0005765679,0.00003469892,0.000056332094,0.000136174,0.0006168729,0.00006398974,0.00023236898],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954294,0.0005216351,0.00066772796,0.0008422241,0.0017827387,0.00075625285],"domain_scores_gemma":[0.99735224,0.0006813895,0.00019551224,0.00062640064,0.0006999122,0.00044454317],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071664347,0.0002610881,0.00079774496,0.00043502456,0.00012255681,0.00008692347,0.00044837553,0.00008913304,0.00010884169],"category_scores_gemma":[0.0007618429,0.00021712547,0.000055371656,0.002220909,0.00061972975,0.00023183627,0.0004058552,0.00087337394,0.000015106541],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10846504,0.0017558951,0.57035893,0.00016615963,0.00015280832,0.00008791468,0.00222159,0.000016704638,0.0013566507,0.0000084761905,0.00006658461,0.31534326],"study_design_scores_gemma":[0.060728446,0.009849124,0.92417264,0.00014349051,0.000021132808,0.0000017558705,0.00032273328,0.0017870397,0.0021129732,0.000007920376,0.0006508669,0.00020186484],"about_ca_topic_score_codex":0.0021542488,"about_ca_topic_score_gemma":0.001053806,"teacher_disagreement_score":0.35381374,"about_ca_system_score_codex":0.0003932603,"about_ca_system_score_gemma":0.00038856716,"threshold_uncertainty_score":0.88541204},"labels":[],"label_agreement":null},{"id":"W3109522219","doi":"10.1016/j.jcyt.2020.11.005","title":"Cell and gene therapy: a snapshot of investor perspectives","year":2020,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"International Society for Cellular Therapy","funders":"","keywords":"Commercialization; Investment (military); Business; Health care; Finance; Public relations; Marketing; Economic growth; Political science; Economics","score_opus":0.05545039414905898,"score_gpt":0.3086664867644414,"score_spread":0.2532160926153824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3109522219","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9745884,0.014729286,0.000071171424,0.0041726045,0.00002317666,0.0005233979,0.0000091338725,0.000042005027,0.005840827],"genre_scores_gemma":[0.984767,0.009174807,0.0012988835,0.0028482117,0.00031970697,0.000021819042,0.000008767381,0.000060252893,0.0015005097],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99892664,0.00006391585,0.00018414183,0.00032272958,0.00028460985,0.00021795275],"domain_scores_gemma":[0.9992665,0.000060158214,0.00005779973,0.000264431,0.00010401253,0.00024710695],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00013344367,0.00015851176,0.00035893533,0.00008590138,0.00003733714,0.000015104581,0.000106766616,0.000080116755,0.0061508613],"category_scores_gemma":[0.00002334858,0.00013065105,0.00010587993,0.00025770877,0.00023676369,0.000047310077,0.000022190332,0.00019256653,0.000011564086],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014608371,0.00016557096,0.0050966344,0.00005129984,0.00010792254,0.000015807214,0.012546444,6.9630227e-7,0.9712654,0.00010303531,0.001674051,0.0075123147],"study_design_scores_gemma":[0.0073533026,0.0029652494,0.010244738,0.000022593607,0.000018449085,0.000027494389,0.0021703101,0.00016995968,0.9125043,0.00014244401,0.06415623,0.00022494863],"about_ca_topic_score_codex":0.00002893802,"about_ca_topic_score_gemma":8.9096187e-7,"teacher_disagreement_score":0.062482174,"about_ca_system_score_codex":0.00003634352,"about_ca_system_score_gemma":0.000120890036,"threshold_uncertainty_score":0.99475765},"labels":[],"label_agreement":null},{"id":"W3109845612","doi":"10.1016/j.xpro.2020.100174","title":"Preclinical Testing of CAR T Cells in a Patient-Derived Xenograft Model of Glioblastoma","year":2020,"lang":"en","type":"article","venue":"STAR Protocols","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Canadian Institutes of Health Research; Terry Fox Research Institute; McMaster University","keywords":"Chimeric antigen receptor; Glioblastoma; Peripheral blood mononuclear cell; Medicine; Chemoradiotherapy; Cancer research; Antigen; Brain tumor; Immunotherapy; Immunology; Cancer; Pathology; Biology; Immune system; Internal medicine; In vitro","score_opus":0.1256574991849608,"score_gpt":0.38675527411642496,"score_spread":0.26109777493146413,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3109845612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9146774,0.000006477354,0.00009333511,0.0001558723,0.0000058088162,0.084324785,0.000039425955,0.0000318603,0.0006650713],"genre_scores_gemma":[0.9585804,0.0000014056068,0.00995928,0.00014359507,0.000048619047,0.03117095,0.0000029498015,0.000043471933,0.000049331637],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99810123,0.00011825864,0.0006935666,0.00029243415,0.0005034906,0.0002910302],"domain_scores_gemma":[0.99884444,0.00021039828,0.00018577074,0.00032474508,0.000244653,0.00019000923],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003131291,0.00013876669,0.00051325874,0.000102684004,0.000014213125,0.000005658438,0.00015851868,0.00010426412,0.00024931852],"category_scores_gemma":[0.0005834757,0.00012541242,0.00011748813,0.00046740012,0.00013872878,0.000046886966,0.00012877419,0.00034261864,0.0000073821634],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032015485,0.00033069775,0.0045386595,0.00077739323,0.000029151875,0.000023581355,0.0019314508,0.00053127593,0.97882825,0.000004871073,0.00007477274,0.0097283665],"study_design_scores_gemma":[0.0037846556,0.0063207024,0.00041090566,0.0005355949,0.000012213305,0.0000024390424,0.00017999893,0.042372268,0.94568086,0.00008092983,0.0005082649,0.00011116653],"about_ca_topic_score_codex":0.00004050152,"about_ca_topic_score_gemma":0.000011294727,"teacher_disagreement_score":0.05315383,"about_ca_system_score_codex":0.000042551877,"about_ca_system_score_gemma":0.00035284244,"threshold_uncertainty_score":0.511417},"labels":[],"label_agreement":null},{"id":"W3109958337","doi":"10.1016/j.drudis.2020.11.024","title":"Market access of gene therapies across Europe, USA, and Canada: challenges, trends, and solutions","year":2020,"lang":"en","type":"review","venue":"Drug Discovery Today","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Fonds Wetenschappelijk Onderzoek; Canadian Armed Forces; Vlaamse regering; McMaster University","keywords":"Market access; Drug discovery; Computational biology; Business; Biology; Bioinformatics; Ecology","score_opus":0.08096664045937163,"score_gpt":0.3571380909215697,"score_spread":0.27617145046219804,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3109958337","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00034265677,0.98867637,0.0000020942075,0.0018210909,0.00016094174,0.0005488236,0.001185971,0.00001510672,0.0072469166],"genre_scores_gemma":[0.00021953604,0.96385276,0.000014566258,0.00009524687,0.00026984027,0.000059214926,0.00016418137,0.00009060666,0.03523405],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99740136,0.00032342764,0.00054164807,0.00066104275,0.0005491353,0.0005234162],"domain_scores_gemma":[0.9984824,0.00034045544,0.00023726917,0.00057295937,0.000092230825,0.00027468227],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000457835,0.0004688921,0.0018868174,0.0001570892,0.00013153534,0.00012392028,0.0003542039,0.00014482575,0.0007518624],"category_scores_gemma":[0.0000860664,0.00035455264,0.00020237184,0.00043469036,0.0003006709,0.00022189955,0.00048205946,0.00054267724,0.0000027472452],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008429199,0.00006139012,0.00009784153,0.008847026,0.0006959387,0.00015354382,0.0003184161,8.5856676e-8,0.000015707528,0.00007761371,0.014073031,0.9755751],"study_design_scores_gemma":[0.00050522346,0.00006645862,0.0017194683,0.0023543192,0.00035699215,0.00014119939,0.00011831111,0.00000298322,0.000010274692,0.000004394803,0.9944286,0.00029182585],"about_ca_topic_score_codex":0.067436986,"about_ca_topic_score_gemma":0.2506449,"teacher_disagreement_score":0.9803555,"about_ca_system_score_codex":0.00017399692,"about_ca_system_score_gemma":0.0013949852,"threshold_uncertainty_score":0.9998906},"labels":[],"label_agreement":null},{"id":"W3110516422","doi":"10.1158/2643-3249.lymphoma20-po-42","title":"Abstract PO-42: TBL1XR1 mutations drive extranodal lymphomagenesis by inducing a protumorigenic memory B-cell fate","year":2020,"lang":"en","type":"article","venue":"Blood Cancer Discovery","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of Toronto","funders":"","keywords":"Germinal center; BCL6; Biology; Transcription factor; Cancer research; Phenotype; Cell fate determination; Lymphoma; Reprogramming; B cell; Immune system; Cell; Gene; Immunology; Genetics; Antibody","score_opus":0.02507749552767352,"score_gpt":0.2904823327413624,"score_spread":0.2654048372136889,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3110516422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98319,0.0045069195,0.00011591066,0.0023621656,0.00019975098,0.0014652708,0.0003025434,0.00012497471,0.0077324808],"genre_scores_gemma":[0.9847895,0.0008380734,0.00012698257,0.0012541156,0.00078807725,0.0005466266,0.00011847178,0.000122053374,0.011416132],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972727,0.00006890841,0.00045949954,0.0007545928,0.00078180735,0.00066253147],"domain_scores_gemma":[0.99872726,0.000093058865,0.00015171376,0.00045480506,0.00012302816,0.00045014903],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00017337079,0.00035436737,0.0005024279,0.00012186278,0.00017224016,0.00014803659,0.00027429892,0.00014184856,0.003855737],"category_scores_gemma":[0.00005003581,0.00033535532,0.0002917231,0.0005646144,0.00014571538,0.00044762445,0.00008935305,0.0004197669,0.00014878645],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00062443415,0.000567794,0.004152598,0.000491583,0.0004036749,0.00026057207,0.0019252253,0.00010150294,0.975775,0.0000042110473,0.0036744247,0.012018963],"study_design_scores_gemma":[0.008136281,0.00048186316,0.012659371,0.00021394703,0.00057742,0.00004868566,0.0012728889,0.00010871315,0.9706259,0.000026169066,0.0053029642,0.0005458255],"about_ca_topic_score_codex":0.0011906317,"about_ca_topic_score_gemma":0.000081175036,"teacher_disagreement_score":0.011473137,"about_ca_system_score_codex":0.0002583301,"about_ca_system_score_gemma":0.0012734112,"threshold_uncertainty_score":0.9999098},"labels":[],"label_agreement":null},{"id":"W3110898018","doi":"10.1111/tan.14168","title":"A one‐step assay for sorted <scp>CD3</scp><sup>+</sup> cell purity and chimerism after hematopoietic stem cell transplantation","year":2020,"lang":"en","type":"article","venue":"HLA","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Flow cytometry; Molecular biology; CD3; Biology; Haematopoiesis; Transplantation; Hematopoietic stem cell transplantation; Stem cell; Polymerase chain reaction; Immunology; Antigen; CD8; Medicine; Genetics; Gene","score_opus":0.025073789143125337,"score_gpt":0.26415380728179283,"score_spread":0.2390800181386675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3110898018","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98716336,0.0012039146,0.0033905196,0.0008962838,0.00004540024,0.001669904,0.00008910653,0.00012059285,0.005420922],"genre_scores_gemma":[0.9903281,0.00045265557,0.0009755334,0.0009029523,0.000251127,0.0002265918,0.000098070734,0.00007923852,0.0066857506],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99812055,0.00012883596,0.00033011258,0.0004964888,0.00046837277,0.00045566953],"domain_scores_gemma":[0.9987978,0.00035772324,0.00006813263,0.00028485805,0.00009861052,0.00039292654],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033050767,0.0002346899,0.00043821905,0.000094208095,0.000078131125,0.00005651342,0.00011127721,0.00018761767,0.0004176437],"category_scores_gemma":[0.000024749621,0.00023211184,0.00016492257,0.00022693136,0.00007813535,0.00008852276,0.000031180032,0.00035228694,0.00009164018],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037146157,0.001577407,0.02018059,0.015788585,0.0004370586,0.0005445668,0.06062141,0.000043037635,0.84947073,0.0000771198,0.011918094,0.03562676],"study_design_scores_gemma":[0.02844177,0.0038822123,0.03022529,0.0005966173,0.0016811097,0.00023761581,0.006375433,0.024389109,0.79111964,0.00026948797,0.11200272,0.0007789808],"about_ca_topic_score_codex":0.000025336964,"about_ca_topic_score_gemma":0.0000065083696,"teacher_disagreement_score":0.100084625,"about_ca_system_score_codex":0.000040708037,"about_ca_system_score_gemma":0.00009169026,"threshold_uncertainty_score":0.94652456},"labels":[],"label_agreement":null},{"id":"W3111908765","doi":"10.1038/s41418-020-00666-y","title":"From the T-cell receptor to cancer therapy: an interview with Tak W. Mak","year":2020,"lang":"en","type":"article","venue":"Cell Death and Differentiation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"Canadian Institutes of Health Research; Stand Up To Cancer; Cancer Research Institute","keywords":"Cancer; Receptor; Cancer research; Medicine; Biology; Internal medicine","score_opus":0.05989008136160202,"score_gpt":0.3039498188343187,"score_spread":0.2440597374727167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3111908765","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892636,0.0020103015,0.0009702318,0.0058666295,0.000077433324,0.0006406836,0.00002795306,0.000040290986,0.0011028612],"genre_scores_gemma":[0.9903188,0.0017901295,0.00018590753,0.0047639254,0.00050628826,0.000060896025,0.00016103218,0.00003085779,0.0021822045],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990459,0.000100686455,0.00013050425,0.00030109947,0.00024017015,0.0001816165],"domain_scores_gemma":[0.9993355,0.000048183007,0.0000435239,0.00022789938,0.0000681895,0.00027670292],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00007926862,0.00014164948,0.00018954437,0.000026081327,0.00007117446,0.00007222396,0.00010551693,0.000052084317,0.004269923],"category_scores_gemma":[0.000007915323,0.000081938175,0.000041154304,0.00013327146,0.000020651794,0.000059446204,0.00003501406,0.000160488,0.0000459278],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017585588,0.00024223179,0.05108979,0.00011079721,0.000082547194,0.000004360722,0.0071181273,0.00000414757,0.7888132,0.00001329992,0.005751924,0.14501104],"study_design_scores_gemma":[0.010360908,0.0042179823,0.2901669,0.000276693,0.00026890505,0.0000029292573,0.0019075857,0.0027710265,0.47612637,0.00011871744,0.21315952,0.00062246114],"about_ca_topic_score_codex":0.00029232528,"about_ca_topic_score_gemma":0.000056021676,"teacher_disagreement_score":0.31268683,"about_ca_system_score_codex":0.000032986907,"about_ca_system_score_gemma":0.000048313388,"threshold_uncertainty_score":0.9966403},"labels":[],"label_agreement":null},{"id":"W3112058853","doi":"10.1016/j.jval.2020.08.393","title":"PCN256 Health Technology Assessment for Chimeric Antigen Receptor (CAR) T-CELL Therapies for Cancer in Europe, US, and Canada","year":2020,"lang":"en","type":"article","venue":"Value in Health","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Chimeric antigen receptor; Nice; Medicine; Clinical trial; Lymphoma; Cancer; Oncology; Immunotherapy; Intensive care medicine; Internal medicine","score_opus":0.06356303064571747,"score_gpt":0.37776048199218754,"score_spread":0.31419745134647004,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3112058853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7873308,0.016228825,0.00025908786,0.19079016,0.00025235178,0.004782237,0.00022031779,0.000049597103,0.000086637585],"genre_scores_gemma":[0.9240383,0.04003305,0.012968285,0.020221898,0.0004724607,0.0010928047,0.00010600071,0.00017083423,0.0008963608],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99794364,0.0001730358,0.00050680316,0.0004481672,0.00024940723,0.00067895855],"domain_scores_gemma":[0.9990474,0.00019513197,0.00014674815,0.00021104174,0.00011224574,0.00028742052],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00076319044,0.0001691224,0.0005857029,0.00020636115,0.00009637,0.000011482001,0.00013251237,0.000072777875,0.00010382106],"category_scores_gemma":[0.00010168562,0.00015757422,0.00002927089,0.00074725575,0.000058458656,0.000027987899,0.00004140189,0.00035883117,6.4513216e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020191853,0.0005479409,0.62564045,0.008231717,0.00016865255,0.000023582788,0.004371586,0.0011294286,0.06376567,0.00095444836,0.030169368,0.262978],"study_design_scores_gemma":[0.009123519,0.0052778833,0.06293564,0.00055634,0.000008969005,0.0000095058185,0.0021936796,0.013227207,0.0028550674,0.00011691292,0.903303,0.0003922248],"about_ca_topic_score_codex":0.6915808,"about_ca_topic_score_gemma":0.3107278,"teacher_disagreement_score":0.87313366,"about_ca_system_score_codex":0.0008702216,"about_ca_system_score_gemma":0.0075440775,"threshold_uncertainty_score":0.9980822},"labels":[],"label_agreement":null},{"id":"W3112202821","doi":"10.1016/j.ygyno.2020.12.005","title":"Co-expression patterns of chimeric antigen receptor (CAR)-T cell target antigens in primary and recurrent ovarian cancer","year":2020,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of Victoria; University of British Columbia","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Chimeric antigen receptor; Medicine; Ovarian cancer; Antigen; Cancer research; Immunology; Cancer; Internal medicine; T cell; Immune system","score_opus":0.03555750875034905,"score_gpt":0.3374122596685919,"score_spread":0.3018547509182429,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3112202821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987126,0.0014126552,0.000052305033,0.0033705106,0.00031801042,0.0010381676,0.00008238361,0.00004330777,0.006556642],"genre_scores_gemma":[0.98961955,0.005765618,0.001729425,0.0019167287,0.00022039184,0.00010101888,0.00012726194,0.00003291114,0.0004871082],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9978638,0.00036457225,0.0004868489,0.0005320785,0.00025994843,0.0004927125],"domain_scores_gemma":[0.99885994,0.00034457844,0.00020886779,0.00023378042,0.00008290775,0.0002699298],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004147706,0.00021329241,0.000829577,0.000158939,0.000050818686,0.0000066697753,0.000180172,0.0003202396,0.011055661],"category_scores_gemma":[0.00016308216,0.00017891375,0.00008766481,0.0002957867,0.00015942384,0.00004878443,0.00014134796,0.0005489422,0.000032125245],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071614236,0.0004114206,0.37947246,0.00021140299,0.00002974281,0.00008600941,0.00081661344,0.000005846044,0.5860498,0.000003013667,0.0021728573,0.030024666],"study_design_scores_gemma":[0.0053162915,0.005487062,0.7132031,0.00008092648,0.000033705506,0.000014598893,0.0004907396,0.00016035135,0.14895895,0.000019736495,0.12597321,0.00026134457],"about_ca_topic_score_codex":0.0001778968,"about_ca_topic_score_gemma":0.00005451796,"teacher_disagreement_score":0.43709087,"about_ca_system_score_codex":0.00035016148,"about_ca_system_score_gemma":0.0005334711,"threshold_uncertainty_score":0.9898484},"labels":[],"label_agreement":null},{"id":"W3112510814","doi":"10.1016/j.jval.2020.08.259","title":"PCN122 Cost-Effectiveness of Brentuximab Vedotin for the Frontline Treatment of Peripheral T-Cell Lymphomas in Canada","year":2020,"lang":"en","type":"article","venue":"Value in Health","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Brentuximab vedotin; Medicine; CHOP; Vincristine; Anaplastic large-cell lymphoma; Internal medicine; Oncology; Population; Prednisone; Lymphoma; CD30; Cyclophosphamide; Chemotherapy; Environmental health","score_opus":0.09055864429809313,"score_gpt":0.34746410205941075,"score_spread":0.2569054577613176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3112510814","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.988081,0.0043368065,0.000077465316,0.0031995282,0.00012522374,0.003935441,0.00009050476,0.000005870784,0.00014817389],"genre_scores_gemma":[0.9985058,0.0007024864,0.0001633848,0.00020927316,0.00006531928,0.00021212077,0.000024137742,0.000024717217,0.00009277996],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9983144,0.0003658256,0.00046091393,0.00022372449,0.00030190442,0.00033324197],"domain_scores_gemma":[0.9984966,0.0009449888,0.00011222263,0.00023812373,0.00006440721,0.00014368155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060925685,0.00012536129,0.000579929,0.00005900777,0.000024042422,0.0000023928148,0.00010572053,0.000035789508,0.00013466728],"category_scores_gemma":[0.000083197854,0.00009058033,0.000079901576,0.00029026563,0.000043531767,0.00001425329,0.000018216999,0.00009552076,4.6447232e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030555557,0.0051455563,0.581339,0.012449266,0.0003150978,0.00011108317,0.011476324,0.05629936,0.08381384,0.00026251312,0.0005867198,0.21764567],"study_design_scores_gemma":[0.08731853,0.016298873,0.48102978,0.0012327501,0.0000795844,0.000023492383,0.0038243358,0.28490257,0.09108557,0.00011196942,0.033670288,0.0004222505],"about_ca_topic_score_codex":0.92808723,"about_ca_topic_score_gemma":0.34434646,"teacher_disagreement_score":0.5837408,"about_ca_system_score_codex":0.0028618136,"about_ca_system_score_gemma":0.0050079543,"threshold_uncertainty_score":0.8883896},"labels":[],"label_agreement":null},{"id":"W3112725336","doi":"10.2196/17005","title":"Developing a Blockchain-Based Supply Chain System for Advanced Therapies: Protocol for a Feasibility Study","year":2020,"lang":"en","type":"article","venue":"JMIR Research Protocols","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Supply chain; Risk analysis (engineering); Process management; Blockchain; Computer science; Business; Computer security","score_opus":0.42012488071286963,"score_gpt":0.5784966818765379,"score_spread":0.15837180116366828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3112725336","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0069571463,0.0000015674226,0.0022869827,0.005509295,0.000005431505,0.9845899,0.000072352675,0.0003811295,0.00019619967],"genre_scores_gemma":[0.016643517,2.5911364e-8,0.0059157736,0.0002905037,0.00047188846,0.97573775,0.000015828544,0.0001873091,0.0007374189],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99272794,0.0011172545,0.00093614793,0.0014345691,0.002098515,0.0016855929],"domain_scores_gemma":[0.9940456,0.0015049884,0.00018213979,0.0011902944,0.0023386579,0.0007383336],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0062261904,0.00046846908,0.0009654828,0.00039355506,0.0006123178,0.00020926738,0.0008076491,0.00022673886,0.0003235578],"category_scores_gemma":[0.0015658722,0.00038100153,0.00037518624,0.0013804636,0.00026102216,0.000062438005,0.00023244663,0.0009234594,0.00003005756],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.35187277,0.013808247,0.030072609,0.08686644,0.0007638906,0.00021993018,0.012165706,0.00011560607,0.3989926,0.0014739651,0.008339036,0.09530922],"study_design_scores_gemma":[0.13850328,0.07249688,0.0019748067,0.008327267,0.000015458143,0.000013267051,0.009441719,0.012929784,0.116748005,0.00030839624,0.6382661,0.0009750423],"about_ca_topic_score_codex":0.000015347394,"about_ca_topic_score_gemma":0.000022172751,"teacher_disagreement_score":0.62992704,"about_ca_system_score_codex":0.0013456765,"about_ca_system_score_gemma":0.002948622,"threshold_uncertainty_score":0.99986416},"labels":[],"label_agreement":null},{"id":"W3112738960","doi":"10.1177/1078155220979047","title":"Blinatumomab use in pediatric ALL: Taking a BiTE out of preparation, administration and toxicity challenges","year":2020,"lang":"en","type":"article","venue":"Journal of Oncology Pharmacy Practice","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Blinatumomab; Medicine; Food and drug administration; Toxicity; Pharmacy; Minimal residual disease; Pharmacology; Monoclonal antibody; CD19; Oncology; Intensive care medicine; Immunology; Antibody; Internal medicine; Family medicine; Leukemia","score_opus":0.23883833877160415,"score_gpt":0.4993435177847658,"score_spread":0.26050517901316167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3112738960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94150895,0.0029000554,0.00006062248,0.0520932,0.00016701277,0.00032760017,0.0000019832146,0.000007803734,0.002932752],"genre_scores_gemma":[0.9774445,0.018465292,0.0019086482,0.0015149422,0.0005849344,0.0000038751155,0.0000014288606,0.000013600815,0.000062747844],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99802804,0.00055567187,0.00068932545,0.00016295623,0.00040215228,0.00016186747],"domain_scores_gemma":[0.996344,0.0015871917,0.0012192458,0.00008908466,0.00055372616,0.00020677659],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017218736,0.00010453944,0.00039756732,0.0002388504,0.000023023036,0.000020899824,0.00009176229,0.00008013938,0.00016824587],"category_scores_gemma":[0.0046321484,0.00009513528,0.00006530109,0.00021799811,0.000051348936,0.00095868023,0.000042749798,0.0007820851,0.0000033953206],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10766957,0.006162295,0.07444525,0.0011207979,0.0010351088,0.008960331,0.026850075,0.00010340559,0.6817323,0.00019819269,0.0052109337,0.08651174],"study_design_scores_gemma":[0.04238403,0.02947216,0.064172156,0.00015188649,0.0024863232,0.011756153,0.0028361657,0.004206711,0.094818175,0.0000890868,0.7471681,0.00045904264],"about_ca_topic_score_codex":0.000010496824,"about_ca_topic_score_gemma":0.000031362877,"teacher_disagreement_score":0.7419572,"about_ca_system_score_codex":0.0001293743,"about_ca_system_score_gemma":0.000849963,"threshold_uncertainty_score":0.55454487},"labels":[],"label_agreement":null},{"id":"W3113017727","doi":"10.1002/anie.202005934","title":"Glycoengineering of NK Cells with Glycan Ligands of CD22 and Selectins for B‐Cell Lymphoma Therapy","year":2020,"lang":"en","type":"article","venue":"Angewandte Chemie International Edition","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Institute of Allergy and Infectious Diseases; National Institute of General Medical Sciences; National Heart, Lung, and Blood Institute; National Institutes of Health; Danmarks Grundforskningsfond; National Research Foundation","keywords":"Glycan; CD22; Selectin; Lymphoma; B-cell lymphoma; Chemistry; Cancer research; Virology; Immunology; Biology; Biochemistry; Glycoprotein; CD20; Cell adhesion molecule","score_opus":0.020694405815921222,"score_gpt":0.2679587866707847,"score_spread":0.2472643808548635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3113017727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99266136,0.00020043529,0.003007841,0.0011099118,0.0001670061,0.0003517923,0.000088302004,0.000027680602,0.0023857034],"genre_scores_gemma":[0.99745804,0.00042640808,0.0006120231,0.00017618667,0.0007797928,0.000030105939,0.00013089144,0.000024151946,0.00036242887],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99923706,0.000003175436,0.00017878681,0.00016486821,0.000306169,0.00010992749],"domain_scores_gemma":[0.99936664,0.000085253516,0.000089395195,0.00007572463,0.00030201775,0.000080987425],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007472075,0.00009865849,0.0001867862,0.00007361391,0.00001568213,0.000008967879,0.00007282142,0.000052781677,0.00025098788],"category_scores_gemma":[0.000031899173,0.000085468295,0.000060636085,0.00012752374,0.000052265135,0.00007154222,0.000016452534,0.000062106,6.2617073e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018904781,0.00013808241,0.000568683,0.00019363803,0.00012265646,0.0000033352221,0.00052989525,0.000017319306,0.99242544,0.000021021817,0.0017637159,0.0023257365],"study_design_scores_gemma":[0.0047137984,0.0009417492,0.0004254705,0.00007131176,0.000019225983,0.000013872857,0.00011376348,0.00080717064,0.9852891,0.000025112577,0.007505467,0.000073977375],"about_ca_topic_score_codex":0.000020971427,"about_ca_topic_score_gemma":0.0000019756872,"teacher_disagreement_score":0.0071363584,"about_ca_system_score_codex":0.00004859677,"about_ca_system_score_gemma":0.00006775832,"threshold_uncertainty_score":0.34852958},"labels":[],"label_agreement":null},{"id":"W3113178349","doi":"10.1093/neuonc/noaa215.463","title":"IMMU-33. MULTI-ANTIGEN RECOGNITION CIRCUITS OVERCOME CHALLENGES OF SPECIFICITY, HETEROGENEITY, AND DURABILITY IN T-CELL THERAPY FOR GLIOBLASTOMA","year":2020,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Chimeric antigen receptor; Antigen; Epidermal growth factor receptor; Cancer research; Glioma; Tumor antigen; Brain tumor; Immunotherapy; Receptor; Priming (agriculture); Biology; Immunology; Medicine; Immune system; Pathology; Internal medicine","score_opus":0.12878803851665777,"score_gpt":0.35772822192127884,"score_spread":0.22894018340462108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3113178349","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99087137,0.0014309443,0.000051572126,0.0046642553,0.00014784135,0.0019044622,0.000062102765,0.00004506772,0.0008223971],"genre_scores_gemma":[0.990192,0.008348877,0.00023656596,0.0008580919,0.00019204267,0.00010067662,0.000013634342,0.000048909795,0.000009225365],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99783975,0.0003858685,0.0005045367,0.0006240518,0.00025429198,0.00039150915],"domain_scores_gemma":[0.9983661,0.0007836259,0.00014953529,0.00030303278,0.00018424536,0.00021341603],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005367792,0.00021335011,0.00071448524,0.0001740678,0.000039793365,0.000009428262,0.00015806712,0.00026117952,0.00023716832],"category_scores_gemma":[0.00029640537,0.00020738652,0.00015325478,0.00022206405,0.00020322955,0.00006764354,0.00011180154,0.0003992185,0.000014603156],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026231613,0.0008713505,0.015743865,0.00025103448,0.000033555087,0.00006188644,0.00091351813,0.0000015857572,0.8183231,0.0000066402895,0.000048100108,0.16112223],"study_design_scores_gemma":[0.016031343,0.014489723,0.089459695,0.000035299632,0.00002700804,0.00011457157,0.0003988495,0.00059880974,0.85658437,0.00018934069,0.021816852,0.00025411742],"about_ca_topic_score_codex":0.00003247153,"about_ca_topic_score_gemma":0.00022886592,"teacher_disagreement_score":0.16086811,"about_ca_system_score_codex":0.00012693211,"about_ca_system_score_gemma":0.00016251355,"threshold_uncertainty_score":0.8456977},"labels":[],"label_agreement":null},{"id":"W3114165421","doi":"10.14740/gr1340","title":"Gastrointestinal Adverse Effects of Immunotherapeutic Agents: A Systematic Review","year":2020,"lang":"en","type":"review","venue":"Gastroenterology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Adverse effect; Immunotherapy; Intensive care medicine; Cancer; Oncology; Diarrhea; Radiation therapy; Cancer immunotherapy; Gastrointestinal cancer; Internal medicine; Colorectal cancer","score_opus":0.09862064302158133,"score_gpt":0.43164132366320884,"score_spread":0.3330206806416275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3114165421","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000030630526,0.98579717,0.00006805014,0.00031409488,0.00010513552,0.013304868,0.000029994833,0.00007005266,0.00028002416],"genre_scores_gemma":[0.000012955406,0.994529,0.00026726513,0.0005329063,0.0001626198,0.002050874,0.00011074953,0.00020322602,0.0021303706],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.98733664,0.0058952677,0.002118172,0.0010477386,0.00193821,0.0016639936],"domain_scores_gemma":[0.99425495,0.0017942643,0.00069495116,0.0019075695,0.0007609695,0.0005873169],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0035121588,0.00077800406,0.008017703,0.0010762656,0.000104597675,0.000019986179,0.0012705385,0.00024064093,0.0016888318],"category_scores_gemma":[0.0027972015,0.0005880857,0.0018420282,0.0013140584,0.00085792434,0.00005752629,0.0006717126,0.0034813606,0.00082590885],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042768946,0.00034866828,0.000119875316,0.97299635,0.0016348126,0.0019298834,0.000031467545,1.8162124e-8,0.00009645481,0.000006678604,0.0013528749,0.021055197],"study_design_scores_gemma":[0.0014270437,0.0042312853,0.000025579133,0.879157,0.004141108,0.008020012,0.000020902948,0.000004935805,0.0000042985,0.0000039529323,0.102796905,0.00016696332],"about_ca_topic_score_codex":0.000022018867,"about_ca_topic_score_gemma":0.0000035562255,"teacher_disagreement_score":0.10144403,"about_ca_system_score_codex":0.00063130446,"about_ca_system_score_gemma":0.0010018427,"threshold_uncertainty_score":0.9999521},"labels":[],"label_agreement":null},{"id":"W3115448914","doi":"10.14740/jocmr3964","title":"Advanced Therapy Medicinal Products Challenges and Perspectives in Regenerative Medicine","year":2020,"lang":"en","type":"review","venue":"Journal of Clinical Medicine Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"University of West Attica","keywords":"Medicine; License; Authorization; European union; Product (mathematics); Clinical trial; Regenerative medicine; Heart Rhythm; Risk analysis (engineering); Health care; Business; Computer security; Law; Pathology","score_opus":0.7289437483623789,"score_gpt":0.6436852727129203,"score_spread":0.08525847564945854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3115448914","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020030554,0.8894211,0.00000244623,0.10179462,0.00061663875,0.0024092179,0.0000028506186,0.000018079356,0.0055347015],"genre_scores_gemma":[0.00021770383,0.9805289,0.00029584122,0.00019545961,0.016585728,0.00006725458,0.000010141111,0.00015578259,0.0019431824],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9807701,0.006354151,0.0053776307,0.0013736978,0.0050659534,0.0010584447],"domain_scores_gemma":[0.9771812,0.014401598,0.0017543929,0.0010088789,0.0039198846,0.0017340545],"candidate_categories":["metaresearch","metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.033617184,0.00081479916,0.010471592,0.0026603597,0.00011322546,0.000018839763,0.0009334107,0.0008546628,0.001340633],"category_scores_gemma":[0.054295782,0.00044528098,0.0006358129,0.002301036,0.004513011,0.0001878091,0.0002910762,0.011530862,0.00002054147],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003095783,0.0005256245,0.000031194166,0.008139276,0.0009290033,0.0029677118,0.0045802556,4.7078135e-8,0.000095729694,0.00036782026,0.0043646106,0.9749029],"study_design_scores_gemma":[0.010273421,0.024877923,0.0004293657,0.06260144,0.00038204764,0.0019191235,0.006118183,0.0000042369384,0.0000104673,0.00040926924,0.8926985,0.00027599296],"about_ca_topic_score_codex":0.000035811037,"about_ca_topic_score_gemma":0.000016852866,"teacher_disagreement_score":0.97462696,"about_ca_system_score_codex":0.0005345408,"about_ca_system_score_gemma":0.0043796822,"threshold_uncertainty_score":0.9997999},"labels":[],"label_agreement":null},{"id":"W3115517794","doi":"10.7554/elife.57063.sa2","title":"Author response: Functionally specialized human CD4+ T-cell subsets express physicochemically distinct TCRs","year":2020,"lang":"en","type":"peer-review","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Biology; Cell biology; Evolutionary biology; Computational biology","score_opus":0.0847407228311366,"score_gpt":0.3872247588021638,"score_spread":0.3024840359710272,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3115517794","genre_codex":"commentary","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0063532707,0.021723237,0.00032922882,0.48340237,0.0036771214,0.008975395,0.0015822174,0.0012787164,0.47267842],"genre_scores_gemma":[0.00068523694,0.0008097246,0.0004799263,0.008338888,0.005390677,0.00038195847,0.007245736,0.00032629434,0.97634155],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9921747,0.0006780842,0.0012849512,0.0016943549,0.0031914753,0.00097646925],"domain_scores_gemma":[0.9949618,0.0008010517,0.00043457714,0.0017912806,0.0010223368,0.0009889553],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0014396171,0.0010414368,0.0024672288,0.00029807742,0.00021665549,0.00012806423,0.00092302164,0.00069809594,0.15511726],"category_scores_gemma":[0.0011464994,0.0009041951,0.0012864007,0.0007823975,0.00034641958,0.00007464848,0.0004661722,0.0023887444,0.0020164812],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003882439,0.00036612706,0.000013062423,0.004096153,0.00026432725,0.0002239453,0.000042755597,8.1363986e-8,0.30116028,0.000032853553,0.6884858,0.0014321783],"study_design_scores_gemma":[0.0032983737,0.0005783615,0.00033057376,0.0027697955,0.0006482906,0.000050415278,0.000016800843,0.0000068710415,0.012681599,0.00007994477,0.9787235,0.00081542303],"about_ca_topic_score_codex":0.00013843554,"about_ca_topic_score_gemma":0.00004194657,"teacher_disagreement_score":0.5036631,"about_ca_system_score_codex":0.0006213208,"about_ca_system_score_gemma":0.0015614261,"threshold_uncertainty_score":0.9999128},"labels":[],"label_agreement":null},{"id":"W3116281132","doi":"10.20944/preprints202012.0795.v1","title":"Advances in Cellular Immunotherapy: Understanding and Preventing T-cell Dysfunction","year":2020,"lang":"en","type":"preprint","venue":"Preprints.org","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Fonds de Recherche du Québec - Santé","keywords":"Immune system; Immunotherapy; Immune Dysfunction; Adoptive cell transfer; Cell therapy; Cell; Immunology; T cell; Biology; Cancer research; Cell biology; Biochemistry","score_opus":0.16282657015144283,"score_gpt":0.3709396698169554,"score_spread":0.20811309966551259,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3116281132","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94747484,0.0057461276,0.0022619185,0.00093341764,0.0004462815,0.0018372673,0.000005504411,0.00017728723,0.041117378],"genre_scores_gemma":[0.9856544,0.010090838,0.00021334317,0.0001184879,0.00026323434,0.00012511463,0.00004919495,0.00010052475,0.0033848726],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9969122,0.00023376818,0.0006050758,0.0011905588,0.00057497446,0.0004834271],"domain_scores_gemma":[0.9984872,0.00013424267,0.00025855895,0.00085572293,0.0000680484,0.0001962776],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010858923,0.00040097145,0.00070587033,0.00033253775,0.00009483082,0.000040524792,0.0002701016,0.0003660164,0.0028329077],"category_scores_gemma":[0.00014340169,0.00042725916,0.00020892377,0.00028566207,0.00013289654,0.00014890463,0.0010425325,0.0018315059,0.00015146923],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00082423486,0.00018862153,0.40063804,0.0016119129,0.0001074161,0.00009094978,0.0016912564,0.000114914335,0.5888441,0.00011621649,0.0000086715745,0.005763612],"study_design_scores_gemma":[0.015038328,0.00058523956,0.18566234,0.00471156,0.00038473454,0.00008562162,0.005207745,0.004752453,0.70070523,0.037085723,0.043426912,0.0023541083],"about_ca_topic_score_codex":0.00013158577,"about_ca_topic_score_gemma":0.000023485183,"teacher_disagreement_score":0.21497571,"about_ca_system_score_codex":0.0007155145,"about_ca_system_score_gemma":0.00022688298,"threshold_uncertainty_score":0.9998179},"labels":[],"label_agreement":null},{"id":"W3117204159","doi":"10.1002/cyto.b.21985","title":"Best practices for the development, analytical validation and clinical implementation of flow cytometric methods for chimeric antigen receptor T cell analyses","year":2020,"lang":"en","type":"review","venue":"Cytometry Part B Clinical Cytometry","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Caprion (Canada)","funders":"Genentech; Navigate BioPharma; Dana-Farber Cancer Institute; American Association of Pharmaceutical Scientists","keywords":"Flow cytometry; Chimeric antigen receptor; Computational biology; Immunology; Medicine; Computer science; Biology; Immunotherapy; Immune system","score_opus":0.6283747946379605,"score_gpt":0.680735279101053,"score_spread":0.052360484463092494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3117204159","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010050036,0.9255253,0.061699405,0.00031796758,0.001376821,0.009146262,0.0005804144,0.00010188266,0.00024696294],"genre_scores_gemma":[0.00016817775,0.85810196,0.13590243,0.00014750428,0.0022652338,0.0006559942,0.0013686114,0.00022579308,0.0011642841],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98611075,0.00269847,0.006827332,0.0020946173,0.0012379499,0.0010308941],"domain_scores_gemma":[0.9288678,0.062486146,0.005250372,0.0013337414,0.0011035001,0.00095845107],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.020444477,0.00102761,0.0065342365,0.0029743745,0.0003841598,0.00022363785,0.0010035257,0.0013400994,0.0014023368],"category_scores_gemma":[0.03193557,0.00072262535,0.0033247327,0.010857062,0.00073351106,0.00027239302,0.00055054337,0.0019522682,0.00009807543],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069527206,0.0009208239,0.009844038,0.011115842,0.0051711574,0.0000032996038,0.000034613837,2.1428427e-7,0.00005704263,0.000003956496,0.0019415825,0.97021216],"study_design_scores_gemma":[0.0036254053,0.0031792657,0.001264381,0.0010986701,0.010936744,0.000026141803,0.0003317376,0.00054309866,0.0007485195,0.0000056876265,0.977548,0.00069236016],"about_ca_topic_score_codex":0.000019427727,"about_ca_topic_score_gemma":0.0000036388412,"teacher_disagreement_score":0.9756064,"about_ca_system_score_codex":0.0003125055,"about_ca_system_score_gemma":0.0026027292,"threshold_uncertainty_score":0.99995637},"labels":[],"label_agreement":null},{"id":"W3118887409","doi":"10.1016/j.xpro.2020.100264","title":"An optimized protocol for the generation of HBV viral antigen-specific T lymphocytes from pluripotent stem cells","year":2021,"lang":"en","type":"article","venue":"STAR Protocols","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; National Taiwan University; Toronto General Hospital Research Institute, University Health Network; National Institutes of Health; National Cancer Institute; National Taiwan University Hospital","keywords":"Induced pluripotent stem cell; Cytotoxic T cell; Virology; Immunotherapy; CD8; Antigen; Hepatitis B virus; Cancer immunotherapy; Adoptive cell transfer; Immunology; Biology; Cancer research; T cell; Medicine; Virus; Immune system; Embryonic stem cell; In vitro","score_opus":0.12216559699626964,"score_gpt":0.3892626040598666,"score_spread":0.26709700706359696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3118887409","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04324754,0.000030765845,0.004825127,0.00017618279,0.000053466876,0.9513659,0.00012090701,0.000055479853,0.00012465604],"genre_scores_gemma":[0.0018742477,0.000012219516,0.011893154,0.00011542276,0.0006398615,0.9842395,0.000057144156,0.00006442922,0.0011039726],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975637,0.00027842933,0.0005613905,0.0005097921,0.0006595773,0.0004270776],"domain_scores_gemma":[0.99783415,0.00018866542,0.00018395817,0.0010410323,0.00058772985,0.0001644776],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00072134135,0.00023055616,0.0004765764,0.00006630646,0.00016358115,0.000115309755,0.0002665794,0.00013112648,0.0029705588],"category_scores_gemma":[0.000022610211,0.00016127693,0.0002089275,0.00020790948,0.00012301655,0.00012188772,0.000067308654,0.00017334557,0.000016156062],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054372684,0.000521448,0.00011571998,0.00018301325,0.00012924316,0.00001889182,0.00066776806,0.00023204347,0.9547979,0.00007017305,0.0011807098,0.036645822],"study_design_scores_gemma":[0.011530188,0.0011156934,0.0002158566,0.00013234421,0.000009114912,0.0000045184897,0.00028545732,0.007544173,0.79048055,0.00007865653,0.1884647,0.0001387612],"about_ca_topic_score_codex":0.000044864915,"about_ca_topic_score_gemma":0.000010221755,"teacher_disagreement_score":0.187284,"about_ca_system_score_codex":0.00029131884,"about_ca_system_score_gemma":0.00073842285,"threshold_uncertainty_score":0.99794084},"labels":[],"label_agreement":null},{"id":"W3119440760","doi":"10.1097/mph.0000000000002051","title":"Precursor B-Cell Acute Lymphoblastic Leukemia With MYC and BCL2 Rearrangements Presenting as Extensive Extranodal Disease in an Adolescent","year":2021,"lang":"en","type":"article","venue":"Journal of Pediatric Hematology/Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Immunophenotyping; Pathology; Medicine; Gene rearrangement; Infiltration (HVAC); Fluorescence in situ hybridization; Precursor cell; Disease; B cell; Lymphoblastic Leukemia; Cancer research; Leukemia; Gene; Cell; Biology; Immunology; Flow cytometry; Antibody","score_opus":0.021604649807720654,"score_gpt":0.33180630222145324,"score_spread":0.3102016524137326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3119440760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99248964,0.0042984127,0.00008809266,0.0013484383,0.00027836778,0.00050377403,0.000006249283,0.000015971866,0.00097103615],"genre_scores_gemma":[0.9926214,0.003428954,0.0014921743,0.0004975336,0.00076481974,0.000021054968,0.000011506371,0.000054841865,0.0011077218],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99680084,0.00057216623,0.0008835338,0.0004665273,0.00062025955,0.0006566461],"domain_scores_gemma":[0.9970354,0.00045750575,0.0005446976,0.00033041622,0.0008033467,0.00082862814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066216185,0.0002779223,0.0010371113,0.00056781207,0.00007592075,0.00003336724,0.0001968112,0.00027914127,0.00047235464],"category_scores_gemma":[0.00043502336,0.00022677166,0.0001454064,0.0005357042,0.00018940748,0.00021484768,0.0001329198,0.0008914611,0.00002072504],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0155270565,0.0038065286,0.80867124,0.0011186054,0.00051215605,0.12806955,0.002346111,0.00007423795,0.029238693,0.000056246292,0.0034860452,0.0070935288],"study_design_scores_gemma":[0.11152788,0.023565432,0.70266056,0.0010370748,0.008523863,0.10712111,0.006911364,0.002757851,0.016498651,0.001063447,0.016494153,0.0018385916],"about_ca_topic_score_codex":0.000014972108,"about_ca_topic_score_gemma":0.000042623655,"teacher_disagreement_score":0.10601067,"about_ca_system_score_codex":0.00072089134,"about_ca_system_score_gemma":0.003921267,"threshold_uncertainty_score":0.924748},"labels":[],"label_agreement":null},{"id":"W3120167422","doi":"10.1101/2021.01.07.425632","title":"Multi-antigen recognition circuits overcome challenges of specificity, heterogeneity, and durability in T cell therapy for glioblastoma","year":2021,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Antigen; Chimeric antigen receptor; Glioblastoma; Priming (agriculture); Cancer research; In vivo; T-cell receptor; Homogeneous; Biology; Immunotherapy; Immunology; T cell; Immune system; Genetics","score_opus":0.06637538692330446,"score_gpt":0.29362866579162844,"score_spread":0.22725327886832397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120167422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98462033,0.011301842,0.00017002055,0.00020839926,0.00034843414,0.0029369043,0.00030078812,0.000102925194,0.000010345578],"genre_scores_gemma":[0.97777647,0.019083656,0.002314158,0.000055336757,0.00024893266,0.0003621301,0.0000016882639,0.00015394848,0.0000036939498],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99627805,0.00032003951,0.0008262693,0.0013983374,0.00056529965,0.0006120017],"domain_scores_gemma":[0.99677783,0.00024269382,0.0003670726,0.0013347928,0.0009839558,0.00029363603],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014594285,0.00056095235,0.0012162065,0.0005162272,0.000066775596,0.00009330287,0.00030525605,0.00072199974,0.00015121674],"category_scores_gemma":[0.00025248335,0.00061096787,0.0003217732,0.00040644643,0.00021274143,0.000117528594,0.0004005462,0.0008248997,0.00000503536],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047342217,0.0012654209,0.049914498,0.0025964945,0.00018913351,0.000060365775,0.000061541694,0.0000036461493,0.9452129,0.000005391519,0.0000051089,0.00021208616],"study_design_scores_gemma":[0.0027303384,0.00033245928,0.3958223,0.00053574715,0.00003450411,8.9714035e-8,0.000017288863,0.00014315547,0.59984756,0.0000021396725,0.0001831135,0.00035129176],"about_ca_topic_score_codex":0.00009575544,"about_ca_topic_score_gemma":0.00009664657,"teacher_disagreement_score":0.3459078,"about_ca_system_score_codex":0.0003470792,"about_ca_system_score_gemma":0.0005725768,"threshold_uncertainty_score":0.99963415},"labels":[],"label_agreement":null},{"id":"W3122370131","doi":"10.1073/pnas.2018861118","title":"Large remodeling of the Myc-induced cell surface proteome in B cells and prostate cells creates new opportunities for immunotherapy","year":2021,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Canadian Institutes of Health Research; National Institute of General Medical Sciences; Government of Canada","keywords":"Cell; Biology; Cell culture; Cancer research; Proteome; Cell type; Immunotherapy; Cell biology; Cell growth; Immune system; Immunology; Bioinformatics; Biochemistry; Genetics","score_opus":0.1104301587127117,"score_gpt":0.345920969728454,"score_spread":0.2354908110157423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3122370131","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912544,0.0004615017,0.0000014690611,0.005782244,0.000018406457,0.0009224285,0.00003028766,0.00000495936,0.0015243107],"genre_scores_gemma":[0.99118924,0.0004949005,0.002144232,0.00021989245,0.0000358931,0.000013148257,2.480468e-7,0.000010223674,0.005892242],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99809617,0.000016265843,0.0004058518,0.00024664545,0.0010087589,0.00022632394],"domain_scores_gemma":[0.99887127,0.0001962978,0.0003278423,0.000021946875,0.0005360187,0.000046650817],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020032388,0.00010911662,0.00026208078,0.00011840644,0.00012583207,0.000026652573,0.00039456718,0.00008664208,0.000040552426],"category_scores_gemma":[0.00018752439,0.00006686191,0.000099303434,0.00062726194,0.00038231438,0.00021331839,0.00013504326,0.0002194096,1.3138518e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010832489,0.000077381716,0.0017595426,0.00026664053,0.000014077057,2.0521764e-8,0.0012060972,0.000063635365,0.9953798,0.0006061158,0.00014347324,0.0003748838],"study_design_scores_gemma":[0.0009902605,0.00011167253,0.0024136626,0.00027358445,0.000010437288,0.0000046985883,0.0023203273,0.0016891945,0.9861434,0.0055479924,0.00042849212,0.00006627167],"about_ca_topic_score_codex":0.000030349052,"about_ca_topic_score_gemma":4.5064905e-7,"teacher_disagreement_score":0.009236401,"about_ca_system_score_codex":0.000040810635,"about_ca_system_score_gemma":0.00032855288,"threshold_uncertainty_score":0.27265495},"labels":[],"label_agreement":null},{"id":"W3123145316","doi":"10.1186/s13643-021-01588-7","title":"Efficacy and safety of CD22 chimeric antigen receptor (CAR) T cell therapy in patients with B cell malignancies: a protocol for a systematic review and meta-analysis","year":2021,"lang":"en","type":"review","venue":"Systematic Reviews","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; Terry Fox Research Institute; University of Ottawa; BC Hydro (Canada); Western University; Ottawa Hospital; University of British Columbia","funders":"","keywords":"Medicine; Chimeric antigen receptor; Clinical trial; Oncology; Adverse effect; Antigen; Targeted therapy; Internal medicine; CD19; Immunology; Immunotherapy; Cancer","score_opus":0.1225571030559747,"score_gpt":0.4045806960754301,"score_spread":0.28202359301945545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3123145316","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000012197983,0.5459217,0.000026206486,0.000008599024,0.000007606483,0.45389977,0.000059766073,0.000009299786,0.00006582876],"genre_scores_gemma":[3.601473e-7,0.56571454,0.00058751233,0.00005763967,0.000012271533,0.43217513,0.00010178339,0.00009082605,0.0012599515],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9833751,0.006471848,0.00723854,0.0012306314,0.0011189821,0.0005649508],"domain_scores_gemma":[0.98909867,0.0017068915,0.0057140975,0.0025694394,0.0006328192,0.00027811198],"candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.008909127,0.001345817,0.042820673,0.0006980851,0.00007494394,0.00007719397,0.00047568575,0.00030221185,0.0009647837],"category_scores_gemma":[0.0010367656,0.0006347285,0.0041672364,0.0028537358,0.00011654103,0.00008623507,0.00012147117,0.00041930497,0.000021946415],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000066950895,0.00041736037,0.000010294078,0.9621172,0.03605642,0.000003374357,0.00014531339,4.971944e-8,0.000002591585,0.000001965938,0.0001576282,0.0010208273],"study_design_scores_gemma":[0.0021947753,0.000646895,0.0000016840459,0.6083916,0.31134477,0.00001459892,0.000023961053,0.0000011350891,0.0000024326985,2.7928465e-7,0.07696579,0.00041209214],"about_ca_topic_score_codex":0.000017078195,"about_ca_topic_score_gemma":0.000004204017,"teacher_disagreement_score":0.3537256,"about_ca_system_score_codex":0.00019724727,"about_ca_system_score_gemma":0.00041135075,"threshold_uncertainty_score":0.99994844},"labels":[],"label_agreement":null},{"id":"W3124365819","doi":"10.1111/pcmr.12960","title":"First‐line atezolizumab monotherapy in patients with advanced <i>BRAF</i><sup>V600</sup> wild‐type melanoma","year":2021,"lang":"en","type":"article","venue":"Pigment Cell & Melanoma Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Atezolizumab; Internal medicine; Pembrolizumab; Adverse effect; Melanoma; Oncology; Gastroenterology; Cohort; Response Evaluation Criteria in Solid Tumors; Surgery; Progressive disease; Cancer; Disease; Cancer research; Immunotherapy","score_opus":0.03026515582306657,"score_gpt":0.31727203411469357,"score_spread":0.287006878291627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3124365819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9772755,0.0023586734,0.000029232988,0.0018945659,0.00012755828,0.002728857,0.000031617623,0.00010327878,0.015450706],"genre_scores_gemma":[0.9705516,0.0028581375,0.00095238886,0.00031327072,0.00030305874,0.00033323056,0.0004037103,0.00023859616,0.024045976],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9914768,0.00072000665,0.00083387294,0.0014900783,0.0033887743,0.0020904678],"domain_scores_gemma":[0.9953069,0.0006057237,0.0001232149,0.001794329,0.0014228062,0.00074704114],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014193536,0.0006050442,0.0009922015,0.0008817943,0.00035310737,0.00017026615,0.00063679705,0.0003297472,0.008860478],"category_scores_gemma":[0.0001988141,0.00051885075,0.00020300003,0.0026666468,0.0003525946,0.0002757349,0.0003476774,0.0017624537,0.0006142508],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041158617,0.0116653,0.77263385,0.001105465,0.00073436514,0.0036294395,0.004060474,0.0023262624,0.06259111,0.00015841935,0.0041736397,0.09576305],"study_design_scores_gemma":[0.10581568,0.027366785,0.33424875,0.001470362,0.00014713767,0.0001397397,0.0018920957,0.0028479763,0.22043574,0.00050549646,0.3028883,0.0022419377],"about_ca_topic_score_codex":0.00034318268,"about_ca_topic_score_gemma":0.00023413352,"teacher_disagreement_score":0.43838513,"about_ca_system_score_codex":0.0012074547,"about_ca_system_score_gemma":0.001019339,"threshold_uncertainty_score":0.9997263},"labels":[],"label_agreement":null},{"id":"W3124724032","doi":"10.1101/2021.01.18.427186","title":"Inflammatory Cytokines Regulate T-Cell Development from Blood Progenitor Cells in a Stage and Dose-Specifc Manner","year":2021,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of Toronto; University of British Columbia","funders":"","keywords":"Stem cell factor; Progenitor cell; Cell biology; T cell; Stem cell; Haematopoiesis; Biology; Cytokine; CD38; Cellular differentiation; CD8; CD34; Immunology; Immune system; Biochemistry","score_opus":0.018035552275513053,"score_gpt":0.2333788489039971,"score_spread":0.21534329662848406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3124724032","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99233246,0.0043440275,0.000023188042,0.00011859042,0.00065941614,0.0020898911,0.00014479404,0.00025715004,0.000030457544],"genre_scores_gemma":[0.98648286,0.0010861219,0.010039155,0.00013845805,0.0008748601,0.00054747466,0.0000043344508,0.00033086078,0.00049586006],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99489444,0.00026000023,0.001068201,0.0018145184,0.0010018542,0.0009610043],"domain_scores_gemma":[0.99648154,0.000116086056,0.0003823664,0.0018030229,0.0005916649,0.00062530255],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00085979654,0.0008908016,0.0012171912,0.00063824066,0.00012285696,0.00035071778,0.0004710844,0.0008957225,0.0009750056],"category_scores_gemma":[0.00008731736,0.00094234955,0.00019494971,0.0006018813,0.00020785269,0.0001513423,0.0011076259,0.0016277467,0.000056819877],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003125705,0.0005107617,0.040384464,0.0013790736,0.00041667235,0.0020844568,0.00013870031,0.000013287414,0.95466304,0.000008700606,0.00006995456,0.000018322968],"study_design_scores_gemma":[0.0030818186,0.00006241576,0.16351454,0.0010271143,0.00014542117,9.0722274e-8,0.000024003075,0.00006060038,0.8133631,3.654629e-7,0.01793124,0.0007893047],"about_ca_topic_score_codex":0.00014817415,"about_ca_topic_score_gemma":0.000044885106,"teacher_disagreement_score":0.14129995,"about_ca_system_score_codex":0.0006124832,"about_ca_system_score_gemma":0.0024905894,"threshold_uncertainty_score":0.99993825},"labels":[],"label_agreement":null},{"id":"W3125616552","doi":"10.1007/s00270-020-02736-7","title":"Ex Vivo Study of Experimental Method Toward Future In Vivo Tissue Processing for Self-Anti-Tumoral Vaccinations","year":2021,"lang":"en","type":"article","venue":"CardioVascular and Interventional Radiology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Montreal General Hospital; McGill University","funders":"","keywords":"Ex vivo; Medicine; In vivo; Vaccination; Pathology; Medical physics; Biotechnology","score_opus":0.03706627292735521,"score_gpt":0.3793830316774757,"score_spread":0.3423167587501205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3125616552","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95776385,0.033000622,0.0071763652,0.00021902958,0.00027029944,0.0009871426,0.000021979446,0.000023400531,0.00053728063],"genre_scores_gemma":[0.9944618,0.00012645137,0.004130397,0.00002950957,0.00035353028,0.00017455006,0.000033531884,0.000023407023,0.00066687044],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99834144,0.0003830942,0.00038104804,0.00040791286,0.00026892766,0.00021757092],"domain_scores_gemma":[0.999278,0.00006755533,0.000052808235,0.00024420116,0.00028377026,0.00007367714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082743674,0.00014067249,0.0007040602,0.0001843455,0.00005271459,0.000015066437,0.0000832294,0.00010733993,0.0008863231],"category_scores_gemma":[0.00006774284,0.00013327479,0.00063073746,0.000217139,0.000032635016,0.00007198942,0.00007618659,0.00017033554,7.945455e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002085972,0.013744963,0.041521363,0.0033149915,0.018841777,0.0014134265,0.015419236,0.0005460414,0.76442885,0.003180053,0.0034176623,0.13208567],"study_design_scores_gemma":[0.047780983,0.010705411,0.1256681,0.0005413859,0.0022341637,0.008299705,0.044648543,0.0035170808,0.623833,0.00066080526,0.13111764,0.0009931818],"about_ca_topic_score_codex":0.000026565054,"about_ca_topic_score_gemma":0.000010811511,"teacher_disagreement_score":0.14059584,"about_ca_system_score_codex":0.000103721366,"about_ca_system_score_gemma":0.00011374993,"threshold_uncertainty_score":0.97046167},"labels":[],"label_agreement":null},{"id":"W3126199907","doi":"10.1158/2326-6074.tumimm20-po081","title":"Abstract PO081: Systematic Generation of Allogeneic Immune-targeting Modalities for Glioblastoma","year":2021,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McMaster University","funders":"","keywords":"Medicine; Population; Haematopoiesis; Immune system; Progenitor cell; Chimeric antigen receptor; Stem cell; Chemoradiotherapy; Oncology; Immunotherapy; Cancer research; Cancer; Immunology; Internal medicine; Biology","score_opus":0.13009358589491676,"score_gpt":0.41780739091948677,"score_spread":0.28771380502457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3126199907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9372614,0.05829698,0.00008592498,0.0013560315,0.0003540789,0.0016456542,0.000039289967,0.000037506237,0.0009231191],"genre_scores_gemma":[0.9826487,0.0024241945,0.00027941246,0.000045736473,0.00038517095,0.0011983513,0.00008408733,0.00006346241,0.012870911],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9967824,0.0005108794,0.00073990494,0.00045523542,0.0007018612,0.00080972083],"domain_scores_gemma":[0.9958113,0.0008266292,0.0001404945,0.00073326955,0.0023957842,0.0000925481],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0025567163,0.00018023993,0.0007637335,0.00039264138,0.00024688622,0.0000427541,0.00028783185,0.00026418874,0.0032909086],"category_scores_gemma":[0.0013593846,0.00016510178,0.00024304831,0.0005475641,0.0004591978,0.00008958994,0.00017525756,0.0006378491,0.000041943626],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009055025,0.00013549853,0.0005042598,0.009320689,0.00071505323,0.000042801646,0.00058396783,0.00003258869,0.98503757,0.0004589469,0.0007050148,0.0015580893],"study_design_scores_gemma":[0.0020708619,0.0006265555,0.0021453784,0.0016518718,0.00006211159,0.00007883313,0.0024299787,0.00055465475,0.98889685,0.0001798139,0.0011485637,0.00015455727],"about_ca_topic_score_codex":0.0002482602,"about_ca_topic_score_gemma":0.00007354591,"teacher_disagreement_score":0.055872783,"about_ca_system_score_codex":0.0004640825,"about_ca_system_score_gemma":0.0013791437,"threshold_uncertainty_score":0.9976202},"labels":[],"label_agreement":null},{"id":"W3126604828","doi":"10.3389/fimmu.2020.618387","title":"Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy","year":2021,"lang":"en","type":"review","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute; University of British Columbia","funders":"BC Cancer Foundation; VGH and UBC Hospital Foundation","keywords":"Chimeric antigen receptor; Tumor microenvironment; Cytokine release syndrome; T cell; Immunotherapy; Cancer research; Immunology; Medicine; Immune system","score_opus":0.02858909250573865,"score_gpt":0.3102956589479955,"score_spread":0.28170656644225683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3126604828","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008726158,0.99377203,0.00002873577,0.00016667004,0.0015824083,0.0019891607,0.000017799097,0.000019416775,0.0015511485],"genre_scores_gemma":[0.000036444035,0.9922258,0.0004750589,0.0001463565,0.00014276941,0.0004909928,0.00015354478,0.00011946097,0.0062095495],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964478,0.00090219395,0.0008002726,0.0007178988,0.00028669363,0.0008451656],"domain_scores_gemma":[0.9983007,0.00023083284,0.00022060356,0.0011631377,0.000021804763,0.000062921485],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00069126656,0.0005021568,0.002492974,0.0007047173,0.000069632406,0.000026665099,0.0006417407,0.00046170372,0.0017308051],"category_scores_gemma":[0.00007210269,0.0003612183,0.00050937524,0.00073187234,0.00044702803,0.000032477496,0.0002723933,0.0021331832,0.00006315867],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011983419,0.0002937227,0.00054681016,0.0010837278,0.0004119038,0.00080701086,0.00047988328,7.4225943e-7,0.0006209085,0.000009352481,0.0050941706,0.9905319],"study_design_scores_gemma":[0.0015523188,0.00021709828,0.000113801914,0.002961772,0.00010431555,0.00026026648,0.00070167484,0.00000313121,0.00017476863,0.000011988082,0.99363,0.00026887725],"about_ca_topic_score_codex":0.00010520632,"about_ca_topic_score_gemma":0.000010300432,"teacher_disagreement_score":0.99026304,"about_ca_system_score_codex":0.0013829591,"about_ca_system_score_gemma":0.00056493393,"threshold_uncertainty_score":0.99988395},"labels":[],"label_agreement":null},{"id":"W3127194872","doi":"10.3390/cancers13040598","title":"T-Cell Dysfunction as a Limitation of Adoptive Immunotherapy: Current Concepts and Mitigation Strategies","year":2021,"lang":"en","type":"review","venue":"Cancers","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Fonds de Recherche du Québec - Santé; Leukemia and Lymphoma Society of Canada","keywords":"Immune system; Immunotherapy; Adoptive cell transfer; Immune Dysfunction; Cell therapy; T cell; Immunology; Cell; Cancer research; Biology; Medicine; Cell biology; Stem cell","score_opus":0.0672659571575848,"score_gpt":0.40845473268434346,"score_spread":0.34118877552675864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3127194872","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00078133773,0.99480736,0.000061061044,0.000014130783,0.0003125065,0.0010756324,0.000027043538,0.000020017105,0.0029009082],"genre_scores_gemma":[0.0004123596,0.9971043,0.00006385196,0.000018404893,0.00018545183,0.00017390295,0.0004535945,0.000046655965,0.0015414734],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99857163,0.00017156014,0.00039366426,0.00034203567,0.000342074,0.00017905263],"domain_scores_gemma":[0.99889135,0.00016590023,0.00030760295,0.00025206854,0.00030070278,0.00008237374],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018099243,0.00024678014,0.0010014318,0.00017528041,0.000038746974,0.00003694108,0.00005992189,0.00018093972,0.00065262994],"category_scores_gemma":[0.000040877483,0.00021942625,0.00025698837,0.00035015034,0.0001905294,0.00009557424,0.000019710942,0.00039531192,0.000012360402],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006411538,0.000019313558,0.000003245071,0.01140186,0.00021497076,0.0000051719594,0.0006428141,0.0000061062037,0.00047778233,0.000118009724,0.00054097566,0.9865056],"study_design_scores_gemma":[0.0010431038,0.00043540308,0.000009680562,0.014119568,0.00046583544,0.000022966953,0.0016456578,0.000015866617,0.00026156355,0.000038322276,0.98175186,0.0001901842],"about_ca_topic_score_codex":0.00009797844,"about_ca_topic_score_gemma":0.000007194952,"teacher_disagreement_score":0.9863154,"about_ca_system_score_codex":0.0013199303,"about_ca_system_score_gemma":0.0043217535,"threshold_uncertainty_score":0.8947943},"labels":[],"label_agreement":null},{"id":"W3128717951","doi":"10.2139/ssrn.3640763","title":"A Reservoir of Stem-Like CD8 T Cells in the Tumor-Draining Lymph Node Maintains the Ongoing Anti-Tumor Immune Response","year":2020,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mila - Quebec Artificial Intelligence Institute","funders":"","keywords":"Immune system; Lymph node; Cytotoxic T cell; Stem cell; Cancer research; Immunology; Biology; Cell biology","score_opus":0.025652277156658607,"score_gpt":0.2926424039016663,"score_spread":0.26699012674500766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3128717951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9721745,0.00304372,0.0003187574,0.023029955,0.000084920495,0.00057591475,0.0000048594934,0.000024583898,0.00074274855],"genre_scores_gemma":[0.9951556,0.0011285588,0.00003969239,0.0020223442,0.00034734354,0.0000169405,0.000002075426,0.00006864597,0.0012188],"study_design_codex":"bench_or_experimental","study_design_gemma":"qualitative","domain_scores_codex":[0.9936919,0.0016202386,0.00077348435,0.00032489674,0.0010991526,0.002490321],"domain_scores_gemma":[0.9977412,0.0009785759,0.00032298669,0.00062592066,0.00016899084,0.00016229201],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0127923265,0.0002654796,0.00055003446,0.0002443319,0.00030044213,0.0000848003,0.0009858984,0.00007041794,0.0001975274],"category_scores_gemma":[0.00041021509,0.0001608048,0.00031879306,0.0010509382,0.00021787314,0.0001186351,0.00016148096,0.003908822,0.000024756111],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012554382,0.0002607081,0.0052881674,0.000096988544,0.00044622767,0.0007896771,0.011888919,0.0006763133,0.9614913,0.0022633283,0.00024295005,0.0040010773],"study_design_scores_gemma":[0.058588162,0.018409913,0.081987664,0.0031586955,0.0009978916,0.039124332,0.53629184,0.020941898,0.1538353,0.016174473,0.0677809,0.0027089347],"about_ca_topic_score_codex":0.00018042763,"about_ca_topic_score_gemma":0.00012481204,"teacher_disagreement_score":0.807656,"about_ca_system_score_codex":0.0012389774,"about_ca_system_score_gemma":0.0053783637,"threshold_uncertainty_score":0.9983892},"labels":[],"label_agreement":null},{"id":"W3129688332","doi":"10.1097/hs9.0000000000000540","title":"Hemophilia Gene Therapy: Approaching the First Licensed Product","year":2021,"lang":"en","type":"review","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Genetic enhancement; Clinical trial; Medicine; Intensive care medicine; Gene; Biology; Internal medicine; Genetics","score_opus":0.10629999907020828,"score_gpt":0.35996604074005584,"score_spread":0.2536660416698476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3129688332","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003363579,0.97966456,0.0000109920775,0.0011339608,0.0003335927,0.003761744,0.000015902155,0.00014074848,0.014904863],"genre_scores_gemma":[0.000005033183,0.9420991,0.0004634087,0.0004331356,0.002365611,0.0005421371,0.0002310747,0.00028029596,0.05358023],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99603647,0.00039877603,0.00073860487,0.0011228212,0.00094522146,0.00075810874],"domain_scores_gemma":[0.99643445,0.00036620256,0.00027262926,0.00250444,0.00019929779,0.00022296683],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009472823,0.00076435576,0.0025713067,0.00008671641,0.00033047036,0.00012112125,0.0005749675,0.00039900182,0.010358447],"category_scores_gemma":[0.00019428607,0.0004443974,0.001315646,0.0010136836,0.00017914515,0.00005059218,0.0002571624,0.0018722111,0.00035048273],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000039521434,0.00021157284,0.0000073565825,0.0115737,0.0008436888,0.00023582933,0.00024033278,5.1857245e-7,0.000047683166,0.00006742776,0.010017993,0.9767144],"study_design_scores_gemma":[0.00062282087,0.00009974595,0.000004135245,0.007547821,0.00046997552,0.0011241598,0.00006388997,0.0000066191915,0.00013706752,0.000005698907,0.9895067,0.0004113487],"about_ca_topic_score_codex":0.000047524674,"about_ca_topic_score_gemma":0.00001993599,"teacher_disagreement_score":0.97948873,"about_ca_system_score_codex":0.0003055897,"about_ca_system_score_gemma":0.0010995639,"threshold_uncertainty_score":0.9998008},"labels":[],"label_agreement":null},{"id":"W3130326316","doi":"10.1080/2162402x.2021.1885778","title":"Synergistic anti-tumor efficacy of oncolytic influenza viruses and B7-H3 immune- checkpoint inhibitors against IC-resistant lung cancers","year":2021,"lang":"en","type":"article","venue":"OncoImmunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster University Medical Centre","funders":"Deutsche Krebshilfe","keywords":"Oncolytic virus; Cancer research; Tumor microenvironment; Immune system; Medicine; Cytotoxic T cell; Immunotherapy; Immune checkpoint; Lung cancer; Cancer; Immunology; Oncolytic adenovirus; Biology; Oncology; Internal medicine","score_opus":0.026666207144907386,"score_gpt":0.32993254255462107,"score_spread":0.3032663354097137,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3130326316","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97577703,0.018232351,0.00001541881,0.00033525383,0.00043828355,0.00051718025,0.000022376655,0.00007333015,0.004588771],"genre_scores_gemma":[0.99632883,0.0014050244,0.00013170838,0.0005664407,0.0001500861,0.00004507751,0.000024557981,0.0000748479,0.0012734426],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972023,0.00023793071,0.0009323905,0.0005684832,0.0004117669,0.000647143],"domain_scores_gemma":[0.9977928,0.0005267597,0.00029680534,0.0008809932,0.00034033536,0.00016229638],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00045403774,0.00032709577,0.0010710605,0.00030632748,0.00013178185,0.000030514047,0.00021409964,0.00023087834,0.0009146469],"category_scores_gemma":[0.0010216157,0.0003108705,0.00024223218,0.0006257617,0.00080545055,0.000077859855,0.00030148754,0.0005846912,0.000025257681],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015076498,0.00030899094,0.0072762743,0.000319211,0.00056823913,0.00074806233,0.00057982735,0.00004115309,0.98029697,0.00015078139,0.00015519728,0.008047625],"study_design_scores_gemma":[0.011371651,0.0012498592,0.10847101,0.0011167958,0.00034707406,0.00025701604,0.0017882922,0.00021966577,0.8337392,0.000041043128,0.04086625,0.00053210964],"about_ca_topic_score_codex":0.0012926534,"about_ca_topic_score_gemma":0.00017696572,"teacher_disagreement_score":0.14655775,"about_ca_system_score_codex":0.00086582405,"about_ca_system_score_gemma":0.0015547447,"threshold_uncertainty_score":0.9999986},"labels":[],"label_agreement":null},{"id":"W3130683366","doi":"10.1158/1078-0432.ccr-20-3365","title":"Mutations in the IFNγ-JAK-STAT Pathway Causing Resistance to Immune Checkpoint Inhibitors in Melanoma Increase Sensitivity to Oncolytic Virus Treatment","year":2021,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Children's Hospital of Eastern Ontario; McGill University; McGill University Health Centre","funders":"Terry Fox Research Institute; Canadian Cancer Society","keywords":"Oncolytic virus; Melanoma; Cancer research; Vesicular stomatitis virus; Herpes simplex virus; Biology; Immune checkpoint; RNA interference; Virology; Immune system; Immunology; Medicine; Virus; Immunotherapy; Gene; RNA","score_opus":0.18968747413423104,"score_gpt":0.5040336254214045,"score_spread":0.31434615128717347,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3130683366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9696056,0.000898076,0.000015009948,0.024212083,0.00016075991,0.002275517,0.00007248379,0.000022430417,0.0027380139],"genre_scores_gemma":[0.99040294,0.00063572824,0.00025161848,0.00087482407,0.00043820764,0.0007973677,0.000034889745,0.000052796873,0.0065116505],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9919252,0.003521517,0.0011186876,0.0009165563,0.0014822464,0.0010358203],"domain_scores_gemma":[0.9925597,0.004980408,0.00006540147,0.0011177016,0.00064898137,0.00062785594],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010387347,0.00023994033,0.00074201974,0.0005073361,0.00020721549,0.00011554384,0.00019433435,0.00018699556,0.000749322],"category_scores_gemma":[0.0061539365,0.00018557187,0.00024555347,0.003199948,0.00032375238,0.00007851061,0.00030885078,0.001490841,0.00014253959],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014938117,0.0058032237,0.081111275,0.00028663257,0.00023620932,0.028346183,0.01254849,0.00044648434,0.71194893,0.00015751006,0.0020501805,0.14212674],"study_design_scores_gemma":[0.013025393,0.0039879763,0.59586906,0.0022170777,0.00007161384,0.0001435103,0.0075861947,0.0004808122,0.25824553,0.00048449202,0.11714828,0.00074005337],"about_ca_topic_score_codex":0.027786134,"about_ca_topic_score_gemma":0.22317065,"teacher_disagreement_score":0.51475775,"about_ca_system_score_codex":0.003056139,"about_ca_system_score_gemma":0.0035851828,"threshold_uncertainty_score":0.97868794},"labels":[],"label_agreement":null},{"id":"W3133229959","doi":"10.1056/nejmoa2024850","title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","year":2021,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2424,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Bristol-Myers Squibb","keywords":"Chimeric antigen receptor; Refractory (planetary science); Multiple myeloma; Antigen; Cancer research; Medicine; Receptor; T cell; Internal medicine; Immunology; Biology; Immune system","score_opus":0.03150045003787461,"score_gpt":0.31717604504497804,"score_spread":0.28567559500710343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3133229959","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9742563,0.008804465,0.000068776055,0.013303698,0.0003462434,0.00011299507,8.7332006e-7,0.000008193773,0.0030984962],"genre_scores_gemma":[0.98610675,0.0032397783,0.00076771853,0.00091327645,0.0027737725,8.551771e-7,0.000004736647,0.000026242456,0.006166843],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981605,0.00017175547,0.0005893305,0.00017319055,0.00065713347,0.00024811993],"domain_scores_gemma":[0.9983024,0.00055595045,0.00016191896,0.00022515439,0.000281102,0.0004734875],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013570098,0.00013785342,0.0005851484,0.0003116011,0.000028966017,0.000009096439,0.00008419499,0.000094055424,0.0021562653],"category_scores_gemma":[0.0017301466,0.00009736062,0.00006195412,0.00034238258,0.00010874939,0.000063590414,0.000036511312,0.00073616015,0.000004530305],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002363184,0.0001199379,0.03945789,0.000056960853,0.00008704776,0.0047743726,0.0014818676,0.0000050237045,0.5668801,0.000014982296,0.0034044988,0.38135412],"study_design_scores_gemma":[0.25373164,0.004298514,0.27528757,0.0017899417,0.00018844673,0.014282658,0.0014415098,0.00026274237,0.03862162,0.0006407821,0.40920728,0.00024730572],"about_ca_topic_score_codex":0.000098081124,"about_ca_topic_score_gemma":0.00017491268,"teacher_disagreement_score":0.5282585,"about_ca_system_score_codex":0.00010425398,"about_ca_system_score_gemma":0.0004184455,"threshold_uncertainty_score":0.9987559},"labels":[],"label_agreement":null},{"id":"W3133720646","doi":"10.1172/jci140752","title":"Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responses","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Investigation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Hôpital Maisonneuve-Rosemont; McGill University; Jewish General Hospital","funders":"Terry Fox Research Institute; Canadian Institutes of Health Research; H2020 European Research Council; Réseau de cancérologie Rossy; Narodowe Centrum Badań i Rozwoju; McGill University","keywords":"Melanoma; Cancer research; Immunotherapy; CD8; EIF4E; Immune system; Immune checkpoint; Phenotype; Tumor microenvironment; Immunology; Biology; Medicine; Gene","score_opus":0.08551406362731641,"score_gpt":0.39733535910964496,"score_spread":0.31182129548232856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3133720646","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98136353,0.002087002,0.00010746988,0.015678626,0.0003076076,0.00013783872,0.0000013227701,0.000012979648,0.00030359143],"genre_scores_gemma":[0.9945776,0.0006216142,0.0021504,0.0009816135,0.0008936422,0.0000013218217,0.000004462829,0.000021870022,0.0007475062],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99688846,0.0007315324,0.0014230477,0.00018376934,0.00056772394,0.00020549398],"domain_scores_gemma":[0.99598545,0.0021606353,0.00071011,0.00023285064,0.00064222637,0.00026871735],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0055084815,0.00012178958,0.0005117523,0.000111207206,0.0001653282,0.000109075,0.00011090198,0.00011953251,0.00025811125],"category_scores_gemma":[0.010339362,0.000079758276,0.000264001,0.00030142433,0.00025521105,0.00022637862,0.000089982816,0.0009999961,0.000008532199],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013871335,0.00012635664,0.25555092,0.00008519722,0.0002761042,0.00034168852,0.0006398038,0.00000918706,0.7014446,0.00024255482,0.00035946866,0.03953694],"study_design_scores_gemma":[0.0033035008,0.0011595499,0.86395115,0.00079060905,0.00024666876,0.0014292594,0.0011296758,0.0009486041,0.12090394,0.0042147296,0.0017720123,0.00015028671],"about_ca_topic_score_codex":0.000026719383,"about_ca_topic_score_gemma":0.000008582694,"teacher_disagreement_score":0.6084002,"about_ca_system_score_codex":0.000038434504,"about_ca_system_score_gemma":0.00064658833,"threshold_uncertainty_score":0.997997},"labels":[],"label_agreement":null},{"id":"W3134407748","doi":"10.12927/hcpol.2021.26430","title":"Understanding the Feasibility of Implementing Car T-Cell Therapies from a Canadian Perspective","year":2021,"lang":"en","type":"article","venue":"Healthcare policy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; University of Waterloo","funders":"","keywords":"Chimeric antigen receptor; Perspective (graphical); CAR T-cell therapy; Qualitative research; Medicine; Engineering ethics; Computer science; Engineering; Sociology; T cell; Immunology; Artificial intelligence","score_opus":0.23635135559261253,"score_gpt":0.44775107770208117,"score_spread":0.21139972210946864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134407748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8025746,0.004653125,0.00006540495,0.15809168,0.00008679132,0.00091799826,0.00030837322,0.00003587816,0.033266153],"genre_scores_gemma":[0.99573374,0.00031097978,0.0000970997,0.0023752504,0.0004119642,0.000013563219,0.000030485819,0.0000289998,0.0009979305],"study_design_codex":"observational","study_design_gemma":"qualitative","domain_scores_codex":[0.998091,0.00031472222,0.00026932987,0.00031777035,0.00036572118,0.0006414647],"domain_scores_gemma":[0.99828696,0.00024609262,0.000074394105,0.0006040084,0.00042039598,0.00036813098],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004990576,0.00013014127,0.0002908299,0.0001790182,0.00028882717,0.00002833657,0.00012219748,0.00008275937,0.0013925995],"category_scores_gemma":[0.00024497847,0.000102190366,0.00014002445,0.00059896015,0.00013324409,0.000032399377,0.000063059626,0.00037714554,0.000007246454],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005555811,0.00030492505,0.5179452,0.0007113124,0.00073600584,0.00026877696,0.18654525,0.0000031383063,0.14932552,0.13028917,0.0024470137,0.010868136],"study_design_scores_gemma":[0.005888557,0.0008792674,0.19824395,0.0004038605,0.00014576367,0.00012762855,0.64471704,0.00021882285,0.034251433,0.095707364,0.018823074,0.00059325993],"about_ca_topic_score_codex":0.8948211,"about_ca_topic_score_gemma":0.7416618,"teacher_disagreement_score":0.45817178,"about_ca_system_score_codex":0.0035324492,"about_ca_system_score_gemma":0.0057726405,"threshold_uncertainty_score":0.9998637},"labels":[],"label_agreement":null},{"id":"W3134659811","doi":"10.1038/s41573-021-00155-y","title":"Beyond immune checkpoint blockade: emerging immunological strategies","year":2021,"lang":"en","type":"review","venue":"Nature Reviews Drug Discovery","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":477,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Immunotherapy; Tumor microenvironment; Immune checkpoint; Blockade; Cancer immunotherapy; Medicine; T cell; Immune system; Immunology; Cancer research; Receptor; Internal medicine","score_opus":0.04113483083086296,"score_gpt":0.3922663755111197,"score_spread":0.35113154468025676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134659811","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000019609399,0.98012024,0.000010591635,0.0004236287,0.001175761,0.004026526,0.000072899355,0.00012748087,0.014023255],"genre_scores_gemma":[0.0000060367365,0.9598526,0.00028621673,0.00016834446,0.0015478814,0.00056871213,0.0014427243,0.00022771583,0.03589981],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9918909,0.0014090594,0.0026757128,0.0016246492,0.0012294081,0.0011702555],"domain_scores_gemma":[0.99541575,0.0004925079,0.0010218867,0.0025378864,0.0002487928,0.00028315248],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.0024586525,0.0015142737,0.0090652,0.00051352667,0.0002032805,0.0005324635,0.0010089935,0.0020244508,0.0049200617],"category_scores_gemma":[0.00087167363,0.0009872231,0.0055562565,0.0018474247,0.00031154393,0.0004868993,0.00076445803,0.009165711,0.00041978114],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003525584,0.00027860526,0.0000010786332,0.044287108,0.00094485143,0.0005236643,0.00006710513,1.6794795e-7,0.00036629615,0.0007170062,0.0024458964,0.95033294],"study_design_scores_gemma":[0.0004916368,0.00008393684,0.000004022353,0.06320865,0.0020397683,0.00082912325,0.00015411331,6.410844e-7,0.000090204856,0.00008083908,0.93220025,0.0008168195],"about_ca_topic_score_codex":0.000022041668,"about_ca_topic_score_gemma":0.000008399574,"teacher_disagreement_score":0.9495161,"about_ca_system_score_codex":0.00075200404,"about_ca_system_score_gemma":0.0022113149,"threshold_uncertainty_score":0.9997606},"labels":[],"label_agreement":null},{"id":"W3134794845","doi":"10.3390/cancers13051106","title":"Parking CAR T Cells in Tumours: Oncolytic Viruses as Valets or Vandals?","year":2021,"lang":"en","type":"review","venue":"Cancers","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"National Cancer Institute; National Institutes of Health","keywords":"Oncolytic virus; Chimeric antigen receptor; T cell; Tumor microenvironment; Immune system; CD8; Biology; Cytotoxic T cell; Context (archaeology); Immunology; Antigen; Cancer research","score_opus":0.14316046081578548,"score_gpt":0.444017945416965,"score_spread":0.3008574846011795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134794845","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00030268263,0.9889109,0.0000013768185,0.000026715927,0.0007885458,0.0015446971,0.000039946306,0.000048976737,0.008336145],"genre_scores_gemma":[0.000036076104,0.9776723,0.00004707662,0.00041141294,0.0008522552,0.00032046,0.00005262721,0.00015644742,0.020451369],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99695134,0.000305196,0.00066080055,0.00072899857,0.00066749286,0.0006861624],"domain_scores_gemma":[0.99809086,0.00053322484,0.00021293802,0.0007296348,0.00011195711,0.00032136618],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00052361796,0.0004848048,0.0026601257,0.0004049709,0.000048938407,0.00006581665,0.0003105528,0.00036350574,0.008808483],"category_scores_gemma":[0.00024897468,0.0003805636,0.00057781383,0.0009955312,0.00012859511,0.000053009426,0.00011192281,0.0010975321,0.00023847097],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00012436202,0.000031186795,0.000018763561,0.016124496,0.000321042,0.0033321409,0.00029204163,0.000010715145,0.00021472154,0.000005332017,0.0062979837,0.9732272],"study_design_scores_gemma":[0.00078941364,0.00020704603,0.0000011661441,0.04415492,0.00053886994,0.00018478112,0.0001624755,0.000005831569,0.00034256227,0.0000025065533,0.95326424,0.00034618154],"about_ca_topic_score_codex":0.0009289476,"about_ca_topic_score_gemma":0.00041269563,"teacher_disagreement_score":0.972881,"about_ca_system_score_codex":0.008677601,"about_ca_system_score_gemma":0.014056124,"threshold_uncertainty_score":0.99986464},"labels":[],"label_agreement":null},{"id":"W3136339776","doi":"10.1097/ppo.0000000000000515","title":"Cytokine Release Syndrome Biology and Management","year":2021,"lang":"en","type":"review","venue":"The Cancer Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"","keywords":"Cytokine release syndrome; Chimeric antigen receptor; Immunosuppression; Immunotherapy; Immunology; Cytokine; Immune system; Medicine; Biology; Bioinformatics; Cancer research","score_opus":0.0882306754738781,"score_gpt":0.43499388329341665,"score_spread":0.34676320781953857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3136339776","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000058990445,0.9963034,0.000019037298,0.0009822916,0.000342093,0.0005832175,0.000023268176,0.000011079805,0.0016766328],"genre_scores_gemma":[0.0000070907417,0.98692244,0.00005519275,0.00026542108,0.00084956404,0.000080829566,0.000021877522,0.000054294713,0.01174329],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99834335,0.00033794795,0.00040902916,0.00027829438,0.00027184215,0.00035955457],"domain_scores_gemma":[0.9989219,0.00010074103,0.00019617399,0.0004684813,0.000085581254,0.00022714295],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007514878,0.00025198556,0.0012526073,0.00018792653,0.00014285672,0.00006169446,0.00028326397,0.00013941547,0.007142346],"category_scores_gemma":[0.000026865413,0.000136791,0.00035240475,0.00030276278,0.00014305912,0.000020233168,0.00020731204,0.0012866665,0.00002891651],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000025779715,0.000020708218,0.000009226864,0.004516526,0.001202564,0.0018004505,0.000017099914,1.7292675e-7,0.0000068644463,0.000116889576,0.003956698,0.988327],"study_design_scores_gemma":[0.00052958063,0.0001150312,0.000021339909,0.011549622,0.0014548864,0.022397388,0.000017972494,0.0000010630476,0.0000012146298,0.00008779018,0.96370006,0.00012402757],"about_ca_topic_score_codex":0.000017502925,"about_ca_topic_score_gemma":0.0000035060414,"teacher_disagreement_score":0.988203,"about_ca_system_score_codex":0.0003891486,"about_ca_system_score_gemma":0.00043810837,"threshold_uncertainty_score":0.99376523},"labels":[],"label_agreement":null},{"id":"W3137447968","doi":"10.1200/jco.20.03175","title":"Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell–Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":413,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Cytokine release syndrome; Internal medicine; Gastroenterology; Refractory (planetary science); Follicular lymphoma; Lymphoma; Rituximab; Adverse effect; CD20; Alemtuzumab; Oncology; T cell; Immunology; Immune system; Transplantation","score_opus":0.26594447380813624,"score_gpt":0.5123547411190288,"score_spread":0.24641026731089255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3137447968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98090696,0.0019094034,0.0001347108,0.0062603615,0.0026310147,0.0005699631,0.000011344359,0.000023838022,0.007552407],"genre_scores_gemma":[0.97916365,0.005144499,0.005942306,0.0011055714,0.0030752723,0.000010009691,0.000024132994,0.00007525072,0.005459333],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99032706,0.0023782093,0.004807657,0.000600286,0.001121412,0.00076539395],"domain_scores_gemma":[0.9844342,0.01085221,0.0023040853,0.00053968444,0.0009294188,0.0009403929],"candidate_categories":["metaresearch","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.012967927,0.0003229704,0.002680075,0.0005304338,0.00017846431,0.00004956509,0.00042109736,0.0007482478,0.0030995267],"category_scores_gemma":[0.01589971,0.00023855723,0.00089482265,0.00095274515,0.00030414425,0.00017027688,0.00021616698,0.003278981,0.00003957582],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15898047,0.032038487,0.0017145505,0.00016274025,0.00022849784,0.010803118,0.00036493794,0.000013631509,0.74148434,0.000007578538,0.004853024,0.049348626],"study_design_scores_gemma":[0.51290476,0.024366738,0.0017364459,0.00068242336,0.00029105323,0.0012110994,0.0022442804,0.00066772493,0.013005949,0.000051604442,0.44248554,0.00035236633],"about_ca_topic_score_codex":0.00004031485,"about_ca_topic_score_gemma":0.000022757056,"teacher_disagreement_score":0.7284784,"about_ca_system_score_codex":0.0007590653,"about_ca_system_score_gemma":0.009032334,"threshold_uncertainty_score":0.9990205},"labels":[],"label_agreement":null},{"id":"W3137935396","doi":"10.1371/journal.pone.0248118","title":"Establishing CD19 B-cell reference control materials for comparable and quantitative cytometric expression analysis","year":2021,"lang":"en","type":"article","venue":"PLoS ONE","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Fluidigm (Canada)","funders":"National Institute of Standards and Technology","keywords":"CD19; Flow cytometry; Peripheral blood mononuclear cell; Calibration; Computational biology; Computer science; Biology; Immunology; Mathematics; In vitro; Statistics; Biochemistry","score_opus":0.17049444200458552,"score_gpt":0.34852562364445133,"score_spread":0.1780311816398658,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3137935396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943278,0.0012451955,0.0015824239,0.00025252657,0.000018189563,0.00060415984,0.00012792456,0.000035185734,0.0018066176],"genre_scores_gemma":[0.98331714,0.00037224818,0.010324204,0.0001175325,0.00007006042,0.00009190467,0.00014668037,0.000022682165,0.0055375774],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983085,0.0001548335,0.00027024007,0.00036736127,0.00060468307,0.00029438623],"domain_scores_gemma":[0.99764556,0.0010689712,0.00009520979,0.0003258161,0.00071333826,0.00015112298],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00069853786,0.0001251003,0.00072168425,0.00048625498,0.00009571525,0.00013678755,0.0000827942,0.00008110291,0.0020247663],"category_scores_gemma":[0.0010640017,0.00011127737,0.00006861684,0.0012729502,0.00004425675,0.00014100726,0.000054810167,0.00014719517,0.000016325952],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008564424,0.00095104164,0.005158089,0.00037834604,0.000882733,0.000018621626,0.00018295964,0.0000052702085,0.9912004,0.000052671545,0.00019338231,0.00012004798],"study_design_scores_gemma":[0.0036006405,0.00035569127,0.0033015113,0.00018702133,0.0013028267,0.0000016894072,0.00031300425,0.001508393,0.98897284,0.00006187993,0.0002702882,0.00012422903],"about_ca_topic_score_codex":0.00007049268,"about_ca_topic_score_gemma":0.000017021257,"teacher_disagreement_score":0.011010666,"about_ca_system_score_codex":0.000078071585,"about_ca_system_score_gemma":0.00009729484,"threshold_uncertainty_score":0.99888754},"labels":[],"label_agreement":null},{"id":"W3138645123","doi":"10.1136/bmjopen-2020-043929","title":"Navigating choice in the face of uncertainty: using a theory informed qualitative approach to identifying potential patient barriers and enablers to participating in an early phase chimeric antigen receptor T (CAR-T) cell therapy trial","year":2021,"lang":"en","type":"article","venue":"BMJ Open","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vancouver General Hospital; Institute for Clinical Evaluative Sciences; Genome British Columbia; University of Ottawa; Ottawa Hospital","funders":"National Cancer Institute","keywords":"Medicine; Chimeric antigen receptor; Qualitative research; Clinical trial; Knowledge translation; Family medicine; Cancer; Internal medicine; Immunotherapy; Knowledge management","score_opus":0.23405634589597232,"score_gpt":0.5237100543812765,"score_spread":0.28965370848530414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3138645123","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876573,0.00007048955,0.00029493432,0.00017189626,0.00007676274,0.011369559,0.00002017389,0.0000085044385,0.00033039966],"genre_scores_gemma":[0.99402696,0.000009140559,0.003366624,0.0005357192,0.00007581439,0.0018562317,0.000037454698,0.00003658726,0.00005547876],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.9954348,0.0020868923,0.0007903186,0.00047603805,0.00068904203,0.00052287773],"domain_scores_gemma":[0.9982466,0.00060001726,0.00023086781,0.0004736239,0.00017064161,0.00027822115],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0045838617,0.00021478525,0.0005690511,0.00013514994,0.00014947836,0.00023647823,0.0003677716,0.00008031335,0.0002155605],"category_scores_gemma":[0.0014612904,0.00017093928,0.00007642164,0.0012087328,0.00008908043,0.00035816288,0.00030104397,0.00043037126,0.0000018045683],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035265394,0.00056941586,0.0024276022,0.00011310951,0.0000826261,0.000027321023,0.5315959,0.0028277242,0.38607946,0.000012114999,0.000012961292,0.04098641],"study_design_scores_gemma":[0.070257194,0.0046219705,0.0024133443,0.0011197985,0.000045372828,0.000013263216,0.8455815,0.0076518953,0.0674756,0.00006463779,0.00018486506,0.0005705759],"about_ca_topic_score_codex":0.0053504263,"about_ca_topic_score_gemma":0.00029156203,"teacher_disagreement_score":0.31860384,"about_ca_system_score_codex":0.0001721872,"about_ca_system_score_gemma":0.00066707766,"threshold_uncertainty_score":0.80882794},"labels":[],"label_agreement":null},{"id":"W3138818958","doi":"10.1182/blood.2020009081","title":"Venetoclax enhances T cell–mediated antileukemic activity by increasing ROS production","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":145,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; Toronto General Hospital; University Health Network","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Venetoclax; Cancer research; Medicine; Leukemia; Immunology; Chronic lymphocytic leukemia","score_opus":0.01551792651846018,"score_gpt":0.28204364045300373,"score_spread":0.26652571393454355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3138818958","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939055,0.0015153448,0.000011316573,0.00030668793,0.0001760173,0.00032755962,0.000010877709,0.000094510964,0.0036521812],"genre_scores_gemma":[0.9923854,0.0005905797,0.00014400699,0.00006533805,0.0004138796,0.000025434465,0.00008349768,0.0000331209,0.0062587834],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99857736,0.0001629379,0.00014556541,0.00040110678,0.0003993208,0.00031372134],"domain_scores_gemma":[0.9991822,0.00010250533,0.00005770314,0.000380119,0.00014668817,0.00013077621],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003167936,0.0001311331,0.00024268561,0.0000639181,0.000082632454,0.000031490516,0.00006729738,0.00010214825,0.0008616227],"category_scores_gemma":[0.00034479168,0.00012905209,0.00007103768,0.00039631253,0.00006361955,0.000093465394,0.000045683355,0.0003162379,0.000059256177],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021812877,0.000518095,0.008052908,0.000101794896,0.000065397944,0.00007529918,0.00010219352,0.0000010377104,0.98544407,4.0358506e-7,0.0009066521,0.004514021],"study_design_scores_gemma":[0.0017825995,0.00012142276,0.008762174,0.000069531656,0.00008024582,0.0001856664,0.00004671388,0.000046585148,0.9840407,0.0000083166615,0.0047378857,0.000118178985],"about_ca_topic_score_codex":0.00021846376,"about_ca_topic_score_gemma":0.000016971624,"teacher_disagreement_score":0.004395842,"about_ca_system_score_codex":0.00016304434,"about_ca_system_score_gemma":0.0005651066,"threshold_uncertainty_score":0.9434164},"labels":[],"label_agreement":null},{"id":"W3139314280","doi":"10.1186/s13063-021-05121-y","title":"Hematologists’ barriers and enablers to screening and recruiting patients to a chimeric antigen receptor (CAR) T cell therapy trial: a theory-informed interview study","year":2021,"lang":"en","type":"article","venue":"Trials","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vancouver General Hospital; Institute for Clinical Evaluative Sciences; University of Ottawa; Ottawa Hospital","funders":"National Cancer Institute","keywords":"Medicine; Context (archaeology); Workload; Clinical trial; Pathology","score_opus":0.22463829307743308,"score_gpt":0.4329605518670708,"score_spread":0.2083222587896377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3139314280","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878566,0.0014740496,0.00015100579,0.00069225056,0.00026469992,0.008498237,0.000017180704,0.00006923701,0.0009767194],"genre_scores_gemma":[0.9887972,0.0018841112,0.003077141,0.0021889294,0.00032476906,0.00074737973,0.00003577758,0.00010027769,0.0028444012],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99540794,0.0019495906,0.0009966228,0.0006089427,0.00052007823,0.00051683694],"domain_scores_gemma":[0.99675155,0.0016432082,0.00022929841,0.0004885742,0.00023707881,0.0006502848],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.007005091,0.0002956226,0.0014040634,0.00027612151,0.00017007651,0.00015332464,0.00015563272,0.00010359556,0.0023416658],"category_scores_gemma":[0.008060158,0.00023062098,0.00016954653,0.0006764942,0.000066431676,0.00009158076,0.00022386806,0.00023471753,0.000022531014],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11588125,0.00079126464,0.025826445,0.00033688705,0.0011660521,0.000087319204,0.032980606,0.0000023224961,0.12973738,0.00002364896,0.0031019857,0.69006485],"study_design_scores_gemma":[0.4370961,0.029353084,0.013213623,0.0020880657,0.00056297285,0.0000636902,0.09911565,0.000026914053,0.25408727,0.00020242423,0.16231248,0.0018777301],"about_ca_topic_score_codex":0.00009370011,"about_ca_topic_score_gemma":0.000018431041,"teacher_disagreement_score":0.6881871,"about_ca_system_score_codex":0.00007780849,"about_ca_system_score_gemma":0.00025551676,"threshold_uncertainty_score":0.9985703},"labels":[],"label_agreement":null},{"id":"W3139471115","doi":"10.1038/s41417-021-00320-w","title":"Engineered cells as glioblastoma therapeutics","year":2021,"lang":"en","type":"review","venue":"Cancer Gene Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Ottawa Hospital","funders":"Canadian Cancer Society Research Institute","keywords":"Glioblastoma; Genetically engineered; Mesenchymal stem cell; Stem cell; Cancer research; Neural stem cell; Computational biology; Cell; Biology; Medicine; Gene; Cell biology; Genetics","score_opus":0.10004991932952766,"score_gpt":0.41356606844291516,"score_spread":0.3135161491133875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3139471115","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021735267,0.9947452,0.000018670446,0.00016152598,0.0011445606,0.0020889193,0.00010938934,0.00016966827,0.001344716],"genre_scores_gemma":[0.0000045925362,0.96175057,0.00011799794,0.0010335577,0.0021429511,0.00070126925,0.00014712519,0.0004236741,0.033678293],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963591,0.00029101642,0.0007328468,0.0009262038,0.0008459363,0.0008448779],"domain_scores_gemma":[0.9973045,0.0002049011,0.00023409713,0.0015504208,0.00032938976,0.00037672053],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00032279026,0.0008998987,0.0030570496,0.0003884677,0.00009079578,0.00009248066,0.00053326564,0.00069030264,0.02035844],"category_scores_gemma":[0.000010007934,0.000715006,0.0013907934,0.0011184642,0.00013284209,0.000042159605,0.00008864126,0.0011472936,0.00039843825],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019245196,0.00015019639,4.655555e-7,0.0025861268,0.0024119106,0.00022476133,0.0001549287,0.0000024081803,0.012527069,0.000013089559,0.0018969389,0.9798397],"study_design_scores_gemma":[0.0014269399,0.000643484,4.8710666e-7,0.004729831,0.00070249697,0.00025646045,0.00001730324,0.000006036928,0.029354403,0.0000089948435,0.96224874,0.0006048309],"about_ca_topic_score_codex":0.000048291717,"about_ca_topic_score_gemma":0.000006973743,"teacher_disagreement_score":0.9792348,"about_ca_system_score_codex":0.000780781,"about_ca_system_score_gemma":0.0030137943,"threshold_uncertainty_score":0.9995301},"labels":[],"label_agreement":null},{"id":"W3140219234","doi":"10.1016/j.jval.2017.08.637","title":"Resource Utilization And Disaggregated Cost Analysis For Initial Treatment Of Melanoma","year":2017,"lang":"en","type":"article","venue":"Value in Health","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cancer Care Ontario; Institute for Clinical Evaluative Sciences; University of Toronto","funders":"","keywords":"Melanoma; Resource (disambiguation); Computer science; Resource use; Natural resource economics; Economics; Medicine; Cancer research; Computer network","score_opus":0.22265516802860844,"score_gpt":0.4504007556636089,"score_spread":0.22774558763500044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3140219234","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99481857,0.00092798827,0.00024263638,0.0020184573,0.00002613522,0.0012567724,0.0000479295,0.00000965535,0.00065187784],"genre_scores_gemma":[0.99784106,0.0010289015,0.00021706092,0.0000423717,0.00006124803,0.000044942914,0.00008901087,0.000011557209,0.00066384714],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99915314,0.00009598147,0.00024877305,0.0001723525,0.0001477473,0.00018200812],"domain_scores_gemma":[0.9991753,0.0001582725,0.00014531681,0.0003616681,0.000047959384,0.000111495545],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039328958,0.00006922296,0.0003451862,0.00021408085,0.00010902854,0.000015044458,0.000048780264,0.00004666654,0.00007296456],"category_scores_gemma":[0.00014736786,0.000057635003,0.000063620435,0.00016264759,0.00008080572,0.000026475404,0.000013724626,0.000038144855,5.578325e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025394985,0.0005721166,0.5959721,0.00045745712,0.00047055856,0.000014889756,0.0026187806,0.00034800344,0.00096426375,0.00038061527,0.00007135589,0.39559034],"study_design_scores_gemma":[0.014287174,0.006350886,0.81099033,0.00033380502,0.0003524904,0.000016394966,0.00045985432,0.10539953,0.008293555,0.00025543323,0.053079065,0.00018149358],"about_ca_topic_score_codex":0.005490328,"about_ca_topic_score_gemma":0.00038768558,"teacher_disagreement_score":0.39540884,"about_ca_system_score_codex":0.00019170473,"about_ca_system_score_gemma":0.00015109092,"threshold_uncertainty_score":0.82997704},"labels":[],"label_agreement":null},{"id":"W3141144532","doi":"10.1158/0008-5472.can-20-2701","title":"Mesothelin-Specific CAR T Cells Target Ovarian Cancer","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":116,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; Vetenskapsrådet; Karolinska Institutet; Cancerfonden; Barncancerfonden; Memorial Sloan-Kettering Cancer Center","keywords":"Mesothelin; Ovarian cancer; Cancer research; CD28; Tumor microenvironment; T cell; Cytotoxic T cell; CD8; Immune system; Medicine; Ovarian tumor; Antigen; Cancer; Immunology; Biology; Internal medicine; In vitro","score_opus":0.11573063686289073,"score_gpt":0.42826269920093607,"score_spread":0.3125320623380453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3141144532","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.84718186,0.060743935,0.00018627064,0.023855474,0.0018873457,0.0022836833,0.00038086588,0.00021905321,0.06326152],"genre_scores_gemma":[0.4381789,0.054320566,0.0014588002,0.0014565504,0.005779876,0.0015034775,0.00011255688,0.0003491544,0.49684012],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9948698,0.00048610457,0.0003487742,0.00088161445,0.0020533996,0.0013602553],"domain_scores_gemma":[0.9961857,0.00028333787,0.000037953872,0.0011669268,0.0016798249,0.00064623094],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014868658,0.00023763135,0.00049829314,0.00036536163,0.00029487436,0.00013905863,0.00040398247,0.00021764918,0.15238012],"category_scores_gemma":[0.000103321785,0.00021883234,0.00020454777,0.0016594967,0.0003981451,0.00009203733,0.0002870471,0.0015954382,0.000746611],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052824087,0.00014687174,0.0016521143,0.0001635762,0.00017003062,0.0006994711,0.00054286525,0.000033803695,0.88268524,0.00035915984,0.093205556,0.01981304],"study_design_scores_gemma":[0.0011873599,0.00007613437,0.0007641304,0.00011899769,0.000009531316,0.000018652874,0.00026119026,0.0000367727,0.48130193,0.00015945439,0.51593524,0.00013057425],"about_ca_topic_score_codex":0.0017163517,"about_ca_topic_score_gemma":0.00043381882,"teacher_disagreement_score":0.4335786,"about_ca_system_score_codex":0.00126385,"about_ca_system_score_gemma":0.0030618208,"threshold_uncertainty_score":0.95964223},"labels":[],"label_agreement":null},{"id":"W3145845511","doi":"10.1101/2021.04.02.437733","title":"Autologous humanized mouse models of iPSC-derived tumors allow for the evaluation and modulation of cancer-immune cell interactions","year":2021,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Immune system; Humanized mouse; Cancer research; Nivolumab; Tumor microenvironment; Cell; Cancer cell; Immunology; Cancer; Biology; Immunotherapy; Medicine","score_opus":0.054378189449212674,"score_gpt":0.32127396295963195,"score_spread":0.26689577351041927,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3145845511","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889854,0.0037036014,0.0035285454,0.00022477173,0.0003555093,0.002998895,0.0001308261,0.00006388741,0.0000085731635],"genre_scores_gemma":[0.99531686,0.0010603181,0.0024536252,0.000027116037,0.00013292936,0.00086566666,0.0000034164668,0.000096321106,0.0000437169],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975946,0.00021188996,0.00071757595,0.00058216514,0.0006075962,0.00028618157],"domain_scores_gemma":[0.99561447,0.00027410322,0.00064605474,0.0010657301,0.0022986596,0.00010101065],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011146176,0.00031419675,0.0007636299,0.00026529253,0.00012397424,0.000056740777,0.00024038408,0.00025289765,0.00025752644],"category_scores_gemma":[0.0002848192,0.0002839042,0.0002300676,0.00030010132,0.00017875746,0.000121591,0.00024052648,0.000531638,5.6293294e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036667442,0.00020530594,0.00068730704,0.0009372862,0.00042141663,0.000002432585,0.00012644354,0.0064785723,0.9906417,0.00004775973,0.000014373636,0.00007073437],"study_design_scores_gemma":[0.0018551593,0.00009542904,0.054984298,0.00043514423,0.0005028671,2.7117238e-8,0.000037123562,0.23384373,0.7079946,0.0000039736487,0.00004846031,0.00019921588],"about_ca_topic_score_codex":0.0007419493,"about_ca_topic_score_gemma":0.00005141331,"teacher_disagreement_score":0.2826471,"about_ca_system_score_codex":0.00036324863,"about_ca_system_score_gemma":0.0011756542,"threshold_uncertainty_score":0.9999613},"labels":[],"label_agreement":null},{"id":"W3145970345","doi":"10.21203/rs.3.rs-355230/v1","title":"Cytokine release syndrome in a patient with colorectal cancer following vaccination with BNT162b2 (tozinameran)","year":2021,"lang":"en","type":"preprint","venue":"Research Square","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Ottawa Mental Health Centre","funders":"Medical Research Council; National Institute for Health and Care Research; Royal Marsden NHS Foundation Trust; Wellcome Trust; Francis Crick Institute; Cancer Research UK; Royal Marsden Cancer Charity","keywords":"Vaccination; Colorectal cancer; Medicine; Cancer; Cytokine; Immunology; Internal medicine","score_opus":0.03231096816779156,"score_gpt":0.3727008006689854,"score_spread":0.34038983250119387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3145970345","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876842,0.0024230403,0.00004225225,0.0018073064,0.00011761658,0.0050065033,0.00007088277,0.000095093405,0.0027531406],"genre_scores_gemma":[0.9930589,0.0009790454,0.000377285,0.000049590017,0.0001405034,0.0029474478,0.0004945651,0.0001928268,0.0017597933],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9915918,0.0008935789,0.00053909025,0.0014321984,0.0041617607,0.0013815752],"domain_scores_gemma":[0.9962401,0.0004077675,0.00013904514,0.0010694346,0.001585751,0.00055795006],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001521669,0.00052479503,0.0010909039,0.0014616477,0.00020016744,0.0002514303,0.00036573794,0.00046076946,0.0033727463],"category_scores_gemma":[0.000404012,0.0004132783,0.0002657969,0.0022934508,0.00014231671,0.00017427972,0.0007435918,0.0044216127,0.000023082628],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04123747,0.0059082294,0.46246153,0.015677813,0.003788961,0.22583294,0.016554667,0.0064804927,0.050211616,0.00007286634,0.0008429966,0.17093042],"study_design_scores_gemma":[0.0297392,0.02605653,0.82441753,0.04827324,0.0004729244,0.004323125,0.014246046,0.008061023,0.036463212,0.00015064866,0.0049661314,0.002830411],"about_ca_topic_score_codex":0.008324486,"about_ca_topic_score_gemma":0.007797323,"teacher_disagreement_score":0.36195597,"about_ca_system_score_codex":0.0030697107,"about_ca_system_score_gemma":0.003997687,"threshold_uncertainty_score":0.9998319},"labels":[],"label_agreement":null},{"id":"W3151543485","doi":"10.1158/2159-8290.cd-20-1677","title":"Integrative Bulk and Single-Cell Profiling of Premanufacture T-cell Populations Reveals Factors Mediating Long-Term Persistence of CAR T-cell Therapy","year":2021,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":205,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of General Medical Sciences; National Cancer Institute; National Institutes of Health; Canadian Institutes of Health Research; European Hematology Association; National Heart, Lung, and Blood Institute; Stand Up To Cancer; Doris Duke Charitable Foundation","keywords":"Persistence (discontinuity); Profiling (computer programming); Cell; Computational biology; Term (time); Biology; Cell biology; Genetics; Computer science; Physics; Engineering","score_opus":0.07317010384896924,"score_gpt":0.32719381558736893,"score_spread":0.25402371173839966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3151543485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9843094,0.012223967,0.00016374918,0.000106600266,0.00019390247,0.00065075903,0.00017302773,0.000015871832,0.0021627282],"genre_scores_gemma":[0.9894916,0.0020146756,0.0004539217,0.0000585933,0.0001211807,0.000030307538,0.00013380666,0.000044851153,0.0076510743],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99818546,0.00011716266,0.000456252,0.00044631184,0.0004880577,0.00030676273],"domain_scores_gemma":[0.9985495,0.00024414365,0.0003103433,0.00042117568,0.0003405756,0.0001342139],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016076773,0.00026060827,0.00060132024,0.00012314752,0.00007219247,0.000037917096,0.00013211569,0.00013897238,0.00040297164],"category_scores_gemma":[0.000086006905,0.00020278296,0.00021230608,0.00030681162,0.0002069385,0.00023038895,0.00007647368,0.00035231098,5.4455245e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014850813,0.00023699415,0.2704699,0.0007011761,0.000061219645,0.00001121916,0.0036138662,0.000059247344,0.723786,0.000005844079,0.000030559346,0.00087545795],"study_design_scores_gemma":[0.0014041321,0.0003103248,0.03470771,0.00043898882,0.00009514775,0.000004840155,0.0034560817,0.00003503464,0.9593183,0.00003082088,0.000024416175,0.00017423481],"about_ca_topic_score_codex":0.00015251849,"about_ca_topic_score_gemma":0.00007704713,"teacher_disagreement_score":0.23576221,"about_ca_system_score_codex":0.0002045663,"about_ca_system_score_gemma":0.00048625487,"threshold_uncertainty_score":0.8269249},"labels":[],"label_agreement":null},{"id":"W3153996944","doi":"10.1002/cjce.24141","title":"Process evolution in cell and gene therapy from discovery to commercialization","year":2021,"lang":"en","type":"article","venue":"The Canadian Journal of Chemical Engineering","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia; Hatch (Canada)","funders":"","keywords":"Commercialization; Computer science; New product development; Process (computing); Quality by Design; Process management; Quality (philosophy); Modular design; Risk analysis (engineering); Engineering; Business","score_opus":0.01445276828322336,"score_gpt":0.2507932958868911,"score_spread":0.23634052760366772,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3153996944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99576396,0.0016076419,0.0005856176,0.0018435642,0.000059430004,0.00007470351,0.0000039791043,0.00000228038,0.000058849822],"genre_scores_gemma":[0.9993574,0.000026984506,0.00014813834,0.00019515454,0.00019597933,0.0000017363284,0.000004935646,0.0000135561895,0.00005613441],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9994747,0.000013557054,0.00015175257,0.00006590434,0.00014278977,0.00015129257],"domain_scores_gemma":[0.99949306,0.00004671649,0.000022710134,0.000086115164,0.000095578296,0.00025580006],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014091883,0.000060062244,0.0001390501,0.000098571116,0.000017676017,0.000034812885,0.00006818927,0.000044011365,0.00007427535],"category_scores_gemma":[0.00011077253,0.00004763278,0.000029325662,0.00023465526,0.000018216699,0.00006297911,0.000006854567,0.0002365392,5.964735e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000057926543,0.000010058274,0.0033398895,0.000014195557,0.000016304166,0.00006907619,0.0005936113,0.0017156525,0.9932103,0.000017705404,0.00003591871,0.00091934274],"study_design_scores_gemma":[0.0010224493,0.000043026175,0.011126405,0.00013852374,0.000012563657,0.00011389122,0.00006080764,0.0016908419,0.98494226,0.00014473284,0.0006217342,0.00008274355],"about_ca_topic_score_codex":0.0015027947,"about_ca_topic_score_gemma":0.0006137355,"teacher_disagreement_score":0.008268038,"about_ca_system_score_codex":0.0002691047,"about_ca_system_score_gemma":0.00050206133,"threshold_uncertainty_score":0.2271786},"labels":[],"label_agreement":null},{"id":"W3155195921","doi":"10.1016/s2352-3026(21)00060-0","title":"Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study","year":2021,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; Canada Research Chairs; University of Toronto","funders":"","keywords":"Medicine; Hazard ratio; Intensive care; Intensive care unit; Cytokine release syndrome; Cohort study; Cohort; Observational study; Proportional hazards model; Internal medicine; Retrospective cohort study; Emergency medicine; Chimeric antigen receptor; Pediatrics; Intensive care medicine; Confidence interval; Immunotherapy","score_opus":0.05996188039825393,"score_gpt":0.35537644755280046,"score_spread":0.2954145671545465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3155195921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993148,0.00011569032,0.0000026088212,0.0034847255,0.00017973113,0.0022765934,0.000053139796,0.000057334484,0.00068216276],"genre_scores_gemma":[0.9939078,0.00015306052,0.00019074394,0.0036248341,0.000090033434,0.00017815683,0.00065851933,0.00004612545,0.0011507324],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99778336,0.00041767076,0.0003554387,0.00051119545,0.0005179028,0.00041442426],"domain_scores_gemma":[0.9973433,0.00017990188,0.00010731052,0.0007509675,0.0014902415,0.00012830588],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00018631862,0.00024284457,0.0010487039,0.00015251554,0.0000738412,0.000031279535,0.0003514657,0.0000870403,0.0012724983],"category_scores_gemma":[0.00022000464,0.00015712697,0.000062865554,0.00045446763,0.000082861436,0.00009193867,0.00010554155,0.0003363021,0.000061939274],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028296572,0.0008739643,0.9875934,0.000018235267,0.00036862039,0.00020426801,0.0054554804,0.000013070122,0.0010806794,0.000011146158,0.0006834619,0.00086803176],"study_design_scores_gemma":[0.009593734,0.0010029307,0.97834086,0.000043463708,0.000035738416,0.000029667739,0.0059760404,0.000051318475,0.0024010981,0.0000026202633,0.0023580415,0.00016448497],"about_ca_topic_score_codex":0.0003150926,"about_ca_topic_score_gemma":0.00063367176,"teacher_disagreement_score":0.009252523,"about_ca_system_score_codex":0.00014479808,"about_ca_system_score_gemma":0.00015194135,"threshold_uncertainty_score":0.99964046},"labels":[],"label_agreement":null},{"id":"W3155376846","doi":"10.1109/jsen.2021.3072578","title":"Miniature Fiber-Spectrophotometer for Real-Time Biomarkers Detection","year":2021,"lang":"en","type":"article","venue":"IEEE Sensors Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Natural Sciences and Engineering Research Council of Canada; Canada First Research Excellence Fund","keywords":"Notation; Spectrometer; Analytical Chemistry (journal); Computer science; Physics; Mathematics; Chromatography; Chemistry; Optics","score_opus":0.021185925962318834,"score_gpt":0.30918506312054483,"score_spread":0.287999137158226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3155376846","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913545,0.00021074705,0.000105586274,0.0011276439,0.00066109013,0.000345244,0.000014613764,0.0000483152,0.006132259],"genre_scores_gemma":[0.5846059,0.0030086413,0.019832974,0.00088346493,0.009216556,0.000052553427,0.00005313201,0.00036438633,0.38198242],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99829763,0.00013606928,0.0003107092,0.0002761162,0.0004972107,0.0004822792],"domain_scores_gemma":[0.99859846,0.00020012658,0.000105587074,0.0002914344,0.0004854786,0.000318892],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00046874085,0.00017311364,0.00032566156,0.0002730667,0.00018076073,0.00009029015,0.0000787886,0.0001834928,0.0064465445],"category_scores_gemma":[0.00017153338,0.00014907688,0.00039926515,0.00040294227,0.00005800896,0.00007073387,0.000012819486,0.0005398497,0.00016914145],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014825342,0.00007312428,0.000036628215,0.000033003897,0.00036611554,0.00069138233,0.00012154554,0.000004665477,0.9655756,3.9491954e-7,0.01289084,0.018724209],"study_design_scores_gemma":[0.0035537954,0.00075103116,0.0015077414,0.00008476533,0.00014825295,0.012036018,0.00012492281,0.0005931614,0.8740603,0.00011600237,0.10681372,0.00021028674],"about_ca_topic_score_codex":0.000008359982,"about_ca_topic_score_gemma":0.000005803719,"teacher_disagreement_score":0.40674862,"about_ca_system_score_codex":0.0002815022,"about_ca_system_score_gemma":0.00021036882,"threshold_uncertainty_score":0.9944617},"labels":[],"label_agreement":null},{"id":"W3157151159","doi":"10.15173/sciential.v1i4.2435","title":"Review on Anti-CD19 CAR T Therapy against B-Cell Malignancies and Future Implications","year":2020,"lang":"en","type":"article","venue":"Sciential - McMaster Undergraduate Science Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Chimeric antigen receptor; Medicine; CD19; Immunotherapy; Clinical trial; Cell therapy; Targeted therapy; Oncology; Immune system; Immunology; Cancer; Internal medicine; Cell; Biology","score_opus":0.048298990145938074,"score_gpt":0.32278358628384246,"score_spread":0.2744845961379044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157151159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6144425,0.014825217,0.0003352434,0.35230476,0.0012130444,0.0014254181,0.00002126959,0.000096076816,0.015336422],"genre_scores_gemma":[0.77816147,0.15767057,0.0013218874,0.056351252,0.0025380766,0.000019490466,0.000010027975,0.000068117224,0.0038591004],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964822,0.0000991133,0.0004586862,0.00072345027,0.0014662963,0.00077025633],"domain_scores_gemma":[0.9977887,0.000030447847,0.00021152651,0.0004063903,0.000519458,0.0010434369],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015127999,0.0002678457,0.00041286479,0.00032430046,0.0010434848,0.000572327,0.0006564483,0.000059385427,0.00077077723],"category_scores_gemma":[0.000079681544,0.00019062636,0.00019242735,0.0022062813,0.0011024781,0.00055158604,0.00016515757,0.00067224033,0.00008761862],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008711061,0.0001275606,0.0007205833,0.00015923016,0.000021570986,0.000027693415,0.00041049233,0.000008343541,0.93682903,0.00016755846,0.012221547,0.049219303],"study_design_scores_gemma":[0.007246503,0.003111224,0.014956164,0.001905531,0.00014315962,0.0017647735,0.00090231665,0.0008738068,0.09651623,0.0008909519,0.8706921,0.0009972892],"about_ca_topic_score_codex":0.000002509921,"about_ca_topic_score_gemma":9.201302e-7,"teacher_disagreement_score":0.8584705,"about_ca_system_score_codex":0.00013187433,"about_ca_system_score_gemma":0.00080429926,"threshold_uncertainty_score":0.843947},"labels":[],"label_agreement":null},{"id":"W3157520262","doi":"10.1126/scitranslmed.abe7378","title":"SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma","year":2021,"lang":"en","type":"article","venue":"Science Translational Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":495,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"UCSF Foundation; National Institute of Neurological Disorders and Stroke; National Cancer Institute; National Institutes of Health; University of California, San Francisco; Parker Institute for Cancer Immunotherapy; Howard Hughes Medical Institute","keywords":"Antigen; Chimeric antigen receptor; Cancer research; Priming (agriculture); Biology; Cytotoxic T cell; Immunology; T cell; Glioma; Medicine; Immune system; In vitro","score_opus":0.0760524279981797,"score_gpt":0.33984175030018243,"score_spread":0.26378932230200275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157520262","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9807355,0.0037434003,0.00009026688,0.007524819,0.000099856035,0.00022348216,0.000006948177,0.000013706909,0.0075620296],"genre_scores_gemma":[0.9974717,0.0010767659,0.0010655542,0.00008394668,0.000117617485,0.00000476219,0.000003025518,0.000010226052,0.00016642682],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9975291,0.000059984042,0.00035742336,0.00047124253,0.0012720762,0.0003101995],"domain_scores_gemma":[0.99891347,0.00029600493,0.000056188735,0.00025518163,0.00028829544,0.00019087378],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010564647,0.00013358108,0.0003720269,0.00040677405,0.00007957435,0.000010070924,0.00014707097,0.000045068253,0.0006259081],"category_scores_gemma":[0.00015363777,0.000112497146,0.000053184223,0.0010550081,0.0013546945,0.0001521897,0.000042016472,0.00019354835,0.0000031230986],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001500993,0.00011067279,0.016614616,0.00016038687,0.000014736099,0.000077291064,0.0019194772,0.000053830016,0.96062666,0.0011280336,0.0000026564485,0.019141547],"study_design_scores_gemma":[0.0053678695,0.0013706161,0.52865964,0.0014634421,0.00006480398,0.00054016203,0.0043933596,0.0052232477,0.45068276,0.001303219,0.0006337972,0.0002970857],"about_ca_topic_score_codex":0.000043429067,"about_ca_topic_score_gemma":0.00030416445,"teacher_disagreement_score":0.512045,"about_ca_system_score_codex":0.00007164725,"about_ca_system_score_gemma":0.00034165892,"threshold_uncertainty_score":0.68532544},"labels":[],"label_agreement":null},{"id":"W3157757987","doi":"10.1097/01.cot.0000752008.06679.fd","title":"Overcoming Challenges to Broaden Adoptive T-Cell Therapy in Lung Cancer","year":2021,"lang":"en","type":"article","venue":"Oncology Times","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Context (archaeology); League; Library science; Medicine; Sociology; Biology; Computer science","score_opus":0.04854358197461878,"score_gpt":0.3835921928836314,"score_spread":0.3350486109090126,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157757987","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6712128,0.034187097,0.0000073846386,0.02437581,0.00025030455,0.00065253535,0.000005536137,0.000046010406,0.26926252],"genre_scores_gemma":[0.65026265,0.049390886,0.0021999883,0.0059512155,0.0009365085,0.00046790243,0.000023492326,0.00010805449,0.29065928],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986502,0.00017842991,0.00018473514,0.00037758995,0.00021582647,0.0003932284],"domain_scores_gemma":[0.99913484,0.00026338946,0.000034889672,0.00028433732,0.00013276565,0.00014980583],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00028495965,0.00014015324,0.00041650634,0.00015912086,0.00003672904,0.000009638733,0.000110281566,0.00019078521,0.014383824],"category_scores_gemma":[0.00005267328,0.0001291653,0.000076727825,0.00026667677,0.00005604493,0.000042109863,0.00009198279,0.00037632647,0.00008431531],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018113813,0.0010618173,0.022617046,0.00011082173,0.0002855773,0.0015172114,0.010661065,0.000053834836,0.43458802,0.0002284425,0.027826415,0.49923837],"study_design_scores_gemma":[0.007474144,0.0015751214,0.037148725,0.00017759066,0.000044404725,0.00008991355,0.0026484379,0.00027702338,0.11797941,0.00009493042,0.8321792,0.00031112903],"about_ca_topic_score_codex":0.00019630637,"about_ca_topic_score_gemma":0.00051876664,"teacher_disagreement_score":0.80435276,"about_ca_system_score_codex":0.0005786629,"about_ca_system_score_gemma":0.00074526365,"threshold_uncertainty_score":0.9865172},"labels":[],"label_agreement":null},{"id":"W3158014403","doi":"10.4049/jimmunol.2100141","title":"Cutting Edge: TCR-β Selection Is Required at the CD4+CD8+ Stage of Human T Cell Development","year":2021,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital; University of Toronto","funders":"National Institute of Allergy and Infectious Diseases; Beijing Municipal Natural Science Foundation; Canadian Institute for Telecommunications Research; Canada First Research Excellence Fund; Krembil Foundation; University of Toronto; National Natural Science Foundation of China; National Institutes of Health; Government of Canada; Canadian Cancer Society Research Institute; Sunnybrook Research Institute","keywords":"T-cell receptor; Biology; CD8; RAG2; Negative selection; T cell; Gene rearrangement; Cell biology; Lineage (genetic); Gene; Molecular biology; Genetics; Antigen; Recombination; Genome; Immune system","score_opus":0.04041199063807256,"score_gpt":0.3296500912389186,"score_spread":0.28923810060084604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3158014403","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894168,0.004198722,0.000067283065,0.002497778,0.00019807892,0.00014074224,0.0000010706606,0.0000064982105,0.003473026],"genre_scores_gemma":[0.9083359,0.00088689016,0.00024685496,0.00029811639,0.00016150613,0.0000022639294,0.0000029915288,0.000025687916,0.09003974],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982134,0.00044510054,0.0005902002,0.000097544114,0.00037453038,0.00027921196],"domain_scores_gemma":[0.9983588,0.00026446563,0.0004540926,0.00031831465,0.00056414347,0.00004017142],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016013328,0.00011168697,0.00033472123,0.00011493508,0.00026706012,0.000009912193,0.00025720132,0.000094160765,0.005177417],"category_scores_gemma":[0.00012132018,0.00006435358,0.00012330606,0.00029045597,0.0002085314,0.000045578578,0.00018221678,0.0006523422,0.000029716666],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00067868485,0.00010874775,0.0010175171,0.000038575334,0.00037217484,0.000033310527,0.0037048075,0.0000064883875,0.9836349,0.000016735603,0.0012537304,0.009134329],"study_design_scores_gemma":[0.0014480762,0.0005894778,0.0046953815,0.00006699599,0.00007008148,0.0010658881,0.0019331232,0.000008098697,0.9486438,0.000039533483,0.041383516,0.000056001452],"about_ca_topic_score_codex":0.00003411965,"about_ca_topic_score_gemma":0.000028750934,"teacher_disagreement_score":0.08656672,"about_ca_system_score_codex":0.00031045536,"about_ca_system_score_gemma":0.0005016585,"threshold_uncertainty_score":0.995732},"labels":[],"label_agreement":null},{"id":"W3158771720","doi":"10.1016/j.ebiom.2021.103354","title":"Delivery technologies for T cell gene editing: Applications in cancer immunotherapy","year":2021,"lang":"en","type":"review","venue":"EBioMedicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institutes of Health; Canadian Aeronautics and Space Institute; Institute for Translational Medicine and Therapeutics; Burroughs Wellcome Fund","keywords":"Immunotherapy; Cancer immunotherapy; Cancer; Genome editing; Computational biology; Gene; Medicine; Biology; Cancer research; Genome; Genetics","score_opus":0.07313519721810581,"score_gpt":0.4149902454000573,"score_spread":0.3418550481819515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3158771720","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00002247286,0.9927388,0.00034728585,0.0008623593,0.00033747547,0.004772141,0.00014889638,0.0003126274,0.00045796233],"genre_scores_gemma":[0.0000059566987,0.98306054,0.0010666476,0.00011322209,0.0013957847,0.0057755727,0.0013024048,0.00020941178,0.0070704482],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99726576,0.000063011,0.0008536471,0.0007417177,0.00046365886,0.00061221555],"domain_scores_gemma":[0.99790657,0.00046542322,0.00027987326,0.0009890662,0.0002543628,0.000104722836],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004946228,0.000500443,0.002501238,0.0010331726,0.00006704006,0.00002025423,0.00042127323,0.0006056892,0.0007303134],"category_scores_gemma":[0.00008345264,0.0003779989,0.00052003894,0.0017072187,0.00027987812,0.000030995143,0.000118195225,0.0008324864,0.000014105379],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027391241,0.00025862138,0.000021092812,0.011389974,0.00023814198,0.000042964737,0.000056311197,8.67179e-8,0.0020659417,0.000015403368,0.004757348,0.9811267],"study_design_scores_gemma":[0.0019051473,0.00027804074,0.0000035772996,0.009137051,0.000420291,0.000051263924,0.00027492963,0.0000048518336,0.0008218436,0.000021819505,0.98680943,0.0002717221],"about_ca_topic_score_codex":0.00012075623,"about_ca_topic_score_gemma":0.000018966412,"teacher_disagreement_score":0.9820521,"about_ca_system_score_codex":0.00067782815,"about_ca_system_score_gemma":0.00099595,"threshold_uncertainty_score":0.9998672},"labels":[],"label_agreement":null},{"id":"W3158886261","doi":"10.1007/978-1-0716-1311-5_19","title":"Transduction of Human T Cell Subsets with Lentivirus","year":2021,"lang":"en","type":"book-chapter","venue":"Methods in molecular biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"","keywords":"Transduction (biophysics); Lentivirus; CD8; Chimeric antigen receptor; Cytotoxic T cell; Biology; T cell; Transgene; Gene; Molecular biology; Cell biology; Antigen; Virology; Immunology; Genetics; Human immunodeficiency virus (HIV); Immune system; In vitro; Biochemistry","score_opus":0.05896044766884998,"score_gpt":0.42310302526023563,"score_spread":0.36414257759138563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3158886261","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013046907,0.008952988,0.2952101,0.00022160073,0.00033006855,0.0013993139,0.000034634915,0.000046529953,0.6807579],"genre_scores_gemma":[0.0021895724,0.001225923,0.4795283,0.00021389194,0.00017865389,0.000055308064,0.0004516285,0.00023550789,0.51592124],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979161,0.00058156846,0.000432105,0.0005782486,0.00020342933,0.00028851823],"domain_scores_gemma":[0.99886006,0.00011476752,0.00015510048,0.00064041326,0.0001579112,0.0000717469],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009691749,0.00029901968,0.0009466874,0.0004418363,0.000020832875,0.0000044258472,0.00014669608,0.0006483048,0.0045924746],"category_scores_gemma":[0.000031536994,0.0002638884,0.00025503302,0.0001056852,0.0003733471,0.000008692724,0.000053135525,0.00083180214,0.000005728583],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023719908,0.00007323542,0.00009527559,0.0002187518,0.00019291606,0.0003520003,0.00008664892,0.0000013050839,0.96038043,0.0072406475,0.000011636064,0.031109966],"study_design_scores_gemma":[0.0015270552,0.0010909713,0.000038257174,0.00021660404,0.00017392727,0.00010143311,0.000016928389,0.0000034077398,0.94807225,0.007335122,0.04116508,0.00025894496],"about_ca_topic_score_codex":0.000054693402,"about_ca_topic_score_gemma":0.00003665988,"teacher_disagreement_score":0.18431823,"about_ca_system_score_codex":0.00009551747,"about_ca_system_score_gemma":0.00016337591,"threshold_uncertainty_score":0.99998134},"labels":[],"label_agreement":null},{"id":"W3159827603","doi":"10.3390/ijms22094590","title":"State-of-Art of Cellular Therapy for Acute Leukemia","year":2021,"lang":"en","type":"review","venue":"International Journal of Molecular Sciences","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Toronto General Hospital; University Health Network","funders":"Canadian Institutes of Health Research; Leukemia and Lymphoma Society","keywords":"Myeloid leukemia; Immune system; Medicine; Immunotherapy; Leukemia; Disease; Cancer; Pillar; Cell therapy; Immunology; Cell; Biology; Internal medicine","score_opus":0.06919861862279716,"score_gpt":0.43671047141343383,"score_spread":0.3675118527906367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3159827603","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019166576,0.99263877,0.0036653718,0.00018621437,0.0006533821,0.00037954183,0.000044698838,0.0000023711189,0.0005129816],"genre_scores_gemma":[0.00038960268,0.99566805,0.002775249,0.0000620106,0.00017040916,0.000008160845,0.000023326606,0.00002309834,0.00088008103],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99663883,0.00012980343,0.0010000251,0.00021668858,0.0018320907,0.00018255206],"domain_scores_gemma":[0.9967475,0.00025407592,0.0010943305,0.00018458568,0.0016196183,0.00009991065],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013405526,0.00018749978,0.0012411636,0.0006444162,0.000022836955,0.000046436286,0.0009778821,0.00009022105,0.0003840958],"category_scores_gemma":[0.00016047299,0.000130394,0.0011631993,0.00039191864,0.00031914297,0.00008726162,0.00008085157,0.00029316964,0.000002545225],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013831975,0.00012185237,0.000006291648,0.0005619125,0.002555442,0.0004593884,0.00007151329,0.000019646113,0.031597875,0.00018209948,0.00042927443,0.9638564],"study_design_scores_gemma":[0.001138177,0.0013012162,0.0000025308852,0.0076150163,0.0004563726,0.00081214256,0.000030547424,0.000036096935,0.04697073,0.00027196115,0.9412146,0.00015061414],"about_ca_topic_score_codex":0.000005628329,"about_ca_topic_score_gemma":4.9617995e-7,"teacher_disagreement_score":0.9637058,"about_ca_system_score_codex":0.00019522908,"about_ca_system_score_gemma":0.0033217045,"threshold_uncertainty_score":0.5892561},"labels":[],"label_agreement":null},{"id":"W3161556153","doi":"10.26685/urncst.227","title":"Efficacy of CRISPR-Cas9 CAR T-Cell Therapy vs. Blinatumomab in the Treatment of Acute Lymphoblastic Leukemia","year":2021,"lang":"en","type":"article","venue":"Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Wilfrid Laurier University; McMaster University","funders":"","keywords":"CRISPR; Chimeric antigen receptor; Medicine; Blinatumomab; Immunology; T cell; Cell therapy; Leukemia; Immunotherapy; Genetic enhancement; Cancer research; Immune system; Oncology; Internal medicine; Cell; Biology; Lymphoblastic Leukemia; Gene","score_opus":0.06254274169820717,"score_gpt":0.4265186770455801,"score_spread":0.36397593534737294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3161556153","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96343124,0.007860862,0.0000026860093,0.027783904,0.000102468046,0.00041660198,0.0000022763822,0.000008264187,0.00039170016],"genre_scores_gemma":[0.90888405,0.09039761,0.00012674145,0.00007263397,0.00006306709,0.000008713829,0.0000013289821,0.000008506619,0.00043736733],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99603236,0.0004963492,0.0007819713,0.0005111139,0.0013927034,0.0007855197],"domain_scores_gemma":[0.996472,0.0018232435,0.00014948288,0.00041658143,0.0009081979,0.00023050614],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.005083143,0.00017611434,0.0006190424,0.0011376508,0.00027908324,0.000075335876,0.00052775827,0.00026499573,0.00003909286],"category_scores_gemma":[0.00096758554,0.000097788674,0.00013519288,0.00429457,0.0043933066,0.00013124458,0.00017669577,0.0018837609,0.0000028930313],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004449469,0.0049477564,0.14656712,0.000091806796,0.00030880264,0.003886595,0.0005376119,0.0000032567223,0.25705495,0.0024915084,0.00033909787,0.57932204],"study_design_scores_gemma":[0.08742579,0.049333736,0.37020302,0.0014708425,0.00028277532,0.01180305,0.0070941052,0.0053159264,0.35258847,0.101027325,0.0125383865,0.0009165687],"about_ca_topic_score_codex":0.00009842736,"about_ca_topic_score_gemma":0.00006640074,"teacher_disagreement_score":0.57840544,"about_ca_system_score_codex":0.0004458155,"about_ca_system_score_gemma":0.0021028947,"threshold_uncertainty_score":0.99831617},"labels":[],"label_agreement":null},{"id":"W3162743464","doi":"10.1007/s12325-021-01756-0","title":"Indirect Treatment Comparison of Liso-Cel vs. Salvage Chemotherapy in Diffuse Large B-Cell Lymphoma: TRANSCEND vs. SCHOLAR-1","year":2021,"lang":"en","type":"article","venue":"Advances in Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"National Cancer Institute; Bristol-Myers Squibb Canada; Bristol-Myers Squibb","keywords":"Medicine; Odds ratio; Internal medicine; Hazard ratio; Confidence interval; Salvage therapy; Oncology; Refractory (planetary science); Chemotherapy","score_opus":0.025367968608400935,"score_gpt":0.35202477845148494,"score_spread":0.326656809843084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3162743464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9219547,0.072464384,0.00004174261,0.00065604836,0.0001798375,0.0009034442,0.000032842272,0.000055963043,0.003711048],"genre_scores_gemma":[0.89742064,0.09894424,0.00080092397,0.0006119916,0.00010334009,0.00011466893,0.00006932973,0.000092136586,0.0018427145],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99684834,0.0003405278,0.0007643779,0.00067885855,0.00062484754,0.0007430692],"domain_scores_gemma":[0.99847144,0.0002941561,0.00016500933,0.00078898045,0.00011300304,0.000167387],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00052899856,0.00042168723,0.0012586727,0.00039579315,0.00007254389,0.00003326583,0.00027404967,0.00022270602,0.0011205068],"category_scores_gemma":[0.000038784765,0.00036899562,0.00028799774,0.0010932891,0.0001471227,0.00030709212,0.000025142723,0.00044897545,0.000017175438],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008911409,0.041892458,0.22275153,0.00018779318,0.00017588015,0.00030364908,0.009410027,0.000024786494,0.18831383,0.000048588903,0.000067098306,0.527913],"study_design_scores_gemma":[0.09929012,0.002066628,0.035357874,0.00020540779,0.000019880901,0.00002051585,0.00089144055,0.00025282378,0.6199778,0.0001343236,0.24141988,0.00036333298],"about_ca_topic_score_codex":0.0001047788,"about_ca_topic_score_gemma":0.0007510213,"teacher_disagreement_score":0.5275496,"about_ca_system_score_codex":0.00052848546,"about_ca_system_score_gemma":0.0003060721,"threshold_uncertainty_score":0.9998762},"labels":[],"label_agreement":null},{"id":"W3163013904","doi":"10.2139/ssrn.3824765","title":"A First-in-Human Phase I/IIa Study of Allogeneic Double Negative T Cell for the Treatment of Relapsed AML Post Allo-HSCT","year":2021,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital; University of Toronto","funders":"","keywords":"Medicine; Complete remission; Internal medicine; Hematopoietic stem cell transplantation; Myeloid leukemia; CD8; Gastroenterology; Transplantation; Disease; Minimal residual disease; Chemotherapy; Oncology; Leukemia; Surgery; Immunology; Immune system","score_opus":0.029445402952557816,"score_gpt":0.3511902579164156,"score_spread":0.3217448549638578,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3163013904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99202615,0.004940743,0.0001034607,0.00089380716,0.00006601688,0.0016445267,0.000008776912,0.0000067290093,0.00030979744],"genre_scores_gemma":[0.98644173,0.005722229,0.000036498535,0.000024190687,0.0001450232,0.00008452321,0.00001179101,0.00004092074,0.00749309],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99730545,0.0001465311,0.000547873,0.00026848336,0.00046371348,0.0012679661],"domain_scores_gemma":[0.9984899,0.0003367707,0.00023704943,0.00042349444,0.00041534874,0.000097411474],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010191158,0.00020307585,0.0005378524,0.00016905199,0.00017599617,0.000016839693,0.00020561863,0.00007043307,0.00046887877],"category_scores_gemma":[0.000041918636,0.0001351186,0.00031575386,0.00032861368,0.00007692616,0.000047148762,0.00002597431,0.0006962976,0.0000023653815],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022857009,0.036790915,0.009461943,0.00013573885,0.0046759318,0.00021520266,0.018378962,0.0004626032,0.8828754,0.0022490304,0.000075977296,0.0218213],"study_design_scores_gemma":[0.25485647,0.16226879,0.0055038366,0.0001815886,0.0017783234,0.0008357166,0.069639675,0.000551363,0.49031883,0.006862267,0.006671245,0.00053186965],"about_ca_topic_score_codex":0.0006755223,"about_ca_topic_score_gemma":0.011362514,"teacher_disagreement_score":0.39255655,"about_ca_system_score_codex":0.0012945633,"about_ca_system_score_gemma":0.0023755801,"threshold_uncertainty_score":0.63405496},"labels":[],"label_agreement":null},{"id":"W3163117957","doi":"10.21203/rs.3.rs-505891/v1","title":"Decade-long remissions of leukemia sustained by the persistence of activated CD4+ CAR T-cells","year":2021,"lang":"en","type":"preprint","venue":"Research Square","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; National Institutes of Health","keywords":"Persistence (discontinuity); Leukemia; Cancer research; Medicine; Immunology; Engineering; Geotechnical engineering","score_opus":0.07782501017433613,"score_gpt":0.4025255716442589,"score_spread":0.32470056146992277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3163117957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98295224,0.004242343,0.000042704414,0.0022162974,0.00011243081,0.0028335217,0.00018881865,0.000047018915,0.007364641],"genre_scores_gemma":[0.9651697,0.0030251988,0.0001363828,0.000024156532,0.00015013432,0.00014908618,0.00036357678,0.0001016144,0.030880116],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9918201,0.0015832875,0.00077052007,0.00093902455,0.0037735626,0.0011135123],"domain_scores_gemma":[0.99031585,0.0020411154,0.0002611351,0.0025641033,0.0042735473,0.0005442729],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003599582,0.00038510526,0.0010567369,0.000608052,0.00025891158,0.000082440434,0.0012271072,0.00074520876,0.0037627874],"category_scores_gemma":[0.0029537757,0.00028148276,0.00064936624,0.0017007064,0.0010948483,0.00006441797,0.0021496655,0.004657077,0.000009314906],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00096289976,0.00030538518,0.0014617287,0.004529212,0.00047021377,0.00019245347,0.0025407544,0.00009197581,0.9745268,0.000020811649,0.009902315,0.004995427],"study_design_scores_gemma":[0.0014020073,0.0005412407,0.0019761508,0.0038873092,0.00009521889,0.000033706998,0.022588912,0.00047809372,0.964927,0.000052126285,0.003761461,0.00025672477],"about_ca_topic_score_codex":0.0019609835,"about_ca_topic_score_gemma":0.000056018314,"teacher_disagreement_score":0.023515476,"about_ca_system_score_codex":0.0017219455,"about_ca_system_score_gemma":0.006078472,"threshold_uncertainty_score":0.99996376},"labels":[],"label_agreement":null},{"id":"W3163431319","doi":"10.1016/s1465324921005934","title":"A novel high-permeability fep bag for gmp-compliant, scalable expansion of t cells in a fully closed system","year":2021,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saint-Gobain (Canada)","funders":"","keywords":"Cyclic gmp; Scalability; Computer science; Chemistry; Biochemistry; Operating system","score_opus":0.038566476367271944,"score_gpt":0.3109121678063043,"score_spread":0.27234569143903237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3163431319","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99257034,0.00051474036,0.0032143372,0.00052538235,0.00023439349,0.0017132185,0.00010139711,0.000067544875,0.0010586405],"genre_scores_gemma":[0.9855203,0.00013280832,0.008637608,0.00027777284,0.00019152017,0.0001980161,0.000044211592,0.00008457852,0.0049132043],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99773306,0.0001236915,0.00058050745,0.0005826853,0.00048268115,0.0004973809],"domain_scores_gemma":[0.9981267,0.00030695667,0.00010924991,0.00087746157,0.00041996202,0.00015967301],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007828292,0.00022873677,0.00077845267,0.0001835527,0.000058119476,0.000024995366,0.00017661495,0.00019165274,0.0013556705],"category_scores_gemma":[0.00006510599,0.00020729876,0.00024276812,0.0005757446,0.000117864256,0.000063761436,0.000036571168,0.00023395118,0.000020835434],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021883904,0.0006840566,0.0015371849,0.0009858616,0.00008182266,0.00004225546,0.00043437115,0.000043427084,0.9840203,0.0003085854,0.0003040367,0.009369687],"study_design_scores_gemma":[0.012519867,0.00072171335,0.009692381,0.0005549946,0.000025863981,0.00006711549,0.0005620918,0.0024736903,0.9672657,0.000115646624,0.005777297,0.00022359406],"about_ca_topic_score_codex":0.00033260576,"about_ca_topic_score_gemma":0.00008337288,"teacher_disagreement_score":0.016754577,"about_ca_system_score_codex":0.0003945346,"about_ca_system_score_gemma":0.000526187,"threshold_uncertainty_score":0.9995572},"labels":[],"label_agreement":null},{"id":"W3164508064","doi":"10.1038/s41591-021-01362-1","title":"Author Correction: Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma","year":2021,"lang":"en","type":"erratum","venue":"Nature Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health Research Institute; University of Calgary; McGill University Health Centre; BC Children's Hospital; University of Toronto; SickKids Foundation; University of British Columbia; Hospital for Sick Children","funders":"National Cancer Institute","keywords":"Medulloblastoma; Ependymoma; Cerebrospinal fluid; Medicine; Pathology","score_opus":0.0291656323447384,"score_gpt":0.34143536405897384,"score_spread":0.31226973171423544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3164508064","genre_codex":"review","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1705425,0.43479067,0.0019247918,0.13462111,0.20535086,0.030812731,0.0029125728,0.0002424623,0.018802298],"genre_scores_gemma":[0.04193588,0.0054979734,0.0016904944,0.0017351697,0.011238778,0.0005914822,0.002300473,0.00024836475,0.9347614],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99645054,0.00016621519,0.0007497922,0.00069337845,0.0014945357,0.00044552676],"domain_scores_gemma":[0.99643254,0.00077565864,0.0003423293,0.0008223436,0.0012682853,0.0003588287],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005759006,0.0005349216,0.0018615936,0.00048065634,0.00010333661,0.000009432554,0.00024990167,0.00070720527,0.0016590036],"category_scores_gemma":[0.0004590926,0.0003175645,0.00038484234,0.0006750237,0.0004862086,0.00002483915,0.00007923217,0.0009603182,0.0000035454484],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029449465,0.00031532263,0.000028330785,0.001266135,0.001262298,0.00022899291,0.0010679854,0.0000047174312,0.041177586,0.000050356015,0.92731446,0.024338862],"study_design_scores_gemma":[0.004710576,0.012649773,0.0007014192,0.002169999,0.0018483441,0.0010189599,0.0010526377,0.00037780078,0.038804732,0.000025028306,0.9363939,0.00024682505],"about_ca_topic_score_codex":0.0002592936,"about_ca_topic_score_gemma":0.00030295612,"teacher_disagreement_score":0.91595906,"about_ca_system_score_codex":0.00034414156,"about_ca_system_score_gemma":0.0010922498,"threshold_uncertainty_score":0.99992764},"labels":[],"label_agreement":null},{"id":"W3165141334","doi":"10.1111/bjh.17551","title":"Mass Cytometry: a robust platform for the comprehensive immunomonitoring of CAR‐T‐cell therapies","year":2021,"lang":"en","type":"letter","venue":"British Journal of Haematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Mass cytometry; Immune system; Medicine; Immunology; Cytometry; Flow cytometry; Immunotherapy; Cancer research; Biology","score_opus":0.06295627033005305,"score_gpt":0.3147752223489589,"score_spread":0.2518189520189058,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165141334","genre_codex":"review","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.24579962,0.47273666,0.0055145635,0.26238045,0.0076191165,0.0035089436,0.00039016778,0.000054453267,0.0019960385],"genre_scores_gemma":[0.28426626,0.21016376,0.041613467,0.3477644,0.060604528,0.00066379126,0.00115188,0.0023260254,0.051445875],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968151,0.00021144883,0.0012017699,0.00029400672,0.0008381618,0.00063953036],"domain_scores_gemma":[0.99398667,0.0024199388,0.0010744991,0.00048092334,0.0019471395,0.000090810194],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.000579611,0.00033003956,0.0021553335,0.00044913264,0.0001696954,0.00009858777,0.0006424121,0.0007889879,0.00078698207],"category_scores_gemma":[0.00023845461,0.00028234816,0.00096250686,0.00032942934,0.00047890932,0.000089031055,0.000111482506,0.003396608,0.00000328975],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013355727,0.0002152733,0.0003857822,0.0040923795,0.005812296,0.15375334,0.0007021,0.000029584486,0.05100097,0.000017029395,0.7570225,0.02563319],"study_design_scores_gemma":[0.0048342566,0.0009978365,0.00024942865,0.0023385072,0.000758443,0.34440628,0.002449804,0.000029177214,0.011361309,0.00022154157,0.6320243,0.0003291512],"about_ca_topic_score_codex":0.00015768607,"about_ca_topic_score_gemma":0.000012388877,"teacher_disagreement_score":0.26257288,"about_ca_system_score_codex":0.0001681034,"about_ca_system_score_gemma":0.0006334516,"threshold_uncertainty_score":0.99996287},"labels":[],"label_agreement":null},{"id":"W3165634478","doi":"10.1016/j.isci.2021.102619","title":"Expanded human NK cells armed with CAR uncouple potent anti-tumor activity from off-tumor toxicity against solid tumors","year":2021,"lang":"en","type":"article","venue":"iScience","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Canadian Institutes of Health Research","keywords":"Chimeric antigen receptor; Cytotoxic T cell; Cytotoxicity; Cancer research; Interleukin 12; Immunology; Context (archaeology); Immunotherapy; NK-92; Biology; Immune system; In vitro","score_opus":0.029172594835564905,"score_gpt":0.3102768838393014,"score_spread":0.2811042890037365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165634478","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99527985,0.0001907773,0.0002209625,0.0004312912,0.00020688714,0.00055589667,0.0000746276,0.00010119671,0.0029385278],"genre_scores_gemma":[0.99553746,0.000046724643,0.00041755708,0.0008612889,0.0002036413,0.000032987216,0.000024966672,0.00004050171,0.0028348635],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99639815,0.00013250939,0.00030543207,0.0009661311,0.0013740005,0.0008237497],"domain_scores_gemma":[0.99795234,0.0001308941,0.00015135795,0.00097386114,0.00030221732,0.0004893195],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000512253,0.00030100223,0.00062102504,0.00013228263,0.00037191497,0.00012977196,0.00041304558,0.000056878707,0.0009968748],"category_scores_gemma":[0.00012918863,0.00024154756,0.00014600929,0.000863306,0.0005826869,0.00023880617,0.00023913107,0.0005048821,0.000060801576],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015539024,0.00044991594,0.0055116764,0.000038506983,0.000034204044,0.0018395473,0.0004246373,0.00008476841,0.9858385,0.0000070962765,0.00020335676,0.0054124054],"study_design_scores_gemma":[0.0016648821,0.00040089636,0.040710904,0.000180312,0.000029421244,0.00009838604,0.0006257815,0.0012559922,0.9537977,0.0000433313,0.00089524686,0.00029712313],"about_ca_topic_score_codex":0.0004782192,"about_ca_topic_score_gemma":0.0004894291,"teacher_disagreement_score":0.03519923,"about_ca_system_score_codex":0.00032103687,"about_ca_system_score_gemma":0.0010196131,"threshold_uncertainty_score":0.9999164},"labels":[],"label_agreement":null},{"id":"W3165951116","doi":"10.1002/sstr.202100026","title":"Improving the Delivery of Drugs and Nucleic Acids to T Cells Using Nanotechnology","year":2021,"lang":"en","type":"article","venue":"Small Structures","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Waterloo; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Chimeric antigen receptor; Drug delivery; Immune system; In vivo; Immunotherapy; Chemistry; Biology; Nanotechnology; Immunology; Materials science; Biotechnology","score_opus":0.01967499877309157,"score_gpt":0.27178763999702976,"score_spread":0.25211264122393817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3165951116","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979465,0.00084967667,0.00010386689,0.00048540346,0.0001186833,0.00023013017,0.000006033845,0.000025228554,0.00023449368],"genre_scores_gemma":[0.99401945,0.00006495721,0.0049306806,0.00041136675,0.00008964832,0.0000025802365,0.0000016952118,0.000022582184,0.00045704126],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99913186,0.000047258978,0.00015721243,0.00023757704,0.00018488568,0.00024119344],"domain_scores_gemma":[0.99929124,0.000078963465,0.00004238994,0.0003869978,0.00012769336,0.00007269524],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00012764712,0.0001074267,0.00021870011,0.0000968095,0.000080188416,0.000021245549,0.00012632592,0.00011949878,0.0004586284],"category_scores_gemma":[0.00007379947,0.00007585362,0.00005677558,0.00024598025,0.00015952323,0.000017532806,0.00023872072,0.00024877765,0.0000016864874],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009134631,0.00000707187,0.00063847366,0.00006938959,0.00004312567,0.000027406999,0.00056948466,0.000019980034,0.9341758,0.00019586917,0.000024959958,0.06413709],"study_design_scores_gemma":[0.00048349204,0.000109111956,0.0028022153,0.000028019536,0.000043511256,0.00011597675,0.00090556085,0.00026992173,0.99274826,0.0004968035,0.0019166595,0.000080479025],"about_ca_topic_score_codex":0.0003159017,"about_ca_topic_score_gemma":0.00006121865,"teacher_disagreement_score":0.06405662,"about_ca_system_score_codex":0.000044445238,"about_ca_system_score_gemma":0.00013769459,"threshold_uncertainty_score":0.5021659},"labels":[],"label_agreement":null},{"id":"W3166095776","doi":"10.71781/32239","title":"Exploitation du potentiel thérapeutique des cellules Natural Killer pour traiter les cancers","year":2020,"lang":"fr","type":"dissertation","venue":"Papyrus : Institutional Repository (Université de Montréal)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Fonds de Recherche du Québec - Santé; Mitacs","keywords":"Chemistry; Medicine","score_opus":0.013231079135965516,"score_gpt":0.2167114447801617,"score_spread":0.20348036564419617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166095776","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8928501,0.064357124,0.0006985959,0.001753623,0.0043781046,0.0010926625,0.000071480434,0.00019778748,0.034600534],"genre_scores_gemma":[0.7340855,0.0044402382,0.0010095896,0.00023416248,0.0010373531,0.00006304017,0.0010851683,0.00009774192,0.25794724],"study_design_codex":"bench_or_experimental","study_design_gemma":"qualitative","domain_scores_codex":[0.9958046,0.00036902196,0.00062519946,0.0010073804,0.0012934369,0.0009003415],"domain_scores_gemma":[0.99736303,0.0002880305,0.00040289565,0.0004029105,0.00082495576,0.0007181826],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00026189565,0.00077068177,0.00074283767,0.0005257102,0.0060540433,0.00011696317,0.0005165594,0.0007451245,0.0014227439],"category_scores_gemma":[0.00014820014,0.00085700443,0.0007384245,0.0006004038,0.00074564794,0.0005570427,0.00014827061,0.001309835,0.00018747662],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056918687,0.00039869384,0.015937036,0.0012410412,0.002005993,0.0067468653,0.13637263,0.0024614925,0.7557171,0.0069506015,0.0026692897,0.06380739],"study_design_scores_gemma":[0.008309719,0.0008373849,0.16194443,0.0027240494,0.0022482886,0.002545999,0.30669132,0.02453804,0.19429986,0.00047965455,0.293145,0.0022362594],"about_ca_topic_score_codex":0.049117673,"about_ca_topic_score_gemma":0.011137401,"teacher_disagreement_score":0.5614172,"about_ca_system_score_codex":0.016206544,"about_ca_system_score_gemma":0.004753426,"threshold_uncertainty_score":0.9994901},"labels":[],"label_agreement":null},{"id":"W3166810068","doi":"10.1200/jco.2021.39.15_suppl.tps2661","title":"Master protocol to assess safety and recommended phase 2 dose of next generation NY-ESO-1–specific TCR T-cells in HLA-A*02 patients with synovial sarcoma or non-small cell lung cancer (Substudies 1 and 2).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Hôpital Maisonneuve-Rosemont","funders":"GlaxoSmithKline","keywords":"Medicine; Internal medicine; Oncology; T-cell receptor; T cell; CD8; Tolerability; Response Evaluation Criteria in Solid Tumors; Synovial sarcoma; Immunology; Cancer; Cancer research; Progressive disease; Sarcoma; Immune system; Pathology; Chemotherapy; Adverse effect","score_opus":0.2679764927034616,"score_gpt":0.49486231230405103,"score_spread":0.22688581960058946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3166810068","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9863551,0.00016917856,0.00012075141,0.0022619218,0.00034242182,0.010324537,0.00001231602,0.0000025882734,0.00041116265],"genre_scores_gemma":[0.9734116,0.0031173108,0.0137989335,0.002595508,0.0019802218,0.0025506823,0.000013491274,0.000083364306,0.0024488636],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963804,0.0006483978,0.0019581527,0.00032467933,0.00040804746,0.0002803405],"domain_scores_gemma":[0.9963245,0.0013761466,0.0008367428,0.00020109002,0.0009119236,0.00034963022],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019937023,0.00018266414,0.0014220863,0.00016968706,0.00004623587,0.00002782395,0.000100608544,0.00024457573,0.0007709032],"category_scores_gemma":[0.00043311002,0.00012021259,0.00011344285,0.0002563525,0.00013665491,0.0001278851,0.0001264969,0.0008229192,0.0000010897561],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11782938,0.011092719,0.37615684,0.0005093768,0.0005777585,0.0011929417,0.0011033257,0.000026439673,0.11114067,0.0000038690264,0.0053013437,0.37506533],"study_design_scores_gemma":[0.2419994,0.08545054,0.47187018,0.0012220582,0.00055277435,0.00019886733,0.0010826862,0.0011745208,0.031060662,0.000019894203,0.16477829,0.0005901263],"about_ca_topic_score_codex":0.000019683708,"about_ca_topic_score_gemma":0.0005734726,"teacher_disagreement_score":0.3744752,"about_ca_system_score_codex":0.00023499818,"about_ca_system_score_gemma":0.0013229895,"threshold_uncertainty_score":0.844085},"labels":[],"label_agreement":null},{"id":"W3167481271","doi":"10.1200/jco.2021.39.15_suppl.e19537","title":"Safety and efficacy of tisagenlecleucel (tisa-cel) plus pembrolizumab (pembro) in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL): Updated analysis of the phase 1b PORTIA study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Internal medicine; Refractory (planetary science); Neutropenia; Phases of clinical research; Surgery; Gastroenterology; Clinical trial; Oncology; Toxicity","score_opus":0.04626106429265371,"score_gpt":0.4152705730423476,"score_spread":0.3690095087496939,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167481271","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99695647,0.00041711357,0.000040439325,0.00041119175,0.00027746736,0.0005667679,0.00003711435,0.0000054125753,0.0012880339],"genre_scores_gemma":[0.99759156,0.0007298065,0.00018854164,0.00039229615,0.000100711106,0.0000027739225,0.000027400098,0.000035946825,0.00093096605],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99228907,0.0018982979,0.0038599453,0.000415156,0.0011257664,0.00041175776],"domain_scores_gemma":[0.99242073,0.0024895233,0.0028752158,0.00072566274,0.001114473,0.00037439147],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033774092,0.0002516124,0.0030385118,0.0004257621,0.00005661354,0.000009656336,0.0003619343,0.0003998045,0.0007449521],"category_scores_gemma":[0.002450545,0.00015966636,0.0007535116,0.001496139,0.00040554046,0.00011871236,0.00023988339,0.0011694562,0.0000023720274],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11346769,0.26078573,0.5494288,0.0000763956,0.005709156,0.001510209,0.0014629823,0.00004097966,0.0024362407,0.000012465897,0.00045062014,0.06461869],"study_design_scores_gemma":[0.32351696,0.017968927,0.6483046,0.000075492506,0.0027843316,0.000049767354,0.0004895469,0.00026469026,0.00043234433,0.0000054455695,0.0059956834,0.00011224765],"about_ca_topic_score_codex":0.00008713536,"about_ca_topic_score_gemma":0.00048193816,"teacher_disagreement_score":0.24281679,"about_ca_system_score_codex":0.00040727973,"about_ca_system_score_gemma":0.002862236,"threshold_uncertainty_score":0.8156703},"labels":[],"label_agreement":null},{"id":"W3167507808","doi":"10.1200/jco.2021.39.15_suppl.9546","title":"KEYNOTE-629: Health-related quality of life (HRQoL) with pembrolizumab (pembro) in patients (pts) with locally advanced (LA) or recurrent or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Discontinuation; Quality of life (healthcare); Cohort; Interim; Interim analysis; Pembrolizumab; Population; Clinical endpoint; Cancer; Clinical trial; Internal medicine; Gerontology; Oncology","score_opus":0.12768831402553285,"score_gpt":0.4580371891146894,"score_spread":0.33034887508915656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3167507808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99334395,0.0010687138,0.00014762973,0.0026800528,0.00040739123,0.00092712435,0.000017611927,0.000013690561,0.0013938269],"genre_scores_gemma":[0.99135035,0.0006318037,0.0050359056,0.0011883167,0.00013077336,0.000013333975,0.000016763173,0.00007024504,0.0015625026],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9870793,0.0042608627,0.005848747,0.00055365474,0.0015592865,0.00069813686],"domain_scores_gemma":[0.9830357,0.009161285,0.0040689874,0.000596441,0.0019894382,0.0011481912],"candidate_categories":["metaresearch","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004827642,0.00037113085,0.004183963,0.00031560854,0.00005486601,0.000015157672,0.00034257572,0.0004055651,0.0015548855],"category_scores_gemma":[0.008989393,0.0002174154,0.00044366546,0.0008759152,0.000526505,0.00012575954,0.000112656504,0.0027174274,0.000010273794],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6098757,0.01808645,0.13624163,0.0011760411,0.000599265,0.010808135,0.00073773635,0.0004613995,0.00039002163,0.00002137811,0.00055280695,0.22104947],"study_design_scores_gemma":[0.23846425,0.3145222,0.42772675,0.001034902,0.00063027046,0.0045239963,0.0015219958,0.000481761,0.0005719725,0.00008908595,0.009823082,0.0006097383],"about_ca_topic_score_codex":0.00020451905,"about_ca_topic_score_gemma":0.0020385887,"teacher_disagreement_score":0.3714114,"about_ca_system_score_codex":0.00077305443,"about_ca_system_score_gemma":0.020216106,"threshold_uncertainty_score":0.99958336},"labels":[],"label_agreement":null},{"id":"W3168253197","doi":"10.1016/j.jval.2021.04.282","title":"PCN191 Cost Associated with Implementation of CAR T-Cell Therapy for the Management of Hematologic Cancers in Canada.","year":2021,"lang":"en","type":"article","venue":"Value in Health","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Gilead Sciences (Canada)","funders":"","keywords":"Health care; Leukapheresis; Audit; Chimeric antigen receptor; Medicine; Cost driver; Unit (ring theory); Business; Operations management; Medical emergency; Immunotherapy; Cancer; Internal medicine; Stem cell; CD34","score_opus":0.07457973308357888,"score_gpt":0.3793339968645089,"score_spread":0.30475426378093007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168253197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99313927,0.0019592622,0.000029668498,0.0024625608,0.000050049945,0.00212582,0.0000467569,0.0000030990198,0.00018353738],"genre_scores_gemma":[0.996201,0.002891567,0.00018292185,0.00035160844,0.00000674256,0.00015524689,0.00003655,0.000012886881,0.00016149698],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987274,0.00014809526,0.00036926818,0.0001486676,0.0003346239,0.0002719342],"domain_scores_gemma":[0.99920547,0.00028842883,0.00015937557,0.00019576433,0.00010526659,0.00004571922],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072722527,0.00007246656,0.00029289623,0.00006143398,0.000024418541,0.0000021269657,0.00007131764,0.000021711723,0.00015286701],"category_scores_gemma":[0.000011363711,0.00005137661,0.000027011227,0.00046787737,0.000025318883,0.000011298453,0.0000132240775,0.0001065921,7.634584e-8],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00223414,0.00063575036,0.8781283,0.0046828743,0.00079928513,0.00017862888,0.0055346345,0.01691106,0.008830221,0.0010394922,0.0020290017,0.07899659],"study_design_scores_gemma":[0.039367512,0.002600132,0.7605934,0.0021741716,0.00008285162,0.0000198991,0.067795984,0.009221297,0.11103435,0.00022409047,0.006534184,0.00035211214],"about_ca_topic_score_codex":0.8950753,"about_ca_topic_score_gemma":0.8531265,"teacher_disagreement_score":0.117534906,"about_ca_system_score_codex":0.0020364034,"about_ca_system_score_gemma":0.00462211,"threshold_uncertainty_score":0.81994253},"labels":[],"label_agreement":null},{"id":"W3168407158","doi":"10.1200/jco.2021.39.15_suppl.8006","title":"Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Institute of Cancer Research; McGill University Health Centre; University of Calgary","funders":"Pfizer","keywords":"Medicine; Cytokine release syndrome; Common Terminology Criteria for Adverse Events; Adverse effect; Neutropenia; Internal medicine; Multiple myeloma; Gastroenterology; Anemia; Toxicity; Chimeric antigen receptor; Oncology; Immunology; Cancer; Immunotherapy","score_opus":0.06914840343259031,"score_gpt":0.42732675216882743,"score_spread":0.3581783487362371,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168407158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99595976,0.0005506964,0.000063415915,0.0013363296,0.0004335226,0.00049484253,0.000010064867,0.0000070243595,0.0011443195],"genre_scores_gemma":[0.9921785,0.003297985,0.0030276948,0.00029479977,0.00034665715,0.0000017309221,0.00003644734,0.000034192148,0.00078198],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952179,0.000872274,0.002521382,0.00033208658,0.0007424827,0.00031382623],"domain_scores_gemma":[0.99283415,0.003978402,0.0014340864,0.00036414192,0.0010502365,0.00033899496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025020423,0.00018606948,0.0016547474,0.00028391686,0.000044445227,0.00001411496,0.0001657843,0.0004751503,0.00089051516],"category_scores_gemma":[0.0040487666,0.00012432084,0.00022535388,0.00046721596,0.00031517533,0.00017536523,0.00008640144,0.0015061096,0.000008018424],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19196032,0.008018151,0.60857147,0.00014777009,0.00038347606,0.0017822467,0.0003223863,0.00001379111,0.02283327,0.000009073268,0.00076076214,0.16519727],"study_design_scores_gemma":[0.05807777,0.01620515,0.88843024,0.0003134708,0.000102511985,0.00012838154,0.00018164929,0.00007814161,0.001418151,0.000011332436,0.034931645,0.00012155338],"about_ca_topic_score_codex":0.00001931834,"about_ca_topic_score_gemma":0.00013772267,"teacher_disagreement_score":0.27985877,"about_ca_system_score_codex":0.00019881416,"about_ca_system_score_gemma":0.0020541963,"threshold_uncertainty_score":0.9750517},"labels":[],"label_agreement":null},{"id":"W3168412060","doi":"10.1200/jco.2021.39.15_suppl.11504","title":"SPEARHEAD-1: A phase 2 trial of afamitresgene autoleucel (Formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Synovial sarcoma; Tolerability; Internal medicine; Sarcoma; Progressive disease; Phases of clinical research; Leukapheresis; Surgery; Clinical endpoint; Response Evaluation Criteria in Solid Tumors; Chemotherapy; Oncology; Gastroenterology; Clinical trial; Pathology; Adverse effect; Stem cell; CD34","score_opus":0.10599834406556526,"score_gpt":0.48494079997412204,"score_spread":0.3789424559085568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168412060","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99251366,0.00033393883,0.000062424915,0.0013036398,0.0012156208,0.0007827143,0.000016464248,0.000009206924,0.003762339],"genre_scores_gemma":[0.98947173,0.0005464066,0.0056405184,0.000640048,0.0011845548,0.000009407634,0.000018050836,0.00005457798,0.00243473],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9929148,0.0010368148,0.0037967765,0.0003972157,0.0012875348,0.00056687556],"domain_scores_gemma":[0.9925403,0.0030614063,0.0019756295,0.00049780036,0.0012882944,0.0006365989],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003131225,0.00027156415,0.0027317991,0.00035469842,0.00003908236,0.000017164934,0.00032901915,0.00050829054,0.0020168666],"category_scores_gemma":[0.0028778187,0.00018337919,0.0006438753,0.00064593274,0.00039369566,0.00020992696,0.00011344022,0.001927728,0.000016505988],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.61791015,0.03680768,0.01983756,0.00009462387,0.00039080973,0.003066973,0.00016272119,0.000011173859,0.0062748706,0.000009360879,0.00046708575,0.314967],"study_design_scores_gemma":[0.614065,0.27536997,0.06258947,0.00028254863,0.00035441644,0.00024133008,0.00031116666,0.00008295749,0.0029347448,0.00006959605,0.04345336,0.00024544165],"about_ca_topic_score_codex":0.000027196125,"about_ca_topic_score_gemma":0.00019605039,"teacher_disagreement_score":0.31472158,"about_ca_system_score_codex":0.00038842647,"about_ca_system_score_gemma":0.0073380694,"threshold_uncertainty_score":0.9988954},"labels":[],"label_agreement":null},{"id":"W3168509201","doi":"10.1101/2020.10.30.360925","title":"Antigenic Sensitivity of Membrane-Proximal Targeting Chimeric Antigen Receptors can be Fine-Tuned through Hinge Truncation","year":2020,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; National Research Council Canada; University of Ottawa","funders":"","keywords":"Epitope; Antigen; Chimeric antigen receptor; Receptor; In vivo; Truncation (statistics); T-cell receptor; Hinge; Cancer research; Chemistry; Biology; Cell biology; Molecular biology; Immunotherapy; Immunology; T cell; Immune system; Biochemistry; Computer science; Genetics; Physics","score_opus":0.03233509677387081,"score_gpt":0.2715262690409532,"score_spread":0.23919117226708242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168509201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99123675,0.0010355462,0.000689968,0.0029090096,0.0011163241,0.0021680628,0.00030306508,0.0004944943,0.000046766112],"genre_scores_gemma":[0.98945385,0.0011925683,0.007476922,0.00035952363,0.0010746445,0.00010174501,0.000010599782,0.0003005281,0.000029637484],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99437696,0.00067265745,0.0011123822,0.0016283593,0.0012572171,0.0009524097],"domain_scores_gemma":[0.9957615,0.00023951825,0.000874626,0.0016230134,0.0010187835,0.00048256107],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018560273,0.0008591137,0.0016554615,0.00037640563,0.00021618072,0.00010698692,0.00046236734,0.00074680866,0.0006611714],"category_scores_gemma":[0.0012937314,0.00092680677,0.00051722303,0.0013901987,0.00033702346,0.00018396422,0.00062872237,0.0017923918,0.000033614997],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042018882,0.00024374525,0.013121234,0.0014902338,0.0006112605,0.00013891941,0.00019044688,0.00002601955,0.9832346,0.00007768697,0.00042713693,0.000018523528],"study_design_scores_gemma":[0.0012653004,0.00020623683,0.04696128,0.00054049207,0.00025381002,1.4447473e-7,0.000020625468,0.000987083,0.94418836,0.0000017290154,0.004803096,0.00077183894],"about_ca_topic_score_codex":0.0010422154,"about_ca_topic_score_gemma":0.000020253787,"teacher_disagreement_score":0.039046243,"about_ca_system_score_codex":0.0005511388,"about_ca_system_score_gemma":0.001881074,"threshold_uncertainty_score":0.99931824},"labels":[],"label_agreement":null},{"id":"W3168836567","doi":"10.1200/jco.2021.39.15_suppl.7519","title":"Glofitamab step-up dosing (SUD): Complete response rates in updated efficacy data in heavily pretreated relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) patients (pts).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Dosing; Refractory (planetary science); Internal medicine; Cytokine release syndrome; Gastroenterology; Rituximab; Neutropenia; Lymphoma; Surgery; Chemotherapy; Cancer; Immunotherapy","score_opus":0.15882958560774624,"score_gpt":0.4813478106215453,"score_spread":0.32251822501379906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168836567","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925511,0.0005506239,0.000035414632,0.004133848,0.0014229161,0.0005771122,0.000050341907,0.000017155697,0.00066149735],"genre_scores_gemma":[0.9940196,0.0008319324,0.0018168606,0.0015795348,0.00044864893,0.000004793106,0.000239376,0.000069558206,0.0009896471],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98774475,0.005270019,0.004511002,0.00071957515,0.0010325257,0.0007221325],"domain_scores_gemma":[0.98457235,0.010893138,0.0015683859,0.0012309629,0.0010853822,0.00064978725],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.011799244,0.00033115046,0.0026062988,0.0006568359,0.000062493804,0.000045062796,0.0007734988,0.0008240389,0.0011440347],"category_scores_gemma":[0.019803915,0.00027900675,0.00037937026,0.0011890327,0.00036989833,0.0003629922,0.00053416996,0.0023111708,0.00006792506],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17325576,0.012332214,0.41637635,0.00005694306,0.0004949633,0.009743982,0.0003387296,0.00001509489,0.0181539,0.0000041891144,0.008017745,0.36121014],"study_design_scores_gemma":[0.073036656,0.011250604,0.8167631,0.0005477823,0.00013444795,0.0003173946,0.00021616161,0.0012764464,0.00043869024,0.000021601472,0.09577714,0.00021998338],"about_ca_topic_score_codex":0.00017243187,"about_ca_topic_score_gemma":0.00042568834,"teacher_disagreement_score":0.40038675,"about_ca_system_score_codex":0.0012317463,"about_ca_system_score_gemma":0.005951606,"threshold_uncertainty_score":0.9999905},"labels":[],"label_agreement":null},{"id":"W3168841030","doi":"10.1200/jco.2021.39.15_suppl.e19568","title":"Association of PET/CT response assessment prior to CAR T-cell infusion with outcomes after CAR T-cell therapy in aggressive B-cell lymphomas.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Internal medicine; Refractory (planetary science); Chimeric antigen receptor; Gastroenterology; CAR T-cell therapy; Nuclear medicine; Surgery; Immunotherapy; Cancer","score_opus":0.05233808995743192,"score_gpt":0.45334641170646206,"score_spread":0.4010083217490301,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168841030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98608714,0.0006176955,0.00001791152,0.009328197,0.00057779555,0.0005557534,0.000008350229,0.0000068981276,0.0028002749],"genre_scores_gemma":[0.978908,0.0022462874,0.0037366392,0.0026004342,0.00033127947,0.000021817788,0.0000032856622,0.000044850603,0.012107422],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9924818,0.002879874,0.002501029,0.0003639434,0.0013233471,0.00044995284],"domain_scores_gemma":[0.98779,0.007077835,0.0026841222,0.00043802965,0.0015194754,0.0004905602],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.008313269,0.00024841525,0.0020993005,0.00037743023,0.000035275527,0.000019597164,0.00024691958,0.00019111727,0.0010964752],"category_scores_gemma":[0.0032832576,0.00017243774,0.0006087376,0.00047624685,0.000104947314,0.000101911115,0.00012678985,0.0013859072,0.000017714334],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.056863762,0.007015934,0.7877309,0.000075133205,0.00036310597,0.021487933,0.0005223255,0.000054754546,0.10264386,0.0000012440697,0.0014422415,0.021798808],"study_design_scores_gemma":[0.046236716,0.025833497,0.84853035,0.00028426456,0.0002442541,0.0006054004,0.00077263115,0.000036792633,0.027066465,0.000027379194,0.05012655,0.00023569628],"about_ca_topic_score_codex":0.00004916132,"about_ca_topic_score_gemma":0.00018011905,"teacher_disagreement_score":0.0755774,"about_ca_system_score_codex":0.00143993,"about_ca_system_score_gemma":0.0072376453,"threshold_uncertainty_score":0.99981666},"labels":[],"label_agreement":null},{"id":"W3170764582","doi":"10.1200/jco.2021.39.15_suppl.tps9138","title":"An open-label, multicenter phase I/IIa study evaluating the safety and clinical activity of clonal neoantigen reactive T cells in patients with advanced non-small cell lung cancer (CHIRON).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lung cancer; Cancer; Oncology; Chemotherapy; Immunotherapy; Immunology; Cancer research; Internal medicine","score_opus":0.15880713877515426,"score_gpt":0.5660918804300211,"score_spread":0.40728474165486683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170764582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964091,0.00013558811,0.000055619217,0.0007087721,0.00054823625,0.0018011603,0.000019053741,0.0000025091242,0.00031995762],"genre_scores_gemma":[0.9953358,0.00073651574,0.002893787,0.0004683925,0.00033573413,0.000013171386,0.000004087921,0.000032605,0.00017988475],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9923408,0.0034730576,0.002579555,0.00048148062,0.0007728493,0.0003522645],"domain_scores_gemma":[0.9903668,0.005296964,0.0021429143,0.0004628015,0.0013138884,0.00041661228],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010163131,0.00020971207,0.0019487765,0.0000871387,0.00007826161,0.00002420476,0.0004141596,0.00026544483,0.00037363192],"category_scores_gemma":[0.0015929625,0.00012891488,0.00015552493,0.00024485152,0.0003253338,0.00025603638,0.0003129316,0.0022351078,0.0000012231275],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.117592625,0.03664686,0.57281137,0.000028895656,0.00051392365,0.00019887893,0.0004699801,0.00003919926,0.016722078,2.9678762e-7,0.00002232322,0.25495356],"study_design_scores_gemma":[0.114943705,0.10483318,0.77476037,0.00016286662,0.0005531841,0.00000940798,0.0005296314,0.0025462785,0.0011598244,0.000002839993,0.00038297035,0.00011575989],"about_ca_topic_score_codex":0.00012116742,"about_ca_topic_score_gemma":0.00060602586,"teacher_disagreement_score":0.25483778,"about_ca_system_score_codex":0.00025160634,"about_ca_system_score_gemma":0.0033975404,"threshold_uncertainty_score":0.97105557},"labels":[],"label_agreement":null},{"id":"W3170891449","doi":"10.1093/neuonc/noab090.121","title":"IMMU-14. COMPUTATIONAL DECONVOLUTION OF TUMOR-INFILTRATING IMMUNE COMPONENTS IN PEDIATRIC NERVOUS SYSTEM TUMORS","year":2021,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Hospital for Sick Children; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Immunotherapy; Immune system; Tumor microenvironment; Cancer research; CD8; Medicine; T cell; Immune checkpoint; Immunology; Biology","score_opus":0.033518168114641644,"score_gpt":0.3120968245030121,"score_spread":0.2785786563883705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3170891449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99242234,0.00049527944,0.00009839322,0.0006327076,0.0005257279,0.00047463097,0.000009493418,0.000056611836,0.005284828],"genre_scores_gemma":[0.9983754,0.00005019474,0.0008400206,0.00022854333,0.00024382245,0.000034151366,0.00009270165,0.000035461286,0.000099687975],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9973104,0.00057012367,0.0008559056,0.00038817836,0.00046890092,0.00040650458],"domain_scores_gemma":[0.9980715,0.0008692611,0.00028348184,0.00029271777,0.0003515807,0.0001314514],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005396122,0.00017073037,0.0006959324,0.0003478425,0.00006436575,0.000012162881,0.00014451791,0.00012901111,0.00034443714],"category_scores_gemma":[0.00033671112,0.0001832867,0.0001424473,0.000698209,0.000099594385,0.00006606847,0.00012409796,0.00057287375,0.000046749243],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053760345,0.0005027125,0.07294712,0.00048417208,0.000036141133,0.0024978686,0.00040210484,0.0018832503,0.9158647,0.0003156852,0.00015831183,0.0043703425],"study_design_scores_gemma":[0.015910653,0.002996121,0.8390509,0.00031667112,0.00018611732,0.009882054,0.0024525255,0.046837095,0.07794656,0.000167985,0.0037467587,0.00050659885],"about_ca_topic_score_codex":0.00014499668,"about_ca_topic_score_gemma":0.000031371,"teacher_disagreement_score":0.8379181,"about_ca_system_score_codex":0.00058857375,"about_ca_system_score_gemma":0.0010084935,"threshold_uncertainty_score":0.74742144},"labels":[],"label_agreement":null},{"id":"W3171042113","doi":"10.1200/jco.2021.39.15_suppl.tps11582","title":"IGNYTE-ESO: A master protocol to assess safety and activity of letetresgene autoleucel (lete-cel; GSK3377794) in HLA-A*02+ patients with synovial sarcoma or myxoid/round cell liposarcoma (Substudies 1 and 2).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Mount Sinai Hospital; Hôpital Maisonneuve-Rosemont","funders":"GlaxoSmithKline","keywords":"Oncology; Medicine; Internal medicine; Anthracycline; Cancer research; Cancer; Breast cancer","score_opus":0.1751760736806835,"score_gpt":0.4692052168953547,"score_spread":0.2940291432146712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171042113","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98691463,0.00011265414,0.00011952155,0.002494056,0.00020593592,0.008908172,0.000014167645,0.000006788444,0.0012240653],"genre_scores_gemma":[0.99223036,0.00020276842,0.004157588,0.00073910336,0.00040014306,0.00059298275,0.0000023108585,0.00004910019,0.0016256194],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948421,0.00119505,0.0021559147,0.00047126078,0.0008648308,0.00047084977],"domain_scores_gemma":[0.9930915,0.0038952925,0.0011210588,0.00035004306,0.00096543034,0.0005766697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002895059,0.00028813444,0.0023790328,0.0002838113,0.00006552295,0.000030307641,0.00018641501,0.00037836313,0.00040652556],"category_scores_gemma":[0.0017919699,0.00019021686,0.00021543255,0.00043363933,0.00045957827,0.00017940109,0.00034703387,0.0013916255,0.0000031685843],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11536046,0.0137212565,0.6311778,0.00057459454,0.00067523815,0.0026434397,0.000489151,0.000009602175,0.023132699,0.000006974801,0.000544481,0.21166433],"study_design_scores_gemma":[0.041698463,0.06106491,0.8533941,0.00039008007,0.00020826414,0.0002923135,0.00027374903,0.00007613975,0.005166346,0.0000291403,0.037157007,0.00024950848],"about_ca_topic_score_codex":0.000038334303,"about_ca_topic_score_gemma":0.00062749564,"teacher_disagreement_score":0.22221631,"about_ca_system_score_codex":0.00027698049,"about_ca_system_score_gemma":0.0021289731,"threshold_uncertainty_score":0.77568185},"labels":[],"label_agreement":null},{"id":"W3171232767","doi":"10.1200/jco.2021.39.15_suppl.11557","title":"Early results of intratumoral INT230-6 alone or in combination with ipilimumab in subjects with advanced sarcomas.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Ipilimumab; Sarcoma; Internal medicine; Combination therapy; Cancer; Dosing; Oncology; Chemotherapy; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Pharmacology; Immunotherapy; Pathology","score_opus":0.08994067627134944,"score_gpt":0.4523935307635861,"score_spread":0.3624528544922367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171232767","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909306,0.00021326945,0.00002221768,0.0060002315,0.00018270775,0.0002898454,0.0000018840822,0.000004352652,0.002354889],"genre_scores_gemma":[0.9935841,0.00048588833,0.0046338993,0.00038860543,0.00013538406,0.00000449677,0.0000052263294,0.000020606829,0.00074182457],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9956031,0.00085975643,0.0023576638,0.0002404222,0.00064907066,0.000290002],"domain_scores_gemma":[0.9943604,0.003124504,0.0011309426,0.00025341602,0.0009008561,0.00022988528],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003902973,0.00013177522,0.0016235057,0.00032016623,0.000011861325,0.0000076799515,0.00014880931,0.00025671424,0.00014912785],"category_scores_gemma":[0.0047553596,0.00008244227,0.00012366094,0.00083749957,0.00030336634,0.00016007591,0.000045888257,0.0016982673,0.0000023423547],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4468972,0.009703353,0.24699646,0.000121923236,0.00030318135,0.022275861,0.00093195855,0.00010218833,0.015602271,0.00010288669,0.0003768798,0.2565858],"study_design_scores_gemma":[0.109006435,0.07509562,0.80557406,0.0007122168,0.00006484353,0.0011324267,0.0005408214,0.00007116805,0.0046543134,0.00020736684,0.0028274064,0.00011330368],"about_ca_topic_score_codex":0.00008602688,"about_ca_topic_score_gemma":0.003383208,"teacher_disagreement_score":0.5585776,"about_ca_system_score_codex":0.0002956679,"about_ca_system_score_gemma":0.00418545,"threshold_uncertainty_score":0.7424809},"labels":[],"label_agreement":null},{"id":"W3171665778","doi":"10.1136/jitc-2020-002140","title":"Immunotherapy using IgE or CAR T cells for cancers expressing the tumor antigen SLC3A2","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Lunenfeld-Tanenbaum Research Institute; Mount Sinai Hospital","funders":"Medical Research Council; Breast Cancer Now; Academy of Medical Sciences; Cancer Research UK","keywords":"Immunotherapy; Medicine; Antigen; Immunoglobulin E; Cancer immunotherapy; Immunology; Cancer research; Immune system; Antibody","score_opus":0.0655862087547177,"score_gpt":0.4044719527983389,"score_spread":0.3388857440436212,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171665778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91266894,0.07230034,0.0074540144,0.0019539227,0.00289958,0.0022932757,0.00018839969,0.00003443174,0.00020712106],"genre_scores_gemma":[0.57735634,0.20230584,0.07370142,0.018675115,0.014483362,0.0019235895,0.00007822077,0.001974198,0.10950191],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971441,0.000137363,0.0008737571,0.00035882543,0.0007173494,0.0007685781],"domain_scores_gemma":[0.9970537,0.00045078518,0.000595892,0.00063392136,0.001123157,0.00014254413],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010305613,0.00034853778,0.00084758503,0.00018299463,0.0006722439,0.00017038705,0.00042262336,0.00013278934,0.0039398656],"category_scores_gemma":[0.00006541557,0.00022822642,0.0008627032,0.00041454154,0.00024823003,0.0002026545,0.00003057571,0.00050636264,0.000001003113],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009939585,0.000100513826,0.00037709097,0.00015258272,0.0012747452,0.000026886824,0.001506791,0.00051308714,0.9078522,0.000013416715,0.0023768398,0.07586629],"study_design_scores_gemma":[0.007427081,0.00057882065,0.0002878859,0.0005057537,0.00009439402,0.0002822567,0.0008889338,0.00096304703,0.6212004,0.00013404514,0.36740494,0.00023248367],"about_ca_topic_score_codex":0.00043853346,"about_ca_topic_score_gemma":0.000105527884,"teacher_disagreement_score":0.36502808,"about_ca_system_score_codex":0.00093935436,"about_ca_system_score_gemma":0.0033832178,"threshold_uncertainty_score":0.99697065},"labels":[],"label_agreement":null},{"id":"W3171995199","doi":"10.1200/jco.2021.39.15_suppl.2593","title":"Nivolumab/ipilimumab primed immunotransplant in post-CAR-T and post-ASCT DLBCL.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Ipilimumab; Fludarabine; Nivolumab; Neutropenia; Internal medicine; Cyclophosphamide; Progressive disease; Chemotherapy; Refractory (planetary science); Oncology; Gastroenterology; Immunotherapy; Cancer; Biology","score_opus":0.09142502707162185,"score_gpt":0.4643852496822118,"score_spread":0.3729602226105899,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3171995199","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9741276,0.0029094527,0.0000141396295,0.017627725,0.0008794923,0.00022707728,0.000006790336,0.000008451116,0.0041992576],"genre_scores_gemma":[0.98323256,0.0069997874,0.0015929979,0.00422826,0.0008804022,0.0000032978712,0.000010449903,0.000033120803,0.0030191042],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99542856,0.0009323049,0.0023576047,0.00029170743,0.00057829526,0.000411524],"domain_scores_gemma":[0.9942257,0.00321788,0.0006049159,0.00032003378,0.0011343063,0.0004971717],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004525709,0.00016804322,0.001719988,0.00022024693,0.000037216374,0.000018891114,0.00019479817,0.00053559,0.001980295],"category_scores_gemma":[0.0041830195,0.00013157385,0.00051752804,0.0002472675,0.00030825025,0.00011580942,0.000091243965,0.0022414154,0.000028503888],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032915644,0.0050895894,0.092467986,0.00012952668,0.0009900911,0.017767116,0.00064745644,0.0000033501808,0.27747914,0.000088114546,0.0007628935,0.5716591],"study_design_scores_gemma":[0.036026392,0.018447418,0.872706,0.00027229605,0.00029033681,0.0074934987,0.0004814379,0.00006339892,0.0033111016,0.00017338141,0.06055064,0.00018409052],"about_ca_topic_score_codex":0.00012607635,"about_ca_topic_score_gemma":0.00034279458,"teacher_disagreement_score":0.78023803,"about_ca_system_score_codex":0.00024132695,"about_ca_system_score_gemma":0.004712392,"threshold_uncertainty_score":0.998932},"labels":[],"label_agreement":null},{"id":"W3172804543","doi":"10.1200/jco.2021.39.15_suppl.9568","title":"Tumor PD-L1 expression and gene panel mutational profile as outcome predictors of PD-1-based checkpoint inhibition therapy in metastatic melanoma: A prospective multicenter DeCOG study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Medicine; Oncology; Internal medicine; Melanoma; Progression-free survival; Prospective cohort study; Chemotherapy; Cancer research","score_opus":0.15827150236902757,"score_gpt":0.48052849117317575,"score_spread":0.3222569888041482,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3172804543","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966218,0.0003424343,0.00008035593,0.0011600486,0.00030132648,0.001265192,0.000012319227,0.0000077381765,0.00020878974],"genre_scores_gemma":[0.99482656,0.00009653527,0.004033506,0.0004871395,0.00027374673,0.00007187593,0.000010841345,0.000023949471,0.00017586276],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99486876,0.0012418167,0.0025892607,0.00030616124,0.0007615584,0.00023243],"domain_scores_gemma":[0.9949627,0.0023928313,0.0012450244,0.00018393164,0.0009389753,0.00027653406],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0037815806,0.00016905589,0.0014471055,0.0002570529,0.000031776082,0.0000115790735,0.00008405874,0.00015045768,0.0010713263],"category_scores_gemma":[0.0043515596,0.00011926632,0.00032225213,0.0002416296,0.00022517874,0.00011778937,0.00006203462,0.00095739705,0.000005543689],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02478472,0.012302588,0.8472686,0.00008390317,0.00046229924,0.005024918,0.00091705815,0.000033895223,0.09842684,0.000004706844,0.000055239736,0.010635223],"study_design_scores_gemma":[0.04045477,0.019559082,0.8773783,0.0001413809,0.00016206241,0.0004999019,0.0012124407,0.00048759885,0.059559643,0.00016317815,0.0002830788,0.00009854967],"about_ca_topic_score_codex":0.000027834603,"about_ca_topic_score_gemma":0.000053263997,"teacher_disagreement_score":0.038867194,"about_ca_system_score_codex":0.0002614442,"about_ca_system_score_gemma":0.0021057485,"threshold_uncertainty_score":0.9998418},"labels":[],"label_agreement":null},{"id":"W3173461290","doi":"10.1073/pnas.2025930118","title":"Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic","year":2021,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada; Ministerio de Ciencia e Innovación","keywords":"CD137; Agonist; Pharmacology; Cancer research; Chemistry; Cytotoxic T cell; Antibody; Monoclonal antibody; Prodrug; Proteases; Immunotherapy; Medicine; Immunology; Receptor; Immune system; In vitro; Biochemistry","score_opus":0.13419463122903236,"score_gpt":0.4037151791293229,"score_spread":0.26952054790029056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3173461290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941173,0.0002852289,7.628237e-7,0.0032086817,0.00001345914,0.00027164078,0.0000033958047,0.000010833498,0.0020886564],"genre_scores_gemma":[0.99777204,0.00007055734,0.0014197525,0.0003289211,0.00009827402,0.0000026342307,1.686579e-7,0.0000063584666,0.00030126795],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980346,0.000013759816,0.0002483775,0.0003000267,0.0012224609,0.00018078777],"domain_scores_gemma":[0.99920505,0.000083222876,0.00017677854,0.000014222707,0.0004537692,0.00006694588],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012523535,0.00008953651,0.00021565259,0.00014738274,0.00019237427,0.000038322403,0.00029652083,0.00006821554,0.0000866388],"category_scores_gemma":[0.0004053758,0.000060373717,0.00005458838,0.0008619366,0.0008843721,0.00032062214,0.00012220489,0.00021202971,3.8771245e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000040586845,0.00016822093,0.0060036196,0.00008448028,0.000025020661,5.722203e-8,0.0001680193,0.000015941534,0.9893448,0.0030912985,0.000019086676,0.0010388659],"study_design_scores_gemma":[0.00046490892,0.00010546807,0.15238848,0.00013007526,0.000023571292,0.00010719513,0.00018309537,0.0019282869,0.8411169,0.003413574,0.00007703087,0.00006140164],"about_ca_topic_score_codex":0.000005124565,"about_ca_topic_score_gemma":4.0203354e-8,"teacher_disagreement_score":0.1482279,"about_ca_system_score_codex":0.000038534654,"about_ca_system_score_gemma":0.000149604,"threshold_uncertainty_score":0.3258506},"labels":[],"label_agreement":null},{"id":"W3174028996","doi":"10.1007/s40273-021-01051-4","title":"Economic Evidence on Potentially Curative Gene Therapy Products: A Systematic Literature Review","year":2021,"lang":"en","type":"review","venue":"PharmacoEconomics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Providence Health Care; Centre for Advancing Health Outcomes; University of British Columbia","funders":"","keywords":"Medicine; Cost effectiveness; MEDLINE; EconLit; CINAHL; Health economics; Systematic review; Economic evaluation; Quality-adjusted life year; Cost–benefit analysis; Intensive care medicine; Public health; Actuarial science; Psychological intervention; Psychiatry; Pathology; Risk analysis (engineering)","score_opus":0.12902176028496853,"score_gpt":0.45309648081650333,"score_spread":0.3240747205315348,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3174028996","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000069727926,0.9853682,0.0000063509688,0.0013902615,0.0011496713,0.011108598,0.00019614273,0.00008805634,0.00068577414],"genre_scores_gemma":[3.0277272e-7,0.9853094,0.0002985924,0.0034094795,0.0016642831,0.001652842,0.0005966763,0.00026179178,0.0068066036],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99424314,0.0011929626,0.0020296925,0.0015486124,0.000328501,0.0006570893],"domain_scores_gemma":[0.9955175,0.00079343835,0.0011285042,0.0018412861,0.00034866872,0.00037062177],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0018764258,0.0010925235,0.0062209903,0.00041712067,0.0001059071,0.00028532688,0.0007880754,0.00033852825,0.003912354],"category_scores_gemma":[0.00036104213,0.0008522398,0.0016315355,0.00046773517,0.00009404145,0.00031720186,0.00017720221,0.0016153348,0.0014498311],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000077236706,0.00011397519,1.5376015e-7,0.58568656,0.0017841272,0.00024882672,0.00005371598,0.0000013125556,0.00009606267,0.00003120484,0.010421184,0.40148562],"study_design_scores_gemma":[0.00040990434,0.00012936948,3.3734967e-8,0.44783658,0.0013690557,0.0008045211,0.0000025589088,0.000007781888,0.00022429528,0.0000015160308,0.54883504,0.00037930926],"about_ca_topic_score_codex":0.0000045990128,"about_ca_topic_score_gemma":0.0000011302848,"teacher_disagreement_score":0.5384139,"about_ca_system_score_codex":0.0017568831,"about_ca_system_score_gemma":0.002725005,"threshold_uncertainty_score":0.9993928},"labels":[],"label_agreement":null},{"id":"W3176532045","doi":"10.1016/s0140-6736(21)00933-8","title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study","year":2021,"lang":"en","type":"article","venue":"The Lancet","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1664,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Janssen Research and Development","keywords":"Chimeric antigen receptor; Antigen; Refractory (planetary science); Medicine; Open label; Multiple myeloma; Receptor; Immunology; Cell; Immunotherapy; Cancer research; Biology; Internal medicine; Immune system; Clinical trial","score_opus":0.06200547005268376,"score_gpt":0.34697997397806435,"score_spread":0.2849745039253806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3176532045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992383,0.0007411539,0.000012197045,0.0005855665,0.00020507812,0.004241194,0.00006735212,0.00018568157,0.0015787625],"genre_scores_gemma":[0.98858535,0.0012846016,0.0015646089,0.00068534684,0.0003316656,0.0002516014,0.00039569495,0.000120121826,0.0067810356],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99630624,0.00076946575,0.00055548624,0.00076433225,0.00088808965,0.0007163756],"domain_scores_gemma":[0.99740744,0.00023139798,0.0002505707,0.0015328029,0.00039706274,0.00018073227],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00080309046,0.00040324123,0.0010064057,0.00016581782,0.00023384007,0.00018755134,0.00068,0.00014180724,0.001824109],"category_scores_gemma":[0.00015637027,0.00025290978,0.000060035654,0.0014078824,0.000103216946,0.00025797178,0.00021658176,0.00073844445,0.00010475065],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.061739452,0.041676722,0.1457231,0.00009114985,0.00037624023,0.00028728676,0.0046166293,0.0000057737716,0.711747,0.0000010362442,0.0076878867,0.02604774],"study_design_scores_gemma":[0.32866243,0.014217069,0.48731974,0.00027148696,0.00008636002,0.000016416026,0.0011856074,0.0010587049,0.123885654,0.000005522557,0.04249538,0.0007956207],"about_ca_topic_score_codex":0.00024032802,"about_ca_topic_score_gemma":0.00034136244,"teacher_disagreement_score":0.5878613,"about_ca_system_score_codex":0.00020933143,"about_ca_system_score_gemma":0.0005457744,"threshold_uncertainty_score":0.9999923},"labels":[],"label_agreement":null},{"id":"W3176850572","doi":"10.1080/19420862.2021.1933690","title":"A T cell redirection platform for co-targeting dual antigens on solid tumors","year":2021,"lang":"en","type":"article","venue":"mAbs","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Terry Fox Research Institute; Genome Canada","keywords":"Antigen; Cancer research; Cytotoxic T cell; Cytotoxicity; Antibody; Chemistry; Biology; Computational biology; In vitro; Immunology; Biochemistry","score_opus":0.04228322408717676,"score_gpt":0.34601758597425425,"score_spread":0.3037343618870775,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3176850572","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9604362,0.00019423042,0.00011180589,0.0007631881,0.00032113484,0.00044988104,0.000018944418,0.00008868463,0.03761589],"genre_scores_gemma":[0.9535718,0.00008039973,0.0005529087,0.0003909273,0.00083093945,0.00004086806,0.00018470867,0.000046304627,0.04430117],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99889416,0.000019415505,0.00018913322,0.00026009144,0.0003092194,0.00032798055],"domain_scores_gemma":[0.99936604,0.00012499378,0.00004153291,0.00020973236,0.00014834703,0.00010937415],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00033582485,0.00010368929,0.00021238711,0.00008842388,0.00012480214,0.000026282049,0.000035586683,0.0000739189,0.001979606],"category_scores_gemma":[0.00016691038,0.0000973559,0.000117808464,0.00014681695,0.00002713766,0.000035043584,0.00002214159,0.00021191474,0.00011116452],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007674539,0.00019814441,0.0009366861,0.00017031927,0.000042534866,0.00022041626,0.0004596083,0.000016842729,0.9495876,0.00005947643,0.036205593,0.011335365],"study_design_scores_gemma":[0.0017894504,0.0005477576,0.0012930605,0.00007614517,0.000018729334,0.00007377626,0.0005604601,0.0010637853,0.8513085,0.00009115982,0.14306395,0.00011317271],"about_ca_topic_score_codex":0.000019094647,"about_ca_topic_score_gemma":0.000007692595,"teacher_disagreement_score":0.10685836,"about_ca_system_score_codex":0.00012190269,"about_ca_system_score_gemma":0.00013953605,"threshold_uncertainty_score":0.9989327},"labels":[],"label_agreement":null},{"id":"W3178189790","doi":"10.1158/1538-7445.am2021-ct219","title":"Abstract CT219: Master protocol to assess the safety and recommended Phase 2 dose of next generation NY-ESO-1-specific TCR T-cells in HLA-A*02 patients with synovial sarcoma and non-small cell lung cancer","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Tolerability; T-cell receptor; Oncology; CD8; Internal medicine; T cell; Immunology; Tumor microenvironment; Cancer; Adverse effect; Antigen; Immune system","score_opus":0.1512024054731531,"score_gpt":0.4203069724784636,"score_spread":0.2691045670053105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3178189790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9613869,0.00042428178,0.000032532425,0.0012714685,0.00007952919,0.035796598,0.000091614354,0.0000082901215,0.00090875156],"genre_scores_gemma":[0.9660466,0.00087818113,0.0002768666,0.00023719957,0.0004041824,0.029315453,0.00004793935,0.00008619865,0.0027074348],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9967941,0.00038649925,0.00047683858,0.0006621587,0.0010163804,0.00066402723],"domain_scores_gemma":[0.99776655,0.00031274676,0.00009180491,0.0005881526,0.0009172153,0.0003235259],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013120946,0.00023135882,0.0004301088,0.00027983479,0.00017960051,0.00017600194,0.0002074233,0.00012800178,0.0029969013],"category_scores_gemma":[0.000047722002,0.00016503414,0.000044740766,0.0008072697,0.00019418234,0.00016364011,0.00024089133,0.00088598375,0.0000044629514],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008389062,0.00090922724,0.043921597,0.0007947953,0.00007814039,0.0000832272,0.0014036719,0.000039108887,0.8746709,0.0000042570255,0.0035335654,0.06617244],"study_design_scores_gemma":[0.040077433,0.0024227528,0.15164596,0.0013548037,0.000045911023,0.000009557675,0.0010518499,0.0012044056,0.75179356,0.000009407007,0.049857654,0.0005267115],"about_ca_topic_score_codex":0.0008443763,"about_ca_topic_score_gemma":0.0019931376,"teacher_disagreement_score":0.12287735,"about_ca_system_score_codex":0.00055773125,"about_ca_system_score_gemma":0.0009708978,"threshold_uncertainty_score":0.9979145},"labels":[],"label_agreement":null},{"id":"W3179219421","doi":"10.1158/1538-7445.am2021-1546","title":"Abstract 1546: Defining the immune microenvironment in Ewing's sarcoma to potentiate IL1RAP-targeted CAR-T immunotherapy","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Chimeric antigen receptor; Stromal cell; Cancer research; T cell; Tumor microenvironment; Medicine; Immunotherapy; Immune system; Cytokine; Biology; Immunology","score_opus":0.04865885854201953,"score_gpt":0.37405951825854866,"score_spread":0.32540065971652915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3179219421","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94469666,0.039021853,0.000012015923,0.011743748,0.00019950034,0.001150575,0.000028125502,0.000034635304,0.003112887],"genre_scores_gemma":[0.98015404,0.007393302,0.00020088113,0.00081345206,0.00021303335,0.0004908091,0.000045815454,0.000116319956,0.010572361],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.995227,0.00047610537,0.00053374533,0.0007274852,0.0016178042,0.0014178875],"domain_scores_gemma":[0.9976659,0.00038196892,0.000052588493,0.0012892074,0.00031084788,0.00029949512],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0026430131,0.00026243972,0.0004814617,0.00044658405,0.00034452026,0.00015161461,0.00057101937,0.0001479845,0.018073408],"category_scores_gemma":[0.00020426742,0.00021000554,0.00021856584,0.0015465883,0.0002961643,0.00008673573,0.00040112436,0.0017656869,0.0004448167],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010831215,0.0002307429,0.006159012,0.00007179126,0.00017901206,0.0005317456,0.0013964842,0.000082362436,0.91880774,0.00005101051,0.0012279546,0.070179015],"study_design_scores_gemma":[0.0028074437,0.00023559378,0.29181537,0.0003650798,0.000011211165,0.000054860204,0.001436034,0.000024782763,0.6204072,0.00008445749,0.0825265,0.00023145213],"about_ca_topic_score_codex":0.0034380183,"about_ca_topic_score_gemma":0.0005119882,"teacher_disagreement_score":0.29840052,"about_ca_system_score_codex":0.001299368,"about_ca_system_score_gemma":0.0009861608,"threshold_uncertainty_score":0.9828242},"labels":[],"label_agreement":null},{"id":"W3180458932","doi":"10.1016/j.jcyt.2021.05.007","title":"Development of a B-cell maturation antigen-specific T-cell antigen coupler receptor for multiple myeloma","year":2021,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Hospital; McMaster University Medical Centre","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Receptor; T-cell receptor; Antigen; Cell biology; T cell; Chimeric antigen receptor; Cancer research; Biology; Monoclonal antibody; Immunology; Chemistry; Antibody; Immune system; Biochemistry","score_opus":0.04379794141137245,"score_gpt":0.30325912682563294,"score_spread":0.2594611854142605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3180458932","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98677045,0.002892493,0.00677517,0.0002908481,0.00026639405,0.0012290666,0.000029654879,0.00006160788,0.0016843029],"genre_scores_gemma":[0.7818779,0.008170132,0.18062471,0.000532248,0.0006201675,0.00023888843,0.0006251734,0.00021523767,0.027095571],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980984,0.000051461935,0.0005076658,0.0004544288,0.00047656576,0.00041148945],"domain_scores_gemma":[0.9985622,0.00014795638,0.00014163504,0.0005046443,0.0004975664,0.00014598884],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00035564246,0.00022708556,0.0004450484,0.00014296248,0.0001310915,0.000037752106,0.00014276346,0.00016449614,0.004638338],"category_scores_gemma":[0.000022832004,0.00021340672,0.00019125603,0.0003579567,0.000070945425,0.000069495174,0.000027920145,0.00016580359,0.00010188715],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015675945,0.000583652,0.0025040621,0.00013813424,0.000088026,0.000009474225,0.0019216602,0.0000021422968,0.9461675,0.00001687378,0.0037504937,0.043250334],"study_design_scores_gemma":[0.003720556,0.00012873541,0.004981136,0.00004141277,0.0000031413094,0.000005757552,0.00028851503,0.00016210246,0.61198103,0.000007596452,0.37854207,0.00013793774],"about_ca_topic_score_codex":0.0000040498953,"about_ca_topic_score_gemma":0.000015045052,"teacher_disagreement_score":0.37479156,"about_ca_system_score_codex":0.00015229941,"about_ca_system_score_gemma":0.00053167087,"threshold_uncertainty_score":0.99627155},"labels":[],"label_agreement":null},{"id":"W3180594295","doi":"10.1136/jitc-2021-002642","title":"Evaluating T-cell cross-reactivity between tumors and immune-related adverse events with TCR sequencing: pitfalls in interpretations of functional relevance","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"Bloomberg~Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University; National Human Genome Research Institute; Swim Across America; International Association for the Study of Lung Cancer; Mark Foundation For Cancer Research; LUNGevity Foundation; Commonwealth Foundation; National Cancer Institute; National Institutes of Health; Bloomberg Philanthropies","keywords":"Blockade; T-cell receptor; Immune system; Confounding; Immune checkpoint; T cell; Medicine; Cell; Immunology; Immunotherapy; Cancer research; Biology; Receptor; Internal medicine; Genetics","score_opus":0.0552863817777128,"score_gpt":0.405616804043211,"score_spread":0.3503304222654982,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3180594295","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927028,0.0054652905,0.0007338165,0.00021254645,0.00015369996,0.00045012895,0.00002913981,0.0000064976043,0.0002460754],"genre_scores_gemma":[0.9941527,0.001094837,0.0014345144,0.000038636117,0.00006506004,0.000037979953,0.000012252758,0.000042189342,0.0031218259],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9980525,0.00012301886,0.00078101654,0.00021634442,0.0005742843,0.0002528423],"domain_scores_gemma":[0.99790835,0.0004366148,0.0005638579,0.00021442912,0.0008052277,0.0000715289],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010807656,0.0001586175,0.00052580965,0.0002006998,0.00009973431,0.00001165317,0.00009034746,0.00008680074,0.00074146513],"category_scores_gemma":[0.00017068001,0.00013492073,0.0002017102,0.00034679283,0.00015712154,0.00022729451,0.000020832016,0.00051428855,5.0660134e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036086203,0.00013162554,0.11402911,0.00015370075,0.0004286798,0.000009513548,0.0010894103,0.0017766287,0.8487166,0.000009276663,0.0000055423725,0.030041302],"study_design_scores_gemma":[0.01926024,0.0018872314,0.52281475,0.0021576327,0.00015111954,0.00021133684,0.00061302085,0.0018001779,0.4495127,0.00088806055,0.00044938046,0.00025437505],"about_ca_topic_score_codex":0.00017317447,"about_ca_topic_score_gemma":0.0000523485,"teacher_disagreement_score":0.40878564,"about_ca_system_score_codex":0.00045419848,"about_ca_system_score_gemma":0.001319345,"threshold_uncertainty_score":0.8118523},"labels":[],"label_agreement":null},{"id":"W3181502328","doi":"10.1158/1538-7445.am2021-lb105","title":"Abstract LB105: In vivo CAR T therapy: targeted in vivo gene delivery of a CAR using a CD8-specific fusogen results in tumor eradication","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Chimeric antigen receptor; Cytotoxic T cell; CD8; Ex vivo; Biology; Transduction (biophysics); T cell; Cancer research; Gene delivery; Viral vector; Cell therapy; CD19; In vivo; Genetic enhancement; Cell biology; Immunology; Antigen; Immune system; In vitro; Stem cell; Biochemistry; Gene; Genetics; Recombinant DNA","score_opus":0.12560361493496577,"score_gpt":0.4004026008070786,"score_spread":0.2747989858721128,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3181502328","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9832042,0.013470727,0.0000015044008,0.00067741843,0.00008851773,0.0012752401,0.00015079914,0.00001659019,0.0011150349],"genre_scores_gemma":[0.9875097,0.010834245,0.00019143267,0.00006621621,0.00024201254,0.00022257093,0.00003544127,0.00007317888,0.00082516746],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9952454,0.0006256141,0.00086816255,0.00081090926,0.0014644027,0.0009855274],"domain_scores_gemma":[0.9976175,0.00039913217,0.00011033778,0.0008524292,0.0007880781,0.0002325437],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0028932863,0.00022504554,0.00063057133,0.0014647635,0.00006596311,0.000041356143,0.00033839507,0.00019431819,0.0035747313],"category_scores_gemma":[0.00028272375,0.00022996348,0.000115807234,0.0033821666,0.0002743287,0.00014416855,0.00013729413,0.0012699955,0.000010519547],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004547,0.0003951308,0.014773329,0.00016034169,0.000049784365,0.0012473279,0.0024114053,0.00042134977,0.97066706,0.000008357386,0.0005530046,0.0047658808],"study_design_scores_gemma":[0.0071415515,0.000189509,0.055491056,0.00063696713,0.0000041699013,0.000030119263,0.0010696176,0.00073396886,0.92666113,0.000049299117,0.007785339,0.00020727348],"about_ca_topic_score_codex":0.017352229,"about_ca_topic_score_gemma":0.007192439,"teacher_disagreement_score":0.04400596,"about_ca_system_score_codex":0.0023871805,"about_ca_system_score_gemma":0.002843282,"threshold_uncertainty_score":0.99733615},"labels":[],"label_agreement":null},{"id":"W3181611529","doi":"10.2196/29912","title":"First-line Advanced Cutaneous Melanoma Treatments: Where Do We Stand?","year":2021,"lang":"en","type":"article","venue":"JMIR Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Clinical trial; Intensive care medicine; Adverse effect; Melanoma; Immunotherapy; Randomized controlled trial; Scarcity; Surgery; Cancer; Internal medicine; Cancer research","score_opus":0.024440085063184718,"score_gpt":0.3555394913036441,"score_spread":0.33109940624045936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3181611529","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.71118796,0.23281392,0.00005637299,0.022686593,0.00075224123,0.0020549884,0.00025418127,0.00025354137,0.029940223],"genre_scores_gemma":[0.29722103,0.15640074,0.00071945175,0.0004862901,0.0011966187,0.0011688053,0.000042819724,0.0001699664,0.54259425],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983912,0.000037843205,0.00022304773,0.00043872133,0.00048116973,0.0004280217],"domain_scores_gemma":[0.99885845,0.00007692324,0.00005183417,0.0005615597,0.00022651456,0.0002247336],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000042817705,0.00021051981,0.00038156216,0.000064821965,0.00008391737,0.000034532135,0.00009463915,0.000112370646,0.04304577],"category_scores_gemma":[0.000022554192,0.00017636409,0.00015032702,0.00034959713,0.000058272057,0.00006400773,0.00005727606,0.00024809982,0.00014775158],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003383244,0.0008090513,0.009963667,0.0007538185,0.00087245606,0.005688016,0.0013228368,0.00019162364,0.08527066,0.000077495606,0.019330552,0.87233657],"study_design_scores_gemma":[0.0044631297,0.00061264395,0.00089128973,0.0006192029,0.00007881933,0.0003487885,0.00026264478,0.00009332457,0.016094696,0.00011158362,0.97623116,0.00019270282],"about_ca_topic_score_codex":0.00007649173,"about_ca_topic_score_gemma":0.0006577966,"teacher_disagreement_score":0.9569006,"about_ca_system_score_codex":0.00070259476,"about_ca_system_score_gemma":0.00045445882,"threshold_uncertainty_score":0.957829},"labels":[],"label_agreement":null},{"id":"W3181940780","doi":"10.1101/2021.07.09.451642","title":"Novel low-avidity glypican-3 specific CARTs resist exhaustion and mediate durable antitumor effects against hepatocellular carcinoma","year":2021,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"National Institutes of Health; Augusta University","keywords":"Avidity; Cart; Effector; Cancer research; Antigen; Hepatocellular carcinoma; Antibody; Chimeric antigen receptor; Epitope; In vivo; Immunology; Biology; Medicine; Immunotherapy; Immune system","score_opus":0.021013534483304605,"score_gpt":0.23492681345557095,"score_spread":0.21391327897226636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3181940780","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880736,0.006695756,0.00034051813,0.00032739903,0.0016138366,0.0023950015,0.00016394716,0.00034875353,0.000041203348],"genre_scores_gemma":[0.99243706,0.0033161147,0.001997879,0.0002106097,0.0013460513,0.0003068667,0.000009276834,0.0002935675,0.00008254503],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9943977,0.00029422977,0.0008364842,0.002075821,0.0012574015,0.0011383522],"domain_scores_gemma":[0.9949635,0.00021242377,0.00041395458,0.00242843,0.001017657,0.0009640191],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012397747,0.0009588146,0.0015227079,0.00055329275,0.00032029918,0.00046573766,0.00045029027,0.00086521613,0.00024183278],"category_scores_gemma":[0.00047454308,0.0010419127,0.0003434124,0.00085262774,0.00041812085,0.0002002768,0.0008144846,0.0019282959,0.00004680657],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002974822,0.00040849543,0.06994044,0.0035167218,0.00023663357,0.0023837574,0.00002461203,0.00000960328,0.92281836,0.00003453643,0.00031938148,0.000009973924],"study_design_scores_gemma":[0.0023387524,0.00012184217,0.34575072,0.0015841954,0.00020409375,5.701902e-7,0.000008405899,0.0006474743,0.6458671,3.6346873e-7,0.0027114146,0.00076509273],"about_ca_topic_score_codex":0.00027306718,"about_ca_topic_score_gemma":0.000011850444,"teacher_disagreement_score":0.27695128,"about_ca_system_score_codex":0.0009291291,"about_ca_system_score_gemma":0.001449961,"threshold_uncertainty_score":0.99920315},"labels":[],"label_agreement":null},{"id":"W3182197846","doi":"10.1016/j.jbc.2021.100966","title":"Structural details of monoclonal antibody m971 recognition of the membrane-proximal domain of CD22","year":2021,"lang":"en","type":"article","venue":"Journal of Biological Chemistry","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; University of Toronto; Hospital for Sick Children","funders":"Western Economic Diversification Canada; Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Canada Research Chairs; National Research Council Canada; Canada Foundation for Innovation; University of Saskatchewan; Canadian Light Source","keywords":"CD22; Epitope; Antibody; SIGLEC; Antigen; Sialic acid; Paratope; Monoclonal antibody; Chemistry; B cell; Molecular biology; Receptor; Biology; Cell biology; Biochemistry; Immunology","score_opus":0.051466291394493956,"score_gpt":0.32593683824821845,"score_spread":0.2744705468537245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3182197846","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974604,0.0005337251,0.000009270433,0.00030940332,0.00006758983,0.00008324679,0.00003708455,0.0000025510021,0.0014967257],"genre_scores_gemma":[0.9983501,0.00021477205,0.0009733793,0.000031606298,0.00023950853,7.0432657e-7,0.000020314552,0.000006735604,0.00016289143],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99838376,0.0001266278,0.00071469566,0.00013028517,0.00047389633,0.00017071841],"domain_scores_gemma":[0.99826175,0.00021401673,0.00057656126,0.00020688235,0.000642398,0.000098397984],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00057355163,0.00011431379,0.0005414554,0.000026250496,0.000022905233,0.000004312878,0.00020761693,0.00020034773,0.003879586],"category_scores_gemma":[0.0005778352,0.000063705724,0.0004272234,0.00021973345,0.00035124464,0.00003062273,0.00008706689,0.00048266028,4.7864347e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013075201,0.00014544645,0.015634941,0.0002673262,0.00014869684,0.000056773995,0.00003824179,0.000002395362,0.9790081,0.0000038237495,0.000022712138,0.0033640647],"study_design_scores_gemma":[0.0014532615,0.00039385323,0.018823443,0.00020660886,0.000052157717,0.00093597005,0.0002402173,0.00001594108,0.9770289,0.0006962031,0.00009455756,0.000058902606],"about_ca_topic_score_codex":0.0000036600059,"about_ca_topic_score_gemma":2.7160178e-7,"teacher_disagreement_score":0.0038791075,"about_ca_system_score_codex":0.000043615106,"about_ca_system_score_gemma":0.00023512426,"threshold_uncertainty_score":0.997031},"labels":[],"label_agreement":null},{"id":"W3182840620","doi":"10.1371/journal.pone.0253864","title":"The KrasG12D;Trp53fl/fl murine model of undifferentiated pleomorphic sarcoma is macrophage dense, lymphocyte poor, and resistant to immune checkpoint blockade","year":2021,"lang":"en","type":"article","venue":"PLoS ONE","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Children's Hospital; Alberta Bone and Joint Health Institute; University of Calgary","funders":"Alberta Children's Hospital Foundation; Alberta Cancer Foundation; Children's Hospital Foundation; Cancer Research Society","keywords":"Immune system; Sarcoma; Biology; Cancer research; Immunology; Macrophage; Lymphocyte; Immune checkpoint; Pathology; Immunotherapy; Medicine","score_opus":0.053299864276414255,"score_gpt":0.2691362608044228,"score_spread":0.21583639652800857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3182840620","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987281,0.006097668,0.000040645147,0.0049095205,0.00002768117,0.0007250355,0.0000885431,0.00005392933,0.0007759591],"genre_scores_gemma":[0.96205825,0.002838457,0.0012132473,0.0003032119,0.000078658086,0.0000515202,0.000043134358,0.000079981546,0.033333544],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971338,0.00013955374,0.0006278061,0.0004903085,0.0010265427,0.00058201846],"domain_scores_gemma":[0.99784327,0.00019830935,0.00012811077,0.000993782,0.0005013075,0.00033521224],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00043581144,0.00027264314,0.0006998922,0.00015534766,0.00019246784,0.00006055756,0.00024109131,0.00013112197,0.0012974761],"category_scores_gemma":[0.0002869412,0.0002148399,0.00015324444,0.0005360861,0.00021267316,0.000036414378,0.00038582727,0.00035397054,0.000041754996],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024305955,0.0011588662,0.00071482593,0.00037543388,0.0009337758,0.0001896095,0.0005009159,0.000005836103,0.9925323,0.000043801207,0.000067149704,0.0010468735],"study_design_scores_gemma":[0.0040619173,0.0004339359,0.007739424,0.00047329054,0.00032333392,0.00004930186,0.00013180457,0.007690562,0.978438,0.0002638615,0.00019215843,0.00020239061],"about_ca_topic_score_codex":0.00026387445,"about_ca_topic_score_gemma":0.00014690647,"teacher_disagreement_score":0.032557588,"about_ca_system_score_codex":0.00022490312,"about_ca_system_score_gemma":0.000353146,"threshold_uncertainty_score":0.9996155},"labels":[],"label_agreement":null},{"id":"W3187322562","doi":"10.3389/fimmu.2021.698565","title":"p16INK4a Regulates Cellular Senescence in PD-1-Expressing Human T Cells","year":2021,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":54,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Canadian Institutes of Health Research","keywords":"Senescence; Cell biology; Downregulation and upregulation; T cell; Immunotherapy; Biology; Ex vivo; Cell; Cell cycle; DNA damage; In vivo; Cancer research; Immune system; Immunology; DNA; Genetics; Gene","score_opus":0.016589656623439412,"score_gpt":0.27872685458128643,"score_spread":0.262137197957847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3187322562","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.981548,0.011398933,0.00100177,0.00062885147,0.0011671481,0.000320573,0.0000023129219,0.000050720475,0.0038816696],"genre_scores_gemma":[0.9717873,0.0009424079,0.0072855866,0.00019171245,0.0001303827,0.000032695345,0.000056118017,0.000060213566,0.019513624],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978768,0.00031116157,0.00042564137,0.0005076343,0.00022594919,0.00065278],"domain_scores_gemma":[0.99902153,0.00006081194,0.0000667943,0.00069651555,0.0000879578,0.000066375454],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00036927813,0.00019496902,0.0005565587,0.0004705962,0.00007247768,0.000027057866,0.00023118056,0.00031024878,0.0011279081],"category_scores_gemma":[0.00008272848,0.00021206228,0.00009843333,0.0006248179,0.00034781577,0.00008477984,0.00017400524,0.0007526945,0.000027809498],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022070137,0.00019381702,0.041035585,0.000054195018,0.00006394296,0.0011749552,0.00076963584,0.000015009942,0.9454373,0.000052134463,0.0016999923,0.009282731],"study_design_scores_gemma":[0.0027759594,0.00013677418,0.022468748,0.00025587325,0.00001565795,0.000072493596,0.0013235604,0.00032919395,0.951374,0.0008839197,0.020142645,0.00022117831],"about_ca_topic_score_codex":0.0001605345,"about_ca_topic_score_gemma":0.000044199278,"teacher_disagreement_score":0.018566838,"about_ca_system_score_codex":0.00035955873,"about_ca_system_score_gemma":0.00020869338,"threshold_uncertainty_score":0.9997852},"labels":[],"label_agreement":null},{"id":"W3190177153","doi":"10.1136/jitc-2020-002287","title":"Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Cytokine release syndrome; Tocilizumab; Leukopenia; Internal medicine; Neutropenia; Gastroenterology; Chimeric antigen receptor; Immunotherapy; Chemotherapy","score_opus":0.006887365602533204,"score_gpt":0.2905556143615081,"score_spread":0.2836682487589749,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3190177153","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.986212,0.012413909,0.0004502668,0.00014772807,0.00007774285,0.0003821468,0.00011463912,0.0000048823404,0.00019666227],"genre_scores_gemma":[0.9693585,0.025869437,0.0008089905,0.00013238144,0.00007877664,0.00002147509,0.00003619167,0.000048314923,0.0036459325],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9984018,0.000060255283,0.00056844414,0.0002245056,0.00045816955,0.00028677963],"domain_scores_gemma":[0.9988142,0.000091296555,0.0003063655,0.0002634663,0.0004285694,0.00009608349],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00033365484,0.00016984165,0.0007716248,0.00045894174,0.000060328024,0.000021414256,0.00011847236,0.00008999315,0.0015183554],"category_scores_gemma":[0.000015370842,0.00013318245,0.00028981472,0.0009144471,0.00010622547,0.00008185775,0.000018816318,0.00024323673,2.50627e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0228827,0.00023671487,0.1916203,0.00010856346,0.01282723,0.000038125778,0.001615838,0.0007357292,0.69644815,0.0000057586553,0.00010549582,0.07337536],"study_design_scores_gemma":[0.027727686,0.0013138159,0.8047592,0.000517835,0.0027263311,0.00033095558,0.00029679533,0.0015587801,0.15976462,0.000026188858,0.0007431938,0.00023459048],"about_ca_topic_score_codex":0.0006286047,"about_ca_topic_score_gemma":0.0005336102,"teacher_disagreement_score":0.6131389,"about_ca_system_score_codex":0.00043037345,"about_ca_system_score_gemma":0.0008402701,"threshold_uncertainty_score":0.9993944},"labels":[],"label_agreement":null},{"id":"W3193753748","doi":"10.1101/2021.08.24.457536","title":"Clinically-relevant T cell expansion protocols activate distinct cellular metabolic programs and phenotypes","year":2021,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stemcell Technologies; University of Victoria","funders":"Canadian Institutes of Health Research","keywords":"Ex vivo; Phenotype; In vivo; Glutamine; Function (biology); Biology; Cell biology; Cell; Metabolism; Cell growth; T cell; Carbohydrate metabolism; Immunotherapy; Cancer research; Biochemistry; Immunology; Immune system; Genetics; Gene","score_opus":0.03399406325955247,"score_gpt":0.29830460958641086,"score_spread":0.2643105463268584,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3193753748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9735701,0.0025232106,0.0005292746,0.00026106025,0.00041909076,0.022112904,0.000043277734,0.0004846163,0.0000564757],"genre_scores_gemma":[0.97818506,0.0009241428,0.0076954253,0.00015812863,0.00095383724,0.011584044,0.0000038349826,0.00035330345,0.00014222301],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9940287,0.0004869603,0.0011959976,0.002039316,0.0011775622,0.0010714919],"domain_scores_gemma":[0.99474716,0.00018701162,0.0006012815,0.002542117,0.0010262439,0.000896185],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0016548814,0.00094515685,0.0017221264,0.00030790194,0.00021018427,0.00052922656,0.00054630404,0.0009697426,0.0005502227],"category_scores_gemma":[0.00050171046,0.0008750051,0.00044036502,0.0006955931,0.00037483338,0.00015910098,0.0012265181,0.002333931,0.000054901142],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006083426,0.0011419365,0.02249052,0.0020196696,0.00035572372,0.00042163645,0.00003780266,0.0000021252074,0.97257626,0.000030788295,0.0000436469,0.0002715501],"study_design_scores_gemma":[0.0029692983,0.00055590225,0.056648478,0.002131338,0.0004543025,1.3947802e-7,0.000016139622,0.00028155616,0.905855,0.0000024350038,0.030000972,0.0010844185],"about_ca_topic_score_codex":0.000091758746,"about_ca_topic_score_gemma":0.0000034232417,"teacher_disagreement_score":0.06672124,"about_ca_system_score_codex":0.00023458277,"about_ca_system_score_gemma":0.0016787718,"threshold_uncertainty_score":0.99996775},"labels":[],"label_agreement":null},{"id":"W3194238275","doi":"10.1126/scisignal.abe2606","title":"Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function","year":2021,"lang":"en","type":"article","venue":"Science Signaling","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":163,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; Lorentz Center; University of Washington; Fred Hutchinson Cancer Research Center; National Multiple Sclerosis Society Michigan Chapter; Takeda Canada; American Cancer Society","keywords":"T-cell receptor; Chimeric antigen receptor; Antigen; T cell; CD3; Biology; Cancer research; Cell biology; Immunology; Immune system; CD8","score_opus":0.04897694173428213,"score_gpt":0.32589205340288135,"score_spread":0.2769151116685992,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3194238275","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99713993,0.00023501132,0.0020427897,0.000037347672,0.000018033463,0.00021873636,0.0000068035347,0.0000116910305,0.00028965558],"genre_scores_gemma":[0.99864185,0.000033475346,0.0011780169,0.00004854075,0.000018681492,0.0000037992547,0.000004416597,0.0000058398923,0.00006536448],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99833596,0.000091618036,0.00024026682,0.00040250525,0.00061380217,0.00031583582],"domain_scores_gemma":[0.99895346,0.00021491825,0.00006754649,0.00018843579,0.00041622634,0.00015940312],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001588833,0.00012710001,0.0005076278,0.0006385467,0.00016465153,0.000073830306,0.00004686999,0.00004550757,0.00017268807],"category_scores_gemma":[0.00008845353,0.00010080364,0.000049044716,0.0032179258,0.0007087271,0.00030528696,0.000060235532,0.00017833593,4.1974263e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021811367,0.000023344848,0.13675728,0.000028393559,0.0001399273,0.00005255294,0.0035957557,0.0032101013,0.8554798,0.000012484507,3.7165904e-7,0.00048186665],"study_design_scores_gemma":[0.0006113632,0.0002303142,0.060107633,0.00011122647,0.00021577257,0.000035634206,0.0070940964,0.021101419,0.91034615,0.0000099614335,0.000013598292,0.00012280671],"about_ca_topic_score_codex":0.0003084423,"about_ca_topic_score_gemma":0.0004757545,"teacher_disagreement_score":0.07664965,"about_ca_system_score_codex":0.000085704,"about_ca_system_score_gemma":0.00048153359,"threshold_uncertainty_score":0.41106534},"labels":[],"label_agreement":null},{"id":"W3194271452","doi":"10.1097/ppo.0000000000000532","title":"Is There a Role for Cellular Therapy in Chronic Lymphocytic Leukemia?","year":2021,"lang":"en","type":"review","venue":"The Cancer Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Chronic lymphocytic leukemia; Chimeric antigen receptor; Medicine; Immunology; Hematopoietic cell; Leukemia; Disease; Transplantation; Hematopoietic stem cell transplantation; Cell therapy; Haematopoiesis; Cancer research; T cell; Cell; Biology; Stem cell; Immune system; Internal medicine","score_opus":0.1016404066681494,"score_gpt":0.4152514179338117,"score_spread":0.3136110112656623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3194271452","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003385792,0.9964947,0.00003123205,0.000306894,0.0003441899,0.0017726236,0.000036188776,0.000015919037,0.0006596659],"genre_scores_gemma":[0.00004388709,0.9837524,0.000021366468,0.00039681178,0.0036189554,0.0005241083,0.000024087398,0.00017280818,0.011445559],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970976,0.0003936395,0.00073447236,0.00042467046,0.0006167099,0.00073287723],"domain_scores_gemma":[0.99812037,0.00029857748,0.00036130907,0.0007955702,0.00021573898,0.00020841332],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001365796,0.00046002783,0.0019164264,0.00023739379,0.00017799254,0.00013474135,0.0007133997,0.00033077245,0.0123971],"category_scores_gemma":[0.000038909748,0.0002624148,0.0012929707,0.00056672684,0.00011020954,0.000049302475,0.0000814275,0.00169231,0.00003627723],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00012865743,0.000015199403,0.000004087036,0.0030461887,0.00081381726,0.00014751547,0.00030305187,0.000025536418,0.00033523844,0.000010607034,0.003770492,0.9913996],"study_design_scores_gemma":[0.0030747638,0.00030321776,0.0000020081839,0.016602082,0.00046905188,0.0008127009,0.00008110517,0.00022559153,0.0003458195,0.0001504773,0.9776819,0.00025131038],"about_ca_topic_score_codex":0.00024736996,"about_ca_topic_score_gemma":0.000051143244,"teacher_disagreement_score":0.9911483,"about_ca_system_score_codex":0.028921835,"about_ca_system_score_gemma":0.034973543,"threshold_uncertainty_score":0.99998283},"labels":[],"label_agreement":null},{"id":"W3194367680","doi":"10.1182/bloodadvances.2020003844","title":"Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma","year":2021,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Hospital","funders":"","keywords":"Cytokine release syndrome; Immunogenicity; Antibody; Immunology; Medicine; Diffuse large B-cell lymphoma; Lymphoma; Internal medicine; B cell; Immunotherapy; Immune system; Oncology; Chimeric antigen receptor","score_opus":0.010106057027941427,"score_gpt":0.2702827667122035,"score_spread":0.2601767096842621,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3194367680","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96110934,0.03364602,0.00002535039,0.00010251954,0.00015902612,0.00028314593,0.000034960638,0.00006607326,0.0045735533],"genre_scores_gemma":[0.9714235,0.013597463,0.00058434723,0.00037928263,0.00013758265,0.00004054303,0.00003919113,0.000059827136,0.013738252],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99785024,0.00012524496,0.0003727296,0.00058271864,0.0004490577,0.00062003575],"domain_scores_gemma":[0.99878573,0.00026107923,0.00008627723,0.000536494,0.00010433504,0.00022608155],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002351789,0.0002649404,0.0004944768,0.00015207574,0.000110754016,0.000043444958,0.00015068185,0.00015337528,0.00057865767],"category_scores_gemma":[0.00014446254,0.00025204188,0.00012075951,0.00045538877,0.00013076274,0.00017625358,0.00018900045,0.00025983754,0.000055582375],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001018589,0.0057943324,0.02520882,0.00029869418,0.00027879846,0.0033500744,0.0006162485,0.0000044068584,0.9236744,0.00006371919,0.00012612353,0.039565768],"study_design_scores_gemma":[0.12177127,0.0013064954,0.097186215,0.00048932055,0.00063394767,0.0016932577,0.0010283766,0.00050032634,0.6543931,0.0004602208,0.11960413,0.00093338167],"about_ca_topic_score_codex":0.00004896283,"about_ca_topic_score_gemma":0.00016382105,"teacher_disagreement_score":0.2692814,"about_ca_system_score_codex":0.00028441413,"about_ca_system_score_gemma":0.0005805511,"threshold_uncertainty_score":0.9999932},"labels":[],"label_agreement":null},{"id":"W3195202932","doi":"10.1503/cmaj.202907","title":"Innovations in cancer immunotherapy: chimeric antigen receptor T-cell therapy (CAR-T)","year":2021,"lang":"en","type":"review","venue":"Canadian Medical Association Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Manitoba; Leukemia & Lymphoma Society of Canada; Canadian Blood Services; Terry Fox Research Institute; University of British Columbia","funders":"","keywords":"Chimeric antigen receptor; Immunotherapy; Cell therapy; Medicine; Cancer immunotherapy; Immunology; Antigen; T cell; CAR T-cell therapy; Cancer; Immune system; Cancer research; Cell; Biology; Internal medicine","score_opus":0.04552432751642645,"score_gpt":0.3670496104793084,"score_spread":0.32152528296288196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3195202932","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00050877314,0.9885368,0.000004838835,0.006330829,0.0013713493,0.00082102313,0.00008405141,0.00003265346,0.0023097321],"genre_scores_gemma":[0.00001056349,0.98421544,0.000073923264,0.0043590353,0.0031251214,0.0001356851,0.0002321255,0.00018232016,0.0076657906],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99386406,0.00085505354,0.0014452788,0.00044773964,0.0023356588,0.0010522093],"domain_scores_gemma":[0.9961766,0.00036424753,0.000680854,0.00036854076,0.0008903243,0.001519462],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0028979685,0.00045583848,0.0020592723,0.0013332749,0.00020442331,0.00017573933,0.0004883462,0.0014298239,0.0746063],"category_scores_gemma":[0.0008174908,0.00039439573,0.0006768205,0.0028501744,0.00007061398,0.00010027684,0.000028047827,0.004660266,0.00017259734],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000009037917,0.00011512325,0.0015850433,0.00028491128,0.000630934,0.00039836977,0.00016045413,1.7928288e-7,0.000027358377,0.0000102483855,0.053555287,0.94322306],"study_design_scores_gemma":[0.001643679,0.00008213802,0.00032583796,0.004873789,0.000060940532,0.00032131549,0.00008169185,0.0000041037997,0.0000049552045,0.0000049189016,0.99226475,0.0003318958],"about_ca_topic_score_codex":0.0071338597,"about_ca_topic_score_gemma":0.010926275,"teacher_disagreement_score":0.9428912,"about_ca_system_score_codex":0.007164779,"about_ca_system_score_gemma":0.040924966,"threshold_uncertainty_score":0.99986655},"labels":[],"label_agreement":null},{"id":"W3195519455","doi":"10.1097/cji.0000000000000386","title":"Potent, Selective CARs as Potential T-Cell Therapeutics for HPV-positive Cancers","year":2021,"lang":"en","type":"article","venue":"Journal of Immunotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovative Targeting Solutions (Canada)","funders":"","keywords":"Medicine; Cancer research","score_opus":0.019090535158918856,"score_gpt":0.32822564717479075,"score_spread":0.3091351120158719,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3195519455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9324292,0.040360235,0.007213967,0.0065946924,0.001638344,0.0013501716,0.00005521964,0.000037398804,0.010320792],"genre_scores_gemma":[0.9441322,0.022153527,0.0040691462,0.0052711093,0.001485843,0.000027317137,0.000023514473,0.00017835881,0.022658996],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997739,0.00017395646,0.0005727162,0.00024647862,0.00079567207,0.00047215624],"domain_scores_gemma":[0.99651825,0.00019243645,0.0006500471,0.0003124453,0.0021568635,0.00016996653],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006070456,0.00024118269,0.0006007682,0.00025743456,0.00014712471,0.000083184495,0.00023384138,0.00017246137,0.0012287457],"category_scores_gemma":[0.000065230146,0.000204577,0.00067232054,0.00044231972,0.00010811025,0.00013591928,0.000022809176,0.0006670063,0.000009979553],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006066801,0.0004281861,0.0002887374,0.00002685453,0.001699186,0.00034852955,0.0013053162,0.00008677077,0.8801858,0.000022429685,0.001231959,0.10830943],"study_design_scores_gemma":[0.015481732,0.0048332857,0.003614572,0.00015638268,0.00031800987,0.0027743252,0.0016614251,0.00020242436,0.9137691,0.00064062525,0.056270853,0.00027721885],"about_ca_topic_score_codex":0.00011736725,"about_ca_topic_score_gemma":0.000012267889,"teacher_disagreement_score":0.10803221,"about_ca_system_score_codex":0.00087692315,"about_ca_system_score_gemma":0.0025385327,"threshold_uncertainty_score":0.9996843},"labels":[],"label_agreement":null},{"id":"W3195992586","doi":"10.1038/s41467-021-25245-8","title":"DL4-μbeads induce T cell lineage differentiation from stem cells in a stromal cell-free system","year":2021,"lang":"en","type":"article","venue":"Nature Communications","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":94,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre; Sunnybrook Hospital; University of Toronto","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Canada First Research Excellence Fund; National Heart, Lung, and Blood Institute; Krembil Foundation; University of Toronto; National Institutes of Health; Government of Canada; Ontario Institute for Regenerative Medicine; Stem Cell Network","keywords":"Biology; Cell biology; Stem cell; Progenitor cell; Stromal cell; CD34; Haematopoiesis; Cellular differentiation; Immunology; T cell; Immune system; Cancer research","score_opus":0.03241476712848236,"score_gpt":0.3110137377167796,"score_spread":0.27859897058829725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3195992586","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9681754,0.01076998,0.00010816471,0.0022527606,0.00034124844,0.0007507532,0.00027699777,0.0001467298,0.01717796],"genre_scores_gemma":[0.9902013,0.0007526282,0.002823089,0.00020262014,0.00015575039,0.000085041196,0.0007866756,0.000054738153,0.0049381405],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976807,0.0005561961,0.00048162637,0.00039982572,0.0005459998,0.00033562433],"domain_scores_gemma":[0.9941944,0.0006510318,0.00014676242,0.004465738,0.0003695613,0.00017252745],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00030837324,0.00022002036,0.0004141302,0.00022444586,0.00016682576,0.000079254176,0.0011891224,0.00059700006,0.0010803818],"category_scores_gemma":[0.000059212372,0.00022252797,0.0001608141,0.0007819997,0.00007533991,0.000099410914,0.0008000598,0.0026104916,0.000057396785],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010499552,0.0012286048,0.009291475,0.0001772048,0.00007032227,0.00005442128,0.0008812959,0.000008130783,0.98342764,0.0005855729,0.0029618745,0.0012084604],"study_design_scores_gemma":[0.0064374297,0.00014451412,0.04605191,0.00042084497,0.00020187761,0.000022842354,0.0033076485,0.0038584091,0.9085533,0.000035113422,0.030533284,0.00043282183],"about_ca_topic_score_codex":0.00019285639,"about_ca_topic_score_gemma":0.0010379357,"teacher_disagreement_score":0.074874334,"about_ca_system_score_codex":0.0004470352,"about_ca_system_score_gemma":0.00033289907,"threshold_uncertainty_score":0.99983275},"labels":[],"label_agreement":null},{"id":"W3197049258","doi":"10.1182/bloodadvances.2020003534","title":"Targeting pediatric leukemia-propagating cells with anti-CD200 antibody therapy","year":2021,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trillium Therapeutics (Canada)","funders":"University of Oxford; University of Bristol; National Institute for Health and Care Research","keywords":"CD19; Minimal residual disease; CD34; Medicine; Leukemia; Immunology; Cancer research; Transplantation; Stem cell; Antigen; Oncology; Internal medicine; Biology","score_opus":0.01476344073809838,"score_gpt":0.3032942440092108,"score_spread":0.2885308032711124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197049258","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9709721,0.023102691,0.00014420912,0.00019937758,0.00016805268,0.00041272596,0.000006971878,0.00013097582,0.0048628678],"genre_scores_gemma":[0.9462808,0.034351893,0.011122001,0.00041496876,0.0017714058,0.00003331635,0.00008452959,0.00011532765,0.005825752],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978205,0.00009730504,0.00031358065,0.0005434518,0.0006530341,0.00057211553],"domain_scores_gemma":[0.99881524,0.00019126492,0.00012891326,0.00039501177,0.0002981493,0.00017142594],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00029839895,0.00024851895,0.0004371494,0.00011589176,0.00018174529,0.00006474006,0.0001467864,0.000076913544,0.0012367402],"category_scores_gemma":[0.000096477306,0.00018884102,0.0000988659,0.00078876794,0.00008428046,0.00021775738,0.000058066078,0.00040944596,0.000041184056],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013541033,0.0002441418,0.10660603,0.00018714527,0.000093974486,0.0005673089,0.0001609635,0.00025637695,0.8794266,0.00001017627,0.000085662105,0.012226185],"study_design_scores_gemma":[0.0048760367,0.0006708011,0.004967663,0.00012166257,0.00011759485,0.00023461551,0.00067384844,0.00017976118,0.9642752,0.000032729433,0.0234774,0.00037272822],"about_ca_topic_score_codex":0.000018918274,"about_ca_topic_score_gemma":0.000004404858,"teacher_disagreement_score":0.10163837,"about_ca_system_score_codex":0.000051168812,"about_ca_system_score_gemma":0.0005304905,"threshold_uncertainty_score":0.9996763},"labels":[],"label_agreement":null},{"id":"W3197223132","doi":"10.1186/s13045-021-01144-9","title":"Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma","year":2021,"lang":"en","type":"article","venue":"Journal of Hematology & Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada); Princess Margaret Cancer Centre","funders":"Bristol-Myers Squibb","keywords":"Medicine; Odds ratio; Internal medicine; Hazard ratio; Oncology; Confidence interval; Surgery","score_opus":0.07529656742620855,"score_gpt":0.4012486531152399,"score_spread":0.32595208568903133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197223132","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98579115,0.005235145,0.000026679058,0.001670333,0.0010404453,0.0003212502,0.000008586143,0.000017492057,0.005888932],"genre_scores_gemma":[0.99389845,0.0011507506,0.0015784509,0.00020809757,0.00016364286,0.000014728796,0.000017563323,0.00004907686,0.0029192155],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9960372,0.00094063167,0.0015818056,0.0003337395,0.00047198572,0.00063467596],"domain_scores_gemma":[0.9956439,0.0021100221,0.0010591652,0.00044500566,0.00046866597,0.0002731985],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00091276685,0.00029121846,0.0024750554,0.0006915795,0.00006584482,0.000008023474,0.0002439739,0.00066375616,0.0023151548],"category_scores_gemma":[0.00037938743,0.0002245435,0.000384175,0.0005499016,0.00019583819,0.000067641544,0.00010669979,0.00079466327,0.000036495563],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15628749,0.0959655,0.14325686,0.0012558127,0.0040773414,0.08125877,0.02649646,0.000073489595,0.40073836,0.00087125326,0.012128428,0.077590264],"study_design_scores_gemma":[0.24881932,0.062652424,0.022088943,0.00068894017,0.0013815971,0.024240874,0.023450091,0.00030001425,0.395127,0.00026843592,0.22032529,0.0006570682],"about_ca_topic_score_codex":0.00009435361,"about_ca_topic_score_gemma":0.0016414354,"teacher_disagreement_score":0.20819686,"about_ca_system_score_codex":0.0015011893,"about_ca_system_score_gemma":0.0032397672,"threshold_uncertainty_score":0.99859685},"labels":[],"label_agreement":null},{"id":"W3197432291","doi":"10.1016/j.jcpo.2021.100303","title":"Experiences and perspectives of individuals accessing CAR-T cell therapy: A qualitative analysis of online Reddit discussions","year":2021,"lang":"en","type":"article","venue":"Journal of Cancer Policy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia, Okanagan Campus; Canadian Centre for Applied Research in Cancer Control; British Columbia Centre of Excellence for Women's Health","funders":"Michael Smith Health Research BC","keywords":"Chimeric antigen receptor; Qualitative research; Inclusion (mineral); Medicine; Social media; Family medicine; Cancer; Psychology; Social psychology; Sociology; Immunotherapy; Internal medicine; World Wide Web; Computer science","score_opus":0.08440601087932618,"score_gpt":0.4918759082904122,"score_spread":0.407469897411086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197432291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97430897,0.019524839,0.00002337857,0.005409498,0.00003342818,0.00007929572,0.000105803476,0.0000022267993,0.0005125357],"genre_scores_gemma":[0.9877895,0.010059236,0.000649756,0.000106961226,0.00032285292,0.00000551866,0.00000438942,0.000012682769,0.0010491115],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.99815637,0.00029332607,0.0005725293,0.00014927956,0.0006527052,0.00017576605],"domain_scores_gemma":[0.99797523,0.0002857229,0.00061676,0.00018208433,0.0007820741,0.00015813687],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004641196,0.00011464069,0.0007593389,0.00084601244,0.00004743848,0.000022791723,0.00012982932,0.000055788954,0.0015339492],"category_scores_gemma":[0.000295645,0.000074227915,0.00031101156,0.0018391159,0.00031221393,0.00014696034,0.00005433053,0.00024169356,5.772711e-8],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045582908,0.0005551565,0.016020795,0.00007645882,0.0031421902,0.000021845772,0.6438108,0.000046179128,0.30159387,0.000065003995,0.00017427283,0.0340376],"study_design_scores_gemma":[0.0023530643,0.0006536552,0.10167916,0.00032039444,0.0008908911,0.000025399628,0.7409134,0.000059572994,0.15146624,0.00019637699,0.0013150617,0.00012680118],"about_ca_topic_score_codex":0.0007864804,"about_ca_topic_score_gemma":0.00013911372,"teacher_disagreement_score":0.15012762,"about_ca_system_score_codex":0.00013622227,"about_ca_system_score_gemma":0.0013163863,"threshold_uncertainty_score":0.9993788},"labels":[],"label_agreement":null},{"id":"W3197920680","doi":"10.1016/j.jcpo.2021.100304","title":"Health-related quality of life data collected in chimeric antigen receptor T-cell (CAR-T) therapy clinical trials","year":2021,"lang":"en","type":"article","venue":"Journal of Cancer Policy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Spinal Cord Injury BC; University of British Columbia; Canadian Centre for Applied Research in Cancer Control; Simon Fraser University","funders":"Janssen Pharmaceuticals; Michael Smith Health Research BC; Teva Pharmaceutical Industries; Roche","keywords":"Chimeric antigen receptor; Clinical trial; Cell therapy; Medicine; Quality of life (healthcare); Receptor; Immunology; Immunotherapy; Cell; Biology; Internal medicine; Immune system; Nursing; Genetics","score_opus":0.40261342603305206,"score_gpt":0.5768524217763609,"score_spread":0.1742389957433088,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197920680","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93889946,0.032314695,0.000012613138,0.026644459,0.00053910055,0.00052855624,0.00014741033,0.000009290852,0.00090443715],"genre_scores_gemma":[0.78852385,0.19948088,0.0006557705,0.0039943475,0.0032148843,0.000008664403,0.00007400815,0.00007254577,0.0039750184],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.98952967,0.004490784,0.004365452,0.0003051041,0.00089525647,0.00041375926],"domain_scores_gemma":[0.99376786,0.001560961,0.0025269971,0.0008429832,0.0007465111,0.00055466365],"candidate_categories":["metaresearch","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.01434034,0.00018033826,0.0025602295,0.00047369377,0.000042417934,0.000022720813,0.00045650726,0.00020330743,0.00435678],"category_scores_gemma":[0.008360287,0.0001415313,0.00044854992,0.0019263824,0.00014714597,0.00011791834,0.000109953464,0.0009966381,0.0000061909955],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02382969,0.003062345,0.20367599,0.00038286528,0.002424612,0.00007893593,0.0017811558,0.00003113617,0.40018293,0.000049875438,0.074871965,0.2896285],"study_design_scores_gemma":[0.05690513,0.0030956916,0.75119656,0.0008426436,0.000099754325,0.000097854085,0.0005242417,0.00017247428,0.02811269,0.00017649312,0.15837833,0.00039810073],"about_ca_topic_score_codex":0.008816536,"about_ca_topic_score_gemma":0.0007595627,"teacher_disagreement_score":0.5475206,"about_ca_system_score_codex":0.00041004777,"about_ca_system_score_gemma":0.019698255,"threshold_uncertainty_score":0.9999927},"labels":[],"label_agreement":null},{"id":"W3198124923","doi":"10.1182/bloodadvances.2020003848","title":"Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma","year":2021,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":83,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Queen's University","funders":"","keywords":"Medicine; Refractory (planetary science); Internal medicine; Lymphoma; Oncology; Fludarabine; Chemotherapy; Survival rate; Surgery; Cyclophosphamide","score_opus":0.015949554239113296,"score_gpt":0.32829919814359676,"score_spread":0.31234964390448344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3198124923","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98405224,0.007704128,0.000020719976,0.00028639153,0.000096132426,0.0003631575,0.000023165774,0.00004299131,0.007411092],"genre_scores_gemma":[0.9887173,0.0015866528,0.0017752947,0.0003116673,0.00007707355,0.000020291072,0.00002719008,0.000059207512,0.00742531],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99802077,0.00009770619,0.00041360114,0.00041362483,0.0006042869,0.0004500217],"domain_scores_gemma":[0.9988019,0.00019946869,0.0001511775,0.0005585694,0.00015885831,0.00013001997],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00021893629,0.00023128308,0.00082164246,0.00014631602,0.00004018285,0.00001579341,0.00016466186,0.00010387871,0.0010087239],"category_scores_gemma":[0.000034435885,0.00018555784,0.00012791077,0.00043863585,0.00011211308,0.00012630889,0.000048499867,0.00023430212,0.000022389278],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010225822,0.006045181,0.60500985,0.0003888153,0.00015187942,0.00025301948,0.0011052536,0.0000122719575,0.37864444,0.000033976485,0.00018394107,0.0071487757],"study_design_scores_gemma":[0.021467749,0.00094398274,0.0646338,0.00016783449,0.00006602813,0.00001351743,0.0018382049,0.00002628141,0.82068217,0.00001640688,0.08991213,0.00023189248],"about_ca_topic_score_codex":0.00003579727,"about_ca_topic_score_gemma":0.00020087723,"teacher_disagreement_score":0.54037607,"about_ca_system_score_codex":0.00007033727,"about_ca_system_score_gemma":0.00025348653,"threshold_uncertainty_score":0.9999045},"labels":[],"label_agreement":null},{"id":"W3198342545","doi":"10.1101/2021.08.30.21262835","title":"Combined PD-L1 and TIM-3 blockade improves the expansion of fit human CD8+ antigen-specific T cells for adoptive immunotherapy","year":2021,"lang":"en","type":"preprint","venue":"medRxiv","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Centre; Centre Hospitalier Universitaire Sainte-Justine; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Antigen; Cytotoxic T cell; Biology; Immune system; T cell; Antigen-presenting cell; Cancer immunotherapy; CD8; Immunotherapy; Immunology; Cancer research; Streptamer; Cell biology; In vitro","score_opus":0.05006156664017174,"score_gpt":0.3238584902247554,"score_spread":0.27379692358458363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3198342545","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875136,0.00753207,0.00020462673,0.00075326284,0.00048373936,0.0029582286,0.000054509732,0.00005281259,0.00044712872],"genre_scores_gemma":[0.98048645,0.011880299,0.0010151722,0.00012602238,0.00038320327,0.00027047706,0.00014056181,0.0001426747,0.0055551236],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99717724,0.0002163105,0.0006656479,0.0008107347,0.00064774544,0.00048230038],"domain_scores_gemma":[0.99710107,0.0004262654,0.00032547006,0.001500489,0.00050444406,0.00014226153],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009855318,0.00045432372,0.0010230172,0.00021171953,0.00020375993,0.00009644369,0.0004731959,0.00040130655,0.0010213046],"category_scores_gemma":[0.00004903622,0.00033153585,0.0004513703,0.0002168044,0.0004587619,0.000039672348,0.00046882272,0.00097379286,0.000004750489],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012371319,0.0002525558,0.0014708473,0.00043677035,0.00045305354,0.000027167767,0.0025484604,0.0000072875832,0.9840468,0.000039190116,0.00046350903,0.00901719],"study_design_scores_gemma":[0.004258503,0.0011620237,0.04162228,0.0006557641,0.00008081024,0.000015689158,0.0011099195,0.00030198047,0.9343117,0.00029801106,0.015776027,0.00040729457],"about_ca_topic_score_codex":0.00010769048,"about_ca_topic_score_gemma":0.0000102568265,"teacher_disagreement_score":0.049735144,"about_ca_system_score_codex":0.00009053151,"about_ca_system_score_gemma":0.00025279442,"threshold_uncertainty_score":0.9999137},"labels":[],"label_agreement":null},{"id":"W3199446885","doi":"10.1158/2326-6066.cir-21-0519","title":"Supporting the Next Generation of Scientists to Lead Cancer Immunology Research","year":2021,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"National Cancer Institute; National Institutes of Health","keywords":"Engineering ethics; Field (mathematics); Cancer immunotherapy; Publishing; Political science; Immunology; Medicine; Immunotherapy; Engineering; Immune system","score_opus":0.3417155636439009,"score_gpt":0.5241351132805301,"score_spread":0.1824195496366292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3199446885","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9260556,0.037591133,0.000030097308,0.03020634,0.0009513747,0.0013822366,0.000032449116,0.000036320085,0.0037144455],"genre_scores_gemma":[0.89935136,0.010883424,0.00017263961,0.00041961132,0.00095601665,0.0013908225,0.000058190737,0.000087441185,0.08668049],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99153906,0.0024706328,0.00072703423,0.0010199741,0.0020036546,0.0022396385],"domain_scores_gemma":[0.99087644,0.0011039063,0.00010956455,0.0017609413,0.0059380867,0.00021108393],"candidate_categories":["sts","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.008331576,0.00022998505,0.00062530604,0.0010951194,0.001012021,0.0001456593,0.001020493,0.00037525425,0.014244776],"category_scores_gemma":[0.0027211993,0.00018450171,0.00017246333,0.0044787093,0.002930552,0.00016096998,0.0013069321,0.0029779153,0.0003181683],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007870575,0.00017116508,0.0054348377,0.000088569075,0.00041896245,0.0001403712,0.0016920291,0.000017294695,0.882949,0.0006197063,0.017925788,0.08975521],"study_design_scores_gemma":[0.0016147078,0.00080855837,0.017194213,0.00022883287,0.000027047969,0.00016636628,0.0031976635,0.0003067875,0.83515257,0.00020946219,0.14090464,0.00018917007],"about_ca_topic_score_codex":0.0047701686,"about_ca_topic_score_gemma":0.002571042,"teacher_disagreement_score":0.122978844,"about_ca_system_score_codex":0.0012893053,"about_ca_system_score_gemma":0.005392414,"threshold_uncertainty_score":0.9997829},"labels":[],"label_agreement":null},{"id":"W3199514812","doi":"10.1007/s00262-021-03051-x","title":"The pivotal role of cytotoxic NK cells in mediating the therapeutic effect of anti-CD47 therapy in mycosis fungoides","year":2021,"lang":"en","type":"article","venue":"Cancer Immunology Immunotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trillium Therapeutics (Canada)","funders":"Drs Martin and Dorothy Spatz Charitable Foundation","keywords":"CD47; Cytotoxic T cell; Cancer research; Mycosis fungoides; Immunotherapy; Immunology; Cutaneous T-cell lymphoma; Lymphoma; Medicine; Antibody; Biology; Immune system; In vitro","score_opus":0.015303673055613896,"score_gpt":0.30924680586576947,"score_spread":0.29394313281015555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3199514812","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7997505,0.1976477,0.0000029262303,0.00096986245,0.00031959504,0.0010245467,0.00001326871,0.000020296042,0.00025126783],"genre_scores_gemma":[0.85859215,0.14019652,0.000013781752,0.00028496463,0.00006623467,0.00039131084,0.000007850972,0.000074148375,0.00037306617],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99605304,0.001346376,0.00094054325,0.00043942413,0.00047305075,0.0007475956],"domain_scores_gemma":[0.99578536,0.0023976339,0.0003557555,0.0012012792,0.00022305161,0.000036901663],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001784249,0.00037634536,0.0010396807,0.00027324556,0.00015318031,0.000027196673,0.00066922366,0.00028879195,0.0008969684],"category_scores_gemma":[0.000108516244,0.00022669943,0.0003545902,0.0012478681,0.0009003985,0.00008335631,0.00009736419,0.000971179,0.000006919166],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027045493,0.0001898822,0.052455533,0.00004094512,0.0006673057,0.000012671541,0.0021445719,0.00003170998,0.7392764,0.00004851251,0.0000072849616,0.2024206],"study_design_scores_gemma":[0.0067703165,0.0011383647,0.124359846,0.00019212985,0.000024304121,0.000028659111,0.0010836694,0.00008698053,0.8627333,0.00014077491,0.003272391,0.00016925679],"about_ca_topic_score_codex":0.001127573,"about_ca_topic_score_gemma":0.0002588613,"teacher_disagreement_score":0.20225134,"about_ca_system_score_codex":0.0002829684,"about_ca_system_score_gemma":0.00057942234,"threshold_uncertainty_score":0.98211753},"labels":[],"label_agreement":null},{"id":"W3200299117","doi":"10.1038/s41598-021-97739-w","title":"In vivo generation of collagen specific Tregs with AAV8 suppresses autoimmune responses and arthritis in DBA1 mice through IL10 production","year":2021,"lang":"en","type":"article","venue":"Scientific Reports","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Université Laval","keywords":"Immunology; Immune system; Arthritis; Epitope; Autoimmune disease; Medicine; Adeno-associated virus; T cell; Antibody; Biology; Vector (molecular biology); Recombinant DNA","score_opus":0.040079469435824765,"score_gpt":0.30136350408658213,"score_spread":0.2612840346507574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3200299117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99202883,0.0038671282,0.000012649647,0.0011194841,0.0013255503,0.0006229598,0.0000031704658,0.00002164733,0.000998578],"genre_scores_gemma":[0.9571932,0.00083481823,0.0012123879,0.000018557617,0.00011928549,0.000040486968,0.000034329292,0.00002560634,0.04052134],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976365,0.00016454759,0.00056675856,0.0007690353,0.00061683514,0.00024632303],"domain_scores_gemma":[0.9986625,0.0000533203,0.00016076301,0.0007119751,0.0003621615,0.000049295882],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014542794,0.0001200042,0.00033394207,0.00029872337,0.00008725126,0.000104245395,0.00004037948,0.000067922905,0.0010552966],"category_scores_gemma":[0.00036664383,0.00010888879,0.000034886827,0.0013205691,0.00036655672,0.0002798486,0.000045173038,0.00011204418,0.000002190683],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036594836,0.00021375399,0.008450097,0.00007178172,0.000013815613,0.0026286,0.0020628062,0.0000437885,0.97802156,0.000012996684,0.005853778,0.0022610435],"study_design_scores_gemma":[0.0007361919,0.00010966456,0.009218874,0.00026824398,0.0000083984705,0.0021891247,0.0007423071,0.000036126978,0.92475814,0.00021365273,0.06161377,0.00010548992],"about_ca_topic_score_codex":0.00020175408,"about_ca_topic_score_gemma":0.0017030757,"teacher_disagreement_score":0.055759992,"about_ca_system_score_codex":0.000096935415,"about_ca_system_score_gemma":0.0005227159,"threshold_uncertainty_score":0.9998579},"labels":[],"label_agreement":null},{"id":"W3200480347","doi":"10.1158/2643-3230.bcd-20-0208","title":"NOT-Gated CD93 CAR T Cells Effectively Target AML with Minimized Endothelial Cross-Reactivity","year":2021,"lang":"en","type":"article","venue":"Blood Cancer Discovery","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":91,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"National Cancer Institute; National Institutes of Health; Parker Institute for Cancer Immunotherapy; Entertainment Industry Foundation; Cancer Research Institute; Burroughs Wellcome Fund; Stanford Maternal and Child Health Research Institute; American Association for Cancer Research","keywords":"Haematopoiesis; Progenitor cell; Proinflammatory cytokine; Cancer research; CD34; Endothelial stem cell; Stem cell; Bone marrow; Myeloid; Immunology; Biology; In vitro; Cell biology; Inflammation","score_opus":0.016251784645069246,"score_gpt":0.3011283694173624,"score_spread":0.2848765847722931,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3200480347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99262184,0.00079679565,0.00020655792,0.00041675504,0.00044464017,0.0009068228,0.0006349438,0.000101585996,0.0038700472],"genre_scores_gemma":[0.96325064,0.00044091296,0.0004809038,0.00058540894,0.0007835646,0.00022153324,0.00009433526,0.0001215949,0.034021094],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99700445,0.00023347301,0.00030028346,0.00084520155,0.0008964175,0.00072017434],"domain_scores_gemma":[0.99821895,0.0003293617,0.00012978411,0.0007128783,0.00033290315,0.00027610234],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00029190205,0.00038748237,0.0007917842,0.000110876084,0.00013674947,0.00020401846,0.00017257116,0.00017505295,0.0023943933],"category_scores_gemma":[0.000091314374,0.0003145029,0.00028834838,0.00047405405,0.00028386252,0.000395641,0.00011913636,0.0005820015,0.000042479587],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008557337,0.0008173629,0.022575436,0.00024469887,0.0009929335,0.00093926874,0.00028787163,0.00010597805,0.962678,0.000011502389,0.000405681,0.0023839392],"study_design_scores_gemma":[0.015430751,0.0005501407,0.018785374,0.00021183533,0.00039193293,0.00011651239,0.00006402778,0.00007699644,0.95239586,0.00001564677,0.01159977,0.00036117286],"about_ca_topic_score_codex":0.0015287383,"about_ca_topic_score_gemma":0.00035777985,"teacher_disagreement_score":0.030151049,"about_ca_system_score_codex":0.00029822087,"about_ca_system_score_gemma":0.0017075749,"threshold_uncertainty_score":0.9999307},"labels":[],"label_agreement":null},{"id":"W3201000277","doi":"10.1016/j.isci.2021.103295","title":"Effective chimeric antigen receptor T cells against SARS-CoV-2","year":2021,"lang":"en","type":"article","venue":"iScience","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Canadian Institutes of Health Research","keywords":"Perforin; Chimeric antigen receptor; Granzyme B; Antigen; Cytolysis; Biology; Granzyme; Virology; Cell biology; Receptor; Cytotoxic T cell; Chemistry; Molecular biology; Immune system; In vitro; T cell; Immunology; CD8; Biochemistry","score_opus":0.029966945812853685,"score_gpt":0.3397855715107883,"score_spread":0.3098186256979346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201000277","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9640681,0.0006702805,0.00017980966,0.00065065105,0.00042178913,0.00039242953,0.000005364317,0.00005367527,0.033557896],"genre_scores_gemma":[0.9846522,0.0005119877,0.0014718092,0.0018267254,0.00024050949,0.000029576582,0.000008906371,0.00002528054,0.011233012],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983624,0.00009553071,0.0001344627,0.00045396134,0.00054855156,0.00040510105],"domain_scores_gemma":[0.9991409,0.00011085735,0.000034962482,0.00043836568,0.00016530344,0.00010956791],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00038443218,0.000117837466,0.0002166379,0.00009025719,0.00011897275,0.000050496114,0.00019028645,0.000052595915,0.0008287027],"category_scores_gemma":[0.00016904388,0.00010100986,0.00009508853,0.0010435209,0.0002750138,0.000100474186,0.000117181226,0.00022687235,0.00079596054],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003359884,0.00008464481,0.0010995344,0.0000168904,0.000014079751,0.00009283814,0.00033822135,0.0000020846066,0.91635215,0.000011503101,0.0026546798,0.079299785],"study_design_scores_gemma":[0.00042259626,0.00014190222,0.0058434214,0.00004538652,0.00000506231,0.000026471744,0.000082620594,0.00020533765,0.90382195,0.000015730006,0.089286804,0.000102704194],"about_ca_topic_score_codex":0.000032420965,"about_ca_topic_score_gemma":0.00000840195,"teacher_disagreement_score":0.086632125,"about_ca_system_score_codex":0.000111166104,"about_ca_system_score_gemma":0.0002904174,"threshold_uncertainty_score":0.99998206},"labels":[],"label_agreement":null},{"id":"W3201013983","doi":"10.1016/s1470-2045(21)00375-2","title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","year":2021,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":561,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont; McMaster University","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Clinical endpoint; Internal medicine; Refractory (planetary science); Cytokine release syndrome; Oncology; Hematopoietic stem cell transplantation; Chimeric antigen receptor; Cohort; Transplantation; Clinical trial; Immunotherapy; Cancer; Biology","score_opus":0.14921257768924856,"score_gpt":0.4590593045005727,"score_spread":0.30984672681132414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201013983","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99253666,0.0002697322,0.000003830933,0.00080118596,0.0003061876,0.0025534676,0.000026896809,0.000028975648,0.0034730316],"genre_scores_gemma":[0.99158174,0.00027298374,0.000530128,0.0013588159,0.00017112056,0.00009773017,0.00006430573,0.0000589181,0.005864256],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957583,0.0016267352,0.00087204034,0.000587235,0.0005590272,0.0005966816],"domain_scores_gemma":[0.9957576,0.0018789989,0.00062302215,0.0011732865,0.00037771024,0.0001894112],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012935429,0.00026962528,0.0016318429,0.00010605504,0.00007406018,0.000030099676,0.00064883503,0.00021939029,0.0019453489],"category_scores_gemma":[0.0010012623,0.0001586251,0.000078771336,0.0004687956,0.00035494828,0.00009412426,0.0005129078,0.00072814734,0.000046637546],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047956515,0.09310974,0.7945369,0.0000778922,0.0005311684,0.003028312,0.0016450561,8.913502e-7,0.0019229373,0.0000026545806,0.00069998216,0.056487966],"study_design_scores_gemma":[0.24618,0.03607895,0.71283954,0.00015527393,0.00029011743,0.00003778403,0.00064855604,0.00002352672,0.0008902606,0.0000069189914,0.002641767,0.00020729087],"about_ca_topic_score_codex":0.00007880131,"about_ca_topic_score_gemma":0.000992425,"teacher_disagreement_score":0.19822349,"about_ca_system_score_codex":0.0004286454,"about_ca_system_score_gemma":0.0010294421,"threshold_uncertainty_score":0.998967},"labels":[],"label_agreement":null},{"id":"W3201609934","doi":"10.1182/blood.2022019117","title":"Outcomes of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; National Heart, Lung, and Blood Institute; Agence Nationale de la Recherche","keywords":"Wiskott–Aldrich syndrome protein; Autoimmunity; Immunology; Wiskott–Aldrich syndrome; Genetic enhancement; Stem cell; Transplantation; Fludarabine; Hematopoietic stem cell transplantation; Biology; Medicine; Immune system; Cyclophosphamide; Internal medicine; Cell; Gene; Actin cytoskeleton; Cell biology; Genetics","score_opus":0.0410312759080021,"score_gpt":0.3152371416997443,"score_spread":0.2742058657917422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3201609934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957948,0.0007728857,0.000027409676,0.00055894034,0.00010261279,0.0011484177,0.00003012031,0.00013431582,0.0014304989],"genre_scores_gemma":[0.96999604,0.0004353816,0.00032726873,0.00011899137,0.000058566155,0.00015056125,0.000028704708,0.00007051914,0.02881397],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99852264,0.000036908623,0.00030884496,0.000276811,0.00045628267,0.0003985364],"domain_scores_gemma":[0.9988715,0.00027095093,0.00007159467,0.00053994276,0.00011897443,0.00012705794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038752245,0.00016163394,0.00051219075,0.00021347038,0.00004575735,0.000011403968,0.00017965531,0.000098907316,0.0004871836],"category_scores_gemma":[0.000016888293,0.00012839712,0.00024017974,0.0004898805,0.000056861023,0.000028297713,0.000049375532,0.00012314072,0.00011977401],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044316193,0.0020453196,0.095012926,0.0008242035,0.00087242073,0.00029383186,0.0012730749,0.0000052929945,0.8905676,0.00011233069,0.0018366921,0.0067131617],"study_design_scores_gemma":[0.015632745,0.0019825639,0.10286403,0.000059989452,0.00018247348,0.00023008532,0.00035337755,0.000059333586,0.8736824,0.0003495455,0.0043444885,0.00025897007],"about_ca_topic_score_codex":0.000014336508,"about_ca_topic_score_gemma":0.0000014284582,"teacher_disagreement_score":0.02738347,"about_ca_system_score_codex":0.000019712685,"about_ca_system_score_gemma":0.00009721788,"threshold_uncertainty_score":0.5334319},"labels":[],"label_agreement":null},{"id":"W3202055454","doi":"10.3390/ijms221910828","title":"Improving CAR T-Cell Persistence","year":2021,"lang":"en","type":"review","venue":"International Journal of Molecular Sciences","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":111,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"","keywords":"T cell; Chimeric antigen receptor; Adoptive cell transfer; Medicine; Persistence (discontinuity); Mechanism (biology); Immunotherapy; Immunology; Bioinformatics; Cancer research; Biology; Immune system","score_opus":0.08065189329571965,"score_gpt":0.3996040435973274,"score_spread":0.31895215030160773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202055454","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00031106724,0.99379855,0.00038305455,0.00023951998,0.0009620071,0.00014466968,0.000005143596,0.0000047578183,0.004151244],"genre_scores_gemma":[0.00029398483,0.9953285,0.002282968,0.00014144585,0.00043550204,0.0000031077434,0.000005577221,0.000020382971,0.0014885238],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965227,0.0001583389,0.0006477628,0.00028657162,0.0021596677,0.00022493741],"domain_scores_gemma":[0.9978776,0.00014010166,0.00064662105,0.00018069756,0.000984907,0.00017007277],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011081448,0.00019810823,0.0008614788,0.0006048424,0.00005223807,0.00019871927,0.0011325311,0.000117236836,0.00073530973],"category_scores_gemma":[0.00031111191,0.00014359123,0.0010499409,0.00042010893,0.0002542026,0.00012402634,0.00018007043,0.00058800285,0.00001643559],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009429556,0.00007975637,0.000006428717,0.00062425015,0.00030530503,0.0032194443,0.000053244057,0.0000055629466,0.0041168844,0.00005097693,0.000112227426,0.9914165],"study_design_scores_gemma":[0.00038726316,0.00035403183,9.686305e-7,0.008015322,0.00040878425,0.00693618,0.00019429448,0.000033826826,0.0013949813,0.00001483934,0.9820834,0.00017610898],"about_ca_topic_score_codex":0.0000135242935,"about_ca_topic_score_gemma":6.9623957e-7,"teacher_disagreement_score":0.9912404,"about_ca_system_score_codex":0.00029932937,"about_ca_system_score_gemma":0.0026714634,"threshold_uncertainty_score":0.80511254},"labels":[],"label_agreement":null},{"id":"W3202152517","doi":"10.1111/bjh.17845","title":"Guidelines: the same evidence but different conclusions — relaxation of indications for irradiation of cellular blood components?","year":2021,"lang":"en","type":"letter","venue":"British Journal of Haematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Transplantation; Stem cell; Total body irradiation; Fludarabine; Hematology; Internal medicine; Graft-versus-host disease; Surgery; Chemotherapy","score_opus":0.10102457520370553,"score_gpt":0.35122052373425006,"score_spread":0.2501959485305445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202152517","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5427571,0.03508281,0.004537012,0.41528052,0.00069961627,0.0013749753,0.00021178309,0.000009639076,0.00004653992],"genre_scores_gemma":[0.790095,0.052935988,0.008325709,0.13092892,0.007436211,0.00029491005,0.0026634922,0.00034056715,0.006979238],"study_design_codex":"not_applicable","study_design_gemma":"case_report","domain_scores_codex":[0.99600697,0.00056666357,0.0020217565,0.00023992459,0.0008852806,0.0002794202],"domain_scores_gemma":[0.9921551,0.0020912024,0.002497667,0.00043190716,0.0027411832,0.00008299265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000982931,0.00019424183,0.0014052071,0.0003483049,0.00012718767,0.00002487128,0.00045436868,0.0005598285,0.00064894714],"category_scores_gemma":[0.0036937061,0.00016652724,0.000561847,0.00022868489,0.0003496833,0.00007682699,0.000110585825,0.0014389667,0.0000015077824],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004037712,0.0007658248,0.0020806293,0.003212453,0.0026743526,0.010150028,0.00059728936,0.000020029764,0.28365856,0.00022760709,0.68921936,0.0069900877],"study_design_scores_gemma":[0.018843861,0.005057988,0.020376662,0.048046693,0.012777415,0.4749801,0.0017049625,0.0010678915,0.10486841,0.004513827,0.30648515,0.0012770635],"about_ca_topic_score_codex":0.00021752063,"about_ca_topic_score_gemma":0.000036503196,"teacher_disagreement_score":0.46483004,"about_ca_system_score_codex":0.00009571645,"about_ca_system_score_gemma":0.000652976,"threshold_uncertainty_score":0.7105516},"labels":[],"label_agreement":null},{"id":"W3202237143","doi":"10.1016/j.annonc.2021.08.878","title":"1548P A phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist BI 907828 in patients (pts) with advanced/metastatic sarcoma","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Antagonist; Sarcoma; Oncology; Internal medicine; Phases of clinical research; Pharmacology; Chemotherapy; Pathology; Receptor","score_opus":0.07771101551057516,"score_gpt":0.43856233399941363,"score_spread":0.36085131848883845,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3202237143","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99490356,0.00020752849,0.000008608105,0.0019195152,0.00010761396,0.0012246375,0.000022743121,0.000009709408,0.0015960676],"genre_scores_gemma":[0.9983941,0.00013845519,0.00021730326,0.00046897723,0.000027703281,0.000046047004,0.000033563447,0.000026693155,0.00064719556],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9975787,0.0005186908,0.0006056945,0.00033680655,0.00062430155,0.000335799],"domain_scores_gemma":[0.9980264,0.0002984032,0.0002773955,0.0006018949,0.0006922904,0.00010364101],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005041815,0.00016493414,0.00067377684,0.00020588093,0.000060036804,0.0000065017134,0.00017981157,0.00007706031,0.00049292535],"category_scores_gemma":[0.00027160504,0.00011358199,0.000102649254,0.0008612058,0.00022427639,0.000081869264,0.00012886687,0.00031761313,0.0000059787435],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012780625,0.043515608,0.36916083,0.00027652676,0.00046854373,0.00041639953,0.0052593597,0.00016294571,0.07539924,0.0000442112,0.0010840998,0.4914316],"study_design_scores_gemma":[0.063324615,0.06485461,0.80275875,0.00038143588,0.00017709578,0.00006572784,0.0055873124,0.00024306352,0.051529348,0.00023139134,0.010573389,0.00027323107],"about_ca_topic_score_codex":0.00017814526,"about_ca_topic_score_gemma":0.00070124073,"teacher_disagreement_score":0.49115837,"about_ca_system_score_codex":0.00008413925,"about_ca_system_score_gemma":0.00056694495,"threshold_uncertainty_score":0.5397187},"labels":[],"label_agreement":null},{"id":"W3203163864","doi":"10.1016/j.annonc.2021.08.1062","title":"540P Safety and efficacy from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating a CD8α co-receptor and an affinity optimized TCR targeting MAGE-A4","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; T-cell receptor; Spear; CD8; Receptor; Oncology; Pharmacology; Immunology; Internal medicine; T cell; Antigen; Immune system","score_opus":0.09642382633896207,"score_gpt":0.39833374095669943,"score_spread":0.30190991461773736,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203163864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98638093,0.0016972551,0.00006262672,0.0064453315,0.00011340052,0.0011445559,0.00008534321,0.000036613998,0.0040339343],"genre_scores_gemma":[0.97692037,0.0063378187,0.0117254285,0.0023882815,0.0011986569,0.000048220016,0.00041722035,0.000091890804,0.0008721273],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9967276,0.0013149097,0.0005721418,0.00054535485,0.00041130802,0.00042872492],"domain_scores_gemma":[0.99615103,0.002324479,0.00035018474,0.00047049538,0.00043804027,0.0002657902],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0021961338,0.00026120897,0.0009503215,0.000075597265,0.00020330763,0.00005565251,0.00017708873,0.00023470842,0.0016644789],"category_scores_gemma":[0.0005649242,0.00017774233,0.00011184843,0.00027924124,0.0005288154,0.000114677416,0.0001273603,0.0006108596,0.0000092476475],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3887689,0.0035099252,0.010893378,0.00008271369,0.0010367262,0.0004609965,0.0063182754,0.000059535134,0.40833563,0.00006241792,0.0063243294,0.17414719],"study_design_scores_gemma":[0.49230954,0.054579925,0.023561796,0.00035334914,0.00038275798,0.00021440545,0.0096581,0.0013558731,0.18902655,0.0003296486,0.22702402,0.0012040309],"about_ca_topic_score_codex":0.00050839386,"about_ca_topic_score_gemma":0.00016956122,"teacher_disagreement_score":0.2206997,"about_ca_system_score_codex":0.000038279868,"about_ca_system_score_gemma":0.00075103977,"threshold_uncertainty_score":0.99924815},"labels":[],"label_agreement":null},{"id":"W3203462303","doi":"10.1038/s41434-021-00295-1","title":"Long-term safety and efficacy of intramyocardial adenovirus-mediated VEGF-DΔNΔC gene therapy eight-year follow-up of phase I KAT301 study","year":2021,"lang":"en","type":"article","venue":"Gene Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Kuopion Yliopistollinen Sairaala","keywords":"Mace; Medicine; Hazard ratio; Internal medicine; Adverse effect; Genetic enhancement; Angina; Confidence interval; Incidence (geometry); Randomized controlled trial; Surgery; Myocardial infarction; Percutaneous coronary intervention; Biology","score_opus":0.03771391769886721,"score_gpt":0.33723897960194077,"score_spread":0.29952506190307354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203462303","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98330414,0.013561641,0.000069980495,0.00024330753,0.00038554636,0.0019473365,0.00012632615,0.00006352863,0.00029821048],"genre_scores_gemma":[0.97087324,0.026879504,0.00020816067,0.00025585265,0.0005567876,0.00004249085,0.00025693214,0.0001236669,0.00080338045],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99620545,0.00050589506,0.00088959554,0.0007339562,0.0010656852,0.00059942744],"domain_scores_gemma":[0.9973339,0.00035665644,0.00024467334,0.0012074517,0.00052227563,0.00033505977],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008826444,0.00043930797,0.0012839419,0.00029144323,0.00010674481,0.000033877783,0.0003093178,0.00022601035,0.0033686387],"category_scores_gemma":[0.000096148055,0.00037673747,0.0003781005,0.00084339,0.00030563504,0.00008394848,0.00011062182,0.0004346684,0.000021971007],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02683783,0.0036450431,0.027299155,0.000038014157,0.0018776223,0.0002157722,0.0028685827,0.0000022262288,0.7741221,0.000004843387,0.00007835336,0.16301045],"study_design_scores_gemma":[0.09605642,0.006920038,0.1642643,0.00005556542,0.00013839596,0.00007702523,0.0003005777,0.000015918606,0.72968215,0.000019280596,0.0021171581,0.00035315327],"about_ca_topic_score_codex":0.000052953226,"about_ca_topic_score_gemma":0.000022937522,"teacher_disagreement_score":0.1626573,"about_ca_system_score_codex":0.00009678001,"about_ca_system_score_gemma":0.00051832513,"threshold_uncertainty_score":0.99986845},"labels":[],"label_agreement":null},{"id":"W3204177860","doi":"10.1111/bjh.17673","title":"Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma","year":2021,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":121,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University of British Columbia","funders":"Gilead Sciences","keywords":"Medicine; Cytokine release syndrome; Tocilizumab; Adverse effect; Internal medicine; Corticosteroid; Lymphoma; Gastroenterology; Surgery; Oncology; Chimeric antigen receptor; Cancer; Immunotherapy; Rheumatoid arthritis","score_opus":0.02358306920221175,"score_gpt":0.29881096608573343,"score_spread":0.27522789688352167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3204177860","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945989,0.001091868,0.0023581777,0.00029187105,0.00044066776,0.00093866035,0.000041427662,0.000007692113,0.00023069051],"genre_scores_gemma":[0.98810875,0.0012497024,0.0055372776,0.00063413597,0.00009541067,0.00006638968,0.000051690582,0.000055629625,0.0042010136],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99783814,0.00013236945,0.00085771194,0.00026903927,0.0003587347,0.0005440249],"domain_scores_gemma":[0.9984425,0.00023026418,0.0002917884,0.0002126987,0.00062809134,0.00019466989],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000612439,0.00013845107,0.00067515264,0.00021653752,0.000072911505,0.000038906674,0.00014059979,0.00012549099,0.00034979105],"category_scores_gemma":[0.00040837034,0.00016247372,0.00031996623,0.00016592312,0.00003490188,0.00014316567,0.00009854413,0.00017996566,0.000006633758],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012539557,0.021407943,0.17436637,0.0040274686,0.00201835,0.14053823,0.0010275742,0.00004975593,0.018086784,0.000394761,0.041635416,0.5839078],"study_design_scores_gemma":[0.16727798,0.0030316461,0.5523684,0.0030652555,0.00072802335,0.06824176,0.0014726645,0.0006374526,0.023608042,0.00063735375,0.17813711,0.00079433736],"about_ca_topic_score_codex":0.000010635985,"about_ca_topic_score_gemma":0.00009951318,"teacher_disagreement_score":0.58311343,"about_ca_system_score_codex":0.00021622163,"about_ca_system_score_gemma":0.0001700006,"threshold_uncertainty_score":0.6625486},"labels":[],"label_agreement":null},{"id":"W3206372141","doi":"10.1016/j.ejca.2021.09.016","title":"Contemporary dose-escalation methods for early phase studies in the immunotherapeutics era","year":2021,"lang":"en","type":"review","venue":"European Journal of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Public Health Ontario; University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"Bristol-Myers Squibb Canada; Astellas Pharma Canada; International Studies Association; Novartis; Celgene; Bayer; AstraZeneca; Amgen; Pfizer; Meso Scale Diagnostics; AbbVie; Merck","keywords":"Maximum tolerated dose; Medicine; Clinical trial; Therapeutic window; Intensive care medicine; Medical physics; Computer science; Pharmacology; Internal medicine","score_opus":0.4579977353478128,"score_gpt":0.597604700362081,"score_spread":0.13960696501426823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3206372141","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000037503294,0.9947623,0.0009935809,0.0005384839,0.0006593621,0.0010042985,0.00001377482,0.000005388504,0.0019853134],"genre_scores_gemma":[0.00003764611,0.99232334,0.0031229095,0.00035025808,0.0014647904,0.000034148743,0.000010715242,0.00011139845,0.0025447733],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99406856,0.0038144207,0.0012463939,0.00019491106,0.00044789922,0.00022781515],"domain_scores_gemma":[0.9968919,0.0011590755,0.0008546776,0.00035673307,0.00066491135,0.00007267442],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00718415,0.00028426579,0.0017645743,0.00029221844,0.00005872762,0.000064003376,0.0003600279,0.000060521492,0.00022467643],"category_scores_gemma":[0.0003179109,0.00016213588,0.00085441396,0.0004303982,0.00012453509,0.000081814935,0.000043794123,0.0011766152,0.0000037009413],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034210095,0.00012896601,0.000004916047,0.0025469433,0.0016226352,0.00035220716,0.0015782521,5.488916e-7,0.0001081411,0.000005836184,0.0029690785,0.99034035],"study_design_scores_gemma":[0.0035094428,0.0009395927,0.000031091076,0.015373161,0.0008476641,0.0002521904,0.0002803322,0.0000025665636,0.000016542845,0.000007886241,0.9786022,0.00013737599],"about_ca_topic_score_codex":0.0000038634894,"about_ca_topic_score_gemma":8.378171e-7,"teacher_disagreement_score":0.990203,"about_ca_system_score_codex":0.00027856923,"about_ca_system_score_gemma":0.0010085541,"threshold_uncertainty_score":0.6611709},"labels":[],"label_agreement":null},{"id":"W3206590901","doi":"10.1007/s00262-021-03073-5","title":"Molecular imaging of cellular immunotherapies in experimental and therapeutic settings","year":2021,"lang":"en","type":"review","venue":"Cancer Immunology Immunotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Robarts Clinical Trials; Western University","funders":"","keywords":"Immune system; Ex vivo; Medicine; Cancer; Biodistribution; Immunotherapy; Cancer research; Bioinformatics; In vivo; Immunology; Biology; Internal medicine","score_opus":0.03297253149538901,"score_gpt":0.37100936070885276,"score_spread":0.3380368292134638,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3206590901","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0077756015,0.9895344,0.000030535542,0.00024226823,0.0003853031,0.0017088887,0.000024128074,0.00006180877,0.00023706316],"genre_scores_gemma":[0.0014398652,0.9961093,0.000106252635,0.00047768277,0.00006903439,0.00074878486,0.000082631705,0.00032100017,0.00064544234],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99573046,0.00068499485,0.0013616504,0.000966085,0.000409672,0.0008471617],"domain_scores_gemma":[0.9976242,0.00025708912,0.0005697947,0.0013001153,0.00017443404,0.000074360934],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00055013003,0.0009104102,0.0038921968,0.00087913603,0.00009055621,0.000054136228,0.00052221405,0.0006132279,0.003199618],"category_scores_gemma":[0.000020691454,0.0008338822,0.00086317386,0.00085250684,0.0009503566,0.00008002853,0.00019524738,0.0013658011,0.000009067236],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023097721,0.00021649658,0.000100368525,0.0017907048,0.002034127,0.00016051676,0.00080456043,2.5508777e-7,0.34025154,0.00009314854,0.000014774634,0.65430254],"study_design_scores_gemma":[0.004077715,0.00033674057,0.00006748669,0.013505464,0.00034903092,0.00042386493,0.0006286302,0.000006334068,0.054598648,0.000030180203,0.92524415,0.000731743],"about_ca_topic_score_codex":0.000238624,"about_ca_topic_score_gemma":0.0000023339985,"teacher_disagreement_score":0.9252294,"about_ca_system_score_codex":0.0006869912,"about_ca_system_score_gemma":0.0010536915,"threshold_uncertainty_score":0.9994112},"labels":[],"label_agreement":null},{"id":"W3206790308","doi":"10.3390/cancers13205039","title":"Enhancing Therapeutic Efficacy of Double Negative T Cells against Acute Myeloid Leukemia Using Idelalisib","year":2021,"lang":"en","type":"article","venue":"Cancers","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital; University of Toronto; University Health Network","funders":"Canadian Cancer Society; Leukemia and Lymphoma Society","keywords":"Idelalisib; Myeloid leukemia; Cancer research; Haematopoiesis; Transplantation; Myeloid; Hematopoietic stem cell transplantation; Leukemia; Medicine; Stem cell; Chemistry; Immunology; Biology; Internal medicine; Cell biology; Ibrutinib; Chronic lymphocytic leukemia","score_opus":0.04518843191315285,"score_gpt":0.3454976100233685,"score_spread":0.3003091781102156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3206790308","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98963827,0.0011790874,0.00044555147,0.000119522374,0.00036514274,0.00043143524,0.000013020444,0.000038213784,0.0077697607],"genre_scores_gemma":[0.99096376,0.0009928981,0.0011722634,0.00078068103,0.00028821777,0.000015564336,0.00002023967,0.0000645818,0.005701781],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983394,0.00006936532,0.00033909106,0.0003697042,0.00045648566,0.000425913],"domain_scores_gemma":[0.9987228,0.00017608773,0.00012104261,0.0004824981,0.0003219575,0.00017561953],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00021867825,0.00018616668,0.00045290816,0.0001140288,0.00008139711,0.000025183768,0.00013257362,0.000109552995,0.0014730694],"category_scores_gemma":[0.000031051757,0.00017832023,0.00019625625,0.0006207962,0.00017386662,0.00008718103,0.00006664432,0.00034798388,0.000018314555],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00081880385,0.00001656416,0.00008976447,0.00009287118,0.00047749883,0.00011470824,0.0015531913,0.0026833538,0.9857569,0.00003197516,0.0001208299,0.008243579],"study_design_scores_gemma":[0.0044722874,0.00011147515,0.00020178397,0.00026625046,0.00016769006,0.000021902506,0.0009220663,0.0016628894,0.9889231,0.000025909249,0.0030638794,0.00016076984],"about_ca_topic_score_codex":0.000602436,"about_ca_topic_score_gemma":0.00008843166,"teacher_disagreement_score":0.00808281,"about_ca_system_score_codex":0.0036989239,"about_ca_system_score_gemma":0.004319381,"threshold_uncertainty_score":0.9994397},"labels":[],"label_agreement":null},{"id":"W3208468707","doi":"10.1182/blood-2021-146200","title":"Ciltacabtagene Autoleucel for Triple-Class Exposed Multiple Myeloma: Adjusted Comparisons of CARTITUDE-1 Patient Outcomes Versus Therapies from Real-World Clinical Practice from the LocoMMotion Prospective Study","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Multiple myeloma; Internal medicine; Clinical trial; Clinical endpoint; Oncology; Lenalidomide","score_opus":0.11321306732251128,"score_gpt":0.3950350964076225,"score_spread":0.2818220290851112,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3208468707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99037194,0.0008109085,0.00013651681,0.0021352111,0.0007003354,0.004294099,0.00036291717,0.00009765533,0.001090437],"genre_scores_gemma":[0.99405366,0.000106631924,0.0038396283,0.00022321526,0.00031744043,0.0004417109,0.00028546163,0.00006219505,0.00067004864],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99599904,0.0009536492,0.0010508709,0.0006928721,0.00092257507,0.00038098544],"domain_scores_gemma":[0.98831505,0.008943069,0.00045805128,0.0011662786,0.00095441897,0.00016312503],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008022668,0.00030465313,0.0010137326,0.000077992176,0.00019336236,0.0000553969,0.00026955284,0.00014380249,0.00038130203],"category_scores_gemma":[0.003052885,0.00022118892,0.00040638496,0.0004506317,0.00016773523,0.00011638271,0.00018935103,0.0005648651,0.000012355364],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011189193,0.018229129,0.91517526,0.000024395613,0.0062877648,0.00010056857,0.007565045,0.0000096096055,0.032357763,0.00005523624,0.0016120417,0.007394005],"study_design_scores_gemma":[0.051917247,0.003050129,0.8804463,0.00006010917,0.0017563498,0.0000022819793,0.016967015,0.00031706254,0.038525607,0.000028963053,0.0067116152,0.0002172777],"about_ca_topic_score_codex":0.003008413,"about_ca_topic_score_gemma":0.0093678655,"teacher_disagreement_score":0.040728055,"about_ca_system_score_codex":0.00014110486,"about_ca_system_score_gemma":0.0004148798,"threshold_uncertainty_score":0.90198225},"labels":[],"label_agreement":null},{"id":"W3208635967","doi":"10.1016/j.htct.2021.10.331","title":"EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135), A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA","year":2021,"lang":"en","type":"article","venue":"Hematology Transfusion and Cell Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Institute of Cancer Research; McGill University Health Centre; University of Calgary","funders":"","keywords":"Medicine; Cytokine release syndrome; Common Terminology Criteria for Adverse Events; Adverse effect; Multiple myeloma; Neutropenia; Internal medicine; Gastroenterology; Oncology; Toxicity; Chimeric antigen receptor; Immunology; Immunotherapy; Cancer","score_opus":0.014867424124680827,"score_gpt":0.2713815356584001,"score_spread":0.2565141115337193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3208635967","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99382734,0.0034682455,0.0001552612,0.0003411021,0.00007759455,0.0011760703,0.000016096856,0.000036189245,0.0009020814],"genre_scores_gemma":[0.9652419,0.033032894,0.0004978055,0.00015843581,0.000019063102,0.000015873862,0.00017317774,0.000051233248,0.00080963364],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99788845,0.00025847592,0.0005317077,0.0005846795,0.0003758429,0.00036081907],"domain_scores_gemma":[0.99878037,0.00032115277,0.00011590718,0.00042659225,0.00019612722,0.00015987385],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00024850617,0.00028395702,0.00074735493,0.00026077728,0.00011946508,0.000018127006,0.00008543296,0.00029559262,0.0015618991],"category_scores_gemma":[0.000021416852,0.00020625177,0.000073440984,0.00047980584,0.00023914747,0.000098289864,0.000024245475,0.00042690968,0.000004847299],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.067554265,0.0030269353,0.25332126,0.00044698507,0.00010302392,0.00027637545,0.0024624814,0.0000015736224,0.64068645,0.00004134764,0.00007163975,0.032007672],"study_design_scores_gemma":[0.078011,0.0029948528,0.59652245,0.000382405,0.000043440417,0.00017313889,0.0008103923,0.00013321007,0.3110132,0.00001744095,0.00950253,0.0003959662],"about_ca_topic_score_codex":0.00004807178,"about_ca_topic_score_gemma":0.00013703798,"teacher_disagreement_score":0.3432012,"about_ca_system_score_codex":0.00003315217,"about_ca_system_score_gemma":0.00016898586,"threshold_uncertainty_score":0.9993508},"labels":[],"label_agreement":null},{"id":"W3208814858","doi":"10.1182/blood-2021-148039","title":"Primary Analysis of ZUMA-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Medicine; Refractory (planetary science); Internal medicine; Oncology; Lymphoma; Biology","score_opus":0.015746695104493107,"score_gpt":0.293887349007926,"score_spread":0.2781406539034329,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3208814858","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99194777,0.0030300056,0.000028000568,0.000017318753,0.000106957385,0.0016462326,0.00034768812,0.000015449452,0.0028606022],"genre_scores_gemma":[0.99754226,0.0010964322,0.00034072067,0.000026896068,0.00004554066,0.00006131666,0.00054595416,0.000046424295,0.00029448266],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9964548,0.000544812,0.00093281653,0.00042497125,0.0012948192,0.00034780137],"domain_scores_gemma":[0.9970913,0.0006221112,0.00045880498,0.00083467545,0.00085913937,0.00013400333],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008832052,0.00025447796,0.0022484777,0.00064623426,0.000029175755,0.000008435667,0.00017564674,0.00017136773,0.0010380979],"category_scores_gemma":[0.00026340567,0.00020030436,0.0007166506,0.0015560773,0.00018555281,0.00006292709,0.000066895234,0.00019466547,0.0000010717482],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9223468,0.027783189,0.004142367,0.000244383,0.0048539834,0.00006534527,0.0012048855,0.0000036171864,0.029363127,0.0000069515168,0.000012986067,0.009972388],"study_design_scores_gemma":[0.851414,0.012311822,0.0016050375,0.00009703243,0.0024511677,4.6508177e-7,0.00026334793,0.000013539349,0.13136865,0.0000026146479,0.0003262276,0.00014606773],"about_ca_topic_score_codex":0.000050170867,"about_ca_topic_score_gemma":0.00004672341,"teacher_disagreement_score":0.10200553,"about_ca_system_score_codex":0.00015279517,"about_ca_system_score_gemma":0.0010228031,"threshold_uncertainty_score":0.99987507},"labels":[],"label_agreement":null},{"id":"W3209556083","doi":"10.1503/cmaj.202907-f","title":"Innovations en immunothérapie anticancéreuse: thérapie par lymphocytes T porteurs de récepteurs antigéniques chimériques (cellules CAR-T)","year":2021,"lang":"fr","type":"letter","venue":"Canadian Medical Association Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute; University of Manitoba; British Columbia Institute of Technology","funders":"","keywords":"Medicine; Molecular biology; Biology","score_opus":0.012899327291608498,"score_gpt":0.27415624710980874,"score_spread":0.26125691981820026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3209556083","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.11280759,0.029736016,0.00043699678,0.832462,0.008114691,0.0010563341,0.0006889774,0.00016935979,0.014528045],"genre_scores_gemma":[0.056038957,0.13334176,0.003039952,0.62017673,0.10944966,0.00019368375,0.0030256482,0.00093878177,0.07379481],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9831544,0.0035487022,0.0025571936,0.0010242682,0.005842944,0.003872504],"domain_scores_gemma":[0.986644,0.0031412498,0.0012951707,0.00091136806,0.00348328,0.004524923],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0096879555,0.0010956471,0.0020027743,0.0018164895,0.0011706846,0.000993075,0.0015118605,0.0055403886,0.09458257],"category_scores_gemma":[0.015121153,0.001162368,0.0009689449,0.0019879253,0.00070216146,0.00043913155,0.00016915536,0.013659301,0.00046706785],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00004902318,0.00022526507,0.0843254,0.00028981172,0.0034448248,0.023529159,0.0025318207,0.000005462198,0.0043413527,0.00039271105,0.82700205,0.05386314],"study_design_scores_gemma":[0.0030776123,0.00029168543,0.029274337,0.0025487468,0.0004629927,0.005782032,0.0016258282,0.0003080378,0.0018140299,0.00049779046,0.9532815,0.0010354053],"about_ca_topic_score_codex":0.020070335,"about_ca_topic_score_gemma":0.02593894,"teacher_disagreement_score":0.21228525,"about_ca_system_score_codex":0.020774914,"about_ca_system_score_gemma":0.06365152,"threshold_uncertainty_score":0.9990826},"labels":[],"label_agreement":null},{"id":"W3210549609","doi":"10.1182/blood-2021-146060","title":"Updated Results from CARTITUDE-1: Phase 1b/2Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Patients With Relapsed/Refractory Multiple Myeloma","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Chimeric antigen receptor; Antigen; Medicine; Multiple myeloma; Immunology; Refractory (planetary science); Immunotherapy; Cancer research; Biology; Immune system","score_opus":0.014589790550367214,"score_gpt":0.25885141836574355,"score_spread":0.24426162781537633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3210549609","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951598,0.0012398261,0.0000074516174,0.00006794328,0.00016832603,0.0015662317,0.00046284057,0.00015306043,0.0011745398],"genre_scores_gemma":[0.99185264,0.0008199868,0.0017372356,0.00007245917,0.00011799161,0.000042060226,0.004002135,0.00010428524,0.0012511915],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99635535,0.000400749,0.0008654362,0.0008688383,0.00096441427,0.00054521003],"domain_scores_gemma":[0.9975428,0.00018486188,0.0003834548,0.0010061137,0.00065167464,0.0002310917],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003093533,0.00040071816,0.00076867425,0.00029957754,0.00009695485,0.000042094664,0.0002267849,0.00024831147,0.0011874613],"category_scores_gemma":[0.0001474936,0.00034955816,0.00013622342,0.0012638603,0.000100041594,0.0001767967,0.000088071305,0.0005338151,0.000048438425],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0114879925,0.024460651,0.13505508,0.000040591083,0.00033032332,0.0001349313,0.0018026995,0.000007864643,0.8222407,1.2824258e-7,0.00052797113,0.0039110663],"study_design_scores_gemma":[0.087663524,0.002183835,0.31882977,0.00010464759,0.00006922202,0.000002230066,0.00015672867,0.0001356892,0.5882228,9.688538e-7,0.0023590706,0.00027147832],"about_ca_topic_score_codex":0.0006267193,"about_ca_topic_score_gemma":0.00017592454,"teacher_disagreement_score":0.23401786,"about_ca_system_score_codex":0.000104790786,"about_ca_system_score_gemma":0.000492756,"threshold_uncertainty_score":0.99989563},"labels":[],"label_agreement":null},{"id":"W3210901280","doi":"10.1016/j.xpro.2021.100920","title":"In vitro evaluation of CAR-T cells in patient-derived glioblastoma models","year":2021,"lang":"en","type":"article","venue":"STAR Protocols","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Canadian Institutes of Health Research; Terry Fox Research Institute; McMaster University","keywords":"Chimeric antigen receptor; Glioblastoma; In vitro; Cancer research; Immunotherapy; Protocol (science); Cytotoxicity; Medicine; Cancer; Biology; Pathology; Internal medicine","score_opus":0.06394935725016467,"score_gpt":0.37811261911016775,"score_spread":0.3141632618600031,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3210901280","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9011197,0.00002815686,0.00002047226,0.00014586365,0.000023505134,0.09705912,0.000019528285,0.000011147223,0.0015724945],"genre_scores_gemma":[0.8881029,0.000004115789,0.0007300087,0.000093154275,0.000035985257,0.11076607,0.00001581146,0.000030850908,0.00022112983],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975031,0.00042070547,0.00043782,0.00030538297,0.0010287883,0.00030421297],"domain_scores_gemma":[0.9988219,0.000059808404,0.00008206115,0.00043304957,0.00052128546,0.000081876555],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00093343225,0.00012557158,0.00035271276,0.00024036919,0.0000136003955,0.000011774813,0.000081545484,0.00009892967,0.001668593],"category_scores_gemma":[0.000121292396,0.00012463245,0.00007660505,0.00057453185,0.000047755897,0.00012716047,0.00007053877,0.0002550829,0.000013279255],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021163474,0.00040956106,0.00010878973,0.00017278537,0.000017308392,0.00009980556,0.0014568303,0.00051289954,0.9758854,0.00001258205,0.00006951646,0.019138174],"study_design_scores_gemma":[0.0058398233,0.00048169075,0.0002850792,0.00025339948,0.000010756301,0.0000087830485,0.00037395832,0.013222113,0.9776666,0.0009758667,0.0007835132,0.0000984149],"about_ca_topic_score_codex":0.000121391226,"about_ca_topic_score_gemma":0.00018343051,"teacher_disagreement_score":0.01903976,"about_ca_system_score_codex":0.0003705855,"about_ca_system_score_gemma":0.00078027206,"threshold_uncertainty_score":0.99924403},"labels":[],"label_agreement":null},{"id":"W3211360047","doi":"10.1182/blood-2021-153166","title":"Preliminary Safety and Efficacy of PBCAR0191, an Allogeneic 'Off-the-Shelf' CD19-Directed CAR-T for Patients with Relapsed/Refractory (R/R) CD19+ B-ALL","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Fludarabine; Population; Internal medicine; Cyclophosphamide; Refractory (planetary science); CAR T-cell therapy; Immunology; Gastroenterology; T cell; Chemotherapy; Chimeric antigen receptor; Biology; Immune system","score_opus":0.017393008910047605,"score_gpt":0.2749539471231319,"score_spread":0.25756093821308434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211360047","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951488,0.0021155642,0.000016213295,0.0002561744,0.00009103043,0.0014814893,0.00009799806,0.00008405418,0.00070868596],"genre_scores_gemma":[0.99416363,0.00063613255,0.0014502362,0.00021568904,0.00017720823,0.000077264376,0.0005282989,0.000103826926,0.0026477128],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9978689,0.00019166677,0.00039867844,0.00053992704,0.0005579769,0.000442826],"domain_scores_gemma":[0.9977774,0.0004789271,0.00013644285,0.0008441038,0.000507357,0.0002557755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003278831,0.0002539186,0.00050331815,0.000102744896,0.00012039731,0.000021412405,0.00017766011,0.00017056536,0.00022101859],"category_scores_gemma":[0.00032133807,0.00018522814,0.0001348852,0.00029325634,0.00018975988,0.00008690973,0.000108947876,0.00030566467,0.0000029083142],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040893633,0.021603929,0.25300968,0.0011984269,0.0040045474,0.0003326063,0.0049776575,0.000023768134,0.5404658,0.00010563389,0.0011642092,0.1322201],"study_design_scores_gemma":[0.05631778,0.015238303,0.8129189,0.0003288173,0.0018135834,0.00016570018,0.0003282237,0.00014918504,0.07317662,0.000043516273,0.038949095,0.0005702767],"about_ca_topic_score_codex":0.000037163885,"about_ca_topic_score_gemma":0.000044699824,"teacher_disagreement_score":0.5599092,"about_ca_system_score_codex":0.000052577758,"about_ca_system_score_gemma":0.00030929776,"threshold_uncertainty_score":0.75533843},"labels":[],"label_agreement":null},{"id":"W3211480515","doi":"10.1182/blood-2021-148709","title":"<i>In Vivo</i> Delivery of a CD20 CAR Using a CD8-Targeted Fusosome in Southern Pig-Tail Macaques (<i>M. nemestrina</i>) Results in B Cell Depletion","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biology; CD8; Ex vivo; In vivo; Chimeric antigen receptor; Gene delivery; T cell; Immunology; Transduction (biophysics); B cell; Cell biology; Genetic enhancement; Molecular biology; Antigen; Immune system; Antibody; Biochemistry","score_opus":0.02224595986032634,"score_gpt":0.27137122919723045,"score_spread":0.2491252693369041,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211480515","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947587,0.0018539145,0.0000038419776,0.00027764126,0.000054135948,0.0004935456,0.00006700845,0.0000253119,0.0024658802],"genre_scores_gemma":[0.99676555,0.0004284846,0.0006660163,0.00017376067,0.00010841046,0.000021501353,0.00003566617,0.00004983497,0.0017507952],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997534,0.00028854387,0.0006909228,0.0004895722,0.00048524162,0.00051176734],"domain_scores_gemma":[0.9989882,0.00014694704,0.00011964752,0.0004675733,0.0001608364,0.00011675957],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005226695,0.00020927905,0.00053545006,0.00048667268,0.000021546386,0.000017203103,0.00013603066,0.00020034098,0.00034253713],"category_scores_gemma":[0.0001522118,0.00022439974,0.00012140655,0.0011836062,0.000064207685,0.000093442875,0.00010166613,0.0004829036,0.000014269923],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010446194,0.0013282349,0.07790306,0.00021204352,0.000028606493,0.0016406203,0.0021735206,0.00006074212,0.91527057,0.0000038934436,0.000050025308,0.00028409017],"study_design_scores_gemma":[0.025867142,0.00041153526,0.009407092,0.0007022154,0.00008452427,0.00013643755,0.0025912295,0.00067032996,0.9587189,0.00009901687,0.0009822107,0.00032939634],"about_ca_topic_score_codex":0.006455986,"about_ca_topic_score_gemma":0.0036871487,"teacher_disagreement_score":0.06849597,"about_ca_system_score_codex":0.00016611899,"about_ca_system_score_gemma":0.00050815346,"threshold_uncertainty_score":0.97595626},"labels":[],"label_agreement":null},{"id":"W3211621704","doi":"10.1182/blood-2021-146393","title":"Real-World Outcomes for Pediatric and Young Adult Patients with Relapsed or Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (ALL) Treated with Tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Cytokine release syndrome; Single Center; Clinical trial; Refractory (planetary science); Hematopoietic stem cell transplantation; Oncology; Pediatrics; Immunotherapy; Transplantation; Chimeric antigen receptor","score_opus":0.0201699544481447,"score_gpt":0.2896246359916098,"score_spread":0.26945468154346514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211621704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950242,0.00017571542,0.00003153255,0.0005543951,0.00012293374,0.0016152684,0.0018661615,0.000047990987,0.0005617964],"genre_scores_gemma":[0.9797805,0.002682773,0.0017837115,0.00026796083,0.00039451072,0.00037422494,0.002214779,0.00013635764,0.0123652],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997374,0.00013920254,0.00037023667,0.00073962647,0.00081071915,0.00056620344],"domain_scores_gemma":[0.9968675,0.0010463198,0.00013348674,0.00054743415,0.0011602014,0.000245063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003194261,0.00030862784,0.0004399505,0.00018283086,0.00021342357,0.00012708559,0.00023262975,0.00013727654,0.00015848296],"category_scores_gemma":[0.0002456113,0.00018095257,0.000086779444,0.0003302635,0.00017598426,0.00012130034,0.00007387865,0.00038841192,0.0000026547689],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014308786,0.0014293247,0.97181463,0.00024278075,0.00173592,0.00035036303,0.0005042157,4.4340055e-7,0.007248244,0.000014699813,0.001800767,0.0005498097],"study_design_scores_gemma":[0.18357106,0.0054750443,0.7735795,0.0006282557,0.00588995,0.0002247313,0.0004035908,0.00021056789,0.023811923,0.00006304908,0.0053312015,0.00081113575],"about_ca_topic_score_codex":0.0004492428,"about_ca_topic_score_gemma":0.0018342269,"teacher_disagreement_score":0.19823515,"about_ca_system_score_codex":0.00015233258,"about_ca_system_score_gemma":0.0005124752,"threshold_uncertainty_score":0.7379032},"labels":[],"label_agreement":null},{"id":"W3211778366","doi":"10.1182/blood-2021-149049","title":"Diffuse Large B-Cell Lymphoma (DLBCL) Patients with Late Relapses Who Are Transplant-Eligible Have Excellent Outcomes and May Represent Unique Biology","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; Spinal Cord Injury BC","funders":"","keywords":"Medicine; Internal medicine; Salvage therapy; Oncology; Lymphoma; Population; Diffuse large B-cell lymphoma; Transplantation; Cancer; Chemotherapy","score_opus":0.014850131788839791,"score_gpt":0.2707231962552273,"score_spread":0.25587306446638747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211778366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99296814,0.0013956232,0.000028127932,0.0008758775,0.00006349477,0.0005677225,0.00013379403,0.000065932705,0.003901259],"genre_scores_gemma":[0.9739213,0.0026108548,0.00017495119,0.00038886647,0.000049777926,0.000046801873,0.00017861222,0.00006013657,0.022568682],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980887,0.00017455316,0.00029782124,0.00059377693,0.00030574013,0.00053937244],"domain_scores_gemma":[0.99863476,0.000169041,0.000089760135,0.00064788124,0.00018994007,0.0002686063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001706816,0.00026710855,0.00059058715,0.00013084878,0.000104419654,0.000034367262,0.0001133515,0.00017990258,0.00029912102],"category_scores_gemma":[0.000040073075,0.00019546156,0.00011324369,0.00016250872,0.000105851366,0.000048785787,0.000108368105,0.00021611828,0.000017518421],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005045853,0.010153548,0.9797643,0.00021173041,0.00033104123,0.00068836927,0.0006280982,2.9159946e-7,0.006564247,0.000051945273,0.00024349157,0.00085836445],"study_design_scores_gemma":[0.1531808,0.0015647782,0.58904773,0.00062630884,0.0006480442,0.0001844255,0.000485393,0.000046937002,0.22673553,0.00020268504,0.026590312,0.0006870782],"about_ca_topic_score_codex":0.0001315153,"about_ca_topic_score_gemma":0.00019558672,"teacher_disagreement_score":0.39071658,"about_ca_system_score_codex":0.000040066552,"about_ca_system_score_gemma":0.0001272679,"threshold_uncertainty_score":0.7970691},"labels":[],"label_agreement":null},{"id":"W3211920496","doi":"10.1016/s2152-2650(21)02092-9","title":"OAB-018: A BCL2L1 armoured BCMA-targeting CAR T cells to overcome exhaustion and enhance persistence in multiple myeloma","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Chimeric antigen receptor; CD28; TIGIT; T cell; CAR T-cell therapy; CD19; Cancer research; Biology; Immunology; Cell biology; Antigen; Medicine; Immune system","score_opus":0.05083502320690806,"score_gpt":0.34308830516624084,"score_spread":0.29225328195933276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211920496","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944144,0.0012286849,0.00013655523,0.0012494337,0.00058830215,0.0008455741,0.000022317743,0.00012827381,0.001386487],"genre_scores_gemma":[0.9852969,0.0007455145,0.004339693,0.0018136441,0.00076712883,0.00008128577,0.00006231568,0.00009983021,0.006793677],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9946033,0.000507167,0.001434727,0.0015247856,0.0008585193,0.0010715397],"domain_scores_gemma":[0.99543494,0.0019674571,0.00021159621,0.0009907403,0.00042991256,0.0009653315],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017740616,0.00047344575,0.0011853194,0.00025518765,0.00019493747,0.00011235586,0.00034288075,0.0005688348,0.0008214122],"category_scores_gemma":[0.004097317,0.00048568405,0.00041820618,0.0010409789,0.00037839773,0.0001940308,0.00045971342,0.00073036185,0.00033926687],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018873105,0.00036983666,0.07355593,0.0002308901,0.00011588274,0.0017544301,0.0010357106,0.000040564217,0.5942529,0.00002055249,0.0015925091,0.32514346],"study_design_scores_gemma":[0.005743489,0.0006334628,0.8556371,0.00055968534,0.00007881848,0.00022345426,0.0009896934,0.0028379168,0.1161997,0.0000658971,0.01646373,0.0005670804],"about_ca_topic_score_codex":0.00020803191,"about_ca_topic_score_gemma":0.00017282135,"teacher_disagreement_score":0.7820811,"about_ca_system_score_codex":0.0016258276,"about_ca_system_score_gemma":0.0014070022,"threshold_uncertainty_score":0.9997595},"labels":[],"label_agreement":null},{"id":"W3211997738","doi":"10.1182/blood-2021-147937","title":"Subcutaneous (SC) Administration of Mosunetuzumab with Cycle 1 Step-up Dosing Is Tolerable and Active in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphomas (R/R B-NHL): Initial Results from a Phase I/II Study","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Roche (Canada); BC Cancer Agency; Jewish General Hospital","funders":"","keywords":"Tolerability; Dosing; Medicine; Pharmacokinetics; Refractory (planetary science); Internal medicine; Neutropenia; Cytokine release syndrome; Gastroenterology; Toxicity; Adverse effect; Pharmacology; Immunotherapy; Cancer","score_opus":0.013300032276117554,"score_gpt":0.2837511359260015,"score_spread":0.27045110364988395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211997738","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958874,0.00009816197,0.0000104352775,0.0000420094,0.000048392376,0.0011927796,0.0002895372,0.00002313156,0.002408176],"genre_scores_gemma":[0.9983506,0.000022469614,0.0004324139,0.000047422815,0.000064583044,0.000031770636,0.0002914294,0.00005370117,0.0007055878],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975939,0.00016182294,0.0004889387,0.00064802566,0.0007646196,0.00034269827],"domain_scores_gemma":[0.998519,0.00021045584,0.00022473725,0.0005460715,0.00032650382,0.00017325596],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017562055,0.0002652371,0.0005404584,0.0001570693,0.00010790545,0.000042059568,0.000092260874,0.0001299678,0.00024477055],"category_scores_gemma":[0.000060618866,0.00022634197,0.000043269614,0.00043599305,0.0001070668,0.0001722464,0.0000775674,0.0003448541,0.0000023959346],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.46395814,0.13627651,0.09669828,0.00030825892,0.0019841194,0.011334039,0.05734,0.0000239586,0.15167756,0.0000029243345,0.00014420206,0.080251984],"study_design_scores_gemma":[0.40025333,0.10357579,0.07485079,0.0007924411,0.00086355495,0.00024686658,0.007324278,0.00043548504,0.41070315,0.000017400054,0.00024761556,0.0006893016],"about_ca_topic_score_codex":0.0008866912,"about_ca_topic_score_gemma":0.0007271631,"teacher_disagreement_score":0.25902557,"about_ca_system_score_codex":0.00013243312,"about_ca_system_score_gemma":0.00078084244,"threshold_uncertainty_score":0.9229958},"labels":[],"label_agreement":null},{"id":"W3212504456","doi":"10.1007/s11307-021-01672-3","title":"Visualizing CAR-T cell Immunotherapy Using 3 Tesla Fluorine-19 MRI","year":2021,"lang":"en","type":"article","venue":"Molecular Imaging and Biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Robarts Clinical Trials; Western University","funders":"","keywords":"Chimeric antigen receptor; CD19; Immunotherapy; Cancer research; Medicine; Magnetic resonance imaging; Bioluminescence imaging; Cancer cell; Antigen; T cell; Leukemia; Cancer; Chemistry; Pathology; Immunology; Internal medicine; Luciferase; Immune system; Radiology; Biochemistry","score_opus":0.030186354002142077,"score_gpt":0.36014957719990087,"score_spread":0.3299632231977588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212504456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9629044,0.027749619,0.004102041,0.0018121459,0.00016921981,0.00017076245,0.0000049607406,0.00006284376,0.003023996],"genre_scores_gemma":[0.98824805,0.0015636046,0.0040419707,0.0038642427,0.00017731292,0.000008551306,0.00006307956,0.000058268834,0.0019749287],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987177,0.00017358975,0.0001893894,0.00041027306,0.00010468816,0.00040435308],"domain_scores_gemma":[0.99934316,0.000054002416,0.00003916756,0.00032874494,0.00010915896,0.00012577766],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022908165,0.00016655761,0.0002966925,0.00012125282,0.00010096035,0.000040844036,0.00007108352,0.00008199125,0.00037255304],"category_scores_gemma":[0.00004334571,0.00015117005,0.00010608191,0.00022534236,0.00015248382,0.000024882898,0.0001007723,0.00024483382,0.000007780649],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006154717,0.000053030348,0.016823715,0.000038097678,0.000061032737,0.0004562648,0.00016174288,0.0000024539502,0.95395565,0.00007238456,0.00013135804,0.028182728],"study_design_scores_gemma":[0.002066533,0.00011933075,0.00057532743,0.00003915328,0.000042467593,0.0009761929,0.00022084669,0.0015403064,0.87408334,0.00025110584,0.11986812,0.00021724802],"about_ca_topic_score_codex":0.00021970508,"about_ca_topic_score_gemma":0.0000012254437,"teacher_disagreement_score":0.11973676,"about_ca_system_score_codex":0.0000642095,"about_ca_system_score_gemma":0.00016310974,"threshold_uncertainty_score":0.6164536},"labels":[],"label_agreement":null},{"id":"W3212697406","doi":"10.1021/acsptsci.1c00188","title":"Enhancing CAR-T Cell Therapy with Functional Nucleic Acids","year":2021,"lang":"en","type":"review","venue":"ACS Pharmacology & Translational Science","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Canadian Institutes of Health Research; Natural Sciences and Engineering Research Council of Canada; Canada Research Chairs","keywords":"Nucleic acid; Chimeric antigen receptor; Ribozyme; Immunotherapy; Aptamer; Computational biology; Cell therapy; Cancer therapy; Biology; Cell; Medicine; RNA; Cancer; Immunology; Immune system; Biochemistry; Molecular biology; Genetics","score_opus":0.07385786044451662,"score_gpt":0.3975091195383652,"score_spread":0.3236512590938486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212697406","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019350351,0.99104905,0.00024491356,0.000490557,0.0006340063,0.0013968623,0.000034571804,0.00007106399,0.0041439543],"genre_scores_gemma":[0.0015313163,0.99194086,0.0008139987,0.0006999903,0.0008026591,0.00023169699,0.0002033728,0.00007345341,0.0037026561],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99568284,0.00022812875,0.00056106993,0.0010888267,0.0016589784,0.0007801487],"domain_scores_gemma":[0.9979992,0.00053551473,0.00018066727,0.00034650508,0.0005588258,0.00037927265],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011314148,0.0004787704,0.0012196773,0.000526835,0.00046732003,0.00006985209,0.0005172831,0.00027431195,0.0161164],"category_scores_gemma":[0.000014600211,0.00035942846,0.00037258852,0.002286505,0.0012293749,0.00026435955,0.000059601432,0.0011314092,0.00013600204],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030668164,0.0005331139,0.00011347128,0.0018074951,0.0005493969,0.00025177916,0.00025934327,0.000033867942,0.19912562,0.00014569543,0.0007252073,0.7961483],"study_design_scores_gemma":[0.0018736786,0.00030237372,0.00016036337,0.00083677284,0.00061028224,0.0005273201,0.00001647716,0.000018850347,0.010884769,0.0000123745685,0.98438025,0.0003765185],"about_ca_topic_score_codex":0.000010933505,"about_ca_topic_score_gemma":0.0000070174733,"teacher_disagreement_score":0.98365504,"about_ca_system_score_codex":0.0003383813,"about_ca_system_score_gemma":0.007764768,"threshold_uncertainty_score":0.9998858},"labels":[],"label_agreement":null},{"id":"W3212730017","doi":"10.1182/blood-2021-149327","title":"Efficacy Comparison of Tisagenlecleucel Versus Standard of Care in Patients with Relapsed or Refractory Follicular Lymphoma","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Internal medicine; Retrospective cohort study; Follicular lymphoma; Refractory (planetary science); Cohort; Clinical trial; Lymphoma","score_opus":0.02377851177416539,"score_gpt":0.3142376873177308,"score_spread":0.2904591755435654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212730017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964527,0.0011714336,0.0000026810715,0.0000198764,0.000057673493,0.00042612533,0.000033696822,0.000013410986,0.0018223904],"genre_scores_gemma":[0.9990148,0.000041201936,0.00049726415,0.00000852717,0.000021502512,0.000007760962,0.00008712895,0.000030570438,0.00029122902],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99841624,0.000092146474,0.00032867756,0.0002331303,0.0007208447,0.00020892714],"domain_scores_gemma":[0.9987667,0.00015048639,0.00010827146,0.00047062477,0.0004142445,0.00008966023],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009541221,0.00012021727,0.00054389244,0.0001103581,0.000019428002,0.000004972237,0.000088816894,0.00009417736,0.00054780586],"category_scores_gemma":[0.00018485765,0.000094770774,0.00008106728,0.00043466102,0.000072269206,0.000029213821,0.000048168884,0.00013345528,0.0000032426144],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17901388,0.011410053,0.6864812,0.000987423,0.0010626656,0.0004872081,0.0055537955,0.000023398532,0.046829544,0.000020333118,0.00020135257,0.06792915],"study_design_scores_gemma":[0.15857323,0.01994964,0.4089593,0.00058219425,0.00034897373,0.000004338863,0.0014694245,0.0000071410327,0.40586302,0.0000014583828,0.0040544206,0.00018686416],"about_ca_topic_score_codex":0.000034851626,"about_ca_topic_score_gemma":0.00020686537,"teacher_disagreement_score":0.35903347,"about_ca_system_score_codex":0.00012321242,"about_ca_system_score_gemma":0.00052447204,"threshold_uncertainty_score":0.599809},"labels":[],"label_agreement":null},{"id":"W3212910936","doi":"10.1182/blood-2021-152149","title":"Mapping the Multiple Myeloma T Cell Landscape By Immunotherapeutic Perturbation Reveals Mechanism and Determinants of Response to Bispecific T Cell Engagers","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Immune system; Chimeric antigen receptor; Bone marrow; Immunotherapy; T cell; Medicine; Multiple myeloma; Antigen; Cancer research; Immunology","score_opus":0.028813889938514223,"score_gpt":0.2679662286620868,"score_spread":0.23915233872357258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212910936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99467963,0.0032957643,0.000068774076,0.00051057764,0.000058955942,0.0005473531,0.000021849777,0.0000229624,0.0007941504],"genre_scores_gemma":[0.9839211,0.00045035314,0.00047445847,0.00030345688,0.00004699153,0.00003337019,0.000010037778,0.000039577684,0.014720668],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99835294,0.00043478952,0.00028753513,0.00030403087,0.0003416161,0.0002790971],"domain_scores_gemma":[0.9984068,0.0007671661,0.00008198449,0.00050342845,0.00013429919,0.00010627836],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009792581,0.00014775169,0.00028323784,0.00012861528,0.00013600936,0.000034800985,0.00012379838,0.00009339834,0.0004436603],"category_scores_gemma":[0.00019337611,0.000114184695,0.0000797014,0.00035053818,0.000044166478,0.000034855348,0.000073734605,0.0002297315,0.000017397617],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00074108626,0.00026049215,0.0048685954,0.000103450715,0.0000373352,0.000046881032,0.003705245,3.6610732e-7,0.98697853,0.0000023134778,0.00018417752,0.00307152],"study_design_scores_gemma":[0.0040053884,0.00033711156,0.01351695,0.00009483404,0.00005384025,0.000068122776,0.0020280967,0.00014352333,0.9752695,0.00005800166,0.004294087,0.0001305251],"about_ca_topic_score_codex":0.000012060368,"about_ca_topic_score_gemma":0.0000039362594,"teacher_disagreement_score":0.013926518,"about_ca_system_score_codex":0.00002544041,"about_ca_system_score_gemma":0.000097202916,"threshold_uncertainty_score":0.4857769},"labels":[],"label_agreement":null},{"id":"W3212994588","doi":"10.1016/j.htct.2021.09.002","title":"Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. II: CAR-T cell therapy for patients with CD19+ acute lymphoblastic leukemia","year":2021,"lang":"en","type":"article","venue":"Hematology Transfusion and Cell Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Chimeric antigen receptor; Cytokine release syndrome; Medicine; CD19; Hematology; Lymphoblastic Leukemia; CAR T-cell therapy; Cell therapy; Oncology; Leukemia; T cell; Internal medicine; Immunology; Disease; Acute lymphocytic leukemia; Cancer research; Antigen; Cell; Immune system; Biology","score_opus":0.015864145573632197,"score_gpt":0.2614555756327584,"score_spread":0.2455914300591262,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212994588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914517,0.002165834,0.0014169215,0.000713107,0.00024162978,0.0023658639,0.00010638043,0.00016163783,0.0013769517],"genre_scores_gemma":[0.9800261,0.009523473,0.002962177,0.0034440032,0.0000760736,0.00023734692,0.0002082726,0.00019568391,0.0033268563],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99572515,0.00039642723,0.00072111713,0.0012588735,0.00068459526,0.0012138413],"domain_scores_gemma":[0.9971703,0.0007508282,0.00018545211,0.0008236217,0.00050963735,0.0005601586],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00031075245,0.00077064685,0.0013986336,0.00025614124,0.0005506749,0.00007379937,0.00026846188,0.0007605376,0.0012719043],"category_scores_gemma":[0.000019142411,0.00061401597,0.00041961193,0.00038680868,0.00042069383,0.000044958542,0.000046046345,0.0006441396,0.000015793214],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019243263,0.0038922317,0.022543114,0.0003666892,0.00080993917,0.00072254456,0.0022339048,0.000029158751,0.93628454,0.00026215127,0.0011773121,0.012435173],"study_design_scores_gemma":[0.045385797,0.007465551,0.0061920113,0.00015478524,0.00020140217,0.0004981991,0.00023899491,0.00086231163,0.9336301,0.00024440815,0.00430077,0.0008256428],"about_ca_topic_score_codex":0.000032568758,"about_ca_topic_score_gemma":0.000015566711,"teacher_disagreement_score":0.026142532,"about_ca_system_score_codex":0.00024075467,"about_ca_system_score_gemma":0.000829947,"threshold_uncertainty_score":0.99964106},"labels":[],"label_agreement":null},{"id":"W3213141384","doi":"10.1182/blood-2021-148881","title":"SCRI-CAR19x22v2 T Cell Product Demonstrates Bispecific Activity in B-ALL","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"","keywords":"CD22; CD19; Antigen; Population; Medicine; Immunology; Chimeric antigen receptor; T cell; Biology; Immune system","score_opus":0.05609788024173643,"score_gpt":0.3150073002991131,"score_spread":0.25890942005737666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213141384","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9512587,0.0018369728,0.0000037034501,0.0013558799,0.00010032629,0.00037248718,0.0000060524044,0.000054141463,0.045011688],"genre_scores_gemma":[0.9846529,0.00043122,0.00044957318,0.00011106229,0.00027355648,0.00002613373,0.000017262559,0.000035521676,0.014002782],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984002,0.00011858057,0.00018273188,0.0004836079,0.00038326837,0.00043158108],"domain_scores_gemma":[0.9990327,0.000079684825,0.000033703513,0.00057440886,0.00012518799,0.00015433146],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00031516058,0.00015392281,0.00030037592,0.00014213375,0.000034792694,0.000041248317,0.00010527946,0.00008333989,0.0019510294],"category_scores_gemma":[0.00010333766,0.00014626585,0.00009965543,0.0005668568,0.00007459573,0.00007357269,0.00007271054,0.00045837517,0.00013840302],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001179884,0.002102424,0.040689673,0.00011749392,0.00005797548,0.00077759183,0.00015093086,8.8919757e-7,0.9437738,0.000019528454,0.0005542516,0.011637459],"study_design_scores_gemma":[0.0032868758,0.00014362323,0.03722485,0.000051702285,0.00005633214,0.00016047612,0.00010586049,0.000019193387,0.9449946,0.000068829875,0.01374475,0.00014289412],"about_ca_topic_score_codex":0.00008465322,"about_ca_topic_score_gemma":0.0001262684,"teacher_disagreement_score":0.03339414,"about_ca_system_score_codex":0.000059357128,"about_ca_system_score_gemma":0.0003650344,"threshold_uncertainty_score":0.9989613},"labels":[],"label_agreement":null},{"id":"W3213192832","doi":"10.1182/blood-2021-146397","title":"Real-World Efficacy and Safety Outcomes for Patients with Relapsed or Refractory (R/R) Aggressive B-Cell Non-Hodgkin's Lymphoma (aBNHL) Treated with Commercial Tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Novartis (Canada); McMaster University; Juravinski Hospital","funders":"","keywords":"Medicine; Internal medicine; Cytokine release syndrome; Diffuse large B-cell lymphoma; Single Center; Oncology; Adverse effect; Aggressive lymphoma; Lymphoma; Surgery; Immunotherapy; Rituximab; Cancer; Chimeric antigen receptor","score_opus":0.02530467328569276,"score_gpt":0.31217945976276346,"score_spread":0.2868747864770707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213192832","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99268174,0.0001713343,0.000028768147,0.0014455118,0.00011876987,0.0023973878,0.0021698407,0.000040124178,0.0009465174],"genre_scores_gemma":[0.98773986,0.0012624727,0.001705484,0.00033031055,0.00035948073,0.0002988794,0.0026336461,0.00013207416,0.0055377823],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99724555,0.00021852819,0.00040766897,0.0007569796,0.00079784606,0.0005734026],"domain_scores_gemma":[0.9959101,0.0019574391,0.00021273745,0.0006514236,0.0010130751,0.00025523026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044004095,0.00033656298,0.00055717834,0.00014751361,0.0003615587,0.00012121838,0.00027339513,0.0001544046,0.00022860219],"category_scores_gemma":[0.00033159443,0.00019835957,0.00009782434,0.00028497953,0.00035317082,0.00010618491,0.00010132036,0.0003705478,0.000002263307],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06504146,0.006222637,0.9019559,0.0002363487,0.0023533772,0.0006080646,0.001173105,4.273945e-7,0.0068355547,0.00001845335,0.0023866063,0.013168061],"study_design_scores_gemma":[0.1561356,0.003773668,0.799766,0.0009827989,0.0010796624,0.00007345251,0.00022654343,0.00003110308,0.017828304,0.000020527577,0.019667892,0.0004144296],"about_ca_topic_score_codex":0.00036075138,"about_ca_topic_score_gemma":0.0014673008,"teacher_disagreement_score":0.10218988,"about_ca_system_score_codex":0.00008668568,"about_ca_system_score_gemma":0.00035353674,"threshold_uncertainty_score":0.8088869},"labels":[],"label_agreement":null},{"id":"W3213274906","doi":"10.1080/2162402x.2021.1995168","title":"Manufacturing T cells in hollow fiber membrane bioreactors changes their programming and enhances their potency","year":2021,"lang":"en","type":"article","venue":"OncoImmunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre; McMaster University; TRIUMF","funders":"Canada Research Chairs","keywords":"Cryopreservation; Bioreactor; Cell; Cell culture; Chemistry; Cell biology; Biotechnology; Biology; Biochemistry; Embryo","score_opus":0.02288096904731359,"score_gpt":0.2790658329351818,"score_spread":0.2561848638878682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213274906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876094,0.005351103,0.0000026798245,0.0019399339,0.0002067954,0.00037710322,0.0000069005987,0.00006231884,0.0044437805],"genre_scores_gemma":[0.98167276,0.0052093207,0.0003960097,0.00016989422,0.00012336098,0.00006396086,0.00003440341,0.000044264067,0.012286],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99848795,0.00014674617,0.00022330895,0.00043985771,0.00014725952,0.0005548715],"domain_scores_gemma":[0.9991742,0.00021492032,0.00006355617,0.0004115459,0.000059125057,0.00007666531],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00027503388,0.00022850833,0.00049978175,0.00023000251,0.00006698946,0.000033308967,0.00012903355,0.00022671954,0.0020116512],"category_scores_gemma":[0.000034783166,0.00017528042,0.000078496334,0.00023730828,0.00022300938,0.0000638247,0.00015636018,0.00050543575,0.000035029123],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013676766,0.00010822797,0.00042662272,0.00006149519,0.000081188875,0.00017258573,0.0013003413,2.3601976e-7,0.63908535,0.0000045656325,0.000008903808,0.35861373],"study_design_scores_gemma":[0.0012702721,0.00031046447,0.008049879,0.00011651456,0.000014372341,0.00021035163,0.0019253546,0.0000053459075,0.8766673,0.000043357297,0.11123374,0.00015304591],"about_ca_topic_score_codex":0.0002616812,"about_ca_topic_score_gemma":0.00047718827,"teacher_disagreement_score":0.35846066,"about_ca_system_score_codex":0.00010047255,"about_ca_system_score_gemma":0.00012422164,"threshold_uncertainty_score":0.99890065},"labels":[],"label_agreement":null},{"id":"W3213324499","doi":"10.1016/j.xpro.2021.100956","title":"Production of human CAR-NK cells with lentiviral vectors and functional assessment in vitro","year":2021,"lang":"en","type":"article","venue":"STAR Protocols","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Canadian Institutes of Health Research","keywords":"Chimeric antigen receptor; Flow cytometry; Cell biology; Ex vivo; Transgene; Transduction (biophysics); Janus kinase 3; Biology; In vitro; Immune system; Effector; Interleukin 21; T cell; Immunology; Gene; Genetics","score_opus":0.04441661667281394,"score_gpt":0.36506743946083814,"score_spread":0.3206508227880242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213324499","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95452046,0.000011045019,0.000020726842,0.00021094104,0.000037282887,0.043907166,0.0000057840807,0.000015617576,0.0012709865],"genre_scores_gemma":[0.9532809,0.0000029065911,0.00096872577,0.00002330886,0.00015750597,0.039993636,0.000042720654,0.000026775511,0.005503491],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987842,0.00010251446,0.0001932606,0.00029304475,0.0004433397,0.00018366241],"domain_scores_gemma":[0.9994511,0.000019349982,0.000054591706,0.00024313788,0.00017583162,0.000055987493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032864654,0.000100846184,0.00023251139,0.00010626827,0.00004133561,0.000016479251,0.000027207374,0.00004374751,0.0005860292],"category_scores_gemma":[0.000015423519,0.000084224426,0.000035195575,0.00024969474,0.00009853653,0.00006921513,0.000037271097,0.0002587495,0.0000017721555],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00096053065,0.00032467867,0.021368323,0.00037982652,0.00004521655,0.0000356313,0.00016119966,0.0000048200022,0.9743806,0.000037331807,0.00014048684,0.0021613447],"study_design_scores_gemma":[0.0023892485,0.00082635274,0.080880225,0.00020360228,0.000012540145,0.000020099387,0.00022236512,0.000013724667,0.9132306,0.000063730266,0.0020568236,0.00008068165],"about_ca_topic_score_codex":0.00004845775,"about_ca_topic_score_gemma":0.00006821277,"teacher_disagreement_score":0.061150007,"about_ca_system_score_codex":0.00013722683,"about_ca_system_score_gemma":0.0003626549,"threshold_uncertainty_score":0.64166087},"labels":[],"label_agreement":null},{"id":"W3213532983","doi":"10.1182/blood-2021-151683","title":"Propensity Score Matching Analysis Comparing Ruxolitinib Vs Historical Controls in 2 nd Line or Beyond Treatment for Chronic Gvhd after Therapy Failure","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; London Health Sciences Centre; Western University; Vancouver General Hospital; Saskatchewan Cancer Agency; University of Saskatchewan; BC Cancer Agency; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Prednisone; Ruxolitinib; Internal medicine; Rituximab; Salvage therapy; Retrospective cohort study; Propensity score matching; Corticosteroid; Surgery; Gastroenterology; Chemotherapy; Myelofibrosis; Lymphoma","score_opus":0.07654796442627441,"score_gpt":0.32601916825522376,"score_spread":0.24947120382894933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213532983","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99248886,0.0039016842,0.00019796484,0.0015345156,0.000056001238,0.0013742299,0.000022286493,0.000041454332,0.00038300265],"genre_scores_gemma":[0.9907196,0.00027554954,0.00086271786,0.00021641585,0.00045298526,0.00042334246,0.00013680794,0.00004309089,0.006869475],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99809426,0.000120696815,0.0004084405,0.000521373,0.00034794377,0.0005072855],"domain_scores_gemma":[0.99879724,0.00024737912,0.00007381991,0.00051468384,0.00018164793,0.00018523162],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002967929,0.00024563423,0.0010398662,0.0002257911,0.00007493986,0.000056071836,0.00009790991,0.00012239588,0.0023740595],"category_scores_gemma":[0.000072145056,0.00017658768,0.00038443442,0.00056111446,0.000035777917,0.00005864913,0.000047842885,0.0002545653,0.000008907049],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01686248,0.00864499,0.7377282,0.0003884971,0.007989038,0.0028187954,0.0023789709,0.00018528094,0.1896837,0.000062493,0.00022955521,0.03302802],"study_design_scores_gemma":[0.1478088,0.0103699835,0.6151176,0.00045319888,0.00608227,0.00039924454,0.0003247083,0.0017950931,0.1493544,0.00032612807,0.06669411,0.0012744302],"about_ca_topic_score_codex":0.00039524736,"about_ca_topic_score_gemma":0.004245752,"teacher_disagreement_score":0.13094632,"about_ca_system_score_codex":0.0011592988,"about_ca_system_score_gemma":0.0004976107,"threshold_uncertainty_score":0.9985379},"labels":[],"label_agreement":null},{"id":"W3213571777","doi":"10.1182/blood-2021-147598","title":"Patient-Reported Outcomes in a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard of Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma (ZUMA-7)","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; McGill University Health Centre; Hôpital de l'Enfant-Jésus; Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Medicine; Quality of life (healthcare); Internal medicine; Refractory (planetary science); Randomization; Randomized controlled trial; Oncology","score_opus":0.04728086257192918,"score_gpt":0.3732617414523252,"score_spread":0.32598087888039606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213571777","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908326,0.0015515517,0.0000021334838,0.000039959497,0.00012530932,0.0065120542,0.000077469886,0.000017103304,0.00084176345],"genre_scores_gemma":[0.9989923,0.00012676365,0.0002017556,0.000045671244,0.000016537768,0.00026782285,0.0000965937,0.00006926243,0.00018328968],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9946901,0.0012666878,0.001309453,0.0005916377,0.0016639072,0.000478168],"domain_scores_gemma":[0.99584925,0.0013273469,0.00060000946,0.0011511298,0.00095370447,0.00011853799],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019653216,0.00034342488,0.0017203197,0.00026334904,0.00008154891,0.0000343355,0.00034899815,0.000116107956,0.00029045285],"category_scores_gemma":[0.001240352,0.00022238663,0.00017333825,0.0008501026,0.00014834663,0.00010690851,0.00026178136,0.00035045017,0.000001659447],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.63299453,0.12286335,0.19195089,0.00010850824,0.0013060179,0.0002881224,0.012161138,0.0000062491363,0.010238739,0.0000033040344,0.0000062527547,0.02807287],"study_design_scores_gemma":[0.91228867,0.0332069,0.026784182,0.00020470511,0.00041390065,0.0000026890168,0.004906,0.0000254045,0.0219238,0.0000033307138,0.00003443279,0.0002060006],"about_ca_topic_score_codex":0.00024656134,"about_ca_topic_score_gemma":0.00029441327,"teacher_disagreement_score":0.2792941,"about_ca_system_score_codex":0.00020478261,"about_ca_system_score_gemma":0.001086524,"threshold_uncertainty_score":0.9068664},"labels":[],"label_agreement":null},{"id":"W3213746728","doi":"10.1182/blood-2021-147568","title":"Novel Agents May be Preferable to Chemotherapy for Large B-Cell Lymphoma Progressing after CD19-CAR-T: A Multicenter Observational Study","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stem Cell Network","funders":"","keywords":"Medicine; Interquartile range; Internal medicine; CAR T-cell therapy; Cumulative incidence; Population; Cohort; Oncology; Cytokine release syndrome; Minimal residual disease; Lymphoma; Cancer; Chimeric antigen receptor; Immunotherapy; Leukemia","score_opus":0.09814892694299518,"score_gpt":0.3666650623625426,"score_spread":0.26851613541954744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213746728","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938518,0.00021842976,0.00031925508,0.0016785006,0.00012621147,0.0029096392,0.000094132345,0.000058685833,0.0007433472],"genre_scores_gemma":[0.9488683,0.000013527582,0.014313709,0.004304891,0.00038152494,0.0011808402,0.00012636761,0.00010447097,0.030706381],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9977901,0.000055340202,0.0003294067,0.0005725706,0.00066012377,0.00059246755],"domain_scores_gemma":[0.9986548,0.000093497576,0.00005678136,0.0005260057,0.0004311703,0.0002377688],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00038709765,0.00023012985,0.0003476079,0.00009703714,0.000119297416,0.00010769902,0.00014557077,0.00009711419,0.0018456295],"category_scores_gemma":[0.0000904507,0.00021383015,0.00016749011,0.0003089617,0.000018814957,0.000099140816,0.000115669754,0.000119882585,0.000030084364],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035584231,0.07194648,0.36241686,0.00042159375,0.0009348683,0.0002693471,0.0046856212,0.0000016212681,0.54801226,0.00001540149,0.0020109338,0.0057266243],"study_design_scores_gemma":[0.14377166,0.0016687725,0.39521402,0.00028095712,0.00042465393,0.00006865181,0.0010287656,0.00058437034,0.30512744,0.000012426103,0.15126386,0.00055442925],"about_ca_topic_score_codex":0.000017190026,"about_ca_topic_score_gemma":0.00004572941,"teacher_disagreement_score":0.2428848,"about_ca_system_score_codex":0.000104177685,"about_ca_system_score_gemma":0.00028751252,"threshold_uncertainty_score":0.9990668},"labels":[],"label_agreement":null},{"id":"W3213817406","doi":"10.1182/blood-2021-148652","title":"Impact of Allogeneic Hematopoietic Cell Transplantation (HCT) As Consolidation Following CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy for Treatment of Relapsed Acute Lymphoblastic Leukemia (ALL)","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"","keywords":"Chimeric antigen receptor; Hematopoietic cell; Medicine; Hematopoietic stem cell transplantation; Transplantation; Hematologic Neoplasms; Acute lymphocytic leukemia; CD19; Immunology; Cancer research; Antigen; Lymphoblastic Leukemia; Leukemia; Oncology; Haematopoiesis; Stem cell; Internal medicine; T cell; Biology; Immune system","score_opus":0.01989192779643441,"score_gpt":0.3112064418056722,"score_spread":0.2913145140092378,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213817406","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99565387,0.0019166694,0.00022737929,0.00003306372,0.000104804116,0.0013121364,0.00011283756,0.000032920525,0.00060632586],"genre_scores_gemma":[0.9898275,0.006901568,0.0012537917,0.000026043945,0.00006603149,0.00009940978,0.00071204157,0.00006951953,0.0010440821],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982008,0.00012229428,0.0005173116,0.0003935333,0.0003996432,0.00036642814],"domain_scores_gemma":[0.99872893,0.0002806827,0.00021504087,0.00042620255,0.00019823918,0.00015088954],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015557124,0.00027342947,0.00068696664,0.00016414172,0.000054228927,0.000015370633,0.00009903962,0.00015775,0.00083643716],"category_scores_gemma":[0.000021564196,0.00023081237,0.0007118564,0.00032452284,0.000053723732,0.0000652455,0.000009139954,0.00005774288,0.000020011516],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017743232,0.0018892037,0.01116278,0.00024051621,0.0015930322,0.00007661029,0.0017128757,0.000046927045,0.9795054,0.0000031752077,0.000028096363,0.0019670266],"study_design_scores_gemma":[0.023236541,0.0051322235,0.0071388534,0.00009445249,0.0010559406,0.00010174821,0.00016673729,0.00005726791,0.9626997,0.000025164798,0.00011369438,0.0001776626],"about_ca_topic_score_codex":0.00019398237,"about_ca_topic_score_gemma":0.000005898539,"teacher_disagreement_score":0.021462217,"about_ca_system_score_codex":0.00028788584,"about_ca_system_score_gemma":0.0011633243,"threshold_uncertainty_score":0.9412255},"labels":[],"label_agreement":null},{"id":"W3213879987","doi":"10.1182/blood-2021-148302","title":"Tafasitamab Plus Lenalidomide Versus Pola-BR, R2, and CAR T: Comparing Outcomes from RE-MIND2, an Observational, Retrospective Cohort Study in Relapsed/Refractory Diffuse Large B-Cell Lymphoma","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Internal medicine; Propensity score matching; Lenalidomide; Cohort; Population; Diffuse large B-cell lymphoma; Chemotherapy regimen; Retrospective cohort study; Regimen; Oncology; Surgery; Cancer; Lymphoma; Multiple myeloma","score_opus":0.0768311610291272,"score_gpt":0.3310662052840418,"score_spread":0.2542350442549146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213879987","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946759,0.0010226028,0.0000028349132,0.00016481962,0.00026501418,0.001028456,0.00008278749,0.00007440808,0.0026831836],"genre_scores_gemma":[0.9971748,0.00011630869,0.00021197705,0.00016054898,0.00021379524,0.00007660725,0.0002418895,0.00007356519,0.0017305161],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99673146,0.00033688228,0.0005266904,0.00088561047,0.0009813827,0.00053796184],"domain_scores_gemma":[0.99790084,0.0005032336,0.00013293736,0.00090582075,0.00026396176,0.00029323177],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000650905,0.0003350183,0.0009843129,0.0001946093,0.00015840887,0.00009180749,0.00020246238,0.0001843963,0.0005662581],"category_scores_gemma":[0.00043902893,0.00033120374,0.00012728744,0.00042386763,0.00008054078,0.00018919731,0.000242543,0.0004975722,0.000021367166],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016828834,0.015304762,0.96069074,0.000026266262,0.0006112261,0.0009393666,0.002370149,0.0000016649841,0.018177744,0.000029500132,0.00007432234,0.00009134989],"study_design_scores_gemma":[0.12651148,0.0006648643,0.8645998,0.000048455855,0.0003426039,0.000012232992,0.0033947688,0.00015814485,0.003748627,0.00003333743,0.00021560819,0.0002700457],"about_ca_topic_score_codex":0.0019375217,"about_ca_topic_score_gemma":0.0040266314,"teacher_disagreement_score":0.12482859,"about_ca_system_score_codex":0.0006689234,"about_ca_system_score_gemma":0.00043062886,"threshold_uncertainty_score":0.999914},"labels":[],"label_agreement":null},{"id":"W3213899689","doi":"10.1016/s2152-2650(21)02101-7","title":"OAB-027: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lenalidomide; Pomalidomide; Fludarabine; Internal medicine; Bortezomib; Carfilzomib; Rituximab; Daratumumab; Regimen; Multiple myeloma; Refractory (planetary science); Clinical endpoint; Oncology; Cyclophosphamide; Gastroenterology; Surgery; Clinical trial; Chemotherapy; Lymphoma","score_opus":0.03591386775633376,"score_gpt":0.310774505472544,"score_spread":0.2748606377162102,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213899689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908775,0.0032405322,0.00003400752,0.00061422604,0.0004479277,0.0028764934,0.0010790719,0.00022152449,0.00060868246],"genre_scores_gemma":[0.9827449,0.0050521935,0.0022925076,0.0006732825,0.0005748494,0.00026900452,0.002379075,0.00021847348,0.0057957405],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9937177,0.00068668264,0.0020287773,0.0016431137,0.0010233179,0.0009004529],"domain_scores_gemma":[0.98888385,0.0062949415,0.0007393107,0.0021724412,0.0012417085,0.00066772127],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008581199,0.0007418296,0.0016604593,0.00016004319,0.00032694652,0.00008827494,0.0004368392,0.0006578644,0.0004542765],"category_scores_gemma":[0.0012122812,0.0004920127,0.0006494287,0.00073070877,0.00076190056,0.00014968123,0.00015393179,0.00038959464,0.000040998388],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.074666865,0.004920714,0.07622638,0.00006924595,0.0020620592,0.00035075203,0.0012070349,0.000011081304,0.0772812,0.0000047654416,0.004443677,0.7587562],"study_design_scores_gemma":[0.07930446,0.006063672,0.7344058,0.0001340962,0.00043389824,0.00001487657,0.00023787346,0.0013025197,0.062352937,0.00003681131,0.115247406,0.0004656463],"about_ca_topic_score_codex":0.00084503146,"about_ca_topic_score_gemma":0.00027638656,"teacher_disagreement_score":0.7582906,"about_ca_system_score_codex":0.001127131,"about_ca_system_score_gemma":0.0022031183,"threshold_uncertainty_score":0.9997532},"labels":[],"label_agreement":null},{"id":"W3214093033","doi":"10.1101/2021.05.07.443194","title":"Decade-long remissions of leukemia sustained by the persistence of activated CD4 <sup>+</sup> CAR T-cells","year":2021,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; National Institutes of Health","keywords":"Chimeric antigen receptor; T-cell receptor; Adoptive cell transfer; Population; Immunology; Leukemia; Cytotoxic T cell; Biology; Cancer research; CD19; Molecular biology; Antigen; T cell; Medicine; Genetics; Immune system","score_opus":0.02179808866004319,"score_gpt":0.2587078643610088,"score_spread":0.2369097757009656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214093033","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949508,0.0022468655,0.00015428955,0.0005186874,0.00020834424,0.0015032748,0.00021361609,0.00013315148,0.00007097622],"genre_scores_gemma":[0.99724317,0.0009829283,0.0007790517,0.00012051583,0.00019758378,0.000110174435,0.000002699847,0.00018440014,0.00037948636],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99535614,0.0004496178,0.0009818214,0.0011271207,0.0012705161,0.00081477326],"domain_scores_gemma":[0.9934636,0.00043031658,0.0006335398,0.0027811688,0.00217907,0.000512316],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012001244,0.0006501641,0.0012975849,0.0003574287,0.00017662806,0.000086019274,0.001000586,0.00086005026,0.0008373996],"category_scores_gemma":[0.001019476,0.00054874644,0.00054384954,0.0013958879,0.0005675884,0.00010351863,0.00084703154,0.0019713652,0.0000071610334],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031898927,0.00024082398,0.0026483354,0.0014474553,0.0006785735,0.00012569637,0.00016816321,0.00022722028,0.99285144,0.000020167307,0.0012614207,0.000011695138],"study_design_scores_gemma":[0.0012821003,0.00013921298,0.0040243166,0.0015085755,0.00036438307,1.8759353e-7,0.00037756155,0.00080054667,0.9889371,2.9176078e-7,0.002118776,0.00044698696],"about_ca_topic_score_codex":0.0003301113,"about_ca_topic_score_gemma":0.0000022163529,"teacher_disagreement_score":0.003914399,"about_ca_system_score_codex":0.0012024305,"about_ca_system_score_gemma":0.004226889,"threshold_uncertainty_score":0.99969643},"labels":[],"label_agreement":null},{"id":"W3214408062","doi":"10.1182/blood-2021-144939","title":"Tisagenlecleucel Leukapheresis and Manufacturing Outcomes in Patients Less Than 3 Years of Age with Relapsed/Refractory Acute Lymphoblastic Leukemia","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Novartis (Canada)","funders":"","keywords":"Leukapheresis; Medicine; Blinatumomab; Internal medicine; Leukemia; Lymphoblastic Leukemia; Stem cell; Biology","score_opus":0.014969082656810635,"score_gpt":0.2531213890440729,"score_spread":0.23815230638726226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214408062","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99799603,0.00018023097,0.0000032958937,0.000022711776,0.0000371672,0.00023830644,0.000014682651,0.00002059435,0.0014869538],"genre_scores_gemma":[0.99559164,0.0001530056,0.00025641342,0.000051146606,0.000020946287,0.000011137978,0.000021793308,0.000042672444,0.003851223],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9986706,0.000061813844,0.00023806172,0.00030805683,0.00043512817,0.00028634048],"domain_scores_gemma":[0.99925715,0.00013707759,0.00006758623,0.00036448045,0.000050437025,0.00012326815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000096681986,0.00015204979,0.00043290737,0.00013956905,0.000024828978,0.000018633478,0.00008689467,0.00009813274,0.00021996979],"category_scores_gemma":[0.000046451936,0.00013491955,0.00006293998,0.00014456807,0.000092181996,0.000064997985,0.00009405412,0.00021276789,0.0000068546706],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006771887,0.0009902118,0.93087304,0.00021114995,0.00065098284,0.0018950629,0.00064309133,0.0000063037337,0.0457479,0.0000054117745,0.00003275389,0.018266909],"study_design_scores_gemma":[0.011038722,0.00044227895,0.88810605,0.00017023357,0.00017283368,0.00003153922,0.00014548641,0.0000034196578,0.099641785,0.000016811468,0.00010314411,0.00012768096],"about_ca_topic_score_codex":0.00022440366,"about_ca_topic_score_gemma":0.0003249582,"teacher_disagreement_score":0.053893887,"about_ca_system_score_codex":0.00013364124,"about_ca_system_score_gemma":0.0002216195,"threshold_uncertainty_score":0.550186},"labels":[],"label_agreement":null},{"id":"W3214517671","doi":"10.1182/blood-2021-145278","title":"A Novel CD34-Specific T-Cell Engager Efficiently Depletes Stem Cells and Acute Myeloid Leukemia Cells <i>in Vitro</i> and <i>In Vivo</i>","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"CD34; Myeloid leukemia; Cancer research; Stem cell; Leukemia; Haematopoiesis; Antigen; T cell; Biology; Immunology; Molecular biology; Chemistry; Cell biology; Immune system","score_opus":0.01639355764875683,"score_gpt":0.23852785130132656,"score_spread":0.22213429365256973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214517671","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98822725,0.0053870794,0.000033542852,0.00015859556,0.00014038639,0.0006836388,0.00011079137,0.000047265457,0.0052114334],"genre_scores_gemma":[0.9784903,0.0049815397,0.0018770035,0.000647025,0.00018049186,0.000055122906,0.000017932745,0.000113164984,0.0136374505],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972482,0.00016267558,0.00046660926,0.0008578793,0.00052302604,0.000741657],"domain_scores_gemma":[0.9985049,0.0004453346,0.00007357551,0.00057291874,0.00009550176,0.00030776844],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00062533974,0.00034279673,0.0006395166,0.00026915254,0.00008674167,0.00010931478,0.00014701423,0.00021212197,0.00026538287],"category_scores_gemma":[0.000012115606,0.00033677206,0.00010926089,0.00064234657,0.00015295563,0.00008292144,0.00020828462,0.00078323396,0.000032665248],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043310307,0.0009698208,0.0009972698,0.00016820943,0.0000673848,0.0010952038,0.00064004754,0.000009238064,0.9932852,0.000008280131,0.00048084607,0.0018454366],"study_design_scores_gemma":[0.0130250305,0.00016922932,0.00045967358,0.000116777606,0.00009763655,0.00025992308,0.00038594098,0.00014296085,0.9642633,0.0000052012992,0.020773113,0.00030120983],"about_ca_topic_score_codex":0.000054875076,"about_ca_topic_score_gemma":0.00004589181,"teacher_disagreement_score":0.029021855,"about_ca_system_score_codex":0.00014008506,"about_ca_system_score_gemma":0.00027440555,"threshold_uncertainty_score":0.99990845},"labels":[],"label_agreement":null},{"id":"W3214889415","doi":"10.1101/2021.11.26.470145","title":"DLL4 and VCAM1 enhance the emergence of T cell-competent hematopoietic progenitors from human pluripotent stem cells","year":2021,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; Université de Montréal; University of Toronto; Institute for Research in Immunology and Cancer; University of British Columbia","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Michael Smith Health Research BC; Stem Cell Network; Universities Space Research Association","keywords":"Progenitor cell; Haematopoiesis; Cell biology; Stem cell; Biology; Induced pluripotent stem cell; CD8; T cell; Immunology; Immune system; Embryonic stem cell; Biochemistry","score_opus":0.01911877460398272,"score_gpt":0.2551806227516626,"score_spread":0.23606184814767986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214889415","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884759,0.007884387,0.00017406249,0.00026442655,0.000989481,0.0019373149,0.000120007106,0.0001334165,0.000020963416],"genre_scores_gemma":[0.9958732,0.0017364328,0.001195823,0.00009047776,0.00052554277,0.00029835294,7.797919e-7,0.00017072461,0.00010863372],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99544674,0.0003190202,0.0010095603,0.0013758774,0.0011556135,0.00069320906],"domain_scores_gemma":[0.99559325,0.00014139147,0.0005874843,0.0024260601,0.00081513455,0.00043667434],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00077567226,0.00068234396,0.0011250821,0.00020170803,0.0002348805,0.00016408005,0.00070950703,0.00047346496,0.00096923555],"category_scores_gemma":[0.000038151313,0.0005790954,0.00036373897,0.0005279524,0.0004020099,0.00007387367,0.0010101658,0.0013287725,0.000025716821],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006909528,0.00035503056,0.0035256138,0.0013579577,0.00039388696,0.00014181822,0.0001469176,0.0000125428405,0.9938241,0.00003213956,0.00013261376,0.0000082585],"study_design_scores_gemma":[0.0006346549,0.00013643524,0.012224762,0.0009754035,0.0003212049,8.555933e-8,0.00010928681,0.00010983606,0.98403317,0.0000014210481,0.0009520693,0.000501699],"about_ca_topic_score_codex":0.0002947245,"about_ca_topic_score_gemma":0.000008325085,"teacher_disagreement_score":0.009790983,"about_ca_system_score_codex":0.00019596735,"about_ca_system_score_gemma":0.00079142913,"threshold_uncertainty_score":0.99994403},"labels":[],"label_agreement":null},{"id":"W3215434289","doi":"10.3390/cancers13235982","title":"Clinical Response to Anti-CD47 Immunotherapy Is Associated with Rapid Reduction of Exhausted Bystander CD4+ BTLA+ T Cells in Tumor Microenvironment of Mycosis Fungoides","year":2021,"lang":"en","type":"article","venue":"Cancers","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trillium Therapeutics (Canada)","funders":"University of California, Davis; Drs Martin and Dorothy Spatz Charitable Foundation","keywords":"Mycosis fungoides; Tumor microenvironment; Cancer research; BTLA; Cytotoxic T cell; Immunotherapy; CD8; Immunology; Medicine; Immune system; T cell; Cutaneous T-cell lymphoma; Cancer; Lymphoma; Biology; Internal medicine","score_opus":0.03334650611139613,"score_gpt":0.32991351711785083,"score_spread":0.2965670110064547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3215434289","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969788,0.00123911,0.000018060544,0.00081395096,0.00013799011,0.0005997644,0.000054113785,0.000012855477,0.00014533558],"genre_scores_gemma":[0.99370843,0.0022188437,0.00029754022,0.0004635762,0.000044802702,0.000033548284,0.00001540995,0.000045682198,0.0031721408],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977454,0.00041751668,0.00063372566,0.0004019025,0.0004860517,0.00031543145],"domain_scores_gemma":[0.9987065,0.00024640418,0.00021084075,0.00051421946,0.0001870761,0.00013493057],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011458297,0.00016394618,0.00066518836,0.00020132997,0.000025652182,0.000007509505,0.000105157626,0.00010792287,0.0026687302],"category_scores_gemma":[0.00013314947,0.00015004969,0.00015322125,0.0007217267,0.00022694856,0.000038957238,0.000034078002,0.0002741815,0.000005301377],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013712467,0.00022574759,0.012387762,0.00005363713,0.00036602598,0.00006390295,0.0012237675,0.00019964647,0.9653883,3.5195745e-7,0.0017392759,0.004639125],"study_design_scores_gemma":[0.005814173,0.001438951,0.11689032,0.00053599,0.00005463236,0.000019199006,0.00155166,0.00003672215,0.8674413,0.0000020840628,0.006067279,0.00014767794],"about_ca_topic_score_codex":0.00023484282,"about_ca_topic_score_gemma":0.000042919914,"teacher_disagreement_score":0.10450256,"about_ca_system_score_codex":0.0016399847,"about_ca_system_score_gemma":0.0011264847,"threshold_uncertainty_score":0.998243},"labels":[],"label_agreement":null},{"id":"W3215641558","doi":"10.1182/blood-2021-153262","title":"Tisagenlecleucel Therapy Is Safe and Effective for Children with Down Syndrome with ALL in First Relapse","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Children's Hospital of Eastern Ontario; Centre Hospitalier Universitaire Sainte-Justine; London Health Sciences Centre; Montreal Children's Hospital; Izaak Walton Killam Health Centre; Hospital for Sick Children","funders":"","keywords":"Medicine; Population; Blinatumomab; Hematopoietic stem cell transplantation; Pediatrics; Cumulative incidence; Chimeric antigen receptor; Transplantation; Cytokine release syndrome; Incidence (geometry); Internal medicine; Oncology; Leukemia; Lymphoblastic Leukemia; Immunotherapy; Cancer","score_opus":0.015171049975039468,"score_gpt":0.2743083153968002,"score_spread":0.2591372654217607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3215641558","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99407923,0.0018631772,0.000022822927,0.0010720659,0.000011489146,0.001808414,0.00002435979,0.000026717735,0.0010917241],"genre_scores_gemma":[0.99437547,0.0007491727,0.0009792314,0.0005593898,0.000053897667,0.00028888675,0.000045349312,0.000059671154,0.0028889116],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99882495,0.00004874015,0.00012531554,0.00041705588,0.00026362084,0.00032028655],"domain_scores_gemma":[0.9992459,0.00016180973,0.00003307256,0.0003415006,0.000087975,0.00012976304],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018433372,0.00017334678,0.00033808124,0.000093109426,0.00005668794,0.000029677316,0.00006300834,0.00008629838,0.00046187916],"category_scores_gemma":[0.000025436932,0.00012258544,0.00004627193,0.0002770363,0.00008567703,0.000052945372,0.00002915676,0.00023016974,0.000008264675],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006918103,0.003825772,0.8889666,0.00035116158,0.004081392,0.0030372515,0.0050512915,0.0000059864346,0.05210482,0.00006243297,0.0009901143,0.034605067],"study_design_scores_gemma":[0.039474443,0.005797186,0.87902737,0.0003032708,0.00020380657,0.004534003,0.000080460035,0.000011945904,0.06665224,0.00007200908,0.0035665338,0.0002767352],"about_ca_topic_score_codex":0.000114869974,"about_ca_topic_score_gemma":0.00030683156,"teacher_disagreement_score":0.03432833,"about_ca_system_score_codex":0.000038216975,"about_ca_system_score_gemma":0.00011477201,"threshold_uncertainty_score":0.50572526},"labels":[],"label_agreement":null},{"id":"W3216096981","doi":"10.1182/blood-2021-153595","title":"Efficacy and Safety of Chimeric Antigen Receptor T Cell Therapy in Chronic Lymphocytic Leukemia: A Systematic Review","year":2021,"lang":"en","type":"review","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Fraser Health","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Chimeric antigen receptor; Internal medicine; Cytokine release syndrome; Ibrutinib; Oncology; Adverse effect; Immunotherapy; Leukemia; Idelalisib; Immunology; Cancer","score_opus":0.03877698807722168,"score_gpt":0.34124428812178104,"score_spread":0.30246730004455935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3216096981","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00035317367,0.99023026,7.5964726e-7,0.000009835734,0.00005900088,0.008539591,0.000020688201,0.000031593365,0.0007551097],"genre_scores_gemma":[0.000018210041,0.9975423,0.00006097652,0.0000596293,0.00014437355,0.00041662453,0.00015356981,0.00013021899,0.0014740535],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9955913,0.0009287451,0.0017153414,0.000677252,0.00060575496,0.0004816335],"domain_scores_gemma":[0.99720544,0.0006055407,0.00063445594,0.0012478267,0.00011962422,0.00018709028],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001218547,0.0005587824,0.0067675263,0.0003274915,0.000035328067,0.000020044681,0.00033400257,0.00036650256,0.0011425251],"category_scores_gemma":[0.0002715725,0.00042098312,0.0007040789,0.0013105032,0.00011231812,0.00003164353,0.00012812893,0.0006418616,0.00007089765],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026632062,0.00016621062,0.0000016447659,0.8674332,0.0007229327,0.000082906554,0.000042867377,1.3618764e-7,0.00023865445,0.0000020835275,0.00006167351,0.13122109],"study_design_scores_gemma":[0.006188942,0.00051965145,0.000003916011,0.83758205,0.003010624,0.00038873285,0.0000068491436,0.0000026638568,0.00014246478,3.4914083e-7,0.15183519,0.00031853435],"about_ca_topic_score_codex":0.000065563545,"about_ca_topic_score_gemma":0.0000035032278,"teacher_disagreement_score":0.15177351,"about_ca_system_score_codex":0.0028525607,"about_ca_system_score_gemma":0.009000612,"threshold_uncertainty_score":0.9998242},"labels":[],"label_agreement":null},{"id":"W3216151293","doi":"10.1093/neuonc/noab196.692","title":"EXTH-53. ANTI-ROBO1 CAR T CELLS EFFECTIVELY TARGET MALIGNANT BRAIN CANCER","year":2021,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada; McMaster University","funders":"","keywords":"Downregulation and upregulation; Cancer research; Chimeric antigen receptor; Glioma; Cancer; Degranulation; Medicine; Antigen; Antibody; Brain tumor; Cancer cell; Immunology; Immunotherapy; Biology; Receptor; Pathology; Internal medicine; Gene","score_opus":0.02928900314783732,"score_gpt":0.3489784364317776,"score_spread":0.3196894332839403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3216151293","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95955694,0.0012991823,0.00016368656,0.018285496,0.0021143008,0.0011853478,0.00006236365,0.00014942928,0.017183261],"genre_scores_gemma":[0.9454763,0.002310294,0.0012705927,0.026353061,0.0023333433,0.0004568011,0.00008867054,0.00028003316,0.02143092],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99663746,0.00087238493,0.00037264943,0.00081407157,0.00047923517,0.00082422275],"domain_scores_gemma":[0.9973201,0.0012473279,0.0001077857,0.00060663465,0.0003390229,0.00037912937],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000501403,0.00029445832,0.0008514581,0.00017904499,0.0001133887,0.000026985506,0.00021164257,0.00033913276,0.00978759],"category_scores_gemma":[0.00042307735,0.00027063492,0.00023556406,0.0005319142,0.00022055344,0.00006121981,0.00021566873,0.0008642348,0.00030789926],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043376393,0.00037099875,0.0037287578,0.00011609287,0.00012864642,0.0057469117,0.00042967655,0.000051788862,0.9349581,0.00005605667,0.031223169,0.02275605],"study_design_scores_gemma":[0.00219098,0.00091694435,0.0029251415,0.000034265642,0.00004437256,0.00041812193,0.00007024702,0.00010404517,0.5603808,0.00003592755,0.4327377,0.00014145183],"about_ca_topic_score_codex":0.00022015955,"about_ca_topic_score_gemma":0.00012293221,"teacher_disagreement_score":0.40151453,"about_ca_system_score_codex":0.000593876,"about_ca_system_score_gemma":0.0016016575,"threshold_uncertainty_score":0.9999746},"labels":[],"label_agreement":null},{"id":"W3216590746","doi":"10.1016/j.jcyt.2021.09.009","title":"ISCT survey on hospital practices to support externally manufactured investigational cell-gene therapy products","year":2021,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; International Society for Cellular Therapy","funders":"","keywords":"Pharmacy; Genetic enhancement; Apheresis; Medicine; Chimeric antigen receptor; Cell therapy; Product (mathematics); Pharmacology; Cell; Gene; Internal medicine; Immunotherapy; Family medicine; Chemistry","score_opus":0.078084679215216,"score_gpt":0.35575757478656456,"score_spread":0.27767289557134855,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3216590746","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9777845,0.00078155496,0.00006154055,0.016592832,0.000495297,0.0012194109,0.0000775592,0.00009781368,0.002889479],"genre_scores_gemma":[0.8850656,0.0025367287,0.0043876832,0.02005059,0.0019148816,0.00016463862,0.00068851805,0.00022673873,0.08496459],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99661916,0.00037802692,0.00039171675,0.0008987312,0.0011568329,0.000555536],"domain_scores_gemma":[0.997352,0.00031576696,0.00024997425,0.0009776374,0.00066920946,0.00043541437],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009608905,0.00036093238,0.00046479743,0.00020144567,0.00012850782,0.00015647362,0.0002941683,0.00015762405,0.009238036],"category_scores_gemma":[0.000499009,0.0003099358,0.00014435661,0.000579629,0.00010734322,0.0001588305,0.000045300163,0.0004693654,0.0004782827],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023946664,0.0011522605,0.027652426,0.000030955034,0.00024135388,0.00034740582,0.0011202758,0.000018040979,0.91488,0.000016693439,0.028544588,0.02360136],"study_design_scores_gemma":[0.002361445,0.002106147,0.25191307,0.00002826168,0.00000817786,0.000046946683,0.0000321938,0.0000035113603,0.63691103,0.000068977526,0.1062752,0.00024503627],"about_ca_topic_score_codex":0.00017869337,"about_ca_topic_score_gemma":0.000056018882,"teacher_disagreement_score":0.27796894,"about_ca_system_score_codex":0.00017593504,"about_ca_system_score_gemma":0.0012055235,"threshold_uncertainty_score":0.99993527},"labels":[],"label_agreement":null},{"id":"W3217304519","doi":"10.1182/blood-2021-149261","title":"A Phase II Study of Blinatumomab for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Blinatumomab; Minimal residual disease; Medicine; Internal medicine; Oncology; Salvage therapy; Hematopoietic stem cell transplantation; Philadelphia chromosome; Transplantation; Maintenance therapy; Donor lymphocyte infusion; Lymphoblastic Leukemia; Leukemia; Immunology; Gastroenterology; Chemotherapy; Chromosomal translocation; Biology","score_opus":0.031048777727325987,"score_gpt":0.32337302358971287,"score_spread":0.29232424586238687,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217304519","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943078,0.002845466,0.000023223216,0.00016709525,0.000052024072,0.0018080834,0.00019633326,0.000016138703,0.0005838418],"genre_scores_gemma":[0.99111825,0.00033931053,0.00009016144,0.00001895211,0.00010632248,0.00023010629,0.00004487538,0.000032998367,0.0080189975],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985326,0.00010335441,0.0002935943,0.00029744665,0.0005116059,0.00026141855],"domain_scores_gemma":[0.9982407,0.00051127543,0.00009512692,0.0005834808,0.00042838263,0.00014102254],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017027486,0.0001615567,0.00043292236,0.0000783795,0.00012792303,0.000010357117,0.00011163356,0.000041926593,0.00017249378],"category_scores_gemma":[0.00009292277,0.00010848567,0.00019108813,0.00028906533,0.00008224972,0.000025982054,0.00004409028,0.00006700092,0.0000023169412],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015642362,0.16373737,0.0018416193,0.0002830528,0.005346893,0.0011245722,0.006398993,0.00004026842,0.7931477,0.000036001107,0.0005192852,0.011881889],"study_design_scores_gemma":[0.11119109,0.045710694,0.002398117,0.000097045915,0.0054928283,0.000047448444,0.001596599,0.00032561447,0.83242595,0.000040314277,0.0005449508,0.00012932526],"about_ca_topic_score_codex":0.00009132804,"about_ca_topic_score_gemma":0.00003471503,"teacher_disagreement_score":0.118026674,"about_ca_system_score_codex":0.00017474063,"about_ca_system_score_gemma":0.0009446017,"threshold_uncertainty_score":0.44239172},"labels":[],"label_agreement":null},{"id":"W3217363670","doi":"10.1182/blood-2021-146237","title":"Cost per Responder Analysis to Assess the Value of CAR-T Therapy for Relapsed or Refractory Multiple Myeloma","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Medicine; Multiple myeloma; Oncology; Clinical trial; Internal medicine; Chimeric antigen receptor; Cost effectiveness; Immunotherapy; Cancer","score_opus":0.09148170366789479,"score_gpt":0.378496741030424,"score_spread":0.2870150373625292,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217363670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942809,0.00070050627,0.0007305455,0.0017838554,0.000084813146,0.0013451257,0.000067830246,0.00003197887,0.00097448676],"genre_scores_gemma":[0.9650378,0.00029133528,0.0030732418,0.0011516123,0.0002539532,0.0002925954,0.00007784096,0.00006432985,0.02975725],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99802685,0.00028880936,0.00033645378,0.00039678023,0.0006050943,0.00034604222],"domain_scores_gemma":[0.9966567,0.0014682339,0.000081197366,0.0010210407,0.0006086249,0.00016419095],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00085440854,0.00016498142,0.0005032678,0.00023724722,0.00010573458,0.000031869957,0.00022399634,0.00012575062,0.002785035],"category_scores_gemma":[0.00093015813,0.00010271498,0.00040099787,0.0011820932,0.00007128023,0.00004112462,0.00006627757,0.0002436921,0.0000142582585],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005629522,0.0012395402,0.02369866,0.000048640963,0.0039788065,0.00007551035,0.0016015174,0.000040308954,0.95095515,0.00005656794,0.001196364,0.011479394],"study_design_scores_gemma":[0.015038091,0.0015749257,0.17127368,0.000051920884,0.0017885389,0.000047323516,0.0017453965,0.00043362647,0.65069836,0.000032360796,0.15704632,0.00026943898],"about_ca_topic_score_codex":0.00008190657,"about_ca_topic_score_gemma":0.00022560118,"teacher_disagreement_score":0.3002568,"about_ca_system_score_codex":0.000062968575,"about_ca_system_score_gemma":0.00051415025,"threshold_uncertainty_score":0.99812657},"labels":[],"label_agreement":null},{"id":"W3217474359","doi":"10.1016/j.prp.2021.153723","title":"Cancer immunotherapy: Challenges and limitations","year":2021,"lang":"en","type":"review","venue":"Pathology - Research and Practice","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":198,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Immunosurveillance; Immunotherapy; Oncolytic virus; Cancer; Cancer immunotherapy; Medicine; Acquired resistance; Cancer research; Oncology; Immunology; Internal medicine","score_opus":0.503183840981943,"score_gpt":0.5564164942590247,"score_spread":0.05323265327708171,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217474359","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000013584336,0.9617853,0.0000024415597,0.009458768,0.00012030882,0.0011292293,0.000023444401,0.000041626274,0.027425295],"genre_scores_gemma":[0.000003389458,0.9874026,0.00059742574,0.00017656693,0.000391523,0.0007337746,0.000054553348,0.000112577385,0.0105275875],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9935433,0.0040113386,0.00036361956,0.00078947825,0.00061298243,0.0006792483],"domain_scores_gemma":[0.98012626,0.01799339,0.00013073062,0.0006519499,0.00079373736,0.000303949],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0052225925,0.00029172492,0.0013317519,0.00050548336,0.0002190173,0.000098014745,0.0001583744,0.0005248796,0.0006136485],"category_scores_gemma":[0.007944271,0.00020987328,0.00013557976,0.00042918467,0.00073435437,0.00017006624,0.00028007838,0.0025201181,0.000037301455],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021257425,0.00019935913,0.0000019427332,0.0053020264,0.00053377735,0.0015010155,0.0008137679,3.0159657e-9,0.00010415128,0.0007485887,0.0005131593,0.9900696],"study_design_scores_gemma":[0.0005253949,0.00066425547,0.000028938426,0.0027638979,0.00029974306,0.00568108,0.0010089945,5.235924e-7,0.0000032080266,0.00017556873,0.98867387,0.00017452148],"about_ca_topic_score_codex":0.000059207978,"about_ca_topic_score_gemma":0.000086335735,"teacher_disagreement_score":0.9898951,"about_ca_system_score_codex":0.00012795688,"about_ca_system_score_gemma":0.0011771481,"threshold_uncertainty_score":0.99978113},"labels":[],"label_agreement":null},{"id":"W3217544539","doi":"10.1016/j.cell.2021.11.016","title":"An NK-like CAR T cell transition in CAR T cell dysfunction","year":2021,"lang":"en","type":"article","venue":"Cell","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":401,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; Stand Up To Cancer; National Cancer Institute; National Institutes of Health; Incyte; Parker Institute for Cancer Immunotherapy; Bayer Fund; American Cancer Society; Stand Up To Cancer Canada; AstraZeneca; Celgene; GlaxoSmithKline","keywords":"Chimeric antigen receptor; Biology; T cell; CD8; Cancer research; Mesothelin; T-cell receptor; Immunology; Cell biology; Antigen; Immune system","score_opus":0.019103117811009353,"score_gpt":0.2763343176554929,"score_spread":0.2572311998444835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217544539","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94984037,0.0011706211,0.0003195388,0.00025470668,0.00040699317,0.00042082954,0.000013478048,0.000072059745,0.04750143],"genre_scores_gemma":[0.96300644,0.0004642919,0.00024502154,0.00053652574,0.00034512245,0.000026076392,0.0002922641,0.000063994405,0.035020296],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981021,0.00019516796,0.00028460074,0.00051790924,0.0004486502,0.00045155172],"domain_scores_gemma":[0.9988562,0.000053640408,0.000041953444,0.0006150344,0.00017028219,0.00026287898],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00031342637,0.0001996609,0.0003141595,0.00018994481,0.00006304055,0.00003666597,0.00010348896,0.00021582881,0.0049037486],"category_scores_gemma":[0.000007137132,0.00021009942,0.0001410004,0.0004829635,0.00005188639,0.0001228986,0.000020966638,0.00051568047,0.00030693994],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026826575,0.0006740131,0.0007516135,0.00035079548,0.000007871402,0.0004627498,0.0019491756,0.00018539054,0.9919459,0.0000018986701,0.0013974002,0.002004933],"study_design_scores_gemma":[0.004079278,0.0005421311,0.0016353327,0.000045487825,0.000060511342,0.000033578675,0.0018484788,0.0014480054,0.95091677,0.000030713487,0.039128892,0.00023082],"about_ca_topic_score_codex":0.0002670627,"about_ca_topic_score_gemma":0.0001392512,"teacher_disagreement_score":0.04102912,"about_ca_system_score_codex":0.0002567745,"about_ca_system_score_gemma":0.00027800674,"threshold_uncertainty_score":0.9960059},"labels":[],"label_agreement":null},{"id":"W3217693816","doi":"10.1007/978-3-030-81261-4_3","title":"Radioimaging of Activated T Cells in Preclinical and Clinical Cancer Investigations","year":2021,"lang":"en","type":"book-chapter","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Immunotherapy; Cancer immunotherapy; Immune system; Function (biology); Medicine; Cancer; Psychology; Cancer research; Computational biology; Immunology; Biology; Internal medicine; Cell biology","score_opus":0.15679950858505728,"score_gpt":0.4406685808928341,"score_spread":0.2838690723077768,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3217693816","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.079648055,0.0034573693,0.000015988451,0.0044070613,0.00043885875,0.0014539192,0.00006542076,0.000060607865,0.9104527],"genre_scores_gemma":[0.0066050976,0.011171452,0.0013085842,0.0005955042,0.00033481067,0.000014608694,0.00005952044,0.000076378565,0.979834],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980183,0.00007826761,0.00086801953,0.00048556956,0.00035589226,0.00019393845],"domain_scores_gemma":[0.9981219,0.00084913097,0.00015695872,0.0004207537,0.00019411749,0.00025711305],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00061570894,0.00019997341,0.00089041685,0.00021114007,0.000016305341,0.000012309885,0.00008504182,0.0004555741,0.014741483],"category_scores_gemma":[0.00024062158,0.00017941916,0.00019891499,0.000079386875,0.00053002144,0.000034293163,0.00012012672,0.0013001297,0.000009378709],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002146361,0.0010403027,0.14787409,0.002208586,0.0036493726,0.0008467817,0.00065901433,0.000014288352,0.41345,0.019595906,0.022584915,0.3859304],"study_design_scores_gemma":[0.017091878,0.0013409216,0.031373423,0.01009873,0.0012788849,0.00012373271,0.00016663324,0.0013015332,0.11290136,0.0052990494,0.8174941,0.0015297711],"about_ca_topic_score_codex":0.00023934069,"about_ca_topic_score_gemma":0.00028578477,"teacher_disagreement_score":0.7949092,"about_ca_system_score_codex":0.00010562729,"about_ca_system_score_gemma":0.00089117483,"threshold_uncertainty_score":0.9861592},"labels":[],"label_agreement":null},{"id":"W4200100973","doi":"10.1182/blood-2021-148009","title":"Primary Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL)","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Internal medicine; B-cell lymphoma; Oncology; Lymphoma","score_opus":0.013679287038108634,"score_gpt":0.27678842652890645,"score_spread":0.26310913949079784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200100973","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969382,0.0008066711,0.000014789687,0.000041130323,0.00003088259,0.0011433265,0.00017592996,0.000025825888,0.0008232094],"genre_scores_gemma":[0.99740326,0.00076552987,0.00015960087,0.000098538956,0.000045493412,0.000060781174,0.00035998595,0.000059503767,0.0010472832],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99670666,0.00028181873,0.0007420079,0.00060873624,0.0012080552,0.00045272856],"domain_scores_gemma":[0.9976636,0.00018393132,0.00032803268,0.0011322306,0.0005080194,0.0001841947],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005099908,0.0002991794,0.0012126438,0.00069678936,0.000062188104,0.000014328411,0.00023290757,0.00012500012,0.0015347445],"category_scores_gemma":[0.00007863709,0.00024367373,0.00025618655,0.0022917453,0.000073901814,0.00006562243,0.00012743643,0.00022665701,0.000006561786],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0066745393,0.21127781,0.7391284,0.00013720892,0.0053929375,0.00032780934,0.0020605256,0.00003500336,0.02229116,0.0000028443947,0.000023196924,0.012648551],"study_design_scores_gemma":[0.2391563,0.016342085,0.6418924,0.00007507315,0.002853234,0.0000037342927,0.0005101446,0.00008690343,0.098501444,0.000008356065,0.0003045764,0.00026574288],"about_ca_topic_score_codex":0.00096054014,"about_ca_topic_score_gemma":0.00082725537,"teacher_disagreement_score":0.23248176,"about_ca_system_score_codex":0.00009868094,"about_ca_system_score_gemma":0.00035146018,"threshold_uncertainty_score":0.99937797},"labels":[],"label_agreement":null},{"id":"W4200266275","doi":"10.1002/hep.32279","title":"Novel low‐avidity glypican‐3 specific CARTs resist exhaustion and mediate durable antitumor effects against HCC","year":2021,"lang":"en","type":"article","venue":"Hepatology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Genentech; National Cancer Institute; Eisai; Bristol-Myers Squibb","keywords":"Avidity; Cancer research; Monoclonal antibody; Epitope; Antigen; In vivo; Immunology; In vitro; Biology; Antibody; Biochemistry","score_opus":0.026228972041253212,"score_gpt":0.2889072019440803,"score_spread":0.2626782299028271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200266275","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902384,0.0020778102,0.000107285625,0.0022853708,0.00061560574,0.00040985714,0.000014447038,0.00007560184,0.0041756066],"genre_scores_gemma":[0.99196804,0.002754538,0.00056659145,0.0006481389,0.0003361789,0.000038149075,0.00011111896,0.00004005948,0.0035371825],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99813896,0.00016924542,0.00028327532,0.00056198327,0.00032497014,0.0005215623],"domain_scores_gemma":[0.99862516,0.00030942677,0.00006727484,0.0005237902,0.00019953721,0.00027479808],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003100159,0.00019926867,0.0005922687,0.00014289063,0.00013613376,0.000031502528,0.000081850674,0.00020305665,0.0007948419],"category_scores_gemma":[0.00030767382,0.00019264859,0.000089162306,0.00032130262,0.00028283533,0.00006337647,0.000113376474,0.00040476452,0.00010552512],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005040413,0.0002699525,0.090758696,0.00048445497,0.000075194,0.0031486566,0.00011842162,9.532889e-7,0.89366025,0.00046068607,0.004692171,0.0058265417],"study_design_scores_gemma":[0.009834019,0.00058815157,0.24304517,0.00040599564,0.00014632483,0.0033402168,0.00015477154,0.001082759,0.609668,0.00029847372,0.13084792,0.0005881978],"about_ca_topic_score_codex":0.00010710658,"about_ca_topic_score_gemma":0.00031823484,"teacher_disagreement_score":0.28399223,"about_ca_system_score_codex":0.00014446302,"about_ca_system_score_gemma":0.00031813915,"threshold_uncertainty_score":0.8702962},"labels":[],"label_agreement":null},{"id":"W4200335416","doi":"10.1182/blood-2021-153871","title":"A BCL2L1 Armoured BCMA Targeting CAR T Cell to Overcome Exhaustion and Enhance Persistence in Multiple Myeloma","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Chimeric antigen receptor; CD28; TIGIT; CD19; T cell; Antigen; Immunology; Cancer research; Biology; Medicine; Immune system","score_opus":0.025327477432969377,"score_gpt":0.2788545808456693,"score_spread":0.2535271034126999,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200335416","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99556136,0.0018350808,0.00004229578,0.0005472713,0.00005346594,0.00033735283,0.00000543514,0.000029596822,0.0015881279],"genre_scores_gemma":[0.99190074,0.00016802293,0.0024682544,0.00020765801,0.0001303667,0.00003075597,0.000014918852,0.000023288363,0.005055989],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987309,0.000065939006,0.0001892608,0.00038540352,0.0002964291,0.00033206816],"domain_scores_gemma":[0.9992989,0.00012322247,0.000029367586,0.00024928022,0.00011512245,0.00018410696],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025952296,0.00012057186,0.00023503127,0.000105722655,0.00005516686,0.000027394293,0.00006575627,0.00008002767,0.00041863322],"category_scores_gemma":[0.00038728656,0.00012551433,0.000055546403,0.0003714789,0.0000330908,0.00005216477,0.00008936677,0.00024247452,0.000033597964],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012470239,0.0003042435,0.05037184,0.00012722227,0.000019130795,0.00032565842,0.0016224819,0.000007442447,0.9446571,0.0000018519036,0.00008872679,0.0023496156],"study_design_scores_gemma":[0.0036767705,0.00023584209,0.09471081,0.00016767147,0.00004308581,0.00008688998,0.001329736,0.0002870429,0.89713883,0.000010613101,0.0021393374,0.00017339064],"about_ca_topic_score_codex":0.00008142122,"about_ca_topic_score_gemma":0.00008981612,"teacher_disagreement_score":0.047518276,"about_ca_system_score_codex":0.00006458909,"about_ca_system_score_gemma":0.000097657015,"threshold_uncertainty_score":0.5118326},"labels":[],"label_agreement":null},{"id":"W4200349633","doi":"10.1016/j.ccell.2021.12.005","title":"GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity","year":2021,"lang":"en","type":"article","venue":"Cancer Cell","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":163,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Hospital for Sick Children","funders":"Christian Doppler Forschungsgesellschaft; Deutsche Krebshilfe; National Cancer Institute; Entertainment Industry Foundation; Damon Runyon Cancer Research Foundation; Virginia and D.K. Ludwig Fund for Cancer Research; Stanford University; Canadian Institute for Advanced Research; Cancer Research Institute; Österreichische Nationalstiftung für Forschung, Technologie und Entwicklung; Alex's Lemonade Stand Foundation for Childhood Cancer; Burroughs Wellcome Fund; National Institutes of Health; Canada Research Chairs; Howard Hughes Medical Institute","keywords":"Chimeric antigen receptor; Neuroblastoma; Antigen; Cancer research; Biology; Immune system; Cell culture; Cell biology; Immunology; T cell; Genetics","score_opus":0.02552886023817936,"score_gpt":0.30407623545582546,"score_spread":0.2785473752176461,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200349633","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99302787,0.00060045626,0.0006272178,0.0007791837,0.0008287923,0.001060486,0.00010133126,0.00009858576,0.002876091],"genre_scores_gemma":[0.9824417,0.0023593046,0.0003767485,0.0015220686,0.00067739695,0.00010078268,0.00003953997,0.000092185895,0.012390224],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99759465,0.00013887169,0.00026477108,0.00072684896,0.00057039625,0.0007044663],"domain_scores_gemma":[0.99811685,0.00014323543,0.00011861835,0.0007219002,0.00045520114,0.00044420254],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00029748777,0.00030129845,0.00060486014,0.000062431274,0.0001515649,0.000046972502,0.0001820902,0.00017876788,0.0011866187],"category_scores_gemma":[0.00006275856,0.0002918047,0.00031814436,0.00027129604,0.00012081464,0.00010825048,0.00014740012,0.00039324784,0.000051557592],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001009067,0.00035413785,0.0026258337,0.00035469705,0.00009817336,0.00018366367,0.00023645198,0.000070519876,0.9770472,0.0000011088472,0.0020818955,0.015937226],"study_design_scores_gemma":[0.002804407,0.00024652676,0.008307863,0.00008274629,0.000073170486,0.000011483198,0.000065993096,0.0015272457,0.9726931,0.000011118429,0.013907158,0.00026920612],"about_ca_topic_score_codex":0.00018536794,"about_ca_topic_score_gemma":0.00061577145,"teacher_disagreement_score":0.01566802,"about_ca_system_score_codex":0.00050218136,"about_ca_system_score_gemma":0.0008008354,"threshold_uncertainty_score":0.9999534},"labels":[],"label_agreement":null},{"id":"W4200379562","doi":"10.1002/jha2.286","title":"Transverse myelitis after anti‐CD19 directed CAR T cell therapy for relapsed large B cell lymphoma","year":2021,"lang":"en","type":"article","venue":"eJHaem","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; North York General Hospital; University Health Network","funders":"","keywords":"Medicine; Vincristine; Cytokine release syndrome; Rituximab; Internal medicine; Lymphoma; Oncology; Gastroenterology; Cyclophosphamide; Surgery; Chimeric antigen receptor; Chemotherapy; Immunotherapy; Cancer","score_opus":0.01654318805029646,"score_gpt":0.2790110379962011,"score_spread":0.2624678499459046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200379562","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9821212,0.004237295,0.00019271216,0.0009277096,0.00043386692,0.0011055989,0.00022790219,0.00021855632,0.010535105],"genre_scores_gemma":[0.9067006,0.0016705109,0.0009079716,0.0009958465,0.00048139252,0.00020950199,0.0002379702,0.00013235696,0.08866385],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997641,0.00015045448,0.00033055927,0.0006017949,0.0005050522,0.0007710826],"domain_scores_gemma":[0.998433,0.00016344481,0.000051973017,0.0007286913,0.0003298849,0.00029302516],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003063721,0.00028877833,0.000528847,0.00013009364,0.000115294904,0.00004583251,0.00014991818,0.00023497122,0.008789985],"category_scores_gemma":[0.00003920904,0.0002670601,0.00043576153,0.00044602557,0.000070662325,0.00008157561,0.00003606928,0.00022503172,0.00018379881],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030960555,0.0022871713,0.0029127605,0.00032853294,0.00017966604,0.0015379433,0.003317012,0.0000011432086,0.95110977,0.00002041301,0.012942006,0.022267511],"study_design_scores_gemma":[0.019903293,0.00045039642,0.006336254,0.000049070553,0.00005983352,0.000043274664,0.00039133962,0.00014623583,0.4985721,0.000022640606,0.47377217,0.0002533712],"about_ca_topic_score_codex":0.00006177715,"about_ca_topic_score_gemma":0.000050021376,"teacher_disagreement_score":0.46083015,"about_ca_system_score_codex":0.00016250712,"about_ca_system_score_gemma":0.0003979333,"threshold_uncertainty_score":0.9999782},"labels":[],"label_agreement":null},{"id":"W4200426158","doi":"10.1101/2021.12.20.473538","title":"Delivery of CAR-T Cells in a Transient Injectable Stimulatory Hydrogel Niche Improves Treatment of Solid Tumors","year":2021,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Natural Sciences and Engineering Research Council of Canada; Bill and Melinda Gates Foundation; National Cancer Institute; National Science Foundation; National Institutes of Health; American Cancer Society","keywords":"Cancer research; Drug delivery; Cell; Medicine; Cell therapy; Materials science; Chemistry; Nanotechnology","score_opus":0.019270274563547917,"score_gpt":0.2598169713100371,"score_spread":0.2405466967464892,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200426158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99192834,0.005225837,0.000034006905,0.000034980563,0.00038205768,0.0019570733,0.00033235826,0.00008566895,0.00001969855],"genre_scores_gemma":[0.99635553,0.001905176,0.0010708738,0.000041909654,0.00015644406,0.00024181213,0.0000015359776,0.00017979121,0.00004690674],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99567795,0.00020226397,0.0012858661,0.0011645453,0.00087655836,0.0007928066],"domain_scores_gemma":[0.99625564,0.00015722925,0.0005179783,0.0018727141,0.00080949743,0.00038694005],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006150554,0.0007067467,0.0020172459,0.0007746886,0.00004349248,0.000032549935,0.00037717682,0.00063217257,0.00035054574],"category_scores_gemma":[0.000078808785,0.00071785745,0.0005666287,0.00088185456,0.00027313086,0.000088993285,0.00025439475,0.0007603368,0.0000063768075],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005393496,0.0018142532,0.0079004,0.0017995121,0.00062412745,0.00037878446,0.0002218141,0.0006172351,0.9860523,0.000005108713,0.000021981152,0.00002515368],"study_design_scores_gemma":[0.003113326,0.00086216826,0.03741712,0.0012135191,0.0002999899,9.740986e-8,0.000052810225,0.00141302,0.9547988,3.2541763e-7,0.00035213566,0.0004766979],"about_ca_topic_score_codex":0.001151062,"about_ca_topic_score_gemma":0.000039279665,"teacher_disagreement_score":0.03125349,"about_ca_system_score_codex":0.0011272125,"about_ca_system_score_gemma":0.0034375535,"threshold_uncertainty_score":0.9995273},"labels":[],"label_agreement":null},{"id":"W4200449197","doi":"10.1182/blood-2021-146177","title":"Meta-Analysis of Ciltacabtagene Autoleucel Versus Physician's Choice in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma","year":2021,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Pomalidomide; Multiple myeloma; Medicine; Refractory (planetary science); Lenalidomide; Internal medicine; Thalidomide; Oncology; Surgery","score_opus":0.08879304162732031,"score_gpt":0.3271464727081697,"score_spread":0.2383534310808494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200449197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997392,0.00095795636,0.0000025514532,0.00010022541,0.000020658304,0.00046403686,0.000087301094,0.000009180819,0.00096610724],"genre_scores_gemma":[0.99733603,0.00009934707,0.0002861576,0.0000654937,0.000031963868,0.000071839764,0.00015569902,0.000021811438,0.0019316586],"study_design_codex":"meta_analysis","study_design_gemma":"observational","domain_scores_codex":[0.9982467,0.00021486504,0.00033376744,0.00029115376,0.0007047553,0.00020874868],"domain_scores_gemma":[0.99790734,0.0007981667,0.00016289977,0.0008162793,0.000260613,0.00005472939],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00015632689,0.00016684769,0.000987758,0.0002010652,0.000026553245,0.000006763641,0.00012495677,0.000062456624,0.0009572888],"category_scores_gemma":[0.000106584645,0.00008802786,0.00056763564,0.0014044907,0.000070664835,0.0000377773,0.000019584457,0.00011017729,0.0000028717109],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014460938,0.052129086,0.21796551,0.00019898755,0.5668073,0.0004764821,0.006171191,0.00019337378,0.12416388,0.000014353614,0.00007843701,0.017340453],"study_design_scores_gemma":[0.036930088,0.0063759373,0.5690952,0.0000151457725,0.24395192,0.0000012784644,0.00050433597,0.00013502804,0.13779028,0.0000016027329,0.005015757,0.00018344165],"about_ca_topic_score_codex":0.00029911753,"about_ca_topic_score_gemma":0.0011116123,"teacher_disagreement_score":0.35112968,"about_ca_system_score_codex":0.00006741086,"about_ca_system_score_gemma":0.0001711217,"threshold_uncertainty_score":0.99995595},"labels":[],"label_agreement":null},{"id":"W4205148539","doi":"10.1111/nyas.14724","title":"Strategies to overcome the side effects of chimeric antigen receptor T cell therapy","year":2022,"lang":"en","type":"review","venue":"Annals of the New York Academy of Sciences","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University","funders":"","keywords":"Chimeric antigen receptor; Cell therapy; Antigen; Receptor; Cytokine release syndrome; Cell; Immunotherapy; Immunology; T cell; Genetic enhancement; Immune system; Cancer research; Medicine; Biology; Gene; Internal medicine; Genetics","score_opus":0.19587190234869334,"score_gpt":0.43507989860712987,"score_spread":0.23920799625843653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205148539","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0039128806,0.9855509,9.781904e-7,0.003992446,0.0002241182,0.0022354908,0.000020412037,0.000014319381,0.004048493],"genre_scores_gemma":[0.0010779892,0.9940166,0.00010598683,0.00076726713,0.00023089496,0.000046900328,0.0000017949585,0.000034871206,0.0037176984],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9955648,0.0006667794,0.000848659,0.0005042839,0.0018959477,0.0005195333],"domain_scores_gemma":[0.9966206,0.0017510637,0.0009478992,0.00046371997,0.000049376526,0.00016732104],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0025519333,0.00037871252,0.0017534452,0.00036980983,0.00023776511,0.000035713907,0.0029606645,0.00020578639,0.0009310386],"category_scores_gemma":[0.00020153908,0.00018381714,0.0009951997,0.002970759,0.0012265097,0.00010799496,0.00044993547,0.00087665516,0.000013135362],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009907065,0.00014463812,0.000025943427,0.005206291,0.00030952014,4.908246e-7,0.0010823493,0.000021149266,0.014174527,0.00023543106,0.019350158,0.9593504],"study_design_scores_gemma":[0.00020925689,0.00088929915,0.00026127804,0.0033893224,0.00010089629,0.000007017859,0.00031412687,0.0000011848865,0.030951465,0.00043641072,0.9632689,0.00017088014],"about_ca_topic_score_codex":0.00030615766,"about_ca_topic_score_gemma":0.0000012628085,"teacher_disagreement_score":0.9591796,"about_ca_system_score_codex":0.00002696652,"about_ca_system_score_gemma":0.0011363487,"threshold_uncertainty_score":0.99998224},"labels":[],"label_agreement":null},{"id":"W4205454814","doi":"10.1200/jco.2022.40.4_suppl.tps363","title":"SURPASS-2 trial design: A phase 2, open-label study of ADP-A2M4CD8 SPEAR T cells in advanced esophageal or esophagogastric junction cancers.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; CD8; Internal medicine; Oncology; Gastroenterology; Adverse effect; Antigen; Phases of clinical research; Chemotherapy; Immunology","score_opus":0.3690196111746434,"score_gpt":0.5659463194330353,"score_spread":0.19692670825839192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205454814","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99184537,0.00028330443,0.00012229415,0.00072881713,0.0033646633,0.0030823452,0.000008956345,0.000008226012,0.00055604865],"genre_scores_gemma":[0.99084526,0.00043235192,0.0026755044,0.0005542071,0.0012768842,0.000106986954,0.0000032096227,0.000044122287,0.004061456],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98990536,0.004008416,0.0039393315,0.00041867307,0.0012762249,0.00045198126],"domain_scores_gemma":[0.9918287,0.0044205994,0.002424365,0.00040388957,0.00048050735,0.00044197965],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.014481993,0.00021840961,0.0026210067,0.0005982699,0.00009613678,0.000017450468,0.00070765533,0.00022928398,0.0044698236],"category_scores_gemma":[0.0029748972,0.00016931357,0.00028342975,0.0011345085,0.00016266307,0.00020555411,0.00038188975,0.0026436795,0.000008521578],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7594308,0.052857883,0.001265367,0.000020722973,0.0004530646,0.005129875,0.00043095608,0.0009928204,0.0041683805,0.0000028822126,0.0037084385,0.17153879],"study_design_scores_gemma":[0.5900089,0.38814935,0.002051999,0.000030845975,0.00028974225,0.0002549624,0.0017682329,0.0004994645,0.00045840375,0.000034443503,0.016333649,0.00012002105],"about_ca_topic_score_codex":0.00030684788,"about_ca_topic_score_gemma":0.0002571214,"teacher_disagreement_score":0.33529148,"about_ca_system_score_codex":0.0013545908,"about_ca_system_score_gemma":0.00883958,"threshold_uncertainty_score":0.9996573},"labels":[],"label_agreement":null},{"id":"W4205468989","doi":"10.1007/s00262-021-03088-y","title":"Combination immunotherapy including OncoVEXmGMCSF creates a favorable tumor immune micro-environment in transgenic BRAF murine melanoma","year":2022,"lang":"en","type":"article","venue":"Cancer Immunology Immunotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Center for Advancing Translational Sciences; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institutes of Health; National Cancer Institute; Fundação para a Ciência e a Tecnologia; U.S. Food and Drug Administration; Swim Across America","keywords":"Oncolytic virus; Medicine; Cancer research; Melanoma; Immunotherapy; Immune system; FOXP3; Cytotoxic T cell; Immune checkpoint; Tumor microenvironment; Combination therapy; CD8; Immunology; Pharmacology; Biology","score_opus":0.026589077853391038,"score_gpt":0.3032453718668765,"score_spread":0.27665629401348546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205468989","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89932996,0.09249949,0.00008554717,0.0039490466,0.00068483595,0.0022044433,0.00006933718,0.00018006937,0.0009972405],"genre_scores_gemma":[0.9436567,0.03960151,0.00033383092,0.0016718444,0.00010764181,0.0028842376,0.00022400761,0.0003069502,0.011213296],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99479383,0.0007803362,0.0012747195,0.0010251746,0.0007875503,0.0013383772],"domain_scores_gemma":[0.997724,0.00026198415,0.0004072736,0.0013954069,0.000105548934,0.000105789615],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013700115,0.00070157455,0.0013527076,0.0010177429,0.0007473299,0.00006968954,0.00094511796,0.00023700745,0.03773011],"category_scores_gemma":[0.000019763018,0.00074638426,0.0005099927,0.0011139358,0.00052038854,0.00026719391,0.00028419253,0.0018658213,0.000087683235],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008976177,0.0015867081,0.014555653,0.000049834096,0.0012571102,0.00013676508,0.0027216836,0.00023582445,0.9079074,0.00009539736,0.00011916022,0.062358286],"study_design_scores_gemma":[0.05519603,0.0071796263,0.13942578,0.0002674263,0.00012009547,0.0009019762,0.0027356562,0.00032447226,0.53172696,0.0010974639,0.2594071,0.0016173815],"about_ca_topic_score_codex":0.0028831866,"about_ca_topic_score_gemma":0.000044596098,"teacher_disagreement_score":0.37618044,"about_ca_system_score_codex":0.003773855,"about_ca_system_score_gemma":0.00067681214,"threshold_uncertainty_score":0.9994987},"labels":[],"label_agreement":null},{"id":"W4205484767","doi":"10.1158/1078-0432.ccr-21-3261","title":"Anti-CD79B Antibody–Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study","year":2022,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"National Cancer Institute; National Institutes of Health","keywords":"Medicine; Neutropenia; Lymphoma; Internal medicine; Adverse effect; Phases of clinical research; Diffuse large B-cell lymphoma; Rituximab; Nausea; Gastroenterology; Pharmacokinetics; Oncology; Chemotherapy","score_opus":0.11104047886958199,"score_gpt":0.516506773739555,"score_spread":0.405466294869973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205484767","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99194425,0.00022705544,0.0000058293726,0.00096430787,0.00031444433,0.004636184,0.0000799618,0.000049364553,0.0017786191],"genre_scores_gemma":[0.99318486,0.00021528768,0.00003277567,0.00028192915,0.0003555292,0.00068061566,0.00017282383,0.00010940691,0.0049667642],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9905149,0.0022723805,0.0011251753,0.0012014365,0.0037045241,0.0011816124],"domain_scores_gemma":[0.9961572,0.001201748,0.00017204885,0.0010886112,0.0008281203,0.0005522558],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.008992269,0.0002956557,0.0009380728,0.00070690643,0.00046693784,0.0000869693,0.0006226296,0.00011561905,0.0060165613],"category_scores_gemma":[0.00036506946,0.0002507533,0.00018202032,0.002342799,0.00053212064,0.00016276792,0.00075023755,0.0022908002,0.000107774715],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020472972,0.024707241,0.9140695,0.00009290611,0.0001394708,0.0003531364,0.0006761297,0.00006437748,0.0028651017,0.000003143101,0.0026404476,0.03391561],"study_design_scores_gemma":[0.081803255,0.0132837575,0.89122796,0.00008893358,0.00005112049,0.0000030876581,0.0010301512,0.0008780451,0.00059191865,0.000020034144,0.010714802,0.00030694253],"about_ca_topic_score_codex":0.0025691653,"about_ca_topic_score_gemma":0.00030044597,"teacher_disagreement_score":0.061330285,"about_ca_system_score_codex":0.0009780086,"about_ca_system_score_gemma":0.0016206908,"threshold_uncertainty_score":0.99999446},"labels":[],"label_agreement":null},{"id":"W4205632133","doi":"10.51731/cjht.2021.187","title":"Brexucabtagene Autoleucel (Tecartus)","year":2021,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Mantle cell lymphoma; Chimeric antigen receptor; Bruton's tyrosine kinase; Medicine; CD19; Lymphoma; Drug; Immunotherapy; Cell therapy; Oncology; Tyrosine kinase; Pharmacology; Immunology; Internal medicine; Cell; Antigen; Receptor; Cancer; Biology; Health care; Political science","score_opus":0.05133370576819875,"score_gpt":0.3399551668119211,"score_spread":0.2886214610437224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205632133","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.45144227,0.24815871,0.00035736483,0.2881648,0.0013007381,0.0005794724,0.00004278888,0.00033601862,0.009617839],"genre_scores_gemma":[0.99132526,0.0019395294,0.0014020939,0.0015761777,0.000042002386,0.000003916299,0.0000055906735,0.000029231438,0.003676175],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99830985,0.00007327688,0.0005312132,0.00016033318,0.00029606858,0.0006292793],"domain_scores_gemma":[0.99862975,0.000055230295,0.00019722056,0.0004322995,0.00043231534,0.00025319948],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00071283686,0.00012244201,0.00048346276,0.0006513828,0.00017738035,0.000038516595,0.0002484294,0.00017894598,0.0010848988],"category_scores_gemma":[0.0008457411,0.000108580214,0.00012358138,0.000692441,0.00022799247,0.00006601106,0.000029968105,0.00080178276,0.000022252983],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026320118,0.000030603904,0.003969183,0.00014488495,0.000087879474,0.0030547979,0.0001890315,0.000004107027,0.009563848,0.00055915274,0.013344038,0.96902615],"study_design_scores_gemma":[0.0009534638,0.0005818601,0.008816459,0.0003123181,0.000018023396,0.0050936756,0.0030774022,0.000011417996,0.023648921,0.00079990696,0.9565656,0.00012091366],"about_ca_topic_score_codex":0.002025114,"about_ca_topic_score_gemma":0.0038781767,"teacher_disagreement_score":0.9689052,"about_ca_system_score_codex":0.00072100526,"about_ca_system_score_gemma":0.01188798,"threshold_uncertainty_score":0.9998282},"labels":[],"label_agreement":null},{"id":"W4205646931","doi":"10.1186/s42466-021-00166-5","title":"Neurological management and work-up of neurotoxicity associated with CAR T cell therapy","year":2022,"lang":"en","type":"article","venue":"Neurological Research and Practice","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Neurotoxicity; Cytokine release syndrome; Neurological examination; Post-concussion syndrome; Internal medicine; Oncology; Surgery; Concussion; Chimeric antigen receptor; Poison control; Immunotherapy; Toxicity; Emergency medicine; Injury prevention","score_opus":0.14597740654451466,"score_gpt":0.39636067233731453,"score_spread":0.2503832657927999,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4205646931","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9764541,0.00069378474,0.00000530771,0.0080541335,0.00003507386,0.001415831,0.00000968805,0.00004562951,0.013286463],"genre_scores_gemma":[0.9895927,0.0029811582,0.000119124255,0.0030350173,0.000034782912,0.00019932493,0.0000088165625,0.000026797883,0.0040023285],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99314934,0.0035009435,0.0002463264,0.0006874527,0.0017323194,0.0006836422],"domain_scores_gemma":[0.9920073,0.006862459,0.00010291491,0.00039269865,0.00027270688,0.00036191312],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0038578573,0.00018308245,0.00035830063,0.0002087328,0.00041716773,0.000059508842,0.00024931363,0.0001047033,0.001519255],"category_scores_gemma":[0.0021536613,0.00012707862,0.00005040588,0.0009998148,0.0006778441,0.00010326043,0.0007143771,0.0024161641,0.000004123197],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4104568,0.0131576415,0.29074368,0.0002897431,0.0007236212,0.020062298,0.0009816936,0.00008707411,0.09979231,0.0016505851,0.008842262,0.1532123],"study_design_scores_gemma":[0.013342468,0.11030273,0.59460133,0.000018442182,0.000103606086,0.0011510445,0.00042449537,0.00041870802,0.0015437682,0.0008210034,0.27687496,0.0003974343],"about_ca_topic_score_codex":0.000023741439,"about_ca_topic_score_gemma":0.0000012324695,"teacher_disagreement_score":0.39711434,"about_ca_system_score_codex":0.000023801022,"about_ca_system_score_gemma":0.0000655255,"threshold_uncertainty_score":0.9998853},"labels":[],"label_agreement":null},{"id":"W4206052126","doi":"10.1016/j.jcyt.2021.10.010","title":"Use of CRISPR/Cas9 gene editing to improve chimeric antigen-receptor T cell therapy: A systematic review and meta-analysis of preclinical studies","year":2022,"lang":"en","type":"review","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Canadian Blood Services; Ottawa Hospital","funders":"Canadian Blood Services","keywords":"Chimeric antigen receptor; CRISPR; Genome editing; Genetic enhancement; Cas9; Biology; Immune system; Cancer; Melanoma; Leukemia; Immunotherapy; Cancer research; Immunology; Gene; Computational biology; Medicine; Genetics","score_opus":0.40247571748708266,"score_gpt":0.48758415601826116,"score_spread":0.0851084385311785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206052126","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010133423,0.98839724,0.000030136103,0.0001731224,0.00012812325,0.010557065,0.0005448116,0.00003784771,0.000030335197],"genre_scores_gemma":[0.000005461448,0.9920004,0.0010122821,0.0009774434,0.00013237903,0.0022620019,0.00011233437,0.00019511438,0.0033025865],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99189216,0.0019866568,0.0033006705,0.0011131107,0.0011940501,0.0005133293],"domain_scores_gemma":[0.99196243,0.0030047554,0.0022377362,0.0020460906,0.00047333413,0.00027566394],"candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0033735645,0.0008925683,0.021645889,0.0010911612,0.00009874646,0.00003464951,0.0005404674,0.00024694353,0.008317916],"category_scores_gemma":[0.0008577343,0.00057109026,0.0058739674,0.0030284175,0.00023414555,0.00007798689,0.00023272251,0.00069731905,0.000012839895],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000829667,0.00035488064,0.0000044017766,0.5982124,0.36461765,0.000009756473,0.00040945486,7.8561135e-7,0.00093625445,0.0000020058815,0.0005348535,0.034834575],"study_design_scores_gemma":[0.00050595327,0.0013126391,0.0000014644638,0.015275064,0.6134766,0.00001868087,0.00009251394,0.0000044042254,0.0005547807,0.0000011785697,0.3682904,0.00046633626],"about_ca_topic_score_codex":0.000053386633,"about_ca_topic_score_gemma":0.000003946909,"teacher_disagreement_score":0.58293736,"about_ca_system_score_codex":0.00018017006,"about_ca_system_score_gemma":0.00034457905,"threshold_uncertainty_score":0.9996741},"labels":[],"label_agreement":null},{"id":"W4206063127","doi":"10.1016/j.jaci.2021.11.007","title":"Emerging strategies for treating autoimmune disorders with genetically modified Treg cells","year":2022,"lang":"en","type":"review","venue":"Journal of Allergy and Clinical Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Children's Hospital","funders":"Canadian Institutes of Health Research","keywords":"Chimeric antigen receptor; Cell therapy; Immunotherapy; Medicine; Immunology; Treg cell; Genetic enhancement; Genome editing; Clinical trial; T cell; Computational biology; Cell; Biology; Immune system; Bioinformatics; Gene; IL-2 receptor; CRISPR","score_opus":0.07861406624080433,"score_gpt":0.41250920472064845,"score_spread":0.3338951384798441,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206063127","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010183767,0.9956135,0.0004398712,0.00031280323,0.00045546165,0.0006023003,0.0000064944943,0.000015272188,0.0015359052],"genre_scores_gemma":[0.000055110635,0.9962151,0.0009868208,0.000053081887,0.00030332254,0.000044152588,0.000022963692,0.00007992621,0.0022395388],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99632424,0.00057065627,0.0019702245,0.00036714325,0.00031542577,0.00045229867],"domain_scores_gemma":[0.9958045,0.0023856894,0.001157175,0.00035600862,0.00015126089,0.00014536503],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012117637,0.00038013357,0.0028476752,0.00029489901,0.0001773024,0.000045092227,0.0003518262,0.00049175875,0.0014856949],"category_scores_gemma":[0.00021562751,0.00025460348,0.0011130009,0.00021342098,0.00047123522,0.0000687362,0.0001386091,0.0019965644,0.0000019883896],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021183514,0.00042009057,0.000003075515,0.00082857994,0.00851327,0.00009333813,0.00008300763,0.000015586196,0.000060228143,0.00030960064,0.00007706988,0.9874778],"study_design_scores_gemma":[0.0037848684,0.0090127215,0.000058121874,0.0016292676,0.0014027414,0.0005511708,0.0005751499,0.00005641877,0.0000014526722,0.00027749047,0.9824087,0.00024186741],"about_ca_topic_score_codex":0.000018481096,"about_ca_topic_score_gemma":0.00003532924,"teacher_disagreement_score":0.98723596,"about_ca_system_score_codex":0.00009625995,"about_ca_system_score_gemma":0.0013837393,"threshold_uncertainty_score":0.99999064},"labels":[],"label_agreement":null},{"id":"W4206319885","doi":"10.1002/jha2.375","title":"Phase Ib study of combinations of avadomide (CC‐122), CC‐223, CC‐292, and rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma","year":2022,"lang":"en","type":"article","venue":"eJHaem","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Celgene; Bristol-Myers Squibb","keywords":"Medicine; Rituximab; Internal medicine; Tolerability; Refractory (planetary science); Adverse effect; Diffuse large B-cell lymphoma; Gastroenterology; Clinical endpoint; Neutropenia; Phases of clinical research; Lymphoma; Pharmacodynamics; Oncology; Toxicity; Pharmacology; Clinical trial; Pharmacokinetics","score_opus":0.014674722346112092,"score_gpt":0.2874215979630838,"score_spread":0.2727468756169717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206319885","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99680364,0.00032420017,0.000004807275,0.000061946936,0.000090931586,0.0015022395,0.000116551404,0.000026009719,0.0010696844],"genre_scores_gemma":[0.9973129,0.00003507405,0.000038412978,0.000058876463,0.000017433495,0.00009617044,0.00009447912,0.000053165535,0.0022935108],"study_design_codex":"nonrandomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9974994,0.00030290644,0.0004907367,0.00037393207,0.0009849813,0.00034806],"domain_scores_gemma":[0.99865466,0.00020762095,0.0002110519,0.0005895407,0.00019141402,0.0001457168],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053863093,0.00019939018,0.00058393483,0.0004455869,0.00013460852,0.000009720708,0.00019487267,0.000057680292,0.0001487711],"category_scores_gemma":[0.000084465835,0.00018247728,0.00006526225,0.0005781693,0.00013355972,0.000098987184,0.00024461685,0.00036441852,0.0000060061816],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032858795,0.95826,0.028015956,0.00008660316,0.0001225149,0.000079993595,0.005805792,1.3575914e-7,0.00034678797,0.000036408874,0.00041116666,0.0035487795],"study_design_scores_gemma":[0.96351314,0.0111431535,0.017331023,0.00004063726,0.000093035,0.0000051846905,0.0041493657,0.00012098072,0.00081472896,0.00002723474,0.0025976496,0.00016386097],"about_ca_topic_score_codex":0.0003038869,"about_ca_topic_score_gemma":0.0001616116,"teacher_disagreement_score":0.96022725,"about_ca_system_score_codex":0.00023409525,"about_ca_system_score_gemma":0.00016104565,"threshold_uncertainty_score":0.7441208},"labels":[],"label_agreement":null},{"id":"W4206716689","doi":"10.1126/science.abm0594","title":"CAR T cells produced in vivo to treat cardiac injury","year":2022,"lang":"en","type":"article","venue":"Science","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1241,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Acuitas Therapeutics (Canada)","funders":"National Institute of Allergy and Infectious Diseases; National Heart, Lung, and Blood Institute","keywords":"In vivo; Chimeric antigen receptor; Cardiac fibrosis; Fibrosis; Cardiac function curve; Ex vivo; Antigen; Messenger RNA","score_opus":0.02245622904933814,"score_gpt":0.33541629015949165,"score_spread":0.3129600611101535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206716689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881242,0.000059222402,7.4402095e-7,0.0010905215,0.00035198996,0.0006176165,0.000015545496,0.000024788033,0.009715394],"genre_scores_gemma":[0.97430634,0.000011518414,0.000097883996,0.0003818581,0.00008510504,0.00010172962,7.167647e-7,0.000010677669,0.025004167],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980599,0.000058999274,0.00010924158,0.00043551504,0.00093217543,0.00040411172],"domain_scores_gemma":[0.9992185,0.00002600949,0.000013364899,0.0004863854,0.00006131297,0.00019440227],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013313579,0.00007029633,0.00015487333,0.0003655348,0.000163409,0.00002284373,0.0003120076,0.000012014727,0.002285717],"category_scores_gemma":[0.00009648245,0.00006426802,0.00003945325,0.0022656808,0.00016534088,0.0000642447,0.00028274622,0.00020345315,0.00006221653],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010151975,0.000045450055,0.004826482,0.000007747376,0.0000011646893,0.000020158219,0.0010976527,0.00003168678,0.98388696,0.000011400897,0.0018827075,0.008087097],"study_design_scores_gemma":[0.00021281747,0.0004021507,0.0030451464,0.000006111312,0.000002935808,0.0000046375117,0.0003918729,0.000036784288,0.9298099,0.000013531803,0.066,0.00007406869],"about_ca_topic_score_codex":0.00017282285,"about_ca_topic_score_gemma":0.0000050845315,"teacher_disagreement_score":0.06411729,"about_ca_system_score_codex":0.0005049471,"about_ca_system_score_gemma":0.00054804387,"threshold_uncertainty_score":0.99862635},"labels":[],"label_agreement":null},{"id":"W4206737391","doi":"10.3390/cancers14030503","title":"Chimeric Antigen Receptor T-Cell Therapy in Metastatic Castrate-Resistant Prostate Cancer","year":2022,"lang":"en","type":"review","venue":"Cancers","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Partenariat Canadien Contre Le Cancer; Australian Government; PA Research Foundation","keywords":"Prostate cancer; Medicine; Chimeric antigen receptor; Immunotherapy; Cancer; Clinical trial; Oncology; Targeted therapy; Prostate; Antigen; Internal medicine; Immunology","score_opus":0.1092525452124946,"score_gpt":0.4015275827211105,"score_spread":0.2922750375086159,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206737391","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0012380505,0.9901325,3.7844035e-7,0.000057870886,0.0006397645,0.004235738,0.00039826165,0.000056398483,0.0032410366],"genre_scores_gemma":[0.000024416224,0.97591895,0.000075611744,0.00015498453,0.00021700982,0.0030532253,0.0003722744,0.00024091583,0.019942617],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961062,0.00047488618,0.000831916,0.00089386944,0.0008086772,0.0008844521],"domain_scores_gemma":[0.99832743,0.00018190968,0.00038495823,0.00074749097,0.000064962005,0.0002932154],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00061091746,0.00065602176,0.0024254129,0.000578604,0.00010880954,0.00004831997,0.0004158443,0.00013986307,0.043761615],"category_scores_gemma":[0.00002758657,0.00053405977,0.0005899918,0.0018022439,0.00017037326,0.00006163096,0.000082189385,0.0013496061,0.00008445324],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00045383186,0.00006786556,0.000026581689,0.009338965,0.0005257982,0.0002794984,0.00045249396,0.000027240218,0.00075979385,0.000001775248,0.0031138381,0.98495233],"study_design_scores_gemma":[0.0016473508,0.0005325024,0.000009354068,0.0031838675,0.00024011968,0.000024117491,0.00022011099,0.0000092358905,0.00010413731,0.0000027687547,0.99355155,0.00047488773],"about_ca_topic_score_codex":0.0046715103,"about_ca_topic_score_gemma":0.00030798028,"teacher_disagreement_score":0.9904377,"about_ca_system_score_codex":0.007733155,"about_ca_system_score_gemma":0.011477147,"threshold_uncertainty_score":0.9997111},"labels":[],"label_agreement":null},{"id":"W4207068215","doi":"","title":"CAR T Cells Produced in vivo to Treat Cardiac Injury","year":2023,"lang":"en","type":"article","venue":"HAL (Le Centre pour la Communication Scientifique Directe)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":940,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Acuitas Therapeutics (Canada)","funders":"","keywords":"In vivo; Spleen; Chimeric antigen receptor; Messenger RNA; Fibrosis; Ex vivo; Antigen; Cardiac fibrosis; Immunology; Cell biology; Cancer research; Biology; Medicine; T cell; Pathology; Immune system; Gene","score_opus":0.019403636445179194,"score_gpt":0.2824189550589764,"score_spread":0.26301531861379723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4207068215","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9347064,0.00012036583,0.00012655146,0.0127994325,0.0001366013,0.00091760943,0.000042158983,0.00025173984,0.05089918],"genre_scores_gemma":[0.8249031,0.00048879767,0.001673659,0.00018446436,0.000053704138,0.00015703523,0.00010665835,0.000068996305,0.17236361],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99609447,0.002017421,0.00032192713,0.0005697563,0.0005122687,0.000484163],"domain_scores_gemma":[0.99654424,0.00066409115,0.000062506864,0.001619174,0.000815092,0.00029489552],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0044002295,0.0001849393,0.00034504212,0.0004757897,0.00012719084,0.00008678381,0.0004044727,0.00010768365,0.0008876223],"category_scores_gemma":[0.00092940393,0.00018655453,0.00014258106,0.0018305506,0.00009803496,0.000076715754,0.0003049398,0.00030359373,0.00044795836],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000746562,0.00020797024,0.0072524967,0.00006439461,0.000022092805,0.000015839676,0.0058181165,0.000006635409,0.9404578,0.0006862337,0.009884249,0.03550951],"study_design_scores_gemma":[0.00057699875,0.0000018471177,0.0054109273,0.0003139835,0.000015012731,0.0000027060353,0.00019363077,0.00040910317,0.9189836,0.00006519201,0.073859245,0.00016776643],"about_ca_topic_score_codex":0.0011015898,"about_ca_topic_score_gemma":0.0003700551,"teacher_disagreement_score":0.121464424,"about_ca_system_score_codex":0.00021321302,"about_ca_system_score_gemma":0.00021458259,"threshold_uncertainty_score":0.97188413},"labels":[],"label_agreement":null},{"id":"W4210288800","doi":"10.1016/j.crmeth.2021.100153","title":"Autologous humanized mouse models of iPSC-derived tumors enable characterization and modulation of cancer-immune cell interactions","year":2022,"lang":"en","type":"article","venue":"Cell Reports Methods","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; Fondation Charles-Bruneau","keywords":"Immune system; Humanized mouse; Nivolumab; Cancer research; Cell; Induced pluripotent stem cell; Cancer cell; Biology; Immunology; Immunotherapy; Cancer; Embryonic stem cell","score_opus":0.053789948680657215,"score_gpt":0.37606945984131085,"score_spread":0.3222795111606536,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210288800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9710927,0.0004372622,0.024705114,0.000059098464,0.00026721542,0.00075793936,0.000014843952,0.00004827846,0.0026175207],"genre_scores_gemma":[0.96086216,0.00021569405,0.015232974,0.000021902939,0.000037124137,0.00013893082,0.00014945933,0.000049475115,0.023292288],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977162,0.00047922294,0.00084221846,0.00036286016,0.00038151746,0.00021799661],"domain_scores_gemma":[0.998134,0.0001526162,0.0008182633,0.00054145843,0.0002667599,0.00008689933],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013769921,0.00015617715,0.00058146665,0.0003119645,0.00014479391,0.000011032956,0.00007604674,0.000057614412,0.0021245908],"category_scores_gemma":[0.00008642633,0.00016185052,0.00012337479,0.00035303595,0.0000939238,0.00013602816,0.00016383738,0.00032114264,2.2332088e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002757226,0.0003208578,0.00080660265,0.0002549583,0.000048640733,0.000046246594,0.0013196745,0.0030086027,0.974655,0.000011886695,0.000011978218,0.019239835],"study_design_scores_gemma":[0.0007625165,0.00022436374,0.004771271,0.000028493449,0.000090792506,0.000117865915,0.00033628914,0.04534075,0.9465127,0.00022287718,0.0014678935,0.0001242157],"about_ca_topic_score_codex":0.00064553437,"about_ca_topic_score_gemma":0.000004637574,"teacher_disagreement_score":0.042332146,"about_ca_system_score_codex":0.0001807717,"about_ca_system_score_gemma":0.0002302956,"threshold_uncertainty_score":0.9987876},"labels":[],"label_agreement":null},{"id":"W4210397134","doi":"10.1038/s41551-021-00820-y","title":"Efficient recovery of potent tumour-infiltrating lymphocytes through quantitative immunomagnetic cell sorting","year":2022,"lang":"en","type":"article","venue":"Nature Biomedical Engineering","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Cell sorting; Immunomagnetic separation; Flow cytometry; Cell; Tumor-infiltrating lymphocytes; Cancer research; Potency; T cell; Chemistry; Immunology; Biology; Molecular biology; Immunotherapy; In vitro; Immune system; Biochemistry","score_opus":0.01051781438049039,"score_gpt":0.2729824301814051,"score_spread":0.26246461580091474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210397134","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9804951,0.011472126,0.0028552506,0.00050466263,0.0009444249,0.0005831977,0.00003848074,0.00015869795,0.0029480865],"genre_scores_gemma":[0.98850185,0.000050127266,0.010641404,0.00013314953,0.00016236336,0.00004485194,0.00004913663,0.000055940094,0.00036116556],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9973433,0.000061148385,0.0005343609,0.0003479626,0.0012204867,0.00049273827],"domain_scores_gemma":[0.9988858,0.00043771352,0.0001409941,0.0002769938,0.000100442885,0.00015802153],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00068492186,0.00021623283,0.00043106818,0.0002833325,0.0001245626,0.000014444292,0.00022854068,0.00018114664,0.0009213724],"category_scores_gemma":[0.00056467956,0.00020279885,0.00021288941,0.0008997644,0.000096577736,0.000029191875,0.00021502773,0.0013678013,0.0000058511946],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029038056,0.00029284396,0.000048505888,0.0003765573,0.00008811317,0.00013633973,0.00075738976,0.021389926,0.9707732,0.00023850946,0.00017455885,0.0054336265],"study_design_scores_gemma":[0.009035935,0.007130388,0.0036615997,0.0008174398,0.00023932641,0.00075357634,0.0045512244,0.57301813,0.37534082,0.00009527728,0.024251949,0.0011043694],"about_ca_topic_score_codex":0.000054098367,"about_ca_topic_score_gemma":2.446681e-7,"teacher_disagreement_score":0.59543246,"about_ca_system_score_codex":0.00046425805,"about_ca_system_score_gemma":0.00028369896,"threshold_uncertainty_score":0.9999919},"labels":[],"label_agreement":null},{"id":"W4210408999","doi":"10.51731/cjht.2022.250","title":"Idecabtagene Vicleucel (Abecma)","year":2022,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Medicine; Drug; Pharmacology; Intensive care medicine; Health care; Political science","score_opus":0.0544646208570626,"score_gpt":0.33944166122287556,"score_spread":0.28497704036581295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210408999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6865142,0.1002418,0.00011263569,0.20816568,0.0008796541,0.00069115974,0.000046353583,0.00020810336,0.0031403971],"genre_scores_gemma":[0.99577945,0.00047110196,0.00044970817,0.0016752302,0.000022728751,0.000014280304,0.0000030334961,0.000025624273,0.0015588556],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998229,0.00010238528,0.0005027673,0.00013850705,0.00042266856,0.00060466584],"domain_scores_gemma":[0.998983,0.000051616167,0.0002514657,0.00035568964,0.00015409419,0.00020408354],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013975806,0.00010662687,0.0003964225,0.0010911936,0.00048929197,0.000021024827,0.00043884284,0.00006993335,0.0026740467],"category_scores_gemma":[0.00034709604,0.00009859243,0.000114811046,0.000676931,0.00018962154,0.000053923115,0.00006601331,0.0011165513,0.000011498694],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009327933,0.000040927196,0.006661861,0.00008058176,0.00007897709,0.0013021476,0.0004474084,0.000033580087,0.0043427185,0.0005025915,0.028130177,0.95828575],"study_design_scores_gemma":[0.0009556166,0.0016037389,0.005288924,0.000051178045,0.000010584598,0.0026070066,0.0067046625,0.000017332663,0.0025000575,0.0015237998,0.97863394,0.0001031492],"about_ca_topic_score_codex":0.004152498,"about_ca_topic_score_gemma":0.0014017356,"teacher_disagreement_score":0.9581826,"about_ca_system_score_codex":0.0015104045,"about_ca_system_score_gemma":0.0063928436,"threshold_uncertainty_score":0.99924},"labels":[],"label_agreement":null},{"id":"W4210794959","doi":"10.1016/j.jtct.2022.01.024","title":"Real-World Eligibility for Second-Line Chimeric Antigen Receptor T Cell Therapy in Large B Cell Lymphoma: A Population-Based Analysis","year":2022,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Alberta Health Services","funders":"","keywords":"Medicine; Chemoimmunotherapy; Population; Oncology; Internal medicine; Autologous stem-cell transplantation; Chimeric antigen receptor; Transplantation; Lymphoma; Surgery; Rituximab; Cancer; Immunotherapy","score_opus":0.024267220530368058,"score_gpt":0.31477420058418687,"score_spread":0.2905069800538188,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210794959","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993644,0.0012674023,0.0017659629,0.00023922554,0.000085596075,0.0017618904,0.00040837572,0.00007424741,0.0007533144],"genre_scores_gemma":[0.98685884,0.004164122,0.000420178,0.00060821685,0.00006528834,0.00032626078,0.0042900243,0.00006001693,0.0032070423],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975509,0.0003499827,0.0005457765,0.0006153624,0.00048988714,0.00044807186],"domain_scores_gemma":[0.9990018,0.00021158252,0.00014769005,0.0004053428,0.00007884006,0.00015471771],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009945522,0.0002829395,0.00057695515,0.00077854085,0.00029461776,0.000035262616,0.00014853882,0.00008265227,0.0076647955],"category_scores_gemma":[0.0000021769033,0.00027256034,0.00034346775,0.00152414,0.00003744969,0.000070325295,0.0000080212785,0.0002126278,0.000004814556],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013083266,0.003471184,0.29186806,0.00030776928,0.0003778051,0.000035769714,0.002652126,0.0006049924,0.67524177,0.000043493226,0.00006222572,0.012251552],"study_design_scores_gemma":[0.0628992,0.002290985,0.28135946,0.000021945334,0.00029956334,0.000005390211,0.0005226933,0.014389364,0.6169384,0.0001444978,0.020327237,0.0008012464],"about_ca_topic_score_codex":0.0009742327,"about_ca_topic_score_gemma":0.0006655611,"teacher_disagreement_score":0.058303334,"about_ca_system_score_codex":0.000178936,"about_ca_system_score_gemma":0.00017071016,"threshold_uncertainty_score":0.99997264},"labels":[],"label_agreement":null},{"id":"W4210799906","doi":"10.3389/fonc.2022.815726","title":"The Road to CAR T-Cell Therapies for Pediatric CNS Tumors: Obstacles and New Avenues","year":2022,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Chimeric antigen receptor; Medicine; Immunogenicity; Adverse effect; Radiation therapy; Chemotherapy; Central nervous system; Immunotherapy; Cancer; Oncology; Bioinformatics; Antigen; Immunology; Internal medicine; Biology","score_opus":0.029027235051284062,"score_gpt":0.32304472279875185,"score_spread":0.2940174877474678,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4210799906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9471619,0.032364346,0.00049649645,0.013710494,0.0017677697,0.0020581626,0.000034044362,0.00004259323,0.0023641824],"genre_scores_gemma":[0.8183897,0.010607885,0.024008226,0.005188443,0.0037046908,0.0024558676,0.00006477406,0.00021605525,0.13536434],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9987562,0.00017813865,0.0002056205,0.0002582499,0.00020691896,0.00039491843],"domain_scores_gemma":[0.99921924,0.0003114102,0.000053882162,0.00023699315,0.000035484998,0.00014297417],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006037208,0.000110376175,0.0003118032,0.00021596752,0.00023686497,0.000017824,0.00020891921,0.000060781706,0.00015081714],"category_scores_gemma":[0.00013481357,0.00008938411,0.000064847576,0.0002854591,0.00008633046,0.000022422084,0.00014037325,0.00031751278,0.000003167578],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025046903,0.00019656886,0.07805968,0.000052057258,0.00007354967,0.00007925738,0.009461592,0.000038930975,0.005194701,0.000077768396,0.43115956,0.47310165],"study_design_scores_gemma":[0.0026453598,0.0022521813,0.012211883,0.0000035300604,0.000034075,0.00002591379,0.0068383934,0.00013894445,0.00026331109,0.0014438112,0.9740312,0.00011141436],"about_ca_topic_score_codex":0.00016265495,"about_ca_topic_score_gemma":0.00009404322,"teacher_disagreement_score":0.54287165,"about_ca_system_score_codex":0.00043308237,"about_ca_system_score_gemma":0.00046682294,"threshold_uncertainty_score":0.36449784},"labels":[],"label_agreement":null},{"id":"W4211196581","doi":"10.23977/misbp.2021036","title":"Universal CAR T cell: engineering of universal T cell, modular CAR system, and applications","year":2021,"lang":"en","type":"article","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Chimeric antigen receptor; Modular design; Computer science; Immunogenicity; T cell; Antigen; Biology; Immune system; Immunology; Operating system","score_opus":0.009362667109904795,"score_gpt":0.2306318754622036,"score_spread":0.2212692083522988,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4211196581","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8917059,0.0018779713,0.019419402,0.00021007641,0.00008589986,0.0008690296,0.000041301973,0.00018395588,0.08560651],"genre_scores_gemma":[0.98051596,0.00015927042,0.0012578293,0.000011616622,0.00007502078,0.000007972844,0.000025081472,0.000026746404,0.017920535],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992014,0.0000245375,0.0001347688,0.00022665167,0.0002277722,0.00018487526],"domain_scores_gemma":[0.99922913,0.000057442074,0.000025870495,0.00035401306,0.00017280185,0.00016073587],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008650227,0.00010130611,0.0002276994,0.000113793045,0.00003407409,0.000009189645,0.00007021801,0.000075586795,0.00041788406],"category_scores_gemma":[0.0000052294736,0.0001036697,0.000063949235,0.00029544916,0.00004529183,0.000041296258,0.00007023967,0.00014754815,0.000010984149],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026820699,0.000058774607,0.0005079093,0.000652993,0.000054715205,0.00010467645,0.00020248479,0.0004750972,0.99464285,0.0027345063,0.0001085901,0.0004305829],"study_design_scores_gemma":[0.0030599672,0.00018318315,0.00051286264,0.00010223738,0.00019672189,0.00011492218,0.008734637,0.020428825,0.88373953,0.0000050840476,0.08266897,0.00025306467],"about_ca_topic_score_codex":0.00019769995,"about_ca_topic_score_gemma":0.0000056686604,"teacher_disagreement_score":0.11090332,"about_ca_system_score_codex":0.00015005283,"about_ca_system_score_gemma":0.00016736664,"threshold_uncertainty_score":0.4575537},"labels":[],"label_agreement":null},{"id":"W4211260249","doi":"10.3324/haematol.2021.279486","title":"A novel CD34-specific T-cell engager efficiently depletes acute myeloid leukemia and leukemic stem cells &lt;i&gt;in vitro&lt;/i&gt; and &lt;i&gt;in vivo&lt;/i&gt;","year":2022,"lang":"en","type":"article","venue":"Haematologica","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"David och Astrid Hageléns Stiftelse; Barncancerfonden; Vetenskapsrådet; Cancerfonden","keywords":"CD34; Stem cell; CD38; Myeloid leukemia; Cancer research; Haematopoiesis; Leukemia; In vivo; Myeloid; Ex vivo; Transplantation; Immunology; Biology; Medicine; Cell biology; Internal medicine","score_opus":0.024029043832638153,"score_gpt":0.25015882293189984,"score_spread":0.22612977909926169,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4211260249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9673061,0.016733337,0.00014765264,0.0005543096,0.00044548925,0.0029652684,0.00028593087,0.00031328737,0.011248651],"genre_scores_gemma":[0.97522473,0.005133606,0.0013898466,0.0006088211,0.00015796282,0.00070852356,0.00009009002,0.00022727638,0.016459117],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99098146,0.0010285592,0.0015964942,0.0023480153,0.0018211829,0.0022242847],"domain_scores_gemma":[0.9951641,0.0018140913,0.00046866928,0.0015898257,0.00019699901,0.0007663009],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0027844755,0.0011320254,0.0023431692,0.0013184943,0.00077215105,0.00021097854,0.0009465398,0.0006083647,0.0033053444],"category_scores_gemma":[0.00012954428,0.0010462505,0.00041449477,0.0017553907,0.000845565,0.00022039314,0.0012726267,0.0020510734,0.00015437344],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002491918,0.00083373906,0.00045732575,0.0003758966,0.0001593398,0.0029725612,0.0019079887,0.00015105821,0.9784522,0.001232513,0.00781035,0.0031550962],"study_design_scores_gemma":[0.021231726,0.0021075702,0.0038823965,0.0003846399,0.00031473069,0.004991431,0.001082971,0.0061165313,0.50952995,0.0001877262,0.4479724,0.0021979446],"about_ca_topic_score_codex":0.00003227347,"about_ca_topic_score_gemma":0.0001209126,"teacher_disagreement_score":0.46892226,"about_ca_system_score_codex":0.0016553705,"about_ca_system_score_gemma":0.0006619863,"threshold_uncertainty_score":0.9991988},"labels":[],"label_agreement":null},{"id":"W4213184823","doi":"10.1016/j.omtm.2022.02.004","title":"Clinically relevant T cell expansion media activate distinct metabolic programs uncoupled from cellular function","year":2022,"lang":"en","type":"article","venue":"Molecular Therapy — Methods & Clinical Development","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stemcell Technologies; University of Victoria","funders":"National Human Genome Research Institute; Canadian Institutes of Health Research; National Cancer Institute; National Institutes of Health; Victoria University; Cancer Prevention and Research Institute of Texas","keywords":"Ex vivo; Glutamine; In vivo; Phenotype; Function (biology); Cell biology; Cell growth; Biology; Cell; T cell; Carbohydrate metabolism; Metabolism; Cancer research; Biochemistry; Immunology; Immune system; Genetics","score_opus":0.09640898408945156,"score_gpt":0.41555566239564085,"score_spread":0.31914667830618926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213184823","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8737716,0.0036819137,0.11653812,0.0007223553,0.0019474432,0.0023957444,0.000013271427,0.00030858745,0.00062093494],"genre_scores_gemma":[0.42727384,0.0023390308,0.5588727,0.004264825,0.000738467,0.0015513839,0.0013645916,0.0004070318,0.003188124],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98588485,0.005979526,0.0028895233,0.0018441371,0.0023303842,0.0010715737],"domain_scores_gemma":[0.99355936,0.0028226988,0.0006957073,0.0016703523,0.00036589094,0.0008859682],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0137462905,0.0007255382,0.0017722842,0.0002820119,0.0005000447,0.000093370974,0.0007601231,0.00041760303,0.0073963725],"category_scores_gemma":[0.0010943639,0.00062089605,0.0010173902,0.0010662089,0.00028332244,0.00008429107,0.0007138061,0.0024515288,0.0001432681],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056914757,0.0019393328,0.0047673252,0.00001725728,0.00065118267,0.00022177055,0.0005016782,0.0000091491875,0.40292946,0.000017400049,0.000071727765,0.5831823],"study_design_scores_gemma":[0.012582889,0.003128981,0.041776624,0.00007017049,0.0003472609,0.000013401956,0.00041698982,0.0005598367,0.2985832,0.0021031343,0.6393805,0.0010370123],"about_ca_topic_score_codex":0.00008951876,"about_ca_topic_score_gemma":0.0000063759676,"teacher_disagreement_score":0.63930875,"about_ca_system_score_codex":0.00034875516,"about_ca_system_score_gemma":0.0013132853,"threshold_uncertainty_score":0.99984986},"labels":[],"label_agreement":null},{"id":"W4213272099","doi":"10.1097/01.cot.0000290089.84253.32","title":"SHOP TALK","year":2005,"lang":"en","type":"article","venue":"Oncology Times","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.032047386799668884,"score_gpt":0.37364294097034956,"score_spread":0.34159555417068066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4213272099","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1542845,0.0005126357,0.000015186179,0.019061629,0.00010314261,0.0002224845,0.0000014922292,0.000084012216,0.8257149],"genre_scores_gemma":[0.26636308,0.00014120444,0.0023814065,0.0023404066,0.0009451538,0.000027875474,0.000012783167,0.00002407361,0.727764],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992485,0.000046974415,0.00012334634,0.00016490159,0.00015865888,0.00025763607],"domain_scores_gemma":[0.9994421,0.00013277079,0.00002204866,0.00022806706,0.00005171799,0.0001233038],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00022200188,0.000076619355,0.0002138767,0.00008451815,0.000038669372,0.000005595758,0.00008061652,0.000135154,0.07511142],"category_scores_gemma":[0.00006221292,0.0000640593,0.00006773128,0.000105231535,0.0001236392,0.000035618,0.00004266608,0.0002278041,0.002074585],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040718884,0.00038862144,0.0024438547,0.000012740352,0.000103712155,0.00022573657,0.0002711249,0.000004386221,0.12754844,0.00049361476,0.23238741,0.63571316],"study_design_scores_gemma":[0.0012693466,0.00059933175,0.0015896868,0.000006561746,0.000023121433,0.0002524472,0.000061195664,0.00023144949,0.01231477,0.0000712413,0.98352075,0.00006010491],"about_ca_topic_score_codex":0.000012671643,"about_ca_topic_score_gemma":0.000029153278,"teacher_disagreement_score":0.7511333,"about_ca_system_score_codex":0.00020597591,"about_ca_system_score_gemma":0.00020472225,"threshold_uncertainty_score":0.9987024},"labels":[],"label_agreement":null},{"id":"W4214859401","doi":"10.1182/blood.2022015789","title":"CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift?","year":2022,"lang":"en","type":"review","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":164,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Medicine; Chimeric antigen receptor; Oncology; Lymphoma; Internal medicine; Chemotherapy; Autologous stem-cell transplantation; Transplantation; Refractory (planetary science); Cell therapy; Surgery; Stem cell; Immunotherapy; Cancer; Biology","score_opus":0.058664802153939176,"score_gpt":0.3534623504236394,"score_spread":0.2947975482697002,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214859401","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00042435672,0.98400337,0.000010371023,0.00008381525,0.0004028777,0.0064791576,0.0009336459,0.00014182307,0.0075205998],"genre_scores_gemma":[0.00003331796,0.95835775,0.00009668014,0.00046506175,0.0011244584,0.002702152,0.0011765374,0.00038396678,0.035660073],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958397,0.00033126812,0.0008663148,0.0010551126,0.0008116149,0.0010959718],"domain_scores_gemma":[0.99697024,0.0007959298,0.0003464485,0.0014231879,0.000045931905,0.0004182692],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010266071,0.0007968589,0.0028841714,0.00043136918,0.00021497456,0.000069276604,0.00065355754,0.0005133056,0.031500578],"category_scores_gemma":[0.000045197205,0.00065912306,0.001909081,0.0006406135,0.000056204448,0.000045823177,0.0001962345,0.00075692736,0.00038544548],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00072136626,0.016288154,0.0000033528263,0.041671894,0.0032338346,0.0010380972,0.0005535907,5.4130773e-8,0.00039919882,0.0004898656,0.0061606513,0.92943996],"study_design_scores_gemma":[0.022308202,0.0020718046,5.779756e-7,0.0009869192,0.0016077897,0.000316934,0.00001976028,0.0000018663719,0.0007758333,0.0001634729,0.9711833,0.0005635425],"about_ca_topic_score_codex":0.000031817537,"about_ca_topic_score_gemma":0.000013480241,"teacher_disagreement_score":0.9650226,"about_ca_system_score_codex":0.0002870576,"about_ca_system_score_gemma":0.0021293252,"threshold_uncertainty_score":0.999586},"labels":[],"label_agreement":null},{"id":"W4220688343","doi":"10.1080/10428194.2022.2043299","title":"Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia","year":2022,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Genetics; National Cancer Institute; Celgene; CLL Global Research Foundation","keywords":"Lenalidomide; Chronic lymphocytic leukemia; Chimeric antigen receptor; CD23; Cancer research; T cell; Antigen; Immunology; Leukemia; Medicine; Immune system; Multiple myeloma; Immunoglobulin E; Antibody","score_opus":0.01615558200279773,"score_gpt":0.26819361320453683,"score_spread":0.2520380312017391,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220688343","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96072435,0.016786728,0.000026742853,0.0001842326,0.0006958763,0.0020120817,0.000069750095,0.0004481219,0.019052096],"genre_scores_gemma":[0.959233,0.009762021,0.00022306881,0.0025040978,0.0009389372,0.0011179772,0.00021473592,0.0003540877,0.025652062],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9905021,0.000766954,0.0016512385,0.0022564614,0.0022963418,0.0025268923],"domain_scores_gemma":[0.995739,0.000711002,0.00049640913,0.001895641,0.00020712704,0.0009508332],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0016713359,0.0013366652,0.0019437582,0.0012803947,0.0010150262,0.0002568287,0.0012000998,0.00059363275,0.0049126637],"category_scores_gemma":[0.00009995303,0.0013267959,0.00069972407,0.0022597092,0.0007399745,0.00048390083,0.0008789208,0.00075323693,0.0002356629],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.009147414,0.00036897612,0.0040763593,0.0007071048,0.0005127616,0.003327858,0.0034664664,0.0040722103,0.59372497,0.00039476968,0.0077624,0.3724387],"study_design_scores_gemma":[0.13733348,0.0058457414,0.03205408,0.0005499504,0.00033469245,0.0055772555,0.003575561,0.049472928,0.32476982,0.0009933906,0.43596607,0.0035270164],"about_ca_topic_score_codex":0.009675176,"about_ca_topic_score_gemma":0.00031558538,"teacher_disagreement_score":0.42820367,"about_ca_system_score_codex":0.18236835,"about_ca_system_score_gemma":0.045460492,"threshold_uncertainty_score":0.9999384},"labels":[],"label_agreement":null},{"id":"W4220744522","doi":"10.1016/s2666-6367(22)00583-8","title":"Cost-Effectiveness of Brexucabtagene Autoleucel Versus Best Supportive Care for the Treatment of Relapsed/ Refractory Mantle Cell Lymphoma Following Treatment with a Bruton’s Tyrosine Kinase Inhibitor in Canada","year":2022,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Mantle cell lymphoma; Refractory (planetary science); Bruton's tyrosine kinase; Ibrutinib; Internal medicine; Lymphoma; Oncology; Cancer research; Tyrosine kinase; Leukemia; Metallurgy","score_opus":0.033842856003265726,"score_gpt":0.2919828620676587,"score_spread":0.258140006064393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220744522","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893752,0.0072370116,0.00009355329,0.000035693458,0.0001372016,0.0026266025,0.00035564363,0.0000072053645,0.00013191224],"genre_scores_gemma":[0.9933897,0.004890814,0.00003692808,0.00001283232,0.00001910279,0.0007489689,0.0005279273,0.00003481567,0.0003388922],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99875224,0.00018299722,0.00025080633,0.000255685,0.0003432506,0.00021502918],"domain_scores_gemma":[0.9991482,0.0004172235,0.00009436029,0.00021059891,0.000058893274,0.00007073708],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014774746,0.0001933236,0.00038992852,0.000098987744,0.00012659635,0.000005321662,0.00005912883,0.00003416313,0.000112116584],"category_scores_gemma":[9.0951386e-7,0.00013310724,0.000113437236,0.00019252159,0.00005032465,0.000030032566,0.0000033631218,0.00005357025,1.5747366e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.084247574,0.0027301747,0.010721339,0.0006609875,0.00066761,0.0005450115,0.018638456,0.00040600158,0.7539477,0.000012057103,0.0000029800212,0.12742014],"study_design_scores_gemma":[0.061935313,0.017109668,0.00613467,0.00009177501,0.00031555115,0.000015014492,0.009321208,0.00017406199,0.898964,0.0000013625419,0.005779471,0.00015791904],"about_ca_topic_score_codex":0.20582387,"about_ca_topic_score_gemma":0.10080304,"teacher_disagreement_score":0.14501631,"about_ca_system_score_codex":0.0012615325,"about_ca_system_score_gemma":0.0011351414,"threshold_uncertainty_score":0.91560495},"labels":[],"label_agreement":null},{"id":"W4220805673","doi":"10.3389/fonc.2022.818679","title":"Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors","year":2022,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Moonshot Research and Development Program; National Institutes of Health","keywords":"Medicine; Fludarabine; Neutropenia; Internal medicine; Melanoma; Leukopenia; Gastroenterology; Context (archaeology); Oncology; Cyclophosphamide; Cancer research; Chemotherapy","score_opus":0.06616726927313714,"score_gpt":0.4223646722286237,"score_spread":0.3561974029554866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220805673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955093,0.00010255872,0.000059515885,0.00042552812,0.00074569986,0.0026447645,0.00006373251,0.000009504409,0.00043939895],"genre_scores_gemma":[0.99647784,0.00008751218,0.0022516304,0.00024736824,0.00017102642,0.00008911144,0.000014233746,0.000035522706,0.00062573736],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99617153,0.0017760226,0.0006721324,0.00046624333,0.00052193785,0.0003921245],"domain_scores_gemma":[0.9984706,0.0007429088,0.000272785,0.0003298204,0.000059224974,0.0001246366],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0035225477,0.00017846709,0.00096097344,0.00023746387,0.0001147452,0.000009357831,0.0001768588,0.00009960629,0.0005558428],"category_scores_gemma":[0.0005353963,0.00012269377,0.000065879445,0.000370643,0.0005555445,0.000056835062,0.00024381395,0.000996026,8.206758e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5366594,0.0035521262,0.30015475,0.0000415296,0.00009187352,0.00019507311,0.0007451678,0.000021770069,0.0014920877,0.0000027308656,0.0005946541,0.15644881],"study_design_scores_gemma":[0.56661606,0.14000466,0.26963505,0.00009076189,0.00014995504,0.000069485555,0.0014759472,0.005693609,0.00046071617,0.000047372367,0.015432875,0.0003234684],"about_ca_topic_score_codex":0.00019176639,"about_ca_topic_score_gemma":0.00013417193,"teacher_disagreement_score":0.15612535,"about_ca_system_score_codex":0.00035674046,"about_ca_system_score_gemma":0.00083541434,"threshold_uncertainty_score":0.6086089},"labels":[],"label_agreement":null},{"id":"W4220860149","doi":"10.15252/emmm.202114297","title":"Autologous, lentivirus‐modified, T‐rapa cell “micropharmacies” for lysosomal storage disorders","year":2022,"lang":"en","type":"article","venue":"EMBO Molecular Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Hospital; Western University; McMaster University; University of Toronto","funders":"Midwest Athletes Against Childhood Cancer; Hope Foundation","keywords":"Ex vivo; Lentivirus; In vivo; Immunology; Biology; Cancer research; Medicine; Pharmacology; Biotechnology; Virus","score_opus":0.022566141087701778,"score_gpt":0.3137677057689892,"score_spread":0.29120156468128744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220860149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.866308,0.011475699,0.019866763,0.023371927,0.0015993887,0.0050276387,0.0001093548,0.00041419,0.07182707],"genre_scores_gemma":[0.97252774,0.00020428056,0.00038724055,0.004883124,0.00036885747,0.00057692005,0.00029838688,0.00015158737,0.020601844],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967446,0.0002661743,0.00047142457,0.0007081084,0.0010028286,0.00080686645],"domain_scores_gemma":[0.99842423,0.00017186969,0.0001825499,0.0007486335,0.00013498205,0.00033771107],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00085109175,0.00036385996,0.0006830663,0.00043500954,0.0003912749,0.00001607493,0.00041402626,0.00009549866,0.008092714],"category_scores_gemma":[0.00015696094,0.00033788788,0.00032111257,0.0006484903,0.00035266537,0.000050921255,0.00025971976,0.0007782423,0.00003002177],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014541384,0.00045204896,0.0001981389,0.00026461112,0.00021055527,0.00050005876,0.00078315847,0.00022474038,0.9623973,0.0005659916,0.022472369,0.010476939],"study_design_scores_gemma":[0.02096844,0.004319737,0.00047296757,0.00006036453,0.00049458403,0.00033707038,0.0012595045,0.0039358144,0.107896715,0.001291921,0.85832155,0.00064133387],"about_ca_topic_score_codex":0.00010284864,"about_ca_topic_score_gemma":0.0000046569908,"teacher_disagreement_score":0.85450053,"about_ca_system_score_codex":0.00030746852,"about_ca_system_score_gemma":0.0002548603,"threshold_uncertainty_score":0.9999073},"labels":[],"label_agreement":null},{"id":"W4220932718","doi":"10.1186/s40164-022-00268-z","title":"Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel","year":2022,"lang":"en","type":"article","venue":"Experimental Hematology and Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; EVERSANA (Canada)","funders":"Bristol-Myers Squibb; American Society of Hematology","keywords":"Medicine; Oncology; Hazard ratio; Internal medicine; Confidence interval; Cytokine release syndrome; Odds ratio; Chimeric antigen receptor; Immunology; Immunotherapy; Cancer","score_opus":0.07916506812500414,"score_gpt":0.3910096793426737,"score_spread":0.3118446112176696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220932718","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9751572,0.02080475,0.000014481248,0.0001983401,0.00060701725,0.0018474646,0.00016204912,0.000055763274,0.0011529126],"genre_scores_gemma":[0.984604,0.0018174122,0.0018441164,0.000094230476,0.000077880206,0.00077092805,0.00030246886,0.00007013754,0.010418821],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99737835,0.00046685102,0.0007682974,0.00056647864,0.00025480965,0.0005652153],"domain_scores_gemma":[0.99815196,0.0007842827,0.00044158584,0.00040426574,0.00005800895,0.00015992516],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00023730734,0.0004053162,0.0016605085,0.00027343072,0.00030761893,0.000005485936,0.00016256783,0.00029794042,0.003685311],"category_scores_gemma":[0.000010543467,0.00029273806,0.00025915971,0.00024561232,0.0003128765,0.000048622915,0.0001324875,0.00014800692,0.0000115055545],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14697213,0.048698273,0.0063490756,0.00028331,0.0014223712,0.0002659425,0.03714463,0.000005012665,0.74205947,0.00010106616,0.0017298503,0.014968886],"study_design_scores_gemma":[0.05965948,0.07529414,0.00046077938,0.000015655087,0.00019029001,0.00018197087,0.016338265,0.00011231668,0.7907352,0.000008381434,0.056762137,0.00024141048],"about_ca_topic_score_codex":0.00015152921,"about_ca_topic_score_gemma":0.00012814146,"teacher_disagreement_score":0.08731266,"about_ca_system_score_codex":0.0009284829,"about_ca_system_score_gemma":0.00048587745,"threshold_uncertainty_score":0.9999525},"labels":[],"label_agreement":null},{"id":"W4220946387","doi":"10.21203/rs.3.rs-1466429/v1","title":"Application of blood brain barrier models in pre-clinical assessment of glioblastoma- targeting CAR-T based immunotherapies","year":2022,"lang":"en","type":"preprint","venue":"Research Square","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada","funders":"","keywords":"Extravasation; Chimeric antigen receptor; Cancer research; Blood–brain barrier; Immunotherapy; Flow cytometry; Viability assay; Cell therapy; Cytotoxicity; Medicine; Cell; Immunology; Biology; In vitro; Stem cell; Central nervous system; Immune system; Cell biology; Internal medicine","score_opus":0.06286738231336,"score_gpt":0.4625168596422706,"score_spread":0.39964947732891054,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220946387","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97996044,0.003715693,0.003952715,0.0013308167,0.000121602236,0.0072608697,0.00040242882,0.00007396972,0.003181448],"genre_scores_gemma":[0.9928338,0.0007911091,0.002561308,0.000043360727,0.00017711811,0.0017230738,0.0003277542,0.00013385931,0.0014086321],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.98943853,0.003110427,0.0017171805,0.0010822024,0.0038085857,0.00084305834],"domain_scores_gemma":[0.99312794,0.0028966493,0.00044088863,0.001974099,0.001293044,0.00026738062],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.014839332,0.00035464927,0.0013231258,0.0015363474,0.0001156998,0.000037906393,0.00091111846,0.0005380728,0.0049376166],"category_scores_gemma":[0.00116449,0.00035534066,0.0005854593,0.0012312342,0.0005791459,0.000072354174,0.0014878715,0.004644339,0.000002699602],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011065248,0.009153551,0.23723175,0.019043144,0.0021624353,0.00020018764,0.005573585,0.07503335,0.6017306,0.0012809986,0.0014818419,0.036043297],"study_design_scores_gemma":[0.018691963,0.011113201,0.15837273,0.004490843,0.0002454714,0.000012745298,0.0038999284,0.7401757,0.047669712,0.0050382465,0.0090853125,0.0012041115],"about_ca_topic_score_codex":0.00255023,"about_ca_topic_score_gemma":0.000104804385,"teacher_disagreement_score":0.66514236,"about_ca_system_score_codex":0.00058667094,"about_ca_system_score_gemma":0.0035856897,"threshold_uncertainty_score":0.99988985},"labels":[],"label_agreement":null},{"id":"W4220949287","doi":"10.1021/acssynbio.1c00236","title":"Sense-and-Respond Payload Delivery Using a Novel Antigen-Inducible Promoter Improves Suboptimal CAR-T Activation","year":2022,"lang":"en","type":"article","venue":"ACS Synthetic Biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; National Institutes of Health; Natural Sciences and Engineering Research Council of Canada; U.S. Department of Defense","keywords":"NFAT; Chimeric antigen receptor; Cancer research; Antigen; Biology; Reporter gene; T cell; Cell biology; Promoter; Molecular biology; Immunology; Immune system; Gene expression; Gene; Transcription factor; Biochemistry","score_opus":0.049114026046286,"score_gpt":0.3148034801829102,"score_spread":0.2656894541366242,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220949287","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99689764,0.00022186869,0.00025793666,0.001270297,0.00017538664,0.0006455552,0.00003137335,0.00005342804,0.00044651702],"genre_scores_gemma":[0.99692154,0.00005974354,0.0013007094,0.00041244042,0.00013157405,0.000055136352,0.00003531794,0.000043222775,0.0010402867],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99825704,0.0002196741,0.00026195508,0.000544392,0.0002275776,0.00048937375],"domain_scores_gemma":[0.9990452,0.00021852684,0.00009745641,0.00042767098,0.00009936842,0.000111798625],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006266984,0.00019510264,0.00035139298,0.00028471148,0.00026713347,0.000019745545,0.000080051126,0.00015939635,0.0011807372],"category_scores_gemma":[0.00013232483,0.00017291214,0.00008299809,0.00028047798,0.00023824644,0.000058653146,0.00031122894,0.00048216362,0.000009719816],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008085462,0.00016505615,0.0011660684,0.000025820402,0.00010618459,0.000032152075,0.0005722198,0.000007011868,0.97973263,0.0001130657,0.000020885065,0.017250378],"study_design_scores_gemma":[0.0035927105,0.0026647127,0.0069678025,0.00005957516,0.00013032852,0.0037956706,0.0009191895,0.0049348646,0.9425903,0.0004080556,0.033378307,0.0005584662],"about_ca_topic_score_codex":0.00054354814,"about_ca_topic_score_gemma":0.0000058550163,"teacher_disagreement_score":0.037142295,"about_ca_system_score_codex":0.00018927208,"about_ca_system_score_gemma":0.00022839328,"threshold_uncertainty_score":0.9997323},"labels":[],"label_agreement":null},{"id":"W4220986427","doi":"10.3389/fped.2022.796994","title":"Is It Possible to Separate the Graft-Versus-Leukemia (GVL) Effect Against B Cell Acute Lymphoblastic Leukemia From Graft-Versus-Host Disease (GVHD) After Hematopoietic Cell Transplant?","year":2022,"lang":"en","type":"review","venue":"Frontiers in Pediatrics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; CancerCare Manitoba; BC Children's Hospital; University of British Columbia","funders":"Cancer Research Institute","keywords":"Medicine; Leukemia; Graft-versus-host disease; Hematopoietic stem cell transplantation; Lymphoblastic Leukemia; Disease; Immunology; Ex vivo; Transplantation; Haematopoiesis; Minimal residual disease; Stem cell; Hematopoietic stem cell; In vivo; Internal medicine; Biology","score_opus":0.022812519924215634,"score_gpt":0.30437206352000057,"score_spread":0.28155954359578494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220986427","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007467147,0.96777576,0.0002760898,0.00018094963,0.009388645,0.006595622,0.0038114262,0.00018890276,0.0043154685],"genre_scores_gemma":[0.00083597575,0.9804445,0.000452423,0.0007244632,0.0015560223,0.0022026182,0.0020096276,0.0005668196,0.011207555],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9894446,0.001255065,0.0018717328,0.0024357787,0.0027790866,0.0022137458],"domain_scores_gemma":[0.9919636,0.0027899698,0.00062289764,0.0028243267,0.00013128585,0.0016679172],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0012875773,0.0020546843,0.0040499223,0.0017234655,0.00043255664,0.00029910717,0.0021492299,0.000988725,0.00471657],"category_scores_gemma":[0.00021307627,0.001631212,0.0024077268,0.0040238798,0.00030043357,0.00021842467,0.0006970683,0.0032828834,0.0007930831],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.052815028,0.001115707,0.005982241,0.07320108,0.0038368183,0.015117528,0.007022244,0.00038028933,0.00003099464,0.0000034728134,0.6149582,0.22553636],"study_design_scores_gemma":[0.012451678,0.001202347,0.000121539895,0.0014257381,0.014564974,0.000018091321,0.00030879353,0.00029867445,0.000046746198,0.00001631161,0.9676163,0.0019287573],"about_ca_topic_score_codex":0.00016992244,"about_ca_topic_score_gemma":0.000029910028,"teacher_disagreement_score":0.35265812,"about_ca_system_score_codex":0.008902674,"about_ca_system_score_gemma":0.006119685,"threshold_uncertainty_score":0.9999849},"labels":[],"label_agreement":null},{"id":"W4221044986","doi":"10.1038/s41591-022-01731-4","title":"Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial","year":2022,"lang":"en","type":"article","venue":"Nature Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":283,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"National Cancer Institute","keywords":"Medicine; Internal medicine; Clinical endpoint; Chemoimmunotherapy; Oncology; Cytokine release syndrome; Phases of clinical research; Lymphoma; Clinical trial; Chimeric antigen receptor; Immunotherapy; Cancer; Rituximab","score_opus":0.021470399588103366,"score_gpt":0.34156739811469566,"score_spread":0.3200969985265923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221044986","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94359344,0.017770827,0.000028178465,0.026624702,0.00201134,0.0030694327,0.00010225617,0.000123374,0.006676436],"genre_scores_gemma":[0.96198,0.0054069636,0.000030294112,0.008045199,0.0037479864,0.00045297793,0.00036230133,0.0001132529,0.019861052],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.9945062,0.0006697564,0.0007690532,0.00078272965,0.0023523169,0.00091995386],"domain_scores_gemma":[0.99704933,0.00087920204,0.00026598357,0.0013046953,0.00016714488,0.0003336361],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00381554,0.00047092277,0.00097192073,0.00054639496,0.00057791785,0.000020160807,0.0007344899,0.00039744697,0.023767408],"category_scores_gemma":[0.0007745428,0.00029236623,0.00025904056,0.00146785,0.00027182986,0.00006187431,0.0002669104,0.0033104212,0.000060718252],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.43654582,0.028290885,0.0021974375,0.0001882071,0.0007703573,0.0035267835,0.007533842,0.000049492857,0.062484793,0.0009104844,0.12791458,0.3295873],"study_design_scores_gemma":[0.4147342,0.01269776,0.0008754396,0.000047163627,0.000111634516,0.00012420552,0.0006361334,0.00029264708,0.005333923,0.00037932125,0.5645286,0.00023896643],"about_ca_topic_score_codex":0.000886745,"about_ca_topic_score_gemma":0.00022683058,"teacher_disagreement_score":0.436614,"about_ca_system_score_codex":0.0005783987,"about_ca_system_score_gemma":0.0004603553,"threshold_uncertainty_score":0.99995285},"labels":[],"label_agreement":null},{"id":"W4221068958","doi":"10.3390/curroncol29030164","title":"Cost-Effectiveness of Brexucabtagene Autoleucel versus Best Supportive Care for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma following Treatment with a Bruton’s Tyrosine Kinase Inhibitor in Canada","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Canadian Blood Services; University of British Columbia; Université Laval; Gilead Sciences (Canada)","funders":"","keywords":"Mantle cell lymphoma; Medicine; Ibrutinib; Internal medicine; Oncology; Cost effectiveness; Quality-adjusted life year; Quality of life (healthcare); Lymphoma; Leukemia","score_opus":0.09165952177948525,"score_gpt":0.38581303641357056,"score_spread":0.29415351463408534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221068958","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98317045,0.010377193,0.000011792152,0.00007391928,0.0014146658,0.0041849944,0.00045243802,0.000009140442,0.0003053934],"genre_scores_gemma":[0.9957449,0.000612618,0.000030457728,0.0000070606166,0.00007985936,0.0028241307,0.0003264623,0.000043807187,0.00033072257],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980087,0.0003511539,0.0003921165,0.0003978202,0.00041817848,0.00043202998],"domain_scores_gemma":[0.99774134,0.0013592306,0.00021199224,0.00040864275,0.00015176735,0.00012701831],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022819423,0.0002634086,0.00080323004,0.00016499113,0.00012883569,0.0000033118488,0.00013687578,0.000058649315,0.00019916304],"category_scores_gemma":[0.000021878082,0.00018405964,0.00020389148,0.000329578,0.00010717593,0.000026692613,0.000056152763,0.00012613524,7.7059224e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.06847869,0.021187712,0.066357076,0.0011344701,0.0011596034,0.000999647,0.010435086,0.00063983205,0.06050695,0.00001579818,0.00023476343,0.7688504],"study_design_scores_gemma":[0.14094143,0.11815147,0.021605454,0.00028201364,0.0014067271,0.000047198133,0.027891777,0.0005371627,0.23793998,0.0000028511256,0.45076072,0.00043319727],"about_ca_topic_score_codex":0.21916632,"about_ca_topic_score_gemma":0.32958797,"teacher_disagreement_score":0.7684172,"about_ca_system_score_codex":0.01684078,"about_ca_system_score_gemma":0.0076855007,"threshold_uncertainty_score":0.99794},"labels":[],"label_agreement":null},{"id":"W4221073412","doi":"10.1111/trf.16820","title":"Cryopreserved hematopoietic stem/progenitor cells stability program‐development, current status and recommendations: A brief report from the AABB‐ISCT joint working group cellular therapy product stability project team","year":2022,"lang":"en","type":"article","venue":"Transfusion","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Héma-Québec; Canadian Blood Services","funders":"","keywords":"Cryopreservation; Standardization; Progenitor cell; Apheresis; Haematopoiesis; Scope (computer science); Medicine; Stem cell; Computer science; Immunology; Biology","score_opus":0.10775657440442783,"score_gpt":0.3267183771694353,"score_spread":0.21896180276500748,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221073412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97771305,0.007460898,0.00014567185,0.0016272762,0.0006368893,0.011849187,0.00007367776,0.00028745728,0.0002058824],"genre_scores_gemma":[0.98931825,0.0041475655,0.0015085881,0.000090319714,0.00028971658,0.0035535458,0.00073792145,0.00011581334,0.00023827821],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.993906,0.0012993428,0.00113871,0.0014106221,0.001440503,0.0008047714],"domain_scores_gemma":[0.9973645,0.00032687493,0.00024895024,0.0015379895,0.00021798043,0.0003037124],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0038774428,0.0004478544,0.00065198255,0.00013455404,0.0009898129,0.00015087584,0.0003257049,0.00007119792,0.0033114592],"category_scores_gemma":[0.000100124824,0.00033223326,0.00024962734,0.0008424104,0.00023688616,0.00014799082,0.00030734518,0.0012674491,0.0000035342273],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025139763,0.0038250587,0.072103836,0.00036929813,0.00022091762,0.00004844184,0.017222488,9.658249e-7,0.4530376,0.0000043135733,0.0008588941,0.44979423],"study_design_scores_gemma":[0.005695094,0.0011936465,0.017994653,0.00029742866,0.00012621736,0.0000874813,0.0068401387,0.0001671767,0.40641952,0.00012788191,0.5603865,0.00066426344],"about_ca_topic_score_codex":0.0014880395,"about_ca_topic_score_gemma":0.00027054234,"teacher_disagreement_score":0.55952764,"about_ca_system_score_codex":0.0006058948,"about_ca_system_score_gemma":0.0010036638,"threshold_uncertainty_score":0.999913},"labels":[],"label_agreement":null},{"id":"W4221137077","doi":"10.1016/j.jcyt.2022.03.001","title":"Cryopreserved hematopoietic stem/progenitor cells stability program-development, current status and recommendations: A brief report from the AABB-ISCT joint working group cellular therapy product stability project team","year":2022,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Héma-Québec; Canadian Blood Services","funders":"","keywords":"Progenitor cell; Haematopoiesis; Stem cell; Apheresis; Medicine; Immunology; Biology; Cell biology","score_opus":0.12208440870288015,"score_gpt":0.33785075553347627,"score_spread":0.21576634683059612,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221137077","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96507746,0.019148974,0.000110963374,0.0019332193,0.0007728758,0.0122182565,0.00010004474,0.00039791575,0.00024027961],"genre_scores_gemma":[0.9771166,0.005983295,0.0040157507,0.00054869667,0.0008911497,0.009278434,0.0009230588,0.00032320013,0.0009198267],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9925907,0.0016012896,0.0013886156,0.0017462502,0.0015544529,0.0011186464],"domain_scores_gemma":[0.99594766,0.00047968162,0.0005262796,0.0023498917,0.00030211525,0.00039436846],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0042910497,0.00062865764,0.0009135775,0.00018370476,0.0010664474,0.0002932477,0.0005349788,0.00008981716,0.004562627],"category_scores_gemma":[0.00014517216,0.0004741711,0.0003247929,0.0010434181,0.000407598,0.00018620654,0.0004414213,0.0014002715,0.000006894207],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003258553,0.005106126,0.13360646,0.00026681638,0.000745059,0.00007632617,0.017109284,0.0000012135323,0.32802072,0.000014163071,0.0044230446,0.50737226],"study_design_scores_gemma":[0.0048020473,0.0009549856,0.009552778,0.00014280915,0.00005344006,0.000078901576,0.0041562677,0.00008582609,0.20436104,0.00020126275,0.77498657,0.00062408973],"about_ca_topic_score_codex":0.00067592604,"about_ca_topic_score_gemma":0.0000991173,"teacher_disagreement_score":0.7705635,"about_ca_system_score_codex":0.0010052857,"about_ca_system_score_gemma":0.0015822628,"threshold_uncertainty_score":0.999771},"labels":[],"label_agreement":null},{"id":"W4223991603","doi":"10.1038/s41375-022-01550-z","title":"Tisagenlecleucel in pediatric and young adult patients with Down syndrome-associated relapsed/refractory acute lymphoblastic leukemia","year":2022,"lang":"en","type":"article","venue":"Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Medicine; Cytokine release syndrome; Minimal residual disease; Blinatumomab; Internal medicine; Refractory (planetary science); Hematopoietic stem cell transplantation; Acute lymphocytic leukemia; Chemotherapy; Pediatrics; Gastroenterology; Leukemia; Lymphoblastic Leukemia; Cancer; Disease; Immunotherapy","score_opus":0.007083279023805119,"score_gpt":0.23065583200335218,"score_spread":0.22357255297954706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4223991603","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99609756,0.00023153909,0.0000047133663,0.00006459405,0.00022708384,0.0008420816,0.000071548675,0.000111212714,0.0023496465],"genre_scores_gemma":[0.9899068,0.00028592325,0.0000583219,0.00034650907,0.00006227125,0.00017461581,0.00023168884,0.00010320267,0.00883067],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967954,0.00020683918,0.0004380728,0.0006464056,0.0011796204,0.00073364127],"domain_scores_gemma":[0.9987102,0.0001814305,0.00017537238,0.0004771773,0.00016644748,0.00028936952],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00034907926,0.00032681762,0.0005338934,0.0005138701,0.00024758867,0.000041681003,0.00023758886,0.000168998,0.001396349],"category_scores_gemma":[0.00015789828,0.00030426934,0.0000838489,0.0012069723,0.000100216166,0.00015280773,0.00026983084,0.0010566233,0.00004997842],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019418531,0.00036567933,0.98851305,0.00010782595,0.00022594696,0.0015524364,0.0009918729,0.000113276605,0.0014509044,0.000011913039,0.002413356,0.0023118893],"study_design_scores_gemma":[0.016784461,0.0022298014,0.97855866,0.000060618207,0.00024511042,0.00029511424,0.00015269786,0.0007670636,0.00006660594,0.000029717048,0.00042457783,0.0003855693],"about_ca_topic_score_codex":0.001080917,"about_ca_topic_score_gemma":0.00029975714,"teacher_disagreement_score":0.014842608,"about_ca_system_score_codex":0.00764596,"about_ca_system_score_gemma":0.0013539324,"threshold_uncertainty_score":0.99994093},"labels":[],"label_agreement":null},{"id":"W4224050212","doi":"10.1126/scitranslmed.abn2231","title":"Oncolytic virus–mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice","year":2022,"lang":"en","type":"article","venue":"Science Translational Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":202,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"National Institute of Allergy and Infectious Diseases; Rosetrees Trust; National Cancer Institute; National Institute for Health and Care Research; Cancer Research UK","keywords":"Chimeric antigen receptor; Oncolytic virus; Cancer research; T-cell receptor; T cell; Antigen; Biology; Vesicular stomatitis virus; Glioma; Immunotherapy; Immunology; Melanoma; Virology; Immune system; Virus","score_opus":0.03534674777181349,"score_gpt":0.3319631336615451,"score_spread":0.2966163858897316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224050212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99214554,0.00061193015,0.00004174062,0.0031489616,0.00038983583,0.0009847296,0.00003590458,0.000036662314,0.0026046946],"genre_scores_gemma":[0.99834496,0.00016738386,0.00025882298,0.00040039103,0.00018534956,0.000046527533,0.00008500995,0.000025809362,0.00048572593],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99526983,0.00012392999,0.0007385372,0.0005751928,0.0027668264,0.0005256535],"domain_scores_gemma":[0.9983964,0.0005803215,0.00014390262,0.00034884247,0.00024253187,0.00028800688],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0024361024,0.00019786065,0.0005222897,0.0010607863,0.00023754305,0.000008632322,0.00035325118,0.00004012085,0.0025129886],"category_scores_gemma":[0.00019350763,0.00016945301,0.000084730906,0.0030501273,0.0014407665,0.00015899794,0.000062975145,0.00056768244,0.000016176216],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00062868797,0.00025858232,0.00036870065,0.0000445345,0.000010348865,0.00007663806,0.0035716472,0.00073772017,0.9841145,0.000104188344,0.0001563476,0.00992809],"study_design_scores_gemma":[0.021992706,0.003988147,0.116184935,0.00074868405,0.000070472044,0.00015197447,0.0054841572,0.019387448,0.8171574,0.00048521144,0.013668491,0.00068038894],"about_ca_topic_score_codex":0.00016417459,"about_ca_topic_score_gemma":0.000024345181,"teacher_disagreement_score":0.16695714,"about_ca_system_score_codex":0.00032322804,"about_ca_system_score_gemma":0.0012715502,"threshold_uncertainty_score":0.99839884},"labels":[],"label_agreement":null},{"id":"W4224279567","doi":"10.1126/sciimmunol.abl3642","title":"Allogeneic double-negative CAR-T cells inhibit tumor growth without off-tumor toxicities","year":2022,"lang":"en","type":"article","venue":"Science Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Biology; CD8; Immunology; Antigen; Cytotoxic T cell; Cancer research; CD19","score_opus":0.02468566003903046,"score_gpt":0.3016648611999601,"score_spread":0.27697920116092967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224279567","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98421144,0.0006786932,0.000007671634,0.0013002332,0.0008396994,0.00087922474,0.000019316198,0.00011480511,0.011948891],"genre_scores_gemma":[0.98578346,0.000054921864,0.00028183017,0.001177367,0.00010237483,0.00025925788,0.000007247143,0.00003904992,0.012294478],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9964147,0.0002030723,0.0003803776,0.0007897508,0.0011133845,0.0010986787],"domain_scores_gemma":[0.9983989,0.00019437869,0.00015160955,0.00071437604,0.00035777388,0.0001829438],"candidate_categories":["sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014116451,0.00025580297,0.0004953075,0.00072265783,0.00089432177,0.000062730185,0.0009300666,0.000047544683,0.0063055544],"category_scores_gemma":[0.00022700314,0.00023362412,0.00013163115,0.0017381142,0.0033241292,0.0002267338,0.0009854354,0.00084750104,0.00014433802],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001121294,0.00014816917,0.0026532211,0.000015865602,0.000057419118,0.00018010521,0.0018221095,0.000015437507,0.9914439,0.001000742,0.0002553565,0.0012864326],"study_design_scores_gemma":[0.00342744,0.0019902273,0.00494043,0.000019834815,0.000028766208,0.0009602713,0.005540234,0.000115586,0.9734172,0.00074261875,0.008518521,0.00029885327],"about_ca_topic_score_codex":0.00077009737,"about_ca_topic_score_gemma":0.00004700967,"teacher_disagreement_score":0.01802663,"about_ca_system_score_codex":0.00082031806,"about_ca_system_score_gemma":0.0016378149,"threshold_uncertainty_score":0.9993883},"labels":[],"label_agreement":null},{"id":"W4224311696","doi":"10.1212/nxi.0000000000001173","title":"Programmed Cell Death Protein 1–Positive CD8 <sup>+</sup> T Cells in Multiple Sclerosis","year":2022,"lang":"en","type":"letter","venue":"Neurology Neuroimmunology & Neuroinflammation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Multiple sclerosis; Programmed cell death; CD8; Cytotoxic T cell; Cell; Cell biology; Chemistry; Biology; Immunology; Apoptosis; Biochemistry; Immune system; In vitro","score_opus":0.036903279635318836,"score_gpt":0.24930107587053896,"score_spread":0.21239779623522012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224311696","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.72936285,0.00017332291,0.0000073689484,0.26020277,0.00068009255,0.007402305,0.00011370339,0.00049336115,0.001564228],"genre_scores_gemma":[0.34332845,0.0015229707,0.00043200096,0.60504293,0.0039110896,0.008244956,0.006180553,0.002073212,0.029263835],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.98689544,0.004549437,0.0018269886,0.0028868676,0.001360801,0.0024804585],"domain_scores_gemma":[0.9945129,0.0016336875,0.00091046724,0.0024162652,0.00032483207,0.00020182891],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.0007610878,0.0014410419,0.0020095517,0.0023871625,0.0005064979,0.00012338502,0.0012625119,0.0024991482,0.002992654],"category_scores_gemma":[0.0005398596,0.001625795,0.0006945285,0.0013522925,0.00080955174,0.00028819396,0.0009522858,0.016346335,0.00046823052],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0072471076,0.00088062225,0.0028252082,0.00055462896,0.00020909065,0.020625127,0.0005650025,0.0008282551,0.9185552,0.000014401677,0.041643925,0.0060514077],"study_design_scores_gemma":[0.014213957,0.0152398925,0.02689005,0.00017170189,0.00043574377,0.0026081153,0.00004403769,0.0071073635,0.07376167,0.0001350982,0.8576356,0.001756763],"about_ca_topic_score_codex":0.00033292908,"about_ca_topic_score_gemma":0.000026763304,"teacher_disagreement_score":0.84479356,"about_ca_system_score_codex":0.00040991395,"about_ca_system_score_gemma":0.0006521968,"threshold_uncertainty_score":0.99983394},"labels":[],"label_agreement":null},{"id":"W4224909487","doi":"10.1016/j.ekir.2022.04.003","title":"Chimeric Antigen Receptor Regulatory T Cell in Transplantation: The Future of Cell Therapy?","year":2022,"lang":"en","type":"editorial","venue":"Kidney International Reports","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Chimeric antigen receptor; Cell therapy; Transplantation; Receptor; Immunology; Cell; Antigen; Cancer research; Immunotherapy; Internal medicine; Immune system; Genetics; Biology","score_opus":0.009161559648392438,"score_gpt":0.28586576617202436,"score_spread":0.2767042065236319,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224909487","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03138879,0.0034013567,0.0000051276957,0.0024528499,0.9242533,0.0014519083,0.0005213398,0.00007896057,0.036446363],"genre_scores_gemma":[0.02083942,0.03901373,0.00026396848,0.0006612268,0.836476,0.00038148445,0.008473187,0.00031494742,0.093575984],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99471855,0.00019108556,0.0010032739,0.0006450007,0.0031389797,0.0003031213],"domain_scores_gemma":[0.9973955,0.00034651923,0.00077703036,0.0008184051,0.00046300213,0.00019952016],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012103807,0.00034192234,0.0005578233,0.00043504324,0.00008107933,0.00003390911,0.0004979866,0.00043634244,0.026535006],"category_scores_gemma":[0.00022667088,0.00026885612,0.00037146575,0.0003983207,0.00012552933,0.00008177501,0.000087056214,0.0015490664,0.000017220358],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008177663,0.000374627,0.0026299781,0.0002197992,0.00019405088,0.00080660696,0.00083722884,0.000008484123,0.03800492,0.000005854295,0.95415944,0.0019412728],"study_design_scores_gemma":[0.0014642541,0.00017760764,0.0016502923,0.00012666918,0.000039342962,0.00012085399,0.00016141127,0.0000065341146,0.014375153,0.000043176035,0.9816188,0.00021590746],"about_ca_topic_score_codex":0.00028033854,"about_ca_topic_score_gemma":0.00001848425,"teacher_disagreement_score":0.08777725,"about_ca_system_score_codex":0.0004507951,"about_ca_system_score_gemma":0.0025185612,"threshold_uncertainty_score":0.99997634},"labels":[],"label_agreement":null},{"id":"W4225319387","doi":"","title":"Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies","year":2022,"lang":"en","type":"review","venue":"White Rose Research Online (University of Leeds, The University of Sheffield, University of York)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; AstraZeneca (Canada); Spinal Cord Injury BC; University of British Columbia; Immunovaccine (Canada)","funders":"","keywords":"Medicine; Adverse effect; Context (archaeology); Intensive care medicine; Clinical trial; Cancer; Hematology; Oncology; Internal medicine","score_opus":0.16223791260157028,"score_gpt":0.3898527533791697,"score_spread":0.22761484077759941,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225319387","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.38054895,0.5899187,0.0011844183,0.012705076,0.0002414733,0.010542723,0.0012950955,0.00011267592,0.0034508964],"genre_scores_gemma":[0.015534873,0.9768904,0.004891676,0.000005258737,0.000046802063,3.255513e-7,0.0001722628,0.00003168749,0.00242673],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960842,0.001122411,0.0005693922,0.00063041586,0.0010752984,0.0005182524],"domain_scores_gemma":[0.9958495,0.0012968825,0.0014719667,0.0007238064,0.00047166538,0.00018617648],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003738031,0.0003202874,0.0019119843,0.0010168125,0.0011936509,0.0000053861972,0.0010035174,0.00042527512,0.00033837295],"category_scores_gemma":[0.00015176601,0.00029940694,0.00067048037,0.0011699381,0.0022649902,0.00020075355,0.0015955871,0.001854949,2.8734007e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031736612,0.0025581755,0.016798167,0.03048861,0.002657984,0.0009109913,0.03739409,0.000087458815,0.0002474607,0.0014568506,0.0005783022,0.90364826],"study_design_scores_gemma":[0.0044680405,0.0014377058,0.011457418,0.0068060355,0.0019484467,0.0003000638,0.24349643,0.0015836782,0.000005601364,0.00028462365,0.7276682,0.00054371863],"about_ca_topic_score_codex":0.0024209835,"about_ca_topic_score_gemma":0.0015228898,"teacher_disagreement_score":0.90310454,"about_ca_system_score_codex":0.00045357805,"about_ca_system_score_gemma":0.0008780236,"threshold_uncertainty_score":0.9999458},"labels":[],"label_agreement":null},{"id":"W4225533228","doi":"10.3389/fimmu.2022.875580","title":"Editorial: T-Cell Signaling Networks in Health and Disease","year":2022,"lang":"en","type":"editorial","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Biology; Computational biology; Immunology","score_opus":0.008365074513652421,"score_gpt":0.2810487425875146,"score_spread":0.2726836680738622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225533228","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00024350492,0.06975775,0.00016657279,0.00047329185,0.9281574,0.0009149354,0.000045205063,0.000045256398,0.00019606651],"genre_scores_gemma":[0.000082671104,0.02657673,0.00044370475,0.00013576374,0.96590954,0.00023591974,0.0011341727,0.00013075543,0.005350766],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958886,0.0008122721,0.0007531792,0.00081494637,0.00077225873,0.00095877977],"domain_scores_gemma":[0.99804217,0.00060539163,0.00024553938,0.00064412435,0.000089280904,0.0003735063],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0015253659,0.0003818332,0.0012704819,0.0009921716,0.000108165994,0.00003105072,0.00037510437,0.0010029121,0.00062378985],"category_scores_gemma":[0.0012423528,0.00042689627,0.00012721057,0.0005331871,0.00028167374,0.000052436055,0.00037202126,0.0049146563,0.0000029322975],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051471423,0.00021280973,0.0023924988,0.00035688828,0.00010711143,0.0001778833,0.00032976255,0.00010782812,0.00008066976,0.0000028221493,0.9854789,0.0056057167],"study_design_scores_gemma":[0.0049214526,0.00077340583,0.000047889454,0.00023916386,0.000024535539,0.0000021309143,0.00050872035,0.0003502929,0.0000023778189,0.00023255016,0.9926187,0.00027879793],"about_ca_topic_score_codex":0.00076458044,"about_ca_topic_score_gemma":0.00002760925,"teacher_disagreement_score":0.043181024,"about_ca_system_score_codex":0.0016842091,"about_ca_system_score_gemma":0.0032975352,"threshold_uncertainty_score":0.99981827},"labels":[],"label_agreement":null},{"id":"W4225543978","doi":"10.1007/s11033-022-07147-0","title":"RETRACTED ARTICLE: Elucidation of CRISPR-Cas9 application in novel cellular immunotherapy","year":2022,"lang":"en","type":"article","venue":"Molecular Biology Reports","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":19,"is_retracted":true,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Emergent BioSolutions (Canada)","funders":"","keywords":"CRISPR; Genome editing; T-cell receptor; Immunotherapy; Cas9; Cancer immunotherapy; Computational biology; T cell; Cell therapy; Biology; Genetic enhancement; Chimeric antigen receptor; Immune system; Transcription activator-like effector nuclease; Cancer research; Immunology; Gene; Cell; Genetics","score_opus":0.013453884977379761,"score_gpt":0.31841823792421714,"score_spread":0.3049643529468374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225543978","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97399664,0.000444612,0.02345946,0.0004710521,0.0001221051,0.0007745177,0.000003875326,0.000046057274,0.00068167044],"genre_scores_gemma":[0.99834627,0.000016883989,0.0006091111,0.00024656928,0.000026476684,0.00019159878,0.00017594428,0.000036086207,0.00035106938],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984159,0.00014462922,0.00054399006,0.00037626195,0.00028234988,0.0002368959],"domain_scores_gemma":[0.9989109,0.000030381192,0.0002445463,0.0006516748,0.00011369808,0.000048786318],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009547959,0.00011107193,0.00027963822,0.00023781942,0.00004927904,0.000003932497,0.00008329106,0.000141066,0.00081624347],"category_scores_gemma":[0.000094442235,0.00011533992,0.00009404031,0.00056060025,0.00008542463,0.000021683118,0.000071445225,0.0004301761,0.0000034505088],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033352038,0.00036636528,0.06386528,0.000013090798,0.00005257216,0.0003062342,0.0001314232,0.000053375625,0.9272956,0.00011635567,0.000021556492,0.0074445833],"study_design_scores_gemma":[0.0012111233,0.0005531523,0.04265454,0.0000077001905,0.000020018464,0.00053848163,0.000062103325,0.00061047403,0.9446094,0.0006219815,0.008980622,0.00013040044],"about_ca_topic_score_codex":0.00032806312,"about_ca_topic_score_gemma":0.0000070461033,"teacher_disagreement_score":0.024349611,"about_ca_system_score_codex":0.00018482476,"about_ca_system_score_gemma":0.00017501881,"threshold_uncertainty_score":0.8937294},"labels":[],"label_agreement":null},{"id":"W4226022053","doi":"10.1016/j.clml.2021.12.003","title":"An Overview of CAR T Cell Mediated B Cell Maturation Antigen Therapy","year":2021,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Emergent BioSolutions (Canada)","funders":"","keywords":"Chimeric antigen receptor; Multiple myeloma; Medicine; Malignancy; Plasma cell; Antigen; Cancer research; Antibody; Clinical trial; Cancer; Immunology; Oncology; Immunotherapy; Internal medicine","score_opus":0.17085119738957352,"score_gpt":0.4525105370994986,"score_spread":0.28165933970992507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226022053","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0132687185,0.9796699,0.0000068765435,0.000038536597,0.00080131274,0.0023270014,0.00016529555,0.00015396539,0.0035683396],"genre_scores_gemma":[0.00045650726,0.99002767,0.00043579144,0.00041203015,0.0015113098,0.00012742546,0.0031017216,0.00033972264,0.0035878038],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98999304,0.002312588,0.0037182337,0.0016571332,0.001413701,0.0009052983],"domain_scores_gemma":[0.9916521,0.0023464023,0.0014716544,0.0028852983,0.00073528604,0.0009092683],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0023817548,0.0010729416,0.006511242,0.00040162855,0.0001141614,0.00009892142,0.001033604,0.0022416296,0.004283728],"category_scores_gemma":[0.00046682,0.0008584643,0.00295525,0.0014365856,0.00047872338,0.00017069957,0.00023690308,0.0012341468,0.0005044041],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032155516,0.0008090205,0.00012222705,0.011139112,0.00046288702,0.00045335642,0.00006405373,3.0230615e-7,0.0011431505,0.000020006768,0.002119622,0.98334473],"study_design_scores_gemma":[0.0037292335,0.001281242,0.0056699193,0.007984215,0.00076715124,0.0001561983,0.000036247297,0.000053275402,0.0008729284,0.0000145504,0.97868925,0.0007457683],"about_ca_topic_score_codex":0.00012472365,"about_ca_topic_score_gemma":0.000008006579,"teacher_disagreement_score":0.98259896,"about_ca_system_score_codex":0.0013104868,"about_ca_system_score_gemma":0.00952791,"threshold_uncertainty_score":0.9993866},"labels":[],"label_agreement":null},{"id":"W4226068368","doi":"10.1038/s41568-022-00466-1","title":"Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities","year":2022,"lang":"en","type":"review","venue":"Nature reviews. Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":513,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; University of British Columbia","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Immunotherapy; Immunology; Immune system; Cancer immunotherapy; Biology; T cell; Immune checkpoint; Antigen; Cancer research; Context (archaeology); Autoimmunity","score_opus":0.3309784990381246,"score_gpt":0.5148692975168264,"score_spread":0.18389079847870182,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226068368","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000007337421,0.9926795,0.0000061264277,0.0002053275,0.0009388109,0.003764775,0.00017172284,0.000098966215,0.0021274735],"genre_scores_gemma":[0.000005266652,0.9921322,0.00025886655,0.0012971944,0.0010166765,0.0011405243,0.00022064251,0.00018106593,0.0037475685],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9931826,0.002195641,0.0018705695,0.0010791671,0.00087480334,0.00079723354],"domain_scores_gemma":[0.99613005,0.0013797003,0.0009362896,0.0010081816,0.00011850666,0.00042730148],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0039242962,0.0009912066,0.0058381977,0.00030660554,0.00023693148,0.0000950067,0.00057311973,0.0015479922,0.035110205],"category_scores_gemma":[0.00044544708,0.0006087865,0.002419734,0.00063661893,0.00027244742,0.00006232337,0.00035271922,0.00837628,0.000046426667],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006762158,0.00009409634,0.000003586,0.014536689,0.00079713814,0.00015230525,0.000025759748,3.6027167e-8,0.00007689542,0.00013586036,0.002414559,0.9816955],"study_design_scores_gemma":[0.00047859995,0.00068369985,0.000007594943,0.012258044,0.0021532697,0.00051647273,0.000044281813,0.0000034668265,0.0000065834524,0.00006344958,0.9832382,0.00054629886],"about_ca_topic_score_codex":0.000037423353,"about_ca_topic_score_gemma":0.000006992943,"teacher_disagreement_score":0.98114914,"about_ca_system_score_codex":0.00081107765,"about_ca_system_score_gemma":0.001945416,"threshold_uncertainty_score":0.99974823},"labels":[],"label_agreement":null},{"id":"W4226242673","doi":"10.1038/s41536-022-00210-1","title":"Multi-objective optimization reveals time- and dose-dependent inflammatory cytokine-mediated regulation of human stem cell derived T-cell development","year":2022,"lang":"en","type":"article","venue":"npj Regenerative Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Wellcome Trust; Hospital for Sick Children; Michael Smith Health Research BC; University of Toronto; BC Children's Hospital","keywords":"Stem cell; Biology; T cell; Cell biology; Stem cell factor; Progenitor cell; Haematopoiesis; Immunology; CD8; Cytotoxic T cell; Cytokine; Cancer research; Immune system; In vitro","score_opus":0.030168865504003477,"score_gpt":0.2855176232633859,"score_spread":0.2553487577593824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226242673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99224615,0.001210425,0.0018728847,0.0003512658,0.0001238642,0.001986517,0.00002928071,0.000085763924,0.0020938488],"genre_scores_gemma":[0.9645375,0.00009041805,0.0035236077,0.00015763991,0.00020223619,0.00022569556,0.000633411,0.00008188611,0.03054761],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9964781,0.0005929552,0.00081798754,0.00058724004,0.0011725998,0.00035113955],"domain_scores_gemma":[0.99817,0.00019143727,0.00044953323,0.00040409729,0.00054281147,0.0002420986],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012527923,0.00033324517,0.0007153758,0.0005018182,0.00039449523,0.000010417787,0.00015082177,0.00011515501,0.0036732296],"category_scores_gemma":[0.00006476325,0.00029109913,0.00005954204,0.0004971815,0.00029066872,0.00009026852,0.00020306876,0.00044922094,0.0000110976625],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005126993,0.00028850528,0.0017293325,0.00015982067,0.00011114328,0.0000344456,0.007931717,0.0040780543,0.9831378,0.000009004544,0.0005351592,0.0014723549],"study_design_scores_gemma":[0.012063268,0.0018742778,0.012579999,0.00015208095,0.000118633216,0.000037381815,0.002392003,0.014315364,0.95531386,0.0000065507725,0.0008153281,0.00033124545],"about_ca_topic_score_codex":0.00004612773,"about_ca_topic_score_gemma":0.000018314326,"teacher_disagreement_score":0.02845376,"about_ca_system_score_codex":0.0006381994,"about_ca_system_score_gemma":0.00032042086,"threshold_uncertainty_score":0.9999541},"labels":[],"label_agreement":null},{"id":"W4226374363","doi":"","title":"Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors","year":2022,"lang":"en","type":"article","venue":"EUR Research Repository (Erasmus University Rotterdam)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":50,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; Princess Margaret Cancer Centre","funders":"Ono Pharmaceutical; Università degli Studi di Milano; Bristol-Myers Squibb","keywords":"Tolerability; Nivolumab; Medicine; Adverse effect; Internal medicine; Dosing; Phases of clinical research; Pharmacology; Gastroenterology; Mesothelin; Pharmacodynamics; Oncology; Clinical trial; Cancer; Pharmacokinetics; Immunotherapy","score_opus":0.02240105381484284,"score_gpt":0.32797840933215977,"score_spread":0.3055773555173169,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226374363","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940899,0.000019732252,0.000012095213,0.00029808824,0.000102859325,0.0040647876,0.00004576181,0.000054452976,0.0013123272],"genre_scores_gemma":[0.9928795,0.000029065046,0.00014627249,0.000036078327,0.000053346634,0.000029742718,0.0002112784,0.000068459725,0.0065462207],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99304366,0.0021581482,0.0005727092,0.00084973994,0.0025322817,0.0008434347],"domain_scores_gemma":[0.9975294,0.00028367134,0.00025994913,0.0008758375,0.00071326224,0.00033791293],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019457733,0.0002966308,0.00081468845,0.0018416552,0.00052304874,0.000051565836,0.0006174591,0.00008372088,0.00039297467],"category_scores_gemma":[0.00009423776,0.00027233385,0.00008658752,0.0022542423,0.0005210475,0.0005703361,0.00036988352,0.0014779255,0.000004874318],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.69440037,0.020140633,0.16269512,0.00024093635,0.00017313869,0.0064533716,0.0030252573,0.00043543807,0.10968735,0.000033853663,0.00027769274,0.0024368057],"study_design_scores_gemma":[0.7537826,0.0737949,0.13219485,0.0006194157,0.000057739824,0.00012101208,0.0065595554,0.0015210203,0.027916567,0.000012231149,0.0027196594,0.0007004636],"about_ca_topic_score_codex":0.001803694,"about_ca_topic_score_gemma":0.00046645288,"teacher_disagreement_score":0.081770785,"about_ca_system_score_codex":0.0012590487,"about_ca_system_score_gemma":0.001272579,"threshold_uncertainty_score":0.9999729},"labels":[],"label_agreement":null},{"id":"W4230910528","doi":"10.3410/f.1022661.260651","title":"Faculty Opinions recommendation of Dynamic molecular interactions linking the T cell antigen receptor to the actin cytoskeleton.","year":2004,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Cytoskeleton; Actin cytoskeleton; Actin; Cell biology; Antigen; Chemistry; Receptor; Computational biology; Biology; Cell; Immunology; Biochemistry","score_opus":0.030247848886077316,"score_gpt":0.3890143738921009,"score_spread":0.3587665250060236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4230910528","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000038665844,0.0008628846,0.000102341,0.3900038,0.0008346016,0.0022794062,0.60576,0.00003016813,0.000122993],"genre_scores_gemma":[0.00003100518,0.0012451551,0.00091583736,0.011391548,0.00043894976,0.0004501316,0.9800358,0.000063931744,0.005427673],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9936394,0.00091937906,0.0017123949,0.00085785106,0.0023102066,0.00056073745],"domain_scores_gemma":[0.98847777,0.00039153578,0.001285313,0.002968213,0.00646614,0.00041100863],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0022209124,0.00063278433,0.0010385854,0.00045874814,0.00049566786,0.00021302118,0.0022406897,0.0006123456,0.0022542684],"category_scores_gemma":[0.00584423,0.00033158704,0.0010830371,0.003689782,0.00040633415,0.00021753694,0.00085605995,0.002780364,0.00025512412],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000055054315,0.00050046516,0.0000018914902,0.004115989,0.00029126572,0.0000010011779,0.00030494333,9.555996e-7,0.00048051725,0.000057430116,0.9860528,0.008137662],"study_design_scores_gemma":[0.0008073281,0.00020548364,0.00031636434,0.01095185,0.00028271097,0.00010509854,0.000113383496,0.000014386609,0.0006158381,0.000019888255,0.98626596,0.0003017374],"about_ca_topic_score_codex":0.00012315948,"about_ca_topic_score_gemma":0.00003452639,"teacher_disagreement_score":0.37861225,"about_ca_system_score_codex":0.00051011215,"about_ca_system_score_gemma":0.0016122886,"threshold_uncertainty_score":0.99991363},"labels":[],"label_agreement":null},{"id":"W4233173587","doi":"10.1182/blood-2019-131818","title":"Obinutuzumab Plus Gemcitabine, Dexamethasone and Cisplatin (O-GDP) As Salvage Chemotherapy Prior to Autologous Stem Cell Transplant in Aggressive B Cell Lymphoma","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Health Sciences Centre; Sunnybrook Health Science Centre; BC Cancer Agency; Simon Fraser University; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Obinutuzumab; Salvage therapy; Internal medicine; Rituximab; Gemcitabine; Oncology; Chemotherapy regimen; Regimen; Autologous stem-cell transplantation; Transplantation; Chemotherapy; Surgery; Lymphoma","score_opus":0.010714106517421475,"score_gpt":0.2580992509205724,"score_spread":0.24738514440315093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4233173587","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98372465,0.0020786214,0.000030877018,0.00034675802,0.00011688768,0.002266318,0.000036600846,0.000096584874,0.011302673],"genre_scores_gemma":[0.97959757,0.0006348223,0.0011883334,0.00067900773,0.00009842292,0.00009464933,0.000021199872,0.000113555965,0.017572448],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99716896,0.00014409449,0.0004791141,0.00079847476,0.00061252184,0.0007968242],"domain_scores_gemma":[0.9983146,0.0003336248,0.0001626972,0.00070301647,0.000082971215,0.00040306867],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00042397212,0.00040746504,0.0008382906,0.00037889654,0.00005919232,0.000052288724,0.00026933683,0.00029798373,0.0011919289],"category_scores_gemma":[0.000021042737,0.00036879818,0.00013369267,0.0005037423,0.00008270612,0.00008035655,0.00007375188,0.0003675549,0.00035955335],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005015551,0.0015823344,0.018626614,0.0008588495,0.00018687939,0.0024569558,0.010496644,0.000038756698,0.8807478,0.00003532146,0.0002571973,0.07969709],"study_design_scores_gemma":[0.09234868,0.0046125436,0.062389642,0.00079180894,0.0002502107,0.001331608,0.0009764565,0.0007509241,0.8300143,0.0000536824,0.005469305,0.0010108646],"about_ca_topic_score_codex":0.00041268018,"about_ca_topic_score_gemma":0.00008139217,"teacher_disagreement_score":0.08733313,"about_ca_system_score_codex":0.00036966498,"about_ca_system_score_gemma":0.0006058515,"threshold_uncertainty_score":0.9998764},"labels":[],"label_agreement":null},{"id":"W4235546527","doi":"10.1200/jco.2017.77.0446","title":"Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology","year":2018,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":138,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital","funders":"","keywords":"Medicine; Cancer; Chimeric antigen receptor; Clinical trial; Immunotherapy; Cancer immunotherapy; Oncology; Clinical Oncology; Internal medicine; Immunology; Family medicine","score_opus":0.24770995579533853,"score_gpt":0.6188850474531973,"score_spread":0.3711750916578588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235546527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92311716,0.0030239623,0.00003887865,0.061113123,0.008383761,0.00060816424,0.000086144064,0.00002342848,0.0036053858],"genre_scores_gemma":[0.74122286,0.11563906,0.011516664,0.055909127,0.07134074,0.000082177154,0.000020490796,0.00014077224,0.0041280906],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9837399,0.0036649308,0.009559057,0.0008130932,0.001500226,0.0007227797],"domain_scores_gemma":[0.9615395,0.021800313,0.01164507,0.0010004477,0.0029658626,0.001048806],"candidate_categories":["metaresearch","sts","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.02420774,0.00036097912,0.005309136,0.000091324124,0.00013730327,0.000014533178,0.0009290253,0.0010732288,0.0015161742],"category_scores_gemma":[0.010348538,0.00021003658,0.0028189982,0.0004886036,0.009241926,0.0001733684,0.00029336134,0.0050763004,0.0000367783],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016251607,0.0025578814,0.38307253,0.000012333922,0.001346793,0.00048289332,0.00012340097,0.0000035440257,0.00007126235,0.0000049638206,0.0893618,0.506711],"study_design_scores_gemma":[0.006279618,0.029660802,0.39365864,0.00018183635,0.0003809205,0.00009767679,0.00039145752,0.00008430905,0.00006327149,0.00007569395,0.5689986,0.00012722265],"about_ca_topic_score_codex":0.0006003127,"about_ca_topic_score_gemma":0.0012317945,"teacher_disagreement_score":0.50658375,"about_ca_system_score_codex":0.0004562285,"about_ca_system_score_gemma":0.0123642,"threshold_uncertainty_score":0.99939656},"labels":[],"label_agreement":null},{"id":"W4235632004","doi":"10.4324/9780203427835_chapter_12","title":"Mammalian cell products","year":2010,"lang":"en","type":"book-chapter","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Cell; Biology; Genetics","score_opus":0.03569124969875622,"score_gpt":0.28870132549110894,"score_spread":0.25301007579235274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4235632004","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022147328,0.000306115,0.0000039054717,0.002375211,0.00039469733,0.00094997894,0.00000971102,0.000115071976,0.9956238],"genre_scores_gemma":[0.0005303395,0.00022021205,0.0012019826,0.0005032752,0.0016968901,0.000010225097,0.00009546789,0.00016010605,0.9955815],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982527,0.000006745273,0.00024002163,0.0005327912,0.00063212466,0.00033560817],"domain_scores_gemma":[0.9982874,0.00003059181,0.000065698616,0.0010882033,0.00027768916,0.00025046567],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00021830888,0.00030988688,0.00044727544,0.00021341599,0.00004089148,0.00002517042,0.00017824926,0.0005843804,0.18297282],"category_scores_gemma":[0.000025115083,0.00024796964,0.00016601953,0.000030232399,0.00015307628,0.000022495322,0.000094214454,0.0014829766,0.004874326],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051703356,0.00015418298,0.000050202765,0.0011458037,0.00020480272,0.0008390538,0.00014231373,3.0277075e-8,0.79524505,0.0247238,0.11974863,0.05722907],"study_design_scores_gemma":[0.0005527691,0.00022180453,0.000018986451,0.000051802188,0.000059896796,0.000083486135,0.0000032409475,5.138516e-7,0.095589824,0.0009566045,0.9022402,0.00022084513],"about_ca_topic_score_codex":0.000034525816,"about_ca_topic_score_gemma":0.00003710635,"teacher_disagreement_score":0.7824916,"about_ca_system_score_codex":0.00007581493,"about_ca_system_score_gemma":0.00033435633,"threshold_uncertainty_score":0.99999726},"labels":[],"label_agreement":null},{"id":"W4236849491","doi":"10.3410/f.726494315.793524865","title":"Faculty Opinions recommendation of Treatment of ongoing autoimmune encephalomyelitis with activated B-cell progenitors maturing into regulatory B cells.","year":2016,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Experimental autoimmune encephalomyelitis; Progenitor cell; Regulatory B cells; B cell; Encephalomyelitis; Immunology; Biology; Medicine; Cell biology; Stem cell; Multiple sclerosis","score_opus":0.02630271096871737,"score_gpt":0.3435737069009207,"score_spread":0.3172709959322033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4236849491","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004683911,0.00162748,0.0000087826775,0.05292381,0.00047439573,0.002652401,0.94211465,0.00004889373,0.00010273678],"genre_scores_gemma":[0.00005904349,0.0016011852,0.0009593489,0.00041781267,0.0003005249,0.00034726708,0.9912125,0.000062299296,0.0050400277],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9945397,0.00051190454,0.0017817569,0.00081720715,0.0018738968,0.00047557452],"domain_scores_gemma":[0.98885643,0.00021739826,0.001825897,0.002159578,0.0065684593,0.0003722572],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00083309045,0.0006705806,0.0015624575,0.00057586515,0.00018557711,0.00005943945,0.0008720662,0.0007477103,0.0012483314],"category_scores_gemma":[0.0010905028,0.00037502294,0.00076095515,0.0020153332,0.0006214517,0.0002700624,0.00030139025,0.0007662655,0.000023134966],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018650004,0.0010859994,0.00001082083,0.014081803,0.0005253803,0.000001824536,0.0003024105,8.576462e-8,0.004676264,0.000018110357,0.9648413,0.014269475],"study_design_scores_gemma":[0.00260549,0.0009520981,0.0011333723,0.021085054,0.00037623174,0.00007920008,0.000052526626,0.0000020289917,0.01661892,0.0000064068986,0.9567673,0.0003213582],"about_ca_topic_score_codex":0.00014733286,"about_ca_topic_score_gemma":0.000006533406,"teacher_disagreement_score":0.052505996,"about_ca_system_score_codex":0.00068694877,"about_ca_system_score_gemma":0.0019302903,"threshold_uncertainty_score":0.9998702},"labels":[],"label_agreement":null},{"id":"W4237314469","doi":"10.3410/f.726930282.793525784","title":"Faculty Opinions recommendation of Specific niches for lung-resident memory CD8+ T cells at the site of tissue regeneration enable CD69-independent maintenance.","year":2016,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Regeneration (biology); Niche; Biology; CD8; Ecological niche; Cell biology; Immunology; Ecology; Immune system","score_opus":0.04013321062593555,"score_gpt":0.36599733623305264,"score_spread":0.3258641256071171,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4237314469","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00000323007,0.0033579918,0.00015751629,0.20161402,0.001022101,0.0039935242,0.7897134,0.00002140418,0.00011684331],"genre_scores_gemma":[0.000006558444,0.0036996847,0.00041613093,0.0017952207,0.00074159866,0.00057988986,0.94273925,0.000055250504,0.04996644],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99322474,0.0006808821,0.0021931713,0.0009188275,0.0024297328,0.0005526263],"domain_scores_gemma":[0.9853195,0.00050914974,0.0020160824,0.0026267879,0.009196916,0.0003315675],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0030213566,0.00059831695,0.0013627147,0.0003936295,0.00030946842,0.000095170704,0.0011434745,0.00077778636,0.0044175726],"category_scores_gemma":[0.0036871592,0.00032008102,0.00093389995,0.0013608051,0.00058442884,0.00024030726,0.000655731,0.00090301404,0.00006316694],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019547707,0.00035782304,0.0000031538211,0.010157872,0.00029317933,7.666952e-7,0.00019549938,4.884376e-7,0.0037571585,0.000106223146,0.9811279,0.0038044213],"study_design_scores_gemma":[0.0018927702,0.00028953055,0.000155265,0.009230204,0.00032386475,0.00006648343,0.00004939102,0.000012315414,0.018718423,0.000034432014,0.9689354,0.00029193776],"about_ca_topic_score_codex":0.0000802665,"about_ca_topic_score_gemma":0.000041951716,"teacher_disagreement_score":0.1998188,"about_ca_system_score_codex":0.0005387416,"about_ca_system_score_gemma":0.00092438934,"threshold_uncertainty_score":0.99992514},"labels":[],"label_agreement":null},{"id":"W4237457482","doi":"10.21203/rs.3.rs-59510/v1","title":"Efficacy and Safety of CD22 Chimeric Antigen Receptor (CAR) T-cell Therapy in Patients With B-cell Malignancies: A Protocol for a Systematic Review and Meta-analysis","year":2020,"lang":"en","type":"review","venue":"Research Square","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; Western University; Ottawa Hospital; University of British Columbia","funders":"","keywords":"Chimeric antigen receptor; Meta-analysis; CD22; Medicine; Protocol (science); B cell; Immunotherapy; Oncology; Immunology; Internal medicine; Cancer; Antibody; Pathology; Alternative medicine","score_opus":0.13489594269038976,"score_gpt":0.44548884738199357,"score_spread":0.31059290469160383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4237457482","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000015374226,0.6211275,0.0000053714416,0.0000740434,0.0000020690568,0.3784183,0.00024251227,0.000014459385,0.00010039112],"genre_scores_gemma":[0.000009128774,0.69470453,0.00021092079,0.000035382232,0.000021111708,0.30373392,0.00018874097,0.00011596158,0.0009802928],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.9913198,0.0027117953,0.0018279043,0.0012095856,0.0020873405,0.00084357045],"domain_scores_gemma":[0.9945458,0.0017784148,0.0007490585,0.0013381629,0.0011223315,0.000466189],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0041824165,0.00075550936,0.011117598,0.0012606712,0.00012466924,0.00007585992,0.0004914341,0.00028991303,0.0012737046],"category_scores_gemma":[0.0006388519,0.00042804293,0.0015932337,0.0045763873,0.0003016599,0.0000802654,0.00023498599,0.0010115954,0.000014806824],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012715674,0.00082619593,0.00009329764,0.9617108,0.028023893,0.000011218026,0.00016407264,1.0471569e-7,0.000014627292,0.0000022213908,0.00024193004,0.0076400805],"study_design_scores_gemma":[0.016387403,0.011846255,0.00010443648,0.29849446,0.20082818,0.000010337256,0.00014048824,0.000010186833,0.000049532537,0.000002944528,0.47112566,0.0010001102],"about_ca_topic_score_codex":0.00006263076,"about_ca_topic_score_gemma":0.0000078047,"teacher_disagreement_score":0.66321635,"about_ca_system_score_codex":0.0002569828,"about_ca_system_score_gemma":0.00093848165,"threshold_uncertainty_score":0.99981713},"labels":[],"label_agreement":null},{"id":"W4237606309","doi":"10.1515/iupac.84.1187","title":"T Cell, Drug-Specific","year":2016,"lang":"en","type":"dataset","venue":"IUPAC Standards Online","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada Research Chairs; University of Toronto","funders":"","keywords":"Glossary; Immunotoxicology; Immunology; Medicine; Immune system; Philosophy; Linguistics","score_opus":0.024827768472563374,"score_gpt":0.42363980525136774,"score_spread":0.3988120367788044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4237606309","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00025086108,0.005353405,0.000030542968,0.0019556698,0.0013201555,0.00092815846,0.98890966,0.00011591701,0.0011356368],"genre_scores_gemma":[0.0000107841415,0.012847578,0.00005562749,0.00039791467,0.003881773,0.00003236066,0.9320882,0.00012983814,0.05055592],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99454206,0.00014833237,0.0006556651,0.0009054097,0.0028503835,0.00089816353],"domain_scores_gemma":[0.99599355,0.00021868099,0.00021351174,0.0021224206,0.00088587357,0.0005659445],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000990646,0.0006455066,0.0011858423,0.0005494373,0.00012367553,0.00009276572,0.0005659246,0.00052588485,0.1159577],"category_scores_gemma":[0.00019326761,0.00047053015,0.00043894182,0.0003820129,0.00033457362,0.000066753506,0.0002707741,0.0013575976,0.0000615794],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00141402,0.0005565745,0.000009370585,0.000408103,0.0001540794,0.0006033226,0.0000186102,1.5890348e-7,0.0011299466,0.000002476633,0.98231906,0.013384301],"study_design_scores_gemma":[0.003986086,0.0004879717,0.000012416955,0.0006449491,0.00012929559,0.0000789289,0.00003290037,0.0000010709389,0.000729279,0.000036544385,0.9933741,0.00048644035],"about_ca_topic_score_codex":0.000102258055,"about_ca_topic_score_gemma":0.0000904185,"teacher_disagreement_score":0.11589612,"about_ca_system_score_codex":0.0012309885,"about_ca_system_score_gemma":0.0017551875,"threshold_uncertainty_score":0.99977463},"labels":[],"label_agreement":null},{"id":"W4238786266","doi":"10.3410/f.7192959.7437055","title":"Faculty Opinions recommendation of Repetitive antigen stimulation induces stepwise transcriptome diversification but preserves a core signature of memory CD8(+) T cell differentiation.","year":2010,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Transcriptome; Diversification (marketing strategy); Signature (topology); CD8; Cytotoxic T cell; Stimulation; Antigen; Biology; Computational biology; Cell biology; Computer science; Immunology; Neuroscience; Gene; Genetics; In vitro; Business; Gene expression; Mathematics; Marketing","score_opus":0.05796864483014669,"score_gpt":0.36773873441947896,"score_spread":0.3097700895893323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4238786266","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00042278704,0.0013615462,0.000040519502,0.04569708,0.0007319101,0.0032415723,0.9483416,0.000043323103,0.00011962583],"genre_scores_gemma":[0.0012283673,0.0011027298,0.0005243427,0.0006867142,0.00030960803,0.0001884122,0.99261075,0.000047733713,0.0033013464],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99334246,0.000640987,0.0020534163,0.00091745803,0.002645257,0.00040039606],"domain_scores_gemma":[0.98224765,0.00033296336,0.0024211342,0.0020119974,0.012620288,0.0003659683],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014651965,0.0006219276,0.0013973241,0.00074814947,0.00023100969,0.00008402597,0.0013014112,0.0014456804,0.002623544],"category_scores_gemma":[0.0048412806,0.00044134544,0.00092164736,0.0023549553,0.0005714301,0.00046797254,0.00036326723,0.0021961941,0.000019269311],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001811335,0.0012311959,0.00006482531,0.014384603,0.0003353658,7.109845e-7,0.0005251722,4.893827e-7,0.007933323,0.00004440137,0.9733355,0.00196327],"study_design_scores_gemma":[0.0020523956,0.00033149647,0.018374667,0.007882505,0.00056283,0.000021825617,0.00015637033,0.00003399985,0.004350576,0.000029121366,0.9658484,0.000355809],"about_ca_topic_score_codex":0.00014128964,"about_ca_topic_score_gemma":0.000014986366,"teacher_disagreement_score":0.045010366,"about_ca_system_score_codex":0.00016933793,"about_ca_system_score_gemma":0.0010061926,"threshold_uncertainty_score":0.99985063},"labels":[],"label_agreement":null},{"id":"W4241026090","doi":"10.21203/rs.2.21605/v2","title":"Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada","year":2020,"lang":"en","type":"preprint","venue":"Research Square","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute of Cancer Research; Health Sciences Centre; Canadian Partnership Against Cancer; Canadian Agency for Drugs and Technologies in Health; Sunnybrook Health Science Centre; Queen's University; Cancer Care Ontario","funders":"Canadian Institutes of Health Research; Government of Ontario; Canadian Centre for Applied Research in Cancer Control; Ontario Ministry of Health and Long-Term Care; Ontario Institute for Cancer Research; Cancer Care Ontario","keywords":"Ipilimumab; Medicine; Internal medicine; Cohort; Population; Clinical trial; Oncology; Proportional hazards model; Cancer registry; Cancer; Immunotherapy","score_opus":0.12475419090019918,"score_gpt":0.4402671681884053,"score_spread":0.3155129772882061,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4241026090","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97324526,0.000103490274,0.000046646615,0.00021811714,0.00013586665,0.023752674,0.000562231,0.000030603376,0.0019051128],"genre_scores_gemma":[0.99014866,0.0000065550867,0.0002702117,0.000015474407,0.00007633419,0.004187146,0.0026723333,0.00008867508,0.0025346328],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99106836,0.003013031,0.0009955287,0.0012335605,0.0028237153,0.00086579483],"domain_scores_gemma":[0.99046123,0.006065082,0.00022727373,0.001146225,0.0016690709,0.00043111303],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005833922,0.00047451878,0.0023257313,0.0011739443,0.00012784069,0.000053612155,0.00049666694,0.00015337253,0.0030069668],"category_scores_gemma":[0.00068784173,0.00044733027,0.00028658012,0.0011943192,0.00013674409,0.00004550609,0.00044789189,0.002857004,0.000005041084],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.012113444,0.0015158065,0.9714622,0.008122283,0.0011025225,0.0003129638,0.0009779226,0.0022393637,0.0015228286,0.000057883608,0.000439572,0.00013324806],"study_design_scores_gemma":[0.007980825,0.0028025433,0.97964895,0.0014555597,0.00014790056,0.0000016096998,0.0007526096,0.0037331542,0.0024854299,0.00037364758,0.00030797676,0.00030980379],"about_ca_topic_score_codex":0.9912029,"about_ca_topic_score_gemma":0.99933267,"teacher_disagreement_score":0.019565528,"about_ca_system_score_codex":0.008373866,"about_ca_system_score_gemma":0.01836434,"threshold_uncertainty_score":0.9997978},"labels":[],"label_agreement":null},{"id":"W4241442457","doi":"10.1093/annonc/mdw589.007","title":"410P Ipilimumab efficacy and safety profile in metastatic melanoma in Saskatchewan","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Saskatchewan Cancer Agency; University of Saskatchewan","funders":"","keywords":"Medicine; Ipilimumab; Metastatic melanoma; Oncology; Internal medicine; Melanoma; Safety profile; Adverse effect; Cancer research; Cancer; Immunotherapy","score_opus":0.08230944959589033,"score_gpt":0.40613393726275415,"score_spread":0.32382448766686384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4241442457","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97654665,0.00045403023,0.000008374836,0.013259042,0.00003807121,0.0006193606,0.000012339248,0.000010710293,0.009051429],"genre_scores_gemma":[0.9949755,0.00062423944,0.00046800368,0.00042885437,0.0000366237,0.000035815578,0.0000054896996,0.000017252694,0.0034082027],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9985326,0.00025708985,0.00041600238,0.00025063343,0.00018032448,0.00036333568],"domain_scores_gemma":[0.99860024,0.0007980261,0.00007907337,0.00031979752,0.00008841091,0.000114443574],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010200822,0.000110841,0.0005579055,0.0002971559,0.000012226732,0.0000023822595,0.00012138927,0.000104729326,0.00196995],"category_scores_gemma":[0.00044297279,0.00007644503,0.000047625505,0.0002476129,0.0002163412,0.000053839925,0.000095787975,0.00017774188,0.00003215124],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059002535,0.0009037752,0.022693869,0.00010089722,0.000088954985,0.0002938234,0.0017820997,7.4751733e-7,0.14216585,0.00012081193,0.0013063648,0.82464254],"study_design_scores_gemma":[0.048351698,0.018113568,0.71001136,0.00064345193,0.00005756128,0.00027385628,0.0027644937,0.00007159901,0.09431571,0.002457305,0.12253301,0.00040639596],"about_ca_topic_score_codex":0.00030909042,"about_ca_topic_score_gemma":0.0016396382,"teacher_disagreement_score":0.82423615,"about_ca_system_score_codex":0.00008648447,"about_ca_system_score_gemma":0.0004269467,"threshold_uncertainty_score":0.9989424},"labels":[],"label_agreement":null},{"id":"W4242295440","doi":"10.5206/uwomj.v89i1.9469","title":"Building the fourth pillar","year":2021,"lang":"en","type":"article","venue":"University of Western Ontario Medical Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Oncolytic virus; Chimeric antigen receptor; Immunotherapy; Cancer immunotherapy; Medicine; Blockade; Cancer; Internal medicine; Receptor","score_opus":0.025012670425371218,"score_gpt":0.27311117658764145,"score_spread":0.24809850616227022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4242295440","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97677547,0.00018349387,0.0047893506,0.012189643,0.00019381603,0.000072550705,0.0000010065868,0.000010928598,0.0057837185],"genre_scores_gemma":[0.8867201,0.0013937026,0.0065921564,0.0024560622,0.00094284536,8.761228e-8,0.000008132428,0.000033146713,0.10185372],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99812376,0.00012005105,0.00016045029,0.00013494909,0.0012126442,0.00024815803],"domain_scores_gemma":[0.998847,0.00013428448,0.00007992427,0.00022845443,0.00025656694,0.00045377653],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00065179967,0.000083431376,0.00024704146,0.00007166549,0.00019871385,0.00002286322,0.0003072972,0.00010712619,0.023898518],"category_scores_gemma":[0.00014399989,0.00006384992,0.00019217272,0.00013081731,0.00022920415,0.00006743817,0.00017105672,0.0010781422,0.000020699637],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016449484,0.00074862206,0.70340693,0.000100139,0.0013699186,0.035650715,0.012028108,0.000021503933,0.023961604,0.00044168837,0.009297608,0.21132824],"study_design_scores_gemma":[0.0045612818,0.00036757567,0.13811693,0.00044088633,0.0001918999,0.011780789,0.0021122997,0.000080892096,0.0014220187,0.00019643782,0.84059256,0.00013640503],"about_ca_topic_score_codex":0.0043058526,"about_ca_topic_score_gemma":0.041403856,"teacher_disagreement_score":0.83129495,"about_ca_system_score_codex":0.00034110888,"about_ca_system_score_gemma":0.0020798612,"threshold_uncertainty_score":0.9769938},"labels":[],"label_agreement":null},{"id":"W4243255191","doi":"10.1515/iupac.84.0743","title":"Immunophilin","year":2016,"lang":"en","type":"dataset","venue":"IUPAC Standards Online","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada Research Chairs; University of Toronto","funders":"","keywords":"Glossary; Immunotoxicology; Medicine; Immunology; Immune system; Philosophy; Linguistics","score_opus":0.024057115433931606,"score_gpt":0.4479425839081203,"score_spread":0.4238854684741887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4243255191","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00022423625,0.0023613973,0.00002012428,0.0019321335,0.0007025578,0.0007931604,0.99340945,0.00009804683,0.00045890108],"genre_scores_gemma":[0.0000069499847,0.0056673335,0.000027427113,0.00054414466,0.0025750555,0.00002867391,0.96930593,0.000097893855,0.021746589],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99555165,0.000116296425,0.00059611746,0.00067503494,0.0023315605,0.00072936027],"domain_scores_gemma":[0.996502,0.00016802561,0.00017707208,0.0019204178,0.0008567061,0.0003757947],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00097090227,0.0005271377,0.0010855774,0.00045447846,0.00009510904,0.000050325543,0.00047754677,0.0006171724,0.10676747],"category_scores_gemma":[0.0007750623,0.00037264155,0.00039810914,0.0002974618,0.00030057572,0.000054200176,0.00026401182,0.001205603,0.000031403302],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018098337,0.0003725739,0.000008038096,0.00029928747,0.00037206904,0.000485866,0.000008773103,5.8333363e-8,0.0017301516,0.000003333644,0.968363,0.026547015],"study_design_scores_gemma":[0.003480571,0.0008930217,0.000040844057,0.00085304957,0.00019692145,0.00016153484,0.000014851662,0.0000011407457,0.00027834997,0.00009137375,0.99360675,0.00038158597],"about_ca_topic_score_codex":0.00017054164,"about_ca_topic_score_gemma":0.00019061934,"teacher_disagreement_score":0.106736064,"about_ca_system_score_codex":0.0010790435,"about_ca_system_score_gemma":0.0022426927,"threshold_uncertainty_score":0.99987257},"labels":[],"label_agreement":null},{"id":"W4245501240","doi":"10.1158/1538-7445.sabcs18-1449","title":"Abstract 1449: MG1 Maraba boost following adenovirus prime generates tumor antigen-specific T cells which are potentiated by anti-PD-1 antibody combination","year":2019,"lang":"en","type":"article","venue":"Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Interface Biologics (Canada)","funders":"","keywords":"Antigen; Antibody; Prime (order theory); Cancer research; Molecular biology; Virology; Chemistry; Immunology; Medicine; Biology; Mathematics","score_opus":0.014153524167485184,"score_gpt":0.2842191339901131,"score_spread":0.27006560982262795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4245501240","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9840662,0.009767023,0.00004239844,0.0007392736,0.0015770897,0.001180735,0.000048076534,0.0001945307,0.0023847136],"genre_scores_gemma":[0.9921525,0.0025004745,0.000068936584,0.00019492817,0.000127968,0.000019501695,0.00078323355,0.00011915423,0.0040333155],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99693096,0.00019519388,0.00062099285,0.00077466766,0.0005536818,0.0009244994],"domain_scores_gemma":[0.99812865,0.00014250146,0.00028762655,0.0008996854,0.00040964782,0.00013189943],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00051049556,0.0004085896,0.0008416858,0.00042833647,0.00019160737,0.00011770826,0.0004051748,0.0003725439,0.0048167193],"category_scores_gemma":[0.000057884314,0.00040017365,0.00024390296,0.0006932227,0.00014111637,0.00024963758,0.00015565871,0.0008569014,0.0019563416],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049892836,0.0005610886,0.043724228,0.000042361225,0.00049289636,0.0002508545,0.000096625336,0.0000052688024,0.9504348,0.000024617011,0.0019870847,0.0018812602],"study_design_scores_gemma":[0.0042096786,0.0005350122,0.33164465,0.0001232055,0.000029710904,0.000101381025,0.00021707265,0.00009979135,0.6368709,0.000016981756,0.025797324,0.0003542876],"about_ca_topic_score_codex":0.00024791982,"about_ca_topic_score_gemma":0.000008657525,"teacher_disagreement_score":0.31356388,"about_ca_system_score_codex":0.00023758897,"about_ca_system_score_gemma":0.00019183078,"threshold_uncertainty_score":0.999845},"labels":[],"label_agreement":null},{"id":"W4246631325","doi":"10.3410/f.13355957.14725146","title":"Faculty Opinions recommendation of Increased sensitivity of antigen-experienced T cells through the enrichment of oligomeric T cell receptor complexes.","year":2011,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Sensitivity (control systems); Antigen; Receptor; Chemistry; Molecular biology; Medicine; Biochemistry; Immunology; Biology; Engineering","score_opus":0.04953735841943186,"score_gpt":0.3701097629927112,"score_spread":0.32057240457327935,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4246631325","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003847137,0.0013043592,0.00006362605,0.03441253,0.0006501266,0.002682137,0.96058315,0.000022928076,0.00024268984],"genre_scores_gemma":[0.00018697689,0.0025145616,0.0014180475,0.0018344366,0.00019324802,0.00016569004,0.9925741,0.000038361777,0.0010745561],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9926479,0.0015293347,0.0022784153,0.0007340767,0.0023546675,0.0004556224],"domain_scores_gemma":[0.9856923,0.0005229187,0.0026102671,0.0024704735,0.008403731,0.0003003041],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002585298,0.0005926556,0.0017942965,0.00033100398,0.0001807617,0.000036374062,0.0012337446,0.00063452387,0.0031901002],"category_scores_gemma":[0.0032515905,0.00034859712,0.0009905525,0.0030085123,0.0012253094,0.00021127997,0.0006442232,0.0011834854,0.0000341548],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011933915,0.001596615,0.00001245698,0.010047906,0.0002887995,5.6732404e-7,0.00080790324,1.0844639e-7,0.0069088023,0.00008089742,0.97894186,0.0011947236],"study_design_scores_gemma":[0.0012679701,0.00037450346,0.00091607776,0.005816225,0.0002518094,0.000033400247,0.00019671375,0.000007619904,0.021756822,0.000012159696,0.9690945,0.00027220065],"about_ca_topic_score_codex":0.0007544538,"about_ca_topic_score_gemma":0.000008626437,"teacher_disagreement_score":0.032578092,"about_ca_system_score_codex":0.00015638306,"about_ca_system_score_gemma":0.0011448861,"threshold_uncertainty_score":0.9998966},"labels":[],"label_agreement":null},{"id":"W4246976359","doi":"10.1158/1538-7445.sabcs18-568","title":"Abstract 568: Decoding shared antigenic epitopes and their cognate TCR genes in melanoma TILs using a library of paired human cell-based pHLA multimers and artificial APCs","year":2019,"lang":"en","type":"article","venue":"Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"T-cell receptor; Epitope; Decoding methods; Gene; Computer science; Computational biology; Antigen; T cell; Biology; Genetics; Algorithm","score_opus":0.043211539481999385,"score_gpt":0.3006870073738447,"score_spread":0.2574754678918453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4246976359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946683,0.0041046077,0.000007296525,0.000116109455,0.00008763748,0.0005404146,0.000026730328,0.000032294447,0.00041659956],"genre_scores_gemma":[0.9989747,0.0003524433,0.00033754157,0.000045947505,0.000036648165,0.000007548941,0.000053767795,0.000039980892,0.00015143064],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987293,0.00012121984,0.00037187955,0.00032663075,0.00009777412,0.00035321325],"domain_scores_gemma":[0.9992528,0.00026250255,0.00012326035,0.0002700466,0.000035205634,0.0000561668],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00024078046,0.0001817685,0.0004874918,0.00035684765,0.00005878049,0.000025656747,0.000111585105,0.00019140998,0.0014480327],"category_scores_gemma":[0.00002282532,0.00016112973,0.00006918504,0.00016855371,0.00024293513,0.00012552003,0.000093658324,0.0002561621,0.000008464068],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00075436314,0.00010787672,0.07629682,0.00012793775,0.000092858914,0.00003488519,0.00059484504,0.0000131797,0.8934003,0.000005792519,0.0000046187442,0.028566487],"study_design_scores_gemma":[0.0034121997,0.0004257485,0.19886522,0.00018723616,0.000023422916,0.000030468545,0.00056766625,0.0037616838,0.7920897,0.000074506395,0.00037218793,0.0001899774],"about_ca_topic_score_codex":0.00025262864,"about_ca_topic_score_gemma":0.00007062599,"teacher_disagreement_score":0.1225684,"about_ca_system_score_codex":0.000025126066,"about_ca_system_score_gemma":0.00011512678,"threshold_uncertainty_score":0.99946475},"labels":[],"label_agreement":null},{"id":"W4247287852","doi":"10.3410/f.735264826.793577575","title":"Faculty Opinions recommendation of Challenges of driving CD30-directed CAR-T cells to the clinic.","year":2020,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"CD30; Medical education; Psychology; World Wide Web; Computer science; Medicine; Tumor cells; Cancer research","score_opus":0.07238136927602407,"score_gpt":0.4035608972835963,"score_spread":0.3311795280075722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4247287852","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[7.207214e-7,0.0015249334,0.0000073324823,0.36351907,0.00065292785,0.0019390105,0.6321613,0.000039956,0.00015475311],"genre_scores_gemma":[0.000009335926,0.0046163662,0.00066576997,0.0056644278,0.00060447445,0.0002686522,0.9850639,0.000053715594,0.0030533224],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9927051,0.0010761135,0.0023239956,0.0009071755,0.0025166715,0.0004709274],"domain_scores_gemma":[0.9858233,0.0005350936,0.001631596,0.0024790922,0.008957868,0.00057306135],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0024821034,0.00059563114,0.0017250227,0.0004250078,0.00018057344,0.00006934141,0.0019085408,0.00080796785,0.0022051844],"category_scores_gemma":[0.013721356,0.00035010383,0.0010641941,0.0031721098,0.0004145188,0.00014951607,0.000910171,0.0018982632,0.00019797147],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006433358,0.00048967364,0.0000041857015,0.01119819,0.00041754564,8.400446e-7,0.0003945019,8.808223e-8,0.00012843251,0.000055137578,0.979354,0.00789307],"study_design_scores_gemma":[0.0009126685,0.00040916642,0.0013376144,0.013465668,0.00036908995,0.000036621757,0.00011575488,0.00000842,0.000386195,0.000009664809,0.9826679,0.0002812163],"about_ca_topic_score_codex":0.000046481375,"about_ca_topic_score_gemma":0.000022699658,"teacher_disagreement_score":0.35785463,"about_ca_system_score_codex":0.0001596219,"about_ca_system_score_gemma":0.001172767,"threshold_uncertainty_score":0.9998951},"labels":[],"label_agreement":null},{"id":"W4248028975","doi":"10.1002/ange.202005934","title":"Glycoengineering of NK Cells with Glycan Ligands of CD22 and Selectins for B‐Cell Lymphoma Therapy","year":2020,"lang":"en","type":"article","venue":"Angewandte Chemie","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"National Institutes of Health; Danmarks Grundforskningsfond","keywords":"CD22; Selectin; Chemistry; Sialyl-Lewis X; Cancer research; Natural killer cell; Glycan; Lymphoma; Antigen; Immunology; Molecular biology; In vitro; Biology; CD20; Biochemistry; Cytotoxic T cell; Cell adhesion molecule; Glycoprotein","score_opus":0.02412454907267412,"score_gpt":0.257451623438061,"score_spread":0.23332707436538688,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4248028975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957531,0.001277022,0.00012355027,0.00033384445,0.00002095319,0.00046254531,0.000020567562,0.0000312966,0.0019771324],"genre_scores_gemma":[0.9972714,0.00086071563,0.00072097493,0.0001662705,0.00016160327,0.000023416704,0.000013652594,0.000047062782,0.0007349121],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991531,0.000004150324,0.0001864033,0.0002151369,0.00021758942,0.00022363239],"domain_scores_gemma":[0.99936473,0.000094486895,0.000069242684,0.00017595913,0.00013648598,0.0001590978],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000092940914,0.00014481603,0.0003715627,0.000053918986,0.000021004413,0.000007105572,0.000081221326,0.00006926311,0.00012911724],"category_scores_gemma":[0.000019240942,0.00011589084,0.000076532175,0.00026703277,0.00007395869,0.0000325712,0.000023314884,0.000077188924,5.82196e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020357391,0.00011810618,0.0011322171,0.00064072944,0.00011369043,0.0000066428515,0.0012798242,0.000005815066,0.99140894,0.0000033375572,0.00070071727,0.002554221],"study_design_scores_gemma":[0.006662769,0.001788896,0.00020247114,0.0000653621,0.000040723506,0.000012380962,0.00018587927,0.00014205843,0.9820667,0.000004763325,0.008719026,0.00010897951],"about_ca_topic_score_codex":0.000030094492,"about_ca_topic_score_gemma":0.0000029998366,"teacher_disagreement_score":0.009342269,"about_ca_system_score_codex":0.000027077764,"about_ca_system_score_gemma":0.000106471285,"threshold_uncertainty_score":0.47258914},"labels":[],"label_agreement":null},{"id":"W4248620541","doi":"10.3410/f.726113687.793527799","title":"Faculty Opinions recommendation of Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits.","year":2017,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Antigen; Electronic circuit; Computer science; Engineering; Medicine; Immunology; Electrical engineering","score_opus":0.04817298631447522,"score_gpt":0.37806546270042246,"score_spread":0.32989247638594726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4248620541","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000062162703,0.00086062384,0.000038052975,0.06545176,0.0017218457,0.0027963226,0.9288256,0.00004647571,0.00025308496],"genre_scores_gemma":[0.000011417733,0.001358636,0.00051563565,0.00191246,0.00058410515,0.00009866115,0.9932332,0.000066637615,0.0022192432],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9930977,0.0007116518,0.001734987,0.001016109,0.0029069553,0.00053257763],"domain_scores_gemma":[0.98247135,0.00027944494,0.0023361302,0.0025188776,0.01188868,0.0005055354],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002115824,0.0006815891,0.001558563,0.0004561042,0.00043519872,0.00024746684,0.0012286718,0.00085095287,0.0013970494],"category_scores_gemma":[0.0069940835,0.0004454047,0.0006874218,0.0015464262,0.0006236249,0.0003975863,0.00043653522,0.001865909,0.000110950794],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013900585,0.000719376,0.000004238526,0.0070806383,0.00027793387,0.0000029255561,0.00006107199,1.8349732e-8,0.00028229805,0.000008664136,0.9668054,0.024618443],"study_design_scores_gemma":[0.0027095336,0.00049463916,0.0003431169,0.026824027,0.00034783865,0.00019585933,0.000021162503,0.0000070469055,0.0013101691,0.000038584934,0.9672871,0.0004208711],"about_ca_topic_score_codex":0.000091250775,"about_ca_topic_score_gemma":0.000006255185,"teacher_disagreement_score":0.06440759,"about_ca_system_score_codex":0.00026549818,"about_ca_system_score_gemma":0.0014294568,"threshold_uncertainty_score":0.9997998},"labels":[],"label_agreement":null},{"id":"W4249102396","doi":"10.3410/f.727097373.793532853","title":"Faculty Opinions recommendation of The Chemokine Receptor CX3CR1 Defines Three Antigen-Experienced CD8 T Cell Subsets with Distinct Roles in Immune Surveillance and Homeostasis.","year":2017,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"CX3CR1; Chemokine receptor; CD8; Immunology; Immune system; Chemokine; Receptor; Antigen; Biology; Genetics","score_opus":0.03127407615262493,"score_gpt":0.3564286586257713,"score_spread":0.3251545824731463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4249102396","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00021855757,0.004371269,0.0000038098708,0.14419323,0.0003744537,0.0018999932,0.848851,0.000020912847,0.00006677026],"genre_scores_gemma":[0.0004217866,0.003361369,0.00025932334,0.00081794086,0.00018264462,0.00025866847,0.9936031,0.000042081512,0.0010530782],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951679,0.00045742042,0.0013734541,0.0008312277,0.0016982689,0.00047173683],"domain_scores_gemma":[0.99138737,0.00021214268,0.0015162741,0.002554715,0.004053348,0.00027616497],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015993058,0.000598605,0.0013907879,0.00027498964,0.00034202004,0.00016256268,0.0015607267,0.0005847429,0.0006781922],"category_scores_gemma":[0.005264657,0.0003199036,0.00043323715,0.0017659719,0.0010131386,0.00023675663,0.00060828147,0.0013455547,0.000015641843],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014640875,0.00046726188,0.0012347919,0.0054327557,0.0001154658,9.74399e-7,0.000155021,3.662727e-8,0.00012492696,0.000015291389,0.986815,0.0054921126],"study_design_scores_gemma":[0.001744104,0.00016670469,0.09556868,0.008819926,0.00007144999,0.00005544903,0.000039264807,0.0000040241985,0.00034273282,0.000006674601,0.8928852,0.0002957556],"about_ca_topic_score_codex":0.00019500664,"about_ca_topic_score_gemma":0.00027255798,"teacher_disagreement_score":0.1447521,"about_ca_system_score_codex":0.00014735214,"about_ca_system_score_gemma":0.00083193136,"threshold_uncertainty_score":0.9999253},"labels":[],"label_agreement":null},{"id":"W4251215396","doi":"10.1142/s021903031400069x","title":"EYE ON CHINA","year":2014,"lang":"en","type":"article","venue":"Asia-Pacific Biotech News","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Milestone; China; General partnership; License; Joint venture; Engineering; Business; Management; Political science; Geography; Finance; Economics; Commerce; Cartography","score_opus":0.019729551572275232,"score_gpt":0.30149630768308666,"score_spread":0.2817667561108114,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251215396","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21252944,0.00015229905,0.00075560535,0.027889132,0.0005108464,0.0009456832,0.000009605846,0.00041657191,0.7567908],"genre_scores_gemma":[0.9152548,0.00018774727,0.0008186106,0.0006236801,0.0007423201,0.00002717258,0.000032054777,0.00007526167,0.08223836],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979522,0.00011468632,0.00026820478,0.00052183727,0.00060035504,0.0005427197],"domain_scores_gemma":[0.9983762,0.00007568369,0.00006085804,0.0011285804,0.000051129467,0.00030756212],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00049253536,0.00025125494,0.000385719,0.00027003814,0.00011046718,0.000049974493,0.00022979478,0.0003306304,0.0038015223],"category_scores_gemma":[0.00016878876,0.00020241599,0.00018537269,0.00046007914,0.00014197263,0.000049338905,0.00005883229,0.00078169454,0.001846425],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005688173,0.00032051408,0.002032563,0.00005899957,0.000076853634,0.000043000506,0.00027131458,0.000002028621,0.46342194,0.0015820739,0.04194771,0.48967418],"study_design_scores_gemma":[0.0014781499,0.0011749824,0.007647616,0.00007360918,0.000022224607,0.00003963831,0.00023467581,0.00023496196,0.15423368,0.00037363192,0.83425814,0.00022871698],"about_ca_topic_score_codex":0.00013982067,"about_ca_topic_score_gemma":0.000014466405,"teacher_disagreement_score":0.7923104,"about_ca_system_score_codex":0.0001289298,"about_ca_system_score_gemma":0.00007479184,"threshold_uncertainty_score":0.99893075},"labels":[],"label_agreement":null},{"id":"W4251633200","doi":"10.21037/tcr.2016.05.29","title":"Innate immunosurveillance: the next frontier in the cancer immunotherapy toolbox","year":2016,"lang":"en","type":"article","venue":"Translational Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster University Medical Centre","funders":"","keywords":"Immunosurveillance; Frontier; Cancer immunotherapy; Immunotherapy; Cancer; Medicine; Toolbox; Immunology; Computer science; Geography; Internal medicine; Programming language","score_opus":0.14147887814801577,"score_gpt":0.4386822039420392,"score_spread":0.2972033257940234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4251633200","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7370505,0.035700954,0.00018996248,0.21469438,0.00033412085,0.0026936356,0.0001237242,0.00007018849,0.00914258],"genre_scores_gemma":[0.9731172,0.0143218255,0.000038544687,0.0010006251,0.00068238546,0.001315765,0.000011479544,0.000074478514,0.00943773],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9952164,0.0008663245,0.00038523832,0.00043311145,0.002293563,0.00080535456],"domain_scores_gemma":[0.99731123,0.0013074824,0.000041271174,0.0007583655,0.000503427,0.000078198194],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004528766,0.00018943328,0.00027460928,0.00027273988,0.0002708716,0.00011173571,0.000799547,0.00011942563,0.013127589],"category_scores_gemma":[0.00007404417,0.000085669206,0.00015402921,0.0011800267,0.00064536714,0.00020235243,0.000031026746,0.0009549957,0.000071579096],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057166703,0.00020120695,0.08399139,0.000058695226,0.0002860634,0.000031799816,0.0045480817,0.000044401397,0.3722694,0.0015832342,0.011431364,0.5198377],"study_design_scores_gemma":[0.005287622,0.00020067145,0.51385254,0.00021499883,0.000009856794,0.000019631781,0.00038574217,0.00011007552,0.0045699817,0.0022151791,0.4729294,0.00020430044],"about_ca_topic_score_codex":0.0047737737,"about_ca_topic_score_gemma":0.0025253098,"teacher_disagreement_score":0.5196334,"about_ca_system_score_codex":0.00038450147,"about_ca_system_score_gemma":0.0010771281,"threshold_uncertainty_score":0.98777455},"labels":[],"label_agreement":null},{"id":"W4253005829","doi":"10.1007/978-1-4939-9597-4_1","title":"Introduction to the Immune System","year":2019,"lang":"en","type":"article","venue":"Methods in molecular biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":167,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada","funders":"","keywords":"Multicellular organism; Immune system; Organism; Biology; Acquired immune system; Innate immune system; Immunity; Mechanism (biology); Autoimmunity; Immunology; Cell; Genetics; Philosophy","score_opus":0.02499319325832197,"score_gpt":0.4248316836432698,"score_spread":0.39983849038494784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4253005829","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16008279,0.0021286872,0.8042434,0.020229353,0.0018719588,0.00202028,0.0000019607146,0.000075327625,0.009346238],"genre_scores_gemma":[0.103263706,0.000050326606,0.878276,0.0014812996,0.0013533131,0.00023946118,0.00003113293,0.00007517128,0.015229603],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99772525,0.0013715203,0.00021843254,0.00032028463,0.00009614301,0.00026837777],"domain_scores_gemma":[0.99900424,0.00013424136,0.000030895848,0.0007236101,0.00005935802,0.000047633814],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029070391,0.000095486954,0.00028837068,0.00017153352,0.000020241794,0.0000068618183,0.00017225106,0.000117704774,0.00084704504],"category_scores_gemma":[0.00033890968,0.00006296773,0.00008056262,0.00041724383,0.000047805723,0.0000073698807,0.000106176005,0.00030101775,0.00026362608],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015979997,0.000017050692,0.0007253513,0.00003052251,0.000034762452,0.00001039085,0.00009338553,0.000031782616,0.94129163,0.004788946,0.000074415424,0.052741956],"study_design_scores_gemma":[0.00065189117,0.0004692931,0.0012309902,0.000022965629,0.000014548248,0.00012867917,0.00018405342,0.00036284898,0.7583575,0.0002653916,0.23822019,0.000091623326],"about_ca_topic_score_codex":0.00007416773,"about_ca_topic_score_gemma":0.000002735943,"teacher_disagreement_score":0.23814577,"about_ca_system_score_codex":0.0001359351,"about_ca_system_score_gemma":0.000037538633,"threshold_uncertainty_score":0.92745495},"labels":[],"label_agreement":null},{"id":"W4254214995","doi":"10.3410/f.717972360.793471504","title":"Faculty Opinions recommendation of Amphiregulin enhances regulatory T cell-suppressive function via the epidermal growth factor receptor.","year":2013,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Amphiregulin; Epidermal growth factor receptor; Function (biology); Cancer research; Factor (programming language); Cell biology; TGF alpha; Epidermal growth factor; Biology; Chemistry; Receptor; Internal medicine; Medicine; Computer science","score_opus":0.03395499331498569,"score_gpt":0.3458721974259459,"score_spread":0.3119172041109602,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4254214995","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000008452242,0.0020709222,0.000045210258,0.19153231,0.0016267087,0.0028677427,0.80167186,0.000051069284,0.00012574586],"genre_scores_gemma":[0.000032854543,0.0014660197,0.00030431835,0.0049207667,0.0009802781,0.00062551483,0.98067886,0.00006344178,0.010927966],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9920255,0.0012552502,0.002173361,0.0010287854,0.0028999404,0.00061715627],"domain_scores_gemma":[0.98291576,0.00050409447,0.002208416,0.0025178797,0.011348457,0.0005053773],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015795479,0.00078778475,0.0014581962,0.0004397705,0.00041006648,0.00016671041,0.0016669295,0.0011425379,0.010007473],"category_scores_gemma":[0.005750618,0.00044449873,0.0011385825,0.002344611,0.0008852435,0.00049334957,0.00063627627,0.0021913631,0.0002898392],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010025252,0.0005642899,0.000009114078,0.00807961,0.00040743852,3.7566892e-7,0.00017030936,5.633556e-8,0.00049013627,0.00007019874,0.9834397,0.0066685113],"study_design_scores_gemma":[0.0011883364,0.0003266974,0.0031403305,0.0065216934,0.0004191774,0.000057888556,0.0000590885,0.000009947955,0.0016760409,0.00004989132,0.9861576,0.00039329912],"about_ca_topic_score_codex":0.000111080546,"about_ca_topic_score_gemma":0.000006246823,"teacher_disagreement_score":0.18661155,"about_ca_system_score_codex":0.00028169056,"about_ca_system_score_gemma":0.0011142975,"threshold_uncertainty_score":0.9998007},"labels":[],"label_agreement":null},{"id":"W4256455700","doi":"10.3410/f.737287958.793573609","title":"Faculty Opinions recommendation of THEMIS-SHP1 Recruitment by 4-1BB Tunes LCK-Mediated Priming of Chimeric Antigen Receptor-Redirected T Cells.","year":2020,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Priming (agriculture); Chimeric antigen receptor; Antigen; Cell biology; Computer science; T cell; Immunology; Biology; Immune system","score_opus":0.0693913031097337,"score_gpt":0.3837607891048951,"score_spread":0.3143694859951614,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4256455700","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000042939146,0.0028781446,0.000014003596,0.13694732,0.000801897,0.003447448,0.85571223,0.000070699774,0.00012398117],"genre_scores_gemma":[0.0000049949363,0.0070688967,0.0009852243,0.0028927606,0.00036564632,0.000406933,0.98519945,0.00007383178,0.0030022736],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9921597,0.0008757001,0.002621069,0.0010595996,0.002716951,0.00056692876],"domain_scores_gemma":[0.9871058,0.00039728728,0.002390449,0.0019155536,0.007557816,0.0006331367],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015937635,0.00077315955,0.0020406125,0.0004775077,0.00018297845,0.00007595968,0.0014891688,0.000976403,0.0031148626],"category_scores_gemma":[0.008481682,0.00053028006,0.0009853875,0.004242244,0.0005767445,0.00021230582,0.00062623847,0.0017256455,0.000108544926],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012913547,0.00097263383,0.0000090536205,0.012776521,0.00063595903,7.931696e-7,0.00026774465,4.0492477e-8,0.0049177683,0.000007503282,0.97265375,0.0076290737],"study_design_scores_gemma":[0.0016091784,0.00039499445,0.00031382925,0.013373314,0.00035699847,0.000029811932,0.000064968015,0.00001189317,0.006546763,0.000003848501,0.97689307,0.000401321],"about_ca_topic_score_codex":0.000088630564,"about_ca_topic_score_gemma":0.0000021205885,"teacher_disagreement_score":0.13405456,"about_ca_system_score_codex":0.00025985105,"about_ca_system_score_gemma":0.0015529013,"threshold_uncertainty_score":0.9998703},"labels":[],"label_agreement":null},{"id":"W4280488168","doi":"10.1136/jitc-2021-003487","title":"Time 2EVOLVE: predicting efficacy of engineered T-cells – how far is the bench from the bedside?","year":2022,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Innovative Medicines Initiative; European Commission; European Federation of Pharmaceutical Industries and Associations","keywords":"T-cell receptor; Cancer immunotherapy; Medicine; Immunotherapy; Translational research; Chimeric antigen receptor; T cell; Cancer research; Immune system; Computational biology; Immunology; Bioinformatics; Biology; Pathology","score_opus":0.05417610846829858,"score_gpt":0.3756960139525929,"score_spread":0.3215199054842943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280488168","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0006766527,0.9925498,0.00003785933,0.001727372,0.0011554898,0.0028408528,0.0008438219,0.000018293995,0.0001498965],"genre_scores_gemma":[0.000018635448,0.9861544,0.00014396278,0.00030620286,0.0014836276,0.000283801,0.000066034794,0.00021065431,0.0113326805],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99613,0.0003790526,0.0012309619,0.00035378282,0.0013840285,0.00052219955],"domain_scores_gemma":[0.9934682,0.0034720085,0.0015469072,0.0010716576,0.00033662794,0.000104587],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019235625,0.00052467594,0.002269962,0.00022651065,0.00037149753,0.00007986027,0.0012794067,0.00026685162,0.019103756],"category_scores_gemma":[0.00017801514,0.00027852377,0.0025081118,0.0005778147,0.00027043978,0.000076517914,0.00010239677,0.0018979325,0.0000045188967],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069495966,0.00012505347,0.0000059309286,0.0013279645,0.005620873,0.000004350858,0.0014960063,0.000021246791,0.008023157,0.0000024632209,0.02128132,0.9613967],"study_design_scores_gemma":[0.0027935572,0.00058979646,0.00002026915,0.004493461,0.0014857678,0.00006830269,0.00019002386,0.00009457572,0.0011908511,0.000022240247,0.9888198,0.00023140581],"about_ca_topic_score_codex":0.0002414264,"about_ca_topic_score_gemma":0.000007102639,"teacher_disagreement_score":0.9675384,"about_ca_system_score_codex":0.00051732204,"about_ca_system_score_gemma":0.0014310507,"threshold_uncertainty_score":0.9999667},"labels":[],"label_agreement":null},{"id":"W4280509433","doi":"10.3390/curroncol29050293","title":"CAR T Cell Therapy for Chronic Lymphocytic Leukemia: Successes and Shortcomings","year":2022,"lang":"en","type":"review","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Fakultet Medicinskih Nauka, Univerziteta U Kragujevcu; Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja","keywords":"Chimeric antigen receptor; Chronic lymphocytic leukemia; Medicine; CAR T-cell therapy; Leukemia; Lymphoma; Cancer research; T cell; Cell therapy; Immunology; Cell; Immune system; Biology","score_opus":0.22125683590318834,"score_gpt":0.4845948981931005,"score_spread":0.26333806228991213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280509433","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00029691737,0.9918791,0.000013920358,0.00004445771,0.0016125048,0.0043372666,0.000086123466,0.00007363234,0.0016560843],"genre_scores_gemma":[0.0000133307785,0.9914847,0.000036059402,0.00006209226,0.0012777442,0.0025916977,0.00058261614,0.00014836737,0.0038033938],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970468,0.00032593636,0.0006887523,0.00085067144,0.00036572485,0.0007221077],"domain_scores_gemma":[0.99713904,0.0015956241,0.00031689423,0.0005872866,0.00009497994,0.00026616215],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006906307,0.0005509543,0.0027626024,0.00040358698,0.00018256674,0.00003200814,0.00040137232,0.00047132862,0.0046904767],"category_scores_gemma":[0.00009704542,0.0004468082,0.0006621395,0.0003612874,0.00025219592,0.000039778377,0.0002664951,0.0011266248,0.000025701205],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00016145161,0.00011363204,0.000008446247,0.02946086,0.00020496949,0.00004781344,0.00009574618,4.4734554e-7,0.00002189041,0.000020003476,0.005029805,0.9648349],"study_design_scores_gemma":[0.003866392,0.0025944312,0.0000011245603,0.0013192077,0.00084600766,0.00036265125,0.0000303917,0.000055706278,0.00001972981,0.000016904136,0.99053866,0.0003487993],"about_ca_topic_score_codex":0.000051095794,"about_ca_topic_score_gemma":0.000017651144,"teacher_disagreement_score":0.98550886,"about_ca_system_score_codex":0.022079289,"about_ca_system_score_gemma":0.01936755,"threshold_uncertainty_score":0.99979836},"labels":[],"label_agreement":null},{"id":"W4280604259","doi":"10.1016/j.cjca.2022.05.013","title":"A New Era: Immunotherapy Applied to Contemporary Cardiovascular Practice","year":2022,"lang":"en","type":"article","venue":"Canadian Journal of Cardiology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Montreal Heart Institute; McGill University; Jewish General Hospital; Université de Montréal; McGill University Health Centre","funders":"Sanofi; AstraZeneca; Novartis; Pfizer; Amgen","keywords":"Medicine; Proprotein convertase; Immunotherapy; Monoclonal antibody; Immune system; Kexin; Immunology; Chimeric antigen receptor; Antibody; Internal medicine; LDL receptor","score_opus":0.030902647651151,"score_gpt":0.28718040020412156,"score_spread":0.2562777525529706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280604259","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06972554,0.06515014,0.022915943,0.051626902,0.0052711265,0.0033420513,0.000099022465,0.0000582214,0.78181106],"genre_scores_gemma":[0.9889522,0.00014234683,0.0012824016,0.0045120157,0.0021717856,0.00002892814,0.0000090168605,0.00005967742,0.0028416375],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978877,0.0004704116,0.00042305698,0.00022064071,0.00053243944,0.0004657522],"domain_scores_gemma":[0.99762225,0.00016614514,0.00012536743,0.00052998634,0.0003038975,0.0012523362],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019874983,0.00015552957,0.00089512876,0.0006489956,0.00018958509,0.000024765093,0.000344611,0.00008566583,0.0013325313],"category_scores_gemma":[0.0002492924,0.00015373381,0.00064983993,0.0004528109,0.00007058266,0.000064567066,0.000039658808,0.0010203194,0.000029460149],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0065078405,0.000015448111,0.003109595,0.000026849926,0.011817725,0.01091561,0.0035646458,0.014400753,0.031043975,0.00079364394,0.60318774,0.31461614],"study_design_scores_gemma":[0.002798558,0.0010463166,0.0018776057,0.00000780475,0.00011743357,0.008034478,0.0012099271,0.0000011998974,0.00017660514,0.00010085303,0.98449767,0.00013153345],"about_ca_topic_score_codex":0.0041346676,"about_ca_topic_score_gemma":0.00012002252,"teacher_disagreement_score":0.91922665,"about_ca_system_score_codex":0.0007798459,"about_ca_system_score_gemma":0.008903491,"threshold_uncertainty_score":0.9995804},"labels":[],"label_agreement":null},{"id":"W4280617218","doi":"10.1097/01.cot.0000832072.72279.6e","title":"Shop talk","year":2022,"lang":"en","type":"article","venue":"Oncology Times","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.03439930018503596,"score_gpt":0.3662236639485787,"score_spread":0.33182436376354274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4280617218","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.19607413,0.00047716103,0.000006324519,0.011043498,0.0003037202,0.00031674028,0.0000069318653,0.00008568782,0.7916858],"genre_scores_gemma":[0.2891305,0.000039199535,0.00034775666,0.0020376327,0.00024330485,0.00013443627,0.000032854678,0.000024133373,0.70801014],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991195,0.00012423273,0.00010702884,0.00017176372,0.00024655787,0.00023090457],"domain_scores_gemma":[0.99948055,0.00014905288,0.000024652862,0.00022727025,0.000030450241,0.000088016495],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003466424,0.000063772524,0.00019673447,0.00010041004,0.00012959901,0.0000038589014,0.00011058401,0.000050099963,0.22005467],"category_scores_gemma":[0.000045197183,0.000059778886,0.00006962743,0.0001771069,0.00009073369,0.000016008644,0.00017319375,0.00037439825,0.00031444474],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013043957,0.00084170443,0.0060368003,0.000022169881,0.00021107092,0.0017391708,0.0007405248,0.000022037784,0.19118035,0.0012191286,0.5620774,0.23460522],"study_design_scores_gemma":[0.001194587,0.0015394181,0.0010272103,0.0000015394231,0.000021895949,0.0005317158,0.0003900572,0.0001494789,0.0019962124,0.00020530846,0.9928862,0.000056363144],"about_ca_topic_score_codex":0.000027093489,"about_ca_topic_score_gemma":0.0000061132305,"teacher_disagreement_score":0.43080878,"about_ca_system_score_codex":0.00032651227,"about_ca_system_score_gemma":0.00030992294,"threshold_uncertainty_score":0.7806583},"labels":[],"label_agreement":null},{"id":"W4281263083","doi":"10.1016/j.jtct.2022.05.026","title":"Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States","year":2022,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":181,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Legend Biotech; Pharmacyclics; Kite Pharma; MorphoSys; Daiichi-Sankyo; Miltenyi Biotec; Omeros Corporation; Astellas Pharma; Adaptive Biotechnologies; Pfizer; Incyte; TG Therapeutics; bluebird bio; Tessa Therapeutics; BeiGene; Atara Biotherapeutics; Kyowa Kirin Pharmaceutical Development; Janssen Pharmaceuticals; Memorial Sloan-Kettering Cancer Center; National Cancer Institute; Servier; Gilead Sciences; Celgene; Novartis; AbbVie; Merck; Bristol-Myers Squibb; Cidara Therapeutics; AstraZeneca; Amgen; Seagen; Sierra Oncology; Astellas Pharma US","keywords":"Medicine; Internal medicine; Cohort; Odds ratio; Confidence interval; Oncology","score_opus":0.05882848758754067,"score_gpt":0.3396543056612309,"score_spread":0.2808258180736902,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281263083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99259704,0.0046221064,0.0005104959,0.0007713343,0.000029424697,0.0011904036,0.00009518535,0.000008150902,0.0001758538],"genre_scores_gemma":[0.9183747,0.07974514,0.00003841231,0.00022656775,0.000018970308,0.00020609537,0.00022441859,0.000014557858,0.001151092],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99888754,0.00022910487,0.0002534147,0.0001462478,0.0003192033,0.00016450987],"domain_scores_gemma":[0.99891543,0.00069670007,0.000076462056,0.00023408349,0.000048386883,0.000028945291],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006137591,0.00010588285,0.00019763006,0.00016306747,0.00012439217,0.0000073862584,0.00012317927,0.000020674788,0.00039433857],"category_scores_gemma":[0.0000014293994,0.00006169817,0.00009783136,0.00042783257,0.00006778174,0.000022145083,0.0000033520105,0.00005628006,3.7839706e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017387534,0.0038581856,0.0067520617,0.00053093716,0.00023373796,0.000057144596,0.062009472,0.00040129648,0.87335104,0.00067451404,0.00007704879,0.03466701],"study_design_scores_gemma":[0.027212216,0.0064107236,0.016614795,0.00008607385,0.00022031342,0.000020852563,0.008475118,0.005289832,0.8844706,0.00018632936,0.05082924,0.00018391213],"about_ca_topic_score_codex":0.0010473158,"about_ca_topic_score_gemma":0.00013798589,"teacher_disagreement_score":0.075123034,"about_ca_system_score_codex":0.000047997357,"about_ca_system_score_gemma":0.000060719867,"threshold_uncertainty_score":0.4317731},"labels":[],"label_agreement":null},{"id":"W4281564783","doi":"10.1089/jir.2021.0236","title":"The Role of Chemokine IL-7 in Tumor and Its Potential Antitumor Immunity","year":2022,"lang":"en","type":"review","venue":"Journal of Interferon & Cytokine Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Chemokine; Biology; Immunology; Cancer research; Cytokine; Lymphoma; Immunity; Tumor microenvironment; Acquired immune system; Immune system","score_opus":0.09748215922676258,"score_gpt":0.42247065406219686,"score_spread":0.3249884948354343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281564783","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.028929384,0.9677991,8.652943e-7,0.00030368587,0.00019317954,0.0012014332,0.000049073275,0.000006108782,0.0015171253],"genre_scores_gemma":[0.02535937,0.9722057,0.000016337599,0.000008606102,0.00052720215,0.00005036299,0.0000158461,0.0001024499,0.0017141192],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99191904,0.0021044447,0.0020266247,0.00036237822,0.00270992,0.0008775805],"domain_scores_gemma":[0.99529946,0.0016714523,0.0008557218,0.0007444818,0.0010912684,0.00033760662],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.010008005,0.0004059682,0.0026026878,0.001979479,0.00024549977,0.0001020587,0.0013327532,0.00019059778,0.0029415959],"category_scores_gemma":[0.0018416176,0.00025589444,0.00076492946,0.0015006884,0.00043655772,0.00013403028,0.0012867583,0.0070848386,0.000013271483],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044123195,0.0007586103,0.000044830434,0.008483181,0.00079996977,0.0015307666,0.00018124004,0.0000013124876,0.03533514,0.00008519567,0.0007046038,0.94766283],"study_design_scores_gemma":[0.0016007081,0.0041416595,0.00007432442,0.008378475,0.00020315006,0.005252324,0.0007211151,0.000055935885,0.0032608279,0.00006784466,0.97605544,0.00018821789],"about_ca_topic_score_codex":0.00014523127,"about_ca_topic_score_gemma":0.000022590299,"teacher_disagreement_score":0.9753508,"about_ca_system_score_codex":0.0009863857,"about_ca_system_score_gemma":0.0019789732,"threshold_uncertainty_score":0.99998933},"labels":[],"label_agreement":null},{"id":"W4281631797","doi":"10.1200/jco.2022.40.16_suppl.8006","title":"Initial safety results for MagnetisMM-3: A phase 2 trial of elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients (pts) with relapsed/refractory (R/R) multiple myeloma (MM).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"Pfizer","keywords":"Medicine; Cytokine release syndrome; Internal medicine; Adverse effect; Gastroenterology; Regimen; Toxicity; Cohort; Antibody; Oncology; Immunology; Cancer; Chimeric antigen receptor; Immunotherapy","score_opus":0.09750823413975031,"score_gpt":0.4644746690344346,"score_spread":0.3669664348946843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281631797","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919752,0.00014850801,0.00015674322,0.0015710101,0.0017029974,0.0021688899,0.00022455548,0.000010270699,0.0020418174],"genre_scores_gemma":[0.99503285,0.000543675,0.002024836,0.00031852524,0.001173978,0.00003380976,0.00023691302,0.000047930473,0.0005874793],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99218005,0.0014650569,0.004289779,0.0004113121,0.0012185058,0.00043530925],"domain_scores_gemma":[0.99072564,0.0047594495,0.002936235,0.0004096395,0.00083822245,0.00033079679],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0072161257,0.000227533,0.0018785831,0.0005671217,0.00011492161,0.000012676709,0.00035697376,0.00038217346,0.00077139406],"category_scores_gemma":[0.0039910767,0.00018065528,0.00057354866,0.00048744032,0.00029295767,0.00019333437,0.0001246999,0.0020240357,0.0000045337656],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.84061193,0.018561851,0.0060265916,0.000058639675,0.00018850397,0.00045525958,0.00032854907,0.00004203807,0.0054578525,0.000008345625,0.0034198032,0.124840654],"study_design_scores_gemma":[0.5726732,0.18655983,0.049713075,0.00007877435,0.00013844877,0.0000697849,0.00028977107,0.0004008899,0.00048452188,0.000036964968,0.18939121,0.00016351353],"about_ca_topic_score_codex":0.00005205762,"about_ca_topic_score_gemma":0.00009676026,"teacher_disagreement_score":0.26793867,"about_ca_system_score_codex":0.00047166186,"about_ca_system_score_gemma":0.0024430186,"threshold_uncertainty_score":0.87935406},"labels":[],"label_agreement":null},{"id":"W4281636766","doi":"10.1182/bloodadvances.2021006193","title":"Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma","year":2022,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McMaster University","funders":"Kite Pharma; Chugai Pharmaceutical; Genentech; MorphoSys; SymBio Pharmaceuticals Limited; Ono Pharmaceutical; Teijin Pharma; TG Therapeutics; Kiadis Pharma; Japan Science and Technology Agency; Juno Therapeutics; Astellas Pharma; Eisai; Daiichi-Sankyo; Omeros Corporation; Pfizer; Incyte; BeiGene; Loxo Oncology; Astex Pharmaceuticals; Nippon Shinyaku; Regeneron Pharmaceuticals; Bristol-Myers Squibb; AstraZeneca; CSL Behring; Karyopharm Therapeutics; Atara Biotherapeutics; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Sanofi; Celgene; Amgen; Fuji Pharma; Japan Society for the Promotion of Science; GlaxoSmithKline","keywords":"Diffuse large B-cell lymphoma; Refractory (planetary science); Lymphoma; Medicine; Term (time); Oncology; Internal medicine; Cancer research; Biology; Physics","score_opus":0.009813489538978077,"score_gpt":0.2651330121369403,"score_spread":0.2553195225979622,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281636766","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99232215,0.0026311039,0.00006887212,0.00008274814,0.0001769831,0.001669959,0.0003442165,0.00013164125,0.0025722997],"genre_scores_gemma":[0.97603625,0.0004987843,0.00036576786,0.00027013128,0.0001397026,0.00040716556,0.000724074,0.000109991866,0.021448141],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977001,0.00010022922,0.00030570623,0.00053214846,0.00074272306,0.0006191035],"domain_scores_gemma":[0.99873877,0.00020969221,0.00014996581,0.0005306643,0.00015698688,0.00021392631],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00020270792,0.0002646341,0.00039998573,0.00015182197,0.0004224969,0.000022825096,0.00023492498,0.00005916246,0.0018037601],"category_scores_gemma":[0.00004240799,0.00021912031,0.00013896242,0.00034861814,0.00007977811,0.00017764544,0.00014131445,0.00022242623,0.000020204556],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012861516,0.03652911,0.86428964,0.00043487898,0.000409317,0.000276709,0.00046600713,0.00000842763,0.012331691,0.00003077112,0.000523236,0.07183868],"study_design_scores_gemma":[0.18801767,0.012454894,0.37387186,0.00013074197,0.0005879141,0.000067638655,0.000292015,0.00004124568,0.019599464,0.000042249274,0.4040797,0.0008145993],"about_ca_topic_score_codex":0.00001066341,"about_ca_topic_score_gemma":0.000033186756,"teacher_disagreement_score":0.4904178,"about_ca_system_score_codex":0.00020227913,"about_ca_system_score_gemma":0.00015044425,"threshold_uncertainty_score":0.99910873},"labels":[],"label_agreement":null},{"id":"W4281649068","doi":"10.1007/s12094-022-02847-2","title":"Overcome tumor relapse in CAR T cell therapy","year":2022,"lang":"en","type":"review","venue":"Clinical & Translational Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Fundamental Research Funds for the Central Universities; Ministry of Economic Development and Trade, Government of Alberta; Innovation and Entrepreneurship Talent Project of Lanzhou","keywords":"Chimeric antigen receptor; Medicine; CAR T-cell therapy; Cell therapy; Genetic enhancement; T cell; Immunotherapy; Antigen; Cancer research; Immune system; Cell; Immunology; Bioinformatics; Gene; Biology; Genetics","score_opus":0.2979011158614083,"score_gpt":0.5288572603495724,"score_spread":0.23095614448816404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281649068","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0002819177,0.97193414,0.000005619427,0.0009265261,0.0009073829,0.0023179497,0.00009910143,0.000049451268,0.023477916],"genre_scores_gemma":[0.000034663608,0.9898426,0.0003640437,0.0012267317,0.00095950346,0.00044424075,0.00071889046,0.00012478419,0.006284546],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9932268,0.0021259033,0.0024088286,0.0009268293,0.00076251297,0.00054912956],"domain_scores_gemma":[0.98947483,0.009102613,0.00039485653,0.00062034454,0.000072884635,0.00033448017],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0031200284,0.00045749836,0.0036804941,0.00046173413,0.00007643715,0.000011197957,0.0004575596,0.0008801967,0.04135942],"category_scores_gemma":[0.0002518286,0.00038666368,0.0017976181,0.00074405543,0.0003526358,0.00004852624,0.00007128491,0.0040689385,0.0003270748],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00085162965,0.0017888,0.0005897851,0.0015530956,0.00022329374,0.0008401003,0.000064398555,0.0000028435525,0.0000058999562,0.00016435835,0.00091385574,0.99300194],"study_design_scores_gemma":[0.0052622757,0.0022370007,0.0005624791,0.0005108378,0.0002822743,0.00022002084,0.000009752452,0.000014745548,3.2555516e-7,0.00024499383,0.9903521,0.00030322393],"about_ca_topic_score_codex":0.000030680018,"about_ca_topic_score_gemma":0.00003747334,"teacher_disagreement_score":0.9926987,"about_ca_system_score_codex":0.00063211453,"about_ca_system_score_gemma":0.0049179955,"threshold_uncertainty_score":0.9998585},"labels":[],"label_agreement":null},{"id":"W4281674079","doi":"10.1200/jco.2022.40.16_suppl.8032","title":"A novel, immunotherapy-based approach for the treatment of relapsed/refractory multiple myeloma (RRMM): Updated phase 1b results for daratumumab in combination with teclistamab (a BCMA x CD3 bispecific antibody).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Daratumumab; Internal medicine; Oncology; Population; Cytokine release syndrome; Lenalidomide; Multiple myeloma; Gastroenterology; Immunotherapy; Cancer","score_opus":0.1389415827981114,"score_gpt":0.46661091116697845,"score_spread":0.3276693283688671,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281674079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9619729,0.0012883034,0.0233324,0.0065422566,0.0008347289,0.0051047336,0.0003720874,0.000020541871,0.00053207466],"genre_scores_gemma":[0.9832642,0.000534056,0.013972618,0.0003709908,0.0003573669,0.00029113493,0.00036761296,0.00006132505,0.00078070426],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.99543244,0.0005960343,0.0025851452,0.00035356887,0.000667164,0.00036563954],"domain_scores_gemma":[0.98863393,0.007867718,0.0021110987,0.00048898236,0.0007455799,0.00015270537],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0055570845,0.00022371911,0.001538428,0.00039736243,0.00018957941,0.000014511047,0.00034067302,0.0002491045,0.00012452425],"category_scores_gemma":[0.0010477795,0.00013665734,0.0006454139,0.00048797476,0.0003621587,0.00007754287,0.000025656507,0.00088833395,4.4059888e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.57370377,0.08936743,0.001750208,0.00006346217,0.0011866437,0.00012472598,0.0007322015,0.0011748564,0.06773417,0.000077206554,0.0019770518,0.26210827],"study_design_scores_gemma":[0.34951854,0.18620624,0.0067052203,0.000039085822,0.00024893734,0.00012410805,0.0008365262,0.021417335,0.0017893502,0.000029870447,0.43293852,0.00014627066],"about_ca_topic_score_codex":0.000053645028,"about_ca_topic_score_gemma":0.000058033223,"teacher_disagreement_score":0.43096146,"about_ca_system_score_codex":0.0008824071,"about_ca_system_score_gemma":0.002313283,"threshold_uncertainty_score":0.55727243},"labels":[],"label_agreement":null},{"id":"W4281714381","doi":"10.1200/jco.22.00842","title":"Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":633,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute","keywords":"Medicine; Internal medicine; Refractory (planetary science); Multiple myeloma; Gastroenterology; Cytokine release syndrome; Progression-free survival; Oncology; Chimeric antigen receptor; Surgery; Immunotherapy; Chemotherapy; Cancer","score_opus":0.10538137358338813,"score_gpt":0.42759963328509365,"score_spread":0.32221825970170553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281714381","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98775184,0.0018202633,0.00022930192,0.0021717225,0.0045590596,0.0013448772,0.000046777208,0.000051483363,0.0020246808],"genre_scores_gemma":[0.9775819,0.0050322423,0.005973665,0.0015737487,0.0027433934,0.00005958544,0.00010681334,0.00012351625,0.0068051284],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9931665,0.0015746745,0.002788658,0.0005926219,0.0011942518,0.0006832584],"domain_scores_gemma":[0.9935372,0.002158103,0.0021388305,0.0006356935,0.000820089,0.0007101148],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0068612625,0.00034321405,0.0019802975,0.00037796027,0.0003750529,0.000042305037,0.0006530831,0.0005373737,0.0041893567],"category_scores_gemma":[0.0011961802,0.00028966737,0.0011406273,0.0004487903,0.00023239947,0.00031874215,0.00017519957,0.0023213292,0.000054483084],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043709017,0.00835889,0.057214297,0.00007416298,0.0006110329,0.00030380648,0.00089110085,0.0001305585,0.7406034,0.000011663969,0.033579167,0.11451292],"study_design_scores_gemma":[0.041736245,0.047503654,0.08018192,0.00002589242,0.0001660369,0.00016370442,0.0008610908,0.0006464586,0.019068746,0.00005061588,0.8092293,0.0003663344],"about_ca_topic_score_codex":0.000045328143,"about_ca_topic_score_gemma":0.000023235747,"teacher_disagreement_score":0.77565014,"about_ca_system_score_codex":0.00046584354,"about_ca_system_score_gemma":0.0030748346,"threshold_uncertainty_score":0.99998033},"labels":[],"label_agreement":null},{"id":"W4281719775","doi":"10.1200/jco.2022.40.16_suppl.11562","title":"Identification of response stratification factors from pooled efficacy analyses of afamitresgene autoleucel (“Afami-cel” [Formerly ADP-A2M4]) in metastatic synovial sarcoma and myxoid/round cell liposarcoma phase 1 and phase 2 trials.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cohort; Internal medicine; Synovial sarcoma; Clinical endpoint; Oncology; Phases of clinical research; Sarcoma; Surgery; Chemotherapy; Clinical trial; Pathology","score_opus":0.3094605390236914,"score_gpt":0.5609863222026947,"score_spread":0.2515257831790033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281719775","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947436,0.0025416121,0.0002744457,0.0010513155,0.0003495861,0.00077166944,0.0002139301,0.0000071877466,0.00004665312],"genre_scores_gemma":[0.9979019,0.00078301446,0.0008152282,0.000075384785,0.00016172338,0.000013769595,0.0000700509,0.000027975846,0.00015096097],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9854052,0.006671175,0.0062449914,0.0004079656,0.0009888721,0.0002818095],"domain_scores_gemma":[0.9765147,0.017227693,0.00498348,0.00042006883,0.00047326667,0.00038080552],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01827708,0.00024236196,0.0028954714,0.0008739915,0.0000846921,0.000027925693,0.00029045608,0.0002231872,0.000674565],"category_scores_gemma":[0.008334837,0.00019512276,0.0005537857,0.0005853306,0.00048967364,0.00020697029,0.00010503466,0.0011940121,0.0000010260587],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08940199,0.013712711,0.0035811483,0.00006277692,0.00088087743,0.00018845031,0.00094809924,0.00003383764,0.7880501,0.00001073946,0.00007229322,0.103056945],"study_design_scores_gemma":[0.19832547,0.11454652,0.38906342,0.0001583311,0.0058915447,0.00021148166,0.0063779913,0.005678995,0.27497005,0.0008512886,0.0034314936,0.0004934118],"about_ca_topic_score_codex":0.00021141165,"about_ca_topic_score_gemma":0.00004771996,"teacher_disagreement_score":0.51308006,"about_ca_system_score_codex":0.00023630547,"about_ca_system_score_gemma":0.0021483498,"threshold_uncertainty_score":0.99781805},"labels":[],"label_agreement":null},{"id":"W4281758080","doi":"10.1186/s12987-022-00342-y","title":"Application of blood brain barrier models in pre-clinical assessment of glioblastoma-targeting CAR-T based immunotherapies","year":2022,"lang":"en","type":"article","venue":"Fluids and Barriers of the CNS","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Natural Sciences and Engineering Research Council of Canada; University of Ottawa; National Research Council Canada","funders":"","keywords":"Chimeric antigen receptor; Extravasation; Cancer research; Immunotherapy; Medicine; Blood–brain barrier; Induced pluripotent stem cell; Cytotoxicity; Antigen; Immunology; In vitro; Biology; Central nervous system; Immune system; Internal medicine; Embryonic stem cell","score_opus":0.014948959537499607,"score_gpt":0.32211808775327105,"score_spread":0.30716912821577147,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281758080","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99625266,0.0008636303,0.00087750575,0.00079448026,0.000057942878,0.0006890495,0.00007281041,0.0000088403785,0.00038309043],"genre_scores_gemma":[0.9985637,0.000058991056,0.00068294164,0.00016529944,0.000027708176,0.00007231441,0.000006908884,0.000022730428,0.00039939265],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9981225,0.0003331947,0.0006123832,0.00022445046,0.00052531465,0.00018211477],"domain_scores_gemma":[0.99886703,0.0002909689,0.00018300486,0.00047329185,0.00010100088,0.000084684565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018420237,0.000112275964,0.00042309257,0.00013526168,0.000084726955,0.0000042698484,0.000248116,0.000066069166,0.0007686479],"category_scores_gemma":[0.00016481904,0.00008790838,0.00018703571,0.00033055808,0.00029999853,0.00003785832,0.00017604716,0.00032784036,6.446196e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009723783,0.00027837447,0.069244355,0.00016909714,0.00020528604,0.0000015171619,0.0013841806,0.0021285042,0.92220163,0.0003425019,0.00029540012,0.0027767888],"study_design_scores_gemma":[0.019910976,0.0070240977,0.11155769,0.00038003895,0.00048031332,0.000022353299,0.0047570006,0.4674963,0.3787875,0.0023031172,0.0067191534,0.00056145847],"about_ca_topic_score_codex":0.00025774434,"about_ca_topic_score_gemma":0.000010906636,"teacher_disagreement_score":0.5434141,"about_ca_system_score_codex":0.000045096866,"about_ca_system_score_gemma":0.0003543598,"threshold_uncertainty_score":0.8416155},"labels":[],"label_agreement":null},{"id":"W4281843434","doi":"10.1200/jco.2022.40.16_suppl.2539","title":"The addition of fludarabine to cyclophosphamide for lymphodepleting chemotherapy enhances the persistence of infused NY-ESO-1 TCR anticancer therapy TBI-1301.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Fludarabine; Medicine; Cyclophosphamide; Internal medicine; Cohort; Immunology; Gastroenterology; Chemotherapy; Oncology","score_opus":0.1395545426387361,"score_gpt":0.4665839838991759,"score_spread":0.32702944126043976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281843434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9594628,0.0015738426,0.00020639556,0.035940018,0.0009155621,0.0009049126,0.000024961168,0.000006584106,0.0009648725],"genre_scores_gemma":[0.98274386,0.0075181955,0.0019713242,0.005519246,0.0010713302,0.000083739505,0.0000036645822,0.000035107976,0.0010535528],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99538434,0.0008215433,0.002286082,0.00021670513,0.00094941625,0.00034188927],"domain_scores_gemma":[0.9844965,0.011880984,0.002084768,0.00039499838,0.00096651743,0.00017626802],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.010578278,0.00014974558,0.001208861,0.00010406335,0.00024794432,0.0000106852,0.0006323665,0.00013323707,0.0015246683],"category_scores_gemma":[0.0037992105,0.00008244894,0.00078581815,0.00041007757,0.0005693727,0.00005461436,0.00009389222,0.00077154,0.0000016315023],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054533448,0.0017135745,0.009070611,0.00004898807,0.0010668256,0.00002596706,0.0015138284,0.00020974963,0.16759534,0.00016771504,0.012769556,0.7512844],"study_design_scores_gemma":[0.017544819,0.04098276,0.06787496,0.00013250898,0.00017065382,0.00013548556,0.0031872485,0.000482108,0.0379396,0.0005788364,0.83079964,0.00017135286],"about_ca_topic_score_codex":0.00003579592,"about_ca_topic_score_gemma":0.000025836163,"teacher_disagreement_score":0.8180301,"about_ca_system_score_codex":0.00025412318,"about_ca_system_score_gemma":0.0017461638,"threshold_uncertainty_score":0.9993881},"labels":[],"label_agreement":null},{"id":"W4281865532","doi":"10.1016/j.omtm.2022.05.006","title":"Selective B cell depletion upon intravenous infusion of replication-incompetent anti-CD19 CAR lentivirus","year":2022,"lang":"en","type":"article","venue":"Molecular Therapy — Methods & Clinical Development","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; University of British Columbia; Canada's Michael Smith Genome Sciences Centre","funders":"BC Cancer Agency","keywords":"CD19; Population; Transduction (biophysics); Transgene; Biology; Chimeric antigen receptor; Genetic enhancement; Virology; Vesicular stomatitis virus; B cell; Viral vector; Molecular biology; Immunology; T cell; Immune system; Virus; Medicine; Antibody; Gene; Genetics; Recombinant DNA","score_opus":0.07497779339291938,"score_gpt":0.4288613776569801,"score_spread":0.35388358426406075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281865532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9469408,0.0010219542,0.048315678,0.00049802306,0.00038278656,0.0018659047,0.000006056504,0.00008784956,0.0008809898],"genre_scores_gemma":[0.7530357,0.0015474868,0.24215768,0.0013907112,0.00009403862,0.00047582938,0.00014389273,0.00012060105,0.0010340554],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9922692,0.0033503922,0.0015655797,0.0010818741,0.001203053,0.00052985974],"domain_scores_gemma":[0.99680805,0.0007316963,0.0005014663,0.001260473,0.00043197846,0.00026632377],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.008714903,0.00034313108,0.00095271156,0.00032967742,0.00029362174,0.000021191376,0.0004325734,0.00019334287,0.0014530818],"category_scores_gemma":[0.00043101708,0.000328501,0.0004514715,0.0008680538,0.0001263602,0.000038417373,0.00037990967,0.0010347887,0.000024846415],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011297199,0.0013713948,0.0051237494,0.000045840734,0.0003070843,0.000040436033,0.0007065809,0.00008161819,0.677093,0.000046506197,0.000047949165,0.31400606],"study_design_scores_gemma":[0.0040419563,0.0020317603,0.06357881,0.000043189168,0.000058821257,0.000036341462,0.00014582156,0.00041275527,0.8314365,0.00035576758,0.09749095,0.00036732573],"about_ca_topic_score_codex":0.00008041973,"about_ca_topic_score_gemma":0.00000341736,"teacher_disagreement_score":0.31363875,"about_ca_system_score_codex":0.0005362723,"about_ca_system_score_gemma":0.0009845956,"threshold_uncertainty_score":0.99991673},"labels":[],"label_agreement":null},{"id":"W4281946301","doi":"10.1200/jco.2022.40.16_suppl.8013","title":"Efficacy and safety of teclistamab (tec), a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients (pts) with relapsed/refractory multiple myeloma (RRMM) after exposure to other BCMA-targeted agents.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Internal medicine; Cytokine release syndrome; Cohort; Oncology; Clinical endpoint; Gastroenterology; Chimeric antigen receptor; Surgery; Clinical trial; Immunotherapy; Cancer","score_opus":0.05040499462910015,"score_gpt":0.38968772971000076,"score_spread":0.3392827350809006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281946301","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996123,0.00045565615,0.0000481366,0.001110081,0.0004930085,0.0009949266,0.00003311898,0.000010293063,0.0007317581],"genre_scores_gemma":[0.9963555,0.00035087005,0.0012619102,0.0008896662,0.00027054906,0.000017422615,0.000022211954,0.000053842716,0.0007780759],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948708,0.0010481199,0.0023247502,0.00038509953,0.0009934363,0.00037783963],"domain_scores_gemma":[0.9961616,0.0013676595,0.0012414604,0.00038146327,0.0004628951,0.00038496178],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002977234,0.00022355873,0.0013939708,0.0004971242,0.000074087155,0.000013169073,0.00025059882,0.0003051022,0.0022121526],"category_scores_gemma":[0.0010341968,0.00016982008,0.00025189226,0.0005092343,0.00021691456,0.00012756517,0.0001801607,0.001697665,0.0000107713195],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17891303,0.0074365586,0.7289701,0.00006769939,0.00027291372,0.0005840105,0.0009984561,0.000105581814,0.01981823,0.0000026129599,0.0013458984,0.061484925],"study_design_scores_gemma":[0.035026573,0.029401146,0.8056704,0.000102163445,0.000067773035,0.000046916033,0.000251682,0.00004647605,0.0003421525,0.000006211056,0.12889627,0.00014225677],"about_ca_topic_score_codex":0.00003990869,"about_ca_topic_score_gemma":0.00007806703,"teacher_disagreement_score":0.14388646,"about_ca_system_score_codex":0.00038026628,"about_ca_system_score_gemma":0.00077287504,"threshold_uncertainty_score":0.99869996},"labels":[],"label_agreement":null},{"id":"W4281974331","doi":"10.1016/j.jconrel.2022.05.040","title":"Real-time evaluation of a hydrogel delivery vehicle for cancer immunotherapeutics within embedded spheroid cultures","year":2022,"lang":"en","type":"article","venue":"Journal of Controlled Release","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Centre; McMaster University","funders":"","keywords":"Spheroid; In vitro; Fluorescence microscope; Self-healing hydrogels; Biophysics; Cell biology; Cancer research; Chemistry; Biology; Fluorescence; Biochemistry; Physics","score_opus":0.02925505119544184,"score_gpt":0.3522589941114541,"score_spread":0.32300394291601225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281974331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906037,0.0061448403,0.00003447637,0.00078953995,0.00021722158,0.0016787839,0.000026550775,0.000010527728,0.00049436535],"genre_scores_gemma":[0.9933862,0.0008535557,0.00044696766,0.00031432023,0.00033052522,0.0001875759,0.000007423946,0.0000466858,0.004426731],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99662757,0.00042899325,0.00089787965,0.00014275144,0.0016676829,0.00023509396],"domain_scores_gemma":[0.9966065,0.00034025966,0.00092388986,0.00025033962,0.0017348365,0.00014411611],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0034309297,0.00015327588,0.0008322672,0.0001941409,0.00013915755,0.00001632805,0.00018940186,0.0000699518,0.0045018457],"category_scores_gemma":[0.00035920803,0.00011623091,0.0005682844,0.0002333698,0.00006078224,0.0000780253,0.000031318414,0.00043582323,0.0000017517245],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060736697,0.0005042694,0.00011713189,0.00003970959,0.0014555859,0.000024572679,0.0010778985,0.011708433,0.9052363,0.000024708348,0.0012811555,0.017793547],"study_design_scores_gemma":[0.29706866,0.008698736,0.00089830323,0.0003284864,0.006151109,0.0004335798,0.0032659217,0.505492,0.16666307,0.0015210104,0.009011223,0.0004679334],"about_ca_topic_score_codex":0.00008978204,"about_ca_topic_score_gemma":0.000010344508,"teacher_disagreement_score":0.7385732,"about_ca_system_score_codex":0.00050914736,"about_ca_system_score_gemma":0.0015646745,"threshold_uncertainty_score":0.99640816},"labels":[],"label_agreement":null},{"id":"W4282018957","doi":"10.1200/jco.2022.40.16_suppl.7548","title":"Clinical and patient (pt)-reported outcomes (PROs) in a phase 3, randomized, open-label study evaluating axicabtagene ciloleucel (axi-cel) versus standard-of-care (SOC) therapy in elderly pts with relapsed/refractory (R/R) large B-cell lymphoma (LBCL; ZUMA-7).","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Quality of life (healthcare); Internal medicine; Phases of clinical research; Chemoimmunotherapy; Adverse effect; Refractory (planetary science); Oncology; Clinical trial; Cancer; Immunotherapy","score_opus":0.21426952189194884,"score_gpt":0.5364124915908745,"score_spread":0.32214296969892564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282018957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893605,0.0030534111,0.000017127579,0.0010848778,0.0011873699,0.0043591596,0.000027978114,0.000013120272,0.00089645525],"genre_scores_gemma":[0.9949788,0.0020597917,0.0015749102,0.00072626525,0.00017412758,0.00019547022,0.000011274685,0.00007540202,0.00020396727],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9796891,0.00893813,0.007761789,0.00077717303,0.0021726745,0.0006611309],"domain_scores_gemma":[0.98029095,0.012828631,0.0045217914,0.0007159382,0.0010733623,0.0005693231],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.034645695,0.00042512058,0.0061393636,0.00056483684,0.00015723388,0.00004085244,0.00063494715,0.00043023512,0.0007424413],"category_scores_gemma":[0.008075761,0.00029694507,0.0006098222,0.0006283142,0.0005603367,0.00021324171,0.0005796015,0.0029720187,0.0000019858087],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5303931,0.055115175,0.082753226,0.000028152634,0.0009005684,0.00266904,0.0020548077,0.000009408277,0.00019443876,0.000004837699,0.000102897706,0.3257743],"study_design_scores_gemma":[0.6753554,0.29911104,0.012730275,0.00009449552,0.00036975782,0.00009988177,0.0072587123,0.00018743021,0.0000387213,0.00003949356,0.004510767,0.00020404578],"about_ca_topic_score_codex":0.00013629755,"about_ca_topic_score_gemma":0.00046596452,"teacher_disagreement_score":0.32557026,"about_ca_system_score_codex":0.0008204192,"about_ca_system_score_gemma":0.0062172874,"threshold_uncertainty_score":0.99994826},"labels":[],"label_agreement":null},{"id":"W4282927325","doi":"10.1158/1538-7445.am2022-ct126","title":"Abstract CT126: A phase 2 trial of first-line AZD0171 + durvalumab and chemotherapy (CT) in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) and CD8+ T cell infiltration","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Durvalumab; Tumor microenvironment; Response Evaluation Criteria in Solid Tumors; CD8; Oncology; Cancer research; Immune system; Internal medicine; Immunotherapy; Phases of clinical research; Cancer; Chemotherapy; Immunology; Nivolumab","score_opus":0.0599190100686973,"score_gpt":0.38013565412632844,"score_spread":0.3202166440576311,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282927325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944394,0.0015063137,0.0000033438553,0.0006120304,0.000043273383,0.0030496113,0.0000882171,0.0000124043445,0.00024536913],"genre_scores_gemma":[0.99757123,0.00084145076,0.000070604205,0.0000373861,0.00008722831,0.000626391,0.000076714845,0.000054126547,0.00063488685],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9967327,0.00030299713,0.00045761387,0.00048112788,0.0015119608,0.00051359483],"domain_scores_gemma":[0.9986681,0.00035177259,0.00011745589,0.00039099998,0.00026143293,0.00021025562],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001542973,0.0001900919,0.0005093466,0.0005414464,0.00019661794,0.000039015114,0.0001491945,0.000032880995,0.0035495067],"category_scores_gemma":[0.00012031119,0.00016373178,0.000048537982,0.00080148736,0.00033596123,0.0001282753,0.00011373178,0.00077942776,0.0000017529719],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36542284,0.0057261656,0.5273042,0.001473424,0.00041828337,0.0003589366,0.0037592452,0.000091482805,0.06489185,0.00002056714,0.00064691715,0.029886086],"study_design_scores_gemma":[0.5290514,0.028464133,0.41785052,0.00030435613,0.000148949,0.00006384695,0.0018398347,0.00081788877,0.01826106,0.00017296306,0.0025195924,0.00050542527],"about_ca_topic_score_codex":0.0017615687,"about_ca_topic_score_gemma":0.00027126088,"teacher_disagreement_score":0.16362858,"about_ca_system_score_codex":0.00041866762,"about_ca_system_score_gemma":0.0005222133,"threshold_uncertainty_score":0.99736136},"labels":[],"label_agreement":null},{"id":"W4282947107","doi":"10.1158/1538-7445.am2022-lb001","title":"Abstract LB001: Identifying MAGE-A4-positive tumors for SPEAR T-cell therapies in HLA-A*02-eligible patients","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Human leukocyte antigen; Antigen; Medicine; Cancer; Oncology; Immunology; Cancer research; Internal medicine","score_opus":0.1094098929922035,"score_gpt":0.4386398053673828,"score_spread":0.3292299123751793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282947107","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848276,0.002133846,0.000010850956,0.0011146623,0.00022455561,0.0029657597,0.00018348682,0.000041749405,0.0084975315],"genre_scores_gemma":[0.9755721,0.00062195904,0.00007623643,0.00020067809,0.00026550208,0.0019190374,0.00011984009,0.00011278703,0.021111833],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9952385,0.0003421785,0.00042748486,0.00069993647,0.0020543307,0.0012375938],"domain_scores_gemma":[0.9980046,0.0005315497,0.00007721628,0.00054384867,0.00058367685,0.0002590915],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0026955102,0.00021859306,0.00041856297,0.00093087595,0.0005322351,0.00011995671,0.0005103094,0.00007725938,0.011375091],"category_scores_gemma":[0.00015550929,0.00021653788,0.00017872248,0.0012454807,0.00023254807,0.00016342971,0.00042204282,0.0015315509,0.00008995299],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007449959,0.0017459404,0.05448961,0.0010464543,0.00021871258,0.0003937289,0.008410841,0.00020469214,0.85943097,0.00011898084,0.024473198,0.042016923],"study_design_scores_gemma":[0.026662441,0.005016233,0.3243546,0.0008789629,0.000057963578,0.00002718702,0.016801983,0.00041988134,0.49313363,0.0021984517,0.12926488,0.0011838134],"about_ca_topic_score_codex":0.0034078755,"about_ca_topic_score_gemma":0.0003016529,"teacher_disagreement_score":0.36629733,"about_ca_system_score_codex":0.001808266,"about_ca_system_score_gemma":0.0008144995,"threshold_uncertainty_score":0.98952866},"labels":[],"label_agreement":null},{"id":"W4282959799","doi":"10.1158/1538-7445.am2022-564","title":"Abstract 564: Targeting axonal guidance with anti-ROBO1 CAR T cells: A new therapeutic strategy for malignant brain cancer","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada; McMaster University","funders":"","keywords":"Cancer; Medicine; Cancer research; Downregulation and upregulation; Glioma; Brain tumor; Chimeric antigen receptor; Cancer cell; Lung cancer; Immunotherapy; Internal medicine; Pathology; Biology; Gene","score_opus":0.1485057133815752,"score_gpt":0.43740882860226404,"score_spread":0.28890311522068884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282959799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9486761,0.02635836,0.00036137077,0.015032164,0.0005216432,0.00531128,0.0004987224,0.00015017703,0.0030901958],"genre_scores_gemma":[0.94276184,0.0011188379,0.00028830106,0.0009366385,0.0013722795,0.0032561668,0.00006932537,0.00020395176,0.04999266],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9941175,0.0003955265,0.00044657572,0.00096309156,0.0023881993,0.0016890815],"domain_scores_gemma":[0.9972501,0.00073428696,0.0001177338,0.00065632147,0.0007050685,0.0005365116],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003285835,0.00032413434,0.00055332965,0.0003906772,0.0008774448,0.00013215054,0.0006471265,0.000110294255,0.027951894],"category_scores_gemma":[0.00009104952,0.0002709027,0.00018670173,0.0011885084,0.00034112795,0.00012452861,0.00023517753,0.0019097955,0.000023490842],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025202439,0.00017916261,0.0026244835,0.00042369665,0.00032595856,0.0001505307,0.0006510832,0.0039390055,0.8703632,0.0001578874,0.07890495,0.039759807],"study_design_scores_gemma":[0.008959225,0.003062911,0.00877841,0.0005531061,0.000085902524,0.0000706366,0.0032016402,0.0012452377,0.32073852,0.0005270662,0.65196455,0.00081278774],"about_ca_topic_score_codex":0.0081578465,"about_ca_topic_score_gemma":0.00079873437,"teacher_disagreement_score":0.5730596,"about_ca_system_score_codex":0.0015045952,"about_ca_system_score_gemma":0.0056668366,"threshold_uncertainty_score":0.9999743},"labels":[],"label_agreement":null},{"id":"W4282959999","doi":"10.1158/1538-7445.am2022-559","title":"Abstract 559: Targeting hematological malignancies and solid tumors with switchable chimeric antigen receptor-engineered iPSC-derived natural killer cells","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Chimeric antigen receptor; Cancer research; CD19; Induced pluripotent stem cell; CD33; NKG2D; Immunotherapy; Biology; Antigen; Immunology; Stem cell; Cell biology; CD34; Cytotoxic T cell; Immune system; Embryonic stem cell; Gene","score_opus":0.042511637850397604,"score_gpt":0.34551406794819167,"score_spread":0.30300243009779404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282959999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906952,0.005092361,0.0000072778284,0.0017288357,0.00030420852,0.0010952669,0.000016295015,0.0001016229,0.00095893187],"genre_scores_gemma":[0.9874752,0.0013470046,0.00040319492,0.00014421859,0.00023589603,0.0005139059,0.00004708693,0.00008839402,0.009745104],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9957684,0.00024273759,0.00034410885,0.00070585357,0.0016774714,0.001261386],"domain_scores_gemma":[0.9984558,0.0003004008,0.00007424238,0.00041704375,0.00037271585,0.0003797989],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015166416,0.0002722695,0.00058923033,0.0003643443,0.00071284483,0.000092294395,0.00034007398,0.00008441575,0.014457868],"category_scores_gemma":[0.00013488567,0.00021244003,0.00009211607,0.0010645986,0.0004527326,0.00011578357,0.00045339562,0.0019194784,0.00004556761],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014416362,0.00012036408,0.002992235,0.00022619514,0.00013281505,0.00034476168,0.0007405561,0.00014153782,0.9761536,0.00002099387,0.01646904,0.0012162684],"study_design_scores_gemma":[0.0046220957,0.0018669066,0.024415929,0.00042891246,0.000028456296,0.00045036475,0.005823365,0.0008628922,0.8778696,0.000061564395,0.08271652,0.00085340353],"about_ca_topic_score_codex":0.0005005588,"about_ca_topic_score_gemma":0.000015982929,"teacher_disagreement_score":0.098284006,"about_ca_system_score_codex":0.00045538164,"about_ca_system_score_gemma":0.00061115314,"threshold_uncertainty_score":0.98644304},"labels":[],"label_agreement":null},{"id":"W4282962127","doi":"10.1158/1538-7445.am2022-572","title":"Abstract 572: Pre-clinical evaluation of Claudin 18.2 TAC T cells for the treatment of gastric cancer","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences","funders":"","keywords":"Cancer research; Cancer; Claudin; Tight junction; In vivo; Immunotherapy; Cytotoxic T cell; Medicine; Cancer cell; Immunology; In vitro; Chemistry; Biology; Internal medicine; Biochemistry","score_opus":0.3995313886288464,"score_gpt":0.5792230089990879,"score_spread":0.17969162037024144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282962127","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9796041,0.012706474,0.000012053678,0.0012783535,0.00035547273,0.0046247034,0.0003080421,0.000009575273,0.0011011985],"genre_scores_gemma":[0.97156894,0.010563517,0.000036572543,0.000030394733,0.000544256,0.0059542805,0.00002655352,0.00004232392,0.011233149],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99526066,0.00062095723,0.00052888866,0.00038596205,0.0026973116,0.0005062466],"domain_scores_gemma":[0.99580467,0.0019263919,0.0001499905,0.0006648794,0.0013113051,0.0001427813],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.007030693,0.00012272199,0.00040004947,0.00026142094,0.00022069685,0.000012096745,0.00032112864,0.000067914334,0.046396267],"category_scores_gemma":[0.00024266014,0.00008560168,0.000267844,0.00078857335,0.00035058951,0.000029365941,0.00009325416,0.00049830653,0.000006062679],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00627985,0.0014440672,0.0076827477,0.00022892425,0.0006480974,0.0000043914265,0.0009738139,0.0022778304,0.39241713,0.000012341933,0.033017974,0.5550128],"study_design_scores_gemma":[0.022397157,0.014454627,0.13971028,0.00022293863,0.0008001229,0.0000081429625,0.001992796,0.012701463,0.4383175,0.00033046334,0.36876717,0.00029732243],"about_ca_topic_score_codex":0.0040874095,"about_ca_topic_score_gemma":0.0003930501,"teacher_disagreement_score":0.5547155,"about_ca_system_score_codex":0.0016611149,"about_ca_system_score_gemma":0.0029011574,"threshold_uncertainty_score":0.95447546},"labels":[],"label_agreement":null},{"id":"W4282969370","doi":"10.1158/1538-7445.am2022-ct247","title":"Abstract CT247: A phase I/II trial investigating safety and efficacy of autologous TAC T cells targeting HER2 in relapsed or refractory solid tumors (TACTIC-2)","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Chimeric antigen receptor; Leukapheresis; Cancer research; T cell; Immunohistochemistry; Breast cancer; Antigen; Cancer; T-cell receptor; Immunotherapy; Oncology; Immunology; Internal medicine; Immune system; Biology; CD34; Stem cell","score_opus":0.10108806075607954,"score_gpt":0.4461038510280492,"score_spread":0.3450157902719697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282969370","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938425,0.0010199918,0.0000011811726,0.0010411355,0.00022704352,0.002340733,0.000059995913,0.00004871044,0.0014187393],"genre_scores_gemma":[0.99485666,0.00045825428,0.00014868852,0.00009493762,0.00036710428,0.00037561014,0.000031215754,0.00008595102,0.003581601],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9944492,0.0009790937,0.000975189,0.0007210833,0.0018150391,0.0010603861],"domain_scores_gemma":[0.9963514,0.0021111919,0.00025312477,0.00056367816,0.00028293036,0.00043767435],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0060776626,0.00023964727,0.00079490885,0.0007448364,0.00062043226,0.000036703295,0.0003759687,0.00013919528,0.008696942],"category_scores_gemma":[0.0029093062,0.00021674881,0.000116623574,0.0014953691,0.0006109251,0.00010259809,0.00061993743,0.0031034201,0.000007117029],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12385982,0.0015007657,0.0003087926,0.00037674035,0.00008945332,0.0005687408,0.0036020314,0.00023029394,0.8367922,0.000009704629,0.0014448967,0.031216592],"study_design_scores_gemma":[0.41210482,0.038028777,0.0050501735,0.0014132877,0.000094276504,0.0001478947,0.012112251,0.0031860431,0.4598448,0.00015483661,0.06679158,0.0010712649],"about_ca_topic_score_codex":0.0023641747,"about_ca_topic_score_gemma":0.00012620317,"teacher_disagreement_score":0.37694737,"about_ca_system_score_codex":0.0012144825,"about_ca_system_score_gemma":0.0028372922,"threshold_uncertainty_score":0.99919647},"labels":[],"label_agreement":null},{"id":"W4282983643","doi":"10.1158/1538-7445.am2022-385","title":"Abstract 385: iRGD mediated delivery of neoantigens to enable immunotherapy in integrin b5-rich tumors","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stemcell Technologies","funders":"","keywords":"Cancer research; Pancreatic cancer; Immunotherapy; Tumor microenvironment; Integrin; Stromal cell; Stroma; Immune system; Immunosurveillance; Medicine; Immunology; Cancer; Immunohistochemistry; Internal medicine; Receptor","score_opus":0.07954352637616002,"score_gpt":0.40651290960471126,"score_spread":0.32696938322855124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4282983643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9867082,0.002682019,0.0000018696215,0.0020499555,0.00015238255,0.0015041849,0.00008184279,0.000037009282,0.006782502],"genre_scores_gemma":[0.9857648,0.0016058941,0.00005141644,0.00031951707,0.00015153213,0.0008701135,0.00003926793,0.00008530544,0.011112175],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9951208,0.00040858434,0.00053970085,0.0005526807,0.0022811454,0.0010970784],"domain_scores_gemma":[0.9977029,0.0005625139,0.00006459181,0.0007574751,0.0005984771,0.00031404803],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0036428063,0.00019295428,0.000531525,0.001471852,0.00019544884,0.000031028023,0.00066475937,0.00008716983,0.04320589],"category_scores_gemma":[0.00027957716,0.00018570447,0.000119990065,0.00316258,0.00021768735,0.00007960323,0.0004465276,0.0020000632,0.000120082],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038119133,0.0003874441,0.019028896,0.00014245074,0.000100241785,0.0003273333,0.0023930287,0.00028909565,0.94617885,0.00003470248,0.007842785,0.01946325],"study_design_scores_gemma":[0.008249728,0.0028369387,0.14955911,0.00054728996,0.000012916037,0.00006053661,0.00909396,0.00023081202,0.6017782,0.00024507515,0.22678207,0.0006033534],"about_ca_topic_score_codex":0.017377645,"about_ca_topic_score_gemma":0.0009632548,"teacher_disagreement_score":0.34440064,"about_ca_system_score_codex":0.0017265053,"about_ca_system_score_gemma":0.001935597,"threshold_uncertainty_score":0.9891657},"labels":[],"label_agreement":null},{"id":"W4283019343","doi":"10.1038/s43018-022-00398-7","title":"Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy","year":2022,"lang":"en","type":"article","venue":"Nature Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"Nationales Centrum für Tumorerkrankungen Heidelberg; Deutsches Krebsforschungszentrum","keywords":"Medicine; Vaccination; Adverse effect; Common Terminology Criteria for Adverse Events; Cancer; Immune system; Immunology; Immunotherapy; Internal medicine; Cohort; Cytokine release syndrome; Cytokine","score_opus":0.031341642417978655,"score_gpt":0.39124105103857426,"score_spread":0.3598994086205956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283019343","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91373795,0.04839489,0.000035454756,0.03486575,0.00093302294,0.0012044082,0.000561679,0.00015723862,0.00010961536],"genre_scores_gemma":[0.9427987,0.009460308,0.000056839574,0.03579138,0.0002748964,0.0014914096,0.000043837117,0.000110627865,0.00997205],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970155,0.0003804774,0.00044529067,0.0006906233,0.001002251,0.0004658819],"domain_scores_gemma":[0.9982596,0.00030387295,0.00020569016,0.0005890014,0.00024575426,0.00039608736],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007822543,0.00029075172,0.00048556572,0.0003057583,0.00023416319,0.000044832497,0.00021625537,0.0003110772,0.02534526],"category_scores_gemma":[0.0001925071,0.00025920972,0.0001595027,0.000585286,0.00008878592,0.00009093782,0.0001829137,0.0019286055,0.0000044110784],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1002619,0.0015115154,0.6552855,0.0013301064,0.0021415693,0.004257272,0.0026649002,0.0014492247,0.051624637,0.0002480909,0.06769297,0.11153234],"study_design_scores_gemma":[0.006507837,0.0007967705,0.49365425,0.000116079944,0.00010629256,0.00027993385,0.00043575483,0.00009480191,0.00056805776,0.0002576007,0.49680954,0.0003730786],"about_ca_topic_score_codex":0.00052493747,"about_ca_topic_score_gemma":0.00064657925,"teacher_disagreement_score":0.42911658,"about_ca_system_score_codex":0.0026072022,"about_ca_system_score_gemma":0.0013922548,"threshold_uncertainty_score":0.999986},"labels":[],"label_agreement":null},{"id":"W4283270985","doi":"10.1126/scitranslmed.abn3353","title":"B cell targeting in CAR T cell therapy: Side effect or driver of CAR T cell function?","year":2022,"lang":"en","type":"review","venue":"Science Translational Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Canadian Institutes of Health Research","keywords":"Chimeric antigen receptor; CD19; CAR T-cell therapy; T cell; Cell; B cell; Cancer research; Cell therapy; Medicine; Antigen; Immunology; Biology; Immune system; Antibody; Genetics","score_opus":0.06806536564021057,"score_gpt":0.3772436598798643,"score_spread":0.3091782942396537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283270985","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0021386454,0.9780902,0.000049287828,0.00022855875,0.0007446026,0.0030080455,0.000045344856,0.000044688295,0.0156506],"genre_scores_gemma":[0.008971919,0.9843902,0.00023476568,0.00014522606,0.00057363114,0.00022724782,0.0002884266,0.000102722515,0.0050658816],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9929256,0.000546038,0.0012955047,0.0010915652,0.0033529843,0.00078830274],"domain_scores_gemma":[0.9961549,0.002165803,0.00042774246,0.0006506126,0.00023275791,0.00036819192],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0048023453,0.00060778396,0.0022455805,0.0016341899,0.00025757795,0.000016486678,0.00074384984,0.00020068002,0.018129881],"category_scores_gemma":[0.00020890657,0.00039884928,0.0004525323,0.0041729147,0.0012408653,0.00017578436,0.000071009774,0.0014157939,0.000037577163],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017299104,0.0008079444,0.0010847711,0.03225431,0.00014767768,0.00033379367,0.003262746,0.00019366945,0.068821765,0.00004100243,0.0017600212,0.88956237],"study_design_scores_gemma":[0.0051838304,0.0027269325,0.00021232697,0.0030200505,0.00048238877,0.00004192527,0.00024324762,0.00012600639,0.0014517833,0.00003488996,0.98603857,0.00043807746],"about_ca_topic_score_codex":0.00023795152,"about_ca_topic_score_gemma":0.000011780225,"teacher_disagreement_score":0.9842785,"about_ca_system_score_codex":0.00042580115,"about_ca_system_score_gemma":0.0032747346,"threshold_uncertainty_score":0.99984634},"labels":[],"label_agreement":null},{"id":"W4283312353","doi":"10.1097/01.hs9.0000843628.63947.e4","title":"S184: EVALUATING TECLISTAMAB IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA FOLLOWING EXPOSURE TO OTHER B-CELL MATURATION ANTIGEN (BCMA)-TARGETED AGENTS","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Institute of Cancer Research","funders":"","keywords":"Medicine; Internal medicine; Multiple myeloma; Cytokine release syndrome; Chimeric antigen receptor; Cohort; Oncology; Antigen; Gastroenterology; Immunology; Cancer; Immunotherapy","score_opus":0.025269656908133178,"score_gpt":0.2987480830311138,"score_spread":0.2734784261229806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283312353","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99369824,0.00031104885,0.000033943223,0.00014628314,0.00021172622,0.0020404204,0.0000262343,0.00009514454,0.0034369833],"genre_scores_gemma":[0.98737437,0.0000031204554,0.0022692238,0.00048483364,0.00008141463,0.00024801565,0.00017648314,0.00012714893,0.009235382],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99657154,0.00031229612,0.00045195472,0.0005880362,0.0015215613,0.0005545841],"domain_scores_gemma":[0.99878716,0.00011611533,0.00014055023,0.00061756244,0.0001434979,0.00019511957],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006909692,0.0002677094,0.00039614105,0.0001802722,0.00025965067,0.000038939448,0.00020476939,0.000101958154,0.008390976],"category_scores_gemma":[0.0001890559,0.00024650546,0.00012746012,0.00078763056,0.000023018532,0.00015346058,0.00016733813,0.0006379975,0.00007816631],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064423904,0.0012554033,0.81108576,0.00013412816,0.00013316648,0.00016654187,0.0038760141,0.00084567256,0.15543461,0.0000025265535,0.0023450896,0.018278716],"study_design_scores_gemma":[0.028788904,0.006485465,0.9138435,0.00037182585,0.000080639,0.000009949596,0.0041620065,0.0017516519,0.011652397,0.000016604965,0.032065213,0.00077184336],"about_ca_topic_score_codex":0.00019784014,"about_ca_topic_score_gemma":0.00013018584,"teacher_disagreement_score":0.14378221,"about_ca_system_score_codex":0.0006328552,"about_ca_system_score_gemma":0.00020132898,"threshold_uncertainty_score":0.99999875},"labels":[],"label_agreement":null},{"id":"W4283325455","doi":"10.1097/01.hs9.0000843736.56298.a7","title":"S211: CLINICAL AND PATIENT-REPORTED OUTCOMES IN A PHASE 3 STUDY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) VS STANDARD-OF-CARE IN ELDERLY PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (ZUMA-7)","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Chemoimmunotherapy; Hazard ratio; Internal medicine; Oncology; Refractory (planetary science); Phases of clinical research; Surgery; Clinical trial; Lymphoma; Confidence interval; Rituximab","score_opus":0.02406320880621695,"score_gpt":0.3345384065848873,"score_spread":0.3104751977786704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283325455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99540466,0.0009576049,0.0000025653915,0.00004033896,0.000115257666,0.0023727186,0.00014806743,0.000027722357,0.0009310806],"genre_scores_gemma":[0.9989232,0.00005449442,0.0001191208,0.000075349315,0.000012688912,0.00015220964,0.00006162871,0.000071405404,0.0005299488],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99556977,0.0004901409,0.0014106806,0.0006510558,0.0014043814,0.00047395864],"domain_scores_gemma":[0.99792856,0.00030057543,0.00047150935,0.00078685686,0.0003049988,0.00020751503],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006756591,0.00030524837,0.0012803646,0.000250436,0.0000824502,0.000010349552,0.00018045299,0.00013163855,0.0016203503],"category_scores_gemma":[0.00020458111,0.00026025408,0.00014196684,0.0006503707,0.000137275,0.00009024134,0.00027342935,0.0005820518,0.0000016728641],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026285527,0.034464825,0.87913305,0.0002541829,0.00018118619,0.0005636227,0.0066617364,0.0000063654475,0.00034813397,0.0000025852582,0.000115015704,0.051983792],"study_design_scores_gemma":[0.2828547,0.12554732,0.5311832,0.00031523747,0.00020611243,0.00001713175,0.049557503,0.0000542705,0.0013634651,0.000012249126,0.008335871,0.00055294635],"about_ca_topic_score_codex":0.00025736753,"about_ca_topic_score_gemma":0.0007365393,"teacher_disagreement_score":0.34794986,"about_ca_system_score_codex":0.00029188173,"about_ca_system_score_gemma":0.00050137093,"threshold_uncertainty_score":0.999985},"labels":[],"label_agreement":null},{"id":"W4283331887","doi":"10.1097/01.hs9.0000843912.35755.7f","title":"S255: EFFICACY AND SAFETY OF TISAGENLECLEUCEL IN PEDIATRIC AND YOUNG ADULT PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) MATURE B-CELL NON-HODGKIN LYMPHOMA (NHL): THE PHASE II BIANCA STUDY","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Fludarabine; Internal medicine; Phases of clinical research; Lymphoma; Clinical endpoint; Refractory (planetary science); Oncology; Cyclophosphamide; Gastroenterology; Surgery; Chemotherapy; Clinical trial","score_opus":0.01166383156354024,"score_gpt":0.2766023768999559,"score_spread":0.2649385453364157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283331887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941341,0.0011369681,0.0000025959368,0.00014297433,0.00009286665,0.0024752994,0.00004329871,0.000028272476,0.0019435994],"genre_scores_gemma":[0.9916879,0.0005613066,0.00011273346,0.00012346802,0.00008340883,0.00013552277,0.000030934036,0.00007257815,0.0071921656],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99753255,0.00026603567,0.00044864585,0.0005237913,0.0008417244,0.00038727935],"domain_scores_gemma":[0.99866694,0.00023838649,0.00019383691,0.0005946165,0.00014268431,0.00016353535],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00048799452,0.00027289536,0.0004917737,0.00013195506,0.00031507498,0.000019661842,0.00019466918,0.000096413845,0.0015676711],"category_scores_gemma":[0.000091721246,0.00017822719,0.00004821904,0.00087488315,0.000112209746,0.00007880796,0.0003200424,0.0005631141,0.0000034226318],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0934571,0.03743836,0.6536688,0.0012893043,0.00036362442,0.0012047271,0.037563395,0.000026378322,0.010590959,0.000009483484,0.008769423,0.15561844],"study_design_scores_gemma":[0.21657382,0.048419956,0.70430994,0.00021615234,0.00051858363,0.00020979824,0.018884404,0.00041164807,0.0010949805,0.000008889905,0.008622909,0.00072894397],"about_ca_topic_score_codex":0.00025467988,"about_ca_topic_score_gemma":0.00038918044,"teacher_disagreement_score":0.15488951,"about_ca_system_score_codex":0.00018209632,"about_ca_system_score_gemma":0.00025624238,"threshold_uncertainty_score":0.999345},"labels":[],"label_agreement":null},{"id":"W4283369873","doi":"10.1111/bjh.18333","title":"Sequential loss of B‐cell target antigens in multiply relapsed high‐grade B‐cell lymphoma treated with targeted therapies","year":2022,"lang":"en","type":"letter","venue":"British Journal of Haematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Lymphoma; Medicine; B cell; Antigen; B-cell lymphoma; Oncology; Immunology; Cancer research; Internal medicine; Antibody","score_opus":0.016211989628227813,"score_gpt":0.25931032101338936,"score_spread":0.24309833138516154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283369873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9577745,0.011652263,0.00003677531,0.028321095,0.00051506463,0.00095933076,0.00025736596,0.00003921681,0.00044437475],"genre_scores_gemma":[0.9414624,0.008000628,0.0044424664,0.033633042,0.001537745,0.000079255675,0.0011778052,0.0005613255,0.0091053145],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9936348,0.0013134409,0.0018765965,0.0006330045,0.0014921351,0.0010500008],"domain_scores_gemma":[0.9965258,0.00045326026,0.0016176567,0.00055231864,0.0006430268,0.00020793888],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007827203,0.0005962791,0.003147029,0.0013428007,0.00012441861,0.00005353936,0.0007261032,0.0010665653,0.007497017],"category_scores_gemma":[0.00009600166,0.0005923075,0.00062512,0.0007670362,0.000716245,0.00013594427,0.00013887178,0.0036416883,0.000010247812],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0046429355,0.0017612189,0.0100779915,0.0013664992,0.0012631858,0.74037415,0.0006722312,0.000038375572,0.03939537,0.000002810883,0.19964738,0.0007578558],"study_design_scores_gemma":[0.051739823,0.006422299,0.004980949,0.0019456252,0.000753093,0.5882111,0.0006957158,0.000057550653,0.08442375,0.00016508902,0.25940087,0.0012041302],"about_ca_topic_score_codex":0.0016314771,"about_ca_topic_score_gemma":0.0001260479,"teacher_disagreement_score":0.15216304,"about_ca_system_score_codex":0.00042535545,"about_ca_system_score_gemma":0.0011578619,"threshold_uncertainty_score":0.99965286},"labels":[],"label_agreement":null},{"id":"W4283392950","doi":"10.1097/01.hs9.0000847476.69621.cd","title":"P1152: RESULTS FROM A PHASE I PHARMACOKINETIC (PK) AND SAFETY STUDY OF TRPH-222, A NOVEL CD22-TARGETING ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (R/R NHL)","year":2022,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Pharmacokinetics; Antibody-drug conjugate; Internal medicine; Cmax; Refractory (planetary science); Phases of clinical research; Gastroenterology; Lymphoma; Oncology; Antibody; Pharmacology; Toxicity; Adverse effect; Monoclonal antibody; Immunology","score_opus":0.012692541623903398,"score_gpt":0.29003734080215277,"score_spread":0.2773447991782494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283392950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926269,0.0006287458,0.000016678285,0.00008173749,0.0001455757,0.0027223558,0.00056025,0.000053800537,0.0031639803],"genre_scores_gemma":[0.997069,0.000073618656,0.00039820958,0.00013290816,0.00008927034,0.00010398449,0.0005388419,0.00011737271,0.0014767859],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9958989,0.00032149494,0.0010032682,0.000932212,0.0012467479,0.0005973951],"domain_scores_gemma":[0.9979665,0.00045026536,0.0004091435,0.00068963756,0.00020730165,0.00027711954],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008402198,0.00041793313,0.0008731701,0.00020057551,0.00020078986,0.000024610628,0.00027509965,0.00008394457,0.0023702653],"category_scores_gemma":[0.00010120622,0.00037740442,0.000092270566,0.0007754774,0.0001327314,0.00013984526,0.0003439179,0.0006788909,0.000007767393],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13880919,0.066234134,0.28211394,0.0005365031,0.00073024275,0.0009035453,0.024662627,0.0003568779,0.44950482,0.0000026062673,0.0031719268,0.03297361],"study_design_scores_gemma":[0.680592,0.019429602,0.22966509,0.0007027533,0.0005127135,0.00003401615,0.023218561,0.004491675,0.020490004,0.0000124293365,0.019537218,0.0013139436],"about_ca_topic_score_codex":0.0019271246,"about_ca_topic_score_gemma":0.00013529345,"teacher_disagreement_score":0.5417828,"about_ca_system_score_codex":0.00032305508,"about_ca_system_score_gemma":0.0002803144,"threshold_uncertainty_score":0.9998678},"labels":[],"label_agreement":null},{"id":"W4283516611","doi":"10.1016/j.jval.2022.04.416","title":"EE167 Use of Cost per Responder Models for CAR-T Therapies in Relapsed or Refractory Multiple Myeloma","year":2022,"lang":"en","type":"article","venue":"Value in Health","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Medicine; Confidence interval; Internal medicine; Multiple myeloma; Hazard ratio; Adverse effect; Oncology; Pembrolizumab; Immunotherapy","score_opus":0.19992756430541408,"score_gpt":0.38641269888520613,"score_spread":0.18648513457979204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283516611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99204475,0.0014124868,0.00011629569,0.002851075,0.00016845728,0.0031693333,0.00012704598,0.00003207199,0.000078488745],"genre_scores_gemma":[0.98849225,0.0006002415,0.00230743,0.0011037833,0.000066290646,0.0006149328,0.000044552173,0.000079041914,0.006691499],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9969556,0.00083474896,0.00067175337,0.0003799857,0.0006141672,0.00054374966],"domain_scores_gemma":[0.9971783,0.0018733249,0.00014996728,0.0005459481,0.00010416482,0.0001482951],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002336476,0.00015607987,0.0005338838,0.0005968568,0.00010993026,0.000009639456,0.0001617691,0.000087213586,0.00094775896],"category_scores_gemma":[0.00045267635,0.00013733824,0.00010233161,0.00055565604,0.00007610483,0.00009399373,0.000087721215,0.0006279906,0.000002210762],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16957392,0.00601166,0.11486866,0.004293541,0.00037602184,0.00033676645,0.11267618,0.25579885,0.2044747,0.0027052935,0.010473723,0.118410684],"study_design_scores_gemma":[0.039618175,0.01219333,0.057826072,0.0008678908,0.00002852452,0.00011498384,0.012942014,0.49318558,0.002415858,0.0019855471,0.37804607,0.00077595626],"about_ca_topic_score_codex":0.009124554,"about_ca_topic_score_gemma":0.0007088437,"teacher_disagreement_score":0.36757234,"about_ca_system_score_codex":0.0011375915,"about_ca_system_score_gemma":0.0013787951,"threshold_uncertainty_score":0.9999655},"labels":[],"label_agreement":null},{"id":"W4283662383","doi":"10.1080/2162402x.2022.2093426","title":"Trogocytosis and fratricide killing impede MSLN-directed CAR T cell functionality","year":2022,"lang":"en","type":"article","venue":"OncoImmunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Cancerföreningen i Stockholm; Vetenskapsrådet; Karolinska Institutet; Cancerfonden","keywords":"Mesothelin; Chimeric antigen receptor; Cancer research; T cell; Antigen; CD28; Tumor microenvironment; Immunology; Medicine; Immune system; Tumor cells","score_opus":0.024159371536268178,"score_gpt":0.29159067560473584,"score_spread":0.26743130406846766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283662383","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9835264,0.005291494,0.000044701985,0.0013792033,0.00036282718,0.00034750093,0.000032280557,0.00017549573,0.008840086],"genre_scores_gemma":[0.98392487,0.00056681124,0.00033783386,0.000499346,0.00015121001,0.00012075654,0.000112785885,0.000039131777,0.014247274],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9982974,0.00030309646,0.00026708868,0.00039149928,0.00033199042,0.00040890806],"domain_scores_gemma":[0.99911135,0.00022758656,0.00007722565,0.00039535516,0.000097348464,0.00009113398],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004599093,0.00015655844,0.00038374958,0.0002308195,0.0003473543,0.000013184694,0.00012927427,0.00011165216,0.011295948],"category_scores_gemma":[0.00006548988,0.00015729707,0.000110354405,0.00044206533,0.00015155383,0.000037442915,0.0002581554,0.00076775753,0.000035308258],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017077044,0.00030652597,0.032490388,0.000043128053,0.00024453728,0.00012298799,0.00061158784,0.000016211614,0.93811417,0.00011127969,0.001967638,0.024263853],"study_design_scores_gemma":[0.010477273,0.0043802327,0.12638816,0.000019056795,0.0003271834,0.0014708294,0.0040986496,0.0013027658,0.051905572,0.0005983719,0.7983909,0.0006409492],"about_ca_topic_score_codex":0.0007438453,"about_ca_topic_score_gemma":0.000018065122,"teacher_disagreement_score":0.8862086,"about_ca_system_score_codex":0.00040438605,"about_ca_system_score_gemma":0.00024542562,"threshold_uncertainty_score":0.9896079},"labels":[],"label_agreement":null},{"id":"W4283825879","doi":"10.3389/fimmu.2022.905768","title":"Dual Antigen T Cell Engagers Targeting CA9 as an Effective Immunotherapeutic Modality for Targeting CA9 in Solid Tumors","year":2022,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McMaster University; Discovery Centre","funders":"Mitacs; Terry Fox Research Institute; University of Toronto; McMaster University","keywords":"Antigen; Medicine; Immunotherapy; Modality (human–computer interaction); Immunology; Cancer research; Immune system; Computer science; Artificial intelligence","score_opus":0.01385012627138225,"score_gpt":0.30272764837600397,"score_spread":0.2888775221046217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4283825879","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9866754,0.0069908337,0.00075635687,0.0004119454,0.0015539008,0.0027315428,0.00003705443,0.000090837144,0.0007521607],"genre_scores_gemma":[0.99343157,0.00027064653,0.0033231315,0.00033066812,0.00014484914,0.0010376278,0.00024553263,0.00012687806,0.0010890879],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9949025,0.0018689083,0.0007608984,0.0008161652,0.00039481482,0.00125674],"domain_scores_gemma":[0.9985778,0.00042697406,0.00022158984,0.0005602087,0.000111895955,0.00010154974],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0035240904,0.00036647465,0.0009877123,0.00083186437,0.00045927966,0.00002739092,0.0004311197,0.00023489141,0.0007868635],"category_scores_gemma":[0.00039687785,0.00041380132,0.0002171155,0.00072296517,0.00032487808,0.00015417875,0.00027363532,0.0019701703,0.000008641055],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008472339,0.00095646724,0.08619545,0.00015727985,0.00042628136,0.00038199313,0.016674347,0.0011049048,0.8604704,0.000055934106,0.0010569353,0.024047667],"study_design_scores_gemma":[0.052984983,0.014741951,0.15069294,0.000254958,0.0002281013,0.00041582773,0.16433541,0.023083927,0.5220231,0.008412425,0.059736516,0.0030898706],"about_ca_topic_score_codex":0.0018781506,"about_ca_topic_score_gemma":0.00003425424,"teacher_disagreement_score":0.3384473,"about_ca_system_score_codex":0.0015216292,"about_ca_system_score_gemma":0.0004060608,"threshold_uncertainty_score":0.9998314},"labels":[],"label_agreement":null},{"id":"W4284976473","doi":"10.1038/s41467-022-31510-1","title":"Multi-modal molecular programs regulate melanoma cell state","year":2022,"lang":"en","type":"article","venue":"Nature Communications","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre","funders":"American Cancer Society; AIM at Melanoma; National Health and Medical Research Council; National Institutes of Health; Cancer Prevention and Research Institute of Texas; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation; Medical Research Council; National Cancer Institute; Melanoma Research Alliance; University of Texas System; University of Texas MD Anderson Cancer Center; Lyda Hill Foundation","keywords":"Melanoma; Transcriptome; Biology; Computational biology; Phenotype; microRNA; Immune checkpoint; DNA methylation; Cancer research; Genetics; Cancer; Gene; Immunotherapy; Gene expression","score_opus":0.03237812463030771,"score_gpt":0.3478284844333382,"score_spread":0.3154503598030305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4284976473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8624032,0.035635423,0.0002679243,0.048487402,0.00038440066,0.0045267316,0.00015810876,0.00066025107,0.047476556],"genre_scores_gemma":[0.96492183,0.00037597195,0.015269874,0.00081392546,0.00001923452,0.00037348163,0.0005283259,0.000054338958,0.017642993],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983575,0.00034099614,0.0002215437,0.0002492212,0.000520489,0.00031029852],"domain_scores_gemma":[0.99662334,0.000092661154,0.00007564348,0.0028762182,0.0001840749,0.00014805685],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00043991464,0.00013850848,0.00019988172,0.00015936329,0.0004543166,0.000032424872,0.0010719193,0.00016330925,0.00077389384],"category_scores_gemma":[0.00004287393,0.00013967672,0.0001465542,0.00064094545,0.00015854344,0.000040513954,0.0010199164,0.0031596466,0.000035920068],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005133872,0.0041876454,0.00802057,0.00008236276,0.00035994462,0.00016036349,0.0022280472,0.00015804644,0.90660256,0.0027222428,0.0065613315,0.06840351],"study_design_scores_gemma":[0.002781713,0.0004740869,0.007009623,0.00001808669,0.000073917305,0.00011650826,0.00039215168,0.006233581,0.012718052,0.00019278881,0.9697217,0.00026781557],"about_ca_topic_score_codex":0.00006303175,"about_ca_topic_score_gemma":0.00008715657,"teacher_disagreement_score":0.96316034,"about_ca_system_score_codex":0.00023113,"about_ca_system_score_gemma":0.00018568567,"threshold_uncertainty_score":0.9991401},"labels":[],"label_agreement":null},{"id":"W4284987950","doi":"10.1016/s1470-2045(22)00335-7","title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","year":2022,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":436,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Princess Margaret Cancer Centre; Jewish General Hospital; University of British Columbia; Spinal Cord Injury BC","funders":"Genentech; F. Hoffmann-La Roche","keywords":"Medicine; Follicular lymphoma; Refractory (planetary science); Internal medicine; Clinical endpoint; Progressive disease; CD20; Follicular phase; Lymphoma; Oncology; Rituximab; Phases of clinical research; Gastroenterology; Chemotherapy; Clinical trial; Biology","score_opus":0.04388713937975811,"score_gpt":0.36045103446850474,"score_spread":0.3165638950887466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4284987950","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955609,0.0002536065,0.0000045153934,0.0005407225,0.00010504566,0.0023646676,0.000029819657,0.0000307758,0.001109952],"genre_scores_gemma":[0.9986775,0.00011004024,0.00011489572,0.00020387679,0.00008862918,0.00006504554,0.000059469156,0.000036435013,0.0006440926],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99735403,0.00090686657,0.000416166,0.00036924324,0.00053078996,0.00042289565],"domain_scores_gemma":[0.9982909,0.000692657,0.00019762738,0.0006369515,0.00009158453,0.00009027102],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010379414,0.0001752809,0.0008325018,0.00018197362,0.00013430319,0.000007697706,0.00024696675,0.00006305294,0.0009686145],"category_scores_gemma":[0.0001644679,0.00010841746,0.00004718837,0.00059148396,0.00022615236,0.000036524078,0.00023718899,0.00040164712,0.0000034706538],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.46851313,0.09002679,0.25895998,0.00013617045,0.00081191753,0.0018731208,0.015202362,0.00012498068,0.016376788,0.000048446665,0.0005647847,0.14736152],"study_design_scores_gemma":[0.3183252,0.072765104,0.5026208,0.00006065432,0.00023188413,0.00010352109,0.0040281704,0.0003231793,0.00018454166,0.0000109579605,0.10109096,0.00025502383],"about_ca_topic_score_codex":0.00018268022,"about_ca_topic_score_gemma":0.00016750593,"teacher_disagreement_score":0.24366085,"about_ca_system_score_codex":0.00068564754,"about_ca_system_score_gemma":0.00029388827,"threshold_uncertainty_score":0.9999446},"labels":[],"label_agreement":null},{"id":"W4285019712","doi":"10.1016/j.ymthe.2022.07.006","title":"Targeting glycans for CAR therapy: The advent of sweet CARs","year":2022,"lang":"en","type":"review","venue":"Molecular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute of General Medical Sciences; National Cancer Institute; National Heart, Lung, and Blood Institute","keywords":"Chimeric antigen receptor; Glycan; Cancer research; Antigen; Stromal cell; Cancer; Glycoprotein; Cancer cell; Targeted therapy; Glycosylation; Immunology; Chemistry; Biology; Immunotherapy; Biochemistry; Genetics","score_opus":0.0856352043509047,"score_gpt":0.3865383807675735,"score_spread":0.3009031764166688,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285019712","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00032991063,0.9910712,0.00022159088,0.0002508989,0.0003160931,0.0068091294,0.0001424296,0.00005632674,0.0008023841],"genre_scores_gemma":[0.000036580866,0.9935116,0.00020872647,0.00053312903,0.00029597752,0.0022170471,0.0005363429,0.00033333173,0.0023272554],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959665,0.0007333422,0.0008779053,0.0006873042,0.001059533,0.0006754238],"domain_scores_gemma":[0.9972812,0.00053949014,0.00045889986,0.0014081429,0.00016458,0.00014771908],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001423744,0.00063634873,0.0021489498,0.00028254127,0.00021448913,0.000032925724,0.00085559895,0.000281525,0.0044126445],"category_scores_gemma":[0.0000920037,0.0004074138,0.0021361944,0.0006963103,0.0001850563,0.00002241371,0.00012176826,0.0009163918,0.00001126097],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003418176,0.0001943415,0.0000020627656,0.002139368,0.0017817209,0.00006716078,0.00040158944,0.000009676482,0.005480901,0.000090556605,0.0009710309,0.9885198],"study_design_scores_gemma":[0.0018936734,0.0011133428,6.8861044e-7,0.0008035117,0.00030736165,0.00005856573,0.00012214194,0.000014903388,0.0012699546,0.000056734007,0.99403983,0.00031929588],"about_ca_topic_score_codex":0.000110582,"about_ca_topic_score_gemma":0.0000017143842,"teacher_disagreement_score":0.9930688,"about_ca_system_score_codex":0.0003320665,"about_ca_system_score_gemma":0.00089510076,"threshold_uncertainty_score":0.99983776},"labels":[],"label_agreement":null},{"id":"W4285337318","doi":"10.30699/mmlj17.4.2.19","title":"Chimeric antigen receptor (CAR) T cell therapy in hepatocellular carcinoma; a review of recent advances","year":2021,"lang":"en","type":"review","venue":"Modern Medical Laboratory Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Chimeric antigen receptor; Hepatocellular carcinoma; Cancer research; Antigen; Receptor; Medicine; Immunotherapy; Immunology; Biology; Internal medicine; Immune system","score_opus":0.0593628573079132,"score_gpt":0.3705468490452738,"score_spread":0.3111839917373606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285337318","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00056200044,0.9960236,0.00006382065,0.0004747592,0.0006306089,0.0016193561,0.00007629982,0.000025081697,0.0005244662],"genre_scores_gemma":[0.000009804512,0.9969437,0.00031425085,0.0010123182,0.0009493049,0.00010689345,0.00019544497,0.00018729358,0.00028097877],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98988307,0.002337946,0.0026279367,0.00079828495,0.003468514,0.00088422763],"domain_scores_gemma":[0.99516326,0.0003169608,0.0011164383,0.0009890152,0.0011719243,0.0012423984],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004474295,0.00078319,0.005266601,0.00058313285,0.00009767359,0.00004085147,0.0008657073,0.00077118323,0.037043],"category_scores_gemma":[0.0010117788,0.0005726223,0.0010705533,0.0022797037,0.00030714617,0.00013981656,0.00016424424,0.0041700774,0.000053242737],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000590653,0.0005841321,0.00060807006,0.059005447,0.00023134502,0.0017373794,0.00007866036,8.905751e-8,0.0002902696,0.0000015154332,0.0022698226,0.93513423],"study_design_scores_gemma":[0.0013349227,0.00032319987,0.000007256811,0.1367203,0.00022242004,0.00050922536,0.000028439606,0.000022223852,0.00019409457,0.000007036216,0.86024857,0.0003822964],"about_ca_topic_score_codex":0.000010847803,"about_ca_topic_score_gemma":0.0000033192252,"teacher_disagreement_score":0.9347519,"about_ca_system_score_codex":0.00062587403,"about_ca_system_score_gemma":0.011847094,"threshold_uncertainty_score":0.99967253},"labels":[],"label_agreement":null},{"id":"W4285389858","doi":"10.1080/10428194.2022.2092853","title":"Phase 1b, open-label study evaluating the safety and pharmacokinetics of atezolizumab (anti–PD-L1 antibody) administered in combination with Hu5F9-G4 to patients with relapsed and/or refractory acute myeloid leukemia","year":2022,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Atezolizumab; Medicine; Myeloid leukemia; Refractory (planetary science); Pharmacokinetics; Antibody; Oncology; Pharmacology; Internal medicine; Immunology; Cancer; Immunotherapy; Nivolumab","score_opus":0.039697565353864255,"score_gpt":0.3630186783913506,"score_spread":0.32332111303748634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285389858","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98412764,0.0006118078,0.000016438224,0.0043880665,0.00027317205,0.009137082,0.00042557283,0.00010190355,0.000918344],"genre_scores_gemma":[0.94762456,0.0027487003,0.00075971667,0.03614579,0.0005151145,0.0011081457,0.0026241483,0.0006819232,0.0077918977],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9899515,0.0012799464,0.0019291501,0.0023442262,0.0029398194,0.0015553775],"domain_scores_gemma":[0.9945693,0.00117444,0.0012198017,0.0018160425,0.00066568423,0.00055472023],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0018875317,0.0015596207,0.0027056776,0.0010595632,0.0008455735,0.00040555067,0.0012278676,0.00080857344,0.00032133114],"category_scores_gemma":[0.00021548654,0.0010925352,0.00012296585,0.0017864072,0.00081276917,0.00049857824,0.0016639541,0.0015894147,0.0000057537873],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.32022327,0.015259066,0.031254243,0.003302249,0.00587833,0.009435024,0.016234297,0.000051642095,0.019379199,0.00003463593,0.024217365,0.5547307],"study_design_scores_gemma":[0.6661444,0.099972434,0.113289766,0.0025301368,0.0037430995,0.0019294006,0.002404309,0.005592987,0.0012721354,0.000026793856,0.10018355,0.0029110045],"about_ca_topic_score_codex":0.0027150386,"about_ca_topic_score_gemma":0.00018134022,"teacher_disagreement_score":0.5518197,"about_ca_system_score_codex":0.011049716,"about_ca_system_score_gemma":0.008408324,"threshold_uncertainty_score":0.9997152},"labels":[],"label_agreement":null},{"id":"W4285492548","doi":"10.1182/blood.2022015478","title":"Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; McGill University Health Centre; Queen Elizabeth II Health Sciences Centre; Royal Victoria Regional Health Centre; Hôpital de l'Enfant-Jésus; Royal Victoria Hospital; Dalhousie University","funders":"Gilead Sciences","keywords":"Medicine; Quality of life (healthcare); Confidence interval; Visual analogue scale; Internal medicine; Phases of clinical research; Oncology; Clinical trial; Physical therapy","score_opus":0.029688413766771723,"score_gpt":0.32612921224861646,"score_spread":0.29644079848184474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285492548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99586535,0.00030970934,8.5795705e-7,0.00007446122,0.00008434694,0.001556772,0.00006736505,0.000031575346,0.0020095608],"genre_scores_gemma":[0.9955928,0.000011162067,0.000026419511,0.00016298925,0.00002254376,0.00025166772,0.000052687872,0.00004272818,0.0038370583],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972984,0.0002482295,0.0008024348,0.0004174174,0.00078981195,0.0004436606],"domain_scores_gemma":[0.9988844,0.000105220046,0.00017841005,0.00064179953,0.00006954733,0.00012064751],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007030301,0.00019036743,0.0006408431,0.000567282,0.000053762928,0.000007332146,0.00016909899,0.000053549633,0.005626909],"category_scores_gemma":[0.000092183596,0.00018417134,0.00011463791,0.00081596995,0.000025950329,0.000040300547,0.00026836607,0.00031933692,0.0000071478426],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002152205,0.2336287,0.5464619,0.0001152204,0.00033244296,0.0040552476,0.007383882,0.000014224706,0.19857126,0.0000037109623,0.00010606402,0.007175147],"study_design_scores_gemma":[0.5549692,0.025180155,0.23320395,0.00005774343,0.00032168985,0.00022926158,0.01743789,0.00044277086,0.16181682,0.000044890505,0.0056655356,0.000630132],"about_ca_topic_score_codex":0.00042014918,"about_ca_topic_score_gemma":0.00057021534,"teacher_disagreement_score":0.552817,"about_ca_system_score_codex":0.00014973588,"about_ca_system_score_gemma":0.00023264695,"threshold_uncertainty_score":0.99528205},"labels":[],"label_agreement":null},{"id":"W4285604187","doi":"10.1097/cco.0000000000000843","title":"Immunotherapy of sarcomas with modified T cells","year":2022,"lang":"en","type":"review","venue":"Current Opinion in Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Ottawa Mental Health Centre","funders":"","keywords":"Medicine; Chimeric antigen receptor; Cancer research; Immunotherapy; Synovial sarcoma; Immune system; Antigen; T cell; Cell therapy; Immunology; T-cell receptor; Sarcoma; Cell; Pathology; Biology","score_opus":0.23424564148982915,"score_gpt":0.48614584247148124,"score_spread":0.2519002009816521,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285604187","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000013434113,0.9902917,0.000025542913,0.000053955555,0.003715391,0.0023530012,0.000047106256,0.000028294568,0.0034715792],"genre_scores_gemma":[0.0000027939475,0.99763954,0.00009742003,0.000012922363,0.0003969395,0.00069905206,0.0004060718,0.00009420753,0.0006510625],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99671924,0.00075616286,0.000976784,0.0005414803,0.00055285415,0.0004534579],"domain_scores_gemma":[0.99779725,0.0007741999,0.0005035406,0.00074037997,0.00006865688,0.000115999246],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00074393785,0.00039666257,0.0027499709,0.0008054415,0.00004021667,0.00000660569,0.0004278734,0.00032272923,0.0080184145],"category_scores_gemma":[0.000032977117,0.00030505066,0.00044225395,0.0008438119,0.00023558475,0.000025421701,0.00016948828,0.0016542416,0.00003036509],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047960968,0.0009560058,0.000016067237,0.017961843,0.00018550442,0.000013748797,0.00020154122,0.0000029348832,0.000027640504,0.00017605226,0.0016595251,0.9783195],"study_design_scores_gemma":[0.0026788986,0.002042411,0.0000073298816,0.006150414,0.00008738419,0.0001364737,0.000046125508,0.000009621458,0.0000064113924,0.00001957676,0.98857796,0.0002373628],"about_ca_topic_score_codex":0.00002832841,"about_ca_topic_score_gemma":0.0000018733404,"teacher_disagreement_score":0.98691845,"about_ca_system_score_codex":0.0011731439,"about_ca_system_score_gemma":0.0022730683,"threshold_uncertainty_score":0.99994016},"labels":[],"label_agreement":null},{"id":"W4285726954","doi":"10.1007/s40273-022-01169-z","title":"The Cost Effectiveness of Axicabtagene Ciloleucel Versus Best Supportive Care in the Treatment of Adult Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL) After Two or More Lines of Systemic Therapy in Canada","year":2022,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Gilead Sciences (Canada); McMaster University","funders":"Gilead Sciences","keywords":"Medicine; Aggressive lymphoma; Cost effectiveness; Quality of life (healthcare); Quality-adjusted life year; Health care; Health economics; Public health; Lymphoma; Health administration; Quality of Life Research; Rituximab; Cost-effectiveness analysis; Intensive care medicine; Oncology; Internal medicine; Risk analysis (engineering); Nursing","score_opus":0.021292195897557455,"score_gpt":0.32236795008721936,"score_spread":0.3010757541896619,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285726954","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949869,0.0013531058,3.936269e-7,0.000039498907,0.00021887559,0.0025745735,0.0007131441,0.0000031108018,0.00011039978],"genre_scores_gemma":[0.99633557,0.0024558841,0.0000044204344,0.00007585262,0.000029445306,0.00084950804,0.00010477584,0.000039707174,0.00010482833],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99808925,0.0004843541,0.0005381157,0.00026743658,0.00031232904,0.0003085329],"domain_scores_gemma":[0.9979218,0.001074707,0.00030637207,0.00041027815,0.00022169796,0.0000651299],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036715946,0.00021474321,0.0005444223,0.000117238604,0.000058779726,0.000005132151,0.00025827895,0.000029786439,0.0002477952],"category_scores_gemma":[0.000018350038,0.00011749979,0.00008814367,0.00024700744,0.000087928514,0.00004251345,0.000044801654,0.00015264342,6.080516e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42984402,0.0073697525,0.47330862,0.0008528711,0.0007740229,0.00026759948,0.015890699,0.0010709045,0.012544731,0.0000037826505,0.00006254686,0.05801045],"study_design_scores_gemma":[0.439332,0.03055054,0.14430559,0.0006181967,0.0004837074,0.00003367684,0.097282834,0.0016317806,0.27601275,0.0000018808836,0.008989558,0.0007574905],"about_ca_topic_score_codex":0.11385025,"about_ca_topic_score_gemma":0.24620423,"teacher_disagreement_score":0.32900304,"about_ca_system_score_codex":0.002386184,"about_ca_system_score_gemma":0.0022766814,"threshold_uncertainty_score":0.8920507},"labels":[],"label_agreement":null},{"id":"W4286298413","doi":"10.1200/jco.2022.40.16_suppl.11515","title":"INT230-6 monotherapy and in combination with ipilimumab (IPI) across a broad spectrum of refractory soft tissue sarcomas (STS) [Intensity IT-01; BMS#CA184-592].","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Cancer; Internal medicine; Nausea; Combination therapy; Gastroenterology; Adverse effect; Vomiting; Common Terminology Criteria for Adverse Events; Oncology","score_opus":0.09199061574928084,"score_gpt":0.4698823754610562,"score_spread":0.37789175971177535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286298413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9805474,0.000746468,0.00012025812,0.016808862,0.00051422534,0.00043594697,0.000006405066,0.000009607925,0.00081081735],"genre_scores_gemma":[0.99453527,0.0013341844,0.00058608403,0.0019910175,0.00031505877,0.000008502983,0.000004138004,0.000035522866,0.0011901995],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9953546,0.0009707404,0.0020996458,0.00030961513,0.0008705564,0.00039485245],"domain_scores_gemma":[0.9952159,0.002253323,0.0014690933,0.0003291471,0.00042099712,0.0003115176],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.006248058,0.0001846583,0.0018060064,0.00029177495,0.00009193774,0.00001281081,0.00027579482,0.00027707245,0.0013404931],"category_scores_gemma":[0.0011564196,0.00014570034,0.00023534909,0.00038521897,0.00056483713,0.00013799426,0.00018373042,0.0026738015,0.000004131447],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16645157,0.011640949,0.28001237,0.00013339601,0.0008964923,0.003077297,0.0036669285,0.000120592355,0.032196954,0.00008801225,0.0044861757,0.49722928],"study_design_scores_gemma":[0.05108101,0.0838832,0.64023393,0.00016256304,0.00013278848,0.0025930994,0.0024126042,0.0005391884,0.0021032672,0.0013607419,0.21522728,0.00027034097],"about_ca_topic_score_codex":0.00020513734,"about_ca_topic_score_gemma":0.0005249907,"teacher_disagreement_score":0.4969589,"about_ca_system_score_codex":0.00056628336,"about_ca_system_score_gemma":0.0013132793,"threshold_uncertainty_score":0.99962705},"labels":[],"label_agreement":null},{"id":"W4286487914","doi":"10.3389/fimmu.2022.864868","title":"Programmable Attenuation of Antigenic Sensitivity for a Nanobody-Based EGFR Chimeric Antigen Receptor Through Hinge Domain Truncation","year":2022,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; National Research Council Canada; Institute of Infection and Immunity; University of Ottawa","funders":"National Research Council Canada","keywords":"Epitope; Jurkat cells; Antigen; Chimeric antigen receptor; Cancer research; Epidermal growth factor receptor; Molecular biology; Biology; Chemistry; Receptor; Cell biology; Immunotherapy; Immunology; T cell; Immune system; Biochemistry","score_opus":0.0204181923470274,"score_gpt":0.29256436696106125,"score_spread":0.27214617461403384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286487914","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94969845,0.0019474672,0.043019157,0.0015337876,0.0011524967,0.0023252228,0.000048202368,0.000059381546,0.00021582219],"genre_scores_gemma":[0.9033956,0.0003054187,0.09310257,0.00022187507,0.000096100004,0.0007987478,0.0008116208,0.000070512964,0.001197579],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99794656,0.00050428184,0.00040196138,0.00038269558,0.00030322364,0.00046127688],"domain_scores_gemma":[0.9990618,0.000119700126,0.00021643055,0.0004360443,0.00013655491,0.000029442923],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011998675,0.00015912439,0.0005201772,0.0003647365,0.00017544325,0.000007857724,0.0001396124,0.0001228377,0.00036832356],"category_scores_gemma":[0.00013811351,0.0001744821,0.00016572367,0.0007754122,0.0002375662,0.00008652014,0.00007220845,0.00035046565,0.0000038526],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0052201175,0.00067341176,0.047702655,0.0001224048,0.00032828047,0.000012324446,0.0017216754,0.00014729057,0.8803342,0.00016272935,0.0034442176,0.060130715],"study_design_scores_gemma":[0.03004689,0.00874575,0.08253319,0.00018336455,0.00020014873,0.00013704627,0.00899193,0.015080559,0.34098163,0.004354234,0.5077076,0.0010376911],"about_ca_topic_score_codex":0.00030889612,"about_ca_topic_score_gemma":0.000019350588,"teacher_disagreement_score":0.53935254,"about_ca_system_score_codex":0.0005733648,"about_ca_system_score_gemma":0.00039259682,"threshold_uncertainty_score":0.7115174},"labels":[],"label_agreement":null},{"id":"W4286539391","doi":"10.2139/ssrn.4163142","title":"CD137 (4-1BB) Signaling Drives a TcR-Independent Exhaustion Program in CD8 T Cells","year":2022,"lang":"en","type":"article","venue":"SSRN Electronic Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"CD137; Immunosurveillance; CD8; T cell; Cancer immunotherapy; Cancer research; Immunotherapy; T-cell receptor; TIGIT; Cytotoxic T cell; Naive T cell; Biology; Cell biology; Immune system; Immunology; Genetics","score_opus":0.015279837366658883,"score_gpt":0.3058047767977226,"score_spread":0.2905249394310637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286539391","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931997,0.002510821,0.00044081575,0.0011784923,0.00025027967,0.00097011914,0.0000021317592,0.00007758051,0.0013700553],"genre_scores_gemma":[0.9851088,0.0015764924,0.00015907944,0.00010416293,0.00044175264,0.0001298383,0.00001382351,0.000059094735,0.012406978],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9950885,0.00030739463,0.0004507241,0.0003484192,0.0011432086,0.0026617567],"domain_scores_gemma":[0.99925786,0.000063534426,0.00014682954,0.00024842267,0.00009525619,0.00018810922],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0033254412,0.0002042976,0.0003309826,0.0005146202,0.00032209264,0.00006766856,0.00029880524,0.00008055833,0.0025970286],"category_scores_gemma":[0.000037040983,0.00019664335,0.00021649024,0.0006204191,0.00005318826,0.00011659491,0.00012740538,0.005532572,0.000030803905],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019834703,0.001546515,0.0069748373,0.000044804154,0.00039707447,0.00044935194,0.0012108575,0.0014845335,0.72537965,0.0026802323,0.00024216996,0.2576065],"study_design_scores_gemma":[0.07376341,0.066348314,0.013797532,0.0008930673,0.0011325304,0.041807197,0.11120966,0.018275665,0.20691518,0.20448028,0.2568416,0.0045355693],"about_ca_topic_score_codex":0.00013936359,"about_ca_topic_score_gemma":0.0002577198,"teacher_disagreement_score":0.51846445,"about_ca_system_score_codex":0.0041776057,"about_ca_system_score_gemma":0.003948174,"threshold_uncertainty_score":0.9996452},"labels":[],"label_agreement":null},{"id":"W4288796560","doi":"10.26443/msurj.v15i1.14","title":"Delivering the “Living Drug”: T Cell Immunotherapy","year":2020,"lang":"en","type":"article","venue":"McGill Science Undergraduate Research Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"McGill University","keywords":"Nanocarriers; Immunotherapy; Medicine; Drug delivery; Drug; Immune system; Chimeric antigen receptor; Cancer; Cancer immunotherapy; Chemotherapy; Cancer research; Immunology; Pharmacology; Nanotechnology; Internal medicine","score_opus":0.08844678524879877,"score_gpt":0.3765944185495841,"score_spread":0.2881476333007853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4288796560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7071026,0.001577932,0.0006890893,0.21057315,0.00035730927,0.0012776101,0.000007097049,0.00013218327,0.07828302],"genre_scores_gemma":[0.98991793,0.0040766965,0.00054570637,0.0012935061,0.00048957486,0.000013655632,4.1715612e-7,0.000049929444,0.0036125965],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9917333,0.00065366656,0.00044437748,0.0005815409,0.0048379144,0.0017491692],"domain_scores_gemma":[0.99600697,0.0008212832,0.0001086125,0.0005656403,0.0012811235,0.0012163835],"candidate_categories":["sts","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.011002956,0.00021991042,0.00030071937,0.0005502981,0.004355576,0.0006558856,0.0016502668,0.000053596348,0.0013511751],"category_scores_gemma":[0.0012474544,0.00014005369,0.00021894269,0.003665754,0.0019292542,0.0005721218,0.00059534993,0.0028600858,0.0003028355],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026169026,0.00013152347,0.0010772302,0.00003869754,0.000046901638,0.00025240902,0.0011494361,0.00012045303,0.94314164,0.00078629644,0.0024076686,0.05058605],"study_design_scores_gemma":[0.0064013544,0.0037893252,0.009302298,0.0007823481,0.000057131907,0.003853681,0.008058719,0.026760263,0.4197284,0.0076116943,0.5124948,0.001159994],"about_ca_topic_score_codex":0.00020256932,"about_ca_topic_score_gemma":0.000017715269,"teacher_disagreement_score":0.52341324,"about_ca_system_score_codex":0.00079957227,"about_ca_system_score_gemma":0.0011109628,"threshold_uncertainty_score":0.9995617},"labels":[],"label_agreement":null},{"id":"W4289878670","doi":"10.1093/noajnl/vdac078.094","title":"SYST-15 TARGETING AXONAL GUIDANCE WITH ANTI-ROBO1 CAR T CELLS: A NEW THERAPEUTIC STRATEGY FOR MALIGNANT BRAIN CANCER","year":2022,"lang":"en","type":"article","venue":"Neuro-Oncology Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; National Research Council Canada; McMaster University","funders":"","keywords":"Cancer research; Cancer; Brain metastasis; Medicine; Metastasis; Population; Pathology; Internal medicine","score_opus":0.04391509565129528,"score_gpt":0.36081792638833643,"score_spread":0.3169028307370412,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4289878670","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8300984,0.09197882,0.0073574367,0.04528821,0.0048084133,0.011473014,0.00052313035,0.00075408927,0.0077184853],"genre_scores_gemma":[0.9637648,0.0020993794,0.003584052,0.013579888,0.0017082985,0.0025310765,0.00008197341,0.00024444395,0.012406103],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99680907,0.00047700887,0.00044348172,0.0008031509,0.0006113047,0.0008559989],"domain_scores_gemma":[0.9976852,0.0012591359,0.00025733566,0.0003729762,0.00018146288,0.00024387299],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006911933,0.0003280676,0.00069138873,0.00016520642,0.0004927039,0.000026772963,0.000366978,0.000102825274,0.0025953534],"category_scores_gemma":[0.000107355685,0.00027205338,0.00015147947,0.0004734142,0.00025532008,0.00014850684,0.00012051668,0.00083224726,0.000008231459],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024969454,0.00022865635,0.0041128346,0.0002237041,0.00016711182,0.00035306264,0.0003787927,0.012850332,0.92146647,0.00023315182,0.010097725,0.047391217],"study_design_scores_gemma":[0.00556518,0.0064359535,0.0006266992,0.0000786878,0.00012433293,0.0004032533,0.0012735332,0.001253577,0.07502054,0.0003513112,0.9084808,0.00038612928],"about_ca_topic_score_codex":0.0001442036,"about_ca_topic_score_gemma":0.00020153819,"teacher_disagreement_score":0.8983831,"about_ca_system_score_codex":0.0004078401,"about_ca_system_score_gemma":0.0016326642,"threshold_uncertainty_score":0.9999732},"labels":[],"label_agreement":null},{"id":"W4289918643","doi":"10.1038/s41434-022-00358-x","title":"Preclinical assessment of antigen-specific chimeric antigen receptor regulatory T cells for use in solid organ transplantation","year":2022,"lang":"en","type":"article","venue":"Gene Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":62,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"Sangamo Therapeutics","keywords":"Immunosuppression; Immunology; Transplantation; Antigen; Human leukocyte antigen; Biology; Immune system; Tacrolimus; Peripheral blood mononuclear cell; Proinflammatory cytokine; Humanized mouse; Medicine; In vitro; Inflammation; Internal medicine","score_opus":0.08355808030394156,"score_gpt":0.3849365013374286,"score_spread":0.30137842103348705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4289918643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99550027,0.0010294892,0.00084974355,0.00021585311,0.00035417295,0.0018062494,0.000116440686,0.00003805451,0.000089727524],"genre_scores_gemma":[0.9643698,0.026224585,0.007348523,0.00027121996,0.0002269045,0.0002291502,0.0003369538,0.000090254274,0.00090265716],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99769515,0.00030605227,0.00057377055,0.00043269678,0.00059407466,0.0003982395],"domain_scores_gemma":[0.99888724,0.00023615595,0.00015067072,0.00051675824,0.00010593492,0.000103218255],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012052554,0.00017774681,0.00046879024,0.00026257828,0.000118887096,0.00001552623,0.00020401663,0.00008194236,0.004492108],"category_scores_gemma":[0.000006298753,0.00017510299,0.00019209633,0.00044330617,0.00008788552,0.00006940639,0.00003061366,0.0003110885,0.000004941916],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031844885,0.0006602986,0.024367243,0.000033781598,0.00012091878,0.000010575491,0.00083229993,0.00018397805,0.9407838,0.000019389685,0.0006760968,0.029127104],"study_design_scores_gemma":[0.0067798984,0.0020901,0.22084591,0.000025819108,0.000009963578,0.000016919439,0.00016234891,0.00043664774,0.7245378,0.00003476862,0.04485345,0.00020639079],"about_ca_topic_score_codex":0.00003703172,"about_ca_topic_score_gemma":0.000008741998,"teacher_disagreement_score":0.21624604,"about_ca_system_score_codex":0.0001821271,"about_ca_system_score_gemma":0.00030935605,"threshold_uncertainty_score":0.99641794},"labels":[],"label_agreement":null},{"id":"W4290851731","doi":"10.1016/j.jtct.2022.08.010","title":"The Cost-Effectiveness of Axicabtagene Ciloleucel as Second-Line Therapy in Patients with Large B-Cell Lymphoma in the United States: An Economic Evaluation of the ZUMA-7 Trial","year":2022,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Institutes of Health; Miltenyi Biotec; Kite Pharma; Division of Cancer Prevention, National Cancer Institute; Gilead Sciences; AstraZeneca; Bristol-Myers Squibb; National Cancer Institute; AbbVie; Merck; Roche; Astellas Pharma US; Amgen","keywords":"Medicine; Chemoimmunotherapy; Cost effectiveness; Quality-adjusted life year; Clinical trial; Oncology; Internal medicine; Lymphoma; Rituximab","score_opus":0.041125326873381204,"score_gpt":0.3165985277671497,"score_spread":0.2754732008937685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4290851731","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946718,0.00043721846,0.000027660943,0.00009294539,0.000077648576,0.0043938705,0.00010527367,0.0000061380756,0.0001874003],"genre_scores_gemma":[0.9971178,0.0015561833,0.0000021361977,0.00017556675,0.0000165755,0.00039677805,0.0006512914,0.000024617451,0.000059061822],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99585134,0.0026167282,0.00037877486,0.00022885282,0.00071618514,0.0002080939],"domain_scores_gemma":[0.9989165,0.00039476782,0.00016373808,0.00037127975,0.00011802225,0.00003571051],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041393405,0.00015696223,0.00025411873,0.00016651551,0.00017887852,0.000019150424,0.00024394081,0.000049237708,0.000525059],"category_scores_gemma":[0.0000044677263,0.000085057596,0.00007213086,0.00040412226,0.00011419475,0.00006181554,0.0000092513255,0.00020148137,6.631718e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.689983,0.010717334,0.05409516,0.00027963982,0.00041953163,0.000019682266,0.036067355,0.006458394,0.09743915,0.00049058016,0.000009959316,0.10402018],"study_design_scores_gemma":[0.5285041,0.01135789,0.27111244,0.00008337739,0.00011487784,0.000011565236,0.0047103525,0.0075179753,0.17383574,0.00044427157,0.0020147816,0.0002926162],"about_ca_topic_score_codex":0.00033872278,"about_ca_topic_score_gemma":0.00020861617,"teacher_disagreement_score":0.2170173,"about_ca_system_score_codex":0.00013908914,"about_ca_system_score_gemma":0.0002595455,"threshold_uncertainty_score":0.57490283},"labels":[],"label_agreement":null},{"id":"W4292018553","doi":"10.1182/bloodadvances.2022008150","title":"Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma","year":2022,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Internal medicine; Refractory (planetary science); Confidence interval; Odds ratio; Oncology","score_opus":0.0166545374254523,"score_gpt":0.31204105543230126,"score_spread":0.29538651800684895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292018553","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939026,0.0041816356,0.0000025073734,0.0000344694,0.00008760141,0.0007815302,0.000030401265,0.00003353142,0.0009457002],"genre_scores_gemma":[0.9982802,0.0000686547,0.00039458697,0.00005668359,0.00003845442,0.000075605545,0.00010915814,0.000039966337,0.0009366525],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979812,0.00014059065,0.0003397089,0.00033325507,0.0009028272,0.00030240064],"domain_scores_gemma":[0.9991185,0.00014255676,0.00014606364,0.0003827336,0.00011293146,0.00009721287],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00012808731,0.00016118003,0.00048108958,0.00018473674,0.00010048113,0.0000070091037,0.00018476596,0.00004338697,0.0009433937],"category_scores_gemma":[0.000069641326,0.00012541607,0.00007066386,0.0005343588,0.00008893285,0.00009010511,0.000102514125,0.00023787166,0.0000041061344],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023043672,0.005441908,0.83839506,0.00024965726,0.00017872015,0.00014947451,0.0033758718,0.00035716634,0.0048344536,0.000008926876,0.000108899956,0.12385622],"study_design_scores_gemma":[0.0628276,0.022680722,0.7575998,0.00023659771,0.00020861963,0.000017315484,0.005046056,0.000052191197,0.025841005,0.000007015986,0.12507537,0.00040773186],"about_ca_topic_score_codex":0.000049353464,"about_ca_topic_score_gemma":0.00009615009,"teacher_disagreement_score":0.124966465,"about_ca_system_score_codex":0.00016525885,"about_ca_system_score_gemma":0.0002214718,"threshold_uncertainty_score":0.9999699},"labels":[],"label_agreement":null},{"id":"W4292302487","doi":"10.7759/cureus.28162","title":"Cardiotoxicity Associated With Chimeric Antigen Receptor (CAR)-T Cell Therapy for Hematologic Malignancies: A Systematic Review","year":2022,"lang":"en","type":"review","venue":"Cureus","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Systematic review; Cochrane Library; Chimeric antigen receptor; Cardiotoxicity; Randomized controlled trial; MEDLINE; Clinical trial; Adverse effect; Intensive care medicine; Narrative review; Internal medicine; Cancer; Immunotherapy; Chemotherapy","score_opus":0.09833758926295857,"score_gpt":0.364639551080973,"score_spread":0.26630196181801447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292302487","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000028401308,0.97142017,0.000019747498,0.0000402776,0.00025012344,0.026286637,0.00031981754,0.00020825591,0.0014265842],"genre_scores_gemma":[0.0000035802063,0.98039013,0.0001383224,0.0004192922,0.00015323926,0.010331098,0.0011822885,0.00028668437,0.0070953625],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99413395,0.0013256528,0.0014225604,0.0010199795,0.0011993196,0.00089855574],"domain_scores_gemma":[0.99514645,0.0012776768,0.0012634062,0.0017415481,0.00028888302,0.0002820573],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0023363442,0.00096428837,0.008827708,0.00020035078,0.00024908292,0.000052383333,0.0008215521,0.0004412944,0.0053867],"category_scores_gemma":[0.0010442465,0.0006118586,0.0021352617,0.001351538,0.00012919959,0.000057831814,0.00014158011,0.00092347857,0.00008266071],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006010269,0.00038227253,0.0000052714922,0.9799378,0.0029946873,0.0000804623,0.00008418442,6.621379e-8,0.00008298312,0.000005141251,0.006998402,0.009368622],"study_design_scores_gemma":[0.0007686322,0.0010174463,4.4430223e-7,0.33595473,0.003240557,0.0002255743,0.000052843123,0.0000012898691,0.00003074802,0.0000024220603,0.6582041,0.0005012153],"about_ca_topic_score_codex":0.000027708149,"about_ca_topic_score_gemma":0.000003902364,"teacher_disagreement_score":0.65120566,"about_ca_system_score_codex":0.001289185,"about_ca_system_score_gemma":0.0012826604,"threshold_uncertainty_score":0.99963325},"labels":[],"label_agreement":null},{"id":"W4292999428","doi":"10.54097/hset.v8i.1182","title":"T Recent advances of FDA-approved CAR-T therapies in multiple myeloma","year":2022,"lang":"en","type":"article","venue":"Highlights in Science Engineering and Technology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Multiple myeloma; Clinical trial; Intensive care medicine; Drug; Cytokine release syndrome; Adverse effect; Refractory (planetary science); Cancer; Oncology; Chimeric antigen receptor; Internal medicine; Pharmacology; Immunotherapy","score_opus":0.014804054338159572,"score_gpt":0.26465415265699166,"score_spread":0.2498500983188321,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292999428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913207,0.0054370402,0.000021736527,0.0025124135,0.00015026992,0.0002426553,0.0000025375427,0.00007745245,0.00023517563],"genre_scores_gemma":[0.9955319,0.0031452316,0.0010735074,0.00001072777,0.000011322586,0.00008405514,8.6438536e-7,0.0000097657485,0.00013258898],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988532,0.000013524069,0.00020112582,0.00029942853,0.00030979826,0.00032292158],"domain_scores_gemma":[0.99954295,0.0000701799,0.000032110103,0.00026495356,0.000049646555,0.000040145886],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005066449,0.00009336667,0.00023566211,0.0013248308,0.00007128165,0.000006033949,0.0002481213,0.00005252818,0.000059091322],"category_scores_gemma":[0.00016997701,0.00008072489,0.0000146053335,0.0025102007,0.00042340744,0.00007163881,0.0001810458,0.00031134486,0.0000012812977],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007183323,0.00010828303,0.013674713,0.00003460946,0.00000695144,0.000048516144,0.0007241558,0.0010295652,0.8951289,0.00727065,0.000008051236,0.08189374],"study_design_scores_gemma":[0.0030875497,0.0009825331,0.023193344,0.00010422542,0.0000062556483,0.00015589193,0.0022573117,0.0201704,0.4224449,0.0007641608,0.5265043,0.0003291648],"about_ca_topic_score_codex":0.000021734166,"about_ca_topic_score_gemma":0.000035125297,"teacher_disagreement_score":0.52649623,"about_ca_system_score_codex":0.00015016299,"about_ca_system_score_gemma":0.00009020577,"threshold_uncertainty_score":0.32918653},"labels":[],"label_agreement":null},{"id":"W4293105725","doi":"10.1126/sciadv.abn5522","title":"DLL4 and VCAM1 enhance the emergence of T cell–competent hematopoietic progenitors from human pluripotent stem cells","year":2022,"lang":"en","type":"article","venue":"Science Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; Université de Montréal; University of Toronto; Institute for Research in Immunology and Cancer; University of British Columbia","funders":"","keywords":"Progenitor cell; Haematopoiesis; Cell biology; Induced pluripotent stem cell; Stem cell; Biology; CD8; T cell; Immunology; Antigen; Immune system; Embryonic stem cell; Biochemistry","score_opus":0.019063850418005956,"score_gpt":0.3141233819719036,"score_spread":0.29505953155389764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293105725","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99243605,0.005173774,0.000037987076,0.0004078363,0.00042566366,0.00062367757,0.000014643184,0.000024020888,0.0008563431],"genre_scores_gemma":[0.99667245,0.00024992114,0.00040255065,0.000075178265,0.00006798158,0.000093038,0.0000014752391,0.000012362789,0.0024250248],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972954,0.00008253376,0.00031375277,0.00051122106,0.0014007335,0.00039639708],"domain_scores_gemma":[0.99895805,0.000095550495,0.00015641132,0.00052598846,0.0001182257,0.00014579264],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00082751137,0.00013703249,0.000237304,0.00011170444,0.00077503413,0.000029296638,0.0006217345,0.000015135314,0.0014310507],"category_scores_gemma":[0.000012935772,0.000095675845,0.00006962913,0.00083401933,0.0012017047,0.00018498822,0.00039663806,0.00025397647,0.000008220416],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000040718744,0.00010124187,0.0017388412,0.00004739795,0.000007596768,0.000009054876,0.0014336902,0.00009449379,0.98737735,0.000060017494,0.00003920545,0.009050369],"study_design_scores_gemma":[0.00026528194,0.00041401727,0.0008994254,0.000028090793,0.000017141778,0.000011660362,0.0061673024,0.00010660305,0.9856499,0.0003588137,0.0059717027,0.00011005483],"about_ca_topic_score_codex":0.00008047881,"about_ca_topic_score_gemma":0.000013124399,"teacher_disagreement_score":0.008940314,"about_ca_system_score_codex":0.00006967522,"about_ca_system_score_gemma":0.00020009205,"threshold_uncertainty_score":0.9994818},"labels":[],"label_agreement":null},{"id":"W4293240917","doi":"10.21203/rs.3.rs-1587568/v1","title":"Safety and efficacy of allogeneic hematopoietic stem cell transplantation in R/R B-NHL patients with disease progression after CAR-T therapy","year":2022,"lang":"en","type":"preprint","venue":"Research Square","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"York University","keywords":"Medicine; Lymphoma; Internal medicine; Hematopoietic stem cell transplantation; Transplantation; Gastroenterology; Regimen; Lymphoblastic lymphoma; Chemotherapy; Surgery; Oncology; T cell; Immunology","score_opus":0.029394059129100415,"score_gpt":0.3602616442129119,"score_spread":0.3308675850838115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293240917","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98727727,0.005500873,0.000011414857,0.0002456363,0.00004300718,0.0061733103,0.00032556802,0.000031756783,0.00039116482],"genre_scores_gemma":[0.9897262,0.00749151,0.00006216165,0.000016885462,0.000047112437,0.0009621379,0.0008136473,0.00010221612,0.0007781694],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9939083,0.00112373,0.0005359665,0.00089489104,0.0028549684,0.000682135],"domain_scores_gemma":[0.9975824,0.00043371928,0.00012589556,0.0009263989,0.0004796555,0.00045197067],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001382666,0.0003468706,0.0006498905,0.00078282814,0.00012003705,0.000048171998,0.00029054395,0.00021281703,0.0021369122],"category_scores_gemma":[0.000028136394,0.0002663156,0.00015582702,0.0005805807,0.00031010783,0.00005863986,0.00041843602,0.001778969,0.0000057617726],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.072054215,0.0024984516,0.8684232,0.009736218,0.00012042466,0.0006185416,0.005207773,0.00016754189,0.0013571637,0.000007747496,0.000019929863,0.03978877],"study_design_scores_gemma":[0.010454307,0.0019808,0.9816353,0.0026701186,0.000048594866,0.000004223463,0.00043256854,0.0000627352,0.0016311983,0.000033596716,0.0007617973,0.0002847781],"about_ca_topic_score_codex":0.00011283295,"about_ca_topic_score_gemma":0.000027700034,"teacher_disagreement_score":0.113212064,"about_ca_system_score_codex":0.00043262113,"about_ca_system_score_gemma":0.000857592,"threshold_uncertainty_score":0.9999789},"labels":[],"label_agreement":null},{"id":"W4293786422","doi":"10.1182/bloodadvances.2022007779","title":"Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r/r DLBCL: phase 1b PORTIA study results","year":2022,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"Novartis Pharmaceuticals Corporation","keywords":"Pembrolizumab; Medicine; Internal medicine; Oncology; Immunotherapy","score_opus":0.014657238399119334,"score_gpt":0.31693442509164627,"score_spread":0.30227718669252696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293786422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955843,0.00097514596,0.000002513281,0.00007062562,0.00004659235,0.0015027879,0.00009250258,0.000025745072,0.0016997484],"genre_scores_gemma":[0.9984875,0.00010194017,0.00009555269,0.000032708518,0.000029263565,0.000045833967,0.00006830039,0.000028130811,0.0011108171],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979794,0.00013352634,0.00045272784,0.00040245077,0.0007491394,0.0002827649],"domain_scores_gemma":[0.99913394,0.0001383155,0.00016107678,0.00037570644,0.0000791721,0.00011177014],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00037069243,0.00015389576,0.0004254365,0.00018678584,0.000100685305,0.000007798048,0.00012999996,0.00002147064,0.00026352503],"category_scores_gemma":[0.00010253554,0.00012763792,0.000035685312,0.00045846342,0.000095808915,0.00009309017,0.00013638842,0.00028269095,0.0000012324131],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19245207,0.06042449,0.57244825,0.00019779682,0.00053037715,0.00063478586,0.0070740026,0.00042808274,0.002865063,0.000020101328,0.00007578406,0.1628492],"study_design_scores_gemma":[0.33431295,0.01990524,0.6347353,0.00006559044,0.00017243516,0.00002759882,0.0017105088,0.000054850665,0.0012783664,0.000010069677,0.007498298,0.00022878876],"about_ca_topic_score_codex":0.000083925974,"about_ca_topic_score_gemma":0.00008115916,"teacher_disagreement_score":0.16262041,"about_ca_system_score_codex":0.00007488937,"about_ca_system_score_gemma":0.00013950226,"threshold_uncertainty_score":0.5204923},"labels":[],"label_agreement":null},{"id":"W4295452672","doi":"10.1007/978-1-0716-2712-9_12","title":"A High-Throughput Strategy for T-Cell Receptor Cloning and Expression","year":2022,"lang":"en","type":"article","venue":"Methods in molecular biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"National Institute of Allergy and Infectious Diseases","keywords":"T-cell receptor; Cloning (programming); clone (Java method); Biology; Gene; Plasmid; Computational biology; Expression cloning; Molecular biology; Genetics; T cell; Computer science; Peptide sequence; Immune system","score_opus":0.060910807934350865,"score_gpt":0.4576712093672733,"score_spread":0.3967604014329224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295452672","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.34793907,0.002302501,0.64690346,0.00059022894,0.00028305888,0.0010310963,0.000021065873,0.000035468816,0.000894081],"genre_scores_gemma":[0.035224862,0.0001046196,0.9618911,0.0004870491,0.00007146267,0.00046664334,0.000080028294,0.00004189515,0.0016323467],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99746954,0.0014039865,0.00023581136,0.0004382256,0.000104697334,0.0003477596],"domain_scores_gemma":[0.9991393,0.00040714166,0.000057148656,0.00028611955,0.000036240184,0.00007402508],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019270375,0.00012945951,0.00034339796,0.0001765215,0.000096463664,0.000008136437,0.00012092947,0.0001185386,0.0011762562],"category_scores_gemma":[0.00022739037,0.000120176766,0.000073726536,0.00021399508,0.00009621588,0.000012382962,0.00023944078,0.00040862607,0.0000011887472],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005245065,0.00008974278,0.00037415288,0.000041806117,0.000017825125,0.000022586499,0.00015697398,0.000050431576,0.9542787,0.00086224056,0.00014956201,0.043431494],"study_design_scores_gemma":[0.0026874319,0.0017169719,0.00004643391,0.000012069834,0.000014492233,0.0000330525,0.00022845948,0.00036969894,0.93908644,0.0067868195,0.048883196,0.00013491743],"about_ca_topic_score_codex":0.00006563437,"about_ca_topic_score_gemma":0.0000014452636,"teacher_disagreement_score":0.31498766,"about_ca_system_score_codex":0.00009540633,"about_ca_system_score_gemma":0.0000827321,"threshold_uncertainty_score":0.9997368},"labels":[],"label_agreement":null},{"id":"W4295817567","doi":"10.1016/j.annonc.2022.07.861","title":"735MO Updated safety and efficacy from SURPASS, the phase I trial of ADP-A2M4CD8, a next-generation autologous T-cell receptor T-cell therapy, in previously treated patients with unresectable or metastatic tumors","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Oncology; CD8; Cancer; Adverse effect; Leukapheresis; Immunotherapy; Antigen; Immunology; CD34","score_opus":0.11352274174321512,"score_gpt":0.37618225927644733,"score_spread":0.2626595175332322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295817567","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936997,0.0006706626,0.0000059611284,0.0010919238,0.00009918287,0.0036258993,0.00020817175,0.000021561824,0.0005768844],"genre_scores_gemma":[0.99611586,0.0010601804,0.00012829741,0.0003472141,0.000057299745,0.00020341294,0.0009822919,0.0000437707,0.0010616668],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9960751,0.0016798249,0.00081678736,0.00042785174,0.00057122146,0.000429221],"domain_scores_gemma":[0.99770457,0.0009180135,0.000489499,0.00045411522,0.00030968006,0.00012409835],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013724355,0.00023954203,0.0009913403,0.00026573264,0.00012496757,0.00001472163,0.00025795394,0.000095268995,0.0032705707],"category_scores_gemma":[0.00018618499,0.00015143694,0.00010175964,0.00074984645,0.00025068794,0.00008715643,0.00011006609,0.00043951947,0.000002818932],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.65868324,0.0173646,0.0044122683,0.000060950337,0.0005217294,0.00011040861,0.002736709,0.00021969447,0.19548975,0.0000064895253,0.005927038,0.11446712],"study_design_scores_gemma":[0.5814768,0.2006162,0.005302669,0.000070319824,0.000311567,0.000022310582,0.0011387223,0.001864026,0.14100946,0.000025741214,0.06769648,0.00046567703],"about_ca_topic_score_codex":0.0017910243,"about_ca_topic_score_gemma":0.000394105,"teacher_disagreement_score":0.18325159,"about_ca_system_score_codex":0.00012765439,"about_ca_system_score_gemma":0.00082505314,"threshold_uncertainty_score":0.99764055},"labels":[],"label_agreement":null},{"id":"W4295819067","doi":"10.1016/j.annonc.2022.07.904","title":"778TiP A phase I/II trial investigating safety and efficacy of autologous TAC T-cells targeting HER2 in relapsed or refractory solid tumors","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Cytokine release syndrome; Chimeric antigen receptor; Cancer research; Immunotherapy; T cell; Cancer; Oncology; Internal medicine; Immunology; Immune system","score_opus":0.10486761897001701,"score_gpt":0.43402916207023273,"score_spread":0.3291615431002157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295819067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933143,0.00043997625,0.0000026151051,0.0025831468,0.0002093756,0.0010646975,0.000026954152,0.000027488139,0.002331426],"genre_scores_gemma":[0.9969969,0.00022658854,0.0005321607,0.00077617273,0.00015067254,0.00005403999,0.000030132307,0.000035863828,0.0011974847],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9967409,0.00086752686,0.001111303,0.0003791629,0.00042133377,0.0004798218],"domain_scores_gemma":[0.9972442,0.0015591331,0.0005586849,0.00029902268,0.00014968973,0.00018931211],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0029165577,0.0001753027,0.001082171,0.00037202603,0.00015109447,0.0000033976457,0.00019147295,0.00015988473,0.0017121648],"category_scores_gemma":[0.0023181168,0.00016070223,0.00012932242,0.00052584073,0.00042113545,0.00004116357,0.00032660417,0.00084551773,0.0000017454862],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18278117,0.004796239,0.00031021083,0.00018097502,0.0001597026,0.0005869376,0.005226729,0.00020238411,0.6809663,0.00003945536,0.0030900626,0.12165981],"study_design_scores_gemma":[0.41096485,0.23884587,0.0016054304,0.00034551657,0.00013864941,0.00035747403,0.0055951225,0.003079735,0.17750518,0.00032743032,0.16061807,0.0006166966],"about_ca_topic_score_codex":0.0002496831,"about_ca_topic_score_gemma":0.000034850713,"teacher_disagreement_score":0.5034612,"about_ca_system_score_codex":0.0001459231,"about_ca_system_score_gemma":0.0011704967,"threshold_uncertainty_score":0.9992004},"labels":[],"label_agreement":null},{"id":"W4295899536","doi":"10.1111/imcb.12587","title":"Training the next generation of Sudanese immunologists: a case for mentorship","year":2022,"lang":"en","type":"article","venue":"Immunology and Cell Biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Mentorship; Medical education; Training (meteorology); Quality (philosophy); Medicine; Psychology; Philosophy","score_opus":0.15324307596501782,"score_gpt":0.34724715435146725,"score_spread":0.19400407838644942,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295899536","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875124,0.009615067,0.00007244518,0.00093280384,0.00027721815,0.0005658363,0.000024410048,0.000017722952,0.0009820773],"genre_scores_gemma":[0.99683446,0.0004011113,0.00008998759,0.00025670495,0.00007757187,0.00029444392,0.00009890577,0.000011738012,0.0019350925],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988426,0.00037828635,0.00023116043,0.00022080225,0.000046974994,0.0002801896],"domain_scores_gemma":[0.999163,0.00039490632,0.00009312674,0.00027083536,0.00005634811,0.000021830578],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00074021734,0.000101643695,0.00025564313,0.00009620985,0.00036841028,0.0000053266094,0.000121798854,0.00012496293,0.0013253432],"category_scores_gemma":[0.00007915167,0.00007282709,0.000077549295,0.000117117226,0.00050750433,0.00002011671,0.00012714956,0.0003334188,0.0000017935037],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009812356,0.000083806844,0.00038625835,0.000016832395,0.00015170137,0.000054386946,0.0028679767,0.0000022916645,0.96014667,0.0011235968,0.000085540894,0.034099713],"study_design_scores_gemma":[0.014727786,0.019594863,0.0013110385,0.000015049264,0.0003649797,0.019179763,0.050770506,0.002432746,0.48543426,0.0041247867,0.4014453,0.0005989102],"about_ca_topic_score_codex":0.00020262992,"about_ca_topic_score_gemma":0.000033355056,"teacher_disagreement_score":0.4747124,"about_ca_system_score_codex":0.000050817813,"about_ca_system_score_gemma":0.00009473132,"threshold_uncertainty_score":0.9995876},"labels":[],"label_agreement":null},{"id":"W4295941831","doi":"10.1158/1557-3265.sarcomas22-pr005","title":"Abstract PR005: PRC2 inactivating mutations amplify cell death in response to DNMT1-targeted therapy through enhanced viral mimicry in malignant peripheral nerve sheath tumor","year":2022,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"PRC2; Cancer research; Biology; Context (archaeology); EZH2; Cancer; Epigenetics; Genetics","score_opus":0.1878447620197086,"score_gpt":0.5002895845280105,"score_spread":0.31244482250830197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295941831","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989485,0.00075390155,0.000020519412,0.004157311,0.00024629675,0.00345814,0.000074480675,0.000069836504,0.0017344787],"genre_scores_gemma":[0.9910409,0.0004233605,0.0007068633,0.0012296431,0.00036504798,0.0030592429,0.000058153015,0.00013676772,0.0029800574],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9899815,0.0035171222,0.001468396,0.0013072019,0.0020562722,0.0016695347],"domain_scores_gemma":[0.9940558,0.003972596,0.00015792249,0.0009112062,0.0004144413,0.0004880065],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.01128455,0.0003502593,0.00089104305,0.0007873459,0.00042253255,0.00009920953,0.0007091783,0.00020510767,0.009609915],"category_scores_gemma":[0.0020143632,0.00033145375,0.0002649796,0.0024693417,0.0003271965,0.00021134515,0.0005257987,0.0049109985,0.000046193963],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054363586,0.0022117659,0.060823165,0.00008165554,0.00005969528,0.0009798914,0.004829666,0.0009518134,0.86625296,0.000024393185,0.00088013936,0.008541291],"study_design_scores_gemma":[0.018513078,0.008683684,0.81183374,0.00043241182,0.000010862889,0.000035292018,0.0066883625,0.0007049505,0.1295875,0.0006380948,0.02208127,0.0007907528],"about_ca_topic_score_codex":0.00843441,"about_ca_topic_score_gemma":0.0009812365,"teacher_disagreement_score":0.75101054,"about_ca_system_score_codex":0.0031207204,"about_ca_system_score_gemma":0.003332015,"threshold_uncertainty_score":0.99991375},"labels":[],"label_agreement":null},{"id":"W4296130327","doi":"10.1158/1557-3265.sarcomas22-pr001","title":"Abstract PR001: Oncogene-induced matrix reorganization controls CD8+ T cell immunity in the UPS microenvironment","year":2022,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Tumor microenvironment; YAP1; Cancer research; Cell biology; T cell; CD8; Biology; Extracellular matrix; Cytotoxic T cell; Immunology; Immune system","score_opus":0.19123344588355604,"score_gpt":0.507720672679515,"score_spread":0.316487226795959,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296130327","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98296946,0.0014441921,0.0000030806204,0.009878872,0.00020517278,0.002319124,0.00003815615,0.0000244298,0.0031174885],"genre_scores_gemma":[0.989648,0.001780389,0.00003234997,0.0008532346,0.00051886146,0.0006512517,0.000061372484,0.0000633503,0.0063912137],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9925644,0.0028863738,0.0008645756,0.00059006823,0.0022620515,0.000832537],"domain_scores_gemma":[0.9958808,0.0023398534,0.00012142475,0.0012044745,0.00020358298,0.00024985237],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.014746562,0.00017613439,0.00046608233,0.00025607887,0.00051609497,0.00007267567,0.00093192025,0.00015532327,0.019736357],"category_scores_gemma":[0.00078760064,0.0001378709,0.00019834515,0.0011528404,0.0003216961,0.00005842687,0.0005701826,0.0042898194,0.00020870844],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005373232,0.0031991398,0.079455435,0.00015549698,0.00010487906,0.00038589246,0.0011526027,0.00010953978,0.86834633,0.000043200056,0.012289603,0.029384632],"study_design_scores_gemma":[0.01649173,0.004698574,0.5929034,0.00010908486,0.00007220164,0.000061108585,0.0052612014,0.00034893816,0.04712284,0.0003710328,0.33208627,0.00047367506],"about_ca_topic_score_codex":0.0021959292,"about_ca_topic_score_gemma":0.00024149384,"teacher_disagreement_score":0.8212235,"about_ca_system_score_codex":0.0013304792,"about_ca_system_score_gemma":0.00090240437,"threshold_uncertainty_score":0.9980073},"labels":[],"label_agreement":null},{"id":"W4296130403","doi":"10.1158/1557-3265.sarcomas22-ia011","title":"Abstract IA011: Identifying tumor-restricted target antigens for adoptive cellular immunotherapy to treat Ewing Sarcoma using multi-omic discovery platforms","year":2022,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Major histocompatibility complex; Immunotherapy; Antigen; Biology; Transcriptome; Cancer research; Sarcoma; Computational biology; Immunology; Medicine; Immune system; Gene; Gene expression; Genetics; Pathology","score_opus":0.3662698473752391,"score_gpt":0.5264424264069669,"score_spread":0.16017257903172782,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296130403","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893138,0.0021871221,0.0024233244,0.00070023804,0.0006794785,0.004065088,0.0003667077,0.00008927073,0.00017501733],"genre_scores_gemma":[0.98681694,0.00062136,0.0029130364,0.0006085272,0.0011268249,0.0010221837,0.0001436118,0.00023364674,0.0065138773],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.993062,0.000419627,0.0012899215,0.0012680086,0.0021726363,0.0017878158],"domain_scores_gemma":[0.9952019,0.0022330855,0.00020607503,0.001055633,0.0006487143,0.00065461505],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0054417457,0.00038562232,0.0010099352,0.00086277846,0.0012727713,0.00025719323,0.0008563163,0.00018089535,0.0041758],"category_scores_gemma":[0.0010025289,0.00035297236,0.00070799864,0.0016317476,0.00041447414,0.0003482981,0.0007555692,0.0027550354,0.00004687508],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015460799,0.0013254021,0.040255565,0.00030739582,0.00041821098,0.00055181957,0.0009641191,0.00074657984,0.92102885,0.00003108477,0.002191707,0.016718468],"study_design_scores_gemma":[0.062790774,0.013412616,0.36590973,0.0015631533,0.00032383957,0.00019357186,0.011622391,0.024711322,0.39723346,0.001333735,0.117802896,0.0031025433],"about_ca_topic_score_codex":0.0029609108,"about_ca_topic_score_gemma":0.00008127847,"teacher_disagreement_score":0.5237954,"about_ca_system_score_codex":0.002454952,"about_ca_system_score_gemma":0.001936264,"threshold_uncertainty_score":0.99989223},"labels":[],"label_agreement":null},{"id":"W4296130421","doi":"10.1158/1557-3265.sarcomas22-a023","title":"Abstract A023: Identifying new therapeutic indications for afamitresgene autoleucel (“afami-cel” [formerly ADP-A2M4]) in adult and pediatric sarcomas using MAGE-A4 immunohistochemistry","year":2022,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Leiomyosarcoma; Sarcoma; Medicine; Immunohistochemistry; Synovial sarcoma; Undifferentiated Pleomorphic Sarcoma; Liposarcoma; Tissue microarray; Pathology; Cancer; Dermatofibrosarcoma protuberans; Cancer research; Soft tissue sarcoma; Internal medicine","score_opus":0.2983232906111273,"score_gpt":0.5464183236075497,"score_spread":0.24809503299642244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296130421","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97831994,0.015825685,0.00010562565,0.0024255156,0.00031160752,0.0019940059,0.000081175924,0.000055725115,0.0008807017],"genre_scores_gemma":[0.98474383,0.005787629,0.00064732257,0.0003719849,0.001023978,0.00087690016,0.0000719719,0.000117765056,0.0063585923],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99461085,0.0004199542,0.0011790595,0.00097328523,0.0016592346,0.0011576214],"domain_scores_gemma":[0.99588394,0.0019739303,0.00022648004,0.0008546607,0.00048681124,0.0005741918],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004832448,0.0002716154,0.00064005784,0.00071251293,0.000710812,0.0001244357,0.00064629834,0.00025721747,0.0032852658],"category_scores_gemma":[0.0009043204,0.00028041084,0.00030208848,0.001540857,0.00038163338,0.00015325233,0.0005488743,0.0030670788,0.000019790801],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064431177,0.0017595497,0.2627071,0.0014448483,0.00042990275,0.00018710927,0.0011304725,0.000076201686,0.46508887,0.0001335029,0.0057935286,0.2548058],"study_design_scores_gemma":[0.02480821,0.0025427581,0.9263146,0.00044579507,0.0004130782,0.00011082887,0.0031211225,0.0040201703,0.008628465,0.0028994193,0.025503254,0.0011922981],"about_ca_topic_score_codex":0.0033080329,"about_ca_topic_score_gemma":0.00018793164,"teacher_disagreement_score":0.6636075,"about_ca_system_score_codex":0.0012950446,"about_ca_system_score_gemma":0.003851179,"threshold_uncertainty_score":0.99996483},"labels":[],"label_agreement":null},{"id":"W4296130477","doi":"10.1158/1557-3265.sarcomas22-a038","title":"Abstract A038: Enrollment of pediatric and adolescent patients with MAGE-A4+ advanced synovial sarcoma into cohort 2 of SPEARHEAD-1: a phase 2 trial of afamitresgene autoleucel (“afami-cel” [formerly ADP-A2M4])","year":2022,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Synovial sarcoma; Sarcoma; Cohort; Internal medicine; Soft tissue sarcoma; Oncology; Surgery; Pathology","score_opus":0.0989514237550265,"score_gpt":0.48197742497487267,"score_spread":0.3830260012198462,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296130477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923232,0.0017346413,0.000007847954,0.00034370832,0.00029519014,0.004371426,0.0002784126,0.000020479287,0.00062508037],"genre_scores_gemma":[0.9953151,0.002771667,0.0002189745,0.000058098874,0.00045987594,0.00042636515,0.00007948578,0.00007634356,0.0005940856],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9911725,0.00081740104,0.001954527,0.0008684559,0.0043590968,0.0008280559],"domain_scores_gemma":[0.995314,0.0011787078,0.00060427113,0.000965842,0.0013572657,0.0005799084],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005594085,0.00030691642,0.0013932764,0.0006649657,0.00017621735,0.000016808335,0.00053873466,0.00018561144,0.002809503],"category_scores_gemma":[0.0007613061,0.00025636886,0.00034176456,0.0012590719,0.0010599986,0.00010598307,0.00062478223,0.0019916652,0.000005154216],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4187276,0.016300514,0.3868354,0.0015474848,0.00056292623,0.00007657357,0.00032039612,0.000035795387,0.017858172,0.000010676784,0.0014341485,0.15629032],"study_design_scores_gemma":[0.2653978,0.05770312,0.6623216,0.00034082262,0.0003368639,0.0000036965394,0.000454117,0.00014443748,0.007825543,0.00006537569,0.004998312,0.00040830043],"about_ca_topic_score_codex":0.0010234457,"about_ca_topic_score_gemma":0.000085307074,"teacher_disagreement_score":0.27548623,"about_ca_system_score_codex":0.0005385306,"about_ca_system_score_gemma":0.0024963946,"threshold_uncertainty_score":0.99998885},"labels":[],"label_agreement":null},{"id":"W4296131175","doi":"10.1158/1557-3265.sarcomas22-a007","title":"Abstract A007: Resident memory T cells express PD-1 in high grade liposarcoma","year":2022,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"CD8; Liposarcoma; Population; Cancer research; Pembrolizumab; Immunotherapy; Immune system; Medicine; Immunology; Biology; Pathology; Sarcoma","score_opus":0.25340882664836867,"score_gpt":0.5239702194661223,"score_spread":0.27056139281775365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296131175","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97988284,0.0023804097,0.0000012662055,0.00885769,0.0009336365,0.0017841841,0.00006790044,0.000059801307,0.0060322783],"genre_scores_gemma":[0.95156723,0.0025270798,0.00007678119,0.0007079918,0.0014429208,0.0011651993,0.000028088369,0.00010646901,0.042378243],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9903912,0.0020445986,0.0012328089,0.0011299043,0.0037374871,0.00146399],"domain_scores_gemma":[0.99393165,0.0034634795,0.00011853166,0.0014007111,0.00034744025,0.0007381735],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.012548595,0.00024760567,0.0008031624,0.00072011724,0.00038042464,0.00007863662,0.0010420361,0.0002264963,0.07207244],"category_scores_gemma":[0.00080955034,0.00023700297,0.00034543392,0.0014238027,0.0007368358,0.0001028951,0.0013229806,0.0060516647,0.00038047024],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02452108,0.0060970816,0.11139312,0.0008492127,0.00043006783,0.0072210887,0.0017641536,0.000657195,0.4308006,0.0003015652,0.30677176,0.10919311],"study_design_scores_gemma":[0.019939244,0.0043971133,0.48384532,0.00042718282,0.00005093784,0.00005695366,0.0028147665,0.00028705795,0.0626141,0.002208493,0.42254877,0.00081006304],"about_ca_topic_score_codex":0.010478064,"about_ca_topic_score_gemma":0.0008163461,"teacher_disagreement_score":0.3724522,"about_ca_system_score_codex":0.0013546795,"about_ca_system_score_gemma":0.0018020615,"threshold_uncertainty_score":0.9962414},"labels":[],"label_agreement":null},{"id":"W4296131450","doi":"10.1158/1557-3265.sarcomas22-a021","title":"Abstract A021: Chimeric antigen receptor armored natural killer cell immunotherapy for osteosarcoma","year":2022,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Chimeric antigen receptor; Immunotherapy; NK-92; Immunology; Antibody-dependent cell-mediated cytotoxicity; Cancer immunotherapy; Cancer research; Antigen; Biology; Immune system; Natural killer T cell; T cell; Antibody; Medicine; Monoclonal antibody","score_opus":0.17991780428112386,"score_gpt":0.5114094580274091,"score_spread":0.33149165374628525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296131450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96993506,0.01045333,0.000008589687,0.009180427,0.0024936884,0.0036402205,0.000115300376,0.000106889456,0.004066482],"genre_scores_gemma":[0.9095518,0.0061512594,0.00061890023,0.0013521387,0.0021382032,0.0023165208,0.00023504457,0.00020923786,0.077426895],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99348104,0.00085606024,0.0009715959,0.001019054,0.0022447319,0.0014275366],"domain_scores_gemma":[0.9951066,0.0025665427,0.00015696633,0.0010975727,0.0005791697,0.00049316784],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0069546406,0.00028427778,0.0007853723,0.00040157218,0.00079569826,0.000086636486,0.0009051275,0.00018789785,0.055025112],"category_scores_gemma":[0.00049419235,0.00025251767,0.00069420045,0.0011587887,0.00066282845,0.000090197784,0.00048509665,0.0036209023,0.00021891648],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026817814,0.0018546338,0.021154325,0.0002587258,0.00050638255,0.00009447501,0.00047473272,0.00001260486,0.4420086,0.000049043723,0.18984218,0.31692648],"study_design_scores_gemma":[0.009642179,0.003232195,0.06466754,0.00004896378,0.000017632157,0.000014438907,0.00048737074,0.0002051365,0.011934178,0.00016546072,0.9092385,0.00034641882],"about_ca_topic_score_codex":0.00069975614,"about_ca_topic_score_gemma":0.000035416404,"teacher_disagreement_score":0.7193963,"about_ca_system_score_codex":0.0006996395,"about_ca_system_score_gemma":0.0015829947,"threshold_uncertainty_score":0.9999927},"labels":[],"label_agreement":null},{"id":"W4296301767","doi":"10.1158/2326-6066.cir-22-0434","title":"Immune Phenotypes and Target Antigens of Clonally Expanded Bone Marrow T Cells in Treatment-Naïve Multiple Myeloma","year":2022,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Deutschen Konsortium für Translationale Krebsforschung; Deutsche Krebshilfe; Deutsche Forschungsgemeinschaft","keywords":"Bone marrow; Immune system; Antigen; Multiple myeloma; Immunology; Phenotype; Immunotherapy; Medicine; Cancer research; Biology; Gene; Genetics","score_opus":0.05314186102276201,"score_gpt":0.3621803626410768,"score_spread":0.30903850161831475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296301767","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9669682,0.028874641,0.0000017696452,0.0012864006,0.00017345611,0.0011939582,0.00011353358,0.000026522,0.0013615428],"genre_scores_gemma":[0.9744443,0.0063206963,0.00019158723,0.000036428548,0.00007341575,0.00073335634,0.000062991654,0.00005597191,0.018081218],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9965948,0.0007727017,0.00046429838,0.0005486563,0.00069552386,0.0009240479],"domain_scores_gemma":[0.99830645,0.0005606204,0.00008499125,0.0006420121,0.00028876885,0.000117145726],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013295147,0.00021073862,0.0007052784,0.0010497236,0.00028286438,0.000015054142,0.00029330654,0.00014447933,0.008183791],"category_scores_gemma":[0.000116307696,0.00019900894,0.000117161406,0.0011474952,0.00087360555,0.000059918588,0.0005088736,0.0010572158,0.000018477354],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005305496,0.00052999135,0.077695824,0.00006814892,0.00034299417,0.00017125085,0.0017570801,0.000024696401,0.8928014,0.000047859572,0.00023317673,0.021022053],"study_design_scores_gemma":[0.012755427,0.004089004,0.18333505,0.000073984564,0.000029820008,0.000121250865,0.0030767513,0.00036120357,0.74881834,0.00022925399,0.046839025,0.00027090107],"about_ca_topic_score_codex":0.00306948,"about_ca_topic_score_gemma":0.0003827191,"teacher_disagreement_score":0.1439831,"about_ca_system_score_codex":0.0008409416,"about_ca_system_score_gemma":0.00090651773,"threshold_uncertainty_score":0.99272287},"labels":[],"label_agreement":null},{"id":"W4297141578","doi":"10.1136/jitc-2022-004725","title":"TEM8 Tri-specific Killer Engager binds both tumor and tumor stroma to specifically engage natural killer cell anti-tumor activity","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Women's Health Research Institute","funders":"National Cancer Institute; National Institutes of Health; National Center for Advancing Translational Sciences; University of Minnesota","keywords":"Stromal cell; Tumor microenvironment; Cancer research; Lymphokine-activated killer cell; Biology; Interleukin 21; Degranulation; Cytokine; T cell; Immunology; Immune system; Tumor cells; Receptor","score_opus":0.03057813303820549,"score_gpt":0.3280423464682694,"score_spread":0.2974642134300639,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297141578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9797854,0.012236766,0.00015174311,0.002009928,0.003227748,0.0018347487,0.000104096864,0.00004645452,0.000603137],"genre_scores_gemma":[0.96828437,0.0020939407,0.0011817566,0.0014631924,0.0011030856,0.0003015415,0.000008504698,0.00021541158,0.025348186],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957072,0.00048180023,0.0008551344,0.0006162963,0.0014543324,0.00088524807],"domain_scores_gemma":[0.99763227,0.0004915616,0.0005324774,0.00061527593,0.00032317566,0.00040524974],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002190273,0.0004855866,0.0011182525,0.00065250543,0.00096418004,0.0001491669,0.00051419076,0.00006858202,0.0124114435],"category_scores_gemma":[0.000066441986,0.00041114644,0.0006175292,0.0006216087,0.0001967814,0.00023315256,0.0001468135,0.0024891368,0.000007035099],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014452739,0.00064476224,0.0017355516,0.00009998504,0.00042099482,0.0001874142,0.0010886563,0.00006088609,0.9301697,0.000027575014,0.02085136,0.030260375],"study_design_scores_gemma":[0.014781913,0.0033620915,0.05135899,0.00013962733,0.00007098372,0.00079421804,0.0010807381,0.00014019576,0.11805802,0.000049040656,0.809571,0.0005931602],"about_ca_topic_score_codex":0.00008260419,"about_ca_topic_score_gemma":0.0000107777105,"teacher_disagreement_score":0.8121117,"about_ca_system_score_codex":0.000866042,"about_ca_system_score_gemma":0.0006186201,"threshold_uncertainty_score":0.99983406},"labels":[],"label_agreement":null},{"id":"W4297312817","doi":"10.1016/j.jcyt.2022.07.014","title":"Particulates are everywhere, but are they harmful in cell and gene therapies?","year":2022,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"International Society for Cellular Therapy","funders":"","keywords":"Particulates; Gene; Biology; Genetics; Ecology","score_opus":0.03025804853908798,"score_gpt":0.2890486513950343,"score_spread":0.2587906028559463,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297312817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98747885,0.008102744,0.000009588109,0.002546748,0.000105390056,0.0007620641,0.000034729826,0.00007735938,0.0008825498],"genre_scores_gemma":[0.983846,0.0022494316,0.00016424722,0.0019348621,0.00015470239,0.00023039983,0.00001499269,0.00009073001,0.011314595],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9980056,0.00023903917,0.00028124423,0.00046541222,0.0005113956,0.0004972592],"domain_scores_gemma":[0.9990175,0.0001249386,0.0001164461,0.0005094044,0.00006543921,0.00016628994],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00047864037,0.00023961031,0.0004430268,0.00020877698,0.00018276554,0.000046552424,0.00018364347,0.00007851856,0.00864705],"category_scores_gemma":[0.000016007774,0.00021167642,0.000111566966,0.00030965055,0.00009394969,0.00006649199,0.00009346542,0.0005057762,0.000029774928],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015467046,0.0006035338,0.31651175,0.00006831994,0.00013549121,0.00038953093,0.003268406,0.00007070817,0.6670484,0.000021442482,0.0010772232,0.009258471],"study_design_scores_gemma":[0.018765103,0.0017975287,0.5348274,0.00012019,0.000056699973,0.0003623701,0.010138257,0.00085101713,0.26353398,0.0016375243,0.16694894,0.0009610017],"about_ca_topic_score_codex":0.00022989434,"about_ca_topic_score_gemma":0.00009942298,"teacher_disagreement_score":0.40351444,"about_ca_system_score_codex":0.00021200595,"about_ca_system_score_gemma":0.000086324064,"threshold_uncertainty_score":0.9922592},"labels":[],"label_agreement":null},{"id":"W4297322118","doi":"10.1136/jitc-2021-004450","title":"Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":55,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Hyundai Hope On Wheels; National Cancer Institute; American Association for Cancer Research; Children's Hospital of Philadelphia; Alex's Lemonade Stand Foundation for Childhood Cancer; Damon Runyon Cancer Research Foundation; Kortney Rose Foundation","keywords":"Chimeric antigen receptor; Medulloblastoma; Neuroblastoma; Cancer research; Glioma; Pediatric cancer; Medicine; Flow cytometry; Brain tumor; Cancer; Immunotherapy; Cell culture; Biology; Immunology; Pathology; Internal medicine","score_opus":0.046226171553148024,"score_gpt":0.37651339021005625,"score_spread":0.33028721865690824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297322118","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98609143,0.01022418,0.0008921219,0.0004106023,0.0010324083,0.0012225871,0.00004771366,0.000022268894,0.00005669968],"genre_scores_gemma":[0.70865566,0.018912513,0.22694127,0.0020702146,0.0048574284,0.001773799,0.00015693573,0.0010021633,0.035630018],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977265,0.00008210912,0.0008630094,0.00019944807,0.00071454246,0.00041439742],"domain_scores_gemma":[0.9984114,0.00018234686,0.0006908939,0.00019950718,0.00041756863,0.000098288765],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012671233,0.0001868249,0.0006004173,0.0005110023,0.00041682832,0.000014632594,0.0002587602,0.00005202628,0.004459669],"category_scores_gemma":[0.0000623605,0.00017116574,0.0003963376,0.00063644326,0.00005690523,0.00006948576,0.000037173995,0.00032556007,3.0309826e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006385172,0.00025558315,0.0073154443,0.0001898512,0.0007285712,0.0000020071193,0.002453852,0.00022587417,0.82618177,0.0000045593006,0.003084469,0.15317287],"study_design_scores_gemma":[0.015294295,0.0025391942,0.015380766,0.00020157167,0.00016330488,0.0001647714,0.0011617218,0.0012393183,0.28695834,0.00013873276,0.6762574,0.0005006176],"about_ca_topic_score_codex":0.00007208594,"about_ca_topic_score_gemma":0.000008157348,"teacher_disagreement_score":0.6731729,"about_ca_system_score_codex":0.0006276277,"about_ca_system_score_gemma":0.0017475178,"threshold_uncertainty_score":0.99645036},"labels":[],"label_agreement":null},{"id":"W4297387081","doi":"10.1136/jitc-2022-005187","title":"GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":105,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre","funders":"Mark Hughes Foundation; Medical Research Council; Flinders Foundation; Tour de Cure; Australian Cancer Research Foundation; Fay Fuller Foundation; Cancer Australia; Cancer Council South Australia; Neurosurgical Research Foundation; National Health and Medical Research Council; Hospital Research Foundation","keywords":"Chimeric antigen receptor; Medicine; Glioma; Flow cytometry; Cancer research; Brain tumor; Antigen; Immune system; Immunotherapy; Tumor antigen; Pathology; Oncology; Immunology","score_opus":0.02121667910910916,"score_gpt":0.3714376681463423,"score_spread":0.35022098903723314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4297387081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9762477,0.016567545,0.0024037587,0.0005433706,0.00074053055,0.0031086307,0.0003258284,0.000031435542,0.000031150033],"genre_scores_gemma":[0.974937,0.016708659,0.0017190848,0.0008869673,0.0006907419,0.001742134,0.00002659523,0.00020247021,0.0030863124],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972492,0.0002970839,0.00079333247,0.00043443544,0.0006821115,0.0005438334],"domain_scores_gemma":[0.99783736,0.000566735,0.0006180159,0.00030757696,0.00045470896,0.00021557251],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017420605,0.00029860935,0.00078638096,0.00019960274,0.00062394666,0.000056452744,0.0003013448,0.00013395815,0.002008677],"category_scores_gemma":[0.000041901847,0.0002505281,0.00054252543,0.00022318258,0.00012811535,0.00018236623,0.000027391685,0.0006759699,3.471185e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040014494,0.00040391245,0.000432482,0.00009575854,0.00041325597,0.0000012839179,0.0016582067,0.00009074553,0.79727316,0.000001059218,0.0031789674,0.15643668],"study_design_scores_gemma":[0.018698853,0.013908248,0.0006554515,0.00015938233,0.000053771848,0.000018369055,0.001010906,0.0001529794,0.8631942,0.00017750927,0.10170798,0.00026230598],"about_ca_topic_score_codex":0.00003990449,"about_ca_topic_score_gemma":0.000013021698,"teacher_disagreement_score":0.15617438,"about_ca_system_score_codex":0.00031473098,"about_ca_system_score_gemma":0.00027358407,"threshold_uncertainty_score":0.9999947},"labels":[],"label_agreement":null},{"id":"W4298109903","doi":"10.3389/fimmu.2022.995191","title":"Pathogenic variant c.1052T&gt;A (p.Leu351Gln) in adenosine deaminase 2 impairs secretion and elevates type I IFN responsive gene expression","year":2022,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Janeway Children's Health and Rehabilitation Centre; BC Children's Hospital; University of British Columbia","funders":"Canadian Institutes of Health Research; Centre for Blood Research, University of British Columbia","keywords":"Biology; Secretion; Glycosylation; Extracellular; Gene; AMP deaminase; Gene expression; Molecular biology; Adenosine; Adenosine deaminase; Cell biology; Genetics; Biochemistry","score_opus":0.010984163337729343,"score_gpt":0.25871640892333697,"score_spread":0.24773224558560764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4298109903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9788654,0.018397514,0.0003001253,0.0006947774,0.00077905174,0.00072457286,0.000023601038,0.00004173019,0.00017325064],"genre_scores_gemma":[0.9883558,0.0031113098,0.0040566097,0.00020102825,0.00008161492,0.00020589939,0.0002230041,0.000066317094,0.0036984135],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99745,0.00080207695,0.00039962816,0.0005093221,0.00028773496,0.0005512514],"domain_scores_gemma":[0.9991176,0.00014321833,0.00010017495,0.00047554343,0.000081361024,0.00008208455],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009085055,0.00020769688,0.00049521914,0.0009038379,0.00013221955,0.000012599682,0.00019865912,0.00019857462,0.0012703829],"category_scores_gemma":[0.0003407412,0.00021272228,0.000060905502,0.0007853611,0.0001993536,0.00007786319,0.00035803157,0.0008545451,0.00000823477],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010752389,0.0002577456,0.026936838,0.000029044371,0.00008095753,0.001309687,0.0017204933,0.000031344727,0.94373864,0.00003539827,0.0028221759,0.012285302],"study_design_scores_gemma":[0.033554863,0.013943975,0.5579997,0.0004173013,0.00019585041,0.004847217,0.019828934,0.0072429297,0.26308918,0.0040027536,0.09330466,0.0015726895],"about_ca_topic_score_codex":0.00013243343,"about_ca_topic_score_gemma":0.0000225824,"teacher_disagreement_score":0.68064946,"about_ca_system_score_codex":0.00066977064,"about_ca_system_score_gemma":0.00027146336,"threshold_uncertainty_score":0.9996426},"labels":[],"label_agreement":null},{"id":"W4299407510","doi":"","title":"CD8+ memory T-cell inflation renders compromised CD4+ T-cell-dependent CD8+ T-cell immunity via na&iuml;ve T-cell anergy","year":2017,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cytotoxic T cell; CD8; T cell; Cell mediated immunity; Cell; Immunology; Immunity; Biology; Immune system; Genetics","score_opus":0.20175693623943394,"score_gpt":0.510866178176193,"score_spread":0.30910924193675904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4299407510","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.838742,0.009040369,0.00035035043,0.00030963623,0.0011889641,0.0024232017,0.00006272321,0.00012924384,0.1477535],"genre_scores_gemma":[0.9574354,0.011299009,0.00034846136,0.00036079026,0.0005695051,0.00011995934,0.00014572263,0.00028946364,0.029431637],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99087006,0.0011249809,0.0021586185,0.001350789,0.0030388345,0.0014567013],"domain_scores_gemma":[0.98977375,0.0008427642,0.0030021707,0.003763139,0.0013195908,0.0012985875],"candidate_categories":["metaepi_narrow","sts","scholarly_communication","open_science","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0042377366,0.0010942614,0.0021799714,0.0016224417,0.001954085,0.00253816,0.006358012,0.0006228591,0.033405885],"category_scores_gemma":[0.00046834856,0.0010548249,0.0008132181,0.00081763754,0.0007537727,0.0028650183,0.0026015425,0.0025394887,0.0002352583],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029331192,0.002188653,0.055514622,0.00077257404,0.00031007198,0.000359111,0.0006927267,0.0003669377,0.9081487,0.000003705943,0.016944094,0.01176568],"study_design_scores_gemma":[0.012845341,0.00020478072,0.076657034,0.0005574269,0.00043834516,0.00008801941,0.00066713255,0.00092372403,0.8982251,0.00049058854,0.00759443,0.0013080561],"about_ca_topic_score_codex":0.0067250323,"about_ca_topic_score_gemma":0.00029759138,"teacher_disagreement_score":0.11869344,"about_ca_system_score_codex":0.00077955204,"about_ca_system_score_gemma":0.00097004685,"threshold_uncertainty_score":0.99988925},"labels":[],"label_agreement":null},{"id":"W4300606952","doi":"","title":"Systematic in-vitro evaluation of the NCI/NIH Developmental Therapeutics Program Approved Oncology Drug Set for the identification of a candidate drug repertoire for MLL-rearranged leukemia","year":2011,"lang":"en","type":"article","venue":"DOAJ (DOAJ: Directory of Open Access Journals)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Drug; Medicine; Identification (biology); Leukemia; Pharmacology; Oncology; Computational biology; Internal medicine; Biology","score_opus":0.39942835403016363,"score_gpt":0.5738789530236104,"score_spread":0.17445059899344673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4300606952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9775078,0.0058351313,0.00017730992,0.0004010023,0.00034245482,0.0150470445,0.0000744203,0.000016244423,0.00059855724],"genre_scores_gemma":[0.995019,0.00096124626,0.0005227338,0.00011400471,0.000055298522,0.0025227983,0.000037395897,0.000056663204,0.000710839],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9954192,0.00093048497,0.0017403531,0.00034938843,0.0012171508,0.00034339944],"domain_scores_gemma":[0.9947858,0.0010882948,0.0018526335,0.0007003583,0.0014852682,0.00008768456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011764336,0.0002425255,0.0009772653,0.0004147924,0.00021070523,0.00013145302,0.0016177376,0.00011797327,0.00057694403],"category_scores_gemma":[0.0010389654,0.0001479901,0.00031292977,0.0007615046,0.0002712835,0.0003788253,0.00025060578,0.00032239573,9.0477363e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003834024,0.00061021955,0.009474907,0.0043558376,0.0010974932,0.0000016915108,0.008928952,0.000031183077,0.90777296,0.000012235517,0.001713413,0.062167116],"study_design_scores_gemma":[0.006152328,0.000075083786,0.09761112,0.002910768,0.0015671249,0.000034785502,0.0037768972,0.010630304,0.87406963,0.0013546473,0.0015187786,0.00029851048],"about_ca_topic_score_codex":0.001388437,"about_ca_topic_score_gemma":0.0005928048,"teacher_disagreement_score":0.08813622,"about_ca_system_score_codex":0.00094739604,"about_ca_system_score_gemma":0.0016390648,"threshold_uncertainty_score":0.6317133},"labels":[],"label_agreement":null},{"id":"W4300816588","doi":"10.1016/j.omtm.2022.09.016","title":"Combined PD-L1 and TIM3 blockade improves expansion of fit human CD8+ antigen-specific T cells for adoptive immunotherapy","year":2022,"lang":"en","type":"article","venue":"Molecular Therapy — Methods & Clinical Development","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Leukemia and Lymphoma Society of Canada","keywords":"Cytotoxic T cell; Immunotherapy; T-cell receptor; T cell; Antigen; Blockade; CD8; Adoptive cell transfer; Biology; Cancer immunotherapy; Immunology; Streptamer; Ex vivo; Cancer research; Immune system; Receptor; In vivo; In vitro","score_opus":0.12668086104690285,"score_gpt":0.45474196063212075,"score_spread":0.3280610995852179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4300816588","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9595618,0.0050786585,0.031022644,0.00048543047,0.00043345182,0.0031241383,0.000017061893,0.00007412856,0.00020267551],"genre_scores_gemma":[0.22448023,0.008702991,0.75896186,0.0020419052,0.0001688612,0.0010973365,0.00015017277,0.0002947912,0.004101861],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99426985,0.0016526697,0.0016000213,0.00097332906,0.00086631795,0.0006377898],"domain_scores_gemma":[0.9969273,0.0011787139,0.0004184679,0.0008694151,0.00031963695,0.00028642415],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0064873435,0.00045401743,0.0012510706,0.00029011644,0.00042960004,0.000038963834,0.00044588366,0.0002283756,0.0014492075],"category_scores_gemma":[0.000100237536,0.00041260297,0.0005246286,0.0004509067,0.00034770506,0.0000427097,0.00029981777,0.00077060104,0.0000046222126],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043271803,0.0006995337,0.000304993,0.000033055716,0.0005481063,0.000026772297,0.0008635138,0.000004825819,0.6493727,0.000075652904,0.00012680904,0.34361687],"study_design_scores_gemma":[0.010242939,0.0042730905,0.012128379,0.000047970003,0.000023049948,0.000012003829,0.00030537645,0.00010568123,0.77133816,0.00071588915,0.20038925,0.00041822394],"about_ca_topic_score_codex":0.00001460193,"about_ca_topic_score_gemma":4.751409e-7,"teacher_disagreement_score":0.7350816,"about_ca_system_score_codex":0.00018202364,"about_ca_system_score_gemma":0.00043381233,"threshold_uncertainty_score":0.9998326},"labels":[],"label_agreement":null},{"id":"W4301397008","doi":"10.51731/cjht.2022.461","title":"Lisocabtagene Maraleucel (Breyanzi)","year":2022,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Lymphoma; Follicular lymphoma; Medicine; Drug; Chimeric antigen receptor; Diffuse large B-cell lymphoma; Oncology; Internal medicine; Cancer research; Cancer; Immunotherapy; Pharmacology; Political science","score_opus":0.05164566627031014,"score_gpt":0.3287784616090058,"score_spread":0.27713279533869567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4301397008","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.59899104,0.13985647,0.00011487785,0.25469986,0.0011241611,0.00086065056,0.000069823924,0.0002401833,0.004042976],"genre_scores_gemma":[0.9939781,0.000697534,0.00045979908,0.0016967141,0.000027735856,0.000016844891,0.0000044932594,0.000027649934,0.0030911341],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99820554,0.00011293557,0.00050793594,0.00014117584,0.0004060827,0.000626325],"domain_scores_gemma":[0.9989812,0.000051960735,0.00026061662,0.00036062178,0.00014853013,0.00019710051],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012985385,0.00011284232,0.00041914324,0.0011431605,0.00048616537,0.000022031483,0.00044809605,0.00007867423,0.003057219],"category_scores_gemma":[0.00032176435,0.00010428134,0.00012844552,0.0006575149,0.00020577808,0.000054182106,0.000068489724,0.0012296649,0.000010844422],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011891676,0.000050503666,0.013745516,0.00011149119,0.000093370756,0.0014889943,0.0003767608,0.000035098732,0.0019476421,0.00056213845,0.05492865,0.9265409],"study_design_scores_gemma":[0.00086128473,0.0016520713,0.007843613,0.000051842562,0.000010752781,0.0026519063,0.004809611,0.000014552259,0.0008778138,0.0011348762,0.9799902,0.000101480895],"about_ca_topic_score_codex":0.003894157,"about_ca_topic_score_gemma":0.0012316558,"teacher_disagreement_score":0.92643946,"about_ca_system_score_codex":0.0014909133,"about_ca_system_score_gemma":0.005987073,"threshold_uncertainty_score":0.99964803},"labels":[],"label_agreement":null},{"id":"W4303446442","doi":"10.1101/2022.10.03.509766","title":"Enhanced STAT5a activation rewires exhausted CD8 T cells during chronic stimulation to acquire a hybrid durable effector like state","year":2022,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"National Institutes of Health; Parker Institute for Cancer Immunotherapy; University of Pennsylvania","keywords":"Effector; CD8; Cytotoxic T cell; Biology; Ex vivo; T cell; Cell biology; Epigenetics; Cancer research; Immune system; Immunology; Genetics","score_opus":0.01501151024700386,"score_gpt":0.2642740642277319,"score_spread":0.24926255398072805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4303446442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99022007,0.0003694834,0.0018206765,0.00022323195,0.0011843747,0.0050482196,0.0003447788,0.000768367,0.000020786396],"genre_scores_gemma":[0.99546117,0.00035636916,0.0007895124,0.00018410088,0.0007390064,0.0013905754,0.000010814851,0.00040621764,0.00066223287],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9940096,0.00042075498,0.00092138484,0.0018582117,0.0015246902,0.0012653426],"domain_scores_gemma":[0.9954946,0.00022983373,0.00054392545,0.0022476022,0.0007846729,0.000699376],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010127476,0.0008927366,0.0011205351,0.0010078797,0.00043182552,0.0002909079,0.0005947496,0.0003349635,0.003444357],"category_scores_gemma":[0.00028061404,0.0010177788,0.0002928154,0.0012713677,0.00010105577,0.00030567963,0.0010053985,0.0016814816,0.00020189401],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015902412,0.000260388,0.00073213974,0.0021311585,0.000396084,0.00016872767,0.00006770627,0.008530451,0.985717,0.0000026153277,0.0003722817,0.000031217252],"study_design_scores_gemma":[0.0026146483,0.0005113653,0.064165354,0.0010077034,0.0001290273,6.950831e-8,0.0000070040737,0.0016227606,0.92491,5.53551e-7,0.0041654515,0.00086602994],"about_ca_topic_score_codex":0.00026292398,"about_ca_topic_score_gemma":0.00000775773,"teacher_disagreement_score":0.063433215,"about_ca_system_score_codex":0.0048090992,"about_ca_system_score_gemma":0.0018640476,"threshold_uncertainty_score":0.9992273},"labels":[],"label_agreement":null},{"id":"W4303473194","doi":"10.1016/s2352-3026(22)00284-8","title":"Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b–2, open-label study","year":2022,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Janssen Research and Development","keywords":"Medicine; Internal medicine; Multiple myeloma; Quality of life (healthcare); Refractory (planetary science); Clinical trial; Cancer; Chimeric antigen receptor; Oncology; Immunotherapy","score_opus":0.19861245780340173,"score_gpt":0.447965213090437,"score_spread":0.2493527552870353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4303473194","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98550344,0.00039563893,0.000018613011,0.006620649,0.00025683246,0.006700232,0.00021645181,0.00006325227,0.00022489387],"genre_scores_gemma":[0.9956942,0.00003194056,0.00027000596,0.0012535392,0.00004727379,0.0011792668,0.00015359843,0.000056073783,0.0013141058],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.994648,0.002147683,0.0013817217,0.00053289003,0.00058990525,0.00069983426],"domain_scores_gemma":[0.996647,0.0012239711,0.00063793693,0.0011386399,0.00017609748,0.00017633062],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0040401174,0.00023247232,0.0023770572,0.00020546335,0.00028099612,0.000014047588,0.0008973071,0.00010748322,0.0009167936],"category_scores_gemma":[0.0014758764,0.00017149161,0.00008639788,0.0005957645,0.00017600757,0.00007278468,0.0007010577,0.0007616857,0.0000116075125],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2542171,0.099208914,0.54782844,0.0019275409,0.0015026473,0.00042886936,0.024513498,0.00006556751,0.012056339,0.0008441198,0.030895956,0.026511047],"study_design_scores_gemma":[0.65644735,0.04339799,0.2684587,0.00017801543,0.00016778019,0.00015786107,0.005820594,0.0029465226,0.0006801172,0.000592676,0.02041736,0.00073501235],"about_ca_topic_score_codex":0.0019027983,"about_ca_topic_score_gemma":0.0014481434,"teacher_disagreement_score":0.4022303,"about_ca_system_score_codex":0.00032321017,"about_ca_system_score_gemma":0.00069824274,"threshold_uncertainty_score":0.9999965},"labels":[],"label_agreement":null},{"id":"W4304165954","doi":"10.1038/s41467-022-33720-z","title":"Evolution and modulation of antigen-specific T cell responses in melanoma patients","year":2022,"lang":"en","type":"article","venue":"Nature Communications","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"National Cancer Institute; Syöpäsäätiö; K. Albin Johanssons Stiftelse; Emil Aaltosen Säätiö; Signe ja Ane Gyllenbergin Säätiö; Suomen Lääketieteen Säätiö; KAUTE-Säätiö; Blood Disease Research Foundation; Biomedicum Helsinki-säätiö; Howard Hughes Medical Institute","keywords":"Repertoire; Melanoma; T-cell receptor; Antigen; Immunology; Biology; Phenotype; TIGIT; T cell; Cancer research; Medicine; Genetics; Gene; Immune system; CD8","score_opus":0.03372958040194517,"score_gpt":0.3277208938570633,"score_spread":0.29399131345511814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4304165954","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98723423,0.008465159,0.000010444079,0.0008531084,0.000044583834,0.00042551672,0.00003401494,0.000014595667,0.0029183493],"genre_scores_gemma":[0.9969247,0.0014546245,0.0008819438,0.000042600783,0.000009832686,0.000042478987,0.00017974905,0.000011724032,0.0004523289],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989865,0.0003195871,0.00019166995,0.00012293781,0.00028024023,0.00009906101],"domain_scores_gemma":[0.99863315,0.0002252372,0.00006842789,0.0009057087,0.00013411194,0.000033345346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003598014,0.00005789295,0.00012222062,0.0003074165,0.00016022571,0.000005169321,0.00024223934,0.000080552636,0.00020221931],"category_scores_gemma":[0.000071612805,0.00006196377,0.000031457475,0.0005156257,0.00008485438,0.00004505478,0.00029832718,0.0007365254,0.0000017252045],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00063898857,0.00082449644,0.84659755,0.000017078592,0.000013459151,0.000001231133,0.0008586063,0.0000368626,0.14109658,0.0022064128,0.0009417287,0.006767034],"study_design_scores_gemma":[0.0011054495,0.00016853283,0.9497031,0.000010721277,0.0000035795338,0.0000034115405,0.00021313272,0.0010306202,0.0008845096,0.00014750629,0.046678018,0.00005145123],"about_ca_topic_score_codex":0.000045442197,"about_ca_topic_score_gemma":0.00006270581,"teacher_disagreement_score":0.14021206,"about_ca_system_score_codex":0.00020164905,"about_ca_system_score_gemma":0.00006644273,"threshold_uncertainty_score":0.31998774},"labels":[],"label_agreement":null},{"id":"W4304588337","doi":"10.1101/2022.10.10.511511","title":"Structural surfaceomics reveals an AML-specific conformation of Integrin-β2 as a CAR-T therapy target","year":2022,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"University of California, San Francisco; Canadian Institutes of Health Research; Bristol-Myers Squibb; National Cancer Institute; National Institutes of Health; National Science Foundation","keywords":"Myeloid leukemia; Chimeric antigen receptor; Immunotherapy; Cancer research; Haematopoiesis; Antigen; Glycoprotein; Cancer; Malignancy; Computational biology; Chemistry; Biology; Cell biology; Immunology; Molecular biology; Stem cell; Genetics","score_opus":0.0336624225361303,"score_gpt":0.2859849146145093,"score_spread":0.25232249207837903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4304588337","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926335,0.002534292,0.00008547402,0.00021043632,0.0011713619,0.0024324572,0.0005260176,0.0002987083,0.00010775941],"genre_scores_gemma":[0.9924515,0.0029467056,0.0033077886,0.0002375479,0.000485758,0.00022542539,0.000014337256,0.0002336625,0.00009725824],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9952732,0.000436205,0.0011553643,0.0010414203,0.0013338294,0.00076000264],"domain_scores_gemma":[0.9950073,0.000119109034,0.00076833647,0.0024318164,0.001180188,0.0004932561],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016134252,0.00073388964,0.0013048607,0.00062534044,0.00020232899,0.00013552027,0.0008778974,0.0006072817,0.0069218013],"category_scores_gemma":[0.00016390509,0.00073201425,0.00036678085,0.00076820556,0.00027383174,0.00027757153,0.0005573153,0.0021868285,0.00004226447],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001117368,0.00018009849,0.014023403,0.0004666002,0.0003847198,0.00006319456,0.00019423939,0.0002176937,0.98218316,0.00073203514,0.0004070971,0.00003037218],"study_design_scores_gemma":[0.0041808644,0.0012905566,0.14766353,0.00043383177,0.000113357695,5.29441e-7,0.00014411111,0.0014154996,0.7899746,0.000030243806,0.05336645,0.0013864468],"about_ca_topic_score_codex":0.000318494,"about_ca_topic_score_gemma":0.0000024928465,"teacher_disagreement_score":0.1922086,"about_ca_system_score_codex":0.0009881925,"about_ca_system_score_gemma":0.0014536141,"threshold_uncertainty_score":0.9995131},"labels":[],"label_agreement":null},{"id":"W4306179806","doi":"10.1038/s41467-022-33597-y","title":"Nanoparticle-based modulation of CD4+ T cell effector and helper functions enhances adoptive immunotherapy","year":2022,"lang":"en","type":"article","venue":"Nature Communications","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bloomberg~Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University; National Institute of Allergy and Infectious Diseases; National Cancer Institute; Natural Sciences and Engineering Research Council of Canada; Johns Hopkins Bloomberg School of Public Health; Department of Pathology, Johns Hopkins University; Newfoundland and Labrador; National Institute of Biomedical Imaging and Bioengineering; Sidney Kimmel Comprehensive Cancer Center; Emerson Collective; Maryland Stem Cell Research Fund; Johns Hopkins University; U.S. Department of Health and Human Services; National Institutes of Health; National Science Foundation; U.S. Department of Defense","keywords":"Cytotoxic T cell; Biology; Cell biology; Antigen-presenting cell; CD8; Major histocompatibility complex; T cell; Streptamer; Immunotherapy; Antigen; Immunology; Effector; MHC class II; Cancer research; Immune system; In vitro; Biochemistry","score_opus":0.02181179341991284,"score_gpt":0.31997203293867593,"score_spread":0.2981602395187631,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306179806","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9839365,0.009535127,0.00012279302,0.0031406095,0.00010848848,0.0007526596,0.00007158025,0.00005451415,0.0022777575],"genre_scores_gemma":[0.9957093,0.00034542882,0.0015989895,0.00032335558,0.000025027637,0.00025762976,0.00016124536,0.000023454797,0.0015555762],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988293,0.00032488495,0.00020395555,0.00016747936,0.00032869074,0.00014566818],"domain_scores_gemma":[0.99796504,0.00050019624,0.000093959075,0.00118352,0.00019843482,0.00005884096],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00037234396,0.00010110415,0.00018846896,0.00016890877,0.00041859245,0.0000127717185,0.00029492495,0.000089500354,0.0010156417],"category_scores_gemma":[0.000054824894,0.000097701086,0.00008484955,0.00052156637,0.00018942967,0.00005681283,0.00016713212,0.0008455766,0.0000071617815],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036603727,0.00048735703,0.007874551,0.000024452382,0.000054144803,4.924845e-7,0.00045389446,0.00012599079,0.98593104,0.00020020914,0.0004883227,0.003993492],"study_design_scores_gemma":[0.007864672,0.0024160612,0.24410945,0.00008246103,0.00019405587,0.000029412138,0.0017467177,0.021841498,0.4869982,0.00014173157,0.23411733,0.0004584076],"about_ca_topic_score_codex":0.000048618775,"about_ca_topic_score_gemma":0.00003647058,"teacher_disagreement_score":0.49893284,"about_ca_system_score_codex":0.0001222617,"about_ca_system_score_gemma":0.00013019337,"threshold_uncertainty_score":0.99989754},"labels":[],"label_agreement":null},{"id":"W4306319940","doi":"10.1016/j.htct.2022.09.415","title":"A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MULTIPLE MYELOMA (MM): INITIAL SAFETY RESULTS FOR MAGNETISMM-3","year":2022,"lang":"en","type":"article","venue":"Hematology Transfusion and Cell Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Cytokine release syndrome; Internal medicine; Adverse effect; Gastroenterology; Regimen; Multiple myeloma; Cohort; Refractory (planetary science); Antibody; Oncology; Immunology; Cancer; Immunotherapy; Chimeric antigen receptor","score_opus":0.022036251958436188,"score_gpt":0.307113675771095,"score_spread":0.2850774238126588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306319940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917379,0.0008981949,0.0003467184,0.0003895461,0.00028719116,0.0045363917,0.00028975037,0.00004602116,0.0014682985],"genre_scores_gemma":[0.9921859,0.0052924897,0.00035300673,0.00017286562,0.00006454025,0.00025069542,0.00097628403,0.000068097535,0.00063611305],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99693567,0.00042696318,0.00089466164,0.00067677785,0.0005942075,0.00047169894],"domain_scores_gemma":[0.9985909,0.00040010212,0.00024094354,0.0004584503,0.0001575616,0.00015205432],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000722335,0.00032361137,0.00083249074,0.0004838299,0.00027991194,0.000015285137,0.00017605812,0.00023214566,0.0011700154],"category_scores_gemma":[0.000023110037,0.000276304,0.00017880186,0.00047884998,0.00021510094,0.0001034364,0.000034425026,0.00057401933,0.0000027038843],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.74124044,0.010250799,0.002261509,0.00019313,0.000059456303,0.000082598795,0.002616507,0.0000050999906,0.20987768,0.000036089074,0.00036904775,0.03300761],"study_design_scores_gemma":[0.80665183,0.04128265,0.0038996597,0.00008488343,0.000050070797,0.000078648365,0.0010184454,0.0005647356,0.094932966,0.00004540429,0.050961524,0.00042920423],"about_ca_topic_score_codex":0.00010794786,"about_ca_topic_score_gemma":0.00008941552,"teacher_disagreement_score":0.11494472,"about_ca_system_score_codex":0.000079546684,"about_ca_system_score_gemma":0.00020626573,"threshold_uncertainty_score":0.9999689},"labels":[],"label_agreement":null},{"id":"W4306721717","doi":"10.1158/2326-6066.cir-22-0095","title":"Characterization of Leukemic Resistance to CD19-Targeted CAR T-cell Therapy through Deep Genomic Sequencing","year":2022,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; National Cancer Institute; National Institutes of Health; American Association for Cancer Research; Children's Hospital of Philadelphia; Stand Up To Cancer; Entertainment Industry Foundation; Doris Duke Charitable Foundation","keywords":"CD19; Chimeric antigen receptor; Medicine; Context (archaeology); Immunotherapy; Immunology; Oncology; Cancer research; Antigen; Biology; Immune system","score_opus":0.07989112111024521,"score_gpt":0.3691113198757585,"score_spread":0.2892201987655133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306721717","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97907823,0.015111041,0.00006054989,0.0016912678,0.00030514837,0.0016320709,0.000073148934,0.00005529503,0.0019932513],"genre_scores_gemma":[0.96047974,0.008420794,0.00019369202,0.00049198593,0.00018775367,0.0012181586,0.00013692467,0.0001012903,0.028769638],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9960631,0.00089211663,0.00047334284,0.0006412506,0.00096242776,0.0009677573],"domain_scores_gemma":[0.9979366,0.00020308001,0.00011898541,0.0009609932,0.000660234,0.00012012441],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014533455,0.00020585,0.00052036374,0.0005760144,0.0004886154,0.000020365103,0.000661422,0.00014310899,0.008250862],"category_scores_gemma":[0.000090339316,0.00021350289,0.0001227569,0.0016721026,0.00042161017,0.00009802899,0.0004579929,0.001459258,0.000056792982],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048158173,0.00010731305,0.0020809788,0.00008185647,0.00019203553,0.00004700162,0.0045722406,0.00005818081,0.983792,0.00009354086,0.00041141588,0.003747589],"study_design_scores_gemma":[0.0030484346,0.0012187973,0.014605378,0.00005108806,0.000013475632,0.00003045486,0.0017301742,0.000075987795,0.8897942,0.00015168946,0.08906082,0.00021952252],"about_ca_topic_score_codex":0.00088157074,"about_ca_topic_score_gemma":0.00007963007,"teacher_disagreement_score":0.09399785,"about_ca_system_score_codex":0.0035481653,"about_ca_system_score_gemma":0.0020844787,"threshold_uncertainty_score":0.99265575},"labels":[],"label_agreement":null},{"id":"W4306867618","doi":"10.3324/haematol.2022.280678","title":"Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia","year":2022,"lang":"en","type":"article","venue":"Haematologica","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Gilead Sciences","keywords":"Medicine; Refractory (planetary science); Gastroenterology; Internal medicine; Cytokine release syndrome; Adverse effect; Anemia; Incidence (geometry); Surgery; Chimeric antigen receptor; Immunotherapy","score_opus":0.03940613311196696,"score_gpt":0.3146591669903849,"score_spread":0.27525303387841793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4306867618","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991781,0.0007700397,0.000036377627,0.00035170553,0.00023316963,0.0006912537,0.00037243046,0.000101294376,0.005662703],"genre_scores_gemma":[0.99717027,0.0005137405,0.00046910916,0.00014729518,0.00013249861,0.000112547925,0.00026982996,0.000044385735,0.0011403005],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9969127,0.00022686519,0.0008050349,0.0006422368,0.00088455406,0.00052856724],"domain_scores_gemma":[0.9977136,0.00087561755,0.0002884544,0.00084380567,0.000090035486,0.00018845596],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006484463,0.00025360112,0.000839422,0.00045285677,0.00012263801,0.0000126466,0.0004166449,0.00017555282,0.007626355],"category_scores_gemma":[0.00053898187,0.00022113774,0.00019978761,0.0009196349,0.00014277086,0.000064989435,0.00037154442,0.0007877015,0.00013877811],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2054958,0.017534636,0.24339247,0.0012340294,0.0018587315,0.04807472,0.010332991,0.0006518695,0.27915046,0.0030806605,0.1472279,0.04196575],"study_design_scores_gemma":[0.36212197,0.04403969,0.36352667,0.0007169862,0.0029596968,0.0045093987,0.006230586,0.012919946,0.051039174,0.016414704,0.13104047,0.004480709],"about_ca_topic_score_codex":0.0005412946,"about_ca_topic_score_gemma":0.000077987825,"teacher_disagreement_score":0.22811128,"about_ca_system_score_codex":0.0006356744,"about_ca_system_score_gemma":0.00061628723,"threshold_uncertainty_score":0.9932808},"labels":[],"label_agreement":null},{"id":"W4307450117","doi":"10.1136/ijgc-2022-esgo.1019","title":"2022-LBA-414-ESGO Preliminary clinical outcome of ADP-A2M4CD8, a next-generation autologous T-cell receptor T-cell therapy, in patients with advanced epithelial ovarian cancer","year":2022,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ovarian cancer; Medicine; Leukapheresis; Internal medicine; Oncology; CD8; Cancer; Population; Immunotherapy; Chemotherapy; Immunology; Antigen; Gastroenterology; Biology; Stem cell","score_opus":0.0713958216413929,"score_gpt":0.3759185532703714,"score_spread":0.30452273162897847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307450117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924234,0.0011861842,0.00004316825,0.0024875505,0.0024865537,0.0007631335,0.00015765279,0.000013973329,0.00043838302],"genre_scores_gemma":[0.99362147,0.0017836996,0.0008440756,0.0012701548,0.0006940468,0.0001790381,0.00005240103,0.00003944869,0.0015156677],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955574,0.00050980266,0.0014641124,0.00040228278,0.0017044696,0.00036192843],"domain_scores_gemma":[0.99691534,0.0005064528,0.0010263956,0.00022156825,0.0011266207,0.00020363079],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011652937,0.000252846,0.0007665096,0.0003636597,0.00008342232,0.000028697741,0.00062718586,0.00017267436,0.022206932],"category_scores_gemma":[0.00029091703,0.00018461756,0.00032506837,0.00033050688,0.00017621074,0.00020706117,0.00020415855,0.0012930732,0.000005894316],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.032017324,0.0045422413,0.7517883,0.000025472526,0.00037277667,0.00022510167,0.0002615663,0.0036801663,0.058477845,0.00001770921,0.0017893054,0.14680216],"study_design_scores_gemma":[0.036976364,0.027309148,0.8977777,0.000106479936,0.00011527654,0.000049114282,0.0002427575,0.0010289856,0.00913057,0.000068710724,0.02675944,0.00043549124],"about_ca_topic_score_codex":0.00016915356,"about_ca_topic_score_gemma":0.000099919656,"teacher_disagreement_score":0.14636666,"about_ca_system_score_codex":0.0012064336,"about_ca_system_score_gemma":0.00081013126,"threshold_uncertainty_score":0.9786869},"labels":[],"label_agreement":null},{"id":"W4307842003","doi":"10.1200/jco.22.00478","title":"Cost-Effectiveness Analysis of Frontline Polatuzumab-Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone and/or Second-Line Chimeric Antigen Receptor T-Cell Therapy Versus Standard of Care for Treatment of Patients With Intermediate- to High-Risk Diffuse Large B-Cell Lymphoma","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Rituximab; Prednisone; Vincristine; Cyclophosphamide; Oncology; Internal medicine; Lymphoma; Chemotherapy","score_opus":0.05108753602228596,"score_gpt":0.4074900151700494,"score_spread":0.35640247914776346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307842003","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921377,0.0034823627,0.00020331459,0.00008333246,0.00043161318,0.0019321016,0.001703931,0.0000049618266,0.000020686175],"genre_scores_gemma":[0.9900961,0.007679954,0.0016900324,0.00007759999,0.000113982955,0.00006508005,0.00012829292,0.000042004547,0.00010696799],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9959841,0.00080289645,0.0018988209,0.0003683753,0.0006321149,0.0003136929],"domain_scores_gemma":[0.99228114,0.0038655703,0.0021090338,0.0003289398,0.001046065,0.0003692508],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014309864,0.00026145906,0.0035651298,0.0005177316,0.00007692299,0.0000052801474,0.00018171231,0.000189182,0.00060862326],"category_scores_gemma":[0.0004502982,0.00017181953,0.00053522916,0.00059516926,0.00025649773,0.00005852575,0.00011416204,0.00025979377,2.2589329e-7],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5491804,0.021630406,0.28521413,0.00019051752,0.0043906565,0.000028367855,0.0014950841,0.000072705676,0.0030283825,0.0000013830627,0.00006011027,0.13470788],"study_design_scores_gemma":[0.26079383,0.31800303,0.3905113,0.00004981048,0.0021153719,0.0000027446488,0.0011361019,0.00012640284,0.012304646,0.0000042946976,0.014804061,0.0001484126],"about_ca_topic_score_codex":0.00014696682,"about_ca_topic_score_gemma":0.00034368254,"teacher_disagreement_score":0.2963726,"about_ca_system_score_codex":0.00056408043,"about_ca_system_score_gemma":0.0010636636,"threshold_uncertainty_score":0.7006597},"labels":[],"label_agreement":null},{"id":"W4307945544","doi":"10.3390/ijms232113217","title":"What Are the Reasons for Continuing Failures in Cancer Therapy? Are Misleading/Inappropriate Preclinical Assays to Be Blamed? Might Some Modern Therapies Cause More Harm than Benefit?","year":2022,"lang":"en","type":"review","venue":"International Journal of Molecular Sciences","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Harm; Medicine; Intensive care medicine; Cancer; Cancer therapy; Psychology; Internal medicine","score_opus":0.15974574582348178,"score_gpt":0.4538704750003089,"score_spread":0.29412472917682714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307945544","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.030998778,0.93505454,0.0000687002,0.030639699,0.001633004,0.0014730502,0.00009477335,0.000012690653,0.000024772251],"genre_scores_gemma":[0.004608477,0.99154025,0.0003328743,0.0015352468,0.0007145748,0.00035976892,0.000012627181,0.00006773333,0.00082842517],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99468756,0.0003960891,0.0010928053,0.0006060852,0.0027226363,0.0004948187],"domain_scores_gemma":[0.996305,0.0011011998,0.001333782,0.0003646971,0.0006850844,0.00021025108],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0033259874,0.00042537003,0.0013540743,0.0008909112,0.0001706878,0.0006365147,0.0022950182,0.00018545614,0.0003647071],"category_scores_gemma":[0.000702481,0.00025672928,0.0010468555,0.00057589274,0.00038856303,0.00044522836,0.0002756515,0.0011341712,0.0000015052299],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005542742,0.00032334385,0.0003650986,0.0003616927,0.0019297962,0.0006221469,0.0050435164,0.0004277175,0.00060142035,0.00015866579,0.0004251984,0.9891871],"study_design_scores_gemma":[0.0017454699,0.00070956326,0.00024328922,0.015108338,0.00034342578,0.00052407937,0.004814885,0.0002830676,0.0002968608,0.00088858546,0.97460234,0.00044011767],"about_ca_topic_score_codex":0.00009916221,"about_ca_topic_score_gemma":0.00022737567,"teacher_disagreement_score":0.988747,"about_ca_system_score_codex":0.00052668195,"about_ca_system_score_gemma":0.00083963806,"threshold_uncertainty_score":0.9999885},"labels":[],"label_agreement":null},{"id":"W4307957799","doi":"10.1016/j.copbio.2022.102822","title":"Manufacturing next-generation regulatory T-cell therapies","year":2022,"lang":"en","type":"review","venue":"Current Opinion in Biotechnology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Children's Hospital; Canada's Michael Smith Genome Sciences Centre","funders":"","keywords":"FOXP3; Induced pluripotent stem cell; Genome editing; Cell therapy; Genetic enhancement; Immunology; Transduction (biophysics); Computational biology; Biology; Cell; Regulatory T cell; T cell; Bioinformatics; Medicine; Gene; Immune system; Genetics; Genome; Embryonic stem cell; IL-2 receptor","score_opus":0.24502948170256564,"score_gpt":0.4107519284894123,"score_spread":0.16572244678684664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307957799","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00010515334,0.9921376,0.000022481192,0.00031326458,0.005143448,0.0017391304,0.00002476899,0.0002321873,0.00028194214],"genre_scores_gemma":[0.0000132284795,0.99674404,0.00007437034,0.000012042978,0.0008490543,0.00047437535,0.0010028384,0.00010635455,0.00072372594],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970012,0.00030572724,0.000840318,0.0008468174,0.0004653763,0.0005405686],"domain_scores_gemma":[0.998372,0.00012800448,0.0002975464,0.0010971262,0.000020356729,0.00008493201],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00054267916,0.00049394416,0.0015098175,0.0016805043,0.00012824876,0.000034513505,0.0005004225,0.0009700775,0.004997388],"category_scores_gemma":[0.00004900146,0.0004430861,0.00042327275,0.00064291205,0.00021384502,0.000061079845,0.00038780965,0.0026552512,0.00010085105],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020536034,0.00018448607,0.0000030245271,0.011272883,0.000056613833,0.0000054935526,0.000038119637,5.80163e-7,0.0002716175,0.00027227795,0.0018774985,0.98599684],"study_design_scores_gemma":[0.0006226133,0.00019842925,0.0000034687866,0.0031065296,0.00005866619,0.0001039485,0.00004415424,0.000019060268,0.0005803449,0.000038697777,0.99488366,0.00034040204],"about_ca_topic_score_codex":0.0000094430825,"about_ca_topic_score_gemma":0.0000020081175,"teacher_disagreement_score":0.99300617,"about_ca_system_score_codex":0.0009453273,"about_ca_system_score_gemma":0.00040931994,"threshold_uncertainty_score":0.9998021},"labels":[],"label_agreement":null},{"id":"W4308200450","doi":"10.1101/2022.11.02.514865","title":"Apoptotic contraction drives target cell release by cytotoxic T cells","year":2022,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto Metropolitan University","funders":"Canadian Institutes of Health Research; Canada Research Chairs; Ludwig Institute for Cancer Research; National Institutes of Health; Memorial Sloan-Kettering Cancer Center; Cancer Research Institute","keywords":"Cytotoxic T cell; CTL*; Cell biology; Contraction (grammar); Immunological synapse; Contractility; Apoptosis; Cytoskeleton; Stimulation; Cell; Biology; Immune system; Chemistry; T cell; Neuroscience; Immunology; T-cell receptor; Biochemistry","score_opus":0.012931866222210547,"score_gpt":0.24784975927627814,"score_spread":0.2349178930540676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308200450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890771,0.0032684577,0.00049341447,0.0005158867,0.002007138,0.0030022785,0.00071616186,0.0007165039,0.00020309494],"genre_scores_gemma":[0.9928978,0.0019037828,0.0018414917,0.00052659627,0.0008002739,0.0006810677,0.0000058295677,0.000396351,0.0009467936],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9946082,0.0004380984,0.00083083386,0.0016607286,0.001362296,0.0010998242],"domain_scores_gemma":[0.9956716,0.00020648526,0.00054922065,0.002236707,0.00049631495,0.0008397315],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010103228,0.0008486027,0.0011306049,0.00054965005,0.00031963692,0.00022045399,0.0006683097,0.00072657503,0.009476774],"category_scores_gemma":[0.0002016757,0.00095703703,0.0004539862,0.00072196784,0.00021671972,0.00015964174,0.0006747692,0.003157962,0.00032826967],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040420474,0.00082481414,0.0018336814,0.0007790087,0.00026558677,0.00028815842,0.00001642868,0.0001180144,0.9878191,0.000020433326,0.0076267105,0.0000038986495],"study_design_scores_gemma":[0.0019448561,0.0003093682,0.0033842898,0.00019836173,0.00023682388,6.6634215e-8,0.00001357515,0.00058376876,0.89908725,0.0000011203942,0.09340338,0.0008371465],"about_ca_topic_score_codex":0.00012958639,"about_ca_topic_score_gemma":7.388845e-7,"teacher_disagreement_score":0.08873182,"about_ca_system_score_codex":0.0014086238,"about_ca_system_score_gemma":0.0014410345,"threshold_uncertainty_score":0.999288},"labels":[],"label_agreement":null},{"id":"W4308294796","doi":"10.1016/j.jconrel.2022.10.043","title":"The past, present, and future of chemotherapy with a focus on individualization of drug dosing","year":2022,"lang":"en","type":"review","venue":"Journal of Controlled Release","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Department of Mechanical Engineering, University of Alberta; National Science Foundation","keywords":"Dosing; Medicine; Pharmacokinetics; Drug; Therapeutic drug monitoring; Pharmacology; Chemotherapy; Intensive care medicine; Distribution (mathematics); Therapeutic index; Oncology; Internal medicine","score_opus":0.021915109450048192,"score_gpt":0.3276433204012992,"score_spread":0.30572821095125097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308294796","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004453304,0.99476624,0.000016095128,0.0019747578,0.00012713959,0.0017496618,0.000012969639,0.0000040095724,0.0009038187],"genre_scores_gemma":[0.00024286189,0.99664176,0.000043130658,0.000042848937,0.0016427638,0.000031563628,0.0000059348417,0.000062993655,0.0012861668],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964563,0.0007147417,0.001180743,0.00016443185,0.001274699,0.00020907041],"domain_scores_gemma":[0.9953806,0.0013343637,0.002429808,0.00036340955,0.00033170462,0.00016015614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015839103,0.0002852135,0.0025913152,0.00044430274,0.00010470726,0.00003234875,0.00024918927,0.00012714698,0.00042091947],"category_scores_gemma":[0.000094850395,0.00013607068,0.00070925365,0.0004323295,0.0001373634,0.000045777815,0.00003570281,0.0009807855,2.6568102e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014798393,0.00025681432,0.000017913386,0.0026094797,0.0025130785,0.0000757067,0.0002646607,0.0000037613536,0.000030263127,0.00006347935,0.0013807566,0.9779857],"study_design_scores_gemma":[0.021397226,0.001737449,0.000013627474,0.0040871017,0.0015362657,0.00039787212,0.00017258702,0.000017929504,0.000024837045,0.000042815547,0.9704659,0.000106395135],"about_ca_topic_score_codex":0.000007833904,"about_ca_topic_score_gemma":0.0000012355443,"teacher_disagreement_score":0.9778793,"about_ca_system_score_codex":0.0001188307,"about_ca_system_score_gemma":0.0007980083,"threshold_uncertainty_score":0.55488014},"labels":[],"label_agreement":null},{"id":"W4308378248","doi":"10.1136/jitc-2022-sitc2022.0234","title":"234 Bead-bound antibody-activation of T cells provides sub-optimal metabolic programming and tumour control compared to dendritic cell-activated T cells","year":2022,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"CD28; T cell; Biology; Cell biology; Cytotoxic T cell; Antigen; Dendritic cell; Cancer research; CD8; Molecular biology; Immunology; Biochemistry; Immune system; In vitro","score_opus":0.018158421451222675,"score_gpt":0.27313632410871636,"score_spread":0.2549779026574937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308378248","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99627477,0.0006951114,0.00009076237,0.0005745799,0.00017586809,0.0019483638,0.000059573696,0.00008767935,0.00009326842],"genre_scores_gemma":[0.9973775,0.00006129488,0.0014665802,0.00026069267,0.000117597665,0.00012816302,0.00008177032,0.000079675876,0.0004266835],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970448,0.00022777493,0.0006259181,0.0006146565,0.0008590001,0.0006278578],"domain_scores_gemma":[0.9981192,0.00015731157,0.00026021068,0.00036616795,0.000225542,0.0008716009],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007713637,0.00035850948,0.00079138705,0.00035059953,0.0003300773,0.0001359187,0.00016137793,0.00011147059,0.00007740449],"category_scores_gemma":[0.00013288403,0.00036324415,0.00012536775,0.00049744436,0.0003836689,0.00021643075,0.00012906286,0.0005204362,0.00000444819],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005789933,0.00028888482,0.0034525988,0.0004305233,0.00016004936,0.00007590632,0.0009903848,0.0006645532,0.99223983,0.000039578787,0.00028432082,0.00079436804],"study_design_scores_gemma":[0.0027692127,0.000579516,0.0206452,0.0001202821,0.00018677227,0.00012937924,0.00087046606,0.0006537552,0.9663994,0.000039901486,0.007273507,0.0003326552],"about_ca_topic_score_codex":0.0004545261,"about_ca_topic_score_gemma":0.0000082322595,"teacher_disagreement_score":0.025840484,"about_ca_system_score_codex":0.00012761833,"about_ca_system_score_gemma":0.00047622147,"threshold_uncertainty_score":0.9998819},"labels":[],"label_agreement":null},{"id":"W4308398717","doi":"10.1136/jitc-2022-sitc2022.0261","title":"261 Evidence for durable anti-tumor responses by TAC-T cells in preclinical models of solid tumors","year":2022,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Cancer research; Flow cytometry; T cell; Antigen; Bone marrow; Immune system; Cytotoxic T cell; Biology; Molecular biology; Immunology; In vitro","score_opus":0.09622014376030799,"score_gpt":0.36606365320160206,"score_spread":0.2698435094412941,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308398717","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99450535,0.0020255444,0.000031283147,0.001634986,0.000171851,0.0012215115,0.00021625977,0.000041256448,0.00015197146],"genre_scores_gemma":[0.993507,0.00029962038,0.00069276115,0.00043136015,0.00007636629,0.00018419439,0.00002924933,0.000058127684,0.0047213174],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9969893,0.00027060232,0.00084487954,0.0005830054,0.0007638278,0.0005483567],"domain_scores_gemma":[0.9977683,0.00078196987,0.00024533444,0.0005161467,0.00013366668,0.0005545891],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024644248,0.00023840647,0.00071470306,0.00022651574,0.00015903005,0.00003086294,0.00024812797,0.00009985931,0.00014733305],"category_scores_gemma":[0.0015024527,0.00023547374,0.00017323847,0.0003326839,0.00042844104,0.00023167177,0.000150282,0.0005358509,0.0000027965186],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020356379,0.00031922275,0.00874896,0.0005342829,0.00006853916,0.00016327706,0.0004896127,0.0016218323,0.97494787,0.00008341233,0.010670227,0.00031710605],"study_design_scores_gemma":[0.004345729,0.0020327915,0.023390304,0.00089942035,0.00013027653,0.00043354073,0.00068315584,0.009260139,0.9429799,0.0024911752,0.012814539,0.00053907215],"about_ca_topic_score_codex":0.0003036767,"about_ca_topic_score_gemma":0.000014775494,"teacher_disagreement_score":0.031968035,"about_ca_system_score_codex":0.00015447053,"about_ca_system_score_gemma":0.0010205022,"threshold_uncertainty_score":0.960234},"labels":[],"label_agreement":null},{"id":"W4308399396","doi":"10.1136/jitc-2022-sitc2022.0558","title":"558 CTX130 allogeneic CRISPR-Cas9–engineered chimeric antigen receptor (CAR) T cells in patients with advanced clear cell renal cell carcinoma: Results from the phase 1 COBALT-RCC study","year":2022,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Renal cell carcinoma; Fludarabine; Medicine; Clear cell renal cell carcinoma; Internal medicine; Refractory (planetary science); Chimeric antigen receptor; Oncology; Gastroenterology; Cyclophosphamide; Cancer research; Immunotherapy; Chemotherapy; Cancer; Biology","score_opus":0.01358275220468149,"score_gpt":0.24546656095012168,"score_spread":0.23188380874544018,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308399396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948153,0.000734407,0.0000027932338,0.0003903091,0.000374313,0.0026352357,0.0006467216,0.00008284593,0.00031807405],"genre_scores_gemma":[0.9971241,0.000079668964,0.0004504296,0.00031321382,0.00018189909,0.00011280946,0.00065600895,0.00013513184,0.000946755],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9953815,0.0004752024,0.00083850307,0.0010716323,0.001405224,0.0008279389],"domain_scores_gemma":[0.99740267,0.00020051353,0.00031999714,0.0011141299,0.00016686933,0.000795816],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009349402,0.0005333969,0.0007176059,0.00022444648,0.00040782272,0.00008895021,0.00045375215,0.00013417855,0.00027000578],"category_scores_gemma":[0.00013852355,0.00041970066,0.00013919923,0.0007407345,0.00028229528,0.00016005739,0.00024692903,0.0010975831,0.000026644493],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010933471,0.004245551,0.1321316,0.00009595619,0.0002380181,0.00046155354,0.006407877,0.0020618755,0.8343323,0.0000015246502,0.007815538,0.0012747386],"study_design_scores_gemma":[0.047919005,0.008442093,0.6575248,0.000094399504,0.00027924794,0.000021849472,0.0041784407,0.0002824638,0.25921926,0.000014803797,0.021096703,0.0009269435],"about_ca_topic_score_codex":0.0013405511,"about_ca_topic_score_gemma":0.00008317419,"teacher_disagreement_score":0.57511306,"about_ca_system_score_codex":0.0003071182,"about_ca_system_score_gemma":0.0005493125,"threshold_uncertainty_score":0.9998255},"labels":[],"label_agreement":null},{"id":"W4308415196","doi":"10.3389/fimmu.2022.1029269","title":"Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer","year":2022,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada; Interface Biologics (Canada); Ottawa Hospital; University of Ottawa","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Terry Fox Research Institute; Canadian Cancer Society","keywords":"Oncolytic virus; Colorectal cancer; Cancer research; Tumor microenvironment; Medicine; Immune system; Immunotherapy; Cancer; Immunogenic cell death; Cancer cell; CD8; Cytotoxic T cell; Immunology; Biology; In vitro; Internal medicine","score_opus":0.01721192061402348,"score_gpt":0.2975827241361198,"score_spread":0.2803708035220963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308415196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98331565,0.004979492,0.0031874974,0.0012789579,0.0029380752,0.0025354978,0.00008100702,0.000084477666,0.0015993776],"genre_scores_gemma":[0.98558694,0.0006379125,0.002655706,0.000725589,0.00008204996,0.0032664493,0.00026516794,0.0000925045,0.006687692],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99839526,0.00012291083,0.00033322014,0.00033787813,0.0002933972,0.0005173485],"domain_scores_gemma":[0.9993026,0.00015165015,0.000118611635,0.00029451918,0.000087622364,0.000044999622],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00039355562,0.00017864781,0.00047371766,0.0005532374,0.00022800105,0.000012988442,0.00028860656,0.00014569022,0.0024377068],"category_scores_gemma":[0.000035191086,0.0001956019,0.00015853804,0.00044206926,0.00019303865,0.00005672749,0.00007439099,0.0006013696,0.0000057420393],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021997267,0.0016487802,0.028383298,0.00007993516,0.0005026282,0.000056248235,0.0015497986,0.0011535547,0.8345759,0.00018092521,0.017567273,0.09230441],"study_design_scores_gemma":[0.07626315,0.0144346235,0.031903297,0.00007500966,0.00013849192,0.0000779536,0.0036918088,0.05956538,0.249471,0.0023539325,0.56107336,0.0009520222],"about_ca_topic_score_codex":0.00041838494,"about_ca_topic_score_gemma":0.00007139096,"teacher_disagreement_score":0.5851049,"about_ca_system_score_codex":0.0021203628,"about_ca_system_score_gemma":0.0006470026,"threshold_uncertainty_score":0.9984742},"labels":[],"label_agreement":null},{"id":"W4308495428","doi":"10.51731/cjht.2022.491","title":"Mogamulizumab (Poteligeo)","year":2022,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Medicine; Refractory (planetary science); Drug; Vial; Intensive care medicine; Family medicine; Pharmacology; Political science; Health care","score_opus":0.04859463929211724,"score_gpt":0.333019264260428,"score_spread":0.2844246249683108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308495428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5264457,0.13544194,0.0001603766,0.33147565,0.0011039989,0.0008967125,0.000054514243,0.00026759863,0.0041534994],"genre_scores_gemma":[0.99665725,0.00042266268,0.00039364534,0.0012452625,0.000015222478,0.000011962099,0.0000025037039,0.000021039148,0.0012304328],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983879,0.000088790766,0.00045297,0.00012182534,0.00039053021,0.00055800925],"domain_scores_gemma":[0.99908936,0.00004642,0.00023075537,0.00031714898,0.00014768788,0.00016864885],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010485917,0.000096714844,0.00036667523,0.0010959409,0.00049216335,0.000017978873,0.00039704348,0.00006699117,0.0021510192],"category_scores_gemma":[0.00037812104,0.0000886195,0.000109407374,0.00059852295,0.00017566526,0.000045416873,0.0000572482,0.0011681049,0.000010304776],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010024847,0.00003141774,0.0043399427,0.000059477294,0.00006104539,0.0012563653,0.0005133024,0.00005067908,0.0007248427,0.0005249957,0.025125718,0.96721196],"study_design_scores_gemma":[0.00083835155,0.0016743378,0.0023988988,0.000045987956,0.0000075205257,0.0031091676,0.0073204865,0.000019739602,0.00090082944,0.0014254929,0.98217696,0.00008222942],"about_ca_topic_score_codex":0.006671861,"about_ca_topic_score_gemma":0.001538729,"teacher_disagreement_score":0.9671297,"about_ca_system_score_codex":0.0015946062,"about_ca_system_score_gemma":0.0067485766,"threshold_uncertainty_score":0.9999428},"labels":[],"label_agreement":null},{"id":"W4308545220","doi":"10.1016/j.anai.2022.10.025","title":"Interleukin-6 and cytokine release syndrome","year":2022,"lang":"en","type":"review","venue":"Annals of Allergy Asthma & Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Humber River Regional Hospital; Queen's University; University of Toronto; Kingston General Hospital; St. Michael's Hospital","funders":"","keywords":"Tryptase; Drug allergy; Medicine; Angioedema; Desensitization (medicine); Drug; Biomarker; Pharmacology; Immunology; Mast cell; Internal medicine; Chemistry","score_opus":0.0930446162973759,"score_gpt":0.37749135255415905,"score_spread":0.2844467362567832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308545220","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011884229,0.99374425,0.0000021542667,0.00056179933,0.00026725215,0.0007036975,0.0000614765,0.0000591842,0.0034117755],"genre_scores_gemma":[0.00010347844,0.98742145,0.000045805496,0.0002471888,0.000089285466,0.00016293148,0.00038624488,0.00014218542,0.011401399],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965108,0.00058351574,0.0010379531,0.00072999456,0.0004373452,0.0007003672],"domain_scores_gemma":[0.9975814,0.0004235054,0.00050172774,0.0011504797,0.00015986244,0.00018298722],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006141874,0.00057046197,0.0030836486,0.0008948856,0.00009806243,0.000015957094,0.00054480956,0.0005293838,0.022365214],"category_scores_gemma":[0.0002393549,0.0005115498,0.00081728236,0.0005535395,0.0005260385,0.00006402539,0.0008183412,0.0015736347,0.00010391939],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047848377,0.00027179057,2.9166338e-7,0.0033770872,0.0041898,0.0013780517,0.000086418244,1.9338907e-7,0.0001459224,0.000592572,0.0014165856,0.9880628],"study_design_scores_gemma":[0.00070848246,0.0028933885,0.00006778033,0.0026135969,0.000028963837,0.0077944444,0.000058442285,0.0000010334813,0.00004860339,0.000054411717,0.98540545,0.00032542113],"about_ca_topic_score_codex":0.00016429483,"about_ca_topic_score_gemma":0.000013077239,"teacher_disagreement_score":0.98773736,"about_ca_system_score_codex":0.000098994984,"about_ca_system_score_gemma":0.00054402667,"threshold_uncertainty_score":0.9997336},"labels":[],"label_agreement":null},{"id":"W4308722894","doi":"10.3390/cancers14225485","title":"T Cells Directed against the Metastatic Driver Chondromodulin-1 in Ewing Sarcoma: Comparative Engineering with CRISPR/Cas9 vs. Retroviral Gene Transfer for Adoptive Transfer","year":2022,"lang":"en","type":"article","venue":"Cancers","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"China Scholarship Council; Deutsche Forschungsgemeinschaft; St. Baldrick's Foundation","keywords":"CRISPR; Genome editing; Chimeric antigen receptor; Adoptive cell transfer; Cancer research; Cytotoxic T cell; Viral vector; Genetic enhancement; T-cell receptor; Cas9; Immunotherapy; T cell; Transduction (biophysics); Biology; Immunology; Gene; Immune system; Genetics; Recombinant DNA","score_opus":0.03485692058424868,"score_gpt":0.2863379827032491,"score_spread":0.25148106211900045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308722894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897922,0.00058050273,0.006118568,0.0003471764,0.00021860133,0.0023219793,0.00019415657,0.000078530415,0.00034825553],"genre_scores_gemma":[0.99650526,0.00008709494,0.0009973018,0.00042046251,0.00008443962,0.00088431704,0.000071354836,0.00007302948,0.000876722],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980504,0.0001490456,0.0002850107,0.00043145125,0.00052510196,0.0005589713],"domain_scores_gemma":[0.9991925,0.00025407714,0.000019437295,0.00029710156,0.00010425418,0.00013267917],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034583325,0.00026964193,0.00055679085,0.00020775045,0.0001838135,0.000023110648,0.00021305421,0.000036683436,0.0005009865],"category_scores_gemma":[0.000011914478,0.00020617871,0.00016715289,0.0007214919,0.00013343526,0.00008934625,0.00002357487,0.00070921757,0.0000023430557],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009041014,0.00014907606,0.00039387954,0.0002368699,0.0009882032,0.00032038073,0.03071684,0.17030495,0.7843745,0.000066982066,0.00082347344,0.0025838574],"study_design_scores_gemma":[0.023601884,0.0044267015,0.0032158417,0.0002469019,0.00056289445,0.00009117099,0.009219115,0.14973544,0.77822864,0.00001268171,0.029662428,0.0009963316],"about_ca_topic_score_codex":0.00022249685,"about_ca_topic_score_gemma":0.00016677537,"teacher_disagreement_score":0.028838955,"about_ca_system_score_codex":0.0021192662,"about_ca_system_score_gemma":0.000555997,"threshold_uncertainty_score":0.84077233},"labels":[],"label_agreement":null},{"id":"W4308840323","doi":"10.1101/2022.11.10.516049","title":"Integration of exogenous and endogenous co-stimulatory signals by CAR-Tregs","year":2022,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"Michael Smith Health Research BC; BC Children's Hospital; Bristol-Myers Squibb; U.S. Department of Defense","keywords":"CD28; Chimeric antigen receptor; In vivo; Immunology; In vitro; Antigen; Biology; Cytokine; Cancer research; Cell biology; T cell; Immune system; Genetics","score_opus":0.03846649051790115,"score_gpt":0.2797519642242023,"score_spread":0.24128547370630113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308840323","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870933,0.008753144,0.00024982568,0.00010100826,0.0003760069,0.002072841,0.00089285197,0.0002494157,0.00021157088],"genre_scores_gemma":[0.9966211,0.0014646945,0.00080702314,0.0001675495,0.00026688172,0.00032257973,0.0000065427407,0.000224369,0.00011926473],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9960296,0.000328532,0.00079450133,0.0011086317,0.00108772,0.00065100443],"domain_scores_gemma":[0.9966805,0.00021174898,0.0004888306,0.0015603191,0.0006019467,0.00045665156],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011481027,0.0006258383,0.0011530849,0.0005304605,0.00020074955,0.00008829441,0.00043818113,0.0005307743,0.002431548],"category_scores_gemma":[0.0002490969,0.0006688493,0.00025918492,0.0004916747,0.00031658108,0.000084922016,0.00050746213,0.0014891716,0.000018443243],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031570988,0.00036370425,0.0039734063,0.00072941394,0.00042213127,0.00017293319,0.00009206348,0.00003535819,0.99318767,0.00004668762,0.0006272428,0.000033664142],"study_design_scores_gemma":[0.0016238727,0.0006018691,0.008222279,0.00031490205,0.00030841833,4.3241752e-7,0.00004059977,0.00027806475,0.9749326,0.0000018070127,0.013023845,0.0006512969],"about_ca_topic_score_codex":0.0003453388,"about_ca_topic_score_gemma":0.0000025099264,"teacher_disagreement_score":0.018255072,"about_ca_system_score_codex":0.0006981026,"about_ca_system_score_gemma":0.0012015267,"threshold_uncertainty_score":0.9995763},"labels":[],"label_agreement":null},{"id":"W4309014062","doi":"10.1007/978-1-0716-2740-2_15","title":"Induction of Human T Cell Development In Vitro with OP9-DL4-7FS Cells Expressing Human Cytokines","year":2022,"lang":"en","type":"article","venue":"Methods in molecular biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Hospital","funders":"Canadian Institutes of Health Research","keywords":"Cell biology; Biology; Haematopoiesis; Stromal cell; Stem cell; Cancer research","score_opus":0.05628862039573744,"score_gpt":0.42594063827114825,"score_spread":0.3696520178754108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309014062","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9638338,0.0002764344,0.033595376,0.000056278754,0.000086455526,0.0005004949,0.0000025445747,0.000018141482,0.0016304578],"genre_scores_gemma":[0.56596136,0.000005099926,0.43309432,0.00011397135,0.000028474433,0.00016589194,0.000053211406,0.000040065202,0.00053763494],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99675786,0.0017420865,0.00046104423,0.00043636354,0.00022992601,0.00037273485],"domain_scores_gemma":[0.9992819,0.00009514542,0.00013714518,0.00037263395,0.00005662847,0.000056544264],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020134822,0.00017531574,0.00048468285,0.0006465828,0.000101926824,0.0000060331727,0.00020828795,0.00012151662,0.0005020556],"category_scores_gemma":[0.000037624945,0.00016183434,0.000058908,0.00055890455,0.00016719429,0.000017784016,0.00025285443,0.0006155169,7.343625e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003916964,0.00027345624,0.0019690932,0.00006487336,0.000028772361,0.00010523556,0.0009967632,0.00008357009,0.9807957,0.00005184935,0.000004843973,0.015234184],"study_design_scores_gemma":[0.0019964133,0.00058143685,0.00063718454,0.000027876702,0.000011664869,0.000026192574,0.0003567987,0.000025040355,0.99278426,0.00041697093,0.002981887,0.00015429352],"about_ca_topic_score_codex":0.00020833028,"about_ca_topic_score_gemma":0.000017185555,"teacher_disagreement_score":0.39949894,"about_ca_system_score_codex":0.0002692176,"about_ca_system_score_gemma":0.00014284461,"threshold_uncertainty_score":0.6599413},"labels":[],"label_agreement":null},{"id":"W4309153013","doi":"10.3390/ijms232214122","title":"Inflammatory Cytokines That Enhance Antigen Responsiveness of Naïve CD8+ T Lymphocytes Modulate Chromatin Accessibility of Genes Impacted by Antigen Stimulation","year":2022,"lang":"en","type":"article","venue":"International Journal of Molecular Sciences","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"Faculty of Medicine and Health, University of Sydney; Natural Sciences and Engineering Research Council of Canada; Université de Sherbrooke","keywords":"Priming (agriculture); Antigen; Biology; Cytokine; Cytotoxic T cell; Chromatin; Cell biology; CD8; Immunology; Antigen-presenting cell; Immune system; T cell; Molecular biology; Gene; In vitro; Genetics","score_opus":0.025427066133956285,"score_gpt":0.35879840258692147,"score_spread":0.3333713364529652,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309153013","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99596334,0.002278065,0.0008174241,0.00031897673,0.00025767434,0.00020213723,0.00003831613,0.0000069494613,0.00011710497],"genre_scores_gemma":[0.9987255,0.00034350713,0.00074067235,0.000057029403,0.000046501704,0.0000037804432,0.000009955092,0.000011335064,0.00006174379],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99622464,0.00031435007,0.0006852331,0.0002218756,0.0023748688,0.00017900884],"domain_scores_gemma":[0.9975075,0.00019909476,0.00093115825,0.00019363762,0.001082837,0.00008577904],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018973828,0.00012772113,0.00034614876,0.000537454,0.000096322714,0.000041837186,0.0008221964,0.000041745527,0.0006911647],"category_scores_gemma":[0.00030545547,0.000107716805,0.00019540204,0.000476335,0.00038194822,0.00032876842,0.00021372884,0.00015105197,5.8063995e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010519786,0.00012838418,0.10373907,0.000023811848,0.0001765524,0.000079817546,0.00028229284,0.0053513106,0.882149,0.000016877224,0.000021427035,0.0069794827],"study_design_scores_gemma":[0.0008662926,0.00046894923,0.17259638,0.000098630604,0.000014900589,0.00014001325,0.0002162865,0.002551309,0.8225035,0.00023385603,0.00023113858,0.00007876094],"about_ca_topic_score_codex":0.0000899785,"about_ca_topic_score_gemma":0.0000028587917,"teacher_disagreement_score":0.068857305,"about_ca_system_score_codex":0.00023490243,"about_ca_system_score_gemma":0.0008979958,"threshold_uncertainty_score":0.75677687},"labels":[],"label_agreement":null},{"id":"W4309407667","doi":"10.1101/2022.11.17.516906","title":"Adaptation to <i>ex vivo</i> culture drives human haematopoietic stem cell loss of repopulation capacity in a cell cycle independent manner","year":2022,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Blood Cancer UK; Cancer Research UK Cambridge Institute, University of Cambridge; National Institute for Health and Care Research; Cancer Research UK","keywords":"Haematopoiesis; Biology; Ex vivo; Stem cell; Cell biology; Cell cycle; Regeneration (biology); Immunology; Cancer research; In vivo; Gene; Genetics","score_opus":0.03236226140086407,"score_gpt":0.2654378159602654,"score_spread":0.23307555455940132,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309407667","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957268,0.00044725058,0.00028206306,0.00012789173,0.00042010742,0.0025225156,0.00015581986,0.000154219,0.00016329915],"genre_scores_gemma":[0.99698514,0.00009320628,0.0016565403,0.000120485485,0.00019074632,0.0003858171,0.0000032056003,0.00016616621,0.00039870184],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9952761,0.0004040351,0.001090769,0.001255586,0.0013558097,0.0006176903],"domain_scores_gemma":[0.99672395,0.00004921714,0.00065164774,0.0016451576,0.0005551186,0.00037493705],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010875546,0.0005684695,0.000994564,0.0007366746,0.000148896,0.000090105656,0.0005103258,0.00056540966,0.00074955507],"category_scores_gemma":[0.000049192888,0.00062024815,0.0002664214,0.00096905685,0.00010664547,0.00012827528,0.0006471237,0.0015879206,0.00002797448],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022213446,0.00070124015,0.029943122,0.0019724157,0.00007407003,0.00023142905,0.0009906439,0.003374653,0.96220565,0.000114604685,0.00016729314,0.000002759957],"study_design_scores_gemma":[0.0025046812,0.0004619367,0.115497865,0.00081903563,0.00018222089,2.2766673e-7,0.00030175073,0.0009415111,0.8752432,0.00001050131,0.0031146924,0.0009223842],"about_ca_topic_score_codex":0.0007399105,"about_ca_topic_score_gemma":0.000052589436,"teacher_disagreement_score":0.08696245,"about_ca_system_score_codex":0.0011173374,"about_ca_system_score_gemma":0.0004719775,"threshold_uncertainty_score":0.9996249},"labels":[],"label_agreement":null},{"id":"W4309411030","doi":"10.1200/jco.22.00642","title":"Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":357,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Lymphoblastic Leukemia; Refractory (planetary science); Oncology; Young adult; Pediatrics; Internal medicine; Leukemia","score_opus":0.04583295466574167,"score_gpt":0.38603387227293473,"score_spread":0.34020091760719307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309411030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99710256,0.00018543296,0.000009465925,0.00090717187,0.0006431332,0.00052818895,0.000007967496,0.0000024723174,0.0006135927],"genre_scores_gemma":[0.9971432,0.0013069097,0.00022458412,0.000654456,0.0005389578,0.0000139326,0.000004313023,0.00002036826,0.00009327727],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958494,0.0009158649,0.0018499172,0.00020338502,0.000913288,0.00026817602],"domain_scores_gemma":[0.9960063,0.0022155975,0.0011234642,0.00023253958,0.00025965623,0.0001624064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004600054,0.00012419488,0.0010355253,0.0003728585,0.000041437033,0.0000069220305,0.00029972792,0.0001858767,0.00040392575],"category_scores_gemma":[0.0015681596,0.00007710081,0.0001851329,0.0005296888,0.00018264845,0.000082170714,0.0001162002,0.0018840298,0.0000037031277],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2215448,0.0024221523,0.748802,0.000028684311,0.00018182545,0.0009481128,0.00035244925,0.000037525137,0.00005908086,0.00002747891,0.0019765997,0.023619272],"study_design_scores_gemma":[0.16406457,0.04032029,0.7919285,0.00002689845,0.00028285576,0.00012870424,0.00022489703,0.00013112667,0.0000031925133,0.0001453118,0.002658744,0.00008487225],"about_ca_topic_score_codex":0.00010900203,"about_ca_topic_score_gemma":0.0004405515,"teacher_disagreement_score":0.057480223,"about_ca_system_score_codex":0.00060482905,"about_ca_system_score_gemma":0.002818517,"threshold_uncertainty_score":0.8185277},"labels":[],"label_agreement":null},{"id":"W4309778403","doi":"10.3389/fimmu.2022.1018786","title":"CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil","year":2022,"lang":"en","type":"review","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada","funders":"","keywords":"Triple-negative breast cancer; Chimeric antigen receptor; Breast cancer; Medicine; Cancer; Targeted therapy; Radiation therapy; Estrogen receptor; Cancer research; Oncology; Immunotherapy; Antigen; Immunology; Internal medicine","score_opus":0.04445785183428317,"score_gpt":0.33926570727339384,"score_spread":0.29480785543911064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4309778403","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00035273298,0.9893915,0.00000729207,0.0004301674,0.0024359028,0.003287436,0.00009247428,0.000043948414,0.00395852],"genre_scores_gemma":[0.0000405953,0.98945487,0.00016488889,0.00022953609,0.00024459034,0.0019693207,0.000116484254,0.00016107147,0.007618662],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9948269,0.0017635643,0.0010598591,0.00083343714,0.00046322055,0.0010529784],"domain_scores_gemma":[0.9976875,0.0006385097,0.0004552397,0.0010787292,0.00006995059,0.00007005648],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012212746,0.0006236785,0.002925294,0.0013633266,0.0001831472,0.000036150475,0.0010719284,0.00059449044,0.005791044],"category_scores_gemma":[0.00014255078,0.0004561886,0.00057390437,0.0023558985,0.00048660944,0.00007821654,0.00039759176,0.0038897244,0.000023385595],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005028103,0.00018637793,0.0018624704,0.0013144813,0.00059194205,0.00012339231,0.0008659922,0.0000025636286,0.000026484875,0.00000944125,0.003941809,0.9905722],"study_design_scores_gemma":[0.0032127334,0.00027435456,0.00054852146,0.0017811813,0.00014121327,0.00017535567,0.0013367203,0.000017814124,0.00002308017,0.00007579152,0.9920342,0.00037901325],"about_ca_topic_score_codex":0.0042505204,"about_ca_topic_score_gemma":0.00038492252,"teacher_disagreement_score":0.99019325,"about_ca_system_score_codex":0.0024076668,"about_ca_system_score_gemma":0.0019504876,"threshold_uncertainty_score":0.999789},"labels":[],"label_agreement":null},{"id":"W4310096555","doi":"10.1182/blood-2022-167804","title":"High Metabolic Tumor Volume Is Associated with Higher Toxicity and Decreased Efficacy of BCMA CAR-T Cell Therapy in Multiple Myeloma","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Multiple myeloma; Bone marrow; Chimeric antigen receptor; Internal medicine; Oncology; Lenalidomide; Cohort; Chemotherapy; Cancer; Immunotherapy","score_opus":0.018692912816314654,"score_gpt":0.25275916974395557,"score_spread":0.2340662569276409,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310096555","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99700177,0.0012585776,8.5850684e-7,0.0002499609,0.0000400533,0.00085584656,0.00008575539,0.000049356866,0.00045780864],"genre_scores_gemma":[0.9956166,0.00008980127,0.00014116397,0.00041003345,0.00005599486,0.000102162994,0.000047340265,0.000058440583,0.00347842],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99796927,0.00026596765,0.0003000641,0.00038769117,0.00068099,0.00039601038],"domain_scores_gemma":[0.99892634,0.00025586906,0.00013222203,0.00040444118,0.00010569189,0.00017546126],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00043806658,0.00020665351,0.00060348946,0.00021502546,0.00009618758,0.000014340682,0.00016230199,0.00006046371,0.0041741137],"category_scores_gemma":[0.00008490994,0.00017674007,0.00009538604,0.0006869475,0.00011353068,0.00003992874,0.00009558397,0.0003939495,0.0000041986696],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022197806,0.006369147,0.4581431,0.000034222423,0.0004652847,0.000220986,0.0009304714,0.000009157034,0.52905035,0.000012236084,0.00026520016,0.0022800472],"study_design_scores_gemma":[0.03457656,0.0014308649,0.7327719,0.0000239791,0.00011850897,0.000021213738,0.00008642768,0.00008653499,0.22821404,0.000011728842,0.0024807556,0.00017751192],"about_ca_topic_score_codex":0.0011908711,"about_ca_topic_score_gemma":0.000079612524,"teacher_disagreement_score":0.30083632,"about_ca_system_score_codex":0.00006912133,"about_ca_system_score_gemma":0.00019373115,"threshold_uncertainty_score":0.9967362},"labels":[],"label_agreement":null},{"id":"W4310096775","doi":"10.1182/blood-2022-168374","title":"Proteomic Profiles of Cytokine Release Syndromes Following Lisocabtagene Maraleucel and Idecabtagene Vicleucel","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cytokine; Immunology; Medicine","score_opus":0.022189981912104303,"score_gpt":0.28224858206499914,"score_spread":0.26005860015289484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310096775","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99504447,0.0014128007,0.0000101933965,0.0004158963,0.00007630369,0.0013460533,0.00005913411,0.00007624977,0.0015588872],"genre_scores_gemma":[0.9916156,0.0001467402,0.0010607382,0.00012728214,0.000094381794,0.00033162578,0.00004247113,0.00006788286,0.0065132887],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99795324,0.00014456223,0.00037668305,0.0004193931,0.00071271835,0.00039338382],"domain_scores_gemma":[0.9990726,0.000066529545,0.000105789186,0.0004990025,0.00005725609,0.00019881869],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00057004625,0.00019831306,0.0004878795,0.00025499656,0.00018777863,0.000018649882,0.00018469618,0.00006188096,0.002013844],"category_scores_gemma":[0.000107626794,0.00019353391,0.0001945835,0.0004372343,0.00008768244,0.00007066216,0.0003380284,0.00036745312,0.000009534802],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040080058,0.0007919887,0.050622046,0.00027338296,0.00034451904,0.00059891504,0.00024929133,0.000005619574,0.94357175,0.00003931685,0.00020819355,0.0028942064],"study_design_scores_gemma":[0.012991661,0.0022802283,0.07255426,0.00013905007,0.0004968835,0.0011074239,0.0003594707,0.00015499388,0.90603215,0.0002087955,0.0032941597,0.00038091204],"about_ca_topic_score_codex":0.00010132615,"about_ca_topic_score_gemma":0.0000021668684,"teacher_disagreement_score":0.03753956,"about_ca_system_score_codex":0.00006896882,"about_ca_system_score_gemma":0.0002066918,"threshold_uncertainty_score":0.99889845},"labels":[],"label_agreement":null},{"id":"W4310104788","doi":"10.1182/blood-2022-171228","title":"<i>DNMT3A</i> Limits Myeloid Signaling Responses in Committed T Cells during Normal and Leukemic Development","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Biology; Progenitor cell; Epigenetics; Myeloid; Haematopoiesis; Cellular differentiation; Stem cell; Cell biology; T cell; Cancer research; Genetics; Gene; Immune system","score_opus":0.02326314419817613,"score_gpt":0.2615291274510778,"score_spread":0.2382659832529017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310104788","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99746776,0.00066874037,0.0000014219388,0.00016952511,0.000048390215,0.00037673808,0.0000059451777,0.000051398194,0.0012101133],"genre_scores_gemma":[0.9940362,0.00007313522,0.00045197387,0.00022319678,0.000060832484,0.00008505454,0.000011988134,0.000034256518,0.00502337],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99841493,0.00016990304,0.00028494507,0.00027790046,0.0004608667,0.00039147038],"domain_scores_gemma":[0.9993961,0.00018985137,0.000044195913,0.00020902192,0.00003246877,0.00012838516],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00063145946,0.0001368287,0.00023750051,0.0002789964,0.00022450395,0.000021454953,0.00012299656,0.000042786825,0.0010080667],"category_scores_gemma":[0.00004336818,0.0001467485,0.000036582438,0.0003553644,0.000041885633,0.0000429587,0.0002233429,0.000512593,0.000011738834],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011532576,0.00032286826,0.067990094,0.00008458275,0.00005668538,0.00040588877,0.0013281408,0.000030514324,0.9269121,0.000001639077,0.000038536156,0.0016756885],"study_design_scores_gemma":[0.006501563,0.00019158171,0.084722206,0.000060491067,0.000026889142,0.00026972298,0.00044299717,0.000022248796,0.9029299,0.0000040247796,0.004658883,0.00016949594],"about_ca_topic_score_codex":0.000054517244,"about_ca_topic_score_gemma":0.000027081149,"teacher_disagreement_score":0.023982208,"about_ca_system_score_codex":0.00018645491,"about_ca_system_score_gemma":0.0002982481,"threshold_uncertainty_score":0.99990517},"labels":[],"label_agreement":null},{"id":"W4310109630","doi":"10.1182/blood-2022-165887","title":"Alberta Cellular and Immunotherapy (ACIT) 001, Results of Decentralized Production of Second Generation, Anti-CD19/41BB/CD3z Chimeric Antigen Receptor (CAR) T-Cells in Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) and Aggressive Non-Hodgkin Lymphoma (NHL)","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Stollery Children's Hospital; Alberta Children's Hospital; University of Alberta; University of Calgary","funders":"","keywords":"Medicine; Fludarabine; Chimeric antigen receptor; Blinatumomab; Internal medicine; Immunotherapy; Oncology; Cyclophosphamide; Clinical trial; CD19; Immunology; Antigen; Chemotherapy; Cancer","score_opus":0.010782009342702245,"score_gpt":0.24570286404493302,"score_spread":0.23492085470223079,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310109630","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940232,0.0037897092,0.0000045409593,0.000117754804,0.00041966853,0.0013390185,0.00014309686,0.000021955837,0.00014105909],"genre_scores_gemma":[0.9884622,0.0073137707,0.00053836097,0.00007259022,0.00014924257,0.00008903187,0.00035742903,0.000091795926,0.0029255685],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99671495,0.00038439292,0.00096718525,0.00079300615,0.0006472999,0.00049317826],"domain_scores_gemma":[0.9980267,0.00019820257,0.00070890714,0.00069117866,0.00020643567,0.0001685444],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007180323,0.0003595754,0.0008495051,0.0004792976,0.00015088748,0.000025376941,0.00021267161,0.00016859092,0.0008634701],"category_scores_gemma":[0.00015754726,0.00035884386,0.00012151701,0.0006643915,0.00029532786,0.00013452744,0.00015002082,0.0002850876,0.0000040417817],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032310893,0.0013127133,0.0032960013,0.00015963525,0.0007133447,0.00008223609,0.0024952157,0.000047792993,0.9830187,0.0000037428335,0.0010354382,0.004604101],"study_design_scores_gemma":[0.033562467,0.0016564054,0.011132455,0.000157464,0.00021491076,0.00026493773,0.00026419098,0.000452689,0.944615,0.000011634266,0.0073160683,0.00035175294],"about_ca_topic_score_codex":0.0013846379,"about_ca_topic_score_gemma":0.00017709924,"teacher_disagreement_score":0.038403664,"about_ca_system_score_codex":0.00029668654,"about_ca_system_score_gemma":0.000541358,"threshold_uncertainty_score":0.99988633},"labels":[],"label_agreement":null},{"id":"W4310120142","doi":"10.1182/blood-2022-157691","title":"Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Princess Margaret Cancer Centre; Jewish General Hospital; McGill University; Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Follicular lymphoma; Medicine; Refractory (planetary science); Safety profile; Oncology; Internal medicine; Rituximab; Lymphoma; Phases of clinical research; Follicular phase; Clinical trial; Adverse effect","score_opus":0.01069748530457965,"score_gpt":0.2509131653512022,"score_spread":0.24021568004662258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310120142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908718,0.00038409,0.00000679511,0.0002086429,0.000045949553,0.0063875197,0.00047701853,0.00018146879,0.0014367469],"genre_scores_gemma":[0.991339,0.00007802617,0.00063504884,0.00012362223,0.00005452605,0.00062911876,0.0011374803,0.000171577,0.005831591],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9952576,0.0005702003,0.00077842467,0.0011758275,0.0014136657,0.0008042759],"domain_scores_gemma":[0.99775434,0.0002228858,0.00032204966,0.0012414363,0.00020914654,0.0002501709],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000669276,0.0005357335,0.00090312294,0.00038383852,0.0006345869,0.00007659404,0.0004279413,0.00011948723,0.0022211059],"category_scores_gemma":[0.000053201955,0.00041441715,0.00011647187,0.0013975521,0.00014394603,0.00024029033,0.00016679423,0.00065139076,0.000013066651],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48169887,0.18706985,0.21324275,0.000076057455,0.007877487,0.0029230125,0.029926667,0.00062238215,0.024418138,0.000007279891,0.0011155286,0.051021975],"study_design_scores_gemma":[0.58849186,0.06744541,0.32310987,0.0002878327,0.0005698654,0.000040132494,0.005796387,0.00066973653,0.0049397824,0.000015333397,0.007660824,0.0009729739],"about_ca_topic_score_codex":0.0017830553,"about_ca_topic_score_gemma":0.0002947648,"teacher_disagreement_score":0.119624436,"about_ca_system_score_codex":0.00045385782,"about_ca_system_score_gemma":0.00057272206,"threshold_uncertainty_score":0.9998308},"labels":[],"label_agreement":null},{"id":"W4310126163","doi":"10.1182/blood-2022-162738","title":"Elranatamab in Combination with Daratumumab for Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 3 Magnetismm-5 Study Safety Lead-in Cohort","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University; Princess Margaret Cancer Centre","funders":"","keywords":"Daratumumab; Medicine; Multiple myeloma; Lenalidomide; Oncology; Internal medicine; Cohort; Refractory (planetary science); Materials science","score_opus":0.016252222328361206,"score_gpt":0.27809086817263956,"score_spread":0.26183864584427835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310126163","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911222,0.0001739158,0.000016776143,0.0004037611,0.00008824611,0.0066067614,0.00063174585,0.000045083412,0.0009114957],"genre_scores_gemma":[0.99614346,0.000028054625,0.0001868662,0.0001094894,0.000052775293,0.0009434267,0.001402029,0.00007024188,0.0010636625],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968168,0.00041327826,0.00053596095,0.0006730472,0.001126286,0.00043460476],"domain_scores_gemma":[0.9979403,0.0008330216,0.00017048538,0.00079256395,0.00017117783,0.00009247091],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010753692,0.00025100165,0.00044179955,0.00021536983,0.00027214718,0.000029704666,0.0003081629,0.000064928354,0.00030271008],"category_scores_gemma":[0.00027187282,0.00017901407,0.000054995897,0.0006697958,0.00009431373,0.00012043351,0.00011735192,0.0007529506,0.0000053691156],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0889956,0.04350357,0.8332185,0.000031628457,0.00038463186,0.00039364913,0.005931898,0.00006829276,0.0019962126,0.000009202409,0.0007647318,0.024702061],"study_design_scores_gemma":[0.29779533,0.023775395,0.6673665,0.000080688515,0.00019697499,0.000012643591,0.002783973,0.0006514437,0.0005312425,0.000015434644,0.006529746,0.00026064223],"about_ca_topic_score_codex":0.001649609,"about_ca_topic_score_gemma":0.004403998,"teacher_disagreement_score":0.20879972,"about_ca_system_score_codex":0.00034688629,"about_ca_system_score_gemma":0.00023546537,"threshold_uncertainty_score":0.7299982},"labels":[],"label_agreement":null},{"id":"W4310142579","doi":"10.3390/curroncol29120725","title":"Cost-Effectiveness Analysis of Sequential Treatment Strategies for Advanced Melanoma in Real Life in France","year":2022,"lang":"en","type":"article","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Population; Neuroblastoma RAS viral oncogene homolog; Cohort; Sequence (biology); Oncology; Melanoma; Internal medicine; Pediatrics; Cancer; KRAS; Genetics; Cancer research; Biology","score_opus":0.19956944273886637,"score_gpt":0.5002350967732713,"score_spread":0.30066565403440493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310142579","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99547935,0.0011579861,0.000345729,0.00011193097,0.00034195228,0.001956504,0.00009035974,0.000012169264,0.0005040092],"genre_scores_gemma":[0.99659175,0.00043313106,0.00005113319,0.000012626502,0.000047348047,0.0025346552,0.00020631264,0.000012908716,0.00011012935],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998427,0.0004360886,0.00034200936,0.00030819455,0.0001990918,0.00028763374],"domain_scores_gemma":[0.9990636,0.00048381602,0.00010192665,0.00020889785,0.00007120883,0.00007053054],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005276762,0.000119958306,0.0007765166,0.0006501214,0.000034562698,0.0000036527442,0.000097696626,0.000055608816,0.0007552303],"category_scores_gemma":[0.00004775411,0.000114446455,0.00018385728,0.0009843333,0.00009854127,0.000037696915,0.000054015167,0.00020964457,8.200401e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009835986,0.0047001527,0.5604919,0.0002884721,0.0010971886,0.00010348655,0.0030678534,0.020161372,0.056324102,0.0010651906,0.000026411804,0.34283787],"study_design_scores_gemma":[0.048257887,0.018269058,0.7881238,0.00009139532,0.0012184854,0.000015748557,0.0062826807,0.023679972,0.0056607574,0.00047716728,0.10750159,0.00042145813],"about_ca_topic_score_codex":0.00045613231,"about_ca_topic_score_gemma":0.0011112505,"teacher_disagreement_score":0.3424164,"about_ca_system_score_codex":0.0014566528,"about_ca_system_score_gemma":0.0008399606,"threshold_uncertainty_score":0.8269242},"labels":[],"label_agreement":null},{"id":"W4310159202","doi":"10.1182/blood-2022-158492","title":"Association of Metabolic Tumor Volume (MTV) and Clinical Outcomes in Second-Line (2L) Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Following Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care (SOC) Therapy in ZUMA-7","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Refractory (planetary science); Oncology; Lymphoma; Internal medicine; Physics","score_opus":0.026009783173247546,"score_gpt":0.3245871880200717,"score_spread":0.29857740484682416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310159202","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98776615,0.009381357,0.000002118958,0.0001845287,0.00047141156,0.0008718096,0.00027828856,0.00003294283,0.0010113834],"genre_scores_gemma":[0.9950174,0.0013918868,0.00018059,0.00014518201,0.0000939913,0.000077653436,0.00008442718,0.000070436756,0.0029384524],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99583423,0.0006989913,0.0011696973,0.0005425171,0.0011788916,0.0005756818],"domain_scores_gemma":[0.99785745,0.00082206697,0.0004425337,0.00054984546,0.00016800268,0.00016010342],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0028638453,0.00028599848,0.0013921453,0.00046901897,0.00009385512,0.000016794704,0.00026483697,0.00019709216,0.0015200649],"category_scores_gemma":[0.00055054534,0.00028643178,0.0004977415,0.0006278887,0.00006290071,0.00010947968,0.00023383182,0.0007042456,0.000005032445],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007073175,0.0070751235,0.9584497,0.00013527375,0.00085546455,0.00022575421,0.0016768972,0.000003417423,0.014978563,0.000023447596,0.000116235344,0.009386924],"study_design_scores_gemma":[0.26024416,0.010864707,0.65930694,0.00009785023,0.00055218494,0.000011984081,0.0036509414,0.00009559107,0.025955703,0.000050149923,0.038615014,0.0005547994],"about_ca_topic_score_codex":0.00015817607,"about_ca_topic_score_gemma":0.00059499673,"teacher_disagreement_score":0.2991428,"about_ca_system_score_codex":0.000387485,"about_ca_system_score_gemma":0.00059601123,"threshold_uncertainty_score":0.9999588},"labels":[],"label_agreement":null},{"id":"W4310163262","doi":"10.1182/blood-2022-160319","title":"A Phase 3 Study of Tafasitamab Plus Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)","year":2022,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Lenalidomide; Diffuse large B-cell lymphoma; Refractory (planetary science); Medicine; Internal medicine; Phases of clinical research; Lymphoma; Oncology; Gastroenterology; Multiple myeloma; Clinical trial; Materials science","score_opus":0.018524220612302716,"score_gpt":0.2875345803979591,"score_spread":0.26901035978565635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310163262","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969411,0.00011065579,0.0000014773514,0.000026595739,0.00005679283,0.0019466557,0.000071240196,0.000034606852,0.00081087544],"genre_scores_gemma":[0.99512947,0.0000083465575,0.00004051003,0.0000841686,0.000038203245,0.00022176445,0.00006631261,0.000068431764,0.004342796],"study_design_codex":"nonrandomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9972245,0.0003000598,0.00044362235,0.00042704638,0.001158219,0.00044655582],"domain_scores_gemma":[0.9987053,0.00014485721,0.00017070623,0.00070507603,0.0001151611,0.00015886882],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00047409747,0.00021106286,0.000545197,0.0003701497,0.00010812747,0.000010959816,0.00023791184,0.00005603421,0.0016859464],"category_scores_gemma":[0.00008165804,0.0001642989,0.00007343883,0.00069487974,0.000043484575,0.00006707201,0.00021215751,0.00036038537,0.000009581936],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.076134086,0.67102426,0.2232356,0.00017811224,0.0004948952,0.0017546273,0.009685215,0.0000046219234,0.013927913,0.0000031384793,0.0003569609,0.003200573],"study_design_scores_gemma":[0.89042866,0.045143336,0.049000047,0.000057610156,0.0003190839,0.000026173244,0.0052669123,0.000040252653,0.0066300007,0.0000025722197,0.0028043306,0.0002810349],"about_ca_topic_score_codex":0.000201694,"about_ca_topic_score_gemma":0.00014182829,"teacher_disagreement_score":0.8142946,"about_ca_system_score_codex":0.00029392843,"about_ca_system_score_gemma":0.0004119538,"threshold_uncertainty_score":0.9992266},"labels":[],"label_agreement":null},{"id":"W4310603204","doi":"10.1016/j.ymthe.2022.11.010","title":"Cellular therapy: Great promise, but at what cost?","year":2022,"lang":"en","type":"article","venue":"Molecular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Toronto General Hospital","funders":"","keywords":"Chimeric antigen receptor; Medicine; Mantle cell lymphoma; Lymphoma; Follicular lymphoma; Cancer research; Oncology; Immunotherapy; Immunology; Internal medicine; Cancer","score_opus":0.0356913478571717,"score_gpt":0.29700168404124355,"score_spread":0.26131033618407185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310603204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9604656,0.028254608,0.00013801099,0.0032783267,0.0003818445,0.003016666,0.000016371145,0.00018725127,0.0042612916],"genre_scores_gemma":[0.8755212,0.01603202,0.0002696361,0.01219798,0.0003435034,0.0020118211,0.0003652948,0.00040261206,0.09285595],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9962848,0.00046014777,0.00035402612,0.0007277769,0.0014184033,0.0007548876],"domain_scores_gemma":[0.9981206,0.000064727414,0.0000993738,0.0012611315,0.00013299815,0.00032117942],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006691923,0.00038846204,0.00051262515,0.00025389026,0.00044254426,0.00012950553,0.00046145928,0.000116690666,0.03882405],"category_scores_gemma":[0.000015303382,0.00035138318,0.00042997664,0.00057684875,0.00015000657,0.00013526194,0.0002517321,0.0006393431,0.00021692688],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032079546,0.00036458907,0.0005510415,0.000013027556,0.0003167469,0.0010531466,0.00063527795,0.00003109673,0.83165014,0.000054474283,0.0013047344,0.16081776],"study_design_scores_gemma":[0.005649475,0.0011014208,0.00018652086,0.000014520773,0.000014437753,0.00016489245,0.00023836223,0.0000946756,0.5217102,0.0001543256,0.4704105,0.00026066598],"about_ca_topic_score_codex":0.000052728392,"about_ca_topic_score_gemma":0.0000023264972,"teacher_disagreement_score":0.46910578,"about_ca_system_score_codex":0.0006035537,"about_ca_system_score_gemma":0.00020514315,"threshold_uncertainty_score":0.99989384},"labels":[],"label_agreement":null},{"id":"W4310747261","doi":"10.1136/jitc-2022-005360","title":"Computational model of CAR T-cell immunotherapy dissects and predicts leukemia patient responses at remission, resistance, and relapse","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Division of Chemical, Bioengineering, Environmental, and Transport Systems; York University; New York University; Leukemia and Lymphoma Society; AstraZeneca; National Institute of General Medical Sciences; Cancer Research Institute; National Cancer Institute; National Institutes of Health; National Science Foundation","keywords":"Chimeric antigen receptor; CD19; Medicine; T cell; Immunotherapy; Clinical trial; Leukemia; Oncology; Internal medicine; Antigen; Immunology; Cancer; Immune system","score_opus":0.020053779762780204,"score_gpt":0.31615903936231066,"score_spread":0.29610525959953043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310747261","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95115995,0.04657307,0.00024552442,0.0006321145,0.00018514412,0.00070570706,0.0002094568,0.000011523874,0.00027751346],"genre_scores_gemma":[0.93907183,0.020687042,0.004105726,0.00044418455,0.000074851596,0.00015539968,0.000022199587,0.00010775303,0.035331033],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99778444,0.00014688513,0.0006844961,0.00025663478,0.00084641896,0.00028111224],"domain_scores_gemma":[0.9983884,0.00032176203,0.00050949317,0.000257722,0.00038496943,0.00013761701],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069969456,0.00020039271,0.00051339954,0.00026886156,0.00044611565,0.000018852204,0.00014294553,0.00007592208,0.0007548997],"category_scores_gemma":[0.00003808342,0.00017414037,0.00018619724,0.00018926381,0.00021860359,0.000088914734,0.00006921101,0.0003931541,8.884756e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.056111697,0.00018607058,0.0027755185,0.00023072305,0.00039759706,0.000009523184,0.0041528447,0.008330196,0.9015805,0.000053386306,0.0057741837,0.020397728],"study_design_scores_gemma":[0.08264099,0.0154927755,0.025465155,0.0017755,0.00039075754,0.0010303404,0.0031105804,0.048229977,0.36775807,0.010587334,0.44206902,0.001449504],"about_ca_topic_score_codex":0.00004117941,"about_ca_topic_score_gemma":0.000008254236,"teacher_disagreement_score":0.5338225,"about_ca_system_score_codex":0.00070655916,"about_ca_system_score_gemma":0.0008747673,"threshold_uncertainty_score":0.8265622},"labels":[],"label_agreement":null},{"id":"W4311504925","doi":"10.3389/fonc.2022.1062592","title":"Theranostic digital twins for personalized radiopharmaceutical therapies: Reimagining theranostics via computational nuclear oncology","year":2022,"lang":"en","type":"article","venue":"Frontiers in Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo; University of British Columbia","funders":"Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research","keywords":"Medicine; Personalized medicine; Scale (ratio); Precision medicine; Medical physics; Computer science; Bioinformatics; Pathology; Biology","score_opus":0.0407797552147476,"score_gpt":0.37007987908496026,"score_spread":0.3293001238702127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311504925","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.33216712,0.012481877,0.41615418,0.13630494,0.018222492,0.015049172,0.000925107,0.00091996347,0.067775145],"genre_scores_gemma":[0.8950705,0.0004311025,0.077547185,0.014071778,0.0010912375,0.00086233614,0.0005146949,0.00030068823,0.010110509],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99725896,0.00048297225,0.000511473,0.00052960886,0.00052305416,0.0006939181],"domain_scores_gemma":[0.99782574,0.0014491003,0.00012945579,0.00024660604,0.00013799751,0.0002110821],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008494903,0.000256679,0.0008178777,0.00041010973,0.00030293255,0.00003431018,0.00034090108,0.0001924217,0.0036063504],"category_scores_gemma":[0.00024772165,0.00023522828,0.00024977972,0.00039365757,0.0006167194,0.000091280715,0.00015228544,0.0011719752,0.000017831115],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04011042,0.003965157,0.02024947,0.00015526258,0.001796001,0.0013106244,0.022155305,0.00301938,0.018695828,0.0034235734,0.09932509,0.7857939],"study_design_scores_gemma":[0.014502128,0.0039781756,0.0005481466,0.000011659727,0.00008883035,0.00047299385,0.0043150075,0.059429906,0.000026054848,0.0033305434,0.9130474,0.00024921147],"about_ca_topic_score_codex":0.000012990707,"about_ca_topic_score_gemma":0.000001375647,"teacher_disagreement_score":0.81372225,"about_ca_system_score_codex":0.0023249357,"about_ca_system_score_gemma":0.0010167655,"threshold_uncertainty_score":0.9973045},"labels":[],"label_agreement":null},{"id":"W4312079433","doi":"10.21203/rs.3.rs-2378631/v1","title":"Harnessing CD3 diversity to optimise CAR T cells","year":2022,"lang":"en","type":"preprint","venue":"Research Square","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"European Commission; Deutsche Forschungsgemeinschaft; European Federation of Pharmaceutical Industries and Associations; McGill University","keywords":"Diversity (politics); Business; Computer science; Sociology; Anthropology","score_opus":0.13631357775516698,"score_gpt":0.43488102919819493,"score_spread":0.298567451443028,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312079433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9340978,0.0014166665,0.00015948123,0.006133949,0.0009666425,0.00719649,0.0004941326,0.0003299392,0.04920487],"genre_scores_gemma":[0.82200223,0.0014897558,0.0021340535,0.00041384003,0.0015240695,0.0008356517,0.00060230086,0.00029523982,0.17070284],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99004304,0.0012097671,0.00039913406,0.001479818,0.005232194,0.0016360655],"domain_scores_gemma":[0.9945497,0.00056635693,0.000075633005,0.0023047787,0.00120294,0.0013006077],"candidate_categories":["metaepi_narrow","sts","open_science","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0044460446,0.00042550694,0.00083299424,0.0015653794,0.0014133917,0.0002748158,0.0013673893,0.00043208888,0.044521116],"category_scores_gemma":[0.00058748364,0.0004391487,0.00050426315,0.0013469621,0.00029462288,0.00007429637,0.02170627,0.006192417,0.0006580086],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012986321,0.0038889025,0.05503701,0.019825764,0.0020079066,0.015219954,0.03454453,0.014605406,0.43388388,0.00029649126,0.28660354,0.12110029],"study_design_scores_gemma":[0.0063352147,0.0041861357,0.026592828,0.0041116923,0.00027635903,0.00009947676,0.013684797,0.003200798,0.0581883,0.0010014843,0.8799546,0.0023683112],"about_ca_topic_score_codex":0.0026030296,"about_ca_topic_score_gemma":0.00005425061,"teacher_disagreement_score":0.59335107,"about_ca_system_score_codex":0.0029050717,"about_ca_system_score_gemma":0.0018328428,"threshold_uncertainty_score":0.99988663},"labels":[],"label_agreement":null},{"id":"W4312137408","doi":"10.21203/rs.3.rs-2355585/v1","title":"Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ- PBMC-HPV) in HLA-A*02+ patients with HPV16+ Solid Tumors","year":2022,"lang":"en","type":"preprint","venue":"Research Square","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Peripheral blood mononuclear cell; Medicine; Pharmacodynamics; Tolerability; CD8; Immune system; Antigen; Immunotherapy; Immunology; Human leukocyte antigen; Internal medicine; Adverse effect; Pharmacokinetics; Biology; In vitro","score_opus":0.08236097604119805,"score_gpt":0.4336529150774708,"score_spread":0.35129193903627276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312137408","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9787639,0.00031927344,0.000087262895,0.0015223237,0.00012210038,0.017358085,0.00041693606,0.000065518725,0.001344631],"genre_scores_gemma":[0.99585736,0.00013798407,0.00021017445,0.00007725346,0.00017402231,0.001021855,0.00022632432,0.00016339385,0.002131627],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9885322,0.0022429205,0.0012085635,0.0016747307,0.0046576234,0.0016839716],"domain_scores_gemma":[0.99401087,0.0011156419,0.0002267581,0.0025396813,0.0012445716,0.00086248235],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0051977653,0.00063260656,0.0016028383,0.001962316,0.00049433217,0.00016529617,0.0011793257,0.00020996846,0.0015696045],"category_scores_gemma":[0.0010506889,0.00045601328,0.00019653485,0.002063963,0.0004495167,0.000079244215,0.005148203,0.0034306087,0.00001348321],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.104787976,0.03783985,0.47578004,0.0054264218,0.0018785812,0.004245485,0.07963523,0.017279241,0.013818167,0.00004786845,0.002306865,0.25695428],"study_design_scores_gemma":[0.03580886,0.056230593,0.8619435,0.0026462073,0.00023501861,0.00007049535,0.020253265,0.007823021,0.007165828,0.00011992938,0.006151204,0.00155211],"about_ca_topic_score_codex":0.0028789649,"about_ca_topic_score_gemma":0.0008339378,"teacher_disagreement_score":0.3861634,"about_ca_system_score_codex":0.0011669825,"about_ca_system_score_gemma":0.001303549,"threshold_uncertainty_score":0.9997892},"labels":[],"label_agreement":null},{"id":"W4313201618","doi":"10.1016/j.clml.2022.12.011","title":"SOHO State of the Art Updates and Next Questions | Optimal Timing of Blinatumomab for the Treatment of B-Acute Lymphoblastic Leukemia","year":2022,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Blinatumomab; Medicine; Hematopoietic stem cell transplantation; CD19; Minimal residual disease; Chemotherapy; Lymphoblastic Leukemia; Oncology; Leukemia; Internal medicine; Transplantation; Immunology; Antibody","score_opus":0.10113126277775292,"score_gpt":0.40438592425702263,"score_spread":0.3032546614792697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313201618","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.025915645,0.9667391,0.00008573849,0.00016331293,0.0007264296,0.0048767724,0.0010238065,0.00004835969,0.00042083857],"genre_scores_gemma":[0.0012175854,0.99185735,0.0006729458,0.00006170161,0.00028509696,0.00066042773,0.00023895975,0.00016446286,0.0048414627],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9941471,0.00063385826,0.0028914507,0.00085973064,0.00083753484,0.00063028216],"domain_scores_gemma":[0.9865071,0.009485436,0.001654427,0.0017819034,0.00030367862,0.00026741254],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014081242,0.00071532436,0.0038421063,0.00026535874,0.00026433598,0.000036818426,0.0008473906,0.0004220765,0.00060806534],"category_scores_gemma":[0.0008155979,0.00041055086,0.0024727036,0.00080603256,0.0016870234,0.000075448945,0.0004498371,0.00044563727,0.000011076022],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009823121,0.00043789455,0.00004893799,0.0039284364,0.0028085755,0.000035852987,0.00016692792,0.000024465608,0.000074987045,0.00007913315,0.0008009368,0.99061155],"study_design_scores_gemma":[0.004830873,0.0038312362,0.003505075,0.0038781858,0.0076842434,0.00037579445,0.00006324329,0.00209604,0.00022082427,0.00007277156,0.9730756,0.000366101],"about_ca_topic_score_codex":0.000121180885,"about_ca_topic_score_gemma":0.0000105909785,"teacher_disagreement_score":0.99024546,"about_ca_system_score_codex":0.0027413687,"about_ca_system_score_gemma":0.007795475,"threshold_uncertainty_score":0.99983466},"labels":[],"label_agreement":null},{"id":"W4313245350","doi":"10.3390/cancers15010094","title":"Adoptive Cell Therapy for T-Cell Malignancies","year":2022,"lang":"en","type":"review","venue":"Cancers","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Cell therapy; Adoptive cell transfer; Medicine; Cell; T cell; Immunology; Immune system; Biology","score_opus":0.12192030993947205,"score_gpt":0.38934349601605395,"score_spread":0.2674231860765819,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313245350","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000012553861,0.96507305,0.000016802473,0.000025472933,0.0006110735,0.0043103565,0.00026034794,0.000062613246,0.02962771],"genre_scores_gemma":[0.0000014964455,0.8983309,0.00016242084,0.0002821519,0.0005592238,0.0027688406,0.00041770848,0.00018285765,0.097294375],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99777347,0.000119194396,0.00040091434,0.000622075,0.0004955806,0.00058879546],"domain_scores_gemma":[0.9984456,0.00036149065,0.00023408265,0.0006606658,0.00009774247,0.00020042491],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00036594292,0.00045279058,0.0016422463,0.00024622766,0.00013990048,0.00002773369,0.0003709444,0.00022842469,0.01796355],"category_scores_gemma":[0.000022799935,0.0003700592,0.0010464924,0.0004700252,0.00012280613,0.000029827266,0.000077143006,0.0006804308,0.000057691843],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00024533377,0.000043711378,8.222125e-7,0.013033951,0.00021083186,0.000035435307,0.00021523224,0.0000025171928,0.000119428536,0.000011874844,0.033842288,0.95223856],"study_design_scores_gemma":[0.001588406,0.0009702335,1.7147347e-7,0.0011689471,0.00034540583,0.000017307959,0.00020284293,0.000004398997,0.00023850604,0.000008046849,0.99511784,0.0003378981],"about_ca_topic_score_codex":0.000089351604,"about_ca_topic_score_gemma":0.0000041573153,"teacher_disagreement_score":0.9612755,"about_ca_system_score_codex":0.0045284885,"about_ca_system_score_gemma":0.0058044,"threshold_uncertainty_score":0.9998751},"labels":[],"label_agreement":null},{"id":"W4313334167","doi":"10.1016/j.clml.2022.12.015","title":"CAR T-Cells for the Treatment of Refractory or Relapsed Large B-Cell Lymphoma: A Single-Center Retrospective Canadian Study","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre hospitalier de l'Université Laval; Université Laval","funders":"","keywords":"Medicine; Cytokine release syndrome; Internal medicine; Refractory (planetary science); Chimeric antigen receptor; Lymphoma; Retrospective cohort study; Cohort; Population; Oncology; Clinical trial; Gastroenterology; Immunotherapy; Cancer","score_opus":0.057318149621745584,"score_gpt":0.3451042323808731,"score_spread":0.28778608275912754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313334167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886291,0.00057768653,0.000010285618,0.0004435907,0.0012631097,0.0053072646,0.0006453031,0.00007775393,0.0030458916],"genre_scores_gemma":[0.9695012,0.00027632347,0.000107912056,0.00081697234,0.00065473316,0.0010734188,0.00010825036,0.00015497737,0.0273062],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99473274,0.0007043006,0.0013693793,0.0010685574,0.0010055576,0.0011194426],"domain_scores_gemma":[0.99428976,0.002490194,0.00040706154,0.0016919238,0.00037769938,0.00074336794],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018170776,0.00048209642,0.0012867709,0.00028802713,0.00072840735,0.000045001638,0.00062495336,0.0002662376,0.0024535113],"category_scores_gemma":[0.00042794517,0.00033539266,0.00091844815,0.0007114791,0.0003409292,0.00006671237,0.000189511,0.00031533212,0.000056242545],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047699645,0.09029494,0.19101757,0.00018411955,0.0038776165,0.0032181714,0.0089595625,0.00001703848,0.017384565,0.000109872206,0.034221962,0.60301495],"study_design_scores_gemma":[0.083782054,0.04187241,0.2637752,0.00003405307,0.0006253144,0.00012954992,0.004502999,0.0005262883,0.0023595658,0.00003074917,0.6019007,0.00046112912],"about_ca_topic_score_codex":0.013987041,"about_ca_topic_score_gemma":0.021778911,"teacher_disagreement_score":0.6025538,"about_ca_system_score_codex":0.014687064,"about_ca_system_score_gemma":0.005274857,"threshold_uncertainty_score":0.9999098},"labels":[],"label_agreement":null},{"id":"W4313349575","doi":"10.4049/jimmunol.190.supp.205.12","title":"Enhancing adoptively transferred T cells by stimulating with dendritic cell stimulation: exploring novel therapies (P4405)","year":2013,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Adoptive cell transfer; Lymphocytic choriomeningitis; Cancer research; In vivo; Immunology; Immunotherapy; T cell; Medicine; Antigen; Biology; Immune system; CD8","score_opus":0.043483782953671106,"score_gpt":0.27548226060323716,"score_spread":0.23199847764956605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313349575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9839824,0.0022390378,0.0118464865,0.00094492116,0.00017465328,0.00043081315,0.0000019928557,0.00002157463,0.00035810863],"genre_scores_gemma":[0.9954122,0.00066248485,0.0026506986,0.00012679287,0.00015551207,0.000013019192,0.0000016574974,0.00005051449,0.000927136],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982388,0.00019123769,0.0005732142,0.00013639728,0.00042486397,0.00043550122],"domain_scores_gemma":[0.9981696,0.0007386838,0.00022343942,0.00028354235,0.0004908079,0.00009391841],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00058532995,0.00020927809,0.00046590177,0.00018159003,0.00016445636,0.00003807352,0.00027705284,0.000090834124,0.0014077452],"category_scores_gemma":[0.000042824522,0.00012772498,0.00011075243,0.00023916211,0.00022339342,0.000328215,0.000033723198,0.00080378,0.000032012387],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011093259,0.00016494539,0.00032188086,0.00003195214,0.00034039718,0.00001135446,0.0044046044,0.0011492941,0.9879494,0.000006929583,0.00004737411,0.0044625574],"study_design_scores_gemma":[0.0070947306,0.00409106,0.0064850245,0.00033369593,0.00021422136,0.0007018537,0.007561631,0.001008605,0.971649,0.000041947453,0.00058981,0.00022843106],"about_ca_topic_score_codex":0.00009272226,"about_ca_topic_score_gemma":0.0000066732587,"teacher_disagreement_score":0.016300395,"about_ca_system_score_codex":0.00013806176,"about_ca_system_score_gemma":0.00016242878,"threshold_uncertainty_score":0.9995051},"labels":[],"label_agreement":null},{"id":"W4313350039","doi":"10.4049/jimmunol.186.supp.100.38","title":"A new dynamic model of three cell interactions by CD4+ T-licensed DCs and DC-primed CD4+ T cells (100.38)","year":2011,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency","funders":"","keywords":"Cytotoxic T cell; CTL*; Priming (agriculture); CD8; Biology; T cell; Cell biology; Immunology; Interleukin 21; Immune system; In vitro","score_opus":0.04139728557869283,"score_gpt":0.29965992901136135,"score_spread":0.2582626434326685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313350039","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869262,0.0035692456,0.0050603068,0.0008331717,0.00026103953,0.00024096282,0.000006893931,0.000011135764,0.0030910247],"genre_scores_gemma":[0.9837159,0.0027411068,0.0025505521,0.000118869975,0.00005075192,0.0000016198975,0.0000018731984,0.00003667617,0.010782678],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99864125,0.00016644539,0.00054005784,0.00011346708,0.0002401123,0.0002986459],"domain_scores_gemma":[0.998515,0.0002594373,0.00042263654,0.00043168457,0.000251042,0.00012019298],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00055029406,0.00015915956,0.0004729368,0.00023997453,0.00006448664,0.0000070601254,0.00034548948,0.00012123882,0.0015796061],"category_scores_gemma":[0.000046307312,0.000107279055,0.00013828672,0.0001556672,0.00027494456,0.00009401932,0.00010690744,0.00086442154,0.00002502628],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031687159,0.00021144845,0.00011469885,0.000019603816,0.00036479553,0.000011411923,0.0024199428,0.000021612366,0.9867183,0.000017531785,0.0015548301,0.0053771273],"study_design_scores_gemma":[0.008111982,0.0037894626,0.004282463,0.00017644673,0.00059577764,0.0016522353,0.0016344418,0.0062963124,0.9682665,0.0021035073,0.0028378465,0.00025303444],"about_ca_topic_score_codex":0.0003661372,"about_ca_topic_score_gemma":0.00007596242,"teacher_disagreement_score":0.018451791,"about_ca_system_score_codex":0.000086835265,"about_ca_system_score_gemma":0.00030071303,"threshold_uncertainty_score":0.9993331},"labels":[],"label_agreement":null},{"id":"W4313350059","doi":"10.4049/jimmunol.186.supp.153.42","title":"Instructional role of ligand in γδ T cell lineage commitment (153.42)","year":2011,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"T-cell receptor; Lineage (genetic); Biology; Cell fate determination; T cell; Cell biology; Ligand (biochemistry); Negative selection; Immunology; Gene; Receptor; Genetics; Transcription factor; Immune system","score_opus":0.02898959373728102,"score_gpt":0.2802784944135813,"score_spread":0.25128890067630033,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313350059","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990495,0.00273651,0.000011603761,0.00023539388,0.00018163263,0.00012508842,0.0000014710338,0.0000027747546,0.0062105],"genre_scores_gemma":[0.9973189,0.0012950369,0.0004275608,0.00005702974,0.00009935534,0.0000012888272,7.6294367e-7,0.000011414694,0.00078864995],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989366,0.0001715362,0.00045603234,0.000052332012,0.0002107478,0.00017278553],"domain_scores_gemma":[0.9991897,0.00012464619,0.00025144382,0.00022540675,0.00017072237,0.000038082988],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00076322135,0.00007983186,0.00030769757,0.00022640207,0.000025502986,0.0000018976107,0.00023430958,0.000083520354,0.0013396852],"category_scores_gemma":[0.000028023656,0.000050624392,0.00008923717,0.0001434807,0.00022937465,0.000041773037,0.00006679888,0.0005827449,0.00001473589],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038022147,0.00041733414,0.007912467,0.0000141135415,0.00019877988,0.000024097913,0.003939391,0.000005203795,0.97365236,0.00009084742,0.000091541595,0.009851629],"study_design_scores_gemma":[0.004054059,0.0023708628,0.09188228,0.00006649615,0.000059434486,0.0013807381,0.0025758783,0.000020622536,0.8923918,0.0005271995,0.004612823,0.000057818143],"about_ca_topic_score_codex":0.00025362367,"about_ca_topic_score_gemma":0.000030219651,"teacher_disagreement_score":0.08396982,"about_ca_system_score_codex":0.00007602389,"about_ca_system_score_gemma":0.00013965862,"threshold_uncertainty_score":0.99957323},"labels":[],"label_agreement":null},{"id":"W4313351792","doi":"10.4049/jimmunol.186.supp.63.29","title":"Embryonic stem cell-derived factors inhibit T effector activation and induce T regulatory cells by modulating PKC-θ activation. (63.29)","year":2011,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Cell biology; Ionomycin; CD28; T cell; Transcription factor; Protein kinase C; Biology; Embryonic stem cell; Immune system; Western blot; FOXP3; Molecular biology; Chemistry; Phosphorylation; Immunology; Biochemistry; Intracellular","score_opus":0.032320520923024114,"score_gpt":0.2620367731275391,"score_spread":0.22971625220451497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313351792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99775064,0.00072210014,0.00025716444,0.00030602032,0.00018780334,0.00037027212,0.0000019548027,0.00002012298,0.00038390528],"genre_scores_gemma":[0.9980971,0.00028290483,0.00009590625,0.00009293205,0.00010091974,0.0000032160392,0.0000036534195,0.000041808707,0.0012815481],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982158,0.0004931036,0.00046899376,0.00015547642,0.00034370588,0.00032291733],"domain_scores_gemma":[0.99815905,0.0005358113,0.00060086866,0.00035190675,0.0002569595,0.0000953878],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00088805234,0.00020651658,0.00043140608,0.0002387795,0.0001621052,0.00001636264,0.00022057755,0.00021849689,0.00041341147],"category_scores_gemma":[0.00007556248,0.00013772793,0.000099535646,0.00021306184,0.0002274478,0.00024949043,0.00009401266,0.00095578394,0.000009946307],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012472802,0.00011314314,0.0010520777,0.000035084588,0.00025181728,0.0000037479515,0.0037781668,0.000006582211,0.9856287,0.0000064969227,0.00028978405,0.0075870827],"study_design_scores_gemma":[0.0019132859,0.0010429731,0.048836045,0.000112760026,0.0000659508,0.00009705374,0.0017657157,0.000032427208,0.94560665,0.00003600087,0.00037747156,0.00011364284],"about_ca_topic_score_codex":0.00008117564,"about_ca_topic_score_gemma":0.0000011112647,"teacher_disagreement_score":0.047783967,"about_ca_system_score_codex":0.00022837597,"about_ca_system_score_gemma":0.0001501365,"threshold_uncertainty_score":0.5616382},"labels":[],"label_agreement":null},{"id":"W4313354752","doi":"10.4049/jimmunol.190.supp.177.6","title":"Discovering optimal targets for adoptive T-cell immunotherapy of leukemia (P4346)","year":2013,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Institute for Research in Immunology and Cancer","funders":"","keywords":"Immunogenicity; Antigen; CD8; Leukemia; Immunology; Biology; Immunotherapy; Adoptive cell transfer; Cytotoxic T cell; T cell; Cancer research; Major histocompatibility complex; Minor histocompatibility antigen; Immune system; In vitro","score_opus":0.017583604569491557,"score_gpt":0.28744322223252067,"score_spread":0.2698596176630291,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313354752","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871654,0.0070893834,0.0029340263,0.0009449465,0.00025608428,0.0005955274,0.000004167038,0.000006987369,0.0010035082],"genre_scores_gemma":[0.99064577,0.0027138104,0.0027824328,0.00013818512,0.000195375,0.000014327215,0.0000027564251,0.000043019245,0.0034643563],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998589,0.00014658557,0.0005732737,0.00009032879,0.00024768512,0.00035317044],"domain_scores_gemma":[0.9981916,0.0004142924,0.0004606896,0.00034717692,0.00053309,0.00005312637],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007693521,0.00015191,0.0005256277,0.00017716597,0.000070967006,0.0000117147565,0.00039600645,0.00011339681,0.0017642978],"category_scores_gemma":[0.00007937237,0.0000925854,0.00026287007,0.00013287668,0.00031464524,0.0001474838,0.00006907689,0.00053476356,0.000019653338],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004529785,0.00012334198,0.0001869315,0.000028150314,0.0005816279,0.0000060573584,0.00170781,0.00021006308,0.9790035,0.000047558104,0.00085695856,0.012718203],"study_design_scores_gemma":[0.011747585,0.00874786,0.014124254,0.00014618081,0.00018203506,0.0010693864,0.0041882535,0.00051348994,0.94279075,0.00053785555,0.01573467,0.00021766116],"about_ca_topic_score_codex":0.00015288376,"about_ca_topic_score_gemma":0.0000017006976,"teacher_disagreement_score":0.036212746,"about_ca_system_score_codex":0.00022487855,"about_ca_system_score_gemma":0.000330951,"threshold_uncertainty_score":0.99914825},"labels":[],"label_agreement":null},{"id":"W4313365647","doi":"10.4049/jimmunol.202.supp.71.3","title":"Optimization of human T cell activation and expansion protocols improves efficiency of genetic modification and overall cell yield","year":2019,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Stemcell Technologies","funders":"","keywords":"Transfection; T cell; Cell biology; Cell; T-cell receptor; Cell culture; Cell growth; Molecular biology; Chemistry; Biology; Immunology; Biochemistry; Immune system; Genetics","score_opus":0.02783875306635918,"score_gpt":0.30995969897452896,"score_spread":0.2821209459081698,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313365647","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951291,0.00038736747,0.0015524672,0.00013118322,0.000020582469,0.0024716575,4.373834e-7,0.0000022747945,0.0003049256],"genre_scores_gemma":[0.9986793,0.00044631003,0.00048294477,0.000014938204,0.00001901226,0.000020978356,0.0000010410948,0.000009705229,0.00032579404],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99916977,0.00011018729,0.00038092028,0.0000720178,0.0001724766,0.00009462388],"domain_scores_gemma":[0.99889755,0.00014022319,0.00050115015,0.00020003758,0.00023987063,0.000021187278],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004326914,0.00006904437,0.00023143757,0.00015041744,0.000031169795,0.0000047487283,0.00009505045,0.00007952983,0.000120772085],"category_scores_gemma":[0.000040160285,0.000046233938,0.00003139034,0.00008128767,0.0001178138,0.00006911064,0.000036768546,0.0001921094,4.8279355e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009780796,0.00015114233,0.001011692,0.00014182349,0.000021801407,2.7255723e-7,0.0008425747,0.0007967119,0.99345386,0.000010712964,0.000006707169,0.0025846325],"study_design_scores_gemma":[0.0021432843,0.0038442928,0.034984127,0.00013756921,0.000035280053,0.00004071853,0.0003317931,0.0021190583,0.9562305,0.000071556795,0.000019146883,0.000042642136],"about_ca_topic_score_codex":0.000035684076,"about_ca_topic_score_gemma":2.8238688e-7,"teacher_disagreement_score":0.03722332,"about_ca_system_score_codex":0.00002540344,"about_ca_system_score_gemma":0.00006428851,"threshold_uncertainty_score":0.18853652},"labels":[],"label_agreement":null},{"id":"W4313369002","doi":"10.4049/jimmunol.204.supp.159.23","title":"Deep characterization of <i>in vitro</i> chronically stimulated T cells via single-cell multiomic analysis","year":2020,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"","keywords":"CD28; Downregulation and upregulation; Effector; Cell; Transcriptome; Biology; Cell biology; In vitro; T cell; Flow cytometry; Stimulation; Molecular biology; Phenotype; Gene; Gene expression; Immunology; Genetics; Immune system; Neuroscience","score_opus":0.018544745343717157,"score_gpt":0.2646893594496181,"score_spread":0.2461446141059009,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313369002","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98997283,0.0006856197,0.0073277573,0.0016686434,0.0000733383,0.00018875547,0.0000026665687,0.0000069125717,0.000073489566],"genre_scores_gemma":[0.99859875,0.00060356746,0.0002593017,0.00031643626,0.00007419837,6.574589e-7,0.000013883351,0.000018416506,0.00011475903],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99835587,0.0003589915,0.0007185216,0.00009970057,0.00024622236,0.00022070286],"domain_scores_gemma":[0.9987156,0.00021832547,0.0004980397,0.00023111264,0.0002680005,0.000068966074],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005206503,0.000112566544,0.0006141081,0.00031713347,0.00002355956,0.0000057369643,0.00027175722,0.000115420524,0.00080491713],"category_scores_gemma":[0.00007062451,0.00007875947,0.00021731493,0.0008458374,0.00014901324,0.000058171558,0.00005818284,0.0005332278,0.000017173004],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00635638,0.00029328364,0.0003279856,0.00002244822,0.0008779585,0.00003284025,0.00084050203,0.001304851,0.9845052,6.005314e-7,0.0000034222337,0.005434543],"study_design_scores_gemma":[0.0036441765,0.0013937934,0.0074440376,0.000017486782,0.0006221744,0.00006307033,0.000077297394,0.018373787,0.9680441,0.0000052025334,0.00024920964,0.000065678476],"about_ca_topic_score_codex":0.000029238468,"about_ca_topic_score_gemma":0.0000032673013,"teacher_disagreement_score":0.017068937,"about_ca_system_score_codex":0.00013100509,"about_ca_system_score_gemma":0.0001113102,"threshold_uncertainty_score":0.8813278},"labels":[],"label_agreement":null},{"id":"W4313369028","doi":"10.4049/jimmunol.204.supp.153.16","title":"Robust serum-free expansion of human B cells with an animal component-free cell culture supplement","year":2020,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Stemcell Technologies","funders":"","keywords":"Antibody; Biology; Population; Peripheral blood mononuclear cell; In vitro; Cell culture; Immunology; Cell; Andrology; Molecular biology; Biochemistry; Medicine; Genetics","score_opus":0.04059105518603894,"score_gpt":0.2878682473164423,"score_spread":0.24727719213040333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313369028","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99091357,0.0010543615,0.00010395141,0.0070510395,0.00007070735,0.00030871,0.000021819458,0.000012069045,0.00046378575],"genre_scores_gemma":[0.99689686,0.0005036273,0.0015054258,0.00033356826,0.00024526098,0.0000013710068,0.000010373172,0.00003494875,0.00046856818],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99813676,0.00034624492,0.0005311062,0.00013491152,0.00053805136,0.00031294057],"domain_scores_gemma":[0.9982725,0.00006969499,0.00041208835,0.0007392412,0.00035999523,0.00014651664],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005774704,0.00017688534,0.0005278586,0.00010462594,0.000099754245,0.00001049103,0.000983347,0.00010574689,0.0023334436],"category_scores_gemma":[0.00003079856,0.00010061588,0.00011801878,0.0001877197,0.0002811903,0.00009407391,0.00028095202,0.0008435811,0.0000074415284],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008347717,0.00026933543,0.00048541228,0.00005964595,0.00026552516,0.00009871386,0.003971614,0.000094074254,0.9799773,0.000033462897,0.006104689,0.00029249938],"study_design_scores_gemma":[0.011791877,0.032104503,0.005644375,0.00010228795,0.00026467882,0.0006855275,0.006416943,0.00008979809,0.9390114,0.00008039888,0.0036636735,0.0001445464],"about_ca_topic_score_codex":0.00007415253,"about_ca_topic_score_gemma":0.000024514708,"teacher_disagreement_score":0.040965922,"about_ca_system_score_codex":0.00007241992,"about_ca_system_score_gemma":0.00013880945,"threshold_uncertainty_score":0.99857855},"labels":[],"label_agreement":null},{"id":"W4313373373","doi":"10.4049/jimmunol.204.supp.239.22","title":"Modulating extracellular TCR-CD3 interaction to identify new immunotherapy targets against cancer","year":2020,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"","keywords":"T-cell receptor; CD3; T cell; Antigen; Biology; Cell biology; Signal transduction; Immune system; CD8; Molecular biology; Immunology","score_opus":0.05120867103629202,"score_gpt":0.36974372431066893,"score_spread":0.3185350532743769,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313373373","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9447897,0.018838601,0.003855697,0.031055432,0.0007401076,0.0003235391,0.0000012874958,0.000022004038,0.00037362098],"genre_scores_gemma":[0.9879933,0.0049189944,0.0005875694,0.0027065808,0.0010931261,0.0000038414673,0.0000021309163,0.000052179286,0.0026423037],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983084,0.0002643812,0.0006052556,0.00013426962,0.00035707685,0.00033058418],"domain_scores_gemma":[0.9987504,0.00016902253,0.00035638871,0.0002806665,0.000270825,0.00017273401],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006674454,0.00016234156,0.0004327606,0.00017054648,0.000101744925,0.000029160956,0.0003909165,0.00010090028,0.0032107602],"category_scores_gemma":[0.00021246866,0.0001122303,0.00018859119,0.00031639764,0.00007003188,0.00014809231,0.00008728194,0.0009922783,0.00009055467],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002967794,0.000040880757,0.0002960735,0.000010810438,0.00052756676,0.000054798675,0.0041302205,0.00073788257,0.8471057,0.000007916299,0.0018049057,0.14231546],"study_design_scores_gemma":[0.00848335,0.00427139,0.022074228,0.0005050584,0.0002481059,0.001471161,0.004402763,0.0021015324,0.6885493,0.0002593253,0.26720384,0.00042993735],"about_ca_topic_score_codex":0.00021154851,"about_ca_topic_score_gemma":0.000010502842,"teacher_disagreement_score":0.26539895,"about_ca_system_score_codex":0.0002293071,"about_ca_system_score_gemma":0.00026052515,"threshold_uncertainty_score":0.99770045},"labels":[],"label_agreement":null},{"id":"W4313381166","doi":"10.4049/jimmunol.202.supp.195.21","title":"CD73-dependent tumor resistance to agonistic anti-4-1BB therapy through TGF-β","year":2019,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"CD137; Downregulation and upregulation; Effector; CD8; T cell; Immune system; Cancer research; Antigen; Antibody; Agonist; Immunotherapy; Immunology; Biology; Receptor; Biochemistry","score_opus":0.027851278586259666,"score_gpt":0.3216469051581989,"score_spread":0.2937956265719392,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313381166","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9749436,0.008269049,0.00015568866,0.008896321,0.0007240151,0.000521116,0.000003102986,0.00001608986,0.006471018],"genre_scores_gemma":[0.9719871,0.003698814,0.00033606082,0.0019267751,0.00028050534,0.000004007005,0.0000010322527,0.000041032188,0.02172463],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980381,0.00034159917,0.00052054395,0.00015142973,0.00051101536,0.00043728718],"domain_scores_gemma":[0.99818486,0.0004068208,0.00028429573,0.0006912801,0.0003522963,0.00008045783],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011727769,0.00017387884,0.0005692597,0.00014977278,0.00009381103,0.000022174476,0.00058548566,0.00008290031,0.0039960383],"category_scores_gemma":[0.00016760139,0.00010453928,0.00016241765,0.00026329557,0.00017220693,0.00008383944,0.00009512383,0.00081699574,0.0004936179],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008047095,0.00017571698,0.0011778357,0.000021947293,0.0004930242,0.00018568867,0.0014187352,0.000025920106,0.9820441,0.00030679314,0.002903378,0.003199794],"study_design_scores_gemma":[0.013842678,0.008818042,0.07354832,0.00053492765,0.00018527568,0.0071210186,0.002587875,0.000013766673,0.3860881,0.0025510767,0.50424045,0.00046845071],"about_ca_topic_score_codex":0.000047123496,"about_ca_topic_score_gemma":0.000011996724,"teacher_disagreement_score":0.59595597,"about_ca_system_score_codex":0.00018244296,"about_ca_system_score_gemma":0.00027453047,"threshold_uncertainty_score":0.99691445},"labels":[],"label_agreement":null},{"id":"W4313381876","doi":"10.4049/jimmunol.200.supp.174.38","title":"Fast and easy immunomagnetic isolation of untouched human naïve T cells in less than 15 minutes","year":2018,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute; BC Cancer Agency","funders":"","keywords":"Antigen; Immunomagnetic separation; Leukapheresis; Antibody; Molecular biology; IL-2 receptor; T cell; Transplantation; Peripheral blood mononuclear cell; CD3; CD8; Chemistry; Biology; Immunology; Immune system; Cell biology; Medicine; In vitro; Biochemistry; Stem cell; CD34; Internal medicine","score_opus":0.026350125166852503,"score_gpt":0.2995187577404267,"score_spread":0.2731686325735742,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313381876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99374336,0.004206426,0.000056985846,0.00053685816,0.00013233167,0.00016638795,0.0000011676175,0.0000033613396,0.0011531363],"genre_scores_gemma":[0.99722856,0.0006929302,0.000162372,0.000037280446,0.00013077553,9.4279744e-7,9.614035e-7,0.000014676121,0.0017314897],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99876505,0.0002892359,0.00047620686,0.000076169614,0.00018393842,0.00020941634],"domain_scores_gemma":[0.9989216,0.00020403718,0.0002999133,0.00025769122,0.00028316944,0.000033641445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008989765,0.00010158565,0.00036358953,0.00028422583,0.000055006894,0.000007906863,0.00021647524,0.000099803154,0.0005335356],"category_scores_gemma":[0.00005767415,0.000068240566,0.00006021118,0.00018930076,0.0006266339,0.00006199199,0.00007364292,0.00040505148,0.000007421371],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016911695,0.00010005448,0.004027293,0.000020126961,0.00013049267,0.0000113728975,0.002688076,0.0000018908374,0.98291934,0.000035490004,0.000049209866,0.008325503],"study_design_scores_gemma":[0.0063322745,0.009255157,0.38637328,0.00029474086,0.00013467346,0.0011600276,0.0041011474,0.00015674613,0.5907158,0.0007130786,0.00062713225,0.00013593686],"about_ca_topic_score_codex":0.0002981184,"about_ca_topic_score_gemma":0.00013966035,"teacher_disagreement_score":0.3922035,"about_ca_system_score_codex":0.000060990074,"about_ca_system_score_gemma":0.00008710751,"threshold_uncertainty_score":0.58418405},"labels":[],"label_agreement":null},{"id":"W4313383005","doi":"10.4049/jimmunol.202.supp.134.16","title":"Ex Vivo Phenotyping and Potency Monitoring of CD19 CAR T Cells With a combined Flow Cytometry and Impedance-based Real-Time Cell Analysis Workflow","year":2019,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Altasciences (Canada)","funders":"","keywords":"CD19; T cell; Flow cytometry; CD8; Antigen; Immunophenotyping; Molecular biology; CD28; HEK 293 cells; Ex vivo; Cytotoxic T cell; Biology; Immunology; Cancer research; Chemistry; Immune system; Receptor; In vitro; Biochemistry","score_opus":0.00887441052586603,"score_gpt":0.25225519664789686,"score_spread":0.24338078612203085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313383005","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963502,0.002471714,0.0002934391,0.00018334576,0.00009697209,0.00023125453,0.0000028312336,0.00000824802,0.0003619718],"genre_scores_gemma":[0.9940802,0.0026440034,0.002123569,0.000017681094,0.000070390706,9.79419e-7,9.715191e-7,0.000026646027,0.0010356004],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985248,0.00025998795,0.00043788765,0.00014539041,0.00033191638,0.00030001436],"domain_scores_gemma":[0.9982601,0.0005325258,0.00040430707,0.00041013543,0.0003051153,0.00008782637],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009547905,0.00016913531,0.000792692,0.00060343504,0.00005712725,0.000014085963,0.00019671918,0.00010969466,0.0003724445],"category_scores_gemma":[0.000030280862,0.00010660732,0.00012653321,0.00074512564,0.00023253956,0.000069539885,0.00006263078,0.0004913019,0.000004948144],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056516505,0.000089570116,0.040617142,0.000075510936,0.0013081154,0.000029043053,0.000672869,0.000506166,0.94675183,9.199103e-7,0.00000722137,0.004289979],"study_design_scores_gemma":[0.014014721,0.006691199,0.106223114,0.0005816056,0.0028686381,0.00038168652,0.0020293707,0.0091972845,0.8575845,0.000051698422,0.00006644731,0.0003097573],"about_ca_topic_score_codex":0.00011219724,"about_ca_topic_score_gemma":0.0000022030317,"teacher_disagreement_score":0.089167334,"about_ca_system_score_codex":0.00008096758,"about_ca_system_score_gemma":0.00015439335,"threshold_uncertainty_score":0.43473202},"labels":[],"label_agreement":null},{"id":"W4313383207","doi":"10.4049/jimmunol.204.supp.165.35","title":"CD28 and glycogen synthase kinase-3 (GSK-3) inhibitor combination therapy generates tumor infiltrating T-cells (TILs) with a reversal of markers for T-cell exhaustion","year":2020,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"CD28; GSK-3; Cancer research; CD8; Immunotherapy; Immune checkpoint; T cell; Biology; Chemistry; Immune system; Kinase; Immunology; Biochemistry","score_opus":0.023303757006828945,"score_gpt":0.26703558174669445,"score_spread":0.24373182473986552,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313383207","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933068,0.0025624402,0.0005432932,0.0027152689,0.00010314714,0.0006488695,0.0000074395834,0.0000093316075,0.00010336982],"genre_scores_gemma":[0.9969621,0.0012145519,0.001105553,0.00033373717,0.00017734447,0.000008499378,0.0000053202075,0.000031036187,0.00016191434],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986815,0.00024686847,0.0004721998,0.00012250784,0.00025724573,0.0002196959],"domain_scores_gemma":[0.99833935,0.00047102076,0.00049690343,0.00016107578,0.0004467125,0.000084921245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000883363,0.00015148243,0.00041312244,0.0001327413,0.000087820576,0.000015980224,0.0001550313,0.00007748032,0.00016134366],"category_scores_gemma":[0.0001733529,0.0000959106,0.000089838904,0.00020470093,0.00025418674,0.000103084545,0.00003284476,0.00039106602,0.0000015548895],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020952165,0.0001888558,0.0005159049,0.00009122931,0.00030552663,0.000027879596,0.0010124217,0.000026986718,0.97065043,0.000019298368,0.0004884152,0.0057208715],"study_design_scores_gemma":[0.010320144,0.0122522535,0.00076979224,0.00015036273,0.00016042539,0.00047653102,0.0018468817,0.0007560983,0.9720403,0.000044811055,0.001075184,0.00010724221],"about_ca_topic_score_codex":0.000027144153,"about_ca_topic_score_gemma":0.000002118483,"teacher_disagreement_score":0.012063397,"about_ca_system_score_codex":0.000057837096,"about_ca_system_score_gemma":0.00020516706,"threshold_uncertainty_score":0.39111206},"labels":[],"label_agreement":null},{"id":"W4313388441","doi":"10.4049/jimmunol.178.supp.b151","title":"Interleukin-12 initiates an immune response that leads to tumour rejection (B151)","year":2007,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Ontario Institute for Cancer Research","funders":"","keywords":"Immune system; Immunotherapy; Immunology; CD8; Cancer research; Biology; Cancer immunotherapy; T cell; Tumor microenvironment; Interleukin 15; Acquired immune system; Cytotoxic T cell; Cytokine; Interleukin","score_opus":0.045586214021727856,"score_gpt":0.34862286851025076,"score_spread":0.3030366544885229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313388441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913756,0.0015499034,0.00048119514,0.004640905,0.0006069863,0.0002387135,8.948597e-7,0.000024414947,0.001081358],"genre_scores_gemma":[0.99530566,0.0004551947,0.00020658436,0.00058156287,0.00032254055,0.0000014096703,0.0000015427769,0.00003678383,0.003088697],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976418,0.0008187363,0.0006021637,0.00011728354,0.0003705039,0.00044953817],"domain_scores_gemma":[0.997955,0.00081444666,0.00029083187,0.00046141085,0.0003414678,0.00013680523],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0074722487,0.00015820838,0.00042436516,0.0006548906,0.00012199729,0.000021283004,0.00043100998,0.000140198,0.0010224426],"category_scores_gemma":[0.0006216245,0.00010318602,0.00015342214,0.00029958182,0.00022221905,0.00016607087,0.000107896805,0.0010529935,0.00008602569],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0699194,0.00014418586,0.00111368,0.000005452768,0.00018388855,0.00021495849,0.0027788437,0.0000050751514,0.91051483,0.000017344342,0.00021447698,0.01488784],"study_design_scores_gemma":[0.0027872466,0.010247842,0.29151827,0.00014281936,0.00009239471,0.010995085,0.004855051,0.0000052161868,0.6704182,0.00014927635,0.008662466,0.0001261445],"about_ca_topic_score_codex":0.00010253193,"about_ca_topic_score_gemma":0.000052501175,"teacher_disagreement_score":0.2904046,"about_ca_system_score_codex":0.00032724848,"about_ca_system_score_gemma":0.00019239055,"threshold_uncertainty_score":0.99989074},"labels":[],"label_agreement":null},{"id":"W4313389535","doi":"10.3389/fimmu.2022.1074740","title":"CLIC-01: Manufacture and distribution of non-cryopreserved CAR-T cells for patients with CD19 positive hematologic malignancies","year":2022,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Victoria; Canada's Michael Smith Genome Sciences Centre; University of Ottawa; Terry Fox Research Institute; Vancouver General Hospital; University of British Columbia; Simon Fraser University; Ottawa Hospital","funders":"Ottawa Hospital Foundation; BC Cancer Foundation","keywords":"Medicine; Fludarabine; Cytokine release syndrome; CD34; Cyclophosphamide; CD19; Internal medicine; Lymphoma; Gastroenterology; Oncology; Immunology; Cancer; Antigen; Chimeric antigen receptor; Stem cell; Immunotherapy; Chemotherapy; Biology","score_opus":0.007283874523590764,"score_gpt":0.23820834050241368,"score_spread":0.23092446597882293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313389535","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952066,0.00077864114,0.001603882,0.00024102842,0.0003661014,0.0013436441,0.00037352907,0.000013948153,0.000072648145],"genre_scores_gemma":[0.9967823,0.00010176838,0.0013467154,0.00005902217,0.000012198184,0.00022479524,0.0007219171,0.0000212089,0.00073005457],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987617,0.00012624849,0.00025128,0.00029644344,0.00020427254,0.0003600227],"domain_scores_gemma":[0.99935806,0.00009484671,0.00012055347,0.00027806134,0.00011047969,0.000037981517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019006737,0.00015078927,0.0005042207,0.00016388188,0.00010797942,0.0000056269687,0.00015172227,0.00011916416,0.00013549812],"category_scores_gemma":[0.000042525327,0.00012865652,0.000066001674,0.00020100434,0.00029083437,0.00004580618,0.00016645943,0.00032492372,4.7189812e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026135407,0.0012968065,0.76878446,0.0004059101,0.00096766016,0.00008379611,0.0026662983,0.00007257174,0.17835549,0.00015688883,0.015538336,0.005536381],"study_design_scores_gemma":[0.01528549,0.008016753,0.8262424,0.00009592874,0.0001310882,0.00005709183,0.0046411105,0.0002875797,0.13503571,0.00061766146,0.009231207,0.00035800124],"about_ca_topic_score_codex":0.000100529505,"about_ca_topic_score_gemma":0.000009017186,"teacher_disagreement_score":0.057457924,"about_ca_system_score_codex":0.00024947574,"about_ca_system_score_gemma":0.0000758951,"threshold_uncertainty_score":0.52464604},"labels":[],"label_agreement":null},{"id":"W4313405848","doi":"10.4049/jimmunol.208.supp.117.15","title":"CD28: A roadblock to designing long-lasting CARs?","year":2022,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Chimeric antigen receptor; CD28; CD86; Medicine; CD80; T cell; Immunology; Cancer research; Biology; Cytotoxic T cell; In vitro; Immune system; CD40; Genetics","score_opus":0.0373835636982445,"score_gpt":0.3178649326347742,"score_spread":0.28048136893652975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313405848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895339,0.0029625413,0.0009842844,0.0045802905,0.00039346714,0.00021948227,8.180603e-7,0.000012714146,0.0013124839],"genre_scores_gemma":[0.9939958,0.00011942277,0.00048053043,0.0006636562,0.00024466353,0.00000692087,6.1657755e-7,0.000027394453,0.0044610337],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99823856,0.0005429195,0.0003766068,0.00008339739,0.0004218722,0.0003366472],"domain_scores_gemma":[0.9988378,0.00041706476,0.00020162527,0.0002769014,0.00018740392,0.00007918768],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020246785,0.000096302814,0.00031214196,0.0002836431,0.0002607292,0.0000102899785,0.0004058271,0.000035394147,0.0031717836],"category_scores_gemma":[0.00029582324,0.0000666663,0.00011280586,0.00037905033,0.000077240955,0.000034075227,0.00029095303,0.0010865158,0.000030787036],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029103423,0.00009361361,0.0022690042,0.0000065375184,0.000407821,0.00034686524,0.0031941864,0.0009258055,0.95348054,0.000016700302,0.0015587417,0.03478984],"study_design_scores_gemma":[0.021043519,0.044408157,0.13728814,0.0005228888,0.001172327,0.15519784,0.03555262,0.00083077134,0.4008208,0.0009431241,0.20131177,0.00090806227],"about_ca_topic_score_codex":0.000052086136,"about_ca_topic_score_gemma":0.00000479132,"teacher_disagreement_score":0.55265975,"about_ca_system_score_codex":0.00027733596,"about_ca_system_score_gemma":0.000244503,"threshold_uncertainty_score":0.99773943},"labels":[],"label_agreement":null},{"id":"W4313405910","doi":"10.4049/jimmunol.208.supp.121.13","title":"Sushi domain containing 2 suppresses CD8+ T cell antitumor immunity by targeting IL-2 receptor signaling","year":2022,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Effector; CD8; T cell; Cytotoxic T cell; Cell biology; Biology; Cancer immunotherapy; Chimeric antigen receptor; CD19; Cytokine; Tumor microenvironment; Cancer research; Adoptive cell transfer; Immunotherapy; Immune system; Immunology; Biochemistry","score_opus":0.017446326755908147,"score_gpt":0.2807663160608957,"score_spread":0.26331998930498757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313405910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9817064,0.0139287785,0.00012844532,0.0023670716,0.00053641485,0.00024583712,0.000020531317,0.00002133161,0.0010452133],"genre_scores_gemma":[0.9962726,0.0011678588,0.00045218156,0.00030240288,0.00022050107,0.0000072057455,0.000022609323,0.00004624513,0.0015083579],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9963926,0.0017251757,0.00069204374,0.00012745611,0.0005424696,0.00052025943],"domain_scores_gemma":[0.99763453,0.001066498,0.0005670149,0.00036323242,0.0002839322,0.00008479563],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004478859,0.0001797927,0.0005453565,0.00021947158,0.000637351,0.000025813537,0.00069600897,0.00007115688,0.01217744],"category_scores_gemma":[0.00029926482,0.0001321529,0.00022997364,0.0003184803,0.00027177736,0.00010286728,0.00038496943,0.00219147,0.000018848703],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048021832,0.00021954988,0.0006339541,0.000022318149,0.00037237885,0.00010079091,0.0027673477,0.00007718323,0.9826795,0.000022241753,0.007313936,0.0009886214],"study_design_scores_gemma":[0.0054682028,0.005539174,0.00024321265,0.000070125025,0.00016803369,0.0028289796,0.038443886,0.000026678628,0.78592867,0.00024971564,0.160792,0.00024133394],"about_ca_topic_score_codex":0.00015053223,"about_ca_topic_score_gemma":0.0000013384838,"teacher_disagreement_score":0.19675083,"about_ca_system_score_codex":0.0002903423,"about_ca_system_score_gemma":0.0003130241,"threshold_uncertainty_score":0.98872554},"labels":[],"label_agreement":null},{"id":"W4313423565","doi":"10.4049/jimmunol.208.supp.66.10","title":"Sex differences in the pre-treatment cytokine signatures associated with response and survival in B cell lymphoma patients treated with anti-CD19 CAR T-cell therapy","year":2022,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Medicine; Internal medicine; Lymphoma; Cytokine; CD19; Oncology; Chemokine; Immunology; Immune system; Lactate dehydrogenase; Biology","score_opus":0.015642742634212944,"score_gpt":0.2561343330318531,"score_spread":0.24049159039764018,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313423565","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99647075,0.0021656023,5.2943386e-7,0.0006010661,0.00003694625,0.00060594216,0.00001378997,0.0000066776047,0.00009867865],"genre_scores_gemma":[0.9975227,0.0015228625,0.0000037037469,0.00010323102,0.000015953307,0.000021252561,0.000009277676,0.000024392202,0.0007766358],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99535054,0.0033180288,0.00033425319,0.00014760515,0.0005209103,0.00032865538],"domain_scores_gemma":[0.997903,0.0013703749,0.00029956296,0.00027388,0.00011692464,0.000036265734],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015976321,0.00020768042,0.0005436977,0.00029874055,0.00014403193,0.000017057924,0.00031511663,0.000076597695,0.00011122171],"category_scores_gemma":[0.000044750504,0.00008934218,0.000049708582,0.0004875868,0.00023212639,0.00004123561,0.000053258,0.0005576584,3.5475563e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07966756,0.0033270575,0.6155847,0.0000047505855,0.00047062105,0.00045733553,0.01063279,0.00007451046,0.28784037,8.7479555e-7,0.000021019336,0.0019184733],"study_design_scores_gemma":[0.024595406,0.023462834,0.93122065,0.000036270205,0.000067934794,0.00020431692,0.0036559454,0.00002588266,0.016450694,0.000007020914,0.00017164758,0.00010138906],"about_ca_topic_score_codex":0.0005422186,"about_ca_topic_score_gemma":0.00014191093,"teacher_disagreement_score":0.315636,"about_ca_system_score_codex":0.00039215075,"about_ca_system_score_gemma":0.0002721362,"threshold_uncertainty_score":0.36432683},"labels":[],"label_agreement":null},{"id":"W4313430064","doi":"10.4049/jimmunol.208.supp.122.22","title":"Novel low-avidity glypican-3 specific CARTs resist exhaustion and mediate durable antitumor effects against hepatocellular carcinoma","year":2022,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Avidity; Hepatocellular carcinoma; Cancer research; Monoclonal antibody; In vivo; Antigen; Epitope; In vitro; Apoptosis; Antibody; Immunology; Biology; Biochemistry","score_opus":0.021495530233803357,"score_gpt":0.25363454232783395,"score_spread":0.2321390120940306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313430064","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865114,0.010095415,0.00006051783,0.0018845388,0.00071176665,0.00040955388,0.000007674445,0.0000137447105,0.00030538838],"genre_scores_gemma":[0.9956093,0.0028463837,0.00007192233,0.000190196,0.00028652448,0.000009843391,0.000008471416,0.00003226254,0.0009451008],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979338,0.0005229836,0.00046073284,0.00016651295,0.00053007243,0.00038587576],"domain_scores_gemma":[0.99854326,0.0003989517,0.0003283903,0.00042662062,0.00019055835,0.00011220421],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018221849,0.00016908694,0.000500783,0.0002695818,0.00038241572,0.000018983179,0.0003109402,0.00007077093,0.0005161612],"category_scores_gemma":[0.00014596786,0.00012313986,0.00012491002,0.00029196008,0.0003542856,0.00007695612,0.00023316061,0.0011495501,0.000009557329],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003592882,0.0002114992,0.008788512,0.000066253204,0.00018524897,0.00071718765,0.0005348197,0.00002742109,0.98260134,0.000037890495,0.00086805277,0.0023688683],"study_design_scores_gemma":[0.01714011,0.0066264872,0.45450315,0.0002459817,0.0004365378,0.018854761,0.0023434712,0.0006334772,0.4605771,0.00023732417,0.03793334,0.00046824882],"about_ca_topic_score_codex":0.00010562866,"about_ca_topic_score_gemma":0.000006056819,"teacher_disagreement_score":0.5220243,"about_ca_system_score_codex":0.00032346134,"about_ca_system_score_gemma":0.0002246294,"threshold_uncertainty_score":0.5651603},"labels":[],"label_agreement":null},{"id":"W4313430181","doi":"10.4049/jimmunol.208.supp.173.06","title":"Quick and Easy Isolation of Immune Cells From Large-Volume Samples","year":2022,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute; Stemcell Technologies","funders":"","keywords":"Cell; Lysis; Chromatography; Cell culture; Isolation (microbiology); CD8; T cell; Chemistry; Antigen; Biology; Immune system; Immunology; Bioinformatics; Biochemistry","score_opus":0.02122845244858797,"score_gpt":0.28193452933073737,"score_spread":0.2607060768821494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313430181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984114,0.013441289,0.0004147812,0.0014064997,0.00025798162,0.00012943656,0.000021082315,0.000004423062,0.0002105258],"genre_scores_gemma":[0.9957289,0.0018218509,0.0003056611,0.000101913916,0.00009337239,0.000001593662,0.0000067484657,0.000015144119,0.0019248268],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9985826,0.0004624223,0.00044475414,0.000064476226,0.00026832556,0.00017739699],"domain_scores_gemma":[0.9988701,0.0003457926,0.0003656114,0.00025217273,0.00013548155,0.000030867483],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012713626,0.00007471683,0.0003405842,0.00014726387,0.000116860785,0.0000045832026,0.00021528947,0.000045262983,0.0060333954],"category_scores_gemma":[0.00007829824,0.00005291996,0.00009461018,0.00013928863,0.00015082351,0.000044541946,0.00018911391,0.0005988813,0.0000063674606],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002811231,0.00012277423,0.002990389,0.00000766163,0.00035470974,0.000012613031,0.0016713318,0.000025208277,0.98702157,0.000043488435,0.00032011178,0.0046188887],"study_design_scores_gemma":[0.017530803,0.012802836,0.46593496,0.00014682708,0.0007598587,0.0034611474,0.017259639,0.0011848856,0.3171612,0.004011588,0.15939496,0.0003512953],"about_ca_topic_score_codex":0.00042445792,"about_ca_topic_score_gemma":0.000007442539,"teacher_disagreement_score":0.66986036,"about_ca_system_score_codex":0.00007624167,"about_ca_system_score_gemma":0.0001169059,"threshold_uncertainty_score":0.99487525},"labels":[],"label_agreement":null},{"id":"W4313562093","doi":"10.1007/978-3-030-80962-1_188-1","title":"Targeting CAR T Cells’ Metabolic Pathways to Boost Their Effectiveness Against Tumors","year":2023,"lang":"en","type":"book-chapter","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Chimeric antigen receptor; Tumor microenvironment; Cancer research; Biology; T cell; Reprogramming; Effector; Antigen; Metabolic pathway; Cell biology; Metabolism; Immune system; Tumor cells; Cell; Immunology; Biochemistry","score_opus":0.040327275887623984,"score_gpt":0.27968821890623513,"score_spread":0.23936094301861116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313562093","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018200448,0.0013212746,0.00012915058,0.00020502142,0.001015439,0.004231816,0.0002741456,0.0008469226,0.9737758],"genre_scores_gemma":[0.01728895,0.0015099462,0.00016065894,0.0008880326,0.0014840374,0.00019382786,0.00041157275,0.00070534577,0.9773576],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99640185,0.00011902109,0.0005720162,0.0010535499,0.000986726,0.00086683314],"domain_scores_gemma":[0.9972262,0.00065390626,0.00012803965,0.0010038384,0.00036226536,0.000625777],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0013122906,0.0007908322,0.0015705343,0.0007270498,0.00015176524,0.00006333551,0.00039361304,0.0004762976,0.0040336475],"category_scores_gemma":[0.00012887885,0.000624603,0.0006076556,0.00021622356,0.00012565155,0.000045887035,0.00041601766,0.0011976827,0.0032496473],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00065090985,0.00006291047,0.000053481945,0.00081053376,0.0009623688,0.0010972625,0.00075577636,0.000084161176,0.94491047,0.011830184,0.005066708,0.033715244],"study_design_scores_gemma":[0.0020447078,0.00065579306,0.00034145146,0.0017192042,0.00022364642,0.000035219393,0.00032178572,0.00014148564,0.23636849,0.0013033096,0.75550234,0.0013425752],"about_ca_topic_score_codex":0.000091698465,"about_ca_topic_score_gemma":0.000022958924,"teacher_disagreement_score":0.75043565,"about_ca_system_score_codex":0.0002965805,"about_ca_system_score_gemma":0.0004028088,"threshold_uncertainty_score":0.99962056},"labels":[],"label_agreement":null},{"id":"W4313887581","doi":"10.1016/j.jtct.2023.01.004","title":"Multi-Stakeholder Qualitative Interviews to Inform Measurement of Patient Reported Outcomes After CAR-T","year":2023,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; Office of Naval Research; Legend Biotech; Pharmacyclics; Kite Pharma; Health Resources and Services Administration; MorphoSys; Astellas Pharma; Adaptive Biotechnologies; Pfizer; Incyte; Kiadis Pharma; bluebird bio; TG Therapeutics; Medac; Jazz Pharmaceuticals; Swedish Orphan Biovitrum; Omeros Corporation; Vertex Pharmaceuticals; StemCyte; Bristol-Myers Squibb; AstraZeneca; CSL Behring; BeiGene; HistoGenetics; Atara Biotherapeutics; CareDx; Actinium Pharmaceuticals; National Cancer Institute; Gilead Sciences; Sanofi; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Amgen; Mallinckrodt Pharmaceuticals; Astellas Pharma US","keywords":"Medicine; Anxiety; Family medicine; Health care; Psychology; Psychiatry","score_opus":0.2083465041368138,"score_gpt":0.38663325994693726,"score_spread":0.17828675581012346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313887581","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99651337,0.00042372738,0.0009939524,0.000614114,0.00007714876,0.0010197955,0.00003364675,0.0000579767,0.0002662681],"genre_scores_gemma":[0.99653804,0.0013030549,0.00032519054,0.00049081555,0.000009719982,0.00015386513,0.000112588255,0.000021876183,0.001044863],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982709,0.00012684257,0.00050448196,0.00022629958,0.000659851,0.0002116141],"domain_scores_gemma":[0.9992581,0.00005183891,0.00008551949,0.00023511593,0.0002284074,0.0001410093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007777422,0.0001640602,0.00032924625,0.00024908417,0.000041204243,0.000013467931,0.00004965929,0.000059948696,0.0006079199],"category_scores_gemma":[0.000016136335,0.00012476416,0.00011910767,0.00037536223,0.000049176186,0.00005433881,0.0000075167177,0.000109887456,0.00003426825],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033868558,0.0002537437,0.009556095,0.00036864154,0.0004592435,0.00015075569,0.19561644,0.0000089640835,0.73456883,0.00001790097,0.00010653321,0.055505995],"study_design_scores_gemma":[0.014485794,0.0018802762,0.14616656,0.00044226839,0.00017443117,0.000039348794,0.020510234,0.00013825977,0.79335046,0.000050815837,0.022210086,0.00055145763],"about_ca_topic_score_codex":0.00009107384,"about_ca_topic_score_gemma":0.000059848848,"teacher_disagreement_score":0.1751062,"about_ca_system_score_codex":0.000043550608,"about_ca_system_score_gemma":0.000045950103,"threshold_uncertainty_score":0.6656296},"labels":[],"label_agreement":null},{"id":"W4313893438","doi":"10.1038/s41591-022-02128-z","title":"Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial","year":2023,"lang":"en","type":"article","venue":"Nature Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":194,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Center for Advancing Translational Sciences; Sylvester Comprehensive Cancer Center, University of Miami Health Systems; Cancer Prevention and Research Institute of Texas; University of Texas MD Anderson Cancer Center; Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute; National Cancer Institute; National Institutes of Health","keywords":"Medicine; Internal medicine; Oncology; Cancer; Antigen; Response Evaluation Criteria in Solid Tumors; Clinical endpoint; Immunotherapy; Melanoma; Clinical trial; Gastroenterology; Phases of clinical research; Immunology; Cancer research","score_opus":0.033600660203183974,"score_gpt":0.41502600831845066,"score_spread":0.3814253481152667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313893438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9756999,0.002810865,0.00003009106,0.008837905,0.0023559658,0.0052510886,0.00006739343,0.00023594002,0.004710827],"genre_scores_gemma":[0.9732702,0.0017954217,0.00012415732,0.0042676283,0.0026825273,0.0006470549,0.00072623126,0.000118373835,0.016368443],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9969451,0.000117030984,0.0005676384,0.000596504,0.0009716997,0.0008020581],"domain_scores_gemma":[0.99814576,0.00056632265,0.00013301946,0.0005507687,0.00032057345,0.00028356194],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011496528,0.0003249542,0.000871575,0.0007678071,0.00008325572,0.000011340806,0.0002700047,0.0005574269,0.0021338481],"category_scores_gemma":[0.0009314258,0.00023265909,0.0001778365,0.0013970156,0.00021819086,0.000058985857,0.000043076943,0.0013727543,0.00004226551],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.27105373,0.0020415129,0.001993301,0.00045981916,0.00029351682,0.00055647653,0.003751772,0.000017021883,0.13400015,0.000060260056,0.282746,0.30302644],"study_design_scores_gemma":[0.592022,0.02072341,0.00307097,0.00032794444,0.00010366959,0.000013589009,0.000522522,0.0012817438,0.02200849,0.00031452827,0.35922414,0.00038696962],"about_ca_topic_score_codex":0.00019701122,"about_ca_topic_score_gemma":0.00009325284,"teacher_disagreement_score":0.3209683,"about_ca_system_score_codex":0.000493238,"about_ca_system_score_gemma":0.00045864828,"threshold_uncertainty_score":0.99877834},"labels":[],"label_agreement":null},{"id":"W4313906308","doi":"10.35493/medu.39.22","title":"CARs on the road: Who gets a seat?","year":2021,"lang":"en","type":"article","venue":"The Meducator","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Chimeric antigen receptor; Immunotherapy; Medicine; Cancer research; Oncology; Immunology; Immune system","score_opus":0.04646088158447804,"score_gpt":0.34686494150690766,"score_spread":0.30040405992242963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313906308","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86603904,0.0014064139,8.4244596e-7,0.079266235,0.00037057468,0.0003780012,0.0000033215836,0.000030258872,0.052505326],"genre_scores_gemma":[0.8141651,0.0003335129,0.000022455497,0.0071142986,0.000895628,0.0000922577,0.0000074732343,0.000044081844,0.17732516],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985555,0.00024075527,0.00012547692,0.00022163306,0.000518422,0.00033822688],"domain_scores_gemma":[0.9983313,0.00036981178,0.000025976786,0.0010121013,0.00010854074,0.0001522769],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006003042,0.0001234441,0.00019768917,0.00003971787,0.00015667835,0.000039458573,0.0002452927,0.000048676855,0.0100797005],"category_scores_gemma":[0.0003598877,0.000060490078,0.00013131757,0.00023522058,0.00014374788,0.000016275726,0.00008078392,0.00044741758,0.0006566482],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008830754,0.0011353486,0.0040531172,0.00012889878,0.0009812171,0.00060430035,0.03278208,0.0000044162457,0.4104243,0.0056250086,0.32753238,0.21584584],"study_design_scores_gemma":[0.00097481086,0.0002503268,0.024564875,0.00015373183,0.00010504772,0.00025614927,0.0070876977,0.00005360635,0.22555201,0.00059033424,0.7402397,0.00017175714],"about_ca_topic_score_codex":0.00012781979,"about_ca_topic_score_gemma":0.000038454247,"teacher_disagreement_score":0.41270727,"about_ca_system_score_codex":0.00012290271,"about_ca_system_score_gemma":0.00059173483,"threshold_uncertainty_score":0.99082524},"labels":[],"label_agreement":null},{"id":"W4315864638","doi":"10.3390/curroncol30010087","title":"Fatal Progression of Mutated TP53-Associated Clonal Hematopoiesis following Anti-CD19 CAR-T Cell Therapy","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"clone (Java method); Cytopenia; Medicine; Context (archaeology); Karyotype; CD19; Somatic evolution in cancer; Lymphoma; Oncology; Cancer research; Immunology; Internal medicine; Biology; Genetics; Gene; Cancer; Bone marrow; Chromosome; Flow cytometry","score_opus":0.12223144844620364,"score_gpt":0.45520251926029737,"score_spread":0.3329710708140937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4315864638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99437225,0.0015686349,0.000007937177,0.0004692199,0.0012929796,0.0009147669,0.000031483418,0.00023266379,0.0011100911],"genre_scores_gemma":[0.9970425,0.0009893697,0.00004550553,0.000037991067,0.00017389127,0.000092192306,0.00045648162,0.000058025536,0.0011040904],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99741495,0.000258494,0.0005215301,0.00042854372,0.0007149458,0.00066153397],"domain_scores_gemma":[0.99862987,0.00037381827,0.00021329199,0.00034211838,0.00023797092,0.00020294076],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00081756886,0.00024100159,0.00080227765,0.0003843172,0.000108716566,0.000012896702,0.00021988017,0.00026777445,0.00094621],"category_scores_gemma":[0.00018665365,0.00020186542,0.00037516304,0.0010921975,0.00017401362,0.00006064534,0.00014674038,0.0005187343,0.00012065603],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00066541904,0.0019326821,0.0747102,0.00021087764,0.0003052857,0.00036909038,0.0014366483,0.000005655998,0.8415192,0.000011421847,0.0065166755,0.072316885],"study_design_scores_gemma":[0.025382197,0.0055319574,0.0915607,0.00077957194,0.00028168925,0.00009359147,0.0015427643,0.0015489245,0.7633722,0.00019056571,0.10901974,0.0006961146],"about_ca_topic_score_codex":0.000027562173,"about_ca_topic_score_gemma":0.00000760252,"teacher_disagreement_score":0.10250307,"about_ca_system_score_codex":0.00032080268,"about_ca_system_score_gemma":0.00050769513,"threshold_uncertainty_score":0.99996704},"labels":[],"label_agreement":null},{"id":"W4316925850","doi":"10.1007/s12032-022-01930-6","title":"RETRACTED ARTICLE: Molecular and therapeutic effect of CRISPR in treating cancer","year":2023,"lang":"en","type":"review","venue":"Medical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":true,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Emergent BioSolutions (Canada)","funders":"","keywords":"CRISPR; Genome editing; Biology; Epigenetics; Gene; Cancer; Genome; Computational biology; DNA repair; Genetics; Cancer cell; Cancer research","score_opus":0.07365655161423457,"score_gpt":0.4941140225092025,"score_spread":0.42045747089496793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4316925850","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00936083,0.9875599,0.000005627899,0.00057977706,0.00015451924,0.0011974889,0.0000052109053,0.0000361509,0.0011004991],"genre_scores_gemma":[0.0005543457,0.99802864,0.000014822122,0.00016573723,0.00019499788,0.00032525262,0.000017377533,0.000066352586,0.00063248957],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99669915,0.0011602836,0.00070730527,0.00036702238,0.0006637121,0.00040253677],"domain_scores_gemma":[0.99621904,0.0030268761,0.00016812354,0.00026298832,0.0000446533,0.00027829953],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0021012204,0.00024567512,0.0026121603,0.0003228958,0.000015373342,0.000003934123,0.00014922352,0.0011321487,0.0026298133],"category_scores_gemma":[0.0017629873,0.00016261383,0.00021762948,0.0007522069,0.00029975877,0.000007922045,0.0000959212,0.0017316898,0.000024848565],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014213643,0.000090520894,0.00035439568,0.0133934645,0.00031771336,0.0014724291,0.00006389547,5.3154448e-8,0.00035973339,0.0000100405005,0.00007413693,0.9837215],"study_design_scores_gemma":[0.0034775774,0.0029370792,0.0003111045,0.018535763,0.0012857899,0.00033381212,0.000014225517,0.00013392733,0.00027467287,0.000020330439,0.9724801,0.0001955796],"about_ca_topic_score_codex":0.00032330642,"about_ca_topic_score_gemma":0.00013988248,"teacher_disagreement_score":0.9835259,"about_ca_system_score_codex":0.00039959757,"about_ca_system_score_gemma":0.0012191423,"threshold_uncertainty_score":0.9982819},"labels":[],"label_agreement":null},{"id":"W4317372334","doi":"10.1186/s13643-022-02158-1","title":"Identifying effect modifiers of CAR-T cell therapeutic efficacy: a systematic review and individual patient data meta-analysis protocol","year":2023,"lang":"en","type":"review","venue":"Systematic Reviews","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; National Research Council Canada; University of British Columbia; Ottawa Hospital","funders":"","keywords":"Medicine; Meta-analysis; Chimeric antigen receptor; Clinical trial; MEDLINE; Systematic review; Oncology; Intensive care medicine; Internal medicine; Immunotherapy; Cancer","score_opus":0.5115059957136703,"score_gpt":0.5026597038941844,"score_spread":0.00884629181948593,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317372334","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[6.108665e-8,0.56876504,0.00003600732,0.000008252305,0.000036846028,0.4308526,0.0001629173,0.000049503942,0.000088744535],"genre_scores_gemma":[5.339867e-7,0.6031882,0.00008554067,0.00005639029,0.000025796766,0.39473215,0.00034913616,0.00015757643,0.001404657],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.963847,0.01996385,0.010881626,0.001816565,0.002725075,0.00076589553],"domain_scores_gemma":[0.9763377,0.005281178,0.008614775,0.009021993,0.00031085484,0.00043352507],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.032596637,0.0017855958,0.057651367,0.001423378,0.00012630645,0.00020656803,0.0022130876,0.0004713932,0.00066601066],"category_scores_gemma":[0.004513782,0.0008728847,0.009913278,0.004500106,0.00015730599,0.00015683487,0.0010377127,0.0010040976,0.00050533644],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000053504523,0.00009287988,2.412417e-7,0.7851897,0.21071021,0.000027466263,0.00015260636,9.868518e-8,8.257101e-7,0.000003111547,0.0002636123,0.0035539316],"study_design_scores_gemma":[0.0002509728,0.00017900596,5.9554278e-8,0.46043408,0.51858443,0.000087423854,0.00002142007,0.0000117370255,7.1709644e-7,0.0000013581595,0.020107536,0.0003212433],"about_ca_topic_score_codex":0.00003726261,"about_ca_topic_score_gemma":0.000007137969,"teacher_disagreement_score":0.32475558,"about_ca_system_score_codex":0.0002376341,"about_ca_system_score_gemma":0.00041118782,"threshold_uncertainty_score":0.9997806},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"meta_analysis","genre":"protocol","about_ca_system":false,"about_ca_topic":false,"confidence":"high"},{"model":"gpt","categories":[],"domain":null,"study_design":"meta_analysis","genre":"protocol","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W4317863112","doi":"10.1200/jco.2023.41.4_suppl.349","title":"Safety and efficacy from the phase 1 SURPASS trial of ADP-A2M4CD8, a next-generation T-cell receptor T-cell therapy, in patients with advanced esophageal, esophagogastric junction, or gastric cancer.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; CD8; Internal medicine; Cancer; Gastroenterology; Oncology; Esophageal cancer; Adverse effect; Antigen; Immunology","score_opus":0.14423713882392886,"score_gpt":0.4446103898628588,"score_spread":0.3003732510389299,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317863112","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944516,0.00083496876,0.000047516518,0.001893167,0.0013170193,0.001315878,0.00003077619,0.000012373186,0.00009673861],"genre_scores_gemma":[0.98172224,0.014343053,0.0005513927,0.00045795902,0.0019133582,0.00002516601,0.000054205953,0.00004019497,0.0008924611],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9949618,0.0011886545,0.0023663426,0.0003360086,0.0008024508,0.00034472466],"domain_scores_gemma":[0.99208266,0.0049562585,0.0016817662,0.00030518824,0.000669481,0.00030463265],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00350462,0.00021796358,0.0014464963,0.00029861848,0.0000764128,0.000019656462,0.00023685716,0.0003041351,0.0009004503],"category_scores_gemma":[0.0019104077,0.00012041513,0.00025628196,0.001122664,0.00024680828,0.00017163115,0.000055052733,0.0011512948,0.000008996559],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5282518,0.0060210987,0.03668603,0.000015008466,0.00021937587,0.00007871096,0.00019994356,0.00016577591,0.007842659,6.734876e-7,0.0039489507,0.41656995],"study_design_scores_gemma":[0.6683839,0.12665272,0.18015535,0.00011279246,0.00025394492,0.000011058686,0.00023408464,0.0004158119,0.0012027088,0.000008821073,0.022401007,0.0001678166],"about_ca_topic_score_codex":0.00011931876,"about_ca_topic_score_gemma":0.00011491547,"teacher_disagreement_score":0.41640213,"about_ca_system_score_codex":0.00023165593,"about_ca_system_score_gemma":0.0024250294,"threshold_uncertainty_score":0.9859299},"labels":[],"label_agreement":null},{"id":"W4317891402","doi":"10.1200/jco.2023.41.4_suppl.tps816","title":"A phase I/II trial investigating the safety and efficacy of autologous TAC T cells targeting HER2 in relapsed or refractory solid tumors.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Cytokine release syndrome; Chimeric antigen receptor; T cell; Tolerability; Cancer; Immunotherapy; Clinical trial; Cancer research; Oncology; Internal medicine; Immune system; Immunology; Adverse effect","score_opus":0.16911744821216934,"score_gpt":0.5104959826276299,"score_spread":0.3413785344154605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4317891402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99013174,0.00019655573,0.000006594726,0.0073753344,0.00090524927,0.0005980965,0.000003233419,0.00001711105,0.00076611724],"genre_scores_gemma":[0.9943537,0.0009954463,0.0009481751,0.000841153,0.0016072685,0.0000052385876,0.0000028959876,0.000031516964,0.001214568],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99299896,0.0017576775,0.00404091,0.00024265336,0.0005577647,0.0004020563],"domain_scores_gemma":[0.97873974,0.018013982,0.0023080246,0.0002615378,0.00028947004,0.00038723057],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.016707368,0.00015629566,0.002006584,0.000260578,0.00010139655,0.0000085452475,0.00026166145,0.00041684858,0.00039053982],"category_scores_gemma":[0.03527804,0.00009017349,0.00036536003,0.00057205424,0.0007019557,0.00005861391,0.00018632907,0.002527927,0.000007935311],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4562477,0.0073142704,0.0019794344,0.00012568373,0.00045629247,0.003184854,0.0026169573,0.00014570184,0.10288568,0.000024720192,0.0063880114,0.4186307],"study_design_scores_gemma":[0.630706,0.22938599,0.021730758,0.00083204784,0.0003876229,0.00058945967,0.0022034063,0.004812969,0.004553754,0.00040265772,0.1040835,0.00031184207],"about_ca_topic_score_codex":0.000031863943,"about_ca_topic_score_gemma":0.000029442737,"teacher_disagreement_score":0.41831887,"about_ca_system_score_codex":0.00014988672,"about_ca_system_score_gemma":0.002735978,"threshold_uncertainty_score":0.99977326},"labels":[],"label_agreement":null},{"id":"W4318263697","doi":"10.1080/13696998.2023.2173466","title":"Cost-effectiveness of idecabtagene vicleucel compared with conventional care in triple-class exposed relapsed/refractory multiple myeloma patients in Canada and France","year":2023,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Bristol-Myers Squibb","keywords":"Medicine; Refractory (planetary science); Multiple myeloma; Internal medicine; Oncology; Surgery","score_opus":0.030366608140798463,"score_gpt":0.2906257714463823,"score_spread":0.26025916330558385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318263697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99871004,0.00022548213,0.00001086294,0.00023281785,0.0002670663,0.00046232692,0.000030414716,0.000002970873,0.000057999398],"genre_scores_gemma":[0.99915165,0.0005444898,0.0000464382,0.00009889619,0.00005528168,0.000013410004,0.000032372332,0.000020273108,0.00003721939],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99804664,0.00018365684,0.00073720707,0.00017104551,0.00061574415,0.00024569687],"domain_scores_gemma":[0.99819905,0.00085600984,0.00028878817,0.00013015547,0.00019958356,0.00032640496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011971653,0.00012289699,0.0006474803,0.00029178074,0.000020383963,0.000007029145,0.00016837177,0.00011058399,0.00024245144],"category_scores_gemma":[0.0004314483,0.00010588551,0.00006162716,0.00023574493,0.0001271953,0.000089108995,0.000048881455,0.0005646777,0.00000140117],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00504278,0.00020737895,0.9744178,0.00030203044,0.00008682426,0.0003066655,0.00037044933,0.0005676012,0.0008559856,0.0000051906704,0.00012243203,0.017714867],"study_design_scores_gemma":[0.029521413,0.0006186555,0.9600152,0.0007186728,0.0000127361245,0.000034536482,0.0009778053,0.0049945777,0.0014318621,0.000012654222,0.0015622367,0.00009969265],"about_ca_topic_score_codex":0.039172087,"about_ca_topic_score_gemma":0.3485931,"teacher_disagreement_score":0.309421,"about_ca_system_score_codex":0.0010997787,"about_ca_system_score_gemma":0.003066805,"threshold_uncertainty_score":0.96722615},"labels":[],"label_agreement":null},{"id":"W4318616170","doi":"10.1038/s41467-023-36126-7","title":"Enhancing CAR-T cell functionality in a patient-specific manner","year":2023,"lang":"en","type":"article","venue":"Nature Communications","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; U.S. Food and Drug Administration; Dana-Farber Cancer Institute; National Cancer Institute; National Science Foundation; U.S. Department of Health and Human Services; National Institutes of Health; Hansjörg Wyss Institute for Biologically Inspired Engineering, Harvard University; Harvard University","keywords":"Chimeric antigen receptor; CD28; CD19; T cell; Stimulation; Cell; Antigen; Co-stimulation; Chronic lymphocytic leukemia; Medicine; Immunology; Computational biology; Biology; Leukemia; Immune system; Internal medicine; Genetics","score_opus":0.04717086020109685,"score_gpt":0.3482251953717439,"score_spread":0.30105433517064706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4318616170","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90820026,0.010292615,0.000021028194,0.014211781,0.0003776858,0.0009885253,0.000041560506,0.0003080027,0.06555853],"genre_scores_gemma":[0.9889442,0.0016783075,0.0008245238,0.0004648687,0.00007425031,0.00012353333,0.00036858517,0.00002731248,0.0074944748],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99871975,0.0001716429,0.0002595029,0.00021784382,0.00036789294,0.000263391],"domain_scores_gemma":[0.9973693,0.00041857443,0.00004460297,0.0018837688,0.00019171736,0.000092018316],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044604056,0.00010530947,0.00017296978,0.0003222081,0.00016175814,0.000020835503,0.0003991042,0.00023393182,0.000860194],"category_scores_gemma":[0.000117505726,0.00010117339,0.00009228941,0.0013501521,0.00009735952,0.000058821268,0.00031206963,0.0015669432,0.00038531236],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047231273,0.0016016003,0.05693931,0.00016722808,0.00012628408,0.00009959158,0.005145883,0.00005800693,0.7720287,0.0089278845,0.10888791,0.045545287],"study_design_scores_gemma":[0.0009897628,0.000079457284,0.102072485,0.000065452165,0.00001334093,0.00001632601,0.0009354767,0.00028773307,0.010199246,0.00028724712,0.8849003,0.00015320843],"about_ca_topic_score_codex":0.00005959007,"about_ca_topic_score_gemma":0.0006865642,"teacher_disagreement_score":0.77601236,"about_ca_system_score_codex":0.00021939444,"about_ca_system_score_gemma":0.000108290915,"threshold_uncertainty_score":0.9418521},"labels":[],"label_agreement":null},{"id":"W4319316777","doi":"10.1136/jitc-2022-005691","title":"Tuned activation of MSLN-CAR T cells induces superior antitumor responses in ovarian cancer models","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; Vetenskapsrådet; Karolinska Institutet; Cancerfonden; Barncancerfonden; Memorial Sloan-Kettering Cancer Center","keywords":"CD28; Mesothelin; Cancer research; T cell; Ovarian cancer; Flow cytometry; Tumor microenvironment; Chimeric antigen receptor; CD19; Immunotherapy; Cytotoxic T cell; Cancer; Biology; Immune system; Immunology; Medicine; In vitro; Antibody; Tumor cells; Internal medicine","score_opus":0.07222553027337288,"score_gpt":0.39572200909368005,"score_spread":0.3234964788203072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319316777","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99377775,0.002569244,0.0001379552,0.0020106432,0.00052669575,0.00078156346,0.0000739888,0.000016838414,0.00010532894],"genre_scores_gemma":[0.97452813,0.01846738,0.0003242875,0.00018668038,0.00030089726,0.0001493233,0.0000060300663,0.00007553053,0.0059617325],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998011,0.000107598564,0.00069013564,0.00019977045,0.0006064821,0.0003850491],"domain_scores_gemma":[0.99864733,0.00024569334,0.0003236683,0.00025772766,0.00044733853,0.000078210534],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010016043,0.00017793773,0.0006016576,0.00076230936,0.00008577728,0.000026494228,0.0002103679,0.0001297052,0.0015758567],"category_scores_gemma":[0.00005332337,0.00015017277,0.0002616877,0.00077512895,0.00011545477,0.00027860492,0.000019886287,0.0003622059,0.0000013139596],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01327943,0.0001159697,0.0023116365,0.00015277007,0.00033236586,0.000008092171,0.0018285996,0.00087781687,0.95346165,0.00002816611,0.0005202325,0.027083253],"study_design_scores_gemma":[0.006698237,0.0006171984,0.01837935,0.00075217994,0.00003186726,0.000011444002,0.00044525947,0.0009036959,0.9645422,0.00046974912,0.0069965078,0.00015230125],"about_ca_topic_score_codex":0.0013564222,"about_ca_topic_score_gemma":0.000091207505,"teacher_disagreement_score":0.026930952,"about_ca_system_score_codex":0.00032906543,"about_ca_system_score_gemma":0.000978523,"threshold_uncertainty_score":0.99933684},"labels":[],"label_agreement":null},{"id":"W4319432270","doi":"10.4049/jimmunol.206.supp.58.07","title":"Lack of stem-like exhausted T cells and increased inhibitory receptor expression distinguishes diffuse large B cell lymphomas from Hodgkin lymphoma","year":2021,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Lymphoma; Cancer research; CD8; Diffuse large B-cell lymphoma; Immunophenotyping; Medicine; Follicular lymphoma; Oncology; Internal medicine; Immunology; Immune system; Flow cytometry","score_opus":0.02556787508587118,"score_gpt":0.2769564302286834,"score_spread":0.2513885551428122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319432270","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857935,0.012653793,0.000028391361,0.0002598274,0.0005292123,0.00016977952,0.00003885571,0.000013326219,0.00051335717],"genre_scores_gemma":[0.99281293,0.0035824685,0.0003783878,0.00017871146,0.0002934635,0.0000022580782,0.000016081787,0.000042561445,0.002693162],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99738187,0.00093355,0.00072159583,0.00018820507,0.00042780867,0.00034699892],"domain_scores_gemma":[0.9972339,0.00100479,0.0005904801,0.00054010836,0.00049387995,0.00013683755],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000903588,0.000205166,0.0007194556,0.00015568442,0.00010428821,0.00001844217,0.0002734843,0.00021270398,0.0012870415],"category_scores_gemma":[0.00018108406,0.00013844285,0.00015840192,0.000218212,0.00031409517,0.00007424779,0.00028031637,0.00038360685,0.000014741947],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003943589,0.0011872217,0.0026934352,0.000062751766,0.00024984067,0.0001679299,0.0014647191,4.4563743e-7,0.9830547,0.0000040295686,0.0019244237,0.005246944],"study_design_scores_gemma":[0.015023958,0.0006697175,0.012882813,0.00036997613,0.00016209253,0.00037812267,0.0029379341,0.000015900692,0.9549526,0.000044197925,0.012440123,0.00012254101],"about_ca_topic_score_codex":0.00017306939,"about_ca_topic_score_gemma":0.000011281228,"teacher_disagreement_score":0.028102046,"about_ca_system_score_codex":0.000147793,"about_ca_system_score_gemma":0.00040459778,"threshold_uncertainty_score":0.9996259},"labels":[],"label_agreement":null},{"id":"W4319432308","doi":"10.4049/jimmunol.206.supp.27.15","title":"Automated Large-Scale T Cell Isolation in a New Closed Cell Separation System","year":2021,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute; BC Cancer Agency; Stemcell Technologies","funders":"","keywords":"Immunomagnetic separation; Isolation (microbiology); Cell; CD8; T cell; Lysis; Cell culture; Computer science; Chromatography; Biology; Chemistry; Immunology; Bioinformatics; Antigen; Biochemistry; Genetics","score_opus":0.01621767350831087,"score_gpt":0.3092339558984663,"score_spread":0.2930162823901554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319432308","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98874176,0.003933655,0.0011334154,0.0013873372,0.0002904748,0.00019441513,0.000001218329,0.000036307036,0.004281426],"genre_scores_gemma":[0.9912055,0.00046831535,0.00045164023,0.0001011406,0.00015234838,9.714624e-7,0.000007335895,0.000017491264,0.0075952723],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99841726,0.00052982953,0.00049271306,0.00008505527,0.00023303603,0.00024209348],"domain_scores_gemma":[0.99899393,0.0001600904,0.0002575905,0.00026571905,0.00026881485,0.000053878084],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000937951,0.000093104616,0.00032344248,0.00018353024,0.000049373888,0.000013785959,0.0001343686,0.00013390089,0.00059583026],"category_scores_gemma":[0.00004361339,0.000066248205,0.00009230062,0.00036639435,0.00003195924,0.00007653296,0.000042433632,0.00053097605,0.000065371765],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013386557,0.00017958427,0.0008466858,0.00004805776,0.000060592723,0.00012992621,0.0022171077,0.00014191406,0.9928819,0.000018423461,0.001367199,0.00076994166],"study_design_scores_gemma":[0.019527642,0.0022399826,0.046313703,0.00039892184,0.00026368204,0.0050054877,0.011061214,0.03520607,0.8644097,0.00010148321,0.015242457,0.00022967502],"about_ca_topic_score_codex":0.000053036987,"about_ca_topic_score_gemma":0.000059669306,"teacher_disagreement_score":0.12847222,"about_ca_system_score_codex":0.00025402126,"about_ca_system_score_gemma":0.0006673231,"threshold_uncertainty_score":0.6523924},"labels":[],"label_agreement":null},{"id":"W4319432320","doi":"10.4049/jimmunol.206.supp.58.06","title":"Inhibition of JAK/STAT signaling sustain stem-like exhausted CD8+ T lymphocytes with enhanced antitumor effects","year":2021,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Cytotoxic T cell; Adoptive cell transfer; CD8; T cell; Biology; Cancer research; JAK-STAT signaling pathway; Progenitor cell; Ex vivo; Interleukin 21; Cytokine; Immunology; Stem cell; Cell biology; In vivo; Signal transduction; Immune system; In vitro; Tyrosine kinase","score_opus":0.012987012272306276,"score_gpt":0.2742844501923555,"score_spread":0.2612974379200492,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319432320","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99211955,0.005660232,0.0009960788,0.0004540126,0.0001634878,0.00026179533,0.0000013190278,0.000010614953,0.00033292937],"genre_scores_gemma":[0.996519,0.0011513062,0.00025861606,0.00013624817,0.000093430586,0.000002957913,0.000003969222,0.00002806027,0.0018063921],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99811,0.000552096,0.0004981825,0.00011479221,0.00040440817,0.00032051973],"domain_scores_gemma":[0.9975301,0.0006915893,0.0004355061,0.00031821642,0.0009634852,0.00006112164],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009347386,0.00014774562,0.0005850313,0.00022361605,0.000074350966,0.00001257699,0.00014194853,0.00009414749,0.00044811628],"category_scores_gemma":[0.00015313475,0.00009125008,0.00011994391,0.0004389567,0.00028506163,0.00009373984,0.000068578585,0.0004720359,0.000007107255],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006003692,0.00017016008,0.0002861189,0.00018280446,0.000613195,0.000715531,0.0010783073,0.00008081725,0.98454475,0.00003455636,0.00004703357,0.0062430482],"study_design_scores_gemma":[0.0060529495,0.0027597186,0.0014739167,0.00066237454,0.00019456426,0.0034319311,0.003684141,0.000018805353,0.9813857,0.00007021088,0.00018226341,0.0000834279],"about_ca_topic_score_codex":0.000029082645,"about_ca_topic_score_gemma":0.000008120132,"teacher_disagreement_score":0.0061596204,"about_ca_system_score_codex":0.00023113504,"about_ca_system_score_gemma":0.0007349099,"threshold_uncertainty_score":0.4906559},"labels":[],"label_agreement":null},{"id":"W4319433798","doi":"10.4049/jimmunol.206.supp.25.02","title":"Engineering T cells with improved TCR-CD3 interaction for optimal tumor killing","year":2021,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"","keywords":"T-cell receptor; CD3; T cell; Extracellular; Biology; Jurkat cells; Cell biology; Immune system; Signal transduction; CD8; Molecular biology; Genetics","score_opus":0.015902051448910753,"score_gpt":0.28349811059690866,"score_spread":0.2675960591479979,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319433798","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9836371,0.0010887865,0.013160326,0.0013232549,0.0004945044,0.000177664,0.0000011131634,0.000009715874,0.000107555104],"genre_scores_gemma":[0.9893741,0.00051729084,0.007455345,0.00015532911,0.00042851738,0.000006171053,0.000002415171,0.000040477607,0.00202038],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99925363,0.000060530914,0.00026924355,0.00007258477,0.00012097534,0.00022303245],"domain_scores_gemma":[0.9988499,0.0003586142,0.00016198888,0.00018583897,0.00040160463,0.00004199839],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005071583,0.000090491216,0.0002646251,0.000105756415,0.000047545567,0.000014188615,0.0001174649,0.00004394021,0.00041924775],"category_scores_gemma":[0.00011154093,0.000055785837,0.00010200431,0.000118028904,0.000046304154,0.00007025766,0.00003332234,0.00054943404,0.000005433191],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003637131,0.00005676511,0.00001708407,0.000026772816,0.00042636332,0.00007802591,0.00037180242,0.001125147,0.98949206,0.000009870566,0.000060147322,0.0046988325],"study_design_scores_gemma":[0.0027690714,0.001934085,0.00025583178,0.00014610228,0.00015233556,0.0073703565,0.0014024915,0.006372969,0.9686856,0.000008631835,0.010826916,0.00007557029],"about_ca_topic_score_codex":0.000008493757,"about_ca_topic_score_gemma":0.00000215918,"teacher_disagreement_score":0.02080642,"about_ca_system_score_codex":0.00011142076,"about_ca_system_score_gemma":0.00018622982,"threshold_uncertainty_score":0.45904687},"labels":[],"label_agreement":null},{"id":"W4319812103","doi":"10.1056/nejmoa2213614","title":"Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma","year":2023,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":705,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"Celgene; Bristol-Myers Squibb","keywords":"Multiple myeloma; Refractory (planetary science); Medicine; Oncology; Internal medicine; Lenalidomide; Materials science; Metallurgy","score_opus":0.0453368430261291,"score_gpt":0.3410931074954077,"score_spread":0.2957562644692786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319812103","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9782991,0.0016215454,0.000035527562,0.01764884,0.00040437252,0.00024826996,0.000003045299,0.000029350189,0.0017099845],"genre_scores_gemma":[0.9727142,0.0046025896,0.00033513643,0.00048157675,0.0029434182,0.000002228262,0.000007003017,0.00004330995,0.018870533],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99777555,0.00015166971,0.0006314427,0.00017970118,0.00092413166,0.00033752035],"domain_scores_gemma":[0.99786794,0.0010038443,0.00019797446,0.000232686,0.00020415505,0.00049338164],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0025767512,0.00016156248,0.000682764,0.00069978985,0.000041321993,0.000009548,0.000113604394,0.00010566149,0.0014521425],"category_scores_gemma":[0.002374972,0.000097197524,0.00005683736,0.0006178869,0.00015895837,0.00006919604,0.00003908023,0.00080943975,0.000010828959],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035269562,0.00012148621,0.07603589,0.00020381986,0.00024356873,0.010215996,0.006509895,0.000016796721,0.20927438,0.000030717787,0.08841035,0.5736675],"study_design_scores_gemma":[0.24614337,0.012710507,0.12305693,0.002255801,0.00015134753,0.004296582,0.0020367028,0.00023672226,0.0031296115,0.000496697,0.60525763,0.00022811937],"about_ca_topic_score_codex":0.00011471944,"about_ca_topic_score_gemma":0.00021057554,"teacher_disagreement_score":0.5734394,"about_ca_system_score_codex":0.00014738986,"about_ca_system_score_gemma":0.00041771107,"threshold_uncertainty_score":0.99946064},"labels":[],"label_agreement":null},{"id":"W4319984037","doi":"10.9734/bpi/mono/978-81-19039-63-0/ch19","title":"CAR T Cells Produced in vivo to Treat Cardiac Injury","year":2023,"lang":"en","type":"book-chapter","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Acuitas Therapeutics (Canada)","funders":"","keywords":"In vivo; Spleen; Chimeric antigen receptor; Messenger RNA; Fibrosis; Ex vivo; Antigen; Cardiac fibrosis; Immunology; Medicine; Cancer research; Cell biology; Biology; T cell; Pathology; Immune system; Gene","score_opus":0.0384824907537155,"score_gpt":0.3167556968768568,"score_spread":0.27827320612314127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319984037","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00862358,0.00012667637,6.761231e-7,0.0010044319,0.00060423644,0.002665312,0.00014664937,0.00022412965,0.98660433],"genre_scores_gemma":[0.0006501588,0.0007670559,0.000055114302,0.0003536261,0.0009287262,0.00009788112,0.00005064499,0.00026225077,0.9968345],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973836,0.00003168454,0.00040939054,0.0008434534,0.0008052202,0.00052663404],"domain_scores_gemma":[0.99819666,0.00011165437,0.000043489224,0.0011295262,0.00015612009,0.00036255197],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00042928068,0.00043293796,0.0010102969,0.00084796693,0.000026634467,0.00002512403,0.00019325603,0.00044440723,0.016948199],"category_scores_gemma":[0.000043054588,0.00037458364,0.00033612575,0.0001821852,0.00005947552,0.000024776682,0.00018643517,0.0007232268,0.0036988668],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00076090347,0.000041407253,0.00012610629,0.00033496952,0.00019890597,0.00041190462,0.00039688806,0.0000015664231,0.79125243,0.0016009966,0.17944963,0.0254243],"study_design_scores_gemma":[0.0005643638,0.0005523864,0.00003400154,0.00030239718,0.00008546997,0.0000041210874,0.000036643207,0.000001723668,0.31031093,0.00022596598,0.6874894,0.00039261128],"about_ca_topic_score_codex":0.0004613474,"about_ca_topic_score_gemma":0.00010361048,"teacher_disagreement_score":0.5080397,"about_ca_system_score_codex":0.0004892459,"about_ca_system_score_gemma":0.00032536866,"threshold_uncertainty_score":0.9998706},"labels":[],"label_agreement":null},{"id":"W4320034434","doi":"10.1016/j.jcyt.2023.01.002","title":"T-cell engineered with a fully humanized B-cell maturation antigen-specific T-cell antigen coupler receptor effectively target multiple myeloma","year":2023,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Chimeric antigen receptor; Antigen; TRAC; Multiple myeloma; Receptor; Immunology; Cancer research; T cell; Medicine; Internal medicine; Computer science; Immune system","score_opus":0.019670174701244204,"score_gpt":0.2607613006876543,"score_spread":0.24109112598641008,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4320034434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98728263,0.0019317585,0.002423774,0.0003350149,0.00036545604,0.0030182777,0.00006398395,0.00075993384,0.0038191907],"genre_scores_gemma":[0.9628732,0.005145748,0.004746616,0.00024519386,0.00073222077,0.00027664436,0.00057401584,0.00038698525,0.025019355],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99632454,0.00020815822,0.00051052176,0.0009486505,0.0009978069,0.0010102988],"domain_scores_gemma":[0.99779445,0.00035688884,0.0001872695,0.0009183967,0.0003935007,0.00034951788],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0006855833,0.0006033172,0.0008074502,0.0005936265,0.000283875,0.00014725004,0.00034569926,0.00031717352,0.005369435],"category_scores_gemma":[0.000025426127,0.00050867826,0.00026831016,0.0014494769,0.00017099673,0.00019513893,0.000048205136,0.00062781625,0.0017679948],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0075659445,0.0006153275,0.007637922,0.00016471678,0.00014619304,0.00010264966,0.0014924869,0.00009595344,0.96087825,0.000008926862,0.018748345,0.002543303],"study_design_scores_gemma":[0.01887446,0.001848597,0.04088204,0.00010160664,0.000016441554,0.000023409684,0.0003480449,0.0029721293,0.77172565,0.000017507355,0.16252406,0.000666018],"about_ca_topic_score_codex":0.00003568437,"about_ca_topic_score_gemma":0.000011770773,"teacher_disagreement_score":0.18915255,"about_ca_system_score_codex":0.00028056366,"about_ca_system_score_gemma":0.00023321091,"threshold_uncertainty_score":0.9997365},"labels":[],"label_agreement":null},{"id":"W4321203706","doi":"10.1016/j.lrr.2023.100364","title":"Neuropsychiatric disorders in adults undergoing chimeric antigen receptor T cells therapy for aggressive lymphomas and acute lymphoblastic leukemia","year":2023,"lang":"en","type":"article","venue":"Leukemia Research Reports","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Cart; Chimeric antigen receptor; Lymphoblastic Leukemia; Internal medicine; Leukemia; Oncology; Immunology; Cancer; Immunotherapy","score_opus":0.02381273821878506,"score_gpt":0.3316124645774158,"score_spread":0.30779972635863073,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321203706","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911249,0.001330717,0.000029103598,0.0009324119,0.0005724345,0.0039441423,0.000016329584,0.00032437727,0.0017255626],"genre_scores_gemma":[0.9414383,0.048687786,0.0004145193,0.00013278914,0.00045819415,0.0008037373,0.00009636546,0.00030265396,0.007665629],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99319464,0.00042237472,0.0009011586,0.0014793363,0.002117648,0.0018848501],"domain_scores_gemma":[0.9957137,0.0017480898,0.0003402209,0.0010823996,0.0005120555,0.0006035247],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00293613,0.00045727062,0.00073768606,0.0019139397,0.000433421,0.00014848774,0.00030660714,0.00031507728,0.00031154975],"category_scores_gemma":[0.0015992653,0.0003762308,0.00025475194,0.0039739544,0.000474121,0.00021143195,0.00030331398,0.0008312848,0.00010396178],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017094195,0.0006135497,0.17024241,0.0020037612,0.0009549794,0.009938476,0.0034651235,0.00061016413,0.3433416,0.0000777638,0.035603914,0.41605407],"study_design_scores_gemma":[0.073487945,0.015217934,0.6586074,0.005280616,0.00019304422,0.004924393,0.0042771753,0.042225514,0.06135004,0.008031632,0.12269674,0.0037075365],"about_ca_topic_score_codex":0.0013012291,"about_ca_topic_score_gemma":0.00048412767,"teacher_disagreement_score":0.48836502,"about_ca_system_score_codex":0.0031892227,"about_ca_system_score_gemma":0.00578685,"threshold_uncertainty_score":0.999869},"labels":[],"label_agreement":null},{"id":"W4321604791","doi":"10.1101/2023.02.23.529741","title":"Human A2-CAR T cells reject HLA-A2+ human islets transplanted into mice without inducing graft versus host disease","year":2023,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia; University of Alberta","funders":"National Institutes of Health; Manpei Suzuki Diabetes Foundation; University of British Columbia; BC Children's Hospital; Juvenile Diabetes Research Foundation Canada","keywords":"Human leukocyte antigen; Graft-versus-host disease; Host (biology); Islet; Human disease; Immunology; Disease; Biology; Medicine; Diabetes mellitus; Antigen; Genetics; Internal medicine; Endocrinology","score_opus":0.041150980030911874,"score_gpt":0.3020467307956627,"score_spread":0.2608957507647508,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321604791","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915364,0.00062146795,0.00008759494,0.00048398093,0.0022137538,0.0029175961,0.0005392034,0.0015286297,0.000071405324],"genre_scores_gemma":[0.99526894,0.00043634683,0.00071468035,0.00021072864,0.0017490054,0.0004918004,0.000016521193,0.00075269764,0.0003592587],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9923016,0.0005031511,0.001230643,0.0026459936,0.0017301828,0.0015884623],"domain_scores_gemma":[0.9935268,0.00021085519,0.00053874275,0.0033569061,0.00086343725,0.0015032598],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0015466863,0.0013701726,0.0017143089,0.001279165,0.00068579096,0.00038607192,0.0012484682,0.0010531576,0.0006463837],"category_scores_gemma":[0.00028216315,0.0015060513,0.00067558,0.001337672,0.00047026627,0.00019485565,0.000746318,0.003309733,0.00040238755],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011283153,0.00039011327,0.005340348,0.0028145895,0.0009800264,0.0014548788,0.00013312035,0.00002677649,0.9869947,0.000064524065,0.00067063444,0.0000019735817],"study_design_scores_gemma":[0.0075455583,0.0005648979,0.08688217,0.004711633,0.0014880614,1.18318106e-7,0.00003095267,0.00020157214,0.8913882,0.000004046719,0.0050256434,0.002157185],"about_ca_topic_score_codex":0.0012797541,"about_ca_topic_score_gemma":0.00008385955,"teacher_disagreement_score":0.095606536,"about_ca_system_score_codex":0.0012806226,"about_ca_system_score_gemma":0.001510856,"threshold_uncertainty_score":0.9999049},"labels":[],"label_agreement":null},{"id":"W4321748193","doi":"10.1158/1078-0432.ccr-22-2955","title":"Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma","year":2023,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Advancing Translational Sciences; National Cancer Institute","keywords":"Medicine; Lymphoma; Follicular lymphoma; Angioimmunoblastic T-cell lymphoma; T cell; Internal medicine; Adverse effect; Oncology; Peripheral T-cell lymphoma; Refractory (planetary science); Pharmacodynamics; Gastroenterology; Immunology; Pharmacokinetics; Immune system","score_opus":0.07551008948559883,"score_gpt":0.395376646050156,"score_spread":0.31986655656455715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321748193","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991787,0.0030769904,0.0000051499283,0.0007350814,0.0002864528,0.0020175308,0.00002352923,0.00008457111,0.0019836996],"genre_scores_gemma":[0.9860142,0.0020559889,0.00006528013,0.00031991818,0.0004879023,0.0002719331,0.00006634114,0.00015579746,0.010562662],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99343276,0.0011090108,0.0008605512,0.0010948601,0.0020468177,0.0014560247],"domain_scores_gemma":[0.99507165,0.0024648544,0.00013526605,0.0010524726,0.0007427418,0.00053303724],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005207708,0.00035819845,0.0007063154,0.00043222064,0.00041224377,0.00014278338,0.0005568498,0.00038302256,0.0016863599],"category_scores_gemma":[0.00084290083,0.0002429018,0.00017901396,0.0021422638,0.0009187142,0.00016159809,0.00054263894,0.0021362004,0.00032234422],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014878745,0.004481699,0.8934972,0.00067744975,0.00019520245,0.00037148187,0.001390897,0.000569884,0.04414655,0.00000976225,0.017130423,0.022650653],"study_design_scores_gemma":[0.071248785,0.01012606,0.8235779,0.00078123854,0.00015619311,0.0000048724382,0.0018615011,0.0064773965,0.005281871,0.0001118922,0.079235464,0.0011368433],"about_ca_topic_score_codex":0.0008347227,"about_ca_topic_score_gemma":0.00007447839,"teacher_disagreement_score":0.06991936,"about_ca_system_score_codex":0.0006155497,"about_ca_system_score_gemma":0.0012369034,"threshold_uncertainty_score":0.9992262},"labels":[],"label_agreement":null},{"id":"W4322011926","doi":"10.1016/j.msard.2023.104590","title":"Are we ready for CD19-targeted CAR T-cell therapies in MS?","year":2023,"lang":"en","type":"editorial","venue":"Multiple Sclerosis and Related Disorders","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Chimeric antigen receptor; CD19; Medicine; Immunology; B cell; Antigen; T cell; Cancer research","score_opus":0.0493028518859097,"score_gpt":0.29498792866946655,"score_spread":0.24568507678355683,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322011926","genre_codex":"editorial","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07356178,0.036452398,0.000011639489,0.004531894,0.87439793,0.0069522033,0.0018125282,0.00071604043,0.0015636084],"genre_scores_gemma":[0.08442077,0.5024886,0.00036799422,0.0001808935,0.2864042,0.002693304,0.009598346,0.0018420045,0.11200386],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964526,0.00015787261,0.000708297,0.0009936347,0.00081635,0.00087121245],"domain_scores_gemma":[0.9965168,0.0020551733,0.00034221154,0.00058701535,0.00025191015,0.00024686172],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00067405036,0.0005946582,0.0011121093,0.000605679,0.0002118658,0.00008458742,0.00024905382,0.0019256099,0.0003260976],"category_scores_gemma":[0.001162562,0.0005055359,0.0003689599,0.0006553906,0.00025956242,0.000073977506,0.00010963329,0.0016853871,0.000047021138],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016872018,0.00046107444,0.0029254525,0.00097043405,0.0005696581,0.000017506423,0.0017303515,0.00005077089,0.014804237,0.0000018339002,0.9622247,0.01455673],"study_design_scores_gemma":[0.017266935,0.00054630917,0.004679954,0.0014286039,0.00020386116,5.98094e-7,0.002058189,0.0009496216,0.0002616496,0.00013960003,0.97178507,0.00067960005],"about_ca_topic_score_codex":0.0011610796,"about_ca_topic_score_gemma":0.0022207326,"teacher_disagreement_score":0.5879937,"about_ca_system_score_codex":0.00019990976,"about_ca_system_score_gemma":0.0002115634,"threshold_uncertainty_score":0.99973965},"labels":[],"label_agreement":null},{"id":"W4322494886","doi":"10.1038/s41587-023-01687-x","title":"Deconvolution of clinical variance in CAR-T cell pharmacology and response","year":2023,"lang":"en","type":"article","venue":"Nature Biotechnology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":67,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia; Hatch (Canada)","funders":"","keywords":"Chimeric antigen receptor; Effector; Immunophenotyping; Cytotoxic T cell; T cell; Antigen; Computational biology; Biology; Immunology; Neuroscience; Immune system; In vitro; Genetics","score_opus":0.028769687787816578,"score_gpt":0.41537531063099037,"score_spread":0.3866056228431738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4322494886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98534447,0.0016923309,0.000014330877,0.011687548,0.0004282321,0.00035119505,0.000007729,0.00013100178,0.0003431394],"genre_scores_gemma":[0.9949739,0.0021250788,0.00040570938,0.0003460542,0.00009237803,0.000014972463,0.0000068769255,0.000016347725,0.002018689],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998603,0.00023585325,0.00036446,0.0003576792,0.00014118108,0.0002978337],"domain_scores_gemma":[0.99891204,0.00059038453,0.000079913,0.00029025748,0.000064817315,0.00006261302],"candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0016614062,0.000097082346,0.00040364207,0.00064648566,0.000019087538,0.0000017530135,0.00013544616,0.001916929,0.00023542179],"category_scores_gemma":[0.0007628975,0.000090452,0.000058053527,0.00097243465,0.00039648422,0.000019882373,0.00013197976,0.0018289924,0.000030989537],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00472238,0.00011631073,0.015518134,0.00005636876,0.000030319217,0.00021610469,0.000048901395,0.0000010192839,0.9529292,0.00033540514,0.0029287701,0.023097072],"study_design_scores_gemma":[0.00732679,0.0015246385,0.25064102,0.000043090142,0.000042027124,0.000120380566,0.00014924609,0.0010626023,0.5945458,0.00050914526,0.1438779,0.00015737698],"about_ca_topic_score_codex":0.000022571032,"about_ca_topic_score_gemma":0.00002204711,"teacher_disagreement_score":0.35838342,"about_ca_system_score_codex":0.00006449301,"about_ca_system_score_gemma":0.00019946035,"threshold_uncertainty_score":0.9993788},"labels":[],"label_agreement":null},{"id":"W4323036146","doi":"10.1007/s10637-023-01342-x","title":"Phase 1 study to determine the safety and dosing of autologous PBMCs modified to present HPV16 antigens (SQZ-PBMC-HPV) in HLA-A*02+ patients with HPV16+ solid tumors","year":2023,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute","keywords":"Peripheral blood mononuclear cell; Medicine; CD8; Tolerability; Immune system; Antigen; Pharmacodynamics; Immunotherapy; Immunology; Human leukocyte antigen; Pharmacology; Adverse effect; Internal medicine; Pharmacokinetics; Biology","score_opus":0.04542277026582583,"score_gpt":0.3424850493680232,"score_spread":0.2970622791021974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323036146","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99120146,0.000023074424,0.000059867154,0.0054301666,0.000066487395,0.0026990478,0.000052470026,0.00005942896,0.00040798387],"genre_scores_gemma":[0.9963501,0.000005654946,0.00058834243,0.0006943876,0.00013225837,0.000062016734,0.000093608236,0.00004474048,0.0020288979],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971601,0.00017321539,0.00060175586,0.00049209595,0.0011161808,0.00045666288],"domain_scores_gemma":[0.9982651,0.0004113993,0.000119714605,0.00045215254,0.00023976136,0.00051186926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000655505,0.00024517544,0.00048079077,0.0004609641,0.00013485705,0.000038527472,0.00023067424,0.000052195086,0.00014648185],"category_scores_gemma":[0.0003382236,0.00017593603,0.00005055867,0.0012931969,0.00023393468,0.00009381686,0.00022005517,0.00026263474,0.000025404264],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015572764,0.0061278977,0.6106052,0.00035269998,0.0007781004,0.0004954622,0.09929199,0.02444713,0.09129136,0.00046198154,0.009926584,0.14064883],"study_design_scores_gemma":[0.016978199,0.0044096815,0.94947124,0.00030178786,0.00008551213,0.000025469808,0.0018809543,0.008083214,0.016231786,0.00055460236,0.0015629157,0.0004146242],"about_ca_topic_score_codex":0.00068927073,"about_ca_topic_score_gemma":0.00017495343,"teacher_disagreement_score":0.33886606,"about_ca_system_score_codex":0.0001375192,"about_ca_system_score_gemma":0.000531893,"threshold_uncertainty_score":0.7174463},"labels":[],"label_agreement":null},{"id":"W4323353350","doi":"10.1016/j.clml.2023.03.002","title":"Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Loxo Oncology; Pharmacyclics; Kite Pharma; Genentech; National Cancer Institute; Gilead Sciences; Servier; Alexion Pharmaceuticals; Apellis Pharmaceuticals; BeiGene; Pfizer; Incyte; Innovent Biologics; Adaptive Biotechnologies; Sierra Oncology; CTI Biopharma; bluebird bio; TG Therapeutics; Regeneron Pharmaceuticals; Sanofi; Amgen; AstraZeneca; Cidara Therapeutics; MorphoSys; Celgene; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Vaccination; Seroconversion; Lymphoma; Immunology; Multiple myeloma; Antibody; Cancer; Chimeric antigen receptor; Immune system; Immunotherapy; Virology; Internal medicine","score_opus":0.03695353903935361,"score_gpt":0.3572703254441805,"score_spread":0.3203167864048269,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323353350","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99179417,0.00006727169,0.000035622776,0.004348734,0.00027556284,0.002760021,0.00006434229,0.0003269323,0.0003273295],"genre_scores_gemma":[0.98907304,0.00021652867,0.00044518532,0.007066525,0.00024790727,0.00018505119,0.00022104535,0.00017180786,0.0023729275],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99411064,0.00093412976,0.0012780533,0.0013875973,0.0012165816,0.0010729772],"domain_scores_gemma":[0.9924431,0.0041198106,0.00023305528,0.0012078487,0.000520679,0.0014755474],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0036738166,0.00055433,0.0010814833,0.0010083125,0.00023722324,0.00010826028,0.00045403966,0.00055972865,0.0005093696],"category_scores_gemma":[0.0059813163,0.00046753572,0.00025166615,0.0021635685,0.00025901027,0.00022969455,0.00033040525,0.0003281375,0.00047448624],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060418032,0.0003920061,0.431937,0.000048039863,0.00010475183,0.0003768191,0.00065035897,0.00002348711,0.0042706984,0.000007019893,0.0017802997,0.49999148],"study_design_scores_gemma":[0.04294798,0.006424471,0.9246277,0.00011952626,0.000028239565,0.000041225863,0.00021965367,0.0010642234,0.00081991515,0.000050254966,0.02315609,0.0005006971],"about_ca_topic_score_codex":0.000434583,"about_ca_topic_score_gemma":0.00020941647,"teacher_disagreement_score":0.49949077,"about_ca_system_score_codex":0.002633385,"about_ca_system_score_gemma":0.0028715823,"threshold_uncertainty_score":0.9997776},"labels":[],"label_agreement":null},{"id":"W4323652962","doi":"10.1002/eji.202250002","title":"Targeting regulatory T cell metabolism in disease: Novel therapeutic opportunities","year":2023,"lang":"en","type":"review","venue":"European Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"Canadian Institutes of Health Research","keywords":"Biology; Autoimmunity; Cell metabolism; Immune system; Adoptive cell transfer; Function (biology); Cancer research; Regulatory T cell; Cancer; Immunology; Transplant rejection; T cell; Cell; Cell biology; Genetics; IL-2 receptor","score_opus":0.16259025924903045,"score_gpt":0.3537250928782405,"score_spread":0.19113483362921005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323652962","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00024467014,0.9959972,0.000028175516,0.00019480925,0.0008785528,0.0004274665,0.00001750676,0.000036077934,0.0021755495],"genre_scores_gemma":[0.000083433,0.9862194,0.00010492015,0.00010454854,0.00080451625,0.0000060420607,0.000039800558,0.00027653173,0.012360779],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9947918,0.0020704297,0.0017831656,0.00030152293,0.0004906516,0.0005624175],"domain_scores_gemma":[0.9974363,0.00036724925,0.0011280909,0.000580404,0.0002480023,0.00023997562],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0035017098,0.0004493232,0.0023362685,0.0014189519,0.000058869806,0.00003578588,0.0006912454,0.00012958978,0.00091050426],"category_scores_gemma":[0.00024653645,0.00034250124,0.0008449388,0.00046440354,0.0002796334,0.000084513864,0.00024252545,0.0021450305,0.00020210378],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035805936,0.00025518713,0.000005166466,0.0056259716,0.0013401802,0.007919934,0.00028678734,0.0000033519289,0.0019186095,0.00010682369,0.0006743401,0.9815056],"study_design_scores_gemma":[0.001471609,0.00024326789,0.00043479924,0.0075514643,0.0008284156,0.00077004783,0.00020152128,0.0000018769599,0.00000523488,0.000011395021,0.98823375,0.00024660525],"about_ca_topic_score_codex":0.0000025526595,"about_ca_topic_score_gemma":2.1537086e-7,"teacher_disagreement_score":0.98755944,"about_ca_system_score_codex":0.00021634111,"about_ca_system_score_gemma":0.0012430169,"threshold_uncertainty_score":0.9999027},"labels":[],"label_agreement":null},{"id":"W4323656441","doi":"10.1016/j.ccell.2023.02.008","title":"The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients","year":2023,"lang":"en","type":"article","venue":"Cancer Cell","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":247,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Institute of Cancer Research; Ontario Institute for Cancer Research","funders":"José Carreras Leukämie-Stiftung; Terry Fox Research Institute; Bundesministerium für Bildung und Forschung; Deutsche Forschungsgemeinschaft; International Myeloma Society; Else Kröner-Fresenius-Stiftung; Deutsche Krebshilfe; Pfizer","keywords":"CD8; Major histocompatibility complex; Immunotherapy; Multiple myeloma; Immune system; MHC class I; Immunology; T cell; Repertoire; Cytotoxic T cell; Biology; Mechanism (biology); Cancer research; Computational biology; Medicine; Genetics; In vitro","score_opus":0.04948049454371408,"score_gpt":0.3285578656138817,"score_spread":0.27907737107016767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323656441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857629,0.0010421991,0.0000031480947,0.0008160268,0.0005221187,0.0013153076,0.000030889267,0.000090477326,0.01041691],"genre_scores_gemma":[0.93918455,0.0007278643,0.000032853597,0.00027466673,0.00027759763,0.00034188546,0.000017951419,0.000077412864,0.059065223],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974509,0.0004286326,0.00036564385,0.0004536949,0.0005624415,0.00073868304],"domain_scores_gemma":[0.9965579,0.0022376606,0.00009118606,0.00075954606,0.00014840714,0.00020531102],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013916182,0.00023351889,0.00025417164,0.00016291763,0.00038732728,0.00008242049,0.00044024643,0.00009334816,0.00060167705],"category_scores_gemma":[0.0003386469,0.00014621958,0.0001170227,0.0009508832,0.00010162259,0.000053759777,0.000198002,0.0004969342,0.00025959822],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010564327,0.00027082697,0.20828119,0.00026705218,0.000027168793,0.00014361391,0.01539131,0.0006418749,0.675301,8.34204e-7,0.0370566,0.052054163],"study_design_scores_gemma":[0.0062282276,0.00060431054,0.29627958,0.00015206115,0.00003512154,0.0000024053377,0.0049092844,0.0034634657,0.23259394,0.000008665222,0.4552904,0.00043253],"about_ca_topic_score_codex":0.000333837,"about_ca_topic_score_gemma":0.00074503623,"teacher_disagreement_score":0.4427071,"about_ca_system_score_codex":0.0003036317,"about_ca_system_score_gemma":0.00020991763,"threshold_uncertainty_score":0.65879416},"labels":[],"label_agreement":null},{"id":"W4323656721","doi":"10.1073/pnas.2216901120","title":"Visualizing cell–cell communication using synthetic notch activated MRI","year":2023,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Institute of Cancer Research; Ontario Institute for Cancer Research; Robarts Clinical Trials; Western University","funders":"Canadian Institutes of Health Research","keywords":"Cancer cell; CD19; Biology; Cell biology; Cell; Antigen; Immune system; Reporter gene; Cancer research; Bioluminescence imaging; Cell culture; Cancer; Immunology; Gene expression; Gene; Biochemistry; Genetics; Transfection","score_opus":0.11779834927070305,"score_gpt":0.4075851612719628,"score_spread":0.2897868120012598,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323656721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97986734,0.00011796809,7.796941e-7,0.0028245149,0.000010927258,0.00029440882,0.0000036682457,0.00003157282,0.01684885],"genre_scores_gemma":[0.99726105,0.00014267307,0.0010806897,0.00012727032,0.000041726467,0.0000062214626,3.7605832e-7,0.000009771892,0.0013302277],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977143,0.000015929098,0.00029653328,0.00021479373,0.0015515725,0.0002068795],"domain_scores_gemma":[0.9989937,0.00027449185,0.00028623603,0.000020055766,0.00037775846,0.000047782698],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002192091,0.000088622444,0.00017492546,0.000365465,0.0002505089,0.000026153053,0.0006671715,0.00008845685,0.00010919852],"category_scores_gemma":[0.00035165442,0.00006340556,0.000085795524,0.002087894,0.0006877621,0.00025817505,0.0002400143,0.00027143443,0.000008254241],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000037253827,0.000054983633,0.0033330962,0.00013005358,0.000009932008,8.824396e-9,0.00033105418,0.00010777274,0.99434483,0.0010070438,0.00039991204,0.00024405199],"study_design_scores_gemma":[0.0003154566,0.000043956214,0.008879561,0.00019778113,0.000017609082,0.0000073712995,0.00058950495,0.009157445,0.9769195,0.0034427643,0.00036552068,0.00006355219],"about_ca_topic_score_codex":0.000022477258,"about_ca_topic_score_gemma":3.5118738e-8,"teacher_disagreement_score":0.01742536,"about_ca_system_score_codex":0.000088635425,"about_ca_system_score_gemma":0.00007710515,"threshold_uncertainty_score":0.25856036},"labels":[],"label_agreement":null},{"id":"W4323663940","doi":"10.1016/j.jtct.2023.03.005","title":"Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Immunogenicity among Chimeric Antigen Receptor T Cell Therapy Recipients","year":2023,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"BC Children's Hospital; Wellcome Trust; National Cancer Institute; Bill and Melinda Gates Foundation","keywords":"Medicine; Immunology; Immunogenicity; Vaccination; Internal medicine; Population; Interquartile range; Antibody","score_opus":0.03830271334259059,"score_gpt":0.3009766478217383,"score_spread":0.26267393447914766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323663940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934336,0.0036452245,0.00011310198,0.00015179739,0.0002736731,0.0012172583,0.00012394326,0.00029063458,0.0007508003],"genre_scores_gemma":[0.90213525,0.09113406,0.00007210264,0.0005560655,0.0000952214,0.000080839185,0.00082623505,0.00010596359,0.004994277],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997555,0.00024582175,0.00045650054,0.00057708006,0.0006133458,0.00055220525],"domain_scores_gemma":[0.9989538,0.00008652898,0.00012147468,0.00047259874,0.00010234631,0.0002632459],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00055122137,0.00036865496,0.0004986981,0.00032879342,0.00026662412,0.000057242374,0.00020739774,0.00021941795,0.0035451301],"category_scores_gemma":[0.000002460676,0.00032337927,0.00020744535,0.00080159295,0.00010800693,0.00018163462,0.000015962645,0.0003990638,0.0002974808],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0048343157,0.0002182262,0.05111765,0.000064006315,0.00043552773,0.00041060988,0.001679782,0.000008506768,0.9108535,0.0000045480724,0.0002687497,0.030104594],"study_design_scores_gemma":[0.015893798,0.0017339365,0.47776332,0.000101028585,0.000086213025,0.00019571565,0.0001815529,0.000099534016,0.4804767,0.00003655643,0.022870172,0.0005614622],"about_ca_topic_score_codex":0.00011663334,"about_ca_topic_score_gemma":0.00000764098,"teacher_disagreement_score":0.43037677,"about_ca_system_score_codex":0.00006308633,"about_ca_system_score_gemma":0.00008967059,"threshold_uncertainty_score":0.9999218},"labels":[],"label_agreement":null},{"id":"W4323783949","doi":"10.1039/d2bm01795d","title":"T cell-loaded injectable chitosan scaffold shows short-term efficacy in localised cancer immunotherapy in mice","year":2023,"lang":"en","type":"article","venue":"Biomaterials Science","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; École de Technologie Supérieure; Centre Hospitalier de l’Université de Montréal","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Flow cytometry; Chemistry; In vitro; Immunotherapy; Biocompatibility; Chitosan; Immune system; Pharmacology; Immunology; Medicine; Pathology; Biochemistry","score_opus":0.04078009132063916,"score_gpt":0.3488355255666527,"score_spread":0.30805543424601356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323783949","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964676,0.0003278834,0.0000021279907,0.0003752174,0.0007256783,0.001097491,0.000021349411,0.00022768768,0.00075497554],"genre_scores_gemma":[0.99848115,0.0003948104,0.00007372258,0.00015446983,0.0001662774,0.00016238363,0.000013946643,0.000056649136,0.00049660396],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99665743,0.00013020413,0.0005497482,0.00074212725,0.0008611566,0.0010593431],"domain_scores_gemma":[0.99902654,0.000093408984,0.000067155845,0.0005532302,0.00005622277,0.00020343813],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016365129,0.00024784208,0.0005066527,0.0010779508,0.00010663275,0.0001934199,0.0006607385,0.00012802186,0.0011845409],"category_scores_gemma":[0.00007458941,0.00021654175,0.000067727226,0.003835212,0.0005622014,0.00025782478,0.000189433,0.00008698081,0.00007037516],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005499456,0.0002270581,0.013979574,0.00007013207,0.0000063315983,0.00009681659,0.000788815,0.000030049192,0.9809085,0.0000047044955,0.00012731417,0.003210751],"study_design_scores_gemma":[0.0022105637,0.00013769045,0.13018325,0.00017872821,0.0000038149897,0.000011213949,0.0001103513,0.00026371784,0.8664345,0.000006496221,0.00025452027,0.00020515491],"about_ca_topic_score_codex":0.0019207682,"about_ca_topic_score_gemma":0.00016385606,"teacher_disagreement_score":0.11620368,"about_ca_system_score_codex":0.00030732923,"about_ca_system_score_gemma":0.00071068876,"threshold_uncertainty_score":0.9997285},"labels":[],"label_agreement":null},{"id":"W4324044824","doi":"10.1038/s41591-023-02234-6","title":"A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy","year":2023,"lang":"en","type":"article","venue":"Nature Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":226,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Heart, Lung, and Blood Institute; Deutschen Konsortium für Translationale Krebsforschung; Nationales Centrum für Tumorerkrankungen Heidelberg; Deutsche Krebshilfe; National Cancer Institute; Weizmann Institute of Science; Ministry of Science and Technology, Israel; Wellcome Trust; Wilhelm Sander-Stiftung; Moffitt Cancer Center; Deutsche Forschungsgemeinschaft; Deutsches Krebsforschungszentrum; Canadian Institute for Advanced Research; Bill and Melinda Gates Foundation; IDSA Foundation; Baden-Württemberg Stiftung; Infectious Diseases Society of America; Universität Heidelberg; Howard Hughes Medical Institute","keywords":"Akkermansia; Microbiome; Antibiotics; Immunology; Medicine; Cancer; Cohort; Population; Gut flora; Internal medicine; Biology; Oncology; Bioinformatics; Bacteroides; Microbiology","score_opus":0.03393981037234582,"score_gpt":0.4145805644084198,"score_spread":0.38064075403607395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324044824","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95720315,0.0030446684,0.000010291233,0.034881912,0.000980092,0.0016288308,0.00009736942,0.00049467053,0.0016589875],"genre_scores_gemma":[0.8714527,0.002639666,0.00021663943,0.019994335,0.0014491363,0.00005157229,0.00022303232,0.00027240303,0.10370053],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.995734,0.00025539653,0.0007761771,0.0009158306,0.0013390078,0.0009796012],"domain_scores_gemma":[0.9964971,0.00096623343,0.00020692368,0.001032492,0.00072407647,0.0005731968],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0023616024,0.00048278822,0.0012983232,0.0009242112,0.00012915678,0.000027937896,0.00043002737,0.0008971282,0.003549409],"category_scores_gemma":[0.00090454763,0.00032342027,0.0002356047,0.003730442,0.0004542266,0.00005505215,0.00011070136,0.0022632293,0.00024605848],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007291299,0.0002947558,0.03918383,0.00008830866,0.0006736468,0.0007107173,0.0014319163,9.56241e-7,0.78113014,0.0000029772184,0.16351566,0.0056758085],"study_design_scores_gemma":[0.0273206,0.0073176157,0.5514822,0.0028358547,0.00049434736,0.00013460517,0.0007482111,0.00022194778,0.11229316,0.000019665926,0.29630703,0.00082475704],"about_ca_topic_score_codex":0.0002992569,"about_ca_topic_score_gemma":0.00012275451,"teacher_disagreement_score":0.66883695,"about_ca_system_score_codex":0.00035688299,"about_ca_system_score_gemma":0.00060414325,"threshold_uncertainty_score":0.9999218},"labels":[],"label_agreement":null},{"id":"W4324342851","doi":"10.1016/j.omtm.2023.03.006","title":"Simultaneous engineering of natural killer cells for CAR transgenesis and CRISPR-Cas9 knockout using retroviral particles","year":2023,"lang":"en","type":"article","venue":"Molecular Therapy — Methods & Clinical Development","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada; Ottawa Hospital; Institute of Infection and Immunity; University of Ottawa","funders":"National Cancer Institute; National Research Council Canada; Ottawa Hospital Research Institute; Canadian Institutes of Health Research; University of Ottawa","keywords":"CRISPR; Transgenesis; Biology; Cas9; Genetics; Computational biology; Gene; Reproductive technology","score_opus":0.11891240073928173,"score_gpt":0.4657807527445325,"score_spread":0.3468683520052508,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4324342851","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89665115,0.0014629652,0.09994093,0.00020486237,0.00059793395,0.001032664,0.0000032972323,0.00009709768,0.000009122493],"genre_scores_gemma":[0.4564626,0.00077010813,0.5414327,0.00030681744,0.00008949675,0.00006399801,0.000014475442,0.00010341176,0.00075640273],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99688524,0.00046198885,0.0010118862,0.000577914,0.00046558183,0.00059737585],"domain_scores_gemma":[0.99676293,0.0022273925,0.00012027757,0.00038916417,0.00022538601,0.00027482712],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0032937706,0.00030490704,0.0008299676,0.00021523179,0.00008624936,0.00002664267,0.00017188338,0.00022502703,0.00007857849],"category_scores_gemma":[0.0008073324,0.0002645172,0.0003568471,0.00049089204,0.00013242959,0.00003442465,0.00007400356,0.00033947657,0.0000051853617],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007429131,0.00008312243,0.00038519598,0.00010642079,0.00039246664,0.00006080596,0.00045042014,0.00040696978,0.66329956,0.000008974609,0.000014513559,0.33404863],"study_design_scores_gemma":[0.0035976728,0.0005373242,0.0031510869,0.000098998236,0.00009266668,0.00001536977,0.00010355503,0.038641103,0.9276743,0.00006989024,0.02566931,0.00034874032],"about_ca_topic_score_codex":0.000012564725,"about_ca_topic_score_gemma":0.0000012182959,"teacher_disagreement_score":0.44149175,"about_ca_system_score_codex":0.00008787936,"about_ca_system_score_gemma":0.00023471298,"threshold_uncertainty_score":0.9999807},"labels":[],"label_agreement":null},{"id":"W4327940554","doi":"10.1016/j.cell.2023.02.027","title":"Human T cell generation is restored in CD3δ severe combined immunodeficiency through adenine base editing","year":2023,"lang":"en","type":"article","venue":"Cell","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Institute of General Medical Sciences; National Cancer Institute; National Institutes of Health; National Heart, Lung, and Blood Institute; National Institute of Allergy and Infectious Diseases; Bill and Melinda Gates Foundation; National Human Genome Research Institute; Howard Hughes Medical Institute","keywords":"Biology; Human immunodeficiency virus (HIV); Base (topology); Virology; CD3; Severe combined immunodeficiency; Immunodeficiency; Cell biology; Genetics; Computational biology; Immunology; Gene; Immune system; CD8","score_opus":0.06127085463604074,"score_gpt":0.32833108210947287,"score_spread":0.2670602274734321,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4327940554","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9585028,0.00038417603,0.000016089523,0.0010177711,0.00031738848,0.0005471576,0.000011922106,0.00014368867,0.03905897],"genre_scores_gemma":[0.9272286,0.000120280376,0.00019861515,0.00035147308,0.00054974743,0.00004111967,0.00027887386,0.00006001804,0.07117127],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99808824,0.00010006804,0.0003882747,0.0004347621,0.00047280316,0.0005158254],"domain_scores_gemma":[0.9990919,0.000060718314,0.00008229018,0.00056255946,0.0001120295,0.00009049737],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005126971,0.00018746911,0.00029105318,0.00023935283,0.00016968204,0.000041312753,0.00018031355,0.00014393055,0.0037228551],"category_scores_gemma":[0.000049654056,0.00018754626,0.00010371203,0.00088501384,0.00006945391,0.00012249798,0.00010793321,0.0004459207,0.0005194598],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006956766,0.000218933,0.0015867549,0.0001246342,0.000006870502,0.00013124172,0.002358553,0.0000779669,0.95578486,0.000018463548,0.0392233,0.00039884198],"study_design_scores_gemma":[0.010040567,0.0009864075,0.009589081,0.00014682564,0.000046598725,0.000024532552,0.0017780401,0.010663073,0.93980515,0.00022107632,0.026211942,0.00048670545],"about_ca_topic_score_codex":0.00032720118,"about_ca_topic_score_gemma":0.00003180478,"teacher_disagreement_score":0.032112297,"about_ca_system_score_codex":0.00019788084,"about_ca_system_score_gemma":0.00011325648,"threshold_uncertainty_score":0.99718785},"labels":[],"label_agreement":null},{"id":"W4328048068","doi":"10.1016/j.jcyt.2023.02.007","title":"International Society for Cell &amp; Gene Therapy Stem Cell Engineering Committee: Cellular therapies for the treatment of graft-versus-host-disease after hematopoietic stem cell transplant","year":2023,"lang":"en","type":"review","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Stem cell; Genetic enhancement; Hematopoietic stem cell; Graft-versus-host disease; Disease; Hematopoietic stem cell transplantation; Cell; Haematopoiesis; Cell therapy; Stem-cell therapy; Medicine; Gene; Cancer research; Immunology; Biology; Internal medicine; Cell biology; Genetics","score_opus":0.08540012506480056,"score_gpt":0.33491598721822236,"score_spread":0.2495158621534218,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4328048068","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0037362573,0.978594,0.0034247031,0.0002590776,0.0010470995,0.01068975,0.002015038,0.00018249203,0.0000516034],"genre_scores_gemma":[0.00038197113,0.9701464,0.00078574714,0.00009892018,0.0009940348,0.0071195746,0.0006789861,0.00058816565,0.019206174],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959884,0.00012345065,0.0011711436,0.0009723446,0.00085740554,0.00088720216],"domain_scores_gemma":[0.9952529,0.0022019166,0.00047355972,0.0014774884,0.00026640447,0.0003276978],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00061268854,0.0011667432,0.0023163138,0.00030043055,0.00018568945,0.0001090701,0.0008197189,0.00047372954,0.00053082255],"category_scores_gemma":[0.00000176882,0.00076933985,0.0046440023,0.00041278952,0.00017626442,0.00006709772,0.00003187165,0.00039603803,0.000039726623],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021272738,0.007474545,0.000058104044,0.08438412,0.020031106,0.00012979006,0.025797697,0.00010535551,0.047076277,0.000051983865,0.005559868,0.7880584],"study_design_scores_gemma":[0.01043378,0.0014518702,0.000003875175,0.001403576,0.0015161665,0.0000062605163,0.00026626748,0.00025278438,0.010906586,0.0000066817147,0.9730934,0.0006587695],"about_ca_topic_score_codex":0.000015858363,"about_ca_topic_score_gemma":0.0000040296136,"teacher_disagreement_score":0.9675335,"about_ca_system_score_codex":0.000621185,"about_ca_system_score_gemma":0.00055697205,"threshold_uncertainty_score":0.9994758},"labels":[],"label_agreement":null},{"id":"W4353086070","doi":"10.54097/hset.v36i.5706","title":"Comprehensive Overview of CAR-T Cell Therapy, Engineering Process and Future Prospects","year":2023,"lang":"en","type":"article","venue":"Highlights in Science Engineering and Technology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Chimeric antigen receptor; Immune system; Antigen; Cancer research; Cell therapy; Antigen-presenting cell; Immunology; Immunotherapy; Cytotoxic T cell; T cell; Medicine; Biology; Stem cell; Cell biology","score_opus":0.019460927381170234,"score_gpt":0.28982051849732815,"score_spread":0.2703595911161579,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4353086070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930728,0.0048260093,0.0000074682684,0.0012689185,0.00013710724,0.00032734862,0.000001917471,0.00025053663,0.00010786193],"genre_scores_gemma":[0.9908545,0.008466517,0.0004510522,0.000008847948,0.000063240666,0.00003621426,0.0000010369743,0.000019323761,0.00009929363],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988154,0.00000386144,0.00017304465,0.00034803987,0.00027625466,0.000383408],"domain_scores_gemma":[0.9994786,0.000045094806,0.000028593853,0.0002516316,0.000113706,0.00008240669],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000207027,0.00014645349,0.0003028137,0.0012273703,0.000045785706,0.000015508922,0.00016860147,0.00013051952,0.000009292262],"category_scores_gemma":[0.000032166357,0.00011851645,0.000017614451,0.0031850045,0.00028460086,0.000079194964,0.00009875164,0.00025771355,0.0000046053456],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000019470439,0.00003665936,0.0022480392,0.0005686011,0.000011934689,0.0000700351,0.0005784843,0.00030310708,0.98154163,0.00893253,0.000012811243,0.0056766993],"study_design_scores_gemma":[0.0024706782,0.0006901257,0.04076039,0.000435391,0.000012850645,0.00021568214,0.0006677844,0.02214238,0.8719725,0.00031872615,0.05988209,0.00043141755],"about_ca_topic_score_codex":0.0000067632996,"about_ca_topic_score_gemma":8.1279376e-7,"teacher_disagreement_score":0.10956915,"about_ca_system_score_codex":0.000037696245,"about_ca_system_score_gemma":0.00006923448,"threshold_uncertainty_score":0.48329607},"labels":[],"label_agreement":null},{"id":"W4353087883","doi":"10.54097/hset.v36i.5685","title":"Advantages and Disadvantages of Car-T Therapy in the Clinical Treatment of Diffuse Large B-Cell Lymphoma (DLBCL)","year":2023,"lang":"en","type":"article","venue":"Highlights in Science Engineering and Technology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Chimeric antigen receptor; CAR T-cell therapy; Medicine; Lymphoma; Cell therapy; Oncology; Chemotherapy; T cell; Cancer; Internal medicine; Immunotherapy; Immunology; Cell; Immune system; Biology","score_opus":0.024159055362451828,"score_gpt":0.3423455755452983,"score_spread":0.3181865201828465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4353087883","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99729455,0.0011858527,0.000007031853,0.0010412405,0.000067179295,0.00026951227,0.000005289758,0.00005122778,0.00007814502],"genre_scores_gemma":[0.9810276,0.018627416,0.00017695974,0.000006209499,0.000016150541,0.000025982083,0.0000011652455,0.000008829243,0.0001097144],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99890083,0.000022506576,0.00027563292,0.00027452456,0.00021759365,0.00030893268],"domain_scores_gemma":[0.99927473,0.00028349296,0.000038766168,0.00033015065,0.000029844277,0.00004302618],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006597453,0.000110447894,0.0003299371,0.0008588102,0.000033533746,0.000006897088,0.00018373565,0.000102200094,0.000002924934],"category_scores_gemma":[0.00008790485,0.00006605376,0.00002889791,0.0015893359,0.00065152155,0.00004591556,0.00006401366,0.000091998765,0.0000017520533],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019315915,0.004333148,0.2803973,0.00012553715,0.000033595563,0.0003005958,0.003190469,0.000021320477,0.6020441,0.014332543,0.000017569275,0.09501064],"study_design_scores_gemma":[0.03480491,0.005684464,0.49925405,0.00023877418,0.000027784017,0.00015539199,0.0037512693,0.005639323,0.4138274,0.0005679138,0.035670657,0.00037807022],"about_ca_topic_score_codex":0.000024725887,"about_ca_topic_score_gemma":0.000014716442,"teacher_disagreement_score":0.21885675,"about_ca_system_score_codex":0.000035305737,"about_ca_system_score_gemma":0.000052448795,"threshold_uncertainty_score":0.26935944},"labels":[],"label_agreement":null},{"id":"W4360825288","doi":"10.1117/12.2669343","title":"Design of a novel CAR T system targeting glioblastoma","year":2023,"lang":"en","type":"article","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Chimeric antigen receptor; Glioblastoma; Limiting; Cancer research; Immune system; Glioma; Antigen; Cytotoxicity; Receptor; T-cell receptor; Immunotherapy; T cell; Biology; Medicine; Immunology; In vitro; Internal medicine; Engineering","score_opus":0.05674340200660939,"score_gpt":0.3215453981473689,"score_spread":0.2648019961407595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4360825288","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94668317,0.000115648625,0.032582853,0.00042600415,0.00020202363,0.0012282857,0.0000066373423,0.0006969445,0.01805842],"genre_scores_gemma":[0.97910994,0.000012248272,0.0031024907,0.000032366006,0.00012048294,0.00002515513,0.0000042100914,0.000033151395,0.017559955],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99892145,0.000039241353,0.00021261799,0.0001637538,0.00039674444,0.00026618972],"domain_scores_gemma":[0.99933,0.00017688081,0.000034739765,0.00022828799,0.00013377846,0.00009635299],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069134356,0.000080207334,0.00023327369,0.00020229408,0.000029723642,0.000006778013,0.00008161774,0.000056299046,0.00081192795],"category_scores_gemma":[0.000094629264,0.00006363739,0.00006497431,0.00063432194,0.000036074824,0.000022849732,0.000050708164,0.000106410174,0.00018275222],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032092183,0.000042776785,0.00038540893,0.00029671352,0.00006065764,0.000055005352,0.00030290533,0.0002636851,0.99338293,0.00022939117,0.0036573901,0.0010022136],"study_design_scores_gemma":[0.0047513903,0.0014042029,0.00094844704,0.00042595516,0.00005767002,0.0001482265,0.0052484535,0.18383345,0.7988339,0.000007801189,0.0041165557,0.00022396517],"about_ca_topic_score_codex":0.00010169404,"about_ca_topic_score_gemma":0.0000032023293,"teacher_disagreement_score":0.19454905,"about_ca_system_score_codex":0.00007850721,"about_ca_system_score_gemma":0.00009463327,"threshold_uncertainty_score":0.8890042},"labels":[],"label_agreement":null},{"id":"W4360992847","doi":"10.1073/pnas.2219086120","title":"Tonic-signaling chimeric antigen receptors drive human regulatory T cell exhaustion","year":2023,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; Université de Montréal; Hôpital Maisonneuve-Rosemont; University of British Columbia","funders":"Canadian Institutes of Health Research; Government of Canada; BC Children's Hospital","keywords":"Chimeric antigen receptor; Biology; Downregulation and upregulation; Immunology; Transcription factor; Chromatin; T cell; CD8; Receptor; Cell biology; Immune system; Cell therapy; Stem cell; Genetics; Gene","score_opus":0.06730328592337548,"score_gpt":0.36110241886607736,"score_spread":0.2937991329427019,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4360992847","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98439,0.00008585619,1.8215806e-7,0.0016030256,0.000030175139,0.00028491436,0.0000027776043,0.00003698566,0.013566055],"genre_scores_gemma":[0.99495393,0.00008533554,0.0003371852,0.00011287566,0.00016216675,0.0000101115065,6.731118e-7,0.000009045988,0.004328649],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973166,0.000008617428,0.00031539972,0.00027638848,0.0018561821,0.00022682713],"domain_scores_gemma":[0.9992312,0.00008446998,0.00028588696,0.00001319252,0.00032591764,0.000059295064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021563268,0.00009536365,0.00018568314,0.00041577077,0.00027737016,0.000018221115,0.00048659297,0.00009386924,0.00029499462],"category_scores_gemma":[0.00021323789,0.00006787263,0.00011199702,0.0019058114,0.00079177687,0.00023217499,0.00013456272,0.00024545746,0.000011252004],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002197801,0.000032540847,0.0135248015,0.000080253165,0.000016120766,1.3664887e-8,0.00028770408,0.000059231636,0.98093665,0.002492188,0.001950777,0.000597755],"study_design_scores_gemma":[0.00027036108,0.00010155975,0.13771328,0.00013059315,0.000012631807,0.0000046402965,0.00041508544,0.0004342036,0.85480946,0.0052335677,0.0008043326,0.000070257556],"about_ca_topic_score_codex":0.0000072090447,"about_ca_topic_score_gemma":2.233834e-8,"teacher_disagreement_score":0.12612715,"about_ca_system_score_codex":0.000078859215,"about_ca_system_score_gemma":0.00006779593,"threshold_uncertainty_score":0.32299843},"labels":[],"label_agreement":null},{"id":"W4361279352","doi":"10.1182/bloodadvances.2022009117","title":"Longitudinal patient-reported outcomes in patients receiving chimeric antigen receptor T-cell therapy","year":2023,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Leukemia and Lymphoma Society","keywords":"Chimeric antigen receptor; Medicine; Receptor; Antigen; Cell therapy; Immunology; Internal medicine; Cell; Immunotherapy; Biology; Immune system; Genetics","score_opus":0.028434535764571875,"score_gpt":0.31652089862229865,"score_spread":0.28808636285772676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361279352","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99396795,0.0013754009,0.000001534812,0.00022772816,0.00040351535,0.000876603,0.000008542205,0.00018742049,0.0029513154],"genre_scores_gemma":[0.9905032,0.0048185945,0.0003652364,0.00012063565,0.00009119851,0.00008379593,0.00009296433,0.00006176747,0.003862602],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976259,0.00008580311,0.0004929375,0.0005063396,0.0007068029,0.0005822234],"domain_scores_gemma":[0.9989639,0.00015769967,0.00016794259,0.00043369897,0.00012896034,0.00014779279],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00025943972,0.00024591596,0.00048765854,0.00038448581,0.00008920313,0.000027115106,0.00015660358,0.00007860247,0.0009169728],"category_scores_gemma":[0.00018272434,0.00019980088,0.0001378995,0.0011564108,0.000076154574,0.00020678196,0.00007136869,0.00027223513,0.00016004007],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031801144,0.0008590913,0.87531924,0.0000335036,0.00010395568,0.000055742872,0.0003370312,0.000009103575,0.022001425,7.731724e-7,0.00019645605,0.10076568],"study_design_scores_gemma":[0.0055491696,0.0010115642,0.94647413,0.000077760415,0.000017670818,0.0000040794334,0.00015767949,0.000010393391,0.02805767,0.000026459222,0.01838813,0.00022527894],"about_ca_topic_score_codex":0.000057049656,"about_ca_topic_score_gemma":0.000022653408,"teacher_disagreement_score":0.10054041,"about_ca_system_score_codex":0.000051689156,"about_ca_system_score_gemma":0.0000791451,"threshold_uncertainty_score":0.9999963},"labels":[],"label_agreement":null},{"id":"W4361817155","doi":"10.1158/1078-0432.c.6528245.v1","title":"Data from Developing Allogeneic Double-Negative T Cells as a Novel Off-the-Shelf Adoptive Cellular Therapy for Cancer","year":2023,"lang":"en","type":"preprint","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Social Innovation; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"CD8; Cancer research; Cytotoxicity; In vitro; In vivo; Transplantation; Cytotoxic T cell; Flow cytometry; Immunology; Chemistry; Molecular biology; Immune system; Biology; Medicine; Biochemistry; Internal medicine","score_opus":0.2841065190242599,"score_gpt":0.4189088756336146,"score_spread":0.13480235660935475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361817155","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6136911,0.026578907,0.17009012,0.060526025,0.012311709,0.06384862,0.03651319,0.0021602418,0.0142800715],"genre_scores_gemma":[0.08090825,0.11562269,0.17175768,0.018268146,0.015884433,0.021455945,0.042930327,0.0029986782,0.53017384],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9948682,0.00012476163,0.0007868232,0.0021202168,0.0011486736,0.0009513096],"domain_scores_gemma":[0.99356693,0.0016136213,0.00035769987,0.003370435,0.0008162558,0.00027508583],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012551066,0.00079012,0.0012035926,0.00028283417,0.00024658188,0.0001964095,0.0022342785,0.0006765606,0.0046149166],"category_scores_gemma":[0.00015426656,0.0005642839,0.0004076586,0.00045340045,0.00029709187,0.00010435366,0.0029997225,0.0014807408,0.00026880126],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012185629,0.0005406327,0.00038612023,0.0006517487,0.010181167,0.00011318968,0.00473575,0.00055018126,0.9025469,0.00048176665,0.02705407,0.04057289],"study_design_scores_gemma":[0.012221266,0.00035592652,0.0006104823,0.0008968299,0.00046820336,0.000005555216,0.0013649113,0.0059767584,0.71364796,0.0030244784,0.26027328,0.0011543481],"about_ca_topic_score_codex":0.016284833,"about_ca_topic_score_gemma":0.0033204712,"teacher_disagreement_score":0.53278285,"about_ca_system_score_codex":0.0007286518,"about_ca_system_score_gemma":0.0036355008,"threshold_uncertainty_score":0.9996809},"labels":[],"label_agreement":null},{"id":"W4361817253","doi":"10.1158/1078-0432.c.6528245","title":"Data from Developing Allogeneic Double-Negative T Cells as a Novel Off-the-Shelf Adoptive Cellular Therapy for Cancer","year":2023,"lang":"en","type":"preprint","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Social Innovation; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"CD8; Cytotoxicity; Cancer research; In vitro; Transplantation; Cytotoxic T cell; In vivo; Flow cytometry; Immunology; Chemistry; Molecular biology; Immune system; Medicine; Biology; Biochemistry; Internal medicine","score_opus":0.2841065190242599,"score_gpt":0.4189088756336146,"score_spread":0.13480235660935475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361817253","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6136911,0.026578907,0.17009012,0.060526025,0.012311709,0.06384862,0.03651319,0.0021602418,0.0142800715],"genre_scores_gemma":[0.08090825,0.11562269,0.17175768,0.018268146,0.015884433,0.021455945,0.042930327,0.0029986782,0.53017384],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9948682,0.00012476163,0.0007868232,0.0021202168,0.0011486736,0.0009513096],"domain_scores_gemma":[0.99356693,0.0016136213,0.00035769987,0.003370435,0.0008162558,0.00027508583],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012551066,0.00079012,0.0012035926,0.00028283417,0.00024658188,0.0001964095,0.0022342785,0.0006765606,0.0046149166],"category_scores_gemma":[0.00015426656,0.0005642839,0.0004076586,0.00045340045,0.00029709187,0.00010435366,0.0029997225,0.0014807408,0.00026880126],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012185629,0.0005406327,0.00038612023,0.0006517487,0.010181167,0.00011318968,0.00473575,0.00055018126,0.9025469,0.00048176665,0.02705407,0.04057289],"study_design_scores_gemma":[0.012221266,0.00035592652,0.0006104823,0.0008968299,0.00046820336,0.000005555216,0.0013649113,0.0059767584,0.71364796,0.0030244784,0.26027328,0.0011543481],"about_ca_topic_score_codex":0.016284833,"about_ca_topic_score_gemma":0.0033204712,"teacher_disagreement_score":0.53278285,"about_ca_system_score_codex":0.0007286518,"about_ca_system_score_gemma":0.0036355008,"threshold_uncertainty_score":0.9996809},"labels":[],"label_agreement":null},{"id":"W4361822960","doi":"10.1158/0008-5472.c.6513447.v1","title":"Data from Mesothelin-Specific CAR T Cells Target Ovarian Cancer","year":2023,"lang":"en","type":"preprint","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; Karolinska Institutet; Cancerfonden; Barncancerfonden; Memorial Sloan-Kettering Cancer Center","keywords":"Mesothelin; Ovarian cancer; Cancer research; CD28; Tumor microenvironment; T cell; CD8; Immune system; Cytotoxic T cell; Medicine; Antigen; Immunology; Cancer; Chemistry; Internal medicine; Tumor cells; In vitro","score_opus":0.1848458817025429,"score_gpt":0.38904224535881604,"score_spread":0.20419636365627314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361822960","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17919627,0.06505058,0.03357601,0.09822928,0.059546772,0.026834417,0.1990156,0.0085327355,0.33001834],"genre_scores_gemma":[0.013580773,0.04637028,0.028088463,0.0019421222,0.013535543,0.0005053432,0.032186978,0.0008969119,0.8628936],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99565923,0.00015094296,0.0005847094,0.0018057668,0.0011322524,0.00066712074],"domain_scores_gemma":[0.9934182,0.00029608863,0.00013322975,0.005529506,0.0002190289,0.0004039483],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00079358084,0.00048603193,0.00096469535,0.0002801863,0.0000695322,0.00013980719,0.001698805,0.0006164665,0.16583388],"category_scores_gemma":[0.000048417623,0.00041725647,0.00022965937,0.0002652018,0.00013110337,0.000056508892,0.003839558,0.0018819541,0.0036680477],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005679004,0.00017884659,0.0012916677,0.00028868736,0.001401345,0.00048277073,0.00044548605,0.00018668585,0.26848423,0.00007688462,0.7187004,0.007895117],"study_design_scores_gemma":[0.0014977654,0.00004226608,0.001744479,0.000356603,0.00014772297,0.0000031289774,0.00018851737,0.003598943,0.03614455,0.0013941616,0.95437455,0.0005073011],"about_ca_topic_score_codex":0.017295543,"about_ca_topic_score_gemma":0.0015372493,"teacher_disagreement_score":0.53287524,"about_ca_system_score_codex":0.00039125295,"about_ca_system_score_gemma":0.0009985338,"threshold_uncertainty_score":0.9998279},"labels":[],"label_agreement":null},{"id":"W4361942601","doi":"10.1158/1078-0432.c.6516061","title":"Data from Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma","year":2023,"lang":"en","type":"preprint","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Gilead Sciences","keywords":"Chemoimmunotherapy; Medicine; Internal medicine; Adverse effect; Clinical endpoint; Refractory (planetary science); Cytokine release syndrome; Oncology; Gastroenterology; Randomized controlled trial; Lymphoma; Surgery; Immunotherapy; Rituximab; Chimeric antigen receptor; Cancer","score_opus":0.04952137718723923,"score_gpt":0.32935372489378223,"score_spread":0.27983234770654297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361942601","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875238,0.0008583826,0.000031744283,0.000026446001,0.00020737556,0.0013481819,0.008190114,0.000030725587,0.0017832118],"genre_scores_gemma":[0.9883418,0.0021691236,0.0009615105,0.00001307884,0.00005091735,0.000010489355,0.0052198605,0.00010911805,0.003124093],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9966958,0.00015513349,0.0007950925,0.0008104153,0.0012080772,0.0003354914],"domain_scores_gemma":[0.9963702,0.0005853947,0.00036399957,0.002190896,0.00033312535,0.0001563605],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004978896,0.000302343,0.001287754,0.00034508517,0.000016171956,0.000009715883,0.0005602796,0.00037149453,0.0011553031],"category_scores_gemma":[0.00026399005,0.00024537512,0.00010331809,0.00030399868,0.00021610626,0.00005147184,0.0017529653,0.0004722645,0.0000053390286],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.71372026,0.010075385,0.11803735,0.010186626,0.0031349943,0.0009061204,0.012873315,0.000079560275,0.009794606,0.000021187065,0.00419361,0.11697696],"study_design_scores_gemma":[0.16788237,0.008768596,0.7959522,0.0029498916,0.00049507164,7.4455744e-7,0.0027997787,0.000091424394,0.01047909,0.000008665595,0.01002189,0.0005502575],"about_ca_topic_score_codex":0.0015679006,"about_ca_topic_score_gemma":0.002786889,"teacher_disagreement_score":0.67791486,"about_ca_system_score_codex":0.00026709028,"about_ca_system_score_gemma":0.0008753783,"threshold_uncertainty_score":0.9999998},"labels":[],"label_agreement":null},{"id":"W4361943767","doi":"10.1158/1078-0432.c.6519491","title":"Data from Phase I Dose Finding Studies of Obatoclax (GX15-070), a Small Molecule Pan-BCL-2 Family Antagonist, in Patients with Advanced Solid Tumors or Lymphoma","year":2023,"lang":"en","type":"preprint","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Tolerability; Medicine; Antagonist; Regimen; Internal medicine; Lymphoma; Pharmacology; Adverse effect; Gastroenterology; Receptor","score_opus":0.17987563151021402,"score_gpt":0.41832344583255215,"score_spread":0.23844781432233814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361943767","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99111545,0.00089555874,0.00013927155,0.00014150032,0.0002879693,0.0033852004,0.0032289065,0.00018430693,0.00062184053],"genre_scores_gemma":[0.9790595,0.002306399,0.0033402727,0.000223896,0.00017397717,0.00039186754,0.008118228,0.00028777833,0.0060980464],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99472046,0.0002064617,0.00125687,0.0017303852,0.0012585946,0.00082722545],"domain_scores_gemma":[0.99513185,0.0006012727,0.0005106024,0.0030306585,0.00047253285,0.00025308228],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006623281,0.00072689244,0.0020531388,0.0006265404,0.00008476387,0.00006020934,0.001191267,0.00029565912,0.00040940687],"category_scores_gemma":[0.0006590123,0.00052516727,0.0001539717,0.00073124684,0.00034460804,0.00012804753,0.0034744265,0.0007440527,0.00004702705],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18992741,0.023344403,0.22718246,0.011718875,0.017284581,0.010670476,0.011825323,0.0010360801,0.19389339,0.000040053463,0.011657471,0.30141947],"study_design_scores_gemma":[0.27249166,0.018931793,0.54006606,0.029816834,0.0022086378,0.000039655606,0.027650326,0.018429382,0.07999438,0.00073171814,0.0038620355,0.005777495],"about_ca_topic_score_codex":0.0020858415,"about_ca_topic_score_gemma":0.001974911,"teacher_disagreement_score":0.31288362,"about_ca_system_score_codex":0.0007125368,"about_ca_system_score_gemma":0.0015549498,"threshold_uncertainty_score":0.99972},"labels":[],"label_agreement":null},{"id":"W4361947401","doi":"10.1158/1078-0432.c.6530741","title":"Data from Combined EZH2 Inhibition and IKAROS Degradation Leads to Enhanced Antitumor Activity in Diffuse Large B-cell Lymphoma","year":2023,"lang":"en","type":"preprint","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vector Institute; University of Toronto; Princess Margaret Cancer Centre; Spinal Cord Injury BC; University Health Network","funders":"Leukemia and Lymphoma Society; Canadian Institutes of Health Research; BC Cancer Foundation; Natural Sciences and Engineering Research Council of Canada; Princess Margaret Cancer Foundation; Gilead Sciences","keywords":"Lenalidomide; Cancer research; Diffuse large B-cell lymphoma; EZH2; Medicine; Lymphoma; Biology; Epigenetics; Immunology; Multiple myeloma; Gene","score_opus":0.08134297010076623,"score_gpt":0.3518199541938775,"score_spread":0.2704769840931113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361947401","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99042964,0.00005469808,0.0034030846,0.0013393018,0.00029561677,0.002096438,0.0012092902,0.00021663443,0.0009552885],"genre_scores_gemma":[0.9776085,0.0004888178,0.0006954184,0.00024606424,0.00017563044,0.00013769342,0.0073976773,0.00008877721,0.013161432],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9969251,0.00019142004,0.000420645,0.0013094558,0.0006671055,0.00048623604],"domain_scores_gemma":[0.99737746,0.00028373994,0.00012626372,0.0018416637,0.00010967295,0.0002612216],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006574542,0.00036393508,0.00072909176,0.0004967984,0.000063747844,0.00012632081,0.0003289674,0.0003629494,0.0006420731],"category_scores_gemma":[0.00027495623,0.00035533664,0.00007003147,0.00040408887,0.000059611622,0.00019466497,0.00243631,0.00060468883,0.00022494564],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017634317,0.0037446734,0.004801397,0.00036834198,0.000054827353,0.00010946058,0.0002677724,0.0000021082828,0.9790695,0.000014544981,0.002515948,0.0072880397],"study_design_scores_gemma":[0.03485872,0.00043576217,0.16994256,0.00090404414,0.000106299245,0.0000048717275,0.0002052227,0.00700181,0.78454936,0.000416761,0.0008876952,0.00068687415],"about_ca_topic_score_codex":0.0034760365,"about_ca_topic_score_gemma":0.0065733343,"teacher_disagreement_score":0.19452009,"about_ca_system_score_codex":0.00035838084,"about_ca_system_score_gemma":0.00030567625,"threshold_uncertainty_score":0.99988985},"labels":[],"label_agreement":null},{"id":"W4361947402","doi":"10.1158/1078-0432.c.6530591","title":"Data from Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors","year":2023,"lang":"en","type":"preprint","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Internal medicine; Adverse effect; Antibody; Melanoma; Gastroenterology; Colorectal cancer; Cancer; Lung cancer; Oncology; Immunology; Cancer research","score_opus":0.18471333416550853,"score_gpt":0.510112216982763,"score_spread":0.3253988828172545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361947402","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917344,0.00018949114,0.00033193475,0.0005066278,0.0006051101,0.0048236935,0.0012715184,0.0001949421,0.00034230438],"genre_scores_gemma":[0.9612833,0.0030963044,0.0016944911,0.00007192099,0.00039672485,0.00005510223,0.032913778,0.0002047128,0.0002836419],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99114573,0.0010759393,0.0026921467,0.0026981374,0.0014868452,0.000901179],"domain_scores_gemma":[0.9936856,0.00069196685,0.0008045156,0.003898251,0.00034357456,0.0005761019],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0040117567,0.00079487695,0.0034587914,0.0012824389,0.00006664349,0.0001362439,0.00123329,0.0008096232,0.00062723993],"category_scores_gemma":[0.00070773595,0.0007120418,0.00017711194,0.00095584436,0.00076430495,0.00074418285,0.0017901508,0.0022773296,0.000017597175],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31310385,0.03155492,0.44934052,0.0013538634,0.0009376566,0.0038079056,0.0008570834,0.0003727735,0.17383055,0.00009146361,0.00026909157,0.024480307],"study_design_scores_gemma":[0.43960118,0.01584162,0.4384218,0.0034613379,0.00039061691,0.00009001783,0.0010475542,0.08992126,0.008566681,0.0008354508,0.00028827167,0.0015342253],"about_ca_topic_score_codex":0.0066340836,"about_ca_topic_score_gemma":0.0071550896,"teacher_disagreement_score":0.16526386,"about_ca_system_score_codex":0.00014267617,"about_ca_system_score_gemma":0.0011773977,"threshold_uncertainty_score":0.9999808},"labels":[],"label_agreement":null},{"id":"W4361948700","doi":"10.1158/1078-0432.c.6516061.v1","title":"Data from Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma","year":2023,"lang":"en","type":"preprint","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Gilead Sciences","keywords":"Medicine; Chemoimmunotherapy; Internal medicine; Adverse effect; Clinical endpoint; Refractory (planetary science); Oncology; Cytokine release syndrome; Gastroenterology; Randomized controlled trial; Lymphoma; Surgery; Rituximab; Immunotherapy; Chimeric antigen receptor; Cancer","score_opus":0.04952137718723923,"score_gpt":0.32935372489378223,"score_spread":0.27983234770654297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361948700","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875238,0.0008583826,0.000031744283,0.000026446001,0.00020737556,0.0013481819,0.008190114,0.000030725587,0.0017832118],"genre_scores_gemma":[0.9883418,0.0021691236,0.0009615105,0.00001307884,0.00005091735,0.000010489355,0.0052198605,0.00010911805,0.003124093],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9966958,0.00015513349,0.0007950925,0.0008104153,0.0012080772,0.0003354914],"domain_scores_gemma":[0.9963702,0.0005853947,0.00036399957,0.002190896,0.00033312535,0.0001563605],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004978896,0.000302343,0.001287754,0.00034508517,0.000016171956,0.000009715883,0.0005602796,0.00037149453,0.0011553031],"category_scores_gemma":[0.00026399005,0.00024537512,0.00010331809,0.00030399868,0.00021610626,0.00005147184,0.0017529653,0.0004722645,0.0000053390286],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.71372026,0.010075385,0.11803735,0.010186626,0.0031349943,0.0009061204,0.012873315,0.000079560275,0.009794606,0.000021187065,0.00419361,0.11697696],"study_design_scores_gemma":[0.16788237,0.008768596,0.7959522,0.0029498916,0.00049507164,7.4455744e-7,0.0027997787,0.000091424394,0.01047909,0.000008665595,0.01002189,0.0005502575],"about_ca_topic_score_codex":0.0015679006,"about_ca_topic_score_gemma":0.002786889,"teacher_disagreement_score":0.67791486,"about_ca_system_score_codex":0.00026709028,"about_ca_system_score_gemma":0.0008753783,"threshold_uncertainty_score":0.9999998},"labels":[],"label_agreement":null},{"id":"W4361949487","doi":"10.1158/1078-0432.c.6519491.v1","title":"Data from Phase I Dose Finding Studies of Obatoclax (GX15-070), a Small Molecule Pan-BCL-2 Family Antagonist, in Patients with Advanced Solid Tumors or Lymphoma","year":2023,"lang":"en","type":"preprint","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Tolerability; Medicine; Antagonist; Regimen; Lymphoma; Pharmacology; Internal medicine; Adverse effect; Gastroenterology; Receptor","score_opus":0.17987563151021402,"score_gpt":0.41832344583255215,"score_spread":0.23844781432233814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361949487","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99111545,0.00089555874,0.00013927155,0.00014150032,0.0002879693,0.0033852004,0.0032289065,0.00018430693,0.00062184053],"genre_scores_gemma":[0.9790595,0.002306399,0.0033402727,0.000223896,0.00017397717,0.00039186754,0.008118228,0.00028777833,0.0060980464],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99472046,0.0002064617,0.00125687,0.0017303852,0.0012585946,0.00082722545],"domain_scores_gemma":[0.99513185,0.0006012727,0.0005106024,0.0030306585,0.00047253285,0.00025308228],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006623281,0.00072689244,0.0020531388,0.0006265404,0.00008476387,0.00006020934,0.001191267,0.00029565912,0.00040940687],"category_scores_gemma":[0.0006590123,0.00052516727,0.0001539717,0.00073124684,0.00034460804,0.00012804753,0.0034744265,0.0007440527,0.00004702705],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18992741,0.023344403,0.22718246,0.011718875,0.017284581,0.010670476,0.011825323,0.0010360801,0.19389339,0.000040053463,0.011657471,0.30141947],"study_design_scores_gemma":[0.27249166,0.018931793,0.54006606,0.029816834,0.0022086378,0.000039655606,0.027650326,0.018429382,0.07999438,0.00073171814,0.0038620355,0.005777495],"about_ca_topic_score_codex":0.0020858415,"about_ca_topic_score_gemma":0.001974911,"teacher_disagreement_score":0.31288362,"about_ca_system_score_codex":0.0007125368,"about_ca_system_score_gemma":0.0015549498,"threshold_uncertainty_score":0.99972},"labels":[],"label_agreement":null},{"id":"W4361953633","doi":"10.1158/1078-0432.c.6530078.v1","title":"Data from CEACAM7 Is an Effective Target for CAR T-cell Therapy of Pancreatic Ductal Adenocarcinoma","year":2023,"lang":"en","type":"preprint","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Cancer Research UK; Pancreatic Cancer UK; Johns Hopkins University; Canary Foundation","keywords":"Cancer research; Pancreatic cancer; In vivo; Pancreas; Adenocarcinoma; Cell culture; Pancreatic ductal adenocarcinoma; Cancer; Medicine; Biology; Internal medicine","score_opus":0.13886998638167972,"score_gpt":0.3811469021155344,"score_spread":0.2422769157338547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361953633","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97579706,0.004414279,0.0012135166,0.0005036875,0.0005737657,0.0068682535,0.008741059,0.00020168643,0.0016866656],"genre_scores_gemma":[0.9281193,0.003406171,0.011435805,0.0003677357,0.0021474406,0.0010549463,0.025217809,0.00046872578,0.027782062],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99611086,0.00027589573,0.0005957179,0.0016343315,0.00081772835,0.0005654975],"domain_scores_gemma":[0.99402237,0.00102089,0.0002329792,0.0040466953,0.00036692873,0.00031015134],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00092970935,0.0005330224,0.001403157,0.00030556254,0.00006053056,0.000050579132,0.0012659922,0.00055142265,0.006055046],"category_scores_gemma":[0.00016684289,0.00044221172,0.00037192128,0.00021537112,0.0001843838,0.00009744939,0.0012264396,0.00093496416,0.000096605756],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012215615,0.0021784198,0.1573673,0.0032483807,0.006255297,0.0002717116,0.006273665,0.00003179659,0.7273389,0.000037212205,0.07096455,0.013817147],"study_design_scores_gemma":[0.024463618,0.009468016,0.2585102,0.0011077955,0.0016087178,0.000039974275,0.0032225472,0.02770748,0.6402045,0.010794238,0.020704743,0.0021681613],"about_ca_topic_score_codex":0.005690116,"about_ca_topic_score_gemma":0.00010522617,"teacher_disagreement_score":0.101142906,"about_ca_system_score_codex":0.0001757174,"about_ca_system_score_gemma":0.00050704164,"threshold_uncertainty_score":0.99980295},"labels":[],"label_agreement":null},{"id":"W4361958335","doi":"10.1158/1078-0432.c.6530741.v1","title":"Data from Combined EZH2 Inhibition and IKAROS Degradation Leads to Enhanced Antitumor Activity in Diffuse Large B-cell Lymphoma","year":2023,"lang":"en","type":"preprint","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vector Institute; University of Toronto; Princess Margaret Cancer Centre; Spinal Cord Injury BC; University Health Network","funders":"Leukemia and Lymphoma Society; Canadian Institutes of Health Research; BC Cancer Foundation; Natural Sciences and Engineering Research Council of Canada; Princess Margaret Cancer Foundation; Gilead Sciences","keywords":"Lenalidomide; Cancer research; Diffuse large B-cell lymphoma; EZH2; Medicine; Lymphoma; Biology; Epigenetics; Immunology; Multiple myeloma; Gene","score_opus":0.08134297010076623,"score_gpt":0.3518199541938775,"score_spread":0.2704769840931113,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361958335","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99042964,0.00005469808,0.0034030846,0.0013393018,0.00029561677,0.002096438,0.0012092902,0.00021663443,0.0009552885],"genre_scores_gemma":[0.9776085,0.0004888178,0.0006954184,0.00024606424,0.00017563044,0.00013769342,0.0073976773,0.00008877721,0.013161432],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9969251,0.00019142004,0.000420645,0.0013094558,0.0006671055,0.00048623604],"domain_scores_gemma":[0.99737746,0.00028373994,0.00012626372,0.0018416637,0.00010967295,0.0002612216],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006574542,0.00036393508,0.00072909176,0.0004967984,0.000063747844,0.00012632081,0.0003289674,0.0003629494,0.0006420731],"category_scores_gemma":[0.00027495623,0.00035533664,0.00007003147,0.00040408887,0.000059611622,0.00019466497,0.00243631,0.00060468883,0.00022494564],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017634317,0.0037446734,0.004801397,0.00036834198,0.000054827353,0.00010946058,0.0002677724,0.0000021082828,0.9790695,0.000014544981,0.002515948,0.0072880397],"study_design_scores_gemma":[0.03485872,0.00043576217,0.16994256,0.00090404414,0.000106299245,0.0000048717275,0.0002052227,0.00700181,0.78454936,0.000416761,0.0008876952,0.00068687415],"about_ca_topic_score_codex":0.0034760365,"about_ca_topic_score_gemma":0.0065733343,"teacher_disagreement_score":0.19452009,"about_ca_system_score_codex":0.00035838084,"about_ca_system_score_gemma":0.00030567625,"threshold_uncertainty_score":0.99988985},"labels":[],"label_agreement":null},{"id":"W4361958339","doi":"10.1158/1078-0432.c.6530591.v1","title":"Data from Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors","year":2023,"lang":"en","type":"preprint","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Internal medicine; Adverse effect; Antibody; Melanoma; Gastroenterology; Colorectal cancer; Cancer; Oncology; Immunology; Cancer research","score_opus":0.18471333416550853,"score_gpt":0.510112216982763,"score_spread":0.3253988828172545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361958339","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917344,0.00018949114,0.00033193475,0.0005066278,0.0006051101,0.0048236935,0.0012715184,0.0001949421,0.00034230438],"genre_scores_gemma":[0.9612833,0.0030963044,0.0016944911,0.00007192099,0.00039672485,0.00005510223,0.032913778,0.0002047128,0.0002836419],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99114573,0.0010759393,0.0026921467,0.0026981374,0.0014868452,0.000901179],"domain_scores_gemma":[0.9936856,0.00069196685,0.0008045156,0.003898251,0.00034357456,0.0005761019],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0040117567,0.00079487695,0.0034587914,0.0012824389,0.00006664349,0.0001362439,0.00123329,0.0008096232,0.00062723993],"category_scores_gemma":[0.00070773595,0.0007120418,0.00017711194,0.00095584436,0.00076430495,0.00074418285,0.0017901508,0.0022773296,0.000017597175],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.31310385,0.03155492,0.44934052,0.0013538634,0.0009376566,0.0038079056,0.0008570834,0.0003727735,0.17383055,0.00009146361,0.00026909157,0.024480307],"study_design_scores_gemma":[0.43960118,0.01584162,0.4384218,0.0034613379,0.00039061691,0.00009001783,0.0010475542,0.08992126,0.008566681,0.0008354508,0.00028827167,0.0015342253],"about_ca_topic_score_codex":0.0066340836,"about_ca_topic_score_gemma":0.0071550896,"teacher_disagreement_score":0.16526386,"about_ca_system_score_codex":0.00014267617,"about_ca_system_score_gemma":0.0011773977,"threshold_uncertainty_score":0.9999808},"labels":[],"label_agreement":null},{"id":"W4361959681","doi":"10.1158/1078-0432.c.6530078","title":"Data from CEACAM7 Is an Effective Target for CAR T-cell Therapy of Pancreatic Ductal Adenocarcinoma","year":2023,"lang":"en","type":"preprint","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Cancer Research UK; Pancreatic Cancer UK; Johns Hopkins University; Canary Foundation","keywords":"Cancer research; Pancreatic cancer; In vivo; Adenocarcinoma; Pancreas; Cell culture; Pancreatic ductal adenocarcinoma; In vitro; Cancer; Medicine; Biology; Internal medicine","score_opus":0.13886998638167972,"score_gpt":0.3811469021155344,"score_spread":0.2422769157338547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4361959681","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97579706,0.004414279,0.0012135166,0.0005036875,0.0005737657,0.0068682535,0.008741059,0.00020168643,0.0016866656],"genre_scores_gemma":[0.9281193,0.003406171,0.011435805,0.0003677357,0.0021474406,0.0010549463,0.025217809,0.00046872578,0.027782062],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99611086,0.00027589573,0.0005957179,0.0016343315,0.00081772835,0.0005654975],"domain_scores_gemma":[0.99402237,0.00102089,0.0002329792,0.0040466953,0.00036692873,0.00031015134],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00092970935,0.0005330224,0.001403157,0.00030556254,0.00006053056,0.000050579132,0.0012659922,0.00055142265,0.006055046],"category_scores_gemma":[0.00016684289,0.00044221172,0.00037192128,0.00021537112,0.0001843838,0.00009744939,0.0012264396,0.00093496416,0.000096605756],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012215615,0.0021784198,0.1573673,0.0032483807,0.006255297,0.0002717116,0.006273665,0.00003179659,0.7273389,0.000037212205,0.07096455,0.013817147],"study_design_scores_gemma":[0.024463618,0.009468016,0.2585102,0.0011077955,0.0016087178,0.000039974275,0.0032225472,0.02770748,0.6402045,0.010794238,0.020704743,0.0021681613],"about_ca_topic_score_codex":0.005690116,"about_ca_topic_score_gemma":0.00010522617,"teacher_disagreement_score":0.101142906,"about_ca_system_score_codex":0.0001757174,"about_ca_system_score_gemma":0.00050704164,"threshold_uncertainty_score":0.99980295},"labels":[],"label_agreement":null},{"id":"W4362451642","doi":"10.1158/1078-0432.ccr-22-3136","title":"Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma","year":2023,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"National Cancer Institute; Gilead Sciences","keywords":"Medicine; Chemoimmunotherapy; Clinical endpoint; Internal medicine; Adverse effect; Oncology; Randomized controlled trial; Surgery; Lymphoma; Rituximab","score_opus":0.10425728756673605,"score_gpt":0.4631420898558782,"score_spread":0.3588848022891421,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362451642","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99627805,0.0009867362,9.770783e-7,0.00011581149,0.00011321125,0.0010171102,0.00024150436,0.000015103383,0.0012315026],"genre_scores_gemma":[0.99167687,0.0056707864,0.000052706026,0.000015244415,0.00008576008,0.00002974003,0.000055602304,0.000052443833,0.0023608438],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9957775,0.00051972864,0.0008608291,0.0004849845,0.0017776184,0.0005793806],"domain_scores_gemma":[0.995661,0.002416512,0.0001540723,0.00066368026,0.00083614007,0.00026857617],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002840907,0.0001418173,0.0008675065,0.00043177186,0.000039600982,0.0000072176867,0.00026528997,0.00022707474,0.00076058053],"category_scores_gemma":[0.001319446,0.00011231091,0.00013237982,0.0013618869,0.00081824634,0.00004587193,0.0003182619,0.0006548512,0.000009004572],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.47259638,0.0035510631,0.2684242,0.0020567828,0.0002959027,0.0003130044,0.0026902242,0.000011603755,0.002892339,0.000024433639,0.0019208934,0.24522316],"study_design_scores_gemma":[0.09835338,0.021386765,0.8583246,0.0007420632,0.00004253005,3.4343915e-7,0.0011047048,0.000016416523,0.004617418,0.000004896298,0.015266697,0.00014023256],"about_ca_topic_score_codex":0.00038161685,"about_ca_topic_score_gemma":0.00087296695,"teacher_disagreement_score":0.5899003,"about_ca_system_score_codex":0.0003034369,"about_ca_system_score_gemma":0.0013417441,"threshold_uncertainty_score":0.8327823},"labels":[],"label_agreement":null},{"id":"W4362525380","doi":"10.1158/2326-6066.c.6550763","title":"Data from Tumor MHC Class I Expression Associates with Intralesional IL2 Response in Melanoma","year":2023,"lang":"en","type":"preprint","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Stand Up To Cancer; University of Texas MD Anderson Cancer Center; National Cancer Institute; National Institutes of Health; Parker Institute for Cancer Immunotherapy; Cycle for Survival; Geoffrey Beene Cancer Research Center; Memorial Sloan-Kettering Cancer Center; University of Pittsburgh; Melanoma Research Alliance","keywords":"CD8; Melanoma; Tumor-infiltrating lymphocytes; Immunotherapy; Medicine; T cell; Cancer; Cancer research; MHC class I; Immunology; Antigen; Internal medicine; Immune system","score_opus":0.11932743449809381,"score_gpt":0.37568513062343856,"score_spread":0.25635769612534476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362525380","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892836,0.00024593112,0.00007328445,0.0054526045,0.000290078,0.0011380246,0.0016037894,0.00025261863,0.0016600399],"genre_scores_gemma":[0.8822475,0.0003789247,0.006083603,0.00069713447,0.0010641741,0.00030891257,0.012499945,0.00032908667,0.09639072],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9953921,0.00069077965,0.0005608659,0.0013789387,0.0013920813,0.000585222],"domain_scores_gemma":[0.99463224,0.0022122713,0.0001816202,0.0025392205,0.00015292913,0.00028168867],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0022515538,0.00041145814,0.0008622493,0.00046556597,0.000054686425,0.000094522366,0.0010769524,0.0004484085,0.009195135],"category_scores_gemma":[0.0011748073,0.00029996573,0.00010234951,0.0002581481,0.0001406439,0.00009891758,0.0034805932,0.0020237928,0.00040871106],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09636438,0.0011446271,0.18954739,0.00043558932,0.00089753803,0.006643604,0.0012162417,0.00012510683,0.5529034,0.00002162285,0.1484171,0.0022833648],"study_design_scores_gemma":[0.009495346,0.001240828,0.8926855,0.0064050094,0.00019700365,0.00006402708,0.0013489013,0.0076108496,0.046090405,0.0017162617,0.031895895,0.0012500136],"about_ca_topic_score_codex":0.0018105356,"about_ca_topic_score_gemma":0.0023029451,"teacher_disagreement_score":0.70313805,"about_ca_system_score_codex":0.00054237165,"about_ca_system_score_gemma":0.00136802,"threshold_uncertainty_score":0.9999452},"labels":[],"label_agreement":null},{"id":"W4362525603","doi":"10.1158/2326-6066.c.6551154","title":"Data from Characterization of Leukemic Resistance to CD19-Targeted CAR T-cell Therapy through Deep Genomic Sequencing","year":2023,"lang":"en","type":"preprint","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Stand Up To Cancer; National Institutes of Health; Children's Hospital of Philadelphia; Canadian Institutes of Health Research; American Association for Cancer Research","keywords":"CD19; Context (archaeology); B cell; Medicine; Molecular biology; Antigen; Biology; Cancer research; Immunology; Antibody","score_opus":0.14527647862626242,"score_gpt":0.35043282589172875,"score_spread":0.20515634726546633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362525603","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9838607,0.0014624537,0.0061388263,0.0008016066,0.0006287656,0.0023797303,0.0021537063,0.00027560888,0.0022986128],"genre_scores_gemma":[0.7455151,0.02907129,0.02752747,0.0024095674,0.0024836736,0.00036009355,0.061192926,0.0008251322,0.13061474],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99621886,0.00018718262,0.00084883726,0.0014221151,0.00081051845,0.0005124923],"domain_scores_gemma":[0.9951877,0.00019392559,0.00032981363,0.003785911,0.0003137609,0.0001888758],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006121345,0.00044798883,0.0009801562,0.0002671045,0.00006396857,0.000061825,0.0012790785,0.00044258987,0.003374242],"category_scores_gemma":[0.00010991223,0.0004235736,0.0001674691,0.00043412406,0.00008478279,0.00012720586,0.0014872906,0.0008779214,0.00026899928],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000972965,0.000054760352,0.00068078487,0.00030687315,0.0002957146,0.000038547914,0.0016233788,0.000077565586,0.99403924,0.000009932642,0.001143931,0.0007563019],"study_design_scores_gemma":[0.003680219,0.000247435,0.026729582,0.0010378276,0.00019411472,0.0000044286007,0.0006585752,0.0054427455,0.92976886,0.0010692436,0.030178051,0.0009889383],"about_ca_topic_score_codex":0.0030508952,"about_ca_topic_score_gemma":0.00079440966,"teacher_disagreement_score":0.2383456,"about_ca_system_score_codex":0.0010587886,"about_ca_system_score_gemma":0.0012666624,"threshold_uncertainty_score":0.9998216},"labels":[],"label_agreement":null},{"id":"W4362540776","doi":"10.1158/1538-7445.am2023-3188","title":"Abstract 3188: Patient-derived TAC01-HER2 TAC T cells produced in Cocoon® Platform is highly functional in models of solid tumors","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences","funders":"","keywords":"In vivo; CD8; In vitro; Population; Cancer research; T cell; Cytotoxic T cell; Medicine; Chimeric antigen receptor; Antigen; Molecular biology; Chemistry; Immunology; Biology; Immune system; Biochemistry","score_opus":0.14977035715370438,"score_gpt":0.40363075826807926,"score_spread":0.2538604011143749,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362540776","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99406385,0.00034386187,0.000002567152,0.0013402833,0.00018699415,0.0018915038,0.00010699931,0.000051103936,0.0020128053],"genre_scores_gemma":[0.99418855,0.00086490804,0.000016680866,0.00010030556,0.00019661851,0.00071088044,0.00006053439,0.00007737623,0.0037841531],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99523246,0.00011216258,0.00068305054,0.0006971291,0.0020981806,0.0011770256],"domain_scores_gemma":[0.99790674,0.00032713875,0.000088537134,0.0006392484,0.00075907167,0.00027923394],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017925507,0.00022098637,0.00056013686,0.0014888264,0.00008350828,0.00002757006,0.0003039914,0.00018197937,0.004092473],"category_scores_gemma":[0.00016404968,0.00020649238,0.00010509154,0.0032221586,0.00030943003,0.00023480583,0.00023523852,0.0013284407,0.00020630231],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024008309,0.00030158623,0.0027045722,0.0004964996,0.000054937667,0.00020196658,0.0026135389,0.0021496331,0.9679134,0.000036509722,0.012103695,0.009022841],"study_design_scores_gemma":[0.0031923598,0.0005170201,0.024715343,0.0006197667,0.000004966886,0.0000047011677,0.0012800046,0.002931706,0.9637224,0.0007445357,0.002048353,0.00021885039],"about_ca_topic_score_codex":0.004702134,"about_ca_topic_score_gemma":0.00072167534,"teacher_disagreement_score":0.022010772,"about_ca_system_score_codex":0.0009808774,"about_ca_system_score_gemma":0.0017301746,"threshold_uncertainty_score":0.99681795},"labels":[],"label_agreement":null},{"id":"W4362540965","doi":"10.1158/1538-7445.am2023-1154","title":"Abstract 1154: Investigating the functional role of GPNMB in glioblastoma and the tumor immune microenvironment and its targeted elimination using CAR-Ts","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Calgary; University of Toronto; McMaster University","funders":"","keywords":"Cancer research; Flow cytometry; Tumor microenvironment; Tissue microarray; Immunotherapy; Glioma; Immune system; Immunohistochemistry; Biology; Medicine; Immunology; Tumor cells","score_opus":0.06544406792514754,"score_gpt":0.3587911702735495,"score_spread":0.293347102348402,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362540965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900011,0.006094536,4.3606826e-7,0.0028937832,0.000033545588,0.00085190363,0.000011195652,0.000010299422,0.00010322156],"genre_scores_gemma":[0.99793655,0.0012387638,0.000009468804,0.000043808832,0.00010803453,0.00014677293,0.0000057265925,0.000024095449,0.0004868016],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9980226,0.00025463567,0.00025898154,0.00024798675,0.00083193183,0.0003838234],"domain_scores_gemma":[0.99890506,0.0005926833,0.00005951436,0.0002109507,0.00014445162,0.00008731589],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022942966,0.00009851457,0.0001989272,0.00027303948,0.00022459237,0.000034810026,0.00011420895,0.000046583376,0.00039248136],"category_scores_gemma":[0.00036359206,0.00006310044,0.000035924044,0.0007298338,0.0006667116,0.000068564084,0.000211549,0.00060257706,0.000007613006],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007586875,0.0000209707,0.006333578,0.000119205644,0.000037715294,0.000010811584,0.0015128586,0.00021636402,0.9855238,0.00008380522,0.00006745559,0.0053147497],"study_design_scores_gemma":[0.0028222683,0.00014216009,0.57653403,0.0002887221,0.000015120155,0.000026905536,0.0033072953,0.012076266,0.40386233,0.00032344615,0.000520736,0.00008072461],"about_ca_topic_score_codex":0.0013185034,"about_ca_topic_score_gemma":0.00016157248,"teacher_disagreement_score":0.58166146,"about_ca_system_score_codex":0.0002500057,"about_ca_system_score_gemma":0.0002295131,"threshold_uncertainty_score":0.42973956},"labels":[],"label_agreement":null},{"id":"W4362541229","doi":"10.1158/1538-7445.am2023-4052","title":"Abstract 4052: Direct selection of PD1+ CD39+ tumor infiltrating lymphocytes (TIL) from tumor dissociates enrich for functional tumor-reactive cells","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Tumor-infiltrating lymphocytes; Cancer research; Cell sorting; Population; Adoptive cell transfer; Antigen; Cancer; Immunotherapy; Medicine; T cell; Immunology; Biology; Flow cytometry; CD8; Immune system; Internal medicine","score_opus":0.08352439900389312,"score_gpt":0.39616652613189246,"score_spread":0.3126421271279993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362541229","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916349,0.000556908,0.0000127026115,0.00040383765,0.00040655033,0.001664888,0.0004843801,0.00017063109,0.0046652155],"genre_scores_gemma":[0.9876118,0.00020663437,0.000102063015,0.000078088946,0.0013186742,0.0012025253,0.00022430354,0.000121817655,0.0091341315],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99545515,0.00023328938,0.0005600421,0.0007768487,0.0018205651,0.001154123],"domain_scores_gemma":[0.99415493,0.0034034736,0.0002006117,0.00038494388,0.0015351688,0.0003208806],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0021907107,0.0002896555,0.0006463099,0.0006698549,0.00040189855,0.000095176954,0.00027987608,0.00010943691,0.0041107475],"category_scores_gemma":[0.0014303668,0.0002682078,0.00028190168,0.0020278625,0.00031963826,0.00020702083,0.00013254838,0.0008244578,0.00016090195],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002704287,0.00020270952,0.021379063,0.0003017661,0.0003013868,0.00004530265,0.00046579464,0.00009884156,0.95601547,0.00002129242,0.012511881,0.0059521953],"study_design_scores_gemma":[0.0025169854,0.0005124292,0.10372667,0.00035356803,0.00004671916,0.000009872258,0.0012771835,0.0011136507,0.8808718,0.00029383227,0.009034428,0.00024290217],"about_ca_topic_score_codex":0.005738012,"about_ca_topic_score_gemma":0.00044482757,"teacher_disagreement_score":0.08234761,"about_ca_system_score_codex":0.0017378707,"about_ca_system_score_gemma":0.002035283,"threshold_uncertainty_score":0.999977},"labels":[],"label_agreement":null},{"id":"W4362541661","doi":"10.1158/1538-7445.am2023-1785","title":"Abstract 1785: Multi-step engineering of gene-edited CAR T cells using RNA lipid nanoparticles","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Precision Nanosystems (Canada)","funders":"","keywords":"CD19; Chimeric antigen receptor; Molecular biology; Transfection; Gene expression; Biology; Cell biology; Chemistry; Flow cytometry; T cell; Gene; Immune system; Immunology; Biochemistry","score_opus":0.1706561909875915,"score_gpt":0.43312415718407987,"score_spread":0.2624679661964884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362541661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977502,0.0005929523,0.000038466787,0.000250549,0.0003401083,0.0006956341,0.00004763229,0.00011623842,0.00016820301],"genre_scores_gemma":[0.99457586,0.0007544851,0.00078940776,0.000018128676,0.0007744564,0.000098833945,0.000015106319,0.000102540944,0.0028711734],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99675035,0.00009315757,0.00037388486,0.00041802667,0.0013444367,0.0010201485],"domain_scores_gemma":[0.9980728,0.00034531215,0.00004809056,0.00057581917,0.00058956037,0.0003684153],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015485662,0.00017285663,0.0003755153,0.00075222366,0.00011681154,0.000040041967,0.0002905158,0.00014065378,0.0017213784],"category_scores_gemma":[0.00025032446,0.00016400522,0.00013133435,0.001903161,0.00021211468,0.00009056167,0.00015861541,0.00071561016,0.00015042246],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024169112,0.00008050716,0.0013091204,0.00045688354,0.000110317465,0.00013289534,0.00045198214,0.0019887353,0.98833513,0.000004616416,0.0013389786,0.0055491384],"study_design_scores_gemma":[0.0013658758,0.000117178846,0.0083421925,0.00026214521,0.000016268963,0.000006893508,0.0003032921,0.019820701,0.96460325,0.0000015464041,0.0050235647,0.00013709733],"about_ca_topic_score_codex":0.0020355731,"about_ca_topic_score_gemma":0.00006783181,"teacher_disagreement_score":0.023731891,"about_ca_system_score_codex":0.0004619645,"about_ca_system_score_gemma":0.00053358753,"threshold_uncertainty_score":0.99919116},"labels":[],"label_agreement":null},{"id":"W4362543748","doi":"10.1158/1538-7445.am2023-892","title":"Abstract 892: Afamitresgene autoleucel (afami-cel; formerly ADP-A2M4) demonstrates durable clinical responses by inducing broad immune engagement with anti-tumor activity","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Immune system; Tumor microenvironment; Medicine; CD8; Cancer research; FOXP3; Immunotherapy; Immunology; T cell; Internal medicine; Oncology","score_opus":0.1878490284929845,"score_gpt":0.4787060654354717,"score_spread":0.2908570369424872,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362543748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873427,0.0021921133,0.000015682182,0.0036276327,0.00023542762,0.0019403773,0.00013646032,0.0003114201,0.0041981474],"genre_scores_gemma":[0.96911985,0.005329354,0.00010118054,0.00011135342,0.00042838606,0.00067950494,0.0000685973,0.00017002897,0.023991747],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9917227,0.0012618626,0.0008410677,0.0012791823,0.0026993041,0.002195903],"domain_scores_gemma":[0.99420977,0.0027045107,0.00019380097,0.0013428823,0.0007869414,0.0007621146],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0105388705,0.00045473225,0.0009628192,0.00086597726,0.00083075714,0.00026579155,0.00068323174,0.00029673608,0.0033189375],"category_scores_gemma":[0.0011567771,0.00037504875,0.00027356815,0.0025811344,0.001008376,0.00039180557,0.0004108158,0.0037308815,0.00047402264],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006663044,0.000582709,0.03645252,0.0003647484,0.00050557946,0.00072132266,0.00025559988,0.000025109051,0.86965305,0.000010562259,0.013909244,0.07085653],"study_design_scores_gemma":[0.004807365,0.0019273999,0.51315534,0.0007543568,0.00006215651,0.000038136546,0.0011669745,0.0003191711,0.4539195,0.00002955429,0.023362221,0.00045781504],"about_ca_topic_score_codex":0.0054144217,"about_ca_topic_score_gemma":0.00040986112,"teacher_disagreement_score":0.47670284,"about_ca_system_score_codex":0.0008138266,"about_ca_system_score_gemma":0.003577513,"threshold_uncertainty_score":0.9998701},"labels":[],"label_agreement":null},{"id":"W4362546428","doi":"10.1158/2159-8290.c.6549640.v1","title":"Data from Genomic and Single-Cell Landscape Reveals Novel Drivers and Therapeutic Vulnerabilities of Transformed Cutaneous T-cell Lymphoma","year":2023,"lang":"en","type":"preprint","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Micropharma (Canada)","funders":"National Institutes of Health; Moffitt Cancer Center","keywords":"Cancer research; Biology; Immune system; Mantle cell lymphoma; Downregulation and upregulation; T cell; Transcriptome; Lymphoma; Immunology; Genetics; Gene; Gene expression","score_opus":0.09745959639451734,"score_gpt":0.308177417878479,"score_spread":0.21071782148396168,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362546428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9842182,0.0035014097,0.00026770317,0.0004369044,0.00020610225,0.0014498925,0.0023268608,0.00012937433,0.0074635474],"genre_scores_gemma":[0.9684117,0.005258469,0.0015136703,0.00015767697,0.00017908319,0.000028084294,0.0012826445,0.00014508115,0.023023607],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997018,0.00011004649,0.00065357913,0.0011769994,0.0005675226,0.00047386496],"domain_scores_gemma":[0.9966351,0.001091144,0.00016903593,0.001723226,0.000120929624,0.0002605824],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005001585,0.00047194777,0.0010959308,0.00029498842,0.00006982165,0.00008378082,0.0005575439,0.00045995944,0.0015037983],"category_scores_gemma":[0.000049527145,0.00040731922,0.00013205026,0.00012639911,0.00040209942,0.00004858366,0.00091401534,0.0005112502,0.000019152558],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011132102,0.00065031415,0.0063520027,0.0021571785,0.0005592983,0.000079735444,0.002371609,0.000022456217,0.97248054,0.0000107402875,0.00065896264,0.013543972],"study_design_scores_gemma":[0.15067519,0.01485014,0.08978342,0.0068062395,0.011561568,0.0024240504,0.05125762,0.08865837,0.48857987,0.01884563,0.065682665,0.010875249],"about_ca_topic_score_codex":0.00150269,"about_ca_topic_score_gemma":0.0003963641,"teacher_disagreement_score":0.48390067,"about_ca_system_score_codex":0.00013870906,"about_ca_system_score_gemma":0.00039919562,"threshold_uncertainty_score":0.9998379},"labels":[],"label_agreement":null},{"id":"W4362547126","doi":"10.1158/2326-6066.c.6550763.v1","title":"Data from Tumor MHC Class I Expression Associates with Intralesional IL2 Response in Melanoma","year":2023,"lang":"en","type":"preprint","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Stand Up To Cancer; University of Texas MD Anderson Cancer Center; National Cancer Institute; National Institutes of Health; Parker Institute for Cancer Immunotherapy; Cycle for Survival; Geoffrey Beene Cancer Research Center; Memorial Sloan-Kettering Cancer Center; University of Pittsburgh; Melanoma Research Alliance","keywords":"CD8; Melanoma; Tumor-infiltrating lymphocytes; Immunotherapy; T cell; Cancer research; Medicine; MHC class I; Cancer; Immunology; Antigen; Immune system; Internal medicine","score_opus":0.11932743449809381,"score_gpt":0.37568513062343856,"score_spread":0.25635769612534476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362547126","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892836,0.00024593112,0.00007328445,0.0054526045,0.000290078,0.0011380246,0.0016037894,0.00025261863,0.0016600399],"genre_scores_gemma":[0.8822475,0.0003789247,0.006083603,0.00069713447,0.0010641741,0.00030891257,0.012499945,0.00032908667,0.09639072],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9953921,0.00069077965,0.0005608659,0.0013789387,0.0013920813,0.000585222],"domain_scores_gemma":[0.99463224,0.0022122713,0.0001816202,0.0025392205,0.00015292913,0.00028168867],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0022515538,0.00041145814,0.0008622493,0.00046556597,0.000054686425,0.000094522366,0.0010769524,0.0004484085,0.009195135],"category_scores_gemma":[0.0011748073,0.00029996573,0.00010234951,0.0002581481,0.0001406439,0.00009891758,0.0034805932,0.0020237928,0.00040871106],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09636438,0.0011446271,0.18954739,0.00043558932,0.00089753803,0.006643604,0.0012162417,0.00012510683,0.5529034,0.00002162285,0.1484171,0.0022833648],"study_design_scores_gemma":[0.009495346,0.001240828,0.8926855,0.0064050094,0.00019700365,0.00006402708,0.0013489013,0.0076108496,0.046090405,0.0017162617,0.031895895,0.0012500136],"about_ca_topic_score_codex":0.0018105356,"about_ca_topic_score_gemma":0.0023029451,"teacher_disagreement_score":0.70313805,"about_ca_system_score_codex":0.00054237165,"about_ca_system_score_gemma":0.00136802,"threshold_uncertainty_score":0.9999452},"labels":[],"label_agreement":null},{"id":"W4362552710","doi":"10.1158/2326-6066.22537889","title":"Supplementary Table 1, Figures 1 - 3 from Optimization of T-cell Reactivity by Exploiting TCR Chain Centricity for the Purpose of Safe and Effective Antitumor TCR Gene Therapy","year":2023,"lang":"en","type":"supplementary-materials","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"National Institutes of Health; Universiteit Leiden; Princess Margaret Cancer Foundation","keywords":"T-cell receptor; Jurkat cells; CD3; CD8; Molecular biology; Tetramer; Chemistry; T cell; Gene; Biology; Antigen; Genetics; Biochemistry; Immune system; Enzyme","score_opus":0.025513284541075404,"score_gpt":0.2993980960641245,"score_spread":0.2738848115230491,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362552710","genre_codex":"empirical","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.47930545,0.007513983,0.0073706647,0.0023809406,0.0018277676,0.033017773,0.46766594,0.00011476211,0.0008027163],"genre_scores_gemma":[0.11592682,0.17063572,0.017963892,0.0016074071,0.0040044137,0.005411565,0.6375294,0.001114948,0.04580584],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99671334,0.00025942232,0.00087501307,0.0007322017,0.00082927133,0.0005907685],"domain_scores_gemma":[0.99552894,0.002748113,0.00063208933,0.0006489121,0.0003176556,0.00012428657],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015540059,0.00049874606,0.0013529338,0.00028579682,0.00018094125,0.00004990319,0.00030104982,0.00025060633,0.04574813],"category_scores_gemma":[0.00017677638,0.00036270238,0.00021494993,0.00037273896,0.00018981598,0.00011714683,0.00023020658,0.00032494788,0.0000014147221],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003189148,0.00046504682,0.00047614568,0.00097169034,0.00091148017,0.000008497215,0.00033033575,0.000075635224,0.82216245,0.0000029539422,0.1636421,0.0077645313],"study_design_scores_gemma":[0.0062467577,0.0010334589,0.000090747395,0.00023276382,0.00031406537,0.0000029268613,0.00071861234,0.0005646747,0.9120591,0.00003158031,0.07843071,0.0002745689],"about_ca_topic_score_codex":0.041524194,"about_ca_topic_score_gemma":0.0005029495,"teacher_disagreement_score":0.36337864,"about_ca_system_score_codex":0.0002134361,"about_ca_system_score_gemma":0.00022133549,"threshold_uncertainty_score":0.9998825},"labels":[],"label_agreement":null},{"id":"W4362557284","doi":"10.3390/curroncol30040305","title":"CAR-T Cells in Canada; Perspective on How to Ensure We Get Our Value’s Worth","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Reimbursement; Chimeric antigen receptor; Medicine; Health care; Health technology; Agency (philosophy); Business; T cell; Immunology; Political science","score_opus":0.112304222274775,"score_gpt":0.4254165059810915,"score_spread":0.3131122837063165,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362557284","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91711134,0.00053549674,0.0000051256106,0.07058303,0.0029478183,0.0011918469,0.000068878566,0.00007306771,0.0074834074],"genre_scores_gemma":[0.9890864,0.00070751266,0.00003290038,0.0005661019,0.00070460135,0.00012982432,0.000033226646,0.000045843964,0.008693579],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978231,0.00024048843,0.0001933387,0.0005008697,0.00054703443,0.0006951491],"domain_scores_gemma":[0.99879503,0.00023378998,0.00004705164,0.0003736416,0.00018699844,0.00036349875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040372997,0.00019579707,0.00048973167,0.0004429431,0.000045071924,0.0000115745515,0.00018895841,0.00011041974,0.0003334869],"category_scores_gemma":[0.00023106503,0.00017885129,0.00008394671,0.00085646554,0.00003039547,0.000020239491,0.00011171432,0.0007762543,0.00024231165],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001988702,0.00091122725,0.06050167,0.0002232204,0.00020846615,0.0025504497,0.009275165,0.0006327028,0.033175047,0.0010276457,0.6403584,0.24914731],"study_design_scores_gemma":[0.0031887905,0.0016471469,0.058179364,0.00016984312,0.00003720913,0.000029267021,0.017494703,0.00051237957,0.0034415051,0.00013897909,0.9148597,0.00030109435],"about_ca_topic_score_codex":0.12034944,"about_ca_topic_score_gemma":0.63463205,"teacher_disagreement_score":0.5142826,"about_ca_system_score_codex":0.0062491987,"about_ca_system_score_gemma":0.0034066548,"threshold_uncertainty_score":0.9975656},"labels":[],"label_agreement":null},{"id":"W4362593403","doi":"10.1158/1538-7445.am2023-ng14","title":"Abstract NG14: Dissecting immune microenvironment of T-cell acute lymphoblastic leukemia","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; University Health Network","funders":"","keywords":"Immune system; Leukemia; Immunology; Immunotherapy; Medicine; Tumor microenvironment; Biology; Cancer research","score_opus":0.056896164349953204,"score_gpt":0.3906074047209294,"score_spread":0.3337112403709762,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362593403","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929152,0.0010630755,0.000004641783,0.0004255663,0.00017838829,0.00072142074,0.000033105378,0.000064814645,0.0045937714],"genre_scores_gemma":[0.9618672,0.0042008013,0.0000380406,0.000021203134,0.00028635815,0.00019244416,0.00003533263,0.00008143338,0.03327715],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9965514,0.000108251894,0.0004064701,0.00046768016,0.0014609714,0.001005231],"domain_scores_gemma":[0.99818456,0.00049582677,0.00006962503,0.0006954603,0.00027265848,0.00028187968],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015985558,0.00017401895,0.00039001834,0.0005165188,0.00017645085,0.00003339811,0.00035285062,0.00012173359,0.007298675],"category_scores_gemma":[0.00018425331,0.00015698808,0.00016665626,0.0011698701,0.0003778499,0.000062446044,0.00032404347,0.0007899989,0.0007248983],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007535942,0.00009479461,0.0025633716,0.0004724391,0.0001550346,0.00021236716,0.00044713743,0.00007792325,0.98064315,0.0000055683254,0.0033943555,0.011180236],"study_design_scores_gemma":[0.0020370162,0.0003250716,0.07659509,0.00031983506,0.000030604067,0.000014682155,0.00061378465,0.0001621784,0.91398644,0.000036901394,0.0057411403,0.0001372621],"about_ca_topic_score_codex":0.001401586,"about_ca_topic_score_gemma":0.000037437312,"teacher_disagreement_score":0.07403172,"about_ca_system_score_codex":0.0016688624,"about_ca_system_score_gemma":0.00087983836,"threshold_uncertainty_score":0.9936088},"labels":[],"label_agreement":null},{"id":"W4362595669","doi":"10.1158/1538-7445.am2023-1128","title":"Abstract 1128: Lineage tracing of CAR T cells in patients with B cell malignancies","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of New Brunswick","funders":"","keywords":"Chimeric antigen receptor; Immunology; T cell; Medicine; Immunotherapy; CD19; Cancer research; T-cell receptor; Cancer immunotherapy; Biology; Antigen; Immune system","score_opus":0.06974373913961528,"score_gpt":0.38487324908452086,"score_spread":0.3151295099449056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362595669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948938,0.00017801468,0.0000010407059,0.00020000615,0.00006676019,0.0009479392,0.000055586515,0.000036860547,0.003620015],"genre_scores_gemma":[0.9895695,0.00046417263,0.000030104313,0.000022861583,0.000109972796,0.00012181143,0.000029707688,0.00005861303,0.009593299],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9968544,0.00010424705,0.00031176116,0.0003780638,0.001539893,0.00081160426],"domain_scores_gemma":[0.9984163,0.00028799448,0.000049403516,0.00047411697,0.00057444564,0.00019775389],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013234741,0.00014053224,0.0003493543,0.00076232164,0.00006727493,0.000024033941,0.00023389686,0.00010501206,0.0022702522],"category_scores_gemma":[0.0000684328,0.000113398826,0.000066306595,0.0018522154,0.00025290877,0.00008235758,0.00010471451,0.0007798477,0.00012701232],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013677904,0.0002840851,0.16601919,0.000941058,0.000036283272,0.0001469556,0.0012667613,0.0002813135,0.8234696,0.000004958544,0.0031625698,0.0030194672],"study_design_scores_gemma":[0.003255852,0.0005732832,0.36856952,0.0005035212,0.000007240323,4.4125846e-7,0.0005816177,0.000062718136,0.623086,0.000007028273,0.003227226,0.00012554888],"about_ca_topic_score_codex":0.0014381876,"about_ca_topic_score_gemma":0.00023387346,"teacher_disagreement_score":0.20255034,"about_ca_system_score_codex":0.00033515232,"about_ca_system_score_gemma":0.0005696639,"threshold_uncertainty_score":0.9986418},"labels":[],"label_agreement":null},{"id":"W4362614405","doi":"10.1038/s41408-023-00820-y","title":"Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma","year":2023,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Medicine; Multiple myeloma; Bone marrow; Internal medicine; Minimal residual disease; Gastroenterology","score_opus":0.036904548148674894,"score_gpt":0.3457851510166651,"score_spread":0.30888060286799024,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362614405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915948,0.0055416776,0.000016589072,0.0011887511,0.00028981108,0.00097118923,0.000042247455,0.00003294673,0.00032198665],"genre_scores_gemma":[0.9868065,0.008351543,0.0003424587,0.00015170369,0.00075437216,0.00021565183,0.000009626798,0.0000720672,0.0032960884],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99788386,0.000095188334,0.0004560862,0.00022015713,0.00064984825,0.00069488114],"domain_scores_gemma":[0.9988742,0.00020668875,0.00014923904,0.00022129499,0.00028656263,0.0002620032],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008148252,0.00015907429,0.0004349918,0.00043602163,0.000071277536,0.000037050457,0.0001411761,0.0000958839,0.00091069704],"category_scores_gemma":[0.00014202383,0.00013278921,0.00019303815,0.000715657,0.000076826196,0.000078384386,0.0000291548,0.00048306203,0.00000788551],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003351037,0.0003809493,0.49447685,0.00019976369,0.00051031535,0.00038862988,0.0018275607,0.00007735031,0.3705435,0.000050357525,0.0022674338,0.12592623],"study_design_scores_gemma":[0.020988008,0.003912775,0.8950074,0.00068684324,0.00017835625,0.0003755989,0.0004164707,0.00030920774,0.061198454,0.00073701906,0.015915193,0.00027470218],"about_ca_topic_score_codex":0.00039738303,"about_ca_topic_score_gemma":0.00011123107,"teacher_disagreement_score":0.40053052,"about_ca_system_score_codex":0.0001426784,"about_ca_system_score_gemma":0.0009496724,"threshold_uncertainty_score":0.9971494},"labels":[],"label_agreement":null},{"id":"W4365512087","doi":"10.1158/1538-7445.am2023-ct234","title":"Abstract CT234: A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors","year":2023,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Chimeric antigen receptor; Breast cancer; Cancer; Leukapheresis; Immunotherapy; T cell; Clinical trial; Oncology; Cancer research; Internal medicine; Immunology; Immune system; Stem cell; CD34","score_opus":0.16290501504143873,"score_gpt":0.48638303389157284,"score_spread":0.3234780188501341,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4365512087","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9937265,0.00045670153,5.860088e-7,0.0016831028,0.00014066056,0.0020411885,0.000039111077,0.000093454786,0.0018186857],"genre_scores_gemma":[0.98996466,0.0011327356,0.000047880032,0.00005881667,0.00040930597,0.00023855268,0.000033356915,0.00007460958,0.008040085],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9957859,0.00042951328,0.0007932173,0.0006154839,0.0013655057,0.0010104042],"domain_scores_gemma":[0.99668145,0.0018212899,0.00013216095,0.0005959144,0.00032133798,0.00044784794],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0046026274,0.00020769896,0.0007357685,0.0009885918,0.00023682971,0.00003223493,0.00029099814,0.00022326823,0.0026947472],"category_scores_gemma":[0.0043669827,0.00017116131,0.0000965648,0.0022682378,0.00084150437,0.00008569469,0.00031234027,0.0017488234,0.00003914682],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13539654,0.0009149428,0.00079684186,0.00060859986,0.00011808622,0.00084022793,0.0034356925,0.00004956128,0.72271,0.00002988347,0.0030185573,0.13208106],"study_design_scores_gemma":[0.6046091,0.036883123,0.10402001,0.0056077065,0.00009041673,0.00012399911,0.005389842,0.0035026749,0.1924989,0.0004856256,0.045639858,0.0011487806],"about_ca_topic_score_codex":0.001801661,"about_ca_topic_score_gemma":0.0004016358,"teacher_disagreement_score":0.5302111,"about_ca_system_score_codex":0.00057338557,"about_ca_system_score_gemma":0.0023839986,"threshold_uncertainty_score":0.9982169},"labels":[],"label_agreement":null},{"id":"W4365513888","doi":"10.3410/f.742552675.793598330","title":"Faculty Opinions recommendation of T cell egress via lymphatic vessels is tuned by antigen encounter and limits tumor control.","year":2023,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Lymphatic system; Control (management); Antigen; Computer science; Medicine; Pathology; Immunology; Artificial intelligence","score_opus":0.031630965820291526,"score_gpt":0.364255964363549,"score_spread":0.3326249985432575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4365513888","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000004636191,0.0026698948,0.000025580115,0.18222542,0.00055711885,0.0021466357,0.81224537,0.00004781078,0.00007752018],"genre_scores_gemma":[0.000018235578,0.0028608225,0.00017265421,0.010208698,0.00026520283,0.00031147667,0.9786927,0.00006932684,0.007400888],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9938301,0.00062544853,0.0018008159,0.00096157653,0.0022313457,0.000550748],"domain_scores_gemma":[0.9896974,0.0004186778,0.0013362607,0.0017238181,0.0062865494,0.00053730496],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001757531,0.0006631479,0.0016015766,0.00048884744,0.0002153547,0.00016929579,0.0010720975,0.000713029,0.0012587525],"category_scores_gemma":[0.0038824985,0.00044434203,0.00064044603,0.0022657618,0.0005112546,0.0002936449,0.0003818576,0.0011273904,0.00019825767],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008066423,0.000553496,0.00001870967,0.013819821,0.00034970164,0.0000024380563,0.000118627875,1.3258292e-8,0.000400767,0.000008328733,0.98269993,0.0019474865],"study_design_scores_gemma":[0.0027567688,0.00027816446,0.0011053212,0.0104726,0.00037496246,0.00010145162,0.000031538097,0.000025771413,0.0006619754,0.000016683285,0.98381263,0.0003621047],"about_ca_topic_score_codex":0.000104379746,"about_ca_topic_score_gemma":0.0000046907044,"teacher_disagreement_score":0.17201672,"about_ca_system_score_codex":0.00017734403,"about_ca_system_score_gemma":0.0008786499,"threshold_uncertainty_score":0.99980086},"labels":[],"label_agreement":null},{"id":"W4365813711","doi":"10.1007/s00262-023-03442-2","title":"Engineered murine IL-21-secreting leukemia cells induce granzyme B+ T cells and CD4+CD44+CD62L− effector memory cells while suppressing regulatory T cells, leading to long-term survival","year":2023,"lang":"en","type":"article","venue":"Cancer Immunology Immunotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"Leukemia and Lymphoma Society of Canada; Leukemia and Lymphoma Society","keywords":"Leukemia; Adoptive cell transfer; Granzyme B; Immunology; Biology; CD8; Immune system; Interleukin 21; Cytotoxic T cell; IL-2 receptor; Granzyme; Cancer research; Molecular biology; T cell; Perforin","score_opus":0.027116800034224724,"score_gpt":0.30158481317946384,"score_spread":0.2744680131452391,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4365813711","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9766282,0.014509907,0.00014036127,0.00048924127,0.004763016,0.0022227284,0.00016344649,0.00068916,0.00039394438],"genre_scores_gemma":[0.9592884,0.014679734,0.0003463991,0.00068761094,0.0010698156,0.0005297505,0.0001771905,0.0006226149,0.02259846],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99362916,0.00065800233,0.0011149078,0.0015694567,0.0008615885,0.0021668815],"domain_scores_gemma":[0.9960973,0.0009422334,0.00034531308,0.0018342145,0.00032528696,0.00045560996],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015900185,0.0010748828,0.0017846461,0.0011595424,0.00059669494,0.00020620093,0.00088398927,0.0008267947,0.0031532901],"category_scores_gemma":[0.000049280836,0.0011010541,0.00042518438,0.0014907088,0.00070736895,0.0003014004,0.0004284991,0.0017929875,0.00052986864],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022619383,0.00011278382,0.0011795373,0.00044419296,0.001078064,0.00026074756,0.0024007563,0.0004637243,0.9582749,0.000005211868,0.0021064267,0.031411693],"study_design_scores_gemma":[0.0070968815,0.0007719738,0.01792353,0.00074697385,0.00012754551,0.00006141473,0.00030513012,0.00015806286,0.95948386,0.0000072366925,0.012310557,0.0010068249],"about_ca_topic_score_codex":0.00045352304,"about_ca_topic_score_gemma":0.00004680606,"teacher_disagreement_score":0.030404868,"about_ca_system_score_codex":0.0015008654,"about_ca_system_score_gemma":0.0007031315,"threshold_uncertainty_score":0.99914396},"labels":[],"label_agreement":null},{"id":"W4366083620","doi":"10.1182/bloodadvances.2022009260","title":"Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma","year":2023,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":93,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Spinal Cord Injury BC; University of British Columbia; Jewish General Hospital","funders":"Loxo Oncology; Pharmacyclics; Kite Pharma; Genentech; MorphoSys; Juno Therapeutics; Adaptive Biotechnologies; Celltrion; Celgene; Alimera Sciences; BeiGene; MEI Pharma; Sunesis; TG Therapeutics; Regeneron Pharmaceuticals; Memorial Sloan-Kettering Cancer Center; Pfizer; Incyte; F. Hoffmann-La Roche; Teva Pharmaceutical Industries; Yuhan; Atara Biotherapeutics; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Sanofi; GlaxoSmithKline; Amgen; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Diffuse large B-cell lymphoma; Refractory (planetary science); Lymphoma; Internal medicine; Medicine; Oncology; Cancer research; Gastroenterology; Biology","score_opus":0.008757305009623545,"score_gpt":0.261308908155294,"score_spread":0.2525516031456705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366083620","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945325,0.0015023827,0.0000031618065,0.00014958788,0.00005734706,0.0006238326,0.000039184575,0.000088247434,0.0030037377],"genre_scores_gemma":[0.9858951,0.0032846006,0.00016529637,0.00037224614,0.00006186047,0.00007601341,0.000044315646,0.00006287171,0.010037715],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99839497,0.000048635287,0.0001963099,0.00042904753,0.00044677922,0.00048425575],"domain_scores_gemma":[0.9992574,0.00012324481,0.00007204143,0.00032793105,0.00007813681,0.00014126739],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010921431,0.00020445397,0.00034343798,0.00022635327,0.00008296247,0.00002423632,0.000099856305,0.00008557074,0.00029631294],"category_scores_gemma":[0.00002086082,0.0001609794,0.000042619202,0.0005354319,0.00007880504,0.0002763665,0.00004690667,0.0001829703,0.000037534377],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009323292,0.01430889,0.7826823,0.000302545,0.00028680832,0.0002369594,0.005222433,0.000010598417,0.011306889,0.000031326927,0.00065631943,0.17563163],"study_design_scores_gemma":[0.15987034,0.004207862,0.63145584,0.00029477547,0.00008677239,0.000009985585,0.0012594233,0.00022579703,0.048154626,0.00023152251,0.15360181,0.00060124346],"about_ca_topic_score_codex":0.000051625713,"about_ca_topic_score_gemma":0.000056396035,"teacher_disagreement_score":0.1750304,"about_ca_system_score_codex":0.000079312915,"about_ca_system_score_gemma":0.000087758,"threshold_uncertainty_score":0.6564549},"labels":[],"label_agreement":null},{"id":"W4366161256","doi":"10.1016/j.xpro.2023.102224","title":"A co-culture model system to quantify antibody-dependent cellular cytotoxicity in human breast cancer cells using an engineered natural killer cell line","year":2023,"lang":"en","type":"article","venue":"STAR Protocols","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"HORIZON EUROPE Marie Sklodowska-Curie Actions; H2020 Marie Skłodowska-Curie Actions; Horizon 2020; Medical Research Council; Horizon 2020 Framework Programme; Ministero della Salute; Natural Sciences and Engineering Research Council of Canada; European Commission; Weston Brain Institute; Canadian Institutes of Health Research; Alzheimer Society; National Institute for Health and Care Research; Alzheimer's Society","keywords":"Antibody-dependent cell-mediated cytotoxicity; Cytotoxicity; CD16; Peripheral blood mononuclear cell; Immune system; Cell culture; Immunology; Jurkat cells; Cancer; Antibody; Cancer research; Natural killer cell; Flow cytometry; Biology; Cancer cell; In vitro; T cell; CD3; Biochemistry","score_opus":0.06271952799619793,"score_gpt":0.41222800101806994,"score_spread":0.34950847302187205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366161256","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8944921,0.00002692416,0.0004495882,0.000112853944,0.000108834865,0.104039215,0.00026926625,0.00031537475,0.00018583205],"genre_scores_gemma":[0.95846254,0.000005920903,0.0007224384,0.00009019755,0.00038027373,0.03556412,0.00017885433,0.0001452118,0.004450427],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.996364,0.00019812335,0.0006115025,0.0008000623,0.0010659733,0.00096035446],"domain_scores_gemma":[0.998329,0.000025064726,0.00011288707,0.0008060388,0.00026579463,0.00046122045],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008772578,0.0004406647,0.00073484884,0.0005242096,0.00017850392,0.00010898531,0.00037870026,0.0002870051,0.00033047385],"category_scores_gemma":[0.000011343049,0.00038193737,0.00016915673,0.0009828846,0.000057431538,0.00017470587,0.00012208751,0.0008771766,0.00007649555],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007966921,0.00036027268,0.00063873973,0.001644095,0.00004491886,0.0003740448,0.0013973995,0.019277487,0.9750815,0.000026579331,0.00025749896,0.00010076788],"study_design_scores_gemma":[0.0038335156,0.0004348307,0.00069597305,0.0010735015,0.000024700059,0.000030424102,0.00050165947,0.22708446,0.7654076,0.0000099323115,0.00044997822,0.0004533909],"about_ca_topic_score_codex":0.00076245004,"about_ca_topic_score_gemma":0.00014806367,"teacher_disagreement_score":0.20967388,"about_ca_system_score_codex":0.0009001435,"about_ca_system_score_gemma":0.00033607605,"threshold_uncertainty_score":0.99986327},"labels":[],"label_agreement":null},{"id":"W4366222007","doi":"10.3389/fimmu.2023.1179827","title":"LCL161 enhances expansion and survival of engineered anti-tumor T cells but is restricted by death signaling","year":2023,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity; University of Ottawa; McMaster University; Children's Hospital of Eastern Ontario; Discovery Centre","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Cancer research","score_opus":0.016899903624781262,"score_gpt":0.27137088684261357,"score_spread":0.2544709832178323,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366222007","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929938,0.0046556205,0.00065552484,0.00021983289,0.00086249557,0.00032227862,0.000037330556,0.00006732982,0.00018583627],"genre_scores_gemma":[0.9911363,0.004692625,0.0011352056,0.0000414978,0.00004683869,0.000022665807,0.00006576591,0.00003710165,0.0028220157],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985313,0.0001356168,0.0003478526,0.00031749718,0.00023635046,0.00043141938],"domain_scores_gemma":[0.9993313,0.00016362999,0.00007595542,0.00029545504,0.00007571785,0.000057954934],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030033322,0.00015719465,0.00056685857,0.0005501307,0.00004022545,0.0000084427475,0.00014931912,0.00016610643,0.00020327902],"category_scores_gemma":[0.000110018096,0.00015252507,0.000058426805,0.00068987417,0.00020273186,0.00004946919,0.00008542855,0.00033904816,0.000010049426],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004553361,0.000059221267,0.011915681,0.00006268545,0.00013763864,0.00006865672,0.00046591737,0.000008256799,0.9771061,0.0000066917173,0.005847727,0.00386608],"study_design_scores_gemma":[0.002381949,0.0004566367,0.018341754,0.000095877585,0.000026710446,0.000013503605,0.0015089441,0.00092367665,0.9715985,0.00009877504,0.004399837,0.00015380942],"about_ca_topic_score_codex":0.0002502066,"about_ca_topic_score_gemma":0.000002007801,"teacher_disagreement_score":0.0064260727,"about_ca_system_score_codex":0.000068342284,"about_ca_system_score_gemma":0.00009195868,"threshold_uncertainty_score":0.6219792},"labels":[],"label_agreement":null},{"id":"W4366405937","doi":"10.1089/genbio.2023.0008","title":"Engineering T Cell Development for the Next Generation of Stem Cell-Derived Immunotherapies","year":2023,"lang":"en","type":"review","venue":"GEN Biotechnology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of Manitoba; CancerCare Manitoba; University of British Columbia","funders":"Canadian Institutes of Health Research; Michael Smith Health Research BC; Stem Cell Network","keywords":"Induced pluripotent stem cell; Stem cell; Cell therapy; Immunotherapy; T cell; Computer science; Medicine; Computational biology; Biology; Immunology; Immune system; Cell biology; Embryonic stem cell","score_opus":0.17443680802377695,"score_gpt":0.3386897575866703,"score_spread":0.16425294956289335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366405937","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00042423466,0.9938652,0.0022127312,0.00021856396,0.0002966845,0.0027328813,0.00001947088,0.00020237044,0.00002788467],"genre_scores_gemma":[0.000030633553,0.9903265,0.0026249029,0.00001585595,0.00016770246,0.0007821611,0.00010456556,0.00013783535,0.0058098463],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.998281,0.00003871968,0.0006541583,0.00040315892,0.0002175928,0.00040535783],"domain_scores_gemma":[0.998562,0.00030056233,0.00024453286,0.00076814165,0.00008973446,0.000035054214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045249893,0.00033710164,0.001150514,0.00048606063,0.000090639754,0.000019709843,0.0004539414,0.00092381705,0.00014564978],"category_scores_gemma":[0.000021131771,0.0002310393,0.00033706776,0.0005208926,0.000101378275,0.000017016962,0.00016369358,0.0005428322,0.00009516398],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000013533138,0.000028190667,7.207649e-8,0.008734901,0.0003818769,0.0000037052328,0.00013283327,0.0000044429516,0.20891255,0.000029161612,0.00019384637,0.7815649],"study_design_scores_gemma":[0.00038747175,0.00012281307,3.1800738e-7,0.0007978539,0.00021351255,0.000017748,0.00008795338,0.00016506689,0.15858243,0.0000015001847,0.839457,0.00016632908],"about_ca_topic_score_codex":0.000011112812,"about_ca_topic_score_gemma":0.0000045256625,"teacher_disagreement_score":0.83926314,"about_ca_system_score_codex":0.00021197363,"about_ca_system_score_gemma":0.000440635,"threshold_uncertainty_score":0.9421509},"labels":[],"label_agreement":null},{"id":"W4366412976","doi":"10.3410/f.742510058.793598333","title":"Faculty Opinions recommendation of Intrathymic dendritic cell-biased precursors promote human T cell lineage specification through IRF8-driven transmembrane TNF.","year":2023,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Lineage (genetic); Transmembrane protein; Cell; Tumor necrosis factor alpha; Cell biology; Biology; Immunology; Genetics; Gene; Receptor","score_opus":0.060017073427398766,"score_gpt":0.3873674926003697,"score_spread":0.3273504191729709,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366412976","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00001285401,0.001069184,0.000049608952,0.11237867,0.00082426064,0.004234332,0.88095576,0.0001243183,0.00035102837],"genre_scores_gemma":[0.000032373013,0.0024233751,0.0009133363,0.0020342343,0.0006528354,0.0005331833,0.9828388,0.000120848665,0.010450996],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9915495,0.0009362041,0.0027351154,0.0013147217,0.0027463967,0.0007180441],"domain_scores_gemma":[0.9884035,0.0003144157,0.0016849987,0.0027143406,0.0063688136,0.0005139583],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00178809,0.0008625401,0.0017323209,0.00063089124,0.0003534812,0.0001713426,0.0017742361,0.0010067115,0.0017764746],"category_scores_gemma":[0.002806855,0.0006372232,0.001194144,0.0039882017,0.00060365006,0.00038883393,0.00035261712,0.0025083756,0.00032114112],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007132522,0.0014961443,0.000002372414,0.026836291,0.00021809287,0.0000042012775,0.000417596,4.167857e-7,0.0011474572,0.00005620429,0.968482,0.0012678592],"study_design_scores_gemma":[0.0025399919,0.00050529296,0.0004667551,0.012863617,0.0005782295,0.00007667802,0.00007983715,0.000024287909,0.0036697916,0.000034615932,0.97864956,0.0005113463],"about_ca_topic_score_codex":0.00011252012,"about_ca_topic_score_gemma":0.000021117005,"teacher_disagreement_score":0.11034444,"about_ca_system_score_codex":0.00035216694,"about_ca_system_score_gemma":0.0011995615,"threshold_uncertainty_score":0.9997929},"labels":[],"label_agreement":null},{"id":"W4366596010","doi":"10.1016/j.bbrc.2023.04.067","title":"Humanized mouse models with endogenously developed human natural killer cells for in vivo immunogenicity testing of HLA class I-edited iPSC-derived cells","year":2023,"lang":"en","type":"article","venue":"Biochemical and Biophysical Research Communications","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Japan Society for the Promotion of Science; Canadian Internet Registration Authority; Japan Agency for Medical Research and Development","keywords":"Human leukocyte antigen; Biology; Induced pluripotent stem cell; Humanized mouse; Immunology; Haematopoiesis; Janus kinase 3; Stem cell; Interleukin 12; Interleukin 21; Cancer research; Cell biology; Antigen; Cytotoxic T cell; T cell; Immune system; In vitro; Embryonic stem cell; Gene; Genetics","score_opus":0.1809811898549389,"score_gpt":0.38739321125058657,"score_spread":0.20641202139564765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366596010","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966301,0.00018678932,0.000026783136,0.00084125076,0.000020086403,0.0015826087,0.000056818757,0.00008788774,0.0005677049],"genre_scores_gemma":[0.99083537,0.00041991327,0.0053986153,0.0000378027,0.000070566464,0.0003365718,0.00019414147,0.000052574833,0.0026544712],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972009,0.00029178825,0.00048716922,0.0004671621,0.00079926,0.00075372495],"domain_scores_gemma":[0.9950035,0.002289622,0.000083434155,0.0012499025,0.001122673,0.00025085863],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009697424,0.00022694135,0.00051847106,0.00038701904,0.00042619838,0.000051573563,0.00083741726,0.00017134781,0.0000389261],"category_scores_gemma":[0.00043913836,0.0001801707,0.00012414964,0.0019160161,0.0013433569,0.000087427725,0.00078308786,0.0009968377,0.000009397314],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008026975,0.00070021016,0.000044954497,0.00016853986,0.00009412582,0.000004746487,0.00037180528,0.0000036448232,0.99561226,0.00043738936,0.00088159234,0.0008780231],"study_design_scores_gemma":[0.0029162937,0.0005230097,0.00030034658,0.00016206567,0.000025079535,0.0000034777468,0.00030793253,0.015823096,0.97836155,0.00046227907,0.0009065221,0.00020832989],"about_ca_topic_score_codex":0.00053653156,"about_ca_topic_score_gemma":0.000074494485,"teacher_disagreement_score":0.017250704,"about_ca_system_score_codex":0.00017321549,"about_ca_system_score_gemma":0.00030954427,"threshold_uncertainty_score":0.7347148},"labels":[],"label_agreement":null},{"id":"W4366683885","doi":"10.3389/fimmu.2023.1192636","title":"Editorial: Next generation MSC therapy manufacturing, potency and mechanism of action analysis","year":2023,"lang":"en","type":"editorial","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto","funders":"Bundesministerium für Bildung und Forschung; Berlin-Brandenburg School for Regenerative Therapies; Deutsche Forschungsgemeinschaft; European Commission","keywords":"Mechanism (biology); Mechanism of action; Medicine; Chemistry; Philosophy; Biochemistry","score_opus":0.03072550979996148,"score_gpt":0.30999577243667575,"score_spread":0.2792702626367143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366683885","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00850065,0.0032235875,0.0009799261,0.000094669515,0.9864487,0.0005385113,0.000045170676,0.000070545524,0.00009825675],"genre_scores_gemma":[0.00047420373,0.05692366,0.00066066056,0.000007725552,0.9328769,0.000096178126,0.0011636923,0.00009779757,0.007699191],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972218,0.00029579457,0.0005982506,0.00064247614,0.0007909771,0.00045064907],"domain_scores_gemma":[0.9984475,0.00026674836,0.00031065586,0.0006501469,0.00026042084,0.00006457235],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00076996913,0.00034196384,0.0012517762,0.0020676588,0.000068225265,0.000036174075,0.00024237589,0.001964201,0.0003176615],"category_scores_gemma":[0.00040967288,0.0003325956,0.00027283642,0.0006579596,0.00018765482,0.00010675987,0.000102216065,0.0014525334,0.000008453226],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010503251,0.0000746552,0.000055558692,0.000067123976,0.0029387516,0.000014703404,0.00020813632,0.00000669365,0.07412148,0.0000076284164,0.8848436,0.036611356],"study_design_scores_gemma":[0.0025867105,0.00072311197,0.00014093434,0.00004584712,0.0005018508,0.0000017814148,0.00024736315,0.00030367443,0.024399139,0.0004860546,0.97030115,0.00026237694],"about_ca_topic_score_codex":0.0016197987,"about_ca_topic_score_gemma":0.00019379971,"teacher_disagreement_score":0.08545757,"about_ca_system_score_codex":0.00043045744,"about_ca_system_score_gemma":0.00033717434,"threshold_uncertainty_score":0.9999126},"labels":[],"label_agreement":null},{"id":"W4366782404","doi":"10.1111/pde.15310","title":"Proceedings of the 10th Pediatric Dermatology Research Alliance (<scp>PeDRA</scp>) Annual Conference","year":2023,"lang":"en","type":"article","venue":"Pediatric Dermatology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; Les Laboratories Pierre Fabre; Regeneron Pharmaceuticals; Sanofi; Pfizer; Eli Lilly and Company; Amryt Pharma; U.S. Department of Health and Human Services","keywords":"Alliance; Session (web analytics); Medicine; Coronavirus disease 2019 (COVID-19); Panel discussion; Theme (computing); Medical education; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Library science; Family medicine; World Wide Web; Computer science; Pathology; History","score_opus":0.0550134225719476,"score_gpt":0.35165486111866956,"score_spread":0.296641438546722,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366782404","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9783823,0.0015817067,0.00001188357,0.0062505733,0.00053835014,0.0013475568,0.0000434392,0.00026666294,0.011577534],"genre_scores_gemma":[0.9770435,0.00678101,0.00013069571,0.0002655342,0.0009026956,0.00023234292,0.000022352862,0.00009331619,0.014528526],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9944738,0.00032757188,0.0009487858,0.0008628887,0.001544262,0.0018427061],"domain_scores_gemma":[0.99452263,0.0019706336,0.00033814195,0.0006872102,0.0020679042,0.00041348548],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011222529,0.00038543946,0.0009804085,0.0011977606,0.00033863314,0.00005072808,0.0012155782,0.0006053472,0.0003376841],"category_scores_gemma":[0.0027989475,0.00030735158,0.00027039502,0.005928424,0.0007575991,0.00020855373,0.0008552987,0.0016790349,0.0010054964],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000097605924,0.00023064637,0.7376012,0.0012742131,0.00007025243,0.00036780752,0.0023798805,0.000002407535,0.0033909802,0.0013129539,0.2527777,0.00049435033],"study_design_scores_gemma":[0.009474817,0.000915895,0.70243466,0.000096334225,0.0008220422,0.014062955,0.009400446,0.0016318823,0.033819046,0.005891636,0.22070166,0.00074862054],"about_ca_topic_score_codex":0.000044569453,"about_ca_topic_score_gemma":0.000013765054,"teacher_disagreement_score":0.035166554,"about_ca_system_score_codex":0.000111565,"about_ca_system_score_gemma":0.0011081069,"threshold_uncertainty_score":0.99993783},"labels":[],"label_agreement":null},{"id":"W4366984296","doi":"10.1158/1078-0432.c.6615932.v1","title":"Data from SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma","year":2023,"lang":"en","type":"preprint","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Ontario Clinical Oncology Group","funders":"Pharmacyclics; Genentech; Bristol-Myers Squibb","keywords":"Medicine; Ipilimumab; Nivolumab; Internal medicine; Adjuvant; Radiation therapy; Melanoma; Adjuvant therapy; Gastroenterology; Surgery; Oncology; Cancer; Immunotherapy","score_opus":0.22064895977477625,"score_gpt":0.4054649721142443,"score_spread":0.18481601233946807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366984296","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97760564,0.00206202,0.0003666213,0.0021992458,0.0015599325,0.007868542,0.004090861,0.0003502686,0.0038968674],"genre_scores_gemma":[0.8667965,0.011323039,0.009088322,0.00045978194,0.0064288145,0.001085732,0.036345463,0.00087666395,0.06759572],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9952809,0.0002685321,0.00098731,0.0016415649,0.0011520351,0.00066964683],"domain_scores_gemma":[0.9935832,0.0017695697,0.000325528,0.0035379797,0.00045403306,0.00032970542],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014500758,0.0005236345,0.0015886815,0.00043061972,0.00008035346,0.0001072566,0.0010902226,0.0007345008,0.0049865036],"category_scores_gemma":[0.0012923941,0.00043626022,0.00031092198,0.00026646056,0.00028458447,0.00008261843,0.002154206,0.0010086956,0.000047861548],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.55161303,0.0035757355,0.00043093972,0.0007609297,0.0035313463,0.00013281495,0.0006815193,0.000002881402,0.23671906,0.00009006761,0.039346054,0.1631156],"study_design_scores_gemma":[0.70017636,0.047195677,0.006607908,0.0018569126,0.0012755462,0.000065863525,0.0013221964,0.013245133,0.10325448,0.01790085,0.1049208,0.002178281],"about_ca_topic_score_codex":0.0058967886,"about_ca_topic_score_gemma":0.0015595241,"teacher_disagreement_score":0.16093732,"about_ca_system_score_codex":0.00020134555,"about_ca_system_score_gemma":0.0012366469,"threshold_uncertainty_score":0.9998089},"labels":[],"label_agreement":null},{"id":"W4366997604","doi":"10.1101/2023.04.21.537841","title":"NR4A3 deficiency in CD8 <sup>+</sup> T cells improves adoptive T cell therapy of cancer","year":2023,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Canadian Institutes of Health Research","keywords":"Effector; Cytotoxic T cell; CD8; Biology; Cancer research; Adoptive cell transfer; T cell; Cell biology; Immunology; Antigen; Immune system; Genetics","score_opus":0.030103347123966125,"score_gpt":0.2822207896416499,"score_spread":0.2521174425176838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366997604","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895463,0.0061140093,0.000057157635,0.00027606834,0.00067849556,0.002568617,0.0003544918,0.00030858003,0.0000963055],"genre_scores_gemma":[0.9867215,0.010137779,0.0011295448,0.0001859285,0.0004820446,0.00064700225,0.0000010534559,0.00035520963,0.00033989633],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99490845,0.00024312819,0.0010378936,0.0015411346,0.0011297533,0.0011396136],"domain_scores_gemma":[0.9959734,0.00021157523,0.00050575857,0.0019718073,0.0009294753,0.0004079968],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012291016,0.00081029366,0.0013628262,0.0010506661,0.0000864248,0.00009141128,0.00082593615,0.00085533765,0.0007926807],"category_scores_gemma":[0.0001119781,0.00079773,0.00040081155,0.0016577565,0.00034787157,0.000109413675,0.00060084736,0.0018816266,0.00010846821],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00046623073,0.0006218324,0.01694257,0.0010014288,0.00018545608,0.00014289601,0.00015999864,0.00069879077,0.9792991,0.000028837745,0.0004095533,0.00004328386],"study_design_scores_gemma":[0.0026552957,0.00037023338,0.06516261,0.0008293486,0.00008580661,1.3759943e-8,0.000047579524,0.0015275493,0.9245884,0.0000026996563,0.0039758612,0.0007546498],"about_ca_topic_score_codex":0.0015713671,"about_ca_topic_score_gemma":0.000025847266,"teacher_disagreement_score":0.05471077,"about_ca_system_score_codex":0.00083893683,"about_ca_system_score_gemma":0.002524957,"threshold_uncertainty_score":0.99944735},"labels":[],"label_agreement":null},{"id":"W4367052591","doi":"10.3410/f.742323959.793598362","title":"Faculty Opinions recommendation of Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus.","year":2023,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Refractory (planetary science); CD19; Medicine; Systemic therapy; Immunology; Dermatology; Internal medicine; Antibody; Biology","score_opus":0.054283156519615856,"score_gpt":0.3868330823229618,"score_spread":0.33254992580334597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367052591","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000088503775,0.003466352,0.000023708071,0.10130351,0.0020564073,0.0048232432,0.8881682,0.00009725918,0.000052444535],"genre_scores_gemma":[0.0000071186805,0.0061465637,0.00032663383,0.0026825941,0.0006719292,0.0008883291,0.9749129,0.00011379088,0.01425014],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.992963,0.00065281574,0.0023078078,0.0010664767,0.0023619663,0.0006479302],"domain_scores_gemma":[0.98393714,0.0005743319,0.0018711408,0.00266005,0.010473348,0.00048396527],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0025449484,0.00076174614,0.0019830274,0.0007112677,0.00026238855,0.00012359809,0.0015369914,0.0012110462,0.00066229166],"category_scores_gemma":[0.0056019304,0.00049827405,0.0014655928,0.0028462159,0.0003944036,0.00023717468,0.00042802657,0.0015881194,0.00020295709],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012093378,0.0008106897,0.000012777795,0.032865193,0.000404975,0.0000015638569,0.00015166946,9.46638e-8,0.0003647835,0.00004192942,0.96349466,0.0017307028],"study_design_scores_gemma":[0.0031319973,0.0004642589,0.00024823175,0.017486708,0.00030575364,0.0003415773,0.000089603745,0.000009186815,0.00029585563,0.000017733237,0.97720283,0.0004062845],"about_ca_topic_score_codex":0.0000652025,"about_ca_topic_score_gemma":0.0000042845268,"teacher_disagreement_score":0.09862092,"about_ca_system_score_codex":0.0003331558,"about_ca_system_score_gemma":0.0016720425,"threshold_uncertainty_score":0.9997469},"labels":[],"label_agreement":null},{"id":"W4367185145","doi":"10.3389/fimmu.2023.1178403","title":"A systematic review and meta-analysis of CD22 CAR T-cells alone or in combination with CD19 CAR T-cells","year":2023,"lang":"en","type":"review","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Terry Fox Research Institute; University of Ottawa; University of British Columbia; Ottawa Hospital; University of Toronto","funders":"","keywords":"CD22; Medicine; Chimeric antigen receptor; CD19; Internal medicine; Oncology; Lymphoma; Immunology; Antigen; Immunotherapy; Cancer","score_opus":0.06912131729448169,"score_gpt":0.35192005123113446,"score_spread":0.2827987339366528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367185145","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00002896983,0.99243504,0.00006223176,0.00010942225,0.00020586578,0.006957446,0.0000941104,0.000028442932,0.00007849021],"genre_scores_gemma":[0.0000068003055,0.9861108,0.0005099338,0.000081133636,0.0000085969095,0.0012998488,0.00024172131,0.00010480276,0.011636356],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9939268,0.0020396605,0.002252066,0.0007491221,0.0005099832,0.00052231597],"domain_scores_gemma":[0.99666464,0.00068653567,0.0010317903,0.0013385498,0.00019989842,0.00007861044],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0023879108,0.0006013533,0.018120764,0.0032686666,0.000027348697,0.000014953445,0.00045543755,0.0005427489,0.00043946315],"category_scores_gemma":[0.00032810506,0.00038193923,0.0012884084,0.004710996,0.00034343,0.000051712836,0.00015097026,0.0009467575,0.000021569527],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00011826009,0.00019350326,0.000006817221,0.74557215,0.25083992,0.00025500814,0.00018602586,0.0000017801286,0.00007729001,0.000014687757,0.00090324966,0.0018312864],"study_design_scores_gemma":[0.0016882439,0.00069783826,0.0000034131517,0.07516934,0.8996157,0.000098184464,0.00030415156,0.000031271076,0.000026242677,0.000016438264,0.021892054,0.00045710002],"about_ca_topic_score_codex":0.00031948483,"about_ca_topic_score_gemma":0.00023659758,"teacher_disagreement_score":0.6704028,"about_ca_system_score_codex":0.0005510476,"about_ca_system_score_gemma":0.00046250102,"threshold_uncertainty_score":0.99986327},"labels":[],"label_agreement":null},{"id":"W4367310554","doi":"10.1177/19418744231167290","title":"Chimeric Antigen Receptor-T Cell Mediated Bilateral Facial Nerve Palsy: A Case Report","year":2023,"lang":"en","type":"article","venue":"The Neurohospitalist","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotchkiss Brain Institute; Ontario Brain Institute; University of Calgary","funders":"","keywords":"Medicine; Chimeric antigen receptor; Encephalopathy; Leukocytosis; Diplopia; Neurotoxicity; Facial nerve; Pathology; Immunotherapy; Internal medicine; Immune system; Immunology; Surgery; Toxicity","score_opus":0.029800700448282792,"score_gpt":0.30647724603038273,"score_spread":0.2766765455820999,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367310554","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9868912,0.0001267782,0.0000014135406,0.00441292,0.00093079905,0.0009731892,0.00006761243,0.00047286498,0.0061231903],"genre_scores_gemma":[0.9665335,0.00026860723,0.00001933779,0.0005864876,0.00066721224,0.000073441806,0.00034990459,0.00011745075,0.031384062],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99726677,0.00021296593,0.0005087289,0.00056916836,0.00072677457,0.0007155748],"domain_scores_gemma":[0.9981516,0.00020617139,0.00015506764,0.0010619722,0.0001348322,0.0002903597],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0007206091,0.00029933013,0.0004274791,0.00020505651,0.00029101435,0.00008785963,0.0002952868,0.00011789036,0.002441858],"category_scores_gemma":[0.00030120357,0.00020766622,0.00025576362,0.0013931436,0.00028323114,0.00008561647,0.00021665839,0.0005395942,0.0014985421],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000600277,0.0003704949,0.039055325,0.00014494218,0.0002168763,0.38482165,0.0027677487,0.000018619181,0.49329886,0.00002055345,0.07224434,0.0064403266],"study_design_scores_gemma":[0.008439975,0.003140803,0.21397112,0.00014261638,0.0003827305,0.11498998,0.0015949289,0.0021596213,0.099799514,0.00027120812,0.55324405,0.001863476],"about_ca_topic_score_codex":0.00096044154,"about_ca_topic_score_gemma":0.000024427787,"teacher_disagreement_score":0.48099968,"about_ca_system_score_codex":0.000065803804,"about_ca_system_score_gemma":0.00014176502,"threshold_uncertainty_score":0.9992789},"labels":[],"label_agreement":null},{"id":"W4367396590","doi":"10.1016/j.blre.2023.101095","title":"Failure of CAR-T cell therapy in relapsed and refractory large cell lymphoma and multiple myeloma: An urgent unmet need","year":2023,"lang":"en","type":"review","venue":"Blood Reviews","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Champlain Regional College","funders":"","keywords":"Chimeric antigen receptor; Medicine; Multiple myeloma; Lymphoma; Salvage therapy; CAR T-cell therapy; Refractory (planetary science); Oncology; Internal medicine; Intensive care medicine; Cancer; Immunotherapy; Chemotherapy","score_opus":0.07481768095768547,"score_gpt":0.3531875806208339,"score_spread":0.2783698996631484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367396590","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01106337,0.98227787,4.3267949e-7,0.00003078768,0.000113141694,0.005951244,0.00011529498,0.000055238193,0.00039262802],"genre_scores_gemma":[0.00018100158,0.9946608,0.0002849123,0.000098579214,0.00021570755,0.0003199576,0.00028999266,0.0002356414,0.003713391],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99457455,0.0013186593,0.0018135556,0.0010386405,0.00055554125,0.000699048],"domain_scores_gemma":[0.9965675,0.0004954286,0.0007864237,0.0013830584,0.000104067265,0.0006635627],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0025903035,0.00081896904,0.0049185306,0.0006913451,0.00007092514,0.000036108515,0.0003442473,0.0006891631,0.000538395],"category_scores_gemma":[0.0003754249,0.00059155887,0.0006707632,0.0010835684,0.00013894094,0.00007274564,0.0002095855,0.0007707449,0.00005370114],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001055708,0.0020788559,0.00035375435,0.07416118,0.0002306269,0.00018978347,0.0005595943,2.3706662e-8,0.0021904137,0.0000037129664,0.0011048282,0.91902167],"study_design_scores_gemma":[0.008507623,0.00085288746,0.00009581563,0.012422478,0.00086480443,0.00006709694,0.00012129118,0.0000048956676,0.00024342211,0.0000026641758,0.9763336,0.00048342784],"about_ca_topic_score_codex":0.00013205882,"about_ca_topic_score_gemma":0.00014718978,"teacher_disagreement_score":0.9752288,"about_ca_system_score_codex":0.00012154864,"about_ca_system_score_gemma":0.0006447105,"threshold_uncertainty_score":0.9996536},"labels":[],"label_agreement":null},{"id":"W4367602086","doi":"10.1016/j.leukres.2023.107274","title":"Topic: AS08-Treatment/AS08h-Allogeneic hematopoietic cell transplantation – Post-transplantation treatment: IN VIVO DUAL T CELL DEPLETION (TCD) IMPROVES TRANSPLANT OUTCOMES IN MYELODYSPLASTIC SYNDROME (MDS) PATIENTS WHO UNDERGO MATCHED UNRELATED ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT)","year":2023,"lang":"en","type":"article","venue":"Leukemia Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Transplantation; Hematopoietic cell; Medicine; Hematopoietic stem cell transplantation; Haematopoiesis; Intensive care medicine; Stem cell; Internal medicine; Biology","score_opus":0.024924774068694554,"score_gpt":0.3027709996817769,"score_spread":0.27784622561308236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367602086","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99175596,0.00027929802,0.00013516599,0.0004562585,0.00026153185,0.0050909333,0.00051102915,0.00028368726,0.0012261204],"genre_scores_gemma":[0.9720798,0.014084098,0.0001306594,0.00007136258,0.00006362593,0.0010678993,0.0040727234,0.00024973913,0.00818006],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99059904,0.0012863514,0.0017162205,0.0017460185,0.0023349896,0.0023174055],"domain_scores_gemma":[0.9960631,0.0018224588,0.00023826395,0.00089164596,0.00037363463,0.0006109025],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012154699,0.0010782965,0.0015281992,0.00293067,0.0003866594,0.00017635252,0.00046472825,0.0009479677,0.0007368377],"category_scores_gemma":[0.000041229974,0.0009740668,0.00047767206,0.0027810605,0.0002811232,0.00047530327,0.000039150116,0.0011869286,0.0004976477],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0077308165,0.003260264,0.3282761,0.006943822,0.00031839364,0.010618381,0.025243035,0.002286358,0.6135923,0.000049413702,0.000036395068,0.0016447004],"study_design_scores_gemma":[0.04044231,0.0062970743,0.63455325,0.0010806442,0.00069917104,0.00075209356,0.0022607436,0.001297944,0.31095812,0.00024497666,0.00011252208,0.00130113],"about_ca_topic_score_codex":0.0063278903,"about_ca_topic_score_gemma":0.005714619,"teacher_disagreement_score":0.3062772,"about_ca_system_score_codex":0.004227055,"about_ca_system_score_gemma":0.0014346268,"threshold_uncertainty_score":0.9995955},"labels":[],"label_agreement":null},{"id":"W4367681764","doi":"10.3410/f.741237310.793598365","title":"Faculty Opinions recommendation of Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer.","year":2023,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; University of British Columbia","funders":"","keywords":"Breast cancer; Suppressor; Cancer; Cancer research; Oncology; Receptor; Cell; Medicine; Internal medicine; Chemistry; Biochemistry","score_opus":0.04610169381906,"score_gpt":0.4034897243944212,"score_spread":0.3573880305753612,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367681764","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000049955055,0.001958447,0.000034455392,0.14194137,0.00062395155,0.0054268013,0.84992045,0.000028696046,0.000015896738],"genre_scores_gemma":[0.00003314957,0.0061352206,0.0010913621,0.0010916069,0.0004621282,0.0012990186,0.9871906,0.000072138064,0.002624756],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.994547,0.00064608187,0.0019164933,0.0008457405,0.0015367045,0.0005079918],"domain_scores_gemma":[0.986828,0.0008743872,0.0017495331,0.0014498595,0.008835531,0.00026267557],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012191047,0.0006118491,0.0017107506,0.00027845625,0.0002085511,0.000045457164,0.0011607745,0.00055650144,0.0007628051],"category_scores_gemma":[0.0023028567,0.00035024394,0.0010996767,0.002771712,0.0004217717,0.00014533146,0.00020856518,0.00054183224,0.000022230905],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00055612833,0.0014112388,0.000003037063,0.007201151,0.0006078728,1.5387266e-7,0.0012416258,0.0000011318352,0.016033934,0.000008868916,0.9642478,0.008687008],"study_design_scores_gemma":[0.0023312136,0.00092922436,0.00086024636,0.0054130964,0.0002861508,0.0000075473645,0.00013298134,0.000005214221,0.062200904,0.0000051314246,0.9275707,0.0002575721],"about_ca_topic_score_codex":0.00043940064,"about_ca_topic_score_gemma":0.000015262598,"teacher_disagreement_score":0.14084977,"about_ca_system_score_codex":0.0003254931,"about_ca_system_score_gemma":0.0013988876,"threshold_uncertainty_score":0.999895},"labels":[],"label_agreement":null},{"id":"W4367834504","doi":"10.1017/erm.2023.13","title":"Targeting N-cadherin (CDH2) and the malignant bone marrow microenvironment in acute leukaemia","year":2023,"lang":"en","type":"review","venue":"Expert Reviews in Molecular Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Merck Canada Inc. (Canada)","funders":"National Centre for the Replacement, Refinement and Reduction of Animals in Research; Children's Cancer and Leukaemia Group","keywords":"Bone marrow; Cancer research; Cadherin; Tumor microenvironment; Medicine; Immunology; Cell; Biology; Tumor cells; Genetics","score_opus":0.05423215016981911,"score_gpt":0.37903037800590894,"score_spread":0.3247982278360898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367834504","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003882356,0.98896515,0.000063931366,0.0024593512,0.0002516628,0.007544899,0.0000049120054,0.00003685904,0.0006343881],"genre_scores_gemma":[0.000002067869,0.99039924,0.000607246,0.0016068066,0.00040608898,0.002197895,0.00017689851,0.00023758765,0.0043661594],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99238336,0.0018940422,0.0026650534,0.0011798455,0.00094491703,0.00093275344],"domain_scores_gemma":[0.9972556,0.00047504768,0.00054436503,0.0014058393,0.000028520086,0.00029060603],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0064092823,0.00096954656,0.0063718148,0.00065980264,0.000065274246,0.000023947818,0.0005361724,0.00043784257,0.0016532793],"category_scores_gemma":[0.0009981516,0.00052966346,0.0006409202,0.0012661465,0.00078696484,0.000037856953,0.00048729184,0.0018437626,0.00018883203],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015445004,0.00008185828,0.000009381353,0.01803908,0.00033447394,0.0050049927,0.00091733545,4.237334e-7,0.0090357065,0.00005937861,0.0059181033,0.9604448],"study_design_scores_gemma":[0.003464123,0.00016739679,0.000004869149,0.08141519,0.00049691455,0.0005744806,0.000108661916,0.000023475892,0.00003395522,0.000021181044,0.9132996,0.00039013656],"about_ca_topic_score_codex":0.0002835768,"about_ca_topic_score_gemma":0.000021022117,"teacher_disagreement_score":0.9600547,"about_ca_system_score_codex":0.0007361912,"about_ca_system_score_gemma":0.00018341528,"threshold_uncertainty_score":0.9997155},"labels":[],"label_agreement":null},{"id":"W4367852216","doi":"10.3389/fimmu.2023.1166038","title":"Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy","year":2023,"lang":"en","type":"review","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada; Institute of Infection and Immunity; University of Ottawa; Ottawa Hospital","funders":"Canadian Institutes of Health Research","keywords":"Chimeric antigen receptor; Cell therapy; CAR T-cell therapy; Immunotherapy; Medicine; Immunology; Bioinformatics; Biology; Immune system; Cell","score_opus":0.15477535705814865,"score_gpt":0.4157809578509788,"score_spread":0.26100560079283014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367852216","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016398598,0.9887842,0.000059252354,0.0015232787,0.0031698013,0.0038966925,0.00015680885,0.00013604767,0.0006340653],"genre_scores_gemma":[0.000011644291,0.9817409,0.00087119424,0.00052704953,0.00026792916,0.0014547375,0.0006497692,0.00032182678,0.014154932],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9944473,0.0010239669,0.0012324497,0.0013788609,0.0005631308,0.0013542945],"domain_scores_gemma":[0.9973782,0.00038092537,0.0002759541,0.0016910209,0.000096549215,0.0001773922],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00080621237,0.00084378885,0.004182342,0.00221112,0.000077832105,0.000038544367,0.0010557108,0.0011462345,0.0013285503],"category_scores_gemma":[0.00022638445,0.00075178366,0.0005948799,0.00212904,0.00028718842,0.00007903722,0.00032780145,0.002330976,0.00026093813],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011183803,0.000252673,0.0004965888,0.00057431863,0.0015960452,0.00032529293,0.0010074426,0.000002472538,0.00036998824,0.000013091383,0.005367045,0.98887664],"study_design_scores_gemma":[0.004391792,0.00065120216,0.0003312857,0.0038736628,0.00008192501,0.00001606916,0.0005832672,0.0000046473765,0.000049254435,0.00027017313,0.98919344,0.00055327965],"about_ca_topic_score_codex":0.0020213518,"about_ca_topic_score_gemma":0.0004338294,"teacher_disagreement_score":0.9883234,"about_ca_system_score_codex":0.0016051944,"about_ca_system_score_gemma":0.00096936896,"threshold_uncertainty_score":0.9999707},"labels":[],"label_agreement":null},{"id":"W4368371666","doi":"10.3410/f.733111646.793598355","title":"Faculty Opinions recommendation of Universal chimeric antigen receptors for multiplexed and logical control of T cell responses.","year":2023,"lang":"en","type":"dataset","venue":"Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Chimeric antigen receptor; Multiplexing; Receptor; Control (management); Computational biology; Antigen; Computer science; Chemistry; Cell biology; Biology; Immunology; T cell; Genetics; Artificial intelligence; Telecommunications; Immune system","score_opus":0.05238407062758756,"score_gpt":0.3816209964834639,"score_spread":0.3292369258558764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4368371666","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000067072096,0.0008981356,0.00006192399,0.108175166,0.00054989906,0.002929133,0.88731456,0.000036196652,0.000028284498],"genre_scores_gemma":[0.000019550165,0.0019013732,0.001080352,0.0012796264,0.00020981183,0.00018879963,0.99013364,0.000044476696,0.0051423516],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953006,0.0006967217,0.0015297295,0.000708267,0.001364724,0.00039999565],"domain_scores_gemma":[0.9900555,0.0008654626,0.0012852729,0.0011824166,0.006239408,0.00037195967],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020036164,0.00046139085,0.0014522322,0.00055914046,0.00015495892,0.000043995067,0.0007750086,0.000775189,0.0005774057],"category_scores_gemma":[0.010934633,0.00030814507,0.0007553948,0.0021537505,0.0006445057,0.00013908432,0.00033484984,0.00092346704,0.000027775819],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004967336,0.00051323505,0.000023080627,0.009951428,0.00030283543,7.0988347e-7,0.00009120297,7.340192e-8,0.000533494,0.00004528375,0.98545057,0.0025913464],"study_design_scores_gemma":[0.003706554,0.0005940009,0.0024638108,0.0051118406,0.00031937042,0.000030295878,0.000064813736,0.000031414693,0.00033175587,0.000012045912,0.9870871,0.00024703884],"about_ca_topic_score_codex":0.00006706271,"about_ca_topic_score_gemma":0.0000045276447,"teacher_disagreement_score":0.10689554,"about_ca_system_score_codex":0.00012902197,"about_ca_system_score_gemma":0.0009382521,"threshold_uncertainty_score":0.99993706},"labels":[],"label_agreement":null},{"id":"W4368373774","doi":"10.1016/j.ymthe.2023.04.021","title":"A chemically inducible IL-2 receptor signaling complex allows for effective in vitro and in vivo selection of engineered CD4+ T cells","year":2023,"lang":"en","type":"article","venue":"Molecular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Akebia Therapeutics; Canadian Institute of Steel Construction; Children’s Hospital of Wisconsin Research Institute; Seattle Children's Research Institute; Leona M. and Harry B. Helmsley Charitable Trust","keywords":"In vivo; Cell biology; Biology; T-cell receptor; FOXP3; CD19; Chimeric antigen receptor; In vitro; T cell; Cancer research; Immunology; Antigen; Immune system; Genetics","score_opus":0.023745303880693867,"score_gpt":0.3002096828997834,"score_spread":0.27646437901908955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4368373774","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969405,0.00017153383,0.0006734879,0.00019878097,0.000032876913,0.0018520232,0.000016399386,0.000044099874,0.00007027511],"genre_scores_gemma":[0.99743706,0.0002271306,0.0015503415,0.00012960852,0.000038581435,0.00030746873,0.000041573083,0.000054336106,0.0002138926],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987821,0.00009937433,0.00024964954,0.00031439966,0.00023496103,0.00031952062],"domain_scores_gemma":[0.99942625,0.00020990608,0.00004286974,0.00015962937,0.000090946945,0.00007039505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00058204174,0.0001508609,0.00037608936,0.00041385952,0.000017798826,0.000010792465,0.00007333264,0.00012904526,0.00020892837],"category_scores_gemma":[0.000050276656,0.00015015295,0.000091719616,0.0008483264,0.000041501728,0.00002792928,0.000016325856,0.00021769769,0.0000032574485],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003171478,0.00013289144,0.00022618206,0.00009711722,0.00008529142,0.000012313667,0.0005409233,0.00018948171,0.9850263,0.0000046385576,0.00008125265,0.010432114],"study_design_scores_gemma":[0.005124017,0.00047825262,0.0006247297,0.00006595385,0.000006615328,0.0000031641005,0.0000497494,0.005088665,0.986113,0.00009006605,0.0022338983,0.00012187324],"about_ca_topic_score_codex":0.000069638336,"about_ca_topic_score_gemma":0.0000073825313,"teacher_disagreement_score":0.010310241,"about_ca_system_score_codex":0.0001091073,"about_ca_system_score_gemma":0.00004992819,"threshold_uncertainty_score":0.61230594},"labels":[],"label_agreement":null},{"id":"W4368377442","doi":"10.14740/wjon1575","title":"Neurological Adverse Effects of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T-Cell Therapy","year":2023,"lang":"en","type":"review","venue":"World Journal of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Chimeric antigen receptor; Adverse effect; Antigen; Immune system; Immunology; Immunotherapy; Receptor; Pharmacology; Internal medicine","score_opus":0.05445517049777401,"score_gpt":0.38029507042618693,"score_spread":0.32583989992841295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4368377442","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013571054,0.98212886,0.0000015164774,0.00034469753,0.0016129372,0.001253163,0.000003855753,0.000020930382,0.001062991],"genre_scores_gemma":[0.00020078185,0.99477166,0.0002664329,0.00009983917,0.00095984916,0.000023702309,0.000009230581,0.0001008992,0.003567629],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99574417,0.0010081002,0.0019228321,0.00033977107,0.0005245751,0.00046052673],"domain_scores_gemma":[0.99549556,0.0017089243,0.0019100454,0.00035554,0.00021429466,0.00031564778],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017561647,0.00043460232,0.004030082,0.0012010718,0.000049548195,0.000008500476,0.00034112378,0.0004399376,0.00096821063],"category_scores_gemma":[0.00033793133,0.00028856308,0.001303218,0.0010460404,0.00038329486,0.00004426999,0.00017328683,0.0020603705,0.000055159275],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009158906,0.0005868399,0.00012991732,0.006855733,0.0007621675,0.0012605293,0.00010220087,3.033868e-7,0.009250137,0.000003091829,0.0017225306,0.97841066],"study_design_scores_gemma":[0.0034297453,0.008640419,0.00048621176,0.0043948325,0.00050367543,0.0010536478,0.000013904993,9.755558e-7,0.00073095126,0.000011765417,0.98054534,0.00018850742],"about_ca_topic_score_codex":0.000012576262,"about_ca_topic_score_gemma":0.00000371299,"teacher_disagreement_score":0.9788228,"about_ca_system_score_codex":0.00020836019,"about_ca_system_score_gemma":0.0010350349,"threshold_uncertainty_score":0.99995667},"labels":[],"label_agreement":null},{"id":"W4375844599","doi":"10.2174/1573404820666230505110617","title":"Recent Developments in Combinatorial Immunotherapy towards OvarianCancer","year":2023,"lang":"en","type":"article","venue":"Current Women s Health Reviews","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Laurentian University","funders":"","keywords":"Immunotherapy; Medicine; Ovarian cancer; Oncolytic virus; Disease; Radiation therapy; Cancer immunotherapy; Cancer; Oncology; Immunology; Internal medicine","score_opus":0.16371118422226963,"score_gpt":0.46338862633506683,"score_spread":0.29967744211279723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4375844599","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.2117593,0.71852756,0.000049244,0.019396001,0.020964291,0.018179948,0.000044345685,0.0005627492,0.010516551],"genre_scores_gemma":[0.0019411709,0.9913745,0.00015043182,0.0018163318,0.00052670884,0.0016964218,0.00011848035,0.00006170987,0.0023142686],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961929,0.00046919918,0.0011057019,0.0004800683,0.00064034143,0.0011118401],"domain_scores_gemma":[0.99865294,0.00004910519,0.00021527229,0.0005448402,0.000104262785,0.00043355578],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0045539294,0.00026303952,0.0010619274,0.000389158,0.00010350337,0.000025604586,0.00022495544,0.00007744561,0.0037657844],"category_scores_gemma":[0.00017329589,0.00021984203,0.0001078448,0.002065302,0.000046229914,0.000067713234,0.0000864771,0.0005989395,0.0009961152],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003416887,0.00023852832,0.0019442498,0.0010095508,0.00002294209,0.0000075840435,0.0023087,1.6921535e-7,0.00016121095,0.00012685578,0.017581664,0.97625685],"study_design_scores_gemma":[0.0037996348,0.00025734352,0.017034987,0.00093910936,0.0000021232167,0.0000046115438,0.000058088175,0.000010193733,0.000032943022,0.00020196018,0.97749037,0.0001686275],"about_ca_topic_score_codex":0.00005146703,"about_ca_topic_score_gemma":0.000009870995,"teacher_disagreement_score":0.9760882,"about_ca_system_score_codex":0.002750738,"about_ca_system_score_gemma":0.0018983651,"threshold_uncertainty_score":0.9997817},"labels":[],"label_agreement":null},{"id":"W4375864821","doi":"10.1080/10428194.2023.2203790","title":"Single-center retrospective study assessing the efficacy and safety of BeEAM (bendamustine, etoposide, cytarabine, melphalan) as conditioning regimen for autologous hematopoietic stem cell transplantation","year":2023,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital du Sacré-Cœur de Montréal","funders":"","keywords":"Medicine; Bendamustine; Internal medicine; Etoposide; Oncology; Carmustine; Febrile neutropenia; Melphalan; Cytarabine; Autologous stem-cell transplantation; Follicular lymphoma; Mucositis; Hematopoietic stem cell transplantation; Regimen; Transplantation; Surgery; Neutropenia; Lymphoma; Chemotherapy; Rituximab","score_opus":0.01950455767052423,"score_gpt":0.2957316072068995,"score_spread":0.2762270495363753,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4375864821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99218255,0.00044699077,0.00016831512,0.00027220137,0.00020687938,0.0030449363,0.00009473959,0.00025921786,0.0033241606],"genre_scores_gemma":[0.9957035,0.00038000496,0.00019305841,0.00020846078,0.00018525521,0.00025708188,0.0002325457,0.00012467161,0.0027153825],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9961804,0.0003064699,0.00093334966,0.0009607004,0.0008169953,0.0008020508],"domain_scores_gemma":[0.9970797,0.0012933504,0.00040004618,0.00063229614,0.0003080773,0.0002865846],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010338663,0.000541055,0.0010044341,0.00039255916,0.0006680043,0.00019159648,0.00026514975,0.0003119671,0.00007458607],"category_scores_gemma":[0.00010366013,0.00043874752,0.00020837686,0.0008431142,0.00046569863,0.00028377312,0.0001246176,0.00020974274,0.0000147351675],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021373857,0.0038764086,0.17069015,0.006017733,0.0029830402,0.002650024,0.07267953,0.0005896101,0.41224876,0.0020880634,0.0037983598,0.30100447],"study_design_scores_gemma":[0.08848645,0.005069642,0.8089337,0.001238978,0.0014833518,0.0035174775,0.018386783,0.0073241903,0.061613347,0.0005126011,0.0023119806,0.0011215247],"about_ca_topic_score_codex":0.0004082615,"about_ca_topic_score_gemma":0.000040354425,"teacher_disagreement_score":0.6382435,"about_ca_system_score_codex":0.0026720865,"about_ca_system_score_gemma":0.0012913175,"threshold_uncertainty_score":0.9998064},"labels":[],"label_agreement":null},{"id":"W4375955180","doi":"10.1111/ejh.13982","title":"<scp>PD‐L1</scp> expression predicts efficacy in the phase <scp>II SPiReL</scp> trial with <scp>MVP‐S</scp>, pembrolizumab, and low‐dose <scp>CPA</scp> in R/R <scp>DLBCL</scp>","year":2023,"lang":"en","type":"article","venue":"European Journal Of Haematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; London Health Sciences Centre; Queen Elizabeth II Health Sciences Centre; Health Sciences Centre; Sunnybrook Hospital; Baker Hughes (Canada); McGill University Health Centre; Sunnybrook Health Science Centre","funders":"Merck","keywords":"Medicine; Pembrolizumab; Internal medicine; Population; Oncology; Discontinuation; Gastroenterology; Immunotherapy; Cancer","score_opus":0.034535795403372906,"score_gpt":0.31449901093513066,"score_spread":0.27996321553175774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4375955180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96771616,0.0049300017,0.00013669698,0.0006814289,0.0016293532,0.0037801461,0.00008085981,0.0003574517,0.020687893],"genre_scores_gemma":[0.97708106,0.0037484576,0.00046429032,0.0012254098,0.0028258422,0.0001424232,0.00017382427,0.0007667362,0.013571927],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.97940725,0.0067289732,0.0043010837,0.0021315077,0.0035299598,0.0039012195],"domain_scores_gemma":[0.97562164,0.016597291,0.002545391,0.0023184945,0.00091090397,0.0020063035],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.010089566,0.0018908354,0.00407878,0.0036917122,0.0007930399,0.00047030515,0.0027885907,0.0008009998,0.000069098554],"category_scores_gemma":[0.025310094,0.001390473,0.0009630422,0.0038036692,0.0016198929,0.0009308767,0.0013537176,0.005913623,0.0005600016],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007013968,0.01827087,0.018692033,0.002383996,0.0024084141,0.23777698,0.08504959,0.0010565511,0.14443585,0.00053939427,0.4695556,0.012816763],"study_design_scores_gemma":[0.37011492,0.03097143,0.043927375,0.005726569,0.0011966919,0.055637363,0.031593956,0.0016670122,0.0385102,0.00045620406,0.41987684,0.00032142986],"about_ca_topic_score_codex":0.00004781089,"about_ca_topic_score_gemma":0.000063178966,"teacher_disagreement_score":0.36310095,"about_ca_system_score_codex":0.00039160735,"about_ca_system_score_gemma":0.0012995338,"threshold_uncertainty_score":0.99938357},"labels":[],"label_agreement":null},{"id":"W4376107823","doi":"10.1200/edbk_390778","title":"COVID-19 and Other Viral Infections in Patients With Hematologic Malignancies","year":2023,"lang":"en","type":"article","venue":"American Society of Clinical Oncology Educational Book","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Tocilizumab; Chimeric antigen receptor; Immunology; Population; Disease; Immune system; Internal medicine; Immunotherapy","score_opus":0.08741768583104755,"score_gpt":0.4779941578406663,"score_spread":0.39057647200961876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376107823","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95500934,0.00005259086,0.000014763898,0.04174773,0.00006648867,0.00039978448,0.0000112595335,0.000030429615,0.0026675991],"genre_scores_gemma":[0.91865665,0.00052510865,0.0030956347,0.057168495,0.00022305512,0.0001857697,0.0000667054,0.00003054025,0.02004807],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985994,0.00017284325,0.0004942458,0.00026979038,0.00024980895,0.0002139049],"domain_scores_gemma":[0.99591756,0.0032601545,0.00023506983,0.00016726043,0.00014066124,0.00027930128],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00074036507,0.000096477794,0.00055110006,0.0000735252,0.000060187576,0.000003360988,0.00006937818,0.000109980836,0.0017866301],"category_scores_gemma":[0.0011484672,0.00007634053,0.00015023566,0.00041886084,0.0021458578,0.000040161878,0.000049473736,0.0003109409,0.00003104582],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033056713,0.001099657,0.9648543,0.000041219726,0.000105007864,0.0000011893735,0.00058312755,0.0000070202664,0.000055964745,0.0004499628,0.025310602,0.007161355],"study_design_scores_gemma":[0.0023347635,0.0021493766,0.7567448,0.000014202288,0.000022968266,0.0000071208974,0.0006738693,0.000023525448,0.0000052040455,0.00040386987,0.23755182,0.000068453264],"about_ca_topic_score_codex":0.0002906861,"about_ca_topic_score_gemma":0.00003107518,"teacher_disagreement_score":0.21224122,"about_ca_system_score_codex":0.00021641064,"about_ca_system_score_gemma":0.0029887112,"threshold_uncertainty_score":0.9991259},"labels":[],"label_agreement":null},{"id":"W4376225548","doi":"10.1007/s00277-023-05196-4","title":"RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma","year":2023,"lang":"en","type":"article","venue":"Annals of Hematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; University of Alberta","funders":"National Cancer Institute; MorphoSys","keywords":"Lenalidomide; Medicine; Rituximab; Internal medicine; Bendamustine; Oncology; Clinical endpoint; Surgery; Multiple myeloma; Lymphoma; Clinical trial","score_opus":0.0815092479124416,"score_gpt":0.3680034390507228,"score_spread":0.28649419113828123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376225548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99470407,0.00086469046,0.000017748614,0.00048408067,0.0001814985,0.001626892,0.0005656123,0.00008459067,0.0014708309],"genre_scores_gemma":[0.9978828,0.00032569183,0.00014594672,0.00015833849,0.000043657958,0.00007358437,0.001136909,0.000109667075,0.00012344735],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9945056,0.001267601,0.0010242247,0.001141476,0.0010279248,0.0010332038],"domain_scores_gemma":[0.99224144,0.0044945125,0.0006358808,0.0018724707,0.00047764633,0.00027806094],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015597171,0.0006175572,0.0026114264,0.0013543569,0.00012586224,0.00002343567,0.0006303233,0.0002788845,0.000112181435],"category_scores_gemma":[0.0004413593,0.00052502233,0.00018102702,0.0014610287,0.00074740633,0.0002441852,0.00038329454,0.0005980902,0.000027264048],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5369094,0.047562033,0.37664667,0.006482841,0.0026078515,0.0011900918,0.0050211325,0.00010966533,0.014680144,0.0017862814,0.0036690221,0.003334859],"study_design_scores_gemma":[0.51140326,0.012537176,0.380853,0.0028589964,0.0003968383,0.000025259045,0.0029046545,0.0046994057,0.08098858,0.00013286345,0.0019885278,0.0012114211],"about_ca_topic_score_codex":0.001544861,"about_ca_topic_score_gemma":0.0017549149,"teacher_disagreement_score":0.06630843,"about_ca_system_score_codex":0.00019152575,"about_ca_system_score_gemma":0.00072400767,"threshold_uncertainty_score":0.99972016},"labels":[],"label_agreement":null},{"id":"W4376226544","doi":"10.1182/bloodadvances.2022007059","title":"CD38 as a pan-hematologic target for chimeric antigen receptor T cells","year":2023,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institutes of Health; Incyte; Andrew McDonough B+ Foundation; American Society of Clinical Oncology; American Association for Cancer Research; St. Baldrick's Foundation; Stand Up To Cancer; National Cancer Institute; Entertainment Industry Foundation; Gilead Sciences; Canadian Institutes of Health Research; Leukemia and Lymphoma Society","keywords":"Chimeric antigen receptor; CD38; Cart; Haematopoiesis; Antigen; Cancer research; Medicine; Immunology; Myeloid leukemia; Immunotherapy; T cell; Myeloid; Leukemia; Stem cell; Biology; CD34; Immune system; Cell biology","score_opus":0.026737103991852498,"score_gpt":0.3417820071623222,"score_spread":0.31504490317046974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376226544","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9809532,0.006208419,0.00010191528,0.0016224319,0.0005990153,0.0017611689,0.000060526167,0.0004989016,0.008194426],"genre_scores_gemma":[0.6930332,0.03283147,0.051041078,0.0017351401,0.0026321225,0.0017317606,0.0006894169,0.00037830096,0.21592747],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99839234,0.00004161825,0.00024514983,0.0004122719,0.0003508039,0.0005578179],"domain_scores_gemma":[0.99906874,0.0002757546,0.000076886485,0.0003351423,0.00009391783,0.00014955184],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00028189336,0.000183546,0.00041724142,0.00016724912,0.00011575421,0.000022488786,0.00018339213,0.000084578154,0.0022350366],"category_scores_gemma":[0.00020107723,0.00014781185,0.00017135177,0.00064824347,0.00010274976,0.00010038018,0.00005757973,0.00015399193,0.0010153071],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043456603,0.00032576232,0.005504507,0.00035869275,0.00020153752,0.00008269846,0.00024865416,0.000012052814,0.9530322,0.00016078453,0.0097165685,0.029921954],"study_design_scores_gemma":[0.0016444862,0.00089061115,0.0005928149,0.000055124536,0.000038274564,0.00003611342,0.00025773735,0.000050863702,0.47841468,0.0012048373,0.5166484,0.00016605317],"about_ca_topic_score_codex":0.000012294833,"about_ca_topic_score_gemma":0.0000033389529,"teacher_disagreement_score":0.50693184,"about_ca_system_score_codex":0.00001935264,"about_ca_system_score_gemma":0.00010484463,"threshold_uncertainty_score":0.99976254},"labels":[],"label_agreement":null},{"id":"W4376608471","doi":"10.1038/s41587-023-01816-6","title":"Author Correction: Deconvolution of clinical variance in CAR-T cell pharmacology and response","year":2023,"lang":"en","type":"erratum","venue":"Nature Biotechnology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia; Hatch (Canada)","funders":"","keywords":"Deconvolution; Variance (accounting); Computational biology; Pharmacology; Clinical pharmacology; Mathematics; Biology; Statistics; Economics","score_opus":0.03218830129564559,"score_gpt":0.4115892689948476,"score_spread":0.379400967699202,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376608471","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.38525215,0.0668095,0.00015962932,0.099760234,0.4255512,0.005976555,0.00031843915,0.0017785395,0.014393725],"genre_scores_gemma":[0.061493013,0.015019612,0.0004986907,0.00067739846,0.0029212618,0.000108569984,0.00021186018,0.00017129692,0.9188983],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.996577,0.000630135,0.0009236467,0.0009644356,0.00036658437,0.00053817],"domain_scores_gemma":[0.99752206,0.001038137,0.00039397698,0.0006857946,0.00022720001,0.00013281268],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0025964503,0.0003344665,0.0013487805,0.0015390156,0.00004650162,0.0000063228067,0.00033145119,0.013428887,0.00055834715],"category_scores_gemma":[0.002426976,0.00032884185,0.00019911957,0.0013529912,0.0007942595,0.00002742527,0.0002869852,0.012703851,0.000045699133],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0077113677,0.00022727509,0.00080788886,0.0003033271,0.00014399362,0.0005006899,0.000050694052,5.8669895e-7,0.07433942,0.0000523133,0.89428174,0.021580672],"study_design_scores_gemma":[0.0030724239,0.0016308354,0.01379022,0.00023910959,0.00014059067,0.00023702173,0.0000879801,0.0006153962,0.017924448,0.000095679075,0.96191585,0.00025042595],"about_ca_topic_score_codex":0.00009840472,"about_ca_topic_score_gemma":0.0001951782,"teacher_disagreement_score":0.9045046,"about_ca_system_score_codex":0.0003308345,"about_ca_system_score_gemma":0.0013448038,"threshold_uncertainty_score":0.9999164},"labels":[],"label_agreement":null},{"id":"W4376611005","doi":"10.1158/1078-0432.c.6516061.v2","title":"Data from Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma","year":2023,"lang":"en","type":"preprint","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Gilead Sciences","keywords":"Chemoimmunotherapy; Medicine; Internal medicine; Adverse effect; Clinical endpoint; Cytokine release syndrome; Refractory (planetary science); Oncology; Gastroenterology; Randomized controlled trial; Lymphoma; Surgery; Rituximab; Immunotherapy; Chimeric antigen receptor; Cancer","score_opus":0.04952137718723923,"score_gpt":0.32935372489378223,"score_spread":0.27983234770654297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376611005","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875238,0.0008583826,0.000031744283,0.000026446001,0.00020737556,0.0013481819,0.008190114,0.000030725587,0.0017832118],"genre_scores_gemma":[0.9883418,0.0021691236,0.0009615105,0.00001307884,0.00005091735,0.000010489355,0.0052198605,0.00010911805,0.003124093],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9966958,0.00015513349,0.0007950925,0.0008104153,0.0012080772,0.0003354914],"domain_scores_gemma":[0.9963702,0.0005853947,0.00036399957,0.002190896,0.00033312535,0.0001563605],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004978896,0.000302343,0.001287754,0.00034508517,0.000016171956,0.000009715883,0.0005602796,0.00037149453,0.0011553031],"category_scores_gemma":[0.00026399005,0.00024537512,0.00010331809,0.00030399868,0.00021610626,0.00005147184,0.0017529653,0.0004722645,0.0000053390286],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.71372026,0.010075385,0.11803735,0.010186626,0.0031349943,0.0009061204,0.012873315,0.000079560275,0.009794606,0.000021187065,0.00419361,0.11697696],"study_design_scores_gemma":[0.16788237,0.008768596,0.7959522,0.0029498916,0.00049507164,7.4455744e-7,0.0027997787,0.000091424394,0.01047909,0.000008665595,0.01002189,0.0005502575],"about_ca_topic_score_codex":0.0015679006,"about_ca_topic_score_gemma":0.002786889,"teacher_disagreement_score":0.67791486,"about_ca_system_score_codex":0.00026709028,"about_ca_system_score_gemma":0.0008753783,"threshold_uncertainty_score":0.9999998},"labels":[],"label_agreement":null},{"id":"W4376645275","doi":"10.3390/curroncol30050378","title":"Management and Prevention of Cellular-Therapy-Related Toxicity: Early and Late Complications","year":2023,"lang":"en","type":"review","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Department of Anesthesiology and Critical Care Medicine, Johns Hopkins Medicine; Memorial Sloan-Kettering Cancer Center","keywords":"Chimeric antigen receptor; Medicine; Cytokine release syndrome; Toxicity; Immunotherapy; Cytokine; Targeted therapy; Immunology; Oncology; Cancer research; Cancer; Internal medicine; Immune system","score_opus":0.28521256016160845,"score_gpt":0.49256499436315554,"score_spread":0.2073524342015471,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4376645275","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0032027988,0.99164516,0.00005359379,0.00008953108,0.0002655873,0.0027922567,0.000024820572,0.000058315185,0.0018679126],"genre_scores_gemma":[0.00005373621,0.99128836,0.000078508616,0.0000058076166,0.0000580924,0.00028737643,0.00023209429,0.000052579137,0.0079434635],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981564,0.0002884061,0.00064208126,0.0004421431,0.00021639868,0.00025453165],"domain_scores_gemma":[0.9989014,0.00019826242,0.00030680132,0.0003758563,0.000082083134,0.00013556001],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00046702925,0.00024676658,0.0013165303,0.00043638225,0.00005411523,0.000012925002,0.00012420658,0.00027871618,0.00025608353],"category_scores_gemma":[0.000017585691,0.000211522,0.0002139484,0.00044605503,0.00021984376,0.000023789626,0.00019106457,0.0004939821,0.00005611373],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028036755,0.00026360524,0.000050838455,0.011918965,0.00055757357,0.00001830095,0.000096834265,3.239122e-8,0.000073290015,0.000360497,0.0001571947,0.9864748],"study_design_scores_gemma":[0.0012681687,0.00068001304,0.0008720066,0.005779918,0.0007307172,0.00003479658,0.000011674629,0.000014163223,0.0000057341704,0.0005261256,0.9899307,0.00014598649],"about_ca_topic_score_codex":0.0000062207305,"about_ca_topic_score_gemma":0.0000036826132,"teacher_disagreement_score":0.9897735,"about_ca_system_score_codex":0.00015768278,"about_ca_system_score_gemma":0.00013798982,"threshold_uncertainty_score":0.86256164},"labels":[],"label_agreement":null},{"id":"W4377077805","doi":"10.1007/978-1-0716-3056-3_1","title":"Cancer Cell Culture: The Basics and Two-Dimensional Cultures","year":2023,"lang":"en","type":"article","venue":"Methods in molecular biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"","keywords":"Psychological intervention; Cancer; Computer science; Engineering ethics; Intervention (counseling); Medicine; Engineering","score_opus":0.04481828783222981,"score_gpt":0.477577311979164,"score_spread":0.4327590241469342,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377077805","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7712709,0.066245645,0.09142244,0.02343868,0.0020023088,0.003747173,0.00007664595,0.0003592593,0.041436967],"genre_scores_gemma":[0.04646948,0.0073272623,0.88666964,0.014909046,0.00080463575,0.00068447145,0.00017240108,0.00017235258,0.0427907],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981776,0.0009041393,0.00016088689,0.000311082,0.00012598712,0.00032030005],"domain_scores_gemma":[0.9993021,0.00026063042,0.000030731622,0.00027527515,0.000060400132,0.00007089224],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012941201,0.00013012155,0.00024052612,0.00006742164,0.000058783262,0.000009436822,0.00012256706,0.00014644633,0.0006039107],"category_scores_gemma":[0.00018895393,0.000076632175,0.00007073929,0.00039253506,0.0002299583,0.000010286837,0.00016093187,0.00035943658,0.000013267678],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000709281,0.000021646492,0.0018435019,0.000016893657,0.000042522992,0.000057681573,0.00037998697,0.000058577018,0.974339,0.0011439639,0.00075776,0.021267544],"study_design_scores_gemma":[0.0024816068,0.00032969576,0.0033712587,0.000034746572,0.000065950546,0.000089622,0.0002699205,0.001763522,0.82449967,0.018924646,0.14791547,0.0002539204],"about_ca_topic_score_codex":0.00023270107,"about_ca_topic_score_gemma":0.000060029553,"teacher_disagreement_score":0.7952472,"about_ca_system_score_codex":0.00005172889,"about_ca_system_score_gemma":0.00006351728,"threshold_uncertainty_score":0.66123986},"labels":[],"label_agreement":null},{"id":"W4377087306","doi":"10.21203/rs.3.rs-2907146/v1","title":"Feasibility of collecting longitudinal patient-reported outcomes in individuals with relapsed or refractory large B-cell lymphoma who received chimeric antigen receptor T-cell (CART) therapy","year":2023,"lang":"en","type":"preprint","venue":"Research Square","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Health Sciences; Juravinski Cancer Centre","funders":"","keywords":"Cart; Medicine; Chimeric antigen receptor; Quality of life (healthcare); Internal medicine; Cohort; Refractory (planetary science); Oncology; Disease; Prospective cohort study; Lymphoma; Immunotherapy; Cancer","score_opus":0.1485487459625802,"score_gpt":0.4187385744424377,"score_spread":0.2701898284798575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377087306","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98461634,0.0013771973,0.000008718394,0.00044781194,0.00027818108,0.009932111,0.00048385139,0.00023608597,0.0026196986],"genre_scores_gemma":[0.9694343,0.006239438,0.0006928431,0.00003218707,0.00016541433,0.0009649572,0.0007491593,0.00038109525,0.02134058],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9851032,0.003032355,0.0020015691,0.0023708672,0.005260707,0.0022312987],"domain_scores_gemma":[0.9898969,0.0029211869,0.0009906334,0.0030622808,0.0024525477,0.0006764442],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.008530177,0.0009235327,0.0026146949,0.0027455776,0.00040985414,0.00017206767,0.000955767,0.001049155,0.0027949265],"category_scores_gemma":[0.0030267457,0.0006963161,0.0005928711,0.0043976987,0.00059842085,0.00016774994,0.0014306046,0.0037980261,0.00008305433],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009884841,0.007948054,0.9495301,0.002478147,0.0007842199,0.0006374198,0.0043293894,0.000023979333,0.017252587,0.0000010570581,0.0024449872,0.0046851933],"study_design_scores_gemma":[0.03428707,0.008089135,0.9151205,0.00355053,0.00007226462,0.000028422164,0.0057447953,0.00016497092,0.027318306,0.00007120638,0.004643864,0.0009089745],"about_ca_topic_score_codex":0.0028998125,"about_ca_topic_score_gemma":0.0008633122,"teacher_disagreement_score":0.034409665,"about_ca_system_score_codex":0.0021710633,"about_ca_system_score_gemma":0.00607384,"threshold_uncertainty_score":0.9995608},"labels":[],"label_agreement":null},{"id":"W4377141625","doi":"10.1016/j.canlet.2023.216242","title":"A costimulatory chimeric antigen receptor targeting TROP2 enhances the cytotoxicity of NK cells expressing a T cell receptor reactive to human papillomavirus type 16 E7","year":2023,"lang":"en","type":"article","venue":"Cancer Letters","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; Institute of Cancer Research; University of Calgary","funders":"","keywords":"T-cell receptor; Cytotoxic T cell; Antigen; Chimeric antigen receptor; Biology; Adoptive cell transfer; CD8; Cancer research; T cell; CD28; Cancer immunotherapy; Immunotherapy; CD3; Immunology; Immune system","score_opus":0.035026598577599696,"score_gpt":0.3340917778599455,"score_spread":0.29906517928234577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377141625","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951731,0.00074948306,0.000053629563,0.0014967636,0.00047328684,0.00090004265,0.000036994927,0.000091022484,0.0010256965],"genre_scores_gemma":[0.99194,0.000585663,0.00045231413,0.0041093836,0.0008733583,0.00014328083,0.000061196,0.00008218252,0.0017526004],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975956,0.00028031218,0.00036853796,0.0005100483,0.00066703255,0.00057843304],"domain_scores_gemma":[0.99871194,0.0002523107,0.0001894844,0.00051190576,0.00016390922,0.00017042123],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00055803143,0.00025254217,0.0004751199,0.00019147554,0.00022277216,0.000044129793,0.0003274936,0.000090228365,0.0024148286],"category_scores_gemma":[0.00007955268,0.00020026468,0.00016971157,0.0009806013,0.00019897101,0.00009621914,0.00009473324,0.00043439455,0.00017158636],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037870853,0.000063999396,0.0008908198,0.00012638728,0.000090043744,0.000018473222,0.003491803,0.00007269224,0.918468,7.539868e-7,0.074847326,0.0015510194],"study_design_scores_gemma":[0.00069043227,0.00021794914,0.0012351106,0.00026743548,0.000033829037,0.0000011208988,0.001024179,0.000017533688,0.95239884,0.0000015274298,0.043903735,0.00020831014],"about_ca_topic_score_codex":0.00036174047,"about_ca_topic_score_gemma":0.000009619132,"teacher_disagreement_score":0.03393086,"about_ca_system_score_codex":0.00037305354,"about_ca_system_score_gemma":0.00017146788,"threshold_uncertainty_score":0.9984971},"labels":[],"label_agreement":null},{"id":"W4377195778","doi":"10.1111/bjh.18863","title":"Granulocyte transfusion during cord blood transplant for relapsed, refractory <scp>AML</scp> is associated with massive <scp>CD8</scp><sup>+</sup> T‐cell expansion, significant cytokine release syndrome and induction of disease remission","year":2023,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Children's Cancer and Leukaemia Group","keywords":"Medicine; Cytokine release syndrome; Internal medicine; Immunology; Hematopoietic stem cell transplantation; Gastroenterology; Transplantation; T cell; Immune system","score_opus":0.015426651381661008,"score_gpt":0.24959361001121064,"score_spread":0.23416695862954962,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377195778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955977,0.0021846755,0.00016345465,0.00038488448,0.00013978315,0.0011098426,0.00029757927,0.00007407756,0.000048011385],"genre_scores_gemma":[0.9851199,0.01273008,0.00016670491,0.00006516885,0.00009714052,0.000039735056,0.00014612229,0.00012051029,0.0015146546],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9959674,0.00042321504,0.0012596914,0.0005946043,0.0010035639,0.00075153576],"domain_scores_gemma":[0.9960708,0.0012036958,0.00078697776,0.0003266704,0.0008093263,0.00080255116],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009885607,0.00037243692,0.0014476471,0.00073536066,0.0002967848,0.000040269566,0.00022644193,0.0004187742,0.00007478133],"category_scores_gemma":[0.0012604812,0.00035530253,0.0003654754,0.0007281544,0.0003391834,0.00025682597,0.000040576877,0.0010636369,0.000003261265],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061786463,0.0019554526,0.010607509,0.0033190846,0.0011528771,0.13932166,0.002992288,0.0002133925,0.82612926,0.000007895812,0.0046697888,0.003452128],"study_design_scores_gemma":[0.07034433,0.016865352,0.10256587,0.020171598,0.004955796,0.29991007,0.007580015,0.001578381,0.4724199,0.00057814067,0.0025130413,0.0005175149],"about_ca_topic_score_codex":0.00007992904,"about_ca_topic_score_gemma":0.000015954005,"teacher_disagreement_score":0.3537094,"about_ca_system_score_codex":0.00013126989,"about_ca_system_score_gemma":0.00048264812,"threshold_uncertainty_score":0.9998899},"labels":[],"label_agreement":null},{"id":"W4377861121","doi":"10.1016/j.jaut.2023.103057","title":"Supraphysiological FOXP3 expression in human CAR-Tregs results in improved stability, efficacy, and safety of CAR-Treg products for clinical application","year":2023,"lang":"en","type":"article","venue":"Journal of Autoimmunity","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"FOXP3; Regulatory T cell; Immunology; Immune system; Autoimmunity; Effector; Biology; Cancer research; T cell; IL-2 receptor","score_opus":0.10417332569156208,"score_gpt":0.41640065756241457,"score_spread":0.3122273318708525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377861121","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99719155,0.00020830595,0.000016576478,0.0010201253,0.00007834321,0.0013406686,0.0000242635,0.000018958166,0.00010121717],"genre_scores_gemma":[0.9985597,0.0006611909,0.00041954382,0.000016067337,0.00013173766,0.000019214953,0.000051282583,0.000019134477,0.00012211222],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99666744,0.0007071806,0.0016427273,0.0002990246,0.0003731829,0.000310447],"domain_scores_gemma":[0.9967793,0.0014890736,0.00055809,0.0005769852,0.00048565774,0.00011084385],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0073903524,0.0001581061,0.0008413287,0.00038089242,0.000072284114,0.000011097172,0.00025644928,0.00023179608,0.000020047568],"category_scores_gemma":[0.003044856,0.000120675584,0.00017558331,0.00071045186,0.00029868755,0.000106115265,0.00019195314,0.0010611997,7.317004e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012338382,0.0010967148,0.03034418,0.00021978414,0.000038015532,0.000009805715,0.0008964667,0.000014296733,0.939384,0.000007941742,0.00018346541,0.015466948],"study_design_scores_gemma":[0.011805646,0.0024757283,0.93164,0.00029034162,0.00002547245,0.000013490123,0.00058264926,0.00034949454,0.051473293,0.0002820403,0.00095787155,0.00010392176],"about_ca_topic_score_codex":0.00013995019,"about_ca_topic_score_gemma":0.00008193565,"teacher_disagreement_score":0.9012959,"about_ca_system_score_codex":0.00015209125,"about_ca_system_score_gemma":0.00026729552,"threshold_uncertainty_score":0.49210078},"labels":[],"label_agreement":null},{"id":"W4378952773","doi":"10.1111/bjh.18900","title":"Genome‐wide <scp>CRISPR</scp> screening uncovers potential targets and mechanisms of vincristine resistance in <scp>DLBCL</scp>","year":2023,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Vincristine; CRISPR; Drug resistance; Cancer research; Biology; Medicine; Cell cycle checkpoint; Computational biology; Apoptosis; Bioinformatics; Cell cycle; Internal medicine; Genetics; Chemotherapy; Gene","score_opus":0.015495743719001967,"score_gpt":0.27458812039269387,"score_spread":0.2590923766736919,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378952773","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9810472,0.008622298,0.007817121,0.00055474037,0.0003096772,0.00037022497,0.000038547743,0.00003821815,0.0012019366],"genre_scores_gemma":[0.98773605,0.0036986964,0.0049222317,0.00022941809,0.0001662705,0.000009296496,0.000027663737,0.00007942543,0.003130924],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9964727,0.00033390045,0.0011626286,0.00038114993,0.0008427784,0.0008068493],"domain_scores_gemma":[0.9971629,0.0011720028,0.0005767345,0.0002495615,0.00048390887,0.00035489674],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018638539,0.00023975915,0.0013167361,0.00081480277,0.00011703438,0.000051601037,0.00032024537,0.00026339706,0.000118315664],"category_scores_gemma":[0.0038054432,0.0002782294,0.0002350266,0.000775897,0.00029984824,0.00017973188,0.00019534782,0.00091617584,0.00001328873],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009583322,0.0009478473,0.035955146,0.0024348607,0.0015155493,0.47933868,0.002173326,0.00045172113,0.41164777,0.0018887122,0.05559775,0.007090309],"study_design_scores_gemma":[0.038884945,0.003357628,0.33009353,0.0057762726,0.00074184756,0.3976549,0.015029029,0.0009803731,0.11057875,0.03591935,0.060560524,0.00042284714],"about_ca_topic_score_codex":0.0001950126,"about_ca_topic_score_gemma":0.00039859593,"teacher_disagreement_score":0.30106902,"about_ca_system_score_codex":0.00009791547,"about_ca_system_score_gemma":0.0002559436,"threshold_uncertainty_score":0.999967},"labels":[],"label_agreement":null},{"id":"W4379185221","doi":"10.2196/45872","title":"Creating an Innovative Artificial Intelligence–Based Technology (TCRact) for Designing and Optimizing T Cell Receptors for Use in Cancer Immunotherapies: Protocol for an Observational Trial","year":2023,"lang":"en","type":"article","venue":"JMIR Research Protocols","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"European Regional Development Fund","keywords":"T-cell receptor; Immunotherapy; Medicine; Observational study; Colorectal cancer; Cancer immunotherapy; Clinical trial; Oncology; Cancer; Internal medicine; Bioinformatics; Immune system; Immunology; T cell; Biology","score_opus":0.6942350076305847,"score_gpt":0.624114053398265,"score_spread":0.07012095423231968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379185221","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.020075258,8.277209e-7,0.009812431,0.00059398083,0.0000131015095,0.9692489,0.00006356213,0.00016425173,0.000027699376],"genre_scores_gemma":[0.0005375956,4.3453917e-7,0.06889607,0.00005338613,0.0004006997,0.92937243,0.00012602215,0.00013168193,0.00048167407],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99591947,0.00040863254,0.00087582227,0.00087472954,0.0007377204,0.0011836545],"domain_scores_gemma":[0.99387777,0.0030111293,0.00021224181,0.0004943218,0.0022260703,0.00017849314],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.006264996,0.0002903758,0.00053756766,0.00167924,0.0005627537,0.0003209548,0.00037076528,0.000375321,0.0002042568],"category_scores_gemma":[0.0020339326,0.00026870688,0.000098679615,0.0029240958,0.00037328142,0.0005768358,0.000099335935,0.00075897505,0.0000020149273],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26726878,0.0018187863,0.0014698183,0.0020718093,0.000057963774,0.0000047296307,0.00216773,0.00029321577,0.5959851,0.00088848866,0.0005115604,0.12746201],"study_design_scores_gemma":[0.08056249,0.04644522,0.00016503719,0.0035379112,0.000006434026,0.0000017574076,0.0046965266,0.10364217,0.6766757,0.00741139,0.076187454,0.0006679126],"about_ca_topic_score_codex":0.00008883737,"about_ca_topic_score_gemma":0.000117862975,"teacher_disagreement_score":0.1867063,"about_ca_system_score_codex":0.0004852955,"about_ca_system_score_gemma":0.0017659542,"threshold_uncertainty_score":0.9999765},"labels":[],"label_agreement":null},{"id":"W4379281047","doi":"10.1200/jco.2023.41.16_suppl.8537","title":"Phase 1 trial of gavocabtagene autoleucel (gavo-cel, TC-210) in patients (pts) with treatment refractory mesothelioma and other mesothelin-expressing solid tumors.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Mesothelin; Medicine; Mesothelioma; Cancer research; Oncology; Ovarian cancer; Internal medicine; Cancer; Gastroenterology; Immunology; Pathology","score_opus":0.1679472589828233,"score_gpt":0.5078129524008199,"score_spread":0.3398656934179966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281047","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958021,0.00023694399,0.000014170055,0.00093184056,0.0004188254,0.0006849795,0.000015948173,0.000017921198,0.001877264],"genre_scores_gemma":[0.995262,0.00085067586,0.0007237453,0.00046442426,0.00094408344,0.000015606647,0.000004834756,0.000065855136,0.001668774],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99472696,0.0008741756,0.0028487775,0.0003276862,0.0007907442,0.00043164307],"domain_scores_gemma":[0.9948467,0.002246776,0.0017585319,0.00035040206,0.0003459749,0.00045163438],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041271714,0.00024608427,0.0023946974,0.00057630864,0.00004241909,0.000014254159,0.00018307885,0.00037218296,0.0005448939],"category_scores_gemma":[0.0014141959,0.00015764423,0.0003755761,0.00039286003,0.00041944362,0.000104428094,0.00006567668,0.0007961294,0.000015384307],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44197443,0.025732752,0.03387544,0.00008055943,0.0009469735,0.0015352076,0.0008973098,0.00002472227,0.024966778,0.000010016469,0.0010821806,0.46887365],"study_design_scores_gemma":[0.6379598,0.24207427,0.03300424,0.0005868001,0.00044557932,0.0001452396,0.00034197568,0.0005073417,0.0056631197,0.00012483083,0.07888478,0.00026205063],"about_ca_topic_score_codex":0.000053362328,"about_ca_topic_score_gemma":0.000034799734,"teacher_disagreement_score":0.4686116,"about_ca_system_score_codex":0.0003407625,"about_ca_system_score_gemma":0.0017344638,"threshold_uncertainty_score":0.6428545},"labels":[],"label_agreement":null},{"id":"W4379281157","doi":"10.1200/jco.2023.41.16_suppl.8003","title":"Talquetamab (tal) + daratumumab (dara) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated TRIMM-2 results.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":63,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary; Princess Margaret Cancer Centre","funders":"Janssen Research and Development","keywords":"Medicine; Daratumumab; Internal medicine; Refractory (planetary science); CD38; Oncology; Tolerability; Gastroenterology; Proteasome inhibitor; Lenalidomide; Multiple myeloma; Adverse effect; CD34","score_opus":0.1027499321914212,"score_gpt":0.4408975407525841,"score_spread":0.3381476085611629,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281157","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.984054,0.000107849395,0.0000098295895,0.004347916,0.0012569732,0.0006069799,0.00002278311,0.000049281192,0.009544353],"genre_scores_gemma":[0.9913082,0.00053487293,0.0005629877,0.00085575273,0.0007926479,0.000009653102,0.00009570947,0.00006748085,0.005772686],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99277025,0.0011301964,0.0037057898,0.00047457067,0.0012526205,0.0006665859],"domain_scores_gemma":[0.99223775,0.0038267232,0.001762348,0.0005585922,0.000954899,0.000659688],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.006891201,0.00027722443,0.0020930343,0.0007391335,0.00007342294,0.00002066575,0.00041203966,0.0007779043,0.000529738],"category_scores_gemma":[0.008776086,0.00019397547,0.00049737754,0.001169497,0.0004301819,0.00024040726,0.00014330263,0.0034354732,0.00023939017],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19995457,0.008048778,0.29590532,0.00005450675,0.0008662594,0.0068422835,0.00041699328,0.00008307042,0.0022096168,0.000019485753,0.053941302,0.43165782],"study_design_scores_gemma":[0.07580209,0.03203242,0.5981579,0.00015325386,0.00010947801,0.00013157271,0.00015152083,0.00026730006,0.00021396698,0.000050669052,0.29275507,0.00017477534],"about_ca_topic_score_codex":0.00005152814,"about_ca_topic_score_gemma":0.0002367697,"teacher_disagreement_score":0.43148306,"about_ca_system_score_codex":0.0006162488,"about_ca_system_score_gemma":0.0025605417,"threshold_uncertainty_score":0.9995734},"labels":[],"label_agreement":null},{"id":"W4379281765","doi":"10.1200/jco.2023.41.16_suppl.7550","title":"Glofitamab monotherapy in pts with relapsed/refractory (R/R) large B-cell lymphoma (LBCL): Extended follow-up and landmark analyses from a pivotal phase II study.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Refractory (planetary science); Post-hoc analysis; Regimen; Phases of clinical research; Nuclear medicine; Clinical endpoint; Internal medicine; Toxicity; Urology; Surgery; Clinical trial","score_opus":0.14952030056499643,"score_gpt":0.5083827260818493,"score_spread":0.3588624255168529,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281765","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949997,0.0009923094,0.000035352106,0.0016193244,0.0006162546,0.0005431761,0.000016765587,0.000029734709,0.0011473639],"genre_scores_gemma":[0.99216354,0.0021380582,0.00047079573,0.00074134074,0.00078876433,0.000015415606,0.000012409677,0.0000536898,0.0036160043],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99497753,0.0011005785,0.0021069977,0.00045377138,0.00083465717,0.00052645575],"domain_scores_gemma":[0.9938801,0.0038491616,0.0009816013,0.00039872996,0.00031644455,0.0005739899],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004837918,0.0002697906,0.0021655292,0.00055032433,0.00009429014,0.000023899705,0.00025849725,0.00043105482,0.0007118282],"category_scores_gemma":[0.0013296729,0.0001821896,0.0004224233,0.0006810144,0.00021152431,0.00016735135,0.00013127214,0.0011980683,0.000024714835],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17426562,0.06614592,0.21556999,0.000038429454,0.002462871,0.017327044,0.002952576,0.000005679735,0.018821718,0.000006629813,0.0061441376,0.4962594],"study_design_scores_gemma":[0.40237117,0.13748512,0.40068352,0.00015750343,0.00058307976,0.0002311549,0.0030442658,0.0005306962,0.00035576278,0.0002116675,0.054058224,0.00028782195],"about_ca_topic_score_codex":0.00019028231,"about_ca_topic_score_gemma":0.0007965136,"teacher_disagreement_score":0.49597156,"about_ca_system_score_codex":0.0002498033,"about_ca_system_score_gemma":0.0015206675,"threshold_uncertainty_score":0.7794019},"labels":[],"label_agreement":null},{"id":"W4379281880","doi":"10.1200/jco.2023.41.16_suppl.tps7586","title":"SUNMO: A phase III trial evaluating the efficacy and safety of mosunetuzumab in combination with polatuzumab vedotin vs rituximab plus gemcitabine and oxaliplatin in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Rituximab; Internal medicine; Oncology; Gemcitabine; Phases of clinical research; Antibody-drug conjugate; Diffuse large B-cell lymphoma; Oxaliplatin; Refractory (planetary science); Lymphoma; Gastroenterology; Clinical trial; Chemotherapy; Cancer; Antibody; Immunology; Monoclonal antibody; Colorectal cancer","score_opus":0.0704012691811073,"score_gpt":0.44661518105052217,"score_spread":0.3762139118694149,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379281880","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965983,0.0002413114,0.000016095273,0.0009792291,0.00024921782,0.0016726098,0.000005547155,0.000007397646,0.0002302908],"genre_scores_gemma":[0.9985871,0.00040926042,0.00044295425,0.00012958069,0.00019779797,0.00001684141,0.000016145239,0.000035559606,0.00016476837],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9945282,0.0013044515,0.0024901857,0.0003331727,0.0009777432,0.00036624484],"domain_scores_gemma":[0.9885821,0.0077494946,0.002614143,0.00026880324,0.0005490532,0.00023643019],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006940499,0.00022382452,0.0018675104,0.00046366843,0.00007054705,0.000016270955,0.00018124294,0.00034287223,0.00006568875],"category_scores_gemma":[0.004132876,0.00013456627,0.00011777189,0.00070765644,0.00052092917,0.00015777432,0.00011496685,0.0012669452,0.0000018429891],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7951437,0.008363641,0.039100613,0.00007210707,0.00019946191,0.0003596518,0.0014504403,0.00011205096,0.00048084874,0.0000092414775,0.00007964517,0.15462856],"study_design_scores_gemma":[0.5783959,0.10828539,0.3085821,0.00043532674,0.00014573708,0.000040192914,0.00030366765,0.0034209762,0.00003242439,0.00003840214,0.00021869756,0.00010117316],"about_ca_topic_score_codex":0.00011235308,"about_ca_topic_score_gemma":0.0001589423,"teacher_disagreement_score":0.26948148,"about_ca_system_score_codex":0.00046638233,"about_ca_system_score_gemma":0.0024144154,"threshold_uncertainty_score":0.55043167},"labels":[],"label_agreement":null},{"id":"W4379283040","doi":"10.1200/jco.2023.41.16_suppl.2519","title":"A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Chimeric antigen receptor; Breast cancer; Immunotherapy; Cancer; Cancer research; Leukapheresis; T cell; Oncology; Internal medicine; Immunology; Immune system; Stem cell; CD34","score_opus":0.2245488059784758,"score_gpt":0.54106261968792,"score_spread":0.3165138137094442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283040","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99157685,0.00014105109,0.00000615804,0.005546326,0.0007866855,0.00053036277,0.0000037711284,0.00002092845,0.0013878448],"genre_scores_gemma":[0.9937527,0.00097072934,0.0010771508,0.0007368769,0.0014227533,0.000005139744,0.000004103916,0.000032939166,0.0019975798],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9932646,0.0012602073,0.0042677517,0.00026022195,0.000561495,0.00038572683],"domain_scores_gemma":[0.9855097,0.011317888,0.0020599363,0.0002639398,0.00030898582,0.0005395596],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.011668635,0.00015768319,0.0025142627,0.00043863617,0.00005729997,0.000006124189,0.00020753357,0.00053318375,0.0005794711],"category_scores_gemma":[0.04261397,0.000109481014,0.0003651439,0.0006164806,0.0006401785,0.000068828915,0.00015734257,0.0022523727,0.000009940634],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44985962,0.007401102,0.0025802823,0.000087043714,0.00031881596,0.0036984275,0.0008790796,0.00002487777,0.018109145,0.000030167252,0.0023341684,0.5146773],"study_design_scores_gemma":[0.60847855,0.2701399,0.058193456,0.0006564194,0.00024827546,0.0008260886,0.0005517745,0.0015584581,0.00069624186,0.0003630169,0.058082785,0.00020501205],"about_ca_topic_score_codex":0.000030506184,"about_ca_topic_score_gemma":0.000050833343,"teacher_disagreement_score":0.51447225,"about_ca_system_score_codex":0.0001910044,"about_ca_system_score_gemma":0.0037389807,"threshold_uncertainty_score":0.97855633},"labels":[],"label_agreement":null},{"id":"W4379283399","doi":"10.1200/jco.2023.41.16_suppl.tps2671","title":"Trial START-001: A phase 1/2 study of STAR0602, a first-in-class, selective T cell receptor (TCR)-targeting, bifunctional antibody-fusion molecule, as monotherapy in patients with antigen-rich tumors post checkpoint inhibitor (CPI) treatment.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Tolerability; T-cell receptor; CD8; Antigen; Immunology; Cytokine release syndrome; Cancer research; T cell; Pharmacology; Oncology; Internal medicine; Immune system; Chimeric antigen receptor; Adverse effect","score_opus":0.057827630948723535,"score_gpt":0.43414341595895894,"score_spread":0.37631578501023544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283399","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99516594,0.000081251725,0.0000037044585,0.0009027962,0.00073104474,0.0027111073,0.000026777743,0.000019270046,0.000358115],"genre_scores_gemma":[0.9974018,0.00076499063,0.00021635636,0.00018723155,0.0007382478,0.00004303924,0.000084753665,0.00006775049,0.0004958467],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99294084,0.0012587,0.0033788823,0.0005413994,0.001300068,0.00058008643],"domain_scores_gemma":[0.9941689,0.0020393792,0.0018734825,0.000286087,0.0012255863,0.00040657833],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0037161252,0.00035292332,0.0022627534,0.0010497774,0.00007517233,0.00001575048,0.00021284369,0.00038276357,0.0013555308],"category_scores_gemma":[0.0017050891,0.00024665083,0.0003896279,0.0014069012,0.00019649054,0.00015724785,0.00007034163,0.0013474617,0.00003574732],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.54294515,0.07703579,0.35097376,0.000033779324,0.0005773166,0.00081942487,0.0015130857,0.00010513005,0.01623584,8.430467e-7,0.001047295,0.008712606],"study_design_scores_gemma":[0.42255232,0.34737232,0.22070044,0.0001479395,0.00010988558,0.000011251054,0.001190309,0.00017326046,0.0025861945,0.000012931807,0.0049405205,0.00020261153],"about_ca_topic_score_codex":0.00055535807,"about_ca_topic_score_gemma":0.0004976713,"teacher_disagreement_score":0.27033654,"about_ca_system_score_codex":0.0008827131,"about_ca_system_score_gemma":0.002850479,"threshold_uncertainty_score":0.99999857},"labels":[],"label_agreement":null},{"id":"W4379283750","doi":"10.1200/jco.2023.41.16_suppl.2062","title":"Efficacy of function-enhanced, re-activatable, dual-specific CAR T cells pre-loaded with oncolytic virus for immunotherapy of high-grade glioma.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Oncolytics Biotech (Canada)","funders":"","keywords":"Chimeric antigen receptor; Oncolytic virus; Cancer research; Medicine; Glioma; Immunotherapy; Immune system; Antigen; Population; T cell; CD8; Cytotoxic T cell; Epitope; Tumor microenvironment; Immunology; Biology; In vitro","score_opus":0.12369999698428902,"score_gpt":0.4475433971989874,"score_spread":0.3238434002146984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379283750","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930684,0.00048908027,0.001750851,0.0014738283,0.0014348159,0.0011143488,0.000025573756,0.000026954067,0.00061616744],"genre_scores_gemma":[0.99075407,0.0021905764,0.0028098463,0.00023598963,0.0014012046,0.000031234504,0.0000112096695,0.000081470855,0.0024843935],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9946211,0.0004855726,0.0031222228,0.00035190803,0.0009328928,0.00048633528],"domain_scores_gemma":[0.98665285,0.008817645,0.0025364487,0.0005770146,0.001072776,0.00034326242],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004014387,0.0002475168,0.0025885366,0.0005218102,0.000058702353,0.000009936345,0.0003053508,0.0005153071,0.0010341804],"category_scores_gemma":[0.0010658292,0.00017604283,0.00079831743,0.000999487,0.0005522323,0.00010703079,0.000055615263,0.001151873,0.000018422877],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11131609,0.0027567595,0.00022741765,0.0001274324,0.0014331321,0.00017090802,0.00028529324,0.00059904705,0.8237289,0.000049192025,0.005441257,0.053864546],"study_design_scores_gemma":[0.07147487,0.08569822,0.05080511,0.0004662831,0.00057006016,0.00018479387,0.0005568816,0.0001524575,0.64370364,0.0004995709,0.1455906,0.0002975103],"about_ca_topic_score_codex":0.00008760691,"about_ca_topic_score_gemma":0.000026265276,"teacher_disagreement_score":0.18002528,"about_ca_system_score_codex":0.00026268684,"about_ca_system_score_gemma":0.0019958103,"threshold_uncertainty_score":0.999879},"labels":[],"label_agreement":null},{"id":"W4379330790","doi":"10.1200/jco.2023.41.16_suppl.tps7592","title":"Phase 3 trial of subcutaneous epcoritamab + R-CHOP versus R-CHOP in patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL): EPCORE DLBCL-2.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Medicine; Rituximab; Diffuse large B-cell lymphoma; Internal medicine; Vincristine; Cytokine release syndrome; CHOP; Oncology; Prednisone; Phases of clinical research; International Prognostic Index; Cyclophosphamide; Lymphoma; Gastroenterology; Discontinuation; CD20; Clinical trial; Chemotherapy; Cancer; Immunotherapy","score_opus":0.10362165935719093,"score_gpt":0.45996181553981313,"score_spread":0.3563401561826222,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379330790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99192995,0.00011644192,0.000014146335,0.001094361,0.0030889525,0.0011217552,0.00003697151,0.000030660456,0.0025667679],"genre_scores_gemma":[0.99484086,0.0013321264,0.00031728018,0.00039954073,0.0015560895,0.00002089182,0.000027758833,0.00008077352,0.0014246689],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9923208,0.001058075,0.0037837415,0.0004670499,0.0015273333,0.0008430157],"domain_scores_gemma":[0.9859727,0.009593224,0.002105987,0.0005991649,0.00088991644,0.00083899853],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004714005,0.00034204352,0.0028003163,0.00069578417,0.000057911315,0.000019420459,0.0005052816,0.00075592566,0.0004920367],"category_scores_gemma":[0.0074156285,0.00025059504,0.00083530654,0.0010283098,0.0003655881,0.00015843015,0.00015845636,0.0015304429,0.000093917886],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.680355,0.12140177,0.015737051,0.000071281924,0.00043270274,0.011401039,0.00028896163,0.000005941582,0.0003164162,0.000016612486,0.0034167797,0.16655646],"study_design_scores_gemma":[0.777863,0.16929454,0.015787352,0.0001386444,0.0002944992,0.00012290047,0.00030096312,0.00017027558,0.000087184286,0.000039478156,0.03570944,0.00019170449],"about_ca_topic_score_codex":0.00005986014,"about_ca_topic_score_gemma":0.00015069662,"teacher_disagreement_score":0.16636476,"about_ca_system_score_codex":0.0005805387,"about_ca_system_score_gemma":0.0027930934,"threshold_uncertainty_score":0.99999464},"labels":[],"label_agreement":null},{"id":"W4379334167","doi":"10.1200/jco.2023.41.16_suppl.e14531","title":"The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly ADP-A2M4]): Pooled analysis of cytokine release syndrome across cohorts in patients with advanced synovial sarcoma.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Synovial sarcoma; Cohort; Internal medicine; Sarcoma; Cytokine release syndrome; Fludarabine; Gastroenterology; Oncology; Surgery; Cyclophosphamide; Chemotherapy; Cancer; Pathology; Immunotherapy; Chimeric antigen receptor","score_opus":0.060239172461123786,"score_gpt":0.4539872028012736,"score_spread":0.3937480303401498,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379334167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964953,0.0001653716,0.000018582714,0.0013465654,0.00068074657,0.00090381224,0.000054279626,0.000013690675,0.00032164427],"genre_scores_gemma":[0.9976663,0.00090638665,0.0003352915,0.00014050219,0.0002465043,0.000013164562,0.00003144774,0.000039611004,0.00062079413],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9917185,0.0010011122,0.0045935786,0.00036004637,0.0016648332,0.00066196994],"domain_scores_gemma":[0.9893608,0.0053388495,0.003040616,0.00064774655,0.0011545958,0.0004573977],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008179289,0.0002555761,0.0036281543,0.0007217112,0.00007455484,0.000013110235,0.0004905053,0.00043742015,0.00020657881],"category_scores_gemma":[0.005045153,0.00015489769,0.0011422168,0.0025550982,0.0007493143,0.00013560103,0.00015247698,0.0014546335,0.000009505285],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4654973,0.006387127,0.3398898,0.00006868944,0.007290996,0.0013315198,0.00021678754,0.00071440917,0.0018500816,0.000015341288,0.00026611972,0.17647187],"study_design_scores_gemma":[0.12367968,0.04996077,0.8206858,0.00015396894,0.0019141043,0.0000313807,0.00020318557,0.00051282113,0.00016796886,0.000044776883,0.0025143484,0.00013117405],"about_ca_topic_score_codex":0.00010250751,"about_ca_topic_score_gemma":0.00046499388,"teacher_disagreement_score":0.48079604,"about_ca_system_score_codex":0.0002985064,"about_ca_system_score_gemma":0.0019374435,"threshold_uncertainty_score":0.631974},"labels":[],"label_agreement":null},{"id":"W4379341611","doi":"10.1200/jco.2023.41.16_suppl.8008","title":"Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MagnetisMM studies.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"Pfizer","keywords":"Medicine; Internal medicine; Refractory (planetary science); Multiple myeloma; Adverse effect; Surgery; Gastroenterology; Oncology","score_opus":0.05691125985349645,"score_gpt":0.40425127325656196,"score_spread":0.34734001340306553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379341611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995839,0.002234191,0.000015422873,0.0010927974,0.00015955362,0.000529005,0.000016407928,0.000017191549,0.00009641161],"genre_scores_gemma":[0.9889269,0.0090521015,0.0014172025,0.00017061643,0.00014370975,0.0000037713708,0.000029805242,0.000022660492,0.00023324392],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99621475,0.00077600626,0.0019019285,0.00030352856,0.00056224194,0.00024152025],"domain_scores_gemma":[0.9917636,0.005977537,0.0011686311,0.00024270006,0.0006211295,0.00022639922],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002357609,0.00017241576,0.00190084,0.0005817469,0.000045748184,0.000009900868,0.00011891303,0.0003192432,0.0002075538],"category_scores_gemma":[0.002545183,0.00011652311,0.00020423876,0.0009206145,0.0003365932,0.00011292446,0.00008095159,0.0008501547,0.0000030167241],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0651968,0.0017919567,0.6755541,0.000051869825,0.004116849,0.00019704022,0.0016253135,0.000016625785,0.0027559863,7.895014e-7,0.0002946577,0.248398],"study_design_scores_gemma":[0.04373744,0.009197646,0.9425158,0.00012347054,0.0009887614,0.0000042563897,0.00056475407,0.0004674442,0.00008273834,0.000024660403,0.0021925592,0.0001004901],"about_ca_topic_score_codex":0.000085784115,"about_ca_topic_score_gemma":0.00030018805,"teacher_disagreement_score":0.2669617,"about_ca_system_score_codex":0.00012126403,"about_ca_system_score_gemma":0.0004095609,"threshold_uncertainty_score":0.47516742},"labels":[],"label_agreement":null},{"id":"W4379345563","doi":"10.1200/jco.2023.41.16_suppl.11563","title":"The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly ADP-A2M4]): Analysis of overall survival in advanced synovial sarcoma.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Synovial sarcoma; Internal medicine; Cohort; Oncology; Sarcoma; Interim analysis; Clinical endpoint; Fludarabine; Progression-free survival; Surgery; Gastroenterology; Cyclophosphamide; Chemotherapy; Clinical trial; Pathology","score_opus":0.1710643192867094,"score_gpt":0.5202117515068317,"score_spread":0.34914743222012234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379345563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98884755,0.0003874303,0.0000301298,0.004184115,0.0017884098,0.00049042195,0.000016064996,0.000011803162,0.004244089],"genre_scores_gemma":[0.9913886,0.0044645197,0.00046133352,0.0001840293,0.0010160931,0.000007693459,0.000010889123,0.000032037206,0.002434773],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9912404,0.0015172703,0.0049704476,0.00029424843,0.0014243143,0.00055332785],"domain_scores_gemma":[0.9839119,0.011901736,0.0025133719,0.0005548166,0.00075912545,0.00035910163],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014530582,0.00020709712,0.0033843399,0.00096666324,0.000048904676,0.00001059256,0.0005586405,0.00048041684,0.00044503616],"category_scores_gemma":[0.0079656625,0.00013454809,0.0018488417,0.0019632932,0.00058094,0.00010645636,0.00015102154,0.00157451,0.0000147535875],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4418058,0.005196823,0.073300324,0.00008124348,0.0072003095,0.00083068165,0.00033423188,0.0009887993,0.026436057,0.00033171524,0.0014950939,0.4419989],"study_design_scores_gemma":[0.16009101,0.04190423,0.74787337,0.00013950258,0.0021051727,0.000028517008,0.00056206324,0.0032330323,0.0007668446,0.00057375885,0.042516988,0.0002055319],"about_ca_topic_score_codex":0.00017784466,"about_ca_topic_score_gemma":0.0008795487,"teacher_disagreement_score":0.674573,"about_ca_system_score_codex":0.0002561319,"about_ca_system_score_gemma":0.00274757,"threshold_uncertainty_score":0.9536218},"labels":[],"label_agreement":null},{"id":"W4379375856","doi":"10.1056/nejmoa2301665","title":"Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma","year":2023,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":410,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; University of British Columbia; Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"Gilead Sciences","keywords":"Medicine; Chemoimmunotherapy; Hazard ratio; Internal medicine; Confidence interval; Lymphoma; Oncology; Transplantation; Autologous stem-cell transplantation; Survival analysis; Surgery; Rituximab","score_opus":0.03199120473262039,"score_gpt":0.31318210441992306,"score_spread":0.28119089968730265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379375856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9749553,0.0010147885,0.00017738754,0.0105200615,0.00044251367,0.00019689802,0.000002540532,0.000028979837,0.012661539],"genre_scores_gemma":[0.97527057,0.0014609845,0.00014208978,0.00044377745,0.0037696725,0.000001822025,0.000012870699,0.000043292737,0.018854909],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99749553,0.00014093872,0.0005387116,0.00017493212,0.0011848109,0.00046509376],"domain_scores_gemma":[0.99852055,0.00034007375,0.00017117354,0.00025459786,0.00021180742,0.00050177565],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0026448385,0.00017767612,0.00067937816,0.000683429,0.00003604716,0.000008979968,0.00017887018,0.00008161392,0.0018358431],"category_scores_gemma":[0.0002637016,0.00010707002,0.000077133,0.0009764982,0.000092032504,0.00006733509,0.000035706733,0.0004463858,0.000042559845],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020377228,0.0015732731,0.16175105,0.00035262134,0.0004349058,0.02290768,0.006344575,0.000077978184,0.21479994,0.00015696562,0.042150505,0.5290733],"study_design_scores_gemma":[0.482251,0.008257372,0.13267823,0.0011462374,0.00018751368,0.0030839143,0.0018279495,0.0003206374,0.006318482,0.00026847704,0.36338925,0.0002709566],"about_ca_topic_score_codex":0.00013369726,"about_ca_topic_score_gemma":0.0001620758,"teacher_disagreement_score":0.52880234,"about_ca_system_score_codex":0.00011999544,"about_ca_system_score_gemma":0.0004840865,"threshold_uncertainty_score":0.9990766},"labels":[],"label_agreement":null},{"id":"W4379375986","doi":"10.1056/nejmoa2303379","title":"Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma","year":2023,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":733,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Janssen Research and Development","keywords":"Lenalidomide; Multiple myeloma; Refractory (planetary science); Standard of care; Medicine; Internal medicine; Oncology; Biology; Astrobiology","score_opus":0.0463347515928686,"score_gpt":0.3503627163535822,"score_spread":0.3040279647607136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379375986","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98099947,0.0037049686,0.00007307681,0.010537922,0.0008796266,0.00038161108,0.000010342678,0.000044649947,0.0033683332],"genre_scores_gemma":[0.9802246,0.003126203,0.00023454598,0.00049035496,0.005864019,0.0000037928944,0.000021787939,0.000054585013,0.009980117],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99694014,0.00018548353,0.00081090175,0.00020319546,0.0014057854,0.00045451443],"domain_scores_gemma":[0.9974999,0.0009403994,0.00022861043,0.0002981931,0.00047158482,0.0005613175],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020605803,0.00021267413,0.00088183885,0.00089841604,0.00004926935,0.000012877957,0.00021640364,0.00012317936,0.004112072],"category_scores_gemma":[0.002297341,0.00012695557,0.00012887301,0.0008456879,0.00014152398,0.000102630336,0.000047312635,0.0009529152,0.00003313168],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036273573,0.000084130166,0.03605159,0.00025511428,0.00020816996,0.0080881845,0.009405449,0.00006186545,0.09386331,0.000009889037,0.047422335,0.7682764],"study_design_scores_gemma":[0.18858555,0.008762415,0.027861066,0.0017162404,0.00013095136,0.001725619,0.005047374,0.00009527098,0.0045707966,0.0001281578,0.76118195,0.00019459444],"about_ca_topic_score_codex":0.00021171874,"about_ca_topic_score_gemma":0.00065987,"teacher_disagreement_score":0.7680818,"about_ca_system_score_codex":0.00034437233,"about_ca_system_score_gemma":0.0009327835,"threshold_uncertainty_score":0.9967983},"labels":[],"label_agreement":null},{"id":"W4379662243","doi":"10.1200/jco.2023.41.17_suppl.lba107","title":"Primary overall survival analysis of the phase 3 randomized ZUMA-7 study of axicabtagene ciloleucel versus standard-of-care therapy in relapsed/refractory large B-cell lymphoma.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Interim analysis; Refractory (planetary science); Intention-to-treat analysis; Censoring (clinical trials); Oncology; Survival analysis; Cumulative incidence; Confidence interval; Proportional hazards model; Randomized controlled trial; Surgery; Cohort","score_opus":0.13418231096971184,"score_gpt":0.4891123781802256,"score_spread":0.3549300672105138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379662243","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934047,0.0012409819,0.000011567205,0.00043908725,0.0011583713,0.00097080425,0.00004527698,0.000007748708,0.0027214815],"genre_scores_gemma":[0.99453294,0.0045253765,0.000082410974,0.00013567017,0.00022795849,0.000010065828,0.000011992288,0.000031035026,0.00044254775],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9890759,0.0042645484,0.004389308,0.00028884422,0.0016211027,0.00036032574],"domain_scores_gemma":[0.9819065,0.012934662,0.003148939,0.00066318305,0.0011254074,0.00022132008],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01602267,0.00021823522,0.0055136066,0.0008694689,0.00003758683,0.0000049657087,0.0005349146,0.00040564509,0.00062317046],"category_scores_gemma":[0.0041433712,0.00013393344,0.002270516,0.0016002043,0.0004403717,0.000057613175,0.00017756817,0.0009881388,0.0000020736275],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8685289,0.023015754,0.02731079,0.000090684305,0.00706943,0.00028535683,0.0022498101,0.00014637869,0.006993024,0.0000153592,0.00028457795,0.064009935],"study_design_scores_gemma":[0.8397578,0.053138345,0.095379256,0.00007355458,0.002485632,0.000003267299,0.0026864568,0.0002238625,0.0010582176,0.00003157861,0.005049707,0.00011234201],"about_ca_topic_score_codex":0.00007912237,"about_ca_topic_score_gemma":0.0002813331,"teacher_disagreement_score":0.06806847,"about_ca_system_score_codex":0.0004061827,"about_ca_system_score_gemma":0.0028683005,"threshold_uncertainty_score":0.682328},"labels":[],"label_agreement":null},{"id":"W4379979795","doi":"10.1002/hon.3164_325","title":"Tafasitamab plus lenalidomide versus standard of care as second‐line (2L) therapy for patients with R/R DLBCL: A post hoc internal 2L analysis of L‐MIND (IN 2L‐MIND)","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Medicine; Lenalidomide; Internal medicine; Post-hoc analysis; Clinical endpoint; Oncology; Autologous stem-cell transplantation; Cohort; Refractory (planetary science); Transplantation; Clinical trial; Multiple myeloma","score_opus":0.04577710757521213,"score_gpt":0.38758623869763525,"score_spread":0.3418091311224231,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379979795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99568635,0.000363592,0.0000505667,0.0005780627,0.00013734482,0.0013895793,0.00033559944,0.000025383713,0.0014335408],"genre_scores_gemma":[0.99789417,0.00013910727,0.00073170825,0.00013664717,0.000042083266,0.00013423187,0.0004206527,0.000033556284,0.00046784003],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9971201,0.00023110794,0.00085598405,0.0005593726,0.00064103986,0.00059244275],"domain_scores_gemma":[0.99639195,0.0017499893,0.00036018938,0.00042562428,0.0008690525,0.00020320444],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005521928,0.00028302884,0.0020827802,0.00085564295,0.00004307112,0.0000090768835,0.00028442938,0.00039717383,0.005068451],"category_scores_gemma":[0.00054681336,0.00019492148,0.00046115534,0.0013738892,0.00039470845,0.000046159457,0.00011740892,0.00039711833,0.000020939076],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6813391,0.003049888,0.23159418,0.00062372343,0.0060421275,0.001192408,0.0059368773,0.0001718491,0.0060992953,0.0004552439,0.000603032,0.062892325],"study_design_scores_gemma":[0.30062312,0.3374096,0.24306437,0.00065626006,0.0031955934,0.00018953823,0.017120078,0.0020458754,0.04893396,0.00035947983,0.045097128,0.0013050174],"about_ca_topic_score_codex":0.000068854984,"about_ca_topic_score_gemma":0.0013634573,"teacher_disagreement_score":0.38071594,"about_ca_system_score_codex":0.00052685314,"about_ca_system_score_gemma":0.0006150251,"threshold_uncertainty_score":0.995841},"labels":[],"label_agreement":null},{"id":"W4379981406","doi":"10.1002/hon.3163_22","title":"PRIMARY OVERALL SURVIVAL ANALYSIS OF THE PHASE 3 RANDOMIZED ZUMA‐7 STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD OF CARE IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nova Scotia Health Authority; Dalhousie University","funders":"Helsingin Yliopisto","keywords":"Medicine; Refractory (planetary science); Internal medicine; Lymphoma; Gastroenterology; Biology","score_opus":0.04697189223102332,"score_gpt":0.3827252295165396,"score_spread":0.33575333728551626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981406","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98924726,0.00067472877,0.000009710322,0.00015083839,0.00022417064,0.001644435,0.000086411565,0.000033674136,0.00792874],"genre_scores_gemma":[0.9990204,0.00032306535,0.00005346542,0.00004703325,0.000019426167,0.00009043645,0.00006294818,0.000020408768,0.0003628383],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99506545,0.0018818062,0.0012547229,0.00043239645,0.0009166211,0.00044902257],"domain_scores_gemma":[0.99450916,0.003782702,0.00052277907,0.00072003587,0.00034620828,0.000119092074],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0022459247,0.00022798305,0.0036081262,0.0006164175,0.000043925,0.0000028271995,0.00035536865,0.00035220076,0.0010667153],"category_scores_gemma":[0.001015381,0.00014378785,0.0007525999,0.0019666264,0.00045555233,0.000021955108,0.00033856893,0.0003423228,0.0000050939198],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.90400237,0.019283121,0.028619286,0.0006466529,0.003129218,0.00070819753,0.0056740274,0.00011266196,0.032311928,0.0005018009,0.00023816995,0.004772542],"study_design_scores_gemma":[0.92407095,0.02093595,0.03146497,0.00006492552,0.0025560302,0.000008995054,0.0077990396,0.00052568637,0.01037044,0.000068509114,0.0019165284,0.00021796796],"about_ca_topic_score_codex":0.00010580153,"about_ca_topic_score_gemma":0.0005764018,"teacher_disagreement_score":0.021941487,"about_ca_system_score_codex":0.00043943647,"about_ca_system_score_gemma":0.0005644103,"threshold_uncertainty_score":0.99984646},"labels":[],"label_agreement":null},{"id":"W4379981428","doi":"10.1002/hon.3163_t05","title":"SUNMO: PHASE III TRIAL OF MOSUNETUZUMAB PLUS POLATUZUMAB VEDOTIN VERSUS RITUXIMAB PLUS GEMCITABINE AND OXALIPLATIN IN RELAPSED/REFRACTORY AGGRESSIVE NON‐HODGKIN LYMPHOMA","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Roche (Canada)","funders":"Astellas Pharma; Pfizer","keywords":"Medicine; Rituximab; Brentuximab vedotin; Internal medicine; Oncology; Refractory (planetary science); Lymphoma; Chimeric antigen receptor; Phases of clinical research; Clinical trial; Immunotherapy; Cancer; CD30","score_opus":0.0644506952634808,"score_gpt":0.3914333370511365,"score_spread":0.3269826417876557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98909247,0.00096953486,0.000019822392,0.0011047367,0.00075544626,0.0020552138,0.000026407422,0.00016512055,0.005811258],"genre_scores_gemma":[0.99671966,0.00072318414,0.000384489,0.00015075404,0.00025049763,0.0002664922,0.00012214936,0.000059698345,0.0013230566],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99552345,0.00055798725,0.0013122263,0.00087258196,0.0007127235,0.0010210302],"domain_scores_gemma":[0.99507874,0.0031028767,0.00059368316,0.0006221767,0.00018248709,0.00042004825],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010181163,0.00044977892,0.0024704686,0.0006755399,0.00011410227,0.000017961238,0.0003199725,0.0009974132,0.001594596],"category_scores_gemma":[0.0022085211,0.00037375937,0.0002632833,0.0011817486,0.0008398453,0.00008218784,0.0004101849,0.00084159325,0.00014683638],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.86310446,0.0066736774,0.0005405866,0.00043724125,0.00042548534,0.014229342,0.002534003,0.000049667455,0.03143402,0.0016513347,0.003501939,0.07541822],"study_design_scores_gemma":[0.94173265,0.028433997,0.0019771731,0.00025698225,0.00017540905,0.0009317852,0.0014759409,0.008136476,0.0034591642,0.00053233514,0.01236687,0.00052120874],"about_ca_topic_score_codex":0.00027841105,"about_ca_topic_score_gemma":0.00018876695,"teacher_disagreement_score":0.078628175,"about_ca_system_score_codex":0.0012950341,"about_ca_system_score_gemma":0.0013588212,"threshold_uncertainty_score":0.99987143},"labels":[],"label_agreement":null},{"id":"W4379981707","doi":"10.1002/hon.3164_398","title":"Neurotoxicity in patients with CNS lymphomas treated with CAR‐T cell therapy. A LOC network study","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Neurotoxicity; Lymphoma; Encephalopathy; Internal medicine; Toxicity; Gastroenterology; Pediatrics; Oncology","score_opus":0.04181337863293949,"score_gpt":0.3220643908578386,"score_spread":0.2802510122248991,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981707","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98956335,0.000052350646,0.0000054679826,0.0003293769,0.00004094035,0.003453785,0.0000029925543,0.00024349996,0.0063082315],"genre_scores_gemma":[0.99761486,0.000049655817,0.00009070879,0.00053453527,0.00005560192,0.0004606533,0.000034902063,0.00004991413,0.0011091472],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969605,0.0005811558,0.0004003694,0.0006563624,0.00053495367,0.00086664717],"domain_scores_gemma":[0.9984854,0.00054353126,0.00011254489,0.00045619273,0.00014984643,0.0002525222],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004303469,0.0003108994,0.0010353029,0.00020395957,0.000095033625,0.000015245906,0.00020029258,0.0002706779,0.0011474206],"category_scores_gemma":[0.000054831955,0.00017877933,0.000073209354,0.0016421925,0.00025893722,0.000037812024,0.00011291201,0.0005097612,0.00012477803],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011912773,0.0053052623,0.97471046,0.000025554618,0.00009612602,0.0038256603,0.00028826212,0.00008086663,0.00029485178,0.00003710375,0.0006195922,0.0028034577],"study_design_scores_gemma":[0.0248569,0.031918406,0.93803394,0.00003445136,0.00004095558,0.00010910332,0.00031391092,0.00014400402,0.0004642086,0.000039859333,0.0038034155,0.000240845],"about_ca_topic_score_codex":0.00011353979,"about_ca_topic_score_gemma":0.00021751612,"teacher_disagreement_score":0.03667655,"about_ca_system_score_codex":0.00025043252,"about_ca_system_score_gemma":0.0002329437,"threshold_uncertainty_score":0.9997657},"labels":[],"label_agreement":null},{"id":"W4379981730","doi":"10.1002/hon.3165_637","title":"COMPARATIVE EFFECTIVENESS OF SALVAGE CHEMOTHERAPY AND CHIMERIC ANTIGEN T‐CELL RECEPTOR THERAPIES IN R/R DLBCL: A SYSTEMATIC REVIEW AND NETWORK META‐ANALYSIS","year":2023,"lang":"en","type":"review","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Takeda Pharmaceuticals International","keywords":"Internal medicine; Oncology; Medicine; Etoposide; Gemcitabine; Carboplatin; Regimen; Ifosfamide; Cytarabine; Rituximab; Chemotherapy; Cisplatin; Lymphoma","score_opus":0.1821421503594694,"score_gpt":0.4575280083319074,"score_spread":0.275385857972438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981730","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00029343582,0.9908216,0.000019969495,0.00011748944,0.000032677082,0.008243389,0.000020396492,0.000058862326,0.0003922052],"genre_scores_gemma":[0.00025614552,0.9969305,0.00031959088,0.00019427028,0.000026320768,0.00185527,0.00007397597,0.00005874368,0.00028520107],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9907655,0.0058581084,0.0016504244,0.00085454935,0.0003311876,0.000540207],"domain_scores_gemma":[0.9900327,0.00814438,0.00092154834,0.00058814,0.000121585705,0.00019168068],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.003809328,0.0006803551,0.026117181,0.0005040702,0.000053526186,0.000015408807,0.00026515243,0.0006841349,0.00077673426],"category_scores_gemma":[0.00021319407,0.00039661443,0.0016066597,0.002685047,0.0005282473,0.000030000007,0.00017451654,0.00079130975,0.000035456284],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012314711,0.00041714223,0.00010423728,0.91087645,0.086425245,0.000112989626,0.00014271098,3.8847622e-7,0.000018172515,0.000108481974,0.00007477569,0.0015962346],"study_design_scores_gemma":[0.0032481293,0.0030094583,0.00032039892,0.2680268,0.6567097,0.0008490842,0.00018758183,0.000027916625,0.000030415296,0.00024366044,0.06615417,0.0011927204],"about_ca_topic_score_codex":0.00002516208,"about_ca_topic_score_gemma":0.000018707551,"teacher_disagreement_score":0.6428497,"about_ca_system_score_codex":0.00014711752,"about_ca_system_score_gemma":0.00023077051,"threshold_uncertainty_score":0.99984854},"labels":[],"label_agreement":null},{"id":"W4379981852","doi":"10.1002/hon.3166_ot28","title":"PHASE 3 TRIAL OF SUBCUTANEOUS EPCORITAMAB + R‐CHOP VERSUS R‐CHOP IN PATIENTS (PTS) WITH NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): EPCORE DLBCL‐2","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"National Institutes of Health; National Cancer Institute; Celgene; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Rituximab; Diffuse large B-cell lymphoma; Vincristine; Cytokine release syndrome; Oncology; Prednisone; CHOP; International Prognostic Index; Cyclophosphamide; Phases of clinical research; CD20; Lymphoma; Discontinuation; Gastroenterology; Clinical trial; Chemotherapy; Cancer; Immunotherapy","score_opus":0.04596949735079359,"score_gpt":0.36019912368922496,"score_spread":0.3142296263384314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981852","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98949367,0.00010939865,0.000016783699,0.00053521566,0.0007027545,0.0025766555,0.00006167234,0.0002182886,0.006285553],"genre_scores_gemma":[0.9971738,0.00031798,0.00027288575,0.00025956339,0.0001837864,0.00032269745,0.00018820848,0.0000764133,0.0012046878],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99525964,0.00052771566,0.0010687826,0.0008815328,0.00093833584,0.0013239966],"domain_scores_gemma":[0.9952233,0.0028781777,0.00033967613,0.0007742813,0.00027351134,0.0005110459],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000682961,0.00046915133,0.0018439078,0.00053311925,0.00009910667,0.00001881077,0.00042483,0.00078271795,0.0013747581],"category_scores_gemma":[0.0012108466,0.00034827145,0.00030886402,0.0014221836,0.00043473672,0.00007857749,0.00026783242,0.00063548714,0.00038314686],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7539799,0.15487291,0.017186893,0.0003221808,0.00025120514,0.027466055,0.0008637865,0.00000424392,0.002359759,0.00069013116,0.0037200686,0.038282827],"study_design_scores_gemma":[0.9072056,0.06839499,0.0039153593,0.000087658635,0.00013700273,0.0002846544,0.00057844026,0.00031540173,0.0009759687,0.00011094862,0.017592983,0.00040103344],"about_ca_topic_score_codex":0.00007857669,"about_ca_topic_score_gemma":0.00014388206,"teacher_disagreement_score":0.15322563,"about_ca_system_score_codex":0.0006317787,"about_ca_system_score_gemma":0.00056500814,"threshold_uncertainty_score":0.99989694},"labels":[],"label_agreement":null},{"id":"W4379981884","doi":"10.1002/hon.3163_83","title":"MOSUNETUZUMAB DEMONSTRATES DURABLE RESPONSES IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND ≥2 PRIOR THERAPIES: UPDATED ANALYSIS OF A PIVOTAL PHASE II STUDY","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Jewish General Hospital; McGill University; University of British Columbia","funders":"","keywords":"Medicine; Follicular lymphoma; Internal medicine; Refractory (planetary science); Follicular phase; Gastroenterology; Phases of clinical research; Clinical endpoint; Dosing; Lymphoma; Urology; Oncology; Surgery; Clinical trial; Materials science","score_opus":0.030225123102663037,"score_gpt":0.34757183728010405,"score_spread":0.317346714177441,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981884","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99775696,0.00021400931,0.0000047525305,0.0003129926,0.00002232678,0.0012876666,0.00001977933,0.000091351416,0.0002901879],"genre_scores_gemma":[0.99885243,0.00009335039,0.00015557022,0.00007901112,0.000006915105,0.00012200133,0.00009005162,0.000021888012,0.00057880394],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973214,0.0005965936,0.00061872357,0.0005358786,0.00045671492,0.00047067576],"domain_scores_gemma":[0.99820656,0.0008628772,0.00018704913,0.00038782615,0.00018371474,0.00017198437],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007303663,0.00023727177,0.0013684266,0.00086833816,0.00011452347,0.000011159788,0.00013921148,0.0002729887,0.0009281465],"category_scores_gemma":[0.0003246997,0.00015634121,0.00012605436,0.0026035307,0.00039914108,0.00006687053,0.00013552429,0.00025068803,0.0000091056445],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029770948,0.015388319,0.9244285,0.00004370991,0.0025651942,0.0017728467,0.0019301848,0.0000124668495,0.0062696747,0.00006319706,0.0001253139,0.017629623],"study_design_scores_gemma":[0.03449585,0.03855675,0.9206368,0.000035532557,0.0007717255,0.000055192497,0.0027058455,0.0007457588,0.0006635947,0.000040998428,0.0010830313,0.00020893279],"about_ca_topic_score_codex":0.000094227296,"about_ca_topic_score_gemma":0.00020101294,"teacher_disagreement_score":0.023168432,"about_ca_system_score_codex":0.00018197746,"about_ca_system_score_gemma":0.000271616,"threshold_uncertainty_score":0.99998516},"labels":[],"label_agreement":null},{"id":"W4379981988","doi":"10.1002/hon.3164_394","title":"Developing CAR‐T‐sparing Radiotherapy ‐ early dosimetric results","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Medicine; Nuclear medicine; Radiation therapy; Surgery","score_opus":0.12701227083581387,"score_gpt":0.412145902536441,"score_spread":0.2851336317006271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379981988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95115143,0.00054147316,0.0005348213,0.0097703645,0.00034233608,0.0007268652,0.000004109469,0.00067047944,0.036258116],"genre_scores_gemma":[0.98340505,0.0012815453,0.0044953884,0.0015507635,0.0003280861,0.00012365112,0.00003812589,0.00005314643,0.008724223],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99732614,0.00024398117,0.0005721515,0.0005763995,0.00044534996,0.0008360117],"domain_scores_gemma":[0.9976182,0.0014517884,0.000109898305,0.0004166145,0.00012703451,0.00027646753],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010433801,0.00021932664,0.00086065126,0.0005988575,0.000136116,0.00002600478,0.00024557908,0.00047333862,0.0010253727],"category_scores_gemma":[0.0010008905,0.0001677464,0.00017402717,0.0022524272,0.00021376497,0.000047717196,0.00016209154,0.0006000218,0.0007744147],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018127054,0.0016677142,0.20086809,0.00078664516,0.0015747402,0.028017672,0.0032611676,0.00006246969,0.2462941,0.07057036,0.057317838,0.37145215],"study_design_scores_gemma":[0.0130574,0.0045818603,0.2001571,0.00014857147,0.000057875455,0.0028090503,0.0003681147,0.0012295393,0.020770205,0.0020988353,0.7540406,0.0006808315],"about_ca_topic_score_codex":0.00007982005,"about_ca_topic_score_gemma":0.00001329604,"teacher_disagreement_score":0.6967228,"about_ca_system_score_codex":0.0008198717,"about_ca_system_score_gemma":0.00033574746,"threshold_uncertainty_score":0.9998878},"labels":[],"label_agreement":null},{"id":"W4380083458","doi":"10.1002/hon.3164_446","title":"Glofitamab plus immunochemotherapy demonstrates durable efficacy with manageable safety in relapsed/refractory non‐Hodgkin lymphoma (R/R NHL): update of a Phase Ib study","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Tolerability; Obinutuzumab; Internal medicine; Rituximab; CHOP; Refractory (planetary science); Gastroenterology; Lymphoma; CD20; Oncology; Dosing; Phases of clinical research; Immunology; Adverse effect; Chemotherapy; Biology","score_opus":0.036268815423270026,"score_gpt":0.3635415401709561,"score_spread":0.32727272474768604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380083458","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856672,0.0003692139,0.000069752256,0.0015195744,0.00009187419,0.0024920607,0.000010318221,0.00021002036,0.009569975],"genre_scores_gemma":[0.9955402,0.0007317093,0.00083642616,0.00031568363,0.00004052937,0.00022440613,0.00005439509,0.00006452201,0.002192141],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99609613,0.0005173232,0.0010315983,0.0007885232,0.0005850125,0.0009813989],"domain_scores_gemma":[0.9973021,0.0012034555,0.00028181152,0.0007945923,0.00016584783,0.00025216152],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014045867,0.00040958132,0.0018237423,0.00052282296,0.00012022984,0.00001910124,0.00041657663,0.00046362483,0.0026224658],"category_scores_gemma":[0.00023034052,0.00029569195,0.00018624203,0.0018004784,0.0005471582,0.00008167589,0.00017903934,0.000603116,0.00027566738],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20094791,0.07920053,0.11537315,0.0012158838,0.003092713,0.0526033,0.0065620025,0.0005945668,0.27744085,0.0021874066,0.0055738837,0.2552078],"study_design_scores_gemma":[0.44749,0.09664349,0.31309813,0.00096877804,0.0006353893,0.005440102,0.018612763,0.009201545,0.050215185,0.0011564605,0.054431297,0.0021068645],"about_ca_topic_score_codex":0.00021970744,"about_ca_topic_score_gemma":0.00014462713,"teacher_disagreement_score":0.25310096,"about_ca_system_score_codex":0.00060249766,"about_ca_system_score_gemma":0.0006969441,"threshold_uncertainty_score":0.9999495},"labels":[],"label_agreement":null},{"id":"W4380083530","doi":"10.1002/hon.3164_386","title":"Matching‐adjusted indirect comparison of axicabtagene ciloleucel versus mosunetuzumab in relapsed/refractory follicular lymphoma patients after 2 prior systemic treatments","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Raincoast Conservation Foundation","funders":"","keywords":"Medicine; Follicular lymphoma; Internal medicine; Oncology; Hazard ratio; Proportional hazards model; Fludarabine; Clinical trial; Alemtuzumab; Progression-free survival; Refractory (planetary science); Lymphoma; Overall survival; Confidence interval; Chemotherapy; Transplantation; Cyclophosphamide","score_opus":0.06551910042501254,"score_gpt":0.36349055388389534,"score_spread":0.2979714534588828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380083530","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994479,0.0007909577,0.000004409184,0.00012804716,0.00040950024,0.0013330373,0.000017572265,0.00016742553,0.0026700683],"genre_scores_gemma":[0.99803555,0.00018750012,0.00017401247,0.00007679179,0.000040016857,0.00038209735,0.00012468906,0.000045451066,0.0009338662],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99646544,0.00054363586,0.0010153084,0.0006087089,0.0006471232,0.00071979436],"domain_scores_gemma":[0.9979138,0.00090351823,0.00029704344,0.0005082406,0.00012747363,0.00024995703],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00043189898,0.0003304534,0.0017322835,0.00047220502,0.000058951508,0.000008393596,0.00023315736,0.0006955277,0.0008197071],"category_scores_gemma":[0.00024927728,0.00025635434,0.00026235593,0.0008962548,0.00020190125,0.000041962445,0.00020520967,0.0003810516,0.00034194256],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03599409,0.01139015,0.8190998,0.0009845968,0.0010398362,0.0053734477,0.0039759506,0.00008483797,0.023695061,0.0001485331,0.0010149035,0.09719879],"study_design_scores_gemma":[0.05762387,0.013693535,0.9080445,0.0005781177,0.00038963888,0.0002253705,0.0017457806,0.0008763457,0.010837922,0.0001747905,0.005235307,0.0005747849],"about_ca_topic_score_codex":0.00010117383,"about_ca_topic_score_gemma":0.00008176491,"teacher_disagreement_score":0.09662401,"about_ca_system_score_codex":0.0012377676,"about_ca_system_score_gemma":0.0002913353,"threshold_uncertainty_score":0.99998885},"labels":[],"label_agreement":null},{"id":"W4380084938","doi":"10.1002/hon.3163_95","title":"GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (<i>R</i>/<i>R</i>) LARGE B‐CELL LYMPHOMA (LBCL): EXTENDED FOLLOW‐UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Kite Pharma; F. Hoffmann-La Roche; Genentech; Celgene; Gilead Sciences; Pharmacyclics; Sanofi; Pfizer; Bristol-Myers Squibb","keywords":"Refractory (planetary science); Medicine; Lymphoma; Oncology; Internal medicine; Physics","score_opus":0.046888727290113154,"score_gpt":0.37710057351762066,"score_spread":0.3302118462275075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380084938","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99541235,0.00047064314,0.000024569534,0.00035554174,0.00015371227,0.0017722467,0.00005874844,0.00021222893,0.0015399548],"genre_scores_gemma":[0.9967512,0.00019842913,0.00026946692,0.00056966813,0.00006749115,0.00024590315,0.00018480557,0.00005964803,0.0016533848],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99626607,0.0005772116,0.00067179,0.00094849337,0.0006576342,0.00087878434],"domain_scores_gemma":[0.9978475,0.00087795674,0.00019165828,0.0005730202,0.00014006387,0.00036981708],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00058888586,0.00042317226,0.0014693358,0.00042042122,0.00019175929,0.000027090528,0.00022984178,0.00042373917,0.0013054968],"category_scores_gemma":[0.0001905736,0.0002909395,0.00015516148,0.0009615636,0.00022947963,0.00010871362,0.00026529477,0.0004959323,0.000087593835],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.055717014,0.06990155,0.81133133,0.00007525838,0.0007295393,0.0058290535,0.003766075,0.0000015442115,0.011061094,0.000049870676,0.0027313347,0.038806316],"study_design_scores_gemma":[0.3111354,0.061396927,0.60506254,0.00008202655,0.0002806676,0.000080377074,0.0028831249,0.00035628222,0.0011977023,0.00032276666,0.016552433,0.0006497646],"about_ca_topic_score_codex":0.00017365608,"about_ca_topic_score_gemma":0.0003299672,"teacher_disagreement_score":0.2554184,"about_ca_system_score_codex":0.00027802447,"about_ca_system_score_gemma":0.00023242233,"threshold_uncertainty_score":0.9999543},"labels":[],"label_agreement":null},{"id":"W4380148586","doi":"10.1016/j.jcyt.2023.05.004","title":"Constitutive expression of interleukin-27 diminishes proinflammatory cytokine production without impairing effector function of engineered T cells","year":2023,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster University Medical Centre; Discovery Centre","funders":"","keywords":"Cytokine; Tumor necrosis factor alpha; Immunology; Proinflammatory cytokine; Immunotherapy; Cancer research; Biology; Immune system; Inflammation","score_opus":0.02125419104203506,"score_gpt":0.2889989854898254,"score_spread":0.2677447944477903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380148586","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964806,0.00016762981,0.0004700133,0.00008864016,0.00063421845,0.0014073933,0.00001796502,0.00019065107,0.0005428925],"genre_scores_gemma":[0.9962408,0.00022441804,0.00024316653,0.000015917287,0.0003224818,0.00008044203,0.00003587245,0.000060650593,0.0027762707],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99837315,0.00011011954,0.00042524317,0.00034885318,0.00045973106,0.00028287867],"domain_scores_gemma":[0.9988977,0.00012771232,0.00018088295,0.00046572855,0.00023004977,0.000097958706],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060059637,0.0002099314,0.0005019239,0.00041564397,0.000041197072,0.000008942006,0.00010507676,0.00011894392,0.0005676074],"category_scores_gemma":[0.00010116635,0.00017455428,0.00016239959,0.00052550115,0.00024382,0.00011898065,0.00003576164,0.00022542015,0.000041302206],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032480282,0.00014008995,0.007153983,0.00055565464,0.00014221689,0.000010211443,0.0012155126,0.00012008518,0.9792503,0.000017405671,0.0010699984,0.0070764828],"study_design_scores_gemma":[0.0022703612,0.0010726907,0.0108717475,0.0006400725,0.000038607148,0.000013211369,0.00025710702,0.0001696933,0.98110837,0.000024443494,0.0033972787,0.00013644579],"about_ca_topic_score_codex":0.000013715219,"about_ca_topic_score_gemma":0.0000031020263,"teacher_disagreement_score":0.006940037,"about_ca_system_score_codex":0.00010579138,"about_ca_system_score_gemma":0.00015202185,"threshold_uncertainty_score":0.71181166},"labels":[],"label_agreement":null},{"id":"W4380150346","doi":"10.1016/j.jval.2023.03.356","title":"EE51 A Cost-Consequence Analysis of Adopting Chimeric Antigen Receptor T-Cell Therapy for Patients with Relapsed or Refractory Large B-Cell Lymphoma in Saudi Arabia: a Multi-Center Comparison","year":2023,"lang":"en","type":"article","venue":"Value in Health","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Gilead Sciences (Canada)","funders":"","keywords":"Chimeric antigen receptor; Refractory (planetary science); Lymphoma; Medicine; Referral; Oncology; Immunotherapy; Internal medicine; Family medicine; Cancer; Biology","score_opus":0.08135585999482925,"score_gpt":0.36770681570183034,"score_spread":0.2863509557070011,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380150346","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950861,0.00065663015,0.00016602788,0.00024343032,0.00010353714,0.0034788023,0.00016615154,0.00005975589,0.000039594517],"genre_scores_gemma":[0.9917783,0.0027646266,0.0037905574,0.00033880578,0.000030763822,0.0002474447,0.00042402963,0.000078067125,0.0005473695],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962758,0.0005195214,0.001054357,0.00061843963,0.00062096503,0.0009109384],"domain_scores_gemma":[0.997735,0.00074487395,0.00051462505,0.0005571148,0.00021692405,0.00023141445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018339432,0.0002723488,0.0011389205,0.0013501989,0.000089562964,0.0000145294725,0.00021447668,0.0001473888,0.00013958968],"category_scores_gemma":[0.00021141239,0.00021678039,0.00017934779,0.0038855362,0.00009146215,0.00007893178,0.000046788246,0.00033942232,0.00001498671],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0089187035,0.01132788,0.9516895,0.00079950667,0.00026229772,0.000028019442,0.0050010877,0.0009127382,0.0054308292,0.000001209123,0.00029944888,0.015328773],"study_design_scores_gemma":[0.117690556,0.008343038,0.7376749,0.0014062189,0.00010983627,0.0000036519943,0.00169439,0.11423219,0.0025708391,0.0000030376198,0.015664361,0.0006069654],"about_ca_topic_score_codex":0.0028852047,"about_ca_topic_score_gemma":0.00050016236,"teacher_disagreement_score":0.21401459,"about_ca_system_score_codex":0.0006974096,"about_ca_system_score_gemma":0.000911533,"threshold_uncertainty_score":0.8840048},"labels":[],"label_agreement":null},{"id":"W4380152961","doi":"10.51731/cjht.2023.668","title":"Brexucabtagene Autoleucel (Tecartus)","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Medicine; Refractory (planetary science); Chimeric antigen receptor; Drug; Intensive care medicine; Family medicine; Pharmacology; Internal medicine; Political science; Cancer; Immunotherapy","score_opus":0.06782205487796064,"score_gpt":0.3562780262120117,"score_spread":0.2884559713340511,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380152961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.70435095,0.044417933,0.0000955645,0.24323179,0.0012285473,0.0008506382,0.00004450161,0.0010079477,0.004772155],"genre_scores_gemma":[0.99341905,0.0016831702,0.0002964643,0.0007359206,0.000040514507,0.000007215902,0.000006284055,0.00003417086,0.0037772073],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981899,0.000051823423,0.00051781675,0.00014598387,0.0003215438,0.0007729142],"domain_scores_gemma":[0.99890715,0.00006949723,0.00019514124,0.00037906982,0.00020346633,0.00024565402],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012089869,0.00012439126,0.00044560965,0.0016679728,0.0002054969,0.000030443167,0.0003367253,0.00017486486,0.00044066913],"category_scores_gemma":[0.0006745132,0.00010562077,0.00011027952,0.0013192331,0.00025748112,0.000066148925,0.000031211504,0.000725033,0.00010577532],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003027891,0.000012020778,0.0042172647,0.0001352812,0.00006397068,0.0012043855,0.00025033244,0.0000101078585,0.003674461,0.00033880275,0.043765757,0.94629735],"study_design_scores_gemma":[0.0009136066,0.0009182039,0.02270704,0.00028118416,0.000013255218,0.0012385043,0.0031949894,0.000050443952,0.0038437939,0.0010752392,0.9656342,0.00012950192],"about_ca_topic_score_codex":0.0031043324,"about_ca_topic_score_gemma":0.0020965394,"teacher_disagreement_score":0.9461678,"about_ca_system_score_codex":0.0006129533,"about_ca_system_score_gemma":0.0052366415,"threshold_uncertainty_score":0.9289577},"labels":[],"label_agreement":null},{"id":"W4380203508","doi":"10.51731/cjht.2023.667","title":"Axicabtagene Ciloleucel (Yescarta)","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Chemoimmunotherapy; Reimbursement; Medicine; Lymphoma; Drug; Refractory (planetary science); Oncology; Intensive care medicine; Internal medicine; Pharmacology; Health care; Rituximab; Political science","score_opus":0.07583853752595779,"score_gpt":0.35787496221602544,"score_spread":0.2820364246900676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380203508","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.72605664,0.053098537,0.00009259111,0.21407883,0.0008835432,0.0006527331,0.000029211224,0.00062262703,0.004485315],"genre_scores_gemma":[0.993377,0.0026225115,0.00025432627,0.0005653551,0.00003953986,0.000006270495,0.0000044909057,0.000028101922,0.003102456],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99829316,0.000049062044,0.00048175262,0.00013857333,0.0003136997,0.0007237371],"domain_scores_gemma":[0.9989392,0.000067667585,0.00017686967,0.0003609667,0.0002130609,0.00024224218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011629545,0.00011525494,0.0004230015,0.0015174673,0.0001968858,0.000027081627,0.00031895985,0.00015931927,0.0004375858],"category_scores_gemma":[0.0006653689,0.00009713814,0.00012273935,0.0010957804,0.00023984493,0.000058777077,0.000027889666,0.00068182976,0.00011617785],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000032314212,0.000011798885,0.0052556726,0.00014239589,0.00006186638,0.0010613168,0.00025411192,0.000006826075,0.0039479164,0.00025263982,0.037794784,0.9511784],"study_design_scores_gemma":[0.0011514898,0.0016920936,0.022370834,0.0004057593,0.000016762755,0.0011554596,0.0054980805,0.000038311508,0.0069623883,0.002325226,0.9582193,0.00016432525],"about_ca_topic_score_codex":0.0016102922,"about_ca_topic_score_gemma":0.0016542585,"teacher_disagreement_score":0.95101404,"about_ca_system_score_codex":0.00052247907,"about_ca_system_score_gemma":0.0043157474,"threshold_uncertainty_score":0.7655951},"labels":[],"label_agreement":null},{"id":"W4380234055","doi":"10.1016/j.jtct.2023.06.007","title":"Leukapheresis and Tisagenlecleucel Manufacturing Outcomes in Patients Age &lt;3 Years with Relapsed/Refractory Acute Lymphoblastic Leukemia","year":2023,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Novartis (Canada)","funders":"Novartis Pharmaceuticals Corporation","keywords":"Leukapheresis; Medicine; Blinatumomab; Leukemia; Lymphoblastic Leukemia; Immunology; Stem cell","score_opus":0.01585269188541878,"score_gpt":0.25388425744362353,"score_spread":0.23803156555820476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380234055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99862003,0.00019775891,0.00005540608,0.000056429268,0.00004234722,0.00046498125,0.000017556604,0.00008088146,0.00046460552],"genre_scores_gemma":[0.99057347,0.005974123,0.00006772849,0.00015357466,0.00001725036,0.000025155752,0.00016929068,0.000047212692,0.0029722254],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99878544,0.0000663697,0.00020420746,0.00030916242,0.0003482668,0.00028654208],"domain_scores_gemma":[0.9995525,0.0000948939,0.000039778337,0.00016692866,0.000018387811,0.00012755218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014697471,0.00018550175,0.00028323173,0.00025525445,0.00006315201,0.000036758007,0.000057817597,0.00009813706,0.00023848358],"category_scores_gemma":[0.0000020705663,0.00015178142,0.000052722913,0.0001850128,0.000086197564,0.000095399446,0.0000075845674,0.00017430139,0.000024248795],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0127965445,0.00040604587,0.44601142,0.00049938186,0.0010076271,0.0036705914,0.010891954,0.0000740094,0.33951074,0.00004311847,0.00011154852,0.18497702],"study_design_scores_gemma":[0.013921883,0.00067234965,0.95258003,0.00009412645,0.000075678596,0.000019166257,0.00012839965,0.000077799035,0.03155514,0.000041186267,0.00062402367,0.00021021352],"about_ca_topic_score_codex":0.00009257146,"about_ca_topic_score_gemma":0.00006827865,"teacher_disagreement_score":0.5065686,"about_ca_system_score_codex":0.00008472265,"about_ca_system_score_gemma":0.000051188345,"threshold_uncertainty_score":0.6189467},"labels":[],"label_agreement":null},{"id":"W4380606669","doi":"10.1101/2023.06.14.545014","title":"Predicting T cell activation based on intracellular calcium fluctuations","year":2023,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Fonds de recherche du Québec – Nature et technologies; Natural Sciences and Engineering Research Council of Canada; Fonds de Recherche du Québec - Santé; Radboud Universiteit","keywords":"T-cell receptor; Antigen; Cytotoxic T cell; Biology; T cell; Cell biology; Polyclonal antibodies; Streptamer; Intracellular; Molecular biology; In vitro; Immunology; Immune system; Biochemistry","score_opus":0.03854715687238681,"score_gpt":0.2796330752602993,"score_spread":0.2410859183879125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380606669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9828191,0.00012314049,0.009063226,0.001957763,0.0013969523,0.0027623565,0.00021025795,0.0014855091,0.00018168554],"genre_scores_gemma":[0.99461323,0.000063569736,0.0023844761,0.00037532402,0.0013634154,0.0005033459,0.0000066146267,0.00036582164,0.0003242215],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9957275,0.00022750323,0.0006784228,0.0012952575,0.0012764016,0.000794946],"domain_scores_gemma":[0.99592793,0.00038579633,0.00037127675,0.0020417548,0.0007976599,0.00047560947],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012050604,0.00062710687,0.0006923994,0.0009213683,0.00025832292,0.00019797057,0.00043083224,0.0008100318,0.00077522337],"category_scores_gemma":[0.0008528789,0.00067974743,0.0002927157,0.0010645627,0.0001283215,0.00010241696,0.00030650044,0.0021077907,0.00037971945],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020465623,0.0003461062,0.007384958,0.00077531004,0.000128932,0.000093066,0.000016433793,0.0015709915,0.98882353,0.000043767628,0.0006060095,0.000006225726],"study_design_scores_gemma":[0.0014673927,0.00023050471,0.062912196,0.0009837778,0.0001760654,1.0536495e-8,0.00000676983,0.04306016,0.88705987,0.0000017906583,0.003521874,0.0005796111],"about_ca_topic_score_codex":0.0001464387,"about_ca_topic_score_gemma":0.0000017973312,"teacher_disagreement_score":0.1017637,"about_ca_system_score_codex":0.0010070832,"about_ca_system_score_gemma":0.0016228122,"threshold_uncertainty_score":0.99956536},"labels":[],"label_agreement":null},{"id":"W4381309016","doi":"10.1080/10428194.2023.2226278","title":"Estimating the impact of early bendamustine failure on feasibility of subsequent CAR-T cell therapy in mantle cell lymphoma","year":2023,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary","funders":"","keywords":"Bendamustine; Medicine; Internal medicine; Lymphoma","score_opus":0.03402183222211579,"score_gpt":0.3065968196357071,"score_spread":0.2725749874135913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381309016","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865731,0.0016418347,0.000007696793,0.0047995914,0.00047135682,0.0030888473,0.0004950789,0.0002038702,0.0027186256],"genre_scores_gemma":[0.98242927,0.0010730997,0.00039970753,0.006277863,0.0018580867,0.000280684,0.0005972477,0.0006033841,0.006480684],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.99003965,0.0008506148,0.0023982194,0.0021066016,0.002466886,0.002138028],"domain_scores_gemma":[0.99249864,0.0018739456,0.0014283129,0.0031463425,0.00057964213,0.0004731153],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0017047372,0.001837959,0.0031671328,0.0012952356,0.00028603466,0.0001582393,0.0014307331,0.002321807,0.00053917227],"category_scores_gemma":[0.00023380447,0.0013288582,0.0015969665,0.002023738,0.0011474094,0.00020696744,0.000463431,0.0013358848,0.00008254185],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.019585883,0.0040578065,0.15305841,0.011419602,0.002950002,0.010158555,0.012452279,0.0028215882,0.23261032,0.00003207385,0.30222276,0.24863072],"study_design_scores_gemma":[0.11582452,0.012767391,0.6871687,0.006000251,0.0010209082,0.0016787478,0.0014109453,0.01352725,0.1357335,0.0007169648,0.019604381,0.0045464137],"about_ca_topic_score_codex":0.024004664,"about_ca_topic_score_gemma":0.00013807244,"teacher_disagreement_score":0.5341103,"about_ca_system_score_codex":0.015190648,"about_ca_system_score_gemma":0.009571923,"threshold_uncertainty_score":0.9994365},"labels":[],"label_agreement":null},{"id":"W4381429777","doi":"10.3390/curroncol30060440","title":"Neurologic Complications of Cancer Immunotherapy","year":2023,"lang":"en","type":"review","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Immunotherapy; Intensive care medicine; Cancer; Clinical Practice; Cancer immunotherapy; Cancer treatment; Internal medicine; Physical therapy","score_opus":0.4827665994145928,"score_gpt":0.5875342349185801,"score_spread":0.10476763550398732,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381429777","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000029827617,0.99478394,0.000009545667,0.00038164915,0.0011675576,0.0018027461,0.00009172118,0.00015463066,0.0015783866],"genre_scores_gemma":[0.0000017442412,0.996518,0.00002204948,0.00006331226,0.00037857072,0.0011047887,0.00019598095,0.000118002885,0.0015975246],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979326,0.00032738183,0.00071888213,0.00041740984,0.00024995668,0.0003537367],"domain_scores_gemma":[0.99801356,0.0006083292,0.00040118053,0.0006803797,0.00018872024,0.00010780794],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00031471063,0.0002769042,0.0021090733,0.00039903814,0.000034637123,0.0000051476222,0.00036737835,0.00034121526,0.001712995],"category_scores_gemma":[0.00007684338,0.00021104292,0.000586338,0.00069490145,0.00026436744,0.000011121432,0.00012171805,0.0009494688,0.00022409056],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00003886925,0.00034388172,0.00008329324,0.011370712,0.0002755558,0.000010791464,0.000031825686,1.8607388e-7,0.000035852565,0.00010262501,0.0030221385,0.9846843],"study_design_scores_gemma":[0.00058531907,0.000508162,0.00018072702,0.00247752,0.00047475516,0.000046913534,0.0000041945295,0.000006899446,0.0000014632093,0.000051366584,0.9955334,0.00012929743],"about_ca_topic_score_codex":0.00004009764,"about_ca_topic_score_gemma":0.000023818917,"teacher_disagreement_score":0.9925113,"about_ca_system_score_codex":0.00039290867,"about_ca_system_score_gemma":0.0013337379,"threshold_uncertainty_score":0.99919957},"labels":[],"label_agreement":null},{"id":"W4381890138","doi":"10.1101/2023.06.20.545790","title":"Engineered CD47 protects T cells for enhanced antitumor immunity","year":2023,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"School of Medicine, Stanford University; Virginia and D.K. Ludwig Fund for Cancer Research; Alliance Nationale pour les Sciences de la Vie et de la Santé; Parker Institute for Cancer Immunotherapy; National Cancer Institute; National Institutes of Health; National Science Foundation","keywords":"CD47; Chimeric antigen receptor; Macrophage; Immune system; T cell; Cancer research; Adoptive cell transfer; Immunology; Cell biology; Biology; In vitro; Biochemistry","score_opus":0.03349499980653457,"score_gpt":0.27783762579723853,"score_spread":0.24434262599070394,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4381890138","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97915334,0.0005676949,0.006886773,0.00045285063,0.0022598803,0.008509451,0.0005877511,0.0015492662,0.00003299273],"genre_scores_gemma":[0.9866613,0.00044703393,0.0077637103,0.00012738058,0.0011997516,0.002656358,0.0000030259882,0.0005143074,0.00062714244],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.995837,0.00016003786,0.00073812227,0.0013042695,0.00079769787,0.0011629065],"domain_scores_gemma":[0.9951457,0.00026030725,0.00032585743,0.0025589718,0.001173725,0.00053546095],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014381645,0.0007838139,0.0012169441,0.0006655432,0.00021139404,0.00019515703,0.00074243726,0.0008109921,0.0003710109],"category_scores_gemma":[0.0008324329,0.0008333826,0.00048414178,0.00089188665,0.00016908052,0.000094598625,0.0006462944,0.0018610795,0.0002929721],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042367473,0.00024304086,0.000094059156,0.002714709,0.0004348198,0.000099542995,0.000019530773,0.000059182756,0.9950601,0.000055455523,0.00078845106,0.0000074270965],"study_design_scores_gemma":[0.002091243,0.00030188527,0.00828154,0.0010024265,0.00015706621,2.8369815e-8,0.0000046489313,0.0005786809,0.9786348,0.0000034229822,0.008183641,0.0007606665],"about_ca_topic_score_codex":0.00011202946,"about_ca_topic_score_gemma":0.0000036889182,"teacher_disagreement_score":0.016425356,"about_ca_system_score_codex":0.0006260716,"about_ca_system_score_gemma":0.0015490233,"threshold_uncertainty_score":0.9994117},"labels":[],"label_agreement":null},{"id":"W4382240403","doi":"10.1158/2326-6066.cir-23-0189","title":"A Bispecific γδ T-cell Engager Targeting EGFR Activates a Potent Vγ9Vδ2 T cell–Mediated Immune Response against EGFR-Expressing Tumors","year":2023,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Landsteiner Foundation for Blood Transfusion Research","keywords":"Cancer research; CD8; T cell; Cytotoxic T cell; Immune system; Immunotherapy; In vivo; Effector; Peripheral blood mononuclear cell; CD3; Antibody; Ex vivo; Immunology; Biology; In vitro","score_opus":0.07868281163372867,"score_gpt":0.3782674942303921,"score_spread":0.2995846825966634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382240403","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96878606,0.016577415,0.000008821689,0.0055099996,0.0005751097,0.0017668369,0.000056574772,0.000546219,0.006172953],"genre_scores_gemma":[0.93046683,0.009989597,0.00011842215,0.00017664679,0.00048365782,0.0009446305,0.00025604927,0.00028953797,0.0572746],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9886678,0.0038841704,0.0010055127,0.0014087021,0.001826041,0.003207763],"domain_scores_gemma":[0.9919721,0.0044935094,0.00022570562,0.0016453154,0.0011722748,0.0004910908],"candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.009356413,0.00058617664,0.0010725881,0.0024841272,0.0013133168,0.00020613219,0.0011047104,0.00062693417,0.004183963],"category_scores_gemma":[0.0027230491,0.0005446633,0.00037505,0.004489066,0.001595349,0.00025162954,0.0011565983,0.00527915,0.0018922117],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013318133,0.00038694128,0.0020905554,0.00025154196,0.0002819085,0.001334624,0.0028285622,0.000065294815,0.9584829,0.0000051039256,0.011151333,0.009803107],"study_design_scores_gemma":[0.0061796093,0.0009588062,0.01686267,0.00056700764,0.000029044073,0.00004146918,0.008180514,0.00090258935,0.8810648,0.000037339065,0.084615365,0.00056082354],"about_ca_topic_score_codex":0.0006278063,"about_ca_topic_score_gemma":0.000007832999,"teacher_disagreement_score":0.077418126,"about_ca_system_score_codex":0.0020265414,"about_ca_system_score_gemma":0.0023754765,"threshold_uncertainty_score":0.9999868},"labels":[],"label_agreement":null},{"id":"W4382700748","doi":"10.1016/j.jtct.2023.06.019","title":"Chimeric Antigen Receptor T Cells as Salvage Therapy for Post-Chimeric Antigen Receptor T Cell Failure","year":2023,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation","funders":"Coins for Alzheimer's Research Trust; Swedish Orphan Biovitrum; Government of South Australia; Juno Therapeutics; Novartis; NIH Clinical Center; National Cancer Institute; National Institutes of Health; U.S. Department of Health and Human Services","keywords":"Cart; Chimeric antigen receptor; Medicine; CD19; Internal medicine; Antigen; T cell; Immunology; Oncology; Immune system","score_opus":0.020929212730782583,"score_gpt":0.28457628878529995,"score_spread":0.26364707605451737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382700748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98920655,0.003167348,0.000879049,0.001743166,0.00042691987,0.0028486182,0.00023771505,0.00038854752,0.0011020706],"genre_scores_gemma":[0.7574631,0.21095058,0.0020451322,0.0024189362,0.0007256603,0.00036709307,0.004500963,0.00035585059,0.02117267],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99707687,0.00021972293,0.0005125848,0.00077923026,0.0006315089,0.0007800567],"domain_scores_gemma":[0.99858475,0.00022824718,0.00014777502,0.0004829116,0.0002011135,0.00035523085],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00059566466,0.00049907656,0.0006129848,0.0004409093,0.00034690002,0.000105973886,0.00025473733,0.0002813196,0.00554263],"category_scores_gemma":[0.000006689229,0.00043545756,0.0003531191,0.00086737453,0.0001666978,0.00017065632,0.0000119081515,0.00035824196,0.0007349366],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038361475,0.00026126532,0.0010896239,0.0002022204,0.00024270047,0.000038615108,0.004238713,0.0000063240386,0.94443876,0.000029826057,0.0022308829,0.043384943],"study_design_scores_gemma":[0.007982999,0.0016108028,0.0027311516,0.000058527105,0.00003797606,0.00002239691,0.00072116486,0.00011708453,0.80790496,0.00005061907,0.17830284,0.0004594924],"about_ca_topic_score_codex":0.00012439572,"about_ca_topic_score_gemma":0.000007782056,"teacher_disagreement_score":0.23174345,"about_ca_system_score_codex":0.00004287011,"about_ca_system_score_gemma":0.00018647184,"threshold_uncertainty_score":0.99980974},"labels":[],"label_agreement":null},{"id":"W4382786855","doi":"10.1016/j.immuni.2023.06.007","title":"TCR-independent CD137 (4-1BB) signaling promotes CD8+-exhausted T cell proliferation and terminal differentiation","year":2023,"lang":"en","type":"article","venue":"Immunity","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":111,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; National Institutes of Health; Institut National Du Cancer; Ligue Contre le Cancer; Bristol-Myers Squibb; Fondation ARC pour la Recherche sur le Cancer; Agence Nationale de la Recherche; Fondation Toulouse Cancer Santé; Cancer Research Institute","keywords":"CD137; Biology; CD8; T cell; T-cell receptor; Cancer research; Cell biology; Immune system; Cytotoxic T cell; Cell growth; Cancer immunotherapy; Immunotherapy; Immunology; Biochemistry","score_opus":0.04049820537544255,"score_gpt":0.3159927071436563,"score_spread":0.2754945017682138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382786855","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99742246,0.0000827608,0.000105843945,0.0003370524,0.00009305031,0.0008337312,0.000006252709,0.00016954403,0.00094929204],"genre_scores_gemma":[0.9914413,0.00006225507,0.00008355156,0.000041212614,0.00014088527,0.00005475843,0.00021927961,0.00003058523,0.007926187],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99855083,0.00018659985,0.00025173664,0.00023007824,0.00047281262,0.000307913],"domain_scores_gemma":[0.99919105,0.000115772156,0.00007088511,0.00033786072,0.00016198252,0.00012245993],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066210126,0.00015271075,0.0002228089,0.00025067464,0.00023465515,0.0000912761,0.00009730685,0.00012109997,0.00081405306],"category_scores_gemma":[0.00010940902,0.00013720964,0.000059735477,0.00036712212,0.0000590848,0.00012414904,0.00011431613,0.00046373985,0.00008313539],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029489325,0.00019907815,0.02921128,0.00023007368,0.000044249933,0.00003932961,0.0015442086,0.000005096356,0.9510139,0.000009317506,0.00010627001,0.017302264],"study_design_scores_gemma":[0.0030564035,0.0007034782,0.30954885,0.00015147649,0.00009848033,0.00009198366,0.00086896797,0.008492206,0.6759866,0.00029348917,0.0004499872,0.00025807865],"about_ca_topic_score_codex":0.0001788147,"about_ca_topic_score_gemma":0.00003376232,"teacher_disagreement_score":0.28033757,"about_ca_system_score_codex":0.000094671064,"about_ca_system_score_gemma":0.00009283915,"threshold_uncertainty_score":0.891331},"labels":[],"label_agreement":null},{"id":"W4382807727","doi":"10.1016/j.annonc.2023.04.087","title":"P-31 A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Medac; Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Ipsen; Servier; Deutsche Krebshilfe; Bundesministerium für Bildung und Forschung; National Center for Global Health and Medicine; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Celgene; MacroGenics; Sanofi; Deutsche Forschungsgemeinschaft","keywords":"Medicine; Chimeric antigen receptor; Leukapheresis; Response Evaluation Criteria in Solid Tumors; T cell; Chemotherapy; Clinical trial; Internal medicine; Oncology; Immunotherapy; Phases of clinical research; Cancer research; Pharmacology; Cancer; Immunology; Immune system; CD34; Stem cell","score_opus":0.16540892445874333,"score_gpt":0.4750678984302584,"score_spread":0.30965897397151504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382807727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99007356,0.00016063679,0.0000011905269,0.0045388355,0.00014403535,0.000926082,0.000016465552,0.00005107469,0.004088136],"genre_scores_gemma":[0.99523634,0.00060056744,0.00020598382,0.00054926396,0.0001729684,0.000033527056,0.000031136162,0.000031607255,0.003138617],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99765265,0.00035627725,0.0009180728,0.00032241183,0.00029783483,0.00045274178],"domain_scores_gemma":[0.9973729,0.0015913912,0.0003447492,0.00032495044,0.00017164687,0.00019432757],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019872494,0.00015623894,0.0010342586,0.000480763,0.000057693484,0.0000031201791,0.00014178784,0.0002687736,0.0004425713],"category_scores_gemma":[0.00394545,0.00013122545,0.000109240005,0.0007788385,0.0005319811,0.00004213909,0.00015794612,0.0004905922,0.000010014718],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21761854,0.0035292208,0.0006941139,0.0003062391,0.00024849494,0.0010284387,0.005314275,0.000037998303,0.33545092,0.00010735597,0.0077299247,0.4279345],"study_design_scores_gemma":[0.5129009,0.23142038,0.031429034,0.001029164,0.00015498468,0.00032496802,0.0024501446,0.0028081492,0.08275448,0.0008051441,0.1333152,0.00060745067],"about_ca_topic_score_codex":0.00019027466,"about_ca_topic_score_gemma":0.00010143081,"teacher_disagreement_score":0.42732704,"about_ca_system_score_codex":0.00007999289,"about_ca_system_score_gemma":0.0011182919,"threshold_uncertainty_score":0.53512186},"labels":[],"label_agreement":null},{"id":"W4382983620","doi":"10.3390/curroncol30070467","title":"Toxicity Profile of Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapies in Multiple Myeloma: Pathogenesis, Prevention and Management","year":2023,"lang":"en","type":"review","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Chimeric antigen receptor; Bispecific antibody; Multiple myeloma; Adverse effect; Malignancy; Immunology; Immunotherapy; Clinical trial; Antigen; Cytokine release syndrome; Antibody; Intensive care medicine; Immune system; Monoclonal antibody; Internal medicine","score_opus":0.18569027681698777,"score_gpt":0.4573332689036392,"score_spread":0.27164299208665144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382983620","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.036863826,0.95801365,0.000013934124,0.000026944914,0.0004921674,0.0040888144,0.000075968564,0.00004289295,0.0003818015],"genre_scores_gemma":[0.00018190216,0.9968299,0.00032863131,0.000003029621,0.00015782432,0.00041429765,0.0005242052,0.0000742933,0.0014858678],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972635,0.0005641968,0.0007932304,0.0006812661,0.00029374086,0.00040410054],"domain_scores_gemma":[0.998779,0.0002706959,0.00037809584,0.00038368435,0.0000675349,0.00012097841],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00080534816,0.00037760372,0.0019057149,0.0007301768,0.00005375269,0.000014476225,0.00016272545,0.0003038121,0.00035770485],"category_scores_gemma":[0.000040449584,0.00031226804,0.00022233905,0.0007226757,0.00024332856,0.000038004448,0.00027243944,0.00043659998,0.00003922854],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000118056625,0.00083683344,0.002660912,0.03873052,0.00020929641,0.000028791965,0.00017784363,2.7748708e-8,0.0019920026,0.000013629074,0.00033250687,0.9548996],"study_design_scores_gemma":[0.0021766294,0.0007963744,0.0061492072,0.0069128172,0.00029677816,0.000025495747,0.00015654725,0.000013942566,0.00009297515,0.000013992582,0.9831091,0.00025615262],"about_ca_topic_score_codex":0.000010029274,"about_ca_topic_score_gemma":0.000024145336,"teacher_disagreement_score":0.9827766,"about_ca_system_score_codex":0.000223998,"about_ca_system_score_gemma":0.00023458242,"threshold_uncertainty_score":0.99993294},"labels":[],"label_agreement":null},{"id":"W4383226811","doi":"10.1016/j.jtct.2023.06.012","title":"ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Diffuse Large B Cell Lymphoma","year":2023,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Diffuse large B-cell lymphoma; Transplantation; ThioTEPA; Oncology; Lymphoma; Rituximab; Hematopoietic cell; Chimeric antigen receptor; Salvage therapy; Internal medicine; CHOP; Chemotherapy; Cancer; Haematopoiesis; Immunotherapy; Stem cell; Cyclophosphamide","score_opus":0.06321421224880473,"score_gpt":0.3757907171074914,"score_spread":0.31257650485868665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383226811","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98258066,0.0020606434,0.008002174,0.004562314,0.00018806725,0.0014879173,0.00014863983,0.000136216,0.0008333629],"genre_scores_gemma":[0.8762243,0.11710369,0.0016386715,0.0011012877,0.00015499581,0.00018958408,0.0016088532,0.00007482001,0.0019038157],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978411,0.00035813628,0.0005820601,0.00048802458,0.00031446642,0.00041617945],"domain_scores_gemma":[0.9984254,0.0009630198,0.00010932622,0.00022118472,0.00010568208,0.00017534655],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015301215,0.00024660048,0.00038000185,0.00032580402,0.00019636152,0.00007075508,0.000084459556,0.00020212495,0.0001965152],"category_scores_gemma":[0.000021823489,0.00022718539,0.00013081581,0.00039892757,0.00009683022,0.00024792567,0.0000060302755,0.00022039599,0.000021010534],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020890525,0.007194937,0.012726423,0.0016080634,0.0005128767,0.00064919854,0.040060144,0.0000057135007,0.5521014,0.0017241698,0.000827255,0.36169934],"study_design_scores_gemma":[0.25119445,0.004154929,0.05333885,0.0005261868,0.0007803914,0.00036188005,0.011766059,0.0060064546,0.2709965,0.0016540774,0.39767006,0.0015501465],"about_ca_topic_score_codex":0.00005434518,"about_ca_topic_score_gemma":0.000045185727,"teacher_disagreement_score":0.3968428,"about_ca_system_score_codex":0.00003012538,"about_ca_system_score_gemma":0.00007862707,"threshold_uncertainty_score":0.9264351},"labels":[],"label_agreement":null},{"id":"W4383342546","doi":"10.22541/au.168864332.23180439/v1","title":"Children’s Oncology Group’s 2023 Blueprint for Research: Cellular Therapy and Stem Cell Transplantation","year":2023,"lang":"en","type":"preprint","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Transplantation; Oncology; Umbilical cord; Stem cell; Minimal residual disease; Leukemia; Internal medicine; Hematopoietic stem cell transplantation; Myeloid leukemia; Cell therapy; Immunology; Biology","score_opus":0.24032965839095258,"score_gpt":0.41958628601329256,"score_spread":0.17925662762234,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383342546","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97110957,0.002195095,0.0035401925,0.0041698557,0.00070380734,0.009810664,0.00026735108,0.0003518218,0.007851621],"genre_scores_gemma":[0.7264211,0.087173104,0.004824055,0.0005097143,0.0030108984,0.0047258087,0.003267235,0.00059453404,0.16947351],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99552286,0.0005586138,0.0006196869,0.0013325879,0.0010253607,0.0009408704],"domain_scores_gemma":[0.99687517,0.001205534,0.00012425972,0.0009595612,0.00043062208,0.00040483294],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003983844,0.00042853676,0.0008589044,0.0008199376,0.00020510396,0.00011271171,0.0004048347,0.0009018862,0.0011029914],"category_scores_gemma":[0.000028761246,0.000372805,0.0003293646,0.00031380405,0.00030575777,0.000042853677,0.00039694752,0.002090574,0.00016016208],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012047823,0.0016121287,0.006684701,0.005046309,0.0014705786,0.0005074763,0.00690555,0.0000989439,0.54359674,0.0013534586,0.014642015,0.40603426],"study_design_scores_gemma":[0.04635146,0.017974881,0.1373965,0.0017344214,0.0007970475,0.00040128097,0.0054927543,0.005231755,0.6144834,0.017988434,0.14892833,0.0032197458],"about_ca_topic_score_codex":0.001291072,"about_ca_topic_score_gemma":0.00033441363,"teacher_disagreement_score":0.40281454,"about_ca_system_score_codex":0.00047057288,"about_ca_system_score_gemma":0.00058006885,"threshold_uncertainty_score":0.9998724},"labels":[],"label_agreement":null},{"id":"W4383561245","doi":"10.1136/jitc-2023-006863","title":"BiTE secretion by adoptively transferred stem-like T cells improves FRα+ ovarian cancer control","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Ovarian Cancer Research Alliance; McMaster University; Roswell Park Cancer Institute","keywords":"Cancer research; T cell; Medicine; Tumor microenvironment; Ovarian cancer; Adoptive cell transfer; Chimeric antigen receptor; Cytotoxic T cell; Immunology; Cancer; Biology; Immune system; Internal medicine; In vitro","score_opus":0.026223649595796015,"score_gpt":0.3397886489431468,"score_spread":0.31356499934735077,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383561245","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9451866,0.032524873,0.005814755,0.008087504,0.003630067,0.0031844648,0.0011133861,0.00014168886,0.00031662293],"genre_scores_gemma":[0.76722014,0.11023648,0.00034984917,0.0037765915,0.0021235214,0.0011336571,0.00007542203,0.00043732362,0.114646986],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974862,0.00010543612,0.00070384616,0.0003056727,0.00076090964,0.0006379526],"domain_scores_gemma":[0.99848497,0.00017907731,0.00029705727,0.0002827613,0.0005522041,0.00020395436],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00086469646,0.00029336312,0.00071620697,0.00034923264,0.00021104126,0.0000706472,0.00025335737,0.0002021216,0.0028046658],"category_scores_gemma":[0.00000844352,0.00024163605,0.00054963457,0.0005116344,0.00014535768,0.00019426663,0.000009395839,0.0005254922,0.000008128845],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007981193,0.000090064794,0.00038323767,0.00012657698,0.0011204556,0.0000065824133,0.0007722836,0.00009999679,0.80136955,0.000008695153,0.013741758,0.17429964],"study_design_scores_gemma":[0.029105632,0.0023546226,0.004280762,0.00056915934,0.00026578858,0.0000364151,0.00045593467,0.0024565319,0.32869834,0.0001471452,0.6311827,0.00044701074],"about_ca_topic_score_codex":0.0005300586,"about_ca_topic_score_gemma":0.00006322333,"teacher_disagreement_score":0.61744094,"about_ca_system_score_codex":0.00041595905,"about_ca_system_score_gemma":0.00060680445,"threshold_uncertainty_score":0.9981069},"labels":[],"label_agreement":null},{"id":"W4383907732","doi":"10.1002/adtp.202300124","title":"A Modular Antibody‐Oligomer T Cell Engager for Applications in Local Therapies","year":2023,"lang":"en","type":"article","venue":"Advanced Therapeutics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; McMaster University","funders":"Canadian Institutes of Health Research; Prostate Cancer Canada","keywords":"Cytotoxicity; Antibody; Cancer research; Antigen; Immunotherapy; Cancer; Cancer immunotherapy; CTL*; Medicine; Chemistry; Pharmacology; In vitro; Immunology; Internal medicine; CD8; Biochemistry","score_opus":0.04357636839134153,"score_gpt":0.3795854253508251,"score_spread":0.3360090569594836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383907732","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90381926,0.0046221325,0.07998421,0.002477097,0.000202858,0.0049651493,0.00006457896,0.00055818434,0.0033065532],"genre_scores_gemma":[0.9832652,0.0028140398,0.0027443809,0.0008031203,0.00012817944,0.0007480026,0.0001564811,0.00011700416,0.00922357],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984492,0.000058510966,0.00027508757,0.00037130434,0.0002997939,0.00054611394],"domain_scores_gemma":[0.99877346,0.00039916535,0.000050133374,0.00054897397,0.00013247725,0.00009578692],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003492237,0.00020556137,0.00032261238,0.0002905988,0.00011961662,0.000018531398,0.00017688585,0.00012496751,0.00015616437],"category_scores_gemma":[0.000011951398,0.00018147746,0.00014596863,0.0009153727,0.00014440964,0.00007882388,0.000039612405,0.00034271297,0.000091479924],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031154114,0.00023908408,0.001373162,0.000109225104,0.00009326466,0.000009273485,0.0011000466,0.0011256438,0.8357109,0.0006442519,0.00001120893,0.1592724],"study_design_scores_gemma":[0.0051538586,0.00046673825,0.007173671,0.000050320763,0.00006789617,0.0000068935897,0.002501849,0.011841328,0.13431804,0.0056661707,0.8323684,0.0003848259],"about_ca_topic_score_codex":0.0000080642685,"about_ca_topic_score_gemma":0.000008546437,"teacher_disagreement_score":0.83235717,"about_ca_system_score_codex":0.000103752776,"about_ca_system_score_gemma":0.00008593099,"threshold_uncertainty_score":0.74004364},"labels":[],"label_agreement":null},{"id":"W4383998685","doi":"10.1002/hon.3202","title":"Diffuse large B‐cell lymphoma","year":2023,"lang":"en","type":"review","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Rituximab; Vincristine; Lymphoma; CHOP; Prednisone; Oncology; Clinical trial; Internal medicine; Intensive care medicine; Cyclophosphamide; Chemotherapy","score_opus":0.1736930225114751,"score_gpt":0.45716910312321773,"score_spread":0.2834760806117427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383998685","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000784785,0.95279425,0.00001462678,0.00027146717,0.00043114458,0.0020066604,0.000045676545,0.00049962744,0.04385804],"genre_scores_gemma":[0.000009796842,0.95193124,0.00021086985,0.00045868923,0.00041144248,0.00064445735,0.00025499964,0.00015776137,0.045920726],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953087,0.0007435638,0.001168261,0.0009862733,0.00054579007,0.0012474171],"domain_scores_gemma":[0.9956437,0.002390917,0.00036226405,0.0009348054,0.00010743682,0.0005609021],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00085072726,0.0006533656,0.0057969415,0.00042366027,0.00011142888,0.000024008901,0.00052792486,0.0022863047,0.0075386898],"category_scores_gemma":[0.00061449734,0.00042372648,0.0013659635,0.00088971533,0.0002849295,0.000022821529,0.00059817976,0.0011143356,0.011692661],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013170153,0.006609725,0.000011590626,0.028278472,0.0003464491,0.011469239,0.0000339808,4.117998e-9,0.0000061769665,0.0016874268,0.019999783,0.93142545],"study_design_scores_gemma":[0.005182715,0.0010109093,0.00000430967,0.0025195617,0.0007302252,0.0040593543,0.000028263345,0.0000049075206,0.0000048947004,0.00016755046,0.98592454,0.00036276216],"about_ca_topic_score_codex":0.000007356631,"about_ca_topic_score_gemma":0.000010187078,"teacher_disagreement_score":0.96592474,"about_ca_system_score_codex":0.00079923635,"about_ca_system_score_gemma":0.0012654415,"threshold_uncertainty_score":0.9998215},"labels":[],"label_agreement":null},{"id":"W4384069921","doi":"10.1093/noajnl/vdad071.009","title":"ROBO1 CAR-T CELL THERAPY FOR TREATMENT REFRACTORY BRAIN CANCER","year":2023,"lang":"en","type":"article","venue":"Neuro-Oncology Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Cancer research; Medulloblastoma; Brain tumor; Medicine; In vivo; Cancer; Immunology; Pathology; Biology; Internal medicine","score_opus":0.056414335125963715,"score_gpt":0.4091929817051589,"score_spread":0.35277864657919517,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384069921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9421057,0.012166947,0.00006405117,0.027238756,0.0021661362,0.0038067126,0.00010951863,0.00056034845,0.011781838],"genre_scores_gemma":[0.53897715,0.19869961,0.0016628128,0.024660911,0.005871047,0.010550175,0.00041176195,0.0005684663,0.21859805],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981088,0.00016306232,0.0002689461,0.00056667987,0.00026027227,0.0006322558],"domain_scores_gemma":[0.99732995,0.0018536312,0.000104627725,0.0004045114,0.00012042294,0.00018685414],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00024119359,0.00025257168,0.0005381476,0.00021282984,0.00016057883,0.000012229524,0.00016095431,0.00017552947,0.0013197917],"category_scores_gemma":[0.00012372204,0.00019828744,0.00020448545,0.00038736494,0.0001811416,0.000105845174,0.0000347172,0.0002023913,0.00009900761],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00183464,0.00030865645,0.0024197453,0.000042231804,0.00006036319,0.00013158021,0.00036781988,0.00010474146,0.6271832,0.000013048178,0.012317697,0.35521626],"study_design_scores_gemma":[0.0056491606,0.0060174954,0.0017705869,0.000012473777,0.000027074575,0.000018610679,0.0001689064,0.000102815844,0.1319517,0.00013256662,0.8540095,0.00013908981],"about_ca_topic_score_codex":0.00007159716,"about_ca_topic_score_gemma":0.00020413735,"teacher_disagreement_score":0.84169185,"about_ca_system_score_codex":0.0004415584,"about_ca_system_score_gemma":0.0005142073,"threshold_uncertainty_score":0.99959314},"labels":[],"label_agreement":null},{"id":"W4384070397","doi":"10.1093/noajnl/vdad071.024","title":"AUTOLOGOUS PATIENT-DERIVED CAR-TS SHOW FUNCTIONAL DEFICITS AGAINST HUMAN GLIOBLASTOMA","year":2023,"lang":"en","type":"article","venue":"Neuro-Oncology Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Chimeric antigen receptor; Medicine; Immunotherapy; Clinical trial; Immune system; Antigen; Glioblastoma; Brain tumor; Cell therapy; Cancer research; Oncology; Immunology; Internal medicine; Cell; Pathology; Biology","score_opus":0.03225344404747963,"score_gpt":0.32698748482459494,"score_spread":0.2947340407771153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384070397","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860061,0.00058237556,0.000015515607,0.001828355,0.0016435568,0.00071408716,0.00001787072,0.00062918954,0.008562958],"genre_scores_gemma":[0.99448633,0.00084782037,0.000118578995,0.0023160193,0.0005704527,0.00021992048,0.00010658761,0.00007943616,0.0012548693],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971803,0.00026918843,0.00043093855,0.00071516226,0.0006027249,0.00080172415],"domain_scores_gemma":[0.99816674,0.00074731227,0.00015159103,0.0004462711,0.00022187675,0.00026622022],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001794112,0.00030182287,0.0005684785,0.00044577193,0.00037163982,0.000020994336,0.00019893814,0.0002609988,0.0013288668],"category_scores_gemma":[0.00039579088,0.00028078712,0.00018228605,0.0007826519,0.00043815997,0.00016937357,0.00018146103,0.0006910852,0.0005489155],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010892473,0.00019126921,0.0062525184,0.000043302094,0.00006634735,0.0013729241,0.00038509784,0.00042501,0.8564899,0.000078601646,0.0059063733,0.12769943],"study_design_scores_gemma":[0.0053230254,0.009534305,0.052168656,0.00005866419,0.00007487316,0.00080355565,0.0012484142,0.00043949622,0.16975184,0.00051446765,0.7595504,0.0005323405],"about_ca_topic_score_codex":0.0000073980464,"about_ca_topic_score_gemma":0.0001451938,"teacher_disagreement_score":0.753644,"about_ca_system_score_codex":0.00023618594,"about_ca_system_score_gemma":0.00027318439,"threshold_uncertainty_score":0.9999644},"labels":[],"label_agreement":null},{"id":"W4384131434","doi":"10.1186/s41231-023-00150-y","title":"Feasibility of manufacture of chimeric antigen receptor-regulatory T cells from patients with end-stage renal disease","year":2023,"lang":"en","type":"article","venue":"Translational Medicine Communications","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of British Columbia; Etablissement Français du Sang; Sangamo Therapeutics","keywords":"Transplantation; Human leukocyte antigen; Chimeric antigen receptor; Population; Medicine; End stage renal disease; Immunology; Cell therapy; Antigen; FOXP3; Kidney transplantation; T cell; Biology; Cell; Internal medicine; Disease; Immune system","score_opus":0.06671789336631592,"score_gpt":0.3459377385188726,"score_spread":0.2792198451525567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384131434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910691,0.0006248283,0.00018157835,0.0050213677,0.000048069687,0.00094706076,0.0010089603,0.00006038299,0.0010386454],"genre_scores_gemma":[0.99208635,0.00036681027,0.0017695765,0.00007419689,0.000056010875,0.000028613234,0.0049162223,0.00003078787,0.00067142025],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978856,0.00019314571,0.0005322035,0.00024856097,0.00095450913,0.00018602521],"domain_scores_gemma":[0.99679875,0.00067547685,0.00018796175,0.0017447234,0.0003685904,0.00022447648],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00035374306,0.0001656536,0.00041496725,0.0002522667,0.00010091225,0.0000025054142,0.00044817533,0.00006683054,0.005934508],"category_scores_gemma":[0.00006975026,0.00012844735,0.00010634138,0.000682408,0.0009071182,0.000072286515,0.000060599257,0.0002956131,0.000018500836],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025189146,0.0011722922,0.74813884,0.00025912485,0.00047356164,0.0000024372762,0.0025493142,0.0002663168,0.23259957,0.00070310925,0.0014816748,0.009834848],"study_design_scores_gemma":[0.0032348149,0.00022001869,0.9840696,0.0002686684,0.00012226195,2.0209784e-7,0.00010505316,0.00029263593,0.005161489,0.00032596051,0.00609155,0.00010778537],"about_ca_topic_score_codex":0.00020609121,"about_ca_topic_score_gemma":0.000054652563,"teacher_disagreement_score":0.23593073,"about_ca_system_score_codex":0.000041661606,"about_ca_system_score_gemma":0.00028176297,"threshold_uncertainty_score":0.9949742},"labels":[],"label_agreement":null},{"id":"W4384134344","doi":"10.58931/cht.2023.2232","title":"Cellular therapy in CLL/iNHL: Therapeutic agents in the pipeline","year":2023,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Chimeric antigen receptor; Mantle cell lymphoma; Lymphoma; Chronic lymphocytic leukemia; Oncology; Refractory (planetary science); Immunology; Internal medicine; Immunotherapy; Leukemia; Immune system","score_opus":0.07791951657750991,"score_gpt":0.3436069837462599,"score_spread":0.26568746716875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384134344","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95955664,0.0019056603,0.000004722751,0.02712512,0.00025206356,0.0011126467,0.000010070509,0.00005719783,0.00997586],"genre_scores_gemma":[0.98620903,0.0005529504,0.0000076034376,0.0072172172,0.00009067142,0.00013970361,0.00006805837,0.00004774961,0.005667011],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976969,0.00034474296,0.00035599503,0.00036965247,0.00028568655,0.0009470346],"domain_scores_gemma":[0.9986937,0.00028226865,0.000035064077,0.0006529991,0.00004735839,0.00028860898],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010861284,0.00019870624,0.00042729138,0.0009729616,0.000077495366,0.000020475154,0.00038654465,0.0002508136,0.0036161651],"category_scores_gemma":[0.00009492399,0.00014934626,0.000098437566,0.0015367885,0.00015859521,0.000036769758,0.000022741107,0.00061961607,0.00065431546],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00063174794,0.00044961314,0.7461829,0.00019023016,0.00021430569,0.024701722,0.01347162,0.000044659446,0.024077864,0.00627175,0.08911082,0.09465274],"study_design_scores_gemma":[0.009557258,0.0005504341,0.26615876,0.00020278341,0.00003318955,0.0009986307,0.0031680118,0.0022483421,0.014053727,0.0040377085,0.6983097,0.0006814162],"about_ca_topic_score_codex":0.029270161,"about_ca_topic_score_gemma":0.17734891,"teacher_disagreement_score":0.6091989,"about_ca_system_score_codex":0.00027509738,"about_ca_system_score_gemma":0.0006679082,"threshold_uncertainty_score":0.99729466},"labels":[],"label_agreement":null},{"id":"W4384463921","doi":"10.58931/cht.2022.1214","title":"Chimeric antigen receptor T-cell therapy for relapsed and refractory large B-cell lymphoma","year":2022,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Chemoimmunotherapy; Medicine; Rituximab; Lymphoma; Vincristine; Internal medicine; Oncology; Cyclophosphamide; Chemotherapy; Refractory (planetary science); Salvage therapy; Prednisone; CHOP; Autologous stem-cell transplantation","score_opus":0.01717987800143865,"score_gpt":0.27041674975359287,"score_spread":0.2532368717521542,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384463921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9726742,0.010041276,0.000016318136,0.0036132943,0.00051438715,0.00153467,0.0002301656,0.000065574895,0.011310116],"genre_scores_gemma":[0.9583949,0.0010404636,0.0003498567,0.004649951,0.00013351465,0.00043928585,0.00027646116,0.00011540147,0.034600202],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978673,0.00018879771,0.00028608603,0.0005295379,0.00022480261,0.00090350397],"domain_scores_gemma":[0.99835014,0.00022676609,0.00008899857,0.000527541,0.00008192792,0.0007246006],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005218869,0.00022864807,0.00051052787,0.00043679535,0.0005250396,0.000016925427,0.00022337848,0.0001836271,0.010150366],"category_scores_gemma":[0.000057007277,0.00023633869,0.00013563696,0.00033036704,0.00013122149,0.00004386452,0.000059082064,0.00032585344,0.00006927795],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003357493,0.0028642928,0.08783472,0.00054017926,0.0005318372,0.0012410562,0.0051588546,0.0000018098776,0.22863387,0.002544416,0.6151634,0.052128125],"study_design_scores_gemma":[0.010377456,0.00086104806,0.00162372,0.00000901973,0.000018633791,0.00032486394,0.0005594392,0.0000637125,0.012140142,0.00007746892,0.9736937,0.00025079303],"about_ca_topic_score_codex":0.0044318335,"about_ca_topic_score_gemma":0.0034568517,"teacher_disagreement_score":0.35853034,"about_ca_system_score_codex":0.0004664207,"about_ca_system_score_gemma":0.0014807993,"threshold_uncertainty_score":0.9907545},"labels":[],"label_agreement":null},{"id":"W4384925159","doi":"10.1186/s12967-023-04329-7","title":"Perspectives in Immunotherapy: meeting report from Immunotherapy Bridge (Naples, November 30th–December 1st, 2022)","year":2023,"lang":"en","type":"article","venue":"Journal of Translational Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"EMD Serono; Genentech; National Institutes of Health; Eisai; MacroGenics; Moderna; Apellis Pharmaceuticals; Incyte; Sanofi; Exelixis; Regeneron Pharmaceuticals; Gilead Sciences; BeiGene; Bristol-Myers Squibb; AstraZeneca; Celldex Therapeutics; Amgen; University of Texas MD Anderson Cancer Center; Pfizer; National Cancer Institute; Emory University","keywords":"Immunotherapy; Medicine; Immune system; Cancer immunotherapy; Melanoma; Adoptive immunotherapy; Immunology; Cancer research","score_opus":0.05524501084084582,"score_gpt":0.36268935682250625,"score_spread":0.3074443459816604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384925159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.916335,0.023707114,0.0007326173,0.045363724,0.00077103806,0.0006099401,0.000028799037,0.000065557324,0.012386196],"genre_scores_gemma":[0.9774609,0.008530312,0.0019542435,0.0007987285,0.0037152944,0.000019655396,0.00016949442,0.00014394744,0.0072074095],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.995553,0.00018533804,0.0015198066,0.00036486128,0.0019368092,0.00044018708],"domain_scores_gemma":[0.99738026,0.00091516704,0.0004900416,0.00039196663,0.000619157,0.00020342573],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0027264592,0.00029499232,0.0009295959,0.0009915262,0.000085981585,0.000021907977,0.00025340583,0.0001716586,0.010546435],"category_scores_gemma":[0.00035597,0.00022871084,0.00034381775,0.0012552079,0.00025311703,0.00023224675,0.000017020382,0.0009781641,0.000031672218],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008073149,0.00060485967,0.10599367,0.00007199181,0.0016418676,0.0048227194,0.015520534,0.00041887892,0.78202736,0.00017449862,0.018414877,0.062235598],"study_design_scores_gemma":[0.019646652,0.0009117514,0.87112457,0.0014531446,0.00012086773,0.0024709578,0.002451916,0.00081007613,0.0019356458,0.0032328248,0.09548525,0.000356354],"about_ca_topic_score_codex":0.00061006815,"about_ca_topic_score_gemma":0.00015232309,"teacher_disagreement_score":0.7800917,"about_ca_system_score_codex":0.0002443622,"about_ca_system_score_gemma":0.00050776225,"threshold_uncertainty_score":0.99035805},"labels":[],"label_agreement":null},{"id":"W4385063875","doi":"10.1002/pbc.30577","title":"Children's Oncology Group's 2023 blueprint for research: Cellular therapy and stem cell transplantation","year":2023,"lang":"en","type":"article","venue":"Pediatric Blood & Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"National Cancer Institute; National Institutes of Health","keywords":"Medicine; Transplantation; Oncology; Stem cell; Umbilical cord; Minimal residual disease; Leukemia; Internal medicine; Hematopoietic stem cell transplantation; Myeloid leukemia; Immunology","score_opus":0.10202665111422239,"score_gpt":0.3807347684414044,"score_spread":0.27870811732718204,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385063875","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98565847,0.009492442,0.000053663865,0.0013185365,0.00026459267,0.002146585,0.00014479567,0.00012480863,0.00079610036],"genre_scores_gemma":[0.8140679,0.1727095,0.00020666799,0.00017654068,0.003750119,0.0013077146,0.0002048166,0.00010539918,0.0074713277],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9974825,0.00020027878,0.00030920203,0.00059265416,0.00065398245,0.00076142384],"domain_scores_gemma":[0.9984901,0.0006191201,0.00007058798,0.00032542177,0.0002208795,0.0002738799],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015375204,0.00019569648,0.00036609865,0.000558156,0.00020090242,0.000037388545,0.00017169221,0.00021367065,0.0005782681],"category_scores_gemma":[0.000016252985,0.00017586828,0.00012779253,0.0011304723,0.00010842534,0.0000632457,0.00005394321,0.0005347693,0.00006657989],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059247282,0.0014781371,0.21653895,0.0026251753,0.0006921934,0.00038768447,0.0058122617,0.00005921652,0.37591392,0.00022509365,0.01672461,0.373618],"study_design_scores_gemma":[0.06801693,0.013910298,0.53943735,0.00019414163,0.002347383,0.00021699724,0.0018794591,0.0009619522,0.20035613,0.0013554018,0.1695049,0.0018190568],"about_ca_topic_score_codex":0.0005253917,"about_ca_topic_score_gemma":0.000089077315,"teacher_disagreement_score":0.37179896,"about_ca_system_score_codex":0.000111120804,"about_ca_system_score_gemma":0.00037083187,"threshold_uncertainty_score":0.71717},"labels":[],"label_agreement":null},{"id":"W4385302690","doi":"10.1038/s41591-023-02452-y","title":"Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results","year":2023,"lang":"en","type":"article","venue":"Nature Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":103,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; National Institutes of Health","keywords":"Mesothelin; Medicine; Internal medicine; Pneumonitis; Interim analysis; Pembrolizumab; Oncology; Cytokine release syndrome; Clinical endpoint; Refractory (planetary science); Gastroenterology; Cancer; Clinical trial; Chimeric antigen receptor; Immunotherapy; Lung","score_opus":0.03486724585317036,"score_gpt":0.3866904057862175,"score_spread":0.35182315993304714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385302690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9668726,0.004352105,0.0000057013626,0.005429965,0.0024151313,0.0021326237,0.000060299215,0.00030662888,0.018424992],"genre_scores_gemma":[0.9734553,0.0059774015,0.00021672493,0.0014375647,0.004512106,0.00006597939,0.00077727117,0.00013411633,0.013423518],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99515456,0.000422499,0.0012568977,0.00088100694,0.001409778,0.0008752572],"domain_scores_gemma":[0.997196,0.0009267135,0.00034990057,0.000793256,0.0003246151,0.00040951304],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0035203972,0.00047351306,0.0011262952,0.0010797734,0.00011558858,0.000022045462,0.00039302852,0.0007188503,0.0054692742],"category_scores_gemma":[0.0018381014,0.0003428407,0.00019523977,0.0016639067,0.00035642803,0.00010040898,0.0001245466,0.0032337299,0.00022477393],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10389332,0.0005986702,0.00008457026,0.00015433929,0.0000316541,0.00041288498,0.0022868372,0.0000012112688,0.81687886,0.0000033250133,0.04560823,0.030046124],"study_design_scores_gemma":[0.268738,0.010062429,0.00007979225,0.0008775994,0.00003293024,0.000029081555,0.002478712,0.0002955698,0.4483346,0.000044638207,0.26866052,0.00036613812],"about_ca_topic_score_codex":0.00010440734,"about_ca_topic_score_gemma":0.000010811535,"teacher_disagreement_score":0.36854422,"about_ca_system_score_codex":0.00031278413,"about_ca_system_score_gemma":0.0003986323,"threshold_uncertainty_score":0.99990237},"labels":[],"label_agreement":null},{"id":"W4385406834","doi":"10.1111/imr.13254","title":"Eras of designer Tregs: Harnessing synthetic biology for immune suppression","year":2023,"lang":"en","type":"review","venue":"Immunological Reviews","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"Breakthrough T1D Canada; Canadian Institutes of Health Research; Juvenile Diabetes Research Foundation Canada","keywords":"FOXP3; Biology; Genome editing; Immunology; Autoimmunity; Chimeric antigen receptor; Immune system; Immune tolerance; Antigen; Immunotherapy; Computational biology; CRISPR; Genetics","score_opus":0.3221200108650642,"score_gpt":0.4857176525348458,"score_spread":0.16359764166978158,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385406834","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000038540506,0.9916591,0.00031915333,0.00007379365,0.0003912897,0.006581837,0.00005215547,0.00011562074,0.00080318475],"genre_scores_gemma":[0.0000022509957,0.98733234,0.0011218754,0.000023609175,0.00018035228,0.002013088,0.00037381006,0.00013541212,0.00881726],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9942337,0.0015079475,0.0023808063,0.00085655233,0.0002542474,0.0007667264],"domain_scores_gemma":[0.9947513,0.0025605026,0.0010031795,0.0013867641,0.00017240515,0.00012590294],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002715654,0.00070479553,0.0069954824,0.00040854287,0.00011674963,0.000027657037,0.000705324,0.001065204,0.0026262233],"category_scores_gemma":[0.0046420023,0.00038658336,0.0026804758,0.0007966762,0.00049055007,0.000041080613,0.00032644157,0.0009980635,0.00054164603],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013638285,0.00015957408,3.80097e-7,0.032981873,0.0003116955,0.000013452364,0.000015758586,1.72383e-8,0.0074033155,0.00014928966,0.0002092547,0.958619],"study_design_scores_gemma":[0.00057918445,0.0007928128,0.000002469526,0.061772097,0.00106646,0.00008695068,0.000009393611,0.0000026796272,0.00023887971,0.00022111622,0.9349093,0.00031865883],"about_ca_topic_score_codex":0.00001320843,"about_ca_topic_score_gemma":3.872058e-7,"teacher_disagreement_score":0.95830035,"about_ca_system_score_codex":0.00021545327,"about_ca_system_score_gemma":0.00031365766,"threshold_uncertainty_score":0.9998586},"labels":[],"label_agreement":null},{"id":"W4385477467","doi":"10.1097/tp.0000000000004709","title":"Human A2-CAR T Cells Reject HLA-A2+ Human Islets Transplanted Into Mice Without Inducing Graft-versus-host Disease","year":2023,"lang":"en","type":"article","venue":"Transplantation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia; University of Alberta","funders":"Breakthrough T1D Canada; National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases; Manpei Suzuki Diabetes Foundation; Genome British Columbia; Stem Cell Network; BC Children's Hospital; Juvenile Diabetes Research Foundation Canada","keywords":"Graft-versus-host disease; Host (biology); Islet; Human leukocyte antigen; Immunology; Human disease; Disease; Transplantation; Biology; Graft vs Host Reaction; Virology; Medicine; Diabetes mellitus; Antigen; Pathology; Genetics; Surgery; Bone marrow transplantation; Endocrinology","score_opus":0.04540071783670685,"score_gpt":0.35078925815447654,"score_spread":0.3053885403177697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385477467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946667,0.0000611241,0.00022628711,0.00043416326,0.00032028777,0.0011409221,0.00015876697,0.00055275793,0.0024390104],"genre_scores_gemma":[0.99333346,0.00055226055,0.00012505404,0.00014718836,0.00032797095,0.00009051366,0.0022546079,0.00012100398,0.0030479315],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9969949,0.00022239632,0.00052690745,0.00069933524,0.0009030089,0.00065345713],"domain_scores_gemma":[0.9986892,0.00016394022,0.00009923751,0.00049144693,0.00013121942,0.0004249995],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00054926984,0.00037577204,0.00046748557,0.0006015208,0.00044181003,0.00006832458,0.00024509933,0.00018813749,0.000958919],"category_scores_gemma":[0.000014515497,0.00037848402,0.00023053637,0.0008441118,0.00015179193,0.0002352791,0.00001339084,0.0005667573,0.00034092675],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003423569,0.00013600581,0.0024286583,0.0013772872,0.00018632387,0.0007003755,0.0067391917,0.000060990496,0.98407876,0.00007838248,0.00025373945,0.0005367069],"study_design_scores_gemma":[0.023826754,0.0013349471,0.10892632,0.001973425,0.00170707,0.000073913405,0.0009987968,0.0009500396,0.857303,0.00020485299,0.0015737617,0.0011271184],"about_ca_topic_score_codex":0.0009132282,"about_ca_topic_score_gemma":0.00059917924,"teacher_disagreement_score":0.12677576,"about_ca_system_score_codex":0.000178915,"about_ca_system_score_gemma":0.00013822231,"threshold_uncertainty_score":0.99995434},"labels":[],"label_agreement":null},{"id":"W4385552853","doi":"10.51731/cjht.2023.706","title":"Ciltacabtagene Autoleucel (Carvykti)","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Medicine; Drug; Refractory (planetary science); Antibody therapy; Intensive care medicine; Pharmacology; Antibody; Immunology; Health care; Monoclonal antibody; Political science","score_opus":0.0766381167478992,"score_gpt":0.36080694697566534,"score_spread":0.2841688302277662,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385552853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.69311696,0.05023756,0.000119854456,0.2497808,0.0010406511,0.00076571346,0.000040084684,0.0008695309,0.0040288707],"genre_scores_gemma":[0.9929139,0.0020516186,0.00035978816,0.000716465,0.000041870597,0.000007052909,0.000005589965,0.000033946064,0.003869744],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981405,0.000052505144,0.00052898255,0.00014854735,0.00034494174,0.0007845046],"domain_scores_gemma":[0.9988563,0.00007371006,0.00020447897,0.00037689664,0.00023960398,0.00024898077],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012719514,0.00012629456,0.00045972367,0.0017217865,0.00020902693,0.00003010469,0.00035645964,0.0001871214,0.00046518137],"category_scores_gemma":[0.0007881792,0.000107061205,0.00012947718,0.0012365481,0.00024181497,0.00006678007,0.000032784126,0.0007674705,0.000114961775],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000032654672,0.000011464834,0.0057937982,0.00014071244,0.00007458132,0.0013529338,0.00025379617,0.000012453224,0.003368208,0.0003301485,0.04686354,0.9417657],"study_design_scores_gemma":[0.0010099204,0.0009587053,0.026227707,0.00029502867,0.000014748444,0.0011452363,0.0032735004,0.00007110045,0.0047805565,0.0020648525,0.96001565,0.00014300938],"about_ca_topic_score_codex":0.002686121,"about_ca_topic_score_gemma":0.0016565348,"teacher_disagreement_score":0.9416227,"about_ca_system_score_codex":0.0007153464,"about_ca_system_score_gemma":0.005581207,"threshold_uncertainty_score":0.99008214},"labels":[],"label_agreement":null},{"id":"W4385578304","doi":"10.1093/noajnl/vdad070.128","title":"SYST-26 INVESTIGATING THE FUNCTIONAL ROLE OF GPNMB IN GLIOBLASTOMA AND THE TUMOR IMMUNE MICROENVIRONMENT AND ITS TARGETED ELIMINATION USING CAR-T CELLS","year":2023,"lang":"en","type":"article","venue":"Neuro-Oncology Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Calgary; University of Toronto; McMaster University","funders":"","keywords":"Cancer research; Downregulation and upregulation; Immune system; Biology; Glioma; Immunotherapy; Tumor microenvironment; Cell culture; In vivo; Immunology","score_opus":0.01791703292439036,"score_gpt":0.283449173471124,"score_spread":0.2655321405467337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385578304","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919947,0.0051295287,0.0000042372085,0.0019461913,0.00014995255,0.0006750245,0.000004780548,0.000023919954,0.00007170016],"genre_scores_gemma":[0.998292,0.0010911867,0.00007645964,0.00030186816,0.000074445816,0.00006117469,0.0000027174938,0.000021312493,0.000078784455],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986199,0.00035335406,0.00030305312,0.00024296262,0.00024978636,0.0002309571],"domain_scores_gemma":[0.99844575,0.001166365,0.00015325441,0.0001431592,0.00004352924,0.000047934136],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006860661,0.00011919433,0.00028834102,0.00013637103,0.00014914798,0.000009283537,0.00007985422,0.000052558684,0.000052689724],"category_scores_gemma":[0.0002965524,0.00007696211,0.00003656116,0.0003309661,0.00057366135,0.000088111155,0.00012772117,0.00031461113,0.0000047008366],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006320665,0.000029521387,0.0038809485,0.00006460943,0.000019545574,0.000022179525,0.00080549973,0.0009467161,0.989372,0.000081886545,0.000012641199,0.0041323886],"study_design_scores_gemma":[0.0052574035,0.00091672956,0.078520656,0.00011197318,0.00008446931,0.0003001658,0.0041717216,0.033401094,0.8707956,0.00054178154,0.0057601356,0.00013826997],"about_ca_topic_score_codex":0.000027308673,"about_ca_topic_score_gemma":0.000037721733,"teacher_disagreement_score":0.11857639,"about_ca_system_score_codex":0.00007973407,"about_ca_system_score_gemma":0.000072594936,"threshold_uncertainty_score":0.3138424},"labels":[],"label_agreement":null},{"id":"W4385578484","doi":"10.1093/noajnl/vdad070.133","title":"SYST-33 GENERATION OF ALLOGENEIC CAR-T CIRCUMVENTS FUNCTIONAL DEFICITS IN PATIENT-DERIVED AUTOLOGOUS PRODUCT FOR GLIOBLASTOMA","year":2023,"lang":"en","type":"article","venue":"Neuro-Oncology Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre; University of Toronto; McMaster University","funders":"","keywords":"Chimeric antigen receptor; Medicine; Clinical trial; Immunotherapy; Immune system; Antigen; T cell; Cell therapy; Cancer research; Immunology; Oncology; Internal medicine; Cell; Biology","score_opus":0.05064917220828051,"score_gpt":0.33389486940954705,"score_spread":0.2832456972012665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385578484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949603,0.000796533,0.00011327011,0.00076102273,0.0014446542,0.0016120649,0.00003579766,0.00010288223,0.00017347038],"genre_scores_gemma":[0.9977923,0.0003662957,0.00028616303,0.00027365523,0.00037742982,0.00056629564,0.00011865626,0.00004017385,0.00017905346],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99795336,0.0002103526,0.0004824015,0.00054931815,0.00035362455,0.00045095297],"domain_scores_gemma":[0.9987107,0.00048292402,0.00017807305,0.00028326985,0.0002585782,0.00008643731],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003089163,0.0001803879,0.0004820466,0.00042013716,0.00008870364,0.000005802383,0.00011020257,0.00014083917,0.00017134965],"category_scores_gemma":[0.0006913311,0.00017206692,0.00011326085,0.00057469634,0.0001637815,0.00011085431,0.000060023733,0.00023020973,0.000033970686],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016553359,0.00021527322,0.008067763,0.00016122182,0.000045052555,0.00012329029,0.00029484867,0.002589362,0.9226785,0.000036045643,0.0008459042,0.06328744],"study_design_scores_gemma":[0.006438767,0.009662804,0.04069426,0.00007395508,0.000095692914,0.0005175112,0.0005127463,0.0031303053,0.8646182,0.0003005994,0.07361723,0.00033795706],"about_ca_topic_score_codex":0.000009490297,"about_ca_topic_score_gemma":0.00016291355,"teacher_disagreement_score":0.072771326,"about_ca_system_score_codex":0.00019242735,"about_ca_system_score_gemma":0.00032706448,"threshold_uncertainty_score":0.70166856},"labels":[],"label_agreement":null},{"id":"W4385620600","doi":"10.1080/10428194.2023.2234528","title":"Comparative effectiveness of salvage chemotherapy regimens and chimeric antigen T-cell receptor therapies in relapsed and refractory diffuse large B cell lymphoma: a network meta-analysis of clinical trials","year":2023,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Oncology; Internal medicine; Rituximab; Gemcitabine; Chimeric antigen receptor; Salvage therapy; Regimen; Clinical trial; Diffuse large B-cell lymphoma; Lymphoma; Chemotherapy regimen; Chemotherapy; Refractory (planetary science); Immunotherapy; Cancer; Biology","score_opus":0.1039930813529429,"score_gpt":0.3912292872957763,"score_spread":0.2872362059428334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385620600","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97637874,0.020166183,0.000032147527,0.000078852056,0.00016589848,0.0019191043,0.00016996318,0.00011641265,0.0009727083],"genre_scores_gemma":[0.9783008,0.018818619,0.00040112287,0.00026018632,0.00016753025,0.00018894488,0.00019089773,0.00013395559,0.0015379392],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.988958,0.004674248,0.0027817981,0.0015323568,0.0009720097,0.0010815862],"domain_scores_gemma":[0.9875373,0.009033001,0.0014255359,0.0011959751,0.00027021577,0.00053797016],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.011959885,0.0009064265,0.008175881,0.0012242864,0.00021103909,0.00007026777,0.00035868897,0.00079004414,0.0002645896],"category_scores_gemma":[0.00042103216,0.00072201295,0.0016750633,0.0034702974,0.0009888879,0.000185249,0.00028533133,0.0002846585,0.000010887978],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.053640377,0.009666849,0.1667114,0.0035615491,0.15903236,0.00049200293,0.018745223,0.0002347698,0.51570547,0.00036669555,0.0034698662,0.06837341],"study_design_scores_gemma":[0.14724663,0.0024539798,0.74568284,0.00031055819,0.033061173,0.000054584692,0.0023758165,0.0090079615,0.04965974,0.00023921006,0.008605747,0.0013017288],"about_ca_topic_score_codex":0.0011109128,"about_ca_topic_score_gemma":0.00008839298,"teacher_disagreement_score":0.57897145,"about_ca_system_score_codex":0.0010282763,"about_ca_system_score_gemma":0.0016907653,"threshold_uncertainty_score":0.9995231},"labels":[],"label_agreement":null},{"id":"W4385644673","doi":"10.1097/01.hs9.0000967692.36989.7b","title":"S195: IDECABTAGENE VICLEUCEL (IDE-CEL) VS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED (TCE) RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): A KARMMA-3 ANALYSIS IN HIGH-RISK SUBGROUPS","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Daratumumab; Medicine; Internal medicine; Regimen; Oncology; Refractory (planetary science); Lenalidomide; Population; Multiple myeloma","score_opus":0.012653030857564059,"score_gpt":0.2517735670351252,"score_spread":0.23912053617756115,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385644673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99667275,0.00033738592,0.000031560317,0.0003601463,0.00008912034,0.0015947944,0.00013345898,0.00019551563,0.0005852845],"genre_scores_gemma":[0.99219865,0.0004018853,0.00064463203,0.00012853189,0.00006774072,0.0001246519,0.0003651806,0.00013942589,0.0059293304],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952936,0.00041739724,0.0008641935,0.0010746615,0.0013596877,0.000990457],"domain_scores_gemma":[0.9973448,0.000576716,0.00028075723,0.0010938407,0.00026280398,0.00044111183],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011548179,0.000489327,0.0012909999,0.0009609066,0.00013629586,0.00006307651,0.00022875647,0.00033814757,0.0016417602],"category_scores_gemma":[0.0004892182,0.00042380654,0.00021027304,0.0045905104,0.00019739731,0.00022316801,0.00016916012,0.0009342292,0.00007390177],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013921869,0.0005299776,0.9605591,0.00015870697,0.0006861307,0.0005541751,0.0016257456,0.00012534503,0.009297656,0.000010253372,0.0012089039,0.011322129],"study_design_scores_gemma":[0.03335174,0.0021022875,0.9538229,0.00023242188,0.0003670098,0.000004340199,0.0011614227,0.00131833,0.0040966487,0.0000466182,0.0030006368,0.0004956046],"about_ca_topic_score_codex":0.0013530658,"about_ca_topic_score_gemma":0.011666938,"teacher_disagreement_score":0.019429874,"about_ca_system_score_codex":0.0007132029,"about_ca_system_score_gemma":0.0002700971,"threshold_uncertainty_score":0.99982136},"labels":[],"label_agreement":null},{"id":"W4385644849","doi":"10.1097/01.hs9.0000967680.90062.ca","title":"S192: TALQUETAMAB (TAL) + DARATUMUMAB (DARA) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED TRIMM-2 RESULTS","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Institute of Cancer Research; University of Calgary","funders":"","keywords":"Daratumumab; Medicine; Internal medicine; Oncology; Refractory (planetary science); CD38; Gastroenterology; Lenalidomide; Multiple myeloma; CD34","score_opus":0.020957787947047585,"score_gpt":0.2764088675186831,"score_spread":0.2554510795716355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385644849","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9692737,0.00016808041,0.000006053307,0.0004644179,0.00026284336,0.0015093635,0.00010288774,0.0004292791,0.027783409],"genre_scores_gemma":[0.9491892,0.00007668828,0.00027136962,0.0001727777,0.00020937163,0.000099057295,0.001294833,0.00016153954,0.048525196],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995917,0.0001966848,0.0007236379,0.0009427381,0.0012264928,0.0009934069],"domain_scores_gemma":[0.9976684,0.00024236541,0.00018303144,0.0011765207,0.00036684828,0.00036285206],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0005894813,0.00044184813,0.0006920364,0.0003424537,0.00016387721,0.000051588577,0.00030613036,0.00034561675,0.0029051793],"category_scores_gemma":[0.00043523867,0.00036938553,0.00015333475,0.0021920467,0.000240462,0.00023409438,0.00017218341,0.0009146763,0.0016829837],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10525242,0.005628404,0.35156307,0.00079401163,0.0010259917,0.0047731865,0.00525307,0.000154778,0.06635723,0.00009054659,0.300951,0.15815628],"study_design_scores_gemma":[0.092767216,0.0068533253,0.540109,0.0009814963,0.000111920875,0.000078184596,0.0015431412,0.0020930998,0.025714695,0.00006267607,0.32848838,0.0011968712],"about_ca_topic_score_codex":0.00026408755,"about_ca_topic_score_gemma":0.00077619165,"teacher_disagreement_score":0.18854593,"about_ca_system_score_codex":0.00048564453,"about_ca_system_score_gemma":0.00037301562,"threshold_uncertainty_score":0.9998758},"labels":[],"label_agreement":null},{"id":"W4385666327","doi":"10.1097/01.hs9.0000967372.19440.62","title":"S115: CONSOLIDATION WITH BLINATUMOMAB IMPROVES OVERALL AND RELAPSE-FREE SURVIVAL IN PATIENTS WITH NEWLY DIAGNOSED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: IMPACT OF AGE AND MRD LEVEL IN ECOG-ACRIN E1910","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Blinatumomab; Internal medicine; Minimal residual disease; Oncology; Rituximab; Induction chemotherapy; Chemotherapy; Acute lymphocytic leukemia; Chemotherapy regimen; Lymphoblastic Leukemia; Leukemia; Lymphoma","score_opus":0.017448307798226627,"score_gpt":0.27229854191145964,"score_spread":0.254850234113233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385666327","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9978395,0.00011902989,0.000010862231,0.00006182109,0.000031947588,0.0009534482,0.00007411314,0.000039206512,0.00087005424],"genre_scores_gemma":[0.99734104,0.00021083542,0.00032228578,0.000025987436,0.000022878417,0.000040756804,0.000105785046,0.00006555446,0.0018648994],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99816394,0.00008663442,0.00034647156,0.00044231626,0.00049140526,0.000469218],"domain_scores_gemma":[0.9988152,0.00033692838,0.00012344924,0.00042350596,0.00011652009,0.00018444107],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025521882,0.000277788,0.0005722096,0.00023457139,0.00003380759,0.000035065303,0.00011392838,0.00015133596,0.00015154478],"category_scores_gemma":[0.00013875596,0.00020817401,0.000045612847,0.0006249098,0.00018951498,0.00018403887,0.00013327146,0.00033896187,0.000005313974],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009475654,0.0005806146,0.9436383,0.00060792983,0.00022545099,0.0013957145,0.0013339017,0.00016390525,0.03555335,0.000030795072,0.0007037716,0.006290597],"study_design_scores_gemma":[0.03756919,0.0030686064,0.95552826,0.000373489,0.00005847605,0.00002071598,0.00029838367,0.0007851392,0.001960393,0.0000784381,0.000022622258,0.00023630496],"about_ca_topic_score_codex":0.001606701,"about_ca_topic_score_gemma":0.002443408,"teacher_disagreement_score":0.033592958,"about_ca_system_score_codex":0.00037380133,"about_ca_system_score_gemma":0.0004465444,"threshold_uncertainty_score":0.84890896},"labels":[],"label_agreement":null},{"id":"W4385667275","doi":"10.1097/01.hs9.0000972412.18474.98","title":"P1381: DISTINCT CYTOKINE SIGNATURES OF IDECABTAGENE VICLEUCEL COMPARED TO AXICABTAGENE CILEUCEL AND LISOCABTAGENE MARALEUCEL","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cytokine release syndrome; Chimeric antigen receptor; Medicine; Immunotherapy; Cytokine; Lymphoma; Oncology; Internal medicine; Immunology; Immune system","score_opus":0.03743959570515347,"score_gpt":0.32109295928812887,"score_spread":0.2836533635829754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385667275","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9854155,0.0014299841,0.0001707952,0.001582028,0.0001844631,0.0012001067,0.00022637034,0.00033350234,0.009457247],"genre_scores_gemma":[0.9665949,0.00033417772,0.0013242575,0.0005089589,0.00035322184,0.00010719134,0.00018448634,0.00013237727,0.030460458],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9965848,0.0001159896,0.0006726936,0.00079382374,0.000984106,0.00084863004],"domain_scores_gemma":[0.9976172,0.0002975372,0.00014094362,0.0009477702,0.00028840164,0.0007081338],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005926757,0.00044132525,0.00097127364,0.00031124032,0.00015472108,0.000047896923,0.00033096084,0.00024719027,0.006603171],"category_scores_gemma":[0.0002618247,0.00040209203,0.00023561301,0.0016167662,0.00022895695,0.000090178786,0.00041101567,0.00043416783,0.0002739035],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011915937,0.0002552616,0.011351358,0.0005917449,0.00023554558,0.00036446538,0.00060338643,0.00013625536,0.9356954,0.00012012693,0.030435275,0.019019559],"study_design_scores_gemma":[0.0077945637,0.0014940448,0.36202928,0.0006169765,0.00025587578,0.00015369407,0.0013548358,0.003110599,0.51187485,0.000363583,0.109874845,0.0010768666],"about_ca_topic_score_codex":0.00017853668,"about_ca_topic_score_gemma":0.00013823605,"teacher_disagreement_score":0.42382059,"about_ca_system_score_codex":0.00012226717,"about_ca_system_score_gemma":0.00016844834,"threshold_uncertainty_score":0.9998431},"labels":[],"label_agreement":null},{"id":"W4385667651","doi":"10.1097/01.hs9.0000971208.36694.eb","title":"P1078: MOSUNETUZUMAB DEMONSTRATES DURABLE RESPONSES IN PATIENTS WITH RELAPSED AND/OR REFRACTORY FOLLICULAR LYMPHOMA WHO HAVE RECEIVED ≥2 PRIOR THERAPIES: UPDATED ANALYSIS OF A PIVOTAL PHASE II STUDY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Jewish General Hospital; McGill University; Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Medicine; Follicular lymphoma; Internal medicine; Refractory (planetary science); Clinical endpoint; Phases of clinical research; Surrogate endpoint; Lymphoma; Clinical trial; Oncology; Surgery; Gastroenterology","score_opus":0.021690606153916586,"score_gpt":0.3096533414890721,"score_spread":0.2879627353351555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385667651","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99711835,0.00034232216,0.0000034091645,0.00012492371,0.000019143063,0.0018577406,0.00005783144,0.00010430349,0.00037196174],"genre_scores_gemma":[0.9850062,0.00017422931,0.00013759002,0.0000380801,0.000015268002,0.00012166351,0.0001800716,0.00007004258,0.014256831],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969408,0.0003981643,0.000635825,0.0006484773,0.000859876,0.00051684043],"domain_scores_gemma":[0.998161,0.0003561858,0.0002159828,0.00075074076,0.0003162814,0.0001997987],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006630454,0.0003369322,0.001075051,0.0006581812,0.0001659041,0.000035170917,0.0001682052,0.00016632889,0.0022365104],"category_scores_gemma":[0.00023444142,0.00024248491,0.00015182182,0.003274766,0.00019884815,0.00015995574,0.00009885259,0.00024158944,0.000007640129],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.080064066,0.008628425,0.8345962,0.00014290381,0.0066662384,0.0008177492,0.011585189,0.00006771899,0.021806011,0.000003241059,0.00063385157,0.034988366],"study_design_scores_gemma":[0.05463182,0.019620892,0.89818454,0.00032562145,0.0013077129,0.000009530123,0.017311921,0.0035800356,0.0036026565,0.000008475543,0.0009788119,0.00043797825],"about_ca_topic_score_codex":0.0005454008,"about_ca_topic_score_gemma":0.0012211355,"teacher_disagreement_score":0.06358831,"about_ca_system_score_codex":0.00020732572,"about_ca_system_score_gemma":0.00037119508,"threshold_uncertainty_score":0.9986756},"labels":[],"label_agreement":null},{"id":"W4385667659","doi":"10.1097/01.hs9.0000972428.19857.ae","title":"P1385: DISTINCT RATES OF ICANS BUT SIMILAR CYTOKINE SIGNATURES BETWEEN TWO CD19-CAR T CELL THERAPIES: LISOCABTAGENE MARALEUCEL AND AXICABTAGENE CILOLEUCEL","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cytokine release syndrome; Medicine; Oncology; Chimeric antigen receptor; Internal medicine; Immunotherapy; Immunology; Cytokine; Immune system","score_opus":0.04156970555081718,"score_gpt":0.32604922160139255,"score_spread":0.28447951605057537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385667659","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98632574,0.0050208527,0.000095416966,0.0012964002,0.00010421813,0.0009147277,0.0003237053,0.0002512426,0.005667684],"genre_scores_gemma":[0.9655217,0.0017213211,0.0006285492,0.0002241179,0.00061250804,0.000068228575,0.00024402716,0.00015449249,0.030825088],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99672335,0.00018945057,0.00062397507,0.00074943394,0.00088383135,0.0008299563],"domain_scores_gemma":[0.997607,0.0006709027,0.00018448617,0.00087079155,0.00023770891,0.00042912303],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00063742325,0.000495612,0.0010130125,0.0002064024,0.00017491098,0.00004954295,0.00034270066,0.00028822714,0.0049899626],"category_scores_gemma":[0.00012778277,0.0004203563,0.00028554097,0.00095665816,0.00042233907,0.00010197161,0.00025333496,0.000632237,0.00011058323],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004924454,0.00019825621,0.06786856,0.00078729703,0.0004004277,0.00023403771,0.0008432514,0.00003473311,0.9112409,0.00004502271,0.006858112,0.010996971],"study_design_scores_gemma":[0.0077323117,0.0014388228,0.17378113,0.00038043523,0.00038786646,0.000028475437,0.0025857766,0.0006901717,0.76726043,0.00054531527,0.044311166,0.00085810135],"about_ca_topic_score_codex":0.0002679382,"about_ca_topic_score_gemma":0.000085448635,"teacher_disagreement_score":0.14398046,"about_ca_system_score_codex":0.00009310389,"about_ca_system_score_gemma":0.00019921869,"threshold_uncertainty_score":0.9998248},"labels":[],"label_agreement":null},{"id":"W4385686800","doi":"10.4049/jimmunol.210.supp.226.07","title":"What did the T cell see? A deep-learning model of CD8+ T cell activation reveals sharp antigen discrimination at the single cell level","year":2023,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University","funders":"","keywords":"Antigenicity; Antigen; Flow cytometry; Cytotoxic T cell; CD8; T cell; Cancer research; Cell; Biology; Immunology; Immune system; In vitro","score_opus":0.07770327271561742,"score_gpt":0.3163797734850131,"score_spread":0.2386765007693957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385686800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870993,0.0027509818,0.0009190001,0.006928913,0.00024588205,0.00040955286,0.0000031380691,0.000016464348,0.001626782],"genre_scores_gemma":[0.9640828,0.008111795,0.00007083799,0.00017708074,0.00012625464,0.0000058256956,0.000012332452,0.000042698724,0.027370391],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99752307,0.00078380806,0.00059223216,0.00013980559,0.0005795484,0.0003815522],"domain_scores_gemma":[0.9971717,0.0011056537,0.0007592341,0.0004972617,0.00042173034,0.000044423236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0027199888,0.00017245629,0.0003673257,0.00022407227,0.0003415702,0.000042423337,0.0005510974,0.0001347753,0.00043872217],"category_scores_gemma":[0.00020350894,0.00008555264,0.00019938622,0.00044999798,0.00030144228,0.00026294665,0.00026509652,0.0009608973,0.000060143582],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010365736,0.00014260507,0.00018346914,0.000054049957,0.00009910515,0.000005309064,0.010076457,0.0043811337,0.9745089,0.0000101456635,0.00069360645,0.008808661],"study_design_scores_gemma":[0.0018628531,0.0010446542,0.007528844,0.0001690744,0.0001702201,0.00013539706,0.013790165,0.00791915,0.9651647,0.0005732105,0.0015210718,0.000120619006],"about_ca_topic_score_codex":0.00003702412,"about_ca_topic_score_gemma":0.00001249242,"teacher_disagreement_score":0.02574361,"about_ca_system_score_codex":0.00022242345,"about_ca_system_score_gemma":0.00012637509,"threshold_uncertainty_score":0.48037001},"labels":[],"label_agreement":null},{"id":"W4385686994","doi":"10.4049/jimmunol.210.supp.142.09","title":"TCR/Chimeric Antigen Receptor (CAR) Cross-Antagonism to Fine-Tune CAR-T cell Immunotherapy","year":2023,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University","funders":"","keywords":"T-cell receptor; Chimeric antigen receptor; Cancer immunotherapy; Immunotherapy; Receptor; T cell; Antigen; Cell biology; Biology; Cancer research; Immunology; Immune system; Biochemistry","score_opus":0.028197414559190212,"score_gpt":0.338542726784412,"score_spread":0.31034531222522177,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385686994","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98223907,0.0050999266,0.00006981296,0.00909932,0.0016483229,0.0004657204,0.000013137941,0.0000639301,0.0013007865],"genre_scores_gemma":[0.92766845,0.017947085,0.00066592667,0.0014101934,0.0013708654,0.000017959337,0.000025804407,0.00018446393,0.050709236],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972336,0.00042907335,0.0007990014,0.00020888486,0.0005744044,0.00075498794],"domain_scores_gemma":[0.9975342,0.000437115,0.000361493,0.0010385094,0.00046581874,0.00016283391],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0019448434,0.00027196645,0.00073102,0.00057463336,0.00023778791,0.00004543063,0.0010821418,0.0001977521,0.0041741417],"category_scores_gemma":[0.00021933253,0.00018101753,0.00033864498,0.0010667053,0.00036744482,0.000101664074,0.00026838115,0.0010931045,0.001269257],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00414371,0.00012134881,0.0017330723,0.000015952804,0.0005649997,0.00010217399,0.002027888,0.000047342528,0.96299523,0.000011821031,0.009621372,0.01861508],"study_design_scores_gemma":[0.0052889455,0.0039575375,0.05759176,0.00007746003,0.000080592916,0.0014066483,0.0011221251,0.000020341877,0.6890883,0.00019040448,0.24089897,0.00027696343],"about_ca_topic_score_codex":0.00021208583,"about_ca_topic_score_gemma":0.000007372653,"teacher_disagreement_score":0.27390698,"about_ca_system_score_codex":0.00019966632,"about_ca_system_score_gemma":0.00037337595,"threshold_uncertainty_score":0.9995084},"labels":[],"label_agreement":null},{"id":"W4385687833","doi":"10.4049/jimmunol.210.supp.145.13","title":"Can Engineering IL-2Rα Expression Improve NK Cell Immunotherapy?","year":2023,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"National Research Council Canada; University of Ottawa","funders":"","keywords":"Chimeric antigen receptor; Immunotherapy; Cancer immunotherapy; Interleukin 21; Interleukin 12; Cancer research; Lymphokine-activated killer cell; Immunology; Cell therapy; Adoptive cell transfer; Interleukin 15; Cell; Janus kinase 3; Biology; T cell; Cell biology; Cytotoxic T cell; Cytokine; Stem cell; Immune system; In vitro; Interleukin","score_opus":0.014909143872700986,"score_gpt":0.2754549711733745,"score_spread":0.2605458273006735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385687833","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99162024,0.003631406,0.00011772703,0.0029613571,0.00074225274,0.00021249425,0.0000037504803,0.00004872519,0.0006620305],"genre_scores_gemma":[0.9822441,0.007879362,0.00018853831,0.00018719627,0.00042261995,0.0000059289846,0.0000033079389,0.00006530683,0.009003685],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986035,0.00015104041,0.00041834882,0.000095187555,0.00031824288,0.00041365175],"domain_scores_gemma":[0.9987727,0.00033623053,0.00020578665,0.00043861312,0.00017641585,0.0000702496],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010908584,0.00014868533,0.00036204216,0.00033426358,0.00008337706,0.000013508073,0.00038629887,0.00012540478,0.0009214185],"category_scores_gemma":[0.00010064558,0.00009223364,0.00016642011,0.00035521184,0.00010114422,0.000055816396,0.00010731998,0.0008960046,0.000074971555],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011625154,0.000048586273,0.000068002,0.000025000923,0.00017774635,0.000083743944,0.0012767814,0.00008010174,0.98403215,0.000009611172,0.0010151454,0.012020611],"study_design_scores_gemma":[0.0032403509,0.0015058791,0.0036401118,0.00012241272,0.000049062244,0.00084980606,0.0010107721,0.00023438972,0.9618575,0.0001241002,0.027243638,0.00012195483],"about_ca_topic_score_codex":0.000043755466,"about_ca_topic_score_gemma":0.0000016798161,"teacher_disagreement_score":0.026228493,"about_ca_system_score_codex":0.00012706024,"about_ca_system_score_gemma":0.00015882171,"threshold_uncertainty_score":0.9999919},"labels":[],"label_agreement":null},{"id":"W4385697656","doi":"10.1097/01.hs9.0000970368.33859.48","title":"P866: IDECABTAGENE VICLEUCEL (IDE-CEL) VS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED (TCE) RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): KARMMA-3 SUBGROUP ANALYSIS BY PRIOR LINES OF THERAPY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Daratumumab; Medicine; Internal medicine; Regimen; Oncology; Multiple myeloma; Lenalidomide; Hazard ratio; Confidence interval","score_opus":0.016896486216187306,"score_gpt":0.26855701842140345,"score_spread":0.2516605322052161,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385697656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958765,0.0012292167,0.000036543963,0.0004159469,0.00007018007,0.0016349669,0.00014203743,0.00015319459,0.00044142836],"genre_scores_gemma":[0.9875108,0.00090287067,0.0006055094,0.00015857763,0.00006361768,0.00008553994,0.00037409688,0.00013278522,0.010166226],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99607325,0.00024634262,0.0008402903,0.00082118437,0.0013125329,0.0007063844],"domain_scores_gemma":[0.99742246,0.0004814112,0.00032869854,0.00097374426,0.00045669515,0.00033700845],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007892984,0.00044378664,0.0012456762,0.00052249443,0.00011482201,0.000040046463,0.00022872574,0.00028851358,0.0014729102],"category_scores_gemma":[0.0002582061,0.00035578286,0.00024398464,0.0029497417,0.00024110453,0.00017233749,0.000100600475,0.0004910164,0.00002028185],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020783672,0.0007819139,0.73491275,0.00022814,0.0012983654,0.000106143256,0.0014076725,0.000025634057,0.21078338,0.000003804793,0.005611556,0.024056938],"study_design_scores_gemma":[0.050439633,0.005448932,0.79455054,0.0003433772,0.00042874124,0.0000049299133,0.0010813816,0.00097095186,0.12102409,0.00002266619,0.024957662,0.0007270874],"about_ca_topic_score_codex":0.00025106908,"about_ca_topic_score_gemma":0.0006712973,"teacher_disagreement_score":0.0897593,"about_ca_system_score_codex":0.0002587707,"about_ca_system_score_gemma":0.00023766466,"threshold_uncertainty_score":0.99988943},"labels":[],"label_agreement":null},{"id":"W4385716931","doi":"10.1158/1078-0432.ccr-22-2181","title":"HDACi-dependent Microenvironmental Normalization Overcomes Tumor Burden–induced T-cell Exhaustion","year":2023,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; McMaster University Medical Centre","funders":"Canadian Institutes of Health Research; Terry Fox Research Institute","keywords":"Cancer research; Reprogramming; Biology; Tumor microenvironment; Immunotherapy; T cell; CD8; Cell; Cytotoxic T cell; Transcriptome; Immunology; Immune system","score_opus":0.2326283083407908,"score_gpt":0.5135318852890013,"score_spread":0.2809035769482105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385716931","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898601,0.00034471534,0.000013437833,0.0031250154,0.00049037253,0.0012942979,0.00003215324,0.000146409,0.00469348],"genre_scores_gemma":[0.9290815,0.003730841,0.000031974185,0.0002969527,0.0015633339,0.00027447095,0.00012030491,0.000087193665,0.06481341],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9945649,0.0006526508,0.0007358324,0.000809533,0.0021929047,0.0010441635],"domain_scores_gemma":[0.99755895,0.00077832554,0.000088663044,0.00074598734,0.00026919047,0.00055887713],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.004759167,0.00020931555,0.0004634765,0.00047642304,0.000271406,0.00008540202,0.0003732625,0.00023501771,0.015691023],"category_scores_gemma":[0.0005499245,0.000191725,0.0002469079,0.0011772953,0.00040676058,0.0001380253,0.00047393987,0.001606673,0.0042387024],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027139764,0.0006111987,0.097414725,0.00029594166,0.00012100595,0.0004886728,0.00023462331,0.000100712445,0.8296211,0.000031971624,0.033521485,0.034844622],"study_design_scores_gemma":[0.020648291,0.005175411,0.44272828,0.00054382026,0.00015595176,0.00010044877,0.002610889,0.0069346325,0.29444283,0.00039977187,0.22526759,0.0009920655],"about_ca_topic_score_codex":0.00101307,"about_ca_topic_score_gemma":0.00006620549,"teacher_disagreement_score":0.53517824,"about_ca_system_score_codex":0.00076683663,"about_ca_system_score_gemma":0.00052642945,"threshold_uncertainty_score":0.9965366},"labels":[],"label_agreement":null},{"id":"W4385751197","doi":"10.1158/1078-0432.ccr-23-1137","title":"Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial.","year":2023,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Ontario Institute for Cancer Research; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Durvalumab; Medicine; Olaparib; Immunotherapy; Response Evaluation Criteria in Solid Tumors; Immune system; Internal medicine; Oncology; Tumor microenvironment; Toxicity; Immunology; Phases of clinical research; Nivolumab; Biology","score_opus":0.3288032443135986,"score_gpt":0.5626271940113787,"score_spread":0.23382394969778014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385751197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98730147,0.00026555473,0.0000023057955,0.007276246,0.00043342213,0.003551713,0.000049734,0.000030030393,0.0010895401],"genre_scores_gemma":[0.9859798,0.01023892,0.000072140414,0.00006145027,0.00020254607,0.00016945503,0.000013498285,0.000043558754,0.0032186627],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9874795,0.0058880537,0.0030723573,0.0010213887,0.0017380071,0.0008006849],"domain_scores_gemma":[0.9812695,0.0159745,0.00047844864,0.0013109444,0.0007223842,0.00024427296],"candidate_categories":["metaresearch","sts","research_integrity"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.038338665,0.00022521091,0.0016056406,0.0004798289,0.00009863581,0.00001912088,0.0006652566,0.0006112918,0.00025322108],"category_scores_gemma":[0.020299884,0.00013611685,0.00033428092,0.0029816304,0.0031857088,0.00013342507,0.0008028259,0.0038739902,0.000012039882],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.48492816,0.0031913002,0.28436086,0.00013463724,0.00015969123,0.00006885542,0.00011711072,0.000009215815,0.001408776,0.000051570372,0.00042110548,0.22514871],"study_design_scores_gemma":[0.17736806,0.011658852,0.8056377,0.0005460176,0.000029823259,0.0000041570243,0.00027136042,0.00044798356,0.0006007409,0.00018811977,0.0031151846,0.00013198408],"about_ca_topic_score_codex":0.0017123721,"about_ca_topic_score_gemma":0.0053501865,"teacher_disagreement_score":0.52127683,"about_ca_system_score_codex":0.00026874655,"about_ca_system_score_gemma":0.002177177,"threshold_uncertainty_score":0.99952704},"labels":[],"label_agreement":null},{"id":"W4385839652","doi":"10.3389/fimmu.2023.1225610","title":"Novel anti-CD30/CD3 bispecific antibodies activate human T cells and mediate potent anti-tumor activity","year":2023,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Cancer Institute; National Institutes of Health; UVA Cancer Center; Midwest Athletes Against Childhood Cancer; University of Virginia","keywords":"CD30; Monoclonal antibody; Antibody; Ex vivo; Immunotherapy; Epitope; Antigen; CD3; T cell; Cancer research; In vivo; Molecular biology; Chemistry; In vitro; Biology; Immunology; Immune system; Biochemistry; CD8; Tumor cells","score_opus":0.030501788103333448,"score_gpt":0.29899380660267594,"score_spread":0.2684920184993425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385839652","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99363303,0.001114878,0.00034072436,0.0010230921,0.0019935984,0.00070822693,0.000040873736,0.00020302809,0.00094252604],"genre_scores_gemma":[0.98937213,0.005190098,0.00074019504,0.000089832945,0.00016635025,0.000042662534,0.00005082271,0.000086098,0.0042617833],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99734384,0.00017796669,0.00039760143,0.0007154296,0.00036547074,0.000999664],"domain_scores_gemma":[0.99884146,0.00012261374,0.00014292434,0.00067127857,0.000088033215,0.00013371446],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00062462385,0.00035117776,0.0009729734,0.001215091,0.00021577779,0.00004418881,0.00029064284,0.000270429,0.00021372625],"category_scores_gemma":[0.0000916493,0.0003344352,0.00013813935,0.00090253743,0.0008226806,0.0001676153,0.0003424526,0.0009053169,0.000075594486],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004430836,0.00027125256,0.048613515,0.000087486405,0.00032349958,0.00032886158,0.0005031042,0.0000084454205,0.9315449,0.000033689295,0.0039802715,0.013861911],"study_design_scores_gemma":[0.0047003645,0.0004412652,0.6401769,0.00010920718,0.000046831683,0.00011395927,0.0010500856,0.00040102506,0.33606297,0.00019594787,0.016311701,0.00038976272],"about_ca_topic_score_codex":0.00026203514,"about_ca_topic_score_gemma":0.000022540462,"teacher_disagreement_score":0.59548193,"about_ca_system_score_codex":0.00023417079,"about_ca_system_score_gemma":0.000118892785,"threshold_uncertainty_score":0.9999108},"labels":[],"label_agreement":null},{"id":"W4385856058","doi":"10.1097/01.hs9.0000971412.45898.1a","title":"P1129: GLOFITAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) LARGE B-CELL LYMPHOMA (LBCL): EXTENDED FOLLOW-UP AND LANDMARK ANALYSES FROM A PIVOTAL PHASE II STUDY","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Refractory (planetary science); Regimen; Post-hoc analysis; Internal medicine; Phases of clinical research; Clinical endpoint; Toxicity; Oncology; Nuclear medicine; Clinical trial; Surgery","score_opus":0.027672898584496907,"score_gpt":0.33315772246846176,"score_spread":0.30548482388396486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385856058","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99557155,0.00088913046,0.000015098681,0.000080581376,0.00011748593,0.0015584069,0.00010069242,0.00017067968,0.0014963814],"genre_scores_gemma":[0.9865863,0.00015133643,0.00013545589,0.00013321597,0.00010403972,0.00012442254,0.0002477394,0.00011557642,0.012401916],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99701273,0.00019559769,0.00044297756,0.0007772852,0.0008901279,0.0006812696],"domain_scores_gemma":[0.9985029,0.00019657926,0.00012287241,0.00074108446,0.00013514703,0.0003014007],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003503783,0.0003974611,0.0007436257,0.00024348064,0.0001781101,0.000050047664,0.00017466667,0.00016909772,0.0024185064],"category_scores_gemma":[0.000056418772,0.0003125345,0.0001299452,0.0009900084,0.00007629924,0.00017058836,0.00014570166,0.0003128774,0.00007902076],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035415124,0.03715246,0.8091195,0.00013612819,0.0011112103,0.001296508,0.008668346,0.0000035696978,0.020414338,0.000005795354,0.0044766054,0.082200415],"study_design_scores_gemma":[0.35747376,0.016907573,0.60605705,0.00023523888,0.00028001962,0.000007013417,0.0071726977,0.0005859952,0.0026662818,0.000065090426,0.007843069,0.00070619344],"about_ca_topic_score_codex":0.0006405698,"about_ca_topic_score_gemma":0.00088887673,"teacher_disagreement_score":0.32205865,"about_ca_system_score_codex":0.00019137945,"about_ca_system_score_gemma":0.00017571493,"threshold_uncertainty_score":0.99993265},"labels":[],"label_agreement":null},{"id":"W4385878518","doi":"10.3390/curroncol30080554","title":"Novel Cellular and Immunotherapy: Toxicities and Perioperative Implications","year":2023,"lang":"en","type":"review","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute","keywords":"Medicine; Perioperative; Immunotherapy; Cancer; Intensive care medicine; Immune system; Immunology; Internal medicine; Surgery","score_opus":0.3280185255880636,"score_gpt":0.5092924379160871,"score_spread":0.18127391232802353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385878518","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016702463,0.9952973,0.00008477568,0.00036417408,0.00037844988,0.0017362086,0.00012228011,0.00007103466,0.0017787572],"genre_scores_gemma":[0.000003704438,0.9915183,0.00011548757,0.000041728035,0.00041319345,0.0006405277,0.00022364361,0.00008673462,0.006956671],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99835044,0.00016634405,0.00046513195,0.00051722326,0.00015063107,0.00035024315],"domain_scores_gemma":[0.9986866,0.00048863416,0.00014303873,0.00039222985,0.00012130429,0.00016821084],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034043423,0.000344747,0.0016628942,0.000319612,0.00014219843,0.000042857795,0.00013561522,0.0003302398,0.0005080651],"category_scores_gemma":[0.00007785899,0.00027054062,0.00019545168,0.0002967564,0.00045647038,0.000033307817,0.00017938581,0.00077257055,0.00005840231],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021497826,0.00014602553,0.0000146304565,0.006060686,0.00027148201,0.0000078975545,0.00053068995,9.087062e-9,0.0009524421,0.00062473724,0.0004352992,0.9909346],"study_design_scores_gemma":[0.0008634985,0.00045073338,0.000049269183,0.00231485,0.00033751677,0.00028209604,0.00015190533,0.00000561182,0.000007899062,0.00003496476,0.9952884,0.00021326543],"about_ca_topic_score_codex":0.000015977068,"about_ca_topic_score_gemma":0.000014109132,"teacher_disagreement_score":0.9948531,"about_ca_system_score_codex":0.00032737583,"about_ca_system_score_gemma":0.00073837745,"threshold_uncertainty_score":0.99997467},"labels":[],"label_agreement":null},{"id":"W4385955561","doi":"10.1097/01.hs9.0000972472.24418.bc","title":"P1396: CD33-DELETED HEMATOPOIETIC STEM AND PROGENITOR CELLS DISPLAY NORMAL ENGRAFTMENT AFTER HEMATOPOIETIC CELL TRANSPLANT (HCT) AND TOLERATE POST-HCT GEMTUZUMAB OZOGAMICIN (GO) WITHOUT CYTOPENIAS","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Gemtuzumab ozogamicin; Medicine; CD33; Plerixafor; Fludarabine; CD34; Myeloid; Hematopoietic stem cell transplantation; Stem cell; Melphalan; Busulfan; Haematopoiesis; Internal medicine; Immunology; Transplantation; Oncology; Chemotherapy; Immune system; CXCR4; Cyclophosphamide; Biology; Chemokine","score_opus":0.013684587279929656,"score_gpt":0.2551828161038957,"score_spread":0.24149822882396604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385955561","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99355906,0.001822019,0.00004185129,0.00058726367,0.00018788248,0.0026207124,0.00013973015,0.0002971518,0.00074430724],"genre_scores_gemma":[0.96930903,0.00071872585,0.000345411,0.00033582115,0.00017248992,0.00036937825,0.00009642667,0.00019172077,0.028461019],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99586874,0.00020233972,0.0007365683,0.0010460215,0.0009653082,0.0011810269],"domain_scores_gemma":[0.99791735,0.00024596447,0.00013708604,0.00078653387,0.00020450416,0.000708561],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00044314982,0.0007001029,0.0010337507,0.00019533341,0.00022355936,0.00023046565,0.00020144413,0.00032101956,0.0018162291],"category_scores_gemma":[0.000011861291,0.00058312673,0.00022693657,0.0005408836,0.0002673021,0.0002624519,0.00019923726,0.00064286415,0.000438489],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064662946,0.0007534248,0.037862785,0.0058961487,0.00056264334,0.005125505,0.014552759,0.000027408876,0.92166567,0.000074869444,0.0016884095,0.005324102],"study_design_scores_gemma":[0.018253384,0.0036125067,0.025221169,0.0022162364,0.0010598728,0.0033995854,0.0058885417,0.0033329825,0.92001337,0.000051206367,0.014694411,0.002256735],"about_ca_topic_score_codex":0.00010619459,"about_ca_topic_score_gemma":0.000110234,"teacher_disagreement_score":0.027716711,"about_ca_system_score_codex":0.00017519243,"about_ca_system_score_gemma":0.00022749658,"threshold_uncertainty_score":0.99966204},"labels":[],"label_agreement":null},{"id":"W4386229155","doi":"10.33844/cjm.2023.6029","title":"Simulation-Based Software Modeling of CAR T Cell Therapy Efficacy Against Solid Malignant Tumors","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McMaster University; University of British Columbia","funders":"","keywords":"Cytotoxic T cell; CD8; Chimeric antigen receptor; Immunotherapy; Immunology; Innate immune system; Cancer research; Biology; Population; Antigen; Immune system; T cell; Medicine; In vitro","score_opus":0.059056928970759204,"score_gpt":0.33031022973351853,"score_spread":0.27125330076275933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386229155","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909262,0.0020322455,0.0016927248,0.0039902763,0.00036240922,0.00040993176,0.000017401797,0.000025184703,0.00054359075],"genre_scores_gemma":[0.9971741,0.00020708994,0.000182199,0.00097096997,0.0006753395,0.000002249775,0.000032958273,0.000060377653,0.0006947601],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9976179,0.00009581198,0.0008110512,0.00018015532,0.00077954645,0.00051551545],"domain_scores_gemma":[0.99667364,0.00067119335,0.0002668334,0.00035189572,0.0008495623,0.001186899],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012155675,0.000196402,0.00069352466,0.0012665851,0.000098871635,0.000009793294,0.00025789873,0.000106823696,0.0012971585],"category_scores_gemma":[0.0012884414,0.00014814676,0.00019843652,0.000828285,0.00023792422,0.000049561597,0.000007660615,0.0004685683,0.000014583105],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00057935814,0.00006169995,0.0062497333,0.00019100468,0.00015808655,0.0022380652,0.0021555114,0.9086112,0.052097566,0.000006087368,0.0020917777,0.025559902],"study_design_scores_gemma":[0.03055744,0.0045090183,0.004922305,0.0044893627,0.00022398274,0.00011893551,0.002541131,0.9195612,0.017295562,0.00020658741,0.0150479665,0.0005265219],"about_ca_topic_score_codex":0.0017782629,"about_ca_topic_score_gemma":0.00050296105,"teacher_disagreement_score":0.034802005,"about_ca_system_score_codex":0.000255572,"about_ca_system_score_gemma":0.003316223,"threshold_uncertainty_score":0.9996158},"labels":[],"label_agreement":null},{"id":"W4386270762","doi":"10.1016/s2152-2650(23)00862-5","title":"POSTER: MM-309 CARTITUDE-1 Final Results: Phase 1b/2 Study of Ciltacabtagene Autoleucel in Heavily Pretreated Patients With Relapsed/Refractory Multiple Myeloma","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; McGill University; Institute of Cancer Research; McGill University Health Centre; University of Calgary","funders":"","keywords":"Refractory (planetary science); Medicine; Multiple myeloma; Phase (matter); Phases of clinical research; Internal medicine; Nuclear medicine; Materials science; Chemistry; Clinical trial; Metallurgy; Organic chemistry","score_opus":0.06028986609263801,"score_gpt":0.36688599263435107,"score_spread":0.30659612654171303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386270762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939722,0.00011529611,0.0000023907432,0.0001869236,0.00037883047,0.003173013,0.000262873,0.00037257685,0.0015359184],"genre_scores_gemma":[0.99425316,0.0001101877,0.000110895664,0.00022540346,0.00026595147,0.00019730152,0.00067712984,0.00017990492,0.0039800843],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99141675,0.0008700582,0.0029672256,0.0016330375,0.0018700112,0.0012429414],"domain_scores_gemma":[0.9937188,0.0020993554,0.00067178864,0.0020053766,0.00073951745,0.0007651409],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020896576,0.0007006908,0.0018371036,0.0007845503,0.00017111625,0.000055880766,0.0006666148,0.00063188886,0.00022635647],"category_scores_gemma":[0.0025290353,0.0005884509,0.00039931154,0.0023527883,0.0005445988,0.00027134878,0.0004170498,0.0009340907,0.00027298287],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.055336956,0.01531882,0.6434467,0.00016508246,0.00055943185,0.0020927608,0.0017091974,0.00004957427,0.0043510757,0.0000022253303,0.0021449695,0.27482322],"study_design_scores_gemma":[0.13267557,0.019314565,0.8409334,0.00046070182,0.00017666274,0.000025460587,0.00045903822,0.00089930225,0.0017976767,0.0000073137858,0.0027685803,0.00048173513],"about_ca_topic_score_codex":0.00087164296,"about_ca_topic_score_gemma":0.00058454653,"teacher_disagreement_score":0.2743415,"about_ca_system_score_codex":0.0016100022,"about_ca_system_score_gemma":0.0018292561,"threshold_uncertainty_score":0.9996567},"labels":[],"label_agreement":null},{"id":"W4386280311","doi":"10.14740/jh1112","title":"Harnessing the Immune System: An Effective Way to Manage Diffuse Large B-Cell Lymphoma","year":2023,"lang":"en","type":"review","venue":"Journal of Hematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"University of South Florida","keywords":"Rituximab; Medicine; Diffuse large B-cell lymphoma; Lymphoma; Chimeric antigen receptor; Tumor microenvironment; Immunology; Monoclonal antibody; Oncology; Immune system; Cancer research; Immunotherapy; Antibody","score_opus":0.04144877747681473,"score_gpt":0.3732354573810576,"score_spread":0.3317866799042429,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386280311","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0021110084,0.9933863,0.00012541193,0.00022604608,0.0010114841,0.0019306275,0.000011976669,0.0000551563,0.0011419507],"genre_scores_gemma":[0.001914353,0.99267805,0.000092733,0.00008329311,0.0007728775,0.00012464232,0.000016282971,0.00022524965,0.0040925443],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99531424,0.0014107232,0.0015212666,0.00037028507,0.000679739,0.0007037275],"domain_scores_gemma":[0.9959692,0.0013358298,0.0011292212,0.00090652896,0.00030113477,0.0003581321],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0028422067,0.00047741822,0.0041888324,0.0009391793,0.0001855638,0.00007630787,0.0007807869,0.00046694008,0.00013990427],"category_scores_gemma":[0.0002966119,0.0002656871,0.001148207,0.00080574915,0.00010030722,0.000084664265,0.0002804798,0.0010817803,0.0004381048],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004453508,0.0017028998,0.000011695181,0.08174228,0.0017913013,0.012033209,0.00073236634,2.7856603e-7,0.00014770823,0.0009645043,0.0010536559,0.8993747],"study_design_scores_gemma":[0.005392039,0.00092396536,0.00005278087,0.032957252,0.0020682162,0.03698685,0.00066644466,0.000018916613,0.00017972132,0.000023103885,0.9204397,0.00029101083],"about_ca_topic_score_codex":0.0000217414,"about_ca_topic_score_gemma":0.000010313151,"teacher_disagreement_score":0.919386,"about_ca_system_score_codex":0.0006321516,"about_ca_system_score_gemma":0.0002502275,"threshold_uncertainty_score":0.99997956},"labels":[],"label_agreement":null},{"id":"W4386282299","doi":"10.1016/s2152-2650(23)00880-7","title":"POSTER: CT-107 Cost-Effectiveness of the Chimeric Antigen Receptor (CAR) T-Cell Treatments, Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axicel), as Second-Line (2L) Treatment of Large B-Cell Lymphoma (LBCL)","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal","funders":"","keywords":"Chimeric antigen receptor; Lymphoma; Medicine; B-cell lymphoma; Cancer research; Virology; Immunology; Internal medicine; Immunotherapy; Cancer","score_opus":0.058699882457818923,"score_gpt":0.36835500546202554,"score_spread":0.3096551230042066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386282299","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9792904,0.0029762045,0.000007947857,0.00023830004,0.0021666444,0.0046840757,0.00092326594,0.00029232033,0.0094208205],"genre_scores_gemma":[0.96003723,0.0068892376,0.00013972336,0.00027480657,0.00067892676,0.0005247976,0.0009999374,0.00033538326,0.030119946],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9899285,0.0019178388,0.0026989426,0.0019422101,0.0016721445,0.0018404057],"domain_scores_gemma":[0.99035156,0.0037238945,0.0011841807,0.0031600164,0.0005866534,0.0009937093],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0022404462,0.0012716224,0.0030159024,0.0005548119,0.0003926021,0.000067007735,0.0012285112,0.00075348007,0.0027876752],"category_scores_gemma":[0.0004971044,0.00097427587,0.0024349913,0.0024737578,0.0010336037,0.00021021336,0.0007090423,0.0003965131,0.0012760385],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028561132,0.014252577,0.05100325,0.0011224145,0.0028328577,0.0008045891,0.0005084975,0.00002450465,0.5288144,0.0000511884,0.002257483,0.36976716],"study_design_scores_gemma":[0.066338725,0.00818862,0.40565202,0.00030599342,0.000721387,0.00008331766,0.00027214587,0.00025149458,0.47671577,0.00003237253,0.040776003,0.0006621578],"about_ca_topic_score_codex":0.00078070496,"about_ca_topic_score_gemma":0.000075885735,"teacher_disagreement_score":0.36910498,"about_ca_system_score_codex":0.0034250326,"about_ca_system_score_gemma":0.0034963097,"threshold_uncertainty_score":0.9995016},"labels":[],"label_agreement":null},{"id":"W4386455160","doi":"10.4049/jimmunol.2300049","title":"Memory T Cells in the Immunoprevention of Cancer: A Switch from Therapeutic to Prophylactic Approaches","year":2023,"lang":"en","type":"review","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Institute of Allergy and Infectious Diseases; Princess Margaret Cancer Foundation; Ministry of Health, Ontario","keywords":"Cancer; Immune system; Medicine; Cancer research; Cancer cell; T cell; Immunology; Internal medicine","score_opus":0.15850057831339184,"score_gpt":0.3948356683118157,"score_spread":0.23633508999842387,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386455160","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009149629,0.98765427,0.000016042455,0.00078406517,0.0004741849,0.0017465308,0.000013015232,0.00000718446,0.00015508701],"genre_scores_gemma":[0.0032662607,0.9947306,0.000028846865,0.00006629996,0.00028786313,0.00008773114,0.0000067099522,0.000071009905,0.0014546578],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9954744,0.0021189158,0.0013074594,0.00017869662,0.000560661,0.00035985577],"domain_scores_gemma":[0.99644893,0.00139471,0.0011178803,0.0008412249,0.00015786925,0.000039353148],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033706615,0.00030772784,0.0019516499,0.0005692864,0.000054634565,0.000016514005,0.0011990453,0.00028966798,0.0004321228],"category_scores_gemma":[0.000106947344,0.00014546038,0.0006237817,0.0009602989,0.00020852448,0.000042264528,0.00015014368,0.0019754497,0.000060431998],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009598617,0.00022000061,0.0000033778401,0.0023753955,0.002208453,0.00004576982,0.0022554388,0.0000074966115,0.012944421,0.000007348538,0.00006030896,0.9789121],"study_design_scores_gemma":[0.006651527,0.008161777,0.0018258078,0.048721198,0.015435953,0.002892301,0.010541083,0.00002059732,0.0069258953,0.0018247953,0.89600927,0.0009897938],"about_ca_topic_score_codex":0.0008729802,"about_ca_topic_score_gemma":0.000084752,"teacher_disagreement_score":0.9779223,"about_ca_system_score_codex":0.00033464577,"about_ca_system_score_gemma":0.00092697237,"threshold_uncertainty_score":0.8582457},"labels":[],"label_agreement":null},{"id":"W4386465406","doi":"10.1172/jci.insight.167215","title":"Tregs integrate native and CAR-mediated costimulatory signals for control of allograft rejection","year":2023,"lang":"en","type":"article","venue":"JCI Insight","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"Michael Smith Health Research BC; BC Children's Hospital; Canadian Institutes of Health Research; Bristol-Myers Squibb; U.S. Department of Defense","keywords":"Control (management); Computer science; Chemistry; Immunology; Cancer research; Medicine; Artificial intelligence","score_opus":0.037498196540220886,"score_gpt":0.3300835142629037,"score_spread":0.2925853177226828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386465406","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876287,0.0008855655,0.0009013515,0.0011483057,0.00027355982,0.0024483178,0.00013465673,0.00019957373,0.0063799815],"genre_scores_gemma":[0.99302685,0.00022638896,0.00004182717,0.00021374923,0.00012781171,0.00012592308,0.00009475404,0.000033282653,0.0061094305],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988988,0.000086345135,0.00025597384,0.0002424576,0.00027753232,0.0002389015],"domain_scores_gemma":[0.998388,0.00087121804,0.00008117324,0.00017406703,0.00036461177,0.000120920144],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041565485,0.0001307047,0.00038168213,0.0003525389,0.000053005475,0.000011377143,0.000052838306,0.00012655869,0.00026285055],"category_scores_gemma":[0.00047076258,0.00010335908,0.00010515817,0.0004887483,0.00014495752,0.00005826561,0.000020299567,0.00018785153,0.000015976557],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020859477,0.00011121753,0.0029642344,0.00014320941,0.0003554194,0.000028384675,0.0019939977,0.000037233116,0.9785871,0.00009709793,0.003990221,0.009605933],"study_design_scores_gemma":[0.040364783,0.008432243,0.035502337,0.00059853477,0.000512495,0.000045429395,0.003365601,0.06955761,0.558953,0.0012772536,0.28064322,0.00074748526],"about_ca_topic_score_codex":0.0000778516,"about_ca_topic_score_gemma":0.000039667128,"teacher_disagreement_score":0.4196341,"about_ca_system_score_codex":0.00008034761,"about_ca_system_score_gemma":0.00011437217,"threshold_uncertainty_score":0.4214861},"labels":[],"label_agreement":null},{"id":"W4386476688","doi":"10.3389/fimmu.2023.1248867","title":"The future of affordable cancer immunotherapy","year":2023,"lang":"en","type":"review","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"HORIZON EUROPE Framework Programme; Deutsche Forschungsgemeinschaft; Friedrich-Alexander-Universität Erlangen-Nürnberg; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation","keywords":"Immunotherapy; Chimeric antigen receptor; Medicine; Cancer immunotherapy; Cancer; Antigen; Cancer research; Immune system; Immunology; Oncology; Internal medicine","score_opus":0.03481279846192579,"score_gpt":0.3630841210880556,"score_spread":0.3282713226261298,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386476688","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000012986415,0.9915744,0.00002023427,0.00034282944,0.005768318,0.0014999824,0.000029266546,0.00008303372,0.00066896935],"genre_scores_gemma":[1.8992452e-7,0.9643398,0.00024952783,0.000027637245,0.00044395443,0.00062139344,0.00004892971,0.00020294994,0.034065653],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974198,0.0003714517,0.0008388211,0.0003880467,0.0002922012,0.0006896962],"domain_scores_gemma":[0.99815387,0.00026874864,0.0003420561,0.0010969351,0.00009756053,0.000040841875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007166496,0.00037672697,0.002441098,0.0006069865,0.00008147853,0.000015814934,0.0007387412,0.0007323479,0.00039553194],"category_scores_gemma":[0.0000476851,0.00023889799,0.0006071497,0.0011658774,0.00052421395,0.000028391229,0.0001439333,0.0014069917,0.000030689658],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00030768322,0.000043627726,0.00006505221,0.0030791971,0.0018801464,0.00002851845,0.00010025397,2.1929169e-7,0.00003350555,0.000117755844,0.02115002,0.973194],"study_design_scores_gemma":[0.0008677016,0.00018366483,0.000035371195,0.0038651265,0.00016741474,0.00003880948,0.00033679043,0.0000029005707,0.000012792434,0.00024839523,0.9940618,0.0001792254],"about_ca_topic_score_codex":0.00023516214,"about_ca_topic_score_gemma":0.00010563121,"teacher_disagreement_score":0.9730148,"about_ca_system_score_codex":0.0005897669,"about_ca_system_score_gemma":0.0010870711,"threshold_uncertainty_score":0.97419775},"labels":[],"label_agreement":null},{"id":"W4386496099","doi":"10.1136/jitc-2023-007277","title":"Targeting T-cell malignancies using allogeneic double-negative CD4-CAR-T cells","year":2023,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Toronto","funders":"Canadian Institutes of Health Research","keywords":"Medicine; T cell; Cancer research; Immunology; Immune system","score_opus":0.06099437135282873,"score_gpt":0.3805189673241266,"score_spread":0.3195245959712979,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386496099","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9866644,0.009342513,0.0005659674,0.00059606344,0.0013100217,0.00099722,0.000044543947,0.000053391093,0.0004258777],"genre_scores_gemma":[0.830801,0.07260696,0.009760436,0.0012741169,0.003546351,0.00029341178,0.000034880213,0.00055230956,0.081130505],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99762464,0.00006846612,0.00067564717,0.00026022582,0.00070169487,0.00066932413],"domain_scores_gemma":[0.9982863,0.00021710093,0.0004325437,0.00027050223,0.00064916763,0.00014436833],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010700105,0.0002579722,0.0006006729,0.00040407566,0.00029576963,0.00006322653,0.00026294368,0.00014164622,0.0026319732],"category_scores_gemma":[0.000026623416,0.00021456245,0.00048990315,0.0006071365,0.00015376405,0.00015062034,0.000038484843,0.00041673705,0.000013446961],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040744473,0.00008215935,0.0013705639,0.00020844875,0.00051143114,0.000021784146,0.0013013756,0.0019255605,0.97948486,0.000007335046,0.002991818,0.008020217],"study_design_scores_gemma":[0.008902804,0.0005673803,0.00042074337,0.00029052785,0.00008681051,0.00004234482,0.00075321243,0.0010596081,0.91835546,0.00022381119,0.0690609,0.00023641597],"about_ca_topic_score_codex":0.00023047913,"about_ca_topic_score_gemma":0.000009222812,"teacher_disagreement_score":0.15586337,"about_ca_system_score_codex":0.0003880445,"about_ca_system_score_gemma":0.0006116625,"threshold_uncertainty_score":0.99827975},"labels":[],"label_agreement":null},{"id":"W4386527000","doi":"10.1186/s13073-023-01219-x","title":"Transcriptional immunogenomic analysis reveals distinct immunological clusters in paediatric nervous system tumours","year":2023,"lang":"en","type":"article","venue":"Genome Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; SickKids Foundation; University Health Network; University of Toronto; BC Cancer Agency; Princess Margaret Cancer Centre; Hospital for Sick Children; University of British Columbia","funders":"NHLBI Division of Intramural Research; Stanford Cancer Institute; National Heart, Lung, and Blood Institute; National Cancer Institute; National Institutes of Health; Deutsche Krebshilfe; Terry Fox Research Institute; University of Toronto; Parker Institute for Cancer Immunotherapy","keywords":"Human genetics; Medicine; Central nervous system; Nervous system; Systems biology; Computational biology; Immunology; Biology; Bioinformatics; Neuroscience; Genetics; Internal medicine; Gene","score_opus":0.03392925098274058,"score_gpt":0.2945778025462837,"score_spread":0.2606485515635431,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386527000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9840443,0.0077168494,0.00021083113,0.0034858258,0.00032850265,0.0009177754,0.000042623167,0.0002874004,0.0029658775],"genre_scores_gemma":[0.991218,0.0011440765,0.000054887038,0.0001783439,0.0007103657,0.000117234,0.00072152365,0.000051692245,0.005803888],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99631184,0.0003183172,0.0009326281,0.0006503894,0.000918204,0.0008685988],"domain_scores_gemma":[0.9984533,0.00030804233,0.00013397343,0.0006833014,0.00012903595,0.0002923322],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018640286,0.00033245186,0.0012133077,0.0022847825,0.0001230889,0.000017131842,0.00037429252,0.00018960661,0.003262633],"category_scores_gemma":[0.00017631687,0.00025528084,0.00038069036,0.0056506307,0.00031288015,0.000059553004,0.000104804334,0.0006294805,0.00041759695],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028473423,0.00029048993,0.18471092,0.00078720285,0.0023430772,0.0032478396,0.0030045065,0.0012218734,0.784351,0.0003238928,0.0007208953,0.016150951],"study_design_scores_gemma":[0.0042292476,0.0006750245,0.98671687,0.00011015617,0.00091097935,0.00019357016,0.002171696,0.0015365268,0.000030924533,0.000042319483,0.0031254552,0.00025725484],"about_ca_topic_score_codex":0.00034095152,"about_ca_topic_score_gemma":0.00004855779,"teacher_disagreement_score":0.80200595,"about_ca_system_score_codex":0.00087562064,"about_ca_system_score_gemma":0.00013251424,"threshold_uncertainty_score":0.9999899},"labels":[],"label_agreement":null},{"id":"W4386537550","doi":"10.1093/neuonc/noad137.155","title":"P06.15.B IMMUNOTHERAPEUTIC TARGETING OF FIBROBLAST ACTIVATION PROTEIN (FAP) IN TREATMENT REFRACTORY GLIOBLASTOMA USING NOVEL CAR-T CELL THERAPY","year":2023,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Fibroblast activation protein, alpha; Chimeric antigen receptor; Cancer research; Stromal cell; Medicine; Glioma; Antigen; U87; Immunology; Immunotherapy; Cancer; Internal medicine; Immune system","score_opus":0.05777059559807561,"score_gpt":0.3468138788377503,"score_spread":0.28904328323967465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386537550","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959329,0.00013853563,0.000046477806,0.00059178536,0.00010816136,0.0018547848,0.000008895874,0.00011202142,0.0012064741],"genre_scores_gemma":[0.99787134,0.00023559603,0.0005116693,0.00025622523,0.00021414093,0.00017053068,0.00002357157,0.00011471897,0.0006022144],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975449,0.0003137208,0.0006020952,0.00050664606,0.000418442,0.00061423186],"domain_scores_gemma":[0.9984264,0.0005813902,0.00028419076,0.00045309617,0.00014555076,0.00010937293],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00044971218,0.0002967861,0.0006475884,0.0006691577,0.000083800376,0.000013742121,0.00016628759,0.00029669897,0.0006174775],"category_scores_gemma":[0.00010029596,0.00026684173,0.00016942427,0.0010271702,0.0001495026,0.000111090936,0.000068980335,0.00049077254,0.000036769194],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038446554,0.0010283088,0.00079141435,0.000083053674,0.00006597051,0.00007773509,0.0016041314,0.00024523906,0.96138495,0.000005521566,0.000050938765,0.030818092],"study_design_scores_gemma":[0.007579278,0.0073850024,0.0016203418,0.0001435713,0.000014509864,0.000033598866,0.00050190825,0.0016096019,0.9446192,0.000017880553,0.036300007,0.00017511072],"about_ca_topic_score_codex":0.00045687967,"about_ca_topic_score_gemma":0.00004869459,"teacher_disagreement_score":0.036249068,"about_ca_system_score_codex":0.0011521401,"about_ca_system_score_gemma":0.0007305089,"threshold_uncertainty_score":0.99997836},"labels":[],"label_agreement":null},{"id":"W4386537716","doi":"10.1093/neuonc/noad137.019","title":"JS03.6.A NEUROTOXICITY IN PATIENTS WITH CNS LYMPHOMAS TREATED WITH CAR T CELL THERAPY. A LOC NETWORK STUDY","year":2023,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Neurotoxicity; Lymphoma; Encephalopathy; Internal medicine; Toxicity; Gastroenterology; Pediatrics; Oncology","score_opus":0.026686438841491265,"score_gpt":0.3005137498712934,"score_spread":0.2738273110298022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386537716","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900736,0.000033450244,0.0000019046873,0.0003549006,0.00014643195,0.004600039,0.000007945984,0.0002629252,0.004518791],"genre_scores_gemma":[0.9970614,0.00009416362,0.000029461595,0.0011302371,0.00019683025,0.0004306104,0.000043440778,0.0001452883,0.0008686144],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996279,0.0007994771,0.00040802252,0.0008171566,0.0007168959,0.0009794735],"domain_scores_gemma":[0.99806863,0.0005388582,0.00014006704,0.0007525838,0.00020699324,0.00029288762],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00042555388,0.00038470826,0.0008288136,0.0003847814,0.00012197252,0.000025269606,0.000268912,0.00019242376,0.0004896737],"category_scores_gemma":[0.000052390795,0.00027411574,0.00007677942,0.0021608965,0.00020114159,0.0000686087,0.00012467566,0.00068615505,0.00011212466],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016736139,0.003526752,0.9351137,0.000022338843,0.00011303954,0.0028554413,0.0010139222,0.00042697488,0.0263734,0.0000017019705,0.001443745,0.012372825],"study_design_scores_gemma":[0.04748793,0.054282676,0.8609701,0.00003165796,0.00008404736,0.0000573003,0.00038096844,0.00033150715,0.004180547,0.000006606266,0.031833604,0.00035310147],"about_ca_topic_score_codex":0.000334788,"about_ca_topic_score_gemma":0.00049985835,"teacher_disagreement_score":0.07414366,"about_ca_system_score_codex":0.00038530666,"about_ca_system_score_gemma":0.00053357985,"threshold_uncertainty_score":0.9999711},"labels":[],"label_agreement":null},{"id":"W4386574738","doi":"10.1016/j.jcyt.2023.07.012","title":"Automated production of gene-modified chimeric antigen receptor T cells using the Cocoon Platform","year":2023,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Octane (Canada)","funders":"National Cancer Institute; McMaster University","keywords":"Chimeric antigen receptor; Cell therapy; Medicine; Process (computing); Clinical trial; Manufacturing process; T cell; Computer science; Immunology; Cell; Immune system; Biology; Internal medicine","score_opus":0.07365111325701204,"score_gpt":0.3572147562017875,"score_spread":0.28356364294477543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386574738","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964858,0.00027956528,0.000113022936,0.0004981626,0.0005732017,0.0012054599,0.0000068730674,0.00047018562,0.00036771313],"genre_scores_gemma":[0.9864109,0.0019065617,0.0009192829,0.0002024807,0.0006771049,0.000051098858,0.00005482255,0.000119484546,0.009658258],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99848646,0.00006812809,0.00030588734,0.00030039818,0.00047412046,0.00036500243],"domain_scores_gemma":[0.998978,0.00006342818,0.00012428855,0.0005785445,0.00017857827,0.00007716787],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005772479,0.00016679725,0.00031691935,0.00023410298,0.00014210591,0.000020197624,0.00017159463,0.00010323302,0.00079585175],"category_scores_gemma":[0.000033176206,0.00011618037,0.00011448783,0.0014858886,0.00017528387,0.00007060284,0.000021436927,0.0001964666,0.000084034735],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00065800746,0.00007900976,0.0006424465,0.00005286079,0.00015228197,0.000004409863,0.0014287767,0.000473951,0.98382056,0.000009445355,0.0031197623,0.009558477],"study_design_scores_gemma":[0.0011504213,0.00026604187,0.005917973,0.00006438473,0.000018823474,0.000024693443,0.00023627313,0.015732031,0.96794516,0.00002212917,0.008492778,0.00012928588],"about_ca_topic_score_codex":0.00011858613,"about_ca_topic_score_gemma":0.00000336607,"teacher_disagreement_score":0.015875407,"about_ca_system_score_codex":0.00010928858,"about_ca_system_score_gemma":0.00017818308,"threshold_uncertainty_score":0.8714019},"labels":[],"label_agreement":null},{"id":"W4386590486","doi":"10.22192/ttdls.2023.010","title":"Immunotherapy: breakthrough in Cancer Treatment","year":2023,"lang":"en","type":"book-chapter","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Society of Microbiologists","funders":"","keywords":"Scope (computer science); Population; Engineering; Engineering ethics; Business; Management science; Computer science; Engineering management; Medicine","score_opus":0.08348273814235774,"score_gpt":0.37140108342471717,"score_spread":0.28791834528235943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386590486","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00033245436,0.002641881,0.0000023982586,0.0019915889,0.00026943587,0.0011853363,0.000045760884,0.00017531411,0.9933558],"genre_scores_gemma":[0.0001808736,0.038590387,0.00004258425,0.00044548645,0.00042807797,0.00016595698,0.00008529485,0.0002264505,0.9598349],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99830997,0.000012949446,0.00034537798,0.00047686623,0.00047374956,0.00038107266],"domain_scores_gemma":[0.9990332,0.00009590569,0.000058363566,0.00063798646,0.00006966898,0.000104845654],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0001254851,0.00038259604,0.00074148405,0.00035806044,0.000027071028,0.00001825502,0.000112323134,0.00037602993,0.094306365],"category_scores_gemma":[0.000003849648,0.0002913759,0.00029614163,0.00007950289,0.00009183376,0.000024059314,0.000041237407,0.0004016197,0.0013380903],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016226578,0.00025922057,0.0006088727,0.00016532406,0.001918619,0.001291749,0.00085203367,0.000004810565,0.008008375,0.01986491,0.012820746,0.95258266],"study_design_scores_gemma":[0.003466424,0.00073882047,0.00055703055,0.00040011038,0.000059336042,0.000028910308,0.000022462184,0.0000141141945,0.00079488003,0.0023339244,0.9912821,0.00030188626],"about_ca_topic_score_codex":0.0056419256,"about_ca_topic_score_gemma":0.0038980313,"teacher_disagreement_score":0.9784614,"about_ca_system_score_codex":0.0013393128,"about_ca_system_score_gemma":0.00045107453,"threshold_uncertainty_score":0.99995387},"labels":[],"label_agreement":null},{"id":"W4386709546","doi":"10.18609/vac.2023.045","title":"Establishing a B cell and T cell receptor data commons using next-generation sequencing","year":2023,"lang":"en","type":"article","venue":"Vaccine Insights","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Commons; Computational biology; Cell; Biology; Genetics; Ecology","score_opus":0.2321827372040129,"score_gpt":0.34205045087419433,"score_spread":0.10986771367018144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386709546","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99483055,0.0009474551,0.00016818376,0.00064580876,0.00029204655,0.00048558373,0.000021353591,0.00017917786,0.0024298136],"genre_scores_gemma":[0.99015605,0.00062994845,0.002261641,0.0002158525,0.0011719125,0.000009531384,0.00087056163,0.00007824339,0.0046062614],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99823546,0.000119525626,0.00031924332,0.0005480434,0.00038985786,0.00038788913],"domain_scores_gemma":[0.9983791,0.00021848989,0.000082246595,0.00097023527,0.00012355784,0.00022634333],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047249475,0.00019717061,0.00031331388,0.00039659775,0.00026168907,0.00022413569,0.00026235712,0.00012276477,0.0005528669],"category_scores_gemma":[0.00013064545,0.0001730012,0.0000384427,0.0009036397,0.000019777362,0.0006902833,0.0004199903,0.00038048244,0.00008777819],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005661851,0.00003966146,0.0013827716,0.00011012956,0.000019547524,0.00007392939,0.00095821626,0.000072220944,0.98022926,0.0000103732855,0.014458425,0.0025888646],"study_design_scores_gemma":[0.0037631793,0.0003091603,0.000785773,0.00019731362,0.00013619574,0.00008651167,0.0012522129,0.31378734,0.57354444,0.00007685242,0.105588555,0.00047245537],"about_ca_topic_score_codex":0.00082045974,"about_ca_topic_score_gemma":0.00043964016,"teacher_disagreement_score":0.40668482,"about_ca_system_score_codex":0.00018119453,"about_ca_system_score_gemma":0.00024253319,"threshold_uncertainty_score":0.7054784},"labels":[],"label_agreement":null},{"id":"W4386815771","doi":"10.1101/2023.09.14.557485","title":"Pharmacological control of CAR T cells through CRISPR-driven rapamycin resistance","year":2023,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Héma-Québec; University of Victoria; Centre hospitalier universitaire de Québec","funders":"Fonds de Recherche du Québec - Santé; Canadian Institutes of Health Research; Mitacs","keywords":"CRISPR; Resistance (ecology); Control (management); Biology; Chemistry; Computational biology; Computer science; Genetics; Gene; Ecology; Artificial intelligence","score_opus":0.041734087164700596,"score_gpt":0.30705475359160783,"score_spread":0.2653206664269072,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386815771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97938854,0.003733491,0.0039087706,0.0022433044,0.002926141,0.0050983503,0.0013203913,0.0011882334,0.00019280938],"genre_scores_gemma":[0.9916285,0.0021481877,0.0034501578,0.00053489837,0.000999783,0.0004531766,9.878945e-7,0.00028841503,0.0004958677],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9947944,0.00043753666,0.001053674,0.0014671893,0.0012178577,0.0010293158],"domain_scores_gemma":[0.995584,0.00042100422,0.0005656634,0.0018028694,0.0011552691,0.00047120458],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010990652,0.0007489751,0.0016926016,0.00036774718,0.00013017001,0.000080431695,0.0008331633,0.0009434224,0.0011678549],"category_scores_gemma":[0.00035462104,0.00073108973,0.0005536072,0.0008934826,0.0004829003,0.000098230594,0.00054162444,0.001998491,0.0002355495],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010035511,0.0003437751,0.0030028352,0.0012343873,0.0009645158,0.0005514548,0.000028533483,0.000107740125,0.9865166,0.00019298714,0.006052561,0.0000010933638],"study_design_scores_gemma":[0.004165057,0.00022999005,0.01583676,0.000808006,0.0006688271,3.066518e-8,0.000008196133,0.00038395682,0.9488348,0.0000052713494,0.028363174,0.0006959666],"about_ca_topic_score_codex":0.000090842266,"about_ca_topic_score_gemma":0.000005334251,"teacher_disagreement_score":0.037681803,"about_ca_system_score_codex":0.00057659217,"about_ca_system_score_gemma":0.0012043918,"threshold_uncertainty_score":0.9997452},"labels":[],"label_agreement":null},{"id":"W4386817435","doi":"10.1002/ajh.27098","title":"Bone marrow fibrosis is associated with non‐response to <scp>CD19 CAR T</scp>‐cell therapy in <scp>B</scp>‐acute lymphoblastic leukemia","year":2023,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; BC Cancer Agency","funders":"CURE Childhood Cancer Association","keywords":"Stromal cell; Bone marrow; Medicine; CD19; Fibrosis; T cell; Cancer research; B cell; Myelofibrosis; Cell therapy; Immunology; Pathology; Cell; Flow cytometry; Biology; Immune system; Antibody","score_opus":0.012103395241732408,"score_gpt":0.2796308972548362,"score_spread":0.26752750201310377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386817435","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965361,0.00038737323,0.00009708182,0.0017084153,0.0001601164,0.0005354855,0.000028395583,0.00006998186,0.00047707773],"genre_scores_gemma":[0.98945224,0.0007717193,0.00058025477,0.0020685603,0.000105673564,0.000046807087,0.000012900111,0.00015236883,0.006809503],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9953598,0.00072261324,0.0010393576,0.0005299538,0.001049992,0.0012983232],"domain_scores_gemma":[0.9915864,0.005761989,0.0008114236,0.00057497784,0.00053570274,0.0007295181],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015815387,0.00047343937,0.0019951996,0.0017089873,0.000103762184,0.00004550934,0.0004776378,0.000215477,0.0001730164],"category_scores_gemma":[0.0019055244,0.0003839406,0.00035462296,0.0033595944,0.0005358109,0.000117170726,0.00011604718,0.00087256246,0.00021987758],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00586323,0.00062317745,0.08164273,0.000079855476,0.0018081156,0.014303101,0.013406591,0.00032193444,0.81102604,0.000007791195,0.06650334,0.0044141193],"study_design_scores_gemma":[0.051424637,0.07244724,0.29093808,0.0024474722,0.0010601939,0.030748215,0.042049516,0.0021284106,0.45506972,0.00021292648,0.05073254,0.0007410599],"about_ca_topic_score_codex":0.00015644306,"about_ca_topic_score_gemma":0.000040104147,"teacher_disagreement_score":0.3559563,"about_ca_system_score_codex":0.0009136392,"about_ca_system_score_gemma":0.0015475987,"threshold_uncertainty_score":0.99986124},"labels":[],"label_agreement":null},{"id":"W4386837057","doi":"10.3390/curroncol30090619","title":"Bispecific T-Cell Engagers and Chimeric Antigen Receptor T-Cell Therapies in Glioblastoma: An Update","year":2023,"lang":"en","type":"review","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Chimeric antigen receptor; Medicine; Cart; Glioblastoma; Radiation therapy; Antigen; Immunotherapy; Clinical trial; Tumor microenvironment; Brain tumor; CD8; Cancer research; T cell; Oncology; Cancer; Immunology; Internal medicine; Immune system; Tumor cells; Pathology","score_opus":0.20809332928761784,"score_gpt":0.46269867400889053,"score_spread":0.2546053447212727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386837057","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0075820275,0.98654574,0.0000022829322,0.000115993906,0.0018108682,0.00238356,0.00006654736,0.00016892885,0.0013240688],"genre_scores_gemma":[0.000058845777,0.99581444,0.00008812493,0.000032936237,0.0008116697,0.00034584358,0.00035897078,0.0002309403,0.0022582219],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99503803,0.0014719995,0.0009847705,0.0011457788,0.0004414855,0.0009179373],"domain_scores_gemma":[0.9976519,0.00063011795,0.00038818995,0.000809246,0.000100251535,0.0004203062],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0013887093,0.00071418023,0.0029617287,0.001362588,0.00011840454,0.00005282375,0.00046122243,0.00066161744,0.0023915828],"category_scores_gemma":[0.00007527991,0.0005927983,0.00040262032,0.0014192776,0.00039406103,0.0000862391,0.00025328094,0.0024303454,0.0011072902],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018507504,0.00097402703,0.00011213234,0.011636195,0.00012134207,0.00013794599,0.0006126668,1.0872564e-7,0.0004847656,0.000008853108,0.005287215,0.98043966],"study_design_scores_gemma":[0.0019564677,0.001399497,0.0000300137,0.0022856588,0.00024163265,0.00006895724,0.00031914044,0.000009545087,0.0000415501,0.000012083925,0.99316144,0.00047401205],"about_ca_topic_score_codex":0.000020439382,"about_ca_topic_score_gemma":0.00006502893,"teacher_disagreement_score":0.9878742,"about_ca_system_score_codex":0.00066066487,"about_ca_system_score_gemma":0.0010622337,"threshold_uncertainty_score":0.9998711},"labels":[],"label_agreement":null},{"id":"W4386871562","doi":"10.5220/0012015600003633","title":"Cancer Immunology: CAR T-Cell Therapy on Renal Cell Carcinoma","year":2022,"lang":"en","type":"article","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Concordia University; McGill University","funders":"","keywords":"Renal cell carcinoma; Cancer; Medicine; Cancer research; Immunology; Oncology; Internal medicine","score_opus":0.03307022250846871,"score_gpt":0.3088625909861549,"score_spread":0.2757923684776862,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386871562","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8716648,0.0031873784,0.000003296339,0.0018015964,0.00027308692,0.00053845526,0.00001882516,0.00007259493,0.12243993],"genre_scores_gemma":[0.7878227,0.000531338,0.00003453419,0.0020163162,0.00018283784,0.00021323284,0.000023744406,0.00004649213,0.2091288],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99822235,0.00016034817,0.00019019026,0.000388202,0.0005741864,0.00046474262],"domain_scores_gemma":[0.9990886,0.00008243468,0.000045054912,0.0005918454,0.00006945061,0.00012261087],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00026598675,0.00017883976,0.0002748798,0.0001914088,0.00020949301,0.000012740903,0.00024271222,0.000067867855,0.09974215],"category_scores_gemma":[0.0000043513005,0.00014691714,0.00015300671,0.00031009468,0.000079144214,0.000022202588,0.00012883812,0.0007432816,0.00013927673],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020356392,0.00047289283,0.0054874825,0.000013914817,0.00006160411,0.0001386021,0.0006466836,0.000040388335,0.95553863,0.000057954563,0.020963995,0.01454222],"study_design_scores_gemma":[0.0051766275,0.0027556815,0.0074503175,0.0000037725167,0.000015860012,0.000030841853,0.0004533207,0.00008919161,0.5974256,0.00002515616,0.3863928,0.00018085931],"about_ca_topic_score_codex":0.002025287,"about_ca_topic_score_gemma":0.000031278003,"teacher_disagreement_score":0.3654288,"about_ca_system_score_codex":0.0004338275,"about_ca_system_score_gemma":0.00035816376,"threshold_uncertainty_score":0.9010808},"labels":[],"label_agreement":null},{"id":"W4386977179","doi":"10.3390/cimb45100486","title":"Targeted Delivery of Chimeric Antigen Receptor into T Cells via CRISPR-Mediated Homology-Directed Repair with a Dual-AAV6 Transduction System","year":2023,"lang":"en","type":"review","venue":"Current Issues in Molecular Biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Fonds de Recherche du Québec - Santé; Canada Research Chairs","keywords":"Chimeric antigen receptor; CRISPR; Insertional mutagenesis; Transduction (biophysics); Biology; Homology directed repair; Cell biology; T cell; Molecular biology; Genetics; Gene; DNA repair; Immune system; Genome","score_opus":0.03301138151884226,"score_gpt":0.37404577756489915,"score_spread":0.3410343960460569,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386977179","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.006666428,0.9872511,0.00046034684,0.00003343376,0.001482878,0.0033075379,0.0001241676,0.00063617365,0.00003790785],"genre_scores_gemma":[0.00028521955,0.99340093,0.0014824747,0.000008870541,0.00025839967,0.00046106873,0.0036875734,0.0002098361,0.00020562987],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9941947,0.0019037536,0.001455692,0.0012535173,0.00041173547,0.0007806078],"domain_scores_gemma":[0.99758554,0.00025164857,0.00056064106,0.0010183455,0.00037259219,0.00021123381],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007984813,0.000786414,0.0036535503,0.0015278067,0.000054843636,0.000009140229,0.0003656776,0.0009522755,0.00041619485],"category_scores_gemma":[0.0001456982,0.000626694,0.00075025775,0.0025264758,0.0005663193,0.000032129537,0.0001387099,0.001234227,0.00020457429],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001172258,0.001115167,0.00027429237,0.10887717,0.0045945165,0.0011481133,0.0012540313,0.0000069181506,0.246863,0.00005218018,0.0016184631,0.6330239],"study_design_scores_gemma":[0.001840952,0.0020503236,0.000020318728,0.021673566,0.0012432334,0.0003144373,0.0001169951,0.00017241777,0.009488027,0.00001845785,0.9621332,0.0009280568],"about_ca_topic_score_codex":0.00044098677,"about_ca_topic_score_gemma":0.000034711506,"teacher_disagreement_score":0.9605147,"about_ca_system_score_codex":0.00044851872,"about_ca_system_score_gemma":0.00056397915,"threshold_uncertainty_score":0.9996184},"labels":[],"label_agreement":null},{"id":"W4387003976","doi":"10.1016/s2152-2650(23)01646-4","title":"P-028 Canadian-made single domain antibody (sdAb) BCMA CAR-T cells for multiple myeloma","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Single-domain antibody; Multiple myeloma; Antibody; Domain (mathematical analysis); Medicine; Immunology; Mathematics","score_opus":0.05718393129945083,"score_gpt":0.3656824003563769,"score_spread":0.3084984690569261,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387003976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.982141,0.00025490214,0.00015825669,0.002510129,0.0022740131,0.0025975797,0.00038863724,0.00065796165,0.009017484],"genre_scores_gemma":[0.9473288,0.00033943742,0.0026089158,0.0028469835,0.003065002,0.0003144137,0.0011270102,0.00039040498,0.041979015],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99255145,0.0003999592,0.0018356332,0.001650656,0.0010680135,0.002494286],"domain_scores_gemma":[0.99041945,0.004590516,0.00029900688,0.001820821,0.0005165489,0.0023536787],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0026640112,0.00072605576,0.0016030294,0.00074594445,0.0005161622,0.00017087442,0.0008628934,0.00110853,0.0015041347],"category_scores_gemma":[0.0027769164,0.00070414855,0.0012202687,0.0016088522,0.00077199127,0.00018855206,0.00029773705,0.00067325955,0.0033351958],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020656923,0.00034625488,0.022674708,0.0002675686,0.00047453117,0.0016679271,0.00034396283,0.000019565818,0.45059925,0.00022086609,0.071964085,0.44935557],"study_design_scores_gemma":[0.010434924,0.001499564,0.4660397,0.00023970036,0.0001474814,0.00015443777,0.00031892039,0.0030273427,0.027752124,0.000641632,0.4889501,0.00079408183],"about_ca_topic_score_codex":0.0083052665,"about_ca_topic_score_gemma":0.008634136,"teacher_disagreement_score":0.4485615,"about_ca_system_score_codex":0.0033943292,"about_ca_system_score_gemma":0.0050632246,"threshold_uncertainty_score":0.999541},"labels":[],"label_agreement":null},{"id":"W4387004108","doi":"10.1016/s2152-2650(23)01644-0","title":"P-026 Safety and efficacy of a locally produced novel anti-BCMA chimeric antigen receptor T-cell (CART) (HBI0101) for the treatment of relapsed and refractory multiple myeloma","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada; Terry Fox Research Institute; University of Calgary","funders":"","keywords":"Chimeric antigen receptor; Cart; Multiple myeloma; Refractory (planetary science); Medicine; Antigen; Receptor; Cancer research; Virology; Immunotherapy; Immunology; Internal medicine; Biology; Immune system","score_opus":0.04908132357785517,"score_gpt":0.34190956089097674,"score_spread":0.2928282373131216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387004108","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99322397,0.0018934039,0.00008689436,0.0007309932,0.00037599067,0.0031236438,0.00015344941,0.00012212202,0.0002895159],"genre_scores_gemma":[0.9789863,0.01575219,0.0011441788,0.0001176509,0.00051634584,0.000118219126,0.00015310099,0.00013154675,0.0030804272],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9958384,0.00023069016,0.0016398759,0.0010183685,0.00059049716,0.0006821476],"domain_scores_gemma":[0.9912067,0.0062792897,0.00053715875,0.0012210048,0.00035736896,0.0003984536],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015621743,0.0004624093,0.0015375824,0.00022220491,0.00022035411,0.00002739835,0.00030820994,0.00041579007,0.00010817182],"category_scores_gemma":[0.0016623785,0.0003247563,0.0005314986,0.0007635352,0.0011363474,0.00008653552,0.00016914961,0.00024050356,0.000030296185],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009604884,0.0012883141,0.0283079,0.00027984724,0.0005393098,0.000020361998,0.00061548065,0.0000115835865,0.34071088,0.000019964578,0.0007044983,0.617897],"study_design_scores_gemma":[0.028085236,0.0056090527,0.84720683,0.00019704971,0.00025665434,0.000035469246,0.00023494563,0.0035276841,0.053324234,0.000009301094,0.061230037,0.00028348257],"about_ca_topic_score_codex":0.00016128435,"about_ca_topic_score_gemma":0.000016370168,"teacher_disagreement_score":0.818899,"about_ca_system_score_codex":0.0004034707,"about_ca_system_score_gemma":0.0010802919,"threshold_uncertainty_score":0.9999204},"labels":[],"label_agreement":null},{"id":"W4387104794","doi":"10.1101/2023.09.26.559329","title":"A synthetic Notch (synNotch) system linking intratumoral immune-cancer cell communication to a synthetic blood biomarker assay","year":2023,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Robarts Clinical Trials; Western University","funders":"Canadian Institutes of Health Research","keywords":"CD19; Immune system; Cancer research; Jurkat cells; Chimeric antigen receptor; Cancer cell; Immunotherapy; Antigen; Cancer immunotherapy; Cancer; Immunology; Biology; T cell; Molecular biology; Medicine; Internal medicine","score_opus":0.031465955752841425,"score_gpt":0.2769455545566925,"score_spread":0.2454795988038511,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387104794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9750366,0.011440869,0.00071195315,0.0017642158,0.0023559087,0.0055624824,0.0004332157,0.0023555623,0.00033916358],"genre_scores_gemma":[0.9911889,0.0020236298,0.0030262456,0.00019147094,0.0005417272,0.0020734088,0.0000036984818,0.00068735675,0.00026357904],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99271035,0.00094676146,0.0014556093,0.0019902,0.0014609873,0.0014361195],"domain_scores_gemma":[0.9913091,0.0005199354,0.0006793934,0.005420383,0.0012592603,0.0008119062],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003851612,0.0011117143,0.0017070879,0.00085698493,0.00038780455,0.0005229361,0.0016591629,0.001095573,0.00055984576],"category_scores_gemma":[0.00048794437,0.0011694747,0.0005703809,0.0016304065,0.00026482434,0.00015384777,0.001989335,0.0022703332,0.000655993],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034951395,0.0005146994,0.0018654327,0.0051756776,0.00077692285,0.00032059808,0.000094055154,0.00007077032,0.99038166,0.00015376796,0.00026105787,0.000035827106],"study_design_scores_gemma":[0.0032444482,0.00035697085,0.03199741,0.024125641,0.0021322798,0.0000013286817,0.00011773804,0.0056116963,0.9220128,0.0000035888836,0.007847506,0.0025485808],"about_ca_topic_score_codex":0.0011258963,"about_ca_topic_score_gemma":0.000033303586,"teacher_disagreement_score":0.06836886,"about_ca_system_score_codex":0.0019536947,"about_ca_system_score_gemma":0.0016052139,"threshold_uncertainty_score":0.99907553},"labels":[],"label_agreement":null},{"id":"W4387115637","doi":"10.1111/ejh.14100","title":"Long‐term survivorship care after <scp>CAR‐T</scp> cell therapy","year":2023,"lang":"en","type":"review","venue":"European Journal Of Haematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Chimeric antigen receptor; Cytokine release syndrome; Medicine; Tocilizumab; Survivorship curve; Population; CAR T-cell therapy; Immune system; Disease; Immunology; Intensive care medicine; Immunotherapy; Cell therapy; T cell; Bioinformatics; Cell; Internal medicine; Biology","score_opus":0.10031656807501967,"score_gpt":0.36828685148472,"score_spread":0.26797028340970036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387115637","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0127384,0.97402275,0.000022832155,0.000057294055,0.0013441503,0.000918212,0.000026660027,0.00007602057,0.010793662],"genre_scores_gemma":[0.00096375233,0.98458517,0.0000825472,0.00016068314,0.0014434004,0.000017488514,0.000059000882,0.00054436707,0.012143598],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99138606,0.0041468763,0.002067064,0.0005770037,0.00088909717,0.00093388325],"domain_scores_gemma":[0.9951082,0.0012303715,0.0013872484,0.0010310048,0.0006278317,0.0006153768],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0024218562,0.0007998585,0.00450831,0.0012430548,0.00008213508,0.00008766283,0.0010596481,0.00033615463,0.0011131972],"category_scores_gemma":[0.00036122306,0.00056731014,0.0019964674,0.0006859377,0.00029173063,0.000080804755,0.00027153603,0.002680046,0.0021715797],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022253126,0.0002831994,0.0013059871,0.04381523,0.0019746942,0.26457736,0.0028068875,3.3824637e-7,0.00004926823,0.00001074004,0.00744663,0.67750716],"study_design_scores_gemma":[0.0018413983,0.001277401,0.000578136,0.011992629,0.0008349432,0.03632629,0.00022039594,1.0746887e-7,0.00005423814,0.000004647265,0.94668746,0.0001823303],"about_ca_topic_score_codex":0.000003916208,"about_ca_topic_score_gemma":0.000011697786,"teacher_disagreement_score":0.9392409,"about_ca_system_score_codex":0.00020193725,"about_ca_system_score_gemma":0.00076735136,"threshold_uncertainty_score":0.9997999},"labels":[],"label_agreement":null},{"id":"W4387135433","doi":"10.1136/ijgc-2023-esgo.866","title":"#24 A phase 2 study (GOG-3084) OF ADP-A2M4CD8 TCR T-cell therapy, alone or in combination with nivolumab, in patients with recurrent ovarian cancers","year":2023,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Oncology; Ovarian cancer; Nivolumab; Medicine; Internal medicine; Population; Ovarian carcinoma; Debulking; CD8; Immunotherapy; Cancer; Immunology; Antigen","score_opus":0.04904749363744676,"score_gpt":0.37701556038881845,"score_spread":0.3279680667513717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387135433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997032,0.00014446788,0.000016015943,0.0011190601,0.00042665217,0.00095192104,0.00002391618,0.000011221384,0.00027477948],"genre_scores_gemma":[0.998402,0.00048606793,0.00009706708,0.00017426311,0.00009855221,0.00008428175,0.000018740291,0.000022656868,0.0006163639],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970501,0.00018072056,0.00071161444,0.00024690913,0.0015344826,0.00027615548],"domain_scores_gemma":[0.9979585,0.00032633738,0.000452036,0.00013316142,0.0010064746,0.00012349502],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000736269,0.00017686833,0.000523987,0.00067179336,0.000023119472,0.000024408931,0.00032246095,0.000080860395,0.0031056823],"category_scores_gemma":[0.00019062131,0.00010665649,0.00007321184,0.00079996104,0.00010799516,0.00015154641,0.000054402994,0.00054512644,0.000003619979],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06641149,0.009584048,0.8449677,0.000026299404,0.00043543478,0.00094691786,0.0012656912,0.00073747686,0.0011834078,0.0000090311405,0.0005073132,0.07392518],"study_design_scores_gemma":[0.073777,0.027650386,0.895285,0.00031092585,0.000033994213,0.000014838845,0.000726532,0.00032247687,0.00055626413,0.000045519802,0.0011243257,0.0001527219],"about_ca_topic_score_codex":0.00053731573,"about_ca_topic_score_gemma":0.0023393102,"teacher_disagreement_score":0.07377246,"about_ca_system_score_codex":0.0014581389,"about_ca_system_score_gemma":0.00079919887,"threshold_uncertainty_score":0.9978056},"labels":[],"label_agreement":null},{"id":"W4387209890","doi":"10.1111/cas.15985","title":"Intratumoral administration of unconjugated Accum™ impairs the growth of pre‐established solid lymphoma tumors","year":2023,"lang":"en","type":"article","venue":"Cancer Science","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Defence Research and Development Canada; Centre Hospitalier Universitaire Sainte-Justine; Université de Sherbrooke; Université de Montréal","funders":"Cancer Research Society","keywords":"Cancer research; Immune system; Programmed cell death; Immunogenic cell death; Endosome; Lymphoma; Pharmacology; Biology; CD8; Cell biology; Immunotherapy; Immunology; Apoptosis; Biochemistry; Intracellular","score_opus":0.033036508945736405,"score_gpt":0.36102301747985954,"score_spread":0.32798650853412314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387209890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960621,0.000104846,0.000012932872,0.0013618823,0.00022681958,0.0004300478,0.000016686361,0.000048800222,0.0017358783],"genre_scores_gemma":[0.9986077,0.00011246981,0.000034177756,0.000087607434,0.000080160826,0.00004736372,0.0000061240644,0.000011599082,0.0010128025],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980913,0.00004355078,0.00031506305,0.00029362633,0.0008767497,0.00037974436],"domain_scores_gemma":[0.99876165,0.000102599006,0.00014682041,0.00043506335,0.0004089397,0.00014493572],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011184756,0.00010398816,0.0002410245,0.00022442949,0.00011122941,0.00004348003,0.00050731405,0.00003554123,0.00034882472],"category_scores_gemma":[0.00041063162,0.000070783775,0.00006221952,0.0034694201,0.001390272,0.000257324,0.00010813598,0.00010590944,0.0000058319497],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007606854,0.00008110369,0.0134668285,0.00014159501,0.000022106526,0.000028224784,0.0014483891,0.000043545333,0.9722475,0.0004863533,0.0011718449,0.010101832],"study_design_scores_gemma":[0.0007557563,0.00057487114,0.22536714,0.00012241399,0.000016266746,0.000027355176,0.00041319054,0.00292707,0.76932615,0.00026779133,0.00012149301,0.00008046985],"about_ca_topic_score_codex":0.0004959004,"about_ca_topic_score_gemma":0.000089763686,"teacher_disagreement_score":0.21190031,"about_ca_system_score_codex":0.00015956453,"about_ca_system_score_gemma":0.0030672115,"threshold_uncertainty_score":0.5441102},"labels":[],"label_agreement":null},{"id":"W4387267794","doi":"10.1038/s43018-023-00634-8","title":"Immunotargeting of a recurrent AML-specific neoantigen","year":2023,"lang":"en","type":"article","venue":"Nature Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Myeloid leukemia; Human leukocyte antigen; Medicine; Immunology; Myeloid; Cancer research; Oncology; Antigen","score_opus":0.03267180719695787,"score_gpt":0.373176615773337,"score_spread":0.3405048085763791,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387267794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9390778,0.04867645,0.00000432353,0.0023206582,0.0012355786,0.00047463106,0.00003208043,0.00012826109,0.008050209],"genre_scores_gemma":[0.97077996,0.013130739,0.0001428881,0.00025410883,0.00089599297,0.000059163765,0.000053678643,0.000051463343,0.014632026],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99875826,0.000032080225,0.00018970156,0.00023320602,0.0004795126,0.00030722862],"domain_scores_gemma":[0.9992633,0.00007439306,0.00005760758,0.0003167634,0.0002106811,0.00007724571],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00031380702,0.00010573946,0.00025034248,0.00018173039,0.00004065829,0.0000086867,0.00012656336,0.0001971528,0.006428238],"category_scores_gemma":[0.00007526373,0.000087971166,0.00012721676,0.00084301684,0.000057164434,0.000026520907,0.000057416277,0.00080859935,0.000087093395],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070035097,0.000049442926,0.00727441,0.00018603182,0.0001396716,0.000047530502,0.0006285516,0.000009096817,0.6879974,0.00016405196,0.07773242,0.22507101],"study_design_scores_gemma":[0.0011290921,0.00012619715,0.04027196,0.000298838,0.000020029698,0.0000073156475,0.00013585661,0.000111218455,0.08709889,0.00006875161,0.8706106,0.00012126499],"about_ca_topic_score_codex":0.00003071058,"about_ca_topic_score_gemma":0.000008753241,"teacher_disagreement_score":0.79287815,"about_ca_system_score_codex":0.00014893859,"about_ca_system_score_gemma":0.00014605452,"threshold_uncertainty_score":0.99448},"labels":[],"label_agreement":null},{"id":"W4387296735","doi":"10.1158/1078-0432.ccr-23-1735","title":"Intratumoral Delivery of Chimeric Antigen Receptor T Cells Targeting CD133 Effectively Treats Brain Metastases","year":2023,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Canada Foundation for Innovation; Mitacs; Canada Research Chairs","keywords":"Chimeric antigen receptor; Medicine; Antigen; Population; Cancer research; Cancer stem cell; Metastasis; Immunotherapy; Immunology; Oncology; Cancer; Internal medicine; Immune system","score_opus":0.20659055628028922,"score_gpt":0.5196007385964388,"score_spread":0.31301018231614963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387296735","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99257493,0.0016323437,0.0000064415335,0.0024158156,0.00043637466,0.0013434242,0.00014014768,0.00012172558,0.0013287993],"genre_scores_gemma":[0.97593004,0.009147096,0.00036766217,0.00024056624,0.0013959099,0.00026282654,0.00012678765,0.00011934073,0.012409804],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99302953,0.0023363137,0.000920219,0.0008340622,0.001701668,0.0011782005],"domain_scores_gemma":[0.99123484,0.006525034,0.00013944623,0.0006339784,0.00088941597,0.0005773085],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.010646242,0.00024277321,0.0009666143,0.0006247214,0.00019677317,0.000045224802,0.00044784186,0.00022151356,0.006939824],"category_scores_gemma":[0.003238428,0.00020170647,0.00044676408,0.0029335297,0.0010991418,0.00010642716,0.00040815116,0.0016849921,0.0007153779],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041161175,0.00044960502,0.03664734,0.00033504213,0.00040387723,0.00017525473,0.00020176118,0.00001355581,0.7083953,0.000018914827,0.13853724,0.110705964],"study_design_scores_gemma":[0.008161984,0.006689226,0.1165526,0.0006952602,0.000103271035,0.000009906421,0.0008606778,0.00082541374,0.7366648,0.00020708055,0.12868743,0.00054239156],"about_ca_topic_score_codex":0.0015536465,"about_ca_topic_score_gemma":0.00006112466,"teacher_disagreement_score":0.11016358,"about_ca_system_score_codex":0.00025143352,"about_ca_system_score_gemma":0.0011780793,"threshold_uncertainty_score":0.99396795},"labels":[],"label_agreement":null},{"id":"W4387398407","doi":"10.1016/j.actbio.2023.10.002","title":"Injectable hydrogels for personalized cancer immunotherapies","year":2023,"lang":"en","type":"review","venue":"Acta Biomaterialia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; University of British Columbia","funders":"Terasaki Institute for Biomedical Innovation; National Center for Advancing Translational Sciences; National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institutes of Health; Foundation for the National Institutes of Health","keywords":"Self-healing hydrogels; Materials science; Cancer; Cancer immunotherapy; Immunotherapy; Biomedical engineering; Medicine; Internal medicine; Polymer chemistry","score_opus":0.1338811687094837,"score_gpt":0.4307899513428981,"score_spread":0.2969087826334144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387398407","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00042185956,0.99143964,0.0000026836503,0.00019015982,0.0025157095,0.0037482583,0.0011784915,0.00033408066,0.00016913239],"genre_scores_gemma":[0.000003503066,0.8848545,0.000105388506,0.00006524374,0.0012728483,0.0026738383,0.0009345092,0.00035640973,0.109733745],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99724954,0.00015996293,0.0007353838,0.00065643963,0.00043577328,0.00076290296],"domain_scores_gemma":[0.99848586,0.00018142854,0.00029813746,0.0007431731,0.0001331107,0.00015830346],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00056847814,0.0006063822,0.0026374108,0.0004248417,0.00013584898,0.00018115102,0.00040616535,0.0005504726,0.011288064],"category_scores_gemma":[0.00007463172,0.00045860253,0.0009298086,0.00058666605,0.00017538248,0.00007126363,0.00012862659,0.00015928104,0.00034980243],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011467695,0.00013172503,0.0000023621124,0.087338164,0.004994873,0.000053688582,0.00043755054,5.074946e-9,0.11785795,0.00008631604,0.03765313,0.7502975],"study_design_scores_gemma":[0.0014738477,0.00026020454,7.404009e-7,0.011186654,0.0010268894,0.000066038156,0.00002323967,0.0000011960917,0.0017241692,0.00003131038,0.9837794,0.00042632897],"about_ca_topic_score_codex":0.00065819855,"about_ca_topic_score_gemma":0.000017019365,"teacher_disagreement_score":0.9461262,"about_ca_system_score_codex":0.00043354454,"about_ca_system_score_gemma":0.0008271547,"threshold_uncertainty_score":0.99978656},"labels":[],"label_agreement":null},{"id":"W4387500323","doi":"10.21203/rs.3.rs-3366592/v1","title":"CAR T cells and T cells phenotype and function are impacted by glucocorticoid exposure with different amplitude.","year":2023,"lang":"en","type":"preprint","venue":"Research Square","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Karolinska Institutet; Memorial Sloan-Kettering Cancer Center; University of Toronto; Cancerfonden; Stiftelsen Tornspiran","keywords":"Glucocorticoid; Phenotype; Function (biology); Amplitude; Cell biology; Biology; Chemistry; Physics; Endocrinology; Genetics; Gene; Optics","score_opus":0.05723631142787739,"score_gpt":0.3549740242073337,"score_spread":0.2977377127794563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387500323","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99002635,0.0034151254,0.00012225399,0.0008630855,0.00024772916,0.0043244255,0.0004835363,0.00020402836,0.00031347995],"genre_scores_gemma":[0.9751744,0.005767309,0.000039528004,0.000048445534,0.00037153534,0.00037654903,0.0005713395,0.00023701364,0.017413873],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99375993,0.0005942814,0.00045316695,0.0014544607,0.0024642223,0.0012739671],"domain_scores_gemma":[0.9959279,0.000717461,0.00015506435,0.0013583051,0.00094637147,0.00089490315],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011027614,0.00059370993,0.0010294513,0.0006987185,0.00024343694,0.00040184107,0.0002638511,0.0006383146,0.00093080243],"category_scores_gemma":[0.00015635267,0.00044658402,0.00014367737,0.00060354604,0.00046587037,0.000075764474,0.0011505049,0.0032945448,0.00009594711],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070521617,0.000645115,0.091266885,0.010997065,0.0011096125,0.00039106346,0.0013388533,0.000056153847,0.85962445,0.000019278743,0.013892711,0.01360663],"study_design_scores_gemma":[0.012630559,0.013834567,0.8144185,0.0073831254,0.0005943308,0.00006901477,0.006553234,0.001502603,0.11769387,0.00079620816,0.022560786,0.001963198],"about_ca_topic_score_codex":0.000958229,"about_ca_topic_score_gemma":0.00025490174,"teacher_disagreement_score":0.7419306,"about_ca_system_score_codex":0.00051920343,"about_ca_system_score_gemma":0.00050125935,"threshold_uncertainty_score":0.9999825},"labels":[],"label_agreement":null},{"id":"W4387540453","doi":"10.1080/17474086.2023.2268273","title":"Immunotherapy for myelodysplastic syndrome and acute myeloid leukemia: where do we stand?","year":2023,"lang":"en","type":"review","venue":"Expert Review of Hematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Chimeric antigen receptor; Immunotherapy; Myeloid leukemia; Clinical trial; Immunology; Myelodysplastic syndromes; Myeloid; Tolerability; T cell; Immune system; Oncology; Cancer research; Internal medicine; Bone marrow; Adverse effect","score_opus":0.049156869697557774,"score_gpt":0.40672588013009886,"score_spread":0.3575690104325411,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387540453","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000029372868,0.9920814,0.000084378786,0.000960588,0.0004321348,0.006003167,0.00012470275,0.00010383528,0.00020687509],"genre_scores_gemma":[1.2106699e-7,0.9905296,0.00088695926,0.00016394329,0.00016327064,0.0021335906,0.00010003373,0.000290968,0.005731514],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99549097,0.00036329802,0.0019239807,0.00093348435,0.0005222914,0.0007659964],"domain_scores_gemma":[0.99588,0.0016534402,0.00072893297,0.0012453918,0.0002492764,0.00024294246],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009519992,0.00083085976,0.008552325,0.00045083085,0.000090788715,0.000021430867,0.000498021,0.00073865394,0.0020374765],"category_scores_gemma":[0.0003012828,0.0005915954,0.0013258228,0.00066126016,0.00036093572,0.00005639731,0.00020094267,0.00075758796,0.00015007594],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00007092124,0.000037272457,5.4743504e-7,0.44213375,0.0015431227,0.00032984267,0.0000535449,2.7803861e-9,0.000024841478,0.00034643873,0.017502638,0.5379571],"study_design_scores_gemma":[0.00079759397,0.00052254525,2.3798954e-7,0.3118623,0.0008005202,0.009463752,0.00001790515,0.000001041804,0.000007834761,0.000052663418,0.676176,0.00029763175],"about_ca_topic_score_codex":0.000010631736,"about_ca_topic_score_gemma":0.0000026785244,"teacher_disagreement_score":0.65867335,"about_ca_system_score_codex":0.00037545888,"about_ca_system_score_gemma":0.0013858941,"threshold_uncertainty_score":0.9996535},"labels":[],"label_agreement":null},{"id":"W4387576459","doi":"10.1038/s41467-023-42010-1","title":"KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors","year":2023,"lang":"en","type":"article","venue":"Nature Communications","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":86,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Key Research and Development Program of China; Chinese Academy of Sciences; Institute of Genetics; National Natural Science Foundation of China","keywords":"KRAS; T-cell receptor; Cancer research; T cell; Immunotherapy; Context (archaeology); Mutant; Biology; Mutation; Molecular biology; Immunology; Immune system; Genetics; Gene","score_opus":0.06662169282579858,"score_gpt":0.3603754140301149,"score_spread":0.2937537212043163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387576459","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.636906,0.065911956,0.0002424558,0.04769915,0.001320211,0.010290891,0.00074974896,0.0016184014,0.23526114],"genre_scores_gemma":[0.8775303,0.06304549,0.011032144,0.0015688933,0.00048158955,0.00054871384,0.002877711,0.00017299037,0.042742215],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99822205,0.00018092022,0.0003314792,0.00037017872,0.00041009553,0.00048524776],"domain_scores_gemma":[0.9955789,0.0008003693,0.00011620564,0.0028193705,0.00048699998,0.00019817504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059467857,0.00023437162,0.0003428028,0.00034747508,0.00044949513,0.000054743243,0.0012000707,0.00036892196,0.00084982015],"category_scores_gemma":[0.00006932476,0.0002144419,0.00027598668,0.0012498121,0.00022586995,0.00007799917,0.00021602174,0.0015720217,0.0007146963],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045983685,0.0006515297,0.0012117814,0.000053309155,0.000101376594,0.0000065167847,0.001863919,0.000012682687,0.69295913,0.0011805258,0.27603537,0.025464026],"study_design_scores_gemma":[0.0019581488,0.00021929717,0.0019454896,0.000040676885,0.000014932262,0.0000024884707,0.00071172806,0.00031041802,0.071458906,0.00014349936,0.92298436,0.00021008018],"about_ca_topic_score_codex":0.000008543345,"about_ca_topic_score_gemma":0.00002375381,"teacher_disagreement_score":0.646949,"about_ca_system_score_codex":0.00016092512,"about_ca_system_score_gemma":0.00027425634,"threshold_uncertainty_score":0.9304935},"labels":[],"label_agreement":null},{"id":"W4387581273","doi":"10.3389/fmolb.2023.1267762","title":"Unlocking the potential of Tregs: innovations in CAR technology","year":2023,"lang":"en","type":"review","venue":"Frontiers in Molecular Biosciences","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Fonds de Recherche du Québec - Santé; Kidney Foundation of Canada","keywords":"Chimeric antigen receptor; Homing (biology); Antigen; Immunology; Receptor; Immunotherapy; FOXP3; Immune system; Cell therapy; Biology; Computational biology; Cell biology; Stem cell; Genetics","score_opus":0.03796710047597518,"score_gpt":0.3643147626166985,"score_spread":0.3263476621407233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387581273","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00043997672,0.99492073,0.0017451303,0.00054240535,0.0006739372,0.0012359644,0.000012960274,0.0000348045,0.0003940988],"genre_scores_gemma":[0.00031004456,0.9966273,0.0022171123,0.000027873595,0.000036500976,0.00012505111,0.000018993254,0.000034058146,0.0006030901],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99768406,0.0001752261,0.00065587094,0.0004675119,0.00059759093,0.0004197556],"domain_scores_gemma":[0.999084,0.000045891487,0.0002103691,0.00054336304,0.00008064085,0.000035741283],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010151558,0.0002212596,0.0010527559,0.0030352874,0.00005804064,0.000023298488,0.00078868255,0.00033169295,0.000023700377],"category_scores_gemma":[0.00038521847,0.00014775284,0.00021772936,0.010016405,0.0009548125,0.0000306897,0.00019636101,0.000686839,0.0000042337497],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008896369,0.000069246715,0.0004917702,0.002157463,0.000101929196,0.0002668359,0.000096704636,0.000012653338,0.0017095681,0.00046649782,0.00035425692,0.9942642],"study_design_scores_gemma":[0.0012716874,0.0004955635,0.0001537925,0.02162011,0.0005010546,0.00017061496,0.005401104,0.00071336713,0.001460886,0.004097414,0.963337,0.00077742036],"about_ca_topic_score_codex":0.00007866791,"about_ca_topic_score_gemma":0.000027572094,"teacher_disagreement_score":0.99348676,"about_ca_system_score_codex":0.00019054217,"about_ca_system_score_gemma":0.0007755147,"threshold_uncertainty_score":0.6025186},"labels":[],"label_agreement":null},{"id":"W4387747059","doi":"10.1016/j.omtm.2023.101139","title":"Lipid nanoparticles outperform electroporation in mRNA-based CAR T cell engineering","year":2023,"lang":"en","type":"article","venue":"Molecular Therapy — Methods & Clinical Development","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":107,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Precision Nanosystems (Canada)","funders":"Bundesministerium für Bildung und Forschung","keywords":"Electroporation; Chimeric antigen receptor; In vitro; In vivo; Messenger RNA; Cell; Ex vivo; T cell; Cell biology; Chemistry; Biology; Immunology; Immune system; Biotechnology; Gene; Biochemistry","score_opus":0.09062217181834831,"score_gpt":0.4393684752559198,"score_spread":0.3487463034375715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387747059","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9746601,0.0004497701,0.022258338,0.0010156494,0.00022190834,0.000925763,7.975377e-7,0.0002265895,0.00024105707],"genre_scores_gemma":[0.6081017,0.00084206474,0.38704765,0.0017567956,0.00019431273,0.0003469462,0.0001335749,0.00016686223,0.0014100319],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99614286,0.00071233977,0.0011088282,0.0006277886,0.0006549913,0.0007532118],"domain_scores_gemma":[0.9983155,0.00058892835,0.00011080963,0.0005361187,0.00014165964,0.0003069412],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.006504457,0.00031060106,0.0006389535,0.0004227856,0.000070572474,0.00004478957,0.00023053831,0.000248383,0.00042091444],"category_scores_gemma":[0.00050051796,0.0002804343,0.00024812878,0.0012320778,0.00006489697,0.000050914357,0.00006870283,0.00067031645,0.00016169652],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038681526,0.00030761812,0.006587092,0.000041343475,0.00007942761,0.00012427733,0.0002120664,0.00035724,0.7241022,0.00001771221,0.000058412134,0.2677258],"study_design_scores_gemma":[0.0036338188,0.00056571164,0.026832107,0.00004329243,0.000014035066,0.0000037535797,0.00004458546,0.008316128,0.89665425,0.00005973334,0.06352914,0.0003034265],"about_ca_topic_score_codex":0.000015757878,"about_ca_topic_score_gemma":0.000005425445,"teacher_disagreement_score":0.36655837,"about_ca_system_score_codex":0.00028695475,"about_ca_system_score_gemma":0.000639143,"threshold_uncertainty_score":0.9999648},"labels":[],"label_agreement":null},{"id":"W4387809673","doi":"10.1016/j.annonc.2023.10.029","title":"LBA9 innovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital","funders":"Ipsen; Astellas Pharma; Eisai; AstraZeneca; University College London; Boston Scientific Corporation; Seagen; Pfizer","keywords":"Medicine; Open label; Chemotherapy; Oncology; Internal medicine; Phases of clinical research; Open label study; Surgery; Randomized controlled trial","score_opus":0.3080902739800833,"score_gpt":0.5448928587729979,"score_spread":0.23680258479291455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387809673","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98322535,0.0008934624,0.000006074113,0.0092317145,0.00027680834,0.0052779214,0.00011740924,0.000037343274,0.00093389704],"genre_scores_gemma":[0.9894304,0.0042443317,0.00048589913,0.0028159872,0.00016116117,0.0011287357,0.0000581219,0.00008253026,0.0015928011],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9943428,0.0013688143,0.0020525767,0.00065015873,0.00085299724,0.0007326589],"domain_scores_gemma":[0.9952242,0.0019436016,0.0008486073,0.0007511754,0.0008765862,0.00035585932],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0040047527,0.00038443774,0.0034558645,0.0006031967,0.000045955418,0.000016259746,0.0008026914,0.00022242877,0.0035935207],"category_scores_gemma":[0.0029311008,0.00028063243,0.00015186195,0.0036459237,0.00068713113,0.00012979524,0.00040790107,0.00054273603,0.000015184556],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6870807,0.024879755,0.0038671156,0.0009651425,0.0025575755,0.00042402634,0.0041038496,0.00001632316,0.021697382,0.00021792174,0.030682499,0.22350775],"study_design_scores_gemma":[0.8898019,0.051446598,0.0030656904,0.00066186,0.00037576183,0.000040365612,0.0019308642,0.00081304647,0.014135143,0.00047224606,0.036862187,0.00039432227],"about_ca_topic_score_codex":0.006909725,"about_ca_topic_score_gemma":0.0055705523,"teacher_disagreement_score":0.22311342,"about_ca_system_score_codex":0.00024269724,"about_ca_system_score_gemma":0.0034121433,"threshold_uncertainty_score":0.9999646},"labels":[],"label_agreement":null},{"id":"W4387811091","doi":"10.1016/j.annonc.2023.09.2185","title":"1046P Phase I/II open-label study on an anti-GPC3 T cell engager, SAR444200, in patients with advanced solid tumors: Preliminary dose escalation results","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"PharmaMar; CRIS Cancer Foundation; Sociedad Española de Oncología Médica; European Society for Medical Oncology; American Society of Clinical Oncology; BeiGene; Sanofi","keywords":"Medicine; Cytokine release syndrome; Glypican 3; Pharmacokinetics; Oncology; Adverse effect; T cell; Internal medicine; Biomarker; Gastroenterology; Cancer; Cancer research; Immunotherapy; Immunology; Chimeric antigen receptor; Immune system","score_opus":0.1514363011465199,"score_gpt":0.47915271221053296,"score_spread":0.32771641106401306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387811091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990332,0.00003574811,9.884747e-7,0.0010460686,0.000094107716,0.0031743064,0.000060295195,0.000058956128,0.0051975227],"genre_scores_gemma":[0.9970495,0.00011298864,0.0001343796,0.00038729195,0.00006603946,0.00012409009,0.0003588006,0.00005519652,0.0017116837],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9968439,0.0006644472,0.0007120424,0.00062989374,0.00058207155,0.00056765415],"domain_scores_gemma":[0.9979386,0.00041210512,0.00029807485,0.0007109378,0.0004217366,0.00021856595],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018763131,0.00024087405,0.0007832483,0.000569102,0.00012803002,0.000015955235,0.00035801396,0.00015452973,0.00010797895],"category_scores_gemma":[0.00034875004,0.0002052322,0.00003923809,0.0010055751,0.000120890654,0.00027339807,0.00026779933,0.0005479914,0.000044789962],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20827283,0.17611565,0.028958252,0.00014224624,0.00021522173,0.0012406918,0.01171881,0.0005466495,0.073085584,0.000011557131,0.006367386,0.49332514],"study_design_scores_gemma":[0.13601974,0.42902943,0.4085512,0.00022081273,0.000042178508,0.000004933295,0.0018734456,0.0006080876,0.019764919,0.000036699712,0.0035495362,0.00029902684],"about_ca_topic_score_codex":0.00009334109,"about_ca_topic_score_gemma":0.000056197965,"teacher_disagreement_score":0.4930261,"about_ca_system_score_codex":0.00009683282,"about_ca_system_score_gemma":0.00033190526,"threshold_uncertainty_score":0.8369126},"labels":[],"label_agreement":null},{"id":"W4387811241","doi":"10.1016/j.annonc.2023.09.2158","title":"1019O Clinical and translational data from the phase I SURPASS trial of ADP-A2M4CD8 T cell receptor (TCR) T cell therapy alone or combined with nivolumab in solid tumors","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Chugai Pharmaceutical; Astellas Pharma; Eisai; Daiichi-Sankyo; Svenska Forskningsrådet Formas; Sierra Oncology; Incyte; Regeneron Pharmaceuticals; BeiGene; Pfizer; INOVIO Pharmaceuticals; Daiichi Sankyo Europe; Sanofi; Amgen; PharmaMar; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Nivolumab; Internal medicine; Neutropenia; Oncology; CD8; Pembrolizumab; Cytokine release syndrome; Melanoma; Immunotherapy; Immunology; Antigen; Chimeric antigen receptor; Chemotherapy; Cancer; Cancer research","score_opus":0.3242130588186991,"score_gpt":0.5044721720448572,"score_spread":0.18025911322615806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387811241","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9853278,0.0003580803,0.000011331064,0.011506118,0.00017260453,0.0013546065,0.00037328503,0.000021497977,0.00087471114],"genre_scores_gemma":[0.99159247,0.0046324674,0.00032027188,0.00072633487,0.00035673936,0.000032089985,0.00084000337,0.00004122108,0.0014584069],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9968837,0.0007934911,0.0009891486,0.0004661516,0.00050921156,0.00035832086],"domain_scores_gemma":[0.9948649,0.0037020058,0.00030493562,0.0007646178,0.00021925516,0.00014431027],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0030469166,0.00017906289,0.0010377038,0.00015799416,0.00004268218,0.000008364159,0.00044835094,0.00022216754,0.002119915],"category_scores_gemma":[0.0002667927,0.000113219496,0.00010548059,0.0005176426,0.0006656356,0.000083418185,0.000107648026,0.00047398184,0.0000209544],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.760273,0.008478294,0.016401831,0.000078542995,0.00041643975,0.00018903369,0.001489478,0.000009034358,0.05665092,0.000010108988,0.056322306,0.099681035],"study_design_scores_gemma":[0.66410774,0.106854334,0.03207642,0.00019175505,0.00014062041,0.00001995383,0.0012181554,0.002413458,0.056613863,0.0003686365,0.135576,0.00041909257],"about_ca_topic_score_codex":0.00045082884,"about_ca_topic_score_gemma":0.00056620076,"teacher_disagreement_score":0.09926195,"about_ca_system_score_codex":0.000011152469,"about_ca_system_score_gemma":0.001056575,"threshold_uncertainty_score":0.9987923},"labels":[],"label_agreement":null},{"id":"W4387812409","doi":"10.1016/j.annonc.2023.09.1440","title":"1528P A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Adverse effect; Pneumonitis; Chimeric antigen receptor; Internal medicine; Oncology; Refractory (planetary science); Chemotherapy; Leukapheresis; Immunotherapy; Gastroenterology; Cancer; Stem cell; Lung","score_opus":0.1673751192360413,"score_gpt":0.47712884700499364,"score_spread":0.3097537277689524,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387812409","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908436,0.0001665162,0.0000014166877,0.00450704,0.00014817569,0.00090793805,0.00001645151,0.000052667914,0.0033561892],"genre_scores_gemma":[0.99591887,0.0005899666,0.00020021683,0.0005329769,0.00017268577,0.000031799154,0.000030177092,0.000033019547,0.0024903065],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99755836,0.00041219665,0.0009302032,0.00032762182,0.00031107903,0.00046053543],"domain_scores_gemma":[0.997314,0.0016302776,0.00034631178,0.00033046267,0.00017765637,0.00020133631],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020340558,0.00015896875,0.0010485001,0.00049439905,0.000058548965,0.0000032128282,0.0001452242,0.0002729409,0.0005751588],"category_scores_gemma":[0.0041000126,0.00013339325,0.00011099831,0.0007867631,0.0005401897,0.00004294137,0.00016045218,0.00049771846,0.000010266361],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.21331583,0.0035012236,0.0007651795,0.00031038685,0.00024800532,0.0010001124,0.005509267,0.000038161063,0.31614983,0.00011077853,0.005322646,0.4537286],"study_design_scores_gemma":[0.520349,0.23628442,0.032379616,0.0010696393,0.00016057088,0.00033400106,0.0027068153,0.002939123,0.08566526,0.00082770735,0.11665938,0.0006244505],"about_ca_topic_score_codex":0.00020005209,"about_ca_topic_score_gemma":0.000108924985,"teacher_disagreement_score":0.45310414,"about_ca_system_score_codex":0.00006903207,"about_ca_system_score_gemma":0.0009978549,"threshold_uncertainty_score":0.62975854},"labels":[],"label_agreement":null},{"id":"W4387824968","doi":"10.1016/j.annonc.2023.09.2005","title":"859MO Sacituzumab govitecan (SG) in patients (pts) with relapsed/refractory (R/R) advanced head and neck squamous cell carcinoma (HNSCC): Results from the phase II TROPiCS-03 basket trial","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Internal medicine; Clinical endpoint; Adverse effect; Head and neck squamous-cell carcinoma; Refractory (planetary science); Phases of clinical research; Cohort; Surgery; Oncology; Clinical trial; Head and neck cancer; Cancer","score_opus":0.06312735777555628,"score_gpt":0.3723666057780799,"score_spread":0.3092392480025236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387824968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890461,0.00031841002,0.0000010041649,0.0042323857,0.00027624727,0.0016055949,0.00031104876,0.0000454742,0.0041637234],"genre_scores_gemma":[0.99588954,0.0003089136,0.00007786753,0.0008291502,0.0002672374,0.000079096746,0.00033406366,0.000052200445,0.0021619175],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9970215,0.00043353572,0.00074104534,0.000604175,0.0005590965,0.00064067583],"domain_scores_gemma":[0.9971561,0.00129058,0.00031448816,0.00073413877,0.00026991556,0.00023478731],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007273694,0.00027496583,0.0008073375,0.00027691014,0.00012958581,0.000012581948,0.0002609663,0.00027983,0.00023003666],"category_scores_gemma":[0.00061920955,0.00019695642,0.00012058543,0.0006116297,0.00033983972,0.00010941293,0.00016687487,0.00068383076,0.000025664278],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6686425,0.006538974,0.022134565,0.00008372469,0.0001145841,0.00045447037,0.0053055366,0.000028370117,0.0143224,0.00001867957,0.020069575,0.2622866],"study_design_scores_gemma":[0.55100214,0.13308117,0.14886814,0.00010075791,0.000079332385,0.000008022293,0.0007813151,0.00013601354,0.0064020357,0.000153165,0.15905589,0.00033202878],"about_ca_topic_score_codex":0.0013391445,"about_ca_topic_score_gemma":0.0010829556,"teacher_disagreement_score":0.26195458,"about_ca_system_score_codex":0.00018543765,"about_ca_system_score_gemma":0.0005704967,"threshold_uncertainty_score":0.80316496},"labels":[],"label_agreement":null},{"id":"W4387866461","doi":"10.1139/bcb-2023-0207","title":"BioCanRx Summit for Cancer Immunotherapy 2022 Proceedings","year":2023,"lang":"en","type":"article","venue":"Biochemistry and Cell Biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Terry Fox Research Institute; University of Calgary; Beatrice Hunter Cancer Research Institute; University of British Columbia; Ottawa Hospital; Canadian Patient Safety Institute; Dalhousie University","funders":"Canadian Institutes of Health Research; Killam Trusts; BC Children's Hospital; BC Cancer Foundation; Children's Hospital Foundation; Beatrice Hunter Cancer Research Institute; Alberta Children's Hospital Research Institute; Cancer Research Institute","keywords":"Summit; Event (particle physics); Session (web analytics); Medicine; Plenary session; Pandemic; Medical education; Panel discussion; Cancer; Public relations; Coronavirus disease 2019 (COVID-19); Political science; Library science; Disease; Pathology; Internal medicine; Computer science; Business","score_opus":0.02352348168894332,"score_gpt":0.3223409686032118,"score_spread":0.2988174869142685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387866461","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989973,0.003906741,0.0000039544025,0.0013459801,0.0001076512,0.0003635834,0.000058187863,0.0001338475,0.0041070553],"genre_scores_gemma":[0.9204443,0.008058887,0.000084705,0.00045387784,0.0006015928,0.00039052626,0.00020244218,0.00005280321,0.06971085],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990714,0.000006014731,0.00014151385,0.0003504478,0.00007061631,0.00035996133],"domain_scores_gemma":[0.9995753,0.00005549513,0.000040841118,0.00013335233,0.000090771166,0.0001042052],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020457146,0.00013441527,0.00021364911,0.00005651603,0.00006866019,0.000012668675,0.00009420426,0.00021793575,0.0008113544],"category_scores_gemma":[0.000025952537,0.00011453182,0.00007906261,0.00022783582,0.00016087256,0.000012372298,0.000043778615,0.00013889791,0.000010452883],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004964651,0.00003494983,0.006174944,0.00024157853,0.000054788325,0.0000022622876,0.00005962153,4.1731404e-8,0.956373,0.000027702987,0.009629631,0.026905034],"study_design_scores_gemma":[0.0010879765,0.00023583227,0.00029944352,0.000014350646,0.000012322894,0.000004363744,0.00014207099,0.000042100815,0.7137663,0.00010924518,0.2841876,0.0000984515],"about_ca_topic_score_codex":0.00003895204,"about_ca_topic_score_gemma":0.0000019464746,"teacher_disagreement_score":0.27455795,"about_ca_system_score_codex":0.000042109266,"about_ca_system_score_gemma":0.00009825171,"threshold_uncertainty_score":0.8883761},"labels":[],"label_agreement":null},{"id":"W4387955394","doi":"10.1016/j.intimp.2023.111093","title":"Strategies for modifying the chimeric antigen receptor (CAR) to improve safety and reduce toxicity in CAR T cell therapy for cancer","year":2023,"lang":"en","type":"review","venue":"International Immunopharmacology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Tabriz University of Medical Sciences","keywords":"Chimeric antigen receptor; Cytokine release syndrome; Toxicity; Suicide gene; Antigen; Cell therapy; Immunotherapy; Cancer; Cancer research; Adverse effect; Monoclonal antibody; Immunology; Immune system; Genetic enhancement; Medicine; T cell; Biology; Cell; Pharmacology; Antibody; Internal medicine; Gene","score_opus":0.10877761384237111,"score_gpt":0.4661448907634555,"score_spread":0.3573672769210844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387955394","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009185477,0.9754711,0.0001222501,0.0018313827,0.0032280325,0.0088044675,0.000968089,0.00005210791,0.00033713793],"genre_scores_gemma":[0.0003423599,0.98357445,0.00018303606,0.0005014379,0.0010327799,0.00506322,0.00023861001,0.000120875666,0.008943218],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99777824,0.0001749202,0.00070988067,0.0006095418,0.00023579056,0.0004916125],"domain_scores_gemma":[0.9980212,0.0010904617,0.0002535446,0.00024913935,0.00029542818,0.000090251764],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00079109543,0.00037902693,0.0011262831,0.00039113473,0.00012263258,0.00007069589,0.0005769753,0.00025687253,0.0006878781],"category_scores_gemma":[0.00006985414,0.00027636092,0.00036459242,0.0003301512,0.00012507605,0.00007986113,0.00017225214,0.0005726297,0.000019312698],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025969164,0.000121216515,0.0000058256733,0.0021653166,0.0012827828,0.0000058534742,0.00041975355,0.000029243296,0.21115832,0.00007852459,0.002016736,0.7801195],"study_design_scores_gemma":[0.002816021,0.00043899962,0.000033575972,0.00075999467,0.00015735102,0.00001224324,0.00020636065,0.00025803238,0.0027932439,0.00007103663,0.9921971,0.00025606522],"about_ca_topic_score_codex":0.00048434047,"about_ca_topic_score_gemma":0.00004762693,"teacher_disagreement_score":0.9901803,"about_ca_system_score_codex":0.0006565898,"about_ca_system_score_gemma":0.0010182161,"threshold_uncertainty_score":0.9999689},"labels":[],"label_agreement":null},{"id":"W4387966068","doi":"10.1038/s41591-023-02591-2","title":"Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis","year":2023,"lang":"en","type":"article","venue":"Nature Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":74,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Heart Institute; Sunnybrook Hospital; McMaster University; University of Toronto","funders":"Fondation ARC pour la Recherche sur le Cancer; Direction Générale de l’offre de Soins; Deutsche Forschungsgemeinschaft; Bundesministerium für Bildung und Forschung; Foundation for the National Institutes of Health","keywords":"Myocarditis; Thymoma; Medicine; Myasthenia gravis; Myositis; Nivolumab; Autoimmunity; Pembrolizumab; Immunology; Internal medicine; Immune system; Immunotherapy","score_opus":0.01963470711067283,"score_gpt":0.3438438234289383,"score_spread":0.3242091163182655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387966068","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9206894,0.0040352056,0.000050660034,0.063268594,0.001033457,0.0012671108,0.000025877032,0.00029777313,0.009331948],"genre_scores_gemma":[0.98170567,0.00077702716,0.00021227734,0.0018285823,0.002404062,0.00006695313,0.00018767003,0.00004548256,0.012772281],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99783987,0.00007963211,0.0003808084,0.00048778875,0.0007882057,0.0004237061],"domain_scores_gemma":[0.998377,0.00023585514,0.000040497805,0.0006405341,0.00028408886,0.00042199672],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012076137,0.00020634857,0.00051043247,0.00041064044,0.00012915343,0.000018520306,0.000111652866,0.00027697877,0.0023753915],"category_scores_gemma":[0.0014941192,0.00015301225,0.000094462106,0.0011998503,0.00022218555,0.000054283246,0.00013025966,0.0010712766,0.00015086308],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032841944,0.000060273152,0.003810192,0.00015505252,0.00010032355,0.00018505829,0.0014892119,0.000001531478,0.91125834,0.00012380765,0.022168502,0.060319297],"study_design_scores_gemma":[0.008081696,0.0032429735,0.3675808,0.0009012052,0.00019018594,0.00038342457,0.0017041622,0.00043190114,0.122613214,0.0007666115,0.49362805,0.00047576503],"about_ca_topic_score_codex":0.000121161334,"about_ca_topic_score_gemma":0.00009170004,"teacher_disagreement_score":0.7886451,"about_ca_system_score_codex":0.00013864739,"about_ca_system_score_gemma":0.000084778396,"threshold_uncertainty_score":0.9985366},"labels":[],"label_agreement":null},{"id":"W4387998434","doi":"10.3389/fimmu.2023.1239132","title":"Mediport use as an acceptable standard for CAR T cell infusion","year":2023,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"Sidney Kimmel Comprehensive Cancer Center; University of Florida Health; University of California, San Francisco; Winship Cancer Institute; Hospital for Sick Children; City of Hope; Johns Hopkins University; University of Minnesota; University of California, Los Angeles; Yale University; Cincinnati Children's Hospital Medical Center; Emory University; Children's National Hospital; Florida Department of Health","keywords":"Medicine; Chimeric antigen receptor; Clinical Practice; Cell therapy; T cell; Cell; Immunology; Immune system; Physical therapy","score_opus":0.027608934302303417,"score_gpt":0.3232360501654752,"score_spread":0.29562711586317175,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387998434","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921806,0.0008299541,0.00094742834,0.0005498803,0.0019815129,0.0010824413,0.000042867945,0.00015269435,0.0022326508],"genre_scores_gemma":[0.7137072,0.010441682,0.028276838,0.0012006059,0.00079162756,0.0009853267,0.0021704738,0.00038463468,0.2420416],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99830496,0.00009946321,0.0003000011,0.00037702403,0.00027379417,0.00064477907],"domain_scores_gemma":[0.99901813,0.00010648069,0.000055782053,0.0005686973,0.00014426155,0.00010662396],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00062275794,0.00015843383,0.0004692979,0.0006333238,0.00008650389,0.000024946228,0.00022757836,0.00028586062,0.0014726322],"category_scores_gemma":[0.00028193998,0.00015330619,0.00009617099,0.0005738397,0.00018584654,0.00017990757,0.00012244593,0.00038507974,0.00006397019],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011548929,0.00030172092,0.13352756,0.00015571568,0.00033174912,0.00039901343,0.0029360922,0.00002875474,0.447778,0.00018892574,0.24507257,0.15773097],"study_design_scores_gemma":[0.007855876,0.0030591039,0.024388472,0.000044268512,0.00005173253,0.00003906398,0.003531918,0.00074118056,0.063329905,0.0016804042,0.8949952,0.00028286316],"about_ca_topic_score_codex":0.00036520505,"about_ca_topic_score_gemma":0.00008178712,"teacher_disagreement_score":0.64992267,"about_ca_system_score_codex":0.00029847748,"about_ca_system_score_gemma":0.00033642343,"threshold_uncertainty_score":0.99944013},"labels":[],"label_agreement":null},{"id":"W4388035612","doi":"10.1038/s43018-023-00652-6","title":"Structural surfaceomics reveals an AML-specific conformation of integrin β2 as a CAR T cellular therapy target","year":2023,"lang":"en","type":"article","venue":"Nature Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University of Waterloo","funders":"National Institute of General Medical Sciences; American Society of Hematology; University of California, San Francisco; NIH Office of the Director; National Science Foundation; Canadian Institutes of Health Research; Michelson Prize and Grants; Bristol-Myers Squibb; National Cancer Institute; U.S. Department of Health and Human Services; National Institutes of Health; Government of Canada","keywords":"Myeloid leukemia; Chimeric antigen receptor; Cancer research; Immunotherapy; Haematopoiesis; Cancer; Glycoprotein; Antigen; Computational biology; Malignancy; Biology; Chemistry; Cell biology; Immunology; Molecular biology; Stem cell; Genetics","score_opus":0.03415566916516265,"score_gpt":0.3550307940967016,"score_spread":0.3208751249315389,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388035612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98967963,0.006919378,0.000007787892,0.0007322927,0.0006162984,0.0006953769,0.000091958325,0.000096219905,0.0011610438],"genre_scores_gemma":[0.9895273,0.004613484,0.00018643562,0.00042574937,0.00043639468,0.000031895564,0.00030655222,0.000047205922,0.0044249697],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99840325,0.00007876869,0.00030742478,0.0002646048,0.0006066206,0.000339346],"domain_scores_gemma":[0.99881154,0.00006267013,0.00011555373,0.00045360468,0.00040828835,0.00014836524],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004239472,0.00018498098,0.00037863103,0.00021282474,0.000055425164,0.000019337365,0.00019871481,0.00038897124,0.0044150082],"category_scores_gemma":[0.000044408407,0.00014523292,0.00011875877,0.00063985214,0.00009732111,0.00015197629,0.00003177757,0.0009819149,0.000041081003],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001114397,0.000019724286,0.0047698333,0.00009613737,0.00010900417,0.00002181713,0.0019800242,0.00017951986,0.9668293,0.00051872834,0.008903869,0.015457664],"study_design_scores_gemma":[0.0035616537,0.0005703684,0.024071135,0.00014769286,0.000021462341,0.00001978725,0.0009654525,0.0021984342,0.76505446,0.0009666905,0.20210195,0.00032088658],"about_ca_topic_score_codex":0.00018219896,"about_ca_topic_score_gemma":0.000025108511,"teacher_disagreement_score":0.20177479,"about_ca_system_score_codex":0.0002500782,"about_ca_system_score_gemma":0.00023045139,"threshold_uncertainty_score":0.99649507},"labels":[],"label_agreement":null},{"id":"W4388042528","doi":"10.1136/jitc-2023-sitc2023.0689","title":"689 Pharmacodynamic results with talquetamab and daratumumab in patients with relapsed/refractory multiple myeloma in TRIMM-2","year":2023,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Daratumumab; Medicine; CD38; Pharmacodynamics; Internal medicine; Multiple myeloma; CD8; Oncology; Refractory (planetary science); Antibody; Monoclonal antibody; Pharmacology; Immunology; Gastroenterology; Bortezomib; Immune system; Pharmacokinetics; Stem cell; Biology; CD34","score_opus":0.014267462257194538,"score_gpt":0.255296573393422,"score_spread":0.24102911113622744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388042528","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99683243,0.00026662578,7.5347697e-7,0.000617281,0.00008523347,0.0010354432,0.00004801195,0.00010770859,0.0010065079],"genre_scores_gemma":[0.9974151,0.0002245841,0.00018358165,0.00012240419,0.000054761134,0.000048919872,0.0002337323,0.00008066261,0.0016362536],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99730474,0.000121445555,0.0005211228,0.00070279546,0.0007097589,0.0006401205],"domain_scores_gemma":[0.9985483,0.00015731035,0.00014187221,0.000418294,0.00010697565,0.000627241],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00069652434,0.0003509132,0.00053343223,0.0005808095,0.000099019184,0.00006509749,0.000111990295,0.00019505827,0.000015545504],"category_scores_gemma":[0.0003450854,0.00027536714,0.000040232015,0.0008645481,0.0004628356,0.0002946041,0.00006913094,0.00073464937,0.000015156915],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010526639,0.0004956867,0.93682307,0.00040292417,0.00016626748,0.0014179156,0.0017336559,0.00018858671,0.040016733,0.00001546938,0.0011487536,0.0070642945],"study_design_scores_gemma":[0.024627326,0.0009638788,0.9647894,0.0005794489,0.000044567398,0.000070810645,0.00020458679,0.00090341805,0.004388939,0.000034161098,0.003049015,0.00034444607],"about_ca_topic_score_codex":0.00042026106,"about_ca_topic_score_gemma":0.0006004384,"teacher_disagreement_score":0.035627794,"about_ca_system_score_codex":0.0001990949,"about_ca_system_score_gemma":0.00037495833,"threshold_uncertainty_score":0.99996984},"labels":[],"label_agreement":null},{"id":"W4388042588","doi":"10.1136/jitc-2023-sitc2023.0347","title":"347 Functional characterization of GUCY2C-TAC T cells for the treatment of colorectal cancer using preclinical models","year":2023,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"In vivo; Cancer research; Receptor; In vitro; Antigen; Cancer; Cancer cell; Colorectal cancer; Cytotoxic T cell; Chemistry; Cell biology; Biology; Medicine; Immunology; Internal medicine; Biochemistry","score_opus":0.11431374849587565,"score_gpt":0.34841567456806927,"score_spread":0.2341019260721936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388042588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99755555,0.00027338174,0.00014818122,0.0005703707,0.00034531546,0.00089691195,0.00013911877,0.000027475771,0.00004371399],"genre_scores_gemma":[0.996488,0.0012821642,0.00025213088,0.000042796688,0.000261602,0.00009274558,0.00011434689,0.000032402415,0.0014338597],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987776,0.000037177455,0.00039138432,0.00023150968,0.00034262927,0.00021964582],"domain_scores_gemma":[0.9990538,0.00021587864,0.00016434009,0.00018715262,0.0001847454,0.00019410576],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003350622,0.00013772548,0.000334264,0.000090380265,0.000085522064,0.000014584451,0.000052974643,0.00012110595,0.000060752227],"category_scores_gemma":[0.00007003504,0.00009701987,0.00015280263,0.00020791369,0.00029330366,0.00007836289,0.00001707701,0.00007767092,0.0000016279678],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005538503,0.00014070107,0.0044476422,0.00015868153,0.00024767127,0.0000033826775,0.00046909216,0.0022007918,0.9887898,0.000068927235,0.00014575792,0.0027736805],"study_design_scores_gemma":[0.0019557725,0.00063671515,0.120559424,0.00013361577,0.0002776565,0.000017532968,0.00008287376,0.06494081,0.80807465,0.0002953559,0.0029056333,0.0001199549],"about_ca_topic_score_codex":0.00017832548,"about_ca_topic_score_gemma":0.000016644652,"teacher_disagreement_score":0.18071516,"about_ca_system_score_codex":0.00008845518,"about_ca_system_score_gemma":0.00043702687,"threshold_uncertainty_score":0.39563555},"labels":[],"label_agreement":null},{"id":"W4388047619","doi":"10.1136/jitc-2023-sitc2023.0778","title":"778 TILVANCE-301, a phase 3 study of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy combined with pembrolizumab (pembro) vs pembro alone in treatment-naïve unresectable or metastatic melanoma","year":2023,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Melanoma; Cancer; Internal medicine; Oncology; Surgery; Immunotherapy; Cancer research","score_opus":0.04680987990646559,"score_gpt":0.31675635918176015,"score_spread":0.2699464792752946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388047619","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942449,0.0008478409,0.0000026040664,0.00020125388,0.00011031,0.0030050995,0.000056665263,0.00017771471,0.0013536421],"genre_scores_gemma":[0.9922957,0.00078574126,0.00040367118,0.000114094306,0.0000929589,0.0003522287,0.00012030092,0.00015650204,0.005678794],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99558187,0.00035608068,0.0010334923,0.0009229711,0.0010918201,0.0010137904],"domain_scores_gemma":[0.99716586,0.00043702757,0.00040301646,0.0008994964,0.00022404554,0.0008705383],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00083323766,0.0006795656,0.0014984278,0.00066468236,0.00020335677,0.00011970147,0.00025927887,0.00013084979,0.00021997825],"category_scores_gemma":[0.0002598752,0.0004904941,0.00015917714,0.0014799213,0.0003957777,0.00029572952,0.00007189978,0.00039783944,0.000027050135],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.082627185,0.013038325,0.075858146,0.0017272828,0.0019930024,0.011136144,0.017941032,0.001208886,0.78167784,0.000048444646,0.0010939229,0.011649788],"study_design_scores_gemma":[0.21657489,0.055012718,0.067867205,0.001080115,0.0006370976,0.0010339958,0.011055015,0.005960967,0.63599324,0.00016773604,0.0032887387,0.0013283034],"about_ca_topic_score_codex":0.0022941015,"about_ca_topic_score_gemma":0.000772726,"teacher_disagreement_score":0.14568463,"about_ca_system_score_codex":0.00039610302,"about_ca_system_score_gemma":0.0016595207,"threshold_uncertainty_score":0.99975467},"labels":[],"label_agreement":null},{"id":"W4388047658","doi":"10.1136/jitc-2023-sitc2023.0654","title":"654 A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors","year":2023,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Cytokine release syndrome; Chimeric antigen receptor; Adverse effect; Refractory (planetary science); Internal medicine; Pharmacokinetics; Immunotherapy; Leukapheresis; T cell; Chemotherapy; Oncology; Gastroenterology; Immunology; Immune system; Cancer; Stem cell","score_opus":0.044519737722509396,"score_gpt":0.3424634879703385,"score_spread":0.2979437502478291,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388047658","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99578595,0.0003389056,0.0000013722903,0.0013888277,0.00024230461,0.0013181565,0.000028099197,0.00018417426,0.00071222545],"genre_scores_gemma":[0.9954566,0.00031045635,0.00044381764,0.00023091046,0.00026211434,0.0000393189,0.00007460593,0.00008337687,0.0030988492],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99653363,0.00023930632,0.0011570164,0.0006746845,0.00068977295,0.0007055704],"domain_scores_gemma":[0.99747515,0.00049549993,0.0003426666,0.000541065,0.000111191126,0.0010344186],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018357565,0.00037431566,0.0010302254,0.00052944047,0.00021232334,0.000046331254,0.00016404911,0.00034434118,0.000101369915],"category_scores_gemma":[0.0046992605,0.00031997493,0.00012958916,0.00090768817,0.0010082473,0.00014803879,0.00016723976,0.0007873501,0.000011363046],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05092726,0.0015941149,0.0068234825,0.0013956184,0.00042536558,0.0024345778,0.008551176,0.00017691917,0.8870169,0.00028869833,0.0030048578,0.03736106],"study_design_scores_gemma":[0.41844836,0.026440293,0.30664232,0.0053464826,0.00059793814,0.0019085334,0.0033132124,0.007852544,0.19676499,0.0017818934,0.028702673,0.0022007492],"about_ca_topic_score_codex":0.00031671743,"about_ca_topic_score_gemma":0.00007595139,"teacher_disagreement_score":0.6902519,"about_ca_system_score_codex":0.0001430145,"about_ca_system_score_gemma":0.0011320155,"threshold_uncertainty_score":0.99992526},"labels":[],"label_agreement":null},{"id":"W4388047947","doi":"10.1136/jitc-2023-sitc2023.0400","title":"400 Preclinical characterization and modelling of allogeneic Vγ9Vδ2 TAC T cells for the treatment of solid tumors","year":2023,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer research; Antigen; T cell; Cytotoxic T cell; Cell therapy; Immunotherapy; Chimeric antigen receptor; Immunology; In vivo; Antigen-presenting cell; Biology; Medicine; In vitro; Immune system; Cell biology; Stem cell","score_opus":0.08392283671548659,"score_gpt":0.3301677903857863,"score_spread":0.24624495367029972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388047947","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972336,0.00054636755,0.00034227132,0.0007297485,0.00011376966,0.00089827663,0.00008506943,0.000029208839,0.000021657657],"genre_scores_gemma":[0.993143,0.004061589,0.00038959002,0.000049115566,0.00015731141,0.000055073353,0.00009191437,0.00003487047,0.0020175],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987348,0.000040392475,0.00045695604,0.00026269394,0.0002619859,0.00024321182],"domain_scores_gemma":[0.9989354,0.00026124282,0.00016277161,0.00027742147,0.000109443914,0.00025373686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004719723,0.00015217633,0.00041361913,0.00009032812,0.00007499827,0.000015128631,0.00006335995,0.000113922084,0.000017063692],"category_scores_gemma":[0.000089261506,0.000106159656,0.000117405856,0.00014456807,0.0003343562,0.000050301747,0.000021154163,0.00007991113,0.000002374693],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031383714,0.00014646172,0.0052886433,0.00036077996,0.00022522984,0.000010537102,0.0010183421,0.0012690176,0.9840428,0.000051727555,0.0000976707,0.0071749073],"study_design_scores_gemma":[0.0021355192,0.0013389619,0.050347712,0.00021916973,0.0002703286,0.000034286524,0.00016557625,0.04926002,0.887566,0.00029021362,0.008204768,0.0001674548],"about_ca_topic_score_codex":0.000046735164,"about_ca_topic_score_gemma":0.0000033771241,"teacher_disagreement_score":0.09647686,"about_ca_system_score_codex":0.00002839981,"about_ca_system_score_gemma":0.0001779815,"threshold_uncertainty_score":0.4329065},"labels":[],"label_agreement":null},{"id":"W4388048003","doi":"10.1136/jitc-2023-sitc2023.0312","title":"312 IL7 increases targeted lipid nanoparticle-mediated mRNA protein expression in T cells<i> in vitro</i> and<i> in situ</i> by enhancing T cell translation","year":2023,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Acuitas Therapeutics (Canada)","funders":"","keywords":"Molecular biology; Biology; T cell; mCherry; CD28; CD8; Cell biology; Antigen; Immune system; Green fluorescent protein; Immunology; Biochemistry","score_opus":0.014291793481288098,"score_gpt":0.24408714815614044,"score_spread":0.22979535467485235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388048003","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99662507,0.0011646225,0.0000020880696,0.0006598669,0.00006474976,0.0011690311,0.000027027761,0.000108558175,0.00017900669],"genre_scores_gemma":[0.9983421,0.00038107112,0.00030947765,0.00017309029,0.00006715395,0.00011808935,0.00018066393,0.000059021968,0.00036931082],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99724984,0.00025977136,0.0006901305,0.00058587326,0.0005297125,0.0006846708],"domain_scores_gemma":[0.9987927,0.00018990925,0.000110493,0.00027207288,0.00004234787,0.00059247046],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011687872,0.00030025837,0.00050928566,0.0004955703,0.00006585507,0.000058732006,0.000097523705,0.0002714994,0.000023907724],"category_scores_gemma":[0.00031254994,0.00029431365,0.000054072556,0.0009788824,0.00018781108,0.00028911352,0.000055429202,0.0005641336,0.000019145022],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000609659,0.0002118607,0.008772786,0.0003407558,0.000007330978,0.00021168096,0.0010365066,0.00005484936,0.9875919,5.359149e-7,0.00031074914,0.00085136277],"study_design_scores_gemma":[0.0037786542,0.00011691838,0.02225545,0.00056297454,0.0000121032845,0.000014933218,0.00028308228,0.0010868533,0.97042656,0.00005757091,0.0011299946,0.0002749355],"about_ca_topic_score_codex":0.00085096,"about_ca_topic_score_gemma":0.00054510316,"teacher_disagreement_score":0.017165393,"about_ca_system_score_codex":0.00013432956,"about_ca_system_score_gemma":0.00025510677,"threshold_uncertainty_score":0.9999509},"labels":[],"label_agreement":null},{"id":"W4388048115","doi":"10.1136/jitc-2023-sitc2023.0372","title":"372 TAC-T cells persist and remain functional during and after repeated tumor exposure <i>in vitro</i> and <i>in vivo</i>","year":2023,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cytotoxic T cell; Cancer research; In vivo; T cell; Antigen; Flow cytometry; In vitro; Tumor antigen; Biology; Immune system; Immunotherapy; Molecular biology; Immunology; Biochemistry","score_opus":0.012901209380400826,"score_gpt":0.22928253968148246,"score_spread":0.21638133030108164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388048115","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99620086,0.0015278256,2.9212927e-7,0.00117271,0.00010472144,0.0004592792,0.00002935227,0.00006984586,0.00043509106],"genre_scores_gemma":[0.99443537,0.0006778711,0.00012759645,0.00037755046,0.00013399062,0.000044351556,0.000021163183,0.0000508055,0.004131298],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9979308,0.00009151958,0.00039538127,0.00065925706,0.00040926092,0.0005137381],"domain_scores_gemma":[0.99887127,0.00009333177,0.00006661135,0.00026457245,0.00004937273,0.00065484055],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007349375,0.0002785781,0.00043622233,0.00034221073,0.0001131558,0.00010290046,0.000044586606,0.00016346357,0.00006362976],"category_scores_gemma":[0.00015525919,0.0002669999,0.00005147758,0.0003734999,0.00045036164,0.00017286505,0.00010265827,0.00043082196,0.00000586198],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00092900946,0.000037356353,0.104512945,0.00044183346,0.000038404494,0.0013027423,0.0005208347,0.000009879146,0.89150333,0.0000049231708,0.0004931794,0.00020558394],"study_design_scores_gemma":[0.0034881744,0.00012844166,0.70659953,0.00038332207,0.000046968747,0.000811597,0.00054026267,0.00021115002,0.2850822,0.00010593318,0.0022861331,0.0003162824],"about_ca_topic_score_codex":0.00013865113,"about_ca_topic_score_gemma":0.00010313855,"teacher_disagreement_score":0.6064211,"about_ca_system_score_codex":0.0000766298,"about_ca_system_score_gemma":0.00012577968,"threshold_uncertainty_score":0.99997824},"labels":[],"label_agreement":null},{"id":"W4388048122","doi":"10.1136/jitc-2023-sitc2023.0738","title":"738 A phase 1/2 study investigating the safety and efficacy of autologous TAC T cells in subjects with unresectable, locally advanced or metastatic claudin 18.2+ solid tumors","year":2023,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Immunotherapy; Leukapheresis; Chimeric antigen receptor; Cancer research; Radioimmunotherapy; Stem cell; Immunology; Immune system; Antibody; Biology; CD34","score_opus":0.037706947430035526,"score_gpt":0.3355257030615537,"score_spread":0.29781875563151816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388048122","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99598956,0.00033429352,0.0000104983,0.0007246959,0.000070891474,0.0024889433,0.000025444378,0.00011330508,0.00024234857],"genre_scores_gemma":[0.99766225,0.00018984548,0.0006498887,0.0001937881,0.000047555455,0.00008007931,0.000026536063,0.000080855694,0.0010692173],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99642986,0.00037539087,0.00087889045,0.00067346334,0.0008954315,0.0007469478],"domain_scores_gemma":[0.997381,0.0008275042,0.00030798966,0.00059963163,0.00015864045,0.000725251],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020417718,0.0004108984,0.0009763315,0.0003828414,0.00021266883,0.00008318114,0.00023085916,0.00010439381,0.000047903966],"category_scores_gemma":[0.0016146795,0.00026264606,0.000069078604,0.0014853235,0.0010909087,0.00017805975,0.00015395154,0.00068248995,0.0000063160805],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01192709,0.0020120016,0.058444187,0.0021608623,0.0011339707,0.00578228,0.01707678,0.0054345066,0.87712514,0.00010433596,0.00083540473,0.017963428],"study_design_scores_gemma":[0.061639514,0.014453293,0.57570887,0.003584063,0.000822011,0.0016906352,0.017840892,0.009871161,0.31121078,0.0005685849,0.001254307,0.0013558749],"about_ca_topic_score_codex":0.0004576085,"about_ca_topic_score_gemma":0.000503426,"teacher_disagreement_score":0.5659144,"about_ca_system_score_codex":0.000098881166,"about_ca_system_score_gemma":0.0011130122,"threshold_uncertainty_score":0.9999826},"labels":[],"label_agreement":null},{"id":"W4388048274","doi":"10.1136/jitc-2023-sitc2023.0277","title":"277 SynNotch-CAR T cells demonstrate potent anti-tumor efficacy in a preclinical immunocompetent mouse model for glioblastoma","year":2023,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Cancer research; Glioma; Immunotherapy; Chimeric antigen receptor; Tumor microenvironment; Flow cytometry; Immune system; Epidermal growth factor receptor; Antigen; Cytotoxic T cell; Brain tumor; Biology; Immunology; Medicine; Receptor; Pathology; Internal medicine; In vitro","score_opus":0.04880684535185395,"score_gpt":0.3212046304507716,"score_spread":0.27239778509891766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388048274","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99541616,0.0002709513,0.00006351903,0.0015340428,0.00023632134,0.0020227206,0.00007587937,0.00024827835,0.00013213416],"genre_scores_gemma":[0.99363077,0.00039304318,0.0014126417,0.0003635834,0.00018537093,0.00017036447,0.00005992677,0.00012074505,0.0036635548],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9964436,0.00011597748,0.0009534693,0.00082501426,0.00067851593,0.0009833813],"domain_scores_gemma":[0.9976794,0.00028788825,0.00017958146,0.0006795624,0.0001657946,0.0010077505],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014620892,0.00042348797,0.0008307323,0.0004082054,0.0001555829,0.000115027884,0.00025292078,0.0002724511,0.000023374463],"category_scores_gemma":[0.00056335324,0.00039117233,0.0003395813,0.00050288613,0.00046697987,0.00015396159,0.00014036559,0.0006435439,0.00007333626],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008185664,0.00050203496,0.0023409303,0.0004764065,0.00019329574,0.00035950696,0.00047322386,0.0052719284,0.9855669,0.000095068484,0.0013587796,0.0025433719],"study_design_scores_gemma":[0.011973687,0.0013386407,0.08728997,0.0009517263,0.00027072066,0.00039410274,0.0003694509,0.20470077,0.68695915,0.0008530629,0.0038406178,0.0010580772],"about_ca_topic_score_codex":0.000071935494,"about_ca_topic_score_gemma":0.00003709058,"teacher_disagreement_score":0.2986077,"about_ca_system_score_codex":0.00015590621,"about_ca_system_score_gemma":0.00073728606,"threshold_uncertainty_score":0.999854},"labels":[],"label_agreement":null},{"id":"W4388048378","doi":"10.1136/jitc-2023-sitc2023.0619","title":"619 First-in-class anti-CD200R1 antibody 23ME-00610 in patients with advanced solid malignancies: updated phase 1 results","year":2023,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University Health Network","funders":"","keywords":"Tolerability; Medicine; Internal medicine; Oncology; Cancer; Cohort; Toxicity; Adverse effect","score_opus":0.016204629377014217,"score_gpt":0.300082005965044,"score_spread":0.28387737658802975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388048378","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99574405,0.00014389156,0.0000016048999,0.0013959521,0.0001967139,0.001244347,0.00013599507,0.0001790157,0.00095842395],"genre_scores_gemma":[0.99613005,0.00033635867,0.00018966554,0.0002521233,0.00008296149,0.000039928345,0.0011178919,0.00009348869,0.0017575382],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963527,0.0000937621,0.0008121071,0.0008335314,0.0009106897,0.0009972404],"domain_scores_gemma":[0.9980352,0.0001029158,0.0001988528,0.0006872838,0.00021712457,0.0007586268],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008369247,0.00041963905,0.00075928227,0.0006457974,0.00012603034,0.00008129671,0.0001976111,0.0002532302,0.0000612431],"category_scores_gemma":[0.00059968594,0.00036229886,0.000085424435,0.0014432089,0.00040833798,0.00032314088,0.00008997677,0.00056678674,0.000070634014],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007755016,0.00198333,0.71719193,0.0007931641,0.0002823839,0.0031678067,0.0022673465,0.0018133172,0.2518743,0.00007357275,0.008843684,0.0039541447],"study_design_scores_gemma":[0.02930551,0.0011445272,0.91361445,0.0011256424,0.000049866867,0.000045500605,0.00027423294,0.00095479813,0.031533495,0.00007550046,0.02132607,0.0005503883],"about_ca_topic_score_codex":0.00023449415,"about_ca_topic_score_gemma":0.0002146794,"teacher_disagreement_score":0.2203408,"about_ca_system_score_codex":0.0001957325,"about_ca_system_score_gemma":0.00044003737,"threshold_uncertainty_score":0.9998829},"labels":[],"label_agreement":null},{"id":"W4388048473","doi":"10.1136/jitc-2023-sitc2023.0442-a","title":"442-A Optimization and validation of novel chimeric antigen receptor (CARs) architectures for the treatment of leukemia and beyond","year":2023,"lang":"en","type":"article","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Chimeric antigen receptor; Leukemia; Computer science; Computational biology; Cancer research; Medicine; Biology; Immunology; Immunotherapy; Immune system","score_opus":0.03970991027185679,"score_gpt":0.3268304874268504,"score_spread":0.2871205771549936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388048473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938832,0.00029480987,0.0038776833,0.000512169,0.000032183572,0.0009544162,0.000028328066,0.000019803265,0.00039744293],"genre_scores_gemma":[0.97866136,0.0044339863,0.011452903,0.00004393627,0.000106785235,0.00008738597,0.00014083805,0.000032309905,0.005040493],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99946386,0.00001536786,0.00014291068,0.00013038277,0.00014494146,0.000102521764],"domain_scores_gemma":[0.9994326,0.00027543475,0.00004843469,0.0001424319,0.00006523583,0.000035818914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00014600327,0.00007302631,0.0001693837,0.00011167525,0.000040819796,0.000006894605,0.000028392746,0.000036571324,0.00020489683],"category_scores_gemma":[0.000035799072,0.000043472566,0.000040998144,0.00021094899,0.00009336704,0.000010864076,0.000013731227,0.00002565181,4.130421e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008007212,0.0002064486,0.00806791,0.00015462878,0.0003806026,3.9703735e-7,0.0032307946,0.01696363,0.8123195,0.00009907928,0.00038396657,0.15739228],"study_design_scores_gemma":[0.0063233087,0.0027787222,0.019260637,0.000036175945,0.00014998413,0.000010601972,0.0008739067,0.14510533,0.82165354,0.000059359936,0.0036375963,0.00011084158],"about_ca_topic_score_codex":0.00011254136,"about_ca_topic_score_gemma":0.000006580624,"teacher_disagreement_score":0.15728144,"about_ca_system_score_codex":0.00003454832,"about_ca_system_score_gemma":0.000049274677,"threshold_uncertainty_score":0.22434765},"labels":[],"label_agreement":null},{"id":"W4388048531","doi":"10.1136/jitc-2023-sitc2023.1372","title":"1372 TriTCE Co-Stim: a novel trispecific T cell engager platform, with integrated CD28 costimulation, engineered to widen the therapeutic window for treatment of poorly infiltrated tumors","year":2023,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"CD28; Cancer research; T cell; CD3; Cytokine; In vivo; Antibody; Immunotherapy; Immunology; Chemistry; Immune system; Medicine; Biology; CD8","score_opus":0.05746762826388186,"score_gpt":0.3030686027193463,"score_spread":0.24560097445546447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388048531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99400556,0.00029563167,0.00040638313,0.0014423704,0.00009382734,0.0030935525,0.00016370494,0.0001696664,0.0003292836],"genre_scores_gemma":[0.99403715,0.000083690895,0.0006982161,0.0002035619,0.00013267972,0.0002266011,0.00038242686,0.00010114272,0.0041345004],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9977126,0.00006698598,0.0005958718,0.00047311903,0.00058994046,0.000561485],"domain_scores_gemma":[0.99766636,0.0006457131,0.0001701086,0.00053446373,0.00037623223,0.00060712086],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000701026,0.00040629657,0.0006760263,0.00037920702,0.00020660085,0.00009508789,0.000166389,0.00017275433,0.000058661422],"category_scores_gemma":[0.00030820843,0.00025835139,0.00015395953,0.001072533,0.00029639143,0.0001294441,0.000016089058,0.00024360557,0.000020233074],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028674614,0.00038268632,0.006558316,0.00023835019,0.00054507435,0.000065793974,0.0033739642,0.0039229845,0.9766834,0.0001143701,0.0019574042,0.0032902367],"study_design_scores_gemma":[0.015544639,0.004881358,0.17084172,0.00043962483,0.00046457222,0.00022413676,0.0019796507,0.0066055153,0.76211023,0.00016341118,0.03611256,0.0006325441],"about_ca_topic_score_codex":0.00021733786,"about_ca_topic_score_gemma":0.00003103505,"teacher_disagreement_score":0.2145731,"about_ca_system_score_codex":0.00020565983,"about_ca_system_score_gemma":0.0007433502,"threshold_uncertainty_score":0.9999869},"labels":[],"label_agreement":null},{"id":"W4388074720","doi":"10.1136/jitc-2023-sitc2023.1396","title":"1396 TriTCE CPI: a novel trispecifc T cell engager platform with integrated PD-1/PD-L1 checkpoint inhibition engineered for the treatment of immunosuppressed tumors","year":2023,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Cancer research; Tumor microenvironment; PD-L1; T cell; Immunotherapy; Immune checkpoint; Cytotoxicity; Cytotoxic T cell; Immune system; Chemistry; Cancer immunotherapy; In vitro; Biology; Immunology; Tumor cells; Biochemistry","score_opus":0.040494279708013003,"score_gpt":0.2694589960541106,"score_spread":0.2289647163460976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388074720","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947912,0.00077489845,0.0001828175,0.0012324762,0.0001732709,0.0021924744,0.00015317387,0.00015346386,0.0003462414],"genre_scores_gemma":[0.9929757,0.00061911315,0.00085485744,0.00006701159,0.00023600523,0.0003144202,0.00032491898,0.00009750415,0.0045104795],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99778,0.000040879942,0.0006060056,0.0004513068,0.00057234016,0.0005494628],"domain_scores_gemma":[0.998096,0.00045454566,0.00019946403,0.0005638284,0.0002563425,0.00042981934],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00072355353,0.0003923426,0.000633489,0.0002808554,0.00019546435,0.0000729547,0.00010831377,0.0001934897,0.00007226085],"category_scores_gemma":[0.00025943885,0.00024564532,0.0002473367,0.0006302821,0.00038036692,0.00013977257,0.000025684316,0.00035329486,0.000010899849],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00228246,0.0005107818,0.00028356066,0.00037839258,0.00038228562,0.000103214756,0.0026099568,0.00029558106,0.99045235,0.00009540874,0.0012804655,0.0013255475],"study_design_scores_gemma":[0.010679793,0.0022503086,0.019320855,0.0003685351,0.00027801626,0.00017412889,0.0015574035,0.002696514,0.93904376,0.00009742066,0.023227677,0.00030557823],"about_ca_topic_score_codex":0.00029792805,"about_ca_topic_score_gemma":0.000027678336,"teacher_disagreement_score":0.051408574,"about_ca_system_score_codex":0.00022296705,"about_ca_system_score_gemma":0.00045152064,"threshold_uncertainty_score":0.9999996},"labels":[],"label_agreement":null},{"id":"W4388081144","doi":"10.1136/jitc-2023-sitc2023.0178","title":"178 Tumor neoantigen prioritization from liquid biopsy whole exome sequencing for selected tumor-infiltrating lymphocyte therapy","year":2023,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Liquid biopsy; Exome sequencing; Tumor-infiltrating lymphocytes; Biopsy; Exome; Transcriptome; Cancer research; Deep sequencing; Medicine; Cancer; Pathology; Computational biology; Immunotherapy; Biology; Mutation; Internal medicine; Gene; Gene expression; Genome; Genetics","score_opus":0.03762420379382995,"score_gpt":0.28809596548987787,"score_spread":0.2504717616960479,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388081144","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954601,0.0010179922,0.000082377635,0.00095753185,0.00030175,0.0013021359,0.00010435107,0.0005162306,0.00025755152],"genre_scores_gemma":[0.9926392,0.00035152698,0.0023571134,0.0006832828,0.0009103733,0.00014639372,0.0008010938,0.00016613175,0.0019449207],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997118,0.00010320894,0.00062207953,0.00071683753,0.00065288105,0.0007870264],"domain_scores_gemma":[0.9979697,0.00021461479,0.00021733086,0.000477618,0.00038485345,0.00073591096],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007726402,0.00038286945,0.00056805945,0.00030198664,0.00035124292,0.00019671879,0.00017599222,0.00017847307,0.00009159065],"category_scores_gemma":[0.0008956134,0.00036613137,0.00015355444,0.00097215455,0.0002461406,0.00027138524,0.000052339055,0.00029975382,0.00006104517],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045841714,0.000030153564,0.005004367,0.00016052059,0.00015367637,0.00022653722,0.0008509376,0.000068513145,0.99043864,0.00003346196,0.0008749243,0.0016998465],"study_design_scores_gemma":[0.0044418867,0.0007468119,0.067955494,0.00056095707,0.000090873036,0.000533926,0.00066932774,0.0050616004,0.9037553,0.00060606527,0.0149698565,0.0006078829],"about_ca_topic_score_codex":0.0004709905,"about_ca_topic_score_gemma":0.000022060716,"teacher_disagreement_score":0.086683325,"about_ca_system_score_codex":0.00032799612,"about_ca_system_score_gemma":0.001511193,"threshold_uncertainty_score":0.99987906},"labels":[],"label_agreement":null},{"id":"W4388087237","doi":"10.1136/jitc-2023-sitc2023.0839","title":"839 TALL<sup>TM</sup> (Targeted Antigen Loaded Liposomes) immunotherapy exploits recall immunity to form an excellent co-therapy option for immune checkpoint inhibitors","year":2023,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Oncolytic virus; Immunotherapy; Adoptive cell transfer; Tumor microenvironment; Medicine; Cancer research; Chimeric antigen receptor; Cancer; Immune system; Tumor-infiltrating lymphocytes; Antigen; Immunology; T cell; Internal medicine","score_opus":0.046547665589573975,"score_gpt":0.31310218700715103,"score_spread":0.2665545214175771,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388087237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99058896,0.0017145034,0.00006580574,0.0027238152,0.00038982293,0.0036604234,0.000071812254,0.0005539064,0.00023092327],"genre_scores_gemma":[0.98738337,0.004455814,0.001324584,0.0006842374,0.0006831393,0.00052403,0.0010646301,0.000291647,0.003588524],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.995191,0.00022549079,0.0012448819,0.0009830808,0.0010613549,0.0012941958],"domain_scores_gemma":[0.99634224,0.00015979096,0.00028357754,0.0012685417,0.00041046416,0.0015354092],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002358448,0.00070607424,0.001011338,0.0007150177,0.00054402184,0.00024112905,0.0004409592,0.0005169459,0.0002296829],"category_scores_gemma":[0.00040104243,0.00066346466,0.00048303793,0.0008947821,0.00037493109,0.00052153174,0.00012142436,0.0007093977,0.00013181182],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019604324,0.00040226374,0.0013118627,0.0002183944,0.00038796713,0.00007412465,0.0053160414,0.00023515,0.97351545,0.000038778104,0.0015055567,0.015033972],"study_design_scores_gemma":[0.0064529506,0.0022592149,0.046384946,0.00035547902,0.000045445733,0.00013855554,0.0016623902,0.001111344,0.88130766,0.0006821412,0.058812227,0.0007876646],"about_ca_topic_score_codex":0.0006228223,"about_ca_topic_score_gemma":0.000019838917,"teacher_disagreement_score":0.09220782,"about_ca_system_score_codex":0.00037836574,"about_ca_system_score_gemma":0.00054021523,"threshold_uncertainty_score":0.99958163},"labels":[],"label_agreement":null},{"id":"W4388231839","doi":"10.51731/cjht.2023.774","title":"Tisagenlecleucel (Kymriah)","year":2023,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Medicine; Refractory (planetary science); Food and drug administration; Drug; Intensive care medicine; Medical emergency; Pharmacology; Political science; Health care","score_opus":0.07828658743759795,"score_gpt":0.36425421196518165,"score_spread":0.28596762452758373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388231839","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6587977,0.05058518,0.00011262694,0.28256747,0.0011293826,0.0007705214,0.000027506785,0.00073769724,0.0052719726],"genre_scores_gemma":[0.9930691,0.0019760625,0.0002993019,0.0006697023,0.000037773163,0.000005433189,0.000003961051,0.000029473527,0.0039091543],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984479,0.000046584686,0.00044579493,0.00012040766,0.0002722802,0.0006670587],"domain_scores_gemma":[0.99906266,0.00006923151,0.00016560315,0.0003138099,0.0001838243,0.0002048801],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011321743,0.000100913625,0.0003732432,0.0014555288,0.00018159772,0.000026335241,0.0002948803,0.00014566822,0.00054942025],"category_scores_gemma":[0.0007393461,0.00008514285,0.000100311925,0.0010811083,0.00021704037,0.000058003618,0.000024747907,0.00063969824,0.00014815117],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000027749025,0.000008786188,0.0042086733,0.000097872864,0.000050833376,0.0010232696,0.00023944123,0.000004533175,0.0018284272,0.00032481435,0.056679673,0.9355059],"study_design_scores_gemma":[0.00094556005,0.0009300045,0.024539348,0.0002705241,0.000011543118,0.0011077208,0.003590792,0.000029656134,0.0027981296,0.0034176807,0.9622409,0.0001181613],"about_ca_topic_score_codex":0.0023837644,"about_ca_topic_score_gemma":0.0018480405,"teacher_disagreement_score":0.9353878,"about_ca_system_score_codex":0.0005156325,"about_ca_system_score_gemma":0.004288062,"threshold_uncertainty_score":0.7606838},"labels":[],"label_agreement":null},{"id":"W4388425287","doi":"10.1038/s41590-023-01658-z","title":"Harnessing CD3 diversity to optimize CAR T cells","year":2023,"lang":"en","type":"article","venue":"Nature Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"FP7 Health; European Commission; Horizon 2020 Framework Programme; FAZIT Stiftung; Deutsche Forschungsgemeinschaft; University of Oxford; European Federation of Pharmaceutical Industries and Associations; McGill University","keywords":"T-cell receptor; CD3; Chimeric antigen receptor; Cell biology; T cell; Intracellular; Biology; Antigen; Chemistry; Immune system; CD8; Immunology","score_opus":0.021956186225114697,"score_gpt":0.31829253788031536,"score_spread":0.29633635165520067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388425287","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9835637,0.0011425924,0.000041486852,0.006341332,0.0014135783,0.00046238748,0.000012448521,0.00030288394,0.006719555],"genre_scores_gemma":[0.9524996,0.00031547254,0.0008333872,0.001657213,0.00027703267,0.000014542513,0.000047583624,0.000041415162,0.04431373],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986491,0.00008382871,0.00013093994,0.0003384763,0.00029163077,0.00050597877],"domain_scores_gemma":[0.9990848,0.00014987114,0.000029061142,0.0004711736,0.0001523064,0.000112797716],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00029626986,0.00013977222,0.00031213675,0.00037209239,0.00022108013,0.000016636826,0.00027128536,0.0005504971,0.0018942085],"category_scores_gemma":[0.00016135671,0.00012844533,0.00011222238,0.0008014887,0.00010949389,0.00004320099,0.00070316094,0.001263345,0.0011601454],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007847456,0.00004754673,0.0014598389,0.000024471106,0.00018905237,0.00038034964,0.00087100005,0.00003288694,0.96299887,0.000086434375,0.017590947,0.015533846],"study_design_scores_gemma":[0.0054616774,0.0009035938,0.077936135,0.00012570368,0.00012521104,0.00020481956,0.001073004,0.00025018098,0.39948037,0.00026407265,0.513655,0.00052019977],"about_ca_topic_score_codex":0.00008691535,"about_ca_topic_score_gemma":0.000009663849,"teacher_disagreement_score":0.5635185,"about_ca_system_score_codex":0.00017252928,"about_ca_system_score_gemma":0.000092439914,"threshold_uncertainty_score":0.9996176},"labels":[],"label_agreement":null},{"id":"W4388541004","doi":"10.1038/s41590-023-01663-2","title":"CD3ζ ITAMs enable ligand discrimination and antagonism by inhibiting TCR signaling in response to low-affinity peptides","year":2023,"lang":"en","type":"article","venue":"Nature Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Mila - Quebec Artificial Intelligence Institute; Université de Montréal; McGill University","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Cancer Institute; National Institutes of Health; U.S. Department of Health and Human Services","keywords":"Immunoreceptor tyrosine-based activation motif; T-cell receptor; CD3; Biology; Cell biology; T cell; Signal transduction; CD8; Antigen; Immune system; Immunology","score_opus":0.015363571418819543,"score_gpt":0.3140258550961627,"score_spread":0.29866228367734315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388541004","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909279,0.001831093,0.000005366,0.005995591,0.00017432951,0.00045953877,0.000014365999,0.00010139264,0.000490437],"genre_scores_gemma":[0.994795,0.00028881998,0.00009997053,0.00046389565,0.00009090702,0.00003806047,0.00008298065,0.00003506209,0.0041052937],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983602,0.00024339538,0.00026809942,0.00038079388,0.0002482558,0.00049924303],"domain_scores_gemma":[0.9988025,0.00073113496,0.000050400442,0.0002182333,0.00011445618,0.00008327221],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014139689,0.00016173742,0.0003161857,0.00058521016,0.00011772696,0.000038777085,0.00011052539,0.00047018778,0.00007800853],"category_scores_gemma":[0.0015833727,0.00015172882,0.00004389629,0.000791307,0.000115009185,0.00009733302,0.00016682321,0.0011936299,0.000048934777],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002789586,0.000060985883,0.0014101905,0.00005617558,0.000034055534,0.00014787405,0.0019614773,0.0000051200836,0.98371685,0.000049479626,0.00080853095,0.008959684],"study_design_scores_gemma":[0.0023553395,0.00060756394,0.024229156,0.00023613688,0.000014618969,0.00008585086,0.0020711056,0.00007491624,0.96415484,0.00031968346,0.005663772,0.00018699041],"about_ca_topic_score_codex":0.00010266599,"about_ca_topic_score_gemma":0.000041309668,"teacher_disagreement_score":0.022818964,"about_ca_system_score_codex":0.00016892582,"about_ca_system_score_gemma":0.00010421819,"threshold_uncertainty_score":0.61873215},"labels":[],"label_agreement":null},{"id":"W4388590696","doi":"10.1093/neuonc/noad179.0862","title":"EXTH-08. IMMUNOTHERAPEUTIC TARGETING OF FIBROBLAST ACTIVATION PROTEIN (FAP) IN TREATMENT REFRACTORY GLIOBLASTOMA USING NOVEL CAR-T CELL THERAPY","year":2023,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Fibroblast activation protein, alpha; Chimeric antigen receptor; Cancer research; U87; Medicine; Stromal cell; Glioma; Antigen; Immunotherapy; Immunology; Cancer; Internal medicine; Immune system","score_opus":0.05985623119210558,"score_gpt":0.3477529791566311,"score_spread":0.2878967479645255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388590696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961199,0.0001598675,0.000063545165,0.00056317425,0.00010449805,0.001844372,0.000008469899,0.00011034217,0.0010258164],"genre_scores_gemma":[0.99775547,0.0003457909,0.00051737926,0.0002345872,0.0002101186,0.00018021128,0.000023106002,0.00011491116,0.00061841676],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975609,0.00031398414,0.0005967502,0.0005062265,0.0004120387,0.00061008596],"domain_scores_gemma":[0.9984575,0.0005677078,0.00027253048,0.0004545919,0.00013954735,0.000108106484],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003692518,0.00029499715,0.00064103544,0.0006592913,0.000082487364,0.000013780935,0.00016431794,0.00029376688,0.0007357519],"category_scores_gemma":[0.00009282708,0.00026528945,0.00016554938,0.0009757852,0.00014521903,0.00011170366,0.00006889742,0.00047944146,0.000038367343],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004019271,0.0010049092,0.00060666486,0.0000865617,0.00006191549,0.00007867858,0.001628575,0.00026457105,0.9538509,0.0000057650004,0.000031115553,0.03836102],"study_design_scores_gemma":[0.007764572,0.0077484557,0.0014278883,0.00015455113,0.000014169429,0.00003453178,0.0005126943,0.0017130645,0.9421493,0.000018141835,0.038287595,0.00017502884],"about_ca_topic_score_codex":0.0003947012,"about_ca_topic_score_gemma":0.000040479055,"teacher_disagreement_score":0.03825648,"about_ca_system_score_codex":0.0011687129,"about_ca_system_score_gemma":0.0007115383,"threshold_uncertainty_score":0.9999799},"labels":[],"label_agreement":null},{"id":"W4388824359","doi":"10.21203/rs.3.rs-3576281/v1","title":"Chimerization of the Anti-Viral CD8+ T Cell Response with A Broad Anti-Tumor T Cell Response Reverses Inhibition of Checkpoint Blockade Therapy by Oncolytic Virotherapy","year":2023,"lang":"en","type":"preprint","venue":"Research Square","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Hyundai Hope On Wheels; National Institutes of Health; University of Minnesota; Richard M. Schulze Family Foundation; Mayo Foundation for Medical Education and Research","keywords":"Oncolytic virus; Blockade; Virotherapy; CD8; Viral therapy; T cell; Cytotoxic T cell; Immunotherapy; Medicine; Virology; Cancer research; Immunology; Biology; Coronavirus disease 2019 (COVID-19); Virus; Immune system; Receptor; Internal medicine; In vitro","score_opus":0.047605455395248665,"score_gpt":0.3637150472437093,"score_spread":0.3161095918484606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388824359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865218,0.0014214546,0.00007744988,0.0034870675,0.00015852816,0.0072486023,0.00065682374,0.00013532284,0.00029296876],"genre_scores_gemma":[0.97960943,0.003794128,0.00019518765,0.00008438155,0.00020024354,0.00047301385,0.00021869846,0.00033668868,0.015088216],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.98561436,0.006159065,0.0012657393,0.0013342014,0.0044183405,0.0012082767],"domain_scores_gemma":[0.9924941,0.0020119546,0.00077674893,0.0027384267,0.0016080071,0.00037076094],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00930225,0.0007039407,0.0014389697,0.0015457995,0.0003207328,0.00011349529,0.0009019333,0.0006235499,0.0009028672],"category_scores_gemma":[0.0010514895,0.0005092662,0.0006590743,0.0025758408,0.0014173505,0.00012781966,0.0008101649,0.003104758,0.000052076502],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08330371,0.0015585712,0.0035575435,0.0019676012,0.00020331123,0.0001399847,0.001959355,0.00026080146,0.9046434,0.0000026423338,0.0017686752,0.00063437736],"study_design_scores_gemma":[0.007051224,0.0053866217,0.037690207,0.0032120547,0.00005852564,0.000026954995,0.0009786222,0.00040754816,0.9409008,0.00008619563,0.0037586233,0.00044262665],"about_ca_topic_score_codex":0.00087884575,"about_ca_topic_score_gemma":0.000024007906,"teacher_disagreement_score":0.07625249,"about_ca_system_score_codex":0.00080352766,"about_ca_system_score_gemma":0.0040391376,"threshold_uncertainty_score":0.9997359},"labels":[],"label_agreement":null},{"id":"W4388850548","doi":"10.1101/2023.11.20.567960","title":"A Synthetic Cytotoxic T cell Platform for Rapidly Prototyping TCR Function","year":2023,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Burnaby Hospital; Simon Fraser University; University of British Columbia; Canada's Michael Smith Genome Sciences Centre","funders":"National Cancer Institute; Genome British Columbia; National Institutes of Health; Michael Smith Health Research BC","keywords":"Cytotoxic T cell; T-cell receptor; Function (biology); Rapid prototyping; T cell; Chemistry; Computer science; Cell biology; Biology; Engineering; Immunology; In vitro; Biochemistry; Immune system","score_opus":0.04006224446447281,"score_gpt":0.2740619521043875,"score_spread":0.23399970763991468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388850548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95963454,0.0016624761,0.009697263,0.00085114525,0.0032842723,0.02177241,0.00042907282,0.0025376307,0.00013115768],"genre_scores_gemma":[0.9846405,0.0005081367,0.0035829707,0.00027752036,0.0017495739,0.007864416,0.0000033218219,0.0006867011,0.00068687176],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9953639,0.00009649108,0.00082615315,0.0016493931,0.0008808013,0.0011832906],"domain_scores_gemma":[0.99581873,0.0002848696,0.0004096628,0.002117854,0.0008322626,0.0005366393],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016819249,0.0007880977,0.0010683711,0.0008411984,0.0002747771,0.0002428671,0.0005163671,0.0009765433,0.00050702726],"category_scores_gemma":[0.00047563875,0.00081611203,0.00056498294,0.0008034676,0.00016042536,0.00014283397,0.00046874056,0.0015326545,0.00039873377],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013025325,0.0002869112,0.00081366266,0.004299269,0.00039194527,0.00007189918,0.00001827475,0.000030348781,0.99175763,0.00014271971,0.00084995775,0.000034873785],"study_design_scores_gemma":[0.004255331,0.001064891,0.014735449,0.0024080025,0.0006544458,1.2997798e-7,0.000016494443,0.002982604,0.91494817,0.000024945568,0.057507887,0.0014016837],"about_ca_topic_score_codex":0.000044697495,"about_ca_topic_score_gemma":0.0000031318802,"teacher_disagreement_score":0.076809466,"about_ca_system_score_codex":0.0008681997,"about_ca_system_score_gemma":0.0014999612,"threshold_uncertainty_score":0.999429},"labels":[],"label_agreement":null},{"id":"W4388921302","doi":"10.1016/j.intimp.2023.111249","title":"Comparative evaluation of antitumor effects of TNF superfamily costimulatory ligands delivered by mesenchymal stem cells","year":2023,"lang":"en","type":"article","venue":"International Immunopharmacology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Higher Education Discipline Innovation Project; Shanghai Jiao Tong University; Science and Technology Commission of Shanghai Municipality; Major Projects of Special Development Funds in Zhangjiang National Independent Innovation Demonstration Zone, Shanghai; Shanghai Municipal Education Commission; Ministry of Education of the People's Republic of China; Shanghai Municipal Health Commission","keywords":"Mesenchymal stem cell; Cancer research; Tumor necrosis factor alpha; Immune system; Immunology; Biology; Pharmacology; Cell biology","score_opus":0.05454021726798623,"score_gpt":0.40266281108958685,"score_spread":0.3481225938216006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388921302","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946721,0.0011383351,0.000013917255,0.00015050141,0.0013942616,0.000897726,0.00007518493,0.00003639872,0.0016215299],"genre_scores_gemma":[0.9967472,0.00037565635,0.000019183793,0.00009649486,0.000081160346,0.00007298052,0.000115157985,0.00001925291,0.0024729287],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99787974,0.00022308786,0.00045044956,0.00024172495,0.0009821642,0.00022283263],"domain_scores_gemma":[0.9976571,0.00068703503,0.0001686873,0.00016834096,0.0012511038,0.0000677288],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008239446,0.00014519344,0.00044521134,0.0003534431,0.000032802476,0.000006422215,0.00025531772,0.000093522714,0.0021752655],"category_scores_gemma":[0.000050891726,0.00014279824,0.00012403709,0.0003333698,0.0002173894,0.000086096195,0.00011187389,0.00022807723,0.00011989336],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012447229,0.00032687228,0.0015126863,0.000089198715,0.00087900955,0.000029079372,0.0005458876,0.0005686521,0.98432094,0.000029203808,0.007790437,0.0026632946],"study_design_scores_gemma":[0.007229856,0.00057286804,0.01361094,0.000067125475,0.00019616778,0.0000111441595,0.00015203175,0.027878365,0.9489297,0.000018856956,0.0012414677,0.000091479335],"about_ca_topic_score_codex":0.000060476592,"about_ca_topic_score_gemma":0.0000012591208,"teacher_disagreement_score":0.035391256,"about_ca_system_score_codex":0.00024394946,"about_ca_system_score_gemma":0.00027751015,"threshold_uncertainty_score":0.99873686},"labels":[],"label_agreement":null},{"id":"W4388943550","doi":"10.3389/fimmu.2023.1166059","title":"Integrated antibody and cellular immunity monitoring are required for assessment of the long term protection that will be essential for effective next generation vaccine development","year":2023,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Immunity; Immune system; Cellular immunity; Clinical trial; Immunology; Vaccine efficacy; Pandemic; Medicine; Risk analysis (engineering); Coronavirus disease 2019 (COVID-19); Biology; Bioinformatics; Disease; Infectious disease (medical specialty)","score_opus":0.05603285182762251,"score_gpt":0.3420147387486446,"score_spread":0.28598188692102205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388943550","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.934835,0.0006018709,0.058636755,0.0003165744,0.0015793376,0.003982322,0.000008037177,0.000034357978,0.0000057191432],"genre_scores_gemma":[0.9942538,0.00022795695,0.0036960884,0.000006996626,0.00011573595,0.0010776435,0.00019558852,0.000031632786,0.00039456543],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987644,0.00021449856,0.00029411324,0.00026951975,0.00015857177,0.00029893042],"domain_scores_gemma":[0.99925715,0.00008645161,0.00016434178,0.00027748945,0.00019001511,0.000024546454],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000689851,0.00015514319,0.00038588612,0.00032189928,0.00019724104,0.000021244834,0.00012683198,0.00017871046,0.000009152991],"category_scores_gemma":[0.00015207444,0.00012283819,0.00007831225,0.0003717981,0.00009445947,0.00012062144,0.00010351368,0.00029377438,1.5419862e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00081321184,0.0000780083,0.12449042,0.00018207624,0.00029781592,0.0000025776424,0.0005172247,0.000011917136,0.8286972,0.000004587889,0.00006053359,0.044844404],"study_design_scores_gemma":[0.0029792537,0.00040191997,0.39716434,0.00017306187,0.000041572144,0.000005011291,0.00088742137,0.003651218,0.59421104,0.000034000004,0.00036099524,0.00009013796],"about_ca_topic_score_codex":0.0000689126,"about_ca_topic_score_gemma":0.000026581823,"teacher_disagreement_score":0.27267393,"about_ca_system_score_codex":0.00041190634,"about_ca_system_score_gemma":0.00015551384,"threshold_uncertainty_score":0.5009196},"labels":[],"label_agreement":null},{"id":"W4389166429","doi":"10.21203/rs.3.rs-3661193/v1","title":"A Synthetic Cytotoxic T cell Platform for Rapidly Prototyping TCR Function","year":2023,"lang":"en","type":"preprint","venue":"Research Square","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Genome British Columbia; National Institutes of Health; Michael Smith Health Research BC","keywords":"T-cell receptor; Cytotoxic T cell; Major histocompatibility complex; Antigen; Biology; T cell; Granzyme; Computational biology; Cell biology; Human leukocyte antigen; Granzyme B; CD8; Immunology; Immune system; In vitro; Genetics; Perforin","score_opus":0.14656178462797836,"score_gpt":0.4190089896662709,"score_spread":0.27244720503829256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389166429","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.71069914,0.008776206,0.011914938,0.01271677,0.0039769253,0.194798,0.0014791087,0.0040098606,0.05162907],"genre_scores_gemma":[0.79055417,0.0028164738,0.0013425589,0.00012809811,0.0037758881,0.04108701,0.0016053623,0.0009585403,0.15773192],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9924418,0.0003785891,0.0006962849,0.0015903644,0.0029543687,0.0019385988],"domain_scores_gemma":[0.9938717,0.0016594598,0.00014576776,0.0020297547,0.0016551514,0.0006381525],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.006313573,0.00052333425,0.00092018297,0.0019001517,0.0005013223,0.00030122,0.00065580994,0.0009482948,0.0026925774],"category_scores_gemma":[0.0015278374,0.00048078634,0.00075021764,0.0010709907,0.00031633335,0.00010406634,0.0012859888,0.004148074,0.001051444],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.039774593,0.003050545,0.00289938,0.12778603,0.0020523765,0.0008389125,0.004076151,0.0005319961,0.5226298,0.001343297,0.060160052,0.23485686],"study_design_scores_gemma":[0.021480756,0.021959597,0.010789628,0.027344516,0.0006609925,0.00016715743,0.007018693,0.038857367,0.21647516,0.04244128,0.6093201,0.003484767],"about_ca_topic_score_codex":0.00024936607,"about_ca_topic_score_gemma":0.00006085396,"teacher_disagreement_score":0.54916006,"about_ca_system_score_codex":0.0013671506,"about_ca_system_score_gemma":0.0021168313,"threshold_uncertainty_score":0.9997644},"labels":[],"label_agreement":null},{"id":"W4389218826","doi":"10.1182/blood-2023-173873","title":"Improved Overall Survival with Axicabtagene Ciloleucel Vs Standard of Care in Second-Line Large B-Cell Lymphoma Among the Elderly: A Subgroup Analysis of ZUMA-7","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Subgroup analysis; Oncology; Chemoimmunotherapy; Aggressive lymphoma; Intention-to-treat analysis; Lymphoma; Randomized controlled trial; Surgery; Confidence interval; Rituximab","score_opus":0.01250162557583315,"score_gpt":0.2699300756294732,"score_spread":0.25742845005364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389218826","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963602,0.0005384959,0.000022784456,0.00009857649,0.00003381468,0.0006344168,0.0003950752,0.000043627213,0.0018729973],"genre_scores_gemma":[0.99673814,0.00016489923,0.000055184482,0.000029639354,0.00005189213,0.000040767445,0.00020567323,0.00004886436,0.0026649383],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9976898,0.00015919423,0.00049555756,0.0003827929,0.00077433133,0.000498311],"domain_scores_gemma":[0.99835426,0.00021755903,0.00017912898,0.0008064171,0.00031916462,0.0001234807],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00085357577,0.00021887315,0.0009363102,0.0006004487,0.000049489252,0.0000169756,0.00026219146,0.00012707312,0.0009611241],"category_scores_gemma":[0.000053387954,0.00015094398,0.00030637273,0.0023167096,0.0001462625,0.000049911603,0.00012123621,0.00021977142,0.0000030071576],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013807829,0.003681588,0.47953957,0.0014531012,0.0059918035,0.00046017414,0.007288915,0.00012540176,0.48126072,0.00008986832,0.00012675552,0.006174265],"study_design_scores_gemma":[0.06629869,0.011726376,0.49943408,0.00021872645,0.003531064,0.000010154666,0.0049302126,0.0028120629,0.40933654,0.000024324794,0.0012107677,0.00046701528],"about_ca_topic_score_codex":0.0006467333,"about_ca_topic_score_gemma":0.011392028,"teacher_disagreement_score":0.071924195,"about_ca_system_score_codex":0.000086226355,"about_ca_system_score_gemma":0.00030761262,"threshold_uncertainty_score":0.99995214},"labels":[],"label_agreement":null},{"id":"W4389219761","doi":"10.1182/blood-2023-173949","title":"Dexamethasone is Associated with a Lower Incidence and Severity of Cytokine Release Syndrome Compared with Other Corticosteroid Regimens When Given as Premedication for Glofitamab Monotherapy in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Premedication; Cytokine release syndrome; Prednisolone; Dexamethasone; Corticosteroid; Internal medicine; Methylprednisolone; Prednisone; Follicular lymphoma; Gastroenterology; Surgery; Lymphoma; Cancer","score_opus":0.013440384799756854,"score_gpt":0.2531730764839318,"score_spread":0.23973269168417494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389219761","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99693036,0.0001359519,0.000084921994,0.00023276712,0.000015240484,0.0022463566,0.00013876095,0.00007820364,0.00013745115],"genre_scores_gemma":[0.9972227,0.000056740297,0.00060982356,0.0002434366,0.000013255503,0.00018576343,0.00014317036,0.000098944074,0.0014261228],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976188,0.000132481,0.0003805015,0.0005345877,0.0008551834,0.00047844535],"domain_scores_gemma":[0.998248,0.0002548017,0.0003452313,0.0005593569,0.00038787455,0.00020474709],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048935524,0.00027388023,0.0006233878,0.00025605754,0.000064153704,0.000019327083,0.00014828176,0.00015330676,0.00016143676],"category_scores_gemma":[0.00013815808,0.00020744666,0.000046997156,0.000637242,0.00018525087,0.00015652613,0.000045954348,0.00019449322,0.000007102488],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023039455,0.010179236,0.9525964,0.00027879095,0.00080250035,0.00020234004,0.0031473022,0.0000034593327,0.008440552,0.000002607521,0.0002703886,0.0010369467],"study_design_scores_gemma":[0.13398916,0.01241472,0.8437309,0.0011506722,0.00035081455,0.00006313766,0.0002344384,0.00042519532,0.0065660006,0.000043494394,0.0006503721,0.00038106466],"about_ca_topic_score_codex":0.00025775057,"about_ca_topic_score_gemma":0.0002486561,"teacher_disagreement_score":0.1109497,"about_ca_system_score_codex":0.00018030239,"about_ca_system_score_gemma":0.00029948395,"threshold_uncertainty_score":0.845943},"labels":[],"label_agreement":null},{"id":"W4389220343","doi":"10.1182/blood-2023-189200","title":"Intensity of Survivin Expression Correlates with Clinical and Biological Markers of Aggressive R/R DLBCL","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Toronto General Hospital; University of Calgary; London Health Sciences Centre; Queen Elizabeth II Health Sciences Centre; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Survivin; Medicine; Immunohistochemistry; Oncology; Internal medicine; Pathology; Cancer","score_opus":0.05891360144423264,"score_gpt":0.3468215963229426,"score_spread":0.28790799487871,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389220343","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984769,0.00020831193,0.000004124529,0.00012148088,0.000047376587,0.00023385494,0.00000940177,0.000030962863,0.0008675936],"genre_scores_gemma":[0.99849135,0.00079973345,0.00018254873,0.000022422853,0.000037453832,0.000004772001,0.0000146332695,0.000010978505,0.00043609669],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9990109,0.00012733515,0.0002685825,0.00021029811,0.00022319968,0.00015964128],"domain_scores_gemma":[0.99877787,0.00055132696,0.00018238368,0.00022405079,0.00016043059,0.000103938626],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00067245046,0.00008416354,0.00040553737,0.000081958846,0.0000191966,0.000002607575,0.000064847874,0.00012822909,0.0002180101],"category_scores_gemma":[0.00081994204,0.000051691477,0.000067944486,0.00022730362,0.0005131379,0.000015693116,0.00012310596,0.00022429698,0.0000062620857],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002602311,0.00043099103,0.8766937,0.000057529604,0.00012796237,0.00009090844,0.00008657265,2.2800498e-7,0.117191225,0.0000067885267,0.00034445937,0.002367268],"study_design_scores_gemma":[0.005511547,0.002261742,0.9159748,0.00047006592,0.00007111808,0.00007827379,0.00032299908,0.000055181274,0.075023405,0.00008837655,0.00007084744,0.00007165944],"about_ca_topic_score_codex":0.000027346056,"about_ca_topic_score_gemma":0.0000045799975,"teacher_disagreement_score":0.042167827,"about_ca_system_score_codex":0.0000032620883,"about_ca_system_score_gemma":0.00004780644,"threshold_uncertainty_score":0.23870578},"labels":[],"label_agreement":null},{"id":"W4389220356","doi":"10.1182/blood-2023-178738","title":"A Systematic Literature Review (SLR) and Meta-Analysis of Clinical Evidence of Second Line or Later (2L+) Treatments for Follicular Lymphoma (FL) in Adult Patients","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Medicine; Oncology; Follicular lymphoma; Internal medicine; Pembrolizumab; Population; MEDLINE; Cochrane Library; Meta-analysis; Systematic review; Lymphoma; Immunotherapy; Cancer","score_opus":0.12261468838760457,"score_gpt":0.4252385404789309,"score_spread":0.3026238520913263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389220356","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9236398,0.07301316,0.0000014851747,0.00019341418,0.000017686962,0.0029477985,0.00015649525,0.000011464871,0.000018709101],"genre_scores_gemma":[0.9132647,0.07231865,0.00069223525,0.0007081893,0.000046200974,0.0011487697,0.0002831472,0.000060249782,0.011477848],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9973106,0.00033580035,0.0013505024,0.00035027484,0.00045434778,0.00019850054],"domain_scores_gemma":[0.997458,0.0010374881,0.00034500944,0.00056654995,0.0004894259,0.00010357261],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014623059,0.00017284091,0.002775165,0.00035871397,0.0000137149345,0.000010739209,0.00011350347,0.00012007302,0.0004229611],"category_scores_gemma":[0.0018535557,0.000097777076,0.0010658614,0.0015644905,0.00003973705,0.00006346845,0.000053347376,0.000076374534,0.0000040191003],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002257764,0.0047022146,0.084876396,0.48168218,0.42131698,0.00032702208,0.0011353098,0.0000020750779,0.0018740678,0.000010675668,0.00037699807,0.0014382962],"study_design_scores_gemma":[0.018940568,0.0040893448,0.055258766,0.048740666,0.8681944,0.000025348078,0.000049248847,0.00059198204,0.0037322703,0.000020752783,0.000084874606,0.00027175466],"about_ca_topic_score_codex":0.000010933217,"about_ca_topic_score_gemma":0.00006989842,"teacher_disagreement_score":0.44687742,"about_ca_system_score_codex":0.000016725166,"about_ca_system_score_gemma":0.00006323378,"threshold_uncertainty_score":0.46311274},"labels":[],"label_agreement":null},{"id":"W4389220803","doi":"10.1182/blood-2023-174510","title":"3-Year Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL)","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Internal medicine; Fludarabine; Chemotherapy regimen; Phases of clinical research; International Prognostic Index; Regimen; Diffuse large B-cell lymphoma; Interim analysis; Surgery; Oncology; Lymphoma; Cyclophosphamide; Chemotherapy; Clinical trial","score_opus":0.01785151884795993,"score_gpt":0.2935026324855429,"score_spread":0.275651113637583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389220803","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997653,0.00014099704,0.000005126361,0.000038061702,0.000032706826,0.0014491716,0.00020687739,0.000059369853,0.0004147011],"genre_scores_gemma":[0.9978167,0.00054790714,0.00004809808,0.000033138625,0.00004683184,0.00008051739,0.00024104344,0.00006825123,0.0011175057],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968692,0.00020353608,0.0006711458,0.00054242386,0.0012010313,0.0005126734],"domain_scores_gemma":[0.99803036,0.00018903721,0.00029212565,0.0009948979,0.0003133602,0.00018023797],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006940915,0.00028406217,0.0010302064,0.0012975946,0.00006652448,0.000012497552,0.00027703043,0.00012004016,0.0011585705],"category_scores_gemma":[0.00008807436,0.00022482012,0.00022669716,0.0035972085,0.00007526853,0.000056567547,0.00011069433,0.00020122358,0.000031672775],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071588275,0.10362299,0.86825323,0.000087463835,0.004302098,0.00014629077,0.0028867158,0.00008027854,0.0070632775,0.0000044616154,0.00005935601,0.006335007],"study_design_scores_gemma":[0.24048768,0.023704436,0.6983905,0.00006251624,0.002117923,9.75832e-7,0.0009916833,0.0003251329,0.033367813,0.000012938499,0.0002692268,0.00026921195],"about_ca_topic_score_codex":0.0016361135,"about_ca_topic_score_gemma":0.00079946575,"teacher_disagreement_score":0.23332886,"about_ca_system_score_codex":0.00006154928,"about_ca_system_score_gemma":0.00014255787,"threshold_uncertainty_score":0.9997545},"labels":[],"label_agreement":null},{"id":"W4389220841","doi":"10.1182/blood-2023-174929","title":"A Phase I/II Trial to Evaluate the Safety, Pharmacokinetics, and Efficacy of Glofitamab As Monotherapy and in Combination with R-ICE Chemoimmunotherapy in Children and Young Adults with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (iMATRIX-GLO)","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Chemoimmunotherapy; Medicine; Tumor lysis syndrome; Neutropenia; Internal medicine; Population; Febrile neutropenia; Rituximab; Cytokine release syndrome; Oncology; Tolerability; Lymphoma; Gastroenterology; Cancer; Adverse effect; Chemotherapy; Immunotherapy; Chimeric antigen receptor","score_opus":0.010659493861115539,"score_gpt":0.30349722035288157,"score_spread":0.29283772649176604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389220841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938626,0.0012820533,0.000006291702,0.00064359664,0.000031382024,0.003902574,0.000016089201,0.00003469914,0.00022071406],"genre_scores_gemma":[0.99504733,0.004108558,0.00013716868,0.00012742137,0.000061000854,0.00011633863,0.00003486599,0.000069531314,0.00029778303],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99801207,0.00017200792,0.0004163113,0.0004838664,0.0005585468,0.0003571778],"domain_scores_gemma":[0.9990566,0.00023909134,0.00011285819,0.0003560864,0.00010962996,0.0001257358],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009955072,0.00027680933,0.00049739267,0.00041018732,0.000088604786,0.000037047343,0.00014038186,0.00010095437,0.000050536008],"category_scores_gemma":[0.000048359583,0.00019253635,0.000035571476,0.00085688505,0.0001899638,0.00009318493,0.0000738648,0.0002479587,0.0000025122556],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5295227,0.012491496,0.033685423,0.00015021904,0.0005402173,0.00008850754,0.012402787,0.000017584047,0.2234015,0.000008807708,0.000061702376,0.18762903],"study_design_scores_gemma":[0.7380643,0.02060133,0.2073425,0.0003246835,0.00015339794,0.00012979863,0.00028427024,0.000629009,0.032051794,0.000017521068,0.00014095329,0.0002604398],"about_ca_topic_score_codex":0.0006509731,"about_ca_topic_score_gemma":0.000095147014,"teacher_disagreement_score":0.20854157,"about_ca_system_score_codex":0.000062876315,"about_ca_system_score_gemma":0.00016980573,"threshold_uncertainty_score":0.78514045},"labels":[],"label_agreement":null},{"id":"W4389220971","doi":"10.1182/blood-2023-174209","title":"Mosunetuzumab Plus Polatuzumab Vedotin Demonstrates a Favorable Safety Profile and Efficacy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Primary Analysis of a Phase Ib/II Study","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan; McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Follicular lymphoma; Internal medicine; Cytokine release syndrome; Regimen; Lymphoma; Interim analysis; Clinical endpoint; Refractory (planetary science); Gastroenterology; Diffuse large B-cell lymphoma; Oncology; Clinical trial; Cancer; Immunotherapy; Chimeric antigen receptor","score_opus":0.015396412424737509,"score_gpt":0.28835124940416645,"score_spread":0.27295483697942896,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389220971","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99536157,0.0003124174,0.0000033566298,0.000027122953,0.000024599929,0.002496994,0.00016081183,0.0001154086,0.0014977138],"genre_scores_gemma":[0.9954981,0.00012646898,0.00016981142,0.000032733624,0.000026279811,0.00010364872,0.0005054843,0.00007543284,0.0034620324],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966424,0.00026963901,0.0007394857,0.0007344897,0.00092894566,0.00068505044],"domain_scores_gemma":[0.99817145,0.00035041483,0.00024527984,0.0007642891,0.00021156362,0.00025697995],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007506445,0.00035128102,0.0011490118,0.0011695853,0.00016949754,0.000028912746,0.00020944128,0.00016372114,0.000416089],"category_scores_gemma":[0.00016131863,0.0002698148,0.00014495222,0.0040952424,0.00012858535,0.00013350173,0.00021801841,0.00033697448,0.000014929828],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.063374765,0.20011914,0.65059596,0.0008692059,0.007551575,0.0013653758,0.01261862,0.000074089454,0.03999279,0.0000069295265,0.0003201329,0.023111429],"study_design_scores_gemma":[0.31984973,0.02201111,0.6446526,0.00023341867,0.0033408506,0.0000125790475,0.002470951,0.0025135588,0.0040345783,0.0000023858472,0.00040752048,0.00047070367],"about_ca_topic_score_codex":0.000336682,"about_ca_topic_score_gemma":0.0003017367,"teacher_disagreement_score":0.25647494,"about_ca_system_score_codex":0.00033258423,"about_ca_system_score_gemma":0.00094343914,"threshold_uncertainty_score":0.9999754},"labels":[],"label_agreement":null},{"id":"W4389222107","doi":"10.1182/blood-2023-173955","title":"A Phase 1 Cohort Dose Escalation and Expansion Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS03 in Patients with Advanced B-Cell Non-Hodgkin Lymphomas (NHL)","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Cancer research; Antibody-drug conjugate; Radioimmunotherapy; In vivo; Medicine; Lymphoma; Follicular lymphoma; Chemistry; Pharmacology; Antibody; Internal medicine; Immunology; Biology; Monoclonal antibody","score_opus":0.012010767958892821,"score_gpt":0.275547729114953,"score_spread":0.2635369611560602,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389222107","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963139,0.00004390986,0.000026872765,0.00008856952,0.000067487344,0.0031739473,0.000026235684,0.000035493886,0.00022354425],"genre_scores_gemma":[0.99930835,0.000087544206,0.00015102826,0.000026566295,0.000049065107,0.0001191037,0.000054871023,0.000035291923,0.0001681798],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99839574,0.0001049062,0.00033032405,0.00040502188,0.00045753882,0.00030644334],"domain_scores_gemma":[0.9990442,0.00025603842,0.00010887256,0.0003261245,0.00012535405,0.00013941413],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035821748,0.00020445656,0.000448829,0.000249084,0.0000746152,0.000018814211,0.00007326118,0.00008926111,0.00003455866],"category_scores_gemma":[0.00010304903,0.00014451653,0.000034412067,0.0007998891,0.00008814796,0.00011477189,0.000102577724,0.00016138575,0.0000029558325],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.36226776,0.0063331015,0.17988722,0.0002593128,0.00007440191,0.000095998264,0.0008164564,0.00012534519,0.2965385,5.670236e-7,0.000030340065,0.153571],"study_design_scores_gemma":[0.23106134,0.011416141,0.7293579,0.00023102741,0.000106651576,0.000011445469,0.00003121341,0.0032338486,0.02436091,0.0000042565166,0.000036407415,0.00014885305],"about_ca_topic_score_codex":0.00005298739,"about_ca_topic_score_gemma":0.000029769373,"teacher_disagreement_score":0.54947066,"about_ca_system_score_codex":0.000032312924,"about_ca_system_score_gemma":0.00011650245,"threshold_uncertainty_score":0.5893213},"labels":[],"label_agreement":null},{"id":"W4389227639","doi":"10.1158/2326-6074.tumimm23-a006","title":"Abstract A006: Understanding the Potential of Human IL-12 and Chimeric IL-15 Combination for Cancer Immunotherapy","year":2023,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Immunotherapy; Interleukin 15; Cancer immunotherapy; Immunology; Cytotoxic T cell; Chimeric antigen receptor; CD8; T cell; Cancer research; STAT4; Biology; Immune system; Medicine; Cytokine; Interleukin; In vitro; stat; STAT3; Cell biology; Signal transduction","score_opus":0.15433649951523956,"score_gpt":0.4428773898484035,"score_spread":0.288540890333164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389227639","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9842798,0.0062150178,0.00008242505,0.0064581903,0.00036449812,0.0017206051,0.00007126751,0.00009252213,0.000715649],"genre_scores_gemma":[0.98213863,0.011500875,0.000008731474,0.00006497721,0.00020408863,0.0007583815,0.000042771713,0.0000854691,0.0051960843],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99759686,0.00022703204,0.00034836982,0.00039628867,0.0006342714,0.00079716416],"domain_scores_gemma":[0.9983662,0.0005277847,0.00010406568,0.00050188415,0.0004284472,0.00007166845],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002012846,0.00017064966,0.00039861485,0.00059604115,0.000556069,0.000047924008,0.0003480041,0.00020071544,0.0013427216],"category_scores_gemma":[0.000096378,0.00013247626,0.00012634679,0.0008794849,0.0013789164,0.0000859736,0.00015508824,0.0008267097,0.000009998557],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017262024,0.00008924712,0.0031831644,0.00017123706,0.0006488573,0.000009659433,0.0011632987,0.000012271245,0.9570907,0.0011524879,0.00216924,0.032583684],"study_design_scores_gemma":[0.020187523,0.004063702,0.76152223,0.00058865553,0.00014383034,0.000056009703,0.014089239,0.0012552477,0.15351903,0.015897522,0.028079692,0.0005973093],"about_ca_topic_score_codex":0.0014271103,"about_ca_topic_score_gemma":0.00019699716,"teacher_disagreement_score":0.80357164,"about_ca_system_score_codex":0.00057789584,"about_ca_system_score_gemma":0.00046049125,"threshold_uncertainty_score":0.9995702},"labels":[],"label_agreement":null},{"id":"W4389227694","doi":"10.1158/2326-6074.tumimm23-b025","title":"Abstract B025: Neutrophil depletion enhances the anti-tumor activity of CAR-T cells in an autochthonous model of non-small cell lung cancer","year":2023,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer research; T cell; CD8; Immunotherapy; Medicine; Infiltration (HVAC); Cell; Lung cancer; Cancer immunotherapy; Immune system; Immunology; Pathology; Biology","score_opus":0.08007744742955278,"score_gpt":0.4022435364212251,"score_spread":0.3221660889916723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389227694","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943529,0.0021457325,0.000026501893,0.00082741963,0.00024230887,0.00162433,0.000098281715,0.00004272163,0.00063981296],"genre_scores_gemma":[0.9896539,0.007624071,0.000030308087,0.000028747281,0.00013446198,0.000739109,0.000013901406,0.00006649765,0.0017090074],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99650586,0.00047358134,0.00051279424,0.0006182937,0.0007998403,0.0010896488],"domain_scores_gemma":[0.9973843,0.00052906625,0.00019237677,0.0010151681,0.0007585008,0.0001205671],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021715816,0.00024302452,0.0007174666,0.00082001695,0.0001682936,0.000022200737,0.00074265193,0.0002640713,0.0006734994],"category_scores_gemma":[0.00006905297,0.00019370519,0.00015517938,0.001640236,0.0010059442,0.00014395372,0.0003066648,0.0016788513,0.000018387962],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016138649,0.00035017828,0.013850313,0.00058944395,0.00013263634,0.00004358806,0.0015949752,0.0053411922,0.97039497,0.00000864022,0.0002454149,0.0058348095],"study_design_scores_gemma":[0.0015164505,0.00041928518,0.17703763,0.00020077275,0.000027449129,0.0000031728976,0.00047860513,0.02700421,0.7930596,0.000032750264,0.00008373239,0.00013633195],"about_ca_topic_score_codex":0.011214337,"about_ca_topic_score_gemma":0.0020025133,"teacher_disagreement_score":0.17733534,"about_ca_system_score_codex":0.00052767684,"about_ca_system_score_gemma":0.0021663036,"threshold_uncertainty_score":0.9953701},"labels":[],"label_agreement":null},{"id":"W4389227770","doi":"10.1158/2326-6074.tumimm23-b003","title":"Abstract B003: Communication is key: Understanding the modulating effect of immune cell crosstalk on T cell therapy function","year":2023,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Tumor microenvironment; Crosstalk; T cell; Immune system; Interactome; CD8; Immunotherapy; Cancer immunotherapy; Cancer research; Cell; Biology; Computational biology; Cell biology; Immunology; Genetics","score_opus":0.15349428235421014,"score_gpt":0.42722960022174505,"score_spread":0.2737353178675349,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389227770","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9724585,0.009772616,0.000020902766,0.002592176,0.00022009572,0.0014368222,0.000014748606,0.000095002,0.013389147],"genre_scores_gemma":[0.98023707,0.011043326,0.00000567815,0.00007605509,0.00009663217,0.00030810817,0.000049642458,0.000075216296,0.008108261],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9964095,0.0009429347,0.00045980868,0.00042430664,0.0009292663,0.0008341904],"domain_scores_gemma":[0.99532104,0.0026019148,0.00016141724,0.0014866214,0.00035744527,0.0000715924],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0047258576,0.00022735524,0.00044926524,0.000582746,0.00078467705,0.00006564279,0.0005922314,0.0002773936,0.0027352227],"category_scores_gemma":[0.0001515012,0.00015973454,0.0002140252,0.001615459,0.0010226234,0.000095145304,0.0002689668,0.0019134894,0.0002227604],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057326993,0.00012486927,0.004479016,0.0002163034,0.0002582108,0.000009205297,0.0021395418,0.00013264561,0.96266425,0.00009573685,0.0018245113,0.022323016],"study_design_scores_gemma":[0.0069587533,0.0038429056,0.08871749,0.00034808918,0.000034437806,0.0000062785107,0.0035241286,0.00086043833,0.88843477,0.0008374104,0.0062098536,0.00022545546],"about_ca_topic_score_codex":0.0010380939,"about_ca_topic_score_gemma":0.000019049676,"teacher_disagreement_score":0.08423848,"about_ca_system_score_codex":0.00077614747,"about_ca_system_score_gemma":0.00031022597,"threshold_uncertainty_score":0.9981764},"labels":[],"label_agreement":null},{"id":"W4389227797","doi":"10.1158/2326-6074.tumimm23-a047","title":"Abstract A047: Tumor specific γδ T cells expand and respond to PD-1 blockade","year":2023,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; TIGIT; T cell; T-cell receptor; Blockade; Immunology; Cancer immunotherapy; Tumor-infiltrating lymphocytes; Immunotherapy; Biology; Cancer research; Medicine; Immune system; Receptor; Internal medicine","score_opus":0.12411425987828946,"score_gpt":0.4345827140921795,"score_spread":0.3104684542138901,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389227797","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97901756,0.006439998,0.0000013369531,0.007480425,0.00040618246,0.0012341504,0.00004331235,0.00014065292,0.005236377],"genre_scores_gemma":[0.87761086,0.009686793,0.00007557194,0.0002811564,0.0007803058,0.0006286568,0.000025009816,0.00012759253,0.11078403],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960081,0.00030099959,0.00037352098,0.0008307386,0.0009505073,0.0015361295],"domain_scores_gemma":[0.9972001,0.0008766485,0.000039105056,0.0009823614,0.00047297296,0.00042886243],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0024449772,0.00024017895,0.0005049801,0.0014445399,0.00041035973,0.00012619022,0.00045455078,0.00022562154,0.010349008],"category_scores_gemma":[0.00028233786,0.00022091187,0.00009124141,0.0021231712,0.0010622065,0.00008020851,0.00055958243,0.0016345475,0.0025950354],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037542947,0.00007314934,0.0019223462,0.000091968635,0.00015288063,0.000716126,0.0010717666,0.0000040759146,0.9209263,0.000032673768,0.041481078,0.029773362],"study_design_scores_gemma":[0.0022097793,0.00076529564,0.12439683,0.00015661416,0.000009368594,0.00008327786,0.0012495402,0.000013595328,0.39248052,0.00013603538,0.47828633,0.0002128082],"about_ca_topic_score_codex":0.0005101557,"about_ca_topic_score_gemma":0.00007911891,"teacher_disagreement_score":0.5284458,"about_ca_system_score_codex":0.00045607027,"about_ca_system_score_gemma":0.0007716668,"threshold_uncertainty_score":0.9981816},"labels":[],"label_agreement":null},{"id":"W4389227931","doi":"10.1158/2326-6074.tumimm23-b008","title":"Abstract B008: GPR64-targeting single-domain CAR-T cells for immunotherapy in Ewing sarcoma","year":2023,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Immunotherapy; Cancer research; Cancer; FLI1; Context (archaeology); Transcriptome; Medicine; Sarcoma; Mesenchymal stem cell; Cancer immunotherapy; Biology; Computational biology; Bioinformatics; Transcription factor; Internal medicine; Pathology; Gene expression; Genetics; Gene","score_opus":0.12010739287825663,"score_gpt":0.42062158504169206,"score_spread":0.30051419216343545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389227931","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97930294,0.0097421985,0.000024379719,0.0048720385,0.0006343467,0.0023129634,0.000042693402,0.00020468785,0.0028637238],"genre_scores_gemma":[0.97676164,0.006323234,0.00046714727,0.00026907882,0.00072107936,0.0018114473,0.00013254202,0.00025067414,0.013263142],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9946935,0.0004742665,0.0007051501,0.000866426,0.00090922543,0.0023514123],"domain_scores_gemma":[0.9964216,0.0018198721,0.00009403719,0.0008762604,0.00061086804,0.0001773601],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00522195,0.00032441222,0.00073807716,0.0016120789,0.00041807818,0.00008793565,0.00067723036,0.00044987103,0.0029592316],"category_scores_gemma":[0.0004468515,0.00031971352,0.00026294118,0.0023268277,0.00074170233,0.00014984782,0.00028396345,0.0019529966,0.0003316449],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003032221,0.00021453331,0.00447842,0.00021856655,0.0002809328,0.00020795637,0.001641143,0.000023736624,0.9185914,0.00006853633,0.006123595,0.065118976],"study_design_scores_gemma":[0.012075991,0.0015778221,0.046221107,0.00064232986,0.000015736652,0.00004123462,0.005136231,0.00031911163,0.678258,0.0015339211,0.25358826,0.00059027004],"about_ca_topic_score_codex":0.0012190626,"about_ca_topic_score_gemma":0.00020922419,"teacher_disagreement_score":0.24746466,"about_ca_system_score_codex":0.0014404083,"about_ca_system_score_gemma":0.0008993654,"threshold_uncertainty_score":0.9999255},"labels":[],"label_agreement":null},{"id":"W4389227987","doi":"10.1158/2326-6074.tumimm23-a010","title":"Abstract A010: Assay development to assess the efficiency and stability of candidate molecules for transcriptional gene silencing of FOXP3, using a human tumor-derived cell line","year":2023,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Gene silencing; Biology; FOXP3; Transcription factor; Cell biology; Transcriptional regulation; Epigenetics; Effector; Cancer research; Therapeutic gene modulation; Gene expression; Immune system; Gene; Immunology; Genetics; Regulator gene","score_opus":0.22277501408679942,"score_gpt":0.4421814979584126,"score_spread":0.21940648387161318,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389227987","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956354,0.0015504141,0.0007254035,0.00042267833,0.000072298906,0.0013907404,0.000076552926,0.000018801507,0.000107739106],"genre_scores_gemma":[0.99873215,0.00018555264,0.0005112772,0.000021416732,0.000046611414,0.00028913526,0.000035095985,0.000030958145,0.00014777394],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975339,0.00027845873,0.00048475183,0.00040184043,0.0006521357,0.0006489042],"domain_scores_gemma":[0.9977914,0.00071671465,0.00008498543,0.00039881637,0.0009061532,0.000101897574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003932715,0.00014518999,0.0004043317,0.00041420187,0.00032129115,0.000019519057,0.00030874385,0.00009687148,0.0004227149],"category_scores_gemma":[0.00026450946,0.00011345085,0.00008021474,0.0007530917,0.0007570448,0.00004477982,0.0001789456,0.0004844191,0.0000029833004],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00092841405,0.00014217758,0.0030769482,0.0004885336,0.00013592065,0.000010165753,0.0023352369,0.00009674374,0.99024147,0.000017221308,0.00001840474,0.0025087867],"study_design_scores_gemma":[0.0013982404,0.00042192577,0.076174214,0.00013246435,0.0000177072,0.000008617831,0.0014901003,0.000505263,0.9195677,0.000040266827,0.00015307027,0.000090417394],"about_ca_topic_score_codex":0.0010531032,"about_ca_topic_score_gemma":0.0001928515,"teacher_disagreement_score":0.073097266,"about_ca_system_score_codex":0.0003390958,"about_ca_system_score_gemma":0.0014053907,"threshold_uncertainty_score":0.46284318},"labels":[],"label_agreement":null},{"id":"W4389229518","doi":"10.1182/blood-2023-178724","title":"A Potential Paradigm for the Robust and Systematic Prioritisation of Assets in Academic-Led, Multi-Industry Collaborative Trials in Rare Populations (Glo-BNHL)","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Clinical trial; Relevance (law); Adverse effect; Intensive care medicine; Medical physics; Pathology; Pharmacology","score_opus":0.143860817377604,"score_gpt":0.40989628892360797,"score_spread":0.26603547154600393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389229518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911448,0.0013622616,0.00022378603,0.0014218875,0.0001011412,0.0055970075,0.000102694314,0.000025179717,0.000021260275],"genre_scores_gemma":[0.99805814,0.00024448332,0.00042305913,0.000018095048,0.000114373586,0.00062815606,0.000054493397,0.000020625372,0.00043856414],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99797314,0.00053261494,0.0007745865,0.0001982889,0.0003026661,0.00021872002],"domain_scores_gemma":[0.9980877,0.0013362033,0.00021463704,0.00019837497,0.00010558793,0.000057503872],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0032636144,0.000109287575,0.00065122615,0.00029609055,0.000055354965,0.000022156864,0.00008623429,0.00029034313,0.000034451085],"category_scores_gemma":[0.0033013602,0.00008105936,0.000071732604,0.00092991727,0.00005112633,0.0000759392,0.000033278284,0.00041209845,0.000002128583],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034992676,0.0025531321,0.60467833,0.032955583,0.0016259513,0.00035877625,0.020428006,0.0055013085,0.31864208,0.0029441598,0.0011404688,0.0056729224],"study_design_scores_gemma":[0.06223839,0.00069619436,0.8563665,0.010660281,0.0012284582,0.00013149291,0.012167287,0.04380244,0.011101346,0.0010866496,0.00008321439,0.00043772242],"about_ca_topic_score_codex":0.00009293081,"about_ca_topic_score_gemma":0.00028973355,"teacher_disagreement_score":0.30754074,"about_ca_system_score_codex":0.000056990604,"about_ca_system_score_gemma":0.0001922362,"threshold_uncertainty_score":0.3952275},"labels":[],"label_agreement":null},{"id":"W4389231884","doi":"10.1182/blood-2023-179474","title":"TRANSCEND FL: Phase 2 Study Primary Analysis of Lisocabtagene Maraleucel as Second-Line Therapy in Patients with High-Risk Relapsed or Refractory Follicular Lymphoma","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Follicular lymphoma; Refractory (planetary science); Clinical endpoint; Oncology; Cohort; Phases of clinical research; Lymphoma; Gastroenterology; Surgery; Chemotherapy; Clinical trial; Biology","score_opus":0.020436914417571526,"score_gpt":0.2999379315298334,"score_spread":0.2795010171122619,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389231884","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99726796,0.00027586505,0.0000039938077,0.000046287205,0.000044211072,0.0018898495,0.00015837546,0.000093953284,0.00021948756],"genre_scores_gemma":[0.9954099,0.00060568145,0.00008535461,0.000110334,0.00005675255,0.00011709905,0.00056811026,0.0000867039,0.0029600344],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968985,0.00032739723,0.00063000544,0.0005998941,0.0010819559,0.00046226347],"domain_scores_gemma":[0.9982796,0.0002085475,0.00020066948,0.0009137799,0.00020491552,0.00019251599],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00072725286,0.00030646755,0.0010421784,0.001218461,0.000062857376,0.000017660404,0.00023279044,0.00014629653,0.0028709387],"category_scores_gemma":[0.00005983869,0.0002199733,0.00026199102,0.0037817035,0.00008630033,0.00009902284,0.000037209596,0.00027431513,0.00002142855],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03143327,0.042663533,0.80884093,0.00012763549,0.012867652,0.0010136877,0.0027029107,0.000044375614,0.051558148,0.0000011289366,0.00009334838,0.048653375],"study_design_scores_gemma":[0.11275834,0.017687561,0.8533951,0.000043989985,0.002212219,0.0000024425824,0.00027231386,0.000059723025,0.012938575,0.0000045414927,0.00039000702,0.00023521051],"about_ca_topic_score_codex":0.00046613775,"about_ca_topic_score_gemma":0.0003885845,"teacher_disagreement_score":0.08132508,"about_ca_system_score_codex":0.000115479364,"about_ca_system_score_gemma":0.00028870383,"threshold_uncertainty_score":0.99804056},"labels":[],"label_agreement":null},{"id":"W4389231975","doi":"10.1182/blood-2023-178868","title":"WU-NK-101 (W-NK), a Memory-like (ML) NK Cell, Naturally Overcomes Tumor Microenvironment (TME) Metabolic Challenges, Retaining Anti-Tumor Potency","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Tumor microenvironment; Immune system; Biology; Cancer research; Cancer immunotherapy; Immunotherapy; Immunology; Cell biology","score_opus":0.025281636456025786,"score_gpt":0.26789262133763597,"score_spread":0.24261098488161018,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389231975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9337072,0.05012411,0.0000025373445,0.0019646941,0.0004121777,0.0013097438,0.00004313447,0.00043367138,0.012002763],"genre_scores_gemma":[0.93543255,0.033751775,0.0006718825,0.0011755804,0.00087980443,0.00017700171,0.000121054036,0.00027003748,0.027520318],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9950466,0.0002606152,0.000690575,0.0011397853,0.0014202023,0.0014421843],"domain_scores_gemma":[0.9975252,0.00022849851,0.00021563175,0.0013993087,0.0001001819,0.0005311831],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0010861161,0.00060676946,0.00109609,0.0005544146,0.00025212643,0.000077466306,0.000582007,0.00019068371,0.0024031503],"category_scores_gemma":[0.00014567167,0.00054411695,0.0004670496,0.00073008967,0.00020803716,0.00017312815,0.00046534534,0.0010782386,0.0011060392],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003503551,0.0018031023,0.0035323105,0.0010741367,0.0009181828,0.005085667,0.0023482658,0.000018559318,0.9634387,0.00010891564,0.0027204338,0.018601386],"study_design_scores_gemma":[0.029905312,0.0022188274,0.12832198,0.0010283985,0.0018389407,0.0023172125,0.004598334,0.00041698283,0.537078,0.00032647612,0.28970417,0.0022453414],"about_ca_topic_score_codex":0.0001409928,"about_ca_topic_score_gemma":0.000027013013,"teacher_disagreement_score":0.42636067,"about_ca_system_score_codex":0.0001338573,"about_ca_system_score_gemma":0.00026684868,"threshold_uncertainty_score":0.999701},"labels":[],"label_agreement":null},{"id":"W4389232148","doi":"10.1182/blood-2023-183001","title":"Improved Survival of R/R Double Hit/Triple Hit Lymphoma in the Era of CD19 Chimeric Antigen T Cell (CART) Therapy","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of New Brunswick","funders":"","keywords":"Medicine; Internal medicine; Cart; Diffuse large B-cell lymphoma; Progression-free survival; Chemoimmunotherapy; BCL6; Oncology; Gastroenterology; Lymphoma; Rituximab; Immunology; Chemotherapy; B cell","score_opus":0.033491921752018955,"score_gpt":0.2998034567588199,"score_spread":0.26631153500680094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389232148","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99104685,0.00081723306,0.0000022640943,0.00042802692,0.00013805475,0.00093503454,0.000017373386,0.00004491428,0.0065702605],"genre_scores_gemma":[0.99553853,0.0015735272,0.000054351593,0.000063885,0.0001358442,0.00004695852,0.00003872915,0.000044512548,0.0025036735],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99814814,0.0001474547,0.0004036343,0.000273762,0.0006050021,0.00042201873],"domain_scores_gemma":[0.99882406,0.00018415267,0.00012270843,0.00068651425,0.00011089005,0.000071691786],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00094370835,0.00016901163,0.00047509803,0.00020253003,0.000039688144,0.00001255691,0.000360571,0.000104628954,0.0005401863],"category_scores_gemma":[0.000029264815,0.00012004001,0.00018693185,0.0013402303,0.00011658866,0.000041390475,0.00007010984,0.00021472322,0.00003050142],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00088211993,0.0015194668,0.05933367,0.000104659186,0.00015547863,0.00003990739,0.0018821524,0.0000023755915,0.92345756,0.000028629402,0.00029884282,0.01229513],"study_design_scores_gemma":[0.027694017,0.0011518614,0.22837484,0.000051746112,0.000052219762,0.000017199802,0.00092073344,0.00020840632,0.7382699,0.00006171725,0.0030365419,0.00016081962],"about_ca_topic_score_codex":0.0012701232,"about_ca_topic_score_gemma":0.00007663765,"teacher_disagreement_score":0.18518767,"about_ca_system_score_codex":0.000024495537,"about_ca_system_score_gemma":0.00025456143,"threshold_uncertainty_score":0.5914661},"labels":[],"label_agreement":null},{"id":"W4389232661","doi":"10.1182/blood-2023-174956","title":"Fixed Duration Mosunetuzumab Plus Polatuzumab Vedotin Has Promising Efficacy and a Manageable Safety Profile in Patients with BTKi Relapsed/Refractory Mantle Cell Lymphoma: Initial Results from a Phase Ib/II Study","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); McGill University; Jewish General Hospital","funders":"","keywords":"Mantle cell lymphoma; Medicine; Internal medicine; Neutropenia; Ibrutinib; Gastroenterology; Population; Adverse effect; Febrile neutropenia; Oncology; Pharmacology; Lymphoma; Chemotherapy; Leukemia; Chronic lymphocytic leukemia","score_opus":0.025440544477267114,"score_gpt":0.2851808303898294,"score_spread":0.25974028591256226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389232661","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935476,0.00010388291,0.000006585225,0.00013137405,0.000091049544,0.0039893575,0.00021319489,0.00018032014,0.0017366338],"genre_scores_gemma":[0.99534386,0.000022947243,0.0002573112,0.000025595926,0.00014600657,0.00010983445,0.001313976,0.0000924504,0.0026880323],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99685836,0.00023465717,0.00069469184,0.0008239372,0.00081778463,0.0005705881],"domain_scores_gemma":[0.9985117,0.00027874616,0.00021031631,0.000656816,0.00013419052,0.00020825113],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00050304877,0.000328768,0.0005461342,0.00041866818,0.00032799304,0.00010374578,0.00015925274,0.00016309271,0.00019008835],"category_scores_gemma":[0.0002479544,0.00029001018,0.000051216277,0.00086850935,0.000107976564,0.00023027521,0.00021118221,0.0003775313,0.000054821245],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42519066,0.1580209,0.089308366,0.0010875679,0.0024873244,0.00738483,0.0954884,0.00021952594,0.12384457,0.00001211958,0.004099519,0.09285622],"study_design_scores_gemma":[0.5959631,0.016333142,0.36676842,0.00053400855,0.00045989675,0.00001475309,0.0019875928,0.0025796674,0.013053736,0.000022046432,0.0016254295,0.00065820187],"about_ca_topic_score_codex":0.0009850436,"about_ca_topic_score_gemma":0.00023804985,"teacher_disagreement_score":0.27746007,"about_ca_system_score_codex":0.000340127,"about_ca_system_score_gemma":0.00049165846,"threshold_uncertainty_score":0.9999552},"labels":[],"label_agreement":null},{"id":"W4389233282","doi":"10.1182/blood-2023-190037","title":"Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Shows Rapid Primary Engraftment with CD33-Negative Hematopoiesis in Patients with High-Risk Acute Myeloid Leukemia (AML) and Avoids Hematopoietic Toxicity during Gemtuzumab Ozogamicin (GO) Maintenance Post-Hematopoietic Cell Transplant (HCT)","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"CD33; Plerixafor; Myeloid leukemia; CD34; Medicine; Hematopoietic stem cell transplantation; Haematopoiesis; Leukemia; Stem cell; Myeloid; Immunology; Cancer research; Transplantation; Internal medicine; Oncology; Biology; CXCR4; Immune system","score_opus":0.00656140965244994,"score_gpt":0.21476699234294463,"score_spread":0.2082055826904947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389233282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99461466,0.00036681758,0.00009690761,0.00033585235,0.00008613371,0.003354402,0.0003825612,0.00040199928,0.00036068898],"genre_scores_gemma":[0.99457306,0.0013915249,0.001487621,0.0002737061,0.00011675296,0.00040007726,0.00036057958,0.00026852137,0.0011281484],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99344724,0.0003921776,0.0010302655,0.0016067849,0.0017724073,0.0017511117],"domain_scores_gemma":[0.9969004,0.0005546208,0.00041444876,0.0011268503,0.00041597584,0.00058775354],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00074766646,0.0010505611,0.001664387,0.00094476715,0.00039460938,0.00013184539,0.00044721965,0.00038178617,0.0002551226],"category_scores_gemma":[0.00008074624,0.00081994326,0.0002505429,0.00164632,0.00049089064,0.00031793342,0.00024798815,0.0012820221,0.00003962646],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018659607,0.0052846675,0.35972056,0.004765871,0.0031545009,0.0069560036,0.02200554,0.00020467957,0.57775307,0.000034663957,0.0002880167,0.0011728337],"study_design_scores_gemma":[0.057382558,0.004912684,0.3565523,0.0021143544,0.0017374693,0.0007966269,0.0016920001,0.0001478948,0.5730904,0.00008043837,0.000054218664,0.001439097],"about_ca_topic_score_codex":0.00045833903,"about_ca_topic_score_gemma":0.0005482474,"teacher_disagreement_score":0.03872295,"about_ca_system_score_codex":0.00091656536,"about_ca_system_score_gemma":0.0005254177,"threshold_uncertainty_score":0.9994251},"labels":[],"label_agreement":null},{"id":"W4389233418","doi":"10.1182/blood-2023-182447","title":"Harnessing TCR/CAR Antagonism to Enhance Immunotherapeutic Precision","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"T-cell receptor; Chimeric antigen receptor; Antigen; Adoptive cell transfer; Biology; CD19; Immunology; Immunotherapy; T cell; Cancer research; Leukemia; Cell biology; Immune system","score_opus":0.033525931763121374,"score_gpt":0.35828287330636066,"score_spread":0.3247569415432393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389233418","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990906,0.00063781114,0.00015283095,0.001621666,0.00026566675,0.00059387734,0.0000052787445,0.00027027348,0.005546569],"genre_scores_gemma":[0.95909077,0.00041682913,0.00058423035,0.0006869595,0.00043525515,0.00006800231,0.000024416093,0.00007935516,0.03861419],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984285,0.00005821898,0.00021178405,0.000349591,0.00050862785,0.00044324138],"domain_scores_gemma":[0.9990384,0.00012786899,0.000030972795,0.00056136394,0.00008510658,0.00015630417],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00044650625,0.0001404137,0.00024810855,0.00024047834,0.00011253166,0.000054997563,0.00017127463,0.000086755485,0.0010270837],"category_scores_gemma":[0.00008431571,0.00012491751,0.000098725825,0.00078149285,0.000040029667,0.000059355953,0.000099288285,0.00022727768,0.0014974995],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015974064,0.00016459433,0.00080383505,0.000033783657,0.00007722642,0.00007688983,0.0005183407,0.0000022758786,0.87267977,0.000010089405,0.00039465885,0.12507881],"study_design_scores_gemma":[0.0016742753,0.0003965451,0.013290277,0.00017536199,0.000060634695,0.000060607323,0.00008951248,0.00007135234,0.9281571,0.0001496838,0.055710696,0.0001639408],"about_ca_topic_score_codex":0.000033478216,"about_ca_topic_score_gemma":0.0000033820518,"teacher_disagreement_score":0.12491488,"about_ca_system_score_codex":0.000053843472,"about_ca_system_score_gemma":0.00010206814,"threshold_uncertainty_score":0.9998861},"labels":[],"label_agreement":null},{"id":"W4389233438","doi":"10.1182/blood-2023-178786","title":"Matching-Adjusted Indirect Comparison (MAIC) of Efficacy and Safety of Lisocabtagene Maraleucel (liso-cel) and Mosunetuzumab for the Treatment (Tx) of Third Line or Later (3L+) Relapsed or Refractory (R/R) Follicular Lymphoma (FL)","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Medicine; Population; Internal medicine; Oncology; Refractory (planetary science); Monoclonal; Monoclonal antibody; Gastroenterology; Immunology; Antibody; Biology","score_opus":0.05250218656409533,"score_gpt":0.32336730339557646,"score_spread":0.2708651168314811,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389233438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943416,0.0028742384,0.000024287841,0.0002927638,0.00007110967,0.0020732782,0.00013315957,0.000058295667,0.0001312603],"genre_scores_gemma":[0.9874179,0.0058546257,0.0006083504,0.000034471555,0.00009523073,0.000097593314,0.00010201162,0.00007038398,0.00571946],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978842,0.00014532858,0.00075941655,0.00038634552,0.0004622524,0.00036242165],"domain_scores_gemma":[0.9970827,0.0016746456,0.0003163196,0.00062397536,0.00016926797,0.00013307997],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006341969,0.00027846126,0.0010427756,0.00023690893,0.00010256846,0.000013519425,0.0001643388,0.00020511827,0.00016479552],"category_scores_gemma":[0.0001726198,0.00016338348,0.00018195846,0.0005087143,0.00023686534,0.00004564503,0.00010134275,0.00013568073,0.0000025518189],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07871413,0.010313919,0.023332106,0.0031653377,0.0070021497,0.00022190275,0.016735611,0.00014785228,0.6833044,0.000054695865,0.00098103,0.17602687],"study_design_scores_gemma":[0.113442615,0.021521432,0.2054174,0.00094567164,0.0033287094,0.00013271382,0.0019881283,0.0026360955,0.63466394,0.00007836223,0.015326212,0.0005187137],"about_ca_topic_score_codex":0.00029389097,"about_ca_topic_score_gemma":0.00018789568,"teacher_disagreement_score":0.18208529,"about_ca_system_score_codex":0.000073451716,"about_ca_system_score_gemma":0.00021686521,"threshold_uncertainty_score":0.66625845},"labels":[],"label_agreement":null},{"id":"W4389233512","doi":"10.1182/blood-2023-177527","title":"Human iPSC-Derived NK Cells with Knock-in of the BCL2 G101V Mutation Are Resistant to Venetoclax and Demonstrate Improved Anti-AML Activity In Vivo","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Venetoclax; Induced pluripotent stem cell; Cancer research; Biology; Immunotherapy; Leukemia; Immunology; Immune system; Embryonic stem cell; Genetics; Gene; Chronic lymphocytic leukemia","score_opus":0.02075981551833654,"score_gpt":0.2862143710152169,"score_spread":0.26545455549688035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389233512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99813336,0.000039075825,0.0000019439344,0.00029890705,0.000020125297,0.00091688393,0.000015899357,0.000025550004,0.0005482284],"genre_scores_gemma":[0.99917364,0.000030700405,0.000049164253,0.000025266956,0.000025139037,0.000042033073,0.0000020633636,0.000025148609,0.00062686607],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99888897,0.00011452915,0.00018928433,0.0002710128,0.00026185066,0.00027433372],"domain_scores_gemma":[0.99939597,0.0000703252,0.000082487255,0.00031369593,0.000058093945,0.00007944874],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003350953,0.00012152217,0.0002786452,0.00019146407,0.00005087498,0.00001667893,0.00009418237,0.000070934206,0.000046702095],"category_scores_gemma":[0.00003748461,0.00008899006,0.000036241658,0.0007086792,0.00008812614,0.00004137773,0.0000623485,0.00021817788,0.000002688452],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003486034,0.0001541945,0.0259823,0.00014471199,0.000030309746,0.000106059815,0.00049303385,0.0000320692,0.97165155,0.000002520903,0.000017326847,0.0010373285],"study_design_scores_gemma":[0.0028069643,0.0003112083,0.3680907,0.00021110482,0.000023252318,0.000006642744,0.00028161524,0.00019096553,0.6279699,0.000020260743,0.00001858811,0.00006878878],"about_ca_topic_score_codex":0.0006341972,"about_ca_topic_score_gemma":0.0029024007,"teacher_disagreement_score":0.3436816,"about_ca_system_score_codex":0.000073770025,"about_ca_system_score_gemma":0.0001567702,"threshold_uncertainty_score":0.36289096},"labels":[],"label_agreement":null},{"id":"W4389234406","doi":"10.1182/blood-2023-177591","title":"Molecular Determinants of Response to Mosunetuzumab Plus CHOP in Patients with Previously Untreated (1L) Diffuse Large B Cell Lymphoma (DLBCL)","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"CHOP; Medicine; Rituximab; Oncology; Internal medicine; Lymphoma; Diffuse large B-cell lymphoma; Chemotherapy regimen; Biomarker; Gene signature; Immunology; Chemotherapy; Cancer research; Biology; Gene expression; Gene","score_opus":0.009579933272469627,"score_gpt":0.2652194575617714,"score_spread":0.25563952428930176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389234406","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99791133,0.00008230903,0.0000024344288,0.00005156448,0.000028519913,0.0014925463,0.000048680326,0.00008464385,0.00029797523],"genre_scores_gemma":[0.9968434,0.00002682114,0.00007165241,0.000092879534,0.000015491947,0.00008987136,0.000040692932,0.00008370755,0.0027354867],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997583,0.00020416561,0.00037825663,0.00043519962,0.00071474264,0.00068466604],"domain_scores_gemma":[0.998604,0.00012824596,0.00008433205,0.0007335104,0.00017219713,0.00027769565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00045931578,0.00023424551,0.0005150221,0.000528372,0.00003592264,0.000015557789,0.00021259983,0.00012214635,0.00010864009],"category_scores_gemma":[0.00021985844,0.00019582467,0.00008197093,0.0013488877,0.00004789074,0.00004466687,0.00014847172,0.00012444603,0.00010529753],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03471138,0.015765542,0.8178933,0.00038670935,0.00017706321,0.0026484032,0.0027846626,0.000024872044,0.12022955,0.0000017743297,0.00016190075,0.0052147876],"study_design_scores_gemma":[0.12891684,0.0035859484,0.71582633,0.00036023627,0.00012503359,0.000015453834,0.000092212074,0.00022727487,0.15006787,0.0000039100937,0.00051699684,0.00026187534],"about_ca_topic_score_codex":0.00016061732,"about_ca_topic_score_gemma":0.00010277534,"teacher_disagreement_score":0.10206699,"about_ca_system_score_codex":0.00018348361,"about_ca_system_score_gemma":0.0003261516,"threshold_uncertainty_score":0.79854983},"labels":[],"label_agreement":null},{"id":"W4389240069","doi":"10.1158/2326-6074.tumimm23-a053","title":"Abstract A053: Notch completes CD4 T cell help in CD8 T cells and ensures timely departure","year":2023,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Priming (agriculture); Cytotoxic T cell; CD8; Antigen-presenting cell; T cell; Cell biology; CD40; IL-2 receptor; Lymph node; Biology; Immunology; Chemistry; Antigen; Immune system; Biochemistry","score_opus":0.10310504523726723,"score_gpt":0.4104980381016099,"score_spread":0.3073929928643427,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389240069","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97571075,0.009905484,5.270044e-7,0.0041031577,0.00022656268,0.0009571278,0.00005882375,0.00011122148,0.008926359],"genre_scores_gemma":[0.96560705,0.010014142,0.000036841553,0.00015254556,0.00023484473,0.000295685,0.00006338981,0.00007635339,0.023519134],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99630886,0.00037414356,0.00038048442,0.00069562776,0.0007873066,0.0014535884],"domain_scores_gemma":[0.9974711,0.0011933455,0.000047640806,0.00068475713,0.00038815918,0.00021499516],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0019113317,0.00024883577,0.0005594259,0.0010364379,0.00022200789,0.000064500506,0.00040789717,0.00039328236,0.0049089557],"category_scores_gemma":[0.00019492059,0.00022755281,0.000091483016,0.0011984342,0.00096915907,0.00008318285,0.00041801718,0.0021663352,0.0009277456],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011044153,0.00012925574,0.028224913,0.00024254639,0.00011551775,0.0004777298,0.0006995266,0.0000126413215,0.9375999,0.000035728688,0.015987664,0.015370135],"study_design_scores_gemma":[0.0044762692,0.0007276456,0.4571661,0.0002524271,0.000018811317,0.00005509213,0.0013016333,0.00025677064,0.40728498,0.00033475997,0.12777337,0.00035214264],"about_ca_topic_score_codex":0.0017261878,"about_ca_topic_score_gemma":0.0005863257,"teacher_disagreement_score":0.530315,"about_ca_system_score_codex":0.00032320857,"about_ca_system_score_gemma":0.0005592145,"threshold_uncertainty_score":0.99985015},"labels":[],"label_agreement":null},{"id":"W4389241392","doi":"10.1158/2326-6074.tumimm23-b007","title":"Abstract B007: Phenotypic Signatures of Circulating Neoantigen-Reactive CD8+ T Cells in Patients with Metastatic Cancers","year":2023,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"CD8; T-cell receptor; Cytotoxic T cell; Immunotherapy; T cell; Biology; Antigen; Cancer immunotherapy; Immunology; Circulating tumor cell; Cancer research; Phenotype; Cancer; Immune system; Metastasis; Gene; In vitro; Genetics","score_opus":0.06538773514156315,"score_gpt":0.38750745095334577,"score_spread":0.3221197158117826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389241392","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944211,0.0017040806,0.0000028999877,0.00024928054,0.0001765342,0.0013964222,0.000047248523,0.00004846099,0.0019539623],"genre_scores_gemma":[0.9973974,0.00052907236,0.0000496665,0.000034384044,0.000060058544,0.0002567028,0.0000604076,0.00007083912,0.0015414424],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99642074,0.00034061456,0.00043872907,0.0005578581,0.0011108476,0.0011311863],"domain_scores_gemma":[0.99750376,0.0008124789,0.00013098349,0.0006019711,0.0008250204,0.00012578012],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013462973,0.00022412672,0.00062446477,0.0012211523,0.00013424699,0.000019679357,0.0003558771,0.00017697008,0.002470825],"category_scores_gemma":[0.00024409637,0.00018716768,0.00009157779,0.002509393,0.00080563064,0.00011946209,0.0001655377,0.0016735472,0.00009615782],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067698783,0.00030541146,0.13419038,0.00039148313,0.0010730521,0.00020986426,0.0024231223,0.0014854929,0.8208587,0.000043233704,0.00072165823,0.03152773],"study_design_scores_gemma":[0.0064220587,0.00096757745,0.91998374,0.00046478127,0.00003498264,0.0000025847467,0.0014720608,0.00022933663,0.06934047,0.0001419456,0.00072227645,0.00021821188],"about_ca_topic_score_codex":0.0036246039,"about_ca_topic_score_gemma":0.00036208227,"teacher_disagreement_score":0.7857933,"about_ca_system_score_codex":0.001072753,"about_ca_system_score_gemma":0.0015103066,"threshold_uncertainty_score":0.99844104},"labels":[],"label_agreement":null},{"id":"W4389241834","doi":"10.1158/2326-6074.tumimm23-b005","title":"Abstract B005: Molecular, metabolic and functional CD4 T cell paralysis in lymph node impedes tumor control","year":2023,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"CD8; Biology; T cell; Lymph node; Adoptive cell transfer; Cancer research; Tumor-infiltrating lymphocytes; Epitope; Antigen; Immunology; Cell biology; Immune system","score_opus":0.053916213096303046,"score_gpt":0.3794539962917979,"score_spread":0.3255377831954948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389241834","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9632997,0.029432656,0.000010117274,0.004065764,0.00013683987,0.0006442239,0.000033283577,0.000075596225,0.0023017982],"genre_scores_gemma":[0.98340917,0.007921193,0.000019888415,0.00028349864,0.00014899237,0.0007679284,0.000045610126,0.000059109636,0.007344624],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9965533,0.0004122803,0.00037711352,0.000638488,0.0008017296,0.0012170717],"domain_scores_gemma":[0.998087,0.0006749421,0.000051200383,0.0005813276,0.0004087726,0.00019676432],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019937197,0.00021712795,0.0006046379,0.0013381785,0.00017862981,0.000057678782,0.00024122541,0.00020600726,0.0048130136],"category_scores_gemma":[0.00031762948,0.00019819262,0.00013906344,0.0017892665,0.0007780047,0.0000982435,0.00020959003,0.0012461906,0.00042535708],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00217296,0.00012776455,0.091616705,0.000106841886,0.00042057794,0.0005401736,0.00016028548,0.00007988878,0.8929096,0.000119586985,0.00097566604,0.010769955],"study_design_scores_gemma":[0.008059416,0.00014634721,0.9085829,0.00007119303,0.00005470845,0.000066842156,0.0005608398,0.00049574714,0.07269591,0.0003343475,0.008717025,0.00021470393],"about_ca_topic_score_codex":0.002278326,"about_ca_topic_score_gemma":0.00009928829,"teacher_disagreement_score":0.8202137,"about_ca_system_score_codex":0.0003108916,"about_ca_system_score_gemma":0.0009234753,"threshold_uncertainty_score":0.99609673},"labels":[],"label_agreement":null},{"id":"W4389241863","doi":"10.1158/1535-7163.targ-23-c028","title":"Abstract C028: A phase 1/2 study investigating the safety and efficacy of autologous TAC T cells in subjects with unresectable, locally advanced or metastatic claudin 18.2+ solid tumors","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Chimeric antigen receptor; Radioimmunotherapy; Cancer research; Leukapheresis; Immunotherapy; Cancer; Monoclonal antibody; Immunology; Pharmacology; Antibody; Stem cell; Internal medicine; Biology; CD34","score_opus":0.056765147181907914,"score_gpt":0.3818371142617724,"score_spread":0.3250719670798645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389241863","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950389,0.0011897564,0.00020857646,0.0005798746,0.000048244856,0.0026333237,0.00002757769,0.00007364039,0.00020005192],"genre_scores_gemma":[0.9977384,0.0006279501,0.00032716888,0.00063412986,0.000023280048,0.00016859181,0.000012840377,0.000098560944,0.00036905127],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971676,0.00029835312,0.0006015302,0.0004925821,0.0008082525,0.0006317239],"domain_scores_gemma":[0.9982912,0.0005565865,0.00022190249,0.00059959805,0.00016772164,0.00016298391],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009315265,0.00033092024,0.0007232495,0.00027276922,0.0001137145,0.00004114186,0.00027589194,0.00006817254,0.00019933787],"category_scores_gemma":[0.00009464605,0.00021119056,0.00007550141,0.0016897517,0.0003912298,0.000058257127,0.00010444097,0.00061046286,0.000004061105],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009122101,0.0009025276,0.0028762452,0.00034081176,0.0009308981,0.0015648254,0.005083534,0.007814811,0.8996138,0.000011416295,0.000014446666,0.07172459],"study_design_scores_gemma":[0.07992512,0.014960535,0.09115031,0.0020494056,0.0012622897,0.00018759067,0.012494756,0.021814516,0.7727379,0.00022243182,0.001970478,0.0012246264],"about_ca_topic_score_codex":0.0003972926,"about_ca_topic_score_gemma":0.00062830787,"teacher_disagreement_score":0.12687586,"about_ca_system_score_codex":0.00017000033,"about_ca_system_score_gemma":0.0008191642,"threshold_uncertainty_score":0.8612101},"labels":[],"label_agreement":null},{"id":"W4389242080","doi":"10.1158/1535-7163.targ-23-b035","title":"Abstract B035: A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors","year":2023,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Cytokine release syndrome; Adverse effect; Chimeric antigen receptor; Pneumonitis; Internal medicine; T cell; Pharmacokinetics; Leukapheresis; Immunotherapy; Refractory (planetary science); Oncology; Gastroenterology; Pharmacology; Cancer; Immunology; Immune system; Lung; Stem cell","score_opus":0.07208883215688347,"score_gpt":0.3961923356484441,"score_spread":0.3241035034915606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389242080","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99553734,0.0012004205,0.000026938344,0.0011293762,0.00016082334,0.0012540789,0.000028394525,0.00011061358,0.0005519982],"genre_scores_gemma":[0.99662226,0.0011010868,0.00019457626,0.00078538933,0.00012902194,0.000075158416,0.000033938664,0.000094959556,0.00096358254],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99753135,0.00016672292,0.00073001557,0.0004459761,0.00058637105,0.0005395694],"domain_scores_gemma":[0.998682,0.00029308564,0.00022620363,0.0004974795,0.000110981055,0.00019022277],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00074949814,0.0002710909,0.00069476163,0.00034032942,0.00009914411,0.000019134948,0.00017921418,0.00021906686,0.00045030337],"category_scores_gemma":[0.00022977324,0.00023366892,0.00013594766,0.0009479497,0.00030888245,0.000040843875,0.00010506751,0.0006639874,0.0000065039208],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.040726554,0.00062844146,0.00021891456,0.00017877246,0.0002958586,0.00053643284,0.0021372298,0.00018509763,0.7938264,0.000024080176,0.00003855026,0.16120365],"study_design_scores_gemma":[0.4675491,0.020061187,0.029140292,0.0022165724,0.00065016403,0.00012714122,0.0015046261,0.012124685,0.42362392,0.00050918193,0.041059125,0.0014340145],"about_ca_topic_score_codex":0.0002461304,"about_ca_topic_score_gemma":0.00007699549,"teacher_disagreement_score":0.42682254,"about_ca_system_score_codex":0.00023822609,"about_ca_system_score_gemma":0.00077050197,"threshold_uncertainty_score":0.9528742},"labels":[],"label_agreement":null},{"id":"W4389242918","doi":"10.1182/blood-2023-179387","title":"Durable Efficacy and Manageable Safety in Patients Age ≥ 75 Years with Relapsed/Refractory Large B-Cell Lymphoma Treated with Tisagenlecleucel in the Real-World Setting","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Cytokine release syndrome; Internal medicine; Oncology; Blinatumomab; Clinical trial; Salvage therapy; Refractory (planetary science); Chimeric antigen receptor; CD19; Immunotherapy; Chemotherapy; Cancer","score_opus":0.011834043048669978,"score_gpt":0.25214075025714483,"score_spread":0.24030670720847486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389242918","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9728662,0.0000679488,4.404986e-7,0.000105384286,0.000011249889,0.0010032867,0.000013225001,0.00007946957,0.025852835],"genre_scores_gemma":[0.9854195,0.0002449128,0.000074784046,0.00012430541,0.0000290871,0.00004593293,0.00011914728,0.00006509543,0.01387725],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980642,0.0001821675,0.00025636633,0.00040243007,0.0005013679,0.0005934275],"domain_scores_gemma":[0.99908566,0.00024405471,0.00006873855,0.00046601053,0.000034816538,0.000100687714],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00071546214,0.00019294118,0.00031234347,0.00039508,0.00008762369,0.000043426546,0.00014941303,0.00007676922,0.00010996706],"category_scores_gemma":[0.00003249158,0.00013214635,0.000028700291,0.0015482034,0.000069644164,0.00008817047,0.00006648559,0.00030711442,0.000044880348],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026598752,0.0040658186,0.9783619,0.00016432042,0.00011006254,0.003482306,0.0022550165,0.000016563028,0.0027242624,0.000015305042,0.000491577,0.005653017],"study_design_scores_gemma":[0.04740965,0.0008249472,0.94782114,0.00023361066,0.000069472604,0.000011405577,0.00038600678,0.000057131692,0.0006789875,0.0000052790724,0.0023416413,0.00016072062],"about_ca_topic_score_codex":0.00088430336,"about_ca_topic_score_gemma":0.0013947992,"teacher_disagreement_score":0.044749774,"about_ca_system_score_codex":0.00011035119,"about_ca_system_score_gemma":0.000077680335,"threshold_uncertainty_score":0.5388772},"labels":[],"label_agreement":null},{"id":"W4389243266","doi":"10.1182/blood-2023-187295","title":"CAR T-Related Toxicities Based on Dynamic Proteomic Profiles Identifies Risk Factors for Cytokine Release Syndrome (CRS) and Immune Effector Cell -Associated Neurotoxicity Syndrome (ICANS)","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cytokine release syndrome; Medicine; Receiver operating characteristic; Oncology; Internal medicine; Immunology; Area under the curve; Immune system; Pharmacology; Immunotherapy; Chimeric antigen receptor","score_opus":0.012366434127539882,"score_gpt":0.255808980568887,"score_spread":0.24344254644134714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389243266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910806,0.000117545445,0.00000945667,0.00015459416,0.00018029952,0.006591262,0.0011648214,0.000604896,0.00009654432],"genre_scores_gemma":[0.9930787,0.0001156301,0.000026346806,0.000031548407,0.000020514968,0.0009271895,0.0006360911,0.00017530439,0.004988675],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99663275,0.00039860865,0.0005988163,0.0007859958,0.0007269878,0.0008568298],"domain_scores_gemma":[0.99755174,0.0010589658,0.00026990255,0.000673923,0.0001459191,0.00029957786],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000824897,0.00049880135,0.0009170854,0.00065232074,0.0003474286,0.00009676165,0.0002515142,0.0003212204,0.0003058201],"category_scores_gemma":[0.0010219542,0.00043944168,0.00035110774,0.0008727021,0.00024973683,0.00010805009,0.00010508371,0.0005922254,0.00007574796],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000995974,0.001037757,0.021248449,0.0009775585,0.00044542822,0.0005821561,0.00025330178,0.00010297867,0.97417355,0.0000024854671,0.00006269403,0.000117694224],"study_design_scores_gemma":[0.014615473,0.006424131,0.4973742,0.0005934178,0.00069772557,0.000144841,0.00015623849,0.0113896085,0.4678448,0.00013075321,0.000020977119,0.00060781365],"about_ca_topic_score_codex":0.00036947356,"about_ca_topic_score_gemma":0.000023771305,"teacher_disagreement_score":0.5063287,"about_ca_system_score_codex":0.00019571622,"about_ca_system_score_gemma":0.00018901983,"threshold_uncertainty_score":0.99980575},"labels":[],"label_agreement":null},{"id":"W4389243316","doi":"10.1182/blood-2023-189747","title":"Bclxl Prevents Progressive Exhaustion in BCMA CAR T Cells with Maintenance of High TCF1 Expressing T Cells","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Stimulation; In vivo; Antigen; Biology; Immunology; Medicine; Cancer research; Endocrinology; Genetics","score_opus":0.01847844680771295,"score_gpt":0.2882705134185854,"score_spread":0.26979206661087246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389243316","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977832,0.00014961346,0.000017044575,0.000097078584,0.0000812134,0.0009142822,0.00001572938,0.00006973069,0.0008721098],"genre_scores_gemma":[0.99224,0.00011193209,0.0008373462,0.000024637864,0.00010760063,0.00009629736,0.000024994586,0.00004877872,0.0065084076],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998276,0.00008004413,0.00028681647,0.0003501834,0.000548876,0.00045808],"domain_scores_gemma":[0.9991506,0.00007487432,0.00012869781,0.0004055189,0.00012606542,0.00011429603],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003052457,0.00016292855,0.00035700042,0.00024322694,0.00003386582,0.00001622354,0.00014134747,0.00009967423,0.0003993531],"category_scores_gemma":[0.000031146148,0.00013046313,0.00006131537,0.00067243533,0.000121496356,0.000075376745,0.00007467211,0.00026225776,0.000045108536],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000496488,0.0006484976,0.0068807984,0.00037157378,0.00008721307,0.000657155,0.00073749915,0.0000865765,0.9847101,0.0000103635675,0.0004509296,0.004862813],"study_design_scores_gemma":[0.006422493,0.0005827098,0.016238967,0.0013426964,0.000077505574,0.000037369042,0.00026556884,0.00014171423,0.97435,0.00005895623,0.0003357914,0.00014624555],"about_ca_topic_score_codex":0.00009443947,"about_ca_topic_score_gemma":0.000009144569,"teacher_disagreement_score":0.01036011,"about_ca_system_score_codex":0.00005889269,"about_ca_system_score_gemma":0.00013520321,"threshold_uncertainty_score":0.5320132},"labels":[],"label_agreement":null},{"id":"W4389243379","doi":"10.1182/blood-2023-187663","title":"CAR T Cell Exhaustion but Not <i>Ex Vivo</i> Cytotoxicity Is Predictive of Patient Clinical Response: An Interim Analysis of ACIT001/EXC002, a Phase Ib/II Trial of Decentralized Production of CAR T Cells for Treatment of Relapsed/Refractory Aggressive NHL and ALL","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; University of Alberta","funders":"","keywords":"Chimeric antigen receptor; Medicine; Immunophenotyping; Ex vivo; Immunotherapy; Oncology; Immunology; Lymphoma; Internal medicine; Cytotoxic T cell; T cell; Antigen; Immune system; In vivo; Biology; In vitro","score_opus":0.0644916410500575,"score_gpt":0.3929571026369683,"score_spread":0.3284654615869108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389243379","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945057,0.00022950475,0.00002167666,0.00004954833,0.00018822432,0.0034387927,0.0015376048,0.000018729646,0.000010226294],"genre_scores_gemma":[0.99722826,0.0018131201,0.00023936878,0.000009124002,0.00008165294,0.000147115,0.00016271012,0.000032750107,0.000285868],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9963918,0.000624898,0.0014964845,0.00054768694,0.00066167023,0.00027751675],"domain_scores_gemma":[0.99610853,0.0006652261,0.001549875,0.00069403066,0.0007949313,0.00018740553],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011330292,0.00024117286,0.0015261055,0.0006364969,0.00003187981,0.0000029832563,0.00011468899,0.0002382733,0.000098344746],"category_scores_gemma":[0.0006866224,0.00020598684,0.0006206713,0.0007482924,0.00039892652,0.00007803433,0.00006299795,0.000118614604,2.561532e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26893783,0.013771686,0.0006897497,0.0002787485,0.003031149,0.000009100867,0.0056550205,0.000036134632,0.70585144,4.382724e-7,0.00007135603,0.0016673638],"study_design_scores_gemma":[0.08416624,0.059174933,0.00095646066,0.000149613,0.0058319233,0.0000021994954,0.0008077828,0.0005470861,0.84807587,0.0000036082972,0.00018040207,0.00010386147],"about_ca_topic_score_codex":0.00022679847,"about_ca_topic_score_gemma":0.000018568597,"teacher_disagreement_score":0.18477157,"about_ca_system_score_codex":0.000100670826,"about_ca_system_score_gemma":0.00028792908,"threshold_uncertainty_score":0.83998996},"labels":[],"label_agreement":null},{"id":"W4389243535","doi":"10.1182/blood-2023-174432","title":"Preliminary Findings of a Phase Ib/II Trial Indicate Manageable Safety and Promising Efficacy for Mosunetuzumab in Combination with Lenalidomide (M+Len) in Previously Untreated (1L) Follicular Lymphoma (FL)","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Lenalidomide; Medicine; Internal medicine; Oncology; Follicular lymphoma; Phases of clinical research; Chemotherapy; Chemotherapy regimen; Lymphoma; Multiple myeloma","score_opus":0.023303801925209075,"score_gpt":0.30396566331727964,"score_spread":0.28066186139207056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389243535","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99308175,0.00033757676,0.000027287722,0.00033176033,0.000021773405,0.005912553,0.0000135320015,0.00006533125,0.00020842878],"genre_scores_gemma":[0.9973974,0.0002732693,0.00026070833,0.000018246395,0.00003248282,0.00025633848,0.00016100638,0.000056533434,0.0015439718],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9980177,0.00012215877,0.0005618442,0.00043831472,0.00039151905,0.00046842935],"domain_scores_gemma":[0.9990566,0.00031482324,0.00015024575,0.00029381667,0.00007722372,0.00010731129],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011458623,0.00020774362,0.00062602473,0.0007216092,0.00008345499,0.000024308538,0.00011981208,0.00014268653,0.00003671338],"category_scores_gemma":[0.00028710434,0.00018188231,0.00008303899,0.0011882039,0.00009940076,0.000120554076,0.00009029627,0.00014658041,0.0000025515315],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7678294,0.021790227,0.0138479415,0.0026771391,0.0011198473,0.0013599789,0.008219026,0.00018692864,0.100994505,0.0002113145,0.00013559376,0.08162809],"study_design_scores_gemma":[0.8821898,0.019057347,0.026964528,0.0016767295,0.00046414844,0.00009403344,0.00021611252,0.004307719,0.06407965,0.00018915853,0.00045604596,0.00030472377],"about_ca_topic_score_codex":0.00022534338,"about_ca_topic_score_gemma":0.00004616902,"teacher_disagreement_score":0.1143604,"about_ca_system_score_codex":0.00016495914,"about_ca_system_score_gemma":0.00022551192,"threshold_uncertainty_score":0.74169457},"labels":[],"label_agreement":null},{"id":"W4389244101","doi":"10.1182/blood-2023-184864","title":"Targeting T-Cell Lymphoma Using CD70-Directed Cord Blood-Derived CAR-NK Cells","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Cancer research; Lymphoma; Chimeric antigen receptor; CD19; Immunotherapy; T cell; Medicine; Immunology; Antigen; Cancer; Internal medicine; Immune system","score_opus":0.03353847504303479,"score_gpt":0.2951050653562019,"score_spread":0.2615665903131671,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389244101","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99107766,0.000721386,0.000015131615,0.000092795,0.00034148572,0.0007046758,0.000022479675,0.0008518916,0.006172483],"genre_scores_gemma":[0.9796978,0.0007455373,0.0021508182,0.00020469794,0.00085248536,0.000039287268,0.00012179572,0.00019712246,0.015990453],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99721247,0.00015602334,0.00042224026,0.0005825675,0.0007159486,0.0009107413],"domain_scores_gemma":[0.9985027,0.00023330127,0.00011432737,0.0005866554,0.00022710292,0.00033596138],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005001438,0.00030555995,0.0005112663,0.00034001595,0.00020818796,0.00006336815,0.00023554603,0.00020187447,0.001503793],"category_scores_gemma":[0.00015246347,0.00030287134,0.00020406277,0.0012210616,0.000110281246,0.00006609956,0.00018836671,0.00027994535,0.00046179452],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019446375,0.00084851397,0.003918336,0.00025261223,0.00023987125,0.00086500164,0.0003645004,0.000022142425,0.9906976,0.0000015921617,0.0010731597,0.0015221626],"study_design_scores_gemma":[0.011149003,0.0003857154,0.0014187358,0.00012775787,0.00044038217,0.00012329145,0.00028355137,0.002585948,0.9780761,0.000017539747,0.0050493367,0.00034266635],"about_ca_topic_score_codex":0.0003580898,"about_ca_topic_score_gemma":0.000008018475,"teacher_disagreement_score":0.012621572,"about_ca_system_score_codex":0.00008313208,"about_ca_system_score_gemma":0.000321332,"threshold_uncertainty_score":0.99994236},"labels":[],"label_agreement":null},{"id":"W4389246812","doi":"10.1182/blood-2023-173951","title":"Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase II Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Internal medicine; Cytokine release syndrome; Oncology; Diffuse large B-cell lymphoma; Phases of clinical research; Lymphoma; Transplantation; Chimeric antigen receptor; Gastroenterology; Immunology; Cancer; Clinical trial; Immunotherapy","score_opus":0.020556797315697723,"score_gpt":0.2984440166044841,"score_spread":0.2778872192887864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389246812","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905719,0.0061194496,0.0000037950633,0.000053552725,0.00008110221,0.0027265635,0.00030183312,0.00011064908,0.00003116015],"genre_scores_gemma":[0.9947625,0.0017284865,0.0002569603,0.000117406984,0.00008826177,0.00020326866,0.0003701616,0.00014512916,0.002327835],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99627227,0.00046534755,0.00066723506,0.0010364995,0.00079313247,0.0007655104],"domain_scores_gemma":[0.99854845,0.00020738828,0.0002021254,0.0006207846,0.000110806286,0.00031044576],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006970965,0.00052332325,0.0011095476,0.00065332424,0.00015806199,0.00006192209,0.00018369028,0.00013807711,0.0006814797],"category_scores_gemma":[0.00008095767,0.00039522976,0.0001065871,0.0016296447,0.00010781545,0.00018391876,0.00011924957,0.00034759234,0.00001622237],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034994885,0.07613132,0.47472617,0.000047091595,0.00073808443,0.00038333802,0.0049730656,4.4940572e-7,0.36925757,1.8533736e-7,0.00037459037,0.038373247],"study_design_scores_gemma":[0.39344645,0.016295888,0.5675602,0.000071352944,0.00021789866,0.000007783371,0.0015403565,0.00055815704,0.01852095,0.0000024632457,0.0012038832,0.00057465973],"about_ca_topic_score_codex":0.0010927675,"about_ca_topic_score_gemma":0.00026560997,"teacher_disagreement_score":0.35845155,"about_ca_system_score_codex":0.00007190151,"about_ca_system_score_gemma":0.0002277697,"threshold_uncertainty_score":0.99985},"labels":[],"label_agreement":null},{"id":"W4389247212","doi":"10.1182/blood-2023-179044","title":"CAR-T Therapy for the Treatment of Relapsed/Refractory CD19 Positive Large B Cell Lymphoma: Canadian Real-World Evidence","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Chimeric antigen receptor; Medicine; CAR T-cell therapy; Lymphoma; Clinical trial; Real world data; Refractory (planetary science); Population; Internal medicine; Oncology; Immunotherapy; Cancer; Environmental health","score_opus":0.044600783763291414,"score_gpt":0.3295677116673361,"score_spread":0.2849669279040447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389247212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9834229,0.0050686765,0.0000035295518,0.0018815654,0.0001865739,0.0022899287,0.00024389767,0.00006786392,0.0068350756],"genre_scores_gemma":[0.94173205,0.018347874,0.000039494673,0.00023195257,0.00030430238,0.00031331406,0.000068682915,0.00006116173,0.03890117],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998411,0.000086620676,0.00023641346,0.00031769954,0.00035612882,0.0005921168],"domain_scores_gemma":[0.9977267,0.0011176293,0.000071457005,0.0006350161,0.00018797969,0.00026125507],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041657194,0.00018937963,0.0003297232,0.00028365102,0.00018507398,0.0000181705,0.00018337354,0.0000894713,0.0004145023],"category_scores_gemma":[0.00004976746,0.00012617806,0.00024204484,0.00060334546,0.00008352594,0.000048454836,0.000016520462,0.00008060677,0.00005848742],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007385268,0.019247925,0.14590923,0.0004766503,0.004346074,0.0013451106,0.024775783,0.000013295772,0.5870878,0.00088485837,0.026227944,0.18230005],"study_design_scores_gemma":[0.044739846,0.009094555,0.26470166,0.0002859026,0.00067718694,0.000028665218,0.0011398403,0.0002038143,0.39637232,0.00010898767,0.28222597,0.00042126703],"about_ca_topic_score_codex":0.10319647,"about_ca_topic_score_gemma":0.1014029,"teacher_disagreement_score":0.25599802,"about_ca_system_score_codex":0.00042565007,"about_ca_system_score_gemma":0.001006149,"threshold_uncertainty_score":0.9149942},"labels":[],"label_agreement":null},{"id":"W4389247484","doi":"10.1182/blood-2023-181181","title":"Predictors of Cytokine Release Syndrome and Neurotoxicity in Patients with Large B-Cell Lymphoma and Their Impact on Survival","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Eurostars; Legend Biotech; Pharmacyclics; Aptitude Health; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Servier; Juno Therapeutics; Astellas Pharma; Swedish Orphan Biovitrum; Omeros Corporation; BeiGene; Incyte; CTI Biopharma; bluebird bio; Jazz Pharmaceuticals; Fred Hutchinson Cancer Research Center; Karyopharm Therapeutics; Atara Biotherapeutics; Massachusetts General Hospital; Leukemia and Lymphoma Society; Kite Pharma; Society for Immunotherapy of Cancer; AstraZeneca; Cidara Therapeutics; MorphoSys; Celgene; Eli Lilly and Company; Bristol-Myers Squibb; Amgen","keywords":"Medicine; Cytokine release syndrome; Internal medicine; Proportional hazards model; Oncology; Cancer; Immunotherapy","score_opus":0.01048107823113658,"score_gpt":0.24786097802336715,"score_spread":0.23737989979223056,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389247484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99876684,0.000034356686,3.1930531e-7,0.000028984703,0.0000203521,0.0006260655,0.0001476835,0.000034980014,0.0003404219],"genre_scores_gemma":[0.9996276,0.00006177515,0.0000027991491,0.000021798183,0.000017769766,0.00001207864,0.00003619117,0.00003076229,0.00018921631],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989504,0.00007667459,0.00015233389,0.00023766374,0.0003015532,0.00028138075],"domain_scores_gemma":[0.9993717,0.00013483538,0.000042519365,0.00024563435,0.000042473017,0.000162815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024236781,0.00014947365,0.00031632202,0.00021345844,0.000024652198,0.000008224908,0.000051595674,0.000057263318,0.00005442631],"category_scores_gemma":[0.000055403943,0.000093570416,0.00003653992,0.00039151486,0.00006469557,0.000036155845,0.00006294561,0.00012011913,0.000003317016],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014337023,0.0024247044,0.98752517,0.00010849791,0.00007911854,0.00013458969,0.00019350472,0.0000012912094,0.0076142806,0.000001686014,0.000019652194,0.00046383555],"study_design_scores_gemma":[0.023202218,0.0037543082,0.96333873,0.0000807389,0.000026531323,0.000020343714,0.000034312594,0.000066049295,0.009358162,0.0000054133375,0.00003604435,0.00007714435],"about_ca_topic_score_codex":0.000074958334,"about_ca_topic_score_gemma":0.00001885636,"teacher_disagreement_score":0.024186404,"about_ca_system_score_codex":0.00002258396,"about_ca_system_score_gemma":0.00005608398,"threshold_uncertainty_score":0.3815691},"labels":[],"label_agreement":null},{"id":"W4389247829","doi":"10.1182/blood-2023-173692","title":"Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies: 3-Year Follow-up from a Pivotal Phase II Study","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Jewish General Hospital; Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Medicine; Follicular lymphoma; Internal medicine; Clinical endpoint; Refractory (planetary science); Phases of clinical research; Surrogate endpoint; Adverse effect; Regimen; Gastroenterology; Chemotherapy regimen; Oncology; Surgery; Lymphoma; Clinical trial; Chemotherapy","score_opus":0.016229743080162895,"score_gpt":0.28606857835725663,"score_spread":0.26983883527709374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389247829","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959715,0.0003881123,0.000002876766,0.00021393543,0.000076272256,0.0030089817,0.00009469603,0.00016415546,0.00007946881],"genre_scores_gemma":[0.991315,0.0001399867,0.00029227967,0.00019099443,0.00007528701,0.00053145457,0.000039662435,0.000115563795,0.007299748],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971987,0.00030054245,0.0004474051,0.0007198142,0.0007436821,0.000589865],"domain_scores_gemma":[0.9985142,0.00028386092,0.000090857924,0.0006883304,0.00015074262,0.00027204005],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004814895,0.00035903242,0.0006520337,0.00044525263,0.00014667002,0.000079304205,0.00017406957,0.00013930429,0.00054480665],"category_scores_gemma":[0.00015649457,0.00026320296,0.00009507592,0.000853742,0.00009458556,0.00015816296,0.000096772,0.00021986413,0.00004078453],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20271368,0.012150587,0.67677075,0.000036077603,0.001426788,0.0015407226,0.0182246,8.141244e-7,0.044583432,9.851274e-7,0.00024940312,0.04230217],"study_design_scores_gemma":[0.19679196,0.030737098,0.76031756,0.0003089365,0.00021951637,0.0000091012125,0.0031023037,0.000025147308,0.005444872,0.000021042779,0.0025611958,0.00046124752],"about_ca_topic_score_codex":0.00044405324,"about_ca_topic_score_gemma":0.00054704247,"teacher_disagreement_score":0.08354683,"about_ca_system_score_codex":0.00010567565,"about_ca_system_score_gemma":0.0002691302,"threshold_uncertainty_score":0.999982},"labels":[],"label_agreement":null},{"id":"W4389247832","doi":"10.1182/blood-2023-178821","title":"Lymphodepletion Enables Successful BCMA CAR-T Cell Engraftment and Tumour Control in the Syngeneic Vk*MYC Model of Aggressive Myeloma","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; National Research Council Canada; Canada's Michael Smith Genome Sciences Centre; University of Ottawa; Terry Fox Research Institute; University of British Columbia","funders":"","keywords":"Chimeric antigen receptor; CD28; Multiple myeloma; Antigen; Cancer research; Immunology; Biology; T cell; Medicine; Immune system","score_opus":0.019522833264658066,"score_gpt":0.27105707369461324,"score_spread":0.25153424042995515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389247832","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99488956,0.0020512012,0.000036269314,0.0006894481,0.000027330036,0.00088719086,0.000040782077,0.000040190735,0.0013380237],"genre_scores_gemma":[0.99740714,0.0011777449,0.000057836318,0.0001840936,0.00008524754,0.00015528203,0.000024802048,0.00003009516,0.0008777866],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983731,0.00017108534,0.0002766153,0.00028511355,0.00053118117,0.00036288786],"domain_scores_gemma":[0.9990537,0.00026478525,0.00015109233,0.0003406532,0.00010263828,0.00008710489],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006353458,0.00016023793,0.00033908657,0.00022774462,0.000060889863,0.000024452384,0.00016721345,0.000088761444,0.00008332342],"category_scores_gemma":[0.00010480806,0.00011305255,0.00008453155,0.00037887043,0.00009490483,0.000043952517,0.000058191017,0.0001604941,0.000014378477],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040422735,0.0006739157,0.026449949,0.0003128218,0.00013095172,0.00033891972,0.0021639476,0.00044225878,0.96490115,0.00007240345,0.00030321997,0.00380625],"study_design_scores_gemma":[0.04162794,0.0015628305,0.11287885,0.00057507574,0.0007458878,0.00028638903,0.003673508,0.07201131,0.76442575,0.0011137844,0.00056972384,0.0005289473],"about_ca_topic_score_codex":0.00021105417,"about_ca_topic_score_gemma":0.000065245295,"teacher_disagreement_score":0.20047538,"about_ca_system_score_codex":0.00004721458,"about_ca_system_score_gemma":0.00016537096,"threshold_uncertainty_score":0.4610149},"labels":[],"label_agreement":null},{"id":"W4389248024","doi":"10.1182/blood-2023-180233","title":"Real-World Tisagenlecleucel Outcomes in Richter-Transformed Chronic Lymphocytic Leukemia: A Center for International Blood &amp; Marrow Transplant Research (CIBMTR) Analysis","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Juravinski Hospital","funders":"","keywords":"Medicine; Cytokine release syndrome; Internal medicine; Aggressive lymphoma; Oncology; Cumulative incidence; Transplantation; Rituximab; Lymphoma; Chimeric antigen receptor; Cancer; Immunotherapy","score_opus":0.06427681933567496,"score_gpt":0.3831817213200614,"score_spread":0.3189049019843864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389248024","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893193,0.00014463246,0.000059426893,0.00085811416,0.00025734075,0.0016100182,0.0003569177,0.00018612413,0.0072081103],"genre_scores_gemma":[0.95225346,0.0019261462,0.00026046566,0.000095138246,0.0004819016,0.00065368623,0.0012493564,0.00009762007,0.042982213],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957045,0.0001891939,0.00071502855,0.0007671724,0.0014022236,0.0012219076],"domain_scores_gemma":[0.99775916,0.0007300298,0.00006526449,0.0007090268,0.00044208826,0.00029442937],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018123533,0.00030921906,0.00077929645,0.003183755,0.00013598854,0.0000821,0.00051655166,0.00019889248,0.0019679966],"category_scores_gemma":[0.00025412187,0.00027785572,0.00059085677,0.003647593,0.0001545886,0.000118009586,0.00008094836,0.00060872466,0.0002145397],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021547365,0.001617159,0.81950814,0.00074671383,0.010659032,0.0008670927,0.0021571273,0.000247676,0.15552495,0.0001241084,0.002119859,0.0042733876],"study_design_scores_gemma":[0.10385809,0.0016702028,0.7848469,0.0007740079,0.005570927,0.0001266064,0.00024588636,0.009667573,0.056515925,0.00051960227,0.034959152,0.0012450975],"about_ca_topic_score_codex":0.0016863263,"about_ca_topic_score_gemma":0.017712446,"teacher_disagreement_score":0.10170335,"about_ca_system_score_codex":0.0028098081,"about_ca_system_score_gemma":0.0016261509,"threshold_uncertainty_score":0.99996734},"labels":[],"label_agreement":null},{"id":"W4389248242","doi":"10.1182/blood-2023-173302","title":"Dose Escalation of HLA-A2-WT1 CD3 T-Cell Bispecific Antibody in a Phase I Study in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Myeloid leukemia; Internal medicine; Tolerability; Refractory (planetary science); Leukemia; Oncology; Gastroenterology; Immunology; Adverse effect; Biology","score_opus":0.020594905653847157,"score_gpt":0.31710687491740386,"score_spread":0.2965119692635567,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389248242","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965004,0.00006684231,0.000002687442,0.000030138019,0.00007048907,0.001932604,0.000024863071,0.00006458723,0.0013074387],"genre_scores_gemma":[0.99781096,0.00011084573,0.000047431357,0.00001597128,0.000055231172,0.00005432157,0.00023226789,0.00006304715,0.0016099298],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975236,0.00016448775,0.00054800074,0.00047106307,0.00085320097,0.00043965608],"domain_scores_gemma":[0.998859,0.00012521735,0.00014340416,0.00059822376,0.00014201314,0.00013215038],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005787821,0.0002223523,0.00051478116,0.00089726894,0.00003542918,0.000017058699,0.00016807766,0.0001272182,0.0002831059],"category_scores_gemma":[0.000054944012,0.00018922324,0.0000696357,0.0017668554,0.00007489912,0.00013504474,0.0000818706,0.0005040947,0.00007008635],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038193513,0.0124534415,0.79433686,0.00008449433,0.00014896432,0.0003792616,0.0021210306,0.000018691375,0.18246771,0.000001420847,0.00007870473,0.0040900777],"study_design_scores_gemma":[0.081593305,0.006335859,0.8963336,0.00015235304,0.00013610524,0.0000030548545,0.0005729478,0.00009840134,0.014324289,0.000009045039,0.00024044918,0.0002005912],"about_ca_topic_score_codex":0.00022065536,"about_ca_topic_score_gemma":0.00013773853,"teacher_disagreement_score":0.16814342,"about_ca_system_score_codex":0.00023330688,"about_ca_system_score_gemma":0.0003018658,"threshold_uncertainty_score":0.77163},"labels":[],"label_agreement":null},{"id":"W4389248280","doi":"10.1182/blood-2023-190517","title":"Immune and Genome Profiling of Myeloma Patients Treated with Sequential Immunotherapies Reveal Differential Non-Overlapping Mechanisms of Resistance","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Cytotoxic T cell; Chimeric antigen receptor; Antigen; Peripheral blood mononuclear cell; Immune system; Medicine; Immunotherapy; Immunology; Cancer research; T cell; Biology; In vitro; Genetics","score_opus":0.014123695186511031,"score_gpt":0.24993359265028006,"score_spread":0.23580989746376904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389248280","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99837357,0.0002341876,0.0001451229,0.000022362869,0.000029464036,0.00068042683,0.00003981462,0.000043076572,0.00043198228],"genre_scores_gemma":[0.997133,0.00012872605,0.0006874094,0.0000047448943,0.000036360652,0.000028492572,0.00008662613,0.000044614102,0.001850035],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986135,0.000050092167,0.00035874353,0.0002511702,0.00045196828,0.0002745535],"domain_scores_gemma":[0.99923396,0.00004399967,0.00016130367,0.0003164222,0.00018838128,0.0000559426],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017470053,0.00015831899,0.00045382834,0.00020368714,0.000057609795,0.000011477044,0.00009907015,0.00007656328,0.00012344687],"category_scores_gemma":[0.000019899104,0.00012853858,0.00007656444,0.0004027237,0.00012627488,0.000046613986,0.000069262525,0.00013312385,0.0000022259221],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017566236,0.00028179088,0.011301409,0.00041571606,0.00051353796,0.000020021733,0.0005014238,4.3467935e-7,0.98465216,0.00007442133,0.0000013160648,0.00048112244],"study_design_scores_gemma":[0.007645423,0.000855152,0.25868315,0.00030971426,0.00014306471,0.0000056219665,0.00014244959,0.0000147471765,0.7320028,0.00007687859,0.000008502843,0.00011247938],"about_ca_topic_score_codex":0.000062182495,"about_ca_topic_score_gemma":0.0000073248693,"teacher_disagreement_score":0.25264937,"about_ca_system_score_codex":0.000024271612,"about_ca_system_score_gemma":0.000063439686,"threshold_uncertainty_score":0.5241651},"labels":[],"label_agreement":null},{"id":"W4389248467","doi":"10.1182/blood-2023-181710","title":"A New Machine Learning-Based Prognostic Prediction Strategy for Patients with Diffuse-Large B-Cell Lymphoma","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Diffuse large B-cell lymphoma; Medicine; Internal medicine; Oncology; Lymphoma; CHOP; ABVD; Rituximab; Chemotherapy; Cyclophosphamide; Vincristine","score_opus":0.01719968098037226,"score_gpt":0.26287813092745027,"score_spread":0.24567844994707802,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389248467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959646,0.000091938404,0.00077405095,0.00010847203,0.000057357433,0.0018083863,0.00009979615,0.00037321978,0.0007221728],"genre_scores_gemma":[0.98560673,0.000017229644,0.0002379946,0.000047097365,0.00017421912,0.00017566084,0.0010491294,0.00008412406,0.012607786],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984794,0.000045136665,0.00018574187,0.0003263536,0.0004931323,0.00047021089],"domain_scores_gemma":[0.9991486,0.00016306549,0.00006149241,0.0002469738,0.00014598313,0.00023385168],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001772883,0.00017125283,0.0002235804,0.00018514848,0.000110425084,0.000033725755,0.000086791544,0.00009059088,0.0003250646],"category_scores_gemma":[0.00013050577,0.00013519486,0.00008494007,0.0004558904,0.000023764616,0.000044416443,0.00002543215,0.00015106301,0.00007027535],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029670226,0.015691143,0.95617497,0.0005318526,0.00027115186,0.000068133195,0.00020991512,0.00012892928,0.0065737097,0.000013416929,0.0017074406,0.015662335],"study_design_scores_gemma":[0.351867,0.024923678,0.5418983,0.0003399115,0.0009204052,0.000018816465,0.0001014954,0.035984192,0.016362509,0.00007533465,0.02696306,0.00054527074],"about_ca_topic_score_codex":0.000043777876,"about_ca_topic_score_gemma":0.000025651383,"teacher_disagreement_score":0.4142766,"about_ca_system_score_codex":0.000043915014,"about_ca_system_score_gemma":0.00031770888,"threshold_uncertainty_score":0.55130863},"labels":[],"label_agreement":null},{"id":"W4389259388","doi":"10.1182/blood-2023-187713","title":"Risk of Bleeding and Thrombosis with CAR T-Cell Therapy: A Scoping Review","year":2023,"lang":"en","type":"review","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Medicine; Chimeric antigen receptor; Thrombosis; Lymphoma; Internal medicine; Venous thrombosis; CAR T-cell therapy; Malignancy; Pediatrics; Oncology; Cancer; Surgery; Immunotherapy","score_opus":0.12163844875201123,"score_gpt":0.40119066190462427,"score_spread":0.279552213152613,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389259388","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00020611822,0.9938475,0.0000014050873,0.000020909278,0.000031477328,0.0040110233,0.00003113433,0.000067240115,0.0017831831],"genre_scores_gemma":[0.0000038813378,0.99848616,0.00014585415,0.000037027934,0.00016765003,0.00024413789,0.00003028198,0.00016164567,0.0007233537],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99772036,0.00022419136,0.0006383511,0.00051068503,0.00054999697,0.00035642882],"domain_scores_gemma":[0.9981549,0.00046141265,0.00044947446,0.00064695004,0.00012894228,0.0001583162],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00096623314,0.00038586193,0.0030126486,0.00024500306,0.000059033537,0.000020480842,0.0001825409,0.00019630259,0.0003347663],"category_scores_gemma":[0.000110403875,0.00025973917,0.00040011713,0.0008381317,0.0001206281,0.00003221369,0.00010088737,0.0006067937,0.000028994878],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001278092,0.00018141007,0.000120419536,0.55964684,0.0015890546,0.00003724287,0.000058457597,1.522487e-8,0.000100281395,0.0000019663005,0.000081373335,0.43817016],"study_design_scores_gemma":[0.001999281,0.000731612,0.000011318004,0.88937736,0.009058853,0.000121334226,0.000015023018,3.5242653e-7,0.00013296393,0.0000032909297,0.098239645,0.00030897622],"about_ca_topic_score_codex":0.000070594,"about_ca_topic_score_gemma":0.000010001991,"teacher_disagreement_score":0.4378612,"about_ca_system_score_codex":0.000033735952,"about_ca_system_score_gemma":0.00059040386,"threshold_uncertainty_score":0.99998546},"labels":[],"label_agreement":null},{"id":"W4389261506","doi":"10.1158/2326-6074.tumimm23-a042","title":"Abstract A042: Quantitative multiplex immunoprecipitation reveals distinct protein interaction networks responsible for discrepant <i>in vivo</i> activity exhibited by two second generation CD22-targeted chimeric antigen receptors","year":2023,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Chimeric antigen receptor; Multiplex; CD19; Antigen; CD22; Immunoprecipitation; In vivo; Cancer research; MUC1; CD28; Immunotherapy; Biology; Computational biology; Immunology; Antibody; CD8; Immune system; Bioinformatics; Genetics","score_opus":0.11106423132623436,"score_gpt":0.43683583407814675,"score_spread":0.3257716027519124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389261506","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98881656,0.0025229384,0.00032928988,0.0016390098,0.0006658119,0.00530167,0.00020901632,0.00016370375,0.0003519858],"genre_scores_gemma":[0.97797054,0.0016668214,0.00033300216,0.00004118009,0.00030010444,0.00408584,0.0010211311,0.00012821233,0.014453168],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99469167,0.001476562,0.0007389008,0.0010326419,0.0006886273,0.0013715758],"domain_scores_gemma":[0.99623215,0.0017344463,0.00027375473,0.0007068482,0.0008928865,0.00015993825],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004265106,0.0003682373,0.00070456055,0.0012371814,0.00051997876,0.00011124898,0.00032496912,0.00037013492,0.0031528969],"category_scores_gemma":[0.0016082346,0.0003577913,0.00019383169,0.002689562,0.000504785,0.0004916971,0.00017297831,0.0016668495,0.0000769973],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014131821,0.00028622992,0.0029564397,0.00011505672,0.0003521903,0.00001854073,0.00082387007,0.00022578269,0.94881105,0.000032541,0.011908245,0.0203382],"study_design_scores_gemma":[0.007304095,0.0019105971,0.12708667,0.0005086805,0.000027692675,0.000010055107,0.001299526,0.02242594,0.81415683,0.00012822266,0.024585297,0.0005563868],"about_ca_topic_score_codex":0.0029082068,"about_ca_topic_score_gemma":0.0027898971,"teacher_disagreement_score":0.13465425,"about_ca_system_score_codex":0.0012664214,"about_ca_system_score_gemma":0.00076870417,"threshold_uncertainty_score":0.9998874},"labels":[],"label_agreement":null},{"id":"W4389374456","doi":"10.1212/wnl.98.18_supplement.2864","title":"Whole Body MRI Quantitative muscle analysis to evaluate Efficacy of Losmapimod in a Phase 2 Placebo-Controlled Study in Subjects with FSHD (ReDUX4) (S23.009)","year":2022,"lang":"en","type":"article","venue":"Neurology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's Hospital of Eastern Ontario; McGill University","funders":"","keywords":"Placebo; Art; Medicine; Art history; Pathology; Alternative medicine","score_opus":0.03689167336412621,"score_gpt":0.38009996554715186,"score_spread":0.3432082921830257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389374456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928143,0.000087682274,0.000032593834,0.0020865856,0.000060632225,0.004315973,0.000018059976,0.000027254891,0.00055693364],"genre_scores_gemma":[0.9980739,0.0000065502377,0.0000532242,0.0006251729,0.000022909831,0.0008018822,0.000022870889,0.000043447162,0.00035008282],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99505687,0.0021676987,0.00062919763,0.0007512718,0.00082901126,0.000565935],"domain_scores_gemma":[0.9977079,0.0011549491,0.00016519368,0.0006671766,0.00014383614,0.00016096054],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002028027,0.00024170506,0.0013803936,0.0020477378,0.00006351679,0.000009242323,0.0002858867,0.00006472487,0.0015766709],"category_scores_gemma":[0.00046321916,0.00021345472,0.00017518138,0.0033341497,0.00010248281,0.00004044018,0.00019763515,0.00081534917,0.000019074268],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6590453,0.014661669,0.11249873,0.000030062683,0.0020066146,0.003137679,0.014117294,0.034108095,0.15840843,0.000031404852,0.00010808971,0.0018466495],"study_design_scores_gemma":[0.33905825,0.119747736,0.49601525,0.000012626747,0.0014249132,0.000045727462,0.0024008467,0.039189164,0.0009983724,0.00004336907,0.00069359323,0.00037014578],"about_ca_topic_score_codex":0.0011077124,"about_ca_topic_score_gemma":0.004862304,"teacher_disagreement_score":0.38351652,"about_ca_system_score_codex":0.00012478727,"about_ca_system_score_gemma":0.00029700118,"threshold_uncertainty_score":0.999336},"labels":[],"label_agreement":null},{"id":"W4389397268","doi":"10.2214/ajr.23.30301","title":"Role of FDG PET/CT in Patients With Lymphoma Treated With Chimeric Antigen Receptor T-Cell Therapy: Current Concepts","year":2024,"lang":"en","type":"review","venue":"American Journal of Roentgenology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Women's College Hospital","funders":"","keywords":"Medicine; Chimeric antigen receptor; Lymphoma; Positron emission tomography; Cell therapy; Radiation therapy; Oncology; Immunotherapy; Internal medicine; Radiology; Cell; Cancer","score_opus":0.018739165852069656,"score_gpt":0.3313885973862729,"score_spread":0.31264943153420327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389397268","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.33740315,0.66147107,0.0000012268862,0.000022813112,0.00010518718,0.00077878736,0.000031869535,0.000011867507,0.00017406502],"genre_scores_gemma":[0.032576907,0.9665948,0.00018852182,0.000025203428,0.00012678179,0.000030402163,0.000079784804,0.00016632109,0.0002112724],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961569,0.00061228004,0.0012900659,0.00050006766,0.0007894051,0.0006512836],"domain_scores_gemma":[0.9967523,0.00013109249,0.0018621096,0.0005269631,0.00044328615,0.00028419893],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000299187,0.0006406334,0.0039690603,0.001282388,0.000028525455,0.000016460112,0.0004781573,0.000042664855,0.0006444946],"category_scores_gemma":[0.000021822363,0.00037163877,0.00053017016,0.0017352182,0.0008941871,0.0000605557,0.00007097234,0.00096054893,0.000037961974],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002377326,0.0011590194,0.017430024,0.0011985464,0.0016585912,0.0005033889,0.00018697018,0.000001269532,0.00007831809,9.108795e-7,0.00013221578,0.97527343],"study_design_scores_gemma":[0.008599871,0.032072976,0.0032914842,0.012048039,0.0016703737,0.0030563069,0.0005246708,0.0000020812886,0.00015826005,0.0000025842792,0.93802685,0.0005465146],"about_ca_topic_score_codex":0.00012881945,"about_ca_topic_score_gemma":0.00000821171,"teacher_disagreement_score":0.9747269,"about_ca_system_score_codex":0.00050746236,"about_ca_system_score_gemma":0.0016193585,"threshold_uncertainty_score":0.9998736},"labels":[],"label_agreement":null},{"id":"W4389443021","doi":"10.3389/fimmu.2023.1302307","title":"CAR-T cell immunotherapy for ovarian cancer: hushing the silent killer","year":2023,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada","funders":"","keywords":"Medicine; Chimeric antigen receptor; Ovarian cancer; Immunotherapy; Bevacizumab; Context (archaeology); Oncology; Taxane; Cancer; Internal medicine; Immunology; Chemotherapy; Breast cancer; Biology","score_opus":0.0225108172773095,"score_gpt":0.3065004900360217,"score_spread":0.2839896727587122,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389443021","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88128155,0.047456115,0.0056786817,0.03220161,0.017933428,0.0059092087,0.00006619211,0.0004944127,0.008978807],"genre_scores_gemma":[0.6909575,0.052088838,0.00794554,0.0041891634,0.0016772611,0.0048983754,0.00030979392,0.00048792808,0.2374456],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.998148,0.00016340146,0.00033748877,0.00036811212,0.00022183888,0.00076113077],"domain_scores_gemma":[0.99891275,0.0002186704,0.00007719828,0.0006577411,0.00008652582,0.00004712301],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000731738,0.00019800266,0.000455545,0.00040085046,0.00017778856,0.00002728837,0.0004089107,0.00022947144,0.00079700194],"category_scores_gemma":[0.000072188814,0.00015105012,0.00018756691,0.0006705303,0.00024957003,0.000052492676,0.00009416524,0.0005696036,0.000041005846],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044218167,0.0002224209,0.03129019,0.00011883646,0.0010265319,0.000077254226,0.007759349,0.00018067927,0.38691193,0.00032683052,0.19854134,0.36912283],"study_design_scores_gemma":[0.008350882,0.00055464375,0.033368554,0.00007617811,0.000046135203,0.000020941652,0.00430358,0.0017826909,0.017417511,0.0012384307,0.93254673,0.00029372817],"about_ca_topic_score_codex":0.0007837793,"about_ca_topic_score_gemma":0.00006006803,"teacher_disagreement_score":0.7340054,"about_ca_system_score_codex":0.0004059983,"about_ca_system_score_gemma":0.00025023083,"threshold_uncertainty_score":0.87266123},"labels":[],"label_agreement":null},{"id":"W4389453684","doi":"10.3389/fphar.2023.1304194","title":"A synthetic notch (synNotch) system linking intratumoral immune-cancer cell communication to a synthetic blood biomarker assay","year":2023,"lang":"en","type":"article","venue":"Frontiers in Pharmacology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lawson Health Research Institute; Western University","funders":"Canadian Institutes of Health Research","keywords":"CD19; Immune system; Cancer research; Jurkat cells; Chimeric antigen receptor; Cancer cell; Immunotherapy; Cancer immunotherapy; Antigen; Cancer; Immunology; Biology; Medicine; T cell; Molecular biology; Internal medicine","score_opus":0.025528909196160816,"score_gpt":0.3345519877506767,"score_spread":0.3090230785545159,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389453684","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96287686,0.010838659,0.0007163885,0.004738401,0.004990468,0.0031573102,0.000042362662,0.0005878243,0.0120517155],"genre_scores_gemma":[0.9903759,0.0023274852,0.0017188037,0.0005174646,0.00019958093,0.00091414864,0.000049407925,0.0001130782,0.0037841562],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99645203,0.00090847915,0.00065005955,0.0006164612,0.00044453723,0.0009284415],"domain_scores_gemma":[0.9983385,0.00033760877,0.00014199533,0.00075712334,0.00015273223,0.00027201528],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020379538,0.00031129285,0.0007515665,0.0007700401,0.00015811203,0.000040492658,0.0006280914,0.00026423446,0.001375726],"category_scores_gemma":[0.00007051283,0.0003153626,0.000173151,0.0014973156,0.00021115941,0.0000959929,0.00035355677,0.00074739,0.000220688],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018013337,0.00057221507,0.00737298,0.0010345429,0.00053100055,0.0005519403,0.0021196094,0.00022322884,0.9148408,0.000035305307,0.03773765,0.033179354],"study_design_scores_gemma":[0.024442546,0.0014183295,0.012853584,0.0035362751,0.0023943135,0.0005875997,0.00970695,0.14489155,0.6510473,0.0003068539,0.14672893,0.0020858026],"about_ca_topic_score_codex":0.00028285882,"about_ca_topic_score_gemma":0.000028930368,"teacher_disagreement_score":0.26379356,"about_ca_system_score_codex":0.00088985194,"about_ca_system_score_gemma":0.00026330657,"threshold_uncertainty_score":0.99992985},"labels":[],"label_agreement":null},{"id":"W4389507960","doi":"10.1007/978-1-0716-3593-3_4","title":"Expansion and Retroviral Transduction of Primary Murine T Cells for CAR T-Cell Therapy","year":2023,"lang":"en","type":"article","venue":"Methods in molecular biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Canada's Michael Smith Genome Sciences Centre","funders":"","keywords":"Transduction (biophysics); Chimeric antigen receptor; Antigen; Biology; T cell; Transgene; Cell biology; Viral vector; Molecular biology; Immune system; Immunology; Genetics; Gene; Biochemistry","score_opus":0.04990881097312872,"score_gpt":0.41780008132419694,"score_spread":0.3678912703510682,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389507960","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8236408,0.001187169,0.17354219,0.0002630857,0.00016806285,0.0007906317,0.000008612374,0.00003097973,0.0003684724],"genre_scores_gemma":[0.10481833,0.0046207756,0.88700676,0.0004646832,0.00014717692,0.00020343419,0.00015501631,0.00009075507,0.0024930649],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99849474,0.000587407,0.00025510378,0.000313513,0.00008915707,0.0002600533],"domain_scores_gemma":[0.99932474,0.00025982189,0.000046198544,0.00026132772,0.000057786037,0.000050126815],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016093382,0.00011703694,0.0003948917,0.0003086938,0.000019228091,0.0000025151978,0.00007226357,0.00018426182,0.00008173595],"category_scores_gemma":[0.000072177,0.00010074185,0.00010657849,0.000357822,0.00014548365,0.000012425218,0.00003168045,0.0001752866,0.0000010907194],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006617906,0.000056207344,0.00054035615,0.000121884455,0.000023665436,0.000010908127,0.00020256428,0.000006507679,0.8532277,0.000042277425,0.000026114689,0.14508007],"study_design_scores_gemma":[0.0027181555,0.0013586013,0.0009794232,0.000014518103,0.000013939809,0.000008980957,0.00005102867,0.00025494085,0.98758966,0.001593204,0.0053336727,0.00008384844],"about_ca_topic_score_codex":0.00004024192,"about_ca_topic_score_gemma":0.0000012422387,"teacher_disagreement_score":0.7188225,"about_ca_system_score_codex":0.00003970457,"about_ca_system_score_gemma":0.000055113964,"threshold_uncertainty_score":0.41081333},"labels":[],"label_agreement":null},{"id":"W4389508010","doi":"10.1007/978-1-0716-3593-3_17","title":"Nano-optogenetic CAR-T Cell Immunotherapy","year":2023,"lang":"en","type":"article","venue":"Methods in molecular biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Chimeric antigen receptor; Optogenetics; Immunotherapy; Cancer immunotherapy; Cytokine release syndrome; Cell; Cancer research; Medicine; Immunology; Chemistry; Biology; Immune system; Neuroscience; Biochemistry","score_opus":0.04397838864026288,"score_gpt":0.44872381175964215,"score_spread":0.4047454231193793,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389508010","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7152524,0.00522267,0.26144516,0.0012533095,0.000618111,0.0011635455,0.000008679148,0.00023227383,0.014803843],"genre_scores_gemma":[0.041735943,0.002452568,0.93370986,0.0021926279,0.00017976793,0.0002926919,0.00010219196,0.00017976307,0.019154591],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99709326,0.0013799747,0.00031697497,0.00046188134,0.00015006732,0.0005978433],"domain_scores_gemma":[0.9988249,0.0003120972,0.00004462932,0.0006637677,0.000056816174,0.00009776708],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001894964,0.00019020186,0.00044362526,0.0004921232,0.00003535287,0.000009243933,0.0002392995,0.00027481382,0.0014473209],"category_scores_gemma":[0.00019058316,0.00017120672,0.00017551066,0.0009877251,0.00017358657,0.000008382188,0.00011880208,0.00035402973,0.00015034087],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014853886,0.000050959145,0.0035403604,0.000025275398,0.000047075864,0.00013554364,0.00016501421,0.000014944604,0.8928667,0.0001522978,0.000070978094,0.10278235],"study_design_scores_gemma":[0.0017360079,0.00045758157,0.0019530678,0.000013564867,0.000012527286,0.000036140525,0.000048899532,0.000228036,0.93458843,0.0036791037,0.05707613,0.00017049338],"about_ca_topic_score_codex":0.000086698354,"about_ca_topic_score_gemma":0.0000040877094,"teacher_disagreement_score":0.67351645,"about_ca_system_score_codex":0.000088330984,"about_ca_system_score_gemma":0.00011138623,"threshold_uncertainty_score":0.99946547},"labels":[],"label_agreement":null},{"id":"W4389513800","doi":"10.1016/j.msard.2023.105364","title":"Emboldened or not: The potential fall-out of a failed anti-EBV trial in multiple sclerosis","year":2023,"lang":"en","type":"editorial","venue":"Multiple Sclerosis and Related Disorders","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Hospital for Sick Children; SickKids Foundation","funders":"","keywords":"Multiple sclerosis; Medicine; Physical medicine and rehabilitation; Immunology","score_opus":0.051789653677591994,"score_gpt":0.2849057615460464,"score_spread":0.2331161078684544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389513800","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.51011145,0.0012484518,0.000012711706,0.0011385494,0.4806989,0.005674345,0.0006339713,0.00026418082,0.0002174372],"genre_scores_gemma":[0.8476875,0.051014762,0.000080599326,0.000056919394,0.09019554,0.0007116859,0.001256699,0.00054652663,0.008449791],"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99306077,0.00057348196,0.001715812,0.0013522936,0.002138392,0.0011592493],"domain_scores_gemma":[0.9936494,0.003913527,0.0006014215,0.0011529169,0.00035002464,0.00033268592],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0017173612,0.00086449087,0.002008943,0.0008010627,0.0003866658,0.0001610263,0.0006804959,0.0023526212,0.00066015887],"category_scores_gemma":[0.005255115,0.0005801004,0.00084070466,0.0013335801,0.00083506684,0.00014154581,0.00045961293,0.0026766509,0.000079309175],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.2536035,0.0031604276,0.004174686,0.001193098,0.0038316334,0.00010086952,0.005238567,0.0006665186,0.11752067,0.0000036904623,0.54659957,0.063906774],"study_design_scores_gemma":[0.71341807,0.006045176,0.06225534,0.00845828,0.002393038,0.0000048557517,0.005401664,0.015024002,0.002391133,0.00006918699,0.18132795,0.003211278],"about_ca_topic_score_codex":0.004193571,"about_ca_topic_score_gemma":0.006538642,"teacher_disagreement_score":0.4598146,"about_ca_system_score_codex":0.00020895666,"about_ca_system_score_gemma":0.0006629899,"threshold_uncertainty_score":0.999665},"labels":[],"label_agreement":null},{"id":"W4389519919","doi":"10.1038/s41591-023-02726-5","title":"Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial","year":2023,"lang":"en","type":"article","venue":"Nature Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":88,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Saskatchewan Cancer Agency; McGill University; Jewish General Hospital","funders":"Genentech; F. Hoffmann-La Roche; Roche","keywords":"Refractory (planetary science); Internal medicine; Lymphoma; Medicine; Oncology; Aggressive lymphoma; Brentuximab vedotin; Cancer research; Biology; Hodgkin lymphoma; Rituximab","score_opus":0.022097220259738714,"score_gpt":0.3634544553876059,"score_spread":0.3413572351278672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389519919","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9786819,0.005331939,0.0000107195965,0.0038540044,0.0010088608,0.0024346397,0.000036355,0.00032797724,0.008313601],"genre_scores_gemma":[0.9582708,0.0008093536,0.000100802245,0.0013801272,0.0021284777,0.00016250514,0.0004166846,0.00015583023,0.036575414],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9951923,0.00026607205,0.0007107452,0.0008719165,0.0018614464,0.0010975513],"domain_scores_gemma":[0.9970591,0.0007954191,0.00035309815,0.0009923475,0.00029630234,0.00050374045],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001264424,0.00050689094,0.001176005,0.0012253145,0.0001303685,0.000017874085,0.00036305777,0.00086190295,0.0030503657],"category_scores_gemma":[0.0019159878,0.00031150662,0.00013701647,0.0032770708,0.00030141993,0.0000896042,0.00011307571,0.002313262,0.00015743799],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7383732,0.010842074,0.00052970543,0.0007065208,0.00039273882,0.03208627,0.0064812433,0.000004313286,0.07579387,0.00011542006,0.08092721,0.053747404],"study_design_scores_gemma":[0.8027437,0.01964016,0.0010643178,0.0014621089,0.00020130597,0.00034083688,0.0018542456,0.00085398194,0.00542948,0.00005652516,0.16590941,0.00044395254],"about_ca_topic_score_codex":0.00015138963,"about_ca_topic_score_gemma":0.00027040756,"teacher_disagreement_score":0.08498221,"about_ca_system_score_codex":0.000756387,"about_ca_system_score_gemma":0.001227151,"threshold_uncertainty_score":0.99998844},"labels":[],"label_agreement":null},{"id":"W4389568253","doi":"10.1016/j.omtm.2023.101171","title":"Manufacture of CD22 CAR T cells following positive versus negative selection results in distinct cytokine secretion profiles and γδ T cell output","year":2023,"lang":"en","type":"article","venue":"Molecular Therapy — Methods & Clinical Development","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stemcell Technologies","funders":"NIH Clinical Center; U.S. Department of Health and Human Services; National Institutes of Health; National Cancer Institute; Australian Government; Center for Cancer Research","keywords":"Cart; CD8; Leukapheresis; Chimeric antigen receptor; Peripheral blood mononuclear cell; Biology; Cytotoxic T cell; T cell; Cytokine; Immunology; Antigen; Cancer research; Cell biology; Immune system; Stem cell; Genetics; In vitro","score_opus":0.07940232075959335,"score_gpt":0.43305341134702346,"score_spread":0.3536510905874301,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389568253","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883507,0.00020055508,0.008083913,0.0004360971,0.00048143847,0.0015310191,0.000019961268,0.00008038579,0.00081593706],"genre_scores_gemma":[0.8357254,0.0007303723,0.16105363,0.00022189828,0.00012128463,0.00013518831,0.0002493121,0.000094069655,0.0016688004],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9950337,0.0018470859,0.0011567221,0.00080278446,0.0006618001,0.00049794576],"domain_scores_gemma":[0.9969224,0.0020699902,0.00026447262,0.00032496173,0.00019218355,0.00022603321],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.005249524,0.00034335305,0.0008261079,0.00035045878,0.00009574696,0.000026937574,0.00015054397,0.00033080668,0.000071713686],"category_scores_gemma":[0.00078799535,0.0002976609,0.00027790692,0.0008812357,0.00014093297,0.000055232056,0.00012734659,0.00071577064,0.00001388676],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009854815,0.0002886859,0.002427789,0.0000731408,0.0004664337,0.00017881642,0.0022328123,0.000035509263,0.7374796,0.000006702805,0.00006426176,0.2468914],"study_design_scores_gemma":[0.010255954,0.0012641763,0.11073145,0.00015792571,0.000052480547,0.000003393183,0.00028078732,0.00039508345,0.872602,0.0001837347,0.0037958538,0.00027718785],"about_ca_topic_score_codex":0.00007149027,"about_ca_topic_score_gemma":0.000015595268,"teacher_disagreement_score":0.24661422,"about_ca_system_score_codex":0.00024590912,"about_ca_system_score_gemma":0.0003518176,"threshold_uncertainty_score":0.99994755},"labels":[],"label_agreement":null},{"id":"W4389623269","doi":"10.1016/j.clml.2023.12.005","title":"Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; Roche (Canada)","funders":"Genentech; F. Hoffmann-La Roche; Roche; Roche Canada","keywords":"Medicine; Internal medicine; Cytokine release syndrome; Follicular lymphoma; Neutropenia; Lymphoma; Adverse effect; Febrile neutropenia; Gastroenterology; Tumor lysis syndrome; Refractory (planetary science); Rituximab; Cyclophosphamide; Oncology; Surgery; Cancer; Chemotherapy; Immunotherapy","score_opus":0.03510957312794868,"score_gpt":0.3631146871045697,"score_spread":0.328005113976621,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389623269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98448855,0.00008218259,0.00003901993,0.00016882575,0.0018329397,0.0045666187,0.00015251042,0.00039251833,0.00827685],"genre_scores_gemma":[0.98246044,0.00045677417,0.001212586,0.00066805887,0.0014178987,0.0006541195,0.0010492281,0.00023348388,0.011847402],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98931116,0.0008861443,0.0037113128,0.0023902368,0.0020970635,0.001604059],"domain_scores_gemma":[0.99340314,0.0021799873,0.0006885421,0.0022943253,0.0002948527,0.0011391819],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0028113595,0.00083861797,0.0021185721,0.0004963415,0.00033979793,0.00009451952,0.0009986726,0.00097482884,0.0020968071],"category_scores_gemma":[0.00085345504,0.0007138659,0.00084036635,0.001819541,0.0010627088,0.00035239558,0.0010109014,0.0009432687,0.0012900822],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25048184,0.011451481,0.056365345,0.00007815563,0.0003407872,0.0016216271,0.00052201084,0.0000050275294,0.00015419292,0.000013778127,0.005902842,0.6730629],"study_design_scores_gemma":[0.34041846,0.015811885,0.61633474,0.0002780947,0.00013969053,0.0000060348325,0.00029018737,0.0012050952,0.00016622979,0.000036005258,0.02472477,0.0005888374],"about_ca_topic_score_codex":0.00029140533,"about_ca_topic_score_gemma":0.000037641963,"teacher_disagreement_score":0.6724741,"about_ca_system_score_codex":0.0025414014,"about_ca_system_score_gemma":0.0021227014,"threshold_uncertainty_score":0.99953127},"labels":[],"label_agreement":null},{"id":"W4389639558","doi":"10.1111/ene.16174","title":"Patterns of neurotoxicity among patients receiving chimeric antigen receptor T‐cell therapy: A single‐centre cohort study","year":2023,"lang":"en","type":"article","venue":"European Journal of Neurology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Neurotoxicity; Encephalopathy; Cohort; Internal medicine; Prospective cohort study; Incidence (geometry); Cohort study; Pediatrics; Toxicity","score_opus":0.03049357398452666,"score_gpt":0.2737641118352143,"score_spread":0.24327053785068767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389639558","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9963474,0.000040046496,0.000009092322,0.0004033691,0.00062205066,0.0009761092,0.000007012543,0.00004617678,0.0015486901],"genre_scores_gemma":[0.9980014,0.00041389072,0.000016714308,0.0003848771,0.00030687384,0.0000019746437,0.000007887782,0.00011481332,0.00075154635],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950994,0.0024006772,0.0009198957,0.00036439014,0.0007463278,0.00046926347],"domain_scores_gemma":[0.9979572,0.00023780596,0.00070481823,0.00045706274,0.0003882724,0.00025483972],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015215335,0.00024300041,0.00066531677,0.00052286225,0.000069524074,0.000022463491,0.00042779717,0.000044938122,0.0009614628],"category_scores_gemma":[0.00029563968,0.00020272376,0.00024476,0.00058270345,0.000097676864,0.00009300129,0.00017934144,0.00083831244,0.00007842464],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001350517,0.0013915014,0.8569985,0.000021507565,0.00015620133,0.0010583675,0.0009753209,0.000019585894,0.12796144,5.9227304e-8,0.0008228582,0.009244148],"study_design_scores_gemma":[0.0042075375,0.011005807,0.97625554,0.000037029153,0.000040351748,0.00005461846,0.000108510416,0.0000237972,0.0047185686,7.223927e-7,0.003428843,0.00011866631],"about_ca_topic_score_codex":0.0000122961355,"about_ca_topic_score_gemma":0.0000044605804,"teacher_disagreement_score":0.12324288,"about_ca_system_score_codex":0.000026702657,"about_ca_system_score_gemma":0.000052695406,"threshold_uncertainty_score":0.9999518},"labels":[],"label_agreement":null},{"id":"W4389669358","doi":"10.3390/curroncol30120762","title":"Low-Frequency PPM1D Gene Mutations Affect Treatment Response to CD19-Targeted CAR T-Cell Therapy in Large B-Cell Lymphoma","year":2023,"lang":"en","type":"article","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Internal medicine; Medicine; Oncology; Diffuse large B-cell lymphoma; Context (archaeology); Cohort; Lymphoma; Immunology; Biology","score_opus":0.08760787529509852,"score_gpt":0.4221598131312722,"score_spread":0.3345519378361737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389669358","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903056,0.0029236123,0.000028057171,0.0016535607,0.00096935965,0.0024518785,0.0001133082,0.00020496061,0.0013496871],"genre_scores_gemma":[0.9866097,0.003575863,0.00022224567,0.00025505672,0.00031796412,0.001044914,0.00046435188,0.00009542593,0.007414492],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964844,0.00093033764,0.00048237172,0.0006785157,0.00041652794,0.0010078356],"domain_scores_gemma":[0.9977915,0.0008403698,0.000088457055,0.0006765924,0.00017095762,0.00043209424],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0010925676,0.00034843056,0.00067381613,0.0010078336,0.00012282186,0.000020108557,0.00023439586,0.00023412392,0.0012437805],"category_scores_gemma":[0.00020232944,0.00030654776,0.00023935629,0.0016193952,0.00009257307,0.000050948005,0.00008617504,0.00026700797,0.0013707354],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0057273386,0.0085831005,0.013843254,0.00007341255,0.000077054705,0.0009826816,0.0044253473,0.000031334966,0.8675897,0.0000135482705,0.002816523,0.095836684],"study_design_scores_gemma":[0.0837495,0.023254061,0.11311714,0.00013224244,0.00011310183,0.000104384504,0.0013383415,0.0010592181,0.3877406,0.00017498764,0.3884093,0.0008071417],"about_ca_topic_score_codex":0.00009391085,"about_ca_topic_score_gemma":0.00018882773,"teacher_disagreement_score":0.47984913,"about_ca_system_score_codex":0.0023669403,"about_ca_system_score_gemma":0.001381971,"threshold_uncertainty_score":0.99993867},"labels":[],"label_agreement":null},{"id":"W4389726359","doi":"10.1101/2023.12.13.571465","title":"Massively parallel base editing screens to map variant effects on anti-tumor hallmarks of primary human T cells","year":2023,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"","keywords":"Massively parallel; Base (topology); Primary (astronomy); Computer science; Computational biology; Biology; Parallel computing; Physics","score_opus":0.02803366770179337,"score_gpt":0.26676837820690297,"score_spread":0.23873471050510958,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389726359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98732525,0.0003097796,0.001217157,0.0016100544,0.0025748545,0.0053908704,0.00057656236,0.0008249646,0.0001704933],"genre_scores_gemma":[0.9868648,0.00010035811,0.0078080622,0.0010887699,0.0026763594,0.00057837035,0.000004585924,0.0005697587,0.00030891015],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99350387,0.0004208104,0.0011294687,0.0018755613,0.0016190456,0.0014512425],"domain_scores_gemma":[0.99419653,0.00052003755,0.00067443534,0.0026225338,0.00089505245,0.0010914167],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002310045,0.0009741683,0.0019109907,0.0011798296,0.00022306059,0.00015562402,0.0008727446,0.0006652277,0.00036506582],"category_scores_gemma":[0.00066925545,0.0010154895,0.0005009484,0.00089588267,0.00018953142,0.00008725062,0.0012214448,0.0020097338,0.00038507534],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038769218,0.00045407726,0.003995625,0.005195271,0.000527073,0.0031097266,0.000018449378,0.00018108264,0.9813671,0.00024133609,0.0045125782,0.000009950548],"study_design_scores_gemma":[0.0025784508,0.00086351874,0.17037617,0.0055678175,0.00031775702,1.4398671e-7,0.000005886512,0.0002893295,0.8142537,0.0000028901409,0.0047445362,0.0009998374],"about_ca_topic_score_codex":0.00058163144,"about_ca_topic_score_gemma":0.000011012673,"teacher_disagreement_score":0.16711348,"about_ca_system_score_codex":0.0009302173,"about_ca_system_score_gemma":0.0013251143,"threshold_uncertainty_score":0.99922955},"labels":[],"label_agreement":null},{"id":"W4389869854","doi":"10.1002/jcph.2397","title":"Pharmacokinetics (PK) of Tiragolumab in First‐in‐Human Study in Patients with Mixed Solid Tumors (GO30103)","year":2023,"lang":"en","type":"article","venue":"The Journal of Clinical Pharmacology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"F. Hoffmann-La Roche","keywords":"Atezolizumab; Pharmacokinetics; TIGIT; Dosing; Medicine; Pharmacology; Chemistry; Internal medicine; Cancer; Immunotherapy; Pembrolizumab","score_opus":0.09254291781798765,"score_gpt":0.4808868178622886,"score_spread":0.38834390004430097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389869854","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966361,0.00004984787,0.0000011077332,0.0013792815,0.00060353667,0.0010499896,0.0000029593507,0.000008589649,0.0002685822],"genre_scores_gemma":[0.99866056,0.00030139866,0.000013998716,0.00034275517,0.00035032647,0.000009975717,0.0000023129403,0.000034677454,0.0002839747],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9948896,0.0013971432,0.0022926172,0.00019787563,0.00074855523,0.0004741688],"domain_scores_gemma":[0.99665743,0.0019950252,0.00064080814,0.000227543,0.0002888119,0.00019037312],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0067281597,0.0001772,0.0011866011,0.0006633154,0.00003220065,0.000004549081,0.00047872672,0.000108050735,0.0010105211],"category_scores_gemma":[0.00036955057,0.00011590459,0.00014266354,0.0010528276,0.0003328563,0.000064080195,0.00015906492,0.0018597624,0.000014362536],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019434469,0.006224545,0.9588514,0.00006408102,0.00028591702,0.0007727169,0.0011027262,0.001664581,0.005496539,0.0000011021457,0.0029837012,0.0031182123],"study_design_scores_gemma":[0.0461553,0.008488831,0.94176185,0.00012337152,0.00017403605,0.000018149645,0.000399118,0.00054483,0.0017180574,0.000050025108,0.00046431695,0.00010212656],"about_ca_topic_score_codex":0.00006300134,"about_ca_topic_score_gemma":0.00022851505,"teacher_disagreement_score":0.02672083,"about_ca_system_score_codex":0.00011951156,"about_ca_system_score_gemma":0.00026915703,"threshold_uncertainty_score":0.99990267},"labels":[],"label_agreement":null},{"id":"W4389943594","doi":"10.1182/bloodadvances.2023011492","title":"Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines","year":2023,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Pharmacyclics; Genentech; Adaptive Biotechnologies; Juno Therapeutics; Incyte; BeiGene; Loxo Oncology; TG Therapeutics; University of Pennsylvania; Seagen; Kite Pharma; Society for Immunotherapy of Cancer; Mallinckrodt Pharmaceuticals; Atara Biotherapeutics; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; GlaxoSmithKline; Regeneron Pharmaceuticals; Leukemia and Lymphoma Society; Legend Biotech; MorphoSys; Celgene; AstraZeneca; Bristol-Myers Squibb","keywords":"Medicine; Bendamustine; Immunology; Lymphoma; Rituximab","score_opus":0.014826103761929521,"score_gpt":0.2868707754483552,"score_spread":0.2720446716864257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389943594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99322754,0.001865515,0.000005297359,0.0021307478,0.00007623614,0.0004053641,0.00003663399,0.00023514501,0.0020175395],"genre_scores_gemma":[0.97317755,0.0037437405,0.00094995776,0.00037389464,0.0006174473,0.00010595078,0.00012706457,0.00008509496,0.02081928],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9983712,0.000041521092,0.00024046464,0.00040385427,0.00052799494,0.0004149725],"domain_scores_gemma":[0.99918485,0.00010545769,0.000101264755,0.0002806347,0.00015838185,0.00016941153],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003007789,0.00020986957,0.0003478128,0.0001992401,0.00014950785,0.000033875822,0.00009381472,0.00009192665,0.00047754514],"category_scores_gemma":[0.00012382893,0.00016162799,0.00006127268,0.0005281441,0.00015321336,0.00017066048,0.00007026947,0.00015594331,0.0000443784],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009654122,0.00020518058,0.254979,0.0005747236,0.0004924662,0.0003391813,0.0013859146,0.000026640319,0.6215054,0.000097680444,0.0012664029,0.11816204],"study_design_scores_gemma":[0.011013107,0.0023332401,0.49964276,0.0006586338,0.00046092598,0.00035253196,0.001088235,0.00038417045,0.33319893,0.0008298041,0.14938144,0.0006562213],"about_ca_topic_score_codex":0.000023978018,"about_ca_topic_score_gemma":0.000071623115,"teacher_disagreement_score":0.28830644,"about_ca_system_score_codex":0.00004994732,"about_ca_system_score_gemma":0.000117117685,"threshold_uncertainty_score":0.6590998},"labels":[],"label_agreement":null},{"id":"W4390030675","doi":"10.54254/2753-8818/24/20231150","title":"Next generation armored CAR-T cells with a drug inducible cytokine circuit","year":2023,"lang":"en","type":"article","venue":"Theoretical and Natural Science","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Chimeric antigen receptor; Immune system; Immunotherapy; Tumor microenvironment; Cytokine; Cancer immunotherapy; Cancer research; T cell; Biology; Immunology","score_opus":0.033263182813825634,"score_gpt":0.297694995493518,"score_spread":0.2644318126796924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390030675","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933868,0.00009519301,0.000021141617,0.0019677836,0.0001164276,0.00028222418,0.000002766526,0.00008276673,0.004044873],"genre_scores_gemma":[0.9959309,0.00010253931,0.00012832871,0.0003080624,0.00018102939,0.000009524478,0.000008910989,0.000010165147,0.0033205345],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99829626,0.000036762867,0.00011314261,0.00039634688,0.0007161826,0.000441313],"domain_scores_gemma":[0.9992588,0.00009225722,0.000018646844,0.00023290208,0.00012985893,0.00026750445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008539496,0.000109551525,0.00016377661,0.00016874155,0.00020744304,0.000099106735,0.00016010212,0.00003909364,0.0005992222],"category_scores_gemma":[0.00010236733,0.00006564462,0.00002749795,0.0015066565,0.0022239082,0.0001532353,0.00009926322,0.0002940283,0.00006149935],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013119676,0.000018194916,0.00015000465,0.000011669318,0.0000053773047,0.00003656446,0.0003002697,0.0000020824846,0.93288624,0.05389896,0.00019028921,0.012369168],"study_design_scores_gemma":[0.0013298747,0.00048147514,0.0057046274,0.000060185208,0.000030434509,0.00013861315,0.00023514901,0.021094011,0.9612491,0.008443597,0.000991119,0.00024179101],"about_ca_topic_score_codex":0.000027916301,"about_ca_topic_score_gemma":0.000004067107,"teacher_disagreement_score":0.045455363,"about_ca_system_score_codex":0.000054858217,"about_ca_system_score_gemma":0.00017525828,"threshold_uncertainty_score":0.81940824},"labels":[],"label_agreement":null},{"id":"W4390427350","doi":"10.1007/978-3-662-67908-1","title":"Gen- und Zelltherapie 2.023 - Forschung, klinische Anwendung und Gesellschaft","year":2023,"lang":"de","type":"book","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Berlin Institute of Health; Stem Cell Network","keywords":"Philosophy; Art","score_opus":0.07130748548204845,"score_gpt":0.382843740178604,"score_spread":0.31153625469655555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390427350","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009166842,0.15038984,0.00047977385,0.004567347,0.0080492925,0.0066942223,0.00046630588,0.0014639527,0.8269726],"genre_scores_gemma":[0.00017892581,0.09122731,0.0006090747,0.0016980695,0.011607465,0.00022004663,0.002120083,0.0014329815,0.89090604],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9859175,0.0007342304,0.0024536285,0.0030695326,0.0041443584,0.003680719],"domain_scores_gemma":[0.9891245,0.0031897577,0.0007235537,0.004087248,0.0008568816,0.0020180906],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.004170182,0.0022855713,0.0032107227,0.0018544131,0.00066943746,0.0004894792,0.002063031,0.0032314504,0.15181279],"category_scores_gemma":[0.00048551615,0.0020909598,0.0017760053,0.0015896603,0.001274531,0.00027024254,0.0011054275,0.0059093917,0.092469275],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031851179,0.0012946819,0.0014360289,0.004282487,0.035990223,0.004517668,0.0020971093,0.00005623465,0.019405143,0.014011322,0.8258842,0.087839745],"study_design_scores_gemma":[0.0057168584,0.0018858707,0.0002286879,0.001427336,0.0031953764,0.000035749443,0.00031241804,0.00090723514,0.0025674049,0.0031742118,0.97859716,0.001951713],"about_ca_topic_score_codex":0.0006302851,"about_ca_topic_score_gemma":0.0004721442,"teacher_disagreement_score":0.1527129,"about_ca_system_score_codex":0.0014449898,"about_ca_system_score_gemma":0.0042294455,"threshold_uncertainty_score":0.99898833},"labels":[],"label_agreement":null},{"id":"W4390482949","doi":"10.1002/inmd.20230030","title":"Immune function assessing of TIM3/CD28‐modified CD19 CAR‐T cells and general CD19 CAR‐T cells through a high‐throughput single‐cell microarray platform","year":2024,"lang":"en","type":"article","venue":"Interdisciplinary medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Artificial Intelligence in Medicine (Canada)","funders":"Major Scientific and Technological Innovation Project of Shandong Province; Key Technology Research and Development Program of Shandong; National Natural Science Foundation of China; National Science Foundation","keywords":"CD28; CD19; Chimeric antigen receptor; Immunotherapy; T cell; Immune system; Cancer research; Immunology; Cytotoxic T cell; Biology; Medicine; In vitro","score_opus":0.04251365988367222,"score_gpt":0.3433641136777488,"score_spread":0.30085045379407654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390482949","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96410936,0.006751886,0.003685528,0.0027556394,0.0039834077,0.0011532867,0.00005379707,0.00025343028,0.017253658],"genre_scores_gemma":[0.9761702,0.0005166045,0.0011372918,0.00027077034,0.0021589275,0.000046428428,0.00024296175,0.00019456237,0.019262267],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99526054,0.00015812537,0.0013727389,0.0011789626,0.0011129178,0.0009167365],"domain_scores_gemma":[0.9974936,0.00053428364,0.00027718602,0.0010327847,0.00030553242,0.00035659544],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010211058,0.00071982475,0.0014623024,0.000594447,0.00026051456,0.00011238659,0.00034751187,0.00043046166,0.0021770876],"category_scores_gemma":[0.000036634923,0.00056049187,0.0003563912,0.0007843382,0.00088741886,0.00058344414,0.0007705712,0.0011832904,0.00007488602],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014820034,0.00037946866,0.000078152254,0.001629139,0.0004397237,0.00056978216,0.007965806,0.000060987946,0.9746811,0.00018245216,0.0072275815,0.0053038113],"study_design_scores_gemma":[0.006601497,0.0061587235,0.0012778293,0.0039626528,0.0010502125,0.0006308935,0.0056236507,0.003140114,0.95820516,0.0022657344,0.010335446,0.0007480819],"about_ca_topic_score_codex":0.0005046892,"about_ca_topic_score_gemma":0.00003162283,"teacher_disagreement_score":0.016475927,"about_ca_system_score_codex":0.00058210513,"about_ca_system_score_gemma":0.00028385955,"threshold_uncertainty_score":0.99968463},"labels":[],"label_agreement":null},{"id":"W4390706466","doi":"10.1007/s41669-023-00464-5","title":"A Systematic Literature Review of Health-Related Quality of Life Outcomes and Associated Utility Values in Relapsed and/or Refractory Large B Cell Lymphoma","year":2024,"lang":"en","type":"review","venue":"PharmacoEconomics - Open","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Bristol-Myers Squibb","keywords":"Medicine; Nivolumab; Quality of life (healthcare); Population; Rituximab; Health care; Systematic review; MEDLINE; Oncology; Family medicine; Lymphoma; Internal medicine; Environmental health; Cancer; Immunotherapy; Nursing","score_opus":0.13180303865277276,"score_gpt":0.47445124690915247,"score_spread":0.3426482082563797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390706466","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0027533253,0.98594123,1.3747591e-7,0.00035241712,0.00021137117,0.009074445,0.0009377258,0.000026558639,0.0007027847],"genre_scores_gemma":[0.0005637765,0.9945741,0.000025925889,0.0007163079,0.0000197285,0.00029118147,0.00036028432,0.000102608494,0.0033460797],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9897941,0.003585661,0.0050771674,0.00080142723,0.0002995402,0.00044215113],"domain_scores_gemma":[0.9943745,0.0016384445,0.0027010494,0.00079655286,0.00016726027,0.00032217792],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.015975345,0.0006039624,0.0099023245,0.00042522646,0.0000482355,0.00008796591,0.00056726206,0.00041486666,0.00059589325],"category_scores_gemma":[0.0014601467,0.00042723195,0.00062004564,0.00059555663,0.00010950529,0.00015483447,0.0006862534,0.0008975699,0.000017103608],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020984186,0.0006834105,0.00018863477,0.96227574,0.0015413911,0.000021966409,0.00046512584,9.903974e-9,0.0000030324945,0.000021642505,0.0014565353,0.03313269],"study_design_scores_gemma":[0.007880236,0.00023362949,0.00026984673,0.9194572,0.0023187015,0.00003848463,0.000081975966,0.00009557559,0.0000029952666,0.00004667323,0.069112465,0.00046220177],"about_ca_topic_score_codex":0.00036565738,"about_ca_topic_score_gemma":0.00004070584,"teacher_disagreement_score":0.06765593,"about_ca_system_score_codex":0.00067879516,"about_ca_system_score_gemma":0.0020548766,"threshold_uncertainty_score":0.99981797},"labels":[],"label_agreement":null},{"id":"W4390912419","doi":"10.1186/s40164-024-00473-y","title":"Outcomes of allogeneic hematopoietic stem cell transplantation in R/R DLBCL patients with failure of CAR-T therapy","year":2024,"lang":"en","type":"letter","venue":"Experimental Hematology and Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"York University","keywords":"Medicine; Internal medicine; Hematopoietic stem cell transplantation; Hematology; Lymphoma; Transplantation; Refractory (planetary science); Surgery; Oncology","score_opus":0.018795935414203605,"score_gpt":0.3165809880801099,"score_spread":0.2977850526659063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390912419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97137296,0.0072733904,0.0000029175194,0.018973816,0.00019980139,0.0011548282,0.000050920436,0.00002131109,0.0009500381],"genre_scores_gemma":[0.98166513,0.00042082265,0.000179299,0.015939422,0.000067789326,0.00017109618,0.00029997004,0.00007948964,0.0011769967],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979555,0.00022926668,0.0006303755,0.0004873167,0.0003277065,0.00036983576],"domain_scores_gemma":[0.9990784,0.0002834936,0.00021814638,0.0002892951,0.00006960218,0.000061064624],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00012817518,0.00035741847,0.0015014583,0.00039921261,0.00002370081,0.0000038477124,0.0001398322,0.0010464677,0.0006542044],"category_scores_gemma":[0.000001566417,0.0002638269,0.00014618831,0.00015594017,0.0004905744,0.000033957913,0.00004327274,0.00093371916,0.000011866058],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008800928,0.0054127676,0.8408344,0.009169917,0.0018160194,0.0065623485,0.02448986,0.0000013468187,0.0505721,0.0004755715,0.0491846,0.0026801825],"study_design_scores_gemma":[0.032808937,0.013970218,0.030935181,0.0009508365,0.0004482626,0.002022998,0.0034360474,0.0000053893823,0.8489534,0.00012440923,0.0654403,0.00090397365],"about_ca_topic_score_codex":0.00005547698,"about_ca_topic_score_gemma":0.000036715548,"teacher_disagreement_score":0.80989915,"about_ca_system_score_codex":0.00014879223,"about_ca_system_score_gemma":0.00021115728,"threshold_uncertainty_score":0.9999814},"labels":[],"label_agreement":null},{"id":"W4390988643","doi":"10.1017/cjn.2024.7","title":"Frontal Lobe Status Epilepticus Related to CAR T-Cell Therapy Responsive to Anakinra","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Status epilepticus; Content (measure theory); Neuroscience; Medicine; Frontal lobe; Psychology; Epilepsy; Mathematics","score_opus":0.03829667992383834,"score_gpt":0.32054205253323426,"score_spread":0.2822453726093959,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390988643","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9704041,0.0037909644,0.000021511878,0.016345415,0.0015840294,0.0005492818,0.000028090273,0.000045887897,0.007230701],"genre_scores_gemma":[0.9875052,0.0008546812,0.0016804244,0.008785656,0.00036540252,0.0000072822995,5.614885e-7,0.000032887598,0.0007678803],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99296844,0.0011462444,0.0010681888,0.0009152099,0.0015249047,0.0023769964],"domain_scores_gemma":[0.991527,0.00091990666,0.0002600637,0.00027337435,0.0007183051,0.0063013136],"candidate_categories":["metaepi_narrow","sts","scholarly_communication","insufficient_payload"],"consensus_categories":["sts"],"category_scores_codex":[0.005397853,0.00045201313,0.0007320695,0.002769094,0.0016329305,0.0012453079,0.0017213702,0.00026430222,0.0020892005],"category_scores_gemma":[0.002494989,0.00029719816,0.00041247963,0.0038346027,0.0034655856,0.0006993396,0.000103883,0.0021782673,0.0000625876],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003908614,0.00022349226,0.66333526,0.000049992348,0.00018962137,0.15016815,0.008979037,0.007880299,0.029106999,0.0015152086,0.021963647,0.11267968],"study_design_scores_gemma":[0.0016391563,0.42825484,0.21855652,0.0003155204,0.00011946741,0.08543727,0.0017888881,0.0017488579,0.003533778,0.009012757,0.24840775,0.0011852097],"about_ca_topic_score_codex":0.0027074274,"about_ca_topic_score_gemma":0.02852767,"teacher_disagreement_score":0.4447787,"about_ca_system_score_codex":0.00085278007,"about_ca_system_score_gemma":0.009083076,"threshold_uncertainty_score":0.999948},"labels":[],"label_agreement":null},{"id":"W4391091122","doi":"10.1200/jco.2024.42.3_suppl.tps419","title":"First-in-human phase 1/2 trial evaluating TAC01-CLDN18.2 autologous T cells in CLDN18.2-positive solid tumors.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Cancer; Radioimmunotherapy; Cancer research; Oncology; Internal medicine; Monoclonal antibody; Antibody; Immunology","score_opus":0.21684933801765216,"score_gpt":0.5891909108825557,"score_spread":0.37234157286490355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391091122","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9821911,0.00081654236,0.000067867804,0.0066172485,0.0031858864,0.0010386849,0.000008599626,0.00002850384,0.0060455548],"genre_scores_gemma":[0.991035,0.0004711911,0.0010157241,0.00090356055,0.004324812,0.00002580943,0.0000060460147,0.000057102443,0.0021607545],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9908735,0.0018919873,0.0050476356,0.00050102064,0.000985969,0.0006998846],"domain_scores_gemma":[0.9887789,0.008806296,0.001097804,0.00033055054,0.00042540755,0.0005610756],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.017840836,0.0002735095,0.002880072,0.00080872385,0.00006564508,0.00004864167,0.00036385242,0.00070274225,0.00249989],"category_scores_gemma":[0.006136658,0.00021450601,0.0008677827,0.00062268967,0.000397781,0.00017707153,0.0001230808,0.0043254546,0.000086531254],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29806265,0.013624428,0.002197019,0.00029727034,0.00089320494,0.05089756,0.002014446,0.00040418722,0.05678502,0.00024954035,0.007749169,0.5668255],"study_design_scores_gemma":[0.5423758,0.31974876,0.013954427,0.0034825734,0.0008781564,0.0030827883,0.00094716816,0.03165707,0.006748776,0.003595195,0.07277315,0.000756158],"about_ca_topic_score_codex":0.000103100465,"about_ca_topic_score_gemma":0.00023370414,"teacher_disagreement_score":0.56606936,"about_ca_system_score_codex":0.0009798347,"about_ca_system_score_gemma":0.0041632317,"threshold_uncertainty_score":0.99841195},"labels":[],"label_agreement":null},{"id":"W4391091436","doi":"10.1200/jco.2024.42.3_suppl.747","title":"A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Cytokine release syndrome; Chimeric antigen receptor; Internal medicine; Immunotherapy; Refractory (planetary science); T cell; Oncology; Pharmacokinetics; Chemotherapy; Leukapheresis; Gastroenterology; Immunology; Immune system; Cancer; Stem cell; CD34","score_opus":0.1868673389277022,"score_gpt":0.5374342180194681,"score_spread":0.3505668790917659,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391091436","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98925644,0.00099013,0.000020108517,0.0059215296,0.0012262483,0.000499601,0.000004034971,0.00001813618,0.0020637945],"genre_scores_gemma":[0.9929837,0.001044612,0.001640767,0.00066924834,0.00185873,0.000004071623,0.000002244482,0.000033487162,0.0017631542],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9936056,0.001101991,0.004174935,0.00028394675,0.0005107118,0.00032280257],"domain_scores_gemma":[0.98672205,0.011085878,0.0012081565,0.00023159914,0.0002468097,0.00050549314],"candidate_categories":["metaresearch","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.009806014,0.00016375101,0.0023219066,0.00037887535,0.000041751813,0.0000121160665,0.00017985151,0.0005343781,0.00086590945],"category_scores_gemma":[0.025583822,0.000108655746,0.00040968606,0.00040513134,0.0006398387,0.00008797592,0.00011727595,0.0027963363,0.000005990804],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32849014,0.006486535,0.00059698033,0.00016203658,0.00040098923,0.004900928,0.0008385487,0.000009382794,0.015042985,0.00007370121,0.0015402326,0.64145756],"study_design_scores_gemma":[0.47756246,0.3380775,0.012418158,0.0018533333,0.00047573182,0.002285002,0.00039670014,0.0027526126,0.00090255914,0.00055496744,0.16247389,0.00024710532],"about_ca_topic_score_codex":0.000028116627,"about_ca_topic_score_gemma":0.000041753217,"teacher_disagreement_score":0.64121044,"about_ca_system_score_codex":0.00025304605,"about_ca_system_score_gemma":0.0051377835,"threshold_uncertainty_score":0.99950427},"labels":[],"label_agreement":null},{"id":"W4391103764","doi":"10.1101/2024.01.17.576100","title":"Integrative genomic analysis identifies unique immune environments associated with immunotherapy response in diffuse large B cell lymphoma","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Spinal Cord Injury BC","funders":"National Cancer Institute; Genentech; Leukemia and Lymphoma Society","keywords":"Immune system; Diffuse large B-cell lymphoma; Lymphoma; Immunotherapy; CD19; Chimeric antigen receptor; Cancer research; Biology; Immunology; T cell; CD20; Medicine","score_opus":0.010102333732425953,"score_gpt":0.24466577801587328,"score_spread":0.23456344428344733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391103764","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919076,0.004752238,0.0002684399,0.00021870817,0.0002745029,0.0017964313,0.0004956167,0.00025981892,0.000026630332],"genre_scores_gemma":[0.9954675,0.0018254478,0.0002701182,0.00013340235,0.00009039299,0.0005274063,0.000008285016,0.00035515378,0.0013223242],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99423075,0.0011497545,0.0010244783,0.0016066326,0.0009556267,0.001032758],"domain_scores_gemma":[0.9963102,0.0003665309,0.00050663576,0.0022554924,0.00025456466,0.00030662518],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0028155586,0.0009941888,0.0017441505,0.0022165973,0.00014063642,0.00032632158,0.0006961255,0.0008661363,0.00051511126],"category_scores_gemma":[0.0002508842,0.00088388426,0.00061414606,0.0025694878,0.0002977803,0.000106049425,0.00082236045,0.0018361666,0.00012880194],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043824706,0.0036630065,0.013206817,0.0001923796,0.005017539,0.0009482071,0.00031117615,0.000032342203,0.9721856,0.000021662645,0.000035684654,0.0000030952315],"study_design_scores_gemma":[0.00960486,0.00038009166,0.5800192,0.0010332203,0.0012167266,5.9627666e-8,0.00006356812,0.00077097124,0.40471512,0.0000038986336,0.0012681627,0.00092418224],"about_ca_topic_score_codex":0.00032642914,"about_ca_topic_score_gemma":0.00007242087,"teacher_disagreement_score":0.5674705,"about_ca_system_score_codex":0.0035714414,"about_ca_system_score_gemma":0.001431918,"threshold_uncertainty_score":0.99936116},"labels":[],"label_agreement":null},{"id":"W4391134430","doi":"10.51731/cjht.2024.819","title":"Axicabtagene Ciloleucel (Yescarta)","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.05406790230311775,"score_gpt":0.35301510937500535,"score_spread":0.2989472070718876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391134430","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.20296691,0.5629997,0.00046295518,0.22378992,0.0015567001,0.0005904535,0.000031228665,0.0005054221,0.0070966803],"genre_scores_gemma":[0.9933316,0.0029771097,0.0004560526,0.00049528945,0.00005783306,0.0000047087005,0.000002071215,0.000029584076,0.0026457203],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99848443,0.000041462627,0.00046914467,0.00015582421,0.0002768254,0.00057230785],"domain_scores_gemma":[0.9991676,0.00006726041,0.00008638309,0.000300864,0.00015731787,0.00022055497],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092624937,0.00012097912,0.00038054463,0.0012350387,0.00013019789,0.00006741134,0.0002640119,0.00015994172,0.0007511813],"category_scores_gemma":[0.0003344078,0.00009614057,0.00014309818,0.000621105,0.00023986596,0.00008268209,0.000018552844,0.000904006,0.000057674828],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018474144,0.000009276335,0.0007093625,0.0003025295,0.00007884435,0.0014551822,0.00022223695,0.0000017462514,0.0029044508,0.00076371094,0.019625913,0.97390825],"study_design_scores_gemma":[0.00034696725,0.0011242805,0.001443966,0.0007979722,0.000019119396,0.0021530795,0.0017242358,0.000039853523,0.0047934474,0.0019482335,0.9855056,0.00010327391],"about_ca_topic_score_codex":0.0015264945,"about_ca_topic_score_gemma":0.0013434807,"teacher_disagreement_score":0.973805,"about_ca_system_score_codex":0.0007630841,"about_ca_system_score_gemma":0.006613403,"threshold_uncertainty_score":0.9990182},"labels":[],"label_agreement":null},{"id":"W4391252618","doi":"10.54097/m670m217","title":"CAR T Cell On-Target, Off-Tumor Toxicity in Solid Tumor Treatment: Generation and Management","year":2023,"lang":"en","type":"article","venue":"Highlights in Science Engineering and Technology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Trinity College","funders":"","keywords":"Solid tumor; Toxicity; Cancer research; Medicine; Internal medicine; Cancer","score_opus":0.016592828226762536,"score_gpt":0.27271439272603876,"score_spread":0.2561215644992762,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391252618","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974812,0.00022086545,0.000020890664,0.0011439855,0.00010702764,0.00033698545,0.0000018420195,0.00015742016,0.00052976666],"genre_scores_gemma":[0.99736685,0.0010562319,0.0007626064,0.000022100896,0.000035592864,0.00007714911,0.0000020624825,0.000011755953,0.0006656519],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998876,0.000007091678,0.00014923095,0.00039345364,0.00019115295,0.00038310903],"domain_scores_gemma":[0.9996352,0.000025788677,0.000016692744,0.000233158,0.000019765594,0.00006938225],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028564513,0.00012283433,0.00019602844,0.0016618181,0.00006538322,0.000021330068,0.000102403275,0.00005391216,0.000009239822],"category_scores_gemma":[0.000029736493,0.00010007728,0.000012048857,0.0017177947,0.00018767282,0.00005579447,0.00007744007,0.00012937344,0.000021798836],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028696917,0.00014072734,0.0029848951,0.000079398334,0.000010540565,0.0009011098,0.00029232548,0.0017688783,0.9730985,0.012342818,0.00006244268,0.008289641],"study_design_scores_gemma":[0.002018546,0.00079460564,0.0095474245,0.00010782673,0.000008350443,0.00007333609,0.00015006812,0.11071467,0.859941,0.00019501678,0.016223779,0.00022537343],"about_ca_topic_score_codex":0.000014701698,"about_ca_topic_score_gemma":0.000020933157,"teacher_disagreement_score":0.11315752,"about_ca_system_score_codex":0.0001875208,"about_ca_system_score_gemma":0.000034159082,"threshold_uncertainty_score":0.40810332},"labels":[],"label_agreement":null},{"id":"W4391309797","doi":"10.1055/s-0043-1777627","title":"Tissue-specific chimeric antigen receptor modified regulatory T cells for the therapy of hepatic inflammation","year":2024,"lang":"de","type":"article","venue":"Zeitschrift für Gastroenterologie","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Associated Medical Services","funders":"","keywords":"Inflammation; Chimeric antigen receptor; Immunology; Antigen; Medicine; Genetic enhancement; Receptor; Cancer research; Biology; Immune system; Immunotherapy; Internal medicine; Gene; Biochemistry","score_opus":0.0448052883331775,"score_gpt":0.32366093961049,"score_spread":0.2788556512773125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391309797","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.77196306,0.18623812,0.014137876,0.007732714,0.009747407,0.008376234,0.00041942924,0.00044116104,0.00094397657],"genre_scores_gemma":[0.89256585,0.09958683,0.00078043196,0.00027844645,0.003516893,0.00040356469,0.00022797639,0.00021741427,0.0024226215],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9948456,0.0005097703,0.0012637322,0.0009884057,0.0010624289,0.0013300049],"domain_scores_gemma":[0.996303,0.0011733078,0.00034653052,0.0015581545,0.00036020906,0.00025877036],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020484633,0.00066836685,0.0010013018,0.00047229094,0.00024403655,0.00019700725,0.00089135894,0.00036873433,0.003875765],"category_scores_gemma":[0.00013549915,0.00047438062,0.00061343395,0.0006176856,0.00070250314,0.00021522626,0.00019655099,0.0008754947,0.0005111904],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004849772,0.00025161172,0.0015481551,0.0006425024,0.0018311008,0.000026477366,0.0011843964,0.00037765715,0.72910345,0.00041735524,0.027392108,0.2323754],"study_design_scores_gemma":[0.0030992664,0.004235419,0.0037266454,0.0005289571,0.00022992032,0.000007366985,0.00030748296,0.006157731,0.3858435,0.000035746085,0.5955655,0.00026250593],"about_ca_topic_score_codex":0.00004765509,"about_ca_topic_score_gemma":0.000006258704,"teacher_disagreement_score":0.56817335,"about_ca_system_score_codex":0.000057789115,"about_ca_system_score_gemma":0.00029748798,"threshold_uncertainty_score":0.99977076},"labels":[],"label_agreement":null},{"id":"W4391596701","doi":"10.1038/d41586-024-00305-3","title":"Turbocharged CAR-T cells melt tumours in mice — using a trick from cancer cells","year":2024,"lang":"en","type":"article","venue":"Nature","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"World Federation of Science Journalists","funders":"","keywords":"Immune system; Cancer cell; Potency; Cancer; Cancer research; Mutation; Biology; Chemistry; Molecular biology; Immunology; Genetics; In vitro; Gene","score_opus":0.021628801775249538,"score_gpt":0.34378085773068545,"score_spread":0.3221520559554359,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391596701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95834637,0.03608708,0.0000075553367,0.0016619102,0.0017134786,0.00057194533,0.0001653574,0.00009774205,0.0013485325],"genre_scores_gemma":[0.9861296,0.00081551785,0.0004491248,0.0011342298,0.001194091,0.00002297552,0.00004169914,0.00008585917,0.010126927],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980192,0.00009298781,0.00023830257,0.00053955126,0.0006333377,0.00047660642],"domain_scores_gemma":[0.99917406,0.00020938503,0.00003285183,0.00030415106,0.00010138363,0.00017819449],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00028508267,0.00022925955,0.00039985403,0.00035354664,0.000036897407,0.00006922013,0.00018744565,0.0010422452,0.004479892],"category_scores_gemma":[0.000039778115,0.00019448884,0.0001677259,0.0009918245,0.00004547431,0.00008254971,0.000057655227,0.004359798,0.0001005375],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027003518,0.000058472626,0.00048057738,0.00013324595,0.00008591589,0.0005930654,0.0009901413,0.000036579953,0.98082966,0.000008402634,0.012544452,0.0039694775],"study_design_scores_gemma":[0.0014678166,0.000056126835,0.0011060156,0.0005869629,0.00012177052,0.000018077095,0.0001932923,0.004205871,0.931863,0.00008595913,0.0600479,0.00024718294],"about_ca_topic_score_codex":0.002947352,"about_ca_topic_score_gemma":0.00042558298,"teacher_disagreement_score":0.04896661,"about_ca_system_score_codex":0.00059733866,"about_ca_system_score_gemma":0.00047073208,"threshold_uncertainty_score":0.9979372},"labels":[],"label_agreement":null},{"id":"W4391718044","doi":"10.1016/j.eclinm.2024.102476","title":"Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee","year":2024,"lang":"en","type":"article","venue":"EClinicalMedicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Position paper; Position statement; Intensive care medicine; Immunosuppression; Best practice; Harmonization; Immunology; Family medicine; Pathology","score_opus":0.12500705885243496,"score_gpt":0.4946712732144844,"score_spread":0.36966421436204944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391718044","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0140946135,0.036467973,0.064168476,0.88104117,0.0010173866,0.002500697,0.00022149578,0.0001820365,0.00030615614],"genre_scores_gemma":[0.41693482,0.11253989,0.21437055,0.2318797,0.010375092,0.0012503932,0.008803222,0.00037937146,0.003466964],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99641454,0.000731729,0.0014721531,0.0005929918,0.00053446856,0.00025410287],"domain_scores_gemma":[0.97391444,0.023530625,0.0003120703,0.00052249717,0.0015375974,0.00018276024],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0045464174,0.00024088981,0.0004940198,0.00010775425,0.00026612403,0.00014588283,0.00012844079,0.00014884394,0.00047749287],"category_scores_gemma":[0.017806912,0.00015560396,0.00010257266,0.00049898034,0.0004779848,0.00035209142,0.00009455598,0.00061261386,0.000010167206],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006591094,0.001632073,0.004396694,0.00019695332,0.0025075332,0.00012841274,0.0031136682,0.0000039571187,0.009084895,0.0014182964,0.30751586,0.66341054],"study_design_scores_gemma":[0.0060312874,0.0022226088,0.007408374,0.0009356311,0.0009248662,0.000023126155,0.004757703,0.017153366,0.00025065982,0.00065555953,0.9594344,0.00020241391],"about_ca_topic_score_codex":0.00021330234,"about_ca_topic_score_gemma":0.000009218382,"teacher_disagreement_score":0.6632081,"about_ca_system_score_codex":0.00009821476,"about_ca_system_score_gemma":0.00041049265,"threshold_uncertainty_score":0.99046654},"labels":[],"label_agreement":null},{"id":"W4391774222","doi":"10.1016/j.omton.2024.200775","title":"Discovery and preclinical development of a therapeutically active nanobody-based chimeric antigen receptor targeting human CD22","year":2024,"lang":"en","type":"article","venue":"Molecular Therapy Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; Ottawa Hospital; University of Ottawa; Terry Fox Research Institute; University of British Columbia; Concordia University; National Research Council Canada; Canada's Michael Smith Genome Sciences Centre; Institute of Infection and Immunity","funders":"BC Cancer Agency; National Research Council Canada; Ottawa Hospital Research Institute","keywords":"CD22; Epitope; Antigen; Antibody; Molecular biology; Biology; Immunology; B cell","score_opus":0.0504285465343114,"score_gpt":0.4044585089451424,"score_spread":0.354029962410831,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391774222","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870579,0.0052962336,0.0030235662,0.001566884,0.00017656114,0.00088918675,0.0000067311257,0.00008455478,0.0018983588],"genre_scores_gemma":[0.9873599,0.00068021246,0.009749191,0.0010661259,0.00012476489,0.000114528826,0.00007614332,0.000090415575,0.0007387388],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99765515,0.00037554302,0.00056269666,0.0005697781,0.00041059504,0.00042621285],"domain_scores_gemma":[0.99901205,0.00033837912,0.00009376165,0.00030037347,0.00011308026,0.00014234472],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008125729,0.00025426355,0.0006115952,0.0002259611,0.000103997154,0.000039557286,0.00016428917,0.00025845077,0.0012016519],"category_scores_gemma":[0.000054211865,0.0002052639,0.00020064367,0.00034056898,0.00037759368,0.000065244974,0.00007199928,0.0004890925,0.000021046912],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014152181,0.00039928942,0.00047213197,0.0000709957,0.0006006743,0.00008742442,0.0009224201,0.0000017367258,0.74976736,0.00016158914,0.00005387452,0.2460473],"study_design_scores_gemma":[0.002946941,0.0030588857,0.0032814937,0.00014621046,0.000049635528,0.000025781956,0.00018577056,0.00020173984,0.832917,0.00015794864,0.15677036,0.00025827388],"about_ca_topic_score_codex":0.000013937796,"about_ca_topic_score_gemma":0.0000046777786,"teacher_disagreement_score":0.24578904,"about_ca_system_score_codex":0.00017849963,"about_ca_system_score_gemma":0.0011043538,"threshold_uncertainty_score":0.9997114},"labels":[],"label_agreement":null},{"id":"W4391838668","doi":"10.1182/bloodadvances.2023012463","title":"Extracorporeal photopheresis as a promising strategy for the treatment of graft-versus-host disease after CAR T-cell therapy","year":2024,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"bluebird bio; Mallinckrodt Pharmaceuticals; Jazz Pharmaceuticals","keywords":"Extracorporeal Photopheresis; Photopheresis; Graft-versus-host disease; Immunology; Medicine; Hematopoietic stem cell transplantation; T cell; Mixed lymphocyte reaction; CD19; Immune system; CD8; Transplantation; Internal medicine; Lymphoma","score_opus":0.040692693254508416,"score_gpt":0.34950940949916676,"score_spread":0.30881671624465834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391838668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8402372,0.15521519,0.00002747761,0.00036125391,0.00023281373,0.0021400615,0.000107768494,0.00006376935,0.0016144788],"genre_scores_gemma":[0.9635819,0.024711484,0.0002645489,0.00003989771,0.0004404261,0.0009230465,0.000021770871,0.000059904472,0.009956994],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986879,0.000038636335,0.00023543653,0.00037556636,0.0003441825,0.00031827248],"domain_scores_gemma":[0.9988004,0.000515348,0.000049175815,0.000386721,0.00008211953,0.00016622974],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000113909504,0.00022182346,0.0002792015,0.00007250384,0.00007393456,0.000058381476,0.000110644505,0.00004693622,0.0010291899],"category_scores_gemma":[0.000016570353,0.00012830352,0.00030893236,0.00020157712,0.00015208582,0.00011049936,0.000010006883,0.000086013024,0.000009991462],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044577625,0.003985932,0.0037810004,0.001205605,0.0017583385,0.00083197514,0.0018501756,0.00006514092,0.4238974,0.00022675435,0.00019692989,0.5176231],"study_design_scores_gemma":[0.019100634,0.013435848,0.0053198333,0.00040219634,0.001511133,0.000030088731,0.0012865213,0.00059458555,0.509402,0.00096549996,0.44748095,0.0004707701],"about_ca_topic_score_codex":0.0001048892,"about_ca_topic_score_gemma":0.000059800645,"teacher_disagreement_score":0.51715237,"about_ca_system_score_codex":0.000059264235,"about_ca_system_score_gemma":0.00030628417,"threshold_uncertainty_score":0.999884},"labels":[],"label_agreement":null},{"id":"W4391886452","doi":"10.1093/intimm/dxae007","title":"Reprogramming T-cell metabolism to enhance adoptive cell therapies","year":2024,"lang":"en","type":"review","venue":"International Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Canada Research Chairs; University Health Network","funders":"National Institutes of Health","keywords":"Reprogramming; Adoptive cell transfer; T cell; Cell metabolism; Cell; Metabolism; Cell biology; Chemistry; Cancer research; Biology; Immunology; Immune system; Biochemistry","score_opus":0.046104247773667534,"score_gpt":0.4189143796292311,"score_spread":0.37281013185556355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391886452","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000097102595,0.9719727,0.00008886259,0.0006345087,0.0026626545,0.0012233374,0.000056344812,0.00014250481,0.023121972],"genre_scores_gemma":[0.0000753884,0.8651581,0.0009997467,0.00018080419,0.00079358264,0.00049462717,0.00023084924,0.0001298408,0.13193709],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99722135,0.00017998181,0.00070931716,0.00089395867,0.0005041624,0.0004911998],"domain_scores_gemma":[0.99838424,0.00021566007,0.0002068303,0.000734353,0.00035070046,0.000108220906],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00039081956,0.0005041801,0.001482311,0.00089174364,0.000046267214,0.000103067876,0.0007592416,0.00044201437,0.004219542],"category_scores_gemma":[0.0000901979,0.0003952688,0.0007785732,0.0004908659,0.00015721108,0.00006164364,0.00047327482,0.001369584,0.004125193],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000120862,0.00018725441,5.7170934e-7,0.001489875,0.0018311703,0.00021712121,0.00045794493,1.3678856e-7,0.0033147933,0.0003049736,0.002073658,0.9900016],"study_design_scores_gemma":[0.00024131262,0.00021779584,0.0000024674289,0.0022898319,0.0006598862,0.0002439963,0.00009526626,0.0000016474487,0.0014519279,0.00007924567,0.9944245,0.00029211227],"about_ca_topic_score_codex":0.00009079495,"about_ca_topic_score_gemma":0.0000066465595,"teacher_disagreement_score":0.9923509,"about_ca_system_score_codex":0.0004598407,"about_ca_system_score_gemma":0.00042869578,"threshold_uncertainty_score":0.9998499},"labels":[],"label_agreement":null},{"id":"W4391989862","doi":"10.1002/9781119824572.ch18","title":"The Scientific Rationale for Targeting Tumor‐Associated Antigens","year":2024,"lang":"en","type":"other","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Antigen; Tumor associated antigen; Computational biology; Biology; Immunology; Immunotherapy; Immune system","score_opus":0.0393911888289574,"score_gpt":0.34260041206276615,"score_spread":0.3032092232338087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391989862","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00015220686,0.0056027495,0.000085297994,0.0019403775,0.0015928252,0.0020597358,0.000110796704,0.00031243506,0.98814356],"genre_scores_gemma":[0.00015845052,0.00009452167,0.00029395672,0.00013528329,0.00079481426,0.00011008265,0.00033028805,0.0004417034,0.9976409],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99851876,0.00003379793,0.0001878279,0.0003739175,0.0005281171,0.00035756643],"domain_scores_gemma":[0.9991984,0.00018657676,0.00006711009,0.0003137188,0.00015826583,0.000075952834],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0010453638,0.00015225174,0.00022651313,0.00019927973,0.00018883582,0.00022992837,0.00014485177,0.00011659824,0.023559012],"category_scores_gemma":[0.00039696172,0.00009292672,0.00018805222,0.0003070481,0.00018037738,0.000009995181,0.000050299903,0.0002462067,0.0010275097],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022651577,0.0000276064,0.000020805122,0.00012247672,0.00021185062,0.000009054708,0.00006311403,8.325389e-8,0.011219142,0.00065454346,0.9869132,0.00073547586],"study_design_scores_gemma":[0.00037025366,0.000044565397,0.0000066730154,0.00017408744,0.000046612615,0.0000034887094,0.0001403966,0.00025345144,0.0010588488,0.00033596912,0.99746376,0.00010191411],"about_ca_topic_score_codex":0.00004698076,"about_ca_topic_score_gemma":0.0002966064,"teacher_disagreement_score":0.022531502,"about_ca_system_score_codex":0.0001073671,"about_ca_system_score_gemma":0.0003296368,"threshold_uncertainty_score":0.9997503},"labels":[],"label_agreement":null},{"id":"W4392050283","doi":"10.1038/s42255-024-00976-2","title":"Metabolic engineering for optimized CAR-T cell therapy","year":2024,"lang":"en","type":"article","venue":"Nature Metabolism","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Spinal Cord Injury BC; University of Victoria","funders":"Canadian Institutes of Health Research; Terry Fox Research Institute; University of Victoria; Government of Canada; U.S. Department of Defense","keywords":"Chimeric antigen receptor; Cytotoxicity; Immune system; Metabolic pathway; Biology; T cell; Computational biology; Cell; Immunotherapy; Genome editing; Metabolic engineering; Function (biology); Genetic enhancement; Bioinformatics; Cancer research; Immunology; Gene; Genome; Cell biology; Genetics","score_opus":0.014721376386846024,"score_gpt":0.30953550042048317,"score_spread":0.29481412403363716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392050283","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12766609,0.84366304,0.004282953,0.0036689646,0.0060876543,0.0047905217,0.00013642767,0.0010917768,0.00861257],"genre_scores_gemma":[0.78011596,0.029601356,0.066398956,0.0037757382,0.012744908,0.001981882,0.00029217437,0.0007876438,0.10430141],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979599,0.000045088153,0.00028675457,0.0005431994,0.0005688445,0.0005961933],"domain_scores_gemma":[0.99871165,0.00029200147,0.000028888306,0.0005272726,0.00020062304,0.00023955423],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00062916527,0.0003369145,0.00069402275,0.00047242307,0.00006082728,0.00012521367,0.00022979641,0.00050320406,0.0014783418],"category_scores_gemma":[0.00013013527,0.0002566178,0.00055188016,0.00069988467,0.000037148995,0.0001217167,0.000042434167,0.0014039603,0.000057004072],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007944132,0.00011575453,0.000009791859,0.00028893375,0.00061308,0.000067685556,0.00046361046,0.00011371589,0.8459301,0.006640694,0.008537061,0.13642518],"study_design_scores_gemma":[0.0028715436,0.00004992689,0.00036307448,0.000033196993,0.00016878809,0.000033437205,0.000014710976,0.0034201161,0.22398826,0.000110539484,0.76875,0.00019641129],"about_ca_topic_score_codex":0.000013282223,"about_ca_topic_score_gemma":5.9616303e-7,"teacher_disagreement_score":0.8140617,"about_ca_system_score_codex":0.000046504738,"about_ca_system_score_gemma":0.00017391625,"threshold_uncertainty_score":0.9999886},"labels":[],"label_agreement":null},{"id":"W4392131538","doi":"10.1002/cam4.7033","title":"Access to innovative therapies in pediatric oncology: Report of the nationwide experience in Canada","year":2024,"lang":"en","type":"article","venue":"Cancer Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; University of Alberta; Janeway Children's Health and Rehabilitation Centre; University of Toronto; Memorial University of Newfoundland; Centre Hospitalier Universitaire de Sherbrooke; Centre Hospitalier Universitaire Sainte-Justine; McMaster Children's Hospital; McGill University Health Centre; CancerCare Manitoba; University of Manitoba; Children's Hospital of Eastern Ontario; Children's Hospital of Western Ontario; London Health Sciences Centre; Montreal Children's Hospital; Hospital for Sick Children; Western University; Saskatoon City Hospital; University of Calgary; Research Institute in Oncology and Hematology; Université Laval; BC Children's Hospital; SickKids Foundation; Stollery Children's Hospital","funders":"Hospital for Sick Children; McGill University Health Centre; BC Children's Hospital; McGill University","keywords":"Medicine; Clinical trial; Context (archaeology); Oncology; Cancer; Everolimus; Internal medicine","score_opus":0.08125349747259299,"score_gpt":0.448215773911411,"score_spread":0.366962276438818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392131538","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94705147,0.00418735,0.000009630889,0.040663302,0.0009182032,0.00064931146,0.000004080884,0.000009805727,0.0065068803],"genre_scores_gemma":[0.9945924,0.0007665694,0.0000123851805,0.0022033793,0.0003850529,0.00025377143,0.0000031328316,0.00001486784,0.0017683889],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984193,0.00005829567,0.00045881164,0.00026071252,0.00058474165,0.0002181668],"domain_scores_gemma":[0.99909127,0.00024983808,0.00006919318,0.00027750662,0.00024164995,0.0000705246],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005329546,0.00010224885,0.00032313974,0.00038340516,0.000016066386,0.0000050433136,0.00023874853,0.00004189604,0.0013430116],"category_scores_gemma":[0.0005483665,0.0000624084,0.00001744263,0.0039222157,0.00011807283,0.000066249784,0.00007983998,0.0003564517,6.87955e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019699686,0.00003303789,0.9119011,0.00023685751,0.00003431562,0.0010312031,0.016312419,0.000041101197,0.015165318,0.00008581436,0.01224879,0.042713013],"study_design_scores_gemma":[0.001092214,0.00015282526,0.9166267,0.0006939638,0.000015736427,0.00006843318,0.0032311801,0.00008774785,0.006744434,0.000075393466,0.07111692,0.00009444955],"about_ca_topic_score_codex":0.65402335,"about_ca_topic_score_gemma":0.8295921,"teacher_disagreement_score":0.17556873,"about_ca_system_score_codex":0.001784157,"about_ca_system_score_gemma":0.0066710827,"threshold_uncertainty_score":0.9995699},"labels":[],"label_agreement":null},{"id":"W4392203306","doi":"10.1016/j.xcrm.2024.101435","title":"Nilotinib in KIT-driven advanced melanoma: Results from the phase II single-arm NICAM trial","year":2024,"lang":"en","type":"article","venue":"Cell Reports Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Medical Research Council; Manchester Biomedical Research Centre; Ipsen; NIHR Cambridge Biomedical Research Centre; Rosetrees Trust; Royal Marsden NHS Foundation Trust; Department of Health and Social Care; Cancer Research UK; National Institute for Health and Care Research; National Institutes of Health; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; Novartis; Melanoma Research Alliance; Francis Crick Institute; Wellcome Trust; Amgen","keywords":"Medicine","score_opus":0.05398573251415962,"score_gpt":0.35691144629571064,"score_spread":0.30292571378155103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392203306","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8948732,0.008552894,0.000035772442,0.015965685,0.0036664014,0.0027059726,0.000030977037,0.00025981755,0.073909305],"genre_scores_gemma":[0.955976,0.0006401535,0.00016192057,0.00061638537,0.0034495003,0.00009936869,0.0004998512,0.000098901735,0.03845792],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951641,0.00018362,0.0016534091,0.0010827959,0.0012749727,0.0006410963],"domain_scores_gemma":[0.99611646,0.0015122921,0.00029524363,0.0015422471,0.00015587712,0.00037785145],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0021789258,0.00038076134,0.00088687526,0.00029220994,0.00013150735,0.00003665155,0.00025280225,0.00021107798,0.0040664217],"category_scores_gemma":[0.002457345,0.00023379645,0.00021259465,0.0008875113,0.00042308852,0.00010297841,0.00017301702,0.001086025,0.00004614068],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08221851,0.004562158,0.000263904,0.00018281974,0.0002690214,0.032351807,0.008776343,0.000026084064,0.58309484,0.000029717648,0.06547905,0.22274578],"study_design_scores_gemma":[0.13343921,0.01510642,0.00024088811,0.001629776,0.0003248589,0.0005886259,0.0010350725,0.0005483988,0.024010196,0.0004176262,0.822308,0.00035091295],"about_ca_topic_score_codex":0.0005967067,"about_ca_topic_score_gemma":0.00011001311,"teacher_disagreement_score":0.75682896,"about_ca_system_score_codex":0.00032745762,"about_ca_system_score_gemma":0.00050242356,"threshold_uncertainty_score":0.996844},"labels":[],"label_agreement":null},{"id":"W4392288363","doi":"10.1002/adma.202313226","title":"Antigen Presenting Cell Mimetic Lipid Nanoparticles for Rapid mRNA CAR T Cell Cancer Immunotherapy","year":2024,"lang":"en","type":"article","venue":"Advanced Materials","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"University of Pennsylvania; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Allergy and Infectious Diseases; Perelman School of Medicine, University of Pennsylvania; National Institutes of Health; Canadian Aeronautics and Space Institute; National Center for Advancing Translational Sciences; Division of Chemical, Bioengineering, Environmental, and Transport Systems; National Cancer Institute; National Science Foundation; Emerson Collective","keywords":"Materials science; Cancer immunotherapy; Immunotherapy; Cancer; Cell; Nanoparticle; Nanotechnology; Cancer research; Medicine; Biology; Biochemistry; Internal medicine","score_opus":0.02429534248655237,"score_gpt":0.3365589295503751,"score_spread":0.31226358706382273,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392288363","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97955686,0.014984016,0.00007163381,0.00043850724,0.0016722911,0.0017503006,0.000111493886,0.000349672,0.0010652425],"genre_scores_gemma":[0.9744691,0.009249627,0.0026268438,0.00022098173,0.0010153785,0.00063084334,0.000038391925,0.00023858596,0.011510237],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978012,0.000078471945,0.00048179366,0.0005379425,0.00040545437,0.0006951237],"domain_scores_gemma":[0.99888724,0.00022854871,0.0000878104,0.00047918572,0.0001793374,0.00013785856],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006138005,0.00027444935,0.0005229155,0.00015149,0.00010010527,0.00016907549,0.00018578887,0.00010602596,0.003912481],"category_scores_gemma":[0.000046854664,0.00023632245,0.00017005313,0.0002399351,0.00008354103,0.00018981779,0.000060935534,0.000119524346,0.00008525436],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007296796,0.00009178772,0.00007009963,0.00091948616,0.000098367884,0.000028686536,0.0004699741,0.00002558361,0.9739197,0.000026863994,0.0009426305,0.022677151],"study_design_scores_gemma":[0.0015547738,0.00022889671,0.00013222826,0.0001602925,0.000039721563,0.00000794695,0.00006961993,0.000043088887,0.7696784,0.00013685238,0.22775602,0.00019213649],"about_ca_topic_score_codex":0.0000918356,"about_ca_topic_score_gemma":0.000004663531,"teacher_disagreement_score":0.2268134,"about_ca_system_score_codex":0.0001532746,"about_ca_system_score_gemma":0.00020287654,"threshold_uncertainty_score":0.9969981},"labels":[],"label_agreement":null},{"id":"W4392303061","doi":"10.1136/jitc-2023-008735","title":"Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy","year":2024,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Iovance Biotherapeutics; Gilead Sciences; Servier; National Cancer Institute; Genentech; Regeneron Pharmaceuticals; National Institutes of Health; Swedish Orphan Biovitrum; Pfizer; Moderna; Incyte; Ipsen; BeiGene; Sun Pharma; Sanofi; Moffitt Cancer Center; Exelixis; Seagen; Agios Pharmaceuticals; Society for Immunotherapy of Cancer; Bristol-Myers Squibb; AstraZeneca; Amgen; GlaxoSmithKline","keywords":"Medicine; Context (archaeology); Intensive care medicine; Clinical trial; Cell therapy; Best practice; Internal medicine; Stem cell","score_opus":0.26030052746488336,"score_gpt":0.5246172299582877,"score_spread":0.2643167024934044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392303061","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014449976,0.99183226,0.000038852682,0.000911978,0.0014690142,0.004261209,0.00013490031,0.000027599714,0.0011796709],"genre_scores_gemma":[0.0000011028455,0.9491868,0.004467408,0.0007347612,0.001843226,0.0010798584,0.000017157063,0.00026795565,0.04240175],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965638,0.00011116425,0.0015749778,0.0005320225,0.000692888,0.0005251685],"domain_scores_gemma":[0.99603516,0.0007288034,0.0019463848,0.0004700342,0.0006691275,0.0001504732],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013649064,0.0006504909,0.002073346,0.0005401865,0.00022590575,0.00020712962,0.00031405006,0.00023029392,0.00045656893],"category_scores_gemma":[0.00009870923,0.00043027033,0.0012551509,0.00025544077,0.00013235593,0.000069500114,0.000032318625,0.00058225973,0.0000050565136],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032378368,0.00018210498,8.8905244e-7,0.015361357,0.0031020774,0.00003938691,0.0001618553,0.0000023597527,0.0016735175,0.000026885446,0.017265212,0.9589465],"study_design_scores_gemma":[0.005394632,0.0025009436,2.4641878e-7,0.025074815,0.0009996322,0.00046256644,0.00025084658,0.000046996614,0.00093369395,0.00006797629,0.9638933,0.00037438],"about_ca_topic_score_codex":0.00013524784,"about_ca_topic_score_gemma":0.000008195481,"teacher_disagreement_score":0.95857215,"about_ca_system_score_codex":0.00056803634,"about_ca_system_score_gemma":0.0011321958,"threshold_uncertainty_score":0.9998149},"labels":[],"label_agreement":null},{"id":"W4392529715","doi":"10.1126/sciadv.adk2298","title":"Machine learning predictions of T cell antigen specificity from intracellular calcium dynamics","year":2024,"lang":"en","type":"article","venue":"Science Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"T-cell receptor; Antigen; Cytotoxic T cell; Polyclonal antibodies; T cell; Cell biology; Biology; CD8; Immunology; Biochemistry; Immune system; In vitro","score_opus":0.022950374647809003,"score_gpt":0.32752769963639977,"score_spread":0.30457732498859075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392529715","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95004004,0.013852016,0.017207395,0.00044421933,0.00078235,0.00029956148,0.00008883842,0.00015820838,0.017127398],"genre_scores_gemma":[0.989905,0.0011192041,0.0020620143,0.000012507839,0.00017373939,0.00000474058,0.00003167645,0.000015172463,0.0066759307],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99829113,0.000030146657,0.00021451115,0.00041639342,0.00073396356,0.00031383024],"domain_scores_gemma":[0.9992955,0.00012831128,0.00004255785,0.00026898045,0.00012221637,0.00014243752],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00054774736,0.00010563586,0.00018909888,0.00025441396,0.00017059778,0.00005806376,0.00024528374,0.00003855819,0.0013225487],"category_scores_gemma":[0.000102550286,0.00008666279,0.000070565766,0.0011893959,0.00068246725,0.00037148688,0.00008211774,0.00039517044,0.000048428457],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000042275413,0.00006352978,0.013873591,0.000064753025,0.000011411015,0.00003422698,0.0003545203,0.0006176118,0.9488997,0.00025893858,0.000014558084,0.03576491],"study_design_scores_gemma":[0.00026778036,0.0003150424,0.0036376151,0.0001431811,0.000025906773,0.000014267126,0.0007649305,0.23248409,0.7161339,0.0006508026,0.045429025,0.00013349124],"about_ca_topic_score_codex":0.00023312987,"about_ca_topic_score_gemma":0.000053150718,"teacher_disagreement_score":0.2327658,"about_ca_system_score_codex":0.0001729812,"about_ca_system_score_gemma":0.00028082114,"threshold_uncertainty_score":0.9995904},"labels":[],"label_agreement":null},{"id":"W4392561740","doi":"10.1128/jvi.01701-23","title":"The human adenovirus PI3K-Akt activator E4orf1 is targeted by the tumor suppressor p53","year":2024,"lang":"en","type":"article","venue":"Journal of Virology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"Deutsche Forschungsgemeinschaft","keywords":"Biology; Suppressor; PI3K/AKT/mTOR pathway; Cancer research; Activator (genetics); Adenoviridae; Protein kinase B; Tumor suppressor gene; Virology; Molecular biology; Cell biology; Carcinogenesis; Genetic enhancement; Gene; Signal transduction; Genetics","score_opus":0.024383124702418966,"score_gpt":0.3449633092336427,"score_spread":0.3205801845312237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392561740","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9414274,0.009961333,0.000027836226,0.04581117,0.00073278917,0.00027991462,0.000019643474,0.000024954037,0.0017149734],"genre_scores_gemma":[0.98171437,0.00038377233,0.000020463902,0.0032378423,0.0012657277,0.000012392016,0.0000028675229,0.000053267515,0.013309301],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99792814,0.00030398378,0.0005137219,0.00019183249,0.00060185697,0.0004604423],"domain_scores_gemma":[0.9983249,0.00075612083,0.00018283437,0.00040394688,0.00015479891,0.00017743939],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011610875,0.00017189086,0.00038082665,0.00014691653,0.00026704845,0.00009949764,0.00049221265,0.0001280198,0.005768389],"category_scores_gemma":[0.00020641503,0.000083456296,0.0002854374,0.00023884597,0.00039026098,0.00009847225,0.00009385119,0.0015303182,0.000105809035],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00072637945,0.00008077907,0.000212498,0.000020302834,0.00043044207,0.00035815404,0.00044385678,8.690018e-7,0.78130555,0.00013198433,0.21239074,0.0038984357],"study_design_scores_gemma":[0.0012609981,0.0016318699,0.0022373516,0.00004094829,0.00014045877,0.0021205468,0.00022213311,0.00009685929,0.19304445,0.00069662137,0.79841673,0.000091001064],"about_ca_topic_score_codex":0.00003511304,"about_ca_topic_score_gemma":0.0000071836357,"teacher_disagreement_score":0.5882611,"about_ca_system_score_codex":0.0001339004,"about_ca_system_score_gemma":0.0002325359,"threshold_uncertainty_score":0.9951405},"labels":[],"label_agreement":null},{"id":"W4392588447","doi":"10.1038/s41467-024-46367-9","title":"Structural basis for self-discrimination by neoantigen-specific TCRs","year":2024,"lang":"en","type":"article","venue":"Nature Communications","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Argonne National Laboratory; Biological and Environmental Research; National Institute of Allergy and Infectious Diseases; National Cancer Institute; Melanoma Research Alliance; University of Chicago; National Institute of General Medical Sciences; Cancer Research Institute; York University; U.S. Department of Energy","keywords":"T-cell receptor; Avidity; Major histocompatibility complex; Epitope; Biology; T cell; Cytolysis; Immunogenicity; Computational biology; Antigen presentation; Cell biology; Antigen; Genetics; Cytotoxic T cell; Immune system; In vitro","score_opus":0.050255254777179514,"score_gpt":0.3819615148023472,"score_spread":0.3317062600251677,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392588447","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.19203898,0.45535356,0.0014966632,0.25432357,0.0027672437,0.007576062,0.0012118159,0.0028846078,0.08234749],"genre_scores_gemma":[0.97464675,0.00609666,0.00957787,0.00047031802,0.0001964145,0.00018198689,0.0010377133,0.000055570497,0.0077366903],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99896425,0.00007680822,0.0002039562,0.00024615607,0.0002841956,0.00022462266],"domain_scores_gemma":[0.9976264,0.0005675622,0.000028989794,0.0014211616,0.00025996604,0.00009588062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00027645886,0.00013167021,0.00016354833,0.00019150178,0.000271325,0.000106521125,0.00054023304,0.00025722492,0.0008671626],"category_scores_gemma":[0.000102447324,0.00011550421,0.00015413425,0.0004820229,0.00010091879,0.00011994497,0.000126062,0.0010243806,0.000052799744],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015546907,0.00023880514,0.00070292817,0.000314439,0.00044696455,0.0000051314037,0.0023935172,0.0000015706668,0.18813425,0.06043294,0.47613117,0.27104282],"study_design_scores_gemma":[0.0003641632,0.00007965405,0.002035561,0.00007693903,0.00006878779,0.0000280021,0.00016110839,0.0045175743,0.004556437,0.00042048772,0.9875673,0.0001239865],"about_ca_topic_score_codex":0.000010317615,"about_ca_topic_score_gemma":0.00004357342,"teacher_disagreement_score":0.7826078,"about_ca_system_score_codex":0.00024161841,"about_ca_system_score_gemma":0.00012270329,"threshold_uncertainty_score":0.94948226},"labels":[],"label_agreement":null},{"id":"W4392600366","doi":"10.1016/j.xcrm.2024.101465","title":"Ex vivo activation of the GCN2 pathway metabolically reprograms T cells, leading to enhanced adoptive cell therapy","year":2024,"lang":"en","type":"article","venue":"Cell Reports Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; Princess Margaret Cancer Foundation","keywords":"Cell biology; Ex vivo; Cell therapy; Chemistry; Biophysics; Biology; Stem cell; Biochemistry; In vitro","score_opus":0.030274837885283092,"score_gpt":0.3158685303698254,"score_spread":0.2855936924845423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392600366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8990592,0.00357412,0.002513487,0.0031045314,0.0019695307,0.0031355515,0.000004568989,0.00024894546,0.08639008],"genre_scores_gemma":[0.9141445,0.000535442,0.0004777931,0.00076850224,0.00083098776,0.00009395915,0.000022039765,0.00010238956,0.08302437],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9959549,0.00013916935,0.0010023254,0.000914545,0.0014351316,0.0005539492],"domain_scores_gemma":[0.9971468,0.00027030238,0.00031599568,0.0014498075,0.00045192274,0.0003651638],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015911048,0.00037077258,0.00080083625,0.00032643028,0.00009388074,0.00003268326,0.00023929638,0.0001918475,0.0033565331],"category_scores_gemma":[0.0002609882,0.00022261069,0.0003049824,0.0014780038,0.0003029796,0.00009585356,0.000116135205,0.0006832101,0.000035158086],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003007487,0.00022950837,0.00014276443,0.0002411613,0.000090523565,0.00024820882,0.0035603377,0.000022429464,0.9123773,0.00001952799,0.005851108,0.07691639],"study_design_scores_gemma":[0.00068051956,0.0007321471,0.000279566,0.00050532253,0.000075014235,0.00006849209,0.00052402896,0.000045210865,0.75761527,0.000058772766,0.23926167,0.00015398968],"about_ca_topic_score_codex":0.00018501136,"about_ca_topic_score_gemma":0.0000054571055,"teacher_disagreement_score":0.23341055,"about_ca_system_score_codex":0.00020131267,"about_ca_system_score_gemma":0.0004648493,"threshold_uncertainty_score":0.99755454},"labels":[],"label_agreement":null},{"id":"W4392634220","doi":"10.1136/ijgc-2024-esgo.7","title":"237 InnovaTV 301/ENGOT-Cx12/GOG-3057: a global, randomized, open-label, phase 3 study of tisotumab vedotin versus investigator’s choice of chemotherapy in 2L Or 3L recurrent or metastatic cervical cancer","year":2024,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital","funders":"","keywords":"Open label; Medicine; Chemotherapy; Oncology; Internal medicine; Phases of clinical research; Randomized controlled trial","score_opus":0.19083547522675567,"score_gpt":0.5127291952406223,"score_spread":0.3218937200138666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392634220","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98537624,0.003915505,0.000046085563,0.00599374,0.0023485085,0.001732954,0.00013515685,0.000016254817,0.00043556778],"genre_scores_gemma":[0.9939144,0.0032188962,0.00058165827,0.0008992688,0.0005113494,0.000283518,0.000009169816,0.000036738922,0.00054496253],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99509543,0.00054747803,0.0018857231,0.0004314682,0.0016674546,0.00037246433],"domain_scores_gemma":[0.99475604,0.0026125535,0.0007218218,0.000231611,0.001363114,0.00031483645],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001944308,0.00032478856,0.0016314867,0.00044722072,0.000030157256,0.000101557634,0.0010441126,0.00014024758,0.020142004],"category_scores_gemma":[0.003992249,0.00019611766,0.0002156643,0.0011932014,0.0003602617,0.00026077332,0.0002683312,0.00087155896,0.0000059214353],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.7358775,0.013869187,0.0067766546,0.00035703753,0.006588321,0.0020981482,0.0012143545,0.0001309089,0.008027918,0.0005067148,0.00586203,0.2186912],"study_design_scores_gemma":[0.92291445,0.025708979,0.011915011,0.0023731836,0.0009165326,0.00022132587,0.0010158028,0.0031303642,0.004041248,0.00083734083,0.026394114,0.00053164875],"about_ca_topic_score_codex":0.001522627,"about_ca_topic_score_gemma":0.0024323524,"teacher_disagreement_score":0.21815956,"about_ca_system_score_codex":0.0016739835,"about_ca_system_score_gemma":0.0030236843,"threshold_uncertainty_score":0.9807537},"labels":[],"label_agreement":null},{"id":"W4392785337","doi":"10.3791/65887-v","title":"JoVE Video Dataset","year":2024,"lang":"pt","type":"article","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"","keywords":"Computer science; Artificial intelligence","score_opus":0.05829413987748627,"score_gpt":0.392553274354005,"score_spread":0.3342591344765187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392785337","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016969299,0.08765262,0.00224929,0.06424225,0.010990465,0.0038902734,0.019558042,0.0011878586,0.7932599],"genre_scores_gemma":[0.07902476,0.0016422762,0.00007056153,0.0023292215,0.001987743,0.000022810453,0.0036233906,0.00010068837,0.91119856],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976272,0.00009695037,0.00031573037,0.0005968328,0.0007459328,0.0006173271],"domain_scores_gemma":[0.9981974,0.00039958395,0.000014588465,0.0009500173,0.000055081757,0.0003833703],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0007641077,0.00023541113,0.0003179843,0.00026371214,0.00005652546,0.0002360357,0.0002582794,0.00016611573,0.36622614],"category_scores_gemma":[0.00012338387,0.00018554214,0.00014522212,0.0005908003,0.00012746333,0.00014503728,0.0002307908,0.0007292648,0.03275261],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017644792,0.000096390744,0.00014614018,0.00054105936,0.00037616308,0.0011163113,0.00039281877,6.086345e-7,0.03631045,0.0012655908,0.8988732,0.060704794],"study_design_scores_gemma":[0.00070007966,0.00037715965,0.0001842606,0.00033361328,0.00014322466,0.00011382871,0.00041650044,0.004222615,0.0076329554,0.00007761342,0.98560077,0.00019740907],"about_ca_topic_score_codex":0.0004626722,"about_ca_topic_score_gemma":0.000099459576,"teacher_disagreement_score":0.33347353,"about_ca_system_score_codex":0.00020284722,"about_ca_system_score_gemma":0.00041196364,"threshold_uncertainty_score":0.96800053},"labels":[],"label_agreement":null},{"id":"W4392785618","doi":"10.3791/65887","title":"Efficient Generation of Murine Chimeric Antigen Receptor (CAR)-T Cells","year":2024,"lang":"en","type":"article","venue":"Journal of Visualized Experiments","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"National Center for Advancing Translational Sciences; National Institute of Biomedical Imaging and Bioengineering","keywords":"Chimeric antigen receptor; Immune system; Context (archaeology); T cell; Cancer research; Antigen; Tumor microenvironment; Immunology; Biology; Medicine","score_opus":0.06399087211917413,"score_gpt":0.46268778668373856,"score_spread":0.3986969145645644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392785618","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910591,0.0058779023,0.00063636346,0.00013644838,0.0012716755,0.0003057269,0.000005459853,0.000020049496,0.0006872521],"genre_scores_gemma":[0.9922553,0.0008033785,0.003124451,0.00007854382,0.0009528253,0.0000066668727,0.000011155034,0.000053164924,0.0027145236],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99782944,0.00012118522,0.0007227924,0.00018145997,0.0009106494,0.00023448493],"domain_scores_gemma":[0.9990819,0.000047356774,0.00021758255,0.00020386276,0.00025619703,0.00019309056],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005832558,0.00015947185,0.00047323265,0.00042486037,0.000036847796,0.00003983305,0.00012674347,0.00007639494,0.005182816],"category_scores_gemma":[0.00003765026,0.00012303265,0.0002932842,0.00039467178,0.0000644989,0.000057521793,0.00004399715,0.00024127324,0.000060964114],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00063984876,0.0005485079,0.00010278334,0.000085728374,0.00036451206,0.00007234456,0.0013052735,0.00007412177,0.9885242,0.000024260538,0.004476523,0.003781896],"study_design_scores_gemma":[0.0021502303,0.0010776117,0.00013201291,0.00027592102,0.000051825147,0.00009156177,0.00022063412,0.004326084,0.9723217,0.0000029867836,0.019253446,0.00009601679],"about_ca_topic_score_codex":0.00001895471,"about_ca_topic_score_gemma":1.5221651e-7,"teacher_disagreement_score":0.01620253,"about_ca_system_score_codex":0.00019327366,"about_ca_system_score_gemma":0.00022102459,"threshold_uncertainty_score":0.9957266},"labels":[],"label_agreement":null},{"id":"W4392796921","doi":"10.1073/pnas.2310866121","title":"Structural insights reveal interplay between LAG-3 homodimerization, ligand binding, and function","year":2024,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Allergy and Infectious Diseases; National Institute of General Medical Sciences; York University; National Cancer Institute; National Institutes of Health; Emerson Collective; Melanoma Research Alliance","keywords":"Ectodomain; Allosteric regulation; Ligand (biochemistry); Cell biology; Receptor; Function (biology); Chemistry; Mutation; Biophysics; Biology; Biochemistry; Gene","score_opus":0.04585850223171072,"score_gpt":0.35700207098395614,"score_spread":0.3111435687522454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392796921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99354666,0.00047880996,0.0000011000866,0.0023094083,0.00003547695,0.00019230292,0.0000089010755,0.000018368419,0.0034089386],"genre_scores_gemma":[0.99783707,0.000050110844,0.00014148164,0.00007864208,0.000213086,0.000004143533,7.265316e-7,0.0000055248465,0.0016692055],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998481,0.0000050498575,0.00023007569,0.0002231827,0.00094985083,0.00011084137],"domain_scores_gemma":[0.99954796,0.000104796425,0.00010105815,0.0000064535893,0.00019403483,0.00004572014],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062968966,0.00007716973,0.00014184038,0.00031151355,0.00013963839,0.000052632728,0.00019573743,0.00007634144,0.000048889768],"category_scores_gemma":[0.00019723232,0.00004696323,0.00004784911,0.0008933234,0.0006430572,0.00037167224,0.000088804074,0.00021741622,0.000001613204],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004121456,0.000008627134,0.03717332,0.00020809648,0.000053680502,1.7413033e-8,0.0005674962,0.0000022246786,0.9480814,0.009493232,0.00074396766,0.0036267485],"study_design_scores_gemma":[0.00035817252,0.00033949816,0.29109362,0.00054801826,0.00006993457,0.000040629347,0.00025086515,0.0014800248,0.67113376,0.03261624,0.0019585066,0.000110717345],"about_ca_topic_score_codex":0.0000044158846,"about_ca_topic_score_gemma":4.874131e-8,"teacher_disagreement_score":0.2769476,"about_ca_system_score_codex":0.000038470185,"about_ca_system_score_gemma":0.0000496504,"threshold_uncertainty_score":0.23693712},"labels":[],"label_agreement":null},{"id":"W4392854760","doi":"10.1177/0272989x241234070","title":"CAR T-cell Therapy for Diffuse Large B-cell Lymphoma in Canada: A Cost-Utility Analysis","year":2024,"lang":"en","type":"article","venue":"Medical Decision Making","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; University of Waterloo; Canadian Centre for Applied Research in Cancer Control; University of Guelph; Toronto General Hospital","funders":"Canadian Institutes of Health Research; Canada First Research Excellence Fund","keywords":"Medicine; Clinical trial; Chimeric antigen receptor; Quality-adjusted life year; Cost-effectiveness analysis; Cost effectiveness; Oncology; Internal medicine; Intensive care medicine; Immunotherapy; Cancer","score_opus":0.03373929135459469,"score_gpt":0.3590436528543052,"score_spread":0.3253043614997105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392854760","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9624999,0.0048601413,0.028095864,0.00085372257,0.00045361373,0.0011617928,0.00007415539,0.00006622109,0.0019345784],"genre_scores_gemma":[0.9956255,0.0006079429,0.00056101655,0.001400391,0.00020164953,0.00012807944,0.000043137683,0.000052147454,0.0013801688],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9954097,0.00014770201,0.0006798898,0.00073249877,0.0022563103,0.00077386375],"domain_scores_gemma":[0.99625355,0.0024186,0.000050538434,0.0006440312,0.00013033811,0.00050294213],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002272016,0.00025220492,0.00071856234,0.000603687,0.000089336456,0.00006838177,0.00036324852,0.0002221761,0.007333224],"category_scores_gemma":[0.00084471045,0.00019219318,0.00040141898,0.0018308705,0.00006115192,0.00005309313,0.00013361129,0.0004560384,0.000028547316],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015349255,0.0015076108,0.015651118,0.00017440016,0.00025316223,0.0016512257,0.00028899417,0.000008341953,0.0014598871,0.000033076867,0.008233175,0.96920407],"study_design_scores_gemma":[0.02817574,0.0003550556,0.034306508,0.00071646,0.00033358362,0.000045209403,0.0004993876,0.490039,0.0019343427,0.00055416237,0.44255394,0.00048659637],"about_ca_topic_score_codex":0.05540683,"about_ca_topic_score_gemma":0.38924697,"teacher_disagreement_score":0.9687175,"about_ca_system_score_codex":0.0012121042,"about_ca_system_score_gemma":0.0034533564,"threshold_uncertainty_score":0.9935742},"labels":[],"label_agreement":null},{"id":"W4392881315","doi":"10.1016/j.jcyt.2024.03.009","title":"Accelerating the development of genetically engineered cellular therapies: a framework for extrapolating data across related products","year":2024,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University","funders":"","keywords":"Chimeric antigen receptor; Genetically engineered; Clinical trial; Cell therapy; Cancer; Medicine; Immune system; Genetically modified organism; Computational biology; Immunotherapy; Bioinformatics; Immunology; Biology; Cell; Internal medicine","score_opus":0.13037486829129202,"score_gpt":0.39490187779802277,"score_spread":0.26452700950673075,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392881315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8759806,0.016790416,0.100299165,0.0032457751,0.00040295595,0.0026605732,0.000060271235,0.00024055707,0.000319697],"genre_scores_gemma":[0.77515423,0.0003353882,0.2210779,0.00020085752,0.0006359301,0.00018816322,0.00014039387,0.00018149697,0.0020856143],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976267,0.00007289065,0.0006595959,0.00062119117,0.00048385546,0.0005357424],"domain_scores_gemma":[0.9975724,0.00078691484,0.000081966966,0.0012709376,0.00019890604,0.00008887719],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017795308,0.00025070042,0.00036915313,0.00008514399,0.00023155242,0.00014210521,0.0005807455,0.0001839317,0.0007253364],"category_scores_gemma":[0.00033989546,0.0001687539,0.00010430535,0.00064168277,0.0001520587,0.00009961536,0.000109716035,0.0005126899,0.000012015499],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019838587,0.000073578456,0.000098572775,0.00034970147,0.00055991474,0.000006411582,0.018422103,0.00001216658,0.7223746,0.0009419374,0.00014961066,0.256813],"study_design_scores_gemma":[0.0027875062,0.0006545423,0.0013789099,0.001506403,0.00010151452,0.000049152317,0.002904716,0.040179417,0.7788336,0.002700219,0.16827698,0.0006270149],"about_ca_topic_score_codex":0.000004279569,"about_ca_topic_score_gemma":0.0000036015854,"teacher_disagreement_score":0.25618595,"about_ca_system_score_codex":0.00007968521,"about_ca_system_score_gemma":0.00051676185,"threshold_uncertainty_score":0.79419243},"labels":[],"label_agreement":null},{"id":"W4392886198","doi":"10.1186/s12967-024-05063-4","title":"CAR T cells and T cells phenotype and function are impacted by glucocorticoid exposure with different magnitude","year":2024,"lang":"en","type":"article","venue":"Journal of Translational Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Karolinska Institutet; National Cancer Institute; Radiumhemmets Forskningsfonder; Cancerfonden; Stiftelsen Tornspiran; Memorial Sloan-Kettering Cancer Center","keywords":"Chimeric antigen receptor; CD28; Cytokine release syndrome; Cytotoxic T cell; Interleukin 21; T cell; IL-2 receptor; CD19; Cancer research; Interleukin 3; Immune system; Medicine; Immunology; Biology; Chemistry; In vitro","score_opus":0.015910685704372277,"score_gpt":0.27530309591415947,"score_spread":0.2593924102097872,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392886198","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9743116,0.016344175,0.0013995412,0.007049842,0.0003250944,0.00032058157,0.000023566055,0.00001624485,0.0002093732],"genre_scores_gemma":[0.99646753,0.0014622088,0.00014689627,0.00023094752,0.00058766536,0.000002351891,0.000019522167,0.000031209667,0.0010516926],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99839103,0.00005093583,0.00039777154,0.00018046722,0.0008028566,0.0001769461],"domain_scores_gemma":[0.9990272,0.00026122158,0.00011060001,0.00009449226,0.00023133816,0.00027515797],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00027558155,0.00017719442,0.00042415294,0.00024413693,0.00003759647,0.000028530409,0.000041288116,0.00008030939,0.0011161452],"category_scores_gemma":[0.000017519931,0.000103967526,0.000055924687,0.00019218924,0.00014498319,0.00012263801,0.0000058317983,0.00047782157,0.0000024805845],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003006787,0.00010139079,0.011611627,0.0005227897,0.0004706968,0.00016215455,0.00072122266,0.000024125022,0.95995504,0.0000212664,0.0021468678,0.021256013],"study_design_scores_gemma":[0.032301627,0.026395692,0.78015506,0.006658927,0.0037875227,0.0030337153,0.0017269142,0.003414553,0.08000111,0.00078589504,0.06101637,0.00072260236],"about_ca_topic_score_codex":0.000012507312,"about_ca_topic_score_gemma":0.0000094408,"teacher_disagreement_score":0.879954,"about_ca_system_score_codex":0.00004701447,"about_ca_system_score_gemma":0.00011680502,"threshold_uncertainty_score":0.999797},"labels":[],"label_agreement":null},{"id":"W4392921484","doi":"10.1038/s41540-024-00355-3","title":"Making drugs from T cells: The quantitative pharmacology of engineered T cell therapeutics","year":2024,"lang":"en","type":"article","venue":"npj Systems Biology and Applications","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Chimeric antigen receptor; Medicine; Systems pharmacology; Immune system; Drug; Translation (biology); Pharmacology; Computational biology; Immunotherapy; Immunology; Biology","score_opus":0.0637748487477591,"score_gpt":0.4028104538280402,"score_spread":0.3390356050802811,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392921484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7289923,0.16601977,0.05324094,0.006179234,0.0024397306,0.0070730816,0.0008058328,0.00039178954,0.034857318],"genre_scores_gemma":[0.9964837,0.0007954834,0.00019617815,0.000112851034,0.00030479388,0.00036570284,0.000038792532,0.000015460373,0.0016870552],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.999243,0.00011829504,0.00021174687,0.00021803548,0.00006377471,0.00014509978],"domain_scores_gemma":[0.99886817,0.0007896871,0.000045187968,0.00019966222,0.00006517351,0.000032122865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002479287,0.00009416964,0.0002017474,0.0000722041,0.00007397278,0.000013245516,0.00010624525,0.00012131175,0.00019976222],"category_scores_gemma":[0.0000023008747,0.000060951093,0.000050198716,0.00020570312,0.00022678715,0.000013808432,0.00003083594,0.00023023886,0.0000398919],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000046489276,0.000048689864,0.00016168853,0.00015571722,0.00025690178,0.0000017232793,0.0011572163,0.00001231643,0.9766301,0.016239848,0.0005480714,0.0047412664],"study_design_scores_gemma":[0.0008423822,0.00028301124,0.0002859524,0.00010702409,0.00037660103,0.000033927357,0.003229213,0.012339056,0.12842098,0.0011731145,0.852734,0.00017471967],"about_ca_topic_score_codex":0.00007715188,"about_ca_topic_score_gemma":0.0000014459516,"teacher_disagreement_score":0.85218596,"about_ca_system_score_codex":0.000022403752,"about_ca_system_score_gemma":0.00005944739,"threshold_uncertainty_score":0.24855135},"labels":[],"label_agreement":null},{"id":"W4392955797","doi":"10.1038/s43018-024-00744-x","title":"Synthetic dual co-stimulation increases the potency of HIT and TCR-targeted cell therapies","year":2024,"lang":"en","type":"article","venue":"Nature Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; National Cancer Institute; U.S. Department of Health and Human Services; Government of Canada; Marie-Josée and Henry R. Kravis Center for Molecular Oncology; Servier; Cycle for Survival","keywords":"T-cell receptor; Chimeric antigen receptor; Ectodomain; Antigen; CD28; Receptor; T cell; Biology; Cell biology; CD80; CD3; Cancer research; Immunology; Molecular biology; Cytotoxic T cell; Immune system; CD8; In vitro; Biochemistry; CD40","score_opus":0.012960246948447891,"score_gpt":0.3315731635100779,"score_spread":0.31861291656163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392955797","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8571389,0.135918,0.0000069706252,0.0024982586,0.00019840225,0.00040169244,0.000055200584,0.0000535175,0.0037290528],"genre_scores_gemma":[0.9918248,0.0025940167,0.000038088037,0.0003083322,0.00029703573,0.000026666774,0.000016570646,0.000027273683,0.0048672077],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990862,0.000062642954,0.00013045344,0.00020472538,0.00035922494,0.00015675715],"domain_scores_gemma":[0.9993134,0.00029558514,0.000028725923,0.00020699139,0.00010047439,0.000054815206],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00021933658,0.00011040559,0.00017353398,0.000099789555,0.000049741288,0.000025584075,0.000059770256,0.00017731455,0.002832113],"category_scores_gemma":[0.000062661085,0.0000656505,0.00006602413,0.00024183479,0.00013824005,0.000043439064,0.000020531998,0.0005494776,0.000006211047],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008888797,0.00013058772,0.00857,0.0008200824,0.00037789711,0.00006819485,0.0022462856,0.000042440806,0.84016806,0.00065758475,0.011096391,0.13493362],"study_design_scores_gemma":[0.0039617326,0.000989905,0.15046494,0.0015635954,0.00075397093,0.0001766035,0.0013327834,0.006041188,0.42534906,0.0020778605,0.40666747,0.0006208902],"about_ca_topic_score_codex":0.00025378517,"about_ca_topic_score_gemma":0.000034780587,"teacher_disagreement_score":0.41481897,"about_ca_system_score_codex":0.00007062501,"about_ca_system_score_gemma":0.00016977427,"threshold_uncertainty_score":0.9980794},"labels":[],"label_agreement":null},{"id":"W4392967953","doi":"10.1101/2024.03.18.584896","title":"Gene editing of <i>CD3 epsilon</i> gene to redirect regulatory T cells for adoptive T cell transfer","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network","funders":"","keywords":"Adoptive cell transfer; Gene; Gene transfer; T cell; Genome editing; CD3; Biology; Cell biology; Genetics; Immune system; CD8; Genome","score_opus":0.020909864188841935,"score_gpt":0.2559609035531854,"score_spread":0.23505103936434346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392967953","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9828102,0.0037463007,0.0018030005,0.0005714048,0.0032032058,0.0051757013,0.0020170591,0.0005202083,0.00015289694],"genre_scores_gemma":[0.96705836,0.00040144703,0.027382636,0.0004381161,0.002792576,0.00092578615,0.00000383425,0.00060326705,0.0003939903],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99439234,0.00016543691,0.0011935332,0.0019056163,0.0011794638,0.0011636065],"domain_scores_gemma":[0.99508953,0.0002206795,0.00023520952,0.0021300698,0.0015069619,0.00081754744],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018075624,0.00093518087,0.0015910036,0.00087387674,0.00012992557,0.00012111014,0.00067247264,0.0009489779,0.0003576416],"category_scores_gemma":[0.00015537349,0.0009942373,0.0007884356,0.0010111613,0.0002206222,0.0000687444,0.00062396616,0.0015664962,0.000099892815],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00065262645,0.00029088205,0.0001791149,0.00354854,0.0005441052,0.0001451082,0.000088433444,0.00013723836,0.99040973,0.000054829878,0.003929138,0.00002024019],"study_design_scores_gemma":[0.0015218825,0.0004993731,0.0011450378,0.0011526791,0.0006324689,1.0425043e-7,0.0000125229035,0.0002670044,0.9795996,0.000003830018,0.014374131,0.00079138775],"about_ca_topic_score_codex":0.000056663906,"about_ca_topic_score_gemma":0.000002459252,"teacher_disagreement_score":0.025579637,"about_ca_system_score_codex":0.00078050315,"about_ca_system_score_gemma":0.0017919051,"threshold_uncertainty_score":0.9992508},"labels":[],"label_agreement":null},{"id":"W4392987439","doi":"10.3390/biology13030196","title":"Engineering a Dual Specificity γδ T-Cell Receptor for Cancer Immunotherapy","year":2024,"lang":"en","type":"article","venue":"Biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Food Inspection Agency; Leucid Bio","keywords":"Biology; T-cell receptor; Cancer immunotherapy; Cytotoxic T cell; Immunotherapy; Cytolysis; Antigen; Cancer research; T cell; Immunology; Molecular biology; Virology; Immune system; Genetics","score_opus":0.03771093852680156,"score_gpt":0.34493183315043147,"score_spread":0.3072208946236299,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4392987439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96732247,0.01920966,0.003019753,0.0034560366,0.0028059706,0.001200802,0.00013653087,0.00050502334,0.0023437308],"genre_scores_gemma":[0.9228948,0.0070288246,0.0040830267,0.00067179813,0.0055446383,0.0007374026,0.00016570279,0.0002505869,0.05862325],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99921626,0.000020350646,0.00014046075,0.00026089663,0.00006316201,0.00029888045],"domain_scores_gemma":[0.9995276,0.00017717901,0.000012028445,0.00017619674,0.000045824,0.00006120559],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00020766995,0.00010940657,0.00020659939,0.00010847609,0.000019411935,0.000015022347,0.00006310162,0.00012784354,0.0048939106],"category_scores_gemma":[0.000024739764,0.0000881615,0.00011516103,0.00013530844,0.00004408369,0.000016306749,0.000018717294,0.0001827204,0.00008623725],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033848343,0.00003347576,0.00027428413,0.00010416659,0.000098015844,0.000006371117,0.00018144614,0.000002881386,0.9520487,0.0005453881,0.0066191517,0.03974762],"study_design_scores_gemma":[0.0006544837,0.00031322852,0.00016962906,0.000031883672,0.000009324946,0.000011282133,0.000014104723,0.00067899376,0.14168176,0.000056740337,0.8562928,0.0000857915],"about_ca_topic_score_codex":0.0000916666,"about_ca_topic_score_gemma":0.000008495414,"teacher_disagreement_score":0.8496736,"about_ca_system_score_codex":0.00013882219,"about_ca_system_score_gemma":0.00012030967,"threshold_uncertainty_score":0.9960157},"labels":[],"label_agreement":null},{"id":"W4393015884","doi":"10.1002/ajh.27283","title":"Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor <scp>ECOG</scp> performance status with relapsed or refractory large B‐cell lymphoma after 2 or more lines of prior therapy","year":2024,"lang":"en","type":"article","venue":"American Journal of Hematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; Office of Naval Research; bluebird bio; Pharmacyclics; Daiichi Sankyo Europe; Takeda Oncology; AstraZeneca; Genentech; Adaptive Biotechnologies; Health Resources and Services Administration; National Institutes of Health; MorphoSys; Seagen; CareDx; BeiGene; Swedish Orphan Biovitrum; Astellas Pharma; GlaxoSmithKline; Kiadis Pharma; Sanofi; TG Therapeutics; Medac; Ipsen; Jazz Pharmaceuticals; Boston Scientific Corporation; StemCyte; U.S. Navy; Legend Biotech; HistoGenetics; Omeros Corporation; Vertex Pharmaceuticals; Leukemia and Lymphoma Society; U.S. Department of Defense; Celgene; CSL Behring; Bristol-Myers Squibb; Amgen; National Heart, Lung, and Blood Institute; Ascentage Pharma; Novartis Pharmaceuticals Corporation; Incyte; Pfizer; Mallinckrodt Pharmaceuticals; Society for Immunotherapy of Cancer; Astellas Pharma US; Atara Biotherapeutics; Actinium Pharmaceuticals; National Cancer Institute; Gilead Sciences","keywords":"Chemoimmunotherapy; Medicine; Internal medicine; Hazard ratio; Refractory (planetary science); Propensity score matching; Lymphoma; Regimen; Salvage therapy; Gastroenterology; Surgery; Oncology; Chemotherapy; Confidence interval; Rituximab","score_opus":0.010061085264894416,"score_gpt":0.2739395781119439,"score_spread":0.2638784928470495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393015884","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964622,0.0026300787,0.000016078999,0.00010796588,0.00012138901,0.0005536207,0.000032659078,0.0000128013235,0.00006319845],"genre_scores_gemma":[0.99329174,0.0045483285,0.0011408469,0.00022723411,0.00003574273,0.000028059556,0.000012729516,0.000091146314,0.00062419975],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974711,0.000098623,0.00087592355,0.00032611605,0.0006693211,0.00055895],"domain_scores_gemma":[0.9976118,0.000592435,0.00069821393,0.0003337018,0.0005695851,0.00019422194],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026172877,0.00032827447,0.001213343,0.00054199813,0.00003351346,0.000013719573,0.0001965152,0.00011264152,0.00040745863],"category_scores_gemma":[0.0000845409,0.00017543293,0.00010927755,0.0007509417,0.00052823353,0.00018280515,0.000044375298,0.00037333122,0.0000020467103],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17754357,0.0049851146,0.6260374,0.0007904191,0.0010550396,0.00058672007,0.0065189446,0.000004158523,0.0037548605,0.00000275228,0.00017363999,0.17854734],"study_design_scores_gemma":[0.098877825,0.07991399,0.7702038,0.001997006,0.0002156076,0.00052090076,0.004139993,0.0001519824,0.0373883,0.000002439741,0.006277054,0.00031106058],"about_ca_topic_score_codex":0.000047032987,"about_ca_topic_score_gemma":0.00005267178,"teacher_disagreement_score":0.17823629,"about_ca_system_score_codex":0.00012817535,"about_ca_system_score_gemma":0.0007673252,"threshold_uncertainty_score":0.71539474},"labels":[],"label_agreement":null},{"id":"W4393032832","doi":"10.1073/pnas.2319856121","title":"IL7 increases targeted lipid nanoparticle–mediated mRNA expression in T cells in vitro and in vivo by enhancing T cell protein translation","year":2024,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Acuitas Therapeutics (Canada)","funders":"","keywords":"Molecular biology; T cell; mCherry; Biology; CD8; Messenger RNA; In vitro; Cell biology; Immune system; Green fluorescent protein; Immunology; Biochemistry","score_opus":0.024774281273011643,"score_gpt":0.30096348590813754,"score_spread":0.2761892046351259,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393032832","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99654406,0.0009192295,3.043545e-7,0.0013335831,0.000008563529,0.00057439186,0.000015047613,0.0000111035615,0.00059370755],"genre_scores_gemma":[0.9991439,0.00009172941,0.00046708318,0.000053679614,0.000029541285,0.000038686918,4.678823e-7,0.000006789121,0.00016812961],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99814427,0.00002274269,0.00040428832,0.00028328,0.0009409964,0.00020441931],"domain_scores_gemma":[0.99953735,0.00024116012,0.00009644965,0.000008272921,0.00006848178,0.00004825978],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019065861,0.00009416266,0.00018918228,0.0005101354,0.000037498263,0.000025830686,0.0001908433,0.00009631219,0.0000626817],"category_scores_gemma":[0.00028991353,0.00006733128,0.000032131076,0.0014995243,0.0002909871,0.00040062098,0.00004969268,0.0002956442,6.81916e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023146287,0.00011099439,0.0025714708,0.00026575045,0.000002154767,1.0312646e-7,0.0005920091,0.00001662194,0.9955473,0.000017145034,0.000068553876,0.00057641935],"study_design_scores_gemma":[0.00062422716,0.00005786882,0.0037592896,0.0006581102,0.000003036386,0.0000020664672,0.00021468928,0.0075225667,0.986317,0.0006630642,0.00011469468,0.0000633955],"about_ca_topic_score_codex":0.0000673105,"about_ca_topic_score_gemma":0.000001869591,"teacher_disagreement_score":0.009230323,"about_ca_system_score_codex":0.00008473842,"about_ca_system_score_gemma":0.00007505007,"threshold_uncertainty_score":0.274569},"labels":[],"label_agreement":null},{"id":"W4393084941","doi":"10.1158/1538-7445.am2024-6716","title":"Abstract 6716: DLL3 TriTCE Co-Stim: A next generation trispecific T cell engager with integrated CD28 costimulation for the treatment of DLL3-expressing cancers","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Cancer research; Medicine; Cell; Cancer; Internal medicine; Biology","score_opus":0.29885606712149465,"score_gpt":0.4732763836450434,"score_spread":0.17442031652354872,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393084941","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96899796,0.020790504,0.0016230764,0.0014406812,0.0003017802,0.0046254313,0.00019256372,0.00008322396,0.0019448097],"genre_scores_gemma":[0.97707474,0.0066966675,0.0002242012,0.000025754134,0.0010130776,0.0014378616,0.00020940439,0.000094666924,0.013223604],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997187,0.00022103351,0.0003749019,0.00055417954,0.0010636785,0.0005991619],"domain_scores_gemma":[0.99677,0.0016860502,0.0000640224,0.00052379805,0.00077644165,0.00017968779],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013098296,0.00023406373,0.00037437904,0.00042434252,0.00036346357,0.0002467265,0.00018032818,0.00013716597,0.0024303293],"category_scores_gemma":[0.0000880719,0.00014103821,0.00015525812,0.0009725064,0.0003434428,0.00017380505,0.000015349648,0.00065753993,0.00001885152],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037152383,0.00019096739,0.00027697659,0.00034091558,0.00024133995,0.0000357466,0.0019414687,0.0021472927,0.8293941,0.000018624283,0.01001552,0.15168183],"study_design_scores_gemma":[0.0049476833,0.0024595712,0.0008573077,0.0005666747,0.00012935326,0.000008017698,0.001327818,0.055035934,0.68828386,0.000011747379,0.24617322,0.00019878523],"about_ca_topic_score_codex":0.0032499742,"about_ca_topic_score_gemma":0.00048989296,"teacher_disagreement_score":0.2361577,"about_ca_system_score_codex":0.0026559213,"about_ca_system_score_gemma":0.0022995113,"threshold_uncertainty_score":0.9984816},"labels":[],"label_agreement":null},{"id":"W4393087951","doi":"10.1158/1538-7445.am2024-6325","title":"Abstract 6325: Lineage tracing defines responding CAR T cells in patients with B cell malignancies","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of New Brunswick","funders":"","keywords":"Lineage (genetic); Cell lineage; Cancer research; Biology; Medicine; Genetics; Gene; Cellular differentiation","score_opus":0.06131275062229219,"score_gpt":0.3844948816443257,"score_spread":0.3231821310220335,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393087951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897762,0.0028350495,0.000005879834,0.0004432155,0.00020022732,0.0010339346,0.000056533805,0.000081025115,0.0055679306],"genre_scores_gemma":[0.97607183,0.0006855978,0.00009015061,0.000045550576,0.0003356953,0.00019050944,0.000024751827,0.00010694093,0.02244899],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9962054,0.00015447443,0.00034108708,0.00065524015,0.001603855,0.001039939],"domain_scores_gemma":[0.998267,0.0005323162,0.000027260965,0.00048399335,0.00042023024,0.0002691865],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001731656,0.0002230953,0.00035408605,0.0015095604,0.00013348373,0.00019105458,0.00025310135,0.00014673146,0.0028227835],"category_scores_gemma":[0.000089729685,0.00017342629,0.00009076578,0.0022384706,0.00023051539,0.0001995784,0.00011160311,0.0014383411,0.00018894208],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025309094,0.00022047965,0.047111545,0.001649279,0.000060550115,0.00077965466,0.0015436427,0.0001039079,0.93619704,0.00004484797,0.0028341895,0.0069239363],"study_design_scores_gemma":[0.0040033613,0.0010825102,0.10976627,0.0035768615,0.0000318774,0.000007514217,0.000771192,0.00018066747,0.8320726,0.00003334138,0.04802755,0.00044625677],"about_ca_topic_score_codex":0.00082952133,"about_ca_topic_score_gemma":0.00021815649,"teacher_disagreement_score":0.104124464,"about_ca_system_score_codex":0.00088098965,"about_ca_system_score_gemma":0.0009234567,"threshold_uncertainty_score":0.9980888},"labels":[],"label_agreement":null},{"id":"W4393093070","doi":"10.1158/1538-7445.am2024-6740","title":"Abstract 6740: Next-generation LNPs induce effective anti-tumor T cell responses","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Pacific Railway (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cancer research; Biology","score_opus":0.18236883560364034,"score_gpt":0.46299014508014313,"score_spread":0.28062130947650277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393093070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9755081,0.009568283,0.000013296567,0.0022914011,0.00051583606,0.001764363,0.00004063764,0.0001422923,0.01015582],"genre_scores_gemma":[0.9665617,0.00155081,0.00003351941,0.00014688775,0.0020040765,0.00074015796,0.000030976447,0.00009949637,0.028832378],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9960567,0.00049647945,0.0002767463,0.00074868096,0.0015504173,0.00087098917],"domain_scores_gemma":[0.9974244,0.0010320735,0.0000327199,0.0005937158,0.0005607199,0.00035635722],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0029160434,0.00021326922,0.00032458347,0.0008237652,0.00025216307,0.00037763864,0.0002546591,0.00015809003,0.008355663],"category_scores_gemma":[0.0005305345,0.00018143415,0.00014665288,0.0013911363,0.0003051461,0.000263828,0.00013895975,0.0017871454,0.0009716549],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00083703425,0.00011319513,0.0007226411,0.00055085524,0.00008362521,0.000709867,0.00048651587,0.000009543595,0.92109376,0.0000723656,0.020488432,0.054832134],"study_design_scores_gemma":[0.00089545414,0.00054525497,0.01588977,0.00040888673,0.000022499476,0.00004516127,0.00021528002,0.0004717254,0.87798846,0.000064582295,0.103260174,0.0001927507],"about_ca_topic_score_codex":0.0010900308,"about_ca_topic_score_gemma":0.00009608167,"teacher_disagreement_score":0.08277174,"about_ca_system_score_codex":0.0010671437,"about_ca_system_score_gemma":0.0017349422,"threshold_uncertainty_score":0.9998062},"labels":[],"label_agreement":null},{"id":"W4393093578","doi":"10.1158/1538-7445.am2024-1868","title":"Abstract 1868: Target-dependent considerations for the design of bispecific T-cell engagers","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AbCellera (Canada)","funders":"","keywords":"Bispecific antibody; Computer science; Medicine; Human–computer interaction; Immunology; Antibody","score_opus":0.27608712638577726,"score_gpt":0.4572063767417708,"score_spread":0.18111925035599352,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393093578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.45613056,0.25952685,0.0498375,0.099913,0.005827312,0.046568617,0.0014917591,0.00087838515,0.07982601],"genre_scores_gemma":[0.972896,0.0032587387,0.0007272375,0.000062795734,0.000538755,0.0010564977,0.0000079301835,0.00006715658,0.0213849],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99746907,0.00023423326,0.00028953317,0.00037708206,0.0010640293,0.0005660373],"domain_scores_gemma":[0.99186707,0.0068077953,0.00002436377,0.0005252191,0.0006114431,0.00016413382],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0041586272,0.0001251599,0.00022393058,0.00034247778,0.0003318729,0.00014490994,0.00021039027,0.00009439087,0.016788596],"category_scores_gemma":[0.00055645214,0.000084776024,0.00014355416,0.0004984061,0.00040137052,0.000068944944,0.000062821826,0.0010578276,0.00010665449],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00047013472,0.0000925009,0.00004778783,0.0005093966,0.00017101935,0.00006674949,0.0008796862,0.00077477,0.9067652,0.0006929584,0.08284973,0.0066800164],"study_design_scores_gemma":[0.0015994705,0.00048037714,0.00038469315,0.00026908764,0.00005567814,0.000023729888,0.0016166273,0.0039305068,0.86400473,0.0024962542,0.124969035,0.000169793],"about_ca_topic_score_codex":0.0003464721,"about_ca_topic_score_gemma":0.000036141253,"teacher_disagreement_score":0.5167654,"about_ca_system_score_codex":0.00037585993,"about_ca_system_score_gemma":0.0019419235,"threshold_uncertainty_score":0.9841102},"labels":[],"label_agreement":null},{"id":"W4393096401","doi":"10.1158/1538-7445.am2024-2373","title":"Abstract 2373: Functional and specific T-cell engagers against a peptide-MHC tumor target","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AbCellera (Canada)","funders":"","keywords":"Major histocompatibility complex; Biology; Computer science; Psychology; Computational biology; Medicine; Antigen; Immunology","score_opus":0.106342958946202,"score_gpt":0.3899743948057807,"score_spread":0.28363143585957873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393096401","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9039788,0.020051964,0.000022803244,0.0023776414,0.00044906564,0.00083470554,0.000062243125,0.00012956219,0.072093174],"genre_scores_gemma":[0.92227244,0.0052960594,0.000120100616,0.00020675123,0.0016587024,0.00026123822,0.00005372747,0.00009978282,0.070031166],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964408,0.00016800992,0.00026240246,0.0007189954,0.0015471029,0.0008626764],"domain_scores_gemma":[0.9981805,0.0005404575,0.000018407996,0.00043274256,0.0003343347,0.00049353193],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0022606198,0.0002013671,0.00027770342,0.0006135503,0.00027043468,0.0002531034,0.00017201755,0.000102505655,0.026211994],"category_scores_gemma":[0.00011079022,0.00017440354,0.00012888177,0.00085516926,0.00047779173,0.00014423441,0.00014099857,0.0021903939,0.00080985716],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069247594,0.00010870425,0.0013005018,0.0007190666,0.00009524991,0.0010396108,0.00044999845,0.000021152255,0.8238206,0.00015194017,0.15074944,0.02085127],"study_design_scores_gemma":[0.001472556,0.0002907702,0.009818063,0.00043368078,0.000011497391,0.00006137076,0.00080350327,0.00033506038,0.07072754,0.00022708347,0.9155804,0.0002384913],"about_ca_topic_score_codex":0.00019626776,"about_ca_topic_score_gemma":0.000021788604,"teacher_disagreement_score":0.76483095,"about_ca_system_score_codex":0.0006798335,"about_ca_system_score_gemma":0.0011295566,"threshold_uncertainty_score":0.9999681},"labels":[],"label_agreement":null},{"id":"W4393096561","doi":"10.1158/1538-7445.am2024-6719","title":"Abstract 6719: TriTCE Co-Stim: A next generation trispecific T cell engager platform with integrated CD28 costimulation, engineered to improve responses in the treatment of solid tumors","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"CD28; Cancer research; T cell; Medicine; Immune system; Immunology","score_opus":0.17556246383653798,"score_gpt":0.43762412715906307,"score_spread":0.2620616633225251,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393096561","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919594,0.002454162,0.00010181147,0.0011863335,0.00009219926,0.0030348597,0.00017582948,0.00004548581,0.0009498968],"genre_scores_gemma":[0.98877674,0.0012082653,0.00009985296,0.00003966954,0.00040952943,0.00097104354,0.00012320622,0.00006456663,0.008307149],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9969885,0.00027276162,0.00045214698,0.0005155636,0.0011824878,0.00058858783],"domain_scores_gemma":[0.99725413,0.0014148412,0.00003586145,0.0005732563,0.0005195807,0.00020235623],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020970714,0.0002298151,0.00039865804,0.0009911354,0.00012457951,0.00015203688,0.00021680875,0.000114951465,0.0018083238],"category_scores_gemma":[0.00022543402,0.00013967729,0.00009204227,0.0018779313,0.00015429397,0.00014742377,0.000017055288,0.00081905985,0.00006211081],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071421256,0.0004304743,0.00022086143,0.00018843959,0.00008870253,0.00029412433,0.0058744876,0.00095349015,0.944751,0.00002468302,0.0039332462,0.036098357],"study_design_scores_gemma":[0.0048224116,0.0059530577,0.0055555226,0.00048014385,0.000039378807,0.000024498258,0.0026755258,0.009947045,0.9151509,0.000016570119,0.055094797,0.0002401845],"about_ca_topic_score_codex":0.0010366677,"about_ca_topic_score_gemma":0.0003746116,"teacher_disagreement_score":0.05116155,"about_ca_system_score_codex":0.0014400111,"about_ca_system_score_gemma":0.001612422,"threshold_uncertainty_score":0.99910414},"labels":[],"label_agreement":null},{"id":"W4393096802","doi":"10.1158/1538-7445.am2024-5241","title":"Abstract 5241: Generation of allogeneic CAR-T circumvents functional deficits in patient-derived autologous product for glioblastoma","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; McMaster University","funders":"","keywords":"Glioblastoma; Medicine; Product (mathematics); Cancer research; Mathematics","score_opus":0.13576936141394785,"score_gpt":0.4057190539522579,"score_spread":0.26994969253831,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393096802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99076355,0.005432908,0.000047981688,0.00090946566,0.00057573343,0.0019000202,0.00006528156,0.000044098015,0.00026093874],"genre_scores_gemma":[0.9965188,0.0003845514,0.0000619091,0.000031698768,0.00072312396,0.0010134184,0.00008331555,0.000057816153,0.0011253742],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997196,0.00012557501,0.00039457018,0.0006023779,0.0010602701,0.0006212056],"domain_scores_gemma":[0.998548,0.00023817441,0.000036757778,0.00035642087,0.00067793386,0.00014274343],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010494726,0.00014938506,0.00029392386,0.00071542413,0.00008954185,0.000045393856,0.00013493522,0.00012331127,0.002287765],"category_scores_gemma":[0.00029234594,0.00013596895,0.00012648993,0.0007986199,0.00018298942,0.000097090204,0.00006828907,0.00054961914,0.00004609961],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012492088,0.00015179554,0.0012274544,0.0006716425,0.00011031948,0.00008060346,0.0005481623,0.00032323715,0.90757465,0.000060654496,0.004545524,0.08345677],"study_design_scores_gemma":[0.0015203519,0.0011867298,0.025376571,0.00039150324,0.000022636945,0.00005229192,0.00019977127,0.0012602801,0.95803344,0.00014351985,0.011642229,0.00017067618],"about_ca_topic_score_codex":0.0004318242,"about_ca_topic_score_gemma":0.0004489798,"teacher_disagreement_score":0.08328609,"about_ca_system_score_codex":0.00077759277,"about_ca_system_score_gemma":0.0013749854,"threshold_uncertainty_score":0.99862427},"labels":[],"label_agreement":null},{"id":"W4393101183","doi":"10.1158/1538-7445.am2024-6333","title":"Abstract 6333: A high-parameter mass cytometry panel for the functional characterization of CAR T cells","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Integrity Testing Laboratory (Canada)","funders":"","keywords":"TIGIT; Mass cytometry; Flow cytometry; Granzyme B; Cytokine; T cell; Immune system; Cancer research; Immunology; Tumor microenvironment; Cell therapy; Biology; Cell biology; Stem cell; Phenotype","score_opus":0.15866238021223067,"score_gpt":0.41540188587425836,"score_spread":0.2567395056620277,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393101183","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99038875,0.0011758509,0.002114043,0.0032195116,0.0007611774,0.0016035424,0.00030556918,0.000047024412,0.0003845134],"genre_scores_gemma":[0.9745691,0.0011328589,0.00007955022,0.00008917658,0.0011660247,0.00073260354,0.00010859176,0.00006303224,0.022059064],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976105,0.000076955395,0.0002632661,0.00037444328,0.0011765647,0.0004982733],"domain_scores_gemma":[0.9973371,0.001462906,0.00003141113,0.0004280003,0.00060855213,0.00013200362],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001511506,0.0001248276,0.00023293629,0.00046048095,0.00012871504,0.000097281154,0.00020676908,0.0001236167,0.008623886],"category_scores_gemma":[0.00014977735,0.00008450487,0.00015753473,0.0009778915,0.00027172192,0.00009733798,0.000059512644,0.000680924,0.00010070109],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009556009,0.000048953443,0.0002915722,0.0007351913,0.00023664809,0.000015997806,0.00014605369,0.000013108868,0.9667868,0.00016134972,0.0036385288,0.026970195],"study_design_scores_gemma":[0.00097121694,0.00032983793,0.040529646,0.0002849892,0.00005591172,0.000007777048,0.00013022048,0.0012487755,0.85288376,0.00022688702,0.10320863,0.00012232472],"about_ca_topic_score_codex":0.0002799415,"about_ca_topic_score_gemma":0.00000870173,"teacher_disagreement_score":0.113903016,"about_ca_system_score_codex":0.00036964763,"about_ca_system_score_gemma":0.000703175,"threshold_uncertainty_score":0.9922824},"labels":[],"label_agreement":null},{"id":"W4393127926","doi":"10.1101/2024.03.21.586084","title":"Endogenous CD28 drives CAR T cell responses in multiple myeloma","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre","funders":"National Cancer Institute; National Institutes of Health","keywords":"Endogeny; Multiple myeloma; Medicine; Immunology; Internal medicine","score_opus":0.03729499252346495,"score_gpt":0.26746490758465735,"score_spread":0.2301699150611924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393127926","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9857554,0.009121239,0.00001983691,0.0004485378,0.0012191262,0.002197672,0.00032486863,0.00063380186,0.00027951304],"genre_scores_gemma":[0.9946449,0.0012382183,0.0015489372,0.00019577748,0.0009020317,0.0005125306,0.0000010515637,0.00039981137,0.0005567861],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9948845,0.00040140105,0.0008506127,0.0017256972,0.00096500944,0.0011728016],"domain_scores_gemma":[0.9960394,0.0004176864,0.00021312178,0.0022822022,0.00047051333,0.000577071],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0012155036,0.0008503307,0.0011799783,0.0013269826,0.00012426086,0.00024413201,0.000665472,0.0009189727,0.0006286285],"category_scores_gemma":[0.000613176,0.00087958726,0.0004088756,0.0011097207,0.00028603963,0.00007109371,0.0012624281,0.0028466508,0.0005643387],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007500686,0.0003667978,0.022476953,0.0018094336,0.00022836319,0.0033007094,0.00010634797,0.000021565385,0.97055537,0.000049254202,0.00031952056,0.00001559206],"study_design_scores_gemma":[0.0020548839,0.00025469484,0.07112241,0.0012457122,0.00019469224,3.9923614e-7,0.000021941145,0.0004195118,0.9053208,0.000004488771,0.0184558,0.00090464385],"about_ca_topic_score_codex":0.00030570512,"about_ca_topic_score_gemma":0.000024340428,"teacher_disagreement_score":0.06523457,"about_ca_system_score_codex":0.0011027008,"about_ca_system_score_gemma":0.0024685988,"threshold_uncertainty_score":0.99945384},"labels":[],"label_agreement":null},{"id":"W4393188520","doi":"10.1038/s41587-024-02205-3","title":"Author Correction: Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors","year":2024,"lang":"en","type":"erratum","venue":"Nature Biotechnology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Immunotherapy; Major histocompatibility complex; T cell; Immunology; Cancer research; Computational biology; Medicine; Biology; Immune system","score_opus":0.015405665824249445,"score_gpt":0.3433121987524451,"score_spread":0.32790653292819566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393188520","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05255078,0.38318765,0.00025618036,0.052765258,0.4628642,0.0068682213,0.00090480037,0.005703559,0.034899358],"genre_scores_gemma":[0.0070530213,0.004665043,0.0008466797,0.0017828104,0.005008056,0.00013024652,0.0004693708,0.00062726875,0.9794175],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9946943,0.00016366552,0.000656974,0.001865326,0.0010452409,0.0015744892],"domain_scores_gemma":[0.9968038,0.000106160805,0.0003284417,0.0020634031,0.00033793575,0.00036024037],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00077862095,0.0010397119,0.0015353895,0.0013306409,0.00035135006,0.00013937478,0.001034508,0.01414148,0.0032211274],"category_scores_gemma":[0.00048920873,0.0009400088,0.0007601962,0.0020973433,0.0009784757,0.0000639658,0.00046297,0.021509746,0.0002759863],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006013916,0.00008411307,0.00003200375,0.0004787614,0.0006409817,0.000840459,0.00022322763,0.0000023656587,0.1931662,0.00003718295,0.7878821,0.016011227],"study_design_scores_gemma":[0.0010821511,0.00078781217,0.000020188489,0.00058564893,0.0002193477,0.0018307201,0.00042556121,0.00062769535,0.087429255,0.00010628899,0.90618706,0.0006982797],"about_ca_topic_score_codex":0.000118133874,"about_ca_topic_score_gemma":0.0001006876,"teacher_disagreement_score":0.94451815,"about_ca_system_score_codex":0.0015228293,"about_ca_system_score_gemma":0.0021625482,"threshold_uncertainty_score":0.99930507},"labels":[],"label_agreement":null},{"id":"W4393191154","doi":"10.1007/978-3-031-50399-3_6","title":"The Future of Cell Replacement Therapies","year":2024,"lang":"en","type":"book-chapter","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Brain Institute; Toronto Western Hospital; University of Toronto","funders":"","keywords":"Medicine","score_opus":0.021814994944936203,"score_gpt":0.29582436123499994,"score_spread":0.2740093662900637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393191154","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006752348,0.040043328,0.000002756346,0.004192398,0.0004987117,0.0006563626,0.000012569812,0.00005257124,0.9544738],"genre_scores_gemma":[0.00039336216,0.021593746,0.00006494903,0.00020976205,0.0009797146,0.000014213769,0.000019241546,0.00008738818,0.9766376],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.99852407,0.000009856171,0.0003037996,0.00028735382,0.0006760748,0.00019883107],"domain_scores_gemma":[0.9987673,0.00012504443,0.00007297067,0.0008224301,0.00013875635,0.00007349575],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003496384,0.00023312158,0.00035058105,0.000105646315,0.000049408252,0.00002902736,0.00017395744,0.00023287888,0.031986143],"category_scores_gemma":[0.0000024310114,0.00012061605,0.0002972743,0.000030071504,0.00016075272,0.000009358482,0.00010571064,0.00062674,0.00040139802],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00201998,0.00006945513,0.0000140005195,0.0012386821,0.0018659609,0.00011207347,0.0009533214,1.5763118e-7,0.030278806,0.5919797,0.2424165,0.12905139],"study_design_scores_gemma":[0.0003854337,0.00046027705,0.0000030962606,0.00015179759,0.000098891534,0.00001503279,0.00028117726,0.0000042260085,0.004647439,0.0092981905,0.9845461,0.00010831295],"about_ca_topic_score_codex":0.000010227372,"about_ca_topic_score_gemma":0.000034001052,"teacher_disagreement_score":0.7421296,"about_ca_system_score_codex":0.000091752576,"about_ca_system_score_gemma":0.00015050161,"threshold_uncertainty_score":0.9688988},"labels":[],"label_agreement":null},{"id":"W4393252428","doi":"10.1200/jco.23.02329","title":"Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Spinal Cord Injury BC; University of British Columbia; McGill University; Jewish General Hospital","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Refractory (planetary science); Clinical endpoint; Internal medicine; Phases of clinical research; Clinical trial; Lymphoma; Non-Hodgkin's lymphoma; Oncology","score_opus":0.08335546380125415,"score_gpt":0.4715924011792489,"score_spread":0.38823693737799475,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393252428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920761,0.0036413441,0.000017080773,0.0012124783,0.0007262353,0.00073537295,0.000006067928,0.000011159452,0.0015741632],"genre_scores_gemma":[0.99238783,0.0020296127,0.0005167757,0.00021787906,0.0003756445,0.000018117631,0.0000012390562,0.000043194104,0.0044097183],"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99464846,0.0012340193,0.0025363262,0.00039097987,0.0008215387,0.00036868034],"domain_scores_gemma":[0.9923086,0.0050814133,0.0013757115,0.00034375733,0.00046340047,0.00042709894],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006456516,0.0002295962,0.0019771957,0.0006359733,0.0000473355,0.000019199826,0.00022045302,0.0003766549,0.00049836375],"category_scores_gemma":[0.0030021733,0.00015111153,0.00032972769,0.00047823327,0.000413403,0.00013204903,0.00013532727,0.0017592354,0.0000058660557],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3023654,0.03589046,0.028282113,0.00031460964,0.0015466606,0.0432778,0.0056131696,0.000011311293,0.03171798,0.000014092608,0.0026274999,0.5483389],"study_design_scores_gemma":[0.26460475,0.57932997,0.10732671,0.0024865929,0.0011177429,0.0036678214,0.0065422216,0.0007877222,0.003403023,0.00026340815,0.030081011,0.00038904417],"about_ca_topic_score_codex":0.00007191792,"about_ca_topic_score_gemma":0.00014619628,"teacher_disagreement_score":0.54794985,"about_ca_system_score_codex":0.00038566854,"about_ca_system_score_gemma":0.004854974,"threshold_uncertainty_score":0.8612515},"labels":[],"label_agreement":null},{"id":"W4393257495","doi":"10.3138/cim-2024-2657","title":"A Discussion with Dr. Natasha Kekre, Hematologist and Clinician Scientist","year":2024,"lang":"en","type":"article","venue":"Clinical and investigative medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of Ottawa; Western University","funders":"","keywords":"Bachelor; Hematologist; Medicine; Transplantation; Family medicine; Medical education; Internal medicine; Political science; Disease","score_opus":0.20757116031735892,"score_gpt":0.44078909034199887,"score_spread":0.23321793002463995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393257495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7099477,0.0069221063,0.00015745014,0.27237242,0.0008130219,0.00090040336,0.000022184937,0.00018568778,0.008679],"genre_scores_gemma":[0.96419525,0.0013888455,0.00074190635,0.0046097613,0.0011693755,0.000033805743,0.000074759264,0.000046517987,0.027739782],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9976562,0.00017903889,0.00063560525,0.00074826623,0.0004710037,0.00030984907],"domain_scores_gemma":[0.99824333,0.0004759973,0.0000714845,0.00030091684,0.000120537734,0.0007877554],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0016443515,0.00023051794,0.00072632317,0.0001632024,0.0001448871,0.00004895228,0.0000946059,0.00014511152,0.00068946474],"category_scores_gemma":[0.0017496189,0.00010058116,0.000063978056,0.00053689507,0.024979753,0.00013061879,0.00013541817,0.0008318862,0.00002991893],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014483787,0.00046328813,0.5227129,0.0022735614,0.0006960355,0.002340882,0.0028373585,1.7660537e-7,0.01150278,0.03432131,0.11661187,0.3047915],"study_design_scores_gemma":[0.011125882,0.0144808935,0.2393253,0.011633173,0.000680366,0.0013781595,0.0026275988,0.0024158368,0.0015674516,0.06609623,0.6479733,0.00069580425],"about_ca_topic_score_codex":0.000046456043,"about_ca_topic_score_gemma":0.000048023536,"teacher_disagreement_score":0.53136146,"about_ca_system_score_codex":0.000021269218,"about_ca_system_score_gemma":0.00019871311,"threshold_uncertainty_score":0.9776737},"labels":[],"label_agreement":null},{"id":"W4393280322","doi":"10.1182/bloodadvances.2023011739","title":"Double-negative T cells utilize a TNFα–JAK1–ICAM-1 cytotoxic axis against acute myeloid leukemia","year":2024,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Calgary; Toronto General Hospital; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Myeloid leukemia; Cytotoxic T cell; Cytotoxicity; Cancer research; Leukemia; Flow cytometry; Tumor necrosis factor alpha; Immunology; Medicine; Chemistry; In vitro; Biochemistry","score_opus":0.022102472702105164,"score_gpt":0.32007254931942475,"score_spread":0.29797007661731956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393280322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8886784,0.01926328,0.000120587836,0.0011948306,0.0009918972,0.0019407639,0.00013903408,0.0007380728,0.086933136],"genre_scores_gemma":[0.87352085,0.017452467,0.0028705483,0.0007074749,0.0013012701,0.000364737,0.00008071489,0.00019615931,0.10350576],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9969078,0.000082148756,0.00046068456,0.0008862813,0.00085894746,0.00080414966],"domain_scores_gemma":[0.99833065,0.00038810182,0.000077240984,0.000666114,0.00015903944,0.00037882125],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003503094,0.00042670086,0.0006249837,0.00032077738,0.00015204177,0.00014767528,0.00033740242,0.00017998945,0.0024570615],"category_scores_gemma":[0.000054095926,0.00034804066,0.0003258011,0.0009851924,0.00034488944,0.00041838878,0.00014881765,0.0007805146,0.0007005728],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012287872,0.00023086279,0.00018615393,0.00051362126,0.00097414444,0.001497166,0.0011530893,0.000035171834,0.9144755,0.00027571435,0.0019865695,0.07744322],"study_design_scores_gemma":[0.0041863793,0.00063212827,0.00016197756,0.00045357374,0.00029910207,0.00014618678,0.00042601995,0.00035046702,0.726286,0.0004601389,0.26623276,0.00036526335],"about_ca_topic_score_codex":0.000053961325,"about_ca_topic_score_gemma":0.00005028595,"teacher_disagreement_score":0.2642462,"about_ca_system_score_codex":0.00031586082,"about_ca_system_score_gemma":0.00063844555,"threshold_uncertainty_score":0.9998972},"labels":[],"label_agreement":null},{"id":"W4393315734","doi":"10.1111/ejh.14208","title":"Ocular adverse events following <scp>CAR‐T</scp> cell therapy: A pharmacovigilance study and systematic review","year":2024,"lang":"en","type":"article","venue":"European Journal Of Haematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Pharmacovigilance; Adverse effect; Medicine; Pharmacology; Intensive care medicine","score_opus":0.02932337168247901,"score_gpt":0.3358748212748156,"score_spread":0.3065514495923366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393315734","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7693297,0.22658257,0.00009708798,0.00031739796,0.00044727352,0.001308354,0.0000011982861,0.00003686298,0.0018795196],"genre_scores_gemma":[0.97584236,0.020558493,0.00013342634,0.0008183951,0.00015241477,0.000010974729,0.0000013026532,0.000090688394,0.0023919707],"study_design_codex":"case_report","study_design_gemma":"systematic_review","domain_scores_codex":[0.9956891,0.0021019108,0.0010153519,0.00028042195,0.0005801884,0.00033304302],"domain_scores_gemma":[0.99855375,0.0004116404,0.00030058384,0.00034594638,0.0001385563,0.0002494979],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039463365,0.0002438883,0.0013645459,0.00028994255,0.00006249785,0.000022854949,0.00028767914,0.000027961807,0.00013034198],"category_scores_gemma":[0.00036625323,0.00016872722,0.00041649232,0.00032291652,0.00004922494,0.0001290944,0.00008853924,0.00063364836,0.00015528096],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025301508,0.0015797018,0.017280051,0.40640634,0.0072360747,0.47180653,0.008368501,0.000006357827,0.07268224,0.000033715176,0.012238766,0.0021087348],"study_design_scores_gemma":[0.038088083,0.015561669,0.0049537746,0.5617852,0.015063252,0.24928437,0.009200406,0.00055992504,0.011821371,0.000109287925,0.09269294,0.00087972666],"about_ca_topic_score_codex":8.810552e-7,"about_ca_topic_score_gemma":1.8638201e-7,"teacher_disagreement_score":0.22252214,"about_ca_system_score_codex":0.000051865347,"about_ca_system_score_gemma":0.000115332645,"threshold_uncertainty_score":0.6880496},"labels":[],"label_agreement":null},{"id":"W4393408771","doi":"10.1016/j.jtha.2024.03.021","title":"A meta-analysis to assess the risk of bleeding and thrombosis following chimeric antigen receptor T-cell therapy: Communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy","year":2024,"lang":"en","type":"review","venue":"Journal of Thrombosis and Haemostasis","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"National Cancer Institute; National Institutes of Health; Incyte; CSL Behring","keywords":"Medicine; Hemostasis; Internal medicine; Malignancy; Thrombosis; Venous thrombosis; Meta-analysis; Incidence (geometry); Chimeric antigen receptor; Gastroenterology; Cancer; Immunotherapy","score_opus":0.34785240354308167,"score_gpt":0.43787012693967725,"score_spread":0.09001772339659558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393408771","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.038898595,0.95422256,0.00003359913,0.0048497356,0.00012862367,0.0012647117,0.00041422842,0.000013812142,0.00017412918],"genre_scores_gemma":[0.018823342,0.97913575,0.0012175652,0.0003588107,0.00014959594,0.00005435535,0.00003981953,0.00011696364,0.00010378896],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99454737,0.0015674339,0.0016705631,0.0006227404,0.0011816062,0.00041031872],"domain_scores_gemma":[0.9933243,0.003161787,0.0016012045,0.0013305292,0.00029268654,0.00028949394],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0037416003,0.00075901026,0.005588941,0.0006907473,0.0005337678,0.0004264543,0.0007771103,0.0003036893,0.0006011433],"category_scores_gemma":[0.000176751,0.00035889022,0.00383344,0.0019285327,0.00029210417,0.00016753767,0.00043862168,0.0014977952,0.000006151221],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020054477,0.00039734118,0.0022046806,0.0016365288,0.5154728,0.000013878087,0.0039979015,0.0000026510197,0.00057482225,0.00003905075,0.006628273,0.4688315],"study_design_scores_gemma":[0.0010930283,0.000999035,0.0027979785,0.0032795654,0.69895625,0.000045793346,0.0020687436,0.000021208882,0.00053959055,0.00014593797,0.28945893,0.00059397274],"about_ca_topic_score_codex":0.00066054316,"about_ca_topic_score_gemma":0.00005216478,"teacher_disagreement_score":0.46823752,"about_ca_system_score_codex":0.00013462687,"about_ca_system_score_gemma":0.00020428258,"threshold_uncertainty_score":0.99988633},"labels":[],"label_agreement":null},{"id":"W4393771747","doi":"10.5281/zenodo.1154256","title":"Generation Of Fluorescently Labelled Op9 Stromal Cells For Growing Patient Leukemic Cells","year":2018,"lang":"en","type":"dataset","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Stromal cell; Cancer research; Cell biology; Chemistry; Biology","score_opus":0.0559423750143571,"score_gpt":0.27985903583277755,"score_spread":0.22391666081842043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393771747","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015494433,0.0001442338,0.0002926896,0.00017364707,0.00061068084,0.0041133794,0.97725546,0.0002707312,0.0016447664],"genre_scores_gemma":[0.0016621668,0.00049233343,0.00055768964,0.0001701967,0.0010778683,7.859137e-7,0.9923087,0.0017777053,0.0019525975],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9961734,0.00044530787,0.0007484514,0.0008349314,0.0010878873,0.00071004796],"domain_scores_gemma":[0.9963476,0.00006911279,0.00037524328,0.001179556,0.0016790342,0.00034944285],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00095815817,0.0003867892,0.0006013891,0.00062097516,0.0010976695,0.00035267815,0.0010262917,0.00032453798,0.03757638],"category_scores_gemma":[0.0004589398,0.00039849617,0.00024244112,0.0005484716,0.00031358437,0.00018701101,0.001129074,0.0006332366,0.0023493937],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004685659,0.00023525165,9.6084314e-8,0.00044956448,0.0001346118,0.000013372835,0.00012617743,0.00001376761,0.37575808,0.000010024149,0.6157932,0.0069972407],"study_design_scores_gemma":[0.0019390653,0.002243923,0.0000035476387,0.00017321993,0.0001305255,0.000048078487,0.00007776358,0.00039694487,0.1278665,0.0000054153434,0.86684054,0.00027449755],"about_ca_topic_score_codex":0.000083832885,"about_ca_topic_score_gemma":0.0000014726912,"teacher_disagreement_score":0.25104725,"about_ca_system_score_codex":0.00059842906,"about_ca_system_score_gemma":0.00005198651,"threshold_uncertainty_score":0.9998467},"labels":[],"label_agreement":null},{"id":"W4393859316","doi":"10.1101/2024.04.02.587705","title":"Combination of oncolytic Maraba virus with immune checkpoint blockade overcomes therapy resistance in an immunologically cold model of advanced melanoma with dysfunctional T cell receptor signalling","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Oncolytic virus; Biology; Melanoma; Immune system; Immunotherapy; Cytotoxic T cell; Immunology; Cancer research; Immune checkpoint; Tumor microenvironment; Antigen; Virology; In vitro","score_opus":0.018991050941669464,"score_gpt":0.24440508383258935,"score_spread":0.22541403289091988,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393859316","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99171716,0.0050538094,0.00036141055,0.00020968326,0.00014604846,0.0021504052,0.00014018123,0.00014938183,0.00007194053],"genre_scores_gemma":[0.98733526,0.0014121974,0.010388051,0.00003249122,0.00007500977,0.00040875346,0.0000034240586,0.00019012412,0.00015466142],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9959986,0.00020093593,0.0010693762,0.001079656,0.0011131173,0.00053831306],"domain_scores_gemma":[0.9965458,0.00017721821,0.00071939226,0.0011873242,0.0011860265,0.00018424435],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00097004883,0.00064158597,0.0012967004,0.0006460975,0.00006626822,0.000064858126,0.00047898875,0.0005274789,0.00021946715],"category_scores_gemma":[0.00006313346,0.0005344149,0.00019814826,0.0009854404,0.00034855353,0.00014440017,0.0002361991,0.0015430425,0.0000061827736],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00910717,0.0013995537,0.0030397163,0.0013353863,0.00039084855,0.000056668137,0.00006980309,0.003748897,0.98054475,0.00029407273,0.0000045804986,0.000008547554],"study_design_scores_gemma":[0.005320792,0.002080415,0.026369106,0.0025414187,0.0001198652,5.782945e-8,0.000022193284,0.0034579302,0.95939076,0.00002008122,0.00011477084,0.0005625867],"about_ca_topic_score_codex":0.00008831514,"about_ca_topic_score_gemma":0.000036304267,"teacher_disagreement_score":0.023329388,"about_ca_system_score_codex":0.00086331525,"about_ca_system_score_gemma":0.0020768167,"threshold_uncertainty_score":0.99971074},"labels":[],"label_agreement":null},{"id":"W4393859731","doi":"10.3390/curroncol31040143","title":"A Review of Practice-Changing Therapies in Oncology in the Era of Personalized Medicine","year":2024,"lang":"en","type":"review","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; McGill University; St Mary's Hospital Centre; Jewish General Hospital","funders":"","keywords":"Medicine; Chimeric antigen receptor; Personalized medicine; Precision medicine; Microbiome; Cancer; Bioinformatics; Cancer treatment; Computational biology; Immunotherapy; Internal medicine; Biology; Pathology","score_opus":0.32305359300402575,"score_gpt":0.5797166237464436,"score_spread":0.25666303074241786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393859731","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000010119773,0.97851706,0.0000026652199,0.008377244,0.0009929368,0.003450976,0.00001717692,0.000013463474,0.008618336],"genre_scores_gemma":[0.0000038998933,0.9975223,0.000058858892,0.00065413746,0.00050547725,0.000684336,0.000113553084,0.000056191988,0.0004012243],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9930209,0.003318144,0.0019939137,0.0005173758,0.0006324165,0.00051727763],"domain_scores_gemma":[0.9933063,0.0047106436,0.0009651521,0.00064028206,0.00029906083,0.00007859542],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.008191031,0.00043786434,0.0050805127,0.0011223246,0.000018317582,0.0000029778992,0.0005218193,0.00043660635,0.0027075736],"category_scores_gemma":[0.0026441677,0.00024178387,0.0006359739,0.0023969903,0.0006976873,0.000042226595,0.00018061436,0.0030363596,0.000030875108],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013225533,0.00065564807,0.000005477272,0.21860868,0.00025780764,0.0001484554,0.005478999,8.918793e-9,0.000006552188,0.0004529118,0.006339611,0.7679136],"study_design_scores_gemma":[0.0011686072,0.0013245214,0.0000018928505,0.265129,0.0017133965,0.00047298137,0.0012434416,0.000002140825,2.1776748e-7,0.000046017598,0.72878844,0.00010934902],"about_ca_topic_score_codex":0.000072447365,"about_ca_topic_score_gemma":0.000052065352,"teacher_disagreement_score":0.76780427,"about_ca_system_score_codex":0.0010421048,"about_ca_system_score_gemma":0.0026356939,"threshold_uncertainty_score":0.9992637},"labels":[],"label_agreement":null},{"id":"W4393871903","doi":"10.1038/s41467-024-47012-1","title":"Loss of CREBBP and KMT2D cooperate to accelerate lymphomagenesis and shape the lymphoma immune microenvironment","year":2024,"lang":"en","type":"article","venue":"Nature Communications","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Princess Margaret Cancer Centre; University of Toronto; University Health Network; Spinal Cord Injury BC; University of British Columbia","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; WorldQuant Foundation; National Institute of Mental Health; Takeda Oncology; Weill Cornell Medical College; National Institutes of Health; BC Cancer Foundation; Leukemia and Lymphoma Society; Michael Smith Health Research BC; Wilhelm Sander-Stiftung; Deutsche Forschungsgemeinschaft; Else Kröner-Fresenius-Stiftung","keywords":"Biology; Epigenetics; Chromatin; Immune system; Germinal center; Enhancer; Epigenome; B cell; Cancer research; Phenotype; Transcription factor; Genetics; Cell biology; Gene; DNA methylation; Gene expression","score_opus":0.026768234445647573,"score_gpt":0.3250207970556583,"score_spread":0.2982525626100107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393871903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7806501,0.18566161,0.000009470298,0.031334467,0.00005949548,0.0006301304,0.000042315525,0.000039043356,0.0015733881],"genre_scores_gemma":[0.9634674,0.032154273,0.00085581077,0.00090244244,0.000035255896,0.000069445814,0.00003333634,0.000032088505,0.0024499495],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.999024,0.00013268518,0.00023316822,0.00022565025,0.00020399496,0.00018051908],"domain_scores_gemma":[0.9979533,0.0003585361,0.000029512634,0.001456851,0.00009252037,0.000109292574],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003997816,0.00013831115,0.00021711022,0.00012353211,0.00022265632,0.000086295266,0.00047232327,0.00014075609,0.00024167332],"category_scores_gemma":[0.0000666207,0.000097203905,0.000055541255,0.00043213365,0.00039369593,0.00005814939,0.0006778954,0.00034684077,0.000024015808],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024511517,0.00025802595,0.004274951,0.00012289788,0.00038135782,0.000019117633,0.0020155497,0.0000031110817,0.81468916,0.0028916744,0.0035835805,0.17151548],"study_design_scores_gemma":[0.001568906,0.0002461692,0.31259975,0.00034936715,0.00023585814,0.00034746755,0.00047161273,0.0030683598,0.07399424,0.000080107064,0.60676545,0.00027268543],"about_ca_topic_score_codex":0.000060119186,"about_ca_topic_score_gemma":0.00004730638,"teacher_disagreement_score":0.7406949,"about_ca_system_score_codex":0.00009046655,"about_ca_system_score_gemma":0.00010221411,"threshold_uncertainty_score":0.39638603},"labels":[],"label_agreement":null},{"id":"W4393983153","doi":"10.1158/1538-7445.am2024-ct081","title":"Abstract CT081: A phase 1/2 study investigating the safety and efficacy of autologous TAC T cells in subjects with unresectable, locally advanced, or metastatic claudin 18.2+ solid tumors","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Phase (matter); Oncology; Internal medicine; Claudin; Phases of clinical research; Cancer research; Toxicity; Chemistry; Tight junction","score_opus":0.09422062859099477,"score_gpt":0.4516854115260862,"score_spread":0.35746478293509143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393983153","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905639,0.0035403606,0.00002251882,0.00085121684,0.000063340565,0.0039714957,0.000044357406,0.00005473955,0.0008880283],"genre_scores_gemma":[0.9957314,0.00092635106,0.00015869476,0.000057436122,0.00009160001,0.00043926638,0.0000075479647,0.00008892071,0.0024987864],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99528414,0.00062090124,0.0006478318,0.00075452204,0.0016927129,0.0009998874],"domain_scores_gemma":[0.9955896,0.0029512753,0.000084109124,0.0006500035,0.00038017635,0.00034484154],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004308021,0.00028160983,0.0007225508,0.0006690536,0.0001988605,0.0001344871,0.00040143018,0.000068679874,0.0014612786],"category_scores_gemma":[0.00083340856,0.00016430633,0.000061714505,0.0027898094,0.0010661116,0.00015943215,0.00023767362,0.001872416,0.000014046047],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031090146,0.0019309843,0.0048362073,0.0033645297,0.00082401576,0.005648416,0.01172042,0.0019128764,0.7933491,0.00006188317,0.0008906994,0.14437073],"study_design_scores_gemma":[0.10801053,0.05052077,0.10628464,0.02118996,0.000628346,0.0009326657,0.053303763,0.018351305,0.62793833,0.00056792155,0.01031038,0.0019613993],"about_ca_topic_score_codex":0.0025684477,"about_ca_topic_score_gemma":0.0030182889,"teacher_disagreement_score":0.16541077,"about_ca_system_score_codex":0.0004999691,"about_ca_system_score_gemma":0.0030827005,"threshold_uncertainty_score":0.9994515},"labels":[],"label_agreement":null},{"id":"W4393983476","doi":"10.1158/1538-7445.am2024-ct286","title":"Abstract CT286: TILVANCE-301, a phase 3 study of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in combination with pembrolizumab vs pembrolizumab alone in treatment-naive unresectable or metastatic melanoma","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Medicine; Tumor-infiltrating lymphocytes; Melanoma; Oncology; Metastatic melanoma; Immunotherapy; Internal medicine; Cancer; Cancer research","score_opus":0.09603221829209885,"score_gpt":0.4251622067439079,"score_spread":0.3291299884518091,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393983476","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98484236,0.005987793,0.000005503065,0.00021311876,0.00009137539,0.0051738974,0.00007123519,0.00006992917,0.0035447848],"genre_scores_gemma":[0.98840004,0.0034807539,0.00005941834,0.000024405215,0.00011559823,0.0023032546,0.000051644234,0.00015385996,0.005411037],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9941031,0.000704745,0.0008814356,0.0010469639,0.001988694,0.0012750997],"domain_scores_gemma":[0.9969649,0.0012389892,0.00013723834,0.0008028239,0.00054740376,0.00030865934],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017209902,0.0004734473,0.0011040944,0.0019095608,0.00014544657,0.0001769076,0.0003964776,0.00010555724,0.0033333658],"category_scores_gemma":[0.00014083477,0.00033970148,0.00012425735,0.0033707514,0.00029452742,0.00038192343,0.00008566132,0.001053767,0.000039391405],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.20488408,0.024453096,0.02388871,0.002737517,0.0010541126,0.012910603,0.027911283,0.0008542972,0.5327596,0.000063654035,0.00046583157,0.16801718],"study_design_scores_gemma":[0.30894998,0.097477615,0.026412793,0.004003556,0.00018751051,0.00030459985,0.020973505,0.012219791,0.52336407,0.00018716772,0.00478766,0.0011317644],"about_ca_topic_score_codex":0.018695673,"about_ca_topic_score_gemma":0.0067522204,"teacher_disagreement_score":0.16688542,"about_ca_system_score_codex":0.003585837,"about_ca_system_score_gemma":0.004228035,"threshold_uncertainty_score":0.9999055},"labels":[],"label_agreement":null},{"id":"W4393988288","doi":"10.1158/1538-7445.am2024-ct002","title":"Abstract CT002: CTX130 allogeneic CRISPR-Cas9-engineered chimeric antigen receptor (CAR) T cells in patients with advanced clear cell renal cell carcinoma: Long-term follow-up and translational data from the phase 1 COBALT-RCC study","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Chimeric antigen receptor; CRISPR; Renal cell carcinoma; Medicine; Antigen; Cancer research; Immunology; Biology; Oncology; Immunotherapy; Immune system; Gene; Genetics","score_opus":0.07240042123301262,"score_gpt":0.3885031541100254,"score_spread":0.3161027328770128,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393988288","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.985897,0.008019612,0.000026606649,0.00037688453,0.00031421825,0.0035367552,0.0015816716,0.000052839005,0.00019439386],"genre_scores_gemma":[0.99579704,0.0011144299,0.000093070455,0.000041069674,0.00037417232,0.00020856236,0.0011701607,0.0001433806,0.0010580933],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99480754,0.0003855651,0.00051570096,0.0013219202,0.00199356,0.00097572926],"domain_scores_gemma":[0.9971608,0.0006658019,0.00005958546,0.0013760602,0.00033828302,0.00039948587],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013267018,0.00038925812,0.00052265264,0.00039633884,0.00023587923,0.00020938432,0.0008535892,0.0001466447,0.0041118558],"category_scores_gemma":[0.000042382228,0.00028169347,0.00008660909,0.0011925678,0.00030757295,0.00032344655,0.00029373114,0.0015807474,0.00009371168],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011309472,0.0019685545,0.29077703,0.00039905688,0.00032934398,0.00032482712,0.0028523807,0.00007494743,0.6675253,7.7179e-7,0.0047675823,0.019670729],"study_design_scores_gemma":[0.02679325,0.0030242228,0.8975617,0.0003870528,0.00014164262,0.0000029091368,0.00084751955,0.00047895912,0.0656823,0.000006006106,0.0045606415,0.00051378086],"about_ca_topic_score_codex":0.0017212562,"about_ca_topic_score_gemma":0.0009848856,"teacher_disagreement_score":0.6067847,"about_ca_system_score_codex":0.00027854863,"about_ca_system_score_gemma":0.0009705118,"threshold_uncertainty_score":0.9999635},"labels":[],"label_agreement":null},{"id":"W4394060769","doi":"10.1158/2159-8290.cd-24-0102","title":"CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma","year":2024,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":139,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Center for Advancing Translational Sciences","keywords":"Renal cell carcinoma; Cell; Cancer research; Cell therapy; Targeted therapy; Clear cell renal cell carcinoma; Medicine; Oncology; Internal medicine; Biology; Cancer; Genetics","score_opus":0.024328738825237905,"score_gpt":0.3122543425206403,"score_spread":0.28792560369540243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394060769","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91652936,0.07131237,0.00048966013,0.0006301611,0.0011386356,0.0017973469,0.0003286822,0.00015334935,0.0076204706],"genre_scores_gemma":[0.8887762,0.0059660072,0.00024797625,0.0007367025,0.0011380116,0.00054797175,0.00016787494,0.00020295412,0.10221631],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972259,0.000072944065,0.00039214545,0.00090978795,0.0005458139,0.0008534212],"domain_scores_gemma":[0.9985828,0.0001911439,0.000073887044,0.0007136588,0.00014660707,0.00029194317],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00026116509,0.00041271606,0.00053031044,0.00023066782,0.0001244673,0.00015800942,0.00029671585,0.00020216376,0.0020265125],"category_scores_gemma":[0.000011415097,0.00034850684,0.00050398736,0.00045500757,0.00014033934,0.00030526432,0.00007360294,0.0004949336,0.00008775343],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031166547,0.00020950982,0.0011598181,0.000819289,0.0001005967,0.00011079376,0.0005216597,0.0002661908,0.9629002,0.000017882452,0.01665315,0.014124234],"study_design_scores_gemma":[0.0044053495,0.0012692162,0.0009467158,0.000110820525,0.000101381906,0.000008111774,0.00023006862,0.0004985394,0.75677055,0.000072790324,0.23521218,0.00037428713],"about_ca_topic_score_codex":0.00021128402,"about_ca_topic_score_gemma":0.00003645084,"teacher_disagreement_score":0.21855903,"about_ca_system_score_codex":0.0005618713,"about_ca_system_score_gemma":0.0011458404,"threshold_uncertainty_score":0.9998967},"labels":[],"label_agreement":null},{"id":"W4394312980","doi":"10.6084/m9.figshare.22604309","title":"Additional file 3 of CAR-T cell therapy followed by allogenic hematopoietic stem cell transplantation yielded comparable outcome between Ph like ALL and other high-risk ALL","year":2023,"lang":"en","type":"dataset","venue":"Open MIND","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Stem cell; Hematopoietic stem cell transplantation; Transplantation; Outcome (game theory); Hematopoietic cell; Oncology; Internal medicine; Haematopoiesis; Medicine; Biology; Genetics; Mathematics","score_opus":0.0715829801705885,"score_gpt":0.33448418309124806,"score_spread":0.26290120292065955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394312980","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00922036,0.00025150552,0.0000015194161,0.00005666072,0.00009631089,0.0019996727,0.98751897,0.000007990494,0.0008470282],"genre_scores_gemma":[0.00017909377,0.00081406237,0.00035021134,0.00018206735,0.0001254911,0.00038977433,0.9548585,0.00010345081,0.042997368],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99661314,0.00028515753,0.0008495742,0.00083500566,0.00086813106,0.00054896297],"domain_scores_gemma":[0.9959361,0.0023289565,0.0005148361,0.00082176673,0.00010037918,0.00029796292],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0004632168,0.0005263167,0.0013136043,0.00024078872,0.000089452624,0.000112646034,0.0007309682,0.0005373228,0.677544],"category_scores_gemma":[0.00001731147,0.00047912335,0.00026110813,0.000247921,0.00014643087,0.00009437168,0.00013899512,0.0007706553,0.0024633885],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005911708,0.00029054645,0.00010007545,0.00032705837,0.000588355,0.00006927672,0.000249462,0.0000015862915,0.002673798,2.7195382e-8,0.9940123,0.001096352],"study_design_scores_gemma":[0.004177555,0.00061566476,0.00020626333,0.00028841954,0.0005379644,0.000017937366,0.00013238854,0.0000050989615,0.0054437784,0.0000044551075,0.98814005,0.0004304315],"about_ca_topic_score_codex":0.002472016,"about_ca_topic_score_gemma":0.0005148067,"teacher_disagreement_score":0.6750806,"about_ca_system_score_codex":0.00009310801,"about_ca_system_score_gemma":0.00027560678,"threshold_uncertainty_score":0.99976605},"labels":[],"label_agreement":null},{"id":"W4394407308","doi":"10.6084/m9.figshare.24062570","title":"Additional file 1 of CAR-T cells targeting CD38 and LMP1 exhibit robust antitumour activity against NK/T cell lymphoma","year":2023,"lang":"en","type":"dataset","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services","funders":"","keywords":"Lymphoma; CD38; Cancer research; Chemistry; Biology; Cell biology; Immunology","score_opus":0.040521320665913206,"score_gpt":0.2737361853603297,"score_spread":0.23321486469441646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394407308","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000035537607,0.00013016701,1.7703222e-8,0.000017431534,0.000079420475,0.0006745423,0.99768704,0.00007650661,0.0012993475],"genre_scores_gemma":[0.0000049870096,0.00011497282,0.00007609653,0.00009524466,0.00078409456,0.0006166178,0.9873967,0.000104802595,0.010806492],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971597,0.00011056953,0.00039230174,0.00074725266,0.0009923918,0.000597745],"domain_scores_gemma":[0.995865,0.0023933444,0.00037821257,0.0007045272,0.00034117015,0.00031774168],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00010085733,0.0004673166,0.000795345,0.00036565872,0.00013588408,0.0000654123,0.00034665634,0.00054211373,0.99140835],"category_scores_gemma":[0.002813573,0.0004747122,0.00028099868,0.00045251142,0.000052787833,0.000103655824,0.0005279257,0.0006998957,0.013899503],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000093882234,0.00022165275,1.8148954e-7,0.0036079905,0.00008784784,0.000382798,0.000009924673,0.000006275795,0.0031655096,6.0648246e-9,0.99155176,0.00087218836],"study_design_scores_gemma":[0.0009241718,0.00013730099,0.00010972561,0.0073641296,0.00003702371,0.000022091466,0.000035575365,0.00009285202,0.005396393,5.2007954e-7,0.985501,0.00037921977],"about_ca_topic_score_codex":0.00011895888,"about_ca_topic_score_gemma":0.00006376317,"teacher_disagreement_score":0.97750884,"about_ca_system_score_codex":0.00019630369,"about_ca_system_score_gemma":0.0007986458,"threshold_uncertainty_score":0.99977046},"labels":[],"label_agreement":null},{"id":"W4394567790","doi":"10.1016/j.stem.2024.03.012","title":"Rebuilding and rebooting immunity with stem cells","year":2024,"lang":"en","type":"article","venue":"Cell stem cell","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia Hospital; University of British Columbia","funders":"Canadian Institutes of Health Research; Genome British Columbia; Natural Sciences and Engineering Research Council of Canada; Wellcome Trust","keywords":"Biology; Reboot; Immune system; Regenerative medicine; Immunity; Immunology; Population; Stem cell; Regeneration (biology); Neuroscience; Computational biology; Computer science; Medicine; Cell biology","score_opus":0.02661360309648523,"score_gpt":0.276535880386647,"score_spread":0.24992227729016178,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394567790","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9012092,0.0074782544,0.00016916006,0.00013347255,0.00022803884,0.00064517383,0.000005721898,0.00023574133,0.08989524],"genre_scores_gemma":[0.8709199,0.0005365256,0.0003762353,0.00007178744,0.0001838715,0.000017017604,0.000004944179,0.00010116216,0.12778859],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99801254,0.00012822519,0.00030395132,0.0005455286,0.0004689899,0.00054077443],"domain_scores_gemma":[0.9986622,0.00032802473,0.000056693894,0.00057557976,0.00008613663,0.00029137463],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073047343,0.00027519022,0.00037967513,0.00020763105,0.00016864626,0.0001865237,0.00015872654,0.0001382571,0.00065809884],"category_scores_gemma":[0.0000015499054,0.0002168386,0.00009709164,0.00041643684,0.00012205647,0.00011109614,0.000152867,0.000752307,0.0001784762],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023697408,0.000088699235,0.0010186792,0.0021959317,0.00006161813,0.0004869282,0.0018968899,0.000014769144,0.9493231,0.00003266926,0.0012218815,0.043421846],"study_design_scores_gemma":[0.0012944728,0.0006239703,0.00013718184,0.0006297147,0.00011820731,0.000136526,0.0023372208,0.0014441432,0.9064718,0.000011250825,0.086483106,0.0003124002],"about_ca_topic_score_codex":0.00007917525,"about_ca_topic_score_gemma":0.000006857549,"teacher_disagreement_score":0.085261226,"about_ca_system_score_codex":0.00017194201,"about_ca_system_score_gemma":0.00016599333,"threshold_uncertainty_score":0.8842421},"labels":[],"label_agreement":null},{"id":"W4394598287","doi":"10.1212/wnl.0000000000204493","title":"Safety of CAR T-Cell Therapy in Patients with Active Autoimmune Diseases: A Case Report (P3-14.003)","year":2024,"lang":"en","type":"article","venue":"Neurology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"","keywords":"Medicine; CAR T-cell therapy; Immunology; T cell; Chimeric antigen receptor; Immune system","score_opus":0.012123533305530865,"score_gpt":0.28467861039281794,"score_spread":0.2725550770872871,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394598287","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99543434,0.0004918335,0.000008110739,0.0007092845,0.00023068409,0.00087871315,0.000041688712,0.000060451348,0.0021449034],"genre_scores_gemma":[0.99838,0.000120783916,0.000015344887,0.000354314,0.000052412284,0.00004567025,0.000057035642,0.000052686395,0.0009217744],"study_design_codex":"case_report","study_design_gemma":"observational","domain_scores_codex":[0.99838156,0.00018522267,0.00034333707,0.000450532,0.0003183076,0.00032102736],"domain_scores_gemma":[0.9989461,0.00021344628,0.00007080796,0.00054462807,0.00012216259,0.00010287823],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016769665,0.0001668276,0.00040720505,0.00025561394,0.00002673156,0.000007311379,0.0000883516,0.0001238529,0.000852082],"category_scores_gemma":[0.00005565801,0.00012594541,0.00008879625,0.00042969413,0.00017676766,0.00005426629,0.000052531905,0.00053764955,0.000011621539],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.105959825,0.002937866,0.3044131,0.0003897876,0.0005573595,0.41018024,0.0024787923,0.000067210254,0.02442591,0.00005393937,0.0006397242,0.14789623],"study_design_scores_gemma":[0.022287399,0.027942719,0.88346744,0.000096167336,0.00016437618,0.015473224,0.00007504728,0.0006252416,0.0038804854,0.00009094981,0.045516036,0.00038094565],"about_ca_topic_score_codex":0.00044526573,"about_ca_topic_score_gemma":0.00005522267,"teacher_disagreement_score":0.5790543,"about_ca_system_score_codex":0.00005736114,"about_ca_system_score_gemma":0.00029634265,"threshold_uncertainty_score":0.93297},"labels":[],"label_agreement":null},{"id":"W4394598356","doi":"10.1212/wnl.0000000000204489","title":"Novel Risk Factors for Predicting Immune-effector Cell Associated Neurotoxicity Syndrome (ICANS) (P3-14.001)","year":2024,"lang":"en","type":"article","venue":"Neurology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"","keywords":"Neurotoxicity; Medicine; Internal medicine; Toxicity","score_opus":0.027879735570361414,"score_gpt":0.29765352635358416,"score_spread":0.2697737907832227,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394598356","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932253,0.00020335225,0.00035880235,0.0007535297,0.0014548561,0.0021309066,0.00040023512,0.0005403912,0.0009326215],"genre_scores_gemma":[0.99621594,0.00007600128,0.000039573737,0.000458301,0.00022777916,0.00021272522,0.0001423659,0.00015228141,0.0024750328],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99718225,0.00030054976,0.000454335,0.0007809916,0.000425959,0.00085592206],"domain_scores_gemma":[0.99626523,0.0027518987,0.000121906756,0.00050128566,0.00012380604,0.00023588295],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006941735,0.00033042184,0.00063455873,0.00030899988,0.00016543068,0.000057368063,0.00026822786,0.00040473018,0.0010534645],"category_scores_gemma":[0.0010917623,0.00029217018,0.000355211,0.00045436856,0.0001498468,0.000080098034,0.00013514333,0.0015121584,0.00009001523],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017440955,0.0008730941,0.03255124,0.00037711734,0.000368191,0.000531563,0.00030759207,0.00006193704,0.95966864,0.000018489272,0.0010347537,0.0024633105],"study_design_scores_gemma":[0.019598218,0.0670246,0.56580526,0.00020655409,0.001389505,0.0021167544,0.00005177167,0.09231529,0.13792457,0.00019221123,0.11200301,0.0013722752],"about_ca_topic_score_codex":0.0005939152,"about_ca_topic_score_gemma":0.000051530704,"teacher_disagreement_score":0.821744,"about_ca_system_score_codex":0.00010058502,"about_ca_system_score_gemma":0.00016655138,"threshold_uncertainty_score":0.99995303},"labels":[],"label_agreement":null},{"id":"W4394621491","doi":"10.14740/jh1211","title":"Successful Treatment of Refractory Post-Transplant Lymphoproliferative Disorder With Chimeric Antigen Receptor T-Cell Therapy in a Heart Transplant Recipient","year":2024,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Chimeric antigen receptor; Refractory (planetary science); Post-transplant lymphoproliferative disorder; Immunology; Cell therapy; Heart transplantation; Immunotherapy; Antigen; Transplant rejection; Transplantation; Cell; Lymphoma; Internal medicine; Immune system; Biology; Rituximab","score_opus":0.01534176998527919,"score_gpt":0.29956876746539796,"score_spread":0.28422699748011876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394621491","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9766036,0.01934791,0.00005945979,0.0028720878,0.00021466252,0.00054768653,0.00002831542,0.000013970753,0.00031228786],"genre_scores_gemma":[0.9813611,0.017580513,0.00040960914,0.00011041078,0.00009405669,0.000021742253,0.000016521524,0.000044298762,0.00036172842],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979922,0.00021916094,0.0007311134,0.00025913963,0.00044043845,0.00035794755],"domain_scores_gemma":[0.99898547,0.00026609222,0.00017109652,0.00021574953,0.00020149437,0.00016010675],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003064954,0.0002507284,0.0010057064,0.00058602326,0.000030664294,0.000014392411,0.00011546651,0.00014029775,0.0011640644],"category_scores_gemma":[0.0000074609156,0.00014915067,0.00024973013,0.0003861636,0.00015653127,0.000102550795,0.000005154887,0.00031884955,0.000012567907],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02691581,0.0046557076,0.3710844,0.0005073695,0.0012347396,0.0040185037,0.019177713,0.00002761061,0.5586365,0.000083110936,0.000305267,0.013353279],"study_design_scores_gemma":[0.032132674,0.07649398,0.056513283,0.0035136372,0.0003889133,0.038163282,0.003156354,0.00021588277,0.6770997,0.00006773229,0.111509055,0.0007454734],"about_ca_topic_score_codex":0.00019232003,"about_ca_topic_score_gemma":0.000113352326,"teacher_disagreement_score":0.3145711,"about_ca_system_score_codex":0.00020786388,"about_ca_system_score_gemma":0.00071754993,"threshold_uncertainty_score":0.999749},"labels":[],"label_agreement":null},{"id":"W4394680557","doi":"10.1016/j.omtm.2024.101249","title":"Metabolic priming of GD2 TRAC-CAR T cells during manufacturing promotes memory phenotypes while enhancing persistence","year":2024,"lang":"en","type":"article","venue":"Molecular Therapy — Methods & Clinical Development","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Grainger Institute for Engineering, University of Wisconsin-Madison; College of Engineering, University of Wisconsin-Madison; National Institute of General Medical Sciences; Engineering Research Centers; Government of the United Kingdom; U.S. Department of Health and Human Services; National Institutes of Health; University of Wisconsin Carbone Cancer Center; St. Baldrick's Foundation; Canadian Thoracic Society; Hyundai Hope On Wheels; National Science Foundation; Michigan Council for Arts and Cultural Affairs; University of Wisconsin-Madison; Division of Graduate Education; National Heart, Lung, and Blood Institute; Wisconsin Alumni Research Foundation","keywords":"CRISPR; Chimeric antigen receptor; Priming (agriculture); Persistence (discontinuity); Cas9; Phenotype; Ribonucleoprotein; Biology; Cell biology; Computational biology; T cell; Genetics; Gene; Engineering; Immune system; RNA","score_opus":0.10272237245015799,"score_gpt":0.4156942167703084,"score_spread":0.3129718443201504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394680557","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9510678,0.013862895,0.031670224,0.00027598543,0.00064697425,0.0012039986,0.0000025357842,0.00019720258,0.0010723973],"genre_scores_gemma":[0.47326842,0.002774651,0.5196941,0.00034334688,0.00026885403,0.00012760704,0.000012771795,0.000180094,0.0033301732],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9944297,0.0011627983,0.0016226415,0.001081296,0.0009413783,0.0007621679],"domain_scores_gemma":[0.9974146,0.0010627096,0.00020538302,0.0007660294,0.0001810876,0.00037018253],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.006162406,0.0004833744,0.0012018525,0.0003807355,0.00015648645,0.000090314206,0.0004187537,0.00029232213,0.0011696231],"category_scores_gemma":[0.0003121774,0.00040870687,0.0006984647,0.00045131272,0.0002213739,0.00011767999,0.00020727541,0.00097242434,0.00005632213],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025848713,0.00017826827,0.00005680027,0.00037033315,0.0007425174,0.00013154496,0.0019220231,0.00001336443,0.6013927,0.000010757633,0.0000035577366,0.39491966],"study_design_scores_gemma":[0.001272114,0.00023605599,0.004516756,0.0007074633,0.0001421975,0.000038331218,0.00029085047,0.00014908948,0.9771777,0.00011893122,0.014946548,0.0004040019],"about_ca_topic_score_codex":0.00001792656,"about_ca_topic_score_gemma":0.000002841908,"teacher_disagreement_score":0.48802388,"about_ca_system_score_codex":0.00017481652,"about_ca_system_score_gemma":0.0007741668,"threshold_uncertainty_score":0.9998365},"labels":[],"label_agreement":null},{"id":"W4394770414","doi":"10.1016/j.tips.2024.03.004","title":"Direct in vivo CAR T cell engineering","year":2024,"lang":"en","type":"article","venue":"Trends in Pharmacological Sciences","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":102,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"BC Cancer Agency; Canadian Institutes of Health Research; BC Cancer Foundation; Michael Smith Health Research BC","keywords":"In vivo; Chimeric antigen receptor; Ex vivo; Cell therapy; Medicine; Immunotherapy; Immunology; Computational biology; Computer science; Biology; Stem cell; Immune system; Biotechnology; Cell biology","score_opus":0.07236072218963159,"score_gpt":0.4097159349219207,"score_spread":0.33735521273228913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394770414","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8647126,0.0015209534,0.0000026232951,0.00087643595,0.00033400545,0.00011094842,0.0000029021526,0.00011065004,0.13232885],"genre_scores_gemma":[0.9905094,0.00024960845,0.00016351131,0.00012355071,0.00012999856,0.000035349094,7.242981e-7,0.0000064724377,0.008781371],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99859196,0.000053813914,0.00017645599,0.00037501295,0.00036615465,0.00043662172],"domain_scores_gemma":[0.9995395,0.0002665116,0.000008542227,0.000058577825,0.000007822969,0.00011905168],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008753242,0.00010891882,0.00019502909,0.0005458365,0.000029015568,0.00004599196,0.00019407034,0.00006097547,0.01857591],"category_scores_gemma":[0.00002967705,0.00007299209,0.00006460632,0.0023021013,0.0001729307,0.00008496048,0.00006579457,0.000344684,0.00003127002],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000055232715,0.00017120647,0.004996734,0.000036962818,0.000009146977,0.0008322747,0.00031241658,0.0010239914,0.9450514,0.00007258747,0.0019509004,0.045487165],"study_design_scores_gemma":[0.002473066,0.0013874398,0.031761065,0.00020663213,0.000051169136,0.00006231438,0.0001720779,0.12695731,0.68652683,0.00011543276,0.14976998,0.00051667576],"about_ca_topic_score_codex":0.00007565194,"about_ca_topic_score_gemma":0.00002065047,"teacher_disagreement_score":0.25852454,"about_ca_system_score_codex":0.00015818237,"about_ca_system_score_gemma":0.00005357236,"threshold_uncertainty_score":0.98232126},"labels":[],"label_agreement":null},{"id":"W4394871491","doi":"10.1016/j.cels.2024.03.004","title":"Integrating multiplexed imaging and multiscale modeling identifies tumor phenotype conversion as a critical component of therapeutic T cell efficacy","year":2024,"lang":"en","type":"article","venue":"Cell Systems","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; National Institute of General Medical Sciences; National Cancer Institute; National Human Genome Research Institute; Hamilton Health Sciences Foundation; Defence Science and Technology Laboratory; U.S. Food and Drug Administration; U.S. Department of Defense; Silicon Valley Community Foundation; Cancer Research Institute; National Institute of Diabetes and Digestive and Kidney Diseases; Bill and Melinda Gates Foundation; National Institutes of Health; Cancer Research UK; National Heart, Lung, and Blood Institute","keywords":"Component (thermodynamics); Phenotype; Computational biology; Computer science; Biology; Biological system; Physics; Genetics; Gene","score_opus":0.02971431905540872,"score_gpt":0.3201112536483638,"score_spread":0.29039693459295507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394871491","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97047216,0.021652494,0.00279561,0.00016718698,0.00084092683,0.00092056015,0.000008441002,0.0001389194,0.0030036757],"genre_scores_gemma":[0.9974115,0.00009152133,0.00021998712,0.00003460438,0.00017676693,0.000022486118,0.0000143250445,0.000059946535,0.001968868],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9980839,0.00016516374,0.000486071,0.00043832595,0.0004777438,0.0003487812],"domain_scores_gemma":[0.99861294,0.0006711559,0.0000495133,0.00030026972,0.00018697364,0.00017912404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005671505,0.000213593,0.000453736,0.00020638782,0.00010200594,0.00015626468,0.0001140841,0.00006460777,0.00019614414],"category_scores_gemma":[0.000085170075,0.00017620428,0.00013128205,0.00018339083,0.00016887907,0.00010572706,0.000094642026,0.00037838068,0.00007292549],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021196352,0.0001557174,0.0005576717,0.0036248856,0.00004266654,0.00012618302,0.0021843486,0.00022405275,0.9909673,0.00011143573,0.00007693338,0.0017168459],"study_design_scores_gemma":[0.0015645934,0.00013486961,0.00007770983,0.0014484467,0.00011321699,0.00009554406,0.005464604,0.8779122,0.112279914,0.000025943566,0.00070363266,0.0001793125],"about_ca_topic_score_codex":0.0009731512,"about_ca_topic_score_gemma":0.0000032001349,"teacher_disagreement_score":0.8786874,"about_ca_system_score_codex":0.00011988996,"about_ca_system_score_gemma":0.00009072076,"threshold_uncertainty_score":0.7185402},"labels":[],"label_agreement":null},{"id":"W4394884067","doi":"10.1016/j.cjco.2024.04.004","title":"Multimodality Imaging of Acute Myocarditis in Cytokine Release Syndrome (CRS) Following CAR-T Therapy","year":2024,"lang":"en","type":"article","venue":"CJC Open","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Wilfrid Laurier University; McGill University","funders":"McGill University Health Centre","keywords":"Medicine; Cytokine release syndrome; Chimeric antigen receptor; Rituximab; Lymphoma; Radiology; Internal medicine; Immunotherapy; Cancer","score_opus":0.031760034121391535,"score_gpt":0.36586832020449317,"score_spread":0.3341082860831016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394884067","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9828631,0.0019004156,0.000053021355,0.0016328237,0.0003278086,0.0014643595,0.00007279053,0.00007277149,0.011612907],"genre_scores_gemma":[0.99468315,0.0005428295,0.00038708583,0.00027844313,0.00008273989,0.000100573634,0.00006185478,0.00006984827,0.0037934755],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9980743,0.00014352023,0.00039760154,0.00049608346,0.0004832737,0.00040523135],"domain_scores_gemma":[0.9989263,0.00014888526,0.000037926748,0.00065973913,0.00006456409,0.00016258714],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009819814,0.0001968211,0.0007169443,0.0002623001,0.00004515225,0.0001312742,0.00043007988,0.000075238844,0.0016778696],"category_scores_gemma":[0.00005903318,0.00017287,0.00028645323,0.00065487484,0.00008209478,0.00031921116,0.0002919352,0.0004255875,0.00006862758],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001528312,0.0004179365,0.087699234,0.00036826203,0.00225636,0.024439514,0.0022942594,0.000018624942,0.6634373,0.00019822526,0.0028249635,0.21451703],"study_design_scores_gemma":[0.039239652,0.0020390514,0.5717327,0.0063459123,0.00096284266,0.0042038905,0.0015109918,0.018271914,0.20179912,0.0023633726,0.14949471,0.0020358518],"about_ca_topic_score_codex":0.0029474834,"about_ca_topic_score_gemma":0.000026615942,"teacher_disagreement_score":0.48403347,"about_ca_system_score_codex":0.00024090837,"about_ca_system_score_gemma":0.0003013107,"threshold_uncertainty_score":0.99923474},"labels":[],"label_agreement":null},{"id":"W4394893537","doi":"10.1016/j.jval.2024.04.004","title":"Economic Evaluations of Chimeric Antigen Receptor T-Cell Therapies for Hematologic and Solid Malignancies: A Systematic Review","year":2024,"lang":"en","type":"review","venue":"Value in Health","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre; Ottawa Public Health; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Hematologic Neoplasms; Medicine; Intensive care medicine; Internal medicine; Cancer","score_opus":0.16152575852155565,"score_gpt":0.4577174283364431,"score_spread":0.2961916698148874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394893537","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000051392763,0.9819552,0.000011811805,0.0005234444,0.00021621762,0.016949398,0.00015831727,0.000036263362,0.00009798654],"genre_scores_gemma":[0.000010756502,0.9954795,0.00060105807,0.0001729866,0.00008160984,0.0022826712,0.00010700827,0.00009828725,0.0011660978],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9954589,0.0009778115,0.00224725,0.00056323624,0.00029873374,0.00045404708],"domain_scores_gemma":[0.997186,0.0010149416,0.0008595149,0.00069482136,0.00008774837,0.0001569842],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00440349,0.0004140231,0.0054631005,0.000509978,0.00005559849,0.000022140688,0.0002241622,0.0001959925,0.00028581874],"category_scores_gemma":[0.00035563397,0.00028498756,0.00058822107,0.00046468695,0.00009893971,0.000031160762,0.00006269812,0.00037069115,0.000104268634],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000007661036,0.000060371865,0.0000023990438,0.9820045,0.00024492198,0.0000019995964,0.00027255085,0.0000010480768,0.0000071850964,0.00015069038,0.0010816364,0.016165037],"study_design_scores_gemma":[0.00033461943,0.0005140201,5.547029e-7,0.8802804,0.001257655,0.00013673551,0.00008541075,0.00018812527,0.000003902637,0.00012975188,0.116863556,0.00020528518],"about_ca_topic_score_codex":0.00019069585,"about_ca_topic_score_gemma":0.000007799341,"teacher_disagreement_score":0.115781926,"about_ca_system_score_codex":0.00064407405,"about_ca_system_score_gemma":0.0028545617,"threshold_uncertainty_score":0.99996024},"labels":[],"label_agreement":null},{"id":"W4395007321","doi":"10.1186/s13045-024-01542-9","title":"Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel","year":2024,"lang":"en","type":"letter","venue":"Journal of Hematology & Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institutes of Health; Incyte; TG Therapeutics; National Cancer Institute; Laffey-McHugh Foundation; Pharmacyclics; Genentech; Celgene; Mallinckrodt Pharmaceuticals; Society for Immunotherapy of Cancer; University of Pennsylvania; Gilead Sciences; Leukemia and Lymphoma Society","keywords":"Bendamustine; Medicine; Cytokine release syndrome; Internal medicine; Fludarabine; Cyclophosphamide; Gastroenterology; Lymphoma; Immunotherapy; Rituximab; Chemotherapy; Cancer; Chimeric antigen receptor","score_opus":0.03244576333228277,"score_gpt":0.3624544389628308,"score_spread":0.33000867563054803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395007321","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.09233999,0.011098578,0.00041293548,0.89095455,0.0020776133,0.0015514443,0.0001049317,0.000031685573,0.0014282621],"genre_scores_gemma":[0.07211879,0.015371605,0.037809227,0.7506124,0.045480557,0.00035576266,0.0016034822,0.0013895866,0.075258635],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966465,0.00028991973,0.0016284252,0.00040214317,0.00046389014,0.0005691197],"domain_scores_gemma":[0.996044,0.0016160832,0.0011130009,0.00035810727,0.0007051632,0.00016366149],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0012929197,0.00037677094,0.0026288144,0.0009291803,0.000059968155,0.000011652863,0.00027433303,0.0019605893,0.00094414304],"category_scores_gemma":[0.0005271291,0.00029567262,0.0005908001,0.00021817967,0.000543031,0.000047811234,0.00013665514,0.0024355855,0.000012573841],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008101726,0.00031252252,0.00080737873,0.0038660287,0.0020802333,0.00675065,0.0003760271,0.0000016681847,0.006693119,0.00024406002,0.9442529,0.026513677],"study_design_scores_gemma":[0.0085519515,0.007830099,0.00077977375,0.00071604794,0.0014013995,0.043488663,0.00005013025,0.000043685857,0.0010185706,0.0006618524,0.9352888,0.00016904861],"about_ca_topic_score_codex":0.000010284876,"about_ca_topic_score_gemma":0.000018286933,"teacher_disagreement_score":0.1403422,"about_ca_system_score_codex":0.00050692796,"about_ca_system_score_gemma":0.0013088466,"threshold_uncertainty_score":0.9999691},"labels":[],"label_agreement":null},{"id":"W4395081939","doi":"10.51731/cjht.2024.873","title":"Glofitamab (Columvi)","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Reimbursement; Vial; Medicine; Refractory (planetary science); Lymphoma; Follicular lymphoma; Drug; Intensive care medicine; Internal medicine; Pharmacology; Health care; Political science","score_opus":0.05172994418768404,"score_gpt":0.35660408707546454,"score_spread":0.3048741428877805,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395081939","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.18935224,0.4806813,0.00034935176,0.31992745,0.0016477423,0.00069730566,0.000027184084,0.0005368732,0.0067805494],"genre_scores_gemma":[0.99505883,0.001592043,0.00048207893,0.0005076203,0.00004579316,0.000004499839,0.0000013185024,0.000025660504,0.00228217],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99863964,0.000034854886,0.00042536223,0.00013228889,0.0002402121,0.0005276313],"domain_scores_gemma":[0.9992641,0.00006446863,0.00007748206,0.00025782024,0.00015238822,0.00018374703],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008342358,0.00010068425,0.00033594065,0.0011165441,0.00011821059,0.00007252395,0.00024102056,0.00014577675,0.00077178143],"category_scores_gemma":[0.00038936248,0.00008172615,0.00011988414,0.00063020806,0.00023090586,0.00008479289,0.000015995056,0.0008502168,0.000056048848],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000018021885,0.00000763986,0.0012945164,0.00025860788,0.0000686457,0.0015063824,0.00016130859,0.0000010264596,0.00060511124,0.0011142421,0.028909191,0.96605533],"study_design_scores_gemma":[0.00033294904,0.0008312458,0.002723834,0.000671247,0.000014049959,0.0023826975,0.0014465201,0.000039429,0.0010449721,0.0026892398,0.98774284,0.00008097284],"about_ca_topic_score_codex":0.0031363901,"about_ca_topic_score_gemma":0.0023751708,"teacher_disagreement_score":0.96597433,"about_ca_system_score_codex":0.0009422469,"about_ca_system_score_gemma":0.007344601,"threshold_uncertainty_score":0.99828285},"labels":[],"label_agreement":null},{"id":"W4395464285","doi":"10.1007/s40487-024-00272-9","title":"Identification of a Patient Suitable for CAR-T Cell Therapy in the Outpatient Setting: A Vodcast and Case Example","year":2024,"lang":"en","type":"article","venue":"Oncology and Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Juravinski Hospital","funders":"","keywords":"Medicine; Referral; Chimeric antigen receptor; CAR T-cell therapy; CD19; Patient education; Cytokine release syndrome; Intensive care medicine; Medical emergency; Immunotherapy; Internal medicine; Cancer; Family medicine; Immunology; Antigen","score_opus":0.046091410346501216,"score_gpt":0.3533299062937665,"score_spread":0.30723849594726527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4395464285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98668087,0.009939328,0.00005649327,0.001172682,0.000117908196,0.0015466862,0.000025163352,0.0000145724125,0.00044630576],"genre_scores_gemma":[0.9946289,0.0038921516,0.0000705713,0.00036296208,0.00005995692,0.00030173353,0.00001762104,0.000018885532,0.00064721075],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989072,0.00019503977,0.000288098,0.00026516354,0.00013424811,0.00021023733],"domain_scores_gemma":[0.99891835,0.000693556,0.00006126109,0.00020761475,0.00007197629,0.000047265636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010898677,0.00011163252,0.0002276834,0.0001323418,0.00008338863,0.000030602525,0.000052844443,0.00012616889,0.000100958416],"category_scores_gemma":[0.000021313193,0.00007237142,0.000054942884,0.00017617803,0.00012881926,0.0000451068,0.000015907932,0.00021025958,0.0000012645089],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018759109,0.00072316447,0.0038104167,0.00017040149,0.00010171235,0.00031875278,0.038066275,0.0000018701593,0.16699217,0.0005356178,0.0005931816,0.7868105],"study_design_scores_gemma":[0.018542169,0.03085217,0.00949454,0.00016600995,0.00011277606,0.0037365407,0.021265656,0.0042097536,0.14383921,0.0036806744,0.7635942,0.0005063023],"about_ca_topic_score_codex":0.00035962762,"about_ca_topic_score_gemma":0.00010683803,"teacher_disagreement_score":0.78630424,"about_ca_system_score_codex":0.000050954794,"about_ca_system_score_gemma":0.00012012983,"threshold_uncertainty_score":0.29512206},"labels":[],"label_agreement":null},{"id":"W4396578915","doi":"10.1186/s12967-024-05179-7","title":"Mechanism of action, potency and efficacy: considerations for cell therapies","year":2024,"lang":"en","type":"review","venue":"Journal of Translational Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"National Institute of Standards and Technology; United States Pharmacopeia","keywords":"Potency; Mechanism (biology); Action (physics); Medicine; Mechanism of action; Bioinformatics; Pharmacology; Computational biology; Chemistry; Biology; Biochemistry; In vitro","score_opus":0.16554820886852453,"score_gpt":0.43302920294581865,"score_spread":0.2674809940772941,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396578915","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000026373968,0.9904846,0.0016696003,0.0057102065,0.000511126,0.0010373621,0.000060022918,0.000009224623,0.0004914758],"genre_scores_gemma":[0.0006235834,0.99320793,0.0029988985,0.00007381478,0.0013725681,0.000017839284,0.00003646324,0.00005744787,0.0016114268],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99750495,0.000101147496,0.0013074434,0.00019071644,0.0007398651,0.00015588911],"domain_scores_gemma":[0.9967534,0.0017562137,0.0005251655,0.00015210817,0.0006484669,0.00016466364],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009848987,0.0002709066,0.0017610315,0.0007589996,0.000058924856,0.000012832597,0.0000814956,0.00022004369,0.0012760822],"category_scores_gemma":[0.00025223842,0.00016581835,0.000553232,0.00024689495,0.00018085298,0.00006556923,0.0000075274315,0.0006377801,0.0000024571143],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036042693,0.00027437785,0.0000018403322,0.037365507,0.0022040894,0.00007176202,0.0012308575,0.0000015187667,0.0032108268,0.0066917907,0.0050581153,0.9435289],"study_design_scores_gemma":[0.003930124,0.0021355439,0.000012559295,0.020851325,0.007404739,0.0021326826,0.00012311059,0.000029881088,0.00011798696,0.017672561,0.9454197,0.00016978636],"about_ca_topic_score_codex":0.000004634366,"about_ca_topic_score_gemma":0.0000033859421,"teacher_disagreement_score":0.9433591,"about_ca_system_score_codex":0.000053153148,"about_ca_system_score_gemma":0.0009710266,"threshold_uncertainty_score":0.9996369},"labels":[],"label_agreement":null},{"id":"W4396613915","doi":"10.51731/cjht.2024.884","title":"Anticytokine Therapy and Corticosteroids for Cytokine Release Syndrome and for Neurotoxicity Following T-Cell Engager or CAR T-Cell Therapy","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cytokine release syndrome; Medicine; Anakinra; Internal medicine; Oncology; Chimeric antigen receptor; T cell; Immunology; Immune system","score_opus":0.07920129161709988,"score_gpt":0.3448582712694659,"score_spread":0.265656979652366,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396613915","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87773067,0.10511212,0.00045215897,0.014038456,0.00029774796,0.0021660724,0.00007363846,0.00010612861,0.000023006627],"genre_scores_gemma":[0.9848395,0.012412043,0.0011378498,0.0007226895,0.000039543273,0.00008415658,0.0000051832353,0.00007871161,0.00068029953],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99800056,0.00008391208,0.0006287268,0.00034475245,0.0002196442,0.00072240713],"domain_scores_gemma":[0.99849933,0.0005697972,0.00016950116,0.00030097348,0.00016129672,0.00029910862],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012835179,0.00026080932,0.00071859156,0.0008496209,0.00033644604,0.00013305352,0.0002038699,0.0002103973,0.000035126326],"category_scores_gemma":[0.00043549307,0.0001876294,0.00018993982,0.00036744273,0.00023254787,0.00014238022,0.000021604506,0.0006032559,6.537602e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016275503,0.000110028064,0.003163271,0.0018278921,0.0002704979,0.0022999402,0.00075316284,0.000002323133,0.15963075,0.00006986661,0.002730633,0.8275141],"study_design_scores_gemma":[0.020631528,0.034796704,0.0071882475,0.001796729,0.00016570839,0.0072974926,0.0035189048,0.00091116794,0.12818721,0.0018418975,0.7928316,0.0008328463],"about_ca_topic_score_codex":0.00047683204,"about_ca_topic_score_gemma":0.00022942817,"teacher_disagreement_score":0.82668126,"about_ca_system_score_codex":0.0002519262,"about_ca_system_score_gemma":0.0022244668,"threshold_uncertainty_score":0.76513046},"labels":[],"label_agreement":null},{"id":"W4396730858","doi":"10.1126/sciadv.adj1468","title":"Phenotypic targeting using magnetic nanoparticles for rapid characterization of cellular proliferation regulators","year":2024,"lang":"en","type":"article","venue":"Science Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Temerty Faculty of Medicine, University of Toronto; Canadian Institutes of Health Research; University of Toronto","keywords":"CRISPR; Phenotype; Computational biology; Cell growth; Cell sorting; Drug discovery; Phenotypic screening; Microfluidics; Cell; Magnetic nanoparticles; Computer science; Workflow; Biology; Nanotechnology; Cell biology; Bioinformatics; Nanoparticle; Materials science; Genetics; Gene","score_opus":0.023698446217568128,"score_gpt":0.31814994376402145,"score_spread":0.29445149754645333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396730858","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923633,0.0025294574,0.003957817,0.00018172548,0.0002915743,0.0005636566,0.000004021957,0.00004200505,0.00006645243],"genre_scores_gemma":[0.99569714,0.000049694816,0.003609587,0.000021919128,0.00016303334,0.000021959586,0.000010174015,0.000012620122,0.00041388915],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988616,0.000018369701,0.00020824073,0.00027288945,0.0003974329,0.00024144199],"domain_scores_gemma":[0.99954575,0.000039476876,0.000045254033,0.00013107406,0.00017634332,0.000062100014],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00069520023,0.000071988026,0.00012357954,0.00018859112,0.0001357914,0.00006149189,0.00008922135,0.000021597092,0.00017761292],"category_scores_gemma":[0.00012985477,0.000059307033,0.000038530376,0.0007934514,0.00032518047,0.00057920907,0.000020709618,0.00004890715,0.000003141583],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000056473986,0.00001740319,0.0004351842,0.00020440394,0.0000026933408,0.0000010028599,0.00028470106,0.000047020716,0.9144327,0.00021852227,0.0000013014244,0.084298596],"study_design_scores_gemma":[0.00017078547,0.00024571834,0.00062146364,0.00012069588,0.000015816027,0.0000034492325,0.00009723912,0.027450887,0.9686658,0.00030818113,0.002239616,0.000060379192],"about_ca_topic_score_codex":0.0000016598066,"about_ca_topic_score_gemma":4.400343e-7,"teacher_disagreement_score":0.08423822,"about_ca_system_score_codex":0.00006522263,"about_ca_system_score_gemma":0.00024744615,"threshold_uncertainty_score":0.24184705},"labels":[],"label_agreement":null},{"id":"W4396773639","doi":"10.1007/s00259-024-06722-w","title":"Imaging CAR-NK cells targeted to HER2 ovarian cancer with human sodium-iodide symporter-based positron emission tomography","year":2024,"lang":"en","type":"article","venue":"European Journal of Nuclear Medicine and Molecular Imaging","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St Joseph's Health Care; Ontario Institute for Cancer Research; Lawson Health Research Institute; Western University","funders":"Natural Sciences and Engineering Research Council of Canada; National Institutes of Health; National Institute of Biomedical Imaging and Bioengineering; Ontario Institute for Cancer Research","keywords":"Sodium-iodide symporter; Bioluminescence imaging; Chimeric antigen receptor; Ovarian cancer; Cancer research; Reporter gene; Positron emission tomography; Medicine; Chemistry; Cell culture; Cancer; Immunotherapy; Luciferase; Biology; Internal medicine; Symporter; Transfection; Nuclear medicine","score_opus":0.010964798856070922,"score_gpt":0.2805226611097397,"score_spread":0.2695578622536688,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396773639","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9047594,0.011985733,0.0028137667,0.065421045,0.0005759562,0.000636046,0.000007919672,0.00017401199,0.013626134],"genre_scores_gemma":[0.9872933,0.00015787638,0.0014419791,0.010108198,0.00060684304,0.0000013063764,0.000007683476,0.0001894849,0.00019335267],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975953,0.0002782692,0.00053849403,0.00039321493,0.0007626051,0.0004320797],"domain_scores_gemma":[0.9985733,0.00003487652,0.00014814005,0.00030791678,0.00027055966,0.00066522445],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011317092,0.00029712083,0.000457923,0.0008317237,0.00014734294,0.00013330411,0.00019966504,0.000019248273,0.00057379314],"category_scores_gemma":[0.00003292836,0.00021228754,0.00016962709,0.0005003126,0.00019621942,0.0001329936,0.00006893296,0.0006912475,0.00000820456],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000427763,0.00004730792,0.0015690033,0.00019361955,0.00018103754,0.014162725,0.0013865782,0.000013004806,0.94251627,0.000008916971,0.016985584,0.022508178],"study_design_scores_gemma":[0.013955552,0.004704928,0.010585525,0.018626247,0.00179484,0.005135033,0.0032666766,0.0037055165,0.16951482,0.000028106675,0.767579,0.0011037185],"about_ca_topic_score_codex":0.00009312926,"about_ca_topic_score_gemma":0.0000011393292,"teacher_disagreement_score":0.7730015,"about_ca_system_score_codex":0.0001005191,"about_ca_system_score_gemma":0.00013715774,"threshold_uncertainty_score":0.86568344},"labels":[],"label_agreement":null},{"id":"W4396839649","doi":"10.17504/protocols.io.rm7vzyb75lx1/v1","title":"AD BONCAT-FCM Screening &amp;amp; Coupled SYBR+ FCM Cell-Counting - 2022 v1","year":2022,"lang":"en","type":"preprint","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Chemistry; Physics; Computer science","score_opus":0.06830435917926243,"score_gpt":0.3558844963020575,"score_spread":0.28758013712279507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396839649","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.618426,0.010379015,0.009345264,0.0058837757,0.0030604163,0.0069676954,0.00022970761,0.0016359733,0.34407213],"genre_scores_gemma":[0.08111913,0.0024057617,0.019952165,0.0020026641,0.0017763335,0.0010050413,0.0039925105,0.0005887817,0.8871576],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99215657,0.00033191955,0.0011611388,0.001853776,0.0030346217,0.0014619809],"domain_scores_gemma":[0.99453443,0.0006257285,0.00047492492,0.0032920009,0.0004781116,0.0005947716],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0031444046,0.0008853881,0.0015299739,0.0008399146,0.0005160176,0.00029046697,0.0012483182,0.0006282009,0.27993235],"category_scores_gemma":[0.00053885987,0.0008894624,0.00086031895,0.0008088894,0.00020241708,0.00010557012,0.0048461645,0.005563396,0.0012315215],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004953895,0.0020188347,0.017832832,0.006227611,0.0031040246,0.0010916486,0.0050274045,0.0035753588,0.59753555,0.00016425658,0.2964695,0.061999064],"study_design_scores_gemma":[0.004318645,0.00021393626,0.0015624986,0.00047394962,0.00044631638,0.00015950219,0.0015689677,0.007443449,0.0027427892,0.00019600653,0.97941667,0.0014572759],"about_ca_topic_score_codex":0.0046584,"about_ca_topic_score_gemma":0.0005485572,"teacher_disagreement_score":0.68294716,"about_ca_system_score_codex":0.0009455399,"about_ca_system_score_gemma":0.0011300407,"threshold_uncertainty_score":0.9995461},"labels":[],"label_agreement":null},{"id":"W4396847734","doi":"10.1111/bjh.19497","title":"Atrial arrhythmias following <scp>CAR‐chimeric</scp> antigen receptor T‐cell therapy: Incidence, risk factors and biomarker profile","year":2024,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"National Cancer Institute; Swim Across America; National Institutes of Health; Memorial Sloan-Kettering Cancer Center","keywords":"Medicine; Chimeric antigen receptor; Atrial fibrillation; Internal medicine; Cardiotoxicity; Cardiology; Cancer; Immunotherapy; Chemotherapy","score_opus":0.02320608738721138,"score_gpt":0.30156380719973097,"score_spread":0.2783577198125196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396847734","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9282153,0.06820283,0.00011196762,0.00020972076,0.0016842148,0.00049676775,0.000032743614,0.000058183115,0.0009882728],"genre_scores_gemma":[0.97018814,0.026080197,0.0010588439,0.00006938886,0.0007774283,0.0000067746814,0.000016689266,0.00009226836,0.0017102488],"study_design_codex":"observational","study_design_gemma":"case_report","domain_scores_codex":[0.99707174,0.0004736438,0.000828503,0.00040355377,0.00064237893,0.0005801971],"domain_scores_gemma":[0.9978315,0.0011038203,0.00031139344,0.00020967968,0.00018344558,0.00036011747],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012902883,0.00027375907,0.0010772042,0.00048622533,0.00017537491,0.00020238441,0.00020694334,0.00029144477,0.0010572437],"category_scores_gemma":[0.00086952996,0.00024288648,0.00072079035,0.00051576947,0.00024172953,0.00027534348,0.000090907575,0.0010303966,0.00004939634],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009780163,0.00036499804,0.26261917,0.00064472295,0.005003915,0.1871867,0.0034816922,0.0000048229135,0.2181123,0.00004053885,0.084214546,0.23734857],"study_design_scores_gemma":[0.013743761,0.0036822013,0.06806094,0.0030701854,0.0008947635,0.4860483,0.0031500754,0.00051730004,0.084123746,0.0007592703,0.33538648,0.00056295353],"about_ca_topic_score_codex":0.00028542225,"about_ca_topic_score_gemma":0.00001950515,"teacher_disagreement_score":0.29886162,"about_ca_system_score_codex":0.00008536478,"about_ca_system_score_gemma":0.00046056343,"threshold_uncertainty_score":0.99985594},"labels":[],"label_agreement":null},{"id":"W4396887610","doi":"10.1016/j.omtm.2024.101265","title":"Identifying MAGE-A4-positive tumors for TCR T cell therapies in HLA-A∗02-eligible patients","year":2024,"lang":"en","type":"article","venue":"Molecular Therapy — Methods & Clinical Development","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"T-cell receptor; Medicine; Human leukocyte antigen; T cell; Oncology; Immunology; Internal medicine; Cancer research; Antigen; Immune system","score_opus":0.11804649378496984,"score_gpt":0.49498310604291246,"score_spread":0.3769366122579426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396887610","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.78546286,0.009502102,0.19639607,0.0011067182,0.0011663637,0.00398134,0.0000161089,0.00022217014,0.002146249],"genre_scores_gemma":[0.22789213,0.0034184076,0.75319904,0.0039580595,0.00029559815,0.0011609881,0.00023221307,0.00038031794,0.009463221],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9937832,0.0014739853,0.0016778975,0.0012498159,0.00088134833,0.00093376724],"domain_scores_gemma":[0.99653155,0.0019742802,0.0001581266,0.0006402309,0.00033662474,0.00035920428],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0070388312,0.0005322575,0.0010654804,0.00056152407,0.00014198988,0.00020598744,0.0004174908,0.0003454929,0.0007516367],"category_scores_gemma":[0.0004246021,0.0004486691,0.0006589836,0.0008581297,0.00019068577,0.00012713337,0.00018057354,0.00094435905,0.00011434429],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016158377,0.0010763385,0.0049769185,0.00029537998,0.00072287995,0.0002818191,0.0029791903,0.000005530556,0.1562056,0.00016006004,0.0003030024,0.83137745],"study_design_scores_gemma":[0.010700942,0.0019713144,0.06507617,0.0010237907,0.00010592186,0.000016351722,0.00041426343,0.00057385745,0.7362573,0.005103018,0.17768766,0.0010694097],"about_ca_topic_score_codex":0.000031391268,"about_ca_topic_score_gemma":0.000007085807,"teacher_disagreement_score":0.830308,"about_ca_system_score_codex":0.00040583825,"about_ca_system_score_gemma":0.00075375946,"threshold_uncertainty_score":0.9997965},"labels":[],"label_agreement":null},{"id":"W4396935974","doi":"10.37766/inplasy2024.5.0069","title":"Metabolic tumor volume and survival of Non-Hodgkin lymphoma on CAR-T","year":2024,"lang":"en","type":"report","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Volume (thermodynamics); Hodgkin lymphoma; Lymphoma; Oncology; Medicine; Internal medicine; Cancer research; Biology; Physics","score_opus":0.040751045214348365,"score_gpt":0.35467243021039013,"score_spread":0.3139213849960418,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396935974","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.24627201,0.009771369,0.000011055242,0.00042964643,0.001850237,0.0011360147,0.00013745515,0.00011987513,0.74027234],"genre_scores_gemma":[0.17246893,0.0070368666,0.00015746997,0.00014513163,0.0014891644,0.00007472613,0.00013335551,0.00025832065,0.81823605],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958401,0.000081214304,0.00063914526,0.00074021093,0.002221749,0.00047760364],"domain_scores_gemma":[0.99795127,0.0001645494,0.00014652622,0.0008817067,0.0005514513,0.00030452138],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014067224,0.0004515433,0.0017208926,0.00066403334,0.000026901947,0.000044303706,0.00018108898,0.00033367166,0.007704526],"category_scores_gemma":[0.00025030941,0.0003435513,0.0004078756,0.00044264502,0.00020530116,0.000026360953,0.00021113295,0.00056613976,0.00022621946],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018934791,0.0009636751,0.012895097,0.0111387335,0.005794824,0.00569638,0.0006015202,0.0000016323877,0.13145833,0.0007662514,0.24388193,0.5849081],"study_design_scores_gemma":[0.0016823339,0.0008818904,0.022023745,0.00084312167,0.0007305679,0.0007912558,0.00014008542,0.000111568916,0.017051132,0.000050978855,0.9552775,0.00041583643],"about_ca_topic_score_codex":0.003675937,"about_ca_topic_score_gemma":0.0001330336,"teacher_disagreement_score":0.71139556,"about_ca_system_score_codex":0.00029005783,"about_ca_system_score_gemma":0.002659165,"threshold_uncertainty_score":0.99990165},"labels":[],"label_agreement":null},{"id":"W4398191044","doi":"10.1016/j.xpro.2024.103078","title":"Protocol for preclinical evaluation of locoregionally delivered CAR T cells in patient-derived xenograft models of brain tumors","year":2024,"lang":"en","type":"article","venue":"STAR Protocols","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Great Ormond Street Institute of Child Health; Medical Research Council; Stand Up To Cancer; China Agricultural Research System; Great Ormond Street Hospital Charity; Fondation Brain Canada; British Microcirculation Society; St. Baldrick's Foundation; Kids Brain Health Network; Children Neurodevelopmental Disorders Network","keywords":"Protocol (science); Medicine; Cancer research; Pathology; Alternative medicine","score_opus":0.18291787763054887,"score_gpt":0.46657308839439465,"score_spread":0.2836552107638458,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398191044","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.114790514,0.00000769124,0.0003788211,0.00021337974,0.000014778118,0.8840622,0.00008886166,0.000034822464,0.00040896633],"genre_scores_gemma":[0.06779484,3.7516935e-7,0.0021503875,0.000043527234,0.00005511276,0.9296899,0.000031176336,0.00005304209,0.00018165719],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99649346,0.00038899743,0.0010141516,0.00046397053,0.0012928696,0.0003465716],"domain_scores_gemma":[0.9977944,0.00045772464,0.00020038178,0.00045978525,0.0009651252,0.00012260216],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025744264,0.00020477803,0.00054704584,0.00030505683,0.000022256238,0.000018640178,0.00018035623,0.00015889993,0.0006534946],"category_scores_gemma":[0.00032488673,0.00017436108,0.00026241722,0.0004236109,0.00017716445,0.00013413824,0.00007153247,0.00027604878,0.0000048100687],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009639544,0.0010152541,0.00022189779,0.0051375395,0.00015079459,0.000018958015,0.001989795,0.0018283288,0.91294813,0.00027713284,0.0014455948,0.06532702],"study_design_scores_gemma":[0.020711498,0.008874531,0.0005347909,0.0055735344,0.00007814585,0.000010929099,0.00028311068,0.23728861,0.70276284,0.008778033,0.014773987,0.00033000144],"about_ca_topic_score_codex":0.00006145254,"about_ca_topic_score_gemma":0.00003708696,"teacher_disagreement_score":0.23546028,"about_ca_system_score_codex":0.00023409567,"about_ca_system_score_gemma":0.0015791488,"threshold_uncertainty_score":0.7155308},"labels":[],"label_agreement":null},{"id":"W4398193496","doi":"10.1016/j.jcyt.2024.03.406","title":"UNLOCKING THE POTENTIAL: TME-PRIMING RADIATION STRATEGIES FOR IMPROVING CAR-T CELL EFFICACY IN SOLID TUMOUR TREATMENT","year":2024,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Priming (agriculture); Cancer research; Medicine; Biology","score_opus":0.03163566684685637,"score_gpt":0.343708207773408,"score_spread":0.3120725409265516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398193496","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9831406,0.0074757026,0.004076318,0.0016683728,0.00038638877,0.0021250327,0.000010472867,0.00016974665,0.00094735296],"genre_scores_gemma":[0.9949439,0.0009193279,0.0002674066,0.00017243667,0.0007326017,0.00017817417,0.000025630627,0.00009580463,0.0026647076],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99852,0.00007835982,0.0002918913,0.0003909221,0.00026476153,0.00045402953],"domain_scores_gemma":[0.99922174,0.00028331965,0.00004912103,0.00031852772,0.000051851795,0.000075442236],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004214312,0.0002239065,0.0002889189,0.00023732042,0.0001380137,0.00026008068,0.00013075316,0.00009716092,0.00025946336],"category_scores_gemma":[0.000015992318,0.00015191236,0.00021928403,0.00028927386,0.00005541344,0.00013005149,0.000014829241,0.0002214688,0.0000160594],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031698556,0.0001416908,0.00007339918,0.00012324202,0.00007698932,0.000052080657,0.003770131,0.00065372017,0.71511483,0.00015670645,0.00007651448,0.27944368],"study_design_scores_gemma":[0.016395647,0.0036171812,0.006735577,0.0004356808,0.0003019301,0.00012925711,0.009604131,0.11036369,0.8036846,0.0013418405,0.046625808,0.0007646888],"about_ca_topic_score_codex":0.0003349703,"about_ca_topic_score_gemma":0.0000573863,"teacher_disagreement_score":0.27867898,"about_ca_system_score_codex":0.0005359431,"about_ca_system_score_gemma":0.00048406734,"threshold_uncertainty_score":0.6194806},"labels":[],"label_agreement":null},{"id":"W4398193540","doi":"10.1016/j.jcyt.2024.03.385","title":"COMPREHENSIVE ASSESSMENT OF PREMANUFACTURE T CELLS IDENTIFIES FUNCTIONAL DEFECTS AMONG NON-RESPONDERS TO CAR T CELL THERAPY","year":2024,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stem Cell Network; Hôpital Maisonneuve-Rosemont; Université de Montréal","funders":"","keywords":"Cell therapy; CAR T-cell therapy; T cell; Medicine; Cell; Immunology; Biology; Chimeric antigen receptor; Immune system; Genetics","score_opus":0.03240886436277794,"score_gpt":0.3354163098976238,"score_spread":0.3030074455348458,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398193540","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892738,0.0020939677,0.0021520797,0.00039674802,0.0008302827,0.0016801918,0.0000376296,0.00013292067,0.0034024152],"genre_scores_gemma":[0.9715437,0.0010141956,0.00042753803,0.0008830322,0.00037341894,0.00011659379,0.0000414777,0.000121889316,0.025478138],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974888,0.00013065367,0.00038252457,0.0006141134,0.0009255372,0.00045835334],"domain_scores_gemma":[0.99843913,0.00035170204,0.00006805384,0.0006144488,0.00026071124,0.00026594594],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00029801863,0.00034913883,0.0005460187,0.00052536716,0.00008944988,0.000110019835,0.0002036058,0.0001908125,0.006224626],"category_scores_gemma":[0.0000051787315,0.00028504,0.0003848457,0.00055636896,0.00018869218,0.00012707652,0.00004367073,0.00048101653,0.000105199404],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000877678,0.00020067338,0.0022149824,0.0003276951,0.00040466108,0.000081236045,0.0016064787,0.00055090745,0.97322905,0.000022524577,0.01574073,0.0047433963],"study_design_scores_gemma":[0.0022240106,0.0010670349,0.07722749,0.00019600178,0.000039119936,0.000013620644,0.00048288578,0.0005291625,0.8468758,0.000094093746,0.07097396,0.00027682396],"about_ca_topic_score_codex":0.00008831399,"about_ca_topic_score_gemma":0.000014060712,"teacher_disagreement_score":0.12635323,"about_ca_system_score_codex":0.00023947567,"about_ca_system_score_gemma":0.00040365287,"threshold_uncertainty_score":0.9999602},"labels":[],"label_agreement":null},{"id":"W4398193808","doi":"10.1016/j.jcyt.2024.03.340","title":"MULTIPLEX GENE EDITING IN CAR T CELLS","year":2024,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stem Cell Network; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Multiplex; Gene; Genome editing; Biology; Computational biology; Genetics; CRISPR","score_opus":0.03450811823970933,"score_gpt":0.33659582609495803,"score_spread":0.3020877078552487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398193808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98633796,0.003901285,0.00026079404,0.0013257108,0.0006549852,0.0006039353,0.000012306642,0.00021045892,0.0066925385],"genre_scores_gemma":[0.9703492,0.001316894,0.0011851365,0.00086387416,0.002118236,0.00006693489,0.000020287764,0.00012219885,0.023957254],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986869,0.000049974224,0.00022015689,0.0003417487,0.00031643352,0.0003848056],"domain_scores_gemma":[0.99939686,0.0001246171,0.00001516909,0.00030556897,0.00003839766,0.00011938814],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003574191,0.0001476065,0.00024346507,0.00027405957,0.00003066464,0.00005388083,0.000102204656,0.00010532575,0.0053169695],"category_scores_gemma":[0.000017952367,0.00012864427,0.00011831703,0.00042919247,0.000063005704,0.0000617205,0.000018686995,0.00037021269,0.0003115085],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012327882,0.00005786858,0.0016876725,0.00007368514,0.000052591084,0.0004078787,0.0010205451,0.0000159063,0.9325598,0.000040350766,0.0022143766,0.06174606],"study_design_scores_gemma":[0.002198218,0.00023360873,0.002252243,0.00020698653,0.000010167225,0.00007006066,0.00017410064,0.0047430857,0.6996014,0.00011729592,0.29020956,0.00018326372],"about_ca_topic_score_codex":0.00012458954,"about_ca_topic_score_gemma":0.000036719284,"teacher_disagreement_score":0.2879952,"about_ca_system_score_codex":0.00019608423,"about_ca_system_score_gemma":0.00012353247,"threshold_uncertainty_score":0.9955923},"labels":[],"label_agreement":null},{"id":"W4398193887","doi":"10.1016/j.jcyt.2024.03.343","title":"ANTI-TUMOR ACTIVITY OF ENDOGLIN CAR T CELLS AGAINST ADVANCED SARCOMAS","year":2024,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Endoglin; Cancer research; Medicine; Biology; Cell biology; Stem cell; CD34","score_opus":0.02439211014069121,"score_gpt":0.323605968976175,"score_spread":0.2992138588354838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398193887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876192,0.0035230166,0.0003275179,0.00045486295,0.000369846,0.0007068318,0.00003924671,0.00017372504,0.0067857406],"genre_scores_gemma":[0.9895521,0.001934504,0.0005159689,0.00034433563,0.00028185552,0.000033970424,0.000009061297,0.00009712523,0.0072310744],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983933,0.00008680322,0.00025133122,0.00041245372,0.00046160186,0.00039451892],"domain_scores_gemma":[0.9989376,0.00019394256,0.00005120316,0.0005672158,0.000091012495,0.00015901095],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00030320912,0.00021660785,0.0005103995,0.00024057664,0.000041969008,0.000029581308,0.00016203537,0.00008701389,0.002213951],"category_scores_gemma":[0.000019898933,0.00018388688,0.00025704605,0.00045856147,0.00016277489,0.00010335167,0.000028989934,0.0003855302,0.00010556496],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045832671,0.00016859171,0.00034227688,0.00020999098,0.00014792905,0.00021956729,0.00033854105,0.000016342941,0.84863436,0.00006503787,0.00049531966,0.14890373],"study_design_scores_gemma":[0.0016493641,0.00040783983,0.0009958444,0.00017438602,0.000017853206,0.00002715254,0.0000499736,0.0006854161,0.8937681,0.000055551034,0.1020174,0.0001511682],"about_ca_topic_score_codex":0.00003102962,"about_ca_topic_score_gemma":0.0000056618164,"teacher_disagreement_score":0.14875256,"about_ca_system_score_codex":0.00014501436,"about_ca_system_score_gemma":0.00025980102,"threshold_uncertainty_score":0.9986982},"labels":[],"label_agreement":null},{"id":"W4398193905","doi":"10.1016/j.jcyt.2024.03.355","title":"INVESTIGATING THE EFFECT OF INVARIANT NATURAL KILLER T CELL RECEPTOR ON T CELL DEVELOPMENT AND FUNCTION FROM HUMAN PLURIPOTENT Stem Cells","year":2024,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"","keywords":"Induced pluripotent stem cell; Cell biology; Biology; Stem cell; Function (biology); Cell; Genetics; Embryonic stem cell; Gene","score_opus":0.020750893923571923,"score_gpt":0.26947251611728706,"score_spread":0.24872162219371513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398193905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99323773,0.0035112354,0.000045604913,0.00040902346,0.00072483625,0.000913165,0.000005046345,0.00007500839,0.0010783672],"genre_scores_gemma":[0.9850864,0.00014709365,0.0003078672,0.00039336382,0.00031218267,0.00006271113,0.000026985166,0.00007349712,0.01358994],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99825853,0.00022890049,0.0003359701,0.00041544187,0.0004928224,0.00026832617],"domain_scores_gemma":[0.99894357,0.0004816106,0.00007721102,0.00033864274,0.00003592707,0.00012301494],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00065586076,0.00025017138,0.00032978266,0.00013388046,0.0001502214,0.00007468033,0.00012273874,0.00011097626,0.0009820404],"category_scores_gemma":[0.000005807126,0.00015002165,0.00010413055,0.00021987502,0.00012895439,0.00004824924,0.00004015529,0.0005065839,0.000080262376],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003797734,0.000044510012,0.0005714735,0.0002504508,0.00014272974,0.000009284985,0.0025119323,0.000009610473,0.9524281,0.00002869742,0.0018992786,0.041724134],"study_design_scores_gemma":[0.0019138406,0.0013498069,0.0011308973,0.00033619296,0.000040357674,0.0000024218755,0.00014190777,0.0002829672,0.94454193,0.000028869159,0.050080977,0.00014982207],"about_ca_topic_score_codex":0.00008241782,"about_ca_topic_score_gemma":0.000007902584,"teacher_disagreement_score":0.048181698,"about_ca_system_score_codex":0.00016343399,"about_ca_system_score_gemma":0.000107506596,"threshold_uncertainty_score":0.9999312},"labels":[],"label_agreement":null},{"id":"W4398194000","doi":"10.1016/j.jcyt.2024.04.051","title":"ENGINEERING CAR-EXPRESSING INNATE LYMPHOID CELLS (ILCS) FROM HUMAN PLURIPOTENT STEM CELLS (HPSCS) FOR CANCER IMMUNOTHERAPY","year":2024,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"","keywords":"Induced pluripotent stem cell; Innate lymphoid cell; Cancer immunotherapy; Biology; Immunotherapy; Cancer research; Immunology; Innate immune system; Immune system; Embryonic stem cell; Genetics; Gene","score_opus":0.028846961111984416,"score_gpt":0.3121160642707506,"score_spread":0.2832691031587662,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398194000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9521996,0.03298963,0.0074114357,0.000956571,0.0022694336,0.002398429,0.0002962125,0.001103857,0.00037485585],"genre_scores_gemma":[0.9014995,0.019268215,0.005812232,0.0035081652,0.006856235,0.0020861768,0.00016772278,0.0020931957,0.058708534],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99694735,0.000069618516,0.00060242054,0.0008914302,0.0006228369,0.0008663583],"domain_scores_gemma":[0.99839044,0.00028860342,0.00009151671,0.00080928655,0.0001570986,0.0002630506],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000446558,0.00053227216,0.0007296718,0.0003850969,0.00016850623,0.00032118623,0.00037008687,0.0002755962,0.0028842594],"category_scores_gemma":[0.0000034057919,0.00048118268,0.0004905891,0.00041257366,0.00010423659,0.00018324147,0.000044881825,0.0004578338,0.00006607828],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00053456094,0.000108115964,0.0000883757,0.000258512,0.00076431857,0.00006965622,0.0020156414,0.00052181265,0.915047,0.000058764854,0.0025407202,0.077992536],"study_design_scores_gemma":[0.0027225567,0.00021394916,0.000083388484,0.0005142752,0.000051066825,0.000010120575,0.00007834365,0.005649683,0.64552194,0.00006795421,0.34473118,0.00035553763],"about_ca_topic_score_codex":0.0007243409,"about_ca_topic_score_gemma":0.000018399684,"teacher_disagreement_score":0.34219047,"about_ca_system_score_codex":0.0008449621,"about_ca_system_score_gemma":0.00031866424,"threshold_uncertainty_score":0.99976397},"labels":[],"label_agreement":null},{"id":"W4398194041","doi":"10.1016/j.jcyt.2024.03.389","title":"ACTIVATION, EXPANSION, AND CULTURE OF HUMAN T CELLS INCORPORATING IMMUNOCULTTM CGMP-COMPLIANT ANCILLARY REAGENTS","year":2024,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute; Stemcell Technologies","funders":"","keywords":"Reagent; Cell biology; Chemistry; Biology","score_opus":0.03546791324614947,"score_gpt":0.33493439853858703,"score_spread":0.2994664852924376,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398194041","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992022,0.0033664552,0.0002864448,0.0004436459,0.0001216687,0.0005919349,0.000012944303,0.000111514855,0.0030434392],"genre_scores_gemma":[0.98745793,0.0010691661,0.0008923309,0.0003354348,0.00022655571,0.000023838187,0.000046712517,0.00006499718,0.009883046],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9986628,0.00006263789,0.00033799003,0.00033560663,0.00038807475,0.00021288365],"domain_scores_gemma":[0.99923205,0.00005459304,0.00007676679,0.00036070234,0.0001732028,0.000102689344],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00032586837,0.00018143872,0.00031787768,0.00015897093,0.00011627561,0.00005307285,0.00009868433,0.00012774985,0.0008752953],"category_scores_gemma":[0.000014494968,0.00014156087,0.0000941333,0.0003694112,0.00014127666,0.00012397899,0.000033671655,0.0002850066,0.000016981012],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014364564,0.00007762257,0.0010385218,0.00023633121,0.00013343642,0.00003282137,0.003319402,0.0000015989433,0.9660129,0.00013745108,0.0036652635,0.025201024],"study_design_scores_gemma":[0.0014783572,0.0006704237,0.0044424837,0.0007044588,0.000024542021,0.00005226911,0.00058822124,0.00026495862,0.96279234,0.0008315738,0.027952138,0.00019826143],"about_ca_topic_score_codex":0.00007546992,"about_ca_topic_score_gemma":0.0000028984405,"teacher_disagreement_score":0.025002765,"about_ca_system_score_codex":0.00009119416,"about_ca_system_score_gemma":0.00011128726,"threshold_uncertainty_score":0.95838696},"labels":[],"label_agreement":null},{"id":"W4398198889","doi":"10.1016/j.jcyt.2024.03.374","title":"INCREASED TRANSFECTION OF T AND NK CELLS WITH MRNA LIPID NANOPARTICLES FOR CELLULAR IMMUNOTHERAPIES","year":2024,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; University of British Columbia","funders":"","keywords":"Transfection; Messenger RNA; Cell biology; Chemistry; Molecular biology; Biology; Gene; Biochemistry","score_opus":0.017874712683085398,"score_gpt":0.2813582223888962,"score_spread":0.2634835097058108,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398198889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98791456,0.007715158,0.0025080794,0.00045933863,0.00008309932,0.0009556257,0.000019835636,0.0001006372,0.0002436407],"genre_scores_gemma":[0.9948812,0.0022236812,0.0008381332,0.00013087338,0.00019458286,0.00009973727,0.0000085616475,0.000081498314,0.0015417071],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990178,0.000048822967,0.0002050748,0.00026981154,0.00022281279,0.00023570772],"domain_scores_gemma":[0.999397,0.00018339613,0.000024934025,0.00023160018,0.00007916763,0.00008392358],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031629083,0.00016013852,0.0002989833,0.00016399806,0.000055237164,0.00004539707,0.00005646888,0.00007747883,0.000699332],"category_scores_gemma":[0.0000046617515,0.00011799554,0.00010944322,0.00024245861,0.00018565581,0.00007748831,0.000004156503,0.00011780141,0.000005078745],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028795206,0.000114010196,0.00040670024,0.0004737968,0.00031168584,0.000009662407,0.0012661279,0.000005913509,0.94543874,0.00017800649,0.00011232359,0.04880349],"study_design_scores_gemma":[0.0032036994,0.00210858,0.0003128777,0.0002350478,0.00006229437,0.000027476271,0.00013467406,0.00094088365,0.9684151,0.00016233308,0.024268605,0.0001284522],"about_ca_topic_score_codex":0.00010892311,"about_ca_topic_score_gemma":0.000016163978,"teacher_disagreement_score":0.048675038,"about_ca_system_score_codex":0.000042587395,"about_ca_system_score_gemma":0.000102599464,"threshold_uncertainty_score":0.7657195},"labels":[],"label_agreement":null},{"id":"W4398199060","doi":"10.1016/j.jcyt.2024.03.035","title":"SINGLE-DOSE GLP-1-BASED PANCREATIC GENE THERAPY PRODUCES SUSTAINED LOWERING OF BLOOD GLUCOSE AND BODY WEIGHT IN MURINE MODELS OF DIABETES AND OBESITY","year":2024,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Cell biology; Chemistry; Biology","score_opus":0.020401762166939643,"score_gpt":0.27069350167856093,"score_spread":0.2502917395116213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398199060","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95736384,0.040996764,0.00006729306,0.00035236892,0.000039664006,0.0009778677,0.000013262943,0.00005888203,0.00013005806],"genre_scores_gemma":[0.9920397,0.006778093,0.0005459794,0.00007365256,0.00009659044,0.00004704542,0.000011242788,0.000071315655,0.0003364187],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983065,0.00008190264,0.0004230187,0.00047280925,0.00034832876,0.00036741726],"domain_scores_gemma":[0.9990028,0.000257653,0.000074231815,0.0004202938,0.000122544,0.00012246534],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057205034,0.0002569637,0.00065808435,0.0004296644,0.00003205154,0.000033998695,0.00010512034,0.00010417229,0.00022865107],"category_scores_gemma":[0.00003589191,0.00020876447,0.000090666166,0.00048715074,0.0002694345,0.00012922744,0.000032874814,0.00019959924,4.13721e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00092324073,0.00081551395,0.04037992,0.0010086879,0.00031006444,0.00005508204,0.00096472877,0.00001666193,0.9388818,0.000048472262,0.000005708438,0.0165901],"study_design_scores_gemma":[0.005777447,0.0017239767,0.010978812,0.000552867,0.00006764778,0.000010618161,0.000073376876,0.0073005287,0.9724797,0.00069673656,0.0001491088,0.00018919395],"about_ca_topic_score_codex":0.000065688844,"about_ca_topic_score_gemma":0.00001110251,"teacher_disagreement_score":0.034675825,"about_ca_system_score_codex":0.000053048472,"about_ca_system_score_gemma":0.00016918087,"threshold_uncertainty_score":0.8513168},"labels":[],"label_agreement":null},{"id":"W4398775452","doi":"10.1016/j.semarthrit.2024.152479","title":"Advancing autoimmune Rheumatic disease treatment: CAR-T Cell Therapies - Evidence, Safety, and future directions","year":2024,"lang":"en","type":"review","venue":"Seminars in Arthritis and Rheumatism","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre; Queen's University","funders":"","keywords":"Medicine; Rheumatic disease; Autoimmune disease; Disease; Dermatology; Immunology; Intensive care medicine; Rheumatoid arthritis; Internal medicine","score_opus":0.019721510685513168,"score_gpt":0.32338727582527316,"score_spread":0.30366576513976,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398775452","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00050511316,0.99519646,0.0000017991437,0.000576557,0.0006028172,0.001970429,0.00014118719,0.00011588248,0.00088977395],"genre_scores_gemma":[0.00010681157,0.9872957,0.00026203587,0.000016338072,0.00016966255,0.00039716208,0.00012422666,0.00014526895,0.011482807],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99696046,0.00029654085,0.0009712009,0.000803531,0.0003959695,0.0005722818],"domain_scores_gemma":[0.9982079,0.0005814979,0.00018508003,0.0006101115,0.000041072883,0.0003743179],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000552538,0.0007213123,0.002374675,0.00065413193,0.00026453048,0.00017635588,0.00012475732,0.0003178994,0.0007965295],"category_scores_gemma":[0.00007415962,0.0005299645,0.0004063433,0.00060473284,0.00026851747,0.00019292117,0.0001554315,0.0007459992,0.00004072493],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000050145016,0.000108706656,0.000044392076,0.017484197,0.0002227293,0.00034666117,0.0021013329,1.0921356e-7,0.000005331988,0.00008291653,0.00032667766,0.9792268],"study_design_scores_gemma":[0.00067175535,0.00027182844,0.00020383952,0.3572032,0.000427146,0.00055362884,0.00028034084,0.00003068614,4.2596525e-7,0.00013065776,0.6399044,0.00032210295],"about_ca_topic_score_codex":0.00024548883,"about_ca_topic_score_gemma":0.00018592921,"teacher_disagreement_score":0.9789047,"about_ca_system_score_codex":0.00041816494,"about_ca_system_score_gemma":0.00045779024,"threshold_uncertainty_score":0.9997152},"labels":[],"label_agreement":null},{"id":"W4398783795","doi":"10.1080/10428194.2024.2353877","title":"Outcomes of patients aged ≥26 years with relapsed or refractory B-cell acute lymphoblastic leukemia in ZUMA-3 and historical trials","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Precision Nanosystems (Canada)","funders":"","keywords":"Medicine; Blinatumomab; Refractory (planetary science); Internal medicine; Clinical trial; Lymphoblastic Leukemia; Oncology; Leukemia","score_opus":0.024587027961861088,"score_gpt":0.2825747664574556,"score_spread":0.25798773849559453,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4398783795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99237055,0.0034931067,0.000035787463,0.00009896062,0.00059713435,0.0014689616,0.00008296545,0.00031046223,0.0015420537],"genre_scores_gemma":[0.9779086,0.0027039454,0.00058128533,0.00037918135,0.00022002967,0.00017417101,0.00009135885,0.00030179886,0.017639598],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9934262,0.0005486377,0.0018784979,0.0015059387,0.0014798299,0.0011608937],"domain_scores_gemma":[0.99525166,0.0023677808,0.00044107265,0.0010033028,0.0001966143,0.0007395697],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015073597,0.0009420999,0.0026795992,0.0011926156,0.00015748083,0.00016937271,0.0003958165,0.0007867681,0.0004302352],"category_scores_gemma":[0.0006116206,0.00069362257,0.00041609973,0.0013192256,0.0005326596,0.00042051813,0.00027284725,0.00044197438,0.000049063838],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.060388055,0.0018406401,0.19997476,0.0044722552,0.0037652575,0.012191083,0.009612683,0.00007267143,0.06768711,0.00029657056,0.019276174,0.6204227],"study_design_scores_gemma":[0.10325694,0.0056889122,0.8225442,0.0017350714,0.0017227012,0.0009674205,0.0005461262,0.003109642,0.00645731,0.00017274225,0.052084576,0.0017143127],"about_ca_topic_score_codex":0.0025798439,"about_ca_topic_score_gemma":0.00021722357,"teacher_disagreement_score":0.6225695,"about_ca_system_score_codex":0.033385873,"about_ca_system_score_gemma":0.009138495,"threshold_uncertainty_score":0.9995515},"labels":[],"label_agreement":null},{"id":"W4399032715","doi":"10.1111/bjh.19569","title":"Outcomes of patients with secondary central nervous system lymphoma treated with chimeric antigen receptor T‐cell therapy: A <scp>CIBMTR</scp> analysis","year":2024,"lang":"en","type":"letter","venue":"British Journal of Haematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Cancer Moonshot; Moonshot Research and Development Program; National Institute of Environmental Health Sciences; National Institute of Allergy and Infectious Diseases; Office of Naval Research; Legend Biotech; Alexion Pharmaceuticals; bluebird bio; Pharmacyclics; Takeda Oncology; AstraZeneca; Genentech; Adaptive Biotechnologies; Health Resources and Services Administration; National Institutes of Health; MorphoSys; Seagen; Pediatric Blood and Marrow Transplant Consortium; Pediatric Transplantation and Cellular Therapy Consortium; CareDx; BeiGene; Juno Therapeutics; Swedish Orphan Biovitrum; Astellas Pharma; GlaxoSmithKline; Kiadis Pharma; Jazz Pharmaceuticals; Medical College of Wisconsin; Gateway for Cancer Research; Celgene; Omeros Corporation; Vertex Pharmaceuticals; Atara Biotherapeutics; Actinium Pharmaceuticals; National Cancer Institute; Gilead Sciences; CSL Behring; Bristol-Myers Squibb; Eli Lilly and Company; National Marrow Donor Program; Mallinckrodt Pharmaceuticals; Astellas Pharma US; National Heart, Lung, and Blood Institute; Novartis Pharmaceuticals Corporation; Incyte; Pfizer; Amgen; Sanofi; HistoGenetics","keywords":"Chimeric antigen receptor; Medicine; Central nervous system; Lymphoma; Antigen; Receptor; Immunology; Oncology; Immunotherapy; Cancer research; Internal medicine; Immune system","score_opus":0.008835141096105326,"score_gpt":0.23265787953333253,"score_spread":0.2238227384372272,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399032715","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9827817,0.009937558,0.00003028931,0.0043865973,0.0003662953,0.000933189,0.00041159306,0.00006397307,0.0010887856],"genre_scores_gemma":[0.9371293,0.0047757607,0.0014527172,0.034066293,0.0019461743,0.000092229246,0.00245881,0.00094290293,0.017135803],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99457085,0.00059750257,0.0015839067,0.0006744463,0.0015114734,0.0010618209],"domain_scores_gemma":[0.9959761,0.0004107588,0.0015922056,0.0005999742,0.0010937481,0.0003272272],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036161745,0.0006767065,0.004355193,0.0016020573,0.00009540658,0.000121341815,0.0005619578,0.0008385587,0.00090826105],"category_scores_gemma":[0.000056218672,0.0005070833,0.0010585731,0.0015237064,0.00043578306,0.00013254551,0.0000729813,0.0020635177,0.000023042261],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012474431,0.0008936216,0.42268667,0.0031178368,0.03540876,0.18765771,0.00051077467,0.000012256123,0.00020645102,0.0000010366728,0.333297,0.014960427],"study_design_scores_gemma":[0.022104207,0.0071710693,0.56538576,0.004457747,0.010758682,0.15607575,0.000835717,0.000043734744,0.002246094,0.0000054049697,0.2302128,0.0007030284],"about_ca_topic_score_codex":0.0005446742,"about_ca_topic_score_gemma":0.00005965648,"teacher_disagreement_score":0.1426991,"about_ca_system_score_codex":0.00035840634,"about_ca_system_score_gemma":0.0010092632,"threshold_uncertainty_score":0.9997381},"labels":[],"label_agreement":null},{"id":"W4399040613","doi":"10.1080/14737140.2024.2344647","title":"Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma","year":2024,"lang":"en","type":"article","venue":"Expert Review of Anticancer Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Ministry of Health, British Columbia","keywords":"Medicine; Multiple myeloma; Antibody-drug conjugate; Bispecific antibody; Antibody; Drug; Immunotherapy; Oncology; Refractory (planetary science); Antibody therapy; Internal medicine; Immunology; Cancer research; Monoclonal antibody; Pharmacology; Cancer","score_opus":0.03972425220517079,"score_gpt":0.37765439056616346,"score_spread":0.33793013836099267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399040613","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.28648666,0.707578,0.000021357533,0.0029542667,0.00038032178,0.0014230888,0.000021630349,0.00007864352,0.0010560387],"genre_scores_gemma":[0.21526301,0.7811222,0.00036852664,0.0018721734,0.00030450363,0.000071132104,0.00003712255,0.000076581935,0.00088476983],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971889,0.00020802805,0.00074311125,0.0006928247,0.0006430452,0.0005240705],"domain_scores_gemma":[0.99851406,0.00037698404,0.00009255427,0.00067712605,0.00017311327,0.00016617906],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00084896607,0.00041131623,0.0012069218,0.00031295084,0.000063638334,0.00006422787,0.00023600395,0.00010064032,0.0030329877],"category_scores_gemma":[0.00003957586,0.0002936404,0.00029847186,0.0007560779,0.0004834713,0.00016458069,0.000053199896,0.0003974107,0.000034946854],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040829706,0.00017644504,0.0045549767,0.002452511,0.00018693894,0.000102007274,0.0013989944,1.353932e-7,0.68368226,0.00007374631,0.003231356,0.3037323],"study_design_scores_gemma":[0.0025521722,0.0005486198,0.005997026,0.015032824,0.000016580203,0.00005583339,0.00022108856,0.00018033391,0.26995024,0.000048314683,0.70501655,0.00038043817],"about_ca_topic_score_codex":0.00041744282,"about_ca_topic_score_gemma":0.000025984431,"teacher_disagreement_score":0.70178515,"about_ca_system_score_codex":0.000096005155,"about_ca_system_score_gemma":0.00023874274,"threshold_uncertainty_score":0.9999516},"labels":[],"label_agreement":null},{"id":"W4399052293","doi":"10.1101/2024.05.22.595383","title":"Timing antigenic escape in multiple myeloma treated with T-cell redirecting immunotherapies","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Cancer Institute; Sylvester Comprehensive Cancer Center, University of Miami Health Systems; Tow Foundation","keywords":"Multiple myeloma; Immunotherapy; Antigen; Immune escape; Immunology; Cancer research; Biology; Immune system","score_opus":0.023750365389989373,"score_gpt":0.2541226220592759,"score_spread":0.2303722566692865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399052293","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987535,0.008830563,0.000035477646,0.00022359387,0.00045666803,0.0018299365,0.00006016424,0.0008210295,0.00020756193],"genre_scores_gemma":[0.9942952,0.0009878979,0.0029718531,0.0000902409,0.0005113696,0.00033895398,0.0000011757623,0.00048504816,0.00031826267],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99557996,0.00021248884,0.0007845196,0.0015646603,0.0007980147,0.0010603756],"domain_scores_gemma":[0.9970455,0.00021720926,0.00028051928,0.0016885789,0.00045830567,0.00030989767],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0010593788,0.00086798216,0.0011619027,0.0011304521,0.00015435515,0.00029765817,0.0004599326,0.0007040372,0.00049050647],"category_scores_gemma":[0.00017209734,0.0008021178,0.00028262046,0.0015479504,0.0002133075,0.00009590527,0.00055760687,0.0025435514,0.00015421768],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069947424,0.00027351434,0.051626198,0.0014206842,0.000496812,0.00095033715,0.00010232221,0.00004217598,0.94424605,0.000008247801,0.00007792258,0.000056274566],"study_design_scores_gemma":[0.0032681082,0.00032021024,0.07387619,0.003951697,0.00026277365,4.1052704e-7,0.00003982324,0.0022983558,0.91205174,0.0000010837779,0.0028640728,0.0010655306],"about_ca_topic_score_codex":0.0005470009,"about_ca_topic_score_gemma":0.00003446379,"teacher_disagreement_score":0.032194294,"about_ca_system_score_codex":0.0008822406,"about_ca_system_score_gemma":0.0011679368,"threshold_uncertainty_score":0.99975765},"labels":[],"label_agreement":null},{"id":"W4399122701","doi":"10.1016/j.ejcskn.2024.100143","title":"A phase 3 study of the efficacy, safety, and pharmacokinetics profile of subcutaneous vs intravenous nivolumab + relatlimab fixed-dose combination in previously untreated metastatic or unresectable melanoma (RELATIVITY-127)","year":2024,"lang":"en","type":"article","venue":"EJC Skin Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital de l'Enfant-Jésus","funders":"","keywords":"Nivolumab; Medicine; Pharmacokinetics; Safety profile; Metastatic melanoma; Melanoma; Oncology; Pharmacology; Internal medicine; Anesthesia; Adverse effect; Cancer; Immunotherapy; Cancer research","score_opus":0.026175707076226656,"score_gpt":0.35289931568384625,"score_spread":0.3267236086076196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399122701","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907767,0.0037417714,0.000013528901,0.00032702117,0.00017723569,0.003828067,0.00009758585,0.000039674538,0.0009983763],"genre_scores_gemma":[0.99240106,0.0011505112,0.00004414492,0.000020915772,0.0000424457,0.0001403111,0.000025364869,0.000056018627,0.0061192447],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99753386,0.00043288773,0.00061531307,0.00041358717,0.00064354524,0.0003608315],"domain_scores_gemma":[0.9984207,0.00075743825,0.00015464118,0.00040815887,0.00016594934,0.00009310001],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00060422736,0.00023686815,0.00064097956,0.00029492725,0.00006263816,0.000026855707,0.0001780083,0.00007939409,0.0021129597],"category_scores_gemma":[0.00018564674,0.00016305604,0.0000838958,0.0012906551,0.00017890104,0.00007536758,0.00012522169,0.00053399743,0.0000053308886],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09090069,0.034466177,0.01834104,0.005805597,0.0040346934,0.0038711557,0.053476084,0.0010790746,0.123730764,0.0002374191,0.0024646968,0.6615926],"study_design_scores_gemma":[0.35004714,0.12244941,0.09860052,0.009587429,0.007848847,0.0033790143,0.0068143425,0.1774182,0.20553239,0.00053116994,0.015551661,0.0022398797],"about_ca_topic_score_codex":0.0018281956,"about_ca_topic_score_gemma":0.0012488702,"teacher_disagreement_score":0.6593527,"about_ca_system_score_codex":0.0003520616,"about_ca_system_score_gemma":0.00052924716,"threshold_uncertainty_score":0.99879926},"labels":[],"label_agreement":null},{"id":"W4399154266","doi":"10.29173/eureka28822","title":"How Fundamental Research on T cell Biology Started a Revolution in Cancer Therapy Development","year":2024,"lang":"en","type":"article","venue":"Eureka","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Transformative learning; Cancer immunotherapy; Immune checkpoint; Immunotherapy; Cancer therapy; Cancer; Cornerstone; Cancer cell; Environmental ethics; Biology; Immune system; Cancer research; Immunology; Sociology; Philosophy; History; Genetics","score_opus":0.18498004284897754,"score_gpt":0.44703414907501104,"score_spread":0.26205410622603353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399154266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9711993,0.010355994,0.000014897235,0.009531196,0.0003269831,0.0008652456,0.00001043282,0.00008029715,0.0076157],"genre_scores_gemma":[0.9475927,0.002371608,0.00012075676,0.00028122647,0.00029861904,0.00020413002,0.00004216969,0.000040039016,0.049048766],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981323,0.00025257232,0.00016426017,0.00042851272,0.0005004959,0.00052186626],"domain_scores_gemma":[0.99937874,0.00015268846,0.00001337912,0.00024071528,0.00010306789,0.00011141097],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00098639,0.00013256421,0.0001869312,0.00059063523,0.000072022034,0.0000623755,0.0001137734,0.000114612485,0.0024164475],"category_scores_gemma":[0.000029834428,0.000104347106,0.00005038339,0.00080131966,0.000111528156,0.00004726006,0.000049391958,0.0007648032,0.00019065572],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012561819,0.00038931434,0.007799111,0.00015948439,0.00008343644,0.00018449582,0.0023320487,0.000003808733,0.7674172,0.00022698622,0.017034207,0.20311373],"study_design_scores_gemma":[0.0016198088,0.000923382,0.010940179,0.00025357687,0.000002877824,0.000005921803,0.00036511966,0.00025810645,0.09064626,0.00012438493,0.8947316,0.00012879752],"about_ca_topic_score_codex":0.00028809704,"about_ca_topic_score_gemma":0.00027033524,"teacher_disagreement_score":0.87769735,"about_ca_system_score_codex":0.0010977973,"about_ca_system_score_gemma":0.0006295791,"threshold_uncertainty_score":0.99849546},"labels":[],"label_agreement":null},{"id":"W4399157658","doi":"10.21203/rs.3.rs-4432372/v1","title":"Limited Immunogenicity of an HLA-A*03:01-restricted Epitope of Erv-k-env in Non-hiv-1 Settings: Implications for Adoptive Cell Therapy in Cancer","year":2024,"lang":"en","type":"preprint","venue":"Research Square","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institutes of Health; National Cancer Institute; Children's National Hospital; George Washington University; U.S. Department of Defense","keywords":"Immunogenicity; Epitope; Human leukocyte antigen; Virology; Human immunodeficiency virus (HIV); Cancer; Adoptive cell transfer; Immunology; Medicine; Cancer research; Antibody; Immune system; T cell; Antigen; Internal medicine","score_opus":0.08717692726774202,"score_gpt":0.44479350366338494,"score_spread":0.3576165763956429,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399157658","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97581536,0.008124768,0.000025015235,0.002875691,0.000104245424,0.0092771705,0.002581446,0.00005091912,0.0011454191],"genre_scores_gemma":[0.9814726,0.01118302,0.00071922416,0.000039012903,0.00025745915,0.0036201288,0.001268872,0.00017423207,0.0012654525],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9941444,0.0008389481,0.0012651512,0.0012353477,0.0013480945,0.0011680693],"domain_scores_gemma":[0.99383587,0.0013602374,0.0002934116,0.001881327,0.0023189378,0.00031024488],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0030304648,0.00046091055,0.0012979584,0.0027530526,0.000085800304,0.000065571876,0.0010245966,0.00077153655,0.0006602079],"category_scores_gemma":[0.00060591457,0.00043061146,0.00047317502,0.0032335443,0.00043590344,0.000082934785,0.0011177962,0.0037607176,0.000015001695],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008646467,0.0037139906,0.03881715,0.009429553,0.00058412686,0.00006253325,0.006808636,0.0009318641,0.86515963,0.00010572417,0.0022423123,0.063498035],"study_design_scores_gemma":[0.013709977,0.006102319,0.6397978,0.008733876,0.00013285823,0.000010817432,0.004635401,0.010693142,0.30695358,0.0042579644,0.0039567854,0.0010154757],"about_ca_topic_score_codex":0.009113949,"about_ca_topic_score_gemma":0.0012191402,"teacher_disagreement_score":0.60098064,"about_ca_system_score_codex":0.0013015073,"about_ca_system_score_gemma":0.0033484658,"threshold_uncertainty_score":0.99981457},"labels":[],"label_agreement":null},{"id":"W4399275929","doi":"10.1101/2024.05.29.596375","title":"Pre-TCR-Targeted Immunotherapy for T-cell Acute Lymphoblastic Leukemia","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Centro Nacional de Biotecnología; Brigham and Women's Hospital; University of Toronto; Universiteit van Amsterdam; European Regional Development Fund; European Commission; Agencia Estatal de Investigación; Fundación Inocente, Inocente; Centro de Biología Molecular Severo Ochoa; Sunnybrook Research Institute; Comunidad de Madrid; Fundación Ramón Areces","keywords":"T-cell receptor; Lymphoblastic Leukemia; Immunotherapy; Medicine; Cancer research; T cell; Leukemia; Immunology; Immune system","score_opus":0.014531618191342218,"score_gpt":0.26593728888083595,"score_spread":0.2514056706894937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399275929","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9756155,0.010584125,0.0019505674,0.0005557424,0.00311567,0.005626944,0.0010112921,0.0014011943,0.00013897677],"genre_scores_gemma":[0.9838715,0.0021976156,0.0065242276,0.0005991799,0.0019353878,0.002037235,0.0000059264185,0.0008947436,0.0019341834],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99458945,0.00014359682,0.0009806607,0.0019340666,0.0009986869,0.0013535155],"domain_scores_gemma":[0.99526846,0.00026987586,0.00035161996,0.0025747544,0.0009263035,0.0006089813],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009907776,0.0011147067,0.0014214802,0.000787757,0.00019677753,0.0004049784,0.000852875,0.001208508,0.0010016991],"category_scores_gemma":[0.0001776612,0.0011011465,0.00082538783,0.0008777623,0.00024028191,0.000087281995,0.0007690787,0.0018527157,0.00037959553],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001485052,0.00028782885,0.0004342695,0.002692106,0.001716542,0.0002582752,0.000035675846,0.000039002407,0.98901886,0.0001186757,0.003882437,0.000031285617],"study_design_scores_gemma":[0.0056886594,0.0007881586,0.007864587,0.0014533882,0.0010946214,2.9738678e-7,0.0000042312786,0.004107606,0.925792,0.000025054675,0.051746458,0.0014349619],"about_ca_topic_score_codex":0.000096984026,"about_ca_topic_score_gemma":0.0000017811318,"teacher_disagreement_score":0.06322687,"about_ca_system_score_codex":0.0026731489,"about_ca_system_score_gemma":0.0049793716,"threshold_uncertainty_score":0.99991155},"labels":[],"label_agreement":null},{"id":"W4399281392","doi":"10.1200/jco.2024.42.16_suppl.10016","title":"Evolution of tisagenlecleucel use for the treatment of pediatric and young adult relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL): Center for International Blood &amp; Marrow Transplant Research (CIBMTR) registry results.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Refractory (planetary science); Lymphoblastic Leukemia; Blinatumomab; Bone marrow transplant; Hematopoietic cell; Acute lymphocytic leukemia; Bone marrow; Oncology; Bone transplantation; Pediatrics; Leukemia; Internal medicine; Bone marrow transplantation; Stem cell; Surgery; Haematopoiesis","score_opus":0.14603389688117718,"score_gpt":0.46044773126579247,"score_spread":0.3144138343846153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399281392","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889353,0.002950978,0.0010751421,0.0022665376,0.002768359,0.0009975557,0.0006025494,0.000008836927,0.00039474122],"genre_scores_gemma":[0.9374718,0.049834978,0.0022618514,0.00006940398,0.0033617772,0.000048480542,0.000057513847,0.000043706,0.0068504578],"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959703,0.00039292182,0.002215825,0.00032865774,0.0007485265,0.0003437587],"domain_scores_gemma":[0.9825937,0.013890515,0.0008035045,0.00032079697,0.0021464399,0.00024505093],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004257105,0.00016503266,0.0008719848,0.00037305424,0.000058199137,0.000025157024,0.0002728525,0.0004186795,0.0000618242],"category_scores_gemma":[0.004493979,0.00010317629,0.0006942013,0.00020032292,0.00039008458,0.00012204315,0.000033815697,0.00070857484,0.0000026454766],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.41417044,0.026798658,0.115354694,0.0026509059,0.01642812,0.0014578312,0.0055225445,0.00013603727,0.13876267,0.0007206189,0.13048637,0.14751111],"study_design_scores_gemma":[0.12833293,0.11484606,0.06900065,0.00082078006,0.008865106,0.0014492534,0.0005205751,0.006621842,0.004714278,0.00082060136,0.6636152,0.0003927026],"about_ca_topic_score_codex":0.00011504514,"about_ca_topic_score_gemma":0.00013553734,"teacher_disagreement_score":0.53312886,"about_ca_system_score_codex":0.0008832704,"about_ca_system_score_gemma":0.002564168,"threshold_uncertainty_score":0.5380037},"labels":[],"label_agreement":null},{"id":"W4399285742","doi":"10.1038/s41591-024-02986-9","title":"Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study","year":2024,"lang":"en","type":"article","venue":"Nature Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":130,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Princess Margaret Cancer Centre","funders":"Loxo Oncology; Pharmacyclics; Chugai Pharmaceutical; Genentech; EMD Serono; MorphoSys; SymBio Pharmaceuticals Limited; BeiGene; Mitsubishi Tanabe Pharma Corporation; Seagen; Celgene; Alimera Sciences; Eisai; Astellas Pharma; Adaptive Biotechnologies; Pfizer; Incyte; TG Therapeutics; bluebird bio; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Calithera Biosciences; Jazz Pharmaceuticals; Regeneron Pharmaceuticals; Alexion Pharmaceuticals; Karyopharm Therapeutics; Sanofi; Amgen; AstraZeneca; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Follicular lymphoma; Refractory (planetary science); Internal medicine; Follicular phase; Lymphoma; Oncology; Confidence interval; Rituximab; CD20; Clinical endpoint; Gastroenterology; Clinical trial; Biology","score_opus":0.022271693998789203,"score_gpt":0.38543607341103714,"score_spread":0.36316437941224794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399285742","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9112136,0.049975596,0.000041909156,0.028083269,0.0010331038,0.00216494,0.000009351789,0.00015443296,0.007323829],"genre_scores_gemma":[0.9827103,0.0007607638,0.000023413371,0.0017909883,0.0016740196,0.00010985662,0.000045747838,0.00007121377,0.012813674],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99701095,0.00020450058,0.00043718517,0.0005730208,0.0012718955,0.00050244655],"domain_scores_gemma":[0.9985991,0.00034479325,0.000028519351,0.0007194084,0.00009906565,0.00020912352],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017033956,0.00030358272,0.0005831437,0.00046993332,0.00007930528,0.0000315349,0.00031262045,0.00031817125,0.0035739313],"category_scores_gemma":[0.00022865161,0.00016509648,0.00016136977,0.0014906409,0.00023061334,0.00006634357,0.00003993403,0.0015603232,0.00005847815],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040610163,0.0050663734,0.0076387534,0.00084051676,0.0013128362,0.019048747,0.017688788,0.0000054820985,0.37962773,0.0005689008,0.04591293,0.51822793],"study_design_scores_gemma":[0.055751454,0.006872099,0.04166045,0.0014943026,0.00093344104,0.0009117946,0.00558337,0.0021571962,0.01280557,0.00032286948,0.8709774,0.00053003355],"about_ca_topic_score_codex":0.00019830976,"about_ca_topic_score_gemma":0.00018054154,"teacher_disagreement_score":0.8250645,"about_ca_system_score_codex":0.00025650804,"about_ca_system_score_gemma":0.00020805508,"threshold_uncertainty_score":0.9973369},"labels":[],"label_agreement":null},{"id":"W4399292909","doi":"10.1038/s41551-024-01216-4","title":"Subcutaneous biodegradable scaffolds for restimulating the antitumour activity of pre-administered CAR-T cells","year":2024,"lang":"en","type":"article","venue":"Nature Biomedical Engineering","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Institutes of Health Research; U.S. Food and Drug Administration; National Cancer Institute; National Institutes of Health; Government of Canada; U.S. Department of Health and Human Services","keywords":"T cell; Chimeric antigen receptor; Scaffold; Chemistry; Cytotoxicity; Cell growth; Cell biology; Pharmacology; Cancer research; Immunology; In vitro; Medicine; Immune system; Biology; Biomedical engineering; Biochemistry","score_opus":0.014981513598037401,"score_gpt":0.31167360044932724,"score_spread":0.29669208685128984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399292909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9812511,0.005426349,0.006864075,0.0024565929,0.0018516062,0.0013404691,0.000120252,0.0003652515,0.0003242655],"genre_scores_gemma":[0.994787,0.000041292187,0.0024371091,0.000044189404,0.0005906671,0.000031525517,0.000023796096,0.00006222727,0.001982208],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99827284,0.000022096161,0.00027050456,0.0003400838,0.0006639673,0.000430516],"domain_scores_gemma":[0.9985091,0.0008028214,0.000035873338,0.00036181085,0.00008814045,0.00020226875],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005475546,0.00020299954,0.00035761658,0.00023383275,0.00005801805,0.000047087906,0.00020951926,0.00043636974,0.00014108479],"category_scores_gemma":[0.0002863951,0.0001352699,0.00021996225,0.000637986,0.00012048782,0.00005014477,0.00007068798,0.0007111112,0.000003647743],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037257661,0.000068951005,0.00001626292,0.0012593085,0.0001506044,0.00016033166,0.00012408163,0.00012263202,0.9806152,0.00014426278,0.0012373419,0.015728462],"study_design_scores_gemma":[0.0010402476,0.0010703856,0.00047456278,0.0010104837,0.00016293187,0.00040203868,0.00002563717,0.35591567,0.5097027,0.000031233845,0.12988505,0.0002790647],"about_ca_topic_score_codex":0.00003065842,"about_ca_topic_score_gemma":0.0000023582486,"teacher_disagreement_score":0.4709125,"about_ca_system_score_codex":0.00012328182,"about_ca_system_score_gemma":0.00021271384,"threshold_uncertainty_score":0.55161464},"labels":[],"label_agreement":null},{"id":"W4399296888","doi":"10.1101/2024.05.29.596014","title":"Conditional CAR T cells with specificity to oncofetal glycosaminoglycans in solid tumors","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health Research Institute; University of British Columbia; Vancouver Coastal Health","funders":"","keywords":"Glycosaminoglycan; Oncofetal antigen; Cell biology; Cancer research; Chemistry; Biology; Biochemistry; Immunology; Immunotherapy; Immune system","score_opus":0.020014724663877652,"score_gpt":0.2707863480388036,"score_spread":0.2507716233749259,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399296888","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938534,0.00030316724,0.00023318412,0.00085838436,0.0008625021,0.0023309533,0.00094874395,0.00036093558,0.00024873027],"genre_scores_gemma":[0.9950693,0.00008065017,0.0021663816,0.00043404417,0.0012188416,0.00044035862,0.00000383181,0.00029730803,0.0002892354],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.995045,0.00015404266,0.00077359425,0.0016884563,0.0012959952,0.0010429159],"domain_scores_gemma":[0.9967721,0.00011091492,0.00017715071,0.0015144465,0.000593478,0.0008318718],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007943041,0.00080335775,0.00121642,0.001077835,0.00008914977,0.00022357563,0.00052556896,0.00054486527,0.0012321223],"category_scores_gemma":[0.00009364235,0.0007726028,0.00025398924,0.0012707231,0.000276381,0.00007068946,0.0007560465,0.0025964603,0.0006604895],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00076731265,0.0003906404,0.0039548003,0.0009998054,0.0003368463,0.0034253486,0.000050941577,0.0004302968,0.9879723,0.0004830048,0.0011849776,0.0000036948288],"study_design_scores_gemma":[0.0022415514,0.0007298352,0.0819564,0.0028473074,0.00023455032,8.036869e-7,0.000026679592,0.0005878602,0.9014051,0.000016530872,0.008577201,0.0013761704],"about_ca_topic_score_codex":0.000252915,"about_ca_topic_score_gemma":0.00006454204,"teacher_disagreement_score":0.08656722,"about_ca_system_score_codex":0.0015768987,"about_ca_system_score_gemma":0.0028211991,"threshold_uncertainty_score":0.9997046},"labels":[],"label_agreement":null},{"id":"W4399304973","doi":"10.1186/s12967-024-05340-2","title":"Local delivery of accutox® synergises with immune-checkpoint inhibitors at disrupting tumor growth","year":2024,"lang":"en","type":"article","venue":"Journal of Translational Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Defence Research and Development Canada; Centre Hospitalier Universitaire Sainte-Justine; Université du Québec à Montréal; Université de Montréal","funders":"Canadian Institutes of Health Research","keywords":"Cancer research; Programmed cell death; Cancer cell; Flow cytometry; Apoptosis; Immune system; Cancer; Cell cycle checkpoint; Cell cycle; Biology; Transcriptome; Endosome; Cell culture; Cell; Chemistry; Molecular biology; Immunology; Biochemistry; Gene; Genetics; Gene expression","score_opus":0.02375582300826361,"score_gpt":0.30952036329841026,"score_spread":0.28576454029014664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399304973","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9605813,0.014592102,0.0040370687,0.018113088,0.00042520292,0.00028298204,0.000011472463,0.000027530621,0.0019292563],"genre_scores_gemma":[0.9970287,0.00039056828,0.00078581483,0.0001505295,0.00093744945,0.0000030120277,0.000014091358,0.000042920765,0.00064688077],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9968474,0.00006617364,0.0010957071,0.00018314243,0.0015675097,0.00024008499],"domain_scores_gemma":[0.9980923,0.00066632684,0.00025847202,0.00013943549,0.0006113307,0.0002321371],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010485172,0.0001964934,0.00062228186,0.00054506905,0.000054812546,0.000010541356,0.0001279967,0.00006627435,0.002154298],"category_scores_gemma":[0.00013566932,0.00012010992,0.0002716125,0.00051125855,0.00045614128,0.00019112878,0.000019293082,0.00056968845,0.000006322451],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00821004,0.00028192086,0.011026208,0.001644582,0.0013439778,0.0026537892,0.002438756,0.0004406849,0.93909216,0.0004904871,0.0013966841,0.030980688],"study_design_scores_gemma":[0.032358952,0.02023082,0.11590562,0.040351007,0.0036700757,0.034051806,0.004244279,0.011871529,0.6906981,0.0020042132,0.043511238,0.0011024001],"about_ca_topic_score_codex":0.000055534096,"about_ca_topic_score_gemma":0.000011664953,"teacher_disagreement_score":0.24839413,"about_ca_system_score_codex":0.00017518194,"about_ca_system_score_gemma":0.0004814401,"threshold_uncertainty_score":0.99875784},"labels":[],"label_agreement":null},{"id":"W4399379462","doi":"10.1101/2024.06.04.597422","title":"IMMUNOTAR - Integrative prioritization of cell surface targets for cancer immunotherapy","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Canada's Michael Smith Genome Sciences Centre; BC Cancer Agency; Terry Fox Research Institute","funders":"National Cancer Institute; Cancer Research UK; National Institutes of Health; Michael Smith Health Research BC; Mark Foundation For Cancer Research","keywords":"Prioritization; Immunotherapy; Cancer immunotherapy; Cancer; Computational biology; Cancer research; Computer science; Medicine; Biology; Engineering; Internal medicine; Management science","score_opus":0.017139886532822945,"score_gpt":0.2873855314952395,"score_spread":0.27024564496241654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399379462","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9483393,0.0399452,0.0026127072,0.00060885074,0.002168046,0.0045887795,0.0011159971,0.00056315714,0.000057994657],"genre_scores_gemma":[0.9785535,0.0077298167,0.011422802,0.00013368718,0.00052820303,0.000654918,0.0000033014023,0.0005290643,0.0004447384],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9967357,0.0001350273,0.0008098474,0.0010410844,0.0006503478,0.00062799023],"domain_scores_gemma":[0.9961898,0.00017019457,0.0004207071,0.0012894381,0.0017290214,0.00020083596],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00082391157,0.00067251537,0.0011398462,0.0003727707,0.00008174533,0.00011904635,0.00044829817,0.00066275545,0.00049171236],"category_scores_gemma":[0.00012945739,0.00063008966,0.00047990234,0.00068665267,0.00021078352,0.00007698638,0.00035165602,0.0013003316,0.000022840994],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069097435,0.0002635927,0.0011268765,0.002907624,0.00075807713,0.000020214387,0.000122651,0.000069434216,0.99313515,0.00021561087,0.00067102053,0.000018799004],"study_design_scores_gemma":[0.0016428514,0.00028546283,0.0043624234,0.0016948411,0.00026210953,1.7292729e-8,0.000016354714,0.0010820447,0.97205096,0.000015585176,0.018030895,0.0005564631],"about_ca_topic_score_codex":0.0003598931,"about_ca_topic_score_gemma":0.000007276932,"teacher_disagreement_score":0.032215383,"about_ca_system_score_codex":0.00072375947,"about_ca_system_score_gemma":0.0023681726,"threshold_uncertainty_score":0.999615},"labels":[],"label_agreement":null},{"id":"W4399391946","doi":"10.21203/rs.3.rs-4381902/v1","title":"Epithelial Cell Adhesion Molecule (EpCAM)-Targeted CAR-T Cells (IMC001) in Patients with Advanced Gastric Cancer: A Phase I Dose-Escalation Trial","year":2024,"lang":"en","type":"preprint","venue":"Research Square","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Biotechnology Research Institute","funders":"","keywords":"Medicine; Tolerability; Epithelial cell adhesion molecule; Cancer; Gastroenterology; Internal medicine; Pharmacokinetics; Cmax; Chemotherapy; Oncology; Nuclear medicine; Adverse effect","score_opus":0.034035100479836954,"score_gpt":0.3872638101725909,"score_spread":0.353228709692754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399391946","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9816728,0.0019890352,0.00002069044,0.0003754352,0.00070881407,0.012865247,0.00089048257,0.00016575579,0.0013117238],"genre_scores_gemma":[0.98910224,0.0014896663,0.00030579034,0.000026880636,0.0009128775,0.002085628,0.0015574627,0.0002944814,0.0042249695],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98956275,0.0011938654,0.00097124785,0.0018799013,0.004623703,0.0017685564],"domain_scores_gemma":[0.99556994,0.00042730483,0.00022089126,0.0014735401,0.0015556106,0.00075270794],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018462647,0.00073246483,0.0011943588,0.0024549789,0.00018468061,0.00022700589,0.0005953488,0.0007789187,0.0023057442],"category_scores_gemma":[0.0002985912,0.0006119936,0.00040641325,0.002568615,0.00026511037,0.00011776834,0.001218624,0.0057181157,0.00021977375],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38545975,0.00796166,0.0042670113,0.007020756,0.0003588573,0.0008612537,0.0017238036,0.0014215983,0.49302816,0.000008101442,0.0025153805,0.09537366],"study_design_scores_gemma":[0.5102259,0.049388193,0.018220607,0.012264693,0.00046757987,0.000008029518,0.00081986346,0.009004521,0.3882924,0.0005165291,0.008439835,0.002351874],"about_ca_topic_score_codex":0.0013433784,"about_ca_topic_score_gemma":0.0002084223,"teacher_disagreement_score":0.12476613,"about_ca_system_score_codex":0.0027130784,"about_ca_system_score_gemma":0.0028807225,"threshold_uncertainty_score":0.99963313},"labels":[],"label_agreement":null},{"id":"W4399452369","doi":"10.1200/jco.2024.42.17_suppl.lba7005","title":"Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Results from the phase 3 ECHELON-3 study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Queen Elizabeth II Health Sciences Centre; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Lenalidomide; Internal medicine; Brentuximab vedotin; Rituximab; Population; Oncology; Refractory (planetary science); Clinical endpoint; Placebo; Phases of clinical research; Diffuse large B-cell lymphoma; Interim analysis; Gastroenterology; Surgery; Lymphoma; CD30; Chemotherapy; Randomized controlled trial; Multiple myeloma; Pathology","score_opus":0.05589310246874222,"score_gpt":0.41747220317367334,"score_spread":0.3615791007049311,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399452369","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944838,0.00062365335,0.00001900444,0.0032660668,0.00035597733,0.00077130203,0.000026867197,0.00001062154,0.00044269336],"genre_scores_gemma":[0.99839675,0.00035699864,0.00019105048,0.00045618764,0.00026123162,0.000009260664,0.00002209482,0.00003441741,0.00027200126],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9953617,0.0012443737,0.0019337584,0.00037356833,0.0007684888,0.00031814902],"domain_scores_gemma":[0.99220467,0.0063139214,0.0006638521,0.00030010543,0.00029413428,0.0002233446],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0058795474,0.00019367614,0.0011969595,0.00027044155,0.000040798863,0.000041223295,0.00020209236,0.0002605969,0.000059651607],"category_scores_gemma":[0.0017355402,0.000104281724,0.00012286425,0.00039506957,0.0002198444,0.00019879123,0.00008209081,0.0016765014,0.000009440501],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17584723,0.2534467,0.39236888,0.000041354542,0.00041434253,0.0033837364,0.0024818354,0.0000018906519,0.000096339514,0.000012464354,0.0011489035,0.17075634],"study_design_scores_gemma":[0.49620098,0.034504604,0.45576248,0.00031073284,0.00016810799,0.000028435104,0.0006200421,0.00023248108,0.000022348264,0.00006715838,0.011983775,0.000098847384],"about_ca_topic_score_codex":0.00019295675,"about_ca_topic_score_gemma":0.00090614223,"teacher_disagreement_score":0.32035375,"about_ca_system_score_codex":0.0004080739,"about_ca_system_score_gemma":0.0012922133,"threshold_uncertainty_score":0.7283657},"labels":[],"label_agreement":null},{"id":"W4399570650","doi":"10.1200/jco.2024.42.16_suppl.tps9602","title":"A phase 3 trial of IMC-F106C (PRAME x CD3) plus nivolumab versus standard nivolumab regimens in HLA-A*02:01+ patients with previously untreated advanced melanoma (PRISM-MEL-301).","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Nivolumab; Medicine; Oncology; Melanoma; Internal medicine; Human leukocyte antigen; Surgery; Immunotherapy; Cancer research; Immunology; Cancer; Antigen","score_opus":0.07968899237102706,"score_gpt":0.47349714728562897,"score_spread":0.3938081549146019,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399570650","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893338,0.0014158011,0.00009695216,0.0021774082,0.0024455427,0.0017928514,0.00003201657,0.000037751695,0.0026678443],"genre_scores_gemma":[0.9932457,0.0015167857,0.0019802244,0.00018260721,0.0010299353,0.000028605615,0.000025623598,0.00009386504,0.0018966517],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99212795,0.0011483729,0.0038851926,0.0005698072,0.0015650279,0.0007036566],"domain_scores_gemma":[0.9916588,0.0044787335,0.0016864785,0.00059239374,0.0008995321,0.000684072],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004319316,0.00036850123,0.0033001632,0.0006101919,0.00004633727,0.00003477876,0.00040160998,0.00070175616,0.0012075334],"category_scores_gemma":[0.004361266,0.00026437666,0.0008078686,0.00079466356,0.0005273584,0.00026886145,0.000112033376,0.0025640705,0.000027374874],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.713407,0.005045418,0.0018226742,0.0001111904,0.0012473505,0.0023717657,0.00046382606,0.000019172436,0.00029152664,0.00002655912,0.0027123517,0.2724812],"study_design_scores_gemma":[0.60790783,0.30353215,0.0021470056,0.00077082106,0.00077028415,0.00012996048,0.0002491962,0.00032623849,0.000272128,0.00009083355,0.08356299,0.00024055014],"about_ca_topic_score_codex":0.0000849197,"about_ca_topic_score_gemma":0.00025384498,"teacher_disagreement_score":0.29848674,"about_ca_system_score_codex":0.0016322319,"about_ca_system_score_gemma":0.006845065,"threshold_uncertainty_score":0.99998087},"labels":[],"label_agreement":null},{"id":"W4399614387","doi":"10.21769/bioprotoc.5021","title":"A Flow Cytometry–Based Method for Assessing CAR Cell Binding Kinetics Using Stable CAR Jurkat Cells","year":2024,"lang":"en","type":"article","venue":"BIO-PROTOCOL","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada; Institute of Infection and Immunity; University of Ottawa","funders":"","keywords":"Jurkat cells; Flow cytometry; Kinetics; Flow (mathematics); Chemistry; Cell biology; Computer science; Cancer research; Molecular biology; Immunology; Biology; T cell; Physics; Mechanics","score_opus":0.09766097975005007,"score_gpt":0.4541910561190355,"score_spread":0.3565300763689854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399614387","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011475234,0.000044179946,0.20724748,0.00018009439,0.00044279383,0.77671593,0.0001496569,0.00039044447,0.0033541971],"genre_scores_gemma":[0.005678704,7.118697e-7,0.28053758,0.00015428162,0.0009226267,0.7075432,0.000039626746,0.00027925766,0.004844014],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9966831,0.00021562346,0.00056393427,0.0007925996,0.0008111118,0.00093360373],"domain_scores_gemma":[0.997957,0.0006147664,0.00011295359,0.0006829618,0.00028440193,0.0003479121],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014192911,0.00041146504,0.0006025924,0.00084694265,0.00020646575,0.0004786965,0.00024899121,0.00030561158,0.0013998102],"category_scores_gemma":[0.000107918204,0.00036128008,0.00037003032,0.001437867,0.00008563353,0.00017425542,0.00008891331,0.0005062824,0.00005795016],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042448405,0.00019905239,0.00019002214,0.0040039015,0.00007477323,0.00011619095,0.00011343943,0.00037142212,0.9787526,0.0000068191807,0.0013919174,0.014355346],"study_design_scores_gemma":[0.0026408122,0.00046871282,0.000011559534,0.00044957,0.00009763538,0.00001539793,0.00008951788,0.1755657,0.6223704,0.000010851432,0.19802529,0.00025451605],"about_ca_topic_score_codex":0.000119666474,"about_ca_topic_score_gemma":0.0000054436437,"teacher_disagreement_score":0.3563822,"about_ca_system_score_codex":0.0008281921,"about_ca_system_score_gemma":0.00087931624,"threshold_uncertainty_score":0.9998839},"labels":[],"label_agreement":null},{"id":"W4399644646","doi":"10.1089/genbio.2024.0010","title":"T-Cell Differentiation from Hematopoietic Progenitor Cells Using 3D Thymic-like Hydrogels","year":2024,"lang":"en","type":"article","venue":"GEN Biotechnology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Canada's Michael Smith Genome Sciences Centre; Dalhousie University; University of British Columbia","funders":"","keywords":"Self-healing hydrogels; Haematopoiesis; Progenitor cell; Cell biology; Progenitor; Stem cell; Chemistry; Biology; Polymer chemistry","score_opus":0.021393005669313934,"score_gpt":0.2838438445043288,"score_spread":0.26245083883501485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399644646","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98718005,0.005623597,0.0031804922,0.00138574,0.00081502565,0.0007660914,0.000035167628,0.0006692588,0.00034460015],"genre_scores_gemma":[0.9915549,0.00046122813,0.0044927043,0.000135713,0.00037417246,0.000039781095,0.000071229224,0.000091632195,0.0027786167],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99821,0.000051674993,0.00031001947,0.0006035722,0.00032651192,0.0004982217],"domain_scores_gemma":[0.99907476,0.00006650166,0.00005038086,0.00065807346,0.000043607037,0.00010668015],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000135113,0.00023565517,0.00036070714,0.00043524173,0.00007531691,0.000057889003,0.00022856776,0.0007005351,0.0023213213],"category_scores_gemma":[0.00001482936,0.0002101571,0.00015248825,0.0005279391,0.00017478019,0.00005380819,0.00017526856,0.00063465623,0.00070620404],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000054599866,0.00011057836,0.00021099825,0.00014345362,0.00014544859,0.0001544611,0.00018184134,0.000002955682,0.9829974,0.00007255558,0.0005693577,0.015356322],"study_design_scores_gemma":[0.00059812696,0.0001768888,0.00003598468,0.00008980542,0.00014289885,0.00011056841,0.00010104348,0.008470813,0.95323056,0.0005444425,0.036311824,0.0001870734],"about_ca_topic_score_codex":0.00012436717,"about_ca_topic_score_gemma":0.000007646496,"teacher_disagreement_score":0.035742465,"about_ca_system_score_codex":0.00022478381,"about_ca_system_score_gemma":0.0001533844,"threshold_uncertainty_score":0.9985907},"labels":[],"label_agreement":null},{"id":"W4399672006","doi":"10.1200/jco.2024.42.16_suppl.2055","title":"Cost-effectiveness of dabrafenib plus trametinib in BRAFV600E-mutant pediatric low-grade glioma: A microsimulation study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"SickKids Foundation; University of Toronto; University of Alberta; Hospital for Sick Children","funders":"","keywords":"Trametinib; Medicine; Dabrafenib; Glioma; Mutant; Oncology; Internal medicine; Cancer research; Cancer; Genetics; Gene; MAPK/ERK pathway; Biology; Phosphorylation; Vemurafenib; Metastatic melanoma","score_opus":0.20529667890765502,"score_gpt":0.5428811047524997,"score_spread":0.3375844258448447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399672006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99436486,0.0012037224,0.00023417213,0.0009202266,0.001477963,0.0014903183,0.0000056838026,0.000015905649,0.00028713007],"genre_scores_gemma":[0.9978143,0.00046489525,0.0002428188,0.0000954265,0.0012179583,0.000018294088,0.0000026470464,0.000037027843,0.000106659674],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99315315,0.0023689761,0.0030358604,0.00033982977,0.00076059415,0.0003415667],"domain_scores_gemma":[0.9843299,0.013906863,0.0007571358,0.00024805157,0.00044427058,0.00031378705],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0144151505,0.00018624286,0.0020342642,0.00084799604,0.000022002845,0.000021779613,0.0002443532,0.00046151076,0.00035499065],"category_scores_gemma":[0.004372146,0.00013746937,0.00065284764,0.0011437995,0.00018693822,0.00013657253,0.00007839875,0.0019352144,0.000017305914],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07109161,0.027020771,0.51476955,0.0019281631,0.0015111368,0.018219132,0.002222371,0.0017747431,0.1504918,0.00014279986,0.00053436577,0.21029352],"study_design_scores_gemma":[0.056853164,0.042396795,0.88098705,0.00075213553,0.0010231464,0.00094193046,0.0006546509,0.0041308496,0.005407752,0.00064968655,0.005919444,0.00028339168],"about_ca_topic_score_codex":0.000045550547,"about_ca_topic_score_gemma":0.000046761757,"teacher_disagreement_score":0.36621746,"about_ca_system_score_codex":0.0006002798,"about_ca_system_score_gemma":0.0031493974,"threshold_uncertainty_score":0.8407651},"labels":[],"label_agreement":null},{"id":"W4399672190","doi":"10.1200/jco.2024.42.16_suppl.2579","title":"Pharmacokinetics and biomarker analysis from a phase 1/2 open-label study of the anti-GPC3 T-cell engager SAR444200, in patients with advanced solid tumors.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Pharmacokinetics; Biomarker; Cancer research; Oncology; Internal medicine; Chemistry","score_opus":0.14415824151901102,"score_gpt":0.5316970850717138,"score_spread":0.38753884355270274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399672190","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9968941,0.0006727766,0.000020271278,0.0007611357,0.0003397693,0.0007832198,0.000021343329,0.0000038405165,0.00050351006],"genre_scores_gemma":[0.998232,0.0004691429,0.0004914649,0.00036092382,0.00013350141,0.000005375506,0.0000042588845,0.00002385956,0.00027947393],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9956698,0.001152325,0.002022318,0.00029935353,0.0006309005,0.00022533462],"domain_scores_gemma":[0.99586827,0.0023761627,0.00081541104,0.000308369,0.00038981327,0.00024197568],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033650887,0.00015827421,0.001777235,0.00035171,0.00003389837,0.000028713665,0.0003667828,0.00014213008,0.00054293155],"category_scores_gemma":[0.0007644899,0.000086912274,0.00019006332,0.0011240372,0.0002296954,0.00011821505,0.0002306516,0.0014071594,0.0000019271874],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02420149,0.04528431,0.66132027,0.000046908903,0.0043073795,0.00094618974,0.0007883058,0.000059429407,0.013642307,0.0000010041937,0.00063253276,0.24876988],"study_design_scores_gemma":[0.12642269,0.03434741,0.82568955,0.00020098296,0.0032479397,0.000014877328,0.00049316656,0.0022478213,0.0008572958,0.000024304029,0.0063135824,0.00014035606],"about_ca_topic_score_codex":0.000062306906,"about_ca_topic_score_gemma":0.000084366045,"teacher_disagreement_score":0.24862953,"about_ca_system_score_codex":0.000092694725,"about_ca_system_score_gemma":0.00073838903,"threshold_uncertainty_score":0.6113485},"labels":[],"label_agreement":null},{"id":"W4399787848","doi":"10.1093/neuonc/noae064.068","title":"DIPG-15. NOVEL CNS SENSING SYNNOTCH-CAR T CELLS FOR TARGETING DIFFUSE MIDLINE GLIOMA","year":2024,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo; University of Toronto","funders":"","keywords":"Glioma; Medicine; Neuroscience; Cancer research; Biology","score_opus":0.04177343121070988,"score_gpt":0.34884445503677874,"score_spread":0.3070710238260689,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4399787848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97117305,0.0008681054,0.004816709,0.01204001,0.0039043948,0.002005384,0.0000903498,0.00053203787,0.004569991],"genre_scores_gemma":[0.9765047,0.00027525783,0.010501718,0.0043779323,0.004404365,0.000088654335,0.00012478081,0.00034361082,0.0033790255],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.997177,0.00015798328,0.00055627903,0.0007990615,0.00042029045,0.00088936416],"domain_scores_gemma":[0.9964679,0.0024107993,0.00008739903,0.00047434293,0.00022921654,0.0003303765],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007098914,0.0003225987,0.00068766356,0.00042257408,0.00014635046,0.00007338413,0.00019017424,0.0003421135,0.0006986011],"category_scores_gemma":[0.0006657834,0.0002918875,0.00032223546,0.00056426454,0.00020121128,0.00008186459,0.00017771989,0.00084896624,0.00017801023],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00072220044,0.00034743347,0.00005051358,0.00031806584,0.00011984476,0.001788562,0.0005176082,0.000014992486,0.94826174,0.00009526596,0.016565338,0.031198416],"study_design_scores_gemma":[0.0028441993,0.0012882524,0.000017323991,0.000065769724,0.0001261982,0.00073449337,0.0001457011,0.014795364,0.40097266,0.000048624748,0.57877976,0.00018163164],"about_ca_topic_score_codex":0.00003357187,"about_ca_topic_score_gemma":0.00001918033,"teacher_disagreement_score":0.56221443,"about_ca_system_score_codex":0.00041229586,"about_ca_system_score_gemma":0.0004791855,"threshold_uncertainty_score":0.9999533},"labels":[],"label_agreement":null},{"id":"W4400109246","doi":"10.1200/jco.2024.42.16_suppl.7008","title":"Glofitamab monotherapy in patients with heavily pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL): Updated analysis from a phase I/II study.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Gastroenterology; Refractory (planetary science); Mantle cell lymphoma; Neutropenia; Urology; Tolerability; Progression-free survival; Surgery; Oncology; Nuclear medicine; Adverse effect; Toxicity; Lymphoma; Chemotherapy","score_opus":0.05460563674213853,"score_gpt":0.44120849765124337,"score_spread":0.38660286090910484,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400109246","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955536,0.0010415071,0.000057220823,0.0009160959,0.0005151005,0.0007119048,0.000039230308,0.000033802517,0.0011315311],"genre_scores_gemma":[0.99643743,0.00039196308,0.0004553349,0.0005064748,0.00033645442,0.000010640342,0.000070271504,0.000059686492,0.0017317223],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943291,0.0010839619,0.0026638247,0.0005256743,0.0009844822,0.00041297812],"domain_scores_gemma":[0.9960606,0.0016505658,0.0008248846,0.0005000993,0.00053106353,0.0004327872],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002658688,0.0002869671,0.0023257819,0.000976757,0.000051973762,0.000037802984,0.00030517526,0.0004815803,0.0038648632],"category_scores_gemma":[0.0003267767,0.00019045261,0.00069209666,0.0016680944,0.00018147226,0.00020420547,0.00007267381,0.0013898743,0.000040346567],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.092221975,0.058342952,0.49154854,0.000020012054,0.0076582097,0.0038247912,0.0008984155,0.000030730374,0.0008634816,0.0000014082049,0.0020366528,0.34255284],"study_design_scores_gemma":[0.1341123,0.13578558,0.673567,0.00013484292,0.003022869,0.000019598698,0.0003389868,0.0011185205,0.0002310624,0.000041823492,0.051378727,0.0002486665],"about_ca_topic_score_codex":0.0003222715,"about_ca_topic_score_gemma":0.00022004737,"teacher_disagreement_score":0.34230417,"about_ca_system_score_codex":0.00068975,"about_ca_system_score_gemma":0.001776295,"threshold_uncertainty_score":0.99704576},"labels":[],"label_agreement":null},{"id":"W4400117070","doi":"10.1097/01.cot.0001026288.74302.f6","title":"Shop Talk","year":2024,"lang":"en","type":"article","venue":"Oncology Times","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Computer science; Business","score_opus":0.034566600306888844,"score_gpt":0.3869763956953666,"score_spread":0.3524097953884778,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400117070","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.061382588,0.0031572299,0.000031735693,0.014053284,0.0005200822,0.00024250212,0.0000033407284,0.00022807375,0.9203812],"genre_scores_gemma":[0.194608,0.00023659502,0.00047960694,0.000729147,0.0006381806,0.000032982512,0.000016039721,0.000029976132,0.80322945],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992883,0.000042475513,0.00010412821,0.00019572303,0.00014990209,0.0002194384],"domain_scores_gemma":[0.9994534,0.00022580769,0.000007566476,0.00018279118,0.00003269108,0.00009772075],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00024100706,0.00007349918,0.00018380281,0.00012088769,0.000027365668,0.00001644173,0.00006447069,0.00012786046,0.06412794],"category_scores_gemma":[0.000049974726,0.0000577474,0.00008085171,0.00017968315,0.00011718639,0.00003153731,0.00004316937,0.00028234886,0.0023986183],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002177998,0.00014210063,0.0005646108,0.00008925549,0.00021489848,0.002345901,0.00035708418,7.81958e-7,0.15263213,0.002313197,0.39317036,0.44795188],"study_design_scores_gemma":[0.00040313363,0.0006340299,0.00038879208,0.000031462503,0.00003858395,0.0004535955,0.00007183071,0.00050491205,0.005837039,0.00042621748,0.99115556,0.000054824894],"about_ca_topic_score_codex":0.000015769934,"about_ca_topic_score_gemma":0.000008458198,"teacher_disagreement_score":0.5979852,"about_ca_system_score_codex":0.00017188386,"about_ca_system_score_gemma":0.00033792824,"threshold_uncertainty_score":0.99837816},"labels":[],"label_agreement":null},{"id":"W4400266836","doi":"10.1007/s00262-024-03740-3","title":"Impact of fludarabine and treosulfan on ovarian tumor cells and mesothelin chimeric antigen receptor T cells","year":2024,"lang":"en","type":"article","venue":"Cancer Immunology Immunotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Karolinska Institutet; Cancerfonden; Memorial Sloan-Kettering Cancer Center","keywords":"Treosulfan; Mesothelin; Fludarabine; Cancer research; Ovarian cancer; Medicine; Immunology; Antigen; Cancer; Internal medicine; Chemotherapy; Cyclophosphamide","score_opus":0.017341642191132958,"score_gpt":0.33033527995686185,"score_spread":0.3129936377657289,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400266836","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.910892,0.08600367,0.000023312561,0.0008971964,0.000644901,0.0007513491,0.00016564885,0.00010322886,0.0005186668],"genre_scores_gemma":[0.8940356,0.096564114,0.00033993844,0.0004197951,0.00025626767,0.00012122721,0.000035028093,0.00019279301,0.008035267],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979381,0.00017406854,0.00047753807,0.0006121233,0.00023978698,0.0005584068],"domain_scores_gemma":[0.998818,0.00021173875,0.00011446522,0.00063767086,0.00010052295,0.00011764104],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003657945,0.00040903708,0.00079675973,0.00048368052,0.00009836925,0.00005554891,0.00019734407,0.00020514432,0.00888327],"category_scores_gemma":[0.000013105183,0.00031931602,0.0002482236,0.0005102768,0.00067604624,0.00009639644,0.00005389336,0.000604042,0.000067868124],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034781534,0.00014296493,0.001472344,0.00007993043,0.0016514647,0.000030603536,0.0010251406,0.000003905286,0.8366307,0.000047205216,0.00092063524,0.15451694],"study_design_scores_gemma":[0.0064057317,0.0055652624,0.061035912,0.00054558605,0.00009277576,0.00015345692,0.00014638588,0.00019732211,0.8331451,0.0000968329,0.0921313,0.00048435613],"about_ca_topic_score_codex":0.00088201923,"about_ca_topic_score_gemma":0.000005726464,"teacher_disagreement_score":0.15403259,"about_ca_system_score_codex":0.00026517484,"about_ca_system_score_gemma":0.0004447783,"threshold_uncertainty_score":0.9999259},"labels":[],"label_agreement":null},{"id":"W4400428906","doi":"10.1038/s41408-024-01084-w","title":"Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission","year":2024,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Environmental Health Sciences; National Institute of Allergy and Infectious Diseases; Office of Naval Research; Legend Biotech; Pharmacyclics; Takeda Oncology; Health Resources and Services Administration; MorphoSys; Swedish Orphan Biovitrum; Vertex Pharmaceuticals; Omeros Corporation; Astellas Pharma; Adaptive Biotechnologies; Pfizer; Incyte; Kiadis Pharma; bluebird bio; Jazz Pharmaceuticals; StemCyte; Actinium Pharmaceuticals; CareDx; National Heart, Lung, and Blood Institute; Novartis Pharmaceuticals Corporation; Bristol-Myers Squibb; CSL Behring; BeiGene; HistoGenetics; Atara Biotherapeutics; National Cancer Institute; Gilead Sciences; Sanofi; GlaxoSmithKline; Gateway for Cancer Research; Mallinckrodt Pharmaceuticals; Astellas Pharma US; Amgen","keywords":"Medicine; Cumulative incidence; Internal medicine; Univariate analysis; Incidence (geometry); Progression-free survival; Hematopoietic cell; Surgery; Retrospective cohort study; Hematopoietic stem cell transplantation; Transplantation; Multivariate analysis; Chemotherapy; Haematopoiesis","score_opus":0.027509978119901374,"score_gpt":0.29665129241502913,"score_spread":0.2691413142951278,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400428906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936263,0.003977149,0.000005035023,0.00094815803,0.00016104551,0.0004495466,0.00003589581,0.000040092382,0.0007567614],"genre_scores_gemma":[0.99570817,0.00308349,0.000050633116,0.00017457319,0.00018769637,0.000030808973,0.000024905174,0.000048898197,0.0006908324],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998252,0.00012318934,0.00034725032,0.00028005795,0.0005547003,0.00044282925],"domain_scores_gemma":[0.9994379,0.000049581264,0.00004686544,0.00017139288,0.000093514274,0.0002007131],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00030557878,0.00019021967,0.00038637564,0.00039407515,0.000055981203,0.00006026892,0.00012314861,0.00010285024,0.0021593762],"category_scores_gemma":[0.000005779332,0.00012589851,0.0000816396,0.0005488389,0.00005178665,0.00008993215,0.000009601227,0.0009242599,0.0000063730326],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055346005,0.0007314117,0.8858428,0.00009325616,0.0002718301,0.0020479988,0.0015777833,0.000041704978,0.022597201,0.0000031896927,0.0005613597,0.08069688],"study_design_scores_gemma":[0.026341168,0.0030004291,0.94474566,0.0027969186,0.00010586156,0.00069428794,0.000054123877,0.00045237946,0.006482588,0.000026241833,0.0150286285,0.00027168376],"about_ca_topic_score_codex":0.00067337876,"about_ca_topic_score_gemma":0.00043655257,"teacher_disagreement_score":0.080425195,"about_ca_system_score_codex":0.00031443126,"about_ca_system_score_gemma":0.00044887236,"threshold_uncertainty_score":0.9987528},"labels":[],"label_agreement":null},{"id":"W4400443280","doi":"10.3390/curroncol31070292","title":"Review of CAR T-Cell Therapy in Multiple Myeloma: A Canadian Perspective","year":2024,"lang":"en","type":"review","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Context (archaeology); Multiple myeloma; CAR T-cell therapy; Intensive care medicine; Immunotherapy; Immunology; Immune system; Chimeric antigen receptor","score_opus":0.25414509971375804,"score_gpt":0.5056507127003103,"score_spread":0.2515056129865522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400443280","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000011791195,0.98199874,2.8280732e-7,0.00042738783,0.0011300175,0.0040142843,0.00013848142,0.000024769053,0.0122542605],"genre_scores_gemma":[0.000011053424,0.9973192,0.00001848885,0.00017307568,0.000435109,0.00058970536,0.00020572834,0.00010017144,0.0011474632],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99685293,0.00060106156,0.0009104516,0.00070014934,0.00030515474,0.0006302763],"domain_scores_gemma":[0.9979995,0.0003619419,0.00023234267,0.0006480318,0.00035425232,0.00040392627],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00087042205,0.00048066897,0.0034839562,0.0011087011,0.000026354483,0.000007721935,0.00035961508,0.000469276,0.0021604255],"category_scores_gemma":[0.00032498722,0.0003596979,0.0008869283,0.0011788658,0.00020303995,0.000020663269,0.00008961495,0.0018876056,0.00031565307],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.000025203826,0.00029818338,0.000020420695,0.15080123,0.0001643382,0.00019714748,0.0002936965,7.309739e-9,0.00000467578,0.000047477988,0.015351717,0.8327959],"study_design_scores_gemma":[0.00084945734,0.000607323,0.000003783846,0.12615462,0.00060475414,0.00012397015,0.00009092127,0.0000025091076,0.000001924384,0.000020698904,0.87132645,0.00021358648],"about_ca_topic_score_codex":0.015612378,"about_ca_topic_score_gemma":0.025628919,"teacher_disagreement_score":0.85597473,"about_ca_system_score_codex":0.0051882416,"about_ca_system_score_gemma":0.010257472,"threshold_uncertainty_score":0.9998855},"labels":[],"label_agreement":null},{"id":"W4400684648","doi":"10.1007/s00281-024-01013-w","title":"Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy","year":2024,"lang":"en","type":"review","venue":"Seminars in Immunopathology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Cancer Institute; Canadian Institutes of Health Research; Leukemia and Lymphoma Society; Alex's Lemonade Stand Foundation for Childhood Cancer","keywords":"Chimeric antigen receptor; Cytokine storm; Cytokine release syndrome; Immune system; Immunology; Immunotherapy; Cytokine; T cell; Medicine; Biology; Disease; Internal medicine","score_opus":0.04047758097940247,"score_gpt":0.35253288456038623,"score_spread":0.31205530358098377,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400684648","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0126881935,0.97343695,8.105752e-7,0.00025779792,0.0012581175,0.0021335133,0.00002015955,0.000104863895,0.010099576],"genre_scores_gemma":[0.0017077203,0.9753215,0.000025010162,0.000108692264,0.00018553824,0.00048646072,0.000103204795,0.0002455618,0.021816317],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951968,0.0010900061,0.0013157992,0.0009055419,0.0004512155,0.0010406359],"domain_scores_gemma":[0.9976777,0.000653601,0.00025564985,0.0012896779,0.00005121087,0.000072153154],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0027562378,0.0007796336,0.0025822686,0.0017069072,0.00009930646,0.000067869645,0.00081780524,0.0008594533,0.0006798425],"category_scores_gemma":[0.00010775451,0.00052781013,0.0006383418,0.001778015,0.00048522008,0.0000656866,0.00042643084,0.003980731,0.00029708413],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013514921,0.00013477873,0.000095565185,0.0065940563,0.0001607218,0.00464989,0.0038824033,0.0000027224585,0.002207558,0.000103804814,0.0005473042,0.981486],"study_design_scores_gemma":[0.0011999259,0.0004842013,0.00004364907,0.028440429,0.00039311286,0.0033439947,0.0010969101,0.000017633307,0.00019895242,0.00043320956,0.9637931,0.0005548804],"about_ca_topic_score_codex":0.00014261155,"about_ca_topic_score_gemma":0.000035724097,"teacher_disagreement_score":0.98093116,"about_ca_system_score_codex":0.0011815161,"about_ca_system_score_gemma":0.0005508038,"threshold_uncertainty_score":0.99971735},"labels":[],"label_agreement":null},{"id":"W4400690992","doi":"10.1080/10428194.2024.2371472","title":"Real-world outcomes with novel therapies in relapsed/refractory diffuse large B-cell lymphoma","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Genmab; AbbVie Canada","keywords":"Refractory (planetary science); Diffuse large B-cell lymphoma; Lymphoma; Medicine; Oncology; Internal medicine; Cancer research; Materials science","score_opus":0.015303812571067062,"score_gpt":0.27597024301362166,"score_spread":0.2606664304425546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400690992","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96398485,0.0055686287,0.000070708265,0.00061489904,0.0005710887,0.0013518605,0.0001474502,0.0008143528,0.026876152],"genre_scores_gemma":[0.9368589,0.0036345166,0.0006329595,0.0013022973,0.00049241004,0.00032247548,0.0001533381,0.0004528916,0.05615019],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9926769,0.00023381088,0.0012764328,0.0020312816,0.0016470453,0.0021345092],"domain_scores_gemma":[0.99590147,0.0010632831,0.00023572988,0.0016926442,0.00020258495,0.0009042782],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0010151571,0.0013701506,0.001809948,0.0017163001,0.00037920522,0.00047731283,0.0006429129,0.000723312,0.00069754483],"category_scores_gemma":[0.00008506615,0.0010640884,0.0005274771,0.002201404,0.00065073714,0.00054632744,0.00036350422,0.0004917065,0.00021189149],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.013833997,0.014523456,0.207663,0.00420281,0.003025507,0.014278404,0.016570522,0.000039175608,0.15971395,0.01033712,0.009341217,0.5464708],"study_design_scores_gemma":[0.16409889,0.0015512953,0.4965601,0.0020535614,0.00058540876,0.0018706475,0.0024150487,0.008335269,0.011179392,0.00042020148,0.30831638,0.0026137924],"about_ca_topic_score_codex":0.005803711,"about_ca_topic_score_gemma":0.002087014,"teacher_disagreement_score":0.54385704,"about_ca_system_score_codex":0.013305703,"about_ca_system_score_gemma":0.006423783,"threshold_uncertainty_score":0.99990493},"labels":[],"label_agreement":null},{"id":"W4401012202","doi":"10.1101/2024.07.26.605251","title":"Identification of a novel myosin antigen activating CD8 <sup>+</sup> T cells in C57BL/6 mice","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"T-cell receptor; Epitope; Antigen; CD8; T cell; Biology; Cell biology; Cytotoxic T cell; Antigen-presenting cell; Molecular biology; Immune system; Immunology; In vitro; Genetics","score_opus":0.026184413956590245,"score_gpt":0.2801596148023852,"score_spread":0.25397520084579495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401012202","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948967,0.0012476905,0.00047315075,0.0003918896,0.000542677,0.001863392,0.00028591088,0.00024647402,0.00005210802],"genre_scores_gemma":[0.9957726,0.00047417116,0.0025221037,0.000088152425,0.0005212753,0.00021923991,0.0000012481094,0.00025672955,0.00014445935],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9954619,0.0001681607,0.0012810201,0.001379842,0.0009802084,0.00072890345],"domain_scores_gemma":[0.9965867,0.00019830416,0.000525041,0.0016879423,0.0007229838,0.00027902774],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001883332,0.0006027732,0.0010081697,0.001172873,0.00007125831,0.00018851449,0.0005981108,0.0007395743,0.00022742816],"category_scores_gemma":[0.00043731323,0.0006631395,0.00029846616,0.0016017554,0.00019060698,0.0001209683,0.00079534005,0.002013179,0.00010206863],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016871534,0.00051353517,0.0023599346,0.0026540793,0.00027842156,0.00007606783,0.00015841842,0.00041721616,0.9930652,0.00011333359,0.00017385928,0.000021269576],"study_design_scores_gemma":[0.0011960925,0.00006978532,0.016421404,0.0023107033,0.000111272435,7.076581e-8,0.000034008997,0.012327837,0.9652233,0.000002678191,0.0017827873,0.0005200308],"about_ca_topic_score_codex":0.0003224125,"about_ca_topic_score_gemma":0.0000035038101,"teacher_disagreement_score":0.02784182,"about_ca_system_score_codex":0.0007902463,"about_ca_system_score_gemma":0.001439924,"threshold_uncertainty_score":0.999582},"labels":[],"label_agreement":null},{"id":"W4401015063","doi":"10.1016/j.jtct.2024.07.011","title":"In Pursuit of Optimal Outcomes: A Framework for Quality Standards in Immune Effector Cell Therapy","year":2024,"lang":"en","type":"editorial","venue":"Transplantation and Cellular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Princess Margaret Cancer Centre; University of Ottawa","funders":"","keywords":"Accreditation; Quality assurance; Transformative learning; Medicine; Quality (philosophy); Multidisciplinary approach; Process management; Business; Medical education; Psychology; External quality assessment; Political science","score_opus":0.026715483915577723,"score_gpt":0.38192068123047324,"score_spread":0.3552051973148955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401015063","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7454265,0.03887847,0.006817237,0.0008493848,0.19484638,0.007958449,0.004515456,0.00012189349,0.00058626494],"genre_scores_gemma":[0.24602708,0.47332013,0.006097032,0.00074622757,0.24086161,0.0033161002,0.011531511,0.0013300701,0.01677026],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960404,0.00034387977,0.0009858236,0.000644629,0.0015243442,0.0004609162],"domain_scores_gemma":[0.99703985,0.0019965938,0.00018708651,0.00042788213,0.00023308,0.000115473216],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0028775684,0.0004958799,0.0013788838,0.000557997,0.0000367012,0.000068282534,0.00025860392,0.0010237937,0.0007449775],"category_scores_gemma":[0.00007554647,0.00040926755,0.0004129225,0.00038681418,0.00013461622,0.00007800608,0.000011164352,0.0013046588,0.000005260642],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.103471875,0.0026102709,0.002694139,0.020276733,0.0013618895,0.00060594373,0.025390845,0.000033689837,0.7866073,0.0006011962,0.026752697,0.029593399],"study_design_scores_gemma":[0.052588318,0.0047574835,0.0027484542,0.0028211954,0.00021234734,0.0000073553897,0.0005381401,0.00008652641,0.27848604,0.0013284379,0.6552438,0.0011819007],"about_ca_topic_score_codex":0.00040468917,"about_ca_topic_score_gemma":0.000058314294,"teacher_disagreement_score":0.6284911,"about_ca_system_score_codex":0.00021161427,"about_ca_system_score_gemma":0.00058641436,"threshold_uncertainty_score":0.9998359},"labels":[],"label_agreement":null},{"id":"W4401074395","doi":"10.1038/s44222-024-00219-9","title":"Genetically engineered hypoimmunogenic cell therapy","year":2024,"lang":"en","type":"article","venue":"Nature Reviews Bioengineering","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lunenfeld-Tanenbaum Research Institute; University of Toronto; Mount Sinai Hospital","funders":"","keywords":"Immune system; Cell therapy; Immunotherapy; Transplantation; Stem cell; Genetic enhancement; Computational biology; Medicine; Biology; Immunology; Gene; Genetics","score_opus":0.0235477653437189,"score_gpt":0.3134757730102026,"score_spread":0.2899280076664837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401074395","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.032503232,0.9585754,0.001647027,0.00057044753,0.00086914486,0.0013017887,0.0000073384163,0.0004701997,0.0040554143],"genre_scores_gemma":[0.49258798,0.48356143,0.0096683735,0.00052132306,0.001560397,0.0001991715,0.00006505001,0.00026592167,0.011570333],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99818313,0.000041507294,0.0004218856,0.00044789808,0.00040540707,0.00050017214],"domain_scores_gemma":[0.9989772,0.00009688969,0.000021516356,0.0006277489,0.00006700775,0.000209626],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00056690513,0.00034386932,0.0005693925,0.0003055153,0.000031829455,0.00008429448,0.00022227014,0.00038635265,0.0019219796],"category_scores_gemma":[0.00008203928,0.0002579482,0.0004664973,0.00087104883,0.000030971132,0.00006357303,0.00004720179,0.0015289705,0.00043729632],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000035371006,0.00003885902,0.000020133051,0.0009623779,0.000106112166,0.00009248761,0.000052739288,0.000023800007,0.7097262,0.00013005463,0.0018349654,0.28697687],"study_design_scores_gemma":[0.00047752517,0.00016615653,0.00034409086,0.0005508689,0.00005287593,0.00016903301,0.000003056642,0.0030093004,0.057629377,0.000010996328,0.9373343,0.0002524347],"about_ca_topic_score_codex":0.0000019901877,"about_ca_topic_score_gemma":2.5436339e-7,"teacher_disagreement_score":0.9354993,"about_ca_system_score_codex":0.00015453142,"about_ca_system_score_gemma":0.00009804344,"threshold_uncertainty_score":0.99998724},"labels":[],"label_agreement":null},{"id":"W4401113081","doi":"10.1021/acsnano.4c07306","title":"Spiky Gold Nanoparticles, a Nanoscale Approach to Enhanced Ex Vivo T-Cell Activation","year":2024,"lang":"en","type":"article","venue":"ACS Nano","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"National Institute of General Medical Sciences; National Institutes of Health","keywords":"Colloidal gold; Nanotechnology; Biocompatibility; Ex vivo; Biophysics; Chemistry; Materials science; T cell; Nanoparticle; In vitro; Biology; Biochemistry; Immunology; Immune system","score_opus":0.02627374760426702,"score_gpt":0.29582464125836283,"score_spread":0.2695508936540958,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401113081","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9078756,0.00036350032,0.00081048603,0.00091645686,0.000212688,0.0009152776,0.0000062904655,0.00023253425,0.088667184],"genre_scores_gemma":[0.8757168,0.00005943079,0.00092570257,0.0005358647,0.0002903738,0.00011711786,0.000018321567,0.00006178619,0.122274585],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99811965,0.000052418214,0.00025509924,0.00052749255,0.0005599048,0.00048546208],"domain_scores_gemma":[0.99899936,0.00009743943,0.000024712494,0.00052395,0.0000974053,0.00025714995],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003140655,0.00019348178,0.00026127914,0.00023670754,0.000051104747,0.000096420146,0.00017326935,0.00013092882,0.000767387],"category_scores_gemma":[0.000073570074,0.00016744023,0.00010451225,0.0009618054,0.000049747927,0.00014645068,0.00009353,0.00025601892,0.00084482937],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024370794,0.00029298608,0.000037818663,0.00019648061,0.000038828348,0.0000136766,0.00080745714,0.000007861811,0.9570674,0.00021283288,0.021238286,0.019842682],"study_design_scores_gemma":[0.00067327486,0.00032140166,0.000101260375,0.000113954244,0.000027561942,0.000015580317,0.00013286957,0.00015652835,0.8621005,0.000063268344,0.13613911,0.00015469297],"about_ca_topic_score_codex":0.00006555863,"about_ca_topic_score_gemma":0.0000040441532,"teacher_disagreement_score":0.11490083,"about_ca_system_score_codex":0.00022766062,"about_ca_system_score_gemma":0.00017787785,"threshold_uncertainty_score":0.9999331},"labels":[],"label_agreement":null},{"id":"W4401155069","doi":"10.1016/j.biomaterials.2024.122731","title":"Patient-specific vascularized tumor model: Blocking monocyte recruitment with multispecific antibodies targeting CCR2 and CSF-1R","year":2024,"lang":"en","type":"article","venue":"Biomaterials","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"National Cancer Institute; National Institutes of Health; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; Ludwig Center at Harvard; Merck KGaA","keywords":"Blocking (statistics); Antibody; Cancer research; Materials science; Biomedical engineering; Biology; Immunology; Medicine; Computer science","score_opus":0.06925131991838904,"score_gpt":0.32448015127052077,"score_spread":0.2552288313521317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401155069","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98845583,0.007739366,0.00040370206,0.0002177406,0.0004768787,0.0018834652,0.000043359094,0.00034829852,0.0004313637],"genre_scores_gemma":[0.98686576,0.0017144987,0.009878207,0.000056111774,0.00033875773,0.00022794104,0.00008116099,0.00012301073,0.00071452634],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976544,0.00012939423,0.00049468083,0.000678018,0.00052250543,0.0005210114],"domain_scores_gemma":[0.9991324,0.00008501205,0.00008211786,0.00040529383,0.000112773996,0.00018240031],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059022446,0.00032542975,0.0005892886,0.0002704215,0.00015832759,0.0004201301,0.00008815494,0.000091945185,0.0008085543],"category_scores_gemma":[0.000029391616,0.00023589014,0.00011103537,0.00023538807,0.00016029821,0.00014479848,0.00013487405,0.000053572738,0.00005499686],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009652558,0.000078358375,0.00024857995,0.00037945423,0.0002735575,0.0004683562,0.0011824708,0.000013784809,0.9801274,0.00008417972,0.00056599185,0.015612644],"study_design_scores_gemma":[0.0026193997,0.0005247059,0.000519811,0.0009787699,0.00011474329,0.00024944593,0.00040016335,0.0075190202,0.93687576,0.00009478318,0.04967505,0.00042832948],"about_ca_topic_score_codex":0.000050536863,"about_ca_topic_score_gemma":0.0000026605644,"teacher_disagreement_score":0.049109057,"about_ca_system_score_codex":0.00016032436,"about_ca_system_score_gemma":0.000085823514,"threshold_uncertainty_score":0.96193206},"labels":[],"label_agreement":null},{"id":"W4401204112","doi":"10.1002/ejhf.3340","title":"Cardiovascular Toxicities of Immune Therapies for Cancer – A Scientific Statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology","year":2024,"lang":"en","type":"review","venue":"European Journal of Heart Failure","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Surgical Specialties (Canada); Ted Rogers Centre for Heart Research; Toronto General Hospital; University of Toronto; Mount Sinai Hospital","funders":"Ministero della Salute","keywords":"Medicine; Myocarditis; Immune system; Heart failure; Adverse effect; Immunology; Immune dysregulation; Cancer; Rash; Internal medicine","score_opus":0.058690383981007004,"score_gpt":0.33045284640168343,"score_spread":0.2717624624206764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401204112","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0057172603,0.9856743,0.000010266217,0.005520959,0.0008025979,0.001943561,0.00020064386,0.000004811223,0.00012556073],"genre_scores_gemma":[0.022218173,0.9715877,0.00059913157,0.00006752859,0.000693726,0.000052844225,0.000008724588,0.00016481311,0.0046073585],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99162245,0.003353271,0.0019843564,0.00028146798,0.0024277503,0.0003307018],"domain_scores_gemma":[0.99431604,0.00064622436,0.0017912782,0.0009231565,0.0022527452,0.000070571026],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.018642707,0.00034648465,0.0030982806,0.00020940625,0.00017806547,0.00005225908,0.00060389104,0.00013654174,0.00009678144],"category_scores_gemma":[0.0006047435,0.0001558364,0.003442666,0.00060170126,0.001041826,0.00006633418,0.00026493557,0.0010216577,0.0000016355261],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002772057,0.0007843993,0.0009918091,0.11209521,0.08616723,0.0000562958,0.049279016,0.00038337658,0.05072179,0.00031281015,0.30104077,0.39539525],"study_design_scores_gemma":[0.001982977,0.0004258899,0.000119636796,0.01010607,0.0033828686,0.0001499239,0.0014087027,0.0000031176473,0.0014443444,0.000014786657,0.98084897,0.00011273878],"about_ca_topic_score_codex":0.00006521517,"about_ca_topic_score_gemma":0.00007165488,"teacher_disagreement_score":0.6798082,"about_ca_system_score_codex":0.00084225053,"about_ca_system_score_gemma":0.0043811863,"threshold_uncertainty_score":0.7772037},"labels":[],"label_agreement":null},{"id":"W4401219225","doi":"10.1080/14656566.2024.2387673","title":"Cytokine release syndrome after CAR T-cell therapy for B-cell acute lymphoblastic leukemia in children and young adolescents: storms make trees take deeper roots","year":2024,"lang":"en","type":"review","venue":"Expert Opinion on Pharmacotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Medicine; Chimeric antigen receptor; Cytokine release syndrome; Lymphoblastic Leukemia; Cytokine storm; Immune system; Cytokine; Immunology; Leukemia; Acute lymphocytic leukemia; Receptor; T cell; Adverse effect; Internal medicine; Disease","score_opus":0.027437902744180738,"score_gpt":0.36035886421433105,"score_spread":0.3329209614701503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401219225","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01318111,0.97629577,0.00003518623,0.00010866269,0.0015703244,0.007887294,0.00061802805,0.00021126536,0.00009235682],"genre_scores_gemma":[0.0023652115,0.98476064,0.000116981755,0.0014176467,0.001458295,0.003124833,0.0007230201,0.0007752739,0.005258102],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99425334,0.0003552264,0.0012732331,0.0019026066,0.0010108285,0.0012047689],"domain_scores_gemma":[0.9977768,0.00015953426,0.00030940087,0.0010070684,0.00011512993,0.0006320869],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0004957089,0.0016211966,0.0028293994,0.0013041081,0.00012182689,0.00017963086,0.0005659848,0.00074313435,0.0010733855],"category_scores_gemma":[0.000011642124,0.001194274,0.0011817106,0.00076767046,0.00018550798,0.0001429917,0.00010041744,0.0013483473,0.000141788],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007189407,0.0016446696,0.00032260915,0.0063641737,0.0019256799,0.00055080873,0.0008011779,0.000003092254,0.006610992,0.0000049421496,0.008583394,0.96599907],"study_design_scores_gemma":[0.020557433,0.0020592243,0.00030099924,0.014040482,0.00028322538,0.001001353,0.000022095885,0.00009877185,0.0009629149,0.000008872487,0.95935416,0.001310448],"about_ca_topic_score_codex":0.00013447744,"about_ca_topic_score_gemma":0.000010186155,"teacher_disagreement_score":0.9646886,"about_ca_system_score_codex":0.002163616,"about_ca_system_score_gemma":0.0010581722,"threshold_uncertainty_score":0.9998398},"labels":[],"label_agreement":null},{"id":"W4401219445","doi":"10.1016/j.omton.2024.200851","title":"Minimally modified off-the-shelf allogeneic CAR T cells","year":2024,"lang":"en","type":"article","venue":"Molecular Therapy Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; Canada's Michael Smith Genome Sciences Centre","funders":"BC Cancer Foundation; Canadian Institutes of Health Research; Fonds Léon Fredericq; Terry Fox Research Institute; Michael Smith Health Research BC","keywords":"Chimeric antigen receptor; Cell therapy; Medicine; Cancer research; In vivo; Induced pluripotent stem cell; Immunotherapy; Stem cell; Immunology; Chemistry; Biology; Biotechnology; Immune system; Cell biology","score_opus":0.03441878770243568,"score_gpt":0.343309674273072,"score_spread":0.30889088657063635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401219445","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9337771,0.024835695,0.00077416643,0.012190748,0.0008573688,0.0014609967,0.000012720466,0.00025103948,0.025840148],"genre_scores_gemma":[0.95473844,0.004885209,0.0007331202,0.008157546,0.0005488753,0.000292567,0.00004888455,0.00018713865,0.030408194],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975193,0.00031551727,0.00038396614,0.0006105883,0.0005118697,0.00065877003],"domain_scores_gemma":[0.9985357,0.00027911112,0.000046928195,0.00078385836,0.0001351144,0.00021927206],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00073132943,0.00030290935,0.0005187834,0.00023748835,0.00010069717,0.00006697082,0.0003947363,0.00033648504,0.0029943746],"category_scores_gemma":[0.000025578116,0.00021559077,0.00040172043,0.00046670763,0.00031409226,0.000036478916,0.000088277004,0.00065368344,0.00046063174],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007678977,0.00017070146,0.000017021264,0.00003264513,0.0004998626,0.0020304092,0.00055025116,0.000044629498,0.78892845,0.00056263193,0.0021348828,0.2042606],"study_design_scores_gemma":[0.0016453109,0.0017785565,0.00008615107,0.00002058426,0.00006585644,0.00028056445,0.000073973475,0.00091277494,0.38721034,0.00050076225,0.6072495,0.00017563054],"about_ca_topic_score_codex":0.000052171894,"about_ca_topic_score_gemma":0.000016785989,"teacher_disagreement_score":0.60511464,"about_ca_system_score_codex":0.0002981008,"about_ca_system_score_gemma":0.0006484439,"threshold_uncertainty_score":0.997917},"labels":[],"label_agreement":null},{"id":"W4401265865","doi":"10.1038/s41591-024-03138-9","title":"Targeting axonal guidance dependencies in glioblastoma with ROBO1 CAR T cells","year":2024,"lang":"en","type":"article","venue":"Nature Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; University of Ottawa; Princess Margaret Cancer Centre; McMaster University Medical Centre; Hospital for Sick Children; University Health Network; University of Toronto; SickKids Foundation; National Research Council Canada; McMaster University","funders":"Mitacs; Canadian Institutes of Health Research; Terry Fox Research Institute; National Cancer Institute; Government of Canada; Foundation for the National Institutes of Health","keywords":"Glioblastoma; Neuroscience; Cancer research; Computational biology; Computer science; Biology","score_opus":0.01016253600359658,"score_gpt":0.3026076256505932,"score_spread":0.2924450896469966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401265865","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87443006,0.083024986,0.0005686454,0.01827877,0.0017232929,0.0013686735,0.000016375832,0.0004305659,0.020158641],"genre_scores_gemma":[0.9831736,0.0003920682,0.0007302252,0.0011105826,0.0017135635,0.000034871897,0.000020329313,0.00007154265,0.0127532035],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99720895,0.000071100316,0.0003476972,0.0005416131,0.001291738,0.00053888414],"domain_scores_gemma":[0.9988942,0.00031014206,0.00003947149,0.00034305395,0.00019651954,0.00021659215],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009492894,0.0002729165,0.00049683684,0.00051758747,0.000048748912,0.00002338226,0.00019268798,0.00034592135,0.0030926922],"category_scores_gemma":[0.00027973013,0.00017341126,0.00006370446,0.0012265388,0.00025557485,0.00009364652,0.000054062475,0.0023571423,0.000061228384],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013205081,0.00007414289,0.0035666039,0.0007075924,0.0001375565,0.0048732054,0.0014499584,0.00008968377,0.94609684,0.00037003227,0.030352948,0.010960934],"study_design_scores_gemma":[0.009091591,0.00522664,0.0069436417,0.009183194,0.00026652985,0.0018568106,0.0023129464,0.0069231153,0.4178791,0.0003020563,0.5391722,0.00084220106],"about_ca_topic_score_codex":0.000104693245,"about_ca_topic_score_gemma":0.0002101088,"teacher_disagreement_score":0.52821773,"about_ca_system_score_codex":0.0002782027,"about_ca_system_score_gemma":0.00029977303,"threshold_uncertainty_score":0.99994445},"labels":[],"label_agreement":null},{"id":"W4401357304","doi":"10.3390/curroncol31080323","title":"Venous Thromboembolism Risk in Hematological Malignancies Post-Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: A Meta-Analysis of Phase 2 and Phase 3 Clinical Trials","year":2024,"lang":"en","type":"review","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Allegheny Health Network","keywords":"Medicine; Chimeric antigen receptor; Venous thromboembolism; Meta-analysis; Clinical trial; Oncology; Internal medicine; Phases of clinical research; CAR T-cell therapy; Immunology; Immunotherapy; Cancer; Thrombosis","score_opus":0.6163136460934728,"score_gpt":0.6136496854667778,"score_spread":0.00266396062669505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401357304","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02725475,0.9652248,0.000015857766,0.00014724371,0.0010992262,0.00425833,0.0017604664,0.000061576524,0.00017776326],"genre_scores_gemma":[0.00041964848,0.9969225,0.0001567909,0.00006306669,0.00042909195,0.0006120801,0.0010583496,0.00010358006,0.00023487236],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9822417,0.009927462,0.004845468,0.0015381745,0.0006788833,0.00076832407],"domain_scores_gemma":[0.98969823,0.0063155727,0.002123394,0.0010859664,0.00032523304,0.00045161383],"candidate_categories":["metaepi_narrow","metaepi_broad","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.01274653,0.00096045574,0.02745265,0.0019931705,0.00006483116,0.00004356434,0.0005040933,0.0012301591,0.0073730606],"category_scores_gemma":[0.002457909,0.00057625753,0.008992833,0.0025064694,0.0008311429,0.00004833991,0.0002936186,0.0025899522,0.00010368951],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000946125,0.012440268,0.000038326045,0.005213207,0.11785735,0.00022809916,0.00037399205,1.034041e-7,0.00022723526,0.000023771869,0.0013679105,0.8612836],"study_design_scores_gemma":[0.0052643865,0.0050299577,0.000008196895,0.0004361199,0.3110953,0.00007079528,0.00006323132,0.000028543633,0.000018837974,0.0000301762,0.677636,0.00031843176],"about_ca_topic_score_codex":0.00006472614,"about_ca_topic_score_gemma":0.000024033814,"teacher_disagreement_score":0.8609652,"about_ca_system_score_codex":0.00026392247,"about_ca_system_score_gemma":0.0018300415,"threshold_uncertainty_score":0.9997111},"labels":[],"label_agreement":null},{"id":"W4401451904","doi":"10.1186/s12885-024-12574-2","title":"Feasibility of collecting longitudinal patient-reported outcomes in individuals with relapsed or refractory large B-cell lymphoma who received chimeric antigen receptor T-cell (CART) therapy","year":2024,"lang":"en","type":"article","venue":"BMC Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University; Institute of Cancer Research; Ontario Clinical Oncology Group; Juravinski Cancer Centre","funders":"","keywords":"Chimeric antigen receptor; Cart; Medicine; Surgical oncology; Refractory (planetary science); Lymphoma; Oncology; Cell therapy; Antigen; Internal medicine; Cell; Immunotherapy; Immunology; Cancer; Biology","score_opus":0.07087076294447868,"score_gpt":0.3612566289399052,"score_spread":0.2903858659954265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401451904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897958,0.0049177473,0.000017075055,0.000126674,0.000354017,0.0021184215,0.000107330394,0.00011408661,0.002448859],"genre_scores_gemma":[0.9803624,0.0021833268,0.0006234317,0.000094766605,0.00011622986,0.00025205826,0.00004483458,0.00011452502,0.016208382],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964354,0.0002991234,0.00082968175,0.0008399484,0.0009453161,0.0006505273],"domain_scores_gemma":[0.99802077,0.0005009429,0.00031227307,0.00070801243,0.00026607083,0.00019194491],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00092627184,0.00037376987,0.0009251001,0.00045574512,0.000100258156,0.000053011732,0.00018146377,0.00020029981,0.004529587],"category_scores_gemma":[0.00017768698,0.00026061723,0.00021980009,0.0016875524,0.00014452924,0.00015626937,0.00007127174,0.00041795225,0.000015699663],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047466126,0.0018033558,0.9308849,0.00042162556,0.0003097924,0.00007897308,0.0024756487,0.000008266076,0.048917707,8.0904493e-7,0.001685781,0.008666531],"study_design_scores_gemma":[0.028797306,0.0032054456,0.8661826,0.0010555947,0.00012599975,0.000034199507,0.0013851639,0.0002261851,0.07005072,0.000008928878,0.028377103,0.0005507318],"about_ca_topic_score_codex":0.0013393878,"about_ca_topic_score_gemma":0.0014366545,"teacher_disagreement_score":0.06470228,"about_ca_system_score_codex":0.0008820981,"about_ca_system_score_gemma":0.0024015177,"threshold_uncertainty_score":0.9999846},"labels":[],"label_agreement":null},{"id":"W4401486739","doi":"10.1016/j.jcyt.2024.08.004","title":"CD19-chimeric antigen receptor-invariant natural killer T cells transactivate NK cells and reduce alloreactivity","year":2024,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Béatrice Ederer-Weber Stiftung; Faculty of Medicine, University of Ottawa; Deutsche Krebshilfe; Essity Germany; Baylor College of Medicine","keywords":"Cytotoxic T cell; Interleukin 21; IL-2 receptor; Interleukin 12; Immunology; Natural killer T cell; CD19; Transactivation; Biology; Chemistry; Immune system; T cell; Cell biology; Cancer research; In vitro; Biochemistry; Transcription factor","score_opus":0.020672316952580296,"score_gpt":0.29724832157250997,"score_spread":0.27657600461992965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401486739","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9840117,0.006083518,0.0005756644,0.002766304,0.0023338078,0.00109756,0.000022261433,0.00033196592,0.002777182],"genre_scores_gemma":[0.9425846,0.013188241,0.0011241536,0.000838556,0.0007016231,0.000047147678,0.000024931644,0.00018900263,0.041301753],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975389,0.00021260409,0.0003063259,0.000780824,0.00053404673,0.0006272627],"domain_scores_gemma":[0.9987079,0.00033320388,0.000048803904,0.00053224684,0.00007202558,0.00030584531],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006244913,0.00038898256,0.0005396579,0.0002719894,0.00012287099,0.00015378994,0.00017413242,0.000202681,0.0052698827],"category_scores_gemma":[0.000012498753,0.00031531585,0.0002409358,0.00054132217,0.00024324683,0.0002218372,0.000023943012,0.00081541995,0.0002190388],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012608016,0.00015301503,0.00009497807,0.00013755185,0.00040110401,0.00012359116,0.0014047317,0.0000024425092,0.9091878,0.000026710883,0.0059226877,0.081284575],"study_design_scores_gemma":[0.0014279612,0.00035753433,0.0011433545,0.00017086643,0.00003546432,0.000062949424,0.00011236231,0.0006070042,0.7469696,0.00005905543,0.24873203,0.00032185751],"about_ca_topic_score_codex":0.00018029085,"about_ca_topic_score_gemma":0.000009814279,"teacher_disagreement_score":0.24280936,"about_ca_system_score_codex":0.0001765478,"about_ca_system_score_gemma":0.00022509471,"threshold_uncertainty_score":0.9999299},"labels":[],"label_agreement":null},{"id":"W4401690600","doi":"10.1101/2024.08.19.608538","title":"Metabolization of microbial postbiotic pentanoate drives anti-cancer CAR T cells","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; University of Calgary","funders":"Instituto de Salud Carlos III; European Regional Development Fund; Horizon 2020 Framework Programme; National Cancer Institute; National Institutes of Health; Ministerio de Ciencia e Innovación; Memorial Sloan-Kettering Cancer Center; Lietuvos Mokslo Taryba; Austrian Science Fund; Centro de Investigación Biomédica en Red de Cáncer; European Commission","keywords":"Crosstalk; Epigenetics; Metabolite; Immunity; Biology; Chemistry; Cancer research; Computational biology; Cell biology; Genetics; Immune system; Gene; Biochemistry; Engineering; Electronic engineering","score_opus":0.0171991688476267,"score_gpt":0.2696200321042862,"score_spread":0.2524208632566595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401690600","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98855114,0.0060681417,0.000085857544,0.0003734828,0.0023325696,0.0015783584,0.00070253544,0.0002774756,0.000030468736],"genre_scores_gemma":[0.9927723,0.004503388,0.0009979759,0.00014240295,0.00094742724,0.00008997608,0.0000016211701,0.00027913073,0.00026577676],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9965526,0.00016747294,0.00076477404,0.0011336637,0.0007372789,0.00064423366],"domain_scores_gemma":[0.9970399,0.000051172665,0.000353683,0.0013349992,0.00089544186,0.00032479624],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00053107686,0.00062066515,0.001173077,0.0006921456,0.000073887306,0.00014936813,0.0004559767,0.0006036721,0.0013263535],"category_scores_gemma":[0.00007502688,0.00062069524,0.00042040023,0.000859019,0.00026827288,0.000072778785,0.00077097974,0.001218986,0.00015442129],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013308591,0.00021553788,0.0029858637,0.0028627645,0.0008035564,0.0000908236,0.000033425098,0.000064519336,0.99204475,0.00014213422,0.00061848783,0.000005061403],"study_design_scores_gemma":[0.00087957917,0.0000800403,0.011137681,0.0012326328,0.0007487469,4.9255515e-8,0.0000041642884,0.00025409908,0.9792556,0.0000014594976,0.0059017744,0.0005041339],"about_ca_topic_score_codex":0.00016593888,"about_ca_topic_score_gemma":0.000003919411,"teacher_disagreement_score":0.0127891,"about_ca_system_score_codex":0.00041687966,"about_ca_system_score_gemma":0.0014733651,"threshold_uncertainty_score":0.99962443},"labels":[],"label_agreement":null},{"id":"W4401698483","doi":"10.1038/s41698-024-00669-9","title":"A synthetic cytotoxic T cell platform for rapidly prototyping TCR function","year":2024,"lang":"en","type":"article","venue":"npj Precision Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Simon Fraser University; University of British Columbia; Canada's Michael Smith Genome Sciences Centre","funders":"National Cancer Institute; Genome British Columbia; National Institutes of Health; Michael Smith Health Research BC; U.S. Department of Health and Human Services","keywords":"T-cell receptor; Cytotoxic T cell; Major histocompatibility complex; Biology; Antigen; Granzyme; Cell biology; T cell; Granzyme B; Computational biology; Immunology; Immune system; In vitro; Genetics; Perforin","score_opus":0.05179868637115881,"score_gpt":0.3708730042852314,"score_spread":0.3190743179140726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401698483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7093907,0.008329466,0.07235608,0.0065725907,0.0064592725,0.02706364,0.000060244824,0.0013761191,0.16839191],"genre_scores_gemma":[0.935978,0.0005735449,0.005020017,0.000760625,0.0013615527,0.0033136243,0.00006386144,0.00016656313,0.05276222],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99799997,0.00008753141,0.00042622897,0.0005974945,0.00039525292,0.00049349637],"domain_scores_gemma":[0.99777645,0.0013682083,0.00005739843,0.00043563388,0.00016708033,0.00019523507],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012907733,0.00020099503,0.0004384203,0.00043362516,0.0001193267,0.000056543355,0.00014914454,0.0003844794,0.0060798996],"category_scores_gemma":[0.00028310335,0.00016159943,0.00026079064,0.00036898936,0.000088251625,0.00012510167,0.00008167698,0.00051772356,0.00058280333],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041563157,0.00021744535,0.00002358239,0.00035680196,0.00006622498,0.000054186825,0.00029977647,0.0000067722603,0.357001,0.00030092805,0.006898197,0.63061875],"study_design_scores_gemma":[0.002591304,0.0064468477,0.00015525661,0.00028795155,0.00011369457,0.00022384465,0.00013764911,0.007667308,0.057123415,0.0026878645,0.922394,0.00017085954],"about_ca_topic_score_codex":0.000008599761,"about_ca_topic_score_gemma":0.000011048738,"teacher_disagreement_score":0.9154958,"about_ca_system_score_codex":0.00061251933,"about_ca_system_score_gemma":0.00061490084,"threshold_uncertainty_score":0.9948287},"labels":[],"label_agreement":null},{"id":"W4401745029","doi":"10.1002/hem3.130","title":"Biomarkers of outcome in patients undergoing CD19 CAR‐T therapy for large B cell lymphoma","year":2024,"lang":"en","type":"review","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"University of Toronto","keywords":"Chimeric antigen receptor; Chemoimmunotherapy; Medicine; Oncology; Refractory (planetary science); Lymphoma; Internal medicine; CD19; Disease; Immunotherapy; Antigen; Immunology; Rituximab; Cancer; Biology","score_opus":0.06631002535945682,"score_gpt":0.379980524641565,"score_spread":0.3136704992821082,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401745029","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016785417,0.9890791,0.0000096612475,0.00002444433,0.00041338615,0.0040462497,0.00019911013,0.00005509227,0.0044943714],"genre_scores_gemma":[0.0006320687,0.983705,0.00021700923,0.000056176443,0.00014399659,0.00032961252,0.00035154072,0.0002614646,0.014303171],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9968094,0.00014309953,0.0011260526,0.000670303,0.0005841402,0.0006670092],"domain_scores_gemma":[0.9982049,0.00047108656,0.00028008706,0.00074614503,0.00013483076,0.00016294833],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005888019,0.0005626128,0.0023997459,0.0003354845,0.000035916037,0.00002783687,0.00028971158,0.00052366586,0.0012914473],"category_scores_gemma":[0.000096737924,0.00041953378,0.0012057062,0.00077009003,0.000049504255,0.000042337986,0.00012309276,0.00033829256,0.000106117615],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003987946,0.0013228985,0.0032899221,0.12960947,0.0008833665,0.000056891375,0.00015790525,5.9464323e-8,0.000017478484,0.0000837355,0.004792445,0.85938704],"study_design_scores_gemma":[0.009081463,0.0006797176,0.000094502604,0.013816611,0.00053717836,0.000008410572,0.00009937505,0.000008314863,0.00004747513,0.00003434288,0.97522485,0.00036774803],"about_ca_topic_score_codex":0.00004985653,"about_ca_topic_score_gemma":0.0000676795,"teacher_disagreement_score":0.9704324,"about_ca_system_score_codex":0.0006318236,"about_ca_system_score_gemma":0.00080788723,"threshold_uncertainty_score":0.99982566},"labels":[],"label_agreement":null},{"id":"W4401876465","doi":"10.1016/s2152-2650(24)01517-9","title":"ABCL-340 Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase 2 Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Chimeric antigen receptor; Refractory (planetary science); Phases of clinical research; Oncology; Lymphoma; Internal medicine; Cancer research; Immunotherapy; Clinical trial; Cancer","score_opus":0.029723763590510346,"score_gpt":0.34594281705386265,"score_spread":0.31621905346335233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401876465","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9778013,0.017909959,0.000024941746,0.00011172041,0.00040744108,0.0031132286,0.0003697743,0.00018845162,0.00007314404],"genre_scores_gemma":[0.99109846,0.0036557904,0.0005914492,0.00045688218,0.0003359686,0.00023766767,0.00041468575,0.00027793527,0.0029311697],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99211454,0.0012626081,0.002055795,0.0022319683,0.0011661389,0.0011689462],"domain_scores_gemma":[0.9961065,0.0014548466,0.00036791922,0.0011167454,0.00019101736,0.00076294877],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018781764,0.00097310415,0.0023025624,0.00069174246,0.00016602867,0.00022784031,0.00039121386,0.00045579948,0.0011164728],"category_scores_gemma":[0.00033939097,0.0007244711,0.00036839096,0.0017022049,0.00039951774,0.00038664028,0.00020298526,0.00072947773,0.00006289966],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060634654,0.021187665,0.28180707,0.00009070414,0.00079581636,0.0010654288,0.0014661201,5.0519526e-7,0.026342621,0.0000011253273,0.0008909985,0.6057173],"study_design_scores_gemma":[0.19248965,0.010094285,0.7842683,0.00021362893,0.00022500864,0.000024597888,0.00072922587,0.0033650526,0.0017220401,0.000009056189,0.0060797296,0.00077940064],"about_ca_topic_score_codex":0.0016823171,"about_ca_topic_score_gemma":0.00025339815,"teacher_disagreement_score":0.6049379,"about_ca_system_score_codex":0.0009801816,"about_ca_system_score_gemma":0.0016796611,"threshold_uncertainty_score":0.9997966},"labels":[],"label_agreement":null},{"id":"W4401877474","doi":"10.1016/s2152-2650(24)00811-5","title":"Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase 2 Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Chimeric antigen receptor; Oncology; Refractory (planetary science); Internal medicine; Lymphoma; Phases of clinical research; Immunotherapy; Clinical trial; Cancer","score_opus":0.030020297283375175,"score_gpt":0.3461436852849306,"score_spread":0.3161233880015554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401877474","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9786215,0.017266657,0.000022876891,0.000096243035,0.00038318732,0.0030224994,0.00033922205,0.00017609993,0.00007172616],"genre_scores_gemma":[0.9920046,0.003339086,0.00056227244,0.00043783922,0.00031578902,0.00022339569,0.0003873222,0.00025890087,0.0024708465],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9925216,0.0012183638,0.0019397578,0.0021207295,0.0010993968,0.0011001943],"domain_scores_gemma":[0.9963248,0.0013894399,0.00033958713,0.0010500003,0.0001800658,0.0007161077],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017930348,0.00091287534,0.0021846658,0.0006550331,0.00015456996,0.00021079788,0.00035983516,0.000425396,0.0010681399],"category_scores_gemma":[0.00033583157,0.0006759042,0.00034200898,0.0016285017,0.0004157016,0.00036380612,0.00019020455,0.000684725,0.000057056186],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06014099,0.02056964,0.277336,0.00008542255,0.0007446889,0.0010058335,0.0014347399,4.4673024e-7,0.026054827,0.0000010850406,0.0008549444,0.6117714],"study_design_scores_gemma":[0.18614067,0.0098855365,0.7913134,0.00019953628,0.0002056887,0.000022277765,0.0006479199,0.0032190462,0.0016922712,0.000007551991,0.0059506777,0.00071540236],"about_ca_topic_score_codex":0.0013099244,"about_ca_topic_score_gemma":0.000194033,"teacher_disagreement_score":0.61105597,"about_ca_system_score_codex":0.0007802566,"about_ca_system_score_gemma":0.001529623,"threshold_uncertainty_score":0.999845},"labels":[],"label_agreement":null},{"id":"W4401892676","doi":"10.1038/s41423-024-01211-4","title":"The emerging roles of B cells in cancer development","year":2024,"lang":"en","type":"article","venue":"Cellular and Molecular Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Hong Kong Government; Innovation and Technology Commission; National Natural Science Foundation of China; McGill University","keywords":"Cancer; Cancer research; Biology; Genetics","score_opus":0.012644560872175874,"score_gpt":0.291482502959603,"score_spread":0.2788379420874271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401892676","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8542738,0.14326008,0.0003608635,0.0007093738,0.00017282048,0.00019322567,8.3807475e-7,0.000014966087,0.0010140258],"genre_scores_gemma":[0.991883,0.005364359,0.00010374709,0.00007066217,0.000018124305,0.000039761762,0.0000052738355,0.000021759946,0.0024933117],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9992118,0.000058896996,0.00019496525,0.00017814706,0.00012099242,0.00023518277],"domain_scores_gemma":[0.99969023,0.000049809056,0.000017157638,0.00018074078,0.00003278063,0.00002930504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002510312,0.000089205314,0.00016520904,0.00013069638,0.000042190437,0.000014493097,0.000080903024,0.00007245918,0.00017590333],"category_scores_gemma":[0.000011711545,0.000064358646,0.00004862968,0.0001710661,0.0001498161,0.000012908302,0.0000787698,0.00022066191,0.0000080323625],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006746872,0.000019899933,0.00011952157,0.00006539079,0.00014235548,0.00015823281,0.00069316523,0.0000037407433,0.8567029,0.00045191988,0.000037209855,0.14153817],"study_design_scores_gemma":[0.00031271772,0.000053824235,0.00028793453,0.00008489138,0.000015419439,0.000014733291,0.00020844805,0.00015325274,0.79209626,0.00007511165,0.20664483,0.000052582418],"about_ca_topic_score_codex":0.00006425699,"about_ca_topic_score_gemma":0.000043234493,"teacher_disagreement_score":0.20660762,"about_ca_system_score_codex":0.000050931787,"about_ca_system_score_gemma":0.00017692798,"threshold_uncertainty_score":0.26244694},"labels":[],"label_agreement":null},{"id":"W4402022196","doi":"10.1016/j.exphem.2024.104575","title":"2018 – TET2-MUTANT CLONAL HEMATOPOIESIS REPROGRAMS THE TUMOUR MICROENVIRONMENT TO PROMOTE IMMUNOTHERAPY RESPONSE","year":2024,"lang":"en","type":"article","venue":"Experimental Hematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; University Health Network","funders":"","keywords":"Mutant; Haematopoiesis; Immunotherapy; Cancer research; Biology; Cell biology; Immunology; Stem cell; Genetics; Immune system; Gene","score_opus":0.021688657688170514,"score_gpt":0.34116289999531396,"score_spread":0.31947424230714344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402022196","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9540237,0.028008068,0.00007669626,0.014411602,0.000525289,0.0018875559,0.000012654014,0.00022133139,0.00083307334],"genre_scores_gemma":[0.98803705,0.00010762884,0.0013840292,0.0012380937,0.00017831611,0.0006636324,0.000015447036,0.00011749217,0.00825832],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9972528,0.0002680999,0.00048183848,0.00075338257,0.0005467354,0.0006971455],"domain_scores_gemma":[0.99860984,0.00020602306,0.000045352022,0.00087594974,0.000022809307,0.00024001295],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0008005429,0.0003352436,0.00050829595,0.0001823387,0.00019561838,0.000088503024,0.00031968392,0.0001437943,0.006252203],"category_scores_gemma":[0.000034841945,0.00023068389,0.0002767179,0.0003516588,0.00040807782,0.000059772505,0.00023868121,0.00039521133,0.0014807796],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055087083,0.0005346444,0.00013274065,0.000048737485,0.00024036238,0.00105993,0.003477005,4.1444568e-7,0.97668236,0.0015496261,0.004746199,0.0060192966],"study_design_scores_gemma":[0.0008033336,0.0012521486,0.00025462982,0.00014105666,0.000015356654,0.004992844,0.001156648,0.000041864732,0.7759206,0.0000636366,0.2151753,0.00018257227],"about_ca_topic_score_codex":0.000051460378,"about_ca_topic_score_gemma":0.0000029758808,"teacher_disagreement_score":0.2104291,"about_ca_system_score_codex":0.000515895,"about_ca_system_score_gemma":0.0001376972,"threshold_uncertainty_score":0.99929667},"labels":[],"label_agreement":null},{"id":"W4402184323","doi":"10.1182/blood.2024025679","title":"Clinical features, pathophysiology, and management of acute myelopathy following CAR T-cell therapy","year":2024,"lang":"en","type":"review","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Royal College of Physicians and Surgeons of Canada","keywords":"Cytokine release syndrome; Medicine; Chimeric antigen receptor; Myelopathy; Cell therapy; Pathophysiology; Immunology; Immunotherapy; Intensive care medicine; Myelitis; Immune system; Internal medicine; Cell; Spinal cord; Biology","score_opus":0.055000010301930566,"score_gpt":0.40441695368018465,"score_spread":0.3494169433782541,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402184323","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016171543,0.99253947,6.492806e-7,0.000036190915,0.0004509186,0.001880623,0.000060494745,0.00005638305,0.0033581033],"genre_scores_gemma":[0.00002228161,0.9875396,0.000514651,0.00007468288,0.00040739187,0.00014082686,0.00013766704,0.00012576098,0.011037136],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973928,0.00027908766,0.00078310265,0.00076178985,0.00040460678,0.00037863688],"domain_scores_gemma":[0.99865305,0.00015609563,0.00017033792,0.00080085074,0.00003925652,0.0001803917],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00075028144,0.00046054774,0.0024565354,0.00022155489,0.00003629668,0.000023735074,0.00026896189,0.00051386945,0.000087786684],"category_scores_gemma":[0.000008290138,0.00031064037,0.0014959406,0.000366357,0.00013009047,0.000018741412,0.00029097826,0.0010261793,0.000050449664],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006684783,0.0005229602,0.000024601793,0.026838897,0.007396496,0.0023942438,0.000038217964,2.2232836e-9,0.00029587973,0.000026327672,0.0011190563,0.9612765],"study_design_scores_gemma":[0.003219454,0.0009538428,0.00008418396,0.013592381,0.016194388,0.00014306381,0.000016811795,2.1392555e-7,0.000045452172,0.000071190785,0.96537775,0.00030126347],"about_ca_topic_score_codex":0.000008309594,"about_ca_topic_score_gemma":4.6314804e-7,"teacher_disagreement_score":0.9642587,"about_ca_system_score_codex":0.000032473617,"about_ca_system_score_gemma":0.00020322835,"threshold_uncertainty_score":0.99993455},"labels":[],"label_agreement":null},{"id":"W4402266730","doi":"10.1158/1538-7445.pediatric24-b053","title":"Abstract B053: Tumor-associated macrophages diminishes IL1RAP-targeting CAR-T cell therapy efficacy in Ewing sarcoma","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cancer research; Chimeric antigen receptor; T cell; Medicine; Immunology; Immune system","score_opus":0.08861207712633722,"score_gpt":0.42057948188926525,"score_spread":0.331967404762928,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402266730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9539904,0.033675883,0.0000010121257,0.0017910192,0.00034891628,0.0012929977,0.0000334533,0.0002145306,0.008651805],"genre_scores_gemma":[0.98331827,0.006410763,0.000034836947,0.00015279517,0.0007267097,0.00030486798,0.000042778942,0.00018276216,0.008826227],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99434114,0.0004636404,0.00057718693,0.00095414487,0.0019408504,0.0017230499],"domain_scores_gemma":[0.9969863,0.0015870974,0.000050446593,0.0005803918,0.000396611,0.00039913453],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003946756,0.0003443998,0.0005877999,0.0009746895,0.00026883473,0.000372716,0.00051752094,0.00021302156,0.007861699],"category_scores_gemma":[0.00048050622,0.00030006532,0.0002546623,0.0022752213,0.000351966,0.00019988947,0.0002072615,0.0027394032,0.00027507346],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007673329,0.00055902766,0.010465907,0.00050767267,0.00016290521,0.0024644972,0.0024293913,0.000027562133,0.9107321,0.000016283879,0.008101688,0.063765675],"study_design_scores_gemma":[0.007291161,0.0009942827,0.14223102,0.0023798302,0.000029694653,0.000034905162,0.0021490138,0.00061546895,0.757681,0.00018903326,0.08566985,0.00073472067],"about_ca_topic_score_codex":0.0031652562,"about_ca_topic_score_gemma":0.00019235458,"teacher_disagreement_score":0.15305103,"about_ca_system_score_codex":0.001440574,"about_ca_system_score_gemma":0.001325232,"threshold_uncertainty_score":0.99994516},"labels":[],"label_agreement":null},{"id":"W4402267177","doi":"10.1158/1538-7445.pediatric24-ia015","title":"Abstract IA015: GD2-specific CAR T cell therapies for pediatric solid cancers","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Solid tumor; Oncology; Cancer; Cancer research; Internal medicine","score_opus":0.12855894036498683,"score_gpt":0.4531213373343368,"score_spread":0.32456239696934996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402267177","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8447252,0.13145822,0.00006936647,0.004184966,0.0012401897,0.0028751292,0.0002282295,0.00024660653,0.014972103],"genre_scores_gemma":[0.89529127,0.048213113,0.00011596187,0.000112824775,0.00508984,0.0015904005,0.00004175127,0.00019151498,0.04935331],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99585,0.00010451107,0.00035905236,0.0008250447,0.0015135036,0.0013478594],"domain_scores_gemma":[0.9973523,0.0008046612,0.000031104188,0.00067226344,0.0007004879,0.00043919566],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018460515,0.00026304368,0.00041208978,0.00083643006,0.00028379727,0.00026618008,0.00041654182,0.00020391426,0.012238909],"category_scores_gemma":[0.000064076405,0.00022156417,0.00028589126,0.001383234,0.00030613938,0.00014579583,0.00010447376,0.0013488954,0.0004048342],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013118809,0.00011309171,0.0007697709,0.0024430898,0.00021683647,0.00027462264,0.0021870083,0.000040104107,0.67046726,0.00023130699,0.24070905,0.08123595],"study_design_scores_gemma":[0.0017024723,0.0006123859,0.0016419732,0.00020939093,0.000045647594,0.000016737706,0.00087273814,0.00017460612,0.098769985,0.00043016043,0.8952105,0.0003134192],"about_ca_topic_score_codex":0.0010932621,"about_ca_topic_score_gemma":0.00017824779,"teacher_disagreement_score":0.65450144,"about_ca_system_score_codex":0.001958029,"about_ca_system_score_gemma":0.0028726077,"threshold_uncertainty_score":0.98866403},"labels":[],"label_agreement":null},{"id":"W4402267246","doi":"10.1158/1538-7445.pediatric24-b047","title":"Abstract B047: Transcriptional signatures associated with persisting CD19 CAR-T cells in children with leukemia","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Leukemia; CD19; Lymphoblastic Leukemia; Cancer research; Medicine; Biology; Immunology; Antigen","score_opus":0.052705287333144335,"score_gpt":0.3661746427095858,"score_spread":0.31346935537644144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402267246","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99082947,0.0035008811,0.000005859469,0.00077134394,0.00006274995,0.0010281762,0.00010234036,0.00010103533,0.0035981736],"genre_scores_gemma":[0.98924,0.00034182973,0.000037441987,0.00006794936,0.00036598346,0.0002163639,0.00009985036,0.0000973847,0.009533234],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99605954,0.0001627992,0.00022652456,0.0006680127,0.0019353804,0.00094773085],"domain_scores_gemma":[0.99864334,0.00036883308,0.000023785704,0.00030539915,0.00038799556,0.00027063338],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014466376,0.00022615188,0.00033121812,0.0006493654,0.00016217829,0.00016261397,0.00025022417,0.00019802335,0.004267388],"category_scores_gemma":[0.00007660097,0.00016495114,0.00009373996,0.0015603428,0.0004033614,0.00014438175,0.0000379455,0.0025455279,0.00004169955],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014962411,0.00013122374,0.04496938,0.00025414088,0.00070823485,0.0005645692,0.0012707466,0.0007827245,0.9414727,0.00009023132,0.0031892313,0.0050705518],"study_design_scores_gemma":[0.0062566465,0.0015219947,0.88756806,0.004259008,0.00012314763,0.00010681013,0.0010180945,0.0009873497,0.0909213,0.000073024414,0.006522847,0.00064170395],"about_ca_topic_score_codex":0.0033708331,"about_ca_topic_score_gemma":0.0017470887,"teacher_disagreement_score":0.8505514,"about_ca_system_score_codex":0.0025803044,"about_ca_system_score_gemma":0.0028632502,"threshold_uncertainty_score":0.9997556},"labels":[],"label_agreement":null},{"id":"W4402267877","doi":"10.1158/1538-7445.pediatric24-b061","title":"Abstract B061: Dissecting pediatric sarcoma microenvironment using single-cell and spatial multi-omics","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Sarcoma; Computational biology; Omics; Medicine; Tumor microenvironment; Cancer; Biology; Cancer research; Bioinformatics; Pathology; Internal medicine","score_opus":0.12593706990709044,"score_gpt":0.4082897044346989,"score_spread":0.2823526345276085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402267877","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9811739,0.016518518,0.00020878359,0.00041522426,0.0003208222,0.00078618224,0.000026808673,0.000059241967,0.0004905451],"genre_scores_gemma":[0.99008584,0.003734328,0.00048046754,0.000031314255,0.0016078543,0.000053508313,0.00001231882,0.00010758316,0.0038867572],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99718505,0.0001135169,0.0002890171,0.00064214016,0.00092079205,0.00084946817],"domain_scores_gemma":[0.9987398,0.00037499325,0.00002930842,0.0003588288,0.00014010267,0.00035699236],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001127469,0.00019789422,0.00026200796,0.00049457065,0.00023505771,0.00021985876,0.00016104177,0.0001374526,0.0020698076],"category_scores_gemma":[0.00012246959,0.00018178321,0.00009449993,0.00051873317,0.00023828003,0.00009782641,0.00025688796,0.001257136,0.000076687225],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025461952,0.00020432839,0.018894013,0.0009650752,0.00004377726,0.00030408223,0.000549699,0.000024129824,0.9283154,0.000002215864,0.0003248525,0.050117824],"study_design_scores_gemma":[0.0057863286,0.0011516698,0.0919504,0.00096380914,0.00021166747,0.00025783683,0.0014590833,0.01765328,0.8427608,0.00006967668,0.036827486,0.00090792845],"about_ca_topic_score_codex":0.0027084986,"about_ca_topic_score_gemma":0.00017949249,"teacher_disagreement_score":0.085554555,"about_ca_system_score_codex":0.0011171242,"about_ca_system_score_gemma":0.00044011843,"threshold_uncertainty_score":0.9988424},"labels":[],"label_agreement":null},{"id":"W4402267976","doi":"10.1158/1538-7445.pediatric24-pr010","title":"Abstract PR010: Developing a safe and potent tumor-targeting gated CAR-T cell therapy for DIPG: A deadly pediatric brain tumor","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Brain tumor; CAR T-cell therapy; Tumor cells; Cancer; Cancer research; Oncology; Internal medicine; Immunotherapy; Pathology; Chimeric antigen receptor","score_opus":0.07872022883180967,"score_gpt":0.4125548820167345,"score_spread":0.33383465318492483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402267976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.953216,0.035274662,0.00012418252,0.006611261,0.0002489502,0.0029653506,0.00006391212,0.00015314632,0.0013425242],"genre_scores_gemma":[0.9809525,0.0066546276,0.0008750068,0.00056954694,0.0018323442,0.0010055364,0.000051186747,0.0001992262,0.0078599965],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99566334,0.00019886348,0.00048424432,0.00092859764,0.0013167936,0.0014081702],"domain_scores_gemma":[0.9969847,0.0014051272,0.000055118297,0.00039439037,0.00069973205,0.00046091457],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0034766232,0.0003125034,0.00046199327,0.0008036503,0.000371178,0.00031391814,0.0002967858,0.00012243133,0.0013357245],"category_scores_gemma":[0.00047706248,0.00026093874,0.00016907809,0.0014116132,0.00019915201,0.00014690442,0.00016876089,0.001280153,0.00006470486],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023603388,0.00015131435,0.0064495225,0.0042118644,0.00019891381,0.0008544601,0.0016208313,0.000013681655,0.8862052,0.00012173131,0.032976653,0.06483547],"study_design_scores_gemma":[0.009934495,0.002131357,0.033270996,0.0015589973,0.00009740352,0.00021347465,0.0017180169,0.0021306009,0.38659707,0.00090076035,0.56018806,0.001258766],"about_ca_topic_score_codex":0.00093038776,"about_ca_topic_score_gemma":0.00006162859,"teacher_disagreement_score":0.5272114,"about_ca_system_score_codex":0.0009058179,"about_ca_system_score_gemma":0.0028985506,"threshold_uncertainty_score":0.99998426},"labels":[],"label_agreement":null},{"id":"W4402279313","doi":"10.1007/s00262-024-03813-3","title":"Correction to: Impact of fludarabine and treosulfan on ovarian tumor cells and mesothelin chimeric antigen receptor T cells","year":2024,"lang":"en","type":"erratum","venue":"Cancer Immunology Immunotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Mesothelin; Treosulfan; Fludarabine; Olaparib; Chimeric antigen receptor; Ovarian cancer; Cancer research; Medicine; Oncology; Antigen; Immunology; Internal medicine; Biology; Immunotherapy; Chemotherapy; Cancer; Gene; Immune system; Poly ADP ribose polymerase; Genetics; Cyclophosphamide","score_opus":0.014802131076722286,"score_gpt":0.3236933696166772,"score_spread":0.3088912385399549,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402279313","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5603884,0.31656024,0.000039821403,0.0028271049,0.10158806,0.005497859,0.001699933,0.00041231458,0.010986272],"genre_scores_gemma":[0.015583796,0.28376523,0.00024355702,0.0011738186,0.002390719,0.0004921049,0.00047549536,0.0007519393,0.6951233],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963475,0.0002969533,0.0008539554,0.0011843311,0.00045627367,0.00086099596],"domain_scores_gemma":[0.9977546,0.00023554698,0.0003804726,0.0011494248,0.00025921414,0.00022077384],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004911789,0.000928516,0.0018679833,0.0011832751,0.00015113162,0.00008644964,0.0003722413,0.0007286538,0.009451214],"category_scores_gemma":[0.000046755744,0.000775609,0.0004927909,0.0008650987,0.0006551108,0.00007352774,0.00013323525,0.002479986,0.00018130752],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004920293,0.0001435204,0.000105823696,0.0001548661,0.0023900003,0.000025119154,0.0008535667,0.0000048724905,0.60539585,0.0000031797376,0.30834934,0.07765358],"study_design_scores_gemma":[0.004143973,0.008323783,0.009197112,0.002210436,0.00022706189,0.00015868389,0.00015034185,0.000114624745,0.19216946,0.000028862441,0.78245246,0.00082317984],"about_ca_topic_score_codex":0.0031843921,"about_ca_topic_score_gemma":0.000052763502,"teacher_disagreement_score":0.68413705,"about_ca_system_score_codex":0.0008691677,"about_ca_system_score_gemma":0.0013708031,"threshold_uncertainty_score":0.9998213},"labels":[],"label_agreement":null},{"id":"W4402340874","doi":"10.1101/2024.09.03.611092","title":"A Digital Microfluidic Platform for the Microscale Production of Functional Immune Cell Therapies","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer; Université de Montréal; Concordia University","funders":"","keywords":"Microscale chemistry; Microfluidics; Production (economics); Immune system; Nanotechnology; Computer science; Biology; Materials science; Immunology; Economics; Mathematics","score_opus":0.023196108972669265,"score_gpt":0.24800599691893774,"score_spread":0.22480988794626847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402340874","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9405453,0.04896109,0.0007109235,0.0017054144,0.003633538,0.0035942444,0.00051242736,0.00027800663,0.00005904084],"genre_scores_gemma":[0.99338406,0.0021965122,0.0003850453,0.00006767602,0.0014412142,0.00064078614,0.0000031219456,0.00021469362,0.0016669094],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997407,0.00002886105,0.0006314993,0.0008576597,0.0005779797,0.0004969761],"domain_scores_gemma":[0.99729836,0.00019335678,0.00025755647,0.0013256032,0.00079333055,0.00013182127],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007775782,0.00047478906,0.0006261757,0.00032855826,0.00016530734,0.00022667162,0.0003604331,0.00040203505,0.0002602159],"category_scores_gemma":[0.0001592662,0.0003620631,0.00051196764,0.0004910775,0.00036398845,0.00009951059,0.00047439634,0.0010461074,0.00005882459],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006827268,0.0002711823,0.00054391066,0.0019643798,0.0006510792,0.000007729888,0.000036187208,0.0000058174833,0.99163777,0.00008661026,0.004034143,0.000078455414],"study_design_scores_gemma":[0.00087363686,0.00018823116,0.010303939,0.00050601846,0.00030447738,1.8181642e-7,0.000024735009,0.00007407167,0.9227547,0.000010686333,0.064621,0.00033833593],"about_ca_topic_score_codex":0.000022578122,"about_ca_topic_score_gemma":5.026584e-7,"teacher_disagreement_score":0.06888309,"about_ca_system_score_codex":0.00033585198,"about_ca_system_score_gemma":0.0010098193,"threshold_uncertainty_score":0.9998831},"labels":[],"label_agreement":null},{"id":"W4402363529","doi":"10.4049/immunohorizons.2300095","title":"Improving Reliability of Immunological Assays by Defining Minimal Criteria for Cell Fitness","year":2024,"lang":"en","type":"article","venue":"ImmunoHorizons","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University Health Centre; Montreal Heart Institute; BC Children's Hospital; University of British Columbia","funders":"Institute of Nutrition, Metabolism and Diabetes; Institute of Infection and Immunity; Genome Canada; Canadian Institutes of Health Research; Genome British Columbia; Institute of Genetics; Government of Canada","keywords":"Cryopreservation; Peripheral blood mononuclear cell; Flow cytometry; Biology; Biomarker; Viability assay; Immune system; Cell; Immunology; Coefficient of variation; Computational biology; Cell biology; In vitro; Chemistry; Genetics; Embryo","score_opus":0.02550995418780715,"score_gpt":0.3363704938689318,"score_spread":0.31086053968112465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402363529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97764075,0.010680015,0.00233269,0.0006863082,0.0007901733,0.0009966564,0.00029494546,0.00021387792,0.0063646105],"genre_scores_gemma":[0.98916304,0.00017910803,0.0043301536,0.000025957426,0.000121846824,0.00018577704,0.00014834716,0.0000663041,0.005779487],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980026,0.00010919367,0.0005262287,0.00050746504,0.00032672824,0.0005278155],"domain_scores_gemma":[0.99807197,0.0009363925,0.000067081986,0.0006125343,0.00021919838,0.000092802366],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011609333,0.0002227874,0.00049007824,0.00013718207,0.00010828746,0.00007395305,0.0002465506,0.00023641947,0.001706619],"category_scores_gemma":[0.00056664733,0.00018782818,0.00033067938,0.00032192867,0.00026016886,0.00011978227,0.0001526219,0.000497348,0.000043923334],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008812093,0.00025246106,0.00039492478,0.00065291376,0.00007740636,0.000015847001,0.00022741023,3.4238087e-7,0.9517339,0.00025395938,0.0030281239,0.042481523],"study_design_scores_gemma":[0.0038343542,0.0064562396,0.0026417458,0.00046202546,0.00030713237,0.00009947174,0.0008505582,0.0037018345,0.8705159,0.0006617901,0.10991017,0.0005588094],"about_ca_topic_score_codex":0.00018215449,"about_ca_topic_score_gemma":0.0000012036645,"teacher_disagreement_score":0.10688204,"about_ca_system_score_codex":0.00018451372,"about_ca_system_score_gemma":0.00028491492,"threshold_uncertainty_score":0.99920595},"labels":[],"label_agreement":null},{"id":"W4402471159","doi":"10.1182/bloodadvances.2024012982","title":"Point-of-care CAR T manufacturing solutions: can 1 model fit all?","year":2024,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Point (geometry); Computer science; Mathematics","score_opus":0.045130513431129046,"score_gpt":0.33922728022692095,"score_spread":0.2940967667957919,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402471159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.82929313,0.14322034,0.00055867055,0.0031330653,0.00048560978,0.0010165893,0.000156894,0.00039718376,0.021738542],"genre_scores_gemma":[0.98441076,0.0033974098,0.0023121668,0.00014912337,0.00024245809,0.000051644063,0.00003096436,0.000043876018,0.009361596],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99880534,0.000019404895,0.00019896773,0.00028910858,0.00035076297,0.00033641263],"domain_scores_gemma":[0.9994181,0.0000805144,0.00002528074,0.00029827195,0.000064344465,0.00011351309],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00011021377,0.00013901951,0.00024204083,0.0001480543,0.000054116947,0.000024179055,0.00011652679,0.000057098245,0.0004435884],"category_scores_gemma":[0.00002985213,0.00011099278,0.00014016239,0.00012001541,0.0000809088,0.00013453742,0.00006356501,0.00023656298,0.000020431315],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00063517835,0.00059260783,0.0016608419,0.008620049,0.001699252,0.00091521366,0.010774638,0.014356721,0.45340356,0.0036866975,0.0024503919,0.50120485],"study_design_scores_gemma":[0.0021532853,0.00079978723,0.0003463697,0.0013128642,0.000557914,0.0002144372,0.0026260905,0.011279971,0.757784,0.0035057422,0.21894975,0.0004697598],"about_ca_topic_score_codex":0.000054572873,"about_ca_topic_score_gemma":0.00010598772,"teacher_disagreement_score":0.50073504,"about_ca_system_score_codex":0.000067264446,"about_ca_system_score_gemma":0.00015774934,"threshold_uncertainty_score":0.48569816},"labels":[],"label_agreement":null},{"id":"W4402492440","doi":"10.1016/j.healthpol.2024.105153","title":"Availability and financing of CAR-T cell therapies: A cross-country comparative analysis","year":2024,"lang":"en","type":"review","venue":"Health Policy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics; Institute for Work & Health","funders":"European Observatory on Health Systems and Policies","keywords":"Business; Finance","score_opus":0.13948010126114785,"score_gpt":0.5300620829097249,"score_spread":0.39058198164857705,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402492440","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00094699155,0.9927465,0.0000043931536,0.00040856437,0.00006800193,0.0017795427,0.00043648027,0.000046642414,0.003562902],"genre_scores_gemma":[0.00062143424,0.9890162,0.0000827662,0.0004520003,0.0004306009,0.0001108849,0.00013541804,0.000053461594,0.009097272],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963973,0.00042740503,0.0012762613,0.0007208476,0.0005144542,0.00066368876],"domain_scores_gemma":[0.997565,0.00046273906,0.00048205012,0.0009208627,0.0001934469,0.00037594268],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014208634,0.00047351792,0.004310522,0.0012658814,0.00011359156,0.00005415498,0.00018057259,0.00043093742,0.0005970152],"category_scores_gemma":[0.000097753,0.00034571823,0.0007714163,0.0032674742,0.00041336348,0.000039610673,0.00013600555,0.0013540115,0.000065554465],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001089911,0.00025426009,0.00059007603,0.3527357,0.0033510171,0.000023366974,0.009347833,0.0000013376496,0.000012123314,0.0003640479,0.0030602557,0.63015103],"study_design_scores_gemma":[0.00036588454,0.0003199294,0.0003612653,0.005013115,0.0018185321,0.000024972074,0.000117671654,0.000028661774,0.0000036322358,0.000034404966,0.9917139,0.00019805077],"about_ca_topic_score_codex":0.010531391,"about_ca_topic_score_gemma":0.0005519369,"teacher_disagreement_score":0.9886536,"about_ca_system_score_codex":0.0009901092,"about_ca_system_score_gemma":0.005888618,"threshold_uncertainty_score":0.9998995},"labels":[],"label_agreement":null},{"id":"W4402499383","doi":"10.1186/s40364-024-00634-5","title":"Updates on CAR T cell therapy in multiple myeloma","year":2024,"lang":"en","type":"review","venue":"Biomarker Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Chimeric antigen receptor; Medicine; Cytokine release syndrome; Immunotherapy; Multiple myeloma; T cell; Cancer research; Immunology; Cancer; Oncology; Internal medicine; Immune system","score_opus":0.30861410387930377,"score_gpt":0.48950730688676003,"score_spread":0.18089320300745626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402499383","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007885154,0.9705516,2.3000092e-7,0.00031066817,0.0002926075,0.004971556,0.000104111714,0.00011835127,0.022862323],"genre_scores_gemma":[0.00030630088,0.9291645,0.000033601274,0.000043116437,0.00048627175,0.0010263049,0.00035125745,0.0003512778,0.06823734],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9915442,0.0017608602,0.00091264205,0.0015354827,0.0025740345,0.0016728215],"domain_scores_gemma":[0.9954907,0.0018062339,0.000080375554,0.0018086912,0.0003066749,0.00050736987],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.004987984,0.00075527537,0.0021397406,0.0037888892,0.00014352542,0.00023459647,0.0009191243,0.0008890493,0.005977034],"category_scores_gemma":[0.00039196626,0.00051692256,0.00093833805,0.003862229,0.00045255455,0.000056886107,0.0005052934,0.0036376126,0.0064042327],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00063485885,0.00051189266,0.00008556058,0.017548302,0.000360267,0.0016295922,0.00008751011,2.157521e-8,0.0011889877,0.000020406293,0.040610343,0.93732226],"study_design_scores_gemma":[0.0013863582,0.0008413785,0.00010808969,0.013140308,0.00008386167,0.00007756877,0.000050568513,0.000028793187,0.00034251754,0.000022865603,0.9835063,0.0004113591],"about_ca_topic_score_codex":0.00044230715,"about_ca_topic_score_gemma":0.00006438211,"teacher_disagreement_score":0.942896,"about_ca_system_score_codex":0.0012835256,"about_ca_system_score_gemma":0.0018207029,"threshold_uncertainty_score":0.99972826},"labels":[],"label_agreement":null},{"id":"W4402558664","doi":"10.1016/j.annonc.2024.08.2144","title":"987TiP First-in-human dose escalation trial of fourth generation chimeric antigen receptor (CAR) T cell therapy (EU307) in patients with glypican-3 (GPC3) positive hepatocellular carcinoma (HCC)","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nexen (Canada)","funders":"","keywords":"Medicine; Glypican 3; Chimeric antigen receptor; Hepatocellular carcinoma; Oncology; Internal medicine; Cancer research; Immunotherapy; Cancer","score_opus":0.06382615843562044,"score_gpt":0.35002115545629187,"score_spread":0.2861949970206714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402558664","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99500024,0.0005937074,0.000025430283,0.00092285365,0.00021368395,0.0020691955,0.000025335552,0.000017876295,0.0011316696],"genre_scores_gemma":[0.9982202,0.00052135816,0.00019100728,0.00012289797,0.00026529472,0.000071333736,0.00027284515,0.00004469675,0.00029038647],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99775684,0.00034197484,0.0006507304,0.00041968198,0.0004709397,0.00035985437],"domain_scores_gemma":[0.9989112,0.000174367,0.00019904479,0.00030698246,0.00030805686,0.00010036076],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00064119394,0.00020881824,0.00068705506,0.00056456355,0.00003923999,0.000012365977,0.00012732926,0.00022867901,0.00051849737],"category_scores_gemma":[0.000036346577,0.00017627237,0.00014091893,0.00064889906,0.00015782009,0.00011863142,0.000034237095,0.00032076458,0.000008166382],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06820361,0.0040271264,0.50522226,0.00018287916,0.00023315767,0.000102252605,0.003456269,0.00009624261,0.3549847,0.00006769586,0.0007206053,0.06270318],"study_design_scores_gemma":[0.08435105,0.054928828,0.5674145,0.000248225,0.00005092402,0.0000047522826,0.00014407326,0.0038041377,0.28133333,0.00007244302,0.007281222,0.00036649988],"about_ca_topic_score_codex":0.00088884664,"about_ca_topic_score_gemma":0.0002494783,"teacher_disagreement_score":0.07365136,"about_ca_system_score_codex":0.00017109142,"about_ca_system_score_gemma":0.00038829978,"threshold_uncertainty_score":0.71881783},"labels":[],"label_agreement":null},{"id":"W4402559898","doi":"10.1016/j.annonc.2024.08.859","title":"808MO Value of early post-treatment FDG PET/CT in diffuse large B-cell lymphoma patients receiving chimeric antigen receptor T cell therapy","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"Wellcome Trust","keywords":"Medicine; Chimeric antigen receptor; Lymphoma; Antigen; Diffuse large B-cell lymphoma; B cell; Nuclear medicine; Cancer research; Oncology; Immunotherapy; Pathology; Internal medicine; Immunology; Cancer; Antibody","score_opus":0.04343359763471496,"score_gpt":0.3659126109900065,"score_spread":0.32247901335529155,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402559898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98454976,0.004065498,0.0000015460735,0.00096505333,0.0003557734,0.000909254,0.00007730854,0.00003973195,0.009036103],"genre_scores_gemma":[0.9815819,0.0139623005,0.00018107393,0.0004018827,0.000100104735,0.000048824506,0.000081484766,0.000069070615,0.0035733518],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99750924,0.00036414943,0.00062594283,0.00046227404,0.00042326504,0.00061512185],"domain_scores_gemma":[0.9984835,0.0004206141,0.00017755646,0.0004581026,0.0002877829,0.00017247112],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005857133,0.00026950447,0.0008017201,0.00050714053,0.000037074173,0.000013740599,0.00021405703,0.00007244746,0.0010769772],"category_scores_gemma":[0.000064305896,0.0002204193,0.0002984299,0.0005727009,0.0001297716,0.000094818155,0.000081780316,0.00019751862,0.000110854795],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042386497,0.04315372,0.16171333,0.00041572662,0.00053428015,0.00096655,0.005453689,0.000002846639,0.35351145,0.00004557759,0.0024073622,0.4275568],"study_design_scores_gemma":[0.035242546,0.0428463,0.24482198,0.00034132603,0.00006251851,0.00006949189,0.00051408244,0.00017599874,0.39788935,0.00006853189,0.27754468,0.00042320063],"about_ca_topic_score_codex":0.0011583692,"about_ca_topic_score_gemma":0.000074201394,"teacher_disagreement_score":0.4271336,"about_ca_system_score_codex":0.000235848,"about_ca_system_score_gemma":0.0006328319,"threshold_uncertainty_score":0.99983615},"labels":[],"label_agreement":null},{"id":"W4402560756","doi":"10.1016/j.annonc.2024.08.1149","title":"1081MO Phase I study of WNT974 in combination with spartalizumab in patients with cutaneous melanoma","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Melanoma; Dermatology; Phase (matter); Oncology; Internal medicine; Cancer research","score_opus":0.05754284482523902,"score_gpt":0.4079441693441884,"score_spread":0.3504013245189494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402560756","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99470246,0.000104117105,0.0000026874072,0.0005224523,0.00003990838,0.0010407806,0.000006329101,0.000011627162,0.0035696647],"genre_scores_gemma":[0.99944305,0.000028821602,0.000026584425,0.000055539673,0.000012395632,0.00003454285,0.000023176053,0.000019754829,0.00035610836],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99872977,0.00014012882,0.00033336802,0.00021977286,0.00036553378,0.00021141574],"domain_scores_gemma":[0.9992959,0.00016045687,0.00007610478,0.00020026526,0.00021331347,0.00005394186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028277354,0.00010303299,0.0004511883,0.00046403354,0.000008207538,0.000004232872,0.00007772206,0.000076193384,0.0003293505],"category_scores_gemma":[0.000038595197,0.000076268974,0.000024793686,0.0005372165,0.000099323675,0.00005295395,0.000026114918,0.00021034526,0.0000047071508],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03398264,0.037818644,0.66350406,0.0003632254,0.00047047428,0.0033484318,0.008625919,0.00007193116,0.0020613486,0.00022976898,0.0005298935,0.24899368],"study_design_scores_gemma":[0.08180632,0.46800137,0.42889243,0.0007586022,0.00013320273,0.00019195139,0.0029296319,0.00075706013,0.0076956926,0.0002430811,0.0082743745,0.00031629126],"about_ca_topic_score_codex":0.0004066408,"about_ca_topic_score_gemma":0.0012956243,"teacher_disagreement_score":0.43018273,"about_ca_system_score_codex":0.00008611721,"about_ca_system_score_gemma":0.00024563583,"threshold_uncertainty_score":0.36061573},"labels":[],"label_agreement":null},{"id":"W4402684921","doi":"10.14740/jmc4287","title":"Combination Therapy With Asciminib and Ponatinib as a Bridge to Brexucabtagene Autoleucel and Maintenance in a Patient With Relapsed Refractory Philadelphia Positive B-Cell Acute Lymphoblastic Leukemia","year":2024,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Ponatinib; Lymphoblastic Leukemia; Refractory (planetary science); Maintenance therapy; Bridge (graph theory); Internal medicine; Oncology; Leukemia; Surgery; Myeloid leukemia; Chemotherapy; Dasatinib","score_opus":0.018904137330430292,"score_gpt":0.30797661611468,"score_spread":0.28907247878424974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402684921","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98634696,0.0025281594,0.0001420255,0.010111083,0.000090517555,0.00044144294,0.000012863255,0.000016660946,0.00031026718],"genre_scores_gemma":[0.99536586,0.0022735812,0.0002303159,0.0015729761,0.00011155602,0.000015006505,0.0000064419187,0.000040019495,0.00038421628],"study_design_codex":"design_other","study_design_gemma":"case_report","domain_scores_codex":[0.99723095,0.00012953933,0.000441428,0.0002892956,0.0016146953,0.00029412133],"domain_scores_gemma":[0.9981422,0.00075319514,0.00013607251,0.00013164103,0.00024492518,0.0005919562],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072863745,0.0002070132,0.00045085727,0.00042191212,0.00004597687,0.000069545116,0.0001006497,0.00013170547,0.00023879012],"category_scores_gemma":[0.00033653804,0.00012615166,0.000047264464,0.0004432102,0.00022600751,0.00015154043,0.000047329126,0.0006974765,0.000003072142],"study_design_candidate":"case_report","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.083772935,0.0032666237,0.00421654,0.0008705071,0.0015334936,0.3465888,0.016933888,0.000033913668,0.07160376,0.00041874748,0.011275755,0.45948505],"study_design_scores_gemma":[0.10181997,0.17126244,0.21837038,0.025819514,0.0009098685,0.40879542,0.004577835,0.0072749606,0.025881622,0.00032532527,0.03346373,0.001498914],"about_ca_topic_score_codex":0.00016377398,"about_ca_topic_score_gemma":0.00004873611,"teacher_disagreement_score":0.45798615,"about_ca_system_score_codex":0.00046274537,"about_ca_system_score_gemma":0.0015231085,"threshold_uncertainty_score":0.51443154},"labels":[],"label_agreement":null},{"id":"W4402715623","doi":"10.1101/2024.09.18.613561","title":"Broadly Reactive Anti-VHH Antibodies for Characterizing, Blocking, or Activating Nanobody-Based CAR-T Cells","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"National Research Council Canada; Institute of Infection and Immunity; University of Ottawa","funders":"","keywords":"Blocking (statistics); Antibody; Blocking antibody; Chemistry; Molecular biology; Biology; Computer science; Immunology","score_opus":0.030285445165221702,"score_gpt":0.2939124376450998,"score_spread":0.2636269924798781,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402715623","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891028,0.0009564291,0.00028144632,0.0009055708,0.0024973443,0.004215047,0.0009424057,0.0010448205,0.00005413303],"genre_scores_gemma":[0.988037,0.0003896502,0.006630072,0.00059550174,0.0022938927,0.0009219975,0.000005456953,0.00070663745,0.00041980125],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9938044,0.00020258084,0.0010709025,0.0022985677,0.0011183049,0.0015052637],"domain_scores_gemma":[0.9946125,0.00051337684,0.0007192523,0.0021577077,0.0014176535,0.0005794756],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0013482982,0.0012758272,0.0018572919,0.001022538,0.00034757564,0.00056324183,0.0007109168,0.001134594,0.00051518134],"category_scores_gemma":[0.0007008782,0.001175245,0.00074410765,0.00097364787,0.00031412003,0.00015695191,0.0008796469,0.0025768601,0.00011531843],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008202973,0.0003905957,0.0022233757,0.0050956225,0.0010453805,0.00042790026,0.00006394392,0.000013370863,0.9888756,0.000052933163,0.0009599714,0.000030975112],"study_design_scores_gemma":[0.0018808972,0.00038776017,0.0070971227,0.004004146,0.00048532983,2.1228986e-7,0.00002266978,0.0011697373,0.943049,0.0000017537668,0.040740337,0.0011610012],"about_ca_topic_score_codex":0.00017789796,"about_ca_topic_score_gemma":0.000005080588,"teacher_disagreement_score":0.0458266,"about_ca_system_score_codex":0.0010917893,"about_ca_system_score_gemma":0.0035933396,"threshold_uncertainty_score":0.99999934},"labels":[],"label_agreement":null},{"id":"W4402784527","doi":"10.1016/j.omton.2024.200876","title":"Innovative approaches to glioma treatment: Oncolytic foamy virus and CAR T cell therapy","year":2024,"lang":"en","type":"article","venue":"Molecular Therapy Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Oncolytic virus; Glioma; Virology; Virus; Medicine; Cancer research","score_opus":0.12167697695646601,"score_gpt":0.35955457143196046,"score_spread":0.23787759447549445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402784527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94927084,0.020955455,0.00063489005,0.0051163994,0.00022778615,0.0023687172,0.000018522875,0.00018670896,0.021220652],"genre_scores_gemma":[0.9841248,0.0037719486,0.0012686029,0.0028268313,0.0003077743,0.0006845227,0.000046106794,0.00017096996,0.0067984806],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975082,0.00031598873,0.00035857206,0.00082056946,0.00037254754,0.0006240694],"domain_scores_gemma":[0.9987368,0.00023082648,0.000049237566,0.0005499835,0.000118121934,0.00031502428],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00041891634,0.00042727203,0.0007079037,0.0006227347,0.00009801431,0.00008797765,0.00017738601,0.00031347468,0.0010656159],"category_scores_gemma":[0.00001770028,0.00032959084,0.00018321593,0.0013881046,0.00023032745,0.000062670544,0.0000637307,0.00037963706,0.00016142859],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001533766,0.000515988,0.00007881164,0.000025997164,0.00047074448,0.0015402478,0.0028050262,0.0000048310235,0.6131186,0.00047827812,0.000268311,0.37915942],"study_design_scores_gemma":[0.0046691066,0.011327113,0.00024136194,0.00002775228,0.000035932448,0.00032473358,0.0002730722,0.00020419956,0.5676813,0.00034442064,0.41460806,0.0002629524],"about_ca_topic_score_codex":0.0001861915,"about_ca_topic_score_gemma":0.000023967204,"teacher_disagreement_score":0.41433975,"about_ca_system_score_codex":0.0006729542,"about_ca_system_score_gemma":0.0006953625,"threshold_uncertainty_score":0.9999156},"labels":[],"label_agreement":null},{"id":"W4402929046","doi":"10.1002/cpt.3445","title":"A Novel Step‐Up Dosage Regimen for Enhancing the Benefit‐to‐Risk Ratio of Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma","year":2024,"lang":"en","type":"article","venue":"Clinical Pharmacology & Therapeutics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Genentech; Roche","keywords":"Medicine; Regimen; Follicular lymphoma; Neutropenia; Dosing; Internal medicine; Adverse effect; Refractory (planetary science); Population; Pharmacokinetics; Oncology; Lymphoma; Gastroenterology; Pharmacology; Toxicity; Biology","score_opus":0.10287831559075052,"score_gpt":0.4523550682450669,"score_spread":0.3494767526543164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402929046","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96901816,0.0040700114,0.0074384566,0.012199003,0.0029355448,0.003928523,0.000081299106,0.00012768197,0.00020131854],"genre_scores_gemma":[0.94140345,0.0052952156,0.0032558849,0.032066137,0.0015905355,0.0007133435,0.000036006248,0.00022820082,0.015411226],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99648076,0.00041867053,0.0013658854,0.0006912565,0.00041951306,0.0006239233],"domain_scores_gemma":[0.99227786,0.006408539,0.00021421963,0.0006332528,0.00024047647,0.00022564235],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0033322533,0.00030884176,0.0008439311,0.0002402723,0.000115265255,0.000030831787,0.00045723587,0.00043339847,0.0007131645],"category_scores_gemma":[0.00022918796,0.00020489824,0.00046346558,0.0007371418,0.00040351058,0.00005682789,0.00014599318,0.00093993073,0.00003952142],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017890375,0.0015412694,0.00058613834,0.00027609224,0.0029223734,0.00011952169,0.0021346777,0.00014315586,0.7796213,0.00010273113,0.0073929396,0.18726942],"study_design_scores_gemma":[0.03772449,0.0105683,0.006229645,0.0005417088,0.0038501918,0.00011573475,0.0009913396,0.06457292,0.112456724,0.00043531577,0.76179725,0.0007163491],"about_ca_topic_score_codex":0.00004496503,"about_ca_topic_score_gemma":0.00014820314,"teacher_disagreement_score":0.7544043,"about_ca_system_score_codex":0.00033990503,"about_ca_system_score_gemma":0.00093566906,"threshold_uncertainty_score":0.8355508},"labels":[],"label_agreement":null},{"id":"W4403094942","doi":"10.54194/iowr5712","title":"Government development of ‘made-in-Canada’ CAR-T cell immunotherapies: assessing cost, risk, access, and alternatives","year":2024,"lang":"en","type":"article","venue":"Canadian Health Policy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Government (linguistics); Business; Risk analysis (engineering)","score_opus":0.05149128024051644,"score_gpt":0.39716694700375493,"score_spread":0.34567566676323846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403094942","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95684505,0.013607181,0.000044668697,0.015500909,0.00023290579,0.0012473377,0.00026805876,0.000019113088,0.012234764],"genre_scores_gemma":[0.99207616,0.0028432023,0.00031367096,0.0025249561,0.00016708898,0.00004005452,0.000012076536,0.0000465814,0.0019761838],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99792045,0.00011580487,0.0004582184,0.00030137852,0.00049019593,0.0007139335],"domain_scores_gemma":[0.99862885,0.000167474,0.00009239258,0.00024111684,0.000039108276,0.0008310695],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005369016,0.00016833376,0.00035482718,0.00037657216,0.00013124966,0.00007679427,0.00016312923,0.00004939314,0.00048392866],"category_scores_gemma":[0.000060303544,0.00016423447,0.000032583855,0.0004439228,0.00006747431,0.000108971006,0.000043789914,0.00038718162,0.0000041726476],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00006218508,0.000040590014,0.083455496,0.0018294448,0.00017010888,0.00016663074,0.010166839,0.000015456022,0.0028883165,0.00032449374,0.0042251167,0.8966553],"study_design_scores_gemma":[0.0013414923,0.00011284883,0.46294117,0.000983211,0.000011594407,0.000027246635,0.0019491682,0.0005197828,0.0063481038,0.000076161516,0.5254109,0.00027832438],"about_ca_topic_score_codex":0.99715483,"about_ca_topic_score_gemma":0.9958236,"teacher_disagreement_score":0.896377,"about_ca_system_score_codex":0.012651714,"about_ca_system_score_gemma":0.060183592,"threshold_uncertainty_score":0.9911385},"labels":[],"label_agreement":null},{"id":"W4403251225","doi":"10.1016/j.ygyno.2024.07.417","title":"GOG-3084: A phase II trial of ADP-A2M4CD8 TCR-T cell therapy, alone or in combination with nivolumab, among patients with recurrent ovarian cancers","year":2024,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Nivolumab; Oncology; Internal medicine; Immunotherapy; Cancer","score_opus":0.03270045354597139,"score_gpt":0.34693050096028794,"score_spread":0.31423004741431654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403251225","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98807895,0.00030421652,0.000034516277,0.00097642455,0.00073889113,0.004145745,0.00002938678,0.00008828576,0.0056036036],"genre_scores_gemma":[0.9945892,0.00040481336,0.00040503038,0.00018620663,0.00011885513,0.00060096564,0.00013865529,0.000051229115,0.0035050053],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971323,0.00043750147,0.0006254839,0.0006326902,0.0005745123,0.0005975293],"domain_scores_gemma":[0.9981742,0.00077569386,0.00024536994,0.00039189757,0.00023112551,0.00018172365],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00088128436,0.00030520762,0.0009095556,0.0004904831,0.00009349509,0.000020836833,0.00021419974,0.00034661693,0.004642578],"category_scores_gemma":[0.00016726802,0.00019385059,0.00009631799,0.0009791004,0.0004327827,0.00012412493,0.00008324709,0.0007061489,0.000014686381],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4389175,0.022673633,0.021521226,0.00032037936,0.0005171212,0.0010807439,0.0033122976,0.00005327437,0.0025564437,0.000117968804,0.0029047758,0.50602466],"study_design_scores_gemma":[0.50805944,0.3968053,0.039677337,0.00030733895,0.00021798797,0.00002846627,0.000625444,0.0011419787,0.0015533193,0.00014999889,0.050939295,0.00049412553],"about_ca_topic_score_codex":0.000724727,"about_ca_topic_score_gemma":0.0043953774,"teacher_disagreement_score":0.50553054,"about_ca_system_score_codex":0.0018988604,"about_ca_system_score_gemma":0.0021527314,"threshold_uncertainty_score":0.9962673},"labels":[],"label_agreement":null},{"id":"W4403262461","doi":"10.25163/angiotherapy.899889","title":"Real-World Insights into CAR T-Cell Therapy: Efficacy and Safety of Kymriah in B-ALL and NHL","year":2024,"lang":"en","type":"article","venue":"Journal of Angiotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"CAR T-cell therapy; Medicine; Internal medicine; Immunotherapy; Chimeric antigen receptor; Cancer","score_opus":0.028834959681595433,"score_gpt":0.34655493619911903,"score_spread":0.3177199765175236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403262461","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94828176,0.04771668,0.000023466915,0.0018655049,0.00013341306,0.00033484635,0.0000013619909,0.000013158685,0.0016297812],"genre_scores_gemma":[0.8923498,0.104528226,0.0006253407,0.00026828458,0.00035800933,0.0000020440991,0.0000014637667,0.0000526085,0.0018142244],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984321,0.00012663932,0.0005943995,0.00020515373,0.0004243191,0.00021737673],"domain_scores_gemma":[0.9990087,0.00033933864,0.00013750253,0.00020243536,0.00012235688,0.00018963854],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006801951,0.00018208908,0.00057231967,0.00081456226,0.00002509035,0.00004423274,0.00011031827,0.00010325088,0.0003570261],"category_scores_gemma":[0.00001574631,0.00012910814,0.00015976523,0.0004884317,0.00014570555,0.00013507322,0.000021635187,0.0004530488,0.0000017415988],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005979826,0.00037385695,0.0103784725,0.00024056992,0.0005201528,0.00042121965,0.012208545,0.0000064750843,0.8410748,0.00029915437,0.00080634246,0.12769057],"study_design_scores_gemma":[0.044643592,0.01136007,0.21568705,0.003120112,0.00021994596,0.0007305459,0.0011447817,0.0006907459,0.16580851,0.0042572618,0.55156285,0.0007745397],"about_ca_topic_score_codex":0.00024237084,"about_ca_topic_score_gemma":0.00009278516,"teacher_disagreement_score":0.6752663,"about_ca_system_score_codex":0.00013538366,"about_ca_system_score_gemma":0.00022166576,"threshold_uncertainty_score":0.5264877},"labels":[],"label_agreement":null},{"id":"W4403429512","doi":"10.1158/2326-6066.cir-24-0138","title":"Preclinical Development of T Cells Engineered to Express a T-Cell Antigen Coupler Targeting Claudin 18.2–Positive Solid Tumors","year":2024,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Hospital","funders":"","keywords":"Cancer research; Immunotherapy; Antigen; Chimeric antigen receptor; Cytotoxicity; Immunology; Cytotoxic T cell; In vivo; Medicine; In vitro; Chemistry; Immune system; Biology; Biochemistry","score_opus":0.09737323653413922,"score_gpt":0.4412458670481349,"score_spread":0.3438726305139957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403429512","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97826976,0.015383852,0.0004510341,0.0009902939,0.00053088827,0.001628835,0.000048060087,0.000103253384,0.0025940405],"genre_scores_gemma":[0.976228,0.0017764741,0.0022968603,0.00007801323,0.00033426718,0.00062540936,0.000046519926,0.000113716276,0.018500755],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9957147,0.00037811013,0.0008131752,0.00082076143,0.0010033025,0.0012699048],"domain_scores_gemma":[0.9970893,0.0010692844,0.00005400367,0.0005832866,0.00089273346,0.00031135388],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0028346914,0.00027026556,0.0007071926,0.00082277565,0.00018057328,0.000055737106,0.0005364447,0.00031135604,0.0061131297],"category_scores_gemma":[0.00034100958,0.00024617038,0.00016603705,0.0011822646,0.0005294217,0.000077876604,0.0005682781,0.0017847499,0.0004126174],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015445728,0.00022546393,0.0008906733,0.00040965807,0.0005265738,0.00016958122,0.0047112578,0.000055795,0.96254015,0.00001742195,0.011230249,0.017678618],"study_design_scores_gemma":[0.0010988519,0.0006899903,0.003786754,0.0008420872,0.000019296915,0.000015168372,0.00084758323,0.0006302129,0.94540703,0.000016671704,0.046421837,0.00022453813],"about_ca_topic_score_codex":0.00018147787,"about_ca_topic_score_gemma":0.000012692936,"teacher_disagreement_score":0.035191588,"about_ca_system_score_codex":0.0007041617,"about_ca_system_score_gemma":0.0025910607,"threshold_uncertainty_score":0.99999905},"labels":[],"label_agreement":null},{"id":"W4403431753","doi":"10.1038/s44321-024-00153-8","title":"Transient CAR T cells with specificity to oncofetal glycosaminoglycans in solid tumors","year":2024,"lang":"en","type":"article","venue":"EMBO Molecular Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health Research Institute; University of British Columbia; Vancouver Coastal Health","funders":"Canadian Institutes of Health Research - Antimicrobial Resistance Research Initiative; Stand Up To Cancer; Novo Nordisk Fonden; National Cancer Institute; National Institutes of Health; Canadian Urological Association Scholarship Fund; Canadian Institutes of Health Research; Canadian Urological Association; American Association for Cancer Research","keywords":"Glycosaminoglycan; Oncofetal antigen; Transient (computer programming); Cell biology; Chemistry; Biology; Medicine; Cancer research; Pathology; Internal medicine; Biochemistry; Cancer; Computer science; Immunotherapy","score_opus":0.018018849299157116,"score_gpt":0.3108578895756146,"score_spread":0.2928390402764575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403431753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95737875,0.0012056219,0.00505989,0.0100132525,0.0004169102,0.0014636448,0.000014007545,0.00015092304,0.024297006],"genre_scores_gemma":[0.99168634,0.00008419258,0.0005165464,0.0017553376,0.00047682258,0.000069233174,0.00004527613,0.000113952716,0.005252289],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9966556,0.000113097376,0.00049919484,0.0007572342,0.0012603073,0.0007145626],"domain_scores_gemma":[0.9985144,0.00009035035,0.000028216298,0.000634813,0.00011516222,0.00061702897],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006305739,0.00036135298,0.0007589459,0.0007127955,0.000037298385,0.000026448037,0.00021192216,0.00011156975,0.0025860625],"category_scores_gemma":[0.000056683435,0.0002628013,0.00012908853,0.0014067821,0.000253879,0.000048486498,0.00004464997,0.0007416357,0.00015825177],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008844394,0.00016274453,0.00013818537,0.00027903196,0.00013743782,0.016297271,0.0033874116,0.0002557243,0.9674329,0.00027008008,0.001960747,0.008793996],"study_design_scores_gemma":[0.009945931,0.010738548,0.0074298433,0.005984315,0.00041677745,0.0017183599,0.0028263784,0.0031299917,0.83777577,0.00019141453,0.11879487,0.0010477806],"about_ca_topic_score_codex":0.00041599784,"about_ca_topic_score_gemma":0.00020640323,"teacher_disagreement_score":0.12965715,"about_ca_system_score_codex":0.00037927448,"about_ca_system_score_gemma":0.00036035135,"threshold_uncertainty_score":0.9999824},"labels":[],"label_agreement":null},{"id":"W4403446436","doi":"10.1126/scitranslmed.adj9331","title":"Human OX40L–CAR-T <sub>regs</sub> target activated antigen-presenting cells and control T cell alloreactivity","year":2024,"lang":"en","type":"article","venue":"Science Translational Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institutes of Health","keywords":"FOXP3; Immunology; Adoptive cell transfer; Immune system; Antigen; T cell; Autoimmunity; Alloimmunity; Chimeric antigen receptor; Cytotoxic T cell; Biology; IL-2 receptor; In vitro","score_opus":0.02752573745987304,"score_gpt":0.32877610976273275,"score_spread":0.3012503723028597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403446436","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9814942,0.00096721685,0.0013999054,0.006210378,0.00040596453,0.000825929,0.000028047049,0.0001599465,0.008508452],"genre_scores_gemma":[0.99802446,0.000111288886,0.00024466924,0.00026394217,0.0006248858,0.000020828184,0.000034673925,0.000038181726,0.00063707755],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99615884,0.000089047244,0.00039935327,0.0008116654,0.0018791363,0.00066194707],"domain_scores_gemma":[0.9984531,0.0004291181,0.00006364686,0.00032481493,0.00026086083,0.00046850447],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020885747,0.00027217035,0.00044642467,0.0006670751,0.00040854944,0.00009084564,0.00023943113,0.000090195594,0.0010106942],"category_scores_gemma":[0.00010242921,0.00021334262,0.00009583154,0.0014231217,0.0017848357,0.00051305786,0.000035003915,0.0006100461,0.000029465578],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009995623,0.000087979366,0.0042477804,0.00015037786,0.000047913974,0.00008800592,0.0008749965,0.000030927764,0.98822314,0.00031080315,0.00022234989,0.005615775],"study_design_scores_gemma":[0.0027390332,0.00028104777,0.049765624,0.00026974842,0.0000748886,0.00006955353,0.0001395124,0.0074891783,0.9343934,0.0010488421,0.0035034558,0.00022570867],"about_ca_topic_score_codex":0.00008944093,"about_ca_topic_score_gemma":0.000011534081,"teacher_disagreement_score":0.053829726,"about_ca_system_score_codex":0.00009593174,"about_ca_system_score_gemma":0.0004900885,"threshold_uncertainty_score":0.99990255},"labels":[],"label_agreement":null},{"id":"W4403520285","doi":"10.1158/2326-6074.tumimm24-b012","title":"Abstract B012: Reviving exhausted T cells in pediatric B-cell acute lymphoblastic leukemia","year":2024,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital","funders":"","keywords":"Lymphoblastic Leukemia; Medicine; Cancer research; Immunology; Leukemia","score_opus":0.05261392441516446,"score_gpt":0.3874645670991617,"score_spread":0.3348506426839973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403520285","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93263596,0.050762724,0.000008222287,0.000945251,0.0008409575,0.001059453,0.000026027905,0.00016026745,0.013561144],"genre_scores_gemma":[0.90571856,0.049128905,0.00004192682,0.00007242505,0.00073695165,0.0004078076,0.000023486706,0.0001213122,0.043748595],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99556595,0.00033820412,0.0005792917,0.00092191575,0.0009581577,0.001636464],"domain_scores_gemma":[0.9972673,0.0012301794,0.00004566561,0.00083838915,0.0003804426,0.00023802341],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0022238542,0.00030388832,0.0005830525,0.0019171622,0.00015747594,0.00013393088,0.0005673095,0.00046604083,0.010058054],"category_scores_gemma":[0.00018841439,0.0002783864,0.00018120377,0.0029466017,0.00048037912,0.00017864528,0.0003735065,0.003002789,0.0017626256],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011108326,0.00017108677,0.0057184696,0.0013588801,0.00029325802,0.00253901,0.0005927523,0.000032883057,0.9424049,0.000039769726,0.01190887,0.033829235],"study_design_scores_gemma":[0.016828515,0.0028637024,0.29941687,0.0037088683,0.00056216365,0.0007469696,0.0013272036,0.0035956255,0.48668218,0.0005007991,0.18199196,0.0017751268],"about_ca_topic_score_codex":0.0010634795,"about_ca_topic_score_gemma":0.00010374635,"teacher_disagreement_score":0.45572275,"about_ca_system_score_codex":0.0035066474,"about_ca_system_score_gemma":0.0037874766,"threshold_uncertainty_score":0.99996686},"labels":[],"label_agreement":null},{"id":"W4403543517","doi":"10.1186/s12951-024-02898-3","title":"Antibody-targeted T cells and natural killer cells for cancer immunotherapy","year":2024,"lang":"en","type":"article","venue":"Journal of Nanobiotechnology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Cytotoxic T cell; Immune system; Cancer immunotherapy; Immunotherapy; Cancer cell; Chimeric antigen receptor; Antigen; Antibody; Natural killer T cell; Oncolytic virus; Cancer research; Immunology; Biology; T cell; Chemistry; Cancer; Biochemistry; In vitro","score_opus":0.012378514101285069,"score_gpt":0.33326258285996413,"score_spread":0.3208840687586791,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403543517","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89722395,0.07797891,0.0014702106,0.016194476,0.0061121695,0.00074570446,0.000016044645,0.00019111812,0.00006742835],"genre_scores_gemma":[0.95450824,0.030372417,0.0030926752,0.0005676893,0.0005956023,0.000014910851,0.0000061406417,0.00012259159,0.010719718],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99874073,0.000029999013,0.00041515045,0.00021862157,0.00023135959,0.00036414736],"domain_scores_gemma":[0.99920094,0.00015857628,0.00012544372,0.00020874228,0.0002228069,0.00008350468],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038985995,0.00017377114,0.0004909892,0.0006391511,0.000045017452,0.00004071237,0.00018175796,0.00039333475,0.0004471922],"category_scores_gemma":[0.000030947445,0.00012585138,0.00023109079,0.00037021356,0.00021367527,0.00008753325,0.00004046887,0.0009102062,0.0000063442712],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00065923407,0.000051900864,0.000045793633,0.0001295497,0.0004008545,0.00015326578,0.00014903405,0.000002259787,0.90350217,0.000084190666,0.00344607,0.09137567],"study_design_scores_gemma":[0.0014754653,0.00078215555,0.000083468156,0.0001698052,0.00005307668,0.00052454293,0.000071287366,0.00038290097,0.5815092,0.00019063512,0.41466478,0.00009270163],"about_ca_topic_score_codex":0.000018008695,"about_ca_topic_score_gemma":0.0000037514337,"teacher_disagreement_score":0.4112187,"about_ca_system_score_codex":0.00015744187,"about_ca_system_score_gemma":0.00025533268,"threshold_uncertainty_score":0.5132071},"labels":[],"label_agreement":null},{"id":"W4403602474","doi":"10.58931/cht.2023.2338","title":"Bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapy for indolent lymphoma","year":2023,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Chimeric antigen receptor; Lymphoma; Antibody; Bispecific antibody; Antigen; Medicine; Virology; Immunology; Antibody therapy; Cancer research; Immunotherapy; Monoclonal antibody; Immune system","score_opus":0.0350963459906627,"score_gpt":0.3005168672949186,"score_spread":0.2654205213042559,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403602474","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98495615,0.0047123744,0.000007291774,0.004927219,0.0004209813,0.0011918569,0.00008333714,0.0001155058,0.0035852902],"genre_scores_gemma":[0.97688884,0.006522119,0.00027832054,0.0013312292,0.00023494173,0.0001944,0.00022932832,0.000103300416,0.01421754],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981642,0.000068697256,0.00026361193,0.00047822588,0.00016580331,0.00085949537],"domain_scores_gemma":[0.99856734,0.00021210642,0.000052913125,0.00041889,0.000111482375,0.0006372928],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00030374792,0.00022858415,0.00052975817,0.000704661,0.00022785112,0.00003053924,0.00015586278,0.00023062735,0.0014701331],"category_scores_gemma":[0.000071752256,0.00021008695,0.000119262484,0.00053551665,0.00026885685,0.000041829826,0.00003114874,0.00013543245,0.0002907468],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00096358446,0.00020333832,0.26554647,0.00049719965,0.00055728,0.00070813607,0.003406832,0.0000013765247,0.24703145,0.0020195497,0.30820274,0.17086206],"study_design_scores_gemma":[0.005138131,0.00058910745,0.07051723,0.00008098828,0.0000235314,0.00035590515,0.00090687734,0.00012371715,0.07378168,0.00022957606,0.8478501,0.0004032098],"about_ca_topic_score_codex":0.0055730385,"about_ca_topic_score_gemma":0.0070688413,"teacher_disagreement_score":0.53964734,"about_ca_system_score_codex":0.00016469216,"about_ca_system_score_gemma":0.0007224753,"threshold_uncertainty_score":0.99944264},"labels":[],"label_agreement":null},{"id":"W4403622162","doi":"10.58931/cht.2023.2342","title":"Chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma: The evolving Canadian landscape","year":2023,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Gilead Sciences; Sanofi","keywords":"Chimeric antigen receptor; Multiple myeloma; Antigen; Immunology; Receptor; Medicine; Cancer research; Virology; Biology; Immunotherapy; Internal medicine; Immune system","score_opus":0.027811339048661968,"score_gpt":0.2724164986273658,"score_spread":0.24460515957870382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403622162","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96235025,0.0025950163,7.0036276e-7,0.014233512,0.0004677128,0.001043054,0.000053912547,0.000089802634,0.019166013],"genre_scores_gemma":[0.9882884,0.00064376346,0.000042898842,0.0022347164,0.00016627417,0.00012855443,0.00015789525,0.00008105114,0.00825642],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973006,0.0001985074,0.0003282807,0.0004732854,0.000236401,0.0014629021],"domain_scores_gemma":[0.99764824,0.00034970944,0.000049323146,0.0007079819,0.00010662961,0.0011380983],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0006168022,0.00025681022,0.000485885,0.0012252289,0.00033339043,0.000039967257,0.00040543906,0.00030360406,0.009503876],"category_scores_gemma":[0.00026482492,0.000206801,0.00012441666,0.0016357894,0.0001934172,0.00005973699,0.000031950083,0.0006183516,0.0014195843],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006236872,0.000031312316,0.83784664,0.000040058996,0.00009537912,0.0012402333,0.0020540575,0.000011136189,0.014552766,0.00013430652,0.13449326,0.009438511],"study_design_scores_gemma":[0.0036238953,0.00021462575,0.43161315,0.00009948407,0.000016424725,0.00040889578,0.0023375468,0.0020370295,0.007701049,0.000089128705,0.55131733,0.00054141134],"about_ca_topic_score_codex":0.7496027,"about_ca_topic_score_gemma":0.96905905,"teacher_disagreement_score":0.4168241,"about_ca_system_score_codex":0.00052396435,"about_ca_system_score_gemma":0.0030424048,"threshold_uncertainty_score":0.99935794},"labels":[],"label_agreement":null},{"id":"W4403709325","doi":"10.1182/blood.2024025454","title":"Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":69,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Spinal Cord Injury BC; Jewish General Hospital; BC Cancer Agency","funders":"Daiichi Sankyo Europe; Janssen Research and Development; Royal Adelaide Hospital; BeiGene; Incyte; F. Hoffmann-La Roche; Pharmacyclics; Genentech; MEI Pharma; Teva Pharmaceutical Industries; Kite Pharma; Gilead Sciences; TG Therapeutics; Amgen; Pfizer; MorphoSys; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Follicular lymphoma; Confidence interval; Refractory (planetary science); Gastroenterology; Adverse effect; Cytokine release syndrome; Surgery; Lymphoma; Immunotherapy; Cancer","score_opus":0.01866792604861877,"score_gpt":0.2919711297431507,"score_spread":0.2733032036945319,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403709325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98649627,0.010652905,0.0000057433595,0.0002311476,0.0002447455,0.0006967423,0.000013663423,0.000100497426,0.0015582975],"genre_scores_gemma":[0.9777855,0.0009375326,0.00018981667,0.00008793171,0.00019980856,0.000120274024,0.000015328686,0.00008976229,0.020574043],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9980583,0.00010053496,0.00041189833,0.00043107753,0.00059535855,0.00040283898],"domain_scores_gemma":[0.9989505,0.00016709647,0.0000450799,0.00062696624,0.00008310074,0.00012724675],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003702033,0.00022589925,0.00046674735,0.00035447895,0.000024188394,0.00004056824,0.00017150525,0.00020018355,0.004127756],"category_scores_gemma":[0.0000892104,0.00016756683,0.00024854674,0.0005609239,0.00011330005,0.000081578764,0.00007424782,0.00025602558,0.00010438854],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019353274,0.004469026,0.2563124,0.0031282704,0.0029867021,0.013686633,0.010134186,0.0000013027674,0.48482567,0.00015520779,0.00074923167,0.20419809],"study_design_scores_gemma":[0.07187207,0.005141206,0.73994815,0.0040014535,0.0009534694,0.00067515695,0.0005796507,0.00012973994,0.15130964,0.00024960638,0.024196258,0.0009435951],"about_ca_topic_score_codex":0.000071070375,"about_ca_topic_score_gemma":0.0001564537,"teacher_disagreement_score":0.48363575,"about_ca_system_score_codex":0.00013953779,"about_ca_system_score_gemma":0.0004329758,"threshold_uncertainty_score":0.9967826},"labels":[],"label_agreement":null},{"id":"W4403735421","doi":"10.1111/ejh.14331","title":"Distance to <scp>CAR</scp>‐T Treatment Center Does Not Impede Delivery","year":2024,"lang":"en","type":"article","venue":"European Journal Of Haematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Apheresis; Refractory (planetary science); Internal medicine; Chimeric antigen receptor; Single Center; Referral; Gastroenterology; Surgery; Immunotherapy; Cancer","score_opus":0.02730334715386731,"score_gpt":0.30890125878051883,"score_spread":0.28159791162665154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403735421","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97766703,0.002111943,0.00092031783,0.0038912788,0.0010026202,0.00023395335,0.000017691069,0.000046095058,0.0141090425],"genre_scores_gemma":[0.97716546,0.0008811786,0.00074547704,0.0007610571,0.0006575893,0.0000026460689,0.0000042744937,0.000078633915,0.019703671],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979657,0.00041886565,0.0005832781,0.00026264667,0.00034661102,0.0004229132],"domain_scores_gemma":[0.99871445,0.00032336861,0.000107511594,0.00030855477,0.00017313384,0.0003730092],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006395852,0.000205475,0.0005832108,0.00034883534,0.00005086472,0.00006497816,0.00022382519,0.0000348962,0.0005677414],"category_scores_gemma":[0.00016928771,0.00012291469,0.0002981264,0.00019628671,0.000100013116,0.000085129876,0.000079122125,0.0003675259,0.0006073604],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018218713,0.0009363229,0.012083004,0.0006123792,0.0025054582,0.37757903,0.008770201,0.000027499626,0.3832412,0.0014684147,0.08281806,0.12813656],"study_design_scores_gemma":[0.0023370779,0.0027429564,0.0023356203,0.00050610217,0.00015723218,0.034417212,0.0005539027,0.00004983985,0.043367393,0.00004203736,0.91340846,0.000082139195],"about_ca_topic_score_codex":0.000005518802,"about_ca_topic_score_gemma":0.000010262988,"teacher_disagreement_score":0.8305904,"about_ca_system_score_codex":0.00019131789,"about_ca_system_score_gemma":0.00014132545,"threshold_uncertainty_score":0.78065914},"labels":[],"label_agreement":null},{"id":"W4403859802","doi":"10.1182/bloodadvances.2024014555","title":"Cancer cachexia and weight loss before CAR T-cell therapy for lymphoma are independently associated with poor outcomes","year":2024,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"Janssen Biotech; Genentech; National Institutes of Health; Swedish Orphan Biovitrum; Omeros Corporation; Incyte; BeiGene; Angiocrine Bioscience; Parker Institute for Cancer Immunotherapy; Servier; Memorial Sloan-Kettering Cancer Center; National Cancer Institute; Medpace; Celgene; Gilead Sciences; Sanofi; Pfizer; Seres Therapeutics; Amgen","keywords":"Medicine; Weight loss; Cachexia; Internal medicine; Cancer; Lymphoma; Oncology; Obesity","score_opus":0.015093004599438645,"score_gpt":0.30787951075646797,"score_spread":0.29278650615702934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403859802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94818836,0.047663767,0.00001410952,0.0019342075,0.00022154392,0.0010172116,0.0001910392,0.00014713517,0.0006226431],"genre_scores_gemma":[0.9715767,0.0045483527,0.0001586721,0.00043660193,0.0002751831,0.00033830223,0.000047407506,0.00009286165,0.022525942],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99831086,0.00003572378,0.0002091774,0.0004946584,0.0004955708,0.00045403442],"domain_scores_gemma":[0.9991699,0.0002060956,0.00007883934,0.00021843181,0.00015933765,0.00016740792],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019239422,0.00027573004,0.00047527137,0.00013535975,0.000110411434,0.000073445386,0.00012527281,0.00012557868,0.00025780103],"category_scores_gemma":[0.00003772872,0.00017880189,0.0001207274,0.00027758005,0.00014271183,0.00018531337,0.000030267764,0.00017259258,0.0000041353974],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009615923,0.0006055286,0.8781882,0.00052946515,0.0015675101,0.0004202147,0.0009172582,0.0000066746943,0.010557531,0.00007141828,0.00042449546,0.10575013],"study_design_scores_gemma":[0.042437945,0.0045867967,0.5293767,0.0017783284,0.0012132019,0.00023601073,0.001319638,0.0004205951,0.12111948,0.0011774987,0.2951421,0.0011917186],"about_ca_topic_score_codex":0.000108516506,"about_ca_topic_score_gemma":0.0009002002,"teacher_disagreement_score":0.3488115,"about_ca_system_score_codex":0.00011909783,"about_ca_system_score_gemma":0.00025606406,"threshold_uncertainty_score":0.72913295},"labels":[],"label_agreement":null},{"id":"W4403931912","doi":"10.36401/jipo-24-23","title":"A Comprehensive Exploration of Agents Targeting Tumor Microenvironment: Challenges and Future Perspectives","year":2024,"lang":"en","type":"review","venue":"Journal of Immunotherapy and Precision Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vitalité Health Network; Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Tumor microenvironment; Engineering ethics; Computer science; Process management; Medicine; Business; Cancer research; Engineering; Tumor cells","score_opus":0.10760450098204283,"score_gpt":0.4100770395047811,"score_spread":0.30247253852273825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403931912","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011749656,0.9966276,0.000014485832,0.00088402856,0.00041406325,0.00063548837,0.000009395587,0.000005246376,0.0002346684],"genre_scores_gemma":[0.000041398802,0.9979146,0.00078791,0.00005253285,0.00082077226,0.000013565481,0.0000060238212,0.000054449254,0.00030872764],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99756914,0.0005974911,0.001012693,0.00028685862,0.00035065753,0.00018312648],"domain_scores_gemma":[0.9981059,0.00052236614,0.00088232395,0.0001904232,0.00019694063,0.000102088045],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00087355345,0.0003120451,0.0020794643,0.0005170572,0.00005297966,0.000021993603,0.00013565991,0.00031621335,0.0005055678],"category_scores_gemma":[0.00003724369,0.00020268267,0.0004249703,0.00012348617,0.00019478373,0.00014401434,0.000080419355,0.0009501819,0.000004633834],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011109251,0.00019441862,5.5167504e-7,0.0041940673,0.0010289525,0.00015862504,0.00780091,1.3626698e-7,0.0019995796,0.000025193796,0.00041264566,0.983074],"study_design_scores_gemma":[0.0015078792,0.0035104158,0.000030845233,0.007251455,0.000514942,0.0020300837,0.0054407194,0.0000022059385,0.000032694283,0.00017132268,0.9793751,0.00013233887],"about_ca_topic_score_codex":0.0000014330263,"about_ca_topic_score_gemma":4.7197446e-7,"teacher_disagreement_score":0.9829416,"about_ca_system_score_codex":0.0002325562,"about_ca_system_score_gemma":0.00026055714,"threshold_uncertainty_score":0.8265159},"labels":[],"label_agreement":null},{"id":"W4403972887","doi":"10.1101/2024.10.30.621196","title":"A novel miniaturized filamentous phagemid as a gene delivery vehicle to target mammalian cells","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"","keywords":"Phagemid; Gene delivery; Gene; Computational biology; Biology; Cell biology; Genetics; Bacteriophage; Genetic enhancement","score_opus":0.018789707945636794,"score_gpt":0.2602479113905176,"score_spread":0.24145820344488084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403972887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98838544,0.0029805636,0.00013664788,0.0011954611,0.0020052684,0.003527391,0.00085854944,0.0007560763,0.00015460083],"genre_scores_gemma":[0.9594885,0.00038240125,0.03190106,0.0023069603,0.0020288853,0.0009774421,0.0000026386115,0.0006123528,0.0022997581],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9943197,0.0001377112,0.0008445988,0.0020462584,0.0013279528,0.0013237965],"domain_scores_gemma":[0.9952864,0.00011327115,0.00023156812,0.002382141,0.00074057956,0.0012460167],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0009818106,0.0009805476,0.0012377806,0.0008864839,0.00013940371,0.00043984255,0.00081737153,0.0008852328,0.002631956],"category_scores_gemma":[0.00021450741,0.0010309119,0.00053031085,0.0011928518,0.00014392237,0.000075392374,0.0017959713,0.0021448738,0.0023896724],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00079235295,0.00049131445,0.000082505794,0.0012099289,0.0006667838,0.002262344,0.00005764251,0.00002804158,0.99009544,0.000038127746,0.004262847,0.000012667236],"study_design_scores_gemma":[0.0021117781,0.00034192333,0.0026287192,0.00083942915,0.0003430039,6.0105333e-7,0.000006270485,0.00033138428,0.92108643,0.0000031543984,0.07137571,0.00093161664],"about_ca_topic_score_codex":0.00036180386,"about_ca_topic_score_gemma":0.0000043457276,"teacher_disagreement_score":0.069009036,"about_ca_system_score_codex":0.0011427477,"about_ca_system_score_gemma":0.0020618008,"threshold_uncertainty_score":0.9992141},"labels":[],"label_agreement":null},{"id":"W4404007927","doi":"10.1002/prp2.70024","title":"Identification of cytokine release syndrome and indicators of severity in retrospective databases among patients receiving immunotherapy","year":2024,"lang":"en","type":"article","venue":"Pharmacology Research & Perspectives","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Ipsen; Flatiron Health; Pharmacyclics; BeiGene; Janssen Scientific Affairs; Servier; TG Therapeutics; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Retrospective cohort study; Tocilizumab; Lasso (programming language); Database; Internal medicine; Emergency medicine; Computer science; Rheumatoid arthritis","score_opus":0.03275787449147814,"score_gpt":0.40947439796442814,"score_spread":0.37671652347295,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404007927","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9933927,0.003989024,0.000012059368,0.00043765147,0.00010721324,0.0012637915,0.00011169491,0.000038037335,0.00064782414],"genre_scores_gemma":[0.99360937,0.005487781,0.000039225066,0.000008912403,0.000055944914,0.00012107276,0.000023672801,0.00004066983,0.00061332434],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99680585,0.0007403943,0.00050587434,0.0006485328,0.0008377967,0.00046157252],"domain_scores_gemma":[0.9981492,0.00069482066,0.000108257984,0.00032783812,0.00057093456,0.00014891208],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002651147,0.0001665627,0.0004878026,0.0019758337,0.00008972527,0.000022445465,0.00020367793,0.000097674725,0.0014013529],"category_scores_gemma":[0.0006635059,0.00015827807,0.000087361994,0.0020058083,0.0016036967,0.00033027865,0.00019173043,0.0010887685,0.000006519209],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013834682,0.0009098561,0.4782085,0.00038982887,0.00038767868,0.000118002856,0.0067465166,0.0000011707806,0.50658864,0.00019842648,0.00031125412,0.0047566523],"study_design_scores_gemma":[0.0017729,0.000652008,0.88581634,0.00021124768,0.000034686847,0.000020270492,0.002120243,0.0002686622,0.10862464,0.00018915503,0.0001831173,0.00010672625],"about_ca_topic_score_codex":0.0004945482,"about_ca_topic_score_gemma":0.00004359592,"teacher_disagreement_score":0.40760782,"about_ca_system_score_codex":0.00066265184,"about_ca_system_score_gemma":0.00030911824,"threshold_uncertainty_score":0.9995115},"labels":[],"label_agreement":null},{"id":"W4404016752","doi":"10.1101/2024.10.29.620998","title":"Tunable differentiation of human CD4+ and CD8+ T cells from pluripotent stem cells","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; University of British Columbia","funders":"","keywords":"Induced pluripotent stem cell; Human Induced Pluripotent Stem Cells; Stem cell; Cell biology; CD8; Biology; Embryonic stem cell; Genetics; Immune system; Gene","score_opus":0.021703536406994437,"score_gpt":0.2500414394659735,"score_spread":0.22833790305897908,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404016752","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99291736,0.0035034744,0.00009351855,0.00015354893,0.0011426635,0.0014080382,0.0004847092,0.00025634162,0.0000403304],"genre_scores_gemma":[0.9972278,0.00084127614,0.000496238,0.000058505913,0.00061097456,0.00011759969,0.0000016190982,0.00021667242,0.00042935397],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99637324,0.00016061057,0.00078525255,0.0012434549,0.00086558575,0.0005718891],"domain_scores_gemma":[0.9971465,0.00009889202,0.00035239698,0.0015127524,0.00047673064,0.00041272363],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005460892,0.00060353347,0.0010553767,0.0004981714,0.00010219729,0.00020797583,0.00035061446,0.00064289995,0.0008098816],"category_scores_gemma":[0.000018775008,0.0005980345,0.0002704902,0.00038731113,0.00018518887,0.000062103085,0.000981302,0.001323571,0.000096714924],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010260335,0.00023092752,0.0017861802,0.002160211,0.00056012545,0.000095457704,0.000048047925,0.000009960201,0.9944078,0.0001166734,0.0004664887,0.000015573678],"study_design_scores_gemma":[0.0010341075,0.00017397296,0.015849458,0.0013507251,0.00049304013,1.6191386e-8,0.0000102379945,0.00052927656,0.97806484,0.000014941108,0.0019982082,0.000481162],"about_ca_topic_score_codex":0.0004245322,"about_ca_topic_score_gemma":0.0000066719335,"teacher_disagreement_score":0.016342897,"about_ca_system_score_codex":0.00042401763,"about_ca_system_score_gemma":0.00048172285,"threshold_uncertainty_score":0.9996471},"labels":[],"label_agreement":null},{"id":"W4404064412","doi":"10.1136/jitc-2024-sitc2024.0361","title":"361 Early differentiation and memory transcription programs drive long-term persistence of NY-ESO-1 specific TCR-T cells in adoptive cell therapy","year":2024,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"T-cell receptor; Term (time); Persistence (discontinuity); Biology; Computer science; T cell; Immunology; Physics; Engineering; Immune system","score_opus":0.035798880816205,"score_gpt":0.2570067381479863,"score_spread":0.2212078573317813,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404064412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905348,0.0074482523,0.000027498507,0.00026499096,0.00024462125,0.0009907808,0.000012910481,0.00006136577,0.00041479393],"genre_scores_gemma":[0.9948377,0.003194623,0.00021575259,0.00003220604,0.00012383757,0.000030472822,0.000057156307,0.000047183043,0.0014610969],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99809605,0.00009960517,0.00041089414,0.0005312538,0.00051062356,0.0003515978],"domain_scores_gemma":[0.99911803,0.000048234953,0.000085045,0.00026423685,0.00010142605,0.00038304247],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038010487,0.00026555042,0.00039389372,0.00027260522,0.000058551974,0.00013768983,0.000090128,0.00020108068,0.00007317883],"category_scores_gemma":[0.000012336704,0.00023272594,0.0001332966,0.0002982597,0.00048407205,0.0002439378,0.000021626129,0.00042500443,0.0000069760736],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025986135,0.0002161864,0.038553733,0.00066064246,0.00008994786,0.00014686644,0.006412554,0.0000045163206,0.9325042,0.00003331924,0.000058611324,0.021059602],"study_design_scores_gemma":[0.0015110129,0.00068505574,0.5453105,0.0006648677,0.00006741556,0.000059010425,0.0005585801,0.00016117674,0.4502512,0.000109015884,0.00039717165,0.00022502753],"about_ca_topic_score_codex":0.00009978317,"about_ca_topic_score_gemma":0.000031166634,"teacher_disagreement_score":0.5067567,"about_ca_system_score_codex":0.00010703714,"about_ca_system_score_gemma":0.00016171928,"threshold_uncertainty_score":0.94902885},"labels":[],"label_agreement":null},{"id":"W4404064451","doi":"10.1136/jitc-2024-sitc2024.1291","title":"1291 Profiling bispecific T-cell engagers: strategies for enhancing potency while minimizing cytokine release","year":2024,"lang":"en","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AbCellera (Canada)","funders":"","keywords":"Profiling (computer programming); Potency; Computer science; Bispecific antibody; Cytokine; Human–computer interaction; Chemistry; Medicine; Immunology; Antibody; Operating system","score_opus":0.03727982372611302,"score_gpt":0.2903729767150358,"score_spread":0.25309315298892276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404064451","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9802872,0.0070718187,0.0007447023,0.0014980761,0.0006876608,0.0013985009,0.00005740968,0.00041285646,0.007841781],"genre_scores_gemma":[0.9852941,0.0005128043,0.006235303,0.00019640203,0.00094086694,0.000113202645,0.00011801734,0.00014059248,0.0064487164],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99719334,0.000086053165,0.0006155145,0.0007989358,0.0005687778,0.0007373813],"domain_scores_gemma":[0.9981292,0.00029579172,0.000095930765,0.00047252205,0.00018434139,0.00082221226],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011593591,0.0003927421,0.0005071518,0.00033475875,0.0002865548,0.000496954,0.0001459186,0.00025623903,0.00012864894],"category_scores_gemma":[0.00040751437,0.0003554688,0.00023972889,0.00037721213,0.00028200078,0.0004402167,0.000057449426,0.0007424626,0.000036683552],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017148316,0.00007828364,0.00023667375,0.0023068902,0.00011780546,0.00038230055,0.0011908703,0.00006926855,0.9880864,0.0009553593,0.002558073,0.0038465739],"study_design_scores_gemma":[0.0017131179,0.00048825087,0.0006736858,0.0014525689,0.0002547257,0.00042698585,0.004905349,0.0027248827,0.92446244,0.0021392514,0.060159173,0.00059957564],"about_ca_topic_score_codex":0.0000950967,"about_ca_topic_score_gemma":0.000029439329,"teacher_disagreement_score":0.06362398,"about_ca_system_score_codex":0.00017195364,"about_ca_system_score_gemma":0.0012993388,"threshold_uncertainty_score":0.99988973},"labels":[],"label_agreement":null},{"id":"W4404133614","doi":"10.1002/cac2.12624","title":"FOXO1 or not FOXO1: that is the question","year":2024,"lang":"en","type":"article","venue":"Cancer Communications","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Nautical Research Society","funders":"Ligue Contre le Cancer; Bristol-Myers Squibb","keywords":"FOXO1; Cytotoxic T cell; Granzyme B; Biology; Cell biology; Transcription factor; Cancer research; Chemistry; In vitro; Biochemistry; Gene","score_opus":0.20355240978209913,"score_gpt":0.4773397007046023,"score_spread":0.2737872909225032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404133614","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.021978255,0.07610897,0.0011102865,0.77606374,0.00095876865,0.0024869505,0.0002064698,0.0007390058,0.12034752],"genre_scores_gemma":[0.8744871,0.028224535,0.00059608533,0.0045870654,0.0002628853,0.00068489125,0.00004972994,0.000046016896,0.09106169],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99912775,0.00012800841,0.00014219244,0.00016488483,0.00025644086,0.0001807106],"domain_scores_gemma":[0.9971877,0.00049247255,0.00002371722,0.0021126205,0.00010838927,0.000075133394],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00035038608,0.00009369826,0.00012467912,0.00007918862,0.00025586656,0.00008792768,0.0006015767,0.000059940514,0.0061646462],"category_scores_gemma":[0.000058470207,0.000057984238,0.00009655617,0.00042466383,0.0002498872,0.000081361235,0.00022356746,0.0004927338,0.00023908878],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049716816,0.0002121412,0.0019825047,0.00028724468,0.0007048007,0.000017470475,0.00867568,0.000007761113,0.051258076,0.024973443,0.21477132,0.6966124],"study_design_scores_gemma":[0.00026106767,0.000056296758,0.0028598022,0.0002881256,0.000112990056,0.00002757193,0.00029226922,0.0028105574,0.0055659916,0.00044052428,0.9872038,0.00008101641],"about_ca_topic_score_codex":0.0007038311,"about_ca_topic_score_gemma":0.00080497854,"teacher_disagreement_score":0.85250884,"about_ca_system_score_codex":0.0002604993,"about_ca_system_score_gemma":0.00041608166,"threshold_uncertainty_score":0.9947438},"labels":[],"label_agreement":null},{"id":"W4404167351","doi":"10.4049/jimmunol.212.supp.1545.5087","title":"HLA-A2 Chimeric antigen receptor regulatory T cells promote allograft acceptance in mice","year":2024,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Chimeric antigen receptor; Human leukocyte antigen; Immunology; Receptor; Antigen; Biology; Cell biology; Immunotherapy; Immune system; Genetics","score_opus":0.016811387056162932,"score_gpt":0.299077918084197,"score_spread":0.28226653102803406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404167351","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96155244,0.03204416,0.000029826615,0.0041991826,0.0009391404,0.0002973323,0.0000018650737,0.000024456755,0.00091157306],"genre_scores_gemma":[0.9773451,0.013134986,0.00044410783,0.00026065565,0.00040859292,0.0000039739675,0.0000017889222,0.00005101103,0.008349802],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99831533,0.00029188502,0.0005371827,0.00015007053,0.000317782,0.00038773485],"domain_scores_gemma":[0.9990596,0.00022688833,0.00016187716,0.00035432418,0.00013251981,0.00006474868],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016423459,0.00015542454,0.00043051795,0.0003847866,0.00004742431,0.000021809185,0.00044302177,0.00014192834,0.0026315835],"category_scores_gemma":[0.000072094525,0.00009941377,0.00016994859,0.00056701177,0.0003059804,0.00011394958,0.00008797853,0.0011988389,0.00014620398],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010814382,0.00009300599,0.00022363348,0.000037551985,0.00039178823,0.00015422849,0.0013430951,0.000009467017,0.9505445,0.000020679605,0.002231564,0.043869052],"study_design_scores_gemma":[0.0021826753,0.0020251137,0.027668322,0.0005965821,0.00012960783,0.0031600469,0.00080127566,0.00015639175,0.7321844,0.00026208346,0.23061134,0.000222137],"about_ca_topic_score_codex":0.00003860336,"about_ca_topic_score_gemma":0.000009665236,"teacher_disagreement_score":0.22837977,"about_ca_system_score_codex":0.00019436152,"about_ca_system_score_gemma":0.0003250184,"threshold_uncertainty_score":0.99828017},"labels":[],"label_agreement":null},{"id":"W4404167771","doi":"10.4049/jimmunol.212.supp.0263.5530","title":"Highly efficient non-viral delivery of macromolecules to unactivated human T cells using microfluidic transfection","year":2024,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stemcell Technologies","funders":"","keywords":"Transfection; Macromolecule; Microfluidics; Nanotechnology; Gene delivery; Cell biology; Chemistry; Materials science; Biology; Biochemistry; Gene","score_opus":0.01835528357172901,"score_gpt":0.30085329056671184,"score_spread":0.28249800699498284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404167771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913941,0.0054029566,0.0017532486,0.00053865736,0.00049533276,0.00024325775,0.0000034667119,0.0000126462,0.0001563058],"genre_scores_gemma":[0.99868625,0.00072812376,0.00007833908,0.00005597958,0.000113463655,8.042399e-7,0.0000011134498,0.000028670527,0.00030727207],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987234,0.00022961873,0.0004487731,0.000101795704,0.00025058433,0.00024585347],"domain_scores_gemma":[0.99929833,0.0001371481,0.000089723704,0.00020008703,0.00022030683,0.000054376113],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00073674717,0.00012188824,0.00034047273,0.00047883907,0.00007594824,0.0000131749985,0.00018854692,0.00009494999,0.00025519088],"category_scores_gemma":[0.000013404939,0.000081150276,0.00018117734,0.00037722097,0.00017077559,0.00003494779,0.000040637566,0.0005425404,0.000017136135],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016856693,0.00012509419,0.000013282173,0.000058082984,0.0004934628,0.00010977933,0.0013550287,0.0002052144,0.9921957,0.000017222852,0.00019524097,0.0035462035],"study_design_scores_gemma":[0.00094832835,0.0020145832,0.0006730259,0.00031437923,0.00019679913,0.0012325514,0.00039207857,0.00021081921,0.99305665,0.00002201882,0.0008729174,0.00006584563],"about_ca_topic_score_codex":0.00024938016,"about_ca_topic_score_gemma":0.0000017848529,"teacher_disagreement_score":0.0072921054,"about_ca_system_score_codex":0.00026902664,"about_ca_system_score_gemma":0.00020917333,"threshold_uncertainty_score":0.33092123},"labels":[],"label_agreement":null},{"id":"W4404200734","doi":"10.1016/j.mednuc.2024.10.007","title":"Évaluation en TEP 18F-FDG de la réponse au traitement par CAR T-Cells et anticorps bispécifiques des lymphomes non hodgkiniens agressifs","year":2024,"lang":"fr","type":"article","venue":"Médecine Nucléaire","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Molecular biology; Chemistry; Gynecology; Biology; Medicine","score_opus":0.039029945066124394,"score_gpt":0.357018279699197,"score_spread":0.31798833463307263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404200734","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9537151,0.0236085,0.0015985197,0.0074737943,0.0023724386,0.0015105198,0.00015546306,0.00034971183,0.00921595],"genre_scores_gemma":[0.9477508,0.014824388,0.0033290705,0.0007240804,0.002587505,0.0001441522,0.00011627582,0.00030125404,0.030222477],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99227196,0.0026925488,0.00093119894,0.0011074271,0.0013755215,0.0016213283],"domain_scores_gemma":[0.99549705,0.0024271368,0.0001421484,0.0009375302,0.00029155987,0.0007045891],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0074597723,0.00076642644,0.00095597777,0.0007460306,0.0003196882,0.00044834416,0.0004468782,0.0005309148,0.005510497],"category_scores_gemma":[0.0006923986,0.000705971,0.00051217026,0.0010933013,0.0010283488,0.00039629472,0.00022502732,0.0009916617,0.00076322444],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006431743,0.0012864826,0.015732422,0.0022450557,0.0006978749,0.002242141,0.024709022,0.00029464948,0.52550894,0.0007338671,0.019385872,0.4065205],"study_design_scores_gemma":[0.011214728,0.00314376,0.33825198,0.015440107,0.0017061186,0.0016481578,0.0046527414,0.06022546,0.2419375,0.00419217,0.31585124,0.001736026],"about_ca_topic_score_codex":0.0020058937,"about_ca_topic_score_gemma":0.0003498841,"teacher_disagreement_score":0.40478447,"about_ca_system_score_codex":0.0028689646,"about_ca_system_score_gemma":0.0026888365,"threshold_uncertainty_score":0.99953914},"labels":[],"label_agreement":null},{"id":"W4404212319","doi":"10.1016/j.autrev.2024.103687","title":"Harnessing the potential of CAR-T cell in lupus treatment: From theory to practice","year":2024,"lang":"en","type":"review","venue":"Autoimmunity Reviews","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Immunology; Medicine; Systemic lupus erythematosus; Lupus nephritis; Chimeric antigen receptor; Antigen; Immune system; CD19; Antibody; T cell; Disease; Internal medicine","score_opus":0.08939971251358837,"score_gpt":0.412783016538474,"score_spread":0.32338330402488563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404212319","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00002837113,0.9877639,0.000038072147,0.00028944082,0.0008403004,0.0053384653,0.00007171812,0.000041715655,0.0055880444],"genre_scores_gemma":[0.0000071803424,0.96721697,0.00045047697,0.000195592,0.00024833478,0.000508178,0.00025375135,0.00013572734,0.030983798],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99176186,0.0050470293,0.0016397568,0.00058070867,0.00049531495,0.00047529984],"domain_scores_gemma":[0.99512583,0.0016177854,0.00061384996,0.0023810875,0.00011868287,0.00014277823],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00412796,0.00070024264,0.004070736,0.0004044032,0.00011622396,0.00010307629,0.00073886046,0.00035283767,0.0017440049],"category_scores_gemma":[0.00090152,0.00037430302,0.0014791796,0.0013937164,0.00017276904,0.000108327455,0.0003890154,0.0017744303,0.0012552354],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008935282,0.00033956653,9.4143786e-7,0.014779561,0.00038765647,0.0001400489,0.001132479,2.8388763e-7,0.00022964927,0.000032850116,0.00085419056,0.9820134],"study_design_scores_gemma":[0.00042471904,0.0002523925,0.000004173568,0.029619005,0.0060423375,0.00019297116,0.00024569267,0.0000037241489,0.000013689834,0.00008582402,0.96285063,0.00026481092],"about_ca_topic_score_codex":0.0020213227,"about_ca_topic_score_gemma":0.00006228112,"teacher_disagreement_score":0.9817486,"about_ca_system_score_codex":0.00076568534,"about_ca_system_score_gemma":0.0010049186,"threshold_uncertainty_score":0.9998709},"labels":[],"label_agreement":null},{"id":"W4404236843","doi":"10.1093/neuonc/noae165.0982","title":"EXTH-51. ENHANCING GLIOBLASTOMA TREATMENT: ALLOGENEIC CAR-T CELLS OVERCOMES FUNCTIONAL DEFICITS OF PATIENT-DERIVED AUTOLOGOUS PRODUCTS","year":2024,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; McMaster University Medical Centre; University of Toronto; McMaster University","funders":"","keywords":"Glioblastoma; Cancer research; Medicine","score_opus":0.02533520469584187,"score_gpt":0.29759105269736946,"score_spread":0.2722558480015276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404236843","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920336,0.0014949106,0.000026053332,0.0017952637,0.0016936833,0.0011387311,0.000023513308,0.00019955047,0.0015946655],"genre_scores_gemma":[0.9968767,0.00052540307,0.00034941966,0.0004773915,0.00043676177,0.00012841327,0.00003755826,0.00008699095,0.001081346],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99736935,0.00025952494,0.0005362391,0.00079025305,0.0004708583,0.0005737756],"domain_scores_gemma":[0.9982419,0.0006719806,0.00011272987,0.0005045184,0.0002565897,0.00021228315],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001652744,0.00032670682,0.00077065954,0.00044842451,0.000080393605,0.000021285237,0.00010249979,0.0002879209,0.0015029251],"category_scores_gemma":[0.00017458148,0.00027390974,0.00025627602,0.00055737415,0.00022496963,0.000072688184,0.000106430634,0.0004180797,0.00014227096],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019042845,0.00056422816,0.00031699231,0.00023587575,0.00027039973,0.001409669,0.0012771473,0.000055204928,0.9135594,0.000043438038,0.0011774285,0.07918595],"study_design_scores_gemma":[0.0016047426,0.01190836,0.00088024413,0.000047879115,0.00018949262,0.0016837128,0.0001688939,0.00012167901,0.84507066,0.000024170273,0.13814984,0.0001503263],"about_ca_topic_score_codex":0.000049495604,"about_ca_topic_score_gemma":0.00008285135,"teacher_disagreement_score":0.13697241,"about_ca_system_score_codex":0.000771415,"about_ca_system_score_gemma":0.0014185372,"threshold_uncertainty_score":0.99997133},"labels":[],"label_agreement":null},{"id":"W4404280348","doi":"10.1101/2024.11.11.623124","title":"TCR-TRANSLATE: Conditional Generation of Real Antigen Specific T-cell Receptor Sequences","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"T-cell receptor; Computational biology; Antigen; Receptor; Computer science; Biology; Cell biology; T cell; Immunology; Genetics; Immune system","score_opus":0.04128630541710477,"score_gpt":0.287002876138793,"score_spread":0.24571657072168823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404280348","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889614,0.005717857,0.000277844,0.00056549296,0.0016373409,0.0013379075,0.000929443,0.00029823298,0.00027447936],"genre_scores_gemma":[0.9849483,0.0083543435,0.0038790936,0.00006490732,0.002195211,0.00014940034,0.000017014565,0.00018698546,0.0002047931],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.996215,0.00017882953,0.00082105346,0.0011570267,0.0010803888,0.00054771535],"domain_scores_gemma":[0.9973618,0.00007378523,0.0002920166,0.0011237657,0.0008134677,0.00033519248],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008817705,0.000543718,0.000812692,0.00055358844,0.000102641134,0.0001576159,0.00038555503,0.0006977676,0.003283389],"category_scores_gemma":[0.000040166866,0.0005521971,0.0003439838,0.0006540205,0.00034141017,0.00008546101,0.0002487429,0.0013279428,0.00035485096],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014531253,0.00017188943,0.0019158623,0.0010234509,0.0002914045,0.00012546824,0.000035367208,0.00003928731,0.9923625,0.00054053107,0.0033366925,0.000012239617],"study_design_scores_gemma":[0.00075887877,0.00017453518,0.0063605034,0.00054222037,0.0001047579,9.346428e-8,0.0000047913622,0.00038786168,0.9657307,0.000013199903,0.025424747,0.00049768947],"about_ca_topic_score_codex":0.00009697136,"about_ca_topic_score_gemma":0.000003606617,"teacher_disagreement_score":0.026631773,"about_ca_system_score_codex":0.00043231365,"about_ca_system_score_gemma":0.0017645994,"threshold_uncertainty_score":0.999693},"labels":[],"label_agreement":null},{"id":"W4404435807","doi":"10.17615/d5s2-9s76","title":"Chimeric antigen receptor T-cell infusion for large B-cell lymphoma in complete remission: a center for international blood and marrow transplant research analysis","year":2024,"lang":"en","type":"article","venue":"UNC Libraries","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute; Office of Naval Research; National Heart, Lung, and Blood Institute; Legend Biotech; bluebird bio; Alexion Pharmaceuticals; Pharmacyclics; Novavax; Adaptive Biotechnologies; Health Resources and Services Administration; Kite Pharma; Takeda Oncology; AstraZeneca; Genentech; MorphoSys; Syndax Pharmaceuticals; Seagen; CTI Biopharma; CareDx; BeiGene; Juno Therapeutics; Swedish Orphan Biovitrum; Astellas Pharma; Atara Biotherapeutics; Jazz Pharmaceuticals; National Institutes of Health; Regeneron Pharmaceuticals; MEI Pharma; Omeros Corporation; Karyopharm Therapeutics; HistoGenetics; Gateway for Cancer Research; Celgene; Mallinckrodt Pharmaceuticals; Spectrum Pharmaceuticals; Actinium Pharmaceuticals; Gilead Sciences; TG Therapeutics; Sanofi; Kiadis Pharma; GlaxoSmithKline; aTyr; CSL Behring; Bristol-Myers Squibb; Eli Lilly and Company; Vertex Pharmaceuticals; Astellas Pharma US; Amgen; Novartis Pharmaceuticals Corporation; Incyte; Pfizer","keywords":"Chimeric antigen receptor; Lymphoma; Medicine; Immunology; B cell; Bone marrow; Antigen; T cell; Antibody; Immune system","score_opus":0.044171672301916605,"score_gpt":0.32548263219582957,"score_spread":0.28131095989391297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404435807","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9715971,0.007133452,0.0022948051,0.005841644,0.0007119242,0.0027697699,0.0018183755,0.00016103747,0.0076719113],"genre_scores_gemma":[0.93822986,0.0013606722,0.015525496,0.00037066775,0.0009876433,0.00036525712,0.003424653,0.000121731384,0.039614048],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980062,0.00010301357,0.00034854404,0.0005205729,0.0005181501,0.00050346705],"domain_scores_gemma":[0.998666,0.0006603784,0.00003212721,0.0002555547,0.00021079852,0.0001751669],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00083208206,0.00017652182,0.0003686312,0.0009916693,0.00014809107,0.00023354011,0.00020557553,0.0001308872,0.0015941339],"category_scores_gemma":[0.00013132597,0.00014515503,0.00021365518,0.00097026146,0.000112340815,0.00024014532,0.00011244888,0.0002140861,0.000011064591],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009633937,0.003560631,0.13176447,0.0031647247,0.0020349056,0.00017273288,0.009747966,0.0000036402653,0.7617111,0.009712086,0.05072838,0.0177654],"study_design_scores_gemma":[0.014216354,0.0007640079,0.0037893543,0.00045667376,0.00027326323,0.0000148369145,0.000532996,0.011728704,0.08738071,0.0020708297,0.87846935,0.0003029377],"about_ca_topic_score_codex":0.000039803952,"about_ca_topic_score_gemma":0.000027215068,"teacher_disagreement_score":0.82774097,"about_ca_system_score_codex":0.00005932766,"about_ca_system_score_gemma":0.00024355832,"threshold_uncertainty_score":0.99931854},"labels":[],"label_agreement":null},{"id":"W4404446714","doi":"10.1016/j.autrev.2024.103692","title":"Treatment of two pediatric patients with refractory systemic lupus erythematosus using CD19-targeted CAR T-cells","year":2024,"lang":"en","type":"review","venue":"Autoimmunity Reviews","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"MD Precision (Canada)","funders":"National Key Research and Development Program of China","keywords":"Refractory (planetary science); Medicine; CD19; Immunology; Antibody; Biology","score_opus":0.0895292656332639,"score_gpt":0.3761407201750377,"score_spread":0.2866114545417738,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404446714","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007904528,0.98182535,0.000003977611,0.0000024564608,0.0008068816,0.008819207,0.0001668795,0.00010999998,0.00036073636],"genre_scores_gemma":[0.000100270394,0.9925652,0.00030330266,0.00000792758,0.00029643674,0.00038011983,0.0006482871,0.00030748846,0.005390925],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9936054,0.0016208366,0.0024188643,0.00079138816,0.00086116575,0.00070235983],"domain_scores_gemma":[0.99497694,0.00032291794,0.0014592389,0.0026242738,0.00034319266,0.00027346393],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009038387,0.0012336964,0.0075129718,0.000864561,0.00013109732,0.00005171451,0.0005053086,0.00043328333,0.0005825513],"category_scores_gemma":[0.00008873438,0.0007276,0.0018488131,0.0017676551,0.00015920865,0.0000929631,0.00018018261,0.0011116224,0.00053168385],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000095788,0.0013174863,0.00045786647,0.2333818,0.0014452043,0.00014711349,0.00046785927,6.1670414e-7,0.00020129349,0.000004964064,0.00036577994,0.7621142],"study_design_scores_gemma":[0.0020176454,0.001447086,0.000004934549,0.047761448,0.014439569,0.0007559626,0.000019752631,0.000007956648,0.000007741813,0.0000016921881,0.9329778,0.0005584024],"about_ca_topic_score_codex":0.00024531104,"about_ca_topic_score_gemma":0.0000067801416,"teacher_disagreement_score":0.932612,"about_ca_system_score_codex":0.0020362001,"about_ca_system_score_gemma":0.0015492437,"threshold_uncertainty_score":0.9995175},"labels":[],"label_agreement":null},{"id":"W4404515472","doi":"10.1016/bs.mcb.2024.10.017","title":"Retrovirus-based manufacturing of chimeric antigen receptor-modified T cells for cancer therapy research","year":2024,"lang":"en","type":"article","venue":"Methods in cell biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"European Research Council; Hector Stiftung; Elitenetzwerk Bayern; José Carreras Leukämie-Stiftung; Ludwig-Maximilians-Universität München; Deutsche Forschungsgemeinschaft; Fritz-Bender-Stiftung; Bundesministerium für Bildung und Forschung; Deutsche Krebshilfe; Wilhelm Sander-Stiftung; Else Kröner-Fresenius-Stiftung; Bayerische Forschungsstiftung; Melanoma Research Alliance","keywords":"Biology; Retrovirus; Chimeric antigen receptor; Antigen; Cancer therapy; Virology; Cancer; Computational biology; Immunology; Cancer research; Immunotherapy; Genetics; Virus","score_opus":0.21418299738036933,"score_gpt":0.5361122738648615,"score_spread":0.32192927648449216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404515472","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93605703,0.020859765,0.022986064,0.001180077,0.0018202165,0.0031346034,0.000104131526,0.00012532064,0.013732792],"genre_scores_gemma":[0.68334866,0.016118493,0.28547478,0.00040378008,0.000896935,0.0009354081,0.00009386391,0.00020714068,0.012520985],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99620366,0.001629211,0.00048787828,0.0006747882,0.00025321235,0.0007512506],"domain_scores_gemma":[0.99576104,0.003369001,0.000062569874,0.0005450577,0.00014810626,0.00011422153],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.006490172,0.0002152009,0.0006310118,0.0008945169,0.00006334878,0.00001898465,0.00030885334,0.0003468294,0.004188282],"category_scores_gemma":[0.00015290237,0.00017082748,0.00022283512,0.0007224722,0.00038457787,0.000027424318,0.00007329913,0.00082603534,0.000018254343],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011070484,0.00008850786,0.0005436415,0.00030252512,0.00005580925,0.000005220882,0.00021504857,0.000036915266,0.69326055,0.00003172204,0.0005918099,0.3037612],"study_design_scores_gemma":[0.0012210406,0.00093310256,0.0002052722,0.00008694441,0.000007890812,7.9819404e-7,0.00005735072,0.0015962996,0.8117541,0.00080444536,0.18320772,0.00012504462],"about_ca_topic_score_codex":0.00069390726,"about_ca_topic_score_gemma":0.000021869893,"teacher_disagreement_score":0.30363616,"about_ca_system_score_codex":0.00017451675,"about_ca_system_score_gemma":0.00045653695,"threshold_uncertainty_score":0.99672204},"labels":[],"label_agreement":null},{"id":"W4404534527","doi":"10.1016/j.jid.2024.10.449","title":"439 Metabolite-driven regulation of T cells in human keratinocyte-derived skin cancer","year":2024,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"","keywords":"Metabolite; Keratinocyte; Skin cancer; Human skin; Cancer research; Cancer; Biology; Chemistry; Medicine; Cell culture; Internal medicine; Genetics","score_opus":0.04099177613358404,"score_gpt":0.35027749739029723,"score_spread":0.30928572125671316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404534527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924745,0.0026260496,0.00010556949,0.0036287943,0.00023913196,0.00026462128,0.000011526495,0.000012395255,0.00063742796],"genre_scores_gemma":[0.99707323,0.00029641675,0.0016325894,0.0002757151,0.00018353695,0.000010847402,0.0000075376197,0.000029698118,0.00049042085],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978563,0.00039475385,0.000908789,0.00018312126,0.0004034829,0.00025353607],"domain_scores_gemma":[0.9986536,0.00022623289,0.00034001868,0.00016710954,0.00043800633,0.00017506415],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00035606947,0.0001645488,0.00075202057,0.0007414111,0.000032956978,0.000020361264,0.00014239429,0.00015305605,0.00092292886],"category_scores_gemma":[0.00013089071,0.00013369849,0.00018730098,0.00052979734,0.00056780135,0.00017870328,0.00004017579,0.00065599725,0.00000812402],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013493992,0.00006541368,0.0042136125,0.00025222043,0.0002695618,0.00038515896,0.0027465834,0.0002199275,0.9883447,0.0011751086,0.0010453725,0.0011473919],"study_design_scores_gemma":[0.0013244712,0.00018756659,0.040103767,0.000425877,0.00009380047,0.00064509764,0.0002515675,0.001463396,0.95032376,0.0021449898,0.0029406997,0.00009498329],"about_ca_topic_score_codex":0.00011339143,"about_ca_topic_score_gemma":0.00008712261,"teacher_disagreement_score":0.038020924,"about_ca_system_score_codex":0.0001812326,"about_ca_system_score_gemma":0.0005876267,"threshold_uncertainty_score":0.99999034},"labels":[],"label_agreement":null},{"id":"W4404538329","doi":"10.1080/10428194.2024.2430703","title":"Severe toxicity, but long-term persistence of CAR T cells after immune checkpoint inhibitors in large B-cell lymphoma","year":2024,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"National Cancer Institute; National Institutes of Health","keywords":"Persistence (discontinuity); Lymphoma; Toxicity; Term (time); Immune system; Immune checkpoint; Cancer research; Biology; Immunology; Medicine; Immunotherapy; Internal medicine","score_opus":0.011446509951488564,"score_gpt":0.2485690102953221,"score_spread":0.23712250034383353,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404538329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97318137,0.017751632,0.00003163023,0.00016009818,0.0008237081,0.0013243541,0.00017915637,0.000276663,0.006271396],"genre_scores_gemma":[0.98174685,0.0030493273,0.00019220616,0.00037256235,0.00053243135,0.00021186631,0.00011305642,0.0002665109,0.013515207],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9927828,0.00027213254,0.0017997994,0.0017761817,0.0015050808,0.0018640104],"domain_scores_gemma":[0.99678683,0.0003978824,0.00028524804,0.0014692015,0.00026584623,0.0007949871],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011409944,0.0011133612,0.0016990561,0.0011090316,0.0001993049,0.00025644762,0.0006501683,0.0009552575,0.0011271161],"category_scores_gemma":[0.00007911779,0.0010497839,0.00097018405,0.0015857565,0.0006894332,0.00052070303,0.00072590023,0.00039629088,0.00023372011],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003806368,0.0016714913,0.034031574,0.005117304,0.0005156179,0.0078315735,0.0054202736,0.000021757287,0.8127867,0.00008531423,0.0006214479,0.12809058],"study_design_scores_gemma":[0.03808711,0.00096084666,0.20020881,0.0035082302,0.00046390598,0.0032742503,0.0017620509,0.004151286,0.73901314,0.00008968057,0.0067292484,0.0017514225],"about_ca_topic_score_codex":0.001727593,"about_ca_topic_score_gemma":0.00025629182,"teacher_disagreement_score":0.16617724,"about_ca_system_score_codex":0.011293455,"about_ca_system_score_gemma":0.005309911,"threshold_uncertainty_score":0.99978596},"labels":[],"label_agreement":null},{"id":"W4404564918","doi":"10.51731/cjht.2024.1029","title":"Ciltacabtagene Autoleucel (Carvykti)","year":2024,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Lenalidomide; Medicine; Chimeric antigen receptor; Drug; Refractory (planetary science); Multiple myeloma; Disease; Thalidomide; Internal medicine; Oncology; Intensive care medicine; Pharmacology; Immunotherapy; Cancer","score_opus":0.05463637822091671,"score_gpt":0.35592399706672717,"score_spread":0.30128761884581046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404564918","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.18820117,0.5416071,0.00059701205,0.25998503,0.0018261716,0.0006900982,0.000042691157,0.00070329854,0.006347418],"genre_scores_gemma":[0.99313444,0.0022824595,0.00063200516,0.0006149004,0.000060001734,0.00000519022,0.000002527095,0.000035018864,0.003233444],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983486,0.000044379416,0.0005151528,0.00016703244,0.00030440986,0.00062042824],"domain_scores_gemma":[0.99910897,0.00007329119,0.00009990011,0.0003141703,0.00017694851,0.00022670609],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010132327,0.00013256216,0.0004136001,0.0014013265,0.00013825919,0.00007491403,0.00029507827,0.00018785396,0.00079842686],"category_scores_gemma":[0.00039631347,0.000105961866,0.00015094533,0.000701016,0.00024183815,0.00009394214,0.000021808322,0.0010173527,0.0000570701],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001849464,0.000008928655,0.0007753444,0.00029600054,0.00009413705,0.0018370147,0.00021984408,0.000003157025,0.0024547447,0.0009878151,0.024135703,0.96916884],"study_design_scores_gemma":[0.00034246073,0.00071662024,0.0019153444,0.0006525581,0.00001891708,0.0023988506,0.0011548145,0.00008318967,0.0037026824,0.0019455433,0.9869679,0.00010111599],"about_ca_topic_score_codex":0.002547982,"about_ca_topic_score_gemma":0.0013461785,"teacher_disagreement_score":0.9690677,"about_ca_system_score_codex":0.0010445801,"about_ca_system_score_gemma":0.008545843,"threshold_uncertainty_score":0.9970748},"labels":[],"label_agreement":null},{"id":"W4404573127","doi":"10.1146/annurev-med-070623-045906","title":"CD70: An Emerging Anticancer Target in Renal Cell Carcinoma and Beyond","year":2024,"lang":"en","type":"review","venue":"Annual Review of Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Chimeric antigen receptor; Cancer research; Immune system; Medicine; Antigen; Renal cell carcinoma; Antibody; Monoclonal antibody; Immunology; Immunotherapy; Oncology","score_opus":0.049437904909689266,"score_gpt":0.42455137488135225,"score_spread":0.375113469971663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404573127","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00003572048,0.98670423,0.0000024559338,0.001845902,0.00026865053,0.0021057415,0.00009750478,0.000026652682,0.008913161],"genre_scores_gemma":[0.000032358523,0.99283284,0.00015083158,0.0011460618,0.0009941083,0.00011323007,0.00035697146,0.00012990384,0.004243671],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9953396,0.0004208971,0.001727713,0.0008475588,0.0011036614,0.00056061684],"domain_scores_gemma":[0.9978072,0.00025074862,0.00036491078,0.00087626145,0.00026174175,0.00043911],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0028580532,0.0006520063,0.005046261,0.0007498627,0.00002890151,0.000007807675,0.00033255303,0.0002735605,0.0036472268],"category_scores_gemma":[0.00043025234,0.00040884037,0.00040106624,0.0013390335,0.0004819006,0.000100303194,0.00018916086,0.0013444215,0.00004486649],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000020377089,0.000060203718,0.000012738115,0.36198145,0.00007469303,0.00035075733,0.00033839286,7.2259834e-9,0.000028410137,0.000036543075,0.01384271,0.6232537],"study_design_scores_gemma":[0.0006577192,0.000852201,0.000013366489,0.27695057,0.0019232971,0.00023057016,0.00010120767,0.0000039303836,0.000006408613,0.00002883949,0.71901447,0.00021739665],"about_ca_topic_score_codex":0.00017506772,"about_ca_topic_score_gemma":0.000013225093,"teacher_disagreement_score":0.70517176,"about_ca_system_score_codex":0.00017381375,"about_ca_system_score_gemma":0.00073877414,"threshold_uncertainty_score":0.9998363},"labels":[],"label_agreement":null},{"id":"W4404622765","doi":"10.1142/9789819807024_0028","title":"Understanding TCR T cell knockout behavior using interpretable machine learning","year":2024,"lang":"en","type":"article","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; National Human Genome Research Institute; Parker Institute for Cancer Immunotherapy; Canadian Institute for Advanced Research","keywords":"T-cell receptor; Computer science; Set (abstract data type); Artificial intelligence; T cell; Biology; Immunology","score_opus":0.15273448791244165,"score_gpt":0.37298749876777376,"score_spread":0.2202530108553321,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404622765","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6634094,0.0034006583,0.0582927,0.00047156189,0.0006919765,0.00086227054,0.0000072495704,0.0007818111,0.2720824],"genre_scores_gemma":[0.8611019,0.00008891882,0.0008216211,0.00007043783,0.00013305439,0.000008837019,0.00001349834,0.00006480867,0.13769688],"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9986517,0.000054184988,0.00020528062,0.00032782386,0.00036540808,0.0003956322],"domain_scores_gemma":[0.9994602,0.00011514714,0.00001775755,0.00021098442,0.000032840937,0.00016304206],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00035972727,0.00015792728,0.00023059356,0.00029536602,0.00011310068,0.00015095681,0.0000827761,0.00008797446,0.023387507],"category_scores_gemma":[0.00002578786,0.00013036726,0.00013895772,0.00036850906,0.000055518532,0.00012248008,0.000101908176,0.00067554694,0.00019398895],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014701443,0.00010943782,0.009594452,0.0003145432,0.00009083787,0.0005120421,0.0008403963,0.00010091262,0.9797005,0.00049149385,0.0006453238,0.0074530323],"study_design_scores_gemma":[0.0031247674,0.0013047572,0.00037871077,0.0012510902,0.00080292387,0.0010876344,0.0040737903,0.62865365,0.26207846,0.00037852445,0.095964395,0.0009013089],"about_ca_topic_score_codex":0.00030422962,"about_ca_topic_score_gemma":0.000025334593,"teacher_disagreement_score":0.71762204,"about_ca_system_score_codex":0.0006625771,"about_ca_system_score_gemma":0.00014152235,"threshold_uncertainty_score":0.97750527},"labels":[],"label_agreement":null},{"id":"W4404728397","doi":"10.3389/fonc.2024.1446995","title":"Recommendations for the effective use of T-cell–redirecting therapies: a Canadian consensus statement","year":2024,"lang":"en","type":"review","venue":"Frontiers in Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Jewish General Hospital; Princess Margaret Cancer Centre; Vancouver General Hospital; Université Laval; Queen Elizabeth II Health Sciences Centre; Dalhousie University; Dr. Everett Chalmers Regional Hospital; Centre hospitalier universitaire de Québec; Ottawa Hospital; BC Cancer Agency; McGill University; Regional Municipality of Durham","funders":"Janssen Canada","keywords":"Statement (logic); Consensus conference; Medicine; MEDLINE; Intensive care medicine; Political science; Internal medicine; Law","score_opus":0.13261888074979708,"score_gpt":0.44220175787301985,"score_spread":0.30958287712322274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404728397","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000087629605,0.98415524,0.0002451765,0.003065419,0.0033753754,0.0074411724,0.0004501861,0.000021851158,0.0012368079],"genre_scores_gemma":[0.0000065085205,0.98297364,0.007248795,0.00018762283,0.00021234104,0.0022585513,0.00017023768,0.00008667634,0.00685566],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9974766,0.0006344765,0.00077637704,0.00041655413,0.00016115367,0.0005348706],"domain_scores_gemma":[0.9951229,0.003883356,0.00026141063,0.00041764943,0.00015189797,0.00016279402],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015982941,0.00030171158,0.0017188252,0.0008967033,0.00009707923,0.000024585277,0.00020301588,0.00039209708,0.0002602964],"category_scores_gemma":[0.0004891078,0.00020045642,0.000446446,0.00059213716,0.00022495064,0.000016926419,0.00005577538,0.00091043155,0.0000087632525],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009128675,0.00006248049,0.000019191784,0.0042962055,0.0010307775,0.000040776835,0.0008733091,7.678918e-7,0.000003484304,0.00001528072,0.22282769,0.7707388],"study_design_scores_gemma":[0.00079688884,0.0006564409,0.0000019510944,0.0030572393,0.001348662,0.000038529175,0.0012196403,0.00013933473,0.000005280252,0.00006457623,0.9925251,0.0001463683],"about_ca_topic_score_codex":0.01730632,"about_ca_topic_score_gemma":0.03321721,"teacher_disagreement_score":0.7705924,"about_ca_system_score_codex":0.0037659043,"about_ca_system_score_gemma":0.0039430386,"threshold_uncertainty_score":0.98923755},"labels":[],"label_agreement":null},{"id":"W4404799289","doi":"10.1016/s1470-2045(24)00508-4","title":"Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study","year":2024,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"CRISPR; Refractory (planetary science); Open label; Medicine; Cancer research; Internal medicine; Adverse effect; Biology; Genetics; Gene","score_opus":0.0810241588147585,"score_gpt":0.3709479855397072,"score_spread":0.2899238267249487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404799289","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99231017,0.0012333905,0.00006528885,0.0007681752,0.00019544469,0.003809394,0.000072768504,0.00008124852,0.0014640994],"genre_scores_gemma":[0.9969431,0.0006690209,0.00026510144,0.00021431407,0.00012953048,0.00014159239,0.00004836416,0.0000776835,0.0015112986],"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99691874,0.00091896777,0.0005131797,0.00059680536,0.0004821728,0.0005701299],"domain_scores_gemma":[0.9979955,0.0007520697,0.00019154494,0.0007296905,0.00019548021,0.00013572851],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015445712,0.00033832277,0.0011085441,0.00025188012,0.00009744061,0.000053297437,0.00039304886,0.00022512896,0.00037854465],"category_scores_gemma":[0.000102319675,0.0002071369,0.00004685271,0.0007652996,0.00024444418,0.00018597953,0.0001989734,0.0007142389,0.0000078093135],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12345661,0.02886194,0.019141052,0.0004357244,0.0005268163,0.000355621,0.006238055,0.000045421155,0.7572447,0.000015055274,0.00079717144,0.062881805],"study_design_scores_gemma":[0.34956372,0.23987713,0.27983335,0.00068602106,0.000768736,0.00009456782,0.0022758562,0.0032849922,0.07492622,0.000097694545,0.047277074,0.0013146468],"about_ca_topic_score_codex":0.00034164783,"about_ca_topic_score_gemma":0.00045282903,"teacher_disagreement_score":0.6823185,"about_ca_system_score_codex":0.0005357053,"about_ca_system_score_gemma":0.00058874505,"threshold_uncertainty_score":0.8446798},"labels":[],"label_agreement":null},{"id":"W4404926477","doi":"10.1136/jitc-2024-009462","title":"Impact of immunological aging on T cell-mediated therapies in older adults with multiple myeloma and lymphoma","year":2024,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"Cilag; Medac; Swedish Orphan Biovitrum; Else Kröner-Fresenius-Stiftung; Incyte; Eli Lilly and Company; AstraZeneca; CSL Behring; Gilead Sciences; BeiGene; Sanofi; Amgen; Pfizer; Les Laboratories Pierre Fabre; Celgene","keywords":"Medicine; Chimeric antigen receptor; Immune system; T cell; Immunotherapy; Immunosenescence; Immunology; Multiple myeloma; Naive T cell; Senescence; Cancer research; Internal medicine; T-cell receptor","score_opus":0.03172640834317397,"score_gpt":0.38804858641614765,"score_spread":0.35632217807297367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404926477","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14735994,0.85051394,0.000004481237,0.000054691776,0.00018984955,0.0016955365,0.000115000665,0.000015805794,0.000050748316],"genre_scores_gemma":[0.0122381365,0.9861202,0.00012102907,0.000028852897,0.00019275093,0.00022410303,0.000026262083,0.0001723177,0.00087632105],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973086,0.0001603894,0.001076337,0.0003926553,0.00056100346,0.000501015],"domain_scores_gemma":[0.99790627,0.0006176801,0.0007154344,0.00037451132,0.0002775835,0.00010850687],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005805246,0.0005830119,0.0025057148,0.00089406845,0.000061472885,0.00004981382,0.00027196112,0.00037135548,0.00071858073],"category_scores_gemma":[0.000039439423,0.00031671656,0.0010713483,0.0005549493,0.00025111905,0.000075881704,0.000032061223,0.0008440925,0.0000021755957],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008495297,0.0004418978,0.0009800859,0.008533251,0.0028626483,0.000051625302,0.0012951508,0.0000024891879,0.0022889578,0.0000014150482,0.000119179735,0.974928],"study_design_scores_gemma":[0.051182617,0.01919272,0.03344565,0.22686796,0.0017584178,0.00123275,0.000739387,0.000113210735,0.0011497748,0.00004440011,0.6628689,0.0014042244],"about_ca_topic_score_codex":0.0002790366,"about_ca_topic_score_gemma":0.00003127417,"teacher_disagreement_score":0.9735238,"about_ca_system_score_codex":0.0007208294,"about_ca_system_score_gemma":0.0011462194,"threshold_uncertainty_score":0.9999285},"labels":[],"label_agreement":null},{"id":"W4404956327","doi":"10.14740/jh1367","title":"A Case of Fulminant Cerebral Edema Leading to Death After Chimeric Antigen Receptor T-Cell Therapy","year":2024,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Fulminant; Chimeric antigen receptor; Medicine; Refractory (planetary science); Cell therapy; Cerebral edema; T cell; Edema; Immunotherapy; Immune system; Cell; Immunology; Antigen; Oncology; Internal medicine; Biology","score_opus":0.03534010633411582,"score_gpt":0.3499590468036861,"score_spread":0.3146189404695703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404956327","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856159,0.010472609,0.00026997383,0.001819007,0.0005234169,0.00027302525,0.000004293428,0.000014227582,0.0010075134],"genre_scores_gemma":[0.994384,0.0006846249,0.002074291,0.0002621261,0.0003194548,0.000008357463,8.336682e-7,0.00004415003,0.0022221417],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99838734,0.00011581792,0.0006390559,0.00019883027,0.0002936146,0.000365353],"domain_scores_gemma":[0.998989,0.00018992058,0.00014832923,0.00023358247,0.00019157685,0.00024759918],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00055639114,0.00016590473,0.00075016596,0.0005742443,0.00003060271,0.000020456207,0.00013020559,0.00012319544,0.004127837],"category_scores_gemma":[0.000062043335,0.00011627198,0.00029907652,0.00036625986,0.00007001655,0.00007885798,0.000043762157,0.00042604248,0.00011596827],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005226892,0.0006503501,0.03548283,0.00080693397,0.00077526417,0.0656036,0.0048773084,0.0000043369496,0.83315,0.00037261602,0.012955163,0.04009467],"study_design_scores_gemma":[0.003433047,0.0059809377,0.001472901,0.0010174931,0.00014451318,0.32892874,0.0008887227,0.00015306074,0.56885797,0.00022266876,0.08857807,0.00032184648],"about_ca_topic_score_codex":0.000023325456,"about_ca_topic_score_gemma":0.000006306396,"teacher_disagreement_score":0.26429206,"about_ca_system_score_codex":0.000084671425,"about_ca_system_score_gemma":0.0002870963,"threshold_uncertainty_score":0.99678254},"labels":[],"label_agreement":null},{"id":"W4404959524","doi":"10.1158/1078-0432.ccr-24-2469","title":"The Society for Immunotherapy of Cancer Perspective on Tissue-Based Technologies for Immuno-Oncology Biomarker Discovery and Application","year":2024,"lang":"en","type":"review","venue":"Clinical Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada); McGill University; Jewish General Hospital","funders":"National Cancer Institute","keywords":"Immunotherapy; Cancer; Medicine; Biomarker; Cancer immunotherapy; Precision oncology; Oncology; Biomarker discovery; Clinical Oncology; Perspective (graphical); Cancer research; Internal medicine; Biology; Computer science; Proteomics","score_opus":0.29019097892027956,"score_gpt":0.6372890486359728,"score_spread":0.34709806971569324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404959524","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000068859714,0.97843486,0.00022809728,0.009207519,0.000352441,0.010829658,0.00060873094,0.000068668036,0.00020114788],"genre_scores_gemma":[0.000120586905,0.9764979,0.00017251381,0.00007881963,0.0005144391,0.017026681,0.00006246153,0.00014783004,0.005378794],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959933,0.0004101048,0.0010786352,0.0010627054,0.0007179057,0.0007373258],"domain_scores_gemma":[0.9839814,0.013409761,0.00031014782,0.0010685088,0.0011427039,0.00008748148],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.006459357,0.0003720801,0.0018869645,0.00027573894,0.0003445312,0.00010792151,0.00068148883,0.0009823064,0.00007110038],"category_scores_gemma":[0.0012068942,0.00021254503,0.0018294889,0.0008725918,0.0028596837,0.0000387884,0.00023697413,0.0018078671,0.000006024038],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036265769,0.00021901316,0.0000090576095,0.010357578,0.0022685393,0.0000014200964,0.000056688503,2.3046739e-7,0.00068321294,0.0010280446,0.010990461,0.97075915],"study_design_scores_gemma":[0.0019611032,0.0027252908,0.000012129203,0.0044865427,0.0006817988,0.0000020571308,0.00051205186,0.00010842748,0.0002784263,0.0012932216,0.98774546,0.0001935072],"about_ca_topic_score_codex":0.0006482619,"about_ca_topic_score_gemma":0.00022519685,"teacher_disagreement_score":0.97675496,"about_ca_system_score_codex":0.0021784862,"about_ca_system_score_gemma":0.0049307537,"threshold_uncertainty_score":0.99985397},"labels":[],"label_agreement":null},{"id":"W4404970989","doi":"10.1158/2643-3230.bcd-23-0258","title":"CD33–CD123 IF-THEN Gating Reduces Toxicity while Enhancing the Specificity and Memory Phenotype of AML-Targeting CAR-T Cells","year":2024,"lang":"en","type":"article","venue":"Blood Cancer Discovery","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Hyundai Hope On Wheels; Saban Research Institute; CureSearch for Children's Cancer; National Cancer Institute; St. Baldrick's Foundation; University of Southern California","keywords":"Interleukin-3 receptor; Cancer research; Haematopoiesis; CD33; Immunotherapy; Progenitor cell; Cytokine release syndrome; Leukemia; T cell; Stem cell; Immunology; Medicine; Biology; CD34; Myeloid; Chimeric antigen receptor; Cell biology; Immune system","score_opus":0.022163457041508895,"score_gpt":0.29113912565701067,"score_spread":0.26897566861550176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404970989","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9764208,0.015897054,0.0000624549,0.0007025814,0.00056905113,0.000578863,0.00007190405,0.00007433481,0.0056229183],"genre_scores_gemma":[0.99099046,0.0018396161,0.00016626346,0.00014157983,0.0013729107,0.000052305593,0.00001032461,0.00006683204,0.005359719],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99776655,0.0001277632,0.0004738519,0.00054291816,0.0006127203,0.00047616288],"domain_scores_gemma":[0.99877864,0.00047339933,0.000120077166,0.00040529645,0.00010426743,0.00011834815],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00089360133,0.00025150957,0.00045762365,0.00010827277,0.00016877812,0.00017346264,0.00020401888,0.000099059056,0.0009253649],"category_scores_gemma":[0.00008964794,0.00017893373,0.00017517034,0.00041179007,0.00024709952,0.00027806696,0.00018558094,0.00052984495,0.000008391725],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017121532,0.00009008976,0.0005537367,0.00067033607,0.00032358512,0.000029645405,0.003757163,0.00007695656,0.9818611,0.000058071248,0.0010518383,0.011356245],"study_design_scores_gemma":[0.00054699025,0.0001704023,0.0008025152,0.0008405838,0.0002746989,0.000014553392,0.003244321,0.00033144187,0.9917364,0.00011794631,0.0017193727,0.00020078401],"about_ca_topic_score_codex":0.0012383814,"about_ca_topic_score_gemma":0.00022245345,"teacher_disagreement_score":0.01456961,"about_ca_system_score_codex":0.00013356378,"about_ca_system_score_gemma":0.0004391604,"threshold_uncertainty_score":0.9999879},"labels":[],"label_agreement":null},{"id":"W4405038296","doi":"10.1182/blood-2024-197948","title":"Matching-Adjusted Indirect Comparison (MAIC) of Efficacy and Safety Outcomes for Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel (tisa-cel) for the Treatment of Third-Line or Later (3L+) Relapsed or Refractory (R/R) Follicular Lymphoma (FL)","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Medicine; Internal medicine","score_opus":0.06928148602245389,"score_gpt":0.3452610976245043,"score_spread":0.2759796116020504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405038296","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9747808,0.017645285,0.00040778462,0.0009538998,0.0005360408,0.0047815978,0.0005300848,0.00016415329,0.00020038453],"genre_scores_gemma":[0.97280407,0.009572942,0.0028670582,0.00013090418,0.00034373716,0.0005556217,0.00024837325,0.00023417485,0.013243139],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99618584,0.00018856839,0.0012219512,0.0009455713,0.00069935963,0.00075873896],"domain_scores_gemma":[0.9934498,0.0046856576,0.00032700502,0.000984059,0.00023838408,0.000315099],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00084716314,0.00066929654,0.001764878,0.00037546677,0.00027732167,0.00009285968,0.0003127566,0.00041111215,0.00031120464],"category_scores_gemma":[0.00030341005,0.00040926348,0.00061831856,0.000504521,0.0003594297,0.00012836324,0.0001334486,0.0002491156,0.0000069992243],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13947262,0.01690093,0.0053714034,0.0059151514,0.019984119,0.0004936089,0.01351816,0.00006966768,0.43153998,0.0002349204,0.00224361,0.36425585],"study_design_scores_gemma":[0.2439772,0.048610263,0.041168034,0.0015128271,0.0142000215,0.00031112268,0.0031928841,0.004865761,0.50212187,0.0001914611,0.13809937,0.0017491851],"about_ca_topic_score_codex":0.00028730938,"about_ca_topic_score_gemma":0.00032259914,"teacher_disagreement_score":0.36250666,"about_ca_system_score_codex":0.00023317235,"about_ca_system_score_gemma":0.00041745146,"threshold_uncertainty_score":0.9998359},"labels":[],"label_agreement":null},{"id":"W4405038423","doi":"10.1182/blood-2024-200937","title":"Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel) for Second-Line (2L) Treatment of Patients (pts) with Refractory/Early Relapsed (R/R) Large B-Cell Lymphoma (LBCL): Update with 34 Months of Liso-Cel Follow-up","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Refractory (planetary science); Medicine; Internal medicine; Second line treatment; Nuclear medicine; Gastroenterology; Oncology; Physics; Chemotherapy","score_opus":0.027326737559294444,"score_gpt":0.28131938889399033,"score_spread":0.2539926513346959,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405038423","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9874224,0.004302579,0.00019827156,0.00008204974,0.00047714307,0.003464281,0.0018355502,0.00018098523,0.002036752],"genre_scores_gemma":[0.9874635,0.00058413035,0.0019004105,0.000036625857,0.00019148426,0.00033521932,0.0012282374,0.0003247557,0.007935647],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9942512,0.00025060616,0.001589655,0.001220011,0.0015572438,0.0011313104],"domain_scores_gemma":[0.99573386,0.00059777,0.000869604,0.0014894186,0.0008225524,0.00048681872],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005900652,0.0009343193,0.0023584457,0.00081558194,0.0001543209,0.00006498282,0.0005067131,0.00047432145,0.0007959737],"category_scores_gemma":[0.000057607293,0.00072536804,0.00065676286,0.0011750188,0.00030579467,0.00027086207,0.0001452155,0.00040097316,0.00002702063],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19162288,0.1282175,0.0789433,0.011183243,0.018965961,0.0007511709,0.019927057,0.00011530266,0.50865614,0.00029229038,0.0027979636,0.03852719],"study_design_scores_gemma":[0.22480704,0.052828714,0.011703153,0.001146913,0.004369085,0.000022869304,0.0013101122,0.0005994272,0.6884345,0.000037716327,0.013680928,0.0010595695],"about_ca_topic_score_codex":0.00072539743,"about_ca_topic_score_gemma":0.0009227286,"teacher_disagreement_score":0.17977832,"about_ca_system_score_codex":0.00048271165,"about_ca_system_score_gemma":0.00084694277,"threshold_uncertainty_score":0.99951977},"labels":[],"label_agreement":null},{"id":"W4405038568","doi":"10.1182/blood-2024-212330","title":"Gene Expression Profile of Enriched T-Cells Prior to Chimeric Antigen Receptor (CAR) T-Cell Manufacturing Is Predictive of CAR T-Cell Response","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Chimeric antigen receptor; Antigen; T cell; Receptor; Molecular biology; Cytotoxic T cell; Biology; Immunology; Immune system; Genetics; In vitro","score_opus":0.014504562979752913,"score_gpt":0.27722097428775544,"score_spread":0.26271641130800255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405038568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926803,0.0021643606,0.000140891,0.00014007166,0.00024757528,0.0018710617,0.00021931816,0.000111471505,0.0024249265],"genre_scores_gemma":[0.97463506,0.00042217443,0.005908615,0.000061031602,0.0002307583,0.00010100967,0.00003530501,0.000117498836,0.018488526],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970975,0.00025037053,0.0005855895,0.0006909469,0.0008673856,0.0005082428],"domain_scores_gemma":[0.9982112,0.00032301864,0.00014165317,0.0008203931,0.00017896174,0.00032476828],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00070279726,0.00031614696,0.0006276267,0.0005088159,0.000056552482,0.000023304721,0.0003008529,0.00020806494,0.002821982],"category_scores_gemma":[0.00007531975,0.00027343037,0.0002698034,0.00055004697,0.000100034,0.00008126262,0.00021969141,0.0003952926,0.00017672428],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004081233,0.0010215441,0.00047338085,0.0008575638,0.00019603908,0.000065351436,0.003807661,0.000009268065,0.98432356,2.7433563e-7,0.0027851688,0.0023789315],"study_design_scores_gemma":[0.0029656098,0.0018843435,0.0014307362,0.00035332638,0.00017967135,0.000015071746,0.0003741001,0.00006103382,0.98826814,0.0000054113266,0.004238415,0.00022411461],"about_ca_topic_score_codex":0.00007336692,"about_ca_topic_score_gemma":6.4585686e-7,"teacher_disagreement_score":0.018045243,"about_ca_system_score_codex":0.000096056996,"about_ca_system_score_gemma":0.00041850007,"threshold_uncertainty_score":0.9999718},"labels":[],"label_agreement":null},{"id":"W4405039315","doi":"10.1182/blood-2024-206375","title":"A Real-World Comparison of CAR T-Cell Therapy Versus a Historical Standard-of-Care Approach for Relapsed-Refractory Large B-Cell Lymphoma in Ontario, Canada","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto; Princess Margaret Cancer Centre; Health Sciences Centre; University Health Network","funders":"Ipsen; Eisai; BeiGene; AstraZeneca; Eli Lilly and Company","keywords":"Refractory (planetary science); Medicine; Lymphoma; Standard of care; Chemotherapy regimen; Oncology; Internal medicine; Chemotherapy; Biology","score_opus":0.03787083616924094,"score_gpt":0.3061754718049588,"score_spread":0.2683046356357179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405039315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9521687,0.012882987,0.00004219699,0.00005613665,0.00046871667,0.0012188156,0.00013206166,0.000038980394,0.03299143],"genre_scores_gemma":[0.9890098,0.0001856593,0.00096873724,0.0000155239,0.00010103506,0.0000965868,0.00013620316,0.00006886883,0.009417584],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977386,0.00007777885,0.00053592847,0.00042591192,0.0007701911,0.00045159843],"domain_scores_gemma":[0.99873286,0.000334213,0.00010112737,0.00047453423,0.00019152035,0.00016572095],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031935907,0.00022627493,0.0007939766,0.0002897821,0.000039307713,0.000011404941,0.0001926522,0.0001434898,0.00029754726],"category_scores_gemma":[0.000026089887,0.00020674196,0.0002170896,0.00043073943,0.00004244183,0.000036587666,0.000041398864,0.00039258428,8.2874686e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12005903,0.050378576,0.31251657,0.015577612,0.0027753718,0.0010575561,0.056702826,0.00009082327,0.294667,0.0009896267,0.10129151,0.043893524],"study_design_scores_gemma":[0.099848606,0.008280519,0.0036486238,0.00030043186,0.00041425604,0.0000067975943,0.0026115025,0.00046491312,0.1511122,0.00001324785,0.732791,0.0005079229],"about_ca_topic_score_codex":0.8123217,"about_ca_topic_score_gemma":0.9360045,"teacher_disagreement_score":0.63149947,"about_ca_system_score_codex":0.004313549,"about_ca_system_score_gemma":0.00534991,"threshold_uncertainty_score":0.99950874},"labels":[],"label_agreement":null},{"id":"W4405039623","doi":"10.1182/blood-2024-201539","title":"Real-World Comparison of Healthcare Costs and Resource Utilization Among Patients with Relapsed-Refractory Large B-Cell Lymphoma Treated with CAR T-Cell Therapy Versus Historical Standard-of-Care: A Cost-Consequence Analysis in Ontario, Canada","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; University of Toronto; Princess Margaret Cancer Centre; Health Sciences Centre; University Health Network","funders":"","keywords":"Medicine; Refractory (planetary science); Standard of care; Health care; Lymphoma; Internal medicine; Economic growth; Economics","score_opus":0.02531581132739111,"score_gpt":0.2880469772701274,"score_spread":0.26273116594273627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405039623","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939614,0.0033433675,0.000006581512,0.000046060595,0.000036584825,0.0009543855,0.00011513679,0.000028367851,0.001508149],"genre_scores_gemma":[0.9984635,0.00018609068,0.000060339848,0.000014790503,0.00001003265,0.000034099718,0.00034450792,0.00004410236,0.000842543],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99763846,0.0001840352,0.00045666873,0.00046879504,0.0009039969,0.00034803324],"domain_scores_gemma":[0.99858665,0.00022682935,0.00017990168,0.00041688076,0.0003705386,0.00021917466],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00018241366,0.0002379538,0.0007725482,0.00050442567,0.000055861616,0.00001649882,0.00010004554,0.00010709602,0.00008634729],"category_scores_gemma":[0.000015124803,0.00018856688,0.000066820685,0.0015301551,0.00011166485,0.0000592999,0.000023386518,0.00031906847,1.6004952e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012235642,0.0012189007,0.9804093,0.0002652503,0.00046781838,0.00018990636,0.0020833916,0.000017100652,0.00049466174,0.0000049857085,0.00011797996,0.0024950558],"study_design_scores_gemma":[0.0676589,0.010744122,0.8807546,0.0007334583,0.0015430008,0.000004370644,0.0014101082,0.00026954117,0.022255566,6.9581165e-7,0.014167286,0.0004583615],"about_ca_topic_score_codex":0.9393347,"about_ca_topic_score_gemma":0.9921956,"teacher_disagreement_score":0.09965472,"about_ca_system_score_codex":0.0045808842,"about_ca_system_score_gemma":0.0026513897,"threshold_uncertainty_score":0.99924034},"labels":[],"label_agreement":null},{"id":"W4405040041","doi":"10.1182/blood-2024-209364","title":"Evaluating the Impact of Socioeconomic Disparities on Access and Outcomes of CAR T-Cell Therapy for Relapsed/Refractory B-Cell Lymphomas in Ontario, Canada","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Socioeconomic status; Medicine; Refractory (planetary science); B cell; Oncology; Immunology; Environmental health; Population; Antibody; Biology","score_opus":0.052192684676009835,"score_gpt":0.3693888399222971,"score_spread":0.31719615524628725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405040041","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99424016,0.0024057953,3.8260868e-7,0.00021010119,0.00008994776,0.0007709164,0.00004623717,0.000007901555,0.0022285697],"genre_scores_gemma":[0.99619097,0.00023250407,0.000021051728,0.00008099485,0.00003456917,0.000056679502,0.0000117083655,0.00003214827,0.0033393493],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9989261,0.00006516761,0.00031050626,0.00021944888,0.00024209057,0.00023666248],"domain_scores_gemma":[0.99856955,0.0009585547,0.000079681406,0.00028182182,0.000051951367,0.00005845316],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053008524,0.00015139816,0.00039166395,0.00010482807,0.00003711374,0.000029508234,0.00015903023,0.0000664091,0.00050870824],"category_scores_gemma":[0.000035476078,0.00009587895,0.000156435,0.000059544316,0.00008256272,0.0000602933,0.000038873182,0.00022847591,5.715924e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00095898396,0.0007944448,0.8915469,0.00040579107,0.0005479502,0.000014403219,0.0020515586,0.000103520964,0.09697195,0.0000420053,0.0007922672,0.005770233],"study_design_scores_gemma":[0.01584157,0.003620195,0.89509773,0.00017226837,0.00016430543,0.000009215066,0.0003900228,0.00071284146,0.08288611,0.000410132,0.00047508557,0.00022050682],"about_ca_topic_score_codex":0.8802214,"about_ca_topic_score_gemma":0.66346776,"teacher_disagreement_score":0.21675363,"about_ca_system_score_codex":0.00050118624,"about_ca_system_score_gemma":0.0029217585,"threshold_uncertainty_score":0.55699986},"labels":[],"label_agreement":null},{"id":"W4405040316","doi":"10.1182/blood-2024-201189","title":"Inferior Survival in Double Refractory Large B-Cell Lymphoma Eligible for Third-Line CD19 Chimeric Antigen T-Cell Therapy","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"CD19; Medicine; Chimeric antigen receptor; Lymphoma; Antigen; Refractory (planetary science); Oncology; Immunology; Internal medicine; Virology; Immunotherapy; Biology; Cancer","score_opus":0.03537496092950763,"score_gpt":0.3317406471556205,"score_spread":0.29636568622611287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405040316","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9589579,0.013899083,0.00007726479,0.0003742244,0.0004824214,0.0015470213,0.0000482184,0.00023600778,0.024377866],"genre_scores_gemma":[0.9542159,0.007009282,0.00038598894,0.00030005063,0.000793827,0.00021665964,0.00013057694,0.00016218472,0.036785543],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99749464,0.00007794939,0.00045451891,0.00062237104,0.0005353572,0.00081514934],"domain_scores_gemma":[0.998757,0.0002414219,0.000057717985,0.00061868114,0.00011494668,0.00021023303],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00094735745,0.00032115006,0.00056241936,0.0004247857,0.0000837169,0.000097215554,0.00025353677,0.00022707993,0.00082251255],"category_scores_gemma":[0.000024915907,0.0002739463,0.00028030897,0.00076124276,0.000057432582,0.00013656987,0.000081788065,0.00034065483,0.00024319152],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020617817,0.0084642535,0.013835129,0.0005769473,0.0002480101,0.00028809655,0.0010306487,0.0000024077056,0.96293217,0.00015203486,0.0021737558,0.008234767],"study_design_scores_gemma":[0.05353731,0.0017004469,0.005213463,0.00015446574,0.000084510764,0.00003762307,0.00014115773,0.00030674814,0.541957,0.00011389983,0.39633432,0.00041903407],"about_ca_topic_score_codex":0.0002949371,"about_ca_topic_score_gemma":0.00008179515,"teacher_disagreement_score":0.42097515,"about_ca_system_score_codex":0.00010746115,"about_ca_system_score_gemma":0.0006660469,"threshold_uncertainty_score":0.9999713},"labels":[],"label_agreement":null},{"id":"W4405040677","doi":"10.1182/blood-2024-209455","title":"A Retrospective Study of Inotuzumab Ozogamicin in Individuals with Down Syndrome and B-Cell Acute Lymphoblastic Leukemia","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"","keywords":"Lymphoblastic Leukemia; Medicine; CD22; Acute lymphocytic leukemia; Retrospective cohort study; Oncology; Pediatrics; Leukemia; Internal medicine; Immunology; B cell; Antibody","score_opus":0.010560562670765536,"score_gpt":0.2686793725623277,"score_spread":0.25811880989156216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405040677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960614,0.00058611244,0.000003401874,0.000037199392,0.000029357227,0.0010749742,0.000024610239,0.000051680465,0.0021312651],"genre_scores_gemma":[0.9980634,0.000085752275,0.00008192811,0.000017443903,0.000028381475,0.00005260325,0.0000063469884,0.000042822518,0.0016213146],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99839693,0.00006798012,0.00026883406,0.0004355721,0.0005419839,0.00028870322],"domain_scores_gemma":[0.99938667,0.00008931699,0.000042255895,0.00032061717,0.000058094043,0.000103077444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029739487,0.00018295331,0.0004980048,0.00045911726,0.000025161306,0.00003584687,0.00010000486,0.00008409737,0.00021829763],"category_scores_gemma":[0.000026307414,0.00013992359,0.000037505128,0.00078747765,0.00010054222,0.00007101662,0.00009489755,0.00034182667,0.000014123861],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006182441,0.003859795,0.8824849,0.0005889349,0.0019002808,0.005943761,0.01165514,0.000009631133,0.09173412,0.000060944047,0.00006972413,0.0010745259],"study_design_scores_gemma":[0.03384009,0.015153692,0.9266707,0.00084984384,0.0012645411,0.0022988517,0.0020798107,0.0001657491,0.017148394,0.00013261176,0.00008075985,0.00031500883],"about_ca_topic_score_codex":0.00036839195,"about_ca_topic_score_gemma":0.00012993555,"teacher_disagreement_score":0.07458572,"about_ca_system_score_codex":0.00031262042,"about_ca_system_score_gemma":0.00038160762,"threshold_uncertainty_score":0.57059187},"labels":[],"label_agreement":null},{"id":"W4405043173","doi":"10.1182/blood-2024-204166","title":"Comprehensive Characterization and Validation of the Tumor Microenvironment in Patients with Relapsed/Refractory Large B-Cell Lymphoma Identifies Subgroups with Greatest Benefit from CD19 CAR T-Cell Therapy","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"Daiichi Sankyo Europe; National Cancer Institute; EMD Serono; Pharmacyclics; Genentech; Incyte; BeiGene; Regeneron Pharmaceuticals; Seagen; Janssen Pharmaceuticals; Gilead Sciences; MorphoSys; Cancer Prevention and Research Institute of Texas; Celgene; AstraZeneca; Bristol-Myers Squibb; TG Therapeutics; Amgen","keywords":"Tumor microenvironment; Lymphoma; Medicine; Refractory (planetary science); Diffuse large B-cell lymphoma; CD19; Oncology; Cancer research; Internal medicine; Tumor cells; Biology; Peripheral blood","score_opus":0.008359443956642763,"score_gpt":0.20839313540628784,"score_spread":0.20003369144964508,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405043173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9979062,0.0008346355,0.000009234119,0.000053052958,0.000058810638,0.0009078211,0.00015156224,0.00002123513,0.000057415797],"genre_scores_gemma":[0.99825567,0.00035765977,0.000029928267,0.00006776666,0.000038130132,0.000032478423,0.00041058412,0.000050481,0.0007573282],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9987308,0.00006904158,0.00022725725,0.00034482614,0.0004259703,0.00020210035],"domain_scores_gemma":[0.99936193,0.000068920905,0.000101073565,0.00034113025,0.00007095797,0.000056013017],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007766996,0.00018498875,0.00024774784,0.00011051413,0.000050988434,0.00004494071,0.00008912833,0.000058165027,0.00014452249],"category_scores_gemma":[0.000002725123,0.00011753346,0.000040950108,0.00021095118,0.00009441722,0.00012820042,0.000047760666,0.00013912836,0.0000072505895],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005868566,0.0016323252,0.44018254,0.000108875036,0.0000814294,0.000019883384,0.00093246443,0.0000013182354,0.555773,0.0000013114671,0.0000035434232,0.0006764485],"study_design_scores_gemma":[0.011552656,0.00057644077,0.64026564,0.0001997459,0.00007930506,0.0000042496536,0.000096157644,0.000013557792,0.34657952,0.000003886384,0.0005360455,0.000092808004],"about_ca_topic_score_codex":0.00014423572,"about_ca_topic_score_gemma":0.000019048373,"teacher_disagreement_score":0.20919348,"about_ca_system_score_codex":0.00007207176,"about_ca_system_score_gemma":0.000052621162,"threshold_uncertainty_score":0.47928753},"labels":[],"label_agreement":null},{"id":"W4405045028","doi":"10.1182/blood-2024-202199","title":"Identification of a Novel Function of B2M Involving T-Cell Exhaustion Via P-Selectin Ligand Upregulation in Diffuse Large B-Cell Lymphoma","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"","keywords":"Diffuse large B-cell lymphoma; Downregulation and upregulation; Identification (biology); Lymphoma; Cancer research; Chemistry; Medicine; Immunology; Biology; Biochemistry","score_opus":0.017036348487291457,"score_gpt":0.27130329152062194,"score_spread":0.2542669430333305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405045028","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99320364,0.0014335436,0.0041420767,0.0000372923,0.00014219627,0.0005058759,0.0000092813725,0.000049112306,0.00047696574],"genre_scores_gemma":[0.9972403,0.00012213485,0.00010093315,0.000009017413,0.00010779919,0.000027727398,0.00005879062,0.000034041066,0.0022992417],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985605,0.00004400231,0.00050487916,0.00028863078,0.00040245356,0.00019954616],"domain_scores_gemma":[0.99929494,0.00008948977,0.00013063563,0.00027639174,0.00015851737,0.00005000275],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006482551,0.00011719655,0.00022410865,0.00045040785,0.000027545706,0.000023043402,0.00006252529,0.00013565956,0.00007441288],"category_scores_gemma":[0.000057999616,0.00011895665,0.00008958986,0.0007900483,0.000031369305,0.00014181866,0.000029917845,0.00012857323,0.00001166536],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00026057367,0.007749787,0.005000667,0.00090246176,0.0000408249,0.0000044359845,0.0006308308,0.000013505653,0.981859,0.00008499154,0.00003132061,0.003421581],"study_design_scores_gemma":[0.014566087,0.00029086202,0.035601024,0.00026235153,0.00016926133,0.000012793189,0.00011555046,0.01744991,0.93121606,0.00010881672,0.00011278031,0.000094489646],"about_ca_topic_score_codex":0.00009312523,"about_ca_topic_score_gemma":0.00004680624,"teacher_disagreement_score":0.050642945,"about_ca_system_score_codex":0.000096998934,"about_ca_system_score_gemma":0.00011394609,"threshold_uncertainty_score":0.48509112},"labels":[],"label_agreement":null},{"id":"W4405047042","doi":"10.1182/blood-2024-209646","title":"Alberta Cellular and Immunotherapy (ACIT) 001, Updated Results of Decentralized Production of Second Generation, Anti-CD19/41BB/CD3z Chimeric Antigen Receptor (CAR) T-Cells in Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) and Aggressive Non-Hodgkin Lymphoma (NHL)","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Stollery Children's Hospital; University of Calgary; University of Alberta","funders":"","keywords":"Chimeric antigen receptor; Medicine; Immunotherapy; Refractory (planetary science); Cancer research; CD19; Blinatumomab; Hematologic Neoplasms; Antigen; Internal medicine; Immunology; Oncology; Cancer; Biology","score_opus":0.010193334808513416,"score_gpt":0.2535019991890671,"score_spread":0.24330866438055365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405047042","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99029183,0.0074864263,0.000009679662,0.00013907847,0.0005325509,0.0012164455,0.00012589396,0.00004338605,0.00015467963],"genre_scores_gemma":[0.98099536,0.014117825,0.0005888476,0.000046305886,0.00020508109,0.00003858583,0.00052674685,0.00010799885,0.0033732592],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9969042,0.00023979203,0.0009992494,0.0008714137,0.00049343635,0.0004919297],"domain_scores_gemma":[0.9983483,0.00018861362,0.00040678453,0.00063015445,0.000244203,0.00018196658],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005815099,0.00040140175,0.0008401623,0.00055925915,0.00006892597,0.000055923247,0.00016703921,0.00029010355,0.00054847135],"category_scores_gemma":[0.00013685026,0.00036574656,0.00012373488,0.00078662345,0.00033506847,0.00019857768,0.00007558708,0.00025628094,0.000013104139],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020367776,0.0007276954,0.0011209326,0.00033396124,0.0011209557,0.00013697453,0.001885973,0.000012517681,0.98406607,0.000006083433,0.0018724799,0.0066795773],"study_design_scores_gemma":[0.01949994,0.0009111629,0.0055681146,0.0005858345,0.00029432197,0.00021975239,0.00009467958,0.00102927,0.96363777,0.000013170672,0.007811879,0.00033413045],"about_ca_topic_score_codex":0.0010731528,"about_ca_topic_score_gemma":0.0002053832,"teacher_disagreement_score":0.020428328,"about_ca_system_score_codex":0.00021391059,"about_ca_system_score_gemma":0.00057297084,"threshold_uncertainty_score":0.9998794},"labels":[],"label_agreement":null},{"id":"W4405047413","doi":"10.1182/blood-2024-202053","title":"Deciphering Minor Histocompatibility Antigen Immunoreactivity through Optimized T Cell Expansion Strategies","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Minor histocompatibility antigen; Immunology; Antigen; Biology; Histocompatibility; Major histocompatibility complex; Human leukocyte antigen","score_opus":0.036205202794188644,"score_gpt":0.3257998966375804,"score_spread":0.28959469384339176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405047413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9510372,0.0039582155,0.0009675708,0.00009685847,0.0001775295,0.00080267136,0.0000077583445,0.00027052857,0.042681616],"genre_scores_gemma":[0.9912215,0.0003422547,0.0054850294,0.000026693593,0.00018978314,0.000059063295,0.000023711575,0.000050616924,0.0026013483],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983442,0.0000930511,0.00027641372,0.00048846775,0.0004245771,0.00037329004],"domain_scores_gemma":[0.99896526,0.00019079159,0.000035298646,0.00063134957,0.00007567671,0.00010164758],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00037959724,0.00020989554,0.00038068212,0.00007261239,0.00008584002,0.00012242583,0.00013999433,0.00011570511,0.002131309],"category_scores_gemma":[0.000030978325,0.00017795806,0.00020592262,0.0002684507,0.00010911456,0.00029811938,0.00008903062,0.00040543094,0.00008832852],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039178235,0.0009694505,0.0017605867,0.00039857582,0.00015059162,0.00022856875,0.0013332615,0.000027542657,0.98694384,0.000051573097,0.00020818287,0.007536029],"study_design_scores_gemma":[0.0074912114,0.000740068,0.021634115,0.0004087077,0.00029534724,0.00016205186,0.0010551747,0.0014350585,0.9485436,0.00097525376,0.016771583,0.00048783538],"about_ca_topic_score_codex":0.00062055816,"about_ca_topic_score_gemma":0.000021563641,"teacher_disagreement_score":0.04018425,"about_ca_system_score_codex":0.00013111088,"about_ca_system_score_gemma":0.0003793825,"threshold_uncertainty_score":0.9987809},"labels":[],"label_agreement":null},{"id":"W4405048123","doi":"10.1182/blood-2024-210635","title":"Patients with Poor Functional Status at Intake Experience Early Failure of CAR T-Cell Therapy for Third Line Treatment of RR-LBCL","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Cart; Population; Internal medicine; Salvage therapy; Cohort; Univariate analysis; Retrospective cohort study; Surgery; Multivariate analysis; Chemotherapy","score_opus":0.024248885918860624,"score_gpt":0.2822549505573605,"score_spread":0.25800606463849984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405048123","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99640405,0.0015808997,0.00004486835,0.00009526164,0.00008353323,0.0011104618,0.00016830929,0.000030943607,0.00048166685],"genre_scores_gemma":[0.9927626,0.00023313702,0.0005449305,0.00002634022,0.00011645814,0.0001778968,0.00012938959,0.000037512127,0.005971701],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987427,0.000021398771,0.00023059077,0.00028165552,0.00046638478,0.00025729992],"domain_scores_gemma":[0.9992224,0.00010892082,0.000055763136,0.00026309272,0.0002366207,0.00011320166],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000054942124,0.00015764002,0.00029745122,0.00011091207,0.00003373209,0.000010747719,0.000051845585,0.00006794552,0.0006587391],"category_scores_gemma":[0.0000098377495,0.00010285913,0.0001318585,0.00019960724,0.000104142404,0.0000477157,0.000017145765,0.00007007473,0.0000074217787],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008970831,0.006653815,0.29108682,0.00036814698,0.001037604,0.000029908426,0.008833145,0.000007693271,0.6656695,0.000046278587,0.00065787777,0.016638374],"study_design_scores_gemma":[0.025858443,0.022732386,0.05765577,0.00013636467,0.00021364204,0.000009781279,0.00041977,0.000048018366,0.8621398,0.000019065541,0.030586604,0.00018032423],"about_ca_topic_score_codex":0.0001197578,"about_ca_topic_score_gemma":0.000029932597,"teacher_disagreement_score":0.23343106,"about_ca_system_score_codex":0.00009558616,"about_ca_system_score_gemma":0.00018748369,"threshold_uncertainty_score":0.7212732},"labels":[],"label_agreement":null},{"id":"W4405048675","doi":"10.1182/blood-2024-210720","title":"Assessing Gender and Racial Inclusion in CAR-T Cell Therapy Clinical Studies: A Scoping Review","year":2024,"lang":"en","type":"review","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Inclusion (mineral); MEDLINE; Inclusion and exclusion criteria; Family medicine; Demography; Gerontology; Alternative medicine; Psychology; Pathology","score_opus":0.38324976935478167,"score_gpt":0.5774928269549707,"score_spread":0.19424305760018906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405048675","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00018115196,0.9931602,9.388e-7,0.00007359683,0.00033473605,0.0042335726,0.000004485818,0.00005679591,0.0019545276],"genre_scores_gemma":[0.0000150012065,0.99755895,0.00015724753,0.00047019808,0.001013412,0.00024504904,0.000031268017,0.00012976545,0.00037912876],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99545443,0.00092527986,0.0015571389,0.0009071604,0.00070642604,0.00044954618],"domain_scores_gemma":[0.99799496,0.00083982374,0.0002701323,0.00059091067,0.00011585231,0.00018831779],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0040891846,0.0005030158,0.003957736,0.0003454995,0.00013340637,0.000090422705,0.00023057245,0.00044540135,0.00021346555],"category_scores_gemma":[0.00043308624,0.00035377056,0.0006995881,0.0007343086,0.00014985104,0.000082775885,0.0016208888,0.0016727399,0.000047338573],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000009722052,0.00027032275,0.000017114991,0.31356832,0.00035956173,0.00038090016,0.00028296656,1.9488322e-9,0.000010561844,0.0000011882979,0.00014182877,0.6849575],"study_design_scores_gemma":[0.0017600863,0.00018975434,0.0000044484514,0.6230013,0.002500392,0.00013219602,0.000035036213,5.862208e-7,0.000004534699,0.00002638029,0.37206906,0.00027625574],"about_ca_topic_score_codex":0.0000081739945,"about_ca_topic_score_gemma":0.000008849332,"teacher_disagreement_score":0.68468124,"about_ca_system_score_codex":0.00014953932,"about_ca_system_score_gemma":0.0017093637,"threshold_uncertainty_score":0.9998914},"labels":[],"label_agreement":null},{"id":"W4405048924","doi":"10.1182/blood-2024-211444","title":"Unwavering Priorities: Global Physician Alignment on Gene Therapy for Hemophilia","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Specialty; Family medicine; Demographics; Demography","score_opus":0.029531622374197895,"score_gpt":0.3249777534739233,"score_spread":0.29544613109972545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405048924","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97834873,0.0028499905,0.00012505689,0.0012230182,0.00036475257,0.0011785396,0.00007744326,0.00019075125,0.015641715],"genre_scores_gemma":[0.9873207,0.0007448308,0.0006688543,0.0012903409,0.0018238595,0.00016916433,0.000032741777,0.000065453554,0.007884025],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988103,0.00001678813,0.00014218467,0.0003212886,0.000377281,0.0003321446],"domain_scores_gemma":[0.99947345,0.00006555688,0.000013372962,0.0003048974,0.000038363534,0.00010434703],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00015266574,0.0001505602,0.00020328775,0.000049606766,0.00005483869,0.000056228408,0.00009242958,0.00005984632,0.00022578597],"category_scores_gemma":[0.000010410642,0.00012723361,0.00017245293,0.00017971486,0.000036298847,0.000032960907,0.000025091644,0.00011069766,0.000063335516],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008565216,0.0011006844,0.0005675241,0.00040785485,0.0009859266,0.00022814199,0.00050905545,0.0000074177447,0.74099946,0.0038946886,0.0021077944,0.24833491],"study_design_scores_gemma":[0.007531773,0.0028852557,0.0016778621,0.0003803293,0.00013185815,0.000067895606,0.0001116871,0.00029200266,0.7681378,0.0029000936,0.21558972,0.000293716],"about_ca_topic_score_codex":0.000014817994,"about_ca_topic_score_gemma":0.0000017351869,"teacher_disagreement_score":0.2480412,"about_ca_system_score_codex":0.00015655623,"about_ca_system_score_gemma":0.00012677709,"threshold_uncertainty_score":0.5188436},"labels":[],"label_agreement":null},{"id":"W4405049075","doi":"10.1182/blood-2024-210199","title":"A Canadian Cost-Utility Analysis of Epcoritamab Versus Current Therapies in Third-Line or Later Large B-Cell Lymphoma","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Lenalidomide; Rituximab; Population; Chemoimmunotherapy; Internal medicine; Oncology; Lymphoma; Multiple myeloma","score_opus":0.041577474496117525,"score_gpt":0.34036101461906393,"score_spread":0.2987835401229464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405049075","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.986857,0.0077777277,0.0000076085626,0.00054263056,0.000265054,0.0005012746,0.00026258448,0.000045192177,0.0037409158],"genre_scores_gemma":[0.9966076,0.0006981791,0.00003766797,0.000052187163,0.000096613716,0.000040356805,0.0001087345,0.000026836185,0.0023318299],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99832207,0.00009517138,0.00033515797,0.00036275628,0.00038843864,0.0004964021],"domain_scores_gemma":[0.99893373,0.00020655821,0.00002866411,0.00047320564,0.000105596,0.0002522701],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005732576,0.00016964349,0.00047761828,0.00096347247,0.000034024833,0.000033924698,0.00015052974,0.00010725343,0.0041900165],"category_scores_gemma":[0.00006751409,0.00012819485,0.0002456475,0.0018395617,0.00005406594,0.000050792154,0.000043732496,0.00023558905,0.00004762978],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01382831,0.023197215,0.51202583,0.0029240744,0.02022366,0.00441204,0.016717307,0.000020629053,0.02907588,0.0005271404,0.00388225,0.37316567],"study_design_scores_gemma":[0.11092205,0.003198301,0.31962952,0.0008504253,0.01163725,0.00005752227,0.0021928162,0.027681502,0.05582407,0.00019362934,0.46653897,0.0012739522],"about_ca_topic_score_codex":0.023128761,"about_ca_topic_score_gemma":0.2934271,"teacher_disagreement_score":0.4626567,"about_ca_system_score_codex":0.0002553482,"about_ca_system_score_gemma":0.0009218807,"threshold_uncertainty_score":0.9967203},"labels":[],"label_agreement":null},{"id":"W4405049108","doi":"10.1182/blood-2024-205736","title":"Routine Pre-Apheresis Markers As Predictors for Efficacy and Safety Outcomes Following CD19 CAR-T Cell Therapy - a Single Center Experience","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Apheresis; Medicine; Single Center; CAR T-cell therapy; Internal medicine; Oncology; Surgery; Chimeric antigen receptor; Immunotherapy; Cancer","score_opus":0.02096156753019747,"score_gpt":0.31125163888140317,"score_spread":0.2902900713512057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405049108","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99033004,0.0031944516,0.00005953265,0.0004918495,0.00042899384,0.0016306447,0.00003480252,0.00019705143,0.003632663],"genre_scores_gemma":[0.982554,0.00029673224,0.000423142,0.0002140801,0.00015907733,0.00015104355,0.000029916677,0.00008920489,0.016082814],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980751,0.00006574398,0.00032542052,0.0005603008,0.0004633248,0.00051010284],"domain_scores_gemma":[0.998774,0.0004940919,0.000035132118,0.00041174953,0.000045875397,0.00023916051],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003187481,0.0002693453,0.00040699195,0.00013210638,0.00012021594,0.00011724394,0.00015113571,0.00012232065,0.0008110829],"category_scores_gemma":[0.00013479755,0.00020962815,0.00030745275,0.00024111354,0.00009164606,0.00011550432,0.000074022326,0.00020603451,0.000010865763],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0039894795,0.0024763502,0.44292566,0.0004498511,0.0018666313,0.00027130754,0.011030019,0.0000019662366,0.5086936,0.000026523807,0.0011806359,0.027087955],"study_design_scores_gemma":[0.09298333,0.009259721,0.3410771,0.0016905813,0.0013227654,0.00025354102,0.0035415932,0.00041214214,0.34885493,0.00010878618,0.19885454,0.0016409836],"about_ca_topic_score_codex":0.00008687599,"about_ca_topic_score_gemma":0.000009764724,"teacher_disagreement_score":0.1976739,"about_ca_system_score_codex":0.00007104004,"about_ca_system_score_gemma":0.00010615308,"threshold_uncertainty_score":0.88807887},"labels":[],"label_agreement":null},{"id":"W4405049338","doi":"10.1182/blood-2024-206502","title":"Single-Cell Immuno-Metabolic Profiling of Apheresis Samples for Chimeric Antigen T Cell Receptor Therapy Using Cytometry By Time of Flight","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Flow cytometry; Mass cytometry; Chimeric antigen receptor; Antigen; Apheresis; Cell; Cell therapy; Immunology; Medicine; Molecular biology; Biology; Immunotherapy; Immune system; Platelet; Biochemistry","score_opus":0.03654596276350723,"score_gpt":0.2995784964865683,"score_spread":0.26303253372306107,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405049338","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.935388,0.06139368,0.00035498172,0.00004463489,0.0001240195,0.0011152137,0.00020106256,0.00007078732,0.0013076143],"genre_scores_gemma":[0.9644496,0.004398381,0.024730887,0.000053708292,0.00041638603,0.0000527539,0.00019618399,0.00022525078,0.0054768356],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981003,0.000087384324,0.0005200743,0.00040016611,0.00046692282,0.0004251536],"domain_scores_gemma":[0.99877125,0.00033215524,0.00014838389,0.00045960015,0.00018715742,0.000101455225],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004673736,0.00024465247,0.0006691543,0.00039384826,0.000057263725,0.000032336928,0.0002154819,0.00014802694,0.0016840249],"category_scores_gemma":[0.000051476698,0.000207846,0.00034030518,0.0010033908,0.0001224577,0.00007662935,0.0000507565,0.00019276477,0.000024558238],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039604583,0.0013510657,0.0019015786,0.0007391362,0.00045359455,0.000002840716,0.0003595989,0.0000013192622,0.9864529,0.0000053101144,0.00041146667,0.007925147],"study_design_scores_gemma":[0.0030617232,0.0007217088,0.00011737665,0.00018682258,0.00019646679,0.000009280061,0.00012156675,0.00020621798,0.98068964,0.000015347292,0.014490879,0.00018297962],"about_ca_topic_score_codex":0.00007754438,"about_ca_topic_score_gemma":3.0151207e-7,"teacher_disagreement_score":0.0569953,"about_ca_system_score_codex":0.000031316777,"about_ca_system_score_gemma":0.00022914125,"threshold_uncertainty_score":0.9992286},"labels":[],"label_agreement":null},{"id":"W4405049957","doi":"10.1182/blood-2024-204282","title":"Lintuzumab-Ac225 Exerts Mutation Agnostic Antileukemic Activity in Preclinical Models of AML","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Mutation; Cancer research; Leukemia; Medicine; Biology; Genetics; Immunology; Gene","score_opus":0.060134507179108974,"score_gpt":0.37524637745984196,"score_spread":0.315111870280733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405049957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930284,0.001048442,0.00020643642,0.00018820664,0.00010685366,0.0004785121,0.000010354126,0.00006663468,0.0048661665],"genre_scores_gemma":[0.9979906,0.0003621992,0.000167964,0.0000254274,0.00011119243,0.000031825188,0.000013560105,0.00002941635,0.0012677903],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998759,0.00008153745,0.00028850022,0.00030483858,0.0003450682,0.00022106999],"domain_scores_gemma":[0.9989489,0.0005898121,0.000033803128,0.0002840744,0.000058674963,0.00008474307],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041140296,0.00010780932,0.0003036136,0.00021126393,0.000012374586,0.000016541417,0.000079245896,0.00013290429,0.00039981696],"category_scores_gemma":[0.0002666216,0.00009780439,0.00011054709,0.00034418976,0.00007459509,0.000110092,0.000043532298,0.00038139764,0.000033289034],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013731611,0.003020978,0.0068876874,0.0017005042,0.00036395845,0.0014226285,0.0017737957,0.0008149835,0.8416465,0.0003385564,0.00039558538,0.1402617],"study_design_scores_gemma":[0.013939816,0.0029763726,0.047948558,0.0033641334,0.0006363916,0.00049406127,0.00010852976,0.1611328,0.7604042,0.0074837813,0.0009833929,0.000527917],"about_ca_topic_score_codex":0.0001483314,"about_ca_topic_score_gemma":0.000037952068,"teacher_disagreement_score":0.16031782,"about_ca_system_score_codex":0.00008265453,"about_ca_system_score_gemma":0.00033199473,"threshold_uncertainty_score":0.43777153},"labels":[],"label_agreement":null},{"id":"W4405050041","doi":"10.1182/blood-2024-201855","title":"Long-Term Outcomes and Adverse Events of CAR T-19 Cell Therapy in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia - a Systematic Review and Meta-Analysis","year":2024,"lang":"en","type":"review","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Adverse effect; Meta-analysis; Lymphoblastic Leukemia; Oncology; Refractory (planetary science); Leukemia; CAR T-cell therapy; Acute lymphocytic leukemia; Internal medicine; Cancer; Chimeric antigen receptor; Biology; Immunotherapy","score_opus":0.08288058284013552,"score_gpt":0.3791185913339176,"score_spread":0.2962380084937821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405050041","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002263661,0.9910733,0.0000011532708,0.000023192277,0.00003511487,0.006270036,0.00017168882,0.000033370412,0.00012849062],"genre_scores_gemma":[0.00034266585,0.974963,0.000046589732,0.00014722392,0.000018578536,0.00074027677,0.00009869734,0.00013522281,0.023507738],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99479,0.00095733994,0.0020531311,0.0009417887,0.00082507415,0.00043262253],"domain_scores_gemma":[0.9964196,0.00088674354,0.00085263315,0.001416315,0.00011516444,0.00030956377],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014205188,0.0008784568,0.013249256,0.001131329,0.000033239503,0.000019784962,0.0003493199,0.0004115099,0.00088950683],"category_scores_gemma":[0.00019002949,0.00047668282,0.0030139922,0.0015719808,0.000104063205,0.00005194754,0.00018100197,0.00068475516,0.000041850224],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004449179,0.00041911015,0.00013146832,0.83897495,0.15902025,0.00068423455,0.00009573264,6.8284855e-8,0.000020122752,3.6629848e-7,0.000028960656,0.0005802388],"study_design_scores_gemma":[0.0033142143,0.00046417338,0.000036441863,0.055516552,0.9387133,0.00023550774,0.00001211136,0.0000016473398,0.00000988388,0.0000014226956,0.0013069686,0.0003877429],"about_ca_topic_score_codex":0.00006510687,"about_ca_topic_score_gemma":0.00003589657,"teacher_disagreement_score":0.7834584,"about_ca_system_score_codex":0.0003545901,"about_ca_system_score_gemma":0.0010069509,"threshold_uncertainty_score":0.9997685},"labels":[],"label_agreement":null},{"id":"W4405051535","doi":"10.1182/blood-2024-211007","title":"Delays from Progression to Initial Appointment Occur with External Referrals for CAR T-Cell Therapy but Do Not Impact Survival","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University Health Network; Princess Margaret Cancer Centre","funders":"Eisai; BeiGene; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Internal medicine; Intensive care medicine","score_opus":0.06841936375932402,"score_gpt":0.39594189204138525,"score_spread":0.32752252828206124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405051535","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99198806,0.0021110114,0.0009110492,0.00039124003,0.00022796482,0.0021802867,0.00030855957,0.00013099775,0.0017508285],"genre_scores_gemma":[0.9935555,0.00013427158,0.0028104316,0.00021145234,0.0012575203,0.00034837873,0.000104285755,0.000101695696,0.0014764867],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978438,0.00008422252,0.00026917664,0.000546316,0.0007447984,0.0005116913],"domain_scores_gemma":[0.99879587,0.00020407881,0.000041173695,0.00045866714,0.00013630388,0.00036390134],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000411781,0.0002805247,0.00039625925,0.00015994732,0.00007036829,0.00014931317,0.00017279651,0.00012036999,0.0014765967],"category_scores_gemma":[0.000022051876,0.00017785875,0.00021124363,0.00020259796,0.000045289715,0.00007417051,0.000056716453,0.00030242282,0.00008410751],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009500839,0.0010997804,0.0038822573,0.00011063187,0.0006017955,0.0006121339,0.0012157309,0.0000042769148,0.8974951,0.000018645145,0.00066060305,0.08479824],"study_design_scores_gemma":[0.019028565,0.013775862,0.006244027,0.0008997553,0.00031093156,0.00018143264,0.00022348088,0.00016829383,0.94358486,0.0002040531,0.014886048,0.00049271155],"about_ca_topic_score_codex":0.00029727048,"about_ca_topic_score_gemma":0.000019468927,"teacher_disagreement_score":0.084305525,"about_ca_system_score_codex":0.00014470346,"about_ca_system_score_gemma":0.0004976466,"threshold_uncertainty_score":0.9994362},"labels":[],"label_agreement":null},{"id":"W4405052961","doi":"10.1182/blood-2024-194331","title":"Glofitamab in Combination with R-ICE Chemoimmunotherapy or as Monotherapy in Children and Adolescents with Relapsed/Refractory B-cell non-Hodgkin Lymphoma: Initial Safety and Efficacy Results from the Ongoing iMATRIX-GLO Study","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Chemoimmunotherapy; Internal medicine; Rituximab; Cohort; Oncology; Lymphoma","score_opus":0.009643382075257279,"score_gpt":0.2786636109654514,"score_spread":0.2690202288901941,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405052961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944031,0.0019669642,0.000015533931,0.00038325836,0.00003562803,0.0027480596,0.00003170015,0.00006466746,0.0003510829],"genre_scores_gemma":[0.9977933,0.0013752425,0.00011761631,0.00017058967,0.00010936646,0.000046546487,0.000051552375,0.000095972595,0.00023977766],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976499,0.00023756015,0.00046833322,0.0007033522,0.0005737508,0.0003671034],"domain_scores_gemma":[0.9988016,0.00044251577,0.00009765549,0.0005005293,0.000059616053,0.0000980773],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007824356,0.0003315481,0.00046624808,0.00025416902,0.000102657505,0.00015384497,0.00018128971,0.00013523703,0.000042151703],"category_scores_gemma":[0.000049943163,0.00020475035,0.000036459718,0.00069512194,0.00015139532,0.00018322663,0.00006211455,0.0005317866,0.000007057438],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15922382,0.019184012,0.6332173,0.0001621977,0.0010567926,0.0012452055,0.02768815,0.000010843297,0.016146032,0.000011002013,0.000042820215,0.14201182],"study_design_scores_gemma":[0.16482039,0.004837608,0.82516545,0.001212112,0.00012185266,0.00015189947,0.00083830976,0.00011667617,0.002339484,0.000013275503,0.000120231256,0.00026271574],"about_ca_topic_score_codex":0.0029169049,"about_ca_topic_score_gemma":0.0007252704,"teacher_disagreement_score":0.19194815,"about_ca_system_score_codex":0.00015525562,"about_ca_system_score_gemma":0.00034108333,"threshold_uncertainty_score":0.8349477},"labels":[],"label_agreement":null},{"id":"W4405056347","doi":"10.1126/science.adl4237","title":"Programming tissue-sensing T cells that deliver therapies to the brain","year":2024,"lang":"en","type":"article","venue":"Science","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Waterloo","funders":"Cancer Moonshot; Moonshot Research and Development Program; University of California, San Francisco; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco; National Institute of Neurological Disorders and Stroke; National Cancer Institute; Advanced Research Projects Agency; National Institutes of Health; Multiple Sclerosis Society; Valhalla Foundation; Parker Institute for Cancer Immunotherapy; Emerson Collective; Sandler Foundation","keywords":"Neuroinflammation; Central nervous system; Chimeric antigen receptor; Antigen; Biology; Cell biology; Extracellular; Extracellular matrix; Neuroscience; Clearance; Receptor; Immunology; Immunotherapy; Medicine; Inflammation; Immune system","score_opus":0.04704679087321421,"score_gpt":0.3627700912532719,"score_spread":0.3157233003800577,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405056347","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9532244,0.0023307675,0.0018301423,0.035928644,0.0008533624,0.0010417294,0.0000018623714,0.00019770356,0.004591355],"genre_scores_gemma":[0.9744223,0.0000448134,0.003324101,0.001524626,0.0002427826,0.000007911488,4.591094e-7,0.000018906314,0.020414142],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.998328,0.000031636213,0.00008103672,0.00034571037,0.0007951475,0.00041851756],"domain_scores_gemma":[0.9992621,0.00014051002,0.000009185801,0.0003602732,0.000084474166,0.00014343571],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001447315,0.0000855812,0.00009080108,0.00016629584,0.00023101785,0.0003527478,0.00027417712,0.000022788021,0.0005110497],"category_scores_gemma":[0.000089080386,0.000049967908,0.000039161634,0.0012164874,0.00046483445,0.00012653017,0.000119290766,0.00018676685,0.00041969583],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000008630145,0.0000047104068,0.000031625586,0.0000112241605,0.0000046640844,0.00003014149,0.003194751,0.0000028152517,0.517527,0.000046613408,0.00092569477,0.47821218],"study_design_scores_gemma":[0.000076185635,0.0001388453,0.0007633838,0.00010156352,0.000006343197,0.000054720753,0.00080660876,0.0010485288,0.3559546,0.000066666704,0.6409072,0.00007530933],"about_ca_topic_score_codex":0.00006610672,"about_ca_topic_score_gemma":0.000026133808,"teacher_disagreement_score":0.63998157,"about_ca_system_score_codex":0.00009886718,"about_ca_system_score_gemma":0.0001977649,"threshold_uncertainty_score":0.5595636},"labels":[],"label_agreement":null},{"id":"W4405062597","doi":"10.26685/urncst.738","title":"Optimizing Chimeric Artificial T Cell Receptor Therapy for Solid Tumour Targeting by Manipulating the Tumour Microenvironment: A Literature Review","year":2024,"lang":"en","type":"review","venue":"Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Chimeric antigen receptor; Cancer research; Tumor microenvironment; Receptor; Targeted therapy; Computational biology; Medicine; Chemistry; Immunotherapy; Biology; Internal medicine; Cancer; Tumor cells","score_opus":0.09181363673023372,"score_gpt":0.4492578110532317,"score_spread":0.35744417432299797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405062597","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010771835,0.9592348,0.0000060948364,0.036698293,0.00034857183,0.0024991909,0.000015716074,0.00003936769,0.000080781574],"genre_scores_gemma":[0.0017993175,0.9952903,0.00068625924,0.00026022753,0.0006466812,0.000118275064,0.000028549151,0.00006562765,0.0011047997],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9930095,0.00079911697,0.001759025,0.0012809366,0.0015115631,0.0016398641],"domain_scores_gemma":[0.9967595,0.001383262,0.00048160902,0.00040312973,0.0005051074,0.00046740574],"candidate_categories":["metaepi_narrow","sts","research_integrity"],"consensus_categories":["sts"],"category_scores_codex":[0.017432906,0.0005582462,0.0018507839,0.0012512088,0.0014422134,0.00073108054,0.0010890675,0.0006234154,0.00005289646],"category_scores_gemma":[0.001867554,0.00029284682,0.0005090795,0.0047408543,0.00312395,0.00024265882,0.0007403589,0.010818265,0.000026899947],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00010260143,0.0001907367,0.000018544562,0.0068223104,0.00013449781,0.00019141239,0.0000321546,8.1224975e-8,0.00804015,0.00011862237,0.008220334,0.9761286],"study_design_scores_gemma":[0.00138022,0.0019101106,0.0000046116384,0.079487965,0.00038224223,0.0028626423,0.0003444016,0.0005677642,0.00039527053,0.0060397433,0.9059786,0.00064643205],"about_ca_topic_score_codex":0.0000061827936,"about_ca_topic_score_gemma":0.0000029970545,"teacher_disagreement_score":0.9754821,"about_ca_system_score_codex":0.00046282914,"about_ca_system_score_gemma":0.0010188045,"threshold_uncertainty_score":0.9999524},"labels":[],"label_agreement":null},{"id":"W4405064946","doi":"10.1101/2024.11.29.626103","title":"Boosting of CAR-T cells with rhabdovirus is limited by type I interferon and rapid contraction","year":2024,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph; Ottawa Hospital; McMaster University","funders":"","keywords":"Boosting (machine learning); Interferon; Contraction (grammar); Virology; Biology; Computer science; Artificial intelligence; Endocrinology","score_opus":0.019376056460681523,"score_gpt":0.255078554392699,"score_spread":0.23570249793201747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405064946","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99094933,0.006270478,0.00006536837,0.00037474354,0.00065943296,0.0011406438,0.00021547341,0.00023040164,0.00009412499],"genre_scores_gemma":[0.99670005,0.0016927036,0.0006777005,0.00021460271,0.00029648968,0.000058236248,0.0000010641169,0.00019618942,0.0001629668],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99738747,0.00010390975,0.0005263566,0.00093819725,0.0005683028,0.00047578107],"domain_scores_gemma":[0.99757,0.00014017565,0.0002972272,0.0009373878,0.00074614026,0.00030908379],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00055508345,0.0004999691,0.0008126338,0.00039526453,0.000063472384,0.0001346056,0.00019741512,0.0005164075,0.00046124938],"category_scores_gemma":[0.00011466675,0.0004563518,0.000114469774,0.0005669483,0.00021979262,0.00006678464,0.00037740055,0.0014929854,0.000042565378],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011013239,0.00012487586,0.0017358937,0.001637827,0.0005735646,0.00008666302,0.000045381257,0.0000027256524,0.9928242,0.000013264944,0.0017985486,0.000055721885],"study_design_scores_gemma":[0.0011279695,0.00085388136,0.003568556,0.0017572634,0.00043132438,1.7479177e-7,0.000013755179,0.0005219287,0.98098826,7.1015916e-7,0.010290373,0.00044581102],"about_ca_topic_score_codex":0.00020889548,"about_ca_topic_score_gemma":0.000003045552,"teacher_disagreement_score":0.011835957,"about_ca_system_score_codex":0.00031374826,"about_ca_system_score_gemma":0.00061194634,"threshold_uncertainty_score":0.9997888},"labels":[],"label_agreement":null},{"id":"W4405092569","doi":"10.1182/blood-2024-211475","title":"Comparative Real-World Outcomes of Commercial CD19-Directed CAR T-Cell Therapies in Large B-Cell Lymphoma","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Lymphoma; Medicine; CD19; Immunology; Cancer research; Internal medicine; Antibody","score_opus":0.036435702091213884,"score_gpt":0.3426034512495697,"score_spread":0.3061677491583558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405092569","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9288317,0.0026910794,0.0000025045117,0.00035515748,0.00015639912,0.0005927751,0.00006650263,0.00016759761,0.0671363],"genre_scores_gemma":[0.9766642,0.00037695424,0.00018089681,0.00012232007,0.00012040874,0.00004225964,0.00004808174,0.000048574402,0.022396348],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.998152,0.00018791853,0.00041918436,0.00034188802,0.00046566856,0.00043330068],"domain_scores_gemma":[0.9989744,0.0003361148,0.00005689269,0.0004088133,0.0001070585,0.00011672115],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003858505,0.00023684649,0.000769212,0.00047725116,0.00004232076,0.000029662338,0.00017615464,0.000102855636,0.0010866458],"category_scores_gemma":[0.000017167118,0.00019386664,0.00020323717,0.00084001024,0.00011442354,0.0000595148,0.00007564095,0.00028117053,0.00008361639],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00088150264,0.01358926,0.5005364,0.0008681015,0.0010310782,0.0006299902,0.017040143,0.0000015811147,0.45609275,0.00062888477,0.0048084585,0.0038918755],"study_design_scores_gemma":[0.028767966,0.0006982319,0.56538236,0.0003005729,0.0003314378,0.000018527926,0.0012221216,0.00034754476,0.37556365,0.00014065317,0.02679979,0.00042710762],"about_ca_topic_score_codex":0.0011247743,"about_ca_topic_score_gemma":0.002394035,"teacher_disagreement_score":0.08052909,"about_ca_system_score_codex":0.00009840507,"about_ca_system_score_gemma":0.00025501067,"threshold_uncertainty_score":0.9998265},"labels":[],"label_agreement":null},{"id":"W4405126172","doi":"10.1182/blood-2024-201784","title":"CD19-CAR T Cells As Definitive Consolidation for Older Adults with B-Cell Acute Lymphoblastic Leukemia in First Complete Remission: A Pilot Study","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Lymphoblastic Leukemia; Medicine; Acute lymphocytic leukemia; CD19; Leukemia; Immunology; Internal medicine; Cancer research; Flow cytometry","score_opus":0.02819512710747323,"score_gpt":0.2907933705097839,"score_spread":0.26259824340231064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405126172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99140185,0.00027303057,0.00012108882,0.00018523246,0.00010732651,0.0034182717,0.00007352233,0.0001073087,0.00431238],"genre_scores_gemma":[0.9954591,0.00009450784,0.000355759,0.00014063006,0.00015066461,0.00043443777,0.00009546203,0.000081228645,0.0031882217],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998081,0.00007605781,0.00033092155,0.0006025021,0.00048527878,0.0004241883],"domain_scores_gemma":[0.99855036,0.00066895375,0.000053065312,0.00035911563,0.00017661313,0.0001919062],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002884434,0.00025459353,0.00039494244,0.00025656525,0.00009141464,0.000071306305,0.00012762722,0.00006809237,0.00063090195],"category_scores_gemma":[0.000060216844,0.00020273993,0.000068948255,0.00046276956,0.0000769092,0.00007520414,0.00005930255,0.0002742361,0.00016168765],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043095954,0.019293092,0.010068947,0.0049675023,0.003081113,0.0086798165,0.028925197,0.00010642647,0.87126225,0.00019901032,0.005816833,0.0045038587],"study_design_scores_gemma":[0.2722165,0.10032233,0.01598238,0.0121048195,0.0048934943,0.0012892049,0.014599139,0.010748796,0.5522407,0.0002936507,0.013177503,0.0021314868],"about_ca_topic_score_codex":0.00022499532,"about_ca_topic_score_gemma":0.00022272201,"teacher_disagreement_score":0.31902155,"about_ca_system_score_codex":0.00034845824,"about_ca_system_score_gemma":0.000744996,"threshold_uncertainty_score":0.82674944},"labels":[],"label_agreement":null},{"id":"W4405177856","doi":"10.1182/blood.2024024965","title":"Tumor burden quantified by soluble B-cell maturation antigen and metabolic tumor volume determines myeloma CAR-T outcomes","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"","keywords":"Medicine; Multiple myeloma; Oncology; Chimeric antigen receptor; Cohort; Internal medicine; Bone marrow; Immunology; Cancer; Immunotherapy","score_opus":0.017851523879817328,"score_gpt":0.28673564636660515,"score_spread":0.26888412248678784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405177856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9833004,0.012795927,0.00002022468,0.0010229372,0.0003180713,0.00064830395,0.00003663082,0.00021565505,0.0016418379],"genre_scores_gemma":[0.9431105,0.00036510223,0.00037760017,0.0001457241,0.00040724388,0.00006016,0.00006750824,0.00008230987,0.055383798],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982155,0.00006463963,0.00032850145,0.0005018809,0.00045391012,0.00043557704],"domain_scores_gemma":[0.9991526,0.00009845741,0.000049859635,0.00040809665,0.000092235874,0.00019872218],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029227373,0.00025563833,0.00048897986,0.00020919325,0.00009886698,0.00022853122,0.00013617439,0.00007582872,0.00090329495],"category_scores_gemma":[0.00006192769,0.00020778396,0.00014407828,0.0002570373,0.00009210691,0.00016546977,0.000086745,0.00026502484,0.00023637636],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012271144,0.00020101047,0.018123414,0.00038128614,0.0002668069,0.00047957417,0.00047234423,4.0380186e-7,0.969147,0.000038701,0.0056513697,0.0051153647],"study_design_scores_gemma":[0.0062921597,0.0005132386,0.06286906,0.00018576124,0.00082284416,0.0009374244,0.00034403676,0.0031056895,0.71397513,0.00012008972,0.21016274,0.0006718233],"about_ca_topic_score_codex":0.0003056692,"about_ca_topic_score_gemma":0.000028641249,"teacher_disagreement_score":0.2551719,"about_ca_system_score_codex":0.000019581294,"about_ca_system_score_gemma":0.00013019009,"threshold_uncertainty_score":0.9890446},"labels":[],"label_agreement":null},{"id":"W4405177945","doi":"10.1182/blood.2024025673","title":"Anti-CD19 antibody cotreatment enhances serial killing activity of anti-CD19 CAR-T/-NK cells and reduces trogocytosis","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"CD19; Chimeric antigen receptor; Antibody; Antigen; Effector; Monoclonal antibody; Biology; Cancer research; Immunology; Chemistry; Cell biology; T cell; Immune system","score_opus":0.022774162309239055,"score_gpt":0.32420242912402375,"score_spread":0.3014282668147847,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405177945","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99497384,0.0026635765,0.000021379452,0.00026687852,0.00052306213,0.0006589409,0.00008663055,0.000111364505,0.00069434126],"genre_scores_gemma":[0.9919318,0.0059031807,0.0002998871,0.000015229576,0.00056069053,0.000021963002,0.00002815974,0.000054992302,0.0011841097],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99798065,0.00011019187,0.00032106426,0.0005966183,0.00053962274,0.0004518711],"domain_scores_gemma":[0.99903965,0.00022097278,0.00008129426,0.0003738501,0.00009512895,0.00018909447],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00034267156,0.00028803205,0.0007195982,0.00023119328,0.00009354339,0.00009313994,0.00012358768,0.00015713592,0.00042869555],"category_scores_gemma":[0.000028252924,0.00023659864,0.00019886368,0.00038407298,0.00020956315,0.0001539248,0.00009071943,0.0002763867,0.000022125905],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023136007,0.00091409625,0.002798098,0.0005690934,0.0007550048,0.00017981247,0.0006586921,0.000002558791,0.9886509,0.000013066198,0.000066811386,0.0051604835],"study_design_scores_gemma":[0.0025710633,0.00087490503,0.003729173,0.00045117814,0.00054259604,0.00008387851,0.00015622804,0.000120092445,0.9903296,0.000016790296,0.00092448393,0.00019999534],"about_ca_topic_score_codex":0.00031239956,"about_ca_topic_score_gemma":0.000011531285,"teacher_disagreement_score":0.0049604885,"about_ca_system_score_codex":0.000055769746,"about_ca_system_score_gemma":0.00023213141,"threshold_uncertainty_score":0.9648213},"labels":[],"label_agreement":null},{"id":"W4405181441","doi":"10.1158/1538-8514.cancerchem24-ia017","title":"Abstract IA017: Transferrin receptor targeting chimeras (TransTACs) for targeted degradation of membrane and extracellular proteins in cancer","year":2024,"lang":"en","type":"article","venue":"Molecular Cancer Therapeutics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Transferrin receptor; Epidermal growth factor receptor; Cancer cell; Cancer; Cancer research; Targeted therapy; Extracellular; Receptor; Biology; Chemistry; Medicine; Cell biology; Biochemistry; Internal medicine","score_opus":0.04099871369861158,"score_gpt":0.3359801257257002,"score_spread":0.2949814120270886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405181441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9100767,0.078445435,0.005893273,0.0026942429,0.00020849134,0.002361409,0.00013122827,0.00006662888,0.00012260476],"genre_scores_gemma":[0.9881216,0.008167126,0.0017143748,0.00020581814,0.00012092138,0.0006335698,0.000086960186,0.00012554949,0.0008240755],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981568,0.000064137195,0.00047325282,0.00045655746,0.0004286867,0.00042057212],"domain_scores_gemma":[0.99940836,0.00007480417,0.000052229952,0.00022501528,0.00013395508,0.000105612315],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00046671843,0.00025937895,0.00041481399,0.00024941016,0.00004786771,0.00004065572,0.00011229879,0.00018173584,0.0010125767],"category_scores_gemma":[0.000011763745,0.0002417866,0.00017103985,0.000440803,0.000091901056,0.00009123356,0.000010558639,0.0003996026,0.0000014643031],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00068959227,0.00011818375,0.00040741803,0.0014281454,0.00038773098,0.000027050854,0.0008820697,0.0001744447,0.8908954,0.00016150027,0.000015002963,0.10481346],"study_design_scores_gemma":[0.0019298355,0.00024223315,0.00057754555,0.000594956,0.0001773451,0.000003955536,0.000110899346,0.0037053418,0.96205103,0.00008838152,0.030276667,0.0002418158],"about_ca_topic_score_codex":0.00072311616,"about_ca_topic_score_gemma":0.00020104059,"teacher_disagreement_score":0.10457164,"about_ca_system_score_codex":0.00020529173,"about_ca_system_score_gemma":0.00038807903,"threshold_uncertainty_score":0.99990064},"labels":[],"label_agreement":null},{"id":"W4405186265","doi":"10.1016/j.stem.2024.11.010","title":"Patient-derived glioblastoma organoids as real-time avatars for assessing responses to clinical CAR-T cell therapy","year":2024,"lang":"en","type":"article","venue":"Cell stem cell","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":82,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Neurological Disorders and Stroke; National Cancer Institute; National Institutes of Health; Ontario Institute for Regenerative Medicine; Abramson Cancer Center; University of Pennsylvania; Diabetes Research Center, Institute for Diabetes, Obesity and Metabolism, Perelman School of Medicine, University of Pennsylvania; Dr. Miriam and Sheldon G. Adelson Medical Research Foundation","keywords":"Organoid; Biology; Glioblastoma; Cell therapy; CAR T-cell therapy; Cancer research; Bioinformatics; Neuroscience; Stem cell; Cell biology; Cancer; Immunotherapy; Genetics; Chimeric antigen receptor","score_opus":0.04223789516226863,"score_gpt":0.36520614074426455,"score_spread":0.32296824558199594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405186265","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97081524,0.002209596,0.00013189398,0.0004920808,0.0011136081,0.0028399753,0.00006914792,0.0006021091,0.021726344],"genre_scores_gemma":[0.8504028,0.0013834651,0.0019732264,0.0008838546,0.00096060225,0.00022222081,0.00006848678,0.00039610092,0.14370927],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9950364,0.00055255275,0.0010805263,0.0013200269,0.0009121132,0.001098362],"domain_scores_gemma":[0.99527884,0.0021619278,0.0001488717,0.0011730377,0.0003888629,0.00084848976],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0014451813,0.0005725768,0.00092958426,0.0004940512,0.00023770868,0.00034377884,0.0003819571,0.00044990133,0.0039119073],"category_scores_gemma":[0.000070621536,0.00050156296,0.00072415447,0.0008466671,0.00017315989,0.0002003238,0.00021075181,0.000713504,0.0024363685],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00483702,0.0005757145,0.0006402986,0.0005338874,0.00009896439,0.0003978671,0.0016017238,0.0000057889515,0.9261324,0.0000030945084,0.020866357,0.044306893],"study_design_scores_gemma":[0.0027565886,0.0051629166,0.0003370438,0.00019671915,0.00010189747,0.00003224082,0.00090044463,0.00037995033,0.7571275,0.000016986807,0.23252198,0.00046570046],"about_ca_topic_score_codex":0.00008381703,"about_ca_topic_score_gemma":0.00000510139,"teacher_disagreement_score":0.21165563,"about_ca_system_score_codex":0.00036700812,"about_ca_system_score_gemma":0.0011415756,"threshold_uncertainty_score":0.9997436},"labels":[],"label_agreement":null},{"id":"W4405248118","doi":"10.1002/cpt.3512","title":"Mapping the Clinical Development Trajectory of Cell and Gene Therapy Products","year":2024,"lang":"en","type":"article","venue":"Clinical Pharmacology & Therapeutics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Cancer Institute","keywords":"Medicine; Chimeric antigen receptor; Clinical trial; Internal medicine; Oncology; Immunotherapy","score_opus":0.2873189533852471,"score_gpt":0.4787642868699958,"score_spread":0.19144533348474868,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405248118","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95785713,0.022755923,0.000098701625,0.01501019,0.002374239,0.0012071587,0.000004409607,0.00010403742,0.00058823195],"genre_scores_gemma":[0.90622336,0.049669713,0.0026292768,0.033224206,0.0027514796,0.00008201495,0.000013775526,0.00011097435,0.005295228],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9964747,0.00081669475,0.0012654226,0.00064495474,0.00035720482,0.00044101872],"domain_scores_gemma":[0.9966122,0.0024151262,0.00013894284,0.0004173258,0.00021570531,0.0002007221],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003852476,0.00025619668,0.00065991096,0.00013102755,0.0001132638,0.000025147576,0.00030264686,0.00031371435,0.0008012384],"category_scores_gemma":[0.00003365189,0.00016456883,0.00026480816,0.00041707497,0.0012583442,0.00004082382,0.00013267228,0.0014491245,0.00005653921],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001567854,0.001373555,0.012013803,0.0002530426,0.002562176,0.00009986289,0.0016836821,0.0000014681359,0.646531,0.000007534905,0.008251415,0.32565463],"study_design_scores_gemma":[0.004218733,0.0012738514,0.047649067,0.000057270212,0.0003965515,0.00006114346,0.00016098308,0.00046490997,0.18299651,0.000073099545,0.762411,0.00023688133],"about_ca_topic_score_codex":0.000001759204,"about_ca_topic_score_gemma":7.369907e-7,"teacher_disagreement_score":0.75415957,"about_ca_system_score_codex":0.000053500113,"about_ca_system_score_gemma":0.0010148847,"threshold_uncertainty_score":0.87729985},"labels":[],"label_agreement":null},{"id":"W4405264395","doi":"10.3389/fimmu.2024.1347404","title":"Cytokine screening identifies TNF to potentially enhance immunogenicity of pediatric sarcomas","year":2024,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"Deutschen Konsortium für Translationale Krebsforschung; Deutsche Forschungsgemeinschaft; Technische Universität München; Wilhelm Sander-Stiftung","keywords":"CD8; ELISPOT; Tumor necrosis factor alpha; Cytotoxic T cell; Cancer research; Immunology; Major histocompatibility complex; T cell; Cytokine; Biology; Medicine; Antigen; Immune system; In vitro","score_opus":0.015744929768898994,"score_gpt":0.2984258400617035,"score_spread":0.28268091029280445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405264395","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.895465,0.05260716,0.046149213,0.0009528176,0.0028140626,0.00066531834,0.000021907299,0.00011948158,0.0012050269],"genre_scores_gemma":[0.9665833,0.0037179787,0.016846472,0.00010520908,0.00036658405,0.00005965439,0.00003467578,0.0000709597,0.012215137],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979141,0.00014561405,0.00056260626,0.00047107632,0.00035240222,0.000554243],"domain_scores_gemma":[0.9990725,0.00009602505,0.000062869985,0.00056553574,0.00012976631,0.00007329377],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060168887,0.0002042397,0.0005853776,0.0012178378,0.000050138377,0.000032242522,0.00036747742,0.00020729304,0.0007430183],"category_scores_gemma":[0.00020007197,0.00020549535,0.00020133879,0.001244636,0.00020131866,0.0001132557,0.00025627273,0.0006141263,0.00006223898],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020710337,0.00015251825,0.015044078,0.0002456422,0.00069491175,0.00031143375,0.0009163058,0.000029710754,0.80716306,0.00011787995,0.009114499,0.16413893],"study_design_scores_gemma":[0.005237721,0.00253188,0.18116951,0.00071537954,0.0005383556,0.0003882699,0.0018921987,0.0009781338,0.6873221,0.0018668121,0.11633529,0.0010243772],"about_ca_topic_score_codex":0.00031330332,"about_ca_topic_score_gemma":0.000028754346,"teacher_disagreement_score":0.16612543,"about_ca_system_score_codex":0.00018951377,"about_ca_system_score_gemma":0.000208713,"threshold_uncertainty_score":0.83798575},"labels":[],"label_agreement":null},{"id":"W4405273291","doi":"10.1182/bloodadvances.2024014903","title":"Safety and efficacy of glofitamab for relapsed/refractory large B-cell lymphoma in a multinational real-world study","year":2024,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovation Cluster (Canada)","funders":"Cilag; Berlin Institute of Health; Swedish Orphan Biovitrum; Incyte; BeiGene; Agios Pharmaceuticals; Regeneron Pharmaceuticals; Amgen; Ariad Pharmaceuticals; Gilead Sciences; Sanofi; Pfizer; Les Laboratories Pierre Fabre; MorphoSys; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Bendamustine; Refractory (planetary science); Cytokine release syndrome; Rituximab; Oncology; Salvage therapy; Gastroenterology; Lymphoma; Surgery; Chemotherapy; Immunotherapy; Cancer; Chimeric antigen receptor; Biology","score_opus":0.016827185534477724,"score_gpt":0.3415337235392444,"score_spread":0.3247065380047667,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405273291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9844513,0.008391415,0.000037459893,0.00019504021,0.00012417293,0.0014329172,0.00006871472,0.00005072142,0.0052482774],"genre_scores_gemma":[0.9889493,0.001203775,0.00078844494,0.000025869142,0.00012974441,0.00007451411,0.000029296218,0.00003124943,0.008767808],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9986608,0.000058124828,0.00034269708,0.00034885976,0.0003408326,0.00024870635],"domain_scores_gemma":[0.99869,0.00090751797,0.000051113333,0.0001916919,0.00008540745,0.000074251424],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00055310386,0.00013179953,0.0003139801,0.00029490876,0.000043217082,0.00001544859,0.000079275276,0.00004214005,0.00014287364],"category_scores_gemma":[0.0001477269,0.00011262638,0.000073057876,0.00039273387,0.00006088756,0.00013086322,0.000050160146,0.000120363475,0.000004170131],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014357091,0.043698173,0.30907306,0.0036572518,0.0007724647,0.00055560947,0.007568967,0.000036401598,0.07643929,0.0037799869,0.00037041755,0.53969127],"study_design_scores_gemma":[0.11408772,0.0048665847,0.5501772,0.00077299145,0.00035006867,0.000033951976,0.0022677497,0.0015859505,0.015757173,0.000400977,0.30925268,0.00044692957],"about_ca_topic_score_codex":0.000055244847,"about_ca_topic_score_gemma":0.00043353974,"teacher_disagreement_score":0.53924435,"about_ca_system_score_codex":0.000072189934,"about_ca_system_score_gemma":0.00015151946,"threshold_uncertainty_score":0.45927703},"labels":[],"label_agreement":null},{"id":"W4405285852","doi":"10.1177/12034754241303057","title":"Molecular-Guided Therapy for Melanoma in Canada: Overview of Current Practices and Recommendations","year":2024,"lang":"en","type":"review","venue":"Journal of Cutaneous Medicine and Surgery","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Health Sciences Centre; Western University; Dalhousie University; University of Toronto; Memorial University of Newfoundland; Nova Scotia Health Authority; University of Calgary","funders":"Memorial University of Newfoundland; University of Toronto; Queen's University; McGill University; University of Ottawa; Université Laval","keywords":"Medicine; Standardization; Biomarker; Cancer; Melanoma; Targeted therapy; Molecular biomarkers; Diagnostic test; Medical physics; Biomarker discovery; Oncology; Internal medicine; Proteomics; Cancer research","score_opus":0.266182314002347,"score_gpt":0.4718297759904469,"score_spread":0.2056474619880999,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405285852","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002208511,0.9924713,0.000003958544,0.0038689838,0.00063968374,0.0006708731,0.000023193952,0.000002613878,0.00011091923],"genre_scores_gemma":[0.00023515249,0.99889207,0.000034481167,0.00021637569,0.00039228395,0.000017615643,0.00003025625,0.000044409448,0.00013733479],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99711174,0.00025111597,0.0016309029,0.00021673623,0.0005540767,0.00023546019],"domain_scores_gemma":[0.99412185,0.0036472909,0.0015202964,0.00018765648,0.0003002778,0.00022262565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016948476,0.0002831283,0.0028721811,0.000778047,0.000022334936,0.000013534778,0.00008990285,0.000109698674,0.00022697778],"category_scores_gemma":[0.0012751886,0.00017278282,0.00033617948,0.00038178204,0.00007794279,0.000046225003,0.000027207961,0.00073990633,2.4174668e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015355455,0.000055131753,0.000113276044,0.022962641,0.00055424345,0.0014062574,0.00008840122,6.843182e-8,0.000029549348,0.000019682391,0.028620405,0.94599676],"study_design_scores_gemma":[0.00047553022,0.00037906368,0.000006827596,0.047423832,0.001162487,0.014203731,0.000118692056,0.000008088157,0.0000062154713,0.00006376131,0.93603235,0.00011941905],"about_ca_topic_score_codex":0.014336455,"about_ca_topic_score_gemma":0.010834161,"teacher_disagreement_score":0.9458774,"about_ca_system_score_codex":0.00029690764,"about_ca_system_score_gemma":0.0057144105,"threshold_uncertainty_score":0.9999223},"labels":[],"label_agreement":null},{"id":"W4405310215","doi":"10.1016/j.ymthe.2024.12.012","title":"Tailoring capsid-directed evolution technology for improved AAV-mediated CAR-T generation","year":2024,"lang":"en","type":"article","venue":"Molecular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Narodowym Centrum Nauki; Wellcome Trust; National Health and Medical Research Council; Narodowe Centrum Nauki; St. Jude Children's Research Hospital; Children's Hospital of Philadelphia","keywords":"Capsid; Biology; Virology; Computational biology; Cell biology; Virus","score_opus":0.025288169104329787,"score_gpt":0.30766485327587845,"score_spread":0.28237668417154865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405310215","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9435393,0.014162596,0.032902207,0.004782388,0.0006508637,0.002325086,0.000028300414,0.0012179328,0.0003913236],"genre_scores_gemma":[0.9906877,0.0006980657,0.0025794492,0.0004186915,0.00053458806,0.0006772584,0.00037472474,0.00014738609,0.0038820896],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984957,0.00005834837,0.0002565772,0.000500996,0.00024772444,0.00044068028],"domain_scores_gemma":[0.9991227,0.000050106763,0.00003389011,0.0004369081,0.00025280705,0.00010359901],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00030141883,0.00021646998,0.00028037681,0.00054105563,0.00009339343,0.000064450636,0.00012153433,0.0002723024,0.00035022985],"category_scores_gemma":[0.00010557047,0.0001968091,0.00017961623,0.0008683119,0.000077859135,0.00006594405,0.000024285857,0.0003105032,0.000047630998],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027679928,0.000044184577,0.000055803856,0.00004259403,0.00025313627,0.00004908973,0.0001127204,0.000010087732,0.93156356,0.0005657366,0.0005307787,0.06649552],"study_design_scores_gemma":[0.0024292138,0.00077951525,0.00010121343,0.00005239584,0.000044442022,0.000053654505,0.000032282005,0.065068096,0.8330845,0.00060875114,0.09752005,0.00022587927],"about_ca_topic_score_codex":0.0000785242,"about_ca_topic_score_gemma":0.000018588,"teacher_disagreement_score":0.09847904,"about_ca_system_score_codex":0.00036764308,"about_ca_system_score_gemma":0.00024554506,"threshold_uncertainty_score":0.8025642},"labels":[],"label_agreement":null},{"id":"W4405737818","doi":"10.3390/curroncol32010002","title":"Real-World Characterization of Toxicities and Medication Management in Recipients of CAR T-Cell Therapy for Relapsed or Refractory Large B-Cell Lymphoma in Nova Scotia, Canada","year":2024,"lang":"en","type":"article","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Dalhousie University; Nova Scotia Health Authority; Health Sciences Centre","funders":"","keywords":"Medicine; Cytokine release syndrome; CAR T-cell therapy; Clinical trial; Retrospective cohort study; Internal medicine; Intensive care medicine; Chimeric antigen receptor; Immunotherapy; Cancer","score_opus":0.06510995503037549,"score_gpt":0.3864192310409812,"score_spread":0.3213092760106057,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405737818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943208,0.0012090874,0.00003792158,0.00036100924,0.0009775108,0.0012258629,0.0000629597,0.0000099514455,0.0017948808],"genre_scores_gemma":[0.99047846,0.0062163784,0.00007071691,0.000054075037,0.00007641095,0.00008158708,0.0002670112,0.00002494131,0.0027303956],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985773,0.00011490239,0.00050506485,0.00027702944,0.00027910888,0.00024657394],"domain_scores_gemma":[0.999298,0.00022486706,0.00013253871,0.00019607761,0.00008474108,0.000063812775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00057310495,0.0001200606,0.00037789124,0.0005268065,0.000012046702,0.000004307887,0.00009227713,0.000085866384,0.00025815846],"category_scores_gemma":[0.000022041751,0.00010396909,0.000034936133,0.00042902588,0.00007133218,0.00005100618,0.000040277184,0.000137843,0.0000010183462],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056135394,0.0049072024,0.06336054,0.004619552,0.0001273831,0.00009886574,0.0034747375,0.0000013087365,0.36340505,0.00044449477,0.0030501694,0.5508972],"study_design_scores_gemma":[0.04215173,0.0035961387,0.38526577,0.0018818531,0.000119193595,0.000009424647,0.001398459,0.002190335,0.10037989,0.00007922797,0.46252796,0.00040002292],"about_ca_topic_score_codex":0.019398605,"about_ca_topic_score_gemma":0.20740484,"teacher_disagreement_score":0.5504971,"about_ca_system_score_codex":0.0009074024,"about_ca_system_score_gemma":0.00091902586,"threshold_uncertainty_score":0.9871313},"labels":[],"label_agreement":null},{"id":"W4405748254","doi":"10.1016/j.jval.2024.10.642","title":"EE361 Long-Term Remission (LTR) Assumptions in Health Technology Assessments (HTAs) of Bispecific Treatments for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Following Two or More Lines of Systemic Therapy (3L+)","year":2024,"lang":"en","type":"article","venue":"Value in Health","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"MD Precision (Canada)","funders":"","keywords":"Refractory (planetary science); Diffuse large B-cell lymphoma; Medicine; Oncology; Term (time); Lymphoma; Internal medicine; Cancer research; Physics","score_opus":0.1088455886547828,"score_gpt":0.4519538653960237,"score_spread":0.3431082767412409,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405748254","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9715983,0.021549856,0.00025378694,0.0016074792,0.0005520934,0.004145395,0.00012278293,0.0001348088,0.000035476252],"genre_scores_gemma":[0.9699126,0.024012363,0.0015312093,0.00013181275,0.00011111965,0.0003720776,0.00015595999,0.00013562641,0.003637268],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99527687,0.0005319078,0.0018204034,0.0007603545,0.00069683645,0.0009136071],"domain_scores_gemma":[0.9974113,0.0008287783,0.0004777704,0.000879139,0.00012514129,0.00027787374],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002080808,0.0003720467,0.001322124,0.0017942804,0.000117379546,0.000020512352,0.00029144503,0.0003236204,0.00011620093],"category_scores_gemma":[0.00018915,0.00027057747,0.00026270282,0.0017505423,0.000084114006,0.00012459443,0.000072455165,0.00045932524,0.0000056394174],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017258009,0.041151866,0.3539001,0.0351589,0.0010945408,0.0011415787,0.008053357,0.000127611,0.24646522,0.00037290328,0.0010043326,0.2942716],"study_design_scores_gemma":[0.49910042,0.059635274,0.13302614,0.16509978,0.00048214075,0.0011402697,0.015981767,0.054305308,0.046360318,0.00071146304,0.021480426,0.0026766853],"about_ca_topic_score_codex":0.001467024,"about_ca_topic_score_gemma":0.00019481324,"teacher_disagreement_score":0.48184243,"about_ca_system_score_codex":0.0022782,"about_ca_system_score_gemma":0.0033838884,"threshold_uncertainty_score":0.99997467},"labels":[],"label_agreement":null},{"id":"W4405748558","doi":"10.1016/j.jval.2024.10.297","title":"EE13 A Cost-Consequence Analysis of Chimeric Antigen Receptor T-Cell Therapy in Patients With Relapsed or Refractory Large B-Cell Lymphoma Across Gulf Cooperation Council Countries","year":2024,"lang":"en","type":"article","venue":"Value in Health","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Gilead Sciences (Canada)","funders":"","keywords":"Chimeric antigen receptor; Refractory (planetary science); Medicine; Lymphoma; Oncology; Cancer research; Internal medicine; Immunotherapy; Biology; Cancer","score_opus":0.051855495934935936,"score_gpt":0.33293342912135687,"score_spread":0.28107793318642094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405748558","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923165,0.0046281368,0.00007856466,0.0003592307,0.00017032414,0.0019256197,0.00029011891,0.000053675514,0.00017781746],"genre_scores_gemma":[0.98676026,0.010130231,0.00023737519,0.00061401795,0.000042407468,0.00009592408,0.0002389309,0.00006114151,0.0018196853],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99610865,0.0004844532,0.0008500003,0.0005936383,0.0012646733,0.0006985756],"domain_scores_gemma":[0.99804145,0.00044984306,0.00020848212,0.0005586576,0.0005570445,0.00018450373],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028454042,0.00026278105,0.00082105387,0.0005371954,0.000098493605,0.000057750833,0.00017300464,0.0001591692,0.0008324714],"category_scores_gemma":[0.00014867283,0.00019604861,0.00010156297,0.003424884,0.00017855232,0.00017802941,0.0000307839,0.00035250463,0.000032669446],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038683087,0.0118492115,0.81535053,0.0037174018,0.0013590492,0.00037194285,0.05179177,0.0040774043,0.03230282,0.000076029224,0.002621809,0.037798963],"study_design_scores_gemma":[0.11227487,0.028603088,0.4753992,0.0047119986,0.00036404474,0.00003365295,0.00368777,0.06508475,0.021248989,0.000029417612,0.28658372,0.0019784998],"about_ca_topic_score_codex":0.0075183697,"about_ca_topic_score_gemma":0.0012946973,"teacher_disagreement_score":0.3399513,"about_ca_system_score_codex":0.0025383497,"about_ca_system_score_gemma":0.005937465,"threshold_uncertainty_score":0.9996979},"labels":[],"label_agreement":null},{"id":"W4405749862","doi":"10.1016/j.jval.2024.10.3254","title":"PCR11 Patient Reported Symptoms, Functioning, and Quality of Life (QoL) in Patients Treated With Chimeric Antigen Receptor T Cells for Hematologic Malignancy: A Systematic Review and Meta Analysis","year":2024,"lang":"en","type":"review","venue":"Value in Health","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Micropharma (Canada)","funders":"","keywords":"Hematologic malignancy; Medicine; Chimeric antigen receptor; Meta-analysis; Quality of life (healthcare); Malignancy; Oncology; Internal medicine; Immunotherapy; Cancer; Nursing","score_opus":0.15851327232871035,"score_gpt":0.39514214647368007,"score_spread":0.23662887414496972,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405749862","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0070353877,0.97773015,0.000005264461,0.00007101614,0.000036041503,0.014909899,0.00016657241,0.000033303662,0.000012383927],"genre_scores_gemma":[0.0007364253,0.99676853,0.00019657762,0.00013221055,0.0000082545075,0.0015015177,0.00033421358,0.000072471455,0.0002497844],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9922196,0.0020517954,0.0037290782,0.0009425006,0.00059394614,0.00046307218],"domain_scores_gemma":[0.99588835,0.0005905841,0.0021813689,0.0008266407,0.00022703753,0.00028598701],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0033150122,0.00055995054,0.0114403255,0.0010795126,0.000046674864,0.000023053852,0.00010855251,0.00023522026,0.000099267876],"category_scores_gemma":[0.0005452346,0.00033885453,0.0007461428,0.0030597073,0.000089932786,0.000039350267,0.00006724279,0.00043090945,0.0000024576264],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000091525275,0.00025399606,0.0041405414,0.9721585,0.021729203,0.0000069630737,0.00014753884,0.0000020615919,4.0744823e-7,0.000007582463,0.000052957646,0.001408739],"study_design_scores_gemma":[0.0023565092,0.0043462925,0.0008465716,0.6080509,0.3771841,0.000055035805,0.00008934843,0.0001093778,0.0000036190338,0.0000083525365,0.006057364,0.0008925381],"about_ca_topic_score_codex":0.002667367,"about_ca_topic_score_gemma":0.000057147317,"teacher_disagreement_score":0.36410758,"about_ca_system_score_codex":0.00037166645,"about_ca_system_score_gemma":0.000802925,"threshold_uncertainty_score":0.99990636},"labels":[],"label_agreement":null},{"id":"W4405750051","doi":"10.1016/j.jval.2024.10.3348","title":"PCR105 Impact of CAR T-Cell Therapy on Health Utilities for Patients Diagnosed With Diffuse Large B-Cell Lymphoma in Canada","year":2024,"lang":"en","type":"article","venue":"Value in Health","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; University of Ottawa; Princess Margaret Cancer Centre; University of Waterloo; University of Toronto","funders":"","keywords":"Diffuse large B-cell lymphoma; Lymphoma; Medicine; Pediatrics; Oncology; Internal medicine","score_opus":0.03961365323178231,"score_gpt":0.3331608637186762,"score_spread":0.2935472104868939,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405750051","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99053246,0.0048945537,0.000004769574,0.00086638913,0.00018268888,0.00284401,0.0004461874,0.00002561785,0.00020329721],"genre_scores_gemma":[0.9944823,0.0038259749,0.00005917596,0.0008334648,0.00006164151,0.00014114364,0.00010062567,0.00008007833,0.0004156155],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99697083,0.00032405922,0.0006539864,0.00043676648,0.0006583221,0.0009560422],"domain_scores_gemma":[0.99805236,0.00093256985,0.00012667124,0.00043768322,0.000083531006,0.00036719633],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008876785,0.00025863393,0.00069960265,0.0004156857,0.000053551255,0.000015130122,0.00013850712,0.0000676375,0.00009943713],"category_scores_gemma":[0.000054090306,0.0001917735,0.000119661076,0.0005691929,0.00004001579,0.00004660985,0.00001945147,0.00028141588,0.000002416998],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.012355489,0.020830924,0.8148026,0.012784937,0.00019559235,0.00024839863,0.024853578,0.0010263623,0.0005993551,0.00020414067,0.013405322,0.09869329],"study_design_scores_gemma":[0.18279833,0.063208506,0.6662469,0.0072695184,0.00002185414,0.000019073392,0.0053960816,0.032645177,0.0036107216,0.00026547562,0.037399326,0.0011190778],"about_ca_topic_score_codex":0.9586266,"about_ca_topic_score_gemma":0.5500959,"teacher_disagreement_score":0.4085307,"about_ca_system_score_codex":0.0055421893,"about_ca_system_score_gemma":0.015478031,"threshold_uncertainty_score":0.99827534},"labels":[],"label_agreement":null},{"id":"W4406033308","doi":"10.1186/s12967-024-06035-4","title":"Risk analysis of cardiovascular toxicity in patients with lymphoma treated with CD19 CAR T cells","year":2025,"lang":"en","type":"article","venue":"Journal of Translational Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Natural Science Foundation of Guizhou Province","keywords":"Medicine; Adverse effect; Chimeric antigen receptor; Cytokine release syndrome; Internal medicine; Cochrane Library; Randomized controlled trial; Lymphoma; Oncology; Immunotherapy; Cancer","score_opus":0.009864634279171941,"score_gpt":0.26411488638474045,"score_spread":0.2542502521055685,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406033308","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954096,0.0010573405,0.0019589628,0.00051612605,0.00003796447,0.000324488,0.000025360227,0.000004528126,0.0006655964],"genre_scores_gemma":[0.99889106,0.00021710998,0.00054298306,0.0000618819,0.0000653311,0.0000025162576,0.000033847547,0.000013497764,0.00017179162],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9972851,0.00015606466,0.0006945813,0.00017795649,0.0015063832,0.00017985901],"domain_scores_gemma":[0.9982192,0.00025464408,0.00026042506,0.00026765044,0.00086810254,0.00012998653],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008511221,0.00016406781,0.0011383268,0.0015845125,0.000029623292,0.0000036793103,0.00011597816,0.00007882477,0.0003984722],"category_scores_gemma":[0.00006057315,0.00009747831,0.00034273523,0.0024121597,0.00018847354,0.00007604661,0.000005093218,0.0002523987,3.487046e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008233287,0.0005571933,0.9422542,0.00008464791,0.017351616,0.000081241364,0.00040236162,0.014299857,0.004651228,0.0000109766825,0.00004552078,0.012027871],"study_design_scores_gemma":[0.019652456,0.0018766916,0.96398497,0.00051145983,0.008855713,0.00000905889,0.00008148468,0.00072593545,0.0035306532,0.000017071847,0.0006726655,0.00008184309],"about_ca_topic_score_codex":0.00030488707,"about_ca_topic_score_gemma":0.00008684732,"teacher_disagreement_score":0.02173077,"about_ca_system_score_codex":0.00014274905,"about_ca_system_score_gemma":0.00029917117,"threshold_uncertainty_score":0.43629912},"labels":[],"label_agreement":null},{"id":"W4406080334","doi":"10.1016/s2352-3026(24)00346-6","title":"Patient reported outcomes with earlier use of chimeric antigen receptor-T cell therapy in multiple myeloma","year":2025,"lang":"en","type":"letter","venue":"The Lancet Haematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; University of Ottawa","funders":"","keywords":"Medicine; Hazard ratio; Internal medicine; Multiple myeloma; Chimeric antigen receptor; Food and drug administration; Standard of care; Oncology; Overall survival; Progression-free survival; Immunotherapy; Cancer; Confidence interval; Pharmacology","score_opus":0.06945262945612482,"score_gpt":0.31280173439360864,"score_spread":0.24334910493748382,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406080334","genre_codex":"empirical","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.76243025,0.00054532546,0.000011333541,0.2331147,0.000286845,0.0018884881,0.000041759016,0.00007104318,0.0016102332],"genre_scores_gemma":[0.22170648,0.0066463426,0.0031595838,0.72201306,0.001481465,0.00077922776,0.0011368567,0.00042723186,0.042649783],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965671,0.00060000824,0.0008270206,0.00060924893,0.0006068866,0.00078976696],"domain_scores_gemma":[0.9961467,0.0011600001,0.0005492611,0.001879643,0.00021180988,0.00005263139],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00035514665,0.00046037056,0.0027680874,0.00043036233,0.000057069097,0.000020335294,0.00040612693,0.0006734625,0.0010249516],"category_scores_gemma":[0.0001992229,0.000266293,0.0002214701,0.000589045,0.000464019,0.00004372784,0.00013922769,0.0021711814,0.00002954558],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025458669,0.00022530647,0.4327664,0.0005819743,0.0007306873,0.0030173806,0.00091700954,0.000006342224,0.0035404346,0.0000073921433,0.5500374,0.0056238016],"study_design_scores_gemma":[0.0055513433,0.0008146323,0.06875738,0.0004135583,0.00009480636,0.00058724795,0.00007313079,0.000026456497,0.010216805,0.00003367381,0.91304517,0.00038578385],"about_ca_topic_score_codex":0.0007558734,"about_ca_topic_score_gemma":0.00008066488,"teacher_disagreement_score":0.5407238,"about_ca_system_score_codex":0.00008659303,"about_ca_system_score_gemma":0.00034263576,"threshold_uncertainty_score":0.9999789},"labels":[],"label_agreement":null},{"id":"W4406091198","doi":"10.58931/cht.2024.3359","title":"The Evolving Landscape of DLBCL Treatment Beyond the First Line in 2024","year":2024,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Saskatchewan","funders":"","keywords":"Line (geometry); Environmental planning; Geography","score_opus":0.018070650475495022,"score_gpt":0.29264030940429214,"score_spread":0.27456965892879714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406091198","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5149542,0.102437295,0.000007365808,0.21198279,0.0018203974,0.001953855,0.000083563355,0.0000717043,0.16668884],"genre_scores_gemma":[0.9721941,0.0007786576,0.000010012938,0.0005065812,0.00012750992,0.00008184679,0.000012436025,0.00002695249,0.026261957],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988975,0.000058537844,0.0002500827,0.00021366721,0.00013232869,0.00044791782],"domain_scores_gemma":[0.9986073,0.0006945713,0.000020703343,0.00043526327,0.00004699888,0.00019517903],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00038282055,0.00012545133,0.00027252658,0.00024982842,0.00012768172,0.00003019673,0.00016307156,0.000116422125,0.0029985667],"category_scores_gemma":[0.00011933465,0.00006687856,0.000098676595,0.0004293347,0.00018892744,0.000022436594,0.000022475884,0.00027633455,0.00010503217],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043292518,0.0003121557,0.32749802,0.0008341025,0.0015181804,0.0081605315,0.011213237,0.000039433282,0.001334763,0.038072634,0.46942928,0.14115474],"study_design_scores_gemma":[0.0011624129,0.000335428,0.007620853,0.00021821399,0.00007340927,0.00083836756,0.00061958743,0.0025145246,0.0015964609,0.00095942186,0.983935,0.00012634393],"about_ca_topic_score_codex":0.021379802,"about_ca_topic_score_gemma":0.5574401,"teacher_disagreement_score":0.5360603,"about_ca_system_score_codex":0.00034678236,"about_ca_system_score_gemma":0.00096505554,"threshold_uncertainty_score":0.9979128},"labels":[],"label_agreement":null},{"id":"W4406127406","doi":"10.1177/10781552241306741","title":"Analysis of real-world safety, tolerability, and cost efficiency of Sub-Cutaneous administration of Daratumumab in Manitoba","year":2025,"lang":"en","type":"article","venue":"Journal of Oncology Pharmacy Practice","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Daratumumab; Medicine; Tolerability; Retrospective cohort study; Toxicity; Subcutaneous injection; Internal medicine; Emergency medicine; Oncology; Surgery; Multiple myeloma; Adverse effect","score_opus":0.054436104547021545,"score_gpt":0.45732928911255444,"score_spread":0.4028931845655329,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406127406","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9665962,0.00046532965,0.000093695584,0.0042249663,0.00015966693,0.000441709,0.00001260357,0.0000028104776,0.028003056],"genre_scores_gemma":[0.99513316,0.0039315047,0.00048072851,0.00015383438,0.00004276787,0.000002863266,0.0000047383332,0.000007467567,0.00024292995],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9968653,0.00071644876,0.0015579744,0.00017355349,0.00050802855,0.00017872722],"domain_scores_gemma":[0.9934962,0.003540055,0.0015153339,0.00023737612,0.0011080769,0.00010296842],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003158544,0.00011936737,0.0010635153,0.0013684301,0.00003176514,0.0000073481297,0.00017534946,0.000077165445,0.0003134574],"category_scores_gemma":[0.0016713862,0.00010789223,0.00018613979,0.0018879774,0.0002804434,0.00022446483,0.000068734815,0.0006818977,4.229392e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08808579,0.008176772,0.24938811,0.00062836066,0.0044587655,0.0017632863,0.0011227683,0.0006603708,0.5204874,0.0002887033,0.00041469836,0.124524914],"study_design_scores_gemma":[0.042208634,0.01755091,0.32461107,0.00078355765,0.024643801,0.0066094543,0.0056264596,0.0115486765,0.44937307,0.0002246538,0.11635834,0.00046138783],"about_ca_topic_score_codex":0.0005988724,"about_ca_topic_score_gemma":0.0018307503,"teacher_disagreement_score":0.12406352,"about_ca_system_score_codex":0.0004738282,"about_ca_system_score_gemma":0.0015639736,"threshold_uncertainty_score":0.43997175},"labels":[],"label_agreement":null},{"id":"W4406211672","doi":"10.33540/2707","title":"Clinical Outcome after Cellular Therapies in Children with Acute Leukemia","year":2025,"lang":"en","type":"dissertation","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Medicine; Immunotherapy; Chimeric antigen receptor; Intensive care medicine; Disease; Leukemia; Acute leukemia; Transplantation; Hematopoietic stem cell transplantation; Immune system; Oncology; Immunology; Internal medicine","score_opus":0.025660354702896716,"score_gpt":0.3757440132774246,"score_spread":0.3500836585745279,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406211672","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9636519,0.0009188427,0.000015578238,0.00018820113,0.00020824395,0.0013588133,0.000014153605,0.0000728856,0.033571396],"genre_scores_gemma":[0.45866045,0.00063176296,0.00040772874,0.0005296762,0.00021912094,0.00017484651,0.0012491781,0.00007339923,0.5380538],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99754685,0.000113804344,0.0007206189,0.0006253156,0.0005938314,0.0003995763],"domain_scores_gemma":[0.9988242,0.000106378466,0.00010005476,0.000691517,0.0001418779,0.00013597458],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00046581216,0.0003767847,0.00094067614,0.00043877814,0.000028175713,0.000040900108,0.00022542872,0.0006004347,0.007104972],"category_scores_gemma":[0.00003311663,0.00025806573,0.0002990397,0.00037234626,0.00006435492,0.00004681666,0.000033216827,0.0014038732,0.00009523135],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056725545,0.0001757546,0.9654496,0.00016492455,0.0015843543,0.00026250782,0.00033471285,4.2362421e-7,0.0013530126,0.000038967493,0.0004582262,0.02450501],"study_design_scores_gemma":[0.004312768,0.0005309488,0.98850286,0.0003012382,0.00045806778,0.000019415218,0.00028668717,0.000015861886,0.0022439545,0.00004729872,0.0029263627,0.00035452595],"about_ca_topic_score_codex":0.0004396531,"about_ca_topic_score_gemma":0.0014268884,"teacher_disagreement_score":0.5049914,"about_ca_system_score_codex":0.00026442736,"about_ca_system_score_gemma":0.0009239051,"threshold_uncertainty_score":0.9999872},"labels":[],"label_agreement":null},{"id":"W4406226722","doi":"10.54254/2753-8818/2024.la19836","title":"On-target off-tumor toxicity from HER2-targeting chimeric antigen receptor (CAR) engineered T cell therapy: current solutions","year":2025,"lang":"en","type":"article","venue":"Theoretical and Natural Science","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Chimeric antigen receptor; Toxicity; Current (fluid); Antigen; Cancer research; Receptor; Cell therapy; CAR T-cell therapy; Medicine; Immunotherapy; Cell; Immunology; Biology; Internal medicine; Immune system; Engineering; Biochemistry","score_opus":0.01086847989251262,"score_gpt":0.28991178859551886,"score_spread":0.27904330870300625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406226722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9840961,0.007798801,0.00023658088,0.0018649885,0.0006036473,0.00043901667,0.000025427771,0.00007809263,0.0048573376],"genre_scores_gemma":[0.99727845,0.00084941444,0.0008157509,0.00044767634,0.00014720112,0.000011767131,0.000017034996,0.000011122864,0.00042157783],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978835,0.00009548239,0.00022592342,0.00054288004,0.0006002206,0.00065199984],"domain_scores_gemma":[0.99884677,0.00040504613,0.000035496072,0.00029295,0.00013581879,0.0002839219],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008049421,0.00020160434,0.00029209335,0.0001701749,0.00038431372,0.00006950668,0.00032773172,0.00005579555,0.0025382342],"category_scores_gemma":[0.0004486831,0.00013648995,0.00009705343,0.0009831126,0.001867674,0.000090971545,0.0001813132,0.0006140755,0.000038810726],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050606,0.00024047369,0.0005619843,0.000018896573,0.000019114164,0.000005823908,0.00017545042,0.0000033569465,0.90865433,0.048604395,0.000628159,0.040581934],"study_design_scores_gemma":[0.0026708767,0.00075630273,0.016724655,0.0002915158,0.000032581018,0.000010433639,0.00017701738,0.01900311,0.8988746,0.04393859,0.016969698,0.0005506636],"about_ca_topic_score_codex":0.000033503686,"about_ca_topic_score_gemma":5.2884036e-7,"teacher_disagreement_score":0.04003127,"about_ca_system_score_codex":0.000105287916,"about_ca_system_score_gemma":0.0002549309,"threshold_uncertainty_score":0.99837357},"labels":[],"label_agreement":null},{"id":"W4406226749","doi":"10.54254/2753-8818/2024.la19838","title":"Challenges and innovations in managing cytokine release syndrome in CAR-T therapy: mechanisms, clinical impact, and future directions","year":2025,"lang":"en","type":"article","venue":"Theoretical and Natural Science","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Cytokine; Cytokine release syndrome; Medicine; Intensive care medicine; Immunology; Immunotherapy; Immune system","score_opus":0.021885036358453975,"score_gpt":0.36297704502978617,"score_spread":0.3410920086713322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406226749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96542114,0.012425147,0.000008517909,0.018989729,0.00009949887,0.00028456922,0.0000019057097,0.000020832043,0.0027486386],"genre_scores_gemma":[0.9638725,0.035481505,0.00016523684,0.00030539714,0.000035880697,0.000009183733,0.0000012214465,0.00000461082,0.00012447043],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"observational","domain_scores_codex":[0.99882287,0.00008440803,0.00020955646,0.00038002568,0.00021366586,0.0002894744],"domain_scores_gemma":[0.9993661,0.00025943446,0.000017994336,0.00015531923,0.00006354976,0.00013757609],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014004394,0.00010832488,0.00024142751,0.00041310416,0.00010902648,0.000036067268,0.00008829364,0.00007882512,0.00006316157],"category_scores_gemma":[0.00021415572,0.00007203855,0.000023093507,0.0011489637,0.0014814418,0.00011376455,0.00012310642,0.0005269709,4.8734165e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002991993,0.00007271246,0.002963818,0.000023091634,0.00001014673,0.000046019723,0.00022548105,7.243236e-8,0.009270371,0.52893144,0.000002345388,0.4581553],"study_design_scores_gemma":[0.0017718696,0.00040600746,0.8371915,0.00015064458,0.000010403357,0.0002183755,0.00039910426,0.0014727139,0.000477098,0.15681474,0.0009552754,0.0001322565],"about_ca_topic_score_codex":0.000037700982,"about_ca_topic_score_gemma":0.000043736207,"teacher_disagreement_score":0.8342277,"about_ca_system_score_codex":0.000053485717,"about_ca_system_score_gemma":0.000105407,"threshold_uncertainty_score":0.54584336},"labels":[],"label_agreement":null},{"id":"W4406226940","doi":"10.1002/mdc3.14335","title":"Parkinsonism and Bilateral Facial Palsy after Chimeric Antigen Receptor T‐Cell Therapy","year":2025,"lang":"en","type":"article","venue":"Movement Disorders Clinical Practice","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto Western Hospital; Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Medicine; Parkinsonism; Plasma cell dyscrasia; Multiple myeloma; Bortezomib; Internal medicine; Immunology; Antibody; Disease","score_opus":0.03227393156992773,"score_gpt":0.3961809974149553,"score_spread":0.3639070658450276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406226940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91401154,0.0056963135,0.00026325864,0.0383381,0.0009365352,0.0018861339,0.000013879485,0.00010296385,0.03875127],"genre_scores_gemma":[0.7802601,0.09909718,0.00325277,0.081647724,0.0005356392,0.00029503572,0.000052246673,0.000093726165,0.03476559],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970097,0.0005148793,0.0007792374,0.0006872302,0.00052328303,0.0004856526],"domain_scores_gemma":[0.9976774,0.0012626826,0.00017757538,0.0005404382,0.0001197604,0.00022214495],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016434874,0.0002769493,0.0005124811,0.00014163041,0.00014239748,0.00010132602,0.00016263471,0.0002201354,0.0035849554],"category_scores_gemma":[0.0008011341,0.00023159789,0.00023697672,0.0003549162,0.0002757667,0.00023861231,0.00015780701,0.0007597056,0.00012788567],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01163207,0.00374203,0.24852538,0.00009332102,0.0006990109,0.000039819297,0.0004805311,0.0000011849817,0.0097301565,0.000068546775,0.0144773945,0.71051055],"study_design_scores_gemma":[0.0057719513,0.0010519798,0.12494006,0.00003889262,0.00007637597,8.765067e-7,0.00027815803,0.00006386421,0.00070300803,0.00085809233,0.8659951,0.00022160533],"about_ca_topic_score_codex":0.00019589702,"about_ca_topic_score_gemma":0.000022092332,"teacher_disagreement_score":0.85151774,"about_ca_system_score_codex":0.00005332615,"about_ca_system_score_gemma":0.00018442844,"threshold_uncertainty_score":0.9973259},"labels":[],"label_agreement":null},{"id":"W4406316580","doi":"10.1200/jco-24-02081","title":"Chimeric Antigen Receptor-T Cells in Colorectal Cancer: Pioneering New Avenues in Solid Tumor Immunotherapy","year":2025,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; McGill University","funders":"","keywords":"Chimeric antigen receptor; Medicine; Immunotherapy; Tumor microenvironment; Colorectal cancer; T cell; Cancer; Cancer research; Immune system; Oncology; Immunology; Internal medicine","score_opus":0.14160946337063576,"score_gpt":0.5378796703098482,"score_spread":0.39627020693921244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406316580","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009726501,0.9842085,0.0000070811907,0.00061787816,0.003427048,0.0009913447,0.000012260402,0.0000102477015,0.0009991281],"genre_scores_gemma":[0.0001106329,0.99410295,0.00066911214,0.00036245622,0.0024993273,0.000032987093,0.000007414571,0.00006838887,0.0021467158],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9919584,0.0014216074,0.0051137474,0.00040725205,0.00052907725,0.0005699318],"domain_scores_gemma":[0.9923397,0.004287543,0.002501848,0.00028242098,0.00019954014,0.00038896408],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0047997115,0.000405576,0.007973881,0.0010508331,0.00002452112,0.000018568051,0.00058649963,0.0009627629,0.0018068054],"category_scores_gemma":[0.0017453429,0.0003155492,0.0016114109,0.0010183706,0.00018248234,0.000075661526,0.000120603494,0.0046380023,0.0000407824],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017611268,0.0007517484,0.0011309882,0.0019266765,0.00058767584,0.0009505505,0.000092793176,0.00000881567,0.0006151362,0.000001851373,0.0028856106,0.989287],"study_design_scores_gemma":[0.0050036777,0.003293334,0.002354728,0.019417858,0.00022375208,0.0002120185,0.000020864121,0.0000075488874,0.00006568212,0.000023370163,0.9691566,0.00022054212],"about_ca_topic_score_codex":0.00028081983,"about_ca_topic_score_gemma":0.00021370177,"teacher_disagreement_score":0.9890665,"about_ca_system_score_codex":0.0013368452,"about_ca_system_score_gemma":0.017710997,"threshold_uncertainty_score":0.99992967},"labels":[],"label_agreement":null},{"id":"W4406400396","doi":"10.54254/2753-8818/2025.gu20456","title":"CRISPR/Cas9-Enhanced CAR-T Cell Therapy for Hematological Malignancies","year":2025,"lang":"en","type":"article","venue":"Theoretical and Natural Science","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"CRISPR; CAR T-cell therapy; Medicine; Cancer research; Biology; Internal medicine; Cancer; Immunotherapy; Chimeric antigen receptor; Genetics; Gene","score_opus":0.013131264166333605,"score_gpt":0.3319525780267485,"score_spread":0.3188213138604149,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406400396","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97260046,0.0020358132,0.0010309152,0.004452079,0.000191228,0.0007018925,0.0000032684773,0.000058737376,0.018925626],"genre_scores_gemma":[0.9930614,0.00035286066,0.000815532,0.0012979794,0.00004640666,0.000037364323,0.0000017055871,0.000005656389,0.0043810974],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99850345,0.000034292974,0.00016021155,0.00042231238,0.00037613892,0.000503587],"domain_scores_gemma":[0.99897975,0.00039707794,0.000020030133,0.00022106821,0.000208627,0.0001734363],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0006895552,0.00013573992,0.0002711582,0.00010696852,0.00025494886,0.00006299671,0.0002480237,0.000081632665,0.0005518442],"category_scores_gemma":[0.0003441116,0.00007924,0.00008313869,0.0005872236,0.003466953,0.00007094989,0.00011512967,0.00024052933,0.0000072249186],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000737802,0.00005677037,0.00014349227,0.000036602116,0.0000052043115,0.0000045400407,0.00007545567,7.241853e-8,0.64964247,0.33084726,0.00013624165,0.01831406],"study_design_scores_gemma":[0.0015377213,0.0005026863,0.0028945776,0.000054183387,0.00001393705,0.000025276106,0.00012731606,0.00068167597,0.9232024,0.067975774,0.002850851,0.00013361424],"about_ca_topic_score_codex":0.000004626154,"about_ca_topic_score_gemma":4.995172e-7,"teacher_disagreement_score":0.2735599,"about_ca_system_score_codex":0.000043483906,"about_ca_system_score_gemma":0.00018717123,"threshold_uncertainty_score":0.99924505},"labels":[],"label_agreement":null},{"id":"W4406447454","doi":"10.1016/j.yonc.2013.08.019","title":"10.1016/j.yonc.2013.08.019","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Cytokine; Blinatumomab; Cytokine release syndrome; Macrophage activation syndrome; Immunology; Immunotherapy; CD19; Immune system","score_opus":0.014059187987949388,"score_gpt":0.24606730121849044,"score_spread":0.23200811323054105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406447454","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0044027846,0.00016080948,3.7754816e-7,0.0017037501,0.0000017502987,0.00047862777,0.000006773255,0.00014532304,0.9930998],"genre_scores_gemma":[0.00024794188,0.0000031228562,0.00008123191,0.00015639997,0.0003728618,0.000028221424,0.000026464275,0.000053643453,0.9990301],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9986096,0.000048444894,0.00018523907,0.00028715312,0.0004417554,0.00042780323],"domain_scores_gemma":[0.9989466,0.00006805904,0.000016350956,0.0005449666,0.0000805287,0.00034346935],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00023639006,0.00015178732,0.00026701303,0.00012903035,0.000053354535,0.000028967277,0.00017550465,0.000090484056,0.9998317],"category_scores_gemma":[0.00004004042,0.0001368335,0.000102846025,0.00030474563,0.00005581049,0.000051607414,0.000043896413,0.00024249035,0.9977712],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005102648,0.00007852059,0.00000105481,0.000011781557,0.000036624995,0.000032023705,0.000024723686,0.0000070970787,0.002697565,2.1798454e-7,0.41492626,0.58167386],"study_design_scores_gemma":[0.0009777991,0.00049963495,0.0001492277,0.000033631903,0.000024773533,0.000054345925,0.0000016947774,0.00016777507,0.0013088059,0.000003764481,0.9966356,0.00014290673],"about_ca_topic_score_codex":0.00008326049,"about_ca_topic_score_gemma":4.2451927e-7,"teacher_disagreement_score":0.5817094,"about_ca_system_score_codex":0.000075881115,"about_ca_system_score_gemma":0.00008041538,"threshold_uncertainty_score":0.55799085},"labels":[],"label_agreement":null},{"id":"W4406520193","doi":"10.1016/s0765-2046(98)80225-6","title":"10.1016/s0765-2046(98)80225-6","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Lymphoma; Virology; Medicine; Family medicine; Immunology","score_opus":0.015552041403016987,"score_gpt":0.25098287916850404,"score_spread":0.23543083776548704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406520193","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0030954457,0.00012929669,3.3525666e-7,0.0012801688,0.0000016855897,0.0004780403,0.000006705625,0.0001288103,0.9948795],"genre_scores_gemma":[0.000184379,0.0000018888674,0.000088576206,0.00015844921,0.00042515594,0.000034510744,0.000025845207,0.000054233922,0.99902695],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985396,0.00004991196,0.00019347442,0.00030011495,0.0004680922,0.0004488058],"domain_scores_gemma":[0.99891824,0.00006745242,0.000016451695,0.0005562855,0.000082765524,0.0003588379],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00024602824,0.00015935898,0.00028419352,0.00013839324,0.00006136596,0.000031115484,0.0001848033,0.00009179172,0.9999113],"category_scores_gemma":[0.000046284225,0.00014416248,0.000109908324,0.0003480749,0.00005742238,0.00005185588,0.000046081852,0.0002575682,0.9980588],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005882731,0.00009049976,5.212112e-7,0.000013235714,0.000041843814,0.00004052167,0.000027775623,0.000005658648,0.0039264555,2.864554e-7,0.396632,0.59863293],"study_design_scores_gemma":[0.0009749464,0.00052779866,0.00012816029,0.000034484114,0.000028115308,0.00005312287,0.0000019017891,0.00013224545,0.0016283937,0.0000059023027,0.9963327,0.00015220608],"about_ca_topic_score_codex":0.00005880932,"about_ca_topic_score_gemma":3.7990614e-7,"teacher_disagreement_score":0.59970075,"about_ca_system_score_codex":0.00011106236,"about_ca_system_score_gemma":0.00008839797,"threshold_uncertainty_score":0.5878775},"labels":[],"label_agreement":null},{"id":"W4406544289","doi":"10.3389/fimmu.2024.1491341","title":"Utilization of donor CLL-1 CAR-T cells for the treatment of relapsed of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation","year":2025,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ministry of Education and Child Care","funders":"Natural Science Foundation of Tianjin City","keywords":"Myeloid leukemia; Stem cell; Medicine; Haematopoiesis; Hematopoietic stem cell transplantation; Transplantation; Leukemia; Immunology; Cancer research; Internal medicine; Biology","score_opus":0.01739932337425429,"score_gpt":0.28432998280340366,"score_spread":0.2669306594291494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406544289","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96693027,0.009159517,0.021075942,0.00010221724,0.00090388395,0.0015016103,0.000041085073,0.00001088878,0.00027458038],"genre_scores_gemma":[0.9815661,0.0131682055,0.0018687942,0.000015970683,0.000010662717,0.00013659585,0.00006784539,0.000021219092,0.003144648],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99878466,0.00011459621,0.00053648365,0.00020525976,0.00013635041,0.000222633],"domain_scores_gemma":[0.9991044,0.00024356133,0.00016565391,0.00037946086,0.0000903355,0.000016615686],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022027409,0.00013952776,0.00059471204,0.0003369778,0.00003514828,0.0000023316231,0.0001594152,0.00018483121,0.000024022702],"category_scores_gemma":[0.000005696754,0.000108276785,0.0002612483,0.0003613812,0.00016979984,0.000027365762,0.000011993488,0.00009200173,3.7457113e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004053321,0.00028646443,0.011861959,0.00050271756,0.0015582441,0.000008368311,0.0047406964,0.00017323066,0.9428383,0.00008046398,0.00020372479,0.03369248],"study_design_scores_gemma":[0.006944147,0.0012648066,0.004353187,0.00012691802,0.00078435225,0.0000038724183,0.0020483485,0.00042237304,0.98246455,0.00011404961,0.0014026709,0.00007072326],"about_ca_topic_score_codex":0.00014256741,"about_ca_topic_score_gemma":0.00002000054,"teacher_disagreement_score":0.03962622,"about_ca_system_score_codex":0.00034428303,"about_ca_system_score_gemma":0.00028863086,"threshold_uncertainty_score":0.44153994},"labels":[],"label_agreement":null},{"id":"W4406550256","doi":"10.1016/s1541-9800(05)70314-8","title":"10.1016/s1541-9800(05)70314-8","year":2000,"lang":"en","type":"article","venue":"Time to knit","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Computational biology; Business; Computer science; Biology","score_opus":0.014568551095336448,"score_gpt":0.2478379553560473,"score_spread":0.23326940426071086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406550256","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0033149065,0.0001244826,4.23748e-7,0.0013415742,0.0000020184586,0.00049080444,0.00000763048,0.00015725609,0.9945609],"genre_scores_gemma":[0.0002207942,0.0000018427587,0.000090250214,0.00018323446,0.0003990044,0.00003451411,0.000028850267,0.00005739784,0.9989841],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99848056,0.00005253824,0.000203029,0.0003121416,0.00048219602,0.00046956426],"domain_scores_gemma":[0.9988724,0.00007127085,0.000017551769,0.0005777213,0.00008598324,0.0003750981],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0002625215,0.00016687033,0.00028731363,0.00014486897,0.000063299136,0.00003265145,0.00019057118,0.00009635588,0.9998506],"category_scores_gemma":[0.000056586585,0.00015155069,0.00011444549,0.00036296036,0.00006221483,0.000053876684,0.000047692276,0.0002646487,0.9970531],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005727436,0.000089734414,4.1817157e-7,0.000012444054,0.000037592323,0.00005321533,0.000025084913,0.0000055054384,0.0041115424,2.4743244e-7,0.4039321,0.5911594],"study_design_scores_gemma":[0.0010550227,0.000622267,0.000100227844,0.000037876573,0.00002860844,0.00008801955,0.0000018277733,0.00013647578,0.0018886776,0.0000058151313,0.9958772,0.0001579798],"about_ca_topic_score_codex":0.000054603846,"about_ca_topic_score_gemma":3.270075e-7,"teacher_disagreement_score":0.5919451,"about_ca_system_score_codex":0.000111210975,"about_ca_system_score_gemma":0.00008982041,"threshold_uncertainty_score":0.61800575},"labels":[],"label_agreement":null},{"id":"W4406571069","doi":"10.1101/2025.01.17.24311574","title":"Delineation and monitoring of the T cell repertoire of adoptive cell transfer product during the treatment of advanced melanoma","year":2025,"lang":"en","type":"preprint","venue":"medRxiv","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Ontario Ministry of Research and Innovation","keywords":"Repertoire; Melanoma; Product (mathematics); Adoptive cell transfer; Cell; Cancer research; Medicine; Biology; T cell; Immunology; Genetics; Mathematics; Art; Immune system","score_opus":0.022419740516605384,"score_gpt":0.29220685984398703,"score_spread":0.26978711932738164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406571069","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99204606,0.004918196,0.000022717286,0.00023168119,0.00024360853,0.0017542036,0.00004303997,0.000011139841,0.0007293447],"genre_scores_gemma":[0.98645437,0.004565094,0.00025572168,0.0000023273872,0.00012832647,0.000094787705,0.000007135671,0.00002215066,0.008470069],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99840486,0.00014523312,0.0004865734,0.00038125276,0.00041518398,0.00016690114],"domain_scores_gemma":[0.99842256,0.00012483208,0.00015687005,0.0009388505,0.0003176253,0.000039287595],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024875352,0.00022066262,0.0005423722,0.00011236269,0.00005371749,0.0000044506373,0.0002031325,0.00011070398,0.000043652395],"category_scores_gemma":[0.00003790272,0.00012375868,0.00023428546,0.00020308683,0.00016741361,0.000018072627,0.00010261601,0.00028266845,1.8314594e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00084696367,0.00038989302,0.18351549,0.0019849122,0.00016904564,0.0000036438921,0.0048554074,0.0006115636,0.7912198,0.0000018607957,0.0000013747954,0.016400084],"study_design_scores_gemma":[0.0013271898,0.00030642483,0.10501531,0.00048467773,0.00019205072,0.0000021564583,0.00047843053,0.000073190335,0.8917329,0.0000063320504,0.00031029826,0.000071067894],"about_ca_topic_score_codex":0.0001404923,"about_ca_topic_score_gemma":0.000011040074,"teacher_disagreement_score":0.10051311,"about_ca_system_score_codex":0.00012978421,"about_ca_system_score_gemma":0.00019904308,"threshold_uncertainty_score":0.5046733},"labels":[],"label_agreement":null},{"id":"W4406584151","doi":"10.1101/2025.01.17.25320737","title":"WITHDRAWN: Novel Risk Factors for Predicting Immune Effector Cell-Associated Neurotoxicity Syndrome","year":2025,"lang":"en","type":"preprint","venue":"medRxiv","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"","keywords":"Neurotoxicity; Effector; Immune system; Neuroscience; Medicine; Immunology; Psychology; Internal medicine; Toxicity","score_opus":0.02835711639482958,"score_gpt":0.30482327721100133,"score_spread":0.27646616081617176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406584151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859142,0.00032273884,0.0013895667,0.00017630716,0.0016577672,0.0070729638,0.0016121722,0.00048197585,0.0013723284],"genre_scores_gemma":[0.98193705,0.0001757022,0.00033516105,0.00006949978,0.00023973014,0.0008914164,0.0006159211,0.00016582354,0.015569686],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99538416,0.000375257,0.00092342705,0.0013002013,0.0010094196,0.0010075653],"domain_scores_gemma":[0.9948814,0.0021660258,0.00064699486,0.0015013915,0.000438608,0.00036557773],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0018735991,0.00078158494,0.0016715558,0.0005202425,0.00031434177,0.00011291769,0.0007292136,0.00089380785,0.00055765465],"category_scores_gemma":[0.0035324981,0.0007028903,0.0009770758,0.00053603103,0.00016416737,0.000055065982,0.00094515225,0.002972045,0.00002006878],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010541992,0.0014841723,0.66732275,0.0037562437,0.0016794966,0.00010928314,0.000903614,0.00033913183,0.3221027,0.0000042320316,0.0002875502,0.0009566365],"study_design_scores_gemma":[0.008755774,0.002012642,0.7672991,0.0022367525,0.0013779277,0.000037740916,0.0001258873,0.009818789,0.20492393,0.00007405907,0.0023194503,0.0010179334],"about_ca_topic_score_codex":0.00091561204,"about_ca_topic_score_gemma":0.000043259042,"teacher_disagreement_score":0.11717875,"about_ca_system_score_codex":0.000591835,"about_ca_system_score_gemma":0.00069222815,"threshold_uncertainty_score":0.99954224},"labels":[],"label_agreement":null},{"id":"W4406665586","doi":"10.1158/1078-0432.ccr-24-2753","title":"Population Pharmacokinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-cell Product, in Patients with Relapsed/Refractory Multiple Myeloma","year":2025,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Aurinia (Canada)","funders":"","keywords":"Multiple myeloma; Cmax; Population; Medicine; Pharmacokinetics; Oncology; Immunology; Pharmacology; Internal medicine","score_opus":0.08116083786380267,"score_gpt":0.4550818260549206,"score_spread":0.3739209881911179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406665586","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9943435,0.00092678773,0.00000608753,0.0005061712,0.00036062414,0.0023979978,0.00004457384,0.00011655035,0.0012976908],"genre_scores_gemma":[0.9922681,0.0012124815,0.00081101194,0.000108546476,0.00023791874,0.00016980055,0.0002433317,0.000074394484,0.00487444],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9941761,0.0014238276,0.0011319496,0.0010100863,0.0014232548,0.0008347917],"domain_scores_gemma":[0.99627477,0.0008836671,0.00020980755,0.0010027225,0.001279236,0.00034981317],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0028018905,0.00026581564,0.0008658932,0.0007675205,0.00012935248,0.000027948694,0.00045774723,0.00027190088,0.00175716],"category_scores_gemma":[0.0013637076,0.00022254058,0.00012378064,0.0024194254,0.0005672349,0.00014479662,0.0002710957,0.0018682088,0.00002686842],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010968919,0.0027481022,0.7949818,0.00027842514,0.000115967254,0.000013987664,0.000098702374,0.00004381788,0.04597851,0.000002660211,0.0019626713,0.14280649],"study_design_scores_gemma":[0.010416441,0.0025622963,0.95414233,0.0002905435,0.000037592046,5.266839e-7,0.000034210803,0.00096786587,0.020572677,0.000015956983,0.010758208,0.00020135644],"about_ca_topic_score_codex":0.0018901193,"about_ca_topic_score_gemma":0.00034337817,"teacher_disagreement_score":0.15916057,"about_ca_system_score_codex":0.00049905106,"about_ca_system_score_gemma":0.0011857415,"threshold_uncertainty_score":0.99915534},"labels":[],"label_agreement":null},{"id":"W4406683378","doi":"10.1136/jitc-2024-010207","title":"Art of TIL immunotherapy: SITC’s perspective on demystifying a complex treatment","year":2025,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Immunotherapy; Chimeric antigen receptor; Cancer immunotherapy; Cancer; Oncology; Intensive care medicine; Internal medicine","score_opus":0.12186916104096639,"score_gpt":0.48237948766339306,"score_spread":0.36051032662242666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406683378","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000056663215,0.9901503,0.0001254374,0.00045255732,0.0007030055,0.003307252,0.000371761,0.000024025581,0.0048090504],"genre_scores_gemma":[0.000012743311,0.9548177,0.00050251797,0.00019155063,0.0005502582,0.00046670248,0.000049077647,0.00017880707,0.043230634],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.996261,0.0002588722,0.0015996649,0.00048188234,0.00082216936,0.00057639426],"domain_scores_gemma":[0.9958547,0.00086867245,0.0014530788,0.0007714929,0.0009189429,0.00013314882],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00068300584,0.0007536161,0.0042325845,0.0010588927,0.0001956101,0.000047460137,0.00047314639,0.00039608145,0.0045169955],"category_scores_gemma":[0.000067143934,0.00053332094,0.0032391842,0.00058643747,0.0002295073,0.0000651433,0.000026031235,0.0007868211,0.0000091013635],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005205721,0.0006597975,0.000008986529,0.006353831,0.0076686954,0.000012027521,0.0006231735,0.000006766334,0.004106653,0.00019829955,0.0027642143,0.97239184],"study_design_scores_gemma":[0.0066115344,0.003855916,0.00002488122,0.028659767,0.0010868458,0.0001270709,0.00016464898,0.0000073495207,0.000671918,0.00015423019,0.95829475,0.00034106875],"about_ca_topic_score_codex":0.00017695273,"about_ca_topic_score_gemma":0.000022891982,"teacher_disagreement_score":0.9720508,"about_ca_system_score_codex":0.0038404176,"about_ca_system_score_gemma":0.0032555577,"threshold_uncertainty_score":0.99998367},"labels":[],"label_agreement":null},{"id":"W4406772134","doi":"10.1002/pbc.31516","title":"Access to CARe: A Narrative of Real‐World Medical Decision‐Making to Access Chimeric Antigen Receptor (CAR) T‐Cell Therapy in Children, Adolescents, and Young Adults","year":2025,"lang":"en","type":"review","venue":"Pediatric Blood & Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"National Cancer Institute; Intramural Research Program; NIH Clinical Center; National Institutes of Health","keywords":"Chimeric antigen receptor; Medicine; Narrative review; Refractory (planetary science); Clinical trial; Oncology; Pediatrics; Immunotherapy; Intensive care medicine; Internal medicine; Cancer","score_opus":0.028568326256725365,"score_gpt":0.4049604464300942,"score_spread":0.37639212017336887,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406772134","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.083869554,0.9077631,0.000010417008,0.00010344873,0.00073185755,0.006818285,0.0002321267,0.000051341198,0.00041986376],"genre_scores_gemma":[0.0073550516,0.9881909,0.00020324725,0.00041538733,0.0019942904,0.0012411752,0.00009075336,0.00015190794,0.00035727074],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9938222,0.00038197095,0.0015135298,0.0015437283,0.0018371292,0.00090142054],"domain_scores_gemma":[0.99689996,0.00043708403,0.00052765943,0.0009278828,0.0004953628,0.00071201916],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00062143884,0.0008583398,0.003202385,0.0026283702,0.0001230128,0.00013621943,0.0015899853,0.0005248103,0.0018728134],"category_scores_gemma":[0.00040630894,0.0007037112,0.00046721194,0.006735121,0.000086788335,0.00017166356,0.0010488008,0.0013600859,0.000010957024],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00074691157,0.00034155,0.19687803,0.014108266,0.0002885068,0.000026316446,0.0016921202,0.0000013011193,0.000004703207,4.054521e-7,0.0023822214,0.78352964],"study_design_scores_gemma":[0.023946503,0.002711494,0.28908807,0.30756378,0.005845957,0.00011870013,0.0007079653,0.000006883294,0.00028134184,0.000012073589,0.36528623,0.0044309795],"about_ca_topic_score_codex":0.0053216885,"about_ca_topic_score_gemma":0.0034379784,"teacher_disagreement_score":0.7790987,"about_ca_system_score_codex":0.00044377276,"about_ca_system_score_gemma":0.0038566825,"threshold_uncertainty_score":0.9995414},"labels":[],"label_agreement":null},{"id":"W4406795493","doi":"10.2196/71293","title":"Peer Review of “Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy for Recurrent Glioblastoma: An Augmented Meta-Analysis of Phase 1 Clinical Trials (Preprint)”","year":2025,"lang":"en","type":"article","venue":"JMIRx Med","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Preprint; Chimeric antigen receptor; Meta-analysis; Glioblastoma; Medicine; Clinical trial; Oncology; Internal medicine; Cancer research; Immunotherapy; Computer science; Cancer; World Wide Web","score_opus":0.2552106420503055,"score_gpt":0.540461303106882,"score_spread":0.2852506610565765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406795493","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8712869,0.09190796,0.0012838164,0.015586546,0.00038574624,0.017245783,0.00083700765,0.00006374721,0.0014024472],"genre_scores_gemma":[0.49762198,0.41443896,0.0070271743,0.0017175336,0.0003894616,0.0012373324,0.0017258844,0.00019154967,0.07565013],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9937575,0.0018105374,0.0027501276,0.0005486632,0.00089966354,0.00023352844],"domain_scores_gemma":[0.9931476,0.0029408438,0.0010877167,0.0010531248,0.0015832086,0.00018748357],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.018767267,0.00023695083,0.0046052327,0.00050766004,0.000032086675,0.0000061420455,0.00025175023,0.00013704126,0.0053765806],"category_scores_gemma":[0.005354453,0.00015080304,0.0026269713,0.0014705156,0.0002164824,0.00004010214,0.000057666617,0.00022892449,0.0000016248259],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08618722,0.012214746,0.0005916242,0.005250854,0.17655772,0.0000019446136,0.00057809264,0.0000046263394,0.3204787,0.0000551163,0.014898897,0.38318047],"study_design_scores_gemma":[0.056184713,0.016491521,0.0035575994,0.0011573413,0.16504863,0.0000014841748,0.00018613666,0.0009397123,0.33501625,0.000024988061,0.42098853,0.00040309297],"about_ca_topic_score_codex":0.00002579982,"about_ca_topic_score_gemma":0.000009505771,"teacher_disagreement_score":0.40608963,"about_ca_system_score_codex":0.000033756747,"about_ca_system_score_gemma":0.00029789165,"threshold_uncertainty_score":0.99553263},"labels":[],"label_agreement":null},{"id":"W4406802045","doi":"10.14309/crj.0000000000001597","title":"Chimeric Antigen Receptor T-Cell-Associated Cholangiopathy: First Reported Case of a Complication of Chimeric Antigen Receptor T-Cell Therapy","year":2025,"lang":"en","type":"article","venue":"ACG Case Reports Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Chimeric antigen receptor; Medicine; Immunotherapy; Refractory (planetary science); Lymphoma; Antigen; Complication; Cell therapy; Mantle cell lymphoma; Immunology; Cancer research; Cell; Immune system; Internal medicine","score_opus":0.028581338956687092,"score_gpt":0.3232871997219937,"score_spread":0.29470586076530664,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406802045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883239,0.0051379516,0.00014202563,0.00048309442,0.00061909115,0.001278136,0.00002988647,0.00007555413,0.0039103553],"genre_scores_gemma":[0.9883099,0.0069505093,0.0007560524,0.00011477653,0.00023335431,0.000032747055,0.0001337701,0.00008993902,0.0033789608],"study_design_codex":"bench_or_experimental","study_design_gemma":"case_report","domain_scores_codex":[0.9951052,0.00032936767,0.002408715,0.00065308006,0.0008670888,0.0006365312],"domain_scores_gemma":[0.99375904,0.00022951586,0.0029343388,0.0012712708,0.0014077537,0.0003981056],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0025288083,0.00042948496,0.0011797432,0.0008002948,0.00041847627,0.00006435987,0.00016813152,0.0002993536,0.002486933],"category_scores_gemma":[0.0005881256,0.00038186208,0.0006123134,0.001845394,0.0002353432,0.0001911904,0.000095902236,0.00089014205,0.000011431154],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006707819,0.0019524789,0.08405518,0.00019504274,0.0010534904,0.099888176,0.0010502853,0.000018705563,0.7870526,0.0000023489279,0.008251168,0.015809782],"study_design_scores_gemma":[0.006143232,0.0014034616,0.02608206,0.00072438293,0.0004168931,0.54970163,0.0009460024,0.000265821,0.37272444,0.000057222678,0.04091036,0.000624499],"about_ca_topic_score_codex":0.0011689676,"about_ca_topic_score_gemma":0.00003640298,"teacher_disagreement_score":0.44981346,"about_ca_system_score_codex":0.00035404225,"about_ca_system_score_gemma":0.0010951901,"threshold_uncertainty_score":0.9998633},"labels":[],"label_agreement":null},{"id":"W4406848242","doi":"10.1038/s41375-024-02482-6","title":"International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma","year":2025,"lang":"en","type":"review","venue":"Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Institute of Cancer Research; McMaster University","funders":"","keywords":"Chimeric antigen receptor; Immunotherapy; Multiple myeloma; Medicine; Antigen; Oncology; Immunology; Internal medicine; Immune system","score_opus":0.08323822165411887,"score_gpt":0.3775774111568178,"score_spread":0.29433918950269894,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406848242","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00035918265,0.9777511,0.0011426867,0.0002772986,0.0015656633,0.006235982,0.00024623857,0.00015644629,0.012265423],"genre_scores_gemma":[0.00016470447,0.9828617,0.002757207,0.00020874303,0.0007667928,0.0012554231,0.0024672362,0.00017070473,0.009347463],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99689627,0.00025558742,0.0011816741,0.0007061117,0.00046651025,0.00049385166],"domain_scores_gemma":[0.99626297,0.0019491066,0.000623733,0.0008962001,0.00018143008,0.00008655263],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00052775,0.00068302825,0.0022768301,0.00081111817,0.0001502128,0.00006578723,0.00046425976,0.00051173783,0.0014421291],"category_scores_gemma":[0.000097957454,0.0005640462,0.0013162574,0.00048539357,0.00008858903,0.00006754603,0.000051615476,0.00038258178,0.000021653208],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012758768,0.00020447717,0.00005078888,0.0029633215,0.0018107195,0.000012694211,0.00025801288,0.0000030737062,0.0014525306,0.000102345104,0.00046867496,0.9913975],"study_design_scores_gemma":[0.0058349483,0.0013420951,0.00003842359,0.012386794,0.00025430913,0.00004419534,0.00004856371,0.00022390102,0.00059090694,0.00004219882,0.9788294,0.0003642959],"about_ca_topic_score_codex":0.00014710269,"about_ca_topic_score_gemma":0.000023305534,"teacher_disagreement_score":0.9910332,"about_ca_system_score_codex":0.009119548,"about_ca_system_score_gemma":0.0011835033,"threshold_uncertainty_score":0.9996811},"labels":[],"label_agreement":null},{"id":"W4406854667","doi":"10.1182/blood.2024025355","title":"Integrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody response","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Spinal Cord Injury BC; BC Cancer Agency","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute","keywords":"Diffuse large B-cell lymphoma; Immune system; Germinal center; CD19; Immunotherapy; Chimeric antigen receptor; B cell; T cell; Cancer research; Lymphoma; CD20; Biology; Immunology; Antibody","score_opus":0.013690929479762403,"score_gpt":0.3065875653718829,"score_spread":0.2928966358921205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406854667","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99611723,0.00074364647,0.000116850606,0.00014970949,0.000031022693,0.00035241028,0.000042217813,0.000022056965,0.0024248578],"genre_scores_gemma":[0.9545522,0.00021659525,0.00004759072,0.00002739039,0.000009151558,0.00001548705,0.00015007149,0.000017724293,0.044963833],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.998475,0.00026922268,0.00034145458,0.0002964731,0.00038426646,0.00023359075],"domain_scores_gemma":[0.99885744,0.0003453571,0.00013105603,0.00053212856,0.00007896298,0.00005502711],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00069557823,0.00015658367,0.00059987506,0.0008836432,0.00006108574,0.000021828931,0.00016054919,0.000086777036,0.0009879472],"category_scores_gemma":[0.00024410212,0.00011963633,0.0002204625,0.0016147194,0.00022086948,0.00004018406,0.00007499688,0.00022061025,0.000015911088],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002504886,0.0012243821,0.09892147,0.000012013121,0.010085155,0.000049497117,0.0005685263,0.000007043159,0.886305,0.000017757058,0.000037046077,0.00026724208],"study_design_scores_gemma":[0.0037911267,0.0003138241,0.7470417,0.00011621666,0.0028381418,0.0000019408117,0.00050740386,0.000058636895,0.24485502,0.0000134859765,0.00037943755,0.00008304028],"about_ca_topic_score_codex":0.000085723346,"about_ca_topic_score_gemma":0.000059263348,"teacher_disagreement_score":0.6481202,"about_ca_system_score_codex":0.00014104263,"about_ca_system_score_gemma":0.00013486574,"threshold_uncertainty_score":0.99992526},"labels":[],"label_agreement":null},{"id":"W4406919094","doi":"10.1186/s13046-024-03247-w","title":"Allogeneic DNT cell therapy synergizes with T cells to promote anti-leukemic activities while suppressing GvHD","year":2025,"lang":"en","type":"article","venue":"Journal of Experimental & Clinical Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Toronto General Hospital; University of Calgary; University Health Network","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Alberta Cancer Foundation","keywords":"Myeloid leukemia; Immunology; CD8; Cancer research; Leukemia; Graft-versus-host disease; Hematopoietic stem cell transplantation; Stem cell; Haematopoiesis; Transplantation; Medicine; Immune system; Biology; Internal medicine; Cell biology","score_opus":0.1471290124295697,"score_gpt":0.5112069163038436,"score_spread":0.36407790387427397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406919094","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98103917,0.010178823,0.000023740375,0.001866298,0.00056656764,0.0010911631,0.00001058012,0.000021095731,0.0052025365],"genre_scores_gemma":[0.98225254,0.0047278255,0.0009312636,0.00068380777,0.0007909426,0.000096318996,0.0000022232675,0.000073162366,0.010441929],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9945945,0.00074429804,0.0010963021,0.00056568795,0.002079969,0.0009192192],"domain_scores_gemma":[0.996877,0.0008726863,0.00024402118,0.00059763284,0.00074187433,0.0006667605],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003417023,0.00030486516,0.0010071903,0.0006907331,0.0002599155,0.00019236055,0.00065533776,0.00021929023,0.004441933],"category_scores_gemma":[0.000115291725,0.00021243606,0.00040014597,0.00089354184,0.0006288885,0.00023228192,0.00030386515,0.0020373706,0.000020626034],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0104310205,0.0016340959,0.007615706,0.000076087425,0.00038562427,0.0002896577,0.00071449875,0.0000475189,0.94233805,0.0000053808108,0.008173207,0.02828914],"study_design_scores_gemma":[0.006108166,0.0061843004,0.0051448215,0.0005548403,0.00003222572,0.00004445482,0.0019091893,0.000026232843,0.93830687,0.000013920422,0.04148188,0.00019308615],"about_ca_topic_score_codex":0.00020077288,"about_ca_topic_score_gemma":0.000013637881,"teacher_disagreement_score":0.03330867,"about_ca_system_score_codex":0.0010376336,"about_ca_system_score_gemma":0.0025596914,"threshold_uncertainty_score":0.9964681},"labels":[],"label_agreement":null},{"id":"W4406995266","doi":"10.3390/curroncol32020079","title":"Tumor-Associated Extracellular Matrix Obstacles for CAR-T Cell Therapy: Approaches to Overcoming","year":2025,"lang":"en","type":"review","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Ministry of Science and Higher Education of the Russian Federation","keywords":"Chimeric antigen receptor; Extracellular matrix; Cancer research; Medicine; Cell therapy; Cytotoxic T cell; T cell; Tumor microenvironment; Infiltration (HVAC); Cell; Immunology; Immune system; Tumor cells; Chemistry; Biology; Cell biology; Materials science","score_opus":0.41884260293245695,"score_gpt":0.4776253732411605,"score_spread":0.05878277030870355,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406995266","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00019778086,0.9868883,0.00024032083,0.00019111515,0.001799559,0.008483649,0.0002495084,0.0001378859,0.0018118746],"genre_scores_gemma":[0.000016732296,0.96804917,0.0005203547,0.00004757481,0.0007779327,0.0024151697,0.0008833062,0.0001637872,0.027125977],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99550813,0.00067921187,0.0011302946,0.0011119707,0.0004874177,0.0010829926],"domain_scores_gemma":[0.99583614,0.0022130937,0.0004801558,0.00085686386,0.00021508998,0.00039864203],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013353588,0.00079191837,0.003930268,0.0007891537,0.00016248366,0.000055761808,0.000622692,0.00074852695,0.0006662594],"category_scores_gemma":[0.0005107026,0.0006676259,0.0014401266,0.00084924727,0.00011851504,0.000038931856,0.00026761045,0.0013522032,0.0000920179],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022661252,0.0012473555,0.000029857956,0.028414888,0.00040653304,0.000047149082,0.00020515618,8.256902e-7,0.00010055298,0.00016660058,0.007551634,0.9616028],"study_design_scores_gemma":[0.002462586,0.001001202,0.0000042414863,0.00734868,0.0010783727,0.000030494673,0.00008059638,0.000035122866,0.000057701214,0.000053198728,0.9873501,0.0004977076],"about_ca_topic_score_codex":0.000015811434,"about_ca_topic_score_gemma":0.00001460927,"teacher_disagreement_score":0.97979844,"about_ca_system_score_codex":0.0022211326,"about_ca_system_score_gemma":0.0029928382,"threshold_uncertainty_score":0.9995775},"labels":[],"label_agreement":null},{"id":"W4407007830","doi":"10.1182/bloodadvances.2024013656","title":"Impact of vein-to-vein time in patients with R/R LBCL treated with axicabtagene ciloleucel","year":2025,"lang":"en","type":"review","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"National Institute of Allergy and Infectious Diseases; Office of Naval Research; Legend Biotech; Pharmacyclics; Takeda Oncology; Health Resources and Services Administration; MorphoSys; Seagen; Astellas Pharma; Adaptive Biotechnologies; Pfizer; Incyte; Kiadis Pharma; bluebird bio; Medac; Jazz Pharmaceuticals; BeiGene; HistoGenetics; Atara Biotherapeutics; CareDx; Actinium Pharmaceuticals; National Cancer Institute; Gilead Sciences; Sanofi; GlaxoSmithKline; CSL Behring; Bristol-Myers Squibb; AstraZeneca; Gateway for Cancer Research; Swedish Orphan Biovitrum; Omeros Corporation; Vertex Pharmaceuticals; Alexion Pharmaceuticals; Mallinckrodt Pharmaceuticals; Astellas Pharma US; Amgen; Novartis Pharmaceuticals Corporation","keywords":"Medicine; Hazard ratio; Odds ratio; Internal medicine; Refractory (planetary science); Leukapheresis; Surgery; Gastroenterology; Confidence interval","score_opus":0.015372867371088561,"score_gpt":0.3482179956828738,"score_spread":0.33284512831178525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407007830","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.027271464,0.96430796,0.000002806168,0.000010966312,0.00002137678,0.0031852515,0.00023343606,0.000050361952,0.004916349],"genre_scores_gemma":[0.00050854945,0.982369,0.000389452,0.000017750026,0.00007237105,0.00019823015,0.00044779218,0.000107636064,0.015889207],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9973091,0.0001571729,0.00061527744,0.00066140364,0.00071638596,0.0005406514],"domain_scores_gemma":[0.9982088,0.0002279533,0.00028623448,0.00078263436,0.00025262806,0.00024175462],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018055011,0.0005943749,0.0026818237,0.00079746224,0.00003107122,0.000018187135,0.00031625965,0.00018871269,0.000793188],"category_scores_gemma":[0.000092658076,0.00034476252,0.00033634933,0.0018326482,0.00011622748,0.00009516531,0.00007890152,0.00045305633,0.000044317392],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016244173,0.0019112296,0.024091424,0.012220926,0.0013910229,0.00011922174,0.000041305193,0.00001293332,0.00005131699,0.0000012036342,0.00010198228,0.95843303],"study_design_scores_gemma":[0.020575501,0.027727375,0.025332525,0.12986079,0.0047774524,0.000059564045,0.000018132283,0.0000031772975,0.00043909124,0.0000062367735,0.7896399,0.0015602376],"about_ca_topic_score_codex":0.00009095041,"about_ca_topic_score_gemma":0.000034091958,"teacher_disagreement_score":0.95687276,"about_ca_system_score_codex":0.00022172242,"about_ca_system_score_gemma":0.0010041173,"threshold_uncertainty_score":0.99990046},"labels":[],"label_agreement":null},{"id":"W4407036945","doi":"10.20944/preprints202501.1882.v2","title":"Optimal Use of Bispecific Antibodies for the Treatment of Diffuse Large B-cell Lymphoma in Canada","year":2025,"lang":"en","type":"preprint","venue":"Preprints.org","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"AbbVie Canada","keywords":"Bispecific antibody; Lymphoma; Medicine; Antibody; Diffuse large B-cell lymphoma; Refractory (planetary science); Antibody therapy; Chimeric antigen receptor; Oncology; Cancer research; Internal medicine; Immunotherapy; Immunology; Cancer; Monoclonal antibody; Biology","score_opus":0.14617016911375658,"score_gpt":0.3699330324314396,"score_spread":0.22376286331768303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407036945","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932306,0.0012068901,0.000048529455,0.00032197582,0.00035361387,0.0030192016,0.00065003464,0.000018621724,0.0011505228],"genre_scores_gemma":[0.9760101,0.007017434,0.0002810739,0.00003643103,0.000073515424,0.0004039315,0.0000948216,0.000039820712,0.016042916],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973815,0.00012441866,0.00077079266,0.0007046484,0.00053104473,0.0004875895],"domain_scores_gemma":[0.9964451,0.0009503877,0.00029169142,0.0019008057,0.0003040289,0.00010797893],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00040481347,0.00036821197,0.0010247673,0.00028180148,0.000050195198,0.0000092142545,0.0004474271,0.00019830717,0.00070785184],"category_scores_gemma":[0.00017609661,0.0002747936,0.00040023748,0.00022060703,0.00013473986,0.000027589398,0.0006354589,0.00026242778,0.0000067883525],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026054953,0.0067034923,0.95637673,0.0015286758,0.0008553908,0.00004975923,0.002105557,0.0009173559,0.023445832,0.00005944531,0.0002004147,0.0051518683],"study_design_scores_gemma":[0.014270571,0.00022443024,0.55544263,0.0005503947,0.0003168489,0.0000044987055,0.000757768,0.0024699403,0.36197323,0.000028785578,0.063657634,0.00030325714],"about_ca_topic_score_codex":0.57651275,"about_ca_topic_score_gemma":0.30552983,"teacher_disagreement_score":0.40093407,"about_ca_system_score_codex":0.0015255791,"about_ca_system_score_gemma":0.0032895852,"threshold_uncertainty_score":0.99997044},"labels":[],"label_agreement":null},{"id":"W4407171542","doi":"10.26685/urncst.677","title":"Chimeric Antigen Receptor T Cells (CAR T-Cells): A New Frontier in Targeted Cancer Therapy","year":2025,"lang":"en","type":"article","venue":"Undergraduate Research in Natural and Clinical Science and Technology (URNCST) Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Queen's University","keywords":"Chimeric antigen receptor; Frontier; Cancer; Antigen; Receptor; Cancer research; Cancer therapy; Immunotherapy; Immunology; Biology; Genetics; Political science","score_opus":0.05283176534618251,"score_gpt":0.4303344833493677,"score_spread":0.3775027180031852,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407171542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.88355166,0.017085224,0.000010910765,0.097522795,0.0006045289,0.000621803,0.000001973991,0.00003264774,0.00056847214],"genre_scores_gemma":[0.82457554,0.16741975,0.00061970495,0.00041445956,0.00017330685,0.0000155735,0.0000011163056,0.000013781544,0.0067667747],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99563456,0.00035269043,0.0007508545,0.00079270557,0.0011805362,0.0012886454],"domain_scores_gemma":[0.9979811,0.00047946462,0.00010834269,0.00033308324,0.0005932037,0.00050481845],"candidate_categories":["sts","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0064145178,0.00022746326,0.0006240175,0.0025478788,0.0004974734,0.00019036996,0.0006825865,0.000411361,0.00026058502],"category_scores_gemma":[0.00074457366,0.00015606506,0.000095954485,0.006803646,0.0035674402,0.00027461976,0.0004023737,0.0047425525,0.000016312883],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007569748,0.0003430113,0.12313879,0.000021360733,0.00008825862,0.00015407395,0.00004768311,0.0000010620462,0.35431346,0.00038029763,0.008642484,0.51211256],"study_design_scores_gemma":[0.041694622,0.006756516,0.21235274,0.002909293,0.000068486115,0.0006071868,0.0029816015,0.008146044,0.22082113,0.2049439,0.2971018,0.0016166907],"about_ca_topic_score_codex":0.0006411865,"about_ca_topic_score_gemma":0.0003129361,"teacher_disagreement_score":0.51049584,"about_ca_system_score_codex":0.0004269316,"about_ca_system_score_gemma":0.0025009732,"threshold_uncertainty_score":0.99914426},"labels":[],"label_agreement":null},{"id":"W4407249781","doi":"10.54097/qqyb3z55","title":"CAR-T cell therapy in treating advanced prostate cancer","year":2024,"lang":"en","type":"article","venue":"Highlights in Science Engineering and Technology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Lakes Environmental (Canada)","funders":"","keywords":"Prostate cancer; Medicine; Cancer; Prostate; Oncology; Internal medicine","score_opus":0.009371166423952837,"score_gpt":0.2873681195778401,"score_spread":0.2779969531538872,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407249781","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895935,0.006658962,0.000015855805,0.0023901123,0.00019711097,0.00028814824,0.0000016312254,0.00023947874,0.00061520736],"genre_scores_gemma":[0.9926641,0.0050741467,0.00090606755,0.0000109021385,0.000031369556,0.00011433246,5.097232e-7,0.000018493309,0.0011800594],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99879813,0.0000051219763,0.0001609812,0.0004110221,0.00019685569,0.00042790116],"domain_scores_gemma":[0.9996511,0.000047164147,0.000011075095,0.0001977674,0.00003500146,0.000057942234],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029635124,0.00012189865,0.0001916087,0.0014710926,0.000038119102,0.000035376852,0.00013657946,0.00009306844,0.000029474371],"category_scores_gemma":[0.000036647743,0.00009405707,0.000015211271,0.0027608648,0.00024338318,0.00011532279,0.00005038052,0.00033988644,0.000009105091],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000021429469,0.00002566588,0.0037844547,0.00006136175,0.0000037172815,0.00016688934,0.0005951851,0.00047459273,0.8874403,0.0029388566,0.0000068687846,0.104480654],"study_design_scores_gemma":[0.002038943,0.0005365511,0.005218531,0.00080619345,0.000005278634,0.00009130151,0.0003179032,0.033103038,0.8842742,0.0003195141,0.07295342,0.0003351155],"about_ca_topic_score_codex":0.000080686084,"about_ca_topic_score_gemma":0.00003060586,"teacher_disagreement_score":0.10414554,"about_ca_system_score_codex":0.0001967597,"about_ca_system_score_gemma":0.00015997545,"threshold_uncertainty_score":0.38355356},"labels":[],"label_agreement":null},{"id":"W4407280299","doi":"10.1016/bs.mcb.2025.01.004","title":"Evaluating transcriptional tumour microenvironment response to immunotherapy using microarray analysis: From harvesting tumours to data analysis","year":2025,"lang":"en","type":"article","venue":"Methods in cell biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre; McMaster University","funders":"Canadian Institutes of Health Research","keywords":"Biology; Microarray analysis techniques; Immunotherapy; Computational biology; Microarray; Tumor microenvironment; Cancer research; Immunology; Immune system; Genetics; Gene expression; Gene","score_opus":0.1756769651994756,"score_gpt":0.5031746313922958,"score_spread":0.32749766619282017,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407280299","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5690981,0.0009785458,0.42803392,0.0009910696,0.00010766222,0.0005017928,0.00012024308,0.000019769379,0.00014888283],"genre_scores_gemma":[0.18651098,0.000043381053,0.8095292,0.0015155253,0.0000769095,0.00005411371,0.0003597738,0.00003227589,0.0018778748],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9912353,0.005473041,0.000926808,0.0014025245,0.00029328742,0.00066902675],"domain_scores_gemma":[0.9955672,0.0023605037,0.00013679276,0.0016574193,0.000074866846,0.00020321726],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.012389182,0.0003277539,0.0011773352,0.0028875603,0.00014340866,0.000051079096,0.0007933877,0.00020724436,0.0024849288],"category_scores_gemma":[0.0009505171,0.00031776357,0.00035876536,0.004839144,0.00013205355,0.00005424932,0.00035483873,0.000512147,0.000016272026],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003831853,0.00016595422,0.041514147,0.000012342725,0.0020560962,0.000014173558,0.0007295798,0.0063534416,0.9204006,0.0000031929508,0.000020537205,0.024898047],"study_design_scores_gemma":[0.0036959122,0.00065797876,0.27844846,0.00012171035,0.005671914,0.0000051274355,0.0009821027,0.0816509,0.61762,0.00041453404,0.01009826,0.00063312834],"about_ca_topic_score_codex":0.0025903669,"about_ca_topic_score_gemma":0.00033273175,"teacher_disagreement_score":0.38258713,"about_ca_system_score_codex":0.00080735056,"about_ca_system_score_gemma":0.00029147213,"threshold_uncertainty_score":0.99992746},"labels":[],"label_agreement":null},{"id":"W4407288611","doi":"10.1136/jitc-2024-009890","title":"Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Hospital","funders":"Iovance Biotherapeutics; Janssen Research and Development; National Institute of Allergy and Infectious Diseases; National Cancer Institute; Office of Naval Research; National Heart, Lung, and Blood Institute; bluebird bio; Pharmacyclics; Takeda Oncology; Legend Biotech; U.S. Navy; Adaptive Biotechnologies; Health Resources and Services Administration; National Institutes of Health; CytoSen Therapeutics; MorphoSys; CareDx; BeiGene; Swedish Orphan Biovitrum; Astellas Pharma; CSL Behring; Kyowa Kirin Pharmaceutical Development; Atara Biotherapeutics; Vertex Pharmaceuticals; Anthem Foundation; GlaxoSmithKline; Kiadis Pharma; Sanofi; TG Therapeutics; Medac; Jazz Pharmaceuticals; Omeros Corporation; U.S. Department of Defense; Medical College of Wisconsin; StemCyte; AbbVie; Actinium Pharmaceuticals; Gilead Sciences; Stanford University; National Marrow Donor Program; Mallinckrodt Pharmaceuticals; Merck; Bristol-Myers Squibb; AstraZeneca; Astellas Pharma US; Be The Match Foundation; Novartis Pharmaceuticals Corporation; Dana-Farber Cancer Institute; Allogene Therapeutics; Incyte; Pfizer; Amgen; Boston Children's Hospital; HistoGenetics","keywords":"Medicine; Cytokine release syndrome; Fludarabine; Internal medicine; Oncology; Hematopoietic stem cell transplantation; Diffuse large B-cell lymphoma; Salvage therapy; Cohort; Lymphoma; Transplantation; Chimeric antigen receptor; Immunotherapy; Chemotherapy; Cancer; Cyclophosphamide","score_opus":0.04027750660366552,"score_gpt":0.41093005155627,"score_spread":0.37065254495260447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407288611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96267164,0.025714718,0.0002495477,0.005086837,0.0004473518,0.00080727914,0.00006387069,0.00001776602,0.0049409796],"genre_scores_gemma":[0.86463904,0.03130359,0.0012359995,0.0022712492,0.00044438642,0.0002138238,0.00001971863,0.00010668829,0.09976552],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9980328,0.00011581438,0.000626729,0.00026448167,0.00056358735,0.00039656204],"domain_scores_gemma":[0.99773777,0.0006657884,0.00060608727,0.0005993374,0.00031732876,0.00007366877],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004930022,0.00025207934,0.00072341977,0.000337913,0.00017258566,0.00007066092,0.0004312576,0.00009986465,0.0011100275],"category_scores_gemma":[0.000054760665,0.00014581127,0.00037525382,0.00069816347,0.00022114642,0.000099195524,0.000029010671,0.0003997311,0.0000014133295],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019657034,0.00088003813,0.34875613,0.00014235624,0.0034420558,0.00013150548,0.0013596656,0.00012336903,0.44678286,0.000088690846,0.014193474,0.16444282],"study_design_scores_gemma":[0.04058722,0.0007702164,0.67979735,0.001976591,0.00044179455,0.000037186703,0.0010663995,0.000140965,0.17527926,0.0013077285,0.09821535,0.00037992973],"about_ca_topic_score_codex":0.0072821504,"about_ca_topic_score_gemma":0.0041100807,"teacher_disagreement_score":0.33104122,"about_ca_system_score_codex":0.000584026,"about_ca_system_score_gemma":0.0009968546,"threshold_uncertainty_score":0.99980307},"labels":[],"label_agreement":null},{"id":"W4407300113","doi":"10.1097/coc.0000000000001171","title":"Efficacy and Safety of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Patients with Non-Hodgkin Lymphoma","year":2025,"lang":"en","type":"review","venue":"American Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences","funders":"","keywords":"Medicine; Internal medicine; Lymphoma; Neutropenia; Adverse effect; Nausea; Chimeric antigen receptor; Hazard ratio; Oncology; Incidence (geometry); Gastroenterology; Chemotherapy; Cancer; Immunotherapy; Confidence interval","score_opus":0.055866799719170517,"score_gpt":0.45606727496103683,"score_spread":0.4002004752418663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407300113","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21776132,0.7766122,0.000021633496,0.00027813495,0.0006032401,0.0021692992,0.00002939752,0.000008728987,0.002516004],"genre_scores_gemma":[0.0028073809,0.99415934,0.0019221276,0.00030323913,0.0003599852,0.000012271566,0.000023788038,0.00006677305,0.00034507518],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9925983,0.0019554917,0.0038632336,0.0004856679,0.0006431095,0.00045421522],"domain_scores_gemma":[0.9880063,0.0063667297,0.004172827,0.0005087703,0.00050596474,0.0004394411],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002748923,0.0004538544,0.008324847,0.00070633757,0.000030312289,0.000008489666,0.00047929565,0.00044339083,0.00039615066],"category_scores_gemma":[0.0008124761,0.0002887363,0.0008730111,0.001243686,0.0013207212,0.000049423557,0.00012279714,0.0014930387,0.0000075336575],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015840214,0.0028045285,0.020980837,0.0009541807,0.00092867017,0.00007183815,0.00006519375,4.0122606e-7,0.000005100677,7.4168304e-7,0.00024075212,0.95810753],"study_design_scores_gemma":[0.022270322,0.054448485,0.07837529,0.007030227,0.00054661,0.000051519357,0.000051585343,6.737368e-7,0.0000040597165,0.0000016459808,0.83697635,0.0002432219],"about_ca_topic_score_codex":0.000067324654,"about_ca_topic_score_gemma":0.0000052343967,"teacher_disagreement_score":0.95786434,"about_ca_system_score_codex":0.00029679184,"about_ca_system_score_gemma":0.005491829,"threshold_uncertainty_score":0.9999565},"labels":[],"label_agreement":null},{"id":"W4407364868","doi":"10.1101/2025.02.10.637482","title":"Precise engineering of chimeric antigen receptor expression levels defines T cell identity and function","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Research Institute in Oncology and Hematology; CancerCare Manitoba","funders":"","keywords":"Chimeric antigen receptor; Identity (music); Function (biology); Expression (computer science); Cell biology; Antigen; Receptor; Computational biology; Biology; T cell; Immunology; Computer science; Genetics; Immune system; Physics","score_opus":0.024331975729834997,"score_gpt":0.2612501688721465,"score_spread":0.23691819314231152,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407364868","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98828304,0.005503758,0.0034391414,0.000055442957,0.001080567,0.0011683622,0.00019565686,0.00023097637,0.000043047214],"genre_scores_gemma":[0.9899854,0.002381197,0.0068128705,0.00003372762,0.00038064443,0.00013498393,0.0000013747646,0.00010165618,0.00016813654],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974265,0.000100543795,0.0005797578,0.000857606,0.0005992226,0.00043633077],"domain_scores_gemma":[0.99768376,0.00010873461,0.00029840934,0.0011026462,0.00054197386,0.00026444913],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00064830977,0.0004733907,0.0008051245,0.00058630126,0.0000842081,0.00008815938,0.0002921473,0.0005153822,0.0004242973],"category_scores_gemma":[0.00026917015,0.00049175194,0.00018599501,0.000665326,0.00009236328,0.00019362802,0.0006389049,0.00080869853,0.000014319144],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018040137,0.00015956821,0.015563613,0.0029004735,0.0001463644,0.0000081232865,0.000013378177,0.000048598267,0.9806937,0.00003250514,0.00023390478,0.000019377563],"study_design_scores_gemma":[0.0008521128,0.00009386116,0.14375304,0.001621073,0.00013895142,1.8328109e-8,0.0000024365468,0.00029156523,0.84803975,8.5816094e-7,0.004862225,0.00034410023],"about_ca_topic_score_codex":0.000047945054,"about_ca_topic_score_gemma":6.6169065e-7,"teacher_disagreement_score":0.13265394,"about_ca_system_score_codex":0.00019022926,"about_ca_system_score_gemma":0.0005391701,"threshold_uncertainty_score":0.9997534},"labels":[],"label_agreement":null},{"id":"W4407396455","doi":"10.1182/blood.2024027347","title":"Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Internal medicine; Lymphoma; Leukapheresis; Fludarabine; Phases of clinical research; Gastroenterology; Chimeric antigen receptor; Surgery; Chemotherapy; Immunotherapy; Cancer; Cyclophosphamide","score_opus":0.021148801557246615,"score_gpt":0.2961322123846648,"score_spread":0.2749834108274182,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407396455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99244624,0.00087578,0.0016593904,0.00051303685,0.00017056869,0.0020160489,0.0002222848,0.000056357556,0.0020402747],"genre_scores_gemma":[0.9873912,0.00021549358,0.00022207134,0.0001115949,0.00016843683,0.00022670726,0.00007941822,0.000040465915,0.011544628],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99777037,0.00010629885,0.000524047,0.0004995344,0.0006104996,0.00048925186],"domain_scores_gemma":[0.9975732,0.00057813164,0.0001629136,0.0012764739,0.00029904372,0.000110269735],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001226889,0.00024564643,0.00081570336,0.00049228565,0.00024402433,0.000029550773,0.00041777274,0.00012571109,0.0007429613],"category_scores_gemma":[0.0002597333,0.00017252762,0.0005804468,0.0016119655,0.00007996856,0.00003259927,0.00019555211,0.00018996086,0.000013723801],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004335172,0.03721049,0.8986417,0.000394677,0.02654219,0.000057215544,0.0016469293,0.000036649253,0.0146891065,0.0005061699,0.004065826,0.011873864],"study_design_scores_gemma":[0.2922968,0.007924117,0.48669502,0.00015193703,0.06986938,0.000005512267,0.0033856842,0.0061599505,0.1101553,0.0013848413,0.021137875,0.0008335848],"about_ca_topic_score_codex":0.00090825616,"about_ca_topic_score_gemma":0.0057392824,"teacher_disagreement_score":0.41194668,"about_ca_system_score_codex":0.00006597576,"about_ca_system_score_gemma":0.00017202251,"threshold_uncertainty_score":0.8134905},"labels":[],"label_agreement":null},{"id":"W4407409544","doi":"10.1080/08820139.2025.2462536","title":"Variable Lymphocyte Receptor B Technologies – Are They Ready for Prime Time?","year":2025,"lang":"en","type":"review","venue":"Immunological Investigations","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"Sick Kids Foundation","keywords":"Receptor; Common variable immunodeficiency; Lymphocyte; Prime (order theory); Immunology; Biology; Computational biology; Genetics; Chemistry; Antibody; Mathematics; Combinatorics","score_opus":0.12314555125493065,"score_gpt":0.3852417675768454,"score_spread":0.26209621632191477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407409544","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000035043267,0.9848388,0.00015106775,0.0009613279,0.0002541711,0.0042761373,0.00052522786,0.0010518796,0.007937897],"genre_scores_gemma":[7.4352715e-7,0.91819364,0.017443744,0.00011544807,0.00014311656,0.0031272136,0.0018252085,0.00006807016,0.05908281],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99706596,0.00028668306,0.0008546632,0.0007182255,0.0003131852,0.0007612962],"domain_scores_gemma":[0.9958471,0.0019778635,0.00039939414,0.0012851158,0.00035102267,0.00013952599],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000632019,0.0005866633,0.0022327523,0.0005136264,0.0003165875,0.00008180102,0.0007006711,0.0015148923,0.0020583232],"category_scores_gemma":[0.005268663,0.00041508084,0.0005819441,0.0011067059,0.00072856393,0.00008863895,0.00039206786,0.0010497795,0.0008343719],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000057629237,0.00029107183,0.0000052300015,0.0072922995,0.00089432404,0.0000051574275,0.000020960853,4.3898447e-7,0.0020164605,0.011018069,0.008268363,0.97012997],"study_design_scores_gemma":[0.00052876264,0.00023963906,0.0000030007882,0.01134864,0.0009058669,0.000047134396,0.00005029219,0.0000070872043,0.00036299296,0.003967304,0.9821701,0.0003691492],"about_ca_topic_score_codex":0.000024813273,"about_ca_topic_score_gemma":8.244785e-7,"teacher_disagreement_score":0.97390175,"about_ca_system_score_codex":0.0008696086,"about_ca_system_score_gemma":0.0017647357,"threshold_uncertainty_score":0.9999436},"labels":[],"label_agreement":null},{"id":"W4407411156","doi":"10.69645/wsam8047","title":"The regulation of cell therapy","year":2025,"lang":"en","type":"article","venue":"˜The œbiomedical & life sciences collection.","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Cell therapy; Cell; Chemistry; Biochemistry","score_opus":0.02775150057847669,"score_gpt":0.3314335778454464,"score_spread":0.3036820772669697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407411156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5449777,0.0110303145,0.005605738,0.11973473,0.0056149187,0.0045688753,0.00000983752,0.00028811628,0.30816978],"genre_scores_gemma":[0.8867008,0.00096179766,0.00016245882,0.0010704765,0.00025178448,0.00005726759,0.0000027293947,0.000007651643,0.11078502],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99777246,0.0001910028,0.00035102994,0.00026441438,0.0011108726,0.00031024666],"domain_scores_gemma":[0.9983743,0.00085357757,0.00009177879,0.00036046127,0.00018730812,0.00013258033],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002139951,0.00010173107,0.0001834971,0.00025185215,0.0011347149,0.000052915348,0.00043634098,0.00008964763,0.0010734802],"category_scores_gemma":[0.00023172244,0.000050156286,0.00011888594,0.004018168,0.0023687992,0.000049598722,0.00007382404,0.0002510368,0.000018630953],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017750626,0.0008893835,0.0057616704,0.0000909541,0.00024282909,0.0000029643834,0.0012059256,0.000045809153,0.47817755,0.0036409134,0.3679108,0.14025612],"study_design_scores_gemma":[0.0027725296,0.0013410993,0.03696918,0.00007157223,0.000038146743,0.000017297178,0.0011578931,0.01016134,0.02453918,0.005548983,0.9172432,0.00013960611],"about_ca_topic_score_codex":0.00015043412,"about_ca_topic_score_gemma":0.00004596014,"teacher_disagreement_score":0.5493324,"about_ca_system_score_codex":0.00009490437,"about_ca_system_score_gemma":0.0012857487,"threshold_uncertainty_score":0.99983966},"labels":[],"label_agreement":null},{"id":"W4407669458","doi":"10.1101/2025.02.16.638489","title":"Pooled screening identifies combinatorial CAR signaling domains for next-generation CAR-M immunotherapies","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Aegera Therapeutics (Canada)","funders":"Basic and Applied Basic Research Foundation of Guangdong Province; Natural Science Foundation of Jiangsu Province; Peking University; Zhejiang University; Government of Jiangsu Province","keywords":"Computational biology; Computer science; Biology","score_opus":0.04168567242878246,"score_gpt":0.28655238925102466,"score_spread":0.2448667168222422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407669458","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9726198,0.005386773,0.010527015,0.0005658211,0.005494378,0.004281637,0.00046892234,0.0006264008,0.000029274112],"genre_scores_gemma":[0.9861795,0.00057467754,0.0075455606,0.00031561646,0.0037147563,0.0011087472,0.000011109983,0.00025217372,0.00029787197],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9954082,0.00029923522,0.0009972329,0.0013902065,0.00096769584,0.0009374723],"domain_scores_gemma":[0.99557227,0.00032122643,0.0004510654,0.001716918,0.0016322761,0.000306231],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016792711,0.00082361675,0.0012841654,0.0007691288,0.00053320936,0.0007298475,0.00064720924,0.00094384485,0.00026986367],"category_scores_gemma":[0.00052801176,0.0009090783,0.00062473427,0.000667162,0.0002182259,0.00024438094,0.00046580218,0.0012644539,0.0000144197],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00065966655,0.00017167292,0.0008135072,0.0010296614,0.0014871357,0.000037949234,0.000075464,0.00013706162,0.99396396,0.001043724,0.00055624364,0.000023936023],"study_design_scores_gemma":[0.00493029,0.00023370607,0.0019932848,0.0013318055,0.0007732576,5.240139e-8,0.000035843546,0.0023035577,0.9755316,0.000019740528,0.011904094,0.0009427835],"about_ca_topic_score_codex":0.00026931468,"about_ca_topic_score_gemma":0.00000867548,"teacher_disagreement_score":0.018432394,"about_ca_system_score_codex":0.00072320394,"about_ca_system_score_gemma":0.0015460162,"threshold_uncertainty_score":0.999336},"labels":[],"label_agreement":null},{"id":"W4407734681","doi":"10.1158/0008-5472.can-24-1643","title":"Targeting PRC2 Enhances the Cytotoxic Capacity of Anti-CD19 CAR T Cells against Hematologic Malignancies","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Structural Genomics Consortium; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro; Conselho Nacional de Desenvolvimento Científico e Tecnológico; Fundação de Amparo à Pesquisa do Estado de São Paulo","keywords":"Cytotoxic T cell; Granzyme B; Chimeric antigen receptor; Granzyme; Cancer research; Immunology; T cell; CD8; Homing (biology); CD19; Biology; Immune system; Medicine; In vitro; Perforin","score_opus":0.08047372379180479,"score_gpt":0.3951829907347449,"score_spread":0.3147092669429401,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407734681","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927142,0.001849211,0.000039348386,0.0021611778,0.00022598256,0.0013577896,0.000028235385,0.00004860076,0.0015754236],"genre_scores_gemma":[0.98711383,0.004641647,0.00008954037,0.00022728404,0.0001717149,0.00032422575,0.0000064545857,0.000028876208,0.0073964405],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99646354,0.00052315556,0.00043305196,0.00048285112,0.0011942157,0.00090316683],"domain_scores_gemma":[0.997418,0.0007593442,0.00008540084,0.0007250325,0.0008769548,0.00013530512],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002618926,0.00019380655,0.00054080464,0.0003662771,0.00035112214,0.000055241624,0.0006191591,0.00015646496,0.0010455912],"category_scores_gemma":[0.00055245706,0.00012821193,0.00016062515,0.0014216908,0.0012057972,0.000072434836,0.00030237559,0.0010230847,0.000039449213],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019007018,0.000099179146,0.0031303414,0.00068917143,0.00012522457,0.00003174644,0.00066188676,0.00004769819,0.98875,0.0003581424,0.0056858286,0.00023075736],"study_design_scores_gemma":[0.0006156135,0.00012648347,0.0011808892,0.00047160283,0.000013957163,0.0000040117848,0.0012138614,0.00011708463,0.9852006,0.00020623962,0.010744399,0.000105256026],"about_ca_topic_score_codex":0.00073912286,"about_ca_topic_score_gemma":0.00008342167,"teacher_disagreement_score":0.005821017,"about_ca_system_score_codex":0.00038557398,"about_ca_system_score_gemma":0.0009997699,"threshold_uncertainty_score":0.9998676},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"bench_or_experimental","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"},{"model":"gpt","categories":[],"domain":null,"study_design":"bench_or_experimental","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high"}],"label_agreement":"agree"},{"id":"W4407776291","doi":"10.1016/j.reth.2025.02.001","title":"Optimizing the commercial manufacturing of tisagenlecleucel for patients in Japan: A 4-year experiential journey","year":2025,"lang":"en","type":"article","venue":"Regenerative Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Novartis (Canada)","funders":"Novartis Pharmaceuticals Corporation","keywords":"Experiential learning; Medicine; Psychology; Mathematics education","score_opus":0.04602210248634406,"score_gpt":0.3520961204929508,"score_spread":0.3060740180066067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407776291","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946323,0.00057899766,0.0011185411,0.00080394396,0.00023271349,0.0015021262,0.000016220149,0.00001452623,0.0011006402],"genre_scores_gemma":[0.99467427,0.0005423021,0.0012250072,0.0003573896,0.00019453526,0.00019815608,0.000032192005,0.000029829089,0.0027463308],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99866986,0.00016562824,0.00033712597,0.00024445023,0.000279812,0.0003031042],"domain_scores_gemma":[0.9991486,0.00022680778,0.00008405172,0.00032596212,0.0001628519,0.00005172842],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003595927,0.00016721155,0.00036020053,0.00020146619,0.0001419161,0.000028347205,0.0001886732,0.000086840715,0.00044009712],"category_scores_gemma":[0.000054280536,0.000116623196,0.00016679874,0.00022272508,0.00013815679,0.00005794297,0.00004801897,0.00023355593,0.0000014676453],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015346228,0.0023342506,0.024535954,0.00017886962,0.001044951,0.000008295815,0.032902636,0.00091133063,0.51895005,0.002358643,0.006160677,0.3952681],"study_design_scores_gemma":[0.01084692,0.0009031312,0.021506593,0.00013295622,0.000018872903,9.65513e-7,0.0011375064,0.000708183,0.95397556,0.00010483133,0.010517451,0.00014703626],"about_ca_topic_score_codex":0.000076338336,"about_ca_topic_score_gemma":0.00007035691,"teacher_disagreement_score":0.4350255,"about_ca_system_score_codex":0.00013415614,"about_ca_system_score_gemma":0.00012860756,"threshold_uncertainty_score":0.48187548},"labels":[],"label_agreement":null},{"id":"W4407863613","doi":"10.1158/2326-6074.io2025-a015","title":"Abstract A015: GPNMB CAR T cells target both Glioblastoma and its immunosuppressive niche to relieve immune evasion","year":2025,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of Toronto; McMaster University","funders":"","keywords":"Evasion (ethics); Glioblastoma; Niche; Immune system; Immunotherapy; Immunology; Cancer immunotherapy; Biology; Cancer research; Medicine; Ecology","score_opus":0.03854279659123545,"score_gpt":0.39178252174718603,"score_spread":0.3532397251559506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407863613","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91989595,0.06258427,0.000010071295,0.007686005,0.00075057853,0.0022959732,0.0000636836,0.00010709639,0.006606374],"genre_scores_gemma":[0.9313163,0.012725157,0.000112735375,0.0004110394,0.00022868771,0.0008139112,0.000026881438,0.00010020979,0.054265086],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9950575,0.00054109574,0.00066658517,0.001087002,0.0009788283,0.0016689472],"domain_scores_gemma":[0.9960871,0.00085387245,0.00009554876,0.0013257508,0.0013033992,0.00033434865],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020202077,0.0004104825,0.0008689252,0.0013337486,0.0005357926,0.00010409084,0.000809947,0.00058769307,0.005206645],"category_scores_gemma":[0.00071201904,0.00037710796,0.0001860335,0.0017334728,0.00071137754,0.00017010028,0.0011547654,0.0027117128,0.00044414724],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0074057127,0.00020976781,0.0011697528,0.00025974287,0.00064746407,0.0001973271,0.00078458287,0.000017451192,0.963058,0.00015614112,0.012547648,0.013546388],"study_design_scores_gemma":[0.0037387104,0.001494872,0.0399599,0.0007203622,0.000045818575,0.00005205015,0.00077911094,0.00008480994,0.8583045,0.000215301,0.0943014,0.0003031493],"about_ca_topic_score_codex":0.00096105476,"about_ca_topic_score_gemma":0.000060640115,"teacher_disagreement_score":0.10475351,"about_ca_system_score_codex":0.0009853891,"about_ca_system_score_gemma":0.0016129848,"threshold_uncertainty_score":0.9998681},"labels":[],"label_agreement":null},{"id":"W4407866624","doi":"10.1158/2326-6074.io2025-a016","title":"Abstract A016: Targeting axonal guidance dependencies in glioblastoma with ROBO1 CAR T cells","year":2025,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; University of Toronto; McMaster University","funders":"","keywords":"Glioblastoma; Cancer research; Medicine; Immunotherapy; Computational biology; Cancer; Biology; Internal medicine","score_opus":0.041151855758443136,"score_gpt":0.38099791652814474,"score_spread":0.3398460607697016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407866624","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96651816,0.016096069,0.00002960735,0.0028632167,0.0002607896,0.0009591643,0.000013399503,0.000067043424,0.013192524],"genre_scores_gemma":[0.9712558,0.0020411415,0.00019887785,0.00016418636,0.00016139036,0.00051442726,0.0000073664937,0.00004922601,0.025607618],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9961923,0.00033739905,0.00045103606,0.00071152044,0.00090697984,0.0014007586],"domain_scores_gemma":[0.9976335,0.0006403597,0.000060406237,0.00069475145,0.0008428569,0.00012809942],"candidate_categories":["research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020754535,0.0002503145,0.00053655263,0.001086793,0.000252056,0.000057049238,0.00057963317,0.00031500857,0.0041359826],"category_scores_gemma":[0.00031168736,0.00021310692,0.00009087665,0.0018479314,0.0011020391,0.0001288306,0.000325551,0.002444342,0.00013458615],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051570437,0.00017983824,0.038626757,0.00024588467,0.00029977073,0.0005112561,0.0003870439,0.00012155627,0.93423796,0.00016414543,0.005085874,0.014982902],"study_design_scores_gemma":[0.0052371286,0.0010416592,0.12967414,0.0011196602,0.00002285257,0.000059142756,0.0020052996,0.00014361345,0.81211644,0.00020330849,0.048046768,0.00032996447],"about_ca_topic_score_codex":0.0022659453,"about_ca_topic_score_gemma":0.0019234141,"teacher_disagreement_score":0.12212146,"about_ca_system_score_codex":0.0011604725,"about_ca_system_score_gemma":0.0023165508,"threshold_uncertainty_score":0.99985707},"labels":[],"label_agreement":null},{"id":"W4407873167","doi":"10.1186/s12935-025-03697-y","title":"Mechanisms of antigen-dependent resistance to chimeric antigen receptor (CAR)-T cell therapies","year":2025,"lang":"en","type":"review","venue":"Cancer Cell International","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Chimeric antigen receptor; Antigen; Medicine; Immunology; Receptor; Immunotherapy; Cancer research; Virology; Immune system; Internal medicine","score_opus":0.04052181563804908,"score_gpt":0.3758730317671781,"score_spread":0.33535121612912905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407873167","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007531663,0.95010275,0.0006638374,0.00023676279,0.002174705,0.0017016152,0.0006516811,0.00005052242,0.04434284],"genre_scores_gemma":[0.00011012929,0.806838,0.0012326739,0.00020548647,0.00040588883,0.00036472696,0.00025812822,0.00008804235,0.19049695],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99655944,0.00014559415,0.00088010484,0.0008138969,0.0011664004,0.00043455188],"domain_scores_gemma":[0.99790156,0.0001927819,0.00044995348,0.0007286885,0.0005212213,0.0002057993],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00036639412,0.00052182603,0.0016039097,0.00050487317,0.00006240219,0.000048719394,0.0009462341,0.0002992582,0.023652589],"category_scores_gemma":[0.000042340936,0.0004590927,0.0006981352,0.00054117496,0.00008225596,0.00006940466,0.00025540087,0.0005065016,0.0001544475],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005473412,0.0005491802,0.000051411625,0.025045227,0.0018782354,0.000045380584,0.00048826454,0.0000052529085,0.06157199,0.00060655514,0.027145866,0.8820653],"study_design_scores_gemma":[0.0005927877,0.00010747245,0.000015736527,0.009225758,0.00018940776,0.000004674121,0.00007912789,0.0000020644384,0.020075068,0.0000615163,0.96930516,0.00034124858],"about_ca_topic_score_codex":0.00027183155,"about_ca_topic_score_gemma":0.00013085059,"teacher_disagreement_score":0.9421593,"about_ca_system_score_codex":0.0010470741,"about_ca_system_score_gemma":0.0015083769,"threshold_uncertainty_score":0.9997861},"labels":[],"label_agreement":null},{"id":"W4407920322","doi":"10.1038/s41598-025-87944-2","title":"Tuning TCR complex recruitment to the T cell antigen coupler (TAC) enhances TAC-T cell function","year":2025,"lang":"en","type":"article","venue":"Scientific Reports","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"TRIUMF; University of Toronto","funders":"Canadian Institutes of Health Research; Mitacs","keywords":"T-cell receptor; T cell; Function (biology); Cell biology; Antigen; Cell; Chemistry; Immunology; Biology; Biochemistry; Immune system","score_opus":0.0834483860972458,"score_gpt":0.35297938832979625,"score_spread":0.26953100223255044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407920322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91952306,0.00081396685,0.0015351055,0.0022759587,0.0093809785,0.0028335112,0.0000025724464,0.00016501879,0.06346981],"genre_scores_gemma":[0.76286376,0.00003705539,0.0002919105,0.00048466786,0.0001658251,0.00014349846,0.000055809232,0.000025575564,0.2359319],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9967606,0.000096870834,0.0005694901,0.00093813735,0.0010881651,0.00054671377],"domain_scores_gemma":[0.997643,0.000085974214,0.00018088936,0.0015010565,0.00038003238,0.00020904846],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0028163407,0.00019945386,0.00030075127,0.0003548271,0.00064908183,0.00033461882,0.00021541896,0.00007740155,0.0041487846],"category_scores_gemma":[0.00007675334,0.00014125196,0.00015702302,0.0013676786,0.00022148811,0.00008821265,0.00019148678,0.00026882786,0.0003016138],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000963375,0.0001542994,0.0042609638,0.00007226658,0.00003504695,0.00014017633,0.0004733049,0.00006845999,0.8446936,0.000011611575,0.13968384,0.010310088],"study_design_scores_gemma":[0.00024526866,0.000111863126,0.0049766116,0.00006655126,0.000038697304,0.000031178588,0.00045761283,0.0004000505,0.2811939,0.00017442837,0.71219254,0.00011129561],"about_ca_topic_score_codex":0.00012976174,"about_ca_topic_score_gemma":0.00009820092,"teacher_disagreement_score":0.5725087,"about_ca_system_score_codex":0.00020388674,"about_ca_system_score_gemma":0.0004350278,"threshold_uncertainty_score":0.99676156},"labels":[],"label_agreement":null},{"id":"W4407954426","doi":"10.3390/curroncol32030135","title":"Influence of Vitamin D and Its Analogues in Type-B Lymphomas","year":2025,"lang":"en","type":"review","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; In vivo; Lymphoma; Internal medicine; Cancer research; Cancer; Oncology; Metastasis; Clinical trial; Overall survival; In vitro; Disease; Biology","score_opus":0.16598168683163025,"score_gpt":0.4942575303144392,"score_spread":0.3282758434828089,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407954426","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0065623964,0.9903091,2.871935e-7,0.00003167954,0.00029599192,0.0009628431,0.000023588946,0.000012635978,0.0018014427],"genre_scores_gemma":[0.0002508573,0.9982171,0.000010797559,0.000015368492,0.00008721022,0.000079509104,0.00009403207,0.000017437058,0.0012276566],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99830014,0.00030509263,0.0005746601,0.00036371683,0.00018146561,0.00027494927],"domain_scores_gemma":[0.9986066,0.0006611931,0.0001759688,0.00028083866,0.0001770845,0.000098265664],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041265786,0.00023247735,0.00196706,0.0006885025,0.000013653924,0.0000037709372,0.00017976602,0.0003574516,0.00019795861],"category_scores_gemma":[0.0005635397,0.0001900771,0.00014151078,0.00078622805,0.00013833841,0.000024509316,0.00018829167,0.0005222804,0.000027799233],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000055528824,0.00022285331,0.00038670178,0.038606167,0.00006795466,0.0000450375,0.00006101659,3.3368806e-7,0.000022347558,0.00012458526,0.00031291362,0.9600946],"study_design_scores_gemma":[0.0008239089,0.00042238098,0.00046697547,0.01755178,0.00028490566,0.00006711507,0.000008885221,0.0000050166796,0.000008175606,0.00001647309,0.9802287,0.000115635674],"about_ca_topic_score_codex":0.000014054387,"about_ca_topic_score_gemma":0.000030150708,"teacher_disagreement_score":0.97991586,"about_ca_system_score_codex":0.00044949286,"about_ca_system_score_gemma":0.0019507662,"threshold_uncertainty_score":0.7751119},"labels":[],"label_agreement":null},{"id":"W4407976290","doi":"10.1016/j.jtct.2025.01.355","title":"Cost and Health Service Utilization Differences between Lymphoma Patients Treated with Commercial CAR-T and Made -in-Alberta Therapies","year":2025,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services; Alberta Cancer Foundation; Alberta Health; University of Alberta; University of Calgary","funders":"","keywords":"Lymphoma; Medicine; Service (business); Business; Intensive care medicine; Marketing; Internal medicine","score_opus":0.062273573678095516,"score_gpt":0.32116510208155385,"score_spread":0.25889152840345836,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407976290","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99502933,0.0013390263,0.00028780164,0.0021188848,0.000013985383,0.00086276064,0.000021591602,0.000020507008,0.0003061352],"genre_scores_gemma":[0.98463947,0.013702285,0.0000283954,0.0008329455,0.000015200243,0.000028259352,0.00035042962,0.000015288775,0.00038771235],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99906415,0.00012332412,0.00019973745,0.00025043968,0.00017001976,0.00019232309],"domain_scores_gemma":[0.99960786,0.00009855763,0.000043971922,0.00009752797,0.000056186298,0.000095883435],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00013265078,0.00016379764,0.00029977784,0.00016247146,0.00012273378,0.000040656414,0.00003871265,0.00007489324,0.0000476469],"category_scores_gemma":[0.0000010016371,0.00012345327,0.000015097505,0.00028549912,0.000080922786,0.00006687108,0.000004374869,0.0000810614,5.147347e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012108347,0.0001008758,0.82428914,0.00020179087,0.000077899924,0.000003198945,0.004912653,1.7387573e-7,0.0018337474,0.00007336506,0.0000029503744,0.16729338],"study_design_scores_gemma":[0.0098307235,0.00047054663,0.98428935,0.00018315967,0.00003840631,0.000004438312,0.00028718243,0.00009508917,0.004237857,0.000034386052,0.0004176658,0.000111209185],"about_ca_topic_score_codex":0.0030655498,"about_ca_topic_score_gemma":0.0017671495,"teacher_disagreement_score":0.16718218,"about_ca_system_score_codex":0.000033388194,"about_ca_system_score_gemma":0.0000599704,"threshold_uncertainty_score":0.5034278},"labels":[],"label_agreement":null},{"id":"W4407976601","doi":"10.1016/j.jtct.2025.01.159","title":"Fludarabine during Lymphodepletion Chemotherapy Prior to CAR-T Cell Therapy in Adult Patients with Non-Hodgkin Lymphoma: Evaluation of a Pharmacokinetic Model and Exploration of Optimal Exposure","year":2025,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Fludarabine; Chemotherapy; Medicine; Pharmacokinetics; Lymphoma; Cyclophosphamide; Oncology; Pharmacology; Internal medicine","score_opus":0.019301962104278456,"score_gpt":0.28665886335044105,"score_spread":0.26735690124616257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407976601","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910521,0.0005954611,0.0057704747,0.0001663119,0.00002503667,0.0021917077,0.000018394421,0.000016758715,0.00016377236],"genre_scores_gemma":[0.9921869,0.00641454,0.0008151489,0.00014015884,0.000014118311,0.00015510841,0.00010894566,0.000032552438,0.00013254283],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982741,0.00013853404,0.00043248263,0.00034912297,0.0006113312,0.0001944375],"domain_scores_gemma":[0.99910057,0.000034438737,0.00011410855,0.00019548282,0.00047921727,0.00007616919],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004303681,0.00021960911,0.0003650601,0.000412678,0.000050417915,0.000014888007,0.000066231485,0.00009809461,0.000069035836],"category_scores_gemma":[0.0000037807251,0.00018808026,0.000050076527,0.00042534468,0.00006716015,0.00017269762,0.0000052233604,0.000076637785,3.8165007e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016969359,0.00066329807,0.014074264,0.0003673768,0.00008631292,0.0000023855084,0.008332841,0.0053586317,0.858712,0.000010472451,0.0000016075854,0.09542144],"study_design_scores_gemma":[0.060529437,0.0011943378,0.122202694,0.0002647761,0.00008999244,0.0000024127069,0.00028946076,0.029428232,0.78578466,0.000028075745,0.000009370197,0.00017653448],"about_ca_topic_score_codex":0.00007243492,"about_ca_topic_score_gemma":0.000017380455,"teacher_disagreement_score":0.10812843,"about_ca_system_score_codex":0.0000816577,"about_ca_system_score_gemma":0.00015809879,"threshold_uncertainty_score":0.766969},"labels":[],"label_agreement":null},{"id":"W4407976889","doi":"10.1016/j.jtct.2025.01.323","title":"Axicabtagene Ciloleucel (Axi-Cel) Versus Standard of Care (SOC) in Patients with Primary Refractory or Early Relapsed Large B-Cell Lymphoma (LBCL)","year":2025,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Refractory (planetary science); B-cell lymphoma; Standard of care; Lymphoma; Oncology; Internal medicine; Materials science","score_opus":0.011799772427328882,"score_gpt":0.2592529896449002,"score_spread":0.2474532172175713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407976889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914937,0.002292891,0.00034644597,0.000056251258,0.00010087786,0.0008828871,0.00011370137,0.000036953534,0.0046763187],"genre_scores_gemma":[0.9917122,0.0053879963,0.00019002247,0.00015872977,0.000018509196,0.000028282358,0.0004500327,0.000037418766,0.002016783],"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983509,0.00012972835,0.00034810416,0.00034347377,0.0005284092,0.00029939297],"domain_scores_gemma":[0.9992215,0.00010843099,0.00008396459,0.0002990119,0.00018511973,0.000101948775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020521798,0.00022163773,0.00043918187,0.000274313,0.00007356693,0.00001911515,0.00010265299,0.00015417386,0.00033455106],"category_scores_gemma":[0.000003678878,0.00017124465,0.000078903984,0.0003756984,0.000092062284,0.00009146936,0.000008422372,0.00018825757,0.0000032636947],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.56938696,0.0036962803,0.10722794,0.0027347354,0.00047835943,0.0002742551,0.01440957,0.000004650722,0.18628477,0.000158422,0.0000737044,0.11527037],"study_design_scores_gemma":[0.31147495,0.017126234,0.29201272,0.00077506556,0.00025560835,0.0000033956483,0.0015737008,0.00001620998,0.36216924,0.000022122926,0.014018733,0.0005520235],"about_ca_topic_score_codex":0.000056020872,"about_ca_topic_score_gemma":0.000081422506,"teacher_disagreement_score":0.257912,"about_ca_system_score_codex":0.00016526249,"about_ca_system_score_gemma":0.00031481413,"threshold_uncertainty_score":0.6983154},"labels":[],"label_agreement":null},{"id":"W4408006873","doi":"10.1101/2025.02.26.24319604","title":"Development and first-in-human CAR T therapy against the pathognomonic MiT-fusion driven protein GPNMB","year":2025,"lang":"en","type":"preprint","venue":"medRxiv","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; McGill University; University of British Columbia; Quest University Canada; University of Calgary","funders":"","keywords":"Pathognomonic; Fusion protein; Fusion; Medicine; Recombinant DNA; Chemistry; Philosophy; Biochemistry; Internal medicine; Disease","score_opus":0.03674016286590534,"score_gpt":0.31214767192650106,"score_spread":0.27540750906059575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408006873","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9861202,0.002905549,0.000015064622,0.0024756687,0.000177353,0.0039953496,0.000010749599,0.00007758474,0.0042224494],"genre_scores_gemma":[0.9786619,0.0031467264,0.000842089,0.0004239884,0.00023972488,0.0013662464,0.00010051176,0.00007352654,0.015145272],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9971231,0.0002505495,0.0005694353,0.0008344207,0.0006911358,0.0005313244],"domain_scores_gemma":[0.99832964,0.00012104315,0.00014295745,0.0011101398,0.000134494,0.0001617009],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012044057,0.00044244126,0.00065599504,0.0003469757,0.00026123322,0.0000767374,0.00052627246,0.0003811028,0.00035270577],"category_scores_gemma":[0.00008303657,0.00030542703,0.00016574231,0.0002837928,0.00017557797,0.000025565056,0.00092751544,0.0015367949,0.00001453925],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00086964754,0.0007999329,0.23880172,0.0021125886,0.0007595852,0.00077704736,0.016670203,0.00010480148,0.45343018,0.00017854047,0.00043493125,0.28506082],"study_design_scores_gemma":[0.007747668,0.0004267679,0.3818927,0.006461646,0.000096015756,0.000025411899,0.00060301076,0.0010469593,0.122123875,0.000542764,0.47778153,0.0012516155],"about_ca_topic_score_codex":0.00013794574,"about_ca_topic_score_gemma":0.0006254066,"teacher_disagreement_score":0.47734663,"about_ca_system_score_codex":0.00038488235,"about_ca_system_score_gemma":0.00070286414,"threshold_uncertainty_score":0.9999398},"labels":[],"label_agreement":null},{"id":"W4408032428","doi":"10.3390/curroncol32030142","title":"Optimal Use of Bispecific Antibodies for the Treatment of Diffuse Large B-Cell Lymphoma in Canada","year":2025,"lang":"en","type":"review","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"University of British Columbia; Fluidigm (Canada); University of Ottawa; University of Calgary; Université de Montréal","funders":"AbbVie Canada","keywords":"Bispecific antibody; Medicine; Lymphoma; Antibody; Chimeric antigen receptor; Diffuse large B-cell lymphoma; Oncology; Refractory (planetary science); Cancer research; Internal medicine; Immunotherapy; Immunology; Cancer; Monoclonal antibody; Biology","score_opus":0.2203581579266412,"score_gpt":0.45881313153067205,"score_spread":0.23845497360403084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408032428","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0033064813,0.9913036,0.000016071492,0.000053633295,0.0010607521,0.0033262747,0.0007542217,0.0000053681483,0.0001735453],"genre_scores_gemma":[0.000099304445,0.99649954,0.00007560866,0.0000071429963,0.000131128,0.0004852248,0.00025783834,0.000031444262,0.0024127688],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978645,0.00023700293,0.0008380196,0.0003581488,0.00025536102,0.00044695503],"domain_scores_gemma":[0.9954469,0.0033490644,0.00035084004,0.000607198,0.00016573678,0.00008021697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021201036,0.00033557756,0.0026099184,0.00034250366,0.000034886347,0.0000052376877,0.00024242848,0.00018834585,0.00017485584],"category_scores_gemma":[0.000112497655,0.0002025357,0.0005552952,0.00037344493,0.00013635252,0.000014617118,0.00007749555,0.00017467853,0.0000015823123],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00027390724,0.006581884,0.00044567906,0.019050062,0.00029322694,0.000029061574,0.00012928697,9.033264e-7,0.000004742256,0.000029810126,0.0031820459,0.9699794],"study_design_scores_gemma":[0.007593973,0.0010183695,0.000090775655,0.0033457903,0.00087566004,0.000010347127,0.00009724291,0.000056821355,0.000035862435,8.5956066e-7,0.9867559,0.0001183908],"about_ca_topic_score_codex":0.05325512,"about_ca_topic_score_gemma":0.2292544,"teacher_disagreement_score":0.98357385,"about_ca_system_score_codex":0.0031178112,"about_ca_system_score_gemma":0.0098478,"threshold_uncertainty_score":0.99576545},"labels":[],"label_agreement":null},{"id":"W4408037706","doi":"10.1101/2025.02.23.639405","title":"Cell surface proteomics of patient-derived malignant rhabdoid tumor organoids identifies ROBO1 as potential CAR T cell target for pediatric solid tumors","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"IONICS Mass Spectrometry (Canada)","funders":"","keywords":"Organoid; Proteomics; Cell; Cancer research; Biology; Computational biology; Cell biology; Genetics; Gene","score_opus":0.009270386752119325,"score_gpt":0.23905950557126165,"score_spread":0.22978911881914232,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408037706","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98536813,0.0025771162,0.0018651847,0.00013098636,0.0016831402,0.0068481066,0.0011883003,0.00030453881,0.000034490575],"genre_scores_gemma":[0.9793319,0.0006841565,0.017770927,0.000118090866,0.0007185796,0.0005845712,0.000008361511,0.00033182456,0.00045156552],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99370295,0.00028614615,0.0016452135,0.0018010887,0.001228172,0.0013364217],"domain_scores_gemma":[0.99355966,0.00015782494,0.0012064993,0.0021575773,0.002321541,0.00059690874],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009912642,0.0010860886,0.0019104289,0.0008050048,0.0002531649,0.00020245112,0.00097549346,0.00077467255,0.00044966038],"category_scores_gemma":[0.00038655577,0.0011527819,0.00073147455,0.0010478218,0.00024954963,0.00014616127,0.0011505226,0.0013944029,0.00005341667],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008578795,0.0007414305,0.004562,0.0075482843,0.00024068185,0.00022287568,0.000068302004,0.0010172398,0.98390347,0.0000127747735,0.00082424376,7.9663954e-7],"study_design_scores_gemma":[0.00262188,0.0007151573,0.0018138146,0.00048526344,0.00062121585,1.7514688e-7,0.00004728368,0.00049047446,0.9917198,0.0000059606664,0.000530218,0.000948748],"about_ca_topic_score_codex":0.00018866673,"about_ca_topic_score_gemma":0.0000018018874,"teacher_disagreement_score":0.015905742,"about_ca_system_score_codex":0.0006216932,"about_ca_system_score_gemma":0.0049114716,"threshold_uncertainty_score":0.9990922},"labels":[],"label_agreement":null},{"id":"W4408098504","doi":"10.1016/j.hlife.2025.02.003","title":"Harnessing allogeneic CAR-T cell therapy for autoimmune conditions","year":2025,"lang":"en","type":"article","venue":"hLife","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Cell therapy; CAR T-cell therapy; Medicine; Immunology; T cell; Cell; Chimeric antigen receptor; Biology; Immune system; Genetics","score_opus":0.0413054508756802,"score_gpt":0.3621299959722013,"score_spread":0.3208245450965211,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408098504","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92852825,0.00625931,0.0021430536,0.0072852327,0.0006645751,0.0021660395,0.00005548184,0.00024139813,0.05265668],"genre_scores_gemma":[0.86282134,0.00044412786,0.00066952076,0.0027980772,0.00019686378,0.00027137206,0.00013868454,0.000039148978,0.13262087],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989795,0.00004413454,0.00021402811,0.00024867503,0.00019188634,0.00032174613],"domain_scores_gemma":[0.9991298,0.00018949535,0.00003744291,0.00040470995,0.00015648533,0.0000820978],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00024998462,0.00012914279,0.00026613983,0.00016841873,0.00018498674,0.000038321694,0.00012185395,0.000099530145,0.0022904377],"category_scores_gemma":[0.000055852044,0.00011459776,0.00017178441,0.00027189692,0.000093138675,0.000038922597,0.00003080078,0.0001692285,0.000047507543],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00036048022,0.00024803425,0.0034092008,0.00011409175,0.00013046643,0.000010320928,0.00018410572,0.000009231928,0.9549429,0.00049312453,0.019834971,0.020263107],"study_design_scores_gemma":[0.0064098183,0.00030484618,0.037281156,0.000120636294,0.00006764778,0.000011022736,0.00023174175,0.0005113629,0.25597987,0.0006133644,0.6982827,0.00018578138],"about_ca_topic_score_codex":0.0000390956,"about_ca_topic_score_gemma":0.000004463547,"teacher_disagreement_score":0.698963,"about_ca_system_score_codex":0.00009796425,"about_ca_system_score_gemma":0.00037519587,"threshold_uncertainty_score":0.9986216},"labels":[],"label_agreement":null},{"id":"W4408123725","doi":"10.1186/s12967-025-06253-4","title":"Analysis of the measurements used as potency tests for the 31 US FDA-approved cell therapy products","year":2025,"lang":"en","type":"review","venue":"Journal of Translational Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Potency; Medicine; Pharmacology; Drug approval; Medical physics; Drug; Chemistry","score_opus":0.19797502453293553,"score_gpt":0.4324895607580021,"score_spread":0.23451453622506657,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408123725","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00016182403,0.9822528,0.00022866669,0.0119500095,0.00066022814,0.0034275013,0.000055520137,0.0000062348286,0.0012572107],"genre_scores_gemma":[0.000817807,0.9910158,0.0003055842,0.00035681066,0.0011238711,0.000070878865,0.00007547,0.000050029543,0.0061837784],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9942906,0.00036709168,0.0019282898,0.00033478657,0.002771623,0.00030763028],"domain_scores_gemma":[0.99278367,0.0027663638,0.0014980211,0.00076540245,0.0020449394,0.00014160744],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036028211,0.00043141175,0.002841146,0.0010769082,0.00014029397,0.000014718549,0.0008201341,0.0002366836,0.0006267844],"category_scores_gemma":[0.001322269,0.0001861223,0.0019589534,0.0029804953,0.0002812381,0.00006163325,0.00002079131,0.000933076,0.0000012549408],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012303875,0.0006650996,0.000834856,0.01253398,0.019720702,0.000011970615,0.00056782796,0.000097651966,0.0047989306,0.000028958519,0.0038631612,0.95564646],"study_design_scores_gemma":[0.0052805506,0.0010341407,0.002281131,0.012100691,0.032053046,0.00008187129,0.0000375872,0.000060435883,0.0003246326,0.00011637266,0.94643986,0.00018970453],"about_ca_topic_score_codex":0.00004207432,"about_ca_topic_score_gemma":0.000019204359,"teacher_disagreement_score":0.9554568,"about_ca_system_score_codex":0.00016123996,"about_ca_system_score_gemma":0.003535819,"threshold_uncertainty_score":0.75898474},"labels":[],"label_agreement":null},{"id":"W4408157999","doi":"10.1186/s40164-025-00610-1","title":"Matching-adjusted indirect comparison of efficacy and safety of lisocabtagene maraleucel and mosunetuzumab for the treatment of third-line or later relapsed or refractory follicular lymphoma","year":2025,"lang":"en","type":"article","venue":"Experimental Hematology and Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Follicular lymphoma; Refractory (planetary science); Medicine; Oncology; Follicular phase; Internal medicine; Lymphoma; Second line; First line; Biology","score_opus":0.051390398366162875,"score_gpt":0.39864506947045025,"score_spread":0.34725467110428737,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408157999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9724488,0.025385559,0.00004516437,0.00042353806,0.000113054484,0.0012847566,0.000017246057,0.000012579776,0.00026928552],"genre_scores_gemma":[0.99492127,0.0022982834,0.0008154823,0.00008536074,0.00001890552,0.00010450908,0.000020473539,0.00001536743,0.0017203577],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99870074,0.00016387632,0.0005561208,0.00027386777,0.00009759803,0.00020782487],"domain_scores_gemma":[0.99794316,0.001508969,0.00019545274,0.00023549407,0.00005427351,0.00006267532],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020520826,0.00018280777,0.0011397226,0.00013284905,0.000104683786,0.0000027138553,0.00007054265,0.00028110994,0.00017862662],"category_scores_gemma":[0.000034679124,0.00010601016,0.000077012905,0.00012487828,0.0006554743,0.000023456827,0.000072871364,0.000082978164,2.9699692e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.22929852,0.011776406,0.040553693,0.0015560932,0.0035676477,0.00017702613,0.028798351,0.000007913149,0.5630775,0.0028107988,0.00074502226,0.11763101],"study_design_scores_gemma":[0.033061285,0.020741874,0.017919594,0.00016236509,0.0003754158,0.00035207992,0.005311446,0.0004244722,0.91102785,0.000067619236,0.010425144,0.00013087844],"about_ca_topic_score_codex":0.00010379922,"about_ca_topic_score_gemma":0.00011245702,"teacher_disagreement_score":0.3479503,"about_ca_system_score_codex":0.00013027152,"about_ca_system_score_gemma":0.0001840478,"threshold_uncertainty_score":0.43229687},"labels":[],"label_agreement":null},{"id":"W4408174527","doi":"10.1016/j.isci.2025.112142","title":"DAP12-associated synthetic antigen receptors enable multi-targeting of T cells with independent chimeric receptors in a small genetic payload","year":2025,"lang":"en","type":"article","venue":"iScience","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Ministry of Colleges and Universities; Mitacs; Canada Research Chairs","keywords":"Chimeric antigen receptor; Receptor; Payload (computing); Computational biology; Antigen; Biology; Chemistry; Cell biology; Immunology; Computer science; Immunotherapy; Genetics; Immune system","score_opus":0.020551267834423972,"score_gpt":0.28104959284969044,"score_spread":0.2604983250152665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408174527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948874,0.0009311216,0.00036464998,0.00016544876,0.00030019117,0.0007557268,0.0000027920914,0.000042162388,0.0025504718],"genre_scores_gemma":[0.9882758,0.0003775735,0.0034877046,0.00008454803,0.000016004205,0.000033851793,0.000003726288,0.000023293682,0.0076974495],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976128,0.00017667859,0.0004393607,0.0005782616,0.0005514601,0.00064148824],"domain_scores_gemma":[0.9989731,0.0001424531,0.00015717286,0.0004110036,0.00017451771,0.00014176274],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001070193,0.00020086949,0.00042767896,0.00047554245,0.000101679674,0.000031966,0.0004023056,0.00011120422,0.0007094009],"category_scores_gemma":[0.0003590267,0.00016136258,0.00007491028,0.0022595944,0.00036502263,0.00006659359,0.00014178905,0.00036427643,0.000023371153],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016416729,0.00048758707,0.17856024,0.00008830466,0.000046440506,0.00003341121,0.0014245416,0.0005379643,0.79018027,0.000005046225,0.00011785868,0.028354146],"study_design_scores_gemma":[0.0037763417,0.00086372637,0.10127776,0.0011657171,0.000056050627,0.000012585429,0.00221213,0.006538166,0.88012093,0.000044516313,0.0034888356,0.00044323754],"about_ca_topic_score_codex":0.0012043207,"about_ca_topic_score_gemma":0.0004066427,"teacher_disagreement_score":0.08994064,"about_ca_system_score_codex":0.00028545153,"about_ca_system_score_gemma":0.0005167538,"threshold_uncertainty_score":0.77674425},"labels":[],"label_agreement":null},{"id":"W4408188213","doi":"10.1016/j.xcrm.2025.101994","title":"Phase 1 study of IMCnyeso, a T cell receptor bispecific ImmTAC targeting NY-ESO-1-expressing malignancies","year":2025,"lang":"en","type":"article","venue":"Cell Reports Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; HCA Healthcare","keywords":"Cancer research; Medicine","score_opus":0.030108361792868146,"score_gpt":0.3431106570374404,"score_spread":0.3130022952445723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408188213","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9256721,0.007925066,0.00022481623,0.0005836349,0.0012677208,0.0019840766,0.0000035487337,0.0001435017,0.062195495],"genre_scores_gemma":[0.9231616,0.0004302289,0.0003974845,0.00018286327,0.0005661873,0.0000811476,0.0000748238,0.00008016099,0.07502546],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9948429,0.00020377121,0.0018812517,0.0009647126,0.0013794783,0.0007278695],"domain_scores_gemma":[0.99642015,0.00036683722,0.0007463542,0.0014544921,0.00066040974,0.0003517392],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0022059206,0.00045720945,0.0013216416,0.0007965152,0.00021502873,0.000028008923,0.00024408338,0.00018700672,0.0046221535],"category_scores_gemma":[0.0007541488,0.00036124862,0.0001943336,0.0012746897,0.00041336092,0.00010212066,0.00020133385,0.0006749005,0.000014920007],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007320445,0.0042529223,0.00833261,0.00077648106,0.00011824179,0.0018472756,0.003966768,0.000007076332,0.93422073,0.0000047413364,0.038654044,0.0070870803],"study_design_scores_gemma":[0.015546133,0.0050820787,0.00075797207,0.0015008331,0.0004516822,0.00012327953,0.020962086,0.000090906695,0.8019379,0.000052960106,0.15312085,0.000373356],"about_ca_topic_score_codex":0.00032055803,"about_ca_topic_score_gemma":0.0000052999403,"teacher_disagreement_score":0.13228284,"about_ca_system_score_codex":0.00023092276,"about_ca_system_score_gemma":0.00047519928,"threshold_uncertainty_score":0.99988395},"labels":[],"label_agreement":null},{"id":"W4408238872","doi":"10.3389/fimmu.2025.1533044","title":"Entinostat, a histone deacetylase inhibitor, enhances CAR-NK cell anti-tumor activity by sustaining CAR expression","year":2025,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; National Research Council Canada; University of Ottawa","funders":"National Cancer Institute; National Research Council Canada; National Research Foundation of Korea; Ottawa Hospital Research Institute; Cancer Research Society; Canadian Institutes of Health Research; National Research Foundation","keywords":"Chimeric antigen receptor; Histone deacetylase; Cancer research; Histone deacetylase inhibitor; Immunotherapy; Cancer immunotherapy; Cytotoxic T cell; Immunology; Biology; Immune system; Histone; In vitro","score_opus":0.007671204556374219,"score_gpt":0.2872052454678329,"score_spread":0.27953404091145867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408238872","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97268826,0.016281959,0.003271486,0.0005653289,0.0021293396,0.0007393779,0.000015463735,0.00009409011,0.004214714],"genre_scores_gemma":[0.9722284,0.0017045444,0.0012657883,0.00017674241,0.00007957954,0.00011185363,0.000043997956,0.00004471687,0.024344357],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99741435,0.00037523522,0.0004130867,0.0006533868,0.00029241652,0.00085150683],"domain_scores_gemma":[0.9988468,0.00015170434,0.0001473177,0.00064019003,0.0001155238,0.00009841403],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000452832,0.00030619718,0.0007900637,0.0006805246,0.0001609048,0.00002674218,0.00030229235,0.00029423414,0.00030024428],"category_scores_gemma":[0.00021258982,0.00030918652,0.00014622558,0.0006092361,0.0004675859,0.0001498932,0.00026353306,0.0009671718,0.000012696141],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016202299,0.00039205537,0.009773935,0.00017392171,0.00010111761,0.00017382528,0.00078329776,0.0000026057494,0.9244666,0.000008260461,0.048860162,0.013643967],"study_design_scores_gemma":[0.0039094654,0.00028528573,0.0025309017,0.00020347428,0.000038836737,0.000015339645,0.0025341827,0.000092098904,0.92005366,0.000046525412,0.07006782,0.00022241038],"about_ca_topic_score_codex":0.0005793732,"about_ca_topic_score_gemma":0.000021693635,"teacher_disagreement_score":0.02120766,"about_ca_system_score_codex":0.0008821135,"about_ca_system_score_gemma":0.0004953094,"threshold_uncertainty_score":0.99993604},"labels":[],"label_agreement":null},{"id":"W4408246183","doi":"10.1007/s10637-025-01518-7","title":"First-in-human, phase 1 dose escalation study of SL-279252, a hexameric PD1-Fc-OX40L fusion protein, in patients with advanced solid tumors and lymphoma","year":2025,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Neutropenia; Medicine; Cmax; Pharmacodynamics; Pharmacokinetics; Adverse effect; Maculopapular rash; Rash; Internal medicine; Gastroenterology; Area under the curve; Lymphoma; Pharmacology; Toxicity","score_opus":0.012745993595768064,"score_gpt":0.30562469083016436,"score_spread":0.2928786972343963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408246183","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960232,0.00005860557,0.000011678168,0.0006373078,0.000025018706,0.0027754349,0.000006973285,0.000024052842,0.00043776786],"genre_scores_gemma":[0.9976623,0.000004787844,0.0005776581,0.00017039094,0.000030148041,0.0001581717,0.00009711495,0.000022739767,0.0012767098],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9979962,0.00009949584,0.000537063,0.0004083334,0.00071748416,0.00024143692],"domain_scores_gemma":[0.99909216,0.00011258883,0.00015911783,0.0002632561,0.0002035361,0.00016932386],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025441975,0.00019466474,0.00039044698,0.0005036395,0.00007660097,0.00001813707,0.0000990263,0.000062506864,0.00014330797],"category_scores_gemma":[0.00016484273,0.0001745344,0.00002879583,0.00094243744,0.00018132299,0.00017888646,0.00007254416,0.00017030157,0.0000033461974],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0071113366,0.0070532802,0.857108,0.0004106667,0.00011069853,0.000041794643,0.006547451,0.0010847833,0.04223701,0.0003148047,0.00017418663,0.07780599],"study_design_scores_gemma":[0.04165766,0.0028754368,0.9474066,0.00096136297,0.000024895206,0.0000018849322,0.0004977352,0.001497122,0.0034824114,0.0011886526,0.0002294,0.00017684253],"about_ca_topic_score_codex":0.0006383174,"about_ca_topic_score_gemma":0.00027533024,"teacher_disagreement_score":0.0902986,"about_ca_system_score_codex":0.0002405996,"about_ca_system_score_gemma":0.0004943268,"threshold_uncertainty_score":0.71173066},"labels":[],"label_agreement":null},{"id":"W4408289832","doi":"10.3390/biomedicines13030664","title":"Digging Through the Complexities of Immunological Approaches in Emerging Osteosarcoma Therapeutics: A Comprehensive Narrative Review with Updated Clinical Trials","year":2025,"lang":"en","type":"review","venue":"Biomedicines","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's Hospital of Eastern Ontario; University of Alberta; Stollery Children's Hospital; University of Ottawa","funders":"Canadian Institutes of Health Research; Cancer Research Society","keywords":"Medicine; Immunotherapy; Tumor microenvironment; Chimeric antigen receptor; Metastasis; Immune system; Immunogenicity; Oncology; Cancer; Clinical trial; Osteosarcoma; Immunology; Cancer research; Internal medicine","score_opus":0.5553001008875875,"score_gpt":0.5392191322367651,"score_spread":0.016080968650822425,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408289832","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000051386436,0.9866245,0.000038955422,0.004224529,0.000259827,0.006718268,0.000056137997,0.00006388777,0.001962533],"genre_scores_gemma":[0.000035639947,0.99612033,0.0003714253,0.00097162573,0.0004200313,0.00047637377,0.0005718511,0.00005788588,0.00097483094],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98879963,0.0054824194,0.003575845,0.00076897175,0.00082064845,0.0005525123],"domain_scores_gemma":[0.98912954,0.007835853,0.0014384883,0.0011202752,0.0003906128,0.00008524342],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00473652,0.00077516993,0.008999558,0.00049307797,0.0001287035,0.000023856282,0.00068839866,0.00044605276,0.00053982745],"category_scores_gemma":[0.000968776,0.0003431758,0.0011186867,0.0022277264,0.0024119166,0.000059772643,0.00027301654,0.001503097,0.000006502026],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005687444,0.0002949245,0.000032900025,0.06256792,0.0029054494,0.00007003147,0.0014486888,9.2155425e-8,0.000017002572,0.0002035299,0.0012797852,0.93061095],"study_design_scores_gemma":[0.0020563228,0.00093584,0.00004167501,0.16330817,0.0030137338,0.00014616494,0.005104525,0.000006944544,0.0000045323914,0.00006685109,0.8250454,0.000269813],"about_ca_topic_score_codex":0.00009858314,"about_ca_topic_score_gemma":0.000014002302,"teacher_disagreement_score":0.9303411,"about_ca_system_score_codex":0.00014045002,"about_ca_system_score_gemma":0.0010247641,"threshold_uncertainty_score":0.999902},"labels":[],"label_agreement":null},{"id":"W4408362108","doi":"10.1158/2326-6066.cir-24-0758","title":"IL-15 Complex Enhances Agonistic Anti-CD40 + Anti-PDL1 by Correcting the T-bet to Tox Ratio in CD8+ T cells Infiltrating Pancreatic Ductal Adenocarcinoma","year":2025,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vector Institute; Amgen (Canada); Lunenfeld-Tanenbaum Research Institute; Ontario Institute for Cancer Research; University of Toronto","funders":"National Center for Advancing Translational Sciences; National Institute on Aging; Congressionally Directed Medical Research Programs; National Institute of Allergy and Infectious Diseases; Natural Sciences and Engineering Research Council of Canada; American Cancer Society; Canadian Institutes of Health Research; National Cancer Institute; National Institutes of Health; Pancreatic Cancer Action Network","keywords":"CD8; CD40; T cell; Cancer research; Cytotoxic T cell; Biology; Immunology; Antigen; Immune system; Genetics; In vitro","score_opus":0.06724943435714295,"score_gpt":0.39998855345792045,"score_spread":0.33273911910077747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408362108","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9756171,0.009019715,0.00012171144,0.006924258,0.00067649275,0.0021362565,0.00004898403,0.00007013297,0.0053853183],"genre_scores_gemma":[0.9827652,0.0011559369,0.00008144896,0.0005897583,0.00026215773,0.0006465534,0.000053380318,0.000056440545,0.014389136],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9946608,0.0012488716,0.0007459805,0.00089205557,0.0008346949,0.0016176058],"domain_scores_gemma":[0.99587935,0.0022127007,0.000106054635,0.0010171715,0.00061795715,0.00016678941],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0025714096,0.00035064016,0.000873105,0.00079945603,0.00076470297,0.00019394273,0.0009058951,0.00026863613,0.0025028063],"category_scores_gemma":[0.000982064,0.00028755423,0.00012358518,0.0026924019,0.0012567829,0.0001246074,0.000534575,0.0023243604,0.00015482894],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060986803,0.0001472781,0.07473718,0.00016167597,0.00029400247,0.00009524355,0.0016297743,0.00003654797,0.90447503,0.00011782561,0.009784404,0.00791115],"study_design_scores_gemma":[0.003198323,0.0010389186,0.20961796,0.00082036504,0.00007677412,0.00016581017,0.008211839,0.00097175484,0.7627731,0.00011846717,0.0125598535,0.0004468483],"about_ca_topic_score_codex":0.0040663923,"about_ca_topic_score_gemma":0.00067091506,"teacher_disagreement_score":0.14170197,"about_ca_system_score_codex":0.00085839775,"about_ca_system_score_gemma":0.0014766072,"threshold_uncertainty_score":0.9999773},"labels":[],"label_agreement":null},{"id":"W4408502164","doi":"10.1038/s43018-025-00921-6","title":"Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial","year":2025,"lang":"en","type":"article","venue":"Nature Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; University of Alberta","funders":"Regeneron Pharmaceuticals","keywords":"Refractory (planetary science); Medicine; Internal medicine; Oncology; Diffuse large B-cell lymphoma; Lymphoma; Phases of clinical research; Clinical trial; Primary (astronomy); Materials science; Physics","score_opus":0.0062235947205640406,"score_gpt":0.30842749525276114,"score_spread":0.3022039005321971,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408502164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893823,0.0069823246,0.000022554505,0.00035577838,0.00017849069,0.0015950613,0.00007903566,0.000028072802,0.0013763558],"genre_scores_gemma":[0.99338096,0.0016866637,0.000057832523,0.0012230831,0.00011048331,0.00010020276,0.00016720538,0.000037988764,0.0032355988],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99794525,0.00014728396,0.0003921213,0.0005677004,0.0005124184,0.00043524613],"domain_scores_gemma":[0.99897873,0.0002040254,0.000097798125,0.0004816822,0.00011377406,0.00012397839],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036225744,0.0002569176,0.00073384814,0.0008938978,0.000051253548,0.00002391008,0.00013863224,0.00045016495,0.0004911537],"category_scores_gemma":[0.000052399355,0.00020167002,0.00011119335,0.0019351672,0.00007150111,0.00009991019,0.000048070855,0.00093474885,0.0000014739242],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.59474444,0.023863137,0.25896683,0.00019718848,0.0010249715,0.00008857661,0.00080074096,0.00002068748,0.0030173054,0.000022723514,0.0010421647,0.11621122],"study_design_scores_gemma":[0.57674515,0.00077754736,0.39281845,0.000120031604,0.00024195002,1.9751988e-7,0.000022756201,0.000103455095,0.00039348597,0.0000054258676,0.028591817,0.00017975738],"about_ca_topic_score_codex":0.00014955473,"about_ca_topic_score_gemma":0.0005489862,"teacher_disagreement_score":0.13385162,"about_ca_system_score_codex":0.0011124284,"about_ca_system_score_gemma":0.0004944228,"threshold_uncertainty_score":0.8223865},"labels":[],"label_agreement":null},{"id":"W4408502996","doi":"10.3390/ijms26062686","title":"Tackling Prostate Cancer with Theranostic E5B9-Bombesin Target Modules (TMs): From Imaging to Treatment with UniCAR T-Cells","year":2025,"lang":"en","type":"article","venue":"International Journal of Molecular Sciences","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"LNCaP; Bombesin; Prostate cancer; In vivo; Immunotherapy; Cancer research; Cancer cell; In vitro; Ex vivo; Cancer immunotherapy; Cancer; Peptide; Chemistry; Biology; Medicine; Receptor; Internal medicine; Biochemistry; Neuropeptide","score_opus":0.011388895319872017,"score_gpt":0.32815359243533093,"score_spread":0.3167646971154589,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408502996","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97753525,0.00227328,0.008532156,0.009920706,0.00025541196,0.0002654472,0.000015911803,0.000009124663,0.0011927264],"genre_scores_gemma":[0.9845435,0.00038927188,0.01320153,0.00089975237,0.00009664421,0.0000119765855,0.0000024522756,0.000012896355,0.0008419819],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99812573,0.00005834678,0.00025893515,0.00024834424,0.0010978197,0.00021083344],"domain_scores_gemma":[0.9988842,0.00009954199,0.00013910637,0.00013474826,0.0006172106,0.0001252188],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00028552217,0.00014225648,0.0002303696,0.00037930362,0.00006823567,0.0001573727,0.000420068,0.0000189359,0.00025146906],"category_scores_gemma":[0.000022174425,0.00008464159,0.000077918274,0.00035931534,0.00021433088,0.00013979313,0.000044832177,0.00013482277,0.000003246775],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017322396,0.00021122102,0.031000054,0.0000060185407,0.0007572207,0.001153183,0.0007734112,0.014766921,0.88490474,0.00010438949,0.00005568894,0.06453493],"study_design_scores_gemma":[0.006114003,0.0025414035,0.007393528,0.0018672101,0.00021010167,0.0002456095,0.0011901445,0.005729277,0.961036,0.0010265445,0.012355228,0.00029090702],"about_ca_topic_score_codex":0.00059192104,"about_ca_topic_score_gemma":0.00006941866,"teacher_disagreement_score":0.07613132,"about_ca_system_score_codex":0.000306222,"about_ca_system_score_gemma":0.0007192937,"threshold_uncertainty_score":0.3451584},"labels":[],"label_agreement":null},{"id":"W4408505554","doi":"10.3390/curroncol32030173","title":"Enhancing CAR-T Efficacy in Large B-Cell Lymphoma with Radiation Bridging Therapy: A Real-World Single-Center Experience","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre intégré universitaire de santé et de services sociaux de l'Est-de-l'Île-de-Montréal; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Hôpital Fleurimont; Hôpital Maisonneuve-Rosemont; Centre Hospitalier Universitaire de Sherbrooke; Université de Sherbrooke","funders":"","keywords":"Medicine; Cytokine release syndrome; Single Center; Internal medicine; Lymphoma; Refractory (planetary science); Oncology; Progression-free survival; Chimeric antigen receptor; Gastroenterology; Overall survival; Immunotherapy; Cancer","score_opus":0.06359163350671208,"score_gpt":0.40190500971638826,"score_spread":0.33831337620967616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408505554","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9818799,0.0015173455,0.00043641753,0.0005478362,0.0006570524,0.0010074852,0.00000337593,0.00007441002,0.013876173],"genre_scores_gemma":[0.99573684,0.00090070756,0.00009415775,0.0003410509,0.0002299346,0.00017657876,0.000040272098,0.000029531728,0.0024509318],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99800366,0.00021737898,0.00039063243,0.00048589744,0.00028865234,0.0006137534],"domain_scores_gemma":[0.99901956,0.00026879762,0.00010479369,0.00037126953,0.00011154464,0.00012401119],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041267218,0.00020781925,0.00046575558,0.00057425065,0.000085570115,0.000028091916,0.00016138959,0.000098967736,0.00038060328],"category_scores_gemma":[0.00006914374,0.00018058043,0.00008234133,0.0009097587,0.000107323176,0.00008448768,0.00007879511,0.0003166036,0.000019756233],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022227962,0.0090964455,0.23783796,0.00014518978,0.00004945578,0.00011428866,0.005807784,0.0000046156815,0.10694525,0.0000942492,0.00057930493,0.63710266],"study_design_scores_gemma":[0.06556287,0.0018861232,0.14515723,0.0009252901,0.00004798622,0.00005408522,0.0011402625,0.0011613587,0.12233279,0.000013867244,0.6612739,0.0004442364],"about_ca_topic_score_codex":0.00012419412,"about_ca_topic_score_gemma":0.00097178994,"teacher_disagreement_score":0.6606946,"about_ca_system_score_codex":0.0014993994,"about_ca_system_score_gemma":0.00060083345,"threshold_uncertainty_score":0.73638564},"labels":[],"label_agreement":null},{"id":"W4408621916","doi":"10.3390/curroncol32030177","title":"The Changing Role of Allogeneic Stem Cell Transplantation in Adult B-ALL in the Era of CAR T Cell Therapy","year":2025,"lang":"en","type":"review","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Chimeric antigen receptor; Transplantation; Hematopoietic stem cell transplantation; Oncology; Stem cell; Internal medicine; Immunology; Immunotherapy; Cancer","score_opus":0.12400400123635356,"score_gpt":0.44257048758442663,"score_spread":0.31856648634807305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408621916","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009472416,0.98529136,0.0000048961315,0.00011473939,0.00037592527,0.0026519906,0.00004259155,0.0000069328034,0.002039158],"genre_scores_gemma":[0.0029935269,0.995987,0.000008023189,0.000040293704,0.00010713039,0.0004231789,0.00013022035,0.000027880073,0.0002827408],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966232,0.0013139676,0.0009143939,0.00033025054,0.00037012278,0.0004480731],"domain_scores_gemma":[0.99731356,0.0016389588,0.00037919552,0.00049381546,0.00013289966,0.000041553565],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014263693,0.00029088283,0.001452833,0.0004703818,0.000034739533,0.0000066942357,0.0005504352,0.000326233,0.000071625014],"category_scores_gemma":[0.000016793249,0.00016589761,0.00039795056,0.00078861025,0.00013087239,0.000017354125,0.000043173623,0.0011959942,0.0000059263234],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018871656,0.00051819754,0.00017792635,0.015643094,0.000053592477,0.00001806256,0.0048055155,0.000002165842,0.00038355502,0.00004794238,0.000043924243,0.9781173],"study_design_scores_gemma":[0.0023599083,0.0006418119,0.00008456015,0.0071610664,0.00032601788,0.000022708557,0.001489313,0.000023531826,0.00074398617,0.000020380578,0.98697436,0.00015234541],"about_ca_topic_score_codex":0.000054794957,"about_ca_topic_score_gemma":0.000163931,"teacher_disagreement_score":0.98693043,"about_ca_system_score_codex":0.00029718733,"about_ca_system_score_gemma":0.0010142233,"threshold_uncertainty_score":0.6765109},"labels":[],"label_agreement":null},{"id":"W4408770668","doi":"10.1038/s43018-025-00934-1","title":"CAR T or NK cells targeting mismatched HLA-DR molecules in acute myeloid leukemia after allogeneic hematopoietic stem cell transplant","year":2025,"lang":"en","type":"article","venue":"Nature Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Japan Society for the Promotion of Science; Ministry of Education, Culture, Sports, Science and Technology; Japan Agency for Medical Research and Development; Takeda Science Foundation","keywords":"Myeloid leukemia; Immunology; Human leukocyte antigen; Haematopoiesis; Stem cell; Myeloid; Leukemia; Medicine; Cancer research; Biology; Antigen; Cell biology","score_opus":0.009192645512119011,"score_gpt":0.2921316737030913,"score_spread":0.2829390281909723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408770668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9632383,0.031363178,0.000073787356,0.0015079943,0.0006109969,0.0009823983,0.000094101066,0.000081606755,0.0020476258],"genre_scores_gemma":[0.9540958,0.0047811177,0.00033868375,0.002768411,0.00019164186,0.00030606496,0.000034737543,0.00007474525,0.037408844],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976062,0.000107737374,0.00043050485,0.0006325744,0.00052768906,0.0006952755],"domain_scores_gemma":[0.9990259,0.00012553913,0.000067926674,0.00046082368,0.00013531923,0.00018451597],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00027460716,0.00035907316,0.00062302116,0.00029775614,0.000053769363,0.000034570458,0.00028120546,0.00067798607,0.0022795037],"category_scores_gemma":[0.0000075694043,0.00027873204,0.00020477672,0.0007171601,0.00008197239,0.0000524593,0.000058655212,0.0015862308,0.000026063437],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003180571,0.00007736817,0.0034134039,0.0012847501,0.00024189011,0.0013405309,0.0021908223,0.00011827283,0.97972846,0.0000107756505,0.005434122,0.0029790418],"study_design_scores_gemma":[0.0035339168,0.000092912785,0.001365635,0.00075013604,0.00023692896,0.000028179707,0.00039314313,0.00023265526,0.9535173,0.00002307902,0.03948275,0.0003433634],"about_ca_topic_score_codex":0.00016490246,"about_ca_topic_score_gemma":0.00033200625,"teacher_disagreement_score":0.035361215,"about_ca_system_score_codex":0.0010032173,"about_ca_system_score_gemma":0.0010510007,"threshold_uncertainty_score":0.9999665},"labels":[],"label_agreement":null},{"id":"W4408810005","doi":"10.26443/msurj.v1i2.303","title":"Characterizing Signals Associated with the pre-TCR during T Cell Development","year":2025,"lang":"en","type":"article","venue":"McGill Science Undergraduate Research Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; McGill University","funders":"","keywords":"T-cell receptor; T cell; Computer science; Biology; Immunology; Immune system","score_opus":0.05802441424722297,"score_gpt":0.367554316256239,"score_spread":0.30952990200901603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408810005","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93857306,0.00012353642,0.00010678915,0.03286742,0.00010456056,0.0007911059,0.0000028361885,0.00005113374,0.027379533],"genre_scores_gemma":[0.95778865,0.00024546759,0.00018926106,0.0002794632,0.00008067226,0.00004047539,0.0000020690886,0.000026979267,0.04134694],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9922022,0.00056447444,0.00044620803,0.00056004536,0.004401395,0.0018256423],"domain_scores_gemma":[0.9964246,0.00059291377,0.0001511712,0.00047487917,0.0017566358,0.0005998058],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.012545615,0.00023018285,0.00032945574,0.0012839083,0.005681016,0.0006451184,0.0010855617,0.00007818402,0.00027639256],"category_scores_gemma":[0.00092958944,0.00013455715,0.000099738754,0.0045802994,0.0014744359,0.00045916258,0.00048957154,0.0021808601,0.000042038915],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045867718,0.00027718983,0.0021499912,0.000057516707,0.00012950422,0.00025408244,0.0003720951,0.000039428232,0.9844425,0.00019241206,0.00051748264,0.011109166],"study_design_scores_gemma":[0.0031352004,0.0005991842,0.05954022,0.001095393,0.00003306365,0.0004162851,0.0010114377,0.00042034723,0.9024357,0.00076219643,0.030241748,0.00030918192],"about_ca_topic_score_codex":0.000029037385,"about_ca_topic_score_gemma":0.00004427279,"teacher_disagreement_score":0.082006715,"about_ca_system_score_codex":0.0022422913,"about_ca_system_score_gemma":0.0030641896,"threshold_uncertainty_score":0.99561346},"labels":[],"label_agreement":null},{"id":"W4408824469","doi":"10.1017/cts.2024.996","title":"372 Defining and designing a remote monitoring tool for CAR T-cell therapy patients","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical and Translational Science","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Computer science; Medicine","score_opus":0.09957007446169311,"score_gpt":0.4425670342879195,"score_spread":0.34299695982622636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408824469","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99234223,0.0009350936,0.0048461393,0.00089556363,0.00021045396,0.00018065509,0.0000016268068,0.000002919785,0.0005852924],"genre_scores_gemma":[0.97764444,0.0006671816,0.021241903,0.00012691028,0.00013954766,8.082262e-7,3.651054e-7,0.0000037106086,0.00017514166],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987068,0.00003640969,0.00051528873,0.00015175094,0.0004442457,0.0001455085],"domain_scores_gemma":[0.9982865,0.0010342157,0.00011376709,0.00005324395,0.00038608068,0.00012618155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0024306325,0.000061118415,0.00022825607,0.00012211192,0.00015793838,0.000043986354,0.0000813221,0.000046785743,0.0000125686865],"category_scores_gemma":[0.00041377984,0.000043644024,0.000093328905,0.00021737856,0.0002871844,0.00016101402,0.000011136163,0.0002254105,2.1379415e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008966613,0.00007323468,0.57566077,0.000022322394,0.000021887381,0.0000021156475,0.00010836131,0.000009837938,0.01348764,0.00011999804,0.000008773975,0.4095884],"study_design_scores_gemma":[0.006857472,0.000821417,0.9800195,0.0002243417,0.000034242148,0.000011343254,0.00003066539,0.0012741442,0.0050944085,0.0031880727,0.002376265,0.000068134985],"about_ca_topic_score_codex":0.0000028156874,"about_ca_topic_score_gemma":2.5918905e-7,"teacher_disagreement_score":0.40952027,"about_ca_system_score_codex":0.000008458494,"about_ca_system_score_gemma":0.0003980121,"threshold_uncertainty_score":0.17797516},"labels":[],"label_agreement":null},{"id":"W4408856819","doi":"10.1016/j.omton.2025.200977","title":"Safety, efficacy and total cost of point-of-care manufactured anti-CD19 CAR-T cell therapy in India: VELCART trial","year":2025,"lang":"en","type":"article","venue":"Molecular Therapy Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Miltenyi Biotec; Indian Council of Medical Research","keywords":"CAR T-cell therapy; CD19; Cell therapy; Medicine; Internal medicine; Cell; Chimeric antigen receptor; Immunotherapy; Chemistry","score_opus":0.015318148437875842,"score_gpt":0.3357818229476246,"score_spread":0.3204636745097488,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408856819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98232085,0.00624025,0.0001233446,0.0008120883,0.00033742696,0.0036257799,0.000021352476,0.00002588939,0.0064930245],"genre_scores_gemma":[0.9942629,0.0040267194,0.00022286981,0.0007043903,0.00006767781,0.000092791684,0.00006224021,0.0000491806,0.00051124016],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974123,0.00054678606,0.00069618406,0.00050135807,0.0003804883,0.00046285955],"domain_scores_gemma":[0.99853253,0.00037768,0.00018684301,0.0005959813,0.00018610735,0.000120872784],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00055355084,0.00030665827,0.0011883,0.00058547227,0.000045797053,0.000011462366,0.00023790736,0.00047131194,0.00059220736],"category_scores_gemma":[0.00005939219,0.00027175227,0.00024483388,0.00052395056,0.0003467765,0.00003509117,0.00009748608,0.00055790704,0.0000037502618],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.081995085,0.0010731874,0.0014708523,0.00009769861,0.00030346794,0.00020763389,0.0017034304,0.000029452447,0.76380736,0.00008538082,0.00008494018,0.14914149],"study_design_scores_gemma":[0.1848001,0.010502072,0.03479401,0.00009571323,0.000052511645,0.00003406988,0.000620059,0.00001766135,0.75020254,0.00010219343,0.018551437,0.00022761631],"about_ca_topic_score_codex":0.00012129955,"about_ca_topic_score_gemma":0.000014828244,"teacher_disagreement_score":0.14891388,"about_ca_system_score_codex":0.00021453104,"about_ca_system_score_gemma":0.0006637301,"threshold_uncertainty_score":0.9999735},"labels":[],"label_agreement":null},{"id":"W4408939564","doi":"10.3390/curroncol32040198","title":"Pathogenesis, Diagnosis, and Management of Cytokine Release Syndrome in Patients with Cancer: Focus on Infectious Disease Considerations","year":2025,"lang":"en","type":"review","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; National Cancer Institute","keywords":"Medicine; Pathogenesis; Disease; Cytokine; Cancer; Intensive care medicine; Immunology; Bioinformatics; Cytokine release syndrome; Infectious disease (medical specialty); Pathology; Internal medicine; Coronavirus disease 2019 (COVID-19); Biology","score_opus":0.07467834341829367,"score_gpt":0.4168006779541516,"score_spread":0.34212233453585794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408939564","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0052915365,0.988797,0.0000025799807,0.00017939949,0.00035300868,0.004499353,0.00044945753,0.000023464694,0.00040418046],"genre_scores_gemma":[0.0026623548,0.993625,0.000017247392,0.000030929503,0.000039797244,0.0031526156,0.00028906617,0.000036723995,0.0001462602],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979072,0.00032554904,0.0005858663,0.00055172574,0.00032496767,0.00030466137],"domain_scores_gemma":[0.9984002,0.00052644627,0.00024420812,0.00045350485,0.00014234042,0.00023326527],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00016297611,0.0003512466,0.0016437329,0.00064110034,0.00004919043,0.000009942123,0.00008239162,0.00015791922,0.0003821593],"category_scores_gemma":[0.000099746605,0.0002730835,0.00016021484,0.00049021456,0.0001484329,0.000023589299,0.00012949725,0.00044949818,0.000005545764],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025136492,0.0022085907,0.037423003,0.040647604,0.00033132685,0.000432309,0.000011213169,0.0000019472532,4.2202537e-8,0.00027891586,0.00046787265,0.9179458],"study_design_scores_gemma":[0.005473825,0.0020107783,0.04789899,0.05697683,0.0027398006,0.000024644145,0.000004062273,0.0000017667961,6.4488495e-7,0.00008453142,0.884475,0.00030912532],"about_ca_topic_score_codex":0.000036832127,"about_ca_topic_score_gemma":0.00010812001,"teacher_disagreement_score":0.9176367,"about_ca_system_score_codex":0.0007764539,"about_ca_system_score_gemma":0.0010224779,"threshold_uncertainty_score":0.99997216},"labels":[],"label_agreement":null},{"id":"W4408957618","doi":"10.1111/bjh.20061","title":"CD19 chimeric antigen receptor‐T cell therapy in murine immune thrombocytopenia","year":2025,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Natural Science Foundation of Shandong Province; National Natural Science Foundation of China","keywords":"Chimeric antigen receptor; Immunology; CD19; Antigen; Immune thrombocytopenia; Medicine; Immune system; Receptor; Virology; T cell; Antibody; Internal medicine","score_opus":0.017159117864516304,"score_gpt":0.3131646132022168,"score_spread":0.2960054953377005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408957618","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9609768,0.028452108,0.00004761231,0.0022258437,0.0004980719,0.00038639628,0.0000027022509,0.000015764454,0.00739472],"genre_scores_gemma":[0.9634304,0.031348705,0.0007290975,0.0005250137,0.00011131792,0.000008118508,0.0000067303786,0.000033065488,0.003807547],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99784267,0.0002823401,0.00089041813,0.00022491952,0.00031708428,0.00044256495],"domain_scores_gemma":[0.99893415,0.00015968518,0.0002570725,0.00026472207,0.00026532327,0.00011905273],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008046894,0.00016407826,0.0012598471,0.0004915389,0.00006670287,0.00004033249,0.00033865802,0.00017670034,0.004620112],"category_scores_gemma":[0.00013520455,0.00016977917,0.00024102221,0.000611641,0.00018804308,0.000107996246,0.000082788094,0.0008665581,0.00004297111],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035569144,0.0021929974,0.066515334,0.00037585397,0.0006794908,0.058026552,0.0005636519,0.000015554262,0.6366197,0.00016787124,0.024526875,0.20675921],"study_design_scores_gemma":[0.03250423,0.0030005802,0.2489988,0.0026722376,0.00009645171,0.17972274,0.0011090472,0.00006465932,0.37757775,0.001077756,0.15257265,0.0006030887],"about_ca_topic_score_codex":0.0003218609,"about_ca_topic_score_gemma":0.00009246332,"teacher_disagreement_score":0.25904194,"about_ca_system_score_codex":0.00011050969,"about_ca_system_score_gemma":0.00042280118,"threshold_uncertainty_score":0.9962898},"labels":[],"label_agreement":null},{"id":"W4409039889","doi":"10.1038/s41591-025-03532-x","title":"An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma","year":2025,"lang":"en","type":"article","venue":"Nature Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":43,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute on Aging","keywords":"Lymphoma; Biomarker; Signature (topology); Medicine; Hodgkin lymphoma; Immunology; Inflammatory response; Inflammation; Oncology; Cancer research; Biology; Genetics; Mathematics","score_opus":0.009917450318926229,"score_gpt":0.33742553321095087,"score_spread":0.32750808289202465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409039889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9761074,0.0061314004,0.000046912763,0.008205451,0.00051454885,0.0014769749,0.000009868712,0.000060970557,0.0074464404],"genre_scores_gemma":[0.9855437,0.00030850573,0.00023779554,0.0049956385,0.0002706656,0.00005859307,0.000035143163,0.000054899858,0.00849506],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99692583,0.000411286,0.0006010323,0.00058838143,0.00096298417,0.00051047246],"domain_scores_gemma":[0.9974369,0.0005960592,0.00009996316,0.0011084677,0.00043228592,0.0003263538],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002468854,0.0003449216,0.0008152532,0.0017084453,0.000045267858,0.000008871169,0.00044553587,0.000874427,0.0011681858],"category_scores_gemma":[0.0006299872,0.0002557427,0.00011793269,0.0022210707,0.00024244394,0.00006955917,0.00007032213,0.0010843473,0.000010819542],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024547165,0.00035498364,0.010181668,0.00016907505,0.00007826857,0.00027031946,0.001623143,0.0000059014487,0.88959605,0.00002685744,0.009387841,0.063758716],"study_design_scores_gemma":[0.017404677,0.002998435,0.49197403,0.0010394647,0.000046498564,0.000022721284,0.00081812247,0.00018553047,0.37658867,0.00008984442,0.108566135,0.00026588564],"about_ca_topic_score_codex":0.0001497106,"about_ca_topic_score_gemma":0.00006554267,"teacher_disagreement_score":0.5130074,"about_ca_system_score_codex":0.00032637166,"about_ca_system_score_gemma":0.0005937269,"threshold_uncertainty_score":0.9999895},"labels":[],"label_agreement":null},{"id":"W4409040539","doi":"10.51731/cjht.2025.1108","title":"Ciltacabtagene Autoleucel (Carvykti)","year":2025,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Computer science","score_opus":0.04058088739669979,"score_gpt":0.3538447205249171,"score_spread":0.3132638331282173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409040539","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.31192797,0.23805399,0.0011994549,0.4228802,0.001577372,0.0011361281,0.000030452484,0.00042877847,0.022765627],"genre_scores_gemma":[0.99013484,0.0013304652,0.0008255905,0.0018232032,0.000019980933,0.0000059211043,0.0000018783985,0.000016562886,0.005841572],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984155,0.000053559983,0.0005604889,0.00014423583,0.00022858969,0.0005975756],"domain_scores_gemma":[0.99889684,0.00006685955,0.00018616699,0.00039302645,0.00029789325,0.00015924248],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009041038,0.00012510897,0.00048663153,0.0015504792,0.00020130629,0.000031966047,0.00037263226,0.00019935027,0.00036771165],"category_scores_gemma":[0.0007594238,0.00010624508,0.00012609373,0.0007909887,0.00026941588,0.00005763929,0.000030154375,0.00082628755,0.000013432046],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000044925582,0.000019034958,0.006936716,0.00017631041,0.00010159456,0.00035263452,0.0000972936,0.0000042714555,0.0021405916,0.0014527361,0.025995184,0.96267873],"study_design_scores_gemma":[0.0010681952,0.0005681099,0.014283395,0.00052323093,0.00002224401,0.00045155708,0.0017072905,0.000023704544,0.0075097485,0.0032455625,0.9704967,0.00010026734],"about_ca_topic_score_codex":0.003416639,"about_ca_topic_score_gemma":0.0023096604,"teacher_disagreement_score":0.9625784,"about_ca_system_score_codex":0.001047831,"about_ca_system_score_gemma":0.009786861,"threshold_uncertainty_score":0.9958267},"labels":[],"label_agreement":null},{"id":"W4409086045","doi":"10.1103/physrevresearch.7.023003","title":"Comparing kinetic proofreading and kinetic segregation for T cell receptor activation","year":2025,"lang":"en","type":"article","venue":"Physical Review Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"Natural Sciences and Engineering Research Council of Canada; Advanced Research Projects Agency; Defense Advanced Research Projects Agency; Oncode Institute; Nederlandse Organisatie voor Wetenschappelijk Onderzoek","keywords":"Kinetic energy; Proofreading; Biophysics; Chemistry; Computational biology; Cell biology; Computer science; Biology; Physics; Biochemistry; Enzyme; Polymerase","score_opus":0.13784381884062546,"score_gpt":0.46845922590877537,"score_spread":0.3306154070681499,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409086045","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92939043,0.01777673,0.0013649124,0.009527298,0.000077112294,0.009786355,0.0000046496034,0.00009118899,0.03198133],"genre_scores_gemma":[0.98249894,0.0071425047,0.0006375541,0.00023439508,0.00021513323,0.00075130607,0.000049165657,0.000029957195,0.008441019],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99803257,0.00024186198,0.00024497617,0.0004008096,0.000638873,0.00044088872],"domain_scores_gemma":[0.997907,0.0010526744,0.000040234016,0.0003437346,0.0005080264,0.00014835292],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012391933,0.00013362836,0.00045630307,0.00021573434,0.00014956629,0.00005416823,0.00013373054,0.00004074149,0.0001525232],"category_scores_gemma":[0.001149113,0.0001105213,0.00010277249,0.0009167318,0.00013780248,0.00008001489,0.00012024475,0.0005118348,0.000041117488],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029015532,0.0003330048,0.0011603072,0.014256886,0.000039011786,6.308443e-7,0.00009031499,0.0000014749443,0.78972226,0.0042094295,0.0067178146,0.18317872],"study_design_scores_gemma":[0.004546443,0.0015901283,0.008752297,0.020217214,0.00019863402,0.0000038494445,0.000083657505,0.016746087,0.5574693,0.01065789,0.37933543,0.00039908415],"about_ca_topic_score_codex":0.000052121388,"about_ca_topic_score_gemma":0.0000024846952,"teacher_disagreement_score":0.37261763,"about_ca_system_score_codex":0.00020756318,"about_ca_system_score_gemma":0.00014839375,"threshold_uncertainty_score":0.45069277},"labels":[],"label_agreement":null},{"id":"W4409109865","doi":"10.1101/2025.03.28.645991","title":"Mapping cellular targets of covalent cancer drugs in the entire mammalian body","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"In vivo; Computer science; Drug discovery; Click chemistry; Computational biology; Chemistry; Nanotechnology; Biology; Combinatorial chemistry; Materials science; Biochemistry","score_opus":0.02043507199465934,"score_gpt":0.27511920938620515,"score_spread":0.25468413739154583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409109865","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871997,0.007089548,0.00015099517,0.0015265903,0.0010062045,0.0024317442,0.0002867771,0.00011261988,0.00019577894],"genre_scores_gemma":[0.996143,0.001542943,0.0004437936,0.0003723076,0.0004713181,0.00056184846,0.0000012880139,0.000087460925,0.00037606337],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9960176,0.00037310753,0.0008363527,0.0009594847,0.0010592663,0.00075422286],"domain_scores_gemma":[0.99679375,0.00013629466,0.00036425874,0.0019376103,0.0005681922,0.00019991377],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017802443,0.00054643105,0.00096998905,0.0007309007,0.00009854405,0.00008246543,0.0008973139,0.00053117424,0.0008757854],"category_scores_gemma":[0.00015139536,0.00047793222,0.00034260293,0.0011629389,0.00021002267,0.000056908895,0.0005687016,0.0016084018,0.00002044372],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017511185,0.00039793033,0.051719815,0.0034199506,0.00037136406,0.00019309924,0.0002956329,0.000028632983,0.9423015,0.00025417338,0.0008258941,0.0000168829],"study_design_scores_gemma":[0.0023344222,0.000108381806,0.22014874,0.0038772132,0.00025319707,3.1243914e-8,0.000121761004,0.0004985552,0.71651006,0.000003829506,0.055384543,0.00075928733],"about_ca_topic_score_codex":0.00089990353,"about_ca_topic_score_gemma":0.000012782714,"teacher_disagreement_score":0.22579147,"about_ca_system_score_codex":0.0007355353,"about_ca_system_score_gemma":0.0017688719,"threshold_uncertainty_score":0.99976724},"labels":[],"label_agreement":null},{"id":"W4409190862","doi":"10.1101/2025.03.31.646438","title":"Epidermal Resident Memory T Cell Fitness Requires Antigen Encounter in the Skin","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institutes of Health; McGill University; University of Pittsburgh","keywords":"Antigen; Psychology; Computer science; Neuroscience; Biology; Immunology","score_opus":0.022976164435485422,"score_gpt":0.28337344675704423,"score_spread":0.2603972823215588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409190862","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98744243,0.0050846157,0.00010815124,0.0021422307,0.0011663595,0.0026557182,0.0001459033,0.00020817106,0.0010464276],"genre_scores_gemma":[0.9934683,0.0020399499,0.00053830905,0.0014585196,0.0010639691,0.00052226905,0.0000011941355,0.00012393127,0.0007835549],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9947491,0.00070525386,0.00095591584,0.0013353832,0.0012413588,0.0010129636],"domain_scores_gemma":[0.9955763,0.0004067982,0.00031335012,0.0029120834,0.00053922867,0.000252207],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002877186,0.0007045946,0.0010166018,0.00078903005,0.00016859097,0.00025192156,0.0012998129,0.00075098895,0.0010229468],"category_scores_gemma":[0.00037339007,0.00058974157,0.00036940933,0.0009881774,0.00028662686,0.00013891405,0.0008909451,0.0022416357,0.000105827785],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00078151515,0.00083709264,0.04557223,0.0035932458,0.00040657603,0.002171399,0.00050443585,0.00013250372,0.9346695,0.00020262168,0.011088333,0.00004053314],"study_design_scores_gemma":[0.002759129,0.00016045666,0.34911016,0.0021930337,0.00021275408,2.1781494e-7,0.000098341254,0.00029087305,0.60134965,0.000007102694,0.042792276,0.0010260058],"about_ca_topic_score_codex":0.0006336279,"about_ca_topic_score_gemma":0.000048251342,"teacher_disagreement_score":0.33331984,"about_ca_system_score_codex":0.0006492194,"about_ca_system_score_gemma":0.001998652,"threshold_uncertainty_score":0.99989027},"labels":[],"label_agreement":null},{"id":"W4409251014","doi":"10.1016/j.tmrv.2025.150897","title":"Identifying Modifiers of CAR T-Cell Therapeutic Efficacy and Safety: A Systematic Review and Individual Patient Data Meta-Analysis","year":2025,"lang":"en","type":"review","venue":"Transfusion Medicine Reviews","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada; Ottawa Public Health; University of Ottawa; University of British Columbia; Ottawa Hospital","funders":"Networks of Centres of Excellence of Canada; Copenhagen School of Energy Infrastructure; Canadian Institutes of Health Research","keywords":"Meta-analysis; Medicine; Internal medicine","score_opus":0.34744195528740296,"score_gpt":0.4512098839360388,"score_spread":0.10376792864863582,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409251014","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000010646812,0.97791255,0.00036115554,0.00037014773,0.0000617986,0.020588439,0.0002583175,0.000028856324,0.00041764765],"genre_scores_gemma":[0.0000010324327,0.99582654,0.00018559789,0.00068419223,0.000043661043,0.0006727331,0.0010313853,0.00007279433,0.0014820813],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98875254,0.0032272802,0.004694163,0.001451537,0.0014162513,0.00045822503],"domain_scores_gemma":[0.9925327,0.0018312705,0.0014340796,0.0035911424,0.00020069361,0.00041015286],"candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.008018001,0.0010601638,0.02574527,0.0012942895,0.00012563998,0.000027278378,0.0008944359,0.0003365078,0.002075058],"category_scores_gemma":[0.0008400896,0.00057302724,0.0024519267,0.0030712057,0.00034906305,0.000092351,0.00034156966,0.001019033,0.000010021005],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000016035183,0.00007538829,5.10439e-7,0.69325674,0.05487394,0.000012114657,0.0002425905,2.6375126e-8,0.000007585024,0.0000056377617,0.00025552788,0.25125393],"study_design_scores_gemma":[0.00056005083,0.00018595708,4.5377894e-7,0.2774229,0.55706584,0.000058497,0.000043349573,0.000002720155,5.7386933e-7,0.0000018783793,0.16444778,0.00020997941],"about_ca_topic_score_codex":0.00018959126,"about_ca_topic_score_gemma":0.00003429476,"teacher_disagreement_score":0.5021919,"about_ca_system_score_codex":0.00007542407,"about_ca_system_score_gemma":0.0003470224,"threshold_uncertainty_score":0.9996721},"labels":[],"label_agreement":null},{"id":"W4409256027","doi":"10.1182/blood.2024026216","title":"Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Stanford Cancer Institute; National Institute of Allergy and Infectious Diseases; Office of Naval Research; Legend Biotech; Pharmacyclics; Takeda Oncology; Health Resources and Services Administration; MorphoSys; Seagen; Astellas Pharma; Adaptive Biotechnologies; Pfizer; Incyte; Kiadis Pharma; bluebird bio; Medac; Jazz Pharmaceuticals; BeiGene; HistoGenetics; Atara Biotherapeutics; National Cancer Institute; Gilead Sciences; Sanofi; GlaxoSmithKline; CSL Behring; Bristol-Myers Squibb; AstraZeneca; Gateway for Cancer Research; Doris Duke Charitable Foundation; Amgen; CareDx; National Heart, Lung, and Blood Institute; Novartis Pharmaceuticals Corporation; Swedish Orphan Biovitrum; Omeros Corporation; Vertex Pharmaceuticals; Alexion Pharmaceuticals; Mallinckrodt Pharmaceuticals; Astellas Pharma US","keywords":"Medicine; Internal medicine; Multiple myeloma; Clinical trial; Refractory (planetary science); Cohort; Surgery; Oncology","score_opus":0.022124320350807025,"score_gpt":0.3219916211097771,"score_spread":0.29986730075897006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409256027","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96768916,0.0045469212,0.0005546059,0.00046785502,0.00021040476,0.0014318293,0.0001503856,0.00009921954,0.024849616],"genre_scores_gemma":[0.9856678,0.00016909954,0.0029475756,0.00019211698,0.00013227967,0.00010455502,0.000054927666,0.0000412391,0.0106903855],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9987107,0.000038181814,0.00029865967,0.00029457491,0.0003473112,0.000310604],"domain_scores_gemma":[0.9986029,0.00032238095,0.00005978963,0.0005278457,0.00037778364,0.00010927653],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024905542,0.00014351822,0.0003983055,0.00019678785,0.000076501085,0.000013519345,0.0001536614,0.0001350909,0.0005123136],"category_scores_gemma":[0.00038510084,0.00013202227,0.0002077102,0.000282824,0.00008042822,0.000041551728,0.00006843314,0.00019433109,0.000012013157],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005043667,0.00075711525,0.024235236,0.0012393858,0.00052767695,0.000039551924,0.00067213294,0.000002502124,0.8680174,0.0004300478,0.0026681337,0.09636718],"study_design_scores_gemma":[0.0185486,0.0017728969,0.010603782,0.0002642373,0.00024628258,0.000007491953,0.00051410415,0.000032238022,0.77984643,0.00019100923,0.18783285,0.00014006576],"about_ca_topic_score_codex":0.000018463721,"about_ca_topic_score_gemma":0.000039415358,"teacher_disagreement_score":0.18516472,"about_ca_system_score_codex":0.00009009559,"about_ca_system_score_gemma":0.0003881763,"threshold_uncertainty_score":0.5609475},"labels":[],"label_agreement":null},{"id":"W4409323048","doi":"10.1016/j.jcyt.2025.04.060","title":"Shaping the future of cell and gene therapy workforce development: training of cell therapy processing personnel - perspectives from the International Society for Cell &amp; Gene Therapy Lab Practices Committee","year":2025,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Blood Services; University of Alberta; International Society for Cellular Therapy","funders":"","keywords":"Workforce; Genetic enhancement; Cell therapy; Training (meteorology); Workforce development; Business; Cell; Gene; Economic growth; Biology; Genetics; Economics; Geography","score_opus":0.09345781902315406,"score_gpt":0.3510643987199699,"score_spread":0.2576065796968159,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409323048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8749486,0.11487746,0.0016397802,0.004847107,0.00020158233,0.0018509635,0.00004750919,0.000050644318,0.0015363416],"genre_scores_gemma":[0.84862494,0.111326985,0.028374612,0.0042673885,0.0013346254,0.0003359336,0.00009652873,0.0001602849,0.005478686],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99729776,0.00018363376,0.00062186527,0.00067214813,0.0007281255,0.0004964491],"domain_scores_gemma":[0.99663925,0.0012273351,0.000805581,0.0006584888,0.0005845461,0.00008481583],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014238426,0.00046382687,0.00064796634,0.0001325676,0.0006116675,0.00017065952,0.00084381434,0.00024696262,0.0003719203],"category_scores_gemma":[0.00003055891,0.00028596894,0.00045178985,0.00051780633,0.00048538702,0.00020819959,0.000068926434,0.0005921483,0.000001262238],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027277197,0.0005142553,0.0025657173,0.0000689701,0.00061669986,7.727686e-7,0.1428243,0.000008045753,0.7309211,0.000035463174,0.0007246234,0.11899235],"study_design_scores_gemma":[0.012544431,0.0003950478,0.004236493,0.00018468418,0.000052066367,0.0000065236354,0.08128442,0.0005212513,0.6995722,0.00024483047,0.2005896,0.00036845796],"about_ca_topic_score_codex":0.00009440387,"about_ca_topic_score_gemma":0.000030065921,"teacher_disagreement_score":0.19986497,"about_ca_system_score_codex":0.0001539905,"about_ca_system_score_gemma":0.00088288775,"threshold_uncertainty_score":0.99995923},"labels":[],"label_agreement":null},{"id":"W4409348483","doi":"10.1016/j.cell.2025.03.017","title":"Engineering TCR-controlled fuzzy logic into CAR T cells enhances therapeutic specificity","year":2025,"lang":"en","type":"article","venue":"Cell","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"Chinese American Medical Society; Natural Sciences and Engineering Research Council of Canada; Canadian Institutes of Health Research; Kennedy Trust for Rheumatology Research; Aspen Center for Physics; Fonds Québécois de la Recherche sur la Nature et les Technologies; Kennedy Memorial Trust; National Cancer Institute; National Institutes of Health; National Science Foundation","keywords":"T-cell receptor; Chimeric antigen receptor; Biology; Antigen; Cancer immunotherapy; Immunotherapy; Cancer research; Crosstalk; T cell; Receptor; Tumor microenvironment; Cell biology; Immunology; Immune system; Tumor cells; Biochemistry","score_opus":0.018741005974053704,"score_gpt":0.28786492790999146,"score_spread":0.26912392193593776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409348483","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.77989125,0.0071106628,0.0027706698,0.0011029353,0.0011782002,0.0017607292,0.0000029661926,0.00024635252,0.20593624],"genre_scores_gemma":[0.92421454,0.0005943728,0.00054385216,0.00049992854,0.0002867915,0.00006135698,0.0000064089877,0.00003126512,0.07376147],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99850523,0.000063808024,0.00031003903,0.00038128812,0.00031229082,0.00042733256],"domain_scores_gemma":[0.99894154,0.0002687971,0.00004693525,0.0005064342,0.000106796564,0.00012952392],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00039477393,0.00022594687,0.0005592925,0.00023800034,0.000073242954,0.000045868273,0.00022151129,0.00013846577,0.0024225265],"category_scores_gemma":[0.00003909365,0.00018443346,0.00022975988,0.00039660055,0.00007016383,0.000040677594,0.000063783766,0.00040432822,0.00033548023],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00064120145,0.000151133,0.000113004884,0.0002146485,0.00011625669,0.000035663157,0.00026438222,0.000092909155,0.9934496,0.00025545512,0.00063240173,0.004033337],"study_design_scores_gemma":[0.004921867,0.00017087042,0.00035955757,0.00006435001,0.0000957156,0.0000028245713,0.00016333388,0.0012648936,0.9340642,0.000680853,0.05803221,0.00017933545],"about_ca_topic_score_codex":0.000046380854,"about_ca_topic_score_gemma":0.0000076212805,"teacher_disagreement_score":0.1443233,"about_ca_system_score_codex":0.00019052163,"about_ca_system_score_gemma":0.00013728505,"threshold_uncertainty_score":0.9984894},"labels":[],"label_agreement":null},{"id":"W4409349463","doi":"10.69690/odmj-018-0425-1030","title":"Allogeneic Stem-Cell Transplantation Following Chimeric Antigen Receptor T-Cell for the Treatment of Relapsed/Refractory Hematologic Malignancy in Pediatrics and Young Adults: A Systematic Review and Meta-Analysis of Clinical Studies","year":2025,"lang":"en","type":"review","venue":"OncoDaily Medical Journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Chimeric antigen receptor; Medicine; Meta-analysis; Transplantation; Hematopoietic stem cell transplantation; Malignancy; Stem cell; Refractory (planetary science); Oncology; Immunology; Immunotherapy; Pediatrics; Internal medicine; Immune system; Biology","score_opus":0.14252855633730416,"score_gpt":0.45015579189447075,"score_spread":0.3076272355571666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409349463","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009154586,0.99363834,0.0000938073,0.0001923826,0.00022774757,0.0047878097,0.00010265675,0.0000070530127,0.00003472773],"genre_scores_gemma":[0.00015729602,0.99784994,0.00031510578,0.00008707659,0.00008632542,0.0005013433,0.000050923754,0.00003631467,0.0009156742],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9911715,0.0021229077,0.004568864,0.0005490232,0.0012251267,0.00036260925],"domain_scores_gemma":[0.9881533,0.008484861,0.002264813,0.0004962047,0.00029085358,0.00030998015],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.006844648,0.00054793566,0.014004593,0.0007322583,0.000098928445,0.000017703005,0.00033699334,0.0004826209,0.0002016719],"category_scores_gemma":[0.0010965101,0.00026522562,0.0046880995,0.001279469,0.00021552606,0.00005138709,0.000043925822,0.00074805634,0.0000011283668],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016252085,0.0007988697,0.0003696988,0.85174793,0.09345107,0.00019445017,0.00051588006,1.9243258e-7,0.0000017603417,0.0000014558135,0.00009967302,0.05265648],"study_design_scores_gemma":[0.00279327,0.0016094834,0.000026588457,0.09072524,0.8995164,0.00025114196,0.00047999856,0.000010775967,0.0000025826025,0.0000023252899,0.004357823,0.00022438566],"about_ca_topic_score_codex":0.00001838452,"about_ca_topic_score_gemma":0.000030529754,"teacher_disagreement_score":0.8060653,"about_ca_system_score_codex":0.00016994588,"about_ca_system_score_gemma":0.0011503494,"threshold_uncertainty_score":0.99998},"labels":[],"label_agreement":null},{"id":"W4409377259","doi":"10.18295/2075-0528.1356","title":"A New Cellular Weapon to Kill Leukaemic B-Cells","year":2012,"lang":"en","type":"article","venue":"Sultan Qaboos University medical journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; McGill University Health Centre; Royal Victoria Regional Health Centre","funders":"","keywords":"Medicine","score_opus":0.018572183402215784,"score_gpt":0.2723575139942364,"score_spread":0.25378533059202063,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409377259","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93692327,0.0007804624,0.0134072425,0.012841108,0.0018052672,0.0005710593,0.000011164093,0.0001225557,0.033537872],"genre_scores_gemma":[0.8077129,0.0011348578,0.004118356,0.0026477284,0.005398299,3.9397906e-7,0.000014921154,0.00007568491,0.17889684],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99653894,0.00019613141,0.0002688787,0.00024202277,0.0018307636,0.000923261],"domain_scores_gemma":[0.99418557,0.00015494024,0.000079233825,0.00031370428,0.00022355554,0.00504299],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0010925563,0.00020901141,0.0003877857,0.0005469364,0.00022256719,0.000032231157,0.00048347507,0.00026899463,0.034487717],"category_scores_gemma":[0.00040574346,0.00019053205,0.00023514988,0.0008096924,0.00011905399,0.00023950089,0.00019196713,0.0014411571,0.00091863784],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034329682,0.0006618008,0.005374059,0.00006416365,0.00041482423,0.0053171194,0.0039108247,0.000004074104,0.57208294,0.0004506527,0.23650655,0.17178003],"study_design_scores_gemma":[0.0056964364,0.0005157645,0.0012433936,0.00024008985,0.00013198791,0.0012756478,0.0013643495,0.000051776566,0.03350222,0.000028052269,0.9556778,0.00027245947],"about_ca_topic_score_codex":0.00012598344,"about_ca_topic_score_gemma":0.000014635723,"teacher_disagreement_score":0.7191713,"about_ca_system_score_codex":0.00070982706,"about_ca_system_score_gemma":0.0012689799,"threshold_uncertainty_score":0.9998593},"labels":[],"label_agreement":null},{"id":"W4409446817","doi":"10.1016/j.xcrm.2025.102076","title":"Evolution of the tumor immune landscape during treatment with tebentafusp, a T cell receptor-CD3 bispecific","year":2025,"lang":"en","type":"article","venue":"Cell Reports Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Immune system; CD3; T-cell receptor; Receptor; T cell; Biology; Cancer research; Medicine; Immunology; Internal medicine; CD8","score_opus":0.009998365414937595,"score_gpt":0.2560175750440299,"score_spread":0.2460192096290923,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409446817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9079354,0.006255277,0.000030260891,0.0009862233,0.0005854199,0.001273871,0.0000022708184,0.00005603597,0.08287524],"genre_scores_gemma":[0.8788035,0.00047804133,0.00006596576,0.000040492647,0.00023939539,0.00006123372,0.00002208981,0.000036488374,0.12025282],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974935,0.00007854991,0.00076122297,0.000498087,0.00076632644,0.00040227865],"domain_scores_gemma":[0.9978437,0.00008665142,0.0003943286,0.0012866404,0.00023760204,0.00015107795],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00046063348,0.000286702,0.0006714407,0.0003296827,0.00014615901,0.000008325571,0.0001388248,0.000083587685,0.003321589],"category_scores_gemma":[0.00006653339,0.00015340961,0.00017161049,0.0009352807,0.0003367745,0.000038013943,0.00007591324,0.0002968451,0.000009545244],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008663218,0.00048978307,0.111248866,0.0004261611,0.00010361258,0.00046097135,0.00047238712,0.000013243377,0.88293713,0.000010919904,0.0016911377,0.001279455],"study_design_scores_gemma":[0.0076319952,0.0018710379,0.08214734,0.0013526187,0.00041223172,0.00064211513,0.0021100177,0.000053466236,0.8353617,0.000035040834,0.06817726,0.00020513365],"about_ca_topic_score_codex":0.00050855835,"about_ca_topic_score_gemma":0.00003083492,"teacher_disagreement_score":0.06648613,"about_ca_system_score_codex":0.0006632197,"about_ca_system_score_gemma":0.00055304315,"threshold_uncertainty_score":0.9975895},"labels":[],"label_agreement":null},{"id":"W4409448922","doi":"10.1097/io9.0000000000000062","title":"Revolutionizing treatment for recurrent glioblastoma with intraventricular CARv3-TEAM-E T cells","year":2024,"lang":"en","type":"article","venue":"International Journal of Surgery Open","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Impact","funders":"","keywords":"Medicine; Glioblastoma; Internal medicine; Cancer research","score_opus":0.0698043182956191,"score_gpt":0.37001763334817445,"score_spread":0.30021331505255533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409448922","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96180224,0.006005809,0.004360276,0.01668728,0.0064327954,0.0020887188,0.00012488998,0.000050261307,0.0024477202],"genre_scores_gemma":[0.98544556,0.0021127942,0.0019849674,0.00015974091,0.00207257,0.00006730562,0.000035944635,0.000062073115,0.0080590295],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9983827,0.000050715276,0.00048095407,0.00018715342,0.0006959048,0.00020257712],"domain_scores_gemma":[0.998339,0.0004555292,0.0001555466,0.00012350535,0.0007685876,0.00015784372],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007902031,0.00013692277,0.00036680614,0.00048314917,0.0000416517,0.0002688756,0.0002729693,0.000044274162,0.000780495],"category_scores_gemma":[0.000075158736,0.00008354286,0.0003166254,0.00020844066,0.00003486411,0.0002841151,0.000059229966,0.00017761043,0.000021297967],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.034095466,0.0014068546,0.0048086606,0.00023622041,0.0073115253,0.0077476515,0.0009605374,0.00032143318,0.05091562,0.00058674783,0.072097234,0.81951207],"study_design_scores_gemma":[0.0030809282,0.0039209784,0.00082332053,0.0027968693,0.00026668835,0.005451754,0.00023311721,0.0016317308,0.080920495,0.00027015203,0.90037066,0.0002332789],"about_ca_topic_score_codex":0.000047635756,"about_ca_topic_score_gemma":0.000023892368,"teacher_disagreement_score":0.8282735,"about_ca_system_score_codex":0.00090705464,"about_ca_system_score_gemma":0.00078741706,"threshold_uncertainty_score":0.85458726},"labels":[],"label_agreement":null},{"id":"W4409493832","doi":"10.1182/bloodadvances.2024015719","title":"Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovation Cluster (Canada)","funders":"MorphoSys; Swedish Orphan Biovitrum; Incyte; Regeneron Pharmaceuticals; Gilead Sciences; Sanofi; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb; Amgen","keywords":"Bispecific antibody; Refractory (planetary science); Lymphoma; Antibody therapy; Medicine; Antibody; CAR T-cell therapy; Cancer research; Oncology; Internal medicine; Immunology; T cell; Chimeric antigen receptor; Biology; Monoclonal antibody; Immune system","score_opus":0.009952427921185381,"score_gpt":0.3055829094655686,"score_spread":0.2956304815443832,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409493832","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95298827,0.03310324,0.000016081556,0.00038693624,0.00022375904,0.00065557583,0.00003302784,0.000051383027,0.012541759],"genre_scores_gemma":[0.9711694,0.0069771796,0.00040440733,0.0003421725,0.00007195838,0.00006595413,0.000023574947,0.000042807715,0.02090251],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979242,0.00011269785,0.0004908565,0.00047842518,0.00047711487,0.00051671424],"domain_scores_gemma":[0.9987452,0.00023726828,0.00011665383,0.00067253434,0.00012788024,0.0001004642],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031418825,0.00028436983,0.0006804487,0.0004833478,0.000045469445,0.000018100383,0.00025437324,0.00016731389,0.0008631068],"category_scores_gemma":[0.000040253162,0.0002272057,0.00022184482,0.00067552144,0.00013457694,0.00013551874,0.00007463719,0.0002787767,0.000031052772],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010495157,0.00502466,0.65719354,0.0003301066,0.000115867864,0.0001711887,0.0004043721,0.000002391574,0.32457748,0.000059561444,0.0002198497,0.010851451],"study_design_scores_gemma":[0.03514592,0.00075069966,0.25944728,0.00026466884,0.00007835125,0.0000079190195,0.0010400073,0.000010758953,0.27324408,0.00016856089,0.4294986,0.00034313384],"about_ca_topic_score_codex":0.00004480345,"about_ca_topic_score_gemma":0.00013821399,"teacher_disagreement_score":0.42927876,"about_ca_system_score_codex":0.000067941815,"about_ca_system_score_gemma":0.00021996463,"threshold_uncertainty_score":0.9450414},"labels":[],"label_agreement":null},{"id":"W4409535425","doi":"10.1136/jitc-2024-010684","title":"Single-cell RNA sequencing of human double-negative T cells reveals a favorable cellular signature for cancer therapy","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Flow cytometry; T cell; Cancer research; Biology; In vivo; Leukemia; Ex vivo; T-cell receptor; Cell; Single-cell analysis; Phenotype; Cancer; RNA; Jurkat cells; Molecular biology; Immunology; Gene; Immune system; Genetics","score_opus":0.055193438543429695,"score_gpt":0.3742840893308047,"score_spread":0.31909065078737503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409535425","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90582204,0.08210574,0.0022445272,0.0013367666,0.0013123042,0.0040576644,0.00022213765,0.00003132579,0.0028674786],"genre_scores_gemma":[0.8158999,0.024008317,0.0035226468,0.0014575594,0.0009916214,0.00085067895,0.000024094425,0.00024931855,0.15299587],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971946,0.000095568816,0.0010696191,0.00038036105,0.0006276581,0.00063219294],"domain_scores_gemma":[0.9965063,0.00039838234,0.00088757713,0.0004743529,0.0016092245,0.0001242144],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011321667,0.00037586997,0.0011373102,0.00048987014,0.00031008443,0.000059518567,0.00041063293,0.000295897,0.0025254048],"category_scores_gemma":[0.000024519091,0.00030768334,0.00083603873,0.0005480181,0.00023106912,0.00017157497,0.000024604946,0.0006480864,5.0233587e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012590591,0.00034438918,0.00021969182,0.0006922609,0.0013399991,0.0000032408072,0.001409861,0.0002784856,0.9347903,0.00007690426,0.005786248,0.04246799],"study_design_scores_gemma":[0.019467954,0.0020118388,0.000043843866,0.0011907266,0.00014380955,0.0000033341216,0.0004348495,0.000065358785,0.9170786,0.0017975827,0.057522465,0.00023963941],"about_ca_topic_score_codex":0.00079368905,"about_ca_topic_score_gemma":0.00009075858,"teacher_disagreement_score":0.1501284,"about_ca_system_score_codex":0.0010255377,"about_ca_system_score_gemma":0.0014077812,"threshold_uncertainty_score":0.99993753},"labels":[],"label_agreement":null},{"id":"W4409566964","doi":"10.1002/cpt.3658","title":"Oncology Dose Optimization: Tailored Approaches to Different Molecular Classes","year":2025,"lang":"en","type":"review","venue":"Clinical Pharmacology & Therapeutics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"Genentech; F. Hoffmann-La Roche","keywords":"Medicine; Clinical trial; Drug; Drug development; Clinical pharmacology; Immunotherapy; Pharmacology; Oncology; Cancer; Medical physics; Computational biology; Bioinformatics; Internal medicine; Biology","score_opus":0.4881619744201073,"score_gpt":0.5448352007766311,"score_spread":0.056673226356523776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409566964","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000045394114,0.9742663,0.0025418585,0.010369113,0.002989999,0.0055776215,0.000038930677,0.000198005,0.003972781],"genre_scores_gemma":[0.000010112093,0.9509794,0.0021752415,0.03630347,0.0014367286,0.00093451573,0.0003084845,0.00017182853,0.0076802033],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.992244,0.0027406747,0.0021649753,0.0013968926,0.00050344854,0.0009500096],"domain_scores_gemma":[0.99345136,0.0040312596,0.00048675272,0.0010469309,0.0002498361,0.0007338618],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.001092421,0.00093803793,0.004943878,0.0005946167,0.00013176317,0.00004557082,0.0009605434,0.0019829234,0.0038125305],"category_scores_gemma":[0.00011805069,0.0007273931,0.0017659102,0.0009942345,0.0007057242,0.00003316235,0.00063895766,0.003068675,0.00020627372],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010443203,0.0026069116,0.000023111797,0.006177538,0.006748184,0.00033863963,0.000044802582,0.00021478397,0.00006794483,0.00003768599,0.010189996,0.9725061],"study_design_scores_gemma":[0.0030506104,0.0020496633,0.000007852816,0.0014978222,0.013558815,0.00006852313,0.000017391552,0.00061293977,0.00004987183,0.000028082808,0.97854066,0.0005177653],"about_ca_topic_score_codex":0.0000012737431,"about_ca_topic_score_gemma":0.0000014393099,"teacher_disagreement_score":0.9719883,"about_ca_system_score_codex":0.00071378663,"about_ca_system_score_gemma":0.0026849722,"threshold_uncertainty_score":0.99951774},"labels":[],"label_agreement":null},{"id":"W4409584925","doi":"10.3390/curroncol32040238","title":"Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple Myeloma","year":2025,"lang":"en","type":"review","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke; McGill University Health Centre; Cégep de Lévis; Jewish General Hospital; Hôpital Charles-Le Moyne; Centre Hospitalier de l’Université de Montréal; Hôpital du Sacré-Cœur de Montréal; Hôpital Maisonneuve-Rosemont; Centre hospitalier universitaire de Québec","funders":"","keywords":"Medicine; Multiple myeloma; Cytokine release syndrome; Immunotherapy; Oncology; T cell; Internal medicine; Intensive care medicine; Immunology; Immune system; Chimeric antigen receptor","score_opus":0.2263227285703102,"score_gpt":0.46895234177489103,"score_spread":0.24262961320458085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409584925","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00042393242,0.98837703,0.000049830483,0.00007477875,0.0016617408,0.0046469006,0.0002375862,0.000047471887,0.0044807326],"genre_scores_gemma":[0.00018966377,0.9926254,0.00024115118,0.000018389372,0.00055789604,0.0010261135,0.00027528225,0.000075424185,0.0049906503],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9969045,0.0006586797,0.0008046702,0.0007657606,0.00037848955,0.00048788593],"domain_scores_gemma":[0.9940718,0.0041379603,0.00042213802,0.0007158228,0.0005170974,0.00013519973],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00062819803,0.00050685764,0.0026828311,0.00083715556,0.00009738209,0.000011948964,0.00034732904,0.00051517703,0.00088455493],"category_scores_gemma":[0.00047496328,0.00038599328,0.0012133253,0.00039643058,0.0002837767,0.000022795366,0.00013474852,0.0012129843,0.000049378872],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00060958724,0.0024197446,0.00002651571,0.029930169,0.0003963657,0.000008580554,0.0019200078,2.0681772e-7,0.000082242244,0.00016715712,0.005416906,0.9590225],"study_design_scores_gemma":[0.0023450619,0.0031927044,0.000012210958,0.0077220453,0.0006613497,0.000007161907,0.0014113956,0.000008362145,0.00008329813,0.0000147349265,0.9842861,0.00025552505],"about_ca_topic_score_codex":0.000004967609,"about_ca_topic_score_gemma":0.0000059733748,"teacher_disagreement_score":0.97886926,"about_ca_system_score_codex":0.0010889705,"about_ca_system_score_gemma":0.0015341251,"threshold_uncertainty_score":0.9998592},"labels":[],"label_agreement":null},{"id":"W4409613957","doi":"10.1136/jitc-2025-011829","title":"MARC, a novel modular chimeric antigen receptor, improves T cell-based cancer immunotherapies by preventing early T cell exhaustion and enhancing persistence","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Aptose Biosciences (Canada); Hôpital Maisonneuve-Rosemont; Université de Montréal; Institute for Research in Immunology and Cancer","funders":"Stem Cell Network; Institute of Infection and Immunity; Leukemia and Lymphoma Society of Canada; Cancer Research Society","keywords":"Chimeric antigen receptor; Receptor; Immune system; T cell; Cancer immunotherapy; Modular design; Immunotherapy; Cancer research; Antigen; Biology; Immunology; Medicine; Computer science; Internal medicine","score_opus":0.015918664833253077,"score_gpt":0.3158186075849806,"score_spread":0.2998999427517275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409613957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.874361,0.1169912,0.0057083257,0.0010255476,0.00062661845,0.0010435521,0.00004995073,0.000026697324,0.00016713113],"genre_scores_gemma":[0.9161602,0.05024198,0.004599048,0.00068937265,0.00028835758,0.00029390055,0.00001182617,0.0001282521,0.027587028],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99779004,0.00006767242,0.00070807006,0.00038530366,0.00050044665,0.00054847467],"domain_scores_gemma":[0.9984477,0.00014629861,0.0005149879,0.00032344164,0.00046277323,0.000104776984],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007505837,0.00032716285,0.00063916825,0.0003470987,0.0003690508,0.00011446234,0.00026057064,0.0001663397,0.00092064595],"category_scores_gemma":[0.000023308497,0.00029243962,0.00039537155,0.00039605514,0.00019266957,0.0002180485,0.00002968372,0.0004955007,7.1225827e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030294661,0.00025248225,0.0037729198,0.00051739026,0.00054453145,6.846321e-7,0.00091046613,0.00008222,0.9130809,0.0000017265877,0.00047208622,0.07733517],"study_design_scores_gemma":[0.008425809,0.0008792044,0.007906012,0.0011262785,0.00013558858,0.000005995719,0.00041800857,0.0009144432,0.93682677,0.000030889,0.043033727,0.00029730293],"about_ca_topic_score_codex":0.00096384244,"about_ca_topic_score_gemma":0.000025175754,"teacher_disagreement_score":0.07703786,"about_ca_system_score_codex":0.00039312537,"about_ca_system_score_gemma":0.00068181806,"threshold_uncertainty_score":0.99999267},"labels":[],"label_agreement":null},{"id":"W4409627226","doi":"10.1158/1538-7445.am2025-3506","title":"Abstract 3506: Clinic enabling development of a TCR-Ab half life extended T cell engager against a novel solid tumor target","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Discovery Centre","funders":"","keywords":"T-cell receptor; Solid tumor; Cancer research; T cell; Medicine; Chemistry; Cancer; Immunology; Internal medicine; Immune system","score_opus":0.13136231778522853,"score_gpt":0.4501290994282303,"score_spread":0.31876678164300176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409627226","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9563498,0.0046979375,0.0002665738,0.0014114456,0.00030516807,0.0018401332,0.000031252803,0.00007597024,0.035021752],"genre_scores_gemma":[0.9562065,0.0011903791,0.0022738816,0.00055788615,0.0003626798,0.0005736773,0.000037183025,0.00008915509,0.03870867],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99477035,0.0002460631,0.000991155,0.00080776843,0.0018596499,0.0013250349],"domain_scores_gemma":[0.9962388,0.00095142564,0.00014215504,0.0008932712,0.0012163355,0.00055799197],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005572912,0.00029481345,0.00075009384,0.0010884955,0.00038149595,0.000075904776,0.00060733705,0.00019745009,0.008470994],"category_scores_gemma":[0.0013558028,0.0002685159,0.00021930321,0.0015270063,0.0004044854,0.00010402453,0.00043407088,0.0022873322,0.00021132712],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016931526,0.00094490446,0.00091985,0.0014797158,0.00028754416,0.00009595878,0.0012222019,0.000030880314,0.9664978,0.000023027435,0.006360781,0.020444203],"study_design_scores_gemma":[0.005043201,0.000214854,0.009146416,0.0011029975,0.000023785848,0.0000031874472,0.0016185603,0.00019805627,0.82684445,0.000050459108,0.15547235,0.0002816557],"about_ca_topic_score_codex":0.00032145774,"about_ca_topic_score_gemma":0.000076300756,"teacher_disagreement_score":0.14911157,"about_ca_system_score_codex":0.00092281343,"about_ca_system_score_gemma":0.009672462,"threshold_uncertainty_score":0.9999767},"labels":[],"label_agreement":null},{"id":"W4409629821","doi":"10.1158/1538-7445.am2025-6106","title":"Abstract 6106: A regulated, cell-intrinsic cytokine engineering strategy to enhance the in vitro and in vivo persistence of iPSC-derived CAR-T cell therapies","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"iCo Therapeutics (Canada)","funders":"","keywords":"In vivo; Persistence (discontinuity); Cytokine; In vitro; Cell; Immunology; Cell biology; Biology; Cancer research; Medicine; Genetics; Engineering","score_opus":0.038009788108527766,"score_gpt":0.35332950943719427,"score_spread":0.3153197213286665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409629821","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885122,0.0062818048,0.000007407329,0.0015488683,0.00004702254,0.0012067911,0.00001611265,0.000016761243,0.0023630331],"genre_scores_gemma":[0.9931024,0.0023835714,0.000056656023,0.00006385124,0.000057464236,0.00025422248,0.000001921797,0.000030739793,0.004049216],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976377,0.0001438849,0.00036542708,0.00047850425,0.00066950783,0.000704968],"domain_scores_gemma":[0.99849874,0.00048238458,0.000037197486,0.00055128447,0.00028865677,0.00014174404],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013607955,0.00018661651,0.00041105924,0.0007486164,0.00006875302,0.000049105292,0.00035601697,0.00011895778,0.0004958514],"category_scores_gemma":[0.000112466,0.0001486962,0.00006463437,0.0017073919,0.00025183766,0.00006968921,0.00017913728,0.0009799119,0.000004254636],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020021817,0.0001072885,0.0008538513,0.00056485157,0.000032908465,0.00005643421,0.0017905295,0.00062528433,0.97997516,0.000008878786,0.00015084833,0.013831797],"study_design_scores_gemma":[0.0011848338,0.0002185922,0.02086802,0.00046274814,0.0000068462036,0.0000026481407,0.00185281,0.00031563168,0.9737916,0.000020690026,0.0011592321,0.00011636879],"about_ca_topic_score_codex":0.0032163693,"about_ca_topic_score_gemma":0.0008398945,"teacher_disagreement_score":0.020014169,"about_ca_system_score_codex":0.000497698,"about_ca_system_score_gemma":0.0006055187,"threshold_uncertainty_score":0.6063655},"labels":[],"label_agreement":null},{"id":"W4409632782","doi":"10.1158/1538-7445.am2025-5815","title":"Abstract 5815: Both CD4 and CD8 T cells mediate antitumor immunity to prevent development of neoantigen-expressing autochthonous sarcomas","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Immunity; CD8; Cytotoxic T cell; Immunology; Cancer research; Biology; Medicine; Immune system; Genetics; In vitro","score_opus":0.07726887156536029,"score_gpt":0.4268249320366299,"score_spread":0.34955606047126964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409632782","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98808426,0.0037141147,0.00010155415,0.0008893145,0.00016958987,0.0015937425,0.000018748331,0.000040261686,0.0053883973],"genre_scores_gemma":[0.9857918,0.0012400739,0.0019018888,0.00010798881,0.00011243683,0.00024672115,0.000011546856,0.000045247412,0.010542268],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99666274,0.00023078117,0.00053710886,0.00051280577,0.0011826981,0.00087384303],"domain_scores_gemma":[0.998008,0.00034828318,0.00006896201,0.00068878575,0.00048195617,0.00040400404],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0026395996,0.00021249041,0.00050842727,0.00074069644,0.0003497584,0.00008045326,0.0004085613,0.00012016913,0.0017350287],"category_scores_gemma":[0.00019784275,0.00019271972,0.00007758926,0.0009356404,0.00034892323,0.00008318508,0.0005797546,0.00090081216,0.000040187973],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00062081974,0.00031008144,0.0016023448,0.00081929006,0.00014484387,0.00004861114,0.0019851988,0.000011672063,0.8903503,0.000022997869,0.0017973868,0.10228649],"study_design_scores_gemma":[0.0010623074,0.00016801053,0.059202727,0.001173229,0.000015662066,0.0000046231903,0.0004257552,0.000031312105,0.8982317,0.000065866916,0.03945804,0.00016078628],"about_ca_topic_score_codex":0.0010519039,"about_ca_topic_score_gemma":0.00021952052,"teacher_disagreement_score":0.102125704,"about_ca_system_score_codex":0.00057249767,"about_ca_system_score_gemma":0.0028083962,"threshold_uncertainty_score":0.9991775},"labels":[],"label_agreement":null},{"id":"W4409633840","doi":"10.1158/1538-7445.am2025-6012","title":"Abstract 6012: PSMA x CD3 T-cell engagers show preclinical efficacy for the treatment of prostate cancer","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AbCellera (Canada)","funders":"","keywords":"Prostate cancer; Medicine; Cancer; Prostate; Oncology; Internal medicine; Cancer research","score_opus":0.19960217398232777,"score_gpt":0.5205241300861528,"score_spread":0.32092195610382507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409633840","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95824,0.018740743,0.000013082288,0.011072699,0.00039393845,0.0061704796,0.00015763912,0.000038650833,0.005172779],"genre_scores_gemma":[0.86984545,0.02836565,0.00005578994,0.00012648199,0.00049855537,0.0037672217,0.000018795363,0.00005610223,0.09726593],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970154,0.00022982084,0.00044587284,0.0005505392,0.00090108666,0.0008572914],"domain_scores_gemma":[0.9936277,0.004475958,0.000067822344,0.0008543321,0.00075687305,0.00021727236],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020267246,0.00020424937,0.0004820664,0.00026891517,0.00031163442,0.00005276607,0.00038375112,0.0001515821,0.0039070523],"category_scores_gemma":[0.00039590264,0.00012915443,0.00031860094,0.00074023666,0.0006160886,0.000042371354,0.00007420479,0.0007547029,0.000020031817],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013074335,0.0021226273,0.015716475,0.001083702,0.0009010728,0.000025695914,0.0023663323,0.00019054639,0.33011472,0.00008152869,0.03194273,0.6023802],"study_design_scores_gemma":[0.01152804,0.0019142042,0.028108502,0.00044263265,0.00016310869,0.0000011864466,0.0007119989,0.00027411207,0.39034444,0.00009774616,0.56624323,0.00017081994],"about_ca_topic_score_codex":0.0023672455,"about_ca_topic_score_gemma":0.0005820974,"teacher_disagreement_score":0.60220945,"about_ca_system_score_codex":0.0009593947,"about_ca_system_score_gemma":0.0023372811,"threshold_uncertainty_score":0.9970035},"labels":[],"label_agreement":null},{"id":"W4409634212","doi":"10.1158/1538-7445.am2025-6114","title":"Abstract 6114: Engineering novel synNotch CAR T cells to precisely and effectively target medulloblastoma","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medulloblastoma; Cancer research; Neuroscience; Medicine; Biology","score_opus":0.036485709218601246,"score_gpt":0.38557038107882885,"score_spread":0.3490846718602276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409634212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877439,0.0013325192,0.00048592067,0.0017602713,0.00029585717,0.0020289565,0.000055162443,0.00008826864,0.0062091216],"genre_scores_gemma":[0.9830528,0.000343822,0.0008148994,0.00017885312,0.000317063,0.0006974428,0.0000056651334,0.00007153564,0.014517914],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99701583,0.0000734386,0.00025695458,0.00066665426,0.0010295558,0.00095755176],"domain_scores_gemma":[0.997632,0.000762636,0.000020120011,0.0005060658,0.0005599008,0.00051923795],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015605754,0.00022741634,0.00043466617,0.0008482089,0.00015323685,0.00010043764,0.000294446,0.00016560446,0.0010839779],"category_scores_gemma":[0.0004694707,0.00021306172,0.00008505731,0.0013150322,0.00015318269,0.00008367001,0.00030296604,0.0010923969,0.0000888941],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00096084067,0.000106975574,0.0010238135,0.000698554,0.00017517163,0.000038429618,0.000338457,0.00026234126,0.97628367,0.000098653945,0.00785123,0.012161871],"study_design_scores_gemma":[0.001985679,0.00040811623,0.04200686,0.0009504592,0.000019671092,0.000010889751,0.000116491225,0.0005094226,0.8511324,0.000036238675,0.10260457,0.00021919498],"about_ca_topic_score_codex":0.0007848333,"about_ca_topic_score_gemma":0.000060400027,"teacher_disagreement_score":0.12515125,"about_ca_system_score_codex":0.0008027084,"about_ca_system_score_gemma":0.0007187133,"threshold_uncertainty_score":0.9998292},"labels":[],"label_agreement":null},{"id":"W4409645431","doi":"10.1093/gpbjnl/qzaf033","title":"TRAIT: A Comprehensive Database for T-cell Receptor–antigen Interactions","year":2025,"lang":"en","type":"article","venue":"Genomics Proteomics & Bioinformatics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Artificial Intelligence in Medicine (Canada)","funders":"Zhejiang University; Natural Science Foundation of Zhejiang Province; National Natural Science Foundation of China","keywords":"T-cell receptor; Antigen; Biology; Trait; Computational biology; T cell; Binding affinities; Chimeric antigen receptor; Database; Immunology; Receptor; Computer science; Immune system; Genetics","score_opus":0.03631192317494432,"score_gpt":0.32680743656705397,"score_spread":0.29049551339210966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409645431","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.66563016,0.00040629104,0.27498084,0.0035869454,0.0015291066,0.014125675,0.0020101434,0.00029022165,0.03744063],"genre_scores_gemma":[0.018910967,0.0015972479,0.9409082,0.0042466545,0.000513168,0.0009764459,0.002675397,0.00014754717,0.030024393],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980552,0.000029142935,0.00081933266,0.0002838852,0.00023783931,0.0005745789],"domain_scores_gemma":[0.9980925,0.00021126402,0.00021803055,0.0008183486,0.00044896078,0.00021093714],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003647166,0.00030586502,0.00050038437,0.0006054639,0.00026321475,0.00012068124,0.00034558607,0.0001598945,0.0003708877],"category_scores_gemma":[0.00010963687,0.000305129,0.00027616307,0.00049341255,0.00014109336,0.00022696804,0.00022555605,0.0005266856,0.0001538635],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015474897,0.00034766787,0.00014004445,0.0013994055,0.00032808352,0.0000031101072,0.0021087374,0.00006245327,0.94242513,0.0014062691,0.021157242,0.029074367],"study_design_scores_gemma":[0.0049655,0.00036858098,0.00008308799,0.00019756718,0.00013306031,0.000038632323,0.0020642255,0.04688156,0.23990196,0.00048199133,0.70450085,0.0003829992],"about_ca_topic_score_codex":0.000027510123,"about_ca_topic_score_gemma":0.000013575634,"teacher_disagreement_score":0.7025232,"about_ca_system_score_codex":0.00050719007,"about_ca_system_score_gemma":0.00083483924,"threshold_uncertainty_score":0.9999401},"labels":[],"label_agreement":null},{"id":"W4409653495","doi":"10.1007/s13402-025-01056-7","title":"State of the art in CAR-based therapy: In vivo CAR production as a revolution in cell-based cancer treatment","year":2025,"lang":"en","type":"review","venue":"Cellular Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Wood Council","funders":"","keywords":"In vivo; Cancer therapy; Cancer; Medicine; Production (economics); Cancer treatment; Internal medicine; Biology; Biotechnology","score_opus":0.05204119636552876,"score_gpt":0.38322254731185706,"score_spread":0.3311813509463283,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409653495","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.021961266,0.9680972,0.0000067055444,0.0007389707,0.00056752877,0.0069356263,0.000040302373,0.000018792345,0.001633615],"genre_scores_gemma":[0.0023998627,0.97908586,0.000031277792,0.00009986177,0.00011991259,0.0020583887,0.00010841482,0.00006170493,0.016034741],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957368,0.0016722812,0.0009785382,0.0007296279,0.00036623213,0.0005165417],"domain_scores_gemma":[0.9982014,0.00034267822,0.00038173044,0.00087674614,0.00012377377,0.000073702264],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009863782,0.00044239144,0.00220156,0.0010657035,0.00003018634,0.000005348782,0.00024916572,0.000493897,0.00061015633],"category_scores_gemma":[0.00011618252,0.00031086002,0.00046146833,0.0016937309,0.00019982667,0.000021187156,0.000041827403,0.00082186825,0.000013121909],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0012701378,0.002467864,0.0015195674,0.01474318,0.00014548926,0.00039943084,0.0005127381,0.0012197847,0.017273799,0.0000032111038,0.00056495034,0.9598799],"study_design_scores_gemma":[0.0046438496,0.0014391409,0.00008101747,0.008941107,0.00023247978,0.000008578517,0.000030590556,0.00013828179,0.019898264,0.000015602094,0.96434194,0.00022912725],"about_ca_topic_score_codex":0.0041635674,"about_ca_topic_score_gemma":0.008614226,"teacher_disagreement_score":0.963777,"about_ca_system_score_codex":0.0072903708,"about_ca_system_score_gemma":0.0102237705,"threshold_uncertainty_score":0.9999344},"labels":[],"label_agreement":null},{"id":"W4409656849","doi":"10.14740/jh2046","title":"Ruxolitinib Is an Effective Therapy for Ciltacabtagene Autoleucel-Associated Parkinsonism in Multiple Myeloma","year":2025,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Ruxolitinib; Multiple myeloma; Parkinsonism; Bortezomib; Oncology; Internal medicine; Myelofibrosis; Disease; Bone marrow","score_opus":0.035472671785467105,"score_gpt":0.3622998982399766,"score_spread":0.3268272264545095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409656849","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923055,0.0019673237,0.0003191566,0.0032966645,0.00031983503,0.0010014498,0.0000107505,0.000020877376,0.00075841363],"genre_scores_gemma":[0.9961657,0.00029106505,0.00062082545,0.0014628674,0.00011240597,0.000070238646,0.000007736852,0.000030023748,0.0012391185],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99801534,0.00032414432,0.00068716577,0.00023570812,0.00027237544,0.0004652341],"domain_scores_gemma":[0.99772716,0.0011187504,0.0002957059,0.0002504366,0.00046044504,0.0001475104],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012276518,0.0001829112,0.00094206113,0.0005843446,0.00007443494,0.000018600691,0.00020779522,0.0002881234,0.00035698642],"category_scores_gemma":[0.00072505686,0.00015030727,0.00034250985,0.00035820244,0.00010496051,0.00008847568,0.000030145899,0.0005384569,0.000004713555],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024708102,0.0047435416,0.31594026,0.0004935824,0.0029967611,0.0015785069,0.0053278212,0.00003341587,0.34947127,0.0018226822,0.012836571,0.28004748],"study_design_scores_gemma":[0.05815776,0.008231909,0.32455957,0.0008067665,0.00019240467,0.0018649435,0.0009828068,0.0042218226,0.48106843,0.0072898553,0.112189084,0.0004346472],"about_ca_topic_score_codex":0.00003885335,"about_ca_topic_score_gemma":0.000051695468,"teacher_disagreement_score":0.27961284,"about_ca_system_score_codex":0.00027506636,"about_ca_system_score_gemma":0.00038325877,"threshold_uncertainty_score":0.61293525},"labels":[],"label_agreement":null},{"id":"W4409690079","doi":"10.1158/1538-7445.am2025-896","title":"Abstract 896: Unleashing the power within: enhancing cancer treatment with invariant natural killer T cells","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Invariant (physics); Cancer; Medicine; Immunology; Mathematics; Internal medicine; Mathematical physics","score_opus":0.05312659537491095,"score_gpt":0.4053088560114074,"score_spread":0.3521822606364965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409690079","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95558,0.007939359,0.000020080195,0.013902644,0.0012575765,0.0022491014,0.000011858861,0.000076904085,0.018962488],"genre_scores_gemma":[0.8726892,0.0019092525,0.000055084744,0.0006546987,0.00036241356,0.00080233044,0.000006534499,0.00006125458,0.12345924],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99617213,0.00024097165,0.00035005188,0.0006785502,0.00147562,0.0010826706],"domain_scores_gemma":[0.99742943,0.000634275,0.00006644489,0.00091890444,0.0006924177,0.00025851474],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015643354,0.00029924244,0.00043358083,0.00038621548,0.00054924784,0.00021505922,0.00044386517,0.00013730717,0.0072087455],"category_scores_gemma":[0.00009303532,0.00016426199,0.00013172172,0.0013001218,0.00048645158,0.00013714585,0.00017328773,0.0016194499,0.00007791831],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033491931,0.00023981398,0.0030674792,0.00024621468,0.0009494622,0.00028873645,0.004129305,0.0001958618,0.9494459,0.00033055226,0.012346842,0.025410641],"study_design_scores_gemma":[0.0059239785,0.0010702257,0.015986044,0.002245019,0.00013367753,0.000030931205,0.003968623,0.00027276226,0.77623487,0.000118801494,0.19356252,0.00045258523],"about_ca_topic_score_codex":0.012115059,"about_ca_topic_score_gemma":0.007718308,"teacher_disagreement_score":0.18121567,"about_ca_system_score_codex":0.0024829817,"about_ca_system_score_gemma":0.003420013,"threshold_uncertainty_score":0.9944633},"labels":[],"label_agreement":null},{"id":"W4409704555","doi":"10.21203/rs.3.rs-5828115/v1","title":"ARM-X: an Adaptable Mesenchymal Stromal Cell-based Vaccination Plaftorm Suitable for Solid Tumors","year":2025,"lang":"en","type":"preprint","venue":"Research Square","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Université de Montréal","funders":"","keywords":"Mesenchymal stem cell; Stromal cell; Vaccination; Cancer research; Medicine; Computer science; Pathology","score_opus":0.08851009591313151,"score_gpt":0.44381167276783184,"score_spread":0.3553015768547003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409704555","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8125577,0.0042370614,0.007956644,0.005332423,0.0014501881,0.03600872,0.0041771014,0.0011122045,0.12716798],"genre_scores_gemma":[0.8803401,0.0001978635,0.0028777553,0.000086547436,0.0012785714,0.0030419624,0.0032404335,0.00018229378,0.10875445],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99083275,0.0008929721,0.0008246615,0.0016941818,0.0034039468,0.0023514633],"domain_scores_gemma":[0.99185264,0.0014794838,0.00018072732,0.0021747868,0.0033974964,0.00091489375],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0060449266,0.00062499515,0.0012046813,0.0020272518,0.0006320315,0.00043292664,0.0010839347,0.00096886774,0.007458065],"category_scores_gemma":[0.0012303985,0.00062049,0.0005711182,0.0010659542,0.00015858776,0.00023370885,0.0010480327,0.00397976,0.00006819426],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.059438795,0.032101233,0.05680743,0.15235545,0.003051472,0.0024448487,0.0064225476,0.053876586,0.27616668,0.006959642,0.18556796,0.16480735],"study_design_scores_gemma":[0.026012503,0.020481817,0.022271207,0.007294524,0.00045656846,0.000047011963,0.0063685165,0.35115516,0.4177741,0.005030401,0.1402814,0.0028267826],"about_ca_topic_score_codex":0.0014161804,"about_ca_topic_score_gemma":0.0002718114,"teacher_disagreement_score":0.29727855,"about_ca_system_score_codex":0.0020571228,"about_ca_system_score_gemma":0.0077828076,"threshold_uncertainty_score":0.99962467},"labels":[],"label_agreement":null},{"id":"W4409785815","doi":"10.70962/cis2025abstract.116","title":"Defects in B Cell Differentiation and Antibody Production due to Biallelic TANK Mutation","year":2025,"lang":"en","type":"article","venue":"Journal of Human Immunity","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"ASTER","funders":"","keywords":"Mutation; Antibody; Biology; Genetics; Gene","score_opus":0.024144439485877748,"score_gpt":0.35030058888543264,"score_spread":0.3261561493995549,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409785815","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99776024,0.00023152733,0.00012542048,0.0005600408,0.00016770815,0.00029717054,3.080215e-7,0.000006261563,0.00085130683],"genre_scores_gemma":[0.9982514,0.000093499104,0.00007833722,0.00005847586,0.000101456135,0.0000022955794,0.0000074079026,0.000007591732,0.0013995373],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9990891,0.00017975914,0.00031471983,0.00008419861,0.00021766649,0.000114516886],"domain_scores_gemma":[0.9993915,0.000050912564,0.000120225646,0.00015352515,0.0002292213,0.00005463331],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072833034,0.0000721829,0.0002222219,0.00064240315,0.00009501748,0.000031110798,0.00006439287,0.000048120397,0.000119363845],"category_scores_gemma":[0.00021042833,0.00006403013,0.000049129296,0.0003224297,0.000027848459,0.000105899155,0.00003550231,0.0004116951,0.00000239433],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003465232,0.0002793408,0.022384914,0.00012179144,0.000028538047,0.000034659995,0.0009805184,0.000015226518,0.970214,0.000024036895,0.0001650649,0.0054053813],"study_design_scores_gemma":[0.0017063989,0.0006670682,0.8597377,0.00025764838,0.00004216933,0.00009079639,0.00038146158,0.00002577926,0.13645776,0.00038437487,0.00019390193,0.000054966873],"about_ca_topic_score_codex":0.000100731544,"about_ca_topic_score_gemma":0.00011411824,"teacher_disagreement_score":0.83735275,"about_ca_system_score_codex":0.00015852976,"about_ca_system_score_gemma":0.00008067538,"threshold_uncertainty_score":0.2611073},"labels":[],"label_agreement":null},{"id":"W4409798211","doi":"10.1016/j.jtct.2025.03.011","title":"Cytokine Release Syndrome and Neurotoxicity Following CD19 CAR-T in B-Cell Lymphoma","year":2025,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"National Institute of Environmental Health Sciences; National Cancer Institute","keywords":"Cytokine release syndrome; CD19; Neurotoxicity; Lymphoma; Cytokine; Immunology; Medicine; Cancer research; T cell; Antigen; Chimeric antigen receptor; Internal medicine; Toxicity; Immune system","score_opus":0.014777245316883587,"score_gpt":0.2716196132885174,"score_spread":0.25684236797163384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409798211","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99429613,0.0018901641,0.00045084808,0.00040784627,0.00006789664,0.00071000005,0.000008697171,0.000045623623,0.0021227717],"genre_scores_gemma":[0.98967254,0.006863708,0.000070123155,0.0006641983,0.000014457361,0.00003618979,0.000049286056,0.000021981126,0.0026075013],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988772,0.00011173909,0.00023796113,0.00032204948,0.00021325385,0.00023777192],"domain_scores_gemma":[0.9995773,0.00008572263,0.000025774016,0.00017783947,0.000021353017,0.000111997855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024509418,0.0001692807,0.00028799337,0.00025351014,0.00007815616,0.000033045744,0.00005708414,0.00010017408,0.00013145038],"category_scores_gemma":[0.000003999107,0.00015740859,0.00007875404,0.00030193856,0.000057700487,0.00007293193,0.0000069760795,0.00015388726,0.000003960175],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001647363,0.00028847952,0.020575067,0.00029190406,0.000059401205,0.0012403869,0.0008543532,0.0000031291743,0.953839,0.00009216862,0.000008717126,0.0211],"study_design_scores_gemma":[0.04135805,0.0008122021,0.1618972,0.0003931832,0.00013852652,0.00038569,0.00031232001,0.0010336703,0.78794336,0.00031512778,0.004994617,0.00041605876],"about_ca_topic_score_codex":0.00017702895,"about_ca_topic_score_gemma":0.000027393036,"teacher_disagreement_score":0.16589569,"about_ca_system_score_codex":0.00003707342,"about_ca_system_score_gemma":0.0000674258,"threshold_uncertainty_score":0.6418936},"labels":[],"label_agreement":null},{"id":"W4409821534","doi":"10.1158/1538-7445.am2025-lb037","title":"Abstract LB037: CD28 drives CAR T cell responses in multiple myeloma","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Multiple myeloma; Medicine; Cancer research; Internal medicine","score_opus":0.10052210901345007,"score_gpt":0.4490982665798321,"score_spread":0.34857615756638205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409821534","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9502745,0.0037691307,0.0000040210703,0.003162273,0.00016364513,0.0011407372,0.000030329606,0.000055716777,0.041399624],"genre_scores_gemma":[0.8917468,0.00186073,0.0000610128,0.00017049085,0.00020531919,0.00040353052,0.000011324196,0.000042765856,0.10549799],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99648243,0.00038065482,0.00035812406,0.0006165483,0.0011153657,0.0010468892],"domain_scores_gemma":[0.99697536,0.0014602749,0.000029688446,0.000799664,0.00046901352,0.00026601704],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0020532238,0.00018909015,0.0003911549,0.0013060392,0.0001901432,0.00007453417,0.0004272501,0.00019709431,0.0050330884],"category_scores_gemma":[0.00077259325,0.0001740574,0.0001201533,0.0017115852,0.00047675188,0.00009603504,0.00024953604,0.0015231863,0.00020405793],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038966802,0.00023502174,0.10027845,0.00040499304,0.000049446535,0.00033190823,0.0005919769,0.000015272282,0.85360736,0.00006528921,0.010126315,0.030397277],"study_design_scores_gemma":[0.0037189098,0.00021493791,0.37581795,0.0004928588,0.000008579143,0.000004436001,0.0009649149,0.00009125465,0.46600947,0.00016157923,0.15234704,0.00016806356],"about_ca_topic_score_codex":0.0030782898,"about_ca_topic_score_gemma":0.0014168156,"teacher_disagreement_score":0.38759792,"about_ca_system_score_codex":0.0010047267,"about_ca_system_score_gemma":0.002011096,"threshold_uncertainty_score":0.99587643},"labels":[],"label_agreement":null},{"id":"W4409831621","doi":"10.14740/jh2029","title":"A Novel Therapeutic Strategy for Central Nervous System Lymphoma: Integrating Chimeric Antigen Receptor T-Cell Therapy and Gamma Knife Radiation","year":2025,"lang":"en","type":"article","venue":"Journal of Hematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Central nervous system; Chimeric antigen receptor; Lymphoma; Radiation therapy; Antigen; Cancer research; Immunology; Immunotherapy; Internal medicine; Immune system","score_opus":0.03339158438928045,"score_gpt":0.31916847033223805,"score_spread":0.2857768859429576,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409831621","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9674335,0.01762162,0.011003149,0.0014089098,0.0005523387,0.00081871665,0.000005536107,0.000026997015,0.0011292099],"genre_scores_gemma":[0.99552286,0.0012502938,0.0019924366,0.0002624426,0.00023073265,0.000017045117,0.000005758189,0.000028569239,0.0006898438],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9984509,0.000116869545,0.0006486385,0.00018956176,0.00021001567,0.00038403634],"domain_scores_gemma":[0.99872917,0.0003235397,0.0003829518,0.00016334558,0.00026847798,0.00013250376],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005147694,0.00018017141,0.0006827937,0.00032269344,0.00009538045,0.000041218063,0.00013374268,0.0001647198,0.00009038756],"category_scores_gemma":[0.00006395288,0.00013305241,0.0001886804,0.00024682644,0.00008208892,0.0000808786,0.000016707629,0.00022829436,0.0000021276],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033475587,0.00053964887,0.009926524,0.0006913156,0.0007042208,0.000059938357,0.00069517293,0.000017662764,0.56364304,0.004184601,0.0010733621,0.41511694],"study_design_scores_gemma":[0.097449414,0.015403977,0.14982076,0.0029309967,0.000921285,0.03161481,0.018089313,0.024966905,0.5534204,0.0012813177,0.10272034,0.0013804773],"about_ca_topic_score_codex":0.000030147012,"about_ca_topic_score_gemma":0.0000041172307,"teacher_disagreement_score":0.41373646,"about_ca_system_score_codex":0.0001906133,"about_ca_system_score_gemma":0.00056395645,"threshold_uncertainty_score":0.542572},"labels":[],"label_agreement":null},{"id":"W4409879933","doi":"10.1016/j.critrevonc.2025.104751","title":"Revolutionizing immunotherapy: The next frontier in CAR T-cell engineering","year":2025,"lang":"en","type":"review","venue":"Critical Reviews in Oncology/Hematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Mount Royal University","keywords":"Chimeric antigen receptor; Immunotherapy; Tumor microenvironment; Cell therapy; Cancer immunotherapy; Medicine; Cytokine release syndrome; Cancer; T cell; Clinical trial; Immunology; Cancer research; Biology; Cell; Immune system; Internal medicine","score_opus":0.09647313472189277,"score_gpt":0.4360006391393491,"score_spread":0.3395275044174563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409879933","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000004688399,0.9834156,0.0002797546,0.0016436706,0.0010704069,0.004254344,0.0000073533215,0.00005194241,0.009272237],"genre_scores_gemma":[0.000009996786,0.9918429,0.0018867962,0.00084100675,0.00024773186,0.002244036,0.00003911028,0.00010372026,0.0027846934],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9924005,0.0022978503,0.002671908,0.0010096991,0.00031157152,0.00130847],"domain_scores_gemma":[0.9908478,0.007098333,0.000247242,0.0014686999,0.00013686894,0.00020103013],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.003631167,0.0007829797,0.0073397704,0.00094503735,0.000092450915,0.00003574734,0.0008920748,0.0015828379,0.0014306204],"category_scores_gemma":[0.007786778,0.00054754235,0.0010954558,0.0016072132,0.0005679201,0.000081408376,0.0003486179,0.0039444407,0.0003397108],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000050409737,0.00037787302,0.00004505628,0.05164036,0.00008332484,0.0006782036,0.00009874298,2.9200604e-7,0.000027862072,0.00712942,0.004843087,0.9350254],"study_design_scores_gemma":[0.0008666306,0.00018188245,0.000004532856,0.05380655,0.00034747508,0.0009234315,0.000043391123,0.00004418519,0.000004426256,0.00020184499,0.94321865,0.00035700062],"about_ca_topic_score_codex":0.000037770442,"about_ca_topic_score_gemma":0.000045856505,"teacher_disagreement_score":0.93837553,"about_ca_system_score_codex":0.0019096911,"about_ca_system_score_gemma":0.0018433827,"threshold_uncertainty_score":0.9997133},"labels":[],"label_agreement":null},{"id":"W4409907906","doi":"10.1158/2159-8290.cd-24-1465","title":"Evolving CAR T-Cell Therapy to Overcome the Barriers in Treating Pediatric Central Nervous System Tumors","year":2025,"lang":"en","type":"review","venue":"Cancer Discovery","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Stand Up To Cancer; National Cancer Institute; National Institutes of Health; Stand Up To Cancer Canada; Washington Research Foundation; American Association for Cancer Research","keywords":"Central nervous system; Medicine; Cell; Bioinformatics; Computational biology; Neuroscience; Cancer research; Biology; Genetics","score_opus":0.02895395773494304,"score_gpt":0.3410489312697332,"score_spread":0.31209497353479015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409907906","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.005327888,0.9852659,0.000013146218,0.000081482845,0.00093995646,0.0038037607,0.00019533506,0.00007115189,0.004301368],"genre_scores_gemma":[0.0027239674,0.9768126,0.000011021421,0.00021189524,0.001703545,0.0012182996,0.00005213349,0.00014384408,0.017122693],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9959301,0.00045607015,0.00090352143,0.0008782287,0.00073408143,0.001098],"domain_scores_gemma":[0.9975576,0.00065306184,0.00026754962,0.0010500153,0.0000837878,0.00038798974],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00056326,0.0006947009,0.0022848784,0.0006735861,0.00016668988,0.00021580499,0.00066036655,0.00028818336,0.00046928856],"category_scores_gemma":[0.00015174432,0.00045043448,0.00087153475,0.0020406644,0.00006523318,0.00016708397,0.00019357952,0.0011329395,0.00002035931],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002669707,0.000085617066,0.009057046,0.08400832,0.00039679994,0.00041987197,0.0014398486,0.00014129339,0.00005562412,0.000044720127,0.003748936,0.90033495],"study_design_scores_gemma":[0.0031447888,0.00039429896,0.0021401062,0.0778644,0.0018424987,0.000090505535,0.0020563204,0.00006221157,0.00004989444,0.000005221301,0.91091007,0.0014396694],"about_ca_topic_score_codex":0.0020834205,"about_ca_topic_score_gemma":0.00012455713,"teacher_disagreement_score":0.9071611,"about_ca_system_score_codex":0.004052016,"about_ca_system_score_gemma":0.005413055,"threshold_uncertainty_score":0.9997947},"labels":[],"label_agreement":null},{"id":"W4409909460","doi":"10.1016/j.jcyt.2025.03.418","title":"DEVELOPMENT OF ROBUST T CELL MANUFACTURING PROTOCOLS IN BIOREACTORS USING CGMP-COMPLIANT ANCILLARY REAGENTS","year":2025,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stemcell Technologies","funders":"","keywords":"Bioreactor; Biochemical engineering; Computer science; Chemistry; Engineering","score_opus":0.09941409715983572,"score_gpt":0.371884300204655,"score_spread":0.2724702030448193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409909460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860936,0.00013527973,0.0011600185,0.00006245014,0.000059012993,0.008371159,0.0000030968245,0.000036030793,0.00407936],"genre_scores_gemma":[0.93755084,0.00014168564,0.05412945,0.0005233343,0.00010485604,0.0021801607,0.000023354956,0.00011998685,0.005226324],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998315,0.000056274832,0.0005261979,0.00033580736,0.00037540423,0.00039133578],"domain_scores_gemma":[0.99926174,0.00004532223,0.000104229584,0.00043279413,0.00006465417,0.00009125627],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004421251,0.00020386561,0.0004369155,0.0004643741,0.00005999943,0.000018107074,0.00018287697,0.00012340856,0.00071172667],"category_scores_gemma":[0.000009743906,0.00018105835,0.000091292975,0.00037114412,0.000066425266,0.000052424,0.000053496937,0.00024409458,0.000008566219],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00068901596,0.0003905367,0.019096121,0.00040569814,0.00007081734,0.000038212245,0.0007932372,0.00005926231,0.9282502,0.0000043565224,0.00006601347,0.050136533],"study_design_scores_gemma":[0.0031661082,0.00008179297,0.036713134,0.00070938386,0.000007026418,0.000005969176,0.00015704357,0.00030135422,0.93619126,0.000015813534,0.022501362,0.00014976671],"about_ca_topic_score_codex":0.00007372642,"about_ca_topic_score_gemma":0.000023754481,"teacher_disagreement_score":0.052969433,"about_ca_system_score_codex":0.00048818497,"about_ca_system_score_gemma":0.0005467084,"threshold_uncertainty_score":0.7792908},"labels":[],"label_agreement":null},{"id":"W4409917909","doi":"10.1101/2025.04.25.650551","title":"Performance of a Modular Robotic Cluster Matches Skilled Human Operators for Complex Cell Therapy Manufacturing Tasks","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Computer science; Manufacturing engineering; Artificial intelligence; Engineering","score_opus":0.03188270739536163,"score_gpt":0.28156022270684755,"score_spread":0.2496775153114859,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409917909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993,0.000764627,0.00067445583,0.00023419349,0.0005084647,0.0043051313,0.00018025633,0.00024489604,0.000087987384],"genre_scores_gemma":[0.9904519,0.0007568666,0.0066389544,0.000343203,0.00042671937,0.00070079736,0.000004461534,0.00021609475,0.00046101873],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99592626,0.00016992804,0.0010218296,0.0012415627,0.00073268183,0.0009077279],"domain_scores_gemma":[0.9961611,0.00015368567,0.0004412189,0.0021318574,0.0007798237,0.00033232744],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00096360047,0.0008459806,0.001594917,0.00070325757,0.00026799284,0.00013179993,0.00082289433,0.0007046051,0.00051649706],"category_scores_gemma":[0.000057124074,0.00082102657,0.00052266306,0.00037573738,0.00023989129,0.00011344993,0.00058308727,0.0010793826,0.00001614032],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00067521434,0.0004965057,0.0058661303,0.0047206054,0.0005778741,0.000015511376,0.0000526201,0.0017728206,0.9854541,0.00002689028,0.00032485076,0.000016881531],"study_design_scores_gemma":[0.0045825006,0.00047117102,0.04779726,0.0011063503,0.00021892227,4.1660392e-8,0.0000087890085,0.0074828495,0.93393016,0.0000013387513,0.003671896,0.0007287295],"about_ca_topic_score_codex":0.00008798454,"about_ca_topic_score_gemma":0.0000021749227,"teacher_disagreement_score":0.051523943,"about_ca_system_score_codex":0.0004869943,"about_ca_system_score_gemma":0.00083086145,"threshold_uncertainty_score":0.99942404},"labels":[],"label_agreement":null},{"id":"W4409980751","doi":"10.4103/abr.abr_531_23","title":"CAR-T Cell Therapy: Managing Side Effects and Overcoming Challenges","year":2025,"lang":"en","type":"review","venue":"Advanced Biomedical Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Trois-Rivières","funders":"","keywords":"Chimeric antigen receptor; Medicine; Cytokine release syndrome; Side effect (computer science); Clinical trial; Toxicity; Cancer; Intensive care medicine; Immunotherapy; Bioinformatics; Oncology; Internal medicine","score_opus":0.10627265928497447,"score_gpt":0.46237238823262217,"score_spread":0.3560997289476477,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409980751","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00004010004,0.9731093,0.000027854712,0.0010575409,0.0002638403,0.0036663883,0.000017078091,0.00011780445,0.02170006],"genre_scores_gemma":[0.000039856823,0.9796571,0.00047638174,0.00010336512,0.0005197492,0.00070645765,0.00010173377,0.00014937813,0.018245978],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9919328,0.0012803642,0.0007458066,0.0015201563,0.0027686895,0.0017521812],"domain_scores_gemma":[0.9884605,0.008828111,0.00012030988,0.0012816952,0.000302131,0.0010072661],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0033821443,0.0006871537,0.0026585467,0.0020997643,0.000306819,0.00009203382,0.00069976534,0.00082891365,0.00030116198],"category_scores_gemma":[0.0017999844,0.00050978665,0.00051297736,0.0019481798,0.0010465041,0.00010169623,0.000980646,0.0036777332,0.000104303195],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016418658,0.00022114147,0.0000010084291,0.09841154,0.00023967911,0.00068210263,0.00008091641,1.766976e-8,0.0010045893,0.00009619398,0.00038574074,0.8987129],"study_design_scores_gemma":[0.0020412486,0.0009645683,0.000010544605,0.037276927,0.00013757155,0.00007406804,0.00010522546,0.000008129316,0.00018189267,0.0004072515,0.95842856,0.0003639984],"about_ca_topic_score_codex":0.00006341506,"about_ca_topic_score_gemma":0.000007453514,"teacher_disagreement_score":0.95804286,"about_ca_system_score_codex":0.00063390174,"about_ca_system_score_gemma":0.0015510384,"threshold_uncertainty_score":0.99973536},"labels":[],"label_agreement":null},{"id":"W4409987547","doi":"10.58931/cht.2025.4164","title":"Central Nervous System Relapse of Aggressive B-cell Lymphoma: Insights Into Current Treatment Approaches","year":2025,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Royal College of Pathologists of Australasia","keywords":"Lymphoma; Central nervous system; Medicine; Current (fluid); Aggressive lymphoma; Oncology; Neuroscience; Intensive care medicine; Internal medicine; Biology; Rituximab; Engineering","score_opus":0.02649810773108343,"score_gpt":0.2737271228354629,"score_spread":0.24722901510437947,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409987547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9254099,0.036252823,0.000054425425,0.0013506125,0.00091755856,0.0013287979,0.000021343696,0.00006663483,0.0345979],"genre_scores_gemma":[0.99450094,0.0003145274,0.000087369735,0.00009275069,0.0000670024,0.00013274695,0.00006447192,0.000028671235,0.0047115213],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980838,0.00016528356,0.00043531298,0.00045120547,0.00018158797,0.000682834],"domain_scores_gemma":[0.9982103,0.00013204996,0.00019545003,0.0006476239,0.00011977395,0.0006947945],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000090691814,0.00026683378,0.000761888,0.00064923504,0.00013002924,0.000011719085,0.00020061088,0.000262291,0.00017077193],"category_scores_gemma":[0.00008131847,0.00022265402,0.00019194392,0.00043103143,0.00025961184,0.000032564672,0.000038651437,0.00016926556,0.000038580863],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020963426,0.004450542,0.1445756,0.012431734,0.0029565878,0.013491542,0.024109691,0.000083878425,0.005551415,0.17031817,0.038493067,0.58144146],"study_design_scores_gemma":[0.041776616,0.002697945,0.029636092,0.0058345883,0.0017324365,0.003332846,0.011084614,0.0048576766,0.283839,0.0015787262,0.6118532,0.0017762595],"about_ca_topic_score_codex":0.02782015,"about_ca_topic_score_gemma":0.046424117,"teacher_disagreement_score":0.5796652,"about_ca_system_score_codex":0.0023373729,"about_ca_system_score_gemma":0.0031240254,"threshold_uncertainty_score":0.97865367},"labels":[],"label_agreement":null},{"id":"W4410031891","doi":"10.1080/13696998.2025.2498853","title":"Axicabtagene ciloleucel compared to standard of care in Canadian patients with relapsed or refractory large B-cell lymphoma: a cost-effectiveness analysis of the ZUMA-7 trial","year":2025,"lang":"en","type":"article","venue":"Journal of Medical Economics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"EVERSANA (Canada); Spinal Cord Injury BC; University of British Columbia; Princess Margaret Cancer Centre","funders":"Gilead Sciences","keywords":"Medicine; Refractory (planetary science); Standard of care; Lymphoma; Oncology; Internal medicine; Pediatrics; Family medicine","score_opus":0.01783357241865267,"score_gpt":0.319916550429289,"score_spread":0.3020829780106363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410031891","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970963,0.00015821986,0.00004299205,0.0006934057,0.00029635988,0.00092878606,0.00016726593,0.0000016156323,0.0006150792],"genre_scores_gemma":[0.99932945,0.00012259788,0.00004955372,0.00029380256,0.000050399336,0.000011557677,0.000015181348,0.000014358617,0.0001131052],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99766827,0.00027760738,0.00091056677,0.00017338057,0.00065921247,0.00031095627],"domain_scores_gemma":[0.9977395,0.00048364568,0.00039944172,0.0003556725,0.00048698927,0.0005347382],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0020589714,0.00013570723,0.0011905603,0.0009523096,0.000039818624,0.000010833235,0.000400472,0.00018251524,0.0005868387],"category_scores_gemma":[0.0007946139,0.00008540181,0.00029491386,0.00090206636,0.00011291606,0.000043488093,0.00007086544,0.000380615,5.555898e-7],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.59660846,0.0037559138,0.342668,0.0006361875,0.0044657383,0.00015593959,0.0024725734,0.0014303069,0.00025975783,0.0001122922,0.00081724854,0.04661759],"study_design_scores_gemma":[0.47702405,0.010454915,0.43833238,0.001748271,0.002115805,0.000009437954,0.0023450914,0.0018136033,0.003473247,0.000019773503,0.062354993,0.00030843503],"about_ca_topic_score_codex":0.006844186,"about_ca_topic_score_gemma":0.16051035,"teacher_disagreement_score":0.15366615,"about_ca_system_score_codex":0.002151214,"about_ca_system_score_gemma":0.0076337354,"threshold_uncertainty_score":0.99976933},"labels":[],"label_agreement":null},{"id":"W4410144747","doi":"10.1038/s41423-025-01290-x","title":"Harnessing nutrient scarcity for enhanced CAR-T-cell potency and safety in solid tumors","year":2025,"lang":"en","type":"article","venue":"Cellular and Molecular Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Agence Nationale de la Recherche; Université Laval; Institut National de la Santé et de la Recherche Médicale; Fondation de l'Avenir pour la Recherche Médicale Appliquée","keywords":"Tumor microenvironment; Integrated stress response; ATF4; Cancer research; Chimeric antigen receptor; Transcription factor; T cell; Biology; Cell biology; Immunology; Biochemistry; Immune system; Gene; Tumor cells; Translation (biology)","score_opus":0.008415842849811271,"score_gpt":0.27618887928522157,"score_spread":0.2677730364354103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410144747","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95061135,0.016080806,0.02806351,0.0006463,0.00013067693,0.0009608904,0.0000041855237,0.000024896835,0.0034773524],"genre_scores_gemma":[0.99499005,0.0009770824,0.00044857137,0.00028202575,0.000017755874,0.00007268057,0.0000399668,0.000024396832,0.0031474873],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985853,0.0001098279,0.0003139739,0.00044648108,0.00010656661,0.00043787752],"domain_scores_gemma":[0.9993766,0.00007278552,0.00004806789,0.00032719312,0.000101075944,0.00007426881],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003125925,0.00018443979,0.00046358473,0.00028514428,0.000112432324,0.000023581653,0.000094169394,0.00018914301,0.000050021175],"category_scores_gemma":[0.00008690699,0.00018334012,0.000093379516,0.00023603385,0.0002651531,0.00003142891,0.00014011722,0.00030877712,0.000001742558],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009294614,0.00012664954,0.0003679496,0.00021446984,0.00006936354,0.000097686505,0.00025629796,0.000002354284,0.9749068,0.0008381789,0.000013103232,0.022177711],"study_design_scores_gemma":[0.0051501715,0.00031325442,0.0018002957,0.00015095901,0.000055260574,0.000029756317,0.00029224265,0.0002365154,0.9854231,0.0012146818,0.0051797135,0.00015403688],"about_ca_topic_score_codex":0.00009375793,"about_ca_topic_score_gemma":0.000008362462,"teacher_disagreement_score":0.04437865,"about_ca_system_score_codex":0.00009208623,"about_ca_system_score_gemma":0.00018050348,"threshold_uncertainty_score":0.7476393},"labels":[],"label_agreement":null},{"id":"W4410186945","doi":"10.1136/jitc-2024-010073","title":"BCL-2 mutant B7H6-CAR-T cells synergized with venetoclax for treating small cell lung cancer","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario College of Art and Design","funders":"China Postdoctoral Science Foundation; Ministry of Education; National Natural Science Foundation of China","keywords":"Venetoclax; Cancer research; Chimeric antigen receptor; Antigen; In vivo; Medicine; In vitro; Cancer; Immunology; Immunotherapy; Biology; Leukemia; Internal medicine","score_opus":0.01716655082443336,"score_gpt":0.350663301073179,"score_spread":0.33349675024874564,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410186945","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95285577,0.03361381,0.0056747566,0.0015384377,0.0014669687,0.0034364958,0.00013770137,0.000041273284,0.0012347987],"genre_scores_gemma":[0.6814392,0.06951649,0.02511079,0.0032164194,0.0034062774,0.005006645,0.000043119464,0.0006931689,0.21156788],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99783087,0.000054070413,0.00070990616,0.00033605407,0.00043210995,0.00063699024],"domain_scores_gemma":[0.9978214,0.00037856837,0.00046782944,0.00039319397,0.0007966824,0.00014234504],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006369873,0.00033131576,0.00083432975,0.0003335463,0.00029296035,0.00007678623,0.00030438715,0.00019899812,0.0014955876],"category_scores_gemma":[0.000023970386,0.0002451744,0.00053115806,0.0003731858,0.0001264226,0.000084844105,0.00001954325,0.0005903086,4.323326e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016296944,0.00012815968,0.0016797766,0.0006872868,0.0013465793,0.000006569909,0.0005367068,0.0006917116,0.9103865,0.000027388318,0.0016164818,0.06659591],"study_design_scores_gemma":[0.020031216,0.0011540339,0.00035273493,0.0012524583,0.00043241194,0.000023005792,0.00021622845,0.0022276633,0.823386,0.000103744256,0.15055566,0.00026482058],"about_ca_topic_score_codex":0.00058012735,"about_ca_topic_score_gemma":0.00034575642,"teacher_disagreement_score":0.27141654,"about_ca_system_score_codex":0.0009327822,"about_ca_system_score_gemma":0.0023996807,"threshold_uncertainty_score":0.9997921},"labels":[],"label_agreement":null},{"id":"W4410258234","doi":"10.1016/j.coph.2025.102537","title":"Allogeneic double-negative T-cell therapy for acute myeloid leukemia","year":2025,"lang":"en","type":"review","venue":"Current Opinion in Pharmacology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Toronto Rehabilitation Institute; University Health Network","funders":"Canadian Institutes of Health Research; Canadian Cancer Society","keywords":"Myeloid leukemia; Medicine; Leukemia; Virology; Immunology; Cancer research","score_opus":0.1592254208433085,"score_gpt":0.5093296194371574,"score_spread":0.3501041985938489,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410258234","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000020261172,0.97076887,0.00006168318,0.00020849933,0.016887696,0.010453453,0.00024756105,0.0000825608,0.0012693956],"genre_scores_gemma":[0.0000018184148,0.982877,0.00010491214,0.00014398726,0.0023897253,0.006545238,0.0013209715,0.00011547732,0.006500837],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99594617,0.00049259345,0.0011295046,0.0011208347,0.00036838718,0.0009425158],"domain_scores_gemma":[0.9972796,0.0013091812,0.00039726024,0.00049994345,0.00025265804,0.00026140042],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006668237,0.0007867033,0.0028616292,0.0011730146,0.00010040619,0.00002776905,0.0006651659,0.00064775173,0.0028024644],"category_scores_gemma":[0.000031046144,0.0006622828,0.0010261702,0.0010210337,0.00021723533,0.00005970077,0.00023739843,0.0017060848,0.00010105187],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017224556,0.0005014695,0.000007898348,0.03557543,0.0009843983,0.000008319713,0.00008406447,0.0000017137913,0.0004360979,0.000045446763,0.076040015,0.8845927],"study_design_scores_gemma":[0.01454169,0.00055320654,0.0000022880802,0.0066879657,0.0008698561,0.00003411565,0.000007775411,0.000023223256,0.00074191554,0.000054170545,0.9760255,0.0004582542],"about_ca_topic_score_codex":0.000011206721,"about_ca_topic_score_gemma":9.3019554e-7,"teacher_disagreement_score":0.89998555,"about_ca_system_score_codex":0.0016127249,"about_ca_system_score_gemma":0.0042945486,"threshold_uncertainty_score":0.9995828},"labels":[],"label_agreement":null},{"id":"W4410425696","doi":"10.1182/bloodadvances.2024015634","title":"Inequalities in CAR T-cell therapy access for US patients with relapsed/refractory DLBCL: a SEER-Medicare data analysis","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health","funders":"National Cancer Institute; Centers for Disease Control and Prevention; University of California, San Francisco; University of Southern California; California Department of Public Health","keywords":"Medicine; Logistic regression; Psychological intervention; Socioeconomic status; Internal medicine; CAR T-cell therapy; Disadvantaged; Oncology; Population; Cancer; Environmental health; Nursing","score_opus":0.043124636876642905,"score_gpt":0.36626355476231093,"score_spread":0.323138917885668,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410425696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98454195,0.010302749,0.00033012062,0.00037752665,0.00013201815,0.0013675324,0.0003834168,0.000062450155,0.0025022055],"genre_scores_gemma":[0.98770195,0.0030508342,0.0009188739,0.000728022,0.00012831736,0.00026073266,0.001520136,0.00004426238,0.0056468616],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99779505,0.000109547684,0.0004009075,0.00066150597,0.00060409406,0.00042891927],"domain_scores_gemma":[0.99784654,0.00047683698,0.00012952188,0.0011622616,0.0002667843,0.000118064505],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004261207,0.00023851218,0.0006300994,0.00061572465,0.00008211565,0.000057386183,0.00069303904,0.00010320916,0.00025162732],"category_scores_gemma":[0.00019122657,0.00017626102,0.00010957632,0.001418231,0.00014000612,0.00046395257,0.00018015743,0.00029006155,0.0000017441284],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018882366,0.0015925323,0.96362853,0.00037078577,0.0011178836,0.000019219182,0.00040422037,0.000044516124,0.0006129694,0.00001963157,0.00041247578,0.029889017],"study_design_scores_gemma":[0.057919066,0.0027317726,0.49420834,0.0006539398,0.002234108,0.0000020062014,0.0023135806,0.0005239315,0.009759965,0.00033292966,0.4285036,0.000816761],"about_ca_topic_score_codex":0.00029442765,"about_ca_topic_score_gemma":0.00090467755,"teacher_disagreement_score":0.4694202,"about_ca_system_score_codex":0.00006750785,"about_ca_system_score_gemma":0.00032823504,"threshold_uncertainty_score":0.7187716},"labels":[],"label_agreement":null},{"id":"W4410464105","doi":"10.1186/s40164-025-00662-3","title":"Next-generation immunotherapeutic approaches for blood cancers: Exploring the efficacy of CAR-T and cancer vaccines","year":2025,"lang":"en","type":"review","venue":"Experimental Hematology and Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria","funders":"National University Health System","keywords":"Cancer immunotherapy; Medicine; Cancer; Immunotherapy; Blood cancer; Immunology; Oncology; Internal medicine","score_opus":0.27417381271174723,"score_gpt":0.4431416177267477,"score_spread":0.16896780501500047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410464105","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.010157102,0.98661405,0.0000075631865,0.00020344208,0.00044440056,0.0023244591,0.000015525979,0.000016621998,0.00021683866],"genre_scores_gemma":[0.004501343,0.990563,0.00014953228,0.00010016932,0.00028992587,0.0036596726,0.000053666397,0.000036599467,0.0006461064],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99842525,0.00023786511,0.0005066463,0.00044442626,0.00009153271,0.00029429872],"domain_scores_gemma":[0.99842125,0.0009965148,0.00019957844,0.0002805249,0.000042031497,0.00006011583],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024320991,0.0003125739,0.0017645961,0.00016972967,0.00016303669,0.000012963978,0.00013387826,0.0003479216,0.00014884102],"category_scores_gemma":[0.000035086316,0.00020890302,0.00021575879,0.00015425927,0.00032367845,0.000048648308,0.00011142729,0.0003025851,5.493244e-7],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00042886933,0.00027750366,0.000050749455,0.009271321,0.001239082,0.000010111783,0.0012392838,3.5834825e-7,0.0020831174,0.002115775,0.000112495094,0.98317134],"study_design_scores_gemma":[0.007085878,0.0025227503,0.000026031847,0.0054531205,0.003429841,0.0013103466,0.0017786052,0.000088262736,0.03141906,0.000032906082,0.9463847,0.0004684933],"about_ca_topic_score_codex":0.00013247837,"about_ca_topic_score_gemma":0.00006507698,"teacher_disagreement_score":0.98270285,"about_ca_system_score_codex":0.0002192761,"about_ca_system_score_gemma":0.00078692444,"threshold_uncertainty_score":0.85188174},"labels":[],"label_agreement":null},{"id":"W4410513091","doi":"10.3899/jrheum.2025-0390.pv250","title":"POTENT AND SPECIFIC KILLING OF SLE B CELLS WITH ALLONK <sup>®</sup> (AB-101), AN ALLOGENEIC CORD BLOOD-NK CELL THERAPY, IN COMBINATION WITH ANTI-CD19 OR ANTI-CD20 MONOCLONAL ANTIBODIES","year":2025,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; CD19; Monoclonal antibody; CD20; B cell; Immunology; Antibody; Cord blood; Monoclonal","score_opus":0.022237671196698828,"score_gpt":0.2815528086136822,"score_spread":0.25931513741698337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410513091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945108,0.0033784967,0.00041895563,0.0008869802,0.000105674044,0.0005459593,0.00000488217,0.000013234939,0.00013497793],"genre_scores_gemma":[0.95713395,0.04108562,0.0012384824,0.00008929124,0.000013304809,0.0000032288956,0.000006020484,0.000038897433,0.00039118028],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975317,0.00045125972,0.0008040913,0.00026590313,0.00051411573,0.0004329063],"domain_scores_gemma":[0.9980279,0.00052421325,0.000508383,0.00039841005,0.0004104423,0.0001306392],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011917638,0.00029229,0.001071911,0.0006174959,0.000115323965,0.000028972905,0.00035147418,0.00015153676,0.0001561446],"category_scores_gemma":[0.000022670547,0.00016284532,0.00008480459,0.0004993988,0.0005510782,0.00014395568,0.00006899739,0.0006385852,0.0000015889653],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01630389,0.0017125855,0.6505531,0.00036676347,0.00081621023,0.00029638552,0.0026660336,0.0023012757,0.319403,0.00015471787,0.00026001854,0.0051660114],"study_design_scores_gemma":[0.08024782,0.045262177,0.23420295,0.004664021,0.0011055493,0.030771345,0.016315674,0.009010006,0.5728918,0.0006535663,0.0035950409,0.0012800653],"about_ca_topic_score_codex":0.00025885637,"about_ca_topic_score_gemma":0.00008795304,"teacher_disagreement_score":0.41635016,"about_ca_system_score_codex":0.00005258688,"about_ca_system_score_gemma":0.000372583,"threshold_uncertainty_score":0.66406393},"labels":[],"label_agreement":null},{"id":"W4410513221","doi":"10.3899/jrheum.2025-0390.pv119","title":"A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF CB-010, A NEXT-GENERATION CRISPR-EDITED ALLOGENEIC ANTI-CD19 CAR-T CELL THERAPY, IN PATIENTS WITH REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS (GALLOP)","year":2025,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Refractory (planetary science); CD19; Open label; Dermatology; Internal medicine; Immunology; Clinical trial; Antibody","score_opus":0.049719025264614955,"score_gpt":0.3411021922081021,"score_spread":0.29138316694348715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410513221","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9949871,0.001575569,0.00008148034,0.00022718882,0.00067485526,0.0023814314,0.0000058202145,0.0000117862655,0.00005478212],"genre_scores_gemma":[0.9976886,0.0016952335,0.00009476923,0.00011481828,0.00001651427,0.000028480232,0.000010489433,0.000043993947,0.00030709882],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.996188,0.0011234456,0.0013699577,0.00026551186,0.0006516056,0.0004015195],"domain_scores_gemma":[0.9970093,0.00040785145,0.0009770949,0.00065776537,0.00082795334,0.00012006888],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014718841,0.00029618933,0.0012704756,0.0006655457,0.000102824866,0.000042294247,0.0007345235,0.00016097495,0.000094406576],"category_scores_gemma":[0.00013613956,0.00018149213,0.0000764738,0.0005988792,0.00014776061,0.00021904164,0.00016556252,0.0006836079,0.0000037490474],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021855973,0.026010457,0.66939443,0.00030933716,0.00094207004,0.000073658746,0.0056553637,0.000056503948,0.27264148,0.000007769391,0.001003125,0.0020498284],"study_design_scores_gemma":[0.8177926,0.07243615,0.0333144,0.00468806,0.0013904246,0.007361774,0.024735156,0.003821737,0.032234535,0.000036970152,0.0011839898,0.0010041917],"about_ca_topic_score_codex":0.0006515987,"about_ca_topic_score_gemma":0.00024498173,"teacher_disagreement_score":0.79593664,"about_ca_system_score_codex":0.00022040728,"about_ca_system_score_gemma":0.00044751435,"threshold_uncertainty_score":0.7401034},"labels":[],"label_agreement":null},{"id":"W4410579459","doi":"10.3899/jrheum.2025-0390.pv262","title":"IANALUMAB’S DUAL MODE OF ACTION: TARGETING B CELLS THROUGH ENHANCED B CELL DEPLETION AND BLOCKADE OF B CELL-ACTIVATING FACTOR RECEPTOR SIGNALING","year":2025,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Receptor; Blockade; Signal transduction; Cell biology; B cell; Mode of action; Cell; Dual (grammatical number); Cancer research; Immunology; Internal medicine; Antibody; Biochemistry; Biology","score_opus":0.02457174578623603,"score_gpt":0.3194643638910647,"score_spread":0.29489261810482864,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410579459","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99112403,0.0008045514,0.0065914704,0.00047925714,0.00028921475,0.00020366565,0.0000047718613,0.000008183997,0.0004948333],"genre_scores_gemma":[0.99481696,0.0021915357,0.0025739686,0.00002562987,0.000028722014,0.0000015590126,0.0000015017462,0.00001971709,0.00034040507],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99800396,0.000347033,0.000904087,0.0001342541,0.00035551583,0.0002551801],"domain_scores_gemma":[0.9974297,0.0009819188,0.00094589015,0.00018973694,0.0003909253,0.000061815255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065128424,0.00015411,0.0006943276,0.00020037475,0.000097785065,0.0000074551153,0.00015212735,0.00014380507,0.00066988857],"category_scores_gemma":[0.00018172002,0.00011280019,0.00013873978,0.0002718325,0.00019024462,0.00010224554,0.0000663568,0.00058082264,0.0000016124862],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013578634,0.00011083958,0.0020406868,0.00052667124,0.00016680139,0.0000020884454,0.0031400744,0.00038225704,0.9906865,0.000015843363,0.00021638251,0.0013540243],"study_design_scores_gemma":[0.0017533947,0.00040930646,0.0001137932,0.0003712249,0.00006929373,0.0001720242,0.0031417392,0.00042600618,0.9930521,0.00011464438,0.00030223574,0.000074206306],"about_ca_topic_score_codex":0.00020588592,"about_ca_topic_score_gemma":0.0000067003466,"teacher_disagreement_score":0.0040175016,"about_ca_system_score_codex":0.00007803057,"about_ca_system_score_gemma":0.0002437945,"threshold_uncertainty_score":0.733481},"labels":[],"label_agreement":null},{"id":"W4410595562","doi":"10.1158/2643-3230.bcd-25-0099","title":"B-cell Receptor Silencing Reveals the Origin and Dependencies of High-Grade B-cell Lymphomas with <i>MYC</i> and <i>BCL2</i> Rearrangements","year":2025,"lang":"en","type":"article","venue":"Blood Cancer Discovery","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Optech (Canada)","funders":"H2020 Marie Skłodowska-Curie Actions; Fondazione Beretta; Fondazione Cariplo; American Society of Hematology; Fondazione AIRC per la ricerca sul cancro ETS","keywords":"Gene silencing; B cell; Cancer research; Biology; Cell; Genetics; Gene; Antibody","score_opus":0.013868097935081475,"score_gpt":0.27053676845694474,"score_spread":0.25666867052186326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410595562","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9735877,0.018330267,0.000022075736,0.0011905009,0.00013884246,0.00079000514,0.000074149044,0.000026276726,0.005840183],"genre_scores_gemma":[0.9560406,0.011563654,0.00023294012,0.0007211455,0.000120391975,0.00012403452,0.0000104115725,0.0000358763,0.031150907],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982505,0.00009296238,0.00030022804,0.00045287472,0.00053152454,0.00037192454],"domain_scores_gemma":[0.9989873,0.00019271935,0.00012964754,0.0004914496,0.00009626776,0.00010261614],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003508456,0.00024147939,0.00045535405,0.00012026266,0.00013124813,0.00008307653,0.00017151976,0.000087982466,0.00016122877],"category_scores_gemma":[0.000020140773,0.00015742116,0.00006348325,0.00040165364,0.0003475352,0.00019879172,0.00014430226,0.00022849762,0.000001825785],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000999358,0.00040511347,0.079197496,0.0011597667,0.00037494686,0.000020002724,0.0006228108,0.000007568217,0.9076926,0.00022886114,0.006892122,0.0023993424],"study_design_scores_gemma":[0.011913997,0.00063136267,0.007419755,0.0011237505,0.0008306054,0.000031362568,0.0015345013,0.0000084954,0.9633613,0.0002340227,0.012614931,0.00029588921],"about_ca_topic_score_codex":0.0022841904,"about_ca_topic_score_gemma":0.00028518846,"teacher_disagreement_score":0.071777746,"about_ca_system_score_codex":0.00009753291,"about_ca_system_score_gemma":0.00045795168,"threshold_uncertainty_score":0.6419449},"labels":[],"label_agreement":null},{"id":"W4410635655","doi":"10.1016/j.jcyt.2025.05.003","title":"Artificial intelligence, machine learning, and digitalization systems in the cell and gene therapy sector: a guidance document from the ISCT industry committees","year":2025,"lang":"en","type":"article","venue":"Cytotherapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Studies","funders":"","keywords":"Genetic enhancement; Political science; Business; Gene; Artificial intelligence; Computer science; Biology; Genetics","score_opus":0.03359672061384604,"score_gpt":0.3204809349915395,"score_spread":0.28688421437769346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410635655","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95552635,0.036403187,0.00085064425,0.0034984192,0.00012501774,0.0012269908,0.000016610851,0.000040273095,0.0023125075],"genre_scores_gemma":[0.98574126,0.009283471,0.000042003743,0.001476641,0.00022169059,0.00010477628,0.00003128381,0.000029181998,0.00306972],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99834746,0.00041033493,0.0003428895,0.00032596354,0.000325743,0.00024759799],"domain_scores_gemma":[0.99894106,0.0005057542,0.00008092886,0.00036801072,0.00005376389,0.000050461105],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007739562,0.00020342902,0.00027851795,0.00011154993,0.00017640734,0.0002673926,0.00021189234,0.0001751695,0.00031239563],"category_scores_gemma":[0.000036089357,0.00011693259,0.000046572528,0.0004339069,0.00020701566,0.000072564544,0.000041262178,0.0006479138,0.000004524386],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020228978,0.00053500035,0.5825033,0.000108096065,0.00035730423,0.00004537046,0.01146818,0.00021761835,0.13686295,0.0024319116,0.0027052918,0.26074207],"study_design_scores_gemma":[0.005147501,0.0018789964,0.116314635,0.0007395173,0.000087581844,0.000077453864,0.0085916445,0.011929022,0.12954326,0.00929496,0.7155398,0.00085561856],"about_ca_topic_score_codex":0.0009806436,"about_ca_topic_score_gemma":0.00016416163,"teacher_disagreement_score":0.71283454,"about_ca_system_score_codex":0.00006749848,"about_ca_system_score_gemma":0.00007323777,"threshold_uncertainty_score":0.47683728},"labels":[],"label_agreement":null},{"id":"W4410715612","doi":"10.3899/jrheum.2025-0390.o006","title":"DISTINCT MOLECULAR PROFILES OF REMISSION POST-CD19 CAR-T CELL THERAPY VERSUS STANDARD IMMUNOSUPPRESSION IN SYSTEMIC LUPUS ERYTHEMATOSUS","year":2025,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Immunosuppression; Lupus erythematosus; CD19; Immunology; Systemic disease; Immunopathology; Systemic therapy; Internal medicine; Peripheral blood; Antibody","score_opus":0.013104186626562186,"score_gpt":0.30200483415097573,"score_spread":0.2889006475244135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410715612","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9841973,0.012379945,0.00012829826,0.00097178883,0.00071231293,0.000534692,0.0000066819703,0.0000113507485,0.0010576141],"genre_scores_gemma":[0.9945658,0.0047194283,0.00011436949,0.00002482322,0.000007044218,0.0000057912084,0.000004064538,0.000026453368,0.00053221395],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973477,0.00067467574,0.00096562225,0.0001507456,0.00053695665,0.00032428405],"domain_scores_gemma":[0.9975442,0.0007923488,0.0005559593,0.00051551155,0.0005066232,0.00008532693],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014366063,0.00019998424,0.0009120326,0.00041736415,0.00006265213,0.000009679051,0.0004277284,0.0001831689,0.00027840733],"category_scores_gemma":[0.00035690042,0.00011795907,0.00020743468,0.00036376013,0.00020306869,0.000051279505,0.00010949487,0.0006585279,0.000003072204],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04685693,0.00017577127,0.04971812,0.0005432376,0.00021837078,0.000099287194,0.0011111577,0.000024511482,0.8973806,0.00015775769,0.0005922727,0.0031219702],"study_design_scores_gemma":[0.037333675,0.005631256,0.0031045254,0.0068505723,0.00023344801,0.0206818,0.0058675827,0.00015650266,0.916512,0.000540876,0.002794437,0.0002933277],"about_ca_topic_score_codex":0.00016750826,"about_ca_topic_score_gemma":0.000011454915,"teacher_disagreement_score":0.046613593,"about_ca_system_score_codex":0.00020611583,"about_ca_system_score_gemma":0.00062989636,"threshold_uncertainty_score":0.48102313},"labels":[],"label_agreement":null},{"id":"W4410715736","doi":"10.3899/jrheum.2025-0390.o029","title":"RESET SLE: CLINICAL TRIAL EVALUATING CABA-201, A FULLY HUMAN, AUTOLOGOUS 4-1BB ANTI-CD19 CAR T CELL THERAPY IN NONRENAL SLE AND LUPUS NEPHRITIS","year":2025,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Lupus nephritis; CD19; Reset (finance); Internal medicine; Immunology; Antibody","score_opus":0.08434236423360857,"score_gpt":0.43476144804059724,"score_spread":0.35041908380698866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410715736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98842144,0.0048436755,0.000055264143,0.003159408,0.0020324015,0.00085836224,0.0000049409364,0.000018610166,0.00060590176],"genre_scores_gemma":[0.9877506,0.009136068,0.00028424434,0.00038457962,0.00011263654,0.000012733199,0.000004488965,0.000033710603,0.0022809412],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9941403,0.0025491186,0.001800404,0.0003024979,0.0006008821,0.0006067907],"domain_scores_gemma":[0.9957046,0.0025590893,0.0006337896,0.0005090115,0.0004035704,0.00018994196],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00838798,0.0002615307,0.0014434468,0.0005372813,0.00020558923,0.000040802985,0.0004852741,0.00038271133,0.0005442268],"category_scores_gemma":[0.0011384672,0.00017714914,0.00027084115,0.00043114202,0.0006078954,0.0000891724,0.00017555195,0.0018813736,0.000010199736],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19030333,0.0016872836,0.5702121,0.0003096169,0.0011932998,0.0009016054,0.0036280688,0.000052981595,0.12784715,0.00034176582,0.036039654,0.0674831],"study_design_scores_gemma":[0.70283926,0.06136052,0.09401401,0.0027675002,0.0009347963,0.07537955,0.0041846167,0.0036479307,0.007232861,0.0059990077,0.040411383,0.0012285496],"about_ca_topic_score_codex":0.0006136394,"about_ca_topic_score_gemma":0.0003319043,"teacher_disagreement_score":0.5125359,"about_ca_system_score_codex":0.00012395196,"about_ca_system_score_gemma":0.000953546,"threshold_uncertainty_score":0.8173737},"labels":[],"label_agreement":null},{"id":"W4410799986","doi":"10.1016/s2352-3026(25)00051-1","title":"Beyond maximum grade: tolerability of immunotherapies, cellular therapies, and targeted agents in haematological malignancies","year":2025,"lang":"en","type":"review","venue":"The Lancet Haematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute; Astellas Pharma; Swedish Orphan Biovitrum; Else Kröner-Fresenius-Stiftung; Incyte; BeiGene; Eli Lilly and Company; AstraZeneca; Arnold Ventures; Adaptive Biotechnologies; Gilead Sciences; Sanofi; Amgen; National Heart, Lung, and Blood Institute; Pfizer; Seagen; Cidara Therapeutics; National Institute of Allergy and Infectious Diseases; Celgene; GlaxoSmithKline","keywords":"Medicine; Tolerability; Oncology; Immunotherapy; Internal medicine; Intensive care medicine; Adverse effect; Cancer","score_opus":0.09745188310624656,"score_gpt":0.37481295902621686,"score_spread":0.2773610759199703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410799986","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009536797,0.9844064,0.000017797514,0.001708119,0.0002551234,0.0027599512,0.000091163995,0.000073758136,0.001150897],"genre_scores_gemma":[0.0017630084,0.9957379,0.00028051727,0.00036675346,0.000094494906,0.00035456495,0.00013877633,0.000064075466,0.0011998806],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99481285,0.0016353792,0.0014468285,0.0007842218,0.00043811722,0.0008826025],"domain_scores_gemma":[0.9961634,0.0014701975,0.00048248886,0.0016634071,0.00012085111,0.00009961771],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016520213,0.0006782862,0.008143624,0.00043616263,0.00009992574,0.000027411426,0.0008438682,0.0008437851,0.0012523094],"category_scores_gemma":[0.00030936053,0.0004109819,0.0005259038,0.00088183593,0.0012491031,0.000041469706,0.00040168088,0.0013586652,0.000017121887],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014702254,0.0014345144,0.008097814,0.20919843,0.00288026,0.0027837942,0.0025269147,7.552357e-7,0.0007742955,0.017308705,0.0058697187,0.74765456],"study_design_scores_gemma":[0.0031792426,0.0003401646,0.00074702944,0.012046858,0.00078151457,0.0023839127,0.00017940115,0.000010369346,0.00027928763,0.011291949,0.96815175,0.0006085444],"about_ca_topic_score_codex":0.0001404334,"about_ca_topic_score_gemma":0.000049580125,"teacher_disagreement_score":0.962282,"about_ca_system_score_codex":0.00014378695,"about_ca_system_score_gemma":0.0005243448,"threshold_uncertainty_score":0.9998342},"labels":[],"label_agreement":null},{"id":"W4410801539","doi":"10.1182/bloodadvances.2025016141","title":"Infection after CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: real-world analysis from CIBMTR","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Pharmaceuticals; National Institute of Environmental Health Sciences; National Institute of Allergy and Infectious Diseases; National Cancer Institute; Office of Naval Research; National Heart, Lung, and Blood Institute; Alexion Pharmaceuticals; bluebird bio; Pharmacyclics; Adaptive Biotechnologies; Health Resources and Services Administration; Kite Pharma; Daiichi Sankyo Europe; Takeda Oncology; AstraZeneca; Fundação de Amparo à Pesquisa do Estado de São Paulo; Genentech; MorphoSys; U.S. Navy; Legend Biotech; Sangamo Therapeutics; Seagen; CTI Biopharma; CareDx; BeiGene; Swedish Orphan Biovitrum; Astellas Pharma; U.S. Department of Health and Human Services; GlaxoSmithKline; Kiadis Pharma; Medac; Jazz Pharmaceuticals; National Institutes of Health; Regeneron Pharmaceuticals; HistoGenetics; Children's Hospital of Philadelphia; Gateway for Cancer Research; Celgene; Omeros Corporation; Vertex Pharmaceuticals; U.S. Department of Defense; Sanofi; Conselho Nacional de Desenvolvimento Científico e Tecnológico; Bristol-Myers Squibb; Cidara Therapeutics; Mallinckrodt Pharmaceuticals; Astellas Pharma US; Novartis Pharmaceuticals Corporation; Incyte; Pfizer; Amgen; Atara Biotherapeutics; Actinium Pharmaceuticals; Gilead Sciences","keywords":"Medicine; Cytokine release syndrome; Chimeric antigen receptor; Lymphoma; Internal medicine; Cumulative incidence; Incidence (geometry); CD19; Immunology; Gastroenterology; Transplantation; Antigen; Immunotherapy; Cancer","score_opus":0.010808022390614186,"score_gpt":0.3128229019549339,"score_spread":0.3020148795643197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410801539","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9699175,0.014040556,0.0010943162,0.00029736297,0.00039298087,0.0011685647,0.00014559164,0.00014729208,0.012795855],"genre_scores_gemma":[0.9167016,0.029757185,0.002904473,0.000722723,0.0005513085,0.0005070483,0.0004050252,0.00006294363,0.048387658],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979596,0.000104603714,0.0003956756,0.0006619279,0.00035566848,0.00052253896],"domain_scores_gemma":[0.99866384,0.00027313572,0.0001373371,0.00061447313,0.00017656987,0.00013463573],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00029984736,0.00029056845,0.00064738846,0.00070581265,0.0001539932,0.000054016826,0.00015954496,0.0001142786,0.002247146],"category_scores_gemma":[0.000030868883,0.0002505533,0.0004885145,0.0020841984,0.00005890038,0.00017557669,0.000052301162,0.00014688411,0.000048210248],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036040973,0.005467801,0.7031714,0.00022296929,0.0026498288,0.000017676668,0.00032961761,0.000014053714,0.21591465,0.0000418075,0.0017013693,0.06686478],"study_design_scores_gemma":[0.015413116,0.00047492236,0.1463173,0.00006483026,0.0010512987,6.176398e-7,0.00007931275,0.00016945443,0.2803166,0.00020188231,0.5555901,0.00032056574],"about_ca_topic_score_codex":0.0008264435,"about_ca_topic_score_gemma":0.0011324768,"teacher_disagreement_score":0.55685407,"about_ca_system_score_codex":0.00009497486,"about_ca_system_score_gemma":0.00016539924,"threshold_uncertainty_score":0.9999947},"labels":[],"label_agreement":null},{"id":"W4410803211","doi":"10.1200/jco.2025.43.16_suppl.tps7091","title":"TITANium: An open-label, global multicenter phase 1/2 study of AZD5492, a first-in-class subcutaneous CD8-guided tri-specific T-cell engager (TCE), in patients (pts) with relapsed or refractory (r/r) B-cell malignancies.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Open label; Refractory (planetary science); CD8; Oncology; Multicenter study; Internal medicine; Cancer research; Clinical trial; Immunology; Antigen; Materials science; Metallurgy; Randomized controlled trial","score_opus":0.15544688119133895,"score_gpt":0.4794816699232975,"score_spread":0.32403478873195857,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410803211","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892247,0.00025358726,0.000014183197,0.0006818753,0.00086893246,0.0023200656,0.000015484358,0.00001083474,0.0066103716],"genre_scores_gemma":[0.99384457,0.0006648285,0.0012831353,0.0008013791,0.00017960973,0.000024795567,0.000007773698,0.000044926914,0.0031490014],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99105,0.0022595085,0.004418959,0.0006314442,0.0010201787,0.00061992486],"domain_scores_gemma":[0.99237883,0.0034142307,0.0018492184,0.0007589636,0.0010927927,0.00050593837],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0058755605,0.00035595757,0.0027504377,0.00046431326,0.00006770981,0.00003816032,0.00092711515,0.0005884351,0.00086208346],"category_scores_gemma":[0.0018395355,0.00024763873,0.00018474126,0.0009780143,0.00028835257,0.00027004638,0.00027746477,0.0024583421,0.000017522289],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4136163,0.2901079,0.21671645,0.00019937426,0.00046970038,0.013471045,0.00086020044,0.000033286862,0.0061804126,0.000010610949,0.008815539,0.04951916],"study_design_scores_gemma":[0.48168644,0.37392834,0.07245705,0.0006241063,0.00041479076,0.0001686551,0.002436066,0.00024553848,0.00051938643,0.000024878054,0.0671174,0.00037736417],"about_ca_topic_score_codex":0.00018601278,"about_ca_topic_score_gemma":0.0017416838,"teacher_disagreement_score":0.14425941,"about_ca_system_score_codex":0.0013809564,"about_ca_system_score_gemma":0.0027782484,"threshold_uncertainty_score":0.9999976},"labels":[],"label_agreement":null},{"id":"W4410803316","doi":"10.1200/jco.2025.43.16_suppl.2521","title":"Phase 1/2, open-label, first-in-human study of the anti-GPC3 T-cell engager SAR444200 in patients with advanced solid tumors: Updated efficacy and biomarker analysis.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Biomarker; Oncology; Cancer research; Internal medicine; Biology","score_opus":0.09818264285640337,"score_gpt":0.5118084556203576,"score_spread":0.4136258127639542,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410803316","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99633425,0.0001234949,0.000004836003,0.0009630128,0.00014147168,0.0012870186,0.0000031866884,0.0000029596617,0.0011397768],"genre_scores_gemma":[0.99884325,0.00010103298,0.00014472358,0.0004002779,0.000035714886,0.000006984429,0.0000046178375,0.000015370735,0.00044800967],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9947621,0.0015007709,0.0026249762,0.00032444843,0.0004952266,0.00029245694],"domain_scores_gemma":[0.99573386,0.0019145383,0.0012435531,0.0004555029,0.00046798046,0.00018456428],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0048806285,0.00017582813,0.0022940997,0.0006445592,0.00007040522,0.000018631303,0.000498994,0.00019387297,0.0002626878],"category_scores_gemma":[0.0014008667,0.0001033374,0.00014467319,0.0017470832,0.0002840316,0.00011811966,0.00028120106,0.0014292774,8.2916154e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024749689,0.07532785,0.8669836,0.000030828793,0.0014280634,0.0002744384,0.0002851305,0.00010589882,0.0025390368,0.0000031437187,0.0003739971,0.027898345],"study_design_scores_gemma":[0.16130349,0.028290126,0.8073136,0.0001605898,0.0006699503,0.0000035775192,0.00025836608,0.00015528538,0.00021075756,0.000011406579,0.0015425925,0.00008024408],"about_ca_topic_score_codex":0.000074540134,"about_ca_topic_score_gemma":0.00059573463,"teacher_disagreement_score":0.1365538,"about_ca_system_score_codex":0.00015427404,"about_ca_system_score_gemma":0.0007311084,"threshold_uncertainty_score":0.62095785},"labels":[],"label_agreement":null},{"id":"W4410803628","doi":"10.1200/jco.2025.43.16_suppl.e24085","title":"Incidence and risk factors for venous thromboembolism after CAR T-cell therapy: A systematic review and meta-analysis.","year":2025,"lang":"en","type":"review","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University","funders":"","keywords":"Medicine; Venous thromboembolism; Meta-analysis; Incidence (geometry); Oncology; Surgery; Internal medicine; Thrombosis","score_opus":0.2845261523703347,"score_gpt":0.5438197238772523,"score_spread":0.2592935715069176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410803628","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00023635161,0.99445975,0.000041602492,0.00040370808,0.00019535815,0.004449645,0.00007843355,0.000006384015,0.00012879586],"genre_scores_gemma":[0.00007808042,0.99582523,0.00038967718,0.0013051094,0.00023267981,0.0002613112,0.000008112713,0.00004262178,0.0018572041],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98875266,0.003983581,0.005822081,0.0005167595,0.0005775566,0.00034734726],"domain_scores_gemma":[0.97003406,0.022454364,0.005598521,0.00066588185,0.0007451733,0.0005019832],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.012942517,0.00052670564,0.037323188,0.0005429691,0.000059163354,0.000033171724,0.0003781553,0.0009495306,0.0004966043],"category_scores_gemma":[0.009345386,0.00026758327,0.008743152,0.00056423893,0.00028643623,0.00007048293,0.00013587877,0.0021979883,0.0000034809302],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023614951,0.00062721566,0.00008128225,0.6577323,0.287965,0.0001763523,0.00006742465,9.871277e-8,1.5503707e-7,0.0000031945167,0.00037382264,0.05273697],"study_design_scores_gemma":[0.00093744847,0.003824979,0.0000817466,0.018755944,0.77909166,0.0001835402,0.0000152367975,0.0000011224454,1.432098e-7,0.00003685222,0.19690965,0.00016165123],"about_ca_topic_score_codex":0.000029523211,"about_ca_topic_score_gemma":0.000024758117,"teacher_disagreement_score":0.6389764,"about_ca_system_score_codex":0.00016697186,"about_ca_system_score_gemma":0.0027279495,"threshold_uncertainty_score":0.99997765},"labels":[],"label_agreement":null},{"id":"W4410810027","doi":"10.1200/jco.2025.43.16_suppl.tps2687","title":"Phase 2 dose expansion of START-001: A phase 1/2 study of invikafusp alfa (STAR0602), a first-in-class, selective T cell receptor (TCR)-targeting, bifunctional antibody-fusion molecule, as monotherapy in patients with antigen-rich tumors resistant to anti-PD(L)-1.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; T-cell receptor; Bifunctional; Antibody; Receptor; Cancer research; Immunology; Pharmacology; Molecular biology; Internal medicine; T cell; Biochemistry; Biology; Immune system","score_opus":0.03909459737228007,"score_gpt":0.4344524656994455,"score_spread":0.39535786832716546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410810027","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956447,0.00025876833,0.00008547329,0.0009826986,0.00037797407,0.0020942949,0.000022067936,0.000009229642,0.00052479026],"genre_scores_gemma":[0.9971644,0.0006353133,0.0011971516,0.0005393789,0.00013912468,0.000021572767,0.00003205163,0.00004673067,0.0002242474],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99219716,0.0013382098,0.003973214,0.0006046156,0.0013594967,0.0005273304],"domain_scores_gemma":[0.9935611,0.0018585214,0.0019613288,0.00041731956,0.0018048711,0.00039689304],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0044356296,0.0003513318,0.002567609,0.0014618321,0.00007221387,0.000011632577,0.00034322514,0.0003733433,0.00065181474],"category_scores_gemma":[0.002175425,0.00026605566,0.00029139718,0.0019121242,0.00023444646,0.00015676791,0.00012286555,0.0015086522,0.000005339804],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.26184356,0.11449828,0.43730736,0.00013295717,0.0005250666,0.0005322141,0.0015343672,0.00031999926,0.16737553,0.0000057021357,0.00247452,0.013450429],"study_design_scores_gemma":[0.2516508,0.28490025,0.4297187,0.0010712766,0.00020768827,0.000009784081,0.0017935403,0.0003544446,0.02205796,0.000051084204,0.007829262,0.0003552036],"about_ca_topic_score_codex":0.00045124444,"about_ca_topic_score_gemma":0.00039957825,"teacher_disagreement_score":0.17040196,"about_ca_system_score_codex":0.000551926,"about_ca_system_score_gemma":0.0030416732,"threshold_uncertainty_score":0.99997914},"labels":[],"label_agreement":null},{"id":"W4410810149","doi":"10.1200/jco.2025.43.16_suppl.tps2671","title":"ARC101-P1-101: A first-in-human phase 1 study of ARC101, a next generation T cell engager (TCE), in patients with advanced solid tumors.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Cancer research; Solid tumor; Oncology; Internal medicine; Cancer","score_opus":0.1303790071812936,"score_gpt":0.4964741971718948,"score_spread":0.3660951899906012,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410810149","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99561995,0.000118307,0.000035374782,0.0007093856,0.00031643145,0.0010878647,0.0000017562775,0.0000051534353,0.002105792],"genre_scores_gemma":[0.9978672,0.0001094911,0.00053063734,0.0004638868,0.00029891453,0.00002110269,0.000006158235,0.000022682962,0.0006799146],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9944258,0.0010572225,0.003198651,0.00031508645,0.0006541336,0.0003491602],"domain_scores_gemma":[0.9959714,0.0016179683,0.0012767315,0.000348651,0.0005479081,0.00023737721],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0039049122,0.00018825753,0.0019261682,0.0006428391,0.000050997238,0.000011708882,0.00024782092,0.0002391609,0.00041116404],"category_scores_gemma":[0.0015764867,0.00013942616,0.00022303447,0.000516507,0.00016651399,0.0001553499,0.000082407365,0.0019564677,0.000003100731],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.044745974,0.07731796,0.7019031,0.00015487403,0.0003861157,0.0012430195,0.001931268,0.000607368,0.019722559,0.000016218793,0.00086965103,0.15110187],"study_design_scores_gemma":[0.16735621,0.1141224,0.7081074,0.00045328762,0.00022483521,0.000015711776,0.001201719,0.00079080166,0.00185333,0.00008506445,0.00559001,0.00019920111],"about_ca_topic_score_codex":0.00006492272,"about_ca_topic_score_gemma":0.0009831717,"teacher_disagreement_score":0.15090267,"about_ca_system_score_codex":0.0003460765,"about_ca_system_score_gemma":0.0012215173,"threshold_uncertainty_score":0.8499988},"labels":[],"label_agreement":null},{"id":"W4410821212","doi":"10.1200/jco.2025.43.16_suppl.7028","title":"Postmarketing safety profile of chimeric antigen receptor (CAR) T cell therapies in diffuse large B-cell lymphoma (DLBCL): Analysis of real-world (RW) AE reporting from the FDA Adverse Event Reporting System (FAERS).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Chimeric antigen receptor; Medicine; Safety profile; Adverse effect; Lymphoma; Adverse Event Reporting System; Postmarketing surveillance; Diffuse large B-cell lymphoma; Pharmacovigilance; Oncology; Antigen; Internal medicine; Cancer research; Immunology; Cancer; Immunotherapy","score_opus":0.06189013748469961,"score_gpt":0.43465728156570516,"score_spread":0.37276714408100553,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410821212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98439413,0.00096774846,0.000073709954,0.0011985528,0.0007624324,0.00065531774,0.000023725343,0.000017239488,0.011907136],"genre_scores_gemma":[0.99377847,0.0016491523,0.0020225386,0.00027692007,0.00040973618,0.000009369582,0.000026954114,0.000035404573,0.0017914657],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.97860026,0.0027309232,0.016655887,0.0004932577,0.0009797551,0.00053991046],"domain_scores_gemma":[0.9562536,0.009465198,0.032165382,0.0008410636,0.0010315048,0.00024326566],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.03596587,0.0002819699,0.0041493005,0.00079214375,0.000108086984,0.0000108441955,0.00047475996,0.00040640493,0.00061466283],"category_scores_gemma":[0.01662991,0.00018923868,0.0020510368,0.0022018051,0.000266831,0.00009167166,0.00025276828,0.001208985,0.0000033903107],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009179362,0.0071357936,0.88046396,0.00029013274,0.0035902108,0.00059424294,0.0011262079,0.000049474074,0.036013097,0.000014560969,0.00044058793,0.061102353],"study_design_scores_gemma":[0.01961262,0.001513823,0.95198935,0.0010793264,0.0021305429,0.00003184292,0.008569708,0.002386158,0.004789656,0.000011557127,0.0077098915,0.00017551311],"about_ca_topic_score_codex":0.0018540497,"about_ca_topic_score_gemma":0.0009158143,"teacher_disagreement_score":0.07152539,"about_ca_system_score_codex":0.0006443731,"about_ca_system_score_gemma":0.0027187672,"threshold_uncertainty_score":0.992676},"labels":[],"label_agreement":null},{"id":"W4410822904","doi":"10.1200/jco.2025.43.16_suppl.e19057","title":"Sex-based differences in complications in patients with diffuse large B cell lymphoma receiving axicabtagene ciloleucel therapy.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brampton Civic Hospital","funders":"","keywords":"Medicine; Lymphoma; Internal medicine; Oncology; Surgery","score_opus":0.10030424752009427,"score_gpt":0.4371271288490954,"score_spread":0.3368228813290011,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410822904","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907425,0.00020746599,0.00019536616,0.0042650364,0.0002131633,0.000423888,0.000004332325,0.000007483951,0.0039407555],"genre_scores_gemma":[0.9951581,0.0004000337,0.0007093628,0.0026375225,0.000099629,0.000015265883,0.0000051478123,0.000014892716,0.00096004095],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99653614,0.000753999,0.0017041565,0.00024230186,0.00043092598,0.000332472],"domain_scores_gemma":[0.99537086,0.0031599205,0.0006254663,0.00030223903,0.00033450627,0.00020702314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002508496,0.00014645555,0.0012452235,0.00046153355,0.000040214712,0.00001333805,0.00028447254,0.0002873416,0.00024297547],"category_scores_gemma":[0.00084327004,0.00009873153,0.00020327742,0.00050947216,0.00014775379,0.000059105332,0.000047194688,0.0008522607,0.00000565494],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005565171,0.023025727,0.8695167,0.00002236323,0.00007553436,0.00006683704,0.00008646804,0.000004261178,0.00039890083,0.000015032325,0.00022253323,0.1010005],"study_design_scores_gemma":[0.0643984,0.0055717896,0.91994804,0.00017569667,0.000027507704,0.0000027455592,0.00007349258,0.0002549115,0.0002187417,0.000089274195,0.009159487,0.00007991358],"about_ca_topic_score_codex":0.000037094604,"about_ca_topic_score_gemma":0.0002043876,"teacher_disagreement_score":0.10092059,"about_ca_system_score_codex":0.00031593582,"about_ca_system_score_gemma":0.0018875209,"threshold_uncertainty_score":0.4026155},"labels":[],"label_agreement":null},{"id":"W4410822970","doi":"10.1200/jco.2025.43.16_suppl.e19049","title":"Matching-adjusted indirect comparison (MAIC) of lisocabtagene maraleucel (liso-cel) versus axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) for treatment of third-line or later (3L+) R/R follicular lymphoma (FL): Update with 24 months of liso-cel follow-up (FU).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Medicine; Follicular lymphoma; Internal medicine; Second line; Oncology; Lymphoma; First line","score_opus":0.14789144499785303,"score_gpt":0.4464841575960615,"score_spread":0.2985927125982085,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410822970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9849022,0.0065568904,0.00094039127,0.0024248136,0.0017823251,0.0019548351,0.00013782864,0.000035676923,0.0012650627],"genre_scores_gemma":[0.97084963,0.010209118,0.0103319585,0.00048272335,0.0005882757,0.000075994925,0.00006917258,0.00012845016,0.0072646555],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9905957,0.0009989036,0.0054922076,0.0008167925,0.0012187182,0.00087769795],"domain_scores_gemma":[0.98728496,0.0056746188,0.0038571146,0.00097327295,0.001504397,0.00070566],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0035556094,0.000715817,0.0062186024,0.0008416666,0.00013663892,0.00003299587,0.0006587109,0.0011199685,0.0004813196],"category_scores_gemma":[0.0013428101,0.00050240086,0.0017055813,0.00083557056,0.00092417473,0.0002090121,0.00024401238,0.0007401602,0.00000691343],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39226028,0.022866108,0.026360953,0.0018367337,0.016354568,0.0015301144,0.0021415467,0.0003361373,0.084149,0.00021919233,0.0072214045,0.44472396],"study_design_scores_gemma":[0.3332532,0.21084903,0.059113093,0.0021708603,0.012920813,0.00060360215,0.0025608193,0.004185478,0.22780393,0.0006544005,0.14455652,0.001328246],"about_ca_topic_score_codex":0.0003877826,"about_ca_topic_score_gemma":0.0010973171,"teacher_disagreement_score":0.4433957,"about_ca_system_score_codex":0.00060230854,"about_ca_system_score_gemma":0.0032632342,"threshold_uncertainty_score":0.99974275},"labels":[],"label_agreement":null},{"id":"W4410823212","doi":"10.1200/jco.2025.43.16_suppl.tps3160","title":"Design of a first-in-human multicenter open-label study of ZW171, a mesothelin x CD3 targeting bispecific T-cell engager, in participants with advanced solid tumors: ZWI-ZW171-101.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"Mesothelin; Medicine; Solid tumor; Cancer research; CD3; Bispecific antibody; Oncology; Nuclear medicine; Internal medicine; Cancer; Monoclonal antibody; Immune system; Immunology; Antibody","score_opus":0.24522242943177328,"score_gpt":0.5255013246005501,"score_spread":0.2802788951687768,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410823212","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950785,0.00051834865,0.00024585615,0.0008015205,0.0002453407,0.001947541,0.0000019726576,0.000005712827,0.0011551883],"genre_scores_gemma":[0.9930915,0.0004964107,0.005313513,0.00024053977,0.00013113156,0.00004664853,0.000001002566,0.000037949452,0.00064125797],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9906175,0.0026845904,0.0049943784,0.0004251999,0.00066520175,0.0006130873],"domain_scores_gemma":[0.989739,0.0065603363,0.0022515925,0.0004572362,0.00070143637,0.0002904007],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.014115176,0.00025167354,0.0031375205,0.0006306347,0.000057147154,0.000016127211,0.0006901761,0.0002752898,0.0004053059],"category_scores_gemma":[0.0041899784,0.00018364735,0.00017014262,0.0006874591,0.00030382772,0.00016182958,0.000262413,0.002111563,0.000003648026],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12146554,0.12356453,0.51947325,0.0005419149,0.0011464466,0.0039768233,0.0068511297,0.0033482546,0.18637413,0.000021896542,0.0008502628,0.032385834],"study_design_scores_gemma":[0.5128251,0.21712615,0.1802159,0.006371977,0.001073617,0.00008376948,0.02594281,0.011218954,0.037621226,0.0003658799,0.0063739284,0.0007807372],"about_ca_topic_score_codex":0.00014501813,"about_ca_topic_score_gemma":0.00086461846,"teacher_disagreement_score":0.39135954,"about_ca_system_score_codex":0.00029755547,"about_ca_system_score_gemma":0.0016049622,"threshold_uncertainty_score":0.9173808},"labels":[],"label_agreement":null},{"id":"W4410864172","doi":"10.1038/s41409-025-02637-8","title":"Harmonisation of quality control tests for academic production of CAR-T cells: a position paper from the WP-bioproduction of the UNITC consortium","year":2025,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"Centre hospitalier régional universitaire de Lille","keywords":"Bioproduction; Critical quality attributes; Limulus amebocyte lysate; Medicine; Quality (philosophy); Reliability engineering; Computer science; Biotechnology; Operations management; Engineering; Immunology; Biology","score_opus":0.034395637906422916,"score_gpt":0.32902000727884795,"score_spread":0.29462436937242503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410864172","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98585165,0.00031898657,0.0022554924,0.008346074,0.00046309605,0.002337804,0.00028886014,0.000019483363,0.00011855036],"genre_scores_gemma":[0.99824965,0.0003476267,0.00016849035,0.00017339924,0.000120161276,0.000099426245,0.00025028273,0.000013329641,0.00057762384],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99819916,0.0003104031,0.00069444114,0.00025485177,0.0004081903,0.0001329539],"domain_scores_gemma":[0.9982493,0.0004602026,0.00038622314,0.00037561523,0.0005065872,0.000022055257],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010484774,0.000120788514,0.00031663518,0.000100803314,0.00008631732,0.000004956173,0.00010216513,0.0001387854,0.00004768424],"category_scores_gemma":[0.00021981665,0.00008382618,0.0001562799,0.0003685482,0.0002218843,0.00011255646,0.0000061505393,0.00021906458,4.9641164e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044410727,0.00011449353,0.010496258,0.0007855079,0.00012881322,2.3052755e-7,0.0012325204,0.00012514126,0.97841495,0.0004892979,0.00022317815,0.0035485122],"study_design_scores_gemma":[0.002340345,0.00011673021,0.20638543,0.00032538947,0.0004917419,0.0000066360126,0.00031841718,0.00012513276,0.78879005,0.00087919855,0.0001648172,0.00005612838],"about_ca_topic_score_codex":0.00086633785,"about_ca_topic_score_gemma":0.00016557073,"teacher_disagreement_score":0.19588917,"about_ca_system_score_codex":0.00007788856,"about_ca_system_score_gemma":0.00018824072,"threshold_uncertainty_score":0.34183323},"labels":[],"label_agreement":null},{"id":"W4410870736","doi":"10.14740/jmc5114","title":"High-Sensitivity Flow Cytometric Detection of a Small Circulating Population of Nodal T-Follicular Helper Cell Lymphoma Angioimmunoblastic Type Cells","year":2025,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; NODAL; Flow cytometry; Follicular lymphoma; Pathology; Lymphoma; Immunology; Internal medicine","score_opus":0.02335803757813309,"score_gpt":0.2972487032172782,"score_spread":0.2738906656391451,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410870736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99346036,0.0013097659,0.004260225,0.00016727787,0.00055748684,0.0001712042,0.0000046083615,0.000009242726,0.00005981915],"genre_scores_gemma":[0.99854875,0.00020125003,0.00078113255,0.000060761424,0.0002586509,9.3681916e-7,0.0000050736408,0.000017457362,0.00012596745],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970004,0.0002684206,0.00085012196,0.00014706542,0.001513681,0.00022031619],"domain_scores_gemma":[0.99727726,0.0011609927,0.00044397687,0.00021228906,0.00071286503,0.00019258763],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017881879,0.0001402133,0.0006542413,0.0009658986,0.00004679848,0.000011522378,0.00011229588,0.00022732986,0.0004082857],"category_scores_gemma":[0.0032685418,0.00011360839,0.00030191554,0.0014570638,0.00009807278,0.000061453444,0.00006198086,0.0003448281,0.000002781315],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015594509,0.00073824637,0.0075261584,0.0006310543,0.00023348439,0.0014494704,0.00009050008,0.0004919913,0.900853,0.0000058588425,0.000060316954,0.08636049],"study_design_scores_gemma":[0.009550549,0.0027872422,0.19554207,0.0019554684,0.0007102697,0.0033371646,0.00028711266,0.020860149,0.7643693,0.000059544484,0.00032221622,0.00021890663],"about_ca_topic_score_codex":0.00069009763,"about_ca_topic_score_gemma":0.000037252485,"teacher_disagreement_score":0.18801591,"about_ca_system_score_codex":0.0002386022,"about_ca_system_score_gemma":0.000440866,"threshold_uncertainty_score":0.46328154},"labels":[],"label_agreement":null},{"id":"W4410893761","doi":"10.3390/curroncol32060322","title":"CAR-T Cell Therapy for Acute Myeloid Leukemia: Where Do We Stand Now?","year":2025,"lang":"en","type":"review","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Cytokine release syndrome; CAR T-cell therapy; Myeloid leukemia; Chimeric antigen receptor; Clinical trial; Disease; Population; Oncology; Internal medicine; Intensive care medicine; Immunology; Immunotherapy; Cancer","score_opus":0.14293709924110634,"score_gpt":0.48779391948154843,"score_spread":0.34485682024044206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410893761","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000009760099,0.9799077,0.00012315191,0.00059659436,0.0037081584,0.0069257915,0.00050737895,0.000105042025,0.008116412],"genre_scores_gemma":[2.0851382e-7,0.93841946,0.00018191522,0.00004017657,0.0016354235,0.001951044,0.00031675978,0.00014464534,0.05731034],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9958469,0.0004666252,0.0010280273,0.0011273937,0.0005093872,0.0010216554],"domain_scores_gemma":[0.9962002,0.0014648809,0.00043382333,0.001099499,0.00043641447,0.00036518346],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00072435784,0.00084220845,0.0042407573,0.00061632966,0.00014422294,0.00005332738,0.00067862304,0.0012587681,0.0026286538],"category_scores_gemma":[0.00006648828,0.0006435104,0.001487931,0.0006577927,0.00023851625,0.000045760185,0.0002394781,0.0020670285,0.0001865633],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043427566,0.0003840886,0.00000665195,0.048890844,0.00077592407,0.00005994503,0.00009994835,7.740646e-8,0.00003695115,0.000034764787,0.13366462,0.8156119],"study_design_scores_gemma":[0.004816358,0.0019711563,6.733629e-7,0.015667016,0.002285298,0.000092752714,0.000041000032,0.000003984483,0.000029629226,0.000062686195,0.97457296,0.00045650266],"about_ca_topic_score_codex":0.000004895484,"about_ca_topic_score_gemma":0.00001870283,"teacher_disagreement_score":0.84090835,"about_ca_system_score_codex":0.0036476566,"about_ca_system_score_gemma":0.011067693,"threshold_uncertainty_score":0.9996016},"labels":[],"label_agreement":null},{"id":"W4410926980","doi":"10.1016/j.soncn.2025.151912","title":"The Experience of Patients with Cancer and Their Informal Caregivers Related to Adoptive Cell Therapy: A Qualitative Systematic Review","year":2025,"lang":"en","type":"review","venue":"Seminars in Oncology Nursing","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"Swiss Cancer Research Foundation","keywords":"Medicine; Cancer; Qualitative research; Psychotherapist; Internal medicine","score_opus":0.03261467924982775,"score_gpt":0.42894866331748793,"score_spread":0.3963339840676602,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410926980","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0011948876,0.9876901,0.000001966141,0.00016810499,0.00016734097,0.007818118,0.000036809513,0.000011777666,0.002910921],"genre_scores_gemma":[0.00007433797,0.99627715,0.000074483716,0.00011685251,0.000007812017,0.001093245,0.000034404475,0.000032192165,0.0022895227],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9968563,0.0010458756,0.00097131403,0.0003812536,0.0003378862,0.00040740008],"domain_scores_gemma":[0.9959304,0.0024919696,0.0006422621,0.0004844443,0.00033828974,0.00011267902],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011583855,0.00039834064,0.00295019,0.00031417838,0.000110865454,0.000010949168,0.0003049569,0.00029005564,0.000043706874],"category_scores_gemma":[0.00030545343,0.00021063627,0.00018700145,0.001104035,0.000633818,0.000058673562,0.00007217307,0.0007003098,0.0000013369095],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003448481,0.000117758835,0.000017805218,0.26241687,0.00021279737,0.000009021929,0.121169925,2.2194386e-7,8.664976e-7,0.000009232045,0.00021545398,0.6154852],"study_design_scores_gemma":[0.0009977844,0.0013638426,0.0000067307737,0.876784,0.00058982323,0.000015974974,0.042025298,0.0000013879393,0.000008050918,0.0000055358496,0.077999346,0.00020219851],"about_ca_topic_score_codex":0.000038512284,"about_ca_topic_score_gemma":0.000018707651,"teacher_disagreement_score":0.615283,"about_ca_system_score_codex":0.001554823,"about_ca_system_score_gemma":0.0015905594,"threshold_uncertainty_score":0.8589498},"labels":[],"label_agreement":null},{"id":"W4410955025","doi":"10.1038/s41590-025-02154-2","title":"Regulatory T cell therapies to treat autoimmune diseases and transplant rejection","year":2025,"lang":"en","type":"article","venue":"Nature Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Immunology; Medicine","score_opus":0.005500535717867823,"score_gpt":0.27628577318921815,"score_spread":0.2707852374713503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410955025","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9215934,0.06536502,0.000030177293,0.005161249,0.0004436949,0.0004841702,0.000013945155,0.00012482353,0.0067834877],"genre_scores_gemma":[0.9597882,0.0022781885,0.00007984502,0.00090762833,0.00006594868,0.000040460523,0.000027183152,0.000019791583,0.036792777],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9990213,0.000096322394,0.00016307617,0.00030983394,0.00013980186,0.0002696639],"domain_scores_gemma":[0.9993032,0.00012533508,0.000023676543,0.0004137945,0.000079039,0.000054938733],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000109689136,0.0001566704,0.0003096027,0.00035064155,0.000104181476,0.000015833859,0.0001028975,0.00041308498,0.00045444313],"category_scores_gemma":[0.000036056543,0.00012806065,0.0000791878,0.00032032476,0.0001496068,0.000036831036,0.000040046332,0.0006760071,0.000014658046],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028152976,0.00015234397,0.005658401,0.000106030544,0.00018326475,0.00003903981,0.0005925865,7.249092e-7,0.91759914,0.00072509027,0.0015212724,0.0706068],"study_design_scores_gemma":[0.0032945417,0.0007218646,0.727897,0.00014617827,0.00016005103,0.0000962556,0.00026772343,0.000010809001,0.11220232,0.00046011232,0.15456863,0.00017453448],"about_ca_topic_score_codex":0.00005625193,"about_ca_topic_score_gemma":0.000011602023,"teacher_disagreement_score":0.80539685,"about_ca_system_score_codex":0.00011579583,"about_ca_system_score_gemma":0.00011132714,"threshold_uncertainty_score":0.5222162},"labels":[],"label_agreement":null},{"id":"W4410973309","doi":"10.1111/imcb.70037","title":"Highlights of 2024: unleashing the power of NK cells—cancer's worst nightmare","year":2025,"lang":"en","type":"article","venue":"Immunology and Cell Biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"Children's Hospital Foundation; PA Research Foundation; University of Queensland; National Breast Cancer Foundation; Canadian Institutes of Health Research; Tour de Cure; Cancer Research Society","keywords":"Cytotoxicity; CRISPR; Cancer cell; Cytokine; Cell; Cancer research; Cancer; Biology; Immunology; Gene; In vitro; Biochemistry; Genetics","score_opus":0.01040844026320787,"score_gpt":0.28655691207170775,"score_spread":0.2761484718084999,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410973309","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94384724,0.02196065,0.000023762208,0.0030119352,0.0007163404,0.0002909847,0.000015314516,0.000014546879,0.030119246],"genre_scores_gemma":[0.97288966,0.0059512327,0.000028586286,0.00029124581,0.000029917293,0.000017756256,0.000009396118,0.000008671058,0.020773552],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989337,0.00020081815,0.0002995448,0.00023916144,0.000057315123,0.0002694744],"domain_scores_gemma":[0.99901277,0.00031692415,0.00010974528,0.0004205584,0.000114185255,0.00002582267],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00026472565,0.00012976189,0.00041812865,0.00016636784,0.000080952625,0.000002983274,0.00021865827,0.00028988722,0.0029049143],"category_scores_gemma":[0.000022128956,0.00008056785,0.00009243308,0.00024553915,0.00091887225,0.000016415335,0.00014943046,0.0003683474,0.000009530754],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008826295,0.000105477564,0.006022399,0.000082116,0.00033296147,0.000005005229,0.0005338598,8.911222e-7,0.9800794,0.004036648,0.0010657173,0.0068528587],"study_design_scores_gemma":[0.0015675799,0.00062835636,0.0077968785,0.00008583194,0.000083594154,0.000008914437,0.0005293717,0.000009285404,0.8288532,0.0014112928,0.1589365,0.000089227025],"about_ca_topic_score_codex":0.00019545841,"about_ca_topic_score_gemma":0.000031157793,"teacher_disagreement_score":0.15787078,"about_ca_system_score_codex":0.000026564223,"about_ca_system_score_gemma":0.00012981275,"threshold_uncertainty_score":0.9980066},"labels":[],"label_agreement":null},{"id":"W4410992159","doi":"10.31219/osf.io/yj5fb_v1","title":"Mid-term neurocognitive outcomes after CAR T cell therapy in central nervous system lymphomas: statistical analysis plan","year":2025,"lang":"en","type":"preprint","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Neurocognitive; Term (time); Central nervous system; CAR T-cell therapy; Statistical analysis; Plan (archaeology); Neuroscience; Medicine; T cell; Psychology; Cognition; Immunology; Biology; Immune system; Statistics; Mathematics","score_opus":0.02619972986616645,"score_gpt":0.3192107432866936,"score_spread":0.29301101342052716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410992159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96477187,0.0006190784,0.0015660588,0.00031023787,0.00055090064,0.0030780435,0.0013884105,0.00022521782,0.027490184],"genre_scores_gemma":[0.9771463,0.0004301457,0.00045645118,0.0006792012,0.00016039371,0.0005186317,0.00083156244,0.000065749235,0.019711541],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951945,0.00056478847,0.00092514214,0.0012993059,0.0009983712,0.0010178951],"domain_scores_gemma":[0.9973399,0.000679058,0.00014585177,0.0011305583,0.00025902368,0.00044560523],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003706271,0.0007036005,0.002012554,0.001410402,0.000045825258,0.00013210802,0.00041243472,0.0005479827,0.005069303],"category_scores_gemma":[0.000058270114,0.0005563758,0.0008016357,0.00078756723,0.00014462053,0.00003623458,0.00049363804,0.001175096,0.000047501893],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038264976,0.0007197627,0.9685575,0.001711342,0.00391028,0.004218701,0.0015213893,0.00014907894,0.0006710541,0.000068644484,0.00019776677,0.014447977],"study_design_scores_gemma":[0.005219816,0.00023624014,0.9864158,0.00036330757,0.0015932348,0.000020845964,0.0008687699,0.0022346273,0.0020524953,0.000032826858,0.0003710365,0.00059100403],"about_ca_topic_score_codex":0.00308471,"about_ca_topic_score_gemma":0.0007823066,"teacher_disagreement_score":0.01785829,"about_ca_system_score_codex":0.0009902259,"about_ca_system_score_gemma":0.0008347333,"threshold_uncertainty_score":0.99968874},"labels":[],"label_agreement":null},{"id":"W4411017159","doi":"10.1200/go-24-00441","title":"Global Access to Multiple Myeloma Therapies","year":2025,"lang":"en","type":"article","venue":"JCO Global Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Multiple myeloma; Expanded access; Family medicine; Chimeric antigen receptor; Oncology; Internal medicine; Cancer; Immunotherapy","score_opus":0.04368081239765278,"score_gpt":0.4343898033175966,"score_spread":0.3907089909199438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411017159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.62292355,0.00071760284,0.00068327686,0.034689642,0.0011062868,0.0012109962,0.00006781301,0.0001916373,0.3384092],"genre_scores_gemma":[0.9706599,0.00010060007,0.0013178512,0.017596379,0.00035559712,0.00013190717,0.00002017543,0.000013962029,0.00980362],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99810886,0.00014870541,0.00031887935,0.00046813473,0.00034165036,0.000613781],"domain_scores_gemma":[0.9987412,0.00017655513,0.00004894926,0.00051100494,0.00023533516,0.00028691808],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002899847,0.0002092823,0.0005423696,0.00010307318,0.000095070085,0.00006153427,0.0004937134,0.0002803116,0.0019757736],"category_scores_gemma":[0.00034028586,0.00018149991,0.00015785193,0.0012646955,0.00016267052,0.00008246539,0.00043144022,0.00018644023,0.0002927147],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003394442,0.00049192016,0.37441418,0.000048854192,0.0003486127,0.0002570662,0.00009750674,0.000017519136,0.0047693066,0.0038760721,0.11295602,0.4993285],"study_design_scores_gemma":[0.0024714924,0.0007309269,0.36940897,0.000029390567,0.00003853833,0.00006697431,0.000116736606,0.000055609922,0.0004416465,0.0012342113,0.62529796,0.00010758102],"about_ca_topic_score_codex":0.0006710452,"about_ca_topic_score_gemma":0.002250818,"teacher_disagreement_score":0.5123419,"about_ca_system_score_codex":0.002057761,"about_ca_system_score_gemma":0.0008927905,"threshold_uncertainty_score":0.99893653},"labels":[],"label_agreement":null},{"id":"W4411063878","doi":"10.1002/advs.202500181","title":"An Engineered Soluble Single‐Chain TCR Engager for KRAS‐G12V Specific Tumor Immunotherapy","year":2025,"lang":"en","type":"article","venue":"Advanced Science","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Chinese Academy of Sciences; Basic and Applied Basic Research Foundation of Guangdong Province; National Key Research and Development Program of China; Peking Union Medical College; Institute of Genetics; Institute of Microbiology, Chinese Academy of Sciences; National Natural Science Foundation of China","keywords":"T-cell receptor; KRAS; Context (archaeology); T cell; Cancer research; Immunotherapy; Avidity; Antigen; Computational biology; Mutation; Biology; Molecular biology; Chemistry; Immunology; Genetics; Immune system; Gene","score_opus":0.029175162036476313,"score_gpt":0.3437539107347228,"score_spread":0.3145787486982465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411063878","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87870276,0.0027175886,0.09537694,0.0019060436,0.0020106689,0.0031240417,0.000017598857,0.00042623092,0.015718117],"genre_scores_gemma":[0.9525674,0.00013591873,0.027897617,0.00087674026,0.00015648463,0.00015750626,0.000010472957,0.00004281078,0.01815506],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976468,0.00004327264,0.00028406654,0.00067582633,0.00058024726,0.00076975446],"domain_scores_gemma":[0.99819624,0.0002862514,0.00005300765,0.0009156922,0.0003431523,0.00020564246],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013355849,0.00019842362,0.00031073322,0.00042112928,0.00041869903,0.00010905369,0.0005772365,0.000047385947,0.0004646701],"category_scores_gemma":[0.00030281264,0.0001813146,0.000104685154,0.001495386,0.0005278585,0.00043312262,0.000053092794,0.000300632,0.000019305517],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004122375,0.00017623535,0.00006262588,0.000026435024,0.000011590643,0.000011166375,0.00027956688,0.00030181318,0.91272515,0.0013783738,0.00020064812,0.08441414],"study_design_scores_gemma":[0.0034011565,0.00091323105,0.0010803175,0.000106941225,0.000008157263,0.000020836142,0.00045883338,0.0050735283,0.8074607,0.0011938389,0.18002288,0.00025955477],"about_ca_topic_score_codex":0.000008311599,"about_ca_topic_score_gemma":0.000005215118,"teacher_disagreement_score":0.17982224,"about_ca_system_score_codex":0.000355684,"about_ca_system_score_gemma":0.00042432206,"threshold_uncertainty_score":0.73937947},"labels":[],"label_agreement":null},{"id":"W4411126573","doi":"10.1186/s40644-025-00888-8","title":"Prognostic value of early post-treatment 18F-FDG PET/CT in diffuse large B-cell lymphoma patients receiving chimeric antigen receptor T-cell therapy","year":2025,"lang":"en","type":"article","venue":"Cancer Imaging","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Women's College Hospital","funders":"","keywords":"Medicine; Standardized uptake value; Proportional hazards model; Nuclear medicine; Lymphoma; Log-rank test; Univariate analysis; Positron emission tomography; Progression-free survival; Internal medicine; Diffuse large B-cell lymphoma; Multivariate analysis; Oncology; Gastroenterology; Chemotherapy","score_opus":0.01174658242552977,"score_gpt":0.29977397794352556,"score_spread":0.2880273955179958,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411126573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865456,0.006814415,0.0000138563,0.0003760715,0.00040740412,0.0015797138,0.00004874473,0.0000625613,0.0041515944],"genre_scores_gemma":[0.990612,0.0044356105,0.00021079005,0.00041178582,0.00007698656,0.00021743632,0.00005981052,0.00007642754,0.003899153],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99764156,0.00016469408,0.00047971142,0.00056794996,0.00043845217,0.00070762524],"domain_scores_gemma":[0.9987159,0.00018107342,0.0001591983,0.0005336837,0.000262873,0.00014729942],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025649945,0.0003307824,0.0005590522,0.0004546425,0.000097287775,0.000046882305,0.0002325932,0.000016899612,0.0004907611],"category_scores_gemma":[0.00006917865,0.0002916836,0.00018502954,0.00080554484,0.00009956565,0.0001386417,0.00009256232,0.00019065583,0.000026001226],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00058574375,0.0046670674,0.80114645,0.00016077026,0.000092241266,0.000103242615,0.0008880579,0.000002595882,0.090026386,0.0000031282586,0.00017206928,0.10215224],"study_design_scores_gemma":[0.044508785,0.00079805707,0.7843192,0.0009843746,0.00008865026,0.0000138706655,0.00045822628,0.0007050004,0.15114044,0.000016272405,0.016544316,0.00042276533],"about_ca_topic_score_codex":0.0026376687,"about_ca_topic_score_gemma":0.00006737004,"teacher_disagreement_score":0.101729475,"about_ca_system_score_codex":0.0008948375,"about_ca_system_score_gemma":0.0006836365,"threshold_uncertainty_score":0.9999535},"labels":[],"label_agreement":null},{"id":"W4411136134","doi":"10.1101/2025.06.06.658308","title":"Imaging CRISPR-Edited CAR-T Cell Therapies with Optical and Positron Emission Tomography Reporters","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba; Lawson Health Research Institute; University of Manitoba; Western University","funders":"National Institutes of Health","keywords":"Positron emission tomography; CRISPR; Physics; Medical physics; Psychology; Neuroscience; Biology; Genetics","score_opus":0.010198859144757967,"score_gpt":0.25104817895860093,"score_spread":0.24084931981384297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411136134","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891216,0.0054347357,0.00090392324,0.001398962,0.00055164454,0.0016684334,0.00007909844,0.0005150416,0.0003265313],"genre_scores_gemma":[0.99219865,0.0008107632,0.005594694,0.00041895884,0.0004359605,0.00017669318,0.0000016832572,0.00015559456,0.00020698852],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9960559,0.00015360746,0.0006273986,0.0014737339,0.00088880066,0.0008005386],"domain_scores_gemma":[0.9965068,0.00013446693,0.0003026759,0.0016751491,0.0007728514,0.0006080405],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00075202575,0.0007441601,0.0009511547,0.00082952884,0.00020368745,0.00028282398,0.00033396238,0.00047655858,0.00013666267],"category_scores_gemma":[0.00010181047,0.0006465449,0.00023673782,0.00081093714,0.00038480267,0.00012469658,0.0004873353,0.001602524,0.000004089583],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00062035496,0.00022316161,0.09856987,0.0011039543,0.0004257057,0.00061029906,0.000045440138,0.0000032998635,0.89779264,0.000030148054,0.0005367593,0.00003835356],"study_design_scores_gemma":[0.0026586396,0.00032348282,0.18944912,0.0022110895,0.000711479,8.570469e-7,0.000041651936,0.00042230423,0.79430526,0.0000019342465,0.008858398,0.0010157947],"about_ca_topic_score_codex":0.00014397685,"about_ca_topic_score_gemma":0.0000017725632,"teacher_disagreement_score":0.103487395,"about_ca_system_score_codex":0.00030748773,"about_ca_system_score_gemma":0.0010654983,"threshold_uncertainty_score":0.99959856},"labels":[],"label_agreement":null},{"id":"W4411148333","doi":"10.1016/j.jiec.2025.06.017","title":"Nanoparticles-Mediated CRISPR-Cas9 systems for CAR T-cell immunotherapy as smart cancer biotherapeutics","year":2025,"lang":"en","type":"article","venue":"Journal of Industrial and Engineering Chemistry","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Trois-Rivières","funders":"Umm Al-Qura University","keywords":"CRISPR; Cancer immunotherapy; Immunotherapy; Genome editing; Cas9; Cancer research; Chemistry; Computational biology; Cancer; Biology; Biochemistry; Gene; Genetics","score_opus":0.029488499934878825,"score_gpt":0.30125258237159114,"score_spread":0.2717640824367123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411148333","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9870023,0.010828062,0.00012674401,0.00075465435,0.00068123406,0.0002633235,0.000015321586,0.00002224199,0.00030610562],"genre_scores_gemma":[0.98699456,0.003953906,0.00008032629,0.00013373428,0.0014036164,0.000028442599,0.0000054116153,0.000046431298,0.0073535875],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989551,0.000011348922,0.00043138614,0.00012281183,0.00022015703,0.00025920765],"domain_scores_gemma":[0.9992153,0.00017258793,0.00012005559,0.0001371027,0.00020110133,0.00015384577],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035804586,0.0001585795,0.00039551707,0.00008867608,0.000041278774,0.000052309355,0.000103734754,0.00025148442,0.00012789502],"category_scores_gemma":[0.00012349272,0.0001324204,0.00012764457,0.00021136057,0.000034262106,0.000041315507,0.0000147212695,0.00048041754,6.537225e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00087875855,0.00008128338,0.0008389544,0.0002895829,0.00036272907,0.00001865074,0.000056221317,0.00034233712,0.9921437,0.0000031366558,0.0018649686,0.0031197118],"study_design_scores_gemma":[0.0068572527,0.00022938485,0.00007355148,0.0005861529,0.00010523586,0.00010747318,0.00014215687,0.0015680126,0.84636754,0.000004575216,0.14382213,0.00013656152],"about_ca_topic_score_codex":0.00004385508,"about_ca_topic_score_gemma":1.2291785e-7,"teacher_disagreement_score":0.14577615,"about_ca_system_score_codex":0.00018065187,"about_ca_system_score_gemma":0.000387711,"threshold_uncertainty_score":0.5399948},"labels":[],"label_agreement":null},{"id":"W4411150706","doi":"10.58931/crt.2025.2160","title":"The Impact of Chimeric Antigen Receptor (CAR) T Cell Therapy: Its Potential to Reshape Rheumatology Practice","year":2025,"lang":"en","type":"article","venue":"Canadian rheumatology today.","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"","keywords":"Chimeric antigen receptor; Rheumatology; Internal medicine; Receptor; Antigen; Medicine; Immunology; Immunotherapy","score_opus":0.01358585037871875,"score_gpt":0.32049053594546567,"score_spread":0.30690468556674694,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411150706","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94868267,0.00812174,0.00003277689,0.019154238,0.00088755187,0.001452494,0.000064710795,0.000059362734,0.02154447],"genre_scores_gemma":[0.9842985,0.006759783,0.00020634329,0.0010271304,0.000022269278,0.00008822964,0.000044198157,0.00006494863,0.0074885585],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9966162,0.00055691745,0.000713527,0.0005746263,0.00030346343,0.0012352635],"domain_scores_gemma":[0.99639326,0.0008991534,0.00022245236,0.0010202988,0.00062822027,0.00083663134],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00086807867,0.00035380622,0.00088876806,0.0008099295,0.0004229879,0.000048309375,0.0006573743,0.0004085864,0.0047973897],"category_scores_gemma":[0.001376096,0.0002681186,0.00033079783,0.0011701293,0.0003844947,0.00009813485,0.00010389832,0.0006663934,0.0003923329],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010082178,0.000655246,0.14698489,0.00038827595,0.004261088,0.0004528957,0.0029763351,0.0001595794,0.24703303,0.004636706,0.4939977,0.08837209],"study_design_scores_gemma":[0.011120227,0.0035875312,0.08629207,0.0006575703,0.00019273613,0.0035376654,0.0033508088,0.0011148975,0.037953306,0.00039390536,0.85053575,0.0012635123],"about_ca_topic_score_codex":0.13498326,"about_ca_topic_score_gemma":0.013555669,"teacher_disagreement_score":0.3565381,"about_ca_system_score_codex":0.00052750856,"about_ca_system_score_gemma":0.0050693164,"threshold_uncertainty_score":0.9999771},"labels":[],"label_agreement":null},{"id":"W4411238360","doi":"10.1016/j.ccell.2025.05.013","title":"CSF1R+ myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma","year":2025,"lang":"en","type":"article","venue":"Cancer Cell","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Horizon 2020; European Research Council; Hector Stiftung; Ministerium für Kultur und Wissenschaft des Landes Nordrhein-Westfalen; José Carreras Leukämie-Stiftung; Bundesministerium für Bildung und Forschung; Horizon 2020 Framework Programme; Imhoff Stiftung; Else Kröner-Fresenius-Stiftung; Bayerische Forschungsstiftung; Deutsche Forschungsgemeinschaft; Fritz-Bender-Stiftung; Deutsche Krebshilfe; Wilhelm Sander-Stiftung; Universität zu Köln; European Commission; Deutsches Zentrum für Infektionsforschung","keywords":"Lymphoma; Myeloid; Cancer research; Myeloid cells; Cell; Biology; Immunology; Genetics","score_opus":0.0135611302673057,"score_gpt":0.30067887263412796,"score_spread":0.28711774236682225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411238360","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.46607956,0.039039303,0.000054647226,0.0007441431,0.00103898,0.0015499666,0.000101354955,0.00011297459,0.49127907],"genre_scores_gemma":[0.6688944,0.008241659,0.00037083216,0.0009882881,0.00024995147,0.00024272536,0.000030055508,0.00008276097,0.3208993],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99634737,0.00017619813,0.00071044284,0.0010655628,0.00063375704,0.0010666995],"domain_scores_gemma":[0.9975296,0.00033835848,0.00031636792,0.0011835548,0.000285612,0.00034650942],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00035527386,0.0004901498,0.0008018841,0.00037354298,0.00013032346,0.000066973254,0.0005303881,0.0003298792,0.0021085145],"category_scores_gemma":[0.00004080867,0.00048925285,0.00026942574,0.0010918052,0.0002480138,0.00012844567,0.00020465322,0.000524993,0.00023284653],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040318966,0.0012633427,0.003056385,0.0024444426,0.000111691996,0.0013602764,0.0038387338,0.00021049863,0.90054286,0.00007481809,0.068399474,0.014665608],"study_design_scores_gemma":[0.011679814,0.00016306085,0.0018523223,0.0006434144,0.00011621919,0.0000025872375,0.0008910608,0.00021411132,0.7737527,0.00016820616,0.21007416,0.0004423282],"about_ca_topic_score_codex":0.0017281066,"about_ca_topic_score_gemma":0.002065461,"teacher_disagreement_score":0.20281485,"about_ca_system_score_codex":0.002956906,"about_ca_system_score_gemma":0.0018965701,"threshold_uncertainty_score":0.9997559},"labels":[],"label_agreement":null},{"id":"W4411259006","doi":"10.1126/sciadv.adx7845","title":"Armored human CAR T <sub>reg</sub> cells with PD1 promoter-driven IL-10 have enhanced suppressive function","year":2025,"lang":"en","type":"article","venue":"Science Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"Canadian Institutes of Health Research; BC Children's Hospital; AstraZeneca","keywords":"Function (biology); Cell biology; Computational biology; Biology; Molecular biology","score_opus":0.013511176984301787,"score_gpt":0.31620300698714404,"score_spread":0.3026918300028423,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411259006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9818671,0.0003264583,0.0014421926,0.00034719915,0.00037464336,0.0010386276,0.000010485434,0.00010451015,0.014488825],"genre_scores_gemma":[0.9814251,0.00006486441,0.0004946117,0.0001632695,0.00012557073,0.000113200316,0.00001400423,0.00001990477,0.01757946],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99719495,0.00005411285,0.00024999445,0.00081982836,0.0010103789,0.00067076046],"domain_scores_gemma":[0.99848884,0.000065413085,0.00012191519,0.0006160757,0.00049730326,0.00021042538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038747423,0.0002329842,0.00033777655,0.00038994726,0.00048143213,0.000104477534,0.00041226146,0.000067311004,0.00035655973],"category_scores_gemma":[0.00008325932,0.0001762576,0.00007402181,0.0012009533,0.0015181031,0.00066064677,0.00011857236,0.0003103812,0.00005320009],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004430262,0.000096510696,0.0004115903,0.00006587889,0.000025915851,0.000022583827,0.00038141597,0.00013276371,0.95881736,0.000046298454,0.00023308897,0.039323542],"study_design_scores_gemma":[0.0013078331,0.0011430223,0.0023376646,0.00021636194,0.000044046967,0.000007646221,0.0006069761,0.00014816134,0.98700184,0.00042866496,0.0065710098,0.00018675548],"about_ca_topic_score_codex":0.000016388592,"about_ca_topic_score_gemma":0.000100868245,"teacher_disagreement_score":0.039136786,"about_ca_system_score_codex":0.00022763638,"about_ca_system_score_gemma":0.00053397275,"threshold_uncertainty_score":0.7187576},"labels":[],"label_agreement":null},{"id":"W4411287882","doi":"10.1101/2025.06.09.658763","title":"Thermally controlled state switches for macrophage immunotherapy","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Natural Sciences and Engineering Research Council of Canada; California Institute of Technology; Sontag Foundation; Beckman Institute, California Institute of Technology; National Institutes of Health; National Science Foundation","keywords":"Immunotherapy; Immune system; Cancer immunotherapy; In vivo; Cytokine; Cell biology; Macrophage; Biology; Cancer research; Immunology; In vitro; Genetics","score_opus":0.01857719081642212,"score_gpt":0.2771008792582714,"score_spread":0.2585236884418493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411287882","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9654949,0.010253717,0.005639301,0.0016222793,0.0019992015,0.012516306,0.0011759676,0.0009575763,0.00034077384],"genre_scores_gemma":[0.9795026,0.0033117624,0.0063716224,0.0016718041,0.0010459478,0.0036739386,0.0000022829292,0.000425449,0.0039945864],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99561393,0.00020552486,0.0010096944,0.0013291752,0.0007479881,0.0010936776],"domain_scores_gemma":[0.9951406,0.0004170077,0.00046823424,0.002273287,0.0013150099,0.00038582072],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017019592,0.00089958106,0.0019536037,0.0005970245,0.00021598233,0.00028077856,0.0007891522,0.00073026353,0.00091038423],"category_scores_gemma":[0.0003886621,0.0008342055,0.00086567743,0.00050818874,0.0002022545,0.000086834196,0.0003930781,0.0013922048,0.000054811546],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0070208344,0.00038159388,0.0013847549,0.0012006335,0.0020586494,0.000082327424,0.000029452734,0.00003189089,0.9869773,0.00014539475,0.0005865382,0.000100622805],"study_design_scores_gemma":[0.030619903,0.00057508197,0.022555191,0.0013005539,0.00054512714,5.650596e-8,0.0000063932266,0.0012053379,0.8756421,0.000018104456,0.0662002,0.0013319482],"about_ca_topic_score_codex":0.00008753456,"about_ca_topic_score_gemma":0.0000033749975,"teacher_disagreement_score":0.111335196,"about_ca_system_score_codex":0.0006456218,"about_ca_system_score_gemma":0.0025522003,"threshold_uncertainty_score":0.99941087},"labels":[],"label_agreement":null},{"id":"W4411319666","doi":"10.1136/jitc-2024-011364","title":"Blockade of colon cancer metastasis via single and double silencing of <i>PCSK7</i> / <i>PCSK9</i> : enhanced T cells cytotoxicity in mouse and human","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont; Montreal Clinical Research Institute","funders":"Canada Research Chairs; Québec Consortium for Drug Discovery; Cancer Research Society","keywords":"Proprotein convertase; Cancer research; T cell; Kexin; Cytotoxic T cell; Immune checkpoint; Biology; Immune system; CD8; Immunotherapy; Immunology; LDL receptor; Endocrinology; Cholesterol","score_opus":0.025767333762424804,"score_gpt":0.360806984194092,"score_spread":0.3350396504316672,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411319666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9803785,0.017732497,0.000341553,0.00028953518,0.00015385455,0.00084003847,0.000056851666,0.0000065219433,0.0002006394],"genre_scores_gemma":[0.9868041,0.0096083945,0.0005553902,0.00015542933,0.00006463264,0.00007772671,0.0000014293119,0.000036927424,0.00269592],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99820167,0.00006416936,0.00082116557,0.00022961418,0.00036491716,0.0003184806],"domain_scores_gemma":[0.99866647,0.00015737524,0.00048755805,0.00023276206,0.00037838487,0.00007746936],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006812011,0.00020188792,0.00088168547,0.00039679004,0.000092290495,0.000018273211,0.00014895164,0.00012364417,0.00033323446],"category_scores_gemma":[0.000012325079,0.0001785832,0.00018619606,0.00035680368,0.00025861614,0.000107880056,0.000038872127,0.0003260867,4.7136652e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006243376,0.0003093993,0.0026481568,0.0006149041,0.00055441965,0.0000015572625,0.00097303593,0.00010341064,0.9572706,0.00001524967,0.000106362364,0.03115953],"study_design_scores_gemma":[0.010600669,0.0009937028,0.0009513117,0.00074948644,0.00011129508,0.000006811881,0.00021175013,0.000046911988,0.98401123,0.00015967184,0.0020304627,0.00012667892],"about_ca_topic_score_codex":0.0026548835,"about_ca_topic_score_gemma":0.0010521073,"teacher_disagreement_score":0.03103285,"about_ca_system_score_codex":0.0002575196,"about_ca_system_score_gemma":0.00030206188,"threshold_uncertainty_score":0.72824115},"labels":[],"label_agreement":null},{"id":"W4411335183","doi":"10.1002/hon.70093_5","title":"5 | LARGE B‐CELL LYMPHOMA MICROENVIRONMENT ARCHETYPE PROFILES (LYMPHOMAPS) IDENTIFY SUBGROUPS WITH GREATEST BENEFIT FROM CD19 CAR T‐CELL THERAPY","year":2025,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"MorphoSys; Genentech; Incyte; Gilead Sciences; AstraZeneca","keywords":"CD19; Lymphoma; Medicine; B cell; Oncology; Internal medicine; Cancer research; Immunology","score_opus":0.02569170392763857,"score_gpt":0.31176753998727297,"score_spread":0.2860758360596344,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411335183","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9724839,0.004723238,0.00021155342,0.0019230605,0.00018086917,0.0015462016,0.00006195896,0.00017174489,0.018697474],"genre_scores_gemma":[0.9777856,0.0021272602,0.0016420031,0.0023805955,0.000121218065,0.00036283061,0.00025251778,0.00006530042,0.015262682],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99634933,0.00030376812,0.00065021246,0.0010822522,0.00053642906,0.0010779774],"domain_scores_gemma":[0.9976739,0.00075896794,0.00019524108,0.00089050934,0.00012232477,0.00035900663],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00040057884,0.0005188739,0.0013189706,0.00022539901,0.00020600941,0.000045313715,0.00046897322,0.0006968649,0.0051694284],"category_scores_gemma":[0.000044951372,0.00036157764,0.00027062598,0.0004496739,0.0005151897,0.00006383354,0.00030251994,0.00049123773,0.00049860805],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010827897,0.0149030015,0.3049172,0.00035881708,0.00066099846,0.004688847,0.0010033909,0.00000505589,0.6376593,0.0019285278,0.005087341,0.017959636],"study_design_scores_gemma":[0.040105928,0.0053975363,0.19324519,0.00020257404,0.00029555397,0.00072221196,0.0012754574,0.00012360231,0.4675849,0.0018853112,0.28839815,0.0007635686],"about_ca_topic_score_codex":0.00022034225,"about_ca_topic_score_gemma":0.00010014397,"teacher_disagreement_score":0.2833108,"about_ca_system_score_codex":0.0007873924,"about_ca_system_score_gemma":0.00043695734,"threshold_uncertainty_score":0.9998836},"labels":[],"label_agreement":null},{"id":"W4411383594","doi":"10.1080/10428194.2025.2518440","title":"Real-world healthcare costs for patients treated with chimeric antigen receptor T-cell therapy in Canada","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Sunnybrook Health Science Centre; University of Waterloo; Princess Margaret Cancer Centre; Toronto General Hospital","funders":"","keywords":"Chimeric antigen receptor; Reimbursement; Medicine; Activity-based costing; Cohort; Health care; Retrospective cohort study; Internal medicine; Immunotherapy; Cancer; Business","score_opus":0.010594177255934879,"score_gpt":0.26298161148964,"score_spread":0.25238743423370513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411383594","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98537946,0.0012486117,0.0000057675798,0.0005258366,0.00025257719,0.002936676,0.00013181068,0.0001147857,0.009404476],"genre_scores_gemma":[0.9777242,0.0045120553,0.00032492576,0.002055834,0.00013621892,0.0005133036,0.0005508315,0.00014685057,0.014035779],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957792,0.00020602239,0.00082052173,0.0011392678,0.000752461,0.0013025228],"domain_scores_gemma":[0.99753344,0.00042465382,0.00023145282,0.0008533586,0.00040094633,0.00055616844],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00029667612,0.0007060567,0.0011570383,0.00067639636,0.000304208,0.00007952349,0.0003543729,0.00027457764,0.00017947148],"category_scores_gemma":[0.00004478113,0.0005947957,0.00016077867,0.0018316775,0.00019168055,0.0001586992,0.000092613445,0.00020109364,0.000009061298],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.007860485,0.00032179186,0.625247,0.0003670323,0.00022851415,0.0000990198,0.0002657637,0.0000073220517,0.005121682,0.000069311085,0.008511086,0.351901],"study_design_scores_gemma":[0.06070096,0.0018639576,0.8242886,0.0007784554,0.00007963658,0.000032548014,0.00052782556,0.0012170905,0.02535935,0.000030975374,0.08426509,0.00085549755],"about_ca_topic_score_codex":0.88760287,"about_ca_topic_score_gemma":0.59286886,"teacher_disagreement_score":0.3510455,"about_ca_system_score_codex":0.036217134,"about_ca_system_score_gemma":0.024667764,"threshold_uncertainty_score":0.99965036},"labels":[],"label_agreement":null},{"id":"W4411401649","doi":"10.1016/j.omtm.2025.101517","title":"Development of iPSC-derived T cells targeting EGFR neoantigens in non-small cell lung cancer","year":2025,"lang":"en","type":"article","venue":"Molecular Therapy — Methods & Clinical Development","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Defense Science and Engineering Graduate; University of California, Los Angeles; National Institutes of Health; Weston Havens Foundation; University of Toronto; Medizinische Universität Wien; Johns Hopkins University; Lung Cancer Research Foundation; Japan Society for the Promotion of Science; Kyushu University; California Institute for Regenerative Medicine","keywords":"Lung cancer; Cancer research; Medicine; Cell; Oncology; Biology; Genetics","score_opus":0.06819337799728677,"score_gpt":0.4599584104786687,"score_spread":0.39176503248138195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411401649","genre_codex":"empirical","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8606297,0.0043961895,0.12973632,0.00039763277,0.0006518473,0.0019331084,0.0000019607066,0.000056049288,0.002197223],"genre_scores_gemma":[0.0525581,0.00347696,0.9377156,0.0019733342,0.00006869464,0.00039305488,0.000029761806,0.00010922982,0.0036752839],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99334276,0.0012364368,0.002683652,0.0010721309,0.00070524466,0.00095975905],"domain_scores_gemma":[0.9972788,0.00086679065,0.00038926667,0.00072445546,0.0004006609,0.00034003437],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.006312461,0.0005430574,0.001462347,0.00053192704,0.00014272163,0.000036473964,0.00056566356,0.00044559964,0.001009334],"category_scores_gemma":[0.0002687772,0.0004953117,0.00041493558,0.0010842095,0.00017416412,0.000039461374,0.0003465712,0.0010094398,0.000018932513],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00062550337,0.00060973066,0.008634493,0.00024156034,0.00045986494,0.00006216523,0.0017948078,0.00003644115,0.62176687,0.0000073061474,0.00009627529,0.36566496],"study_design_scores_gemma":[0.005347476,0.000105248735,0.030379869,0.0005125277,0.000048166366,0.0000010557628,0.00025383628,0.0005151564,0.8968357,0.000040023206,0.06552556,0.00043537488],"about_ca_topic_score_codex":0.00006766486,"about_ca_topic_score_gemma":0.000031348165,"teacher_disagreement_score":0.80807155,"about_ca_system_score_codex":0.0005486839,"about_ca_system_score_gemma":0.0032182033,"threshold_uncertainty_score":0.99990386},"labels":[],"label_agreement":null},{"id":"W4411412184","doi":"10.1016/j.ccell.2025.06.002","title":"Large B cell lymphoma microenvironment archetype profiles","year":2025,"lang":"en","type":"article","venue":"Cancer Cell","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Spinal Cord Injury BC","funders":"National Cancer Institute; Leukemia and Lymphoma Society; Lymphoma Research Foundation","keywords":"Lymphoma; Cancer research; Tumor microenvironment; Archetype; Biology; Cell biology; Computational biology; Medicine; Immunology; Tumor cells","score_opus":0.016007983191194113,"score_gpt":0.3006595645842687,"score_spread":0.28465158139307456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411412184","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7457953,0.017783819,0.00015111367,0.0013365971,0.0003909991,0.00095300237,0.00004970582,0.00007157496,0.23346786],"genre_scores_gemma":[0.6449478,0.0042835516,0.00022278742,0.0015202838,0.00019236132,0.00016142154,0.00003321277,0.00003763059,0.3486009],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99867207,0.000042616746,0.00018575836,0.0003641706,0.00026298696,0.00047239353],"domain_scores_gemma":[0.99926,0.00004038777,0.000037621026,0.00047985598,0.00003950845,0.00014262967],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00015512176,0.0001650947,0.00024319964,0.00007203344,0.00007283227,0.000017295348,0.00015885354,0.000095850664,0.0113533465],"category_scores_gemma":[0.0000058979563,0.00014939976,0.00011622954,0.0001770651,0.00007926541,0.000031968335,0.00012349624,0.0001514512,0.00025409035],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00051823276,0.0011844952,0.011687745,0.00068809197,0.00007738924,0.00005207083,0.00057797506,0.0000040507935,0.91476154,0.000063429485,0.0436709,0.026714072],"study_design_scores_gemma":[0.003230793,0.00007728319,0.003934375,0.000057410107,0.00004030661,0.0000016916522,0.0002050712,0.000056614368,0.48305175,0.000025738913,0.50922704,0.00009190991],"about_ca_topic_score_codex":0.00018053269,"about_ca_topic_score_gemma":0.000043919925,"teacher_disagreement_score":0.46555614,"about_ca_system_score_codex":0.00070968067,"about_ca_system_score_gemma":0.0003522738,"threshold_uncertainty_score":0.9895504},"labels":[],"label_agreement":null},{"id":"W4411429251","doi":"10.1080/10428194.2025.2504719","title":"Combinability of epcoritamab CD20-targeting T-cell engager and CD20 antibody-targeted therapies in B-cell non-Hodgkin lymphoma","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"AbbVie Canada","keywords":"Chemoimmunotherapy; CD20; Rituximab; CHOP; Monoclonal antibody; Vincristine; Cancer research; Lymphoma; Medicine; B cell; Antibody-dependent cell-mediated cytotoxicity; Diffuse large B-cell lymphoma; Antibody; Immunology; Internal medicine; Chemotherapy; Cyclophosphamide","score_opus":0.008323771422152333,"score_gpt":0.27149745491985194,"score_spread":0.2631736834976996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411429251","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96999377,0.012283346,0.00012849424,0.0003155423,0.0004374459,0.0017746828,0.000049478032,0.00020082959,0.01481644],"genre_scores_gemma":[0.9874826,0.004625492,0.0010268245,0.0006664795,0.0001744433,0.00015127273,0.00015713794,0.00017126305,0.005544452],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.992766,0.00081961224,0.0018408488,0.0018376623,0.0010581731,0.0016776773],"domain_scores_gemma":[0.9954346,0.0015413818,0.0004770201,0.0014906956,0.00046266054,0.0005936772],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0025844881,0.0011468632,0.002182156,0.0011645015,0.0004799308,0.0001818097,0.0006516594,0.00096037175,0.00031708326],"category_scores_gemma":[0.00043555268,0.0010984143,0.0004641565,0.0019005138,0.0011511382,0.00040740444,0.0006082803,0.00047443475,0.000024361074],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040856707,0.0017476416,0.18375774,0.0036090668,0.0003727351,0.00048401728,0.0045617255,0.00002392998,0.6231491,0.00031678035,0.0013417973,0.1765498],"study_design_scores_gemma":[0.082103185,0.0012317924,0.49259093,0.0012308107,0.0004025664,0.00028193346,0.005616783,0.010348707,0.3827328,0.0014206499,0.020331599,0.001708223],"about_ca_topic_score_codex":0.005008964,"about_ca_topic_score_gemma":0.00009136943,"teacher_disagreement_score":0.3088332,"about_ca_system_score_codex":0.0053948592,"about_ca_system_score_gemma":0.0050655515,"threshold_uncertainty_score":0.9991466},"labels":[],"label_agreement":null},{"id":"W4411431464","doi":"10.1016/j.ard.2025.05.101","title":"OP0079 Clinical, Cellular Kinetics, Pharmacodynamics and Biomarker Data Up to 12 Months After YTB323 (Rapcabtagene Autoleucel), a Rapidly Manufactured CD19 CAR-T Therapy, From an Open-Label, Phase 1/2 Study in Severe Refractory SLE","year":2025,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Pharmacodynamics; Biomarker; Pharmacology; Pharmacokinetics","score_opus":0.1711146996053166,"score_gpt":0.4758479427257691,"score_spread":0.30473324312045247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411431464","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98432326,0.007075854,0.000033564815,0.002145094,0.0005462901,0.004176105,0.0015405333,0.000044804845,0.000114516835],"genre_scores_gemma":[0.99092245,0.0038334185,0.00017614121,0.002331826,0.000053464955,0.00017851013,0.00037893126,0.00007426898,0.0020509604],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99544144,0.001085979,0.0012109424,0.0010062044,0.00073467696,0.0005207508],"domain_scores_gemma":[0.9951413,0.000663137,0.00028072673,0.0032065741,0.0001913832,0.00051684614],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013196757,0.00045149785,0.0011274555,0.00030308217,0.000105394516,0.00018072037,0.0019491772,0.0001396638,0.0012023681],"category_scores_gemma":[0.000509309,0.00033011127,0.00012914668,0.00046588664,0.00027156208,0.00036316115,0.0017235412,0.0003527192,0.000008832988],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.042743124,0.03820259,0.056654118,0.0005703232,0.0044519366,0.00020679616,0.0029806593,0.000022751843,0.03696692,0.000004295448,0.037121598,0.7800749],"study_design_scores_gemma":[0.08676921,0.009345207,0.84106195,0.003146023,0.0017628242,0.0000070185133,0.0035131874,0.019569773,0.010677744,0.0010906517,0.021534141,0.0015222823],"about_ca_topic_score_codex":0.0015186069,"about_ca_topic_score_gemma":0.00041387219,"teacher_disagreement_score":0.7844078,"about_ca_system_score_codex":0.00005348088,"about_ca_system_score_gemma":0.00038027434,"threshold_uncertainty_score":0.9999151},"labels":[],"label_agreement":null},{"id":"W4411516648","doi":"10.1111/ene.70236","title":"Baseline Cognitive and Neurological Status Does Not Modify the Occurrence of <scp>ICANS</scp> in <scp>CAR</scp> T‐Cell Therapy for Aggressive B‐Cell Lymphoma","year":2025,"lang":"en","type":"article","venue":"European Journal of Neurology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Montreal Cognitive Assessment; Cognitive impairment; Disease","score_opus":0.028718000725559318,"score_gpt":0.30248808326568627,"score_spread":0.27377008254012697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411516648","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902498,0.0033987889,0.00038776902,0.0019628082,0.00041608393,0.0008486982,0.00013729767,0.000016840884,0.0025819198],"genre_scores_gemma":[0.98496497,0.006859342,0.00010683438,0.006788006,0.00025261962,0.0000133759695,0.000011115832,0.000047661084,0.0009560984],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9946626,0.0026528873,0.0009889252,0.00051551085,0.00044864975,0.0007314418],"domain_scores_gemma":[0.98827857,0.00956466,0.00087445497,0.00035978862,0.00065372256,0.00026880982],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021572688,0.00034808207,0.0008123765,0.00050952804,0.000107179316,0.000038253867,0.000515041,0.00012070025,0.00003666719],"category_scores_gemma":[0.0044230917,0.00020957124,0.00026220153,0.00044393685,0.0007442109,0.000080273196,0.00020836701,0.0010942178,0.000005265128],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018679952,0.0055040754,0.118175805,0.00064093387,0.00069024315,0.014300974,0.0077330233,0.00038501775,0.55554414,0.000116889394,0.016501531,0.26172742],"study_design_scores_gemma":[0.08135226,0.04847042,0.48661378,0.0004612445,0.0006004291,0.0025170962,0.0027161518,0.0047984812,0.14509468,0.0005555839,0.22657141,0.0002484637],"about_ca_topic_score_codex":0.000009590541,"about_ca_topic_score_gemma":0.0000055117926,"teacher_disagreement_score":0.41044945,"about_ca_system_score_codex":0.000020513642,"about_ca_system_score_gemma":0.00033946687,"threshold_uncertainty_score":0.85460675},"labels":[],"label_agreement":null},{"id":"W4411544535","doi":"10.1080/16078454.2025.2519865","title":"Revaccination following CAR-T therapy: a needs assessment","year":2025,"lang":"en","type":"article","venue":"Hematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Hospital; McMaster University; Hamilton Health Sciences; Canadian Sleep Society","funders":"Canadian Hematology Society","keywords":"Medicine; Intensive care medicine; Oncology","score_opus":0.028503807906213013,"score_gpt":0.3848523500138798,"score_spread":0.35634854210766675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411544535","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.869346,0.002002073,0.0013398868,0.009857597,0.0004974944,0.00076907355,6.251702e-7,0.0001320589,0.11605518],"genre_scores_gemma":[0.9765732,0.00018272798,0.0005973934,0.001301626,0.000047884732,0.000095495685,0.000014767592,0.000017945356,0.02116896],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989793,0.00010315501,0.00022604014,0.0002008961,0.00021036528,0.00028028287],"domain_scores_gemma":[0.99929345,0.00016238331,0.000034612112,0.00036349025,0.0000861472,0.000059897153],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003503962,0.00011294881,0.00036988454,0.00039722087,0.00007233256,0.000014674387,0.00009579379,0.00013518041,0.001451517],"category_scores_gemma":[0.00007208579,0.000098501965,0.00014996695,0.0005458042,0.000026542508,0.000037699363,0.000048062324,0.00024413511,0.00003586356],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007341561,0.00069055933,0.4182882,0.000426687,0.0011873401,0.0005076913,0.0010611489,0.0000025349352,0.29887837,0.11939523,0.02024715,0.1385809],"study_design_scores_gemma":[0.025009587,0.001503396,0.15592271,0.0007525461,0.0003511631,0.0010602332,0.0027812321,0.0017464975,0.17979716,0.011538957,0.6187881,0.0007484303],"about_ca_topic_score_codex":0.000027770428,"about_ca_topic_score_gemma":0.0000114860095,"teacher_disagreement_score":0.59854096,"about_ca_system_score_codex":0.00014971412,"about_ca_system_score_gemma":0.0002724817,"threshold_uncertainty_score":0.9994613},"labels":[],"label_agreement":null},{"id":"W4411550209","doi":"10.1007/978-1-0716-4654-0_13","title":"Chimeric Antigen Receptor T Cell Production for Brain Cancers","year":2025,"lang":"en","type":"article","venue":"Methods in molecular biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Chimeric antigen receptor; Antigen; Cancer research; Neuroscience; Biology; Computational biology; Immunology; Immunotherapy; Immune system","score_opus":0.034395821996669775,"score_gpt":0.4687643660926454,"score_spread":0.4343685440959756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411550209","genre_codex":"methods","genre_gemma":"methods","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.092866965,0.00212475,0.89093786,0.0066644666,0.0010631216,0.0017004029,0.000005885047,0.000046264347,0.0045902883],"genre_scores_gemma":[0.0027998874,0.0002970744,0.9783114,0.0017689762,0.00014318092,0.0003351837,0.00005264227,0.00003197599,0.016259642],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9981223,0.0008092012,0.0002277612,0.00044477437,0.000059887203,0.0003361074],"domain_scores_gemma":[0.99924576,0.00022090206,0.000043850407,0.0003631494,0.00008076216,0.00004557728],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018021608,0.00012374879,0.0003260714,0.0003229726,0.000036693007,0.0000050262124,0.000121228215,0.0001685956,0.0002827993],"category_scores_gemma":[0.0010635678,0.00011436867,0.00010743942,0.0005941745,0.00013137957,0.000010155943,0.00004901515,0.00022901385,0.0000042507027],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024856173,0.000041044565,0.0019706697,0.00007154508,0.000049261762,0.0000019075228,0.00007206009,0.000014560355,0.8592771,0.00025681095,0.0011909176,0.1368055],"study_design_scores_gemma":[0.00083565596,0.0002345928,0.0003779137,0.000023545315,0.000013918653,0.00000325815,0.000035815323,0.0001523927,0.80409974,0.0020376842,0.19210176,0.00008370387],"about_ca_topic_score_codex":0.00012350938,"about_ca_topic_score_gemma":0.000011496876,"teacher_disagreement_score":0.19091085,"about_ca_system_score_codex":0.0002238585,"about_ca_system_score_gemma":0.00026986425,"threshold_uncertainty_score":0.4663819},"labels":[],"label_agreement":null},{"id":"W4411603000","doi":"10.1182/bloodadvances.2025015881","title":"Real-world data for tisagenlecleucel in patients with R/R B-ALL: subgroup analyses from the CIBMTR registry","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children","funders":"Cancer Moonshot; National Institute of Allergy and Infectious Diseases; Office of Naval Research; Legend Biotech; Pharmacyclics; Kite Pharma; Takeda Oncology; National Institutes of Health; MorphoSys; Health Resources and Services Administration; Syndax Pharmaceuticals; BeiGene; Astellas Pharma; Adaptive Biotechnologies; Kiadis Pharma; bluebird bio; Jazz Pharmaceuticals; Swedish Orphan Biovitrum; Omeros Corporation; Vertex Pharmaceuticals; StemCyte; Actinium Pharmaceuticals; CareDx; University of Pittsburgh; HistoGenetics; U.S. Department of Defense; Moonshot Research and Development Program; Sanofi; GlaxoSmithKline; CSL Behring; Bristol-Myers Squibb; AstraZeneca; Mallinckrodt Pharmaceuticals; Astellas Pharma US; U.S. Navy; Gateway for Cancer Research; National Heart, Lung, and Blood Institute; Novartis Pharmaceuticals Corporation; Incyte; Pfizer; Amgen; Atara Biotherapeutics; National Cancer Institute; Servier; Gilead Sciences","keywords":"Medicine; Refractory (planetary science); Internal medicine; Gastroenterology; Pediatrics; Biology","score_opus":0.07493340698245726,"score_gpt":0.4053863752245954,"score_spread":0.33045296824213816,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411603000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98695415,0.0028767549,0.00022659304,0.0016236791,0.00012116841,0.0013313834,0.00050081813,0.00005758193,0.006307846],"genre_scores_gemma":[0.9747265,0.0015282469,0.0055472273,0.0011092605,0.00031777285,0.00015981996,0.0020753455,0.000056199875,0.01447964],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984941,0.0000641727,0.00025584016,0.0005099648,0.0003632596,0.0003126453],"domain_scores_gemma":[0.997701,0.0006213185,0.000096433614,0.0014261532,0.00009349778,0.00006160878],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002551334,0.00015890709,0.00034008466,0.00012154056,0.00007456541,0.00004041975,0.00056917424,0.000034832326,0.00012140154],"category_scores_gemma":[0.0001998633,0.00009885885,0.00004857946,0.0006472186,0.00016189928,0.00017230415,0.00016077158,0.00021261559,0.000003471337],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022231261,0.0005951548,0.95234704,0.000091246715,0.0005119216,0.000018285773,0.000078425845,0.000010932293,0.004077081,0.000119040946,0.004032359,0.035895366],"study_design_scores_gemma":[0.008577385,0.00043586481,0.8109422,0.000375952,0.00049565424,7.175803e-7,0.000250885,0.000115887146,0.0070020277,0.0006619373,0.17093429,0.00020720257],"about_ca_topic_score_codex":0.0015677714,"about_ca_topic_score_gemma":0.012229716,"teacher_disagreement_score":0.16690193,"about_ca_system_score_codex":0.00004366028,"about_ca_system_score_gemma":0.00013460603,"threshold_uncertainty_score":0.6824469},"labels":[],"label_agreement":null},{"id":"W4411710914","doi":"10.1016/j.jtct.2025.06.028","title":"Improving Patient Access through Value-Based CAR T Delivery: Examples Using a Micro-costing Tool","year":2025,"lang":"en","type":"review","venue":"Transplantation and Cellular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Kite Pharma","keywords":"Activity-based costing; Computer science; Operations management; Business; Engineering; Marketing","score_opus":0.1110565043690317,"score_gpt":0.36560730706037725,"score_spread":0.25455080269134556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411710914","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.021681111,0.96748686,0.0075714057,0.000018880539,0.0001677018,0.0025556989,0.00015469549,0.00009430041,0.0002693347],"genre_scores_gemma":[0.00044681638,0.99565506,0.0019847152,0.0003512674,0.00012448429,0.00011033092,0.0010326171,0.00009679853,0.00019789241],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972865,0.00038825377,0.0007267988,0.000684493,0.00046291546,0.00045102363],"domain_scores_gemma":[0.9986603,0.0004189063,0.00027148574,0.00041142805,0.00012977673,0.00010810681],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032326972,0.00055894314,0.0013122235,0.00033789806,0.00024825652,0.00017905177,0.00022239759,0.00034053298,0.00033739844],"category_scores_gemma":[0.000012959094,0.0004678595,0.0004738765,0.00048081914,0.00009265951,0.00015444186,0.000023299299,0.00051936443,0.000004437349],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003535081,0.00011044945,0.00004037952,0.031117683,0.0003038047,0.0001590181,0.00056916603,0.000013250907,0.025445007,0.000019696645,0.000006331884,0.9418617],"study_design_scores_gemma":[0.010923544,0.0009104729,0.000022226877,0.058400176,0.004921992,0.00038912328,0.00025883442,0.0014361662,0.073423706,0.00004763372,0.84723085,0.0020352677],"about_ca_topic_score_codex":0.000741394,"about_ca_topic_score_gemma":0.000008018172,"teacher_disagreement_score":0.9398264,"about_ca_system_score_codex":0.00018418235,"about_ca_system_score_gemma":0.00085335906,"threshold_uncertainty_score":0.9997773},"labels":[],"label_agreement":null},{"id":"W4411872495","doi":"10.1172/jci184043","title":"Targeting immune checkpoint LAIR1 with antibody blockade or 3-in-1 CAR T cells enhances antitumor response","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Investigation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"National Cancer Institute","keywords":"Blockade; Blocking (statistics); Blocking antibody; Immune system; Immune checkpoint; Antibody; Immunology; Cancer research; Medicine; Chemistry; Immunotherapy; Receptor; Computer science; Internal medicine","score_opus":0.05981472004056149,"score_gpt":0.43013826727697013,"score_spread":0.37032354723640865,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411872495","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99124384,0.00039744537,0.0002897625,0.0069843386,0.00043890488,0.00033566586,0.000001409723,0.000014993137,0.00029366088],"genre_scores_gemma":[0.9884126,0.0006677681,0.0053511895,0.00052891986,0.00048704311,0.0000037260006,0.0000051482602,0.00002113666,0.004522464],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9960802,0.00072750286,0.0020820557,0.00023309526,0.0006060328,0.0002710733],"domain_scores_gemma":[0.9964397,0.0017492146,0.00080601516,0.00024984195,0.0005123416,0.0002429008],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007867296,0.00015748126,0.00081140146,0.00037971415,0.000060512808,0.000043007247,0.00018822872,0.0001657591,0.0003042706],"category_scores_gemma":[0.0051736482,0.00010257379,0.00021709646,0.00070278725,0.00037455402,0.00018790568,0.000042881995,0.0011123369,0.000011388217],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017511098,0.00022175975,0.035333265,0.00011427834,0.00012470024,0.0004957097,0.00019046383,0.00010118922,0.9443225,0.000013296594,0.00028050822,0.0012912054],"study_design_scores_gemma":[0.0065550767,0.0029898467,0.16352628,0.0020855267,0.00012879273,0.00013125713,0.00041557165,0.0010442293,0.8174779,0.00026453473,0.005226585,0.00015441324],"about_ca_topic_score_codex":0.000031536816,"about_ca_topic_score_gemma":0.000012408891,"teacher_disagreement_score":0.128193,"about_ca_system_score_codex":0.00011083679,"about_ca_system_score_gemma":0.0017382718,"threshold_uncertainty_score":0.6193714},"labels":[],"label_agreement":null},{"id":"W4411932984","doi":"10.1038/s41584-025-01272-3","title":"CAR T cell therapy for children with rheumatic disease: the time is now","year":2025,"lang":"en","type":"review","venue":"Nature Reviews Rheumatology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"National Institute of Arthritis and Musculoskeletal and Skin Diseases; National Institute of Diabetes and Digestive and Kidney Diseases; National Institutes of Health","keywords":"Medicine; Rheumatic disease; Disease; MEDLINE; Cell therapy; Intensive care medicine; Pediatrics; Cell; Internal medicine","score_opus":0.021762212896210036,"score_gpt":0.35942272931541003,"score_spread":0.3376605164192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411932984","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000006961033,0.9777105,0.000039302522,0.0014017827,0.0002671344,0.019430786,0.00025246813,0.00009416876,0.00079691276],"genre_scores_gemma":[0.0000013584854,0.9670084,0.00023762012,0.001176835,0.000107791566,0.0034677337,0.0010292446,0.00019847951,0.02677252],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.994697,0.0010627756,0.0014843399,0.0012283896,0.00060454576,0.0009229453],"domain_scores_gemma":[0.99417055,0.0017475359,0.00089084846,0.0025610253,0.0002880041,0.00034203817],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0013492319,0.0011925929,0.0070313867,0.00043827554,0.00024466953,0.00006419875,0.0012268805,0.0014355357,0.0025416613],"category_scores_gemma":[0.00041753583,0.0005778886,0.0022092604,0.0011398742,0.00032164317,0.000047859885,0.00015631103,0.002983932,0.000648429],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016568747,0.00014601726,0.0000615217,0.07197915,0.0009994486,0.000007799026,0.000031477444,2.6182542e-8,4.9024607e-7,0.000075406744,0.116664946,0.80986804],"study_design_scores_gemma":[0.0015122581,0.00024829627,0.00001412905,0.048484877,0.0020172205,0.00057052367,0.0000018712379,0.0000071486984,0.0000017773693,0.000040121893,0.9466138,0.00048799135],"about_ca_topic_score_codex":0.0000108052545,"about_ca_topic_score_gemma":0.0000060080292,"teacher_disagreement_score":0.82994884,"about_ca_system_score_codex":0.00022832685,"about_ca_system_score_gemma":0.0021174287,"threshold_uncertainty_score":0.9998608},"labels":[],"label_agreement":null},{"id":"W4411954611","doi":"10.51643/22562915.688","title":"In-House CAR-T: una revisión","year":2025,"lang":"en","type":"article","venue":"Revista Colombiana de Hematología y Oncología","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"House call; Political science; Law","score_opus":0.019290031417698545,"score_gpt":0.35516031699063955,"score_spread":0.335870285572941,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411954611","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87227774,0.009456802,0.00022450133,0.019379146,0.0003429541,0.0036532262,0.000013781823,0.0006416958,0.09401013],"genre_scores_gemma":[0.91192746,0.0028551198,0.0018045384,0.009556969,0.00018345485,0.0004606714,0.000020828424,0.00015760037,0.07303333],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960026,0.00048583193,0.0010138359,0.00085375016,0.00047224297,0.0011717052],"domain_scores_gemma":[0.99722725,0.0007639715,0.00018456735,0.0012104278,0.00023821626,0.00037555778],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016271522,0.00042742566,0.0015819342,0.0007893009,0.0001537515,0.00010392423,0.00051719375,0.0006012493,0.0028967836],"category_scores_gemma":[0.0013555292,0.00042212565,0.00036442175,0.0019366986,0.000374445,0.00013373623,0.0002536986,0.001108168,0.00038089562],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037640915,0.0031538766,0.3296604,0.009778415,0.0008733038,0.011132434,0.00076805626,0.000012280757,0.0992563,0.10762806,0.388672,0.045300785],"study_design_scores_gemma":[0.0061844657,0.00072238006,0.017067328,0.002353483,0.00023653581,0.0010506336,0.00030929098,0.00034063548,0.0075484547,0.0017042211,0.9619415,0.0005411177],"about_ca_topic_score_codex":0.0002652913,"about_ca_topic_score_gemma":0.0001866777,"teacher_disagreement_score":0.5732695,"about_ca_system_score_codex":0.0019650336,"about_ca_system_score_gemma":0.0018199543,"threshold_uncertainty_score":0.99982303},"labels":[],"label_agreement":null},{"id":"W4412002759","doi":"10.1016/j.ccell.2025.06.014","title":"Engineering myeloid cells for cancer immunotherapy","year":2025,"lang":"en","type":"article","venue":"Cancer Cell","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology; Leukemia and Lymphoma Society of Canada; Parker Institute for Cancer Immunotherapy; Leukemia and Lymphoma Society","keywords":"Myeloid cells; Immunotherapy; Cancer immunotherapy; Myeloid; Cancer; Cancer research; Cancer cell; Immunology; Biology; Medicine; Immune system; Genetics","score_opus":0.01717821939778622,"score_gpt":0.32465989203873363,"score_spread":0.3074816726409474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412002759","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6619034,0.20088436,0.015178409,0.009945519,0.010344077,0.008962742,0.00031152315,0.0012899275,0.09118005],"genre_scores_gemma":[0.3347118,0.04023872,0.0029156639,0.0057415427,0.0020323228,0.003617239,0.000033580563,0.00036355632,0.6103456],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99895823,0.0000101963615,0.0001853876,0.00028859935,0.0001644187,0.0003931487],"domain_scores_gemma":[0.99930763,0.00009535792,0.000031483312,0.00034626818,0.00013109864,0.00008814097],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001355802,0.0001615464,0.00028213175,0.00009281362,0.00004343365,0.000023609142,0.00014690835,0.0000959195,0.0046860557],"category_scores_gemma":[0.000007474813,0.00015241501,0.00015335539,0.00023293124,0.000031677744,0.00004286896,0.000026399164,0.00017787218,0.000011798653],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003955286,0.00004947233,0.00039268192,0.00040119968,0.00012950039,0.0000027225249,0.00018545188,0.00028115654,0.9227567,0.000046916906,0.012829172,0.06252951],"study_design_scores_gemma":[0.0015444076,0.00004530754,0.00028273833,0.00009167172,0.000027725604,3.605545e-7,0.00002892198,0.00087987457,0.47891358,0.000012516909,0.51808405,0.0000888539],"about_ca_topic_score_codex":0.0007295824,"about_ca_topic_score_gemma":0.00009496712,"teacher_disagreement_score":0.5191655,"about_ca_system_score_codex":0.00057509815,"about_ca_system_score_gemma":0.00040987926,"threshold_uncertainty_score":0.9962238},"labels":[],"label_agreement":null},{"id":"W4412024111","doi":"10.1101/2025.06.30.660492","title":"Peptide-Specific CARs Recognize WT1 Promiscuously Presented by Diverse HLA Class II Alleles","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; Princess Margaret Cancer Foundation; Amgen","keywords":"Allele; Human leukocyte antigen; Class (philosophy); Genetics; Biology; Computational biology; Computer science; Antigen; Gene; Artificial intelligence","score_opus":0.02679706647982766,"score_gpt":0.26427387162972354,"score_spread":0.2374768051498959,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412024111","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97657925,0.008895608,0.00017782456,0.0025049725,0.002062723,0.0058766054,0.0017104013,0.0012895152,0.0009030835],"genre_scores_gemma":[0.95621353,0.017507153,0.0054833856,0.0012858083,0.0025430245,0.0020669787,0.000030456109,0.00077056856,0.014099096],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9934677,0.00041338868,0.0010622259,0.0023311486,0.0013166748,0.0014088621],"domain_scores_gemma":[0.9938444,0.00020864738,0.00046694223,0.0030976236,0.0015259389,0.0008564852],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001135207,0.0011483249,0.0015817548,0.00076643005,0.00043938987,0.00028130194,0.0011566731,0.0012895787,0.0017139857],"category_scores_gemma":[0.000467649,0.001191472,0.00060347316,0.0011120292,0.00043221685,0.00016014012,0.0021054323,0.0028098808,0.00019766015],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007792669,0.00078670465,0.004796037,0.0011861494,0.0011269439,0.00028465854,0.00006184618,0.000012176879,0.8348015,0.000065494256,0.15603574,0.0000634842],"study_design_scores_gemma":[0.0038297258,0.00033930183,0.008168557,0.0017742314,0.0003943713,1.5260582e-7,0.00003405199,0.00025348007,0.24850531,0.000002288265,0.7354984,0.001200116],"about_ca_topic_score_codex":0.00035959747,"about_ca_topic_score_gemma":0.000018233612,"teacher_disagreement_score":0.5862962,"about_ca_system_score_codex":0.0011861774,"about_ca_system_score_gemma":0.0019189388,"threshold_uncertainty_score":0.9994907},"labels":[],"label_agreement":null},{"id":"W4412040747","doi":"10.3345/cep.2025.00031","title":"Allogeneic stem-cell transplantation following chimeric antigen receptor T-cell therapy for treatment of relapsed/refractory hematologic malignancy in children and young adults: a systematic review and meta-analysis","year":2025,"lang":"en","type":"review","venue":"Clinical and Experimental Pediatrics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Chimeric antigen receptor; Refractory (planetary science); Medicine; Malignancy; Hematologic malignancy; Transplantation; Hematologic Neoplasms; Hematopoietic stem cell transplantation; Meta-analysis; Oncology; Immunology; Immunotherapy; Internal medicine; Immune system; Biology","score_opus":0.07731408315595743,"score_gpt":0.4035482887950692,"score_spread":0.32623420563911176,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412040747","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.027528696,0.96332514,0.000007164912,0.000016091346,0.000063498,0.008777383,0.00023922227,0.000016869973,0.000025923595],"genre_scores_gemma":[0.0024214354,0.99472106,0.00024445824,0.00006968024,0.000047474623,0.0012252361,0.00047326242,0.000044304554,0.000753073],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99561936,0.00065940554,0.0022262335,0.00089879887,0.00029107791,0.00030514871],"domain_scores_gemma":[0.99751276,0.0010769261,0.00072444807,0.00043964395,0.00005023958,0.00019599903],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008778093,0.00059987966,0.008333217,0.00043276054,0.00006750364,0.000025399388,0.00013884227,0.0004173358,0.00006868184],"category_scores_gemma":[0.0000403842,0.00038078043,0.0026146593,0.0007315289,0.000109389046,0.000057417394,0.000042640444,0.00019368828,0.000001716288],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004605355,0.0030111228,0.007772394,0.9325568,0.0405859,0.000034290242,0.00045710703,8.3303185e-8,0.000038878497,0.0000023568978,0.00004827629,0.015032246],"study_design_scores_gemma":[0.010992114,0.0058146734,0.00022182781,0.020883603,0.9592867,0.00009661825,0.00028261566,0.0000043042996,0.0002071621,0.0000041560747,0.0011946422,0.0010115949],"about_ca_topic_score_codex":0.000045951452,"about_ca_topic_score_gemma":0.000002848795,"teacher_disagreement_score":0.9187008,"about_ca_system_score_codex":0.00007136119,"about_ca_system_score_gemma":0.00015943538,"threshold_uncertainty_score":0.9998644},"labels":[],"label_agreement":null},{"id":"W4412066586","doi":"10.1186/s12943-025-02386-8","title":"Advancing CAR-based cell therapies for solid tumours: challenges, therapeutic strategies, and perspectives","year":2025,"lang":"en","type":"review","venue":"Molecular Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"Uppsala Universitet","keywords":"Chimeric antigen receptor; Oncolytic virus; Biology; Tumor microenvironment; Immune system; Immunotherapy; Cancer research; Cell; Immunology","score_opus":0.06666268807641285,"score_gpt":0.3953721075754012,"score_spread":0.32870941949898835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412066586","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000016748825,0.99223167,0.0013732149,0.0007819714,0.00014634134,0.0031864215,0.000076444645,0.000077031706,0.002110143],"genre_scores_gemma":[0.0003645328,0.99419886,0.0004121918,0.00023198462,0.00024851435,0.0018339426,0.00006319518,0.00016953918,0.0024772268],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99746275,0.00022689313,0.0003835053,0.0008746588,0.00040526487,0.0006469482],"domain_scores_gemma":[0.9984311,0.00031127452,0.00017359912,0.0006566824,0.0002608659,0.00016647665],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00033299602,0.00062158797,0.0018115045,0.0003862685,0.00010732851,0.00010998461,0.00023856707,0.00033658664,0.0003699638],"category_scores_gemma":[0.000035275505,0.0005079429,0.0006670048,0.00029793844,0.00016635058,0.00007043181,0.000056858884,0.0005897404,0.0000023741784],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000116750765,0.000111807,0.0000011042775,0.04474177,0.00075571926,0.000058085905,0.0005663467,0.000004726927,0.0020111208,0.00034833094,0.00009063474,0.95119363],"study_design_scores_gemma":[0.0014593636,0.00044085836,0.000005130334,0.012731684,0.0017471075,0.000015018761,0.0017711907,0.000026502203,0.00093952304,0.00016317224,0.9801884,0.00051200006],"about_ca_topic_score_codex":0.00010386696,"about_ca_topic_score_gemma":0.00010582066,"teacher_disagreement_score":0.98009783,"about_ca_system_score_codex":0.0006390337,"about_ca_system_score_gemma":0.0039590155,"threshold_uncertainty_score":0.9997372},"labels":[],"label_agreement":null},{"id":"W4412093048","doi":"10.3390/ijtm5030028","title":"Protein Engineering Paving the Way for Next-Generation Therapies in Cancer","year":2025,"lang":"en","type":"article","venue":"International Journal of Translational Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Trois-Rivières","funders":"","keywords":"Cancer; Medicine; Engineering; Computer science; Computational biology; Biology; Internal medicine","score_opus":0.07552677918434995,"score_gpt":0.3792414076941884,"score_spread":0.30371462850983844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412093048","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.687148,0.0077452,0.033176206,0.26804575,0.001975664,0.0011495644,0.000015000697,0.000015292324,0.00072932185],"genre_scores_gemma":[0.9945668,0.00029356295,0.0013910714,0.0006875228,0.0018642,0.000066800065,0.000016451992,0.000012889487,0.0011007098],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9985461,0.00003382152,0.0005194475,0.00010241791,0.0006740125,0.00012418347],"domain_scores_gemma":[0.9987522,0.00033804413,0.00011487277,0.000074495976,0.0006805195,0.00003988668],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00081135286,0.00009975982,0.00021347648,0.00045025093,0.000034637655,0.000023472923,0.0002125138,0.00004963914,0.00057901716],"category_scores_gemma":[0.0002690869,0.00006291845,0.00010602668,0.000206606,0.000060755665,0.0001442384,0.000007810571,0.00027318386,4.576322e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011218954,0.00011455722,0.004879186,0.000058542024,0.00055590464,0.000020742013,0.0010056945,0.002649886,0.86131763,0.0062101213,0.0007296564,0.12133618],"study_design_scores_gemma":[0.0496724,0.001994611,0.27190337,0.01133797,0.00053521234,0.00048911275,0.0013754003,0.18020912,0.11281532,0.013357781,0.35565698,0.0006527143],"about_ca_topic_score_codex":0.0000537193,"about_ca_topic_score_gemma":0.00005998513,"teacher_disagreement_score":0.7485023,"about_ca_system_score_codex":0.0001540592,"about_ca_system_score_gemma":0.00020279348,"threshold_uncertainty_score":0.6339832},"labels":[],"label_agreement":null},{"id":"W4412461972","doi":"10.1111/bjh.70012","title":"Distinct patient, tumour and chimeric antigen receptor T‐cell characteristics are associated with initiating versus sustaining responses to idecabtagene vicleucel in relapsed and refractory multiple myeloma","year":2025,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada","keywords":"Chimeric antigen receptor; Cytokine release syndrome; Multiple myeloma; Antigen; Medicine; Cancer research; Refractory (planetary science); Immunology; T cell; Oncology; Biology; Immune system","score_opus":0.019908754751251426,"score_gpt":0.2897263368892645,"score_spread":0.2698175821380131,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412461972","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99684185,0.0019112553,0.000025439213,0.00045455113,0.00015887567,0.00033496658,0.000028947148,0.00001651708,0.0002276246],"genre_scores_gemma":[0.99849844,0.00043782018,0.000594218,0.00019348408,0.000039208335,0.000008635672,0.000012429933,0.000032881962,0.00018286204],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99795294,0.0004334785,0.0006906159,0.00026305305,0.00026636,0.00039355835],"domain_scores_gemma":[0.99745274,0.0013142749,0.00051518856,0.000116697986,0.0003942334,0.00020688317],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000673284,0.00016892783,0.0008157621,0.00045255796,0.00013668172,0.000060451137,0.00009760285,0.00013580172,0.00006488351],"category_scores_gemma":[0.005688026,0.00017876149,0.000047508118,0.0004387638,0.00014780364,0.0000859751,0.000106532265,0.00062730676,0.0000011533521],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017306326,0.00045794758,0.82299924,0.00028727244,0.00029816467,0.041669723,0.0015086209,0.0000014974595,0.06190017,0.0000048632683,0.00052310235,0.053043053],"study_design_scores_gemma":[0.009303012,0.0018665697,0.9715003,0.0024229148,0.000067332694,0.007647402,0.0028591624,0.000073869116,0.0033871662,0.00000894255,0.00066208787,0.00020125258],"about_ca_topic_score_codex":0.0000729417,"about_ca_topic_score_gemma":0.00023488319,"teacher_disagreement_score":0.14850102,"about_ca_system_score_codex":0.00016668557,"about_ca_system_score_gemma":0.00031056118,"threshold_uncertainty_score":0.7289682},"labels":[],"label_agreement":null},{"id":"W4412492231","doi":"10.1182/bloodadvances.2024015519","title":"In vivo CRISPR screening reveals cooperation of <i>KMT2D</i> and <i>TP53</i> deficiencies in B-cell lymphomagenesis","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre; Simon Fraser University","funders":"","keywords":"Biology; Cancer research; CRISPR; YAP1; Diffuse large B-cell lymphoma; Transplantation; Lymphoma; Genetics; Gene; Immunology; Transcription factor; Medicine","score_opus":0.013408603913164462,"score_gpt":0.30233026421181747,"score_spread":0.288921660298653,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412492231","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9675561,0.020928344,0.0002396537,0.0004054736,0.000047946505,0.00041610308,0.0000060194325,0.000016110947,0.010384214],"genre_scores_gemma":[0.9879123,0.0035425893,0.0022147214,0.0004395772,0.00002566561,0.000035519308,0.000002390122,0.000011719471,0.0058155134],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99885416,0.000073050294,0.00034423883,0.00027032502,0.00022004779,0.00023817361],"domain_scores_gemma":[0.9994278,0.00019475233,0.000055229324,0.00019138466,0.00008740046,0.000043462955],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042761877,0.000118146476,0.0003334671,0.00031724744,0.000039694114,0.000016373591,0.00008745677,0.000058533333,0.00009650581],"category_scores_gemma":[0.00013742605,0.00010894823,0.000034960318,0.00077367394,0.000112080066,0.0001974764,0.000055580967,0.00009785407,9.987303e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021232948,0.00030586027,0.127594,0.0002981495,0.000010588562,0.000028822607,0.00026921622,0.000107913744,0.8620596,0.00017425479,0.00012950234,0.008809805],"study_design_scores_gemma":[0.0043861875,0.00022608903,0.012960217,0.0003914243,0.00004023228,0.000014380299,0.0006427856,0.00018813492,0.97161096,0.00013846146,0.009278505,0.00012259462],"about_ca_topic_score_codex":0.0001940899,"about_ca_topic_score_gemma":0.00033443182,"teacher_disagreement_score":0.114633776,"about_ca_system_score_codex":0.000030087678,"about_ca_system_score_gemma":0.000106281375,"threshold_uncertainty_score":0.444278},"labels":[],"label_agreement":null},{"id":"W4412552497","doi":"10.1038/s41590-025-02232-5","title":"LARP4-mediated hypertranslation drives T cell dysfunction in tumors","year":2025,"lang":"en","type":"article","venue":"Nature Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"National Natural Science Foundation of China","keywords":"Cancer research; Cell biology; Medicine; Biology; Chemistry","score_opus":0.00667346609264948,"score_gpt":0.28099900434285374,"score_spread":0.2743255382502043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412552497","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95362633,0.009503302,0.00007230378,0.0046912087,0.0006577687,0.0005038921,0.0000034734987,0.00009768195,0.03084401],"genre_scores_gemma":[0.9871268,0.0004376545,0.00011010894,0.00074693654,0.000057888254,0.00002726535,0.000112854206,0.000016165632,0.011364319],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9989582,0.00011648295,0.00022180588,0.00026438988,0.00015323731,0.00028594022],"domain_scores_gemma":[0.99937254,0.0001869124,0.000034164357,0.00027727842,0.000101841084,0.00002727492],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00020739468,0.00012438215,0.00026484017,0.0005749127,0.00004042886,0.00000831459,0.00010145355,0.00064426387,0.0008452368],"category_scores_gemma":[0.0001630426,0.00011266239,0.00006592898,0.00073227054,0.000098145334,0.000053871,0.000028375776,0.0014747273,0.000070064925],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012360045,0.00018613771,0.020946598,0.000052112966,0.00006988897,0.000053649175,0.00020508283,0.00000519921,0.95211005,0.00034611957,0.0006719679,0.024117196],"study_design_scores_gemma":[0.01120482,0.00067920395,0.60933316,0.00020333135,0.000059813356,0.00006515677,0.000392621,0.0005646737,0.2030328,0.0008791086,0.17332828,0.00025703994],"about_ca_topic_score_codex":0.000068491565,"about_ca_topic_score_gemma":0.00007972343,"teacher_disagreement_score":0.74907726,"about_ca_system_score_codex":0.00015345625,"about_ca_system_score_gemma":0.00017822692,"threshold_uncertainty_score":0.92547506},"labels":[],"label_agreement":null},{"id":"W4412620438","doi":"10.1182/bloodadvances.2024015014","title":"Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Environmental Health Sciences; National Institute of Allergy and Infectious Diseases; Office of Naval Research; National Heart, Lung, and Blood Institute; Legend Biotech; Pharmacyclics; Eurostars; Genentech; Health Resources and Services Administration; Aptitude Health; Seagen; Incyte; Juno Therapeutics; Astellas Pharma; Adaptive Biotechnologies; Kiadis Pharma; bluebird bio; Actinium Pharmaceuticals; CareDx; Jazz Pharmaceuticals; BeiGene; HistoGenetics; Gateway for Cancer Research; Celgene; Atara Biotherapeutics; National Cancer Institute; Gilead Sciences; Sanofi; GlaxoSmithKline; CSL Behring; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Alexion Pharmaceuticals; Spectrum Pharmaceuticals; Mallinckrodt Pharmaceuticals; Kite Pharma; Society for Immunotherapy of Cancer; Astellas Pharma US; Amgen","keywords":"Medicine; Hazard ratio; Internal medicine; Bendamustine; Mantle cell lymphoma; Cumulative incidence; Oncology; Confidence interval; Salvage therapy; Odds ratio; Melphalan; Gastroenterology; Lymphoma; Surgery; Transplantation; Chemotherapy; Rituximab","score_opus":0.02176219910519934,"score_gpt":0.3536270628012587,"score_spread":0.3318648636960594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412620438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9294157,0.0062037413,0.0006131905,0.0008560135,0.00038973204,0.0016546652,0.00016565189,0.00019112424,0.060510173],"genre_scores_gemma":[0.61905813,0.002536795,0.0067363135,0.00028120002,0.00010569273,0.00018290292,0.000096731,0.00004888052,0.37095338],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99806744,0.00006430601,0.00055838743,0.00048176287,0.00041990125,0.00040818303],"domain_scores_gemma":[0.99804133,0.0006861803,0.00020537579,0.0007396956,0.00020485176,0.00012255725],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035191607,0.00023646788,0.0009528131,0.00083631446,0.000090591035,0.000017169428,0.00025032004,0.00009613335,0.00081185903],"category_scores_gemma":[0.0001732828,0.00017738283,0.00042830638,0.0018695785,0.0001260198,0.00011220471,0.000073309246,0.00011568226,0.0000066493712],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0074413763,0.0070218565,0.45128974,0.0031322755,0.009529235,0.00017671246,0.00046860514,0.00010392432,0.37761146,0.00080823514,0.0029834465,0.13943312],"study_design_scores_gemma":[0.025752038,0.0015426169,0.30243748,0.0002602939,0.007935948,0.000006718378,0.00053474447,0.00045090422,0.40280434,0.00042438274,0.25730103,0.0005494983],"about_ca_topic_score_codex":0.00026548374,"about_ca_topic_score_gemma":0.0010504911,"teacher_disagreement_score":0.3104432,"about_ca_system_score_codex":0.00010100378,"about_ca_system_score_gemma":0.0003858145,"threshold_uncertainty_score":0.8889287},"labels":[],"label_agreement":null},{"id":"W4412654447","doi":"10.1080/10428194.2025.2532674","title":"Matching-adjusted indirect comparison of lisocabtagene maraleucel versus axicabtagene ciloleucel for second-line treatment of patients with early relapsed or refractory large B-cell lymphoma","year":2025,"lang":"en","type":"article","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"European Union Studies Association; Kite Pharma; Genmab; Genentech Foundation; Daiichi Sankyo Europe; Janssen Biotech; AbbVie Canada; Pharmacyclics; Seattle Genetics; Genentech; MorphoSys; Seagen; Incyte; TG Therapeutics; bluebird bio; Novartis Portugal; BeiGene; Merck KGaA; Regeneron Pharmaceuticals; Astellas Pharma; Takeda Pharmaceuticals U.S.A.; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Adverse effect; Oncology; Confidence interval; Odds ratio; Refractory (planetary science); Lymphoma; Cytokine release syndrome; Clinical trial; Chimeric antigen receptor; Immunotherapy; Cancer","score_opus":0.027151610728664,"score_gpt":0.29862573315635244,"score_spread":0.2714741224276884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412654447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98949534,0.0026576174,0.00024006332,0.000046705773,0.00052119995,0.0028458738,0.0007227768,0.0001759134,0.0032945327],"genre_scores_gemma":[0.9780204,0.0006231789,0.0013712341,0.00016943067,0.00017788816,0.00035809682,0.0007778961,0.00020642462,0.018295396],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99417025,0.00026076357,0.0017578737,0.0013598277,0.0011181107,0.001333177],"domain_scores_gemma":[0.9951044,0.0011920858,0.0009311276,0.0014885972,0.00072839553,0.00055543485],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00046536388,0.001084548,0.0026698764,0.0009382521,0.00036599147,0.00007454427,0.0005164542,0.00081366784,0.00048669605],"category_scores_gemma":[0.00010553652,0.0008585396,0.0005844917,0.0012770882,0.00048395016,0.00026801025,0.00021159538,0.00015891464,0.000013811475],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25950179,0.02129625,0.10508328,0.005252095,0.00525222,0.00027308182,0.008254904,0.00007657519,0.10110358,0.00036499064,0.0026349518,0.4909063],"study_design_scores_gemma":[0.3399427,0.020676166,0.3058644,0.0008813177,0.0019024517,0.00003361755,0.0017650548,0.0019615986,0.2863197,0.00007454043,0.0392715,0.0013069682],"about_ca_topic_score_codex":0.0011732552,"about_ca_topic_score_gemma":0.00052214443,"teacher_disagreement_score":0.48959932,"about_ca_system_score_codex":0.0077009825,"about_ca_system_score_gemma":0.00559261,"threshold_uncertainty_score":0.99938655},"labels":[],"label_agreement":null},{"id":"W4412679455","doi":"10.1101/2025.07.25.25332228","title":"International Multi-site Implementation of Local Cell-Free Protein Biomanufacturing to Advance Health and Research Equity","year":2025,"lang":"en","type":"preprint","venue":"medRxiv","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sinai Health System; Emmanuel Bible College; IMPCO Technologies (Canada); University of Toronto","funders":"CHIST-ERA; Canadian Institutes of Health Research; Shastri Indo-Canadian Institute; Agencia Nacional de Investigación y Desarrollo; Indian Institute of Science Education and Research Mohali; Ministry of Colleges and Universities; Indian Institute of Science Education and Research Pune; Agenția Națională pentru Cercetare și Dezvoltare; Conselho Nacional de Desenvolvimento Científico e Tecnológico; National Institutes of Health; Canada Research Chairs; International Development Research Centre; CYTED Ciencia y Tecnología para el Desarrollo; University of Toronto","keywords":"Biomanufacturing; Equity (law); Business; Political science; Biology; Biotechnology","score_opus":0.10420849113128612,"score_gpt":0.4891772292764831,"score_spread":0.384968738145197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412679455","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97676086,0.00063739915,0.010043173,0.0070702108,0.00025471096,0.0034841977,0.0002475266,0.000043385484,0.0014585343],"genre_scores_gemma":[0.98064995,0.0005483217,0.011692164,0.00023712651,0.0001871564,0.00040110646,0.00017617387,0.00003753727,0.006070455],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99669904,0.0002855671,0.0005504577,0.00069033966,0.0012749737,0.00049962534],"domain_scores_gemma":[0.9980381,0.00012189409,0.00015142043,0.00088043197,0.0004588493,0.00034928063],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025035362,0.00020750478,0.00044730847,0.0008011011,0.00008634397,0.000043410106,0.00055350433,0.00013872124,0.00053702143],"category_scores_gemma":[0.00019758259,0.00020381899,0.00008861459,0.00027690313,0.00016310687,0.00004744238,0.003747069,0.0009215768,0.000010221763],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016389866,0.0005125469,0.050080154,0.007853714,0.0002611106,0.000055197437,0.005248187,0.00009830803,0.3826892,0.00014636369,0.0013263051,0.5500899],"study_design_scores_gemma":[0.004797165,0.00089542824,0.0569332,0.0018278253,0.000018592344,0.000008265758,0.0018494519,0.0006393604,0.90384984,0.00045639646,0.02842284,0.00030164412],"about_ca_topic_score_codex":0.0029957162,"about_ca_topic_score_gemma":0.00072662765,"teacher_disagreement_score":0.5497883,"about_ca_system_score_codex":0.00070093625,"about_ca_system_score_gemma":0.0010037544,"threshold_uncertainty_score":0.8311497},"labels":[],"label_agreement":null},{"id":"W4412693854","doi":"10.1186/s12935-025-03846-3","title":"Targeting cancer stem cells with CAR-based immunotherapy: biology, evidence, and future directions","year":2025,"lang":"en","type":"review","venue":"Cancer Cell International","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Innovative Medicines Canada","funders":"","keywords":"Immunotherapy; Cancer stem cell; Medicine; Tumor microenvironment; Cancer immunotherapy; Cancer; Cancer research; Limiting; Immunology; Tumor cells; Internal medicine","score_opus":0.047690582780398644,"score_gpt":0.39325160684750643,"score_spread":0.34556102406710776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412693854","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000027902404,0.99165106,0.000058321308,0.00068109797,0.0023124332,0.0012483993,0.00042535696,0.00007039517,0.003525044],"genre_scores_gemma":[0.000016911552,0.96151876,0.0001784791,0.00029268384,0.0022015492,0.0012583383,0.00015497496,0.000079638965,0.034298662],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99788624,0.00015900924,0.00048240527,0.0007210927,0.00039381123,0.0003574634],"domain_scores_gemma":[0.99840325,0.00038540026,0.00029501456,0.00036467117,0.00041987357,0.00013181809],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00024675293,0.00046918314,0.0011050481,0.00034117815,0.00012735896,0.0000756449,0.00035477363,0.00034352907,0.00835599],"category_scores_gemma":[0.000007941542,0.00034456205,0.00031023432,0.00042002453,0.00021884953,0.00008967826,0.000079387995,0.00073029083,0.0000091204165],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00019554315,0.000079070014,0.00025644814,0.007910387,0.00093700225,0.000015096294,0.00007655673,0.000011152986,0.0007631364,0.000028601155,0.0031159208,0.98661107],"study_design_scores_gemma":[0.0007507252,0.00010458319,0.000007748597,0.015467202,0.00047508464,0.000009206075,0.000048043148,0.00006441274,0.0002904183,0.0000020080772,0.98247945,0.00030111484],"about_ca_topic_score_codex":0.0011608523,"about_ca_topic_score_gemma":0.00019932153,"teacher_disagreement_score":0.98630995,"about_ca_system_score_codex":0.0013956903,"about_ca_system_score_gemma":0.0024538618,"threshold_uncertainty_score":0.99990064},"labels":[],"label_agreement":null},{"id":"W4412712532","doi":"10.3390/curroncol32080425","title":"Clinical Impact of CTLA-4 Single-Nucleotide Polymorphism in DLBCL Patients Treated with CAR-T Cell Therapy","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Medicine; Single-nucleotide polymorphism; Internal medicine; Oncology; Bioinformatics; Genetics; Computational biology; Biology; Genotype; Gene","score_opus":0.1158453225711534,"score_gpt":0.45693172936193194,"score_spread":0.3410864067907785,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412712532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856172,0.0013340435,0.0000073029078,0.00018943263,0.0004013874,0.0009469866,0.000017154836,0.000031141186,0.0114553515],"genre_scores_gemma":[0.99721295,0.0010360318,0.00003638536,0.00009979824,0.00011950301,0.000032143973,0.000062881314,0.000030900588,0.0013693869],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99776125,0.0003963072,0.00067956804,0.00041686898,0.00027985126,0.00046612762],"domain_scores_gemma":[0.99847955,0.00041889524,0.0001837276,0.00045135926,0.0002851987,0.00018125853],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00042175912,0.00023184606,0.0008936007,0.00044460339,0.00002761461,0.0000072111197,0.00018799772,0.00021997167,0.00071902486],"category_scores_gemma":[0.000091450245,0.00016471694,0.00026611643,0.0006866548,0.00033126865,0.000040753486,0.000066652865,0.00060959184,0.000015519448],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040059215,0.0065908483,0.7439123,0.000042322936,0.00012283165,0.00002648039,0.00014578423,0.0000013898932,0.009570922,0.000004089525,0.0014315062,0.23414564],"study_design_scores_gemma":[0.026458714,0.011847268,0.92675614,0.0002308042,0.00006812975,0.00000498479,0.000035698376,0.00009399236,0.0057680532,0.000019750743,0.028556878,0.00015959056],"about_ca_topic_score_codex":0.0003324944,"about_ca_topic_score_gemma":0.000060699498,"teacher_disagreement_score":0.23398605,"about_ca_system_score_codex":0.0007140126,"about_ca_system_score_gemma":0.0008194948,"threshold_uncertainty_score":0.7872818},"labels":[],"label_agreement":null},{"id":"W4412727668","doi":"10.1016/j.jprot.2025.105507","title":"Proteomics analysis reveal early event molecular effectors of anti-CD19 CAR-T cell therapy in hematological cancer","year":2025,"lang":"en","type":"article","venue":"Journal of Proteomics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Conselho Nacional de Desenvolvimento Científico e Tecnológico; Coordenação de Aperfeiçoamento de Pessoal de Nível Superior; Fundação de Amparo à Pesquisa do Estado de São Paulo; International Union of Biochemistry and Molecular Biology; Royal Society of Chemistry; Biochemical Society; European Association for Cancer Research","keywords":"Jurkat cells; Chimeric antigen receptor; CD28; CD19; Biology; T cell; Cancer immunotherapy; Cell biology; Immunotherapy; Antigen; Immunology; Immune system","score_opus":0.015941541869590813,"score_gpt":0.3349791735705588,"score_spread":0.319037631700968,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412727668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99212503,0.0011393104,0.0040491587,0.0007652879,0.00011579391,0.001659817,0.000007478177,0.000007730922,0.0001303883],"genre_scores_gemma":[0.9907661,0.0009290953,0.0075798114,0.00013047385,0.00007212525,0.00005924412,0.0000021625012,0.000025279847,0.0004356901],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997372,0.0003035233,0.0010532291,0.00025420156,0.00065191346,0.00036514463],"domain_scores_gemma":[0.99830586,0.000116343545,0.00056767894,0.00037613176,0.00048095864,0.00015305671],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013575372,0.00023000105,0.0012427846,0.0010242925,0.000031195228,0.000024866547,0.00032507157,0.00024153969,0.00019129078],"category_scores_gemma":[0.00015816282,0.00017353993,0.00069075805,0.0015510095,0.00011469899,0.00007158054,0.00006918449,0.0008902781,0.0000011036448],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016207543,0.00042968962,0.23836674,0.00017424855,0.00084106886,0.00018680404,0.00019488226,0.0010514566,0.75624853,0.000024678158,0.000036765476,0.00082440337],"study_design_scores_gemma":[0.0044757924,0.0011449559,0.08156081,0.00035287204,0.00039137233,0.000035486224,0.000057463552,0.0005650499,0.9110416,0.00016551657,0.00006416073,0.00014487248],"about_ca_topic_score_codex":0.00029264338,"about_ca_topic_score_gemma":0.000019376877,"teacher_disagreement_score":0.15680592,"about_ca_system_score_codex":0.00038955075,"about_ca_system_score_gemma":0.0006679049,"threshold_uncertainty_score":0.7076753},"labels":[],"label_agreement":null},{"id":"W4412805889","doi":"10.1093/eurheartjsupp/suaf083.016","title":"Cardiovascular adverse events after CAR-T, BiTEs and TILs therapies: a systematic review and meta-analysis","year":2025,"lang":"en","type":"article","venue":"European Heart Journal Supplements","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Meta-analysis; Adverse effect; Intensive care medicine; Dermatology; Internal medicine","score_opus":0.056024992447638255,"score_gpt":0.3505701393222382,"score_spread":0.29454514687459993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412805889","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.066914804,0.92088944,0.00026741865,0.005654597,0.00009612424,0.0044544097,0.00012348821,0.000047638543,0.0015521114],"genre_scores_gemma":[0.8781295,0.075014696,0.0012221853,0.01146287,0.00015936213,0.00021515945,0.000044723165,0.00012755145,0.03362396],"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9961594,0.0015991679,0.0007863189,0.00036383828,0.00073009415,0.0003612],"domain_scores_gemma":[0.9986555,0.00010205636,0.00011737792,0.0006446595,0.0002027949,0.00027762307],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003777339,0.0002699465,0.0021542332,0.0004464198,0.00016295532,0.00005647264,0.0001357925,0.000027173739,0.0062610516],"category_scores_gemma":[0.00013953599,0.00017864484,0.0017086896,0.000583373,0.000054951237,0.000116576775,0.00015850697,0.00034645363,0.000045029825],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001703458,0.00018340259,0.041558024,0.075269066,0.87519544,0.0007930734,0.0008010885,0.0000042096945,0.000532882,0.0000044697363,0.0052685197,0.00021948152],"study_design_scores_gemma":[0.0022021004,0.00024402248,0.02384245,0.0037279602,0.9161833,0.0006787668,0.0002844709,0.000014215821,0.00007303613,0.00001964331,0.052421883,0.00030818584],"about_ca_topic_score_codex":0.000024040166,"about_ca_topic_score_gemma":0.0000056631275,"teacher_disagreement_score":0.8458747,"about_ca_system_score_codex":0.00006952408,"about_ca_system_score_gemma":0.000044390243,"threshold_uncertainty_score":0.9946474},"labels":[],"label_agreement":null},{"id":"W4412824780","doi":"10.1038/s41746-025-01809-6","title":"Design specifications for biomedical virtual twins in engineered adoptive cellular immunotherapies","year":2025,"lang":"en","type":"review","venue":"npj Digital Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Care Foundation","funders":"National Cancer Institute; European Commission","keywords":"Immune system; Computer science; Computational biology; Adoptive cell transfer; Psychology; Neuroscience; Human–computer interaction; Medicine; Biology; Immunology; T cell","score_opus":0.12884270219560104,"score_gpt":0.36965207301881325,"score_spread":0.24080937082321222,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412824780","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000038667104,0.96043867,0.026643433,0.0007860695,0.00055038976,0.005582032,0.00027360438,0.00013206461,0.0055898754],"genre_scores_gemma":[0.00008460083,0.9661688,0.00079281884,0.00010164869,0.001140763,0.0011407314,0.00224981,0.00015386239,0.028166967],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9960421,0.00013362191,0.0013869228,0.0008283198,0.00087389245,0.0007351715],"domain_scores_gemma":[0.9946447,0.0035917908,0.0002206656,0.0009488014,0.00025045974,0.00034355448],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00077651057,0.0007374867,0.0031019393,0.0017448247,0.00006715735,0.000057265428,0.0005374105,0.000608582,0.0012429545],"category_scores_gemma":[0.001866009,0.00054455746,0.00056134723,0.0017684257,0.00062553986,0.0001242459,0.00009662259,0.0009737919,0.00008340365],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028931172,0.00043786998,9.927357e-7,0.007837864,0.0005988689,0.000100696816,0.00038506425,8.54526e-7,0.000320146,0.00062814984,0.005102884,0.9842973],"study_design_scores_gemma":[0.0031681072,0.0018169979,0.0000031221696,0.028620174,0.000510317,0.00005279911,0.00027344134,0.00004072999,0.000028420009,0.0001303284,0.9649762,0.0003793913],"about_ca_topic_score_codex":0.000011088187,"about_ca_topic_score_gemma":0.0000010590156,"teacher_disagreement_score":0.9839179,"about_ca_system_score_codex":0.0006443802,"about_ca_system_score_gemma":0.0013899063,"threshold_uncertainty_score":0.9997006},"labels":[],"label_agreement":null},{"id":"W4412825944","doi":"10.1158/2326-6066.cir-24-0897","title":"Endoglin-Directed CAR T Cells Comprehensively Target Tumors in Advanced Sarcomas","year":2025,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; Sarcoma Foundation of America","keywords":"Chimeric antigen receptor; Cancer research; Metastasis; Sarcoma; Cytotoxic T cell; Stromal cell; Tumor microenvironment; Immunotherapy; Cancer; Antigen; Medicine; Immunology; Biology; Immune system; Pathology; In vitro; Internal medicine","score_opus":0.053936030644522716,"score_gpt":0.4012525384342819,"score_spread":0.34731650778975914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412825944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9438518,0.024988696,0.000011314441,0.0037474502,0.00051894836,0.001845649,0.00003083654,0.00018077891,0.024824472],"genre_scores_gemma":[0.9356631,0.0051739383,0.0005676387,0.0004169759,0.000114957154,0.0007184064,0.000040830797,0.00007489848,0.05722923],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99583584,0.0007230624,0.00052861305,0.00079777057,0.00066846213,0.001446266],"domain_scores_gemma":[0.99701244,0.00071858405,0.00005502262,0.0009470261,0.0011027111,0.00016423274],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010164889,0.00028003243,0.0007923771,0.001569649,0.00022155227,0.000031121257,0.00058978744,0.0003098043,0.005020108],"category_scores_gemma":[0.00040603452,0.00027566022,0.00014137506,0.002187043,0.0011086268,0.00008589392,0.00044208657,0.0025080417,0.00018122536],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034451773,0.00021228672,0.01791928,0.0001358507,0.0002822406,0.00039391057,0.00032820288,0.000044670174,0.9461976,0.00050800235,0.0023457492,0.028186973],"study_design_scores_gemma":[0.00914861,0.00073056406,0.10437742,0.00063705276,0.00002190802,0.00004374902,0.0010974598,0.0004714586,0.6905146,0.0010302071,0.19158484,0.00034211928],"about_ca_topic_score_codex":0.0015980076,"about_ca_topic_score_gemma":0.00025197738,"teacher_disagreement_score":0.25568303,"about_ca_system_score_codex":0.0011259331,"about_ca_system_score_gemma":0.0015502064,"threshold_uncertainty_score":0.99996954},"labels":[],"label_agreement":null},{"id":"W4412850991","doi":"10.1016/j.ajt.2025.07.1935","title":"T Cell-Mediated Rejection Produces Unique Patterns of Molecular Injury: An Underestimated Menace","year":2025,"lang":"en","type":"article","venue":"American Journal of Transplantation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; BP (Canada)","funders":"","keywords":"Medicine; Graft rejection; Immunology; Transplantation; Surgery","score_opus":0.011268260520574187,"score_gpt":0.3203634147639454,"score_spread":0.30909515424337125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412850991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97736967,0.00008490712,0.021276748,0.00062522775,0.00007323112,0.00022740466,0.000016827451,0.000017447715,0.00030853858],"genre_scores_gemma":[0.9972154,0.0009076091,0.0015285201,0.00013872913,0.000026827796,0.000003612902,0.000046147372,0.000016137828,0.00011704343],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99873143,0.0002219641,0.00042094119,0.00013410966,0.0003498728,0.00014168282],"domain_scores_gemma":[0.99899864,0.000084941435,0.000317919,0.00015260112,0.0003536107,0.00009231186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038887985,0.000104746505,0.00031319857,0.00043101158,0.00002761134,0.000011531715,0.00009861738,0.00003901705,0.00007952099],"category_scores_gemma":[0.00002993956,0.00009161695,0.00007814805,0.00055144425,0.00009131409,0.00012554773,0.0000034918824,0.00024518868,8.758248e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0030836193,0.00020596199,0.011613664,0.00023438326,0.000115111834,0.00006715751,0.00073239196,0.0002049374,0.96966326,0.000024854524,0.000024826639,0.0140298465],"study_design_scores_gemma":[0.0015264255,0.003290338,0.030987473,0.00046466483,0.00026261364,0.00011883728,0.0008694777,0.00026088383,0.9619936,0.000073790034,0.000064747976,0.000087174114],"about_ca_topic_score_codex":0.0003075663,"about_ca_topic_score_gemma":0.00001678468,"teacher_disagreement_score":0.019845705,"about_ca_system_score_codex":0.00008431637,"about_ca_system_score_gemma":0.00026981573,"threshold_uncertainty_score":0.3736031},"labels":[],"label_agreement":null},{"id":"W4412852294","doi":"10.1016/j.ajt.2025.07.659","title":"Defining Optimal Cryoprotectant Agent Conditions for Cryopreservation of Regulatory T Cells for Tolerogenic Cell Therapy in Transplant Recipients","year":2025,"lang":"en","type":"article","venue":"American Journal of Transplantation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Cryopreservation; Medicine; Cryoprotectant; Cell therapy; Transplantation; Cell; Immunology; Surgery; Cell biology; Biology; Biochemistry","score_opus":0.019912428608731977,"score_gpt":0.31912979925128027,"score_spread":0.2992173706425483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412852294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96281385,0.0002851673,0.03509664,0.00030091667,0.00015154587,0.0011062211,0.00016141702,0.000007188406,0.00007706665],"genre_scores_gemma":[0.9907254,0.0013712153,0.0074151102,0.00012657206,0.000037857862,0.00009707931,0.00008893932,0.000022672457,0.00011513],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99842864,0.00009420238,0.0007553419,0.00016965474,0.00031963215,0.00023250795],"domain_scores_gemma":[0.99863005,0.00040167948,0.00040128914,0.00014265567,0.0003499633,0.00007434672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006689664,0.00013653967,0.00045758745,0.00052029453,0.00005625613,0.000010729297,0.00013218558,0.00005923547,0.000048891736],"category_scores_gemma":[0.0000183993,0.00012572827,0.00027680473,0.00039758201,0.000114671086,0.0001155718,0.0000023831203,0.00018107703,3.7696918e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015554662,0.00038967663,0.0063531166,0.00036682302,0.00022257578,0.000014498682,0.0021706896,0.0033713158,0.9501287,0.00014546719,0.00008037826,0.02120211],"study_design_scores_gemma":[0.013093548,0.0055218474,0.064464144,0.0010680137,0.0003283541,0.000058812548,0.0007085564,0.0022554793,0.9116873,0.00026097937,0.00037801263,0.00017495992],"about_ca_topic_score_codex":0.000044306442,"about_ca_topic_score_gemma":0.000012139531,"teacher_disagreement_score":0.058111027,"about_ca_system_score_codex":0.00012451704,"about_ca_system_score_gemma":0.000300671,"threshold_uncertainty_score":0.512705},"labels":[],"label_agreement":null},{"id":"W4412865633","doi":"10.1016/j.ajt.2025.07.1806","title":"Canadian Transplant Pharmacists’ Knowledge and Perspectives on Chimeric Antigen Receptor T Cell Therapy","year":2025,"lang":"en","type":"article","venue":"American Journal of Transplantation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; Occupational Cancer Research Centre; University of Alberta; BC Children's Hospital","funders":"","keywords":"Medicine; Chimeric antigen receptor; Cell therapy; Antigen; Immunology; Intensive care medicine; Immunotherapy; Cell; Immune system; Genetics","score_opus":0.01873298544881717,"score_gpt":0.3185463200908913,"score_spread":0.2998133346420741,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412865633","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877648,0.0027541157,0.0003458489,0.0015156051,0.00014653448,0.00024874223,0.00003286605,0.000011195859,0.0071803243],"genre_scores_gemma":[0.9438056,0.054650154,0.00034997688,0.000305111,0.00010310177,0.0000039059846,0.000014643885,0.000018307534,0.00074923405],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989368,0.00013898197,0.0002810642,0.00017823903,0.00022389414,0.00024104834],"domain_scores_gemma":[0.9992259,0.0001308397,0.00011222987,0.00010208563,0.00016422952,0.00026472996],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002799217,0.00015198816,0.0003379111,0.0006413991,0.000091371716,0.000022690132,0.000103267994,0.000034936482,0.0004155498],"category_scores_gemma":[0.000005124357,0.00012538978,0.00011724152,0.00045841988,0.00016280344,0.000075464486,0.0000013596572,0.00033353968,0.000008425151],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009842182,0.00050589617,0.032638337,0.00017154776,0.00058504514,0.0002781052,0.033591725,0.000016981712,0.49489388,0.00007601838,0.0006817888,0.42671847],"study_design_scores_gemma":[0.028964622,0.016187629,0.36390397,0.0017688897,0.000882065,0.0027822978,0.016048813,0.0003185933,0.5154523,0.00010520608,0.05250761,0.0010779883],"about_ca_topic_score_codex":0.0017157923,"about_ca_topic_score_gemma":0.0003350176,"teacher_disagreement_score":0.4256405,"about_ca_system_score_codex":0.00019557943,"about_ca_system_score_gemma":0.0005653637,"threshold_uncertainty_score":0.5113247},"labels":[],"label_agreement":null},{"id":"W4412957745","doi":"10.1016/j.jtct.2025.07.021","title":"Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: A CIBMTR Analysis","year":2025,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Institute of Environmental Health Sciences; National Institute of Allergy and Infectious Diseases; National Cancer Institute; National Heart, Lung, and Blood Institute","keywords":"Medicine; Chimeric antigen receptor; Cytokine release syndrome; Internal medicine; Cumulative incidence; Oncology; Immunotherapy; Gastroenterology; Immunology; Transplantation; Cancer","score_opus":0.020433082632561664,"score_gpt":0.3003773014187984,"score_spread":0.27994421878623676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412957745","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91110307,0.0054659215,0.07420385,0.001450223,0.00010795075,0.0017145723,0.000053714615,0.00009037996,0.0058102943],"genre_scores_gemma":[0.93577415,0.053983964,0.00078791246,0.0013552246,0.00008054235,0.0001851017,0.0008785098,0.00003201526,0.0069225803],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99868304,0.00009027275,0.00034746484,0.00033757984,0.0002598397,0.00028180232],"domain_scores_gemma":[0.99938494,0.00009533378,0.00005483991,0.00024514878,0.000113912174,0.00010584226],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00033081928,0.00021970725,0.000402673,0.00048884674,0.00017240742,0.000056360645,0.00009853622,0.00012629632,0.001853932],"category_scores_gemma":[0.00000139882,0.00018278557,0.0003188212,0.00091735146,0.00007061299,0.000104898754,0.0000019625604,0.00014487105,0.00001234541],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005047772,0.00035584703,0.0072057974,0.00021442246,0.0015295098,0.0000056474796,0.003883344,0.000013536386,0.8329876,0.00026786746,0.0001667664,0.14832187],"study_design_scores_gemma":[0.018505305,0.0007518182,0.022623705,0.000051969637,0.0006179769,0.000007960041,0.00031945956,0.0011722175,0.85742337,0.0001653775,0.097999305,0.0003615386],"about_ca_topic_score_codex":0.000029636418,"about_ca_topic_score_gemma":0.0000071282034,"teacher_disagreement_score":0.14796034,"about_ca_system_score_codex":0.000027836275,"about_ca_system_score_gemma":0.00008122663,"threshold_uncertainty_score":0.9990585},"labels":[],"label_agreement":null},{"id":"W4413094417","doi":"10.1007/s40264-025-01596-9","title":"Pharmacovigilance in Cell and Gene Therapy: Evolving Challenges in Risk Management and Long-Term Follow-Up","year":2025,"lang":"en","type":"review","venue":"Drug Safety","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kootenay Association for Science & Technology","funders":"","keywords":"Pharmacovigilance; Medicine; Blueprint; Clinical trial; Risk analysis (engineering); Intensive care medicine; Bioinformatics; Adverse effect; Pharmacology; Pathology","score_opus":0.055418353736730035,"score_gpt":0.36289067018476684,"score_spread":0.3074723164480368,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413094417","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0010654912,0.9865122,0.00000424746,0.00013170898,0.00017868253,0.0026083558,0.00003819255,0.000031911546,0.009429224],"genre_scores_gemma":[0.0003064779,0.98903817,0.00010091884,0.000053941792,0.00011317124,0.0002156977,0.00006430334,0.00006307837,0.010044268],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9972748,0.00045249518,0.0006126865,0.0008304192,0.00034637886,0.00048318115],"domain_scores_gemma":[0.99868184,0.0004519588,0.0001597817,0.00053951767,0.000033017273,0.00013387932],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012623676,0.00046859964,0.001632955,0.0006455923,0.000056634042,0.000031900283,0.00022510863,0.00018883235,0.00025923614],"category_scores_gemma":[0.000023872391,0.00039658463,0.00019124748,0.00044171503,0.00007209684,0.00006183624,0.00028050377,0.00088332617,0.000008571317],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023165451,0.00011191067,0.0034665116,0.036082562,0.00019875226,0.00031128095,0.000421388,2.8304183e-7,0.0000070449655,0.000008362952,0.00007699066,0.95908326],"study_design_scores_gemma":[0.007914019,0.000071725626,0.010579256,0.024767503,0.0004255603,0.000032954744,0.000097499345,0.00002540045,0.00002565448,0.000028730321,0.95550466,0.0005270195],"about_ca_topic_score_codex":0.000055333843,"about_ca_topic_score_gemma":0.00015463604,"teacher_disagreement_score":0.95855623,"about_ca_system_score_codex":0.00030832904,"about_ca_system_score_gemma":0.00014503901,"threshold_uncertainty_score":0.9998486},"labels":[],"label_agreement":null},{"id":"W4413114150","doi":"10.3390/cells14151223","title":"Exploiting TCR Repertoire Analysis to Select Therapeutic TCRs for Cancer Immunotherapy","year":2025,"lang":"en","type":"review","venue":"Cells","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Medical Research Council; Chulabhorn Royal Academy","keywords":"T-cell receptor; Immunotherapy; Cancer immunotherapy; Antigen; Cancer; Adoptive cell transfer; T cell; Biology; Computational biology; Immunology; Immune system; Cancer research; Medicine; Genetics","score_opus":0.08142222239966064,"score_gpt":0.4294910818292818,"score_spread":0.3480688594296212,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413114150","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000019563562,0.99189997,0.0010862183,0.00023442597,0.00035642486,0.004495046,0.000105913925,0.00017862344,0.0016238157],"genre_scores_gemma":[0.0000069897274,0.9019037,0.0003923077,0.0008717878,0.00050067535,0.002363734,0.00015884044,0.00022596368,0.09357599],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99654686,0.00023159542,0.0008699009,0.0010098424,0.0005170253,0.0008247533],"domain_scores_gemma":[0.99695015,0.0009710147,0.00025049908,0.0012693361,0.0003250833,0.00023392921],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007066038,0.0006477284,0.003412222,0.0013098151,0.00014546083,0.00009080236,0.000509003,0.00042396807,0.002772477],"category_scores_gemma":[0.000075479846,0.00051324564,0.0024466086,0.003414991,0.00005590741,0.00003623204,0.00008032336,0.0006057682,0.00004996524],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001226292,0.00007253288,0.0000051134643,0.0117102545,0.007859653,0.000017514227,0.0001818835,0.000007191081,0.0016449328,0.000006564218,0.0019659258,0.9764058],"study_design_scores_gemma":[0.00055950467,0.00019672788,0.0000016114817,0.007089609,0.0072013503,0.000008402903,0.00003786199,0.000029326131,0.0014346832,0.000009976981,0.9829931,0.00043782048],"about_ca_topic_score_codex":0.00016934836,"about_ca_topic_score_gemma":0.00005908255,"teacher_disagreement_score":0.9810272,"about_ca_system_score_codex":0.0008210233,"about_ca_system_score_gemma":0.001417079,"threshold_uncertainty_score":0.9997319},"labels":[],"label_agreement":null},{"id":"W4413127351","doi":"10.1101/2025.08.08.669387","title":"CART-GPT: A T Cell-Informed AI Linguistic Framework for Interpreting Neurotoxicity and Therapeutic Outcomes in CAR-T Therapy","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada; University of Ottawa","funders":"National Cancer Institute; National Research Council Canada; Alliance de recherche numérique du Canada; Comprehensive Cancer Center at Wake Forest Baptist Medical Center","keywords":"Chimeric antigen receptor; Cart; Neurotoxicity; Immunotherapy; T cell; Computational biology; Computer science; Cell; Medicine; Neuroscience; Immune system; Bioinformatics; Artificial intelligence; Biology; Immunology; Internal medicine; Engineering; Toxicity","score_opus":0.027483994754852994,"score_gpt":0.32159501169713206,"score_spread":0.2941110169422791,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413127351","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98408854,0.0032350298,0.0027868112,0.0011945163,0.0014004592,0.0065357084,0.00026128144,0.00038570535,0.00011192622],"genre_scores_gemma":[0.9900445,0.001107851,0.004395749,0.0024543907,0.00039024287,0.0013351863,7.4829865e-7,0.00017781033,0.0000935692],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9959668,0.00022021905,0.0009366176,0.0012933641,0.00057688745,0.0010061333],"domain_scores_gemma":[0.99565756,0.0013885286,0.00033636342,0.0015909926,0.00066368753,0.00036285934],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0010207848,0.0008464603,0.0014773639,0.00076140603,0.00016609272,0.0002587012,0.00055856776,0.0009529431,0.00010948659],"category_scores_gemma":[0.0019887006,0.00081177696,0.00038431247,0.0006138521,0.00021888701,0.00005560213,0.00050766364,0.002419964,0.000006131931],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022688569,0.00095614966,0.35160583,0.006095473,0.0010425911,0.00019836474,0.00073255366,0.000056917783,0.6348504,0.0018633044,0.0001017559,0.00022780187],"study_design_scores_gemma":[0.011793085,0.0015919515,0.2749904,0.007980778,0.00062525657,2.3387685e-7,0.0000680842,0.008015658,0.6660621,0.00029657807,0.025579285,0.0029965662],"about_ca_topic_score_codex":0.00014676468,"about_ca_topic_score_gemma":0.000013926221,"teacher_disagreement_score":0.076615416,"about_ca_system_score_codex":0.00060657,"about_ca_system_score_gemma":0.0018348583,"threshold_uncertainty_score":0.9998815},"labels":[],"label_agreement":null},{"id":"W4413139122","doi":"10.1182/bloodadvances.2024015599","title":"New comorbidity index associated with survival after chimeric antigen receptor T-cell therapy for large B-cell lymphoma","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"Legend Biotech; Pharmacyclics; Eurostars; Genentech; National Institutes of Health; Juno Therapeutics; Astellas Pharma; Swedish Orphan Biovitrum; Omeros Corporation; BeiGene; Pfizer; Incyte; bluebird bio; Jazz Pharmaceuticals; National Cancer Institute; Servier; Gilead Sciences; Moffitt Cancer Center; Society for Immunotherapy of Cancer; Cidara Therapeutics; Celgene; Fred Hutchinson Cancer Research Center; Karyopharm Therapeutics; Memorial Sloan-Kettering Cancer Center; Massachusetts General Hospital; Amgen; Bristol-Myers Squibb","keywords":"Medicine; Comorbidity; Internal medicine; Hazard ratio; Lymphoma; Diabetes mellitus; Gastroenterology; Confidence interval","score_opus":0.01401590502790424,"score_gpt":0.2952427108687055,"score_spread":0.2812268058408013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413139122","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.973092,0.01315073,0.0014079666,0.00046886518,0.0004231048,0.0016381199,0.00009827484,0.00015077404,0.009570167],"genre_scores_gemma":[0.9316506,0.0047819745,0.0015941453,0.00067220157,0.00033627747,0.00019824614,0.00014039189,0.00007917768,0.060546983],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979939,0.000109652836,0.00027862843,0.0005030301,0.00048130917,0.00063352135],"domain_scores_gemma":[0.99875677,0.00030233635,0.00012335599,0.0004267159,0.00020123454,0.00018961105],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00037372924,0.00029606387,0.0005480803,0.00015901266,0.00013623075,0.00004609204,0.00022537891,0.00013978544,0.0011087407],"category_scores_gemma":[0.00006395172,0.00023103759,0.00017059837,0.000650824,0.000069174566,0.00014058096,0.000051431787,0.00018302453,0.000020548077],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013637892,0.009900228,0.73351663,0.00036271662,0.0012494336,0.00007145196,0.0005205183,0.000005765432,0.124691665,0.00006350302,0.006232975,0.10974721],"study_design_scores_gemma":[0.05803588,0.0020124048,0.12753688,0.00023980044,0.0001682274,0.0000044192993,0.00025240902,0.000054100758,0.20951216,0.00016703538,0.6015111,0.000505576],"about_ca_topic_score_codex":0.00007815458,"about_ca_topic_score_gemma":0.0001754661,"teacher_disagreement_score":0.60597974,"about_ca_system_score_codex":0.000079960235,"about_ca_system_score_gemma":0.00053746754,"threshold_uncertainty_score":0.9998044},"labels":[],"label_agreement":null},{"id":"W4413148372","doi":"10.18295/2075-0528.1377","title":"Immunotherapy for B-Cell Neoplasms using T Cells expressing Chimeric Antigen Receptors : From antigen choice to clinical implementation","year":2012,"lang":"en","type":"article","venue":"Sultan Qaboos University medical journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Victoria Hospital; University of Saskatchewan; McGill University Health Centre","funders":"","keywords":"Chimeric antigen receptor; Medicine; Immunotherapy; Antigen; Receptor; Immunology; Antigen-presenting cell; T cell; Immune system; Internal medicine","score_opus":0.060186006952712354,"score_gpt":0.39417967200392956,"score_spread":0.3339936650512172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413148372","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9805894,0.00041556155,0.015371104,0.000769849,0.0016877443,0.00070605206,0.00004352765,0.000042414635,0.00037433938],"genre_scores_gemma":[0.9455018,0.0045479625,0.037203353,0.0019050507,0.007843932,0.0000021675864,0.00013287764,0.00014380661,0.0027190559],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99657524,0.0004237005,0.00060249184,0.0003552106,0.0011703027,0.00087306584],"domain_scores_gemma":[0.9967272,0.0007189229,0.00027888437,0.0002913852,0.00030510084,0.0016784951],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017663586,0.0002483148,0.0005390809,0.00038947162,0.0005071152,0.00006738032,0.00042663474,0.00027725467,0.010703519],"category_scores_gemma":[0.00023668875,0.00023827837,0.00035233647,0.00056527636,0.00017337533,0.00039547103,0.000120588455,0.0008766169,0.000055817698],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0033688834,0.0008619283,0.20679376,0.000031236108,0.0005707863,0.00011877843,0.0039781686,0.000007048342,0.57197577,0.000004447102,0.009192333,0.20309684],"study_design_scores_gemma":[0.022033967,0.0012971346,0.061002504,0.00036594976,0.00025504612,0.0001465602,0.008658525,0.00065955997,0.099994585,0.00001642987,0.80489826,0.0006714853],"about_ca_topic_score_codex":0.00038217675,"about_ca_topic_score_gemma":0.000024581157,"teacher_disagreement_score":0.7957059,"about_ca_system_score_codex":0.00043159793,"about_ca_system_score_gemma":0.0008129861,"threshold_uncertainty_score":0.9902008},"labels":[],"label_agreement":null},{"id":"W4413160413","doi":"10.1016/j.drudis.2025.104453","title":"Commercialization of cell and gene therapy in Canada: Current landscape, challenges and opportunities","year":2025,"lang":"en","type":"review","venue":"Drug Discovery Today","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Queen's University","funders":"Natural Sciences and Engineering Research Council of Canada","keywords":"Commercialization; Current (fluid); Genetic enhancement; Gene; Biotechnology; Computational biology; Business; Biology; Engineering; Genetics; Marketing","score_opus":0.09829680913850976,"score_gpt":0.3382983723454111,"score_spread":0.24000156320690136,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413160413","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016227391,0.99395794,0.0000014274575,0.00022414915,0.00016565672,0.0008377323,0.00016017663,0.000005779,0.0030244242],"genre_scores_gemma":[0.0005513937,0.996173,0.0000031647385,0.000051573756,0.00007460175,0.00006452644,0.00032055037,0.000030185998,0.0027309733],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99848837,0.0002365247,0.00044311205,0.0003098648,0.00030537322,0.00021674992],"domain_scores_gemma":[0.99910146,0.0003098908,0.00015243431,0.0002955405,0.00005200744,0.00008869551],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029837363,0.00027967663,0.0013450352,0.0003119106,0.00002492467,0.000020552547,0.00010516295,0.00008983715,0.00008293568],"category_scores_gemma":[0.000018318357,0.00021832577,0.00009100928,0.00013517757,0.00006703274,0.00007517197,0.00009874176,0.00028711994,2.1857223e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000402968,0.000076853226,0.00014405111,0.023236424,0.000062146544,0.000018561059,0.0002915041,1.849769e-7,0.000004460095,0.00011960704,0.0007336973,0.97527224],"study_design_scores_gemma":[0.00086926593,0.000060927843,0.00034267028,0.010589163,0.00014610932,0.000009444366,0.00039543936,0.0000057707925,0.00005327046,0.000021353217,0.9872907,0.00021587893],"about_ca_topic_score_codex":0.043873254,"about_ca_topic_score_gemma":0.14170386,"teacher_disagreement_score":0.986557,"about_ca_system_score_codex":0.0001780262,"about_ca_system_score_gemma":0.0031538683,"threshold_uncertainty_score":0.96249366},"labels":[],"label_agreement":null},{"id":"W4413220663","doi":"10.58931/cect.2025.4258","title":"Adverse Events Associated With Novel Cancer Therapies","year":2025,"lang":"en","type":"article","venue":"Canadian Eye Care Today","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St Joseph's Health Care; Western University","funders":"","keywords":"Adverse effect; Medicine; Cancer; Intensive care medicine; Bioinformatics; Pharmacology; Biology; Internal medicine","score_opus":0.017739685335443157,"score_gpt":0.3056143570413656,"score_spread":0.2878746717059224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413220663","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9363665,0.0025322759,0.000018300178,0.005962869,0.0004216234,0.00095716893,0.00041953762,0.00008706038,0.05323468],"genre_scores_gemma":[0.915958,0.00006794515,0.000028124454,0.0030415591,0.000080369704,0.0000900597,0.00010932334,0.00003688229,0.08058777],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99873585,0.000035792207,0.00013326324,0.00028577202,0.00027881938,0.0005304987],"domain_scores_gemma":[0.9987218,0.00004770385,0.000031495478,0.00035815273,0.00040206427,0.00043883416],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000109346,0.00017192762,0.00026481715,0.00032694038,0.00013050607,0.000009693478,0.00015178333,0.0001382182,0.00348118],"category_scores_gemma":[0.00009040694,0.00014583385,0.00008422029,0.00057401246,0.00008919264,0.000044813583,0.000017019334,0.00028599158,0.00001834469],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00050710153,0.00011604783,0.89114624,0.00021645964,0.0020710493,0.00036337622,0.0066601736,0.00007035475,0.01940395,0.0003565088,0.01844537,0.060643367],"study_design_scores_gemma":[0.0049538263,0.00022123008,0.6118771,0.000979574,0.00019654926,0.000004395706,0.0038776333,0.00004552377,0.0024567659,0.000024541554,0.37499553,0.00036737337],"about_ca_topic_score_codex":0.09785032,"about_ca_topic_score_gemma":0.5654511,"teacher_disagreement_score":0.4676008,"about_ca_system_score_codex":0.0021925434,"about_ca_system_score_gemma":0.0031577116,"threshold_uncertainty_score":0.9974298},"labels":[],"label_agreement":null},{"id":"W4413257665","doi":"10.1182/bloodadvances.2025016778","title":"Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphoma","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal","funders":"Omeros Corporation; Angiocrine Bioscience; Gilead Sciences; Sanofi; Bristol-Myers Squibb; National Cancer Institute; Incyte; Royal College of Physicians and Surgeons of Canada; Amgen","keywords":"CD19; Lymphoma; B cell; Cell; Cancer research; Medicine; Biology; Immunology; Antibody; Genetics","score_opus":0.020859460373952095,"score_gpt":0.3463436107200448,"score_spread":0.32548415034609274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413257665","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8826783,0.009559349,0.000007353844,0.0002787138,0.0001300541,0.00063480274,0.00003024559,0.00009654752,0.106584646],"genre_scores_gemma":[0.93993074,0.0022718247,0.00075436325,0.00017438407,0.000035056903,0.000059851292,0.0000214789,0.000020814603,0.056731492],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982537,0.00014928693,0.00044960534,0.00035961563,0.00037044927,0.00041733115],"domain_scores_gemma":[0.9988324,0.00037500096,0.00012548784,0.00042616515,0.00016367694,0.0000772855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026576206,0.00023635224,0.00086620584,0.00048241008,0.000055954886,0.000013460794,0.00020946455,0.00006945393,0.00037091455],"category_scores_gemma":[0.00003581298,0.00019127665,0.0001478909,0.0010024436,0.00014890764,0.00010923364,0.0000709204,0.00017674995,0.00001363188],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007491549,0.004817383,0.7908512,0.0004386912,0.00032732254,0.000059682683,0.0022413058,0.000010431314,0.19498992,0.0005141642,0.0004249892,0.004575768],"study_design_scores_gemma":[0.020921735,0.00036778793,0.39261222,0.00024574687,0.00014511695,0.00000246636,0.0023398332,0.00009239961,0.52514774,0.00039980432,0.05745122,0.0002739249],"about_ca_topic_score_codex":0.00040176304,"about_ca_topic_score_gemma":0.0025353234,"teacher_disagreement_score":0.39823896,"about_ca_system_score_codex":0.000075878444,"about_ca_system_score_gemma":0.00021551909,"threshold_uncertainty_score":0.7800035},"labels":[],"label_agreement":null},{"id":"W4413316564","doi":"10.1182/bloodadvances.2024015282","title":"Association of PET4 response with outcomes of BV-CHP vs CHOP in the ECHELON-2 trial in CD30+ peripheral T-cell lymphoma","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"National Cancer Institute; Takeda Oncology; Genentech; National Institutes of Health; Kyowa Hakko Kirin; Memorial Sloan-Kettering Cancer Center; Chugai Pharmaceutical; Celltrion; Seagen; Kite Pharma; Gilead Sciences; Eisai; BeiGene; Daiichi Sankyo Europe; Sanofi; MorphoSys; Celgene; Bristol-Myers Squibb; AstraZeneca; Pfizer","keywords":"CHOP; Medicine; Prednisone; Internal medicine; Vincristine; Anaplastic large-cell lymphoma; Cyclophosphamide; Lymphoma; Oncology; Peripheral T-cell lymphoma; Chemotherapy; Gastroenterology; Immunology; T cell; Immune system","score_opus":0.011150924414558954,"score_gpt":0.3162519335843498,"score_spread":0.3051010091697908,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413316564","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928603,0.00082615396,0.00000392441,0.0022281355,0.00008220494,0.00082257384,0.0000069291777,0.000010372821,0.0031594085],"genre_scores_gemma":[0.99021626,0.0003027412,0.00024924806,0.00015999669,0.000039433973,0.00007051973,0.000003363359,0.000011283116,0.008947178],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9981914,0.00042806534,0.0004054427,0.00019839528,0.0005439734,0.0002327302],"domain_scores_gemma":[0.9982365,0.0011681808,0.00017423746,0.00029464375,0.000101497084,0.000024975001],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015947819,0.00012463967,0.000477765,0.00024429942,0.000022736109,0.000009788639,0.00018412663,0.00008284899,0.00009317133],"category_scores_gemma":[0.00067879685,0.000080747435,0.00008973454,0.00066091225,0.00006261886,0.000088613444,0.000027392703,0.0001645931,0.0000010378643],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18379147,0.002180246,0.75769,0.00018336937,0.00014419471,0.000039387116,0.0018885649,0.000029952367,0.047465947,0.000035527864,0.00006906072,0.006482257],"study_design_scores_gemma":[0.14599614,0.002384686,0.78620076,0.00022750287,0.000116706666,0.000004576729,0.0018799468,0.000028113513,0.054546166,0.0001262934,0.008356874,0.00013223293],"about_ca_topic_score_codex":0.00013694825,"about_ca_topic_score_gemma":0.00066225184,"teacher_disagreement_score":0.037795343,"about_ca_system_score_codex":0.00015097513,"about_ca_system_score_gemma":0.00034368155,"threshold_uncertainty_score":0.3292785},"labels":[],"label_agreement":null},{"id":"W4413349976","doi":"10.1126/scitranslmed.adp6519","title":"CAR T <sub>reg</sub> cells mediate linked suppression and infectious tolerance in islet transplantation in mice","year":2025,"lang":"en","type":"article","venue":"Science Translational Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Children's Hospital; University of British Columbia","funders":"","keywords":"Alloimmunity; Immunology; Autoimmunity; Islet; Transplantation; Biology; Adoptive cell transfer; Antigen; Immune system; T cell; Medicine; Diabetes mellitus; Endocrinology; Internal medicine","score_opus":0.015457513228790817,"score_gpt":0.3159360446472166,"score_spread":0.3004785314184258,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413349976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869473,0.00085477444,0.000524268,0.0072004637,0.00039974277,0.00071600016,0.000008832814,0.000029326964,0.0033193082],"genre_scores_gemma":[0.9976287,0.0013484079,0.00014095589,0.0005293085,0.000109228386,0.000036868423,0.000029986144,0.00000999644,0.00016655114],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99773055,0.00008819294,0.00044184006,0.0004890503,0.0008718767,0.0003784885],"domain_scores_gemma":[0.9991538,0.00035437153,0.000045393983,0.00015939146,0.0001388549,0.00014817083],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001403054,0.00016382348,0.00033390446,0.0010820265,0.000101020596,0.000015203045,0.00013351176,0.00008900701,0.0001203987],"category_scores_gemma":[0.000115617906,0.00013804538,0.000029656874,0.0020615328,0.00082253054,0.00025882147,0.000011335246,0.00041455275,0.0000041337935],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004242218,0.00006901842,0.018419689,0.00015220924,0.0000050182607,0.00004240743,0.0026494737,0.00037930912,0.9645023,0.00020617212,0.000047914727,0.013102282],"study_design_scores_gemma":[0.011616049,0.00029191657,0.490859,0.0015123346,0.000046056044,0.000054576154,0.00022255217,0.013761943,0.4790102,0.0018582062,0.0005461929,0.00022096587],"about_ca_topic_score_codex":0.00022934673,"about_ca_topic_score_gemma":0.00050392526,"teacher_disagreement_score":0.48549208,"about_ca_system_score_codex":0.00011417639,"about_ca_system_score_gemma":0.00043949563,"threshold_uncertainty_score":0.5629327},"labels":[],"label_agreement":null},{"id":"W4413416908","doi":"10.3390/curroncol32080460","title":"Practical Guidance for the Expanded Implementation and Provision of Bispecific Antibodies for Diffuse Large B-Cell Lymphoma (DLBCL) Across Canada","year":2025,"lang":"en","type":"review","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Memorial University of Newfoundland; Université Laval; Université de Montréal; London Health Sciences Centre; Hôpital Maisonneuve-Rosemont; St. John’s Health Sciences Centre; Hôpital Charles-Le Moyne; Université de Sherbrooke; Western University; Southlake Regional Health Center; Occupational Cancer Research Centre; CancerCare Manitoba; Ottawa Hospital; University of Manitoba; University of Calgary","funders":"Roche Canada","keywords":"Medicine; Health care; Health professionals","score_opus":0.21394395431071667,"score_gpt":0.5635384590925364,"score_spread":0.34959450478181975,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413416908","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00046920465,0.98795426,0.0011669655,0.00051650737,0.0011864349,0.007431251,0.0011991771,0.000012383582,0.00006382858],"genre_scores_gemma":[0.00014980309,0.9960223,0.00033510485,0.000037914,0.00030680798,0.0015517183,0.0006136563,0.000036231802,0.0009464628],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9977466,0.00019987814,0.00075610424,0.0004703241,0.00029281038,0.00053430453],"domain_scores_gemma":[0.9947318,0.0039311633,0.00047183564,0.00040107087,0.00036470976,0.0000994368],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00092498056,0.00029452672,0.0014366207,0.000075956224,0.00019986335,0.000023722641,0.00018247528,0.00020347022,0.00005318995],"category_scores_gemma":[0.000502888,0.00019031785,0.00028836538,0.00018937833,0.00014652146,0.000035618217,0.00017922495,0.00022885247,5.7723037e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033531696,0.0012430314,0.00007863003,0.035887647,0.0001431777,0.0000041357684,0.00013604859,5.4731575e-9,0.00001909778,0.00012407615,0.02675296,0.93527585],"study_design_scores_gemma":[0.011396154,0.00062340044,0.000042742093,0.0021182809,0.0006766978,0.000029023735,0.00065389264,0.00003345624,0.00008294616,0.000011455549,0.9841886,0.00014334424],"about_ca_topic_score_codex":0.001834409,"about_ca_topic_score_gemma":0.040262923,"teacher_disagreement_score":0.95743567,"about_ca_system_score_codex":0.0007506368,"about_ca_system_score_gemma":0.0046269037,"threshold_uncertainty_score":0.9772498},"labels":[],"label_agreement":null},{"id":"W4413494869","doi":"10.1038/s41551-025-01470-0","title":"Directed evolution-based discovery of ligands for in vivo restimulation of chimeric antigen receptor T cells","year":2025,"lang":"en","type":"article","venue":"Nature Biomedical Engineering","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"School of Engineering and Applied Science, University of Pennsylvania; National Center for Advancing Translational Sciences; Society for Immunotherapy of Cancer; Mallinckrodt Pharmaceuticals; Perelman School of Medicine, University of Pennsylvania; National Cancer Institute; Institute for Translational Medicine and Therapeutics; University of Pennsylvania; Massachusetts General Hospital; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology; Children's Hospital of Philadelphia; National Institutes of Health; National Science Foundation","keywords":"Chimeric antigen receptor; CD19; Cancer research; In vivo; Antigen; T cell; Immunology; Biology; Medicine; Chemistry; Immune system","score_opus":0.005535937912300631,"score_gpt":0.28179288182267503,"score_spread":0.2762569439103744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413494869","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9651121,0.0015784148,0.030938607,0.00052631146,0.0007248012,0.00082824583,0.000079022655,0.00008742897,0.00012505484],"genre_scores_gemma":[0.99617535,0.000030165966,0.0030740348,0.000025733958,0.00009919342,0.00002101556,0.000058005207,0.000017774173,0.0004987415],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99892384,0.000008929259,0.0003319222,0.00018535765,0.00034823528,0.00020170688],"domain_scores_gemma":[0.9991945,0.00038885948,0.000049790084,0.00018938184,0.000112747635,0.00006471137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002817991,0.00011069997,0.00033640268,0.0006355047,0.000011638629,0.000004105656,0.0000938336,0.00033340248,0.00007746559],"category_scores_gemma":[0.00067174295,0.00009862135,0.00010510485,0.0012450507,0.00006810444,0.00003766284,0.000019854868,0.00034957778,2.9264237e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004338698,0.0001489196,0.0017906072,0.00062831084,0.0000527268,0.0000015097822,0.000023374812,0.0011491124,0.9939006,0.000101412894,0.0006188114,0.0011507579],"study_design_scores_gemma":[0.002423683,0.00020951233,0.017265523,0.0008231702,0.000024773157,4.099316e-7,0.000007822817,0.143977,0.82973,0.000014444779,0.005432054,0.00009165523],"about_ca_topic_score_codex":0.000032895892,"about_ca_topic_score_gemma":0.000001982299,"teacher_disagreement_score":0.16417064,"about_ca_system_score_codex":0.00015057779,"about_ca_system_score_gemma":0.00025074737,"threshold_uncertainty_score":0.4021662},"labels":[],"label_agreement":null},{"id":"W4413505578","doi":"10.1101/2025.08.22.671679","title":"WITHDRAWN: AAV-Mediated CAR-T therapy eradicate HIV reservoirs with augmented safety and persistence","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; A&L Canada Laboratories (Canada); Université de Sherbrooke; Centre Hospitalier Universitaire Sainte-Justine; Institut National de la Recherche Scientifique; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Persistence (discontinuity); Human immunodeficiency virus (HIV); Antiretroviral therapy; Medicine; Virology; Viral load; Engineering; Geotechnical engineering","score_opus":0.02283886266749234,"score_gpt":0.24965152402738072,"score_spread":0.22681266135988837,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413505578","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98380524,0.005891014,0.0003438245,0.004206854,0.0004154057,0.0035586548,0.00063179433,0.0007233099,0.00042392127],"genre_scores_gemma":[0.98282635,0.010694853,0.0028869577,0.0010229241,0.0004321855,0.00043684422,0.000008427993,0.0002702126,0.001421234],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.994919,0.00032464048,0.0007335252,0.0018147571,0.0011748064,0.0010332913],"domain_scores_gemma":[0.99518186,0.00023952851,0.00037496208,0.0023718528,0.0010610148,0.00077076314],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010573874,0.00093762466,0.0013305622,0.0006968324,0.00032905667,0.00023534714,0.0006937743,0.000734497,0.00055873214],"category_scores_gemma":[0.0002462935,0.0008182602,0.00021939064,0.001299412,0.00072130945,0.00014241354,0.0005993604,0.002022992,0.000038913404],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009104806,0.0005133109,0.07694881,0.0019874603,0.0028426084,0.00074996304,0.00019565015,0.000066956156,0.90601957,0.0001589662,0.0013761983,0.000035686764],"study_design_scores_gemma":[0.025064766,0.002190159,0.39083993,0.008357602,0.0012261451,0.000001524423,0.00014534226,0.0043159267,0.33341098,0.0000026152106,0.23043402,0.004011001],"about_ca_topic_score_codex":0.00015442124,"about_ca_topic_score_gemma":0.000013366089,"teacher_disagreement_score":0.5726086,"about_ca_system_score_codex":0.0007532031,"about_ca_system_score_gemma":0.002406109,"threshold_uncertainty_score":0.99942684},"labels":[],"label_agreement":null},{"id":"W4413539704","doi":"10.64628/aam.73wewhtus","title":"All for one, not one for all: The promise and challenges of personalized medicine","year":2024,"lang":"en","type":"article","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Personalized medicine; Precision medicine; Medicine; Internet privacy; Data science; Computer science; Bioinformatics; Biology; Pathology","score_opus":0.2042038018108626,"score_gpt":0.3993359464152614,"score_spread":0.1951321446043988,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413539704","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05591179,0.07233955,0.0014946371,0.83164847,0.00026292616,0.009940046,0.00007197651,0.00021266963,0.028117953],"genre_scores_gemma":[0.69465345,0.07367443,0.009494178,0.0077733286,0.002714399,0.0025991902,0.000127918,0.0002786562,0.20868443],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.998878,0.000029679266,0.00021511553,0.0002744683,0.00035789187,0.00024483353],"domain_scores_gemma":[0.99846333,0.0010081779,0.000025767315,0.0002460546,0.0001492661,0.00010740057],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010456581,0.000117346004,0.00036182205,0.00009039196,0.000029503892,0.000011050195,0.00009352209,0.00007025413,0.0015492628],"category_scores_gemma":[0.0002180661,0.00006603108,0.00010526257,0.00006676505,0.00023885624,0.000028839926,0.000032262134,0.00011984598,0.0000031736756],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007760403,0.00038203827,0.000020749532,0.008348361,0.0022408718,0.000009109172,0.011155207,1.5131546e-7,0.6497328,0.10173732,0.019870935,0.198742],"study_design_scores_gemma":[0.0101495925,0.0034653423,0.00047469846,0.00067758077,0.00063149736,0.000033220447,0.002127299,0.0029336144,0.034608703,0.0035161322,0.9412179,0.00016444811],"about_ca_topic_score_codex":0.00007012064,"about_ca_topic_score_gemma":0.000058470876,"teacher_disagreement_score":0.92134696,"about_ca_system_score_codex":0.000031177256,"about_ca_system_score_gemma":0.00007920027,"threshold_uncertainty_score":0.9993635},"labels":[],"label_agreement":null},{"id":"W4413618388","doi":"10.1101/2025.08.18.670666","title":"<i>Sleeping Beauty</i> mutagenesis identifies <i>BACH2</i> and other regulators of CD8 <sup>+</sup> T cell exhaustion, persistence <i>in vivo</i> , and CAR-T function under tumor-associated chronic antigen stimulation","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Adler","funders":"Kite Pharma; Genentech; National Institutes of Health; University of Minnesota","keywords":"Mutagenesis; Persistence (discontinuity); Beauty; Function (biology); CD8; In vivo; Biology; T cell; Genetics; Cancer research; Mutation; Cell biology; Immune system; Philosophy; Gene; Engineering; Epistemology","score_opus":0.01791341842263895,"score_gpt":0.24077072055189255,"score_spread":0.22285730212925361,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413618388","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.990646,0.0066728597,0.0003410919,0.00009855338,0.0003078601,0.001489602,0.00020000315,0.00017766682,0.00006634071],"genre_scores_gemma":[0.9978815,0.0010126879,0.00024604175,0.00023189391,0.00020386324,0.00010313385,0.0000019470433,0.00012316201,0.00019581805],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99611217,0.00028694808,0.0008880132,0.0012884366,0.00073761976,0.00068683265],"domain_scores_gemma":[0.99737865,0.0001883249,0.0005099469,0.0009961384,0.0006599103,0.0002670069],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012831179,0.0006235782,0.0010296094,0.00077111035,0.00019853967,0.0001391362,0.00024431787,0.0006258723,0.00017469382],"category_scores_gemma":[0.00016938102,0.00071189215,0.0001997131,0.0010251853,0.0003453489,0.00019586859,0.00033024122,0.00075562607,0.000003514136],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024358765,0.00019431645,0.13215384,0.0022508358,0.0003396511,0.000020855288,0.00011038916,0.0038729522,0.8606666,0.000033209162,0.000104757826,0.00000901468],"study_design_scores_gemma":[0.004108748,0.00036168267,0.26675612,0.0038721436,0.0008683696,2.2271281e-7,0.00015851668,0.011170436,0.7103826,0.0000073107544,0.0012647444,0.0010491288],"about_ca_topic_score_codex":0.0004717993,"about_ca_topic_score_gemma":0.00003986734,"teacher_disagreement_score":0.150284,"about_ca_system_score_codex":0.0009263292,"about_ca_system_score_gemma":0.00096752594,"threshold_uncertainty_score":0.99953324},"labels":[],"label_agreement":null},{"id":"W4413675912","doi":"10.64628/aap.csrtypcng","title":"La médecine personnalisée est prometteuse, mais ses enjeux, dont son coût, sont nombreux","year":2025,"lang":"fr","type":"preprint","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Humanities; Political science; Art; Philosophy","score_opus":0.04815926023584218,"score_gpt":0.35028271963117813,"score_spread":0.30212345939533597,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413675912","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14858478,0.03039466,0.0035217323,0.07979089,0.006094524,0.01053268,0.000986492,0.0009670991,0.7191271],"genre_scores_gemma":[0.13006942,0.013735151,0.0079897735,0.00265676,0.0045842463,0.0010754237,0.00065038115,0.00029691658,0.83894193],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98878896,0.0014650675,0.0016999,0.0026709782,0.0025615825,0.002813532],"domain_scores_gemma":[0.99101186,0.0022499522,0.00043050767,0.0035166405,0.001315844,0.0014752065],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.00490108,0.0017148112,0.0028495127,0.0012911352,0.0003295518,0.0005194794,0.0018649561,0.0020657855,0.06498241],"category_scores_gemma":[0.0016149457,0.0015213994,0.00131787,0.0012631165,0.000984546,0.00022262323,0.0028656153,0.00536719,0.0013831003],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007547261,0.009806845,0.06135932,0.021598004,0.010887908,0.004389176,0.015484998,0.0005564986,0.06515438,0.052167486,0.2727238,0.47832432],"study_design_scores_gemma":[0.010989021,0.0013698768,0.022742838,0.0075195697,0.0014401277,0.00054843724,0.0060067293,0.0025795915,0.010572904,0.0014090396,0.9328771,0.0019447565],"about_ca_topic_score_codex":0.011615891,"about_ca_topic_score_gemma":0.002771699,"teacher_disagreement_score":0.6601533,"about_ca_system_score_codex":0.0026514188,"about_ca_system_score_gemma":0.0046580737,"threshold_uncertainty_score":0.9995598},"labels":[],"label_agreement":null},{"id":"W4413734272","doi":"10.33540/3174","title":"Unmet needs in T cell-based cancer therapies: opportunities for translational innovation","year":2025,"lang":"en","type":"dissertation","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Translational science; Translational research; Medicine; Oncology; Cancer research; Pathology","score_opus":0.11400931596028135,"score_gpt":0.3894417403053376,"score_spread":0.27543242434505627,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413734272","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.5503068,0.0039608455,0.003936757,0.016011534,0.0015566683,0.007956983,0.0006597727,0.00024072277,0.41536993],"genre_scores_gemma":[0.16043918,0.0006723854,0.0007984192,0.0017987787,0.00025965902,0.001677156,0.018450169,0.000083350016,0.81582093],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99852467,0.000039835115,0.00050036237,0.00024878295,0.00043311983,0.00025322128],"domain_scores_gemma":[0.99873424,0.00026814773,0.000106172185,0.00020328976,0.0006475591,0.00004060368],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00037812043,0.0002406896,0.00041143145,0.0020396132,0.000052954703,0.000030138697,0.0001051546,0.00033721424,0.008254945],"category_scores_gemma":[0.00003292321,0.00022449892,0.00013183977,0.0011684241,0.000024676732,0.000056067664,0.0000027115432,0.00033141486,0.0000016144085],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01887307,0.0012934712,0.0045163864,0.012502923,0.0009713529,0.000028721126,0.009283414,0.00058896985,0.21460158,0.021413626,0.03067879,0.6852477],"study_design_scores_gemma":[0.030184053,0.0013408675,0.012463794,0.003658826,0.0006299055,0.000002026579,0.04086705,0.011059532,0.27027708,0.004633887,0.6230156,0.0018674142],"about_ca_topic_score_codex":0.00036098462,"about_ca_topic_score_gemma":0.0013500417,"teacher_disagreement_score":0.6833803,"about_ca_system_score_codex":0.00017710966,"about_ca_system_score_gemma":0.0027188142,"threshold_uncertainty_score":0.99265164},"labels":[],"label_agreement":null},{"id":"W4413774493","doi":"10.1016/s2152-2650(25)02385-7","title":"ABCL-1487: Large B-Cell Lymphoma Microenvironment Archetype Profiles (LymphoMAPs) Clinically Identify Subgroups With Greatest Benefit From CD19 CAR T-Cell Therapy","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Spinal Cord Injury BC","funders":"","keywords":"Medicine; CD19; Lymphoma; Oncology; Internal medicine; Immunology; Antigen","score_opus":0.02548499021004296,"score_gpt":0.3236153303053004,"score_spread":0.2981303400952574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413774493","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9792811,0.0040947385,0.00022775748,0.001111524,0.000925673,0.0028426305,0.0003319269,0.00045970854,0.010724896],"genre_scores_gemma":[0.93748593,0.0070042037,0.002664729,0.005052947,0.0011878713,0.00039942464,0.0009208133,0.0003812105,0.044902865],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9882563,0.0008265137,0.0035647391,0.0031787727,0.0018620446,0.002311671],"domain_scores_gemma":[0.9903213,0.0031899977,0.0008929107,0.0036940218,0.0004972577,0.001404523],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0026828551,0.0014708221,0.0027577942,0.00048949267,0.0005362576,0.000318604,0.0017473452,0.0015449597,0.002489491],"category_scores_gemma":[0.0003808309,0.0012303126,0.0015043712,0.0011886897,0.001287185,0.00030002109,0.0008797054,0.0010581422,0.0016513724],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01847873,0.008791785,0.4733893,0.00030291243,0.0014025941,0.0016070281,0.0004230345,0.000008424993,0.08758232,0.00015673082,0.005344894,0.40251222],"study_design_scores_gemma":[0.05626212,0.0029266821,0.811587,0.0005534137,0.00050631986,0.000099733734,0.00027984663,0.0003142815,0.045402177,0.00058287935,0.08036857,0.0011169767],"about_ca_topic_score_codex":0.0015090642,"about_ca_topic_score_gemma":0.00019989155,"teacher_disagreement_score":0.40139526,"about_ca_system_score_codex":0.0038187208,"about_ca_system_score_gemma":0.004077554,"threshold_uncertainty_score":0.99980414},"labels":[],"label_agreement":null},{"id":"W4413783187","doi":"10.1016/s2152-2650(25)01538-1","title":"ALL-562: Outcomes in Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Receiving Inotuzumab Ozogamicin Stratified by Cumulative Dose","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"","keywords":"Medicine; Lymphoblastic Leukemia; Oncology; Internal medicine; Pediatrics; Leukemia","score_opus":0.02242904538383347,"score_gpt":0.3368691806410551,"score_spread":0.31444013525722164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413783187","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852603,0.00013705358,0.00009750677,0.00048818247,0.0005052343,0.002319205,0.00010235232,0.00021995377,0.0108702015],"genre_scores_gemma":[0.9722633,0.00014536556,0.0006658632,0.0020290236,0.00012255633,0.00015049473,0.0003556755,0.00014790264,0.02411985],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9927637,0.0006452333,0.0022487321,0.0016747884,0.0012826533,0.0013849238],"domain_scores_gemma":[0.99382335,0.0030560552,0.00051147334,0.0015173701,0.000456074,0.0006356993],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011400672,0.0008866989,0.0020468722,0.0005516521,0.00017659119,0.00014192626,0.0007655647,0.0008487226,0.0005587312],"category_scores_gemma":[0.0011641727,0.0007249262,0.0005008046,0.0012602078,0.00068103825,0.00034408807,0.0003826429,0.0009993411,0.0002185456],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016173393,0.0021750086,0.7315467,0.00024425433,0.0015218307,0.00029708364,0.00047041842,0.00008001621,0.0038700243,0.00010156493,0.007634167,0.23588552],"study_design_scores_gemma":[0.041704487,0.0020775092,0.946709,0.0006128044,0.00043616834,0.000009108023,0.000101992,0.0018259941,0.002597349,0.00018039696,0.0030655512,0.00067966984],"about_ca_topic_score_codex":0.00049978687,"about_ca_topic_score_gemma":0.00015484182,"teacher_disagreement_score":0.23520584,"about_ca_system_score_codex":0.0078433845,"about_ca_system_score_gemma":0.004850331,"threshold_uncertainty_score":0.9995202},"labels":[],"label_agreement":null},{"id":"W4413791664","doi":"10.1016/s2152-2650(25)01097-3","title":"POSTER: ABCL-1487 Large B-Cell Lymphoma Microenvironment Archetype Profiles (LymphoMAPs) Clinically Identify Subgroups With Greatest Benefit From CD19 CAR T-Cell Therapy","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Spinal Cord Injury BC","funders":"","keywords":"Medicine; CD19; Lymphoma; CAR T-cell therapy; Internal medicine; Oncology; Immunology; Immunotherapy; Chimeric antigen receptor; Cancer; Antigen","score_opus":0.024492328462297062,"score_gpt":0.3206075723707601,"score_spread":0.29611524390846305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413791664","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9783328,0.0040743873,0.00012089519,0.0011485838,0.0009355935,0.002955039,0.00038479682,0.00044306862,0.011604834],"genre_scores_gemma":[0.9491367,0.005968685,0.0016524275,0.0059551257,0.0011010066,0.00035067156,0.0010047137,0.0003801301,0.034450553],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98823506,0.0008528237,0.003609632,0.0031679107,0.0018323412,0.0023022324],"domain_scores_gemma":[0.9904331,0.003050992,0.00090769154,0.003704028,0.00051168504,0.0013925271],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0025402883,0.0014874763,0.0027515234,0.0004993659,0.00052298163,0.00034019112,0.0017473849,0.001533175,0.002202207],"category_scores_gemma":[0.00034460032,0.0012433694,0.0015067159,0.0011052657,0.0013886543,0.0003165658,0.00094079616,0.0010372999,0.0016011781],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020759579,0.008275289,0.50669026,0.0003042705,0.0013664063,0.0016891871,0.00048025305,0.0000045030915,0.09251461,0.00010115022,0.0040896516,0.36372486],"study_design_scores_gemma":[0.05617129,0.0033774155,0.82428724,0.0005827644,0.00050337834,0.00012885376,0.00023579443,0.00017518544,0.04966481,0.00038691354,0.06338356,0.0011028246],"about_ca_topic_score_codex":0.0011565035,"about_ca_topic_score_gemma":0.00015913758,"teacher_disagreement_score":0.36262202,"about_ca_system_score_codex":0.0030336848,"about_ca_system_score_gemma":0.0035200464,"threshold_uncertainty_score":0.99978745},"labels":[],"label_agreement":null},{"id":"W4413792288","doi":"10.1016/s2152-2650(25)02748-x","title":"CT-041: Third-Line (3L) CAR T-Cell Therapy in the Golden Years: A Single-Center Experience on Outcomes for Elderly Patients in Large B-Cell Lymphoma","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Single Center; Center (category theory); Aggressive lymphoma; Oncology; Lymphoma; Internal medicine; Rituximab","score_opus":0.04795534734860198,"score_gpt":0.36277100446945076,"score_spread":0.3148156571208488,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413792288","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98795164,0.00031714395,0.00001991615,0.00084029825,0.0006964103,0.0031184237,0.00005874478,0.000085841035,0.00691158],"genre_scores_gemma":[0.9829394,0.00036915392,0.00017330066,0.00859892,0.00024368298,0.00061562797,0.00010612519,0.00009369815,0.0068600667],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99434686,0.00061325857,0.0017128787,0.0011824069,0.0009413611,0.0012032571],"domain_scores_gemma":[0.99487287,0.0029102215,0.00026672185,0.0014794708,0.00021562407,0.00025509598],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018294319,0.0005603865,0.0012168665,0.00044700917,0.00012431355,0.00012173914,0.0010652757,0.00042330584,0.00015768496],"category_scores_gemma":[0.0008826446,0.00041584863,0.00070625136,0.0009542835,0.00032597984,0.00015306869,0.00021505346,0.00051339203,0.00012053826],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00420144,0.01092942,0.5007,0.00009975842,0.00007875549,0.00029759115,0.0016639108,0.0000025461413,0.0012574624,0.00009537541,0.0032496415,0.4774241],"study_design_scores_gemma":[0.067149654,0.0035101562,0.8486403,0.000300679,0.000030492307,0.0000107837905,0.00071420014,0.00028820313,0.0025432867,0.00016612725,0.07623959,0.00040648613],"about_ca_topic_score_codex":0.0002603273,"about_ca_topic_score_gemma":0.00021120565,"teacher_disagreement_score":0.4770176,"about_ca_system_score_codex":0.0017105241,"about_ca_system_score_gemma":0.0010121816,"threshold_uncertainty_score":0.99982935},"labels":[],"label_agreement":null},{"id":"W4413804340","doi":"10.4110/in.2025.25.e29","title":"Adoptive Cellular Therapies in Pediatric Leukemia Patients After Allogeneic-Hematopoietic Stem Cell Transplants","year":2025,"lang":"en","type":"review","venue":"Immune Network","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Ontario Institute for Cancer Research","funders":"Alberta Children's Hospital Research Institute; Canadian Institutes of Health Research; Arnie Charbonneau Cancer Institute, University of Calgary","keywords":"Medicine; Stem cell; Hematopoietic stem cell; Haematopoiesis; Hematopoietic stem cell transplantation; Leukemia; Immunology; Cancer research; Transplantation; Internal medicine; Biology; Cell biology","score_opus":0.019952025183029125,"score_gpt":0.2829232855194382,"score_spread":0.26297126033640905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413804340","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.002918419,0.9904166,0.000016052063,0.000008990005,0.00078813086,0.0034220202,0.00005288206,0.00007209192,0.002304845],"genre_scores_gemma":[0.0024546247,0.98250943,0.00006853512,0.00006313108,0.00073716906,0.00076895516,0.0003914316,0.00018183507,0.012824862],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9951159,0.00065947935,0.0014310498,0.0008982441,0.00074601034,0.0011493589],"domain_scores_gemma":[0.9975996,0.00060445635,0.0003486602,0.0011294052,0.00013568244,0.00018217051],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006383299,0.000921596,0.003183281,0.0005952793,0.00008371895,0.000050704348,0.0005933647,0.0008655909,0.00095946545],"category_scores_gemma":[0.000008695442,0.0007599516,0.0010826557,0.0016614299,0.00009288026,0.000057828227,0.00017867045,0.0015798346,0.00020410432],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000836807,0.00056961115,0.0072293673,0.08373322,0.0006830413,0.00071152876,0.001071713,0.000031370444,0.000007724484,0.000006168074,0.0011408591,0.9039786],"study_design_scores_gemma":[0.0038467376,0.0004974262,0.0019928801,0.039654505,0.002924517,0.0000186902,0.00004954687,0.000004919971,0.000037081834,0.000024924837,0.94974345,0.0012053206],"about_ca_topic_score_codex":0.000028287312,"about_ca_topic_score_gemma":0.000011575733,"teacher_disagreement_score":0.9486026,"about_ca_system_score_codex":0.00079247274,"about_ca_system_score_gemma":0.0011681947,"threshold_uncertainty_score":0.9999538},"labels":[],"label_agreement":null},{"id":"W4413880346","doi":"10.3389/fimmu.2025.1690655","title":"Editorial: Repurposing cancer immunotherapies for use in autoimmunity and transplantation","year":2025,"lang":"en","type":"editorial","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Children's Hospital","funders":"","keywords":"Repurposing; Autoimmunity; Medicine; Transplantation; Cancer; Immunology; Immunotherapy; Cancer immunotherapy; Immune system; Biology; Internal medicine","score_opus":0.014779445130986826,"score_gpt":0.31550982959040474,"score_spread":0.3007303844594179,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413880346","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004410584,0.030740933,0.0004967511,0.00016640109,0.9621763,0.0016067718,0.00026434564,0.000053039472,0.00008482247],"genre_scores_gemma":[0.00006807425,0.12479784,0.003935458,0.000048894868,0.8592114,0.0011053004,0.0012344602,0.00012069208,0.009477897],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975057,0.00033324366,0.0006505166,0.0005803112,0.00035885736,0.0005713216],"domain_scores_gemma":[0.9977257,0.0012475678,0.00017018177,0.0005307414,0.0002920596,0.00003374167],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0008558114,0.00036626015,0.0011327637,0.0011791684,0.00009724297,0.00006606809,0.0002601752,0.0018356423,0.00005638698],"category_scores_gemma":[0.00077912153,0.00038995358,0.00013430696,0.00039018644,0.00035952762,0.000162926,0.000061301595,0.0020714987,4.4091195e-7],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011121076,0.00011432749,0.002310822,0.0007006164,0.00053259474,0.0000201339,0.0012319137,0.000004184496,0.003143191,0.000007398201,0.9230613,0.05775246],"study_design_scores_gemma":[0.008215738,0.0003556207,0.001703472,0.001197118,0.00013096353,0.000003593579,0.00023056779,0.000060705952,0.00033972535,0.0002693478,0.98720604,0.00028713283],"about_ca_topic_score_codex":0.0077581382,"about_ca_topic_score_gemma":0.0012535757,"teacher_disagreement_score":0.10296497,"about_ca_system_score_codex":0.0010211754,"about_ca_system_score_gemma":0.0011965698,"threshold_uncertainty_score":0.9998552},"labels":[],"label_agreement":null},{"id":"W4413883555","doi":"10.1016/j.ymthe.2025.08.046","title":"T cell exhaustion in poorly immunogenic HCC is partially rescued by checkpoint blockade but suppressed by oncolytic virotherapy","year":2025,"lang":"en","type":"article","venue":"Molecular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canada's Michael Smith Genome Sciences Centre","funders":"National Cancer Institute; National Institutes of Health; King's College London; Mayo Foundation for Medical Education and Research; University of Minnesota; Hyundai Hope On Wheels; National Institute of Allergy and Infectious Diseases; Mayo Clinic","keywords":"Oncolytic virus; Blockade; Immune checkpoint; Immune system; Cancer research; T cell; Immunotherapy; Biology; Cytotoxic T cell; Cell; Immunology; Virology; Receptor","score_opus":0.01066415550059916,"score_gpt":0.2920930423690289,"score_spread":0.2814288868684297,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413883555","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96829736,0.018893464,0.0017333893,0.005670911,0.00014488562,0.002203547,0.00004378383,0.00012591886,0.0028867482],"genre_scores_gemma":[0.95644325,0.005802717,0.00026651358,0.0062103006,0.00007285296,0.00040389007,0.0001696665,0.00015937115,0.03047141],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9964478,0.00035174814,0.00072428136,0.0008234084,0.0008032543,0.00084948604],"domain_scores_gemma":[0.99828947,0.00008638225,0.0001190442,0.0011510192,0.00014575689,0.00020835367],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006615004,0.00047752893,0.000721296,0.00037863082,0.00010771924,0.000102970516,0.00046782673,0.0003803677,0.0033270137],"category_scores_gemma":[0.000031164607,0.00046351526,0.00037682202,0.00088710204,0.00016306672,0.000085385545,0.00006184273,0.0007238198,0.00009372624],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037522388,0.0010239636,0.0005541963,0.000057516965,0.0002765339,0.00011171954,0.00041655925,0.000014699538,0.96990913,0.0000128471165,0.008086015,0.015784597],"study_design_scores_gemma":[0.012315485,0.00080078724,0.0007394956,0.00010806989,0.00003969193,0.000008238764,0.0000786519,0.0004289694,0.8790779,0.00021820537,0.10584426,0.00034021062],"about_ca_topic_score_codex":0.0007379758,"about_ca_topic_score_gemma":0.000015423318,"teacher_disagreement_score":0.09775824,"about_ca_system_score_codex":0.00048355357,"about_ca_system_score_gemma":0.00040351853,"threshold_uncertainty_score":0.99978167},"labels":[],"label_agreement":null},{"id":"W4413885244","doi":"10.1016/j.bneo.2025.100164","title":"Inferior survival in double refractory large B-cell lymphoma eligible for third-line CD19 CAR T-cell therapy","year":2025,"lang":"en","type":"article","venue":"Blood Neoplasia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"CD19; Refractory (planetary science); Lymphoma; Oncology; Medicine; Internal medicine; CAR T-cell therapy; Cancer research; Chimeric antigen receptor; Biology; Immunotherapy; Cancer","score_opus":0.025083253545016972,"score_gpt":0.320445708459025,"score_spread":0.29536245491400803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413885244","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94537723,0.0032750515,0.000080350095,0.0006559585,0.00051824725,0.0021470974,0.00004714257,0.00015575829,0.047743134],"genre_scores_gemma":[0.9016338,0.0022194127,0.00045224448,0.000907168,0.000368428,0.00037359053,0.000121717414,0.000108295266,0.093815334],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9970832,0.00011543557,0.00060572295,0.00069466105,0.00053241575,0.00096855056],"domain_scores_gemma":[0.998114,0.0004264446,0.00011032786,0.0008851725,0.00023792482,0.0002261636],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00092569354,0.000400237,0.0007899906,0.0005532729,0.00013503472,0.000068040245,0.000353112,0.00037176305,0.0004399346],"category_scores_gemma":[0.00006283319,0.00036791115,0.00030136533,0.0008277727,0.00007328348,0.0001173486,0.00012079873,0.00040931097,0.00008823907],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0094164265,0.010178617,0.043047212,0.0006757572,0.00030975195,0.00020049461,0.0009616373,0.00000982941,0.92062664,0.000690824,0.007218414,0.0066643828],"study_design_scores_gemma":[0.08981885,0.0012877597,0.0048126234,0.00013097533,0.0001129242,0.000019394673,0.00028244208,0.00013401489,0.5452175,0.00013250622,0.35769743,0.0003536049],"about_ca_topic_score_codex":0.00042743713,"about_ca_topic_score_gemma":0.000500725,"teacher_disagreement_score":0.37540916,"about_ca_system_score_codex":0.00019866908,"about_ca_system_score_gemma":0.0011553831,"threshold_uncertainty_score":0.9998773},"labels":[],"label_agreement":null},{"id":"W4413924802","doi":"10.1101/2025.08.31.25334789","title":"Efficacy and Safety of CAR T-cell Therapy in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia: A Systematic Review and Meta-analysis","year":2025,"lang":"en","type":"preprint","venue":"medRxiv","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Lymphoblastic Leukemia; Refractory (planetary science); Medicine; Oncology; Leukemia; Meta-analysis; Cancer research; Internal medicine; Biology","score_opus":0.04058267434142196,"score_gpt":0.32124358521947605,"score_spread":0.2806609108780541,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413924802","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.43603528,0.55296993,0.00007449989,0.0005733042,0.00007076396,0.0077619334,0.00017553616,0.000052661733,0.002286119],"genre_scores_gemma":[0.6291146,0.34133837,0.0002788605,0.0008931771,0.00003467011,0.000826493,0.00010333547,0.00009769513,0.02731281],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9948848,0.0011210736,0.0017050927,0.0010689002,0.0007983045,0.0004218572],"domain_scores_gemma":[0.9954917,0.0013538989,0.00068773184,0.0019323627,0.0002854396,0.00024886717],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00264291,0.00065955555,0.006944131,0.0009904887,0.000046936533,0.00003177566,0.0004327873,0.00048160457,0.00078201946],"category_scores_gemma":[0.0003484059,0.0004698602,0.0012963904,0.0011319512,0.00020998693,0.00003071792,0.00050058245,0.0011869947,0.000007723777],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013300506,0.0008706001,0.0020420414,0.7820014,0.19866705,0.0002764105,0.0011356918,0.00014052652,0.013179143,0.000013334788,0.00016807299,0.00017568756],"study_design_scores_gemma":[0.009281849,0.0006473992,0.0023227406,0.014110584,0.9687497,0.000038354618,0.000078406556,0.0005269595,0.0031624334,0.00003859327,0.00031605028,0.00072693056],"about_ca_topic_score_codex":0.00023751323,"about_ca_topic_score_gemma":0.00003398289,"teacher_disagreement_score":0.77008265,"about_ca_system_score_codex":0.00042478647,"about_ca_system_score_gemma":0.0007260894,"threshold_uncertainty_score":0.9997753},"labels":[],"label_agreement":null},{"id":"W4413949817","doi":"10.3390/curroncol32090495","title":"CAR-T Access Disparities for Multiple Myeloma in the Midwest: A Social Determinants of Health Perspective","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Perspective (graphical); Medicine; Multiple myeloma; Social determinants of health; Health equity; Gerontology; Immunology; Pathology; Public health","score_opus":0.23815776165681662,"score_gpt":0.5489496916085798,"score_spread":0.31079192995176314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413949817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9809423,0.0030415957,0.00015449757,0.011725101,0.00065354904,0.0019799785,0.000047865648,0.000014555205,0.0014405577],"genre_scores_gemma":[0.99840605,0.00025248138,0.000034792578,0.00035890928,0.00017024386,0.00039622356,0.000014334694,0.000009562994,0.00035740953],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99859595,0.00032428367,0.00033856457,0.0002239157,0.00016965457,0.00034764907],"domain_scores_gemma":[0.9986917,0.0007923012,0.000110223824,0.00017108023,0.00020160056,0.000033106477],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008051929,0.000104530554,0.00051149353,0.00019925796,0.00011624996,0.000011862577,0.00026455979,0.00008991695,0.00005270885],"category_scores_gemma":[0.00041964644,0.000078116864,0.00012253567,0.00030155064,0.00026006787,0.000039882474,0.00009333777,0.00029109072,0.0000010152247],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018620843,0.0016188016,0.47744384,0.0011018508,0.0000705508,0.000010962076,0.014520699,7.91076e-7,0.0006721166,0.0031779497,0.007061411,0.49245894],"study_design_scores_gemma":[0.0077933506,0.0014221292,0.89514303,0.00025624604,0.00005800313,0.000016275964,0.01162334,0.00065285584,0.001135699,0.002749907,0.07902021,0.00012895613],"about_ca_topic_score_codex":0.0005944901,"about_ca_topic_score_gemma":0.0030347598,"teacher_disagreement_score":0.49232998,"about_ca_system_score_codex":0.00062833476,"about_ca_system_score_gemma":0.00095740013,"threshold_uncertainty_score":0.31855133},"labels":[],"label_agreement":null},{"id":"W4413969506","doi":"10.3390/biom15081096","title":"CD4/CD8–p56lck Induced T-Cell Receptor Signaling and Its Implications for Immunotherapy","year":2025,"lang":"en","type":"review","venue":"Biomolecules","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"National Institute of Allergy and Infectious Diseases; National Institutes of Health","keywords":"Business","score_opus":0.09640532206609212,"score_gpt":0.41620899136199985,"score_spread":0.31980366929590776,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413969506","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00014507734,0.9934013,0.00025844897,0.00045845108,0.00014832827,0.0039800783,0.00028678973,0.00008640551,0.0012351094],"genre_scores_gemma":[0.000047595768,0.9864525,0.00088766933,0.00015996202,0.0002626187,0.0011408459,0.0005226487,0.00012064251,0.010405493],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979612,0.00014077513,0.00058691256,0.0006620445,0.000203255,0.0004457937],"domain_scores_gemma":[0.9981931,0.00056762644,0.00020889571,0.00061544665,0.0002428652,0.00017210544],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00035344894,0.00045475113,0.0013618801,0.00048745336,0.00015570095,0.000077617915,0.00030488297,0.0004687037,0.00037465928],"category_scores_gemma":[0.00014294712,0.0003825668,0.00056392,0.00061024807,0.00007407644,0.000032648295,0.00009363193,0.00034260494,0.000043946115],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000053335432,0.00009698473,0.0000011392278,0.013624307,0.0002672021,0.0000017659594,0.000030266168,6.7317343e-9,0.262091,0.00031472836,0.001064739,0.7224545],"study_design_scores_gemma":[0.0009943221,0.0002759406,0.0000020112334,0.0061665904,0.000414946,0.000023459852,0.000016380687,0.0000014421661,0.012128249,0.000045483433,0.9795944,0.00033678312],"about_ca_topic_score_codex":0.000017477523,"about_ca_topic_score_gemma":0.0000021912024,"teacher_disagreement_score":0.97852963,"about_ca_system_score_codex":0.00017819238,"about_ca_system_score_gemma":0.0008585303,"threshold_uncertainty_score":0.9998626},"labels":[],"label_agreement":null},{"id":"W4413998514","doi":"10.3389/fimmu.2025.1649891","title":"FLT3L combined with GM-CSF induced dendritic cells drive broad tumor-specific CD8+ T cell responses and remodel the tumor microenvironment to enhance anti-tumor efficacy","year":2025,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Optech (Canada)","funders":"","keywords":"Tumor microenvironment; Cancer research; Dendritic cell; Cytotoxic T cell; Follicular dendritic cells; CD8; Tumor cells; Chemistry; Cell biology; Biology; T cell; Immune system; Immunology; Antigen-presenting cell; In vitro; Biochemistry","score_opus":0.009622239950817412,"score_gpt":0.2608458648255901,"score_spread":0.2512236248747727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413998514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9871252,0.0052834484,0.001599713,0.002221111,0.0007974684,0.002099508,0.000012766686,0.000053659445,0.0008071337],"genre_scores_gemma":[0.9832121,0.0010098781,0.0043078493,0.0014284163,0.000047316338,0.00017374082,0.000011082302,0.0000694472,0.00974013],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99683803,0.00054174225,0.0005416615,0.00086619507,0.00033111378,0.0008812735],"domain_scores_gemma":[0.9980764,0.00041961359,0.00012366392,0.0011581831,0.00008593946,0.00013623579],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00051122473,0.00040964276,0.00086236175,0.0006500171,0.00021359327,0.00005796493,0.00053197984,0.00012845671,0.00015711029],"category_scores_gemma":[0.00010758355,0.00032415302,0.000094002986,0.00069320085,0.000781909,0.00007152085,0.00033070976,0.0009966868,0.00005501714],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010588318,0.00049182685,0.004268269,0.00006679033,0.00018442581,0.00045951523,0.0010106604,0.000024003633,0.9715331,0.000030558087,0.0057314932,0.005610997],"study_design_scores_gemma":[0.008589548,0.0027080344,0.06473384,0.0004634834,0.00010618389,0.00020763572,0.003470621,0.0002867535,0.88678896,0.00013844026,0.03199183,0.0005146592],"about_ca_topic_score_codex":0.000088619716,"about_ca_topic_score_gemma":0.000024100016,"teacher_disagreement_score":0.08474417,"about_ca_system_score_codex":0.00051399984,"about_ca_system_score_gemma":0.0002821612,"threshold_uncertainty_score":0.999921},"labels":[],"label_agreement":null},{"id":"W4414029944","doi":"10.1101/2025.08.30.673295","title":"Off-the-shelf allogeneic polyclonal CD38KO/CD38-CAR γδT cells for the treatment of T cell malignancies","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Discovery Centre","funders":"Common Fund; Nationwide Children's Hospital","keywords":"Polyclonal antibodies; CD38; Cancer research; T cell; Medicine; Immunology; Biology; Stem cell; Cell biology; Antibody; Immune system","score_opus":0.02531008067084267,"score_gpt":0.2674429040765548,"score_spread":0.24213282340571213,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414029944","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95689625,0.027029777,0.00070549623,0.0021703588,0.0025144638,0.008215247,0.0020820082,0.00025292786,0.0001334961],"genre_scores_gemma":[0.973486,0.014463167,0.0033952452,0.00058140734,0.0014451941,0.0024417853,0.0000032873886,0.00024656835,0.003937323],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9961484,0.00016508895,0.0008416685,0.0010859548,0.0008370483,0.0009218511],"domain_scores_gemma":[0.9947707,0.0008329076,0.0004506922,0.0027425792,0.0009323207,0.0002707657],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00084647146,0.00079902395,0.0011451036,0.0003353739,0.000305144,0.00011728255,0.0009676548,0.00058683136,0.00035442086],"category_scores_gemma":[0.00009213296,0.0005344702,0.0009055645,0.0005980724,0.00046167438,0.00004257382,0.0003693943,0.0005974839,0.00002858272],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006285161,0.0007681264,0.0015833614,0.0009522315,0.0010800778,0.00003326667,0.000068452675,0.00007008167,0.99352366,0.0002127013,0.0010099158,0.00006962936],"study_design_scores_gemma":[0.0018913294,0.0005639341,0.00800818,0.0002657932,0.0008246911,4.3648416e-8,0.000016357913,0.0002975254,0.83805794,0.000003447392,0.14968158,0.0003891836],"about_ca_topic_score_codex":0.00019599003,"about_ca_topic_score_gemma":0.000011431337,"teacher_disagreement_score":0.1554657,"about_ca_system_score_codex":0.0006917632,"about_ca_system_score_gemma":0.0019214357,"threshold_uncertainty_score":0.9997107},"labels":[],"label_agreement":null},{"id":"W4414145598","doi":"10.54254/2753-8818/2025.ld26551","title":"CRISPR/Cas9 Applications in T Cell Modifications for Tumor Immunotherapy","year":2025,"lang":"en","type":"article","venue":"Theoretical and Natural Science","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Immunotherapy; T cell; Immune system; Cancer immunotherapy; T-cell receptor; Cell; Cytokine; Function (biology)","score_opus":0.011052386314404947,"score_gpt":0.3438042944885486,"score_spread":0.33275190817414363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414145598","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94078106,0.0021094196,0.007563725,0.00972901,0.000104071,0.002266507,0.000012571731,0.00005994738,0.037373662],"genre_scores_gemma":[0.99560165,0.00009865893,0.0011497498,0.00047948587,0.00002166625,0.00014779791,0.000003175861,0.000004420387,0.0024933938],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991237,0.000017483982,0.0001333262,0.00027096935,0.0001850854,0.00026944475],"domain_scores_gemma":[0.99928164,0.00027788364,0.000014271352,0.00022826968,0.00011311405,0.00008479465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000500336,0.00007321898,0.00012762638,0.00017347293,0.00018668291,0.000037376067,0.00020007115,0.000028723738,0.00017744623],"category_scores_gemma":[0.000105114676,0.000050732655,0.000037207035,0.00087055395,0.0016672055,0.0000542837,0.000046284324,0.00018085132,0.0000044077237],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014604487,0.000077367484,0.00033988903,0.000021248825,0.000002038453,4.1411582e-7,0.000072144874,4.0916467e-7,0.3774441,0.60819614,0.000034921082,0.013665295],"study_design_scores_gemma":[0.004032361,0.00038066859,0.045568995,0.00010109529,0.000036615376,0.000019887406,0.0005803154,0.020126104,0.47165933,0.42756185,0.029583864,0.00034891872],"about_ca_topic_score_codex":0.000012904146,"about_ca_topic_score_gemma":0.0000017464483,"teacher_disagreement_score":0.18063429,"about_ca_system_score_codex":0.000062366205,"about_ca_system_score_gemma":0.00017874937,"threshold_uncertainty_score":0.6142888},"labels":[],"label_agreement":null},{"id":"W4414179163","doi":"10.3899/jrheum.2024-1301","title":"Effects of CD19 CAR T Cell Therapy on Quality of Life and Direct Healthcare Costs in Systemic Lupus Erythematosus: A Preliminary Analysis","year":2025,"lang":"en","type":"article","venue":"The Journal of Rheumatology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Quality of life (healthcare); CD19; Disease; CAR T-cell therapy; Systemic lupus erythematosus; Lupus erythematosus; T cell; Cell therapy","score_opus":0.019540261994958504,"score_gpt":0.3337058611835677,"score_spread":0.3141655991886092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414179163","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.970011,0.028120035,0.000036905643,0.0010004208,0.000138699,0.00052889326,0.000003927619,0.0000053821277,0.00015472322],"genre_scores_gemma":[0.9828685,0.016823605,0.000023744951,0.00010706393,0.0000044241788,0.00000661572,0.0000010325871,0.000012749014,0.00015225785],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99632454,0.0018186605,0.0011007546,0.00014327039,0.0003795561,0.0002332163],"domain_scores_gemma":[0.9947756,0.0036815086,0.00076496194,0.00038209715,0.00028699182,0.00010886252],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023923074,0.00015674529,0.0016570828,0.00082984986,0.00003272411,0.0000035508199,0.00022643438,0.0001468158,0.00002416352],"category_scores_gemma":[0.00046295254,0.00009839508,0.00024278527,0.0007945776,0.00019771914,0.000026910117,0.000052403262,0.00046388013,6.1864006e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017070653,0.00043455363,0.9214095,0.0040087514,0.0015540501,0.000023298326,0.003478872,0.00007156577,0.04987571,0.00014419547,0.00016345148,0.0017654324],"study_design_scores_gemma":[0.051873423,0.017822793,0.7692697,0.0130574675,0.0023233485,0.00790786,0.0107121775,0.0011534399,0.12445703,0.00064767787,0.00016217477,0.0006128887],"about_ca_topic_score_codex":0.0015539917,"about_ca_topic_score_gemma":0.00014211069,"teacher_disagreement_score":0.15213975,"about_ca_system_score_codex":0.0001278801,"about_ca_system_score_gemma":0.00034632455,"threshold_uncertainty_score":0.4012435},"labels":[],"label_agreement":null},{"id":"W4414249926","doi":"10.1111/hae.70128","title":"The Critical Need to Consolidate All Gene Therapy Data in Haemophilia","year":2025,"lang":"en","type":"letter","venue":"Haemophilia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Hemophilia Society","funders":"","keywords":"Haemophilia; Clinical trial; Genetic enhancement; Dosing; Haemophilia A; Haemophilia B; Milestone; Targeted therapy","score_opus":0.10614457363458844,"score_gpt":0.39548131582477275,"score_spread":0.2893367421901843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414249926","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0020166382,0.0027420514,0.00003181142,0.9805992,0.0015050503,0.0029066314,0.00075285294,0.00014780836,0.009297913],"genre_scores_gemma":[0.0014893895,0.0043628216,0.00054564443,0.90297073,0.00639135,0.00031918843,0.0030312624,0.00023537652,0.08065424],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9932675,0.00057650043,0.0010057013,0.0017388964,0.0016375716,0.0017738767],"domain_scores_gemma":[0.9907652,0.0022371316,0.00009896954,0.006189326,0.00033691374,0.00037245086],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016865298,0.0008024259,0.0013526571,0.0006979872,0.00023385974,0.0002921985,0.00284908,0.0011904507,0.0022436571],"category_scores_gemma":[0.0016682098,0.0005960264,0.00028490892,0.00096546713,0.00066700263,0.00012231783,0.0013786644,0.004721299,0.00060655084],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009423653,0.00011418652,0.0001554408,0.00021474638,0.00034126444,0.0041054436,0.00014974513,8.72845e-7,0.0043411306,0.00008493787,0.9704194,0.019130448],"study_design_scores_gemma":[0.0019332226,0.00029412788,0.00040132436,0.00038739355,0.00010881945,0.00023025324,0.00002860221,0.00016455262,0.0016640241,0.0011799581,0.9930792,0.0005285107],"about_ca_topic_score_codex":0.00040943778,"about_ca_topic_score_gemma":0.00012927433,"teacher_disagreement_score":0.07762852,"about_ca_system_score_codex":0.0003922182,"about_ca_system_score_gemma":0.00090010924,"threshold_uncertainty_score":0.9996491},"labels":[],"label_agreement":null},{"id":"W4414308830","doi":"10.1101/2025.09.17.676755","title":"Identifying Distinct Molecular Response of CAR-T cells to Solid Tumors by Synthetic Single-Cell Transcriptomic Analyses","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Transcriptome; CD8; Context (archaeology); Immune system; Solid tumor; Cell; Haematopoiesis; Cell therapy; Antigen","score_opus":0.034055235638650594,"score_gpt":0.306821314338097,"score_spread":0.2727660786994464,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414308830","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895791,0.002010388,0.0043578986,0.0002528849,0.0006151295,0.001988814,0.0008709809,0.00026673067,0.000058077163],"genre_scores_gemma":[0.9964568,0.00010947923,0.0022959805,0.00022052742,0.00010885112,0.00021661978,0.0000016524405,0.00022186407,0.0003682198],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99414754,0.000732098,0.0012755896,0.0016481098,0.0011946696,0.0010020176],"domain_scores_gemma":[0.99505186,0.00034768388,0.0004546421,0.0025948077,0.0008441148,0.00070686213],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015970937,0.0008879569,0.0017733421,0.0012936748,0.00012465699,0.00017947349,0.00095583295,0.00058769545,0.0004141046],"category_scores_gemma":[0.00056845305,0.0009730177,0.0006910521,0.0014451036,0.0002668589,0.000072872834,0.00054936233,0.0012217443,0.00005369294],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019673402,0.000605784,0.00057258713,0.0021865645,0.0004934457,0.00034394732,0.00006157307,0.00011899956,0.99315685,0.0000060167104,0.00048294757,0.000003937695],"study_design_scores_gemma":[0.0011505401,0.00031738318,0.0032514406,0.002192824,0.0007107802,7.692058e-8,0.000017269733,0.0001733179,0.98994523,7.426574e-7,0.0015105451,0.0007298684],"about_ca_topic_score_codex":0.00022614613,"about_ca_topic_score_gemma":0.000003242262,"teacher_disagreement_score":0.006877709,"about_ca_system_score_codex":0.00091896707,"about_ca_system_score_gemma":0.0015892677,"threshold_uncertainty_score":0.99927205},"labels":[],"label_agreement":null},{"id":"W4414352545","doi":"10.3390/cancers17183068","title":"Future Directions and Priorities for Cellular Therapy in Sarcoma: A Report from the Strategic Advances in Sarcoma Science Cell Therapy Breakout","year":2025,"lang":"en","type":"review","venue":"Cancers","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; National Institutes of Health","keywords":"Cell therapy; Synovial sarcoma; Sarcoma; Cell; Cancer therapy; Tumor microenvironment; Breakout","score_opus":0.052632595061025814,"score_gpt":0.37778315722771433,"score_spread":0.32515056216668853,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414352545","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004881033,0.9868628,0.0000051757233,0.00023296074,0.00075046124,0.0038373896,0.00011800859,0.000037967307,0.0032742126],"genre_scores_gemma":[0.0004614985,0.9949252,0.000104022576,0.00013125093,0.00069640984,0.0011307589,0.00006765345,0.00005530055,0.0024279186],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99707776,0.00019546662,0.00066774763,0.0009336714,0.00052043865,0.0006049054],"domain_scores_gemma":[0.9978142,0.0008275068,0.000245224,0.0008334114,0.00015279953,0.00012687665],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009983428,0.00046878224,0.0014288513,0.0005069265,0.00022541355,0.00012235025,0.0005074236,0.00026081916,0.00014566028],"category_scores_gemma":[0.000048272726,0.00030801378,0.00031092178,0.0016814847,0.00068840384,0.0001639585,0.00006491078,0.0008666381,0.0000010588483],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00021747504,0.000037017136,0.00032958217,0.0023078308,0.000060159437,0.00010934173,0.0005316486,0.0000016257336,0.00030890873,0.000054653246,0.00010610944,0.9959356],"study_design_scores_gemma":[0.0018444912,0.00021999018,0.00015294043,0.0045786947,0.000062088104,0.00004313019,0.0010217518,0.000013375703,0.00013545746,0.00035078436,0.9912922,0.00028512676],"about_ca_topic_score_codex":0.0017530557,"about_ca_topic_score_gemma":0.0013207815,"teacher_disagreement_score":0.99565053,"about_ca_system_score_codex":0.0018531686,"about_ca_system_score_gemma":0.008436021,"threshold_uncertainty_score":0.9999372},"labels":[],"label_agreement":null},{"id":"W4414384084","doi":"10.58931/cht.2025.4271","title":"Cellular Therapy and Follicular Lymphoma: Where Do We Stand in 2025?","year":2025,"lang":"en","type":"article","venue":"Canadian Hematology Today","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Follicular lymphoma; Follicular phase; Adverse effect; Lymphoma; Disease; International Prognostic Index","score_opus":0.01828241181672316,"score_gpt":0.28201133139322987,"score_spread":0.2637289195765067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414384084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7346095,0.2284148,0.000017563512,0.019495293,0.00019102835,0.00074002176,0.0000120113955,0.00002783374,0.01649195],"genre_scores_gemma":[0.95529467,0.015546653,0.00011945053,0.0010825109,0.000054277658,0.000090216214,0.000008923679,0.000042665826,0.027760653],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984555,0.00011756436,0.00025993004,0.00041085767,0.00014136164,0.0006147325],"domain_scores_gemma":[0.99887145,0.00012663883,0.00002659828,0.00046319785,0.00007016229,0.0004419421],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00029729234,0.00019196747,0.0005075844,0.00065639603,0.00009101761,0.000029229172,0.00014008286,0.00030531036,0.0025796834],"category_scores_gemma":[0.000056041295,0.00018036929,0.00007181005,0.00051821914,0.0001945148,0.000038401187,0.00002973457,0.00023000466,0.00003849186],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009839648,0.0003393996,0.5228735,0.0012788993,0.0008113506,0.013024284,0.0024974514,0.0000032926055,0.02491939,0.051498547,0.11643169,0.2653382],"study_design_scores_gemma":[0.005014966,0.000113061644,0.008106302,0.00041048875,0.00002278418,0.0002301118,0.0004364645,0.00007089125,0.0081141675,0.0015814005,0.9756973,0.00020207804],"about_ca_topic_score_codex":0.015265656,"about_ca_topic_score_gemma":0.07766174,"teacher_disagreement_score":0.85926557,"about_ca_system_score_codex":0.0004008025,"about_ca_system_score_gemma":0.001584829,"threshold_uncertainty_score":0.9983321},"labels":[],"label_agreement":null},{"id":"W4414444386","doi":"10.1136/jitc-2024-010792","title":"T-cell responses against CD19-targeted CAR T cells varnimcabtagene autoleucel (ARI-0001): implications for immune response and therapy outcomes","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada","funders":"European Regional Development Fund; Instituto de Salud Carlos III; Generalitat de Catalunya; Agència de Gestió d'Ajuts Universitaris i de Recerca; Fundación Bancaria Caixa d'Estalvis i Pensions de Barcelona; Fundación Científica Asociación Española Contra el Cáncer","keywords":"Immune system; Immunogenicity; Peripheral blood mononuclear cell; Monoclonal antibody; Antigen; Antibody; Chimeric antigen receptor; Immunotherapy","score_opus":0.0330377316831344,"score_gpt":0.38629744154714707,"score_spread":0.35325970986401267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414444386","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91959614,0.06400789,0.0016296176,0.010753636,0.00078108296,0.002609964,0.0003435271,0.000053562344,0.00022454861],"genre_scores_gemma":[0.68119293,0.12615038,0.0083978055,0.005206827,0.00044045804,0.0017651793,0.00005686568,0.0003412517,0.1764483],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973352,0.00026369258,0.0010267118,0.0004073344,0.00034990482,0.00061716296],"domain_scores_gemma":[0.9961493,0.0016241452,0.00047825451,0.00070566515,0.0008747175,0.0001679228],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019237226,0.00038941312,0.00097293354,0.0006823561,0.0005177614,0.00010050996,0.00038822027,0.00023989649,0.00042419147],"category_scores_gemma":[0.00017417579,0.000316898,0.000718369,0.0004283178,0.00024282245,0.00013752539,0.000036781334,0.00045085276,0.0000013586272],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.054494828,0.00033267474,0.0032383092,0.00011668359,0.0010870302,0.0000021276842,0.00048300385,0.00003095527,0.8429961,0.00004323273,0.003684439,0.09349057],"study_design_scores_gemma":[0.017799461,0.0014864145,0.086710736,0.00016595423,0.00012162219,0.000016405696,0.0001688288,0.000095168456,0.54096013,0.00052341796,0.35167468,0.00027716387],"about_ca_topic_score_codex":0.00007296849,"about_ca_topic_score_gemma":0.0000063511084,"teacher_disagreement_score":0.34799024,"about_ca_system_score_codex":0.0003766637,"about_ca_system_score_gemma":0.0014420304,"threshold_uncertainty_score":0.9999283},"labels":[],"label_agreement":null},{"id":"W4414466003","doi":"10.1158/2326-6074.cimm25-b004","title":"Abstract B004: Route dependent T-cell activation by mRNA cluster therapies","year":2025,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Peripheral blood mononuclear cell; Immunogenicity; Flow cytometry; Messenger RNA; Cell; T cell; Immunotherapy; CD8; Cancer vaccine","score_opus":0.053018574797816256,"score_gpt":0.40494907590402934,"score_spread":0.3519305011062131,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414466003","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91889566,0.016534615,0.0000801547,0.017370569,0.0003757936,0.0013109833,0.000024521047,0.00009070237,0.045317],"genre_scores_gemma":[0.83821005,0.0057142773,0.000030270849,0.0006570776,0.00014645472,0.0004826727,0.000052112213,0.000043568125,0.15466353],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9969571,0.00035852825,0.00035308005,0.00058583135,0.0007768401,0.0009685789],"domain_scores_gemma":[0.99775755,0.00058978784,0.00005937921,0.00082316523,0.0006610124,0.00010908423],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014203568,0.00021868094,0.00039020297,0.0006389248,0.00032124828,0.000085330445,0.00049133936,0.00037353608,0.0072064023],"category_scores_gemma":[0.00016203162,0.00019192658,0.00011858978,0.0007953858,0.00059395866,0.00015069327,0.00028032198,0.0018906455,0.00022640369],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024649033,0.0002782587,0.008289086,0.00012761872,0.0004661818,0.000014676295,0.00038328586,0.000003926602,0.8761973,0.00008415427,0.035719827,0.07597078],"study_design_scores_gemma":[0.005314747,0.00039243454,0.047958214,0.0002253162,0.000026273765,0.000009814951,0.0009276779,0.000042092975,0.68448514,0.00046866486,0.25993836,0.00021126162],"about_ca_topic_score_codex":0.0019208571,"about_ca_topic_score_gemma":0.000102728874,"teacher_disagreement_score":0.22421852,"about_ca_system_score_codex":0.0011164527,"about_ca_system_score_gemma":0.0010645494,"threshold_uncertainty_score":0.99370116},"labels":[],"label_agreement":null},{"id":"W4414490680","doi":"10.1182/bloodadvances.2025017081","title":"Patient-reported outcomes in patients with hematologic malignancies treated with CAR T-cell therapy in Europe","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"Bundesamt für Gesundheit; European Commission; European Federation of Pharmaceutical Industries and Associations; Ministerie van Volksgezondheid, Welzijn en Sport; AstraZeneca; Celgene; Gilead Sciences; National Institute for Health and Care Excellence; Eli Lilly and Company; Pulmonary Fibrosis Foundation","keywords":"Quality of life (healthcare); Cohort; Anxiety; Disease; Cohort study; MEDLINE; Depression (economics)","score_opus":0.011472708846043041,"score_gpt":0.2682026959169495,"score_spread":0.25672998707090644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414490680","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923828,0.0015236174,0.0000024179812,0.00014050459,0.000029721694,0.0012325083,0.000005287958,0.00006424537,0.0046188524],"genre_scores_gemma":[0.99602556,0.0004308196,0.0002742593,0.00023599056,0.0000049117407,0.0001121261,0.00002767592,0.000029273333,0.0028593978],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99829423,0.000089426176,0.0003824173,0.00042822037,0.00040560044,0.00040009047],"domain_scores_gemma":[0.9990724,0.00010187628,0.00012140538,0.00038857205,0.00025091588,0.000064828855],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000096025295,0.0002571247,0.0005764455,0.00034793303,0.000037699792,0.000018461284,0.00010913899,0.000060653798,0.00009035292],"category_scores_gemma":[0.00006405202,0.0001524198,0.000036552043,0.0013167291,0.00012378191,0.0001287075,0.000030746232,0.00021787932,0.00000390402],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020823656,0.0018341762,0.9863088,0.00007311999,0.00011050599,0.00039331682,0.00019410129,0.0000262532,0.00413622,0.000013118594,0.000010188045,0.0048178],"study_design_scores_gemma":[0.0182368,0.0029997653,0.92925364,0.00033517813,0.00004635599,0.000010623099,0.0002470386,0.0000036578158,0.046269175,0.000019346264,0.002358229,0.00022018842],"about_ca_topic_score_codex":0.00012693969,"about_ca_topic_score_gemma":0.00020982996,"teacher_disagreement_score":0.05705519,"about_ca_system_score_codex":0.000048420792,"about_ca_system_score_gemma":0.00014965858,"threshold_uncertainty_score":0.6215499},"labels":[],"label_agreement":null},{"id":"W4414491793","doi":"10.1158/2326-6074.cimm25-ia08","title":"Abstract IA08: Development and use of Engineered Regulatory T cells to treat Autoimmune Diseases","year":2025,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Immune system; Peripheral tolerance; Immune tolerance; Effector; T cell; Population; Immunotherapy; Antigen; Regulatory T cell","score_opus":0.06425826163130895,"score_gpt":0.3799349477968155,"score_spread":0.3156766861655066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414491793","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9803175,0.016157994,0.000010586185,0.0013706614,0.00016059019,0.00088356266,0.000026251018,0.00004713493,0.0010257731],"genre_scores_gemma":[0.9416598,0.0022169591,0.0003247299,0.00010946716,0.00004382759,0.00034027421,0.000020236337,0.000037625512,0.05524706],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99790424,0.00013613074,0.0003798575,0.00043674934,0.0004792623,0.0006637885],"domain_scores_gemma":[0.9979977,0.00055654556,0.000033265645,0.00071909727,0.0005201379,0.00017325627],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004995611,0.00017900478,0.00047891223,0.0009196588,0.000146487,0.000032220792,0.00024294184,0.00018220874,0.0014185273],"category_scores_gemma":[0.00020947916,0.00016264427,0.00006789103,0.0008148562,0.0005692166,0.00007405013,0.00033047266,0.00058698864,0.000033675893],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019885942,0.00018814017,0.0062912735,0.00036426558,0.0004437198,0.00004064031,0.0005110101,0.000017459497,0.88314384,0.00011401494,0.005143004,0.10175404],"study_design_scores_gemma":[0.0013593417,0.00017455379,0.47778124,0.00032108906,0.000029297984,0.0000041268777,0.00018011611,0.000012676095,0.4519066,0.000021423459,0.068103954,0.000105573075],"about_ca_topic_score_codex":0.00047462338,"about_ca_topic_score_gemma":0.00002640692,"teacher_disagreement_score":0.47148997,"about_ca_system_score_codex":0.000537126,"about_ca_system_score_gemma":0.0014194452,"threshold_uncertainty_score":0.9994943},"labels":[],"label_agreement":null},{"id":"W4414508324","doi":"10.1080/2162402x.2025.2562210","title":"IL-21-reprogrammed Vδ1 T cells exert killing against solid tumors which is enhanced by CAR arming for off-the-shelf immunotherapy","year":2025,"lang":"en","type":"article","venue":"OncoImmunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Discovery Centre","funders":"Canadian Institutes of Health Research; Ontario Ministry of Health and Long-Term Care","keywords":"Chimeric antigen receptor; Immunotherapy; Cancer immunotherapy; T cell; Ovarian cancer; Tumor microenvironment; Cell therapy; Antigen; Cancer","score_opus":0.01529819831688233,"score_gpt":0.32126101308457927,"score_spread":0.30596281476769693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414508324","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9517187,0.019283997,0.004289195,0.009208886,0.0015440088,0.0038868904,0.00007006763,0.0003271735,0.009671088],"genre_scores_gemma":[0.891757,0.01273727,0.0015822335,0.005242776,0.00036903934,0.001555572,0.00022809448,0.00023631235,0.086291686],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9964743,0.00019799611,0.0008303996,0.00086895877,0.0003701087,0.0012582327],"domain_scores_gemma":[0.9970073,0.0007045821,0.00023079602,0.0014146043,0.00053590216,0.00010681042],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00097951,0.00046153838,0.0010500976,0.0003273629,0.00043916027,0.00007515052,0.0006886699,0.00044230462,0.00061190856],"category_scores_gemma":[0.00019237219,0.00038783276,0.00039531387,0.00087927683,0.0004161361,0.00008383631,0.00016685623,0.00090920314,0.0000749672],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001294934,0.00022058493,0.00007407863,0.000072797055,0.00055354275,0.0000071010704,0.0012560483,0.0000048662014,0.6996263,0.00004715084,0.0035658071,0.2932768],"study_design_scores_gemma":[0.004004264,0.0006445776,0.00009508045,0.000161978,0.00006404407,0.0000119561455,0.000986268,0.000364969,0.6471291,0.00017845523,0.34610602,0.00025326316],"about_ca_topic_score_codex":0.00021384489,"about_ca_topic_score_gemma":0.000040241746,"teacher_disagreement_score":0.3425402,"about_ca_system_score_codex":0.00045500507,"about_ca_system_score_gemma":0.00062450254,"threshold_uncertainty_score":0.99985737},"labels":[],"label_agreement":null},{"id":"W4414542568","doi":"10.1038/s41467-025-63338-w","title":"CD137L promotes immune surveillance in melanoma via HLTF regulation","year":2025,"lang":"en","type":"article","venue":"Nature Communications","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SKiN Health","funders":"National Key Research and Development Program of China; Xiangya Hospital, Central South University; China Postdoctoral Science Foundation; Central South University; National Natural Science Foundation of China","keywords":"Immune system; Melanoma; Transcription factor; Immune checkpoint; Immunotherapy; Regulator; Immunity; Transcriptome; Transcriptional regulation; Mediator","score_opus":0.020476741972426715,"score_gpt":0.3537408475515789,"score_spread":0.3332641055791522,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414542568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.49980167,0.09110703,0.00064997503,0.15266341,0.0005984048,0.0045204307,0.000037286754,0.00050405925,0.25011772],"genre_scores_gemma":[0.98843056,0.000765387,0.0021714494,0.000281165,0.000030276098,0.00008635193,0.00022605991,0.000016728101,0.007992014],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.998844,0.0002443636,0.00030260463,0.0001947475,0.00021217145,0.00020209105],"domain_scores_gemma":[0.99686354,0.00043755976,0.000059203576,0.0023501504,0.0002458018,0.000043768257],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00062665367,0.00011241334,0.00024462258,0.00032278095,0.00013814928,0.000023333476,0.0006077718,0.00029737133,0.0002736342],"category_scores_gemma":[0.00039828994,0.00010790524,0.00007690202,0.0011174271,0.00013917848,0.00006423982,0.0002665617,0.0012686738,0.000025146197],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004921478,0.0011298613,0.33614406,0.0001616017,0.00024228291,0.000008625827,0.00074849813,0.000011500037,0.50953335,0.024693144,0.0052414243,0.12159349],"study_design_scores_gemma":[0.0012709423,0.000059400958,0.8793987,0.00015103995,0.000015639167,0.000013645064,0.00005051329,0.00263528,0.007799577,0.0015964935,0.10688629,0.00012249351],"about_ca_topic_score_codex":0.00013246773,"about_ca_topic_score_gemma":0.0015585589,"teacher_disagreement_score":0.5432546,"about_ca_system_score_codex":0.00020976088,"about_ca_system_score_gemma":0.00016158538,"threshold_uncertainty_score":0.5511827},"labels":[],"label_agreement":null},{"id":"W4414582304","doi":"10.1158/1538-7445.pancreatic25-a114","title":"Abstract A114: CCK-B Receptor Blockade with Proglumide Enhances Antitumor Activity and Persistence of CD8+CD161+ CAR-T Cells in Pancreatic Ductal Adenocarcinoma","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Carleton University","funders":"","keywords":"CD8; Immunotherapy; Tumor microenvironment; Immune system; T cell; Receptor; Flow cytometry; Proglumide","score_opus":0.05291562931985745,"score_gpt":0.3681261127798817,"score_spread":0.3152104834600243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414582304","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98993737,0.004141747,0.0000028258485,0.0013265687,0.00007502353,0.0015750059,0.00003215258,0.000023920678,0.0028854108],"genre_scores_gemma":[0.98800206,0.002440592,0.00015800743,0.000021696025,0.00011766182,0.00031022847,0.0000050731846,0.00003430167,0.008910381],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99682504,0.00023130118,0.00031496174,0.0007026753,0.0011040757,0.0008219672],"domain_scores_gemma":[0.99810547,0.0004540634,0.000077151926,0.00056230277,0.0005633013,0.00023771635],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012171746,0.00022826825,0.0006125738,0.0006342467,0.00013515321,0.00005693653,0.000305956,0.0001322968,0.0012687963],"category_scores_gemma":[0.00021760068,0.00018777492,0.000070521404,0.0015519736,0.0010782662,0.00016231461,0.00017561622,0.001065766,0.00001568019],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002791538,0.00023402524,0.13879889,0.0013807754,0.00013450225,0.00012380879,0.0006124789,0.0000038785684,0.8525812,0.000013299592,0.00029472407,0.0030308927],"study_design_scores_gemma":[0.0016807625,0.00055308477,0.24397431,0.0011118981,0.000032817556,0.000016124191,0.0011048765,0.00003448884,0.75065637,0.000014353202,0.00068269577,0.00013823512],"about_ca_topic_score_codex":0.0054997127,"about_ca_topic_score_gemma":0.0014804251,"teacher_disagreement_score":0.10517542,"about_ca_system_score_codex":0.00053876906,"about_ca_system_score_gemma":0.0020162358,"threshold_uncertainty_score":0.99964416},"labels":[],"label_agreement":null},{"id":"W4414606164","doi":"10.1038/s41467-025-63579-9","title":"Interleukin-12 anchored drug conjugate (tolododekin alfa) in patients with advanced solid tumors: first-in-human Phase 1 trial","year":2025,"lang":"en","type":"article","venue":"Nature Communications","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Tolerability; Pharmacokinetics; Adverse effect; Clinical trial; Drug; Immunotherapy; Pharmacodynamics","score_opus":0.018662909956790878,"score_gpt":0.3753721925454597,"score_spread":0.35670928258866885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414606164","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9801849,0.0012784386,0.000008816235,0.0057281316,0.00013818369,0.00276009,0.000034925004,0.00007272126,0.009793791],"genre_scores_gemma":[0.9960809,0.00020928263,0.0006645482,0.00053436775,0.00003636945,0.00035695004,0.00051688845,0.000033806366,0.0015669318],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99810684,0.00026634143,0.0005571711,0.0003530149,0.0003435764,0.00037307973],"domain_scores_gemma":[0.99677455,0.00039955362,0.00012843756,0.002336846,0.00025744058,0.00010315595],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00044572915,0.00022026063,0.0005222609,0.00059921655,0.0001828481,0.000038280043,0.00094677234,0.00021677234,0.00017573245],"category_scores_gemma":[0.0003315759,0.00019606212,0.00009041595,0.0008961895,0.000259701,0.00014123396,0.00032890495,0.002186043,0.0000075857615],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3430187,0.04579713,0.4292626,0.0006502445,0.0012019712,0.00015930543,0.011901813,0.00016807883,0.024687342,0.013917991,0.027344663,0.101890154],"study_design_scores_gemma":[0.625692,0.0038621803,0.18027867,0.003391865,0.00017535883,0.0000062556796,0.000888524,0.0016295625,0.0065387976,0.0010758505,0.17553394,0.0009270102],"about_ca_topic_score_codex":0.000115496085,"about_ca_topic_score_gemma":0.008539586,"teacher_disagreement_score":0.2826733,"about_ca_system_score_codex":0.00047351015,"about_ca_system_score_gemma":0.00022730086,"threshold_uncertainty_score":0.9497391},"labels":[],"label_agreement":null},{"id":"W4414800233","doi":"10.1093/neuonc/noaf193.286","title":"P08.18.B PROSPECTIVE EVALUATION OF NEUROLOGICAL SAFETY AFTER ANTI-BCMA CAR T-CELL THERAPY IN A SINGLE-CENTRE COHORT","year":2025,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Neurocognitive; Cohort; Prospective cohort study; Neurotoxicity; Cognition; Post-concussion syndrome; Neurological examination; Cohort study","score_opus":0.04003583211486778,"score_gpt":0.350929074696149,"score_spread":0.3108932425812812,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414800233","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9558937,0.0004220261,0.000009677396,0.0030276724,0.00036414928,0.0033631548,0.000008635724,0.00004528286,0.03686569],"genre_scores_gemma":[0.9966176,0.0003074555,0.00006811855,0.0020812433,0.00010364876,0.00023678389,0.000013504866,0.000029855673,0.00054179394],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9963411,0.001273542,0.0005582251,0.0006671432,0.00069032534,0.0004696545],"domain_scores_gemma":[0.99802613,0.0006985769,0.0001291311,0.0004884873,0.00055167533,0.00010600998],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013588984,0.00023078757,0.0007371477,0.00036039823,0.000040083403,0.000010358313,0.00017827307,0.00034952365,0.0032723332],"category_scores_gemma":[0.00053822366,0.00019813376,0.00015558989,0.00072388106,0.00026481575,0.000050252806,0.000113216964,0.000733878,0.000022942642],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056883837,0.001486071,0.45405844,0.000028256443,0.00005096028,0.00019013364,0.00034086453,0.000034683442,0.50252396,0.000021113396,0.00041453546,0.035162598],"study_design_scores_gemma":[0.017070783,0.0067055193,0.8357001,0.00004086447,0.00017697578,0.000054427466,0.00012597152,0.0018674304,0.10043535,0.0002625492,0.03737109,0.00018892447],"about_ca_topic_score_codex":0.000032079683,"about_ca_topic_score_gemma":0.00007524597,"teacher_disagreement_score":0.4020886,"about_ca_system_score_codex":0.0006206073,"about_ca_system_score_gemma":0.00089254964,"threshold_uncertainty_score":0.9976388},"labels":[],"label_agreement":null},{"id":"W4414857438","doi":"10.1093/oncolo/oyaf330","title":"Management of Canadian patients with refractory or relapsed diffuse large B-cell lymphoma in the real world: a subanalysis of the RE-MIND2 study","year":2025,"lang":"en","type":"article","venue":"The Oncologist","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Maisonneuve-Rosemont; University of Alberta","funders":"Daiichi Sankyo Europe; U.S. Food and Drug Administration; Celgene; MorphoSys; Gilead Sciences; Kite Pharma; Incyte; BeiGene; TG Therapeutics; Seagen; Karyopharm Therapeutics; AstraZeneca","keywords":"Refractory (planetary science); Diffuse large B-cell lymphoma; Lymphoma; Standard of care; Salvage therapy; Clinical trial","score_opus":0.02572095470819502,"score_gpt":0.3219684897978651,"score_spread":0.29624753508967006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414857438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92835385,0.000038421007,6.9877814e-7,0.0016288375,0.000051565432,0.0019587094,0.000019459207,0.0000070424985,0.06794145],"genre_scores_gemma":[0.9643642,0.00010138986,0.000020384174,0.00033812664,0.000013619447,0.0001081396,0.000009269563,0.000014023546,0.0350309],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99778795,0.0006089992,0.00039772718,0.00023925735,0.0006201856,0.00034588636],"domain_scores_gemma":[0.99795294,0.00039974757,0.00018607626,0.0012812895,0.00012095604,0.000058979283],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015421032,0.0001497378,0.00039255852,0.0005367419,0.00014148901,0.00001340004,0.0007379623,0.000055989887,0.00025815333],"category_scores_gemma":[0.000069513,0.000060355993,0.00010232012,0.0030825904,0.0002872572,0.000021208067,0.00015460813,0.00025621403,0.000003251109],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047708065,0.017357757,0.9565137,0.00017196659,0.0008777835,0.00023881943,0.0057838024,0.0000093100025,0.0001195742,0.00028916163,0.0032140675,0.010653242],"study_design_scores_gemma":[0.015612142,0.0011121293,0.95633656,0.000113574984,0.0004990515,4.087946e-7,0.011777466,0.000022768347,0.00013057195,0.000017562548,0.014303623,0.00007417145],"about_ca_topic_score_codex":0.10866405,"about_ca_topic_score_gemma":0.73218834,"teacher_disagreement_score":0.6235243,"about_ca_system_score_codex":0.00067035743,"about_ca_system_score_gemma":0.0005282476,"threshold_uncertainty_score":0.89727145},"labels":[],"label_agreement":null},{"id":"W4414913470","doi":"10.1007/978-3-032-00767-4_188","title":"Targeting CAR T Cells’ Metabolic Pathways to Boost Their Effectiveness Against Tumors","year":2025,"lang":"en","type":"book-chapter","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Chimeric antigen receptor; Tumor microenvironment; Metabolic pathway; T cell; Immunotherapy; Immune system; Metabolism; Effector; Antigen","score_opus":0.024557285015834134,"score_gpt":0.2725037007201503,"score_spread":0.24794641570431616,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414913470","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0062013012,0.0028820247,0.00027326084,0.0001765993,0.00060651323,0.0033474432,0.0001890577,0.00030871134,0.9860151],"genre_scores_gemma":[0.016347347,0.001343214,0.00032913758,0.0016571622,0.00093357044,0.00015770161,0.00031103956,0.00028506972,0.9786357],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99675804,0.0001265187,0.00056739856,0.0010211756,0.0007795651,0.00074730674],"domain_scores_gemma":[0.997342,0.00059097295,0.00011690795,0.0010353224,0.0004190988,0.0004957121],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001001855,0.0007869383,0.0016182673,0.00074057956,0.00014978307,0.000060641203,0.00040557265,0.00048113504,0.0050002397],"category_scores_gemma":[0.00012115477,0.0006232723,0.00060249795,0.00018063505,0.00011753792,0.000043274253,0.0004105295,0.0011930822,0.0005975271],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00095520966,0.000101357175,0.000067360525,0.0013144909,0.0011973653,0.0005869215,0.00055179955,0.000049906255,0.88731426,0.021411562,0.00988744,0.07656234],"study_design_scores_gemma":[0.0013229182,0.00030997035,0.00009735571,0.0014992658,0.00017499852,0.00001379169,0.000117347845,0.00007597326,0.19908567,0.00052212866,0.79607415,0.0007064196],"about_ca_topic_score_codex":0.000084972286,"about_ca_topic_score_gemma":0.000015425696,"teacher_disagreement_score":0.78618675,"about_ca_system_score_codex":0.00036388708,"about_ca_system_score_gemma":0.00066641,"threshold_uncertainty_score":0.99962187},"labels":[],"label_agreement":null},{"id":"W4414925391","doi":"10.3389/fimmu.2025.1675786","title":"Production of functional CD19 CAR T cells under hypoxic manufacturing conditions","year":2025,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Center for Innovative Medicine; National Cancer Institute; Vetenskapsrådet; Karolinska Institutet; Cancerfonden","keywords":"CD19; Phenotype; Hypoxia (environmental); Chimeric antigen receptor; T cell; Cell","score_opus":0.016065437097900395,"score_gpt":0.2731994918521396,"score_spread":0.2571340547542392,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414925391","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855576,0.0011270565,0.003128314,0.0015022411,0.0048844153,0.0004435949,0.0000059793642,0.000035377056,0.0033154325],"genre_scores_gemma":[0.9582086,0.00032375872,0.000837099,0.00012541458,0.000080597274,0.000050047973,0.00005380389,0.0000146531465,0.040306035],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99905914,0.000082452694,0.00024850186,0.0002442222,0.00012847362,0.0002371864],"domain_scores_gemma":[0.9994968,0.000043782893,0.000048211583,0.00032025352,0.00006933537,0.000021577414],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001629237,0.000098849254,0.0002823848,0.000630077,0.00005233412,0.000003870229,0.000083262064,0.00014636351,0.0008040246],"category_scores_gemma":[0.000041582796,0.00010106253,0.00007467771,0.00026434072,0.00029898915,0.000047950107,0.000045737583,0.00034402887,0.000014412094],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00058795215,0.0001653765,0.0044468585,0.00006606541,0.00036459643,0.0000072929256,0.00009999226,0.00038574054,0.9683346,0.00041305495,0.021349909,0.0037785354],"study_design_scores_gemma":[0.0019094261,0.00015556408,0.13247332,0.00008272352,0.00005639895,0.000030358282,0.0011427754,0.000059640523,0.8407187,0.004091984,0.0191777,0.000101429614],"about_ca_topic_score_codex":0.00004822748,"about_ca_topic_score_gemma":0.000010349455,"teacher_disagreement_score":0.12802646,"about_ca_system_score_codex":0.00029373614,"about_ca_system_score_gemma":0.00017944054,"threshold_uncertainty_score":0.88035053},"labels":[],"label_agreement":null},{"id":"W4415050492","doi":"10.1158/0008-5472.can-25-3596","title":"Distinct Cellular and Molecular Patterns in Pretreatment Peripheral Blood Are Associated with CAR T-cell Outcomes in Diffuse Large B-cell Lymphoma","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Helen and Martin Kimmel Center for Molecular Design, Weizmann Institute of Science; National Cancer Institute; European Research Council; Azrieli Foundation; Israel Science Foundation; Lotte and John Hecht Memorial Foundation; Elsie and Marvin Dekelboum Family Foundation; Deutsche Forschungsgemeinschaft","keywords":"Lymphoma; Peripheral blood; Immune system; Diffuse large B-cell lymphoma; Peripheral","score_opus":0.02317539412967375,"score_gpt":0.3376043002972652,"score_spread":0.31442890616759145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415050492","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930532,0.0028385813,0.000011267354,0.00081103685,0.000048269914,0.0015889469,0.00010092512,0.000030927924,0.0015168429],"genre_scores_gemma":[0.9764091,0.00049931783,0.000010129181,0.00012419584,0.00002290577,0.0006067173,0.000049478065,0.000060763774,0.022217391],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99641633,0.00049068703,0.00031840111,0.0007025409,0.0009930638,0.0010790016],"domain_scores_gemma":[0.99864143,0.00026190357,0.000052343206,0.00057593064,0.00022710297,0.00024127495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008493987,0.0002866393,0.00061865366,0.0005970193,0.00010329642,0.000078413635,0.00023418473,0.00018048141,0.00037162795],"category_scores_gemma":[0.00013727591,0.00023020779,0.00008347586,0.0010300017,0.00017352757,0.00005600596,0.00023362231,0.0006547877,0.0000040410887],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006086885,0.0064114076,0.9019373,0.00036468098,0.00017414498,0.0022753035,0.000724438,0.0000026879368,0.08685033,0.000011194129,0.000073488874,0.00056633045],"study_design_scores_gemma":[0.0660525,0.0008655386,0.78978246,0.0010437521,0.000093749004,0.0000044007916,0.0012426676,0.00027806617,0.13951877,0.000038051352,0.00074488966,0.00033516425],"about_ca_topic_score_codex":0.0035242487,"about_ca_topic_score_gemma":0.008278812,"teacher_disagreement_score":0.11215485,"about_ca_system_score_codex":0.0015323008,"about_ca_system_score_gemma":0.0006157484,"threshold_uncertainty_score":0.93876016},"labels":[],"label_agreement":null},{"id":"W4415054617","doi":"10.1016/j.retram.2025.103547","title":"HLA molecules: Another challenge for CAR T cell therapy","year":2025,"lang":"en","type":"review","venue":"Current Research in Translational Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Human leukocyte antigen; Immune system; T cell; Disease; Evasion (ethics); CAR T-cell therapy; Genetic enhancement; Cell therapy","score_opus":0.39991823808502097,"score_gpt":0.5431795299907464,"score_spread":0.1432612919057254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415054617","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000026954388,0.97127247,0.00037376425,0.0036242674,0.00051389256,0.009079635,0.00018079532,0.000047880167,0.014904628],"genre_scores_gemma":[0.000020102216,0.987912,0.00015543801,0.00005756045,0.0018080283,0.0028322951,0.0014089519,0.00014322274,0.005662378],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99284804,0.0008974829,0.0012653478,0.0011682634,0.0026071735,0.0012136783],"domain_scores_gemma":[0.99385035,0.0039993976,0.00013757014,0.000885756,0.000777366,0.00034957737],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004048107,0.0006737525,0.0025383588,0.002996225,0.00015220235,0.000027105667,0.00068608066,0.0005385629,0.0028590856],"category_scores_gemma":[0.00033734372,0.0004877433,0.0007080977,0.0021834145,0.00067502103,0.00006437821,0.000058246285,0.0028328982,0.00005271054],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004036466,0.00065437256,0.00001006498,0.062913455,0.00015742866,0.000034764336,0.0003102167,0.0000012224705,0.000043108514,0.00063811964,0.003923013,0.9309106],"study_design_scores_gemma":[0.005473762,0.00088776334,0.000008310285,0.04880048,0.00014954223,0.000011631473,0.000039156206,0.00007968427,0.000012920101,0.00091669924,0.9433163,0.0003037829],"about_ca_topic_score_codex":0.00003637627,"about_ca_topic_score_gemma":0.000013470884,"teacher_disagreement_score":0.9393933,"about_ca_system_score_codex":0.00046476763,"about_ca_system_score_gemma":0.0031984996,"threshold_uncertainty_score":0.9997574},"labels":[],"label_agreement":null},{"id":"W4415071401","doi":"10.1016/j.jtct.2025.10.006","title":"CAR-T for Management of R/R PTLD Following Lung Transplant: A Multi-center Retrospective Study","year":2025,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Sleep Society; University Health Network; Dalhousie University; Princess Margaret Cancer Centre; Juravinski Hospital; Juravinski Cancer Centre","funders":"","keywords":"Tocilizumab; Immunosuppression; Lung; Retrospective cohort study; Cytokine release syndrome; Lung transplantation; Lymphoproliferative disorders; Malignancy","score_opus":0.026374471961739816,"score_gpt":0.3312877172294737,"score_spread":0.3049132452677339,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415071401","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96612823,0.0010965351,0.028112246,0.0001338335,0.00012767418,0.0028085269,0.000047313613,0.00004075687,0.0015048562],"genre_scores_gemma":[0.99291736,0.0028652956,0.0005534532,0.000100434016,0.000017100649,0.00016097973,0.00010293289,0.000023320228,0.0032591193],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99887764,0.00006266364,0.00028460732,0.00031163674,0.00025471998,0.00020874212],"domain_scores_gemma":[0.99961895,0.00003550739,0.00003829555,0.00019121473,0.00005952747,0.00005652978],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003126258,0.00016441836,0.00032989297,0.00017232068,0.000094317096,0.000016822447,0.00007697797,0.00006195549,0.000092622766],"category_scores_gemma":[7.9893965e-7,0.00014475452,0.00018192483,0.00020669207,0.000036738416,0.00004679102,0.00000388064,0.00011337749,7.6964074e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01675652,0.005136104,0.40382057,0.0030687645,0.0058072503,0.0004343868,0.025299342,0.00000802771,0.5017313,0.0014105235,0.000049320322,0.036477923],"study_design_scores_gemma":[0.19982581,0.0034430905,0.41256878,0.0019098168,0.0025401087,0.00003712963,0.008012866,0.0025965774,0.36536065,0.0002706701,0.0026290151,0.0008054937],"about_ca_topic_score_codex":0.000034906945,"about_ca_topic_score_gemma":0.000019136733,"teacher_disagreement_score":0.18306929,"about_ca_system_score_codex":0.000043911965,"about_ca_system_score_gemma":0.000023567503,"threshold_uncertainty_score":0.5902918},"labels":[],"label_agreement":null},{"id":"W4415071610","doi":"10.1101/2025.10.09.681473","title":"Autophagy disruption primes CAR-T cell metabolism for sustained rejection of ovarian tumors","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Centre hospitalier de l'Université Laval; Centre hospitalier universitaire de Québec; University of Victoria","funders":"Canadian Institutes of Health Research; Ovarian Cancer Canada; Université Laval","keywords":"Autophagy; Cytolysis; Chimeric antigen receptor; Tumor microenvironment; Ovarian cancer; Immunotherapy; Cytotoxicity; Reprogramming; Cell culture","score_opus":0.015645507621628862,"score_gpt":0.2742481101298869,"score_spread":0.25860260250825806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415071610","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97800565,0.0030505562,0.0068994192,0.0006913388,0.0025286002,0.0070329155,0.00079829514,0.0006771032,0.00031610925],"genre_scores_gemma":[0.9887467,0.0003681592,0.00742874,0.00014539185,0.0010193828,0.00076679484,0.000004957984,0.00017039265,0.001349488],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99625456,0.00021807071,0.0009248377,0.0011636837,0.0006938524,0.000744993],"domain_scores_gemma":[0.99505424,0.00017980103,0.0005678221,0.0017061034,0.0021776464,0.00031439256],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012561687,0.00062620913,0.0012900451,0.0009282466,0.00015335856,0.00009563091,0.00043622457,0.0007605581,0.0002444765],"category_scores_gemma":[0.00063080655,0.00065868424,0.0005330633,0.00090308057,0.00016760045,0.000116553994,0.00039955927,0.0009598747,0.0000083214045],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00095606176,0.0003973772,0.0011881198,0.0040868954,0.00041750105,0.000031981395,0.000038199916,0.00004556298,0.99089074,0.00145001,0.00047331277,0.0000242324],"study_design_scores_gemma":[0.0029731167,0.00021949514,0.038254272,0.00064166717,0.0006420746,4.4913968e-8,0.00002376864,0.0010843105,0.9410763,0.000011808651,0.014528074,0.00054507505],"about_ca_topic_score_codex":0.00025624753,"about_ca_topic_score_gemma":0.000003305537,"teacher_disagreement_score":0.04981445,"about_ca_system_score_codex":0.0007151416,"about_ca_system_score_gemma":0.0028067732,"threshold_uncertainty_score":0.99958646},"labels":[],"label_agreement":null},{"id":"W4415237419","doi":"10.3389/fimmu.2025.1680410","title":"Multiplex engineering and multifunction T cells for precise and effective immunotherapies","year":2025,"lang":"en","type":"article","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Chimeric antigen receptor; Immunotherapy; Adoptive cell transfer; Cancer immunotherapy; T cell; Multiplex; Antigen","score_opus":0.006261329684152147,"score_gpt":0.2544441701112436,"score_spread":0.24818284042709146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415237419","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94766337,0.020917602,0.027211592,0.00029799202,0.001512442,0.0021513167,0.000006665438,0.00005812301,0.0001808862],"genre_scores_gemma":[0.95931196,0.004567972,0.026798472,0.00012927873,0.00007720576,0.000878722,0.000019266636,0.00005484299,0.00816226],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99924403,0.000047121273,0.00015974481,0.00025429897,0.00004785621,0.00024693116],"domain_scores_gemma":[0.99946135,0.00026966713,0.000024342424,0.00017483557,0.000046672947,0.00002315597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021917837,0.00012854791,0.00032293928,0.000415435,0.000047225734,0.000014056607,0.00004889718,0.00015908961,0.000022089165],"category_scores_gemma":[0.0001429487,0.00012527288,0.000041506708,0.00015482376,0.00015014363,0.00004888187,0.00004839082,0.00022588507,6.8855223e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029114252,0.00005920743,0.012329939,0.00016022526,0.0003828774,0.0000032985756,0.0007215883,0.000025468107,0.69124824,0.00004697356,0.00051615987,0.29159456],"study_design_scores_gemma":[0.033717614,0.0020617428,0.35604954,0.00058636925,0.00017121779,0.00004661474,0.0021464187,0.043544266,0.3757057,0.0009561511,0.18446013,0.00055423507],"about_ca_topic_score_codex":0.000057468493,"about_ca_topic_score_gemma":0.000005937771,"teacher_disagreement_score":0.3437196,"about_ca_system_score_codex":0.00012957306,"about_ca_system_score_gemma":0.00002771461,"threshold_uncertainty_score":0.510848},"labels":[],"label_agreement":null},{"id":"W4415306280","doi":"10.1101/2025.10.17.683068","title":"Engineering human protein switches for functional control of CARs and transcription factors via oral drug administration","year":2025,"lang":"","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"IONICS Mass Spectrometry (Canada)","funders":"Universität für Bodenkultur Wien; Austrian Science Fund; Christian Doppler Forschungsgesellschaft; Cancer Research Institute; Österreichische Forschungsförderungsgesellschaft; Österreichischen Akademie der Wissenschaften; Österreichische Nationalstiftung für Forschung, Technologie und Entwicklung","keywords":"Transcription factor; Drug; Transcription (linguistics); Transcriptional regulation; Drug administration; Drug discovery","score_opus":0.022791915726199652,"score_gpt":0.2531602087881917,"score_spread":0.23036829306199202,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415306280","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.950126,0.001074006,0.040343855,0.00025819862,0.0009264576,0.006311732,0.0007852854,0.00016894905,0.000005500363],"genre_scores_gemma":[0.99687797,0.00010349272,0.0009701024,0.000031636664,0.0005440682,0.0011556696,0.0000062410786,0.00014579063,0.00016502997],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9953339,0.00018117108,0.001353065,0.0014103362,0.0008804047,0.000841112],"domain_scores_gemma":[0.9964275,0.00025131353,0.000545438,0.0009967772,0.0013038934,0.00047507798],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016301558,0.000939656,0.001452738,0.0007824552,0.00029464278,0.00016083429,0.0003340026,0.0007930823,0.00034860152],"category_scores_gemma":[0.00033972287,0.0010481419,0.00046777722,0.0005790839,0.00026836418,0.00024778701,0.0000981216,0.0011407672,0.0000030245437],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001238937,0.00037985053,0.00835813,0.004300751,0.0009972575,0.0000072408843,0.000064177126,0.00013392417,0.983807,0.0006673759,0.000023584797,0.000021745176],"study_design_scores_gemma":[0.0051475028,0.00060396834,0.084117465,0.0015086565,0.00073874614,3.5628144e-8,0.00002397173,0.00395203,0.90130633,0.0000031272143,0.0018957534,0.0007024269],"about_ca_topic_score_codex":0.000171544,"about_ca_topic_score_gemma":0.000018351551,"teacher_disagreement_score":0.0825007,"about_ca_system_score_codex":0.0006403546,"about_ca_system_score_gemma":0.0015380078,"threshold_uncertainty_score":0.9991969},"labels":[],"label_agreement":null},{"id":"W4415457678","doi":"10.3389/fimmu.2025.1677548","title":"Reprogramming the tumor microenvironment to boost adoptive T cell therapy","year":2025,"lang":"en","type":"review","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke; Université de Sherbrooke","funders":"Canadian Institutes of Health Research; Mitacs","keywords":"Reprogramming; Tumor microenvironment; Oncolytic virus; Stromal cell; T cell; Immunotherapy; Immune system; Adoptive cell transfer","score_opus":0.026193884130190866,"score_gpt":0.3185648156557382,"score_spread":0.29237093152554733,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415457678","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00006284735,0.99001294,0.00024552157,0.00041468412,0.0014896351,0.0048627653,0.000020540707,0.000043636053,0.0028474259],"genre_scores_gemma":[0.0000024358005,0.96550107,0.003113841,0.00051535864,0.00014249503,0.0011518531,0.00009704784,0.000090551956,0.029385349],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99655616,0.0006341164,0.0007615569,0.00089640083,0.00028389524,0.0008678803],"domain_scores_gemma":[0.99778146,0.00024566698,0.00021737338,0.0016218305,0.000041371863,0.00009227935],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006958617,0.0005599847,0.0022623697,0.0007900662,0.000115746814,0.000034327903,0.00083501224,0.0004164312,0.000615993],"category_scores_gemma":[0.00009606368,0.00038362123,0.00060585723,0.00087596243,0.0004044799,0.000024151657,0.00040420468,0.0016915321,0.00013090917],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037229827,0.00021261348,0.000078582365,0.0014761846,0.00057364366,0.00014990874,0.0003175698,3.9917848e-7,0.00012364592,0.000006310846,0.013086483,0.98360234],"study_design_scores_gemma":[0.000993901,0.0005416722,0.000046059755,0.0033431547,0.00020471885,0.000083626364,0.00045909773,7.615839e-7,0.00013772842,0.000017352872,0.993894,0.00027797467],"about_ca_topic_score_codex":0.00007291902,"about_ca_topic_score_gemma":0.0000051839666,"teacher_disagreement_score":0.9833244,"about_ca_system_score_codex":0.0011392103,"about_ca_system_score_gemma":0.0006013662,"threshold_uncertainty_score":0.9998616},"labels":[],"label_agreement":null},{"id":"W4415459514","doi":"10.1002/hon.70144","title":"The French Experience of Pharmacists and CAR T‐Cells: A Study of the French Society of Oncology Pharmacy (SFPO)","year":2025,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmacy; Observational study; Software deployment; Retrospective cohort study; Pharmacy practice; Pharmacist; MEDLINE","score_opus":0.07731557741980553,"score_gpt":0.441086529883501,"score_spread":0.36377095246369545,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415459514","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9891926,0.001419785,0.000025015064,0.0016450499,0.00028748612,0.0013239578,0.0000062261142,0.000017328957,0.0060825297],"genre_scores_gemma":[0.9966379,0.0010063321,0.00023781406,0.0003888709,0.000028038103,0.00015671145,9.28181e-7,0.000008543253,0.001534895],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9973398,0.00068010465,0.00082490535,0.00037495687,0.00040376597,0.00037645805],"domain_scores_gemma":[0.99644053,0.0022848179,0.00034698562,0.0005146696,0.00031377102,0.00009920262],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00083269057,0.00018874744,0.0010310189,0.000059916067,0.00014674976,0.0000045707066,0.0005096966,0.00021332897,0.0005978152],"category_scores_gemma":[0.0002792215,0.00009930185,0.0002346539,0.00056490354,0.001852251,0.000024048937,0.00052345335,0.00058294955,0.0000016083075],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014390807,0.008017342,0.17161812,0.0006349144,0.0009295562,0.00012056319,0.021724734,0.0000065972813,0.7189215,0.0007487838,0.016208922,0.05962989],"study_design_scores_gemma":[0.02813104,0.011229131,0.05506806,0.00018981722,0.0007145712,0.0007660071,0.023360457,0.0016557372,0.67988944,0.0013545741,0.19725573,0.00038545343],"about_ca_topic_score_codex":0.00030014242,"about_ca_topic_score_gemma":0.00009250559,"teacher_disagreement_score":0.18104681,"about_ca_system_score_codex":0.00013931248,"about_ca_system_score_gemma":0.00055574306,"threshold_uncertainty_score":0.6824696},"labels":[],"label_agreement":null},{"id":"W4415469677","doi":"10.54254/2753-8818/2025.au27984","title":"Combined Immunotherapy of Dual-Targeted CAR NK Cells and Modified Oncolytic Virus Against Glioblastoma","year":2025,"lang":"","type":"article","venue":"Theoretical and Natural Science","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Oncolytic virus; Immunotherapy; Chimeric antigen receptor; Tumor microenvironment; Chemokine; Immune system; Glioblastoma; Virus","score_opus":0.006806896578322443,"score_gpt":0.28482404955225815,"score_spread":0.2780171529739357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415469677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9795289,0.008738237,0.00004223255,0.0013191944,0.0007039715,0.0010550028,0.00002761668,0.000038409937,0.008546414],"genre_scores_gemma":[0.9901703,0.006575479,0.00009529232,0.00067795516,0.0000713931,0.000010598336,0.0000023500684,0.000021368644,0.002375283],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9959081,0.00026821962,0.0006851582,0.0009077975,0.001168959,0.0010617595],"domain_scores_gemma":[0.99733245,0.00096162537,0.00012956382,0.0006198821,0.0004339355,0.00052254886],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.002114355,0.0004287933,0.000883478,0.0005310868,0.00048104965,0.00014720863,0.0005304828,0.0002474705,0.0008935557],"category_scores_gemma":[0.0004466425,0.00031748659,0.00014273378,0.002328242,0.017511548,0.00019936508,0.000503783,0.0009184852,0.0000102282165],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056900573,0.0002325821,0.000078992955,0.00019693092,0.00008213654,0.000036929836,0.000566894,0.0000033375782,0.8132041,0.13457444,0.00002929553,0.045304283],"study_design_scores_gemma":[0.006624412,0.0028738612,0.0035435506,0.0007099938,0.000109935754,0.000020190184,0.0003217913,0.035017073,0.9300826,0.019914376,0.0003442248,0.00043800054],"about_ca_topic_score_codex":0.00007360025,"about_ca_topic_score_gemma":0.000005206726,"teacher_disagreement_score":0.11687848,"about_ca_system_score_codex":0.000198309,"about_ca_system_score_gemma":0.000798837,"threshold_uncertainty_score":0.9999277},"labels":[],"label_agreement":null},{"id":"W4415516512","doi":"10.1186/s13045-025-01741-y","title":"B cell maturation antigen is a novel target for immunotherapy of acute myeloid leukemia","year":2025,"lang":"en","type":"letter","venue":"Journal of Hematology & Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Nutrasource","funders":"National Cancer Institute; National Institutes of Health; Center for Cancer Research","keywords":"Chimeric antigen receptor; Immunotherapy; Myeloid leukemia; Antigen; Leukemia; B cell; Myeloid; Flow cytometry","score_opus":0.02319117376752284,"score_gpt":0.3493004129627951,"score_spread":0.3261092391952723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415516512","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02999666,0.0084291855,0.00873268,0.9414389,0.0034081652,0.0024837388,0.00031382957,0.00003356283,0.0051632756],"genre_scores_gemma":[0.0028181605,0.012194153,0.072738566,0.8387432,0.0071224812,0.00017521631,0.0006147853,0.00032749993,0.06526593],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9963265,0.00024421036,0.0018248458,0.00039356836,0.00054927386,0.0006616093],"domain_scores_gemma":[0.9947186,0.0011862479,0.002096537,0.0005540738,0.0013471987,0.000097332086],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.00094022613,0.00043584305,0.0030054238,0.0011205714,0.00007970949,0.000014771337,0.0005833894,0.0025430217,0.0018128712],"category_scores_gemma":[0.00010635136,0.00036084736,0.0010553737,0.00029609245,0.00033728758,0.00008588184,0.00007974268,0.003193668,0.000011844825],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005039026,0.00024427814,0.00017304522,0.0007914389,0.002685541,0.00094082643,0.00034550444,0.0000013889978,0.19863671,0.000039143335,0.7894746,0.0016284764],"study_design_scores_gemma":[0.00779278,0.0044855364,0.00010565415,0.00026544605,0.00064894825,0.007375201,0.00005553281,0.00004260756,0.07663176,0.00041304738,0.90197796,0.00020554177],"about_ca_topic_score_codex":0.00002282525,"about_ca_topic_score_gemma":0.0000023748667,"teacher_disagreement_score":0.12200494,"about_ca_system_score_codex":0.0009667583,"about_ca_system_score_gemma":0.0049489015,"threshold_uncertainty_score":0.99988437},"labels":[],"label_agreement":null},{"id":"W4415524675","doi":"10.1007/978-3-031-97297-3_8","title":"Raw Material Considerations for the Manufacture of Cell-Based Therapies","year":2025,"lang":"en","type":"review","venue":"Advances in experimental medicine and biology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stemcell Technologies","funders":"","keywords":"Commercialization; Raw material; Quality (philosophy); Product (mathematics); Pace; New product development; Clinical trial","score_opus":0.07799450206240785,"score_gpt":0.4580216582267075,"score_spread":0.3800271561642996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415524675","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00007196794,0.99596465,0.000055270313,0.00058594666,0.0005405623,0.0018943469,0.000053078926,0.000009713729,0.0008244638],"genre_scores_gemma":[0.002944668,0.9948219,0.00035597902,0.00051546306,0.00030099513,0.00054833613,0.00017582321,0.000016497965,0.0003203259],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988131,0.00013355221,0.0004718887,0.00029317176,0.00008552379,0.00020274836],"domain_scores_gemma":[0.99714136,0.0023845802,0.00014657751,0.0002538884,0.00003641062,0.00003720691],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00022398267,0.00025234505,0.0012745495,0.00019639968,0.00006466599,0.0000045864685,0.000111530346,0.00020362588,0.0011377998],"category_scores_gemma":[0.00010398344,0.0001248809,0.00013631658,0.000110812856,0.000741288,0.000022246883,0.000045666577,0.00020045786,4.6326687e-7],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00069518713,0.00024998453,0.000023934714,0.016723134,0.00023503037,0.00001130807,0.00066503097,9.684239e-7,0.024007704,0.0009806511,0.0008486525,0.9555584],"study_design_scores_gemma":[0.0018421144,0.0013238789,0.0000011634183,0.0035993806,0.00020047739,0.000022186241,0.00052628684,0.000003411011,0.01796037,0.00045888912,0.9739497,0.00011216921],"about_ca_topic_score_codex":0.00002951477,"about_ca_topic_score_gemma":0.000012759386,"teacher_disagreement_score":0.973101,"about_ca_system_score_codex":0.000045068926,"about_ca_system_score_gemma":0.00017488576,"threshold_uncertainty_score":0.9997753},"labels":[],"label_agreement":null},{"id":"W4415534276","doi":"10.1101/2025.10.23.684261","title":"Immunometabolic determinants of long-term response in leukemia patients receiving CD19 CAR T cell therapy","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Cancer Institute; National Institutes of Health; Hyundai Hope On Wheels; Albert and Bettie Sacchi Foundation","keywords":"Chimeric antigen receptor; Leukemia; CD19; CAR T-cell therapy; T cell; Bone marrow; PI3K/AKT/mTOR pathway; Cell therapy","score_opus":0.020088476824742154,"score_gpt":0.27924940910928003,"score_spread":0.2591609322845379,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415534276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992752,0.0036670093,0.000014428149,0.000032489177,0.0008515597,0.0023078385,0.0002065778,0.0001317605,0.0000363363],"genre_scores_gemma":[0.9948847,0.0037947528,0.00038648373,0.00011037635,0.00016134388,0.00027771038,0.0000012465609,0.0001709933,0.00021234556],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9948785,0.00072449667,0.0012894812,0.0012664229,0.0009018234,0.00093928707],"domain_scores_gemma":[0.99524087,0.00034717974,0.0006300604,0.0025464005,0.00092631613,0.00030917212],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001934736,0.0007781323,0.0016234095,0.0015390101,0.00009018153,0.000091115835,0.0009025705,0.00086163677,0.0002782274],"category_scores_gemma":[0.0005365508,0.00081202836,0.00038971822,0.0013461,0.00021937603,0.00012987353,0.00073740655,0.001622561,0.000026599597],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031284625,0.00039909303,0.44433948,0.00082179427,0.00010938367,0.000118206124,0.000050903127,0.000011967395,0.55090064,9.938876e-7,0.000015617574,0.000103461534],"study_design_scores_gemma":[0.0029653416,0.0002281351,0.6067063,0.0012913821,0.000054006294,1.7260863e-8,0.0000019948116,0.000037146478,0.3880285,1.4527085e-7,0.0003122848,0.00037473353],"about_ca_topic_score_codex":0.0002475449,"about_ca_topic_score_gemma":0.000011115029,"teacher_disagreement_score":0.16287212,"about_ca_system_score_codex":0.0015298473,"about_ca_system_score_gemma":0.0035670125,"threshold_uncertainty_score":0.99943304},"labels":[],"label_agreement":null},{"id":"W4415535704","doi":"10.1016/j.jtct.2025.10.024","title":"CRS or ICANS Are Rare Beyond 2 Weeks After Lisocabtagene Maraleucel Infusion: Data From Clinical Trials and the Real-World Setting","year":2025,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; Office of Naval Research; National Heart, Lung, and Blood Institute; Legend Biotech; Takeda Oncology; U.S. Public Health Service; Health Resources and Services Administration; National Institutes of Health; Jazz Pharmaceuticals; Medac; MorphoSys; Astellas Pharma; Adaptive Biotechnologies; Incyte; Kiadis Pharma; bluebird bio; Actinium Pharmaceuticals; CareDx; Atara Biotherapeutics; National Cancer Institute; Gilead Sciences; Bristol-Myers Squibb; AstraZeneca; CSL Behring; BeiGene; HistoGenetics; Gateway for Cancer Research; Alexion Pharmaceuticals; Mallinckrodt Pharmaceuticals; Astellas Pharma US; Amgen","keywords":"Clinical trial; Cytokine release syndrome; Safety monitoring; Food and drug administration; Data monitoring committee; Confidence interval","score_opus":0.12455555396610758,"score_gpt":0.4200015351121382,"score_spread":0.29544598114603066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415535704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98302007,0.0052642096,0.00059445255,0.0064710397,0.00022431952,0.001376416,0.00037295063,0.00005829082,0.0026182502],"genre_scores_gemma":[0.86076856,0.118148915,0.00038832182,0.0043467926,0.0004491888,0.00009198425,0.0012307469,0.00004101003,0.014534503],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9967251,0.001333195,0.0008129034,0.00055086246,0.00033765312,0.00024027994],"domain_scores_gemma":[0.9966204,0.0023100467,0.00016186979,0.0006971614,0.00006702972,0.00014346927],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0036698105,0.00022771381,0.0007506313,0.0001381607,0.00018424705,0.00010502913,0.00022759946,0.00016215716,0.0026872207],"category_scores_gemma":[0.00008408568,0.00013496671,0.00012827603,0.00027228845,0.00032761195,0.00010706987,0.00004643542,0.00042374164,0.0000071936893],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14628693,0.00044687907,0.24432695,0.000681552,0.0018850715,0.0006590302,0.0046371385,0.0000022101501,0.07851907,0.00024154701,0.0033046994,0.51900893],"study_design_scores_gemma":[0.113143064,0.000878098,0.720825,0.0016328368,0.0021489034,0.000056156136,0.0024481427,0.0036787223,0.037467018,0.0010842002,0.1157113,0.0009265142],"about_ca_topic_score_codex":0.00032182192,"about_ca_topic_score_gemma":0.0005982639,"teacher_disagreement_score":0.51808244,"about_ca_system_score_codex":0.000017218494,"about_ca_system_score_gemma":0.00013978346,"threshold_uncertainty_score":0.99822444},"labels":[],"label_agreement":null},{"id":"W4415567205","doi":"10.3389/fimmu.2025.1664403","title":"Non-signaling but all important: how the linker, hinge, and transmembrane domains in the CAR hold it all together","year":2025,"lang":"en","type":"review","venue":"Frontiers in Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"Canadian Institutes of Health Research; BC Cancer Foundation; Terry Fox Research Institute; Canada Research Chairs; Michael Smith Health Research BC","keywords":"Chimeric antigen receptor; Transmembrane protein; Antigen; Transmembrane domain; Modular design; Immune system; Cytolysis; Cell; Signal transduction","score_opus":0.03990709242569941,"score_gpt":0.3267499709263403,"score_spread":0.2868428785006409,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415567205","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009080083,0.98823106,0.00010932179,0.0051086806,0.0010148328,0.0030684872,0.000035762056,0.000027011181,0.0014968063],"genre_scores_gemma":[0.00017498124,0.990418,0.0003249794,0.0011842042,0.00020036803,0.00046601694,0.00013386036,0.000092831084,0.007004764],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99596673,0.0010223108,0.0009200972,0.0007580855,0.00040240635,0.0009303499],"domain_scores_gemma":[0.9975591,0.00082760095,0.00026050943,0.0012341746,0.000053376534,0.00006524202],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0024758393,0.0006316103,0.0024988288,0.0008040721,0.00009963625,0.000076660515,0.0011008407,0.0010620729,0.00012739575],"category_scores_gemma":[0.0001657099,0.00037400358,0.0005135267,0.00076574285,0.00062204077,0.00005943671,0.00015567451,0.0033185687,0.000004811611],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00063781766,0.0003398241,0.0005549739,0.011506785,0.0037198244,0.0013374194,0.008988194,0.0000014071387,0.0010118835,0.00012029497,0.014756137,0.95702547],"study_design_scores_gemma":[0.0022630915,0.00021561861,0.000048989812,0.004907071,0.000759176,0.0002808544,0.0017166717,0.000021174805,0.000023955205,0.00013991719,0.98929495,0.0003285429],"about_ca_topic_score_codex":0.00029964207,"about_ca_topic_score_gemma":0.00019385827,"teacher_disagreement_score":0.9745388,"about_ca_system_score_codex":0.0003445528,"about_ca_system_score_gemma":0.0005718729,"threshold_uncertainty_score":0.9998712},"labels":[],"label_agreement":null},{"id":"W4415620886","doi":"10.1002/jha2.70164","title":"Secondary Malignancies Following CAR T‐Cell Therapy for B‐Cell Malignancies: A Retrospective Analysis","year":2025,"lang":"en","type":"article","venue":"eJHaem","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University Medical Centre; Ontario Clinical Oncology Group; McMaster University; Juravinski Cancer Centre; Juravinski Hospital","funders":"Ontario Institute for Cancer Research; Government of Ontario; Leukemia and Lymphoma Society of Canada; Cancer Research Society","keywords":"Complication; Malignancy; Retrospective cohort study; Clinical trial; Adverse effect; MEDLINE","score_opus":0.01787858321658435,"score_gpt":0.3086770106493665,"score_spread":0.2907984274327821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415620886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92806536,0.006576405,0.0021127774,0.00079842843,0.0004075873,0.0018114398,0.000077469274,0.00017103879,0.059979472],"genre_scores_gemma":[0.8406456,0.00037059092,0.0012223513,0.0011071361,0.00017986343,0.00029106115,0.0000761964,0.000057284637,0.15604989],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99750584,0.00008720995,0.00043790427,0.00072614104,0.00053431955,0.00070860784],"domain_scores_gemma":[0.9982945,0.00028048843,0.000102244776,0.00083848595,0.00031829203,0.00016602475],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00068903144,0.00033666848,0.00092240353,0.00071292906,0.00024835314,0.00008103493,0.00029038297,0.00020107922,0.00200154],"category_scores_gemma":[0.00009421095,0.000300348,0.001216402,0.0019452563,0.00011013497,0.00010940221,0.00008594597,0.00037843184,0.000036185862],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014106387,0.0008665012,0.10711407,0.00044985913,0.0045956965,0.0002209056,0.0040744417,0.00002358144,0.85113806,0.00052154675,0.020700792,0.008883924],"study_design_scores_gemma":[0.013227726,0.0019287465,0.0673481,0.00021088643,0.0021130415,0.000008900851,0.0038756942,0.0006660828,0.73165745,0.0013048293,0.1768977,0.00076084485],"about_ca_topic_score_codex":0.00015957063,"about_ca_topic_score_gemma":0.00006983911,"teacher_disagreement_score":0.1561969,"about_ca_system_score_codex":0.00043488012,"about_ca_system_score_gemma":0.00056782033,"threshold_uncertainty_score":0.99994487},"labels":[],"label_agreement":null},{"id":"W4415641374","doi":"10.1016/j.isci.2025.113887","title":"Resource: A compendium of HLA types and expression in pediatric cancer models","year":2025,"lang":"en","type":"article","venue":"iScience","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Faculty of Information Technology, Monash University; Medical Research Future Fund; National Cancer Institute; National Health and Medical Research Council; University of California; Children’s Cancer Foundation; Hudson Institute of Medical Research; Institute of Cancer Research; Robert Connor Dawes Foundation; McKenna Claire Foundation; Children's Hospital Los Angeles; St. Jude Children's Research Hospital; Royal Children's Hospital Foundation; Chordoma Foundation; McGill University; Dana-Farber Cancer Institute; Duke University; Johns Hopkins University; Murdoch Children's Research Institute; Deutsches Krebsforschungszentrum; University of Colorado; Victorian Cancer Agency; Children's Hospital of Philadelphia; Swifty Foundation; Children’s Oncology Group; Stanford University; Children's Cancer Foundation","keywords":"Human leukocyte antigen; Immunotherapy; Immune system; Pediatric cancer; Compendium; Cancer immunotherapy; Loss of heterozygosity; Antigen; Cancer; RNA splicing","score_opus":0.031876325645396865,"score_gpt":0.35403362347869244,"score_spread":0.32215729783329555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415641374","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97578055,0.004388021,0.00012139188,0.0006161032,0.00003760924,0.0001654311,0.0000019540755,0.000007816939,0.018881142],"genre_scores_gemma":[0.9933984,0.00067975203,0.00019919613,0.00008999505,0.000023313574,0.000009897154,3.6610783e-7,0.0000028018771,0.005596248],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99936223,0.000023148144,0.00010148796,0.00016227245,0.00021895727,0.00013191045],"domain_scores_gemma":[0.99969965,0.000064146625,0.000020293095,0.00014186538,0.000033401826,0.000040626284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024582836,0.00004186102,0.00011343815,0.00019712232,0.000025499341,0.000007237481,0.0000953062,0.000028406213,0.00014091906],"category_scores_gemma":[0.00003481533,0.000032568307,0.000013244284,0.0005290531,0.000108662374,0.000049135204,0.000087316475,0.00009778524,0.0000010317654],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00038335,0.00015284885,0.23168343,0.00035853867,0.0000051916713,0.000019676141,0.00201485,0.00085682626,0.7237363,0.0005971323,0.0024701534,0.037721686],"study_design_scores_gemma":[0.005541719,0.0004418376,0.6251329,0.0012529766,0.00006344947,0.000018781866,0.00094422733,0.063386925,0.27732235,0.0038187087,0.021716198,0.00035992294],"about_ca_topic_score_codex":0.00013631339,"about_ca_topic_score_gemma":0.00003505852,"teacher_disagreement_score":0.44641396,"about_ca_system_score_codex":0.000030260684,"about_ca_system_score_gemma":0.0001437183,"threshold_uncertainty_score":0.1542965},"labels":[],"label_agreement":null},{"id":"W4415871413","doi":"10.1136/jitc-2025-sitc2025.1303","title":"1303 Phase I/Ib study of next generation JAK-STAT CAR-T therapy for patients with relapsed or refractory CD19 <sup>+</sup> B-cell lymphoma, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL)","year":2025,"lang":"","type":"article","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Chronic lymphocytic leukemia; Refractory (planetary science); Lymphoma; CD20; Phases of clinical research; CD19; Ibrutinib; Leukemia","score_opus":0.04467810406372259,"score_gpt":0.31022548861920235,"score_spread":0.26554738455547977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415871413","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96353346,0.007966494,0.0016165244,0.00006626838,0.0013584776,0.02288706,0.00023704929,0.00033021168,0.0020044607],"genre_scores_gemma":[0.92894423,0.0068219597,0.00070935435,0.0009487228,0.0010686251,0.0021398147,0.00095654733,0.00068499654,0.05772577],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98330075,0.0016242496,0.004340189,0.0039339266,0.0033404306,0.0034604627],"domain_scores_gemma":[0.98668426,0.0024473635,0.0015717668,0.0047315275,0.003281865,0.0012831937],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0020726293,0.0027880182,0.0040150383,0.0023534235,0.0012142167,0.0005607741,0.0019254963,0.0013718017,0.0049963375],"category_scores_gemma":[0.00057162956,0.0022159652,0.0010406706,0.0038728851,0.0009966007,0.0009928204,0.0005269607,0.00058452744,0.00013507364],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.213321,0.053640768,0.004483386,0.005212488,0.009142923,0.0005040737,0.015139914,0.01963376,0.09736273,0.00009764518,0.0065307743,0.57493055],"study_design_scores_gemma":[0.47741622,0.07819166,0.0007739734,0.0011292782,0.0023022883,0.0000361382,0.007639059,0.37838373,0.03745305,0.000019999112,0.014562518,0.0020920846],"about_ca_topic_score_codex":0.0074315853,"about_ca_topic_score_gemma":0.0016676112,"teacher_disagreement_score":0.5728385,"about_ca_system_score_codex":0.09066237,"about_ca_system_score_gemma":0.07544004,"threshold_uncertainty_score":0.9999246},"labels":[],"label_agreement":null},{"id":"W4415896981","doi":"10.1136/jitc-2024-011382","title":"Targeting the extracellular matrix with Tenascin-C-specific CAR T cells extends survival in preclinical models of glioblastoma","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Genetics and Genomics of Geneva; Université de Genève; Ligue Genevoise Contre le Cancer; University of Pennsylvania; Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung; Fondation ISREC; Institut National Du Cancer; National Science Foundation; McMaster University; Fondation privée des Hôpitaux universitaires de Genève","keywords":"Bystander effect; Glioblastoma; Extracellular matrix; Cytotoxic T cell; Domain (mathematical analysis); T cell; Extracellular","score_opus":0.036324732330809476,"score_gpt":0.3776838244149533,"score_spread":0.34135909208414383,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415896981","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8887851,0.098922715,0.0075430903,0.0019033328,0.000909342,0.0014052079,0.00003632587,0.000015553478,0.00047931005],"genre_scores_gemma":[0.9415088,0.03285331,0.002553787,0.0001175054,0.00049622473,0.00012511965,0.000003592325,0.000113329465,0.02222831],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99740577,0.00017202216,0.0010346023,0.00025609502,0.00069526286,0.0004362445],"domain_scores_gemma":[0.99796236,0.00054464355,0.0004215759,0.00043545695,0.00056432624,0.0000716452],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021484327,0.00022067696,0.0007562087,0.00033548384,0.00011794865,0.000033272212,0.0003894246,0.00014065807,0.00063907495],"category_scores_gemma":[0.000029280109,0.00013426371,0.00037043676,0.00056400686,0.00027996814,0.00011825976,0.00003033752,0.000718656,4.9665965e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018047689,0.00031604696,0.0022465796,0.00018515674,0.00062435365,0.000013540224,0.00083652604,0.008138172,0.931252,0.00038298592,0.0010434982,0.036913477],"study_design_scores_gemma":[0.042265106,0.0069470047,0.005228573,0.0036274046,0.00033394355,0.00011674947,0.0033312344,0.01913554,0.6181233,0.003530615,0.29660916,0.00075140165],"about_ca_topic_score_codex":0.00012775697,"about_ca_topic_score_gemma":0.00005511711,"teacher_disagreement_score":0.3131287,"about_ca_system_score_codex":0.00022784651,"about_ca_system_score_gemma":0.0006078823,"threshold_uncertainty_score":0.6997422},"labels":[],"label_agreement":null},{"id":"W4415898666","doi":"10.1136/jitc-2025-sitc2025.1196","title":"1196 TriTCE Co-stim: a differentiated T cell engager platform with conditional <i>cis</i> CD28 co-stimulation is transferable to diverse targeting strategies","year":2025,"lang":"","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Zymeworks (Canada)","funders":"","keywords":"T cell; CD28; Cell; T-cell receptor; Ubiquitin-Protein Ligases","score_opus":0.02448960916072105,"score_gpt":0.2953962097737661,"score_spread":0.27090660061304506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415898666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9799175,0.0013642333,0.0019999642,0.0017965677,0.00044636521,0.0027241944,0.00068802165,0.00019774283,0.010865402],"genre_scores_gemma":[0.9831001,0.0004657071,0.00054245297,0.0015284496,0.00034423164,0.000099936704,0.0012670392,0.00013038587,0.012521707],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99376106,0.00029245106,0.0013237586,0.0014388312,0.0017144734,0.0014694303],"domain_scores_gemma":[0.99600846,0.000537852,0.00028271895,0.000708244,0.00060243695,0.0018603079],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013581888,0.0010364705,0.001292229,0.0007343168,0.0011856618,0.0007968379,0.00037600432,0.0006765417,0.002248572],"category_scores_gemma":[0.00027728995,0.0009694797,0.00030119505,0.0009926505,0.0010256135,0.0009090611,0.000086397056,0.001693882,0.00012707207],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059109284,0.0012636986,0.023028985,0.0036670414,0.0017723464,0.00067324744,0.009340936,0.0050074933,0.90846276,0.0013585747,0.038099818,0.0014141396],"study_design_scores_gemma":[0.020765455,0.002527903,0.07019233,0.0028708414,0.001689698,0.00013912695,0.009095258,0.0061053433,0.8383158,0.0025208995,0.043664083,0.0021132794],"about_ca_topic_score_codex":0.0004535168,"about_ca_topic_score_gemma":0.000050561775,"teacher_disagreement_score":0.070147015,"about_ca_system_score_codex":0.0004372144,"about_ca_system_score_gemma":0.0026166844,"threshold_uncertainty_score":0.99927557},"labels":[],"label_agreement":null},{"id":"W4415898865","doi":"10.1136/jitc-2025-sitc2025.0320","title":"320 Integrated efficacy and safety analysis of letetresgene autoleucel, a T-cell receptor T-cell therapy, across clinical trials of patients with synovial sarcoma and myxoid/round cell liposarcoma","year":2025,"lang":"","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Princess Margaret Cancer Centre","funders":"","keywords":"Clinical trial; Soft tissue sarcoma; Synovial sarcoma; Liposarcoma; Sarcoma; Receptor","score_opus":0.043261942524745856,"score_gpt":0.3526277013207987,"score_spread":0.3093657587960528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415898865","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9757227,0.018359037,0.000059380334,0.00040182174,0.00056674395,0.0029771354,0.0013652322,0.0000523378,0.0004956187],"genre_scores_gemma":[0.98405814,0.011662312,0.00081691594,0.00020395567,0.00018392058,0.000028798611,0.00054373953,0.00012744243,0.0023747983],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.98742527,0.0028122189,0.0050639743,0.0018942828,0.0015501023,0.0012541672],"domain_scores_gemma":[0.9894531,0.0036798862,0.0023896308,0.0015068159,0.0011283653,0.0018422224],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.009336512,0.0012042648,0.005119988,0.0011019962,0.00041137432,0.00028807187,0.0005344919,0.0011041712,0.00034351915],"category_scores_gemma":[0.0021838353,0.000963808,0.0008480129,0.00268932,0.0041630827,0.00029336743,0.00040954686,0.0015220008,0.000003841447],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030498484,0.008257327,0.4102369,0.0026938596,0.011027036,0.00006389936,0.0033823065,0.00008841859,0.48485848,0.000031759173,0.0011305858,0.047730945],"study_design_scores_gemma":[0.05950972,0.009370269,0.6304628,0.0015268609,0.008596866,0.0000104382525,0.0017050919,0.0012206468,0.27055848,0.000049219514,0.015635626,0.0013539951],"about_ca_topic_score_codex":0.0010191945,"about_ca_topic_score_gemma":0.00013834979,"teacher_disagreement_score":0.2202259,"about_ca_system_score_codex":0.00020502145,"about_ca_system_score_gemma":0.0020993468,"threshold_uncertainty_score":0.9992812},"labels":[],"label_agreement":null},{"id":"W4415898942","doi":"10.1136/jitc-2025-sitc2025.0283","title":"283 Functional profiling of CAR T cells using high-dimensional CyTOF: integrating cytokine, transcription factor and immune checkpoint marker signatures","year":2025,"lang":"","type":"article","venue":"Regular and Young Investigator Award Abstracts","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Standards Association","funders":"","keywords":"Transcription factor; Profiling (computer programming); Immune system; Immune checkpoint; Transcription (linguistics); Gene expression profiling","score_opus":0.023002610327908395,"score_gpt":0.26604151805324533,"score_spread":0.24303890772533693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415898942","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9849887,0.010400533,0.00035537317,0.00065765216,0.0016847099,0.0013313207,0.00020905418,0.00005762559,0.00031505947],"genre_scores_gemma":[0.9928414,0.00048894563,0.004104604,0.00018537372,0.00041578308,0.000021798858,0.00013706279,0.00009261254,0.0017123964],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99482137,0.00035287085,0.0016763043,0.0010876536,0.0012027138,0.0008590622],"domain_scores_gemma":[0.99717915,0.0003118093,0.00051674485,0.0005546439,0.0006402379,0.00079741766],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014743786,0.0007816111,0.0012454208,0.0006499299,0.00045976473,0.00017983324,0.00018095422,0.00075936056,0.00042154276],"category_scores_gemma":[0.0006355616,0.00072808104,0.0003699505,0.0006142326,0.0013007489,0.00038995675,0.00015770677,0.0015378918,0.0000032442742],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00113785,0.00019955816,0.0037854423,0.0019383437,0.0007870046,0.00006646165,0.00057728513,0.0008220927,0.9879309,0.0006118576,0.00010265324,0.002040554],"study_design_scores_gemma":[0.0030119454,0.00030365336,0.09544119,0.0026502542,0.0005416315,0.000105546584,0.00063348975,0.010151053,0.885762,0.0005467396,0.00034364636,0.0005088883],"about_ca_topic_score_codex":0.0009672146,"about_ca_topic_score_gemma":0.000029833762,"teacher_disagreement_score":0.10216894,"about_ca_system_score_codex":0.00037779514,"about_ca_system_score_gemma":0.001748066,"threshold_uncertainty_score":0.999517},"labels":[],"label_agreement":null},{"id":"W4415952016","doi":"10.3324/haematol.2025.288838","title":"CD19 directed CAR T therapy for intravascular large B-cell lymphoma","year":2025,"lang":"en","type":"article","venue":"Haematologica","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada; BC Cancer Agency","funders":"Cancer Moonshot; National Institute of Allergy and Infectious Diseases; National Cancer Institute; Office of Naval Research; National Heart, Lung, and Blood Institute; Astellas Pharma US; Health Resources and Services Administration; National Institutes of Health; Gilead Sciences; Actinium Pharmaceuticals; Adaptive Biotechnologies; Moonshot Research and Development Program; AstraZeneca; Gateway for Cancer Research; Astellas Pharma; Alexion Pharmaceuticals; Amgen","keywords":"Lymphoma; CD19; Chimeric antigen receptor; Aggressive lymphoma; CAR T-cell therapy; Antibody therapy","score_opus":0.023826367591453696,"score_gpt":0.3159687436674928,"score_spread":0.2921423760760391,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415952016","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95335734,0.005662326,0.0013753413,0.0022503058,0.00026070667,0.0025106561,0.000025202247,0.000525264,0.03403283],"genre_scores_gemma":[0.97316366,0.0013479919,0.0014916367,0.002101981,0.000086292945,0.0004478852,0.0000741755,0.000039366314,0.021246985],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.998284,0.000115649826,0.0002957998,0.000452754,0.0002752635,0.00057656126],"domain_scores_gemma":[0.9987361,0.00024311745,0.0000523764,0.0006264768,0.00021625267,0.00012570785],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00043002577,0.00022154069,0.0006350143,0.0001850926,0.00015916344,0.000031486787,0.00022583615,0.0002381786,0.0015319117],"category_scores_gemma":[0.00019496404,0.00016384888,0.0003140663,0.00044514408,0.00009638,0.000030309657,0.000068264024,0.00014440824,0.00007172512],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0134387,0.013259407,0.028702505,0.002455554,0.0026167606,0.0015580679,0.0017520257,0.0000034042594,0.46463484,0.020363329,0.17980275,0.27141267],"study_design_scores_gemma":[0.021677982,0.0007436206,0.006043782,0.000112937494,0.00010020967,0.00009346741,0.00032441545,0.0007352885,0.20130487,0.0012636418,0.7673032,0.00029653584],"about_ca_topic_score_codex":0.000033209904,"about_ca_topic_score_gemma":0.0000136983235,"teacher_disagreement_score":0.5875005,"about_ca_system_score_codex":0.000091407725,"about_ca_system_score_gemma":0.00019654412,"threshold_uncertainty_score":0.9993808},"labels":[],"label_agreement":null},{"id":"W4415987224","doi":"10.1007/s11899-025-00764-z","title":"Transforming the Treatment of Acute Lymphoblastic Leukemia: the Role of Bispecific Antibodies, Antibody-Drug Conjugates, and CAR T-cell Therapy","year":2025,"lang":"en","type":"review","venue":"Current Hematologic Malignancy Reports","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Blinatumomab; Chimeric antigen receptor; Ponatinib; Immunotherapy; Hematology; Minimal residual disease; Chemotherapy","score_opus":0.03765103770373049,"score_gpt":0.34985800668731853,"score_spread":0.312206968983588,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415987224","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.007804587,0.98449033,0.000011633464,0.000035119043,0.000578867,0.0054900693,0.000103164166,0.000067949986,0.0014182893],"genre_scores_gemma":[0.00560227,0.9925035,0.000018393419,0.000006822223,0.00009012566,0.00038457746,0.0002023366,0.000077704455,0.0011142698],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99519175,0.000358428,0.00217328,0.00092385826,0.00071314175,0.0006395133],"domain_scores_gemma":[0.99554056,0.0009655469,0.0014394647,0.0016544135,0.00026091893,0.0001390772],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00067285204,0.0008997026,0.0040207603,0.00032036417,0.00021082074,0.000038010967,0.00037270342,0.00034123965,0.00020627263],"category_scores_gemma":[0.00004872687,0.00041733246,0.0012697629,0.0007245983,0.000726948,0.000046659243,0.0000897747,0.00045754304,0.000003503768],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012749094,0.0008939296,0.0018078088,0.033501495,0.0015594112,0.00086581206,0.0007905782,3.3022886e-7,0.0013158014,0.00037841956,0.0002369252,0.958522],"study_design_scores_gemma":[0.0010888547,0.00053400436,0.00001883434,0.023118827,0.0031727443,0.0039650486,0.00018169427,0.000006786236,0.00903216,0.00029480408,0.95819235,0.00039386677],"about_ca_topic_score_codex":0.000104574356,"about_ca_topic_score_gemma":0.000006204569,"teacher_disagreement_score":0.95812815,"about_ca_system_score_codex":0.00031705768,"about_ca_system_score_gemma":0.0018631427,"threshold_uncertainty_score":0.99982786},"labels":[],"label_agreement":null},{"id":"W4416085335","doi":"10.1093/neuonc/noaf201.1397","title":"EXTH-64. Allogeneic CAR-DNT cell therapy to overcome spatial heterogeneity in glioblastoma","year":2025,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Fonds Wetenschappelijk Onderzoek","keywords":"Chimeric antigen receptor; Cytotoxicity; Cytotoxic T cell; Cell therapy; In vitro; Glioblastoma; Immunotherapy; CD19; Antigen; Cell","score_opus":0.02928261303002896,"score_gpt":0.35076667718269267,"score_spread":0.32148406415266373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416085335","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98363173,0.00045750715,0.000116568764,0.0046157744,0.00095532543,0.0015867099,0.000011953615,0.000095028336,0.008529425],"genre_scores_gemma":[0.9866341,0.00046165354,0.00014150805,0.0106719,0.00034006883,0.00022384505,0.000007413712,0.000059937636,0.0014596167],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9968774,0.0005696946,0.00053665094,0.0007862076,0.0004261501,0.0008039492],"domain_scores_gemma":[0.99812853,0.0005293288,0.00007469296,0.00080214,0.00013795524,0.00032734935],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00049559504,0.00032301285,0.00078980107,0.0006909996,0.000075165415,0.000024522025,0.00038592832,0.000362446,0.0014943033],"category_scores_gemma":[0.00015145882,0.00030435703,0.00021167063,0.00079916604,0.00012967945,0.000043303648,0.00027384248,0.0007477268,0.00018841811],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044060033,0.00067645963,0.026948119,0.000039501214,0.000048195387,0.00074964424,0.0003584541,0.000056808272,0.8790224,0.00001681697,0.0018861934,0.0857914],"study_design_scores_gemma":[0.006077971,0.004990905,0.032653015,0.000022475164,0.00002187947,0.000098527926,0.000047159006,0.00013593977,0.5566103,0.00004444919,0.39910161,0.00019576316],"about_ca_topic_score_codex":0.0007430923,"about_ca_topic_score_gemma":0.0029739828,"teacher_disagreement_score":0.39721543,"about_ca_system_score_codex":0.00082676986,"about_ca_system_score_gemma":0.00078820024,"threshold_uncertainty_score":0.9999409},"labels":[],"label_agreement":null},{"id":"W4416086893","doi":"10.1182/bloodadvances.2025016845","title":"A phase 1 study of blinatumomab/lenalidomide in relapsed/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysis","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Daiichi Sankyo Europe; Ipsen; Mallinckrodt Pharmaceuticals; Seagen; National Institutes of Health; Incyte; BeiGene; Genentech; AstraZeneca","keywords":"Lenalidomide; Blinatumomab; Concomitant; Adverse effect; Phases of clinical research; Toxicity; Lymphoma; Neurotoxicity","score_opus":0.01619469634600543,"score_gpt":0.3483985157154631,"score_spread":0.33220381936945764,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416086893","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848545,0.008581989,0.00003266428,0.00007155662,0.00006207179,0.00093560404,0.000010327207,0.000028377877,0.0054228706],"genre_scores_gemma":[0.9946317,0.0005951137,0.0001393998,0.0000529449,0.000026062164,0.00004390438,0.000008650034,0.00001512194,0.004487085],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9981231,0.00020525554,0.0005076387,0.00047284312,0.00041305646,0.000278105],"domain_scores_gemma":[0.99848497,0.00070568797,0.00015830333,0.00041110505,0.00013538827,0.00010454794],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004456186,0.00020355059,0.00078660925,0.0010149619,0.0000574774,0.000014906185,0.00014963647,0.00008543303,0.00015979503],"category_scores_gemma":[0.00023995413,0.00017743859,0.00011822519,0.0021414626,0.00016610521,0.00010065198,0.00011997289,0.0002499533,0.0000031146942],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015573525,0.16148128,0.52501845,0.00066694344,0.0048757927,0.0008793194,0.0066714403,0.00040331553,0.17715356,0.000115508345,0.00012239853,0.107038446],"study_design_scores_gemma":[0.48310062,0.025235202,0.26385763,0.00074331055,0.009366643,0.000035898876,0.015344477,0.002056342,0.1930216,0.0005222859,0.0058426373,0.0008733431],"about_ca_topic_score_codex":0.00015756904,"about_ca_topic_score_gemma":0.00038622358,"teacher_disagreement_score":0.4675271,"about_ca_system_score_codex":0.00007061047,"about_ca_system_score_gemma":0.00014965127,"threshold_uncertainty_score":0.72357357},"labels":[],"label_agreement":null},{"id":"W4416114352","doi":"10.1038/s41598-025-23159-9","title":"Added prognostic value of baseline pre-infusion 18F-FDG PET/CT in diffuse large B-cell lymphoma patients receiving chimeric antigen receptor T-cell therapy","year":2025,"lang":"en","type":"article","venue":"Scientific Reports","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Women's College Hospital","funders":"","keywords":"Multivariate analysis; Lymphoma; Retrospective cohort study; Prognostic variable; Diffuse large B-cell lymphoma; Overall survival; Multivariate statistics; Antigen; Predictive value; Survival analysis","score_opus":0.01104840940962449,"score_gpt":0.2823102877517549,"score_spread":0.2712618783421304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416114352","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98930603,0.00090124924,0.000041526982,0.00009522534,0.003251449,0.0026695814,0.000012611541,0.00012084273,0.0036015094],"genre_scores_gemma":[0.9729291,0.0003986134,0.0005335324,0.00008218194,0.000057748253,0.00009501082,0.00029061877,0.00007258702,0.025540609],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9946585,0.00038606534,0.0013684519,0.0013183515,0.0014392488,0.00082932983],"domain_scores_gemma":[0.9966844,0.00027424496,0.0005624956,0.0016568182,0.00057582377,0.0002462641],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004001004,0.00036253268,0.0007039266,0.0010085147,0.00025164525,0.00011970349,0.00029876924,0.00004776256,0.0011899752],"category_scores_gemma":[0.0010289996,0.00031345797,0.0002706332,0.0025651145,0.0002564683,0.00016872736,0.00024132883,0.00028738202,0.00003834522],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005564463,0.014770544,0.55222064,0.00037869558,0.000052620057,0.00092407234,0.00057600864,0.000009957398,0.40006548,0.0000030039732,0.006812496,0.023630038],"study_design_scores_gemma":[0.027272234,0.00089498784,0.29232806,0.0016507966,0.00009453667,0.00022812583,0.00033175646,0.0030914478,0.5946565,0.0002544822,0.07844297,0.0007540843],"about_ca_topic_score_codex":0.0002470743,"about_ca_topic_score_gemma":0.00004988379,"teacher_disagreement_score":0.25989258,"about_ca_system_score_codex":0.00026111415,"about_ca_system_score_gemma":0.00093494455,"threshold_uncertainty_score":0.99993175},"labels":[],"label_agreement":null},{"id":"W4416116967","doi":"10.1158/0008-5472.can-24-3329","title":"Response to Immune Checkpoint Blockade Is Enhanced in the Presence of Hematopoietic TET2 Inactivation","year":2025,"lang":"en","type":"article","venue":"Cancer Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; Princess Margaret Cancer Centre; Queen's University; University Health Network","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Department of Medicine, University of Toronto; Terry Fox Research Institute; Deutsches Krebsforschungszentrum; Physicians' Services Incorporated Foundation; Princess Margaret Cancer Foundation; Leukemia and Lymphoma Society of Canada; Ministry of Health, Ontario","keywords":"Blockade; Immune checkpoint; Haematopoiesis; Immunotherapy; Immune system; Cancer immunotherapy","score_opus":0.05917256912853262,"score_gpt":0.44006774784438407,"score_spread":0.38089517871585143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416116967","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95316154,0.0007267852,0.00008456202,0.03955045,0.000056332115,0.0017696025,0.0000058133937,0.000013421876,0.0046315026],"genre_scores_gemma":[0.9772269,0.00028964927,0.000055851608,0.00027348317,0.00004978171,0.0007819185,0.0000019298245,0.000018161443,0.021302305],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99654776,0.0008280339,0.0004068386,0.00038067353,0.001282666,0.0005540067],"domain_scores_gemma":[0.99689734,0.0014268343,0.000040882813,0.0009454659,0.0005957123,0.00009378395],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0053944434,0.00011967558,0.00031193162,0.00080614205,0.00009992608,0.00003365776,0.0005410292,0.000099457466,0.0016681751],"category_scores_gemma":[0.0021692368,0.000089176,0.00008420783,0.0031382677,0.00027757793,0.000058865284,0.00023024688,0.00084006693,0.00003475263],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008465814,0.00017304298,0.00056861213,0.0002382246,0.000034813274,0.000019763216,0.006270637,0.000011978924,0.9765384,0.00007193072,0.001051108,0.006555659],"study_design_scores_gemma":[0.0012738396,0.0003649899,0.018044129,0.0007345506,0.0000059225104,0.0000048749575,0.0024697336,0.000037384194,0.9648899,0.00047819977,0.011628184,0.00006829299],"about_ca_topic_score_codex":0.0015756623,"about_ca_topic_score_gemma":0.00009436801,"teacher_disagreement_score":0.03927697,"about_ca_system_score_codex":0.00062912435,"about_ca_system_score_gemma":0.0011071234,"threshold_uncertainty_score":0.99924445},"labels":[],"label_agreement":null},{"id":"W4416126817","doi":"10.21203/rs.3.rs-7949545/v1","title":"Engagement of the T cell receptor against an oncolytic virus generates a population of hypereffector CAR T cells with potent antitumor activity","year":2025,"lang":"","type":"preprint","venue":"Research Square","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of British Columbia","funders":"National Institutes of Health","keywords":"Oncolytic virus; Chimeric antigen receptor; T cell; Vesicular stomatitis virus; T-cell receptor; Cytotoxic T cell; Population; Streptamer; Antigen","score_opus":0.07020830993468759,"score_gpt":0.38896211950153603,"score_spread":0.31875380956684846,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416126817","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9813083,0.0011368616,0.000044877874,0.0002916069,0.0007150497,0.012811829,0.0012620242,0.00004354506,0.0023859204],"genre_scores_gemma":[0.98548114,0.004557652,0.0003681974,0.000026812968,0.00058431324,0.0006245788,0.00030484516,0.00015339913,0.007899081],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.97862315,0.00993569,0.0013915336,0.0019516536,0.0063174516,0.0017804971],"domain_scores_gemma":[0.98881376,0.0019104051,0.0008558187,0.0041970885,0.0034974727,0.00072547],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.009532342,0.0009693534,0.0021260858,0.0014787602,0.00074936217,0.0001668538,0.0018487669,0.00075724616,0.0021156135],"category_scores_gemma":[0.0007384786,0.00068837235,0.0007955482,0.0026910352,0.0011375768,0.0002108401,0.0025517028,0.005504446,0.000041070274],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059792227,0.00411155,0.014232938,0.01645018,0.00066244113,0.000045403733,0.0019238964,0.0058910022,0.9229633,0.000023660374,0.00025812452,0.027458273],"study_design_scores_gemma":[0.0035760496,0.004769621,0.038385954,0.0067182337,0.00026096898,0.0000025204392,0.0012559303,0.0064372136,0.9366204,0.000016007127,0.001420134,0.0005369478],"about_ca_topic_score_codex":0.009766459,"about_ca_topic_score_gemma":0.0008131636,"teacher_disagreement_score":0.026921326,"about_ca_system_score_codex":0.0029956752,"about_ca_system_score_gemma":0.0057437783,"threshold_uncertainty_score":0.9998927},"labels":[],"label_agreement":null},{"id":"W4416140366","doi":"10.1093/neuonc/noaf201.1473","title":"EXTH-142. Quantitative surfaceome profiling of high-risk medulloblastoma prioritizes the oncofetal antigen GPC2 for potent CAR-T cell therapy","year":2025,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Centre for Applied Research in Cancer Control; BC Children's Hospital; BC Cancer Agency; McMaster University","funders":"","keywords":"Medulloblastoma; Antigen; Potency; Disease; Tumor antigen; Immunotherapy; Cell","score_opus":0.034950985266482486,"score_gpt":0.3582756843886205,"score_spread":0.323324699122138,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416140366","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98464346,0.0019197604,0.00077299133,0.0044138003,0.0010302649,0.0035903703,0.0001163829,0.00008406987,0.0034289013],"genre_scores_gemma":[0.9892466,0.0035157457,0.004220604,0.00090804603,0.00021474682,0.0002884172,0.000033461776,0.000078018194,0.0014943291],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9968122,0.0007400062,0.00067180116,0.00062383525,0.00049172645,0.0006603998],"domain_scores_gemma":[0.9947976,0.0034988692,0.00031088272,0.0006693839,0.0005832757,0.0001400215],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011353703,0.00032139776,0.0009458889,0.00027887616,0.00023274004,0.000023530829,0.00042539262,0.00029101883,0.00020251694],"category_scores_gemma":[0.0005652262,0.00022901814,0.00035194634,0.0005538873,0.0005260479,0.00006351017,0.00015274477,0.00074539275,0.000017463442],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056624347,0.0005952867,0.006004405,0.00014112522,0.000302905,0.000060586433,0.0010598949,0.000076280485,0.94001997,0.0010402974,0.00087430753,0.044162538],"study_design_scores_gemma":[0.008973045,0.010400625,0.007910933,0.000056126377,0.00016958508,0.000043625034,0.0019557022,0.0008551797,0.88437355,0.00075005845,0.0842912,0.00022040233],"about_ca_topic_score_codex":0.00036161987,"about_ca_topic_score_gemma":0.00011538968,"teacher_disagreement_score":0.08341689,"about_ca_system_score_codex":0.00027525172,"about_ca_system_score_gemma":0.0012741288,"threshold_uncertainty_score":0.9339089},"labels":[],"label_agreement":null},{"id":"W4416296108","doi":"10.5430/jst.v15n1p41","title":"Effectiveness of chimeric antigen receptor-T therapy on prostate cancer: A preclinical and clinical systematic review","year":2025,"lang":"","type":"article","venue":"Journal of Solid Tumors","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"Student Research Committee, Tabriz University of Medical Sciences","keywords":"Prostate cancer; Tumor microenvironment; Clinical trial; Prostate; Immune system; Antigen; Immunotherapy; Prostate-specific antigen","score_opus":0.04234880502121697,"score_gpt":0.4446988460932782,"score_spread":0.40235004107206124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416296108","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.64112973,0.35113573,0.000012493457,0.0012119845,0.0013195671,0.004942018,0.000027925587,0.000008383096,0.00021214921],"genre_scores_gemma":[0.43125346,0.56713533,0.00003278087,0.0004262849,0.0002880539,0.000052064886,0.0000015140959,0.000045139102,0.00076533505],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9868007,0.00537818,0.00532496,0.0005582613,0.0013368896,0.0006010643],"domain_scores_gemma":[0.98847276,0.0056783445,0.0032473523,0.00077335094,0.0013120292,0.0005161525],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.019033689,0.0005250413,0.0057453467,0.00053130375,0.00011142174,0.000040920222,0.00057045615,0.0002656049,0.0007044069],"category_scores_gemma":[0.0045205858,0.00036236603,0.0012323513,0.0011445403,0.00073630456,0.00014768835,0.00013303528,0.0020470964,0.000014984072],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027927266,0.0033866796,0.07953328,0.8291915,0.00883698,0.0002967602,0.0005368902,0.000018029601,0.014147915,0.000039068713,0.001241258,0.034844376],"study_design_scores_gemma":[0.010421808,0.012945346,0.07776227,0.887009,0.0019422013,0.0002136096,0.00014551508,0.0000923048,0.008571119,0.000094466675,0.0004847365,0.00031761726],"about_ca_topic_score_codex":0.000038826707,"about_ca_topic_score_gemma":0.0000016601446,"teacher_disagreement_score":0.21599963,"about_ca_system_score_codex":0.00032856755,"about_ca_system_score_gemma":0.0022964193,"threshold_uncertainty_score":0.9998828},"labels":[],"label_agreement":null},{"id":"W4416330185","doi":"10.1200/jco-25-00507","title":"Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; McMaster University; Juravinski Hospital","funders":"","keywords":"Lymphoma; Lactate dehydrogenase; Refractory (planetary science); Cytokine release syndrome; Clinical trial; Survival analysis; Overall survival; Immunotherapy; Prospective cohort study","score_opus":0.048001974939657285,"score_gpt":0.42936079321755405,"score_spread":0.38135881827789675,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416330185","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98962796,0.000100242534,0.000017689805,0.0008332676,0.00057491707,0.00037693785,0.000011465329,0.0000018845064,0.008455618],"genre_scores_gemma":[0.99551874,0.0002112757,0.00022139632,0.0005215699,0.000138817,0.0000022795998,0.0000032484293,0.000010998414,0.003371694],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99550796,0.00096633297,0.0024105094,0.00017195307,0.0007212239,0.00022205034],"domain_scores_gemma":[0.9943999,0.0026483326,0.0017552049,0.0004147415,0.0006476252,0.00013419446],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004136093,0.00011178642,0.0018819331,0.0005226544,0.000021081156,0.000003115414,0.00033260533,0.00036352142,0.0005487493],"category_scores_gemma":[0.0026440101,0.00006473713,0.0008517683,0.0012080525,0.00026985555,0.000048688515,0.00010452058,0.0008008874,0.0000028099894],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25281504,0.021714035,0.6869728,0.000050858896,0.0026337483,0.00004601045,0.00016516108,0.000029483783,0.0003131596,0.000041904597,0.002597739,0.03262006],"study_design_scores_gemma":[0.22828169,0.015105234,0.7361104,0.000085225205,0.0014437685,0.000001006087,0.000090273425,0.000058551126,0.00018652307,0.000038742906,0.018552601,0.00004600143],"about_ca_topic_score_codex":0.000035331213,"about_ca_topic_score_gemma":0.00012423571,"teacher_disagreement_score":0.049137574,"about_ca_system_score_codex":0.00020761223,"about_ca_system_score_gemma":0.0022994743,"threshold_uncertainty_score":0.600842},"labels":[],"label_agreement":null},{"id":"W4416388565","doi":"10.20944/preprints202511.1469.v1","title":"Assessing Canadaʹs Health System Readiness for Complex Therapies - The Current and Future State of T-Cell Redirecting Therapies","year":2025,"lang":"","type":"preprint","venue":"Preprints.org","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Health care; Psychological intervention; Deliberation; Intervention (counseling); Data collection; Flexibility (engineering); Healthcare system; Health informatics","score_opus":0.1900785494135644,"score_gpt":0.43381133449116704,"score_spread":0.24373278507760265,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416388565","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9050355,0.056591116,0.0010170956,0.012504813,0.0057235616,0.012518075,0.00067549857,0.00026843295,0.00566594],"genre_scores_gemma":[0.96260947,0.029827215,0.0005503191,0.0002125777,0.001773151,0.0009031273,0.00014931108,0.0001685046,0.0038062956],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9899163,0.0021101434,0.0025589264,0.0022637595,0.0015182286,0.0016326226],"domain_scores_gemma":[0.99057853,0.0021199614,0.0022139593,0.0030246032,0.0015356251,0.0005273205],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.009099572,0.0012300564,0.002777929,0.0005998692,0.0012907395,0.00018515614,0.0014230075,0.00034766257,0.0005200663],"category_scores_gemma":[0.0002819253,0.00095612335,0.0006342373,0.0007735128,0.0008104278,0.00020980906,0.0018411361,0.0030302529,0.000009439314],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018866679,0.0006002494,0.08404881,0.04311975,0.0026309586,0.000011767045,0.044449296,0.00014775775,0.07012572,0.00028849315,0.00022930415,0.75246125],"study_design_scores_gemma":[0.009505863,0.0005212665,0.49789858,0.022412257,0.0011606425,0.00009494455,0.07101232,0.007766531,0.054075617,0.0012205181,0.33188602,0.0024454375],"about_ca_topic_score_codex":0.009947822,"about_ca_topic_score_gemma":0.0014065126,"teacher_disagreement_score":0.7500158,"about_ca_system_score_codex":0.0016668868,"about_ca_system_score_gemma":0.0049192742,"threshold_uncertainty_score":0.9992889},"labels":[],"label_agreement":null},{"id":"W4416392126","doi":"10.1177/03009858251391388","title":"Characterization of host immune cell infiltrate in human CAR T cell-mediated xenogeneic graft versus host disease in NSG mice","year":2025,"lang":"en","type":"article","venue":"Veterinary Pathology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Altasciences (Canada)","funders":"University of Pennsylvania","keywords":"Immune system; Graft-versus-host disease; Histiocyte; Antigen; Chimeric antigen receptor; Antigen presentation; Population; Cytotoxic T cell; Immunohistochemistry","score_opus":0.028297569353368465,"score_gpt":0.3133089044087582,"score_spread":0.2850113350553897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416392126","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967891,0.00050534157,0.000008546707,0.00018800632,0.00032381425,0.0007461348,0.000088139546,0.000035706864,0.0013151944],"genre_scores_gemma":[0.9970962,0.00050268444,0.00003253895,0.00010248622,0.000041356983,0.000092413895,0.0005752374,0.000036735473,0.0015203877],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9980027,0.00036850534,0.000567503,0.00043998827,0.00017635219,0.0004449173],"domain_scores_gemma":[0.9990297,0.00012368691,0.0001266451,0.000522522,0.00008215017,0.000115327326],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00033494126,0.00022724635,0.0005141193,0.0008919241,0.000041964726,0.000009498667,0.00021144064,0.00019520323,0.00036262328],"category_scores_gemma":[0.000055330052,0.00024558138,0.0000953792,0.0008821002,0.00019106953,0.00007693919,0.00016659654,0.00038033805,0.000026306694],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044580316,0.00055813376,0.035480127,0.0004026906,0.000014858984,0.0024218748,0.00042908048,0.0000038019932,0.9560439,0.000008679117,0.0000036176893,0.00017518894],"study_design_scores_gemma":[0.0073494343,0.0021883673,0.6920148,0.00014459938,0.000037886242,0.000026419197,0.00010740576,0.00008814239,0.296684,0.0000065751647,0.0011557941,0.0001965374],"about_ca_topic_score_codex":0.00014373426,"about_ca_topic_score_gemma":0.000024219706,"teacher_disagreement_score":0.65935993,"about_ca_system_score_codex":0.00014398825,"about_ca_system_score_gemma":0.00019487231,"threshold_uncertainty_score":0.99999964},"labels":[],"label_agreement":null},{"id":"W4416394020","doi":"10.1016/j.jgo.2025.102392","title":"Geriatric assessment in patients aged 70 and over considered for CAR-T therapy: A descriptive study","year":2025,"lang":"en","type":"article","venue":"Journal of Geriatric Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval; Institut Universitaire de Gériatrie de Montréal; Quebec - Clinical Research Organization in Cancer; Centres Intégré Universitaires de Santé et de Services Sociaux; Canadian Institute for International Peace and Security","funders":"","keywords":"Descriptive research; Descriptive statistics; Geriatrics; MEDLINE; Cross-sectional study","score_opus":0.03592266160567572,"score_gpt":0.3871580336817469,"score_spread":0.3512353720760712,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416394020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993964,0.00091037527,0.00008828141,0.0007588359,0.00075161766,0.0023157047,0.0000057627317,0.0000074174854,0.0011979848],"genre_scores_gemma":[0.99639064,0.00064534304,0.0011468357,0.0003426951,0.00024485536,0.00006205242,0.0000025938507,0.000022077204,0.0011429235],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9976814,0.00049900444,0.0008576594,0.00025164682,0.000366937,0.00034336178],"domain_scores_gemma":[0.9979883,0.000811619,0.00041621405,0.0001908962,0.0004529672,0.00014001346],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016739966,0.00018322718,0.0009289892,0.0010733062,0.00007251386,0.000031032647,0.00012835485,0.00017692315,0.00034711385],"category_scores_gemma":[0.00032008652,0.00014529815,0.00016272382,0.00066299795,0.000068950445,0.00009476438,0.00007268532,0.00060228613,6.446118e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014903014,0.0053509013,0.88615924,0.00008281566,0.0009431671,0.00027518749,0.002707643,0.0000047953113,0.011337872,0.00003204635,0.008044398,0.070158936],"study_design_scores_gemma":[0.04738699,0.015887877,0.92445815,0.000028482582,0.00023779496,0.000042412543,0.0018913797,0.000031238404,0.00013410406,0.0003589157,0.009426285,0.000116406874],"about_ca_topic_score_codex":0.000092572765,"about_ca_topic_score_gemma":0.00007276868,"teacher_disagreement_score":0.070042536,"about_ca_system_score_codex":0.0011885012,"about_ca_system_score_gemma":0.0018415246,"threshold_uncertainty_score":0.5925087},"labels":[],"label_agreement":null},{"id":"W4416426245","doi":"10.1016/j.jtct.2025.11.026","title":"Impact of Chimeric Antigen Receptor T-Cell Therapy on Health Utilities of Patients Diagnosed with Diffuse Large B-Cell Lymphoma in Canada","year":2025,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Waterloo; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; Toronto General Hospital; Toronto Public Health","funders":"Canadian Institutes of Health Research; Ontario Institute for Cancer Research","keywords":"Chimeric antigen receptor; Lymphoma; Population; Baseline (sea); Cancer; Health care; Clinical trial; Health economics; Disease","score_opus":0.01213776183665281,"score_gpt":0.2695603418211101,"score_spread":0.2574225799844573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416426245","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99579126,0.002338223,0.000056156347,0.00007328875,0.000041444007,0.00091561826,0.00018903583,0.000010291819,0.000584682],"genre_scores_gemma":[0.9633612,0.035688374,0.000027174983,0.00026504468,0.0000074901263,0.000020815336,0.00028583678,0.000024272565,0.00031980412],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99853015,0.00017088346,0.00037913458,0.00024322844,0.00037466295,0.0003019304],"domain_scores_gemma":[0.99931437,0.00013637598,0.00013089787,0.00023077767,0.000083058745,0.00010450698],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017349166,0.00020617826,0.00046617052,0.00023513082,0.000045891713,0.0000066782677,0.00008737992,0.00005355144,0.00031774052],"category_scores_gemma":[0.000001823202,0.00015123285,0.000084515654,0.0003630641,0.000061759856,0.000037544603,0.0000030123217,0.00010969706,6.676925e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019846052,0.007519771,0.79332185,0.000666371,0.00023780794,0.000023859768,0.007492294,0.0000129279615,0.1110323,0.000022462606,0.00013223429,0.05969209],"study_design_scores_gemma":[0.059248168,0.0032142587,0.7042148,0.00023362006,0.000011854707,8.6177994e-7,0.0005939504,0.00006727156,0.23148857,0.000007070086,0.0007546718,0.0001648582],"about_ca_topic_score_codex":0.25170597,"about_ca_topic_score_gemma":0.044447694,"teacher_disagreement_score":0.20725827,"about_ca_system_score_codex":0.00019888581,"about_ca_system_score_gemma":0.0012512266,"threshold_uncertainty_score":0.97298867},"labels":[],"label_agreement":null},{"id":"W4416446307","doi":"10.1093/jimmun/vkaf283.1196","title":"Preclinical development of a single domain mesothelin-specific chimeric antigen receptor (CAR) T cell therapy for ovarian cancer and other solid tumours 3385","year":2025,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"National Research Council Canada","funders":"National Institutes of Health; Multiple Sclerosis Society","keywords":"Chimeric antigen receptor; Ovarian cancer; Antigen; Antibody; T cell; Single-domain antibody; Cancer; Immunotherapy; Adoptive cell transfer","score_opus":0.04909471744990439,"score_gpt":0.3562863423110805,"score_spread":0.30719162486117607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416446307","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9652696,0.028952891,0.0013188252,0.0028348719,0.00040282507,0.0006036394,0.000007280481,0.000007754962,0.0006022741],"genre_scores_gemma":[0.9513876,0.02657621,0.015507454,0.001004319,0.00046092004,0.00004494323,0.0000034395953,0.000086530104,0.0049286145],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998301,0.0002697949,0.0007725239,0.0001457354,0.00020438257,0.0003065129],"domain_scores_gemma":[0.9984423,0.0005298654,0.0004215936,0.0002776901,0.00027308508,0.000055447494],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0016958347,0.00015910876,0.000587856,0.00022727209,0.00010838768,0.0000110832025,0.00030168128,0.00013247189,0.0008526131],"category_scores_gemma":[0.00005220936,0.00009968175,0.00014676878,0.00020796752,0.00034377878,0.000029996905,0.00006222333,0.00039478057,0.0000034826212],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0088287955,0.0003695702,0.001883332,0.000027160615,0.0007323425,0.0000017854935,0.0023317002,0.0000026595976,0.91508555,0.000046428337,0.00076800317,0.06992265],"study_design_scores_gemma":[0.008493731,0.001977136,0.017980319,0.00024722682,0.0000688582,0.000088697314,0.0013272088,0.0000065905547,0.71502906,0.00038147144,0.25426883,0.00013084422],"about_ca_topic_score_codex":0.0000268732,"about_ca_topic_score_gemma":0.00001027692,"teacher_disagreement_score":0.25350082,"about_ca_system_score_codex":0.000120052355,"about_ca_system_score_gemma":0.0005968459,"threshold_uncertainty_score":0.93355155},"labels":[],"label_agreement":null},{"id":"W4416446808","doi":"10.1093/jimmun/vkaf283.1249","title":"Development and preclinical validation of a therapeutic γδ TCR-engineered cell product for pan-cancer targeting 3442","year":2025,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network","funders":"Canadian Institutes of Health Research","keywords":"T-cell receptor; Chimeric antigen receptor; Antigen; Population; T cell; Adoptive cell transfer; CRISPR; Cell","score_opus":0.05388783730068482,"score_gpt":0.3671076135907055,"score_spread":0.3132197762900207,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416446808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9769889,0.017774148,0.0014757228,0.0028514857,0.00026324613,0.00044647622,9.536587e-7,0.000004966957,0.00019411487],"genre_scores_gemma":[0.9935539,0.0019321146,0.0023280275,0.00007754467,0.000101894104,0.000013946539,0.0000018742729,0.00001209847,0.0019786193],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99893886,0.00014541215,0.000529603,0.00008241611,0.00013736186,0.0001663351],"domain_scores_gemma":[0.9987298,0.0005289813,0.0002425974,0.00014646108,0.00033195363,0.000020165082],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017331078,0.000083018494,0.0003211432,0.00013489996,0.000052550993,0.0000055264863,0.0001398639,0.00006292332,0.00011924744],"category_scores_gemma":[0.0002475563,0.000051662566,0.00006617994,0.00013731795,0.000104465755,0.00003289752,0.00004334323,0.00031430798,8.248867e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027540668,0.000120972894,0.0007928169,0.00013207387,0.00055673125,0.0000012584562,0.0011278945,0.000023031329,0.9143375,0.00003380672,0.00017651901,0.079943344],"study_design_scores_gemma":[0.0028194336,0.0005694738,0.010243248,0.00015754416,0.00019720438,0.00006333022,0.0004678444,0.000077671604,0.9676554,0.0002308672,0.017461078,0.00005689755],"about_ca_topic_score_codex":0.0000054220973,"about_ca_topic_score_gemma":7.064184e-7,"teacher_disagreement_score":0.079886444,"about_ca_system_score_codex":0.00006607458,"about_ca_system_score_gemma":0.0003721704,"threshold_uncertainty_score":0.21067384},"labels":[],"label_agreement":null},{"id":"W4416448454","doi":"10.1093/jimmun/vkaf283.2021","title":"Using oncolytic viruses to exploit endogenous TCR signaling for modulation of CAR T phenotype and function against solid tumors 4322","year":2025,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of British Columbia","funders":"National Institutes of Health","keywords":"Cytotoxic T cell; T-cell receptor; T cell; Granzyme B; Epitope; Phenotype; Vesicular stomatitis virus; Priming (agriculture); Interleukin 21","score_opus":0.09687229563756208,"score_gpt":0.351987154741734,"score_spread":0.25511485910417186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416448454","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9859293,0.0014540348,0.011574696,0.00024038945,0.00021244705,0.00039018723,0.0000012873156,0.0000053342333,0.00019230276],"genre_scores_gemma":[0.99869245,0.00015907912,0.00061390636,0.0002707817,0.00011042703,0.0000033595877,8.91297e-7,0.000015000023,0.00013408964],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990676,0.00012503297,0.00041456445,0.00007447219,0.00014438634,0.00017396073],"domain_scores_gemma":[0.9989572,0.00032019932,0.00022380278,0.0001561551,0.00030868358,0.000033933866],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007514094,0.000085798274,0.00034609853,0.00026667627,0.00009450278,0.0000067990973,0.0000974243,0.000060562463,0.00004981158],"category_scores_gemma":[0.00022737474,0.000062630206,0.000074594085,0.00020978153,0.0000860851,0.000055052227,0.000050065068,0.0002055893,9.959024e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005057196,0.00005190364,0.0003809592,0.000040286843,0.00033775528,0.0000048774264,0.00092332193,0.0038842591,0.96589905,0.000042077845,0.000015608835,0.023362728],"study_design_scores_gemma":[0.0068450705,0.0065225735,0.0064937943,0.00074519997,0.0008705372,0.0006203332,0.0041886154,0.0070523815,0.9620148,0.0024460442,0.0020045196,0.00019611267],"about_ca_topic_score_codex":0.00005749504,"about_ca_topic_score_gemma":0.000006044161,"teacher_disagreement_score":0.023166616,"about_ca_system_score_codex":0.0001819557,"about_ca_system_score_gemma":0.00020393891,"threshold_uncertainty_score":0.25539857},"labels":[],"label_agreement":null},{"id":"W4416449055","doi":"10.1093/jimmun/vkaf283.844","title":"Development of human ex vivo expanded Vδ1 γδ T cells armed with CAR as a metabolically fit, off-the-shelf cell therapy for solid tumors 2995","year":2025,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University","funders":"","keywords":"Cytotoxicity; Chimeric antigen receptor; Cytotoxic T cell; Ovarian cancer; Tumor microenvironment; T cell; Antigen; Ex vivo; Cancer cell","score_opus":0.02635398681630415,"score_gpt":0.3300299734459684,"score_spread":0.3036759866296643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416449055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98996615,0.004997465,0.00036167575,0.0018982699,0.000185411,0.00097600155,0.0000033087774,0.000012008896,0.0015997331],"genre_scores_gemma":[0.98320407,0.0019180111,0.0014792389,0.0007679486,0.0001329899,0.00004286792,0.0000027751337,0.000049292055,0.012402818],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976839,0.00031615293,0.000920676,0.00016524196,0.00043760185,0.00047641792],"domain_scores_gemma":[0.9976354,0.0005348886,0.0005645072,0.000552295,0.00063544465,0.000077426186],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017258419,0.00024505405,0.0008714944,0.00030853366,0.00022426505,0.0000165773,0.00071346085,0.00012479107,0.0006045208],"category_scores_gemma":[0.00006402998,0.00012494458,0.00023605023,0.00032152864,0.0004531236,0.000045444016,0.00010061706,0.0006646155,0.0000068093655],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009650526,0.0003905013,0.000057497797,0.00004532278,0.0013845821,0.000017504728,0.00445862,0.000012057234,0.9696285,0.000079592806,0.0006803706,0.013594918],"study_design_scores_gemma":[0.007664895,0.0026211024,0.0017735481,0.00012895759,0.00020297321,0.00023614192,0.0021988768,0.000008937727,0.9456154,0.000276877,0.039155383,0.00011688973],"about_ca_topic_score_codex":0.000040567185,"about_ca_topic_score_gemma":0.000028599829,"teacher_disagreement_score":0.03847501,"about_ca_system_score_codex":0.0001294732,"about_ca_system_score_gemma":0.0012332574,"threshold_uncertainty_score":0.66190785},"labels":[],"label_agreement":null},{"id":"W4416449288","doi":"10.1093/jimmun/vkaf283.736","title":"Engineering Intracellular Signaling Domains to Drive CAR-T Cell Differentiation from Pluripotent Stem Cell 2865","year":2025,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Induced pluripotent stem cell; Chimeric antigen receptor; Progenitor cell; Cellular differentiation; Cell therapy; Stem cell; Signal transduction; Intracellular","score_opus":0.009207760652358715,"score_gpt":0.23789154237939308,"score_spread":0.22868378172703438,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416449288","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97413963,0.0046933834,0.018441515,0.0014822014,0.00061878865,0.00030397312,0.000003413353,0.000017109885,0.0002999883],"genre_scores_gemma":[0.9955761,0.000598601,0.0005278396,0.00015948642,0.00021171915,0.0000039706847,0.0000041106405,0.00002498175,0.002893237],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99849623,0.00022156516,0.0005267509,0.000132783,0.00030104598,0.00032162142],"domain_scores_gemma":[0.9986734,0.00043724524,0.00020468906,0.00036292782,0.00023517682,0.00008657243],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00060711574,0.0001660371,0.0004279066,0.00035105232,0.0000822756,0.000023360213,0.00034878077,0.00012888257,0.00049060857],"category_scores_gemma":[0.000037839654,0.00011733319,0.00016081412,0.00026577179,0.000047706835,0.000047399026,0.00012653637,0.0007956565,0.00003632386],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00095415,0.000112747584,0.00027518778,0.000029908559,0.00038867287,0.000051965206,0.0017819919,0.0016736643,0.9900441,0.000027567461,0.00013783561,0.0045221997],"study_design_scores_gemma":[0.0023340362,0.0005648024,0.0041875127,0.0001773971,0.00029595473,0.000058297424,0.0013256829,0.00072395476,0.9857438,0.00009160868,0.0043903966,0.00010651939],"about_ca_topic_score_codex":0.0000747197,"about_ca_topic_score_gemma":0.0000038056717,"teacher_disagreement_score":0.021436427,"about_ca_system_score_codex":0.00031356484,"about_ca_system_score_gemma":0.00014531001,"threshold_uncertainty_score":0.537182},"labels":[],"label_agreement":null},{"id":"W4416449582","doi":"10.1093/jimmun/vkaf283.545","title":"Highly efficient engineering of human immune cells and hematopoietic stem and progenitor cells using microfluidic transfection 2651","year":2025,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Stemcell Technologies","funders":"","keywords":"Transfection; Haematopoiesis; Electroporation; Stem cell; Nucleofection; Progenitor cell; Cytotoxic T cell","score_opus":0.013274604470746807,"score_gpt":0.2679398683414312,"score_spread":0.2546652638706844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416449582","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96971625,0.028839806,0.0006762933,0.00017580237,0.00028464413,0.00027689643,0.0000010639284,0.000006925628,0.000022322913],"genre_scores_gemma":[0.99755245,0.0020917323,0.000072369854,0.000010159534,0.000039684295,0.0000011318507,1.9347033e-7,0.000014957746,0.0002173004],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989958,0.00013550004,0.00045942032,0.00008259629,0.00013819466,0.00018850098],"domain_scores_gemma":[0.99936783,0.00015533039,0.00013373344,0.00017148288,0.00013684735,0.000034797697],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00072051265,0.000114200615,0.00040240624,0.0003018044,0.00007878452,0.000009430535,0.00010451071,0.00008951761,0.000027083597],"category_scores_gemma":[0.000008611922,0.00008088586,0.00008101407,0.00019313455,0.0001917487,0.000024241719,0.000046141067,0.0003764814,5.445425e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005021186,0.000084453735,0.000071743234,0.00021769301,0.0003262691,0.000011242127,0.001100762,0.000053863892,0.9958851,0.000028888924,0.000009019004,0.0017088498],"study_design_scores_gemma":[0.0017576327,0.0007497685,0.0010614708,0.0003191175,0.00022883252,0.0007682706,0.00062209077,0.00019784682,0.9940299,0.000009882797,0.00020176166,0.00005343081],"about_ca_topic_score_codex":0.000035884586,"about_ca_topic_score_gemma":3.4395399e-7,"teacher_disagreement_score":0.027836226,"about_ca_system_score_codex":0.00007795332,"about_ca_system_score_gemma":0.000075501135,"threshold_uncertainty_score":0.32984298},"labels":[],"label_agreement":null},{"id":"W4416548268","doi":"10.1158/2326-6066.cir-25-0445","title":"Phenotypic Characterization and Prognostic Impact of CD103+ Tissue-Resident Memory T Cells in Diffuse Large B-cell Lymphoma","year":2025,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Victoria; Canada's Michael Smith Genome Sciences Centre; Spinal Cord Injury BC; University of British Columbia; Terry Fox Research Institute; BC Cancer Agency","funders":"BC Cancer Foundation; Canada Research Chairs; Canadian Cancer Society; Michael Smith Health Research BC; Terry Fox Research Institute; Canadian Institutes of Health Research; Cancer Research Society","keywords":"Flow cytometry; Lymph node; Phenotype; Lymphoma; Cytotoxic T cell; Population; Immunophenotyping; Diffuse large B-cell lymphoma; T cell; Transcriptome","score_opus":0.02971413439104169,"score_gpt":0.38436654717757895,"score_spread":0.35465241278653725,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416548268","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99011844,0.0065560495,0.00003166673,0.00048103655,0.00014696314,0.00145102,0.000044259403,0.000024418305,0.0011461505],"genre_scores_gemma":[0.9706055,0.005098554,0.000011670334,0.000041115083,0.00005709829,0.00027808113,0.000047139645,0.00003340253,0.02382742],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9974026,0.0004997236,0.0004012155,0.0004548687,0.0004179448,0.0008236348],"domain_scores_gemma":[0.9984474,0.00038645967,0.00006915244,0.0005606918,0.00043073163,0.00010555314],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010535344,0.0001849098,0.00050864316,0.001073857,0.00010363147,0.000029533656,0.00026558666,0.0002479786,0.0013355372],"category_scores_gemma":[0.00022881932,0.00016399051,0.00007446022,0.0011594567,0.00051331084,0.00009023839,0.00032205632,0.00057784264,0.00003094403],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019078226,0.0014737098,0.06697901,0.0003395458,0.00016779611,0.000052601696,0.0008026561,0.0000010172265,0.88812965,0.00004125688,0.00022619416,0.039878722],"study_design_scores_gemma":[0.013461799,0.0007345654,0.6317052,0.00030882403,0.000027266091,0.0000090911,0.00023679472,0.00015743481,0.35148665,0.000060139595,0.0016981811,0.0001140084],"about_ca_topic_score_codex":0.0017669401,"about_ca_topic_score_gemma":0.0001253289,"teacher_disagreement_score":0.56472623,"about_ca_system_score_codex":0.00075152674,"about_ca_system_score_gemma":0.0013074725,"threshold_uncertainty_score":0.9995774},"labels":[],"label_agreement":null},{"id":"W4416734638","doi":"10.1002/hem3.70248","title":"Patterns and safety of glucocorticosteroid use following CD19 CAR‐T therapy for large B‐cell lymphoma","year":2025,"lang":"en","type":"article","venue":"HemaSphere","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"National Cancer Institute; National Institutes of Health; Memorial Sloan-Kettering Cancer Center","keywords":"Corticosteroid; Hazard ratio; Cumulative dose; Lymphoma; Cytokine release syndrome; Cumulative incidence; Toxicity; Methylprednisolone; Prednisone","score_opus":0.022807049954925034,"score_gpt":0.3072871860336976,"score_spread":0.28448013607877254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416734638","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99239045,0.0020791646,0.0016611203,0.00029159457,0.00014902146,0.001400635,0.000051177514,0.000041926236,0.0019348842],"genre_scores_gemma":[0.9787595,0.000744447,0.0005361276,0.00057975645,0.00006007864,0.00008573463,0.00003419461,0.000043677956,0.019156458],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99863756,0.000049909555,0.00034242903,0.00033021963,0.00025239165,0.00038749445],"domain_scores_gemma":[0.99892724,0.000320116,0.00006408227,0.0004641994,0.000111330286,0.000113028495],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026539413,0.00018185443,0.0004463566,0.00006834121,0.000082735416,0.000030608946,0.00009851616,0.00012624239,0.00059562945],"category_scores_gemma":[0.00006904041,0.00015748637,0.00023995784,0.00018588961,0.000026124735,0.00008601666,0.00007382853,0.000096994,0.0000033705448],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00477338,0.0012367312,0.4539907,0.0012398625,0.0006027192,0.00007349811,0.0009916716,0.0000010813415,0.43312243,0.0004764192,0.001850701,0.10164081],"study_design_scores_gemma":[0.071683735,0.0015449502,0.2364938,0.0011607952,0.00029300965,0.0000343148,0.0019567122,0.0005905639,0.4764916,0.00030397705,0.20890315,0.00054341246],"about_ca_topic_score_codex":0.00015576184,"about_ca_topic_score_gemma":0.00010448846,"teacher_disagreement_score":0.21749689,"about_ca_system_score_codex":0.00008571297,"about_ca_system_score_gemma":0.00015320543,"threshold_uncertainty_score":0.6521725},"labels":[],"label_agreement":null},{"id":"W4416808330","doi":"10.1002/acr2.70139","title":"A Guide for Initiating and Managing Chimeric Antigen Receptor T Cell Therapy Clinical Trials in Autoimmune Rheumatic Diseases","year":2025,"lang":"en","type":"article","venue":"ACR Open Rheumatology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Clinical trial; Chimeric antigen receptor; Autoimmunity; Translational research; Immune system; Cell therapy; Rheumatology","score_opus":0.128755947908628,"score_gpt":0.4867129642659138,"score_spread":0.35795701635728583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416808330","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9717092,0.010329486,0.00055287516,0.005208746,0.00052962796,0.005108649,0.000019413063,0.00007032568,0.0064717126],"genre_scores_gemma":[0.9322717,0.049939167,0.0076974747,0.0018649972,0.00004145037,0.0011232881,0.00014514283,0.00009665559,0.0068201064],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9950468,0.0016238902,0.0020370525,0.0005977324,0.00015824518,0.0005362951],"domain_scores_gemma":[0.991472,0.00729953,0.00041335943,0.00057560555,0.00010348191,0.000136033],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0073700054,0.00024795407,0.0021622072,0.0003671009,0.00015921173,0.00011529195,0.0004894618,0.00019513145,0.000979563],"category_scores_gemma":[0.0051284158,0.00021019894,0.00023628109,0.0004443,0.00021544183,0.00014648895,0.00040614486,0.0003446976,0.000022291231],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003976604,0.0006930215,0.28224805,0.0007347198,0.00065317156,0.000024692352,0.001094518,0.0000024120068,0.0061971555,0.0010967144,0.009962533,0.6933164],"study_design_scores_gemma":[0.12970574,0.0038538068,0.52452,0.0066443747,0.00044496742,0.00028353787,0.009389348,0.013635143,0.0054518874,0.012433821,0.29177594,0.0018614398],"about_ca_topic_score_codex":0.00089510565,"about_ca_topic_score_gemma":0.000046198194,"teacher_disagreement_score":0.69145495,"about_ca_system_score_codex":0.000066081215,"about_ca_system_score_gemma":0.0005648436,"threshold_uncertainty_score":0.99993366},"labels":[],"label_agreement":null},{"id":"W4416910450","doi":"10.1136/jitc-2025-013420","title":"The science of tumor-infiltrating lymphocytes (TIL): perspectives from the SITC Surgery Committee","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"School of Medicine, Emory University; National Cancer Institute; National Institutes of Health; University of Connecticut Health Center; Society for Immunotherapy of Cancer; Ohio State University; University of Pittsburgh; Emory University; Massachusetts General Hospital","keywords":"Tumor-infiltrating lymphocytes; T cell; Immunotherapy; Cancer; Immune system; Immune checkpoint; Adoptive cell transfer; Blockade; Clinical trial","score_opus":0.027962384859575633,"score_gpt":0.3661467783282843,"score_spread":0.33818439346870866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416910450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.90732557,0.07966732,0.00012990828,0.010148488,0.0008324601,0.0005173015,0.0000249506,0.000010619918,0.0013433554],"genre_scores_gemma":[0.9787475,0.016766457,0.00029829287,0.00062949985,0.00043953696,0.000049830036,8.751475e-7,0.000028953895,0.0030390578],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99815995,0.00009738576,0.0005555504,0.00016509171,0.00068152585,0.00034047893],"domain_scores_gemma":[0.9950985,0.0030844575,0.00039729616,0.0004459791,0.0009263206,0.00004747058],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0023141254,0.000137779,0.00041008342,0.00015563412,0.00075172074,0.0001049403,0.00053973903,0.00003664606,0.00044325014],"category_scores_gemma":[0.00049020903,0.00007377641,0.00039259237,0.00058858737,0.0011804077,0.000121788995,0.000037006554,0.00031494536,4.4181965e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003302473,0.00008402943,0.010541046,0.000029428918,0.0005778456,0.0000016738757,0.002781126,0.000024820014,0.79751015,0.00049449527,0.0056549036,0.178998],"study_design_scores_gemma":[0.0045719496,0.00041178684,0.069812514,0.0012822027,0.00011893261,0.00004760367,0.014181727,0.00046150995,0.76905644,0.003205481,0.13664985,0.0002000383],"about_ca_topic_score_codex":0.00068342296,"about_ca_topic_score_gemma":0.00005887805,"teacher_disagreement_score":0.17879796,"about_ca_system_score_codex":0.00042247784,"about_ca_system_score_gemma":0.0023153466,"threshold_uncertainty_score":0.5781704},"labels":[],"label_agreement":null},{"id":"W4416931943","doi":"10.1136/jitc-2025-013518","title":"Enabling access to genetically modified cell therapies through flexible approaches to manufacturing and cost recovery","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"Perelman School of Medicine, University of Pennsylvania; Children's Hospital of Philadelphia; Children's National Hospital; Universitat de Barcelona; University of Pennsylvania; Gilead Sciences; Bristol-Myers Squibb","keywords":"Transformative learning; Genetically modified organism; Cancer immunotherapy; Ethical issues; Bridge (graph theory); Translational research; Genetically engineered; Public funding","score_opus":0.15005957271258458,"score_gpt":0.39586612709767544,"score_spread":0.24580655438509086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416931943","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.91466,0.023053478,0.042800978,0.011199456,0.0006802414,0.0026540873,0.000025266227,0.00003354776,0.0048929485],"genre_scores_gemma":[0.8164891,0.059449248,0.028750198,0.014867945,0.0012281579,0.0010971194,0.000008676399,0.00025364727,0.077855915],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99839646,0.00004571464,0.00047280645,0.0002923322,0.0003588067,0.00043385717],"domain_scores_gemma":[0.99907255,0.00018684402,0.00012124424,0.00030617087,0.0001726229,0.00014054791],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005122369,0.00021558016,0.0005016737,0.00035379597,0.00020029121,0.00021616966,0.00032249655,0.00010534606,0.00053509825],"category_scores_gemma":[0.000025938452,0.00017504282,0.00019848859,0.00026231498,0.0000657745,0.00019739683,0.000076541204,0.00030574022,0.0000012333059],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008984148,0.00011744364,0.00043722396,0.00023893167,0.00058538246,0.0000022683605,0.0013020344,0.0019490303,0.38230735,0.00007966528,0.001736858,0.6022597],"study_design_scores_gemma":[0.0038931854,0.0007285309,0.00366144,0.00039368423,0.000055352095,0.000013165141,0.0002952022,0.000090800946,0.7607763,0.0018345905,0.22806308,0.0001946682],"about_ca_topic_score_codex":0.00015283519,"about_ca_topic_score_gemma":0.000029637245,"teacher_disagreement_score":0.602065,"about_ca_system_score_codex":0.00024016759,"about_ca_system_score_gemma":0.00030428523,"threshold_uncertainty_score":0.7138039},"labels":[],"label_agreement":null},{"id":"W4417001687","doi":"10.1182/blood-2025-62","title":"Fixed treatment duration subcutaneous mosunetuzumab monotherapy in elderly/unfit patients with previously untreated diffuse large B-cell lymphoma: Interim results from the Phase II MorningSun study","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Atlantic Cancer Research Institute","funders":"","keywords":"Chemoimmunotherapy; Interim analysis; Clinical endpoint; Phases of clinical research; Follicular lymphoma; Cohort; Lymphoma; Regimen; Pharmacokinetics","score_opus":0.013817240001792937,"score_gpt":0.2851206098193621,"score_spread":0.27130336981756914,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417001687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9940216,0.0003799589,0.000014036233,0.0003051274,0.000062561754,0.004121486,0.00018728647,0.00010863786,0.0007992862],"genre_scores_gemma":[0.99315995,0.00016369845,0.000051752264,0.00013359498,0.000057209316,0.00028441573,0.0006210462,0.000057242105,0.005471074],"study_design_codex":"nonrandomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99740624,0.00028876588,0.00064080924,0.0006846868,0.00047391292,0.00050559983],"domain_scores_gemma":[0.9983024,0.00029893065,0.00018010665,0.0009444785,0.00016025179,0.000113837465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00023252136,0.00038911615,0.0005492281,0.00018860292,0.00021721967,0.00007704821,0.00023403796,0.00012101784,0.00017940835],"category_scores_gemma":[0.000076772994,0.00024371277,0.000101956626,0.000580527,0.000058555113,0.00007244386,0.00007617151,0.00019353593,0.000014418362],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12673539,0.45534316,0.22045071,0.00005712117,0.0030574773,0.0018460343,0.04727868,0.00001634242,0.026380388,0.0000076773695,0.0005264359,0.11830058],"study_design_scores_gemma":[0.8586064,0.060199,0.0494408,0.00036424526,0.0009743892,0.000023233826,0.0019474176,0.0006046054,0.02372316,0.000025768963,0.0036029883,0.00048798425],"about_ca_topic_score_codex":0.0024975585,"about_ca_topic_score_gemma":0.0022831277,"teacher_disagreement_score":0.731871,"about_ca_system_score_codex":0.00042542786,"about_ca_system_score_gemma":0.00024750974,"threshold_uncertainty_score":0.9938318},"labels":[],"label_agreement":null},{"id":"W4417001848","doi":"10.1182/blood-2025-325","title":"Lipid uptake via FATP2 enhances CAR-t therapy resistance in B-cell acute lymphoblastic leukemia","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Leukemia; Chemotherapy regimen; Acute lymphocytic leukemia; Chemotherapy; Antigen; T-cell leukemia; Perforin; T cell; Immunotherapy","score_opus":0.012976977087274388,"score_gpt":0.28214832654264144,"score_spread":0.269171349455367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417001848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.92931426,0.0046206787,0.00014093569,0.00045786644,0.00024615435,0.00079876254,0.000008780609,0.000098004624,0.06431458],"genre_scores_gemma":[0.9227185,0.0032241335,0.00061903655,0.0006428006,0.0002601846,0.00015445962,0.000016240781,0.000047104542,0.072317496],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99793774,0.00010376508,0.00042106395,0.0005149739,0.00046443954,0.00055800984],"domain_scores_gemma":[0.9987749,0.00026193392,0.00006848624,0.0006476317,0.000116437644,0.0001306151],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00035312396,0.00025711718,0.00051360414,0.00030934723,0.00007736226,0.000040354833,0.00029480786,0.00017289007,0.00077315164],"category_scores_gemma":[0.00007103228,0.00022577804,0.00015197023,0.0008431884,0.00012110234,0.00006873115,0.00006231669,0.0003582161,0.00008704924],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013191943,0.00081239856,0.0037433677,0.00017928932,0.0002933871,0.00022768522,0.00044859573,0.0000024717497,0.9792841,0.000102068305,0.0014966177,0.012090837],"study_design_scores_gemma":[0.020249631,0.00047687502,0.020751288,0.00039436328,0.00016218149,0.000022863242,0.00010469541,0.000074534946,0.8642041,0.0005463367,0.09267859,0.00033455485],"about_ca_topic_score_codex":0.00012526552,"about_ca_topic_score_gemma":0.00038751605,"teacher_disagreement_score":0.11508001,"about_ca_system_score_codex":0.00031661327,"about_ca_system_score_gemma":0.00072153343,"threshold_uncertainty_score":0.92069614},"labels":[],"label_agreement":null},{"id":"W4417002069","doi":"10.1182/blood-2025-2730","title":"Patient journey with axicabtagene ciloleucel for relapsed or refractory large B cell lymphoma in Canada: Manufacturing experience and impact of patient location to treatment centre","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; Hôtel-Dieu de Québec; Hôpital Maisonneuve-Rosemont; Princess Margaret Cancer Centre","funders":"","keywords":"Chimeric antigen receptor; Real world data; Lymphoma; CAR T-cell therapy; Follicular lymphoma; Rituximab; Refractory (planetary science); Apheresis","score_opus":0.01346666025648666,"score_gpt":0.2753726718758079,"score_spread":0.2619060116193212,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417002069","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981139,0.00030955832,0.000033092907,0.000098499375,0.00003117428,0.0011464246,0.000035923305,0.0000066847347,0.00022478736],"genre_scores_gemma":[0.9987487,0.00008613793,0.00025386357,0.000081920436,0.000011355554,0.00010155264,0.000015349471,0.000015956863,0.00068516546],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9989021,0.000033872373,0.00025895413,0.0002547715,0.00024225582,0.0003080931],"domain_scores_gemma":[0.9993231,0.00007586938,0.00007389139,0.0002626157,0.000094553114,0.00016994613],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00005533438,0.00014888734,0.00026934966,0.00014696049,0.000042771713,0.000008738458,0.00004587911,0.000039272098,0.000094428586],"category_scores_gemma":[0.000026190406,0.00009880371,0.00003890908,0.0001822789,0.00001566685,0.00003275424,0.00002986119,0.000048349633,3.7892482e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027456215,0.01978594,0.35032558,0.0012258949,0.0010382178,0.00066992396,0.041327592,0.0005848504,0.19123262,0.000015047224,0.0009709271,0.3653672],"study_design_scores_gemma":[0.0203982,0.005556685,0.11819387,0.00037442017,0.0000877502,0.000015726842,0.0039587594,0.00009505777,0.84710896,0.0000024204073,0.0040409425,0.0001671763],"about_ca_topic_score_codex":0.15006334,"about_ca_topic_score_gemma":0.19343495,"teacher_disagreement_score":0.6558764,"about_ca_system_score_codex":0.0013250281,"about_ca_system_score_gemma":0.0019036012,"threshold_uncertainty_score":0.8555965},"labels":[],"label_agreement":null},{"id":"W4417002179","doi":"10.1182/blood-2025-4419","title":"Consensus on cytokine release syndrome (CRS) monitoring practices: A Delphi approach","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Agfa-Gevaert (Canada)","funders":"","keywords":"Delphi method; Cytokine release syndrome; Delphi; MEDLINE; Patient safety; Chimeric antigen receptor; Grading (engineering); Health care","score_opus":0.062168909495097215,"score_gpt":0.35368419703172876,"score_spread":0.29151528753663153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417002179","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9087038,0.000637774,0.00003484889,0.0013365225,0.00016225474,0.000700562,0.000008431879,0.00014318994,0.088272594],"genre_scores_gemma":[0.9796056,0.0001279839,0.0027226722,0.00021344637,0.00024841222,0.00008834339,0.000013694802,0.000038939947,0.01694091],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983209,0.00010900971,0.00026018254,0.0004277505,0.0004942158,0.000387944],"domain_scores_gemma":[0.9984688,0.0004100652,0.00012475715,0.00067777134,0.00013516331,0.00018343411],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040615426,0.00018334214,0.00033429373,0.00027095745,0.00009862427,0.00004273288,0.00015326744,0.00013218354,0.0002164494],"category_scores_gemma":[0.00096674607,0.0001640423,0.00010860021,0.000528166,0.00007761014,0.000035191173,0.000057328216,0.0005710246,0.00008852402],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059121554,0.013509969,0.059340145,0.0020960828,0.0031324653,0.00818036,0.0010562423,0.00006840705,0.8820441,0.001261918,0.0032807773,0.020117376],"study_design_scores_gemma":[0.07967964,0.0076726065,0.07771299,0.0041688033,0.004284592,0.011563945,0.005907352,0.0011738534,0.58177507,0.0006114649,0.22348592,0.0019637838],"about_ca_topic_score_codex":0.00012463584,"about_ca_topic_score_gemma":0.0000018706256,"teacher_disagreement_score":0.30026904,"about_ca_system_score_codex":0.000090621084,"about_ca_system_score_gemma":0.00026298114,"threshold_uncertainty_score":0.6689451},"labels":[],"label_agreement":null},{"id":"W4417004861","doi":"10.1182/blood-2025-652","title":"γ9δ2 T-cell (γ9δ2TC) activation with ICT01 and azacitidine-venetoclax (Aza-Ven) induces high rates of remission and overall survival in patients with newly diagnosed (ND) acute myeloid leukemia (AML): Results from the phase 1/2 study eviction","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Bone marrow; Immunosurveillance; Cohort; Myeloid leukemia; Interim analysis; Phases of clinical research; Chemotherapy; Dosing; Chemotherapy regimen; Cancer","score_opus":0.01582501349393114,"score_gpt":0.28506090680109153,"score_spread":0.2692358933071604,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417004861","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973867,0.000117351774,0.000012012764,0.00022321589,0.00004640877,0.0018539954,0.00007002617,0.00002727804,0.00026300465],"genre_scores_gemma":[0.9987838,0.0002014532,0.0001237804,0.000056595207,0.00006512652,0.00005546425,0.00023432342,0.000028634651,0.0004507835],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9980631,0.00023000281,0.000398453,0.00051455095,0.0005519122,0.00024201538],"domain_scores_gemma":[0.9984671,0.0006050139,0.00019937995,0.0004309812,0.0002015592,0.0000959853],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040785287,0.0002484677,0.0004322942,0.00018329825,0.00010683762,0.000050000486,0.00011475149,0.00011762009,0.000022390152],"category_scores_gemma":[0.0001360706,0.00015652289,0.000025005815,0.00048350325,0.000106385545,0.00020173928,0.00007752192,0.0003703436,4.4429274e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038671862,0.004045439,0.5457393,0.00011361963,0.0007949795,0.000045040346,0.0038887083,0.000046619694,0.39482534,0.000009182999,0.0001943404,0.011625543],"study_design_scores_gemma":[0.09279776,0.004228128,0.71380204,0.00060691725,0.00031124993,0.0000012175726,0.00068020856,0.000055044417,0.18723246,0.00003509476,0.0000842067,0.0001656745],"about_ca_topic_score_codex":0.004045345,"about_ca_topic_score_gemma":0.00026529198,"teacher_disagreement_score":0.20759289,"about_ca_system_score_codex":0.00016154961,"about_ca_system_score_gemma":0.0003611709,"threshold_uncertainty_score":0.63828176},"labels":[],"label_agreement":null},{"id":"W4417004910","doi":"10.1182/blood-2025-1031","title":"Evidence for pre-existing myeloma cells with a gene expression pattern associated with resistance to BCMA CAR T cells.","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"CD19; Cell culture; Multiple myeloma; Gene expression; Antigen; Annexin A5; Gene; Chimeric antigen receptor","score_opus":0.04496808679528664,"score_gpt":0.3337368869448775,"score_spread":0.2887688001495909,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417004910","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99070287,0.0006652641,0.0039344723,0.0004914587,0.0000628971,0.0020040877,0.000036977468,0.00011493339,0.0019870615],"genre_scores_gemma":[0.94610876,0.00004717632,0.006126968,0.00043970728,0.0001362553,0.00035891458,0.000019227704,0.00006574896,0.046697233],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979889,0.000089589914,0.00026265462,0.00057864335,0.0005624685,0.0005177826],"domain_scores_gemma":[0.99813485,0.0005930353,0.00010707913,0.0005933847,0.00037963077,0.00019202493],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043636697,0.00022915055,0.00038694168,0.00014310014,0.00015456327,0.000054923505,0.00022404606,0.00010681604,0.00009990066],"category_scores_gemma":[0.00028265512,0.00017279673,0.00006993292,0.0005298738,0.000058990317,0.000067529,0.000082023806,0.00023527109,0.0000075812827],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023519457,0.00032686838,0.012796762,0.00038062804,0.00019307916,0.00010739236,0.00060269004,0.000020384778,0.979674,0.000001890025,0.0016348242,0.0019095244],"study_design_scores_gemma":[0.0048726965,0.0009611205,0.0116771655,0.005744915,0.00023677111,0.0000052546643,0.000074456686,0.00005189306,0.9746357,0.000009474719,0.001520326,0.00021018245],"about_ca_topic_score_codex":0.000042694086,"about_ca_topic_score_gemma":0.00024739737,"teacher_disagreement_score":0.04471017,"about_ca_system_score_codex":0.00014308374,"about_ca_system_score_gemma":0.00029321594,"threshold_uncertainty_score":0.7046446},"labels":[],"label_agreement":null},{"id":"W4417005135","doi":"10.1182/blood-2025-4517","title":"The impact of distance to CAR-T centre on CAR-T delivery and CAR-T outcomes: A single centre retrospective cohort study","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Juravinski Cancer Centre; McMaster University Medical Centre","funders":"","keywords":"Retrospective cohort study; Cohort; Cohort study; Young adult; Systemic therapy; Propensity score matching; Log-rank test","score_opus":0.01285999277351518,"score_gpt":0.3074315453285909,"score_spread":0.2945715525550757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417005135","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9892918,0.00043462642,0.0000039883103,0.0006449555,0.00010442954,0.0023860047,0.0000857597,0.00004280712,0.007005638],"genre_scores_gemma":[0.9885461,0.000074026815,0.000016317641,0.00008256679,0.000056108747,0.000029287483,0.000007993654,0.000031445696,0.011156187],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978677,0.00015156872,0.00033457845,0.0005109644,0.00064562156,0.00048956095],"domain_scores_gemma":[0.998194,0.00033859967,0.00007912863,0.0008255945,0.00035210283,0.00021061112],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00038778211,0.00027037057,0.0006404975,0.00014600951,0.00016800924,0.000053072305,0.00020190711,0.000078755766,0.00014174159],"category_scores_gemma":[0.00036962592,0.00017446314,0.00021223674,0.00053909665,0.000121813166,0.000035688146,0.00014063364,0.00031602348,0.000008440688],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007838725,0.0019632275,0.9798797,0.00003106387,0.0013792971,0.00006798997,0.0018133575,0.0000042606785,0.011662844,0.000055318647,0.0009615442,0.0013975388],"study_design_scores_gemma":[0.004486222,0.0014694027,0.98553437,0.00013775156,0.00033559097,0.000004723784,0.0024480037,0.000012661568,0.004862934,0.000039486717,0.00052078225,0.00014808048],"about_ca_topic_score_codex":0.0016242862,"about_ca_topic_score_gemma":0.0015328372,"teacher_disagreement_score":0.0067999098,"about_ca_system_score_codex":0.0005135434,"about_ca_system_score_gemma":0.0002025557,"threshold_uncertainty_score":0.71144},"labels":[],"label_agreement":null},{"id":"W4417006218","doi":"10.1182/blood-2025-7600","title":"Real-world treatment landscape after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma: An international Study","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Cohort; Multiple myeloma; CAR T-cell therapy; Second line; Overall survival; Second-line therapy; First line therapy","score_opus":0.02281320235758821,"score_gpt":0.32365944172801614,"score_spread":0.3008462393704279,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417006218","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97653925,0.00052085915,6.370218e-7,0.00018820398,0.00021461543,0.0011958705,0.000016709446,0.00006970147,0.021254173],"genre_scores_gemma":[0.977092,0.0009899768,0.00007646516,0.00009906114,0.00021776097,0.0002645232,0.000044146025,0.00003710634,0.021178912],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99836993,0.00015333421,0.0003128306,0.0004717131,0.00037905658,0.00031315105],"domain_scores_gemma":[0.9990018,0.00012970949,0.000045743105,0.0006127772,0.000094007315,0.00011594973],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00025725074,0.0002212101,0.00036368493,0.000544168,0.00004241685,0.000037885995,0.00018927015,0.000084772655,0.0013231995],"category_scores_gemma":[0.000021536029,0.00017871092,0.00010648487,0.00038975014,0.000037441274,0.00007913341,0.000052212545,0.00025467516,0.000034374785],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015879608,0.014146708,0.93479526,0.000014877118,0.00032261436,0.0004969815,0.0013457617,0.0000031393793,0.036592413,0.0000047844205,0.00007569063,0.010613787],"study_design_scores_gemma":[0.032066327,0.0022793266,0.9378508,0.000049723883,0.00007316111,0.0000043576433,0.0005059608,0.000097233096,0.017742055,0.000007961671,0.00917171,0.00015139152],"about_ca_topic_score_codex":0.0009691479,"about_ca_topic_score_gemma":0.002486723,"teacher_disagreement_score":0.030478364,"about_ca_system_score_codex":0.0001911038,"about_ca_system_score_gemma":0.00019172057,"threshold_uncertainty_score":0.99958974},"labels":[],"label_agreement":null},{"id":"W4417006357","doi":"10.1182/blood-2025-5728","title":"Pomalidomide promotes activation induced cell death of pre-activated, memory BCMA CAR-T cells in a model of high, but not low, tumor burden multiple myeloma","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; Spinal Cord Injury BC","funders":"","keywords":"Pomalidomide; Multiple myeloma; Cancer; Flow cytometry; Cancer cell; T cell; Tumor microenvironment; Bortezomib","score_opus":0.024890221459246457,"score_gpt":0.2771451017268084,"score_spread":0.25225488026756193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417006357","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961673,0.00003217087,0.000096713076,0.00015443245,0.000048787635,0.0016884168,0.00004651823,0.000046522582,0.0017191462],"genre_scores_gemma":[0.9955997,0.000015606713,0.0012713603,0.00005548498,0.00006279807,0.00010796934,0.000025466477,0.000049115628,0.0028125388],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99787486,0.00012905966,0.00061999244,0.00044063583,0.0005439543,0.0003915138],"domain_scores_gemma":[0.9984379,0.00031336586,0.00023387141,0.0006196441,0.0002898818,0.00010537284],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036406127,0.0002529201,0.0006854282,0.00052746054,0.00003402729,0.000012201598,0.00024164791,0.0001944672,0.000105408144],"category_scores_gemma":[0.00026827276,0.00024266384,0.00013947008,0.0005224788,0.00007102071,0.00011497812,0.00013430936,0.00041350414,0.0000034741045],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025988417,0.0015229164,0.0019874508,0.000838408,0.0001526552,0.000023763481,0.0009125248,0.0006338719,0.9902077,0.000020172178,0.000011240654,0.0010904896],"study_design_scores_gemma":[0.011345712,0.00038260067,0.011010267,0.0004900893,0.00010407386,0.0000046884443,0.00022399393,0.00758284,0.96858305,0.00010232717,0.000004355845,0.00016603434],"about_ca_topic_score_codex":0.003320921,"about_ca_topic_score_gemma":0.00003505524,"teacher_disagreement_score":0.021624647,"about_ca_system_score_codex":0.00013256582,"about_ca_system_score_gemma":0.00058254134,"threshold_uncertainty_score":0.9895544},"labels":[],"label_agreement":null},{"id":"W4417009527","doi":"10.1182/blood-2025-4079","title":"Trial in progress: QUINTESSENTIAL—a phase 2 study of arlocabtagene autoleucel (arlo-cel) in patients with relapsed/refractory multiple myeloma (RRMM)","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute of Cancer Research; Juravinski Cancer Centre","funders":"","keywords":"Multiple myeloma; Chimeric antigen receptor; Clinical trial; Phases of clinical research; Carfilzomib; Bortezomib; Antigen; Overall survival","score_opus":0.016579407795935888,"score_gpt":0.3164352646403779,"score_spread":0.29985585684444205,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417009527","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99413544,0.00028828654,0.000005367467,0.000065883134,0.00016936769,0.004634768,0.000012144932,0.000047114696,0.000641656],"genre_scores_gemma":[0.9984102,0.000012291376,0.00012974147,0.000027401473,0.00007332747,0.0003010906,0.000039501574,0.000042889602,0.00096351845],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99729156,0.0002481281,0.0007338684,0.00052791,0.000753327,0.00044522647],"domain_scores_gemma":[0.9986538,0.00017524466,0.00016472103,0.0006852576,0.00020752242,0.00011343805],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004967456,0.00025525497,0.0007016512,0.00073233526,0.000037274967,0.000020737694,0.00023437987,0.0001412879,0.00023028065],"category_scores_gemma":[0.00024109462,0.00021513428,0.000084953106,0.0010201595,0.00013782813,0.00009865181,0.00011732058,0.00051687646,0.0000053975546],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12550978,0.10233653,0.7380933,0.0001964389,0.00040484135,0.000233351,0.0017662214,0.0000053062768,0.010746754,0.000004325544,0.0000809346,0.02062217],"study_design_scores_gemma":[0.7016144,0.018093254,0.26337567,0.0004980147,0.00021485756,0.000001751451,0.00083902176,0.00009290645,0.0146675315,0.000010450313,0.00037014115,0.0002220411],"about_ca_topic_score_codex":0.00032733133,"about_ca_topic_score_gemma":0.0006492464,"teacher_disagreement_score":0.5761046,"about_ca_system_score_codex":0.00012810856,"about_ca_system_score_gemma":0.0003877305,"threshold_uncertainty_score":0.8772921},"labels":[],"label_agreement":null},{"id":"W4417009678","doi":"10.1182/blood-2025-5339","title":"Stepwise engineering of human germinal center B cells to model dark zone high-grade B cell lymphoma driven by sequential BCL2 and MYC deregulation","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Optech (Canada)","funders":"","keywords":"Germinal center; Gene silencing; Lymphoma; Follicular lymphoma; B cell; Gene; Phenotype; Gene rearrangement; B-cell receptor","score_opus":0.011601034071110537,"score_gpt":0.2662502802555481,"score_spread":0.25464924618443757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417009678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958064,0.00016024445,0.0025697523,0.0001891576,0.000056499564,0.00047320724,0.000040237483,0.000036951194,0.00066755054],"genre_scores_gemma":[0.9926689,0.000022208462,0.0018335753,0.000061289065,0.000077355,0.000019053588,0.00004883384,0.000029670593,0.0052391123],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99888045,0.00002566258,0.00025380144,0.00027748305,0.00029419115,0.00026842678],"domain_scores_gemma":[0.9994337,0.00002593298,0.000041442585,0.00028663018,0.00006774396,0.0001445598],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000105666055,0.00015195356,0.00027622553,0.00021008358,0.000044746987,0.000021679612,0.00009729626,0.000093941635,0.00006673165],"category_scores_gemma":[0.0000051304733,0.00015763962,0.00006361172,0.00017826846,0.000033697397,0.000047490405,0.00009418508,0.00009521171,0.0000035930298],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000105825864,0.00074815535,0.0011322626,0.0002479817,0.00009318864,0.00001545964,0.00024168863,0.00047839124,0.9946922,0.000046326244,0.0010063052,0.0011922201],"study_design_scores_gemma":[0.008997939,0.00025482583,0.0032950938,0.0001497596,0.00018571058,0.000010808169,0.00003142284,0.009900659,0.9765407,0.000034838376,0.00044879297,0.0001494803],"about_ca_topic_score_codex":0.000086008484,"about_ca_topic_score_gemma":0.0000075552184,"teacher_disagreement_score":0.018151525,"about_ca_system_score_codex":0.00006417304,"about_ca_system_score_gemma":0.00006863837,"threshold_uncertainty_score":0.64283574},"labels":[],"label_agreement":null},{"id":"W4417009721","doi":"10.1182/blood-2025-5962","title":"Individualizing apheresis processing volumes using a predictive algorithm: Analysis of the CAR T-cell collection protocol utilized in ACIT001/EXC002, a phase lb/ll trial of decentralized production of CAR T-cells for treatment of relapsed/refractory aggressive NHL and ALL","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Foothills Medical Centre; University of Alberta","funders":"","keywords":"Apheresis; Leukapheresis; Blood collection; Plateletpheresis; Data collection; Chimeric antigen receptor","score_opus":0.04184067357787266,"score_gpt":0.3720435590733941,"score_spread":0.33020288549552146,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417009721","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93969727,0.00061212364,0.00021790685,0.000017715927,0.00007372459,0.05921386,0.000108760214,0.000011130986,0.00004749718],"genre_scores_gemma":[0.97868776,0.0002768012,0.002912449,0.000004320011,0.00005161161,0.017508868,0.000031005053,0.00003577167,0.00049139967],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974982,0.0003692779,0.00093850645,0.00043063474,0.0004966219,0.00026672243],"domain_scores_gemma":[0.99761754,0.0002200321,0.0011538488,0.0003637205,0.0005847825,0.00006006844],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000544367,0.00022988975,0.0011476659,0.000847537,0.00007196208,0.000010312085,0.00010902368,0.00017693426,0.000027662809],"category_scores_gemma":[0.00035047813,0.00017551664,0.00036031156,0.0020574864,0.00025103876,0.00008871331,0.00004165915,0.000108115855,1.4273183e-8],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.061379157,0.010768828,0.004474235,0.0016219056,0.0044715707,0.000004028087,0.0067349775,0.00013050865,0.8845173,7.929328e-7,0.000016081922,0.025880605],"study_design_scores_gemma":[0.16174679,0.0036765863,0.00039412043,0.0007819489,0.0075637978,0.0000030273516,0.0011185375,0.011831347,0.8126183,0.000014520671,0.00014843777,0.0001025681],"about_ca_topic_score_codex":0.00049386756,"about_ca_topic_score_gemma":0.0001019018,"teacher_disagreement_score":0.100367635,"about_ca_system_score_codex":0.00022458713,"about_ca_system_score_gemma":0.0008009906,"threshold_uncertainty_score":0.7157361},"labels":[],"label_agreement":null},{"id":"W4417009738","doi":"10.1182/blood-2025-5352","title":"Fixed treatment duration mosunetuzumab continues to demonstrate clinically meaningful outcomes in patients with relapsed/refractory (R/R) follicular lymphoma (FL) after ≥2 prior therapies: 5-year follow-up of a pivotal Phase II study","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Jewish General Hospital; Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Follicular lymphoma; Adverse effect; Tolerability; Dosing; Incidence (geometry); Progressive disease; Phases of clinical research; Lymphoma","score_opus":0.013852790504268511,"score_gpt":0.30590820073459446,"score_spread":0.29205541023032594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417009738","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954867,0.00012842934,0.000014090295,0.00015547706,0.00009999071,0.0036390298,0.00003130492,0.00005091148,0.00039409593],"genre_scores_gemma":[0.99520814,0.000023091441,0.00046461797,0.00010525923,0.000027883485,0.00041569103,0.000030467763,0.000043758755,0.0036810937],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99734443,0.00022164668,0.0008879841,0.0005414454,0.0006294701,0.00037499005],"domain_scores_gemma":[0.99852467,0.00020025567,0.00018880256,0.0006506093,0.00028401503,0.00015162597],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040734076,0.00033055965,0.00086760934,0.00033035286,0.00008046061,0.000031979816,0.00015169456,0.00013179076,0.00017558639],"category_scores_gemma":[0.00020999805,0.00023645611,0.000209204,0.00045952306,0.000077437864,0.000102687794,0.00007675966,0.00014365258,0.000008219728],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024005271,0.029787682,0.90900373,0.00003477488,0.0017532135,0.00010874128,0.005477026,9.1750996e-7,0.0045954213,0.0000045798943,0.000016770584,0.025211869],"study_design_scores_gemma":[0.1879177,0.044910073,0.75988674,0.00025624296,0.000631984,0.0000018401647,0.0012393153,0.000010795878,0.00455756,0.000011833679,0.00033437033,0.00024153624],"about_ca_topic_score_codex":0.00015412213,"about_ca_topic_score_gemma":0.00042148397,"teacher_disagreement_score":0.16391242,"about_ca_system_score_codex":0.00022038948,"about_ca_system_score_gemma":0.00037883534,"threshold_uncertainty_score":0.96424},"labels":[],"label_agreement":null},{"id":"W4417009748","doi":"10.1182/blood-2025-5353","title":"Fixed-duration subcutaneous mosunetuzumab continues to demonstrate high rates of durable responses in patients with relapsed/refractory follicular lymphoma after ≥2 prior therapies: 3-year follow-up from a pivotal Phase II study","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Spinal Cord Injury BC; University of British Columbia; Jewish General Hospital","funders":"","keywords":"Follicular lymphoma; Refractory (planetary science); Dosing; Complete response; Phases of clinical research; Progressive disease; Follicular phase; Lymphoma","score_opus":0.008669991846502094,"score_gpt":0.2697400038793466,"score_spread":0.2610700120328445,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417009748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99625397,0.00047629973,0.000010215051,0.00013814865,0.00011011621,0.0027015642,0.00011177691,0.00005433684,0.00014360041],"genre_scores_gemma":[0.9952738,0.00003114545,0.00031993416,0.00008750123,0.000037926162,0.0002569819,0.00006694504,0.000050735376,0.0038750242],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9974633,0.00031475685,0.0006227124,0.0005578136,0.0006392273,0.00040221302],"domain_scores_gemma":[0.99843496,0.0003105438,0.000148701,0.00063844834,0.00033618623,0.00013113616],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003260136,0.00031056226,0.0006639345,0.00040379915,0.00010665686,0.000051321156,0.00018130594,0.00013925252,0.00038430243],"category_scores_gemma":[0.00023550811,0.00025227413,0.00010696487,0.00065504154,0.00009445592,0.00014048516,0.00008556595,0.00019280461,0.000010398807],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13951607,0.018051282,0.7074319,0.000073731826,0.0014957509,0.0007654167,0.0058516753,0.0000029987377,0.1132653,0.000006766785,0.00011620773,0.013422899],"study_design_scores_gemma":[0.14456281,0.03236981,0.7322958,0.00070463616,0.00061395834,0.000012240209,0.0023500572,0.000020713149,0.08604454,0.000059592425,0.00052038376,0.00044542656],"about_ca_topic_score_codex":0.0008617866,"about_ca_topic_score_gemma":0.00076854747,"teacher_disagreement_score":0.027220756,"about_ca_system_score_codex":0.00014690091,"about_ca_system_score_gemma":0.00040637745,"threshold_uncertainty_score":0.99999297},"labels":[],"label_agreement":null},{"id":"W4417009848","doi":"10.1182/blood-2025-5959","title":"Expanding access to haploidentical transplantation : Clinical feasibility of a centralized nationwide distribution model for fresh TCRα/β-depleted grafts in France","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire Sainte-Justine","funders":"","keywords":"Transplantation; Apheresis; Stem cell; CD19; Hematopoietic stem cell transplantation; Immune system; Interim","score_opus":0.09580000145381803,"score_gpt":0.44903173316484646,"score_spread":0.3532317317110284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417009848","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8999519,0.000049934337,0.097175226,0.0007977736,0.00007597506,0.0016520417,0.0001685683,0.000031308646,0.000097301185],"genre_scores_gemma":[0.9982041,0.000077529,0.0008981322,0.0001449551,0.00003657268,0.00014323286,0.00022020169,0.000011210635,0.00026406086],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99837726,0.00010216877,0.00061482645,0.00033632753,0.00030639413,0.00026303725],"domain_scores_gemma":[0.99899155,0.0003847236,0.000057895086,0.00023919197,0.00021922542,0.000107436004],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080564443,0.00010164167,0.00036043042,0.00014412265,0.000040898452,0.000025927966,0.0001482924,0.00012573515,0.000047622874],"category_scores_gemma":[0.00089076645,0.00010076787,0.00015234337,0.00048653182,0.000057746758,0.000106880485,0.000028485823,0.00018025955,0.0000010051973],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035237742,0.0023115408,0.892685,0.0006868567,0.00011340033,0.000010207237,0.00031107,0.00015226117,0.09718634,0.00053163216,0.0002085428,0.0022793843],"study_design_scores_gemma":[0.021497529,0.00021914615,0.866702,0.00044405082,0.00021788044,0.000003333887,0.000023263616,0.028245332,0.08012203,0.002345009,0.000052522708,0.00012788907],"about_ca_topic_score_codex":0.000058751484,"about_ca_topic_score_gemma":0.00021680849,"teacher_disagreement_score":0.09825224,"about_ca_system_score_codex":0.00007231813,"about_ca_system_score_gemma":0.00018406379,"threshold_uncertainty_score":0.41091946},"labels":[],"label_agreement":null},{"id":"W4417010329","doi":"10.1182/blood-2025-925","title":"Initial results of a CRUK phase I/II, first in human trial of the CAR t-cell engager protein aleta-001 in patients who have received anti-CD19 CAR t-cell therapy for the treatment of b-cell malignancies","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Drug Research and Development","funders":"","keywords":"Tolerability; CD20; CD19; Phases of clinical research; Adverse effect; Refractory (planetary science); Cytokine release syndrome; Antigen; Chimeric antigen receptor","score_opus":0.04077552201564379,"score_gpt":0.3264877264865539,"score_spread":0.2857122044709101,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417010329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9866212,0.00063280755,0.0000012117995,0.00020502435,0.00010187165,0.009993084,0.00037046964,0.000008699722,0.0020656316],"genre_scores_gemma":[0.9916183,0.0005196129,0.000035047928,0.000033156357,0.00008632778,0.00065392215,0.00007428392,0.0000385072,0.006940854],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99713254,0.00044489017,0.0010758421,0.00038378395,0.0005540179,0.0004089367],"domain_scores_gemma":[0.9977138,0.0005819754,0.00041641173,0.00092927454,0.00030346095,0.000055064935],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000873035,0.00030239546,0.00089826854,0.00029714996,0.00014179845,0.0000108315535,0.00036881774,0.00018865927,0.000073520234],"category_scores_gemma":[0.00017259012,0.0001839482,0.00038025685,0.00045117282,0.0002737491,0.000043660275,0.00007329644,0.00028148858,4.8976057e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060293023,0.050808273,0.0036400964,0.00036301423,0.00023927739,0.000010627675,0.008761378,0.000013216309,0.87381184,0.0000057920506,0.0002890534,0.0017643938],"study_design_scores_gemma":[0.3223266,0.0116880005,0.0013543684,0.00024865652,0.0001279124,2.0355574e-7,0.0003885876,0.000022801612,0.6612291,0.000016629958,0.0025000726,0.000097094606],"about_ca_topic_score_codex":0.0013331787,"about_ca_topic_score_gemma":0.00040564727,"teacher_disagreement_score":0.26203358,"about_ca_system_score_codex":0.00011127531,"about_ca_system_score_gemma":0.00033534452,"threshold_uncertainty_score":0.750119},"labels":[],"label_agreement":null},{"id":"W4417011029","doi":"10.1182/blood-2025-269","title":"Safety and efficacy of AZD0120, a BCMA/CD19 dual-targeting CAR T-cell therapy, in relapsed/refractory multiple myeloma: Preliminary Results from the DURGA-1 Phase 1b/2 study","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Multiple myeloma; Clinical trial; Adverse effect; Phases of clinical research; Lenalidomide; Progressive disease; Safety profile","score_opus":0.02062231640243224,"score_gpt":0.30420295861852553,"score_spread":0.2835806422160933,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417011029","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989489,0.0050952532,0.0000031301604,0.00061663636,0.00012334986,0.0025012689,0.00012505511,0.00005816286,0.0019881297],"genre_scores_gemma":[0.99662423,0.0009662846,0.00011676361,0.00012072245,0.00016816509,0.000049740018,0.00009064255,0.000048739224,0.0018146854],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99692875,0.0005616004,0.0008711592,0.00066769554,0.00053169095,0.00043909272],"domain_scores_gemma":[0.9954496,0.003140746,0.00019512343,0.0009456077,0.00014231323,0.00012660393],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014662836,0.00030094857,0.00063449517,0.00021836524,0.00015361737,0.000025780597,0.00025488916,0.00016940341,0.000127417],"category_scores_gemma":[0.0011654687,0.00022095972,0.00013501282,0.0005834772,0.00017917145,0.00005823019,0.00022572718,0.00074753386,0.0000070116953],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07597603,0.043819595,0.10807712,0.00012261319,0.00091173203,0.0006068554,0.022688186,0.000020135092,0.71185845,0.0000048038046,0.0010275368,0.03488696],"study_design_scores_gemma":[0.40401012,0.011054579,0.45158297,0.0005885728,0.0005340716,0.000019994539,0.008428671,0.0004403971,0.11530091,0.000031754622,0.0075273775,0.00048059123],"about_ca_topic_score_codex":0.0013463425,"about_ca_topic_score_gemma":0.00010702818,"teacher_disagreement_score":0.59655756,"about_ca_system_score_codex":0.000066948414,"about_ca_system_score_gemma":0.00025925622,"threshold_uncertainty_score":0.9010476},"labels":[],"label_agreement":null},{"id":"W4417011298","doi":"10.1182/blood-2025-2369","title":"INO-transit: Inotuzumab ozogamicin treatment prior to chimeric antigen receptor T-cell therapy in Relapsed/Refractory B-cell acute lymphoblastic leukemia: Real-world patient characteristics and outcomes in Spain, the UK and US","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Société de Protection des Forêts contre les Insectes et Maladies","funders":"","keywords":"Blinatumomab; Chimeric antigen receptor; Gemtuzumab ozogamicin; Minimal residual disease; Salvage therapy; Acute lymphocytic leukemia; Cytokine release syndrome; Hematopoietic stem cell transplantation","score_opus":0.011148621871947857,"score_gpt":0.2673398979002521,"score_spread":0.2561912760283042,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417011298","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944978,0.0010672869,0.0000041172893,0.00068234245,0.00014115943,0.0021749807,0.000047875103,0.000036963214,0.001347474],"genre_scores_gemma":[0.9839186,0.011054668,0.0001596355,0.00084069173,0.00004769183,0.00014638357,0.000031791373,0.000051510753,0.003748992],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9977281,0.00021517747,0.00058798934,0.000596257,0.00032689143,0.0005455834],"domain_scores_gemma":[0.99863863,0.00042613692,0.00011177113,0.000572244,0.00006464225,0.0001865792],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000287161,0.00040726288,0.0007781313,0.0006114206,0.00010346617,0.00005172118,0.00015735893,0.0001584071,0.00012698978],"category_scores_gemma":[0.000044532102,0.0002839564,0.00009225598,0.00072850374,0.00012920565,0.00004032022,0.00009281337,0.00038563737,0.000013687],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00199737,0.0022939255,0.70779055,0.00010111146,0.00028369523,0.00019290039,0.003855434,0.000005302856,0.22656545,0.000008186931,0.000071240924,0.056834854],"study_design_scores_gemma":[0.022174807,0.0031766517,0.9215983,0.00021793444,0.00017605825,0.00001474178,0.00027786635,0.00006937729,0.04821357,0.0000103945895,0.0037434148,0.00032685956],"about_ca_topic_score_codex":0.0020399024,"about_ca_topic_score_gemma":0.0010670617,"teacher_disagreement_score":0.21380779,"about_ca_system_score_codex":0.00074270274,"about_ca_system_score_gemma":0.00052459294,"threshold_uncertainty_score":0.99996126},"labels":[],"label_agreement":null},{"id":"W4417011616","doi":"10.1182/blood-2025-5807","title":"Trial in progress: A phase 1 study to evaluate the safety and preliminary efficacy of arlocabtagene autoleucel (arlo-cel), a GPRC5D-targeted chimeric antigen receptor (CAR) T cell therapy, in combination with mezigdomide (MEZI) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary","funders":"","keywords":"Chimeric antigen receptor; T cell; Clinical trial; Phases of clinical research; Cytotoxicity; Hematopoietic stem cell transplantation; Antigen; Stem cell","score_opus":0.016471332803316262,"score_gpt":0.3027173890597998,"score_spread":0.2862460562564835,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417011616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9849818,0.0008220645,0.000009004537,0.00023938807,0.00006951997,0.013693961,0.000016497108,0.00003814225,0.00012965231],"genre_scores_gemma":[0.9984964,0.00015270866,0.00029928118,0.0000575273,0.000027407357,0.0006172351,0.000067166446,0.00006219841,0.00022008727],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9960425,0.0009771731,0.0008663608,0.00072086195,0.00088983367,0.0005032898],"domain_scores_gemma":[0.99825495,0.00048082237,0.00021599905,0.0006771697,0.00023943352,0.00013163553],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016150359,0.00038417036,0.0008587226,0.00082739483,0.00008395432,0.00003083022,0.0002862707,0.00012221921,0.000070101996],"category_scores_gemma":[0.00024172322,0.00025607474,0.00006877842,0.0019063413,0.00019019979,0.000121985635,0.00012700749,0.00057539286,0.0000025204884],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4532793,0.058246564,0.40816155,0.00009941815,0.000326558,0.00005584069,0.007947551,0.00006756978,0.02616641,0.0000012518409,0.00001744057,0.045630574],"study_design_scores_gemma":[0.44490728,0.038851548,0.49924603,0.0003836327,0.000112090136,0.0000016343514,0.0008510907,0.00042213761,0.0149330245,0.0000023791058,0.00008374503,0.0002054258],"about_ca_topic_score_codex":0.00041910348,"about_ca_topic_score_gemma":0.00037373995,"teacher_disagreement_score":0.09108449,"about_ca_system_score_codex":0.00020549311,"about_ca_system_score_gemma":0.00050102494,"threshold_uncertainty_score":0.99998915},"labels":[],"label_agreement":null},{"id":"W4417011724","doi":"10.1182/blood-2025-914","title":"Enhanced efficacy of TRAIL or TRAIL-CD28 chimera armored anti-BCMA CAR T cells in multiple myeloma","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Chimeric antigen receptor; Chimera (genetics); CD28; T cell; Multiple myeloma; Immunotherapy; Jurkat cells; Cell culture; Receptor","score_opus":0.025723857366887964,"score_gpt":0.3050658594412568,"score_spread":0.2793420020743688,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417011724","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99221873,0.0003302192,0.00004462091,0.00026436558,0.00013647765,0.0010852573,0.000028314522,0.000062189436,0.0058298125],"genre_scores_gemma":[0.98991627,0.00018334034,0.00049712963,0.00013608043,0.00010852132,0.000046948982,0.000023701698,0.0000393549,0.00904864],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980505,0.00010843586,0.00051610084,0.00043840497,0.00040266383,0.0004838626],"domain_scores_gemma":[0.99871343,0.00040152407,0.00007702371,0.00056662614,0.000102010184,0.00013940538],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003050137,0.00022661845,0.00067577756,0.00038197314,0.00004228019,0.000014560709,0.00023785513,0.00016812666,0.0013280525],"category_scores_gemma":[0.00026187737,0.00019117602,0.00019372298,0.00088262715,0.00014864726,0.000043400978,0.000057938974,0.00038077208,0.000032063974],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013330152,0.002061101,0.0028298695,0.00023798287,0.0002366363,0.00011461987,0.0011584916,0.000008600941,0.9656354,0.000013255288,0.00017904349,0.026191978],"study_design_scores_gemma":[0.020002425,0.00038962855,0.123646714,0.0002483172,0.00011395339,0.00001124246,0.00016648161,0.000102629274,0.8538312,0.000009408604,0.0013340991,0.00014395769],"about_ca_topic_score_codex":0.00012115806,"about_ca_topic_score_gemma":0.00012536548,"teacher_disagreement_score":0.12081684,"about_ca_system_score_codex":0.00004798582,"about_ca_system_score_gemma":0.00036659924,"threshold_uncertainty_score":0.99958485},"labels":[],"label_agreement":null},{"id":"W4417011989","doi":"10.1182/blood-2025-2178","title":"Tumor intrinsic mechanisms leading to cevostamab resistance in multiple myeloma","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Frameshift mutation; Transcriptome; Romidepsin; Multiple myeloma; Exome sequencing; Bone marrow; Exome; Mutation","score_opus":0.02039897027117914,"score_gpt":0.29339179084607436,"score_spread":0.2729928205748952,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417011989","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96970904,0.0005416795,0.00042467855,0.0019036396,0.00014631607,0.0008971521,0.000006408143,0.00009207794,0.02627899],"genre_scores_gemma":[0.96421427,0.000019703879,0.0045217243,0.0009271475,0.000078192905,0.000089128655,0.0000045091606,0.000027258617,0.030118056],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998627,0.000054217002,0.00024882104,0.0003585204,0.0002998032,0.00041162389],"domain_scores_gemma":[0.9991606,0.0001593818,0.000024997422,0.00044579178,0.00007919123,0.00013002135],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003397911,0.00013494359,0.00030910934,0.00042606564,0.000055846005,0.00002646098,0.0001631949,0.00006034292,0.00035914977],"category_scores_gemma":[0.00046159467,0.00013462933,0.0000628484,0.00090361986,0.000029190998,0.000038576585,0.0001078118,0.0002800662,0.00013309724],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010710272,0.0006164791,0.009712164,0.00023336447,0.000090194386,0.00061905617,0.0005110237,0.0000019284757,0.96675617,0.004847397,0.0014491419,0.014092088],"study_design_scores_gemma":[0.012908372,0.00038058046,0.06767484,0.0009617627,0.000076909884,0.000030278235,0.00035165084,0.000031909563,0.8718037,0.003567234,0.041905142,0.00030764434],"about_ca_topic_score_codex":0.00005453825,"about_ca_topic_score_gemma":0.00088190817,"teacher_disagreement_score":0.09495246,"about_ca_system_score_codex":0.00014854355,"about_ca_system_score_gemma":0.00016761674,"threshold_uncertainty_score":0.54900247},"labels":[],"label_agreement":null},{"id":"W4417012274","doi":"10.1182/blood-2025-3735","title":"Fixed-duration intravenous mosunetuzumab plus polatuzumab vedotin combination therapy continues to demonstrate durable responses in patients with large B-cell lymphoma: 3-year follow-up from a Phase Ib/II study","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Saskatchewan Cancer Agency; University of Saskatchewan; McGill University; Jewish General Hospital","funders":"","keywords":"Clinical endpoint; Follicular lymphoma; Refractory (planetary science); Regimen; Phases of clinical research; Salvage therapy; Lymphoma; Combination therapy","score_opus":0.011221494668720168,"score_gpt":0.2776723305511716,"score_spread":0.2664508358824514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417012274","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99420345,0.0002843477,0.00007268785,0.00022074254,0.000157355,0.0037345057,0.00010124832,0.00010285952,0.0011228136],"genre_scores_gemma":[0.9936492,0.000044187647,0.00018981728,0.00018376972,0.00004731155,0.0002039481,0.0002625251,0.000055616038,0.005363636],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9971466,0.00037710078,0.0005725939,0.0006233069,0.0006909392,0.00058945693],"domain_scores_gemma":[0.99851984,0.00021328677,0.00014146067,0.0005968226,0.00036638582,0.0001622129],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005348154,0.00032769766,0.00059775665,0.0005367846,0.00025629438,0.00010205149,0.00022385761,0.00015102814,0.0002065707],"category_scores_gemma":[0.000192365,0.00029083266,0.00008064299,0.0009504276,0.000050281127,0.00016411474,0.00009661626,0.00026470897,0.000023949015],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12420034,0.121953845,0.5925055,0.000097951204,0.0012418005,0.00034502562,0.016701119,0.000007998087,0.101412185,0.00013137975,0.0007315784,0.04067129],"study_design_scores_gemma":[0.4912271,0.020990498,0.41163337,0.0003053591,0.00027178775,0.0000039155825,0.002872377,0.00021589607,0.070672415,0.000117408315,0.001207299,0.0004826005],"about_ca_topic_score_codex":0.0009004711,"about_ca_topic_score_gemma":0.00088701275,"teacher_disagreement_score":0.36702675,"about_ca_system_score_codex":0.000390393,"about_ca_system_score_gemma":0.0007151118,"threshold_uncertainty_score":0.9999544},"labels":[],"label_agreement":null},{"id":"W4417012633","doi":"10.1182/blood-2025-3730","title":"First-line consolidation with cemacabtagene ansegedleucel (cema-cel) in patients with large B-cell lymphoma (LBCL) and minimal residual disease (MRD) after response to standard therapy: The pivotal, randomized, open‑label Phase 2 ALPHA3 study","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Lymphoma; Minimal residual disease; Refractory (planetary science); Aggressive lymphoma; Rituximab; Phases of clinical research","score_opus":0.01633925364020866,"score_gpt":0.31334122923914537,"score_spread":0.2970019755989367,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417012633","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98548096,0.0010414148,0.00006618165,0.0017809926,0.00003736854,0.010900194,0.0004076898,0.000039366743,0.0002458507],"genre_scores_gemma":[0.99453145,0.0001442594,0.000249861,0.00095942,0.000049786904,0.0014440683,0.00008315282,0.00007523786,0.002462757],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9959766,0.0011049965,0.00058235397,0.00080373074,0.0009364865,0.0005957806],"domain_scores_gemma":[0.99741554,0.0008020855,0.00013233507,0.00091927283,0.0003635179,0.00036724214],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024902362,0.0004379218,0.0009298006,0.00039613564,0.00025467906,0.00022394552,0.00033586862,0.00008514284,0.0002941348],"category_scores_gemma":[0.0003223291,0.00026227834,0.000060290316,0.00079594506,0.00026425903,0.00018101858,0.00028820307,0.00024990138,0.0000060043885],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.8773725,0.032055482,0.08497355,0.000078355355,0.0005243323,0.00045838032,0.0017594394,0.0000029012815,0.0010895121,0.000005048044,0.00021347847,0.0014670137],"study_design_scores_gemma":[0.8948574,0.0122529175,0.08591776,0.00029759126,0.00060190907,0.0000067716082,0.00043175774,0.000050674138,0.0036438804,0.00001441034,0.0015905395,0.0003343635],"about_ca_topic_score_codex":0.00009965959,"about_ca_topic_score_gemma":0.00036601015,"teacher_disagreement_score":0.019802563,"about_ca_system_score_codex":0.00011605134,"about_ca_system_score_gemma":0.00073710055,"threshold_uncertainty_score":0.99998295},"labels":[],"label_agreement":null},{"id":"W4417014679","doi":"10.1182/blood-2025-3921","title":"Spatial proteomics of the bone marrow reveals distinct Tumor–Immune niches in smoldering and relapsed myeloma and their remodeling in response to bispecific antibody and CAR-T therapy","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Integrity Testing Laboratory (Canada)","funders":"","keywords":"Multiple myeloma; Bone marrow; Hematologic malignancy; Tumor microenvironment; Immunotherapy; Immunophenotyping; Flow cytometry","score_opus":0.018818863979529792,"score_gpt":0.28286349146779455,"score_spread":0.26404462748826474,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417014679","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931485,0.0037343525,0.000037523158,0.0013771884,0.000034084005,0.0015271034,0.000008381846,0.000013880835,0.000118952354],"genre_scores_gemma":[0.9985113,0.00057840935,0.0003707021,0.00007139804,0.000025119207,0.00004097719,0.000002268728,0.00002623901,0.0003735463],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9984812,0.00029564727,0.00042885225,0.000357861,0.00017116535,0.00026526616],"domain_scores_gemma":[0.9990542,0.00032608752,0.0000711157,0.00043086536,0.000052543575,0.00006520033],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014839617,0.00017876065,0.000469947,0.00031697477,0.00006379713,0.000030166379,0.00010709366,0.00008292764,0.000009896268],"category_scores_gemma":[0.00042299056,0.0001279286,0.000041472875,0.00047879445,0.00014710851,0.00003795861,0.00018603702,0.0003287984,1.3860164e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037769454,0.000116819436,0.22912654,0.000101070196,0.000025109197,0.000023941313,0.0012041286,0.000002416426,0.75894916,0.000006634395,0.0000017421158,0.006665479],"study_design_scores_gemma":[0.0062138527,0.00028921026,0.79367054,0.0008687344,0.0000137337465,0.000059539387,0.0003503747,0.00034553374,0.19778593,0.00020392537,0.000084286556,0.000114335824],"about_ca_topic_score_codex":0.00047764258,"about_ca_topic_score_gemma":0.00027542008,"teacher_disagreement_score":0.564544,"about_ca_system_score_codex":0.00004201356,"about_ca_system_score_gemma":0.00011847137,"threshold_uncertainty_score":0.5216777},"labels":[],"label_agreement":null},{"id":"W4417014962","doi":"10.1182/blood-2025-5505","title":"Late immune effector cell-associated hematotoxicity (ICAHT) in patients with relapsed refractory large B-cell lymphoma receiving anti-CD19 chimeric antigen receptor T-cell therapy","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Cytopenia; Neutropenia; Rituximab; Febrile neutropenia; Lymphoma; Leukopenia; Salvage therapy; Anemia; Refractory (planetary science)","score_opus":0.006640684584130754,"score_gpt":0.23728001324453102,"score_spread":0.23063932866040027,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417014962","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900732,0.0018489915,0.000006484777,0.00007833979,0.00023962927,0.0023240875,0.000051113824,0.00021198724,0.0051661823],"genre_scores_gemma":[0.989285,0.0014007341,0.00015200448,0.00023643275,0.000058623587,0.000086837514,0.00025823902,0.00014431016,0.008377799],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99592215,0.00057944295,0.0007336484,0.00084189343,0.00084519474,0.0010776838],"domain_scores_gemma":[0.9977964,0.0003865144,0.00034729604,0.0009913042,0.00025306822,0.00022540358],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001027698,0.00053960166,0.0010855473,0.0005315188,0.0002143057,0.00006129717,0.00040311,0.0004005752,0.0008165135],"category_scores_gemma":[0.00014524002,0.00045985202,0.00025661805,0.0016332645,0.00010352842,0.00015284766,0.00014848734,0.0007067066,0.00014351681],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013424985,0.018352423,0.44659084,0.00022035874,0.00023854547,0.00004272632,0.00036082556,0.0000010936467,0.5317518,6.576986e-7,0.00035059277,0.00074762694],"study_design_scores_gemma":[0.06961717,0.0013385165,0.5271156,0.0004813363,0.000076935125,0.0000011471333,0.00003980004,0.000027215561,0.3993811,0.0000033167073,0.0015390809,0.0003788254],"about_ca_topic_score_codex":0.0002069275,"about_ca_topic_score_gemma":0.000019320103,"teacher_disagreement_score":0.1323707,"about_ca_system_score_codex":0.00036508398,"about_ca_system_score_gemma":0.00041897962,"threshold_uncertainty_score":0.9997853},"labels":[],"label_agreement":null},{"id":"W4417016543","doi":"10.1182/blood-2025-5524","title":"A first-in-human Phase 1 trial of LY4152199, a B-cell activation factor receptor (BAFF-R) T-cell engager bispecific antibody, in patients with previously treated B-cell malignancies (BAF_FRontier-1 Trial in Progress)","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Lymphoma; Follicular lymphoma; Dosing; Macroglobulinemia; In vivo; Antibody; Waldenstrom macroglobulinemia; Chronic lymphocytic leukemia; Toxicity","score_opus":0.019152295503091648,"score_gpt":0.30541245797784644,"score_spread":0.2862601624747548,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417016543","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885959,0.00031677904,0.000007934139,0.000075394586,0.00017341574,0.008969468,0.00004662863,0.000054446646,0.0017600427],"genre_scores_gemma":[0.99495804,0.00011798174,0.00022072058,0.000016220578,0.00012297012,0.00047849352,0.00030511103,0.00006995521,0.003710534],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9961399,0.00046678042,0.0011206232,0.0007567606,0.00080392504,0.0007120504],"domain_scores_gemma":[0.9983826,0.00022641233,0.00036247453,0.0006758293,0.0002155753,0.00013710004],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000678773,0.0004390757,0.0010839683,0.0013347844,0.000075153825,0.000051865085,0.00028600887,0.00031428676,0.0005390599],"category_scores_gemma":[0.00013964677,0.00037276943,0.0001915553,0.00165367,0.00016893592,0.00019891562,0.00007812075,0.00068281085,0.000007689779],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4685816,0.070693344,0.24770664,0.0009112355,0.00012658648,0.000055339046,0.0016893339,0.0000053135823,0.20770977,0.0000045849138,0.0003436475,0.002172615],"study_design_scores_gemma":[0.73561156,0.010549262,0.012150013,0.0007631242,0.000108434266,3.2553353e-7,0.00014959634,0.000024614008,0.23910409,0.000005791381,0.0012368544,0.00029633206],"about_ca_topic_score_codex":0.0003432296,"about_ca_topic_score_gemma":0.0001924609,"teacher_disagreement_score":0.26702997,"about_ca_system_score_codex":0.00031881707,"about_ca_system_score_gemma":0.00041411974,"threshold_uncertainty_score":0.99987245},"labels":[],"label_agreement":null},{"id":"W4417017123","doi":"10.1182/blood-2025-2719","title":"Prehabilitation prior to CAR T-cell therapy in non-Hodgkin lymphoma: Baseline physical function and toxicity outcomes","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Prehabilitation; Logistic regression; Rehabilitation; Retrospective cohort study; Prospective cohort study; Minimal clinically important difference; Adverse effect","score_opus":0.012517721578787345,"score_gpt":0.3067540450047023,"score_spread":0.294236323425915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417017123","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99550897,0.00015340677,0.00028182968,0.0014227841,0.00007190895,0.001128394,0.0000044548397,0.00003836143,0.001389878],"genre_scores_gemma":[0.9959769,0.000037767764,0.00043235166,0.00063607417,0.00009370547,0.00011172436,0.000008512096,0.000016983324,0.0026859834],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99890965,0.00010228556,0.00019728966,0.00032966243,0.0002451109,0.00021600374],"domain_scores_gemma":[0.9991809,0.00032438265,0.00002269906,0.000290891,0.000086724685,0.000094411575],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00041386014,0.00013735391,0.0002996443,0.00022271513,0.00003978625,0.000018716473,0.000058850346,0.00007264919,0.00007723316],"category_scores_gemma":[0.00016430074,0.000114566225,0.0000739125,0.000409041,0.0000390918,0.000051196253,0.000040037514,0.00011168538,0.0000139139265],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00089593214,0.0027945777,0.17320843,0.00010149856,0.000060456943,0.0000055586706,0.00072185136,0.0000054851157,0.73214394,0.000025998672,0.00014439385,0.089891896],"study_design_scores_gemma":[0.014111023,0.0014546525,0.8160831,0.000058648016,0.000055095796,0.0000017838414,0.00014409809,0.00037242824,0.16651346,0.0002525117,0.0008347548,0.00011848505],"about_ca_topic_score_codex":0.00012655246,"about_ca_topic_score_gemma":0.000039124603,"teacher_disagreement_score":0.64287466,"about_ca_system_score_codex":0.00007942358,"about_ca_system_score_gemma":0.00010640866,"threshold_uncertainty_score":0.46718752},"labels":[],"label_agreement":null},{"id":"W4417017792","doi":"10.1182/blood-2025-133","title":"Efficacy and safety of frail adults treated with ciltacabtagene autoleucel in the real-world: A CIBMTR analysis","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Cytopenia; Comorbidity; Retrospective cohort study; Transplantation; Cohort; Cohort study; Multiple myeloma; Multivariate analysis","score_opus":0.013317002783837507,"score_gpt":0.30222040276787254,"score_spread":0.288903399984035,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417017792","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9740128,0.00031077513,0.000011710901,0.00062554923,0.000004383897,0.00058812543,0.0000110462615,0.000024621286,0.024411023],"genre_scores_gemma":[0.9932822,0.00036250227,0.00013237914,0.00010791343,0.000020838454,0.000029477458,0.00003330469,0.000011277806,0.006020135],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9987741,0.00012980447,0.00027242067,0.00028096398,0.0003246367,0.00021803779],"domain_scores_gemma":[0.99899036,0.00027609142,0.000054647375,0.00053212506,0.00008808428,0.000058692465],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039234894,0.0001307601,0.0004389137,0.00063459703,0.000041389307,0.000013131356,0.0001322397,0.000060095255,0.00030069877],"category_scores_gemma":[0.00005558212,0.0000802558,0.00008299085,0.0031478174,0.000112198584,0.0000202694,0.000038318864,0.00021035761,0.0000017221602],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064440514,0.0018258335,0.9445138,0.00020093052,0.0030889339,0.0001702999,0.0014623633,0.0000190396,0.020740107,0.00018161238,0.00009773884,0.021255318],"study_design_scores_gemma":[0.01472972,0.0003912193,0.9727964,0.00020735971,0.0015959126,0.0000061180162,0.00015705053,0.00017331056,0.0091621885,0.0000082709275,0.0006933306,0.000079139805],"about_ca_topic_score_codex":0.0014849169,"about_ca_topic_score_gemma":0.0023042557,"teacher_disagreement_score":0.028282609,"about_ca_system_score_codex":0.000030949454,"about_ca_system_score_gemma":0.000120272765,"threshold_uncertainty_score":0.32924408},"labels":[],"label_agreement":null},{"id":"W4417017939","doi":"10.1182/blood-2025-803","title":"Deletion of TRAF3 and CYLD and NIK amplification activates NF-kb signalling and drives resistance to T cell based therapies in multiple myeloma by suppressing T cell activity","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"CRISPR; Cas9; Chimeric antigen receptor; T cell; HEK 293 cells; Gene; Genome editing; Multiple myeloma; Cell","score_opus":0.015826011956377666,"score_gpt":0.2684716832338972,"score_spread":0.2526456712775195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417017939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953967,0.0022134297,0.0010136692,0.00050191354,0.000008304522,0.00046936542,0.000013590944,0.000017267828,0.00036580217],"genre_scores_gemma":[0.99752915,0.00032453402,0.0014938854,0.000045247434,0.000012324015,0.000023402028,0.000008651787,0.00001435944,0.0005484654],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99912584,0.00009899096,0.00015987658,0.0002973713,0.00014963018,0.00016829756],"domain_scores_gemma":[0.9992253,0.00044744546,0.000058330155,0.0001516874,0.00005078415,0.00006641517],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024121517,0.00011858081,0.00023041523,0.00017074082,0.00006867781,0.000037092195,0.000044127497,0.00007616446,0.000012760739],"category_scores_gemma":[0.000054372304,0.00011373035,0.000020204496,0.00019200458,0.000097634256,0.000081198006,0.000025603598,0.00014286503,1.5263733e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000678132,0.00033647867,0.041597087,0.00038752015,0.000019118892,0.0000016402108,0.0008961759,0.000004103094,0.94741124,0.0000036473646,0.000024144572,0.008640712],"study_design_scores_gemma":[0.0030616673,0.00011319297,0.08722563,0.0002224879,0.00003091745,7.1240027e-7,0.00024114944,0.00041967013,0.9082854,0.000055161672,0.0002595726,0.00008446539],"about_ca_topic_score_codex":0.00006693287,"about_ca_topic_score_gemma":0.00008744001,"teacher_disagreement_score":0.045628548,"about_ca_system_score_codex":0.00002117045,"about_ca_system_score_gemma":0.000050550327,"threshold_uncertainty_score":0.46377888},"labels":[],"label_agreement":null},{"id":"W4417018394","doi":"10.1182/blood-2025-5918","title":"Lipid nanoparticle-mediated mRNA transfection enables efficient and safe generation of CAR macrophages.","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Transfection; Chimeric antigen receptor; Genetic enhancement; Carcinogenesis; Cytokine; Immune system; Cancer cell; Cancer; Immunotherapy","score_opus":0.01825271170035706,"score_gpt":0.272377285400817,"score_spread":0.25412457370045993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417018394","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962539,0.001216824,0.00011344516,0.00037282886,0.00010942649,0.0004062074,0.00000760922,0.00003037723,0.0014893764],"genre_scores_gemma":[0.9978937,0.00032095183,0.00008251296,0.000065314205,0.000118803626,0.000020237769,0.000016410693,0.000010491895,0.0014715834],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99919724,0.00005885144,0.00019444058,0.00018300602,0.00020068446,0.00016574997],"domain_scores_gemma":[0.99959284,0.000056289435,0.000022197975,0.00016660347,0.00009668231,0.00006537478],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000234283,0.0000822284,0.00018086964,0.00013576733,0.00005367369,0.000012622749,0.000032767344,0.00006587044,0.00025456405],"category_scores_gemma":[0.00006634304,0.00007293428,0.000045038225,0.0003108775,0.00006879567,0.000019642786,0.000014610293,0.00009647356,0.0000057973693],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013520248,0.00043020258,0.0032944134,0.0001337546,0.00009171273,0.000009380919,0.00022651513,0.000043930406,0.98930323,0.000052168405,0.000112023175,0.006167458],"study_design_scores_gemma":[0.0041118315,0.00030381588,0.006944208,0.000051139556,0.00014158059,0.00001517578,0.000040077673,0.0022411083,0.98497653,0.0000064216238,0.0011142008,0.000053897205],"about_ca_topic_score_codex":0.0000814593,"about_ca_topic_score_gemma":0.000025598594,"teacher_disagreement_score":0.0061135604,"about_ca_system_score_codex":0.000027300839,"about_ca_system_score_gemma":0.0000806235,"threshold_uncertainty_score":0.29741734},"labels":[],"label_agreement":null},{"id":"W4417018574","doi":"10.1182/blood-2025-5661","title":"Multiomic correlates of ex vivo αCD19 chimeric antigen receptor T-cell (CART) cytotoxicity in venetoclax-treated patients with chronic lymphocytic leukemia (CLL)","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Concordia University; McGill University","funders":"","keywords":"Cytotoxicity; CD19; Peripheral blood mononuclear cell; Ex vivo; Chronic lymphocytic leukemia; Immune system; Flow cytometry; Immunotherapy; CD20","score_opus":0.007096418163613456,"score_gpt":0.2436032348991928,"score_spread":0.23650681673557936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417018574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99444085,0.00087172864,0.0000072717667,0.000008244976,0.00008379858,0.001510625,0.000032605432,0.00006986057,0.0029750234],"genre_scores_gemma":[0.99590695,0.0003598755,0.00013239526,0.000031858348,0.000042633124,0.00005361086,0.00009595677,0.000051501975,0.003325196],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980221,0.00010881623,0.00045842945,0.00046900215,0.0004397384,0.0005019496],"domain_scores_gemma":[0.99887234,0.0001274118,0.0001442591,0.00056097656,0.00016764953,0.00012735717],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001749797,0.00027876356,0.0005906989,0.0004049934,0.000053239793,0.000016201839,0.00023240177,0.00019169677,0.0008275444],"category_scores_gemma":[0.00005594413,0.00024046104,0.00011232295,0.0010291386,0.000178331,0.000065709515,0.000092910384,0.0003032172,0.00006596724],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009845201,0.000491937,0.5369294,0.00026146212,0.00022718566,0.000020301815,0.0001355587,0.00030923012,0.45963675,0.0000027347985,0.00012762078,0.0008732961],"study_design_scores_gemma":[0.030065136,0.0013105954,0.29971877,0.0006165916,0.00017263091,0.000005564278,0.000034722656,0.0024387124,0.6650935,0.00000592784,0.0003148422,0.00022303048],"about_ca_topic_score_codex":0.0017247429,"about_ca_topic_score_gemma":0.00018217781,"teacher_disagreement_score":0.23721066,"about_ca_system_score_codex":0.0040139793,"about_ca_system_score_gemma":0.0030057833,"threshold_uncertainty_score":0.99980944},"labels":[],"label_agreement":null},{"id":"W4417018940","doi":"10.1182/blood-2025-443","title":"CD19-CAR T cell therapy as a definitive consolidation in older adults with b-ALL in CR1 is safe and induces durable MRD- remission","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Fludarabine; Minimal residual disease; Chimeric antigen receptor; Tolerability; Cohort; Toxicity; Discontinuation; CAR T-cell therapy; Maintenance therapy","score_opus":0.023340242369378365,"score_gpt":0.3057704639602916,"score_spread":0.28243022159091324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417018940","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96541584,0.0013460711,0.0000021983903,0.0012829206,0.000018230056,0.00088647724,0.000004149504,0.00001920861,0.031024912],"genre_scores_gemma":[0.99289423,0.0022277802,0.00015204164,0.0009723409,0.00002141464,0.000064367,0.000019829507,0.00001960095,0.0036283964],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99880147,0.00010016346,0.00022168788,0.0003547056,0.0002543647,0.00026762678],"domain_scores_gemma":[0.99937516,0.00017157031,0.000048885136,0.00022157897,0.00009839054,0.00008443439],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00026707142,0.00014989366,0.00026678538,0.00031984798,0.00003477635,0.000027211818,0.00006650886,0.00013943121,0.0005986475],"category_scores_gemma":[0.000063118445,0.00011876594,0.00002630195,0.00046210198,0.00006828225,0.00007819356,0.000032261378,0.00033084519,0.000012349915],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008051482,0.0038503828,0.28200158,0.0005123462,0.00021564806,0.00043778445,0.018249985,0.000001885824,0.66261446,0.00011655384,0.00071823393,0.02322963],"study_design_scores_gemma":[0.037294537,0.0009639725,0.13988508,0.001788762,0.00004994326,0.000034969846,0.0030509362,0.000044751625,0.8146272,0.00030093003,0.0017370903,0.0002218878],"about_ca_topic_score_codex":0.0006202319,"about_ca_topic_score_gemma":0.0001669213,"teacher_disagreement_score":0.15201266,"about_ca_system_score_codex":0.000052754818,"about_ca_system_score_gemma":0.00025860715,"threshold_uncertainty_score":0.65547705},"labels":[],"label_agreement":null},{"id":"W4417019591","doi":"10.1182/blood-2025-3567","title":"Single-cell metabolic profiling of T cells identifies a fitness signature associated with early CAR T failure in large B cell lymphoma","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada; Princess Margaret Cancer Centre","funders":"","keywords":"Metabolic pathway; Peripheral blood mononuclear cell; Pentose phosphate pathway; Citric acid cycle; Metabolism; T cell; Leukapheresis; Glycolysis; Lymphoma","score_opus":0.010410907551201793,"score_gpt":0.24733133903413448,"score_spread":0.23692043148293268,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417019591","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99161935,0.00239254,0.000019225174,0.000084537925,0.00008135619,0.0008941748,0.000055489512,0.000062212435,0.004791119],"genre_scores_gemma":[0.9857123,0.000044130644,0.0002611998,0.00006527292,0.000044391974,0.000045831057,0.000048800495,0.000048632082,0.013729446],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9979134,0.00016654826,0.00038657288,0.00041810394,0.00057006575,0.00054531224],"domain_scores_gemma":[0.9987922,0.0001896143,0.00014585277,0.0004532468,0.0003230697,0.00009604529],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048389472,0.00024920344,0.00065361935,0.00044385428,0.00005716443,0.000044466862,0.0002314605,0.00025357786,0.00015277148],"category_scores_gemma":[0.00009144351,0.00021200016,0.00014203844,0.0013135675,0.00008801203,0.000090756,0.00009444683,0.00039959283,0.000008196767],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002562693,0.004463262,0.04469784,0.00041291857,0.00024676687,0.0001817687,0.00080581283,0.0000062074687,0.9486363,0.00003339248,0.00010436075,0.00015512205],"study_design_scores_gemma":[0.01763393,0.00027742775,0.012450848,0.00039584603,0.00035917485,0.0000044629296,0.0005422284,0.000035125064,0.967606,0.000031422634,0.000483986,0.00017956912],"about_ca_topic_score_codex":0.00012664901,"about_ca_topic_score_gemma":0.00031354686,"teacher_disagreement_score":0.032246992,"about_ca_system_score_codex":0.00007137907,"about_ca_system_score_gemma":0.0003659109,"threshold_uncertainty_score":0.86451155},"labels":[],"label_agreement":null},{"id":"W4417019669","doi":"10.1182/blood-2025-4596","title":"Real-world incidence and management of non-icans neurologic events following ciltacabtagene autoleucel in multiple myeloma","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis; Innovative Research Group (Canada)","funders":"","keywords":"Incidence (geometry); Multiple myeloma; Lenalidomide; Medical record; Cohort; Retrospective cohort study; Interim analysis; Chart; Medical diagnosis","score_opus":0.02433128109997328,"score_gpt":0.3200725747195481,"score_spread":0.2957412936195748,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417019669","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869422,0.00021383008,0.00003138891,0.00041110095,0.000067521636,0.0006790205,0.0000024429985,0.000028417478,0.011624127],"genre_scores_gemma":[0.99137324,0.00047998264,0.0011223723,0.000142627,0.000016050042,0.000058228772,0.0000047524154,0.0000137154,0.0067890207],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99877,0.000056361598,0.00028417396,0.0003165493,0.00029600845,0.00027692018],"domain_scores_gemma":[0.9993936,0.00011150902,0.00004434793,0.00035426283,0.000031351286,0.000064955995],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003628728,0.00012320624,0.00030669218,0.00032003783,0.00003763487,0.000006990475,0.00014832469,0.00005431342,0.00005449404],"category_scores_gemma":[0.000049631446,0.00011686389,0.000068584246,0.000707823,0.000044580185,0.000038619153,0.00021131786,0.0001840157,0.0000038714397],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023175558,0.0004900385,0.790232,0.00050673814,0.00019287835,0.0006067035,0.00011299063,0.000008576833,0.19744499,0.00005568176,0.00004179404,0.010075824],"study_design_scores_gemma":[0.005533821,0.00018436497,0.9643162,0.00032776606,0.0001315029,0.000005373903,0.000049598366,0.0005809887,0.028395902,0.00008576012,0.00030626412,0.0000824643],"about_ca_topic_score_codex":0.00046567892,"about_ca_topic_score_gemma":0.00030372373,"teacher_disagreement_score":0.17408417,"about_ca_system_score_codex":0.000041854768,"about_ca_system_score_gemma":0.000066322995,"threshold_uncertainty_score":0.4765571},"labels":[],"label_agreement":null},{"id":"W4417020065","doi":"10.1182/blood-2025-2647","title":"Healthcare resource utilization with prophylactic intravenous anakinra following anti-CD19 CAR-T therapy in B-cell lymphoma: A Canadian single-center quality improvement experience.","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Cancer Foundation","funders":"","keywords":"Anakinra; Population; Cytokine release syndrome; Incidence (geometry); Retrospective cohort study; Adverse effect; Quality management","score_opus":0.041472522109953135,"score_gpt":0.3212215139428803,"score_spread":0.2797489918329272,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417020065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927546,0.00067030167,0.000021156855,0.0011335156,0.00009302135,0.0018873453,0.0000096356125,0.0000505628,0.003379873],"genre_scores_gemma":[0.9973362,0.00005961593,0.0000933174,0.0013149309,0.000058638034,0.00016876087,0.000044562345,0.0000422211,0.0008817434],"study_design_codex":"observational","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9976095,0.0001912422,0.00042441158,0.0005534177,0.000514643,0.00070677226],"domain_scores_gemma":[0.99885446,0.00004977836,0.00008445502,0.000582057,0.0001342007,0.0002950593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00039733914,0.00024253142,0.00042498432,0.0004522541,0.00016144494,0.000071413175,0.00017756938,0.00014360978,0.00008264183],"category_scores_gemma":[0.00004802192,0.00020904772,0.0000958357,0.00093281805,0.00007369162,0.00007913228,0.000035711073,0.00022164888,0.000003008318],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015319597,0.008254624,0.4517922,0.00069734507,0.0002654371,0.0008268065,0.012506713,0.0000053658414,0.40790117,0.00006952055,0.000037152004,0.11611169],"study_design_scores_gemma":[0.115114756,0.012185327,0.23740424,0.0015758509,0.0002170839,0.00015578695,0.018168725,0.00019057849,0.58381623,0.00007919959,0.029642355,0.0014498747],"about_ca_topic_score_codex":0.09357223,"about_ca_topic_score_gemma":0.07759377,"teacher_disagreement_score":0.21438798,"about_ca_system_score_codex":0.000835088,"about_ca_system_score_gemma":0.0014210306,"threshold_uncertainty_score":0.9392377},"labels":[],"label_agreement":null},{"id":"W4417021970","doi":"10.1182/blood-2025-4119","title":"Identifying splice variants of cell surface proteins for chimeric antigen receptor T cell therapy of Acute Myeloid Leukemia","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute","funders":"","keywords":"Gene isoform; Alternative splicing; Myeloid leukemia; Transcriptome; Protein isoform; Exon; Intron; Chimeric antigen receptor; RNA splicing","score_opus":0.025361823637314998,"score_gpt":0.3108893188318013,"score_spread":0.28552749519448634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417021970","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98718315,0.0020723238,0.0012260305,0.00009480699,0.00014488447,0.0024010208,0.00007853165,0.000039645245,0.006759629],"genre_scores_gemma":[0.94430065,0.0057151266,0.026248157,0.00009577798,0.000116989526,0.00009373717,0.00005552492,0.0000769146,0.023297137],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983067,0.00007627817,0.00046333135,0.00037869462,0.00038949755,0.0003855008],"domain_scores_gemma":[0.9986789,0.00013898454,0.00020987153,0.0006080864,0.0002720938,0.00009201372],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00047920813,0.00020220975,0.00057189504,0.00017903428,0.00006772396,0.000012672249,0.0003013726,0.0001454942,0.0005261588],"category_scores_gemma":[0.00002776898,0.00018475525,0.00023368513,0.00063915603,0.00009050582,0.00006566244,0.00008005007,0.00021607727,0.000012785585],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00086025044,0.000893412,0.0038911328,0.00063416426,0.0005505676,0.000004672079,0.0005049056,0.000003300095,0.9907766,0.000015220445,0.00044306734,0.0014227347],"study_design_scores_gemma":[0.008123314,0.0006595023,0.0067126467,0.00017128076,0.00017286744,0.0000035875776,0.00010382391,0.000054617136,0.9814745,0.000053141575,0.0023369952,0.00013368287],"about_ca_topic_score_codex":0.00025778063,"about_ca_topic_score_gemma":0.0000045569464,"teacher_disagreement_score":0.04288249,"about_ca_system_score_codex":0.00006419231,"about_ca_system_score_gemma":0.0005974539,"threshold_uncertainty_score":0.75341004},"labels":[],"label_agreement":null},{"id":"W4417034000","doi":"10.15173/m.v1i48.4040","title":"Shifting Gears: CAR NK-Cell Therapy vs. CAR T-cell Therapy","year":2025,"lang":"","type":"article","venue":"The Meducator","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Population health; MEDLINE; Public health; Population; Health care","score_opus":0.033220540556206136,"score_gpt":0.3329429600252085,"score_spread":0.29972241946900235,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417034000","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.80563164,0.118602306,0.000023099388,0.015051536,0.0049899095,0.0042403727,0.000035901918,0.00018664681,0.05123861],"genre_scores_gemma":[0.76220226,0.05770818,0.000100887315,0.007542096,0.003273722,0.0003781143,0.00002924265,0.00031956998,0.1684459],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9904188,0.0018503786,0.0015111208,0.0017464822,0.0017262885,0.0027469667],"domain_scores_gemma":[0.99169296,0.0021557738,0.00046804704,0.004172404,0.0006092385,0.0009015605],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.004413503,0.0013712383,0.0017560316,0.00078248786,0.0011334404,0.0004467735,0.002690145,0.0006993473,0.0233303],"category_scores_gemma":[0.0002990333,0.0009833879,0.0010643374,0.0025140692,0.0012238536,0.00020646123,0.00045316305,0.0031409322,0.0016221817],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004658197,0.0034928818,0.0055169165,0.0006662155,0.0013222336,0.000072365176,0.04137687,0.000011677572,0.79750323,0.00027420762,0.036018893,0.10908634],"study_design_scores_gemma":[0.010758166,0.0015037421,0.001816465,0.0005321958,0.00027852308,0.000024360843,0.013451703,0.00018213535,0.44385228,0.00038760866,0.52628976,0.00092305674],"about_ca_topic_score_codex":0.0013677963,"about_ca_topic_score_gemma":0.000030869207,"teacher_disagreement_score":0.49027085,"about_ca_system_score_codex":0.0010186294,"about_ca_system_score_gemma":0.0053794337,"threshold_uncertainty_score":0.99990386},"labels":[],"label_agreement":null},{"id":"W4417116629","doi":"10.64898/2025.12.01.691479","title":"Cryptic leukemia antigens share homology with microbial epitopes and stimulate T-cell responses in healthy donors","year":2025,"lang":"","type":"article","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Research in Immunology and Cancer; Computer Research Institute of Montréal; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Epitope; T-cell receptor; Antigen; Leukemia; Repertoire; Major histocompatibility complex; Homology (biology); Myeloid leukemia","score_opus":0.014099169579146295,"score_gpt":0.2628099371199695,"score_spread":0.24871076754082316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417116629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9832074,0.011877825,0.000079312675,0.0015801806,0.00067144143,0.0022164392,0.00017117485,0.00014801732,0.000048215858],"genre_scores_gemma":[0.99042594,0.0061635156,0.0011049039,0.0012485449,0.0003180243,0.00011101633,4.6515228e-7,0.00018352941,0.00044405207],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99379593,0.0008783853,0.0011169404,0.0018116338,0.00051507173,0.001882018],"domain_scores_gemma":[0.996037,0.00076411717,0.00030587672,0.0015304853,0.00065984204,0.00070267916],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016193404,0.0008906281,0.0014431328,0.0016464124,0.00041692465,0.00024800998,0.0005460175,0.0007352056,0.0009897719],"category_scores_gemma":[0.00049444655,0.000901134,0.00013816277,0.0027114183,0.0009414168,0.00025088727,0.00035899866,0.0015927218,0.00010755151],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011366981,0.00044575467,0.13426979,0.0015160664,0.00026552015,0.0012650167,0.000080994636,0.00005072304,0.8502634,0.00011316589,0.00033741695,0.00002517807],"study_design_scores_gemma":[0.016951976,0.0031104635,0.5748383,0.0025863242,0.00034969364,6.4912444e-7,0.00005984372,0.00080786203,0.38449684,0.0000014623429,0.015562936,0.0012336532],"about_ca_topic_score_codex":0.0007050702,"about_ca_topic_score_gemma":0.000110547364,"teacher_disagreement_score":0.46576655,"about_ca_system_score_codex":0.001613761,"about_ca_system_score_gemma":0.0060954066,"threshold_uncertainty_score":0.99992347},"labels":[],"label_agreement":null},{"id":"W4417129324","doi":"10.1158/2326-6066.cir-25-0070","title":"A Universal Boosting Strategy for Adoptive T-cell Therapy Using a Paired Vaccine/Chimeric Antigen Receptor","year":2025,"lang":"en","type":"article","venue":"Cancer Immunology Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Ottawa Hospital; McMaster University Medical Centre","funders":"Institute of Cancer Research; Terry Fox Foundation; Canada Research Chairs","keywords":"Boosting (machine learning); Antigen; Chimeric antigen receptor; Adoptive cell transfer; Cytotoxic T cell; Epitope; Immunotherapy; Cancer immunotherapy","score_opus":0.1669757946377332,"score_gpt":0.44288927577131776,"score_spread":0.27591348113358455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417129324","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96825784,0.020806085,0.00048991665,0.0018737466,0.00036515595,0.0027894212,0.000037737736,0.00010247502,0.0052776355],"genre_scores_gemma":[0.93677354,0.012277675,0.0013189516,0.00030262885,0.0004525652,0.0006023048,0.000083836814,0.00013027414,0.048058253],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9966863,0.00054730923,0.00036316048,0.00070667564,0.0004263774,0.0012701993],"domain_scores_gemma":[0.99717945,0.00071314396,0.00008351064,0.00064287527,0.0012467963,0.00013423276],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013301707,0.00026496808,0.0005782261,0.0008939781,0.00054321904,0.000059666185,0.0004705526,0.00032491592,0.002776491],"category_scores_gemma":[0.00019749331,0.00024830727,0.0001960917,0.0017381279,0.00045508295,0.000116997115,0.00022020465,0.0011759585,0.000028572804],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008959454,0.00024202901,0.008065829,0.000102303435,0.0007487063,0.000025312691,0.0005308835,0.000038075494,0.89037526,0.00015581335,0.0043301904,0.08642616],"study_design_scores_gemma":[0.03142487,0.0063185575,0.022767255,0.0008064578,0.00012657871,0.000048695016,0.010912823,0.0059625343,0.6463122,0.00058730075,0.27389824,0.00083446415],"about_ca_topic_score_codex":0.0016015321,"about_ca_topic_score_gemma":0.00004504729,"teacher_disagreement_score":0.26956806,"about_ca_system_score_codex":0.0010429347,"about_ca_system_score_gemma":0.003168024,"threshold_uncertainty_score":0.9999969},"labels":[],"label_agreement":null},{"id":"W4417129956","doi":"10.58931/cht.2025.4378","title":"Practical Management of Aggressive B-Cell Lymphomas with CD20×CD3 Bispecific Antibodies","year":2025,"lang":"","type":"article","venue":"Canadian Hematology Today","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval; Centre hospitalier de l'Université Laval","funders":"Centre Hospitalier Universitaire de Québec; Royal College of Physicians and Surgeons of Canada; Université Laval","keywords":"Chimeric antigen receptor; Lymphoma; Cytokine release syndrome; Bispecific antibody; Blinatumomab; Immunotherapy; Aggressive lymphoma; Antibody","score_opus":0.023746943467071464,"score_gpt":0.3227101856237286,"score_spread":0.29896324215665715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417129956","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.24636526,0.03952887,0.00038127546,0.030794457,0.0021160725,0.0043539964,0.00019306401,0.00008546287,0.67618155],"genre_scores_gemma":[0.8903856,0.0058518383,0.0016034837,0.0009858153,0.000101808124,0.00011683424,0.000054681143,0.00009842192,0.1008015],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9949015,0.0003983452,0.0009948107,0.001152375,0.0006414291,0.0019115687],"domain_scores_gemma":[0.99521327,0.00066555775,0.0006528414,0.0016202866,0.0005921928,0.0012558358],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005983038,0.000652518,0.0015977531,0.0016538082,0.00035409242,0.00006057588,0.00055083726,0.0006537355,0.013036072],"category_scores_gemma":[0.00023106558,0.00060288294,0.00025635646,0.0015595196,0.0019136383,0.00012180258,0.0002014722,0.0008363511,0.00037236977],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00589489,0.0023886615,0.18980613,0.015011109,0.010520357,0.11140203,0.002928428,0.000017059618,0.0028775982,0.35505593,0.27384803,0.030249797],"study_design_scores_gemma":[0.03242429,0.0032580993,0.034765646,0.016648395,0.004707188,0.0072899447,0.024791086,0.0005711749,0.11227702,0.002152853,0.7584899,0.0026244042],"about_ca_topic_score_codex":0.014549318,"about_ca_topic_score_gemma":0.04270713,"teacher_disagreement_score":0.6440204,"about_ca_system_score_codex":0.0012456971,"about_ca_system_score_gemma":0.0064796284,"threshold_uncertainty_score":0.99964225},"labels":[],"label_agreement":null},{"id":"W4417240262","doi":"10.1038/s41409-025-02756-2","title":"Securing raw materials, reagents, and consumable supplies in the academic bioproduction UNITC network: because the chain is only as strong as its weakest link","year":2025,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"Centre hospitalier régional universitaire de Lille","keywords":"Supply chain; Quality assurance; Consumables; Quality (philosophy); Production (economics); Vendor; Work (physics); Bioproduction; Product (mathematics)","score_opus":0.025242305742883667,"score_gpt":0.31009439351359885,"score_spread":0.2848520877707152,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417240262","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9822511,0.0015624282,0.00003875239,0.013220884,0.00021479683,0.0012787465,0.000042491363,0.00004229551,0.0013484836],"genre_scores_gemma":[0.9833648,0.008748208,0.000020669864,0.0007269109,0.00029349021,0.000076452525,0.00031228026,0.000022842678,0.00643432],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9983562,0.00027024123,0.00035915783,0.00032375992,0.0003395568,0.0003510667],"domain_scores_gemma":[0.9993528,0.00019487091,0.00007330214,0.0002777539,0.00005709285,0.000044193755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013218169,0.00017791378,0.00023745697,0.00016448187,0.00023004957,0.00007893893,0.00013075133,0.00015730866,0.0004035032],"category_scores_gemma":[0.000035993304,0.00012555814,0.00003456381,0.00041838162,0.000115849114,0.00013302181,0.00001924929,0.00049514096,0.000025042222],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006379666,0.00011645644,0.011925783,0.0015301631,0.00027872896,0.00023250339,0.016135287,0.00022915972,0.92918885,0.011699519,0.002391221,0.019892648],"study_design_scores_gemma":[0.013383148,0.0006937225,0.25021228,0.0029699898,0.0011663692,0.002585588,0.00609044,0.0008276441,0.68604904,0.0035773753,0.031619713,0.0008247073],"about_ca_topic_score_codex":0.00082781137,"about_ca_topic_score_gemma":0.00048470928,"teacher_disagreement_score":0.24313985,"about_ca_system_score_codex":0.000064688276,"about_ca_system_score_gemma":0.0001495245,"threshold_uncertainty_score":0.51201123},"labels":[],"label_agreement":null},{"id":"W4417314003","doi":"10.64898/2025.12.08.692978","title":"Plasma cell identity escape drives resistance to anti-BCMA T-cell–redirecting therapy in multiple myeloma","year":2025,"lang":"en","type":"preprint","venue":"bioRxiv (Cold Spring Harbor Laboratory)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Multiple myeloma; CD8; Gene; Chimeric antigen receptor; Plasma cell; Immune system; Transcriptome; Antigen; Cell","score_opus":0.022029275944860698,"score_gpt":0.27076268269340675,"score_spread":0.24873340674854605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417314003","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906481,0.0027998248,0.00025196935,0.00050599035,0.0014210345,0.0030818633,0.0001912762,0.0005186881,0.0005812443],"genre_scores_gemma":[0.98848134,0.0022005932,0.0064560384,0.00035985222,0.00063560024,0.0004993305,0.0000011386674,0.00021931069,0.0011467647],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9939478,0.00041043828,0.0010820726,0.0020681033,0.0012009126,0.0012906432],"domain_scores_gemma":[0.9953129,0.00043548283,0.0004068183,0.002402399,0.0008393072,0.0006030684],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016647269,0.000939984,0.0014527689,0.0013485316,0.00026216797,0.00034559966,0.0011171858,0.00086617353,0.00037425465],"category_scores_gemma":[0.0006726425,0.0010504851,0.00038128527,0.0021854239,0.00017044894,0.00025308345,0.0009733813,0.0021654752,0.0001264225],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00068085117,0.00060022704,0.0801619,0.0012997442,0.0001456206,0.00029470355,0.00011635173,0.000085424756,0.91573316,0.000026828062,0.00081894867,0.00003622146],"study_design_scores_gemma":[0.0033183605,0.0001244093,0.15794589,0.0015072967,0.00005634084,2.5847346e-8,0.000026566955,0.00037906776,0.817696,0.0000015263598,0.01811262,0.00083193084],"about_ca_topic_score_codex":0.000280326,"about_ca_topic_score_gemma":0.00018554639,"teacher_disagreement_score":0.09803721,"about_ca_system_score_codex":0.0011239988,"about_ca_system_score_gemma":0.0017301952,"threshold_uncertainty_score":0.99919456},"labels":[],"label_agreement":null},{"id":"W4417329705","doi":"10.18609/cgti.2025.034","title":"CAR-T manufacturing intensification: the next wave of CAR-T commercialization","year":2025,"lang":"en","type":"article","venue":"Cell and Gene Therapy Insights","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Medical Association","funders":"","keywords":"Commercialization; Manufacturing; Manufacturing sector; Advanced manufacturing; Intersection (aeronautics); Health care","score_opus":0.062189352294689616,"score_gpt":0.29876343330783983,"score_spread":0.23657408101315022,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417329705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9782938,0.007884405,0.0002878188,0.0015763782,0.00019292759,0.00058999227,0.0000019257031,0.0000276,0.011145189],"genre_scores_gemma":[0.98250693,0.007920393,0.00006552053,0.0011763504,0.00013299634,0.000022309536,0.000029130682,0.000017174852,0.008129214],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99903935,0.00010230691,0.00025637425,0.0002265474,0.00020875274,0.00016664597],"domain_scores_gemma":[0.9991053,0.00011399509,0.00006823711,0.00046620195,0.00018603627,0.000060232698],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016646092,0.00014573871,0.00026108808,0.00013663045,0.00017004715,0.00003333973,0.00010942974,0.000092366114,0.00029439354],"category_scores_gemma":[0.000009092733,0.00009244479,0.000080545455,0.00021854108,0.00018048697,0.000049173283,0.00004367757,0.00018153961,0.000004522456],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005169902,0.000112498274,0.00049359276,0.0000835738,0.00012701192,0.0000066886632,0.004175512,0.000008012203,0.89864796,0.0004415268,0.0008728716,0.09451378],"study_design_scores_gemma":[0.0013059383,0.00015457539,0.0089077875,0.000038985894,0.00003471294,0.000009499612,0.0006091747,0.0002280545,0.89843845,0.00070424046,0.089481495,0.00008709766],"about_ca_topic_score_codex":0.00013478323,"about_ca_topic_score_gemma":0.000028328328,"teacher_disagreement_score":0.094426684,"about_ca_system_score_codex":0.0000399683,"about_ca_system_score_gemma":0.00008388807,"threshold_uncertainty_score":0.3769789},"labels":[],"label_agreement":null},{"id":"W4417334990","doi":"10.18609/cgti.2025.008","title":"Driving innovation in cell and gene therapy: the role of AI and robotics","year":2025,"lang":"en","type":"article","venue":"Cell and Gene Therapy Insights","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"OmniActive Health Technologies (Canada)","funders":"","keywords":"Robotics; Pharmaceutical industry; Field (mathematics); Robot","score_opus":0.017972079512783453,"score_gpt":0.2777696302803272,"score_spread":0.25979755076754374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417334990","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9555563,0.039965775,0.000110642046,0.00082177133,0.00005695157,0.00057458464,0.0000013710089,0.000015048605,0.0028975664],"genre_scores_gemma":[0.96574754,0.030779622,0.00023393979,0.0008730275,0.00007395213,0.00001702312,0.000009817467,0.000021779222,0.0022433198],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99884045,0.00010667169,0.00034153953,0.00029486424,0.00019693979,0.00021952126],"domain_scores_gemma":[0.9992913,0.00012995284,0.000077274424,0.00030877854,0.0001382227,0.000054481825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033572773,0.0001869078,0.00031653314,0.00031922734,0.00011972118,0.000042277676,0.00009254916,0.00012511661,0.000054527136],"category_scores_gemma":[0.000008474121,0.00012339684,0.000031366148,0.00061968615,0.00019414649,0.000062316285,0.000060018225,0.00029693783,7.8271074e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035694268,0.00015268128,0.020080093,0.000041869367,0.00004676702,0.0000046831083,0.002729525,0.000022692673,0.8954117,0.0003634872,0.00003921077,0.080750406],"study_design_scores_gemma":[0.0038060236,0.0004372071,0.027226739,0.000048790986,0.000015544014,0.000008325798,0.00037041644,0.0011177391,0.9463578,0.0047484203,0.015716977,0.00014603321],"about_ca_topic_score_codex":0.0000837893,"about_ca_topic_score_gemma":0.00003968655,"teacher_disagreement_score":0.080604374,"about_ca_system_score_codex":0.000024301162,"about_ca_system_score_gemma":0.00010415723,"threshold_uncertainty_score":0.5031977},"labels":[],"label_agreement":null},{"id":"W4417360235","doi":"10.1186/s13073-025-01583-w","title":"Delineation and monitoring of the T cell repertoire of adoptive cell transfer product during the treatment of advanced melanoma","year":2025,"lang":"en","type":"article","venue":"Genome Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Public Health Ontario; Ontario Institute for Cancer Research; University of Toronto; University Health Network","funders":"Canada Foundation for Innovation; Princess Margaret Cancer Foundation","keywords":"Repertoire; Peripheral blood mononuclear cell; Adoptive cell transfer; Melanoma; Immunotherapy; T cell; Cancer immunotherapy","score_opus":0.015885862884638263,"score_gpt":0.2818221286523561,"score_spread":0.26593626576771784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417360235","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9841308,0.012216785,0.000038861697,0.0011037249,0.00012600422,0.0010509056,0.00000707154,0.0000069863377,0.0013188891],"genre_scores_gemma":[0.9869722,0.0033958526,0.000105131985,0.000011496426,0.00015656918,0.000029107177,0.000004649684,0.000013331917,0.009311625],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9988609,0.00006377231,0.00039540487,0.00020947469,0.00031901806,0.00015140894],"domain_scores_gemma":[0.9990649,0.00009831404,0.00007945814,0.0004956466,0.00022301266,0.000038653532],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002233826,0.00013057512,0.00040137497,0.00011652903,0.000058962774,0.0000011803727,0.000107156484,0.000037548318,0.00009777271],"category_scores_gemma":[0.000034092987,0.00006512165,0.00007684934,0.00037068478,0.00027314818,0.000018808276,0.000021871821,0.00010160806,2.1198724e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000702016,0.00017955819,0.02484687,0.00050487404,0.00008187119,0.0000025104614,0.0053857113,0.00006646421,0.9471573,0.0000040102104,0.00000311651,0.021065647],"study_design_scores_gemma":[0.0035383012,0.0010611723,0.12386825,0.00023061395,0.00017112299,0.0000044571934,0.0021475712,0.000021098389,0.86725736,0.0000058613105,0.0016542497,0.000039925464],"about_ca_topic_score_codex":0.00011284086,"about_ca_topic_score_gemma":0.0000062705085,"teacher_disagreement_score":0.099021375,"about_ca_system_score_codex":0.000103554106,"about_ca_system_score_gemma":0.000086153035,"threshold_uncertainty_score":0.26555836},"labels":[],"label_agreement":null},{"id":"W4417412714","doi":"10.33540/3350","title":"Empowering CAR T Cell Therapy","year":2025,"lang":"","type":"dissertation","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"Granzyme B; Cytotoxic T cell; T cell; Chimeric antigen receptor; Granzyme; Immune system; Immunotherapy; Effector","score_opus":0.03078821477318786,"score_gpt":0.3795749101656454,"score_spread":0.3487866953924575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417412714","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.29875702,0.016054723,0.00007405001,0.00023792389,0.0054040942,0.0025928027,0.00001807958,0.00014598717,0.6767153],"genre_scores_gemma":[0.1427093,0.03176663,0.00009944384,0.00046262675,0.0007276604,0.00015724832,0.00088294473,0.00015744148,0.82303673],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99467427,0.00021981519,0.0010571216,0.0013356475,0.0014800321,0.0012331173],"domain_scores_gemma":[0.9965471,0.0004545697,0.00023474255,0.0015220064,0.000761627,0.00047995406],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00072846364,0.00097160845,0.001366203,0.0009944153,0.0003067253,0.00017819346,0.000696,0.0011011326,0.15618283],"category_scores_gemma":[0.000095529744,0.0008946841,0.0008078785,0.0011140396,0.00008503711,0.000107623026,0.000092187925,0.001977225,0.00090240344],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0037334769,0.00065814843,0.0007355966,0.0017190414,0.000780386,0.00014479624,0.0052444176,0.000012015026,0.79168403,0.0001315069,0.006361922,0.18879466],"study_design_scores_gemma":[0.005938143,0.0011213897,0.0012378569,0.0009830588,0.00019840914,0.000006472532,0.009673586,0.0004648601,0.65313435,0.000056406378,0.32632953,0.00085595506],"about_ca_topic_score_codex":0.0012150048,"about_ca_topic_score_gemma":0.00020110437,"teacher_disagreement_score":0.3199676,"about_ca_system_score_codex":0.00047900048,"about_ca_system_score_gemma":0.002260987,"threshold_uncertainty_score":0.9998755},"labels":[],"label_agreement":null},{"id":"W4417432359","doi":"10.1080/13696998.2025.2600217","title":"Cost-effectiveness of chimeric antigen receptor T-cell therapy for relapsed or refractory large B-cell lymphoma: a systematic review and meta-analysis","year":2025,"lang":"en","type":"review","venue":"Journal of Medical Economics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Chimeric antigen receptor; Refractory (planetary science); Antibody therapy; Immunotherapy; Salvage therapy; Cell therapy; Safety profile","score_opus":0.12464273081717334,"score_gpt":0.41862964772985595,"score_spread":0.29398691691268264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417432359","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000047787325,0.9913105,0.0003353497,0.0002738021,0.00019218659,0.0074601523,0.00023064927,0.000007813033,0.0001418069],"genre_scores_gemma":[0.000009722615,0.9958249,0.00034651312,0.0005322463,0.00013406937,0.00047905577,0.000085478976,0.00008389057,0.0025041657],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99271446,0.0018937646,0.0036828073,0.0005123682,0.00076641585,0.00043020316],"domain_scores_gemma":[0.9878282,0.006544362,0.0037019248,0.0008422884,0.0004929572,0.00059024635],"candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0147611005,0.0006225117,0.018531851,0.0009625957,0.000060706847,0.0000363834,0.0008039645,0.00072236196,0.0028751655],"category_scores_gemma":[0.00215938,0.00035605903,0.006480167,0.00082224683,0.00014529367,0.000093352275,0.00012379418,0.00082912896,0.000007899725],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052293384,0.001245834,9.3925087e-7,0.84676564,0.12146892,0.000028725637,0.00002429471,2.3171498e-7,0.0000024299763,0.000008619028,0.00073830684,0.029193157],"study_design_scores_gemma":[0.006390558,0.0010415169,5.739735e-7,0.07257721,0.49285993,0.00017289708,0.000027402039,0.000021339574,0.000017613718,0.000006101327,0.42661116,0.0002737211],"about_ca_topic_score_codex":0.000007701538,"about_ca_topic_score_gemma":0.000003496884,"teacher_disagreement_score":0.7741884,"about_ca_system_score_codex":0.00052496046,"about_ca_system_score_gemma":0.004335918,"threshold_uncertainty_score":0.99988914},"labels":[],"label_agreement":null},{"id":"W4417524948","doi":"10.1016/j.cels.2025.101458","title":"Harnessing heterogeneity for the rational design of cell manufacturing","year":2025,"lang":"en","type":"article","venue":"Cell Systems","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"National Research Council Canada; Natural Sciences and Engineering Research Council of Canada; Juvenile Diabetes Research Foundation Canada; Killam Trusts; Canadian Institutes of Health Research; Breakthrough T1D Canada; Sick Kids Foundation; Michael Smith Health Research BC; Stem Cell Network; Hospital for Sick Children; University of British Columbia; Paul G. Allen Frontiers Group; Canada Research Chairs","keywords":"Robustness (evolution); Multicellular organism; Quality by Design; Synthetic biology; Quality (philosophy); Bioprocess; Macro; Systems biology; Rational design","score_opus":0.05901936482559499,"score_gpt":0.3237736670058372,"score_spread":0.2647543021802422,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4417524948","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.4457545,0.0071163843,0.5244386,0.0004476083,0.0015796744,0.005513636,0.000020977828,0.00007406332,0.015054531],"genre_scores_gemma":[0.9723343,0.000039787014,0.0005650176,0.000048563335,0.0001755612,0.00013873805,0.000008582044,0.000016842083,0.026672568],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9990112,0.000098892524,0.00026890432,0.0001812274,0.00024273548,0.00019702836],"domain_scores_gemma":[0.99880576,0.0006332731,0.0000812089,0.00032934154,0.00010686301,0.000043542193],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007013149,0.000099327204,0.0002282795,0.00008062859,0.00012869285,0.000040817296,0.00013906785,0.00006770124,0.00008797999],"category_scores_gemma":[0.00002325502,0.00006821517,0.00010798905,0.000089448215,0.000053152973,0.000028763418,0.000032815504,0.00010913438,0.000008043546],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003420129,0.00009195755,0.00055039604,0.0015128965,0.000087610046,0.000002969134,0.00013833265,0.0035331587,0.9884858,0.00005023825,0.0022798479,0.0029247836],"study_design_scores_gemma":[0.0012132562,0.000071759794,0.00050252175,0.00012685494,0.000057814083,0.0000050128033,0.0002066639,0.018912228,0.96420175,0.000018560591,0.014623184,0.000060377664],"about_ca_topic_score_codex":0.00005301356,"about_ca_topic_score_gemma":0.0000017038858,"teacher_disagreement_score":0.52657986,"about_ca_system_score_codex":0.00008649288,"about_ca_system_score_gemma":0.00016590797,"threshold_uncertainty_score":0.2781734},"labels":[],"label_agreement":null},{"id":"W48601634","doi":"10.1182/blood.v122.21.168.168","title":"Effective Treatment Of Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma With Autologous T Cells Genetically-Engineered To Express An Anti-CD19 Chimeric Antigen Receptor","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; CD19; Antigen; Immunology; Cyclophosphamide; Chimeric antigen receptor; T cell; Internal medicine; Immune system; Chemotherapy","score_opus":0.007627921460208917,"score_gpt":0.2469499303169068,"score_spread":0.23932200885669788,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W48601634","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995311,0.0004849068,0.0002336524,0.00008328966,0.00007366472,0.0030663854,0.000043586042,0.000121090474,0.0005823829],"genre_scores_gemma":[0.9937548,0.00047891086,0.0032469041,0.00012117427,0.00019172873,0.00035269017,0.00003957156,0.00012488467,0.0016893287],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9978492,0.00015380539,0.00030485948,0.0005762617,0.00045400273,0.0006618259],"domain_scores_gemma":[0.9982111,0.0001375831,0.000090604124,0.00086082163,0.00019624557,0.00050363253],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00011301977,0.0003866421,0.0007458694,0.00021374879,0.000061863895,0.000030361922,0.00020612108,0.00017117648,0.0015116751],"category_scores_gemma":[0.0000140019665,0.00028434227,0.00014454538,0.00033704445,0.00010166136,0.000077109675,0.00003800065,0.00010667184,0.0001817103],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005476073,0.026576353,0.0053864503,0.000076930024,0.00043568574,0.00003812104,0.0014547673,0.0000046317014,0.9406276,0.000001415323,0.0001259475,0.024724534],"study_design_scores_gemma":[0.0315844,0.0098839495,0.07051893,0.000048837734,0.00013091261,0.000026699581,0.000090121444,0.00009926903,0.88295436,0.0000020401922,0.004372175,0.00028830036],"about_ca_topic_score_codex":0.00022136167,"about_ca_topic_score_gemma":0.000005499131,"teacher_disagreement_score":0.065132484,"about_ca_system_score_codex":0.00011448019,"about_ca_system_score_gemma":0.00012942075,"threshold_uncertainty_score":0.9999609},"labels":[],"label_agreement":null},{"id":"W52169269","doi":"10.12816/0003105","title":"A New Cellular Weapon to Kill Leukaemic B-Cells = سلاح خلوي جديد لقتل خلايا ( ب ) المسببة لإبيضاض الدم","year":2012,"lang":"ar","type":"article","venue":"Sultan Qaboos University medical journal","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Pathology","score_opus":0.019287422055067893,"score_gpt":0.27191967702565834,"score_spread":0.25263225497059044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W52169269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8609679,0.013082533,0.014225821,0.029544702,0.0149551295,0.002643955,0.00020584356,0.0003747787,0.06399938],"genre_scores_gemma":[0.6802191,0.011376063,0.002059589,0.003232815,0.01883293,0.0000015351284,0.00006913071,0.00029668736,0.28391212],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9872333,0.0013667612,0.0011692178,0.000990867,0.0057133255,0.0035265444],"domain_scores_gemma":[0.9820361,0.00084271363,0.0004758208,0.0011488878,0.0008214218,0.014675034],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.0042356635,0.0009751175,0.001555917,0.0017759658,0.0009895558,0.0001946694,0.0022239862,0.0013067704,0.10588829],"category_scores_gemma":[0.0015934897,0.0009669411,0.00093141355,0.00260519,0.00064828515,0.00082723703,0.0009747799,0.005981712,0.008387568],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009658021,0.0025775568,0.0068882904,0.00044466768,0.002419277,0.019459963,0.01748253,0.00002142504,0.3088555,0.00094193814,0.4069546,0.22429624],"study_design_scores_gemma":[0.015574995,0.0020979242,0.001056471,0.0018332801,0.0009515434,0.0018697361,0.007720757,0.00027774402,0.028007314,0.000071564275,0.9393151,0.0012235718],"about_ca_topic_score_codex":0.00085021014,"about_ca_topic_score_gemma":0.00010022046,"teacher_disagreement_score":0.5323605,"about_ca_system_score_codex":0.003178064,"about_ca_system_score_gemma":0.0054587666,"threshold_uncertainty_score":0.99998975},"labels":[],"label_agreement":null},{"id":"W56457892","doi":"10.1182/blood.v122.21.144.144","title":"Co-Administration Of Gene-Modified CD4+ T Cells Targeting HLA Class I-Restricted WT1 Epitope Diversely Enhances The Antitumor Effect Mediated By Redirected T-Cell Based Adoptive Immunotherapy Against Human Leukemia","year":2013,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research","funders":"","keywords":"CD8; Cytotoxic T cell; Biology; T cell; Immunotherapy; Adoptive cell transfer; Epitope; T-cell receptor; Interleukin 21; Cancer research; Immunology; Molecular biology; Antigen; Immune system; In vitro","score_opus":0.012433194291963979,"score_gpt":0.2701206179103804,"score_spread":0.2576874236184164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W56457892","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9923614,0.0007932254,0.000059152342,0.00013201547,0.00013425623,0.002374634,0.00010668832,0.00015585299,0.003882772],"genre_scores_gemma":[0.99679416,0.0006198038,0.00026438438,0.0001695491,0.00019008877,0.00018587474,0.0008696739,0.00007578058,0.0008306954],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.996617,0.0006482951,0.00070109527,0.0005354892,0.000903567,0.00059455534],"domain_scores_gemma":[0.9974085,0.00087541697,0.000458732,0.0006102546,0.0004523,0.00019481494],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006442379,0.00040532296,0.000688147,0.00020123285,0.00029944745,0.00008617733,0.00042305165,0.00025699846,0.00072056917],"category_scores_gemma":[0.00019145866,0.00029817742,0.00022984175,0.0006510701,0.00035164296,0.00013761099,0.000028996257,0.00057989435,0.000070702525],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00080617826,0.0006818377,0.0012987339,0.000105255094,0.0002626366,0.000043466807,0.00026491584,0.000018558541,0.9926673,0.000001301197,0.0031941158,0.00065566105],"study_design_scores_gemma":[0.010181792,0.0018459272,0.004113636,0.00008985004,0.00011844051,0.0000043667,0.0001389351,0.00089714886,0.9816241,0.0000022579384,0.0007034784,0.00028001424],"about_ca_topic_score_codex":0.00049102056,"about_ca_topic_score_gemma":0.000010144086,"teacher_disagreement_score":0.011043186,"about_ca_system_score_codex":0.00016643485,"about_ca_system_score_gemma":0.00047558692,"threshold_uncertainty_score":0.999947},"labels":[],"label_agreement":null},{"id":"W6893073646","doi":"10.5281/zenodo.14529586","title":"A guide to selecting high-performing antibodies for hnRNP H2 (UniProt ID: P55795) for use in western blot and immunoprecipitation","year":2024,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Neurological Institute and Hospital","funders":"","keywords":"Immunoprecipitation; Western blot; Gene knockdown; Antibody; Blot; Cell culture","score_opus":0.04721923933878736,"score_gpt":0.31920405446804484,"score_spread":0.2719848151292575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6893073646","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96311617,0.0006330491,0.022381436,0.0023448218,0.0002168228,0.0056553725,0.000282507,0.000927695,0.004442129],"genre_scores_gemma":[0.9569195,0.0005325292,0.012242286,0.00037992027,0.0006191555,0.0000062389454,0.0021036381,0.0031501146,0.024046646],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980914,0.00012913646,0.00036199752,0.00055065047,0.00034408376,0.0005227531],"domain_scores_gemma":[0.9986237,0.00022336969,0.000047799127,0.00030849522,0.0006231424,0.0001734907],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014343885,0.00017864136,0.00025667195,0.00070211367,0.000843888,0.00097554235,0.00027747755,0.00007958252,0.0012046446],"category_scores_gemma":[0.0013160661,0.00018245526,0.000057064964,0.0007283171,0.0000785749,0.00047918843,0.00041256577,0.00028244802,0.0003155782],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015393195,0.00015412108,0.00020677259,0.0014940994,0.00016940749,0.00003414658,0.005956893,0.00006461135,0.34531048,0.0011909993,0.029339852,0.6145393],"study_design_scores_gemma":[0.0017794183,0.0012922835,0.0015859485,0.00040293267,0.000038851445,0.00016590144,0.0006469797,0.0044920025,0.0078878235,0.00011124866,0.98136777,0.00022884528],"about_ca_topic_score_codex":0.000120994744,"about_ca_topic_score_gemma":0.0000125606175,"teacher_disagreement_score":0.9520279,"about_ca_system_score_codex":0.00029998348,"about_ca_system_score_gemma":0.000016994716,"threshold_uncertainty_score":0.9997084},"labels":[],"label_agreement":null},{"id":"W6893197593","doi":"10.5281/zenodo.14529585","title":"A guide to selecting high-performing antibodies for hnRNP H2 (UniProt ID: P55795) for use in western blot and immunoprecipitation","year":2024,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Montreal Neurological Institute and Hospital","funders":"","keywords":"Immunoprecipitation; Western blot; Gene knockdown; Antibody; Blot; Cell culture","score_opus":0.04721923933878736,"score_gpt":0.31920405446804484,"score_spread":0.2719848151292575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6893197593","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96311617,0.0006330491,0.022381436,0.0023448218,0.0002168228,0.0056553725,0.000282507,0.000927695,0.004442129],"genre_scores_gemma":[0.9569195,0.0005325292,0.012242286,0.00037992027,0.0006191555,0.0000062389454,0.0021036381,0.0031501146,0.024046646],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9980914,0.00012913646,0.00036199752,0.00055065047,0.00034408376,0.0005227531],"domain_scores_gemma":[0.9986237,0.00022336969,0.000047799127,0.00030849522,0.0006231424,0.0001734907],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014343885,0.00017864136,0.00025667195,0.00070211367,0.000843888,0.00097554235,0.00027747755,0.00007958252,0.0012046446],"category_scores_gemma":[0.0013160661,0.00018245526,0.000057064964,0.0007283171,0.0000785749,0.00047918843,0.00041256577,0.00028244802,0.0003155782],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015393195,0.00015412108,0.00020677259,0.0014940994,0.00016940749,0.00003414658,0.005956893,0.00006461135,0.34531048,0.0011909993,0.029339852,0.6145393],"study_design_scores_gemma":[0.0017794183,0.0012922835,0.0015859485,0.00040293267,0.000038851445,0.00016590144,0.0006469797,0.0044920025,0.0078878235,0.00011124866,0.98136777,0.00022884528],"about_ca_topic_score_codex":0.000120994744,"about_ca_topic_score_gemma":0.0000125606175,"teacher_disagreement_score":0.9520279,"about_ca_system_score_codex":0.00029998348,"about_ca_system_score_gemma":0.000016994716,"threshold_uncertainty_score":0.9997084},"labels":[],"label_agreement":null},{"id":"W6901869847","doi":"10.6084/m9.figshare.13627439","title":"Additional file 1 of Efficacy and safety of CD22 chimeric antigen receptor (CAR) T cell therapy in patients with B cell malignancies: a protocol for a systematic review and meta-analysis","year":2021,"lang":"en","type":"article","venue":"Open MIND","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of Ottawa; Western University; Ottawa Hospital; University of British Columbia","funders":"","keywords":"Chimeric antigen receptor; CD22; B cell; Immunotherapy; CAR T-cell therapy; T cell; Antigen","score_opus":0.059103660297845015,"score_gpt":0.3460429781788807,"score_spread":0.28693931788103566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6901869847","genre_codex":"protocol","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"protocol","genre_consensus":"protocol","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.022483438,0.0033530884,0.000015739985,0.00022145484,0.0000056674257,0.7377715,0.23162395,0.0000029660537,0.0045222095],"genre_scores_gemma":[0.0033340408,0.0004614896,0.045780063,0.00040742,0.000030213332,0.8729248,0.035789624,0.00012546472,0.0411469],"study_design_codex":"systematic_review","study_design_gemma":"not_applicable","domain_scores_codex":[0.99839497,0.00020749123,0.0005747178,0.00033126664,0.00034027442,0.00015125527],"domain_scores_gemma":[0.99808776,0.00073258026,0.00036062632,0.00037809025,0.00036652695,0.00007443732],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00037934913,0.00015508331,0.0016967433,0.000110061395,0.000027991322,0.000020324891,0.00012431908,0.00004289501,0.6698337],"category_scores_gemma":[0.00017941475,0.00009954411,0.00021102239,0.0006603676,0.00007016695,0.000061416344,0.00006845712,0.00007284941,0.0000067749693],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017154755,0.013233901,0.0029899573,0.52862805,0.13416125,0.00003856255,0.0035645487,0.000012017732,0.025383782,0.0000021939097,0.26893494,0.005896066],"study_design_scores_gemma":[0.088806815,0.019050846,0.027659934,0.08239264,0.23572148,0.000033730084,0.001834579,0.00016132914,0.109441556,0.00001268751,0.4325922,0.0022921881],"about_ca_topic_score_codex":0.0000143518255,"about_ca_topic_score_gemma":0.000012749662,"teacher_disagreement_score":0.6698269,"about_ca_system_score_codex":0.000021731212,"about_ca_system_score_gemma":0.0002238694,"threshold_uncertainty_score":0.4059291},"labels":[],"label_agreement":null},{"id":"W6901903496","doi":"10.6084/m9.figshare.22611196.v1","title":"Additional file 1 of Identifying effect modifiers of CAR-T cell therapeutic efficacy: a systematic review and individual patient data meta-analysis protocol","year":2023,"lang":"en","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; National Research Council Canada; University of British Columbia; Ottawa Hospital","funders":"","keywords":"Protocol (science); Patient data; MEDLINE; Data collection; Systematic review","score_opus":0.2836596883364506,"score_gpt":0.4036598257093907,"score_spread":0.12000013737294007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6901903496","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000008870549,0.0018573856,1.3896468e-7,0.000018374058,0.0000019168995,0.05069287,0.947158,0.000028534068,0.00023394794],"genre_scores_gemma":[0.0006349542,0.0000072479497,0.000034760436,0.000076209464,0.000009980331,0.20414814,0.79416966,0.000024075287,0.0008949475],"study_design_codex":"not_applicable","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9975139,0.00039111564,0.0005976536,0.00037053178,0.0009154939,0.00021133089],"domain_scores_gemma":[0.9948647,0.0033526793,0.00041489565,0.0010567327,0.000208308,0.000102690145],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003818236,0.00018464019,0.0015974405,0.00031847396,0.000040496576,0.000022362445,0.00035716261,0.000068093104,0.9732354],"category_scores_gemma":[0.0030152034,0.00012807809,0.0005776307,0.0012693412,0.000022018854,0.00007403767,0.00035018136,0.00017655561,0.00033351005],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022117689,0.000055928896,9.4948854e-7,0.22803387,0.02579198,0.000010369141,0.00007122912,0.0000031273944,0.00005855524,6.615076e-8,0.7458041,0.0001477389],"study_design_scores_gemma":[0.0036475963,0.0022165366,0.001858751,0.21559423,0.6373496,0.000056912497,0.00029543714,0.0031504866,0.003923614,0.000011388154,0.1309438,0.0009516498],"about_ca_topic_score_codex":0.0000059115305,"about_ca_topic_score_gemma":0.0000025447587,"teacher_disagreement_score":0.9729019,"about_ca_system_score_codex":0.000021914237,"about_ca_system_score_gemma":0.00011823201,"threshold_uncertainty_score":0.5222873},"labels":[],"label_agreement":null},{"id":"W6901931657","doi":"10.6084/m9.figshare.12284570.v1","title":"Additional file 4 of Effect of flavophospholipol on fecal microbiota in weaned pigs challenged with Salmonella Typhimurium","year":2020,"lang":"en","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Guelph","funders":"","keywords":"Feces; Salmonella; Enterobacteriaceae; Bacteria; Strain (injury); Weaning","score_opus":0.029424589864597814,"score_gpt":0.2664882744342145,"score_spread":0.2370636845696167,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6901931657","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0074327406,0.00007763824,1.1640746e-8,0.00023921482,0.000006025073,0.0005962146,0.98482853,0.000023351813,0.0067962543],"genre_scores_gemma":[0.1794619,0.0000037672557,0.000045024055,0.00017176979,0.00014752778,0.00035850532,0.8185218,0.000047184716,0.001242517],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9988758,0.000073119634,0.00020452398,0.00026537996,0.00036336866,0.00021779332],"domain_scores_gemma":[0.9980068,0.0014232774,0.00009064872,0.00023441727,0.00011008872,0.0001347559],"candidate_categories":["insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000035757173,0.00015974825,0.00040788835,0.00009526179,0.000014336711,0.00000432973,0.00013539141,0.0001149348,0.99212384],"category_scores_gemma":[0.0013202501,0.00012675914,0.00010450951,0.00032335002,0.000027014716,0.000022363789,0.00005801173,0.00033796462,0.0012567193],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027604296,0.00011083478,0.000016334392,0.00084182835,0.00005206925,0.0000940137,0.00011016761,0.000004918362,0.023919752,3.25349e-7,0.97118556,0.00090376614],"study_design_scores_gemma":[0.0069629927,0.010375506,0.014993019,0.014964696,0.000027318934,0.000052548836,0.00007121477,0.0003027413,0.21083625,0.0000016892293,0.74105185,0.00036018708],"about_ca_topic_score_codex":0.000006362774,"about_ca_topic_score_gemma":0.000007642858,"teacher_disagreement_score":0.9908671,"about_ca_system_score_codex":0.00004961892,"about_ca_system_score_gemma":0.00015207722,"threshold_uncertainty_score":0.9995209},"labels":[],"label_agreement":null},{"id":"W6901999208","doi":"10.6084/m9.figshare.13093610.v1","title":"Additional file 3 of Partnering with patients to get better outcomes with chimeric antigen receptor T-cell therapy: towards engagement of patients in early phase trials","year":2020,"lang":"en","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; Canada's Michael Smith Genome Sciences Centre; University of Ottawa; Ottawa Hospital","funders":"","keywords":"Chimeric antigen receptor; Clinical trial; Phase (matter); MEDLINE; Antigen; Immune system","score_opus":0.10496957802123638,"score_gpt":0.33786207164941817,"score_spread":0.2328924936281818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6901999208","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.34827855,0.0000068828663,2.237019e-7,0.000091114955,0.0000059233025,0.0010625159,0.6501025,0.0000115185285,0.00044079882],"genre_scores_gemma":[0.18138802,0.000003103329,0.0009370019,0.00078525057,0.00008795874,0.0012562275,0.8150619,0.00006152803,0.00041896562],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981284,0.00014907986,0.00044165525,0.00028646918,0.0007476125,0.00024674865],"domain_scores_gemma":[0.99864763,0.00042266573,0.00024256278,0.00021584232,0.0002950531,0.00017626175],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00008571526,0.00018910383,0.00060874975,0.00013420745,0.000023879842,0.000012211309,0.00014821702,0.000049161477,0.96069574],"category_scores_gemma":[0.0011841499,0.00012986705,0.00009966961,0.00039083514,0.000013866628,0.00007587526,0.00007022729,0.00018895372,0.00020695895],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027560084,0.0009259073,0.018490182,0.00017330029,0.0001539792,0.000006290294,0.001116731,0.000004602999,0.00053642853,1.3709812e-8,0.9543454,0.021491146],"study_design_scores_gemma":[0.012401768,0.0069599804,0.3464421,0.0015684793,0.000012847209,1.3586241e-7,0.00006203122,0.0000125556835,0.01634299,2.2612085e-7,0.6159731,0.00022376062],"about_ca_topic_score_codex":0.000015415293,"about_ca_topic_score_gemma":0.000003098487,"teacher_disagreement_score":0.9604888,"about_ca_system_score_codex":0.000044128905,"about_ca_system_score_gemma":0.00015347052,"threshold_uncertainty_score":0.5295825},"labels":[],"label_agreement":null},{"id":"W6902180895","doi":"10.6084/m9.figshare.22611196","title":"Additional file 1 of Identifying effect modifiers of CAR-T cell therapeutic efficacy: a systematic review and individual patient data meta-analysis protocol","year":2023,"lang":"en","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; National Research Council Canada; University of British Columbia; Ottawa Hospital","funders":"","keywords":"Protocol (science); Patient data; MEDLINE; Data collection; Systematic review","score_opus":0.2836596883364506,"score_gpt":0.4036598257093907,"score_spread":0.12000013737294007,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902180895","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000008870549,0.0018573856,1.3896468e-7,0.000018374058,0.0000019168995,0.05069287,0.947158,0.000028534068,0.00023394794],"genre_scores_gemma":[0.0006349542,0.0000072479497,0.000034760436,0.000076209464,0.000009980331,0.20414814,0.79416966,0.000024075287,0.0008949475],"study_design_codex":"not_applicable","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9975139,0.00039111564,0.0005976536,0.00037053178,0.0009154939,0.00021133089],"domain_scores_gemma":[0.9948647,0.0033526793,0.00041489565,0.0010567327,0.000208308,0.000102690145],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003818236,0.00018464019,0.0015974405,0.00031847396,0.000040496576,0.000022362445,0.00035716261,0.000068093104,0.9732354],"category_scores_gemma":[0.0030152034,0.00012807809,0.0005776307,0.0012693412,0.000022018854,0.00007403767,0.00035018136,0.00017655561,0.00033351005],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022117689,0.000055928896,9.4948854e-7,0.22803387,0.02579198,0.000010369141,0.00007122912,0.0000031273944,0.00005855524,6.615076e-8,0.7458041,0.0001477389],"study_design_scores_gemma":[0.0036475963,0.0022165366,0.001858751,0.21559423,0.6373496,0.000056912497,0.00029543714,0.0031504866,0.003923614,0.000011388154,0.1309438,0.0009516498],"about_ca_topic_score_codex":0.0000059115305,"about_ca_topic_score_gemma":0.0000025447587,"teacher_disagreement_score":0.9729019,"about_ca_system_score_codex":0.000021914237,"about_ca_system_score_gemma":0.00011823201,"threshold_uncertainty_score":0.5222873},"labels":[],"label_agreement":null},{"id":"W6902248215","doi":"10.6084/m9.figshare.28920986.v1","title":"Axicabtagene ciloleucel compared to standard of care in Canadian patients with relapsed or refractory large B-cell lymphoma: a cost-effectiveness analysis of the ZUMA-7 trial","year":2025,"lang":"en","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Chemoimmunotherapy; Refractory (planetary science); Standard of care; Clinical trial; Confidence interval","score_opus":0.03081814673992698,"score_gpt":0.32723172556437974,"score_spread":0.29641357882445274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6902248215","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.850022,0.00015645684,6.5516184e-7,0.00003632235,0.0000486361,0.0036410734,0.14350067,0.000010034526,0.0025841503],"genre_scores_gemma":[0.98282236,0.0000016696597,0.000008952592,0.00009461223,0.000012815306,0.0003864697,0.016006883,0.000020881174,0.00064533635],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99814826,0.00025551088,0.00033940416,0.00030718104,0.00056601997,0.00038360545],"domain_scores_gemma":[0.99799144,0.00030724364,0.00011971122,0.0006522891,0.00071836467,0.00021094269],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00019987833,0.000166725,0.00074968487,0.0007873986,0.00006252044,0.000011710549,0.00027017746,0.000119976154,0.02261222],"category_scores_gemma":[0.0007927342,0.00011147965,0.00019038751,0.0027571325,0.000017947426,0.000031444757,0.000095758034,0.00016477455,0.000008803499],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6980813,0.004574411,0.22857176,0.0050921505,0.0038289218,0.00016057324,0.0058709737,0.0006655532,0.0024386586,0.000010501308,0.02818058,0.022524629],"study_design_scores_gemma":[0.1940653,0.0034069738,0.6777421,0.0043891403,0.00063328055,3.1908013e-7,0.0007019271,0.00016243757,0.013266048,8.5867686e-7,0.105359994,0.00027156257],"about_ca_topic_score_codex":0.012997977,"about_ca_topic_score_gemma":0.28808975,"teacher_disagreement_score":0.504016,"about_ca_system_score_codex":0.0013364126,"about_ca_system_score_gemma":0.0026581206,"threshold_uncertainty_score":0.99357456},"labels":[],"label_agreement":null},{"id":"W6903021297","doi":"10.7939/r3-wt63-hj84","title":"The Clinical Adoption of anti-CD19 CAR T-cell Therapy in Alberta: A Historical Review and Retrospective Comparative Case Study","year":2022,"lang":"en","type":"dissertation","venue":"University of Alberta Library","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Timeline; Stakeholder; Product (mathematics); Health care; Process (computing); Comparative case; Perspective (graphical); Comparative effectiveness research; Grey literature","score_opus":0.04373236393315394,"score_gpt":0.32866209514437955,"score_spread":0.2849297312112256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6903021297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9766728,0.010751541,1.0565484e-7,0.00049306836,0.00014190671,0.002085555,0.000007748229,0.0000084073245,0.009838832],"genre_scores_gemma":[0.80532414,0.062036898,0.000035161636,0.00006536064,0.000041111594,0.000004889271,0.00034578302,0.000040025145,0.13210662],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99770033,0.00070515904,0.0005185521,0.00048234727,0.00040229922,0.00019130588],"domain_scores_gemma":[0.99763715,0.0011873816,0.0004521281,0.00048795078,0.0001154102,0.00011999129],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00037671163,0.00024081378,0.0012428082,0.00022552433,0.00016663857,0.000008315416,0.00027343727,0.00018151822,0.0014679555],"category_scores_gemma":[0.00005702598,0.00021355512,0.00027206878,0.00052904844,0.00016096445,0.00018478087,0.00012260879,0.0009311145,0.0000030914375],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019886104,0.010906412,0.7296407,0.0039957855,0.0028309987,0.004040979,0.17110088,0.0000037592515,0.0010715314,0.0003201568,0.050267566,0.005935107],"study_design_scores_gemma":[0.025476186,0.021298168,0.40636852,0.002218847,0.0028001987,0.0005019179,0.27846408,0.00010185875,0.00043922567,0.00007616556,0.26085913,0.0013956926],"about_ca_topic_score_codex":0.03112725,"about_ca_topic_score_gemma":0.0124243,"teacher_disagreement_score":0.32327217,"about_ca_system_score_codex":0.00024021008,"about_ca_system_score_gemma":0.00045193953,"threshold_uncertainty_score":0.99944484},"labels":[],"label_agreement":null},{"id":"W6907653799","doi":"10.25384/sage.c.5104085.v1","title":"Mapping as a Complementary Perspective on the Dynamics of Participation in a City’s Musical Life","year":2020,"lang":"en","type":"other","venue":"Sage Journals Data","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Legibility; Musical; Perspective (graphical); Dynamics (music); Attendance; Subject (documents)","score_opus":0.1742411750248867,"score_gpt":0.43432938045346076,"score_spread":0.260088205428574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6907653799","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.013861145,0.014114751,0.0018906337,0.21858609,0.0005374002,0.00581704,0.010150821,0.00012875597,0.73491335],"genre_scores_gemma":[0.4637937,0.0632941,0.0029882146,0.040324338,0.012198124,0.0002675012,0.00938138,0.0026994906,0.40505317],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99794805,0.00028916815,0.0003927071,0.00034845443,0.00076767505,0.00025396395],"domain_scores_gemma":[0.9982885,0.00026009537,0.00026431817,0.0009653946,0.000049089656,0.00017258289],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00089501153,0.00017750227,0.00049185805,0.0003405449,0.000033304364,0.000030404364,0.0005734042,0.00010948622,0.1096352],"category_scores_gemma":[0.0009214018,0.00012694063,0.00008084964,0.0004115587,0.00010171691,0.000041279585,0.00040532686,0.001019986,0.000050733786],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017491911,0.0015853078,0.0062099732,0.00045719318,0.002851483,0.000989413,0.008975941,0.000005044488,0.00488947,0.0010099824,0.87974215,0.09153483],"study_design_scores_gemma":[0.013675728,0.0027023007,0.034618188,0.03363484,0.0007838776,0.00019621651,0.057057057,0.034815434,0.00023147787,0.003054158,0.81793344,0.0012972528],"about_ca_topic_score_codex":0.00236938,"about_ca_topic_score_gemma":0.0027510044,"teacher_disagreement_score":0.44993255,"about_ca_system_score_codex":0.00030888183,"about_ca_system_score_gemma":0.00029687517,"threshold_uncertainty_score":0.8911787},"labels":[],"label_agreement":null},{"id":"W6907797343","doi":"10.25318/3610028701-eng","title":"Personal income, personal income per person, and personal disposable income, annual, 1926 - 1990","year":2019,"lang":"en","type":"dataset","venue":"Statistics Canada Dissemination","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Personal income; Table (database); Personal account; Personal life; Personal computer; Payment","score_opus":0.012182798874675712,"score_gpt":0.29672873825564255,"score_spread":0.28454593938096684,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6907797343","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.015791344,0.0011970996,0.000068844616,0.0005741586,0.00086148304,0.001226447,0.9800332,0.0000345821,0.00021285033],"genre_scores_gemma":[0.018869359,0.0005252323,0.00041599094,0.0003282504,0.00069873495,0.0001115013,0.9553945,0.00015839995,0.023498053],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9932327,0.00022699228,0.00076148025,0.0012843827,0.0033354405,0.0011589845],"domain_scores_gemma":[0.99603254,0.0010605378,0.00046051765,0.0006237582,0.0009353331,0.0008873368],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007062459,0.000980669,0.0013042038,0.00069277606,0.0004965847,0.00022792218,0.0004354705,0.0006036283,0.012725702],"category_scores_gemma":[0.0006710425,0.0009884799,0.00015861556,0.0005611074,0.00046459082,0.0002479082,0.00024327928,0.001817082,0.0000858302],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00043840622,0.00015062683,0.006673248,0.0024786522,0.0003702973,0.00046039023,0.0011464559,5.7570423e-7,0.00025751133,0.00003361378,0.98509526,0.002894936],"study_design_scores_gemma":[0.0025067872,0.00090956216,0.14271681,0.0012824327,0.00073807064,0.0005535204,0.005390124,0.0017798386,0.00003092297,0.000021670616,0.8424722,0.0015980543],"about_ca_topic_score_codex":0.12001945,"about_ca_topic_score_gemma":0.22760841,"teacher_disagreement_score":0.14262308,"about_ca_system_score_codex":0.002353412,"about_ca_system_score_gemma":0.0033702913,"threshold_uncertainty_score":0.99925655},"labels":[],"label_agreement":null},{"id":"W6908840949","doi":"10.3389/fphys.2022.1059686.s001","title":"Presentation1_Early mechanisms of neutrophil activation and transmigration in acute lung injury.PPTX","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Lipopolysaccharide; Lung; Tidal volume; Ventilation (architecture); Selectin; P-selectin; Respiratory system","score_opus":0.0319064628073427,"score_gpt":0.3209760167151325,"score_spread":0.28906955390778977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6908840949","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9373421,0.00020633117,0.0001278767,0.002280549,0.000055420078,0.0028963613,0.055314727,0.000081420156,0.0016952099],"genre_scores_gemma":[0.976686,0.000008216755,0.00007522048,0.000115556184,0.000024715197,0.00035569663,0.021755734,0.000017169828,0.0009617063],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9991685,0.000065630586,0.00015237318,0.00015441382,0.00034447323,0.000114603725],"domain_scores_gemma":[0.9996618,0.000052425003,0.00005328993,0.00012609993,0.00006517246,0.000041211715],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000069185706,0.00006617494,0.0001260538,0.00019118004,0.000051077393,0.000011864868,0.000057835103,0.000033983313,0.118740045],"category_scores_gemma":[0.0000569452,0.00006934456,0.00003444512,0.00033400627,0.0000044654203,0.000121174475,0.00004331402,0.00020047397,0.0000074726267],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009278641,0.00013855277,0.000517757,0.0002806753,0.000064761116,0.000018771958,0.0016835926,0.000074401345,0.9675934,0.000111090136,0.016281646,0.012307522],"study_design_scores_gemma":[0.005969385,0.002331119,0.14522149,0.00081014977,0.000073926996,0.000062821,0.0009798092,0.011315233,0.815508,0.0011523269,0.016204432,0.00037133196],"about_ca_topic_score_codex":0.000050576244,"about_ca_topic_score_gemma":0.000009426285,"teacher_disagreement_score":0.1520854,"about_ca_system_score_codex":0.00008309684,"about_ca_system_score_gemma":0.00007525346,"threshold_uncertainty_score":0.88206553},"labels":[],"label_agreement":null},{"id":"W6911827169","doi":"10.5281/zenodo.15125672","title":"Personalized Medicine in Cancer: An Overview with Chimeric Antigen Receptor Therapy and Health Canada Regulatory Insights","year":2025,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Personalized medicine; Regulatory science; Chimeric antigen receptor; Precision medicine; MEDLINE; Cancer; Risk management; Good manufacturing practice","score_opus":0.07921043495232297,"score_gpt":0.3295970178244372,"score_spread":0.25038658287211424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6911827169","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9215896,0.029014248,0.00004795831,0.022971075,0.00012194262,0.0020653987,0.000062169114,0.00033639456,0.023791185],"genre_scores_gemma":[0.9076136,0.069073886,0.00025140506,0.0077878446,0.0003657348,0.0000010367006,0.0017111034,0.0018953013,0.011300089],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979266,0.00041622607,0.0002681798,0.00046441588,0.0005510316,0.0003735499],"domain_scores_gemma":[0.9988342,0.00002162967,0.00008004039,0.0004362544,0.00033294494,0.0002949158],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00066473085,0.00016868477,0.00036041735,0.00034515557,0.00072335114,0.00008764446,0.00032367333,0.000046660745,0.015810953],"category_scores_gemma":[0.00006947622,0.00013698406,0.000019832081,0.0010949359,0.0002934047,0.00011467694,0.00017696021,0.00032543694,0.000028778088],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019569234,0.00034651163,0.0012559431,0.000542464,0.00027001512,0.00005371852,0.00578754,0.000010807152,0.030891912,0.0028742515,0.21303107,0.7429788],"study_design_scores_gemma":[0.003227849,0.00087289646,0.04632325,0.00037005817,0.000007044516,0.000039620812,0.000723478,0.00009684108,0.0003796093,0.00002370827,0.94780916,0.00012646278],"about_ca_topic_score_codex":0.08212398,"about_ca_topic_score_gemma":0.0066545964,"teacher_disagreement_score":0.7428524,"about_ca_system_score_codex":0.00069360196,"about_ca_system_score_gemma":0.00018750229,"threshold_uncertainty_score":0.9850887},"labels":[],"label_agreement":null},{"id":"W6912163997","doi":"10.5281/zenodo.15125673","title":"Personalized Medicine in Cancer: An Overview with Chimeric Antigen Receptor Therapy and Health Canada Regulatory Insights","year":2025,"lang":"en","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Personalized medicine; Regulatory science; Chimeric antigen receptor; Precision medicine; MEDLINE; Cancer; Risk management; Good manufacturing practice","score_opus":0.07921043495232297,"score_gpt":0.3295970178244372,"score_spread":0.25038658287211424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6912163997","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9215896,0.029014248,0.00004795831,0.022971075,0.00012194262,0.0020653987,0.000062169114,0.00033639456,0.023791185],"genre_scores_gemma":[0.9076136,0.069073886,0.00025140506,0.0077878446,0.0003657348,0.0000010367006,0.0017111034,0.0018953013,0.011300089],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979266,0.00041622607,0.0002681798,0.00046441588,0.0005510316,0.0003735499],"domain_scores_gemma":[0.9988342,0.00002162967,0.00008004039,0.0004362544,0.00033294494,0.0002949158],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00066473085,0.00016868477,0.00036041735,0.00034515557,0.00072335114,0.00008764446,0.00032367333,0.000046660745,0.015810953],"category_scores_gemma":[0.00006947622,0.00013698406,0.000019832081,0.0010949359,0.0002934047,0.00011467694,0.00017696021,0.00032543694,0.000028778088],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019569234,0.00034651163,0.0012559431,0.000542464,0.00027001512,0.00005371852,0.00578754,0.000010807152,0.030891912,0.0028742515,0.21303107,0.7429788],"study_design_scores_gemma":[0.003227849,0.00087289646,0.04632325,0.00037005817,0.000007044516,0.000039620812,0.000723478,0.00009684108,0.0003796093,0.00002370827,0.94780916,0.00012646278],"about_ca_topic_score_codex":0.08212398,"about_ca_topic_score_gemma":0.0066545964,"teacher_disagreement_score":0.7428524,"about_ca_system_score_codex":0.00069360196,"about_ca_system_score_gemma":0.00018750229,"threshold_uncertainty_score":0.9850887},"labels":[],"label_agreement":null},{"id":"W6920673451","doi":"10.6084/m9.figshare.13093610","title":"Additional file 3 of Partnering with patients to get better outcomes with chimeric antigen receptor T-cell therapy: towards engagement of patients in early phase trials","year":2020,"lang":"en","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; Canada's Michael Smith Genome Sciences Centre; University of Ottawa; Ottawa Hospital","funders":"","keywords":"Chimeric antigen receptor; Clinical trial; Phase (matter); MEDLINE; Antigen; Immune system","score_opus":0.10496957802123638,"score_gpt":0.33786207164941817,"score_spread":0.2328924936281818,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920673451","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.34827855,0.0000068828663,2.237019e-7,0.000091114955,0.0000059233025,0.0010625159,0.6501025,0.0000115185285,0.00044079882],"genre_scores_gemma":[0.18138802,0.000003103329,0.0009370019,0.00078525057,0.00008795874,0.0012562275,0.8150619,0.00006152803,0.00041896562],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981284,0.00014907986,0.00044165525,0.00028646918,0.0007476125,0.00024674865],"domain_scores_gemma":[0.99864763,0.00042266573,0.00024256278,0.00021584232,0.0002950531,0.00017626175],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00008571526,0.00018910383,0.00060874975,0.00013420745,0.000023879842,0.000012211309,0.00014821702,0.000049161477,0.96069574],"category_scores_gemma":[0.0011841499,0.00012986705,0.00009966961,0.00039083514,0.000013866628,0.00007587526,0.00007022729,0.00018895372,0.00020695895],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027560084,0.0009259073,0.018490182,0.00017330029,0.0001539792,0.000006290294,0.001116731,0.000004602999,0.00053642853,1.3709812e-8,0.9543454,0.021491146],"study_design_scores_gemma":[0.012401768,0.0069599804,0.3464421,0.0015684793,0.000012847209,1.3586241e-7,0.00006203122,0.0000125556835,0.01634299,2.2612085e-7,0.6159731,0.00022376062],"about_ca_topic_score_codex":0.000015415293,"about_ca_topic_score_gemma":0.000003098487,"teacher_disagreement_score":0.9604888,"about_ca_system_score_codex":0.000044128905,"about_ca_system_score_gemma":0.00015347052,"threshold_uncertainty_score":0.5295825},"labels":[],"label_agreement":null},{"id":"W6920674398","doi":"10.6084/m9.figshare.13093604.v1","title":"Additional file 1 of Partnering with patients to get better outcomes with chimeric antigen receptor T-cell therapy: towards engagement of patients in early phase trials","year":2020,"lang":"en","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; Canada's Michael Smith Genome Sciences Centre; University of Ottawa; Ottawa Hospital","funders":"","keywords":"Chimeric antigen receptor; Clinical trial; Phase (matter); MEDLINE; Antigen","score_opus":0.10676808617153956,"score_gpt":0.3383602675787483,"score_spread":0.23159218140720877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920674398","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.34714514,0.0000068504833,2.2254306e-7,0.00009156961,0.000005870398,0.0010629114,0.6512375,0.000011537046,0.00043841347],"genre_scores_gemma":[0.17890559,0.0000030472318,0.000943832,0.00078247563,0.00008660364,0.0012741011,0.8175338,0.000061268205,0.0004093144],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981285,0.0001492207,0.00044146276,0.0002865917,0.00074746355,0.00024676727],"domain_scores_gemma":[0.99864614,0.00042636791,0.00024252792,0.00021616237,0.00029252828,0.00017627836],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00008575334,0.00018912992,0.00060868886,0.00013425137,0.000023881854,0.0000121867715,0.00014830845,0.000049165577,0.9616075],"category_scores_gemma":[0.0011844612,0.00012989949,0.000099675846,0.00039097725,0.0000138656615,0.00007581808,0.00007027707,0.00018899157,0.0002047651],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027182994,0.0009190318,0.01832009,0.00016910593,0.00015288875,0.000006167774,0.0011078645,0.0000045652646,0.000530895,1.3685544e-8,0.9550478,0.021023313],"study_design_scores_gemma":[0.012312557,0.0070125754,0.3501901,0.0015814605,0.00001304155,1.3796469e-7,0.000062706335,0.000012613586,0.016104927,2.2686872e-7,0.6124845,0.00022511971],"about_ca_topic_score_codex":0.0000152457105,"about_ca_topic_score_gemma":0.0000030779893,"teacher_disagreement_score":0.9614028,"about_ca_system_score_codex":0.000043957993,"about_ca_system_score_gemma":0.00015338742,"threshold_uncertainty_score":0.52971476},"labels":[],"label_agreement":null},{"id":"W6920886201","doi":"10.6084/m9.figshare.25397536","title":"Additional file 1 of CAR T cells and T cells phenotype and function are impacted by glucocorticoid exposure with different magnitude","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"CD19; CD8; T cell; Cytotoxic T cell; Interleukin 21; Phenotype; Interleukin 3","score_opus":0.017155511829438915,"score_gpt":0.2405484962564494,"score_spread":0.22339298442701047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6920886201","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.032685015,0.000797044,3.5444177e-7,0.00003288326,0.000021163949,0.0004011649,0.9653722,0.000046397352,0.0006437669],"genre_scores_gemma":[0.10677579,0.000026848813,0.000032442837,0.000085450614,0.00014500415,0.0003164822,0.8810251,0.000049927738,0.011542973],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990794,0.000024232288,0.0001308966,0.00026896765,0.00031023592,0.0001862821],"domain_scores_gemma":[0.9990029,0.00051309797,0.000048386708,0.0001604893,0.00012890427,0.00014625565],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000012780866,0.0001520115,0.0002178139,0.00008005002,0.000029517912,0.000046372406,0.000036596073,0.000087290915,0.9837069],"category_scores_gemma":[0.000106283944,0.00011206195,0.000041111423,0.0001463778,0.000021782234,0.00006350021,0.000043911743,0.00022206988,0.00027020747],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022852897,0.000051248393,0.000031991185,0.00091447134,0.00009492279,0.000029657152,0.000055650133,6.58083e-7,0.06822157,1.6170397e-7,0.92643857,0.003932586],"study_design_scores_gemma":[0.0010231137,0.0015089564,0.032417573,0.005721532,0.000076659264,0.000040004532,0.00015241952,0.00038435214,0.030214667,0.0000054404322,0.9282352,0.00022011666],"about_ca_topic_score_codex":0.000005793973,"about_ca_topic_score_gemma":0.0000106854695,"teacher_disagreement_score":0.9834367,"about_ca_system_score_codex":0.000041739782,"about_ca_system_score_gemma":0.000093848714,"threshold_uncertainty_score":0.45697537},"labels":[],"label_agreement":null},{"id":"W6921018313","doi":"10.6084/m9.figshare.29387378","title":"Revaccination following CAR-T therapy: a needs assessment","year":2025,"lang":"en","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Focus group; CLARITY; Needs assessment; Audit; Primary care; Qualitative research; Patient education; Schedule","score_opus":0.056052696427784744,"score_gpt":0.3870660347820867,"score_spread":0.3310133383543019,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6921018313","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12636411,0.0065103676,0.000040466744,0.010164584,0.00070117746,0.005353892,0.01700846,0.00081971526,0.8330372],"genre_scores_gemma":[0.8768684,0.00005253231,0.00018503911,0.0019959796,0.00026349418,0.00065898406,0.037092026,0.000047533038,0.082835965],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990246,0.00004985342,0.00015647826,0.0001858912,0.0003506429,0.00023250016],"domain_scores_gemma":[0.99927807,0.00012383553,0.000030769614,0.00035154392,0.00014463974,0.000071148184],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00012523394,0.00011581794,0.00019847424,0.0002801824,0.000080784324,0.000052698593,0.00012467375,0.000092154914,0.27669695],"category_scores_gemma":[0.0003045049,0.00010276156,0.00017426573,0.0006619773,0.000002122225,0.00007395758,0.00006681772,0.00025149394,0.00031867184],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016105242,0.00019781358,0.005099095,0.00039745195,0.00039273346,0.00009784263,0.00036002175,0.0000040823497,0.052554674,0.00011639439,0.69120485,0.24941398],"study_design_scores_gemma":[0.002668078,0.00018761896,0.048171896,0.0019559548,0.000025129073,0.0000068692684,0.00017529356,0.00035138289,0.011223595,0.00007986185,0.93500894,0.00014540528],"about_ca_topic_score_codex":0.000009863204,"about_ca_topic_score_gemma":0.0000044149647,"teacher_disagreement_score":0.7505043,"about_ca_system_score_codex":0.00024609486,"about_ca_system_score_gemma":0.00033979933,"threshold_uncertainty_score":0.7239643},"labels":[],"label_agreement":null},{"id":"W6921038188","doi":"10.6084/m9.figshare.14313463.v1","title":"Additional file 1 of Hematologists’ barriers and enablers to screening and recruiting patients to a chimeric antigen receptor (CAR) T cell therapy trial: a theory-informed interview study","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Canada's Michael Smith Genome Sciences Centre; University of Ottawa; Ottawa Hospital","funders":"","keywords":"CAR T-cell therapy; Chimeric antigen receptor; Immunotherapy; Antibody therapy; T cell; Antigen; MEDLINE","score_opus":0.08753466445652208,"score_gpt":0.33392228397746976,"score_spread":0.24638761952094768,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6921038188","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0888802,0.00027052185,0.0000010150271,0.00008651339,0.0000243898,0.0027316064,0.90581787,0.000038657683,0.0021492522],"genre_scores_gemma":[0.06383971,0.00008801974,0.003814266,0.0022613856,0.00023831292,0.0062876656,0.9171552,0.00013892027,0.006176507],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984034,0.00021534799,0.00033698414,0.0003679614,0.00038142712,0.0002948825],"domain_scores_gemma":[0.9974549,0.0014772281,0.00011868704,0.0002650367,0.0003227234,0.00036141984],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00016866584,0.0001784065,0.00043243135,0.00015394128,0.00009642546,0.000048352602,0.00011420774,0.000066588254,0.97000897],"category_scores_gemma":[0.007812931,0.00015694565,0.000085844644,0.00046810848,0.000018267618,0.00007345703,0.0002207018,0.00017316068,0.00011141985],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031393403,0.00015348595,0.00016139947,0.00023301247,0.0001221224,0.000017662314,0.0023124765,3.75192e-7,0.00053723657,2.0975304e-7,0.91967964,0.07364306],"study_design_scores_gemma":[0.01587452,0.003469816,0.0064183315,0.005714925,0.000016067534,0.000015066352,0.009423597,0.000015892358,0.0047421474,0.000004610442,0.9539902,0.00031478293],"about_ca_topic_score_codex":0.00000783271,"about_ca_topic_score_gemma":0.0000088561455,"teacher_disagreement_score":0.9698975,"about_ca_system_score_codex":0.000043486132,"about_ca_system_score_gemma":0.00027030447,"threshold_uncertainty_score":0.93533725},"labels":[],"label_agreement":null},{"id":"W6921051786","doi":"10.6084/m9.figshare.25744470","title":"Additional file 2 of Mechanism of action, potency and efficacy: considerations for cell therapies","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Mechanism (biology); Potency; Key (lock); Cell; Mechanism of action","score_opus":0.08141334175345424,"score_gpt":0.32790889355422725,"score_spread":0.246495551800773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6921051786","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008163535,0.0002822479,0.0000028410595,0.00020261145,0.000014871351,0.0003644313,0.99587417,0.000026673242,0.0031505509],"genre_scores_gemma":[0.025091242,0.000014802992,0.0016168265,0.000080918035,0.00016907742,0.00087809237,0.95542127,0.000027692195,0.01670008],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995224,0.000012580125,0.000121582016,0.00011898063,0.00014285604,0.0000816],"domain_scores_gemma":[0.9970182,0.002607938,0.000030761657,0.000099209465,0.00020500971,0.00003883792],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000021001639,0.00005861804,0.000119512064,0.00008394077,0.000035531386,0.000013233756,0.000022914164,0.00005174154,0.9964434],"category_scores_gemma":[0.0010621176,0.000051121307,0.00007007878,0.00008060194,0.000012975374,0.000039323448,0.000016206932,0.00007735147,0.00011227854],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000233605,0.000045020723,5.7166066e-8,0.000533536,0.000045934754,0.000003279285,0.00013712022,2.5908992e-7,0.013881801,0.00012608184,0.98155797,0.003645587],"study_design_scores_gemma":[0.00041164862,0.00028689433,0.00015255762,0.0016208467,0.000015361748,0.000026074387,0.00010169923,0.00037698055,0.04125034,0.0018942283,0.95380515,0.000058211845],"about_ca_topic_score_codex":0.000002078764,"about_ca_topic_score_gemma":0.0000042171414,"teacher_disagreement_score":0.9963311,"about_ca_system_score_codex":0.000013273408,"about_ca_system_score_gemma":0.00020661016,"threshold_uncertainty_score":0.20846663},"labels":[],"label_agreement":null},{"id":"W6923603246","doi":"10.14288/1.0449064","title":"Abstracts of the Cell Therapy Transplant Canada 2022 Annual Conference","year":2025,"lang":"en","type":"article","venue":"Open Collections","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Session (web analytics); Presentation (obstetrics); Transplantation; Cell therapy; MEDLINE","score_opus":0.02356228923068407,"score_gpt":0.2973331447189159,"score_spread":0.2737708554882319,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6923603246","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.07921889,0.00012972364,0.000019756922,0.002708654,0.00035987643,0.0012951093,0.00020833843,0.000008479469,0.91605115],"genre_scores_gemma":[0.45508778,0.00014693718,0.000016875869,0.00025882624,0.000012585797,0.000047266836,0.0000043863397,0.000005033791,0.5444203],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992048,0.00006131197,0.0001815431,0.00014861087,0.0002447453,0.00015894645],"domain_scores_gemma":[0.99926674,0.00011046565,0.00003974832,0.00032082287,0.00020589889,0.000056324923],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00015730652,0.000076258075,0.00017082527,0.000040669674,0.0005773178,0.000087723776,0.0003218932,0.000041305855,0.0064864657],"category_scores_gemma":[0.000020576334,0.000054339293,0.00005383808,0.0009292767,0.00006159885,0.000035552017,0.000051463307,0.00024003495,0.000001028986],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007600129,0.00040527873,0.00095606165,0.000045393026,0.00018476792,0.000015618643,0.0007140382,0.000065669556,0.0568886,0.00006223969,0.9357935,0.004108798],"study_design_scores_gemma":[0.0028195183,0.0001862014,0.015344985,0.0000979264,0.00004327067,0.00002177562,0.0012408795,0.00008253782,0.21551073,0.00016126885,0.764387,0.00010391913],"about_ca_topic_score_codex":0.7844387,"about_ca_topic_score_gemma":0.7669142,"teacher_disagreement_score":0.3758689,"about_ca_system_score_codex":0.00015400964,"about_ca_system_score_gemma":0.0044992273,"threshold_uncertainty_score":0.9944217},"labels":[],"label_agreement":null},{"id":"W6926407573","doi":"10.25316/ir-13003","title":"The Nanaimo Free Press [Thursday, June 13, 1889]","year":2019,"lang":"en","type":"other","venue":"VIUSpace (Vancouver Island University Library)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"","score_opus":0.010036661538751442,"score_gpt":0.214977185860959,"score_spread":0.20494052432220758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6926407573","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000035140267,0.0019441615,0.00004358419,0.0035805618,0.00212699,0.001385694,0.00031422134,0.00047742217,0.9900922],"genre_scores_gemma":[0.00006704583,0.0065690656,0.0001658688,0.00021346977,0.00075521827,0.0000025214133,0.000028726068,0.0005647749,0.9916333],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99729985,0.00019457166,0.00018161738,0.00073464663,0.0008301579,0.00075916696],"domain_scores_gemma":[0.9970203,0.0002431376,0.00022762439,0.002124843,0.00005309931,0.00033099588],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00009887352,0.00053669396,0.000722352,0.00042428402,0.00023929514,0.00011387915,0.0013033525,0.0006272562,0.009746436],"category_scores_gemma":[0.00003448457,0.0004093777,0.00037931377,0.000507484,0.0003594859,0.0003043271,0.0008554417,0.00096394843,0.00041012114],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007747044,0.00010087983,0.00009637058,0.00020011907,0.0005634938,0.00033048738,0.00016803705,0.000002329486,0.00005521859,0.00038146856,0.9960329,0.0012939868],"study_design_scores_gemma":[0.0039113243,0.00020243919,0.00004465,0.00032847183,0.00019966914,0.0000077677305,0.00042371085,0.000033560562,0.00021044585,0.00004807369,0.9941268,0.00046308132],"about_ca_topic_score_codex":0.0017108535,"about_ca_topic_score_gemma":0.24730222,"teacher_disagreement_score":0.24559137,"about_ca_system_score_codex":0.00014164085,"about_ca_system_score_gemma":0.00049868494,"threshold_uncertainty_score":0.9998358},"labels":[],"label_agreement":null},{"id":"W6939276113","doi":"10.6084/m9.figshare.13093604","title":"Additional file 1 of Partnering with patients to get better outcomes with chimeric antigen receptor T-cell therapy: towards engagement of patients in early phase trials","year":2020,"lang":"en","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; Canada's Michael Smith Genome Sciences Centre; University of Ottawa; Ottawa Hospital","funders":"","keywords":"Chimeric antigen receptor; Clinical trial; Phase (matter); MEDLINE; Antigen","score_opus":0.10676808617153956,"score_gpt":0.3383602675787483,"score_spread":0.23159218140720877,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939276113","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.34714514,0.0000068504833,2.2254306e-7,0.00009156961,0.000005870398,0.0010629114,0.6512375,0.000011537046,0.00043841347],"genre_scores_gemma":[0.17890559,0.0000030472318,0.000943832,0.00078247563,0.00008660364,0.0012741011,0.8175338,0.000061268205,0.0004093144],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981285,0.0001492207,0.00044146276,0.0002865917,0.00074746355,0.00024676727],"domain_scores_gemma":[0.99864614,0.00042636791,0.00024252792,0.00021616237,0.00029252828,0.00017627836],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00008575334,0.00018912992,0.00060868886,0.00013425137,0.000023881854,0.0000121867715,0.00014830845,0.000049165577,0.9616075],"category_scores_gemma":[0.0011844612,0.00012989949,0.000099675846,0.00039097725,0.0000138656615,0.00007581808,0.00007027707,0.00018899157,0.0002047651],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027182994,0.0009190318,0.01832009,0.00016910593,0.00015288875,0.000006167774,0.0011078645,0.0000045652646,0.000530895,1.3685544e-8,0.9550478,0.021023313],"study_design_scores_gemma":[0.012312557,0.0070125754,0.3501901,0.0015814605,0.00001304155,1.3796469e-7,0.000062706335,0.000012613586,0.016104927,2.2686872e-7,0.6124845,0.00022511971],"about_ca_topic_score_codex":0.0000152457105,"about_ca_topic_score_gemma":0.0000030779893,"teacher_disagreement_score":0.9614028,"about_ca_system_score_codex":0.000043957993,"about_ca_system_score_gemma":0.00015338742,"threshold_uncertainty_score":0.52971476},"labels":[],"label_agreement":null},{"id":"W6939335640","doi":"10.6084/m9.figshare.22611199","title":"Additional file 2 of Identifying effect modifiers of CAR-T cell therapeutic efficacy: a systematic review and individual patient data meta-analysis protocol","year":2023,"lang":"en","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; National Research Council Canada; University of British Columbia; Ottawa Hospital","funders":"","keywords":"Protocol (science); Patient data; Sample (material); Data collection; Identification (biology)","score_opus":0.2762720757223113,"score_gpt":0.4029468743318842,"score_spread":0.12667479860957287,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939335640","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000008813392,0.0018880628,1.3599809e-7,0.000018284934,0.0000019289325,0.05062587,0.9471889,0.000028537897,0.00023942691],"genre_scores_gemma":[0.00062608474,0.0000074598292,0.0000340722,0.0000764022,0.000010154909,0.20152658,0.796795,0.000024100696,0.0009001528],"study_design_codex":"not_applicable","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9975143,0.0003909819,0.000597925,0.00037025122,0.0009152632,0.0002112523],"domain_scores_gemma":[0.9949147,0.003304723,0.00041545878,0.001054622,0.00020782763,0.00010266903],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003797161,0.00018458081,0.0015978354,0.00031826313,0.000040499577,0.000022411534,0.00035696162,0.000068093505,0.9727297],"category_scores_gemma":[0.0029785065,0.00012803575,0.0005775178,0.0012683445,0.000022018547,0.00007408898,0.00035013157,0.00017651451,0.00032991267],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022011613,0.00005595039,9.19698e-7,0.22980797,0.025811022,0.000010663815,0.00007134084,0.000003144842,0.000056545483,6.7376334e-8,0.74400836,0.00015202396],"study_design_scores_gemma":[0.0036726105,0.0022167657,0.001828367,0.21293877,0.6350521,0.000057036435,0.0002923681,0.003128986,0.0038986804,0.000011479101,0.13595326,0.0009495669],"about_ca_topic_score_codex":0.0000059717863,"about_ca_topic_score_gemma":0.000002559992,"teacher_disagreement_score":0.9723998,"about_ca_system_score_codex":0.000021920585,"about_ca_system_score_gemma":0.00011769991,"threshold_uncertainty_score":0.52211463},"labels":[],"label_agreement":null},{"id":"W6939411255","doi":"10.6084/m9.figshare.28920986","title":"Axicabtagene ciloleucel compared to standard of care in Canadian patients with relapsed or refractory large B-cell lymphoma: a cost-effectiveness analysis of the ZUMA-7 trial","year":2025,"lang":"en","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Chemoimmunotherapy; Refractory (planetary science); Standard of care; Clinical trial; Confidence interval","score_opus":0.03081814673992698,"score_gpt":0.32723172556437974,"score_spread":0.29641357882445274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939411255","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.850022,0.00015645684,6.5516184e-7,0.00003632235,0.0000486361,0.0036410734,0.14350067,0.000010034526,0.0025841503],"genre_scores_gemma":[0.98282236,0.0000016696597,0.000008952592,0.00009461223,0.000012815306,0.0003864697,0.016006883,0.000020881174,0.00064533635],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99814826,0.00025551088,0.00033940416,0.00030718104,0.00056601997,0.00038360545],"domain_scores_gemma":[0.99799144,0.00030724364,0.00011971122,0.0006522891,0.00071836467,0.00021094269],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00019987833,0.000166725,0.00074968487,0.0007873986,0.00006252044,0.000011710549,0.00027017746,0.000119976154,0.02261222],"category_scores_gemma":[0.0007927342,0.00011147965,0.00019038751,0.0027571325,0.000017947426,0.000031444757,0.000095758034,0.00016477455,0.000008803499],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6980813,0.004574411,0.22857176,0.0050921505,0.0038289218,0.00016057324,0.0058709737,0.0006655532,0.0024386586,0.000010501308,0.02818058,0.022524629],"study_design_scores_gemma":[0.1940653,0.0034069738,0.6777421,0.0043891403,0.00063328055,3.1908013e-7,0.0007019271,0.00016243757,0.013266048,8.5867686e-7,0.105359994,0.00027156257],"about_ca_topic_score_codex":0.012997977,"about_ca_topic_score_gemma":0.28808975,"teacher_disagreement_score":0.504016,"about_ca_system_score_codex":0.0013364126,"about_ca_system_score_gemma":0.0026581206,"threshold_uncertainty_score":0.99357456},"labels":[],"label_agreement":null},{"id":"W6939567774","doi":"10.6084/m9.figshare.25744470.v1","title":"Additional file 2 of Mechanism of action, potency and efficacy: considerations for cell therapies","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Mechanism (biology); Potency; Key (lock); Cell; Mechanism of action","score_opus":0.08141334175345424,"score_gpt":0.32790889355422725,"score_spread":0.246495551800773,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939567774","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008163535,0.0002822479,0.0000028410595,0.00020261145,0.000014871351,0.0003644313,0.99587417,0.000026673242,0.0031505509],"genre_scores_gemma":[0.025091242,0.000014802992,0.0016168265,0.000080918035,0.00016907742,0.00087809237,0.95542127,0.000027692195,0.01670008],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9995224,0.000012580125,0.000121582016,0.00011898063,0.00014285604,0.0000816],"domain_scores_gemma":[0.9970182,0.002607938,0.000030761657,0.000099209465,0.00020500971,0.00003883792],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000021001639,0.00005861804,0.000119512064,0.00008394077,0.000035531386,0.000013233756,0.000022914164,0.00005174154,0.9964434],"category_scores_gemma":[0.0010621176,0.000051121307,0.00007007878,0.00008060194,0.000012975374,0.000039323448,0.000016206932,0.00007735147,0.00011227854],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000233605,0.000045020723,5.7166066e-8,0.000533536,0.000045934754,0.000003279285,0.00013712022,2.5908992e-7,0.013881801,0.00012608184,0.98155797,0.003645587],"study_design_scores_gemma":[0.00041164862,0.00028689433,0.00015255762,0.0016208467,0.000015361748,0.000026074387,0.00010169923,0.00037698055,0.04125034,0.0018942283,0.95380515,0.000058211845],"about_ca_topic_score_codex":0.000002078764,"about_ca_topic_score_gemma":0.0000042171414,"teacher_disagreement_score":0.9963311,"about_ca_system_score_codex":0.000013273408,"about_ca_system_score_gemma":0.00020661016,"threshold_uncertainty_score":0.20846663},"labels":[],"label_agreement":null},{"id":"W6939576725","doi":"10.6084/m9.figshare.14313463","title":"Additional file 1 of Hematologists’ barriers and enablers to screening and recruiting patients to a chimeric antigen receptor (CAR) T cell therapy trial: a theory-informed interview study","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Canada's Michael Smith Genome Sciences Centre; University of Ottawa; Ottawa Hospital","funders":"","keywords":"CAR T-cell therapy; Chimeric antigen receptor; Immunotherapy; Antibody therapy; T cell; Antigen; MEDLINE","score_opus":0.08753466445652208,"score_gpt":0.33392228397746976,"score_spread":0.24638761952094768,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939576725","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0888802,0.00027052185,0.0000010150271,0.00008651339,0.0000243898,0.0027316064,0.90581787,0.000038657683,0.0021492522],"genre_scores_gemma":[0.06383971,0.00008801974,0.003814266,0.0022613856,0.00023831292,0.0062876656,0.9171552,0.00013892027,0.006176507],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9984034,0.00021534799,0.00033698414,0.0003679614,0.00038142712,0.0002948825],"domain_scores_gemma":[0.9974549,0.0014772281,0.00011868704,0.0002650367,0.0003227234,0.00036141984],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00016866584,0.0001784065,0.00043243135,0.00015394128,0.00009642546,0.000048352602,0.00011420774,0.000066588254,0.97000897],"category_scores_gemma":[0.007812931,0.00015694565,0.000085844644,0.00046810848,0.000018267618,0.00007345703,0.0002207018,0.00017316068,0.00011141985],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031393403,0.00015348595,0.00016139947,0.00023301247,0.0001221224,0.000017662314,0.0023124765,3.75192e-7,0.00053723657,2.0975304e-7,0.91967964,0.07364306],"study_design_scores_gemma":[0.01587452,0.003469816,0.0064183315,0.005714925,0.000016067534,0.000015066352,0.009423597,0.000015892358,0.0047421474,0.000004610442,0.9539902,0.00031478293],"about_ca_topic_score_codex":0.00000783271,"about_ca_topic_score_gemma":0.0000088561455,"teacher_disagreement_score":0.9698975,"about_ca_system_score_codex":0.000043486132,"about_ca_system_score_gemma":0.00027030447,"threshold_uncertainty_score":0.93533725},"labels":[],"label_agreement":null},{"id":"W6939767888","doi":"10.6084/m9.figshare.25744317","title":"Additional file 1 of Mechanism of action, potency and efficacy: considerations for cell therapies","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Potency; Mechanism (biology); Cell; Product (mathematics); Clinical trial","score_opus":0.08471419520195171,"score_gpt":0.3286717834675676,"score_spread":0.24395758826561587,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6939767888","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008224683,0.00027718156,0.0000029111307,0.00020376364,0.000014771116,0.00036509702,0.99595636,0.000026675496,0.0030709817],"genre_scores_gemma":[0.025597788,0.000014398422,0.0016608255,0.00008105451,0.00016658014,0.0008990909,0.9548848,0.000027784565,0.016667621],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99952227,0.000012584956,0.000121520454,0.00011908163,0.00014289652,0.00008163406],"domain_scores_gemma":[0.99697524,0.0026502293,0.000030713938,0.00009942822,0.0002055324,0.00003884548],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000021132071,0.000058639125,0.00011947898,0.00008400297,0.00003552844,0.0000132013465,0.000022928596,0.0000517412,0.9965188],"category_scores_gemma":[0.0010767896,0.000051140214,0.00007009411,0.000080672864,0.000012975577,0.000039292994,0.00001620951,0.00007737162,0.00011364875],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00002350356,0.000045034223,5.9283842e-8,0.0005280856,0.000045931098,0.000003180441,0.00013698003,2.5767096e-7,0.014436905,0.0001236105,0.9811226,0.003533825],"study_design_scores_gemma":[0.00041327096,0.00029020122,0.00015720486,0.0016630042,0.00001560566,0.000026313897,0.000104091734,0.00038430153,0.042022854,0.0018993422,0.9529648,0.000059034104],"about_ca_topic_score_codex":0.0000020553236,"about_ca_topic_score_gemma":0.00000418909,"teacher_disagreement_score":0.9964052,"about_ca_system_score_codex":0.000013269109,"about_ca_system_score_gemma":0.00020765481,"threshold_uncertainty_score":0.20854373},"labels":[],"label_agreement":null},{"id":"W6949277524","doi":"10.5281/zenodo.14640141","title":"PREreview of \"Safety and Efficacy of Chimeric Antigen Receptor T-cell Therapy for Recurrent Glioblastoma: An Augmented Meta-analysis of Phase 1 Clinical Trials\"","year":2025,"lang":"en","type":"peer-review","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Chimeric antigen receptor; Adverse effect; Disease; Compassionate Use; CAR T-cell therapy; Progression-free survival; Phases of clinical research; Glioblastoma","score_opus":0.2629647973709968,"score_gpt":0.4665238097959352,"score_spread":0.2035590124249384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6949277524","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.014674808,0.77996624,0.0056431475,0.023432765,0.0017595477,0.064619415,0.076232515,0.00096962595,0.032701954],"genre_scores_gemma":[0.0031820561,0.8692299,0.0014499989,0.0005939078,0.0004987826,0.000004399311,0.058589466,0.0028572187,0.063594244],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9894492,0.0049035833,0.0031532352,0.0009833501,0.0011106574,0.00039997135],"domain_scores_gemma":[0.9917698,0.0010191487,0.0020414677,0.0015700912,0.0032521738,0.00034733737],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.014446818,0.0004460805,0.00539682,0.0011303915,0.00029487867,0.00006845575,0.0010877688,0.0002574811,0.06318778],"category_scores_gemma":[0.007046387,0.00033028598,0.002503764,0.0026027441,0.0004501103,0.000083693645,0.00065001025,0.0006417134,0.00004956736],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011404846,0.003990947,9.627228e-7,0.008729543,0.057708137,0.0000019131237,0.00017441867,0.0000032009073,0.005988725,0.000036972357,0.33873925,0.5732211],"study_design_scores_gemma":[0.0063205217,0.008202466,0.000028443783,0.00072595815,0.048401978,0.000004521448,0.00002568023,0.000146683,0.0014615605,0.0000026857685,0.9344629,0.00021659413],"about_ca_topic_score_codex":0.000024005389,"about_ca_topic_score_gemma":0.0000011455973,"teacher_disagreement_score":0.5957236,"about_ca_system_score_codex":0.000102133,"about_ca_system_score_gemma":0.000092321774,"threshold_uncertainty_score":0.99991494},"labels":[],"label_agreement":null},{"id":"W6950229199","doi":"10.5281/zenodo.6132564","title":"Homaxinella amphispicula","year":2014,"lang":"pt","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Griffin; Fish <Actinopterygii>; Fish habitat","score_opus":0.03822627206587388,"score_gpt":0.2734444410469378,"score_spread":0.23521816898106396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6950229199","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08244062,0.000987284,0.008351404,0.00566549,0.0009775924,0.0027410414,0.00037443475,0.0024318877,0.89603025],"genre_scores_gemma":[0.87684244,0.000638415,0.00015908008,0.00083403796,0.0024651128,1.11756016e-7,0.0027440425,0.006661869,0.10965487],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99441683,0.001338889,0.000615532,0.0010423961,0.0013641921,0.0012221549],"domain_scores_gemma":[0.99591637,0.0001148063,0.0002000213,0.0015860688,0.0013157596,0.0008669629],"candidate_categories":["metaepi_narrow","sts","scholarly_communication","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0025345897,0.00042969405,0.0005433545,0.0006369243,0.0028345592,0.00124547,0.0017168476,0.00026843158,0.23296227],"category_scores_gemma":[0.0021462513,0.00045267955,0.00023948184,0.001305743,0.00053504296,0.00022355623,0.0020210396,0.0010477698,0.07157537],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00062944816,0.00064060366,0.000043242315,0.00047194416,0.0002992311,0.0000930819,0.0019760523,0.00004148284,0.074818164,0.0043588593,0.52488977,0.39173812],"study_design_scores_gemma":[0.0026193731,0.001434105,0.0017012844,0.000191541,0.00008852963,0.00034924786,0.00048985303,0.002169031,0.0022101915,0.00009888286,0.9882095,0.00043846987],"about_ca_topic_score_codex":0.00005188266,"about_ca_topic_score_gemma":7.770058e-7,"teacher_disagreement_score":0.7944018,"about_ca_system_score_codex":0.00052635634,"about_ca_system_score_gemma":0.000016000211,"threshold_uncertainty_score":0.9997925},"labels":[],"label_agreement":null},{"id":"W6958028467","doi":"10.6084/m9.figshare.13627439.v1","title":"Additional file 1 of Efficacy and safety of CD22 chimeric antigen receptor (CAR) T cell therapy in patients with B cell malignancies: a protocol for a systematic review and meta-analysis","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of Ottawa; Western University; Ottawa Hospital; University of British Columbia","funders":"","keywords":"Chimeric antigen receptor; CD22; B cell; Immunotherapy; CAR T-cell therapy; T cell; Antigen","score_opus":0.05712757881856177,"score_gpt":0.3170791003207258,"score_spread":0.259951521502164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958028467","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009087386,0.0013054083,2.4435093e-7,0.000020291453,5.5971685e-7,0.08986655,0.9084986,0.000005424986,0.00021205508],"genre_scores_gemma":[0.00022458775,0.00004140838,0.0008908303,0.00017444008,0.000010197629,0.45544234,0.54009724,0.000034463053,0.003084503],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.998536,0.00015024607,0.00049251044,0.00028788572,0.00037437343,0.00015896736],"domain_scores_gemma":[0.99768376,0.000994071,0.00034828184,0.00034297412,0.000556206,0.00007467482],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00010155834,0.00016419841,0.0014565215,0.00012323499,0.000024898938,0.000009193756,0.00007699486,0.000051425057,0.96328694],"category_scores_gemma":[0.00072209974,0.00010800089,0.00028984773,0.00070346706,0.000018440098,0.00004148527,0.000041152332,0.00008454239,0.000014431652],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005812052,0.00068748393,0.000056968904,0.30418512,0.008826583,0.0000034447648,0.00012653251,0.0000011647546,0.00039557065,1.0978229e-7,0.6850777,0.000058073132],"study_design_scores_gemma":[0.03633319,0.008972778,0.027524853,0.29243597,0.070816375,0.00001900475,0.00037237525,0.00013864586,0.021981632,0.000005771998,0.53985065,0.0015487814],"about_ca_topic_score_codex":0.0000031615245,"about_ca_topic_score_gemma":0.000003617675,"teacher_disagreement_score":0.9632725,"about_ca_system_score_codex":0.000022664131,"about_ca_system_score_gemma":0.00017573973,"threshold_uncertainty_score":0.44041485},"labels":[],"label_agreement":null},{"id":"W6958064869","doi":"10.6084/m9.figshare.14313469","title":"Additional file 3 of Hematologists’ barriers and enablers to screening and recruiting patients to a chimeric antigen receptor (CAR) T cell therapy trial: a theory-informed interview study","year":2021,"lang":"en","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Canada's Michael Smith Genome Sciences Centre; University of Ottawa; Ottawa Hospital","funders":"","keywords":"Chimeric antigen receptor; CAR T-cell therapy; Antibody therapy; Immunotherapy; T cell; Antigen; MEDLINE","score_opus":0.0861324749895752,"score_gpt":0.333462124646558,"score_spread":0.2473296496569828,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958064869","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08978707,0.00027285077,0.0000010242499,0.00008642664,0.000024703437,0.0027413114,0.9048786,0.00003874776,0.0021692654],"genre_scores_gemma":[0.06523703,0.00009024541,0.0038134232,0.0022851364,0.0002436843,0.0062438427,0.9155819,0.00014047528,0.0063643013],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99840355,0.00021514733,0.0003371295,0.00036780618,0.0003815024,0.00029486066],"domain_scores_gemma":[0.9974652,0.0014645777,0.000118704615,0.00026465068,0.0003254769,0.0003613884],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00016859185,0.00017838218,0.0004324741,0.00015389152,0.00009641743,0.000048448772,0.00011413819,0.00006658277,0.9692991],"category_scores_gemma":[0.0078109154,0.00015690693,0.00008583934,0.0004679404,0.000018268876,0.00007351175,0.00022054737,0.00017312642,0.000112599206],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031849125,0.0001547444,0.00016301214,0.0002389128,0.00012308166,0.000018023355,0.0023326331,3.7855946e-7,0.00054320425,2.1028933e-7,0.9179611,0.07527978],"study_design_scores_gemma":[0.01592397,0.003430261,0.0063167475,0.0056458404,0.000015767404,0.000014779941,0.0092861205,0.000015756757,0.0047928407,0.000004576974,0.9542417,0.00031164894],"about_ca_topic_score_codex":0.000007918777,"about_ca_topic_score_gemma":0.000008914407,"teacher_disagreement_score":0.9691865,"about_ca_system_score_codex":0.000043653163,"about_ca_system_score_gemma":0.00027044915,"threshold_uncertainty_score":0.9350959},"labels":[],"label_agreement":null},{"id":"W6958106387","doi":"10.6084/m9.figshare.19424825.v1","title":"Additional file 1 of Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; EVERSANA (Canada)","funders":"","keywords":"Sensitivity (control systems); Table (database); Refractory (planetary science); Immunotherapy; Primary (astronomy); Clinical trial","score_opus":0.10080985751320244,"score_gpt":0.33478981893570675,"score_spread":0.23397996142250432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958106387","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.090621606,0.0012307542,4.1734765e-7,0.00003188724,0.00008907066,0.0016939127,0.9050517,0.000056174908,0.0012244942],"genre_scores_gemma":[0.077776656,0.00018097236,0.0014528454,0.000034845238,0.00016403614,0.0036482136,0.8624591,0.00012148852,0.054161824],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99743587,0.00020777223,0.00073291396,0.00047536416,0.000679819,0.00046827373],"domain_scores_gemma":[0.99590856,0.0024655429,0.00066830555,0.00056931196,0.00024402405,0.00014423531],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000081392245,0.00039116447,0.0010804469,0.00029784694,0.00018215722,0.000010383153,0.00024705913,0.00015876153,0.9687058],"category_scores_gemma":[0.00021516591,0.00028980238,0.00046140474,0.0005016803,0.000039070113,0.00006625303,0.00011085867,0.00013293291,0.00015275922],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020820517,0.01141919,0.00004315236,0.0005908573,0.0007944025,0.000031493964,0.0026550845,0.00001682678,0.02536262,1.5207218e-7,0.9240289,0.014236831],"study_design_scores_gemma":[0.0245909,0.020705104,0.0013667793,0.00042826045,0.00013776013,0.000008605829,0.0013976977,0.00031779072,0.119177505,0.000001242736,0.8315922,0.000276153],"about_ca_topic_score_codex":0.00004975305,"about_ca_topic_score_gemma":0.000065215325,"teacher_disagreement_score":0.96855307,"about_ca_system_score_codex":0.000632791,"about_ca_system_score_gemma":0.0008403606,"threshold_uncertainty_score":0.9999554},"labels":[],"label_agreement":null},{"id":"W6958268367","doi":"10.6084/m9.figshare.13093607","title":"Additional file 2 of Partnering with patients to get better outcomes with chimeric antigen receptor T-cell therapy: towards engagement of patients in early phase trials","year":2020,"lang":"en","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; Canada's Michael Smith Genome Sciences Centre; University of Ottawa; Ottawa Hospital","funders":"","keywords":"Chimeric antigen receptor; Clinical trial; Phase (matter); MEDLINE; Antigen","score_opus":0.10340761571144173,"score_gpt":0.33772088003794015,"score_spread":0.2343132643264984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958268367","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.34678704,0.0000069726807,2.1839682e-7,0.00009131801,0.000005917124,0.0010635003,0.6515843,0.0000115606845,0.00044912694],"genre_scores_gemma":[0.1765956,0.0000031283334,0.00092458754,0.0007832734,0.00008793423,0.0012515923,0.8198816,0.000061244085,0.0004110228],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99812883,0.00014917157,0.000441655,0.0002863831,0.0007472821,0.00024667897],"domain_scores_gemma":[0.99865276,0.00042050247,0.00024285015,0.00021575269,0.00029188767,0.00017624792],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00008529857,0.0001890715,0.00060883356,0.000134166,0.000023883555,0.000012212464,0.00014822827,0.000049165854,0.9609195],"category_scores_gemma":[0.0011705876,0.00012985825,0.00009965712,0.0003906821,0.000013865475,0.00007586855,0.000070267466,0.00018894931,0.0002026431],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002712258,0.0009215618,0.01781839,0.00017111807,0.00015335952,0.0000063511166,0.0011121763,0.0000046006576,0.0005146121,1.3962156e-8,0.9549353,0.021650264],"study_design_scores_gemma":[0.012281423,0.0069501377,0.34263176,0.0015483662,0.00001287796,1.3700968e-7,0.00006152218,0.000012418168,0.015863318,2.2655225e-7,0.6204152,0.00022262581],"about_ca_topic_score_codex":0.000015394926,"about_ca_topic_score_gemma":0.0000030956835,"teacher_disagreement_score":0.96071684,"about_ca_system_score_codex":0.000043970223,"about_ca_system_score_gemma":0.00015272437,"threshold_uncertainty_score":0.52954656},"labels":[],"label_agreement":null},{"id":"W6958323770","doi":"10.6084/m9.figshare.19960075","title":"Additional file 4 of Application of blood brain barrier models in pre-clinical assessment of glioblastoma-targeting CAR-T based immunotherapies","year":2022,"lang":"en","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; National Research Council Canada","funders":"","keywords":"Table (database); Antibody; Immune system; Immunotherapy; Monoclonal antibody","score_opus":0.03444660161805825,"score_gpt":0.34538094404969144,"score_spread":0.3109343424316332,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958323770","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.004835948,0.00010851708,0.0000098227765,0.000054914974,0.0000065013924,0.00060870417,0.9931672,0.000013963752,0.0011944005],"genre_scores_gemma":[0.29706362,0.000001549448,0.0014517895,0.000110572946,0.000054310854,0.0028150543,0.6976274,0.00003486519,0.00084083254],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99816656,0.00020113462,0.00059861434,0.0002255711,0.00064876524,0.00015936064],"domain_scores_gemma":[0.9965573,0.0025232155,0.00031256108,0.00032558935,0.00022920182,0.00005215812],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000282137,0.00009911726,0.00035124892,0.00018135867,0.000032886208,0.0000029296766,0.00018553104,0.00006755333,0.98845696],"category_scores_gemma":[0.0011237365,0.000104648236,0.0001729317,0.0003554146,0.000030191359,0.000045140296,0.0001169023,0.00032801146,0.000008334741],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044157516,0.00074503827,0.00015031557,0.0004089213,0.00012536236,0.0000052904993,0.00018845762,0.0021804373,0.026379723,0.0000065144327,0.9663816,0.0029867345],"study_design_scores_gemma":[0.008169523,0.0040963814,0.035536766,0.003776685,0.00006128835,0.000016434287,0.0005518017,0.28992617,0.025316471,0.00019787106,0.6319015,0.0004490691],"about_ca_topic_score_codex":0.00003315678,"about_ca_topic_score_gemma":0.000009148771,"teacher_disagreement_score":0.9884486,"about_ca_system_score_codex":0.00006134063,"about_ca_system_score_gemma":0.0005782292,"threshold_uncertainty_score":0.42674312},"labels":[],"label_agreement":null},{"id":"W6958564055","doi":"10.6084/m9.figshare.28920986.v2","title":"Axicabtagene ciloleucel compared to standard of care in Canadian patients with relapsed or refractory large B-cell lymphoma: a cost-effectiveness analysis of the ZUMA-7 trial","year":2025,"lang":"en","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Chemoimmunotherapy; Refractory (planetary science); Standard of care; Clinical trial; Confidence interval","score_opus":0.03081814673992698,"score_gpt":0.32723172556437974,"score_spread":0.29641357882445274,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6958564055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.850022,0.00015645684,6.5516184e-7,0.00003632235,0.0000486361,0.0036410734,0.14350067,0.000010034526,0.0025841503],"genre_scores_gemma":[0.98282236,0.0000016696597,0.000008952592,0.00009461223,0.000012815306,0.0003864697,0.016006883,0.000020881174,0.00064533635],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99814826,0.00025551088,0.00033940416,0.00030718104,0.00056601997,0.00038360545],"domain_scores_gemma":[0.99799144,0.00030724364,0.00011971122,0.0006522891,0.00071836467,0.00021094269],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00019987833,0.000166725,0.00074968487,0.0007873986,0.00006252044,0.000011710549,0.00027017746,0.000119976154,0.02261222],"category_scores_gemma":[0.0007927342,0.00011147965,0.00019038751,0.0027571325,0.000017947426,0.000031444757,0.000095758034,0.00016477455,0.000008803499],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6980813,0.004574411,0.22857176,0.0050921505,0.0038289218,0.00016057324,0.0058709737,0.0006655532,0.0024386586,0.000010501308,0.02818058,0.022524629],"study_design_scores_gemma":[0.1940653,0.0034069738,0.6777421,0.0043891403,0.00063328055,3.1908013e-7,0.0007019271,0.00016243757,0.013266048,8.5867686e-7,0.105359994,0.00027156257],"about_ca_topic_score_codex":0.012997977,"about_ca_topic_score_gemma":0.28808975,"teacher_disagreement_score":0.504016,"about_ca_system_score_codex":0.0013364126,"about_ca_system_score_gemma":0.0026581206,"threshold_uncertainty_score":0.99357456},"labels":[],"label_agreement":null},{"id":"W6968743015","doi":"10.5281/zenodo.15058299","title":"Actualización de Seguridad - Health Canada realizó una evaluación del riesgo potencial de neoplasia maligna secundaria a las terapias CAR-T.","year":2025,"lang":"es","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Public health; Cancer; Epidemiology; Disease; Radiation therapy","score_opus":0.021146751330155006,"score_gpt":0.3102873918132703,"score_spread":0.2891406404831153,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6968743015","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.573179,0.005046033,0.009459726,0.05018837,0.0017096825,0.008062095,0.006158623,0.002705638,0.34349087],"genre_scores_gemma":[0.95811474,0.0023296191,0.00044488924,0.005744171,0.0012383624,9.768974e-7,0.0039175544,0.0035754582,0.024634227],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9911846,0.0027381731,0.00096987555,0.0011815464,0.0017471476,0.0021786457],"domain_scores_gemma":[0.9952608,0.00019755492,0.00031955415,0.0014231786,0.00153734,0.0012615842],"candidate_categories":["metaepi_narrow","sts","scholarly_communication","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0036481288,0.00060904736,0.00082034187,0.00084575516,0.0042466284,0.0015956678,0.0018146994,0.00033809163,0.038421135],"category_scores_gemma":[0.0023602715,0.00068454415,0.00021023896,0.0021781889,0.0005574155,0.00024421696,0.0016953772,0.0014191038,0.0012776181],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021064698,0.0005113367,0.00047279708,0.0018207878,0.0009113793,0.0005147533,0.0070349616,0.00014693513,0.026876006,0.012638123,0.79140925,0.15555722],"study_design_scores_gemma":[0.0030956906,0.00095718843,0.0062794755,0.00082733214,0.00014138862,0.0004896776,0.00190447,0.0015424957,0.0027911242,0.0004299882,0.98102903,0.00051216304],"about_ca_topic_score_codex":0.17726518,"about_ca_topic_score_gemma":0.0056387526,"teacher_disagreement_score":0.38493577,"about_ca_system_score_codex":0.0064087454,"about_ca_system_score_gemma":0.0024837537,"threshold_uncertainty_score":0.9995606},"labels":[],"label_agreement":null},{"id":"W6976873748","doi":"10.6084/m9.figshare.29387378.v1","title":"Revaccination following CAR-T therapy: a needs assessment","year":2025,"lang":"en","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Focus group; CLARITY; Needs assessment; Audit; Primary care; Qualitative research; Patient education; Schedule","score_opus":0.056052696427784744,"score_gpt":0.3870660347820867,"score_spread":0.3310133383543019,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6976873748","genre_codex":"other","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12636411,0.0065103676,0.000040466744,0.010164584,0.00070117746,0.005353892,0.01700846,0.00081971526,0.8330372],"genre_scores_gemma":[0.8768684,0.00005253231,0.00018503911,0.0019959796,0.00026349418,0.00065898406,0.037092026,0.000047533038,0.082835965],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990246,0.00004985342,0.00015647826,0.0001858912,0.0003506429,0.00023250016],"domain_scores_gemma":[0.99927807,0.00012383553,0.000030769614,0.00035154392,0.00014463974,0.000071148184],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00012523394,0.00011581794,0.00019847424,0.0002801824,0.000080784324,0.000052698593,0.00012467375,0.000092154914,0.27669695],"category_scores_gemma":[0.0003045049,0.00010276156,0.00017426573,0.0006619773,0.000002122225,0.00007395758,0.00006681772,0.00025149394,0.00031867184],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016105242,0.00019781358,0.005099095,0.00039745195,0.00039273346,0.00009784263,0.00036002175,0.0000040823497,0.052554674,0.00011639439,0.69120485,0.24941398],"study_design_scores_gemma":[0.002668078,0.00018761896,0.048171896,0.0019559548,0.000025129073,0.0000068692684,0.00017529356,0.00035138289,0.011223595,0.00007986185,0.93500894,0.00014540528],"about_ca_topic_score_codex":0.000009863204,"about_ca_topic_score_gemma":0.0000044149647,"teacher_disagreement_score":0.7505043,"about_ca_system_score_codex":0.00024609486,"about_ca_system_score_gemma":0.00033979933,"threshold_uncertainty_score":0.7239643},"labels":[],"label_agreement":null},{"id":"W6976939000","doi":"10.6084/m9.figshare.25397536.v1","title":"Additional file 1 of CAR T cells and T cells phenotype and function are impacted by glucocorticoid exposure with different magnitude","year":2024,"lang":"en","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"CD19; CD8; T cell; Cytotoxic T cell; Interleukin 21; Phenotype; Interleukin 3","score_opus":0.017155511829438915,"score_gpt":0.2405484962564494,"score_spread":0.22339298442701047,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6976939000","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.032685015,0.000797044,3.5444177e-7,0.00003288326,0.000021163949,0.0004011649,0.9653722,0.000046397352,0.0006437669],"genre_scores_gemma":[0.10677579,0.000026848813,0.000032442837,0.000085450614,0.00014500415,0.0003164822,0.8810251,0.000049927738,0.011542973],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9990794,0.000024232288,0.0001308966,0.00026896765,0.00031023592,0.0001862821],"domain_scores_gemma":[0.9990029,0.00051309797,0.000048386708,0.0001604893,0.00012890427,0.00014625565],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000012780866,0.0001520115,0.0002178139,0.00008005002,0.000029517912,0.000046372406,0.000036596073,0.000087290915,0.9837069],"category_scores_gemma":[0.000106283944,0.00011206195,0.000041111423,0.0001463778,0.000021782234,0.00006350021,0.000043911743,0.00022206988,0.00027020747],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022852897,0.000051248393,0.000031991185,0.00091447134,0.00009492279,0.000029657152,0.000055650133,6.58083e-7,0.06822157,1.6170397e-7,0.92643857,0.003932586],"study_design_scores_gemma":[0.0010231137,0.0015089564,0.032417573,0.005721532,0.000076659264,0.000040004532,0.00015241952,0.00038435214,0.030214667,0.0000054404322,0.9282352,0.00022011666],"about_ca_topic_score_codex":0.000005793973,"about_ca_topic_score_gemma":0.0000106854695,"teacher_disagreement_score":0.9834367,"about_ca_system_score_codex":0.000041739782,"about_ca_system_score_gemma":0.000093848714,"threshold_uncertainty_score":0.45697537},"labels":[],"label_agreement":null},{"id":"W6976993400","doi":"10.6084/m9.figshare.21968360.v1","title":"Cost-effectiveness of idecabtagene vicleucel compared with conventional care in triple-class exposed relapsed/refractory multiple myeloma patients in Canada and France","year":2023,"lang":"en","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Multiple myeloma; Population; Clinical trial; Standard of care; Survival analysis; Relative survival","score_opus":0.05145052267298273,"score_gpt":0.29677436454742906,"score_spread":0.24532384187444634,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6976993400","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96940976,0.00022050159,1.5101449e-7,0.000010910024,0.00004374298,0.0016052269,0.02850507,0.000019589626,0.00018503152],"genre_scores_gemma":[0.9603241,0.000008055609,0.000008857122,0.000030873747,0.000014595598,0.00047790463,0.038904235,0.00003132356,0.00020006963],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99838865,0.00016664347,0.00027974474,0.0003178664,0.0005362136,0.000310862],"domain_scores_gemma":[0.9986782,0.00059974304,0.00008762087,0.0002268781,0.0002784991,0.00012905583],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000111165005,0.000156968,0.0003971728,0.00022068048,0.000032620494,0.000007776752,0.00010944631,0.00007276994,0.009340559],"category_scores_gemma":[0.00042637144,0.00014823102,0.000036200152,0.0006523771,0.000021649077,0.00007256297,0.000067387824,0.0002667104,0.000026990409],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029761535,0.0001574722,0.9776492,0.0017786978,0.000041940028,0.00025287393,0.00056833966,0.0001963523,0.007291063,2.9794217e-7,0.0031917302,0.0058958633],"study_design_scores_gemma":[0.014483879,0.00027260772,0.9680693,0.0029467542,0.0000042539828,0.000002305554,0.00045337252,0.0009026412,0.008912871,9.653936e-7,0.0038093664,0.00014168379],"about_ca_topic_score_codex":0.07748421,"about_ca_topic_score_gemma":0.53130984,"teacher_disagreement_score":0.45382565,"about_ca_system_score_codex":0.0006569659,"about_ca_system_score_gemma":0.0009798157,"threshold_uncertainty_score":0.99156505},"labels":[],"label_agreement":null},{"id":"W6977145869","doi":"10.6084/m9.figshare.13093607.v1","title":"Additional file 2 of Partnering with patients to get better outcomes with chimeric antigen receptor T-cell therapy: towards engagement of patients in early phase trials","year":2020,"lang":"en","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; Canada's Michael Smith Genome Sciences Centre; University of Ottawa; Ottawa Hospital","funders":"","keywords":"Chimeric antigen receptor; Clinical trial; Phase (matter); MEDLINE; Antigen","score_opus":0.10340761571144173,"score_gpt":0.33772088003794015,"score_spread":0.2343132643264984,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6977145869","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.34678704,0.0000069726807,2.1839682e-7,0.00009131801,0.000005917124,0.0010635003,0.6515843,0.0000115606845,0.00044912694],"genre_scores_gemma":[0.1765956,0.0000031283334,0.00092458754,0.0007832734,0.00008793423,0.0012515923,0.8198816,0.000061244085,0.0004110228],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99812883,0.00014917157,0.000441655,0.0002863831,0.0007472821,0.00024667897],"domain_scores_gemma":[0.99865276,0.00042050247,0.00024285015,0.00021575269,0.00029188767,0.00017624792],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00008529857,0.0001890715,0.00060883356,0.000134166,0.000023883555,0.000012212464,0.00014822827,0.000049165854,0.9609195],"category_scores_gemma":[0.0011705876,0.00012985825,0.00009965712,0.0003906821,0.000013865475,0.00007586855,0.000070267466,0.00018894931,0.0002026431],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002712258,0.0009215618,0.01781839,0.00017111807,0.00015335952,0.0000063511166,0.0011121763,0.0000046006576,0.0005146121,1.3962156e-8,0.9549353,0.021650264],"study_design_scores_gemma":[0.012281423,0.0069501377,0.34263176,0.0015483662,0.00001287796,1.3700968e-7,0.00006152218,0.000012418168,0.015863318,2.2655225e-7,0.6204152,0.00022262581],"about_ca_topic_score_codex":0.000015394926,"about_ca_topic_score_gemma":0.0000030956835,"teacher_disagreement_score":0.96071684,"about_ca_system_score_codex":0.000043970223,"about_ca_system_score_gemma":0.00015272437,"threshold_uncertainty_score":0.52954656},"labels":[],"label_agreement":null},{"id":"W6977398995","doi":"10.6084/m9.figshare.28301094","title":"Additional file 2 of Allogeneic DNT cell therapy synergizes with T cells to promote anti-leukemic activities while suppressing GvHD","year":2025,"lang":"en","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Toronto General Hospital; University of Calgary","funders":"","keywords":"Cell therapy; Cell; Immunotherapy; T cell; Antibody therapy; Transplantation; Cell culture; Disease","score_opus":0.02810389943053269,"score_gpt":0.27530042683255035,"score_spread":0.24719652740201767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6977398995","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0133197745,0.00019505431,5.9712147e-7,0.000081471364,0.000022839422,0.0007188635,0.96159,0.00006364494,0.024007758],"genre_scores_gemma":[0.049131416,0.000021594118,0.0012789062,0.0005069676,0.00018684856,0.0017468455,0.8774587,0.000077773315,0.06959094],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99859416,0.000050356037,0.00020047578,0.00035598257,0.00044337488,0.0003556236],"domain_scores_gemma":[0.9984192,0.00074152276,0.00008736778,0.00041282622,0.00021439885,0.00012463071],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000034489836,0.00021008105,0.0003562986,0.00022233662,0.00008646405,0.00004362938,0.000210086,0.000109739536,0.99490553],"category_scores_gemma":[0.00018149757,0.00016991088,0.000114378156,0.00037350535,0.000030367986,0.000088360124,0.000102648286,0.00024387256,0.0005288988],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002095471,0.00012900445,0.0000051317725,0.00028923867,0.00007554185,0.000027599692,0.00011263183,0.000029473298,0.15393515,1.829985e-7,0.8359139,0.009272576],"study_design_scores_gemma":[0.0005480408,0.00025119592,0.001092606,0.0023760092,0.0000072623466,0.0000068510963,0.00006591762,0.00004274352,0.39135113,0.00000223801,0.60414135,0.000114652896],"about_ca_topic_score_codex":0.0000067225074,"about_ca_topic_score_gemma":0.0000044627113,"teacher_disagreement_score":0.9943766,"about_ca_system_score_codex":0.00012031711,"about_ca_system_score_gemma":0.00071810134,"threshold_uncertainty_score":0.69287646},"labels":[],"label_agreement":null},{"id":"W6981320802","doi":"","title":"EDSP 553-01 Assessment and Program Planning for Transition Education and Services","year":2016,"lang":"en","type":"article","venue":"Exhibit - A Showcase of Scholarship, Creativity and Preservation Provided by Xavier University Library (Xavier University)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences","funders":"","keywords":"Program evaluation; Transition (genetics); Program Design Language; Plan (archaeology)","score_opus":0.027443273586005075,"score_gpt":0.29899967708934533,"score_spread":0.27155640350334026,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6981320802","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9862825,0.0005445491,0.00073935714,0.0051468457,0.000027715332,0.0019433832,0.00024991328,0.00011280235,0.004952928],"genre_scores_gemma":[0.95232415,0.001437598,0.0060398798,0.00020221253,0.000062768195,0.000008115897,0.00041479117,0.000039094237,0.0394714],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.99822366,0.00034660555,0.00020829178,0.0006070656,0.00031442006,0.00029996556],"domain_scores_gemma":[0.9986046,0.00037077797,0.0001880169,0.00028719043,0.0001893497,0.00036006237],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00038831,0.0002623556,0.0003971417,0.00052464876,0.00039203907,0.00012056306,0.000171811,0.00023854934,0.0003321765],"category_scores_gemma":[0.00003359681,0.0002538814,0.00009291762,0.0005091127,0.0002774388,0.0064958395,0.00018956522,0.00029732607,5.828399e-7],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008414113,0.0020265437,0.55568403,0.0032484827,0.00054101937,0.00010159499,0.0038740796,0.0000018381614,0.10916543,0.0074824807,0.0016410167,0.3078194],"study_design_scores_gemma":[0.021969344,0.0046168882,0.29790387,0.0045939498,0.0013299504,0.00013022711,0.012981622,0.0008379548,0.0382495,0.0033212404,0.6125648,0.0015006888],"about_ca_topic_score_codex":0.00008288111,"about_ca_topic_score_gemma":0.00002739178,"teacher_disagreement_score":0.61092377,"about_ca_system_score_codex":0.00011329192,"about_ca_system_score_gemma":0.0003814916,"threshold_uncertainty_score":0.99999136},"labels":[],"label_agreement":null},{"id":"W69901490","doi":"10.4049/jimmunol.182.supp.41.37","title":"Adoptive therapy of a fast growing tumor with reactivated memory T cells combined with anti-4-1BB eliminates tumors through effects of anti-4-1BB on transferred but not host cells (41.37)","year":2009,"lang":"en","type":"article","venue":"The Journal of Immunology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Adoptive cell transfer; Immunotherapy; Immunology; CD8; Cancer research; Cytotoxic T cell; Priming (agriculture); Cancer immunotherapy; T cell; Biology; Ex vivo; In vivo; Immune system; In vitro","score_opus":0.013069246956785657,"score_gpt":0.2555432166990163,"score_spread":0.24247396974223065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W69901490","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959594,0.0010604456,0.00008361346,0.0012294841,0.00015702371,0.0011114992,0.000011720213,0.000026023241,0.00036081762],"genre_scores_gemma":[0.996229,0.0027230864,0.0002545651,0.000421277,0.000069897964,0.000005369478,0.0000044587846,0.00007383745,0.00021849899],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9967013,0.0006824711,0.00089837966,0.00028176827,0.0008078425,0.0006282524],"domain_scores_gemma":[0.9963689,0.0012927846,0.0008656778,0.0006522796,0.0007161615,0.00010420131],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008089843,0.00048589957,0.0016964078,0.00037011085,0.00011820645,0.000014319253,0.0005853145,0.00014866849,0.00012748706],"category_scores_gemma":[0.00007322618,0.00026749846,0.00027693415,0.00066096795,0.0008380189,0.00025227474,0.000031776035,0.0012947045,0.000004553436],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.057918124,0.0013366682,0.00010581444,0.00011872118,0.0013434951,0.00063393876,0.0044323187,0.00015585941,0.93162566,0.000019594761,0.00003996555,0.002269841],"study_design_scores_gemma":[0.01452549,0.04401688,0.024048354,0.0015464212,0.00024844837,0.001068604,0.0027883912,0.00002310468,0.91144353,0.000022090831,0.000034132645,0.00023452369],"about_ca_topic_score_codex":0.000153581,"about_ca_topic_score_gemma":0.000003063951,"teacher_disagreement_score":0.043392632,"about_ca_system_score_codex":0.00012505757,"about_ca_system_score_gemma":0.00035540486,"threshold_uncertainty_score":0.9999777},"labels":[],"label_agreement":null},{"id":"W6996006929","doi":"","title":"Profil d'application québécois de métadonnées pour les opportunités d'étude, d'apprentissage et de formation (v0.7.5)","year":2011,"lang":"fr","type":"other","venue":"Bibliothèque et Archives nationales du Québec (Québec government)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Work (physics); Process (computing); Term (time)","score_opus":0.03026081497946018,"score_gpt":0.2740971606121987,"score_spread":0.2438363456327385,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6996006929","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.08533496,0.01694073,0.0359912,0.01934558,0.00021331497,0.0035471434,0.00072666234,0.00042028373,0.8374801],"genre_scores_gemma":[0.20976812,0.015319071,0.005614448,0.0022077006,0.0016297428,0.0017028878,0.0004236785,0.00078256126,0.7625518],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9924724,0.0012830634,0.0013887332,0.0012268329,0.002244094,0.0013848455],"domain_scores_gemma":[0.98985916,0.0066226376,0.0012304557,0.0011281952,0.00025246863,0.0009070597],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0019761962,0.0011751463,0.0010505201,0.0022876211,0.00042196433,0.00042510996,0.0013784694,0.00054814643,0.10155823],"category_scores_gemma":[0.00297095,0.0012125585,0.00069887267,0.0011291014,0.00075396703,0.0008388341,0.00066443917,0.001608188,0.0016456017],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0027388646,0.005479807,0.21544257,0.005312397,0.0031474424,0.00029019322,0.041470867,0.00025656397,0.15796238,0.10736053,0.3568941,0.10364428],"study_design_scores_gemma":[0.0028775223,0.00041196376,0.2145045,0.0014680154,0.00041857836,0.00038489877,0.0013487769,0.0027274294,0.005255734,0.00073433993,0.7687655,0.001102715],"about_ca_topic_score_codex":0.31644782,"about_ca_topic_score_gemma":0.92691815,"teacher_disagreement_score":0.61047035,"about_ca_system_score_codex":0.014960044,"about_ca_system_score_gemma":0.10276203,"threshold_uncertainty_score":0.99913174},"labels":[],"label_agreement":null},{"id":"W7008270954","doi":"","title":"Biotech Stock News Bite - Heron Therapeutics, Inc. (Nasdaq: HRTX) Higher on Fourth Quarter and Full-Year 2023 Financial Results","year":2024,"lang":"en","type":"other","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Heron; Stock (firearms); Quarter (Canadian coin); Stock exchange","score_opus":0.038414313554182344,"score_gpt":0.32102282507862245,"score_spread":0.2826085115244401,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7008270954","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00066316046,0.003517997,0.000038248978,0.009271821,0.001597517,0.0019046703,0.00036753257,0.0005830734,0.98205596],"genre_scores_gemma":[0.00048367726,0.002304775,0.0004782417,0.0019991123,0.003133496,0.000053022053,0.00016542811,0.00087935,0.9905029],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9965793,0.00013009287,0.00050073257,0.0011684397,0.0009053729,0.00071605283],"domain_scores_gemma":[0.9982241,0.00010434584,0.00013599762,0.0011754694,0.000075198426,0.0002849205],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0003763923,0.0006809509,0.0008464823,0.00086135056,0.00005021424,0.00013013183,0.00024946156,0.0012342914,0.023910584],"category_scores_gemma":[0.000029345862,0.0005102832,0.00021235437,0.00044760297,0.00021266293,0.00003312325,0.00015004029,0.0014904195,0.0044607483],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023179317,0.00015190733,0.000028423021,0.00027968007,0.00038132456,0.000151,0.00012298962,1.4973106e-7,0.0034570016,0.00028468826,0.96970564,0.023119256],"study_design_scores_gemma":[0.0034132658,0.0023133534,0.00022817096,0.0007385156,0.00015677536,0.000021254264,0.000056801935,0.000028283797,0.00027007985,0.00014216443,0.99211085,0.00052049884],"about_ca_topic_score_codex":0.0013346063,"about_ca_topic_score_gemma":0.0013936523,"teacher_disagreement_score":0.022598756,"about_ca_system_score_codex":0.00017672316,"about_ca_system_score_gemma":0.00023319389,"threshold_uncertainty_score":0.9997349},"labels":[],"label_agreement":null},{"id":"W7008907978","doi":"","title":"Cytokinetics Reports First Quarter 2020 Financial Results","year":2020,"lang":"en","type":"other","venue":"","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Payment; Government (linguistics)","score_opus":0.018847881570827358,"score_gpt":0.28743966741341825,"score_spread":0.2685917858425909,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7008907978","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000019385438,0.00040264984,0.000059693448,0.009527019,0.0005907537,0.00093992054,0.00007896018,0.00034999548,0.9880316],"genre_scores_gemma":[0.0003404422,0.00063058373,0.0009655217,0.0015178381,0.0041719805,0.000028950562,0.00034306585,0.0005051571,0.99149644],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9975518,0.00003230013,0.00052654394,0.00073097215,0.0007520383,0.00040635577],"domain_scores_gemma":[0.99838537,0.000055983113,0.00019854576,0.0009615788,0.000058713144,0.00033980174],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00017454835,0.00034904736,0.0006741613,0.0001670391,0.000031419004,0.000030019122,0.00013779945,0.0005384705,0.07490095],"category_scores_gemma":[0.00038703778,0.00029066284,0.00022858281,0.0003089955,0.00009420867,0.0000113573215,0.00009461562,0.00065314746,0.00092969765],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00048126865,0.00007223724,0.00012389387,0.0002063474,0.000091665264,0.0041152444,0.00009683708,1.5569302e-7,0.00053223333,0.000015751459,0.99211323,0.002151111],"study_design_scores_gemma":[0.0014389929,0.0005394208,0.00040121656,0.00026630925,0.000068027075,0.00029475687,0.000013835818,0.00001757604,0.0003553418,0.000020173826,0.9963067,0.0002776521],"about_ca_topic_score_codex":0.00035810575,"about_ca_topic_score_gemma":0.00068657106,"teacher_disagreement_score":0.07397125,"about_ca_system_score_codex":0.000077752375,"about_ca_system_score_gemma":0.0003201546,"threshold_uncertainty_score":0.9999545},"labels":[],"label_agreement":null},{"id":"W7072023979","doi":"","title":"Understanding Goals of Care for Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy: A Qualitative Descriptive Study","year":2024,"lang":"en","type":"dissertation","venue":"MacSphere (McMaster University)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Qualitative research; Content analysis; Health care; Descriptive statistics; Health professionals; Nurse practitioners; Descriptive research; Chimeric antigen receptor","score_opus":0.0781463891152325,"score_gpt":0.32092183032084565,"score_spread":0.24277544120561315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7072023979","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.64627516,0.001253965,0.0002651584,0.000024219858,0.0007754044,0.006219947,0.00026155845,0.000111081186,0.3448135],"genre_scores_gemma":[0.4482739,0.0005081522,0.0003573992,0.000011950412,0.000081029924,0.000016967277,0.00094056036,0.00016741028,0.5496426],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.99725014,0.0003665188,0.00041554403,0.0008082976,0.00068664236,0.0004728684],"domain_scores_gemma":[0.9981909,0.00037496327,0.00033816425,0.00035125308,0.0005762677,0.00016846515],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00021732945,0.00051087124,0.0009082456,0.0006769426,0.00019960852,0.000060417093,0.0003155978,0.00031192636,0.027618153],"category_scores_gemma":[0.000044037937,0.00051758526,0.0004559866,0.0010004983,0.000091053946,0.00015814356,0.0000806364,0.0004968252,0.00003165905],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027367067,0.002522741,0.011936408,0.007390824,0.0047654365,0.00013043289,0.83198535,0.000011840672,0.012499303,0.00043317597,0.0016207594,0.09933664],"study_design_scores_gemma":[0.008828813,0.006455158,0.000772497,0.0011755218,0.0005493871,4.3489786e-7,0.9518831,0.000015265972,0.0028855435,0.000105707935,0.026814258,0.0005143555],"about_ca_topic_score_codex":0.00020675421,"about_ca_topic_score_gemma":0.0012236343,"teacher_disagreement_score":0.20482911,"about_ca_system_score_codex":0.0016828299,"about_ca_system_score_gemma":0.00065099646,"threshold_uncertainty_score":0.99972755},"labels":[],"label_agreement":null},{"id":"W7083882660","doi":"","title":"U.S. health officials alarmed by paralyzing illness in kids","year":2019,"lang":"en","type":"other","venue":"Internet Archive (Internet Archive)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Public health; Health care; MEDLINE; Sociology of health and illness","score_opus":0.019011597961485247,"score_gpt":0.30973603303536773,"score_spread":0.29072443507388246,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7083882660","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0041496917,0.0030950177,0.0027623533,0.0015853437,0.0013352111,0.0045850007,0.0012653851,0.00047124614,0.98075074],"genre_scores_gemma":[0.016109476,0.0018077634,0.0007595247,0.0016770975,0.00088304956,0.00022157923,0.002410329,0.0014684119,0.9746628],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99250346,0.0010299116,0.0014633349,0.0019173195,0.0012038467,0.0018821303],"domain_scores_gemma":[0.99625516,0.0006533263,0.00071415096,0.001516625,0.000050692048,0.000810032],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0008134081,0.0012331164,0.0026982073,0.0020861975,0.00003213029,0.0001342234,0.0013731807,0.000426926,0.030175831],"category_scores_gemma":[0.0001811937,0.0011630262,0.0007334651,0.00036215867,0.0006515491,0.000075024436,0.0009824474,0.002470353,0.004033238],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015460697,0.00058961613,0.00398648,0.0010629027,0.0007535425,0.00030651604,0.003509262,0.0000031850084,0.0056567965,0.00049544696,0.9726722,0.009417958],"study_design_scores_gemma":[0.0039967117,0.001184402,0.0011530427,0.005735677,0.00006635123,0.00015591946,0.00015566855,0.0008417164,0.0009729162,0.00022137251,0.9844512,0.0010650285],"about_ca_topic_score_codex":0.06729574,"about_ca_topic_score_gemma":0.0326274,"teacher_disagreement_score":0.034668338,"about_ca_system_score_codex":0.00044367657,"about_ca_system_score_gemma":0.0007524494,"threshold_uncertainty_score":0.99983096},"labels":[],"label_agreement":null},{"id":"W7084101606","doi":"10.6084/m9.figshare.29982898.v1","title":"Raw data for Quebec dairy herd housing and management survey (2020–2021)","year":2025,"lang":"en","type":"dataset","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Raw data; Survey data collection; Herd; Aerial survey; Raw milk; Dairy farming","score_opus":0.12636119696762343,"score_gpt":0.3878958058395975,"score_spread":0.26153460887197405,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7084101606","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0000015917933,0.0020550939,0.0000016176111,0.00020222101,0.00016561564,0.002198378,0.9950318,0.000033398323,0.0003102877],"genre_scores_gemma":[7.4971825e-7,0.0009843113,0.00008154448,0.00044658728,0.00052676396,0.0003631053,0.9752132,0.000039693135,0.022343993],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99760205,0.00012925419,0.0003248172,0.0009798728,0.00049417955,0.00046980623],"domain_scores_gemma":[0.99607706,0.0006509857,0.00011451897,0.0027864662,0.0001907213,0.00018027535],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00043206057,0.0003540741,0.00060754997,0.00023460375,0.000120327466,0.00018316018,0.0008703525,0.00032136188,0.2450722],"category_scores_gemma":[0.0016121432,0.00034359985,0.000087172724,0.00033990102,0.00001939401,0.000092836795,0.0021355685,0.0005107916,0.00016339336],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028131125,0.00006245487,0.0000055814908,0.00816297,0.00037426248,0.00022861082,0.0000042655006,3.2801105e-7,0.000003367877,1.3916781e-7,0.9614432,0.029433547],"study_design_scores_gemma":[0.0013059708,0.000072271374,0.0006214215,0.006160052,0.00014865019,0.000009220581,0.000015205529,0.000063633626,0.000010276058,0.0000014556042,0.991316,0.00027582425],"about_ca_topic_score_codex":0.0030667991,"about_ca_topic_score_gemma":0.022587277,"teacher_disagreement_score":0.24490881,"about_ca_system_score_codex":0.00018455979,"about_ca_system_score_gemma":0.00046979563,"threshold_uncertainty_score":0.9999016},"labels":[],"label_agreement":null},{"id":"W7092477290","doi":"10.51731/cjht.2025.1256","title":"Glofitamab (Columvi)","year":2025,"lang":"","type":"article","venue":"Canadian Journal of Health Technologies","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Oxaliplatin; Gemcitabine; Refractory (planetary science); Lymphoma; Drug; Chemotherapy; Diffuse large B-cell lymphoma","score_opus":0.0406180561604166,"score_gpt":0.3553585270236323,"score_spread":0.3147404708632157,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7092477290","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.037663367,0.63014287,0.0004506971,0.3146594,0.003821993,0.001307657,0.000049761085,0.00013870717,0.0117655955],"genre_scores_gemma":[0.96906686,0.015890565,0.00039661088,0.002303218,0.000070130496,0.000011633036,0.0000021942626,0.00004414886,0.012214641],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9949108,0.00027867084,0.0019317513,0.0003853828,0.0005597314,0.0019336626],"domain_scores_gemma":[0.99650466,0.0002805648,0.00079766725,0.0010031188,0.00094620977,0.00046777548],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0031200633,0.0003818092,0.0014204368,0.0041709393,0.0007275847,0.00016367379,0.0013325637,0.0007094966,0.002305758],"category_scores_gemma":[0.0031810326,0.00036778144,0.00036407102,0.0024886942,0.0013247795,0.00017206105,0.00010508289,0.0028830355,0.00006778003],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00013111763,0.000055158478,0.008538809,0.0007618598,0.0003623947,0.0008260594,0.0002872741,0.000005612654,0.0003166235,0.002435342,0.04880955,0.9374702],"study_design_scores_gemma":[0.0025003876,0.0020291551,0.010827104,0.0036055874,0.000095331176,0.0005358975,0.011293873,0.000043932832,0.0017150557,0.0063721,0.96072245,0.0002591138],"about_ca_topic_score_codex":0.018266972,"about_ca_topic_score_gemma":0.014826883,"teacher_disagreement_score":0.9372111,"about_ca_system_score_codex":0.004537081,"about_ca_system_score_gemma":0.049583577,"threshold_uncertainty_score":0.9998774},"labels":[],"label_agreement":null},{"id":"W7104251354","doi":"10.71781/6671","title":"Besoins de formation continue d’infirmières en oncologie quant à la thérapie CAR-T : un sondage","year":2025,"lang":"fr","type":"dissertation","venue":"Open MIND","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Occupational training; Context (archaeology); Research methodology; Retraining","score_opus":0.06682323657882001,"score_gpt":0.4012862733458188,"score_spread":0.3344630367669988,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7104251354","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6959559,0.0029940193,0.00018869354,0.0014531923,0.0011835786,0.003475976,0.00028407964,0.000010271943,0.29445428],"genre_scores_gemma":[0.38853845,0.0045739687,0.006301111,0.0001996548,0.0010615112,0.00050671166,0.005330107,0.00014071167,0.5933478],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956256,0.00096355355,0.00092683436,0.00073803565,0.0007154095,0.0010305282],"domain_scores_gemma":[0.9960613,0.002041528,0.00039845632,0.00077127054,0.00038370196,0.00034372776],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0026989146,0.0005771077,0.0010938705,0.00043308403,0.00034472084,0.00053213385,0.0011851277,0.0011340197,0.030839348],"category_scores_gemma":[0.0011692843,0.0005695873,0.00032917358,0.00053679006,0.00015063611,0.00043906283,0.0003656292,0.0014774901,0.0010724041],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018054795,0.0007048267,0.0011759449,0.000699549,0.0006477723,0.00056856184,0.033063732,0.000048922495,0.12237302,0.00047879422,0.0033523885,0.835081],"study_design_scores_gemma":[0.0057538226,0.0009062764,0.008704041,0.0026632717,0.0007972676,0.000089985064,0.030795114,0.0024114917,0.19771907,0.00016883649,0.7493822,0.0006086142],"about_ca_topic_score_codex":0.0035145972,"about_ca_topic_score_gemma":0.011348981,"teacher_disagreement_score":0.8344724,"about_ca_system_score_codex":0.0013738204,"about_ca_system_score_gemma":0.0037916186,"threshold_uncertainty_score":0.9997054},"labels":[],"label_agreement":null},{"id":"W7108450376","doi":"10.1182/blood-2025-6296","title":"Pre-existing cognitive impairment is associated with reduced long-term survival following chimeric antigen receptor T-cell therapy for non-Hodgkin's lymphoma","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cohort; Proportional hazards model; Lymphoma; Retrospective cohort study; Survival analysis; Cohort study; Chimeric antigen receptor; Surrogate endpoint; CAR T-cell therapy","score_opus":0.025455255169864653,"score_gpt":0.3288733749213329,"score_spread":0.30341811975146826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7108450376","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890854,0.00054086786,0.00022592743,0.00019634179,0.00034296533,0.0032616262,0.000054933495,0.00013982499,0.0061521353],"genre_scores_gemma":[0.98558295,0.00021992139,0.0003791722,0.00033248734,0.00022502466,0.00034922318,0.0002376797,0.00010352477,0.012570032],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974816,0.00014085436,0.00038632494,0.00065917714,0.000589282,0.0007427763],"domain_scores_gemma":[0.99840325,0.00054384023,0.00017268823,0.00037600743,0.00032524066,0.00017899724],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007009345,0.00036190875,0.00067771884,0.00021898684,0.0002681857,0.000078273944,0.00020314608,0.00017439392,0.00034709083],"category_scores_gemma":[0.00017291014,0.00030781497,0.00034635086,0.00072529295,0.000083703584,0.00007715534,0.00006821038,0.00020164838,0.000012132918],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0059920643,0.0059266393,0.38881618,0.0002345778,0.005490682,0.00014915608,0.0023134893,4.509192e-7,0.5521762,0.0000024228993,0.00044107763,0.03845709],"study_design_scores_gemma":[0.04991319,0.0037959118,0.41931957,0.0013476833,0.0006100223,0.0000100755815,0.00032527794,0.000057385863,0.5239371,0.000011338998,0.00022683412,0.0004455925],"about_ca_topic_score_codex":0.000069610134,"about_ca_topic_score_gemma":0.00001312391,"teacher_disagreement_score":0.043921128,"about_ca_system_score_codex":0.00019283789,"about_ca_system_score_gemma":0.0006335949,"threshold_uncertainty_score":0.9999374},"labels":[],"label_agreement":null},{"id":"W7108452450","doi":"10.1182/blood-2025-2395","title":"Ultra-low-dose IL-10-expressing CAR-T cells achieve high efficacy in R/R DLBCL: An update analysis","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Artificial Intelligence in Medicine (Canada)","funders":"","keywords":"Cytokine release syndrome; Tolerability; Fludarabine; Adverse effect; Clinical trial; Chimeric antigen receptor; Lymphoma; Immunotherapy","score_opus":0.014438933948381607,"score_gpt":0.30784283175018984,"score_spread":0.29340389780180826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7108452450","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9914431,0.000256071,0.00004971442,0.00055137515,0.00010448326,0.00053377455,0.00003816643,0.00011042832,0.00691286],"genre_scores_gemma":[0.9893602,0.00015671323,0.0005192731,0.0003551094,0.00016132752,0.000033073782,0.00018233054,0.000043603344,0.009188332],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974734,0.00025954135,0.00047193083,0.0006632394,0.00051784783,0.000614049],"domain_scores_gemma":[0.99826,0.00020998614,0.00007785989,0.0010685554,0.00012818792,0.0002553932],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005867993,0.00027177212,0.0006955898,0.00095999404,0.00010029641,0.000096634125,0.00033186082,0.00019017298,0.0020749709],"category_scores_gemma":[0.000099715726,0.00025437062,0.00027545416,0.0022486453,0.000114446426,0.00011924498,0.00007603076,0.00051365356,0.00007359626],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00068935315,0.004241093,0.012436289,0.000103865415,0.0012539638,0.00026447128,0.0004740574,0.00019148938,0.9697076,0.000048684622,0.00034977024,0.010239358],"study_design_scores_gemma":[0.019620534,0.00042917358,0.10458818,0.0002607114,0.0025804283,0.000010970646,0.00023767477,0.0005881628,0.8643677,0.00011535749,0.006742557,0.00045850873],"about_ca_topic_score_codex":0.00052443624,"about_ca_topic_score_gemma":0.00019286825,"teacher_disagreement_score":0.10533986,"about_ca_system_score_codex":0.00009953828,"about_ca_system_score_gemma":0.00022649522,"threshold_uncertainty_score":0.9999909},"labels":[],"label_agreement":null},{"id":"W7108452504","doi":"10.1182/blood-2025-2287","title":"Real-world sequencing of anti-BCMA CAR T-cells and bispecific T-cell engagers in Relapsed/Refractory multiple myeloma: A multi-country analysis","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Clinical Practice; CAR T-cell therapy; Clinical trial; Multiple myeloma; Real world data; Daratumumab; Bispecific antibody; Hematologic Neoplasms","score_opus":0.02518383271107581,"score_gpt":0.2919276031433316,"score_spread":0.2667437704322558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7108452504","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99132454,0.0010854012,0.000031440988,0.000045667763,0.000089606925,0.0005901712,0.000040500778,0.000055267094,0.0067374003],"genre_scores_gemma":[0.99020565,0.0011764114,0.0011599269,0.000056084344,0.000050461895,0.00002508454,0.00003453714,0.00003939478,0.0072524454],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99765116,0.00024059827,0.0006102908,0.0005942056,0.00043144662,0.0004722944],"domain_scores_gemma":[0.9982277,0.00059674843,0.00014599493,0.00072253397,0.00014653326,0.00016047219],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008967571,0.00026252744,0.0008472687,0.0017754588,0.000085707434,0.000026578045,0.00017834698,0.00018531004,0.00022657355],"category_scores_gemma":[0.00016112223,0.00025636522,0.00021241805,0.0028481823,0.00019718087,0.00006374164,0.00010181203,0.0007237885,0.000007525745],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00014559628,0.0007440055,0.28167927,0.000257959,0.00051627075,0.00016681156,0.000685169,0.00006381428,0.7152208,0.000009546637,0.0000621322,0.000448623],"study_design_scores_gemma":[0.01883377,0.00023013832,0.22542886,0.00032282266,0.0016124664,0.000007884879,0.0017718801,0.0034145927,0.74650013,0.000008975427,0.0015045556,0.0003639247],"about_ca_topic_score_codex":0.0027966576,"about_ca_topic_score_gemma":0.0023125987,"teacher_disagreement_score":0.056250405,"about_ca_system_score_codex":0.0002481711,"about_ca_system_score_gemma":0.00036757175,"threshold_uncertainty_score":0.99998885},"labels":[],"label_agreement":null},{"id":"W7108461223","doi":"10.1182/blood-2025-7647","title":"BCMA-targeted CAR-NK cell therapy using lipid nanoparticle mRNA delivery for multiple myeloma","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Alberta","funders":"","keywords":"Chimeric antigen receptor; Multiple myeloma; Genetic enhancement; Immunogenicity; Cancer; Cell therapy; Cytokine release syndrome; Immunotherapy","score_opus":0.03345951169619087,"score_gpt":0.3009155936766589,"score_spread":0.267456081980468,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7108461223","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993729,0.0026178372,0.00015003086,0.0002909971,0.00025116222,0.0012887468,0.000022182348,0.000119776756,0.001530246],"genre_scores_gemma":[0.9906669,0.00028745676,0.0024708526,0.0005668934,0.00033713324,0.000091685164,0.000022959872,0.000055098477,0.0055010137],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99837655,0.00007196843,0.0003016827,0.00039280657,0.000296683,0.00056029443],"domain_scores_gemma":[0.99876523,0.00026952053,0.00005501514,0.0005064175,0.00024450917,0.00015930156],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00029715255,0.0002025511,0.00035257498,0.00018204005,0.00017700717,0.000043407304,0.00017278979,0.0001328533,0.00047385407],"category_scores_gemma":[0.0001058088,0.0001849353,0.0002128983,0.00042956762,0.00007505149,0.00007263102,0.000064669905,0.00019622139,0.000025453763],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009931449,0.00091039215,0.021149885,0.00012611534,0.00020868274,0.000021422053,0.00024296282,0.000015464424,0.9647585,0.000010347447,0.0005986369,0.010964407],"study_design_scores_gemma":[0.014248091,0.00047834805,0.0034210826,0.000073231706,0.0001317829,0.00001253443,0.00012731482,0.0032299147,0.96079236,0.000040870098,0.017274218,0.00017026495],"about_ca_topic_score_codex":0.00014793949,"about_ca_topic_score_gemma":0.000024861667,"teacher_disagreement_score":0.017728802,"about_ca_system_score_codex":0.00008323802,"about_ca_system_score_gemma":0.00030570177,"threshold_uncertainty_score":0.7541443},"labels":[],"label_agreement":null},{"id":"W7108472195","doi":"10.1182/blood-2025-4496","title":"Incidence of thrombosis and bleeding in patients receiving CAR-T cell therapy: A multicentric retrospective analysis of the Canadian experience","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Dalhousie University; Vancouver General Hospital; University of Calgary; Hôpital Maisonneuve-Rosemont; Juravinski Cancer Centre; Ottawa Hospital; Princess Margaret Cancer Centre; Université Laval","funders":"","keywords":"Thrombosis; Retrospective cohort study; Incidence (geometry); Population; Venous thrombosis; Deep vein; Cytokine release syndrome","score_opus":0.018863630296467995,"score_gpt":0.29893779854187236,"score_spread":0.2800741682454044,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7108472195","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966547,0.00027447107,9.744479e-7,0.00008406837,0.000033348395,0.00040956872,0.0000071796226,0.000003776877,0.0025319078],"genre_scores_gemma":[0.99945706,0.00027549508,0.00005198254,0.000053552016,0.000005559429,0.0000139308395,0.000001420435,0.0000065448703,0.00013447332],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99891865,0.00006821714,0.0002445749,0.00021998916,0.0003340725,0.00021451394],"domain_scores_gemma":[0.99921006,0.000108314096,0.00009055998,0.00030492485,0.00021482377,0.00007129736],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00025544883,0.0000874503,0.00033891006,0.0006394039,0.00006477157,0.000010907687,0.00015192914,0.00006429185,0.00010939734],"category_scores_gemma":[0.0002292273,0.000067002235,0.00008389909,0.0028548436,0.00012813284,0.000043984193,0.00006443617,0.00016830473,1.4810422e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000026906391,0.00020657985,0.9568725,0.000027963073,0.00027507616,8.7693803e-7,0.0046303496,0.0000051764473,0.037443828,0.000010011645,0.0000029680884,0.0004977387],"study_design_scores_gemma":[0.0017789949,0.00008025237,0.9352744,0.00010703256,0.00027013186,1.1781061e-7,0.00047809348,0.00023695591,0.061712157,0.000007923119,0.000007674487,0.000046244568],"about_ca_topic_score_codex":0.089105666,"about_ca_topic_score_gemma":0.0846221,"teacher_disagreement_score":0.024268327,"about_ca_system_score_codex":0.00021469695,"about_ca_system_score_gemma":0.0002460633,"threshold_uncertainty_score":0.93208116},"labels":[],"label_agreement":null},{"id":"W7108516095","doi":"10.1182/blood-2025-7650","title":"Pre-clinical characterization and process development of a BCMA-directed CAR NK-cell therapy product for relapsed/refractory multiple myeloma","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Chimeric antigen receptor; Immune system; Cytokine release syndrome; Human leukocyte antigen; Multiple myeloma; Transplantation; Antigen; CAR T-cell therapy; Blood product","score_opus":0.033852035526264625,"score_gpt":0.3372780528990568,"score_spread":0.3034260173727922,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7108516095","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960142,0.0007762705,0.00021047142,0.00013167788,0.0001143566,0.0023167387,0.000013834081,0.00008961163,0.00033283926],"genre_scores_gemma":[0.9879192,0.00049077434,0.00240698,0.000091501395,0.0001451955,0.0003048295,0.00015201054,0.000036615744,0.008452882],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985058,0.00007662593,0.0005203842,0.0004197836,0.00024500885,0.00023244829],"domain_scores_gemma":[0.99889904,0.00018352868,0.00013944457,0.00030538984,0.00038280862,0.00008976458],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053409446,0.00015681097,0.000393183,0.0001472556,0.00007492184,0.000014305626,0.000103564875,0.00010506101,0.00007696875],"category_scores_gemma":[0.0003613398,0.00013408659,0.000068497924,0.0002758747,0.00008132337,0.000058345766,0.000034433506,0.00018976921,0.0000018725403],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020188454,0.002090862,0.07847154,0.00072201784,0.00024436731,0.0000027098986,0.001180916,1.0339766e-7,0.8204467,0.0000015606549,0.000055958484,0.0947644],"study_design_scores_gemma":[0.0120342905,0.0005425356,0.3057042,0.00018178445,0.000072303665,0.0000045122774,0.00004128853,0.00010752393,0.6660151,0.000008187538,0.015165387,0.00012291159],"about_ca_topic_score_codex":0.0000053766908,"about_ca_topic_score_gemma":0.0000072428443,"teacher_disagreement_score":0.22723268,"about_ca_system_score_codex":0.000026168498,"about_ca_system_score_gemma":0.0006167912,"threshold_uncertainty_score":0.5467892},"labels":[],"label_agreement":null},{"id":"W7108696894","doi":"10.1182/blood-2025-2410","title":"Development of multi-targeting CAR-double-negative T cells for allogeneic immunotherapy in B-cell leukemia","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; Alberta Children's Hospital; University of Calgary","funders":"","keywords":"Chimeric antigen receptor; Antigen; Leukemia; Immunotherapy; CD19; Myeloid leukemia; Cancer immunotherapy; Immune system; T cell","score_opus":0.03209382223099345,"score_gpt":0.3197897275302218,"score_spread":0.28769590529922834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7108696894","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926225,0.0014446544,0.0005580946,0.000050682444,0.00009535333,0.0015598475,0.0000071626205,0.000027048407,0.0036346372],"genre_scores_gemma":[0.9027005,0.00023279536,0.08486741,0.00015658369,0.00005231179,0.00032376294,0.0000291433,0.000051874424,0.011585615],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9985609,0.000040808514,0.00049424416,0.0003046194,0.00022564462,0.00037380512],"domain_scores_gemma":[0.9992352,0.00018780745,0.000091203685,0.00026259795,0.00016623129,0.00005695787],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005629897,0.00017109254,0.00041478532,0.00026216236,0.000058967453,0.000009966605,0.00016878363,0.00011971134,0.00018323361],"category_scores_gemma":[0.00003575725,0.00016020836,0.00011979674,0.00035353878,0.00005532886,0.000027095244,0.000056038047,0.00020192802,0.00000722374],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008806613,0.00083370274,0.0035307507,0.0002933488,0.00022243215,0.0000075330577,0.002210626,0.000023590004,0.98272824,0.000014668494,0.000070233225,0.009184213],"study_design_scores_gemma":[0.02677084,0.00011833804,0.0018979647,0.00013900785,0.000036997128,0.0000010552953,0.0004525452,0.00016734967,0.96289945,0.000017337148,0.00737238,0.00012671317],"about_ca_topic_score_codex":0.00014952502,"about_ca_topic_score_gemma":0.00012498209,"teacher_disagreement_score":0.08992202,"about_ca_system_score_codex":0.00026209134,"about_ca_system_score_gemma":0.0009789021,"threshold_uncertainty_score":0.6533107},"labels":[],"label_agreement":null},{"id":"W7108742579","doi":"10.1182/blood-2025-2402","title":"Expansion, differentiation, and culture of hematopoietic stem &amp; progenitor cells using an ancillary GMP-compliant medium","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute; Stemcell Technologies","funders":"","keywords":"Progenitor cell; Haematopoiesis; Cord blood; Stem cell; Cell therapy; CD34; Induced pluripotent stem cell; Cell culture","score_opus":0.03631323697064287,"score_gpt":0.30975795947561624,"score_spread":0.27344472250497337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7108742579","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966501,0.0018628789,0.00030891987,0.00014346503,0.00013222214,0.0006001864,0.000012049149,0.000040828763,0.00024935274],"genre_scores_gemma":[0.99515665,0.00015630819,0.0012723648,0.0000796439,0.00014263064,0.00001655991,0.000026483789,0.000023596887,0.0031257365],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.998742,0.00007511632,0.00029659172,0.0002823684,0.00037903222,0.00022493525],"domain_scores_gemma":[0.9990783,0.000035102188,0.00007158444,0.00041000842,0.00026191954,0.0001431312],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00017846886,0.0001476406,0.000339494,0.00012825278,0.00007785878,0.000022918288,0.00009627056,0.000120846205,0.00016705836],"category_scores_gemma":[0.000020811663,0.000117839874,0.00006525479,0.00026695558,0.00009037452,0.000054737542,0.000069352696,0.00016169855,0.0000036994822],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000077502744,0.00070067454,0.015172358,0.0006033026,0.00014033381,0.000012141042,0.0017651066,9.330332e-7,0.9806643,0.000016213631,0.00032867317,0.0005184619],"study_design_scores_gemma":[0.003144753,0.00019320809,0.009119368,0.00039510877,0.00032824514,0.00009619144,0.0006564336,0.00014393644,0.98412025,0.00015972719,0.0015019177,0.00014088834],"about_ca_topic_score_codex":0.00002273633,"about_ca_topic_score_gemma":0.000013253231,"teacher_disagreement_score":0.006052989,"about_ca_system_score_codex":0.000030091232,"about_ca_system_score_gemma":0.00017467188,"threshold_uncertainty_score":0.48053706},"labels":[],"label_agreement":null},{"id":"W7108839697","doi":"10.1182/blood-2025-6140","title":"Real-time multimodal AI outperforms conventional scores for early risk prediction in BCMA CAR-T–Treated myeloma","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"","keywords":"Overfitting; Multiple myeloma; Concordance; Pomalidomide; Logistic regression; Random forest; Framingham Risk Score; Clinical trial; Nomogram","score_opus":0.012459371308312156,"score_gpt":0.2928575631419537,"score_spread":0.28039819183364156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7108839697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928273,0.00007706338,0.00007017966,0.00026048237,0.00011487403,0.0014191341,0.00018233703,0.000120901874,0.0049277465],"genre_scores_gemma":[0.96694434,0.00009626151,0.00048742408,0.00004894524,0.00020611225,0.0002841271,0.00027504622,0.0000328318,0.031624895],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9984881,0.00006416963,0.00036415225,0.0003691252,0.00033988507,0.0003745648],"domain_scores_gemma":[0.99917233,0.00012933889,0.000059603277,0.0003080255,0.00022161097,0.000109082204],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00042104087,0.00016869284,0.00032126068,0.00036633326,0.00009982497,0.00003220856,0.00010649623,0.0001803315,0.0011072966],"category_scores_gemma":[0.00017452551,0.00014850666,0.00017066507,0.00036745757,0.00009098799,0.000095159434,0.000043098014,0.00030239744,0.00007262936],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018080893,0.0008752172,0.8533886,0.00012480028,0.0003635452,0.000025232051,0.00016500207,0.000009709361,0.13600753,0.00007959898,0.00114384,0.0060088304],"study_design_scores_gemma":[0.017855437,0.0008702658,0.9269986,0.0002419851,0.0002469614,0.000014868008,0.000032312797,0.004739487,0.047850754,0.00030940594,0.000711448,0.0001284618],"about_ca_topic_score_codex":0.0010544397,"about_ca_topic_score_gemma":0.00006485974,"teacher_disagreement_score":0.08815677,"about_ca_system_score_codex":0.00012255853,"about_ca_system_score_gemma":0.00022805709,"threshold_uncertainty_score":0.9998058},"labels":[],"label_agreement":null},{"id":"W7111239512","doi":"10.5281/zenodo.17860575","title":"Conscience Issue Tracker - December 2025","year":2025,"lang":"","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Conscience; Pipeline (software); Drug industry; Government (linguistics); Threatened species; Drug development; Headline; MEDLINE","score_opus":0.03902573762325673,"score_gpt":0.31188429161514586,"score_spread":0.27285855399188913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7111239512","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02124659,0.0021588,0.0023384206,0.010048648,0.0010201,0.002422671,0.00029842724,0.0009133603,0.959553],"genre_scores_gemma":[0.4682585,0.0037275208,0.0003633358,0.002653901,0.0010749373,2.911368e-7,0.0013958765,0.0037919672,0.5187337],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99373186,0.0011296358,0.00083408883,0.0014001746,0.0014393798,0.0014648469],"domain_scores_gemma":[0.99507487,0.00019529088,0.00017995913,0.0016875268,0.0021490837,0.00071325887],"candidate_categories":["metaepi_narrow","sts","scholarly_communication","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0028446112,0.00046625626,0.00060251105,0.0010964549,0.0045265285,0.0019774279,0.0023802784,0.00030344294,0.4986735],"category_scores_gemma":[0.0030734544,0.0005027214,0.00021326113,0.0036559037,0.0015586186,0.00045027368,0.002905916,0.0013831905,0.06739237],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006102664,0.00056618085,0.000024970002,0.00036979766,0.0002502983,0.000098045275,0.001263135,0.000019741321,0.05965267,0.0037080878,0.6091998,0.324237],"study_design_scores_gemma":[0.002568604,0.00063316367,0.0010040464,0.00040151938,0.00012920475,0.00018375227,0.001124509,0.00097315136,0.007526753,0.00024941878,0.98480994,0.0003959505],"about_ca_topic_score_codex":0.000081697915,"about_ca_topic_score_gemma":0.0000018195872,"teacher_disagreement_score":0.4470119,"about_ca_system_score_codex":0.00084489485,"about_ca_system_score_gemma":0.000097565375,"threshold_uncertainty_score":0.99974245},"labels":[],"label_agreement":null},{"id":"W7111273469","doi":"10.5281/zenodo.17860574","title":"Conscience Issue Tracker - December 2025","year":2025,"lang":"","type":"article","venue":"Zenodo (CERN European Organization for Nuclear Research)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"","keywords":"Conscience; Pipeline (software); Drug industry; Government (linguistics); Threatened species; Drug development; Headline; MEDLINE","score_opus":0.03902573762325673,"score_gpt":0.31188429161514586,"score_spread":0.27285855399188913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7111273469","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02124659,0.0021588,0.0023384206,0.010048648,0.0010201,0.002422671,0.00029842724,0.0009133603,0.959553],"genre_scores_gemma":[0.4682585,0.0037275208,0.0003633358,0.002653901,0.0010749373,2.911368e-7,0.0013958765,0.0037919672,0.5187337],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99373186,0.0011296358,0.00083408883,0.0014001746,0.0014393798,0.0014648469],"domain_scores_gemma":[0.99507487,0.00019529088,0.00017995913,0.0016875268,0.0021490837,0.00071325887],"candidate_categories":["metaepi_narrow","sts","scholarly_communication","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0028446112,0.00046625626,0.00060251105,0.0010964549,0.0045265285,0.0019774279,0.0023802784,0.00030344294,0.4986735],"category_scores_gemma":[0.0030734544,0.0005027214,0.00021326113,0.0036559037,0.0015586186,0.00045027368,0.002905916,0.0013831905,0.06739237],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006102664,0.00056618085,0.000024970002,0.00036979766,0.0002502983,0.000098045275,0.001263135,0.000019741321,0.05965267,0.0037080878,0.6091998,0.324237],"study_design_scores_gemma":[0.002568604,0.00063316367,0.0010040464,0.00040151938,0.00012920475,0.00018375227,0.001124509,0.00097315136,0.007526753,0.00024941878,0.98480994,0.0003959505],"about_ca_topic_score_codex":0.000081697915,"about_ca_topic_score_gemma":0.0000018195872,"teacher_disagreement_score":0.4470119,"about_ca_system_score_codex":0.00084489485,"about_ca_system_score_gemma":0.000097565375,"threshold_uncertainty_score":0.99974245},"labels":[],"label_agreement":null},{"id":"W7112568180","doi":"","title":"Étude des toxicités neurologiques (ICANS) chez les patients atteints de lymphome B diffus à grandes cellules traités par CAR-T cells : expérience d'une cohorte bordelaise","year":2025,"lang":"fr","type":"dissertation","venue":"HAL (Le Centre pour la Communication Scientifique Directe)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cytokine release syndrome; Neurotoxicity; Immunotherapy; Immune system; Ferritin; Cognition; Refractory (planetary science)","score_opus":0.014562375231285646,"score_gpt":0.25743596388841095,"score_spread":0.2428735886571253,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7112568180","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97164494,0.0046334383,0.006460429,0.0013006334,0.00047483403,0.0017551548,0.00026376333,0.00031058496,0.013156215],"genre_scores_gemma":[0.9261572,0.012477835,0.0038115869,0.00018735592,0.00008573397,0.00036940293,0.0022123274,0.00016705289,0.054531507],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9829525,0.010822712,0.0014444899,0.0017167191,0.0013946918,0.0016689092],"domain_scores_gemma":[0.9880548,0.0039324006,0.0007827112,0.002339019,0.004045454,0.00084562716],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.005433483,0.0010803083,0.0012972923,0.00061091466,0.0013087861,0.00047141602,0.0020917866,0.0010191767,0.0015169848],"category_scores_gemma":[0.0028530231,0.0011437864,0.00064546283,0.0015757189,0.0015491119,0.00029573232,0.00047130635,0.0014722836,0.000062863975],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00054578966,0.0035216406,0.17638835,0.0014872919,0.000417606,0.000085056636,0.06676128,0.000057621877,0.4295344,0.001747745,0.00020214528,0.31925106],"study_design_scores_gemma":[0.0032056624,0.000022434391,0.36941338,0.0052718823,0.00037698826,0.000016354712,0.0025834108,0.003928863,0.6095085,0.0004645815,0.004261699,0.00094623724],"about_ca_topic_score_codex":0.018545846,"about_ca_topic_score_gemma":0.031290267,"teacher_disagreement_score":0.31830484,"about_ca_system_score_codex":0.0007893838,"about_ca_system_score_gemma":0.0012294907,"threshold_uncertainty_score":0.99999136},"labels":[],"label_agreement":null},{"id":"W7112784928","doi":"","title":"Mid-term neurocognitive outcomes after CAR T cell therapy in central nervous system lymphomas: statistical analysis plan","year":2025,"lang":"","type":"preprint","venue":"OSF Preprints (OSF Preprints)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Neurocognitive; Central nervous system; Primary central nervous system lymphoma; CAR T-cell therapy; T cell; Cognition","score_opus":0.019891959025142233,"score_gpt":0.2980047512375751,"score_spread":0.27811279221243285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7112784928","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6772672,0.000077347206,0.0032181104,0.0003262888,0.0021698144,0.011594218,0.002445966,0.0004035641,0.3024975],"genre_scores_gemma":[0.77144045,0.0025501647,0.00056777423,0.00044022553,0.00036221487,0.0034562284,0.00084120594,0.00027435648,0.22006737],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.96689314,0.008246796,0.0049803634,0.012051471,0.0035778855,0.004250353],"domain_scores_gemma":[0.9756358,0.0056162933,0.001489674,0.013774111,0.0012265762,0.0022575334],"candidate_categories":["metaepi_narrow","open_science","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.009744175,0.0031992192,0.0066725584,0.0040297084,0.00044967743,0.00085555797,0.0045488803,0.0025783593,0.648892],"category_scores_gemma":[0.0028613408,0.0034049186,0.0033607502,0.00311584,0.0012545254,0.00037713753,0.008474331,0.005987093,0.22807053],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01430246,0.004670405,0.8722704,0.0047267806,0.013556033,0.005865659,0.011136927,0.0048665577,0.0042835376,0.00018873275,0.00065932976,0.063473195],"study_design_scores_gemma":[0.012609552,0.000032549644,0.949555,0.002096877,0.0060391314,0.0001222043,0.0025408564,0.006806869,0.011079124,0.00031800152,0.0059932317,0.0028066097],"about_ca_topic_score_codex":0.0065160487,"about_ca_topic_score_gemma":0.0010995291,"teacher_disagreement_score":0.42082143,"about_ca_system_score_codex":0.006372281,"about_ca_system_score_gemma":0.003934793,"threshold_uncertainty_score":0.9995449},"labels":[],"label_agreement":null},{"id":"W7115194976","doi":"10.18609/cgti.2025.013","title":"Enhancing CAR-T therapy development: harnessing cell selection flexibility","year":2025,"lang":"en","type":"article","venue":"Cell and Gene Therapy Insights","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre; Lonza (Canada)","funders":"","keywords":"Flexibility (engineering); Automation; Cellular manufacturing; Selection (genetic algorithm); Product (mathematics); Upstream (networking); Isolation (microbiology)","score_opus":0.032145931485373466,"score_gpt":0.3007684147657189,"score_spread":0.26862248328034544,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7115194976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96636146,0.01733366,0.00085356535,0.00014836727,0.00024067308,0.00074394257,7.422219e-7,0.00013173862,0.014185867],"genre_scores_gemma":[0.9600477,0.006186847,0.001189123,0.000850104,0.00020329111,0.00005580018,0.000023694569,0.000042476247,0.031400956],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980202,0.00015904232,0.00040930256,0.00062947476,0.00033471873,0.0004472896],"domain_scores_gemma":[0.9990484,0.00010506785,0.00007987537,0.00038377542,0.0002095148,0.00017336925],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00040116298,0.000322293,0.00043232227,0.00029806807,0.0004901843,0.00009574525,0.00013012292,0.00020270632,0.0007001573],"category_scores_gemma":[0.000007857682,0.00025522185,0.00010873093,0.0005790945,0.00011695455,0.00011369494,0.00004620546,0.00038319506,0.000023827388],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00088525855,0.0002999138,0.0020031615,0.00009965831,0.00007981136,0.0000080843665,0.003017553,0.0000046000473,0.87389785,0.000011796084,0.00009737458,0.11959493],"study_design_scores_gemma":[0.0032939925,0.00025484673,0.00597842,0.000054244956,0.000012894077,0.000008365471,0.00015437402,0.000097566095,0.8817779,0.00030423707,0.107840225,0.00022293336],"about_ca_topic_score_codex":0.00007544933,"about_ca_topic_score_gemma":0.000060451952,"teacher_disagreement_score":0.119371995,"about_ca_system_score_codex":0.00018186773,"about_ca_system_score_gemma":0.00054434786,"threshold_uncertainty_score":0.99999},"labels":[],"label_agreement":null},{"id":"W7115567204","doi":"10.18609/cgti.2024.167","title":"From the lab to the bench: scaling up regulatory T cell therapy","year":2024,"lang":"en","type":"article","venue":"Cell and Gene Therapy Insights","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Effector; Automation; T cell; Cell therapy; Immune system; Portfolio; Key (lock); Regulatory T cell","score_opus":0.03740910209825789,"score_gpt":0.2891359515679986,"score_spread":0.2517268494697407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7115567204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87331754,0.11480631,0.00006145524,0.0056459964,0.00083601184,0.0009484745,0.000015515165,0.00011080464,0.0042578885],"genre_scores_gemma":[0.93921286,0.024437716,0.00009398914,0.005994687,0.0023666797,0.000077122015,0.000036490444,0.000093031165,0.027687417],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9978697,0.00023829946,0.00029207204,0.00059874373,0.000575801,0.00042541086],"domain_scores_gemma":[0.9982229,0.0004494775,0.000037291276,0.0009633898,0.00009401169,0.00023295006],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005236057,0.00032381967,0.00031609632,0.00010866857,0.00038902546,0.00023800091,0.0003832627,0.00014978452,0.0019251226],"category_scores_gemma":[0.0000062534064,0.00015461569,0.00018937072,0.00047602804,0.00018253383,0.000073002106,0.00008815376,0.0005248422,0.00022621019],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006751302,0.000100274476,0.00011353478,0.000022626597,0.00017092418,0.000046807883,0.023697853,0.000015349908,0.7836264,0.000073467505,0.0172879,0.17416975],"study_design_scores_gemma":[0.0011166362,0.00027104007,0.0015988937,0.000041244075,0.000021590604,0.000011362721,0.0006053919,0.00020641093,0.41786993,0.0007828409,0.57730263,0.00017201799],"about_ca_topic_score_codex":0.00028276726,"about_ca_topic_score_gemma":0.000033634136,"teacher_disagreement_score":0.5600147,"about_ca_system_score_codex":0.000056829034,"about_ca_system_score_gemma":0.00017432022,"threshold_uncertainty_score":0.99898726},"labels":[],"label_agreement":null},{"id":"W7115817632","doi":"","title":"Bastin_Donald_J_2017Sept_MSc","year":2017,"lang":"en","type":"dissertation","venue":"MacSphere (McMaster University)","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Oncolytic virus; Adoptive cell transfer; Antigen; Chimeric antigen receptor; Context (archaeology); Cancer; Immunotherapy","score_opus":0.02734260555132089,"score_gpt":0.2781799247809676,"score_spread":0.2508373192296467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7115817632","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00168489,0.00023477088,0.000011854295,0.00018301734,0.00057920656,0.0005765513,0.000027711454,0.000110328925,0.9965917],"genre_scores_gemma":[0.0011723302,0.00023086074,0.00018038621,0.00008056761,0.0004066073,0.000001995982,0.0005273345,0.000102097285,0.9972978],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.997959,0.00007069551,0.00019662283,0.00064557954,0.0006237025,0.00050439354],"domain_scores_gemma":[0.99820566,0.000057483194,0.00024782325,0.0009248001,0.000237151,0.00032706474],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.00012847265,0.00040991898,0.0006137294,0.00034081851,0.00031132493,0.000110871486,0.00066917867,0.00053729897,0.960802],"category_scores_gemma":[0.0000575979,0.00044016817,0.00039077146,0.0002146903,0.00011822734,0.00016762562,0.000092312206,0.00086134067,0.0009497624],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016713407,0.00009584098,0.0010218001,0.00042172047,0.00032620988,0.0009062038,0.00023952204,7.391152e-7,0.0055349604,0.00017447013,0.0077607133,0.98184645],"study_design_scores_gemma":[0.0019749138,0.00020307308,0.005218118,0.00052094855,0.00030519147,0.00002988845,0.0008543555,0.000024581166,0.0024731446,0.000036532718,0.98798186,0.00037740817],"about_ca_topic_score_codex":0.0002315545,"about_ca_topic_score_gemma":0.0008048281,"teacher_disagreement_score":0.9814691,"about_ca_system_score_codex":0.00031800786,"about_ca_system_score_gemma":0.00046840793,"threshold_uncertainty_score":0.9998281},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"not_applicable","genre":"other","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":["insufficient_payload"],"domain":null,"study_design":"design_other","genre":"other","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"split"},{"id":"W7116844175","doi":"10.1016/s2352-3026(25)00318-7","title":"Chimeric antigen receptor T-cell therapy and bispecific antibody sequence for large B-cell lymphoma: a systematic review and meta-analysis","year":2025,"lang":"en","type":"article","venue":"The Lancet Haematology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Jewish General Hospital; McGill University; Université de Montréal; Université de Sherbrooke; McGill University Health Centre","funders":"Fonds de recherche du Québec","keywords":"Bispecific antibody; Chimeric antigen receptor; Sequence (biology); Antibody; Antigen; Antibody therapy; Immunotherapy","score_opus":0.10609664797253764,"score_gpt":0.39051698920371775,"score_spread":0.2844203412311801,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116844175","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.14032172,0.8248948,0.0012399887,0.022788228,0.00009152913,0.007993149,0.00016012204,0.00012251432,0.002387977],"genre_scores_gemma":[0.6010231,0.35297126,0.0019676827,0.017554678,0.00011134402,0.0017397265,0.00019176795,0.00009874352,0.02434172],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.99755585,0.00059228693,0.0005751314,0.00052573025,0.00021330104,0.0005377245],"domain_scores_gemma":[0.9977043,0.00072093244,0.00023696947,0.001090109,0.00015613678,0.00009152759],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00179105,0.00029622592,0.0048559285,0.00024558554,0.00018348025,0.00004289541,0.00033131387,0.00012128113,0.0005886104],"category_scores_gemma":[0.00012385387,0.00016667967,0.00051697996,0.0009639907,0.00020908729,0.00004314465,0.0001037838,0.00016897352,0.000024822188],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013551994,0.0019450352,0.006037166,0.6954398,0.17055345,0.00020788405,0.0016040575,9.4895466e-7,0.08892169,0.011693589,0.021834591,0.0004066109],"study_design_scores_gemma":[0.029960657,0.0010972796,0.0014257865,0.0039038754,0.86795586,0.0016989772,0.00096601446,0.0013192056,0.02318631,0.0018219323,0.06508586,0.0015782351],"about_ca_topic_score_codex":0.000030541298,"about_ca_topic_score_gemma":0.000011910774,"teacher_disagreement_score":0.6974024,"about_ca_system_score_codex":0.00003207955,"about_ca_system_score_gemma":0.00009360292,"threshold_uncertainty_score":0.67969996},"labels":[],"label_agreement":null},{"id":"W7116897573","doi":"10.1016/j.soncn.2025.152095","title":"Theoretical Perspectives on Patient and Caregiver Experiences After CAR T-Cell Therapy","year":2025,"lang":"en","type":"article","venue":"Seminars in Oncology Nursing","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Encana (Canada)","funders":"","keywords":"MEDLINE; Qualitative research; Nursing practice; Clinical Practice","score_opus":0.010609680346704016,"score_gpt":0.3485681004946785,"score_spread":0.3379584201479745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7116897573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8979874,0.012160241,0.000007622942,0.0024331952,0.00025585314,0.00040477177,8.144454e-7,0.000018734303,0.08673135],"genre_scores_gemma":[0.995966,0.0021105045,0.00022290692,0.0005620441,0.000053915497,0.000116517345,0.0000011311656,0.00001373209,0.0009532593],"study_design_codex":"design_other","study_design_gemma":"qualitative","domain_scores_codex":[0.9987464,0.00019065403,0.00016120884,0.00039121887,0.00019227421,0.00031827812],"domain_scores_gemma":[0.99927133,0.00034685733,0.000025210915,0.00021970813,0.000057081757,0.00007980774],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000210193,0.00014256472,0.0002882615,0.00025905634,0.0000647978,0.000013873194,0.00007287157,0.00017965739,0.0010793095],"category_scores_gemma":[0.000052207855,0.000116956435,0.000052907242,0.00022734134,0.0013618428,0.000029757499,0.000027983706,0.00038015484,0.0000033524063],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0060201962,0.0012015448,0.004816007,0.000019988063,0.000032650438,0.00036906815,0.4573455,0.0000017561399,0.015715297,0.0044322954,0.00097379443,0.50907195],"study_design_scores_gemma":[0.0058345785,0.008346059,0.005036588,0.001561796,0.000043679913,0.000115110415,0.8926884,0.00030253167,0.061410345,0.0038987086,0.020419696,0.00034251815],"about_ca_topic_score_codex":0.000008718794,"about_ca_topic_score_gemma":0.000002111331,"teacher_disagreement_score":0.5087294,"about_ca_system_score_codex":0.00082215416,"about_ca_system_score_gemma":0.00019850706,"threshold_uncertainty_score":0.9998338},"labels":[],"label_agreement":null},{"id":"W7117120037","doi":"10.1111/bph.70296","title":"Immunotherapy in cancer: novel approaches and future perspectives","year":2025,"lang":"en","type":"article","venue":"British Journal of Pharmacology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; University of British Columbia","funders":"","keywords":"Immunotherapy; Chimeric antigen receptor; Tumor microenvironment; Cancer immunotherapy; Immune system; Cancer; Cancer therapy","score_opus":0.03375880342256229,"score_gpt":0.36619829137457494,"score_spread":0.33243948795201267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117120037","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8668082,0.11636873,0.000055667282,0.013672104,0.00051563245,0.00026203462,0.000006281344,0.00000654714,0.0023048013],"genre_scores_gemma":[0.8942172,0.10032463,0.0004988322,0.0011428872,0.0013657772,0.000019396643,8.41855e-7,0.000018306964,0.0024121539],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.9991616,0.0000866486,0.00027069933,0.00013711987,0.00014130656,0.000202653],"domain_scores_gemma":[0.9996045,0.000069794834,0.000084021056,0.000036122732,0.00014492118,0.00006059342],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00043103087,0.00008108247,0.00034122416,0.00027106795,0.000042316835,0.000022354337,0.00010466131,0.0000855862,0.0017121525],"category_scores_gemma":[0.000014901854,0.000086020555,0.00007808085,0.00025382376,0.0001509512,0.00007269577,0.000027574564,0.000650218,3.9232145e-7],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015401809,0.0005801442,0.0032695814,0.0000647438,0.0004415344,0.0005405948,0.00093582075,0.0000074775653,0.5316275,0.00012908486,0.005272932,0.45559043],"study_design_scores_gemma":[0.06360077,0.0016437863,0.35357243,0.0008475154,0.00038098422,0.021273233,0.013356757,0.00052177353,0.07432229,0.00042994504,0.4695869,0.0004636218],"about_ca_topic_score_codex":0.00015189825,"about_ca_topic_score_gemma":0.000055399523,"teacher_disagreement_score":0.46431395,"about_ca_system_score_codex":0.00019138167,"about_ca_system_score_gemma":0.00031476823,"threshold_uncertainty_score":0.9992004},"labels":[],"label_agreement":null},{"id":"W7117247313","doi":"10.14740/jmc5211","title":"Cyclophosphamide for the Treatment of Refractory Immune Effector Cell-Associated Neurotoxicity Syndrome Following CD19-Targeted CAR T-Cell Therapy","year":2025,"lang":"en","type":"article","venue":"Journal of Medical Cases","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Cyclophosphamide; Neurotoxicity; Cytokine release syndrome; Refractory (planetary science); Immune system; Chimeric antigen receptor; Effector","score_opus":0.02515273333043373,"score_gpt":0.33416742708227276,"score_spread":0.30901469375183904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117247313","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96337515,0.03229735,0.000076418444,0.0019451113,0.0009195447,0.0012294782,0.000020115462,0.000018133427,0.00011870497],"genre_scores_gemma":[0.98624384,0.011095705,0.00004656464,0.0003708489,0.0001902193,0.00005223471,0.000009370841,0.000037182544,0.001954003],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9965872,0.00033242803,0.00091285486,0.00020010359,0.0015650047,0.0004023814],"domain_scores_gemma":[0.9933434,0.00526296,0.00043543952,0.00036997444,0.00028524062,0.0003029835],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017129381,0.00025184843,0.0010017331,0.00022197688,0.00014172088,0.000021743168,0.00036240811,0.00024857026,0.00077630015],"category_scores_gemma":[0.0017127434,0.00014396333,0.0010682164,0.0004062929,0.00015093564,0.000054916865,0.000032429416,0.0005525652,0.0000023853897],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010127884,0.009043342,0.01493928,0.0004547653,0.0031486778,0.009375075,0.0007738513,0.000021296732,0.885603,0.0000047097533,0.004553788,0.0619543],"study_design_scores_gemma":[0.062308155,0.047837086,0.0847315,0.0016795967,0.001754964,0.0012962612,0.00087814365,0.00056369917,0.6863056,0.000059841816,0.11212805,0.0004571414],"about_ca_topic_score_codex":0.00023591694,"about_ca_topic_score_gemma":0.000010451062,"teacher_disagreement_score":0.19929746,"about_ca_system_score_codex":0.00041403165,"about_ca_system_score_gemma":0.0009216103,"threshold_uncertainty_score":0.84999424},"labels":[],"label_agreement":null},{"id":"W7117300967","doi":"10.3390/curroncol33010009","title":"Abstracts of the Cell Therapy Transplant Canada 2024 Annual Conference","year":2025,"lang":"en","type":"article","venue":"Current Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; University of Manitoba; Capital District Health Authority; McMaster University; Hamilton Health Sciences; University of Alberta; Université de Montréal; Université Laval","funders":"","keywords":"Presentation (obstetrics); Session (web analytics); Transplantation; Alternative medicine; MEDLINE; Case presentation","score_opus":0.0765301098284932,"score_gpt":0.39302016838052695,"score_spread":0.3164900585520337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117300967","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94889295,0.0027145925,0.0000136470635,0.0049926997,0.0025292977,0.0005689809,0.00008551682,0.0000105265835,0.04019178],"genre_scores_gemma":[0.98526627,0.0012845324,0.000013340198,0.00030812938,0.00008230871,0.000022057806,0.000011214833,0.000007447737,0.013004676],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9989174,0.00010393458,0.00026925636,0.00018567777,0.0002703888,0.00025336168],"domain_scores_gemma":[0.99900275,0.00024077558,0.000068724505,0.00039731877,0.00021145634,0.0000789931],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00020273785,0.00010885106,0.00028658492,0.000060212446,0.00004165502,0.0000041473927,0.00031323152,0.00008406328,0.0017767814],"category_scores_gemma":[0.00005127366,0.00007134393,0.00007877952,0.00020914807,0.00015656243,0.000014625795,0.00004986713,0.00045947655,0.0000045851302],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002024069,0.0019230483,0.06904605,0.0007259214,0.00025341543,0.00009570605,0.0034234733,0.00002147315,0.12041631,0.00044234516,0.2095,0.59212816],"study_design_scores_gemma":[0.0021496883,0.00026719365,0.05880805,0.00011298412,0.000035929443,0.000013270591,0.00036079984,0.000029674633,0.051556416,0.000112581576,0.8864849,0.00006848218],"about_ca_topic_score_codex":0.024018748,"about_ca_topic_score_gemma":0.08014289,"teacher_disagreement_score":0.6769849,"about_ca_system_score_codex":0.0002508403,"about_ca_system_score_gemma":0.004304488,"threshold_uncertainty_score":0.99913573},"labels":[],"label_agreement":null},{"id":"W7117308422","doi":"10.1038/s41409-025-02786-w","title":"Real-world eligibility, utilization, and barriers to CAR T-cell therapy in relapsed/refractory mantle cell lymphoma","year":2025,"lang":"en","type":"article","venue":"Bone Marrow Transplantation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of Alberta; Alberta Health Services","funders":"","keywords":"Mantle cell lymphoma; Lymphoma; Aggressive lymphoma; Hematopoietic cell; Bone marrow; Stem cell","score_opus":0.021781706536507857,"score_gpt":0.31696089384082893,"score_spread":0.2951791873043211,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117308422","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96463484,0.0006867021,0.00017016972,0.0007612382,0.00012253212,0.0011286464,0.00003219283,0.000068811154,0.0323949],"genre_scores_gemma":[0.975462,0.0076725367,0.00021452137,0.00073921314,0.00003365166,0.00007475518,0.00013419605,0.000035323366,0.015633794],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9982899,0.00015317259,0.0004077733,0.0004818275,0.00034507609,0.0003222545],"domain_scores_gemma":[0.9990974,0.00015091318,0.000047179194,0.0003479161,0.00010443571,0.0002521314],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004882724,0.00020526677,0.00031879457,0.00064415927,0.0000932187,0.00003414123,0.00009050381,0.0001280803,0.0004950263],"category_scores_gemma":[0.000025593768,0.00020674108,0.00006501155,0.000811495,0.00006864149,0.00008102469,0.000013698263,0.00015904424,0.000017127086],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00601434,0.00048353424,0.12836365,0.0010002248,0.000040143826,0.00017006992,0.0036817084,0.00004612079,0.82408,0.00021888857,0.0017086951,0.03419266],"study_design_scores_gemma":[0.024936633,0.0008950937,0.3828741,0.00047262743,0.00013843666,0.000030109262,0.00088358443,0.000623318,0.5579665,0.0005806289,0.030039158,0.00055983773],"about_ca_topic_score_codex":0.0010365838,"about_ca_topic_score_gemma":0.0015510531,"teacher_disagreement_score":0.2661135,"about_ca_system_score_codex":0.0002413724,"about_ca_system_score_gemma":0.000380621,"threshold_uncertainty_score":0.8430657},"labels":[],"label_agreement":null},{"id":"W7117311906","doi":"10.1016/j.iotech.2025.101202","title":"117eP In vitro assessment of an EphA2-targeting CAR-T cell therapy for NSCLC","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"In vitro; Radiation therapy; Cell; Cancer therapy; Cancer; Cell therapy","score_opus":0.016533222373132594,"score_gpt":0.38570954537494284,"score_spread":0.36917632300181025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117311906","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97676665,0.003793592,0.00092327927,0.0048723184,0.00046768456,0.002218661,0.000015892565,0.00020353215,0.010738382],"genre_scores_gemma":[0.9826821,0.0007099387,0.013606397,0.00042709627,0.000057848094,0.0007128812,0.0000701089,0.000047555597,0.0016860567],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975818,0.00020606015,0.0007450049,0.0005525969,0.00019389937,0.00072067755],"domain_scores_gemma":[0.9980789,0.00050176075,0.00020472397,0.0008498998,0.00030967445,0.00005508411],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012621586,0.00025739777,0.0009825905,0.0014669632,0.0000932394,0.0000083471705,0.0005475813,0.00089271157,0.0003437459],"category_scores_gemma":[0.00016251257,0.0002458367,0.00016935302,0.001086934,0.0005264028,0.00006296124,0.00018282888,0.0008109734,0.00000374628],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001783348,0.00095357304,0.005370138,0.0000738544,0.00012473625,0.000040963063,0.00011344431,0.0000035616347,0.76973933,0.0005585441,0.00023677333,0.22100176],"study_design_scores_gemma":[0.012888544,0.0037012557,0.0029280016,0.0000534191,0.000046962083,0.00003914337,0.0014458022,0.00095991814,0.892676,0.0019574375,0.08310503,0.00019848872],"about_ca_topic_score_codex":0.00015246005,"about_ca_topic_score_gemma":0.00005042448,"teacher_disagreement_score":0.22080326,"about_ca_system_score_codex":0.00071168947,"about_ca_system_score_gemma":0.0011563607,"threshold_uncertainty_score":0.9999994},"labels":[],"label_agreement":null},{"id":"W7117312005","doi":"10.1016/j.iotech.2025.101572","title":"395P Synthetic IL-12 immunotherapy reverses immune suppression and halts metastasis in pancreatic cancer","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Immunotherapy; Pancreatic cancer; Immune system; Pancreatic ductal adenocarcinoma; Metastasis; Cytokine; Infiltration (HVAC); Tumor microenvironment","score_opus":0.016928231344369164,"score_gpt":0.3463640821661589,"score_spread":0.3294358508217897,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7117312005","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9337994,0.04133784,0.00006646678,0.017494418,0.00056075386,0.0013729606,0.000020766398,0.00028292404,0.0050644586],"genre_scores_gemma":[0.96097594,0.027245099,0.0011665507,0.0006136368,0.000034246452,0.000835129,0.00001555124,0.00006637912,0.009047446],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9971619,0.00032080198,0.0007577194,0.000707639,0.00022575741,0.0008261502],"domain_scores_gemma":[0.99797153,0.00049374724,0.00017617313,0.0011449015,0.00014635787,0.00006726763],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00076994393,0.00038013436,0.0013003272,0.0017901582,0.00017713,0.000020776513,0.00041879746,0.00089665886,0.002161692],"category_scores_gemma":[0.00039857457,0.00033631866,0.0001483326,0.0012527746,0.0011363664,0.0000946428,0.00037626855,0.001085126,0.000025762689],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018344977,0.00032208444,0.023975272,0.0001168879,0.0005082222,0.00018214001,0.00027401204,0.0000020140992,0.67196006,0.00057568855,0.00044982415,0.29979932],"study_design_scores_gemma":[0.017948141,0.0026364936,0.063185856,0.0016083232,0.00053724536,0.00096784515,0.0028437555,0.0001898182,0.4751865,0.0046093403,0.42956856,0.00071813475],"about_ca_topic_score_codex":0.0009315402,"about_ca_topic_score_gemma":0.00029661687,"teacher_disagreement_score":0.42911872,"about_ca_system_score_codex":0.000793934,"about_ca_system_score_gemma":0.0005996829,"threshold_uncertainty_score":0.99990886},"labels":[],"label_agreement":null},{"id":"W7118063928","doi":"10.1093/geroni/igaf122.3203","title":"Geriatric assessment in patients aged 70 and over considered for CAR-T therapy: Adescriptive study","year":2025,"lang":"en","type":"article","venue":"Innovation in Aging","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Université Laval","funders":"","keywords":"Geriatric oncology; Geriatrics; Medical record; Geriatric care; Risk assessment; Clinical Practice; Cancer; MEDLINE","score_opus":0.046763167701504474,"score_gpt":0.379507360857487,"score_spread":0.3327441931559825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7118063928","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99558145,0.000060484297,0.00017165577,0.00047484005,0.00015306748,0.0024236953,0.0000035730716,0.00001879904,0.0011124364],"genre_scores_gemma":[0.99803483,0.000014584173,0.00024968933,0.00058536464,0.000027868487,0.00023215846,0.000026559886,0.000013488846,0.00081547204],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9988121,0.00009013733,0.0004350839,0.00025303394,0.00022213875,0.000187536],"domain_scores_gemma":[0.9993627,0.00016549157,0.00007628129,0.00015591928,0.00022428724,0.000015331847],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008351726,0.00010244772,0.0002277149,0.0011080113,0.000045745765,0.000038018963,0.000042926127,0.00004722033,0.000098262906],"category_scores_gemma":[0.00015186938,0.0000990184,0.000016255399,0.0017926315,0.000027043065,0.00008562044,0.000038530572,0.00025703842,2.7173894e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000372653,0.0004259353,0.9627933,0.000040519597,0.000052127067,0.000004831476,0.0021092666,0.0000031612044,0.013658387,0.00034224265,0.00034407523,0.0198535],"study_design_scores_gemma":[0.013705498,0.00027906368,0.98202205,0.00008062648,0.0000071193335,2.4704127e-7,0.0016496449,0.00021534757,0.00087386725,0.0005286101,0.000559669,0.000078250734],"about_ca_topic_score_codex":0.00018755406,"about_ca_topic_score_gemma":0.000058908623,"teacher_disagreement_score":0.019775249,"about_ca_system_score_codex":0.00031700887,"about_ca_system_score_gemma":0.00017866673,"threshold_uncertainty_score":0.40378532},"labels":[],"label_agreement":null},{"id":"W7130728508","doi":"10.6084/m9.figshare.28537978","title":"Additional file 1 of Analysis of the measurements used as potency tests for the 31 US FDA-approved cell therapy products","year":2025,"lang":"","type":"article","venue":"Figshare","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre; Thermo Fisher Scientific (Canada)","funders":"","keywords":"Potency; Set (abstract data type); Stability (learning theory); Statistical analysis; Table (database)","score_opus":0.11822858874791327,"score_gpt":0.3380872051762991,"score_spread":0.21985861642838583,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7130728508","genre_codex":"dataset","genre_gemma":"dataset","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"dataset","genre_consensus":"dataset","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0004764994,0.002162036,4.6335228e-7,0.0010188239,0.00011846789,0.0044624605,0.98148346,0.000017096012,0.010260689],"genre_scores_gemma":[0.028949583,0.00006203644,0.000103668775,0.00067541463,0.00033697832,0.0056225923,0.8572855,0.00007026192,0.10689394],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99585164,0.00028182482,0.0008384222,0.0007075214,0.0017265578,0.0005940154],"domain_scores_gemma":[0.9875515,0.0067602526,0.00070012873,0.0019080557,0.0029685725,0.00011145868],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00040237643,0.00040154194,0.0008457201,0.00044308256,0.00031486657,0.000051627212,0.0012032918,0.00023736808,0.9910362],"category_scores_gemma":[0.017414963,0.00024852762,0.0010392789,0.0042457,0.000120663055,0.00008419086,0.0002559867,0.00048290996,0.00020334175],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005542144,0.00074738765,0.000090993715,0.0007746616,0.0043526883,0.0000012491946,0.0002529033,0.00006387516,0.027850829,0.0000011501295,0.9561312,0.009178801],"study_design_scores_gemma":[0.002130563,0.00043162872,0.027817609,0.0034560156,0.0010675311,9.2986295e-7,0.00015594374,0.0014101418,0.087648824,0.000030809748,0.87563634,0.00021367718],"about_ca_topic_score_codex":0.00007726356,"about_ca_topic_score_gemma":0.00008234625,"teacher_disagreement_score":0.9908328,"about_ca_system_score_codex":0.00020079009,"about_ca_system_score_gemma":0.0030861895,"threshold_uncertainty_score":0.9999967},"labels":[],"label_agreement":null},{"id":"W7131812083","doi":"10.5376/cge.2025.13.0021","title":"Bottlenecks and Breakthrough Pathways of CAR-T Cell Therapy in Solid Tumors","year":2025,"lang":"","type":"article","venue":"Cancer Genetics and Epigenetics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Cell therapy; Cell; Cancer therapy; Radiation therapy; Antibody therapy; Cancer","score_opus":0.0310972616995913,"score_gpt":0.32711754724674585,"score_spread":0.29602028554715454,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7131812083","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7329635,0.26124406,0.00011378669,0.0005723862,0.0004954502,0.0010067108,0.00014418845,0.000009235864,0.0034506791],"genre_scores_gemma":[0.5856967,0.41033044,0.00022800844,0.00029291905,0.00017411764,0.000050143586,0.00000858641,0.000055052347,0.0031640031],"study_design_codex":"design_other","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99613667,0.00017915787,0.0011506347,0.0009147695,0.0006398611,0.000978934],"domain_scores_gemma":[0.99780184,0.00021670043,0.00024267376,0.0008421301,0.0005234296,0.0003732345],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00061489956,0.00057720626,0.0011956919,0.00043269526,0.00014046603,0.000081815655,0.00032365246,0.00046265507,0.0006527782],"category_scores_gemma":[0.000046877565,0.00059169496,0.00014518813,0.0007855903,0.0009010413,0.00003021796,0.00034209323,0.00061987474,0.0000021636079],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007038416,0.00047683812,0.19021097,0.0013649262,0.00029147693,0.000046429803,0.0047073793,0.00068625977,0.3277299,0.00013085494,0.00042040806,0.47323072],"study_design_scores_gemma":[0.0096697975,0.002769069,0.23959188,0.0014474721,0.00028243728,0.000011065223,0.0018422657,0.0060111587,0.68893886,0.0021905976,0.046380423,0.00086496264],"about_ca_topic_score_codex":0.0010354487,"about_ca_topic_score_gemma":0.0004253139,"teacher_disagreement_score":0.47236577,"about_ca_system_score_codex":0.00019850829,"about_ca_system_score_gemma":0.0013415391,"threshold_uncertainty_score":0.99965346},"labels":[],"label_agreement":null},{"id":"W7131875803","doi":"10.5376/cge.2025.13.0014","title":"Trends in CAR-T Cell Therapy for Hematologic Malignancies","year":2025,"lang":"","type":"article","venue":"Cancer Genetics and Epigenetics","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":true,"route_about_ca":false,"ca_institutions":"","funders":"","keywords":"Radiation therapy; Antibody therapy; Cancer; Immunotherapy; Cell therapy; Disease","score_opus":0.04609918735745401,"score_gpt":0.3568766324347804,"score_spread":0.3107774450773264,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7131875803","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6369973,0.35490394,0.00050485716,0.0017841054,0.0010693433,0.0013128078,0.000157203,0.000018853312,0.0032516222],"genre_scores_gemma":[0.59760445,0.36714694,0.0006249503,0.0007734674,0.0002876942,0.00037470824,0.000027528053,0.000067876616,0.033092406],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99630964,0.00012637406,0.00090536225,0.0010035842,0.0003905112,0.0012645471],"domain_scores_gemma":[0.9980804,0.00027491202,0.0001624897,0.00080851396,0.00036093313,0.00031279682],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00049946737,0.0006007471,0.0010408841,0.0007958126,0.00021479209,0.00012806512,0.00039129553,0.0005480912,0.0015320822],"category_scores_gemma":[0.00003340509,0.0005848077,0.00027611837,0.0011700945,0.0004861724,0.00002239048,0.00019548257,0.00043438675,0.0000042264433],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013011952,0.0006038152,0.14980254,0.0013185233,0.00034475874,0.000035203717,0.0017686605,0.0008142145,0.15815361,0.00037834424,0.004569367,0.68090975],"study_design_scores_gemma":[0.013289222,0.0024705518,0.10635856,0.0007300284,0.00037931892,0.000008104533,0.0010917773,0.008467416,0.41159922,0.0026820814,0.4518671,0.0010565971],"about_ca_topic_score_codex":0.00023257566,"about_ca_topic_score_gemma":0.0004425786,"teacher_disagreement_score":0.6798532,"about_ca_system_score_codex":0.00030884382,"about_ca_system_score_gemma":0.000807741,"threshold_uncertainty_score":0.9996603},"labels":[],"label_agreement":null},{"id":"W7132882460","doi":"","title":"Allogeneic Double Negative T cell Therapy as a Novel Treatment for AML Patients","year":2019,"lang":"","type":"dissertation","venue":"TSpace","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"T cell; Leukemia; Peripheral blood mononuclear cell; Priming (agriculture); Transplantation; Bone marrow; Minimal residual disease; Graft-versus-host disease; Disease","score_opus":0.06602140056888346,"score_gpt":0.40649389517122275,"score_spread":0.3404724946023393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7132882460","genre_codex":"empirical","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93303835,0.002679141,0.0000850623,0.00031522042,0.0019959135,0.0177017,0.00015870383,0.0000673495,0.043958567],"genre_scores_gemma":[0.38112167,0.005945624,0.00035914057,0.00025621598,0.0005512367,0.0018652064,0.0038704164,0.00037928045,0.6056512],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9946074,0.00013101705,0.0007977452,0.0016461669,0.0013528785,0.001464828],"domain_scores_gemma":[0.99522835,0.0007398213,0.000722935,0.0013909341,0.0013508302,0.0005671557],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.00035537442,0.0013196024,0.0016705542,0.0005204871,0.00032908586,0.00014105222,0.0005125924,0.0009457875,0.012208764],"category_scores_gemma":[0.00007619377,0.001126932,0.0010077304,0.0005443302,0.00013144795,0.000118549346,0.00005152288,0.0006240986,0.0012672053],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0912989,0.009451131,0.0024843535,0.0010356724,0.0029515058,0.00001571822,0.09437154,0.000069744965,0.7297949,0.000095802985,0.00096876157,0.06746196],"study_design_scores_gemma":[0.11234917,0.02790592,0.0036113332,0.0005134782,0.0006945445,0.0000040982413,0.018457849,0.00036638588,0.7568935,0.000043335844,0.07782215,0.0013382351],"about_ca_topic_score_codex":0.004120778,"about_ca_topic_score_gemma":0.00023299892,"teacher_disagreement_score":0.56169266,"about_ca_system_score_codex":0.001682981,"about_ca_system_score_gemma":0.00208255,"threshold_uncertainty_score":0.99995553},"labels":[],"label_agreement":null},{"id":"W7132905998","doi":"","title":"Development of Class II-agnostic CAR T Cell Therapy Targeting WT1 Peptide Presented by Diverse HLA class II Molecules","year":2022,"lang":"","type":"dissertation","venue":"TSpace","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"T-cell receptor; Epitope; Chimeric antigen receptor; Human leukocyte antigen; T cell; Antigen; MHC class II; MHC class I; Peptide","score_opus":0.025819202718483175,"score_gpt":0.34084757167315133,"score_spread":0.3150283689546681,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7132905998","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9561765,0.023985595,0.000073076335,0.00051862,0.0011975166,0.0038584804,0.00010515799,0.00012906324,0.013955993],"genre_scores_gemma":[0.601729,0.0174361,0.001699147,0.0003409796,0.00043270647,0.0008020893,0.007911277,0.00061757484,0.36903113],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99033767,0.0008910851,0.0018039413,0.0017989867,0.003328234,0.0018400721],"domain_scores_gemma":[0.99490225,0.00075320393,0.0012967507,0.001292148,0.0010210199,0.00073460507],"candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0015378357,0.001408861,0.0019381006,0.0008305574,0.0019046825,0.00007373553,0.0012696675,0.00076411804,0.027315719],"category_scores_gemma":[0.0006041676,0.001498368,0.0006897858,0.0013780312,0.0003387445,0.00013741344,0.0009677459,0.002644251,0.00009530623],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038466307,0.001770409,0.0004411947,0.0013560059,0.0011239272,0.0001210183,0.10857586,0.00020852363,0.84633183,0.000013741632,0.029504929,0.006705919],"study_design_scores_gemma":[0.0050759665,0.001273859,0.0002325186,0.00065430923,0.00026576238,0.000005827515,0.090943284,0.00092146726,0.49678287,0.000003854099,0.40290064,0.00093963667],"about_ca_topic_score_codex":0.0017238904,"about_ca_topic_score_gemma":0.00019012613,"teacher_disagreement_score":0.3733957,"about_ca_system_score_codex":0.0013445029,"about_ca_system_score_gemma":0.0026401188,"threshold_uncertainty_score":0.9998662},"labels":[],"label_agreement":null},{"id":"W7132935331","doi":"","title":"Elucidating Cytotoxic Mechanisms of Allogeneic Double-Negative T cells Against Acute Myeloid Leukemia","year":2025,"lang":"","type":"dissertation","venue":"TSpace","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Cytotoxic T cell; Myeloid leukemia; Leukemia; Haematopoiesis; Myeloid; Cytokine; Immunotherapy; Stem cell; Effector","score_opus":0.02953809217371737,"score_gpt":0.3558772237053055,"score_spread":0.3263391315315881,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7132935331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86562675,0.0015455222,0.004621995,0.00038601668,0.0031125324,0.008060267,0.00021716683,0.00022050805,0.116209246],"genre_scores_gemma":[0.5044678,0.0072155623,0.0036108221,0.00035445904,0.00054565415,0.00047189998,0.0020911745,0.00036849096,0.48087412],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9912716,0.0005461663,0.0019341484,0.0019956531,0.0024536976,0.0017987328],"domain_scores_gemma":[0.99299824,0.0010676533,0.0016480467,0.00204416,0.0015840826,0.00065781706],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity"],"category_scores_codex":[0.0016285363,0.0015634327,0.00280053,0.0014113158,0.00046451142,0.00013496916,0.0013009132,0.0016615719,0.012131216],"category_scores_gemma":[0.00031464372,0.0016450952,0.0010617999,0.002104139,0.0002921197,0.00018507816,0.00040001082,0.0027477543,0.00045678258],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007304095,0.00025833916,0.000011608706,0.0026666387,0.0034820777,0.00021986802,0.017011072,0.00040908737,0.9533923,0.0006251233,0.00045018177,0.01416957],"study_design_scores_gemma":[0.0084290365,0.0011368725,0.00008424883,0.0036256684,0.001544318,0.000011851484,0.025975522,0.0015136024,0.95552814,0.00038830802,0.0007220939,0.0010403611],"about_ca_topic_score_codex":0.0014480919,"about_ca_topic_score_gemma":0.00036373278,"teacher_disagreement_score":0.36466488,"about_ca_system_score_codex":0.0024501064,"about_ca_system_score_gemma":0.0060251467,"threshold_uncertainty_score":0.9997114},"labels":[],"label_agreement":null},{"id":"W7133054292","doi":"","title":"Donor-derived Double Negative T cells as a Vehicle for the Off-the-shelf Delivery of Chimeric Antigen Receptor Therapies for B-ALL","year":2021,"lang":"","type":"dissertation","venue":"TSpace","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Toronto General Hospital Research Institute, University Health Network","keywords":"Chimeric antigen receptor; Antigen; In vitro; Leukemia; Receptor; Monoclonal antibody; Refractory (planetary science)","score_opus":0.045298494829115125,"score_gpt":0.36837171112693623,"score_spread":0.3230732162978211,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7133054292","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93540853,0.041197654,0.00039239757,0.005493444,0.001980425,0.01349016,0.00017551328,0.000053215812,0.0018086593],"genre_scores_gemma":[0.4941918,0.101032786,0.0027857537,0.0014206001,0.0027374208,0.006001235,0.002291165,0.0008288375,0.3887104],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9952428,0.00039154285,0.0009805596,0.0010974183,0.0010907107,0.001197009],"domain_scores_gemma":[0.98985493,0.0052505056,0.0009812032,0.0014657319,0.0021967134,0.00025092243],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0014020839,0.0008774854,0.0015020171,0.00024483268,0.00078459043,0.00018879575,0.0010548068,0.0005783227,0.0074579404],"category_scores_gemma":[0.0003399917,0.0006058527,0.001289967,0.00088432693,0.000619624,0.00014003787,0.00013739195,0.0009211054,0.000081332],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020866899,0.0003860726,0.00003892313,0.00095320866,0.004087854,0.0000035426322,0.10379646,0.00004624215,0.8260249,0.000094633,0.0031149518,0.04058634],"study_design_scores_gemma":[0.007983423,0.0019811061,0.0003813193,0.00049688376,0.0008990719,0.0000038858925,0.1349131,0.0012574977,0.7607553,0.000106824584,0.09070024,0.0005213545],"about_ca_topic_score_codex":0.003447585,"about_ca_topic_score_gemma":0.00053368194,"teacher_disagreement_score":0.4412167,"about_ca_system_score_codex":0.00026408024,"about_ca_system_score_gemma":0.0017846064,"threshold_uncertainty_score":0.9996393},"labels":[],"label_agreement":null},{"id":"W7133088234","doi":"","title":"Expansion and Characterization of Tumour Derived T Lymphocytes from Undifferentiated Pleomorphic Sarcoma","year":2022,"lang":"","type":"dissertation","venue":"TSpace","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Sarcoma; CD8; Limiting; Soft tissue sarcoma; Phenotype; Soft tissue; Adoptive cell transfer; T cell","score_opus":0.027783520130231214,"score_gpt":0.3268898674382498,"score_spread":0.2991063473080186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7133088234","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934798,0.0030405005,0.00007375818,0.0002100111,0.0008694558,0.001683854,0.00025110683,0.00007195991,0.0003195485],"genre_scores_gemma":[0.9456157,0.0075695943,0.000043185726,0.000056092078,0.00024355289,0.00011721192,0.027699493,0.00018859835,0.018466562],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99539644,0.00065374665,0.000912303,0.0010184937,0.001400949,0.0006180596],"domain_scores_gemma":[0.99717265,0.0004002931,0.0009286046,0.00073302275,0.0004230883,0.00034232202],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00030132194,0.00070050673,0.0013913915,0.0006673118,0.00033052315,0.00008129832,0.00033746922,0.00049564254,0.066568725],"category_scores_gemma":[0.00017341942,0.0007549197,0.00023309462,0.0007382439,0.00019394488,0.00012853093,0.00021680072,0.0008103399,0.000038108854],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005304279,0.00041712527,0.004326878,0.00073527027,0.0005287833,0.00006922344,0.02193847,0.0000017274069,0.95800686,0.000013655445,0.000019207724,0.008638544],"study_design_scores_gemma":[0.0050449446,0.000774163,0.38168868,0.0008454701,0.0005394677,0.000015063935,0.01084332,0.0018556592,0.59751076,0.00003037348,0.0003810516,0.00047107504],"about_ca_topic_score_codex":0.004782782,"about_ca_topic_score_gemma":0.0002181762,"teacher_disagreement_score":0.3773618,"about_ca_system_score_codex":0.00048124086,"about_ca_system_score_gemma":0.0008747817,"threshold_uncertainty_score":0.9994902},"labels":[],"label_agreement":null},{"id":"W7133092310","doi":"","title":"In Vitro Generation of Human CD4 T Lineage Cells from Stem Cells","year":2024,"lang":"","type":"dissertation","venue":"TSpace","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Cytotoxic T cell; Stem cell; T cell; CD8; Progenitor cell; Interleukin 21; Natural killer T cell; Antigen-presenting cell","score_opus":0.05747263454086639,"score_gpt":0.39209500581805756,"score_spread":0.3346223712771912,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7133092310","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98013395,0.0069432305,0.00004163426,0.0002073779,0.0038404872,0.0020959692,0.00016289574,0.000052141117,0.0065223346],"genre_scores_gemma":[0.63464737,0.0015566318,0.00017394341,0.000082360435,0.0024566497,0.0000896757,0.00236295,0.00024578188,0.35838464],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9944318,0.00045950097,0.0014577195,0.0013344986,0.0015178848,0.0007985892],"domain_scores_gemma":[0.9971984,0.0003332558,0.0005198947,0.0012196804,0.0004041121,0.00032462768],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.000935429,0.0008036734,0.0015694118,0.0010457501,0.000108276836,0.00013601739,0.00047325625,0.0010624223,0.016734336],"category_scores_gemma":[0.000022292532,0.0008540209,0.00049386837,0.0009931298,0.00013876529,0.00012880014,0.000110355686,0.001995703,0.0010271689],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012569749,0.00042866802,0.000012446608,0.0016572544,0.00034822017,0.00028156495,0.040773857,0.00007649205,0.9470587,0.000025344085,0.0040425756,0.0040379167],"study_design_scores_gemma":[0.0021814532,0.00056520454,0.00004058172,0.0011458485,0.00042973045,0.0000015721996,0.013217452,0.0062230877,0.9701632,0.000019448733,0.005456108,0.00055626105],"about_ca_topic_score_codex":0.007297873,"about_ca_topic_score_gemma":0.0015619721,"teacher_disagreement_score":0.3518623,"about_ca_system_score_codex":0.00064245774,"about_ca_system_score_gemma":0.0006795201,"threshold_uncertainty_score":0.9997507},"labels":[],"label_agreement":null},{"id":"W7147334668","doi":"10.1093/immadv/ltaf038","title":"Chimeric CD3ζ chains containing CD28 signalling motifs enhance antigen-specific IL-2 production and expansion of human TCR-engineered T cells <i>in vitro</i>","year":2025,"lang":"en","type":"article","venue":"Immunotherapy Advances","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Infection and Immunity","funders":"","keywords":"CD28; T-cell receptor; Cytotoxic T cell; Chimeric antigen receptor; Antigen; Effector; Streptamer; Signal transduction; Jurkat cells","score_opus":0.015110604342451496,"score_gpt":0.30191830494043137,"score_spread":0.2868077005979799,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7147334668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94647014,0.04904118,0.0024550683,0.00023834554,0.0003600529,0.000885364,0.000005959098,0.00007234754,0.00047152356],"genre_scores_gemma":[0.957327,0.039588153,0.001051579,0.000085394546,0.0001239662,0.00005477454,0.000015209878,0.000045615674,0.0017083165],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9980705,0.00010594326,0.00055081287,0.00053334417,0.0003391381,0.00040028626],"domain_scores_gemma":[0.9991052,0.00012894873,0.00015729279,0.00042060832,0.00013754683,0.00005040276],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00052738335,0.00026408865,0.0005970307,0.00044039995,0.00013802732,0.000027632734,0.00015478545,0.00009562122,0.00013449778],"category_scores_gemma":[0.000027844355,0.00025401742,0.00010131546,0.0007116862,0.0002049776,0.00023141743,0.000029271947,0.0003522184,0.0000022545503],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013655149,0.00013627474,0.00048495748,0.00012034351,0.000069941,0.0000072240696,0.0010894163,0.00022996006,0.85177666,0.0000426141,0.000010365676,0.14466672],"study_design_scores_gemma":[0.0016001479,0.0003944313,0.001963606,0.0005686674,0.0000069502353,0.00000585311,0.0005926897,0.00021653864,0.98385954,0.00009575941,0.0105022695,0.00019355788],"about_ca_topic_score_codex":0.000050176764,"about_ca_topic_score_gemma":0.000010914817,"teacher_disagreement_score":0.14447317,"about_ca_system_score_codex":0.000110447305,"about_ca_system_score_gemma":0.00008050163,"threshold_uncertainty_score":0.9999912},"labels":[],"label_agreement":null},{"id":"W7165358678","doi":"10.32598/jvc.5.3.175.1","title":"Optimizing Allogeneic Stem Cell Transplantation Following CAR-T Therapy in Acute Lymphoblastic Leukemia","year":2024,"lang":"en","type":"article","venue":"Journal of Vessels and Circulation","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université du Québec à Trois-Rivières","funders":"","keywords":"Lymphoblastic Leukemia; Stem cell; Transplantation; Hematopoietic stem cell transplantation; Acute lymphocytic leukemia; Myeloid leukemia; Immunotherapy","score_opus":0.023898680649489353,"score_gpt":0.2946250213738157,"score_spread":0.27072634072432633,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W7165358678","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901742,0.0062957024,0.00278046,0.00012631019,0.00021951502,0.00016308959,0.000001260649,0.0000114252725,0.00022808003],"genre_scores_gemma":[0.99447167,0.0049784016,0.0001984129,0.00004097713,0.00013902216,0.0000028489649,0.000005207549,0.00002175184,0.00014172553],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9989873,0.00005568505,0.00034863714,0.00013122305,0.0003312245,0.00014594152],"domain_scores_gemma":[0.9996316,0.00009504868,0.00007187978,0.000065422915,0.00005723615,0.00007880484],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00043349247,0.00009904928,0.00022694693,0.00029993313,0.000036246845,0.00007249742,0.00004030631,0.00007889889,0.000051488183],"category_scores_gemma":[0.0000026985063,0.000080533406,0.00013407179,0.00024848885,0.000013570756,0.00023249908,0.0000037091363,0.00020079922,0.000001611126],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034566363,0.00003273408,0.00691311,0.00017970038,0.00017842952,0.00071555434,0.0030025588,0.0040103234,0.9223523,0.000015792315,0.000007547602,0.062246274],"study_design_scores_gemma":[0.023032552,0.0032392154,0.6319727,0.005061767,0.0016310699,0.006258562,0.0024311498,0.08526023,0.23721935,0.0009806035,0.0020044695,0.00090833346],"about_ca_topic_score_codex":0.000011889802,"about_ca_topic_score_gemma":0.0000023211312,"teacher_disagreement_score":0.685133,"about_ca_system_score_codex":0.00027411326,"about_ca_system_score_gemma":0.00023968604,"threshold_uncertainty_score":0.32840568},"labels":[],"label_agreement":null}]}